{"meta":{"query_hash":"fe77064d49b2","filters":{"topic":"Pharmaceutical Economics and Policy"},"cohort_total":1682,"direct_labels_cover":5,"predictions_cover":1682,"exported":1682,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/fe77064d49b2","api":"https://metacan.xera.ac/api/v1/cohort?topic=Pharmaceutical+Economics+and+Policy"},"results":[{"id":"W102432712","doi":"","title":"Pharmacy Education in India","year":2008,"lang":"en","type":"article","venue":"American Journal of Pharmaceutical Education","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy; Government (linguistics); Health care; Pharmaceutical care; Bureaucracy; Developing country; Medicine; Population; Nursing; Family medicine; Economic growth; Political science; Politics; Environmental health","score_opus":0.05753423844105215,"score_gpt":0.3736813859025616,"score_spread":0.31614714746150946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W102432712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9597973,0.0029703442,0.00018796565,0.0046043033,0.0016514265,0.00015365201,0.00001299827,0.000009939058,0.030612025],"genre_scores_gemma":[0.9864376,0.0026294258,0.001189635,0.008794162,0.000675535,0.000011840134,0.000005127393,0.000024056386,0.0002326074],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982545,0.00005556652,0.001089274,0.00022094087,0.0000597249,0.0003200412],"domain_scores_gemma":[0.9984812,0.00009326501,0.00078450533,0.00015269358,0.00009657265,0.00039177272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005698224,0.00015875665,0.0004644604,0.00064915547,0.00006171666,0.000028032078,0.00031023799,0.000033763037,0.0006433021],"category_scores_gemma":[0.00016852969,0.00018229613,0.00014741246,0.0005404104,0.00024696277,0.00044188186,0.00002942182,0.00047755972,0.00031558238],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029685546,0.0035393361,0.44364992,0.00004562286,0.00011883848,0.000017436587,0.002060333,0.000067095185,0.00045222172,0.11429194,0.018250966,0.41720942],"study_design_scores_gemma":[0.0019111432,0.00023962006,0.2192825,0.00005423633,0.000027682532,0.0006362987,0.00055848376,0.0011765403,0.0011116005,0.018190263,0.7562683,0.0005432865],"about_ca_topic_score_codex":0.00016930833,"about_ca_topic_score_gemma":0.0000012565941,"teacher_disagreement_score":0.7380174,"about_ca_system_score_codex":0.00032504357,"about_ca_system_score_gemma":0.0013509551,"threshold_uncertainty_score":0.7433821},"labels":[],"label_agreement":null},{"id":"W103850937","doi":"","title":"Are brand-name and generic warfarin interchangeable? A survey of Ontario patients and physicians.","year":2005,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Joseph’s Healthcare Hamilton","funders":"","keywords":"Warfarin; Medicine; Brand names; Family medicine; Likert scale; Generic drug; Pediatrics; Internal medicine; Advertising; Drug; Psychiatry; Psychology","score_opus":0.11369663477764512,"score_gpt":0.2406447882081845,"score_spread":0.1269481534305394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W103850937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99346524,0.00098204,0.000013779337,0.00051442813,0.000109427594,0.00023671208,0.00026855478,0.0000071427553,0.004402688],"genre_scores_gemma":[0.9975945,0.00027283235,0.000047891637,0.0013440924,0.000048246777,0.00008279556,0.000013036507,0.000013446632,0.0005831729],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99911606,0.000012493748,0.00034016024,0.00025067263,0.000015228704,0.00026541034],"domain_scores_gemma":[0.99943644,0.000036098016,0.0002760519,0.00012081998,0.000020384043,0.00011019905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033124466,0.000108097745,0.00033441532,0.00009768887,0.00003098789,0.00003648775,0.00009264584,0.000053080217,0.000052863805],"category_scores_gemma":[0.00006310404,0.00012639716,0.000033222303,0.00007349118,0.00006255499,0.00015183305,0.00009082761,0.000094543946,0.00001812644],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027901604,0.00008736122,0.90755373,0.000018875657,0.000039320494,1.7003103e-7,0.00041332442,0.0000058228957,3.3712368e-7,0.00088678306,0.00062313693,0.09034326],"study_design_scores_gemma":[0.000723726,0.000011105846,0.95361865,0.000002703402,0.00000406728,3.7357063e-7,0.0000028454317,0.00039223285,0.000027048938,0.00078977423,0.04429441,0.00013304145],"about_ca_topic_score_codex":0.011576142,"about_ca_topic_score_gemma":0.026437908,"teacher_disagreement_score":0.09021022,"about_ca_system_score_codex":0.0001355665,"about_ca_system_score_gemma":0.000007845078,"threshold_uncertainty_score":0.99500585},"labels":[],"label_agreement":null},{"id":"W109161873","doi":"10.1533/9781908818089.201","title":"Implications of empirical data: are pharmaceutical linkage regulations a success? * *This chapter is based upon material in R.A. Bouchard, ‘I’m Still Your Baby: Canada’s Continuing Support of U.S. Linkage Regulations for Pharmaceuticals,’ Marquette Intellectual Property Law Review 15(1): 79–146 (2011).","year":2012,"lang":"en","type":"book-chapter","venue":"Elsevier eBooks","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Competitor analysis; Linkage (software); Legitimacy; Legislation; Enforcement; Political science; Law and economics; Politics; Law; Business; Public administration; Economics; Marketing","score_opus":0.13605083076033583,"score_gpt":0.34532430427076116,"score_spread":0.20927347351042533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W109161873","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016202921,0.027916167,0.00025266968,0.032155856,0.0018787659,0.009448457,0.13166393,0.00013548577,0.7949284],"genre_scores_gemma":[0.5315779,0.02956086,0.0037482576,0.07526191,0.0036341506,0.0018319988,0.01494217,0.0012793568,0.3381634],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99408156,0.000073258925,0.0034651556,0.0012772046,0.00018977717,0.0009130764],"domain_scores_gemma":[0.99505925,0.0004872213,0.0018622259,0.001740319,0.00031298734,0.0005379705],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016710075,0.00079332653,0.0023235886,0.00047057137,0.00015087682,0.00007534651,0.0011767043,0.00059565017,0.013856737],"category_scores_gemma":[0.00023019496,0.0008030022,0.0004782022,0.00007515402,0.00046385368,0.00029509744,0.0005133037,0.00085525576,0.00015366382],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011847704,0.0011436557,0.0028001412,0.020342987,0.0026485045,0.000040551684,0.0022468765,0.000049443777,0.00061617047,0.35035947,0.12092148,0.49764594],"study_design_scores_gemma":[0.0012780719,0.000061445826,0.0001753381,0.00093476835,0.00040905416,0.000010807753,0.000003443856,0.001996198,0.00048159275,0.0030194172,0.9907649,0.00086493755],"about_ca_topic_score_codex":0.0010392312,"about_ca_topic_score_gemma":0.006558922,"teacher_disagreement_score":0.8698434,"about_ca_system_score_codex":0.0004266513,"about_ca_system_score_gemma":0.0005819484,"threshold_uncertainty_score":0.9994421},"labels":[],"label_agreement":null},{"id":"W111982779","doi":"10.4000/interventionseconomiques.1441","title":"Procès de production d’une recherche orientée entre chercheurs, malades et entrepreneurs : Le cas d’une « biotech à but non lucratif »","year":2011,"lang":"fr","type":"article","venue":"Interventions économiques","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Humanities; Political science; Philosophy","score_opus":0.3378487349127251,"score_gpt":0.3770503880068065,"score_spread":0.03920165309408141,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W111982779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81892854,0.009738929,0.008324769,0.09873222,0.003296401,0.0013700821,0.00083784154,0.00022882392,0.05854239],"genre_scores_gemma":[0.930439,0.010980093,0.009201538,0.0011674459,0.0006557107,0.00030267457,0.00009675163,0.00013345237,0.047023367],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99571836,0.00036141393,0.0017682433,0.0011706952,0.00003249386,0.0009487802],"domain_scores_gemma":[0.99757904,0.00017484119,0.0009255145,0.00081367395,0.00014770997,0.00035923836],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0024558906,0.00054002245,0.00081934844,0.00051294797,0.00023750142,0.00030680074,0.0006462298,0.00079484255,0.0022879299],"category_scores_gemma":[0.0007664344,0.00074903155,0.0009013486,0.0005870598,0.00042587277,0.00113696,0.00026710308,0.0012197612,0.0010445686],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040351515,0.0072146403,0.06356838,0.0022166644,0.0018279104,0.000076190096,0.04061595,0.00043623068,0.0014696297,0.7451189,0.025013665,0.11203832],"study_design_scores_gemma":[0.0030029477,0.0011211034,0.062210727,0.0025381302,0.00035958918,0.00028697323,0.0044840635,0.0092693195,0.091927946,0.5375762,0.28437346,0.0028495092],"about_ca_topic_score_codex":0.03279724,"about_ca_topic_score_gemma":0.006618334,"teacher_disagreement_score":0.2593598,"about_ca_system_score_codex":0.0018640396,"about_ca_system_score_gemma":0.00038776748,"threshold_uncertainty_score":0.9997332},"labels":[],"label_agreement":null},{"id":"W112126374","doi":"10.1016/j.jacc.2013.08.1665","title":"Polypills","year":2014,"lang":"en","type":"article","venue":"Journal of the American College of Cardiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"Wellcome Trust","keywords":"Polypill; Medicine; Essential medicines; Secondary prevention; Formulary; Psychological intervention; Intensive care medicine; Alternative medicine; Pharmacy; Family medicine; Traditional medicine; Environmental health; Public health; Internal medicine; Nursing","score_opus":0.027303465693074826,"score_gpt":0.26753332908341915,"score_spread":0.24022986339034433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W112126374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93126035,0.0007418484,0.0017761134,0.011652782,0.0012678665,0.00007700001,0.00017685535,0.000003621426,0.05304357],"genre_scores_gemma":[0.99668336,0.00021151023,0.00031361432,0.0020915912,0.00052422064,7.10696e-7,1.0010766e-7,0.000009932011,0.00016497937],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989583,0.00007369973,0.000676925,0.00009267523,0.000024273988,0.00017411304],"domain_scores_gemma":[0.99813503,0.00016718908,0.0013311649,0.00024474927,0.000044600234,0.00007725667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078212545,0.00008019085,0.00080049015,0.00013591161,0.000034690816,0.0000040278087,0.00045241188,0.00003171411,0.000024299161],"category_scores_gemma":[0.0002802561,0.000063008214,0.00039547408,0.000183662,0.00031132787,0.000047165307,0.00007482106,0.00017032654,0.000029159035],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000265923,0.000053714368,0.20684099,0.00002740611,0.0007513974,0.00001315137,0.00005460673,0.002673382,0.00092518254,0.72827333,0.05756035,0.0025605725],"study_design_scores_gemma":[0.0008245827,0.0004530605,0.08356948,0.000011876063,0.000030150424,0.00032329644,0.00004067799,0.0006531541,0.0004488567,0.086202204,0.82727444,0.0001682403],"about_ca_topic_score_codex":0.000011266817,"about_ca_topic_score_gemma":9.867109e-7,"teacher_disagreement_score":0.76971406,"about_ca_system_score_codex":0.00004698969,"about_ca_system_score_gemma":0.000035521276,"threshold_uncertainty_score":0.25694004},"labels":[],"label_agreement":null},{"id":"W1135736076","doi":"10.71781/4972","title":"Développement d'une technique optique ayant pour but l'analyse de procédés en ligne de comprimés pharmaceutiques","year":2008,"lang":"fr","type":"dissertation","venue":"Papyrus : Institutional Repository (Université de Montréal)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Natural Sciences and Engineering Research Council of Canada; Université de Montréal","keywords":"Humanities; Physics; Art","score_opus":0.01954608343942198,"score_gpt":0.24460302182764937,"score_spread":0.22505693838822738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1135736076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9080341,0.031158026,0.010931643,0.0070789927,0.0010155437,0.0013885595,0.0006702281,0.00018966485,0.03953324],"genre_scores_gemma":[0.9029714,0.03808981,0.017551936,0.001745597,0.0006821266,0.00031520537,0.0006318764,0.00013590405,0.03787614],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99603057,0.00020982228,0.0012945775,0.0011035734,0.0001805249,0.0011809376],"domain_scores_gemma":[0.99711365,0.00019812144,0.0011238101,0.0005195182,0.0002177649,0.0008271143],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0008253191,0.00081153866,0.0011084502,0.0008083334,0.0038862887,0.00013204411,0.0009274027,0.0010175535,0.00025538006],"category_scores_gemma":[0.00010860734,0.0011641192,0.00071467325,0.0004951347,0.00034234402,0.00045552416,0.000290785,0.0011918468,0.00030012458],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035877095,0.0048038256,0.2682057,0.0024948968,0.00672691,0.011962449,0.13514097,0.045211952,0.16998132,0.327673,0.011990114,0.0122211855],"study_design_scores_gemma":[0.005324294,0.00036738015,0.085032076,0.0008251108,0.0008758772,0.0045854887,0.014080623,0.07910376,0.40369472,0.008888323,0.3934546,0.0037677493],"about_ca_topic_score_codex":0.057811428,"about_ca_topic_score_gemma":0.0038590694,"teacher_disagreement_score":0.38146448,"about_ca_system_score_codex":0.01953905,"about_ca_system_score_gemma":0.0035454305,"threshold_uncertainty_score":0.9990809},"labels":[],"label_agreement":null},{"id":"W113649872","doi":"10.1155/2002/525819","title":"Funding the New Biologics – Public Policy Issues in Drug Formulary Decision Making","year":2002,"lang":"en","type":"article","venue":"Canadian Journal of Gastroenterology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Formulary; Actuarial science; Public economics; Medicine; Health care; Intervention (counseling); Business; Health economics; Public health; Cost–benefit analysis; Quality (philosophy); Economic evaluation; Family medicine; Economics; Economic growth; Nursing","score_opus":0.07883856683017838,"score_gpt":0.29135276207516325,"score_spread":0.21251419524498488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W113649872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87383837,0.0049963007,0.0010920512,0.11397716,0.00071563286,0.00009785873,0.00003984021,0.000004111399,0.005238688],"genre_scores_gemma":[0.98629314,0.0006703745,0.00041428758,0.011930343,0.00053233124,0.0000010807269,8.411232e-7,0.000013170701,0.0001444218],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99839544,0.000039141138,0.0007401553,0.0001501784,0.000018512865,0.00065653963],"domain_scores_gemma":[0.998875,0.000084322906,0.00038473032,0.00017592438,0.00002235832,0.0004576381],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074215163,0.00012155492,0.00036609007,0.00096534955,0.00010365654,0.00010277555,0.000532653,0.000075387776,0.0007862951],"category_scores_gemma":[0.00035433535,0.00010770597,0.00013053358,0.00020239346,0.000099294746,0.00023058454,0.000035434146,0.00036205797,0.000110168694],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060966606,0.000031488384,0.77214444,0.00000596294,0.000074354924,0.00009394269,0.0008306965,0.00031595977,0.000003936927,0.14793646,0.067563236,0.010938542],"study_design_scores_gemma":[0.001330967,0.00031678833,0.061643556,0.0000365749,0.0000055392793,0.0004079881,0.000071596725,0.0029957509,0.0000027378637,0.1269269,0.8061025,0.00015906409],"about_ca_topic_score_codex":0.00324946,"about_ca_topic_score_gemma":0.03178496,"teacher_disagreement_score":0.7385393,"about_ca_system_score_codex":0.00033827708,"about_ca_system_score_gemma":0.00012075252,"threshold_uncertainty_score":0.98588246},"labels":[],"label_agreement":null},{"id":"W1156621861","doi":"","title":"Les conflits d'intérêts des groupes de défense de patients financés par l'industrie pharmaceutique : le cas du remboursement public des médicaments","year":2013,"lang":"fr","type":"article","venue":"Papyrus : Institutional Repository (Université de Montréal)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Political science; Humanities; Philosophy","score_opus":0.032601946078762316,"score_gpt":0.2190637746046361,"score_spread":0.18646182852587379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1156621861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9246545,0.03324942,0.0008901844,0.00676798,0.0008207483,0.00056796084,0.0003844291,0.000067078894,0.03259771],"genre_scores_gemma":[0.9756681,0.010064071,0.0010632096,0.0012875622,0.00028532365,0.000076840726,0.000060018436,0.000051592026,0.011443329],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968096,0.00018357314,0.0008038527,0.00072438864,0.00013241486,0.0013461411],"domain_scores_gemma":[0.9976396,0.00014540098,0.0005526681,0.00037756388,0.0002532466,0.0010315083],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0006219269,0.00048660612,0.00056349335,0.00036229464,0.005152017,0.00028179126,0.00057844503,0.0004940838,0.0006406728],"category_scores_gemma":[0.0002259025,0.00068315095,0.00033353228,0.00033139685,0.0012125499,0.0012181139,0.00039318384,0.00059151265,0.00033855316],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016416477,0.0011975933,0.7970467,0.00016677125,0.00056858535,0.00031001715,0.0106143765,0.0010902069,0.00028268123,0.12652695,0.0053793304,0.056652576],"study_design_scores_gemma":[0.003034587,0.00014888243,0.5070235,0.00014249946,0.00009708087,0.00024806315,0.0013501534,0.008744485,0.0028584,0.008600624,0.46700135,0.00075032905],"about_ca_topic_score_codex":0.10118266,"about_ca_topic_score_gemma":0.0023813809,"teacher_disagreement_score":0.46162203,"about_ca_system_score_codex":0.013018741,"about_ca_system_score_gemma":0.0011464874,"threshold_uncertainty_score":0.99956197},"labels":[],"label_agreement":null},{"id":"W1165099382","doi":"","title":"La gestion de l’Avastin par le bioéthicien : transfert d’une responsabilité politique?","year":2012,"lang":"fr","type":"article","venue":"Papyrus : Institutional Repository (Université de Montréal)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Political science; Humanities; Philosophy","score_opus":0.01953958751887841,"score_gpt":0.20186407410113155,"score_spread":0.18232448658225314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1165099382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77058315,0.053172875,0.0016201659,0.030634046,0.0011567711,0.00026922958,0.0005053638,0.00007789608,0.1419805],"genre_scores_gemma":[0.9713517,0.0044819675,0.00060856895,0.0010182906,0.00041218245,0.00001412478,0.00003060093,0.00003819627,0.022044394],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99750763,0.00030868166,0.0006131407,0.0004436184,0.00008977072,0.0010371421],"domain_scores_gemma":[0.998125,0.0004437552,0.00023812887,0.0003866187,0.000058929418,0.0007475379],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0015479061,0.00033726185,0.00044925773,0.0003211905,0.002675033,0.00006245587,0.00036635634,0.00061279966,0.00019183659],"category_scores_gemma":[0.00017672207,0.0004944971,0.000307799,0.00036035597,0.0007404362,0.0007541532,0.0001489294,0.0006304223,0.00034817553],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005787828,0.0007588552,0.094826944,0.00014694655,0.00022998425,0.00014779693,0.024327736,0.001510718,0.0025722529,0.86542785,0.002202983,0.0072691278],"study_design_scores_gemma":[0.0013588241,0.00009498537,0.14116833,0.00009617794,0.00010940686,0.001020042,0.002712516,0.0057711136,0.0039781947,0.00610347,0.83693004,0.0006569047],"about_ca_topic_score_codex":0.09116845,"about_ca_topic_score_gemma":0.0015866697,"teacher_disagreement_score":0.8593244,"about_ca_system_score_codex":0.005700058,"about_ca_system_score_gemma":0.00088121684,"threshold_uncertainty_score":0.9997507},"labels":[],"label_agreement":null},{"id":"W128384471","doi":"","title":"Canadian court dismisses Pfizer attempt to prevent approval of generic fluconazole.","year":2001,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Appeal; Federal court; Fluconazole; Law; Political science; Business; Medicine; Supreme court; Antifungal","score_opus":0.06609035721949574,"score_gpt":0.24512501679093854,"score_spread":0.1790346595714428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W128384471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8750809,0.0010813011,0.00016910337,0.015603839,0.0005717854,0.0008174326,0.0003973289,0.000023880508,0.10625442],"genre_scores_gemma":[0.99154943,0.00027153353,0.00011739184,0.0042870394,0.00021679493,0.00044878185,0.000012062276,0.00002549632,0.003071474],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985264,0.000009057314,0.00051720795,0.00031792943,0.000025292684,0.0006041434],"domain_scores_gemma":[0.9988512,0.000026254258,0.0001376168,0.00028481495,0.000020133411,0.0006800166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038783593,0.0001404854,0.00034466712,0.00027140256,0.00005348833,0.000041084953,0.00029258354,0.00007252663,0.00043252952],"category_scores_gemma":[0.000069648515,0.00016756152,0.00010758066,0.00024165088,0.000032111166,0.00010085373,0.000055265664,0.000091846756,0.00039243817],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015429338,0.001004262,0.2846764,0.00019987725,0.00072165095,0.000052477983,0.0011048771,0.0023106448,0.00007968296,0.2859377,0.15137681,0.27238134],"study_design_scores_gemma":[0.0002796678,0.000012433983,0.18182161,0.0000022787558,0.000006417541,0.0000059497916,0.000009684826,0.0005693285,0.00022909332,0.004641143,0.81217897,0.00024342761],"about_ca_topic_score_codex":0.019351304,"about_ca_topic_score_gemma":0.0056047523,"teacher_disagreement_score":0.6608021,"about_ca_system_score_codex":0.00027635426,"about_ca_system_score_gemma":0.000057940466,"threshold_uncertainty_score":0.9871789},"labels":[],"label_agreement":null},{"id":"W138698383","doi":"","title":"The Case for Mutual Recognition of Drug Approvals","year":2013,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Fraser Institute","funders":"","keywords":"Jurisdiction; Harm; Agency (philosophy); Business; Medicine; Population; Drug approval; Quality (philosophy); Food and drug administration; Work (physics); Public economics; Pharmaceutical industry; Drug; Pharmacology; Risk analysis (engineering); Political science; Environmental health; Economics; Law; Engineering","score_opus":0.041189549932308396,"score_gpt":0.2703527557907076,"score_spread":0.22916320585839922,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W138698383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96894604,0.007135438,0.0046864455,0.009154454,0.00050383114,0.00058216276,0.000115041854,0.000013640756,0.008862974],"genre_scores_gemma":[0.99381125,0.004168549,0.00013237106,0.00036040548,0.00031258567,0.00004584331,0.0000039281226,0.000018982826,0.0011460893],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99816394,0.00001731122,0.0005635637,0.00014041137,0.000014279569,0.001100495],"domain_scores_gemma":[0.9991731,0.00017518617,0.00039125714,0.00012698978,0.000057286532,0.00007614689],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020395638,0.00009324836,0.00020115176,0.00008031766,0.00023953494,0.00008690457,0.00019525981,0.000045461435,0.00010507312],"category_scores_gemma":[0.00013577663,0.00007959933,0.0001655094,0.00007003759,0.000057564455,0.00019869488,0.000022006741,0.0005068745,0.00027607562],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030508818,0.000047225592,0.00022543652,0.000010933217,0.00016396867,0.0000012327749,0.00013903358,0.000008647204,0.000027434444,0.9232716,0.0033194935,0.0727545],"study_design_scores_gemma":[0.0006130937,0.00009086506,0.000036520174,0.0000026448593,0.000008349054,0.00045809863,0.0004531516,0.0025427896,0.00012657378,0.96676755,0.028786829,0.00011351803],"about_ca_topic_score_codex":0.00019333673,"about_ca_topic_score_gemma":0.00026245482,"teacher_disagreement_score":0.072640985,"about_ca_system_score_codex":0.00024378896,"about_ca_system_score_gemma":0.00018823652,"threshold_uncertainty_score":0.35484856},"labels":[],"label_agreement":null},{"id":"W140674789","doi":"","title":"New drug approval times and 'therapeutic potential' in Canada, Australia, Sweden and the United States during the period 1992 to 1998.","year":2000,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Memorial University of Newfoundland","funders":"","keywords":"Medicine; Food and drug administration; Family medicine; Environmental health","score_opus":0.028610665608134037,"score_gpt":0.22185855994449738,"score_spread":0.19324789433636336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W140674789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773637,0.0010955984,0.0000030711374,0.019547137,0.00007062472,0.0005111889,0.00007162726,0.00000629137,0.0013307343],"genre_scores_gemma":[0.9912035,0.00061791495,0.000011242114,0.0029418697,0.00007922357,0.00014091728,0.0000045800584,0.000012788059,0.004987969],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989911,0.000026069009,0.00032046917,0.00023938563,0.000025240857,0.00039778728],"domain_scores_gemma":[0.99952245,0.00005954398,0.00006108884,0.00016787021,0.0000026532969,0.0001864123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035537969,0.00012666224,0.0002333916,0.000090683,0.00011712116,0.00014838438,0.00019381664,0.000027502838,0.00023764135],"category_scores_gemma":[0.000010702898,0.000096014606,0.000030873605,0.00017267746,0.00007285376,0.000056824287,0.00005282038,0.00015378538,0.000034545814],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025002111,0.00020668317,0.31557196,0.00030149822,0.0013723047,0.000082332896,0.024352824,0.0381416,0.000010270764,0.1269104,0.03824787,0.452302],"study_design_scores_gemma":[0.0021523053,0.000005244858,0.7105762,0.0000035392306,0.000014021533,0.000014808886,0.00018868924,0.0074758567,0.000021551159,0.01131101,0.267945,0.00029178584],"about_ca_topic_score_codex":0.73157096,"about_ca_topic_score_gemma":0.2603084,"teacher_disagreement_score":0.47126254,"about_ca_system_score_codex":0.00013146923,"about_ca_system_score_gemma":0.000030171912,"threshold_uncertainty_score":0.753189},"labels":[],"label_agreement":null},{"id":"W1416739048","doi":"10.12927/whp.2008.19597","title":"Medicinal Products Liability of the Pharmacists: An Overview of Some Emerging Legal Issues in Nigeria","year":2008,"lang":"en","type":"article","venue":"World health & population","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Business; Liability; Engineering ethics; Risk analysis (engineering); Engineering; Accounting","score_opus":0.17839019245958845,"score_gpt":0.4098828398031117,"score_spread":0.23149264734352323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1416739048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9770945,0.007887791,0.000003865176,0.013648933,0.00046705286,0.00034410314,0.000057147474,0.000009420099,0.00048721948],"genre_scores_gemma":[0.9960069,0.00200056,0.0001404464,0.0014520487,0.00019811947,0.000008047768,0.000019701818,0.000010966682,0.00016318882],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99830514,0.00006968873,0.0011010999,0.00024937707,0.00004569364,0.00022900508],"domain_scores_gemma":[0.9989774,0.000025245407,0.00060774677,0.00029986954,0.000024077768,0.000065622145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010260573,0.00009793444,0.00044259906,0.00019794682,0.000084031526,0.0000048236943,0.00016182315,0.000029459768,0.000106390675],"category_scores_gemma":[0.000093683484,0.00009622861,0.000059018672,0.00040893114,0.00006675019,0.0003017228,0.000035386587,0.00015543053,0.000007215141],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040389303,0.00019634182,0.7350296,0.00044961067,0.000009588002,3.9322438e-7,0.0014350739,0.00035809612,0.000035758272,0.25945702,0.0008096562,0.0021784874],"study_design_scores_gemma":[0.0006137347,0.000047995698,0.91074747,0.00006259394,0.0000022321065,0.0000025512481,0.000015670837,0.0035653934,0.00022900858,0.036478527,0.048095293,0.00013955608],"about_ca_topic_score_codex":0.0036509924,"about_ca_topic_score_gemma":0.00074567884,"teacher_disagreement_score":0.22297849,"about_ca_system_score_codex":0.00017831639,"about_ca_system_score_gemma":0.00007127739,"threshold_uncertainty_score":0.5519233},"labels":[],"label_agreement":null},{"id":"W142923118","doi":"10.25071/1929-8404.37158","title":"Catastrophic Drug Coverage in Canada","year":2013,"lang":"en","type":"article","venue":"Healthy Dialogue","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Government (linguistics); Drug; Commission; Medicine; Prescription drug; Environmental health; Business; Pharmacology; Finance","score_opus":0.03444523553367898,"score_gpt":0.2421871737346611,"score_spread":0.2077419382009821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W142923118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96519655,0.0009635733,0.000030959673,0.01508019,0.00063366967,0.00032411385,0.0005149812,0.000012632525,0.017243328],"genre_scores_gemma":[0.98095465,0.0005240919,0.000033925007,0.018104784,0.00014243842,0.000063508254,0.000049697912,0.000017359787,0.00010956344],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985834,0.000018157276,0.0005893247,0.00028148107,0.000019391367,0.000508286],"domain_scores_gemma":[0.99927706,0.00007225477,0.0001408182,0.00023141022,0.00000966898,0.00026879305],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00020569957,0.00011976887,0.00032939386,0.00011736312,0.000050657767,0.00003520465,0.00018482229,0.00004021004,0.0011018666],"category_scores_gemma":[0.000042176216,0.00014809585,0.000037614933,0.00013899746,0.000021024649,0.0001476736,0.000042689713,0.00022285385,0.002034137],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036595953,0.00017016727,0.585427,0.00014189658,0.000031230702,0.000027385218,0.00050117675,0.00090658956,0.000009359802,0.2552968,0.15152016,0.0059316675],"study_design_scores_gemma":[0.0018839525,0.000047004898,0.5391718,0.000013347857,0.00000173113,0.0000061621595,0.000046605423,0.006226047,0.000027538572,0.08963888,0.36233097,0.0006059599],"about_ca_topic_score_codex":0.9808926,"about_ca_topic_score_gemma":0.91372025,"teacher_disagreement_score":0.21081081,"about_ca_system_score_codex":0.000821456,"about_ca_system_score_gemma":0.0004810506,"threshold_uncertainty_score":0.99981123},"labels":[],"label_agreement":null},{"id":"W1479833118","doi":"10.3386/w19247","title":"Physician Agency and Competition: Evidence from a Major Change to Medicare Chemotherapy Reimbursement Policy","year":2013,"lang":"en","type":"article","venue":"National Bureau of Economic Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"National Cancer Institute; Robert Wood Johnson Foundation","keywords":"Reimbursement; Agency (philosophy); Competition (biology); Profit margin; Chemotherapy; Business; Health care; Medicine; Family medicine; Finance; Economics; Internal medicine; Economic growth","score_opus":0.42314513704236006,"score_gpt":0.4974304854129782,"score_spread":0.07428534837061812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1479833118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.669533,0.00343492,0.00007947093,0.15486495,0.0003609946,0.0018135314,0.00070601265,0.00003035415,0.16917673],"genre_scores_gemma":[0.9915954,0.0012568469,0.0003964022,0.00489518,0.0011430631,0.00031460702,0.00004581739,0.000023403743,0.00032929247],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99836224,0.000040725434,0.00059506315,0.00048999145,0.00011657037,0.00039540525],"domain_scores_gemma":[0.99870986,0.00040736725,0.000168211,0.0002626168,0.00016023828,0.00029172277],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010488423,0.00014401208,0.00036241693,0.00058659643,0.00011381339,0.000102159196,0.00040345377,0.00009586756,0.0028730007],"category_scores_gemma":[0.0002675813,0.00016978306,0.000080129714,0.00021928012,0.00017331669,0.00043584584,0.00016865623,0.0002124792,0.0022720043],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022865323,0.0000679926,0.0038605891,0.00002822104,0.0000846625,4.2049328e-7,0.00080105785,0.000016135114,0.00035893128,0.9797945,0.0074752807,0.00748935],"study_design_scores_gemma":[0.00065388624,0.00011072947,0.039982066,0.000065425935,0.0000020342818,6.952759e-7,0.00005532375,0.0022713477,0.0003999613,0.937414,0.018829899,0.00021464995],"about_ca_topic_score_codex":0.009199745,"about_ca_topic_score_gemma":0.00008509108,"teacher_disagreement_score":0.32206237,"about_ca_system_score_codex":0.00055525533,"about_ca_system_score_gemma":0.00013969495,"threshold_uncertainty_score":0.9985048},"labels":[],"label_agreement":null},{"id":"W1484626618","doi":"10.1002/hec.3075","title":"Price‐cap Regulation, Uncertainty and the Price Evolution of New Pharmaceuticals","year":2014,"lang":"en","type":"article","venue":"Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"Canadian Institutes of Health Research; European Commission","keywords":"Economics; Monetary economics; Econometrics","score_opus":0.06528709711794856,"score_gpt":0.31855257200655196,"score_spread":0.2532654748886034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1484626618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.54354215,0.029705472,0.043071676,0.24067292,0.0026294792,0.0033166201,0.0005272384,0.00017468623,0.13635978],"genre_scores_gemma":[0.9855435,0.004043399,0.0005997009,0.00865998,0.0004221492,0.000019951733,0.000011403713,0.00003044528,0.0006694577],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978531,0.000064731474,0.0012239864,0.00039715995,0.00001939177,0.00044160814],"domain_scores_gemma":[0.99802387,0.00033444606,0.00086000597,0.00039793245,0.00002709398,0.00035667047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002316823,0.00017917895,0.00065791357,0.00014550796,0.0001739428,0.000055138218,0.0002507039,0.000099883,0.000265468],"category_scores_gemma":[0.00021546004,0.00017462064,0.00011329979,0.00013414546,0.00023745553,0.00019220142,0.00009196268,0.00019593422,0.00016930395],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000086001455,0.000027001945,0.0023991775,0.0000746436,0.000036771053,1.6799708e-8,0.00036646612,0.0013691547,0.0000014980382,0.98745817,0.004137866,0.004043231],"study_design_scores_gemma":[0.0024663778,0.000045498764,0.009578144,0.000009674642,0.000006336829,0.0000039250785,0.000022738452,0.15973635,0.000015306257,0.31841633,0.5095214,0.00017789507],"about_ca_topic_score_codex":0.0009211724,"about_ca_topic_score_gemma":0.00005333923,"teacher_disagreement_score":0.6690418,"about_ca_system_score_codex":0.00033870843,"about_ca_system_score_gemma":0.00019864083,"threshold_uncertainty_score":0.71208227},"labels":[],"label_agreement":null},{"id":"W1486715292","doi":"","title":"Loophole closure outrages generic drug companies","year":2000,"lang":"en","type":"article","venue":"Europe PMC (PubMed Central)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Champion; Closure (psychology); Medicine; Computer science; Operations research; Medical emergency; History; Law; Engineering; Political science; Archaeology","score_opus":0.03978401165739506,"score_gpt":0.23134642111648057,"score_spread":0.1915624094590855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1486715292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8276801,0.0044207363,0.00002747742,0.0032790687,0.00078022125,0.00027244442,0.00031302037,0.00011223782,0.1631147],"genre_scores_gemma":[0.97449386,0.004931762,0.00014397879,0.0036680598,0.00067759346,0.000036399666,0.000028094264,0.000070149494,0.01595009],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99753684,0.000038982856,0.00066627644,0.00055857847,0.000041810945,0.0011575351],"domain_scores_gemma":[0.9988455,0.00003736257,0.00016438456,0.00045355514,0.000017521164,0.00048167413],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00038307434,0.0002719052,0.0004582668,0.00011966656,0.0001293472,0.00018014235,0.00049071177,0.000068913585,0.004355143],"category_scores_gemma":[0.000046483925,0.00030817548,0.00016990284,0.0003211684,0.00010861619,0.0002375288,0.00006387508,0.00028735845,0.005745569],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034088877,0.0014635981,0.3232159,0.00024468466,0.00077176536,0.00020155821,0.014560345,0.006605589,0.00012918563,0.23572193,0.30087054,0.11587401],"study_design_scores_gemma":[0.00065401924,0.000014009746,0.120321155,0.0000049866744,0.00000914744,0.000008176803,0.000012132799,0.000601225,0.0003243022,0.0027638557,0.87490994,0.0003770496],"about_ca_topic_score_codex":0.000089313246,"about_ca_topic_score_gemma":0.0000121063595,"teacher_disagreement_score":0.5740394,"about_ca_system_score_codex":0.00010695711,"about_ca_system_score_gemma":0.00002784601,"threshold_uncertainty_score":0.99993706},"labels":[],"label_agreement":null},{"id":"W1490652015","doi":"10.1111/j.1365-2966.2007.00417.x","title":"Market structure and communicable diseases","year":2007,"lang":"en","type":"article","venue":"Canadian Journal of Economics/Revue canadienne d économique","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Monopoly; Externality; Competition (biology); Planner; Social planner; Economics; Communicable disease; Public economics; Microeconomics; Welfare; Market structure; Public health; Industrial organization; Medicine; Computer science; Market economy; Biology","score_opus":0.13311413747276057,"score_gpt":0.21288657263101296,"score_spread":0.07977243515825239,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1490652015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97846854,0.0033057332,0.00007031508,0.0028983648,0.0011492396,0.00016667623,0.0013635294,0.0000065737036,0.012571018],"genre_scores_gemma":[0.994974,0.0005716345,0.0005248019,0.0027050152,0.0006268619,0.0000023638572,0.000014876783,0.000057573783,0.00052285154],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99731886,0.00002306458,0.0013610872,0.0003590265,0.0000011795586,0.0009367534],"domain_scores_gemma":[0.99562854,0.0002261158,0.00084818254,0.0004676299,0.000069523114,0.0027600345],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011113725,0.00029468111,0.0008717598,0.0008920593,0.00022200716,0.00020312314,0.0006479258,0.00021840639,0.0016186335],"category_scores_gemma":[0.00024663715,0.00038964816,0.000207424,0.00012528751,0.00028184266,0.00052044756,0.000050631086,0.00046723965,0.000035504287],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007162781,0.000013451671,0.071808204,0.000038830276,0.00017555771,0.00007327888,0.00048549118,0.00025130442,0.000004314996,0.92179877,0.0033515352,0.0019276447],"study_design_scores_gemma":[0.0009977559,0.00016396685,0.020210968,0.000029468927,0.000027798107,0.00040448795,0.00015392966,0.0016422059,0.000051648763,0.6768668,0.29889607,0.0005548619],"about_ca_topic_score_codex":0.045686882,"about_ca_topic_score_gemma":0.80125165,"teacher_disagreement_score":0.75556475,"about_ca_system_score_codex":0.0011205141,"about_ca_system_score_gemma":0.000517716,"threshold_uncertainty_score":0.9998555},"labels":[],"label_agreement":null},{"id":"W1492226602","doi":"10.1016/s0277-9536(02)00462-8","title":"Public and private sector responses to essential drugs policies:","year":2003,"lang":"en","type":"article","venue":"Social Science & Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Private sector; Public sector; Business; Medical prescription; Public economics; Essential drugs; Medicine; Economics; Economic growth; Pharmacology; Environmental health; Health services; Population","score_opus":0.08369354771743316,"score_gpt":0.34139876110673884,"score_spread":0.2577052133893057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1492226602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85885304,0.00027921094,0.0001548521,0.029522303,0.0004971859,0.00015218064,0.000031490967,0.000025164978,0.11048456],"genre_scores_gemma":[0.9891874,0.00008378715,0.000040519157,0.009773983,0.00045020581,0.000010602831,9.0168885e-7,0.000010888035,0.00044171224],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985951,0.000023118484,0.00036492827,0.00039517213,0.00007546997,0.0005461884],"domain_scores_gemma":[0.9992052,0.0000664093,0.00012216443,0.00015302988,0.000036821744,0.00041637613],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018054795,0.00012199415,0.00029943473,0.00037741038,0.0004403559,0.00010838808,0.00030149746,0.00005211566,0.0006318753],"category_scores_gemma":[0.0009008586,0.000121924335,0.0000353343,0.00086530217,0.0009670036,0.0002563765,0.00006973207,0.00011744548,0.0001280977],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010311918,0.00002061011,0.011356558,0.0000062925556,0.000007957318,7.2487114e-7,0.007142505,2.2553982e-7,0.0009289832,0.9776167,0.0018369241,0.0010721564],"study_design_scores_gemma":[0.0009296618,0.0001295221,0.025243226,0.000011855492,0.0000081533335,0.000006042919,0.0005609522,0.000102930724,0.0007928747,0.12360059,0.84820145,0.00041276356],"about_ca_topic_score_codex":0.00017565838,"about_ca_topic_score_gemma":0.000007785237,"teacher_disagreement_score":0.8540162,"about_ca_system_score_codex":0.00014543007,"about_ca_system_score_gemma":0.00010131535,"threshold_uncertainty_score":0.6918591},"labels":[],"label_agreement":null},{"id":"W1493856646","doi":"10.1002/dta.1326","title":"Regulatory aspects of workplace drug testing in Europe","year":2012,"lang":"en","type":"article","venue":"Drug Testing and Analysis","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nutrasource","funders":"","keywords":"Legislation; Drug; European union; Occupational safety and health; Business; Political science; Risk analysis (engineering); Medicine; Law; Pharmacology; Economic policy","score_opus":0.060245089088305115,"score_gpt":0.2702190533312976,"score_spread":0.20997396424299247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1493856646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.919049,0.0024069825,0.00003753988,0.0002990968,0.0000585555,0.000046915095,0.000031354324,0.000026826321,0.078043714],"genre_scores_gemma":[0.9974576,0.00004980454,0.0017417403,0.00023504793,0.00011346383,0.0000035199355,0.0000046720806,0.000016728245,0.00037740148],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99868906,0.000029879893,0.00061326055,0.0002767814,0.00002647163,0.0003645241],"domain_scores_gemma":[0.9986669,0.00055307895,0.00035198813,0.00022804968,0.00004046716,0.0001595092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012235546,0.00013822714,0.0005004824,0.0005127471,0.00006908576,0.000036842677,0.000134694,0.000036606998,0.00005089986],"category_scores_gemma":[0.0012671377,0.00016005698,0.000078129924,0.002131822,0.00006360891,0.0001682622,0.00008453757,0.00016227791,0.00004539004],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000023913433,0.000060955193,0.9763625,0.00002827935,0.00010264942,0.0000011937457,0.00036348432,0.00086466584,0.00004724879,0.02024979,0.000113995244,0.0018027911],"study_design_scores_gemma":[0.00050358864,0.000011683068,0.8886213,0.000055449244,0.00016107447,0.0000037751693,0.00008337679,0.096022725,0.0002448012,0.010382918,0.0034470237,0.00046232538],"about_ca_topic_score_codex":0.0007431784,"about_ca_topic_score_gemma":0.000039325194,"teacher_disagreement_score":0.09515806,"about_ca_system_score_codex":0.000038250557,"about_ca_system_score_gemma":0.000018105127,"threshold_uncertainty_score":0.6526934},"labels":[],"label_agreement":null},{"id":"W1494421313","doi":"10.1111/j.1758-5899.2011.00110.x","title":"Promising Trends in Access to Medicines","year":2012,"lang":"en","type":"article","venue":"Global Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Developing country; Business; Context (archaeology); Language change; Access to medicines; Intellectual property; Principal (computer security); Market access; Economic growth; Economics; Political science; Computer security","score_opus":0.11607057374730569,"score_gpt":0.3984328689915157,"score_spread":0.28236229524421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1494421313","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4090589,0.00091555074,0.00007954278,0.06471405,0.0005909895,0.00016216663,0.0002782781,0.000043152857,0.52415735],"genre_scores_gemma":[0.97462285,0.000042680025,0.00011220454,0.023762887,0.0011869593,0.000017310966,0.0000075649787,0.00001234914,0.00023519958],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.998616,0.000009357392,0.0004499894,0.00023058032,0.00002195761,0.0006721287],"domain_scores_gemma":[0.9992587,0.000013996367,0.0000967109,0.00021601004,0.000007246527,0.00040732263],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00034061176,0.0001412091,0.000312999,0.0004496807,0.000037838,0.000077901044,0.00033102377,0.0000736838,0.00041781398],"category_scores_gemma":[0.0001397765,0.00015981066,0.00006836397,0.0009483692,0.000032646833,0.00041616664,0.00016054351,0.00009101443,0.0010942506],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022082575,0.0001270457,0.35744253,0.000013734575,0.00002065856,0.0000014787821,0.00036916736,0.000060713875,0.000008787319,0.56134546,0.052777417,0.027810901],"study_design_scores_gemma":[0.0005464094,0.00002105317,0.5068922,0.000009217776,0.000002314239,0.00000651827,0.000009488068,0.00022728725,0.0000307223,0.03964215,0.45236114,0.0002514898],"about_ca_topic_score_codex":0.0021978137,"about_ca_topic_score_gemma":0.00015307358,"teacher_disagreement_score":0.5655639,"about_ca_system_score_codex":0.0003895652,"about_ca_system_score_gemma":0.000024328581,"threshold_uncertainty_score":0.9996835},"labels":[],"label_agreement":null},{"id":"W1497115428","doi":"10.1016/j.aogh.2015.02.004","title":"Assessing 15 Proposals for Promoting Innovation and Access to Medicines Globally","year":2015,"lang":"en","type":"review","venue":"Annals of Global Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Ottawa","funders":"","keywords":"Panacea (medicine); General partnership; Transferability; Business; Product (mathematics); Politics; Access to medicines; Intellectual property; Public relations; Essential medicines; Public economics; Political science; Developing country; Economic growth; Economics; Medicine; Finance; Health care; Alternative medicine","score_opus":0.464331985099038,"score_gpt":0.5653241806127831,"score_spread":0.10099219551374511,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1497115428","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001646347,0.97229916,0.0003859282,0.019262467,0.0003886476,0.0019141006,0.0018286861,0.000022813498,0.003733537],"genre_scores_gemma":[0.00046600125,0.98500586,0.0007983058,0.0130840195,0.000396757,0.000085292995,0.00011741179,0.000032578653,0.000013802393],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968112,0.000041613002,0.0020349075,0.0005283894,0.000057042744,0.000526847],"domain_scores_gemma":[0.9973028,0.00007455467,0.0017761328,0.00024857334,0.00025175014,0.00034623104],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0033234395,0.0003028155,0.0021875561,0.00024131882,0.00009045093,0.00024186619,0.00044309773,0.0001913604,0.000010102463],"category_scores_gemma":[0.00057804177,0.000302111,0.00014417397,0.0008858688,0.00005332844,0.00041739095,0.00020726668,0.00013451643,0.000023980245],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000067081996,0.000044419583,0.00013177244,0.011624266,0.00006454883,2.926995e-7,0.00002952956,6.656463e-7,7.4489406e-9,0.11455363,0.03808374,0.8354604],"study_design_scores_gemma":[0.0001811982,0.00018536244,0.000094263254,0.0024598106,0.000016630234,0.00000645728,0.0000056306594,0.00008570918,2.5324204e-7,0.053399928,0.94333184,0.00023294678],"about_ca_topic_score_codex":0.00018541714,"about_ca_topic_score_gemma":0.000032992582,"teacher_disagreement_score":0.90524805,"about_ca_system_score_codex":0.00027223316,"about_ca_system_score_gemma":0.0009929398,"threshold_uncertainty_score":0.9999431},"labels":[],"label_agreement":null},{"id":"W1498710310","doi":"10.1186/1472-6963-5-21","title":"International variation in prescribing antihypertensive drugs: Its extent and possible explanations","year":2005,"lang":"en","type":"article","venue":"BMC Health Services Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Health informatics; Nursing research; Health administration; Variation (astronomy); Public health; Quality of Life Research; Nursing","score_opus":0.14787201953803972,"score_gpt":0.4117310898434494,"score_spread":0.26385907030540967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1498710310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9344391,0.0055660554,0.000229767,0.020310124,0.000327648,0.0007502601,0.00025654907,0.000031479445,0.038089003],"genre_scores_gemma":[0.99156564,0.0037889513,0.0007718812,0.0032196788,0.00027814525,0.00004893328,0.000024137318,0.000014213419,0.00028843866],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9984944,0.00006351897,0.0005571274,0.00035715522,0.00007624127,0.00045159436],"domain_scores_gemma":[0.999269,0.00015773305,0.00012808558,0.00015730278,0.00009383804,0.00019400431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016912008,0.000085262254,0.00020926938,0.0006219585,0.00016962216,0.00014721682,0.00024546296,0.000064429434,0.00027651008],"category_scores_gemma":[0.00004310864,0.00010155163,0.000026004027,0.00028401418,0.00002364607,0.00047297688,0.00013995393,0.00025225346,0.00051200954],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023577125,0.0009843747,0.23989229,0.0015404454,0.0001175788,0.000006340283,0.04851657,0.003865071,0.0002767589,0.6695685,0.001529526,0.033466775],"study_design_scores_gemma":[0.0014044823,0.000046340876,0.3185586,0.00009814312,9.577884e-7,0.000004692386,0.0009895669,0.52398825,0.00004576533,0.0071229544,0.14752436,0.00021590982],"about_ca_topic_score_codex":0.0011830414,"about_ca_topic_score_gemma":0.0005435516,"teacher_disagreement_score":0.66244555,"about_ca_system_score_codex":0.0003157702,"about_ca_system_score_gemma":0.000096211515,"threshold_uncertainty_score":0.6581018},"labels":[],"label_agreement":null},{"id":"W1500858166","doi":"10.71781/1833","title":"Encadrement normatif visant l'utilisation de la marijuana à des fins médicales en Occident","year":2006,"lang":"fr","type":"dissertation","venue":"Open MIND","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Humanities; Political science; Art","score_opus":0.06149798826525806,"score_gpt":0.34680005933611036,"score_spread":0.2853020710708523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1500858166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77571696,0.0024894078,0.0007074516,0.00087383454,0.0007346883,0.0007436289,0.0009792481,0.0000031057823,0.21775168],"genre_scores_gemma":[0.95584637,0.004284805,0.008528531,0.0006573133,0.0005177346,0.00014022176,0.0023921516,0.0000960006,0.027536849],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967729,0.00017801071,0.0015258517,0.00073903624,0.00007333684,0.0007108806],"domain_scores_gemma":[0.9979706,0.00039589053,0.0008960959,0.00041108977,0.000045754936,0.00028059658],"candidate_categories":["metaepi_narrow","scholarly_communication","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0019408525,0.00046983655,0.0008083309,0.00032663872,0.00035541042,0.001059207,0.0009951212,0.00061978534,0.013278611],"category_scores_gemma":[0.00020611548,0.0006279249,0.0002780282,0.00019814572,0.000251079,0.00058563385,0.00024809933,0.0005739735,0.0039068265],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000305577,0.0020477644,0.18189333,0.0006335211,0.0008247197,0.00006812767,0.024837999,0.003018342,0.00057289423,0.058077548,0.013929209,0.71379095],"study_design_scores_gemma":[0.0012422068,0.000102073805,0.25276425,0.00025946516,0.00012404862,0.000014684843,0.000924463,0.023560297,0.0037278393,0.0126007525,0.7037054,0.00097453035],"about_ca_topic_score_codex":0.006506902,"about_ca_topic_score_gemma":0.0029742278,"teacher_disagreement_score":0.7128164,"about_ca_system_score_codex":0.0011316034,"about_ca_system_score_gemma":0.00031234688,"threshold_uncertainty_score":0.99997777},"labels":[],"label_agreement":null},{"id":"W1504134900","doi":"10.2202/1935-1682.2665","title":"Pecuniary and Non-Pecuniary Incentives in Prescription Pharmaceuticals: The Case of Statins","year":2011,"lang":"en","type":"article","venue":"The B E Journal of Economic Analysis & Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"","keywords":"Indemnity; Incentive; Actuarial science; Business; Medical prescription; Order (exchange); Affect (linguistics); Managed care; Value (mathematics); Prescription drug; Health care; Health insurance; Differential (mechanical device); Public economics; Economics; Microeconomics; Finance; Medicine; Pharmacology","score_opus":0.07780076434958608,"score_gpt":0.3308751229542903,"score_spread":0.2530743586047042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1504134900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857778,0.0020627868,0.00036965974,0.0020817504,0.00009737888,0.00014466654,0.00011821757,0.0000027543374,0.009344988],"genre_scores_gemma":[0.99426043,0.0045231506,0.00012958203,0.0008009827,0.00018884282,0.00000354242,0.0000015776444,0.000016147904,0.00007571711],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99786586,0.00013590587,0.0014880094,0.00018321931,0.000021917567,0.00030506894],"domain_scores_gemma":[0.9978768,0.000278367,0.0013090972,0.00034776822,0.00003396686,0.00015395255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002415508,0.00017932459,0.000709944,0.00093570945,0.00010106913,0.000037864473,0.00048730354,0.00006659704,0.00039834942],"category_scores_gemma":[0.000095202064,0.00013387199,0.0002948356,0.00042561008,0.000339632,0.00037026778,0.00013880027,0.0003446455,0.000037181708],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009942681,0.0008306267,0.24156727,0.00010830193,0.007893775,0.00016377094,0.042910893,0.0058724848,0.00031033065,0.68712634,0.0015463519,0.0106756],"study_design_scores_gemma":[0.0056969537,0.0005184144,0.3889004,0.000065750544,0.0026459466,0.0011297952,0.007678191,0.23106755,0.0015431204,0.34728673,0.0122692725,0.0011978725],"about_ca_topic_score_codex":0.005997056,"about_ca_topic_score_gemma":0.00071098324,"teacher_disagreement_score":0.3398396,"about_ca_system_score_codex":0.00017747832,"about_ca_system_score_gemma":0.000101523365,"threshold_uncertainty_score":0.9065795},"labels":[],"label_agreement":null},{"id":"W1517734398","doi":"10.31235/osf.io/5w8xs_v1","title":"Pharmaceutical Lemons: Innovation and Regulation in the Drug Industry","year":2016,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Pharmaceutical industry; Business; Drug; Drug industry; Industrial organization; Pharmacology; Medicine; Engineering; Biochemical engineering","score_opus":0.10152226655298108,"score_gpt":0.32529602586044093,"score_spread":0.22377375930745985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1517734398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85750043,0.00021371282,0.0007949956,0.060438585,0.0001127199,0.00017188473,0.0000286836,0.000017024895,0.08072193],"genre_scores_gemma":[0.9920948,0.00012234556,0.00006878576,0.0064473087,0.0000981344,0.000014657374,0.0000020548703,0.000006792732,0.001145126],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992136,0.000017209632,0.00039315605,0.0001888668,0.000015639753,0.00017154556],"domain_scores_gemma":[0.9996198,0.00011850103,0.00008415937,0.00013359258,0.000009869535,0.000034072233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081681286,0.00007349516,0.00011928601,0.00018197758,0.0000397602,0.00004337131,0.00011138104,0.00009099847,0.0006581655],"category_scores_gemma":[0.00008896511,0.00004970024,0.00001716637,0.00026980124,0.00006495681,0.00022919412,0.00003318871,0.00016926654,0.00020248984],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000065663635,0.000022567416,0.043045305,0.0000033492718,0.0000045038005,3.7832422e-7,0.000090729525,0.0000013048548,0.000077431025,0.9435844,0.0032734682,0.0098900385],"study_design_scores_gemma":[0.0013124528,0.000014037604,0.11379329,0.00001193119,0.000002506279,0.0000071548498,0.00004991134,0.0032815223,0.0005138252,0.42556024,0.4552377,0.00021545905],"about_ca_topic_score_codex":0.000041679057,"about_ca_topic_score_gemma":0.000013348309,"teacher_disagreement_score":0.51802415,"about_ca_system_score_codex":0.000038210408,"about_ca_system_score_gemma":0.000010422658,"threshold_uncertainty_score":0.72064507},"labels":[],"label_agreement":null},{"id":"W1529002352","doi":"10.18433/j3001b","title":"Generic Drug Product Development Bioequivalence Issues","year":2008,"lang":"en","type":"article","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Bioequivalence; Drug development; Drug; New product development; Generic drug; Product (mathematics); Pharmacology; Computer science; Risk analysis (engineering); Medicine; Business; Pharmacokinetics; Mathematics; Marketing","score_opus":0.2384531563392742,"score_gpt":0.3924089915411238,"score_spread":0.1539558352018496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1529002352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9251303,0.0429606,0.00033464248,0.017011672,0.0018869361,0.00023415731,0.00002533269,0.000040813877,0.012375531],"genre_scores_gemma":[0.9779289,0.012070906,0.004497053,0.003835898,0.0010237165,0.000006968188,8.675537e-7,0.000021736034,0.0006139777],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99688345,0.000062807914,0.001581259,0.000492976,0.00022929581,0.00075022],"domain_scores_gemma":[0.9982383,0.00011907074,0.00075121905,0.00016841532,0.00011347622,0.00060948957],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0024075117,0.00028542714,0.0006104823,0.00043608216,0.00050804036,0.00011284083,0.0011108173,0.000033004544,0.0018080666],"category_scores_gemma":[0.00017789379,0.0002590476,0.00024132873,0.00071652676,0.00081019965,0.00094598177,0.00017963267,0.00048084708,0.00071520807],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007090405,0.0035382758,0.5133565,0.0004606584,0.0009792483,0.0007497131,0.0090641165,0.0022674354,0.027014373,0.09828308,0.15519924,0.18837829],"study_design_scores_gemma":[0.0011142732,0.000052560503,0.0024295044,0.0000148945555,0.000017318464,0.00031851217,0.000027286605,0.0035833388,0.043460686,0.001931478,0.9466713,0.00037886068],"about_ca_topic_score_codex":0.000038450424,"about_ca_topic_score_gemma":0.0000014605741,"teacher_disagreement_score":0.791472,"about_ca_system_score_codex":0.00017017625,"about_ca_system_score_gemma":0.0003226133,"threshold_uncertainty_score":0.9999862},"labels":[],"label_agreement":null},{"id":"W1531634388","doi":"10.1017/cbo9781107238985.012","title":"India's Pharmaceutical Industry: Policy Space That Fosters Technological Capability","year":2014,"lang":"en","type":"book-chapter","venue":"Cambridge University Press eBooks","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Space (punctuation); Business; Pharmaceutical industry; Industrial organization; Content (measure theory); Marketing; Knowledge management; Computer science; Mathematics; Biotechnology","score_opus":0.07733723758424157,"score_gpt":0.256644806748543,"score_spread":0.17930756916430143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1531634388","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013898712,0.0002884147,0.0003884038,0.0017032229,0.0003076854,0.0005974401,0.0018184488,0.0002245467,0.99328196],"genre_scores_gemma":[0.13934621,0.00045222678,0.00007756249,0.0019354487,0.0004577341,0.0000039402153,0.000056925284,0.00010281089,0.85756713],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973307,0.00004249191,0.00056185684,0.0011729592,0.00008847752,0.000803476],"domain_scores_gemma":[0.99756765,0.00016401688,0.00060551864,0.0009715133,0.000048118916,0.00064317026],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.000514309,0.00066381536,0.0011386825,0.00065782666,0.0002249896,0.000116021125,0.0010963199,0.0020591847,0.000106614476],"category_scores_gemma":[0.0000951924,0.00086655427,0.0004863593,0.000034742658,0.001106884,0.000114343326,0.00092767406,0.0024366393,0.00037584847],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006643272,0.000024182684,0.00018817166,0.00008053625,0.00019073377,0.00005317368,0.00002040571,0.0000028564157,0.0000046303458,0.9833916,0.014243408,0.0017338891],"study_design_scores_gemma":[0.0010056128,0.000043778397,0.000159861,0.00004335399,0.000068911,0.000019004054,0.000010889597,0.00026648754,0.00019674726,0.0022252498,0.9950733,0.0008867997],"about_ca_topic_score_codex":0.00023643888,"about_ca_topic_score_gemma":0.0000015886529,"teacher_disagreement_score":0.9811663,"about_ca_system_score_codex":0.0009338817,"about_ca_system_score_gemma":0.0001406372,"threshold_uncertainty_score":0.99986476},"labels":[],"label_agreement":null},{"id":"W1535329335","doi":"","title":"International Experience With Pharmaceutical Policy: Common Challenges and Lessons for Canada","year":2001,"lang":"en","type":"preprint","venue":"RePEc: Research Papers in Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmaceutical policy; Scrutiny; Government (linguistics); Pharmaceutical industry; Business; Health care; Investment (military); Public economics; Access to medicines; Health policy; Economic growth; Economic policy; Political science; Developing country; Economics; Medicine","score_opus":0.16579989514939428,"score_gpt":0.4106165206196218,"score_spread":0.2448166254702275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1535329335","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.27529982,0.005576179,0.000030109435,0.08059099,0.001347712,0.0018636694,0.0025475284,0.00005297527,0.632691],"genre_scores_gemma":[0.8695351,0.12705527,0.00029340212,0.001082029,0.00060528313,0.00053658476,0.00006708265,0.00007739332,0.00074784347],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99683833,0.000048539572,0.0008681678,0.0011915012,0.00007562599,0.0009778348],"domain_scores_gemma":[0.99809796,0.0005127696,0.00029096723,0.00060311076,0.00006213757,0.0004330294],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010351321,0.00037221162,0.00081398705,0.0005772852,0.0001506956,0.00018301175,0.0008587656,0.00031409855,0.00010496881],"category_scores_gemma":[0.0002615903,0.0004424865,0.000104947365,0.000082569655,0.00038698612,0.00013901891,0.0008582039,0.0011449226,0.0000052767805],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005051022,0.00033829737,0.014747979,0.00040691756,0.00047821767,0.00005636746,0.0017634046,0.002780607,0.000008712237,0.52678037,0.0004600351,0.451674],"study_design_scores_gemma":[0.0014703249,0.00007078335,0.007592967,0.00008556159,0.0000055664646,0.000027542568,0.00041249456,0.03659053,0.000037867336,0.027092144,0.9259369,0.0006773501],"about_ca_topic_score_codex":0.031647403,"about_ca_topic_score_gemma":0.11727058,"teacher_disagreement_score":0.92547685,"about_ca_system_score_codex":0.0017629148,"about_ca_system_score_gemma":0.0007988151,"threshold_uncertainty_score":0.9998027},"labels":[],"label_agreement":null},{"id":"W1541980932","doi":"","title":"Drug price index sees first increase in 5 years","year":2000,"lang":"en","type":"article","venue":"Europe PMC (PubMed Central)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Index (typography); Price index; Producer price index; Consumer price index (South Africa); Agricultural economics; Medicine; Economics; Computer science; Monetary economics; Price level; Econometrics; Mid price; World Wide Web","score_opus":0.023213357532807847,"score_gpt":0.22149733307872724,"score_spread":0.1982839755459194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1541980932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85931134,0.0010774158,0.0000065079116,0.0020205611,0.00029108915,0.00027872573,0.00012431941,0.000048825274,0.13684124],"genre_scores_gemma":[0.98970693,0.0028123402,0.000047754766,0.0023747482,0.00027865285,0.00004221646,0.000012121793,0.00004830777,0.0046769297],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99778795,0.00003343779,0.00062331103,0.00048456935,0.00003612383,0.0010345805],"domain_scores_gemma":[0.9989953,0.00005867674,0.00013079854,0.00035536473,0.000008736815,0.0004511327],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00053615344,0.00019736383,0.00034780233,0.0001982153,0.00005625912,0.00011177534,0.00040829965,0.00006857595,0.003574637],"category_scores_gemma":[0.000120607496,0.0002487953,0.00011340709,0.00044133418,0.00006548393,0.0002650678,0.00007298343,0.00030421745,0.0031646101],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002222302,0.00065560464,0.889292,0.00007389339,0.00012305599,0.0001761758,0.0065907664,0.0017240157,0.000004037591,0.047108173,0.022943676,0.031086342],"study_design_scores_gemma":[0.0006244286,0.000005424717,0.42473826,0.0000064506826,0.0000022215152,0.0000032030287,0.0000051303614,0.00069743773,0.0000118152775,0.0015277142,0.57217085,0.0002070505],"about_ca_topic_score_codex":0.0006833377,"about_ca_topic_score_gemma":0.00014674966,"teacher_disagreement_score":0.5492272,"about_ca_system_score_codex":0.0002014829,"about_ca_system_score_gemma":0.000035186527,"threshold_uncertainty_score":0.9999964},"labels":[],"label_agreement":null},{"id":"W1545748427","doi":"","title":"The impact of reference pricing system on brand name’s prices : the case of Tunisia","year":2010,"lang":"en","type":"preprint","venue":"RePEc: Research Papers in Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Competition (biology); Quarter (Canadian coin); Order (exchange); Brand names; Reference price; Business; Economics; Marketing; Advertising; Microeconomics; Finance","score_opus":0.09301644793570664,"score_gpt":0.37873120150350936,"score_spread":0.28571475356780274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1545748427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83090836,0.0007356065,0.0000028474963,0.00041502135,0.00037684664,0.00080999464,0.0006668828,0.000012972026,0.16607149],"genre_scores_gemma":[0.9910287,0.008300814,0.000055682038,0.000035671885,0.00017444533,0.00011107823,0.000013213176,0.000057907575,0.00022244311],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99635524,0.00016335987,0.0018033156,0.00079535285,0.00006384777,0.0008188771],"domain_scores_gemma":[0.9943872,0.0021087695,0.0013412078,0.0018412189,0.000116334064,0.00020525417],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0053469525,0.00037819293,0.0010536024,0.00050556514,0.0003363981,0.00021363184,0.0015458777,0.00051274564,0.000084478896],"category_scores_gemma":[0.0006411801,0.0002782875,0.0004512732,0.0001844323,0.0007224813,0.000095147334,0.0009554752,0.0027500712,0.00003103196],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009410744,0.00065405946,0.017556103,0.0016954117,0.0015062351,0.00015948848,0.0029095837,0.043659948,0.00019957924,0.7589091,0.000327242,0.17148218],"study_design_scores_gemma":[0.0063452404,0.0019401431,0.07469255,0.0020204543,0.00009501436,0.0007044297,0.0049682246,0.6958523,0.0016212525,0.13051045,0.07762597,0.003623997],"about_ca_topic_score_codex":0.0031170913,"about_ca_topic_score_gemma":0.0007092503,"teacher_disagreement_score":0.65219235,"about_ca_system_score_codex":0.0008989618,"about_ca_system_score_gemma":0.00046582986,"threshold_uncertainty_score":0.9999669},"labels":[],"label_agreement":null},{"id":"W1550526788","doi":"10.5912/jcb711","title":"The Globetrotting Regulator","year":2015,"lang":"en","type":"article","venue":"Journal of Commercial Biotechnology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Fraternity; Government (linguistics); Battle; China; Health care; Politics; Political science; Economic growth; Public administration; Law; Economics; History; Ancient history","score_opus":0.08344887446268374,"score_gpt":0.2980808370679797,"score_spread":0.214631962605296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1550526788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.69043875,0.011666467,0.0022827792,0.2583031,0.0037924778,0.00016137109,0.000032508957,0.000049339364,0.033273175],"genre_scores_gemma":[0.99677587,0.00054962403,0.0005246527,0.0015614061,0.0004855528,0.000001222166,2.8489018e-7,0.000011662633,0.00008970959],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99884874,0.000017849683,0.0007576199,0.0000935446,0.000028927441,0.00025331392],"domain_scores_gemma":[0.99881834,0.000084205945,0.0006884219,0.00021872857,0.00005793312,0.00013240015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013026142,0.000086450396,0.00031831174,0.00017300379,0.0001109231,0.00005290137,0.0005425364,0.00018714012,0.00002280012],"category_scores_gemma":[0.00060364394,0.00007077384,0.00012228388,0.00018182803,0.00017643564,0.00010461261,0.00010649825,0.00040727077,0.0001790763],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059957438,0.000037571255,0.0041848617,0.0000022213412,0.000061427425,0.000006000606,0.00007021026,0.00001415767,0.000078622106,0.9398313,0.025986841,0.029666806],"study_design_scores_gemma":[0.0005214255,0.00012845296,0.0013704507,0.0000034458658,0.000003979078,0.00005508604,0.000045434528,0.00021762759,0.0008538354,0.16429944,0.8324199,0.000080954705],"about_ca_topic_score_codex":0.000019185445,"about_ca_topic_score_gemma":0.0000104421815,"teacher_disagreement_score":0.806433,"about_ca_system_score_codex":0.00012575655,"about_ca_system_score_gemma":0.000056098997,"threshold_uncertainty_score":0.28860736},"labels":[],"label_agreement":null},{"id":"W155288181","doi":"","title":"Abstract 6230: Willingness-to-Pay to Avoid Restenosis Following Percutaneous Coronary Intervention in Canadian Patients; A Contingent Valuation","year":2008,"lang":"en","type":"article","venue":"Circulation","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Contingent valuation; Willingness to pay; Restenosis; Percutaneous coronary intervention; Cardiology; Coronary restenosis; Internal medicine; Stent; Myocardial infarction","score_opus":0.06584740804379367,"score_gpt":0.2832931928196446,"score_spread":0.21744578477585091,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W155288181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948437,0.00011615697,0.0004070139,0.00096934114,0.0005602433,0.0005397012,0.00006709786,0.000019779212,0.0024769474],"genre_scores_gemma":[0.9983627,0.000020698402,0.000114351984,0.0012233433,0.00008139294,0.00003606576,0.00010236675,0.000025258363,0.00003379129],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99852616,0.000018163362,0.0006665281,0.0003681106,0.00004705327,0.00037396283],"domain_scores_gemma":[0.9992833,0.00003746069,0.0001472937,0.00017782094,0.00004027684,0.00031382646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005086641,0.00013189418,0.00024475233,0.0004368969,0.00015332729,0.00005027147,0.00012117149,0.000095211595,0.00015534097],"category_scores_gemma":[0.00024735145,0.00016717405,0.0001273421,0.00026299545,0.000011297932,0.00022930428,0.000023684916,0.00012606029,0.0007186896],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015978983,0.000067087836,0.98705447,0.000014030482,0.000017678214,0.000013107969,0.001053957,0.006823913,0.00007358534,0.001570465,0.0000986759,0.0031970465],"study_design_scores_gemma":[0.000459654,0.000029559293,0.98306745,0.00003594071,0.00000437138,0.0000052153277,0.000016234671,0.008867186,0.000013328392,0.0021468762,0.0051347385,0.00021946589],"about_ca_topic_score_codex":0.0479299,"about_ca_topic_score_gemma":0.023752466,"teacher_disagreement_score":0.024177436,"about_ca_system_score_codex":0.00091908115,"about_ca_system_score_gemma":0.000057574805,"threshold_uncertainty_score":0.9940615},"labels":[],"label_agreement":null},{"id":"W1555399285","doi":"10.1211/jphsr.01.01.0009","title":"Canada's Access to Medicines Regime: a present failure or a future success?","year":2010,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Health Services Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"National Institutes of Health","keywords":"Legislation; TRIPS architecture; Legislature; Government (linguistics); Key (lock); Intellectual property; Access to medicines; Medicine; Public administration; Economic growth; Business; Law; Political science; Economics; Computer science; Computer security","score_opus":0.12930781882747566,"score_gpt":0.47886333216621346,"score_spread":0.3495555133387378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1555399285","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19509672,0.0040634074,0.00006894827,0.7921671,0.0031477064,0.0009548618,0.0003212956,0.00001854211,0.004161388],"genre_scores_gemma":[0.9047282,0.0027972206,0.00052455266,0.08468084,0.006776217,0.00003274708,0.0000065198087,0.000059705166,0.00039405303],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959206,0.00015380891,0.0017029168,0.00045693183,0.00044406048,0.001321673],"domain_scores_gemma":[0.99529386,0.0005261012,0.00060531223,0.00043999695,0.00051511877,0.0026196376],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0046892595,0.0002562666,0.0008681761,0.00076515315,0.00033786555,0.0003293311,0.0020109068,0.00017849053,0.002890614],"category_scores_gemma":[0.00014150939,0.0002097953,0.00013207311,0.0011306613,0.00012529829,0.0005734001,0.00048240574,0.0026409724,0.00013693116],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033977388,0.0011207835,0.040844902,0.0045340387,0.0005276463,0.00051705254,0.0026091235,0.00017080111,0.0005031558,0.047758203,0.8567601,0.041256495],"study_design_scores_gemma":[0.0012608876,0.00026754473,0.0062965653,0.000102590384,0.000006272247,0.00011097733,0.00024734047,0.0024018614,0.00025596432,0.0020829055,0.9867538,0.00021324854],"about_ca_topic_score_codex":0.07790241,"about_ca_topic_score_gemma":0.34632754,"teacher_disagreement_score":0.70963144,"about_ca_system_score_codex":0.0004707199,"about_ca_system_score_gemma":0.0025203917,"threshold_uncertainty_score":0.99965996},"labels":[],"label_agreement":null},{"id":"W1559347722","doi":"","title":"Empirical Analysis of Drug Approval-Drug Patenting Linkage for High Value Pharmaceuticals","year":2010,"lang":"en","type":"article","venue":"Northwestern journal of technology and intellectual property","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Alberta Heritage Foundation for Medical Research; Fondation pour la Recherche Médicale","keywords":"Drug; Business; Intellectual property; New drug application; Approved drug; Linkage (software); Value (mathematics); Drug approval; Law and economics; Law; Pharmacology; Economics; Political science; Medicine; Computer science; Chemistry","score_opus":0.06102010696471208,"score_gpt":0.30913543230919827,"score_spread":0.2481153253444862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1559347722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99098116,0.0009286732,0.0031283747,0.0037576938,0.0003814956,0.0001975817,0.00010321985,0.000020282849,0.0005015242],"genre_scores_gemma":[0.99625534,0.00058149954,0.0020564895,0.0006522131,0.00012303509,0.000009101896,0.0000055897362,0.000021672688,0.00029506552],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979831,0.00002245203,0.0013116432,0.00030990609,0.000041916246,0.00033100415],"domain_scores_gemma":[0.9983925,0.0003173355,0.0007477961,0.00023263425,0.00016226896,0.0001474281],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011494025,0.00019617115,0.0009160081,0.0014272673,0.00010620891,0.000041569376,0.00044101136,0.00022540062,0.00029970153],"category_scores_gemma":[0.0006721197,0.00014325404,0.00031840146,0.0007108594,0.0003566552,0.00018677628,0.0001357223,0.00080580806,0.000017120243],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009573288,0.0013687247,0.83348364,0.00035539738,0.007196941,0.00002381119,0.005557667,0.00041853715,0.0075375373,0.0695102,0.0047321566,0.06885808],"study_design_scores_gemma":[0.011115641,0.0021207924,0.024923055,0.0001948857,0.0034737648,0.0005216273,0.0011461751,0.20012937,0.09759142,0.13326256,0.52293277,0.0025879468],"about_ca_topic_score_codex":0.000055762026,"about_ca_topic_score_gemma":0.000046890884,"teacher_disagreement_score":0.80856055,"about_ca_system_score_codex":0.00002529613,"about_ca_system_score_gemma":0.000044857843,"threshold_uncertainty_score":0.584173},"labels":[],"label_agreement":null},{"id":"W1559802115","doi":"10.3386/w17226","title":"Cross-National Evidence on Generic Pharmaceuticals: Pharmacy vs. Physician-Driven Markets","year":2011,"lang":"en","type":"report","venue":"National Bureau of Economic Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy; Real world evidence; Business; Family medicine; Medicine; Actuarial science; Internal medicine","score_opus":0.7529492878495362,"score_gpt":0.5967567802891278,"score_spread":0.15619250756040837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1559802115","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003040682,0.005790375,0.000018719955,0.002819976,0.0021312356,0.0012320847,0.0032771884,0.000045488658,0.9816443],"genre_scores_gemma":[0.922531,0.0406836,0.0003052905,0.003312085,0.008122812,0.0008469004,0.00088127854,0.00029859858,0.023018448],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99358875,0.0002068919,0.0024810166,0.0016552483,0.00091174484,0.0011563268],"domain_scores_gemma":[0.99377865,0.0018455255,0.0013999379,0.0006520272,0.0018265995,0.00049728557],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.010977206,0.0006181289,0.0014122949,0.002035237,0.00029850568,0.00026315334,0.0018219276,0.0005176004,0.008802298],"category_scores_gemma":[0.0026596377,0.00075905956,0.0006937412,0.00044003408,0.0006766441,0.0007078051,0.000527213,0.0018270086,0.010391495],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006380745,0.0005850072,0.0056088935,0.0004512253,0.0008612318,0.000009082119,0.00007000156,0.0018788555,0.000049574715,0.6417822,0.34446082,0.003604998],"study_design_scores_gemma":[0.0011998754,0.00012552914,0.0028516331,0.00018376647,0.000019336267,0.000012902706,0.0000026656664,0.010777128,0.0005993068,0.2135948,0.76990074,0.0007323023],"about_ca_topic_score_codex":0.0008578688,"about_ca_topic_score_gemma":0.000032642525,"teacher_disagreement_score":0.9586258,"about_ca_system_score_codex":0.00479115,"about_ca_system_score_gemma":0.003864182,"threshold_uncertainty_score":0.999486},"labels":[],"label_agreement":null},{"id":"W1561889056","doi":"10.3386/w20799","title":"Intellectual Property Rights and Access to Innovation: Evidence from TRIPS","year":2014,"lang":"en","type":"preprint","venue":"National Bureau of Economic Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"","keywords":"TRIPS architecture; Intellectual property; Business; Competition (biology); TRIPS Agreement; Price premium; Product (mathematics); International economics; International trade; Drug prices; Industrial organization; Economics; Public economics; Microeconomics","score_opus":0.6725693421532669,"score_gpt":0.5429627906360296,"score_spread":0.12960655151723732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1561889056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.69745904,0.0027691603,0.0010027776,0.030411985,0.0016550416,0.0024744796,0.001699264,0.000053017975,0.26247525],"genre_scores_gemma":[0.9950933,0.0005299425,0.0005940266,0.0009285723,0.0010606175,0.00020277416,0.00017333536,0.000036532674,0.001380894],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9966642,0.00010406391,0.001522907,0.0011050075,0.00015270659,0.00045106275],"domain_scores_gemma":[0.99627805,0.0019698446,0.0004966456,0.00052252074,0.00050654233,0.00022637202],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.004212121,0.00028299403,0.0008240685,0.0017292311,0.00015897086,0.00047172248,0.0013091619,0.00038836963,0.0018259243],"category_scores_gemma":[0.003029735,0.00027742196,0.0001148805,0.0003700779,0.0002754778,0.0004169274,0.0018073284,0.0009942069,0.0012894601],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024264019,0.00009798103,0.0026926617,0.00016673311,0.00026587825,9.658222e-7,0.00067212473,0.0030146213,0.000072223396,0.86794686,0.12290169,0.0019256125],"study_design_scores_gemma":[0.00037085908,0.0000733705,0.0010926854,0.00013713336,0.00000421914,0.0000011502561,0.000004833289,0.02033078,0.00059516827,0.9121141,0.06494334,0.000332348],"about_ca_topic_score_codex":0.004973866,"about_ca_topic_score_gemma":0.00016296025,"teacher_disagreement_score":0.29763427,"about_ca_system_score_codex":0.00082347344,"about_ca_system_score_gemma":0.00047248456,"threshold_uncertainty_score":0.9999678},"labels":[],"label_agreement":null},{"id":"W1565226743","doi":"","title":"Ententes entre gouvernements et compagnies pharmaceutiques","year":2012,"lang":"fr","type":"preprint","venue":"RePEc: Research Papers in Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science; Humanities; Publics; Art; Law","score_opus":0.11776891826027439,"score_gpt":0.38860896667140243,"score_spread":0.2708400484111281,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1565226743","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3989566,0.012602184,0.000022260476,0.011992687,0.0053104167,0.0020241358,0.0031422598,0.00009770374,0.56585175],"genre_scores_gemma":[0.7508534,0.22620215,0.0009152248,0.0030672345,0.00106278,0.00044721854,0.0004576866,0.00023881554,0.01675549],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9908725,0.00060185447,0.0029943984,0.0021416661,0.00017664554,0.0032129367],"domain_scores_gemma":[0.9949732,0.0011488434,0.0011640167,0.0015424034,0.0001415981,0.0010299804],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.006087626,0.0010754894,0.0021179633,0.0012740494,0.00038955858,0.000646336,0.0019832514,0.0010237134,0.0058680894],"category_scores_gemma":[0.00048513018,0.0015111304,0.000804947,0.00030592186,0.0010822744,0.0007679582,0.002984288,0.0042691105,0.0021541312],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045957838,0.0035836825,0.46976778,0.0012178213,0.001851839,0.000066155975,0.004719091,0.0061024735,0.00012144041,0.2615767,0.006397136,0.24413627],"study_design_scores_gemma":[0.0022104073,0.00010090731,0.030224955,0.00035877852,0.00003493314,0.00001842945,0.00060086855,0.026348822,0.0002756569,0.011672846,0.92670465,0.0014487494],"about_ca_topic_score_codex":0.00072794943,"about_ca_topic_score_gemma":0.0005880881,"teacher_disagreement_score":0.9203075,"about_ca_system_score_codex":0.004164965,"about_ca_system_score_gemma":0.0004838861,"threshold_uncertainty_score":0.99965787},"labels":[],"label_agreement":null},{"id":"W1566282614","doi":"10.3386/w20927","title":"Patient Responses to Incentives in Consumer-directed Health Plans: Evidence from Pharmaceuticals","year":2015,"lang":"en","type":"article","venue":"National Bureau of Economic Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; Common Fund; Vanderbilt University; McGill University; California Health Care Foundation; University of Minnesota; University of Southern California; National Institute on Aging; Emory University","keywords":"Incentive; Business; Marketing; Public economics; Health plan; Health care; Economics; Microeconomics; Economic growth","score_opus":0.661288991782228,"score_gpt":0.5713846724613029,"score_spread":0.08990431932092513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1566282614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92043597,0.008205398,0.000037174952,0.024106985,0.0005094975,0.0010792251,0.0018182726,0.000039437244,0.043768067],"genre_scores_gemma":[0.9964628,0.0010562704,0.0006730017,0.0013567314,0.00013348318,0.0000906854,0.000047435966,0.00002164507,0.00015793063],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9971846,0.000268695,0.001217762,0.00059770327,0.00016078714,0.00057049014],"domain_scores_gemma":[0.9967844,0.0019559294,0.00026552923,0.0002654098,0.00020333008,0.00052539236],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004969403,0.00015818726,0.0005500718,0.00103492,0.00006980671,0.000074033785,0.00043691744,0.00010254425,0.00049261877],"category_scores_gemma":[0.0029645166,0.00019321578,0.00007666317,0.00036899798,0.00018861722,0.00034423755,0.0002278412,0.00037580333,0.0016474839],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022044382,0.0006084429,0.18853088,0.000064343054,0.00020905654,0.000008418328,0.004434637,0.0026331255,0.0002933015,0.7234684,0.07169443,0.0058504865],"study_design_scores_gemma":[0.002648624,0.0004907505,0.029299542,0.00021705378,0.0000028292452,0.00000352164,0.00035473012,0.018350735,0.0017278321,0.84257334,0.1037779,0.00055311027],"about_ca_topic_score_codex":0.0047424026,"about_ca_topic_score_gemma":0.00042134966,"teacher_disagreement_score":0.15923133,"about_ca_system_score_codex":0.0015911403,"about_ca_system_score_gemma":0.0008269645,"threshold_uncertainty_score":0.99912983},"labels":[],"label_agreement":null},{"id":"W1568860282","doi":"","title":"Should Americans be able to buy cheaper drugs from Canada","year":2015,"lang":"en","type":"article","venue":"Drug Topics E-News","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Drug industry; Medicine; Internet privacy; Actuarial science; Computer science; Engineering","score_opus":0.11547643919255628,"score_gpt":0.29921680350307106,"score_spread":0.18374036431051477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1568860282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5535387,0.0011184452,0.0002641586,0.10753532,0.0023098667,0.00035669006,0.0015703222,0.00006150517,0.333245],"genre_scores_gemma":[0.8642597,0.00024469115,0.0018091757,0.116321966,0.0015499807,0.000057142082,0.00009538167,0.0000662372,0.015595704],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99836296,0.000014854462,0.0005739678,0.00048413832,0.00006167301,0.00050241314],"domain_scores_gemma":[0.9986058,0.000047496324,0.0001528692,0.00050414394,0.000033418808,0.0006562619],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020477535,0.00021379629,0.0004982077,0.000096588985,0.00006986117,0.000096663476,0.000430124,0.00007961823,0.000832324],"category_scores_gemma":[0.00011667663,0.00025322603,0.000089383815,0.0001996151,0.000035849906,0.00013035693,0.0001450066,0.00023069694,0.0007369835],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029716515,0.00009430156,0.028146682,0.000012853411,0.00009034715,0.000010449427,0.003677244,0.00054235326,0.000014522513,0.06850639,0.89063483,0.00824033],"study_design_scores_gemma":[0.0004346227,0.000014931953,0.0010361508,0.0000033288864,0.0000066928133,5.359985e-7,0.00043022793,0.0008999404,0.00013300694,0.013120851,0.9835819,0.0003377965],"about_ca_topic_score_codex":0.84811944,"about_ca_topic_score_gemma":0.40149763,"teacher_disagreement_score":0.44662178,"about_ca_system_score_codex":0.0004439271,"about_ca_system_score_gemma":0.00029048047,"threshold_uncertainty_score":0.999992},"labels":[],"label_agreement":null},{"id":"W1573407744","doi":"","title":"Investigating Generic and Brand Name Pharmaceutical’s Market Shares and Prices in Tunisia","year":2008,"lang":"en","type":"preprint","venue":"RePEc: Research Papers in Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Market share; Competition (biology); Product (mathematics); Generic drug; Brand names; Quarter (Canadian coin); Business; Advertising; Marketing; Economics; Monetary economics; Drug; Medicine; Mathematics; Pharmacology; Geography","score_opus":0.11948443549014058,"score_gpt":0.35720654513371236,"score_spread":0.23772210964357177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1573407744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.863581,0.007894006,0.0000023843565,0.0017413825,0.00025245023,0.0007764179,0.00041239941,0.00003010936,0.12530987],"genre_scores_gemma":[0.7537663,0.2428699,0.0011172041,0.0010924645,0.00026422064,0.00022260993,0.000042517004,0.000104966086,0.0005198235],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9955425,0.00012431161,0.0015118199,0.0015843844,0.00007079597,0.0011661794],"domain_scores_gemma":[0.99761087,0.00071220635,0.00041622017,0.00064047065,0.00003343667,0.00058678346],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025907077,0.0005014859,0.0011892654,0.0011564199,0.00019871858,0.00037132323,0.00062547484,0.00056791096,0.00029787002],"category_scores_gemma":[0.00064857723,0.0006473474,0.00012650284,0.0002140268,0.00083894463,0.00027921508,0.0017377925,0.0022124366,0.000025385789],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002686437,0.0005797109,0.64956,0.0023521627,0.0004933564,0.00017624296,0.003932541,0.0041222055,0.0001222516,0.036191765,0.0014688581,0.30073228],"study_design_scores_gemma":[0.0041967034,0.00013518645,0.19823276,0.00047274205,0.000015064326,0.00009490756,0.00026770844,0.41495356,0.00008454395,0.07598007,0.30341953,0.0021472487],"about_ca_topic_score_codex":0.00034687543,"about_ca_topic_score_gemma":0.00019005734,"teacher_disagreement_score":0.45132723,"about_ca_system_score_codex":0.0006130235,"about_ca_system_score_gemma":0.00024198742,"threshold_uncertainty_score":0.9995978},"labels":[],"label_agreement":null},{"id":"W1573991396","doi":"10.3386/w13862","title":"Is Medicine an Ivory Tower? Induced Innovation, Technological Opportunity, and For-Profit vs. Non-Profit Innovation","year":2008,"lang":"en","type":"report","venue":"National Bureau of Economic Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"National Institute on Aging","keywords":"Ivory tower; Profit (economics); Business; For profit; Industrial organization; Economics; Microeconomics; Political science; Finance; Law","score_opus":0.7419069268046703,"score_gpt":0.567247715320468,"score_spread":0.17465921148420227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1573991396","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34438157,0.0011979006,0.00015316033,0.023861315,0.0010611532,0.002586285,0.0020877323,0.000073305695,0.62459755],"genre_scores_gemma":[0.9827484,0.005766922,0.00037338582,0.0017078767,0.0015445523,0.0004341864,0.0021205521,0.00010491763,0.005199209],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9948913,0.00003826797,0.002856245,0.0011798127,0.00036790932,0.0006664841],"domain_scores_gemma":[0.99418575,0.00059839326,0.0015349155,0.0006058436,0.0028557312,0.00021939028],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.011150483,0.00042218523,0.0012992163,0.0049474672,0.00032682225,0.000081607985,0.00083558814,0.0011792792,0.0013715642],"category_scores_gemma":[0.0044700084,0.0004793696,0.00012384653,0.0012596837,0.0009000918,0.00046949025,0.0003572199,0.0012947465,0.000105760635],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000080300364,0.000037596816,0.008786903,0.0002031538,0.00018655903,0.0000018043947,0.00009408476,0.000008426509,0.00013331173,0.8858869,0.10163741,0.0029435363],"study_design_scores_gemma":[0.0013693726,0.00046031023,0.0050909314,0.0000815146,0.0000106443795,0.000031997795,0.000042695083,0.0022651607,0.00045155486,0.8843354,0.10532253,0.00053790055],"about_ca_topic_score_codex":0.00093782967,"about_ca_topic_score_gemma":0.00003128317,"teacher_disagreement_score":0.6383668,"about_ca_system_score_codex":0.0015289002,"about_ca_system_score_gemma":0.0025759588,"threshold_uncertainty_score":0.9997658},"labels":[],"label_agreement":null},{"id":"W1583275573","doi":"10.2139/ssrn.2567637","title":"Structure-Function Analysis of Global Pharmaceutical Linkage Regulations","year":2015,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University; University of Calgary; University of Manitoba","funders":"","keywords":"Linkage (software); Function (biology); Computational biology; Business; Genetics; Biology; Gene","score_opus":0.046827087808560125,"score_gpt":0.31188395082265036,"score_spread":0.26505686301409026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1583275573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91829586,0.008249373,0.05179328,0.003744962,0.00081049645,0.00014948123,0.00042982478,0.000033858625,0.016492862],"genre_scores_gemma":[0.9981975,0.0006703529,0.00013552586,0.00054504134,0.00025043264,0.0000014013294,0.000020287966,0.000011458604,0.00016802325],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9979515,0.000030023542,0.0006789398,0.0002223927,0.00005979297,0.0010573494],"domain_scores_gemma":[0.999102,0.000026171183,0.00037749065,0.00018799481,0.0000693247,0.00023699366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013846781,0.00013283321,0.00042207856,0.00026513025,0.000077965626,0.000052909767,0.00025264607,0.0001039637,0.00025351034],"category_scores_gemma":[0.00009699722,0.00014563499,0.00026989388,0.0008241591,0.0000620943,0.00020791359,0.000041092982,0.0006979568,0.0000691201],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005510984,0.000049708004,0.049151145,0.0000023278485,0.0014599691,3.8161588e-7,0.000040212246,0.0025600838,0.000019195595,0.9444129,0.0002151004,0.002033849],"study_design_scores_gemma":[0.00093925954,0.00012453631,0.019102562,0.0000017263468,0.00037308873,0.000028813098,0.000088482804,0.023219533,0.000023499148,0.93663853,0.019275896,0.00018409525],"about_ca_topic_score_codex":0.00007920284,"about_ca_topic_score_gemma":0.0003291289,"teacher_disagreement_score":0.07990161,"about_ca_system_score_codex":0.0011903953,"about_ca_system_score_gemma":0.0005177673,"threshold_uncertainty_score":0.5938822},"labels":[],"label_agreement":null},{"id":"W158415122","doi":"10.1177/009885880803400209","title":"Ending Drug Registration Apartheid: Taming Data Exclusivity and Patent/Registration Linkage","year":2008,"lang":"en","type":"article","venue":"American Journal of Law & Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Intellectual property; Monopoly; Competitor analysis; China; Latin Americans; Government (linguistics); Business; Quarter (Canadian coin); Pharmaceutical industry; International trade; Gold rush; Economics; Market economy; Marketing; Law; Political science","score_opus":0.17800802551524444,"score_gpt":0.3249422304955516,"score_spread":0.14693420498030715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W158415122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9412471,0.0033054354,0.007027436,0.016947867,0.0006020792,0.0001375786,0.000094904084,0.00001670731,0.030620916],"genre_scores_gemma":[0.9935523,0.0028842518,0.0005299642,0.00210646,0.0007801225,8.363968e-7,0.000022106315,0.000014242459,0.000109675515],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99853224,0.00003460722,0.00092359923,0.00023926732,0.00006454172,0.0002057452],"domain_scores_gemma":[0.99789727,0.00018342312,0.0013487969,0.00031814177,0.000040148618,0.00021219377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013360871,0.00013093675,0.0005327613,0.00012124083,0.00015609457,0.000025702646,0.00029050416,0.000029247454,0.0000783167],"category_scores_gemma":[0.000264024,0.00012491381,0.000043712767,0.00012995781,0.00061094755,0.0005027808,0.000052218988,0.0002661256,0.000009634321],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042742124,0.00048537305,0.09680703,0.00017874142,0.00066679786,0.00046087653,0.015994739,0.00040314574,0.0020772154,0.7923903,0.021976,0.06813236],"study_design_scores_gemma":[0.006386391,0.0017313353,0.033579014,0.00040056888,0.00016133336,0.0020189798,0.0016040499,0.02707386,0.0004484735,0.026496643,0.8989862,0.0011131096],"about_ca_topic_score_codex":0.0009942112,"about_ca_topic_score_gemma":0.00006700422,"teacher_disagreement_score":0.8770102,"about_ca_system_score_codex":0.000058481,"about_ca_system_score_gemma":0.000037357197,"threshold_uncertainty_score":0.50938374},"labels":[],"label_agreement":null},{"id":"W1584507582","doi":"","title":"How safe are new drugs? Market withdrawal of drugs approved in Canada between 1990 and 2009.","year":2014,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Interquartile range; Family medicine; Internal medicine","score_opus":0.024051972051048937,"score_gpt":0.1936623092082921,"score_spread":0.16961033715724316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1584507582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9151407,0.00092186895,0.00010430501,0.014628309,0.0002861461,0.00054410216,0.00059308734,0.000011255703,0.06777025],"genre_scores_gemma":[0.99673307,0.00012376675,0.000062114974,0.00088091707,0.00019651171,0.00006506476,0.000007560947,0.000019022727,0.0019119977],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987216,0.000020173662,0.00045845134,0.00031758938,0.000031430573,0.00045075186],"domain_scores_gemma":[0.99899316,0.00013393677,0.00032251872,0.00022307693,0.000009274728,0.00031802323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053744693,0.00014946148,0.0005226575,0.00014763234,0.00002727484,0.000056249584,0.0002042621,0.00006797708,0.000046450084],"category_scores_gemma":[0.00013598987,0.00017576893,0.000045656918,0.00014471791,0.00004560133,0.00014287386,0.0000743754,0.00015668664,0.000005209327],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000049679475,0.00003184935,0.8170145,0.000106831074,0.000088307264,0.000001139385,0.00024117896,0.000014729237,7.318111e-7,0.015983496,0.030773172,0.13569438],"study_design_scores_gemma":[0.00095301686,0.0000056223184,0.7477592,0.0000048913553,0.0000052798882,3.6911888e-7,0.00004681768,0.0010275133,0.00003212626,0.007631388,0.24232884,0.00020489124],"about_ca_topic_score_codex":0.39644504,"about_ca_topic_score_gemma":0.19792442,"teacher_disagreement_score":0.21155566,"about_ca_system_score_codex":0.00021663014,"about_ca_system_score_gemma":0.0000964237,"threshold_uncertainty_score":0.81671137},"labels":[],"label_agreement":null},{"id":"W158531728","doi":"","title":"Hospital Procurement with Concentrated Sellers: A Case Study of Hip Prostheses","year":2013,"lang":"en","type":"preprint","venue":"UEA Digital Repository (University of East Anglia)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"","keywords":"Procurement; Diversity (politics); Oligopoly; Business; Competition (biology); Industrial organization; Operations management; Marketing; Economics; Welfare; Market economy; Political science","score_opus":0.04457979910193236,"score_gpt":0.21533992488041975,"score_spread":0.1707601257784874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W158531728","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98159,0.00041453933,0.000034571323,0.00010326479,0.00020885913,0.0012034541,0.00040088937,0.00003569144,0.016008768],"genre_scores_gemma":[0.99892086,0.000024127556,0.00007966427,0.000014211166,0.000051879342,0.000004910564,0.000021294996,0.000027360415,0.00085572095],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.9985169,0.000017272554,0.0004966138,0.0006039256,0.00008026342,0.00028502117],"domain_scores_gemma":[0.9980338,0.000026117877,0.0010604414,0.00048694626,0.00018692088,0.00020572386],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000085082786,0.00029162804,0.0007319638,0.00017180688,0.00011372582,0.00014417224,0.00041327113,0.00017267402,0.00006350624],"category_scores_gemma":[0.000016587983,0.00035811414,0.0001858135,0.00014483511,0.0002492764,0.0004576619,0.00042816406,0.0002891588,0.000043727836],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009928356,0.014932244,0.8824929,0.0021275815,0.0057211877,0.0068421075,0.067613564,0.002706477,0.00008536981,0.008616853,0.00439769,0.0034711987],"study_design_scores_gemma":[0.053666048,0.034564573,0.11730229,0.0037507913,0.0025027827,0.0033136455,0.6363758,0.05261074,0.0024438696,0.02240263,0.05434514,0.016721692],"about_ca_topic_score_codex":0.0027759876,"about_ca_topic_score_gemma":0.00006863716,"teacher_disagreement_score":0.7651906,"about_ca_system_score_codex":0.00015944388,"about_ca_system_score_gemma":0.0001200987,"threshold_uncertainty_score":0.9998871},"labels":[],"label_agreement":null},{"id":"W1585529854","doi":"10.18433/j3659z","title":"Assessing Bioequivalence of Antiepileptic Drugs: Are the Current Requirements too Permissive?","year":2014,"lang":"en","type":"article","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Bioequivalence; Cmax; Confidence interval; Medicine; Pharmacokinetics; Pharmacology; Mathematics; Statistics","score_opus":0.2325925722123949,"score_gpt":0.44261156354970543,"score_spread":0.21001899133731053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1585529854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9489936,0.013326615,0.0018388958,0.015969647,0.0029922596,0.00026616117,0.000047086553,0.000018242277,0.016547473],"genre_scores_gemma":[0.9927779,0.0037661905,0.00031320474,0.0024629596,0.00063468737,0.0000033941892,4.5521904e-7,0.000015287233,0.000025935606],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99693257,0.00016290839,0.0016641628,0.00036675186,0.0002680418,0.00060557324],"domain_scores_gemma":[0.9969179,0.00049056526,0.0018277885,0.00021177989,0.00014861906,0.0004033305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049172603,0.00024434936,0.00063336676,0.00030318575,0.00034179934,0.0003004999,0.0013298587,0.00003640074,0.0004766066],"category_scores_gemma":[0.00053238176,0.00018195198,0.00034497833,0.00059266464,0.0009880778,0.0012820035,0.00019952281,0.00062667683,0.00009243099],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002172782,0.0013119825,0.2795494,0.00052898703,0.00032878196,0.000015551097,0.0013008561,0.00097302406,0.009413887,0.12732324,0.0076227062,0.5714143],"study_design_scores_gemma":[0.00266243,0.00019721211,0.00894133,0.00018320803,0.00012899103,0.00003750409,0.0002757257,0.07736398,0.011339144,0.022210155,0.8761312,0.0005291601],"about_ca_topic_score_codex":0.000014261953,"about_ca_topic_score_gemma":2.890498e-7,"teacher_disagreement_score":0.86850846,"about_ca_system_score_codex":0.00010747247,"about_ca_system_score_gemma":0.00014055833,"threshold_uncertainty_score":0.74197865},"labels":[],"label_agreement":null},{"id":"W1585859626","doi":"10.1007/s10754-015-9172-2","title":"The impact of pharmaceutical innovation on premature cancer mortality in Canada, 2000–2011","year":2015,"lang":"en","type":"article","venue":"International Journal of Health Economics and Management","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Mortality rate; Demography; Cumulative incidence; Incidence (geometry); Cancer; Cancer incidence; Toxicology; Internal medicine; Biology; Cohort","score_opus":0.13403582872422404,"score_gpt":0.40428684232802925,"score_spread":0.2702510136038052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1585859626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97755885,0.0029368137,0.000029680676,0.014425719,0.0011580776,0.0001683075,0.00015983038,0.000001069042,0.0035616471],"genre_scores_gemma":[0.9788642,0.019260617,0.00003844712,0.0016637982,0.00011037536,0.0000060785073,0.0000034084671,0.0000074389354,0.000045647856],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9984707,0.000019596298,0.0011607878,0.00012146241,0.00004770564,0.00017974833],"domain_scores_gemma":[0.9987189,0.00004260981,0.00095634576,0.000089647045,0.0000834212,0.00010908543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013663982,0.00009216356,0.00028795196,0.00023079097,0.00002747593,0.000038483417,0.00026199225,0.00002422849,0.000041418873],"category_scores_gemma":[0.000023592447,0.000077840254,0.00005463662,0.000061007926,0.000028559694,0.00011706889,0.000059708214,0.00015281781,0.000004208472],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039070135,0.00019136159,0.19590975,0.000052899955,0.00091739534,0.000012517471,0.0002815298,0.025908837,7.019369e-7,0.7213218,0.014715497,0.040296968],"study_design_scores_gemma":[0.0036027113,0.000249343,0.59396714,0.00008029186,0.000010568361,0.00001855267,0.00015274328,0.03312116,0.000028706207,0.06657168,0.30193594,0.0002611638],"about_ca_topic_score_codex":0.15875386,"about_ca_topic_score_gemma":0.047981873,"teacher_disagreement_score":0.65475017,"about_ca_system_score_codex":0.0019476147,"about_ca_system_score_gemma":0.0007913448,"threshold_uncertainty_score":0.96939},"labels":[],"label_agreement":null},{"id":"W1592662300","doi":"","title":"Flexible Drug Patent Terms: A Proposed Mechanism to Stimulate Global Innovation and Health","year":2013,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of British Columbia Hospital","funders":"","keywords":"Incentive; Balance (ability); Business; Public economics; Component (thermodynamics); Law and economics; Access to medicines; Industrial organization; Mechanism (biology); Drug development; Drug; Developing country; International trade; Economic growth; Economics; Market economy; Pharmacology; Medicine","score_opus":0.06278375253874424,"score_gpt":0.30034832197545624,"score_spread":0.237564569436712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1592662300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91662455,0.0019482049,0.02068066,0.055576283,0.00039107102,0.000755682,0.000052236457,0.000050697592,0.0039205956],"genre_scores_gemma":[0.9900115,0.0014648576,0.0003160344,0.007370423,0.00016394953,0.000013148422,0.0000049287755,0.000018801726,0.0006363442],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9974386,0.000016585536,0.00067550194,0.00027650504,0.00003455755,0.0015582697],"domain_scores_gemma":[0.9992838,0.000007892171,0.00031808598,0.00013510411,0.000042432144,0.00021271946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015802756,0.00015535466,0.00030265455,0.00021623602,0.00018162794,0.00018207889,0.00018357082,0.000050189105,0.00012169801],"category_scores_gemma":[0.000026724174,0.00016143544,0.000051590803,0.00032994777,0.000019787958,0.00028551306,0.00006619819,0.0005598739,0.00050363544],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000111922145,0.000039690112,0.002821581,0.00000831064,0.000055496912,2.8424188e-7,0.0000972619,0.000043614684,0.000027833941,0.97886026,0.00078011566,0.017254354],"study_design_scores_gemma":[0.0007445496,0.00021970173,0.0034480812,0.000009468563,0.0000025344195,0.000049348357,0.00006918919,0.0021708973,0.000049262777,0.9872543,0.0057917014,0.00019091484],"about_ca_topic_score_codex":0.0007161354,"about_ca_topic_score_gemma":0.00015368206,"teacher_disagreement_score":0.073386945,"about_ca_system_score_codex":0.0014143905,"about_ca_system_score_gemma":0.0004386264,"threshold_uncertainty_score":0.65831465},"labels":[],"label_agreement":null},{"id":"W1592821973","doi":"10.4212/cjhp.v53i4.754","title":"Drugs of Choice: a Formulary for General Practice","year":2000,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Formulary; Family medicine; Medicine","score_opus":0.039194251329043965,"score_gpt":0.30857888820507473,"score_spread":0.26938463687603076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1592821973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90226614,0.006079128,0.00005706746,0.04190723,0.00103079,0.00038132723,0.0004887464,0.0000042577644,0.047785293],"genre_scores_gemma":[0.9927182,0.00046204042,0.0004840208,0.004873457,0.00075438304,0.000006291359,0.0000035363994,0.00002429852,0.0006737718],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99874485,0.000017195978,0.0007348531,0.000116687814,0.000032719803,0.00035371355],"domain_scores_gemma":[0.9986117,0.00016791093,0.0005342647,0.00016335354,0.00010288874,0.00041991397],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00082418945,0.00012036379,0.00031543488,0.00015742495,0.000163489,0.000076536875,0.00047613177,0.000036339985,0.0012556806],"category_scores_gemma":[0.00020159506,0.00010944213,0.00025109382,0.00012406224,0.000112442496,0.00049597287,0.000009949667,0.00024586424,0.00008794418],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007475596,0.0006186701,0.018340537,0.00018584759,0.0021206818,0.00008048531,0.011407126,0.0027492188,0.000100161036,0.6320385,0.21841577,0.11319547],"study_design_scores_gemma":[0.0015280704,0.00018369954,0.0009047307,0.0000086081145,0.000038330025,0.00002588316,0.000031476735,0.0019233912,0.00024091941,0.027678575,0.96727496,0.00016132614],"about_ca_topic_score_codex":0.00955854,"about_ca_topic_score_gemma":0.0007043898,"teacher_disagreement_score":0.7488592,"about_ca_system_score_codex":0.00015155601,"about_ca_system_score_gemma":0.00036642392,"threshold_uncertainty_score":0.99965733},"labels":[],"label_agreement":null},{"id":"W1595600554","doi":"","title":"The link between publicly funded health care and compulsory licensing.","year":2002,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Government (linguistics); Order (exchange); Business; Government regulation; Health care; Law; Finance; Political science","score_opus":0.12873320509855748,"score_gpt":0.26773405691954083,"score_spread":0.13900085182098335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1595600554","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18997014,0.112770766,0.00014730997,0.36852428,0.001486992,0.0019632569,0.0005487124,0.000212664,0.32437587],"genre_scores_gemma":[0.99034023,0.0028794466,0.00006458115,0.005009054,0.00089043676,0.00009924955,0.0000088684665,0.000022737868,0.00068540423],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99857223,0.000022485981,0.00047903432,0.0003138252,0.000021940421,0.00059047894],"domain_scores_gemma":[0.9989902,0.00015573387,0.00021762625,0.0002873207,0.000017189768,0.00033194505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052590715,0.00012777864,0.00030529953,0.00009619715,0.00034431828,0.00026701717,0.00021711232,0.00006871405,0.000042655873],"category_scores_gemma":[0.00008297797,0.00012282262,0.000070935814,0.00013045798,0.00011150459,0.0001309951,0.000097544464,0.00021009815,0.00018877981],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000033620147,0.0000072632542,0.029078668,0.000022012064,0.000048138176,3.8463978e-7,0.00054314744,0.0000018062443,1.7387332e-8,0.050619584,0.009546609,0.910129],"study_design_scores_gemma":[0.00036084317,0.00001553279,0.14436373,0.0000012841545,0.0000025322452,0.0000015309676,0.00003851083,0.00061543554,0.0000019779438,0.0046663783,0.84978986,0.00014241449],"about_ca_topic_score_codex":0.00021556698,"about_ca_topic_score_gemma":0.00007178147,"teacher_disagreement_score":0.9099866,"about_ca_system_score_codex":0.00013574037,"about_ca_system_score_gemma":0.0000065053823,"threshold_uncertainty_score":0.5008561},"labels":[],"label_agreement":null},{"id":"W1597065337","doi":"","title":"Why Canada’s Access to Medicines Regime Can Never Succeed","year":2010,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa","funders":"","keywords":"Pledge; Scrutiny; Law; Wonder; Business; China; House of Commons; Political science; Legislation; Parliament","score_opus":0.024292638566285295,"score_gpt":0.2733392153780239,"score_spread":0.2490465768117386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1597065337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.51459455,0.0012764216,0.0007196049,0.45280087,0.002829973,0.0002689946,0.00009660366,0.000030392159,0.02738255],"genre_scores_gemma":[0.9209363,0.00087013707,0.00003169816,0.07554958,0.0011261986,0.000007489334,0.0000048368142,0.00003666737,0.0014371129],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970592,0.000011074536,0.00054559525,0.00029633523,0.00005448428,0.0020332925],"domain_scores_gemma":[0.9989722,0.000041435345,0.00024745413,0.0002606647,0.000047088142,0.00043115582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010903879,0.0001862872,0.000358368,0.0002221327,0.00019104125,0.00015403242,0.00075362594,0.00008942379,0.00061615277],"category_scores_gemma":[0.00017125285,0.00019494002,0.00009118159,0.00020411838,0.000039672213,0.00032549078,0.00008674961,0.001843019,0.00008965361],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003640981,0.000038386337,0.019548913,0.0000061825817,0.00016582393,0.000007054113,0.00007806257,0.00004331859,0.00013763632,0.79343826,0.18397962,0.0025203454],"study_design_scores_gemma":[0.0005181817,0.000054745193,0.0048380336,0.0000037775126,0.000007985136,0.00012458698,0.000042557574,0.00017610396,0.00007367044,0.1992045,0.79469156,0.00026431197],"about_ca_topic_score_codex":0.20912598,"about_ca_topic_score_gemma":0.92836076,"teacher_disagreement_score":0.71923476,"about_ca_system_score_codex":0.0009587669,"about_ca_system_score_gemma":0.0027006648,"threshold_uncertainty_score":0.8007103},"labels":[],"label_agreement":null},{"id":"W1601475699","doi":"10.1002/cncr.29246","title":"Comparison of oncology drug approval between Health Canada and the US Food and Drug Administration","year":2015,"lang":"en","type":"article","venue":"Cancer","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario; BC Cancer Agency; University of Calgary","funders":"","keywords":"Medicine; Formulary; Interquartile range; Drug; Food and drug administration; Timeline; New drug application; Family medicine; Internal medicine; Pharmacology","score_opus":0.13941762883649994,"score_gpt":0.3770549472656633,"score_spread":0.23763731842916336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1601475699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9630183,0.008728619,0.000024971025,0.022798654,0.000246007,0.00017419123,0.00033446727,0.000003535288,0.004671239],"genre_scores_gemma":[0.9974578,0.00041182849,0.00003848757,0.0018323741,0.000139766,0.000016298474,0.000006967401,0.0000063073476,0.00009019439],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992772,0.000025044883,0.00038580073,0.00015065732,0.00001729229,0.00014403925],"domain_scores_gemma":[0.9993698,0.00008490177,0.000279628,0.000094410265,0.00001478109,0.00015649629],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048129563,0.0000686367,0.00038451984,0.00002617501,0.000047978283,0.000016946162,0.00007677363,0.00002705191,0.000014528666],"category_scores_gemma":[0.000026820242,0.00006206825,0.000017682785,0.000043909342,0.00012502393,0.000043758268,0.000035270583,0.00010440199,0.0000016478868],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015700776,0.000054108237,0.6842823,0.000117920754,0.00015390926,3.8320434e-7,0.0048756883,0.00012388811,6.981257e-7,0.21751189,0.063463226,0.029258959],"study_design_scores_gemma":[0.0033936666,0.00019049048,0.04085762,0.00000983092,0.000016031387,0.0000019635017,0.000337059,0.0044488795,0.0001791073,0.018344203,0.93201244,0.0002087307],"about_ca_topic_score_codex":0.24968395,"about_ca_topic_score_gemma":0.44488567,"teacher_disagreement_score":0.86854917,"about_ca_system_score_codex":0.00020040688,"about_ca_system_score_gemma":0.00054428243,"threshold_uncertainty_score":0.7553125},"labels":[],"label_agreement":null},{"id":"W1603625064","doi":"10.1007/s10198-006-0345-2","title":"Outcomes research collaborations between third-party payers, academia, and pharmaceutical manufacturers","year":2006,"lang":"en","type":"article","venue":"The European Journal of Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Documentation; Harmonization; Business; Quality (philosophy); Process (computing); Pharmaceutical industry; Public relations; Political science; Medicine; Computer science; Pharmacology","score_opus":0.22480921121266492,"score_gpt":0.40771578315318063,"score_spread":0.1829065719405157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1603625064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83088547,0.00661372,0.00044390964,0.1203777,0.0006500033,0.00038757274,0.00034250395,0.000020683994,0.040278427],"genre_scores_gemma":[0.9889204,0.0040663653,0.00039709834,0.005298685,0.00096983474,0.0000022181082,0.000007481943,0.000048525853,0.00028937988],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964428,0.00060539675,0.0019943023,0.00028176294,0.00005151242,0.00062422134],"domain_scores_gemma":[0.99766284,0.00057008467,0.0010721538,0.0002908284,0.0000676932,0.0003363743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013405572,0.00019856625,0.00069055945,0.00032088658,0.000522157,0.00019221684,0.00058708544,0.000088321154,0.00006908807],"category_scores_gemma":[0.00013354159,0.00016781516,0.00013995277,0.00016550366,0.00032045072,0.00029615892,0.00015652929,0.001519289,0.00029973785],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014282869,0.00027527267,0.2878509,0.00017730225,0.00059188606,0.000025604084,0.0026592044,0.0023820633,0.000015024626,0.50948995,0.1576724,0.038717557],"study_design_scores_gemma":[0.0013237445,0.0001320804,0.17784901,0.000014042686,0.000014424284,0.000028564515,0.00017487208,0.00038384396,0.000037839527,0.05149672,0.76831967,0.000225166],"about_ca_topic_score_codex":0.00009625811,"about_ca_topic_score_gemma":0.000018761764,"teacher_disagreement_score":0.61064726,"about_ca_system_score_codex":0.00028084373,"about_ca_system_score_gemma":0.00016870901,"threshold_uncertainty_score":0.68433034},"labels":[],"label_agreement":null},{"id":"W1606568036","doi":"10.1136/bmj.321.7264.833/b","title":"Effect of drug patents in developing countries","year":2000,"lang":"en","type":"letter","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Per capita; Developing country; Gross domestic product; Human immunodeficiency virus (HIV); Business; Developed country; Drug; Development economics; Economic growth; Medicine; International trade; Environmental health; Economics; Virology; Pharmacology; Population","score_opus":0.04751275463281795,"score_gpt":0.3042359931747397,"score_spread":0.25672323854192175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1606568036","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06000055,0.0025017671,0.000009476358,0.8547465,0.0010344221,0.0008106777,0.0009287216,0.000026711261,0.079941146],"genre_scores_gemma":[0.02034743,0.00500806,0.00010599376,0.96792024,0.0023264436,0.00013953414,0.0002251025,0.000101470134,0.0038257136],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99814796,0.000046199828,0.0010153934,0.0003644708,0.00003117135,0.00039478246],"domain_scores_gemma":[0.9989937,0.00022915198,0.00043710723,0.00029571878,0.00000888165,0.00003545974],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008333957,0.00024692583,0.00087506254,0.00037155455,0.000025218502,0.000039185816,0.0003175745,0.0003598168,0.0007776219],"category_scores_gemma":[0.00004957372,0.0002783974,0.00015395116,0.00012599875,0.0000615927,0.00008434173,0.0000584171,0.00057170884,0.0013833701],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033618766,0.000007299963,0.007793316,0.0005223803,0.000058947528,0.000041845695,0.000098580196,0.000016851205,9.779687e-8,0.0038471695,0.9866992,0.00088068587],"study_design_scores_gemma":[0.0005624145,0.000026868522,0.0007190033,0.00009556897,0.000006067421,0.0000029428634,3.7812757e-7,0.00016407158,0.00008116773,0.0032271063,0.99480414,0.00031028016],"about_ca_topic_score_codex":0.00032623264,"about_ca_topic_score_gemma":0.0000118177095,"teacher_disagreement_score":0.11317372,"about_ca_system_score_codex":0.00016914755,"about_ca_system_score_gemma":0.0000517847,"threshold_uncertainty_score":0.9999668},"labels":[],"label_agreement":null},{"id":"W1607471832","doi":"10.2139/ssrn.258289","title":"Should the U.S. Allow Prescription Drug Reimports from Canada?","year":2001,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Drug; Prescription drug; Medicine; Pharmacology","score_opus":0.033626949842100136,"score_gpt":0.24569918266906204,"score_spread":0.21207223282696192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1607471832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9146378,0.014812747,0.00079537457,0.047620445,0.0012159889,0.0001698284,0.00009360562,0.000019057989,0.020635152],"genre_scores_gemma":[0.97594285,0.014990019,0.000012915232,0.0056400374,0.00067091157,0.0000062522427,0.00001287708,0.000025094643,0.0026990653],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.997574,0.000025691632,0.0005474829,0.00024519995,0.00005298696,0.0015546768],"domain_scores_gemma":[0.99923015,0.00004943363,0.00030365036,0.00025417664,0.000019296189,0.00014326828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012921196,0.00015273159,0.00023973912,0.00006517323,0.0002548952,0.000113292015,0.00042128062,0.00005961139,0.0005272792],"category_scores_gemma":[0.00005285788,0.00013472416,0.00011905432,0.000110605906,0.000034958648,0.00020622846,0.000043737105,0.0014119126,0.00012679276],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008820154,0.00008909862,0.11544047,0.000003165747,0.00048265723,0.000021195454,0.00025722533,0.00035030016,0.000038562575,0.8295538,0.043993134,0.009682207],"study_design_scores_gemma":[0.0003535408,0.000018803608,0.008564045,0.0000028941295,0.000010183697,0.00008325129,0.00013746158,0.0009941019,0.000015183685,0.5345978,0.45505294,0.00016977187],"about_ca_topic_score_codex":0.38001505,"about_ca_topic_score_gemma":0.7065367,"teacher_disagreement_score":0.4110598,"about_ca_system_score_codex":0.0013853454,"about_ca_system_score_gemma":0.001145338,"threshold_uncertainty_score":0.6241135},"labels":[],"label_agreement":null},{"id":"W1608419","doi":"","title":"�IN CIPRO WE TRUST�: BUT HOW DO WE FEEL ABOUT OUR DRUG PATENT LAWS?","year":2002,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Legislature; Political science; Incentive; Law; Law and economics; Public administration; Sociology; Economics","score_opus":0.14061384842621152,"score_gpt":0.2672517558786675,"score_spread":0.12663790745245598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1608419","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15886395,0.026331108,0.00045676992,0.28611907,0.0022243015,0.00075612316,0.0008870058,0.00025966455,0.524102],"genre_scores_gemma":[0.9180967,0.019266259,0.00037245874,0.0039154748,0.0005787934,0.00005146277,0.000007044356,0.00005873534,0.057653073],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99779207,0.000020558266,0.0007080626,0.000675783,0.000045386365,0.0007581355],"domain_scores_gemma":[0.9986796,0.000045861576,0.00029209803,0.00055266,0.000025771144,0.0004040438],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00039134256,0.00033434905,0.0006166791,0.00027233185,0.0001539045,0.00035555306,0.0004819589,0.00016593968,0.005152043],"category_scores_gemma":[0.00004926416,0.00035717434,0.000296505,0.00021668978,0.000051838706,0.00034938267,0.00015215273,0.00033879583,0.009491447],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021863341,0.00036794756,0.006180793,0.00008906208,0.00015966133,0.000015939737,0.0007163071,0.000077718236,0.00004199603,0.6909035,0.2761822,0.025243016],"study_design_scores_gemma":[0.0012016309,0.00003815571,0.00082757644,0.00001877411,0.000009711752,0.0000070836336,0.0002040725,0.016335094,0.00034037765,0.02985412,0.95056945,0.00059397623],"about_ca_topic_score_codex":0.00020758458,"about_ca_topic_score_gemma":0.000041346695,"teacher_disagreement_score":0.75923276,"about_ca_system_score_codex":0.00016314455,"about_ca_system_score_gemma":0.000013148809,"threshold_uncertainty_score":0.999888},"labels":[],"label_agreement":null},{"id":"W1618254171","doi":"","title":"Need for an improved submission process for listing drugs for reimbursement in Canadian provinces.","year":2003,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Formulary; CLARITY; Listing (finance); Reimbursement; Medicine; Work (physics); Process (computing); Public relations; Business; Marketing; Family medicine; Finance; Health care; Economic growth; Political science; Computer science","score_opus":0.09467310414187498,"score_gpt":0.300856754266625,"score_spread":0.20618365012475004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1618254171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8846979,0.0013650631,0.0050478983,0.010618688,0.00225884,0.02950768,0.003788302,0.00010778344,0.062607825],"genre_scores_gemma":[0.98498327,0.000013821026,0.0006486206,0.0013259327,0.0001712387,0.012141527,0.00006439167,0.00004154826,0.0006096377],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99806297,0.0000068235368,0.00054835225,0.0004342242,0.000013034558,0.0009345933],"domain_scores_gemma":[0.99900573,0.000091989416,0.0002046494,0.00017064459,0.000044760545,0.00048222666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014727609,0.00014937797,0.00030758316,0.0002522172,0.00014126857,0.00009284923,0.00019212924,0.00010593656,0.000011442188],"category_scores_gemma":[0.0006739496,0.00017865583,0.00009547548,0.00011644424,0.000020718406,0.00021757008,0.000008226555,0.00007338783,0.0000022336121],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005757225,0.0005691593,0.04524985,0.0013593914,0.00014266784,7.471735e-7,0.002021097,0.0005327343,0.000054297696,0.74581146,0.0046002194,0.19908263],"study_design_scores_gemma":[0.0047224145,0.00013446415,0.008028197,0.000010081216,0.000014617417,7.570328e-7,0.00018648131,0.08517256,0.0011261557,0.11645506,0.78350955,0.00063968595],"about_ca_topic_score_codex":0.014571678,"about_ca_topic_score_gemma":0.034335796,"teacher_disagreement_score":0.7789093,"about_ca_system_score_codex":0.0005037523,"about_ca_system_score_gemma":0.00019248083,"threshold_uncertainty_score":0.9919904},"labels":[],"label_agreement":null},{"id":"W1637876992","doi":"","title":"Price, Property and Trade Across a Regulatory Border: Pharmaceuticals (Re)importation from Canada and Beyond","year":2006,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"International trade; Intellectual property; Business; Property (philosophy); International economics; Economics; Economic geography; Political science; Law","score_opus":0.016352294784881295,"score_gpt":0.26776685351961865,"score_spread":0.25141455873473734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1637876992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96860343,0.018692212,0.0001772405,0.0077092685,0.0001574444,0.00014829294,0.0002046778,0.00001360634,0.0042938357],"genre_scores_gemma":[0.9893656,0.006821907,0.000057032805,0.0029572984,0.00031168235,0.0000063632497,0.00001623638,0.00002648171,0.00043743942],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9976318,0.000019995123,0.0005962704,0.00032150085,0.000047763137,0.001382684],"domain_scores_gemma":[0.9993428,0.000050976818,0.00028474972,0.000119319,0.000013100587,0.00018907932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008752402,0.00017857089,0.00031585267,0.00005961251,0.00023429339,0.00012632953,0.00013164507,0.00008536013,0.0000921574],"category_scores_gemma":[0.000026829179,0.00016539024,0.000049410854,0.00008870206,0.00008047593,0.00024640298,0.0000350214,0.00080226804,0.0000072411626],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018862786,0.00024173435,0.23042308,0.00005035179,0.00062123686,0.00002279851,0.0007037465,0.00010904057,0.0005985025,0.71044654,0.008057345,0.048536994],"study_design_scores_gemma":[0.00241632,0.00009289034,0.104426205,0.000008211705,0.000029345176,0.00012549761,0.00033115403,0.0027849416,0.00025313557,0.5940459,0.2949248,0.0005616558],"about_ca_topic_score_codex":0.14350237,"about_ca_topic_score_gemma":0.36827338,"teacher_disagreement_score":0.28686744,"about_ca_system_score_codex":0.00062142743,"about_ca_system_score_gemma":0.0006990214,"threshold_uncertainty_score":0.8622011},"labels":[],"label_agreement":null},{"id":"W1648976812","doi":"10.4212/cjhp.v61i4.61","title":"Bilan comparatif des médicaments : Par qui et comment?","year":2008,"lang":"fr","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Gynecology; Medicine","score_opus":0.10740282034183495,"score_gpt":0.3154597458317358,"score_spread":0.20805692548990085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1648976812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70850104,0.04620187,0.00004935933,0.21963228,0.00513921,0.00025721657,0.00066672504,0.000005378329,0.019546917],"genre_scores_gemma":[0.9666689,0.008671977,0.00018401034,0.022330757,0.0008014062,0.0000042949505,0.00000857029,0.000045904024,0.0012841575],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997465,0.00012122736,0.0012440166,0.00022885126,0.00007242942,0.0008684372],"domain_scores_gemma":[0.9971932,0.00014086443,0.00091328897,0.0002921685,0.00011931296,0.0013411242],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011111654,0.00030720828,0.0006551869,0.000325765,0.0008427507,0.00026093578,0.0009259318,0.00008390177,0.0026545157],"category_scores_gemma":[0.000104047955,0.0003099346,0.0003762231,0.00027461073,0.0013000367,0.00068119034,0.00006025518,0.0009239224,0.0007700779],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059329323,0.00039673297,0.3079626,0.0000589214,0.0008483992,0.00047766807,0.008740165,0.0006176173,0.0000060998477,0.057085987,0.62015986,0.0035866024],"study_design_scores_gemma":[0.0019378235,0.0003041699,0.025433213,0.00007123302,0.00005794756,0.00029067555,0.00012370376,0.0011805083,0.00011807287,0.01728631,0.95279634,0.00039997668],"about_ca_topic_score_codex":0.028668664,"about_ca_topic_score_gemma":0.009366977,"teacher_disagreement_score":0.33263648,"about_ca_system_score_codex":0.0007427575,"about_ca_system_score_gemma":0.0010420005,"threshold_uncertainty_score":0.99993527},"labels":[],"label_agreement":null},{"id":"W165696036","doi":"","title":"Pharmaceutical arbitrage: balancing access and innovation in international prescription drug markets.","year":2005,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Arbitrage; Incentive; Economic rent; Business; TRIPS architecture; Public economics; Medical prescription; Economics; Industrial organization; Microeconomics; Financial economics","score_opus":0.0723133381837423,"score_gpt":0.3070397556881053,"score_spread":0.23472641750436302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W165696036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8727678,0.0004335992,0.00017010464,0.015699167,0.00055792154,0.000368745,0.000054633038,0.000029329007,0.10991872],"genre_scores_gemma":[0.99386513,0.00044152772,0.000112236274,0.004429566,0.0002758369,0.00025871134,0.000015182659,0.000013041179,0.00058873993],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9988039,0.000012341522,0.000575504,0.00028510785,0.000026156766,0.00029696853],"domain_scores_gemma":[0.9996192,0.000038324604,0.00014437351,0.00009663527,0.000016635453,0.000084836734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092668063,0.00009985539,0.0001695982,0.0005268408,0.000031413307,0.00016869031,0.00020045297,0.000053695756,0.00023134632],"category_scores_gemma":[0.00015041526,0.00012581096,0.000026014266,0.00030650012,0.00003559909,0.00074939715,0.00010634203,0.00023159182,0.000049074766],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011652758,0.000189966,0.32731652,0.000042856118,0.000058870628,0.0000034703785,0.00027566333,0.0001759852,0.000025754865,0.43135843,0.004663101,0.23577286],"study_design_scores_gemma":[0.00096414506,0.000001319248,0.6216544,0.0000033912452,0.0000022816262,0.0000035787807,0.0000048891857,0.025205245,0.00020870559,0.016293839,0.33549076,0.00016745512],"about_ca_topic_score_codex":0.00004695941,"about_ca_topic_score_gemma":0.000028201184,"teacher_disagreement_score":0.4150646,"about_ca_system_score_codex":0.00017973437,"about_ca_system_score_gemma":0.000008357446,"threshold_uncertainty_score":0.5130422},"labels":[],"label_agreement":null},{"id":"W1664544119","doi":"10.1063/1.3137923","title":"Toward a Better Representation of Women in Physics in Burkina Faso","year":2009,"lang":"en","type":"article","venue":"AIP conference proceedings","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Preference; Quarter (Canadian coin); Population; Representation (politics); Mathematics education; Physics; Social science; Demography; Sociology; Geography; Political science; Mathematics; Statistics","score_opus":0.1079414189788852,"score_gpt":0.3114034167226903,"score_spread":0.20346199774380508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1664544119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95860696,0.000054390814,0.0002516243,0.0032057876,0.000042330794,0.00015443524,0.00001244667,0.000011639252,0.03766041],"genre_scores_gemma":[0.99807787,0.00016207108,0.00019226283,0.0014010306,0.00007082088,0.000027223547,0.000002898194,0.000008128078,0.00005769101],"study_design_codex":"observational","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99868315,0.0000029858174,0.0005536075,0.00030732967,0.000025933443,0.00042699746],"domain_scores_gemma":[0.999546,0.000020175848,0.00022375314,0.000085373315,0.00003457955,0.00009012456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037221814,0.00011682796,0.00041253306,0.00021163374,0.000012546955,0.0000503038,0.00020379132,0.00007646483,0.00012525212],"category_scores_gemma":[0.00010040165,0.00014640742,0.00004778,0.00036569196,0.000041355866,0.0003671163,0.000035474313,0.00017325602,0.00006127629],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005968847,0.00018069347,0.57210064,0.000050116087,0.000011597655,0.0000018771942,0.011930833,0.000009704984,0.0009992658,0.402159,0.00015967195,0.012336913],"study_design_scores_gemma":[0.0012228099,0.0001308914,0.2522664,0.000043527707,0.000001835333,0.0000013779207,0.00043969747,0.02299631,0.0014435465,0.71812296,0.0030356487,0.000295013],"about_ca_topic_score_codex":0.00020343931,"about_ca_topic_score_gemma":0.0000050860936,"teacher_disagreement_score":0.3198342,"about_ca_system_score_codex":0.0002471769,"about_ca_system_score_gemma":0.000029172908,"threshold_uncertainty_score":0.5970321},"labels":[],"label_agreement":null},{"id":"W1671872086","doi":"10.5539/gjhs.v7n5p311","title":"Assessing the Factors Associated With Iran’s Intra-Industry Trade in Pharmaceuticals","year":2015,"lang":"en","type":"article","venue":"Global Journal of Health Science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"Iran University of Medical Sciences","keywords":"Business; Order (exchange); Pharmaceutical industry; Tariff; Intra-industry trade; Product (mathematics); International trade; Trade barrier; International economics; Economics; Biotechnology","score_opus":0.3115110540027074,"score_gpt":0.43956482908499883,"score_spread":0.12805377508229143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1671872086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9759427,0.001651958,0.00012405515,0.01737181,0.00055389525,0.00010911477,0.000029168606,0.0000061733313,0.0042111822],"genre_scores_gemma":[0.99609524,0.00008641284,0.00008177461,0.0036644964,0.00006220959,8.147901e-7,4.2319985e-7,0.0000054619954,0.0000031919228],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979995,0.000051778465,0.0009998014,0.00020393655,0.00014615738,0.00059883],"domain_scores_gemma":[0.9982688,0.00007746063,0.0009301212,0.00013344632,0.000048687376,0.0005415311],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005864529,0.00012402063,0.00042570446,0.00015894225,0.00017074721,0.00025420965,0.00063278974,0.00008067337,0.000023114788],"category_scores_gemma":[0.000449791,0.000088354136,0.00005517579,0.00097165763,0.00039287755,0.00086364156,0.00004762907,0.00065032,0.000008907084],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015430063,0.00015215587,0.9805754,0.000007985375,0.000022141065,0.000010076446,0.00035790418,0.0008148596,0.000005790486,0.013741935,0.0009608243,0.0033355125],"study_design_scores_gemma":[0.0016352593,0.00018560117,0.97105443,0.00008149741,0.0000058188693,0.00008193067,0.0007361533,0.0035932688,0.00006386903,0.014309193,0.008042416,0.00021052922],"about_ca_topic_score_codex":0.000102034624,"about_ca_topic_score_gemma":0.000019121591,"teacher_disagreement_score":0.02015257,"about_ca_system_score_codex":0.0011077011,"about_ca_system_score_gemma":0.0010098814,"threshold_uncertainty_score":0.3602977},"labels":[],"label_agreement":null},{"id":"W168617775","doi":"","title":"Les risques liés à la création de PHARMA-QUEBEC","year":2014,"lang":"fr","type":"preprint","venue":"RePEc: Research Papers in Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science; Humanities; Geography; Economy; Economics; Art","score_opus":0.08679357500565897,"score_gpt":0.3933359261391098,"score_spread":0.3065423511334508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W168617775","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39410123,0.001978496,0.00017674746,0.008329664,0.0013203935,0.0009557975,0.00067617284,0.00007325001,0.5923883],"genre_scores_gemma":[0.8878515,0.08293406,0.001387235,0.0013332865,0.0016059947,0.00041750475,0.00018625402,0.00023548352,0.024048679],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99246925,0.0007932259,0.0024347745,0.0019750406,0.000109279405,0.00221842],"domain_scores_gemma":[0.99477136,0.0020168524,0.00093333697,0.0014258394,0.00012549476,0.0007271227],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.008159082,0.00078958727,0.0016668746,0.0013242685,0.00042362075,0.00080277055,0.0016254617,0.001555779,0.0020324711],"category_scores_gemma":[0.0011526663,0.0011557675,0.00065150124,0.00027171653,0.0010376421,0.00040479895,0.0013206886,0.0039037168,0.00073945225],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019255286,0.0006461524,0.03997421,0.0006107748,0.0004285078,0.00003800816,0.0013241859,0.034538485,0.00005708721,0.28674546,0.0015337854,0.6339108],"study_design_scores_gemma":[0.0012314181,0.000080227306,0.023326453,0.00021398644,0.000019100893,0.000019550775,0.00013866843,0.18436074,0.00016656659,0.028814062,0.760653,0.00097618205],"about_ca_topic_score_codex":0.01093193,"about_ca_topic_score_gemma":0.0045685316,"teacher_disagreement_score":0.7591193,"about_ca_system_score_codex":0.0052364804,"about_ca_system_score_gemma":0.0008195987,"threshold_uncertainty_score":0.9997404},"labels":[],"label_agreement":null},{"id":"W1718518342","doi":"10.1111/j.1360-0443.2006.01315.x","title":"The dangerousness of drugs","year":2006,"lang":"en","type":"review","venue":"Addiction","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psychology; MEDLINE; Medicine; Psychiatry; Criminology; Political science; Law","score_opus":0.07672741082469664,"score_gpt":0.3225229041115093,"score_spread":0.24579549328681266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1718518342","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000032408238,0.9367731,0.00004665323,0.00006521394,0.00073788356,0.00020891688,0.0005034051,0.000016763723,0.061644796],"genre_scores_gemma":[0.000071997296,0.99802816,0.0000118352355,0.000050792594,0.0003586102,0.000057353245,0.00009714952,0.00003253077,0.0012915718],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99860585,0.000020691707,0.000916026,0.00023537141,0.000017859937,0.00020423334],"domain_scores_gemma":[0.9986557,0.0001663873,0.00079172506,0.00033066023,0.000013032199,0.0000425363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000404496,0.00017234978,0.00083374453,0.00012965794,0.00010684064,0.00004389424,0.00026984146,0.00017670279,0.00009231216],"category_scores_gemma":[0.000027662792,0.00014394974,0.0003760357,0.00018354034,0.00007279498,0.0000626608,0.000049711405,0.00021163227,0.00064852193],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000001101554,0.000018168113,0.00000387228,0.0004959247,0.000093965304,1.7357337e-7,0.000012937346,0.0000014546769,6.573327e-9,0.11702954,0.011468243,0.8708746],"study_design_scores_gemma":[0.00007064279,0.000009468014,0.0000073271617,0.00020197427,0.00005601355,0.0000018940348,0.0000013741138,0.000057944766,3.235789e-7,0.004473437,0.99498147,0.00013810936],"about_ca_topic_score_codex":0.00014748842,"about_ca_topic_score_gemma":0.000009133415,"teacher_disagreement_score":0.98351324,"about_ca_system_score_codex":0.0001156468,"about_ca_system_score_gemma":0.00003461302,"threshold_uncertainty_score":0.83356535},"labels":[],"label_agreement":null},{"id":"W174126088","doi":"10.1017/s0317167100051957","title":"Generic Substitution for Brand Name Antiepileptic Drugs: A Survey","year":2000,"lang":"en","type":"article","venue":"Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Substitution (logic); Medicine; Brand names; Lamotrigine; Generic drug; Tolerability; Epilepsy; Drug; Family medicine; Psychiatry; Alternative medicine; Advertising; Business; Computer science","score_opus":0.09312740072709752,"score_gpt":0.2876731702053891,"score_spread":0.19454576947829155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W174126088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98602414,0.002761084,0.000095050964,0.003352293,0.0009134585,0.00016920113,0.00014725968,0.000010356188,0.006527161],"genre_scores_gemma":[0.9913623,0.0012228896,0.0007413701,0.0062421253,0.00033474568,0.000003780423,0.0000011281466,0.000011898277,0.00007980698],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996601,0.00029741257,0.0011862968,0.00052283646,0.00013281987,0.0012596463],"domain_scores_gemma":[0.99691117,0.00053843,0.00072323356,0.00013075535,0.00018130816,0.0015150997],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":["sts"],"category_scores_codex":[0.006463508,0.0002646033,0.0006028816,0.0007180969,0.0019936126,0.0008375956,0.0015914914,0.00016968854,0.0010617024],"category_scores_gemma":[0.0014879719,0.00021795963,0.0002874273,0.0008456902,0.00363919,0.0010041285,0.000024555831,0.0006276902,0.000039672235],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002032941,0.0000601277,0.95322263,0.000012705036,0.000036929698,0.00042000556,0.00045978156,0.008970999,0.0000072955336,0.024052842,0.0029520793,0.009601309],"study_design_scores_gemma":[0.0016624989,0.045185797,0.46521986,0.000036933565,0.000041563,0.0077050193,0.000065757864,0.026779318,0.00005840322,0.27176568,0.1803351,0.0011440797],"about_ca_topic_score_codex":0.0022315204,"about_ca_topic_score_gemma":0.018582793,"teacher_disagreement_score":0.48800278,"about_ca_system_score_codex":0.00021453852,"about_ca_system_score_gemma":0.0011982389,"threshold_uncertainty_score":0.99985147},"labels":[],"label_agreement":null},{"id":"W1743375347","doi":"10.1111/j.1755-5949.2010.00210.x","title":"Switching from Brand‐Name to Generic Psychotropic Medications: A Literature Review","year":2010,"lang":"en","type":"review","venue":"CNS Neuroscience & Therapeutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Lamotrigine; Venlafaxine; Tolerability; Medicine; Psychiatry; Topiramate; Quetiapine; Clonazepam; Cobicistat; Pharmacology; Psychology; Adverse effect; Anxiety; Epilepsy; Schizophrenia (object-oriented programming); Antidepressant","score_opus":0.16065040076187992,"score_gpt":0.3863121722456307,"score_spread":0.22566177148375077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1743375347","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000018757346,0.9890103,0.0009132288,0.0036468005,0.0027553965,0.0010133192,0.0010569971,0.000069835725,0.0015154044],"genre_scores_gemma":[0.000015642176,0.92877316,0.00039399238,0.06959752,0.0006060144,0.00018540652,0.00007613335,0.000091622285,0.0002605302],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963631,0.000073996685,0.0015035055,0.0012903525,0.00009931983,0.00066969334],"domain_scores_gemma":[0.9971212,0.00015520786,0.00085411296,0.0013718039,0.000031149815,0.00046652486],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005398974,0.00060222286,0.0019291643,0.0004220479,0.00024846764,0.00041179304,0.0018911603,0.00040335863,0.00019632412],"category_scores_gemma":[0.00010677565,0.00056875765,0.00057397824,0.0013437627,0.00013058503,0.000245348,0.00019564865,0.0013703926,0.0010969745],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000022117217,0.000113737144,0.000018583756,0.0031972856,0.00005823954,0.000009066765,0.00019542703,0.0000013038748,0.000021874263,0.009559663,0.0015932336,0.9852294],"study_design_scores_gemma":[0.00011555963,0.000034661913,0.000022037424,0.00570492,0.00018742692,0.000025235824,6.236113e-7,0.00016782325,6.9208227e-7,0.0034909162,0.9896769,0.0005732019],"about_ca_topic_score_codex":0.0000090802705,"about_ca_topic_score_gemma":0.000007077122,"teacher_disagreement_score":0.98808366,"about_ca_system_score_codex":0.00011304513,"about_ca_system_score_gemma":0.00016487078,"threshold_uncertainty_score":0.99968076},"labels":[],"label_agreement":null},{"id":"W1748239555","doi":"10.1111/dewb.12046","title":"Access to Medicines and Distributive Justice: Breaching <scp>D</scp>oha's Ethical Threshold","year":2014,"lang":"en","type":"article","venue":"Developing World Bioethics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"McGill University","keywords":"Distributive justice; Mirroring; Economic Justice; Public health; Right to health; Essential medicines; Global health; TRIPS architecture; Global justice; Political science; Access to medicines; Human rights; Law and economics; Medicine; Sociology; Law; Nursing","score_opus":0.14679517657460406,"score_gpt":0.38401018005297527,"score_spread":0.2372150034783712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1748239555","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23375982,0.0015760078,0.086201005,0.5332471,0.0037575494,0.0009678296,0.0005590135,0.0003412073,0.13959043],"genre_scores_gemma":[0.8952819,0.00049755845,0.0023936064,0.1006057,0.00071165856,0.000027549602,0.000040760842,0.000045449222,0.0003958132],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979103,0.000045370693,0.0007207155,0.00064659055,0.000075443124,0.000601577],"domain_scores_gemma":[0.99759674,0.0013902853,0.0002478115,0.0003092824,0.00007546226,0.00038040432],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00227642,0.00028600718,0.00055819214,0.000382774,0.00036554944,0.00037152023,0.0005351705,0.00035347306,0.000028980743],"category_scores_gemma":[0.0028341878,0.0003072821,0.000072481576,0.00057006115,0.00034110365,0.00020254662,0.0005016333,0.0013536495,0.00021375093],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000042728816,0.000017812434,0.022756115,0.00013032951,0.00004157153,0.0000022269646,0.0008004715,0.00003386606,0.0000062072163,0.9607244,0.014642337,0.00084034883],"study_design_scores_gemma":[0.0005592748,0.00003769982,0.049556226,0.00013839164,0.000027202417,0.000008071433,0.000091151785,0.0049484023,0.00030639427,0.1894932,0.7544991,0.00033489245],"about_ca_topic_score_codex":0.00012416135,"about_ca_topic_score_gemma":0.00028540098,"teacher_disagreement_score":0.77123123,"about_ca_system_score_codex":0.00014552499,"about_ca_system_score_gemma":0.0000782521,"threshold_uncertainty_score":0.99993795},"labels":[],"label_agreement":null},{"id":"W1757527718","doi":"10.1111/j.1475-6773.2005.00420.x","title":"The Impact of Reference Pricing of Nonsteroidal Anti‐Inflammatory Agents on the Use and Costs of Analgesic Drugs","year":2005,"lang":"en","type":"article","venue":"Health Services Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St Joseph's Health Centre; University of British Columbia; McMaster University; St. Joseph's Hospital; University of Toronto","funders":"Canadian Institutes of Health Research; Health Canada; Michael Smith Health Research BC; Canadian Health Services Research Foundation","keywords":"Reimbursement; Medicine; Subsidy; Beneficiary; Analgesic; Actuarial science; Business; Pharmacology; Finance; Health care; Economics","score_opus":0.21737116999918057,"score_gpt":0.4334958081180873,"score_spread":0.21612463811890673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1757527718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938927,0.0013875006,0.0000015316989,0.0018481786,0.000021182199,0.0003262078,0.00015145256,0.0000026940504,0.0023685005],"genre_scores_gemma":[0.99366814,0.005826072,0.000017823644,0.0004017697,0.00003465301,0.0000072491184,0.0000028415393,0.000010857416,0.00003061753],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998477,0.00011460395,0.00071381405,0.00019655323,0.000090844136,0.0004072204],"domain_scores_gemma":[0.9980008,0.00079784496,0.00055786635,0.00040028477,0.0001028567,0.00014036328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026489908,0.00009279316,0.0003162365,0.00021488847,0.00018870714,0.000047014724,0.00038819097,0.00005194031,0.000060869355],"category_scores_gemma":[0.000042276304,0.00006292163,0.00006171939,0.00026516247,0.00019162646,0.00014151138,0.00014867053,0.00028968882,0.000029071063],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006234954,0.00050986855,0.7152424,0.0017578922,0.00034384764,0.0000010882404,0.012049352,0.0020055585,0.00042565298,0.22492391,0.0018627758,0.040254183],"study_design_scores_gemma":[0.00087974186,0.00047803338,0.9249355,0.00034415268,0.000002616963,0.0000013225579,0.00058132794,0.061197266,0.0008210171,0.001756102,0.008845183,0.00015773594],"about_ca_topic_score_codex":0.0054272455,"about_ca_topic_score_gemma":0.00030061082,"teacher_disagreement_score":0.2231678,"about_ca_system_score_codex":0.00013474846,"about_ca_system_score_gemma":0.000120997174,"threshold_uncertainty_score":0.8204408},"labels":[],"label_agreement":null},{"id":"W176030775","doi":"","title":"How Countries of the Southern African Development Community (SADC) can use the World Trade Organisation and the European Community flexibilities for better access to affordable HIV/AIDS Medicines","year":2008,"lang":"en","type":"book-chapter","venue":"WestminsterResearch (University of Westminster)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"TRIPS architecture; Declaration; Interim; Intellectual property; TRIPS Agreement; International trade; Business; Developing country; Economic growth; Political science; Economics; Law; Engineering","score_opus":0.1502989219528176,"score_gpt":0.26912785873179174,"score_spread":0.11882893677897413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W176030775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.71045613,0.00063608657,0.00045832744,0.10024626,0.00039445754,0.004615147,0.0054059285,0.000059254282,0.17772843],"genre_scores_gemma":[0.92799765,0.00035459048,0.00023895343,0.002462978,0.00011308537,0.000007460303,0.00008258675,0.00007583439,0.06866684],"study_design_codex":"qualitative","study_design_gemma":"not_applicable","domain_scores_codex":[0.99806017,0.00046059242,0.0005565972,0.00030138993,0.00020868384,0.0004125736],"domain_scores_gemma":[0.9963463,0.0015202911,0.000683167,0.0011432664,0.00013368751,0.00017327695],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":["sts"],"category_scores_codex":[0.0032836108,0.000353197,0.00079715543,0.0003869811,0.0017070861,0.00023262078,0.0023270696,0.00012317499,0.00009391172],"category_scores_gemma":[0.00019888123,0.00026540365,0.00023608215,0.00014828579,0.0027192174,0.00034989402,0.0014931902,0.0010536349,0.000019469182],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023641,0.0005882888,0.030434305,0.0028393832,0.0026310638,0.000013102612,0.59205353,0.0000799002,0.000046128454,0.26822466,0.071306065,0.02941949],"study_design_scores_gemma":[0.002434689,0.00017953057,0.018574636,0.0002697466,0.00008772531,0.000008163574,0.013910469,0.00013736774,0.00006491153,0.0065606306,0.9572794,0.000492733],"about_ca_topic_score_codex":0.0024071173,"about_ca_topic_score_gemma":0.02067844,"teacher_disagreement_score":0.88597333,"about_ca_system_score_codex":0.00026479003,"about_ca_system_score_gemma":0.00020579268,"threshold_uncertainty_score":0.9999948},"labels":[],"label_agreement":null},{"id":"W176444246","doi":"","title":"Views on pharmaceutical access and governance in Australia, Canada and the United Kingdom (UK)","year":2011,"lang":"en","type":"article","venue":"Queensland's institutional digital repository (The University of Queensland)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Kingdom; Corporate governance; Political science; Public administration; Business; Finance","score_opus":0.10989707020272044,"score_gpt":0.27125805862034813,"score_spread":0.1613609884176277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W176444246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9264849,0.00019723136,0.00006430245,0.001033866,0.00020474763,0.00022173804,0.00022805025,0.000007947735,0.07155723],"genre_scores_gemma":[0.9984135,0.00020594163,0.000015857433,0.00060853857,0.000045205747,0.0000011109007,0.000009944943,0.0000058119954,0.0006940869],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9990631,0.000034607194,0.00033419215,0.00028367108,0.00006724332,0.0002172298],"domain_scores_gemma":[0.9992603,0.00018363661,0.00021733598,0.00019127359,0.000028212024,0.00011925291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020539647,0.00015630461,0.00030297437,0.00008076887,0.00023299974,0.0000681642,0.00034578683,0.000070064896,0.00008822858],"category_scores_gemma":[0.000058646936,0.00012602216,0.00006575601,0.0001518682,0.00086729584,0.0002755027,0.0001531808,0.00026101404,0.0000154765],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006510574,0.00007182305,0.21796404,0.00003171945,0.00009492124,0.00007014742,0.00051814556,0.00019093868,0.0000018127008,0.77862245,0.0014597167,0.00032322053],"study_design_scores_gemma":[0.0044899997,0.000069765854,0.6680225,0.00008985123,0.00003296081,0.000087972,0.00006836225,0.0031774908,0.000085107706,0.029054325,0.29438835,0.00043328537],"about_ca_topic_score_codex":0.34022066,"about_ca_topic_score_gemma":0.044832084,"teacher_disagreement_score":0.74956816,"about_ca_system_score_codex":0.00014498111,"about_ca_system_score_gemma":0.00010715872,"threshold_uncertainty_score":0.97259724},"labels":[],"label_agreement":null},{"id":"W1766634659","doi":"10.1111/jlme.12066","title":"Corruption of Pharmaceutical Markets: Addressing the Misalignment of Financial Incentives and Public Health","year":2013,"lang":"en","type":"article","venue":"The Journal of Law Medicine & Ethics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Carleton University","funders":"Canadian Institutes of Health Research","keywords":"Incentive; Business; Language change; Value (mathematics); Financial market; Public economics; Public health; Finance; Economics; Microeconomics; Medicine","score_opus":0.37081870959387464,"score_gpt":0.42308298481208667,"score_spread":0.05226427521821203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1766634659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.66627026,0.021018999,0.0016244851,0.30141023,0.0008193257,0.00036950328,0.00004407633,0.000004498191,0.008438624],"genre_scores_gemma":[0.9787998,0.0095111,0.00009031419,0.011300276,0.00026341024,0.0000014660335,8.6797075e-7,0.000009034158,0.000023713732],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99817765,0.00023999035,0.0011572716,0.00008523311,0.000110963636,0.00022888275],"domain_scores_gemma":[0.9971227,0.001080271,0.0013280533,0.00015903125,0.00014350479,0.00016640793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0073876483,0.00010326332,0.0004750328,0.00008563817,0.00014389529,0.00001796864,0.00029285916,0.00008625524,0.00025967025],"category_scores_gemma":[0.00088733115,0.00006258331,0.00006776855,0.00010508248,0.0010058538,0.00018027566,0.00007498485,0.0007871475,0.000004682549],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019928259,0.00025403872,0.004366017,0.0004221369,0.0001833901,0.0000011945461,0.023582086,0.000029972305,0.00075803767,0.94253963,0.005336305,0.02232792],"study_design_scores_gemma":[0.0073206285,0.001758206,0.07146114,0.0012494962,0.00017921704,0.00021154496,0.004204023,0.009198556,0.0012053826,0.26311088,0.6395943,0.00050661573],"about_ca_topic_score_codex":0.00048021288,"about_ca_topic_score_gemma":0.0000151284485,"teacher_disagreement_score":0.67942876,"about_ca_system_score_codex":0.00006222311,"about_ca_system_score_gemma":0.00014171023,"threshold_uncertainty_score":0.370611},"labels":[],"label_agreement":null},{"id":"W1772410503","doi":"","title":"U.S. prosecutors investigating Valeant Pharmaceuticals","year":2015,"lang":"en","type":"article","venue":"Drug Topics E-News","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science; Business; Criminology; Law; Sociology","score_opus":0.15823392659555977,"score_gpt":0.3316713487022646,"score_spread":0.17343742210670485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1772410503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5869036,0.004127805,0.00086526125,0.036476485,0.0031826382,0.0007229816,0.00025805374,0.00024204317,0.36722118],"genre_scores_gemma":[0.9695426,0.0004887815,0.004458193,0.01814631,0.0017906014,0.000058922666,0.000026762269,0.00006938545,0.0054184496],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99810904,0.000032309435,0.00080286217,0.00047635142,0.000052703763,0.0005267157],"domain_scores_gemma":[0.99861145,0.00006663725,0.00026440734,0.0003949745,0.000036931,0.0006256054],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006578555,0.00022513024,0.0004651627,0.00014963225,0.00008941338,0.0001424821,0.00037926342,0.00010397856,0.0003405179],"category_scores_gemma":[0.000504112,0.00025600268,0.00013708638,0.00020368084,0.000109646775,0.00024791682,0.00016637424,0.00032532008,0.0021614078],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010515438,0.00011471432,0.06553923,0.000054645363,0.000069559785,0.000008197164,0.0025979723,0.00013132147,0.000035301546,0.88302094,0.043128844,0.0052887695],"study_design_scores_gemma":[0.0006464334,0.000020423298,0.00043655324,0.000010493889,0.000009322233,0.000004755083,0.00015321691,0.005322965,0.000615384,0.22395155,0.7684795,0.0003493785],"about_ca_topic_score_codex":0.0003181649,"about_ca_topic_score_gemma":0.000030151963,"teacher_disagreement_score":0.7253507,"about_ca_system_score_codex":0.00015078165,"about_ca_system_score_gemma":0.00007980248,"threshold_uncertainty_score":0.9999892},"labels":[],"label_agreement":null},{"id":"W1777587551","doi":"10.1016/s0140-6736(15)00469-9","title":"Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data","year":2015,"lang":"en","type":"article","venue":"The Lancet","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":394,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; Université Laval; Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"Canadian Institutes of Health Research; International Development Research Centre; Heart and Stroke Foundation of Canada","keywords":"Pharmacy; Medicine; Environmental health; Disease; Middle income; Rural area; Socioeconomics; Business; Economics; Demographic economics; Family medicine","score_opus":0.08904064535655133,"score_gpt":0.29706354220641584,"score_spread":0.20802289684986452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1777587551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99388623,0.0023879022,0.0000057872007,0.0006554763,0.000085917294,0.0005765268,0.0023353128,0.000007533029,0.000059308084],"genre_scores_gemma":[0.9991928,0.0005129233,0.00000804343,0.0001633641,0.00007693163,0.000014492522,0.000016622973,0.000010681929,0.000004163733],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99838823,0.00025956985,0.0005763113,0.0004965509,0.00006931196,0.00021002535],"domain_scores_gemma":[0.9967376,0.0006037784,0.00023100141,0.0022329662,0.000031623644,0.00016305508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004747976,0.00018649812,0.0012895038,0.00014503885,0.000063571526,0.0000514309,0.0005747137,0.000051117313,0.000011344269],"category_scores_gemma":[0.00071149634,0.00011225965,0.000092204966,0.00036362538,0.00045776795,0.00022304997,0.00043508387,0.00016895354,0.0000011966977],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027841853,0.00009765139,0.9959713,0.00018319684,0.00072298327,7.5305104e-7,0.00058689923,0.00040159147,4.0118314e-7,0.0015936781,0.000008930417,0.00015415631],"study_design_scores_gemma":[0.0018684773,0.00017005297,0.9794902,0.000039289884,0.00031203358,4.0339586e-7,0.000098331584,0.01405162,0.0000088590705,0.0033374284,0.00049911166,0.0001241717],"about_ca_topic_score_codex":0.0017661012,"about_ca_topic_score_gemma":0.0009820965,"teacher_disagreement_score":0.01648112,"about_ca_system_score_codex":0.00004815723,"about_ca_system_score_gemma":0.000025726182,"threshold_uncertainty_score":0.45778158},"labels":[],"label_agreement":null},{"id":"W1802737629","doi":"","title":"The Globalization of Clinical Trials for New Medicines: Where are the Trials Going and Why?","year":2007,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Quest University Canada","funders":"","keywords":"Globalization; Latin Americans; Clinical trial; Market size; Intellectual property; Business; International trade; Development economics; Economics; Medicine; Political science; Commerce; Market economy","score_opus":0.22067453449043675,"score_gpt":0.44408514317785824,"score_spread":0.2234106086874215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1802737629","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10508402,0.3333007,0.34611416,0.1953665,0.0057201516,0.0029380575,0.00018364035,0.000039590803,0.011253171],"genre_scores_gemma":[0.8257519,0.16542703,0.00011487462,0.003353597,0.0045297677,0.000007824321,0.0000034485772,0.00003258485,0.00077898044],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99554634,0.0002449101,0.0029993446,0.00018753675,0.000044062497,0.0009777902],"domain_scores_gemma":[0.992075,0.0049084406,0.0026396548,0.00017596346,0.00005726765,0.00014367035],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.092750795,0.00012340232,0.00092510023,0.0000690709,0.0002689459,0.00009393373,0.00029871904,0.00011745611,0.000022758244],"category_scores_gemma":[0.009838533,0.000074612166,0.00038425304,0.00011992347,0.00010284208,0.00010591443,0.000029324296,0.00062986504,0.000008097134],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034102748,0.000022323436,0.009188474,0.000008945003,0.0003411995,1.6256718e-7,0.00007126267,0.0000150333435,0.0000052413216,0.90844953,0.009622208,0.0719346],"study_design_scores_gemma":[0.0022176248,0.00015096828,0.00088393094,0.00001797433,0.00005355278,0.000020372652,0.00048508268,0.0008158811,0.000013259772,0.616686,0.37856853,0.00008684244],"about_ca_topic_score_codex":0.00006098182,"about_ca_topic_score_gemma":0.0012808534,"teacher_disagreement_score":0.7206679,"about_ca_system_score_codex":0.00016210297,"about_ca_system_score_gemma":0.00050416193,"threshold_uncertainty_score":0.998502},"labels":[],"label_agreement":null},{"id":"W1822053319","doi":"10.1515/9783828260160-009","title":"Wettbewerbspotenziale im deutschen Apothekenmarkt","year":2011,"lang":"de","type":"book-chapter","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mitel (Canada)","funders":"","keywords":"Pharmacy; Competition (biology); Business; Industrial organization; Actuarial science; Marketing; Medicine; Family medicine","score_opus":0.10010311090639015,"score_gpt":0.2540085539864817,"score_spread":0.15390544308009155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1822053319","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003273143,0.012247122,0.000668537,0.002618707,0.003472724,0.0007182798,0.002196955,0.00011632486,0.977634],"genre_scores_gemma":[0.0541968,0.044764683,0.0015887424,0.017554967,0.0040795295,0.00006368883,0.00031003953,0.00064024655,0.8768013],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99429166,0.000019999898,0.0025344628,0.0017525736,0.00007611745,0.0013251557],"domain_scores_gemma":[0.995891,0.00017272412,0.0013780183,0.0015293619,0.00008919843,0.0009397144],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00091632653,0.0012215865,0.0021442927,0.00079475937,0.00034464526,0.00026213942,0.0012986019,0.0014356637,0.14501156],"category_scores_gemma":[0.00007711973,0.0015190032,0.0011929994,0.000089546484,0.0005452421,0.00033209563,0.0005595441,0.0013128942,0.16234627],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008617085,0.00011771097,0.00046017606,0.00010014017,0.0008907268,0.000024421124,0.0001720372,0.000004617076,0.0000039797696,0.97380644,0.018153552,0.0061800317],"study_design_scores_gemma":[0.0007409169,0.00010422935,0.00015157899,0.000043705793,0.00010146553,0.000010377542,0.000004363982,0.0004703013,0.00005222527,0.29927573,0.69773847,0.0013066042],"about_ca_topic_score_codex":0.00044073834,"about_ca_topic_score_gemma":0.000057799385,"teacher_disagreement_score":0.6795849,"about_ca_system_score_codex":0.00034191206,"about_ca_system_score_gemma":0.00014152612,"threshold_uncertainty_score":0.9998607},"labels":[],"label_agreement":null},{"id":"W1826192669","doi":"10.1177/1355819615593302","title":"Why does increasing public access to medicines differ between countries? Qualitative comparison of nine countries","year":2015,"lang":"en","type":"article","venue":"Journal of Health Services Research & Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Douglas Pharmaceuticals","keywords":"Pharmacy; Government (linguistics); Medical prescription; Business; Flexibility (engineering); Qualitative research; Marketing; Medicine; Family medicine; Nursing; Economics","score_opus":0.37846617348477435,"score_gpt":0.5591695413858547,"score_spread":0.18070336790108038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1826192669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7084692,0.0058981376,0.00020525123,0.28250992,0.00026953002,0.00037227696,0.00048605373,0.000010039258,0.0017795396],"genre_scores_gemma":[0.97293746,0.0016713357,0.0002182615,0.02362794,0.0014392433,0.000009475627,0.0000141936225,0.00003283664,0.00004924628],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949195,0.00065098284,0.002703707,0.0002898421,0.00043502744,0.0010009352],"domain_scores_gemma":[0.9935027,0.0014667126,0.0019184147,0.00033772792,0.0013979548,0.001376492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015220636,0.0002224349,0.0015248605,0.002199537,0.00025621668,0.00036045315,0.0012487785,0.00012600672,0.00021487866],"category_scores_gemma":[0.0011935587,0.0001813167,0.0001208429,0.001102549,0.0002844883,0.0010840159,0.0003961204,0.0006690123,0.000062677755],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088567566,0.00044670564,0.6881288,0.0022977437,0.0005272449,0.0000060497446,0.14325513,0.000070110116,0.000014650591,0.07400054,0.08801196,0.002355358],"study_design_scores_gemma":[0.0021760175,0.0012060364,0.04291624,0.00045777689,0.000011318073,0.000009955439,0.013162333,0.00052413053,0.00021610191,0.05325632,0.8857469,0.0003168737],"about_ca_topic_score_codex":0.018644039,"about_ca_topic_score_gemma":0.0009802607,"teacher_disagreement_score":0.7977349,"about_ca_system_score_codex":0.00091974234,"about_ca_system_score_gemma":0.0013298342,"threshold_uncertainty_score":0.9878909},"labels":[],"label_agreement":null},{"id":"W1828580554","doi":"10.2139/ssrn.2171392","title":"Innovation Incentives Under Transferable Fast-Track Regulatory Review","year":2012,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Incentive; Track (disk drive); Business; Industrial organization; Computer science; Economics; Microeconomics","score_opus":0.042028063192406595,"score_gpt":0.28862421108840336,"score_spread":0.24659614789599676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1828580554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45023796,0.4490275,0.01771432,0.020916462,0.0013934677,0.0005088987,0.00005607368,0.00006725073,0.060078055],"genre_scores_gemma":[0.873475,0.118984595,0.000040929055,0.0056203385,0.00047543042,0.000007173803,0.000008348272,0.000026075202,0.0013620965],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9972056,0.000029564493,0.00073533884,0.00017818008,0.0000377176,0.0018135929],"domain_scores_gemma":[0.9993689,0.000023016224,0.0002814475,0.00017103823,0.00003927744,0.000116321746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031643535,0.00015241925,0.00033269936,0.0002041538,0.00015065582,0.000043759806,0.00021247605,0.00007955424,0.00051318377],"category_scores_gemma":[0.0000450647,0.0001662398,0.00012778472,0.00035169887,0.000043816428,0.00065360154,0.000019746203,0.0010835215,0.0005585483],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008033897,0.00007265686,0.0033994971,0.000040419847,0.00009714328,1.02686656e-7,0.000057454316,0.000008767704,0.00004138654,0.9896869,0.0010554511,0.005532167],"study_design_scores_gemma":[0.0006634385,0.00006767636,0.006323098,0.00008185305,0.000023246017,0.00009416852,0.00010538473,0.000081809834,0.00012978862,0.77575505,0.21632221,0.0003522532],"about_ca_topic_score_codex":0.000013866385,"about_ca_topic_score_gemma":0.000014698948,"teacher_disagreement_score":0.42323706,"about_ca_system_score_codex":0.0007884818,"about_ca_system_score_gemma":0.0002782466,"threshold_uncertainty_score":0.7179195},"labels":[],"label_agreement":null},{"id":"W1834765452","doi":"10.1185/03007990903044374","title":"Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries","year":2009,"lang":"en","type":"article","venue":"Current Medical Research and Opinion","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Topiramate; Medicine; Demography; Cohort; Pharmacoepidemiology; Pediatrics; Medical prescription; Epilepsy; Psychiatry; Internal medicine","score_opus":0.32516430329213475,"score_gpt":0.5214437338699924,"score_spread":0.19627943057785768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1834765452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98698723,0.0023644527,0.00003393912,0.000851693,0.00040601852,0.00019473599,0.0002479334,0.0000061022934,0.008907899],"genre_scores_gemma":[0.97794515,0.021650339,0.000015781976,0.000060653572,0.0002743586,0.0000018703502,0.00002490011,0.000008285678,0.000018653947],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99791926,0.00012769515,0.0012109457,0.00028924167,0.00011869286,0.000334153],"domain_scores_gemma":[0.99870723,0.00038144548,0.00029862,0.0002139391,0.000058991634,0.00033976685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035518424,0.000110600544,0.0005581226,0.00028048892,0.000035563215,0.000017950624,0.00029269632,0.0000863736,0.00046534446],"category_scores_gemma":[0.0009665867,0.000099057426,0.0001635084,0.00013458672,0.00040618214,0.00007131389,0.00007934543,0.0004029169,0.0000753767],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014266545,0.001704871,0.27922228,0.00084219506,0.00023908315,0.000004899126,0.0005298531,0.000053283038,0.00007480089,0.3761495,0.02833694,0.31141564],"study_design_scores_gemma":[0.004375562,0.005708117,0.8048131,0.00054964615,0.0000060103184,0.0000035326054,0.000018495692,0.014072636,0.00077957066,0.017507982,0.15181279,0.00035257856],"about_ca_topic_score_codex":0.000081715174,"about_ca_topic_score_gemma":0.000001423736,"teacher_disagreement_score":0.5255908,"about_ca_system_score_codex":0.00007448733,"about_ca_system_score_gemma":0.00025719518,"threshold_uncertainty_score":0.5095195},"labels":[],"label_agreement":null},{"id":"W1838448105","doi":"","title":"NABP pushes for cross-border pharmacy regulation","year":2004,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy; Medicine; Community practice; Community pharmacy; Clinical pharmacy; Pharmaconomist; Family medicine; Multistate Pharmacy Jurisprudence Examination","score_opus":0.08503043637552603,"score_gpt":0.4146419413176108,"score_spread":0.32961150494208474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1838448105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.48284566,0.0014370983,0.053001344,0.018853815,0.0014042279,0.0009514363,0.0004970414,0.00019486998,0.4408145],"genre_scores_gemma":[0.98569053,0.00012827133,0.0025840418,0.004956092,0.00034113528,0.000059547518,0.000028479883,0.00002915401,0.006182766],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989234,0.0000020297991,0.00045914034,0.00030168245,0.000012757071,0.0003009876],"domain_scores_gemma":[0.99950963,0.000036412337,0.00013182627,0.0001812463,0.000027745544,0.000113139635],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00025683668,0.00011973126,0.00022085685,0.00010505593,0.00011588722,0.00012506262,0.00012530916,0.00005316492,0.002643159],"category_scores_gemma":[0.000057324178,0.00013884382,0.00012943194,0.000097410884,0.000051998853,0.0003248065,0.000031441985,0.00006895342,0.0010761952],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003048463,0.000064850385,0.004509163,0.000022262602,0.000033432327,2.2688762e-7,0.000073928546,0.001563617,0.00009010247,0.9893088,0.0014553303,0.0028478296],"study_design_scores_gemma":[0.0019688394,0.000020689296,0.0044860253,0.0000022188651,0.0000025997547,0.0000020966866,0.0000029428372,0.0043128408,0.0022097563,0.2998212,0.6869728,0.00019796815],"about_ca_topic_score_codex":0.00018754725,"about_ca_topic_score_gemma":0.00001721096,"teacher_disagreement_score":0.6894876,"about_ca_system_score_codex":0.00010945957,"about_ca_system_score_gemma":0.000026830076,"threshold_uncertainty_score":0.99970156},"labels":[],"label_agreement":null},{"id":"W1844756772","doi":"","title":"US states ponder buying drugs from Canada.","year":2003,"lang":"en","type":"article","venue":"Europe PMC (PubMed Central)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Governor; Medical prescription; State (computer science); Drug industry; Medicine; Business; Pharmacology; Computer science; Engineering; Engineering ethics","score_opus":0.030629865585705834,"score_gpt":0.21895842542021451,"score_spread":0.1883285598345087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1844756772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8793045,0.0025454347,0.00008976805,0.0023204547,0.0016722811,0.00023092101,0.00078538316,0.000044910757,0.11300634],"genre_scores_gemma":[0.989675,0.0010724517,0.0001606362,0.0069618216,0.00024324469,0.000021499913,0.000044571643,0.00005954719,0.0017612498],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99761987,0.00004290902,0.000606303,0.0005145294,0.00004700134,0.0011694173],"domain_scores_gemma":[0.99872845,0.00009277378,0.00021156528,0.00036888506,0.00002237284,0.00057597045],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035205763,0.00023392067,0.00036923875,0.00008311937,0.00011221736,0.0001349919,0.0003073137,0.000058674457,0.0015155368],"category_scores_gemma":[0.00022021175,0.0002759964,0.00007903702,0.00022692929,0.00004564447,0.00017273871,0.000055854267,0.0002546386,0.0005155501],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007544506,0.00030249124,0.5021663,0.000057444126,0.000562117,0.00011825113,0.005889776,0.0015176468,0.000080942584,0.39664426,0.08634433,0.006241034],"study_design_scores_gemma":[0.0006025538,0.00000562488,0.07185085,0.000004104642,0.000007822496,0.0000020751934,0.000038797774,0.0003960838,0.00067959185,0.008624043,0.9174257,0.00036274132],"about_ca_topic_score_codex":0.117374554,"about_ca_topic_score_gemma":0.014518419,"teacher_disagreement_score":0.8310814,"about_ca_system_score_codex":0.00037697586,"about_ca_system_score_gemma":0.00019556178,"threshold_uncertainty_score":0.99996924},"labels":[],"label_agreement":null},{"id":"W1852804143","doi":"10.4212/cjhp.v60i5.198","title":"Nouvelles normes de gestion des médicaments pour l’agrément de 2008 : de meilleures pratiques pour plus de sécurité","year":2007,"lang":"fr","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario","funders":"","keywords":"Political science; Gynecology; Medicine","score_opus":0.051439282843818886,"score_gpt":0.29703963736234135,"score_spread":0.24560035451852247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1852804143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86597025,0.037520967,0.0014094642,0.08783501,0.0010741244,0.00023617037,0.00023357003,0.000009227384,0.0057111993],"genre_scores_gemma":[0.9739392,0.013300071,0.0022867026,0.006426362,0.0015458347,0.0000064168526,0.0000036572121,0.000062425635,0.0024293372],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968437,0.0001408007,0.0010926423,0.00024163611,0.000075696575,0.0016055201],"domain_scores_gemma":[0.99679047,0.00026242857,0.00078746123,0.00020026448,0.00013690827,0.0018224631],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003539417,0.00033892572,0.0004962005,0.000417096,0.00055269396,0.00034665116,0.0007632899,0.00018998705,0.0011881278],"category_scores_gemma":[0.0004407156,0.00036209243,0.00033300353,0.00019700211,0.0004351295,0.00045781783,0.00005234919,0.0009876653,0.00012994488],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038426003,0.0008016335,0.5482874,0.00028255858,0.001671295,0.0014837517,0.03125289,0.009982801,0.0004254037,0.11522846,0.23922662,0.050972912],"study_design_scores_gemma":[0.0056677083,0.00072693225,0.17938128,0.0004940225,0.00035891446,0.0016799576,0.0019900666,0.03196561,0.009663546,0.10426316,0.6624402,0.0013685912],"about_ca_topic_score_codex":0.06087245,"about_ca_topic_score_gemma":0.03546383,"teacher_disagreement_score":0.4232136,"about_ca_system_score_codex":0.0048549054,"about_ca_system_score_gemma":0.005559078,"threshold_uncertainty_score":0.9998831},"labels":[],"label_agreement":null},{"id":"W1853635131","doi":"10.1111/jphs.12029","title":"Societal monetary benefits of pharmaceutical innovation: the case of ramipril in Canada","year":2013,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Health Services Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Institute of Health Economics","funders":"Pfizer Canada","keywords":"Ramipril; Medicine; Productivity; Population; Health care; Developing country; Economic growth; Economics; Environmental health","score_opus":0.1717247181537969,"score_gpt":0.43546610408512715,"score_spread":0.26374138593133023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1853635131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9641913,0.012182326,0.000018795436,0.020778118,0.00038050325,0.0005359281,0.00018026934,0.000002749495,0.0017299905],"genre_scores_gemma":[0.99040425,0.0040780543,0.00016165529,0.0050389487,0.0002501348,0.000013221661,0.000004031926,0.000023307843,0.000026409067],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9954141,0.00026934154,0.0029014768,0.00026841415,0.00026588,0.00088082557],"domain_scores_gemma":[0.9965963,0.0009190495,0.0010280281,0.0002927358,0.00066835753,0.00049555895],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0054154694,0.00019005909,0.0008401748,0.0006144897,0.00014390903,0.00004887753,0.0008011336,0.00010628591,0.0011486534],"category_scores_gemma":[0.000089311456,0.00016165662,0.00014018247,0.0015592532,0.00026737078,0.0004178436,0.00024815692,0.0015578074,0.00004187279],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019685142,0.0038619088,0.2401009,0.013422439,0.001595306,0.00078373204,0.011025825,0.011845036,0.0013305492,0.40975603,0.028817406,0.27549237],"study_design_scores_gemma":[0.015753672,0.0015434669,0.118758105,0.0010444712,0.000070344584,0.0021381131,0.010097343,0.6086227,0.008338635,0.063353464,0.16892672,0.0013529554],"about_ca_topic_score_codex":0.40203372,"about_ca_topic_score_gemma":0.06097852,"teacher_disagreement_score":0.5967777,"about_ca_system_score_codex":0.000732968,"about_ca_system_score_gemma":0.0014382997,"threshold_uncertainty_score":0.99976444},"labels":[],"label_agreement":null},{"id":"W1866068151","doi":"","title":"Prescription Drug Importation Beyond Canada","year":2005,"lang":"en","type":"article","venue":"California Western international law journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Prescription drug; TRIPS architecture; Business; Medicare Part D; Health insurance; Drug; Health care; Public health; Public economics; Actuarial science; Medicine; Economic growth; Pharmacology; Economics; Computer science","score_opus":0.02157989954778157,"score_gpt":0.2526976405134175,"score_spread":0.23111774096563592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1866068151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.59035486,0.0012925193,0.00350304,0.07179853,0.006436849,0.0002519951,0.003145392,0.000054882552,0.32316193],"genre_scores_gemma":[0.98489517,0.000128424,0.000282499,0.01179281,0.0013199174,0.0000069585208,0.000071893744,0.0000215239,0.0014808149],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986767,0.000012086795,0.0007660284,0.0002057567,0.00008264849,0.00025677847],"domain_scores_gemma":[0.99915,0.000028894563,0.00041344186,0.000114713235,0.000069713205,0.00022327574],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00035544756,0.00013487815,0.00019326022,0.00010000744,0.00017891148,0.00023447159,0.00032861912,0.00004694879,0.001535231],"category_scores_gemma":[0.000033122793,0.00015253137,0.00009694882,0.000040970466,0.000036173653,0.00046505927,0.000041678664,0.00027873184,0.0008297944],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000071646566,0.00014058997,0.12010681,0.0000135926775,0.00025376971,0.000029087432,0.00026518505,0.0023609186,0.000063677486,0.80485964,0.06792821,0.003906905],"study_design_scores_gemma":[0.0005774764,0.000007912248,0.0052132835,0.000007887271,0.0000050486324,0.00009841749,0.000015437694,0.004303065,0.00015696921,0.025549907,0.963878,0.00018663767],"about_ca_topic_score_codex":0.03365414,"about_ca_topic_score_gemma":0.33890754,"teacher_disagreement_score":0.8959497,"about_ca_system_score_codex":0.00062506116,"about_ca_system_score_gemma":0.000078332414,"threshold_uncertainty_score":0.9999482},"labels":[],"label_agreement":null},{"id":"W188107344","doi":"","title":"Minnesota: Leading the Way on Canadian Prescription Medicine Importation","year":2005,"lang":"en","type":"article","venue":"William Mitchell law review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Business; Law; Medicine; Political science; Pharmacology","score_opus":0.07033288168608894,"score_gpt":0.3005335662890904,"score_spread":0.23020068460300147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W188107344","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032051357,0.18465571,0.000031992604,0.15683384,0.00067195017,0.0008210915,0.00012131762,0.00003819821,0.6536208],"genre_scores_gemma":[0.6365754,0.17780958,0.00009713303,0.18048656,0.0012742745,0.00009775203,0.00007940327,0.000051481275,0.003528402],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99849814,0.000025217252,0.0007460268,0.00032713418,0.000035777943,0.00036770687],"domain_scores_gemma":[0.99900675,0.00006378941,0.00027018262,0.00039544806,0.000023359084,0.00024048117],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0009249623,0.00018317532,0.00044822975,0.00007983466,0.0001812518,0.000036810317,0.00026963756,0.000075051496,0.0017326726],"category_scores_gemma":[0.00009496542,0.00014714328,0.00012635584,0.00017486459,0.00009365705,0.00022842627,0.000015155864,0.0002110046,0.004431207],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000022605855,0.00001757931,0.00031606696,0.00019113411,0.000026729049,0.0000010623309,0.00009716951,0.000021290913,0.000008714114,0.9060237,0.085854225,0.0074400827],"study_design_scores_gemma":[0.00018888027,0.000028046377,0.0006174719,0.00033997037,0.000020810467,0.0000035180954,0.0000020331795,0.0003055211,0.000036590496,0.0058447355,0.9924373,0.00017511327],"about_ca_topic_score_codex":0.010628289,"about_ca_topic_score_gemma":0.02337581,"teacher_disagreement_score":0.9065831,"about_ca_system_score_codex":0.00024624149,"about_ca_system_score_gemma":0.000025179428,"threshold_uncertainty_score":0.9991799},"labels":[],"label_agreement":null},{"id":"W1887794268","doi":"10.15406/mojbb.2015.01.00009","title":"Governments Need to Act on Cancer Drug Shortages Affecting Public Health","year":2015,"lang":"en","type":"article","venue":"MOJ Bioequivalence & Bioavailability","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Works and Government Services Canada","funders":"","keywords":"Economic shortage; Drug; Cancer drugs; Public health; Business; Environmental health; Medicine; Government (linguistics); Pharmacology; Nursing","score_opus":0.21432905966513396,"score_gpt":0.36100572859547686,"score_spread":0.1466766689303429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1887794268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.932846,0.0013355161,0.0000952333,0.046759695,0.0011126051,0.0007055542,0.000997085,0.000115777446,0.016032537],"genre_scores_gemma":[0.9870201,0.00034361618,0.00022367503,0.011163278,0.0002776025,0.00007773494,0.000012458778,0.000038814254,0.00084277417],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968192,0.0000917294,0.0009146554,0.0010332674,0.00013268548,0.0010084619],"domain_scores_gemma":[0.99743277,0.00012025985,0.00039409968,0.00081200333,0.000056861452,0.0011839892],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003272647,0.0003422652,0.00065174344,0.00020269067,0.00018701192,0.00020174439,0.00062927377,0.000110699686,0.0007931393],"category_scores_gemma":[0.000727811,0.00037318835,0.00017101638,0.0004881281,0.00016462791,0.00036892697,0.0002799721,0.0003219922,0.002124725],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000120343306,0.0007560033,0.9043365,0.00014881906,0.00009688539,0.000002866014,0.0025736652,0.00014275612,0.0001420673,0.022332503,0.044338424,0.025009133],"study_design_scores_gemma":[0.001827692,0.0007570595,0.2368385,0.00008184462,0.000011280627,0.0000028178301,0.00073076296,0.0024135704,0.0013963216,0.007935135,0.7465134,0.0014915614],"about_ca_topic_score_codex":0.0026443289,"about_ca_topic_score_gemma":0.00029723128,"teacher_disagreement_score":0.702175,"about_ca_system_score_codex":0.0018964902,"about_ca_system_score_gemma":0.0002354458,"threshold_uncertainty_score":0.999872},"labels":[],"label_agreement":null},{"id":"W1903125184","doi":"","title":"Drug prices stable but total spending rises by 15","year":2002,"lang":"en","type":"article","venue":"Europe PMC (PubMed Central)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug prices; Drug industry; Medicine; Business; Agricultural economics; Economics; Monetary economics; Biotechnology; Biology","score_opus":0.04841724448494258,"score_gpt":0.23150444944660753,"score_spread":0.18308720496166495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1903125184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75441104,0.008820057,0.000072017836,0.0023239453,0.0013019957,0.00036391127,0.00070620934,0.00015135582,0.23184948],"genre_scores_gemma":[0.9713231,0.0042194906,0.0001776066,0.0010911345,0.00051125855,0.00003305355,0.000020804151,0.00006975043,0.022553837],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973332,0.000025527012,0.00066248,0.00057986565,0.000049310227,0.0013495653],"domain_scores_gemma":[0.9987085,0.000068252724,0.00029372046,0.00035872983,0.0000143157595,0.0005564906],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0003990612,0.00026445882,0.00041664788,0.00014269762,0.00015318404,0.00027312967,0.00041294712,0.000063108564,0.0050207344],"category_scores_gemma":[0.00015091054,0.00030774105,0.0001282088,0.00028716595,0.000075995915,0.0004776205,0.00013563149,0.0002807649,0.004023023],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000063319676,0.00096853107,0.1957531,0.00014789728,0.00038082871,0.00006978688,0.0054583065,0.00029874584,0.00032017124,0.121877275,0.6619657,0.012696344],"study_design_scores_gemma":[0.0007307491,0.000017723201,0.019133259,0.000007433159,0.000011254733,0.000009724545,0.00002955586,0.0031329677,0.0011838877,0.0012704126,0.9739699,0.0005031659],"about_ca_topic_score_codex":0.00013875999,"about_ca_topic_score_gemma":0.000005823775,"teacher_disagreement_score":0.31200418,"about_ca_system_score_codex":0.00018204178,"about_ca_system_score_gemma":0.000009738926,"threshold_uncertainty_score":0.9999375},"labels":[],"label_agreement":null},{"id":"W1903355409","doi":"10.1016/j.jval.2015.09.2429","title":"The Budget Impact of Orphan Drugs In The Us and Canada: A 2007-2013 Midas Sales Data Analysis","year":2015,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Orphan drug; Incentive; Medicine; Economics; Bioinformatics","score_opus":0.12856453629218972,"score_gpt":0.3496087187334243,"score_spread":0.22104418244123458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1903355409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9752707,0.009968174,0.000008318063,0.012639833,0.00011338342,0.00019690263,0.0009031266,0.0000022561987,0.0008973396],"genre_scores_gemma":[0.99488676,0.003765194,0.000042966232,0.0011762227,0.00005606905,0.0000057600164,0.000037856025,0.0000073903525,0.000021760328],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986001,0.00010499794,0.00067529414,0.00024727985,0.000038935606,0.0003333913],"domain_scores_gemma":[0.99864197,0.00032101863,0.0002832732,0.00058528857,0.000011847235,0.00015662365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033313297,0.0000973767,0.00037525166,0.00018189875,0.000056075532,0.000043821397,0.0005204091,0.00003650201,0.000017027773],"category_scores_gemma":[0.00016894146,0.00006981587,0.000045339657,0.00040368363,0.00006497631,0.00009286057,0.00010554059,0.00015988995,0.000010487077],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000038954615,0.0000760636,0.9268717,0.000044340683,0.00014860716,0.0000021301662,0.0017513837,0.012391063,1.4767797e-7,0.028507741,0.029413868,0.0007539894],"study_design_scores_gemma":[0.0009019399,0.000092988106,0.6365197,0.000014183452,0.000016836742,0.0000035205483,0.00034779235,0.2530112,6.174335e-7,0.014204855,0.09467943,0.00020698881],"about_ca_topic_score_codex":0.9689037,"about_ca_topic_score_gemma":0.7381144,"teacher_disagreement_score":0.29035205,"about_ca_system_score_codex":0.00036068753,"about_ca_system_score_gemma":0.0007264624,"threshold_uncertainty_score":0.28470084},"labels":[],"label_agreement":null},{"id":"W1905212215","doi":"10.1186/s12992-015-0118-8","title":"Does Pharmaceutical Pricing Transparency Matter? Examining Brazil’s Public Procurement System","year":2015,"lang":"en","type":"article","venue":"Globalization and Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"University of Toronto; Canadian Institutes of Health Research; University of Ottawa","keywords":"Transparency (behavior); Procurement; Purchasing; Economics; Unit (ring theory); Business; Econometrics; Accounting; Computer science; Operations management; Marketing; Mathematics","score_opus":0.2224954896083243,"score_gpt":0.37173131422169103,"score_spread":0.14923582461336674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1905212215","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15023586,0.020772502,0.20168956,0.22244865,0.0062836683,0.0036423046,0.0011094199,0.0008642403,0.39295378],"genre_scores_gemma":[0.9885443,0.00056286115,0.0003177424,0.01024167,0.00015220931,0.000020365707,0.000034402685,0.000016901966,0.00010958881],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984574,0.00003212301,0.00069479324,0.00035805115,0.000047418052,0.00041025045],"domain_scores_gemma":[0.9990117,0.000009525502,0.00024557608,0.0001431391,0.000035407324,0.0005546578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009921325,0.0001423868,0.00033252052,0.00012694203,0.0001464918,0.00014876874,0.000118902666,0.00006313884,0.00015347287],"category_scores_gemma":[0.000020583278,0.00012509002,0.000028586406,0.00019049337,0.000036886133,0.00022868984,0.00003787878,0.000094497074,0.00026161177],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010942302,0.00007294204,0.2749473,0.00041910174,0.000029271943,0.0000010162164,0.0009243291,0.00003515642,0.0000014797815,0.7120244,0.0085195815,0.00301452],"study_design_scores_gemma":[0.0037440306,0.00020113352,0.07033188,0.00014592278,0.000016307966,0.000028048551,0.00084565574,0.045566313,0.000033049902,0.013872749,0.864458,0.00075690396],"about_ca_topic_score_codex":0.00019129062,"about_ca_topic_score_gemma":0.00003882851,"teacher_disagreement_score":0.85593843,"about_ca_system_score_codex":0.0004246384,"about_ca_system_score_gemma":0.00011145306,"threshold_uncertainty_score":0.5101023},"labels":[],"label_agreement":null},{"id":"W1911828822","doi":"","title":"Just the berries: Nephrotoxic drugs.","year":2004,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cape Breton Regional Hospital","funders":"","keywords":"Nephrotoxicity; Computer science; Data science; Medicine; World Wide Web; Kidney; Internal medicine","score_opus":0.07821927676451151,"score_gpt":0.2533487448095745,"score_spread":0.17512946804506296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1911828822","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.35944033,0.0027746637,0.00026022212,0.062505394,0.0013573068,0.0015695558,0.0002388737,0.00012238974,0.57173127],"genre_scores_gemma":[0.98603827,0.00025128765,0.000039943825,0.011218091,0.0003559482,0.0009348335,0.0000039132,0.0000211747,0.0011365375],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99887246,0.0000064445167,0.0003795131,0.00025367553,0.000019889463,0.00046803316],"domain_scores_gemma":[0.99932873,0.000039496314,0.00013510014,0.00032683538,0.000008193277,0.00016161778],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00048506595,0.00012046362,0.00020764925,0.000078327466,0.00014328229,0.00011324378,0.0003460559,0.00006304589,0.00019906371],"category_scores_gemma":[0.00007472778,0.00010727269,0.00011665721,0.00016777516,0.000115971045,0.00015883571,0.00007597462,0.0001698108,0.0012617985],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009798152,0.000057825586,0.0011624347,0.000010406001,0.000055498735,0.000001444968,0.0006147883,0.00019374347,8.206108e-7,0.979803,0.0047359057,0.013354309],"study_design_scores_gemma":[0.00067896454,0.0000060471866,0.04539638,0.0000012323592,0.0000050527988,0.0000031367654,0.00004871648,0.00008205015,0.00010120841,0.1755364,0.7779493,0.00019151694],"about_ca_topic_score_codex":0.00018343356,"about_ca_topic_score_gemma":0.000019466761,"teacher_disagreement_score":0.80426663,"about_ca_system_score_codex":0.00015098367,"about_ca_system_score_gemma":0.000016636797,"threshold_uncertainty_score":0.99951583},"labels":[],"label_agreement":null},{"id":"W1916719231","doi":"10.3917/rac.012.0071","title":"Le passage des frontières de médecines pas très douces : prévenir l’innocuité ou préserver l’authenticité ?","year":2011,"lang":"fr","type":"article","venue":"Revue d anthropologie des connaissances","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Humanities; Political science; Philosophy","score_opus":0.24803775046646437,"score_gpt":0.33815055367739405,"score_spread":0.09011280321092968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1916719231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5816153,0.24050552,0.002270028,0.022043824,0.0069674654,0.000702453,0.0011568449,0.00023267395,0.14450587],"genre_scores_gemma":[0.9239518,0.06371979,0.00280554,0.0010852005,0.0010649976,0.000094477415,0.00002364435,0.000109562396,0.007144996],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9952001,0.0001829698,0.0015774303,0.0011627552,0.000059491107,0.001817266],"domain_scores_gemma":[0.99742293,0.00032422855,0.00092551106,0.000758799,0.00012329705,0.00044524248],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010872374,0.00070147647,0.0013993874,0.00034957455,0.00093236857,0.00028399227,0.0011581815,0.00056326954,0.0046874536],"category_scores_gemma":[0.0005704202,0.0008478427,0.0005862094,0.00048057112,0.00796021,0.0011434731,0.0003239702,0.0005467014,0.0007202278],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013071255,0.0009238699,0.19031438,0.0009762434,0.00049626426,0.0001384918,0.00501364,0.000034475564,0.00005816135,0.755672,0.0063495864,0.039892197],"study_design_scores_gemma":[0.0019528809,0.0006072839,0.08363858,0.000698514,0.00016393319,0.00013331167,0.0029988277,0.0022312396,0.0062194853,0.4547887,0.44491425,0.0016529667],"about_ca_topic_score_codex":0.0053385664,"about_ca_topic_score_gemma":0.002706697,"teacher_disagreement_score":0.43856466,"about_ca_system_score_codex":0.00029500484,"about_ca_system_score_gemma":0.00020602223,"threshold_uncertainty_score":0.9993972},"labels":[],"label_agreement":null},{"id":"W191744706","doi":"10.1533/9781908818089.47","title":"Empirical analysis of drug approval * *This chapter is based upon material in M. Sawicka and R.A. Bouchard, ‘Empirical Analysis of Canadian Drug Approval Data 2001-2008: Are Canadian Pharmaceutical Players “Doing More With Less”?’ McGill Journal of Law &amp; Health 3: 87-151 (2009).","year":2012,"lang":"en","type":"book-chapter","venue":"Elsevier eBooks","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Drug development; Business; Actuarial science; Medicine; Pharmacology; Risk analysis (engineering); Computer science","score_opus":0.13997755886015173,"score_gpt":0.3333490565088204,"score_spread":0.19337149764866868,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W191744706","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14543295,0.014910547,0.000074729345,0.02359677,0.0013952467,0.0031033696,0.20024712,0.000052505548,0.61118674],"genre_scores_gemma":[0.9343401,0.003988896,0.0033671816,0.031534597,0.00083443813,0.000039306702,0.0036007997,0.00045306777,0.02184161],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99418694,0.00010399955,0.002964896,0.0011486806,0.00027648068,0.0013189885],"domain_scores_gemma":[0.99389714,0.00016900912,0.0023475909,0.0012262069,0.0001875496,0.0021724862],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0026297267,0.00079907145,0.0038710055,0.007514709,0.00021427988,0.0000942341,0.0010271315,0.0005161954,0.0018944909],"category_scores_gemma":[0.00004252701,0.0008341818,0.0007105826,0.0006071815,0.0005657272,0.00026019412,0.00021895157,0.0011377372,0.000022153783],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051935394,0.0016832079,0.22986649,0.0052579385,0.12026265,0.00078774325,0.0277097,0.005629487,0.000040861712,0.13042472,0.03879578,0.43434787],"study_design_scores_gemma":[0.0012722594,0.00005698777,0.0017792352,0.00015553788,0.0029430923,0.000016254962,0.000056619538,0.009128558,0.00001879014,0.00022055871,0.98348755,0.00086458377],"about_ca_topic_score_codex":0.14451057,"about_ca_topic_score_gemma":0.7742903,"teacher_disagreement_score":0.9446917,"about_ca_system_score_codex":0.0009265418,"about_ca_system_score_gemma":0.0010938427,"threshold_uncertainty_score":0.9994109},"labels":[],"label_agreement":null},{"id":"W1919945669","doi":"10.7202/1019196ar","title":"Facteurs associés à l’exposition élevée aux médicaments psychotropes identifiés lors d’une étude épidémiologique montréalaise","year":2013,"lang":"fr","type":"article","venue":"Santé mentale au Québec","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"McGill University; Douglas Mental Health University Institute","funders":"","keywords":"Art; Humanities","score_opus":0.035378647755679095,"score_gpt":0.3006221221372502,"score_spread":0.2652434743815711,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1919945669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9160446,0.015725335,0.00023098667,0.042806104,0.0045676897,0.001055952,0.0014330316,0.000087709996,0.018048616],"genre_scores_gemma":[0.975194,0.009839386,0.0002506987,0.007613079,0.00095723406,0.00025690888,0.00020652766,0.00010695295,0.0055752485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955201,0.00016914589,0.0017010086,0.0010999095,0.000106744286,0.0014030619],"domain_scores_gemma":[0.9974129,0.00023221533,0.00096533616,0.0007116739,0.00006664497,0.00061122864],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0007154065,0.00064595765,0.0010382008,0.00030379402,0.0005335871,0.00038665975,0.0007255129,0.00049654016,0.008817833],"category_scores_gemma":[0.00013279052,0.00080197654,0.00054712937,0.0003368253,0.0006230064,0.0011850861,0.0002691428,0.0007010016,0.014658218],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020145444,0.0038966828,0.55020255,0.00047467707,0.0022548032,0.000062985746,0.0100956345,0.00037333553,0.003220731,0.03347286,0.23352188,0.1622224],"study_design_scores_gemma":[0.0034537602,0.00046245707,0.58828735,0.00020740941,0.00013536235,0.000049171613,0.0009978599,0.005202173,0.0013241345,0.017742002,0.3804576,0.0016806942],"about_ca_topic_score_codex":0.34663504,"about_ca_topic_score_gemma":0.04237076,"teacher_disagreement_score":0.3042643,"about_ca_system_score_codex":0.0029306777,"about_ca_system_score_gemma":0.0003509362,"threshold_uncertainty_score":0.9994431},"labels":[],"label_agreement":null},{"id":"W1931429111","doi":"","title":"Perspective face aux causes des ruptures d’approvisionnement de médicaments","year":2012,"lang":"fr","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Political science; Humanities; Art","score_opus":0.10714835934722142,"score_gpt":0.3507433770448012,"score_spread":0.24359501769757977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1931429111","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3594102,0.18247843,0.005370768,0.037944432,0.003460738,0.0005927872,0.0007660662,0.00007831187,0.40989825],"genre_scores_gemma":[0.92820644,0.011203021,0.0028364197,0.008676941,0.0010136666,0.00003947863,0.00000819398,0.00005674174,0.047959067],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973902,0.000048388152,0.0006606943,0.00046079102,0.000043240052,0.0013966947],"domain_scores_gemma":[0.9985303,0.0001271557,0.00025597384,0.00035272233,0.000050353552,0.000683486],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00081129733,0.00033028104,0.0004908789,0.00020507474,0.0003033817,0.00018259852,0.00033574514,0.00024765456,0.010197023],"category_scores_gemma":[0.00023513689,0.00040258645,0.0002446027,0.00019162777,0.00041787577,0.0006608708,0.00023307829,0.0003428532,0.0034343528],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018306748,0.000737699,0.062281966,0.000066537425,0.00026827859,0.0000021231538,0.0054909885,0.00010689011,0.000017277041,0.8994442,0.025319777,0.0062459456],"study_design_scores_gemma":[0.00085188675,0.00010211989,0.030710494,0.00003760683,0.000046997113,0.000016345368,0.0025922162,0.0032593294,0.0005320409,0.08219873,0.8790443,0.0006079108],"about_ca_topic_score_codex":0.0047757137,"about_ca_topic_score_gemma":0.00015509945,"teacher_disagreement_score":0.85372454,"about_ca_system_score_codex":0.001581856,"about_ca_system_score_gemma":0.000104668245,"threshold_uncertainty_score":0.9998426},"labels":[],"label_agreement":null},{"id":"W1937413232","doi":"","title":"Drug sales up 12.6% annually since 1988","year":2003,"lang":"en","type":"article","venue":"Europe PMC (PubMed Central)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Drug industry; Brand names; Advertising; Medicine; Engineering","score_opus":0.04091809963677959,"score_gpt":0.23944891243817537,"score_spread":0.19853081280139578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1937413232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.51979893,0.004904145,0.00028696534,0.0050452813,0.0038280836,0.00061286724,0.0005783123,0.00017502697,0.4647704],"genre_scores_gemma":[0.98117155,0.0018414328,0.00028129248,0.0040437,0.0003545434,0.000039125036,0.000022075168,0.00008150757,0.012164775],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.997124,0.000067121175,0.0007560669,0.00064128445,0.000047153153,0.0013643723],"domain_scores_gemma":[0.99847484,0.00007967006,0.0002789738,0.0005088507,0.000031451476,0.00062619435],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00077126216,0.0002942149,0.0004486812,0.00016094206,0.00013445213,0.00018192078,0.00046369983,0.00007934181,0.0006737964],"category_scores_gemma":[0.00046768854,0.00034261175,0.00016366152,0.0002754299,0.000116304276,0.00033805685,0.00008371744,0.00031188145,0.0034804998],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003455506,0.00018444107,0.0717128,0.000040195908,0.00010145663,0.000026593323,0.0024653412,0.000082448525,0.000020435036,0.88506067,0.037692837,0.0025782506],"study_design_scores_gemma":[0.0007291117,0.0000139659705,0.04083068,0.0000067000374,0.000008023995,0.000007930688,0.000026973592,0.00013704793,0.00049183413,0.010259824,0.94705355,0.0004343719],"about_ca_topic_score_codex":0.000043491145,"about_ca_topic_score_gemma":0.000025902664,"teacher_disagreement_score":0.9093607,"about_ca_system_score_codex":0.00016921392,"about_ca_system_score_gemma":0.00006876701,"threshold_uncertainty_score":0.9999026},"labels":[],"label_agreement":null},{"id":"W1946372495","doi":"10.1111/j.1525-139x.2011.00970.x","title":"Conditionally Funded Field Evaluations—A Solution to the Economic Barriers Limiting Evidence Generation in Dialysis?","year":2011,"lang":"en","type":"article","venue":"Seminars in Dialysis","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital; Humber River Regional Hospital","funders":"","keywords":"Medicine; Limiting; Nephrology; Intensive care medicine; Patient care; Dialysis; Internal medicine; Nursing","score_opus":0.14000141090134874,"score_gpt":0.33257184363255893,"score_spread":0.1925704327312102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1946372495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97812474,0.0011622161,0.0012656398,0.008054448,0.00048066775,0.00041355062,0.00009138349,0.000016521031,0.010390852],"genre_scores_gemma":[0.9951555,0.00063077704,0.00054882956,0.0030148888,0.00028004844,0.00020334075,0.000035148936,0.000016279035,0.00011517929],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99806875,0.000088871035,0.0009621988,0.00047976195,0.00004435314,0.0003560374],"domain_scores_gemma":[0.99882364,0.00035296453,0.000281518,0.0003820018,0.000023972429,0.00013590395],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020449574,0.00016092604,0.00035673627,0.0005531413,0.00014477757,0.00008348206,0.00036467658,0.000117440686,0.0018908264],"category_scores_gemma":[0.0013614785,0.00017992903,0.0001539309,0.00043293336,0.000043173,0.00038644605,0.0000983331,0.0001991796,0.0007161358],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026439797,0.00023707337,0.6099447,0.000046922567,0.00040413276,0.000014207293,0.019656237,0.12578897,0.0010704554,0.18572852,0.023285974,0.033558406],"study_design_scores_gemma":[0.0020986078,0.00032291445,0.1291863,0.00021225895,0.00016936036,0.000006526619,0.00089777383,0.71201116,0.0085090725,0.12331383,0.02153641,0.0017357785],"about_ca_topic_score_codex":0.0019078138,"about_ca_topic_score_gemma":0.008806587,"teacher_disagreement_score":0.5862222,"about_ca_system_score_codex":0.0006594832,"about_ca_system_score_gemma":0.00009376217,"threshold_uncertainty_score":0.9990216},"labels":[],"label_agreement":null},{"id":"W1948163795","doi":"","title":"2006-5 Price Control, Different Demands between Countries, and Parallel Trade in Pharmaceuticals","year":2006,"lang":"en","type":"preprint","venue":"Scholarship@Western (Western University)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Government (linguistics); Welfare; Economics; Social Welfare; Control (management); International economics; International trade; European union; Supply and demand; Public economics; Market economy; Microeconomics; Political science","score_opus":0.1531073960490598,"score_gpt":0.336889435040506,"score_spread":0.1837820389914462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1948163795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856642,0.0040042275,0.0013854156,0.0030424946,0.00038975172,0.0008495452,0.0029382142,0.00010133138,0.001624839],"genre_scores_gemma":[0.99327826,0.0028369906,0.000032168784,0.002173404,0.00034199012,0.000010390869,0.00018019982,0.00008966815,0.0010568948],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960558,0.00017908357,0.0012126103,0.0013955187,0.00011701309,0.0010400082],"domain_scores_gemma":[0.997631,0.00030475747,0.0007672777,0.00067696325,0.000031907395,0.0005880905],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00083930546,0.0007773652,0.0016936668,0.0010651001,0.000173855,0.00055277144,0.0010608791,0.00086113525,0.000078756784],"category_scores_gemma":[0.000034750658,0.0009998571,0.0002952955,0.00025012097,0.000266719,0.0007198192,0.00090678997,0.0020020201,0.00018059871],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011342222,0.00014631305,0.9953703,0.0002644064,0.00022079208,0.00008990867,0.00011238908,0.0002153072,0.0000042053966,0.0032622833,0.000013479297,0.00018717628],"study_design_scores_gemma":[0.004164418,0.0000556046,0.9342879,0.00016138729,0.00012426585,0.000006483581,0.000008115947,0.000045684203,0.000044018063,0.007774415,0.052297387,0.0010303291],"about_ca_topic_score_codex":0.000055368004,"about_ca_topic_score_gemma":0.0006816441,"teacher_disagreement_score":0.061082426,"about_ca_system_score_codex":0.00066122616,"about_ca_system_score_gemma":0.000099392855,"threshold_uncertainty_score":0.99924517},"labels":[],"label_agreement":null},{"id":"W1950143140","doi":"","title":"Encouraging the use of generic medicines: implications for transition economies.","year":2002,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":190,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Competition (biology); Business; Payment; Generic drug; Promotion (chess); Public economics; Marketing; Market share; Demand side; Quality (philosophy); Industrial organization; Economics; Finance; Drug; Microeconomics; Medicine","score_opus":0.24958483105771556,"score_gpt":0.26881950643647756,"score_spread":0.019234675378762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1950143140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4825684,0.010084107,0.045656405,0.39943874,0.002000246,0.006283408,0.0039141285,0.00015449608,0.049900036],"genre_scores_gemma":[0.9916984,0.00081177906,0.00022844851,0.0055319252,0.00020029233,0.001261111,0.000011245517,0.000015665519,0.00024112497],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991018,0.0000061718515,0.00045484953,0.0001822254,0.000007629026,0.00024730538],"domain_scores_gemma":[0.9992931,0.00017854884,0.00019665468,0.00023608046,0.000018122484,0.000077521676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026388137,0.00008111093,0.00020937761,0.00009731288,0.000082945735,0.00003679878,0.00015936728,0.000040170766,0.0001090605],"category_scores_gemma":[0.000085455285,0.00007517795,0.000112668735,0.00010539077,0.00007263521,0.00018258645,0.000013489826,0.000056122622,0.00002624388],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029752466,0.0002523606,0.011337235,0.00011544072,0.00029427218,2.4183834e-7,0.0016991108,0.0041831383,0.000027875263,0.5929715,0.1023286,0.28676048],"study_design_scores_gemma":[0.0007261123,0.000013910503,0.080241956,0.0000023751363,0.000023429784,0.0000037667592,0.000019758112,0.046727993,0.00007210079,0.03636394,0.83560646,0.00019817194],"about_ca_topic_score_codex":0.00004022333,"about_ca_topic_score_gemma":0.00000874863,"teacher_disagreement_score":0.73327786,"about_ca_system_score_codex":0.000054456923,"about_ca_system_score_gemma":0.0000036027639,"threshold_uncertainty_score":0.3065668},"labels":[],"label_agreement":null},{"id":"W1965203992","doi":"10.1353/cpp.2011.0038","title":"Socioeconomic Status and the Use of Medicines in the Ontario Public Drug Program","year":2011,"lang":"en","type":"article","venue":"Canadian Public Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Publishing; Indigenous; Politics; Socioeconomic status; The Renaissance; Public culture; Slavic languages; Social science; Sociology; Media studies; Library science; Political science; History; Classics; Art history; Law; Demography","score_opus":0.1678272396124274,"score_gpt":0.27541479054964996,"score_spread":0.10758755093722255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965203992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83933663,0.0008084158,0.000002079784,0.093364954,0.000178858,0.0006955166,0.00024916953,0.000015771186,0.065348595],"genre_scores_gemma":[0.9798193,0.0003767631,0.0000754645,0.019022916,0.00014416048,0.000108884764,0.000015450805,0.000019641308,0.00041744742],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981528,0.00006214111,0.00064650853,0.00028226138,0.000025259264,0.00083101756],"domain_scores_gemma":[0.9985454,0.0001727153,0.0002505255,0.0004582225,0.000027258582,0.0005458801],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010596485,0.00017361886,0.00040573475,0.00074993994,0.00014749917,0.00023472341,0.00053689035,0.000091185604,0.000689035],"category_scores_gemma":[0.00034361496,0.00013239302,0.000101580736,0.0002991841,0.00069230195,0.0004748294,0.00006290496,0.0003154621,0.00008859733],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000069580838,0.000035397552,0.15427877,0.000007657039,0.000041407202,0.0000012990276,0.0065185437,3.931989e-7,3.6273047e-8,0.8275712,0.0054028975,0.006135427],"study_design_scores_gemma":[0.0009734737,0.000019793035,0.1733781,0.0000024980384,0.000004508084,0.000005504963,0.00014257611,0.00034663177,5.2488156e-7,0.050649643,0.7743304,0.0001463458],"about_ca_topic_score_codex":0.926602,"about_ca_topic_score_gemma":0.95450807,"teacher_disagreement_score":0.7769216,"about_ca_system_score_codex":0.00060762605,"about_ca_system_score_gemma":0.0015458348,"threshold_uncertainty_score":0.754445},"labels":[],"label_agreement":null},{"id":"W1965399548","doi":"10.1093/eurheartj/eht308.991","title":"Programming strategies to reduce non-essential therapies and mortality - a systematic review","year":2013,"lang":"en","type":"review","venue":"European Heart Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre","funders":"","keywords":"Medicine; Randomized controlled trial; Confidence interval; MEDLINE; Internal medicine; Meta-analysis","score_opus":0.20067122972659585,"score_gpt":0.40480216938165536,"score_spread":0.20413093965505952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965399548","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000056230645,0.9923582,0.00007466474,0.00055704213,0.00043738433,0.001779394,0.00005510737,0.000023663211,0.004658287],"genre_scores_gemma":[0.00011347173,0.9969534,0.00041648597,0.0013263751,0.00074437633,0.00007605834,0.0000074099626,0.00009570609,0.0002666824],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967481,0.00031005376,0.0019432025,0.00046384046,0.000054789907,0.00048003276],"domain_scores_gemma":[0.99789363,0.000081112696,0.001080978,0.00044863133,0.000038897113,0.00045676198],"candidate_categories":["metaepi_narrow","scholarly_communication","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002704072,0.00044636827,0.0029435547,0.00026142644,0.00020563437,0.001093224,0.00046760764,0.00007944623,0.00030472645],"category_scores_gemma":[0.00014613301,0.00038094498,0.00058408704,0.00020608159,0.0000673606,0.00033035167,0.00017516511,0.0007008973,0.0025104638],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000016133347,0.00007286959,0.000022342863,0.9316868,0.0011379089,0.00004931214,0.0003261645,7.342244e-7,4.8066676e-7,0.004093673,0.017073665,0.045534402],"study_design_scores_gemma":[0.00008588489,0.000044942462,0.00003251533,0.11851916,0.00035051754,0.0004018198,0.000016509088,0.0000064570945,5.969465e-8,0.00027389417,0.87986696,0.00040130375],"about_ca_topic_score_codex":0.000010539141,"about_ca_topic_score_gemma":8.5255476e-7,"teacher_disagreement_score":0.86279327,"about_ca_system_score_codex":0.00009018981,"about_ca_system_score_gemma":0.000100010664,"threshold_uncertainty_score":0.99994373},"labels":[],"label_agreement":null},{"id":"W1965514038","doi":"10.1377/hlthaff.2013.0388","title":"Despite Increased Use And Sales Of Statins In India, Per Capita Prescription Rates Remain Far Below High-Income Countries","year":2014,"lang":"en","type":"article","venue":"Health Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Global Health Research","funders":"","keywords":"Per capita; Medical prescription; Per capita income; Business; Economics; Environmental health; Demographic economics; Medicine; Population","score_opus":0.02993697283097848,"score_gpt":0.2774550255136146,"score_spread":0.24751805268263613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965514038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99317986,0.0019741978,0.00014568977,0.0029843086,0.00014848418,0.00032261387,0.0006199925,0.000019445391,0.0006054019],"genre_scores_gemma":[0.99394464,0.0031863614,0.00081291894,0.001870847,0.000055238736,0.000023231361,0.000044294637,0.00002381812,0.000038672748],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99836147,0.000079356774,0.00081091345,0.00031642718,0.000031229432,0.00040062168],"domain_scores_gemma":[0.9988527,0.000258798,0.0004110546,0.00022373503,0.000025221854,0.00022843714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011141669,0.00015445921,0.00052763853,0.0003279141,0.00007979698,0.00006666199,0.000112256355,0.00009324821,0.00009441518],"category_scores_gemma":[0.00018395598,0.0001810208,0.00003932275,0.000091320006,0.00012014927,0.00033198623,0.000050021114,0.00015789628,0.00012361952],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006604404,0.000057638157,0.5488085,0.00036666455,0.000019213203,7.4992016e-7,0.0011420208,0.000046044537,0.0000172338,0.44869956,0.000477703,0.0002986341],"study_design_scores_gemma":[0.0013382765,0.00017593363,0.9399198,0.000049884635,0.0000033960425,0.0000016666045,0.00012426502,0.0042320667,0.000054923315,0.0154735455,0.038386814,0.00023937106],"about_ca_topic_score_codex":0.0054502687,"about_ca_topic_score_gemma":0.0013077493,"teacher_disagreement_score":0.43322602,"about_ca_system_score_codex":0.00015725261,"about_ca_system_score_gemma":0.000077955505,"threshold_uncertainty_score":0.8239212},"labels":[],"label_agreement":null},{"id":"W1965564826","doi":"10.12927/hcpol.2011.22392","title":"Purchasing Prescription Drugs in Canada: Hang Together or Hang Separately","year":2011,"lang":"en","type":"article","venue":"Healthcare policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Purchasing; Medical prescription; Hang; Population; Business; Prescription drug; Medicine; Marketing; Environmental health; Pharmacology; Computer science","score_opus":0.17135874554552846,"score_gpt":0.32830337483653627,"score_spread":0.1569446292910078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965564826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8968101,0.0023207043,0.000057333455,0.022221187,0.0007999176,0.0005595111,0.0004341115,0.000054648524,0.07674249],"genre_scores_gemma":[0.98615056,0.00052590756,0.00019815171,0.011884596,0.00035642833,0.000048177397,0.000010156049,0.00004172358,0.0007842763],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99802846,0.000041338535,0.00074190623,0.0004026697,0.00003587689,0.00074972736],"domain_scores_gemma":[0.99907374,0.00003598853,0.00023401299,0.0003062255,0.000024104285,0.00032590752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036372792,0.00019468831,0.00041651755,0.0003791042,0.00009644156,0.000035744004,0.000237149,0.00011319329,0.0004975562],"category_scores_gemma":[0.00008361722,0.00021794594,0.000061980725,0.00036195412,0.00003718758,0.00021814005,0.0000720183,0.00026973727,0.00029034456],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037506822,0.00018473245,0.20890361,0.00036023857,0.000069195536,0.00004618548,0.018239623,0.000047709258,0.000026869435,0.7223278,0.005769053,0.04364988],"study_design_scores_gemma":[0.003037327,0.00024531386,0.37050053,0.00014154229,0.000010159967,0.000046917707,0.0013194295,0.011160558,0.0008505531,0.12150711,0.48948628,0.0016942829],"about_ca_topic_score_codex":0.9813995,"about_ca_topic_score_gemma":0.89299554,"teacher_disagreement_score":0.6008207,"about_ca_system_score_codex":0.0017330399,"about_ca_system_score_gemma":0.0012200937,"threshold_uncertainty_score":0.88875777},"labels":[],"label_agreement":null},{"id":"W1967997471","doi":"10.1371/journal.pone.0023030","title":"The Short-Term Impact of Ontario's Generic Pricing Reforms","year":2011,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Generic drug; Medical prescription; Purchasing; Reimbursement; Public economics; Economics; Audit; Capital expenditure; Agricultural economics; Business; Demographic economics; Finance; Economic growth; Accounting; Operations management; Drug; Medicine; Health care","score_opus":0.20478650214225946,"score_gpt":0.27752195977273875,"score_spread":0.07273545763047928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967997471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88452554,0.00040356093,0.00001725458,0.00006699333,0.000051168437,0.00012528147,0.000036843423,0.000011797424,0.114761576],"genre_scores_gemma":[0.99805355,0.0003816175,0.0003888913,0.00011733644,0.000072839124,0.000014213126,0.0000036557415,0.000018108823,0.0009497755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990045,0.0000045647116,0.0004905042,0.00018103766,0.000023565099,0.00029587004],"domain_scores_gemma":[0.99932873,0.0000248144,0.00018192542,0.00033952724,0.000020013427,0.000104967636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027849723,0.00011140599,0.00031442256,0.000075302734,0.000085181695,0.000026382368,0.00028024736,0.00005493385,0.0007591606],"category_scores_gemma":[0.000026548481,0.000085345884,0.00014725738,0.00009051932,0.0000608177,0.0001232504,0.00007412123,0.00014929769,0.00018921855],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008837676,0.0010688829,0.9098165,0.000045355257,0.001089807,0.0000023468604,0.0031847572,0.000009950536,0.00123432,0.08119466,0.000190152,0.002074857],"study_design_scores_gemma":[0.0005484903,0.00039049188,0.9438521,0.00003659825,0.000053696436,0.0000027128165,0.000015850177,0.0023186097,0.008516589,0.040758774,0.0030505992,0.00045546918],"about_ca_topic_score_codex":0.009740102,"about_ca_topic_score_gemma":0.0017922131,"teacher_disagreement_score":0.1138118,"about_ca_system_score_codex":0.0003935982,"about_ca_system_score_gemma":0.00006960564,"threshold_uncertainty_score":0.9968541},"labels":[],"label_agreement":null},{"id":"W1968616336","doi":"10.1016/j.jhealeco.2012.02.004","title":"Pricing of drugs with heterogeneous health insurance coverage","year":2012,"lang":"en","type":"article","venue":"Journal of Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Metropolitan University; York University","funders":"","keywords":"Market segmentation; Competition (biology); Business; Brand loyalty; Health insurance; Brand names; Price discrimination; First-mover advantage; Product differentiation; Segmentation; Economics; Microeconomics; Marketing; Health care; Computer science","score_opus":0.059672437391580846,"score_gpt":0.3060569529771553,"score_spread":0.24638451558557445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968616336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97532994,0.014572884,0.0014423373,0.004573504,0.00083721534,0.00021392724,0.00016302755,0.0000074539175,0.002859723],"genre_scores_gemma":[0.9766728,0.014703984,0.0014307647,0.006784603,0.00034078988,0.0000024481978,0.000003001833,0.000037785365,0.000023791612],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99675995,0.000046896384,0.0023504582,0.00017477313,0.00003093169,0.0006369827],"domain_scores_gemma":[0.9950299,0.00012791304,0.0040764976,0.0002520868,0.000033456043,0.00048011707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002498724,0.00018854505,0.0011429732,0.0003033011,0.000107969514,0.000030773357,0.00026724517,0.000067842826,0.0000869338],"category_scores_gemma":[0.000040525283,0.00019415535,0.00018349226,0.00011535791,0.000064206426,0.0004990142,0.000040073453,0.00030524124,0.00004776215],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006592807,0.0015289536,0.6835798,0.0014527556,0.0008682129,0.00000502974,0.010809813,0.017648108,0.000009984524,0.16807826,0.0031828787,0.1121769],"study_design_scores_gemma":[0.0075584566,0.0028968009,0.124142386,0.00032110309,0.000017202578,0.00069142494,0.00033078477,0.00321751,0.00052703184,0.02341097,0.8356658,0.0012204938],"about_ca_topic_score_codex":0.00016119762,"about_ca_topic_score_gemma":0.000013541338,"teacher_disagreement_score":0.83248293,"about_ca_system_score_codex":0.00056215224,"about_ca_system_score_gemma":0.00036480802,"threshold_uncertainty_score":0.7917425},"labels":[],"label_agreement":null},{"id":"W1968691101","doi":"10.1016/s0140-6736(07)61094-0","title":"The African private sector steps in to fill the drug gap","year":2007,"lang":"en","type":"article","venue":"The Lancet","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Pill; Legislation; Government (linguistics); Business; Index (typography); Law; Artificial intelligence; Political science; Computer science; Medicine; Pharmacology; World Wide Web; Philosophy","score_opus":0.09596589198122327,"score_gpt":0.30302982838767734,"score_spread":0.20706393640645407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968691101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.65785307,0.0011758425,0.00017039446,0.15844601,0.0006337847,0.000494567,0.00014859148,0.000032682747,0.18104506],"genre_scores_gemma":[0.9821129,0.0002993933,0.000047437814,0.015474653,0.00083413406,0.000024489362,0.0000014919913,0.000017182349,0.0011883213],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988196,0.000027967362,0.00039600692,0.00019417443,0.00002581815,0.0005364709],"domain_scores_gemma":[0.9987243,0.00043358438,0.00012800712,0.0006252552,0.0000075546623,0.0000812945],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00252989,0.000111371126,0.0002704284,0.000054667675,0.00020004966,0.00011697541,0.00089727953,0.00003124108,0.0001380623],"category_scores_gemma":[0.00010885283,0.000063629974,0.00006377431,0.00026392378,0.00008745269,0.00004941693,0.00014571818,0.00027609678,0.0008570122],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010961409,0.000026239,0.014732504,0.0000070097585,0.000036628746,0.0000020016873,0.0018460942,0.00014472206,0.000018479335,0.93242484,0.048024513,0.0026273332],"study_design_scores_gemma":[0.0003305357,0.000010915319,0.05021691,0.0000037244167,0.0000018144924,0.0000011719222,0.00008413557,0.0006121083,0.000082983584,0.062309116,0.8862353,0.0001113091],"about_ca_topic_score_codex":0.00034084596,"about_ca_topic_score_gemma":0.0009404661,"teacher_disagreement_score":0.87011576,"about_ca_system_score_codex":0.00008830736,"about_ca_system_score_gemma":0.0000106142215,"threshold_uncertainty_score":0.99992096},"labels":[],"label_agreement":null},{"id":"W1968800010","doi":"10.1016/s1098-3015(10)72458-x","title":"PHP78 UNDERSTANDING DRUG REIMBURSEMENT RECOMMENDATIONS IN CANADA BY THE COMMON DRUG REVIEW (CDR)","year":2010,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Drug; Business; Medicine; Pharmacology; Political science; Law; Health care","score_opus":0.1478424321879946,"score_gpt":0.33522112337367155,"score_spread":0.18737869118567696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968800010","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15812808,0.033862505,0.00007536185,0.7770945,0.0026022973,0.0015061854,0.0008093163,0.00002220446,0.025899544],"genre_scores_gemma":[0.9349858,0.028052313,0.00006566096,0.03653293,0.00006398307,0.000046584566,0.000038040896,0.000019316978,0.0001953644],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981422,0.000089749024,0.0010354681,0.0002707169,0.00003326963,0.000428592],"domain_scores_gemma":[0.99891615,0.00027575795,0.00033632468,0.00033396904,0.0000051502593,0.00013267303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023867125,0.00012445335,0.0003933138,0.00010308005,0.0001338215,0.000030265759,0.00029932262,0.00002656685,0.00040781393],"category_scores_gemma":[0.00007478882,0.00012575094,0.000043083917,0.0002748662,0.000030056817,0.000088681445,0.000054246644,0.00058904965,0.000047258487],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000004774538,0.00008761096,0.03914747,0.0003988235,0.000014488415,0.0000016307442,0.00049348286,0.0004043747,0.0000012435777,0.49969724,0.45692953,0.002819305],"study_design_scores_gemma":[0.00049399846,0.0000093530225,0.0016980285,0.0003119969,0.0000020017612,0.000002437137,0.00020057833,0.01237539,0.0000070068177,0.053244337,0.93142515,0.00022972973],"about_ca_topic_score_codex":0.9280627,"about_ca_topic_score_gemma":0.8929106,"teacher_disagreement_score":0.77685773,"about_ca_system_score_codex":0.001982946,"about_ca_system_score_gemma":0.00047653934,"threshold_uncertainty_score":0.51853347},"labels":[],"label_agreement":null},{"id":"W1969013485","doi":"10.2165/00019053-200826080-00001","title":"Waiting for Reimbursement of New Medicines in Canada","year":2008,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Fraser Institute","funders":"","keywords":"Reimbursement; Public health; Health economics; Public health insurance; Certification; Medicine; Family medicine; Quality of Life Research; Environmental health; Health insurance; Health administration; Business; Health care; Economic growth; Nursing; Political science","score_opus":0.11448916653243718,"score_gpt":0.31835818760973206,"score_spread":0.20386902107729488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969013485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98063654,0.0013453155,0.000222443,0.004704014,0.0008113638,0.00036063025,0.00031390143,0.000009752073,0.011596063],"genre_scores_gemma":[0.9932519,0.0011269279,0.0004550928,0.0044869008,0.0003233112,0.000028048884,0.000016302132,0.00002764105,0.00028385167],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982724,0.000005414091,0.0010298156,0.00030122086,0.000017013965,0.00037413771],"domain_scores_gemma":[0.9991093,0.00012749546,0.00038232034,0.00016924315,0.00001553175,0.00019609332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030363936,0.00015338346,0.00051933544,0.00015474141,0.00004653509,0.000006574064,0.0002554548,0.000036612983,0.00047524108],"category_scores_gemma":[0.000053617863,0.00019987761,0.000093698465,0.00008252069,0.00003769744,0.00012786877,0.000044389937,0.0001167443,0.00003371706],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033258655,0.00023309384,0.48262694,0.0003069064,0.0003776843,0.00002119813,0.0016899729,0.012916117,0.00057965,0.22403584,0.26271424,0.014165773],"study_design_scores_gemma":[0.0072939787,0.00006623928,0.013963995,0.00002709854,0.000019984363,0.000018577097,0.00015552444,0.18829371,0.008974875,0.02694179,0.7534628,0.0007814596],"about_ca_topic_score_codex":0.46897626,"about_ca_topic_score_gemma":0.17135203,"teacher_disagreement_score":0.49074855,"about_ca_system_score_codex":0.00045314367,"about_ca_system_score_gemma":0.00066174095,"threshold_uncertainty_score":0.84376866},"labels":[],"label_agreement":null},{"id":"W1969347689","doi":"10.1071/ah090295","title":"Medicines policy and drug company investments: the Irish experience","year":2009,"lang":"en","type":"article","venue":"Australian Health Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Multinational corporation; Jurisdiction; Business; Globalization; Pharmaceutical industry; European union; Irish; Harmonization; International trade; Economic growth; Economic policy; Economics; Finance; Political science; Biotechnology; Market economy; Law","score_opus":0.18058848397700697,"score_gpt":0.42472291646651983,"score_spread":0.24413443248951286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969347689","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011621225,0.25167224,0.000006747009,0.7241461,0.0001973063,0.00075611245,0.00006731624,0.000031700492,0.011501197],"genre_scores_gemma":[0.218671,0.36875463,0.00010791465,0.41103134,0.00031034352,0.000032991557,0.000008493548,0.000010982516,0.0010723163],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983595,0.00004509113,0.0008277865,0.00030105293,0.000029987596,0.00043656657],"domain_scores_gemma":[0.99888706,0.000055181932,0.00034411738,0.0003429011,0.000012108023,0.00035863122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082316383,0.00016171922,0.0005609974,0.00007332969,0.000165493,0.000044976405,0.00027255403,0.000031750842,0.0002503291],"category_scores_gemma":[0.00015210366,0.00013024073,0.00007121945,0.000269009,0.00012922737,0.00014774477,0.000031835058,0.0001853295,0.00026944105],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000003260486,0.000062642735,0.0033637958,0.0010295516,0.000020838217,0.0000019227555,0.001030451,9.4129365e-7,7.2287787e-7,0.37793708,0.57671046,0.03983836],"study_design_scores_gemma":[0.00019427421,0.000037244878,0.019482514,0.00038782434,0.0000039491656,0.00001209894,0.000023861612,0.000024682868,0.0000019236502,0.014353175,0.9653436,0.00013486574],"about_ca_topic_score_codex":0.0006712715,"about_ca_topic_score_gemma":0.000009235182,"teacher_disagreement_score":0.38863316,"about_ca_system_score_codex":0.00010769098,"about_ca_system_score_gemma":0.00006569552,"threshold_uncertainty_score":0.5311063},"labels":[],"label_agreement":null},{"id":"W1969868159","doi":"10.2190/4m3e-l0yf-w1td-ekg0","title":"Effects of Prescription Drug User Fees on Drug and Health Services Use and on Health Status in Vulnerable Populations: A Systematic Review of the Evidence","year":2004,"lang":"en","type":"review","venue":"International Journal of Health Services","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":199,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Cost sharing; Medical prescription; Prescription drug; Subsidy; Drug; Health care; Prescription costs; Business; Medicine; Public economics; Environmental health; Actuarial science; Economic growth; Economics; Pharmacology; Nursing","score_opus":0.11319537075335327,"score_gpt":0.40640472417967133,"score_spread":0.29320935342631804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969868159","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002978373,0.98823076,0.0000037674447,0.006356126,0.00061864423,0.0015888582,0.00021113423,0.0000032374294,0.000009107286],"genre_scores_gemma":[0.011557267,0.97936803,0.00009937459,0.008832247,0.000061218925,0.00002937002,0.000013589502,0.000023539376,0.000015381142],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9950224,0.00054926466,0.003668869,0.00028801634,0.00019332039,0.0002781164],"domain_scores_gemma":[0.99068654,0.0006559519,0.008100194,0.00024532893,0.00013170176,0.00018028157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037542186,0.00027525082,0.002554495,0.00057640375,0.00009082754,0.000088708824,0.0005377771,0.0000657675,0.0000061833603],"category_scores_gemma":[0.00011089847,0.00020718349,0.00023364963,0.00021623092,0.000033851607,0.00050455774,0.00010098576,0.00045807488,0.0000035568742],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016996835,0.00013734389,0.000998342,0.98485357,0.00012913083,8.6753283e-7,0.00086683995,0.000056242843,1.774048e-8,0.00895297,0.00006796981,0.003919709],"study_design_scores_gemma":[0.0004935649,0.00016106243,0.004492421,0.9769756,0.000050661885,0.000018490178,0.000048171627,0.00009289875,4.4965088e-7,0.0021296765,0.015398262,0.00013869327],"about_ca_topic_score_codex":0.0105601065,"about_ca_topic_score_gemma":0.0009849998,"teacher_disagreement_score":0.015330292,"about_ca_system_score_codex":0.0007902818,"about_ca_system_score_gemma":0.00051111006,"threshold_uncertainty_score":0.99602866},"labels":[],"label_agreement":null},{"id":"W1969906875","doi":"10.1377/hlthaff.2011.0209","title":"Longer Exclusivity Does Not Guarantee Better Drugs","year":2011,"lang":"en","type":"letter","venue":"Health Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Download; Library science; Political science; Medicine; Computer science; World Wide Web","score_opus":0.06695582585118953,"score_gpt":0.2903711058576489,"score_spread":0.22341528000645938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969906875","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010205396,0.0019640566,0.00009312281,0.90917814,0.0034320464,0.00064793596,0.0028751092,0.00012183112,0.0806672],"genre_scores_gemma":[0.033786688,0.0023190668,0.00032219684,0.94988555,0.006325308,0.00010676689,0.0002489994,0.00018324605,0.0068221823],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952992,0.000079983445,0.0016915591,0.0012437467,0.00008355262,0.0016019354],"domain_scores_gemma":[0.99716413,0.00016409258,0.0012232917,0.0011010733,0.00003558884,0.00031182807],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010401587,0.0006524859,0.0015923316,0.00053339073,0.00024506604,0.00013257188,0.000798907,0.0009926178,0.0040544798],"category_scores_gemma":[0.000053859825,0.00065207435,0.00050367677,0.00016787232,0.00020190745,0.00024740782,0.00025349893,0.0025270295,0.008990399],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019815698,0.00004953194,0.00024714103,0.00046071384,0.00009245027,0.000033745804,0.00080971874,6.5912525e-7,2.6596743e-7,0.011450827,0.9850504,0.0017847795],"study_design_scores_gemma":[0.00053395296,0.000060410726,0.00021681275,0.00004669112,0.0000102596205,0.0000075262647,0.00002390842,0.0001527343,0.000016626504,0.031225612,0.9669479,0.00075754],"about_ca_topic_score_codex":0.0012039847,"about_ca_topic_score_gemma":0.00007178738,"teacher_disagreement_score":0.07384502,"about_ca_system_score_codex":0.00052126887,"about_ca_system_score_gemma":0.00020607938,"threshold_uncertainty_score":0.99977416},"labels":[],"label_agreement":null},{"id":"W1970577443","doi":"10.1016/j.healthpol.2010.12.002","title":"The cost of drug development: A systematic review","year":2011,"lang":"en","type":"review","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":497,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University; University of Toronto; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Audit; Citation; Actuarial science; Medicine; Cash; Transparency (behavior); Confidentiality; Accounting; Business; Computer science; Finance; Library science","score_opus":0.2564027925749183,"score_gpt":0.43412845224029106,"score_spread":0.17772565966537274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970577443","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[2.5693641e-8,0.9772317,0.0000121988405,0.0020361135,0.00024267168,0.0034366853,0.00034297162,0.000020508005,0.01667715],"genre_scores_gemma":[0.0000011366548,0.9902976,0.000043750537,0.0068058837,0.00018331927,0.0008004837,0.00003382401,0.000068796006,0.0017651757],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99443114,0.0001878854,0.0042231614,0.00039732674,0.00003617679,0.0007243366],"domain_scores_gemma":[0.99443525,0.00036821156,0.0039244015,0.00089251145,0.000030951443,0.00034864637],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0033453465,0.00040777656,0.0045925425,0.00035104327,0.00024819092,0.000037729496,0.0009144416,0.00014109437,0.00010200793],"category_scores_gemma":[0.00057814823,0.0003068283,0.0005776665,0.00051008066,0.00009888268,0.000056778004,0.00016887132,0.00040996695,0.0027761338],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[3.6731402e-7,0.000017253979,2.7282016e-7,0.66550606,0.00010400629,1.5326631e-7,0.0001285677,9.538913e-9,3.427033e-11,0.26240677,0.0052878954,0.06654864],"study_design_scores_gemma":[0.000062356055,0.0000075435346,5.2568913e-7,0.1824499,0.000056883026,0.000008656494,0.0000017663909,0.0000018729631,1.571266e-8,0.0015153047,0.8156887,0.00020646039],"about_ca_topic_score_codex":0.0006620385,"about_ca_topic_score_gemma":0.00006349517,"teacher_disagreement_score":0.81040084,"about_ca_system_score_codex":0.0006073146,"about_ca_system_score_gemma":0.0015870592,"threshold_uncertainty_score":0.99993837},"labels":[],"label_agreement":null},{"id":"W1970738061","doi":"10.1038/sj.clpt.6100359","title":"The Morally Uncomfortable Global Drug Gap","year":2007,"lang":"en","type":"article","venue":"Clinical Pharmacology & Therapeutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Essential medicines; Population; Human rights; Consumption (sociology); Quality (philosophy); Economic growth; Medicine; Business; Development economics; Public relations; Law and economics; Political science; Law; Health care; Economics; Sociology; Environmental health; Social science","score_opus":0.17917928466033714,"score_gpt":0.4357705111054546,"score_spread":0.25659122644511745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970738061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6694574,0.017684886,0.0032310144,0.111534074,0.02148343,0.001154318,0.00035768814,0.00029296827,0.17480426],"genre_scores_gemma":[0.7605448,0.0060601346,0.00039117786,0.22902218,0.0018718439,0.00002040087,0.000009685961,0.00004651816,0.002033305],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967376,0.000081731036,0.0016685727,0.00051874516,0.00004559081,0.00094774464],"domain_scores_gemma":[0.9975604,0.0011009139,0.0005031915,0.00041920433,0.000051682688,0.00036461538],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003934658,0.00025999462,0.0005455152,0.000051212704,0.00040563088,0.000092655646,0.00085180375,0.00023771918,0.00052263745],"category_scores_gemma":[0.00003632337,0.00023138129,0.0003547163,0.000273506,0.00065909297,0.00012591326,0.00019102196,0.00068004994,0.0016258394],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009083705,0.0011703641,0.33724707,0.000023999892,0.0021621322,0.000047080186,0.00019431218,0.00016905514,0.000090831374,0.34012854,0.29127252,0.026585707],"study_design_scores_gemma":[0.0014903964,0.00008512961,0.01680743,0.0000017731725,0.000074766154,0.0000059829117,0.000023822462,0.0021754089,0.00010156659,0.08081648,0.8981309,0.00028632712],"about_ca_topic_score_codex":0.000036275735,"about_ca_topic_score_gemma":0.000072799055,"teacher_disagreement_score":0.6068584,"about_ca_system_score_codex":0.00018797476,"about_ca_system_score_gemma":0.00008595106,"threshold_uncertainty_score":0.9991515},"labels":[],"label_agreement":null},{"id":"W1970783892","doi":"10.1371/journal.pmed.1000208","title":"Are Patents Impeding Medical Care and Innovation?","year":2010,"lang":"en","type":"article","venue":"PLoS Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto; McGill University","funders":"","keywords":"Incentive; Health care; Intellectual property; Business; Medical care; Medical research; Medical device; Public relations; Medicine; Economic growth; Economics; Law; Political science; Family medicine","score_opus":0.10565661841791527,"score_gpt":0.3219407716179689,"score_spread":0.21628415320005365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970783892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95098716,0.0008877761,0.000026294672,0.011232486,0.00069245487,0.00010397117,0.00004417448,0.00003050726,0.035995148],"genre_scores_gemma":[0.9919581,0.00034194678,0.00006214463,0.0065884744,0.0008763686,0.00001193062,0.00001610682,0.000017058419,0.00012787298],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.998981,0.0000041010453,0.0004929698,0.0002545805,0.00004986699,0.00021751226],"domain_scores_gemma":[0.99924225,0.00007865826,0.0002581326,0.00016890587,0.00004902993,0.00020300076],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00033362175,0.00011092123,0.00031265285,0.00030791765,0.00007424793,0.000018051735,0.00015391459,0.00012469185,0.0023305637],"category_scores_gemma":[0.0013904301,0.00010597093,0.000019582845,0.0002721764,0.00014204632,0.00008931055,0.00006971819,0.00036851817,0.00018255199],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001312283,0.00005655486,0.439702,0.0001597587,0.0000808131,0.000018902081,0.002099251,3.6608043e-7,0.0005944007,0.5434332,0.006763228,0.0070784064],"study_design_scores_gemma":[0.007294482,0.0002948245,0.17682959,0.00029177376,0.000053957607,0.00006411721,0.0017519116,0.010407435,0.0008754544,0.11535055,0.68568504,0.0011008319],"about_ca_topic_score_codex":0.000040061477,"about_ca_topic_score_gemma":0.000023308527,"teacher_disagreement_score":0.6789218,"about_ca_system_score_codex":0.00002211203,"about_ca_system_score_gemma":0.000015032956,"threshold_uncertainty_score":0.99858147},"labels":[],"label_agreement":null},{"id":"W1972080304","doi":"10.1503/cmaj.130814","title":"Delays in the submission of new drugs in Canada","year":2014,"lang":"en","type":"review","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"Canadian Institutes of Health Research; Organisation de Coopération et de Développement Économiques; Government of Canada; Mylan; Teva Pharmaceutical Industries","keywords":"Process (computing); Drug approval; Computer science; Medicine; Data science; Pharmacology; Drug","score_opus":0.04566880837996752,"score_gpt":0.29182912028722147,"score_spread":0.24616031190725396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972080304","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028727212,0.97168607,0.0000052840055,0.015356113,0.0008354788,0.00018388829,0.00016313113,0.0000010875304,0.01148168],"genre_scores_gemma":[0.0016157527,0.98955435,0.0000072787757,0.007830019,0.00081647973,0.0000055658456,0.0000146109405,0.000017935987,0.00013800754],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99738455,0.00014817534,0.001636786,0.00017498429,0.00017213776,0.00048338497],"domain_scores_gemma":[0.99757963,0.00039869637,0.00096599,0.00013669001,0.00002403414,0.0008949819],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003694601,0.00016572811,0.0011581099,0.00042711274,0.000047061116,0.00004716367,0.00064244797,0.0004091144,0.0018924155],"category_scores_gemma":[0.0011464147,0.00014327613,0.00019844538,0.00037033137,0.000013152545,0.00005207171,0.000017625644,0.0015194309,0.000111941124],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0000011255387,0.000015706479,0.0076380246,0.0004215581,0.000070504,0.000057391662,0.0003287915,0.000006307356,6.678108e-10,0.00881053,0.22295591,0.75969416],"study_design_scores_gemma":[0.0002749713,0.0000053830677,0.00063480996,0.00060322793,0.000009795487,0.00002774259,0.00003346547,0.00016863245,6.563777e-9,0.0016800461,0.9964207,0.00014124201],"about_ca_topic_score_codex":0.91737497,"about_ca_topic_score_gemma":0.9865292,"teacher_disagreement_score":0.77346474,"about_ca_system_score_codex":0.0050146445,"about_ca_system_score_gemma":0.016175931,"threshold_uncertainty_score":0.99902},"labels":[],"label_agreement":null},{"id":"W1972149089","doi":"10.1586/14760584.2013.850035","title":"Vaccine development costs: a review","year":2013,"lang":"en","type":"review","venue":"Expert Review of Vaccines","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Alberta Innovates - Health Solutions","keywords":"Drug development; Pharmaceutical industry; Business; Public economics; Risk analysis (engineering); Medicine; Actuarial science; Drug; Economics; Pharmacology","score_opus":0.11465758690193695,"score_gpt":0.39211783474024897,"score_spread":0.277460247838312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972149089","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[8.262894e-8,0.9812578,0.000020263278,0.0017688095,0.00059006485,0.002603319,0.0001368489,0.00004025977,0.013582541],"genre_scores_gemma":[4.7153033e-8,0.98338056,0.0010830433,0.012788536,0.00047024,0.0011559182,0.00023616431,0.0001141542,0.00077134796],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9938371,0.0000834368,0.004657001,0.0008235526,0.000064721535,0.00053415296],"domain_scores_gemma":[0.9956447,0.0001758424,0.0026770516,0.0011058595,0.00011086517,0.00028566463],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0011847668,0.00081960525,0.00731328,0.00030750417,0.00006671123,0.000036436402,0.0010851766,0.00024116074,0.009973328],"category_scores_gemma":[0.0004980449,0.0006860072,0.0012614852,0.00058017584,0.000019160878,0.00019884214,0.00031066596,0.00038455543,0.0064793914],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[3.6822024e-7,0.0000471257,0.0000013696068,0.2663241,0.00016649796,9.626351e-7,0.0000059929475,2.593839e-9,1.4469371e-8,0.003181613,0.19409202,0.53617996],"study_design_scores_gemma":[0.00011941477,0.00001568879,0.0000010204177,0.28866366,0.00010217288,0.000019160616,5.2935854e-7,0.0000010769498,7.41614e-7,0.000086726206,0.7104796,0.0005101793],"about_ca_topic_score_codex":0.000056511388,"about_ca_topic_score_gemma":0.0000028055015,"teacher_disagreement_score":0.53566974,"about_ca_system_score_codex":0.00037136106,"about_ca_system_score_gemma":0.00021865442,"threshold_uncertainty_score":0.9995591},"labels":[],"label_agreement":null},{"id":"W1972281338","doi":"10.1503/cmaj.109-3904","title":"Drug shortage registry under discussion","year":2011,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Economic shortage; Negotiation; Drug; Medicine; Family medicine; Pharmacology; Political science; Government (linguistics)","score_opus":0.040721444869526245,"score_gpt":0.25408855231782657,"score_spread":0.2133671074483003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972281338","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14160323,0.0010187697,0.0008411865,0.21475756,0.0045411666,0.00018466674,0.00034883397,0.000047053938,0.63665754],"genre_scores_gemma":[0.9537289,0.00035309623,0.00012366424,0.039630555,0.0012980525,0.0000042145443,0.0000076466185,0.000023238357,0.0048306454],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986029,0.00003136512,0.0005970692,0.00017932247,0.00010785281,0.0004814461],"domain_scores_gemma":[0.99779016,0.000034589408,0.00031978183,0.0001303418,0.00004270349,0.001682429],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0015524472,0.00010477662,0.00023314494,0.0001825695,0.00020393796,0.00008876035,0.0003177334,0.00024755098,0.02387515],"category_scores_gemma":[0.00042811103,0.0000929714,0.00012611033,0.000120524215,0.00003646688,0.00018604286,0.000021525288,0.0007266909,0.0018494625],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007813999,0.000069681635,0.20592149,0.000007675904,0.00016416801,0.00014321748,0.001129413,0.00000451473,0.000001264982,0.22175261,0.562923,0.007875118],"study_design_scores_gemma":[0.0004154085,0.000010661882,0.03800547,0.000012247237,0.0000047373583,0.000050308397,0.00015791999,0.00043612954,0.0000070514116,0.051641718,0.9090668,0.00019153814],"about_ca_topic_score_codex":0.0028659937,"about_ca_topic_score_gemma":0.011026127,"teacher_disagreement_score":0.8121257,"about_ca_system_score_codex":0.000787715,"about_ca_system_score_gemma":0.00050773245,"threshold_uncertainty_score":0.9989277},"labels":[],"label_agreement":null},{"id":"W1972305079","doi":"10.3821/1913-701x(2008)141[215:bgtnnc]2.0.co;2","title":"BC government to negotiate new compensation framework and lower payments for generic drugs","year":2008,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Negotiation; Payment; Government (linguistics); Compensation (psychology); Business; Law and economics; Finance; Economics; Political science; Law; Psychology; Social psychology","score_opus":0.07628393862383165,"score_gpt":0.26896363727336203,"score_spread":0.19267969864953038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972305079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98299193,0.0016435839,0.0034512342,0.0020674379,0.0038357647,0.0007096618,0.0019907008,0.000019102907,0.0032905673],"genre_scores_gemma":[0.97206944,0.004920698,0.001472422,0.018914439,0.0012344255,0.00002506781,0.000015068525,0.00006043978,0.0012879679],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99767774,0.00002518712,0.0007706743,0.00047912152,0.00010785562,0.00093939144],"domain_scores_gemma":[0.99615055,0.0001016819,0.0003207001,0.00020643101,0.000082791084,0.0031378197],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041107702,0.00031980348,0.00046582942,0.0002164974,0.0007427223,0.00018220094,0.00041458127,0.000073817995,0.00087262527],"category_scores_gemma":[0.00014835395,0.00040286258,0.00013808854,0.0002973677,0.00008689459,0.00029791077,0.000054531913,0.0003643073,0.000072880255],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012502869,0.00033425554,0.044215742,0.00050812034,0.0015939678,0.011319473,0.013619895,0.012100179,0.0007591118,0.036235217,0.7154517,0.16261204],"study_design_scores_gemma":[0.0038481562,0.000098509816,0.00034941692,0.000018203504,0.00005039507,0.022255357,0.000009158692,0.012042018,0.0006044647,0.005671131,0.9540258,0.0010273709],"about_ca_topic_score_codex":0.017742539,"about_ca_topic_score_gemma":0.009391312,"teacher_disagreement_score":0.2385741,"about_ca_system_score_codex":0.002617016,"about_ca_system_score_gemma":0.0009477709,"threshold_uncertainty_score":0.99984235},"labels":[],"label_agreement":null},{"id":"W1972313906","doi":"10.1017/s0266462312000499","title":"BENEFITS OF PHARMACEUTICAL INNOVATION: THE CASE OF SIMVASTATIN IN CANADA","year":2012,"lang":"en","type":"review","venue":"International Journal of Technology Assessment in Health Care","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Institute of Health Economics","funders":"","keywords":"Overtime; Simvastatin; Revenue; Business; Population; Health care; Private sector; Productivity; Medicine; Public economics; Economics; Labour economics; Finance; Economic growth; Environmental health; Pharmacology","score_opus":0.13917123586863284,"score_gpt":0.4498081869635117,"score_spread":0.3106369510948789,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972313906","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0057957713,0.98583305,0.000021538854,0.0057590115,0.0011359084,0.00027638397,0.0007575271,0.0000020101181,0.00041880945],"genre_scores_gemma":[0.26532444,0.7338856,0.00028810065,0.00036026063,0.00009272448,0.000013417456,0.000018675062,0.000014712472,0.0000020838463],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960093,0.000060077506,0.00344345,0.00015525479,0.00007610436,0.0002558394],"domain_scores_gemma":[0.9955857,0.00027532666,0.0036629313,0.0001799015,0.00024279939,0.000053354368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001167001,0.00017381935,0.00128909,0.0016427867,0.000019803017,0.000008335036,0.0007472842,0.0001736893,0.00011698489],"category_scores_gemma":[0.0001301378,0.00015439895,0.00013291165,0.00070165977,0.00007750381,0.00009244759,0.0001459824,0.0010769867,0.0000018102535],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008852028,0.00008772362,0.004891528,0.001995846,0.00016572463,0.00008063945,0.00009529806,0.00017318218,2.563716e-8,0.29630616,0.000115498384,0.69607955],"study_design_scores_gemma":[0.00085852813,0.00008729536,0.0006928045,0.0027112784,0.000033537413,0.0010441046,0.00072481204,0.00013504033,0.00000405961,0.003218069,0.9902789,0.00021158639],"about_ca_topic_score_codex":0.055227865,"about_ca_topic_score_gemma":0.06360523,"teacher_disagreement_score":0.9901634,"about_ca_system_score_codex":0.0024352618,"about_ca_system_score_gemma":0.0025797891,"threshold_uncertainty_score":0.95348155},"labels":[],"label_agreement":null},{"id":"W1972382554","doi":"10.3821/1913-701x-143.2.62","title":"A Step Forward for Medication Safety: Stakeholders Agree to a Common Standard for Barcoding Pharmaceuticals","year":2010,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"DNA barcoding; Medicine; Psychology; Business; Biology; Ecology","score_opus":0.12424883608485915,"score_gpt":0.32362095805091196,"score_spread":0.1993721219660528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972382554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7456144,0.0031015268,0.098542124,0.024467258,0.02723837,0.009773176,0.07429172,0.00019626062,0.01677515],"genre_scores_gemma":[0.97407645,0.0015091915,0.0036998235,0.017840352,0.0019595635,0.0002314198,0.000120158504,0.00013178246,0.0004312594],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959354,0.000041573327,0.0014749533,0.00071201654,0.0001402205,0.0016958566],"domain_scores_gemma":[0.9940297,0.00041078374,0.00053574744,0.00037612932,0.00036010894,0.0042875377],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0024082863,0.00047235453,0.00084591075,0.0007076969,0.001185997,0.00038937083,0.0010099995,0.0001429238,0.001222154],"category_scores_gemma":[0.0007359525,0.00058867503,0.00036129134,0.00043183882,0.00018274723,0.0004490567,0.00006153001,0.00084470067,0.000042392618],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002316311,0.00019451277,0.0040552923,0.0011194521,0.0013842825,0.0018535034,0.0025938603,0.002295295,0.0062943823,0.076417275,0.4063816,0.49509424],"study_design_scores_gemma":[0.0042964495,0.000095945405,0.000016828788,0.000014203256,0.00008804284,0.007412727,0.000011355042,0.02914824,0.001736691,0.0047532576,0.9516414,0.0007848993],"about_ca_topic_score_codex":0.0054019713,"about_ca_topic_score_gemma":0.08856425,"teacher_disagreement_score":0.5452598,"about_ca_system_score_codex":0.0023329107,"about_ca_system_score_gemma":0.0019989861,"threshold_uncertainty_score":0.9996909},"labels":[],"label_agreement":null},{"id":"W1972463951","doi":"10.1007/s11151-005-5469-5","title":"How do Brands’ “Own Generics” Affect Pharmaceutical Prices?","year":2005,"lang":"en","type":"article","venue":"Review of Industrial Organization","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Institute of Health Economics","funders":"Health Canada; Mylan; Teva Pharmaceutical Industries","keywords":"Competition (biology); Drug prices; Affect (linguistics); Brand names; Business; Point (geometry); Market share; Economics; Advertising; Generic drug; Marketing; Industrial organization; Microeconomics; Monetary economics; Drug; Mathematics","score_opus":0.09828502141127128,"score_gpt":0.31119688039122434,"score_spread":0.21291185897995307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972463951","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24427259,0.48034218,0.012895249,0.20909356,0.0042258264,0.0052530826,0.0009180746,0.00036966696,0.042629786],"genre_scores_gemma":[0.84158564,0.1468674,0.00050545606,0.008493157,0.0021457258,0.000013429842,0.000091246206,0.00006630978,0.00023164993],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984584,0.00003637627,0.0008605828,0.00031792634,0.00005293366,0.00027382033],"domain_scores_gemma":[0.9987607,0.0000667152,0.0006550831,0.00026964975,0.00008737015,0.00016045595],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008427735,0.00018270583,0.0006208527,0.00013561215,0.0000930885,0.00007406112,0.00027341052,0.00017242496,0.0017686024],"category_scores_gemma":[0.001122953,0.00019397246,0.00012330571,0.0007952555,0.000048367292,0.0003454268,0.00010219202,0.00022575728,0.00034975933],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000061815044,0.00091795373,0.075202495,0.004940514,0.00056347647,0.0000048862235,0.00041208236,0.00018743474,0.001134209,0.51350266,0.17273018,0.2303423],"study_design_scores_gemma":[0.001206226,0.000042421736,0.00028942566,0.000449802,0.00004671673,0.0000066201096,0.0000029745681,0.00045715977,0.003989633,0.00034789255,0.99286807,0.000293035],"about_ca_topic_score_codex":0.000004462059,"about_ca_topic_score_gemma":5.9184305e-7,"teacher_disagreement_score":0.8201379,"about_ca_system_score_codex":0.00014423733,"about_ca_system_score_gemma":0.000061590894,"threshold_uncertainty_score":0.9991439},"labels":[],"label_agreement":null},{"id":"W1972682547","doi":"10.1017/s104161020999086x","title":"International price comparisons of Alzheimer's drugs: a way to close the affordability gap","year":2009,"lang":"en","type":"article","venue":"International Psychogeriatrics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Douglas Mental Health University Institute","funders":"","keywords":"Donepezil; Purchasing power parity; Memantine; Rivastigmine; High income countries; Galantamine; Purchasing power; Developing country; Development economics; Business; Economic growth; Economics; Medicine; Dementia; Disease; Finance","score_opus":0.06440307358875255,"score_gpt":0.34824507148014056,"score_spread":0.283841997891388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972682547","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26610166,0.0009323861,0.006262507,0.10784949,0.0072136368,0.0007198639,0.0015253314,0.000073117684,0.609322],"genre_scores_gemma":[0.9915498,0.00025217352,0.0017378626,0.0055319434,0.0006409438,0.00001540115,0.000030549414,0.000014573362,0.00022678447],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99828017,0.000017842654,0.0009242878,0.00041301735,0.00010653425,0.00025816835],"domain_scores_gemma":[0.9987824,0.00011142835,0.000439744,0.00040198918,0.00011769299,0.00014675393],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00078372867,0.00016849801,0.00030372175,0.00029516552,0.00006599295,0.00009810684,0.0010060691,0.00007948858,0.0009837557],"category_scores_gemma":[0.0001943988,0.00016259126,0.00021558252,0.0003088221,0.00005376837,0.0001891909,0.00010207384,0.00020324321,0.0005398383],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001956483,0.0006843885,0.008787827,0.0000060940224,0.00040796088,0.0000011889919,0.0010377679,0.00054463616,0.00016204428,0.88657665,0.08960208,0.011993718],"study_design_scores_gemma":[0.00074959395,0.00007990717,0.047493313,0.000006915292,0.000014244402,0.0000042532647,0.00006300971,0.0041387836,0.00018932481,0.08780303,0.85918957,0.0002680835],"about_ca_topic_score_codex":0.00006353793,"about_ca_topic_score_gemma":0.0000050655626,"teacher_disagreement_score":0.79877365,"about_ca_system_score_codex":0.00012480814,"about_ca_system_score_gemma":0.000020311074,"threshold_uncertainty_score":0.9999295},"labels":[],"label_agreement":null},{"id":"W1973148128","doi":"10.1208/s12248-009-9142-z","title":"Bioequivalence; Its History, Practice, and Future","year":2009,"lang":"en","type":"review","venue":"The AAPS Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":107,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Bioequivalence; Pharmaceutical industry; Business; Quality (philosophy); Management science; Risk analysis (engineering); Engineering ethics; Medicine; Pharmacology; Engineering","score_opus":0.17332650120090864,"score_gpt":0.3625870007169042,"score_spread":0.18926049951599555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973148128","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000014154548,0.93244606,0.00000719139,0.008181836,0.0015825292,0.00019799279,0.00007915131,0.000011510531,0.057492282],"genre_scores_gemma":[0.0000038948424,0.98994136,0.000093300376,0.0041191573,0.004437767,0.000006640292,0.000004631532,0.000040306873,0.0013529246],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99814343,0.000093300296,0.0010194145,0.0003066049,0.000038871036,0.0003983599],"domain_scores_gemma":[0.9977693,0.0001722504,0.0014396257,0.000334883,0.00003266429,0.0002512558],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0015411879,0.00033003258,0.0012264304,0.00025095145,0.00019763577,0.00019412201,0.00063937594,0.0002471684,0.0010419632],"category_scores_gemma":[0.00014184491,0.00024387582,0.0004106465,0.0001179618,0.000089425324,0.00032536662,0.000094355724,0.0013249145,0.0011826464],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000062055124,0.000037461632,6.7250653e-7,0.00049844425,0.00019503328,0.000021682508,0.00013341931,2.0792349e-7,2.7979581e-8,0.110685065,0.068974786,0.819447],"study_design_scores_gemma":[0.00016395423,0.000045754758,0.0000028111992,0.00025953085,0.0001819338,0.0013462703,0.000009690049,0.000020619473,2.3733216e-8,0.0070255296,0.9906454,0.00029848667],"about_ca_topic_score_codex":0.000004439148,"about_ca_topic_score_gemma":5.06935e-7,"teacher_disagreement_score":0.9216706,"about_ca_system_score_codex":0.00047075367,"about_ca_system_score_gemma":0.00017141698,"threshold_uncertainty_score":0.9998712},"labels":[],"label_agreement":null},{"id":"W197381804","doi":"10.1001/virtualmentor.2006.8.12.ccas1-0612","title":"Pragmatic Principles of Pharmaceutical Donation","year":2006,"lang":"en","type":"article","venue":"The AMA Journal of Ethic","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Family Medicine; University of British Columbia","funders":"","keywords":"Donation; Business; Political science; Law","score_opus":0.10079377026139226,"score_gpt":0.32729092442757823,"score_spread":0.226497154166186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W197381804","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89839566,0.0044410946,0.0023046825,0.027486065,0.0005641023,0.00015425534,0.000045908742,0.000007823862,0.06660038],"genre_scores_gemma":[0.9976843,0.00044467364,0.0003016939,0.0010084993,0.00032174002,0.0000013199339,0.0000010690999,0.000010728997,0.00022598563],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9986638,0.00004801156,0.0009968507,0.00007921962,0.000050952523,0.00016117444],"domain_scores_gemma":[0.998479,0.00032033178,0.0009287567,0.0001447104,0.00007050449,0.00005667757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002277423,0.00008235073,0.00030145852,0.0001450927,0.00005236129,0.000030211932,0.00031580785,0.00006955904,0.0003059992],"category_scores_gemma":[0.00024172637,0.00006491651,0.0001506737,0.00012468622,0.00013467028,0.0001332807,0.000040435883,0.0004160248,0.00008521815],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030388866,0.00010327515,0.0049133184,0.000046368943,0.00006548569,0.0000023327582,0.00020988002,0.0014580275,0.0005358847,0.99102366,0.00085329823,0.00075807783],"study_design_scores_gemma":[0.0016091395,0.00012186027,0.032780692,0.000060527782,0.000048191632,0.00008811991,0.00003511298,0.017618934,0.0031461974,0.6776989,0.2665839,0.00020843785],"about_ca_topic_score_codex":0.00004120259,"about_ca_topic_score_gemma":0.000007130752,"teacher_disagreement_score":0.31332478,"about_ca_system_score_codex":0.00005000637,"about_ca_system_score_gemma":0.0000441016,"threshold_uncertainty_score":0.33504766},"labels":[],"label_agreement":null},{"id":"W1974464736","doi":"10.1016/j.cjca.2011.07.110","title":"153 Non-adherence to statin therapy: Discontinuation after a single dispensation","year":2011,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Saskatoon Medical Imaging","funders":"","keywords":"Medicine; Discontinuation; Statin; Intensive care medicine; Internal medicine","score_opus":0.11609255210633694,"score_gpt":0.26794075840639947,"score_spread":0.15184820630006252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974464736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93942887,0.00053853693,0.010245473,0.0010251036,0.0009183283,0.0001452388,0.00012860859,0.000002593885,0.047567245],"genre_scores_gemma":[0.9977692,0.00005486926,0.00043378578,0.0012161237,0.0004051705,0.000008539513,0.0000024571282,0.0000127170815,0.000097160584],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99906695,0.000023670675,0.0004928704,0.0001357727,0.0000127173325,0.00026801947],"domain_scores_gemma":[0.9991378,0.000023251434,0.00024271167,0.00012899959,0.0000551224,0.00041209767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039322485,0.000091092974,0.00033820324,0.00029245915,0.00003665998,0.00003353052,0.0001712864,0.00006852454,0.0003807664],"category_scores_gemma":[0.00008938738,0.00009651113,0.00011780009,0.00009296975,0.000055527176,0.00015845035,0.000008857115,0.00012219971,0.00024508775],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054532173,0.000046769324,0.7783264,0.000019576812,0.00061122084,0.00016192168,0.015594966,0.0010740488,0.0006089635,0.081618324,0.023972146,0.09742033],"study_design_scores_gemma":[0.0010437524,0.0011983282,0.5208564,0.00002051074,0.000013292666,0.000047571677,0.000119019125,0.00015954748,0.00039573933,0.03961727,0.43614686,0.0003817725],"about_ca_topic_score_codex":0.0018113656,"about_ca_topic_score_gemma":0.0023099482,"teacher_disagreement_score":0.4121747,"about_ca_system_score_codex":0.00013894244,"about_ca_system_score_gemma":0.00014952123,"threshold_uncertainty_score":0.41691253},"labels":[],"label_agreement":null},{"id":"W1975879435","doi":"10.1097/01.mlr.0000129494.36245.4b","title":"Drug Spending in Canada","year":2004,"lang":"en","type":"article","venue":"Medical Care","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; U.S. Food and Drug Administration","keywords":"Per capita; Medical prescription; Inflation (cosmology); Drug prices; Public economics; Drug; Investment (military); Economics; Prescription drug; Demographic economics; Medicine; Environmental health; Pharmacology","score_opus":0.03267895508712495,"score_gpt":0.26378780988782446,"score_spread":0.2311088548006995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975879435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90972036,0.0022577227,0.00003785016,0.00795985,0.00065525057,0.00007815476,0.00009067956,0.000010995948,0.079189144],"genre_scores_gemma":[0.9953117,0.00012798018,0.000037618047,0.0043114484,0.00013571561,0.000006214624,0.000010546285,0.000010419437,0.00004835417],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991099,0.0000045358343,0.0003499766,0.00020348682,0.000044323853,0.00028773208],"domain_scores_gemma":[0.9995333,0.000028352302,0.000051264604,0.0001233668,0.0000047348417,0.00025896035],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017084378,0.000079582074,0.00021783289,0.00007286934,0.000028811028,0.000014423012,0.00021396585,0.000044917157,0.002004723],"category_scores_gemma":[0.000114427814,0.00009260752,0.000038090995,0.00010917362,0.000023160175,0.000051100003,0.00005383952,0.0002251163,0.0003207448],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009925608,0.00004160481,0.51007664,0.000083495564,0.00001964949,0.0002457142,0.0019549716,0.00051886373,0.000001175816,0.47622412,0.003543656,0.007280164],"study_design_scores_gemma":[0.004646627,0.000026991058,0.16897486,0.000104754334,0.000004147437,0.000020887708,0.0014147944,0.0018692316,0.00030251415,0.084458135,0.737322,0.0008550588],"about_ca_topic_score_codex":0.82943624,"about_ca_topic_score_gemma":0.94176877,"teacher_disagreement_score":0.73377836,"about_ca_system_score_codex":0.0012090581,"about_ca_system_score_gemma":0.00048124173,"threshold_uncertainty_score":0.99890757},"labels":[],"label_agreement":null},{"id":"W1975925894","doi":"10.1016/s0140-6736(04)16243-0","title":"Canada draws near to approving Africa drugs deal","year":2004,"lang":"en","type":"article","venue":"The Lancet","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Legislature; Government (linguistics); Honour; Malaria; Human immunodeficiency virus (HIV); Business; Political science; Law; International trade; Medicine; Virology","score_opus":0.05802132812413667,"score_gpt":0.25756473030568133,"score_spread":0.19954340218154465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975925894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.48139763,0.00092525396,0.00061122346,0.15072829,0.0006318363,0.00035294855,0.00065569096,0.00006094119,0.3646362],"genre_scores_gemma":[0.97651714,0.000038901777,0.0009520366,0.021302637,0.0006624432,0.000017145745,0.0000033812646,0.000017660392,0.0004886458],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.999063,0.0000068171407,0.00026615502,0.00021159732,0.000023871022,0.00042853472],"domain_scores_gemma":[0.9993594,0.000040759154,0.00008231748,0.00036399628,0.0000074825575,0.00014600655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003237357,0.000103637896,0.00031477303,0.000029577935,0.00015832939,0.000108887776,0.00046325166,0.00003169528,0.00014815493],"category_scores_gemma":[0.000041714226,0.00009464757,0.000044496002,0.0001362562,0.00003613511,0.000057301088,0.00009421844,0.00015953586,0.000723213],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040885752,0.000032627133,0.0017527107,0.000023273393,0.00005622751,0.000005205355,0.0024553165,0.0049326555,0.000017068971,0.8695064,0.11877728,0.0024003412],"study_design_scores_gemma":[0.0004977534,0.000012417883,0.002419157,0.0000042234183,0.0000021602386,0.0000016505907,0.000024714782,0.0007255793,0.00005393175,0.04189027,0.95421296,0.00015519177],"about_ca_topic_score_codex":0.25357676,"about_ca_topic_score_gemma":0.06753265,"teacher_disagreement_score":0.8354357,"about_ca_system_score_codex":0.0002536035,"about_ca_system_score_gemma":0.00019441794,"threshold_uncertainty_score":0.94948244},"labels":[],"label_agreement":null},{"id":"W1976743353","doi":"10.1136/bmj.f6159","title":"Maine allows importation of mail order prescription drugs","year":2013,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Mail order; Medical prescription; Order (exchange); Computer science; World Wide Web; Data science; Medicine; Business; Pharmacology; Advertising; Finance","score_opus":0.04107958634110478,"score_gpt":0.2869182180752086,"score_spread":0.24583863173410384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976743353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8721233,0.00032305537,0.0011379747,0.007059538,0.00040152765,0.00051075005,0.00008912962,0.000024727471,0.11832998],"genre_scores_gemma":[0.9954103,0.000076874865,0.0012366301,0.001261943,0.00017139204,0.000067313114,0.000024581188,0.000015379124,0.0017355538],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99905044,0.0000059001923,0.0005809004,0.00017013344,0.000017819744,0.00017479784],"domain_scores_gemma":[0.9993924,0.000021508242,0.00028703827,0.00019043394,0.000035519093,0.000073086],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00029969073,0.00008048199,0.00021003823,0.00009965853,0.000024805788,0.000030066867,0.00010732093,0.000060385577,0.0029896463],"category_scores_gemma":[0.00006251806,0.000092804934,0.000063113905,0.000102011974,0.000030062809,0.00022260129,0.000027002132,0.00006473895,0.0017912954],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033784025,0.00020824869,0.07437251,0.00010812381,0.00013799533,9.987755e-7,0.0008500899,0.0003749132,0.001114671,0.76443064,0.14864813,0.009719904],"study_design_scores_gemma":[0.0016498924,0.00009499586,0.2647871,0.000017094964,0.000013153828,0.000003418159,0.00009749701,0.07364117,0.00066788145,0.26956615,0.388934,0.0005276589],"about_ca_topic_score_codex":0.00076168485,"about_ca_topic_score_gemma":0.000023685037,"teacher_disagreement_score":0.49486446,"about_ca_system_score_codex":0.00003355711,"about_ca_system_score_gemma":0.000014953697,"threshold_uncertainty_score":0.99898595},"labels":[],"label_agreement":null},{"id":"W1976796263","doi":"10.4212/cjhp.v65i3.1138","title":"Drug Shortages: What Can Hospital Pharmacists Do?","year":2012,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Children's Hospital of Eastern Ontario","funders":"","keywords":"Economic shortage; Pharmacy; Business; Government (linguistics); Hospital pharmacy; Medicine; Quality (philosophy); Medical emergency; Nursing","score_opus":0.04301117159928134,"score_gpt":0.28383707247736617,"score_spread":0.24082590087808484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976796263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9136506,0.03146163,0.000015121837,0.03489534,0.009629915,0.00030947907,0.00026174553,0.00001272011,0.009763455],"genre_scores_gemma":[0.9908861,0.002048633,0.00003784916,0.004518633,0.0021191323,0.000008112113,0.0000058631176,0.000053417945,0.00032228083],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977293,0.000041177573,0.0009539636,0.00020758792,0.00007607675,0.000991867],"domain_scores_gemma":[0.99712974,0.00008265478,0.0006673167,0.00030192698,0.0000938649,0.0017244784],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013249742,0.00028622177,0.00048272038,0.00033427487,0.00036580148,0.0006226383,0.00093649945,0.00005258612,0.0018459391],"category_scores_gemma":[0.00010231831,0.0002582852,0.00035257303,0.00024415547,0.00025915116,0.0018008921,0.00005149444,0.00069575256,0.00059108506],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008001664,0.00069384364,0.45908487,0.000083105064,0.0014641179,0.0003025669,0.0412213,0.00021112098,0.00003101977,0.13863067,0.33226743,0.025929928],"study_design_scores_gemma":[0.0025285531,0.0001748627,0.009801187,0.000051095634,0.00010132767,0.00016598754,0.00081407645,0.00024239536,0.0010368392,0.021542752,0.96251416,0.0010267753],"about_ca_topic_score_codex":0.003062058,"about_ca_topic_score_gemma":0.0009715933,"teacher_disagreement_score":0.6302467,"about_ca_system_score_codex":0.00047643727,"about_ca_system_score_gemma":0.000378672,"threshold_uncertainty_score":0.99998695},"labels":[],"label_agreement":null},{"id":"W1977501151","doi":"10.1503/cmaj.109-4199","title":"Africa struggles to improve drug safety","year":2012,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Pharmacovigilance; Nothing; Drug; Medicine; Computer science; Medical emergency; Risk analysis (engineering); Data science; Pharmacology","score_opus":0.021389976256235517,"score_gpt":0.24593028549524906,"score_spread":0.22454030923901355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977501151","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16360213,0.0043620467,0.00082939246,0.32370055,0.010673855,0.00040466644,0.0015889929,0.00005301046,0.49478537],"genre_scores_gemma":[0.93900496,0.00020286067,0.000227015,0.054429334,0.004183576,0.00000786774,0.0000048934817,0.000024188612,0.0019153124],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982079,0.00003507365,0.0006502137,0.00014639282,0.000121152916,0.0008392653],"domain_scores_gemma":[0.9958529,0.000113889386,0.00024768198,0.00010740219,0.00005543839,0.0036226998],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0028173102,0.00011100491,0.00026705104,0.00024044431,0.00022417298,0.00011273619,0.00027643994,0.00019499256,0.010597604],"category_scores_gemma":[0.0013165064,0.00012612517,0.00011301225,0.00017755716,0.00001720187,0.00024393229,0.000029422079,0.0005863562,0.004736975],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000088662255,0.000053208874,0.11067556,0.0000061402575,0.00013889286,0.000011970442,0.0019361186,0.000009456083,0.0000032018665,0.11938495,0.74655837,0.02121328],"study_design_scores_gemma":[0.00033710856,0.000009952651,0.013677969,0.0000051717575,0.0000032793419,0.000014132158,0.00008035842,0.00020617987,0.0000063247276,0.0039655077,0.98153305,0.00016097438],"about_ca_topic_score_codex":0.0012086745,"about_ca_topic_score_gemma":0.0026678292,"teacher_disagreement_score":0.77540284,"about_ca_system_score_codex":0.0014313732,"about_ca_system_score_gemma":0.00041120907,"threshold_uncertainty_score":0.99603796},"labels":[],"label_agreement":null},{"id":"W1977946142","doi":"10.1212/wnl.0b013e3181ae7b04","title":"Selegiline shortage","year":2009,"lang":"en","type":"article","venue":"Neurology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Center for Research Resources; National Institutes of Health","keywords":"Selegiline; Medicine; Internal medicine; Parkinson's disease","score_opus":0.05087514791795878,"score_gpt":0.28112146551710226,"score_spread":0.2302463175991435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977946142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7101906,0.00046194997,0.00025553093,0.03600413,0.0004970072,0.000094714465,0.000049737173,0.000067000925,0.25237933],"genre_scores_gemma":[0.9385605,0.00012982971,0.00006486955,0.06073375,0.00023610587,0.0000027847464,0.0000051957736,0.000008826709,0.00025813677],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991295,0.000008174016,0.00030751145,0.0002706819,0.0000074579984,0.0002766866],"domain_scores_gemma":[0.9995896,0.00002689951,0.000078408935,0.00020258782,0.0000055778096,0.0000969175],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014097385,0.00008917205,0.00022673885,0.000097094075,0.00003736367,0.000016909938,0.00016715609,0.00009004606,0.00082089443],"category_scores_gemma":[0.0000302132,0.00010864346,0.00006470217,0.00007931687,0.000031652453,0.000065756765,0.00002092964,0.00018867276,0.0016305532],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005173838,0.00008188689,0.009176337,0.0000020531572,0.000010991843,0.000016421478,0.000038372757,0.00006300092,0.00010258409,0.98120403,0.006334643,0.0029179587],"study_design_scores_gemma":[0.00034994874,0.00032937224,0.0416016,2.4130645e-7,0.0000017093768,0.000016137674,2.2076723e-7,0.004019115,0.00005806599,0.14227554,0.81121343,0.0001346171],"about_ca_topic_score_codex":0.000019428497,"about_ca_topic_score_gemma":0.000006548832,"teacher_disagreement_score":0.83892846,"about_ca_system_score_codex":0.000008638008,"about_ca_system_score_gemma":0.0000061269193,"threshold_uncertainty_score":0.9991468},"labels":[],"label_agreement":null},{"id":"W1978024090","doi":"10.1016/s0828-282x(07)70816-4","title":"Would a national pharmaceuticals strategy be bad for the cardiovascular health of Canadians?","year":2007,"lang":"en","type":"editorial","venue":"Canadian Journal of Cardiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences","funders":"","keywords":"Medicine; Disease; Intensive care medicine; Coronary artery disease; Clopidogrel; Clinical trial; Cardiovascular health; Pharmacotherapy; Angiotensin Receptor Blockers; Aspirin; Internal medicine; Blood pressure","score_opus":0.1101832410553085,"score_gpt":0.351082428882589,"score_spread":0.2408991878272805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978024090","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010789749,0.10093541,0.0069833733,0.0146324495,0.81524676,0.0009983398,0.026477635,0.00000635073,0.034611814],"genre_scores_gemma":[0.08407556,0.008935914,0.00016333177,0.005707051,0.90035504,0.000039433955,0.00021653152,0.00012862352,0.00037853236],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967861,0.000089021516,0.001756462,0.00033949642,0.00014860906,0.0008802876],"domain_scores_gemma":[0.99536824,0.0013069717,0.0011809441,0.00034966765,0.00068228866,0.001111882],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0063877725,0.00030169386,0.0019415038,0.000844097,0.00019216111,0.000058747726,0.0008503178,0.0010473595,0.00009232823],"category_scores_gemma":[0.0017942304,0.0002951771,0.0014391027,0.00020176232,0.00037063856,0.000088143584,0.000021025971,0.0018126579,0.00001425395],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030879964,0.000002219764,0.00006511482,0.000081087615,0.002287549,0.000012495109,0.00007214923,0.004705433,2.1394068e-7,0.015839627,0.97398067,0.0029225473],"study_design_scores_gemma":[0.00092895026,0.0001515813,0.00014154143,0.000019586769,0.00009817384,0.0000336667,0.00003855304,0.00015129935,0.0000022359404,0.0052405293,0.9929478,0.0002460572],"about_ca_topic_score_codex":0.023605386,"about_ca_topic_score_gemma":0.011878018,"teacher_disagreement_score":0.091999486,"about_ca_system_score_codex":0.0012914734,"about_ca_system_score_gemma":0.009442112,"threshold_uncertainty_score":0.99995005},"labels":[],"label_agreement":null},{"id":"W1978784436","doi":"10.1057/palgrave.jgm.4940034","title":"Editorial: Canada First to Pass Legislation on Delivering Generic Medicines to Developing Countries","year":2004,"lang":"en","type":"editorial","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Innovative Medicines Canada","funders":"","keywords":"Legislation; Business; Developing country; Medicine; International trade; Political science; Law; Economic growth; Economics","score_opus":0.052324298369772655,"score_gpt":0.2877537100870722,"score_spread":0.23542941171729953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978784436","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027514978,0.014605204,0.01924857,0.12369802,0.83814615,0.0010538811,0.00038559682,0.000021984222,0.000089112364],"genre_scores_gemma":[0.0016458221,0.025949325,0.00076067494,0.023455728,0.94741166,0.00010503885,0.00006671581,0.00024813393,0.00035691308],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99205357,0.00011983351,0.004220845,0.0007933937,0.0014633109,0.0013490471],"domain_scores_gemma":[0.9872195,0.0033201363,0.0045668096,0.00092080666,0.0028968295,0.0010759115],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0052714273,0.0012047532,0.002806681,0.0011078398,0.0013507552,0.0003321513,0.0028509786,0.00060976757,0.00018184479],"category_scores_gemma":[0.007996707,0.0007368599,0.0005014606,0.0017527225,0.00027023195,0.00030277923,0.00027052214,0.0017687592,0.000037861046],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006081528,0.000038686605,0.0000694318,0.0003504489,0.00070603547,0.0000489178,0.0008186815,0.03502321,0.000044659493,0.00018399392,0.9609652,0.0011425639],"study_design_scores_gemma":[0.0027953284,0.0006750757,0.000397494,0.0013764263,0.00048365595,0.00028426503,0.00020893403,0.00065944,0.000032865508,0.00079939683,0.9914408,0.00084636733],"about_ca_topic_score_codex":0.014977005,"about_ca_topic_score_gemma":0.020149909,"teacher_disagreement_score":0.10926551,"about_ca_system_score_codex":0.003112663,"about_ca_system_score_gemma":0.0054084244,"threshold_uncertainty_score":0.99994934},"labels":[],"label_agreement":null},{"id":"W1978872749","doi":"10.1016/j.jval.2013.08.1356","title":"Statins in Canada: The Case for Disinvestment","year":2013,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Agency for Drugs and Technologies in Health","funders":"","keywords":"Disinvestment; Reimbursement; Atorvastatin; Statin; Unit (ring theory); Medicine; Unit cost; Generic drug; Public health; Business; Operations management; Health care; Economics; Drug; Internal medicine; Pharmacology; Mathematics","score_opus":0.13835606983133678,"score_gpt":0.3103241599661802,"score_spread":0.1719680901348434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978872749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94154674,0.0016034435,0.00009435564,0.05287062,0.00032891714,0.0010148986,0.0003733194,0.000004426573,0.0021632686],"genre_scores_gemma":[0.9860413,0.00028849905,0.0003172017,0.013061042,0.000047607584,0.00017032285,0.000004685871,0.00001146939,0.00005785047],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.998794,0.000026249592,0.00060990074,0.0001837993,0.000010269384,0.00037576753],"domain_scores_gemma":[0.99933386,0.00022365307,0.0001467788,0.00016555584,0.0000055283094,0.00012460134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059003837,0.00007604203,0.00021864861,0.000076148,0.000057520323,0.00002545253,0.00011417195,0.000020371574,0.00011662517],"category_scores_gemma":[0.000065070526,0.00007024142,0.000026200141,0.00010872679,0.000017556284,0.00006590943,0.000022912687,0.00011555266,0.000055836546],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000066499006,0.00007449989,0.035317775,0.0001292035,0.000011250244,0.000021887334,0.00093328604,0.010426978,4.275804e-7,0.93395954,0.013837801,0.0052806963],"study_design_scores_gemma":[0.0013394207,0.00007635762,0.047306493,0.000024628363,8.764474e-7,0.000029122602,0.0004593729,0.492226,0.000007312405,0.27568367,0.18257408,0.000272666],"about_ca_topic_score_codex":0.9913377,"about_ca_topic_score_gemma":0.8742197,"teacher_disagreement_score":0.6582759,"about_ca_system_score_codex":0.0011754287,"about_ca_system_score_gemma":0.0005157687,"threshold_uncertainty_score":0.30737054},"labels":[],"label_agreement":null},{"id":"W1979553117","doi":"10.1177/1715163513494593","title":"Distribution of diluted chemo drugs leads to new oversight in Ontario","year":2013,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Distribution (mathematics); Business; Mathematics","score_opus":0.043675568637932274,"score_gpt":0.2417652534534388,"score_spread":0.19808968481550654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979553117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98848367,0.00040322266,0.00013884746,0.00092598144,0.0012662575,0.0003777717,0.00072181295,0.000008458004,0.00767401],"genre_scores_gemma":[0.99238074,0.00051730603,0.00012473766,0.0044518206,0.00031821153,0.000013710937,0.00005388748,0.00003490387,0.0021046908],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997428,0.000028284387,0.001062061,0.00040067517,0.000083375184,0.0009976147],"domain_scores_gemma":[0.9965545,0.00005470927,0.00035720013,0.00023244055,0.0001377646,0.0026633884],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00043284852,0.00029817587,0.0005694921,0.000494896,0.00019169465,0.00015617789,0.0006080558,0.000081462385,0.005797295],"category_scores_gemma":[0.00011424767,0.00038212157,0.00015790206,0.0005963826,0.000081907056,0.000511306,0.000056990633,0.0006359745,0.00021738539],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030582427,0.0003262756,0.21005768,0.00033205538,0.0005926151,0.005772176,0.012368657,0.00951456,0.0028444657,0.017140796,0.677588,0.063156895],"study_design_scores_gemma":[0.0057936,0.000095282994,0.008062227,0.000048202317,0.00005240205,0.015290396,0.000016680262,0.005732401,0.0040029655,0.0069763917,0.95221704,0.0017124105],"about_ca_topic_score_codex":0.8372018,"about_ca_topic_score_gemma":0.80583185,"teacher_disagreement_score":0.27462903,"about_ca_system_score_codex":0.00706521,"about_ca_system_score_gemma":0.0028939224,"threshold_uncertainty_score":0.9998631},"labels":[],"label_agreement":null},{"id":"W1979792032","doi":"10.1016/s1098-3015(10)67721-2","title":"PHP20 GENERIC DRUG PRICES REMAIN HIGHER IN CANADA THAN IN THE UNITED STATES","year":2005,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Business; Economics; Medicine; Pharmacology","score_opus":0.09635049559894734,"score_gpt":0.29200393933434815,"score_spread":0.1956534437354008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979792032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94418746,0.0028993976,0.0000038762496,0.049204983,0.00020016535,0.00025162564,0.000093516624,0.000006053115,0.0031528964],"genre_scores_gemma":[0.97498506,0.0031184389,0.00014836514,0.021465927,0.00012319621,0.000025489286,0.000024552679,0.00001564629,0.00009333853],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982222,0.000101169746,0.0008423144,0.0002724288,0.000034190452,0.00052772526],"domain_scores_gemma":[0.99922097,0.00021956819,0.0002187746,0.00022942136,0.0000048569314,0.00010643192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015026813,0.0001267518,0.00032147352,0.00037614067,0.000041293923,0.000031461484,0.0003131397,0.000036565285,0.00011221136],"category_scores_gemma":[0.00003013113,0.00012315248,0.00002755964,0.00071539707,0.000021252643,0.00009715103,0.000033503493,0.00030152322,0.00005345054],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030009754,0.00022669551,0.523183,0.00015103593,0.000013472066,0.000016749005,0.0054526953,0.24467146,8.159013e-7,0.2145462,0.009876268,0.0018316064],"study_design_scores_gemma":[0.0007605275,0.000019641002,0.23096848,0.000031041913,5.3334446e-7,0.0000015760286,0.00025526067,0.18228066,0.000004521979,0.015272264,0.5701772,0.0002282879],"about_ca_topic_score_codex":0.97699606,"about_ca_topic_score_gemma":0.90443885,"teacher_disagreement_score":0.56030095,"about_ca_system_score_codex":0.0014593324,"about_ca_system_score_gemma":0.00039418103,"threshold_uncertainty_score":0.50220126},"labels":[],"label_agreement":null},{"id":"W1981868458","doi":"10.1016/j.jval.2011.08.801","title":"PCV81 Cost-Effectiveness of Ticagrelor Versus Clopidogrel in Patients with Acute Coronary Syndrome: Results from the Plato Study: A Canadian Analysis","year":2011,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada); University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Ticagrelor; Medicine; Clopidogrel; Acute coronary syndrome; Myocardial infarction; Stroke (engine); Internal medicine; Cardiology; Emergency medicine; Intensive care medicine","score_opus":0.13223122112659944,"score_gpt":0.30803283665559306,"score_spread":0.17580161552899362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981868458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946445,0.00016335407,0.0000087524195,0.00028268565,0.00020948943,0.0011634986,0.0025724794,0.0000055918126,0.0009496328],"genre_scores_gemma":[0.9993818,0.000095713986,0.000085220134,0.00026641245,0.000009133199,0.00004975628,0.00009060413,0.000017127044,0.0000042393294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99806565,0.0001744402,0.00085528503,0.00042730052,0.000046629808,0.00043068334],"domain_scores_gemma":[0.9984796,0.0004941857,0.00033217226,0.0004384654,0.000022881859,0.00023271811],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014893459,0.0001534997,0.00064123084,0.0004953125,0.00006192499,0.000014069173,0.0003074975,0.00007915915,0.00006168397],"category_scores_gemma":[0.0000886075,0.00013902133,0.000069687456,0.0008725257,0.000062244726,0.0000953907,0.00004793928,0.00025910666,0.00004575127],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001542673,0.00032713733,0.9902528,0.0000126748155,0.0004927072,0.00001680201,0.0016756804,0.0013431588,9.710127e-9,0.003991741,0.000015679612,0.00032894957],"study_design_scores_gemma":[0.005778526,0.00057063776,0.98870045,0.0000310486,0.000038983984,3.6155794e-7,0.00008736934,0.0034017316,5.767558e-7,0.00094507524,0.00029656987,0.00014866161],"about_ca_topic_score_codex":0.73589325,"about_ca_topic_score_gemma":0.17560342,"teacher_disagreement_score":0.5602898,"about_ca_system_score_codex":0.00061922404,"about_ca_system_score_gemma":0.0002721558,"threshold_uncertainty_score":0.8394397},"labels":[],"label_agreement":null},{"id":"W1983081217","doi":"10.3821/1913-701x-142.3.116","title":"Drug Expenditures on the Rise","year":2009,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Drug; Medicine; Pharmacology","score_opus":0.05999633044758467,"score_gpt":0.2690579111071113,"score_spread":0.20906158065952662,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983081217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84601414,0.007218823,0.000060216014,0.017052632,0.005757226,0.0006889072,0.0022274733,0.0000571702,0.120923415],"genre_scores_gemma":[0.95363563,0.004142057,0.000028356102,0.03936589,0.0014827063,0.000011528002,0.000008930017,0.00004022357,0.0012847005],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99741423,0.00007535068,0.0008155377,0.000448496,0.00010107252,0.0011453063],"domain_scores_gemma":[0.9970537,0.00014410912,0.0003831894,0.00037253895,0.00007107011,0.0019754337],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009679974,0.00037711053,0.00044180488,0.0003945311,0.0010850444,0.00039793123,0.0010617956,0.000060201906,0.003931372],"category_scores_gemma":[0.00015095095,0.0003590658,0.00023547559,0.00027155125,0.00015756504,0.000310501,0.000028277935,0.00093563885,0.00034801537],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011162703,0.000120298006,0.0010693293,0.000036863916,0.000252975,0.012625392,0.0014382175,0.0019291652,0.00017504251,0.10564212,0.8400529,0.036546055],"study_design_scores_gemma":[0.0011387462,0.000040165465,0.00008912571,0.00000942182,0.000023211664,0.03155323,0.00000812505,0.004960488,0.0009114139,0.016489435,0.9441015,0.0006750969],"about_ca_topic_score_codex":0.011616288,"about_ca_topic_score_gemma":0.018960925,"teacher_disagreement_score":0.11963872,"about_ca_system_score_codex":0.0018872404,"about_ca_system_score_gemma":0.000838931,"threshold_uncertainty_score":0.99988616},"labels":[],"label_agreement":null},{"id":"W1983088377","doi":"10.1016/j.cjca.2012.05.010","title":"Clinical Equivalence of Proprietary and Generic Atorvastatin in Lipid Clinic Patients","year":2012,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Western University","funders":"Health Canada","keywords":"Atorvastatin; Medicine; Rosuvastatin; Statin; Creatine; Retrospective cohort study; Creatine kinase; Adverse effect; Cohort; Cholesterol; Internal medicine; Pharmacology","score_opus":0.11814041679586458,"score_gpt":0.3213305382368629,"score_spread":0.20319012144099835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983088377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886285,0.0032594695,0.00011468361,0.0003099512,0.0011980524,0.00006754492,0.000086672124,7.1989734e-7,0.006334393],"genre_scores_gemma":[0.997564,0.0009744213,0.00023548036,0.0005428143,0.0006529191,0.0000011432533,0.0000017877171,0.0000089606665,0.000018450442],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983678,0.00007047682,0.001105698,0.00011136468,0.000013454865,0.00033121256],"domain_scores_gemma":[0.99872994,0.00011562909,0.0004814992,0.000110899215,0.00004056269,0.00052147533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014946986,0.00007976606,0.00061033573,0.00025982375,0.00001981807,0.0000065405284,0.00015396495,0.000117312324,0.0000763695],"category_scores_gemma":[0.00034978308,0.00008596056,0.00013544403,0.00008540266,0.00019138733,0.00013787564,0.000021595191,0.0002552752,0.00003834748],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013174866,0.0000062650292,0.99063295,0.000011467874,0.000042684613,0.0000023779655,0.00009602194,0.000027935906,0.0000011843732,0.0021708745,0.0016064878,0.0053885444],"study_design_scores_gemma":[0.0006745189,0.00014916502,0.84836835,0.0000085444135,0.000007805169,0.000013869541,0.000013979766,0.0000376457,0.000003424393,0.0020236748,0.14860687,0.00009212746],"about_ca_topic_score_codex":0.0002728689,"about_ca_topic_score_gemma":0.00011827044,"teacher_disagreement_score":0.14700039,"about_ca_system_score_codex":0.00006595606,"about_ca_system_score_gemma":0.00019841542,"threshold_uncertainty_score":0.35053697},"labels":[],"label_agreement":null},{"id":"W1983266155","doi":"10.1016/j.jval.2012.03.095","title":"PHP18 The Impact of Patent Expiries on Future Drug Spending in Canada","year":2012,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Institute for Health Information","funders":"","keywords":"Generic drug; Prescription drug; Market share; Competition (biology); Business; Audit; Medical prescription; Drug; Drug prices; Product (mathematics); Brand names; Public economics; Marketing; Medicine; Economics; Pharmacology; Accounting","score_opus":0.1685645391951565,"score_gpt":0.3302935532945758,"score_spread":0.16172901409941934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983266155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98792744,0.0036506269,0.0000013985745,0.0043386254,0.00055350043,0.00017271806,0.00014374862,0.0000024326694,0.0032094885],"genre_scores_gemma":[0.9976165,0.0011022977,0.000015150552,0.0009987085,0.00022755627,0.000007195486,0.0000031016134,0.00001071896,0.000018752287],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987621,0.00004487079,0.00059027673,0.00013170356,0.00002286658,0.0004482112],"domain_scores_gemma":[0.9993155,0.00012102663,0.0002390299,0.00018630845,0.0000030581314,0.00013505583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093677005,0.00009878638,0.00030618918,0.00013330387,0.00003702438,0.000009632759,0.00015353746,0.00002630533,0.00015621432],"category_scores_gemma":[0.000032374057,0.000081466904,0.000058400186,0.00016853365,0.00001924373,0.00008364234,0.000028313136,0.00021379827,0.000030396488],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016358596,0.000060148814,0.8754621,0.000038387774,0.00000978367,6.1941114e-7,0.0014592938,0.008330934,5.7526546e-7,0.11193935,0.0017255279,0.00095688744],"study_design_scores_gemma":[0.0005212823,0.000045063392,0.9616387,0.000041782612,5.641344e-7,0.0000016135496,0.00036486686,0.010488544,0.000035945148,0.0075096567,0.019187236,0.000164752],"about_ca_topic_score_codex":0.9492229,"about_ca_topic_score_gemma":0.24157228,"teacher_disagreement_score":0.7076506,"about_ca_system_score_codex":0.001447604,"about_ca_system_score_gemma":0.00032043294,"threshold_uncertainty_score":0.77226704},"labels":[],"label_agreement":null},{"id":"W1983949690","doi":"10.5367/000000007781698356","title":"Surveying the Need for Technology Management for Global Health Training Programmes","year":2007,"lang":"en","type":"article","venue":"Industry and Higher Education","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Profitability index; Training (meteorology); Public relations; Public health; Marketing; Knowledge management; Political science; Medicine; Computer science","score_opus":0.15211797836511234,"score_gpt":0.4071693464668992,"score_spread":0.25505136810178686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983949690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.577024,0.010391251,0.013319845,0.3232826,0.0052941777,0.00432816,0.0004170356,0.00015546876,0.06578749],"genre_scores_gemma":[0.9924145,0.000049384198,0.001619589,0.003938578,0.0004037932,0.00019459185,0.000022320964,0.000008781511,0.001348509],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99923444,0.0000040001237,0.000282664,0.00018670873,0.000008247787,0.00028394905],"domain_scores_gemma":[0.9996131,0.00004974599,0.00014693842,0.00010347941,0.000015070551,0.00007165966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083277526,0.00007358319,0.00013419417,0.00007545967,0.0001819811,0.0000562682,0.00009746409,0.00014227403,0.000017426028],"category_scores_gemma":[0.000014821152,0.000072532064,0.000032767508,0.00015055244,0.000045737455,0.000057237805,0.000017673245,0.00011459113,0.0000036981255],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010484832,0.000042034622,0.011080016,0.000029594648,0.000023728191,2.3773541e-8,0.00011142196,0.0000017608457,2.833971e-7,0.7953877,0.002279196,0.19103377],"study_design_scores_gemma":[0.00033026093,0.000041399253,0.053666502,0.000008619739,0.0000045377174,0.0000015889357,0.0004801775,0.000053063402,0.0000057220095,0.20624094,0.73908,0.00008715064],"about_ca_topic_score_codex":0.00004785131,"about_ca_topic_score_gemma":0.000016034392,"teacher_disagreement_score":0.73680085,"about_ca_system_score_codex":0.000107254506,"about_ca_system_score_gemma":0.000054945533,"threshold_uncertainty_score":0.29577717},"labels":[],"label_agreement":null},{"id":"W1985999538","doi":"10.1002/ddr.10404","title":"Patenting the sun: Enclosing the scientific commons and transforming the university—ethical concerns","year":2004,"lang":"en","type":"article","venue":"Drug Development Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"License; Commons; Legislation; Quarter (Canadian coin); Political science; Engineering ethics; Environmental ethics; Public relations; Sociology; Engineering; Law; History","score_opus":0.205140735119185,"score_gpt":0.35160149033589466,"score_spread":0.14646075521670965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985999538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8806494,0.0009261685,0.000300233,0.09512297,0.0002032506,0.00044303015,0.000022802798,0.000017202188,0.022314932],"genre_scores_gemma":[0.9977032,0.00024678887,0.00007982318,0.00071575603,0.00006730908,0.00000911947,0.000004533087,0.000010934019,0.0011625572],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99863774,0.00009733883,0.0003009146,0.0003093712,0.00011191607,0.000542706],"domain_scores_gemma":[0.99897224,0.00054080156,0.00006319293,0.00027024152,0.00005100187,0.0001025319],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0061753024,0.0001021647,0.00014212161,0.00013765824,0.00329315,0.0004848267,0.00068681344,0.0000671222,0.00009847012],"category_scores_gemma":[0.00010837973,0.00006434913,0.000052135645,0.00047427026,0.0010501354,0.00012151362,0.00030876815,0.0010088651,0.00020782073],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000180834,0.00004353164,0.0067469943,0.000028434186,0.00007278565,0.0000074793884,0.025717169,0.00014188842,0.00008052738,0.95589757,0.0025533508,0.008692183],"study_design_scores_gemma":[0.00048250213,0.0000068898844,0.005931654,0.000026355901,0.000003533528,0.0000058449064,0.002501755,0.0009308014,0.0008637313,0.02632524,0.96276253,0.00015916459],"about_ca_topic_score_codex":0.00036679138,"about_ca_topic_score_gemma":0.0004157084,"teacher_disagreement_score":0.9602092,"about_ca_system_score_codex":0.00024022549,"about_ca_system_score_gemma":0.00022317174,"threshold_uncertainty_score":0.99800444},"labels":[],"label_agreement":null},{"id":"W1986191029","doi":"10.3821/1913-701x(2008)141[89:bvocbf]2.0.co;2","title":"BC vision of competitive bidding for Pharmacare meets with opposition from pharmacists and drug industry","year":2008,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Opposition (politics); Bidding; Drug; Business; Advertising; Marketing; Medicine; Political science; Pharmacology; Law; Politics","score_opus":0.05816575695350652,"score_gpt":0.27104782155833795,"score_spread":0.21288206460483144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986191029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983526,0.0027960972,0.00020745563,0.00065447006,0.0011191708,0.00055280013,0.007741056,0.000021142767,0.003381808],"genre_scores_gemma":[0.98783946,0.007184524,0.0005558223,0.003258403,0.00073867495,0.000032221946,0.000117011565,0.00007948854,0.00019440975],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972937,0.00006691753,0.0010097577,0.0006097569,0.00012278922,0.0008970968],"domain_scores_gemma":[0.99663484,0.00021931961,0.0006973362,0.00020546721,0.0003050314,0.0019380128],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005268273,0.0004395772,0.0007510702,0.000528107,0.0008313261,0.00013109698,0.00048913754,0.0001264407,0.0008690613],"category_scores_gemma":[0.00007222104,0.0005071592,0.00016649613,0.0003833837,0.00038760787,0.00064453355,0.000058312395,0.000840764,0.000011967368],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077774148,0.0017656389,0.19183816,0.0042511304,0.009938426,0.09227449,0.036616493,0.015838485,0.036274604,0.04499856,0.3731093,0.1853173],"study_design_scores_gemma":[0.033054445,0.0004912935,0.0012321041,0.00031601766,0.0006512095,0.22993265,0.00013251159,0.07007045,0.05412205,0.0055180495,0.59962875,0.004850476],"about_ca_topic_score_codex":0.014195589,"about_ca_topic_score_gemma":0.00877142,"teacher_disagreement_score":0.22651944,"about_ca_system_score_codex":0.0012517882,"about_ca_system_score_gemma":0.0011019172,"threshold_uncertainty_score":0.999738},"labels":[],"label_agreement":null},{"id":"W1986635261","doi":"10.1016/j.clinthera.2007.02.005","title":"Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy","year":2007,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Lamotrigine; Medicine; Epilepsy; Adverse effect; Adverse drug reaction; Audit; Drug; Psychiatry; Pharmacology","score_opus":0.17360845331881697,"score_gpt":0.37379915629465627,"score_spread":0.2001907029758393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986635261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99402475,0.0000650237,0.004193701,0.00021474645,0.0003248639,0.00037737837,0.00022894113,0.0000075044754,0.0005631108],"genre_scores_gemma":[0.99882895,0.00023302158,0.0002188542,0.00056396006,0.000055428667,0.00000776204,0.00003394905,0.000013775116,0.000044280663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99833256,0.000016193679,0.0012123729,0.00022661343,0.000032218213,0.00018003157],"domain_scores_gemma":[0.9985695,0.00033581245,0.0007215689,0.0002530489,0.000058074704,0.00006202826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011372836,0.00009810849,0.00036149216,0.00017711266,0.000027989281,0.0000042032407,0.00012825317,0.00011860979,0.000016026079],"category_scores_gemma":[0.000084797524,0.00009851539,0.0001246019,0.00019121957,0.00012910276,0.00006586869,0.000010325562,0.00013364344,0.000009097356],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078278786,0.00082853046,0.9132987,0.0000441318,0.000092201655,1.5583515e-7,0.000059090387,0.0004114707,0.000046948076,0.08135929,0.000013554292,0.0030631404],"study_design_scores_gemma":[0.0040144594,0.00038368307,0.9718198,0.000021708878,0.000024927036,1.18826414e-7,0.000011247866,0.002750514,0.0015403903,0.0073900428,0.011880098,0.00016300888],"about_ca_topic_score_codex":0.000019301364,"about_ca_topic_score_gemma":0.000032944838,"teacher_disagreement_score":0.073969245,"about_ca_system_score_codex":0.00006549691,"about_ca_system_score_gemma":0.000027711843,"threshold_uncertainty_score":0.4017341},"labels":[],"label_agreement":null},{"id":"W1986874544","doi":"10.1016/j.jval.2014.03.108","title":"Impact Of Drug Reimbursement Modalities On Treatment Adherence In Patients Covered By Private Drug Insurance","year":2014,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Reimbursement; Medicine; Cohort; Retrospective cohort study; Drug; Internal medicine; Private insurance; Drug class; Emergency medicine; Family medicine; Medicaid; Pharmacology; Health care","score_opus":0.06202613729766446,"score_gpt":0.31449148139421884,"score_spread":0.2524653440965544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986874544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951109,0.0005025609,0.000007252117,0.0006112119,0.00017153812,0.000437446,0.00085053744,0.000008134839,0.0023003658],"genre_scores_gemma":[0.99804914,0.0011521174,0.000043955035,0.0005120966,0.000026206806,0.00003389325,0.000030679952,0.00001757376,0.0001343631],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99813765,0.000088306275,0.0009840404,0.00033754858,0.00003837482,0.00041410667],"domain_scores_gemma":[0.9989688,0.00013239027,0.00045333154,0.0002965242,0.000010098101,0.00013887101],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006648835,0.00018249442,0.0005765402,0.0002164941,0.00003141858,0.000017392134,0.00017042845,0.00004169451,0.000059308193],"category_scores_gemma":[0.00006190661,0.00018286043,0.000098276614,0.00015903327,0.00003756064,0.00009715017,0.000027445421,0.00012548355,0.00006745778],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011214082,0.0007445982,0.93855417,0.000078042394,0.000021469015,1.6339914e-7,0.0012017497,0.011643723,0.0000015433596,0.044382375,0.00073379546,0.0025262232],"study_design_scores_gemma":[0.0048636687,0.0013515509,0.934184,0.00014559073,0.0000011019889,1.014277e-7,0.0000163351,0.019785136,0.000117763484,0.032111436,0.007107323,0.00031598302],"about_ca_topic_score_codex":0.0309723,"about_ca_topic_score_gemma":0.00009037274,"teacher_disagreement_score":0.030881926,"about_ca_system_score_codex":0.001153913,"about_ca_system_score_gemma":0.00007053038,"threshold_uncertainty_score":0.97548056},"labels":[],"label_agreement":null},{"id":"W1987743296","doi":"10.1016/s0140-6736(13)60756-4","title":"Evaluation of the Affordable Medicines Facility—malaria","year":2013,"lang":"en","type":"letter","venue":"The Lancet","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Artemisinin; Malaria; Psychological intervention; Scopus; Medicine; Intervention (counseling); Developing country; Quarter (Canadian coin); Access to medicines; Family medicine; Traditional medicine; Economic growth; Political science; MEDLINE; Economics; Nursing; Geography; Law; Plasmodium falciparum","score_opus":0.1813568597527854,"score_gpt":0.32017461101852934,"score_spread":0.13881775126574394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987743296","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0046913465,0.0014149965,0.000014773994,0.8580729,0.0011277371,0.0005490965,0.0011313234,0.000013142763,0.13298471],"genre_scores_gemma":[0.10060989,0.00081910135,0.00002284482,0.8870794,0.008323909,0.0001536077,0.000109826535,0.000035682267,0.0028457188],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99857855,0.00011579375,0.0005743664,0.00026218983,0.000121375284,0.00034774252],"domain_scores_gemma":[0.99811095,0.00013900017,0.0005525104,0.0010827534,0.00008801135,0.00002676784],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0029013467,0.0001830911,0.0007080159,0.0000614504,0.000088533474,0.000050912586,0.0010116028,0.0002747096,0.0028428934],"category_scores_gemma":[0.0003472365,0.00011451513,0.00017430526,0.00012327121,0.00017853585,0.00007085398,0.00013906982,0.0008416102,0.0010105058],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000002502971,0.000006985266,0.000566953,0.00005686909,0.00009849726,1.4202799e-7,0.00009622002,0.00009770069,0.0000022157376,0.005543927,0.9926349,0.00089307164],"study_design_scores_gemma":[0.0004780344,0.000008804158,0.0024065587,0.00001720102,0.00006603153,0.000001504014,0.00000445941,0.0057113506,0.000021547414,0.06901675,0.9221352,0.00013258023],"about_ca_topic_score_codex":0.0003843126,"about_ca_topic_score_gemma":0.000017888406,"teacher_disagreement_score":0.130139,"about_ca_system_score_codex":0.00011226786,"about_ca_system_score_gemma":0.00007198513,"threshold_uncertainty_score":0.9997673},"labels":[],"label_agreement":null},{"id":"W1987752370","doi":"10.1016/j.vaccine.2009.09.117","title":"Joint reviews and inspections: Strategic forms of collaboration for strengthening the regulatory oversight of vaccine clinical trials in Africa","year":2009,"lang":"en","type":"review","venue":"Vaccine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"European and Developing Countries Clinical Trials Partnership","keywords":"Clinical trial; Regulatory affairs; Quality (philosophy); Process (computing); Business; Joint (building); Regulatory authority; Medicine; Public relations; Political science; Public administration; Engineering; Computer science; Pathology","score_opus":0.43720334627745616,"score_gpt":0.4470390179293779,"score_spread":0.009835671651921729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987752370","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00070203457,0.99485016,0.000036932863,0.00038720135,0.00022151315,0.0019762744,0.0004623143,0.0000060868056,0.0013574869],"genre_scores_gemma":[0.0023173934,0.9969238,0.00018532046,0.00007889486,0.00024996386,0.00010142954,0.00004854984,0.000023224873,0.00007140335],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9935336,0.0002476033,0.005596643,0.00038353936,0.000023484783,0.00021513292],"domain_scores_gemma":[0.99418145,0.0011824889,0.0041109524,0.0004161485,0.000045128847,0.000063807944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010194229,0.00026848304,0.0044062063,0.00042626835,0.000047558457,0.0000314716,0.00021069105,0.00027256302,0.000079466445],"category_scores_gemma":[0.0016030017,0.00019164062,0.0006823965,0.00049262715,0.000015760716,0.0001280137,0.00004788547,0.0002892459,0.0000080677455],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012137569,0.00030796826,0.00013438305,0.007881506,0.0003862883,5.2199096e-7,0.00022811866,0.000016121636,0.0000013733646,0.52140695,0.0058655953,0.46364978],"study_design_scores_gemma":[0.0012903551,0.0002077664,0.00014960814,0.0012848858,0.00018663582,0.0000017198383,0.000025031364,0.00034394825,0.0000019602433,0.033640895,0.9626715,0.00019570693],"about_ca_topic_score_codex":0.0000105428935,"about_ca_topic_score_gemma":0.00004196807,"teacher_disagreement_score":0.9568059,"about_ca_system_score_codex":0.00009934119,"about_ca_system_score_gemma":0.00011605623,"threshold_uncertainty_score":0.78148776},"labels":[],"label_agreement":null},{"id":"W1988578472","doi":"10.1002/hec.1332","title":"Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progression","year":2008,"lang":"en","type":"article","venue":"Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Formulary; Markov chain; Disease; Markov process; Economics; Drug; Drug prices; Externality; Actuarial science; Microeconomics; Computer science; Medicine; Pharmacology; Public economics; Mathematics; Statistics; Machine learning","score_opus":0.13874511098233144,"score_gpt":0.33214207833061843,"score_spread":0.19339696734828699,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988578472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98731774,0.0023353205,0.00053955166,0.003572114,0.00021515459,0.0009596297,0.004304425,0.000031758846,0.0007243168],"genre_scores_gemma":[0.9847574,0.007513033,0.0045592766,0.0024720551,0.00010923558,0.00011780127,0.00024644707,0.00004490078,0.00017981636],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99801576,0.000016433882,0.0010541332,0.0004672367,0.000014828281,0.00043159325],"domain_scores_gemma":[0.9982879,0.00018507945,0.00066611986,0.00030719434,0.000036205296,0.0005174587],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036350827,0.00020200537,0.000580815,0.00021184598,0.0002702714,0.000053278738,0.00014470847,0.00008026581,0.000038471546],"category_scores_gemma":[0.000053215317,0.00025320452,0.00012050987,0.000072153314,0.00013708821,0.0005146292,0.00006360906,0.00012765625,0.0000133305675],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004270027,0.0004024313,0.02360288,0.0004682324,0.00010412099,0.0000011619617,0.00090093334,0.03385777,0.0000022704924,0.9290455,0.008117609,0.0030700848],"study_design_scores_gemma":[0.0034048154,0.00031623448,0.048111077,0.000085157415,0.000020409469,0.0000108992435,0.00004704036,0.8640685,0.000061725244,0.043394707,0.0397524,0.00072700164],"about_ca_topic_score_codex":0.00014900588,"about_ca_topic_score_gemma":0.00004214934,"teacher_disagreement_score":0.8856508,"about_ca_system_score_codex":0.00012517671,"about_ca_system_score_gemma":0.00020487611,"threshold_uncertainty_score":0.999992},"labels":[],"label_agreement":null},{"id":"W1988649996","doi":"10.1038/clpt.2010.90","title":"Refilling and Switching of Antiepileptic Drugs and Seizure-Related Events","year":2010,"lang":"en","type":"article","venue":"Clinical Pharmacology & Therapeutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute; National Institute on Aging","keywords":"Medicine; Medical prescription; Odds ratio; Confidence interval; Epilepsy; Antiepileptic drug; Odds; Pediatrics; Emergency medicine; Anesthesia; Internal medicine; Psychiatry; Pharmacology","score_opus":0.07577093616275075,"score_gpt":0.3784942365549937,"score_spread":0.30272330039224293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988649996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98833776,0.0011317371,0.00006316818,0.0057944236,0.0019631055,0.00018941752,0.000033412045,0.00002798326,0.002459016],"genre_scores_gemma":[0.97581834,0.005051712,0.0005077236,0.018271131,0.00023883677,0.0000056964554,0.0000034398574,0.00003081366,0.00007233133],"study_design_codex":"observational","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9979702,0.000058056226,0.0011930079,0.0004293907,0.000023192602,0.0003261279],"domain_scores_gemma":[0.99853367,0.000547271,0.00048128763,0.00019511148,0.000029700568,0.00021296732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012925257,0.00018510946,0.00061463617,0.00012438964,0.00010374756,0.000018903836,0.00020836247,0.00031917763,0.00030409553],"category_scores_gemma":[0.00003541031,0.00020181444,0.00012298106,0.000107792664,0.0002819238,0.00011304445,0.00017157347,0.000906406,0.0000623691],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047093577,0.0013883878,0.80336934,0.00021928934,0.003124987,0.000013974516,0.0025306381,0.00004381395,0.03900278,0.09083413,0.0018015092,0.057200216],"study_design_scores_gemma":[0.014846987,0.00085668324,0.2503883,0.000043534084,0.0008647283,0.00007036176,0.00012964208,0.09615108,0.0037840437,0.319761,0.31136936,0.0017343006],"about_ca_topic_score_codex":0.000015332656,"about_ca_topic_score_gemma":0.0000025442805,"teacher_disagreement_score":0.5529811,"about_ca_system_score_codex":0.000012595742,"about_ca_system_score_gemma":0.00002729627,"threshold_uncertainty_score":0.8229754},"labels":[],"label_agreement":null},{"id":"W1988914230","doi":"10.1007/s00228-012-1396-1","title":"Statistical approaches to indirectly compare bioequivalence between generics: a comparison of methodologies employing artemether/lumefantrine 20/120 mg tablets as prequalified by WHO","year":2012,"lang":"en","type":"article","venue":"European Journal of Clinical Pharmacology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Bioequivalence; Medicine; Bioavailability; Confidence interval; Statistics; Pharmacology; Mathematics; Internal medicine","score_opus":0.7357467910902785,"score_gpt":0.5167654140692793,"score_spread":0.21898137702099918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988914230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9315488,0.004131315,0.047626797,0.004013854,0.0025239594,0.00034898135,0.0006379708,0.000028443408,0.009139914],"genre_scores_gemma":[0.97509044,0.0005940677,0.019075166,0.003227342,0.0018179266,0.0000042965016,0.000015814694,0.00005772579,0.0001172177],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9923109,0.002060751,0.004382949,0.00040764126,0.00010829399,0.00072947156],"domain_scores_gemma":[0.9924732,0.0037084748,0.0026346154,0.00024875236,0.00008253952,0.00085246016],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.012929584,0.00030365254,0.0021964945,0.00030535331,0.00008964313,0.00004276361,0.0008826963,0.000107124695,0.00081744726],"category_scores_gemma":[0.001988958,0.00030210047,0.00032640382,0.00027110276,0.00036322503,0.00026793877,0.00033282302,0.00095412345,0.0004607458],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013551111,0.0016338922,0.7103875,0.00021157235,0.001929149,0.00003986219,0.0023464507,0.0010027079,0.002646782,0.009462664,0.21328531,0.055698976],"study_design_scores_gemma":[0.0060839946,0.002606608,0.13799404,0.00006895387,0.00042447686,0.000037137313,0.0002596231,0.0017990528,0.0068160803,0.0044219797,0.838444,0.0010440358],"about_ca_topic_score_codex":0.000012072683,"about_ca_topic_score_gemma":6.452192e-7,"teacher_disagreement_score":0.6251587,"about_ca_system_score_codex":0.000060290655,"about_ca_system_score_gemma":0.00007057386,"threshold_uncertainty_score":0.99994314},"labels":[],"label_agreement":null},{"id":"W1989028508","doi":"10.1503/cmaj.1041606","title":"Rofecoxib (Vioxx) voluntarily withdrawn from market","year":2004,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":143,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Sepsis; SOFA score; Internal medicine; Pediatrics; Emergency medicine","score_opus":0.01529079297004724,"score_gpt":0.22892535020679736,"score_spread":0.21363455723675012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989028508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.41076535,0.0019942017,0.00095475395,0.29091054,0.005249841,0.00021334381,0.0012663926,0.00004840379,0.28859717],"genre_scores_gemma":[0.9085145,0.00055724813,0.00037902474,0.08560306,0.0033634158,0.0000071690392,0.000025894724,0.000036714362,0.0015130035],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982324,0.000030001827,0.00073450356,0.00024070598,0.00014996972,0.00061240885],"domain_scores_gemma":[0.9973662,0.0000940109,0.00037133586,0.00013692764,0.00006575417,0.0019657696],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0014180623,0.00014240756,0.00034051406,0.00022597874,0.00025903052,0.00022118652,0.0003581245,0.00037927652,0.03395306],"category_scores_gemma":[0.00088472554,0.0001684897,0.00015139498,0.00016300866,0.000040787472,0.00024043761,0.000023506227,0.00090589223,0.0034957398],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001904508,0.00009893808,0.23024324,0.0000064905275,0.00045555286,0.00029251797,0.0006789187,0.00008235759,0.0000030616688,0.09837014,0.6605266,0.009223154],"study_design_scores_gemma":[0.0012711632,0.000019770647,0.053167976,0.00001574085,0.000006395498,0.000036189307,0.00003393391,0.00052998523,0.0000052666155,0.08353569,0.8611666,0.00021130787],"about_ca_topic_score_codex":0.026528176,"about_ca_topic_score_gemma":0.05148334,"teacher_disagreement_score":0.49774912,"about_ca_system_score_codex":0.002323787,"about_ca_system_score_gemma":0.0013231303,"threshold_uncertainty_score":0.9972802},"labels":[],"label_agreement":null},{"id":"W1989247444","doi":"10.1001/jama.2008.758","title":"Clinical Equivalence of Generic and Brand-Name Drugs Used in Cardiovascular Disease","year":2008,"lang":"en","type":"review","venue":"JAMA","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":430,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute; National Institute on Aging; Agency for Healthcare Research and Quality","keywords":"Medicine; Randomized controlled trial; Jadad scale; Medical prescription; Bioequivalence; Generic drug; Brand names; Clinical trial; MEDLINE; Context (archaeology); Drug; Internal medicine; Pharmacology; Advertising","score_opus":0.17981195311984713,"score_gpt":0.3666103435232169,"score_spread":0.1867983904033698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989247444","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014310117,0.9944,0.000025551071,0.000094587456,0.00029728987,0.00041377798,0.00060723466,0.000010992567,0.0027195015],"genre_scores_gemma":[0.0018516114,0.9971995,0.00007382325,0.00027186383,0.00037226095,0.00004646986,0.0000321008,0.000048336027,0.00010406229],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969912,0.00010222995,0.0018062966,0.00070797314,0.000044650653,0.00034764805],"domain_scores_gemma":[0.99812776,0.00028285713,0.0005611567,0.0006986545,0.0000148166555,0.0003147772],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009745704,0.00031569952,0.0030976683,0.00030945946,0.00003164321,0.000040304796,0.00038349396,0.00032457788,0.000092867675],"category_scores_gemma":[0.00025767292,0.00033903992,0.0013796891,0.0002496177,0.00020394752,0.00013622189,0.00019329209,0.00046417324,0.00021491136],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010389336,0.00008509225,0.0024407369,0.0034960366,0.0004117227,0.000023336324,0.000048682654,0.000015308484,3.0184901e-9,0.0053847046,0.00038447743,0.9876995],"study_design_scores_gemma":[0.0008403142,0.000016997916,0.0013233061,0.0006651851,0.00011031846,0.0000075513767,0.0000012435124,0.000427993,3.6270418e-8,0.001286884,0.99496794,0.00035224797],"about_ca_topic_score_codex":0.000105080755,"about_ca_topic_score_gemma":0.0000013163182,"teacher_disagreement_score":0.9945834,"about_ca_system_score_codex":0.000090053014,"about_ca_system_score_gemma":0.00014232328,"threshold_uncertainty_score":0.9999062},"labels":[],"label_agreement":null},{"id":"W1990037294","doi":"10.1093/jiplp/jpq218","title":"Methods of medical treatment still unpatentable in Canada","year":2011,"lang":"en","type":"article","venue":"Journal of Intellectual Property Law & Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Windsor","funders":"","keywords":"Notice; Patentability; Allegation; Respondent; Law; Business; Estoppel; Patent infringement; Formulary; Political science; Law and economics; Patent law; Medicine; Intellectual property; Family medicine; Economics","score_opus":0.21113481399395895,"score_gpt":0.3562154891790996,"score_spread":0.14508067518514067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990037294","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.33768463,0.010703311,0.004555299,0.012921378,0.0023016413,0.00054993934,0.00007437047,0.000011716008,0.63119775],"genre_scores_gemma":[0.98739314,0.0029959006,0.0060266918,0.0032053434,0.00009609097,0.0000037638438,6.029229e-7,0.000020602425,0.000257873],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978907,0.0001550762,0.0014065877,0.00017128864,0.00009949287,0.00027684506],"domain_scores_gemma":[0.997702,0.00090401387,0.00086109334,0.00017360061,0.000108493536,0.0002508144],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002375338,0.00014901794,0.00062607316,0.00014233273,0.000027923255,0.000025530606,0.0004027833,0.00008892915,0.003685544],"category_scores_gemma":[0.0031317926,0.000103610284,0.00011903529,0.00018426646,0.00007802339,0.0005543751,0.000069113354,0.00041060144,0.000055250992],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00960143,0.008550559,0.0105687,0.00031973666,0.0039927443,0.0012095548,0.04234125,0.00062587095,0.00055798294,0.6550413,0.023898011,0.24329287],"study_design_scores_gemma":[0.0015869435,0.00093001977,0.00016141291,0.000052547464,0.000045311215,0.00033618484,0.0009989146,0.005384053,0.008597819,0.0052833464,0.97636527,0.00025815095],"about_ca_topic_score_codex":0.84497464,"about_ca_topic_score_gemma":0.22326711,"teacher_disagreement_score":0.95246726,"about_ca_system_score_codex":0.000816805,"about_ca_system_score_gemma":0.001197509,"threshold_uncertainty_score":0.9972252},"labels":[],"label_agreement":null},{"id":"W1990831008","doi":"10.1002/art.21709","title":"Approval process and access to prescription drugs in Canada","year":2006,"lang":"en","type":"article","venue":"Arthritis Care & Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Arthritis Research Centre of Canada; Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Medical prescription; Process (computing); Medicine; MEDLINE; Business; Family medicine; Pharmacology; Computer science; Political science","score_opus":0.06717020037170766,"score_gpt":0.3467901967328571,"score_spread":0.2796199963611494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990831008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9497849,0.004881817,0.0000073047345,0.0021717108,0.000113133734,0.00038704844,0.00017344413,0.000008474078,0.04247221],"genre_scores_gemma":[0.99859977,0.00045929226,0.000021526686,0.0005273301,0.00013415255,0.000119894656,0.00001575058,0.000017236898,0.00010505726],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986087,0.000025795724,0.00036025298,0.0004031277,0.00007379309,0.0005283462],"domain_scores_gemma":[0.9995042,0.00005070451,0.00003775206,0.00017228271,0.000067351655,0.00016768531],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043978286,0.00009373536,0.00021631244,0.00029585935,0.00010299412,0.00021161814,0.0002655827,0.00004644975,0.00011604149],"category_scores_gemma":[0.000050549046,0.00012264436,0.00002067534,0.00036146923,0.000050081857,0.0002795927,0.00015801979,0.00025769172,0.0000753322],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006745882,0.000081962055,0.7848185,0.0002187658,0.000013218334,0.000039013466,0.0032121195,0.0006953639,0.00004262995,0.09925448,0.015163315,0.09639318],"study_design_scores_gemma":[0.0029454487,0.000121596015,0.6284932,0.00012648357,0.0000013987136,0.000011280144,0.0027982418,0.0034132665,0.0011096833,0.079975985,0.28018817,0.0008152636],"about_ca_topic_score_codex":0.871929,"about_ca_topic_score_gemma":0.90345925,"teacher_disagreement_score":0.26502487,"about_ca_system_score_codex":0.00050602335,"about_ca_system_score_gemma":0.00028758295,"threshold_uncertainty_score":0.50012916},"labels":[],"label_agreement":null},{"id":"W1990933841","doi":"10.1057/jgm.2008.1","title":"Climate of Change Continues in Canada","year":2008,"lang":"en","type":"article","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Liberian dollar; Market share; Business; Brand names; Generic drug; Reimbursement; Value (mathematics); Marketing; Industrial organization; Economics; Finance; Health care; Economic growth; Drug","score_opus":0.19256701491646183,"score_gpt":0.2973795869913426,"score_spread":0.10481257207488076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990933841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.865595,0.075091384,0.0018635467,0.044147454,0.012299728,0.0005681904,0.00012518566,0.0000050236704,0.0003045106],"genre_scores_gemma":[0.92306393,0.059311636,0.00024905393,0.009497869,0.0076621333,0.000026492444,0.000004755213,0.000055068118,0.00012903933],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965461,0.00006909907,0.0023788621,0.00019020682,0.00023713241,0.0005786052],"domain_scores_gemma":[0.99543625,0.00070648355,0.0027750628,0.00034165243,0.00048464807,0.00025589007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025663942,0.00030097997,0.0012552029,0.00036393027,0.00028960037,0.00002034993,0.0010022217,0.00007474501,0.00021939918],"category_scores_gemma":[0.00083686464,0.00016683094,0.00025051113,0.0008001814,0.00029216026,0.00020247811,0.00007510632,0.00046502793,0.0000034931604],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030865772,0.0006795959,0.36753052,0.0016073111,0.002464145,0.0009470851,0.013174224,0.013043562,0.0038619423,0.004511632,0.5363712,0.05272224],"study_design_scores_gemma":[0.010238212,0.0006972477,0.30202797,0.00074986473,0.00039369814,0.008892218,0.002004691,0.017445453,0.00048297775,0.0040124347,0.6522173,0.00083789264],"about_ca_topic_score_codex":0.028294278,"about_ca_topic_score_gemma":0.016545936,"teacher_disagreement_score":0.115846194,"about_ca_system_score_codex":0.00032248092,"about_ca_system_score_gemma":0.0007301982,"threshold_uncertainty_score":0.9781764},"labels":[],"label_agreement":null},{"id":"W1994686939","doi":"10.1186/1744-8603-10-3","title":"“To patent or not to patent? the case of Novartis’ cancer drug Glivec in India”","year":2014,"lang":"en","type":"article","venue":"Globalization and Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Global Health Research; Public Health Ontario; University of Toronto","funders":"","keywords":"Supreme court; Medicine; Patentability; Lawsuit; Appeal; Bosutinib; Law; Generic drug; Political science; Intellectual property; Imatinib; Nilotinib; Drug; Myeloid leukemia; Patent law; Pharmacology","score_opus":0.15754371096470804,"score_gpt":0.36710358044380226,"score_spread":0.20955986947909422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1994686939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9537661,0.00047821613,0.0017310479,0.040068813,0.00036527205,0.0006254357,0.0005253428,0.000013603254,0.002426173],"genre_scores_gemma":[0.95889986,0.00086816045,0.000091588336,0.039958663,0.000056970144,0.000022432763,0.000006215245,0.000008171248,0.00008792513],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9989871,0.000026350908,0.00051140046,0.00021669386,0.00001678449,0.00024169152],"domain_scores_gemma":[0.99942744,0.000023306002,0.00016871728,0.00014594897,0.000021163,0.00021341296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006777938,0.000085840715,0.00025208402,0.0001250427,0.000077309174,0.00003097324,0.00009106543,0.000032000476,0.00016047276],"category_scores_gemma":[0.00004612879,0.00007295333,0.000023272407,0.0002948653,0.000019348514,0.000047694404,0.000055142496,0.000055560762,0.00006588477],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000115755196,0.00012706722,0.14723349,0.00019936253,0.000022504822,0.000007680911,0.00500215,0.0014483973,0.0000030846772,0.79785603,0.012952204,0.035032254],"study_design_scores_gemma":[0.0020266061,0.00022957602,0.6926386,0.00008629544,0.0000062412,0.000028039238,0.00031601955,0.032406386,0.00006618613,0.009444752,0.26232916,0.00042219777],"about_ca_topic_score_codex":0.0107679,"about_ca_topic_score_gemma":0.0047209347,"teacher_disagreement_score":0.7884113,"about_ca_system_score_codex":0.00013631603,"about_ca_system_score_gemma":0.000051592513,"threshold_uncertainty_score":0.9958195},"labels":[],"label_agreement":null},{"id":"W1994958655","doi":"10.2139/ssrn.1523385","title":"Monopoly Pricing Under a Medicaid-Style Most-Favored-Customer Clause and its Welfare Implication","year":2009,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"","keywords":"Monopoly; Medicaid; Style (visual arts); Welfare; Business; Price discrimination; Economics; Microeconomics; Marketing; Market economy; Art","score_opus":0.021935355371576374,"score_gpt":0.2735931863704176,"score_spread":0.2516578309988412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1994958655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84724176,0.029339697,0.0038785797,0.093985334,0.00034521733,0.0004146833,0.00006180914,0.00008385687,0.024649076],"genre_scores_gemma":[0.9820604,0.013584887,0.000041736286,0.0034393023,0.00030744146,0.00000549557,0.000006637371,0.000025301835,0.0005288202],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9974257,0.00001936557,0.0006073893,0.00033683254,0.000045401084,0.0015653465],"domain_scores_gemma":[0.9991399,0.000029271425,0.00036012265,0.0001855192,0.000036004247,0.00024915746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011652439,0.00019277225,0.00033029687,0.00025953283,0.00029819077,0.000117446354,0.00026464928,0.00013398877,0.00013919456],"category_scores_gemma":[0.00006896256,0.00020783018,0.00009044732,0.00022219017,0.000034094053,0.00038443116,0.000038246602,0.0011781354,0.00022273889],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021458764,0.000054454184,0.00046346898,0.000004085779,0.00008048854,9.3439917e-7,0.00012439505,0.00003979122,0.00017899019,0.9863356,0.0002521972,0.012444141],"study_design_scores_gemma":[0.0017092725,0.00030493955,0.009959023,0.000012937268,0.000032148637,0.00035013462,0.00034733838,0.0054879393,0.00018353868,0.90853375,0.07254704,0.0005319553],"about_ca_topic_score_codex":0.000050721574,"about_ca_topic_score_gemma":0.000048246857,"teacher_disagreement_score":0.13481863,"about_ca_system_score_codex":0.00075392926,"about_ca_system_score_gemma":0.00025764605,"threshold_uncertainty_score":0.8475068},"labels":[],"label_agreement":null},{"id":"W1994964073","doi":"10.1371/journal.pmed.0030510","title":"Intellectual Property and Access to ART: Authors' Reply","year":2006,"lang":"en","type":"article","venue":"PLoS Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"U.S. National Library of Medicine; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Intellectual property; Argument (complex analysis); Law and economics; Poverty; Access to medicines; Property (philosophy); Political science; Law; Business; Medicine; Sociology","score_opus":0.11607268975520503,"score_gpt":0.30765335830689255,"score_spread":0.19158066855168754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1994964073","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.336451,0.0018330127,0.0010285396,0.14977649,0.0006626359,0.0006697548,0.00008195549,0.000107057225,0.5093896],"genre_scores_gemma":[0.9583619,0.00029513866,0.00018237912,0.025312286,0.0010757805,0.00004074332,0.000017488848,0.000032788535,0.014681466],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99881095,0.000009049758,0.00050804595,0.00036620873,0.000027698723,0.0002780498],"domain_scores_gemma":[0.9993333,0.00010382272,0.000098690645,0.0002241421,0.000019934821,0.00022008366],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00034581617,0.0001352647,0.00037221896,0.00022184146,0.000064416585,0.000056630266,0.00021128805,0.000050772862,0.0018058337],"category_scores_gemma":[0.0005697501,0.00010480867,0.00002829745,0.00019985042,0.000098038305,0.00014196185,0.00011833428,0.00015024206,0.0012994463],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006815252,0.00016336278,0.016182888,0.00007467034,0.00006442195,0.000008971489,0.000996435,0.000023859153,0.00033940875,0.07781183,0.90080816,0.003457865],"study_design_scores_gemma":[0.0005471822,0.00013066051,0.0054165707,0.00003225083,0.000009114597,0.000006238732,0.000011553931,0.0034196302,0.00032188062,0.02117345,0.96873397,0.00019747551],"about_ca_topic_score_codex":0.00035898236,"about_ca_topic_score_gemma":0.000033553308,"teacher_disagreement_score":0.6219109,"about_ca_system_score_codex":0.00005052349,"about_ca_system_score_gemma":0.000011612992,"threshold_uncertainty_score":0.99947816},"labels":[],"label_agreement":null},{"id":"W1995123216","doi":"10.20430/ete.v76i302.486","title":"¿A quién beneficia el comercio paralelo de medicamentos en la Unión Europea?","year":2017,"lang":"es","type":"article","venue":"El Trimestre Económico","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Association of Emergency Physicians","funders":"","keywords":"Humanities; Political science; Philosophy","score_opus":0.04689818322439119,"score_gpt":0.3357949456912912,"score_spread":0.2888967624669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995123216","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.72336376,0.0050355163,0.00004130311,0.010544048,0.0015668556,0.00042352622,0.0012656237,0.00007886558,0.25768048],"genre_scores_gemma":[0.97031343,0.01838537,0.00018115962,0.0028230587,0.0016181085,0.00003629813,0.000057382473,0.00016343176,0.006421745],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99565214,0.00018018374,0.0015843225,0.0011383834,0.000080677055,0.0013643038],"domain_scores_gemma":[0.99523365,0.0005291676,0.0014744069,0.0018466115,0.000045658056,0.0008705057],"candidate_categories":["metaepi_narrow","scholarly_communication","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0019420278,0.00070281053,0.0013548736,0.00041791826,0.0007890644,0.0013290875,0.0021971338,0.0006120827,0.0016667793],"category_scores_gemma":[0.0007128118,0.00089484436,0.0005167806,0.00013264164,0.0005483298,0.0006485809,0.00068992254,0.0010609383,0.0065007717],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016800626,0.0008386775,0.49350753,0.0003049779,0.00095459237,0.00019261171,0.0011907216,0.00018571124,0.00012190762,0.4275881,0.038781606,0.036165547],"study_design_scores_gemma":[0.0025674256,0.00012968537,0.26688486,0.000119065044,0.00008416279,0.000034291512,0.000043587672,0.0044885566,0.00029961858,0.014844305,0.7095607,0.0009437405],"about_ca_topic_score_codex":0.0012063701,"about_ca_topic_score_gemma":0.000036366062,"teacher_disagreement_score":0.6707791,"about_ca_system_score_codex":0.00043866984,"about_ca_system_score_gemma":0.00061605015,"threshold_uncertainty_score":0.99970764},"labels":[],"label_agreement":null},{"id":"W1995683175","doi":"","title":"Patents and Pharmaceutical R&D: Consolidating Private-Public Partnership Approach to Global Public Health Crises","year":2010,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Intellectual property; Incentive; General partnership; Credibility; Business; Law and economics; Public economics; Public relations; Public administration; Economics; Political science; Market economy; Law; Finance","score_opus":0.15744305108989082,"score_gpt":0.35183458807669227,"score_spread":0.19439153698680145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995683175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87467515,0.0051577426,0.01968306,0.06590166,0.00084095274,0.0006132438,0.00015604893,0.00010747836,0.03286465],"genre_scores_gemma":[0.98853874,0.0019080912,0.0007511273,0.00817391,0.00046598798,0.000018352766,0.000015195496,0.000033734566,0.00009486481],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99491185,0.00006882951,0.00086024543,0.0005169765,0.000072682145,0.0035694418],"domain_scores_gemma":[0.99808407,0.00005361599,0.000375357,0.0002536274,0.000048686583,0.0011846673],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004269287,0.00026675596,0.00050138775,0.00022819698,0.00041602517,0.00050676224,0.000496229,0.00013631493,0.0000894373],"category_scores_gemma":[0.0004217606,0.0002887591,0.00012469971,0.00033605538,0.00011031856,0.00043535672,0.00016740574,0.0021448513,0.00024218591],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001477093,0.0001695341,0.045857698,0.00001568246,0.00011622743,6.2980456e-7,0.0001185452,0.0000042789434,0.00001293937,0.94257987,0.00048789856,0.010621917],"study_design_scores_gemma":[0.0023629346,0.00028968364,0.0073532783,0.000008502962,0.000013611219,0.00071561144,0.00038828963,0.00546121,0.000020417445,0.54468226,0.43793875,0.00076543895],"about_ca_topic_score_codex":0.00004756427,"about_ca_topic_score_gemma":0.00008969868,"teacher_disagreement_score":0.43745086,"about_ca_system_score_codex":0.00076874415,"about_ca_system_score_gemma":0.0010187278,"threshold_uncertainty_score":0.9999564},"labels":[],"label_agreement":null},{"id":"W1996591595","doi":"10.3821/145.3.cpj105","title":"New Generic Pricing Rules Come to Newfoundland and Labrador and New Brunswick","year":2012,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Geography; Oceanography; Geology","score_opus":0.07199614444530232,"score_gpt":0.2699920714320161,"score_spread":0.19799592698671376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996591595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97787416,0.013524687,0.0006244907,0.0016508548,0.0020880706,0.00029477561,0.00033131847,0.000019342471,0.0035923244],"genre_scores_gemma":[0.972152,0.007784141,0.0014960886,0.014101419,0.0024568548,0.000003034777,0.000010023282,0.00006598244,0.0019304531],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99753135,0.00003240437,0.0007016279,0.0004022795,0.00006781103,0.0012645395],"domain_scores_gemma":[0.99211967,0.00007804295,0.000255986,0.00018752046,0.00005121322,0.007307547],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005671189,0.000354242,0.0005284687,0.0005030602,0.0005294171,0.00039543115,0.00036264298,0.00007186189,0.0009772663],"category_scores_gemma":[0.00011183351,0.00042919052,0.00007842048,0.00035681928,0.00007833527,0.00062138465,0.00008926305,0.00044812204,0.00009800188],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017435291,0.00008153308,0.36352882,0.00038236845,0.0007343994,0.003626432,0.00922409,0.0006814356,0.00069250446,0.04503488,0.19800852,0.37783065],"study_design_scores_gemma":[0.002255425,0.000042991618,0.0051939883,0.000015156008,0.00006066484,0.0667283,0.0000080581085,0.002069121,0.00012342398,0.0018275358,0.92070407,0.00097124826],"about_ca_topic_score_codex":0.31317565,"about_ca_topic_score_gemma":0.23108493,"teacher_disagreement_score":0.7226956,"about_ca_system_score_codex":0.001569732,"about_ca_system_score_gemma":0.00199035,"threshold_uncertainty_score":0.999936},"labels":[],"label_agreement":null},{"id":"W1996784805","doi":"10.1179/cih.2009.2.4.341","title":"Drug pricing and reimbursement in Europe: Strategy and tactics","year":2009,"lang":"en","type":"article","venue":"Journal of Communications In Healthcare","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Pricing strategies; Business; Product (mathematics); Marketing; Investment (military); Control (management); New product development; Investment strategy; Finance; Health care; Economics","score_opus":0.14868549785318158,"score_gpt":0.39255738209891966,"score_spread":0.24387188424573808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996784805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82364506,0.03561989,0.00002328357,0.13172816,0.00006873301,0.00014321863,0.000015230702,0.000003221288,0.008753236],"genre_scores_gemma":[0.95650584,0.040489495,0.0010857921,0.0018658864,0.000024082457,0.0000011666352,0.0000010528851,0.0000048991706,0.000021798282],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99893737,0.00005458499,0.0007763975,0.00008111457,0.000016350828,0.00013417607],"domain_scores_gemma":[0.9991343,0.00010697728,0.0003462043,0.0002751375,0.000046589557,0.000090803595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008871847,0.00006123629,0.00023970912,0.0002808772,0.00005237815,0.000039718798,0.00023478424,0.00003509796,0.000004304975],"category_scores_gemma":[0.0001033455,0.00006991263,0.00001625607,0.00021564748,0.000038301867,0.00017458902,0.000059969225,0.00042568482,0.0000022059505],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022693592,0.00015563723,0.1891925,0.000041240473,0.000010250123,0.0000056656636,0.001353912,0.00014776712,0.00001072419,0.77882516,0.00020341217,0.030031027],"study_design_scores_gemma":[0.0016169838,0.00031563189,0.6968175,0.00018500985,0.000005725551,0.00006949021,0.0004573285,0.00960567,0.000013656736,0.18894781,0.1017079,0.0002572655],"about_ca_topic_score_codex":0.00022994562,"about_ca_topic_score_gemma":0.00023098223,"teacher_disagreement_score":0.58987737,"about_ca_system_score_codex":0.0001015608,"about_ca_system_score_gemma":0.000050122406,"threshold_uncertainty_score":0.28509545},"labels":[],"label_agreement":null},{"id":"W1998357119","doi":"10.1503/cmaj.109-3828","title":"Comparison shopping for drugs","year":2011,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Suite; Medical prescription; Computer science; Drug industry; Drug; Web application; Prescription drug; World Wide Web; Internet privacy; Medicine; Pharmacology; Political science; Engineering; Law","score_opus":0.09065336197807232,"score_gpt":0.30246702599453584,"score_spread":0.2118136640164635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998357119","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1723739,0.0023043964,0.007885722,0.11605255,0.0075538955,0.0005443837,0.00069356395,0.0000618099,0.6925298],"genre_scores_gemma":[0.9627039,0.00013512111,0.00058243994,0.0344939,0.0014790494,0.000012063171,0.000007052,0.000020101965,0.0005663769],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986804,0.000015950323,0.00063713855,0.00013852591,0.00006678477,0.0004611739],"domain_scores_gemma":[0.99824435,0.00008921708,0.00032455177,0.0000702558,0.0000685762,0.0012030607],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017932415,0.00008176925,0.00026875967,0.00018722062,0.00019980474,0.00007339249,0.00023834592,0.00022406466,0.007773818],"category_scores_gemma":[0.00073759665,0.00009783262,0.00012957641,0.00008720422,0.000020676243,0.00012710245,0.000010882012,0.0004158842,0.00077656953],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011870074,0.000063982334,0.2749793,0.000012711836,0.00020858044,0.000013384568,0.0020820305,0.0000046584682,8.692581e-7,0.2841875,0.4194845,0.018950637],"study_design_scores_gemma":[0.0005684423,0.000023722423,0.009644126,0.0000073281267,0.0000044843177,0.000011281201,0.00011070107,0.003977155,0.0000069429448,0.020300532,0.96520364,0.00014165553],"about_ca_topic_score_codex":0.0009956532,"about_ca_topic_score_gemma":0.0026847473,"teacher_disagreement_score":0.79033,"about_ca_system_score_codex":0.0006627861,"about_ca_system_score_gemma":0.00039559047,"threshold_uncertainty_score":0.9981489},"labels":[],"label_agreement":null},{"id":"W1998634611","doi":"10.4212/cjhp.v66i2.1249","title":"Drug Shortages: The Survey Says . . .","year":2013,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Economic shortage; Pharmacy; Harm; Medicine; Family medicine; Work (physics); Public relations; Medical education; Psychology; Political science; Government (linguistics); Engineering; Social psychology","score_opus":0.05687214641304922,"score_gpt":0.2709435487748774,"score_spread":0.2140714023618282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998634611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8957715,0.0051361723,0.00001961605,0.07277994,0.002289217,0.00033370533,0.0002445713,0.0000059589383,0.023419306],"genre_scores_gemma":[0.9929715,0.00028512228,0.00001460725,0.0054535354,0.00051523827,0.0000074989725,0.0000032309295,0.000025353876,0.0007239083],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998584,0.00006343253,0.0007063118,0.00013811719,0.000040968178,0.00046721284],"domain_scores_gemma":[0.9983765,0.00019903571,0.00044032565,0.00027733258,0.000110418616,0.00059638213],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0016712522,0.00015677891,0.00029221782,0.00014416248,0.00037243517,0.00038702003,0.0010254646,0.000029088518,0.0029752962],"category_scores_gemma":[0.00021080459,0.00010604957,0.00019340933,0.00019539817,0.00024519255,0.00040480285,0.000034589193,0.0005262973,0.001502291],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013538359,0.00005852736,0.30533993,0.000009961354,0.00034885426,0.000024701585,0.0027029067,0.00021570719,0.0000066810508,0.057550076,0.6301901,0.003539024],"study_design_scores_gemma":[0.0008957353,0.000079257305,0.23240092,0.000010958615,0.000024115403,0.000036432495,0.00012818954,0.0015346542,0.0000970542,0.06435695,0.70003784,0.00039790894],"about_ca_topic_score_codex":0.10515232,"about_ca_topic_score_gemma":0.030001007,"teacher_disagreement_score":0.09719999,"about_ca_system_score_codex":0.00017834519,"about_ca_system_score_gemma":0.00032268485,"threshold_uncertainty_score":0.99927515},"labels":[],"label_agreement":null},{"id":"W1999287793","doi":"10.1016/j.jval.2013.08.849","title":"Investigating the Economic Impacts of New Public Pharmaceutical Policies in Greece","year":2013,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cost sharing; Reimbursement; Medicine; Quarter (Canadian coin); Population; Average cost; Business; Public economics; Environmental health; Economics; Health care; Economic growth; Geography","score_opus":0.22237617927370337,"score_gpt":0.36778010867386485,"score_spread":0.14540392940016147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999287793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92378753,0.0029895776,0.000014549429,0.0670159,0.00024457695,0.00045829266,0.00004552553,0.000014020291,0.005429989],"genre_scores_gemma":[0.99047023,0.0012808492,0.000264584,0.0077088377,0.00017161279,0.000023203995,0.0000031932266,0.000022275748,0.000055210574],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.997588,0.00007964942,0.0013381797,0.00028791773,0.00002673982,0.0006795611],"domain_scores_gemma":[0.9985927,0.00027313794,0.00043534418,0.00029498042,0.000008563174,0.00039531806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014877138,0.00015590621,0.00048447945,0.00037331783,0.000056701036,0.0000801899,0.0003890892,0.00008100601,0.00044129064],"category_scores_gemma":[0.00027642385,0.00015179513,0.00007710355,0.00030638173,0.00013401423,0.00032392735,0.000105878025,0.00036683187,0.0005135224],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000003925084,0.000059878268,0.31124273,0.00012899825,0.000018762772,3.4811842e-7,0.0022401302,0.0047973557,0.000023607665,0.67139375,0.004283651,0.005806868],"study_design_scores_gemma":[0.0019595963,0.0001080044,0.26880878,0.00009805197,0.0000019104366,0.000008684305,0.0002277101,0.33351916,0.00015149143,0.32652548,0.06816189,0.00042922466],"about_ca_topic_score_codex":0.1209733,"about_ca_topic_score_gemma":0.00075333606,"teacher_disagreement_score":0.34486827,"about_ca_system_score_codex":0.0006073215,"about_ca_system_score_gemma":0.00048163725,"threshold_uncertainty_score":0.88488024},"labels":[],"label_agreement":null},{"id":"W1999320018","doi":"10.1503/cmaj.109-4474","title":"Drug patents: the high price of watchdog litigation","year":2013,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Drug industry; Ask price; Drug; Business; Generic drug; Drug prices; Brand names; Pharmaceutical industry; Internet privacy; Computer science; Medicine; Advertising; Pharmacology; Finance; Economics; Biotechnology","score_opus":0.01719887629675221,"score_gpt":0.21945551415941666,"score_spread":0.20225663786266446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999320018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7188641,0.00044014142,0.000102089594,0.25427327,0.0010667553,0.00016628181,0.00009181719,0.0000074340464,0.024988124],"genre_scores_gemma":[0.97581613,0.00032068748,0.000040791525,0.022435417,0.00071934983,0.000009290686,0.0000050563513,0.000009868896,0.00064338284],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99872476,0.00004403737,0.00065923075,0.000107485546,0.00012132062,0.00034318108],"domain_scores_gemma":[0.99842006,0.00014029582,0.0004672423,0.00010043285,0.00013814327,0.00073383737],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0015840266,0.000075166594,0.00020121857,0.00011549848,0.00015729807,0.00010669399,0.00029207807,0.00014299541,0.011503708],"category_scores_gemma":[0.00083976245,0.00006478479,0.000089360525,0.00014842224,0.000041011383,0.0002123569,0.000016532653,0.00047270293,0.0013637749],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000023419893,0.000051081744,0.19603223,0.000014761572,0.00021304328,0.000007647565,0.0009895818,0.00003220271,0.0000066026996,0.17218353,0.6141518,0.016315231],"study_design_scores_gemma":[0.00062552426,0.000016050682,0.16310783,0.000016960996,0.000005908676,0.000017614015,0.0001403185,0.0018819807,0.00003496705,0.09133969,0.7426554,0.0001577511],"about_ca_topic_score_codex":0.014390901,"about_ca_topic_score_gemma":0.0020898604,"teacher_disagreement_score":0.25695208,"about_ca_system_score_codex":0.00051136897,"about_ca_system_score_gemma":0.00033935285,"threshold_uncertainty_score":0.9994138},"labels":[],"label_agreement":null},{"id":"W1999613105","doi":"10.3821/1913-701x(2007)140[218b:ttcdsr]2.0.co;2","title":"Threat to Canada's drug supply recedes – CPhA","year":2007,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science; Economics; Natural resource economics","score_opus":0.04375517619715809,"score_gpt":0.26144733454338864,"score_spread":0.21769215834623057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999613105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93024266,0.0035661308,0.00028292133,0.005147664,0.008265624,0.00066747447,0.0044866176,0.000045413948,0.047295507],"genre_scores_gemma":[0.9625181,0.0028058493,0.0002517434,0.030094972,0.0016905993,0.000013763127,0.00003676469,0.00009997086,0.0024882439],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954529,0.00004510871,0.0014267561,0.0007023764,0.00016893884,0.0022039325],"domain_scores_gemma":[0.9926783,0.00017643736,0.00042687068,0.00040358191,0.0002467429,0.006068096],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017086248,0.0005327558,0.000728615,0.00074508594,0.00095604867,0.0003268145,0.0011581288,0.00008567691,0.0027998395],"category_scores_gemma":[0.00026823604,0.00067381404,0.00020221825,0.0008345126,0.00012685734,0.0003237582,0.000089295696,0.00085143326,0.00016329598],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032201895,0.00012411283,0.032773957,0.00025124615,0.0007250275,0.055871036,0.0030236647,0.0030694413,0.00053711864,0.014229531,0.7527984,0.1362745],"study_design_scores_gemma":[0.0014785216,0.00002737166,0.00045068067,0.000015645124,0.00003537013,0.051367447,0.00002287033,0.0011360026,0.0021074845,0.0019322534,0.9402698,0.0011565109],"about_ca_topic_score_codex":0.91927904,"about_ca_topic_score_gemma":0.99411654,"teacher_disagreement_score":0.1874715,"about_ca_system_score_codex":0.00845135,"about_ca_system_score_gemma":0.0050260755,"threshold_uncertainty_score":0.9995713},"labels":[],"label_agreement":null},{"id":"W2000554966","doi":"10.1503/cmaj.071831","title":"US considers establishing behind-the-counter drugs","year":2007,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Food and drug administration; Agency (philosophy); Over-the-counter; Drug labeling; Medicine; Perspective (graphical); Administration (probate law); Advertising; Medical prescription; Political science; Drug; Law; Pharmacology; Business; Computer science; Sociology","score_opus":0.020246180386641686,"score_gpt":0.25299542395434654,"score_spread":0.23274924356770485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000554966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.37526187,0.001502021,0.00085987267,0.30097494,0.0053929687,0.00019756999,0.00020615394,0.00003062637,0.31557396],"genre_scores_gemma":[0.86384374,0.00019213863,0.00005715274,0.13276713,0.0022629742,0.0000019985896,0.000004653496,0.000019651183,0.0008505925],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981434,0.000030698317,0.0007749157,0.00016931322,0.00016938726,0.00071230525],"domain_scores_gemma":[0.9975615,0.00038705405,0.0003942928,0.00011870445,0.00008867739,0.0014497428],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.006586143,0.00011141625,0.00023632766,0.0002523785,0.00038282268,0.00035478533,0.00036078598,0.00028566932,0.007076958],"category_scores_gemma":[0.0018277541,0.0001092468,0.00013458464,0.00013993138,0.00006275773,0.0002809973,0.000022462325,0.0010719206,0.0011984174],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009455832,0.00003200917,0.25021067,0.000006350799,0.00025112534,0.00017985087,0.0022393644,0.000022085102,0.0000014687819,0.08184293,0.6482271,0.016977577],"study_design_scores_gemma":[0.00047748574,0.000008504974,0.015617844,0.000007699846,0.0000050324106,0.000074375304,0.00019614326,0.0005735203,0.0000050830968,0.011218409,0.9716714,0.00014448828],"about_ca_topic_score_codex":0.005611757,"about_ca_topic_score_gemma":0.030933788,"teacher_disagreement_score":0.48858184,"about_ca_system_score_codex":0.0012863094,"about_ca_system_score_gemma":0.00062939036,"threshold_uncertainty_score":0.99957925},"labels":[],"label_agreement":null},{"id":"W2001741737","doi":"10.1080/0003684042000222106","title":"The price premium of generic to brand-names and pharmaceutical price index","year":2004,"lang":"en","type":"article","venue":"Applied Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Carbon Engineering (Canada)","funders":"","keywords":"Economics; Generic drug; Brand names; Order (exchange); Market share; Competition (biology); Index (typography); Product (mathematics); Incentive; Marketing; Advertising; Microeconomics; Business; Mathematics; Computer science; Drug","score_opus":0.03745401551847522,"score_gpt":0.26619502292078334,"score_spread":0.22874100740230813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001741737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.909459,0.0013809248,0.0024416142,0.0054644323,0.0003806536,0.0006529188,0.00013493549,0.00003882845,0.080046676],"genre_scores_gemma":[0.9920404,0.0027017617,0.000822038,0.003991411,0.00019580075,0.00007165439,0.000004562287,0.00004321963,0.00012917856],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99806607,0.0000066412226,0.0008606422,0.0005088953,0.000021045944,0.0005366834],"domain_scores_gemma":[0.99875695,0.00015766491,0.0003210891,0.0004145262,0.000016792312,0.00033299092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005956806,0.00023669306,0.00048634622,0.00013893929,0.00018475321,0.00012040535,0.0004365573,0.00012731268,0.00007453825],"category_scores_gemma":[0.00004425802,0.00024310606,0.000095351556,0.00017239497,0.00019011671,0.00013069916,0.00024050026,0.0002232279,0.00031752622],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001233131,0.0000809404,0.0027305456,0.000038348506,0.00011712118,3.4715808e-7,0.0004139258,0.0058411593,0.00017546694,0.9851629,0.00040833218,0.0049076076],"study_design_scores_gemma":[0.0036036803,0.00010298938,0.019302065,0.000011272233,0.000024743656,0.000016479844,0.0001217291,0.005407107,0.004996764,0.2818178,0.68370706,0.00088835595],"about_ca_topic_score_codex":0.000056772584,"about_ca_topic_score_gemma":0.000020578073,"teacher_disagreement_score":0.7033451,"about_ca_system_score_codex":0.00019302462,"about_ca_system_score_gemma":0.00006416498,"threshold_uncertainty_score":0.9913577},"labels":[],"label_agreement":null},{"id":"W2001840509","doi":"10.7202/1002468ar","title":"Jongler avec le chaos. Effets de l’hégémonie des pratiques biomédicales en psychiatrie du point de vue des usagers","year":2011,"lang":"fr","type":"article","venue":"Cahiers de recherche sociologique","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Humanities; Political science; Philosophy","score_opus":0.16325844159232467,"score_gpt":0.34780185898936067,"score_spread":0.184543417397036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001840509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.845375,0.02473439,0.036469657,0.010246477,0.0006164078,0.0005009351,0.00027365985,0.0001528498,0.08163063],"genre_scores_gemma":[0.7305325,0.15452759,0.10055172,0.008980963,0.0008216373,0.00017839672,0.000029213377,0.00014379053,0.004234189],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9924604,0.003939644,0.0010364376,0.0007994784,0.000034527326,0.0017294614],"domain_scores_gemma":[0.9951992,0.0029354116,0.00051772187,0.0004911732,0.00007736501,0.00077910104],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.017109819,0.00056455395,0.0009215107,0.0002743663,0.00047535443,0.00013306172,0.00081824546,0.0061964886,0.0009808558],"category_scores_gemma":[0.0069274763,0.0006985215,0.00055527955,0.00032173615,0.0038052185,0.00043486996,0.00013287639,0.0048031234,0.00029933825],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021871709,0.0011514312,0.14456514,0.00072968577,0.0009980112,0.00010503445,0.18471299,0.00008603598,0.0005966634,0.62501174,0.0074814325,0.03434314],"study_design_scores_gemma":[0.0013664144,0.0004740195,0.038157,0.00013713942,0.00009383165,0.00013488012,0.004982651,0.0031267067,0.0065715285,0.911217,0.032625247,0.0011135893],"about_ca_topic_score_codex":0.0014139679,"about_ca_topic_score_gemma":0.00024795526,"teacher_disagreement_score":0.28620526,"about_ca_system_score_codex":0.005642796,"about_ca_system_score_gemma":0.0015392012,"threshold_uncertainty_score":0.9999324},"labels":[],"label_agreement":null},{"id":"W2002586717","doi":"10.1176/pn.45.22.psychnews_45_22_018","title":"Patients Abandon Antidepressants, Deterred by High Costs","year":2010,"lang":"en","type":"article","venue":"Psychiatric News","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Abandonment (legal); Pharmacy; Medicine; Payment; Quarter (Canadian coin); Depression (economics); Family medicine; Psychiatry; Business; Geography; Finance; Political science; Pharmacology; Economics","score_opus":0.014448483322413164,"score_gpt":0.24540265883315804,"score_spread":0.23095417551074487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002586717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9412924,0.00094885845,0.00014745753,0.0017811041,0.0040324987,0.00029168188,0.00069679576,0.0000578103,0.050751418],"genre_scores_gemma":[0.99503213,0.0005173127,0.00054441113,0.002920627,0.0004611491,0.000022654258,0.000071125854,0.000040456798,0.00039010952],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983166,0.000010668357,0.0007002009,0.0004911114,0.000034220593,0.00044718405],"domain_scores_gemma":[0.9989019,0.00004615888,0.00034540895,0.00043429132,0.000019385174,0.00025286045],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00019476072,0.00020848142,0.00038821786,0.00019385175,0.00011353403,0.00010609152,0.00038119266,0.00014984616,0.0009632985],"category_scores_gemma":[0.00006428978,0.00023723781,0.00013930722,0.00022355518,0.000045190525,0.00021464983,0.00006666788,0.0003540388,0.0018348272],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045164477,0.000435987,0.70846933,0.00001614964,0.000057588524,6.8014936e-7,0.00005084807,0.0000017680733,0.00012267116,0.054864187,0.22071578,0.015219829],"study_design_scores_gemma":[0.0030648457,0.00007453142,0.10384704,0.0000023990385,0.000015199833,0.0000018223765,0.0000038593257,0.00044665707,0.00017071867,0.025036268,0.8667967,0.0005400135],"about_ca_topic_score_codex":0.0012728634,"about_ca_topic_score_gemma":0.00014834433,"teacher_disagreement_score":0.64608085,"about_ca_system_score_codex":0.000036844707,"about_ca_system_score_gemma":0.0000151558725,"threshold_uncertainty_score":0.99994993},"labels":[],"label_agreement":null},{"id":"W2002852368","doi":"10.1377/hlthaff.2010.0317","title":"The Level Of Income Appears To Have No Consistent Bearing On Pharmaceutical Prices Across Countries","year":2011,"lang":"en","type":"article","venue":"Health Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Smiths Detection (Canada)","funders":"","keywords":"High income countries; Middle income; Developing country; Economics; Low and middle income countries; Developed country; Demographic economics; International economics; Business; Development economics; Economic growth; Population","score_opus":0.27357667007689496,"score_gpt":0.3832275978072387,"score_spread":0.10965092773034374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002852368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6037055,0.0067411466,0.0010151836,0.044154517,0.0038391843,0.0026234356,0.0034246598,0.00015079105,0.33434555],"genre_scores_gemma":[0.9925951,0.0011189224,0.0004169503,0.005337956,0.00010791848,0.00003796007,0.0000026565817,0.000026069298,0.00035649797],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979364,0.0000239928,0.0009003337,0.00035440404,0.000055437755,0.0007293782],"domain_scores_gemma":[0.99859303,0.00019561447,0.00037055716,0.00036371482,0.000047281173,0.0004297748],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013600208,0.00017366934,0.0004461706,0.00009669031,0.00031590796,0.000059068796,0.0003601384,0.0000726828,0.00015021315],"category_scores_gemma":[0.00014345314,0.00015986848,0.00011228177,0.00011569681,0.00021132208,0.000089892834,0.00015674773,0.00024898545,0.0014469132],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005283572,0.00024613985,0.046766184,0.0003580899,0.0001469033,0.0000038785174,0.006849971,0.00005948689,0.0000054745237,0.9349766,0.005234146,0.004824797],"study_design_scores_gemma":[0.0013540195,0.0005648897,0.05536538,0.00009101977,0.0000062268964,0.0000056234508,0.001361917,0.0019002852,0.0005852724,0.008102651,0.9301771,0.00048564633],"about_ca_topic_score_codex":0.00055476633,"about_ca_topic_score_gemma":0.00015859713,"teacher_disagreement_score":0.9268739,"about_ca_system_score_codex":0.00019666087,"about_ca_system_score_gemma":0.000090331625,"threshold_uncertainty_score":0.9993306},"labels":[],"label_agreement":null},{"id":"W2003146599","doi":"10.1097/01.mlr.0000178217.84354.f1","title":"Booming Prescription Drug Expenditure","year":2005,"lang":"en","type":"article","venue":"Medical Care","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"Health Canada","keywords":"Per capita; Medical prescription; Cohort; Prescription drug; Population; Medicine; Population ageing; Demography; Gerontology; Environmental health","score_opus":0.03361706033256837,"score_gpt":0.28354789835629796,"score_spread":0.2499308380237296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003146599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4964873,0.023981366,0.0009317108,0.04168953,0.0021434382,0.00036389625,0.0002921822,0.0001902906,0.4339203],"genre_scores_gemma":[0.9887718,0.0002708417,0.00021806736,0.008560091,0.0010696868,0.000019372255,0.000032060918,0.000018621573,0.0010394721],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.998979,0.000010101186,0.00038883206,0.000278528,0.000053368876,0.00029018667],"domain_scores_gemma":[0.9993681,0.000029019675,0.000086676555,0.00019669312,0.0000120118575,0.00030752967],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002539326,0.00011177077,0.00022848256,0.00008304455,0.00007743684,0.000044960838,0.00025433535,0.00012707285,0.0067289774],"category_scores_gemma":[0.0001179817,0.00012308726,0.00010168355,0.000054777982,0.000047008278,0.00016560464,0.00007426236,0.0002708558,0.0023083873],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046293182,0.00021195128,0.035906307,0.00019357122,0.00009688667,0.00003380184,0.012999971,0.00013094039,0.000044881643,0.51793665,0.295774,0.13662475],"study_design_scores_gemma":[0.00048792185,0.000009746064,0.0017489345,0.000011388996,0.0000026878208,0.000004371814,0.00014434762,0.0027972274,0.000171473,0.0030857215,0.99136496,0.00017121721],"about_ca_topic_score_codex":0.0000880707,"about_ca_topic_score_gemma":0.00011224188,"teacher_disagreement_score":0.695591,"about_ca_system_score_codex":0.00014245762,"about_ca_system_score_gemma":0.000026788977,"threshold_uncertainty_score":0.99846846},"labels":[],"label_agreement":null},{"id":"W2003270914","doi":"10.1016/j.cjca.2012.08.012","title":"Statins: Is It Safe and Effective to Use Generic “Equivalents”?","year":2012,"lang":"en","type":"letter","venue":"Canadian Journal of Cardiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; Health Sciences Centre; University Health Network","funders":"Canadian Institutes of Health Research; Heart and Stroke Foundation of Canada","keywords":"Medicine; Equivalent; Intensive care medicine; Internal medicine","score_opus":0.09915420524323709,"score_gpt":0.28593933402837424,"score_spread":0.18678512878513714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003270914","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023324678,0.00782912,0.0020587514,0.9112805,0.006095864,0.00063742127,0.0058095097,0.0000049337814,0.04295923],"genre_scores_gemma":[0.1077681,0.00096169295,0.0002491361,0.8803078,0.009268903,0.000015424464,0.00002936197,0.00006811411,0.0013314502],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99801445,0.00008394406,0.00080659427,0.00030486786,0.00002561711,0.0007644986],"domain_scores_gemma":[0.997935,0.00023641397,0.0005331658,0.0002634617,0.000078961464,0.000952978],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00055754103,0.00027769347,0.001197828,0.0008209896,0.00008138735,0.00010337671,0.0003312204,0.0005583115,0.00041839827],"category_scores_gemma":[0.00025718258,0.00031411884,0.00029825512,0.000109844055,0.00013960563,0.00019087632,0.000041842795,0.0011359045,0.0005336399],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007825767,6.61869e-7,0.011503568,0.00003098997,0.00038421375,0.00012847254,0.00024057906,0.000063686275,9.4504907e-7,0.00082597916,0.98528427,0.0015287983],"study_design_scores_gemma":[0.0003129127,0.00011706043,0.009414576,0.000018493973,0.000048994614,0.00022683796,0.000006756079,0.000012536166,0.0000025442255,0.0020787169,0.9874456,0.00031496646],"about_ca_topic_score_codex":0.0016512868,"about_ca_topic_score_gemma":0.00021083005,"teacher_disagreement_score":0.08444343,"about_ca_system_score_codex":0.00044171582,"about_ca_system_score_gemma":0.00027377805,"threshold_uncertainty_score":0.9999311},"labels":[],"label_agreement":null},{"id":"W2004660332","doi":"10.3821/1913-701x-145.4.160b","title":"PEI Moves to Lower Generic Drug Prices","year":2012,"lang":"fr","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Drug; Business; Computer science; Medicine; Pharmacology","score_opus":0.06312541263013982,"score_gpt":0.2716118327538594,"score_spread":0.2084864201237196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004660332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80602866,0.09952006,0.00028365958,0.00877176,0.04989647,0.00079912104,0.0068472163,0.000037665286,0.027815383],"genre_scores_gemma":[0.8980629,0.039063595,0.0007403159,0.03624942,0.00890138,0.000035024976,0.000033163506,0.000178882,0.016735338],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99333966,0.00013612931,0.0017490573,0.0007978021,0.00018517613,0.0037921518],"domain_scores_gemma":[0.98849964,0.00017595958,0.0007728988,0.00052193244,0.00027686002,0.009752698],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0018372263,0.00082801416,0.0010595665,0.0010424126,0.0012037072,0.0007073086,0.0014040087,0.00018755229,0.010819209],"category_scores_gemma":[0.00029596649,0.0011480838,0.0004625763,0.00121834,0.00033170453,0.0015565831,0.00018212695,0.0013651594,0.0014014338],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015421756,0.00044188602,0.017290642,0.0006786372,0.0011055766,0.013643491,0.006749644,0.005325658,0.00025904438,0.013386319,0.8174328,0.123532064],"study_design_scores_gemma":[0.0011465142,0.00003789837,0.00018031073,0.000032648437,0.00011882684,0.06705887,0.000015292226,0.0044217785,0.00042199265,0.00047094712,0.92474365,0.0013512959],"about_ca_topic_score_codex":0.06265948,"about_ca_topic_score_gemma":0.08068341,"teacher_disagreement_score":0.12218077,"about_ca_system_score_codex":0.0075866836,"about_ca_system_score_gemma":0.0025608493,"threshold_uncertainty_score":0.9993761},"labels":[],"label_agreement":null},{"id":"W2005311616","doi":"10.3821/1913-701x(2007)140[354a:baapsi]2.0.co;2","title":"BC and Alberta pharmacists seek input into joint buying strategy","year":2007,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Joint (building); Business; Marketing; Engineering","score_opus":0.06874095744618008,"score_gpt":0.2767010859288065,"score_spread":0.2079601284826264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005311616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9440075,0.00530682,0.00070202997,0.00083198707,0.0037307986,0.0005344228,0.00069963036,0.000042713567,0.04414409],"genre_scores_gemma":[0.98044616,0.008113114,0.00021831352,0.00842731,0.0013805883,0.000011666747,0.000031034986,0.00010665983,0.0012651739],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954462,0.00006121962,0.0016677238,0.00079609564,0.00013574692,0.0018929944],"domain_scores_gemma":[0.9941659,0.00019319092,0.00064862514,0.00033194956,0.00019723982,0.0044630766],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019582056,0.0006034196,0.00081646926,0.0009101112,0.0011017064,0.00052457023,0.00071074866,0.00014437884,0.0023256275],"category_scores_gemma":[0.00024003933,0.00075997354,0.00022876062,0.0006160847,0.00032864246,0.00076576864,0.00011500923,0.0011458603,0.00017960789],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008198188,0.00053611974,0.046582054,0.002029813,0.0029525238,0.118718915,0.015127983,0.0058465907,0.008131347,0.062302835,0.13439567,0.60255635],"study_design_scores_gemma":[0.0069554583,0.00013044338,0.00043640388,0.000043579465,0.00015205485,0.26566246,0.00004215533,0.03593034,0.0040474604,0.016437056,0.6671504,0.0030122157],"about_ca_topic_score_codex":0.10187044,"about_ca_topic_score_gemma":0.14546987,"teacher_disagreement_score":0.5995441,"about_ca_system_score_codex":0.0029584717,"about_ca_system_score_gemma":0.0014112411,"threshold_uncertainty_score":0.99948514},"labels":[],"label_agreement":null},{"id":"W2005821732","doi":"10.4212/cjhp.v65i1.1102","title":"Gestion des ruptures d’approvisionnement de médicaments : perspectives en France, aux États-Unis et au Canada","year":2012,"lang":"fr","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Humanities; Political science; Art","score_opus":0.0387480593997115,"score_gpt":0.29158616115629316,"score_spread":0.25283810175658167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005821732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7521367,0.0797197,0.000094101255,0.1539462,0.0048646745,0.00021949723,0.0005229104,0.000003522424,0.008492675],"genre_scores_gemma":[0.98491406,0.004686713,0.00022522666,0.006720787,0.002000662,0.000006896668,0.0000040692967,0.000043526412,0.0013980727],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99759895,0.00015755271,0.0007791558,0.00019576232,0.000094853254,0.0011737503],"domain_scores_gemma":[0.99726886,0.0002072727,0.00060728757,0.0002092029,0.00013086158,0.0015765284],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016756424,0.00028342876,0.00042595915,0.00023628872,0.00088392716,0.00020309979,0.00064341264,0.00008561023,0.0015659007],"category_scores_gemma":[0.00039513098,0.00028573626,0.00022159012,0.00019870295,0.0006077149,0.00075655134,0.00005415806,0.00091889926,0.00006656506],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00006837198,0.00057706254,0.4439526,0.00016115398,0.0012923068,0.00016007332,0.0756185,0.0024598471,0.0000137912375,0.29444197,0.12857491,0.052679416],"study_design_scores_gemma":[0.0011353529,0.00015316128,0.1241775,0.00011133451,0.000090177695,0.00007944964,0.001469965,0.00088179094,0.00007814978,0.010705623,0.8607128,0.00040464266],"about_ca_topic_score_codex":0.922689,"about_ca_topic_score_gemma":0.7534699,"teacher_disagreement_score":0.7321379,"about_ca_system_score_codex":0.004647449,"about_ca_system_score_gemma":0.005828181,"threshold_uncertainty_score":0.99995947},"labels":[],"label_agreement":null},{"id":"W2006055263","doi":"10.1016/j.urology.2013.05.014","title":"The Relative Value of Some New Drugs Used to Treat Prostate Cancer","year":2013,"lang":"en","type":"letter","venue":"Urology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Value (mathematics); Prostate; Relative value; Cancer; Oncology; Gynecology; Internal medicine; Statistics","score_opus":0.048831931774595626,"score_gpt":0.28660222319086026,"score_spread":0.23777029141626463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006055263","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008681803,0.00445032,0.000043979333,0.9694292,0.0011423635,0.0006180206,0.000721265,0.000019915095,0.014893146],"genre_scores_gemma":[0.009390188,0.0023924205,0.00005262306,0.93691057,0.0032521577,0.00021464837,0.00005559764,0.00010165377,0.04763014],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998006,0.0000466656,0.0007780524,0.0005205212,0.000028630227,0.0006201252],"domain_scores_gemma":[0.99834,0.00044002806,0.00055969355,0.0004933628,0.000026084881,0.00014079362],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002379121,0.00028439407,0.0007402292,0.00022334997,0.00008795497,0.000049847236,0.0005293398,0.0005488597,0.00076209416],"category_scores_gemma":[0.000084472405,0.00025065013,0.00020208197,0.00012020695,0.00015980168,0.0001231613,0.0001450237,0.0009393247,0.0023753382],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025206913,0.000008691631,0.0002770592,0.000021214584,0.00012586692,0.0000032202802,0.0007774195,0.00013598679,0.0000031812056,0.14519057,0.8523799,0.0010516547],"study_design_scores_gemma":[0.00038543678,0.00009770787,0.00013675641,0.0000034755449,0.000021614764,0.00000116698,0.0000020152866,0.00043640687,0.000023090797,0.16595379,0.8327217,0.00021685411],"about_ca_topic_score_codex":0.0022558277,"about_ca_topic_score_gemma":0.00003039838,"teacher_disagreement_score":0.03273699,"about_ca_system_score_codex":0.00013773648,"about_ca_system_score_gemma":0.00011749091,"threshold_uncertainty_score":0.9999946},"labels":[],"label_agreement":null},{"id":"W2006204153","doi":"10.1177/2168479012474281","title":"A Review of Regulatory Mechanisms Used by the WHO, EU, and US to Facilitate Access to Quality Medicinal Products in Developing Countries With Constrained Regulatory Capacities","year":2013,"lang":"en","type":"review","venue":"Therapeutic Innovation & Regulatory Science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Micropharma (Canada)","funders":"","keywords":"Business; Regulatory agency; Agency (philosophy); Regulatory authority; Quality (philosophy); Regulatory science; European union; Developing country; Pharmacy; Market access; Product (mathematics); Regulatory affairs; Risk analysis (engineering); Public economics; Public administration; Economic growth; Medicine; International trade; Political science; Economics","score_opus":0.26289231732796264,"score_gpt":0.3732875543130458,"score_spread":0.11039523698508313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006204153","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015142271,0.9709496,0.0007937806,0.008143347,0.00029362636,0.003473251,0.000327731,0.00003549619,0.00084089977],"genre_scores_gemma":[0.0078065465,0.95937866,0.0007767078,0.030989226,0.00007403067,0.0004907981,0.000030446588,0.00006704247,0.00038656296],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99555665,0.00014559782,0.0023606394,0.0010215762,0.0002918415,0.0006236721],"domain_scores_gemma":[0.9967649,0.0002027509,0.0014516601,0.0009605991,0.00046370033,0.00015640118],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0076664034,0.0005176807,0.001971857,0.001065371,0.00025732678,0.00019640775,0.001156921,0.00015907273,0.00008342636],"category_scores_gemma":[0.0002705744,0.00040434243,0.00007299441,0.0037274624,0.0020094218,0.0006926304,0.00023456766,0.00033113253,0.00003598144],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019529989,0.00002511746,0.000069437425,0.019946316,0.00009811547,4.953202e-7,0.0012980468,0.0000046937357,0.000065952125,0.90421706,0.001246153,0.07300906],"study_design_scores_gemma":[0.00032769213,0.00009619779,0.0013242746,0.013812904,0.00004316786,0.000017555427,0.000092380134,0.00002025828,0.00020684478,0.006764081,0.97654146,0.0007531845],"about_ca_topic_score_codex":0.00015464216,"about_ca_topic_score_gemma":0.000016859538,"teacher_disagreement_score":0.9752953,"about_ca_system_score_codex":0.00058185594,"about_ca_system_score_gemma":0.0013714024,"threshold_uncertainty_score":0.99984086},"labels":[],"label_agreement":null},{"id":"W2006585203","doi":"10.1016/s0140-6736(07)61138-6","title":"Is G8 putting profits before the world's poorest children?","year":2007,"lang":"en","type":"article","venue":"The Lancet","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Economic growth; Coronavirus disease 2019 (COVID-19); Political science; Medicine; Business; Economics; Geography; Disease; Infectious disease (medical specialty)","score_opus":0.07303109596224984,"score_gpt":0.31311419465028273,"score_spread":0.2400830986880329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006585203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70298547,0.0013856317,0.00012267697,0.1147814,0.00049187755,0.00040903207,0.00029449767,0.00006607447,0.17946336],"genre_scores_gemma":[0.97070533,0.000077564146,0.00015170909,0.024373356,0.0025017231,0.000010475686,0.000008375601,0.000024105351,0.0021473863],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9987555,0.000012088801,0.0004137471,0.00024543254,0.000027517994,0.000545723],"domain_scores_gemma":[0.9990405,0.000088644054,0.00021211134,0.00056836335,0.000011158833,0.00007924385],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015598091,0.00013742935,0.00032138827,0.00007844178,0.00024921692,0.00011718899,0.0007038558,0.000047381367,0.00043521373],"category_scores_gemma":[0.000057864276,0.00009263573,0.000104036924,0.00025673528,0.00011225565,0.00009024397,0.00012898717,0.0003302431,0.0013638135],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017704471,0.00002606977,0.40443137,0.000008851012,0.000080895006,0.0000011503485,0.0007249887,0.000012788759,0.000003279036,0.5403741,0.04807222,0.0062465607],"study_design_scores_gemma":[0.00051253865,0.000016238659,0.50646585,0.0000078944195,0.000007306942,0.000007370285,0.00001552139,0.0008071599,0.00015327413,0.09155345,0.4003163,0.0001371245],"about_ca_topic_score_codex":0.00014561799,"about_ca_topic_score_gemma":0.00024748553,"teacher_disagreement_score":0.44882068,"about_ca_system_score_codex":0.000049462626,"about_ca_system_score_gemma":0.000009461233,"threshold_uncertainty_score":0.9994137},"labels":[],"label_agreement":null},{"id":"W2008667512","doi":"10.1177/1715163512473933","title":"BC government reveals plans to lower generic drug prices to 20% of brand-name price by April 2014","year":2013,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Brand names; Government (linguistics); Business; Advertising; Drug prices; Economics; Monetary economics; Linguistics; Philosophy","score_opus":0.028064279524157503,"score_gpt":0.2382762028005628,"score_spread":0.2102119232764053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008667512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9687438,0.002087997,0.0004224758,0.0032662917,0.002666872,0.0009590824,0.007827154,0.000019014882,0.014007297],"genre_scores_gemma":[0.97101676,0.0030954622,0.0004376587,0.020930536,0.0006676319,0.00006809381,0.00002270604,0.0000810572,0.0036800646],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99630105,0.000052097774,0.0014033763,0.00064577477,0.0002024362,0.0013952603],"domain_scores_gemma":[0.9943133,0.00011568062,0.0006121529,0.00039577764,0.00019285295,0.0043702633],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00084865966,0.00045824735,0.0007919527,0.00037145097,0.0003802298,0.00029373058,0.001130751,0.00007720074,0.0065553617],"category_scores_gemma":[0.00015172258,0.0005448701,0.00020841687,0.0005543353,0.00009309054,0.00048356308,0.000115877505,0.00048194776,0.0007956688],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000730531,0.00009624387,0.005713195,0.00015087631,0.00025765673,0.0007066407,0.0009681593,0.0020551821,0.0035250671,0.0006657005,0.9778472,0.0079409955],"study_design_scores_gemma":[0.0013737963,0.00007396216,0.00024942838,0.00002133504,0.00003734879,0.004773625,0.0000109450275,0.0023007928,0.0024454722,0.00057855155,0.98716027,0.0009744996],"about_ca_topic_score_codex":0.049839955,"about_ca_topic_score_gemma":0.02244421,"teacher_disagreement_score":0.027395748,"about_ca_system_score_codex":0.0031356271,"about_ca_system_score_gemma":0.00073427026,"threshold_uncertainty_score":0.9999823},"labels":[],"label_agreement":null},{"id":"W2008814643","doi":"10.1111/anae.12059","title":"Ensuring a sustainable supply of drugs for anaesthesia and peri‐operative care","year":2012,"lang":"en","type":"editorial","venue":"Anaesthesia","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Economic shortage; Government (linguistics); Medical emergency; Intensive care medicine","score_opus":0.018883530357095547,"score_gpt":0.2777896521429329,"score_spread":0.25890612178583733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008814643","genre_codex":"editorial","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26380163,0.21785057,0.00026513496,0.0043486846,0.42128265,0.0073951655,0.010879325,0.0002761585,0.07390067],"genre_scores_gemma":[0.7353113,0.010171099,0.00084695406,0.0004990093,0.24889286,0.0004075149,0.0005801153,0.00028808395,0.0030030534],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976359,0.000028515748,0.0008529544,0.0006290909,0.000062324434,0.0007912136],"domain_scores_gemma":[0.9983452,0.00017857389,0.0005884945,0.00043873847,0.0002000599,0.0002489518],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006592662,0.00043518443,0.001184345,0.00035764038,0.00018714243,0.00012720106,0.0003786627,0.00063988625,0.000080421705],"category_scores_gemma":[0.00023393393,0.0005113151,0.00027659364,0.0001380477,0.000165428,0.00030065715,0.00011311122,0.0004048122,0.00004921373],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016684916,0.00013222378,0.004280895,0.0018699286,0.00028612174,0.000011310873,0.009332038,0.000017797061,0.000002977945,0.29399338,0.6828527,0.0070537636],"study_design_scores_gemma":[0.00084865943,0.0002408394,0.00037960897,0.000046711066,0.00005222797,9.190879e-7,0.00080446305,0.0001150778,0.00004765436,0.004408496,0.9924986,0.00055677665],"about_ca_topic_score_codex":0.000890736,"about_ca_topic_score_gemma":0.00003392624,"teacher_disagreement_score":0.47150967,"about_ca_system_score_codex":0.00027621147,"about_ca_system_score_gemma":0.00019639985,"threshold_uncertainty_score":0.99973387},"labels":[],"label_agreement":null},{"id":"W2009112625","doi":"10.1057/jos.2011.26","title":"A multi-agent simulation of the pharmaceutical supply chain","year":2012,"lang":"en","type":"article","venue":"Journal of Simulation","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Profitability index; Supply chain; Computer science; Tracing; Discrete event simulation; Pharmaceutical industry; Industrial organization; Product (mathematics); Work (physics); Quarter (Canadian coin); Business; Operations research; Marketing; Simulation; Finance","score_opus":0.1422285680625195,"score_gpt":0.3678816463697102,"score_spread":0.22565307830719072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009112625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9716894,0.001430501,0.023445958,0.0011397395,0.0012621256,0.0001839919,0.000043243042,0.000004706964,0.00080035435],"genre_scores_gemma":[0.99839044,0.0000640247,0.00036528704,0.00054505526,0.00056328677,8.199737e-7,0.0000012449418,0.000012397777,0.000057452864],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99877954,0.000032408403,0.0008642485,0.00007618441,0.000052176667,0.00019544057],"domain_scores_gemma":[0.99868816,0.00016293692,0.00083227054,0.0001279031,0.000065087304,0.00012361912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009346625,0.00008835798,0.00025415907,0.00014003814,0.00005058053,0.000017503782,0.00015548061,0.000069649555,0.00026480507],"category_scores_gemma":[0.00024547795,0.00007449639,0.00019814001,0.00013916091,0.00004076767,0.00035888073,0.000037943886,0.00018494834,0.000050219103],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042904525,0.00024521767,0.09882318,0.000020130685,0.00006196348,2.5400143e-7,0.0006795869,0.89064246,0.000626802,0.0068458123,0.00011304935,0.0018986483],"study_design_scores_gemma":[0.00094766036,0.000025867752,0.06641466,0.0000116024285,0.000018082674,0.0000027527635,0.000012718763,0.8885471,0.0005346412,0.00095039787,0.04244824,0.00008627786],"about_ca_topic_score_codex":0.0000052343694,"about_ca_topic_score_gemma":6.0748766e-7,"teacher_disagreement_score":0.04233519,"about_ca_system_score_codex":0.0001108502,"about_ca_system_score_gemma":0.000017926985,"threshold_uncertainty_score":0.30378747},"labels":[],"label_agreement":null},{"id":"W2009416878","doi":"10.1016/j.jval.2013.08.814","title":"A 10-Year Review of the Canadian Common Drug Review: Pharmaceutical Manufacturers’ Success Rate","year":2013,"lang":"en","type":"review","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Formulary; Medicine; Reimbursement; Listing (finance); Family medicine; Business; Health care; Political science","score_opus":0.18501130182309475,"score_gpt":0.3940084444685437,"score_spread":0.20899714264544897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009416878","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000025662623,0.96418136,2.3219319e-7,0.016390916,0.0005522608,0.0031722968,0.0011206027,0.000010653498,0.014569135],"genre_scores_gemma":[0.000017600476,0.9709925,0.000023974999,0.027418263,0.00014348053,0.00020161668,0.00008624295,0.00007122483,0.0010451027],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9944764,0.0006839295,0.003259137,0.00064331765,0.0000704708,0.00086674665],"domain_scores_gemma":[0.9961055,0.00031597965,0.0018746539,0.0010136458,0.00003567394,0.00065457006],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0047362475,0.0004968586,0.0038883998,0.00036554204,0.0001460261,0.000049381866,0.0012701688,0.0002385875,0.0058981674],"category_scores_gemma":[0.00032745383,0.0004088976,0.00076722406,0.000668112,0.00013680493,0.00010674029,0.0001795735,0.0011956115,0.003052882],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000018204219,0.000056790705,0.00005452532,0.59785175,0.00009172309,0.0000027535198,0.000028360479,0.000006899519,9.139307e-10,0.026620483,0.2424439,0.132841],"study_design_scores_gemma":[0.00014315906,0.000012249746,0.000014674145,0.123480715,0.000054197073,0.000006758474,4.6241186e-7,0.0000872949,1.2046976e-7,0.0009887546,0.87489796,0.00031363888],"about_ca_topic_score_codex":0.15528753,"about_ca_topic_score_gemma":0.006361374,"teacher_disagreement_score":0.6324541,"about_ca_system_score_codex":0.0014266757,"about_ca_system_score_gemma":0.0015297807,"threshold_uncertainty_score":0.99983627},"labels":[],"label_agreement":null},{"id":"W2009842811","doi":"10.1503/cmaj.1040937","title":"Stockholders protest Pfizer's drug prices","year":2004,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Shareholder; Drug; Drug industry; Drug prices; Economic Justice; Drug Company; Faith; Business; Drug pricing; Finance; Computer science; Medicine; Monetary economics; Economics; Pharmacology; Actuarial science; Management; Microeconomics; Biology; Corporate governance; Biotechnology","score_opus":0.022230739515691357,"score_gpt":0.24482837157388138,"score_spread":0.22259763205819003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009842811","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.31682122,0.0020083487,0.0007981,0.4999423,0.0033092082,0.00047109608,0.0003257345,0.00005932971,0.17626466],"genre_scores_gemma":[0.925974,0.00040164747,0.00033889335,0.07037632,0.002100382,0.000017302802,0.0000079830925,0.000030553736,0.0007528765],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984447,0.000017971659,0.0006279784,0.00019363496,0.00014112331,0.00057462975],"domain_scores_gemma":[0.99765754,0.00005739578,0.000380564,0.00010078981,0.00006760737,0.0017361303],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0017015986,0.0001185734,0.00026294176,0.0002537678,0.0002700815,0.00019722305,0.00032662286,0.00022318584,0.0049110437],"category_scores_gemma":[0.000923652,0.00013554729,0.00012371286,0.0001899746,0.000038211987,0.00024452864,0.000017735694,0.00078269053,0.0023464186],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001207181,0.00018987611,0.13102353,0.00003080869,0.00044637095,0.00031477227,0.0018398847,0.00045315182,0.0000051872375,0.48296744,0.37070975,0.012007136],"study_design_scores_gemma":[0.0011303027,0.000018939765,0.010128712,0.000018198914,0.0000040354466,0.000064305874,0.00006120177,0.00023030314,0.0000110246965,0.048877917,0.93924576,0.00020928025],"about_ca_topic_score_codex":0.0047385884,"about_ca_topic_score_gemma":0.014258685,"teacher_disagreement_score":0.6091528,"about_ca_system_score_codex":0.0017505488,"about_ca_system_score_gemma":0.001197337,"threshold_uncertainty_score":0.9984304},"labels":[],"label_agreement":null},{"id":"W2010859221","doi":"10.1186/s12889-015-1475-1","title":"Perceptions of the population regarding generic drugs in Brazil: a nationwide survey","year":2015,"lang":"en","type":"article","venue":"BMC Public Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Universidade de São Paulo","keywords":"Medicine; Biostatistics; Population; Socioeconomic status; Public health; Gerontology; Perception; Environmental health; Family medicine; Nursing; Psychology","score_opus":0.2085078237389088,"score_gpt":0.3697604662547268,"score_spread":0.161252642515818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010859221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799928,0.00028041986,0.0007824642,0.011111649,0.00037152888,0.00022509627,0.00017911616,0.000015036223,0.007041881],"genre_scores_gemma":[0.99721456,0.00007225788,0.00031115295,0.0020607994,0.0000751803,0.000013305873,0.000044979155,0.000012892777,0.00019485997],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986014,0.00014877657,0.00071644544,0.0002038342,0.000039231294,0.00029034755],"domain_scores_gemma":[0.9990607,0.00008586071,0.00035124656,0.00025922645,0.000042073163,0.00020088855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037966792,0.000077772085,0.0002670092,0.00026259097,0.00007298433,0.00004721739,0.00021472343,0.000056104895,0.000057214027],"category_scores_gemma":[0.0007771037,0.00007675201,0.00006565956,0.00056288607,0.00003164228,0.00023510761,0.000065762855,0.00012573651,0.00006733312],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000026256803,0.000041581847,0.9218714,0.0000149922635,0.0000034789525,1.1493791e-8,0.0004914665,0.00023248087,3.2205963e-7,0.07519094,0.0014446847,0.0007060062],"study_design_scores_gemma":[0.0004344798,0.000011390024,0.96588427,0.000004432523,3.435808e-7,6.921298e-7,0.00006547632,0.010615165,5.376507e-7,0.0072183125,0.015685972,0.00007893037],"about_ca_topic_score_codex":0.009031875,"about_ca_topic_score_gemma":0.0042712297,"teacher_disagreement_score":0.06797262,"about_ca_system_score_codex":0.00045013794,"about_ca_system_score_gemma":0.0003388898,"threshold_uncertainty_score":0.99756706},"labels":[],"label_agreement":null},{"id":"W2011832705","doi":"10.1377/hlthaff.20.6.306","title":"Rationalizing The Drug Patent System","year":2001,"lang":"en","type":"letter","venue":"Health Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Care Foundation","funders":"","keywords":"Health care; Foundation (evidence); Download; Library science; Medicine; Political science; World Wide Web; Computer science; Law","score_opus":0.13248523850078142,"score_gpt":0.28998387008263093,"score_spread":0.1574986315818495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011832705","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000032647797,0.007561178,0.00016064386,0.8929495,0.0018896676,0.00054961204,0.0006271142,0.00008168548,0.09614793],"genre_scores_gemma":[0.020159198,0.0020291011,0.00007353719,0.9652761,0.0069811204,0.00015354685,0.00032864782,0.00009296568,0.004905746],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972308,0.00007700295,0.0012296622,0.0005743221,0.000062144405,0.0008260266],"domain_scores_gemma":[0.99811614,0.00017121393,0.0009107288,0.00059535675,0.000024652207,0.0001818972],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010835802,0.00031671746,0.00073429267,0.0002086345,0.0003484942,0.00015733815,0.0005125447,0.0002959928,0.0005167757],"category_scores_gemma":[0.000029734632,0.00029085964,0.00025879493,0.00017791003,0.00007308362,0.00009165725,0.00008828801,0.0013596797,0.0035968223],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000024996802,0.000008764587,0.00011470951,0.00033419768,0.00003930242,0.000015141854,0.00017488166,0.000027141265,1.2547156e-8,0.094462864,0.90464365,0.00017682038],"study_design_scores_gemma":[0.00024222425,0.000014516803,0.00004598186,0.0000643146,0.000004940972,0.000023494502,0.000117006835,0.0018784305,3.5507645e-7,0.004423159,0.9928979,0.00028763898],"about_ca_topic_score_codex":0.0009274628,"about_ca_topic_score_gemma":0.00004196737,"teacher_disagreement_score":0.09124219,"about_ca_system_score_codex":0.00085568224,"about_ca_system_score_gemma":0.00019386828,"threshold_uncertainty_score":0.99995434},"labels":[],"label_agreement":null},{"id":"W2012264231","doi":"10.1136/bmj.331.7522.958","title":"Foreign free riders and the high price of US medicines","year":2005,"lang":"en","type":"review","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Computer science; Data science; World Wide Web; Medicine; Business","score_opus":0.11168298525667418,"score_gpt":0.35494946050225307,"score_spread":0.24326647524557887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012264231","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000009227692,0.88909096,0.000027817272,0.0029180748,0.00023633444,0.0006593006,0.00037191215,0.000008554873,0.10667782],"genre_scores_gemma":[0.000108738306,0.99655354,0.0002055323,0.0017097829,0.00085316744,0.00008418803,0.000015814421,0.000033186006,0.00043606764],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981765,0.000031618674,0.0012269712,0.00029975263,0.000025630448,0.00023951412],"domain_scores_gemma":[0.9979185,0.000433056,0.0009823,0.00055971823,0.000013620673,0.0000927981],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011156539,0.00024005362,0.0017565945,0.00017044652,0.00004783349,0.000029757222,0.00049478246,0.00017989764,0.00034379843],"category_scores_gemma":[0.00036006546,0.00017310295,0.00031237435,0.00014081337,0.00027571287,0.00006099177,0.00017263746,0.0002432755,0.00015550875],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009308521,0.000015873073,0.000023889095,0.0018841267,0.00021923274,0.0000011226779,0.000038831276,0.0000021142907,2.1032949e-9,0.71200645,0.028510822,0.25728825],"study_design_scores_gemma":[0.00078705203,0.000012798641,0.000023214629,0.0003550333,0.00010152989,0.0000144136475,0.0000036487672,0.00009780603,6.5922976e-8,0.039871447,0.95854527,0.00018773394],"about_ca_topic_score_codex":0.00024440716,"about_ca_topic_score_gemma":0.000014687927,"teacher_disagreement_score":0.93003446,"about_ca_system_score_codex":0.000050453506,"about_ca_system_score_gemma":0.00005485235,"threshold_uncertainty_score":0.70589334},"labels":[],"label_agreement":null},{"id":"W2013299482","doi":"10.17159/1727-3781/2012/v15i2a2498","title":"Comparative analysis of access to patented HIV/AIDS pharmaceutical medicines through the Canadian and EU TRIPS flexibilities measures: are they efficacious or overly burdensome and ineffective measures?","year":2012,"lang":"en","type":"article","venue":"Potchefstroom Electronic Law Journal/Potchefstroomse Elektroniese Regsblad","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"African Union","keywords":"TRIPS architecture; Access to medicines; Human immunodeficiency virus (HIV); TRIPS Agreement; Medicine; Business; Actuarial science; Traditional medicine; Intellectual property; Virology; Computer science; Political science; Law","score_opus":0.11063137299792307,"score_gpt":0.3449586732713687,"score_spread":0.23432730027344562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013299482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9372034,0.035781533,0.0010051362,0.016814403,0.0004914625,0.0017401685,0.00076662295,0.00008921782,0.006108055],"genre_scores_gemma":[0.99186105,0.004068488,0.0001299355,0.002966789,0.0005830458,0.00011493411,0.000024923129,0.000079100166,0.00017171862],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940494,0.00047517524,0.001763948,0.00088441186,0.00035000994,0.002477085],"domain_scores_gemma":[0.9954311,0.0008967969,0.0011280484,0.00073428906,0.00033361043,0.0014761008],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003323365,0.00083351694,0.0023890464,0.00093475194,0.0010707468,0.00054223783,0.0009783076,0.00034367706,0.00020311643],"category_scores_gemma":[0.0006668049,0.000633099,0.0005045186,0.0013209803,0.00080500083,0.0011613029,0.00026435853,0.0018298393,0.000034855286],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047358423,0.0012142921,0.15038477,0.00034346108,0.034591436,0.0000545459,0.045738578,0.005519212,0.0006958708,0.7479583,0.0037124227,0.0050512906],"study_design_scores_gemma":[0.017111452,0.003724378,0.07757349,0.00045182506,0.008494473,0.001033325,0.017504547,0.012182846,0.004178285,0.054215,0.7987113,0.00481906],"about_ca_topic_score_codex":0.017969722,"about_ca_topic_score_gemma":0.14710431,"teacher_disagreement_score":0.7949989,"about_ca_system_score_codex":0.0017367909,"about_ca_system_score_gemma":0.00046816524,"threshold_uncertainty_score":0.99961203},"labels":[],"label_agreement":null},{"id":"W2014140411","doi":"10.12927/hcq.2005.17684","title":"Opinions: Another Face of Healthcare Innovation: Commercialization","year":2005,"lang":"en","type":"article","venue":"Healthcare Quarterly","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Commercialization; Face (sociological concept); Health care; Business; Best practice; Public relations; Marketing; Economic growth; Political science; Management; Economics; Sociology","score_opus":0.10540149285423325,"score_gpt":0.35652408991742957,"score_spread":0.2511225970631963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014140411","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1219098,0.010697991,0.016726498,0.8178455,0.0020353906,0.0016041488,0.0028063087,0.00023694555,0.026137382],"genre_scores_gemma":[0.98178864,0.00017373326,0.00061436294,0.016606247,0.00043478093,0.000029814842,0.00013078425,0.000030758536,0.00019085767],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981151,0.00003743321,0.0011680005,0.00030652573,0.00003825848,0.00033464568],"domain_scores_gemma":[0.99890566,0.00004045878,0.00050188677,0.00034514777,0.0001056891,0.00010118227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041475662,0.00014890802,0.0004030846,0.0003209528,0.00010517053,0.00003124931,0.00019355192,0.00014501196,0.00030552238],"category_scores_gemma":[0.0000236891,0.0001877329,0.00007210143,0.0005140206,0.000053635333,0.000250483,0.000013458945,0.00017630398,0.00045237242],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016955028,0.00007184869,0.0061458913,0.00013025149,0.000016150523,2.2348098e-7,0.0019559567,0.000017283142,0.000006728006,0.9457127,0.003978116,0.041947883],"study_design_scores_gemma":[0.00093990576,0.0004397459,0.011797728,0.000048959326,0.0000026533075,0.000004846728,0.00029148447,0.0025355755,0.000114032504,0.04975048,0.93371904,0.00035556074],"about_ca_topic_score_codex":0.0011792878,"about_ca_topic_score_gemma":0.00036391674,"teacher_disagreement_score":0.9297409,"about_ca_system_score_codex":0.00015332307,"about_ca_system_score_gemma":0.00009451283,"threshold_uncertainty_score":0.7655525},"labels":[],"label_agreement":null},{"id":"W2014505378","doi":"10.1186/1472-6963-11-64","title":"Canada's Patented Medicine Notice of Compliance regulations: balancing the scales or tipping them?","year":2011,"lang":"en","type":"article","venue":"BMC Health Services Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; University of Toronto; York University","funders":"Industry Canada; Department of Industry and Science, Australian Government","keywords":"Notice; Compliance (psychology); Business; Tipping point (physics); Law; Political science; Engineering; Psychology; Social psychology","score_opus":0.4058565063433296,"score_gpt":0.4238891179555788,"score_spread":0.018032611612249227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014505378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81546,0.013112978,0.0008739221,0.03377157,0.0012366452,0.0027294534,0.0007744016,0.000081228274,0.13195975],"genre_scores_gemma":[0.99400157,0.00079718896,0.00044054998,0.0041962564,0.00017334385,0.000028272645,0.000010113386,0.000019073588,0.000333659],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979859,0.00012733473,0.00086605165,0.00030212785,0.00011832372,0.00060027576],"domain_scores_gemma":[0.99820256,0.0005888355,0.00035165905,0.0004730937,0.00015008495,0.00023376661],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026928904,0.000114114795,0.00039318355,0.00014004359,0.0003586365,0.000020453434,0.00063477637,0.00005210479,0.0007219658],"category_scores_gemma":[0.00009653194,0.000085271255,0.00003514874,0.00054704555,0.00017533322,0.000103828075,0.00014753442,0.00029584218,0.00012302233],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005349907,0.00027206345,0.6302942,0.0076930886,0.00016051783,0.000007079481,0.014256873,0.00019878542,0.000040374554,0.33691835,0.004327963,0.0052957255],"study_design_scores_gemma":[0.0010664047,0.00015249058,0.85000366,0.00077761384,0.000003888765,0.000008059997,0.003094103,0.054591116,0.00009454665,0.017548468,0.072399676,0.00025996598],"about_ca_topic_score_codex":0.63249564,"about_ca_topic_score_gemma":0.4125663,"teacher_disagreement_score":0.31936988,"about_ca_system_score_codex":0.0002534412,"about_ca_system_score_gemma":0.0005718553,"threshold_uncertainty_score":0.79050195},"labels":[],"label_agreement":null},{"id":"W2015182177","doi":"10.1126/scitranslmed.3003490","title":"Recalibrating Intellectual Property Rights to Enhance Translational Research Collaborations","year":2012,"lang":"en","type":"review","venue":"Science Translational Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Provincial Laboratory of Public Health","funders":"National Center for Research Resources","keywords":"Intellectual property; Construct (python library); Translational research; Business; Property rights; Knowledge management; Computer science; Law and economics; Political science; Medicine; Economics; Law","score_opus":0.4425351314643522,"score_gpt":0.4822118095595027,"score_spread":0.03967667809515052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015182177","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000014095453,0.9160655,0.0024943638,0.009508975,0.0008963985,0.0013431283,0.00051554374,0.000039473212,0.06912253],"genre_scores_gemma":[0.006421341,0.9818091,0.0040273806,0.001002567,0.0032472801,0.00046858808,0.0002864782,0.00008634134,0.0026509461],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99601144,0.00011234242,0.0016239585,0.0009785985,0.00037512943,0.0008985414],"domain_scores_gemma":[0.9972071,0.0011638945,0.00027707647,0.00042107567,0.0002710628,0.00065980665],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.005605062,0.0003656122,0.0012301733,0.0016934633,0.0008914781,0.00013225531,0.0009590154,0.0001766124,0.0036569203],"category_scores_gemma":[0.0007650834,0.00027158592,0.00016161216,0.0043363017,0.0012601309,0.00068619207,0.00005950781,0.0007873652,0.0023701256],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016955555,0.00012870041,0.000017756247,0.0010658893,0.0000719977,0.0000015048927,0.0039885943,0.00004652458,0.0000113833075,0.55644923,0.0043909457,0.4338105],"study_design_scores_gemma":[0.00012789604,0.00006248342,0.00001153477,0.00091077597,0.0000323657,0.000007656051,0.000014412935,0.0006385455,0.00000675229,0.023007052,0.9748261,0.00035441827],"about_ca_topic_score_codex":0.00012077175,"about_ca_topic_score_gemma":0.000077357494,"teacher_disagreement_score":0.97043514,"about_ca_system_score_codex":0.00023805942,"about_ca_system_score_gemma":0.0009860911,"threshold_uncertainty_score":0.99997365},"labels":[],"label_agreement":null},{"id":"W2015351537","doi":"10.1016/j.seizure.2005.12.010","title":"Are there potential problems with generic substitution of antiepileptic drugs?","year":2006,"lang":"en","type":"review","venue":"Seizure","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":143,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Dosing; Intensive care medicine; Adverse effect; Bioequivalence; Drug; Epilepsy; Risk analysis (engineering); Psychiatry; Pharmacology; Pharmacokinetics","score_opus":0.07921406813877387,"score_gpt":0.2875214318073167,"score_spread":0.20830736366854286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015351537","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00044604499,0.98690194,0.00023341672,0.00006511329,0.00032740028,0.0005819746,0.0010571243,0.0000313674,0.010355594],"genre_scores_gemma":[0.0047768676,0.99342924,0.00010195629,0.00011515136,0.0004020866,0.00005591755,0.00020242865,0.00007964114,0.00083672034],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99795777,0.000027943788,0.0010467164,0.00053731113,0.000041540636,0.00038871734],"domain_scores_gemma":[0.99751556,0.00002386391,0.001871224,0.0004508089,0.00003630172,0.00010225032],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023252144,0.00041110895,0.0018716801,0.0002943942,0.00007296407,0.00006706815,0.00037395972,0.00035782633,0.00022508486],"category_scores_gemma":[0.000012184788,0.00036619435,0.0004535287,0.00036685407,0.00013509982,0.00012590278,0.000063787855,0.0003743018,0.00043865378],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007238354,0.0014106048,0.0021926316,0.11600778,0.0034250212,0.00020587452,0.00025894458,0.0039280346,0.0000014544302,0.3378241,0.029163014,0.50551015],"study_design_scores_gemma":[0.00028908992,0.00003464107,0.00010156398,0.001308338,0.00015990467,0.000021862865,0.0000037583106,0.00024027909,5.3642947e-7,0.0019156652,0.9954761,0.00044824876],"about_ca_topic_score_codex":0.000113613,"about_ca_topic_score_gemma":0.000016889913,"teacher_disagreement_score":0.9663131,"about_ca_system_score_codex":0.00013724956,"about_ca_system_score_gemma":0.00009945594,"threshold_uncertainty_score":0.999879},"labels":[],"label_agreement":null},{"id":"W2015750704","doi":"10.1177/009286150804200604","title":"Publishing a Drug Information Bulletin: Experiences From a Developing Country","year":2008,"lang":"en","type":"article","venue":"Drug Information Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Publishing; Pharmacy; Library science; Bulletin board; Medicine; Publication; Quarter (Canadian coin); Developing country; Information center; Political science; Family medicine; Advertising; Business; Sociology; Geography; Computer science; Social science","score_opus":0.035906299612316867,"score_gpt":0.23543577925372022,"score_spread":0.19952947964140336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015750704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85907716,0.00047361417,0.009632668,0.024957625,0.0021032954,0.00021331498,0.000328804,0.000088274304,0.10312527],"genre_scores_gemma":[0.9661565,0.0008982451,0.0025855005,0.029529717,0.0005379827,0.000028316834,0.00015615627,0.000009722106,0.0000978626],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99807745,0.000016387892,0.0013829779,0.00009240428,0.00009563676,0.000335113],"domain_scores_gemma":[0.9985047,0.000064484026,0.0009830969,0.00012070005,0.00011589694,0.00021112751],"candidate_categories":["scholarly_communication","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0008125532,0.00015579295,0.00026516346,0.00039780408,0.0005454997,0.0015288005,0.0003962424,0.000078988436,0.0015605158],"category_scores_gemma":[0.00034356205,0.00017001665,0.000092075934,0.00021999601,0.00006402314,0.013695918,0.000077068165,0.0004366476,0.002463497],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007025677,0.00003543884,0.008805468,0.000045448593,0.00011888657,0.000004989899,0.20011306,0.0008462426,0.0000011336947,0.07402516,0.7052834,0.010650526],"study_design_scores_gemma":[0.0007651411,0.00000560658,0.0036535214,0.000019469911,0.00000200184,0.00008727662,0.004061262,0.004991234,0.00004199693,0.0036867037,0.98242897,0.00025682116],"about_ca_topic_score_codex":0.00019349434,"about_ca_topic_score_gemma":0.0000036325616,"teacher_disagreement_score":0.27714556,"about_ca_system_score_codex":0.00023924129,"about_ca_system_score_gemma":0.00012224808,"threshold_uncertainty_score":0.9995077},"labels":[],"label_agreement":null},{"id":"W2016116452","doi":"10.12927/hcq.2013.23040","title":"Ethical Framework for Resource Allocation during a Drug Supply Shortage","year":2012,"lang":"en","type":"article","venue":"Healthcare Quarterly","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Economic shortage; Scarcity; Business; Health care; Context (archaeology); Scope (computer science); Redistribution (election); Medicine; Economic growth; Economics; Political science; Government (linguistics)","score_opus":0.06107863323110095,"score_gpt":0.3420003014944191,"score_spread":0.28092166826331816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016116452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8124193,0.004837431,0.008842901,0.166065,0.0014153753,0.0011871131,0.0007035579,0.00017831099,0.0043510073],"genre_scores_gemma":[0.9860184,0.000065447915,0.002132921,0.010046671,0.0012468537,0.00016277327,0.00004986898,0.000047386904,0.00022968676],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980773,0.00004187613,0.00070905837,0.0003643054,0.000035186495,0.000772275],"domain_scores_gemma":[0.9986925,0.0002311114,0.00022213331,0.00037156386,0.000027770802,0.00045493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009524461,0.0001780999,0.0003695941,0.0001474025,0.00021674941,0.00006907082,0.00020589585,0.0003466082,0.0001777605],"category_scores_gemma":[0.00009090532,0.00022185533,0.0001541696,0.00012730878,0.000045337303,0.00020176961,0.000016946638,0.0006356916,0.00049372803],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005089577,0.00006329973,0.018086135,0.00019074917,0.000022584225,4.7275282e-7,0.004578692,0.0000023025286,0.0000090978965,0.9712634,0.0021241042,0.0036082384],"study_design_scores_gemma":[0.0010970313,0.00029850157,0.07829658,0.000082029255,0.000012881035,0.00001485081,0.0008593277,0.0013469128,0.00017447706,0.27921844,0.6377994,0.00079956173],"about_ca_topic_score_codex":0.00020460083,"about_ca_topic_score_gemma":0.00005647015,"teacher_disagreement_score":0.692045,"about_ca_system_score_codex":0.00018137804,"about_ca_system_score_gemma":0.000037228594,"threshold_uncertainty_score":0.90469974},"labels":[],"label_agreement":null},{"id":"W2016339789","doi":"10.2307/3527681","title":"Pushing the Borders: The Moral Dilemma of International Internet Pharmacies","year":2004,"lang":"en","type":"article","venue":"The Hastings Center Report","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Dilemma; The Internet; Moral dilemma; Pharmacy; Business; Ethical dilemma; Internet privacy; Public relations; Political science; Psychology; Law; Social psychology; Computer science; World Wide Web","score_opus":0.09138039927924876,"score_gpt":0.31007249083598376,"score_spread":0.218692091556735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016339789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.885345,0.00036973128,0.0012367558,0.042228647,0.0022948827,0.00031649333,0.00011275566,0.000040675463,0.0680551],"genre_scores_gemma":[0.9964998,0.000088144625,0.000057242887,0.0025638964,0.00029241684,0.000017477938,0.000012391764,0.000017521916,0.000451127],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99872357,0.000013236429,0.0007396724,0.00022128523,0.000054864642,0.00024737066],"domain_scores_gemma":[0.99882346,0.00008135208,0.000646787,0.00035638924,0.00004893006,0.000043069147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001082099,0.00013013174,0.00019967472,0.000051300398,0.00012634345,0.00014461624,0.0007563896,0.000030021465,0.00026559862],"category_scores_gemma":[0.0002870641,0.00007684729,0.0001592014,0.00010049697,0.00024448926,0.00018479249,0.00026532082,0.0002583086,0.00009952396],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012101671,0.00035420753,0.2670715,0.000044582957,0.0007690828,0.00004946047,0.014110942,0.0024413445,0.00015023458,0.69785446,0.015074685,0.0019584754],"study_design_scores_gemma":[0.001181386,0.000030500334,0.013737572,0.000042989177,0.000023073377,0.00040178926,0.0002828656,0.0031977058,0.0009495338,0.04302973,0.9368705,0.00025230873],"about_ca_topic_score_codex":0.0007363773,"about_ca_topic_score_gemma":0.000021331676,"teacher_disagreement_score":0.92179585,"about_ca_system_score_codex":0.00007014885,"about_ca_system_score_gemma":0.000025756053,"threshold_uncertainty_score":0.31337416},"labels":[],"label_agreement":null},{"id":"W2016350863","doi":"10.2217/dmt.10.5","title":"Improving access to insulin: what can be done?","year":2011,"lang":"en","type":"article","venue":"Diabetes Management","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Toronto","keywords":"Medicine; Insulin; Insulin degludec; Internal medicine; Intensive care medicine; Endocrinology; Hypoglycemia; Insulin glargine","score_opus":0.09691919552221963,"score_gpt":0.27278003648240057,"score_spread":0.17586084096018095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016350863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7600504,0.0013137722,0.0007600872,0.011591477,0.00190741,0.0010146935,0.0001722584,0.0001297861,0.2230601],"genre_scores_gemma":[0.96826994,0.0006535106,0.00081985747,0.029349329,0.00011493689,0.00013207945,0.0000130013805,0.000035377616,0.0006119569],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99855274,0.0000072529847,0.00044349383,0.00045486295,0.000026078653,0.0005155722],"domain_scores_gemma":[0.999167,0.000015500118,0.00015322054,0.00041747384,0.000012465714,0.00023428508],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00032793917,0.000174283,0.000286535,0.0002968194,0.00008009863,0.00039545214,0.000603738,0.000048372844,0.0006412372],"category_scores_gemma":[0.000018455408,0.00021230825,0.00009004884,0.00022375604,0.000028344917,0.00061461877,0.0005361113,0.00009771379,0.00078152417],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027603348,0.00036058272,0.058556885,0.00031310093,0.00043649314,0.000014115876,0.0018109948,0.000077317316,0.000031277497,0.7741733,0.012601437,0.1515969],"study_design_scores_gemma":[0.0016944,0.00018989806,0.1233227,0.000071038,0.000052610474,3.4121283e-7,0.00025019396,0.00500132,0.0038334923,0.1065296,0.7575564,0.0014980414],"about_ca_topic_score_codex":0.00023357273,"about_ca_topic_score_gemma":0.000044219054,"teacher_disagreement_score":0.74495494,"about_ca_system_score_codex":0.000109232584,"about_ca_system_score_gemma":0.000005269846,"threshold_uncertainty_score":0.9999965},"labels":[],"label_agreement":null},{"id":"W2018123025","doi":"10.1016/j.jval.2014.03.156","title":"Dissecting The Delays: The Impact Of New Policies And Practices On Total Time To Reimbursement In Ontario","year":2014,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Formulary; Reimbursement; Receipt; Notice; Business; Medicine; Actuarial science; Operations management; Accounting; Family medicine; Health care; Economics; Political science","score_opus":0.15040004591590553,"score_gpt":0.37749601616266476,"score_spread":0.22709597024675923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018123025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97456354,0.00027463687,0.000006138593,0.016501084,0.000069859096,0.00027058792,0.000011495698,0.0000030898716,0.008299597],"genre_scores_gemma":[0.9977096,0.00007319113,0.000041873303,0.0016577018,0.00009427354,0.0000069726766,8.915375e-7,0.000008349505,0.00040717807],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99900436,0.00004663876,0.00049154053,0.00017270603,0.000020239579,0.00026451264],"domain_scores_gemma":[0.998888,0.00040354815,0.00039776653,0.00019994429,0.0000054452894,0.00010525146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016371179,0.00008844752,0.00024341034,0.00012648206,0.00006006512,0.000040986288,0.00013837562,0.000029104613,0.000098722325],"category_scores_gemma":[0.00036346566,0.00006191741,0.000043433287,0.0001343692,0.000023223914,0.00006739253,0.00005153775,0.00022585606,0.000071500595],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016548469,0.0002464877,0.574214,0.000047252448,0.00006991746,6.192523e-7,0.03763558,0.15423119,0.00002011676,0.22258426,0.003170355,0.007614774],"study_design_scores_gemma":[0.0005441449,0.000568877,0.9131129,0.00006251731,0.00000176941,0.000003765144,0.00014751361,0.04039482,0.000013660848,0.02292811,0.022073448,0.00014851667],"about_ca_topic_score_codex":0.67857176,"about_ca_topic_score_gemma":0.02737067,"teacher_disagreement_score":0.65120107,"about_ca_system_score_codex":0.00037351748,"about_ca_system_score_gemma":0.00012214277,"threshold_uncertainty_score":0.9903773},"labels":[],"label_agreement":null},{"id":"W2018336017","doi":"10.1111/1475-6773.01058","title":"Quantifying Components of Drug Expenditure Inflation: The British Columbia Seniors' Drug Benefit Plan","year":2002,"lang":"en","type":"article","venue":"Health Services Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Per capita; Medical prescription; Incentive; Drug; Prescription drug; Public economics; Product (mathematics); Population; Medicine; Business; Actuarial science; Environmental health; Pharmacology; Economics","score_opus":0.170694112784534,"score_gpt":0.3744954558472355,"score_spread":0.20380134306270148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018336017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97211343,0.008984542,0.000002484667,0.0070661725,0.00029799552,0.00055852754,0.0004816559,0.000025566216,0.010469637],"genre_scores_gemma":[0.9908292,0.0042017032,0.000045659363,0.0024847637,0.0002601709,0.00003759062,0.00006183731,0.000028569058,0.0020504792],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99773484,0.000103242804,0.00088956545,0.00040620775,0.00014397234,0.0007221905],"domain_scores_gemma":[0.99844974,0.00028813982,0.00044853025,0.00045423015,0.00007680677,0.00028255198],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002005257,0.000107439904,0.00042522154,0.00013309179,0.0011126605,0.0007609572,0.0006642535,0.00007956567,0.0021606127],"category_scores_gemma":[0.000014244004,0.00014630331,0.00008938473,0.00039277077,0.00011725926,0.00024054988,0.00022444021,0.0005700512,0.0006641561],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007144519,0.000829686,0.7734213,0.004163054,0.00023138977,0.000022442016,0.035440642,0.00065248425,0.00003990056,0.026452703,0.14066537,0.018009622],"study_design_scores_gemma":[0.0014413019,0.00006841938,0.24830636,0.00033214464,0.0000031672787,0.0000188662,0.0018533061,0.063816,0.00002574258,0.011448926,0.6722907,0.00039508732],"about_ca_topic_score_codex":0.1741111,"about_ca_topic_score_gemma":0.11869652,"teacher_disagreement_score":0.53162533,"about_ca_system_score_codex":0.00014024312,"about_ca_system_score_gemma":0.000026546828,"threshold_uncertainty_score":0.9987515},"labels":[],"label_agreement":null},{"id":"W2019670979","doi":"10.1126/science.311.5758.161c","title":"Canada Targets Chemicals","year":2006,"lang":"en","type":"article","venue":"Science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computational biology; Chemistry; Biology","score_opus":0.027073133688221212,"score_gpt":0.2486312245197851,"score_spread":0.2215580908315639,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019670979","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4745539,0.0015333858,0.0001997949,0.0078835925,0.00082208763,0.000105691994,0.00021592177,0.00002854424,0.5146571],"genre_scores_gemma":[0.99557334,0.000014313592,0.00021403571,0.0030669842,0.00012393053,0.0000036359809,0.0000020337015,0.000004932609,0.0009967955],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99909866,0.0000012665224,0.00024951732,0.0002723661,0.000031515916,0.00034668113],"domain_scores_gemma":[0.9995999,0.000016545671,0.000079647776,0.00017376622,0.000015097851,0.00011505954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003255851,0.00006412389,0.00012582676,0.00006650156,0.000114076436,0.000059033333,0.0003454878,0.000018882132,0.0004136245],"category_scores_gemma":[0.00005970866,0.000073439645,0.000024203353,0.00026881092,0.0001796804,0.00015529497,0.000059486967,0.000062916886,0.0003075273],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000001776973,0.000029829678,0.015407969,0.0000055115906,0.0000028596357,0.000002967982,0.000014783721,0.000120209435,0.0027420681,0.93850917,0.042734776,0.00042807363],"study_design_scores_gemma":[0.00012121454,0.0000038403737,0.024004743,0.000001125974,4.5638478e-7,0.0000018505627,0.0000018934949,0.002549124,0.008486119,0.08907074,0.87560403,0.00015483792],"about_ca_topic_score_codex":0.2887096,"about_ca_topic_score_gemma":0.046187427,"teacher_disagreement_score":0.8494384,"about_ca_system_score_codex":0.0002174822,"about_ca_system_score_gemma":0.00028668434,"threshold_uncertainty_score":0.97121716},"labels":[],"label_agreement":null},{"id":"W2020026521","doi":"10.1038/clpt.2009.243","title":"The (Possible) Impact of Comparative Effectiveness Research on Pharmaceutical Industry Decision Making","year":2010,"lang":"en","type":"review","venue":"Clinical Pharmacology & Therapeutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nickel Institute","funders":"National Institutes of Health","keywords":"Pharmaceutical industry; Comparative effectiveness research; Management science; Business; Medicine; Pharmacology; Economics; Alternative medicine","score_opus":0.637574940144511,"score_gpt":0.6468215544832479,"score_spread":0.009246614338736858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020026521","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009270178,0.9779322,0.000047717585,0.00041959647,0.004866098,0.0019588459,0.0006797468,0.00003981188,0.004785761],"genre_scores_gemma":[0.014838242,0.9807009,0.0000632973,0.0024861402,0.0015037908,0.00019910352,0.000019100054,0.00011939106,0.00007005093],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9919478,0.0020853004,0.003373339,0.0011880189,0.00015732321,0.0012481773],"domain_scores_gemma":[0.96397007,0.03291662,0.0015245078,0.0009333583,0.00021929019,0.00043613356],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.011044039,0.00076014065,0.0039521237,0.00058751745,0.00056655175,0.00014896462,0.0020537283,0.0026581052,0.00064889924],"category_scores_gemma":[0.00020506335,0.00055316015,0.0021076084,0.0009213202,0.002377206,0.00010305505,0.0005607996,0.012189281,0.0012915763],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012761515,0.0016355854,0.0010336216,0.0010653031,0.00506369,0.000020041052,0.00007631191,0.00007268078,0.0000041268618,0.013870401,0.009572573,0.9663095],"study_design_scores_gemma":[0.0013326199,0.00070844614,0.0006033635,0.0009572714,0.00055844075,0.000012999972,0.0000058366045,0.0009778799,0.000010939334,0.011130478,0.9831852,0.000516538],"about_ca_topic_score_codex":0.000006597323,"about_ca_topic_score_gemma":0.0000025301536,"teacher_disagreement_score":0.9736126,"about_ca_system_score_codex":0.0005587625,"about_ca_system_score_gemma":0.00076458964,"threshold_uncertainty_score":0.99969196},"labels":[],"label_agreement":null},{"id":"W2020503419","doi":"10.1503/cmaj.061513","title":"Supreme Court rules against drug patent \"evergreening\"","year":2006,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Supreme court; Law; Supreme Court Decisions; Drug industry; Generic drug; Head (geology); Law and economics; Operations research; Political science; Medicine; Drug; Economics; Engineering; Pharmacology; Engineering ethics","score_opus":0.02847752819179248,"score_gpt":0.2285559366361893,"score_spread":0.20007840844439684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020503419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.62712777,0.0019052443,0.00026290404,0.17931235,0.0027594122,0.00015620221,0.0007231109,0.00004179519,0.18771122],"genre_scores_gemma":[0.9591922,0.00055467075,0.00015070234,0.034512915,0.0031682856,0.0000058065525,0.00004570409,0.000029829534,0.0023398462],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981353,0.000036814374,0.00081841304,0.00020313077,0.00016441787,0.0006418778],"domain_scores_gemma":[0.9980958,0.000081545906,0.0003987669,0.00010561982,0.000087075394,0.0012311972],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0017846031,0.00013634984,0.0003077085,0.00025700912,0.00026803528,0.00019337496,0.00030511522,0.00024157552,0.005207357],"category_scores_gemma":[0.0003795216,0.00015832213,0.00016358744,0.0001232058,0.000035712455,0.00017806546,0.00002135312,0.0006797466,0.0024674793],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000034389004,0.000041422212,0.19930913,0.0000052298114,0.00008855227,0.000099619436,0.00009660661,0.00007957599,0.0000017867087,0.060223017,0.73524225,0.0048093726],"study_design_scores_gemma":[0.000665953,0.000007859675,0.03722842,0.00001206135,0.0000040442073,0.000027073718,0.000019993458,0.0032496129,0.000005187616,0.020197744,0.93837744,0.00020461694],"about_ca_topic_score_codex":0.0077175987,"about_ca_topic_score_gemma":0.017315315,"teacher_disagreement_score":0.33206448,"about_ca_system_score_codex":0.0013120318,"about_ca_system_score_gemma":0.00055358006,"threshold_uncertainty_score":0.9988901},"labels":[],"label_agreement":null},{"id":"W2021009463","doi":"10.3821/1913-701x(2008)141[21a:pntic]2.0.co;2","title":"Pharmacist named to immunization coalition","year":2008,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Immunization; Pharmacist; Medicine; Family medicine; Pharmacy; Immunology; Antibody","score_opus":0.10187058854414159,"score_gpt":0.273123690131257,"score_spread":0.17125310158711538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021009463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9589203,0.0021249931,0.0017059059,0.0016697781,0.0056961738,0.00071324717,0.0031129818,0.000075656426,0.025980992],"genre_scores_gemma":[0.9723926,0.007029092,0.00030698767,0.01747192,0.0012419135,0.000031776675,0.00008502577,0.00008810092,0.0013525789],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967422,0.00007591205,0.0011971792,0.0005623776,0.0001268707,0.0012954514],"domain_scores_gemma":[0.9954789,0.00007172203,0.000423038,0.00033646417,0.00027910428,0.00341072],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007512009,0.00042155237,0.0005914837,0.0007842926,0.001378192,0.00021881645,0.0008402563,0.00008917863,0.0030730045],"category_scores_gemma":[0.00024869206,0.0005582739,0.00020660624,0.0008641588,0.00018822632,0.0006136655,0.000070529655,0.0006696625,0.00072575576],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006400248,0.00047004994,0.036758464,0.00047941148,0.0013156999,0.06991154,0.010054816,0.017381445,0.0045631705,0.02514885,0.7908718,0.042404722],"study_design_scores_gemma":[0.0027279765,0.00004984656,0.00018802159,0.000011861598,0.00003513374,0.18277065,0.0000064851397,0.01279174,0.0017919348,0.001432337,0.79708034,0.0011136594],"about_ca_topic_score_codex":0.024021575,"about_ca_topic_score_gemma":0.016242864,"teacher_disagreement_score":0.11285911,"about_ca_system_score_codex":0.0034799238,"about_ca_system_score_gemma":0.0016614846,"threshold_uncertainty_score":0.99992186},"labels":[],"label_agreement":null},{"id":"W2021329838","doi":"10.3821/1913-701x(2008)141[13:pccbct]2.0.co;2","title":"Pharmacists counter Competition Bureau claim that generic drug rebates don't benefit consumers","year":2008,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Competition (biology); Over-the-counter; Business; Drug; Advertising; Medicine; Pharmacology; Medical prescription","score_opus":0.0923088144656868,"score_gpt":0.2633609550079636,"score_spread":0.1710521405422768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021329838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.960214,0.0071592163,0.00012805214,0.0011037622,0.005759307,0.00055361533,0.0041106837,0.00007573353,0.02089559],"genre_scores_gemma":[0.94857216,0.033667456,0.00014706845,0.0137299355,0.0011803977,0.000035812987,0.00017285583,0.00012952775,0.0023647605],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99559385,0.00008388731,0.0014051397,0.0008621956,0.0002074137,0.0018475071],"domain_scores_gemma":[0.9949531,0.00014062894,0.0007902798,0.0004372824,0.000291804,0.0033869008],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008335958,0.00070727983,0.0009525172,0.0008244208,0.0016229969,0.00034257097,0.0010919232,0.00013374824,0.0066727404],"category_scores_gemma":[0.000080519836,0.0008813939,0.0003931304,0.0006490255,0.0005317977,0.0008714675,0.00008950227,0.0011139085,0.000391641],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007292622,0.00059150334,0.11980286,0.00093934947,0.002963091,0.11553905,0.0084296055,0.007971835,0.0021608197,0.027909486,0.68467134,0.028291805],"study_design_scores_gemma":[0.0043870956,0.00003590529,0.00021143275,0.000023990604,0.00010165998,0.2470927,0.000014399808,0.01253876,0.00210457,0.0033848083,0.7283697,0.001734942],"about_ca_topic_score_codex":0.036610145,"about_ca_topic_score_gemma":0.03342699,"teacher_disagreement_score":0.13155364,"about_ca_system_score_codex":0.003909448,"about_ca_system_score_gemma":0.0014384994,"threshold_uncertainty_score":0.99991435},"labels":[],"label_agreement":null},{"id":"W2021619142","doi":"10.2190/y8ur-ywvr-budp-cdr0","title":"Intellectual Property Rights and the Canadian Pharmaceutical Marketplace: Where Do We Go from Here?","year":2005,"lang":"en","type":"article","venue":"International Journal of Health Services","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University","funders":"","keywords":"Intellectual property; Order (exchange); Access to medicines; Argument (complex analysis); Pharmaceutical industry; Investment (military); International trade; Patent Act; Law and economics; TRIPS architecture; Business; Economics; Political science; Law; Patent law; Medicine; Finance; Pharmacology","score_opus":0.03862274916873651,"score_gpt":0.31634609149799225,"score_spread":0.2777233423292558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021619142","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2843043,0.12110017,0.00009928727,0.56775427,0.0025045236,0.00036957886,0.0004678265,0.000015488868,0.023384593],"genre_scores_gemma":[0.9730812,0.011036399,0.00032152853,0.014177457,0.0010568799,0.0000035039902,0.0000036192423,0.000013408185,0.00030604878],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99840647,0.00007395822,0.00097308087,0.00018107073,0.0000871638,0.00027826795],"domain_scores_gemma":[0.9986061,0.00027417578,0.0005508374,0.00010626309,0.000106307416,0.00035635656],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012770384,0.00013431977,0.00036692704,0.0002145475,0.00018281957,0.00026402625,0.0006013913,0.00007192503,0.0017659618],"category_scores_gemma":[0.000028885273,0.000087659115,0.00009944834,0.00006228761,0.00010829565,0.000331738,0.00007027198,0.00037608715,0.00031132516],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004700804,0.00074013165,0.04479448,0.00045014004,0.003712271,0.00010521142,0.04503382,0.00080496276,0.000013020936,0.39190218,0.12028871,0.3874543],"study_design_scores_gemma":[0.0019126898,0.000027091983,0.00096395036,0.0000952119,0.000006534551,0.000056556855,0.000109683126,0.012731518,0.000009049031,0.030311404,0.9536676,0.00010872103],"about_ca_topic_score_codex":0.06597639,"about_ca_topic_score_gemma":0.09768856,"teacher_disagreement_score":0.8333789,"about_ca_system_score_codex":0.0004010248,"about_ca_system_score_gemma":0.00020222443,"threshold_uncertainty_score":0.9991466},"labels":[],"label_agreement":null},{"id":"W2021817527","doi":"10.1001/jama.300.12.1453","title":"Risks and Benefits of Importing Prescription Medications From Lower-Income Countries","year":2008,"lang":"en","type":"article","venue":"JAMA","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Family medicine; Otorhinolaryngology; Psychiatry","score_opus":0.082842806099664,"score_gpt":0.29137975669927507,"score_spread":0.20853695059961108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021817527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984309,0.0033973122,0.000111503694,0.002358012,0.00019915047,0.00007689956,0.0006459723,0.000015600877,0.008886559],"genre_scores_gemma":[0.99537873,0.003284561,0.00026258104,0.0007564182,0.00020310991,0.000008232152,0.000013332415,0.000009869309,0.000083166844],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991378,0.0000053132053,0.00050885795,0.00018598518,0.000020941774,0.00014106311],"domain_scores_gemma":[0.99931633,0.00007870226,0.00032712627,0.0001670023,0.000022955895,0.000087890076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020461646,0.000075137374,0.00022990759,0.00008504685,0.0000854391,0.00002367438,0.00010308116,0.00008040376,0.00031531224],"category_scores_gemma":[0.00011546946,0.00008865141,0.000042662337,0.00006248246,0.00010337174,0.00020876637,0.00004883508,0.000096705946,0.000102949714],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028405457,0.000044328244,0.82765955,0.000030236923,0.000083862906,0.000001702628,0.0007641837,0.000083152394,0.000025993284,0.16685182,0.0012301093,0.0031966693],"study_design_scores_gemma":[0.00064808514,0.000027212687,0.91860926,0.000017673769,0.000008483951,0.0000038768653,0.000008769654,0.003293766,0.00029262135,0.01962592,0.05732908,0.00013525235],"about_ca_topic_score_codex":0.00096523535,"about_ca_topic_score_gemma":0.000025791911,"teacher_disagreement_score":0.14722589,"about_ca_system_score_codex":0.00002782904,"about_ca_system_score_gemma":0.000016847818,"threshold_uncertainty_score":0.36150995},"labels":[],"label_agreement":null},{"id":"W2022022436","doi":"10.1007/s11673-013-9494-z","title":"Drugs, Money, and Power: The Canadian Drug Shortage","year":2013,"lang":"en","type":"article","venue":"Journal of Bioethical Inquiry","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Memorial University of Newfoundland","funders":"Sandoz Canada; Australian Government","keywords":"Economic shortage; Scarcity; Medical law; Business; Obligation; Health care; Order (exchange); Public relations; Medicine; Law; Government (linguistics); Economics; Political science; Finance; Market economy","score_opus":0.07767136248439625,"score_gpt":0.3065182377083792,"score_spread":0.22884687522398295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022022436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8045196,0.0045009227,0.00007227355,0.16337945,0.0012595888,0.00018265242,0.000048045127,0.000007654432,0.026029792],"genre_scores_gemma":[0.9836505,0.000730845,0.00015919145,0.014833905,0.00041628524,0.0000030845265,7.5866666e-7,0.000014502802,0.00019094186],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987224,0.000031893196,0.0007261624,0.00015093548,0.00004473047,0.0003238963],"domain_scores_gemma":[0.9987182,0.00017062077,0.00032588077,0.000182476,0.00006203364,0.00054077007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012613115,0.000121627534,0.00032612812,0.00020285197,0.00017976385,0.00024549238,0.00033132412,0.00016710402,0.00090259383],"category_scores_gemma":[0.00016315182,0.00009382272,0.0001330061,0.00011090785,0.000436351,0.00026491724,0.00006161791,0.00083543017,0.00042110533],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002624047,0.00009589018,0.019497002,0.00002730117,0.0002518696,0.000025485442,0.008500389,0.000032304943,0.00006564415,0.78112644,0.18461488,0.0057365485],"study_design_scores_gemma":[0.00077319104,0.00013724848,0.04093742,0.000025611822,0.000019892695,0.00008836883,0.0008904225,0.0018650951,0.00012032265,0.2528763,0.7018533,0.00041283676],"about_ca_topic_score_codex":0.01925343,"about_ca_topic_score_gemma":0.0035374747,"teacher_disagreement_score":0.52825016,"about_ca_system_score_codex":0.000119172146,"about_ca_system_score_gemma":0.00010070637,"threshold_uncertainty_score":0.9882769},"labels":[],"label_agreement":null},{"id":"W2022778498","doi":"10.3386/w16431","title":"Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century After the 1984 Waxman-Hatch Legislation","year":2010,"lang":"en","type":"report","venue":"National Bureau of Economic Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Competition (biology); Legislation; Loyalty; Business; Brand loyalty; Industrial organization; Advertising; Marketing; Commerce; Economics","score_opus":0.3011440009757697,"score_gpt":0.4848980425436471,"score_spread":0.1837540415678774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022778498","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20341295,0.016445812,0.000013163637,0.02286874,0.0013638652,0.0021664954,0.0008490604,0.000012061407,0.7528679],"genre_scores_gemma":[0.9775477,0.019779444,0.000024171999,0.0007262548,0.0009377385,0.00027550594,0.00019433226,0.000035233163,0.0004796348],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968445,0.00022332031,0.0014060987,0.0006540833,0.00029334764,0.00057866226],"domain_scores_gemma":[0.9975347,0.0013084714,0.00046648146,0.00039789625,0.0001860301,0.0001064231],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0099187,0.00026682147,0.00061072654,0.00094649073,0.00011908813,0.00021497945,0.0006347695,0.00044776555,0.000989624],"category_scores_gemma":[0.00037342653,0.00022694677,0.00015278734,0.0002989971,0.00040510984,0.0002815811,0.00017869737,0.0018154326,0.00023327458],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049611455,0.0006559911,0.062765844,0.00053295447,0.00024851903,0.000018257128,0.0018558113,0.00060847495,0.00007626064,0.89147264,0.036429387,0.004839769],"study_design_scores_gemma":[0.0016453741,0.000062563086,0.06268559,0.00008095067,0.000011731577,0.000040491694,0.000086379725,0.007489332,0.000022146378,0.33056492,0.5968689,0.0004416541],"about_ca_topic_score_codex":0.0014924725,"about_ca_topic_score_gemma":0.0010178691,"teacher_disagreement_score":0.77413476,"about_ca_system_score_codex":0.0007729638,"about_ca_system_score_gemma":0.00057701016,"threshold_uncertainty_score":0.9999236},"labels":[],"label_agreement":null},{"id":"W2022953054","doi":"10.1177/1078155212442562","title":"Using expired supply in times of drug shortage","year":2012,"lang":"en","type":"letter","venue":"Journal of Oncology Pharmacy Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Economic shortage; Drug; Intensive care medicine; Pharmacology; Emergency medicine","score_opus":0.18364378929511835,"score_gpt":0.4199983429826919,"score_spread":0.23635455368757355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022953054","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024723716,0.017779492,0.00006278824,0.84068304,0.0052731116,0.00043967058,0.00038096088,0.0000101751675,0.11064702],"genre_scores_gemma":[0.24278189,0.010089815,0.006142996,0.7297675,0.00995301,0.0000111982645,0.000023910523,0.00014933986,0.0010803584],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958962,0.00031185668,0.0027787464,0.0002973127,0.00009325905,0.0006225814],"domain_scores_gemma":[0.9918785,0.001618954,0.0058795637,0.00027841088,0.00015931753,0.00018521726],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0035846815,0.00033880095,0.0016502229,0.0010026532,0.00004543853,0.000043807486,0.0006803033,0.00044812832,0.003421731],"category_scores_gemma":[0.000703357,0.00038408182,0.0004055249,0.0002507708,0.00014675241,0.0014420581,0.00013809893,0.0035979806,0.00016743499],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005084111,0.0007765817,0.0083021615,0.00021178571,0.00085597805,0.0010725883,0.001058041,0.00020791405,0.0001245335,0.002575331,0.9821721,0.0021345853],"study_design_scores_gemma":[0.0025714592,0.000091022725,0.00010292419,0.00004557577,0.00022695267,0.00067961373,0.00005943192,0.0008699605,0.0001961965,0.001991636,0.9928339,0.00033131635],"about_ca_topic_score_codex":0.00030114903,"about_ca_topic_score_gemma":0.0000052160685,"teacher_disagreement_score":0.21805818,"about_ca_system_score_codex":0.0007615424,"about_ca_system_score_gemma":0.00051172305,"threshold_uncertainty_score":0.9998611},"labels":[],"label_agreement":null},{"id":"W2023356500","doi":"10.1007/s40258-013-0052-y","title":"Private Expenditures on Brand Name Prescription Drugs after Generic Entry","year":2013,"lang":"en","type":"article","venue":"Applied Health Economics and Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of British Columbia; St. Michael's Hospital; University of Toronto","funders":"","keywords":"Generic drug; Brand names; Medical prescription; Drug; Business; Prescription drug; Medicine; Pharmacology; Marketing","score_opus":0.055373062857518564,"score_gpt":0.32074227162697666,"score_spread":0.2653692087694581,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023356500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6675749,0.01092859,0.00016610613,0.25203776,0.0009691507,0.0032610362,0.0007473595,0.00015166219,0.06416344],"genre_scores_gemma":[0.8085479,0.032891378,0.0004081676,0.15606168,0.0011174455,0.0005107785,0.000055106833,0.00007649682,0.00033105072],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99629354,0.000029658278,0.0015236462,0.0008634065,0.000031730688,0.0012579848],"domain_scores_gemma":[0.9975153,0.000058331705,0.0008260749,0.0005239076,0.0000098923065,0.001066459],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007603132,0.00040823704,0.0009531698,0.00049328536,0.00039963395,0.00023989016,0.00026208017,0.00019698,0.0005807049],"category_scores_gemma":[0.000008830857,0.00047831258,0.00011816367,0.00009521096,0.00011433152,0.00025854164,0.0001396125,0.00039176436,0.0020655775],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056171913,0.000115417686,0.0011334232,0.00024330216,0.000043427972,2.1735211e-7,0.0012387098,0.00010148523,0.0000017974905,0.9513673,0.017510502,0.028188223],"study_design_scores_gemma":[0.001818216,0.00021349678,0.047950733,0.000025422589,0.0000022665063,0.0000044876306,0.000065332075,0.0023263625,0.000014713322,0.15912649,0.7878993,0.0005531795],"about_ca_topic_score_codex":0.0061992006,"about_ca_topic_score_gemma":0.00010329833,"teacher_disagreement_score":0.79224086,"about_ca_system_score_codex":0.000766734,"about_ca_system_score_gemma":0.00032439077,"threshold_uncertainty_score":0.9997668},"labels":[],"label_agreement":null},{"id":"W2023573506","doi":"10.1016/j.jval.2011.08.1043","title":"PRM12 An Application of a Proposed Framework for Formulary Listing in Low-income Countries: Case of Côte d'Ivoire","year":2011,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Formulary; Reimbursement; Listing (finance); Actuarial science; Medicine; Prior authorization; Family medicine; Business; Health care; Finance; Economics; Pharmacology; Economic growth","score_opus":0.12049046560661278,"score_gpt":0.3506844670838989,"score_spread":0.2301940014772861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023573506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98617685,0.00069171103,0.010589999,0.0004262699,0.00010074739,0.0010709383,0.00036254196,0.000011088031,0.0005698587],"genre_scores_gemma":[0.9880286,0.00018289647,0.011278628,0.0003705201,0.00004862391,0.000059348768,0.000008038801,0.000020046473,0.0000033195483],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9981994,0.000028423054,0.0011931208,0.0002606144,0.000016659113,0.00030175614],"domain_scores_gemma":[0.99873745,0.00018346902,0.0006684739,0.00027940812,0.000026323109,0.000104848616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014717553,0.00010200486,0.00045814275,0.00027467034,0.000039444618,0.000006996989,0.00015694194,0.00011494917,0.000021404412],"category_scores_gemma":[0.00016969735,0.00012468298,0.000054473112,0.00022613644,0.000051535542,0.00015087948,0.00002877089,0.000152491,0.000006425876],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009881532,0.00022237487,0.07924147,0.0015907347,0.000008912975,0.0000040449167,0.0037843173,0.0009100549,0.000002905717,0.9126045,0.0000030871681,0.0015287525],"study_design_scores_gemma":[0.0013085353,0.00042420474,0.014130431,0.00036285078,0.0000030889003,0.00001568274,0.00016331555,0.41168517,0.00031317945,0.56981677,0.0015092264,0.00026754453],"about_ca_topic_score_codex":0.012435428,"about_ca_topic_score_gemma":0.00030688598,"teacher_disagreement_score":0.41077513,"about_ca_system_score_codex":0.00017694007,"about_ca_system_score_gemma":0.00012358584,"threshold_uncertainty_score":0.99414086},"labels":[],"label_agreement":null},{"id":"W2023657343","doi":"10.1186/1472-698x-10-1","title":"Framing access to medicines in developing countries: an analysis of media coverage of Canada's Access to Medicines Regime","year":2010,"lang":"en","type":"article","venue":"BMC International Health and Human Rights","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Framing (construction); Newspaper; Legislation; Stakeholder; Civil society; Public relations; Government (linguistics); Intellectual property; Developing country; Political science; News media; Public administration; Business; Economic growth; Law; Economics; Engineering; Politics","score_opus":0.0704420946088392,"score_gpt":0.381917748642545,"score_spread":0.3114756540337058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023657343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98175776,0.00008486274,0.00057300646,0.013976916,0.0005894084,0.00019767883,0.00029552475,0.0000047346566,0.0025201368],"genre_scores_gemma":[0.9849937,0.00007622765,0.00021823199,0.014374797,0.00021169594,0.0000125566885,0.00006783823,0.000007711395,0.00003724375],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99849427,0.0000122995525,0.0008881996,0.0002855885,0.00008757286,0.00023205999],"domain_scores_gemma":[0.9988487,0.00017419606,0.00036378548,0.00016453977,0.00009494192,0.00035384687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052989624,0.00011514311,0.0005403599,0.00093845656,0.00009676629,0.00005000376,0.0004926231,0.000051990333,0.00030656936],"category_scores_gemma":[0.000107565385,0.00011237851,0.000033542365,0.00029225295,0.00004969465,0.00024572975,0.000094807736,0.00011308451,0.0000017437304],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006719888,0.000043019478,0.47134578,0.00013785795,0.00010647897,0.0000019082865,0.0015086596,0.0002712276,0.000003809155,0.52393997,0.0023982732,0.00017580608],"study_design_scores_gemma":[0.0005802728,0.000054685926,0.8376316,0.00007827664,0.000012051164,9.113072e-7,0.000026712678,0.003209674,0.00006451726,0.017793631,0.14035486,0.000192847],"about_ca_topic_score_codex":0.15401362,"about_ca_topic_score_gemma":0.92360336,"teacher_disagreement_score":0.7695897,"about_ca_system_score_codex":0.0001571745,"about_ca_system_score_gemma":0.00034756956,"threshold_uncertainty_score":0.8516199},"labels":[],"label_agreement":null},{"id":"W2024103874","doi":"10.1111/j.1541-1338.2008.00378.x","title":"The Power of Pills: Social, Ethical and Legal Issues in Drug Development, Marketing and Pricing – By Jillian Clare Cohen, Patricia Illingworth, and Udo Schuklenk","year":2009,"lang":"en","type":"article","venue":"Review of Policy Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pill; Drug pricing; Politics; Political science; Power (physics); Ethical issues; Medicine; Business; Law; Pharmacology; Engineering; Engineering ethics","score_opus":0.07567575780615235,"score_gpt":0.41578370577721196,"score_spread":0.3401079479710596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024103874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4660604,0.4563602,0.000003867132,0.066528134,0.000025384601,0.00055524777,0.00008181706,0.0000070759356,0.010377887],"genre_scores_gemma":[0.5808758,0.41717398,0.00008937261,0.0016435321,0.000058773203,0.0000072054127,0.0000026816529,0.00001082236,0.00013779696],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980128,0.00022689474,0.00089988165,0.00030715155,0.00009243024,0.00046085048],"domain_scores_gemma":[0.9986941,0.000700998,0.00025205617,0.00015908682,0.000078184254,0.00011554129],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008091331,0.00013606079,0.0005884772,0.00026863668,0.00023931141,0.00008126003,0.00020404655,0.00012652921,0.000020664755],"category_scores_gemma":[0.0016817115,0.00012001057,0.00004677726,0.0004791879,0.00031959935,0.000100116275,0.00016565944,0.0006690957,0.0000047574913],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015490256,0.00024112119,0.03774574,0.010573626,0.00015929792,0.000007851784,0.004316654,7.816677e-7,0.00023696534,0.5660472,0.043714244,0.33680165],"study_design_scores_gemma":[0.0005389727,0.000067206536,0.03399453,0.0015188296,0.000005374201,0.0000051493425,0.00017816137,0.00014336348,0.00012864807,0.009293245,0.9538708,0.0002557455],"about_ca_topic_score_codex":0.00054217956,"about_ca_topic_score_gemma":0.000044283755,"teacher_disagreement_score":0.91015655,"about_ca_system_score_codex":0.00007752476,"about_ca_system_score_gemma":0.00011032778,"threshold_uncertainty_score":0.4893889},"labels":[],"label_agreement":null},{"id":"W2024556879","doi":"10.1086/467458","title":"Does Regulation Drive Out Competition in Pharmaceutical Markets?","year":2000,"lang":"en","type":"article","venue":"The Journal of Law and Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":242,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Competitor analysis; Competition (biology); Drug prices; Industrial organization; Business; Economics; Pharmacy; Public economics; Marketing","score_opus":0.0416971653487621,"score_gpt":0.2816545989510505,"score_spread":0.23995743360228838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024556879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9151264,0.00061892124,0.000073484094,0.006145249,0.00036403368,0.00009399013,0.00004177985,0.000004239432,0.07753192],"genre_scores_gemma":[0.9880691,0.007967958,0.00008953652,0.0032414957,0.00027287126,0.0000012202174,0.0000020809225,0.000012582381,0.00034312875],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988611,0.000035925572,0.0007715173,0.000118415825,0.000013029457,0.00020004364],"domain_scores_gemma":[0.9993306,0.00012788252,0.0002940921,0.00012653231,0.000012463416,0.00010843715],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001132945,0.00010854124,0.0003205888,0.00008617934,0.000079221485,0.00006314156,0.00017290768,0.00006650356,0.0014567737],"category_scores_gemma":[0.000011653152,0.00007763297,0.00007657811,0.000031303764,0.00013918705,0.0003529039,0.000025584986,0.00023274659,0.00014148018],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035091996,0.000078192235,0.0034502598,0.00001597701,0.00006286945,0.0000021839073,0.0008976858,0.00090228935,0.000027571694,0.98796916,0.00021491217,0.006027994],"study_design_scores_gemma":[0.001795367,0.000069355876,0.013383344,0.000023556591,0.00002211495,0.000055045424,0.000058988928,0.015534028,0.00027992466,0.34106094,0.62747675,0.00024055685],"about_ca_topic_score_codex":0.000042559648,"about_ca_topic_score_gemma":0.00008641439,"teacher_disagreement_score":0.6469082,"about_ca_system_score_codex":0.000091658134,"about_ca_system_score_gemma":0.000013859836,"threshold_uncertainty_score":0.99945605},"labels":[],"label_agreement":null},{"id":"W2025080629","doi":"10.1503/cmaj.045021","title":"Drug withdrawals from the Canadian market for safety reasons, 1963-2004","year":2005,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University Health Network","funders":"","keywords":"Postmarketing surveillance; Drug; Business; Risk analysis (engineering); Medicine; Pharmacology; Adverse effect","score_opus":0.015897718768807714,"score_gpt":0.2403460625558178,"score_spread":0.2244483437870101,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025080629","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010659593,0.0024857286,0.0001658046,0.8455706,0.0017755395,0.00034684973,0.004736882,0.00001557932,0.13424337],"genre_scores_gemma":[0.6929862,0.0012734631,0.00057387684,0.28839695,0.010237926,0.00003405258,0.00010357019,0.00005953464,0.006334407],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99802583,0.000062680534,0.00075873773,0.00023076619,0.00013483335,0.0007871309],"domain_scores_gemma":[0.9962988,0.00046647424,0.00036723085,0.00017352795,0.00010087529,0.0025931294],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0037090422,0.00014693457,0.00031724884,0.0001684504,0.0008332796,0.00030910148,0.00050984044,0.00030704544,0.013621438],"category_scores_gemma":[0.0020449078,0.00014134869,0.00017929346,0.00014445744,0.000049017744,0.00018595447,0.000014088694,0.0007620303,0.0009213667],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000074328614,0.000008943131,0.036521684,0.0000013414743,0.00011898435,0.0000073450587,0.00023650385,0.000017676526,5.7614354e-8,0.020035531,0.93098015,0.012064339],"study_design_scores_gemma":[0.00075251673,0.000006725094,0.023030248,0.000012868241,0.0000093365215,0.000015567268,0.000043026255,0.0029658102,9.495085e-7,0.009509838,0.96347445,0.00017863493],"about_ca_topic_score_codex":0.3817088,"about_ca_topic_score_gemma":0.9719173,"teacher_disagreement_score":0.6823266,"about_ca_system_score_codex":0.003994175,"about_ca_system_score_gemma":0.003244769,"threshold_uncertainty_score":0.99985653},"labels":[],"label_agreement":null},{"id":"W2025798541","doi":"10.1016/j.healthpol.2013.05.022","title":"Canadian policy makers’ views on pharmaceutical reimbursement contracts involving confidential discounts from drug manufacturers","year":2013,"lang":"en","type":"article","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Reimbursement; Confidentiality; Business; Drug; Law and economics; Internet privacy; Law; Economics; Political science; Medicine; Pharmacology; Health care; Computer science","score_opus":0.07997151151293332,"score_gpt":0.3627774933127338,"score_spread":0.2828059817998005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025798541","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.33196858,0.003480479,0.000048607963,0.56103504,0.0018361468,0.0022927413,0.0027906701,0.00010506764,0.09644266],"genre_scores_gemma":[0.78976196,0.0018476838,0.00007408598,0.20430951,0.0021183346,0.00011001721,0.00011485403,0.000065656895,0.0015979194],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958109,0.00009768154,0.0013784702,0.0007934805,0.00009847916,0.001820948],"domain_scores_gemma":[0.99624693,0.00016634882,0.0005253567,0.00061997556,0.000035447763,0.0024059275],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0006568162,0.00045123877,0.0008538744,0.0009945217,0.00042206902,0.0003513927,0.000528488,0.00018856241,0.004498931],"category_scores_gemma":[0.00022000767,0.00051035616,0.0002161807,0.00030955215,0.00013250626,0.00037630234,0.0000960604,0.0006542301,0.011244818],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045946654,0.00021332002,0.003878991,0.00009418355,0.00021199198,0.000011932056,0.0030670082,0.000105659834,0.000033897526,0.77711546,0.20216434,0.013057253],"study_design_scores_gemma":[0.001787321,0.000065579894,0.018149212,0.000050398103,0.000007750737,0.0000047564276,0.00011671633,0.0015704263,0.0001374604,0.067839146,0.9096735,0.00059774186],"about_ca_topic_score_codex":0.8781688,"about_ca_topic_score_gemma":0.11275902,"teacher_disagreement_score":0.7654098,"about_ca_system_score_codex":0.0031533977,"about_ca_system_score_gemma":0.0013746734,"threshold_uncertainty_score":0.9997348},"labels":[],"label_agreement":null},{"id":"W2026426103","doi":"10.3821/145.6.cpj251","title":"New Pharmacy — Where Healthcare Interfaces Innovation","year":2012,"lang":"fr","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy; Health care; Curriculum; Capstone; Equity (law); Competition (biology); Capstone course; Strategic management; Entrepreneurship; Business; Management; Medical education; Public relations; Marketing; Medicine; Nursing; Sociology; Political science; Computer science; Pedagogy; Economics; Finance","score_opus":0.10685401501462963,"score_gpt":0.31550996603366466,"score_spread":0.20865595101903503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026426103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5090053,0.3442427,0.0013031249,0.039947607,0.07578895,0.0012230462,0.009166094,0.000079491314,0.019243674],"genre_scores_gemma":[0.8605847,0.09198263,0.00065262005,0.020955758,0.010164917,0.000016671804,0.000080980135,0.00017377782,0.01538796],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9929779,0.0002055671,0.0024159781,0.0007423478,0.00019301602,0.0034651738],"domain_scores_gemma":[0.9911833,0.0001514908,0.0013122435,0.00044671152,0.00048480995,0.0064214543],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0019157563,0.0008552562,0.0010649867,0.0013110396,0.001203823,0.0006990453,0.0012313545,0.00023205594,0.016872559],"category_scores_gemma":[0.0002716416,0.0012232146,0.00030773916,0.0018957814,0.0003020765,0.0023793338,0.00014302091,0.00213768,0.00080202083],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000117479336,0.0001358484,0.025551632,0.0008251487,0.00068378146,0.0037389162,0.003270488,0.00050128496,0.00018720223,0.023326667,0.59332937,0.34833217],"study_design_scores_gemma":[0.0024732973,0.000039996397,0.00006147994,0.00007358708,0.00010927266,0.09647548,0.000018270854,0.0030317581,0.0011239513,0.0015521249,0.893836,0.0012047302],"about_ca_topic_score_codex":0.23024984,"about_ca_topic_score_gemma":0.16697916,"teacher_disagreement_score":0.35157937,"about_ca_system_score_codex":0.00934623,"about_ca_system_score_gemma":0.0066147423,"threshold_uncertainty_score":0.999976},"labels":[],"label_agreement":null},{"id":"W202721108","doi":"10.3833/pdr.v2011i8.1518","title":"Bayer Licenses Regional Rights to Trius Therapeutics’ Phase III Antibiotic for Serious Gram-Positive Infections","year":2011,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"China; Latin Americans; Medicine; International trade; Political science; Business; Law","score_opus":0.20075728967151268,"score_gpt":0.38651749375098643,"score_spread":0.18576020407947375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W202721108","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13221096,0.60074824,0.015413489,0.045798536,0.0048426082,0.020525659,0.006681586,0.0006921367,0.17308679],"genre_scores_gemma":[0.7765279,0.1392045,0.0011192099,0.08106887,0.00057288195,0.00042156578,0.00009892743,0.000095372096,0.00089079066],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99791235,0.000039588624,0.0009631228,0.0005301001,0.00003269618,0.00052214117],"domain_scores_gemma":[0.9987439,0.0001286626,0.0003685088,0.00033356302,0.00007806227,0.0003473219],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00054371654,0.00029458865,0.0008335509,0.0002003308,0.00022472888,0.000049155668,0.00030380543,0.000070519105,0.0011350551],"category_scores_gemma":[0.000038668906,0.0003009978,0.00037274428,0.0003244164,0.00006486375,0.0002267457,0.000053272353,0.00018768213,0.0013885911],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079316803,0.0053813867,0.0011047038,0.003678282,0.0023312415,0.00003615201,0.0026855583,0.000015715228,0.0006814833,0.7699059,0.121351786,0.09203458],"study_design_scores_gemma":[0.002414549,0.0002743804,0.00025649587,0.00029012884,0.00014219612,0.000031915646,0.0000027524557,0.0002660568,0.001192837,0.013946181,0.9807003,0.00048218045],"about_ca_topic_score_codex":0.00019283971,"about_ca_topic_score_gemma":0.000015395704,"teacher_disagreement_score":0.85934854,"about_ca_system_score_codex":0.00010169739,"about_ca_system_score_gemma":0.00003599252,"threshold_uncertainty_score":0.9999442},"labels":[],"label_agreement":null},{"id":"W2027403669","doi":"10.1017/s0266462312000438","title":"HEALTH TECHNOLOGY REASSESSMENT OF NON-DRUG TECHNOLOGIES: CURRENT PRACTICES","year":2012,"lang":"en","type":"review","venue":"International Journal of Technology Assessment in Health Care","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Current (fluid); Drug; Health technology; Medicine; Intensive care medicine; Political science; Pharmacology; Engineering; Health care","score_opus":0.15253103293523793,"score_gpt":0.5156082285207999,"score_spread":0.36307719558556195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027403669","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009038108,0.95612025,0.00027015718,0.03856167,0.0031579412,0.00073673757,0.00047347927,0.0000629967,0.0005263681],"genre_scores_gemma":[0.02179857,0.9735973,0.0039687827,0.00020678689,0.0002122906,0.00009321396,0.000057246267,0.000056201097,0.000009638333],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9933339,0.000093225455,0.0051349085,0.0005307701,0.00018978615,0.0007174157],"domain_scores_gemma":[0.98013544,0.00020071816,0.018569233,0.0006039068,0.00034169902,0.00014900866],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002269324,0.0004815911,0.0034437194,0.006600591,0.00007588228,0.000043606684,0.0024971068,0.00066712016,0.00006045697],"category_scores_gemma":[0.00036372922,0.00048663223,0.00050566474,0.0010469694,0.0002549828,0.0003440879,0.0006348176,0.0029927809,0.000036482987],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000087447825,0.00038702512,0.0030691242,0.005536231,0.00033632663,0.000012546112,0.00010246111,0.0000033773222,4.8951804e-8,0.09271844,0.0006337176,0.89719194],"study_design_scores_gemma":[0.00059860933,0.00024983633,0.0001440148,0.006555974,0.000039950155,0.00018469116,0.0009702371,0.000016045036,0.0000015011045,0.0077570034,0.983175,0.00030712996],"about_ca_topic_score_codex":0.00011929245,"about_ca_topic_score_gemma":0.00004342156,"teacher_disagreement_score":0.98254126,"about_ca_system_score_codex":0.0039880015,"about_ca_system_score_gemma":0.0024153758,"threshold_uncertainty_score":0.9998355},"labels":[],"label_agreement":null},{"id":"W2029406121","doi":"10.1136/bmj.328.7442.728-d","title":"Canada's plan to sell generic drugs to developing countries is threatened","year":2004,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Parliament; Prime minister; Action plan; Human immunodeficiency virus (HIV); Malaria; Action (physics); Developing country; Business; Advertising; Political science; Medicine; Law; Economic growth; Family medicine; Economics; Politics; Management","score_opus":0.06543473972507491,"score_gpt":0.28533471291931906,"score_spread":0.21989997319424415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029406121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.62374955,0.0004718225,0.0020935077,0.31557485,0.0009514653,0.0006747752,0.0011677943,0.000049539503,0.055266652],"genre_scores_gemma":[0.8147674,0.00019066266,0.0035956067,0.17965609,0.00038833113,0.00006369629,0.000013802813,0.0000371291,0.0012872778],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987499,0.000003474995,0.00046518687,0.00033515733,0.000032316042,0.00041398092],"domain_scores_gemma":[0.99932635,0.00002221896,0.00009695176,0.00024326544,0.000022898883,0.0002883191],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021464853,0.00015031353,0.00029599515,0.00012745924,0.000102409685,0.000076144985,0.0002444591,0.000052683747,0.00024529794],"category_scores_gemma":[0.000031970696,0.00018117552,0.000042967073,0.00020767134,0.000013383461,0.00006558453,0.00008508256,0.00006631732,0.0018487417],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000062360705,0.000031274667,0.008444468,0.00006234082,0.00013037144,0.000021398326,0.0024856497,0.0043604453,0.000021102767,0.6362545,0.34678543,0.0013406301],"study_design_scores_gemma":[0.00034701382,0.000020079837,0.0057399767,0.000012542457,0.0000024145443,0.000003582955,0.000021152413,0.00011639846,0.0010824632,0.009863086,0.982459,0.0003322744],"about_ca_topic_score_codex":0.20950083,"about_ca_topic_score_gemma":0.07508464,"teacher_disagreement_score":0.6356736,"about_ca_system_score_codex":0.00061747455,"about_ca_system_score_gemma":0.00048435185,"threshold_uncertainty_score":0.9989284},"labels":[],"label_agreement":null},{"id":"W2030886922","doi":"10.1517/14656566.3.9.1235","title":"The pharmacoeconomic impact of generics: an evolutionary tale","year":2002,"lang":"en","type":"editorial","venue":"Expert Opinion on Pharmacotherapy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Pride; Human immunodeficiency virus (HIV); Medicine; Position (finance); Law and economics; Economics; Law; Political science; Virology; Finance","score_opus":0.06265118156813454,"score_gpt":0.38548996348098574,"score_spread":0.3228387819128512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030886922","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010511117,0.08980655,0.00007071862,0.0017195819,0.8838996,0.0008522562,0.005499254,0.00012839753,0.016972512],"genre_scores_gemma":[0.002136347,0.42247272,0.00012619265,0.0019160649,0.5713834,0.0002174431,0.0004994324,0.00025847377,0.0009898905],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99643594,0.00011714589,0.0015506047,0.00096761034,0.00014474659,0.0007839629],"domain_scores_gemma":[0.9966907,0.00062915584,0.0012818078,0.00089571887,0.00009659889,0.00040605143],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0007083825,0.0007077685,0.001042517,0.00038934135,0.00036003362,0.00016903593,0.0013636911,0.00055913697,0.0047884183],"category_scores_gemma":[0.00006884338,0.0006344796,0.0008709006,0.00020423374,0.00026744872,0.00036917988,0.000085117455,0.0009459979,0.0010394057],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032180408,0.00039889003,0.0000514546,0.000015979962,0.0004326337,0.0000011951063,0.00022206214,0.00035216942,0.00019746553,0.0018781235,0.9871032,0.009025022],"study_design_scores_gemma":[0.0022493831,0.00045428783,0.00003241347,0.00002041798,0.0000035768653,0.0000018192835,0.0000067793376,0.016587658,0.0002144713,0.0021415362,0.9775928,0.00069485826],"about_ca_topic_score_codex":0.0003416175,"about_ca_topic_score_gemma":0.000001722034,"teacher_disagreement_score":0.33266616,"about_ca_system_score_codex":0.0008303962,"about_ca_system_score_gemma":0.00021436972,"threshold_uncertainty_score":0.9997384},"labels":[],"label_agreement":null},{"id":"W2030895155","doi":"10.1016/j.jval.2011.02.177","title":"PHP108 THE CASE OF RARE DISEASE DRUGS BEFORE AND AFTER THE INTRODUCTION OF PRICING BODIES: LESSONS LEARNED FROM BRAZIL AND CANADA, IMPLICATIONS FOR THE UNITED STATES","year":2011,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Context (archaeology); Drug prices; Purchasing; Natalizumab; Drug pricing; Disease; Economics; Business; Public economics; Actuarial science; Medicine; Marketing; Pathology","score_opus":0.10565085449068398,"score_gpt":0.323450803452887,"score_spread":0.21779994896220303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030895155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88452893,0.002385401,0.000094530544,0.110643014,0.00006362881,0.00035973312,0.0018971384,0.0000022316676,0.000025395391],"genre_scores_gemma":[0.99563605,0.0024375166,0.000049670343,0.0017129371,0.00006608604,0.000054251504,0.000021878295,0.000008466724,0.000013136855],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9992639,0.000035792662,0.00038240437,0.00015993447,0.000009526869,0.0001484583],"domain_scores_gemma":[0.9990297,0.00039678093,0.00023575652,0.00024819584,0.000021258698,0.00006832571],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052046584,0.000066857385,0.00016197037,0.00005771166,0.0001630171,0.000012823586,0.000096522606,0.00001845427,0.000014583888],"category_scores_gemma":[0.000106159736,0.000043742428,0.000023721817,0.00008561332,0.00012760867,0.00004262966,0.00004174984,0.00009200095,2.4977638e-7],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049832615,0.00016674832,0.27937484,0.0006426921,0.00022683768,0.0000028397576,0.061705656,0.0043697436,0.0000029561056,0.61956424,0.0046178834,0.028827272],"study_design_scores_gemma":[0.00079600967,0.00007846821,0.5863044,0.000034387136,0.0000343643,0.000009131501,0.003694988,0.0859485,0.000017163738,0.2798359,0.043081544,0.00016509109],"about_ca_topic_score_codex":0.7582309,"about_ca_topic_score_gemma":0.2194919,"teacher_disagreement_score":0.538739,"about_ca_system_score_codex":0.00006134934,"about_ca_system_score_gemma":0.000106398664,"threshold_uncertainty_score":0.79475033},"labels":[],"label_agreement":null},{"id":"W2031324922","doi":"10.4088/jcp.v67n0706","title":"Evaluation of an Interchangeability Switch in Patients Treated With Clozapine","year":2006,"lang":"en","type":"article","venue":"The Journal of Clinical Psychiatry","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba","funders":"","keywords":"Clozapine; Discontinuation; Medicine; Adverse effect; Population; Schizophrenia (object-oriented programming); Medical record; Retrospective cohort study; Brand names; Pediatrics; Psychiatry; Internal medicine","score_opus":0.15434824418344043,"score_gpt":0.40465260828503863,"score_spread":0.2503043641015982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031324922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943604,0.0004926956,0.00003432189,0.0013766465,0.00045148013,0.00015574547,0.000025048503,0.0000020853279,0.0031015612],"genre_scores_gemma":[0.99898195,0.000091898764,0.00022268573,0.00032987425,0.00035171516,0.0000011540506,0.0000030581955,0.000009829768,0.000007837663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99747956,0.00023436866,0.0019383051,0.000120860655,0.00009414096,0.00013276808],"domain_scores_gemma":[0.9980358,0.0001480155,0.0013142972,0.00023985365,0.00018980635,0.00007225251],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009727222,0.00008861933,0.00047784252,0.000119790064,0.000019588393,0.000009313068,0.000259329,0.00008001474,0.00014578002],"category_scores_gemma":[0.00024476054,0.00006183014,0.00012518482,0.00015394301,0.00009533043,0.00015992249,0.000020138492,0.00031356083,0.000013366904],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007510422,0.0014104506,0.9888089,0.000008874543,0.000052487478,1.0734278e-7,0.000041897325,0.0004751642,6.003135e-7,0.002858245,0.000305621,0.005286647],"study_design_scores_gemma":[0.004541501,0.0009781363,0.91523504,0.0000228015,0.000055200468,0.0000013501531,0.000014884953,0.0038421983,0.000007091387,0.074617215,0.0006071211,0.00007745849],"about_ca_topic_score_codex":0.0002139292,"about_ca_topic_score_gemma":0.0003565764,"teacher_disagreement_score":0.07357382,"about_ca_system_score_codex":0.00005963733,"about_ca_system_score_gemma":0.0000938503,"threshold_uncertainty_score":0.337128},"labels":[],"label_agreement":null},{"id":"W2031631370","doi":"10.1136/bmj.327.7409.246-a","title":"US agrees to cheap drug imports—as Florida officials break fake drugs ring","year":2003,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Drug; Ring (chemistry); Internet privacy; Medicine; Pharmacology; Chemistry; Computer science","score_opus":0.042227142237231056,"score_gpt":0.304939372926408,"score_spread":0.26271223068917693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031631370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.64341027,0.0006712498,0.0000641355,0.0049159024,0.001066126,0.00037703157,0.00011615927,0.0000473838,0.34933177],"genre_scores_gemma":[0.9848291,0.00017434567,0.0004594687,0.009309766,0.00071924477,0.000057066314,0.000008635083,0.00004845981,0.0043938896],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99796057,0.000020376485,0.0009122238,0.0004979093,0.000039815717,0.00056908064],"domain_scores_gemma":[0.9988177,0.000077089935,0.00026123517,0.00045499366,0.000020230136,0.00036875412],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010881032,0.0002276051,0.00050840125,0.0002248323,0.0001263393,0.00012501936,0.00027209014,0.00009666732,0.0016006626],"category_scores_gemma":[0.0002724779,0.0002791654,0.00018099877,0.00023766351,0.00003652077,0.00016161682,0.0000869945,0.00017452653,0.005801746],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000038365404,0.00011828158,0.033494644,0.0000432327,0.00011832118,0.000018788916,0.0012002805,0.00063684006,0.00010924448,0.89448506,0.066281974,0.003454997],"study_design_scores_gemma":[0.00050373754,0.000026513206,0.006926561,0.000012756464,0.000007165474,0.000014454064,0.00005951466,0.00047889663,0.00140997,0.028157124,0.9619186,0.00048473573],"about_ca_topic_score_codex":0.00084194576,"about_ca_topic_score_gemma":0.00009063399,"teacher_disagreement_score":0.8956366,"about_ca_system_score_codex":0.00014027196,"about_ca_system_score_gemma":0.00007092321,"threshold_uncertainty_score":0.999966},"labels":[],"label_agreement":null},{"id":"W2031692846","doi":"10.1211/ijpp.17.02.0002","title":"Consumers' views on generic medicines: A review of the literature","year":2009,"lang":"en","type":"review","venue":"International Journal of Pharmacy Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":102,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; MEDLINE; Reimbursement; Grey literature; Scopus; Health care; Seriousness; Family medicine; Public relations; Political science","score_opus":0.18519468087731014,"score_gpt":0.4623296083132797,"score_spread":0.27713492743596957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031692846","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000001645603,0.9620614,0.000015952544,0.016152306,0.0032152054,0.00032538382,0.00031924504,0.0000033611045,0.017905522],"genre_scores_gemma":[0.000028053648,0.96403354,0.0001486157,0.034360826,0.0011609461,0.000007650233,0.000016995358,0.000029092309,0.00021424786],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964472,0.00022920493,0.0026887113,0.0002473721,0.00020279016,0.00018470836],"domain_scores_gemma":[0.99126416,0.0007764889,0.007045558,0.0003139774,0.00045853306,0.00014125097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021064037,0.0003229056,0.0016984667,0.0004169548,0.0000345798,0.000076426426,0.0015682658,0.00009929134,0.0006400926],"category_scores_gemma":[0.002566754,0.00022556103,0.0011554509,0.00038200567,0.000069413574,0.00045664792,0.00010261413,0.0011933604,0.00019627974],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011268862,0.00047686868,0.0000126329405,0.016715689,0.002006211,0.00012759196,0.00015500496,0.000003940969,7.127849e-7,0.016759835,0.10396851,0.8596603],"study_design_scores_gemma":[0.0007654225,0.00004008379,0.000001632125,0.042767856,0.00048159657,0.0008688019,0.0000028638228,0.000010382566,0.000002986873,0.00050800975,0.9543718,0.00017854705],"about_ca_topic_score_codex":0.000008346272,"about_ca_topic_score_gemma":2.9882273e-7,"teacher_disagreement_score":0.85948175,"about_ca_system_score_codex":0.00027371492,"about_ca_system_score_gemma":0.00032806338,"threshold_uncertainty_score":0.9198112},"labels":[],"label_agreement":null},{"id":"W2031771150","doi":"10.1016/j.jval.2012.08.2176","title":"PCN136 Expenditures on Orphan Drugs in Canada, Europe (EU5 + Belgium, Sweden and the Netherlands) and Australia in 2009","year":2012,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Orphan drug; Per capita; Authorization; Agency (philosophy); Eu countries; European union; Medicine; Demography; Business; Environmental health; International trade; Population; Biology","score_opus":0.09226563942851991,"score_gpt":0.3095126234444604,"score_spread":0.2172469840159405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031771150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821881,0.0058223945,6.9263683e-7,0.008884966,0.00029556346,0.00028113247,0.000082710285,0.000003142187,0.002441267],"genre_scores_gemma":[0.99252105,0.0027728828,0.00001638352,0.0043805623,0.00014572835,0.0000160935,0.0000035564342,0.000013954489,0.00012981372],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985458,0.000108247965,0.0005800936,0.00023258616,0.000026160436,0.0005071148],"domain_scores_gemma":[0.9992653,0.00023086778,0.00015435868,0.00015697505,0.0000023827486,0.00019009819],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014637293,0.00013030422,0.0003700193,0.0001815658,0.000045459932,0.000030398825,0.00012721994,0.000050001632,0.00007548522],"category_scores_gemma":[0.00005068532,0.00011670656,0.000016469057,0.00012646706,0.00005179659,0.000098634126,0.000045877947,0.00030010098,0.000031770323],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009836045,0.000066612956,0.8136658,0.00006561391,0.00000850454,0.000003301387,0.0027594315,0.00096896733,5.914873e-7,0.17714939,0.004201628,0.001011783],"study_design_scores_gemma":[0.0027691582,0.000043910462,0.8995297,0.000052829542,0.0000011491082,0.0000049122345,0.00015819575,0.005917942,0.000007866884,0.007926606,0.08334349,0.00024424435],"about_ca_topic_score_codex":0.90344775,"about_ca_topic_score_gemma":0.43541387,"teacher_disagreement_score":0.46803388,"about_ca_system_score_codex":0.0003404844,"about_ca_system_score_gemma":0.0001212431,"threshold_uncertainty_score":0.57488835},"labels":[],"label_agreement":null},{"id":"W2031814675","doi":"10.1002/pds.3230","title":"The U.S. Food and Drug Administration's Mini‐Sentinel Program","year":2012,"lang":"en","type":"article","venue":"Pharmacoepidemiology and Drug Safety","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Hamilton Health Sciences Foundation; U.S. Department of Health and Human Services","keywords":"Medicine; Food and drug administration; Administration (probate law); Drug; Pharmacoepidemiology; Drug administration; Environmental health; Pharmacology","score_opus":0.06481087761012193,"score_gpt":0.34486078034882545,"score_spread":0.2800499027387035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031814675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7610524,0.061883066,0.00021435038,0.129075,0.0016155522,0.00082206505,0.00030545186,0.00013727302,0.04489481],"genre_scores_gemma":[0.98092175,0.011075452,0.00030181406,0.006468895,0.00055013166,0.00008352252,0.000017321094,0.000018373828,0.000562773],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980374,0.00017605493,0.00076630583,0.0003553331,0.000016458258,0.00064844213],"domain_scores_gemma":[0.9977829,0.0013381537,0.00030414283,0.00019793319,0.000014786346,0.00036208428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038319991,0.00020971114,0.00042568162,0.000059590755,0.000481269,0.00004532104,0.00017180412,0.00008710007,0.0001230011],"category_scores_gemma":[0.000372636,0.00017967814,0.0000927098,0.00008228324,0.000359939,0.00025307422,0.00013238558,0.0003214603,0.00013300081],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014146914,0.00017969507,0.2768341,0.000046166562,0.00018240968,7.8375433e-7,0.00044511852,0.0000028548836,0.000007831899,0.65789634,0.041409776,0.022853447],"study_design_scores_gemma":[0.0007443557,0.000027192484,0.05929272,0.0000036252563,0.000021626402,0.000021110076,0.000043730324,0.0018712368,0.000062297986,0.019680629,0.91798365,0.00024780308],"about_ca_topic_score_codex":0.0000305607,"about_ca_topic_score_gemma":0.000019680843,"teacher_disagreement_score":0.8765739,"about_ca_system_score_codex":0.000026326377,"about_ca_system_score_gemma":0.000019086707,"threshold_uncertainty_score":0.7327062},"labels":[],"label_agreement":null},{"id":"W2031834292","doi":"","title":"A Review of the Pharmaceutical Industry of Canada","year":2008,"lang":"en","type":"review","venue":"RePEc: Research Papers in Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmaceutical industry; Intellectual property; Business; Divergence (linguistics); Drug industry; International trade; Industrial organization; Commerce; Engineering; Law; Political science; Medicine; Pharmacology","score_opus":0.16890998709085156,"score_gpt":0.4079537679486644,"score_spread":0.23904378085781283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031834292","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000049814404,0.85390544,6.314364e-8,0.00040421952,0.00034897059,0.0008381184,0.0007940434,0.0000039074425,0.14365539],"genre_scores_gemma":[0.00015203997,0.9975223,0.00001746203,0.00095578795,0.00014017666,0.000115654526,0.000017297773,0.00007194046,0.0010073533],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99530345,0.00022813641,0.0028241572,0.00068466493,0.000097535776,0.00086206757],"domain_scores_gemma":[0.99648744,0.000745056,0.0012401923,0.0011709585,0.00006702167,0.0002893185],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0017777063,0.0004014496,0.0029212483,0.00038923434,0.000101750935,0.000014545484,0.001512647,0.00059093005,0.0005552201],"category_scores_gemma":[0.001037056,0.00036746074,0.0007475691,0.0005891958,0.00053914543,0.00007231119,0.0005706405,0.0025747397,0.00001662318],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011668352,0.00021019451,0.0004054164,0.06950766,0.0003932333,0.000012016902,0.000037084075,0.000024868852,1.2207825e-7,0.014985732,0.009422626,0.90498936],"study_design_scores_gemma":[0.00022670077,0.000017304505,0.000032903616,0.015259323,0.000020812624,0.000033875753,0.000006455832,0.00010843117,0.0000029695993,0.00035330004,0.9836337,0.00030424463],"about_ca_topic_score_codex":0.006491885,"about_ca_topic_score_gemma":0.0043741013,"teacher_disagreement_score":0.97421104,"about_ca_system_score_codex":0.0013424844,"about_ca_system_score_gemma":0.003398253,"threshold_uncertainty_score":0.99987775},"labels":[],"label_agreement":null},{"id":"W2031885918","doi":"10.3109/17453671003685467","title":"The Canadian Joint Replacement Registry—what have we learned?","year":2010,"lang":"en","type":"article","venue":"Acta Orthopaedica","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Armed Forces; Dalhousie University; Canadian Mennonite University; University of Manitoba","funders":"","keywords":"Medicine; Joint replacement; Arthroplasty; Physical therapy; Surgery","score_opus":0.05969153513577381,"score_gpt":0.2770479774793396,"score_spread":0.21735644234356583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031885918","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20797355,0.0036637767,0.0000185971,0.4408384,0.0048389905,0.0005768267,0.000214262,0.000082416234,0.34179318],"genre_scores_gemma":[0.981472,0.0046775425,0.000095618,0.0069889654,0.0005546044,0.000040339295,0.000015854936,0.000036377594,0.00611867],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981634,0.000016303435,0.00062758906,0.0004500256,0.000051678522,0.00069098943],"domain_scores_gemma":[0.99806154,0.00009702185,0.00029757767,0.0008536004,0.00002797436,0.00066226505],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0012452643,0.00018862473,0.00027337894,0.00014661199,0.0006790415,0.00061497896,0.0004916089,0.0001890715,0.0018525998],"category_scores_gemma":[0.00040287606,0.00017442812,0.00017378453,0.00010828429,0.00023695035,0.00020817015,0.000108936874,0.00075985113,0.0013413309],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053011066,0.00008738586,0.021994317,0.000028354918,0.00018811524,0.000025626761,0.0006221266,0.000009116254,0.000115179355,0.7524182,0.17704727,0.047411267],"study_design_scores_gemma":[0.00033166353,0.000030807863,0.0027285786,0.0000075425105,0.0000047647304,0.000013818103,0.00006431321,0.0013179707,0.000059816062,0.019011484,0.97620195,0.00022726197],"about_ca_topic_score_codex":0.024321118,"about_ca_topic_score_gemma":0.2587187,"teacher_disagreement_score":0.7991547,"about_ca_system_score_codex":0.0001714256,"about_ca_system_score_gemma":0.0002498453,"threshold_uncertainty_score":0.99943626},"labels":[],"label_agreement":null},{"id":"W2031939437","doi":"10.1586/14737167.4.2.179","title":"Evaluating the true cost of hypertension management: evidence from actual practice","year":2004,"lang":"en","type":"article","venue":"Expert Review of Pharmacoeconomics & Outcomes Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GLS Industries (Canada)","funders":"","keywords":"Observational study; Medicine; Intensive care medicine; Cost effectiveness; Pharmacotherapy; Argument (complex analysis); Internal medicine; Risk analysis (engineering)","score_opus":0.3416650622691229,"score_gpt":0.586591635498591,"score_spread":0.24492657322946804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031939437","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21520475,0.6000734,0.0009024157,0.13323647,0.0020808878,0.005728181,0.0007368759,0.000059281334,0.041977752],"genre_scores_gemma":[0.36193192,0.6097854,0.0052081514,0.022202043,0.0003024716,0.0002750388,0.000026801674,0.000067165245,0.00020104036],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962027,0.00028275297,0.0019899711,0.0006899099,0.00020399535,0.0006306556],"domain_scores_gemma":[0.9947741,0.002781784,0.00094581116,0.0010282384,0.00025166527,0.00021839817],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.007741547,0.0002950674,0.0011419331,0.00029028053,0.00020466831,0.00007238303,0.0013662413,0.00009086254,0.0012533704],"category_scores_gemma":[0.0022374927,0.00025155142,0.00042149375,0.0003902619,0.00033272465,0.00069506594,0.00058423926,0.0006046724,0.0008113359],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016880726,0.0032936982,0.0065991264,0.012064662,0.0056883474,0.00008340893,0.0095221605,0.004153083,0.010174835,0.51324326,0.05678048,0.3767089],"study_design_scores_gemma":[0.008455652,0.0006621333,0.0042650867,0.007602733,0.0002736849,0.000037749527,0.0010335534,0.014086936,0.012577257,0.036655445,0.9127687,0.0015810725],"about_ca_topic_score_codex":0.0015218469,"about_ca_topic_score_gemma":0.000009129255,"teacher_disagreement_score":0.8559882,"about_ca_system_score_codex":0.00043896603,"about_ca_system_score_gemma":0.00015598859,"threshold_uncertainty_score":0.9999937},"labels":[],"label_agreement":null},{"id":"W2032458713","doi":"10.1016/j.sapharm.2006.07.003","title":"Canadian Internet pharmacies: Price, policy, and perspective","year":2007,"lang":"en","type":"article","venue":"Research in Social and Administrative Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"U.S. Food and Drug Administration; Pfizer; University of Minnesota; American Heart Association","keywords":"Medical prescription; Discontinuation; Misinformation; Medicine; Direct-to-consumer advertising; Scopus; Testosterone replacement; Family medicine; Advertising; MEDLINE; Psychiatry; Business; Internal medicine; Political science; Pharmacology","score_opus":0.3862383656046429,"score_gpt":0.517372483249521,"score_spread":0.1311341176448781,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032458713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5303424,0.0020439348,0.00003503888,0.028578795,0.000100500765,0.00040527206,0.00046185544,0.000015713023,0.4380165],"genre_scores_gemma":[0.9964464,0.001069482,0.00004016716,0.0011888529,0.00045172175,0.000020176563,0.0000047635926,0.000013822878,0.00076464337],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981938,0.000059270395,0.0003996012,0.00043303042,0.00005630367,0.0008580175],"domain_scores_gemma":[0.9988876,0.00023046507,0.00007676937,0.00006536253,0.000069018795,0.0006707697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020606813,0.00015444489,0.00028684989,0.00056550343,0.0002790063,0.00015869606,0.00017933462,0.0000659107,0.0002662641],"category_scores_gemma":[0.00018644964,0.0001828392,0.000044972912,0.0006299595,0.00045734821,0.0002343536,0.00011363135,0.00051721546,0.00008634271],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007880408,0.00006723055,0.061481953,0.000028971474,0.000041498133,0.000038409304,0.0040190504,8.353368e-8,0.000026367028,0.93018365,0.0009642259,0.0030697668],"study_design_scores_gemma":[0.0021765705,0.00010980248,0.031127082,0.00001630551,0.0000032658374,0.000025156196,0.0030644091,0.0005609235,0.0003823733,0.38525817,0.5768359,0.00044010134],"about_ca_topic_score_codex":0.14274171,"about_ca_topic_score_gemma":0.025138358,"teacher_disagreement_score":0.57587165,"about_ca_system_score_codex":0.0011301704,"about_ca_system_score_gemma":0.00047433915,"threshold_uncertainty_score":0.99265033},"labels":[],"label_agreement":null},{"id":"W2032555144","doi":"10.1016/j.econlet.2008.04.011","title":"Can health insurance coverage explain the generic competition paradox?","year":2008,"lang":"en","type":"article","venue":"Economics Letters","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Competition (biology); Health insurance; Economics; Actuarial science; Business; Health care; Biology","score_opus":0.0610946542756907,"score_gpt":0.2430156554677373,"score_spread":0.1819210011920466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032555144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89765686,0.0006323735,0.00077691936,0.09307705,0.00075377035,0.00027630682,0.0006376905,0.00004260201,0.006146431],"genre_scores_gemma":[0.89955574,0.0040504923,0.00018322955,0.095542915,0.00039775108,0.000044223874,0.000053314965,0.000039445487,0.00013288538],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99811,0.000037799477,0.0008156093,0.00047250153,0.000018790915,0.0005453216],"domain_scores_gemma":[0.99872553,0.00009079523,0.00048498556,0.00049334014,0.000007391109,0.00019796198],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00045365733,0.00023340264,0.0004906645,0.00013843391,0.0004357995,0.00007945069,0.00042573182,0.000061536746,0.00023882676],"category_scores_gemma":[0.000019474506,0.00025263987,0.00017935333,0.00012234425,0.00019983522,0.00020920223,0.00007123531,0.0002661263,0.0008531793],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006068217,0.00018913131,0.14988908,0.00005317625,0.00023128156,0.00001961876,0.0027865707,0.016174037,0.00012723455,0.762113,0.06538911,0.0029671194],"study_design_scores_gemma":[0.0021377045,0.00009267578,0.18124218,0.000013486395,0.0000038242492,0.00012570975,0.000040951247,0.010560476,0.00016610477,0.033500478,0.77107894,0.0010374815],"about_ca_topic_score_codex":0.00046124827,"about_ca_topic_score_gemma":0.00010325168,"teacher_disagreement_score":0.7286125,"about_ca_system_score_codex":0.00039702212,"about_ca_system_score_gemma":0.000060186325,"threshold_uncertainty_score":0.9999926},"labels":[],"label_agreement":null},{"id":"W2032655361","doi":"10.1016/j.joca.2012.02.499","title":"Compliance with thromboprophylaxis using an oral factor Xa inhibitor rivaroxaban after total hip and knee arthroplasty. Is oral therapy better? An examination of the non-adherence rate of rivaroxaban","year":2012,"lang":"en","type":"article","venue":"Osteoarthritis and Cartilage","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; University of Toronto","funders":"","keywords":"Medicine; Rivaroxaban; Arthroplasty; Perioperative; Medical prescription; Knee replacement; Hip replacement; Surgery; Anesthesia; Internal medicine; Warfarin; Atrial fibrillation","score_opus":0.057411922642819184,"score_gpt":0.2694667141147721,"score_spread":0.21205479147195289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032655361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970399,0.0013852044,0.000027946217,0.000061363426,0.00024622947,0.00033518905,0.00061952975,0.000008417201,0.00027618458],"genre_scores_gemma":[0.99911404,0.00011713881,0.00022966236,0.00032376015,0.00013479695,0.000018941208,0.00000738591,0.000030758245,0.000023493829],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99870247,0.00006415166,0.0004752128,0.0003511942,0.000051161413,0.00035583114],"domain_scores_gemma":[0.99908435,0.000024941235,0.0003210864,0.00033342914,0.000045000674,0.00019118002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029195854,0.0002316115,0.00047316877,0.000081057064,0.0001260335,0.00008210498,0.00009931379,0.00010220118,0.00018843991],"category_scores_gemma":[0.000008213715,0.00020179906,0.000067564455,0.00014284952,0.0003878428,0.0007864488,0.00007615989,0.00014250903,0.0000067083906],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045316148,0.0007876374,0.73258615,0.00024233152,0.00006663971,0.0000064691003,0.014707111,0.000015874539,0.11453495,0.0029231405,0.000030591407,0.13364594],"study_design_scores_gemma":[0.003517372,0.0022892696,0.9134045,0.00013360077,0.000019977004,0.000033694407,0.00027276727,0.0008582297,0.076595664,0.0009791891,0.0012384909,0.000657211],"about_ca_topic_score_codex":0.00012125156,"about_ca_topic_score_gemma":0.00008663442,"teacher_disagreement_score":0.18081838,"about_ca_system_score_codex":0.000024516314,"about_ca_system_score_gemma":0.000018424484,"threshold_uncertainty_score":0.8229127},"labels":[],"label_agreement":null},{"id":"W2034097717","doi":"10.4212/cjhp.v63i3.920","title":"Doit-on s’inspirer de la tarification à l’activité pour le financement des médicaments onéreux en établissements de santé ?","year":2010,"lang":"fr","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Political science; Humanities; Art","score_opus":0.033628147013296444,"score_gpt":0.30574105495618803,"score_spread":0.27211290794289156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034097717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93162286,0.0043722247,0.00031650477,0.039648864,0.002795422,0.00025037728,0.0002920102,0.000004923093,0.020696796],"genre_scores_gemma":[0.98959416,0.0023716893,0.0007253273,0.0037716134,0.0012573265,0.000013931879,0.000004509432,0.00005143026,0.002209982],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99784315,0.00015693653,0.00079637923,0.00025475133,0.00006989571,0.0008789181],"domain_scores_gemma":[0.9977206,0.0002512701,0.00075502135,0.00030174124,0.00008369978,0.00088766107],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0025549552,0.00027347033,0.00038267398,0.00032982498,0.0005187079,0.00040908204,0.00083778717,0.00015672736,0.0011241012],"category_scores_gemma":[0.00036130022,0.0002947427,0.0002485123,0.00019838191,0.00048306343,0.0005418885,0.000040666106,0.0013484608,0.00026205913],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026847393,0.0022520407,0.3596898,0.00017069849,0.0014329143,0.00040424883,0.013065543,0.0029441123,0.003053865,0.31748256,0.105569325,0.19366641],"study_design_scores_gemma":[0.0025988217,0.0002596513,0.11268206,0.00009616518,0.00008030895,0.00010744648,0.00015722237,0.0037734993,0.003772176,0.05444141,0.821573,0.00045819258],"about_ca_topic_score_codex":0.027884902,"about_ca_topic_score_gemma":0.006511997,"teacher_disagreement_score":0.7160037,"about_ca_system_score_codex":0.0012651304,"about_ca_system_score_gemma":0.00217496,"threshold_uncertainty_score":0.99995047},"labels":[],"label_agreement":null},{"id":"W2034460365","doi":"10.1016/j.cjca.2014.07.196","title":"A HYBRID STRATEGY OF BARE METAL COMBINED WITH DRUG-ELUTING STENTING OR DRUG-ELUTING STENTING ONLY FOR MULTIVESSEL PERCUTANEOUS CORONARY INTERVENTION: Results OF LONG-TERM FOLLOW-UP","year":2014,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Medicine; Conventional PCI; Percutaneous coronary intervention; TIMI; Mace; Internal medicine; Cardiology; Coronary artery disease; Drug-eluting stent; Fractional flow reserve; Angioplasty; Revascularization; Stent; Surgery; Myocardial infarction; Coronary angiography","score_opus":0.043170417720170634,"score_gpt":0.26773635511140964,"score_spread":0.224565937391239,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034460365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923257,0.0007369881,0.0019128118,0.00025313027,0.00071840076,0.00027328377,0.0006329638,0.000005460984,0.0031412125],"genre_scores_gemma":[0.99873555,0.00003932218,0.00039411875,0.00007811511,0.00038057135,0.0000038100738,0.00003291105,0.000040497664,0.00029512568],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99706596,0.00012382484,0.0018367647,0.00033114955,0.000045109027,0.00059717975],"domain_scores_gemma":[0.9970883,0.00046076812,0.001535926,0.00023779755,0.00029229038,0.00038493006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019146547,0.00023912711,0.0013001881,0.00046235087,0.00015926667,0.000045133558,0.0004127774,0.000091361864,0.000030352714],"category_scores_gemma":[0.0006631028,0.00023452625,0.0005678264,0.0001226935,0.00021184476,0.00020074974,0.000047496487,0.00032439057,0.0000035280814],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011502119,0.00018550809,0.7599744,0.0029161004,0.009795081,0.0014543906,0.0059739095,0.040734336,0.0012353015,0.03627509,0.002861791,0.12709196],"study_design_scores_gemma":[0.11545284,0.015727503,0.67419714,0.0054129604,0.0028784503,0.026508356,0.0143744,0.07340088,0.005753292,0.012839415,0.047170684,0.0062840898],"about_ca_topic_score_codex":0.00081435195,"about_ca_topic_score_gemma":0.0025700375,"teacher_disagreement_score":0.12080787,"about_ca_system_score_codex":0.00016771385,"about_ca_system_score_gemma":0.00041570113,"threshold_uncertainty_score":0.9563703},"labels":[],"label_agreement":null},{"id":"W2036463549","doi":"10.1016/j.sapharm.2011.12.004","title":"Generic medications for you, but brand-name medications for me","year":2012,"lang":"en","type":"article","venue":"Research in Social and Administrative Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Family medicine; Medicaid; Brand names; Generic drug; Pharmacist; Medical prescription; Pharmacy; Health care; Quarter (Canadian coin); Alternative medicine; Advertising; Nursing; Drug; Psychiatry","score_opus":0.5563216677394746,"score_gpt":0.536764510440715,"score_spread":0.01955715729875951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036463549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.57990015,0.02286977,0.0116191255,0.25000787,0.0013860255,0.00641175,0.016422099,0.00010590754,0.111277305],"genre_scores_gemma":[0.9940296,0.0014328249,0.00054784975,0.00077919953,0.0014008166,0.0011319416,0.000091847156,0.000018441491,0.0005675011],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983861,0.000056830104,0.0004931615,0.00030855037,0.000060347742,0.00069501734],"domain_scores_gemma":[0.99874014,0.00055452884,0.00013215061,0.000102967264,0.00007830687,0.00039193706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002024806,0.00012792986,0.00030181446,0.00016063594,0.0005256254,0.00006607063,0.00022528855,0.000072593764,0.00025697623],"category_scores_gemma":[0.00014321021,0.00014330145,0.00010010505,0.00029336615,0.0003733955,0.00026725745,0.00006213607,0.00023774084,0.00006402766],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008749843,0.00036832396,0.01909965,0.00010048719,0.00016723378,3.7211964e-7,0.0016339148,4.550448e-7,0.0001445051,0.9670767,0.0052955584,0.0060252743],"study_design_scores_gemma":[0.0031494603,0.000097558426,0.010888512,0.00001076282,0.000029475106,0.0000032104929,0.00062638585,0.003261688,0.000454107,0.2457945,0.73534846,0.00033588332],"about_ca_topic_score_codex":0.00009715632,"about_ca_topic_score_gemma":0.000018473476,"teacher_disagreement_score":0.7300529,"about_ca_system_score_codex":0.00015414515,"about_ca_system_score_gemma":0.00020707982,"threshold_uncertainty_score":0.5843664},"labels":[],"label_agreement":null},{"id":"W2036483116","doi":"10.1001/jamainternmed.2013.1529","title":"When Choosing Statin Therapy","year":2013,"lang":"en","type":"review","venue":"JAMA Internal Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Statin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intensive care medicine; Reduction (mathematics); Physical therapy; Internal medicine","score_opus":0.20453207105522306,"score_gpt":0.38694937927341116,"score_spread":0.1824173082181881,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036483116","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000014146298,0.9059189,0.00023623557,0.0029101789,0.0015205442,0.00050598127,0.00018696528,0.000035135006,0.08867191],"genre_scores_gemma":[0.000024056,0.9864674,0.00020879913,0.0050316844,0.0028191584,0.00011400673,0.00006544861,0.0000973597,0.005172058],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99709654,0.000044540975,0.0017578756,0.0005801757,0.000049452265,0.0004714284],"domain_scores_gemma":[0.99773496,0.0003251099,0.0011297438,0.00046915372,0.000032087304,0.0003089492],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00068183156,0.00048826478,0.002495449,0.00047771033,0.00005097494,0.0001418448,0.00075939327,0.00031180592,0.012741972],"category_scores_gemma":[0.00032252356,0.00039433732,0.00039931288,0.00013531538,0.00014248256,0.00021554952,0.00012188982,0.0008754465,0.0061396607],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000005260407,0.000027503724,0.000019256084,0.0010521255,0.00023773112,0.000007620947,0.00016907924,1.265616e-7,1.12013765e-7,0.018299935,0.07784698,0.9023343],"study_design_scores_gemma":[0.0007463317,0.000114844755,0.000008718571,0.0038243236,0.000034415127,0.000029749506,0.0000066380785,0.0001009812,6.0264443e-7,0.017649138,0.9771112,0.0003730422],"about_ca_topic_score_codex":0.0010714465,"about_ca_topic_score_gemma":0.0000037416019,"teacher_disagreement_score":0.9019612,"about_ca_system_score_codex":0.00026323853,"about_ca_system_score_gemma":0.000046608133,"threshold_uncertainty_score":0.99985087},"labels":[],"label_agreement":null},{"id":"W2036492388","doi":"10.1503/cmaj.050444","title":"Canadian prescription drug costs surpass $18 billion","year":2005,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; Michael Smith Health Research BC","keywords":"Medical prescription; Prescription drug; Drug; Medicine; Prescription costs; Family medicine; Pharmacology","score_opus":0.023348975075944734,"score_gpt":0.24799636833172806,"score_spread":0.2246473932557833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036492388","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20749097,0.0018497969,0.00013190221,0.5134544,0.0039574895,0.00027648566,0.0007688036,0.00003878112,0.27203143],"genre_scores_gemma":[0.93484056,0.0006886125,0.00006361604,0.058816794,0.0025364,0.0000071960744,0.000024590809,0.000025971265,0.002996266],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99798423,0.000054705688,0.0007500037,0.00023106512,0.00015473514,0.00082524086],"domain_scores_gemma":[0.9956854,0.00006744399,0.00031349884,0.00012927731,0.000112435446,0.003691957],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.002394601,0.00014295633,0.00028376607,0.0005875279,0.0003496748,0.0002581227,0.00033399678,0.00034498933,0.020961419],"category_scores_gemma":[0.0007847495,0.00017091347,0.00013277678,0.00022904552,0.00002582166,0.00037301448,0.000013887918,0.00083494774,0.00467612],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000029950354,0.000022011805,0.08830017,0.000003359995,0.00007887222,0.000038342256,0.00020688154,0.000041054227,0.0000011949976,0.025594613,0.8586078,0.027102651],"study_design_scores_gemma":[0.0005207778,0.000009452892,0.017010698,0.00001180465,0.000004344521,0.000047757538,0.000025462448,0.0032672337,0.000005578125,0.003359549,0.9755339,0.00020346275],"about_ca_topic_score_codex":0.35577556,"about_ca_topic_score_gemma":0.9103339,"teacher_disagreement_score":0.7273496,"about_ca_system_score_codex":0.008225553,"about_ca_system_score_gemma":0.0018821792,"threshold_uncertainty_score":0.9960989},"labels":[],"label_agreement":null},{"id":"W2037874618","doi":"10.1212/wnl.0b013e3181aa5300","title":"The risks and costs of multiple-generic substitution of topiramate","year":2009,"lang":"en","type":"article","venue":"Neurology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Streptokinase; Myocardial infarction; Artery; Internal medicine; Cardiology; Angiography; Surgery","score_opus":0.09161091702826282,"score_gpt":0.29802624314812626,"score_spread":0.20641532611986343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037874618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99080837,0.0011058272,0.00008129514,0.0029135202,0.00016405128,0.00006869045,0.00003305754,0.0000047407125,0.00482047],"genre_scores_gemma":[0.9971845,0.0012145753,0.000021896047,0.0015327083,0.000031537296,0.0000018812342,0.0000012452751,0.000003035711,0.000008609578],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99943215,0.000014026191,0.00030069976,0.000119587916,0.000007199657,0.00012635991],"domain_scores_gemma":[0.99953854,0.00011083626,0.00017490213,0.00013203152,0.000010932348,0.000032736985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016948943,0.000051203184,0.00017046361,0.00004580898,0.000038110356,0.000006863169,0.00009705713,0.000054125,0.00001247159],"category_scores_gemma":[0.000081912774,0.000047082423,0.000033549157,0.00005052472,0.00011471029,0.000033284472,0.00002132234,0.00007654482,0.000012079222],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001243908,0.000044225995,0.0696381,0.0000060526913,0.000014647384,9.587629e-7,0.000046476725,0.00018265202,0.00084184104,0.9138269,0.000089856316,0.015183901],"study_design_scores_gemma":[0.0014082798,0.00085859495,0.75052476,0.000002801109,0.000009265131,0.000015646345,0.0000019857014,0.025964722,0.0023955617,0.08558384,0.13305299,0.00018153361],"about_ca_topic_score_codex":0.00012358115,"about_ca_topic_score_gemma":0.000021392472,"teacher_disagreement_score":0.8282431,"about_ca_system_score_codex":0.000006020896,"about_ca_system_score_gemma":0.0000055012506,"threshold_uncertainty_score":0.19199656},"labels":[],"label_agreement":null},{"id":"W2039581669","doi":"10.1136/bmj.d7706","title":"Developing countries are not making the most of TRIPS flexibilities because of political pressure","year":2011,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"TRIPS architecture; Politics; Computer science; Developing country; Data science; Medicine; Political science; Economic growth; Economics; Law","score_opus":0.22487005983131028,"score_gpt":0.34714454430073993,"score_spread":0.12227448446942965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039581669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7495583,0.0044305623,0.0012094607,0.026085049,0.0011064874,0.0010429354,0.0029162613,0.000058923946,0.21359201],"genre_scores_gemma":[0.9962619,0.00010033407,0.000579325,0.0025791419,0.00012073745,0.000016614065,0.0000019912732,0.0000145230715,0.0003254627],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99870116,0.000018993213,0.0007749546,0.00018343648,0.00003011491,0.0002913723],"domain_scores_gemma":[0.99897754,0.00016262382,0.00044023964,0.0003183583,0.000051004183,0.00005025672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005959709,0.00010969058,0.00037890158,0.00009065011,0.00005798076,0.00001825836,0.00028116087,0.00007864798,0.00039994266],"category_scores_gemma":[0.00026936308,0.00009898378,0.00008841718,0.000094122115,0.00023789702,0.00010801443,0.000104636594,0.00010366727,0.00005097383],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004459036,0.00002622059,0.021353863,0.00012555275,0.00007681518,6.06481e-7,0.00082565483,0.0000070900305,0.0000021106484,0.97600913,0.0014728566,0.00005551408],"study_design_scores_gemma":[0.0010933529,0.000099316145,0.19386066,0.00016645092,0.000060862105,0.000012108551,0.001012838,0.002322984,0.008617108,0.29745585,0.49469623,0.00060224073],"about_ca_topic_score_codex":0.00034263215,"about_ca_topic_score_gemma":0.000026893751,"teacher_disagreement_score":0.6785533,"about_ca_system_score_codex":0.00003797437,"about_ca_system_score_gemma":0.00006739357,"threshold_uncertainty_score":0.43790916},"labels":[],"label_agreement":null},{"id":"W2040835663","doi":"10.3821/145.6.cpj245","title":"Private Insurers Implementing Policies Making Generic Substitution Mandatory","year":2012,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Substitution (logic); Business; Actuarial science; Medicine; Computer science","score_opus":0.0986726546523255,"score_gpt":0.29789719547724236,"score_spread":0.19922454082491686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040835663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97493446,0.0051986263,0.00035081562,0.00026917405,0.0038087023,0.00025190716,0.0011098994,0.000031977204,0.014044461],"genre_scores_gemma":[0.9857919,0.0037767515,0.00023812715,0.007714933,0.0021784885,0.00001569099,0.00003193453,0.00006521849,0.0001869169],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964174,0.000058797275,0.0010353775,0.00036016246,0.00009739263,0.0020308453],"domain_scores_gemma":[0.9968992,0.000046578516,0.0005740664,0.00024998048,0.00010677346,0.002123401],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014027368,0.00036537525,0.00047285823,0.00064070796,0.0011506487,0.0003350941,0.0006132453,0.00007950433,0.0017846944],"category_scores_gemma":[0.00013535192,0.00047335698,0.00019271766,0.0005141721,0.00016646308,0.0010075582,0.00009253717,0.0006059933,0.00014509473],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001685358,0.00030304157,0.5650972,0.0008221905,0.0017167911,0.008787599,0.008114384,0.0037683672,0.0033109533,0.23825495,0.09200657,0.07764939],"study_design_scores_gemma":[0.0012062556,0.000013813833,0.0009902829,0.000011463805,0.00004977163,0.04215803,0.000009199061,0.0032075178,0.0008605578,0.0011779304,0.949474,0.0008411861],"about_ca_topic_score_codex":0.012053389,"about_ca_topic_score_gemma":0.014048342,"teacher_disagreement_score":0.8574674,"about_ca_system_score_codex":0.0034870463,"about_ca_system_score_gemma":0.0008463803,"threshold_uncertainty_score":0.99977183},"labels":[],"label_agreement":null},{"id":"W2040946909","doi":"10.1071/ah090176","title":"PBS reform &amp;mdash; a missed opportunity?","year":2009,"lang":"en","type":"article","venue":"Australian Health Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Library of Parliament","funders":"","keywords":"Formulary; Pharmaceutical Benefits Scheme; Health economics; Government (linguistics); Population health; Pharmaceutical policy; Business; Public economics; Economics; Medicine; Health care; Health policy; Pharmacology; Economic growth","score_opus":0.3741985915968059,"score_gpt":0.42552529880083695,"score_spread":0.05132670720403104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040946909","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016267517,0.13135962,0.000049120514,0.745387,0.00046847068,0.0012208592,0.00035385718,0.00012472674,0.11940959],"genre_scores_gemma":[0.049372744,0.46092072,0.0012377467,0.47546685,0.0003632163,0.000044470176,0.00015605224,0.000042214248,0.01239598],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99738675,0.00003607308,0.0014027621,0.0004307556,0.00003457679,0.000709074],"domain_scores_gemma":[0.99785346,0.000019177352,0.00058237906,0.00059436617,0.000022507138,0.00092812564],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0013190818,0.00023604897,0.00092440506,0.0001241101,0.00013252095,0.000046381374,0.00034560965,0.00009466116,0.0031222068],"category_scores_gemma":[0.00009610154,0.0002535416,0.00023058757,0.0002970237,0.000046780904,0.00020104417,0.000025204386,0.0003286939,0.0044870167],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009283371,0.00018213171,0.0003216374,0.0026662147,0.000037960675,0.0000061819333,0.000085744665,9.681179e-7,0.0000028063287,0.44511145,0.47211057,0.07946505],"study_design_scores_gemma":[0.00024646157,0.000088797155,0.0021229517,0.0004968292,0.0000061381675,0.000015775913,0.0000027865883,0.000011196481,0.000002651536,0.018825728,0.97791976,0.0002609075],"about_ca_topic_score_codex":0.00042716486,"about_ca_topic_score_gemma":0.000029947098,"teacher_disagreement_score":0.5058092,"about_ca_system_score_codex":0.00041671484,"about_ca_system_score_gemma":0.00015675792,"threshold_uncertainty_score":0.99999166},"labels":[],"label_agreement":null},{"id":"W2040971445","doi":"10.1002/hec.976","title":"Analysis of a pharmaceutical risk sharing agreement based on the purchaser's total budget","year":2005,"lang":"en","type":"article","venue":"Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Western University","funders":"","keywords":"Business; Actuarial science; Economics","score_opus":0.09140007972480259,"score_gpt":0.3384640381809,"score_spread":0.2470639584560974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040971445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.925704,0.0009477977,0.001038267,0.045456573,0.00036163113,0.0006072931,0.0021256665,0.000036167527,0.023722632],"genre_scores_gemma":[0.97612864,0.0013059134,0.00032532914,0.02176603,0.00022567189,0.00004814761,0.000042860287,0.00002958935,0.00012785038],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99731714,0.00004342474,0.0014063442,0.0005876818,0.00003225446,0.00061313895],"domain_scores_gemma":[0.9977307,0.0003064965,0.00087659986,0.00071561604,0.000018833109,0.0003518072],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020366102,0.00024048681,0.00081276917,0.00054442225,0.00021193188,0.000069876885,0.0004441377,0.00009336318,0.002451729],"category_scores_gemma":[0.000088536624,0.00024199451,0.0004274914,0.0003719136,0.000103977065,0.00012491034,0.000109652436,0.000371387,0.0005940212],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018561476,0.00068882236,0.09775537,0.000079258505,0.0015024157,7.655807e-7,0.0006387152,0.2890184,0.0000019371464,0.5863771,0.002695138,0.021056473],"study_design_scores_gemma":[0.0007029382,0.00008775482,0.01244426,0.0000062275317,0.00006591185,5.391224e-7,0.000018949451,0.8703248,0.000042833926,0.0022258551,0.113854654,0.00022526117],"about_ca_topic_score_codex":0.00038249345,"about_ca_topic_score_gemma":0.00016289229,"teacher_disagreement_score":0.58415127,"about_ca_system_score_codex":0.00051624153,"about_ca_system_score_gemma":0.00010325223,"threshold_uncertainty_score":0.9984602},"labels":[],"label_agreement":null},{"id":"W2041840751","doi":"10.2174/1874613601004020025","title":"Achieving a Dream: Meeting Policy Goals Related to Improving Drug Access","year":2010,"lang":"en","type":"article","venue":"The Open AIDS Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto; Canadian Society for International Health; AIDS Vancouver; Health Canada","funders":"","keywords":"Human immunodeficiency virus (HIV); Medicine; Face (sociological concept); Economic growth; Access to medicines; Public relations; Developing country; Development economics; Political science; Social science; Family medicine; Sociology; Economics","score_opus":0.05368159080485699,"score_gpt":0.35792932113244624,"score_spread":0.3042477303275892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041840751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78412926,0.00019911192,0.00011454239,0.031189192,0.0008998537,0.0003593584,0.00003890388,0.00002062238,0.18304914],"genre_scores_gemma":[0.98687905,0.00013408174,0.0011900516,0.008319925,0.00084282324,0.00001692828,0.0000015427303,0.00005142228,0.002564198],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979584,0.000057400845,0.0009821213,0.00033587642,0.000046115238,0.0006200489],"domain_scores_gemma":[0.9982484,0.00016707834,0.0006260592,0.00047833033,0.000043619788,0.00043648764],"candidate_categories":["scholarly_communication","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.004477764,0.0002074546,0.00045310194,0.00036032478,0.00074957724,0.002456236,0.002816333,0.000089797366,0.0012516481],"category_scores_gemma":[0.00086937024,0.00017711127,0.00016632197,0.00048696017,0.00006902679,0.001082757,0.0013023064,0.0012114558,0.0008842102],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013283234,0.00018768369,0.050931875,0.000029073883,0.00035223152,0.000020917973,0.0044972156,0.0007662574,0.009522923,0.8393119,0.016173417,0.07807368],"study_design_scores_gemma":[0.0032728673,0.0001865141,0.031031705,0.00011280384,0.000052854182,0.00057478296,0.00031447114,0.005052267,0.0025713716,0.38724306,0.56811744,0.0014698878],"about_ca_topic_score_codex":0.0012715727,"about_ca_topic_score_gemma":0.000097438526,"teacher_disagreement_score":0.551944,"about_ca_system_score_codex":0.00014267248,"about_ca_system_score_gemma":0.00013741328,"threshold_uncertainty_score":0.9998937},"labels":[],"label_agreement":null},{"id":"W2041879862","doi":"10.1503/cmaj.090861","title":"Rational use of medications: If Canada can't do it ...","year":2009,"lang":"en","type":"review","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Medicine; Data science; Computer science; World Wide Web; Family medicine; Pharmacology","score_opus":0.07216155283132238,"score_gpt":0.3056133835646304,"score_spread":0.23345183073330805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041879862","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000006546991,0.94501716,0.000028048255,0.041429028,0.0014856897,0.00023810411,0.0032558152,0.0000056622557,0.008533958],"genre_scores_gemma":[0.00007076918,0.97448653,0.00006773131,0.022855077,0.0014824321,0.000013924217,0.00015627114,0.00002979997,0.0008374809],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964362,0.00011016974,0.0022243394,0.00029814214,0.0003444582,0.0005867061],"domain_scores_gemma":[0.99507785,0.00055442046,0.0019140864,0.00022194242,0.00020090508,0.002030778],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017960488,0.0002728967,0.0014577316,0.0005085437,0.00019519628,0.00016392334,0.0005758248,0.0007374545,0.008634917],"category_scores_gemma":[0.0028240492,0.0002962715,0.0003746856,0.0003694391,0.0000481413,0.0001542714,0.000023795756,0.0013993527,0.00020074306],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[5.8040007e-7,0.000020960895,0.00026023373,0.00019903328,0.0004044691,0.000045565106,0.000041651707,0.0000053486383,1.0601023e-9,0.024399739,0.69094086,0.28368157],"study_design_scores_gemma":[0.0001960011,0.000010182489,0.000102181606,0.00062342477,0.00006671645,0.00009506049,0.00000926621,0.00009452315,1.4763875e-8,0.0014908928,0.99704313,0.00026857745],"about_ca_topic_score_codex":0.27619785,"about_ca_topic_score_gemma":0.74735266,"teacher_disagreement_score":0.4711548,"about_ca_system_score_codex":0.004613719,"about_ca_system_score_gemma":0.023234004,"threshold_uncertainty_score":0.9999489},"labels":[],"label_agreement":null},{"id":"W2041905260","doi":"10.1002/cmdc.200700008","title":"Pharmaceutical Strategy and Innovation: An Academics Perspective","year":2007,"lang":"en","type":"review","venue":"ChemMedChem","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada); TransCanada (Canada)","funders":"","keywords":"Pharmaceutical industry; Business; Outsourcing; Context (archaeology); SAFER; Marketing; Productivity; Profit (economics); Perspective (graphical); Industrial organization; Economics; Computer science","score_opus":0.4698464303725707,"score_gpt":0.4730202975959993,"score_spread":0.003173867223428606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041905260","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006221116,0.87218404,0.0000696952,0.0002634365,0.00023114323,0.00036584245,0.0003015043,0.00005551689,0.12646663],"genre_scores_gemma":[0.00015757474,0.9959088,0.00017291051,0.0015378657,0.0010427213,0.000046722227,0.0001352608,0.0000983252,0.000899835],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99700767,0.00001981773,0.0014014029,0.0009169854,0.000040265015,0.00061387225],"domain_scores_gemma":[0.99841714,0.00014413534,0.0006141398,0.0003908431,0.000068508925,0.00036524585],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009703532,0.0005233366,0.0017129867,0.00077738275,0.00009773986,0.0001307903,0.00044089995,0.0008519802,0.0005081126],"category_scores_gemma":[0.0001436311,0.0005894715,0.00021833439,0.0009915499,0.0002508539,0.00028206685,0.00016213239,0.0013602906,0.0005577935],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000003937186,0.00005259683,0.000006468757,0.0011704729,0.000113684364,0.0000048536067,0.000075982614,1.5589015e-7,3.9962683e-7,0.68150336,0.0006790957,0.316389],"study_design_scores_gemma":[0.00030191007,0.00002973971,0.0000023602424,0.00020274962,0.00007490225,0.000048397123,0.000040752726,0.00014727144,0.000045398374,0.03461422,0.9638713,0.00062101404],"about_ca_topic_score_codex":0.000014661731,"about_ca_topic_score_gemma":0.000001104024,"teacher_disagreement_score":0.96319216,"about_ca_system_score_codex":0.00048017097,"about_ca_system_score_gemma":0.00014437654,"threshold_uncertainty_score":0.99965566},"labels":[],"label_agreement":null},{"id":"W2042215339","doi":"10.1016/s1098-3015(11)70806-3","title":"PMDH6: AN ECONOMIC EVALUATION OF PHARMACEUTICAL COST CONTAINMENT POLICIES IN ALBERTA, CANADA","year":2000,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Containment (computer programming); Business; Computer science","score_opus":0.13911449783376312,"score_gpt":0.3716451540720326,"score_spread":0.23253065623826946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042215339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97333914,0.000911743,0.0000023274179,0.00755756,0.00024359839,0.00064072286,0.0002453346,0.0000045927395,0.017055001],"genre_scores_gemma":[0.9952075,0.0010186916,0.000032062002,0.0034820673,0.000079679514,0.000052886495,0.000023692126,0.000018368359,0.00008506363],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9976731,0.00014977144,0.0012564823,0.00035085686,0.00005890655,0.00051090773],"domain_scores_gemma":[0.9990922,0.00014913232,0.00023501086,0.0002576629,0.000011473387,0.00025447021],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002349377,0.00014748528,0.000498698,0.0002145421,0.00003862835,0.000019157509,0.00020766596,0.00006668456,0.002251083],"category_scores_gemma":[0.000049809296,0.00019205161,0.000043894644,0.00013331785,0.000048882313,0.00015442235,0.000020751178,0.00019244813,0.0001108432],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001491137,0.00048709317,0.18743296,0.00014571907,0.000042930977,0.0000025647048,0.0021350943,0.41216615,0.0000046036075,0.3578428,0.0012326563,0.038358323],"study_design_scores_gemma":[0.002907603,0.00010100058,0.08550211,0.00003851899,0.0000046407,0.0000034990724,0.00007750007,0.77581215,0.00008467656,0.01723193,0.1179238,0.00031258242],"about_ca_topic_score_codex":0.9652375,"about_ca_topic_score_gemma":0.75195116,"teacher_disagreement_score":0.363646,"about_ca_system_score_codex":0.0027429126,"about_ca_system_score_gemma":0.0010900338,"threshold_uncertainty_score":0.998661},"labels":[],"label_agreement":null},{"id":"W2042746249","doi":"10.1016/s1098-3015(10)64509-3","title":"PMH8 COST-EFFECTIVENESS OF VENLAFAXINE: A CANADIAN PERSPECTIVE","year":2006,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Venlafaxine; Perspective (graphical); Medicine; Psychiatry; Computer science; Artificial intelligence; Anxiety","score_opus":0.09630133463843947,"score_gpt":0.3330484847993053,"score_spread":0.23674715016086584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042746249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8286979,0.008467525,0.0002267078,0.008224624,0.00071782246,0.0014100375,0.0011028637,0.000027165115,0.15112536],"genre_scores_gemma":[0.99890107,0.00020419083,0.00010268338,0.00060146285,0.0000861477,0.00003309522,0.00001102486,0.000017221368,0.00004309696],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.998654,0.00006845314,0.00056068733,0.00027262224,0.000017180404,0.0004270321],"domain_scores_gemma":[0.9992691,0.00014242527,0.00019277171,0.00018284665,0.000023444903,0.00018938686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012403647,0.00010390344,0.00040459214,0.0004175432,0.00004945328,0.0000144436335,0.00014191057,0.00006759906,0.00009993872],"category_scores_gemma":[0.00008345419,0.00013527091,0.000068743306,0.00029102506,0.00004924721,0.00007292544,0.000017664364,0.00015947153,0.00013108764],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016205993,0.00006725391,0.04122269,0.00009201968,0.0000084963185,0.0000024516594,0.0001687945,0.0069534103,0.0000044543895,0.9510577,0.00027906374,0.0001275056],"study_design_scores_gemma":[0.0015912874,0.00013967826,0.29461336,0.000112230875,0.0000019637698,0.00000592807,0.000086140266,0.021732606,0.00014100946,0.60270554,0.078527585,0.00034267438],"about_ca_topic_score_codex":0.8729861,"about_ca_topic_score_gemma":0.041086685,"teacher_disagreement_score":0.83189934,"about_ca_system_score_codex":0.0014466131,"about_ca_system_score_gemma":0.0003574353,"threshold_uncertainty_score":0.976411},"labels":[],"label_agreement":null},{"id":"W2042978277","doi":"10.1007/s00228-007-0277-5","title":"Characterizing early prescribers of newly marketed drugs in Canada: a population-based study","year":2007,"lang":"en","type":"article","venue":"European Journal of Clinical Pharmacology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Manitoba Health","funders":"Pfizer","keywords":"Medical prescription; Medicine; Celecoxib; Early adopter; Family medicine; Logistic regression; Pharmacovigilance; Specialty; Population; Drug; Pharmacology; Internal medicine; Environmental health; Business","score_opus":0.08873143451036468,"score_gpt":0.36007470077563947,"score_spread":0.2713432662652748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042978277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99079597,0.00011545268,0.00008688346,0.0011712367,0.0022091868,0.00018730682,0.000031735846,0.0000038341004,0.005398368],"genre_scores_gemma":[0.9955541,0.000037959664,0.00017406531,0.0035956982,0.0005804349,6.283508e-7,0.0000019409397,0.000027294911,0.000027872244],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950728,0.00044885732,0.0038406113,0.00023019382,0.000061739156,0.0003457885],"domain_scores_gemma":[0.99650764,0.00089068623,0.0020948097,0.00013740775,0.00006601278,0.00030342114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008237216,0.00014340907,0.00085408054,0.0003235217,0.000028397804,0.000013121218,0.00042292802,0.00003821101,0.00044315954],"category_scores_gemma":[0.00037643174,0.00015742502,0.0001978767,0.00020087032,0.00004288804,0.0001345561,0.000059490205,0.0006354037,0.000025242689],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00089264545,0.0004646557,0.9924669,0.000013806228,0.00014883747,0.00016421791,0.00021476374,0.00026517373,0.00006828689,0.00014093245,0.0009551121,0.0042046225],"study_design_scores_gemma":[0.004921731,0.00037182713,0.9850664,0.000012926842,0.000023299022,0.0000025129643,0.000058005036,0.0007849882,0.00004201589,0.000092873954,0.008480856,0.00014252983],"about_ca_topic_score_codex":0.038311288,"about_ca_topic_score_gemma":0.015557366,"teacher_disagreement_score":0.02275392,"about_ca_system_score_codex":0.0002193552,"about_ca_system_score_gemma":0.00032433224,"threshold_uncertainty_score":0.9680927},"labels":[],"label_agreement":null},{"id":"W2042983142","doi":"10.1503/cmaj.110226","title":"Is this pill safe? Substandard medicines, mistaken solutions","year":2011,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Pill; Wonder; Vendor; Medical prescription; Medicine; Developing country; Internet privacy; Medical emergency; Business; Computer science; Marketing; Pharmacology; Economic growth","score_opus":0.0755745522056978,"score_gpt":0.2609466279303425,"score_spread":0.1853720757246447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042983142","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017684752,0.0032784727,0.0005691231,0.1845042,0.0031657703,0.00016879365,0.0010539356,0.000032072712,0.7895429],"genre_scores_gemma":[0.79663706,0.0030213213,0.00035592474,0.19096771,0.0032292127,0.000012700308,0.000023594488,0.00005486446,0.0056975926],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99803627,0.000036543537,0.000815161,0.00021686513,0.00017344169,0.0007217294],"domain_scores_gemma":[0.99718815,0.00007198025,0.000388843,0.00014895554,0.00013674986,0.0020653212],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0024051426,0.00013813975,0.0003423795,0.00029123662,0.0003702321,0.0000780699,0.00035998758,0.00034620552,0.099075325],"category_scores_gemma":[0.00094622717,0.00015284558,0.00016604988,0.00020850461,0.00006995656,0.00018371432,0.000019826242,0.0007863502,0.003439884],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000005894252,0.000030574614,0.049257252,0.000004693753,0.00014615632,0.000059271057,0.0012873979,3.2816243e-7,5.701637e-7,0.051539585,0.8943077,0.0033605834],"study_design_scores_gemma":[0.0006643944,0.000027067881,0.01297894,0.000013418762,0.000010316136,0.00006638541,0.000066688175,0.00043665382,0.000005444115,0.019706212,0.9658404,0.00018405949],"about_ca_topic_score_codex":0.0057520224,"about_ca_topic_score_gemma":0.011328436,"teacher_disagreement_score":0.7838453,"about_ca_system_score_codex":0.0012998807,"about_ca_system_score_gemma":0.0009840109,"threshold_uncertainty_score":0.99733603},"labels":[],"label_agreement":null},{"id":"W2043088524","doi":"10.3821/1913-701x(2008)141[160a:ssgicp]2.0.co;2","title":"2007 saw slowest growth in Canadian prescription drug sales in a decade","year":2008,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Prescription drug; Business; Drug; Medicine; Pharmacology","score_opus":0.0558902058270993,"score_gpt":0.2571253401250214,"score_spread":0.2012351342979221,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043088524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97496307,0.003770859,0.000012390277,0.0011427641,0.0025325916,0.00041082117,0.0014976359,0.000016047054,0.015653802],"genre_scores_gemma":[0.9763533,0.014479468,0.0000671403,0.0076783975,0.00060916727,0.00002895602,0.00005036489,0.00007332654,0.0006598918],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99574995,0.00009042627,0.0013445584,0.0006162516,0.00010132779,0.0020974865],"domain_scores_gemma":[0.99516994,0.00007966832,0.00032602056,0.00024090394,0.00012551136,0.004057945],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011496339,0.00043395045,0.000663924,0.0020127902,0.000564034,0.0001707771,0.00082373247,0.00012805956,0.0014675733],"category_scores_gemma":[0.00027061478,0.00059142313,0.00016317578,0.0009657456,0.00021554525,0.0007221587,0.000040280203,0.0011378614,0.00022471583],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013562573,0.00017070265,0.7478138,0.00023663449,0.00017993775,0.09089919,0.0049512344,0.0047402643,0.00010225124,0.009949531,0.13675112,0.0040696836],"study_design_scores_gemma":[0.00725329,0.000048462876,0.024229031,0.000072838135,0.00003582172,0.13940047,0.00002720275,0.03590876,0.00039708096,0.0052705863,0.78471285,0.002643618],"about_ca_topic_score_codex":0.9398615,"about_ca_topic_score_gemma":0.9907388,"teacher_disagreement_score":0.7235848,"about_ca_system_score_codex":0.009293346,"about_ca_system_score_gemma":0.0050257044,"threshold_uncertainty_score":0.9996537},"labels":[],"label_agreement":null},{"id":"W2043186204","doi":"10.3138/cras.2013.003","title":"The Maple Peril: From Presidential Policy to Pharmaceutical Importation, 1992–Present","year":2013,"lang":"en","type":"article","venue":"Canadian Review of American Studies","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Presidential system; Legislature; Politics; Executive branch; Public administration; Balance (ability); Public policy; Political science; Presidential campaign; Political economy; Law; Economics; Medicine","score_opus":0.06143048892045852,"score_gpt":0.3578666847622647,"score_spread":0.29643619584180614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043186204","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06866778,0.5120007,0.000031592717,0.3825699,0.00069607364,0.0019615327,0.0015956905,0.000032524502,0.032444227],"genre_scores_gemma":[0.5921429,0.3364489,0.0003283413,0.06930249,0.00082834327,0.00038523093,0.000022344117,0.000042902197,0.0004985548],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982787,0.00003482553,0.00082984014,0.00031367774,0.000044780703,0.0004981878],"domain_scores_gemma":[0.9984144,0.0001932212,0.00033262893,0.00037981808,0.00009390155,0.000586005],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003003646,0.00017692738,0.0006700568,0.00016148754,0.00019729855,0.000059894173,0.0003933346,0.000021355989,0.0007683178],"category_scores_gemma":[0.0005926739,0.00015455244,0.0001626404,0.00039676612,0.0003841157,0.00009771472,0.00009693278,0.000116755524,0.0010147329],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010189043,0.000032340868,0.009481147,0.00061961653,0.0008593969,0.0000052805253,0.0009097165,0.000013090861,0.000016177682,0.08374765,0.82107395,0.08323146],"study_design_scores_gemma":[0.000109738714,0.000032133063,0.015124295,0.00013242952,0.000020240592,0.0000010269855,0.0002605815,0.000079928286,0.000021450145,0.006084642,0.97794104,0.0001924733],"about_ca_topic_score_codex":0.28137264,"about_ca_topic_score_gemma":0.023956714,"teacher_disagreement_score":0.5234751,"about_ca_system_score_codex":0.00026519416,"about_ca_system_score_gemma":0.0001960804,"threshold_uncertainty_score":0.9997631},"labels":[],"label_agreement":null},{"id":"W20432676","doi":"10.15173/m.v1i6.647","title":"Big Pharma: In Whose Best Interest?","year":2012,"lang":"en","type":"article","venue":"The Meducator","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Peer review; Medicine; Political science; Law","score_opus":0.19788396286989712,"score_gpt":0.3421402852854408,"score_spread":0.1442563224155437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W20432676","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94030106,0.005033541,0.000011385515,0.010234603,0.0023203362,0.00013866801,0.000044643268,0.000013299208,0.04190244],"genre_scores_gemma":[0.9934562,0.00041914594,0.000034341127,0.0039826985,0.0010481264,0.000038052993,0.0000027310546,0.00002135557,0.0009973488],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989841,0.000019055557,0.00037466278,0.00015941821,0.000012147963,0.00045061583],"domain_scores_gemma":[0.99933344,0.000079274396,0.00010949571,0.00028244904,0.0000049419473,0.0001904184],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00069714483,0.000117254,0.00022259206,0.00013954642,0.000052080446,0.000037802303,0.00032782034,0.00004690703,0.0009781924],"category_scores_gemma":[0.000083319545,0.00010269123,0.00007304243,0.0001663561,0.00007107504,0.00015172859,0.000086938955,0.00022408442,0.006339422],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003854464,0.0010187686,0.16431992,0.00003919983,0.000084833904,0.0000016704873,0.006267233,0.0000054948873,0.00024343486,0.79124343,0.022068663,0.014668806],"study_design_scores_gemma":[0.0004961879,0.000017417506,0.017009417,0.000009000783,0.000007181039,0.000006647477,0.0002252977,0.00016943843,0.00079891103,0.017182468,0.9638274,0.00025065528],"about_ca_topic_score_codex":0.00019595746,"about_ca_topic_score_gemma":0.000027392258,"teacher_disagreement_score":0.9417587,"about_ca_system_score_codex":0.00011174846,"about_ca_system_score_gemma":0.00002612994,"threshold_uncertainty_score":0.99993503},"labels":[],"label_agreement":null},{"id":"W2043816730","doi":"10.1016/j.jval.2012.09.004","title":"What Is Wrong with Orphan Drug Policies?","year":2012,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":110,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Orphan drug; Business; Bioinformatics; Biology","score_opus":0.1068436613679914,"score_gpt":0.32903839067299734,"score_spread":0.22219472930500594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043816730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9178277,0.02178853,0.000078201454,0.04159255,0.0012867494,0.00040608068,0.00010972743,0.00004089371,0.016869549],"genre_scores_gemma":[0.97310513,0.0055900025,0.0003065683,0.019950412,0.00035809996,0.000018865401,0.0000053506556,0.000032125296,0.00063342904],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99830735,0.000031496078,0.0006052117,0.00025663528,0.000026887832,0.00077243923],"domain_scores_gemma":[0.9990151,0.000069481874,0.00025392103,0.00028678196,0.0000073033048,0.00036744477],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010731455,0.00014723075,0.00037919314,0.00023944143,0.00008107169,0.00009097789,0.00017807126,0.000054567146,0.00040515652],"category_scores_gemma":[0.00001616593,0.0001564841,0.00005316387,0.00025235157,0.000049305312,0.0007034296,0.000047917954,0.00020890738,0.0009743754],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028618675,0.00025358883,0.26574966,0.00016963732,0.0000339072,0.00000126383,0.009866913,0.00075921864,0.0000013492112,0.7127651,0.0075385906,0.0028321662],"study_design_scores_gemma":[0.0014314024,0.0001129177,0.050309613,0.0001409249,0.0000030244173,0.000015578926,0.0005140444,0.010636137,0.00010759523,0.030660031,0.90547216,0.0005965818],"about_ca_topic_score_codex":0.0074958545,"about_ca_topic_score_gemma":0.0000632816,"teacher_disagreement_score":0.89793354,"about_ca_system_score_codex":0.00031640043,"about_ca_system_score_gemma":0.000067162495,"threshold_uncertainty_score":0.9998035},"labels":[],"label_agreement":null},{"id":"W2043981535","doi":"10.1111/j.1365-3156.2008.02186.x","title":"Pharmacy customers’ knowledge of side effects of purchased medicines in Mexico","year":2008,"lang":"en","type":"article","venue":"Tropical Medicine & International Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; Simon Fraser University; Rijksuniversiteit Groningen","keywords":"Medical prescription; Pharmacy; Medicine; Family medicine; Multinomial logistic regression; Odds ratio; Logistic regression; Community pharmacy; Environmental health; Traditional medicine; Nursing; Internal medicine","score_opus":0.08161809352521997,"score_gpt":0.3808070559063829,"score_spread":0.29918896238116294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043981535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89234203,0.008007748,0.0009719103,0.04997145,0.0019851292,0.0004748606,0.00007752711,0.00002355614,0.046145786],"genre_scores_gemma":[0.9927008,0.0031880932,0.00012816988,0.00344869,0.00037323212,0.000015372221,0.0000146951525,0.000014183146,0.00011677697],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99815583,0.000036556696,0.0012256952,0.00024939468,0.00006843726,0.00026406194],"domain_scores_gemma":[0.9987584,0.00037733492,0.00044405088,0.00015398298,0.000052624226,0.00021360438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028900985,0.00013677843,0.00072446384,0.00048490672,0.000026580536,0.0000011776174,0.00027145803,0.00004521761,0.00028300742],"category_scores_gemma":[0.0004273507,0.0001303381,0.000084778454,0.00023203378,0.0003054191,0.00007337702,0.000048010043,0.00022080715,0.000058003356],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033201402,0.0011674173,0.47497278,0.00083908555,0.00017553518,0.000024172256,0.0048095714,0.00005907679,0.00037567702,0.49300316,0.007346384,0.01689511],"study_design_scores_gemma":[0.014539169,0.001029919,0.73490363,0.0005642236,0.000012766779,0.000035048368,0.000076826014,0.012294167,0.0015951362,0.014538943,0.22006415,0.0003460164],"about_ca_topic_score_codex":0.0011019018,"about_ca_topic_score_gemma":0.000056426743,"teacher_disagreement_score":0.47846422,"about_ca_system_score_codex":0.00018412215,"about_ca_system_score_gemma":0.000108558896,"threshold_uncertainty_score":0.5315034},"labels":[],"label_agreement":null},{"id":"W2044157541","doi":"10.1503/cmaj.110808","title":"The backlash against bioequivalence and the interchangeability of brand-name and generic drugs","year":2011,"lang":"en","type":"letter","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Agency for Healthcare Research and Quality","keywords":"Interchangeability; Bioequivalence; Brand names; Medicine; Computer science; Pharmacology; Advertising; Business","score_opus":0.03577305740974529,"score_gpt":0.23814005675801553,"score_spread":0.20236699934827024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044157541","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015346889,0.0073502,0.000015646905,0.9649998,0.0011012459,0.00017443845,0.00036737268,0.0000038099447,0.0106406],"genre_scores_gemma":[0.052650798,0.03098792,0.000020200772,0.91163826,0.0038262738,0.000015485153,0.000012632588,0.000030949734,0.0008174621],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99812603,0.0001709216,0.00085452944,0.00023126943,0.00013746416,0.00047978017],"domain_scores_gemma":[0.99761933,0.0007849126,0.00080047484,0.00019288849,0.00008794281,0.00051442574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045431987,0.00016891144,0.00049667247,0.00013436531,0.00032239454,0.00017727388,0.00048120553,0.00061844965,0.0007415651],"category_scores_gemma":[0.0013948041,0.00011958049,0.0001502412,0.00009164303,0.000554777,0.000082493614,0.00007721725,0.0020817404,0.00006401357],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012663689,0.000005731347,0.0055511915,0.000042267326,0.00023769305,0.000016934493,0.0010341088,1.6704158e-7,8.541551e-8,0.0067824367,0.9642988,0.02201796],"study_design_scores_gemma":[0.0007177414,0.0000136845665,0.0015707078,0.000025199333,0.000015617336,0.000026437374,0.000040147414,0.00048816617,5.141515e-7,0.015475782,0.98148763,0.00013834499],"about_ca_topic_score_codex":0.0024525372,"about_ca_topic_score_gemma":0.0026272954,"teacher_disagreement_score":0.05336152,"about_ca_system_score_codex":0.00039819835,"about_ca_system_score_gemma":0.00043469877,"threshold_uncertainty_score":0.9044242},"labels":[],"label_agreement":null},{"id":"W2044978514","doi":"10.1515/fhep-2012-0036","title":"Should Global Health be Tailored Toward the Rich? Altruism and Efficient R&amp;D for Neglected Diseases","year":2013,"lang":"en","type":"article","venue":"Forum for Health Economics & Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Altruism (biology); Economics; Perspective (graphical); Affect (linguistics); Public economics; Developing country; Microeconomics; Economic growth; Sociology; Psychology; Social psychology; Computer science","score_opus":0.09748944440223069,"score_gpt":0.3743577228096235,"score_spread":0.2768682784073928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044978514","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16962165,0.0095574185,0.0056807348,0.79216003,0.0011954155,0.0059174635,0.01443591,0.00013467875,0.001296723],"genre_scores_gemma":[0.79204696,0.0044251285,0.001909331,0.19767718,0.001277409,0.0017113431,0.00048329498,0.00013057934,0.0003387707],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957152,0.00003586966,0.0015964458,0.00084220513,0.000029721206,0.0017805424],"domain_scores_gemma":[0.9970062,0.00033980852,0.0009694811,0.00060958386,0.000059779733,0.0010151488],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00051657297,0.00044038086,0.001047508,0.00027030686,0.0007499877,0.00032174445,0.0005303267,0.00017213103,0.0000925897],"category_scores_gemma":[0.000303698,0.00043988324,0.0003404554,0.00024788722,0.00020437967,0.00023008308,0.00018825526,0.00020375449,0.00017027],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000103231294,0.0001606482,0.0022610927,0.00028359034,0.00013296057,3.7993697e-8,0.0009014994,0.00069706264,7.317537e-7,0.8837593,0.099179134,0.01252069],"study_design_scores_gemma":[0.0019620198,0.0003275847,0.008310662,0.0000126154955,0.000010251777,0.000006510376,0.00013959619,0.03584076,0.0000029650942,0.2701691,0.6827657,0.00045220673],"about_ca_topic_score_codex":0.006072138,"about_ca_topic_score_gemma":0.00074208755,"teacher_disagreement_score":0.6224253,"about_ca_system_score_codex":0.0013921565,"about_ca_system_score_gemma":0.0008930039,"threshold_uncertainty_score":0.9998053},"labels":[],"label_agreement":null},{"id":"W2045148891","doi":"10.1038/clpt.2011.10","title":"The Value and Benefits of the International Conference on Harmonisation to Drug Regulatory Authorities: Advancing Harmonization for Better Public Health","year":2011,"lang":"en","type":"article","venue":"Clinical Pharmacology & Therapeutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Harmonization; Public health; Drug approval; Drug; Value (mathematics); Business; Pharmacology; Medicine; Environmental health; Public administration; Political science; Computer science","score_opus":0.35828282244946014,"score_gpt":0.40471093666152846,"score_spread":0.04642811421206833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045148891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6047359,0.0013415398,0.0028325168,0.3808842,0.0061427513,0.0012063982,0.0003160603,0.00003430765,0.0025063024],"genre_scores_gemma":[0.8491364,0.0027541579,0.0009570142,0.14650528,0.0003827744,0.000060450413,0.000006225445,0.000023973285,0.00017370879],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99839026,0.000097116856,0.0008615751,0.00030633292,0.00003942914,0.00030529217],"domain_scores_gemma":[0.99857765,0.00047644918,0.00049408467,0.00021563924,0.00008961321,0.00014656645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019102311,0.00012705434,0.0002702764,0.0000685716,0.00026876328,0.000043671993,0.0004667518,0.000087856075,0.00006867489],"category_scores_gemma":[0.00007208916,0.00010311548,0.000112748756,0.00008325039,0.00025775976,0.00009770159,0.00012295923,0.00024195372,0.000017091206],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037249658,0.00050505647,0.038204495,0.000053711075,0.0007013452,1.5731176e-7,0.003944124,0.00014615398,0.00018289882,0.8872354,0.023454117,0.04520005],"study_design_scores_gemma":[0.0031700165,0.0005543884,0.10495766,0.000033373537,0.00008374166,0.0000020769708,0.00029219716,0.047595054,0.002722764,0.11831528,0.721806,0.0004674709],"about_ca_topic_score_codex":0.000011097819,"about_ca_topic_score_gemma":0.000010024324,"teacher_disagreement_score":0.7689201,"about_ca_system_score_codex":0.00010047323,"about_ca_system_score_gemma":0.00009967994,"threshold_uncertainty_score":0.42049274},"labels":[],"label_agreement":null},{"id":"W2045226478","doi":"10.2165/00019053-200523120-00002","title":"Comment on ???The Economics of Follow-On Drug Research and Development: Trends in Entry Rates and the Timing of Development???","year":2005,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":104,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Institute of Health Economics","funders":"","keywords":"Drug development; Drug; Pharmaceutical industry; Competition (biology); Drug class; Medicine; Marketing; Pharmacology; Business; Actuarial science","score_opus":0.17386903855911948,"score_gpt":0.36626858022991754,"score_spread":0.19239954167079806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045226478","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30284533,0.0021530846,0.0000031684242,0.66745406,0.00045643083,0.0007538246,0.00038263848,0.000011826156,0.02593963],"genre_scores_gemma":[0.39112824,0.011201588,0.00045612326,0.5935367,0.0011462971,0.00029434063,0.00019959321,0.00018109851,0.0018560202],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99642813,0.00013848575,0.0019458369,0.00073435216,0.00005736765,0.0006958169],"domain_scores_gemma":[0.99641544,0.0019935677,0.00096657936,0.00047638261,0.00003473847,0.000113301045],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0035384097,0.0004730193,0.0011875338,0.0010368249,0.00023918953,0.00012665002,0.00076226855,0.0002879849,0.00046115],"category_scores_gemma":[0.00005377648,0.000412589,0.00013282712,0.0001691405,0.00064278004,0.00014019283,0.00039802215,0.0017316799,0.000113092174],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082493835,0.00034722823,0.0033070864,0.00039480894,0.0009802178,0.000007226528,0.0060030334,0.00035285958,0.00000480708,0.1211744,0.8376201,0.028983342],"study_design_scores_gemma":[0.00327224,0.000036809153,0.000305818,0.00006951567,0.000012380837,0.000002519693,0.000070211296,0.0030909202,0.0015946514,0.0046613575,0.9864572,0.00042636957],"about_ca_topic_score_codex":0.00011354283,"about_ca_topic_score_gemma":0.000047002104,"teacher_disagreement_score":0.14883715,"about_ca_system_score_codex":0.0004484579,"about_ca_system_score_gemma":0.00014372668,"threshold_uncertainty_score":0.9998326},"labels":[],"label_agreement":null},{"id":"W2045394072","doi":"10.1056/nejmsa003087","title":"Outcomes of Reference Pricing for Angiotensin-Converting–Enzyme Inhibitors","year":2002,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":181,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ministry of Health","funders":"Ministry of Health, British Columbia; Pfizer; Bristol-Myers Squibb; Deutsche Forschungsgemeinschaft; Agency for Healthcare Research and Quality; U.S. Department of Health and Human Services","keywords":"Medicine; Medical prescription; Cost sharing; Angiotensin-converting enzyme; Confidence interval; Christian ministry; Hazard ratio; Emergency medicine; Internal medicine; Pharmacology; Blood pressure","score_opus":0.10480406409050488,"score_gpt":0.29846945812680237,"score_spread":0.19366539403629748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045394072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90952677,0.010705283,0.0031626814,0.057888918,0.0022817987,0.00026615313,0.00005411822,0.00001421679,0.016100053],"genre_scores_gemma":[0.99464554,0.00072767347,0.00067564787,0.0018328414,0.0016126741,6.233625e-7,0.0000013345817,0.000014928251,0.00048875425],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984352,0.000011299528,0.0011680331,0.00012624021,0.00004737184,0.0002118532],"domain_scores_gemma":[0.9983433,0.00028664182,0.0009514435,0.00013149233,0.00008271199,0.00020440047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089996733,0.00012242919,0.00071156706,0.0002722817,0.000033630327,0.000008051879,0.0001765384,0.000064544176,0.00044388193],"category_scores_gemma":[0.00067673175,0.00009859036,0.00012803209,0.000111286885,0.00006739284,0.00011793808,0.000019394081,0.00019168593,0.000017541253],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006793668,0.0004624257,0.3113986,0.00032629547,0.0012025832,0.000049873954,0.008406687,0.00051210675,0.0036170422,0.18624951,0.24708174,0.24001378],"study_design_scores_gemma":[0.04713032,0.0015479714,0.023165217,0.0002552846,0.00010791707,0.00014457302,0.00008918616,0.0066034873,0.002162066,0.051229693,0.8671482,0.0004160832],"about_ca_topic_score_codex":0.00008955059,"about_ca_topic_score_gemma":0.00000674011,"teacher_disagreement_score":0.62006646,"about_ca_system_score_codex":0.000042684493,"about_ca_system_score_gemma":0.000018001398,"threshold_uncertainty_score":0.4860196},"labels":[],"label_agreement":null},{"id":"W2045581095","doi":"10.1016/j.actpha.2014.11.024","title":"Les grossistes-répartiteurs : comparaison Québec/France","year":2015,"lang":"fr","type":"article","venue":"Actualités Pharmaceutiques","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Humanities; Political science; Art","score_opus":0.3103670087201568,"score_gpt":0.4105464221074696,"score_spread":0.10017941338731279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045581095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39487347,0.3574774,0.00071236095,0.10371927,0.0071331095,0.00074295595,0.0015850717,0.00032126936,0.13343509],"genre_scores_gemma":[0.89870095,0.011589028,0.00085364096,0.023956317,0.0019408129,0.00009591023,0.00008398742,0.00017487067,0.062604494],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99538964,0.00024963001,0.0017621894,0.0010664401,0.00012596861,0.0014061342],"domain_scores_gemma":[0.99670994,0.00038608143,0.0008012314,0.0007374221,0.00015125157,0.0012140846],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0018704087,0.0007142924,0.0012692221,0.00030845325,0.0002751942,0.00041528489,0.00089457876,0.00046820386,0.0038085543],"category_scores_gemma":[0.0003548205,0.0009555995,0.00047409235,0.00044276542,0.0006955058,0.0010188323,0.00028940482,0.0010137015,0.006980903],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029121712,0.0012112885,0.12367363,0.0005056874,0.00081883295,0.00006669091,0.013276586,0.00050416694,0.00011500088,0.3553372,0.3257588,0.17844088],"study_design_scores_gemma":[0.0021021885,0.00015985005,0.0023585504,0.000097969714,0.0000724019,0.00004232236,0.0002043421,0.009885099,0.0026223133,0.007873701,0.97350585,0.0010754291],"about_ca_topic_score_codex":0.032867823,"about_ca_topic_score_gemma":0.001454414,"teacher_disagreement_score":0.64774704,"about_ca_system_score_codex":0.0008930482,"about_ca_system_score_gemma":0.00034722092,"threshold_uncertainty_score":0.99928945},"labels":[],"label_agreement":null},{"id":"W2046217307","doi":"10.4212/cjhp.v66i3.1251","title":"Leçons tirées des tragédies liées aux préparations magistrales de médicaments","year":2013,"lang":"fr","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Art; Gynecology; Political science; Medicine","score_opus":0.08379221427125566,"score_gpt":0.3147730043262652,"score_spread":0.23098079005500954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046217307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7275905,0.054445613,0.00006179715,0.20100631,0.0025888635,0.0002976506,0.00052495464,0.000005998672,0.013478296],"genre_scores_gemma":[0.9804832,0.0070247394,0.00039492184,0.0034660832,0.0010438045,0.000015983955,0.000004752831,0.000041308824,0.0075252466],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977307,0.00006670489,0.0010245802,0.00019923739,0.000051179195,0.0009276096],"domain_scores_gemma":[0.9976325,0.00013646382,0.0006426032,0.00022553411,0.00017764501,0.001185272],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0006460466,0.0002724386,0.0004618873,0.0003112569,0.00075544347,0.0007738211,0.00078907015,0.000090225934,0.0053329803],"category_scores_gemma":[0.00022764878,0.00027395168,0.00034812762,0.0002162173,0.0012788597,0.0011096596,0.000037141726,0.00067227264,0.0011895089],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002529411,0.00040736585,0.19511601,0.00016452548,0.0013289034,0.00013732766,0.010858656,0.0011229406,0.000055123826,0.22108354,0.53618085,0.03351943],"study_design_scores_gemma":[0.0010268127,0.00025087327,0.046960592,0.000108388966,0.000118360964,0.00014172084,0.00035321838,0.0025505887,0.0002517034,0.13244931,0.8153224,0.0004660071],"about_ca_topic_score_codex":0.06908878,"about_ca_topic_score_gemma":0.025363192,"teacher_disagreement_score":0.27914155,"about_ca_system_score_codex":0.00070888293,"about_ca_system_score_gemma":0.0014191762,"threshold_uncertainty_score":0.9999713},"labels":[],"label_agreement":null},{"id":"W2046246470","doi":"10.5433/2176-6665.2006v11n2p113","title":"O medicamento, um objeto de futuro na antropologia da saúde","year":2006,"lang":"pt","type":"article","venue":"Mediações Revista de Ciências Sociais","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint Paul University","funders":"","keywords":"Humanities; Philosophy; Medicine","score_opus":0.03538798236954625,"score_gpt":0.29161400727968695,"score_spread":0.2562260249101407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046246470","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.72818667,0.112730265,0.003944845,0.03984833,0.004717219,0.0016087883,0.0046873353,0.00037424255,0.10390232],"genre_scores_gemma":[0.96830195,0.010745558,0.000574639,0.009886352,0.0045597027,0.00010156868,0.00023295126,0.0001805234,0.005416749],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99403036,0.00023103149,0.002110297,0.001162706,0.00017957807,0.0022860295],"domain_scores_gemma":[0.9963788,0.00055110396,0.0012202627,0.00083372125,0.00009018549,0.00092592405],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0025685048,0.000774056,0.0017156833,0.0004531777,0.000539108,0.00071049674,0.001146385,0.0008852721,0.0054438408],"category_scores_gemma":[0.0010335001,0.00097009685,0.00078216376,0.000665749,0.0007264765,0.00029613436,0.00035295758,0.0011492532,0.002151135],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008745753,0.0006721763,0.25537607,0.00055630115,0.0005782956,0.00017707045,0.0023843707,0.00005888499,0.0001511472,0.32376343,0.40595606,0.01023873],"study_design_scores_gemma":[0.001926989,0.00015179403,0.053232126,0.00010811156,0.00018087735,0.000031872678,0.00041439797,0.0057453476,0.00015155446,0.018784894,0.9179147,0.0013573456],"about_ca_topic_score_codex":0.0018078673,"about_ca_topic_score_gemma":0.00015380062,"teacher_disagreement_score":0.51195866,"about_ca_system_score_codex":0.0027472593,"about_ca_system_score_gemma":0.0006378788,"threshold_uncertainty_score":0.99927497},"labels":[],"label_agreement":null},{"id":"W2046439479","doi":"10.1503/cmaj.1070167","title":"France's health care system","year":2008,"lang":"en","type":"letter","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"LOPES; Healthcare system; Health care; Medicine; Political science; Law","score_opus":0.022216905179399008,"score_gpt":0.24609099521230207,"score_spread":0.22387409003290307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046439479","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010746253,0.0097455485,0.000037059333,0.9333266,0.004495972,0.00014965599,0.0014952369,0.000028561903,0.050613914],"genre_scores_gemma":[0.0017964637,0.0021439043,0.00004326254,0.9701704,0.023563452,0.000011690089,0.0001556966,0.00006463529,0.0020504962],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99666876,0.00009898157,0.0014028988,0.00038034498,0.0002927595,0.0011562601],"domain_scores_gemma":[0.9963355,0.00010742799,0.0012769724,0.0002231545,0.00014910464,0.0019078573],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0012166784,0.00028021864,0.0009248085,0.00053076877,0.00053216825,0.00019883772,0.0006042603,0.0017980766,0.0036463563],"category_scores_gemma":[0.000371846,0.00033903023,0.00035164203,0.00018276389,0.000047227637,0.000114308255,0.000024267154,0.005135997,0.0041546156],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[4.6691036e-7,0.0000030320298,0.002157498,0.00007462383,0.00012070489,0.0005622063,0.0002900507,0.0000015913377,1.7232529e-9,0.0013955603,0.99368125,0.0017129865],"study_design_scores_gemma":[0.00045939544,0.000023786994,0.00036499076,0.00007823905,0.0000046683986,0.00038449213,0.000058727757,0.00013444436,6.666171e-8,0.00020134175,0.99797326,0.00031655497],"about_ca_topic_score_codex":0.0076860124,"about_ca_topic_score_gemma":0.0033589667,"teacher_disagreement_score":0.048563417,"about_ca_system_score_codex":0.0076713227,"about_ca_system_score_gemma":0.0045439852,"threshold_uncertainty_score":0.9999062},"labels":[],"label_agreement":null},{"id":"W2046647352","doi":"10.1097/mlr.0b013e31818af850","title":"Is There a Relationship Between Patient Beliefs or Communication About Generic Drugs and Medication Utilization?","year":2009,"lang":"en","type":"article","venue":"Medical Care","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute; National Institute on Aging; Canadian Institutes of Health Research","keywords":"Pharmacy; Scale (ratio); Medical prescription; Medicine; Generic drug; Family medicine; Health communication; Drug; Actuarial science; Psychology; Nursing; Business; Pharmacology","score_opus":0.13411466758024482,"score_gpt":0.3455821168426299,"score_spread":0.2114674492623851,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046647352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8816594,0.03082979,0.001209892,0.048341308,0.00018227336,0.00045488274,0.00034437687,0.00009423022,0.036883846],"genre_scores_gemma":[0.9891664,0.0022161896,0.00022534833,0.007939878,0.00014126369,0.000019021949,0.00017167963,0.000013316959,0.000106943335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988372,0.000037857328,0.0005630192,0.00027495922,0.000086261374,0.00020074302],"domain_scores_gemma":[0.9989404,0.00019373819,0.00020527164,0.00033929,0.000036372378,0.00028494],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00032850198,0.00012243398,0.0002477171,0.00010895547,0.00018683611,0.000048594076,0.0002411269,0.0001945836,0.0009547992],"category_scores_gemma":[0.00038010688,0.00011867366,0.00005079319,0.0001909847,0.00009416531,0.00012700328,0.00006224902,0.00024503717,0.00016378063],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021488706,0.00008821399,0.595376,0.00007811483,0.000039391354,0.0000021853093,0.016339654,0.000004810406,4.4452815e-7,0.17189808,0.008440377,0.20771125],"study_design_scores_gemma":[0.0007640566,0.000111337315,0.7642189,0.000059586502,0.0000146771345,0.0000028598504,0.00037425413,0.0018105238,0.000020937287,0.031960264,0.20040305,0.0002595559],"about_ca_topic_score_codex":0.000060774226,"about_ca_topic_score_gemma":0.000018024208,"teacher_disagreement_score":0.20745169,"about_ca_system_score_codex":0.00009943398,"about_ca_system_score_gemma":0.000061509665,"threshold_uncertainty_score":0.99995846},"labels":[],"label_agreement":null},{"id":"W2047820600","doi":"10.1136/bmj.327.7419.832-e","title":"Canada decides to lead the way in exempting AIDS drugs from patent laws","year":2003,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Law; Computer science; Data science; Political science","score_opus":0.09205129873463155,"score_gpt":0.2849247797897849,"score_spread":0.19287348105515337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047820600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90054154,0.0006566449,0.00008048164,0.012192083,0.0005315443,0.00025498125,0.00019990209,0.00000826007,0.085534535],"genre_scores_gemma":[0.98609364,0.000056360044,0.00044083758,0.012610766,0.00015021772,0.000040528535,0.0000044321446,0.000015998088,0.00058720313],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99883014,0.000023714345,0.0005265513,0.00025974217,0.0000249053,0.00033492385],"domain_scores_gemma":[0.9993192,0.00016684622,0.000114889874,0.00027535268,0.000008339941,0.00011539781],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063633185,0.0001124036,0.00024363257,0.000066164925,0.00006897883,0.000055973404,0.00022400172,0.000042581796,0.00044300652],"category_scores_gemma":[0.00023714257,0.000105979125,0.00005119047,0.00014940072,0.00001842029,0.000059989477,0.000049456572,0.00014021854,0.00040643272],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003496446,0.0000919468,0.22878988,0.000015759457,0.00009873255,0.000021588592,0.0018501946,0.002379111,0.00008032269,0.6199935,0.12929483,0.017349133],"study_design_scores_gemma":[0.00043119624,0.000013639263,0.027504846,0.000011197903,0.0000023990149,0.000001080615,0.0001666706,0.0012675866,0.00048799766,0.024457611,0.9454029,0.00025283164],"about_ca_topic_score_codex":0.506097,"about_ca_topic_score_gemma":0.31590313,"teacher_disagreement_score":0.8161081,"about_ca_system_score_codex":0.00023459147,"about_ca_system_score_gemma":0.000104440114,"threshold_uncertainty_score":0.6965799},"labels":[],"label_agreement":null},{"id":"W2048129967","doi":"10.1503/cmaj.109-3919","title":"Company profits from side effects of glaucoma treatment","year":2011,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Bimatoprost; Glaucoma; Medicine; Open angle glaucoma; Side effect (computer science); Optometry; Ophthalmology; Computer science; Ocular hypertension","score_opus":0.03451371428176609,"score_gpt":0.24105030886724152,"score_spread":0.20653659458547544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048129967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93033445,0.001154323,0.00008831868,0.006109058,0.0012873021,0.00014326102,0.00026174678,0.000009632007,0.06061191],"genre_scores_gemma":[0.9929418,0.00034852058,0.00016628082,0.005701441,0.0006128882,0.000006581246,0.000008482676,0.00001333662,0.00020065634],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99879986,0.000036652382,0.00059568003,0.00014163106,0.00007777645,0.00034842905],"domain_scores_gemma":[0.9982124,0.00015098501,0.0004022837,0.00009933376,0.000047006262,0.0010880218],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004632792,0.00010374277,0.00035467977,0.00016060461,0.00008397514,0.000028662924,0.00019988767,0.00020742348,0.0033272128],"category_scores_gemma":[0.00045397822,0.000108488304,0.00012965464,0.00009010376,0.000029700586,0.00009375621,0.000011193869,0.00026709624,0.0006637809],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001753645,0.00020935306,0.8959094,0.000017649032,0.0006518277,0.00017046595,0.0020269812,5.680244e-7,0.00001302023,0.052390322,0.01981229,0.02878054],"study_design_scores_gemma":[0.0020092975,0.00014541105,0.5817312,0.000035380242,0.000023578434,0.00001935145,0.000042093612,0.00088030106,0.00050903525,0.030234132,0.38413143,0.00023879852],"about_ca_topic_score_codex":0.017984042,"about_ca_topic_score_gemma":0.010251686,"teacher_disagreement_score":0.36431915,"about_ca_system_score_codex":0.00085611653,"about_ca_system_score_gemma":0.0004486682,"threshold_uncertainty_score":0.99758387},"labels":[],"label_agreement":null},{"id":"W2048384137","doi":"10.1159/000103270","title":"Availability and Costs of Antiepileptic Drugs and Quality of Phenobarbital in Vientiane Municipality, Lao PDR","year":2007,"lang":"en","type":"article","venue":"Neuroepidemiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Francophone University Association","funders":"","keywords":"Phenobarbital; Medicine; Carbamazepine; Clonazepam; Pharmacy; Diazepam; Phenytoin; Pharmacology; Epilepsy; Family medicine; Psychiatry","score_opus":0.1166024646436997,"score_gpt":0.3604408273471674,"score_spread":0.24383836270346773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048384137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98816943,0.0014469516,0.00007288894,0.00044355026,0.00014607397,0.00016060303,0.00012972392,0.0000063790285,0.009424375],"genre_scores_gemma":[0.9980163,0.0007989923,0.00014675355,0.00097434164,0.00002432079,0.0000026734974,0.0000049351906,0.00000968874,0.000021989876],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997482,0.00017795309,0.0015722591,0.0004068254,0.00001724615,0.00034373646],"domain_scores_gemma":[0.99752384,0.0014603483,0.00056064205,0.00030401337,0.00002039098,0.00013073522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005002266,0.0001306393,0.0009048968,0.00018698395,0.000021697044,0.0000042080133,0.00014474973,0.00013073036,0.00007567943],"category_scores_gemma":[0.0014604017,0.00015119511,0.00007136548,0.00013387858,0.00059568946,0.000087824155,0.00016894066,0.00022363134,0.0000092807795],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005580894,0.00007813407,0.8030147,0.00007416512,0.000012628227,6.38973e-7,0.0001752642,0.0000074011423,0.00022518192,0.19551115,0.000033617172,0.0008113372],"study_design_scores_gemma":[0.0007583169,0.00009167793,0.9705367,0.000010150782,0.000004042741,0.0000023048242,0.000036199846,0.0009563248,0.00016369099,0.02602832,0.0012810801,0.00013117219],"about_ca_topic_score_codex":0.00317717,"about_ca_topic_score_gemma":0.0005899728,"teacher_disagreement_score":0.16948283,"about_ca_system_score_codex":0.000035494333,"about_ca_system_score_gemma":0.000010669398,"threshold_uncertainty_score":0.61655575},"labels":[],"label_agreement":null},{"id":"W2048635853","doi":"10.1016/s0828-282x(07)70815-2","title":"Lessons for a national pharmaceuticals strategy in Canada from Australia and New Zealand","year":2007,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"GlaxoSmithKline (Canada); Hôtel-Dieu de Montréal","funders":"GlaxoSmithKline; AstraZeneca; Pfizer; Bristol-Myers Squibb","keywords":"Formulary; Medicine; Health care; Environmental health; Economic growth; Family medicine","score_opus":0.1997814222660779,"score_gpt":0.3553022238896094,"score_spread":0.15552080162353152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048635853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9637946,0.002435003,0.001700807,0.015402731,0.0011756321,0.0001865745,0.00215398,0.0000016193757,0.013149078],"genre_scores_gemma":[0.9977561,0.000059267553,0.000109301574,0.0010893876,0.00076046877,0.0000010147965,0.0000070322367,0.000007828956,0.00020956199],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989364,0.000011237522,0.0005425447,0.00013118687,0.00001674411,0.0003618927],"domain_scores_gemma":[0.9988328,0.00019333788,0.0001671892,0.00004940517,0.000038891027,0.00071835925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006402034,0.000084255415,0.00038554685,0.00023386242,0.000029664125,0.000022821172,0.00012903537,0.00007770039,0.00015261196],"category_scores_gemma":[0.00012241112,0.00009913502,0.000062513674,0.00006300823,0.0000456701,0.000068599824,0.000005773303,0.00018906943,0.00000608103],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013455556,0.0000036409506,0.49760842,0.000013967138,0.00038189202,0.00013732328,0.00014833747,0.004153213,0.000082195394,0.24975821,0.24156232,0.0060159084],"study_design_scores_gemma":[0.0009441286,0.000024814692,0.21394756,0.000003825712,0.00000600296,0.000034983845,0.000017582342,0.00015351702,0.000032421052,0.059611306,0.725118,0.000105889725],"about_ca_topic_score_codex":0.80001855,"about_ca_topic_score_gemma":0.9719077,"teacher_disagreement_score":0.48355564,"about_ca_system_score_codex":0.0005902972,"about_ca_system_score_gemma":0.0022939665,"threshold_uncertainty_score":0.40693983},"labels":[],"label_agreement":null},{"id":"W2049305235","doi":"10.2217/cer.12.71","title":"Use of relative effectiveness information in reimbursement and pricing decisions in Europe","year":2012,"lang":"en","type":"article","venue":"Journal of Comparative Effectiveness Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Reimbursement; Process (computing); Medicine; Comparative effectiveness research; Actuarial science; Public economics; Economics; Health care; Computer science; Alternative medicine; Economic growth","score_opus":0.34571217471328664,"score_gpt":0.45467960943436125,"score_spread":0.10896743472107462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049305235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930772,0.0013200952,0.0028371976,0.00007786272,0.00014159991,0.00045949031,0.000017732798,0.000001415042,0.0020673587],"genre_scores_gemma":[0.99910265,0.00060342153,0.0002102283,0.000016766448,0.000035032517,0.000018732617,0.0000014144805,0.000007533279,0.0000042347906],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99750584,0.00096301327,0.0009451497,0.00012291354,0.00011057018,0.00035252268],"domain_scores_gemma":[0.9937418,0.005194146,0.00045024892,0.0001228106,0.00035079877,0.00014018772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0091525,0.00011915842,0.0006887649,0.0014609034,0.000053425738,0.0000529855,0.0001521679,0.0000682036,0.000014755726],"category_scores_gemma":[0.0017043377,0.00011468702,0.00005804933,0.0010197281,0.00014646916,0.002253537,0.00012301421,0.00064742705,0.000027570688],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012264026,0.0004868354,0.8179194,0.00013006983,0.000108595865,0.0000051952907,0.0043438156,0.0064261425,0.0008851999,0.16584791,0.000043011947,0.0025774154],"study_design_scores_gemma":[0.0015028378,0.0003115293,0.9777347,0.00036334846,0.0000033017657,0.000007638392,0.00011903185,0.0028296693,0.0028005287,0.00988289,0.004327418,0.0001171509],"about_ca_topic_score_codex":0.00014337344,"about_ca_topic_score_gemma":0.000010810992,"teacher_disagreement_score":0.15981525,"about_ca_system_score_codex":0.00037658957,"about_ca_system_score_gemma":0.0000756811,"threshold_uncertainty_score":0.4676801},"labels":[],"label_agreement":null},{"id":"W2049843830","doi":"10.1111/j.1365-2710.2006.00776.x","title":"Attitudes of Slovene general practitioners towards generic drug prescribing and comparison with international studies","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Pharmacy and Therapeutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Global Positioning System; Generic drug; Family medicine; Quarter (Canadian coin); Health care; Population; Quality (philosophy); Sample (material); Actuarial science; Drug; Business; Environmental health; Pharmacology; Geography; Computer science","score_opus":0.2811160729881908,"score_gpt":0.4623177939581965,"score_spread":0.1812017209700057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049843830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9757047,0.017319925,0.00029767674,0.0040027923,0.00057811214,0.00006393444,0.00003629438,0.0000040548625,0.0019924578],"genre_scores_gemma":[0.9696751,0.026353816,0.0020506114,0.0012757713,0.0005385692,0.0000010854911,0.0000020126827,0.0000117356585,0.000091279726],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981979,0.000040819123,0.0014227555,0.00015066157,0.00005669414,0.00013117633],"domain_scores_gemma":[0.99823856,0.00022912028,0.0012620218,0.00007072778,0.000112731344,0.00008683893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010116526,0.000118234224,0.00060586724,0.00010657845,0.00004744063,0.000045011646,0.00013076652,0.000036280373,0.000030333176],"category_scores_gemma":[0.00004478225,0.00009951482,0.00010877798,0.00006029746,0.00021690021,0.00027217562,0.00005109244,0.00028141646,0.0000017905422],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009226201,0.0009653105,0.9001225,0.000105543906,0.002218673,0.000012576715,0.00041025106,0.0012842116,0.0002723353,0.05930043,0.001791126,0.032594405],"study_design_scores_gemma":[0.011161247,0.0005619865,0.24643388,0.000117699885,0.00033734975,0.00011866374,0.00018991473,0.023836583,0.0019850852,0.047595806,0.6670818,0.00058002106],"about_ca_topic_score_codex":0.000044152504,"about_ca_topic_score_gemma":0.000007872446,"teacher_disagreement_score":0.66529065,"about_ca_system_score_codex":0.000023607474,"about_ca_system_score_gemma":0.000040130493,"threshold_uncertainty_score":0.40580967},"labels":[],"label_agreement":null},{"id":"W2050192040","doi":"10.1016/s1098-3015(10)70023-1","title":"CASE 2 DRUG ELUTING STENTS—AN EXAMPLE OFTHETRANSITION FROM EVIDENCETO POLICYTHROUGHTHE ONTARIO COMPREHENSIVE APPROACHTOTHE DIFFUSION OF HEALTHTECHNOLOGIES","year":2008,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Diffusion; Drug-eluting stent; Medicine; Internal medicine; Pharmacology; Stent; Physics; Thermodynamics; Restenosis","score_opus":0.3444027444756034,"score_gpt":0.32492176232762154,"score_spread":0.01948098214798183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050192040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939861,0.0018014312,0.00037485446,0.0022544973,0.00019726645,0.00048435037,0.00022289495,0.00005113265,0.0006274359],"genre_scores_gemma":[0.9940467,0.00169219,0.0022886025,0.0017610268,0.00009440816,0.000020237536,0.00002860142,0.000027031338,0.00004121788],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99752545,0.00011554257,0.0012578894,0.0005295157,0.000049979706,0.00052162295],"domain_scores_gemma":[0.9984679,0.00022933651,0.00059944304,0.0005004647,0.00002450731,0.00017834941],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006533971,0.0002008372,0.0007049634,0.00032820046,0.00023471036,0.000017494693,0.00025609776,0.00013103266,0.0001041572],"category_scores_gemma":[0.00003855581,0.00022519736,0.000103065046,0.0002693887,0.00015248457,0.0002601567,0.00008162966,0.00041014678,0.0000419142],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004996975,0.0028357382,0.32462403,0.0012661981,0.00020864354,0.0004387782,0.23043147,0.035026174,0.00029497108,0.3904182,0.0010199867,0.012936102],"study_design_scores_gemma":[0.011332387,0.0018703955,0.23752207,0.00091253966,0.000030006906,0.0017449382,0.011259444,0.33662942,0.001180536,0.33094978,0.06371096,0.0028575135],"about_ca_topic_score_codex":0.84050316,"about_ca_topic_score_gemma":0.0341028,"teacher_disagreement_score":0.80640036,"about_ca_system_score_codex":0.0005840835,"about_ca_system_score_gemma":0.00020851962,"threshold_uncertainty_score":0.9835223},"labels":[],"label_agreement":null},{"id":"W2051453363","doi":"10.1016/j.vaccine.2013.06.055","title":"Toward more specific and transparent research and development costs: The case of seasonal influenza vaccines","year":2013,"lang":"en","type":"article","venue":"Vaccine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada); Dalhousie University; University of Toronto","funders":"","keywords":"Seasonal influenza; Virology; Medicine; Coronavirus disease 2019 (COVID-19); Infectious disease (medical specialty); Disease; Internal medicine","score_opus":0.21976071450235382,"score_gpt":0.3590766264748642,"score_spread":0.1393159119725104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051453363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98439723,0.0078072464,0.000039837007,0.0060205623,0.000058128815,0.00029552326,0.0000588915,0.000007423898,0.0013151332],"genre_scores_gemma":[0.99745333,0.0015490509,0.00021941237,0.0005666866,0.0000824524,0.0000417878,0.0000037161976,0.000013525027,0.00007003216],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99898255,0.000014679304,0.0004546026,0.0002585312,0.000022748953,0.00026689057],"domain_scores_gemma":[0.9993764,0.00014818108,0.00008892076,0.00018280551,0.000057420235,0.0001462366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005242097,0.00011372417,0.00026045617,0.00013750223,0.0001272352,0.00007468762,0.00013384139,0.0000502464,0.00059408555],"category_scores_gemma":[0.000029438615,0.00009229237,0.000022418311,0.00013829368,0.00003836216,0.00012505673,0.00009763489,0.00017198762,0.0000997576],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023571229,0.00046308042,0.4475988,0.0004449291,0.00039047012,0.000096182775,0.008987203,0.000049229388,0.00026876363,0.390931,0.025818812,0.12471583],"study_design_scores_gemma":[0.0032781814,0.00017725994,0.4856605,0.000041889598,0.000007694132,0.00029909483,0.0011792997,0.0039424985,0.0010035286,0.026523758,0.4774078,0.0004784822],"about_ca_topic_score_codex":0.00047754828,"about_ca_topic_score_gemma":0.00006092426,"teacher_disagreement_score":0.45158902,"about_ca_system_score_codex":0.000056685534,"about_ca_system_score_gemma":0.000019104884,"threshold_uncertainty_score":0.650482},"labels":[],"label_agreement":null},{"id":"W2052186938","doi":"10.1212/wnl.0b013e3181df091b","title":"Generic antiepileptic drugs and associated medical resource utilization in the United States","year":2010,"lang":"en","type":"article","venue":"Neurology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Antiepileptic drug; Resource (disambiguation); MEDLINE; Medicine; Epilepsy; Intensive care medicine; Business; Psychiatry; Computer science; Political science","score_opus":0.05237934913727455,"score_gpt":0.28304846131644285,"score_spread":0.2306691121791683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052186938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9742004,0.00010746911,0.000019782936,0.020586425,0.00018598439,0.00008217286,0.000026785687,0.00001485186,0.0047761207],"genre_scores_gemma":[0.96021545,0.00049949787,0.000005188047,0.039120752,0.00006803342,0.000008045462,0.00005289536,0.000010893697,0.000019254634],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991498,0.00006688386,0.00030983117,0.0002171482,0.0000237181,0.00023262831],"domain_scores_gemma":[0.9993991,0.00026457687,0.00010513951,0.00015021498,0.000007330352,0.00007362779],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007589671,0.00008038416,0.00017649605,0.00018652833,0.00005409779,0.000029873489,0.00020684492,0.00016844827,0.0002688628],"category_scores_gemma":[0.00031049823,0.00007500552,0.000023491964,0.00025533175,0.00013060415,0.000038048045,0.000051822884,0.00046848095,0.000062093204],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015550961,0.000479008,0.41428402,0.000026483016,0.000061193685,0.000058071986,0.004068809,0.00035016082,0.00007643752,0.5619314,0.0124897035,0.006019244],"study_design_scores_gemma":[0.0008895327,0.00014136986,0.16656816,0.0000011436662,0.0000038264793,0.000020629668,0.000016789261,0.16551149,0.0000071288823,0.026421843,0.64027244,0.00014565629],"about_ca_topic_score_codex":0.0003144974,"about_ca_topic_score_gemma":0.00021015127,"teacher_disagreement_score":0.6277827,"about_ca_system_score_codex":0.000005938048,"about_ca_system_score_gemma":0.000011352112,"threshold_uncertainty_score":0.30586362},"labels":[],"label_agreement":null},{"id":"W2052701745","doi":"10.5539/ibr.v6n1p211","title":"Pharmacokinetic Tests: A Public Policy Tool of Science, Technology, and Innovation in Pharmaceutical Drugs for Brazil","year":2012,"lang":"en","type":"article","venue":"International Business Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Bioequivalence; Incentive; Pharmaceutical industry; Bioavailability; Government (linguistics); Business; Public economics; Public policy; Scope (computer science); Pharmacology; Accounting; Economics; Medicine; Economic growth; Computer science","score_opus":0.16683643636581413,"score_gpt":0.4613731958151695,"score_spread":0.29453675944935537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052701745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93836075,0.00089078734,0.0003438409,0.03383078,0.00038415496,0.000414497,0.00017617801,0.000016705775,0.025582302],"genre_scores_gemma":[0.99800104,0.00034436,0.0004035715,0.00055180537,0.00033577654,0.00011865997,0.0000130987455,0.0000148865975,0.00021678967],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983556,0.000012044356,0.0006348835,0.00028547,0.00012322588,0.00058876735],"domain_scores_gemma":[0.99874145,0.00020720909,0.00013864585,0.0001450421,0.0006765887,0.00009103965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002567677,0.0000959242,0.00020179608,0.010593939,0.00010574744,0.00009982283,0.0005063097,0.00007850003,0.00016067944],"category_scores_gemma":[0.0030822537,0.00010962256,0.000022969258,0.008267832,0.0011277895,0.0007462405,0.00030961583,0.00024872686,0.00004830848],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032939366,0.00024656905,0.09891332,0.000040477666,0.000017802311,2.576195e-7,0.00016128746,0.000008886149,0.0028789765,0.88685566,0.0002699783,0.0105738705],"study_design_scores_gemma":[0.0031160682,0.000039205825,0.20429708,0.00003835172,0.000002661617,0.000014009254,0.00012171899,0.008337568,0.0052808016,0.22232272,0.55611134,0.00031848997],"about_ca_topic_score_codex":0.00006408355,"about_ca_topic_score_gemma":0.0000014262113,"teacher_disagreement_score":0.6645329,"about_ca_system_score_codex":0.0003117655,"about_ca_system_score_gemma":0.00024190747,"threshold_uncertainty_score":0.9452861},"labels":[],"label_agreement":null},{"id":"W2052791582","doi":"10.1016/j.jhealeco.2009.11.007","title":"Monopoly pricing of an antibiotic subject to bacterial resistance","year":2009,"lang":"en","type":"article","venue":"Journal of Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Monopoly; Economics; Externality; Microeconomics; Antibiotic resistance; Antibiotics; Population; Quality (philosophy); Industrial organization; Biology; Medicine; Microbiology","score_opus":0.061884719706315594,"score_gpt":0.32484066913720366,"score_spread":0.26295594943088807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052791582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98356616,0.0013884243,0.00039939472,0.009562981,0.0009203334,0.00018856928,0.00010527371,0.0000074752106,0.0038613973],"genre_scores_gemma":[0.9881858,0.0011614654,0.004832536,0.0052302713,0.00049818045,4.514661e-7,0.0000033307008,0.000022932463,0.00006502078],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969115,0.000039035353,0.0023453247,0.00025380866,0.000022998796,0.0004273289],"domain_scores_gemma":[0.99704486,0.00006123868,0.0021221268,0.00030535684,0.000050869414,0.00041554208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019692571,0.00016976024,0.0010028682,0.00045593004,0.0000842033,0.00006546007,0.00040455034,0.000086777276,0.000076181255],"category_scores_gemma":[0.000106493026,0.00020120437,0.00017869884,0.00014534296,0.000032509713,0.0004539928,0.000026810585,0.00022178942,0.000049509297],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034630224,0.0025282763,0.020455826,0.0007340947,0.0005457106,0.000032034164,0.006598605,0.010527839,0.0022704757,0.8133648,0.015436871,0.12404243],"study_design_scores_gemma":[0.008241847,0.007177646,0.20954333,0.00040489828,0.000043822452,0.0001614263,0.00032626465,0.0059726187,0.008335804,0.20328386,0.55464333,0.0018651456],"about_ca_topic_score_codex":0.00006298765,"about_ca_topic_score_gemma":0.000052744646,"teacher_disagreement_score":0.61008096,"about_ca_system_score_codex":0.00037432753,"about_ca_system_score_gemma":0.0002596111,"threshold_uncertainty_score":0.8204876},"labels":[],"label_agreement":null},{"id":"W2052972684","doi":"10.1016/j.mib.2003.08.003","title":"Why is big Pharma getting out of antibacterial drug discovery?","year":2003,"lang":"en","type":"review","venue":"Current Opinion in Microbiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":501,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Drug discovery; Bureaucracy; Clinical trial; Drug development; Drug; Biology; Investment (military); Business; Process (computing); Intensive care medicine; Biotechnology; Pharmacology; Bioinformatics; Medicine; Political science; Law; Computer science","score_opus":0.184830175105148,"score_gpt":0.39166833003440066,"score_spread":0.20683815492925267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052972684","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009254282,0.9640946,0.00006239012,0.0001994119,0.029638289,0.000504968,0.0048054187,0.000010909995,0.0005915166],"genre_scores_gemma":[0.000022383318,0.99754673,0.0000395805,0.0003484437,0.0010652924,0.000039348033,0.000766333,0.00005606199,0.0001158263],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962846,0.00014181845,0.0021790592,0.00080570753,0.000011443993,0.0005773384],"domain_scores_gemma":[0.9978894,0.0001449361,0.0014437799,0.0004133134,0.000019308702,0.000089246714],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006232254,0.0004885378,0.0025329865,0.00061310583,0.00004288015,0.00005754605,0.00056637725,0.0003424662,0.00043691928],"category_scores_gemma":[0.000052875937,0.0005229187,0.00063312904,0.00023883356,0.00016691131,0.00012758536,0.00022915447,0.0006169641,0.00050338777],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035273923,0.0007472128,0.00060113915,0.037172943,0.00049663003,0.0000011737179,0.0005772609,0.0000024171975,0.00005775901,0.056457542,0.20764561,0.696205],"study_design_scores_gemma":[0.0005671842,0.0000178409,0.0000018693241,0.0018461479,0.000024145014,0.0000084024305,0.0000023065224,0.000006245468,0.000012028752,0.00076355226,0.99623907,0.00051122904],"about_ca_topic_score_codex":0.00002825121,"about_ca_topic_score_gemma":0.000003049945,"teacher_disagreement_score":0.7885934,"about_ca_system_score_codex":0.00018341573,"about_ca_system_score_gemma":0.00012208443,"threshold_uncertainty_score":0.99972224},"labels":[],"label_agreement":null},{"id":"W2053086896","doi":"10.1177/097226290000400209","title":"Privatisation: The Berlin-Chemie Way","year":2000,"lang":"en","type":"article","venue":"Vision The Journal of Business Perspective","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Context (archaeology); German; Public sector; Quarter (Canadian coin); Communism; Business; Management; Economic history; Political science; Economy; Economics; History; Law; Politics","score_opus":0.0362725886722212,"score_gpt":0.2878927191570368,"score_spread":0.2516201304848156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053086896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6602656,0.009359301,0.0013450863,0.19703928,0.0010418487,0.00035787132,0.00008118812,0.000027192204,0.13048263],"genre_scores_gemma":[0.99336356,0.0028737066,0.00011447804,0.002245758,0.00062968355,0.000001641641,4.6799218e-7,0.000015877536,0.00075481343],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.999048,0.00003140152,0.00057246984,0.00012112012,0.000055112796,0.00017189473],"domain_scores_gemma":[0.99879146,0.00020947265,0.0004666196,0.00025381288,0.00021499912,0.000063624415],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010232248,0.000115726165,0.0002622013,0.00009685852,0.0002119125,0.00008376711,0.0004634574,0.00005247806,0.0033030831],"category_scores_gemma":[0.00018291976,0.00007035226,0.000121221165,0.00036986367,0.00014845964,0.0002901717,0.00003863211,0.00029327042,0.00042627723],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009029735,0.00075220905,0.003709827,0.000036993835,0.0007622713,0.000020491203,0.022028774,0.012239863,0.000426961,0.8174143,0.082440056,0.0592653],"study_design_scores_gemma":[0.0017480567,0.00016665904,0.17415716,0.000050731513,0.000055591467,0.00021099865,0.0012812864,0.005431417,0.0005928643,0.37709358,0.4388324,0.00037924692],"about_ca_topic_score_codex":0.00009775119,"about_ca_topic_score_gemma":0.0000048190686,"teacher_disagreement_score":0.4403207,"about_ca_system_score_codex":0.00018158935,"about_ca_system_score_gemma":0.000040803017,"threshold_uncertainty_score":0.997608},"labels":[],"label_agreement":null},{"id":"W2054254219","doi":"10.1016/j.drudis.2014.11.012","title":"Drug hunters incorporated! Is there a formula?","year":2014,"lang":"en","type":"editorial","venue":"Drug Discovery Today","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vertex Pharmaceuticals (Canada)","funders":"","keywords":"Drug; Drug discovery; Pharmaceutical sciences; Computational biology; Pharmacology; Computer science; Chemistry; Medicine; Biology; Biochemistry","score_opus":0.01916430772263744,"score_gpt":0.25769857305484684,"score_spread":0.2385342653322094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054254219","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0048751268,0.003777498,0.00025374492,0.0039040574,0.82339716,0.00054130564,0.011781914,0.000119539836,0.15134965],"genre_scores_gemma":[0.09021339,0.003933717,0.00009279577,0.0067407703,0.8153828,0.00015563481,0.0019292954,0.0004017939,0.0811498],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99623543,0.000050629365,0.0014374442,0.0012498978,0.00013579268,0.00089078833],"domain_scores_gemma":[0.9968026,0.0004680868,0.0012478878,0.0010916349,0.00006443589,0.00032531223],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010276957,0.00075337454,0.0014856426,0.00040614992,0.00019226506,0.00074932654,0.0011934895,0.00070497906,0.0011810173],"category_scores_gemma":[0.000249026,0.0008304148,0.0006578596,0.00024688433,0.00016318356,0.0008616186,0.00038791072,0.0012758609,0.005672502],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046668378,0.000089569665,0.00036596452,0.000164002,0.00020754333,0.000006255945,0.00043918914,0.00004231801,9.469417e-7,0.024925496,0.9734947,0.00021731787],"study_design_scores_gemma":[0.0009257433,0.000028882321,0.00003393972,0.00009011831,0.00003207343,6.6790517e-7,0.000034375364,0.0009360243,0.000057811605,0.04071802,0.9561575,0.0009848207],"about_ca_topic_score_codex":0.00094864395,"about_ca_topic_score_gemma":0.00019353014,"teacher_disagreement_score":0.085338265,"about_ca_system_score_codex":0.0004579123,"about_ca_system_score_gemma":0.00023500496,"threshold_uncertainty_score":0.999732},"labels":[],"label_agreement":null},{"id":"W2054408060","doi":"10.1177/1715163513482704","title":"Provincial/territorial governments join forces to make further cuts to generic drug prices","year":2013,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Join (topology); Business; Operations management; Economics; Mathematics","score_opus":0.03739916178167512,"score_gpt":0.24956288412597552,"score_spread":0.2121637223443004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054408060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9660209,0.0007170377,0.00018936119,0.0034277234,0.009742054,0.0012355759,0.0032739155,0.000035285542,0.015358144],"genre_scores_gemma":[0.9639121,0.0007637269,0.00048574185,0.027617363,0.0045148814,0.000121799014,0.000019626259,0.00010447015,0.0024602714],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99630624,0.0000496647,0.0011573172,0.0007054267,0.00018295829,0.0015983707],"domain_scores_gemma":[0.9942061,0.00006041622,0.00042789293,0.00034934198,0.00018599245,0.004770271],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00063016603,0.00048950844,0.0006429104,0.00057310436,0.00060021505,0.0007151084,0.0011184491,0.00008172062,0.0030448327],"category_scores_gemma":[0.00017191091,0.000583168,0.00020284033,0.0006064624,0.00007549156,0.00056368846,0.00014128044,0.00051340455,0.000788251],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017982532,0.00016662343,0.01092334,0.00023976144,0.00061577494,0.0044809724,0.0054604723,0.0032934449,0.0023059265,0.0036364454,0.90151364,0.06718381],"study_design_scores_gemma":[0.0014368185,0.000058358375,0.00024080851,0.0000135719865,0.000031602885,0.0072502913,0.0000142103345,0.0035867405,0.0010114535,0.0011377056,0.9841677,0.0010507514],"about_ca_topic_score_codex":0.13671541,"about_ca_topic_score_gemma":0.16525467,"teacher_disagreement_score":0.08265408,"about_ca_system_score_codex":0.004554049,"about_ca_system_score_gemma":0.0012826821,"threshold_uncertainty_score":0.99998975},"labels":[],"label_agreement":null},{"id":"W2054930055","doi":"10.1016/j.healthpol.2005.12.015","title":"A comparison of new drug availability in Canada and the United States and potential therapeutic implications of differences","year":2006,"lang":"en","type":"article","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Drug; Value (mathematics); Family medicine; Pharmacology","score_opus":0.07921757057824212,"score_gpt":0.35509443292711473,"score_spread":0.2758768623488726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054930055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95156986,0.0027163492,0.000036808455,0.044855244,0.000019862242,0.00018552374,0.00022131864,0.0000022517247,0.00039278917],"genre_scores_gemma":[0.99563503,0.0017641725,0.00002376989,0.0024862206,0.00003330985,0.0000058845917,0.000010305968,0.0000045837855,0.0000366947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989548,0.000037831447,0.0006705132,0.00013226476,0.000015100466,0.00018949274],"domain_scores_gemma":[0.9992431,0.00019372259,0.00033085007,0.00013743952,0.000011134055,0.00008379559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028349546,0.0000705869,0.00038049516,0.00013409024,0.000048427064,0.000010430782,0.00009101651,0.000018982739,0.000020625028],"category_scores_gemma":[0.00002705493,0.000060957405,0.000019785713,0.00020108516,0.00014721316,0.000026262758,0.000032124542,0.00008229655,8.144198e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022084147,0.00003630142,0.693014,0.00007782744,0.000009422344,1.7461788e-8,0.00093259104,0.00018249021,0.0000010927848,0.3031679,0.0008268946,0.0017293581],"study_design_scores_gemma":[0.0007849988,0.000014641981,0.8554528,0.0000052538426,0.0000018835511,4.3573564e-7,0.00009275601,0.0085346345,0.00000786,0.13137117,0.003680844,0.00005272957],"about_ca_topic_score_codex":0.9927517,"about_ca_topic_score_gemma":0.8672399,"teacher_disagreement_score":0.17179674,"about_ca_system_score_codex":0.00012563323,"about_ca_system_score_gemma":0.00055822753,"threshold_uncertainty_score":0.24857709},"labels":[],"label_agreement":null},{"id":"W2055400723","doi":"10.1177/0046958015584641","title":"The Opportunity Cost of Capital","year":2015,"lang":"en","type":"article","venue":"INQUIRY The Journal of Health Care Organization Provision and Financing","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada); Sanofi (Canada); University of Toronto","funders":"","keywords":"Cost of capital; Implicit cost; Capital (architecture); Economics; Capital cost; Value (mathematics); Relevant cost; Opportunity cost; Weighted average cost of capital; Field (mathematics); Total cost; Microeconomics; Business; Neoclassical economics; Economic capital; Individual capital; Computer science; Mathematics; Macroeconomics; Incentive","score_opus":0.10587017775234542,"score_gpt":0.3294780776599226,"score_spread":0.22360789990757718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055400723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92824596,0.027052762,0.011451997,0.02963242,0.0022444788,0.00045286657,0.00004822123,0.000011754752,0.0008595162],"genre_scores_gemma":[0.9945638,0.0031145492,0.00007880853,0.0020672048,0.00012991963,4.839594e-7,0.000002859534,0.000013022929,0.000029362596],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987147,0.00006671457,0.00093852065,0.000075679905,0.00004978354,0.00015460284],"domain_scores_gemma":[0.9980946,0.0001145994,0.0011715703,0.0001425794,0.0003060108,0.00017063944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024146962,0.00007570822,0.00026560476,0.00008132087,0.0002631497,0.00004114607,0.00019367375,0.00005797348,0.00001707089],"category_scores_gemma":[0.00090958824,0.00005110764,0.000031016025,0.00019273849,0.00010474624,0.00017184297,0.00006961435,0.00023317311,0.00000896421],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035008942,0.00028103578,0.09486331,0.0005093985,0.00016427312,0.0000084274025,0.18951868,0.0016249792,0.00011179751,0.36498678,0.08869851,0.2588827],"study_design_scores_gemma":[0.00509228,0.0019364493,0.06559521,0.00025524647,0.00004572893,0.00035836064,0.05214228,0.002421599,0.0010986297,0.03650986,0.8338686,0.00067573297],"about_ca_topic_score_codex":0.00006540164,"about_ca_topic_score_gemma":0.000011810588,"teacher_disagreement_score":0.7451701,"about_ca_system_score_codex":0.00013407845,"about_ca_system_score_gemma":0.00039823732,"threshold_uncertainty_score":0.2084109},"labels":[],"label_agreement":null},{"id":"W2057067950","doi":"10.1002/hec.1392","title":"Competition between brand‐name and generics – analysis on pricing of brand‐name pharmaceutical","year":2008,"lang":"en","type":"article","venue":"Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Brand names; Competition (biology); Business; Brand management; Advertising; Marketing; Biology","score_opus":0.12970522711036553,"score_gpt":0.33977328384453725,"score_spread":0.21006805673417173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057067950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98238397,0.002299162,0.001848391,0.005517994,0.00025127476,0.00034065518,0.0008530865,0.00003910383,0.006466388],"genre_scores_gemma":[0.9773723,0.014917792,0.00062870403,0.006575311,0.00028083476,0.000013655155,0.000096501615,0.000040273895,0.000074643656],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99722,0.0000464868,0.0014957291,0.0006235322,0.00003214926,0.00058214186],"domain_scores_gemma":[0.9980652,0.0002587624,0.0007678818,0.0003857698,0.000025538608,0.0004969002],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008174569,0.00027537404,0.001305944,0.00058088923,0.00025052158,0.000039752616,0.00022268062,0.00015837586,0.00030742926],"category_scores_gemma":[0.00004345737,0.00034757482,0.0002625798,0.00030696427,0.00020978198,0.00019591271,0.00008304578,0.00031905394,0.00019395292],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020765753,0.0004119871,0.61680794,0.00042271044,0.0013960648,0.000005191042,0.0017199743,0.005342501,0.000008852247,0.35856158,0.0013057909,0.013809723],"study_design_scores_gemma":[0.00680677,0.000708965,0.39348727,0.000057206915,0.0002560904,0.00003739346,0.00006761008,0.1606181,0.0003869728,0.022224242,0.4137257,0.0016236663],"about_ca_topic_score_codex":0.00022222038,"about_ca_topic_score_gemma":0.00003582635,"teacher_disagreement_score":0.41241992,"about_ca_system_score_codex":0.00028918736,"about_ca_system_score_gemma":0.000110441535,"threshold_uncertainty_score":0.9998976},"labels":[],"label_agreement":null},{"id":"W2057160780","doi":"10.1097/00043764-200107000-00002","title":"Workers??? Compensation Claims From Latex Glove Use","year":2001,"lang":"en","type":"letter","venue":"Journal of Occupational and Environmental Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Officer; Workers' compensation; Occupational medicine; Public health; Occupational safety and health; West virginia; Occupational exposure; Environmental health; Unit (ring theory); Medicine; Medical examiner; Family medicine; Compensation (psychology); Gerontology; Political science; Poison control; Human factors and ergonomics; Psychology; Geography; Nursing","score_opus":0.10458523623908458,"score_gpt":0.2848355416102437,"score_spread":0.18025030537115913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057160780","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4528685,0.005752831,0.00062553975,0.5333501,0.0020707734,0.0002377366,0.0022643877,0.000008940505,0.0028211682],"genre_scores_gemma":[0.4098933,0.006719911,0.0005425668,0.5659462,0.01319844,0.000004100437,0.0016331425,0.00006200762,0.0020003046],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983604,0.000022616185,0.0010576902,0.00024509104,0.00011128088,0.00020290037],"domain_scores_gemma":[0.99836385,0.00025577107,0.001091978,0.00013857934,0.000009602445,0.00014018771],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023992175,0.00023290284,0.0006471411,0.00023484605,0.000059564474,0.000040665174,0.00016239831,0.00030499656,0.0034542836],"category_scores_gemma":[0.000040424915,0.00021398065,0.00012532738,0.000051667288,0.00019560465,0.00028953215,0.000047230205,0.0008387,0.00015450023],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016679289,0.00006048764,0.16312148,0.000018600473,0.0002847305,0.00012005179,0.00017039699,0.00006368025,0.000026290707,0.00045918155,0.8343359,0.0011724221],"study_design_scores_gemma":[0.0011068096,0.00012676808,0.17643031,0.00007366825,0.0000474074,0.00007007217,0.000025441872,0.0005508619,0.000002579176,0.010125513,0.8112344,0.00020617936],"about_ca_topic_score_codex":0.00019187656,"about_ca_topic_score_gemma":0.0000028633342,"teacher_disagreement_score":0.04297519,"about_ca_system_score_codex":0.00021728735,"about_ca_system_score_gemma":0.000016281529,"threshold_uncertainty_score":0.99745667},"labels":[],"label_agreement":null},{"id":"W2058625864","doi":"10.1071/ah090241","title":"PBS copayments and safety nets - A commentary on Sweeny and Doran and Robertson","year":2009,"lang":"en","type":"letter","venue":"Australian Health Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmaceutical Benefits Scheme; Access to medicines; Subsidy; Health economics; Pharmaceutical policy; Wonder; Government (linguistics); Business; Health care; Population health; Public administration; Public economics; Health policy; Political science; Economic growth; Economics; Medicine; Law; Developing country; Nursing","score_opus":0.11510145559668244,"score_gpt":0.35933535845088277,"score_spread":0.24423390285420032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058625864","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016704692,0.18294846,0.0000011451305,0.8135953,0.00017882972,0.000946273,0.00080367306,0.000015598287,0.0013436667],"genre_scores_gemma":[0.000221367,0.41709372,0.000051746527,0.58153206,0.00035749664,0.000017663706,0.00019339989,0.000025566313,0.0005069696],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99719644,0.000090798036,0.0012431858,0.00076441135,0.000041617346,0.0006635271],"domain_scores_gemma":[0.9984407,0.00009636966,0.0006556583,0.0003866818,0.000008680323,0.000411933],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007534829,0.00044722098,0.0015240539,0.00015203095,0.0001763518,0.00009550749,0.0001703456,0.00031017416,0.00034811647],"category_scores_gemma":[0.000014245754,0.00048282344,0.00009836706,0.000097577744,0.0001233102,0.000121031655,0.00007629309,0.001095856,0.00009743807],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008029579,0.00002016042,0.00054825377,0.0045818933,0.000049943133,0.000013736533,0.000025631336,1.16216334e-7,1.6229427e-8,0.0013844228,0.9637599,0.029607905],"study_design_scores_gemma":[0.00057642616,0.00022369267,0.002463109,0.0024995108,0.000032039858,0.000027074426,9.093573e-7,0.000013872961,1.7734726e-7,0.0022915634,0.9914636,0.00040804222],"about_ca_topic_score_codex":0.0010587543,"about_ca_topic_score_gemma":0.000027418186,"teacher_disagreement_score":0.23414528,"about_ca_system_score_codex":0.00019621052,"about_ca_system_score_gemma":0.000029582876,"threshold_uncertainty_score":0.99976236},"labels":[],"label_agreement":null},{"id":"W2058801790","doi":"10.1586/14737167.3.3.303","title":"Fixed and flexible formularies as cost-control mechanisms","year":2003,"lang":"en","type":"article","venue":"Expert Review of Pharmacoeconomics & Outcomes Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Centre for Addiction and Mental Health","funders":"Natural Sciences and Engineering Research Council of Canada; Ontario Ministry of Health and Long-Term Care","keywords":"Formulary; Control (management); Cost control; Fixed cost; Operations management; Computer science; Medicine; Intensive care medicine; Operations research; Risk analysis (engineering); Business; Economics; Pharmacology; Mathematics; Accounting","score_opus":0.08692920275430051,"score_gpt":0.49891468068463857,"score_spread":0.4119854779303381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058801790","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023046657,0.60933757,0.005981052,0.044905175,0.0024043603,0.00675943,0.0010786083,0.00016025052,0.30632693],"genre_scores_gemma":[0.43435037,0.500194,0.0032825647,0.057781868,0.00021304765,0.00075671694,0.000033376997,0.0001559249,0.0032321431],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99654907,0.00018414322,0.0015386477,0.00071314134,0.000100264624,0.0009147206],"domain_scores_gemma":[0.9977415,0.0006087034,0.00042112047,0.00062263716,0.00012351814,0.00048250452],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0047374284,0.00035633508,0.0014089701,0.00044867463,0.00024005046,0.00012757503,0.0006013443,0.00013804564,0.0047588367],"category_scores_gemma":[0.0008489296,0.00037315465,0.00036073898,0.00026227898,0.00026376397,0.0004466736,0.0001868652,0.00053204375,0.0012133737],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041060277,0.0001473875,0.0022534884,0.0010767162,0.00028110656,0.000004295108,0.00021748475,0.000009722567,0.0003740823,0.9785874,0.0119976755,0.0050096093],"study_design_scores_gemma":[0.0023671903,0.00009773251,0.00019154591,0.00020502585,0.000016098144,0.000016741642,0.00005563777,0.0010098033,0.005254217,0.10196004,0.88834107,0.00048490323],"about_ca_topic_score_codex":0.00022115842,"about_ca_topic_score_gemma":0.0000053582835,"teacher_disagreement_score":0.8766273,"about_ca_system_score_codex":0.00024631337,"about_ca_system_score_gemma":0.00016286032,"threshold_uncertainty_score":0.999872},"labels":[],"label_agreement":null},{"id":"W2059053469","doi":"10.1016/s0140-6736(13)60845-4","title":"A modest but meaningful decision for Indian drug patents","year":2014,"lang":"en","type":"article","venue":"The Lancet","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Supreme court; Victory; Imatinib mesylate; Political science; Medicine; High Court; Law; Imatinib; Internal medicine","score_opus":0.10131092052055442,"score_gpt":0.2985495018781089,"score_spread":0.1972385813575545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059053469","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9248316,0.00031238256,0.005987724,0.010975899,0.0006087751,0.0003177572,0.0005112588,0.00004719275,0.0564074],"genre_scores_gemma":[0.99126273,0.00013818638,0.00071560696,0.0064730137,0.00095889746,0.00003793339,0.000011865821,0.00002167436,0.00038007033],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991048,0.000011804626,0.00030776055,0.00022220956,0.000017032262,0.00033641243],"domain_scores_gemma":[0.9991475,0.00020370628,0.00014331579,0.00040884892,0.000011844944,0.000084800675],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008766386,0.00010369086,0.00035958696,0.000058099078,0.0001257667,0.000087119435,0.0004535684,0.000045089277,0.00010377138],"category_scores_gemma":[0.0001814396,0.00008762136,0.00009007056,0.00006217361,0.000037047528,0.000083024235,0.00006712896,0.00011733256,0.00081079704],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014835299,0.000059049584,0.014469946,0.000042386986,0.000060469843,5.9486246e-7,0.00088040874,0.00049312564,0.000027794307,0.899804,0.063572295,0.020441556],"study_design_scores_gemma":[0.0011926742,0.000022525403,0.004255825,0.00000920295,0.000003879921,0.0000015227891,0.000010969136,0.02966921,0.00012748473,0.4416939,0.52285844,0.00015437539],"about_ca_topic_score_codex":0.0000993655,"about_ca_topic_score_gemma":0.00003328941,"teacher_disagreement_score":0.45928612,"about_ca_system_score_codex":0.000037564376,"about_ca_system_score_gemma":0.000007081796,"threshold_uncertainty_score":0.99996716},"labels":[],"label_agreement":null},{"id":"W2059657285","doi":"10.1377/hlthaff.25.5.1353","title":"Prices And Availability Of Biopharmaceuticals: An International Comparison","year":2006,"lang":"en","type":"article","venue":"Health Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Per capita; European union; Product (mathematics); International trade; Agricultural economics; Economics; Member states; International economics; Business; Environmental health; Medicine; Mathematics","score_opus":0.09391597464132455,"score_gpt":0.3715708587017222,"score_spread":0.2776548840603976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059657285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87656873,0.006649491,0.000496056,0.012619994,0.000656046,0.0003592994,0.0005450648,0.00005635908,0.10204893],"genre_scores_gemma":[0.99735534,0.0005889989,0.0010804341,0.00075030286,0.00013383296,0.0000072948187,0.000022588396,0.000010286366,0.000050921702],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986239,0.000017052933,0.0007941026,0.00029021967,0.000025538151,0.0002491534],"domain_scores_gemma":[0.999215,0.000052350708,0.00034786508,0.00017702085,0.000019087855,0.00018868168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065666024,0.00009622101,0.00034325465,0.00012393255,0.000052747193,0.000032419222,0.00015877592,0.000052230916,0.0003982216],"category_scores_gemma":[0.000032925815,0.00011246881,0.000042231823,0.00008493956,0.0001155833,0.00020509445,0.000048044658,0.00011319443,0.00008680706],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039073653,0.00038364908,0.2990074,0.0001316373,0.000020322193,3.5255704e-7,0.0002459174,0.00006065661,0.000025171747,0.6946358,0.0015829594,0.003867092],"study_design_scores_gemma":[0.0013198883,0.00019623015,0.27275085,0.000014912645,0.000004565144,0.0000041236003,0.00018773745,0.04671723,0.00029992202,0.052105736,0.6260672,0.0003315669],"about_ca_topic_score_codex":0.000744429,"about_ca_topic_score_gemma":0.00008257479,"teacher_disagreement_score":0.6425301,"about_ca_system_score_codex":0.000080812446,"about_ca_system_score_gemma":0.000032932865,"threshold_uncertainty_score":0.45863453},"labels":[],"label_agreement":null},{"id":"W2060894663","doi":"10.1038/clpt.2014.145","title":"Accelerated Access to Innovative Medicines for Patients in Need","year":2014,"lang":"en","type":"article","venue":"Clinical Pharmacology & Therapeutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada; Institut National d'Excellence en Santé et en Services Sociaux","funders":"Innovative Medicines Initiative; National Comprehensive Cancer Network; European Federation of Pharmaceutical Industries and Associations; Bill and Melinda Gates Foundation","keywords":"Clinical pharmacology; Variety (cybernetics); Access to medicines; Business; Health care; Medicine; Pharmacology; Economic growth; Computer science; Economics; Nursing; Public health","score_opus":0.27197532223787846,"score_gpt":0.47316314814981514,"score_spread":0.20118782591193668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060894663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9314828,0.00011362818,0.0019921304,0.05626208,0.0040067793,0.0012863263,0.0001678716,0.00005149665,0.0046369187],"genre_scores_gemma":[0.6852491,0.00023407863,0.00024872582,0.3133848,0.00063016044,0.00011988289,0.000029662962,0.000033476637,0.00007012796],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99739456,0.000085540916,0.0014412655,0.00053601543,0.000025983709,0.0005166369],"domain_scores_gemma":[0.9980677,0.0009785938,0.00036191402,0.0002086038,0.00016284936,0.0002203555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012798416,0.00022051496,0.00073129806,0.0003089916,0.00007252107,0.000051873525,0.00062673516,0.00023442687,0.00028303146],"category_scores_gemma":[0.00022079723,0.00023561655,0.00011473943,0.0006055627,0.00015981705,0.00017481025,0.0001620974,0.00038802298,0.0002781101],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009943907,0.0018376801,0.8510924,0.000046674584,0.00053183973,0.00000124083,0.00038280475,0.0001737468,0.00015627695,0.012872812,0.11588067,0.016029464],"study_design_scores_gemma":[0.0077915164,0.0007416323,0.21174043,0.000009115063,0.00004208693,2.3521297e-7,0.0000088847355,0.013629195,0.00033255323,0.019243348,0.7460267,0.00043428355],"about_ca_topic_score_codex":0.00001728171,"about_ca_topic_score_gemma":0.0000119322185,"teacher_disagreement_score":0.63935196,"about_ca_system_score_codex":0.000089494664,"about_ca_system_score_gemma":0.000043651024,"threshold_uncertainty_score":0.9608164},"labels":[],"label_agreement":null},{"id":"W2061118140","doi":"10.1503/cmaj.050663","title":"Nonpatentable drugs and the cost of our ignorance","year":2006,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Université Laval","funders":"Canadian Institutes of Health Research","keywords":"Pharmaceutical industry; Ignorance; Drug industry; Randomized controlled trial; Clinical trial; Medicine; Computer science; Data science; Operations research; Pharmacology; Surgery; Engineering; Political science; Law; Engineering ethics; Pathology","score_opus":0.015219609763506317,"score_gpt":0.23308183254714138,"score_spread":0.21786222278363507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061118140","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.27750885,0.006205042,0.0005657367,0.4698457,0.0025482576,0.00044271513,0.00064257655,0.0000149996995,0.24222611],"genre_scores_gemma":[0.98637563,0.00049781904,0.000027801516,0.011636748,0.0007783134,0.0000043440373,0.0000028345992,0.000007469706,0.00066902884],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99899685,0.000031558728,0.0005190056,0.00009326665,0.000080587044,0.00027870902],"domain_scores_gemma":[0.9990539,0.000084618834,0.00034600258,0.0000627253,0.00005274709,0.0003999972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00204124,0.00006329549,0.00024072421,0.00009346754,0.00014616238,0.00007438229,0.00016113573,0.00012082805,0.00063524506],"category_scores_gemma":[0.00031312488,0.000055497756,0.000070813396,0.00008275784,0.000047873964,0.00009010071,0.000012852853,0.00034043958,0.00013246998],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024678342,0.000040500123,0.20610332,0.000014478573,0.00013088356,0.00001596009,0.00040109237,0.00008251707,0.0000018164794,0.48287275,0.30064082,0.009671204],"study_design_scores_gemma":[0.002628311,0.0000091834945,0.022822466,0.000012131489,0.000007166792,0.000031760093,0.00013450075,0.004567666,0.000009744728,0.047067083,0.92258686,0.00012310997],"about_ca_topic_score_codex":0.012710597,"about_ca_topic_score_gemma":0.007982156,"teacher_disagreement_score":0.7088668,"about_ca_system_score_codex":0.0002667473,"about_ca_system_score_gemma":0.0002401222,"threshold_uncertainty_score":0.9938638},"labels":[],"label_agreement":null},{"id":"W2061120801","doi":"10.1038/nbt1106-1324","title":"Democracy unleashed—unpacking the tooth fairy in drug industry R&amp;D","year":2006,"lang":"en","type":"letter","venue":"Nature Biotechnology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Institutes of Health","keywords":"Unpacking; Democracy; Drug; Drug industry; Political science; Biology; Biotechnology; Pharmacology; Philosophy; Law","score_opus":0.02973020496102218,"score_gpt":0.2746882769496241,"score_spread":0.24495807198860192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061120801","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013029058,0.007894253,0.00003677064,0.94984514,0.002256759,0.00041234863,0.0005246342,0.0001662493,0.025834799],"genre_scores_gemma":[0.12589249,0.0007299827,0.00029528866,0.8599289,0.0035741902,0.000056996272,0.00030174066,0.0001503441,0.00907008],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967822,0.00004722156,0.0010404076,0.0010456844,0.000058416816,0.0010261054],"domain_scores_gemma":[0.99783236,0.00023296585,0.00066385255,0.0011936753,0.000022773307,0.000054375712],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00060637563,0.0005390676,0.0009565556,0.0011191575,0.00016270064,0.00012290274,0.0015545149,0.013344796,0.0004648464],"category_scores_gemma":[0.00023322985,0.00051364244,0.00026490336,0.0007353284,0.0003729845,0.0001219385,0.0003905361,0.023739005,0.0011220041],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000038738217,0.000028224416,0.0020430458,0.000042123254,0.000053413034,0.000056996905,0.000023101828,0.000012357871,0.0000062161657,0.081189565,0.9156849,0.0008561963],"study_design_scores_gemma":[0.00034512766,0.000009174583,0.0007682046,0.00002899687,0.00001010085,0.000020477868,0.000005829191,0.00007698061,0.00008373252,0.12047325,0.87767446,0.00050368696],"about_ca_topic_score_codex":0.00063144,"about_ca_topic_score_gemma":0.00042321425,"teacher_disagreement_score":0.11286342,"about_ca_system_score_codex":0.0004611061,"about_ca_system_score_gemma":0.0000862843,"threshold_uncertainty_score":0.99973154},"labels":[],"label_agreement":null},{"id":"W2061188413","doi":"10.1056/nejmp048284","title":"Merck's Recall of Rofecoxib — A Strategic Perspective","year":2004,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Rofecoxib; Medicine; Quarter (Canadian coin); Recall; Stock (firearms); Anesthesia; Psychology","score_opus":0.0945081546443999,"score_gpt":0.31959761944108106,"score_spread":0.22508946479668115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061188413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78530985,0.011725658,0.0013804858,0.053320456,0.0013082852,0.00012990255,0.000033391298,0.000008723005,0.14678325],"genre_scores_gemma":[0.99471295,0.0016507419,0.00045733873,0.0010317361,0.001971288,3.8937225e-7,9.796328e-7,0.000012550294,0.00016204886],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9987444,0.000015666008,0.00087762414,0.0001289183,0.00004933522,0.00018402554],"domain_scores_gemma":[0.99873155,0.0000874475,0.0006964977,0.00012774907,0.00009214674,0.0002645977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009268186,0.00011586622,0.00059979106,0.0002663424,0.000023971632,0.000008821516,0.00020453776,0.0000618306,0.00066521484],"category_scores_gemma":[0.00022592228,0.00009705108,0.00011268252,0.00014989889,0.00010453739,0.00011651186,0.000016945227,0.00029705264,0.000036338883],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024787115,0.00011487681,0.001230803,0.000022958482,0.00019077923,0.00003857519,0.0025799696,0.0006155222,0.00040966822,0.9895225,0.001420493,0.0036059935],"study_design_scores_gemma":[0.031319905,0.0011244555,0.0016630992,0.000105633284,0.000037162856,0.00020906303,0.00046239208,0.000111141686,0.0003340491,0.9161862,0.04829299,0.00015391209],"about_ca_topic_score_codex":0.0006731241,"about_ca_topic_score_gemma":0.000045132307,"teacher_disagreement_score":0.20940307,"about_ca_system_score_codex":0.00014533535,"about_ca_system_score_gemma":0.00012778834,"threshold_uncertainty_score":0.7283636},"labels":[],"label_agreement":null},{"id":"W2061307501","doi":"10.3821/1913-701x(2007)140[227b:pdssft]2.0.co;2","title":"Prescription drug spending slowing for the first time in more than 20 years","year":2007,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Drug; Medical prescription; Economics; Medicine; Pharmacology","score_opus":0.05143248377977991,"score_gpt":0.27388826716450476,"score_spread":0.22245578338472485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061307501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98305506,0.0032918395,0.0004445757,0.0019553746,0.0040252637,0.00083025126,0.0014365909,0.000022462773,0.0049385577],"genre_scores_gemma":[0.9915853,0.0016522419,0.000102912425,0.00452453,0.0010334058,0.00001954691,0.000021856222,0.000059765327,0.001000433],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974303,0.00001920204,0.0008962838,0.00038513736,0.00007533562,0.0011936896],"domain_scores_gemma":[0.99811035,0.00024012478,0.00030685347,0.0002183272,0.000061109575,0.0010632185],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020583805,0.00026865062,0.00038336354,0.0005497257,0.0006458481,0.00026157833,0.0007165689,0.00006250196,0.0006985918],"category_scores_gemma":[0.0001456148,0.00030307163,0.0002014807,0.0004338471,0.00011776455,0.0004317766,0.000044455785,0.0005722523,0.00006884355],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013218515,0.00039398557,0.22245456,0.00091487676,0.0021372372,0.042214267,0.023388475,0.035714082,0.0019097951,0.022961548,0.4691463,0.177443],"study_design_scores_gemma":[0.0031152382,0.000020109152,0.0027528312,0.00002527406,0.000053819127,0.017106436,0.000027806307,0.06393131,0.0005114578,0.0016476149,0.9099676,0.00084052497],"about_ca_topic_score_codex":0.03163964,"about_ca_topic_score_gemma":0.23041047,"teacher_disagreement_score":0.44082126,"about_ca_system_score_codex":0.0028023398,"about_ca_system_score_gemma":0.00047194678,"threshold_uncertainty_score":0.9999421},"labels":[],"label_agreement":null},{"id":"W2061389534","doi":"10.1016/j.jval.2012.03.075","title":"UT3 Firm- and Drug-Specific Patterns of Generic Drug Prices Experienced by United States Medicaid Programs: 1991-2008","year":2012,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicaid; Generic drug; Reimbursement; Unit price; Drug prices; Quarter (Canadian coin); Drug; Business; Relative price; Economics; Actuarial science; Demographic economics; Monetary economics; Medicine; Health care; Pharmacology; Microeconomics; Economic growth","score_opus":0.09323204748075149,"score_gpt":0.30785787904224043,"score_spread":0.21462583156148896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061389534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9655316,0.029946158,0.00006369139,0.0031881365,0.00031301295,0.0003375193,0.00029679417,0.000022100096,0.000301006],"genre_scores_gemma":[0.97123605,0.026477395,0.00029523898,0.0015775138,0.00011679118,0.00005295983,0.00015591671,0.000025093035,0.000063051346],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979581,0.000060491722,0.000939487,0.0003126107,0.000046475932,0.00068283034],"domain_scores_gemma":[0.9987941,0.00013320213,0.0004475081,0.00022797693,0.000013009365,0.00038421754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011847602,0.00016905338,0.00046241147,0.00030189208,0.00007902157,0.000032756125,0.00020477147,0.00005936763,0.00011499431],"category_scores_gemma":[0.000028313967,0.00018324629,0.000047037163,0.00035495122,0.000108032815,0.00021479004,0.00007747098,0.00018054234,0.000029847984],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006658283,0.0013887492,0.8062767,0.0010616235,0.00008260245,0.000002691416,0.06232034,0.0007266254,0.0000281246,0.08320036,0.018570822,0.026274804],"study_design_scores_gemma":[0.0010656805,0.00010060532,0.017738614,0.00008179254,0.0000022181794,0.000004124498,0.001412626,0.014922783,0.000102268365,0.002445275,0.96173036,0.00039365003],"about_ca_topic_score_codex":0.012525097,"about_ca_topic_score_gemma":0.000036947647,"teacher_disagreement_score":0.9431595,"about_ca_system_score_codex":0.00014185328,"about_ca_system_score_gemma":0.000029267449,"threshold_uncertainty_score":0.99405056},"labels":[],"label_agreement":null},{"id":"W2062153244","doi":"10.1345/aph.1k249","title":"Drug Importation and Safety of Drugs Obtained from Canada","year":2007,"lang":"en","type":"review","venue":"Annals of Pharmacotherapy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Drug; Drug prices; Opposition (politics); Competition (biology); Pharmacology; Public economics; Law","score_opus":0.14255423938027267,"score_gpt":0.39979936934093113,"score_spread":0.25724512996065846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062153244","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016010625,0.98874664,0.000015490159,0.00042687825,0.00032013544,0.0003686125,0.0042911903,0.000007940589,0.004222075],"genre_scores_gemma":[0.0020275197,0.99521804,0.000063285894,0.0021009827,0.00020275051,0.000009981678,0.00015599446,0.000053857733,0.00016760455],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99742025,0.000035855886,0.0017919586,0.00038968012,0.00005098719,0.00031128383],"domain_scores_gemma":[0.9975765,0.00032591936,0.0016079225,0.00025352175,0.000050340503,0.00018579692],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007199799,0.0003228144,0.0018501806,0.00026132472,0.000036195826,0.000014719921,0.00030034967,0.00013365818,0.0007673493],"category_scores_gemma":[0.00001900356,0.00035136094,0.000326126,0.0002092361,0.0000778118,0.000098050405,0.00003193194,0.00022994091,0.000012936014],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000080807826,0.00008808191,0.000200013,0.0029228593,0.0010762869,0.000003259998,0.000340122,0.0000038854455,0.000012090845,0.014177115,0.013454407,0.96764106],"study_design_scores_gemma":[0.0004989368,0.00001364906,0.000046852827,0.00034861217,0.000045112585,5.847451e-7,0.000009053607,0.000055056265,0.0004081562,0.0030586838,0.995207,0.0003082918],"about_ca_topic_score_codex":0.16841388,"about_ca_topic_score_gemma":0.006739868,"teacher_disagreement_score":0.9817526,"about_ca_system_score_codex":0.00006103318,"about_ca_system_score_gemma":0.00029717476,"threshold_uncertainty_score":0.99989384},"labels":[],"label_agreement":null},{"id":"W2062442241","doi":"10.1089/dis.2007.104649","title":"The Economic Consequences of Generic Substitution for Antiepileptic Drugs in a Public Payer Setting: The Case of Lamotrigine","year":2007,"lang":"en","type":"article","venue":"Disease Management","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Group for Research in Decision Analysis; Montreal Neurological Institute and Hospital","funders":"","keywords":"Lamotrigine; Medicine; Pharmacy; Pill; Medical prescription; Drug; Generic drug; Pharmacology; Family medicine; Epilepsy; Psychiatry","score_opus":0.05154753667624997,"score_gpt":0.2957712121430586,"score_spread":0.24422367546680865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062442241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98583573,0.0018259938,0.000895206,0.0037438676,0.00027788765,0.0007599603,0.00022880446,0.000008711866,0.0064238203],"genre_scores_gemma":[0.99867827,0.0006501684,0.00008455568,0.00035578376,0.000050775172,0.00006431786,0.000010554045,0.000009775422,0.000095791],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99875146,0.000016406024,0.00069934514,0.00021707671,0.000017928805,0.00029778556],"domain_scores_gemma":[0.9990509,0.00019255972,0.00034552097,0.00030283324,0.000017328772,0.00009086122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015304385,0.000105196494,0.00020259075,0.00017944782,0.00011223278,0.00004843035,0.0002611867,0.000023798388,0.000042505144],"category_scores_gemma":[0.00004895345,0.00008282144,0.00012744164,0.00014626753,0.00024362527,0.00009540122,0.00007113342,0.00005217233,0.000020921856],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000067404355,0.00005462301,0.009499978,0.00011955114,0.00008020243,0.000015954141,0.00007587263,0.00051026314,0.000004971027,0.98509157,0.00040354664,0.004076088],"study_design_scores_gemma":[0.0050302376,0.00013035984,0.11917167,0.00007203671,0.00017058842,0.000018638206,0.0012937733,0.09934918,0.00068253896,0.3530518,0.42015296,0.00087621465],"about_ca_topic_score_codex":0.00014333012,"about_ca_topic_score_gemma":0.00007778367,"teacher_disagreement_score":0.6320397,"about_ca_system_score_codex":0.00014126842,"about_ca_system_score_gemma":0.00004091631,"threshold_uncertainty_score":0.33773604},"labels":[],"label_agreement":null},{"id":"W2062511238","doi":"10.1177/1715163513494586","title":"Report says extending use of pharmacists and generic drugs can save health care system up to $11 billion over 3 years","year":2013,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Health care; Medicine; Business; Economic growth; Economics","score_opus":0.06725005893130952,"score_gpt":0.2769036334247863,"score_spread":0.20965357449347677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062511238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98907065,0.0029746762,0.00008692662,0.000483692,0.0031173131,0.0007366144,0.0026833217,0.000028112827,0.0008186944],"genre_scores_gemma":[0.9891286,0.0036948419,0.00030014102,0.0055971174,0.0006046236,0.000039326038,0.00005246419,0.00009522281,0.00048769978],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99608976,0.00008985685,0.0016403218,0.00071201427,0.00015454684,0.0013135157],"domain_scores_gemma":[0.9944635,0.000086256,0.0009373409,0.0003922139,0.00027222026,0.003848457],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007246833,0.000450404,0.00088988023,0.00097601843,0.00052512094,0.00040035884,0.00050332607,0.0000869556,0.00064689753],"category_scores_gemma":[0.00011828158,0.00055903906,0.00019817127,0.00068620883,0.00014603359,0.0005847851,0.000107045445,0.00048456137,0.000038668168],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030034964,0.00017908798,0.1049151,0.0046461173,0.0018451235,0.049378574,0.039298244,0.007960977,0.0032921871,0.013157416,0.49668607,0.27834076],"study_design_scores_gemma":[0.004788338,0.00013589356,0.0023645922,0.00013115679,0.00013781534,0.20465933,0.00021399613,0.018001439,0.0016012342,0.0003465961,0.76515496,0.0024646395],"about_ca_topic_score_codex":0.15910351,"about_ca_topic_score_gemma":0.02920819,"teacher_disagreement_score":0.2758761,"about_ca_system_score_codex":0.004960498,"about_ca_system_score_gemma":0.0017304511,"threshold_uncertainty_score":0.9996861},"labels":[],"label_agreement":null},{"id":"W2062605727","doi":"10.1038/nbt1206-1515","title":"Moving goalposts—regulatory oversight of antibacterial drugs","year":2006,"lang":"en","type":"article","venue":"Nature Biotechnology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Antimicrobial; Business; Drug approval; Infectious disease (medical specialty); Investment (military); Drug; Pharmacology; Biotechnology; Disease; Biology; Medicine; Microbiology; Political science; Law; Internal medicine","score_opus":0.008325642742799032,"score_gpt":0.22911719331785813,"score_spread":0.2207915505750591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062605727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95517266,0.0036834225,0.00010778658,0.0051085576,0.000999983,0.00012453363,0.00025341532,0.00009773671,0.034451906],"genre_scores_gemma":[0.99806833,0.00014226495,0.00047344132,0.00074053113,0.00027700234,0.0000025418042,0.000019210482,0.000020161393,0.00025653542],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988218,0.000006739941,0.00048763165,0.00035027496,0.00002198379,0.0003116043],"domain_scores_gemma":[0.99923867,0.000033775905,0.00030562488,0.0003652288,0.00001659276,0.000040087907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001929172,0.00014634142,0.00039742526,0.00037367374,0.00004808238,0.000016184249,0.0003256439,0.0010730209,0.0003333101],"category_scores_gemma":[0.000047313224,0.00017233657,0.00012532204,0.00022039338,0.00018827901,0.00010461813,0.000119938704,0.0005214454,0.00015545248],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022098795,0.000056622855,0.0030397289,0.000017808705,0.00002929855,0.000001930407,0.00001438902,0.000006415814,0.012630509,0.98000383,0.003295721,0.00088162074],"study_design_scores_gemma":[0.0011279922,0.0000700876,0.01890658,0.000010599607,0.000009521228,0.000008642166,0.000011839093,0.0005127091,0.11186301,0.11242445,0.7546775,0.00037707106],"about_ca_topic_score_codex":0.00011865871,"about_ca_topic_score_gemma":0.000010131038,"teacher_disagreement_score":0.8675794,"about_ca_system_score_codex":0.000089926936,"about_ca_system_score_gemma":0.000020504174,"threshold_uncertainty_score":0.8276119},"labels":[],"label_agreement":null},{"id":"W2063171295","doi":"10.1186/2047-2994-2-s1-p325","title":"P325: Evaluation of rational prescribing of essential generic drugs in a rural community in Mali","year":2013,"lang":"en","type":"article","venue":"Antimicrobial Resistance and Infection Control","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medical prescription; Medicine; Euros; Brand names; Alternative medicine; Family medicine; Traditional medicine; Pharmacology; Advertising","score_opus":0.038771741700659584,"score_gpt":0.2789625073523325,"score_spread":0.24019076565167294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063171295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99558926,0.00030379216,0.00030902383,0.0004351682,0.000115835384,0.0003614699,0.000055428445,0.000003885992,0.0028261435],"genre_scores_gemma":[0.9993457,0.00023821645,0.00003846449,0.000259283,0.000037349153,0.000033266246,0.000012239791,0.0000069088924,0.000028534967],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989253,0.000112998365,0.00065693725,0.00012034597,0.00003337472,0.00015101481],"domain_scores_gemma":[0.999394,0.000080336715,0.00029546846,0.000117964686,0.00008261937,0.000029624423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010674439,0.00008675511,0.00031349086,0.0002458262,0.00004823063,0.000027089985,0.00006472286,0.000069543654,0.00018909697],"category_scores_gemma":[0.00011885537,0.00010645682,0.000056980956,0.0001757076,0.00007756876,0.00033165864,0.000022368253,0.00015128501,0.000011889499],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048441286,0.0010073124,0.80266815,0.000469166,0.00016157574,3.57403e-7,0.0023097724,0.0068974285,0.09324982,0.08351664,0.0025399032,0.0066954815],"study_design_scores_gemma":[0.0071047647,0.00005525061,0.9145896,0.00011927793,0.00002233013,0.0000011651008,0.00007040364,0.054028135,0.006510255,0.016590562,0.0006349443,0.0002733134],"about_ca_topic_score_codex":0.005299197,"about_ca_topic_score_gemma":0.0012644338,"teacher_disagreement_score":0.11192147,"about_ca_system_score_codex":0.00007807139,"about_ca_system_score_gemma":0.0000398782,"threshold_uncertainty_score":0.8010836},"labels":[],"label_agreement":null},{"id":"W2063448633","doi":"10.1503/cmaj.100375","title":"New approaches to rewarding pharmaceutical innovation","year":2010,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Ontario Drug Policy Research Network; University of Toronto","funders":"","keywords":"Pharmaceutical industry; Pharmaceutical sciences; Computer science; Data science; Drug industry; Knowledge management; Management science; Engineering ethics; Medicine; Pharmacology; Engineering","score_opus":0.1239400253679965,"score_gpt":0.29322301626275654,"score_spread":0.16928299089476004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063448633","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21557273,0.00017435753,0.0055598165,0.606835,0.0061068134,0.00024963514,0.000119454446,0.000042956213,0.16533922],"genre_scores_gemma":[0.90649486,0.00005062727,0.0022662352,0.083549425,0.006118847,0.0000074441177,0.000009802254,0.00003204788,0.0014706906],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99832755,0.000020222997,0.0007336178,0.00021665599,0.00014441626,0.00055753865],"domain_scores_gemma":[0.9971756,0.000079598336,0.00023662171,0.00011210221,0.00005427799,0.0023418474],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0027368413,0.000115360126,0.0002489334,0.0005274906,0.00020186296,0.00022244328,0.0003193452,0.00034502606,0.011584824],"category_scores_gemma":[0.0020200387,0.00013676242,0.00008043163,0.000525994,0.000017265296,0.00019891003,0.000027967733,0.001395228,0.0025659036],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000050551957,0.00001664922,0.03347757,0.000003434739,0.00007057509,0.000018266337,0.0002260732,0.000011463157,0.000023946173,0.65350896,0.2642216,0.04841639],"study_design_scores_gemma":[0.000468468,0.000012052874,0.00514118,0.000004702958,0.0000033702302,0.00005650238,0.000014911034,0.001493449,0.00004297071,0.024774808,0.9678172,0.0001703757],"about_ca_topic_score_codex":0.00093963067,"about_ca_topic_score_gemma":0.0039843144,"teacher_disagreement_score":0.7035956,"about_ca_system_score_codex":0.0005493073,"about_ca_system_score_gemma":0.0009922435,"threshold_uncertainty_score":0.9982107},"labels":[],"label_agreement":null},{"id":"W2063658953","doi":"10.1016/s0140-6736(04)17630-7","title":"The black market in prescription drugs","year":2004,"lang":"en","type":"article","venue":"The Lancet","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"British Columbia Centre of Excellence for Women's Health; University of British Columbia","funders":"","keywords":"Black market; Biosimilar; Business; Multinational corporation; Profit (economics); Market access; Medical prescription; Developing country; Government (linguistics); International trade; Market economy; Economic growth; Finance; Economics; Medicine","score_opus":0.059949966516962175,"score_gpt":0.2803978101395967,"score_spread":0.22044784362263453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063658953","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.42508218,0.0017227338,0.00008119421,0.08990202,0.00046523107,0.00025365676,0.000092931696,0.000029736882,0.48237032],"genre_scores_gemma":[0.99133044,0.0018854509,0.000037528112,0.004842101,0.0005179339,0.000017623073,0.0000018743375,0.000010460131,0.0013565837],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992655,0.000015813948,0.00027261692,0.00014116743,0.000014290014,0.0002906188],"domain_scores_gemma":[0.9994399,0.00006883977,0.000090876376,0.00036120974,0.0000043649998,0.000034791934],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00089236756,0.000072803465,0.00019603928,0.000032559205,0.00009344293,0.00009418325,0.00039976838,0.000035793044,0.00015772997],"category_scores_gemma":[0.000057939244,0.000051363073,0.00004703918,0.00010028362,0.000099074445,0.000082311475,0.00005585171,0.00017952287,0.000906815],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005950744,0.000026877191,0.004622784,0.000008750175,0.000017734312,7.092411e-7,0.00076053425,0.0004946431,0.0000069100015,0.9535837,0.03917713,0.001240709],"study_design_scores_gemma":[0.0007985312,0.000008308271,0.031594507,0.0000049577015,0.0000011221381,7.247553e-7,0.000032097607,0.0020578497,0.000024996856,0.38434532,0.5810525,0.00007912651],"about_ca_topic_score_codex":0.00020487812,"about_ca_topic_score_gemma":0.000100630714,"teacher_disagreement_score":0.5692384,"about_ca_system_score_codex":0.00009110676,"about_ca_system_score_gemma":0.000011879092,"threshold_uncertainty_score":0.9998711},"labels":[],"label_agreement":null},{"id":"W2063959707","doi":"10.1211/ijpp.14.2.0003","title":"A review of pharmaceutical scheduling processes in six countries and the effect on consumer access to medicines","year":2006,"lang":"en","type":"review","venue":"International Journal of Pharmacy Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Medicine; Pharmacy; Family medicine; Developed country; Alternative medicine; Traditional medicine; Environmental health; Pharmacology","score_opus":0.13992365188237044,"score_gpt":0.49070401458939733,"score_spread":0.3507803627070269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063959707","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000054242435,0.97307515,0.000042088548,0.021544356,0.0009857428,0.0006853622,0.00015827549,0.0000035800865,0.0034511834],"genre_scores_gemma":[0.0006376232,0.9747087,0.00007806972,0.0238475,0.0006325452,0.000044228003,0.000007859007,0.000029659988,0.000013838691],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996783,0.00025914988,0.0023023554,0.0002695658,0.00017491706,0.000210967],"domain_scores_gemma":[0.990724,0.0057374756,0.0028851235,0.00013884764,0.00037705654,0.00013746225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044063157,0.00030597587,0.0018370512,0.0006037197,0.000032663633,0.00016181318,0.0010238868,0.00006706799,0.00019068121],"category_scores_gemma":[0.007039785,0.00021542556,0.00028647075,0.00033344724,0.00018135647,0.0006893628,0.00018441677,0.000823866,0.00006391442],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006264642,0.00082968385,0.0021608952,0.21034059,0.005134938,0.000374746,0.0003476992,0.00019623795,7.4181395e-7,0.029630814,0.04885666,0.69586235],"study_design_scores_gemma":[0.0034012261,0.00006332641,0.0000026799894,0.026200105,0.00048021902,0.0003110036,0.000002910672,0.00007712602,0.000008834114,0.00021478717,0.9690554,0.00018236865],"about_ca_topic_score_codex":0.00007147069,"about_ca_topic_score_gemma":0.000002982662,"teacher_disagreement_score":0.92019874,"about_ca_system_score_codex":0.00018166535,"about_ca_system_score_gemma":0.0002833801,"threshold_uncertainty_score":0.87847996},"labels":[],"label_agreement":null},{"id":"W2064173156","doi":"10.1177/1715163512473930","title":"Don’t sacrifice generic drug industry for sake of Canada-European trade deal","year":2013,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Government (linguistics); Intellectual property; European union; Commission; Business; CITES; International trade; Brand names; Generic drug; Political science; Law; Finance; Drug; Marketing; Medicine","score_opus":0.057729886446134374,"score_gpt":0.2433459687130251,"score_spread":0.18561608226689075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064173156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96126926,0.0033342855,0.00015716888,0.0029015315,0.003566809,0.00084193016,0.0058863135,0.000022109589,0.022020617],"genre_scores_gemma":[0.9851113,0.001409823,0.00029281405,0.010786475,0.0011490248,0.000033659617,0.000038312333,0.00009830781,0.0010803163],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964936,0.000082511106,0.0013745037,0.0005038172,0.00010906066,0.0014364999],"domain_scores_gemma":[0.9957214,0.00012974026,0.0006909196,0.00030148184,0.00017271172,0.0029837373],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008814167,0.0004150784,0.0006688953,0.0003746149,0.0006177721,0.0002040196,0.00095489586,0.00009984242,0.002471004],"category_scores_gemma":[0.00013269925,0.00051527366,0.00022155489,0.00040215458,0.0001583587,0.00040150547,0.000047260073,0.00091880554,0.000024809691],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000720625,0.00010407544,0.007633693,0.0004909977,0.0006558167,0.0035735385,0.0010742652,0.0044769295,0.0010147834,0.0050656414,0.9272294,0.048608772],"study_design_scores_gemma":[0.0025475444,0.000033799144,0.0006322189,0.00001628146,0.00006124052,0.020710846,0.000026595722,0.012997858,0.0016480486,0.0013709011,0.9588757,0.0010789597],"about_ca_topic_score_codex":0.7155238,"about_ca_topic_score_gemma":0.8108882,"teacher_disagreement_score":0.09536443,"about_ca_system_score_codex":0.0029427803,"about_ca_system_score_gemma":0.0045475364,"threshold_uncertainty_score":0.9997299},"labels":[],"label_agreement":null},{"id":"W2064908274","doi":"10.1057/jors.2013.106","title":"Health-based pharmaceutical pay-for-performance risk-sharing agreements","year":2013,"lang":"en","type":"article","venue":"Journal of the Operational Research Society","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Actuarial science; Markov chain; Clinical trial; Risk analysis (engineering); Population; Health care; Business; Marketing; Computer science; Medicine; Economics; Environmental health","score_opus":0.22293858660637894,"score_gpt":0.4309106411635537,"score_spread":0.20797205455717477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064908274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8247374,0.0016941937,0.0033613073,0.1654205,0.0009814682,0.0011668704,0.00025273403,0.000008927034,0.002376535],"genre_scores_gemma":[0.9884897,0.0013486481,0.0022104182,0.0063267294,0.00066714955,0.000035594494,0.0000040927325,0.00001737967,0.0009002794],"study_design_codex":"not_applicable","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99834603,0.000061446044,0.00078347005,0.0001818048,0.00017399206,0.0004532478],"domain_scores_gemma":[0.9985506,0.00028519213,0.0003935337,0.00019509731,0.00032903205,0.00024655543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004735869,0.00009831335,0.00026288306,0.0000777329,0.0006554707,0.00022223216,0.0006242672,0.0000619057,0.0006106795],"category_scores_gemma":[0.00041867606,0.000068567824,0.00035291654,0.00020291212,0.00012203766,0.00039143118,0.00013037515,0.0008095724,0.00020322003],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017273215,0.0005884543,0.40376273,0.0003492855,0.0007705932,5.594928e-7,0.0011867046,0.02734155,0.0005928381,0.10147718,0.44384408,0.019913288],"study_design_scores_gemma":[0.0022955677,0.00023070113,0.056567762,0.000058025016,0.0000064477495,0.0000057643488,0.000051211566,0.62081915,0.0007107843,0.029460153,0.28959534,0.00019911153],"about_ca_topic_score_codex":0.000094618656,"about_ca_topic_score_gemma":0.0000022609404,"teacher_disagreement_score":0.5934776,"about_ca_system_score_codex":0.00044848287,"about_ca_system_score_gemma":0.00034977045,"threshold_uncertainty_score":0.6686513},"labels":[],"label_agreement":null},{"id":"W2065142793","doi":"10.1136/bmj.327.7417.700-d","title":"Illinois is to estimate savings from letting its employees import cheap drugs","year":2003,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Economics; Actuarial science","score_opus":0.06270099590364692,"score_gpt":0.3378026839206845,"score_spread":0.2751016880170376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065142793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88502,0.0007914845,0.00023082475,0.012839341,0.0007355469,0.00032227952,0.0003926554,0.000061811574,0.099606045],"genre_scores_gemma":[0.9767664,0.000093948336,0.0033149414,0.01732354,0.0005577192,0.00005106063,0.000014484142,0.000055213084,0.0018226727],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99818254,0.000011459097,0.0007874106,0.00050393265,0.000032620694,0.00048205603],"domain_scores_gemma":[0.99900085,0.00007605715,0.00025333877,0.00035841044,0.000022090404,0.00028922726],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00061500433,0.00020160634,0.00042198336,0.00014067435,0.00011220879,0.000119450226,0.00024656646,0.00010516026,0.001890301],"category_scores_gemma":[0.00029469913,0.0002490925,0.00014189952,0.00016977405,0.000023879535,0.00017745797,0.00007930348,0.00016282657,0.005423714],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005012438,0.00030009638,0.18475327,0.00008543992,0.0003475992,0.00002644148,0.006762472,0.0004792683,0.0008402269,0.45876795,0.3419847,0.0056024366],"study_design_scores_gemma":[0.00050827744,0.000034544653,0.010607281,0.000019030778,0.0000092877,0.000003243156,0.000034581353,0.0020559002,0.0041900035,0.020683458,0.9613292,0.000525158],"about_ca_topic_score_codex":0.00033226513,"about_ca_topic_score_gemma":0.000012514721,"teacher_disagreement_score":0.61934453,"about_ca_system_score_codex":0.000104249644,"about_ca_system_score_gemma":0.00003512951,"threshold_uncertainty_score":0.9999961},"labels":[],"label_agreement":null},{"id":"W2066125418","doi":"10.1300/j371v12n01_02","title":"Canadian Public Policies and Practices Related to Drug Prices, Utilization and Expenditures","year":2004,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Finance Economics & Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Public economics; Business; Public policy; Drug; Economics; Economic growth; Medicine; Pharmacology","score_opus":0.09016908950677895,"score_gpt":0.36679151783508546,"score_spread":0.2766224283283065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066125418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86567396,0.006729483,0.00007606486,0.12034175,0.00044372855,0.00024903702,0.0001624372,0.000014317835,0.0063092215],"genre_scores_gemma":[0.96548396,0.02254889,0.0012721138,0.010035071,0.00049520854,0.000008698063,0.0000050215103,0.00004448595,0.0001065576],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974769,0.000023592804,0.0013046195,0.00042196046,0.000039593255,0.00073335523],"domain_scores_gemma":[0.9971809,0.00012814396,0.0012870155,0.0002233533,0.00006749368,0.001113105],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009660726,0.000298789,0.0006562676,0.0012033968,0.00024513435,0.00036928474,0.00039987848,0.00016679193,0.000094584684],"category_scores_gemma":[0.00052105694,0.00034202283,0.000121745245,0.00029924064,0.0001727701,0.0011454463,0.00014135007,0.0005097684,0.00011876299],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044058852,0.00007761511,0.0057242005,0.000029862022,0.000103964354,0.00001095057,0.0009790872,0.00037476912,0.000034174253,0.9829345,0.0008805629,0.008806301],"study_design_scores_gemma":[0.0017993882,0.00011064808,0.01063381,0.000030789746,0.000023455135,0.00025869595,0.00011717288,0.001193353,0.00039176887,0.2362487,0.74873704,0.00045517206],"about_ca_topic_score_codex":0.007827347,"about_ca_topic_score_gemma":0.0038962218,"teacher_disagreement_score":0.7478565,"about_ca_system_score_codex":0.00082466396,"about_ca_system_score_gemma":0.0006691318,"threshold_uncertainty_score":0.9999032},"labels":[],"label_agreement":null},{"id":"W2067181723","doi":"10.1016/j.healthpol.2012.02.005","title":"International comparison of assessments of pharmaceutical innovation","year":2012,"lang":"en","type":"article","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University; University of Toronto; University Health Network","funders":"","keywords":"Business; Medicine","score_opus":0.31662892213048066,"score_gpt":0.5343481796147236,"score_spread":0.21771925748424292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067181723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6017174,0.0023587467,0.004387033,0.041803557,0.002310048,0.0005258766,0.0010331691,0.000040641196,0.3458235],"genre_scores_gemma":[0.99416983,0.00029130295,0.0008332827,0.0041162944,0.00043322446,0.000006971882,0.000027976412,0.000011710491,0.000109385335],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983719,0.000019180052,0.0011288216,0.0001168884,0.000037878013,0.00032534907],"domain_scores_gemma":[0.9989004,0.000048272374,0.0007294162,0.00014070644,0.000041601485,0.00013957308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007328078,0.000082729806,0.0003723924,0.00048496344,0.000030413219,0.000006987665,0.00016645635,0.000055450346,0.00045174436],"category_scores_gemma":[0.00011688336,0.00010085769,0.000051466974,0.00038361782,0.000057191657,0.0001805607,0.00006121254,0.00012994363,0.0001100789],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014443899,0.00028700224,0.13686396,0.00007928464,0.000034709003,1.47103005e-8,0.00040864322,0.000012137993,0.00007068509,0.8491568,0.0027024085,0.01036994],"study_design_scores_gemma":[0.00092480506,0.00008735456,0.06017361,0.000016902919,0.000002877118,0.000001443553,0.00003971638,0.005909987,0.0016050678,0.0112533765,0.91983515,0.00014973554],"about_ca_topic_score_codex":0.00048829353,"about_ca_topic_score_gemma":0.0000016016736,"teacher_disagreement_score":0.91713274,"about_ca_system_score_codex":0.00017531963,"about_ca_system_score_gemma":0.00009382804,"threshold_uncertainty_score":0.4946284},"labels":[],"label_agreement":null},{"id":"W2067457166","doi":"10.7326/0003-4819-144-3-200602070-00027","title":"Savings from Canadian Internet Pharmacies Are Limited","year":2006,"lang":"en","type":"article","venue":"Annals of Internal Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Pharmacy; Family medicine","score_opus":0.10869930703517935,"score_gpt":0.3256653015680864,"score_spread":0.21696599453290702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067457166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84596336,0.0046700076,0.00013095,0.028320197,0.00077400566,0.00008733406,0.0005967376,0.00002018623,0.11943724],"genre_scores_gemma":[0.9816893,0.00039762515,0.00003413331,0.0157873,0.0005539665,0.0000043827727,0.000033316737,0.000019070461,0.0014809183],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985844,0.000009844544,0.0007853077,0.00025626662,0.000034147935,0.000330046],"domain_scores_gemma":[0.9989816,0.000092529954,0.00042355753,0.00018503325,0.000060918337,0.00025637713],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00028952394,0.00015620045,0.00048666244,0.00036669796,0.000024589906,0.000021424217,0.00034983986,0.00006917892,0.0036651916],"category_scores_gemma":[0.00016788827,0.00015834124,0.00010463478,0.00011906565,0.00015028381,0.00012092476,0.000045009365,0.00017900499,0.00040554433],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000098409364,0.00010088184,0.34840265,0.000046255314,0.00026539026,0.000040995812,0.00063070905,0.000023229513,0.00042017334,0.13009234,0.5178969,0.0019821108],"study_design_scores_gemma":[0.0010123203,0.0001233924,0.08580172,0.000216258,0.000012379023,0.00000778761,0.00005866644,0.0025624018,0.0044854786,0.065812014,0.839617,0.000290571],"about_ca_topic_score_codex":0.54970354,"about_ca_topic_score_gemma":0.023979407,"teacher_disagreement_score":0.5257241,"about_ca_system_score_codex":0.000049619972,"about_ca_system_score_gemma":0.000019561267,"threshold_uncertainty_score":0.9972456},"labels":[],"label_agreement":null},{"id":"W2067675266","doi":"10.1016/j.jhealeco.2010.06.007","title":"Is newer always better? Re-evaluating the benefits of newer pharmaceuticals","year":2010,"lang":"en","type":"article","venue":"Journal of Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"U.S. Department of Veterans Affairs","keywords":"Observational study; Replicate; Actuarial science; Medicine; Test (biology); Economics; Econometrics; Statistics; Internal medicine","score_opus":0.243692680031206,"score_gpt":0.41715412907153016,"score_spread":0.17346144904032415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067675266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9025576,0.0038718763,0.00011975341,0.08344278,0.0026165664,0.00026135897,0.00023024654,0.000007742777,0.006892045],"genre_scores_gemma":[0.9516538,0.0048334906,0.0019608852,0.03991752,0.0014002973,0.0000043919217,0.000002882799,0.000059778173,0.00016700037],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.996035,0.000056376033,0.0029950296,0.00029380902,0.00005263877,0.000567142],"domain_scores_gemma":[0.9953593,0.00039511337,0.0032817356,0.00048116432,0.00011950814,0.0003631946],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005197029,0.00023454247,0.0009840726,0.0002793637,0.00020098085,0.000093262024,0.0007112739,0.00015730094,0.0013925182],"category_scores_gemma":[0.00027064435,0.00021378614,0.00038478966,0.00014012336,0.000150592,0.00037465303,0.00009408894,0.00093919237,0.00016726906],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049975887,0.00085261674,0.08911045,0.0004560221,0.0011088679,0.0000037921002,0.0054939934,0.0062630717,0.0005771409,0.6091138,0.09745306,0.18906742],"study_design_scores_gemma":[0.0030816542,0.0006693629,0.017393395,0.000055608263,0.000048229682,0.00009461375,0.00012922018,0.0242967,0.0016884169,0.0977741,0.85421824,0.00055045536],"about_ca_topic_score_codex":0.00011240592,"about_ca_topic_score_gemma":0.000030805517,"teacher_disagreement_score":0.7567652,"about_ca_system_score_codex":0.00015410618,"about_ca_system_score_gemma":0.00032635682,"threshold_uncertainty_score":0.99952036},"labels":[],"label_agreement":null},{"id":"W2068029045","doi":"10.4212/cjhp.v65i5.1182","title":"Additional Thoughts on Drug Shortages","year":2012,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Thunder Bay Regional Health Sciences Centre","funders":"","keywords":"Economic shortage; Drug; Medicine; Pharmacology; Philosophy","score_opus":0.048423556585147236,"score_gpt":0.2774468638294957,"score_spread":0.22902330724434844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068029045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6236324,0.011155517,0.00002699241,0.08580321,0.012417655,0.00048262486,0.026033156,0.000023897728,0.24042456],"genre_scores_gemma":[0.9904619,0.00009484108,0.000052716823,0.0047571594,0.003809064,0.000006025684,0.0000353821,0.000021572876,0.0007613344],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99889976,0.000020792852,0.00047765236,0.00009766495,0.00004067422,0.00046347876],"domain_scores_gemma":[0.9985152,0.00016466461,0.0003402858,0.00014385169,0.00003870127,0.0007972913],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0005609835,0.00013357007,0.0002287597,0.00020580433,0.0002468085,0.000101012796,0.0004144389,0.0000267127,0.02235574],"category_scores_gemma":[0.00013669334,0.00011216282,0.00018501889,0.00011098231,0.00012396715,0.00040784958,0.00001495419,0.00039596623,0.0014418045],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010707038,0.00006110121,0.007210947,0.000003405274,0.00009746578,0.0000128191305,0.00065041863,0.000035065408,8.0689665e-7,0.08117498,0.90984935,0.0008929399],"study_design_scores_gemma":[0.00032285947,0.00004224557,0.0068549206,0.00001069311,0.000009023082,0.000022132646,0.000024418589,0.00006811259,0.000092646,0.016671007,0.9757208,0.00016109817],"about_ca_topic_score_codex":0.00088754855,"about_ca_topic_score_gemma":0.00081969856,"teacher_disagreement_score":0.3668295,"about_ca_system_score_codex":0.00021641438,"about_ca_system_score_gemma":0.00020233329,"threshold_uncertainty_score":0.9993357},"labels":[],"label_agreement":null},{"id":"W2068054498","doi":"10.1136/bmj.g6153","title":"Canada bans imports of drugs from three Indian facilities","year":2014,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Quality (philosophy); Environmental health; Medicine","score_opus":0.03501038781365816,"score_gpt":0.2477762149291287,"score_spread":0.21276582711547054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068054498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80561805,0.00029789054,0.00013833142,0.00476746,0.0005380494,0.00013833273,0.002856079,0.000011264831,0.18563454],"genre_scores_gemma":[0.9966617,0.000024870704,0.00010048997,0.0020017184,0.00023005591,0.000009729215,0.000027010856,0.0000112342905,0.000933149],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990202,0.000006774673,0.0005376009,0.00019653265,0.000023116167,0.00021574971],"domain_scores_gemma":[0.99927604,0.00008507816,0.00022820097,0.0002840801,0.000008732113,0.00011787789],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002757357,0.000097012075,0.00030567826,0.000049806582,0.000041644515,0.000023133764,0.00017667399,0.000054924887,0.0011976287],"category_scores_gemma":[0.00007401565,0.00011527401,0.00006523926,0.00004941608,0.000041686842,0.0000658176,0.00004513781,0.00008424807,0.00009934974],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026553234,0.000060526374,0.35013258,0.00008878087,0.00019334086,0.0000062021354,0.0013642258,0.00018062127,0.000017432712,0.3695577,0.27002686,0.008345152],"study_design_scores_gemma":[0.0003252263,0.000014897313,0.04399395,0.0000058952023,0.0000027622368,7.2607355e-7,0.000050688832,0.0018506863,0.0001740007,0.10104348,0.85233307,0.0002045878],"about_ca_topic_score_codex":0.82620907,"about_ca_topic_score_gemma":0.56904566,"teacher_disagreement_score":0.58230627,"about_ca_system_score_codex":0.00007393412,"about_ca_system_score_gemma":0.00012209718,"threshold_uncertainty_score":0.9997154},"labels":[],"label_agreement":null},{"id":"W2068434752","doi":"10.1080/11926422.2009.9673491","title":"Canada's menu of choices to improve global drug access","year":2009,"lang":"en","type":"article","venue":"Canadian Foreign Policy Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Internet privacy; Political science; Business; Drug; Advertising; Public relations; Marketing; Computer science; Medicine; Pharmacology","score_opus":0.030255649483672684,"score_gpt":0.2923043864660658,"score_spread":0.2620487369823931,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068434752","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08318449,0.00066853,0.000045969548,0.023505544,0.00024105929,0.00022532618,0.0028565251,0.00000830512,0.8892642],"genre_scores_gemma":[0.95307237,0.00007734829,0.0000798676,0.045424767,0.00079783966,0.0000029134846,0.000004730069,0.000013736378,0.0005264164],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981965,0.000011119892,0.0007111874,0.00024387162,0.00004764102,0.00078972214],"domain_scores_gemma":[0.9974842,0.000022720471,0.000331801,0.00024589236,0.000057069894,0.0018583277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003076067,0.00018414948,0.00040829243,0.0004435917,0.00016880085,0.00020011918,0.00078213157,0.00006983128,0.00037064773],"category_scores_gemma":[0.00018612338,0.00021630492,0.00012416595,0.00041923157,0.000036521087,0.0002703381,0.000037259113,0.00022206463,0.000056075984],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008959544,0.000011203563,0.0060022045,0.00000591016,0.000034748547,0.0000141354385,0.000039375587,0.00011453411,0.0000052391447,0.91362786,0.07773821,0.0023976008],"study_design_scores_gemma":[0.00043608804,0.000052113213,0.032074682,0.000010702729,0.00000545145,0.000046243087,0.000012603388,0.00018795383,0.0001338067,0.46896902,0.49780035,0.0002709874],"about_ca_topic_score_codex":0.91012,"about_ca_topic_score_gemma":0.8636032,"teacher_disagreement_score":0.88873786,"about_ca_system_score_codex":0.0020066095,"about_ca_system_score_gemma":0.0032735604,"threshold_uncertainty_score":0.8820659},"labels":[],"label_agreement":null},{"id":"W2068750827","doi":"10.1007/s40271-013-0042-z","title":"Patient Perceptions of Generic Medicines: A Mixed-Methods Study","year":2014,"lang":"en","type":"article","venue":"Patient","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Likert scale; Quality (philosophy); Pharmacy; Family medicine; Medicine; Irish; Preference; Generic drug; Quarter (Canadian coin); Qualitative property; Medical prescription; Legislation; Alternative medicine; Medical education; Psychology; Nursing; Computer science; Drug; Political science; Pharmacology; Statistics","score_opus":0.0486403129079753,"score_gpt":0.3380780943796304,"score_spread":0.2894377814716551,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068750827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9738856,0.0002887705,0.005189018,0.00034056132,0.0007212996,0.00030892345,0.00006709476,0.000018717612,0.019180022],"genre_scores_gemma":[0.99594194,0.000050183105,0.0026754446,0.0011341284,0.00008622261,0.000060052796,0.000007140446,0.000018294699,0.000026598254],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985893,0.00007550871,0.00078193046,0.00029263506,0.00003249534,0.0002281772],"domain_scores_gemma":[0.99906075,0.00010168532,0.00031713405,0.000349155,0.000031561314,0.00013971941],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048176356,0.00013206326,0.0003991498,0.00018185978,0.00006197903,0.000013801443,0.0001366782,0.000045526474,0.0005923836],"category_scores_gemma":[0.00016426561,0.00013552183,0.00010810939,0.00016760566,0.000057490066,0.00005421767,0.000099660865,0.00009992398,0.00028406194],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006376958,0.004351143,0.22474599,0.00012935403,0.00033318697,0.0000033104795,0.027840586,0.0019140433,0.00056298473,0.097469434,0.014186899,0.6283993],"study_design_scores_gemma":[0.0033382857,0.0056548547,0.2461906,0.000043472075,0.000082739665,0.000011476096,0.006493343,0.06949701,0.0011796872,0.04543733,0.62076753,0.0013036554],"about_ca_topic_score_codex":0.00013710887,"about_ca_topic_score_gemma":0.00001318073,"teacher_disagreement_score":0.62709564,"about_ca_system_score_codex":0.000060775765,"about_ca_system_score_gemma":0.000010754992,"threshold_uncertainty_score":0.6486185},"labels":[],"label_agreement":null},{"id":"W2069359870","doi":"10.1016/s1098-3015(10)64771-7","title":"PHP22 PRESCRIPTION DRUG PRICE COMPARISONS BETWEEN CANADIAN AND US ON-LINE PHARMACIES OVER A SIX-MONTH PERIOD","year":2006,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Pharmacy; Period (music); Prescription drug; Medicine; Drug; Family medicine; Pharmacology","score_opus":0.11288744499185155,"score_gpt":0.3256395606394327,"score_spread":0.21275211564758117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069359870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9675993,0.0029659648,0.000042446536,0.013481978,0.00031767364,0.00042486028,0.0009312239,0.000025687812,0.014210876],"genre_scores_gemma":[0.99536794,0.0006435248,0.00016692703,0.0031196414,0.00028584292,0.000019362258,0.000045144407,0.000023635155,0.00032798506],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982455,0.000045472345,0.0007250867,0.00037530955,0.000030650124,0.00057798374],"domain_scores_gemma":[0.99913216,0.0000790263,0.0002233458,0.0001853055,0.000009051925,0.00037109305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068934116,0.00016801825,0.00044168445,0.0003904495,0.00016772753,0.00008659941,0.00014212634,0.00006651595,0.0001382601],"category_scores_gemma":[0.000025191765,0.00020766181,0.00005080378,0.00019289432,0.0000566091,0.00014542119,0.000031456475,0.0002851616,0.000118217824],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030210005,0.00015050685,0.84162754,0.0001439774,0.000026752705,0.0000052379414,0.000688914,0.008576779,0.0000031014765,0.13039048,0.017443549,0.00091297325],"study_design_scores_gemma":[0.0011873966,0.00008020425,0.33095035,0.00002985235,0.0000032356147,0.0000024325627,0.00001873548,0.08937585,0.000012063163,0.006516118,0.5715492,0.00027460678],"about_ca_topic_score_codex":0.53336835,"about_ca_topic_score_gemma":0.043936696,"teacher_disagreement_score":0.5541056,"about_ca_system_score_codex":0.00057445705,"about_ca_system_score_gemma":0.0001599625,"threshold_uncertainty_score":0.97350895},"labels":[],"label_agreement":null},{"id":"W2069391653","doi":"10.1592/phco.31.4.386","title":"Brand Name versus Generic Warfarin: A Systematic Review of the Literature","year":2011,"lang":"en","type":"review","venue":"Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Warfarin; Observational study; Medicine; Randomized controlled trial; Clinical trial; Clinical study design; MEDLINE; Anticoagulant; Crossover study; Intensive care medicine; Internal medicine; Alternative medicine; Placebo; Atrial fibrillation","score_opus":0.11062478987365605,"score_gpt":0.371436240655243,"score_spread":0.26081145078158696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069391653","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042801886,0.9938948,0.0000038762278,0.0008411002,0.0022119975,0.0017333105,0.00015844035,0.000010393425,0.000718045],"genre_scores_gemma":[0.00041626522,0.99126893,0.000008726194,0.007099855,0.00067042204,0.0000713744,0.0000046623804,0.00009134455,0.00036839777],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951625,0.0010654356,0.0029204472,0.00032836827,0.00009164908,0.00043161097],"domain_scores_gemma":[0.9933692,0.0006538305,0.005143549,0.00051720894,0.00012899537,0.00018721053],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0036374216,0.00064757274,0.0037501734,0.0003298407,0.00029785073,0.00005175475,0.0018522071,0.00022064417,0.0014452827],"category_scores_gemma":[0.000035694164,0.00036309895,0.0013718039,0.00044657156,0.00039985473,0.00021152914,0.00012952978,0.0013968057,0.00003115625],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010070906,0.000855777,0.000016503447,0.8816587,0.012908857,0.000023332905,0.0048649614,0.0000031040922,0.00014808965,0.008977518,0.04982978,0.039706305],"study_design_scores_gemma":[0.003463043,0.00020554654,0.0000015236209,0.06397073,0.0020694777,0.00021665049,0.000010259848,0.000007640578,0.00011707192,0.0018204667,0.9276577,0.0004598514],"about_ca_topic_score_codex":0.00000939809,"about_ca_topic_score_gemma":7.96351e-7,"teacher_disagreement_score":0.87782794,"about_ca_system_score_codex":0.000109863526,"about_ca_system_score_gemma":0.0001428771,"threshold_uncertainty_score":0.9998821},"labels":[],"label_agreement":null},{"id":"W2069756197","doi":"10.1503/cmaj.109-3070","title":"China's counterfeit medicine trade booming","year":2009,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"U.S. Department of Justice","keywords":"Counterfeit; China; Government (linguistics); Counterfeit Drugs; Traditional medicine; Business; Computer security; Medicine; Computer science; Advertising; Political science; Law; Philosophy","score_opus":0.02268013354975217,"score_gpt":0.26129972802682777,"score_spread":0.2386195944770756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069756197","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04361693,0.0017540661,0.00022443663,0.7498498,0.001747479,0.00009211229,0.00007890836,0.000023418843,0.20261286],"genre_scores_gemma":[0.883477,0.0006191908,0.00003436152,0.11251872,0.0028600763,0.00000129742,0.0000059043305,0.000011941217,0.00047152385],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998342,0.000027860639,0.00075325515,0.00017914231,0.00014604616,0.0005516965],"domain_scores_gemma":[0.9978162,0.000049232138,0.00034890932,0.00009943153,0.000026045573,0.0016601527],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002089724,0.00012402574,0.0003522822,0.0002744875,0.00022750617,0.000097098215,0.00030147823,0.00026971838,0.01023689],"category_scores_gemma":[0.00095831626,0.00013225709,0.000102146594,0.0001646628,0.00003529731,0.00017999673,0.000006564527,0.00080268254,0.0006125984],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000076265405,0.000049333514,0.020966971,0.000005778631,0.00013318197,0.0001646302,0.0009429012,0.000022648255,0.000007739898,0.16174462,0.7702585,0.045696057],"study_design_scores_gemma":[0.00079227466,0.0000568097,0.08190137,0.000020922442,0.0000049788114,0.00010742528,0.000028604167,0.001937722,0.0000022650117,0.021464683,0.89353853,0.00014439214],"about_ca_topic_score_codex":0.0012151268,"about_ca_topic_score_gemma":0.0020764112,"teacher_disagreement_score":0.8398601,"about_ca_system_score_codex":0.0010382659,"about_ca_system_score_gemma":0.000354796,"threshold_uncertainty_score":0.9906679},"labels":[],"label_agreement":null},{"id":"W2069951160","doi":"10.12927/hcpap..16909","title":"Let Evidence be the Arbiter","year":2002,"lang":"en","type":"letter","venue":"A Nudge Too Far? A Nudge at All? On Paying People to Be Healthy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"C17 Council","funders":"","keywords":"Arbiter; Negotiation; Formulary; Courage; Value (mathematics); Business; Law and economics; Public relations; Internet privacy; Political science; Economics; Computer science; Medicine; Law; Pharmacology","score_opus":0.2378774069783038,"score_gpt":0.34068040933946403,"score_spread":0.10280300236116022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069951160","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01709165,0.0035613482,0.0000629794,0.95994747,0.0019533574,0.0015486582,0.0016562388,0.00018620136,0.013992099],"genre_scores_gemma":[0.0020357207,0.0047051045,0.00014957768,0.9795325,0.0010071317,0.0006364592,0.00023214403,0.00031273015,0.011388656],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9927053,0.0002233547,0.0022560158,0.0021338118,0.00025969336,0.0024218562],"domain_scores_gemma":[0.99394476,0.0018003936,0.0011860068,0.0022253662,0.00008480686,0.00075864355],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0017342728,0.0011652792,0.0019089452,0.00066587405,0.00076659163,0.00050615316,0.0019553367,0.0011728402,0.004039377],"category_scores_gemma":[0.000577306,0.0010991915,0.0007807104,0.00072153803,0.0001420695,0.00035956642,0.00069623266,0.0034025935,0.0143054705],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013518787,0.0001088376,0.0007882693,0.00018086156,0.00017251616,0.00007091472,0.0021535277,0.000015139828,0.0000027631809,0.0051591867,0.99037546,0.00083736],"study_design_scores_gemma":[0.00076635694,0.0004640179,0.00076627993,0.0000037034654,0.00004836415,0.000050611976,0.000018300252,0.0015043308,0.000006783592,0.0011208463,0.9939737,0.0012767292],"about_ca_topic_score_codex":0.0014664304,"about_ca_topic_score_gemma":0.00035603694,"teacher_disagreement_score":0.01958501,"about_ca_system_score_codex":0.0017803648,"about_ca_system_score_gemma":0.00018583627,"threshold_uncertainty_score":0.9991458},"labels":[],"label_agreement":null},{"id":"W2070185921","doi":"10.1503/cmaj.109-4513","title":"PEI government announces catastrophic drug plan","year":2013,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Formulary; Surprise; Government (linguistics); Plan (archaeology); Medical prescription; Ceiling (cloud); Medicine; Family medicine; History; Geography; Pharmacology","score_opus":0.017372502552922664,"score_gpt":0.21553988146523992,"score_spread":0.19816737891231725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070185921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5517582,0.0012932237,0.000084281084,0.30532515,0.0025193063,0.00023297206,0.000991577,0.0000234623,0.13777177],"genre_scores_gemma":[0.95302176,0.00043237914,0.000067353256,0.042664316,0.0018584058,0.000014422642,0.000013378776,0.000016193408,0.0019117916],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984842,0.000028594875,0.0005854574,0.0001677146,0.0001997096,0.0005343534],"domain_scores_gemma":[0.99779093,0.0000736508,0.00032628063,0.00009611475,0.00005257657,0.0016604698],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0011637902,0.00010799286,0.00024684472,0.00009379127,0.00020807411,0.00024629684,0.00030789778,0.00016099252,0.017026572],"category_scores_gemma":[0.00050989666,0.00011729335,0.00009368394,0.00009892423,0.000030625677,0.00025091277,0.000020593772,0.00060997286,0.0056999014],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000014957276,0.000023865734,0.113249004,0.0000039999795,0.0000900894,0.000026569473,0.00021691815,0.00001025177,0.0000015378342,0.017860893,0.86462575,0.0038896275],"study_design_scores_gemma":[0.00041760475,0.000014381153,0.03127718,0.000007802804,0.0000028857858,0.00003812028,0.00010196891,0.0012056648,0.0000034337536,0.0085658915,0.95820713,0.00015794612],"about_ca_topic_score_codex":0.006255113,"about_ca_topic_score_gemma":0.0073068724,"teacher_disagreement_score":0.4012635,"about_ca_system_score_codex":0.0014735623,"about_ca_system_score_gemma":0.00040063926,"threshold_uncertainty_score":0.9950743},"labels":[],"label_agreement":null},{"id":"W2071408769","doi":"10.1016/j.socscimed.2011.06.059","title":"Product development public–private partnerships for public health: A systematic review using qualitative data","year":2011,"lang":"en","type":"review","venue":"Social Science & Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Public Health Ontario","funders":"","keywords":"Transparency (behavior); Business; Public relations; Public health; Population; General partnership; Citizen journalism; Public–private partnership; Stakeholder; Medicine; Political science; Environmental health; Nursing; Finance","score_opus":0.8603555550577737,"score_gpt":0.5468427409509209,"score_spread":0.31351281410685283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071408769","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000010032777,0.9823405,0.0007119618,0.009650167,0.00069053995,0.0039960467,0.00043957497,0.000035633464,0.002134585],"genre_scores_gemma":[0.000052912015,0.9938704,0.00039712767,0.0040017716,0.00073395687,0.0004480838,0.00032449118,0.000053514676,0.00011778865],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99354,0.00030482482,0.0033236877,0.0014006399,0.0001666758,0.001264205],"domain_scores_gemma":[0.9944328,0.00030946868,0.0033671057,0.0010823044,0.00016481479,0.00064350234],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.03126939,0.0005000258,0.004805454,0.00061785977,0.0008476438,0.00015318164,0.0028760324,0.00013310825,0.00015976054],"category_scores_gemma":[0.007466115,0.00041486215,0.00024745497,0.0017199212,0.0010456326,0.00072165445,0.00047174707,0.0003896775,0.00014805715],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[7.71269e-7,0.000060755283,0.0000014635292,0.56261396,0.00017798305,3.9649967e-7,0.007392856,2.2057711e-9,1.9843423e-8,0.35376447,0.0031682628,0.07281903],"study_design_scores_gemma":[0.00016397236,0.000025827298,2.6815587e-7,0.058114167,0.00014470943,0.0000054185243,0.00014523593,0.000026784071,2.5057329e-8,0.0028954225,0.9380623,0.00041586426],"about_ca_topic_score_codex":0.000052694388,"about_ca_topic_score_gemma":0.000012084198,"teacher_disagreement_score":0.934894,"about_ca_system_score_codex":0.0012821299,"about_ca_system_score_gemma":0.002707607,"threshold_uncertainty_score":0.9998303},"labels":[],"label_agreement":null},{"id":"W2071714847","doi":"10.3821/1913-701x-145.1.6","title":"Call for Political Action to Address Continuing Drug Shortages","year":2012,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Government (linguistics); House of Commons; Politics; Public administration; Medicine; Medical prescription; Economic shortage; Political science; Health care; Call to action; Public relations; Law; Business; Nursing","score_opus":0.10549187281686004,"score_gpt":0.32419602098714306,"score_spread":0.21870414817028302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071714847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9636691,0.0027372136,0.001050156,0.0026241478,0.008989926,0.0010256437,0.0053876657,0.000047658425,0.014468449],"genre_scores_gemma":[0.9820098,0.00074664183,0.00029591372,0.012231243,0.0033570202,0.00006180642,0.000033308246,0.000078759294,0.0011854754],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963653,0.000044970733,0.0009155158,0.0004092677,0.00007937678,0.0021855563],"domain_scores_gemma":[0.99368566,0.00016017698,0.00027048087,0.0002249301,0.00017375126,0.005484972],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011220438,0.00035353634,0.0005497588,0.00051761896,0.0005469336,0.00026980776,0.0005622735,0.00007951554,0.00093188905],"category_scores_gemma":[0.00032060404,0.00044767812,0.00023159182,0.00030646246,0.00009678166,0.00061552244,0.000050182538,0.00052282645,0.000120041776],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046942555,0.00035812563,0.051455114,0.00081955304,0.0010992778,0.0036584307,0.0076898932,0.0017425177,0.0020443564,0.1777179,0.66035676,0.09258866],"study_design_scores_gemma":[0.0015644099,0.000028338805,0.00019030554,0.000015016796,0.000061656305,0.02301867,0.000020891517,0.0032391183,0.0023073822,0.0013551785,0.9672942,0.0009048366],"about_ca_topic_score_codex":0.021086968,"about_ca_topic_score_gemma":0.03894335,"teacher_disagreement_score":0.30693746,"about_ca_system_score_codex":0.003177641,"about_ca_system_score_gemma":0.0005849124,"threshold_uncertainty_score":0.9999814},"labels":[],"label_agreement":null},{"id":"W2071885854","doi":"10.1136/bmj.38582.703866.ae","title":"“Breakthrough” drugs and growth in expenditure on prescription drugs in Canada","year":2005,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":107,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver Hospital and Health Sciences Centre; University of British Columbia","funders":"","keywords":"Medical prescription; Medicine; Drug industry; Computer science; Data science; Pharmacology; Biology; Biotechnology","score_opus":0.030169819471617676,"score_gpt":0.2681968652973627,"score_spread":0.23802704582574502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071885854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90764534,0.0006165239,0.00000418264,0.016463561,0.0002298438,0.00022101842,0.00008758602,0.000006897489,0.07472502],"genre_scores_gemma":[0.9942002,0.00031458636,0.00008161201,0.004851703,0.00023168884,0.00003178885,0.0000075225057,0.000012769423,0.0002680941],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99898344,0.000012176499,0.00044679144,0.00027168298,0.00002217765,0.00026374098],"domain_scores_gemma":[0.9996333,0.000042602183,0.0001036996,0.00013108448,0.000003879684,0.00008543022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026984635,0.000111049696,0.00023513632,0.00014958144,0.000022863995,0.000028427978,0.000106203246,0.000059346567,0.00020281224],"category_scores_gemma":[0.00003046608,0.00013432899,0.000024080597,0.00008839662,0.00001754992,0.00017397384,0.000035452344,0.00017906443,0.00012109979],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012976213,0.00021402068,0.36092627,0.000070457056,0.000031935793,0.000015207763,0.0038616145,0.0013254505,0.000010885418,0.54260266,0.077017754,0.013793974],"study_design_scores_gemma":[0.0031518722,0.000044283523,0.52031964,0.000052301715,0.000002786409,0.0000062064846,0.00034480778,0.026224576,0.0002778022,0.035886277,0.41297716,0.0007122779],"about_ca_topic_score_codex":0.54687107,"about_ca_topic_score_gemma":0.4506807,"teacher_disagreement_score":0.5067164,"about_ca_system_score_codex":0.0005893602,"about_ca_system_score_gemma":0.000083008745,"threshold_uncertainty_score":0.559343},"labels":[],"label_agreement":null},{"id":"W2072560809","doi":"10.1016/s0160-2527(03)00084-0","title":"Manufacturing uncertainty: Adverse effects of drug development for women","year":2003,"lang":"en","type":"article","venue":"International Journal of Law and Psychiatry","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Drug; Drug development; Adverse effect; Medicine; Medical emergency; Risk analysis (engineering); Pharmacology","score_opus":0.018478166774410033,"score_gpt":0.2727999053773897,"score_spread":0.25432173860297963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072560809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97619873,0.0012385314,0.00067906897,0.0010556118,0.0029917583,0.00008566217,0.00003224741,0.0000024692106,0.017715905],"genre_scores_gemma":[0.9954132,0.00015584468,0.002450243,0.0016007711,0.0001806035,0.0000047545786,0.0000011408125,0.000007903376,0.00018555668],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992267,0.000008941876,0.0005233356,0.00008875564,0.000030809268,0.000121442594],"domain_scores_gemma":[0.99932915,0.00009404656,0.0004032711,0.00004675694,0.00003939104,0.00008741084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043927022,0.00007336935,0.00020461997,0.00010995015,0.000036186368,0.000018165536,0.00014349194,0.000030403366,0.00006942563],"category_scores_gemma":[0.00003320397,0.000074829564,0.00008286927,0.000013587733,0.000028884397,0.00010610024,0.0000141858545,0.000090008536,0.000006112661],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010631754,0.0001185315,0.006195991,0.000100951824,0.00035836955,0.0000019061168,0.0009409863,0.0001255014,0.000017699482,0.99035054,0.00052956317,0.001153608],"study_design_scores_gemma":[0.0024670481,0.000073169336,0.0028697592,0.000058763355,0.0000070224105,0.000024291436,0.0000896671,0.00006407218,0.002739477,0.29034045,0.7011169,0.00014937198],"about_ca_topic_score_codex":0.000009697826,"about_ca_topic_score_gemma":0.000008375923,"teacher_disagreement_score":0.70058733,"about_ca_system_score_codex":0.000069751164,"about_ca_system_score_gemma":0.000051208208,"threshold_uncertainty_score":0.3051461},"labels":[],"label_agreement":null},{"id":"W2073143549","doi":"10.1186/1475-9276-8-43","title":"Towards equitable access to medicines for the rural poor: analyses of insurance claims reveal rural pharmacy initiative triggers price competition in Kyrgyzstan","year":2009,"lang":"en","type":"article","venue":"International Journal for Equity in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"United States Agency for International Development","keywords":"Pharmacy; Quarter (Canadian coin); Competition (biology); Access to medicines; Market share; Drug prices; Competitor analysis; Medicine; Business; Public health; Family medicine; Finance; Marketing; Economics; Public economics; Geography","score_opus":0.32962598135848,"score_gpt":0.5338731273743518,"score_spread":0.2042471460158718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073143549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.64179283,0.0037526465,0.018519739,0.32246706,0.003905229,0.002113838,0.0027564073,0.000018834959,0.004673406],"genre_scores_gemma":[0.97864014,0.0020546531,0.0003546795,0.018316135,0.00051867036,0.000048178506,0.000032478038,0.000010966279,0.000024078587],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99774534,0.000040451676,0.0014502625,0.00017352853,0.000111631416,0.00047880664],"domain_scores_gemma":[0.9983315,0.00041913718,0.0007916373,0.000098324046,0.00018959896,0.00016980003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025119947,0.00014703543,0.0005000859,0.00055946136,0.00012464263,0.00013384761,0.000787469,0.00004232645,0.000075587755],"category_scores_gemma":[0.00038537045,0.00013192512,0.0001696077,0.00029930423,0.00004783769,0.00057663175,0.00009370322,0.00027420608,0.0000041476787],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073870886,0.0017354402,0.0930199,0.0006173843,0.00079983583,0.0000151665645,0.0070671025,0.03559612,0.0010323949,0.61236864,0.02543085,0.21493007],"study_design_scores_gemma":[0.014845678,0.0015761366,0.25386703,0.00086474465,0.000022320306,0.00006184735,0.001013335,0.04253464,0.0014092575,0.61228544,0.070809305,0.0007102626],"about_ca_topic_score_codex":0.00088382565,"about_ca_topic_score_gemma":0.00019125504,"teacher_disagreement_score":0.33684734,"about_ca_system_score_codex":0.00087310706,"about_ca_system_score_gemma":0.00025532587,"threshold_uncertainty_score":0.537975},"labels":[],"label_agreement":null},{"id":"W2074251263","doi":"10.1504/ijbt.2006.008961","title":"Enabling knowledge societies in developing countries: the example of genomics","year":2006,"lang":"en","type":"article","venue":"International Journal of Biotechnology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Naval Medical Research Center; New Partnership for Africa's Development; Office of Naval Research; Bill and Melinda Gates Foundation","keywords":"Transformative learning; Futures studies; Expansive; Intellectual property; Developing country; Corporate governance; Business; Knowledge management; Global public good; Equity (law); Action plan; Public good; Public relations; Political science; Economic growth; Sociology; Economics; Computer science; Management","score_opus":0.05318838713030455,"score_gpt":0.2953390947559154,"score_spread":0.24215070762561086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074251263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9363729,0.0064541865,0.0054132515,0.045709107,0.0010517869,0.00007048737,0.00005268358,0.000009025423,0.004866619],"genre_scores_gemma":[0.9934733,0.0045525646,0.0007834123,0.0008588562,0.00025319858,0.0000015267229,0.0000016312254,0.000008815425,0.00006667615],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99890554,0.000008168965,0.00082353636,0.00009677861,0.000027141163,0.00013881532],"domain_scores_gemma":[0.99910563,0.00011402046,0.0005978552,0.00008993135,0.00007938974,0.000013169351],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000593923,0.00007020087,0.00023743954,0.0004039056,0.000024634046,0.00002644638,0.00055372453,0.00012832577,0.00004972651],"category_scores_gemma":[0.00006294242,0.00006450557,0.00008679425,0.000117620795,0.00015570194,0.00009228886,0.000094487164,0.00021164601,0.000026949043],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018662171,0.00004064105,0.003796785,0.0000072759735,0.000065784305,0.0000038740172,0.00022931967,0.00023804595,0.00041276656,0.9928559,0.0011879579,0.0011429864],"study_design_scores_gemma":[0.0005103185,0.000024157604,0.002234585,0.000019716927,0.0000024453739,0.000036756366,0.000064884334,0.0007515833,0.01120893,0.15704685,0.8280154,0.000084389],"about_ca_topic_score_codex":0.00028404038,"about_ca_topic_score_gemma":0.00006657143,"teacher_disagreement_score":0.83580905,"about_ca_system_score_codex":0.00024775462,"about_ca_system_score_gemma":0.00008546048,"threshold_uncertainty_score":0.2630461},"labels":[],"label_agreement":null},{"id":"W2075267475","doi":"10.1503/cmaj.1070071","title":"Reforming Canada's Access to Medicines Regime","year":2007,"lang":"en","type":"letter","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug industry; Access to medicines; Developing country; Drug approval; Business; Medicine; Law and economics; Political science; Drug; Law; Intellectual property; Engineering ethics; Pharmacology; Economics; Economic growth; Engineering","score_opus":0.038196808491926255,"score_gpt":0.2840582139326335,"score_spread":0.24586140544070723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075267475","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00041442682,0.0005653602,0.000046844598,0.931991,0.0046188873,0.00015059042,0.0005108739,0.000011767492,0.06169026],"genre_scores_gemma":[0.0007662866,0.00030048686,0.000024700963,0.9703746,0.024771158,0.000008221651,0.000069961454,0.00005910896,0.0036254872],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963278,0.000043240216,0.001408239,0.0004036607,0.0004666978,0.0013503636],"domain_scores_gemma":[0.99552697,0.0002510822,0.00087618124,0.0002456222,0.00020431163,0.002895853],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0028664921,0.00030358342,0.0007744681,0.0008433627,0.0002976778,0.0003141679,0.001193104,0.0014793625,0.009163517],"category_scores_gemma":[0.0025197866,0.00033691252,0.00017270549,0.0003745372,0.00003253739,0.00019917775,0.00007234383,0.0044713016,0.0008365554],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0000016306514,0.000002763355,0.0036945147,0.000015897998,0.00011861274,0.0010581656,0.000037203816,0.0000021920403,2.5581288e-8,0.00025312905,0.99224263,0.002573229],"study_design_scores_gemma":[0.00030589872,0.000014741923,0.0012103803,0.000068477486,0.000010873954,0.00016020906,0.000013749354,0.00007217988,9.1842725e-7,0.0010707882,0.9966804,0.00039143112],"about_ca_topic_score_codex":0.61443317,"about_ca_topic_score_gemma":0.9444075,"teacher_disagreement_score":0.32997435,"about_ca_system_score_codex":0.008131401,"about_ca_system_score_gemma":0.0069078202,"threshold_uncertainty_score":0.9999414},"labels":[],"label_agreement":null},{"id":"W2076220047","doi":"10.1182/blood-2010-09-308858","title":"Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Clinical trial; Stakeholder; Process (computing); Diversification (marketing strategy); Data monitoring committee; Public relations; Business; Institutional review board; Stakeholder engagement; Process management; Accounting; Medicine; Political science; Computer science; Marketing","score_opus":0.3393740713216744,"score_gpt":0.40507151576369416,"score_spread":0.06569744444201975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076220047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98768246,0.0013897757,0.00011398021,0.0058327275,0.00038519528,0.00027672967,0.00019972556,0.000020518599,0.004098866],"genre_scores_gemma":[0.9945002,0.00033377996,0.00015126854,0.004011037,0.00049171457,0.00001931013,0.0000030164229,0.000021942145,0.0004677018],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9978634,0.000100697944,0.0011497549,0.00040895108,0.000023577139,0.00045360965],"domain_scores_gemma":[0.9983025,0.0007880216,0.0004091355,0.00030474595,0.00000839237,0.00018716817],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0071364343,0.00015655802,0.00055018667,0.00014156211,0.00009478231,0.000073681476,0.00032976843,0.0006785794,0.0002005233],"category_scores_gemma":[0.0023048355,0.00014097622,0.00014777377,0.00012496322,0.0001138149,0.0001860944,0.00012272102,0.0024475893,0.00008213019],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015975325,0.00069502025,0.46750364,0.000063115425,0.0001844028,0.000008630138,0.0010068372,0.000074983844,0.0008846305,0.52245355,0.0029049937,0.0040604235],"study_design_scores_gemma":[0.029948018,0.00019406741,0.124321446,0.00005869907,0.00019839504,0.00004158613,0.0005817175,0.5315567,0.001962652,0.16005315,0.14929985,0.0017836966],"about_ca_topic_score_codex":0.00004782669,"about_ca_topic_score_gemma":0.00006094965,"teacher_disagreement_score":0.53148174,"about_ca_system_score_codex":0.000016552107,"about_ca_system_score_gemma":0.00004874343,"threshold_uncertainty_score":0.9998538},"labels":[],"label_agreement":null},{"id":"W2076826991","doi":"10.4088/jcp.09m05315","title":"Comparison of Pharmacokinetic Profiles of Brand-Name and Generic Formulations of Citalopram and Venlafaxine","year":2009,"lang":"en","type":"article","venue":"The Journal of Clinical Psychiatry","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Citalopram; Venlafaxine; Bioequivalence; Crossover study; Pharmacokinetics; Confidence interval; Pharmacology; Placebo; Psychology; Medicine; Anesthesia; Internal medicine; Serotonin; Antidepressant","score_opus":0.1563976754259859,"score_gpt":0.44028342190431324,"score_spread":0.2838857464783273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076826991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98385954,0.009711768,0.0003259512,0.0038146258,0.00035622143,0.00009428347,0.000051926065,0.0000014833084,0.001784197],"genre_scores_gemma":[0.9949601,0.0029343048,0.0014763955,0.00039667654,0.00021298972,2.3851013e-7,8.096573e-7,0.000006362616,0.0000120647155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997592,0.00003987047,0.002139795,0.000084535524,0.000037157486,0.000106652165],"domain_scores_gemma":[0.9974861,0.00030593722,0.0019255314,0.00013289643,0.000051445368,0.00009805865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012790177,0.000085344276,0.00074781064,0.00010740064,0.000027006652,0.00000599269,0.00017530414,0.00006797047,0.000054953227],"category_scores_gemma":[0.00013515077,0.000067223074,0.00015605944,0.00010154086,0.00017848892,0.00008990738,0.000027367381,0.00023803955,0.000001658562],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008633791,0.0011990384,0.8753638,0.00019702296,0.0003382246,2.654721e-7,0.000541445,0.0005532217,0.00046679433,0.09605735,0.0023420872,0.022077335],"study_design_scores_gemma":[0.003368197,0.0013236854,0.8331621,0.00007498743,0.00013654972,0.000016306367,0.000055731325,0.0086604245,0.0003805356,0.14878279,0.0038923766,0.00014626747],"about_ca_topic_score_codex":0.0000060976704,"about_ca_topic_score_gemma":0.0000014264018,"teacher_disagreement_score":0.052725438,"about_ca_system_score_codex":0.000004388385,"about_ca_system_score_gemma":0.000037665384,"threshold_uncertainty_score":0.27412775},"labels":[],"label_agreement":null},{"id":"W2076928451","doi":"10.1016/s0167-6296(02)00035-8","title":"Should the US allow prescription drug reimports from Canada?","year":2002,"lang":"en","type":"article","venue":"Journal of Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":76,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Outrage; Legislation; Economics; Drug prices; Bargaining problem; Unit price; Business; Public economics; Microeconomics; Law","score_opus":0.11640730136987056,"score_gpt":0.28394609539247034,"score_spread":0.1675387940225998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076928451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88325673,0.014159509,0.00007253285,0.091874205,0.0030096876,0.00020334419,0.00030575236,0.000007976437,0.007110259],"genre_scores_gemma":[0.9566664,0.010639496,0.00022691616,0.03134424,0.00070463214,0.0000040075174,0.000006460395,0.000031678792,0.0003761556],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972561,0.000045576195,0.0020016853,0.0002327557,0.000034912744,0.0004289645],"domain_scores_gemma":[0.9971571,0.00013503365,0.0020274143,0.00033862406,0.000032446187,0.00030937287],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013340425,0.00017624523,0.00065073505,0.00011988192,0.00019349692,0.0001014049,0.0004573541,0.00007219745,0.0010534509],"category_scores_gemma":[0.00007522521,0.00016469095,0.00018218409,0.00006671075,0.0000476163,0.00032218485,0.000051826162,0.00047590415,0.00010889434],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009052488,0.00031718373,0.1224708,0.000078492456,0.00053987576,0.000026801965,0.001894599,0.008037621,0.000005180873,0.06854247,0.77953,0.018466447],"study_design_scores_gemma":[0.00063573045,0.00004814989,0.024687469,0.000013423756,0.000008329096,0.000030967018,0.000044086148,0.01256241,0.00001628364,0.019187192,0.94256663,0.00019934993],"about_ca_topic_score_codex":0.1877539,"about_ca_topic_score_gemma":0.11219941,"teacher_disagreement_score":0.16303661,"about_ca_system_score_codex":0.00084895885,"about_ca_system_score_gemma":0.0003162545,"threshold_uncertainty_score":0.99985975},"labels":[],"label_agreement":null},{"id":"W2077018378","doi":"10.1038/nm0712-991b","title":"Accord could make Canadian generics industry a 'rust bucket'","year":2012,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Rust (programming language); Business; Operations management; Computer science; Engineering","score_opus":0.06759830387206095,"score_gpt":0.3187807513350691,"score_spread":0.25118244746300816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077018378","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34502888,0.037456375,0.00010997964,0.082146674,0.0073161265,0.0004042087,0.0006331156,0.0000831766,0.5268215],"genre_scores_gemma":[0.93069774,0.00045977952,0.00013040268,0.063739866,0.003272091,0.000012891234,0.00004949165,0.000035878063,0.0016018358],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99839765,0.000011016202,0.0004888176,0.00028527444,0.000045733745,0.00077152596],"domain_scores_gemma":[0.998408,0.000053739743,0.00017693284,0.00035607925,0.000030466654,0.0009747551],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007189883,0.00021193609,0.00044268998,0.00037825442,0.000110733185,0.000023334736,0.00031627738,0.0010014783,0.003172605],"category_scores_gemma":[0.00030730266,0.0002113406,0.00006772855,0.00036626583,0.000113337876,0.00013231134,0.000048031772,0.0018567727,0.0007501534],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018494135,0.00007626365,0.18594432,0.000040612544,0.00010843567,0.00001553315,0.00052355445,0.000008027917,0.00003881668,0.5175445,0.28611895,0.009562479],"study_design_scores_gemma":[0.00055915205,0.000028646864,0.03195484,0.000012303167,0.000012008175,0.000017836208,0.00004063355,0.00019122056,0.000046287892,0.003785181,0.96311027,0.00024161304],"about_ca_topic_score_codex":0.009999347,"about_ca_topic_score_gemma":0.004856395,"teacher_disagreement_score":0.67699134,"about_ca_system_score_codex":0.0003112506,"about_ca_system_score_gemma":0.00008750439,"threshold_uncertainty_score":0.99773866},"labels":[],"label_agreement":null},{"id":"W2077165819","doi":"10.1177/0091270011402500","title":"Optimizing Drug Development and Use in Patients With Kidney Disease","year":2011,"lang":"en","type":"article","venue":"The Journal of Clinical Pharmacology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Kidney disease; Intensive care medicine; Population; Public health; Disease; Dosing; Drug development; Health care; Clearance; Drug; Internal medicine; Environmental health; Pharmacology; Pathology; Economic growth","score_opus":0.15558054303457677,"score_gpt":0.35719692523095314,"score_spread":0.20161638219637637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077165819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99672884,0.00026486814,0.00007335427,0.0013292991,0.0006295471,0.000118561795,0.000015233914,0.0000027774965,0.00083749363],"genre_scores_gemma":[0.9891392,0.00042074738,0.0012469144,0.008975036,0.00014956357,0.0000018986232,8.9298675e-7,0.000012158388,0.000053581334],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99830323,0.00009618587,0.0012411738,0.00012600243,0.000025327963,0.0002080707],"domain_scores_gemma":[0.9984085,0.00035093704,0.00069595705,0.00008822651,0.00003803373,0.00041834026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018301257,0.000100444864,0.00041673606,0.00011625799,0.000044957418,0.0000135988175,0.00023015606,0.00004070314,0.00031052355],"category_scores_gemma":[0.00021470398,0.00007213095,0.000058371308,0.000066900895,0.00015016526,0.00023321222,0.000080246595,0.0004048853,0.000033127253],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024136654,0.00056724134,0.9883336,0.000012434975,0.00016688777,0.000014469156,0.00091462774,0.0000633423,6.9025435e-7,0.002112572,0.0042323056,0.0011682104],"study_design_scores_gemma":[0.005481275,0.00015739346,0.92593676,0.000016629168,0.00004495912,0.0000021802418,0.000012396351,0.00046429934,0.00003215963,0.0026157945,0.06507865,0.00015748561],"about_ca_topic_score_codex":0.0000149681655,"about_ca_topic_score_gemma":0.0000046665773,"teacher_disagreement_score":0.062396783,"about_ca_system_score_codex":0.00003235199,"about_ca_system_score_gemma":0.00009973307,"threshold_uncertainty_score":0.3400015},"labels":[],"label_agreement":null},{"id":"W2077420003","doi":"10.1136/bmj.e4348","title":"Pharmaceutical research and development: what do we get for all that money?","year":2012,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":225,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Incentive; Mythology; Business; Economics; Market economy; Art; Literature","score_opus":0.4040375696304965,"score_gpt":0.44863132398909544,"score_spread":0.04459375435859897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077420003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47700423,0.30707163,0.0028111637,0.13682842,0.004226873,0.0041554733,0.00047477163,0.00015679671,0.06727066],"genre_scores_gemma":[0.9703236,0.020290233,0.003220136,0.0035818068,0.0009971269,0.0002907064,0.0000205449,0.00005234756,0.001223462],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984062,0.00002010279,0.00042940804,0.00031430915,0.00004177637,0.0007882128],"domain_scores_gemma":[0.9989944,0.00026721167,0.0000950297,0.00020746166,0.00002545467,0.00041043072],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023444954,0.00013947285,0.00027556668,0.0001962602,0.00015505428,0.00025325763,0.00019523154,0.000116758645,0.00040288855],"category_scores_gemma":[0.000087474065,0.00015589093,0.000050689036,0.00008203465,0.00013925816,0.0006689558,0.00016616842,0.00022374195,0.0010142837],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014942928,0.00036568125,0.04035497,0.00019809073,0.00022587396,0.0000021889607,0.0030633816,0.0000039755078,0.000052341733,0.7756871,0.062493764,0.11740321],"study_design_scores_gemma":[0.0006807642,0.000023301278,0.0014935767,0.00001676948,0.000003036563,0.000006533468,0.00012168997,0.00068989454,0.00071015256,0.028085575,0.9679484,0.0002203025],"about_ca_topic_score_codex":0.000006970816,"about_ca_topic_score_gemma":0.0000018804146,"teacher_disagreement_score":0.90545464,"about_ca_system_score_codex":0.00009734391,"about_ca_system_score_gemma":0.000029601766,"threshold_uncertainty_score":0.99976355},"labels":[],"label_agreement":null},{"id":"W2079994436","doi":"10.1176/pn.40.2.00400004","title":"Govt. Cites Few Benefits From Legal Drug Imports","year":2005,"lang":"en","type":"article","venue":"Psychiatric News","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"CITES; Government (linguistics); Legislation; Business; Prescription drug; Incentive; Scope (computer science); Medical prescription; Law; Medicine; Political science; Pharmacology; Economics","score_opus":0.02926849896999632,"score_gpt":0.25710285615216455,"score_spread":0.22783435718216824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079994436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7541343,0.028991915,0.00011115406,0.024523651,0.0018653657,0.00028452452,0.00085103186,0.00011983012,0.1891182],"genre_scores_gemma":[0.9776986,0.0030419356,0.0029077576,0.011253658,0.0030912121,0.000015703621,0.00005279048,0.000056786692,0.001881559],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99791175,0.000011652288,0.00092914246,0.0006027014,0.00003672809,0.000508038],"domain_scores_gemma":[0.99876416,0.000069954505,0.00037693945,0.0004792848,0.000011422894,0.00029822584],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00024883277,0.00025540777,0.0004789364,0.0002526507,0.00012566021,0.00015897509,0.0003861914,0.00010765942,0.0025203053],"category_scores_gemma":[0.000029703073,0.00030036177,0.00024766035,0.00030903058,0.000033949676,0.00037984975,0.0000847647,0.000259391,0.005041909],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040112576,0.00034874893,0.15253639,0.000017666376,0.00014667184,0.0000034210657,0.00036649368,0.0003552783,0.000010268316,0.5627978,0.24999061,0.033386514],"study_design_scores_gemma":[0.00082105934,0.00001857707,0.023392178,0.0000035794785,0.000017118216,0.000003934006,0.00001783557,0.00160128,0.00002926336,0.05269903,0.9209752,0.0004209329],"about_ca_topic_score_codex":0.002011555,"about_ca_topic_score_gemma":0.00052853103,"teacher_disagreement_score":0.67098457,"about_ca_system_score_codex":0.000090500645,"about_ca_system_score_gemma":0.000037322894,"threshold_uncertainty_score":0.99994487},"labels":[],"label_agreement":null},{"id":"W2080608213","doi":"10.1161/hc4301.101126","title":"Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001","year":2001,"lang":"en","type":"article","venue":"Circulation","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Biostatistics; Food and drug administration; Advisory committee; Steering committee; Library science; Internal medicine; Management; Epidemiology; Pharmacology","score_opus":0.05232949601813492,"score_gpt":0.2585653543213317,"score_spread":0.2062358583031968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080608213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94171154,0.006102445,0.0012985286,0.0025041085,0.00029382753,0.00019598413,0.000059051767,0.000034741322,0.047799755],"genre_scores_gemma":[0.99715215,0.0007766236,0.00009055849,0.001198636,0.0004944385,0.000013644661,0.000066249995,0.000021398999,0.00018632256],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.998823,0.000031058305,0.00049014494,0.0003681534,0.000041803178,0.0002458797],"domain_scores_gemma":[0.9990763,0.0000976963,0.00021687991,0.000487967,0.000022324033,0.00009881021],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090246706,0.00012810696,0.00028958666,0.000059029546,0.00016478138,0.00008693267,0.00013590962,0.00009157398,0.00025753392],"category_scores_gemma":[0.00011201969,0.00012889116,0.00018105048,0.00011895621,0.00006660258,0.00017037548,0.000055995315,0.00013302344,0.00017984027],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000089049845,0.000030761137,0.9694608,0.000006284733,0.00023088804,0.000017427765,0.0003703953,0.0019771727,0.00002867537,0.01637765,0.007245042,0.004246013],"study_design_scores_gemma":[0.00043134802,0.0000025298066,0.38961977,0.000007856905,0.000026760166,0.000025417721,0.000026174162,0.010170401,0.000012593793,0.019815564,0.5796871,0.00017446923],"about_ca_topic_score_codex":0.002207853,"about_ca_topic_score_gemma":0.00007406227,"teacher_disagreement_score":0.579841,"about_ca_system_score_codex":0.00007313137,"about_ca_system_score_gemma":0.0000152471175,"threshold_uncertainty_score":0.5256029},"labels":[],"label_agreement":null},{"id":"W2081257393","doi":"10.7326/0003-4819-150-8-200904210-02006","title":"Review: Brand-name drugs are not more effective than generic versions for treating cardiovascular disease","year":2009,"lang":"en","type":"letter","venue":"Annals of Internal Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Brand names; Disease; Intensive care medicine; Internal medicine; Advertising","score_opus":0.08459671899370333,"score_gpt":0.3395196093529283,"score_spread":0.254922890359225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081257393","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023099307,0.28605482,0.0003067971,0.7043465,0.0007140741,0.001067554,0.002007799,0.000023684548,0.0031688486],"genre_scores_gemma":[0.015620019,0.077666715,0.000036312227,0.90019315,0.0051787742,0.00015237284,0.00026802978,0.00007222143,0.0008123838],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975405,0.000040468858,0.0011353736,0.0006723867,0.00010575275,0.0005055703],"domain_scores_gemma":[0.99750847,0.00039243855,0.0010015222,0.0006813108,0.00014978905,0.00026644833],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00089057785,0.0004385166,0.002022158,0.0003479925,0.00007170183,0.00001767936,0.00054088404,0.0002459795,0.00020588936],"category_scores_gemma":[0.0008713443,0.00040938213,0.0014017934,0.00014231411,0.00017114385,0.00010193602,0.00007705869,0.0007049183,0.00007626911],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011323255,0.000036610138,0.0002400237,0.0021354978,0.0013118166,0.000046025474,0.00011192372,0.000029522043,0.0000016326244,0.00025085433,0.9886506,0.007072228],"study_design_scores_gemma":[0.0011175023,0.00023845313,0.0008695683,0.0051881233,0.0003389993,0.000006092265,0.000009829314,0.00068106136,0.000057517525,0.0022726846,0.9888282,0.00039200147],"about_ca_topic_score_codex":0.00047882777,"about_ca_topic_score_gemma":9.461593e-7,"teacher_disagreement_score":0.2083881,"about_ca_system_score_codex":0.00008303786,"about_ca_system_score_gemma":0.000029482622,"threshold_uncertainty_score":0.9998358},"labels":[],"label_agreement":null},{"id":"W2081303573","doi":"10.1016/j.jval.2011.08.712","title":"PHP162 Impact of AMNOG on Pharmaceutical Pricing Trends in Germany","year":2011,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Inflation (cosmology); Deflation; German; Biosimilar; Price setting; Health care; Business; Product (mathematics); Economics; Reference price; Monetary economics; Monetary policy; Geography; Medicine; Economic growth; Microeconomics","score_opus":0.26620551699215866,"score_gpt":0.40005730019361646,"score_spread":0.1338517832014578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081303573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9452559,0.00089646154,0.00002369783,0.00075051445,0.00020673304,0.00016016625,0.0000977572,0.0000139782,0.052594822],"genre_scores_gemma":[0.9979406,0.00063564815,0.00016681962,0.0010993527,0.00006235693,0.000009255562,0.000003413756,0.000022307198,0.000060244864],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9979874,0.000055293138,0.001066489,0.0003252008,0.000027003012,0.00053859735],"domain_scores_gemma":[0.9991457,0.00008739089,0.00030641892,0.00024086781,0.000006399557,0.00021323582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011399877,0.00015476532,0.0005409332,0.00088650314,0.000024929366,0.000009117988,0.00020041838,0.00008459487,0.0007838124],"category_scores_gemma":[0.00004321335,0.00016995976,0.00014653632,0.00047606582,0.000048215967,0.000106090134,0.0000407809,0.00033851175,0.00016244814],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003271928,0.0013564865,0.44070354,0.00021109449,0.000068151974,0.000017507624,0.0053155716,0.0076950556,0.000040809653,0.5219819,0.0007092615,0.021573396],"study_design_scores_gemma":[0.0025826425,0.00063461,0.84210765,0.0001111166,0.0000026147575,0.0000057568186,0.00002299103,0.11692134,0.00019623902,0.030681198,0.0063219867,0.0004118581],"about_ca_topic_score_codex":0.011260811,"about_ca_topic_score_gemma":0.000044447297,"teacher_disagreement_score":0.49130073,"about_ca_system_score_codex":0.00053300295,"about_ca_system_score_gemma":0.00007508647,"threshold_uncertainty_score":0.9953233},"labels":[],"label_agreement":null},{"id":"W2081870126","doi":"10.1001/2013.jamainternmed.332","title":"Drug Shortages and Clinicians","year":2012,"lang":"en","type":"letter","venue":"Archives of Internal Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Women's College Hospital","funders":"Canadian Institutes of Health Research","keywords":"Economic shortage; Drug; Medical prescription; Medicine; Business; Pharmacology","score_opus":0.057614419204155,"score_gpt":0.31515617728646855,"score_spread":0.25754175808231355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081870126","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0050477977,0.014325507,0.00024038083,0.7235116,0.0014693056,0.00017096206,0.00043472706,0.00001778172,0.25478193],"genre_scores_gemma":[0.12362026,0.00642267,0.0002893884,0.8512688,0.009371119,0.000013239677,0.00007261794,0.000074028605,0.008867863],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99822,0.000023201192,0.0010179058,0.00034262674,0.000033666736,0.00036258704],"domain_scores_gemma":[0.9983326,0.00062143797,0.0006005825,0.0003011179,0.0000075694593,0.00013666076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029744473,0.00024822622,0.00090766593,0.0003751364,0.00002608979,0.000011118653,0.0003992811,0.00015300034,0.000832821],"category_scores_gemma":[0.0001474912,0.00023292324,0.00014939933,0.000037552112,0.00053779606,0.00006635691,0.00014847209,0.0010330982,0.00011317096],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029255061,0.000028149347,0.019962331,0.00029408597,0.0002764679,0.000025848196,0.001341416,3.2838187e-7,0.000013529235,0.01810958,0.95294654,0.0069724848],"study_design_scores_gemma":[0.00043597125,0.00008369393,0.0028423588,0.00024195354,0.00002937111,0.000015798529,0.000019003608,0.00017464685,0.000024346895,0.040547207,0.95537394,0.00021171838],"about_ca_topic_score_codex":0.0006035779,"about_ca_topic_score_gemma":0.000012675168,"teacher_disagreement_score":0.24591409,"about_ca_system_score_codex":0.000014298836,"about_ca_system_score_gemma":0.000010241815,"threshold_uncertainty_score":0.9498334},"labels":[],"label_agreement":null},{"id":"W2081991539","doi":"10.1177/1715163513488327","title":"BC pharmacists propose new clinical services to save millions in health care budget","year":2013,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Health care; Business; Medicine; Economic growth; Economics","score_opus":0.06418847774852117,"score_gpt":0.32281917203691335,"score_spread":0.2586306942883922,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081991539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95460445,0.012695451,0.00014433409,0.010803127,0.0073555983,0.0023503383,0.002931042,0.00006915387,0.009046499],"genre_scores_gemma":[0.9468052,0.009427757,0.0006386945,0.039618153,0.0018024693,0.000056208788,0.00006625258,0.00010967235,0.0014756103],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940976,0.00016750988,0.0025592113,0.0009339276,0.00014772225,0.0020940478],"domain_scores_gemma":[0.9905356,0.00012310939,0.00072641013,0.00045450038,0.0002627964,0.007897575],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0012105774,0.00059220113,0.0010962479,0.0010885735,0.0006523239,0.00053259503,0.0013065273,0.00014040648,0.0045174058],"category_scores_gemma":[0.00015147761,0.0007238402,0.00031808848,0.0010191664,0.00014323769,0.0007543601,0.0001336437,0.0012841288,0.0011178927],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026444628,0.00038596106,0.088679545,0.0014872642,0.0007302976,0.014092754,0.014316962,0.0051459875,0.00017099344,0.0063266368,0.5752923,0.29310688],"study_design_scores_gemma":[0.0049126027,0.00014469126,0.0009200254,0.00006217434,0.000031108102,0.024106055,0.000051882012,0.0072763083,0.00015938794,0.002547891,0.9582466,0.0015412732],"about_ca_topic_score_codex":0.23718621,"about_ca_topic_score_gemma":0.2176905,"teacher_disagreement_score":0.38295433,"about_ca_system_score_codex":0.004776204,"about_ca_system_score_gemma":0.00484048,"threshold_uncertainty_score":0.99965984},"labels":[],"label_agreement":null},{"id":"W2082327598","doi":"10.3917/seve.042.0047","title":"Xavier Bertrand 2011 : électrochoc dans le monde du médicament","year":2014,"lang":"fr","type":"article","venue":"Les Tribunes de la santé","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"World Federation of Science Journalists","funders":"","keywords":"Humanities; Political science; Philosophy","score_opus":0.014492646420290854,"score_gpt":0.265330714982783,"score_spread":0.25083806856249213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082327598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6346731,0.07675888,0.040070884,0.040880308,0.002051008,0.0005069509,0.001000898,0.000104046005,0.20395392],"genre_scores_gemma":[0.9588275,0.025313707,0.0008389139,0.003941425,0.0012404236,0.00004783368,0.000038677263,0.00008197236,0.009669525],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.997224,0.00024513385,0.0008839112,0.0006254683,0.00004636521,0.00097512826],"domain_scores_gemma":[0.998201,0.00056956604,0.0003494573,0.00048341646,0.000025969706,0.00037059476],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0016190558,0.0003797632,0.00076173595,0.00017640664,0.00031492277,0.00023609734,0.00048915204,0.00047321804,0.0026224519],"category_scores_gemma":[0.00017392966,0.000489749,0.0003780282,0.00015876367,0.00046952598,0.00024344034,0.0001309671,0.00057794014,0.0014819743],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011732837,0.00078470184,0.07084045,0.0001948384,0.00033842036,0.000019399433,0.0017141745,0.00042015358,0.00029489317,0.774591,0.043095574,0.10758903],"study_design_scores_gemma":[0.001921898,0.00011423514,0.05288269,0.000033697648,0.0000495402,0.000040392144,0.00006135306,0.017889898,0.00077095896,0.07554607,0.85016316,0.0005260903],"about_ca_topic_score_codex":0.0011900291,"about_ca_topic_score_gemma":0.00013387676,"teacher_disagreement_score":0.80706763,"about_ca_system_score_codex":0.00036486317,"about_ca_system_score_gemma":0.000081634775,"threshold_uncertainty_score":0.99975544},"labels":[],"label_agreement":null},{"id":"W2082354773","doi":"10.1377/hlthaff.2012.1268","title":"International Best Practices For Negotiating ‘Reimbursement Contracts’ With Price Rebates From Pharmaceutical Companies","year":2013,"lang":"en","type":"article","venue":"Health Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health","funders":"Canadian Institutes of Health Research","keywords":"Reimbursement; Transparency (behavior); Negotiation; Business; Confidentiality; Best practice; Globe; Work (physics); Public economics; Actuarial science; Finance; Economics; Health care; Economic growth; Medicine","score_opus":0.14597376048653304,"score_gpt":0.375892090641841,"score_spread":0.22991833015530794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082354773","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2923617,0.01466405,0.013234103,0.34254894,0.0049189436,0.005816981,0.0030344361,0.00029107163,0.32312977],"genre_scores_gemma":[0.9853016,0.001390709,0.006279406,0.0055796667,0.0006402018,0.0002673591,0.00011051128,0.00003806155,0.00039245895],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99817413,0.000022480128,0.0007536254,0.00044175392,0.000051587114,0.00055640657],"domain_scores_gemma":[0.9977567,0.0004972814,0.0011102394,0.00019450711,0.00007682892,0.00036445327],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00047009502,0.00018982157,0.0004179273,0.000112158,0.00017674569,0.00029329804,0.0002728815,0.0000664586,0.0011637938],"category_scores_gemma":[0.00023889681,0.00019335414,0.00006546771,0.00007862668,0.000069858055,0.00056092587,0.00005599703,0.00023441337,0.00069807493],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007692243,0.0023190335,0.064318836,0.0005291311,0.001624844,0.00000779508,0.0048407116,0.003278611,0.00017145777,0.7697708,0.10789067,0.044478875],"study_design_scores_gemma":[0.0018568259,0.0002066511,0.0026635828,0.000033279386,0.000011513797,0.0000038443886,0.0011594748,0.093955226,0.000045623834,0.0045274906,0.89523816,0.00029830358],"about_ca_topic_score_codex":0.0039319214,"about_ca_topic_score_gemma":0.00006337241,"teacher_disagreement_score":0.7873475,"about_ca_system_score_codex":0.00021887282,"about_ca_system_score_gemma":0.000085663065,"threshold_uncertainty_score":0.9997493},"labels":[],"label_agreement":null},{"id":"W2082501248","doi":"10.1111/j.1528-1167.2007.01007.x","title":"Compulsory Generic Switching of Antiepileptic Drugs: High Switchback Rates to Branded Compounds Compared with Other Drug Classes","year":2007,"lang":"en","type":"article","venue":"Epilepsia","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":178,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Group for Research in Decision Analysis; McGill University; Montreal Neurological Institute and Hospital","funders":"","keywords":"Medicine; Lamotrigine; Clobazam; Pharmacy; Epilepsy; Adverse effect; Drug; Anticonvulsant; Generic drug; Brand names; Pharmacology; Family medicine; Psychiatry; Advertising","score_opus":0.03838946776967719,"score_gpt":0.28095209294857937,"score_spread":0.24256262517890217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082501248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9659482,0.0004976469,0.0079425275,0.0011777077,0.00043411864,0.000369719,0.00009828155,0.00006330515,0.023468481],"genre_scores_gemma":[0.9915635,0.00006582194,0.0038809837,0.0038473567,0.0002656327,0.000011754748,0.000019267567,0.00007245458,0.00027324609],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99754965,0.0000292253,0.0011368168,0.0005556407,0.00007183579,0.0006568274],"domain_scores_gemma":[0.9983324,0.00027143746,0.00052187004,0.00048669477,0.000056415887,0.00033120764],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008835395,0.00033338714,0.00094539364,0.00041752515,0.00013545534,0.000092852235,0.00046207546,0.000093225775,0.00038886393],"category_scores_gemma":[0.000029295123,0.00034461607,0.0001485732,0.0004930465,0.0000934355,0.0002028891,0.00010529606,0.0002607203,0.00058976514],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017189144,0.0013498918,0.6326828,0.00044456607,0.0010561573,0.000026187783,0.008531898,0.0056169718,0.009189392,0.30691653,0.028441997,0.0040246854],"study_design_scores_gemma":[0.010170668,0.00062560634,0.5979829,0.0002797222,0.00009886632,0.00003129039,0.0011766742,0.01902511,0.016485749,0.03176872,0.31939498,0.0029597252],"about_ca_topic_score_codex":0.00073058176,"about_ca_topic_score_gemma":0.00011223676,"teacher_disagreement_score":0.29095298,"about_ca_system_score_codex":0.00012935455,"about_ca_system_score_gemma":0.000043432916,"threshold_uncertainty_score":0.9999006},"labels":[],"label_agreement":null},{"id":"W2082560103","doi":"10.1002/hec.698","title":"The importance of being first: evidence from Canadian generic pharmaceuticals","year":2002,"lang":"en","type":"article","venue":"Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"Health Canada","keywords":"Competitor analysis; Market share; Generic drug; Business; Drug industry; Drug approval; Industrial organization; Economics; Marketing; Public economics; Drug; Medicine; Pharmacology; Engineering","score_opus":0.18842965258691116,"score_gpt":0.334590399991603,"score_spread":0.14616074740469184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082560103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.68546385,0.08356744,0.00015157202,0.1949498,0.002034736,0.00087223854,0.0012513829,0.00005637818,0.03165261],"genre_scores_gemma":[0.898099,0.08282002,0.00045404,0.01784369,0.00036088662,0.00004207764,0.000010863534,0.000046120822,0.00032331105],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99720657,0.000027209804,0.0014351063,0.00048706925,0.000020114547,0.00082391995],"domain_scores_gemma":[0.99747384,0.0004954539,0.0006934401,0.00061342324,0.000022135042,0.0007017368],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0009413891,0.00020979774,0.00056324835,0.0001466336,0.0004655501,0.000099262485,0.000580887,0.00010637795,0.001454166],"category_scores_gemma":[0.00018677564,0.00022671884,0.00015538473,0.00015427041,0.00014864461,0.00026458775,0.00007865633,0.0002593151,0.0010482059],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039886094,0.000116606214,0.41410246,0.00016463346,0.00027239465,0.0000056443164,0.0024789225,0.0014731162,0.0000050530634,0.49579802,0.06238314,0.023160111],"study_design_scores_gemma":[0.00040833303,0.000043152253,0.010232508,0.000029767953,0.0000061300107,0.000003442698,0.0000286887,0.09967349,0.00004669917,0.029752977,0.8594491,0.00032572076],"about_ca_topic_score_codex":0.032905977,"about_ca_topic_score_gemma":0.07718357,"teacher_disagreement_score":0.797066,"about_ca_system_score_codex":0.0006907353,"about_ca_system_score_gemma":0.00016286103,"threshold_uncertainty_score":0.9997296},"labels":[],"label_agreement":null},{"id":"W2082675534","doi":"10.1177/0269881107081126","title":"Generic medications: another variable in the treatment of illnesses","year":2007,"lang":"en","type":"editorial","venue":"Journal of Psychopharmacology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa","funders":"","keywords":"Bioequivalence; Audit; Medicine; Enforcement; Pharmacovigilance; European union; Government (linguistics); Agency (philosophy); Generic drug; Postmarketing surveillance; Family medicine; Actuarial science; Public economics; Accounting; Business; Drug; Pharmacology; Adverse effect; Political science; Pharmacokinetics; Economics","score_opus":0.0472767077174043,"score_gpt":0.36010374439530696,"score_spread":0.3128270366779027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082675534","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01123637,0.028678266,0.0003839917,0.0022007413,0.9424517,0.0003482136,0.00040602701,0.000004450871,0.014290235],"genre_scores_gemma":[0.013373119,0.1244533,0.00076954655,0.0036296824,0.8570095,0.000060071467,0.000035802776,0.00008282045,0.00058618834],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99758565,0.00007466348,0.0017217203,0.00021927561,0.000093514245,0.00030516315],"domain_scores_gemma":[0.9965968,0.00097633747,0.0019866768,0.0002387,0.00012142825,0.00008002598],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017438167,0.00021790883,0.000917425,0.0006847695,0.0000365881,0.00002120465,0.00065320317,0.0004474471,0.0013716214],"category_scores_gemma":[0.0001378874,0.00017336263,0.00024393937,0.00036330565,0.00012435435,0.00008530109,0.000013591823,0.0005665188,0.000065039356],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020682318,0.00091805117,0.00018225654,0.00004161675,0.00036771753,0.000019239398,0.00067608774,0.00007257214,0.000031435582,0.0019307396,0.9945614,0.0009920957],"study_design_scores_gemma":[0.0027438088,0.0004511731,0.00015333087,0.000015496706,0.00007939975,0.000011305216,0.000036672096,0.000065535154,0.000027725806,0.006575953,0.98969245,0.00014715386],"about_ca_topic_score_codex":0.000118916716,"about_ca_topic_score_gemma":0.000014094716,"teacher_disagreement_score":0.09577503,"about_ca_system_score_codex":0.00027131737,"about_ca_system_score_gemma":0.00025312373,"threshold_uncertainty_score":0.9995413},"labels":[],"label_agreement":null},{"id":"W2083690385","doi":"10.1016/s1359-6446(05)03456-2","title":"Canadian drug reimportation debate goes on","year":2005,"lang":"en","type":"article","venue":"Drug Discovery Today","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Drug discovery; Pharmaceutical sciences; Pharmacology; Computational biology; Chemistry; Medicine; Biology; Biochemistry","score_opus":0.022656620041822086,"score_gpt":0.25049837565374244,"score_spread":0.22784175561192035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083690385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7308261,0.00060333975,0.00002568413,0.029834349,0.0005643544,0.00016881317,0.0006466412,0.000034197143,0.23729652],"genre_scores_gemma":[0.9703141,0.00027354975,0.00006483777,0.012472896,0.0004231797,0.00002005773,0.00007620067,0.000031830805,0.016323337],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986143,0.000013055755,0.0004937846,0.0003895915,0.00002789868,0.00046137505],"domain_scores_gemma":[0.9991578,0.000053839074,0.00016789192,0.0003101941,0.000010096405,0.00030016326],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035177148,0.00017790362,0.00026725282,0.00027375505,0.00015005162,0.00019525553,0.00023829359,0.000058335332,0.0008364988],"category_scores_gemma":[0.00004383206,0.00020221467,0.00012330948,0.00012945861,0.000033964927,0.00064527144,0.000025120264,0.00018432883,0.004390106],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026623724,0.00010959804,0.019682812,0.00001602067,0.00006668238,0.000009892938,0.0010842162,0.0025134229,0.0000143614725,0.8632115,0.1084718,0.0047930325],"study_design_scores_gemma":[0.000443925,0.00001333687,0.0091700405,0.000011480412,0.0000051962,0.0000018605567,0.00004383554,0.0036614374,0.0006606358,0.031056948,0.9545377,0.00039360076],"about_ca_topic_score_codex":0.045782194,"about_ca_topic_score_gemma":0.10822018,"teacher_disagreement_score":0.8460659,"about_ca_system_score_codex":0.00044102714,"about_ca_system_score_gemma":0.0000935074,"threshold_uncertainty_score":0.9963851},"labels":[],"label_agreement":null},{"id":"W2084635253","doi":"10.1016/j.jval.2012.08.2038","title":"PRS39 Preference and Willingness to Pay for a Treatment of Pulmonary Arterial Hypertension","year":2012,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; McMaster University; PharmIdeas (Canada)","funders":"","keywords":"Treprostinil; Medicine; Willingness to pay; Preference; Population; Confidence interval; Descriptive statistics; Pulmonary hypertension; Demography; Physical therapy; Internal medicine; Environmental health; Economics; Statistics","score_opus":0.26733216273145527,"score_gpt":0.33045040279658777,"score_spread":0.0631182400651325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084635253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933392,0.0019795033,0.00031524364,0.002746065,0.0004351005,0.0005886555,0.00021762436,0.0000065482664,0.00037209908],"genre_scores_gemma":[0.99693775,0.0012506793,0.0008498256,0.0006449529,0.00019822105,0.00006221077,0.000006735175,0.000011414192,0.00003819755],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990293,0.000014875713,0.00045948982,0.00018269736,0.000010253436,0.00030343232],"domain_scores_gemma":[0.99945545,0.00009063147,0.0001345161,0.00012369228,0.000007751872,0.00018797567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035227236,0.00008663783,0.00035439522,0.00009430812,0.000034111992,0.000008478505,0.000048939415,0.0000438159,0.000014408544],"category_scores_gemma":[0.000032952743,0.000078281686,0.000034506786,0.00006774437,0.000014386951,0.00007700549,0.00001734165,0.000024173356,0.000017008007],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082791655,0.0028023333,0.51419073,0.0010580037,0.00007119404,0.000001781452,0.0073582893,0.0015531859,0.00063913106,0.36132485,0.00053507445,0.109637514],"study_design_scores_gemma":[0.0041004294,0.0015654957,0.39368212,0.00015190226,0.000010545969,0.000020796244,0.000085949134,0.10405729,0.0007374597,0.051168356,0.44376278,0.00065686513],"about_ca_topic_score_codex":0.001193749,"about_ca_topic_score_gemma":0.0000071921013,"teacher_disagreement_score":0.4432277,"about_ca_system_score_codex":0.00011451174,"about_ca_system_score_gemma":0.000031062038,"threshold_uncertainty_score":0.31922343},"labels":[],"label_agreement":null},{"id":"W2084964497","doi":"10.3366/ajicl.2013.0062","title":"Rwanda's New Intellectual Property Law and Compulsory Licensing for Export Under the WTO: Not Quite a Panacea","year":2013,"lang":"en","type":"article","venue":"African Journal of International and Comparative Law","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Intellectual property; Panacea (medicine); TRIPS architecture; International trade; Order (exchange); Business; TRIPS Agreement; International trade law; Access to medicines; Law; Political science; Law and economics; Economics; Engineering; Finance; Medicine","score_opus":0.1383288975416506,"score_gpt":0.30431759133223574,"score_spread":0.16598869379058515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084964497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81265795,0.0024938716,0.007838245,0.047704443,0.0009743364,0.0005151636,0.00010033654,0.000011416774,0.12770423],"genre_scores_gemma":[0.9899338,0.00014154254,0.00041363022,0.008254955,0.00037653284,0.0000056322515,0.0000019701358,0.0000072238345,0.0008647367],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991384,0.00001782087,0.00050734886,0.00014728955,0.000040004943,0.00014910556],"domain_scores_gemma":[0.99900657,0.00032011396,0.0003473543,0.000065060005,0.00011935417,0.00014153603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024234458,0.000120744706,0.00032575324,0.000063171115,0.00013611515,0.00020431662,0.0001895659,0.000029588173,0.00019679713],"category_scores_gemma":[0.000021043017,0.00007618307,0.00008702118,0.00003436188,0.00025705723,0.0002842141,0.0000643782,0.00016929347,0.00002267009],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001210222,0.000047080335,0.0003258056,0.000004749093,0.0002465932,7.647123e-7,0.002739894,0.000059569917,0.00010194211,0.9876652,0.0077637522,0.0009236239],"study_design_scores_gemma":[0.0015705865,0.00039260424,0.002798374,0.000035130302,0.000021105592,0.000107982894,0.0018706401,0.0155242095,0.00050210126,0.13649032,0.8404239,0.0002630466],"about_ca_topic_score_codex":0.0003578369,"about_ca_topic_score_gemma":0.000084866086,"teacher_disagreement_score":0.8511749,"about_ca_system_score_codex":0.000045415225,"about_ca_system_score_gemma":0.000024745434,"threshold_uncertainty_score":0.31066555},"labels":[],"label_agreement":null},{"id":"W2085083234","doi":"10.1038/bjp.2008.248","title":"The failure of torcetrapib: what have we learned?","year":2008,"lang":"en","type":"letter","venue":"British Journal of Pharmacology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Adverse effect; Cholesterylester transfer protein; Blood pressure; Heart failure; Internal medicine; Aldosterone; Pharmacology; Cardiology; Cholesterol","score_opus":0.0595520396669502,"score_gpt":0.2968323390963135,"score_spread":0.23728029942936332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085083234","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0045042164,0.15919542,0.00003630168,0.8266761,0.0059110164,0.00023865455,0.00035056978,0.000009852339,0.0030778858],"genre_scores_gemma":[0.01990514,0.5586215,0.00012005348,0.4064573,0.011663225,0.000013867482,0.000017725786,0.000112037014,0.0030891106],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99682003,0.00013282437,0.001983106,0.00032903347,0.000087374036,0.00064760004],"domain_scores_gemma":[0.99645174,0.00050862855,0.0025644784,0.00016236292,0.00016960138,0.00014317803],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008895923,0.00028793275,0.0012027457,0.00031598037,0.00021577673,0.0002383862,0.0011029203,0.0006789981,0.0014887975],"category_scores_gemma":[0.0000980273,0.00032314012,0.0006852059,0.00012676152,0.00048276363,0.00046247806,0.00012727175,0.003288692,0.0001467373],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003525127,0.000051584444,0.000036745496,0.00007163485,0.000540717,0.0010132041,0.00010188413,0.000031311403,0.000056363726,0.00037320022,0.98723614,0.010451958],"study_design_scores_gemma":[0.0012642199,0.00013757878,0.00003970108,0.00010268171,0.000061664054,0.0032604742,0.00003873548,0.000100807476,0.00036155188,0.005664658,0.9886723,0.00029563688],"about_ca_topic_score_codex":0.000076544864,"about_ca_topic_score_gemma":0.000020518823,"teacher_disagreement_score":0.42021877,"about_ca_system_score_codex":0.00017729659,"about_ca_system_score_gemma":0.00017413925,"threshold_uncertainty_score":0.99992204},"labels":[],"label_agreement":null},{"id":"W2085556622","doi":"10.1016/j.socscimed.2009.11.034","title":"Pharmaceutical innovation: Can we live forever? A commentary on Schnittker and Karandinos","year":2010,"lang":"en","type":"letter","venue":"Social Science & Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Medicine; Sociology; Gerontology","score_opus":0.0954362643238633,"score_gpt":0.35672899975091255,"score_spread":0.2612927354270492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085556622","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014139318,0.00039809218,0.000015174399,0.9501164,0.0017463628,0.00039367063,0.00034761446,0.000033813765,0.032809544],"genre_scores_gemma":[0.09214217,0.0004430022,0.000015983414,0.89595145,0.01086837,0.00003597094,0.000088546534,0.000032932883,0.00042157382],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99752444,0.000017975413,0.0007782726,0.0007608513,0.00016805709,0.00075040734],"domain_scores_gemma":[0.99887705,0.00015927611,0.00042890367,0.0002591402,0.000077314144,0.00019832351],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013014697,0.0003416506,0.00073553977,0.00071982964,0.0005861675,0.00009510455,0.00059819437,0.0006720911,0.0016268856],"category_scores_gemma":[0.00021580914,0.0003332459,0.00007556421,0.0008642844,0.002593272,0.00017638339,0.00013955483,0.0033036498,0.00016052704],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014974248,0.000026185891,0.0009867763,0.00004918959,0.000031189917,0.000019568059,0.001697823,6.620203e-8,0.000033155626,0.062913075,0.92977685,0.004451125],"study_design_scores_gemma":[0.00097201526,0.00009821673,0.0002688529,0.00004694601,0.000021660593,0.000006715849,0.00003906371,0.00014031652,0.000026076277,0.062658325,0.93536884,0.00035294486],"about_ca_topic_score_codex":0.00029074054,"about_ca_topic_score_gemma":0.000014410152,"teacher_disagreement_score":0.078002855,"about_ca_system_score_codex":0.0003143981,"about_ca_system_score_gemma":0.00010891119,"threshold_uncertainty_score":0.99991196},"labels":[],"label_agreement":null},{"id":"W2086522963","doi":"10.3821/145.3.cpj106","title":"Quebec Pharmacists and Physicians Call for Legislative Changes to Combat Drug Shortages in Canada","year":2012,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Legislation; Legislature; Economic shortage; Pharmacy; Notice; Mandate; Business; Political science; Medicine; Family medicine; Law; Government (linguistics)","score_opus":0.05665391661493917,"score_gpt":0.27021478609281496,"score_spread":0.21356086947787578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086522963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9776331,0.0052090883,0.000097497556,0.0029909716,0.0039482308,0.000975977,0.005809012,0.000016167724,0.0033199086],"genre_scores_gemma":[0.97259545,0.0031424253,0.00013214618,0.021255283,0.0012789218,0.00009212407,0.000041166473,0.00008360132,0.0013788656],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964386,0.00006707697,0.00089873566,0.00054458523,0.000109664485,0.0019412944],"domain_scores_gemma":[0.9959808,0.00021728146,0.0003685065,0.00022740322,0.00013615005,0.0030698334],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00085979415,0.0004909272,0.000793787,0.00056608213,0.0004945782,0.00019386409,0.00058607187,0.00005825643,0.0003656583],"category_scores_gemma":[0.00012414531,0.00062714895,0.000114837785,0.00048623967,0.00011737765,0.00056219794,0.00007448502,0.0005960038,0.000017561037],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004409307,0.00028535863,0.13204852,0.00087308465,0.0010391446,0.007597179,0.021551667,0.003492935,0.0011033963,0.011176003,0.632999,0.18739279],"study_design_scores_gemma":[0.0035298425,0.000038023107,0.0015972932,0.000037257036,0.000074394455,0.012901981,0.0000689686,0.009463207,0.0016762534,0.0004995108,0.9683621,0.0017511628],"about_ca_topic_score_codex":0.97415626,"about_ca_topic_score_gemma":0.9987848,"teacher_disagreement_score":0.33536312,"about_ca_system_score_codex":0.0076562944,"about_ca_system_score_gemma":0.0031786377,"threshold_uncertainty_score":0.999618},"labels":[],"label_agreement":null},{"id":"W2086566703","doi":"10.12927/hcpap..16912","title":"Drugs, Health and the Economy: Investment, Innovation, Outcomes, Growth","year":2002,"lang":"en","type":"review","venue":"A Nudge Too Far? A Nudge at All? On Paying People to Be Healthy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"","keywords":"Investment (military); Business; Innovation economics; Economics; Economic system; Political science","score_opus":0.1729561571059661,"score_gpt":0.3656938275191458,"score_spread":0.1927376704131797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086566703","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016552961,0.5396889,0.000022592883,0.44353086,0.0005313853,0.0021952318,0.0007625276,0.000093016984,0.013009975],"genre_scores_gemma":[0.000014451981,0.4921894,0.00008133266,0.50566864,0.000053951717,0.00057201175,0.00020482815,0.00012242678,0.001092917],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9923833,0.00032132346,0.0038976674,0.0017044308,0.00010376424,0.0015895127],"domain_scores_gemma":[0.9938466,0.0011681588,0.0025018572,0.0012795926,0.00008185531,0.0011219218],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0029610284,0.0011621579,0.004733656,0.0011612418,0.0007977868,0.00036517665,0.000979574,0.00048581112,0.00038608556],"category_scores_gemma":[0.00055848976,0.0009871346,0.00066946767,0.001425637,0.00017100257,0.00026250968,0.000584949,0.0011339436,0.0028900462],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000052109513,0.00012276063,0.00013969566,0.0017850802,0.0002666324,0.0000017418052,0.0017469518,4.4330034e-7,2.1653672e-9,0.469291,0.4921406,0.03445299],"study_design_scores_gemma":[0.0022153945,0.00027684515,0.0000430611,0.000013359044,0.00006331393,0.000024112333,0.00003346092,0.00019197827,4.300618e-8,0.008454528,0.9877495,0.00093436835],"about_ca_topic_score_codex":0.0010967796,"about_ca_topic_score_gemma":0.00015590823,"teacher_disagreement_score":0.49560896,"about_ca_system_score_codex":0.0024291598,"about_ca_system_score_gemma":0.00065636303,"threshold_uncertainty_score":0.9992579},"labels":[],"label_agreement":null},{"id":"W2086814699","doi":"10.3821/145.5.cpj202","title":"Provinces and territories agree to work together to purchase generic drugs and to expand use of bulk purchasing for brand-name drugs","year":2012,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Purchasing; Procurement; Business; Bidding; Medical prescription; Brand names; Health care; Work (physics); Marketing; Economics; Economic growth; Medicine; Engineering","score_opus":0.07661303361822375,"score_gpt":0.2787111270980182,"score_spread":0.20209809347979446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086814699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906689,0.0024972258,0.00043960675,0.0015615234,0.0015278832,0.00078559486,0.0022169556,0.000009655734,0.0002926624],"genre_scores_gemma":[0.986403,0.0009787871,0.0021128035,0.008793095,0.0011724578,0.00006106183,0.00000935758,0.00006422092,0.00040522817],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975254,0.000034158827,0.0007807643,0.0004431791,0.000081868384,0.0011346429],"domain_scores_gemma":[0.9951903,0.00015145351,0.0002514698,0.00020600925,0.00013339079,0.004067346],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00081612886,0.000340174,0.0005875703,0.0005866272,0.00045407136,0.00033621304,0.00034310136,0.000064292486,0.00013183398],"category_scores_gemma":[0.0002607889,0.00039717043,0.00009656921,0.0004284757,0.0001246047,0.00056223373,0.000103641934,0.0002383756,0.000010436375],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019517858,0.00029541142,0.09979518,0.0012934098,0.0011322304,0.000914456,0.090806805,0.0041212994,0.004547461,0.0067604636,0.07057957,0.7178019],"study_design_scores_gemma":[0.0018308043,0.00012158577,0.00041298245,0.000043765343,0.00006311087,0.0041079,0.000057418187,0.001023346,0.0022723188,0.00052017375,0.98854494,0.0010016366],"about_ca_topic_score_codex":0.0222127,"about_ca_topic_score_gemma":0.010162374,"teacher_disagreement_score":0.9179654,"about_ca_system_score_codex":0.00093253143,"about_ca_system_score_gemma":0.0004248344,"threshold_uncertainty_score":0.999848},"labels":[],"label_agreement":null},{"id":"W2086929860","doi":"10.12927/hcpol.2013.21638","title":"Canada's Access to Medicines Regime: Promise or Failure of Humanitarian Effort?","year":2010,"lang":"fr","type":"article","venue":"Healthcare policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Ontario Drug Policy Research Network","funders":"","keywords":"Intellectual property; Business; Access to medicines; Production (economics); International trade; Law and economics; Law; Political science; Economics","score_opus":0.07243743497400673,"score_gpt":0.3606102366693208,"score_spread":0.28817280169531406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086929860","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14525503,0.0026067486,0.00002024207,0.83433014,0.0040865466,0.0010609458,0.0033824777,0.000024841836,0.009233033],"genre_scores_gemma":[0.8892522,0.0012678346,0.00055359426,0.09518375,0.0046898494,0.00009603391,0.00005186014,0.00010556315,0.008799339],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99641544,0.000038380473,0.0015458466,0.00069335976,0.00009592685,0.0012110766],"domain_scores_gemma":[0.9968371,0.00016343125,0.00069724227,0.00089410914,0.00017593788,0.0012322003],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006215116,0.00040924232,0.0010807656,0.00062691054,0.00022677527,0.00012418622,0.0010131536,0.00041316595,0.0019503026],"category_scores_gemma":[0.0008300709,0.00046801192,0.0001537558,0.0008275547,0.0002314309,0.00030386372,0.0003150931,0.00088848145,0.0001789285],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013500926,0.0001464714,0.02440536,0.0015148498,0.00011281177,0.0000305488,0.0008988444,0.000018342633,0.000027165626,0.6202895,0.32884133,0.02357974],"study_design_scores_gemma":[0.0007819895,0.00020179835,0.026573064,0.00015417623,0.000017039014,0.000037091886,0.00005452825,0.00035975198,0.00016254131,0.009213224,0.96197665,0.00046813107],"about_ca_topic_score_codex":0.9287504,"about_ca_topic_score_gemma":0.9816606,"teacher_disagreement_score":0.74399716,"about_ca_system_score_codex":0.0006630814,"about_ca_system_score_gemma":0.0051536593,"threshold_uncertainty_score":0.99977714},"labels":[],"label_agreement":null},{"id":"W2087882132","doi":"10.7326/0003-4819-144-3-200602070-00026","title":"Savings from Canadian Internet Pharmacies Are Limited","year":2006,"lang":"en","type":"letter","venue":"Annals of Internal Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy; Medicine; The Internet; Drug prices; Purchasing; Advertising; Family medicine; Business; Marketing","score_opus":0.12809494610255967,"score_gpt":0.3250109907026511,"score_spread":0.19691604460009143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087882132","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022866767,0.0073632468,0.000046215744,0.88016915,0.002187465,0.0001776103,0.0041326885,0.000029027284,0.083027855],"genre_scores_gemma":[0.1726229,0.00081058993,0.000021462734,0.8143944,0.0043290867,0.000012255641,0.00051928766,0.00007381169,0.007216179],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99713403,0.000026410797,0.001509992,0.0005821075,0.00007902502,0.00066844886],"domain_scores_gemma":[0.9976515,0.00022975267,0.0012676356,0.0004259119,0.000116926836,0.0003082336],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0003679387,0.00043572622,0.0013463432,0.0009347969,0.00003259215,0.000047887883,0.00090227596,0.00050831266,0.006773938],"category_scores_gemma":[0.000236521,0.00045200853,0.0002935552,0.00015321042,0.0002855519,0.00012767734,0.000100761616,0.0014018329,0.00093594193],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015468097,0.000016737027,0.009341679,0.00008777347,0.00032215434,0.00014144764,0.00016451639,0.0000016849549,0.000005986153,0.0012413124,0.98832005,0.00034119195],"study_design_scores_gemma":[0.0005151007,0.00008986382,0.0024418293,0.0005203027,0.000027472437,0.000007802971,0.00001000736,0.0003804966,0.0002319734,0.015400619,0.9799825,0.0003920216],"about_ca_topic_score_codex":0.5554622,"about_ca_topic_score_gemma":0.01299433,"teacher_disagreement_score":0.54246783,"about_ca_system_score_codex":0.00013208856,"about_ca_system_score_gemma":0.00005654616,"threshold_uncertainty_score":0.9998419},"labels":[],"label_agreement":null},{"id":"W2088456832","doi":"10.1002/mde.1348","title":"A primer on the economics of re‐importation of prescription drugs","year":2007,"lang":"en","type":"article","venue":"Managerial and Decision Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Profitability index; Revenue; Politics; Economics; Market size; Outcome (game theory); Medical prescription; International economics; Economy; Microeconomics; Political science; Finance; Law","score_opus":0.050657124121851534,"score_gpt":0.27538065293150327,"score_spread":0.22472352880965174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088456832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9630015,0.00019611775,0.0013970548,0.00060478115,0.0006831687,0.00026518272,0.00013535487,0.000009057484,0.03370777],"genre_scores_gemma":[0.99671847,0.0012812979,0.0007717068,0.0009082264,0.0001689502,0.0000062598237,0.000010447708,0.000022248394,0.00011237012],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9981487,0.00000952927,0.0012507965,0.000344689,0.000019009076,0.00022728412],"domain_scores_gemma":[0.9982858,0.00041977022,0.0007869037,0.00038725662,0.00002370927,0.000096599455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015827223,0.00016193306,0.00045478152,0.0002623122,0.00007283686,0.000049304126,0.00024090917,0.00011692454,0.00019653412],"category_scores_gemma":[0.0001069277,0.00015345984,0.00014266768,0.000090000416,0.00013389361,0.00019556812,0.00009357774,0.00010639282,0.00006197306],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004428409,0.000081920414,0.0017251169,0.000020164935,0.00006289735,3.127533e-7,0.00033026235,0.0005718383,0.00005579905,0.96446204,0.0007704986,0.03147629],"study_design_scores_gemma":[0.0019091575,0.00028061506,0.023972947,0.000029903696,0.000023625857,0.0000022579754,0.00032013978,0.012292318,0.003529724,0.8450911,0.1121023,0.0004459324],"about_ca_topic_score_codex":0.00011377435,"about_ca_topic_score_gemma":0.000042447715,"teacher_disagreement_score":0.119370975,"about_ca_system_score_codex":0.000059042985,"about_ca_system_score_gemma":0.000016868149,"threshold_uncertainty_score":0.6257911},"labels":[],"label_agreement":null},{"id":"W2088519281","doi":"10.1163/15691497-12341254","title":"Ethical Ramifications for a Proposed FTA between India and the EU","year":2013,"lang":"en","type":"article","venue":"Perspectives on Global Development and Technology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University","funders":"","keywords":"Disadvantaged; Negotiation; Position (finance); Compensation (psychology); International trade; Development economics; Economic growth; Economics; Political science; Business; Law","score_opus":0.032097307783126354,"score_gpt":0.2847090548554232,"score_spread":0.25261174707229683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088519281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77018934,0.0021383157,0.0005794023,0.20362623,0.00009400154,0.0014059526,0.00015428218,0.00010907893,0.021703383],"genre_scores_gemma":[0.99635154,0.0002777145,0.001959133,0.001061069,0.000038516642,0.00018431486,0.000008020621,0.00000725075,0.00011244532],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9991295,0.000009198631,0.00027571394,0.00033807583,0.000015400243,0.0002321659],"domain_scores_gemma":[0.99955046,0.00010889416,0.000099877194,0.00013776339,0.00003788456,0.00006513816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002826234,0.00011787714,0.00025978865,0.00012436157,0.000209807,0.00007167098,0.00016251684,0.00022516372,0.000039933453],"category_scores_gemma":[0.00019619554,0.00009687571,0.000025715168,0.00017949453,0.00048582494,0.000046989637,0.000086982844,0.00023112482,0.00013044626],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000131830275,0.00002834519,0.007967952,0.00000594741,0.000067547444,9.177046e-8,0.00045674408,6.547761e-8,0.0000018413132,0.9832494,0.0004655767,0.0077432995],"study_design_scores_gemma":[0.0025614516,0.00007092941,0.082387336,0.0000062020554,0.000009666562,0.0000038311414,0.0008305476,0.00041512656,0.00007085049,0.7256037,0.18778026,0.00026006743],"about_ca_topic_score_codex":0.00003045716,"about_ca_topic_score_gemma":0.000004564709,"teacher_disagreement_score":0.25764567,"about_ca_system_score_codex":0.00009344494,"about_ca_system_score_gemma":0.000027217846,"threshold_uncertainty_score":0.3950477},"labels":[],"label_agreement":null},{"id":"W2088820584","doi":"10.1377/hlthaff.w4.396","title":"Doughnut Holes And Price Controls","year":2004,"lang":"en","type":"article","venue":"Health Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicare Part D; Drug prices; Prescription drug; Business; Pharmaceutical industry; Cost sharing; Drug industry; Public economics; Drug pricing; Medical prescription; Actuarial science; Economics; Medicine; Pharmacology","score_opus":0.05110420427915781,"score_gpt":0.3001486910607471,"score_spread":0.2490444867815893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088820584","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2985831,0.047208857,0.0068718493,0.30237812,0.0015497371,0.0016304869,0.00081267447,0.0002959747,0.3406692],"genre_scores_gemma":[0.9868251,0.0023897982,0.00057398726,0.00985315,0.00016711294,0.000021601629,0.0000058729147,0.000019311481,0.00014402933],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99873996,0.000008410337,0.00048632247,0.00030709177,0.000016312411,0.0004418876],"domain_scores_gemma":[0.99920154,0.000038367045,0.00021056151,0.00018357996,0.000008461947,0.00035746736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004189882,0.00012288202,0.0003621375,0.0001110495,0.00011815334,0.000057726676,0.00010912787,0.000063478954,0.00010532443],"category_scores_gemma":[0.00004705713,0.00014339304,0.00005354709,0.00009558442,0.00009249426,0.00013690093,0.000041331743,0.00014954037,0.0006097643],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013916265,0.000050569506,0.002071222,0.000058192065,0.00001626526,0.0000016460477,0.0003592335,0.00006619692,0.0000041935546,0.99448454,0.0016608147,0.0012131946],"study_design_scores_gemma":[0.0030189608,0.00015738548,0.009668786,0.000024782365,0.000002384501,0.000016004655,0.00012486345,0.0005346174,0.000035429108,0.26906615,0.7170151,0.0003355532],"about_ca_topic_score_codex":0.00026704717,"about_ca_topic_score_gemma":0.000032423995,"teacher_disagreement_score":0.7254184,"about_ca_system_score_codex":0.00016161513,"about_ca_system_score_gemma":0.00007771471,"threshold_uncertainty_score":0.783749},"labels":[],"label_agreement":null},{"id":"W2089278217","doi":"10.2165/00148365-200806010-00002","title":"Differences in Generic Drug Prices between the US and Canada","year":2008,"lang":"en","type":"article","venue":"Applied Health Economics and Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; St. Michael's Hospital; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Medical prescription; Pharmacy; Medicine; Generic drug; Drug prices; Prescription drug; Pharmacoepidemiology; Drug; Brand names; Family medicine; Business; Advertising; Pharmacology; Public economics; Economics","score_opus":0.12126561824674134,"score_gpt":0.3206131181645682,"score_spread":0.19934749991782688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089278217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8404798,0.0053280843,0.000008878227,0.14919594,0.000115839575,0.00051218265,0.00027608837,0.000012583464,0.004070631],"genre_scores_gemma":[0.8829956,0.057579715,0.00011528386,0.058703415,0.00044728653,0.000057992,0.000013989559,0.000026142898,0.000060561466],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9973348,0.000023500654,0.0012114475,0.00053507346,0.000023043664,0.00087214826],"domain_scores_gemma":[0.9983467,0.0001501982,0.0006277786,0.00027676384,0.000006273271,0.0005922953],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00092397886,0.00025098096,0.0008863073,0.0002478944,0.0007489528,0.000074254254,0.00025250006,0.00007377892,0.000018217133],"category_scores_gemma":[0.000011477665,0.00024654804,0.000034393935,0.0001590269,0.00021479282,0.00008720002,0.00013480909,0.000323396,0.000019544725],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009478878,0.000028254859,0.35844737,0.00016056783,0.00003150847,6.559486e-7,0.0019298437,0.000031691063,6.0959636e-8,0.628449,0.0049273977,0.0059841233],"study_design_scores_gemma":[0.00067584286,0.000036270787,0.67069685,0.000007007806,0.0000011213104,0.0000076170936,0.00006773422,0.00083946873,0.0000010214275,0.017593244,0.3098131,0.000260674],"about_ca_topic_score_codex":0.8642563,"about_ca_topic_score_gemma":0.57737356,"teacher_disagreement_score":0.6108558,"about_ca_system_score_codex":0.0006660962,"about_ca_system_score_gemma":0.0020628192,"threshold_uncertainty_score":0.9999987},"labels":[],"label_agreement":null},{"id":"W2089453005","doi":"10.1038/clpt.2009.179","title":"Expediting Patients’ Access to Medicines by Improving the Predictability of Drug Development and the Regulatory Approval Process","year":2009,"lang":"en","type":"article","venue":"Clinical Pharmacology & Therapeutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Expediting; Drug development; Clinical pharmacology; Regulatory science; Risk analysis (engineering); Drug approval; Business; Access to medicines; Process (computing); Medicine; Drug; Process management; Pharmacology; Computer science; Engineering","score_opus":0.08671489304942995,"score_gpt":0.38417699705932334,"score_spread":0.29746210400989337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089453005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9563873,0.0013991256,0.00016522764,0.03972129,0.0008507557,0.00078862166,0.000039833234,0.000023223762,0.0006246119],"genre_scores_gemma":[0.8789926,0.00024608482,0.00007146765,0.12021002,0.0003838307,0.000050619703,0.000005321696,0.00001410013,0.000025948375],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976326,0.00013283438,0.0013979479,0.00043346142,0.000059188846,0.00034395163],"domain_scores_gemma":[0.99796224,0.00093846844,0.00059501966,0.00026319147,0.0000806916,0.00016039179],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00276248,0.00019207675,0.000556442,0.00005260948,0.00021040939,0.000043169945,0.00070336444,0.00011413793,0.000051991374],"category_scores_gemma":[0.00013400879,0.00012998898,0.00010581129,0.00015232434,0.00072735065,0.0001354014,0.0001758235,0.00043067397,0.000009914551],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032168853,0.0032463558,0.6921648,0.000333316,0.0017100896,0.0000019140223,0.020322055,0.00019548733,0.00041403936,0.00817947,0.09721923,0.17299636],"study_design_scores_gemma":[0.020913687,0.00066732743,0.62209046,0.000045641107,0.0005327695,0.0000037441857,0.00064087304,0.017559495,0.0083449,0.028811026,0.29916903,0.0012210765],"about_ca_topic_score_codex":0.000008252768,"about_ca_topic_score_gemma":0.0000021562353,"teacher_disagreement_score":0.20194979,"about_ca_system_score_codex":0.0000479653,"about_ca_system_score_gemma":0.0000722611,"threshold_uncertainty_score":0.53007966},"labels":[],"label_agreement":null},{"id":"W2089540131","doi":"10.1071/hp070411","title":"Reshaping Australian drug policy: the dilemmas of generic medicines policy","year":2007,"lang":"en","type":"article","venue":"Australia and New Zealand Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmaceutical Benefits Scheme; Health economics; Population health; Public health; Health policy; Public policy; Public relations; Pharmaceutical policy; Pharmaceutical industry; Economics; Public administration; Political science; Health care; Medicine; Economic growth; Medical prescription","score_opus":0.17439772928819594,"score_gpt":0.40428571970651417,"score_spread":0.22988799041831823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089540131","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34258696,0.001469016,0.000042723488,0.6485991,0.00034223768,0.0005230187,0.00032051804,0.000049577608,0.0060668564],"genre_scores_gemma":[0.93992573,0.002701775,0.00016863066,0.032738637,0.0049174996,0.0000083416635,0.000022760645,0.000044570963,0.019472074],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968661,0.000040941624,0.0013781708,0.00044181917,0.00007498828,0.0011979849],"domain_scores_gemma":[0.9977157,0.00016391753,0.00069263944,0.00044335084,0.000028092458,0.00095628214],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014833364,0.0003134437,0.0007401668,0.0009059765,0.0002699478,0.00006189984,0.00039175662,0.00015337145,0.0001632436],"category_scores_gemma":[0.00018846866,0.00026903997,0.00014965601,0.0009163349,0.0003355606,0.00015594641,0.000108384294,0.00036675198,0.00011459716],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005584258,0.000052573345,0.028795531,0.00015037053,0.00008021484,0.0000030047051,0.0030410264,0.000019120953,0.000060666545,0.7674207,0.19511649,0.005204444],"study_design_scores_gemma":[0.0010978263,0.000119210235,0.10573486,0.000042282623,0.00000818172,0.000028320512,0.00007290468,0.000035542096,0.00018556071,0.07223383,0.820168,0.0002734396],"about_ca_topic_score_codex":0.22672412,"about_ca_topic_score_gemma":0.002412047,"teacher_disagreement_score":0.6951869,"about_ca_system_score_codex":0.0002635102,"about_ca_system_score_gemma":0.0006250378,"threshold_uncertainty_score":0.99997616},"labels":[],"label_agreement":null},{"id":"W2090189145","doi":"10.1517/14656560903140525","title":"The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Pharmacotherapy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Food and drug administration; Bioequivalence; Generic drug; MEDLINE; Drug; Substitution (logic); Drug approval; Antiepileptic drug; Alternative medicine; Epilepsy; Family medicine; Psychiatry; Pharmacology","score_opus":0.2535574849152221,"score_gpt":0.45538050080739784,"score_spread":0.20182301589217572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090189145","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008359441,0.992677,0.000053941374,0.0018776554,0.0009710949,0.0011127152,0.00045422965,0.000013603243,0.0028314167],"genre_scores_gemma":[0.00005518436,0.99733245,0.00008682827,0.00192273,0.00030140838,0.00017447826,0.000052275394,0.00004594436,0.000028701668],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99632394,0.00013118015,0.0026873616,0.0004966805,0.000058114325,0.00030272544],"domain_scores_gemma":[0.9955675,0.00047410614,0.0029449093,0.0008226661,0.00007501689,0.00011581486],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010991759,0.0003857666,0.002090633,0.000281274,0.00008624232,0.000019800085,0.0008816244,0.00015258935,0.0007732454],"category_scores_gemma":[0.000079389974,0.00032477724,0.00079393585,0.00036566128,0.00020087259,0.00014066689,0.00004290134,0.00024381897,0.00011546058],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027910866,0.0001253196,0.0000035843138,0.006725058,0.000231974,6.131808e-8,0.00006021839,0.000009947917,0.0000143690295,0.072260186,0.011018476,0.9095229],"study_design_scores_gemma":[0.00028300626,0.00010865496,0.0000064363344,0.013175982,0.000020933814,0.0000025965626,0.00000167988,0.00007488462,0.00015300399,0.0010539544,0.98484176,0.00027713063],"about_ca_topic_score_codex":0.000036983412,"about_ca_topic_score_gemma":4.802883e-7,"teacher_disagreement_score":0.97382325,"about_ca_system_score_codex":0.0003881249,"about_ca_system_score_gemma":0.00034693797,"threshold_uncertainty_score":0.9999204},"labels":[],"label_agreement":null},{"id":"W2090343559","doi":"10.3917/riges.274.0017","title":"L'évolution du commerce électronique et la performance de la chaîne d'approvisionnement du secteur de la santé : changement de paradigme","year":2002,"lang":"fr","type":"article","venue":"Gestion","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"HEC Montréal; Bell (Canada)","funders":"","keywords":"Political science; Humanities; Art","score_opus":0.02758046922631156,"score_gpt":0.28057207084959995,"score_spread":0.2529916016232884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090343559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8870209,0.0076227696,0.012437722,0.040666353,0.0004980712,0.00040825346,0.00015096771,0.00007339832,0.051121555],"genre_scores_gemma":[0.9139766,0.07942814,0.0009871473,0.003363321,0.0006565435,0.00010448645,0.00003241099,0.000042902808,0.0014084594],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99770796,0.0005877187,0.0005075642,0.000399194,0.000044731893,0.00075280457],"domain_scores_gemma":[0.99870497,0.00050327345,0.0002835079,0.00025929295,0.000021071846,0.00022787834],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003868316,0.0002682916,0.00032997012,0.00019187416,0.00022877892,0.00019280151,0.00022633497,0.00040372112,0.0009271263],"category_scores_gemma":[0.00020628877,0.0003664817,0.00012797349,0.00017316449,0.00020923592,0.00028798045,0.000098501885,0.0006396971,0.00030660033],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000100434336,0.0014718346,0.16085371,0.00038230157,0.00016261847,0.00002304932,0.005657962,0.011181613,0.00021158996,0.6023695,0.02209616,0.19548923],"study_design_scores_gemma":[0.0007815759,0.00013648807,0.18914719,0.00007049056,0.000024097033,0.00009230782,0.00001811648,0.33386248,0.00012009373,0.0052500563,0.47022596,0.00027112273],"about_ca_topic_score_codex":0.0004889567,"about_ca_topic_score_gemma":0.000052441934,"teacher_disagreement_score":0.59711945,"about_ca_system_score_codex":0.0014966885,"about_ca_system_score_gemma":0.00006852872,"threshold_uncertainty_score":0.9999862},"labels":[],"label_agreement":null},{"id":"W2090997748","doi":"10.1017/s1744133108004477","title":"Addressing legal and political barriers to global pharmaceutical access: Options for remedying the impact of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and the imposition of TRIPS-plus standards","year":2008,"lang":"en","type":"article","venue":"Health Economics Policy and Law","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Institutes of Health Research; University of Toronto","funders":"","keywords":"TRIPS architecture; Intellectual property; TRIPS Agreement; Legitimacy; Politics; International trade; Business; Developing country; Human rights; Political science; Public economics; Economics; Economic growth; Law; Engineering","score_opus":0.13388102143293948,"score_gpt":0.40779007139012363,"score_spread":0.2739090499571841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090997748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93337893,0.0015716499,0.000109125984,0.04520348,0.00015013559,0.001666906,0.00293744,0.00000808801,0.014974229],"genre_scores_gemma":[0.99445975,0.0011518353,0.000034933815,0.004173345,0.00012011242,0.000030008727,0.000004703665,0.000012625717,0.000012695794],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9981037,0.000099898905,0.0010019644,0.00029918214,0.000041547737,0.00045370968],"domain_scores_gemma":[0.9984238,0.00046436623,0.0004248667,0.00024323363,0.000034470824,0.00040922724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011792158,0.00019333453,0.00062876556,0.0001078665,0.00057706714,0.00006348551,0.00023694828,0.00009564085,0.000030441162],"category_scores_gemma":[0.00029406138,0.00011144347,0.00018047137,0.00016608297,0.0010701268,0.0001600833,0.00012826911,0.00021145011,6.2367985e-7],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067999045,0.000043835465,0.00021683006,0.00008162831,0.00012776538,1.5126771e-7,0.0012996244,0.0003695205,0.000004771891,0.9962025,0.00037700683,0.0005963448],"study_design_scores_gemma":[0.028335957,0.003166188,0.021633985,0.00045248136,0.00020048869,0.0003890132,0.00063544896,0.15462258,0.0029239242,0.6765941,0.10979882,0.0012470244],"about_ca_topic_score_codex":0.005833854,"about_ca_topic_score_gemma":0.00022617303,"teacher_disagreement_score":0.31960845,"about_ca_system_score_codex":0.00053894427,"about_ca_system_score_gemma":0.00068354583,"threshold_uncertainty_score":0.8819081},"labels":[],"label_agreement":null},{"id":"W2091189859","doi":"10.1007/s10198-014-0626-0","title":"Using price–volume agreements to manage pharmaceutical leakage and off-label promotion","year":2014,"lang":"en","type":"article","venue":"The European Journal of Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Lakehead University","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Profit (economics); Leakage (economics); Volume (thermodynamics); Decision maker; Business; Promotion (chess); Marketing; Operations research; Microeconomics; Economics; Mathematics","score_opus":0.2031576688548169,"score_gpt":0.35376807473931415,"score_spread":0.15061040588449726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091189859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93057364,0.0019068377,0.018585285,0.024788113,0.0009929836,0.00040432307,0.00005041825,0.000015410687,0.022682993],"genre_scores_gemma":[0.9843242,0.0021514012,0.0024236857,0.010138162,0.00069278147,0.0000012875211,0.0000018748881,0.00006106357,0.00020550274],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99734104,0.0003310077,0.00154778,0.0002757357,0.00002892536,0.00047549792],"domain_scores_gemma":[0.99802184,0.00007018022,0.0011603478,0.00028014017,0.000030874984,0.0004366376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0077077625,0.00019308779,0.000554767,0.0002434484,0.00024255637,0.00014084695,0.0004601621,0.000028617436,0.00009457538],"category_scores_gemma":[0.00011030806,0.0001842634,0.00009645355,0.00010188814,0.00008314356,0.0002690877,0.00018785843,0.00034769124,0.00043699655],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037143784,0.0009750192,0.015492904,0.00056044845,0.00069314486,0.000030064466,0.0056216833,0.007983133,0.00017686043,0.24645525,0.009152872,0.71248716],"study_design_scores_gemma":[0.0027508629,0.0006942327,0.018484127,0.00006889632,0.000026801423,0.00014737264,0.00006025675,0.107091285,0.000026275053,0.010647887,0.85955936,0.00044263486],"about_ca_topic_score_codex":0.000015970601,"about_ca_topic_score_gemma":0.0000029391183,"teacher_disagreement_score":0.85040647,"about_ca_system_score_codex":0.00023257,"about_ca_system_score_gemma":0.000038158363,"threshold_uncertainty_score":0.7514043},"labels":[],"label_agreement":null},{"id":"W2091361563","doi":"10.3821/1913-701x(2008)141[15a:gpdmlp]2.0.co;2","title":"Government policies don't mean lower prescription drug costs","year":2008,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Government (linguistics); Medical prescription; Drug; Prescription drug; Business; Medicine; Pharmacology; Philosophy","score_opus":0.052727717648247845,"score_gpt":0.2477164549479737,"score_spread":0.19498873729972585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091361563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9519992,0.0025228027,0.000096408425,0.0010144018,0.004782279,0.00037103903,0.0027740553,0.00003555317,0.036404286],"genre_scores_gemma":[0.9722167,0.01218711,0.000070536684,0.010987365,0.0012122284,0.000020358264,0.000020934966,0.00007754505,0.0032072014],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967407,0.00006358314,0.0010932797,0.00054483,0.00018844775,0.0013691658],"domain_scores_gemma":[0.99615586,0.00006791647,0.00050572923,0.00034647615,0.000142023,0.0027819942],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000691083,0.00044313105,0.0005866222,0.00033117065,0.0011222818,0.00024127535,0.0008010745,0.00008045843,0.0029592041],"category_scores_gemma":[0.00012283333,0.00055069587,0.00026273736,0.000413644,0.00027409513,0.0006409821,0.00007722333,0.0007336166,0.0002121323],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037882302,0.00041584263,0.04800796,0.00028853805,0.0011038411,0.048352607,0.008001318,0.0033915977,0.0012508859,0.022894684,0.83682454,0.029089352],"study_design_scores_gemma":[0.0023653787,0.000043004635,0.00037509625,0.000014793577,0.000043546203,0.11367917,0.000014366181,0.005302799,0.0011324779,0.001317293,0.8746122,0.0010998844],"about_ca_topic_score_codex":0.095244616,"about_ca_topic_score_gemma":0.13088551,"teacher_disagreement_score":0.065326564,"about_ca_system_score_codex":0.007503517,"about_ca_system_score_gemma":0.0012178576,"threshold_uncertainty_score":0.99969447},"labels":[],"label_agreement":null},{"id":"W2092680813","doi":"10.1080/15265161.2011.634952","title":"Are We Asking the Right Ethics Questions on Drug Shortages? Suggestions for a Global and Anticipatory Ethics Framework","year":2012,"lang":"en","type":"letter","venue":"The American Journal of Bioethics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Salary; Sociology; Economic shortage; Corporate governance; Research ethics; Ethics committee; Political science; Engineering ethics; Law; Management; Public administration; Philosophy; Government (linguistics); Engineering","score_opus":0.2229923078224549,"score_gpt":0.41785784958102357,"score_spread":0.19486554175856866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092680813","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0030927337,0.0061622197,0.004688487,0.9822206,0.0016591548,0.00031607415,0.0013687771,0.000018993289,0.00047294554],"genre_scores_gemma":[0.1656548,0.016542153,0.0013096007,0.8109827,0.0052561774,0.00002685844,0.0000120978175,0.000086297165,0.00012931658],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968724,0.00059877074,0.0012632821,0.00036511017,0.00020369707,0.0006967421],"domain_scores_gemma":[0.9835089,0.010990928,0.0043153553,0.0006870238,0.00027647184,0.00022133197],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0076883147,0.00044190406,0.0011190963,0.00021874065,0.000974938,0.0002787565,0.0010736748,0.0010431915,0.000037869457],"category_scores_gemma":[0.0035639796,0.00031328262,0.00050085376,0.00036316318,0.0030948585,0.00013383718,0.00015221183,0.017285379,0.000036542227],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012336938,0.000111232584,0.0017484706,0.00024654335,0.0007530527,0.00003092529,0.0054955333,0.00021120642,5.0603154e-7,0.7471481,0.24281688,0.0013141937],"study_design_scores_gemma":[0.00016589792,0.00015158227,0.0015075266,0.0004140798,0.00020169637,0.00008238879,0.00035285874,0.00023249813,0.0000024380754,0.21116611,0.78534,0.0003828929],"about_ca_topic_score_codex":0.0001692015,"about_ca_topic_score_gemma":0.00007430816,"teacher_disagreement_score":0.54252315,"about_ca_system_score_codex":0.00027959238,"about_ca_system_score_gemma":0.00036897062,"threshold_uncertainty_score":0.99993193},"labels":[],"label_agreement":null},{"id":"W2093516009","doi":"10.1038/430141b","title":"Saving vital time in the war on drug resistance","year":2004,"lang":"en","type":"letter","venue":"Nature","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Drug; Drug resistance; Pharmacology; Business; Medicine; Biology; Microbiology","score_opus":0.01875605575970608,"score_gpt":0.25510164080641295,"score_spread":0.23634558504670689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093516009","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016735174,0.0063891816,0.0000011723102,0.8432062,0.0006557131,0.0002611225,0.00067240646,0.000023693105,0.14711694],"genre_scores_gemma":[0.027069636,0.0003323781,0.0000515362,0.95759934,0.002935898,0.000026472939,0.00017288708,0.000060387203,0.011751488],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99834377,0.000031217096,0.0005004798,0.000569553,0.00006204294,0.0004929534],"domain_scores_gemma":[0.9988913,0.00021697143,0.00027552622,0.0005638178,0.000011363107,0.000041038616],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0005169308,0.0003066941,0.0005042554,0.00028031523,0.0000842689,0.00009664493,0.0008375996,0.0024169895,0.0004040363],"category_scores_gemma":[0.000106905776,0.000279924,0.00021570262,0.0002236444,0.000056962614,0.000096012445,0.0000542586,0.011136666,0.0028884285],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009914612,0.000024756562,0.000036411086,0.000048798523,0.000021181404,0.000092256574,0.00021464138,0.0000130639355,7.823703e-7,0.025070468,0.9744217,0.000046070745],"study_design_scores_gemma":[0.00032770843,0.000008026801,0.0002705526,0.0000643435,0.000004176032,0.0000033356798,0.0000031335123,0.00002471839,0.000006397692,0.057960942,0.9410071,0.00031955843],"about_ca_topic_score_codex":0.000033090615,"about_ca_topic_score_gemma":0.000044235116,"teacher_disagreement_score":0.13536546,"about_ca_system_score_codex":0.00036974036,"about_ca_system_score_gemma":0.000044818094,"threshold_uncertainty_score":0.9999653},"labels":[],"label_agreement":null},{"id":"W2093520537","doi":"10.1377/hlthaff.20.5.301","title":"Drug Cost Containment In Canada","year":2001,"lang":"en","type":"letter","venue":"Health Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Fraser Institute","funders":"","keywords":"Liberian dollar; Statement (logic); Health care; Medicine; Business; Political science; Law; Finance","score_opus":0.050987000387542926,"score_gpt":0.2757853900753864,"score_spread":0.22479838968784346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093520537","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00036094274,0.0042356984,0.000013275397,0.9225404,0.0014812308,0.00073385553,0.0014026128,0.000018239884,0.06921375],"genre_scores_gemma":[0.042041466,0.0036897394,0.00003240783,0.949487,0.0015535826,0.00013709549,0.00030599188,0.00007531593,0.002677421],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99664307,0.00004397321,0.0013702061,0.000656311,0.000058274058,0.001228166],"domain_scores_gemma":[0.9984224,0.00012571803,0.000649037,0.00046312553,0.000010854558,0.00032886083],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00052768923,0.00034628808,0.0010652543,0.0002957035,0.00007425095,0.000047008267,0.00040272417,0.00023835174,0.0014508489],"category_scores_gemma":[0.00002985939,0.0004528639,0.00011127094,0.00019063157,0.00003553931,0.00007000344,0.000074805335,0.0016370303,0.000734782],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000005204488,0.00001524143,0.004177842,0.00015386376,0.000019019004,0.000117712596,0.000085924556,0.00003528968,5.6120477e-9,0.004057072,0.9906598,0.0006730345],"study_design_scores_gemma":[0.0005995163,0.000014788227,0.00061595265,0.00004108081,0.0000014963309,0.000007353942,0.00007783436,0.00061194354,4.5962562e-7,0.0029133093,0.9947078,0.00040843416],"about_ca_topic_score_codex":0.94433045,"about_ca_topic_score_gemma":0.9267695,"teacher_disagreement_score":0.06653632,"about_ca_system_score_codex":0.0072265007,"about_ca_system_score_gemma":0.0022349274,"threshold_uncertainty_score":0.99979234},"labels":[],"label_agreement":null},{"id":"W2094376331","doi":"10.1503/cmaj.070779","title":"US Senate passes FDA Revitalization Act","year":2007,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Legislation; Elixir (programming language); Food and drug administration; Medical prescription; Administration (probate law); Political science; Medicine; Public administration; Law; Pharmacology; Computer science","score_opus":0.024163765709815016,"score_gpt":0.26878868739818307,"score_spread":0.24462492168836805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094376331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.572755,0.0026105922,0.0028663706,0.12579466,0.0052569346,0.00025068296,0.0002482648,0.00005617016,0.29016137],"genre_scores_gemma":[0.95010066,0.0007394307,0.00007587766,0.046544567,0.0019399312,0.0000015635492,0.000011092081,0.000019906633,0.0005669536],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983416,0.000026462956,0.00075789844,0.00016495728,0.00013187154,0.0005771708],"domain_scores_gemma":[0.9977666,0.000098494056,0.00040986948,0.00009093048,0.000096023774,0.0015380833],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0036222253,0.000105454856,0.00024741294,0.0002997422,0.00021194086,0.00015802344,0.00021554115,0.00030020418,0.0051238686],"category_scores_gemma":[0.0015836365,0.00012220135,0.00011206547,0.00023087562,0.000023877776,0.00022570559,0.000014093687,0.00054525584,0.0013239989],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009882651,0.00005422291,0.6001609,0.00001877974,0.00021481585,0.0002156516,0.00027674815,0.000022497363,0.000009958903,0.13112453,0.24543685,0.022455212],"study_design_scores_gemma":[0.00041055237,0.0000121323565,0.04279062,0.000013893261,0.000004012499,0.00006307043,0.00001979178,0.00060208375,0.000021997024,0.0061274054,0.9497785,0.00015594061],"about_ca_topic_score_codex":0.0016251766,"about_ca_topic_score_gemma":0.012460558,"teacher_disagreement_score":0.70434165,"about_ca_system_score_codex":0.0012542113,"about_ca_system_score_gemma":0.00049357704,"threshold_uncertainty_score":0.9994536},"labels":[],"label_agreement":null},{"id":"W2094681946","doi":"10.1310/3ere-blaq-69dk-r6vb","title":"The Two Towers: Quest for Drugs from Discovery to Approval","year":2004,"lang":"en","type":"article","venue":"Topics in Spinal Cord Injury Rehabilitation","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute","funders":"","keywords":"Viewpoints; Process (computing); Medicine; Pharmaceutical industry; Marketing; Engineering ethics; Public relations; Business; Computer science; Pharmacology; Engineering; Political science","score_opus":0.046141533259630906,"score_gpt":0.35824610851286365,"score_spread":0.31210457525323276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094681946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96433514,0.00039755052,0.004658255,0.02442387,0.0009982797,0.0007443041,0.000262778,0.00002060523,0.0041592238],"genre_scores_gemma":[0.990017,0.00005620597,0.0072594974,0.0017057483,0.0004789624,0.00021386417,0.00001824297,0.000017849292,0.0002326288],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9987159,0.000015168552,0.0005970564,0.00036493083,0.000030325356,0.0002766456],"domain_scores_gemma":[0.99924237,0.00021443826,0.00013405815,0.0003025981,0.000029839346,0.00007670185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006351507,0.00012553755,0.00022934451,0.00011269113,0.00011626741,0.00014436268,0.0002525746,0.000059088736,0.0000144368505],"category_scores_gemma":[0.00047623037,0.00012587677,0.00010833805,0.00016503605,0.00007889345,0.0003005224,0.000057112444,0.00014365611,0.000105721185],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010171103,0.00007207565,0.0021736277,0.000022024245,0.0000103257835,1.7569404e-7,0.0004217945,0.00013635785,0.000035578956,0.946019,0.0002722719,0.04981965],"study_design_scores_gemma":[0.000829671,0.0015081273,0.012986279,0.0000226796,0.0000033393005,1.620478e-7,0.00017027995,0.00027731713,0.00011509304,0.7579245,0.22595334,0.0002092342],"about_ca_topic_score_codex":0.0007527277,"about_ca_topic_score_gemma":0.00020514008,"teacher_disagreement_score":0.22568107,"about_ca_system_score_codex":0.00038945215,"about_ca_system_score_gemma":0.000042059542,"threshold_uncertainty_score":0.51331055},"labels":[],"label_agreement":null},{"id":"W2096039402","doi":"10.12927/hcpol.2015.24046","title":"The Drivers of Overspending on Prescription Drugs in Quebec","year":2014,"lang":"en","type":"article","venue":"Healthcare policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Per capita; Context (archaeology); Health spending; Rest (music); Demographic economics; Public economics; Business; Economics; Geography; Medicine; Health services; Environmental health; Pharmacology; Internal medicine","score_opus":0.05142054456718465,"score_gpt":0.3235295969694712,"score_spread":0.27210905240228656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096039402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77096164,0.0006830946,0.000053606967,0.09782448,0.00067889324,0.00040632486,0.0001371551,0.00003320815,0.1292216],"genre_scores_gemma":[0.994852,0.0006418783,0.000021160185,0.003483944,0.0002627357,0.000012267104,0.0000037493044,0.00001471816,0.0007075205],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988342,0.00004423889,0.000510813,0.00022087166,0.000028169592,0.00036169036],"domain_scores_gemma":[0.99917114,0.00016730912,0.00024152703,0.0002880948,0.000013542066,0.000118390046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061302347,0.00010161757,0.000244406,0.00028503538,0.00010132175,0.00003651075,0.0002038812,0.00007666612,0.000032196942],"category_scores_gemma":[0.00021362606,0.00010023879,0.00007604861,0.00020446288,0.00007054401,0.00010079186,0.00004248259,0.00018813,0.00021391922],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020085952,0.00001994531,0.009128363,0.000028971399,0.000005830628,1.2117539e-7,0.00091041287,0.00004624488,0.0000045745714,0.97969306,0.0006708451,0.0094715655],"study_design_scores_gemma":[0.0012238208,0.00015467845,0.09891208,0.000058923237,0.0000019530146,0.000001035559,0.0002819661,0.007946968,0.00019198116,0.23829491,0.6526284,0.0003032539],"about_ca_topic_score_codex":0.1060442,"about_ca_topic_score_gemma":0.009232926,"teacher_disagreement_score":0.74139816,"about_ca_system_score_codex":0.00041921443,"about_ca_system_score_gemma":0.000066425644,"threshold_uncertainty_score":0.8999087},"labels":[],"label_agreement":null},{"id":"W2096719808","doi":"10.1016/j.hcmf.2012.11.003","title":"From Framework to the Frontline: Designing a Structure and Process for Drug Supply Shortage Planning","year":2013,"lang":"en","type":"article","venue":"Healthcare Management Forum","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Economic shortage; Process (computing); Business; Process management; Drug; Operations management; Knowledge management; Medicine; Computer science; Pharmacology; Engineering","score_opus":0.045671777907375165,"score_gpt":0.3230099725547227,"score_spread":0.27733819464734755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096719808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6802889,0.0059250616,0.04694193,0.25611317,0.0012308074,0.005081826,0.0017018052,0.00011475383,0.0026017055],"genre_scores_gemma":[0.96791494,0.00010476005,0.005833885,0.025076639,0.00033254543,0.000416108,0.00005134732,0.000037318903,0.00023243076],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9984697,0.000012669343,0.00045658037,0.0004731381,0.00003282204,0.00055505504],"domain_scores_gemma":[0.99919766,0.00011402277,0.0001489849,0.00030403954,0.000022429227,0.00021285738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023382882,0.00018484428,0.00029800658,0.00012518707,0.00027983676,0.00020411111,0.00031000952,0.000081669314,0.00022360467],"category_scores_gemma":[0.00003652883,0.00017025927,0.00005680609,0.00012377604,0.000023894807,0.00016394515,0.00014267585,0.0002088461,0.00010644059],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009924697,0.0000548453,0.24290526,0.0007221757,0.00033890925,0.0000050206713,0.00885353,0.0013191778,0.0000043721375,0.5773936,0.13085037,0.03745347],"study_design_scores_gemma":[0.000567197,0.000070473696,0.033968963,0.00011321842,0.000016969096,8.095783e-7,0.0027234654,0.015806796,0.00005052534,0.66579485,0.2804332,0.00045354405],"about_ca_topic_score_codex":0.00089763344,"about_ca_topic_score_gemma":0.00011821505,"teacher_disagreement_score":0.28762603,"about_ca_system_score_codex":0.000062713065,"about_ca_system_score_gemma":0.0000093353565,"threshold_uncertainty_score":0.69429713},"labels":[],"label_agreement":null},{"id":"W2096918198","doi":"10.1212/01.wnl.0000349653.30398.e8","title":"CLINICAL CONSEQUENCES OF GENERIC SUBSTITUTION OF LAMOTRIGINE FOR PATIENTS WITH EPILEPSY","year":2009,"lang":"en","type":"letter","venue":"Neurology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lamotrigine; Epilepsy; Substitution (logic); Medicine; Clinical neurology; Psychiatry; Psychology; Neuroscience; Computer science","score_opus":0.07985443588549204,"score_gpt":0.3069363065674907,"score_spread":0.22708187068199867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096918198","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7559682,0.000809714,0.00046718866,0.23434572,0.0015618397,0.00091841246,0.0023089994,0.000022249325,0.0035976528],"genre_scores_gemma":[0.47085065,0.00068146305,0.000540278,0.5262509,0.0011893006,0.00003188365,0.0003430437,0.000040257873,0.00007225576],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99804777,0.000039092778,0.0011532482,0.00043970862,0.00002522709,0.00029498333],"domain_scores_gemma":[0.9981253,0.000300528,0.0011541538,0.00029565816,0.00007732031,0.00004705174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025809227,0.00018932432,0.00096640235,0.00021973599,0.000022621583,0.000006869034,0.00028660562,0.0005782798,0.000080559366],"category_scores_gemma":[0.00011126228,0.00019047798,0.0002066673,0.00009538696,0.00047011892,0.000050415474,0.000024428444,0.00054336764,0.00002615088],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014012419,0.0006143333,0.56138015,0.00056150364,0.00041786756,0.000026386155,0.000027540947,0.00018360346,0.000009298685,0.08730576,0.34543562,0.0026367067],"study_design_scores_gemma":[0.0014859191,0.002301119,0.033322707,0.0000075624516,0.00003242789,0.000003008618,4.1212683e-8,0.00023323233,0.000020498008,0.014033246,0.9483601,0.00020018166],"about_ca_topic_score_codex":0.000052213,"about_ca_topic_score_gemma":0.000004571221,"teacher_disagreement_score":0.6029244,"about_ca_system_score_codex":0.000013689818,"about_ca_system_score_gemma":0.00006323382,"threshold_uncertainty_score":0.77674663},"labels":[],"label_agreement":null},{"id":"W2097263300","doi":"","title":"Are drug too expensive in Canada? No.","year":2006,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University","funders":"","keywords":"Data science; Computer science; Medicine; World Wide Web","score_opus":0.04188622934438089,"score_gpt":0.2062551664396284,"score_spread":0.16436893709524752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097263300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78974974,0.00093202706,0.000003754645,0.0046458053,0.00070159964,0.0003170724,0.00020609924,0.0000132436335,0.20343067],"genre_scores_gemma":[0.990637,0.00004526832,0.00002018016,0.005812129,0.00023802413,0.00029562705,0.0000069433545,0.000015434887,0.0029294025],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988174,0.0000070198735,0.0004328433,0.00025707527,0.000017822626,0.00046787984],"domain_scores_gemma":[0.999433,0.00004275494,0.0002220522,0.00017180931,0.000015290258,0.00011511796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018821369,0.00010673372,0.00027764682,0.000107126245,0.000028992126,0.000035257723,0.00016187518,0.000032824802,0.00013711826],"category_scores_gemma":[0.00008198802,0.00013461726,0.000046192163,0.000108649416,0.000019494259,0.00010250588,0.000041910327,0.00011866862,0.00034605726],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020679287,0.0000727361,0.6753141,0.000022043152,0.000021706,0.000041072653,0.000039759147,0.00034784427,9.662983e-7,0.06722014,0.25304797,0.0038509683],"study_design_scores_gemma":[0.0003202651,5.7906686e-7,0.6223413,0.00000101235,6.7500395e-7,7.156023e-7,0.000013004231,0.00032930603,0.000044986078,0.00872322,0.36808127,0.00014366173],"about_ca_topic_score_codex":0.77984464,"about_ca_topic_score_gemma":0.7970177,"teacher_disagreement_score":0.20088726,"about_ca_system_score_codex":0.0006509223,"about_ca_system_score_gemma":0.00005598726,"threshold_uncertainty_score":0.54895324},"labels":[],"label_agreement":null},{"id":"W2098786187","doi":"10.1016/j.healthpol.2008.01.003","title":"Balancing health and industrial policy objectives in the pharmaceutical sector: Lessons from Australia","year":2008,"lang":"en","type":"article","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Services and Policy Research; University of British Columbia; Vancouver Coastal Health; University of Toronto; Providence Health Care","funders":"","keywords":"Pharmaceutical policy; Pharmaceutical industry; Reimbursement; Health policy; Incentive; Government (linguistics); Business; Industrial policy; Audit; Public economics; Economics; Accounting; Health care; Economic growth; Medicine; Market economy; International trade","score_opus":0.3553180744422676,"score_gpt":0.4494373061556191,"score_spread":0.09411923171335151,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098786187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5875388,0.004158932,0.0000493187,0.39860725,0.00040757083,0.00076893053,0.0012201004,0.00005356057,0.0071955933],"genre_scores_gemma":[0.9229513,0.005127929,0.00008476553,0.06920229,0.0023971782,0.000036967267,0.00002967347,0.000029321844,0.00014061383],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971108,0.00020626542,0.0010157428,0.00053787517,0.000060153197,0.0010691918],"domain_scores_gemma":[0.99830544,0.00028180314,0.00037638473,0.00034140647,0.00000978854,0.00068515755],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010836769,0.00026100746,0.00069669256,0.0005672426,0.00040152203,0.00006950959,0.0003232491,0.00016330866,0.00013071315],"category_scores_gemma":[0.00033989412,0.00025767687,0.000096652904,0.0005317944,0.00021220856,0.00018525208,0.0000960032,0.0007716195,0.00021358609],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000097994154,0.0003119609,0.11147371,0.000101309255,0.00007079554,0.000013350362,0.028863788,0.00003465792,0.000006854933,0.8245764,0.025313197,0.009135983],"study_design_scores_gemma":[0.0038343945,0.00026154245,0.17594068,0.00005475981,0.0000029127389,0.00007717758,0.00045066976,0.0012536923,0.000016173606,0.054641977,0.76292324,0.00054280774],"about_ca_topic_score_codex":0.09920488,"about_ca_topic_score_gemma":0.0012517759,"teacher_disagreement_score":0.7699344,"about_ca_system_score_codex":0.0007647701,"about_ca_system_score_gemma":0.0011812465,"threshold_uncertainty_score":0.99998754},"labels":[],"label_agreement":null},{"id":"W2099171964","doi":"10.1002/pds.1283","title":"Epidemiology in the pharmaceutical Industry: a Canadian perspective","year":2006,"lang":"en","type":"article","venue":"Pharmacoepidemiology and Drug Safety","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"GlaxoSmithKline (Canada); Memorial University of Newfoundland; University of Toronto; University of Waterloo","funders":"","keywords":"Library science; Pharmacy; Medicine; Management; Family medicine","score_opus":0.09028622778025515,"score_gpt":0.3635956619330042,"score_spread":0.27330943415274905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099171964","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16606061,0.030073041,0.00049814495,0.5026506,0.00097230996,0.000892028,0.00073133595,0.00006682391,0.2980551],"genre_scores_gemma":[0.9318543,0.0012144446,0.00016020499,0.065996215,0.00049141346,0.00005524778,0.00002617429,0.000017137627,0.00018486349],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99638945,0.0008328796,0.0011291424,0.0006388615,0.000016810804,0.0009928544],"domain_scores_gemma":[0.9961254,0.0030527676,0.00023475899,0.0002416724,0.000020584106,0.00032480276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008887097,0.0002615405,0.00076082617,0.00031412183,0.000251037,0.00001152033,0.00038810473,0.00034590714,0.00067809265],"category_scores_gemma":[0.0011978161,0.00023331311,0.00012872243,0.0002743045,0.00042975083,0.00014680499,0.00006916738,0.00145567,0.00030780802],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036206104,0.000041610616,0.29089898,0.0000051601587,0.00002330764,0.000011027642,0.00024483644,0.00015156248,0.000001592379,0.69399416,0.014376828,0.00021474507],"study_design_scores_gemma":[0.0009965269,0.000013221127,0.16170603,0.0000042237893,0.0000128408055,0.000047047884,0.00016717047,0.007876488,0.0000057043308,0.42459363,0.4043015,0.000275623],"about_ca_topic_score_codex":0.18428268,"about_ca_topic_score_gemma":0.026724128,"teacher_disagreement_score":0.7657937,"about_ca_system_score_codex":0.00030461006,"about_ca_system_score_gemma":0.00008416294,"threshold_uncertainty_score":0.99103564},"labels":[],"label_agreement":null},{"id":"W2099473096","doi":"10.1002/agr.20156","title":"Firm, market, and regulatory factors influencing innovation and commercialization in Canada's functional food and nutraceutical sector","year":2008,"lang":"en","type":"article","venue":"Agribusiness","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Guelph","funders":"","keywords":"Commercialization; EconLit; Business; New product development; Product (mathematics); Harmonization; Marketing; Scale (ratio); Nutraceutical; Industrial organization; Economics","score_opus":0.06595811088790704,"score_gpt":0.22734285664943646,"score_spread":0.16138474576152942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099473096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99711907,0.0006423218,0.00008375394,0.00085629174,0.00015078975,0.00010220468,0.00008112079,0.000007457046,0.00095701526],"genre_scores_gemma":[0.9987098,0.00022788311,0.00001950467,0.0009010328,0.00006154861,0.0000054343914,0.00002460552,0.000010438451,0.00003975203],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991988,0.000010210381,0.00036461372,0.00022917833,0.000025050042,0.0001721657],"domain_scores_gemma":[0.99964184,0.000074345284,0.0001077637,0.00007510769,0.000031902633,0.00006902691],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015831472,0.00011185656,0.00021766499,0.00017105801,0.00010664605,0.000027677965,0.000034251356,0.00007022241,0.00006598165],"category_scores_gemma":[0.00007558827,0.00012764167,0.000008300819,0.00027784053,0.00007353715,0.00021402312,0.00004565115,0.00010655218,0.0000010174429],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015898773,0.000014194542,0.92884886,0.000037146085,0.000012659597,0.0000013648566,0.000119196404,0.00003167039,0.000028546521,0.069973655,0.00060854893,0.00030823395],"study_design_scores_gemma":[0.0004649671,0.000010059418,0.9839617,0.000008949764,0.0000022223626,0.000012100851,0.000025807,0.003203097,0.000034918645,0.0033058876,0.008815334,0.00015496934],"about_ca_topic_score_codex":0.06106548,"about_ca_topic_score_gemma":0.080662124,"teacher_disagreement_score":0.066667765,"about_ca_system_score_codex":0.0001769995,"about_ca_system_score_gemma":0.00011187584,"threshold_uncertainty_score":0.945187},"labels":[],"label_agreement":null},{"id":"W2099541887","doi":"10.1108/14468951111123346","title":"Encouraging pharmaceutical innovation to meet the needs of both developed and developing countries","year":2011,"lang":"en","type":"article","venue":"International Journal of Development Issues","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Developing country; Government (linguistics); Variety (cybernetics); Business; Pharmaceutical industry; Originality; Product (mathematics); Value (mathematics); Limiting; Donation; Public economics; Marketing; Economics; Medicine; Economic growth; Engineering; Political science","score_opus":0.13290009156767474,"score_gpt":0.35000216518785787,"score_spread":0.21710207362018313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099541887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96398973,0.00111859,0.008259535,0.016808903,0.0009963812,0.00012117577,0.000016736809,0.000008151327,0.008680779],"genre_scores_gemma":[0.9795974,0.000658292,0.015845386,0.0036519328,0.00013833726,0.00000372375,0.0000012853534,0.000010822395,0.00009280434],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985931,0.000012322009,0.0010641768,0.0000904154,0.00008916741,0.00015079712],"domain_scores_gemma":[0.9989902,0.00006445423,0.0005333749,0.00005943077,0.00029138822,0.00006120128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010121949,0.00010887109,0.00024705706,0.00059820036,0.000055700395,0.0000625576,0.00040182087,0.000036570495,0.00016308126],"category_scores_gemma":[0.0001465205,0.000093747934,0.000031313768,0.00024194898,0.000061236475,0.00026366592,0.0001235503,0.00008929193,0.000023472627],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010885096,0.00004440721,0.05659725,0.000018688792,0.00037949448,0.000005876433,0.018321028,0.000009956445,0.00011509831,0.91743106,0.0015258673,0.0054424508],"study_design_scores_gemma":[0.0008621575,0.000048180067,0.053857572,0.00013065326,0.000011426083,0.00006759337,0.00059348607,0.00012945879,0.023537116,0.041127477,0.8793243,0.00031056313],"about_ca_topic_score_codex":0.000022163604,"about_ca_topic_score_gemma":0.0000060311236,"teacher_disagreement_score":0.87779844,"about_ca_system_score_codex":0.000118325355,"about_ca_system_score_gemma":0.00015553081,"threshold_uncertainty_score":0.382293},"labels":[],"label_agreement":null},{"id":"W2099722439","doi":"10.1503/cmaj.110493","title":"Canada’s laws on pharmaceutical intellectual property: the case for fundamental reform: Figure 1:","year":2011,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Intellectual property; Government (linguistics); Value (mathematics); Law; Property (philosophy); Computer science; Law and economics; Political science; Sociology; Epistemology; Philosophy","score_opus":0.08612977742327967,"score_gpt":0.2756571802187956,"score_spread":0.18952740279551594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099722439","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13443413,0.00089437905,0.0002059508,0.5963172,0.007407826,0.0010386237,0.0024054833,0.000033830504,0.25726262],"genre_scores_gemma":[0.8542976,0.00010832275,0.000048529277,0.14251184,0.0013166608,0.000026105177,0.00000862291,0.000024549401,0.001657772],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99838525,0.00004517551,0.0006112783,0.00020329466,0.00011719522,0.00063778553],"domain_scores_gemma":[0.9979777,0.00021329052,0.00022817591,0.00012006851,0.00007711459,0.0013837045],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015955393,0.00014461744,0.0002493018,0.00011157088,0.000514848,0.000100493235,0.00034158264,0.00020855601,0.0097814165],"category_scores_gemma":[0.0012161772,0.0001025974,0.00012603303,0.00010411172,0.00005471742,0.00009764302,0.000022078893,0.00087510684,0.00032385706],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006125028,0.000057181227,0.00204842,0.0000105561885,0.00020103807,0.00058512425,0.00072037865,0.0000023647654,4.188143e-7,0.047861543,0.9356963,0.012755399],"study_design_scores_gemma":[0.0007126105,0.000085606545,0.0003256076,0.0000073967713,0.000009854824,0.00069845817,0.00023902468,0.0028315492,0.000017350263,0.0022666797,0.99263865,0.00016720705],"about_ca_topic_score_codex":0.55321676,"about_ca_topic_score_gemma":0.8769642,"teacher_disagreement_score":0.7198635,"about_ca_system_score_codex":0.0035069052,"about_ca_system_score_gemma":0.0022432457,"threshold_uncertainty_score":0.9911238},"labels":[],"label_agreement":null},{"id":"W2099981452","doi":"10.1002/hpm.819","title":"Regulating the Dutch pharmaceutical market: improving efficiency or controlling costs?","year":2005,"lang":"en","type":"article","venue":"The International Journal of Health Planning and Management","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"","keywords":"Incentive; Government (linguistics); Business; Competition (biology); Public economics; Health care; Medical prescription; Industrial organization; Pharmaceutical industry; Market share; Economics; Marketing; Market economy; Economic growth; Medicine; Pharmacology","score_opus":0.07771333742491245,"score_gpt":0.3658252932535264,"score_spread":0.288111955828614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099981452","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24045037,0.0402613,0.057519123,0.5906223,0.004183486,0.0011474423,0.00006882277,0.000049048696,0.06569812],"genre_scores_gemma":[0.98071635,0.0016646989,0.00064504665,0.015853694,0.0005907563,0.0000048116094,7.105275e-7,0.000009893265,0.0005140243],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99869525,0.000041015508,0.0008191221,0.0001232285,0.00008619473,0.00023518532],"domain_scores_gemma":[0.9988508,0.00026025614,0.00068037934,0.000093743474,0.000035124383,0.00007967725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034790104,0.00009211156,0.00021326666,0.00012293122,0.00023223182,0.00014387806,0.00043619162,0.000020182628,0.00009219014],"category_scores_gemma":[0.00008041478,0.00005732543,0.00006389802,0.000055125452,0.000050928465,0.00012107637,0.00011756097,0.00023993854,0.000014002334],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012724067,0.00026423074,0.006972374,0.00018069414,0.0011756619,0.000055046537,0.004079727,0.019258669,0.000024264093,0.35537934,0.03797174,0.57336587],"study_design_scores_gemma":[0.002418859,0.00010619258,0.004288361,0.0001529517,0.000023841367,0.00014795046,0.00065283454,0.2693913,0.0000226456,0.0029357863,0.71969485,0.00016443283],"about_ca_topic_score_codex":0.000036892925,"about_ca_topic_score_gemma":0.0000033026486,"teacher_disagreement_score":0.74026597,"about_ca_system_score_codex":0.00019685982,"about_ca_system_score_gemma":0.00002905982,"threshold_uncertainty_score":0.23376632},"labels":[],"label_agreement":null},{"id":"W2102168783","doi":"10.1111/j.1475-6773.2005.00495.x","title":"Prescription Drug Expenditures and Population Demographics","year":2006,"lang":"en","type":"article","venue":"Health Services Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Centre for Disease Control; University of British Columbia","funders":"Canadian Institutes of Health Research; Michael Smith Health Research BC","keywords":"Prescription drug; Medical prescription; Population; Per capita; Medicine; Pharmacy; Medical Expenditure Panel Survey; Drug; Demography; Environmental health; Health care; Health insurance; Economic growth; Economics; Family medicine","score_opus":0.08342037843931394,"score_gpt":0.39128446189343646,"score_spread":0.30786408345412253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102168783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9695421,0.012334834,0.00004139943,0.00628539,0.00020709103,0.00042816304,0.00011828877,0.000044013283,0.010998735],"genre_scores_gemma":[0.9953046,0.0021416058,0.00014630497,0.0016933413,0.00025642756,0.000032274274,0.00008813467,0.000018556553,0.0003187447],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9985013,0.000067085006,0.00049206853,0.0003533182,0.0000647931,0.0005214593],"domain_scores_gemma":[0.99931324,0.000073074916,0.00019162458,0.00020949854,0.000026448743,0.00018612506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001496577,0.00009637478,0.0002241106,0.00043541688,0.00035357455,0.00015672475,0.00016607178,0.000073685456,0.00012336625],"category_scores_gemma":[0.0000054115635,0.00011199402,0.000036616777,0.00020767411,0.00005314761,0.0002527552,0.00009042947,0.00028083532,0.00016438951],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003266695,0.000105343264,0.48463026,0.00064887136,0.000012779918,0.0000011967938,0.0007343589,0.00006833141,0.000013410329,0.50601846,0.0053787124,0.002355587],"study_design_scores_gemma":[0.00040496187,0.000039996652,0.64895374,0.000032106258,7.518468e-7,0.0000024027809,0.00013246649,0.011709075,0.000015606502,0.17585033,0.16270582,0.00015272142],"about_ca_topic_score_codex":0.035380736,"about_ca_topic_score_gemma":0.0042801816,"teacher_disagreement_score":0.33016813,"about_ca_system_score_codex":0.0001031971,"about_ca_system_score_gemma":0.0000212059,"threshold_uncertainty_score":0.97104275},"labels":[],"label_agreement":null},{"id":"W2104086837","doi":"10.1002/hec.1103","title":"A re‐examination of the impact of reference pricing on anti‐hypertensive drug plan expenditures in British Columbia","year":2006,"lang":"en","type":"article","venue":"Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; University of Toronto; Canadian Institutes of Health Research","funders":"","keywords":"Reimbursement; Counterfactual thinking; Context (archaeology); Drug pricing; Drug; Actuarial science; Plan (archaeology); Drug prices; Medicine; Public economics; Business; Economics; Pharmacology; Health care; Economic growth; Geography; Psychology","score_opus":0.0656231207171754,"score_gpt":0.2997996327226722,"score_spread":0.23417651200549677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104086837","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98732585,0.0005109317,0.0000025927638,0.0005272057,0.00017759358,0.00034438792,0.0007289557,0.0000071166805,0.010375368],"genre_scores_gemma":[0.998164,0.0007936605,0.000036376572,0.0007620724,0.00006988902,0.000011580967,0.000029704363,0.000020310481,0.0001124],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99820846,0.00004010163,0.0010994242,0.00030901315,0.000017435088,0.00032554407],"domain_scores_gemma":[0.99853206,0.00012542628,0.000947251,0.0003032197,0.000020477455,0.00007155195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058324815,0.00011020028,0.0006468693,0.0001347286,0.00007757841,0.00006034488,0.00024532824,0.00008659499,0.00012503806],"category_scores_gemma":[0.000045164183,0.00015251007,0.0001335566,0.00010466551,0.00007561917,0.000121806064,0.00005148794,0.00020005491,0.0000169035],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036700123,0.0005884895,0.92580545,0.00026840696,0.00006802842,0.0000024559954,0.0010061708,0.01517282,0.000022427655,0.036175154,0.014884355,0.0059695425],"study_design_scores_gemma":[0.0006826881,0.00008413547,0.982134,0.0000722902,0.0000015802375,0.0000034868533,0.000094820905,0.006445593,0.000060095837,0.008359236,0.0019033033,0.00015880451],"about_ca_topic_score_codex":0.14840953,"about_ca_topic_score_gemma":0.08188574,"teacher_disagreement_score":0.06652379,"about_ca_system_score_codex":0.00042909037,"about_ca_system_score_gemma":0.00013883928,"threshold_uncertainty_score":0.93486744},"labels":[],"label_agreement":null},{"id":"W2104400639","doi":"10.1503/cmaj.141564","title":"Estimated cost of universal public coverage of prescription drugs in Canada","year":2015,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Women's College Hospital; University of Toronto; University of British Columbia","funders":"Canadian Institutes of Health Research; Health Canada; Michael Smith Health Research BC","keywords":"Medical prescription; Government (linguistics); Prescription drug; Business; Public health; Public economics; Medicine; Economics; Pharmacology","score_opus":0.04436535506075406,"score_gpt":0.2471488685197388,"score_spread":0.20278351345898474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104400639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92764765,0.000424636,0.00012329248,0.030961769,0.0011228237,0.00012814684,0.0006586282,0.0000033676793,0.038929667],"genre_scores_gemma":[0.99690086,0.00015259956,0.000020022831,0.0027358613,0.00010808902,0.0000011173289,0.00001246959,0.0000064908613,0.00006251044],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987949,0.000038692393,0.0006512326,0.0000888746,0.00013760578,0.0002887025],"domain_scores_gemma":[0.99822736,0.000065733504,0.00045440477,0.00006278209,0.0001674,0.0010223472],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013355042,0.00006241114,0.00026942982,0.00025398325,0.0000258209,0.000021769441,0.00018624055,0.00012160565,0.000961635],"category_scores_gemma":[0.0013984839,0.00007739296,0.000039608523,0.0002137044,0.000022292445,0.00016733703,0.000013267687,0.00032555318,0.000021906324],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000012422357,0.000037520877,0.8758592,0.000012015878,0.00007687633,0.00002905756,0.00041830266,0.00046481483,0.0000013381908,0.030767467,0.08563035,0.006690621],"study_design_scores_gemma":[0.0042305468,0.00005334259,0.21322829,0.000053798234,0.000008356472,0.000028389017,0.000671439,0.048618812,0.000026385356,0.009963197,0.7228078,0.000309632],"about_ca_topic_score_codex":0.8635032,"about_ca_topic_score_gemma":0.9515233,"teacher_disagreement_score":0.6626309,"about_ca_system_score_codex":0.00431747,"about_ca_system_score_gemma":0.0076065725,"threshold_uncertainty_score":0.9999516},"labels":[],"label_agreement":null},{"id":"W2105192804","doi":"10.1038/nchembio.1113","title":"A public-private partnership to unlock the untargeted kinome","year":2012,"lang":"en","type":"article","venue":"Nature Chemical Biology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":151,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Structural Genomics Consortium","funders":"Engineering and Physical Sciences Research Council; Cancer Research UK; Wellcome Trust","keywords":"Kinome; General partnership; Drug discovery; Business; Redundancy (engineering); Access to medicines; Kinase; Intellectual property; Computational biology; Computer science; Data science; Chemistry; Biology; Bioinformatics; Biochemistry; Finance","score_opus":0.10390653320461236,"score_gpt":0.31861269691085775,"score_spread":0.2147061637062454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105192804","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8437263,0.008926798,0.00023131409,0.05814983,0.0012772479,0.0003724228,0.0002495782,0.00009660244,0.08696994],"genre_scores_gemma":[0.97040796,0.000054709948,0.00039336795,0.027980959,0.00094220764,0.000037702353,0.000044307268,0.000020000554,0.00011880063],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983541,0.000024033889,0.00045358986,0.00034883493,0.000016947104,0.00080251583],"domain_scores_gemma":[0.9988945,0.00016739567,0.00013405234,0.00037624387,0.000020716216,0.00040710808],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006040714,0.0001846899,0.00035357528,0.00011229069,0.000084863015,0.000040273208,0.0005792358,0.00053680944,0.00068648],"category_scores_gemma":[0.0005380684,0.00014779858,0.00013858062,0.00030581985,0.000118746386,0.00010083057,0.00022804418,0.0007770772,0.0019925372],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022590582,0.000068065114,0.022175258,0.000006528332,0.000055410095,2.1489643e-7,0.00016546353,4.0082477e-7,0.0067309644,0.96372,0.0060664834,0.0009885881],"study_design_scores_gemma":[0.00026192173,0.000016134836,0.0020108372,0.000001782301,0.0000039437527,0.0000040466552,0.000006117747,0.00006889025,0.0070198737,0.054176364,0.93619,0.00024008156],"about_ca_topic_score_codex":0.000008624643,"about_ca_topic_score_gemma":0.000002198649,"teacher_disagreement_score":0.9301235,"about_ca_system_score_codex":0.00011236014,"about_ca_system_score_gemma":0.000016390588,"threshold_uncertainty_score":0.99878454},"labels":[],"label_agreement":null},{"id":"W2106708480","doi":"","title":"Getting ready for inspection of investigational site at short notice.","year":2010,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Micropharma (Canada)","funders":"","keywords":"Notice; Quality (philosophy); Clinical trial; Business; Audit; Process (computing); Public relations; Accounting; Operations management; Medicine; Process management; Political science; Computer science; Engineering; Law","score_opus":0.11332516057880392,"score_gpt":0.2772018098902221,"score_spread":0.16387664931141815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106708480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9641115,0.00006211539,0.00015071467,0.0017263473,0.0006775725,0.0004033082,0.00037522247,0.000028181634,0.032465015],"genre_scores_gemma":[0.9972908,0.000013954965,0.0006698841,0.0008208751,0.00038165302,0.00035659655,0.000049357757,0.000015431988,0.00040142925],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99912024,0.000003078166,0.0004179947,0.00020648542,0.000016266358,0.00023592575],"domain_scores_gemma":[0.9994598,0.00008760038,0.00016627219,0.00013616076,0.000027843098,0.00012229639],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053744414,0.000075623684,0.00018577937,0.00011290602,0.00007739774,0.000022693112,0.000097805874,0.000080148035,0.000059888458],"category_scores_gemma":[0.00029013774,0.00009379887,0.00007109157,0.00007358469,0.000071789174,0.00013391473,0.00004034071,0.00011622458,0.00006643902],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004032689,0.00008179022,0.19510758,0.000061568,0.00006557667,2.4847742e-7,0.00016653529,0.00009108388,0.0016612054,0.78617847,0.0046545113,0.011891127],"study_design_scores_gemma":[0.00060005876,0.000015670557,0.6683422,0.0000016814522,0.000011493402,0.0000033978283,0.0000037263112,0.011595449,0.006609925,0.058430538,0.25411737,0.00026850172],"about_ca_topic_score_codex":0.000050885294,"about_ca_topic_score_gemma":0.00008455295,"teacher_disagreement_score":0.7277479,"about_ca_system_score_codex":0.00006254143,"about_ca_system_score_gemma":0.0000098216515,"threshold_uncertainty_score":0.3825007},"labels":[],"label_agreement":null},{"id":"W2107091005","doi":"10.12927/hcpap..16872","title":"To Build a Wooden Horse … Integrating Drugs into the Public Health System","year":2004,"lang":"en","type":"letter","venue":"A Nudge Too Far? A Nudge at All? On Paying People to Be Healthy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Mental Health Commission of Canada","funders":"","keywords":"Horse; Public health; Business; Engineering; Medicine; Biology; Nursing","score_opus":0.08394013748423351,"score_gpt":0.31707520575465736,"score_spread":0.23313506827042385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107091005","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02455039,0.0016334692,0.0006323844,0.9603187,0.0024098167,0.002971508,0.0012305498,0.00038420013,0.0058690216],"genre_scores_gemma":[0.014158158,0.00060722244,0.00092667714,0.97960186,0.00094256835,0.0013254927,0.00040941872,0.00041360478,0.0016150007],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99016774,0.00037898257,0.0033028556,0.0025045096,0.00032763486,0.0033182884],"domain_scores_gemma":[0.993152,0.00086488365,0.0017488021,0.0022358971,0.00014103779,0.0018573814],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0040163957,0.0013867819,0.0027157841,0.0013194279,0.0013874262,0.0008679076,0.0022831906,0.00106093,0.00029179544],"category_scores_gemma":[0.0005673593,0.001305445,0.0007731338,0.0014629674,0.00009717054,0.00031405478,0.0009770171,0.00361843,0.0075009707],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000097987984,0.000120537305,0.00017325034,0.0005485421,0.000204454,0.000035094996,0.018576631,0.000033315464,0.0000015705674,0.04618275,0.93086857,0.0031572904],"study_design_scores_gemma":[0.0011405882,0.00076183584,0.00012306306,0.00001155899,0.000022635382,0.00004851143,0.000585341,0.00091940706,0.000003417076,0.0009785156,0.9940898,0.0013153218],"about_ca_topic_score_codex":0.01190778,"about_ca_topic_score_gemma":0.0029313439,"teacher_disagreement_score":0.06322123,"about_ca_system_score_codex":0.010146389,"about_ca_system_score_gemma":0.0013043022,"threshold_uncertainty_score":0.9999126},"labels":[],"label_agreement":null},{"id":"W2107227483","doi":"10.1287/mksc.1120.0743","title":"Offering Pharmaceutical Samples: The Role of Physician Learning and Patient Payment Ability","year":2012,"lang":"en","type":"article","venue":"Marketing Science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"Social Sciences and Humanities Research Council of Canada","keywords":"Subsidy; Payment; Sample (material); Prescription drug; Business; Sampling (signal processing); Investment (military); Product (mathematics); Marketing; Actuarial science; Medical prescription; Medicare Part D; Reimbursement; Microeconomics; Industrial organization; Economics; Medicine; Health care; Computer science; Finance; Pharmacology","score_opus":0.0378308833169652,"score_gpt":0.28986280227076816,"score_spread":0.25203191895380295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107227483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9625965,0.0019457692,0.00004245101,0.00044515307,0.00014825907,0.000111621135,0.00001210094,0.000012247754,0.034685917],"genre_scores_gemma":[0.99907494,0.00010992208,0.00024032718,0.00048962433,0.00006169339,0.00000795897,3.0271943e-7,0.0000067292353,0.000008487429],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988866,0.000044819848,0.00034172976,0.00024783917,0.000050896884,0.00042810448],"domain_scores_gemma":[0.99919504,0.00030479344,0.00017928149,0.00015453508,0.00001807975,0.0001482775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034743329,0.00008975573,0.00017100172,0.00006467436,0.00026526974,0.000058762766,0.0002075192,0.000021072197,0.000083606945],"category_scores_gemma":[0.000544234,0.00007804219,0.000043652264,0.00021123845,0.00048022126,0.00021647236,0.00022572168,0.00016465061,0.000022298542],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000038354287,0.00014410372,0.7045761,0.000047394762,0.000019267545,1.0339178e-7,0.0028311505,0.00007541475,0.010695864,0.092780195,0.000027502165,0.18876459],"study_design_scores_gemma":[0.00036075086,0.000061126964,0.551332,0.000034966244,0.000010934571,0.0000042336846,0.0014032763,0.04220199,0.013201605,0.009082503,0.3818941,0.00041249444],"about_ca_topic_score_codex":0.000039252827,"about_ca_topic_score_gemma":4.9383226e-7,"teacher_disagreement_score":0.38186663,"about_ca_system_score_codex":0.00006979664,"about_ca_system_score_gemma":0.000016554879,"threshold_uncertainty_score":0.31824684},"labels":[],"label_agreement":null},{"id":"W2107229542","doi":"10.1093/jlb/lsv013","title":"Orphan drug incentives in the pharmacogenomic context: policy responses in the US and Canada","year":2015,"lang":"en","type":"article","venue":"Journal of Law and the Biosciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Saskatchewan; University of Toronto","funders":"University of Toronto; Government of Canada; Genome Canada; Ontario Genomics; University of Saskatchewan; Ontario Genomics Institute","keywords":"Pharmacogenomics; Orphan drug; Incentive; Context (archaeology); Legislation; Medicine; Biotechnology; Business; Political science; Pharmacology; Bioinformatics; Biology; Economics; Law","score_opus":0.058914420877443766,"score_gpt":0.30186397327622577,"score_spread":0.24294955239878202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107229542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9440159,0.005356661,8.415047e-7,0.04355011,0.00019386552,0.000090898895,0.000026778613,5.0477405e-7,0.006764431],"genre_scores_gemma":[0.9821989,0.0013682619,0.0000049663568,0.016253788,0.00013644376,0.0000019602226,9.5796544e-8,0.0000021861792,0.000033416723],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991221,0.0001552401,0.0003974594,0.00009770748,0.00005398735,0.0001735249],"domain_scores_gemma":[0.9991613,0.00041863395,0.00025782836,0.00007915644,0.00001391216,0.00006917242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041348087,0.00007391685,0.00020368771,0.00010463364,0.00012279468,0.00016089423,0.0004686,0.00001577256,0.0000046403925],"category_scores_gemma":[0.00015772619,0.00003620208,0.000031552467,0.00015264351,0.0005353131,0.00019372824,0.000043761065,0.00016522985,0.0000013533165],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002578635,0.00004828095,0.041739784,0.0000053219796,0.000016861835,0.00001765071,0.0094837975,0.0000137163115,0.000019162815,0.94674975,0.001012534,0.0006353091],"study_design_scores_gemma":[0.005729793,0.00014133102,0.0769037,0.000028486422,0.000015359317,0.00026792538,0.007355355,0.0012674555,0.00014435366,0.19313255,0.71474016,0.00027351468],"about_ca_topic_score_codex":0.2572147,"about_ca_topic_score_gemma":0.16742614,"teacher_disagreement_score":0.75361717,"about_ca_system_score_codex":0.000059834467,"about_ca_system_score_gemma":0.00023841907,"threshold_uncertainty_score":0.84776616},"labels":[],"label_agreement":null},{"id":"W2107260549","doi":"10.1503/cmaj.051687","title":"Do manufacturers of brand-name drugs engage in price competition? An analysis of introductory prices","year":2006,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Competition (biology); Brand names; Drug industry; Drug prices; Business; Market competition; Marketing; Pharmaceutical industry; Industrial organization; Commerce; Advertising; Computer science; Medicine; Economics; Pharmacology; Public economics; Biotechnology; Market economy","score_opus":0.01142841339657643,"score_gpt":0.2441961481669817,"score_spread":0.23276773477040527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107260549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979121,0.00049420184,0.000105251136,0.006472338,0.00027886927,0.00006321655,0.0003173331,0.0000035316586,0.013144202],"genre_scores_gemma":[0.99737054,0.00020054972,0.000074179865,0.0018766066,0.00038487127,0.0000016590598,0.000031306594,0.000008012761,0.00005226216],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983326,0.000072093615,0.0009780714,0.0001739358,0.00013980853,0.00030348814],"domain_scores_gemma":[0.998462,0.00015896038,0.00071522215,0.00011742022,0.00007862614,0.00046777836],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0026125715,0.00009129908,0.00049279287,0.0009883969,0.00006544163,0.000042834577,0.00024725517,0.00019440104,0.0053839767],"category_scores_gemma":[0.00033896609,0.00010564295,0.00015453214,0.00047432494,0.00005082571,0.00018136694,0.000010792609,0.00048975716,0.00002821602],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016809172,0.00021146036,0.83616763,0.00002897691,0.00066281884,0.000017894607,0.0016369161,0.0020813416,0.000013116004,0.15158784,0.005357587,0.002217601],"study_design_scores_gemma":[0.001156386,0.00003575946,0.8224542,0.000016472482,0.00006430225,0.0000048836214,0.00029073015,0.0065699844,0.000040257317,0.010934581,0.1582048,0.00022761396],"about_ca_topic_score_codex":0.009619755,"about_ca_topic_score_gemma":0.017891278,"teacher_disagreement_score":0.15284722,"about_ca_system_score_codex":0.00070686085,"about_ca_system_score_gemma":0.00033982593,"threshold_uncertainty_score":0.99837536},"labels":[],"label_agreement":null},{"id":"W2110275302","doi":"10.1017/s0963180107070107","title":"Montréal Statement on the Human Right to Essential Medicines","year":2006,"lang":"en","type":"article","venue":"Cambridge Quarterly of Healthcare Ethics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Statement (logic); Medicine; Business; Political science; Law","score_opus":0.06832354498650149,"score_gpt":0.34676617438847385,"score_spread":0.27844262940197234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110275302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.63616806,0.0012156316,0.000671379,0.3440935,0.00083378836,0.00058359734,0.00061316893,0.00003859315,0.01578227],"genre_scores_gemma":[0.98763084,0.00006691574,0.000057115372,0.01094311,0.00057076913,0.0000385108,0.000035218938,0.00002779216,0.0006297022],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99788713,0.000082043414,0.0011195738,0.0003780965,0.000098833385,0.0004343247],"domain_scores_gemma":[0.99855334,0.00032022488,0.00037789872,0.00046692102,0.00009170106,0.00018993794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015516254,0.00019692912,0.00043880026,0.00018271578,0.00029743533,0.000045581983,0.00032624468,0.00017126002,0.00009113453],"category_scores_gemma":[0.000052676238,0.00017241584,0.00012776026,0.00016400337,0.00014465394,0.000066844266,0.000025502373,0.00065325305,0.00041414352],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019525609,0.00008306574,0.00047398382,0.00009654335,0.000022080838,0.0000043019363,0.00093280757,0.000026265698,0.00008444423,0.9595702,0.03801587,0.00067088363],"study_design_scores_gemma":[0.0018406918,0.0033039376,0.01679779,0.00019103379,0.000023604998,0.000012510799,0.0008771875,0.001155444,0.0023600832,0.16674504,0.80575204,0.0009406472],"about_ca_topic_score_codex":0.016796745,"about_ca_topic_score_gemma":0.0018670287,"teacher_disagreement_score":0.79282516,"about_ca_system_score_codex":0.00014621018,"about_ca_system_score_gemma":0.00008063808,"threshold_uncertainty_score":0.9897505},"labels":[],"label_agreement":null},{"id":"W2110388478","doi":"10.3386/w9598","title":"Intellectual Property &amp; External Consumption Effects: Generalizations from Pharmaceutical Markets","year":2003,"lang":"en","type":"report","venue":"National Bureau of Economic Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; University of Toronto","funders":"","keywords":"Consumption (sociology); Intellectual property; Property (philosophy); Business; Industrial organization; Microeconomics; Economics; Commerce; Monetary economics; Computer science","score_opus":0.5935807885117556,"score_gpt":0.537475263079884,"score_spread":0.05610552543187153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110388478","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017524043,0.017025022,0.0012013271,0.0016415066,0.003629662,0.0017829972,0.0040756045,0.000058153568,0.9530617],"genre_scores_gemma":[0.7272163,0.12467842,0.004476116,0.0027000704,0.009473942,0.001377737,0.007128501,0.0006948057,0.12225412],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952812,0.00029917984,0.002009586,0.0011687577,0.00043527095,0.0008059736],"domain_scores_gemma":[0.9953016,0.0022955881,0.0007280518,0.00056221464,0.00071105,0.00040149523],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0056540226,0.00045442386,0.0011583851,0.0013451631,0.0002366611,0.00021500223,0.00081681827,0.00070610305,0.016550016],"category_scores_gemma":[0.0041106627,0.0004711803,0.000421188,0.00024001928,0.00054323877,0.00028520083,0.00028940864,0.0013784261,0.0067393086],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022191343,0.00050633424,0.0072946874,0.00058087567,0.001033257,0.000006465608,0.00020990058,0.00042327624,0.00027922014,0.4289246,0.55783415,0.0026853557],"study_design_scores_gemma":[0.0009827081,0.000042019066,0.0005607131,0.00011410029,0.000025794085,0.000018138315,0.0000033653375,0.00348269,0.0004022404,0.27744883,0.7164263,0.0004930905],"about_ca_topic_score_codex":0.0017429118,"about_ca_topic_score_gemma":0.0001327893,"teacher_disagreement_score":0.83080757,"about_ca_system_score_codex":0.003147732,"about_ca_system_score_gemma":0.001747957,"threshold_uncertainty_score":0.999774},"labels":[],"label_agreement":null},{"id":"W2110607907","doi":"10.18553/jmcp.2005.11.9.746","title":"Product-Line Extensions and Pricing Strategies of Brand-Name Drugs Facing Patent Expiration","year":2005,"lang":"en","type":"article","venue":"Journal of Managed Care Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria","funders":"","keywords":"Generic drug; Prescription drug; Medicine; Marketing; Medical prescription; Brand extension; Brand loyalty; Product (mathematics); Advertising; Market share; Brand names; Panel data; Expiration date; Drug; Business; Brand management; Economics; Pharmacology","score_opus":0.09298290153023488,"score_gpt":0.3140020313484577,"score_spread":0.22101912981822286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110607907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9755655,0.01302233,0.0014713551,0.0032047313,0.0002963997,0.00016492109,0.00003547054,0.0000099988665,0.006229299],"genre_scores_gemma":[0.9952087,0.0030825508,0.00067724264,0.00053156883,0.00042944483,0.0000020826208,0.0000028605746,0.000016453261,0.00004913833],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99860704,0.000025571078,0.0009383155,0.00018084976,0.000049756167,0.00019844608],"domain_scores_gemma":[0.9988198,0.00005677009,0.00076046796,0.00012845831,0.000110818226,0.00012366462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057586475,0.00013559629,0.00041282902,0.00028960436,0.000084671854,0.00008083024,0.00015050893,0.000025040863,0.00010566021],"category_scores_gemma":[0.000052998523,0.00013693584,0.00012577434,0.00010856601,0.000044698652,0.00069184403,0.000056199162,0.00026609583,0.000015972784],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087920274,0.00092027424,0.039243426,0.0019065789,0.0014108093,0.00007998451,0.048389185,0.07970852,0.020328872,0.1835191,0.0051006945,0.61851335],"study_design_scores_gemma":[0.02876414,0.0009534616,0.031152409,0.0006432354,0.00064103166,0.00037093606,0.018596252,0.09633659,0.07075662,0.07037943,0.6787976,0.0026083176],"about_ca_topic_score_codex":0.00004496575,"about_ca_topic_score_gemma":0.000007299803,"teacher_disagreement_score":0.6736969,"about_ca_system_score_codex":0.000097892975,"about_ca_system_score_gemma":0.000040811214,"threshold_uncertainty_score":0.55840814},"labels":[],"label_agreement":null},{"id":"W2111161004","doi":"10.1177/1745790413516971","title":"Use of generic medicines: Perspectives of consumers living in urban and suburban areas of Klang Valley in Malaysia","year":2013,"lang":"en","type":"article","venue":"Journal of Medical Marketing Device Diagnostic and Pharmaceutical Marketing","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Government (linguistics); Perception; Medicine; Guideline; Medical prescription; Willingness to pay; Quarter (Canadian coin); Health care; Business; Marketing; Family medicine; Nursing; Economic growth; Geography; Psychology; Economics","score_opus":0.04710268892922692,"score_gpt":0.2984243311579019,"score_spread":0.251321642228675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111161004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97550803,0.020392599,0.000041389554,0.002809261,0.00014024593,0.00021614693,0.00001715944,0.0000033999802,0.00087175576],"genre_scores_gemma":[0.9826792,0.016099859,0.0005911576,0.0004894182,0.00010520158,0.000006420885,9.2459624e-7,0.000022131888,0.0000057044685],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963211,0.00051471026,0.002239363,0.00029802072,0.00021732805,0.00040951394],"domain_scores_gemma":[0.972946,0.025155984,0.0011689074,0.00013094171,0.00013797736,0.0004601761],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010060042,0.00022379996,0.0010998738,0.0005613278,0.00002787349,0.000031191095,0.00027275854,0.00019277415,0.00081856066],"category_scores_gemma":[0.04737172,0.00021631477,0.00012375817,0.00036767995,0.0004790334,0.0002629362,0.00019049931,0.0006735971,0.0000016582892],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002142742,0.00025169985,0.98692554,0.0009834091,0.000108022956,0.00002819529,0.0012067608,0.00003252372,0.0001215735,0.0013235561,0.00028361756,0.008520846],"study_design_scores_gemma":[0.0017430342,0.00009460674,0.9483545,0.003325397,0.000064084226,0.000053360094,0.0018793904,0.0425319,0.00004761559,0.00050722016,0.0011419465,0.00025698057],"about_ca_topic_score_codex":0.0003441766,"about_ca_topic_score_gemma":0.000013605288,"teacher_disagreement_score":0.042499375,"about_ca_system_score_codex":0.00006429791,"about_ca_system_score_gemma":0.00009129281,"threshold_uncertainty_score":0.96065265},"labels":[],"label_agreement":null},{"id":"W2111436115","doi":"10.1111/j.1468-2354.2010.00615.x","title":"A DYNAMIC OLIGOPOLY STRUCTURAL MODEL FOR THE PRESCRIPTION DRUG MARKET AFTER PATENT EXPIRATION*","year":2010,"lang":"en","type":"article","venue":"International Economic Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":166,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Oligopoly; Expiration date; Welfare; Nested logit; Microeconomics; Expiration; Economics; Prescription drug; Consumer welfare; Medical prescription; Market structure; Business; Industrial organization; Econometrics; Medicine; Market economy; Pharmacology","score_opus":0.06074069930950473,"score_gpt":0.3125100873626672,"score_spread":0.2517693880531625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111436115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3434102,0.16023631,0.037235152,0.24466689,0.036000524,0.009949024,0.014155982,0.00026158828,0.15408432],"genre_scores_gemma":[0.95780975,0.021521203,0.0013048106,0.011783772,0.000364449,0.0008316826,0.00007986055,0.000038359245,0.0062661194],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99850535,0.000009025643,0.00084728154,0.000380396,0.000025006577,0.00023293395],"domain_scores_gemma":[0.99904895,0.00009672801,0.0003730324,0.00035876682,0.000035071622,0.00008747012],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006320802,0.0001821337,0.0003228536,0.00008017056,0.000090856316,0.00014580826,0.0005369772,0.000058486752,0.0046050036],"category_scores_gemma":[0.00008094031,0.00016349593,0.00028552304,0.000025338344,0.00006575972,0.00037560286,0.000083764,0.00020421462,0.0006521429],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017521487,0.00006620227,0.0038583488,0.00060304254,0.0005750634,0.0000013557874,0.00036404788,0.0035769215,0.000053666317,0.84947866,0.10769263,0.033554863],"study_design_scores_gemma":[0.00026974687,0.0000044274584,0.0016502285,0.00003422469,0.000013835691,0.0000053820686,0.0000016624124,0.6382266,0.0000041817084,0.043521624,0.3161087,0.0001593858],"about_ca_topic_score_codex":0.00007846757,"about_ca_topic_score_gemma":0.00028798383,"teacher_disagreement_score":0.805957,"about_ca_system_score_codex":0.00018377908,"about_ca_system_score_gemma":0.00004436963,"threshold_uncertainty_score":0.9963049},"labels":[],"label_agreement":null},{"id":"W2111850269","doi":"10.1377/hlthaff.25.4.1185-a","title":"Drugs Down Under: The Authors Respond","year":2006,"lang":"en","type":"article","venue":"Health Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Download; Public health; Foundation (evidence); Political science; Library science; Internet privacy; Medicine; Computer science; World Wide Web; Law; Nursing","score_opus":0.044547687794190514,"score_gpt":0.30449440926837334,"score_spread":0.25994672147418285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111850269","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09828057,0.009992143,0.00089078327,0.3662114,0.0017630697,0.00071649754,0.00048312297,0.00016897004,0.52149343],"genre_scores_gemma":[0.9860706,0.000407157,0.00015454096,0.009119286,0.00042358378,0.000027778686,0.000018745997,0.000028284796,0.00375003],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982732,0.000040045557,0.00071620697,0.0003413051,0.000031879164,0.00059736776],"domain_scores_gemma":[0.99895513,0.000121292316,0.0003036207,0.00039143788,0.00001416966,0.00021435108],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012324858,0.0001497371,0.0003178805,0.00014745576,0.00029158778,0.00008843342,0.0002879808,0.000085013526,0.00057776173],"category_scores_gemma":[0.000028097213,0.00013745055,0.0001052315,0.0002960298,0.00010108326,0.00010623785,0.000059633992,0.0002685773,0.002070705],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014776417,0.000038441503,0.0008072386,0.000018394856,0.000009337447,5.8798685e-7,0.00023227357,0.00017114438,0.0000011836289,0.89417094,0.10378792,0.00074775866],"study_design_scores_gemma":[0.00040036542,0.0000381478,0.009259633,0.0000052734486,0.000001555822,0.0000032693329,0.00027980364,0.0014772209,0.000012010747,0.15090428,0.83744454,0.0001739241],"about_ca_topic_score_codex":0.0015923091,"about_ca_topic_score_gemma":0.0001820377,"teacher_disagreement_score":0.88779,"about_ca_system_score_codex":0.00023578334,"about_ca_system_score_gemma":0.00011619322,"threshold_uncertainty_score":0.9987063},"labels":[],"label_agreement":null},{"id":"W2112595571","doi":"10.3821/145.5.cpj197a","title":"Canada falls short on safeguarding its drug supply","year":2012,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Canadian Pharmacists Association","funders":"","keywords":"Government (linguistics); Safeguarding; Legislature; Medicine; Legislation; Business; Parliament; Intensive care medicine; Political science; Law; Nursing","score_opus":0.06841401077393293,"score_gpt":0.2652409268873919,"score_spread":0.19682691611345898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112595571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9214836,0.006203463,0.000028252045,0.0017317444,0.010069645,0.0005095342,0.0063018487,0.00003357035,0.053638373],"genre_scores_gemma":[0.9696087,0.004033756,0.000044212124,0.02188871,0.0025966312,0.000020869524,0.000044542016,0.00010254217,0.0016599828],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956786,0.00007825748,0.00120597,0.00053778064,0.00018095119,0.0023184104],"domain_scores_gemma":[0.9939174,0.00015757214,0.0003594496,0.00035113064,0.00015667532,0.0050577708],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011944098,0.00055126724,0.0007307175,0.0005344695,0.0009554254,0.00027068082,0.0009416694,0.00008623152,0.0033986],"category_scores_gemma":[0.00020969698,0.0006848568,0.00023303692,0.00050648977,0.00009978141,0.000721046,0.000069940645,0.001058363,0.00022540521],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015806517,0.00019617798,0.050691377,0.00030961374,0.00095479557,0.01536012,0.0018169195,0.0034953337,0.00041630672,0.028258674,0.85996145,0.038381174],"study_design_scores_gemma":[0.0010893388,0.000018424967,0.00031006552,0.000017451852,0.000046219455,0.038208153,0.000010943077,0.0037539902,0.0017605778,0.00026328204,0.95340496,0.0011165661],"about_ca_topic_score_codex":0.71821094,"about_ca_topic_score_gemma":0.8847168,"teacher_disagreement_score":0.16650587,"about_ca_system_score_codex":0.008054723,"about_ca_system_score_gemma":0.004596712,"threshold_uncertainty_score":0.99956024},"labels":[],"label_agreement":null},{"id":"W2113321591","doi":"10.1177/171516350513800105","title":"Drug Shortages — Risk or Reality?","year":2005,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Economic shortage; Pharmacy; Medicine; Drug; Business; Environmental health; Family medicine; Pharmacology","score_opus":0.07657052916478492,"score_gpt":0.2888910542361798,"score_spread":0.21232052507139487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113321591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9061853,0.008864115,0.00037027724,0.010933911,0.0064818384,0.00084209454,0.011384509,0.00011538108,0.054822564],"genre_scores_gemma":[0.9512279,0.02201875,0.00029706937,0.02011659,0.0032116743,0.000018770477,0.000030344414,0.00008651734,0.0029923946],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99633396,0.00009492996,0.0013434998,0.00062491297,0.000108053784,0.0014946391],"domain_scores_gemma":[0.99530435,0.00014341506,0.0006424438,0.00039970822,0.00015386632,0.003356206],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014392309,0.00046206737,0.00067664764,0.0005682275,0.0010241584,0.00039760562,0.0009841308,0.00009065751,0.0066766595],"category_scores_gemma":[0.0003085263,0.00051481865,0.00026442856,0.00053283246,0.00021003759,0.0007324062,0.000067744,0.001056133,0.0003595],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020853206,0.00013962762,0.013271748,0.00015905916,0.00065221,0.014603236,0.002121354,0.00635634,0.00006645633,0.006490214,0.82919663,0.12673458],"study_design_scores_gemma":[0.0014870912,0.000019809671,0.00007142988,0.0000072880107,0.00005109577,0.044191774,0.0000059971926,0.0145487385,0.0003472468,0.0016785399,0.9368246,0.0007663791],"about_ca_topic_score_codex":0.06939692,"about_ca_topic_score_gemma":0.36957783,"teacher_disagreement_score":0.3001809,"about_ca_system_score_codex":0.003464499,"about_ca_system_score_gemma":0.001555605,"threshold_uncertainty_score":0.99973035},"labels":[],"label_agreement":null},{"id":"W2113782760","doi":"10.1016/j.jval.2014.03.852","title":"Impact Of The Pan-Canadian Pricing Alliance (Pcpa) On Access To Drug Treatment Options For Canadian Patients","year":2014,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada); Université de Montréal","funders":"","keywords":"Medicine; Formulary; Listing (finance); Drug; Pharmacotherapy; Medical prescription; Emergency medicine; Internal medicine; Intensive care medicine; Family medicine; Pharmacology; Business; Finance","score_opus":0.13799005764256228,"score_gpt":0.3637228376764445,"score_spread":0.2257327800338822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113782760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786195,0.00012085683,0.00002460126,0.013925955,0.00036575858,0.0011108664,0.0013561748,0.0000039652546,0.004472314],"genre_scores_gemma":[0.9947522,0.00015829907,0.00010432428,0.004735751,0.00006761088,0.00006650948,0.000011960698,0.00001696112,0.00008633216],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987377,0.00003095161,0.0004646102,0.00024007008,0.000016492946,0.00051017833],"domain_scores_gemma":[0.99889076,0.000103279315,0.00017532494,0.0002836402,0.000017397819,0.0005295973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042798917,0.00011312841,0.0002807102,0.0002764654,0.00015354496,0.000039868617,0.0002841616,0.000040448267,0.00003595998],"category_scores_gemma":[0.00012698556,0.00010155266,0.00011329424,0.00022416396,0.000015385784,0.00007029157,0.00001646191,0.00007540643,0.000061458115],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020114285,0.0001600801,0.7894778,0.000052709744,0.000036537374,1.1353807e-7,0.00096023484,0.06522423,3.9653992e-7,0.12919603,0.0043761935,0.01049551],"study_design_scores_gemma":[0.0007314383,0.00032363023,0.848432,0.00005049918,0.0000017417939,1.1618902e-7,0.0000045488046,0.024183236,0.000009788906,0.007927001,0.11817656,0.00015940955],"about_ca_topic_score_codex":0.9436283,"about_ca_topic_score_gemma":0.75385684,"teacher_disagreement_score":0.18977147,"about_ca_system_score_codex":0.0027018003,"about_ca_system_score_gemma":0.0005934053,"threshold_uncertainty_score":0.70651144},"labels":[],"label_agreement":null},{"id":"W2115652323","doi":"10.1503/cmaj.070680","title":"Drug spending tops $25 billion","year":2007,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Medicine; Health spending; Drug industry; Drug; Prescription drug; Environmental health; Business; Health services; Pharmacology; Biotechnology; Biology","score_opus":0.029667406675378975,"score_gpt":0.27027860883123067,"score_spread":0.2406112021558517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115652323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45518827,0.0014032767,0.0013640424,0.116777174,0.005819425,0.00016368437,0.0001574996,0.00003746254,0.41908914],"genre_scores_gemma":[0.9682469,0.00036232368,0.00012150102,0.026830869,0.002768194,0.0000011337654,0.000005959928,0.000018352175,0.0016448139],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99829936,0.00002034637,0.00072949915,0.000167762,0.00013021757,0.00065281277],"domain_scores_gemma":[0.9975666,0.00014240808,0.00033543885,0.00008720742,0.000048231577,0.0018201246],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.004874679,0.00010018178,0.00023746419,0.0004015341,0.00023793745,0.0001385492,0.0002564051,0.00023312609,0.011131853],"category_scores_gemma":[0.00095786265,0.00011519814,0.000120674165,0.00021445782,0.000023768753,0.00018525876,0.000017652019,0.00073122774,0.0024038106],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000006694557,0.000038761085,0.45335755,0.0000075605185,0.000130987,0.00023365609,0.0005004027,0.000008093118,0.0000044842177,0.23987214,0.27583003,0.030009627],"study_design_scores_gemma":[0.00043866094,0.000008142398,0.04227317,0.000008981673,0.0000026444059,0.000063517116,0.000058506666,0.00043737036,0.000014966214,0.012908752,0.94363505,0.0001502354],"about_ca_topic_score_codex":0.0023274757,"about_ca_topic_score_gemma":0.016338881,"teacher_disagreement_score":0.667805,"about_ca_system_score_codex":0.0015279612,"about_ca_system_score_gemma":0.00031111477,"threshold_uncertainty_score":0.9983729},"labels":[],"label_agreement":null},{"id":"W2115689023","doi":"10.4212/cjhp.v64i6.1084","title":"Perspective sur les ruptures d’approvisionnement de médicaments en établissement de santé de 2006 à 2010","year":2011,"lang":"fr","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Economic shortage; Stock (firearms); Pharmacy; Medicine; Descriptive statistics; Business; Geography; Family medicine; Statistics; Mathematics","score_opus":0.05291684109774701,"score_gpt":0.29069162013084665,"score_spread":0.23777477903309963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115689023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8100906,0.07745295,0.00049305684,0.077242374,0.004257419,0.00045616616,0.00091543025,0.000008333144,0.029083634],"genre_scores_gemma":[0.98491794,0.00594784,0.0007310167,0.0046440447,0.0013784472,0.000010296862,0.0000021667886,0.000053373882,0.002314871],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.997362,0.00015980047,0.00090854557,0.00027109313,0.00007397328,0.0012245413],"domain_scores_gemma":[0.99727035,0.00013146004,0.0007572522,0.0002625611,0.00017627058,0.0014021079],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002358892,0.0003131956,0.00047316228,0.0003851035,0.00042745835,0.0002543132,0.0010037139,0.00014056002,0.0048902067],"category_scores_gemma":[0.00034554183,0.000319594,0.00036299982,0.00017777106,0.00036770222,0.00042645764,0.00007427494,0.0010075693,0.00015218329],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022945041,0.0011823322,0.3300717,0.0001264091,0.0021478245,0.0006519484,0.06469158,0.0007323049,0.00010633162,0.26508552,0.30371195,0.031262662],"study_design_scores_gemma":[0.0030986187,0.0006571814,0.11380377,0.00016428193,0.000273626,0.00020469919,0.0027412786,0.0043652253,0.0013550478,0.07133502,0.80118567,0.00081560464],"about_ca_topic_score_codex":0.31352386,"about_ca_topic_score_gemma":0.02749959,"teacher_disagreement_score":0.49747372,"about_ca_system_score_codex":0.0031747757,"about_ca_system_score_gemma":0.0020137306,"threshold_uncertainty_score":0.9999256},"labels":[],"label_agreement":null},{"id":"W2115986688","doi":"10.5539/ijef.v4n11p24","title":"Private Health Care and Drug Quality in Germany – A Game-Theoretical Approach","year":2012,"lang":"en","type":"article","venue":"International Journal of Economics and Finance","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Statutory law; Business; Casualty insurance; Group insurance; Actuarial science; Health insurance; General insurance; Self-insurance; Quality (philosophy); German; Insurance policy; Public economics; Health care; Key person insurance; Insurance law; Economics; Income protection insurance; Economic growth; Law; Political science","score_opus":0.044308962508070815,"score_gpt":0.324868741184755,"score_spread":0.2805597786766842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115986688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9781243,0.012343756,0.00019215932,0.0040088734,0.00053590495,0.00007916978,0.00011350653,0.0000021157798,0.0046001994],"genre_scores_gemma":[0.9748207,0.021188837,0.0017008348,0.001932962,0.00031750445,0.000003490121,0.000003612775,0.000013125566,0.00001893064],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985217,0.000022761558,0.0009835338,0.00018455918,0.000020258556,0.00026720125],"domain_scores_gemma":[0.9989911,0.00006608827,0.00067638606,0.00009928899,0.0000325238,0.0001346529],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010634697,0.00012542566,0.0004342154,0.00021309452,0.000029492498,0.00007640324,0.00022634916,0.000056207085,0.000021344526],"category_scores_gemma":[0.00004963327,0.00014104972,0.00008178785,0.000037587048,0.00013900318,0.0004017511,0.000099425466,0.00022314968,0.00001062274],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005135904,0.00007906898,0.02107321,0.000015988433,0.000035626148,0.0000010637867,0.0015325915,0.00017866108,8.304503e-7,0.97154933,0.000085991625,0.005396303],"study_design_scores_gemma":[0.0043646595,0.00015611506,0.19146965,0.000072966184,0.000008181436,0.00023052027,0.00038220276,0.014413717,0.00005129763,0.28109428,0.5070248,0.00073161966],"about_ca_topic_score_codex":0.0000461209,"about_ca_topic_score_gemma":0.000008281292,"teacher_disagreement_score":0.690455,"about_ca_system_score_codex":0.00019093989,"about_ca_system_score_gemma":0.000038878607,"threshold_uncertainty_score":0.57518405},"labels":[],"label_agreement":null},{"id":"W2116893689","doi":"10.4212/cjhp.v54i2.630","title":"Sept stratégies pour consolider notre système d’utilisation des médicaments","year":2001,"lang":"fr","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Gynecology; Medicine","score_opus":0.06667956537304386,"score_gpt":0.29474832488228175,"score_spread":0.22806875950923788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116893689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75891066,0.047943544,0.00014223949,0.15855928,0.006349543,0.00029625813,0.00060846686,0.000008190109,0.027181847],"genre_scores_gemma":[0.9822893,0.006078592,0.00014906083,0.0042482303,0.0019959693,0.000004290051,0.0000063147477,0.00005040132,0.0051778234],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99738425,0.00009355181,0.001247511,0.0002548243,0.00007517244,0.00094471325],"domain_scores_gemma":[0.9973209,0.0001716259,0.0009729044,0.000278725,0.00019855621,0.001057283],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0011045183,0.00031491692,0.00061325193,0.00035966616,0.0005601,0.00057202927,0.0007633454,0.00011995669,0.0047352463],"category_scores_gemma":[0.0002655049,0.00032666407,0.00037805698,0.0003049177,0.0008292785,0.0009042278,0.000042221043,0.0007405177,0.00091159245],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016481767,0.0005073991,0.3855192,0.00024762645,0.002096922,0.0010388626,0.009685892,0.002725824,0.00003010721,0.2114653,0.3375344,0.048983637],"study_design_scores_gemma":[0.002520731,0.00022889074,0.02882323,0.00017641037,0.00015495105,0.0004066599,0.0005473666,0.004024764,0.00011992523,0.086376466,0.8760769,0.0005437248],"about_ca_topic_score_codex":0.0284373,"about_ca_topic_score_gemma":0.012296014,"teacher_disagreement_score":0.5385425,"about_ca_system_score_codex":0.0013604473,"about_ca_system_score_gemma":0.0013636589,"threshold_uncertainty_score":0.9999185},"labels":[],"label_agreement":null},{"id":"W2117061783","doi":"10.12927/hcpap..16876","title":"Recognize the Role of Employers","year":2004,"lang":"en","type":"letter","venue":"A Nudge Too Far? A Nudge at All? On Paying People to Be Healthy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Health care; Public health; Equity (law); Population health; Public policy; Health policy; Health equity; Library science; Sociology; Political science; Management; Medicine; Nursing","score_opus":0.08843719614225959,"score_gpt":0.3039964429660322,"score_spread":0.2155592468237726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117061783","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03474749,0.0018635275,0.000031443797,0.9405254,0.001215664,0.0012831679,0.0021556965,0.00011744061,0.01806013],"genre_scores_gemma":[0.005373296,0.0015352155,0.0002115664,0.98963135,0.0004434009,0.0003569714,0.0003198879,0.00027070107,0.0018576197],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9943038,0.00012986927,0.002180256,0.001472517,0.00018078189,0.0017327568],"domain_scores_gemma":[0.9957196,0.0007909535,0.0013415728,0.0015208784,0.00008619085,0.0005407631],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0012219845,0.00086990674,0.0018508292,0.00062381226,0.00041866003,0.00015607127,0.0013864923,0.0010153889,0.0011830345],"category_scores_gemma":[0.00031230669,0.0008431358,0.00073579577,0.000638275,0.00012476779,0.00015879532,0.00044728222,0.0022204723,0.0046716235],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001915531,0.00013450456,0.0007967318,0.00015063022,0.00023079512,0.000018340656,0.0019625416,0.00003257109,0.000011203989,0.01170381,0.98311013,0.0016571864],"study_design_scores_gemma":[0.0011226905,0.0004948202,0.0006665718,0.0000021067597,0.00004459565,0.000021728587,0.000046376063,0.00024908697,0.000046397457,0.01148733,0.9849196,0.0008987113],"about_ca_topic_score_codex":0.003030883,"about_ca_topic_score_gemma":0.00046607602,"teacher_disagreement_score":0.049105898,"about_ca_system_score_codex":0.0015971402,"about_ca_system_score_gemma":0.00038787554,"threshold_uncertainty_score":0.99973},"labels":[],"label_agreement":null},{"id":"W2117161914","doi":"","title":"International drug price comparisons: quality assessment.","year":2011,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Drug prices; Public economics; Business; Drug; Health care; Quality (philosophy); Order (exchange); Socioeconomic status; Balance (ability); Drug pricing; Actuarial science; Environmental health; Economics; Economic growth; Medicine; Finance; Pharmacology","score_opus":0.2676717146812108,"score_gpt":0.33966954075130457,"score_spread":0.07199782607009375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117161914","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05720014,0.00018524886,0.0011627701,0.002424687,0.0011502665,0.00027574145,0.00016934134,0.000049990904,0.9373818],"genre_scores_gemma":[0.9942755,0.0001541734,0.0011178023,0.0020724267,0.00018400012,0.00036179935,0.000013098847,0.000014222255,0.0018069698],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99878645,0.000017268787,0.0005568462,0.0002834168,0.000025473159,0.00033056573],"domain_scores_gemma":[0.9992703,0.000046054778,0.00026554498,0.00022909393,0.000018100487,0.00017087272],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009391573,0.00010351302,0.00025027953,0.00012069426,0.000050666666,0.0000611,0.00037372852,0.00004461599,0.0015220322],"category_scores_gemma":[0.00007422645,0.00012500412,0.000096726704,0.00008690752,0.000049180573,0.00024099623,0.00010359709,0.0001589254,0.00051213836],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001524113,0.00019196936,0.20818785,0.000008448846,0.00009332423,9.3957755e-7,0.00018147785,0.0000021909702,6.043802e-7,0.7700797,0.013886271,0.007352018],"study_design_scores_gemma":[0.00029621684,0.0000017343717,0.5706548,4.7824363e-7,0.0000017134712,6.238427e-7,0.000013369867,0.00039722578,0.000022218454,0.02306899,0.40541932,0.00012331309],"about_ca_topic_score_codex":0.00031080074,"about_ca_topic_score_gemma":0.000011617412,"teacher_disagreement_score":0.9370754,"about_ca_system_score_codex":0.0001352418,"about_ca_system_score_gemma":0.000010374111,"threshold_uncertainty_score":0.9993907},"labels":[],"label_agreement":null},{"id":"W2117404492","doi":"10.4212/cjhp.v65i2.1123","title":"Drug Shortages in Health Care Institutions: Perspectives in Early 2012","year":2012,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"AstraZeneca","keywords":"Economic shortage; Health care; Business; Medicine; Political science; Law; Government (linguistics)","score_opus":0.07052146778960224,"score_gpt":0.32873195397487165,"score_spread":0.2582104861852694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117404492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8878943,0.07976721,0.0000046159,0.020206414,0.0009612493,0.00018569815,0.00010145216,0.0000026627847,0.010876403],"genre_scores_gemma":[0.99702865,0.0011033891,0.000036263707,0.0013148832,0.00040011472,0.0000050445765,0.0000015864711,0.000014388261,0.00009570961],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985802,0.00003997527,0.00068695884,0.00011176821,0.000027925798,0.0005531662],"domain_scores_gemma":[0.99892426,0.00003605437,0.00030423515,0.00012528177,0.00003267844,0.0005775158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009480315,0.00012226877,0.00030411512,0.00051205116,0.00013849912,0.00007632441,0.00034853813,0.000026644633,0.00021276138],"category_scores_gemma":[0.00006451489,0.000116475385,0.00010419246,0.00024618104,0.00013445053,0.00084314443,0.000018572517,0.0005006688,0.00010729282],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015173826,0.00010148445,0.6538423,0.000021622034,0.00004532762,0.000020001433,0.04766553,0.0002207408,6.0254786e-7,0.29237795,0.0047426824,0.0009466204],"study_design_scores_gemma":[0.001968447,0.00010980856,0.39640638,0.00006368245,0.0000076200463,0.000024330051,0.0047326866,0.00008808573,0.000025932595,0.006184011,0.5899708,0.00041816646],"about_ca_topic_score_codex":0.05434299,"about_ca_topic_score_gemma":0.046419065,"teacher_disagreement_score":0.58522815,"about_ca_system_score_codex":0.0010040994,"about_ca_system_score_gemma":0.0006653883,"threshold_uncertainty_score":0.9709813},"labels":[],"label_agreement":null},{"id":"W2117505050","doi":"","title":"Perspective canadienne du contrôle des prix des médicaments","year":2000,"lang":"fr","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Political science; Humanities; Art","score_opus":0.04585698487684167,"score_gpt":0.26889104693639404,"score_spread":0.22303406205955237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117505050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4845715,0.021678125,0.00012230247,0.014107041,0.0006236427,0.00021774811,0.00057140173,0.000029061202,0.4780792],"genre_scores_gemma":[0.75638515,0.026645774,0.0010759436,0.0060619223,0.0005884359,0.000027769504,0.00001048619,0.000057592948,0.2091469],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99738306,0.00003568465,0.0007154244,0.0006279563,0.000022234595,0.0012156131],"domain_scores_gemma":[0.9986769,0.00010298364,0.00015903787,0.0003313415,0.0000711245,0.00065860647],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0005073974,0.0003147391,0.0005838172,0.00017425114,0.0003810446,0.00020765381,0.00035412365,0.00020463587,0.090622984],"category_scores_gemma":[0.00013606729,0.0004153187,0.00023572463,0.00027360505,0.00093806733,0.0005099224,0.00006486556,0.00027266037,0.007974088],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053297288,0.00040833422,0.024303287,0.000050574003,0.00032182696,0.000022726834,0.002937855,0.00018578123,0.0000036097417,0.85991883,0.014312578,0.09748132],"study_design_scores_gemma":[0.0012222113,0.00012352158,0.016673204,0.000033543147,0.000025681746,0.000028680133,0.00033255023,0.0073431707,0.000044994355,0.18606754,0.7876394,0.0004655545],"about_ca_topic_score_codex":0.09615804,"about_ca_topic_score_gemma":0.022877585,"teacher_disagreement_score":0.77332675,"about_ca_system_score_codex":0.002011431,"about_ca_system_score_gemma":0.00010317851,"threshold_uncertainty_score":0.9998299},"labels":[],"label_agreement":null},{"id":"W2118900911","doi":"10.3821/1913-701x-142.3.126","title":"The Future of Canadian Pharmacy","year":2009,"lang":"fr","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy; Medicine; Family medicine","score_opus":0.051226179959604545,"score_gpt":0.2707043559813752,"score_spread":0.21947817602177067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118900911","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23322317,0.46133894,0.000059859383,0.11935468,0.06792132,0.0015679956,0.018918063,0.00004127251,0.097574696],"genre_scores_gemma":[0.6977657,0.2722951,0.00010856888,0.018589789,0.0051980014,0.000008142766,0.00003437208,0.00007769467,0.0059226444],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9936488,0.00018978014,0.002164217,0.00069873786,0.00018966061,0.0031088002],"domain_scores_gemma":[0.9909397,0.00021100679,0.0011006378,0.00060071395,0.00051699276,0.0066309487],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019394691,0.0007403863,0.0010001628,0.0017310685,0.0024147208,0.0006734577,0.0020493867,0.0002096796,0.0036885643],"category_scores_gemma":[0.00020276972,0.00086214516,0.0005546996,0.0020473355,0.0006493719,0.0007704707,0.000053563155,0.001898742,0.00017980221],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00011019037,0.000086774104,0.001888238,0.00017636646,0.00057031173,0.013809191,0.0011543741,0.001148441,0.00007813552,0.04963403,0.450733,0.48061094],"study_design_scores_gemma":[0.0018199057,0.00005877181,0.000088823224,0.000030154177,0.00010947502,0.074498326,0.000018275401,0.0070670703,0.00033411148,0.004152129,0.9109706,0.00085234566],"about_ca_topic_score_codex":0.66533154,"about_ca_topic_score_gemma":0.9357696,"teacher_disagreement_score":0.4797586,"about_ca_system_score_codex":0.006656635,"about_ca_system_score_gemma":0.010785124,"threshold_uncertainty_score":0.9993829},"labels":[],"label_agreement":null},{"id":"W2119190560","doi":"10.1177/0306312714536270","title":"The shipwreck of the singular","year":2014,"lang":"en","type":"letter","venue":"Social Studies of Science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Reactionary; Epistemology; Sociology; Law and economics; Philosophy; Law; Political science; Politics","score_opus":0.15997032251670426,"score_gpt":0.3446144239884833,"score_spread":0.18464410147177904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119190560","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009691552,0.005643433,0.000007801289,0.93936723,0.0022283583,0.00022016882,0.00010847962,0.0000071466075,0.042725798],"genre_scores_gemma":[0.5061527,0.0023821,0.000058106743,0.48619536,0.0033152706,0.000024858138,0.0000016004104,0.00003486807,0.0018351555],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99858785,0.000022992648,0.00061161374,0.00028695122,0.0000998633,0.00039072157],"domain_scores_gemma":[0.99838144,0.0002797972,0.0008782673,0.00032629792,0.000112021895,0.00002220678],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0016790747,0.00013884254,0.00051219977,0.00006903991,0.0011764732,0.00004555353,0.001459466,0.000136118,0.0000133082385],"category_scores_gemma":[0.0006561975,0.0000943826,0.00024349192,0.00038778223,0.008165818,0.00006201343,0.00044892926,0.00045908114,0.000030180754],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000025052157,0.000011053868,0.00072106434,0.00010046242,0.00012747885,3.3352495e-7,0.0017239215,0.0000025700776,0.000019625591,0.22716013,0.76927084,0.00086001575],"study_design_scores_gemma":[0.00007403399,0.000012876685,0.000723998,0.000013839007,0.000008912597,2.5199088e-7,0.00010025802,0.000033833665,0.00010937895,0.10234163,0.8964677,0.00011328653],"about_ca_topic_score_codex":0.000083252824,"about_ca_topic_score_gemma":0.0000098671235,"teacher_disagreement_score":0.49646115,"about_ca_system_score_codex":0.00013070877,"about_ca_system_score_gemma":0.000084865846,"threshold_uncertainty_score":0.99453336},"labels":[{"model":"gemma","categories":["sts"],"domain":null,"study_design":"theoretical_or_conceptual","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"not_applicable","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W2119369919","doi":"10.1371/journal.pmed.1001054","title":"Global Pharmacovigilance for Antiretroviral Drugs: Overcoming Contrasting Priorities","year":2011,"lang":"en","type":"article","venue":"PLoS Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; Ministério da Saúde; Centers for Disease Control and Prevention; U.S. President’s Emergency Plan for AIDS Relief; amfAR, The Foundation for AIDS Research; Kaiser Permanente; European Commission; World Health Organization; National Institutes of Health; United States Agency for International Development; Global Fund to Fight AIDS, Tuberculosis and Malaria; University of Washington; York University; Bristol-Myers Squibb; Pfizer; Bill and Melinda Gates Foundation; Gilead Sciences; Incyte; U.S. Department of State","keywords":"Pharmacovigilance; Global health; Stakeholder; ANTIRETROVIRAL AGENTS; Medicine; Human immunodeficiency virus (HIV); Antiretroviral therapy; Drug; Public health; Pharmacology; Political science; Family medicine; Public relations","score_opus":0.134963732930019,"score_gpt":0.31449395320421347,"score_spread":0.17953022027419446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119369919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.65384656,0.005735556,0.004605329,0.0026226516,0.001944589,0.0008142271,0.00089123944,0.00017441915,0.32936543],"genre_scores_gemma":[0.9931613,0.00029067724,0.00094824034,0.004286769,0.00095791096,0.00003999463,0.000011529144,0.000024384717,0.0002791446],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9984982,0.000008775576,0.0006454842,0.00034906593,0.0000332708,0.00046517779],"domain_scores_gemma":[0.99921024,0.0001276227,0.00027123792,0.00017975373,0.000031324835,0.00017984593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042474727,0.00018435055,0.00053632533,0.00008995585,0.00010995481,0.000019585032,0.00024907672,0.00006760558,0.0005927594],"category_scores_gemma":[0.00029952993,0.0001955719,0.000092625975,0.00012734876,0.000150788,0.00020553748,0.000046206143,0.00011221662,0.00009759696],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024213873,0.00017327775,0.23117928,0.00030642777,0.00029858784,0.000007795399,0.002664993,0.0000035481767,0.00031553322,0.7506019,0.008354271,0.0058522606],"study_design_scores_gemma":[0.02138454,0.0017911175,0.050650634,0.000553015,0.00028423464,0.00003252376,0.0009307434,0.077932835,0.003485112,0.4694104,0.37118438,0.0023604804],"about_ca_topic_score_codex":0.00017664497,"about_ca_topic_score_gemma":0.0000035887936,"teacher_disagreement_score":0.36283013,"about_ca_system_score_codex":0.00012495097,"about_ca_system_score_gemma":0.00002309649,"threshold_uncertainty_score":0.7975191},"labels":[],"label_agreement":null},{"id":"W2119432905","doi":"10.2139/ssrn.1003132","title":"The Determinants of Pricing in Pharmaceuticals: Are U.S. Prices Really Higher than Those of Canada?","year":2007,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Ministerio de Ciencia y Tecnología; Merck Company Foundation","keywords":"Nationality; Economics; Product (mathematics); Market power; Quality (philosophy); Power (physics); Monetary economics; Business; Microeconomics; Immigration; Geography","score_opus":0.03920626024854755,"score_gpt":0.3084373042249196,"score_spread":0.26923104397637204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119432905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9723645,0.016772958,0.00013501782,0.0017011034,0.00035383442,0.00013066227,0.000025621994,0.0000033584347,0.008512967],"genre_scores_gemma":[0.9872313,0.012008244,0.000025912983,0.0002652528,0.00011980606,0.0000017568908,3.747608e-7,0.000017276396,0.00033008523],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99698985,0.000021964004,0.0010906595,0.00017008632,0.00006251781,0.0016649392],"domain_scores_gemma":[0.99853164,0.00022706675,0.0009125162,0.00017097306,0.00004026786,0.00011750998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004570661,0.00013162788,0.00039309738,0.00016020967,0.00011067952,0.000021817443,0.00042442224,0.00006544859,0.000027501537],"category_scores_gemma":[0.00012330455,0.00011345778,0.00009540954,0.00022624747,0.00007393313,0.00011423549,0.000050758896,0.00084130495,0.000003859602],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022557918,0.00014022642,0.4629582,0.00004709929,0.00017462332,0.000011468922,0.00019789214,0.0000802371,0.000118494376,0.5131386,0.00019847155,0.022709135],"study_design_scores_gemma":[0.0027766963,0.0002773285,0.3737231,0.00012996695,0.000032686465,0.00010318051,0.0012400426,0.0023098479,0.0038915293,0.5326419,0.08223446,0.0006392516],"about_ca_topic_score_codex":0.018979678,"about_ca_topic_score_gemma":0.3994771,"teacher_disagreement_score":0.38049743,"about_ca_system_score_codex":0.00077494275,"about_ca_system_score_gemma":0.0010740203,"threshold_uncertainty_score":0.987553},"labels":[],"label_agreement":null},{"id":"W2120237434","doi":"10.1503/cmaj.104001","title":"Internet pharmacy: prices on the up-and-up","year":2004,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Vancouver Coastal Health","funders":"","keywords":"The Internet; Pharmacy; Advertising; Business; Medical prescription; Marketing; GRASP; Prescription drug; Internet privacy; Commerce; World Wide Web; Engineering; Computer science; Medicine; Family medicine; Pharmacology","score_opus":0.05119907451602446,"score_gpt":0.27570261363029475,"score_spread":0.2245035391142703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120237434","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3723351,0.0008348774,0.00014207068,0.56304055,0.0030729454,0.00012727792,0.000112066016,0.000014653388,0.060320448],"genre_scores_gemma":[0.8957564,0.00071663235,0.000013193546,0.101543255,0.00098802,0.0000048862403,0.000002146593,0.000011840884,0.0009635938],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989483,0.00002231071,0.0004222381,0.00014467936,0.00009808646,0.00036442635],"domain_scores_gemma":[0.99856967,0.00013492985,0.0002460246,0.00007236607,0.00003418199,0.00094283023],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0015628039,0.000094180185,0.00017762762,0.0001379063,0.00018287277,0.00018711883,0.00026480094,0.00011712249,0.0054750466],"category_scores_gemma":[0.0007940696,0.00008081405,0.00007612908,0.000099304176,0.000041959498,0.0001116337,0.000019837173,0.0007322485,0.0014393334],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009107718,0.000024609231,0.021947546,0.000004436944,0.00016989233,0.000029752537,0.0009557375,0.000015371419,9.881214e-7,0.74033093,0.22654507,0.009966539],"study_design_scores_gemma":[0.0008578581,0.000018703699,0.0042101094,0.000012935593,0.00000381053,0.000041130137,0.000043367032,0.00061314774,0.000018418885,0.03179457,0.9622735,0.00011246821],"about_ca_topic_score_codex":0.0030798991,"about_ca_topic_score_gemma":0.003965108,"teacher_disagreement_score":0.7357284,"about_ca_system_score_codex":0.0007721296,"about_ca_system_score_gemma":0.00043143515,"threshold_uncertainty_score":0.99933815},"labels":[],"label_agreement":null},{"id":"W2121002488","doi":"10.12927/hcpap..16910","title":"More of the Same Is Not Enough","year":2002,"lang":"en","type":"review","venue":"A Nudge Too Far? A Nudge at All? On Paying People to Be Healthy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"Health care; Public health; Population health; Equity (law); Health policy; Public policy; Health equity; Library science; Political science; Sociology; Medicine; Nursing","score_opus":0.23949401677181467,"score_gpt":0.3790834923111838,"score_spread":0.13958947553936915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121002488","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011378404,0.59572935,0.00000886049,0.3892323,0.0010946214,0.0017065821,0.003740502,0.000068246685,0.007281693],"genre_scores_gemma":[0.00006706719,0.50677985,0.00006887479,0.4904474,0.00006425682,0.00020631745,0.000045796714,0.00013174656,0.002188692],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9938341,0.00014487923,0.0029410857,0.0014912195,0.00016795873,0.0014208079],"domain_scores_gemma":[0.9947104,0.00064798316,0.0019393307,0.0018959027,0.00005936101,0.0007470537],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0009938425,0.0010035146,0.0038735305,0.00054682366,0.00039428603,0.00011705968,0.0016327463,0.0007105474,0.0018269791],"category_scores_gemma":[0.00029984358,0.0008860178,0.0015999941,0.0010369627,0.00010996628,0.00014097472,0.00072978035,0.0011190588,0.004756554],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007406539,0.0003632921,0.00009659992,0.0038149424,0.00036587604,0.0000058537867,0.0033102476,0.0000054404572,4.0177818e-7,0.030570384,0.83599806,0.12539485],"study_design_scores_gemma":[0.0006205999,0.00023477325,0.00010603377,0.000022868773,0.0001236437,0.000026192454,0.000017659964,0.00025593684,0.0000036160134,0.00031932472,0.99738455,0.00088480173],"about_ca_topic_score_codex":0.00085836585,"about_ca_topic_score_gemma":0.00014138265,"teacher_disagreement_score":0.1613865,"about_ca_system_score_codex":0.0014146832,"about_ca_system_score_gemma":0.0003009263,"threshold_uncertainty_score":0.9993591},"labels":[],"label_agreement":null},{"id":"W2121098095","doi":"10.1016/j.healthpol.2003.07.007","title":"The effect of generic competition on the price of brand-name drugs","year":2003,"lang":"en","type":"article","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":100,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; York University; University Health Network","funders":"","keywords":"Competition (biology); Formulary; Competitor analysis; Brand names; Business; Generic drug; Product (mathematics); Market share; Government (linguistics); Marketing; Economics; Advertising; Medicine","score_opus":0.04911101962320849,"score_gpt":0.33301550369442395,"score_spread":0.2839044840712155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121098095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70709234,0.0042613386,0.00014083755,0.07069798,0.0004737247,0.0009380003,0.00028586786,0.00002102409,0.21608888],"genre_scores_gemma":[0.99056727,0.00205158,0.00001773181,0.006980978,0.00012770577,0.000026066933,0.00000249712,0.000015224186,0.00021095322],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986976,0.00014450679,0.00062891905,0.00015702538,0.000031312706,0.00034067535],"domain_scores_gemma":[0.9983008,0.0007186122,0.00051943696,0.00034253686,0.000013215071,0.00010539276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017035633,0.00011193428,0.00035471108,0.0001124081,0.0001860046,0.000016756023,0.00020792191,0.00004579122,0.0001168306],"category_scores_gemma":[0.000319808,0.00007636485,0.00011586754,0.00025333458,0.00012409966,0.000032732052,0.000022890825,0.00014859729,0.00017892163],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002402465,0.000022671296,0.00080487225,0.000079155354,0.000019283843,3.8762476e-8,0.00029323695,0.000060085993,0.000006600424,0.9953755,0.0016791857,0.0016353502],"study_design_scores_gemma":[0.0011832424,0.00060732086,0.0054459604,0.000031603355,0.0000039269185,0.000002645286,0.000028678569,0.0012038363,0.0017300207,0.047326047,0.9422706,0.00016616026],"about_ca_topic_score_codex":0.00075941975,"about_ca_topic_score_gemma":0.000009610133,"teacher_disagreement_score":0.9480494,"about_ca_system_score_codex":0.00012184091,"about_ca_system_score_gemma":0.000100714184,"threshold_uncertainty_score":0.31140682},"labels":[],"label_agreement":null},{"id":"W2121918894","doi":"10.1071/ah11153","title":"The affordability of prescription medicines in Australia: are copayments and safety net thresholds too high?","year":2012,"lang":"en","type":"article","venue":"Australian Health Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences","funders":"Hunter Medical Research Institute","keywords":"Medical prescription; Medicine; Pharmaceutical Benefits Scheme; Health economics; Family medicine; Environmental health; Population health; Public health; Population; Nursing","score_opus":0.1618427688143668,"score_gpt":0.3890418043736473,"score_spread":0.22719903555928053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121918894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49811554,0.35950795,0.000011315864,0.13649921,0.0013008076,0.0024662348,0.00061161857,0.000022678358,0.0014646614],"genre_scores_gemma":[0.7785522,0.21639398,0.0000493815,0.0044245874,0.00010221767,0.000038514157,0.00001579959,0.000009769002,0.0004135726],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978749,0.00007400447,0.0012826547,0.00022367267,0.0000367274,0.00050800084],"domain_scores_gemma":[0.9986996,0.00008897026,0.0006090273,0.00032449135,0.00001611191,0.00026180607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002711804,0.00014958308,0.000676581,0.000052372037,0.00008677419,0.000015380145,0.00017054674,0.00006915184,0.00020226587],"category_scores_gemma":[0.00012745424,0.00012278692,0.00006691989,0.00017471892,0.00012725075,0.00021272304,0.000047993173,0.0002054502,0.00006063825],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035648354,0.00015801584,0.7982233,0.0059033474,0.000037182795,4.7624818e-7,0.0002032522,0.0000034444215,0.0000013331065,0.12778409,0.05835333,0.009296571],"study_design_scores_gemma":[0.00035448011,0.00004641798,0.51823455,0.00055175985,0.000007353315,0.0000034476816,0.00001596027,0.000009181082,0.0000044693834,0.004177692,0.4764819,0.00011277872],"about_ca_topic_score_codex":0.0013905049,"about_ca_topic_score_gemma":0.0001656885,"teacher_disagreement_score":0.41812858,"about_ca_system_score_codex":0.0001489157,"about_ca_system_score_gemma":0.000024439807,"threshold_uncertainty_score":0.5007105},"labels":[],"label_agreement":null},{"id":"W2121948404","doi":"10.1345/aph.1d110","title":"Canadian and US Drug Approval Times and Safety Considerations","year":2003,"lang":"en","type":"article","venue":"Annals of Pharmacotherapy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Drug approval; Drug; Family medicine; Pharmacology","score_opus":0.08089578326775908,"score_gpt":0.3286247004778745,"score_spread":0.24772891721011542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121948404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7957948,0.01561703,0.000039294606,0.026610358,0.00025295012,0.00035906665,0.0007306478,0.000020506888,0.16057537],"genre_scores_gemma":[0.97157156,0.010228221,0.00026254865,0.01718409,0.000044794946,0.0000072977255,0.0000033418078,0.000017007984,0.0006811256],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99914134,0.000022829608,0.00035271636,0.00021720001,0.000013342128,0.00025260577],"domain_scores_gemma":[0.9994072,0.00007304994,0.00011180079,0.00010459282,0.000023619314,0.0002797669],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004207196,0.000113767695,0.00025587814,0.00016520017,0.000111609086,0.00004560875,0.00005058262,0.000041153668,0.0018024882],"category_scores_gemma":[0.00003141498,0.00013491936,0.00004679419,0.0000652543,0.00009106835,0.00013843544,0.000008118231,0.00008979729,0.00003696812],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020962694,0.000047749014,0.016613334,0.00002370351,0.00014889901,0.0000025487232,0.00053055445,0.00003111012,0.0007496635,0.9545089,0.02576357,0.0015589923],"study_design_scores_gemma":[0.0009955106,0.000025660362,0.0025566309,0.0000045871116,0.0000048107795,0.000011420482,0.000018318313,0.0011024954,0.010664672,0.13831364,0.84606004,0.00024220573],"about_ca_topic_score_codex":0.006996005,"about_ca_topic_score_gemma":0.0015961729,"teacher_disagreement_score":0.82029647,"about_ca_system_score_codex":0.000015970645,"about_ca_system_score_gemma":0.00006367524,"threshold_uncertainty_score":0.9996165},"labels":[],"label_agreement":null},{"id":"W2122150879","doi":"10.1002/jps.22300","title":"Increasing Access to Essential Medicines: Diversifying Canada's Approach","year":2010,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Sciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Access to medicines; Intellectual property; Essential medicines; Legislation; Business; Developing country; International trade; TRIPS Agreement; Medicine; Political science; Economic growth; Law; Health care; Economics","score_opus":0.10628549659776387,"score_gpt":0.3686975397853304,"score_spread":0.2624120431875665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122150879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93396324,0.0003800265,0.0013797397,0.020848265,0.0026381519,0.00013128706,0.000034691286,0.000008336215,0.040616266],"genre_scores_gemma":[0.9885143,0.0000851187,0.002044054,0.008437365,0.0008902041,0.0000014493872,4.5719418e-7,0.000008131222,0.000018907962],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983679,0.000027746959,0.00074569223,0.00025950954,0.00015405391,0.00044510642],"domain_scores_gemma":[0.99854124,0.0002181722,0.00038265024,0.00010398697,0.00006440734,0.00068952155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024432056,0.00013619302,0.00038084513,0.00027865721,0.0002440139,0.00025140468,0.0010640211,0.000057613866,0.00075115653],"category_scores_gemma":[0.0006327433,0.000120425095,0.00010088452,0.00047872154,0.0002558363,0.0005635269,0.00020847023,0.00052831345,0.00002722434],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005502579,0.0008829427,0.56213313,0.00024045748,0.00043855945,0.00016133291,0.0013916946,0.0034617025,0.021917513,0.3052625,0.07724995,0.026309952],"study_design_scores_gemma":[0.0021800585,0.00019283053,0.031913705,0.00004886857,0.000067101195,0.00050464674,0.0002784295,0.033604674,0.0051760934,0.014306883,0.91089445,0.00083226844],"about_ca_topic_score_codex":0.017099084,"about_ca_topic_score_gemma":0.004385946,"teacher_disagreement_score":0.8336445,"about_ca_system_score_codex":0.000107127154,"about_ca_system_score_gemma":0.00033850066,"threshold_uncertainty_score":0.98944616},"labels":[],"label_agreement":null},{"id":"W2122650459","doi":"10.1503/cmaj.081913","title":"Long-term trends in use of and expenditures for cardiovascular medications in Canada","year":2009,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Université Laval; Health Sciences Centre; University of British Columbia; McGill University Health Centre; Sunnybrook Health Science Centre; Statistics Canada; University of Ottawa; University of Toronto; Dalhousie University","funders":"Department of Family and Community Medicine, University of Toronto; Health Canada; Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval; University of Toronto; Dalhousie University; Western University of Health Sciences; Toronto Rehabilitation Institute; Department of Medicine, University of Toronto; University of Ottawa; McGill University Health Centre; Institute for Clinical Evaluative Sciences; McGill University; Jewish General Hospital; University of Alberta; Université Laval","keywords":"Medicine; Medical prescription; Population; Health care; Prescription drug; Drug class; Demographics; Environmental health; Demography; Drug; Economic growth; Pharmacology; Economics","score_opus":0.03664679675875496,"score_gpt":0.26689873036555134,"score_spread":0.23025193360679638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122650459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92638403,0.005861501,0.00018284128,0.06459087,0.0005075527,0.00015948131,0.00045367976,0.0000027286942,0.0018572862],"genre_scores_gemma":[0.9929167,0.00087601395,0.0000485414,0.0059037115,0.00019829442,0.0000047522167,0.000012749832,0.0000050276444,0.000034202487],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989288,0.000022308748,0.0005579298,0.0001210121,0.00008556853,0.00028439838],"domain_scores_gemma":[0.99908084,0.000105686195,0.00017233536,0.00007375339,0.00002317924,0.0005442008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089257443,0.00006472804,0.00030218693,0.00038980573,0.000040030653,0.000028897946,0.000113737966,0.00012035819,0.00040390453],"category_scores_gemma":[0.00038115465,0.00007660603,0.00009417751,0.00012406422,0.000013476479,0.00011363321,0.000004921446,0.00027160748,0.000002051858],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000005726571,0.000027503325,0.87964326,0.00000755788,0.00015958158,0.00005257753,0.00018427,0.00016956523,3.6433136e-7,0.013313084,0.019501401,0.08693509],"study_design_scores_gemma":[0.00084813463,0.000012169838,0.853522,0.000015306396,0.0000062640443,0.000011125172,0.000018270823,0.001619635,0.0000014156084,0.002046069,0.14180523,0.000094358256],"about_ca_topic_score_codex":0.53910494,"about_ca_topic_score_gemma":0.97212124,"teacher_disagreement_score":0.43301627,"about_ca_system_score_codex":0.0013324802,"about_ca_system_score_gemma":0.0010660272,"threshold_uncertainty_score":0.4639642},"labels":[],"label_agreement":null},{"id":"W2124890015","doi":"10.1016/s0149-2918(03)80080-2","title":"Timeliness of review and approval of new drugs in Canada from 1999 through 2001: Is progress being made?","year":2003,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Health Canada","keywords":"Medicine; European union; Agency (philosophy); Drug approval; Family medicine; International trade; Drug; Business; Pharmacology","score_opus":0.1803435469890641,"score_gpt":0.38183239178521533,"score_spread":0.20148884479615123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124890015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7914912,0.1870734,0.00019889287,0.008586602,0.00061681005,0.00063815503,0.00052277127,0.000009652995,0.010862529],"genre_scores_gemma":[0.88058525,0.097553864,0.0032831596,0.018187325,0.00011810451,0.000007844943,0.0000114689665,0.00003478904,0.00021820578],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99775165,0.000046964313,0.0015910737,0.00031927926,0.0000343326,0.0002566964],"domain_scores_gemma":[0.99873954,0.00029120332,0.0005230778,0.00029983246,0.000026329199,0.0001200074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069903955,0.00014743261,0.00091674237,0.000033392036,0.000016053902,0.000009106845,0.00021510111,0.00010852307,0.00034808353],"category_scores_gemma":[0.000095841395,0.00015686233,0.00011039735,0.00017473237,0.00013291491,0.00007095188,0.000047159487,0.00024308193,0.000011331871],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007758935,0.00047592015,0.8287239,0.0008628035,0.00059891504,0.000002836274,0.0009558712,0.000015374988,0.0000075927296,0.09647108,0.007618804,0.06418928],"study_design_scores_gemma":[0.0032284425,0.00012169344,0.034237586,0.0004246807,0.0001722513,0.0000020969965,0.00008896679,0.0039552376,0.00057017035,0.20914198,0.74737567,0.0006811948],"about_ca_topic_score_codex":0.0831066,"about_ca_topic_score_gemma":0.007247969,"teacher_disagreement_score":0.79448634,"about_ca_system_score_codex":0.00006723367,"about_ca_system_score_gemma":0.00037032686,"threshold_uncertainty_score":0.9229991},"labels":[],"label_agreement":null},{"id":"W2127520342","doi":"10.1016/s0140-6736(02)11527-3","title":"The pharmaceutical industry as a medicines provider","year":2002,"lang":"en","type":"review","venue":"The Lancet","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":167,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University; University of Toronto","funders":"","keywords":"Business; Intellectual property; Developing country; Drug prices; Essential drugs; Production (economics); Pharmaceutical industry; Essential medicines; International trade; Developed country; Access to medicines; Marginal cost; Industrial organization; Public economics; Commerce; Health care; Economic growth; Economics; Environmental health; Medicine; Health services; Pharmacology","score_opus":0.2876269035881042,"score_gpt":0.41387446557552665,"score_spread":0.12624756198742243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127520342","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000004145736,0.8614521,0.0000023285284,0.023455942,0.00083853456,0.00054545474,0.0002364005,0.000042726268,0.11342239],"genre_scores_gemma":[0.0000423036,0.9804286,0.000008311551,0.009170808,0.004932548,0.00018042124,0.000013059367,0.00006423602,0.0051597487],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99766695,0.00009137471,0.0010227906,0.00044131608,0.00004969405,0.0007278493],"domain_scores_gemma":[0.9975477,0.00068359677,0.00055689673,0.0010070292,0.000014202248,0.0001905977],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0013095516,0.00039252645,0.001974614,0.00008237848,0.00031891267,0.00024206072,0.0015476242,0.00047855367,0.0014708352],"category_scores_gemma":[0.00036530328,0.00022165145,0.0004088784,0.00026734907,0.00032856496,0.00007256273,0.00023805772,0.0020721059,0.0071630566],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007979101,0.000028362183,0.000020014044,0.0012517502,0.00029668148,0.0000065281997,0.00007071264,7.6328394e-7,6.238762e-9,0.20247766,0.2546573,0.5411823],"study_design_scores_gemma":[0.00034044465,0.000016285521,0.0000035600744,0.00041380883,0.00011398913,0.000048687398,0.0000063430552,0.00027687967,1.1874883e-7,0.01587341,0.98261815,0.00028834658],"about_ca_topic_score_codex":0.000031268464,"about_ca_topic_score_gemma":0.00000450601,"teacher_disagreement_score":0.7279608,"about_ca_system_score_codex":0.00012779568,"about_ca_system_score_gemma":0.000076756696,"threshold_uncertainty_score":0.999442},"labels":[],"label_agreement":null},{"id":"W2128772904","doi":"10.1371/journal.pone.0039737","title":"Potential Savings of Harmonising Hospital and Community Formularies for Chronic Disease Medications Initiated in Hospital","year":2012,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; Institute for Clinical Evaluative Sciences; Women's College Hospital; University of Toronto","funders":"Institute of Nutrition, Metabolism and Diabetes; Canadian Institutes of Health Research; Ontario Ministry of Health and Long-Term Care; Institute for Clinical Evaluative Sciences","keywords":"Formulary; Medicine; Medical prescription; Emergency medicine; Pharmacology","score_opus":0.10075004349833491,"score_gpt":0.2830804431393995,"score_spread":0.1823303996410646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128772904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933762,0.0025442308,0.0002761079,0.0024585777,0.00007047683,0.0003358075,0.000515476,0.000012486214,0.0004106137],"genre_scores_gemma":[0.99858683,0.000525584,0.0004785511,0.00015254309,0.00011181297,0.000053396485,0.00006273305,0.000016036853,0.000012509974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991921,0.000016673377,0.00038729623,0.00011101985,0.000021959017,0.0002709318],"domain_scores_gemma":[0.99934405,0.00010489148,0.0001831084,0.00017372389,0.000022916029,0.00017128461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040763614,0.00009045985,0.00027121406,0.000120256496,0.0001348245,0.000028569615,0.00012801251,0.00005393275,0.00006157621],"category_scores_gemma":[0.00023115914,0.00011439862,0.000050616374,0.000068933,0.00012371276,0.00034730745,0.000084949235,0.0001960978,0.00001711678],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010828819,0.014157614,0.7217914,0.0011484665,0.0007367482,0.0000011779805,0.0075361812,0.00001661952,0.00089324184,0.25224653,0.00039226928,0.00097148155],"study_design_scores_gemma":[0.0038522582,0.0006309079,0.87669975,0.00019003697,0.00019410255,5.537608e-7,0.00025941478,0.020181367,0.0029034389,0.092745185,0.001617004,0.00072599197],"about_ca_topic_score_codex":0.00015527007,"about_ca_topic_score_gemma":0.000010519262,"teacher_disagreement_score":0.15950136,"about_ca_system_score_codex":0.0000812879,"about_ca_system_score_gemma":0.000030446223,"threshold_uncertainty_score":0.46650404},"labels":[],"label_agreement":null},{"id":"W2129720637","doi":"10.1126/scitranslmed.3002678","title":"Leveraging Crowdsourcing to Facilitate the Discovery of New Medicines","year":2011,"lang":"en","type":"article","venue":"Science Translational Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Structural Genomics Consortium; University of Toronto","funders":"","keywords":"Crowdsourcing; Data science; Drug discovery; Medicine; Computer science; Computational biology; Bioinformatics; Biology; World Wide Web","score_opus":0.27718716008632155,"score_gpt":0.32208033763943295,"score_spread":0.044893177553111396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129720637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.63512945,0.0019542428,0.07236557,0.09451994,0.0013143048,0.00046568763,0.0000736087,0.000030208326,0.19414699],"genre_scores_gemma":[0.99540305,0.00003128228,0.00075178687,0.0030837962,0.00018639794,0.0000036073843,0.000001428431,0.00000571682,0.00053291325],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.998902,0.000005785946,0.00049507787,0.000261507,0.00009296334,0.00024265781],"domain_scores_gemma":[0.99939215,0.00009774776,0.00011392583,0.0001965092,0.000032739306,0.00016691111],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013067424,0.00009212241,0.0002264364,0.00025725667,0.00012540132,0.000013929407,0.00042034496,0.000015271335,0.00054308353],"category_scores_gemma":[0.00020282103,0.00006679041,0.00004275531,0.0005544788,0.00061307003,0.00032986572,0.000026308086,0.00008981761,0.0000717751],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007565181,0.000047569494,0.049101293,0.000036888065,0.000040374216,0.000001498731,0.07436169,0.0006596601,0.0036812006,0.8601153,0.0032946765,0.008584234],"study_design_scores_gemma":[0.0015699961,0.00020575593,0.39628667,0.00012078502,0.00002063322,0.000009683278,0.0010200968,0.005917097,0.0023165566,0.5360491,0.056109946,0.00037364362],"about_ca_topic_score_codex":0.0010392125,"about_ca_topic_score_gemma":0.000023941238,"teacher_disagreement_score":0.36027363,"about_ca_system_score_codex":0.000023978819,"about_ca_system_score_gemma":0.00009165318,"threshold_uncertainty_score":0.5946384},"labels":[],"label_agreement":null},{"id":"W2130342117","doi":"10.1345/aph.1h117","title":"Relationship Between Pharmaceutical Company User Fees and Drug Approvals in Canada and Australia: A Hypothesis-Generating Study","year":2006,"lang":"en","type":"article","venue":"Annals of Pharmacotherapy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University; University of Toronto; University Health Network","funders":"","keywords":"Revenue; Government (linguistics); Workload; Pharmaceutical industry; Medicine; Public economics; Business; Accounting; Economics; Pharmacology; Management","score_opus":0.27145347124165425,"score_gpt":0.3802026077202118,"score_spread":0.10874913647855755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130342117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949605,0.002001582,0.000010620394,0.001985606,0.00006732711,0.0003634321,0.0002014549,0.000009513815,0.00039995546],"genre_scores_gemma":[0.99782014,0.00027774883,0.00016016682,0.0013428445,0.00016490958,0.000023657061,0.0000046247774,0.000025511501,0.00018039427],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99829346,0.00007606291,0.00084914,0.0003690052,0.000049137427,0.0003632056],"domain_scores_gemma":[0.9989879,0.00044714732,0.00025780752,0.00013294151,0.000021004309,0.00015320365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007810666,0.00019967424,0.00052442675,0.00019211209,0.00007625501,0.00005170872,0.00014832945,0.00004315332,0.00013046086],"category_scores_gemma":[0.000031375755,0.00023014969,0.000047818165,0.00017826792,0.000074345546,0.00018402499,0.000035750003,0.00022482063,0.000008112577],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027190048,0.00012582603,0.99090284,0.000031513464,0.00005392718,0.0000031519528,0.00021301553,0.00014980808,0.0005250531,0.00550286,0.0016711307,0.0007936709],"study_design_scores_gemma":[0.002062956,0.00003476396,0.97471356,0.000009318594,0.000013731058,0.0000016657303,0.00007638296,0.0014473146,0.006129023,0.00739971,0.007784158,0.00032739365],"about_ca_topic_score_codex":0.4476303,"about_ca_topic_score_gemma":0.14206907,"teacher_disagreement_score":0.3055612,"about_ca_system_score_codex":0.000055444285,"about_ca_system_score_gemma":0.00006193313,"threshold_uncertainty_score":0.9385232},"labels":[],"label_agreement":null},{"id":"W2130482828","doi":"10.1186/1744-8603-10-53","title":"Innovation in regulation of rapidly changing health markets","year":2014,"lang":"en","type":"article","venue":"Globalization and Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"Economic and Social Research Council","keywords":"Context (archaeology); Goods and services; Business; Public economics; Health services research; Health care; Accountability; Health policy; Quality (philosophy); Social policy; Industrial organization; Economics; Economic growth; Market economy; Political science","score_opus":0.06476299931814562,"score_gpt":0.3320488705674759,"score_spread":0.2672858712493303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130482828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.53241265,0.005965465,0.21868305,0.13525619,0.0011897391,0.0016471664,0.0003327205,0.00010467771,0.10440833],"genre_scores_gemma":[0.9887623,0.0007204623,0.00045378614,0.009886701,0.000047898135,0.0000032141604,0.000061629944,0.0000065843565,0.000057415724],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9986656,0.000037769314,0.00090191886,0.00017379588,0.00002030439,0.0002006214],"domain_scores_gemma":[0.9992063,0.000013187348,0.00059237453,0.00010509143,0.000022089373,0.00006093843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002503062,0.000063893756,0.00027810317,0.0004269177,0.00005881123,0.000017410122,0.00004416498,0.00003891665,0.00008226182],"category_scores_gemma":[0.00006446865,0.00007958503,0.000016095608,0.00059443957,0.000017996586,0.000097178905,0.000014097372,0.00004272726,0.000013399738],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000005458119,0.000019929415,0.04008136,0.00008345205,0.0000022703227,8.335144e-9,0.00033254223,0.000077961755,0.0000021844187,0.9439216,0.0012331002,0.0142400805],"study_design_scores_gemma":[0.000978165,0.00007363228,0.6960505,0.0000486775,4.5323705e-7,0.0000011190778,0.000038376544,0.073909074,0.000015917305,0.11424065,0.11451308,0.00013034137],"about_ca_topic_score_codex":0.000236314,"about_ca_topic_score_gemma":0.000055843702,"teacher_disagreement_score":0.82968104,"about_ca_system_score_codex":0.00012514807,"about_ca_system_score_gemma":0.00004091441,"threshold_uncertainty_score":0.32453832},"labels":[],"label_agreement":null},{"id":"W2130616861","doi":"10.2471/blt.12.109827","title":"Assessing implementation mechanisms for an international agreement on research and development for health products","year":2012,"lang":"en","type":"article","venue":"Bulletin of the World Health Organization","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Unanimity; Delegation; Voting; Business; Compliance (psychology); Public relations; Politics; Law and economics; Public economics; Political science; Economics; Law","score_opus":0.2516505935752133,"score_gpt":0.4590684949775408,"score_spread":0.20741790140232752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130616861","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13312227,0.0008047649,0.047404014,0.804106,0.0037993079,0.007806955,0.00050294935,0.000054056978,0.0023996842],"genre_scores_gemma":[0.9629446,0.000099587225,0.026509564,0.009325048,0.00033294916,0.000085587475,0.00017614987,0.00003244268,0.00049405824],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988938,0.00003746828,0.0005157012,0.00019955779,0.000048892543,0.0003045577],"domain_scores_gemma":[0.9991645,0.000083196566,0.00040028617,0.00013531958,0.000115852745,0.00010083663],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028254355,0.00006976093,0.000154083,0.00016157076,0.00038310775,0.000056395853,0.0001397556,0.000020264493,0.00016590743],"category_scores_gemma":[0.00014600594,0.00006953541,0.000012134453,0.00014109684,0.000019766378,0.000089693836,0.000057958812,0.00006424535,0.0000190286],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032498414,0.00029189407,0.009464945,0.00028925674,0.00002964343,3.3969803e-9,0.001548092,0.000023803323,0.000054636475,0.9351032,0.041124042,0.012038031],"study_design_scores_gemma":[0.00083076576,0.00018945304,0.03897468,0.000032729415,0.0000012578568,4.4553525e-7,0.00018712634,0.00013182563,0.0040552607,0.0078983335,0.94758636,0.000111745525],"about_ca_topic_score_codex":0.00008055281,"about_ca_topic_score_gemma":0.00005578632,"teacher_disagreement_score":0.92720485,"about_ca_system_score_codex":0.00040098542,"about_ca_system_score_gemma":0.00013405833,"threshold_uncertainty_score":0.29465938},"labels":[],"label_agreement":null},{"id":"W2132811452","doi":"10.1002/chir.20520","title":"A consideration of the patentability of enantiomers in the pharmaceutical industry in the United States","year":2008,"lang":"en","type":"review","venue":"Chirality","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Chemistry; Patentability; Enantiomer; Pharmaceutical industry; Nanotechnology; Pharmacology; Stereochemistry; Law; Patent law; Intellectual property","score_opus":0.30351961201780536,"score_gpt":0.40379211505860124,"score_spread":0.10027250304079588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132811452","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17942181,0.81064934,0.000004006921,0.0032227733,0.000293312,0.0017767356,0.0013856582,0.00000608852,0.003240304],"genre_scores_gemma":[0.18499048,0.8133963,0.0000036853976,0.0014334307,0.000038888862,0.000052447078,0.00006800072,0.000010892998,0.0000058914457],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972113,0.0005412036,0.0016262587,0.00029755785,0.00005832411,0.00026538037],"domain_scores_gemma":[0.99791247,0.00065122097,0.00077383476,0.00060660625,0.000020085246,0.000035784647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002158795,0.00022772334,0.001054516,0.00020627854,0.000061971616,0.000026762915,0.0007246881,0.00041066084,0.0000808195],"category_scores_gemma":[0.00030467898,0.00012871406,0.00038281735,0.00091920816,0.0004613012,0.000066590736,0.00009600537,0.0015370122,0.000011303531],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012658784,0.0049954215,0.25118005,0.02628478,0.000838702,0.00002665346,0.0210538,0.0006605772,0.0000012224473,0.5087687,0.006826245,0.17923728],"study_design_scores_gemma":[0.0005231015,0.000021859634,0.01789028,0.00040765954,0.00004807039,0.00001521119,0.00016348675,0.0005263154,0.00000558313,0.012468935,0.96768737,0.00024211292],"about_ca_topic_score_codex":0.0012784427,"about_ca_topic_score_gemma":0.000090459864,"teacher_disagreement_score":0.96086115,"about_ca_system_score_codex":0.000114471826,"about_ca_system_score_gemma":0.00011997987,"threshold_uncertainty_score":0.6677638},"labels":[],"label_agreement":null},{"id":"W2133193005","doi":"10.1111/fcp.12155","title":"Generic medicines: issues and relevance for global health","year":2015,"lang":"en","type":"review","venue":"Fundamental and Clinical Pharmacology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Product (mathematics); Quality (philosophy); Biosimilar; European union; Sustainability; Cornerstone; Generic drug; International trade; Marketing; Medicine; Pharmacology; Drug","score_opus":0.31138506214660017,"score_gpt":0.5373507876161616,"score_spread":0.22596572546956145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133193005","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000083261446,0.98753154,0.000035471367,0.004941449,0.0033179796,0.0010176729,0.0018358382,0.000029071567,0.001207707],"genre_scores_gemma":[0.000037862097,0.9825211,0.0003017501,0.014244274,0.0021796909,0.00013334499,0.00012803209,0.000036835423,0.00041706747],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966511,0.00010185948,0.001868602,0.00083644316,0.000026744907,0.000515225],"domain_scores_gemma":[0.9977678,0.0005291273,0.00086871214,0.0001583931,0.00002032158,0.0006556496],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013905782,0.00038475113,0.0028314912,0.00007440504,0.00011729665,0.000045939767,0.00024321205,0.00033918605,0.00018482284],"category_scores_gemma":[0.00012745257,0.0003651356,0.00033066332,0.000119855475,0.0004154406,0.00008092213,0.00023703225,0.00036831177,0.00015820347],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037778853,0.00015425296,0.00024275518,0.002539033,0.00042377503,0.0000029082207,0.000018105522,1.2906007e-7,1.3259672e-8,0.012331211,0.14189258,0.84235746],"study_design_scores_gemma":[0.0014322071,0.0005290866,0.000032102216,0.00016756446,0.00020715207,0.000029734778,0.000007442494,0.00018652859,2.1004032e-8,0.01577234,0.9813091,0.0003266853],"about_ca_topic_score_codex":0.000055780274,"about_ca_topic_score_gemma":0.000011864581,"teacher_disagreement_score":0.84203076,"about_ca_system_score_codex":0.00025673347,"about_ca_system_score_gemma":0.00020310412,"threshold_uncertainty_score":0.9998801},"labels":[],"label_agreement":null},{"id":"W2134418108","doi":"10.1503/cmaj.081429","title":"Policy alternatives for treatments for rare diseases","year":2010,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Bench to bedside; Medicine; Intensive care medicine; Drug industry; Risk analysis (engineering); Computer science; Drug approval; Business; Pharmacology; Engineering ethics; Medical physics; Drug; Engineering","score_opus":0.028035951907171727,"score_gpt":0.3042755118506796,"score_spread":0.27623955994350785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134418108","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.37539044,0.001145453,0.0036135467,0.5465458,0.0097691,0.0015760256,0.020014519,0.000060154398,0.04188498],"genre_scores_gemma":[0.9285444,0.00047786842,0.00087373407,0.05390101,0.012321105,0.00016626417,0.00011236672,0.000057374717,0.003545902],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988706,0.000009612285,0.0004314247,0.00016364722,0.00006084052,0.0004638865],"domain_scores_gemma":[0.99790525,0.00022220632,0.00028212983,0.00007907123,0.00009317871,0.0014181609],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005892514,0.0001003386,0.00023977378,0.00024703925,0.00026083164,0.00013374766,0.00023099834,0.00019470899,0.0014634874],"category_scores_gemma":[0.002781789,0.00010886564,0.00019284466,0.000077544486,0.000027968825,0.00014393887,0.000008842409,0.00028856235,0.0001327546],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028884217,0.000120457116,0.12837337,0.000018598272,0.00062290573,0.000012696042,0.00030388348,0.0000062796366,0.000009918107,0.6009016,0.22360425,0.045997135],"study_design_scores_gemma":[0.0015268594,0.00003894284,0.01356414,0.000004226642,0.000012080455,0.000012068453,0.00001580343,0.0018499218,0.000010092416,0.107427984,0.87540233,0.00013553882],"about_ca_topic_score_codex":0.0008938181,"about_ca_topic_score_gemma":0.004718461,"teacher_disagreement_score":0.65179807,"about_ca_system_score_codex":0.0005361769,"about_ca_system_score_gemma":0.000913452,"threshold_uncertainty_score":0.9994493},"labels":[],"label_agreement":null},{"id":"W2134825292","doi":"10.4000/quaderni.262","title":"Orphan Drugs, Patient Activism and Contemporary Healthcare","year":2009,"lang":"en","type":"article","venue":"Quaderni","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Carleton University","funders":"","keywords":"Humanities; Political science; Orphan drug; Philosophy","score_opus":0.07357785694484663,"score_gpt":0.29333490683515,"score_spread":0.21975704989030337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134825292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8162538,0.010487611,0.00011513723,0.050587673,0.000346765,0.00031845944,0.000230449,0.000081304344,0.121578805],"genre_scores_gemma":[0.98416495,0.00036787675,0.000083983716,0.015008248,0.00011604008,0.0000068604086,0.000011007921,0.000014091185,0.0002269562],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.998984,0.00001359235,0.00040106932,0.00031600575,0.000019165058,0.00026620756],"domain_scores_gemma":[0.99937403,0.000031439995,0.00017536794,0.00019359487,0.000009747441,0.00021583008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016163963,0.00013399703,0.00029336536,0.00010518067,0.00008532993,0.000059459657,0.000101405225,0.000082892526,0.00017073113],"category_scores_gemma":[0.000020596875,0.00015548433,0.00006019783,0.00006710724,0.000038358547,0.000174861,0.000029501836,0.00016507329,0.00044107568],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000812566,0.00026494145,0.014643437,0.00005962623,0.00006671117,0.000014457531,0.004861422,0.0000070276405,0.00007230035,0.854167,0.01989942,0.10586244],"study_design_scores_gemma":[0.0008873547,0.00032497811,0.016320188,0.000017298455,0.0000026519085,0.000008330745,0.00017678639,0.00158575,0.00034532533,0.15649347,0.8233783,0.0004595254],"about_ca_topic_score_codex":0.00019452658,"about_ca_topic_score_gemma":0.000003458198,"teacher_disagreement_score":0.80347896,"about_ca_system_score_codex":0.00005755914,"about_ca_system_score_gemma":0.000024307123,"threshold_uncertainty_score":0.63404673},"labels":[],"label_agreement":null},{"id":"W2134917281","doi":"","title":"Multimarket Contact in Pharmaceutical Markets","year":2007,"lang":"en","type":"preprint","venue":"RECERCAT (Consorci de Serveis Universitaris de Catalunya)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Universidad Carlos III de Madrid; Ministerio de Ciencia y Tecnología; Merck Company Foundation","keywords":"Market power; Economics; Industrial organization; Contrast (vision); Microeconomics; Business; International economics","score_opus":0.06695236867343733,"score_gpt":0.3045806709896152,"score_spread":0.23762830231617788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134917281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73436844,0.007870099,0.001026034,0.0049551902,0.0012951301,0.0011720469,0.002884249,0.0002077583,0.24622102],"genre_scores_gemma":[0.983693,0.008043034,0.0018200057,0.0037441063,0.00032295208,0.000028881193,0.00044801424,0.00014285103,0.0017571443],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952906,0.00018174261,0.0013249489,0.0014426471,0.00009304075,0.0016670455],"domain_scores_gemma":[0.99685156,0.0005039634,0.00061100465,0.0010291688,0.00007899587,0.0009253146],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0030813622,0.00075145136,0.0013893385,0.0017992487,0.00015665908,0.0002047539,0.0014311238,0.0013341176,0.004496109],"category_scores_gemma":[0.00030534828,0.0010957271,0.00060934963,0.0006202609,0.00021308925,0.00037740005,0.0012301449,0.0026374313,0.00090919423],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030246412,0.0020374777,0.6723402,0.0022695148,0.0022655153,0.0018944754,0.0049187443,0.0038484752,0.00023889646,0.24077995,0.04789745,0.018484663],"study_design_scores_gemma":[0.0063606794,0.00009719832,0.15711342,0.00035886356,0.00019415206,0.00011015782,0.000440046,0.095549114,0.00080208405,0.040399633,0.6955693,0.0030053577],"about_ca_topic_score_codex":0.0034279213,"about_ca_topic_score_gemma":0.0004224703,"teacher_disagreement_score":0.6476718,"about_ca_system_score_codex":0.0044936286,"about_ca_system_score_gemma":0.0005240362,"threshold_uncertainty_score":0.9999624},"labels":[],"label_agreement":null},{"id":"W2135561239","doi":"10.1136/bmjopen-2014-006235","title":"How innovative are new drugs launched in the UK? A retrospective study of new drugs listed in the British National Formulary (BNF) 2001–2012","year":2014,"lang":"en","type":"article","venue":"BMJ Open","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute for Health and Care Research","keywords":"Formulary; Medicine; Observational study; Family medicine; Quarter (Canadian coin); Drug; Pharmacology; Internal medicine","score_opus":0.15231994535985727,"score_gpt":0.37573199912965044,"score_spread":0.22341205376979317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135561239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8652378,0.0001602387,0.00006158748,0.021592228,0.00015090186,0.0053465054,0.00020100678,0.0000072124253,0.10724253],"genre_scores_gemma":[0.99116963,0.000023978537,0.00008910385,0.006102289,0.00024699638,0.000248732,0.000022850867,0.000016759033,0.0020796375],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984049,0.00011537997,0.0006952662,0.0003635539,0.00010934043,0.00031156742],"domain_scores_gemma":[0.9987364,0.00019536882,0.0005558463,0.00037093385,0.00007599731,0.00006547296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034212694,0.00015615846,0.0005189322,0.00016981784,0.00011090764,0.00065727497,0.001156776,0.0000830598,0.00019245672],"category_scores_gemma":[0.0005560404,0.00014223135,0.00005434536,0.00082790584,0.000043754393,0.00049550587,0.00027071673,0.0003427783,0.000046821384],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002825939,0.0013381597,0.39784563,0.00004407304,0.00019269953,0.000012286442,0.048827987,0.000105346815,0.0000051368547,0.29255268,0.25096446,0.007828942],"study_design_scores_gemma":[0.0048623392,0.00019214553,0.8375415,0.000047619866,0.0000057945895,0.000006076332,0.0038202736,0.0012434747,0.00000550553,0.1036567,0.04830253,0.0003160031],"about_ca_topic_score_codex":0.014852194,"about_ca_topic_score_gemma":0.013361344,"teacher_disagreement_score":0.4396959,"about_ca_system_score_codex":0.00018146056,"about_ca_system_score_gemma":0.00017788183,"threshold_uncertainty_score":0.991708},"labels":[],"label_agreement":null},{"id":"W2135643683","doi":"10.1093/heapol/czh021","title":"Interactions between patent medicine vendors and customers in urban and rural Nigeria","year":2004,"lang":"en","type":"article","venue":"Health Policy and Planning","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":179,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Rockefeller Foundation; United States Agency for International Development","keywords":"Medical prescription; Quarter (Canadian coin); Business; Payment; Medicine; Position (finance); Marketing; Family medicine; Advertising; Nursing; History","score_opus":0.15448731554912754,"score_gpt":0.3877181498090497,"score_spread":0.23323083425992214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135643683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9626251,0.0039236275,0.000026653504,0.028585026,0.00013850718,0.00014113182,0.0001309543,0.000013955504,0.0044150595],"genre_scores_gemma":[0.9922407,0.0015382649,0.00004330538,0.00568547,0.00042727587,0.0000075921066,0.000017189946,0.00001049951,0.000029698918],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99900216,0.000015637957,0.00044433927,0.0001936057,0.000012891424,0.0003313448],"domain_scores_gemma":[0.99938834,0.000106581734,0.00014847786,0.00007034961,0.0000040110267,0.00028224295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036236568,0.00011339069,0.0003480427,0.0003678186,0.00013528929,0.000027002248,0.000040047653,0.000049004495,0.000014788683],"category_scores_gemma":[0.00006614575,0.00012326833,0.000014649043,0.00012677096,0.0000908175,0.00012501434,0.000037364312,0.00021128738,0.000010573941],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036002875,0.000025935955,0.77826035,0.00020073798,0.000040126295,0.0000065713457,0.019615073,0.00015285268,0.000006117175,0.19403148,0.00097109284,0.006653674],"study_design_scores_gemma":[0.0030121638,0.00021461002,0.7753092,0.00028834032,0.0000049413065,0.000029047626,0.0009475666,0.00070927036,0.0000052737428,0.048907626,0.17021199,0.00035998374],"about_ca_topic_score_codex":0.006218251,"about_ca_topic_score_gemma":0.00008872583,"teacher_disagreement_score":0.16924089,"about_ca_system_score_codex":0.00011447814,"about_ca_system_score_gemma":0.000039548726,"threshold_uncertainty_score":0.94001764},"labels":[],"label_agreement":null},{"id":"W2136610976","doi":"10.1177/097206340801000303","title":"A Status Report on the Health Care Sector in France","year":2008,"lang":"en","type":"article","venue":"Journal of Health Management","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Government (linguistics); Order (exchange); Pharmaceutical industry; TRIPS architecture; Gross domestic product; Product (mathematics); Business; Health care; Medical prescription; Economic growth; Economics; Finance; Medicine","score_opus":0.11200114911072016,"score_gpt":0.34457385578135447,"score_spread":0.2325727066706343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136610976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.71827173,0.035364605,0.00070640026,0.18849741,0.0020485278,0.0010677961,0.000087539855,0.00001677731,0.053939205],"genre_scores_gemma":[0.9540584,0.011207519,0.00037787858,0.033812255,0.00016222848,0.000009594342,0.0000020851169,0.000015865844,0.00035414874],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978579,0.000047174413,0.0014378054,0.00017445724,0.00005955251,0.00042308558],"domain_scores_gemma":[0.9982435,0.000046157744,0.0012712713,0.00024862823,0.000019831441,0.00017060588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016084523,0.00010415509,0.0004439443,0.00028461305,0.00015024537,0.00001897954,0.00019883201,0.00002429516,0.00012636771],"category_scores_gemma":[0.00003546634,0.00008826564,0.000103595616,0.00018258877,0.000029867579,0.00007693595,0.00003829889,0.00030125582,0.00007854129],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001855275,0.0008513711,0.2359663,0.0009859562,0.00032829167,0.00083193916,0.012589112,0.0023675347,2.478866e-7,0.47809297,0.22441247,0.0433883],"study_design_scores_gemma":[0.00071069755,0.00026387133,0.16032478,0.00005029547,9.167212e-7,0.00005140471,0.00021785831,0.00012713711,8.812571e-7,0.0029719032,0.835189,0.000091274815],"about_ca_topic_score_codex":0.00032420488,"about_ca_topic_score_gemma":0.000026102747,"teacher_disagreement_score":0.6107765,"about_ca_system_score_codex":0.00064058555,"about_ca_system_score_gemma":0.00014521994,"threshold_uncertainty_score":0.35993683},"labels":[],"label_agreement":null},{"id":"W2136777787","doi":"10.12927/hcpol.2008.19525","title":"The Effect of Evidence-Based Drug Coverage Policies on Pharmaceutical R&amp;D: A Case Study from British Columbia - Abridged Version -","year":2008,"lang":"en","type":"article","venue":"Healthcare policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Political science; Operations research; Medicine; Pharmacology; Engineering","score_opus":0.18334742511102717,"score_gpt":0.38648175497601084,"score_spread":0.20313432986498367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136777787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9753509,0.002472739,0.000007798835,0.018610178,0.0003822735,0.000981514,0.0015410371,0.00005346187,0.0006000993],"genre_scores_gemma":[0.98902667,0.0024646942,0.000011924032,0.0073538017,0.0005238204,0.000086833126,0.000021152442,0.000046929224,0.00046416148],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972863,0.00034389514,0.0009890675,0.0005630729,0.000115664116,0.00070197345],"domain_scores_gemma":[0.99643767,0.0019896405,0.00040439743,0.00065478845,0.000053866203,0.00045961406],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001089507,0.00024139631,0.00073165196,0.00017653934,0.0009119862,0.0002226831,0.00039969958,0.00012170597,0.0001903212],"category_scores_gemma":[0.00079137506,0.00027396882,0.00025830537,0.0004194971,0.0002769738,0.00017558769,0.00012237139,0.0005023218,0.0003531779],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007449373,0.0006062841,0.92542464,0.00023074594,0.00023046404,0.0007962443,0.0016804772,0.00015024951,0.000016797312,0.0023422274,0.052900665,0.014876296],"study_design_scores_gemma":[0.018955417,0.0050284592,0.36071151,0.000497607,0.00013006854,0.0012895946,0.00028194318,0.005246554,0.00074441574,0.0074286894,0.59751767,0.0021680752],"about_ca_topic_score_codex":0.6983774,"about_ca_topic_score_gemma":0.044689357,"teacher_disagreement_score":0.653688,"about_ca_system_score_codex":0.00048357982,"about_ca_system_score_gemma":0.00023957457,"threshold_uncertainty_score":0.9999713},"labels":[],"label_agreement":null},{"id":"W2137840922","doi":"10.1111/jlme.12012","title":"Pharmaceutical Knowledge Governance: A Human Rights Perspective","year":2013,"lang":"en","type":"article","venue":"The Journal of Law Medicine & Ethics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Transparency (behavior); Misrepresentation; Human rights; Corporate governance; Obligation; Business; Political science; Pharmaceutical industry; Drug control; Public relations; Law and economics; Public economics; Public administration; Economics; Law; Medicine; Pharmacology","score_opus":0.20270876457574855,"score_gpt":0.4249189313450158,"score_spread":0.22221016676926725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137840922","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07920286,0.016217792,0.00034945383,0.16504818,0.001580149,0.00033377163,0.000028766477,0.0000213452,0.73721766],"genre_scores_gemma":[0.9870358,0.00092156226,0.000057582853,0.009235853,0.0016784909,0.0000035444273,6.5181905e-7,0.000021970116,0.0010445118],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.998224,0.00012956488,0.0010358383,0.00016035471,0.00010219992,0.00034804447],"domain_scores_gemma":[0.9975289,0.00082896015,0.0007505528,0.0002710045,0.0003238472,0.00029675034],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0034357617,0.0001889152,0.0005773825,0.00008443371,0.00038609782,0.0000377888,0.00062859687,0.00017314963,0.0026358452],"category_scores_gemma":[0.0003525775,0.00012667206,0.00014959583,0.00014888962,0.00082492776,0.00029699143,0.000084853054,0.0020638455,0.00070760417],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023369212,0.000082625265,0.00005493822,0.000019381408,0.00010327692,0.0000037176435,0.007009004,0.000008407913,0.00013177544,0.9781338,0.014328573,0.000101162936],"study_design_scores_gemma":[0.0011651871,0.00020399077,0.00045051804,0.0000593353,0.00004298225,0.00007064985,0.00018927283,0.00040941226,0.0001550525,0.47710705,0.5200123,0.00013421747],"about_ca_topic_score_codex":0.0026866498,"about_ca_topic_score_gemma":0.00016521844,"teacher_disagreement_score":0.907833,"about_ca_system_score_codex":0.0002664809,"about_ca_system_score_gemma":0.000059149297,"threshold_uncertainty_score":0.9982759},"labels":[],"label_agreement":null},{"id":"W2138122752","doi":"10.3329/jce.v27i2.17801","title":"Pharmaceutical Waste Water Treatment &amp; Related Economic Aspects for Reuse in the Context of Bangladesh","year":2014,"lang":"en","type":"article","venue":"Journal of Chemical Engineering","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McGill University","keywords":"Reuse; Context (archaeology); Waste management; Water treatment; Wastewater; Environmental science; Business; Engineering; Geography","score_opus":0.03840331859545675,"score_gpt":0.2712852651911948,"score_spread":0.23288194659573802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138122752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935246,0.00043267896,0.000442372,0.0041341647,0.00032009295,0.00014407212,0.000031932846,0.0000056995123,0.0009643678],"genre_scores_gemma":[0.99876946,0.000099291385,0.0004495363,0.0003417244,0.00028832967,0.00000849165,0.00000472801,0.000021140637,0.000017302393],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985943,0.000010400169,0.0009616563,0.00013426882,0.000024271467,0.00027509258],"domain_scores_gemma":[0.9991592,0.0002778376,0.00022831136,0.00021090535,0.00001703974,0.00010667998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007376082,0.00013933564,0.0004977759,0.00015590752,0.000011955845,0.000024210432,0.0003459141,0.00009227094,0.00007294829],"category_scores_gemma":[0.00018172778,0.00010332002,0.00024423786,0.000046642177,0.00003202914,0.00013750797,0.00003294536,0.00021543718,0.000033459186],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006979726,0.0010169517,0.0013570014,0.00041449827,0.0010442472,0.000017425891,0.006159746,0.036538783,0.26551378,0.67814684,0.003704062,0.0053887093],"study_design_scores_gemma":[0.007282369,0.00031642697,0.000069281436,0.00007059199,0.00006506598,0.000102502636,0.000045427605,0.12166947,0.43617007,0.02497247,0.40877694,0.00045935847],"about_ca_topic_score_codex":0.000008631923,"about_ca_topic_score_gemma":7.079608e-7,"teacher_disagreement_score":0.65317434,"about_ca_system_score_codex":0.00021170199,"about_ca_system_score_gemma":0.000014712375,"threshold_uncertainty_score":0.4213268},"labels":[],"label_agreement":null},{"id":"W2138250448","doi":"10.12927/hcpol.2013.23477","title":"Product Listing Agreements (PLAs): A New Tool for Reaching Quebec's Pharmaceutical Policy Objectives?","year":2013,"lang":"en","type":"article","venue":"Healthcare policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Listing (finance); Product (mathematics); Drug pricing; Confidentiality; Business; Pharmaceutical industry; Actuarial science; Public economics; Risk analysis (engineering); Economics; Finance; Law; Medicine; Political science; Pharmacology","score_opus":0.11662815094573493,"score_gpt":0.38250331873034626,"score_spread":0.26587516778461134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138250448","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.33566082,0.0048071984,0.004216615,0.5876259,0.001864614,0.0070496514,0.0015817775,0.000537323,0.05665608],"genre_scores_gemma":[0.95138085,0.00047305346,0.0025281361,0.031977694,0.0069599403,0.00038346587,0.00006391323,0.00012025383,0.006112665],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961683,0.0000627885,0.0012831754,0.0009346409,0.000069425194,0.0014816388],"domain_scores_gemma":[0.9977068,0.00022937564,0.0004948478,0.0005882775,0.00010123562,0.0008795098],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00069195725,0.00041935247,0.0007325163,0.00075718196,0.00039723044,0.0003152194,0.00047300942,0.00018298817,0.00033848503],"category_scores_gemma":[0.0015806165,0.0004954346,0.00027615472,0.00056941283,0.00009607154,0.00063110894,0.00019270305,0.0005176515,0.0014885647],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006173787,0.00013924137,0.010883449,0.00036397952,0.00011605714,0.0000014415172,0.0017317911,0.000025450237,0.00012130296,0.8510065,0.019565795,0.11598324],"study_design_scores_gemma":[0.0030777561,0.00019858575,0.032029375,0.000088305605,0.000017424116,0.00002281872,0.000091540845,0.0076933973,0.0004582451,0.2608329,0.6943189,0.001170753],"about_ca_topic_score_codex":0.2199996,"about_ca_topic_score_gemma":0.0013153312,"teacher_disagreement_score":0.6747531,"about_ca_system_score_codex":0.0013435979,"about_ca_system_score_gemma":0.0010202418,"threshold_uncertainty_score":0.9997497},"labels":[],"label_agreement":null},{"id":"W2138404206","doi":"10.1016/j.jhealeco.2005.07.001","title":"Extraordinary claims require extraordinary evidence","year":2005,"lang":"en","type":"letter","venue":"Journal of Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":83,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Michael Smith Health Research BC; University of Victoria","funders":"","keywords":"Intellectual property; Developing country; Exploit; Negative binomial distribution; Profit (economics); Empirical evidence; Economics; Business; Public economics; Computer science; Economic growth; Microeconomics","score_opus":0.2200125721140884,"score_gpt":0.35990576374524014,"score_spread":0.13989319163115174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138404206","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0047729798,0.07526324,0.0003345831,0.90693325,0.004665943,0.00045107838,0.0005287645,0.000032469845,0.0070176995],"genre_scores_gemma":[0.009204105,0.088903815,0.0017289545,0.87677747,0.019718852,0.000019598498,0.00005112213,0.00024523417,0.0033508427],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9914798,0.0001573649,0.006050977,0.000849899,0.0000808035,0.0013811712],"domain_scores_gemma":[0.9897968,0.0005816416,0.008054061,0.00092481053,0.00011463545,0.00052803726],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.004154929,0.0007441225,0.0030014964,0.0010947883,0.0002811623,0.00026065903,0.0015827481,0.0011689276,0.0019343807],"category_scores_gemma":[0.00017777653,0.0008904231,0.0011195666,0.00017413324,0.00021380681,0.0018364526,0.00021863914,0.0042160433,0.001337923],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000065427674,0.00009139213,0.000462843,0.0005245996,0.00025431905,0.00012561743,0.00018047288,0.00029334135,7.88225e-7,0.00654117,0.9795193,0.0119407065],"study_design_scores_gemma":[0.00072410854,0.00051959715,0.00029100338,0.00035680045,0.000027007845,0.0006464284,0.000020516092,0.0006287723,0.0000028377212,0.03774866,0.95828813,0.0007461569],"about_ca_topic_score_codex":0.000099173514,"about_ca_topic_score_gemma":0.000009243868,"teacher_disagreement_score":0.031207489,"about_ca_system_score_codex":0.0022942869,"about_ca_system_score_gemma":0.0012138059,"threshold_uncertainty_score":0.99943966},"labels":[],"label_agreement":null},{"id":"W2140068746","doi":"10.1017/s0266462309990249","title":"Scanning the horizon of obsolete technologies: Possible sources for their identification","year":2009,"lang":"en","type":"article","venue":"International Journal of Technology Assessment in Health Care","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Identification (biology); Agency (philosophy); Nice; Ranking (information retrieval); Health technology; Medicine; Food and drug administration; Emerging technologies; Family medicine; Business; Operations management; Environmental health; Computer science; Health care; Political science; Engineering","score_opus":0.04611526574616532,"score_gpt":0.3792387491165271,"score_spread":0.3331234833703618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140068746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7575346,0.015944036,0.008042315,0.215421,0.0013034069,0.0004787895,0.0002359722,0.000050917428,0.0009889132],"genre_scores_gemma":[0.9963848,0.001360523,0.0016462224,0.0005052245,0.000068650486,0.000012295018,0.0000064582373,0.0000069134735,0.000008934555],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9984455,0.000011617257,0.0011682162,0.00014271795,0.000048238617,0.00018368335],"domain_scores_gemma":[0.9980734,0.00008536188,0.0014762053,0.00016828143,0.00017372647,0.0000230419],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079332193,0.00008851371,0.0003061993,0.00080924015,0.00006388637,0.000035207406,0.0008215705,0.000121741985,0.000008202398],"category_scores_gemma":[0.00016470283,0.00007625231,0.00011217914,0.00020747396,0.00008342442,0.00014283055,0.000051291183,0.00034386333,0.0000016086645],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007109454,0.00015443332,0.029058106,0.00006257192,0.0001332076,0.0000028820027,0.00076123193,0.0008507078,0.00044481602,0.7678812,0.0005896616,0.19999005],"study_design_scores_gemma":[0.0030563276,0.0024300949,0.040749587,0.00048298037,0.000012925823,0.000080236874,0.015518838,0.0047606295,0.010587064,0.7940003,0.12792605,0.00039496963],"about_ca_topic_score_codex":0.000017397242,"about_ca_topic_score_gemma":0.0000066302255,"teacher_disagreement_score":0.23885013,"about_ca_system_score_codex":0.00038875794,"about_ca_system_score_gemma":0.00012641345,"threshold_uncertainty_score":0.31094792},"labels":[],"label_agreement":null},{"id":"W2140732319","doi":"10.1377/hlthaff.w4.561","title":"Re-Naming And Re-Gaming: Medicare's Doomed Attempt To Reform Reimbursement For Injectable Drugs","year":2004,"lang":"en","type":"article","venue":"Health Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Care Foundation","funders":"","keywords":"Reimbursement; Modernization theory; Government (linguistics); Medical prescription; Drug; Prescription drug; Public economics; Medicine; Actuarial science; Business; Public administration; Law; Pharmacology; Economics; Political science; Health care","score_opus":0.05815838577290411,"score_gpt":0.3272348721042413,"score_spread":0.2690764863313372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140732319","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20187739,0.010083139,0.0075228456,0.5804147,0.0028445635,0.0044810777,0.0011152329,0.0002860539,0.19137499],"genre_scores_gemma":[0.97913164,0.0009482659,0.0031534731,0.015745047,0.00031386883,0.00018899764,0.00003384783,0.00004872327,0.00043611432],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976123,0.000011575777,0.0009162483,0.0005878124,0.000049182956,0.0008228617],"domain_scores_gemma":[0.99848634,0.0000770564,0.00031829203,0.0003606251,0.000025792637,0.0007319059],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014688439,0.0002088243,0.0005634368,0.00028759037,0.00026233232,0.00007092637,0.00021397223,0.00010799186,0.00010170131],"category_scores_gemma":[0.00013611336,0.00023918341,0.00008996435,0.00021918317,0.00005351416,0.00016586835,0.00011310163,0.00019142673,0.000159187],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033050613,0.00039151238,0.0027505439,0.0016299896,0.00022012288,0.0000070031483,0.023162715,0.00058442855,0.000031245443,0.88518876,0.054317433,0.031385724],"study_design_scores_gemma":[0.0033532875,0.0006208797,0.0010956627,0.00014210511,0.000008424626,0.0000036030142,0.005281926,0.0012271836,0.00017677716,0.042720843,0.94477195,0.0005973358],"about_ca_topic_score_codex":0.0016629826,"about_ca_topic_score_gemma":0.000549547,"teacher_disagreement_score":0.89045453,"about_ca_system_score_codex":0.0012054727,"about_ca_system_score_gemma":0.00016403904,"threshold_uncertainty_score":0.97536165},"labels":[],"label_agreement":null},{"id":"W2141595217","doi":"10.5430/bmr.v1n4p20","title":"Pharmaceutical Wholesalers Service in Macau: An Investigation from the Perspective of Stakeholders","year":2012,"lang":"en","type":"article","venue":"Business and Management Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Business; Pharmacy; Perspective (graphical); Circulation (fluid dynamics); Service (business); Marketing; Medicine; Nursing; Computer science","score_opus":0.4101102207270177,"score_gpt":0.4059066512492269,"score_spread":0.0042035694777907695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141595217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9662986,0.002049648,0.00006427206,0.016846932,0.00010221917,0.0004029035,0.00006665744,0.000008340514,0.014160421],"genre_scores_gemma":[0.9960771,0.0021837205,0.00010785427,0.0013732159,0.00012230955,0.000037347505,0.000015875714,0.00001309004,0.000069467285],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9989479,0.00006274491,0.00028372655,0.00025631787,0.000065231165,0.00038405514],"domain_scores_gemma":[0.9993952,0.00010322109,0.000065799824,0.00022558143,0.00007406514,0.00013613465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001568676,0.00009139253,0.00017398209,0.00023181103,0.00008819746,0.00006793887,0.00023863638,0.0000465779,0.00014980733],"category_scores_gemma":[0.000035742385,0.00008399611,0.000019596104,0.00064373453,0.00017891711,0.00037902634,0.00019331204,0.00020012932,0.000058719153],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050698058,0.00015677215,0.14293578,0.00010618463,0.00005513847,0.0000015420042,0.0025143167,0.000054220174,0.00007831417,0.8506969,0.00086100074,0.00248909],"study_design_scores_gemma":[0.0010067804,0.000014136456,0.88058084,0.00003195705,0.000009190587,4.894641e-7,0.0037547615,0.00361221,0.00007009698,0.06389862,0.04685118,0.00016973722],"about_ca_topic_score_codex":0.005801605,"about_ca_topic_score_gemma":0.00029571954,"teacher_disagreement_score":0.7867983,"about_ca_system_score_codex":0.00009355665,"about_ca_system_score_gemma":0.000013802565,"threshold_uncertainty_score":0.877033},"labels":[],"label_agreement":null},{"id":"W2141749161","doi":"10.1177/1745790413497388","title":"Product lifecycle management through patents and regulatory strategies","year":2013,"lang":"en","type":"article","venue":"Journal of Medical Marketing Device Diagnostic and Pharmaceutical Marketing","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Product lifecycle; Business; Product management; New product development; Product (mathematics); Application lifecycle management; Commercialization; European union; Outsourcing; Service product management; Product life-cycle management; Service (business); Process management; Marketing; Service provider; Computer science","score_opus":0.04338497239815697,"score_gpt":0.30866686158725953,"score_spread":0.26528188918910256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141749161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92811996,0.023380307,0.00044075603,0.021251421,0.00076398806,0.00044216184,0.000013490599,0.000030708034,0.0255572],"genre_scores_gemma":[0.9701962,0.02245558,0.001702607,0.0048868167,0.0006451859,0.000020549425,0.000001773397,0.000036399968,0.00005487953],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9968357,0.00034972627,0.0014884468,0.00045217344,0.0002715094,0.00060245866],"domain_scores_gemma":[0.9929315,0.0053535243,0.0006455355,0.0001844631,0.0000908713,0.0007941299],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009737382,0.000291899,0.00066201785,0.00016432522,0.00018298006,0.00032370744,0.00038265012,0.0001629234,0.0017453078],"category_scores_gemma":[0.0083315745,0.00027434982,0.00012450463,0.00017912497,0.00029971707,0.00061902584,0.0003458355,0.00079313526,0.000072040995],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009390846,0.001016164,0.33953488,0.0058782646,0.0015523732,0.0005485758,0.0009834162,0.00003657949,0.00015606255,0.11912408,0.029153237,0.5010773],"study_design_scores_gemma":[0.005062819,0.00014536106,0.73557574,0.0021472569,0.00023214836,0.0005491739,0.0012646801,0.013495763,0.00008078199,0.046066854,0.19427967,0.0010997618],"about_ca_topic_score_codex":0.000035275323,"about_ca_topic_score_gemma":8.538716e-7,"teacher_disagreement_score":0.49997753,"about_ca_system_score_codex":0.000057771773,"about_ca_system_score_gemma":0.00005186884,"threshold_uncertainty_score":0.99997085},"labels":[],"label_agreement":null},{"id":"W2142000732","doi":"10.1504/ijipm.2006.011024","title":"Pledges and pitfalls: Canada's legislation on compulsory licensing of pharmaceuticals for export","year":2006,"lang":"en","type":"article","venue":"International Journal of Intellectual Property Management","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Legislation; TRIPS architecture; Business; International trade; World trade; TRIPS Agreement; Intellectual property; Law; Political science; Engineering","score_opus":0.06511728233811544,"score_gpt":0.28739083885113015,"score_spread":0.22227355651301473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142000732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7062355,0.0041113887,0.046702795,0.02758579,0.0047903527,0.001282414,0.00035994372,0.000024099054,0.20890766],"genre_scores_gemma":[0.99593174,0.00045131397,0.00087465387,0.0014223029,0.00031918197,0.0000037133323,0.000006124113,0.000013314275,0.0009776363],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987864,0.000011951165,0.0008261028,0.00014880029,0.00008582888,0.00014090909],"domain_scores_gemma":[0.9990854,0.0001795832,0.00044869355,0.00006933215,0.00015984238,0.00005712825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043883384,0.00010784936,0.00026089806,0.00026009325,0.00003446553,0.000048283942,0.00023428761,0.000028053455,0.00014294358],"category_scores_gemma":[0.0001280984,0.000089127534,0.00008509667,0.0000489369,0.000049758208,0.00010378523,0.000062164036,0.00010327476,0.000007809038],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028386249,0.0014343342,0.0050027194,0.00032855256,0.002987716,0.00008369224,0.0015812292,0.010221883,0.0009273232,0.4460908,0.33908337,0.18941976],"study_design_scores_gemma":[0.0016213793,0.00023956144,0.001958973,0.00010192438,0.000029870838,0.000025962388,0.000114759365,0.032224394,0.0034818156,0.013197959,0.9467586,0.00024475754],"about_ca_topic_score_codex":0.004091992,"about_ca_topic_score_gemma":0.00088168634,"teacher_disagreement_score":0.60767525,"about_ca_system_score_codex":0.00021604856,"about_ca_system_score_gemma":0.000048170536,"threshold_uncertainty_score":0.6185895},"labels":[],"label_agreement":null},{"id":"W2142139579","doi":"10.1126/scitranslmed.aaa2360","title":"Financing translation: Analysis of the NCATS rare-diseases portfolio","year":2015,"lang":"en","type":"review","venue":"Science Translational Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada); Alpha Technologies (Canada)","funders":"National Center for Advancing Translational Sciences; National Institutes of Health","keywords":"Portfolio; Medicine; Translation (biology); Business; Finance; Genetics; Biology","score_opus":0.2232317094537266,"score_gpt":0.3972406493256112,"score_spread":0.1740089398718846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142139579","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000026549356,0.9767476,0.00026594053,0.0013614438,0.00061420415,0.0003905662,0.0011154789,0.00001306712,0.019465199],"genre_scores_gemma":[0.0066048517,0.9922184,0.0001316696,0.00035471923,0.000314486,0.000030085974,0.00014876267,0.000023044524,0.00017402199],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99732786,0.000031462238,0.0015101446,0.0005714249,0.00022964491,0.00032948438],"domain_scores_gemma":[0.99806404,0.00022283269,0.000852898,0.00051611156,0.000104313214,0.00023983045],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016284991,0.00027376463,0.0019264051,0.0013702613,0.00016751316,0.000025352714,0.00092415843,0.00010037809,0.0009431136],"category_scores_gemma":[0.0001823848,0.0002007091,0.0006439583,0.0049864934,0.0010673773,0.0002420605,0.0000346259,0.00023986583,0.000045888566],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010862807,0.00011104841,0.0016899983,0.0019881953,0.0010810011,0.0000023402883,0.0008207914,0.0008365482,8.0823037e-7,0.28508428,0.0013903243,0.7069838],"study_design_scores_gemma":[0.0002768229,0.000017379365,0.0016877673,0.00057313085,0.0014638251,0.0000032891282,0.0000063718176,0.002712281,3.0044484e-7,0.014263142,0.97875637,0.00023934573],"about_ca_topic_score_codex":0.00006959653,"about_ca_topic_score_gemma":0.000015338566,"teacher_disagreement_score":0.97736603,"about_ca_system_score_codex":0.0001255987,"about_ca_system_score_gemma":0.00080628495,"threshold_uncertainty_score":0.99997014},"labels":[],"label_agreement":null},{"id":"W2144684304","doi":"10.2190/x4xq-y1a8-7lwe-lwma","title":"Globalization and International Trade in the Twenty-First Century: Opportunities for and Threats to the Health Sector in the South","year":2000,"lang":"en","type":"review","venue":"International Journal of Health Services","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"International Development Research Centre; World Bank Group","keywords":"Globalization; International trade; Developing country; Business; Goods and services; Liberalization; International health; Health care; Free trade; Trade barrier; Global health; Economic growth; Health policy; International economics; Economics; Economy; Market economy","score_opus":0.2126795629489433,"score_gpt":0.40347154867325546,"score_spread":0.19079198572431216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144684304","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003939608,0.85827464,0.000030809155,0.1384748,0.0007939295,0.00067945756,0.0009578789,0.0000021011172,0.00039241652],"genre_scores_gemma":[0.009996197,0.96109277,0.000040235747,0.02816692,0.00057376846,0.00003881155,0.000067626344,0.0000147130895,0.000008982595],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99785763,0.00014316158,0.001459883,0.00020194892,0.000103652754,0.00023371607],"domain_scores_gemma":[0.9981709,0.00030628423,0.0012899584,0.0001255548,0.000022091353,0.00008521172],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027324,0.00018792601,0.0006736293,0.00038623685,0.00011730066,0.0002882466,0.0009960971,0.00006930365,0.000026728256],"category_scores_gemma":[0.00001822425,0.000114372946,0.00013232487,0.0001310408,0.000032327942,0.00018409082,0.000054266187,0.00028147566,0.0000031023555],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009747411,0.00018000303,0.0011467518,0.0030203927,0.00025949214,0.00000844506,0.02109326,0.000077274315,1.3236932e-9,0.10209084,0.002308483,0.8697176],"study_design_scores_gemma":[0.00040221435,0.00008197867,0.001155371,0.0012813358,0.000009678992,0.000087123335,0.0010820114,0.00026503464,2.5202338e-9,0.004422583,0.9911175,0.000095201416],"about_ca_topic_score_codex":0.00033589604,"about_ca_topic_score_gemma":0.000816521,"teacher_disagreement_score":0.988809,"about_ca_system_score_codex":0.00025449053,"about_ca_system_score_gemma":0.00017917331,"threshold_uncertainty_score":0.46639934},"labels":[],"label_agreement":null},{"id":"W2145692217","doi":"10.2139/ssrn.4362460","title":"AIDS Policy and Pharmaceutical Patents: Brazil’s Strategy to Safeguard Public Health","year":2023,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Safeguard; Public health; Business; Public policy; Public administration; Political science; International trade; Law; Medicine","score_opus":0.10121770095333617,"score_gpt":0.36222705573137776,"score_spread":0.2610093547780416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145692217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7083303,0.010416581,0.004212616,0.25366154,0.0008299322,0.0006546993,0.0003156328,0.00023722676,0.021341495],"genre_scores_gemma":[0.95757383,0.028488798,0.000043212833,0.011301141,0.00079445133,0.000014200779,0.000012887777,0.0000523931,0.001719093],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99473023,0.000057331068,0.0008148565,0.00043762964,0.00006406362,0.0038958793],"domain_scores_gemma":[0.99854714,0.000065327054,0.0002396009,0.00020827955,0.00003292313,0.0009067531],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0038634073,0.00023715169,0.0004835119,0.00088444125,0.000330299,0.00028141934,0.0003767431,0.00009917704,0.00017396073],"category_scores_gemma":[0.00022220034,0.00026495015,0.00014069874,0.00083879224,0.000070640184,0.0003460135,0.0001482259,0.0013423172,0.0017222938],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001989606,0.000059202946,0.0027115806,0.00001290458,0.00013394438,0.0000025532074,0.00016408204,0.000042173182,0.000013339378,0.8948434,0.0017726115,0.10022434],"study_design_scores_gemma":[0.0013202406,0.00063861447,0.0040664426,0.0000084386065,0.0000049011956,0.00016816136,0.00030882307,0.001425701,0.000009219807,0.6109225,0.38075155,0.00037538915],"about_ca_topic_score_codex":0.00021079333,"about_ca_topic_score_gemma":0.00015005138,"teacher_disagreement_score":0.37897894,"about_ca_system_score_codex":0.001529441,"about_ca_system_score_gemma":0.001687188,"threshold_uncertainty_score":0.9999803},"labels":[],"label_agreement":null},{"id":"W2145803845","doi":"","title":"Why is calling an ACE an ACE so controversial? Evaluating reference-based pricing in British Columbia.","year":2002,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Computer science; Data science; Medicine; World Wide Web","score_opus":0.17617993243603366,"score_gpt":0.290734989946972,"score_spread":0.11455505751093834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145803845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98526907,0.0008998085,0.00018243006,0.0030075083,0.00026559996,0.00073215103,0.0002539603,0.00006154279,0.009327914],"genre_scores_gemma":[0.98324966,0.00020765592,0.00046287914,0.01502292,0.00020871777,0.00030141335,0.000021773782,0.000041141862,0.00048382714],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99767697,0.000059397662,0.0007438283,0.00066257565,0.000057563997,0.00079967926],"domain_scores_gemma":[0.99879986,0.00012218844,0.00030896818,0.00036659985,0.00003797952,0.0003643954],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012550334,0.00015420618,0.0004876505,0.00014591952,0.00021058484,0.00086146663,0.0003726367,0.00016662208,0.0011348305],"category_scores_gemma":[0.00029307927,0.00029415844,0.00008720285,0.00026411787,0.000075808726,0.0005959058,0.00005544035,0.0003313986,0.000089957095],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010155061,0.0014946074,0.41038835,0.00018962809,0.00017866204,0.000059859947,0.0025984072,0.0051895645,0.00005801716,0.0064678253,0.030629031,0.5426445],"study_design_scores_gemma":[0.004929324,0.00014478396,0.19201486,0.00003306158,0.00002214004,0.000007487045,0.00011516419,0.5558835,0.000054919386,0.006738697,0.23906705,0.0009889839],"about_ca_topic_score_codex":0.028033124,"about_ca_topic_score_gemma":0.03192516,"teacher_disagreement_score":0.5506939,"about_ca_system_score_codex":0.00034320998,"about_ca_system_score_gemma":0.00002654767,"threshold_uncertainty_score":0.99995106},"labels":[],"label_agreement":null},{"id":"W2146907829","doi":"10.1038/sj.clpt.6100074","title":"Tackling Corruption in the Pharmaceutical Systems Worldwide with Courage and Conviction","year":2007,"lang":"en","type":"review","venue":"Clinical Pharmacology & Therapeutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"World Bank Group","keywords":"Language change; Poverty; Counterfeit; Conviction; Business; Pharmaceutical industry; Economics; Economic growth; Law; Medicine; Political science; Pharmacology","score_opus":0.33285393291899273,"score_gpt":0.4837387517086571,"score_spread":0.15088481878966437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146907829","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00064645824,0.99020743,0.0005203808,0.002063182,0.002899424,0.00161364,0.00015969817,0.000049424118,0.0018403399],"genre_scores_gemma":[0.0021415579,0.9666013,0.00004917535,0.029476693,0.0012984351,0.00015333416,0.000053824002,0.00009214159,0.00013352696],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950653,0.00053258886,0.0026375214,0.00091138924,0.00007574662,0.0007774968],"domain_scores_gemma":[0.99545723,0.0027379033,0.0011044971,0.00039477093,0.00005279262,0.00025281424],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0045447955,0.0005970682,0.0023712304,0.00041226775,0.00016752136,0.00015909906,0.0006474714,0.00079553714,0.000146625],"category_scores_gemma":[0.00002966497,0.00046260154,0.00034337278,0.0006006317,0.00066668406,0.00017661335,0.000115282375,0.0025885398,0.000298744],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087799836,0.002743795,0.007410705,0.010042801,0.0058552898,0.00045473,0.00087592046,0.00019580948,0.000002001815,0.044732176,0.010658548,0.9161502],"study_design_scores_gemma":[0.0015741332,0.0001692439,0.00013964828,0.00037645566,0.0009896725,0.00011742187,0.000032077718,0.0036583473,2.4184286e-7,0.00031282663,0.992107,0.0005229321],"about_ca_topic_score_codex":0.00001969685,"about_ca_topic_score_gemma":0.000008211848,"teacher_disagreement_score":0.9814485,"about_ca_system_score_codex":0.00022374919,"about_ca_system_score_gemma":0.00014078392,"threshold_uncertainty_score":0.99978256},"labels":[],"label_agreement":null},{"id":"W2147450289","doi":"10.1345/aph.1p389","title":"Physician Perceptions About Generic Drugs","year":2011,"lang":"en","type":"article","venue":"Annals of Pharmacotherapy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":193,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute","keywords":"Medicine; Family medicine; Descriptive statistics; Likert scale; Generic drug; Logistic regression; Perception; Population; Quarter (Canadian coin); Health care; Environmental health; Drug; Internal medicine; Pharmacology; Psychology","score_opus":0.21927570371910032,"score_gpt":0.36698745182271336,"score_spread":0.14771174810361304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147450289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7225703,0.0042898944,0.0004043307,0.001989431,0.00043753535,0.00020442937,0.0003656863,0.00005510728,0.2696833],"genre_scores_gemma":[0.9658314,0.008771364,0.0003523073,0.024126988,0.00028915738,0.000022755747,0.000006723201,0.000038010825,0.00056131725],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988108,0.000016093658,0.00052984053,0.00027287324,0.0000248662,0.00034550382],"domain_scores_gemma":[0.99926394,0.00001832443,0.00027797365,0.0002463946,0.000037444977,0.00015591238],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002761954,0.00015945034,0.00034682782,0.0001823318,0.0000665127,0.000017242717,0.00030921944,0.000055750083,0.005534103],"category_scores_gemma":[0.0000043559135,0.00018716259,0.00024111442,0.00018802524,0.000103610626,0.000215594,0.00002564977,0.000120092045,0.0010757949],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002745682,0.0018435781,0.014539412,0.000108802284,0.00095768477,0.0000046062814,0.015620226,0.00007118313,0.057335895,0.7177698,0.09562302,0.09585123],"study_design_scores_gemma":[0.0016881346,0.00017984667,0.018811755,0.00001661634,0.000014905944,0.0000017747155,0.00013991864,0.0028308341,0.13750571,0.12381597,0.7142316,0.0007629329],"about_ca_topic_score_codex":0.00016092628,"about_ca_topic_score_gemma":0.0000015466076,"teacher_disagreement_score":0.6186086,"about_ca_system_score_codex":0.000013583111,"about_ca_system_score_gemma":0.000015841366,"threshold_uncertainty_score":0.999702},"labels":[],"label_agreement":null},{"id":"W2147598538","doi":"10.1016/j.jval.2014.08.1028","title":"The Trend of the Prices Of New Marketed Drugs in Turkey","year":2014,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Christian ministry; Factory (object-oriented programming); Government (linguistics); Business; Quarter (Canadian coin); Health care; Descriptive statistics; Consumption (sociology); Agricultural economics; Agricultural science; Geography; Economics; Economic growth; Mathematics; Political science; Statistics; Computer science; Environmental science","score_opus":0.07080932889010885,"score_gpt":0.30057025108409685,"score_spread":0.229760922193988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147598538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9649689,0.0026061898,0.000013831374,0.012248929,0.00034756731,0.00022137752,0.000045148412,0.0000037021218,0.019544357],"genre_scores_gemma":[0.99782306,0.0012330277,0.00007924136,0.000599051,0.000050827133,0.0000038622447,7.612993e-7,0.000008093636,0.00020205788],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99870616,0.000069079375,0.00082065095,0.00014475039,0.000022113249,0.00023727337],"domain_scores_gemma":[0.99883306,0.0003639905,0.00045748032,0.0002768019,0.000004270021,0.000064374886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018300855,0.00006973708,0.00028927758,0.00011478222,0.0000364033,0.000010400476,0.00030699134,0.000042630003,0.000034290373],"category_scores_gemma":[0.00018096514,0.000052508614,0.00006430538,0.00028632907,0.000059501574,0.000040391966,0.000053747863,0.00014530022,0.000010511515],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055848264,0.00010380261,0.115690425,0.00019612128,0.000017810982,5.8088908e-8,0.0030186852,0.0064674374,0.000006661223,0.85710686,0.002296282,0.015040018],"study_design_scores_gemma":[0.0016023621,0.00009777461,0.33233818,0.000113386865,0.0000018779176,6.690908e-7,0.000107737134,0.15728574,0.00012969249,0.21308903,0.29504803,0.00018551524],"about_ca_topic_score_codex":0.015196534,"about_ca_topic_score_gemma":0.00035434234,"teacher_disagreement_score":0.6440178,"about_ca_system_score_codex":0.00008304321,"about_ca_system_score_gemma":0.00008378011,"threshold_uncertainty_score":0.9913614},"labels":[],"label_agreement":null},{"id":"W2147650534","doi":"10.5539/gjhs.v7n4p70","title":"R&amp;D Implementation in a Department of Laboratory Medicine and Pathology: A Systematic Review Based on Pharmaceutical Companies","year":2015,"lang":"en","type":"review","venue":"Global Journal of Health Science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Stollery Children's Hospital; University of Alberta","funders":"","keywords":"Productivity; Profitability index; Commercialization; Health care; Business; Cash flow; Marketing; Pharmaceutical industry; Systematic review; Investment (military); MEDLINE; Accounting; Economics; Medicine; Finance","score_opus":0.24407936914804043,"score_gpt":0.5052441182236047,"score_spread":0.2611647490755643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147650534","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011538056,0.9964307,0.000033374763,0.0015959833,0.00028079556,0.00091544614,0.0004316048,0.0000022631425,0.00019446653],"genre_scores_gemma":[0.0013755582,0.9946371,0.00019303951,0.0037255187,0.00003650979,0.00001752188,0.000007725008,0.0000065737813,4.746367e-7],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958449,0.00017980504,0.0032039513,0.00027196296,0.00015335386,0.000346036],"domain_scores_gemma":[0.99584794,0.00011575644,0.0033456632,0.00021619757,0.00012991423,0.00034453423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010682843,0.00020817037,0.0032356132,0.00044828645,0.000049814305,0.000019937595,0.00042462704,0.000056873985,0.000030920743],"category_scores_gemma":[0.00036970375,0.00016360646,0.00012124006,0.00082727615,0.00033058348,0.00012659644,0.000058021044,0.00025346063,0.000017137227],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020526684,0.00021682221,0.000738173,0.9262442,0.000067793,0.000023354967,0.00009483211,0.000011930098,7.0871884e-8,0.025072347,0.0035643892,0.043945577],"study_design_scores_gemma":[0.0018363302,0.00081463775,0.00022993023,0.33946878,0.00032467014,0.0003594158,0.00005513331,0.00026333844,1.6492137e-7,0.002654055,0.65358657,0.00040698354],"about_ca_topic_score_codex":0.000023790457,"about_ca_topic_score_gemma":0.00000818072,"teacher_disagreement_score":0.65002215,"about_ca_system_score_codex":0.00097000145,"about_ca_system_score_gemma":0.0013500828,"threshold_uncertainty_score":0.6671678},"labels":[],"label_agreement":null},{"id":"W2148406648","doi":"10.1345/aph.1a044","title":"Influence of Socioeconomic Status on Drug Selection for the Elderly in Canada","year":2002,"lang":"en","type":"article","venue":"Annals of Pharmacotherapy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; University of Toronto","funders":"","keywords":"Medicine; Socioeconomic status; Drug; Population; Defined daily dose; Demography; Statin; Internal medicine; Environmental health; Pharmacology","score_opus":0.08166526870339184,"score_gpt":0.3332222127991411,"score_spread":0.25155694409574925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148406648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98932135,0.0024967324,0.00001371168,0.0061688945,0.000116893054,0.00028380082,0.00032567658,0.0000041056855,0.0012688208],"genre_scores_gemma":[0.98483723,0.008309899,0.000017023962,0.0065943147,0.00006057787,0.000036908383,0.0000014744346,0.000017447774,0.00012512729],"study_design_codex":"simulation_or_modeling","study_design_gemma":"not_applicable","domain_scores_codex":[0.99886966,0.000014154985,0.00059314846,0.00018903316,0.000022406939,0.0003115985],"domain_scores_gemma":[0.99913937,0.0002754949,0.000355974,0.00013035147,0.000032109354,0.0000666812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031547068,0.0001138606,0.00030013343,0.0001179692,0.00004159998,0.000009532857,0.00021195499,0.000028014649,0.00068374927],"category_scores_gemma":[0.000017987655,0.00011366626,0.000096634634,0.0000990443,0.00004420906,0.00011006474,0.000008126576,0.00011829973,0.00002623264],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009371689,0.0009380938,0.24612148,0.000317964,0.001084752,0.0000012610183,0.00378848,0.28362662,0.012184696,0.15226597,0.17930402,0.11942951],"study_design_scores_gemma":[0.0047591873,0.00046507455,0.04138562,0.000031899333,0.000012219101,0.0000010231399,0.000099272,0.15946059,0.14138421,0.02379022,0.6279593,0.0006513978],"about_ca_topic_score_codex":0.2913098,"about_ca_topic_score_gemma":0.08274288,"teacher_disagreement_score":0.44865528,"about_ca_system_score_codex":0.00011529548,"about_ca_system_score_gemma":0.00008520999,"threshold_uncertainty_score":0.93399465},"labels":[],"label_agreement":null},{"id":"W2149939436","doi":"10.1503/cmaj.109-3171","title":"Canada lags behind United States in drug return, reuse and recycling programs","year":2010,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reuse; Toilet; Computer science; Food and drug administration; Work (physics); Flushing; Drug; Business; Risk analysis (engineering); Medicine; Ecology; Biology; Pharmacology; Engineering; Pathology","score_opus":0.016534088556982546,"score_gpt":0.23664467077426815,"score_spread":0.2201105822172856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149939436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8808989,0.00017739178,0.0000018280681,0.11444167,0.0008200926,0.00007106093,0.00012346092,0.0000049593145,0.0034606473],"genre_scores_gemma":[0.9658373,0.00065539463,0.00011183341,0.03221471,0.0006881052,0.0000049105706,0.000040774972,0.000018314742,0.00042863254],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99858123,0.000033432854,0.0006183442,0.00017273084,0.00010376082,0.00049048546],"domain_scores_gemma":[0.9980045,0.00013777267,0.0002720619,0.00011840462,0.0000609048,0.0014063522],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020889018,0.00010123851,0.00023808559,0.00028520823,0.00014756869,0.0001612704,0.00027382738,0.00021233776,0.0010767786],"category_scores_gemma":[0.0017759454,0.00011669718,0.000033850938,0.00018094497,0.00003490359,0.0001282261,0.00002830006,0.0013968928,0.000029352823],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000006159868,0.000032090844,0.79213387,0.000010805042,0.00006810489,0.00017994555,0.0009720704,0.000013147675,0.0000023697967,0.00973906,0.18690723,0.009935181],"study_design_scores_gemma":[0.00054706185,0.0000073777746,0.021265509,0.000013861627,0.0000022402644,0.0000380676,0.00009593911,0.004284006,0.0000028085262,0.007161639,0.96643007,0.00015144338],"about_ca_topic_score_codex":0.8294639,"about_ca_topic_score_gemma":0.9935289,"teacher_disagreement_score":0.77952284,"about_ca_system_score_codex":0.0007897935,"about_ca_system_score_gemma":0.0015168037,"threshold_uncertainty_score":0.9998364},"labels":[],"label_agreement":null},{"id":"W2151809988","doi":"10.1136/bmjopen-2013-004289","title":"Postmarket safety in Canada: are significant therapeutic advances and biologics less safe than other drugs? A cohort study","year":2014,"lang":"en","type":"article","venue":"BMJ Open","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Cohort; Patient safety; Pharmacology; Family medicine; Health care; Internal medicine","score_opus":0.09530373278615463,"score_gpt":0.34116526251797635,"score_spread":0.24586152973182174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151809988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91102093,0.0007811467,0.0000433157,0.0030020517,0.00025959426,0.004642562,0.00037816458,0.0000092489745,0.07986296],"genre_scores_gemma":[0.9949633,0.00031908118,0.000037137015,0.004037508,0.000060583905,0.0002963614,0.000006050465,0.000021156384,0.00025883655],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99838233,0.000103735634,0.00064969395,0.0004928399,0.000032730193,0.00033867493],"domain_scores_gemma":[0.99895597,0.00018481228,0.0003435336,0.00037799307,0.00001334203,0.00012438148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021063585,0.00018307581,0.0006358095,0.00008346527,0.00008548115,0.00010904878,0.0005153614,0.000053444157,0.00023370082],"category_scores_gemma":[0.000078495075,0.00017617982,0.00003328793,0.00012773446,0.00004944191,0.00017882328,0.0002607157,0.00014882941,0.000044319037],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013176711,0.00007926819,0.98084325,0.00001902088,0.000050352883,0.0000024140104,0.00016017162,0.000047676916,7.255382e-7,0.01335157,0.00016296869,0.0051508355],"study_design_scores_gemma":[0.0011123575,0.00006849848,0.8602628,0.000015861531,0.000005882771,0.0000011716771,0.0006533813,0.0024487665,0.0000043466216,0.007130813,0.12797207,0.00032406359],"about_ca_topic_score_codex":0.47232863,"about_ca_topic_score_gemma":0.64274454,"teacher_disagreement_score":0.17041588,"about_ca_system_score_codex":0.0002494343,"about_ca_system_score_gemma":0.0001523469,"threshold_uncertainty_score":0.7184405},"labels":[],"label_agreement":null},{"id":"W2153297078","doi":"10.1186/2052-3211-7-8","title":"The future of medicines use and access research: using the Journal of Pharmaceutical Policy and Practice as a platform for change","year":2014,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Policy and Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trent University","funders":"","keywords":"Globe; Pharmacy; Publication; Pharmaceutical policy; Medicine; Access to medicines; Alternative medicine; Public relations; Dissemination; Health policy; Political science; Public health; Family medicine; Nursing","score_opus":0.5367016781329578,"score_gpt":0.5493782482278896,"score_spread":0.012676570094931838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153297078","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24184899,0.07370595,0.0019288831,0.67110705,0.0016607359,0.001334238,0.00019892814,0.000010406795,0.008204806],"genre_scores_gemma":[0.84029675,0.124450386,0.0011764683,0.025560252,0.008420827,0.000006656893,6.52522e-7,0.00004467101,0.000043346052],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99661136,0.0007551504,0.0015282362,0.00021927246,0.00025316025,0.00063282886],"domain_scores_gemma":[0.9650614,0.031182408,0.0020294632,0.0002291148,0.0008155215,0.00068204256],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01946078,0.00025125363,0.00068597234,0.0005878076,0.00054400315,0.0004590162,0.0005639832,0.00018336214,0.00002070945],"category_scores_gemma":[0.037409853,0.00016616956,0.00014901516,0.00050797616,0.0010090544,0.003156224,0.00031518622,0.0013822898,0.000002135317],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012505761,0.00049297616,0.0009082586,0.00048950635,0.0011494097,0.000024317394,0.0054089944,0.00003166932,0.0012559937,0.8882418,0.0050199227,0.08447135],"study_design_scores_gemma":[0.0029278547,0.0006135503,0.00045425753,0.00006925599,0.000330596,0.0035775441,0.0011301854,0.005544703,0.0003675608,0.038787436,0.94601125,0.00018583838],"about_ca_topic_score_codex":0.00038652663,"about_ca_topic_score_gemma":0.000010747901,"teacher_disagreement_score":0.9409913,"about_ca_system_score_codex":0.00012717534,"about_ca_system_score_gemma":0.00033152534,"threshold_uncertainty_score":0.9706985},"labels":[],"label_agreement":null},{"id":"W2153458009","doi":"","title":"Time required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996-1998.","year":2000,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Medicine; Food and drug administration; Family medicine; Drug approval; Environmental health; Drug; Pharmacology","score_opus":0.1003660951352786,"score_gpt":0.27103814390293113,"score_spread":0.17067204876765252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153458009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895101,0.00016671114,0.0000025956017,0.007877631,0.00006802451,0.0008598201,0.00024299533,0.0000046170794,0.0012674662],"genre_scores_gemma":[0.99530107,0.0002239469,0.000015167661,0.0019903376,0.000057659006,0.00026434334,0.00006204038,0.000014742863,0.002070667],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99866015,0.000034451277,0.00062338746,0.00022080263,0.000026633294,0.0004345882],"domain_scores_gemma":[0.99913687,0.00036390888,0.00017288509,0.00020711872,0.0000076333745,0.000111580805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009278923,0.0001283,0.00035138286,0.00022352561,0.00004484851,0.000041149844,0.00027905763,0.000053284664,0.00010506905],"category_scores_gemma":[0.00007895723,0.00010098632,0.00005104273,0.0004857953,0.00014833492,0.00007480117,0.00003568605,0.00015373009,0.000014717616],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00561231,0.0005572878,0.20620613,0.00041494996,0.00094157725,0.000014129992,0.018753964,0.049246017,0.000007532465,0.5050372,0.08389345,0.12931547],"study_design_scores_gemma":[0.008128915,0.00001904106,0.23506358,0.000013200463,0.000019005112,0.0000026230873,0.0001848886,0.11443148,0.000047849317,0.04610187,0.59559345,0.00039409605],"about_ca_topic_score_codex":0.8733295,"about_ca_topic_score_gemma":0.2537841,"teacher_disagreement_score":0.61954546,"about_ca_system_score_codex":0.00020454185,"about_ca_system_score_gemma":0.000068894886,"threshold_uncertainty_score":0.7598324},"labels":[],"label_agreement":null},{"id":"W2153769961","doi":"10.1185/030079904125003250","title":"Generic replacement of clozapine: a simple decision model from a Canadian perspective","year":2004,"lang":"en","type":"article","venue":"Current Medical Research and Opinion","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada); Royal Ottawa Mental Health Centre","funders":"","keywords":"Clozapine; Medicine; Schizophrenia (object-oriented programming); Incidence (geometry); Psychiatry","score_opus":0.22165207092856176,"score_gpt":0.4459791323805348,"score_spread":0.22432706145197306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153769961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85761356,0.07678151,0.023883203,0.023905987,0.001418115,0.0009148972,0.0018004237,0.000029592567,0.01365268],"genre_scores_gemma":[0.97491896,0.024178626,0.00022987588,0.0003212509,0.00025414376,0.000022780696,0.000053931504,0.000011682647,0.000008720675],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99852663,0.000018829438,0.00043508946,0.00040221095,0.00015803093,0.00045919247],"domain_scores_gemma":[0.99847,0.00014694146,0.0000705749,0.00022648196,0.00008754831,0.0009984624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010754191,0.00009968031,0.00026506177,0.00034054485,0.00011942425,0.000036042722,0.00024811426,0.000105543695,0.00051841664],"category_scores_gemma":[0.0010873391,0.00010198279,0.000055799086,0.0002232321,0.00020244998,0.00008466082,0.00011615833,0.0003960107,0.00011982686],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021462841,0.0003277721,0.0025065788,0.000049336933,0.000050675615,0.0000033732567,0.00096012006,0.0003875583,0.000014612632,0.93375677,0.012442282,0.04928627],"study_design_scores_gemma":[0.0017833441,0.00018197397,0.0015311101,0.00008783296,0.000001206109,0.0000011249847,0.00008048607,0.062044784,0.000062029656,0.7712854,0.16279528,0.00014541432],"about_ca_topic_score_codex":0.055329096,"about_ca_topic_score_gemma":0.0052524083,"teacher_disagreement_score":0.16247138,"about_ca_system_score_codex":0.0004711633,"about_ca_system_score_gemma":0.00060279586,"threshold_uncertainty_score":0.95096153},"labels":[],"label_agreement":null},{"id":"W2154163772","doi":"10.1177/009286150904300612","title":"A Matrix to Determine Health Economic Viability Throughout Product Development: A Pharmaceutical Industry Perspective","year":2009,"lang":"en","type":"article","venue":"Drug Information Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Market penetration; Reimbursement; New product development; Drug development; Business; Risk analysis (engineering); Product (mathematics); Pharmaceutical industry; Industrial organization; Marketing; Process management; Public economics; Environmental economics; Operations management; Operations research; Management science; Economics; Drug; Health care; Economic growth; Medicine; Pharmacology; Engineering; Mathematics","score_opus":0.05471813702570248,"score_gpt":0.362655317404229,"score_spread":0.3079371803785265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154163772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7049516,0.0014199255,0.0065463106,0.21231595,0.0021213454,0.0015955196,0.00045829927,0.0001692998,0.07042177],"genre_scores_gemma":[0.9727291,0.000116383155,0.0029864984,0.023441253,0.00052484573,0.000013879053,0.0000151401355,0.000012627329,0.0001602964],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99761987,0.000030574243,0.0014991105,0.0002413489,0.000054635864,0.000554445],"domain_scores_gemma":[0.9984336,0.00002802328,0.0006101045,0.00022189145,0.000074119685,0.0006322884],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016023017,0.0002179982,0.00043896906,0.00041135194,0.00032875972,0.00033747088,0.000329082,0.0000923469,0.00072595995],"category_scores_gemma":[0.00015064373,0.00024383611,0.00012249705,0.00017741795,0.000037771246,0.001746242,0.000058609956,0.00080748525,0.0025983425],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056940474,0.00072347844,0.01754893,0.00017734538,0.00039482708,0.000009743687,0.07742715,0.008526801,0.000023052628,0.5188539,0.11228306,0.26346233],"study_design_scores_gemma":[0.0015273001,0.00010677629,0.013570796,0.000021137477,0.000005251321,0.0001609963,0.00060942397,0.0071129655,0.0003863555,0.020586241,0.9553834,0.0005293445],"about_ca_topic_score_codex":0.000029704126,"about_ca_topic_score_gemma":0.000005294495,"teacher_disagreement_score":0.84310037,"about_ca_system_score_codex":0.0015950421,"about_ca_system_score_gemma":0.00041468034,"threshold_uncertainty_score":0.99817824},"labels":[],"label_agreement":null},{"id":"W2154209739","doi":"10.7202/019618ar","title":"Quelques réflexions sur des pratiques d’utilisation des médicaments hors cadre médical","year":2009,"lang":"fr","type":"article","venue":"Drogues santé et société","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal","funders":"","keywords":"Humanities; Political science; Philosophy","score_opus":0.0792959884621629,"score_gpt":0.3667453148892661,"score_spread":0.2874493264271032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154209739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6699161,0.048647724,0.001578746,0.029011758,0.0016000551,0.000690093,0.0014442716,0.00023727978,0.24687397],"genre_scores_gemma":[0.92878354,0.041004892,0.0022162523,0.022304988,0.0007882755,0.00003957507,0.00021062788,0.000072886345,0.0045789424],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9963412,0.00023116742,0.0013793058,0.000816162,0.00010288055,0.0011292419],"domain_scores_gemma":[0.99801475,0.00030110794,0.00058892515,0.0004713799,0.00011384606,0.00050998287],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0012458668,0.00053799903,0.0009297453,0.00028386785,0.0005218619,0.0004820597,0.0004871173,0.0006012045,0.0029141575],"category_scores_gemma":[0.00057193055,0.00070287654,0.0004799547,0.00036072734,0.0010417892,0.0014353634,0.00013108499,0.000729867,0.0008707125],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000065575754,0.0010298882,0.01586818,0.00016465267,0.0002820183,0.000017917162,0.0077938624,0.000079964026,0.0000645523,0.73696756,0.009449987,0.22821583],"study_design_scores_gemma":[0.0016014734,0.0005800472,0.104156494,0.00029962452,0.00010014528,0.000031181044,0.0024275423,0.008500568,0.00083466165,0.655825,0.22444223,0.001201036],"about_ca_topic_score_codex":0.0009827259,"about_ca_topic_score_gemma":0.00037470143,"teacher_disagreement_score":0.25886747,"about_ca_system_score_codex":0.00090373645,"about_ca_system_score_gemma":0.0002328198,"threshold_uncertainty_score":0.9999072},"labels":[],"label_agreement":null},{"id":"W2154416265","doi":"10.3821/1913-701x-142.1.3.b","title":"Quelques Perspectives Pharmaceutiques Internationales","year":2009,"lang":"fr","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Political science","score_opus":0.06381744080790648,"score_gpt":0.3037903348477171,"score_spread":0.23997289403981065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154416265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46654218,0.36440423,0.00068232365,0.041798048,0.02521261,0.0011346729,0.011247132,0.00012572766,0.08885306],"genre_scores_gemma":[0.7714904,0.18881947,0.0003966694,0.024758192,0.0043639047,0.000011671869,0.000049881717,0.00008982304,0.010020019],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945718,0.00020715412,0.0017833903,0.0009910442,0.00019909118,0.0022475123],"domain_scores_gemma":[0.99404514,0.00014551362,0.0009348008,0.00040014338,0.0005881915,0.0038861842],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013668898,0.00083455414,0.0010347995,0.0011041118,0.0012828339,0.00097525585,0.0014695408,0.0002371521,0.009543995],"category_scores_gemma":[0.00038212445,0.0011823139,0.0005500305,0.00073806575,0.0005856693,0.001545454,0.000078611345,0.0018283274,0.0003243172],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026968462,0.000623378,0.0031447415,0.00044567726,0.0016608477,0.04751968,0.010747944,0.0027800468,0.00037419065,0.1362139,0.36028957,0.4359303],"study_design_scores_gemma":[0.0021203673,0.00010399405,0.00013868211,0.00007002557,0.00012662698,0.1391443,0.000047029633,0.014951493,0.0007205394,0.012220799,0.8289521,0.0014040943],"about_ca_topic_score_codex":0.053170938,"about_ca_topic_score_gemma":0.067360066,"teacher_disagreement_score":0.46866247,"about_ca_system_score_codex":0.009928913,"about_ca_system_score_gemma":0.0036155982,"threshold_uncertainty_score":0.99906266},"labels":[],"label_agreement":null},{"id":"W2155067918","doi":"10.1016/j.jval.2014.03.118","title":"A Comparison Of The Medicare Average Sales Price And The Average Wholesaler Price","year":2014,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Medicaid; Medicine; Business; Actuarial science; Health care; Economics","score_opus":0.07900655963932553,"score_gpt":0.32525023505912637,"score_spread":0.24624367541980086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155067918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9007217,0.010631665,0.001333864,0.053600956,0.00075114175,0.00091122324,0.00014118683,0.000023639384,0.031884607],"genre_scores_gemma":[0.99399185,0.0011411214,0.00009249021,0.0045449384,0.000099895384,0.000013629322,0.000002410013,0.000014018553,0.00009962998],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9984056,0.00017435352,0.00083259505,0.00024353228,0.000043193035,0.00030072586],"domain_scores_gemma":[0.9984739,0.00055302255,0.0004969243,0.00035284684,0.000011552651,0.00011176712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002370687,0.00011447299,0.0005085589,0.000084994484,0.00012160376,0.00002904468,0.0003306656,0.00006753724,0.00004862386],"category_scores_gemma":[0.00032969916,0.00008221453,0.0000759609,0.00019214097,0.00021414075,0.000058189416,0.00012809559,0.00031252144,0.000047271857],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036823945,0.00008963221,0.10017371,0.00028780368,0.000022611424,1.73012e-7,0.0047135893,0.005157426,0.0000022202482,0.886983,0.001176165,0.0013568394],"study_design_scores_gemma":[0.0033615977,0.000082886785,0.14302717,0.00014995926,0.0000044349927,0.0000047914837,0.000119304525,0.42729485,0.00003215824,0.08585084,0.33980796,0.00026406415],"about_ca_topic_score_codex":0.0014532219,"about_ca_topic_score_gemma":0.000045688008,"teacher_disagreement_score":0.80113214,"about_ca_system_score_codex":0.00008900674,"about_ca_system_score_gemma":0.000058904025,"threshold_uncertainty_score":0.33526114},"labels":[],"label_agreement":null},{"id":"W2155126456","doi":"10.1586/erp.09.34","title":"How should we support pharmaceutical innovation?","year":2009,"lang":"en","type":"article","venue":"Expert Review of Pharmacoeconomics & Outcomes Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University","funders":"","keywords":"Incentive; Subsidy; Business; Productivity; Pharmaceutical industry; Risk analysis (engineering); Industrial organization; Marketing; Economics; Medicine; Pharmacology; Economic growth","score_opus":0.21842768923524403,"score_gpt":0.557909442245123,"score_spread":0.33948175300987893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155126456","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009905452,0.22112045,0.0006452181,0.61722493,0.0018867571,0.002698252,0.0007229199,0.00015441283,0.14564158],"genre_scores_gemma":[0.30728486,0.5537402,0.0014653759,0.13092871,0.0009731457,0.00020222257,0.00011530952,0.000113208676,0.0051769638],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952993,0.00014646456,0.002245449,0.0009217827,0.00019268288,0.001194355],"domain_scores_gemma":[0.99732643,0.0004028581,0.0006413042,0.0008707571,0.00029827774,0.00046035947],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0048732026,0.00046859292,0.001656628,0.0010627877,0.0002001344,0.00021790684,0.0013262536,0.00018721941,0.005378555],"category_scores_gemma":[0.00063573895,0.0004863049,0.00052193314,0.0010499068,0.00029456947,0.0007647875,0.00027852156,0.0010533442,0.0013760121],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007243289,0.00067332044,0.0024332497,0.0017066441,0.00033184243,0.00001621209,0.00036528605,0.0000074841373,0.00133965,0.5934669,0.32505608,0.0745309],"study_design_scores_gemma":[0.0012816903,0.00013043264,0.0003502873,0.00023177308,0.000012008524,0.000010642932,0.000033159155,0.0009634242,0.0029002118,0.019859178,0.9737118,0.0005154284],"about_ca_topic_score_codex":0.000027569542,"about_ca_topic_score_gemma":0.0000012292053,"teacher_disagreement_score":0.64865565,"about_ca_system_score_codex":0.00043489647,"about_ca_system_score_gemma":0.00019835419,"threshold_uncertainty_score":0.99975884},"labels":[],"label_agreement":null},{"id":"W2155298214","doi":"10.1016/j.healthpol.2008.12.002","title":"Pricing of multiple dosage prescription medications: An analysis of the Ontario Drug Benefit Formulary","year":2009,"lang":"en","type":"article","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University","funders":"","keywords":"Formulary; Generic drug; Listing (finance); Business; Actuarial science; Medical prescription; Drug; Drug pricing; Medicine; Pharmacology; Finance","score_opus":0.06052141823828256,"score_gpt":0.34002259709760074,"score_spread":0.2795011788593182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155298214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773825,0.0007264698,0.00041808072,0.013813502,0.0001039665,0.00035823052,0.00027732976,0.000015120951,0.006904836],"genre_scores_gemma":[0.9917583,0.0004662895,0.00026236798,0.007138934,0.00008623918,0.000007836974,0.000031096995,0.000007610241,0.00024135527],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99852306,0.000022417342,0.00092090864,0.00021348761,0.00004024998,0.0002798874],"domain_scores_gemma":[0.9985448,0.00005957664,0.0007285793,0.00048373337,0.000020953754,0.00016234194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062093954,0.00009933165,0.00047260028,0.00052514736,0.00010927738,0.000012032892,0.00028857912,0.00005532285,0.00012401964],"category_scores_gemma":[0.000085314605,0.00009497273,0.00018576783,0.0006748709,0.000044651926,0.00017390495,0.00003580756,0.00013908719,0.000008984331],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033718912,0.0005137106,0.21566392,0.00011165357,0.00038325478,1.1399219e-7,0.019575927,0.004367724,0.000068453206,0.7435569,0.00048019332,0.015244387],"study_design_scores_gemma":[0.0004973633,0.00007774701,0.8766922,0.000018993787,0.000053399246,5.150772e-7,0.000052457744,0.055087395,0.0001468054,0.031933088,0.03530514,0.00013493137],"about_ca_topic_score_codex":0.17271172,"about_ca_topic_score_gemma":0.04966339,"teacher_disagreement_score":0.71162385,"about_ca_system_score_codex":0.0003835171,"about_ca_system_score_gemma":0.00019916393,"threshold_uncertainty_score":0.9676778},"labels":[],"label_agreement":null},{"id":"W2156182284","doi":"10.1016/j.healthpol.2010.04.001","title":"Assessment of the impact of market regulation in Mali on the price of essential medicines provided through the private sector","year":2010,"lang":"en","type":"article","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Decree; Private sector; Government (linguistics); Enforcement; Business; Essential medicines; Pharmacy; Public sector; Distribution (mathematics); Public economics; Economic growth; Economics; Medicine; Economy; Health care; Law; Family medicine","score_opus":0.062318028672044556,"score_gpt":0.40377774122570437,"score_spread":0.3414597125536598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156182284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9164904,0.00007196093,0.000043784068,0.05891902,0.00021852071,0.00074722746,0.00019831955,0.000003944775,0.023306834],"genre_scores_gemma":[0.9964823,0.00017393309,0.00006311799,0.0029340622,0.0002296212,0.00002071856,0.0000022496276,0.000013000361,0.000081007085],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9985513,0.00009585274,0.0008771944,0.00015798003,0.00005343237,0.00026426034],"domain_scores_gemma":[0.9980269,0.00032087349,0.0010535314,0.0005205452,0.00002766307,0.00005045144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013259674,0.00011340545,0.00036980424,0.00011927305,0.00006992171,0.000009358406,0.00036014948,0.00006537537,0.00037620924],"category_scores_gemma":[0.00027604098,0.00006225981,0.00013918542,0.00038884103,0.000172795,0.0000663157,0.000075121374,0.0002862794,0.0000032938751],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004068407,0.0001478153,0.04219301,0.00015546239,0.00004625148,4.3634117e-8,0.001193287,0.00027329542,0.0005676158,0.95183516,0.003316822,0.00023053389],"study_design_scores_gemma":[0.0005366143,0.00011638912,0.9360384,0.000039958155,0.0000031532509,0.0000011511073,0.000022162007,0.0070810216,0.00055456744,0.04843932,0.007097435,0.00006986723],"about_ca_topic_score_codex":0.01010736,"about_ca_topic_score_gemma":0.00025230955,"teacher_disagreement_score":0.90339583,"about_ca_system_score_codex":0.00013206973,"about_ca_system_score_gemma":0.0003961718,"threshold_uncertainty_score":0.9964844},"labels":[],"label_agreement":null},{"id":"W2157246911","doi":"10.1007/s12630-013-9920-z","title":"Drug shortages in Canadian anesthesia: a national survey","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Anesthesia/Journal canadien d anesthésie","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec; Ottawa Hospital; Capital District Health Authority; University of Ottawa; Dalhousie University","funders":"","keywords":"Economic shortage; Anesthesia; Medicine","score_opus":0.03657152801939509,"score_gpt":0.24802814337633716,"score_spread":0.21145661535694207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157246911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96107584,0.0023162544,0.0000025629154,0.028425068,0.00032701963,0.00024226645,0.000061612416,0.00000570494,0.007543694],"genre_scores_gemma":[0.99651736,0.00017416934,0.00012921807,0.0018295402,0.0005491368,0.000009570951,0.000016331272,0.00007318674,0.0007014814],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9956727,0.00015203757,0.0018806282,0.00036998614,0.00016511593,0.0017595377],"domain_scores_gemma":[0.99268943,0.00016738297,0.00088717294,0.0002528943,0.00058555737,0.0054175504],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0045893076,0.00041298126,0.00094851665,0.002995901,0.00039964804,0.0006856986,0.0011067451,0.00027398468,0.0025448059],"category_scores_gemma":[0.00051955663,0.00046427172,0.0003072224,0.00077850797,0.00022355234,0.0010736793,0.000008761115,0.0011481333,0.0005826897],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037227805,0.000074359275,0.71050733,0.000033354474,0.00017860434,0.1552699,0.0018988921,0.0010354943,0.0000028455815,0.03496486,0.09510338,0.00089370797],"study_design_scores_gemma":[0.00088803796,0.00015602946,0.37025633,0.00006864416,0.000012293833,0.4782854,0.00017958955,0.00053274684,0.0000062888785,0.019948214,0.12895647,0.0007099684],"about_ca_topic_score_codex":0.8685902,"about_ca_topic_score_gemma":0.927414,"teacher_disagreement_score":0.34025103,"about_ca_system_score_codex":0.0032415115,"about_ca_system_score_gemma":0.007843392,"threshold_uncertainty_score":0.9997809},"labels":[],"label_agreement":null},{"id":"W2157428390","doi":"10.2139/ssrn.946395","title":"Informational Spillovers and Strategic Launch Delay of Pharmaceutical Drugs","year":2006,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"International Health Economics Association","funders":"","keywords":"Business; Industrial organization; Marketing; Process management","score_opus":0.024375922371507697,"score_gpt":0.2646331026692938,"score_spread":0.2402571802977861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157428390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8878691,0.0055934926,0.0006422099,0.0018908336,0.00017468269,0.000093858886,0.00007822947,0.0000120986015,0.10364549],"genre_scores_gemma":[0.9949916,0.0038185287,0.00006790662,0.00047124617,0.00020912758,0.0000019227969,0.000007949221,0.000012582926,0.0004191646],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9981036,0.0000110606925,0.0006543164,0.0001432223,0.000042721033,0.001045052],"domain_scores_gemma":[0.9994415,0.00004020062,0.00030416402,0.000084226915,0.00002827828,0.000101620164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001119472,0.00012555876,0.00025404693,0.00017600706,0.000088906,0.0000570592,0.00015515878,0.00007307555,0.00022723639],"category_scores_gemma":[0.00001374783,0.00013593111,0.00009970089,0.00011134177,0.000091451504,0.00027117695,0.0000329087,0.0007426897,0.00009498219],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025362442,0.000039725892,0.0035653543,0.0000103362045,0.00006296293,4.8158614e-7,0.00004098191,0.00012354263,0.00002458561,0.9951748,0.00014226437,0.00078959845],"study_design_scores_gemma":[0.0011862068,0.00007956775,0.0007562876,0.0000038483813,0.0000094609995,0.00012486897,0.00014140757,0.0056657493,0.00006560117,0.9612975,0.03049828,0.00017123837],"about_ca_topic_score_codex":0.00010824836,"about_ca_topic_score_gemma":0.000043184962,"teacher_disagreement_score":0.107122466,"about_ca_system_score_codex":0.00031680395,"about_ca_system_score_gemma":0.0003270726,"threshold_uncertainty_score":0.554311},"labels":[],"label_agreement":null},{"id":"W2157607103","doi":"10.1504/ijtip.2004.004925","title":"A wealth of failures: sensemaking in a pharmaceutical R&amp;D pipeline","year":2004,"lang":"en","type":"article","venue":"International Journal of Technology Intelligence and Planning","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Illinois at Urbana-Champaign; Canada Research Chairs","keywords":"Shadow (psychology); Sensemaking; Investment (military); Pipeline (software); Business; Proposition; Economics; Marketing; Industrial organization; Computer science; Knowledge management; Political science; Psychology","score_opus":0.09550204824972933,"score_gpt":0.37904234430300304,"score_spread":0.2835402960532737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157607103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93340856,0.0058257035,0.043149453,0.015447541,0.0006070578,0.000067952744,0.00003630416,0.0000120094,0.0014454047],"genre_scores_gemma":[0.994734,0.0012951369,0.003257475,0.00057713484,0.00011775724,0.0000011209308,0.0000012065082,0.0000068550426,0.00000932014],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99875253,0.000005985195,0.0008960475,0.00013315596,0.000043729437,0.00016857231],"domain_scores_gemma":[0.99920344,0.00007183589,0.00050801673,0.0000713412,0.00008802978,0.000057359946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049086515,0.00009088408,0.00030356727,0.0009968047,0.00001825794,0.000020128307,0.00032793597,0.00011420872,0.000054923454],"category_scores_gemma":[0.00027983775,0.00009684723,0.00006388647,0.00018220728,0.00011940987,0.00014445974,0.00006984051,0.00039504498,0.000019678253],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030778555,0.00031787783,0.17009847,0.000052585943,0.00026376685,0.00030960873,0.0025398068,0.013819878,0.0011720432,0.771508,0.00018122583,0.03942897],"study_design_scores_gemma":[0.002079033,0.0002640743,0.0031036332,0.00082618947,0.00001935671,0.0014507719,0.0013076816,0.0063242977,0.014378266,0.8941071,0.075685486,0.00045410922],"about_ca_topic_score_codex":0.000048670467,"about_ca_topic_score_gemma":0.000009538723,"teacher_disagreement_score":0.16699483,"about_ca_system_score_codex":0.00008596759,"about_ca_system_score_gemma":0.000043061278,"threshold_uncertainty_score":0.39493155},"labels":[],"label_agreement":null},{"id":"W2158310952","doi":"10.1016/s0140-6736(02)09096-7","title":"Drug development for neglected diseases: a deficient market and a public-health policy failure","year":2002,"lang":"en","type":"review","venue":"The Lancet","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":882,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Incentive; Private sector; Public health; Pharmaceutical industry; Drug development; Developing country; Business; Market failure; Medicine; Disease; Neglected tropical diseases; Agency (philosophy); Economic growth; Public economics; Drug; Economics; Pharmacology","score_opus":0.15799736751510596,"score_gpt":0.3480298722680117,"score_spread":0.19003250475290573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158310952","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008490049,0.9668686,0.00011942296,0.022770908,0.00015588645,0.0012301928,0.003152366,0.000051319268,0.005642811],"genre_scores_gemma":[0.00005507301,0.99123055,0.0005121932,0.0050217174,0.0011409022,0.00047600648,0.00015832948,0.00006846124,0.0013367783],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99738085,0.000076920674,0.0010281741,0.00056069705,0.000032983986,0.00092034333],"domain_scores_gemma":[0.9979887,0.00028148884,0.0007416889,0.0006108446,0.000020065147,0.00035721986],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00065100606,0.00039487716,0.002312477,0.00033776442,0.0002944,0.0002946695,0.00069800287,0.00012961484,0.0002684645],"category_scores_gemma":[0.0002702012,0.00031701924,0.00028694107,0.00038306284,0.00008844235,0.000079262005,0.00020523241,0.00031693763,0.00022626627],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000073772017,0.000094128736,0.000035618334,0.006846917,0.00026282412,5.5923016e-7,0.0004449814,3.9887934e-7,1.8519379e-9,0.12783389,0.3012603,0.563213],"study_design_scores_gemma":[0.00051072653,0.000014778421,0.00005982597,0.00038705414,0.00002959497,0.000008376984,0.00001006133,0.00028520162,7.2554016e-9,0.0034908203,0.99484843,0.0003551278],"about_ca_topic_score_codex":0.00007767534,"about_ca_topic_score_gemma":0.00005709513,"teacher_disagreement_score":0.69358814,"about_ca_system_score_codex":0.0004654626,"about_ca_system_score_gemma":0.00043458672,"threshold_uncertainty_score":0.9999282},"labels":[],"label_agreement":null},{"id":"W2158413176","doi":"10.12927/hcpap..16873","title":"Taking Our Medicine: Who Should Pay for What?","year":2004,"lang":"en","type":"letter","venue":"A Nudge Too Far? A Nudge at All? On Paying People to Be Healthy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Liberian dollar; Point (geometry); Risk analysis (engineering); Actuarial science; Law and economics; Business; Engineering ethics; Economics; Engineering; Finance; Mathematics","score_opus":0.21902921022448749,"score_gpt":0.3804007118734278,"score_spread":0.1613715016489403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158413176","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0028350987,0.002455708,0.00065912877,0.97950506,0.0048395093,0.0024923887,0.001731742,0.00023562845,0.0052457177],"genre_scores_gemma":[0.0012390547,0.004349257,0.00044435504,0.9842739,0.0022249,0.0010679661,0.00090210966,0.00048437342,0.0050140843],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9917077,0.00010246108,0.0027754987,0.0024296143,0.00024031005,0.0027444467],"domain_scores_gemma":[0.9945301,0.00082777353,0.0019472458,0.0015454914,0.00013112904,0.0010182606],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0018452031,0.0013526579,0.002965106,0.0011235543,0.0006809117,0.00048955367,0.0013930743,0.0016766968,0.0009051326],"category_scores_gemma":[0.0006997171,0.0013254024,0.000826721,0.0006498749,0.000068340116,0.00053285324,0.0004107789,0.0027984655,0.0024882464],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026532603,0.00010815929,0.00021617202,0.0005389737,0.00024041043,0.00004927829,0.0021848956,0.00004810114,0.0000040244736,0.015106424,0.97810656,0.0031316772],"study_design_scores_gemma":[0.0029453787,0.0009877364,0.00035839563,0.000013247273,0.00007219964,0.00003368015,0.00012081455,0.0008116686,0.000011087276,0.006184491,0.9868855,0.0015758094],"about_ca_topic_score_codex":0.0019902291,"about_ca_topic_score_gemma":0.00054083945,"teacher_disagreement_score":0.008921933,"about_ca_system_score_codex":0.0030344082,"about_ca_system_score_gemma":0.00044273536,"threshold_uncertainty_score":0.99992245},"labels":[],"label_agreement":null},{"id":"W2158467616","doi":"10.18553/jmcp.2009.15.1.71","title":"Prior Authorization and Clopidogrel Use - The Truth Lies in the Details","year":2009,"lang":"en","type":"editorial","venue":"Journal of Managed Care Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prior authorization; Clopidogrel; Authorization; Internal medicine; Aspirin; Pharmacology; Computer security","score_opus":0.05385844944678472,"score_gpt":0.3197232124911843,"score_spread":0.26586476304439954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158467616","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03124028,0.05253344,0.00031337282,0.016662216,0.88743496,0.0011104299,0.0008221558,0.000028917637,0.009854214],"genre_scores_gemma":[0.4369858,0.053548843,0.00016879682,0.00288838,0.50592405,0.000019202704,0.000063988395,0.000085257816,0.00031571102],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99790233,0.0001565038,0.0012079203,0.00027551185,0.00013479362,0.0003229088],"domain_scores_gemma":[0.99661416,0.0015780246,0.0013169231,0.00027424181,0.000112040994,0.00010461398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019628897,0.0002845623,0.00064751157,0.0004098383,0.00017954854,0.00058338,0.0008236442,0.00019234439,0.000042043863],"category_scores_gemma":[0.0011118856,0.00020262667,0.00025237497,0.0002441915,0.00008574245,0.0005219303,0.000084276355,0.0017040018,0.000023689281],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017520897,0.00008025629,0.0011198791,0.00016513235,0.00020319983,0.000060726812,0.0033857767,0.00012032579,0.000001467425,0.021850655,0.9469799,0.025857503],"study_design_scores_gemma":[0.0014222512,0.00006541727,0.0015704482,0.00004936501,0.000087904235,0.000011814991,0.00022244912,0.00028062845,0.0000047764665,0.0057078763,0.9903445,0.0002325207],"about_ca_topic_score_codex":0.00009692713,"about_ca_topic_score_gemma":0.00003036707,"teacher_disagreement_score":0.4057455,"about_ca_system_score_codex":0.0001934534,"about_ca_system_score_gemma":0.00010867868,"threshold_uncertainty_score":0.8262876},"labels":[],"label_agreement":null},{"id":"W2158818165","doi":"10.2139/ssrn.1818243","title":"Access Delayed, Access Denied: Waiting for New Medicines in Canada: 2010 Report","year":2010,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Fraser Institute","funders":"","keywords":"Access to medicines; Business; Internet privacy; Medicine; Computer security; Computer science; Nursing; Public health","score_opus":0.0512746259876294,"score_gpt":0.3188238063129418,"score_spread":0.26754918032531244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158818165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9614584,0.0023303758,0.0035306364,0.024475995,0.0027773837,0.0003183082,0.000050062354,0.000014492364,0.0050443574],"genre_scores_gemma":[0.99346375,0.0017644085,0.00008857782,0.0022093903,0.0014876203,0.000016102877,0.0000122758975,0.00003875902,0.0009191145],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9965446,0.000008735619,0.0010325699,0.00034381496,0.000048535716,0.0020217414],"domain_scores_gemma":[0.99870354,0.00011739804,0.00061984063,0.00023321313,0.00004393911,0.00028206693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002058473,0.00018896301,0.00043570175,0.00025605297,0.0001450797,0.00018707068,0.00084433536,0.00010584882,0.0002489094],"category_scores_gemma":[0.00038488093,0.00020422705,0.00011306618,0.0001962915,0.00002842648,0.00057663035,0.000098952,0.0019560005,0.000015977777],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012452679,0.00006139276,0.37870085,0.000023468818,0.0002733794,0.000054751188,0.00008694522,0.0002780676,0.00006577944,0.57858753,0.020192046,0.021551257],"study_design_scores_gemma":[0.0022459328,0.00006174114,0.026060576,0.00001274434,0.000020603751,0.0011360291,0.00010813312,0.007385413,0.00013414744,0.86605406,0.096282914,0.00049771945],"about_ca_topic_score_codex":0.6189259,"about_ca_topic_score_gemma":0.96830904,"teacher_disagreement_score":0.35264027,"about_ca_system_score_codex":0.0012127532,"about_ca_system_score_gemma":0.00794208,"threshold_uncertainty_score":0.997682},"labels":[],"label_agreement":null},{"id":"W2158936341","doi":"10.4212/cjhp.v66i6.1297","title":"Drug Shortages through the Decades: A Big-Picture Perspective","year":2013,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Pharmacy; Negotiation; Economic shortage; Pooling; Purchasing; Business; Health care; Perspective (graphical); Pharmacist; Product (mathematics); Pharmaceutical industry; Marketing; Medicine; Nursing; Political science; Economic growth; Economics; Pharmacology","score_opus":0.04306039342203261,"score_gpt":0.28697491198936326,"score_spread":0.24391451856733065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158936341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6712315,0.016109489,0.000054696906,0.24476188,0.0026051411,0.0005156253,0.0001659528,0.000010223526,0.06454546],"genre_scores_gemma":[0.98739064,0.0004764541,0.00004125511,0.010354326,0.0011054102,0.000012064755,0.0000010005133,0.000028164815,0.00059067865],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99866647,0.00003590799,0.0005936881,0.00017566526,0.000046280264,0.00048198766],"domain_scores_gemma":[0.9986092,0.00011996754,0.0004253996,0.00026215156,0.00014261136,0.00044070373],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00047383347,0.00019020404,0.00031383234,0.00013473425,0.00044168864,0.00038202843,0.0009513243,0.00004131729,0.0017145063],"category_scores_gemma":[0.00014644417,0.00012465271,0.0002635786,0.00021078506,0.00032571418,0.00047639848,0.00003644348,0.00070192147,0.0006254225],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021770204,0.00009227837,0.021831902,0.000015621947,0.00078649656,0.000056560424,0.03775056,0.00043673016,0.000018974668,0.6126915,0.3232881,0.0030095023],"study_design_scores_gemma":[0.00078129815,0.00007939412,0.006730229,0.00001368451,0.000037814487,0.000052766,0.0024802473,0.0004253309,0.00017676264,0.34694558,0.6419534,0.00032350744],"about_ca_topic_score_codex":0.053612642,"about_ca_topic_score_gemma":0.008174431,"teacher_disagreement_score":0.3186653,"about_ca_system_score_codex":0.00035726975,"about_ca_system_score_gemma":0.00036891672,"threshold_uncertainty_score":0.9991981},"labels":[],"label_agreement":null},{"id":"W2159056885","doi":"","title":"Effects of 'Authorized-Generics' on Canadian Drug Prices","year":2007,"lang":"en","type":"article","venue":"Social and Economic Dimensions of an Aging Population Research Papers","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Business; Earnings; Competitor analysis; Competition (biology); Brand names; Incentive; Market share; Prescription drug; Monetary economics; Product (mathematics); Advertising; Economics; Medical prescription; Marketing; Microeconomics; Finance; Pharmacology","score_opus":0.0706960881479631,"score_gpt":0.3656404973994411,"score_spread":0.294944409251478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159056885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9809096,0.00016683596,0.0000022068443,0.0013047814,0.0002128371,0.00019847897,0.00007173322,0.000009868409,0.017123656],"genre_scores_gemma":[0.99902,0.000167975,0.00015865777,0.0003009259,0.00012598101,0.0000050351437,0.000020775798,0.00001730268,0.00018336937],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9986944,0.00003434283,0.0005093713,0.0002930958,0.000041174477,0.00042759694],"domain_scores_gemma":[0.99909276,0.00023923976,0.00019460349,0.00013690598,0.000026261017,0.0003102049],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016309115,0.00010811414,0.0003202806,0.0006017258,0.00031598378,0.00003143777,0.00015187306,0.00008657865,0.000077614415],"category_scores_gemma":[0.00008525796,0.00011645167,0.00007758046,0.00014039168,0.00015302472,0.00014803697,0.000048702594,0.00018094624,0.0000364736],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000118882046,0.00018158645,0.055001304,0.00019469827,0.00015493178,0.0000057798075,0.0031534864,0.0004749671,0.0014447207,0.9206858,0.0012813755,0.017302448],"study_design_scores_gemma":[0.0019565204,0.00029181974,0.86393195,0.00006894351,0.000020314636,0.0000017650003,0.0010196803,0.00398142,0.0035995422,0.06629245,0.058146402,0.0006892032],"about_ca_topic_score_codex":0.05917599,"about_ca_topic_score_gemma":0.0151361935,"teacher_disagreement_score":0.85439336,"about_ca_system_score_codex":0.0002087798,"about_ca_system_score_gemma":0.000056999022,"threshold_uncertainty_score":0.947089},"labels":[],"label_agreement":null},{"id":"W2159099688","doi":"10.1586/14737167.2014.868313","title":"Determining the price for pharmaceuticals in Germany: comparing a shortcut for IQWiG's efficiency frontier method with the price set by the manufacturer for ticagrelor","year":2013,"lang":"en","type":"article","venue":"Expert Review of Pharmacoeconomics & Outcomes Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Economics; Ticagrelor; Set (abstract data type); Frontier; Efficient frontier; Microeconomics; Actuarial science; Public economics; Econometrics; Financial economics; Medicine; Computer science; Internal medicine","score_opus":0.1267396604495972,"score_gpt":0.5269130122506183,"score_spread":0.4001733518010211,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159099688","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13200152,0.22521399,0.1635259,0.38428628,0.0024832608,0.07184611,0.0035366414,0.00012260524,0.016983705],"genre_scores_gemma":[0.6549713,0.09804125,0.026723398,0.16970475,0.0018243546,0.043157786,0.00025579735,0.00063311285,0.004688248],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99598235,0.00023489959,0.0015949047,0.0007801042,0.000120932404,0.0012868234],"domain_scores_gemma":[0.9910778,0.0070826258,0.0006133035,0.00075576204,0.00023653657,0.00023398697],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.008363053,0.00043125977,0.001311243,0.00020416883,0.0005317834,0.000261197,0.0018957484,0.00010874001,0.00041716153],"category_scores_gemma":[0.0005589796,0.00024870274,0.0005226408,0.00026931564,0.00034688326,0.00034501418,0.00030716008,0.0006272579,0.00008090515],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067989883,0.00089257484,0.009190057,0.006967988,0.0017830738,9.616158e-7,0.0047785416,0.0006367605,0.0005932252,0.044649884,0.86298996,0.06683707],"study_design_scores_gemma":[0.0026712334,0.00010915731,0.0007285777,0.00014165338,0.000046413057,0.0000030600916,0.00016171786,0.09349675,0.0010203391,0.0018141698,0.8993929,0.0004140566],"about_ca_topic_score_codex":0.000110860856,"about_ca_topic_score_gemma":0.000014709438,"teacher_disagreement_score":0.5229698,"about_ca_system_score_codex":0.00032682045,"about_ca_system_score_gemma":0.00014070724,"threshold_uncertainty_score":0.99999654},"labels":[],"label_agreement":null},{"id":"W2159386167","doi":"10.1503/cmaj.109-4716","title":"Putting patients first in the age of pharma","year":2014,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Alliance; Drug industry; Health professionals; Medicine; Global health; Alternative medicine; Drug approval; Business; Family medicine; Political science; Public relations; Engineering ethics; Nursing; Health care; Drug; Public health; Pathology; Engineering; Pharmacology; Law","score_opus":0.024014485658968254,"score_gpt":0.24669898776605353,"score_spread":0.2226845021070853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159386167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7614343,0.00024659256,0.00017728916,0.118203275,0.0014173934,0.00016622963,0.00012796397,0.0000057987227,0.11822112],"genre_scores_gemma":[0.9728772,0.00009267162,0.000034459485,0.026448628,0.00049761886,0.0000023654802,0.0000056249532,0.000006203846,0.000035240973],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988992,0.000051627776,0.00056966965,0.0000882256,0.00009977748,0.0002914811],"domain_scores_gemma":[0.99908024,0.00020464769,0.0002953392,0.00006724993,0.000036739246,0.0003157604],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0029544784,0.000058500736,0.00018543,0.00016011506,0.00010230061,0.000054349464,0.00029052753,0.00011754858,0.0012678923],"category_scores_gemma":[0.0017458758,0.00005460604,0.00006881763,0.00013963644,0.000021618567,0.000082778926,0.000010659914,0.00043445357,0.00017753127],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000017198456,0.000049916813,0.9050089,0.0000084952035,0.00002890938,0.000011490531,0.00071188435,0.000020589097,2.310138e-7,0.030130675,0.051618133,0.012409033],"study_design_scores_gemma":[0.0006696557,0.000015375352,0.17210352,0.000009696168,0.0000016699383,0.0000039076517,0.0000167251,0.001643166,9.962392e-7,0.009440319,0.81603616,0.000058831447],"about_ca_topic_score_codex":0.0016917743,"about_ca_topic_score_gemma":0.008411058,"teacher_disagreement_score":0.764418,"about_ca_system_score_codex":0.0003251151,"about_ca_system_score_gemma":0.00011661868,"threshold_uncertainty_score":0.99964505},"labels":[],"label_agreement":null},{"id":"W2159480705","doi":"10.7939/r39g5gf7c","title":"Challenges for Intellectual Property Management of HIV Vaccine-Related Research and Development: Part 2, The Canadian Context","year":2014,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"HIV vaccine; Context (archaeology); Government (linguistics); Economic growth; Political science; Public health; Global health; Public relations; Health care; Medicine; Public administration; Human immunodeficiency virus (HIV); Immunology; Economics; Vaccine trial","score_opus":0.2698144403549777,"score_gpt":0.2967032603739566,"score_spread":0.02688882001897891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159480705","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14635137,0.013531195,0.00016762844,0.07695982,0.0008987837,0.005574006,0.00018698968,0.000043735632,0.7562865],"genre_scores_gemma":[0.99404985,0.0011867371,0.000048604852,0.00038727603,0.00004858484,0.0009526549,0.000006343888,0.000015150214,0.0033047847],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988547,0.000020924366,0.00038576312,0.00025686345,0.00002322926,0.00045854473],"domain_scores_gemma":[0.99931085,0.00019325461,0.000078202975,0.0001924326,0.00003948126,0.00018575687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002247413,0.00008557135,0.00020205138,0.00017159875,0.00020040089,0.000047598143,0.00023074637,0.00006115708,0.00005922683],"category_scores_gemma":[0.00015563716,0.00006344812,0.000028335617,0.00009111125,0.0000794305,0.000049750677,0.00007542357,0.00012603491,0.00009255731],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003162851,0.000039199174,0.0009137147,0.00010318762,0.00017523876,3.432251e-7,0.0012346266,0.0000033861822,6.8352946e-8,0.53123534,0.008158556,0.45810473],"study_design_scores_gemma":[0.00057674857,0.000017327518,0.023542102,0.0000064987744,0.000002697084,9.756753e-7,0.000114967894,0.0006714376,0.00003956963,0.014084036,0.96084344,0.000100187564],"about_ca_topic_score_codex":0.0014595434,"about_ca_topic_score_gemma":0.01574947,"teacher_disagreement_score":0.9526849,"about_ca_system_score_codex":0.000110291236,"about_ca_system_score_gemma":0.00002759014,"threshold_uncertainty_score":0.8788574},"labels":[],"label_agreement":null},{"id":"W2159809648","doi":"10.1503/cmaj.120527","title":"Canadian drug shortage: recent history of a mystery","year":2012,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Economic shortage; Prochlorperazine; Street drugs; Medicine; Pharmacist; Drug; Computer science; World Wide Web; Pharmacy; Family medicine; Pharmacology; Surgery","score_opus":0.032619379993617734,"score_gpt":0.23999918819182958,"score_spread":0.20737980819821183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159809648","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17185017,0.021109466,0.000049257116,0.17669535,0.015454622,0.00026098883,0.00071139715,0.000020577794,0.61384815],"genre_scores_gemma":[0.9458523,0.0014486911,0.000053527427,0.045891907,0.0020568958,0.0000053232643,0.00001273601,0.000025032567,0.0046535884],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99822974,0.00004402694,0.0007379681,0.00011777114,0.00011867643,0.00075180933],"domain_scores_gemma":[0.9955844,0.0000682317,0.00037681195,0.00011269183,0.000088985194,0.0037688531],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.002702887,0.0001035714,0.0003074415,0.00043182744,0.00008332215,0.000028918465,0.0002553499,0.00024271033,0.023101645],"category_scores_gemma":[0.0008089101,0.00012560321,0.00011413135,0.00012085372,0.00003208852,0.00022415094,0.00001195486,0.0006069304,0.00094668707],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000017143425,0.000023051944,0.22926147,0.000007018555,0.000084538566,0.000014372875,0.0008556717,0.0000018944497,6.73048e-7,0.020284828,0.7441256,0.0053391405],"study_design_scores_gemma":[0.00025309707,0.0000060603006,0.015417097,0.0000086676555,0.0000051599472,0.000028991815,0.000049993778,0.00017674868,0.0000019620798,0.00097139674,0.98294693,0.00013391403],"about_ca_topic_score_codex":0.1782539,"about_ca_topic_score_gemma":0.47952762,"teacher_disagreement_score":0.77400213,"about_ca_system_score_codex":0.0106953075,"about_ca_system_score_gemma":0.0038731995,"threshold_uncertainty_score":0.9998312},"labels":[],"label_agreement":null},{"id":"W2159987332","doi":"10.3238/arztebl.2009.0783","title":"The Effect of Introducing Rebate Contracts to Promote Generic Drug Substitution, on Doctors’ Prescribing Practices","year":2009,"lang":"de","type":"article","venue":"Deutsches Ärzteblatt international","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Medicine; Statutory law; Health insurance; Prescription drug; Substitution (logic); Quarter (Canadian coin); Family medicine; Drug; Health economics; Population; Actuarial science; Environmental health; Health care; Public health; Law; Business; Pharmacology; Nursing","score_opus":0.043471832872591765,"score_gpt":0.3126113739242415,"score_spread":0.2691395410516497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159987332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94236594,0.004303277,0.00021682419,0.03379613,0.0060169436,0.0008381971,0.0003663421,0.000038529633,0.012057809],"genre_scores_gemma":[0.9924262,0.0017285096,0.00027475122,0.0021981883,0.0023667875,0.00003243819,0.000060047307,0.000034544635,0.0008784918],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99692905,0.0001126977,0.0013937394,0.00078502554,0.00016642478,0.00061308296],"domain_scores_gemma":[0.99635375,0.0008563041,0.0017893977,0.0005884302,0.00013394,0.0002781621],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0024474484,0.0004051741,0.0006345008,0.0003748965,0.000333681,0.0005058304,0.0009518842,0.00014827512,0.00019070192],"category_scores_gemma":[0.0027245907,0.00036921984,0.00028129405,0.00029304592,0.00012725973,0.00049728085,0.00014231875,0.00055146083,0.0011460515],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00454561,0.0010487768,0.054846548,0.00020817346,0.0036313657,0.000052456482,0.004090165,0.026487416,0.005137793,0.78753835,0.038488783,0.07392454],"study_design_scores_gemma":[0.0016078268,0.0007628058,0.017040165,0.0001699547,0.00009450362,0.000008643382,0.000016720236,0.021213735,0.02194027,0.003244799,0.9333075,0.00059302594],"about_ca_topic_score_codex":0.00011994428,"about_ca_topic_score_gemma":0.000018927441,"teacher_disagreement_score":0.8948188,"about_ca_system_score_codex":0.0003677067,"about_ca_system_score_gemma":0.0000727234,"threshold_uncertainty_score":0.99987596},"labels":[],"label_agreement":null},{"id":"W2160118117","doi":"10.18433/j31k51","title":"Determination of Bioequivalence for Drugs with Narrow Therapeutic Index: Reduction of the Regulatory Burden","year":2013,"lang":"en","type":"article","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Bioequivalence; Replicate; Food and drug administration; Statistics; Econometrics; Pharmacology; Mathematics; Medicine; Toxicology; Computer science; Pharmacokinetics; Biology","score_opus":0.08461377102741516,"score_gpt":0.35033936272757626,"score_spread":0.2657255917001611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160118117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855294,0.0027794782,0.00087239523,0.0077170893,0.00069360086,0.00047909914,0.00003192505,0.000006097045,0.0018909053],"genre_scores_gemma":[0.9980059,0.00028288382,0.0008929955,0.00046878456,0.00025281074,0.000013619535,2.6706812e-7,0.000012454018,0.00007027097],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99816495,0.000051831787,0.0010684202,0.00022450593,0.00017230773,0.00031799194],"domain_scores_gemma":[0.99795383,0.0001814514,0.0013310153,0.0001526469,0.00021711386,0.00016395038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015198216,0.00015334562,0.000398801,0.00024085004,0.00014125023,0.000052465402,0.00072332885,0.00004619946,0.00032903193],"category_scores_gemma":[0.00007283742,0.00010709688,0.00023411354,0.00046532287,0.0008857816,0.00072196545,0.00005797446,0.0002340782,0.000008455314],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014828712,0.0013805721,0.09996996,0.0012129472,0.00061566953,0.0000030693234,0.006343384,0.0066295513,0.22223382,0.22545126,0.002886384,0.4317905],"study_design_scores_gemma":[0.008242887,0.0010561614,0.013205012,0.0002148242,0.0002885657,0.00017947513,0.00079508196,0.24800935,0.48303032,0.10272725,0.14138998,0.0008610912],"about_ca_topic_score_codex":0.00006342317,"about_ca_topic_score_gemma":6.3291066e-7,"teacher_disagreement_score":0.43092942,"about_ca_system_score_codex":0.00008144538,"about_ca_system_score_gemma":0.00014407528,"threshold_uncertainty_score":0.4367284},"labels":[],"label_agreement":null},{"id":"W2160490347","doi":"10.1002/jps.23474","title":"Review of the Quality of Pediatric Medications in Developing Countries","year":2013,"lang":"en","type":"review","venue":"Journal of Pharmaceutical Sciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Developing country; MEDLINE; Quality (philosophy); Adverse effect; Family medicine; Alternative medicine; Traditional medicine; Intensive care medicine; Environmental health; Pediatrics; Pharmacology; Pathology","score_opus":0.38852537713787966,"score_gpt":0.49931259627354735,"score_spread":0.11078721913566769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160490347","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000108387074,0.99218553,0.000032152348,0.004267347,0.00055513164,0.00033952348,0.00009307461,0.0000014713177,0.0024173905],"genre_scores_gemma":[0.00013075264,0.99779785,0.00029240866,0.0015699511,0.00017539371,0.000009472194,6.6210254e-7,0.000008219998,0.000015303462],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99535674,0.00018862855,0.0038110907,0.00020867852,0.00015857193,0.0002762677],"domain_scores_gemma":[0.9943967,0.0008258817,0.004331415,0.00018978244,0.000119551085,0.0001366639],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006554454,0.00018934932,0.0019872955,0.00038439003,0.0000627065,0.000025969262,0.0013046033,0.00012034147,0.0005719851],"category_scores_gemma":[0.0009656982,0.00012333046,0.0005796493,0.0011778178,0.00054805964,0.0002241557,0.00016734855,0.00047792264,0.000040848026],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000006402795,0.0002898984,0.0070852516,0.19388622,0.00033057522,0.0000015059003,0.00012700987,0.000006058793,5.999342e-7,0.60889196,0.0077468418,0.18162766],"study_design_scores_gemma":[0.0001442029,0.00001714841,0.00024259464,0.009575984,0.00012571678,0.000008812164,0.000003459199,0.000021243994,0.0000028971951,0.0031276105,0.9865865,0.00014379364],"about_ca_topic_score_codex":0.000031116393,"about_ca_topic_score_gemma":0.0000028860684,"teacher_disagreement_score":0.9788397,"about_ca_system_score_codex":0.00015804348,"about_ca_system_score_gemma":0.00087187736,"threshold_uncertainty_score":0.6262835},"labels":[],"label_agreement":null},{"id":"W2160754141","doi":"10.2174/1875692110806020108","title":"Personalized Medicine, Bioethics and Social Responsibilities: Re-thinking the Pharmaceutical Industry to Remedy Inequities in Patient Care and International Health","year":2008,"lang":"en","type":"article","venue":"Current pharmacogenomics and personalized medicine (Online)/Current pharmacogenomics and personalized medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Canadian Institutes of Health Research; Mayo Clinic","keywords":"Bioethics; Personalized medicine; Pharmacogenomics; Pharmaceutical industry; Biobank; Sustainability; Business; Health care; Prosperity; Public relations; Medicine; Economic growth; Political science; Pharmacology; Economics","score_opus":0.2833368804131214,"score_gpt":0.44206263021824593,"score_spread":0.15872574980512455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160754141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6155914,0.26447353,0.00009157997,0.112325616,0.0029080976,0.0015285161,0.0025622505,0.00006546936,0.0004535426],"genre_scores_gemma":[0.5707156,0.39282224,0.00027114755,0.029963473,0.0046730037,0.0001562359,0.0010025857,0.0001707651,0.00022495314],"study_design_codex":"qualitative","study_design_gemma":"not_applicable","domain_scores_codex":[0.9928746,0.00043855511,0.0028018132,0.0019497176,0.00051268545,0.0014226151],"domain_scores_gemma":[0.9957277,0.00096958195,0.0010829858,0.00038509534,0.00028592107,0.001548674],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0032870725,0.001233433,0.002402517,0.0012108774,0.0012406398,0.000112675065,0.0007420436,0.00039019607,0.0008651768],"category_scores_gemma":[0.00048207073,0.0010506642,0.0002196089,0.0005999406,0.0069167404,0.00033865913,0.000730961,0.0029830437,0.000007736062],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063594785,0.0011269386,0.027426794,0.0042181313,0.001429522,0.00014109934,0.5612684,0.00003118849,0.0030138975,0.12279943,0.030642642,0.2415425],"study_design_scores_gemma":[0.022836665,0.0008565236,0.0012929109,0.0009655881,0.00033639005,0.0003784251,0.03484086,0.0067122104,0.0000331097,0.0037849993,0.926562,0.0014003023],"about_ca_topic_score_codex":0.00088195794,"about_ca_topic_score_gemma":0.0000988182,"teacher_disagreement_score":0.8959194,"about_ca_system_score_codex":0.0006598818,"about_ca_system_score_gemma":0.00043434306,"threshold_uncertainty_score":0.9993171},"labels":[],"label_agreement":null},{"id":"W2160956735","doi":"","title":"The Misguided War against Medicines 2011","year":2011,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Fraser Institute","funders":"","keywords":"Health care; Public economics; Medical prescription; Business; Government (linguistics); Population; Goods and services; Monopoly; Revenue; Prescription drug; Subsidy; Consumption (sociology); Government spending; Government revenue; Tax revenue; Economics; Economic growth; Welfare; Finance; Medicine; Environmental health; Market economy","score_opus":0.04930729963309457,"score_gpt":0.2615680378649145,"score_spread":0.21226073823181993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160956735","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.29308292,0.11976204,0.0035380223,0.037934344,0.0037000356,0.00048154112,0.000049310267,0.00010751655,0.5413443],"genre_scores_gemma":[0.9064731,0.08627788,0.000058003676,0.003579457,0.0007138976,0.000008740252,0.000002116274,0.00003603075,0.0028507726],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99719375,0.000022195833,0.00065245194,0.00020622098,0.00003237984,0.0018929833],"domain_scores_gemma":[0.9991622,0.000056299268,0.00033803046,0.00024992306,0.000031974498,0.00016157997],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002556199,0.00015390376,0.00025433121,0.00010879379,0.00037673116,0.000039894065,0.00054310093,0.00007387602,0.00035299078],"category_scores_gemma":[0.00009948281,0.000120971075,0.00016509842,0.000080609294,0.000109806584,0.00016423443,0.000047734742,0.0011191756,0.0014590377],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034659726,0.000039841725,0.0031573751,0.0000022154973,0.00018153497,0.0000022379609,0.00028743976,0.0000022459376,0.000011338395,0.9786893,0.007183747,0.010408057],"study_design_scores_gemma":[0.00050487055,0.000087899905,0.00093395053,0.0000029661878,0.0000074284976,0.000063432766,0.00025254374,0.00031069393,0.000044836364,0.7608988,0.2367327,0.00015983621],"about_ca_topic_score_codex":0.000106779764,"about_ca_topic_score_gemma":0.0002557649,"teacher_disagreement_score":0.6133902,"about_ca_system_score_codex":0.0003872902,"about_ca_system_score_gemma":0.00032727493,"threshold_uncertainty_score":0.9993184},"labels":[],"label_agreement":null},{"id":"W2161016869","doi":"10.1377/hlthaff.2014.0658","title":"Compulsory Licensing Often Did Not Produce Lower Prices For Antiretrovirals Compared To International Procurement","year":2015,"lang":"en","type":"article","venue":"Health Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Population and Public Health","funders":"Canadian Institutes of Health Research","keywords":"Procurement; License; Business; Developing country; Quality (philosophy); Work (physics); Public economics; International economics; Economics; Economic growth; Marketing; Political science; Law","score_opus":0.1985946618427264,"score_gpt":0.36835580051017586,"score_spread":0.16976113866744946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161016869","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3075817,0.0034718618,0.018727362,0.5564821,0.012921116,0.0071125976,0.0020251528,0.00037532905,0.09130281],"genre_scores_gemma":[0.9751178,0.000058348378,0.005297009,0.018443247,0.00060040446,0.00007447591,0.000044467106,0.00003150925,0.00033275152],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981259,0.000012757876,0.0007885266,0.00050114957,0.000059480542,0.000512156],"domain_scores_gemma":[0.998703,0.000047482503,0.00038966778,0.00025364116,0.000092418326,0.00051375804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010668198,0.00016648017,0.0004585715,0.00021583872,0.0000996744,0.000101129226,0.000294819,0.000050054317,0.000048207177],"category_scores_gemma":[0.0002071091,0.00019460531,0.00008781206,0.00013853636,0.000032994572,0.00018269494,0.00010103884,0.000115420866,0.0004449295],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014685963,0.0013662712,0.023801155,0.00071222044,0.00032512358,0.000005004931,0.008497648,0.004093772,0.0001347554,0.24777533,0.6955975,0.01622261],"study_design_scores_gemma":[0.0013164082,0.0002818146,0.0025805917,0.000032700977,0.000002686911,0.0000021855683,0.00018532142,0.015146016,0.00013670955,0.002605694,0.9774084,0.00030144744],"about_ca_topic_score_codex":0.00014460321,"about_ca_topic_score_gemma":0.000027767597,"teacher_disagreement_score":0.6675361,"about_ca_system_score_codex":0.00045703852,"about_ca_system_score_gemma":0.00015109823,"threshold_uncertainty_score":0.79357743},"labels":[],"label_agreement":null},{"id":"W2161560309","doi":"10.1071/ah090258","title":"Policy challenges of nanomedicine for Australia's PBS","year":2009,"lang":"en","type":"article","venue":"Australian Health Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Health Canada; National Institutes of Health; Anhui University of Science and Technology","keywords":"Government (linguistics); Pharmaceutical Benefits Scheme; Health economics; Risk analysis (engineering); Population health; Business; Pharmaceutical industry; Precautionary principle; Public economics; Medicine; Public health; Economics; Population; Pharmacology; Environmental health; Biotechnology","score_opus":0.32554781708392805,"score_gpt":0.45355650347110005,"score_spread":0.128008686387172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161560309","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011126415,0.29358238,0.000081116596,0.6930188,0.00033134967,0.0017364175,0.00058734184,0.000045127483,0.009504824],"genre_scores_gemma":[0.2898067,0.657988,0.0009225382,0.047859207,0.0006261101,0.0000688434,0.000040613228,0.00002813676,0.0026598414],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976098,0.000022700287,0.0014006813,0.00036062635,0.000029925048,0.00057624845],"domain_scores_gemma":[0.99845827,0.00005460233,0.0006964958,0.00039811284,0.000033057742,0.0003594395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011802794,0.00019671858,0.0011014799,0.00019120167,0.00005504127,0.000009181225,0.0002791796,0.000084050946,0.0003309869],"category_scores_gemma":[0.00017500097,0.00020867912,0.00023696819,0.0002391375,0.000055770815,0.00010193909,0.000014905964,0.0001418382,0.00024070026],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008090511,0.0000891409,0.00014380101,0.0050390125,0.00002723176,4.3003374e-7,0.00006960036,0.0000012189381,0.0000030728127,0.9002651,0.042299964,0.052053336],"study_design_scores_gemma":[0.00056016946,0.00045123335,0.007194491,0.0010761475,0.000010164995,0.0000064615497,0.0000058140636,0.000009086735,0.00002675727,0.06669267,0.9237556,0.00021142476],"about_ca_topic_score_codex":0.00021226723,"about_ca_topic_score_gemma":0.0000068293457,"teacher_disagreement_score":0.8814556,"about_ca_system_score_codex":0.00012681827,"about_ca_system_score_gemma":0.00009611239,"threshold_uncertainty_score":0.8509688},"labels":[],"label_agreement":null},{"id":"W2162449291","doi":"10.1111/jphs.12007","title":"Changes in use of antidiabetic medications following price regulations in China (1999–2009)","year":2013,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Health Services Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novartis Foundation","keywords":"Medicine; Per capita; Population; China; Quarter (Canadian coin); Environmental health","score_opus":0.17448598034800167,"score_gpt":0.45411405832387014,"score_spread":0.27962807797586847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162449291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95984006,0.0053826976,0.000058700458,0.03277459,0.0002602157,0.00058148394,0.000053671065,0.0000054373018,0.001043172],"genre_scores_gemma":[0.9914402,0.0059646284,0.00059312367,0.0017593649,0.00013685196,0.000025760428,0.00000469824,0.000021377573,0.000054017666],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967687,0.00024423588,0.0017301659,0.0002550328,0.00020166587,0.000800192],"domain_scores_gemma":[0.997807,0.0006689003,0.0005773816,0.00024491744,0.00014140087,0.0005603711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046424656,0.0001358973,0.0006691338,0.0016634557,0.00009881939,0.000078615856,0.0005042006,0.00011815425,0.00060044916],"category_scores_gemma":[0.00014076364,0.0001414843,0.00011781277,0.0013643572,0.000110933724,0.0006746324,0.00013678642,0.0010111015,0.00011364398],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021291556,0.0027507024,0.91571814,0.0029060054,0.00028319386,0.000042608768,0.009824327,0.0016714883,0.0014460689,0.039149698,0.002207174,0.023787688],"study_design_scores_gemma":[0.0027142572,0.00030326308,0.82712775,0.0006292489,0.000008248323,0.0000128345655,0.0003998318,0.09782584,0.00046737847,0.023035033,0.04720628,0.00027005628],"about_ca_topic_score_codex":0.0027736083,"about_ca_topic_score_gemma":0.0004706709,"teacher_disagreement_score":0.09615435,"about_ca_system_score_codex":0.000359967,"about_ca_system_score_gemma":0.00022135698,"threshold_uncertainty_score":0.6574497},"labels":[],"label_agreement":null},{"id":"W2163707071","doi":"10.1377/hlthaff.w3.521","title":"Prices And Availability Of Pharmaceuticals: Evidence From Nine Countries","year":2003,"lang":"en","type":"article","venue":"Health Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":206,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Liberian dollar; Pound (networking); Economics; Agricultural economics; International economics; Demographic economics; Business; Finance","score_opus":0.11861515730467714,"score_gpt":0.35180144592992774,"score_spread":0.2331862886252506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163707071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80881524,0.12815331,0.0007829309,0.023153758,0.0006821301,0.00069877674,0.0009233128,0.0000638924,0.036726635],"genre_scores_gemma":[0.9822349,0.014031508,0.0013251553,0.0022341278,0.000053079482,0.0000141753635,0.000003715842,0.000014099202,0.000089268535],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99831665,0.000044988512,0.00083886756,0.00039737162,0.000033096945,0.00036904775],"domain_scores_gemma":[0.9985651,0.0004257576,0.00039198325,0.00027306154,0.000026359312,0.0003177351],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013238968,0.0001403762,0.0005108531,0.0000889951,0.00008340555,0.000033510423,0.0001355248,0.00006876539,0.0018647906],"category_scores_gemma":[0.0004583094,0.00015740958,0.000056398087,0.00012761987,0.00020044565,0.00022677008,0.000042855117,0.00015506773,0.00024002469],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000100758,0.00019595944,0.29194555,0.0007173097,0.00008961341,0.000001521075,0.00185581,0.000022552402,0.000037184065,0.69497997,0.008252259,0.0018014945],"study_design_scores_gemma":[0.0015259108,0.00022342954,0.042148158,0.00013372196,0.000015662321,0.000005063163,0.0003116078,0.0030970161,0.0015585516,0.077678405,0.87277097,0.0005314839],"about_ca_topic_score_codex":0.00058288884,"about_ca_topic_score_gemma":0.000044497825,"teacher_disagreement_score":0.8645187,"about_ca_system_score_codex":0.00011166021,"about_ca_system_score_gemma":0.00012534848,"threshold_uncertainty_score":0.99904764},"labels":[],"label_agreement":null},{"id":"W2164632177","doi":"10.1016/s1474-4422(04)00883-x","title":"Comparison studies of cholinesterase inhibitors for Alzheimer's disease","year":2004,"lang":"en","type":"review","venue":"The Lancet Neurology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; McMaster University; Toronto Rehabilitation Institute; University of Toronto; University of Calgary","funders":"Pfizer","keywords":"Checklist; Cholinesterase; Medicine; Disease; Alzheimer's disease; Clinical trial; Consolidated Standards of Reporting Trials; Psychology; Pharmacology; Internal medicine","score_opus":0.43499645769402145,"score_gpt":0.4622165648417724,"score_spread":0.02722010714775097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164632177","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018212548,0.9921236,0.000012160275,0.004064355,0.0011298966,0.0008271278,0.001259592,0.000022301094,0.00037883918],"genre_scores_gemma":[0.0016843461,0.9940148,0.000024617193,0.002651293,0.0012656559,0.0002319658,0.000053775184,0.000053768934,0.000019756159],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977902,0.00006196799,0.0012709576,0.00044009893,0.000017444487,0.0004192841],"domain_scores_gemma":[0.99762076,0.00058005215,0.001070707,0.00059562194,0.000024405772,0.0001084314],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005161283,0.00032021516,0.0031204303,0.00015653609,0.000077181736,0.000019865936,0.0006057824,0.00016161095,0.000024826139],"category_scores_gemma":[0.00020227952,0.0002512216,0.0005340424,0.00013205105,0.0002607352,0.000044357635,0.0001679702,0.0003964568,0.00014579948],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051507325,0.0005731743,0.0015140341,0.03452585,0.003549186,0.00002210998,0.0005372237,0.00087015284,1.00361625e-7,0.6438875,0.03554257,0.27846304],"study_design_scores_gemma":[0.0004825444,0.00008063548,0.00003381969,0.0002664731,0.0003236981,0.0000044680114,0.0000010858449,0.00012935493,4.403151e-7,0.023524743,0.97493976,0.0002129933],"about_ca_topic_score_codex":0.0000111276195,"about_ca_topic_score_gemma":0.0000037815316,"teacher_disagreement_score":0.93939716,"about_ca_system_score_codex":0.000030348405,"about_ca_system_score_gemma":0.000076070246,"threshold_uncertainty_score":0.999994},"labels":[],"label_agreement":null},{"id":"W2165570102","doi":"10.1016/j.vaccine.2009.08.113","title":"Regulatory oversight of clinical trials in Africa: Progress over the past 5 years","year":2009,"lang":"en","type":"article","venue":"Vaccine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Clinical trial; Medicine; Clinical research; Developed country; Developing country; Alternative medicine; Intensive care medicine; Economic growth; Environmental health; Pathology","score_opus":0.17828205870286468,"score_gpt":0.39057357714760393,"score_spread":0.21229151844473926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165570102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815823,0.0031085238,0.000011552351,0.0054654907,0.0003297067,0.00025558734,0.000063734304,0.000011016245,0.009172134],"genre_scores_gemma":[0.9978622,0.00039237496,0.000057003985,0.0011693127,0.00031366895,0.0000053110703,0.000002724443,0.000008750319,0.00018866263],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997804,0.00009792205,0.0016137691,0.00023363579,0.000024081342,0.00022659064],"domain_scores_gemma":[0.9985986,0.00036744223,0.00062060315,0.00032357904,0.00001026912,0.00007956008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005207343,0.000096255506,0.0007876871,0.00014705404,0.000019457408,0.000021003772,0.00024735386,0.00010316819,0.0004389475],"category_scores_gemma":[0.00043753043,0.000080666585,0.00024256062,0.00021160736,0.000021944918,0.00009429099,0.000041175754,0.00019391943,0.00009946468],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026378193,0.00046895468,0.62162405,0.000017632585,0.000101220896,0.000007099556,0.00034395666,0.000047833215,0.000014722208,0.3059814,0.052227322,0.018902045],"study_design_scores_gemma":[0.001464128,0.00006765007,0.77524954,0.000007149537,0.0000063570064,5.2249703e-7,0.000006305579,0.00075627567,0.000013855866,0.016413461,0.20592335,0.000091406095],"about_ca_topic_score_codex":0.000016918706,"about_ca_topic_score_gemma":0.000005102701,"teacher_disagreement_score":0.28956795,"about_ca_system_score_codex":0.000030083005,"about_ca_system_score_gemma":0.000018673081,"threshold_uncertainty_score":0.48061672},"labels":[],"label_agreement":null},{"id":"W2167152117","doi":"10.1111/j.1468-0009.2007.00496.x","title":"Public/Private Partnerships for Prescription Drug Coverage: Policy Formulation and Outcomes in Quebec's Universal Drug Insurance Program, with Comparisons to the Medicare Prescription Drug Program in the United States","year":2007,"lang":"en","type":"article","venue":"Milbank Quarterly","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Université de Montréal; Pierre Elliott Trudeau Foundation","funders":"","keywords":"Prescription drug; Medical prescription; Government (linguistics); Principal (computer security); Public administration; Modernization theory; Private sector; Parallels; Business; Private insurance; Drug; Health insurance; Political science; Medicine; Economics; Law; Pharmacology; Health care","score_opus":0.06209852393718964,"score_gpt":0.3045910277155536,"score_spread":0.24249250377836393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167152117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95625585,0.0001666471,0.001395485,0.03839421,0.000117572075,0.002945006,0.00023184533,0.00006959721,0.000423782],"genre_scores_gemma":[0.996357,0.000059750964,0.00042031342,0.0020775932,0.00008778805,0.00046491742,0.00027082677,0.0000287491,0.00023304787],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997975,0.00009977274,0.0007304961,0.00043562602,0.00009072677,0.00066836795],"domain_scores_gemma":[0.9988699,0.00028022865,0.00027650266,0.00034939247,0.000057315352,0.00016665513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016004234,0.00026256614,0.00039181113,0.00061961135,0.00019658403,0.0004156126,0.00040538303,0.000079659156,0.0000070364817],"category_scores_gemma":[0.00007315807,0.00019839435,0.00007541947,0.00080082973,0.000113749615,0.00063848175,0.000030700758,0.00033062894,0.000012054206],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054038636,0.0009221688,0.65838295,0.00014001933,0.00010064878,0.000005197188,0.048232414,0.0006993,0.0000043667887,0.2293255,0.006528242,0.05511878],"study_design_scores_gemma":[0.0028704144,0.00036189772,0.587406,0.000038946793,0.000011946079,0.0000018703031,0.0035949564,0.024179528,0.000009577267,0.00839829,0.37272444,0.00040215612],"about_ca_topic_score_codex":0.02604719,"about_ca_topic_score_gemma":0.15780173,"teacher_disagreement_score":0.3661962,"about_ca_system_score_codex":0.00027195332,"about_ca_system_score_gemma":0.000050145543,"threshold_uncertainty_score":0.9804385},"labels":[],"label_agreement":null},{"id":"W2167341868","doi":"10.1016/j.diagmicrobio.2012.11.020","title":"Perspectives and concerns regarding antimicrobial agent shortages among infectious disease specialists","year":2013,"lang":"en","type":"article","venue":"Diagnostic Microbiology and Infectious Disease","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"U.S. Public Health Service; National Institute of Allergy and Infectious Diseases; Centers for Disease Control and Prevention; U.S. Food and Drug Administration; Association des pharmaciens du Canada","keywords":"Medicine; Economic shortage; Antimicrobial; Pharmacy; Infectious disease (medical specialty); Antimicrobial stewardship; Intensive care medicine; Disease; Family medicine; Antibiotics; Internal medicine; Antibiotic resistance; Microbiology; Biology","score_opus":0.018614195525129513,"score_gpt":0.251248768188824,"score_spread":0.2326345726636945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167341868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98628294,0.0056240973,0.000096263524,0.0013810135,0.0005688669,0.00063402817,0.00069791573,0.00008824469,0.004626651],"genre_scores_gemma":[0.9915679,0.0053337035,0.000009753537,0.002248285,0.00044768426,0.00010837198,0.00008077353,0.000034544042,0.00016895265],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99818426,0.00005942985,0.0004912814,0.00074626005,0.000012894388,0.0005058639],"domain_scores_gemma":[0.9984124,0.0003843082,0.00021608242,0.0002665076,0.000048301943,0.0006724165],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001799735,0.00032463638,0.000490217,0.00022441243,0.00032733424,0.00021519323,0.00012228361,0.00013963641,0.0009874386],"category_scores_gemma":[0.00094828993,0.00036000606,0.00014297414,0.00010698324,0.0006825801,0.00035112555,0.00017337663,0.0002471353,0.0003106341],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030903295,0.00022724358,0.92680585,0.0000838088,0.00015280899,0.000030998985,0.00043699733,0.000034474862,0.00019187687,0.06331941,0.008302938,0.0003827054],"study_design_scores_gemma":[0.0019923355,0.00010779045,0.9416273,0.00006555529,0.00011514551,0.000033007094,0.00008581045,0.000477825,0.00006574336,0.028191606,0.026311621,0.0009262315],"about_ca_topic_score_codex":0.00041682966,"about_ca_topic_score_gemma":0.00006601813,"teacher_disagreement_score":0.035127804,"about_ca_system_score_codex":0.0001094764,"about_ca_system_score_gemma":0.000042543226,"threshold_uncertainty_score":0.9999258},"labels":[],"label_agreement":null},{"id":"W2167393130","doi":"10.1506/ap.7.2.6","title":"Transition Therapeutics inc.*","year":2008,"lang":"en","type":"article","venue":"Accounting Perspectives","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"HEC Montréal","funders":"","keywords":"Business; Accounting; Equity (law); Shareholder; Pro forma; Finance; Actuarial science; Political science; Corporate governance","score_opus":0.07396176409851335,"score_gpt":0.2826814762400178,"score_spread":0.20871971214150448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167393130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89831966,0.0032266038,0.0009999431,0.0049296045,0.00022502906,0.00011808078,0.000064693886,0.00009784597,0.09201853],"genre_scores_gemma":[0.99513793,0.0011156783,0.00034386356,0.0028271016,0.00032609943,0.000008793262,0.0000053288995,0.00002376805,0.00021146087],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.999117,0.0000074417558,0.00029392482,0.00029935423,0.000021760796,0.00026051005],"domain_scores_gemma":[0.9995785,0.00003870673,0.00012509558,0.00017599667,0.000032508775,0.0000492283],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019994253,0.000121610494,0.00021784683,0.0001402492,0.0002132689,0.000045223736,0.00015404118,0.00007037273,0.0004826984],"category_scores_gemma":[0.000026192003,0.00014623017,0.000091342634,0.00014007476,0.000121172365,0.00031034212,0.000023912899,0.00016300728,0.00093448313],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046404875,0.00036848284,0.03362883,0.000024602406,0.00023915317,0.0000132700225,0.04059758,0.00016019396,0.00052147615,0.92016476,0.0029383637,0.0012968685],"study_design_scores_gemma":[0.0028057008,0.00015792028,0.16299233,0.000021291065,0.00003397198,0.00013396451,0.004899834,0.022487786,0.0010761223,0.19717512,0.6065103,0.0017056915],"about_ca_topic_score_codex":0.00013998826,"about_ca_topic_score_gemma":0.000004711432,"teacher_disagreement_score":0.7229897,"about_ca_system_score_codex":0.000095120726,"about_ca_system_score_gemma":0.000018197747,"threshold_uncertainty_score":0.9998434},"labels":[],"label_agreement":null},{"id":"W2168785648","doi":"10.3109/j058v16n03_08","title":"Internet Pharmacy: Undoing Canada's Goals for Life Science Innovation?","year":2004,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Marketing & Management","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Undoing; Attractiveness; Pharmacy; Business; The Internet; Legislation; Investment (military); Marketing; Public economics; Economics; Political science","score_opus":0.08319619769619306,"score_gpt":0.336420053319961,"score_spread":0.2532238556237679,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168785648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7633888,0.0044162236,0.03719822,0.066542365,0.007300964,0.0017627887,0.00020773448,0.00007456967,0.11910834],"genre_scores_gemma":[0.9843761,0.00030604776,0.0041417335,0.010407588,0.00045453061,0.00001496669,0.0000018776094,0.000029816776,0.0002673448],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99722284,0.000027855885,0.0016076128,0.00035259617,0.00015964622,0.00062944373],"domain_scores_gemma":[0.9980812,0.00023901669,0.00089775294,0.00017468103,0.00020990577,0.000397433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0056413,0.00020930506,0.00045435783,0.0006520584,0.00017178248,0.00020060073,0.00072828634,0.00003161729,0.00031368496],"category_scores_gemma":[0.0009977686,0.00022828342,0.00014035581,0.0007635016,0.00015727757,0.0003815461,0.00022735553,0.00034018685,0.000029929723],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075617444,0.0003371222,0.0052618766,0.00046167176,0.0005973397,0.00005603738,0.00011472236,0.002532988,0.0004704998,0.949396,0.022230096,0.01778547],"study_design_scores_gemma":[0.0070907637,0.00007061257,0.006663149,0.00015435461,0.000093221046,0.00003164486,0.00008669191,0.010337284,0.0024227835,0.041518368,0.93098396,0.0005471659],"about_ca_topic_score_codex":0.001511393,"about_ca_topic_score_gemma":0.00023149943,"teacher_disagreement_score":0.9087539,"about_ca_system_score_codex":0.0009887976,"about_ca_system_score_gemma":0.0004732355,"threshold_uncertainty_score":0.9309128},"labels":[],"label_agreement":null},{"id":"W2168880717","doi":"10.4212/cjhp.v65i5.1181","title":"Drug Shortages: What Does France Do Better than Canada?","year":2012,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Economic shortage; Drug; Geography; Medicine; Pharmacology","score_opus":0.023056351909771525,"score_gpt":0.24944907714120787,"score_spread":0.22639272523143633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168880717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9131415,0.024503723,0.000007540797,0.0499337,0.0066877333,0.00014233492,0.00019099555,0.0000039938977,0.005388471],"genre_scores_gemma":[0.98596334,0.00069466996,0.000027471584,0.011145344,0.0016903052,0.0000040100877,0.0000023556427,0.000031559273,0.0004409569],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983464,0.000026223232,0.0006836585,0.00014769247,0.000060385155,0.00073564536],"domain_scores_gemma":[0.99806017,0.000073712516,0.00044960852,0.00024842346,0.00005508507,0.0011130009],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007942845,0.00019642519,0.00035913667,0.00015657472,0.00027177244,0.000357021,0.0006957609,0.00003444277,0.0013693292],"category_scores_gemma":[0.000055929966,0.00014882018,0.00017583881,0.00013583136,0.00013615975,0.0012741433,0.000023399094,0.0004999873,0.00015083789],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001748845,0.000075796874,0.84759593,0.000029267576,0.00041028493,0.00007386473,0.0058184075,0.000077972516,0.000007775904,0.03481492,0.104056716,0.0070215883],"study_design_scores_gemma":[0.0005208433,0.00002074846,0.027869472,0.000024094814,0.000021602085,0.000022764098,0.00032312187,0.00007960897,0.00026705296,0.0061718686,0.96435946,0.00031936754],"about_ca_topic_score_codex":0.45008206,"about_ca_topic_score_gemma":0.5512321,"teacher_disagreement_score":0.86030275,"about_ca_system_score_codex":0.00039954096,"about_ca_system_score_gemma":0.0006523813,"threshold_uncertainty_score":0.99954355},"labels":[],"label_agreement":null},{"id":"W2168932305","doi":"10.1080/13880200590963736","title":"Linking Medicinal/Nutraceutical Products Research with Commercialization","year":2005,"lang":"en","type":"article","venue":"Pharmaceutical Biology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Fredericton; Natural Resources Canada; Canadian Forest Service","funders":"","keywords":"Commercialization; Nutraceutical; Biotechnology; Business; Marketing; Product (mathematics); Biology","score_opus":0.3249006839457479,"score_gpt":0.44568582610875074,"score_spread":0.12078514216300285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168932305","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24854119,0.02014812,0.011846997,0.36899355,0.0016625862,0.002124594,0.0003309181,0.00045769472,0.34589434],"genre_scores_gemma":[0.98602253,0.0010318855,0.0014875334,0.00956332,0.001563484,0.000055028922,0.000055033353,0.000041592586,0.00017960244],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99733937,0.00014863434,0.0007144734,0.0007288409,0.00006809389,0.0010005956],"domain_scores_gemma":[0.99862456,0.00036415635,0.00012749288,0.00036055368,0.00013033308,0.00039291746],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0023181934,0.00022898664,0.000489401,0.00034569314,0.00027855192,0.00006672391,0.00042651797,0.0002325576,0.0011237379],"category_scores_gemma":[0.00033283426,0.00021490573,0.000063160274,0.0005734918,0.00079586584,0.00019708108,0.00016278082,0.0009314729,0.0025305096],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015655882,0.0002842055,0.020173168,0.000054409134,0.000069738024,0.000004988217,0.00019975353,0.000036421166,0.0006858092,0.9543651,0.0024259486,0.021543948],"study_design_scores_gemma":[0.0012097368,0.0001756024,0.0009880875,0.00001777071,0.000013395888,0.000024512705,0.000014190628,0.010516115,0.0030580221,0.034777686,0.94889206,0.00031281856],"about_ca_topic_score_codex":0.000029664883,"about_ca_topic_score_gemma":0.000014113722,"teacher_disagreement_score":0.9464661,"about_ca_system_score_codex":0.00022445901,"about_ca_system_score_gemma":0.00007674245,"threshold_uncertainty_score":0.99978936},"labels":[],"label_agreement":null},{"id":"W2169253622","doi":"10.1186/1744-8603-3-12","title":"Canada's implementation of the Paragraph 6 Decision: is it sustainable public policy?","year":2007,"lang":"en","type":"article","venue":"Globalization and Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research; Connaught Fund; University of Toronto","keywords":"Legislation; Population; Developing country; Incentive; Business; Government (linguistics); Economics; Public administration; Economic growth; Law; Political science; Medicine; Environmental health; Market economy","score_opus":0.0641052028159014,"score_gpt":0.3724271668373059,"score_spread":0.30832196402140455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169253622","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2650021,0.0060164416,0.01853352,0.6251187,0.0009073144,0.0014795626,0.0012338938,0.000032539585,0.08167594],"genre_scores_gemma":[0.9520604,0.00082428224,0.000057884954,0.04676624,0.00005334303,0.0000020360474,0.000010556499,0.0000052052455,0.00022007654],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989437,0.0000061639835,0.00053529884,0.00015163707,0.000037919228,0.0003253153],"domain_scores_gemma":[0.9993316,0.000014439606,0.00030057007,0.0001459685,0.000045599554,0.00016184988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007368396,0.0000690599,0.00016812763,0.00011310209,0.0001828052,0.000036989415,0.00011391829,0.000033353528,0.00024992178],"category_scores_gemma":[0.000026104364,0.00006633663,0.000032782933,0.0004353877,0.000031031093,0.00008735212,0.000050414543,0.000043044096,0.000004525573],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000022167067,0.000008694442,0.14322713,0.000023517685,0.000007310041,1.260834e-7,0.00014254506,0.000002915843,6.512589e-8,0.80427897,0.04968628,0.0026202633],"study_design_scores_gemma":[0.00035115794,0.000014750754,0.2939471,0.000003425153,9.65779e-7,0.0000016974293,0.0004157754,0.00018067796,0.000017744931,0.03104035,0.6739598,0.00006653472],"about_ca_topic_score_codex":0.6231525,"about_ca_topic_score_gemma":0.3976323,"teacher_disagreement_score":0.7732386,"about_ca_system_score_codex":0.00036339436,"about_ca_system_score_gemma":0.0008251175,"threshold_uncertainty_score":0.61335933},"labels":[],"label_agreement":null},{"id":"W2169369869","doi":"10.1185/030079907x199655","title":"Comment on: The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease","year":2007,"lang":"en","type":"letter","venue":"Current Medical Research and Opinion","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal; PharmIdeas (Canada)","funders":"Amgen","keywords":"Medicine; Darbepoetin alfa; Epoetin alfa; Dosing; Kidney disease; Internal medicine; Erythropoietin","score_opus":0.23062913471945348,"score_gpt":0.4338414552437033,"score_spread":0.20321232052424984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169369869","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008913585,0.030495452,0.00008260579,0.96133393,0.00064981624,0.0005818908,0.00050519337,0.0000063598122,0.0054533794],"genre_scores_gemma":[0.057556853,0.18827091,0.00002818054,0.74560946,0.0070024934,0.00021549307,0.0009606748,0.00011193087,0.00024401951],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972542,0.00022184172,0.0008510957,0.000603934,0.00030660295,0.00076231884],"domain_scores_gemma":[0.9966323,0.0019854023,0.0002386313,0.00035572704,0.0000423999,0.0007455338],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0044953055,0.00024256944,0.0005320308,0.00052206044,0.00015163266,0.000076690136,0.00040795017,0.00037286786,0.0005635479],"category_scores_gemma":[0.002911774,0.00020036969,0.00009219454,0.000263845,0.00092048995,0.00007496187,0.00032073385,0.0037789769,0.0000822356],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007227092,0.00009961322,0.0009841688,0.0005504913,0.000032137024,0.000016237935,0.00011189822,3.2787784e-7,2.712374e-7,0.09344596,0.8926325,0.012054144],"study_design_scores_gemma":[0.0007818649,0.00017539132,0.0006649739,0.0010711254,0.0000025927677,0.0000012130757,0.0000064021615,0.0018849067,0.0000054309876,0.04570972,0.94950956,0.00018680983],"about_ca_topic_score_codex":0.00014676755,"about_ca_topic_score_gemma":0.0000062280265,"teacher_disagreement_score":0.2157245,"about_ca_system_score_codex":0.0003636546,"about_ca_system_score_gemma":0.00038856454,"threshold_uncertainty_score":0.99851936},"labels":[],"label_agreement":null},{"id":"W2169845877","doi":"10.1038/clpt.2014.144","title":"Adjusted Indirect Treatment Comparison of the Bioavailability of WHO-Prequalified First-Line Generic Antituberculosis Medicines","year":2014,"lang":"en","type":"article","venue":"Clinical Pharmacology & Therapeutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"World Health Organization","keywords":"Bioequivalence; Interchangeability; Medicine; Confidence interval; Pharmacology; Bioavailability; Innovator; Clinical pharmacology; Isoniazid; Ethambutol; Pyrazinamide; Internal medicine; Tuberculosis; Computer science","score_opus":0.2971360709396938,"score_gpt":0.4304960972344246,"score_spread":0.13336002629473082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169845877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9793091,0.0024389233,0.0002055084,0.013198138,0.0019813643,0.00044631044,0.00019854163,0.000024755445,0.0021973562],"genre_scores_gemma":[0.9805212,0.0037795084,0.00010145806,0.015057291,0.00039521363,0.000020439653,0.000008073249,0.00002572463,0.000091090755],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99679786,0.00027603112,0.002103971,0.00044194242,0.000048304508,0.00033190908],"domain_scores_gemma":[0.99686086,0.0012653499,0.0011149276,0.00054013875,0.0000761758,0.00014255458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012279721,0.0002471634,0.0013582209,0.000108466076,0.000100249476,0.000007850175,0.0005445356,0.00027452022,0.00045370884],"category_scores_gemma":[0.00010555023,0.00019265841,0.00046025022,0.0003143917,0.0008753675,0.000047831723,0.0001265882,0.00030013683,0.000061817795],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003086128,0.0023209641,0.9744973,0.0001239184,0.0016562379,3.3632404e-7,0.00058075006,0.0006714933,0.0010299087,0.0035057564,0.0039752456,0.011329478],"study_design_scores_gemma":[0.0083905,0.0021149344,0.34185332,0.000038521157,0.001183926,0.0000020629882,0.000040093062,0.091849975,0.036288306,0.007821752,0.5097827,0.00063393876],"about_ca_topic_score_codex":0.00007568697,"about_ca_topic_score_gemma":0.00006702463,"teacher_disagreement_score":0.632644,"about_ca_system_score_codex":0.000082497776,"about_ca_system_score_gemma":0.00005406303,"threshold_uncertainty_score":0.7856382},"labels":[],"label_agreement":null},{"id":"W2170271804","doi":"10.2308/accr-10199","title":"Gray Markets and Multinational Transfer Pricing","year":2011,"lang":"en","type":"article","venue":"The Accounting Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Transfer pricing; Multinational corporation; Grey market; Business; Monetary economics; Gray (unit); Subsidiary; Variable pricing; Revenue; Economics; Microeconomics; Market economy; Finance","score_opus":0.08662903373861464,"score_gpt":0.28044761961464937,"score_spread":0.19381858587603473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170271804","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3240939,0.35407767,0.0009718984,0.013055929,0.0006065809,0.0011736318,0.00009460241,0.00009391261,0.30583188],"genre_scores_gemma":[0.92513293,0.0614075,0.00026706158,0.012871105,0.00011212465,0.000025202244,0.0000027612273,0.000017827333,0.00016348572],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992098,0.000014148274,0.00039527196,0.00018346569,0.00001655398,0.00018071505],"domain_scores_gemma":[0.99959344,0.00007527831,0.00009833634,0.0001779384,0.000014955003,0.00004005838],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012996648,0.00009641693,0.00025361634,0.00004097293,0.00010348906,0.000031376007,0.00019587495,0.000027231023,0.0009140081],"category_scores_gemma":[0.00012648664,0.00007779848,0.00006842021,0.00009961083,0.000049638842,0.00015270247,0.000048179158,0.00011871535,0.00035165588],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014896915,0.000087275155,0.046876773,0.0017197048,0.000117600415,0.0000020026284,0.0009224787,7.182795e-7,0.00001758974,0.8800904,0.004847257,0.06530332],"study_design_scores_gemma":[0.00046054373,0.000014443184,0.14839655,0.0005581868,0.000045997476,0.00002286173,0.000011938755,0.001453924,0.00005276913,0.05791108,0.7906682,0.00040351177],"about_ca_topic_score_codex":0.000063815176,"about_ca_topic_score_gemma":0.000003316574,"teacher_disagreement_score":0.8221793,"about_ca_system_score_codex":0.000017219172,"about_ca_system_score_gemma":0.000006877372,"threshold_uncertainty_score":0.9999993},"labels":[],"label_agreement":null},{"id":"W2171407238","doi":"10.1016/j.drudis.2008.09.015","title":"Value networks identify innovation in 21st century pharmaceutical research","year":2008,"lang":"en","type":"review","venue":"Drug Discovery Today","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Pharmaceutical industry; Identification (biology); Value (mathematics); Productivity; CLARION; Pharmaceutical sciences; Business; Knowledge management; Marketing; Computer science; Medicine; Pharmacology; Economics","score_opus":0.18888439426689835,"score_gpt":0.4271825262802506,"score_spread":0.23829813201335226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171407238","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020194445,0.95105976,0.0000581137,0.00038791067,0.0017275033,0.0009518762,0.0005638665,0.000035513152,0.045013517],"genre_scores_gemma":[0.0016895002,0.9941835,0.00002174899,0.0007717824,0.0011028248,0.00020986235,0.0005089907,0.00013564955,0.001376189],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99428225,0.0003006653,0.002821044,0.0012053384,0.00012981676,0.0012609137],"domain_scores_gemma":[0.99765325,0.00060077163,0.00072353194,0.0007567502,0.00005521402,0.00021051182],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0028120256,0.0005904484,0.002227244,0.0020723476,0.0002140357,0.00042026624,0.0009784003,0.0005723913,0.00036171117],"category_scores_gemma":[0.0003239313,0.00065293274,0.00054736994,0.002743656,0.00028820636,0.00078247394,0.00051468326,0.0025160618,0.0020685864],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001939642,0.00038989415,0.00030700403,0.0027083927,0.00020424639,0.000054902714,0.00019665074,0.00021468168,9.010598e-8,0.77592784,0.019916594,0.20006032],"study_design_scores_gemma":[0.00043080284,0.0000118680555,0.000054282587,0.0010474415,0.000020767027,0.000020743828,0.000019082368,0.0010319275,6.146388e-7,0.0067283544,0.98997885,0.0006552688],"about_ca_topic_score_codex":0.00021769939,"about_ca_topic_score_gemma":0.000014172203,"teacher_disagreement_score":0.97006226,"about_ca_system_score_codex":0.0010022396,"about_ca_system_score_gemma":0.00030025706,"threshold_uncertainty_score":0.9997852},"labels":[],"label_agreement":null},{"id":"W2171639414","doi":"10.1001/jama.286.15.1886","title":"Do Patents for Antiretroviral Drugs Constrain Access to AIDS Treatment in Africa?","year":2001,"lang":"en","type":"article","venue":"JAMA","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Intellectual property; Market access; Scarcity; Developing country; Access to medicines; De facto; Antiretroviral treatment; Business; Universal design; Human immunodeficiency virus (HIV); Economic growth; Development economics; International trade; Medicine; Political science; Antiretroviral therapy; Geography; Economics; Virology; Law","score_opus":0.1285627916980011,"score_gpt":0.33598889894447,"score_spread":0.20742610724646887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171639414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92346007,0.00027271526,0.00033851672,0.0039012714,0.00031570223,0.0005929035,0.000643814,0.000022409546,0.07045258],"genre_scores_gemma":[0.99555045,0.00021998011,0.00033577066,0.0025527265,0.00020508221,0.0001478795,0.000015644502,0.000021682294,0.0009508094],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986576,0.000009200204,0.00047303815,0.0003727702,0.00001697686,0.00047041054],"domain_scores_gemma":[0.9994128,0.00007548204,0.00010719021,0.00021090938,0.000013937193,0.00017971228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031061872,0.00015407166,0.00036548445,0.00028386226,0.00004821403,0.00022082953,0.0002666544,0.000091044574,0.00033097542],"category_scores_gemma":[0.00007273075,0.00016936722,0.00012304624,0.0002370529,0.000025202356,0.00027354775,0.00006211202,0.00007205317,0.0004416077],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028012853,0.00052895246,0.4949612,0.000029165276,0.00009582941,0.000017879913,0.0018332923,0.00018556141,0.000043350152,0.18416749,0.006424406,0.31143275],"study_design_scores_gemma":[0.0049826214,0.0005471757,0.042874612,0.000015550966,0.0000072240027,0.0000033122883,0.00009020992,0.0032944975,0.00021323274,0.041180808,0.9063439,0.00044687017],"about_ca_topic_score_codex":0.00029930903,"about_ca_topic_score_gemma":0.000029693152,"teacher_disagreement_score":0.89991945,"about_ca_system_score_codex":0.00025433162,"about_ca_system_score_gemma":0.000024660443,"threshold_uncertainty_score":0.6906595},"labels":[],"label_agreement":null},{"id":"W2172637990","doi":"10.12927/hcpol.2015.24359","title":"Canada’s New Generic Pricing Policy: A Reasoned Approach to a Challenging Problem","year":2015,"lang":"en","type":"article","venue":"Healthcare policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Drug pricing; Economics; Business; Public economics; Operations research; Computer science; Actuarial science; Engineering","score_opus":0.1629821833149132,"score_gpt":0.32281812955915223,"score_spread":0.15983594624423902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2172637990","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017515497,0.005340855,0.0034572887,0.6182765,0.00052436546,0.0014440644,0.0005494364,0.00020409188,0.35268793],"genre_scores_gemma":[0.9266821,0.00031575383,0.0044193324,0.06311815,0.0029605057,0.000080885125,0.000026478556,0.000091481954,0.0023052907],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.997194,0.00003687142,0.0008446129,0.0006603059,0.00008356721,0.0011806701],"domain_scores_gemma":[0.9968841,0.000032601132,0.0002769569,0.00053042057,0.000061043196,0.0022148439],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005474713,0.0003076835,0.0006369869,0.0007129959,0.00016407536,0.000094172996,0.00043678482,0.00014066088,0.000015494199],"category_scores_gemma":[0.00035598635,0.00037441787,0.00009363996,0.0009670455,0.000023887364,0.00014659688,0.00018769036,0.00030245897,0.00028435234],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025325679,0.000054021206,0.001412466,0.00011577889,0.000038428254,0.0000031076352,0.0024600031,0.0011190398,0.0000032558394,0.9361629,0.05191907,0.0066866092],"study_design_scores_gemma":[0.0009381373,0.00009099603,0.0019864687,0.000028811151,0.000003728687,0.000035541867,0.00014606731,0.005776903,0.000019783065,0.050727792,0.9396427,0.0006030131],"about_ca_topic_score_codex":0.96739256,"about_ca_topic_score_gemma":0.22339849,"teacher_disagreement_score":0.90916663,"about_ca_system_score_codex":0.0027933458,"about_ca_system_score_gemma":0.0074555185,"threshold_uncertainty_score":0.9998708},"labels":[],"label_agreement":null},{"id":"W2173121992","doi":"10.1200/jco.2015.61.8736","title":"Proposing Essential Medicines to Treat Cancer: Methodologies, Processes, and Outcomes","year":2015,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":102,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Cancer Institute; National Institutes of Health; World Health Organization","keywords":"Medicine; Cancer; Intensive care medicine; Internal medicine","score_opus":0.6455804736146742,"score_gpt":0.6181926204129479,"score_spread":0.02738785320172632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2173121992","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012480069,0.9831463,0.00021057208,0.008661706,0.0031248848,0.0003987745,0.0001409982,0.000009851754,0.0041821105],"genre_scores_gemma":[0.00002991032,0.9902899,0.003904022,0.0028618067,0.0024794089,0.000022981427,0.000004198587,0.00004373077,0.0003639962],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99300015,0.00035662513,0.0057453704,0.00045157693,0.00006951604,0.0003767843],"domain_scores_gemma":[0.9892389,0.0039029254,0.0056164176,0.00022945904,0.00023507973,0.00077721744],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.008823883,0.00036998434,0.008587727,0.00044073584,0.000047752983,0.000051926672,0.00057258975,0.00082208513,0.00013045612],"category_scores_gemma":[0.011655809,0.00026548203,0.00070855947,0.00027416414,0.00023560057,0.0001645421,0.00022515608,0.0011898938,0.000073902884],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008537916,0.00015349753,0.00072116824,0.0025552092,0.00046117185,0.000043615208,0.00005559047,0.0000023099228,1.8289095e-8,0.0019634732,0.012431621,0.981527],"study_design_scores_gemma":[0.0011268234,0.0010645243,0.00007916171,0.0007558966,0.0006084512,0.00009761869,0.000010921669,0.0000058849646,1.8967862e-7,0.007720141,0.988259,0.00027136807],"about_ca_topic_score_codex":0.00009296312,"about_ca_topic_score_gemma":0.000047092697,"teacher_disagreement_score":0.9812556,"about_ca_system_score_codex":0.00035184238,"about_ca_system_score_gemma":0.0029823328,"threshold_uncertainty_score":0.99997973},"labels":[],"label_agreement":null},{"id":"W2183209710","doi":"10.22270/ijdra.v2i2.130","title":"A PRAGMATIC WAY TO SUSTAIN IN GENERIC PHARMA ENVIRONMENT: PLCM THROUGH REGULATORY STRATEGIES","year":2018,"lang":"en","type":"article","venue":"International Journal of Drug Regulatory Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Scope (computer science); Profitability index; Business; Quality (philosophy); Product (mathematics); Sustainability; Preference; Marketing; Work (physics); Competitive advantage; Process management; Risk analysis (engineering); Economics; Computer science; Engineering; Finance","score_opus":0.025933142335729867,"score_gpt":0.28150899596129453,"score_spread":0.2555758536255647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2183209710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95497376,0.0011316371,0.0010459145,0.0067637335,0.0015743251,0.00019115584,0.00007270872,0.000014774082,0.034232017],"genre_scores_gemma":[0.9960975,0.00020893871,0.0010725039,0.0009089546,0.0010763515,0.00000843293,0.000003931405,0.00003356017,0.0005897921],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.997917,0.00004505901,0.0012486249,0.00029323713,0.00015273958,0.0003433402],"domain_scores_gemma":[0.9986523,0.000068989684,0.0007320771,0.00025382926,0.000096527605,0.00019628827],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00097144063,0.00020850197,0.00041766276,0.00054436724,0.00005317392,0.00013479593,0.00076512026,0.0000784339,0.0015045663],"category_scores_gemma":[0.00007267164,0.00023202354,0.00018784209,0.00015342003,0.00017942254,0.0008661583,0.00014541179,0.0002546972,0.00046326633],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000543895,0.0007305868,0.01066522,0.000070067,0.0009640499,0.00014331452,0.012793758,0.013549829,0.0018900852,0.91971356,0.03430475,0.00463087],"study_design_scores_gemma":[0.0047512087,0.000301228,0.042027377,0.00017774291,0.0000348275,0.00019801974,0.0043243403,0.0053974004,0.0045603113,0.272177,0.6650456,0.0010049166],"about_ca_topic_score_codex":0.000032903656,"about_ca_topic_score_gemma":0.00001919678,"teacher_disagreement_score":0.6475366,"about_ca_system_score_codex":0.0006206882,"about_ca_system_score_gemma":0.000098015145,"threshold_uncertainty_score":0.9994082},"labels":[],"label_agreement":null},{"id":"W2185030980","doi":"","title":"THE SIGNIFICANCE OF BRANDING IN THE PHARMACEUTICAL INDUSTRY","year":2005,"lang":"en","type":"dissertation","venue":"Summit (Simon Fraser University)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Simon Fraser University","keywords":"Pharmaceutical industry; Business; Advertising; Biotechnology; Biology","score_opus":0.04684109745479109,"score_gpt":0.2808766986261215,"score_spread":0.23403560117133043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2185030980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6175339,0.0020802598,0.00001174944,0.0023284573,0.0007254505,0.0005677549,0.00032010608,0.000020033485,0.37641227],"genre_scores_gemma":[0.99009687,0.0020654062,0.000010124222,0.00052894204,0.00019250768,0.000004423562,0.00006996974,0.000025557552,0.0070061726],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99859166,0.000063717554,0.0005278072,0.0003684266,0.00005721046,0.00039120283],"domain_scores_gemma":[0.9987643,0.00033233946,0.00042244387,0.00035904258,0.000027300368,0.000094575145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006031854,0.00022710502,0.00040603528,0.0003701643,0.00019843137,0.00006754681,0.0009953659,0.00046259834,0.00031768426],"category_scores_gemma":[0.00006765977,0.00020937526,0.0001980568,0.00060290203,0.00012837953,0.00017574542,0.0000441902,0.0012342805,0.00012635003],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057248893,0.0003239544,0.25838622,0.00019854623,0.00027427892,0.00005494118,0.0004637104,0.00030742216,0.000006144626,0.7071038,0.024275506,0.008032971],"study_design_scores_gemma":[0.00089002703,0.000023607174,0.004184874,0.00003499781,0.00003289077,8.2316305e-9,0.008742532,0.00059694244,0.0002857808,0.003379611,0.98152107,0.00030764434],"about_ca_topic_score_codex":0.00018799888,"about_ca_topic_score_gemma":0.017195094,"teacher_disagreement_score":0.9572456,"about_ca_system_score_codex":0.00019403164,"about_ca_system_score_gemma":0.00008746714,"threshold_uncertainty_score":0.9595266},"labels":[],"label_agreement":null},{"id":"W2186044971","doi":"10.1016/j.jval.2015.09.2007","title":"Comparative Analysis of The Reimbursement Landscape of Orphan Drugs on An International Level","year":2015,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Orphan drug; Reimbursement; Listing (finance); Medicine; Family medicine; Business; Public economics; Health care; Economic growth; Economics; Finance; Bioinformatics","score_opus":0.3080938908832449,"score_gpt":0.39867403604382745,"score_spread":0.09058014516058255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2186044971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.978322,0.00020133778,0.000051880845,0.003060295,0.0003032862,0.00013159722,0.0005197525,0.0000027523752,0.017407048],"genre_scores_gemma":[0.9988217,0.00009474706,0.00012555697,0.00083853,0.000035144825,0.0000042399756,0.000016542946,0.000003605632,0.000059977807],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9989973,0.000051584844,0.000620903,0.00016083402,0.00004156587,0.00012786998],"domain_scores_gemma":[0.9991745,0.000055555032,0.0004223781,0.00023147436,0.000025657699,0.00009046066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010021086,0.00006298313,0.00038484356,0.00033973728,0.000016385118,0.0000075677453,0.00025013147,0.0000271521,0.00009425443],"category_scores_gemma":[0.000037380083,0.0000569622,0.000080255886,0.00037615284,0.00004320814,0.00006126172,0.00003819826,0.000086081935,0.000015802512],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058104448,0.0003356073,0.2114123,0.000018593437,0.0002649252,1.2415158e-7,0.0048658103,0.09414258,0.0000027905692,0.6879229,0.000599852,0.0003764406],"study_design_scores_gemma":[0.0016113991,0.0003150775,0.34301877,0.000040550516,0.000025151316,3.01166e-7,0.00058946107,0.6026945,0.0002685298,0.024035625,0.02720654,0.00019408356],"about_ca_topic_score_codex":0.002361801,"about_ca_topic_score_gemma":0.00011013032,"teacher_disagreement_score":0.66388726,"about_ca_system_score_codex":0.00014693185,"about_ca_system_score_gemma":0.00007808553,"threshold_uncertainty_score":0.35703525},"labels":[],"label_agreement":null},{"id":"W2189839493","doi":"10.1007/s40258-015-0208-z","title":"A Review of “The New Drug Reimbursement Game: A Regulator’s Guide to Playing and Winning”","year":2015,"lang":"en","type":"review","venue":"Applied Health Economics and Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Reimbursement; Health economics; Regulator; Health administration; Quality of Life Research; Public health; Drug; Public finance; Medicine; Business; Pharmacology; Nursing; Political science; Health care; Law","score_opus":0.17407458428908373,"score_gpt":0.44635993039105404,"score_spread":0.2722853461019703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2189839493","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000009348878,0.90806836,0.000014705694,0.08119848,0.00032769376,0.003232291,0.0006713543,0.000021695903,0.0064560715],"genre_scores_gemma":[0.000010762331,0.88453275,0.0006741164,0.11306413,0.00078466727,0.00018369102,0.00004342676,0.00011346697,0.0005930148],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9934116,0.00007296769,0.004228941,0.0011044274,0.00004912773,0.0011329391],"domain_scores_gemma":[0.9934055,0.00010148779,0.0035323538,0.0010329618,0.000031520343,0.0018961615],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0041361134,0.0006789289,0.0047273124,0.00059897767,0.00029159628,0.000082571634,0.00063184096,0.00024090112,0.000040557694],"category_scores_gemma":[0.00008166454,0.0006669325,0.00033100715,0.0004764105,0.00012908103,0.00008048718,0.00065176137,0.0005970855,0.00011658898],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000004051612,0.000021931042,0.000007129749,0.053504054,0.00007449224,7.839229e-8,0.00033964316,0.0000028251793,2.665936e-9,0.35059607,0.19214858,0.40330115],"study_design_scores_gemma":[0.00052742346,0.00006616919,0.000033524087,0.013038636,0.00003420779,0.00001568703,0.000011735385,0.000034080556,5.0402566e-8,0.0091478815,0.97660834,0.0004822864],"about_ca_topic_score_codex":0.0069176233,"about_ca_topic_score_gemma":0.00027560766,"teacher_disagreement_score":0.78445977,"about_ca_system_score_codex":0.0017849947,"about_ca_system_score_gemma":0.00581869,"threshold_uncertainty_score":0.9998174},"labels":[],"label_agreement":null},{"id":"W2199056744","doi":"10.4000/ethiquepublique.1858","title":"L’impact psychosocial du rationnement de l’accès aux traitements antirétroviraux dans les pays à ressources limitées","year":2006,"lang":"fr","type":"article","venue":"Éthique Publique","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Humanities; Political science; Human immunodeficiency virus (HIV); Philosophy; Medicine; Virology","score_opus":0.04091444852943463,"score_gpt":0.2973324199794017,"score_spread":0.25641797144996703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2199056744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.72872245,0.007870903,0.005524867,0.12893753,0.00154458,0.00063728023,0.0016153398,0.00010033666,0.1250467],"genre_scores_gemma":[0.97230357,0.0063201985,0.00082078396,0.013441503,0.003006,0.00013533673,0.00019745452,0.00010518996,0.0036699856],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99624467,0.00019468123,0.0014508,0.0007848182,0.00008774993,0.0012372916],"domain_scores_gemma":[0.9980754,0.00020950609,0.00077450444,0.00044881416,0.00013127104,0.00036048828],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015735207,0.0005209678,0.0007080826,0.0004276344,0.0005816086,0.0007911877,0.0006675624,0.0007036117,0.0017711819],"category_scores_gemma":[0.00028973367,0.00065867946,0.00053068704,0.00037410797,0.00034438574,0.0009081232,0.00012377524,0.0007671788,0.00028582546],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005425906,0.0007961245,0.23226598,0.000091793045,0.00021483688,0.000011694113,0.0014267017,0.0009045128,0.00013404127,0.7210968,0.0382035,0.00479975],"study_design_scores_gemma":[0.0013404819,0.00017686447,0.15735409,0.000053730462,0.000037361282,0.000016065045,0.000115013674,0.008989691,0.00035004193,0.07577263,0.75511837,0.00067567563],"about_ca_topic_score_codex":0.010163247,"about_ca_topic_score_gemma":0.0035132915,"teacher_disagreement_score":0.71691483,"about_ca_system_score_codex":0.001418988,"about_ca_system_score_gemma":0.00033140017,"threshold_uncertainty_score":0.99958646},"labels":[],"label_agreement":null},{"id":"W2199975518","doi":"10.1161/circoutcomes.7.suppl_1.22","title":"Abstract 22: Impact Of Drug Policy On Regional Trends In Ezetimibe Use","year":2014,"lang":"en","type":"article","venue":"Circulation Cardiovascular Quality and Outcomes","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences","funders":"","keywords":"Ezetimibe; Formulary; Population; Medicine; Restrictiveness; Demography; Proxy (statistics); Geography; Environmental health; Statistics; Family medicine; Internal medicine; Mathematics","score_opus":0.148349463738525,"score_gpt":0.36434580763360935,"score_spread":0.21599634389508435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2199975518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99042237,0.00054683577,0.0002517181,0.0012001236,0.000079787846,0.00009278085,0.00011821506,0.000016299127,0.0072718854],"genre_scores_gemma":[0.9986522,0.00017041762,0.000039783175,0.00092311506,0.00010516882,0.000005784251,0.000036362224,0.000016460723,0.00005070078],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998483,0.000083078376,0.00076597376,0.00035805395,0.00006985439,0.00024005317],"domain_scores_gemma":[0.9989017,0.00024821953,0.00024039355,0.0004630915,0.000022754206,0.00012382565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016706942,0.00017543408,0.00078845106,0.0005726216,0.00004964393,0.000053574353,0.00010910052,0.000104533756,0.000109261135],"category_scores_gemma":[0.00028907566,0.00018209871,0.0010190663,0.00025880686,0.00007679752,0.00023684693,0.000028296989,0.00014881,0.00003635512],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001443385,0.00006197994,0.7608472,0.00003087978,0.00038681875,5.0870716e-7,0.00018618377,0.012330203,0.0000049486166,0.2186585,0.00010352167,0.0073747984],"study_design_scores_gemma":[0.0010340104,0.000010702754,0.97515523,0.000008291422,0.000008811177,0.0000012819643,0.000006248737,0.001481865,0.000005648322,0.01586747,0.006217768,0.00020267392],"about_ca_topic_score_codex":0.004047383,"about_ca_topic_score_gemma":0.000021629292,"teacher_disagreement_score":0.21430802,"about_ca_system_score_codex":0.0001566512,"about_ca_system_score_gemma":0.000026692394,"threshold_uncertainty_score":0.742577},"labels":[],"label_agreement":null},{"id":"W2209930065","doi":"10.2139/ssrn.2649260","title":"Funding Translational Medicine via Public Markets: The Business Development Company","year":2015,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nexen (Canada)","funders":"","keywords":"Translational medicine; Business; Industrial organization; Medicine","score_opus":0.1077964548714761,"score_gpt":0.28855949494863287,"score_spread":0.18076304007715677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2209930065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3303228,0.048011273,0.20714813,0.3072854,0.0031179227,0.00056411483,0.000035778965,0.00009593444,0.10341862],"genre_scores_gemma":[0.995045,0.001484276,0.00012194786,0.0017626818,0.00073929346,0.0000076882925,0.000011765317,0.000023497329,0.00080385536],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99746436,0.000035160403,0.00069490256,0.00020456844,0.000074072224,0.0015269218],"domain_scores_gemma":[0.9991596,0.00007420247,0.00029933362,0.00014576629,0.00008592653,0.00023522128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047773686,0.00016002613,0.00028948204,0.00021248277,0.00029194134,0.00009641468,0.00043558286,0.0000625325,0.00033190503],"category_scores_gemma":[0.00013146694,0.0001286703,0.0000653086,0.00031314176,0.00010056518,0.0002904087,0.00003713033,0.000922236,0.00030956126],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039958115,0.00005162226,0.008253521,0.0000049743817,0.00020892576,9.638552e-7,0.00050706265,0.00008306189,0.000006079435,0.97154564,0.0018249372,0.017473264],"study_design_scores_gemma":[0.0011045366,0.000029041033,0.010578044,0.000006493745,0.0000068210525,0.0001687405,0.00019530159,0.0024038272,0.0000025580505,0.55577785,0.42954773,0.00017907044],"about_ca_topic_score_codex":0.000039447958,"about_ca_topic_score_gemma":0.00014261367,"teacher_disagreement_score":0.6647222,"about_ca_system_score_codex":0.0009169501,"about_ca_system_score_gemma":0.0011834357,"threshold_uncertainty_score":0.5247023},"labels":[],"label_agreement":null},{"id":"W2216816010","doi":"","title":"Federal Delays in Approving New Medicines 2013","year":2013,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Fraser Institute","funders":"","keywords":"Notice; Harmonization; Government (linguistics); Order (exchange); Business; Population; Medicine; Political science; Environmental health; Law; Finance","score_opus":0.026471493947228805,"score_gpt":0.25366425673031895,"score_spread":0.22719276278309014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2216816010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8241321,0.028412176,0.013756977,0.081043914,0.001079801,0.0005192791,0.000009952675,0.000052202577,0.0509936],"genre_scores_gemma":[0.9847214,0.008520696,0.00018590207,0.0029711397,0.0007776288,0.000009930516,0.0000025262987,0.000029696314,0.0027810335],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9971363,0.000014918186,0.0006526556,0.00023914792,0.000029164621,0.0019278306],"domain_scores_gemma":[0.99935067,0.00003754861,0.00023617048,0.00014021141,0.000016421998,0.00021897517],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010266573,0.00015752252,0.00033347827,0.00026712602,0.000101447695,0.00013773923,0.0003040281,0.00009180186,0.0008470204],"category_scores_gemma":[0.00006688977,0.0001638608,0.000107064574,0.00014908667,0.000031769112,0.00043963405,0.000044154796,0.0013180042,0.0014737234],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016708886,0.000073221585,0.043359365,0.000008445122,0.00010583304,0.0000024520516,0.00028800638,0.00016432397,0.00004147867,0.91190135,0.0143423565,0.029696425],"study_design_scores_gemma":[0.0011033284,0.00008880148,0.004399741,0.000008949662,0.0000028790212,0.000100373196,0.00019235922,0.006255803,0.000006742052,0.95615566,0.03145007,0.00023532494],"about_ca_topic_score_codex":0.0030458423,"about_ca_topic_score_gemma":0.0018583955,"teacher_disagreement_score":0.16058935,"about_ca_system_score_codex":0.00071626756,"about_ca_system_score_gemma":0.00049671635,"threshold_uncertainty_score":0.99930376},"labels":[],"label_agreement":null},{"id":"W2221479424","doi":"10.1016/j.ejpb.2007.01.003","title":"Drug delivery: A Canadian perspective","year":2007,"lang":"en","type":"editorial","venue":"European Journal of Pharmaceutics and Biopharmaceutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Perspective (graphical); Drug; Drug delivery; Pharmacology; Medicine; Chemistry; Computer science","score_opus":0.05037846334896324,"score_gpt":0.31348842040875363,"score_spread":0.2631099570597904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2221479424","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009553078,0.07182397,0.00013055486,0.00445797,0.8246946,0.00055498496,0.004456347,0.000058896294,0.084269606],"genre_scores_gemma":[0.19462176,0.08907632,0.00096698455,0.007288099,0.7063068,0.000002748798,0.00009308161,0.0004752282,0.0011689729],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99493784,0.00023371541,0.0024831535,0.000727965,0.00028581475,0.0013315188],"domain_scores_gemma":[0.9936919,0.0004903687,0.0022342904,0.00040045983,0.0009109103,0.002272057],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0075212917,0.00080396706,0.0013800627,0.0016996906,0.00031032716,0.00041788947,0.0012243286,0.00037348905,0.00042295203],"category_scores_gemma":[0.0005423184,0.0008895764,0.0005482562,0.00044641105,0.00039210296,0.00032604273,0.0003084441,0.0039292006,0.0005735762],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019872429,0.00014771854,0.00020626158,0.00016400198,0.0008876072,0.0010710927,0.0012877565,0.000018289238,0.00008610265,0.0040767575,0.9883002,0.0035554809],"study_design_scores_gemma":[0.0025835144,0.00013972359,0.00005058603,0.000093588795,0.00023262808,0.00008169683,0.00025448087,0.000722252,0.00029357595,0.0021496604,0.9924665,0.00093176076],"about_ca_topic_score_codex":0.002628202,"about_ca_topic_score_gemma":0.0008316579,"teacher_disagreement_score":0.18506868,"about_ca_system_score_codex":0.001154162,"about_ca_system_score_gemma":0.0008769533,"threshold_uncertainty_score":0.9993555},"labels":[],"label_agreement":null},{"id":"W2226623001","doi":"","title":"Employers favor legalizing Rx purchases from Canada","year":2005,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Medical prescription; Government (linguistics); Community practice; Pharmacy; Family medicine; Nursing","score_opus":0.07846345986425894,"score_gpt":0.2732057644464797,"score_spread":0.19474230458222075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2226623001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.65743065,0.001789899,0.00048170116,0.01985786,0.0005457124,0.00012427538,0.0008495279,0.00006159057,0.3188588],"genre_scores_gemma":[0.980541,0.00014600389,0.0007732107,0.016020073,0.00044811578,0.00000863268,0.000023687693,0.000022863782,0.0020164414],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99882615,0.0000053095564,0.00046908797,0.00031942126,0.00002162034,0.000358392],"domain_scores_gemma":[0.9993537,0.000066226305,0.00011542155,0.00024176502,0.000009203609,0.00021367436],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000121106605,0.00013907408,0.0002820835,0.00007451196,0.00008340972,0.00007890347,0.00023300228,0.00005258201,0.0037663518],"category_scores_gemma":[0.00004543088,0.0001632079,0.00007478776,0.00007983486,0.000029188888,0.00021317483,0.000056876823,0.00012465022,0.0010558347],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021024476,0.00010591611,0.054566912,0.000011578285,0.00018526177,0.000009108376,0.00022745275,0.00082436897,0.00008636119,0.7409151,0.1913653,0.011681581],"study_design_scores_gemma":[0.00038210384,0.000008570081,0.007036785,0.0000027583264,0.0000032054418,0.000001004208,0.000025228512,0.0048846756,0.0007121157,0.008035801,0.97864,0.00026775742],"about_ca_topic_score_codex":0.7534581,"about_ca_topic_score_gemma":0.5498439,"teacher_disagreement_score":0.7872747,"about_ca_system_score_codex":0.0002841605,"about_ca_system_score_gemma":0.00010340099,"threshold_uncertainty_score":0.99972194},"labels":[],"label_agreement":null},{"id":"W2227034299","doi":"","title":"The politics of the EU pharmaceutical industry","year":2004,"lang":"en","type":"book-chapter","venue":"London School of Economics and Political Science Research Online (London School of Economics and Political Science)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Politics; Pharmaceutical industry; Business; Political science; Law; Medicine; Pharmacology","score_opus":0.11704074008761553,"score_gpt":0.38505406423716715,"score_spread":0.2680133241495516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2227034299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6601404,0.003427384,0.0000040069913,0.04420907,0.0010830695,0.0013321944,0.004292599,0.000018734783,0.28549254],"genre_scores_gemma":[0.97595567,0.013060256,0.00031340387,0.0022529552,0.0008552798,0.000018661018,0.000013273117,0.0000940828,0.0074364105],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9896647,0.000092069626,0.0036141328,0.0018145904,0.0003802572,0.004434247],"domain_scores_gemma":[0.98883426,0.0017249542,0.0012767381,0.0017207782,0.0007595484,0.005683737],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":["sts"],"category_scores_codex":[0.009897391,0.00079019176,0.0019345027,0.0012900442,0.0013499727,0.00070452964,0.00365251,0.00095480075,0.00064621546],"category_scores_gemma":[0.0039489535,0.00064858363,0.0005790933,0.000604779,0.02770446,0.00088562537,0.0028025236,0.0033394317,0.000118641234],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006001942,0.00013980725,0.0022798094,0.000118131255,0.00008438437,0.0000014917118,0.000024978224,0.00007858056,0.00005343632,0.9965701,0.00016375349,0.0004254681],"study_design_scores_gemma":[0.0013287958,0.00036762143,0.0070201224,0.00017829133,0.0000563386,0.000038067978,0.0001325608,0.0044983258,0.0013296402,0.86662143,0.11768612,0.00074269803],"about_ca_topic_score_codex":0.002090218,"about_ca_topic_score_gemma":0.00018133887,"teacher_disagreement_score":0.31581527,"about_ca_system_score_codex":0.0021052007,"about_ca_system_score_gemma":0.006952717,"threshold_uncertainty_score":0.9999501},"labels":[],"label_agreement":null},{"id":"W2245971688","doi":"","title":"How should we support pharmaceutical innovation","year":2009,"lang":"en","type":"article","venue":"RePEc: Research Papers in Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Incentive; Business; Subsidy; Health care; Pharmaceutical industry; Risk analysis (engineering); Industrial organization; Marketing; Pharmacology; Medicine; Economics; Economic growth","score_opus":0.18106743541340944,"score_gpt":0.3992432614849622,"score_spread":0.21817582607155275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2245971688","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22307327,0.00051273126,0.000057994897,0.07031298,0.000629362,0.0007747154,0.00020377617,0.00009963755,0.7043355],"genre_scores_gemma":[0.9812502,0.007838282,0.00031258477,0.0049606725,0.00041627372,0.000050503844,0.00003921296,0.00004687126,0.005085377],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968534,0.00005442624,0.0010290083,0.0008334625,0.000072717594,0.0011569576],"domain_scores_gemma":[0.99861205,0.00020035496,0.00022728606,0.0005957618,0.000065555985,0.00029898493],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002273549,0.000281086,0.00059456704,0.001151194,0.00016737972,0.00033352434,0.0005894589,0.00028123223,0.00067461166],"category_scores_gemma":[0.00045114008,0.00034673384,0.00014794164,0.00063876464,0.00022082844,0.0005215533,0.0001384823,0.0010205352,0.00029377942],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000108839224,0.00036100738,0.0065731723,0.00003445683,0.000055201348,0.000026049931,0.00022917574,0.0001903508,0.00040421184,0.6242034,0.0019135984,0.36590052],"study_design_scores_gemma":[0.0013002449,0.00018597183,0.0044617443,0.000013773262,0.0000026171692,0.000014685201,0.00008936882,0.011368856,0.0006359761,0.08268067,0.8987769,0.0004691728],"about_ca_topic_score_codex":0.000009764909,"about_ca_topic_score_gemma":0.000013049966,"teacher_disagreement_score":0.89686334,"about_ca_system_score_codex":0.00066308834,"about_ca_system_score_gemma":0.00012946964,"threshold_uncertainty_score":0.9998985},"labels":[],"label_agreement":null},{"id":"W2248814847","doi":"10.1016/j.hcmf.2012.07.017","title":"Drug Shortages: Canadian Strategies for a Complex Global Problem","year":2012,"lang":"en","type":"article","venue":"Healthcare Management Forum","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Purchasing; Procurement; Economic shortage; Competition (biology); Supply chain; Marketing; Service (business); Industrial organization","score_opus":0.09820773978414382,"score_gpt":0.33362530713366084,"score_spread":0.23541756734951702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2248814847","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010991542,0.0052392753,0.005247696,0.1987565,0.0018257699,0.003672409,0.0044684014,0.00018312856,0.7696153],"genre_scores_gemma":[0.9763133,0.00024315811,0.0026181028,0.019303124,0.00021073956,0.00025021425,0.00013018391,0.000028223862,0.0009029819],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99781984,0.000011670504,0.0005430497,0.00032953327,0.000027712575,0.001268201],"domain_scores_gemma":[0.99890006,0.000016689617,0.00014660649,0.0002880816,0.000019958956,0.0006286233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048335324,0.00019278645,0.00031652834,0.00017679611,0.00026101782,0.00013474078,0.00027423658,0.00007074129,0.00030576877],"category_scores_gemma":[0.000004946495,0.0002377156,0.00012601109,0.00017513578,0.000037676542,0.00033009096,0.000080447055,0.00009439816,0.0004945444],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007799504,0.000032799246,0.03435015,0.00022197224,0.000055496574,8.8671123e-7,0.0001425257,0.000015769288,6.0333406e-8,0.882537,0.079644516,0.002991032],"study_design_scores_gemma":[0.00033659328,0.000020582895,0.010506877,0.000008850455,0.000006376919,0.0000013485692,0.00071556144,0.0009995496,3.855927e-7,0.17142199,0.81575,0.00023187818],"about_ca_topic_score_codex":0.044109594,"about_ca_topic_score_gemma":0.11445632,"teacher_disagreement_score":0.9653217,"about_ca_system_score_codex":0.0005553122,"about_ca_system_score_gemma":0.00006722222,"threshold_uncertainty_score":0.96937615},"labels":[],"label_agreement":null},{"id":"W2253608104","doi":"","title":"Рынок ОНЛС РФ по итогам i квартала 2011 г.","year":2011,"lang":"ru","type":"article","venue":"Ремедиум. Журнал о российском рынке лекарств и медицинской технике","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Agricultural economics; Commerce; Business; Economics; Geography","score_opus":0.16935549050366325,"score_gpt":0.2793907760325379,"score_spread":0.11003528552887468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2253608104","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19573481,0.037207205,0.0017245668,0.010525144,0.017706344,0.0034724448,0.006487876,0.0010016703,0.72613996],"genre_scores_gemma":[0.9239527,0.015956609,0.0026729852,0.012577768,0.004709941,0.00036824498,0.0003684776,0.000945637,0.038447663],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.98378193,0.00030533114,0.00576921,0.004457091,0.00047136284,0.005215092],"domain_scores_gemma":[0.9883863,0.0005987741,0.003287044,0.004360152,0.00038827315,0.002979493],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.0033838842,0.002887562,0.0043882667,0.00216791,0.0012329228,0.0009109697,0.0041621667,0.0022553531,0.061941627],"category_scores_gemma":[0.00057723257,0.0036202655,0.0023269525,0.0015096032,0.0014314177,0.0021584386,0.0017313374,0.0031226205,0.10208222],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001231759,0.004896442,0.072931744,0.0011587129,0.0033365542,0.0006298847,0.008408596,0.00010797479,0.00041092173,0.5942212,0.29288432,0.019781947],"study_design_scores_gemma":[0.0066551226,0.0011437342,0.02604493,0.00028116346,0.000534344,0.00020934176,0.0005378194,0.005552793,0.002700795,0.07937644,0.8708754,0.0060881237],"about_ca_topic_score_codex":0.0033927173,"about_ca_topic_score_gemma":0.00043337644,"teacher_disagreement_score":0.72821784,"about_ca_system_score_codex":0.0013465399,"about_ca_system_score_gemma":0.00079765293,"threshold_uncertainty_score":0.9991772},"labels":[],"label_agreement":null},{"id":"W2254545690","doi":"","title":"Denaturalizing Transparency in Drug Regulation","year":2015,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"","keywords":"Transparency (behavior); Business; Drug; Law and economics; Accounting; Political science; Law; Pharmacology; Economics; Medicine","score_opus":0.05359186535836978,"score_gpt":0.27909450932715746,"score_spread":0.22550264396878766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2254545690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9174458,0.019716775,0.003646683,0.009731038,0.00073831656,0.0001591898,0.00001446704,0.000029703358,0.048518043],"genre_scores_gemma":[0.9959002,0.0024789348,0.000071277755,0.00044671458,0.00022429768,0.0000030850758,0.0000038236126,0.000016374388,0.0008552988],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9980106,0.000020959178,0.00053338095,0.00017911034,0.00002844462,0.0012275296],"domain_scores_gemma":[0.9995369,0.000017058766,0.00018772403,0.00010824504,0.000018195553,0.0001319],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002110612,0.00010398172,0.00022047586,0.00023208432,0.000051971667,0.00005542891,0.00020345021,0.000058264475,0.000060884253],"category_scores_gemma":[0.000055749773,0.0001178882,0.00007754639,0.00017436958,0.0000207489,0.00033514763,0.000014394611,0.00096987316,0.00024072119],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002320411,0.00003019725,0.014487648,0.0000025675915,0.000024631245,0.0000013340409,0.00044479303,0.00036235474,0.000009047403,0.98172516,0.00045089505,0.0024382004],"study_design_scores_gemma":[0.0009765871,0.000034032655,0.00310818,0.000006349326,0.000002726638,0.00005409072,0.0002036308,0.002368038,0.000024903002,0.9631773,0.029881675,0.00016246426],"about_ca_topic_score_codex":0.00026152664,"about_ca_topic_score_gemma":0.0012543746,"teacher_disagreement_score":0.078454405,"about_ca_system_score_codex":0.0011837835,"about_ca_system_score_gemma":0.00035602256,"threshold_uncertainty_score":0.48073414},"labels":[],"label_agreement":null},{"id":"W2255400834","doi":"","title":"Access Delayed, Access Denied 2012: Waiting for New Medicines in Canada","year":2011,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Fraser Institute","funders":"","keywords":"Government (linguistics); Medicine; Business; Environmental health; Public administration; Political science","score_opus":0.09396964474850476,"score_gpt":0.3085533339003749,"score_spread":0.21458368915187015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2255400834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94389665,0.013456599,0.011736773,0.009469757,0.0014944146,0.0005194925,0.00011005116,0.000018945411,0.019297305],"genre_scores_gemma":[0.9921368,0.0041476847,0.0000728123,0.0025630926,0.0005816711,0.00001387911,0.0000055406576,0.00003330208,0.00044527027],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9969177,0.000012883102,0.00077366375,0.00026787896,0.00003410992,0.001993728],"domain_scores_gemma":[0.99912816,0.00007673304,0.0003806302,0.00014781658,0.000027822683,0.00023885982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011412667,0.00017320964,0.00038943338,0.00023616462,0.00011037837,0.00009653965,0.0008323701,0.00006674718,0.00043079976],"category_scores_gemma":[0.0001035058,0.00018720521,0.00009660349,0.00018433122,0.00002020239,0.0007272175,0.00008636029,0.0008525738,0.000023272822],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024678832,0.000067030436,0.25780973,0.000024929826,0.00032368943,0.0000091168295,0.00027358232,0.00015291077,0.0000053354343,0.70947975,0.011806271,0.019800834],"study_design_scores_gemma":[0.0023539832,0.00009251552,0.011352804,0.000016528276,0.000017919565,0.00008615637,0.00024976055,0.004739782,0.00008688358,0.9561525,0.024454892,0.00039629286],"about_ca_topic_score_codex":0.6630983,"about_ca_topic_score_gemma":0.9398858,"teacher_disagreement_score":0.27678755,"about_ca_system_score_codex":0.0017184707,"about_ca_system_score_gemma":0.0046250536,"threshold_uncertainty_score":0.8204647},"labels":[],"label_agreement":null},{"id":"W2255665729","doi":"10.1177/0020731418789610","title":"Intellectual Property Protection and Drug Plan Coverage: Evidence From Ontario","year":2018,"lang":"en","type":"article","venue":"International Journal of Health Services","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Eli Lilly (Canada); York University; McMaster University; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Formulary; Listing (finance); Business; Intellectual property; Generic drug; Drug; Medicine; Finance; Pharmacology; Law; Political science","score_opus":0.09767670350483715,"score_gpt":0.3186185929819469,"score_spread":0.22094188947710974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2255665729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98002124,0.0021787423,0.00090375583,0.01398628,0.0015475714,0.00012206288,0.000052108593,0.00000671803,0.0011815454],"genre_scores_gemma":[0.9924735,0.0011243456,0.00029137777,0.005108516,0.0007715025,0.000002481619,0.0000032336716,0.000008203671,0.00021683623],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988523,0.000026825533,0.00075583195,0.00016237462,0.000060499075,0.00014218436],"domain_scores_gemma":[0.9988517,0.00009165309,0.0007315736,0.00007494479,0.00013509682,0.000115017734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007017902,0.00008917678,0.00024496237,0.00016581474,0.000080206904,0.0001312907,0.00031754325,0.000036270892,0.00077761733],"category_scores_gemma":[0.000049248563,0.00007424027,0.00004784868,0.00004325802,0.000042518248,0.0005137525,0.00007154439,0.00020839387,0.00015250004],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004121876,0.00090143573,0.5578549,0.0005553476,0.001950231,0.00005541785,0.19990422,0.00025524563,0.00051578844,0.013735912,0.017703716,0.2024459],"study_design_scores_gemma":[0.0017061515,0.0006731765,0.11319241,0.0008069034,0.000009978843,0.0001245493,0.00032748032,0.0076020597,0.00046664252,0.045536794,0.8292132,0.00034068341],"about_ca_topic_score_codex":0.06665982,"about_ca_topic_score_gemma":0.01824451,"teacher_disagreement_score":0.81150943,"about_ca_system_score_codex":0.00031757925,"about_ca_system_score_gemma":0.00014920162,"threshold_uncertainty_score":0.99966997},"labels":[],"label_agreement":null},{"id":"W2260302947","doi":"","title":"U.S. Senate Testimony on the Dept. of Commerce OECD Drug Pricing Report","year":2005,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Prescription drug; Business; Government (linguistics); Drug prices; Cash; Medical prescription; International trade; International economics; Health care; Economics; Development economics; Economic growth; Public economics; Finance; Medicine","score_opus":0.03214763514563925,"score_gpt":0.2723394979906702,"score_spread":0.24019186284503094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2260302947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88851225,0.0043955296,0.00085388555,0.048569813,0.0002512965,0.00017386857,0.000014185605,0.000021643727,0.05720755],"genre_scores_gemma":[0.9919742,0.0026991207,0.00006522628,0.0032288723,0.0003863472,0.0000039022325,0.0000016630062,0.000026396925,0.0016143185],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9976614,0.000027801716,0.00080086186,0.00021459017,0.000044852917,0.0012504747],"domain_scores_gemma":[0.9988085,0.00013164965,0.00063895236,0.00029929323,0.000026233118,0.00009538801],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030036713,0.0001517737,0.00031424913,0.00014702398,0.00018778627,0.000050967363,0.00037977178,0.000053485128,0.0001851074],"category_scores_gemma":[0.00013748412,0.00012831189,0.00017463039,0.00010517128,0.00006535826,0.0001444196,0.00004789858,0.0013781528,0.00044886174],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023927672,0.00010213958,0.0065536425,0.000005073576,0.00014676018,0.0000039081506,0.0001564565,0.00054709124,0.00007150306,0.98171616,0.002118921,0.008554421],"study_design_scores_gemma":[0.0010635194,0.00016002014,0.0036052426,0.000029388444,0.0000256063,0.00085067964,0.00019497726,0.0075103105,0.0015337516,0.7416891,0.24288528,0.00045212085],"about_ca_topic_score_codex":0.000110052366,"about_ca_topic_score_gemma":0.00021474372,"teacher_disagreement_score":0.24076635,"about_ca_system_score_codex":0.0006150948,"about_ca_system_score_gemma":0.0002977472,"threshold_uncertainty_score":0.5987464},"labels":[],"label_agreement":null},{"id":"W2262056843","doi":"","title":"Twelve years after Canada's access to medicines regime : should South Africa follow the path?","year":2015,"lang":"en","type":"article","venue":"South African Law Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Legislation; Exportation; Order (exchange); Business; Mechanism (biology); Drug industry; International trade; Developing country; Economic growth; Law; Political science; Economics; Finance; Engineering","score_opus":0.09757953290351798,"score_gpt":0.28458232801573463,"score_spread":0.18700279511221665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2262056843","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34382564,0.0070130434,0.0011328564,0.17965375,0.006906444,0.0011514764,0.0023205553,0.00010687728,0.45788938],"genre_scores_gemma":[0.9744147,0.000015793428,0.000107327876,0.02379139,0.0011316286,0.000030200414,0.0000023709838,0.000044562712,0.00046204773],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979803,0.000045315785,0.00073025894,0.00036387247,0.00015017706,0.000730074],"domain_scores_gemma":[0.9979143,0.00008689641,0.00040136586,0.00043785205,0.00008111312,0.0010784657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010647768,0.00024720936,0.0004898432,0.00015516854,0.00023441292,0.00040347755,0.00094204344,0.00008868559,0.00044649484],"category_scores_gemma":[0.00030148966,0.0002034024,0.00017330321,0.00035760814,0.00013428467,0.00021853042,0.0002254827,0.00055198953,0.00031066593],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082536344,0.00016046343,0.0770499,0.00003511528,0.000735053,0.00054415874,0.071580455,0.0012048833,0.000003013275,0.11881122,0.72673184,0.0023185299],"study_design_scores_gemma":[0.0008955873,0.00008033023,0.005310139,0.000016882268,0.00002838404,0.00003141582,0.0019066916,0.00022846505,0.000003853368,0.016085912,0.97503644,0.0003758904],"about_ca_topic_score_codex":0.01732383,"about_ca_topic_score_gemma":0.045841567,"teacher_disagreement_score":0.63058907,"about_ca_system_score_codex":0.0003737399,"about_ca_system_score_gemma":0.0003558504,"threshold_uncertainty_score":0.9892199},"labels":[],"label_agreement":null},{"id":"W2271290295","doi":"","title":"Formulary Pricing with Optional Participation: Reconciling Static and Dynamic Efficiency","year":2007,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Formulary; Dynamic efficiency; Incentive; Economic surplus; Public economics; Listing (finance); Variety (cybernetics); Externality; Business; Negotiation; Economics; Welfare; Industrial organization; Microeconomics; Finance; Market economy","score_opus":0.024026847104903656,"score_gpt":0.2851835727259557,"score_spread":0.261156725621052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2271290295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85956186,0.0032939464,0.13207506,0.0013108226,0.00010083968,0.00010339023,0.000007844614,0.000014620414,0.0035316364],"genre_scores_gemma":[0.99656004,0.0019481651,0.0005739654,0.0005688325,0.00010739541,0.000003124034,0.0000036012611,0.000018845576,0.00021606138],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99777776,0.000009030436,0.00051918364,0.00021570697,0.000039072635,0.0014392353],"domain_scores_gemma":[0.9993922,0.00008118104,0.00026072655,0.00009345454,0.00002747706,0.00014495096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026331658,0.00012434271,0.00021310756,0.00018556144,0.00021444239,0.00007115791,0.00011377919,0.00004952497,0.00005501784],"category_scores_gemma":[0.000050539176,0.0001234317,0.000048720904,0.00014126372,0.000053108124,0.00027050156,0.000022199576,0.00072366744,0.000047499514],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010617429,0.00008704628,0.020942723,0.000018488267,0.00015130504,0.0000062040936,0.0004284102,0.0011079133,0.00004701026,0.95844424,0.000012218499,0.018648297],"study_design_scores_gemma":[0.0025173852,0.0007081888,0.025271412,0.000034085246,0.00003360415,0.0006691283,0.0005807495,0.06789232,0.000073839605,0.89574474,0.005876965,0.0005976054],"about_ca_topic_score_codex":0.000018728446,"about_ca_topic_score_gemma":0.00024796312,"teacher_disagreement_score":0.13699816,"about_ca_system_score_codex":0.0006892952,"about_ca_system_score_gemma":0.00032514762,"threshold_uncertainty_score":0.5033398},"labels":[],"label_agreement":null},{"id":"W2277482329","doi":"10.2139/ssrn.920063","title":"Economic Prizes: Filling the Gaps in Pharmaceutical Innovations","year":2005,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Business; Economics","score_opus":0.03866585999831631,"score_gpt":0.30853067608029533,"score_spread":0.26986481608197904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2277482329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8498671,0.014998783,0.0030164213,0.08512387,0.00076867186,0.0003775361,0.0000678366,0.000044855242,0.045734912],"genre_scores_gemma":[0.98327494,0.010919531,0.00010377742,0.0040969877,0.00093910843,0.000014903852,0.000004058907,0.00002823693,0.0006184369],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99698573,0.000028399072,0.0008737956,0.00026081785,0.000027023625,0.0018242522],"domain_scores_gemma":[0.99932134,0.00009668587,0.00026672715,0.00020113452,0.000014840242,0.00009925539],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00273438,0.00016444136,0.00027822398,0.00028324136,0.00021121804,0.00012367361,0.00046043022,0.00008571037,0.000545641],"category_scores_gemma":[0.00006794691,0.00015489708,0.00013146293,0.00021570947,0.00007612231,0.00034729842,0.000056531706,0.001991606,0.0013324582],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016568403,0.000052128216,0.0069980477,0.0000022349566,0.000068171095,5.7306175e-7,0.0001420351,0.0015747378,0.000012250532,0.9832169,0.0005197643,0.007396619],"study_design_scores_gemma":[0.0011444149,0.000040233466,0.0011699847,0.0000063343955,0.0000069995663,0.00010843951,0.0001524154,0.0195312,0.00006177986,0.52434,0.4531816,0.00025663528],"about_ca_topic_score_codex":0.000057147772,"about_ca_topic_score_gemma":0.00077510544,"teacher_disagreement_score":0.4588769,"about_ca_system_score_codex":0.0018446641,"about_ca_system_score_gemma":0.0005506102,"threshold_uncertainty_score":0.99944514},"labels":[],"label_agreement":null},{"id":"W2279506649","doi":"10.1371/journal.pone.0148939","title":"Is Patent “Evergreening” Restricting Access to Medicine/Device Combination Products?","year":2016,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bruyère; University of Ottawa","funders":"Canadian Institutes of Health Research; Canadian Foundation for Healthcare Improvement","keywords":"Medicine; Food and drug administration; Intellectual property; Product (mathematics); Pulmonary disease; Active ingredient; Business; Pharmacology; Law; Internal medicine","score_opus":0.3945351596196885,"score_gpt":0.325407430884167,"score_spread":0.06912772873552148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2279506649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8137723,0.0003378067,0.00031941428,0.1596898,0.00022051211,0.00040590906,0.00009233723,0.00006205275,0.02509985],"genre_scores_gemma":[0.98869985,0.00035165474,0.0003836524,0.008520115,0.00040626805,0.000043811408,0.000004865713,0.000027480564,0.0015622916],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99860567,0.000012570006,0.0005469203,0.0004512391,0.000057768168,0.00032582905],"domain_scores_gemma":[0.99903834,0.00009956605,0.00024925012,0.00034429177,0.0000844583,0.00018410495],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004258147,0.00013836719,0.00034974795,0.00025992878,0.00008771065,0.00006424183,0.00037944556,0.00006053348,0.00078658265],"category_scores_gemma":[0.0006445845,0.00012420832,0.000036467278,0.00034840117,0.0000367482,0.00038641397,0.00015657132,0.00009968666,0.0017303153],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017697095,0.0026482996,0.5608815,0.00051917427,0.00077557773,0.000009195636,0.0025409213,0.000009071484,0.013519376,0.33075643,0.06816748,0.019996036],"study_design_scores_gemma":[0.008485714,0.0012545229,0.34446976,0.0012654979,0.00018886823,0.0000049892533,0.000067597175,0.0046503874,0.09585998,0.22860801,0.31257227,0.0025724305],"about_ca_topic_score_codex":0.00018020389,"about_ca_topic_score_gemma":0.000006895872,"teacher_disagreement_score":0.24440478,"about_ca_system_score_codex":0.00014829014,"about_ca_system_score_gemma":0.000017752942,"threshold_uncertainty_score":0.999047},"labels":[],"label_agreement":null},{"id":"W2280050709","doi":"10.1186/s12889-015-2589-1","title":"Essential psychiatric medicines: wrong selection, high consumption and social problems","year":2015,"lang":"en","type":"article","venue":"BMC Public Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Public health; Essential medicines; Biostatistics; Environmental health; Government (linguistics); Essential drugs; Product (mathematics); Family medicine; Psychiatry; Population; Nursing; Health services","score_opus":0.14454133153575027,"score_gpt":0.34378474755607297,"score_spread":0.1992434160203227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2280050709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82622045,0.0049761278,0.019056998,0.13784182,0.0024251905,0.0009488284,0.00023956451,0.00021436515,0.00807665],"genre_scores_gemma":[0.991978,0.0004928243,0.00072581595,0.005494309,0.001025946,0.00003294576,0.00004914586,0.000024041905,0.00017699845],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983655,0.000052822623,0.0006923968,0.00035990708,0.000042566837,0.000486803],"domain_scores_gemma":[0.99899435,0.000034175966,0.00035597035,0.0001088396,0.00004604322,0.00046060383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017011893,0.00013604315,0.00036808598,0.0003035454,0.00021633547,0.00012553357,0.000119716395,0.000105302875,0.00020192708],"category_scores_gemma":[0.00008607349,0.00015500358,0.00004541229,0.000248016,0.000086788394,0.00028658888,0.000044117838,0.00018387636,0.00029453472],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016112626,0.00015814818,0.29586256,0.00028000303,0.000037400114,1.837257e-7,0.0012801345,0.000019782687,0.0000010891644,0.65360016,0.04612041,0.0026240118],"study_design_scores_gemma":[0.0037002447,0.0002136561,0.12770195,0.000007270954,0.000007427763,0.000024913266,0.00013192855,0.010223231,0.0000014600791,0.061779752,0.79576427,0.00044386764],"about_ca_topic_score_codex":0.00083355955,"about_ca_topic_score_gemma":0.00029206747,"teacher_disagreement_score":0.74964386,"about_ca_system_score_codex":0.00028450822,"about_ca_system_score_gemma":0.0004260412,"threshold_uncertainty_score":0.6320862},"labels":[],"label_agreement":null},{"id":"W2281013566","doi":"","title":"Should the U.S. Permit Reimport of Prescripton Drugs from Canada","year":2002,"lang":"en","type":"article","venue":"Journal of Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine","score_opus":0.13511193497949156,"score_gpt":0.2888259963581512,"score_spread":0.15371406137865964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2281013566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9033964,0.018897103,0.00004540684,0.058396295,0.0021441814,0.00020233735,0.00060300285,0.000004872086,0.016310347],"genre_scores_gemma":[0.97665,0.009630146,0.00020337531,0.012788658,0.00046325542,0.0000024787307,0.0000040343853,0.000027151926,0.00023091397],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997002,0.00003492767,0.0023637307,0.00019798601,0.000037630038,0.00036374753],"domain_scores_gemma":[0.99660236,0.00017949943,0.002573896,0.00035374155,0.000043334407,0.0002471647],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012306948,0.00016170171,0.000814553,0.00012584963,0.000114002134,0.000041582138,0.00053603394,0.00007947208,0.0010611055],"category_scores_gemma":[0.00008256991,0.0001491463,0.00020510341,0.00007631017,0.00006981069,0.0002237683,0.000058234473,0.0004121179,0.000039727372],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020347434,0.00066065637,0.14047447,0.0002839383,0.0012457229,0.000018588053,0.0062163547,0.0051982105,0.000017986174,0.19362305,0.59547794,0.05657962],"study_design_scores_gemma":[0.0008968868,0.00011556642,0.012662588,0.000022061637,0.00001248565,0.000021773732,0.00017316623,0.00791176,0.00008186252,0.018090846,0.95979273,0.0002182515],"about_ca_topic_score_codex":0.14195049,"about_ca_topic_score_gemma":0.022829564,"teacher_disagreement_score":0.36431482,"about_ca_system_score_codex":0.00056688156,"about_ca_system_score_gemma":0.0004379474,"threshold_uncertainty_score":0.99985206},"labels":[],"label_agreement":null},{"id":"W2283867889","doi":"10.1093/annonc/mdu438.33","title":"Cross-Comparison of Cancer Drug Approvals Among International Regulatory Bodies","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Drug; Cancer drugs; Drug approval; Cancer; Oncology; Pharmacology; Internal medicine","score_opus":0.15396424428328415,"score_gpt":0.44321385571232835,"score_spread":0.2892496114290442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2283867889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86735123,0.001181819,0.000044011,0.0033936873,0.00064366835,0.0000673646,0.000116071664,0.000008165092,0.12719396],"genre_scores_gemma":[0.997036,0.0005298449,0.00013171375,0.001215307,0.00021501124,0.00001627816,0.0000065119434,0.000011483996,0.00083786884],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987133,0.000019649113,0.00082099834,0.000216817,0.000025608064,0.00020362153],"domain_scores_gemma":[0.9987634,0.00012438372,0.0007624244,0.00019285509,0.00008557006,0.00007136412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073796394,0.00009486606,0.00056153355,0.00016529053,0.000029290582,0.00001327969,0.00030805587,0.000104965926,0.0006265245],"category_scores_gemma":[0.00014647079,0.00010985877,0.00013888859,0.000047213205,0.0002960791,0.00013202487,0.000087860906,0.0001134445,0.00005421525],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053255695,0.00027976747,0.71236295,0.0000450698,0.00016997664,2.1457072e-7,0.0006626688,0.00061632175,0.000094715695,0.25089854,0.011280933,0.023535598],"study_design_scores_gemma":[0.00069719256,0.00013195004,0.28073427,0.000011163858,0.0000053324143,3.2081567e-7,0.000023783505,0.0066448105,0.007002409,0.037664544,0.66693264,0.0001516074],"about_ca_topic_score_codex":0.0005676161,"about_ca_topic_score_gemma":0.00014498144,"teacher_disagreement_score":0.6556517,"about_ca_system_score_codex":0.00003482986,"about_ca_system_score_gemma":0.000032099364,"threshold_uncertainty_score":0.6860004},"labels":[],"label_agreement":null},{"id":"W2285334580","doi":"","title":"Orphan drug pricing and payer management in the United States: are we approaching the tipping point?","year":2010,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"inVentiv Health Clinical","funders":"","keywords":"Orphan drug; Scrutiny; Tipping point (physics); Business; Public economics; Medicine; Economics; Bioinformatics; Political science; Engineering","score_opus":0.06686367527375277,"score_gpt":0.2490064903042446,"score_spread":0.18214281503049184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2285334580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9259444,0.00048763937,0.00020103565,0.045272425,0.00030097825,0.00094035413,0.00003042522,0.000024143008,0.02679861],"genre_scores_gemma":[0.9909332,0.0009549912,0.00006830549,0.007275543,0.00011613928,0.00040451414,0.0000071072363,0.00001637942,0.0002238146],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989513,0.00003116356,0.00034590898,0.00025618303,0.000024653535,0.00039078077],"domain_scores_gemma":[0.9993203,0.00014650292,0.00016763242,0.0002881812,0.0000054120346,0.000071938564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017897727,0.00012080361,0.00017243499,0.00021262931,0.0001526784,0.00021017608,0.00033716968,0.000036978654,0.000021467973],"category_scores_gemma":[0.000045297325,0.0000866072,0.000041518444,0.00027260112,0.00006193325,0.00013583267,0.00012225729,0.00039711228,0.000023801216],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000038643106,0.00022325524,0.06776356,0.00018980255,0.000223227,0.000018190249,0.013214848,0.0010226553,0.000002418037,0.81375104,0.0064177094,0.09713462],"study_design_scores_gemma":[0.00093781727,0.0000040897385,0.24681965,0.000010877767,0.000014712704,0.000008916673,0.0020784773,0.030908903,0.000012895631,0.07596189,0.64290047,0.00034130935],"about_ca_topic_score_codex":0.0002513398,"about_ca_topic_score_gemma":0.00012385083,"teacher_disagreement_score":0.73778915,"about_ca_system_score_codex":0.00003548066,"about_ca_system_score_gemma":0.0000022946724,"threshold_uncertainty_score":0.3531739},"labels":[],"label_agreement":null},{"id":"W2285593923","doi":"10.1016/j.ahj.2016.02.004","title":"The impact of drug shortages on patients with cardiovascular disease: causes, consequences, and a call to action","year":2016,"lang":"en","type":"review","venue":"American Heart Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences","funders":"","keywords":"Medicine; Economic shortage; Scope (computer science); Stakeholder; Call to action; Action (physics); Disease; Public health; Drug; Health care; Intensive care medicine; Risk analysis (engineering); Public relations; Business; Economic growth; Nursing; Marketing; Pharmacology; Economics","score_opus":0.07750357332300327,"score_gpt":0.3612219542229399,"score_spread":0.2837183808999366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2285593923","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0073389686,0.99050695,0.000014434461,0.00049908523,0.00015237778,0.00040294667,0.00086149795,0.000005734512,0.00021802503],"genre_scores_gemma":[0.015278229,0.98420227,0.000022580658,0.00018616584,0.0001915485,0.000023299755,0.0000052564365,0.000037141017,0.00005352745],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99851334,0.000095191375,0.00065883325,0.0003152207,0.000070479575,0.00034691754],"domain_scores_gemma":[0.9982814,0.00022480375,0.00057255273,0.00038936522,0.000044225962,0.000487627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055107556,0.00027310158,0.0014352979,0.00021158873,0.00017394108,0.000110790184,0.0002037181,0.000037368394,0.00003856169],"category_scores_gemma":[0.000108937,0.00015505057,0.00072277244,0.00017519254,0.0004237147,0.000086037864,0.00004267071,0.0003271182,0.00006970961],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000111164416,0.000095611744,0.017811991,0.00035586613,0.0032788333,0.00001281713,0.000045438195,0.000064649175,5.4127636e-8,0.0011432092,0.008874429,0.9682059],"study_design_scores_gemma":[0.00016670207,0.000228744,0.0066702077,0.00071739434,0.00010996763,0.000027522674,0.0000033730207,0.000003552945,1.1165088e-7,0.00023149076,0.9916051,0.00023580901],"about_ca_topic_score_codex":0.00047624324,"about_ca_topic_score_gemma":0.000009474879,"teacher_disagreement_score":0.9827307,"about_ca_system_score_codex":0.00029714842,"about_ca_system_score_gemma":0.00024794982,"threshold_uncertainty_score":0.63227785},"labels":[],"label_agreement":null},{"id":"W2288154790","doi":"10.21450/rahis.v12i1.2574","title":"Health insurance in Canada and Brazil, access to drugs, co-payment cards, loyalty programs, brand name drugs","year":2015,"lang":"en","type":"article","venue":"RAHIS - Revista de Administração Hospitalar e Inovação em Saúde","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"École Nationale d'Administration Publique","funders":"","keywords":"Business; Brand names; Payment; Generic drug; Loyalty; Pharmaceutical industry; Brand loyalty; Marketing; Typology; Actuarial science; Drug; Public economics; Finance; Economics; Pharmacology; Medicine","score_opus":0.04674130838534073,"score_gpt":0.3254032239373113,"score_spread":0.27866191555197056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2288154790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9794622,0.0062069064,0.000063033396,0.007808619,0.0003579848,0.0011961549,0.001284421,0.000049763064,0.003570931],"genre_scores_gemma":[0.98860884,0.001130196,0.0003423908,0.009278909,0.00014544422,0.00012841559,0.00012235224,0.00008116913,0.00016228102],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959921,0.00007748748,0.0015607122,0.0009903754,0.00016279609,0.0012165117],"domain_scores_gemma":[0.99710023,0.000077499455,0.00056595664,0.0006768532,0.00006501865,0.0015144259],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014668488,0.00050077034,0.0012557753,0.00027588467,0.0001401505,0.0006536078,0.0007672785,0.00014725853,0.00008698284],"category_scores_gemma":[0.00016055496,0.0006142167,0.00012751315,0.0005014832,0.000101657126,0.00043372298,0.00023855174,0.0005018618,0.00011740029],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014354133,0.0003023816,0.92795897,0.00039811447,0.00011705342,0.00006316632,0.003241051,0.000073381074,0.0000016680524,0.012558003,0.018469881,0.03667282],"study_design_scores_gemma":[0.0034055528,0.00054211327,0.339642,0.00023316777,0.000012789734,0.000044804325,0.00060004,0.0007309768,0.000074986354,0.0025938686,0.65061784,0.0015019113],"about_ca_topic_score_codex":0.31938177,"about_ca_topic_score_gemma":0.11040146,"teacher_disagreement_score":0.6321479,"about_ca_system_score_codex":0.002654918,"about_ca_system_score_gemma":0.002370687,"threshold_uncertainty_score":0.9996309},"labels":[],"label_agreement":null},{"id":"W2290251572","doi":"10.1016/j.mayocp.2015.12.012","title":"Lowering the High Cost of Cancer Drugs—III","year":2016,"lang":"en","type":"letter","venue":"Mayo Clinic Proceedings","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Pharmacy; Scopus; The Internet; Cancer drugs; Family medicine; Cancer; Advertising; MEDLINE; Law; Business; Political science; World Wide Web; Internal medicine","score_opus":0.07221531348669695,"score_gpt":0.3235453162530976,"score_spread":0.25133000276640066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2290251572","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0068348134,0.0017393728,0.000021960645,0.87752146,0.002425672,0.0006153742,0.0013467977,0.000054166616,0.10944037],"genre_scores_gemma":[0.087860584,0.0064556464,0.000030091389,0.86898285,0.010835615,0.0003122,0.000027787853,0.00016122042,0.025334021],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969267,0.000004739046,0.00153273,0.000727917,0.00007159809,0.0007362791],"domain_scores_gemma":[0.9976155,0.00027729484,0.001551261,0.00036514254,0.00008953996,0.000101226375],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0009892667,0.00039812925,0.0010707405,0.00022955991,0.00011855839,0.000112914946,0.001081515,0.00070964906,0.0040379837],"category_scores_gemma":[0.00013530202,0.00031827053,0.00039162778,0.0001886482,0.00030765682,0.00018240717,0.0002898737,0.0014420286,0.0015125473],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022527782,0.000014840656,0.0012313308,0.0002123216,0.00020153515,0.000002085244,0.00022096727,3.608311e-7,0.000005509649,0.010077753,0.98528165,0.0027291302],"study_design_scores_gemma":[0.0007232127,0.00003101169,0.00023706246,0.00014371991,0.000036337286,0.0000015744708,0.00001121939,0.00005560021,0.00014432649,0.02393291,0.9742563,0.00042674382],"about_ca_topic_score_codex":0.00047745416,"about_ca_topic_score_gemma":0.0000052470295,"teacher_disagreement_score":0.08410635,"about_ca_system_score_codex":0.00023057743,"about_ca_system_score_gemma":0.00007573529,"threshold_uncertainty_score":0.9999269},"labels":[],"label_agreement":null},{"id":"W2293256549","doi":"10.5430/jha.v5n3p48","title":"Regulatory uncertainties in the pharmaceutical sector: Perceptions among Nigerian pharmacists and policy implications for decision making","year":2016,"lang":"en","type":"article","venue":"Journal of Hospital Administration","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Enforcement; Context (archaeology); Pharmacy; Pharmaceutical policy; Government (linguistics); Business; Pharmaceutical care; Pharmacist; Medicine; Public relations; Family medicine; Political science; Nursing; Health policy","score_opus":0.050833635302058554,"score_gpt":0.3530211771930406,"score_spread":0.30218754189098207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2293256549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9771111,0.00025151353,0.003831094,0.017394463,0.0002585964,0.00023662324,0.00014466929,0.0000050704593,0.0007668426],"genre_scores_gemma":[0.9979133,0.00041024995,0.00044896995,0.0006571935,0.00050723995,0.000023054927,0.0000019639388,0.000011856785,0.000026175523],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9988698,0.000021362312,0.00071511767,0.00016112305,0.000035201774,0.00019739132],"domain_scores_gemma":[0.9989856,0.00033823508,0.00040011836,0.00012845261,0.00005398778,0.000093603274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007208299,0.000108573266,0.0002112347,0.00022818334,0.00011242299,0.00010666634,0.00019591683,0.00006448206,0.000058813665],"category_scores_gemma":[0.00031650244,0.00007930534,0.00011874277,0.0001215956,0.00012728249,0.00043518184,0.000020489138,0.00011989087,0.000008099075],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028943396,0.0005671356,0.47338924,0.000043826498,0.000087796296,0.000005878809,0.0019685302,0.000026644086,0.0006400594,0.4883467,0.0044544977,0.030180266],"study_design_scores_gemma":[0.0013491035,0.00086972624,0.75873184,0.000064669,0.000018480125,0.000072401665,0.00016555809,0.0004597672,0.00011380721,0.23007946,0.007842941,0.00023221894],"about_ca_topic_score_codex":0.0000023986756,"about_ca_topic_score_gemma":0.000011402633,"teacher_disagreement_score":0.28534263,"about_ca_system_score_codex":0.00015154065,"about_ca_system_score_gemma":0.00008026559,"threshold_uncertainty_score":0.32339782},"labels":[],"label_agreement":null},{"id":"W2294169926","doi":"10.1053/j.ackd.2016.01.013","title":"Drug Disposition Issues in CKD: Implications for Drug Discovery and Regulatory Approval","year":2016,"lang":"en","type":"review","venue":"Advances in Chronic Kidney Disease","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Lawson Health Research Institute","funders":"","keywords":"Medicine; Kidney disease; Drug; Intensive care medicine; Pharmacokinetics; Adverse effect; Hemodialysis; Population; Pharmacology; Diabetes mellitus; Internal medicine; Endocrinology","score_opus":0.03579520739453439,"score_gpt":0.35924449413193615,"score_spread":0.32344928673740175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2294169926","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000051217085,0.9866452,0.00014978656,0.0023387265,0.0003487894,0.0012479377,0.008013886,0.000021809574,0.0011826132],"genre_scores_gemma":[0.00093859306,0.9954026,0.000079235186,0.00044183605,0.0005033237,0.0012095821,0.00049837097,0.00006934281,0.0008571296],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974365,0.00003859856,0.0010995836,0.00089008023,0.000024022364,0.0005112133],"domain_scores_gemma":[0.9982471,0.00024904386,0.00050052133,0.00054962345,0.000010648832,0.00044308935],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004017282,0.00039440437,0.0012314641,0.00039491637,0.00008009392,0.00009530159,0.00037151217,0.0001142815,0.000049477327],"category_scores_gemma":[0.0001976208,0.00038790464,0.0003157104,0.0001970361,0.00018096782,0.0010348135,0.00013263318,0.00021931114,0.00006745197],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004057226,0.00017290583,0.0010225436,0.01670022,0.000060533897,0.0000027601345,0.00005783491,0.000028168162,1.5328833e-7,0.5157487,0.0042335787,0.46193203],"study_design_scores_gemma":[0.0006977815,0.000008513012,0.00031159996,0.0028057955,0.000038669325,9.535825e-7,0.000002224447,0.00016536558,2.2213514e-7,0.108415484,0.88708884,0.00046455642],"about_ca_topic_score_codex":0.000026889986,"about_ca_topic_score_gemma":0.000053013984,"teacher_disagreement_score":0.88285524,"about_ca_system_score_codex":0.0011831608,"about_ca_system_score_gemma":0.0005420515,"threshold_uncertainty_score":0.9998573},"labels":[],"label_agreement":null},{"id":"W2302160661","doi":"10.1377/hlthaff.2015.0453","title":"Compulsory Licenses: The Authors Reply","year":2015,"lang":"en","type":"letter","venue":"Health Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Library science; Alternative medicine; Human immunodeficiency virus (HIV); Medicine; Variety (cybernetics); Political science; Family medicine; Computer science","score_opus":0.1330706287951086,"score_gpt":0.32944839848747554,"score_spread":0.19637776969236695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2302160661","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000029615136,0.008468695,0.00005210746,0.8732947,0.002768385,0.00056088355,0.0008118275,0.000095611234,0.11391818],"genre_scores_gemma":[0.0028525665,0.0013960995,0.00014889568,0.9803714,0.0064075775,0.00007408606,0.00025377132,0.00012217733,0.008373416],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99637514,0.000121952195,0.001451815,0.0008273551,0.000082098726,0.0011416398],"domain_scores_gemma":[0.99696344,0.00023041543,0.0011747662,0.0011465467,0.00004825244,0.00043660557],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020728502,0.00043239063,0.0010846085,0.00028906603,0.0002771259,0.00016755528,0.0008713528,0.00055086816,0.0006743965],"category_scores_gemma":[0.00017690884,0.00040427473,0.00030132075,0.0002442405,0.00020270988,0.00010497148,0.0001856906,0.002695259,0.006427534],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000067328133,0.000018224755,0.000054327706,0.0001602114,0.00005158342,0.000015086799,0.0005416761,0.000012631874,9.861749e-9,0.0132194655,0.98541075,0.0005092839],"study_design_scores_gemma":[0.0003305718,0.000074664145,0.000055955436,0.000031190953,0.0000063870466,0.000019662706,0.000094745956,0.00086058065,2.0202944e-7,0.023158837,0.97495425,0.00041292552],"about_ca_topic_score_codex":0.0010308392,"about_ca_topic_score_gemma":0.000030432078,"teacher_disagreement_score":0.10707671,"about_ca_system_score_codex":0.00066931744,"about_ca_system_score_gemma":0.0004880431,"threshold_uncertainty_score":0.9998409},"labels":[],"label_agreement":null},{"id":"W2304031919","doi":"10.1056/nejmp1512206","title":"Uber’s Message for Health Care","year":2016,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Mount Sinai Hospital","funders":"","keywords":"Medicine; Health care; Medical care; Public relations; Nursing; Economic growth; Political science; Economics","score_opus":0.06441006312412344,"score_gpt":0.33722741803269984,"score_spread":0.2728173549085764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2304031919","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07806222,0.052742075,0.045172162,0.77641976,0.005086872,0.00049906486,0.00037634358,0.00002645886,0.041615024],"genre_scores_gemma":[0.97994035,0.0029175351,0.00074041536,0.009549244,0.005841034,0.000001932269,0.0000026740313,0.000020714599,0.0009860835],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988345,0.000013376466,0.0007727494,0.00011873601,0.00003086845,0.0002297614],"domain_scores_gemma":[0.9987152,0.00020485531,0.0005702528,0.00011766207,0.00004805991,0.00034393236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009749074,0.00009611075,0.0005009335,0.00017130145,0.000042570067,0.000008635127,0.00017110514,0.00003924474,0.0005015743],"category_scores_gemma":[0.0003070305,0.00006201109,0.00009486852,0.000053903408,0.000048494352,0.00010452065,0.0000135211,0.00009902786,0.00003289184],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044048319,0.00004101186,0.005242319,0.00009050135,0.00016032606,0.000009754462,0.0029311005,0.000009537056,0.00014164203,0.21144015,0.28033254,0.49916065],"study_design_scores_gemma":[0.023124319,0.0006057004,0.00083935395,0.00007757836,0.000007797864,0.00004082281,0.00003620006,0.000017201366,0.000053404256,0.037157033,0.9379585,0.000082085724],"about_ca_topic_score_codex":0.00005128201,"about_ca_topic_score_gemma":0.000023203638,"teacher_disagreement_score":0.9018782,"about_ca_system_score_codex":0.00012283688,"about_ca_system_score_gemma":0.00009618146,"threshold_uncertainty_score":0.5491887},"labels":[],"label_agreement":null},{"id":"W2304820100","doi":"10.9745/ghsp-d-15-00173","title":"Results-Based Financing in Mozambique’s Central Medical Store: A Review After 1 Year","year":2016,"lang":"en","type":"review","venue":"Global Health Science and Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute on Governance","funders":"World Bank Group; United States Agency for International Development","keywords":"Incentive; Accountability; Interdependence; Payment; Business; Teamwork; Finance; Process management; Computer science; Economics; Political science","score_opus":0.13055569122884803,"score_gpt":0.4700580465584649,"score_spread":0.33950235532961687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2304820100","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000018438024,0.9516109,0.000035798508,0.031287294,0.0005467096,0.0006696368,0.0008824568,0.00001576501,0.014949558],"genre_scores_gemma":[0.000061077546,0.9627827,0.0002794754,0.036553778,0.00018595337,0.00007297963,0.000011528124,0.000014486835,0.000038047383],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959221,0.00013346666,0.0017366929,0.0009596143,0.00020221542,0.001045932],"domain_scores_gemma":[0.997025,0.0004839173,0.0011303367,0.00046803895,0.00006575855,0.0008269296],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.011609816,0.000311066,0.001518429,0.0002133548,0.00014333821,0.000110874775,0.0006067111,0.00023200102,0.000189995],"category_scores_gemma":[0.004879398,0.0002709079,0.00014901542,0.0010800041,0.0003581437,0.0006240561,0.00018471433,0.0005254328,0.0006507272],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000048299793,0.00006816877,0.000039205886,0.008257145,0.000009155754,0.00002831699,0.000019086801,1.1220712e-7,5.4251464e-10,0.02167722,0.00898715,0.96086615],"study_design_scores_gemma":[0.00039077614,0.00005651068,0.000116348754,0.018273612,0.000014869236,0.00006369972,0.0000022813113,0.00006258179,6.1671632e-9,0.0006720746,0.98006624,0.00028100878],"about_ca_topic_score_codex":0.00063534646,"about_ca_topic_score_gemma":0.00009658349,"teacher_disagreement_score":0.97107905,"about_ca_system_score_codex":0.0017737836,"about_ca_system_score_gemma":0.0054034954,"threshold_uncertainty_score":0.9999743},"labels":[],"label_agreement":null},{"id":"W2305745693","doi":"","title":"Potential effects of rational prescribing on national health care spending: More than half a billion dollars in annual savings.","year":2016,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bruyère; College of Family Physicians of Canada","funders":"","keywords":"Medical prescription; Medicine; Health care; Drug class; Public health; Drug; Business; Environmental health; Pharmacology; Economics; Economic growth","score_opus":0.04209483166030748,"score_gpt":0.2714040410703456,"score_spread":0.22930920941003813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2305745693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98137677,0.0009306238,0.0003606861,0.008568861,0.0008538768,0.0009694957,0.0008434958,0.000023304025,0.006072861],"genre_scores_gemma":[0.99854517,0.00011596293,0.00006277668,0.00075563387,0.00021396537,0.00017117875,0.000020045893,0.000015697993,0.000099551915],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99877673,0.000022389622,0.00048555728,0.0003001326,0.00006367753,0.00035148862],"domain_scores_gemma":[0.99936455,0.00010489058,0.00026301108,0.00011119044,0.000028670722,0.00012766734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044227648,0.00011604962,0.0002732232,0.00034926482,0.000048268994,0.000023841138,0.00014623623,0.00006723953,0.00003284163],"category_scores_gemma":[0.00024143116,0.00010850503,0.000088214394,0.00013817188,0.000047528098,0.00020854187,0.00004867498,0.000088505556,0.00003262783],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003187607,0.00044412338,0.14817697,0.0003415441,0.00013318934,0.000009654432,0.002156605,0.0010039533,0.000076312615,0.7787205,0.0034573886,0.065161],"study_design_scores_gemma":[0.0023068178,0.00006516631,0.97117114,0.00004905732,0.0000023729556,0.0000026273055,0.000044875207,0.00040974387,0.0008770919,0.014151359,0.010669674,0.00025004652],"about_ca_topic_score_codex":0.00013368663,"about_ca_topic_score_gemma":0.000039834562,"teacher_disagreement_score":0.82299423,"about_ca_system_score_codex":0.00041888625,"about_ca_system_score_gemma":0.00004998643,"threshold_uncertainty_score":0.44247067},"labels":[],"label_agreement":null},{"id":"W2306501823","doi":"10.71781/4465","title":"L’assurance médicaments et son impact sur l’adhésion des patients à leurs médicaments","year":2014,"lang":"fr","type":"dissertation","venue":"Open MIND","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"LEO Pharma; Université de Montréal; Purdue Pharma; AstraZeneca Canada; Pfizer Canada; Sanofi; Purdue University; AstraZeneca; Amgen Canada; Pfizer; Amgen","keywords":"Medicine; Pharmacology; Gynecology","score_opus":0.1289340829678552,"score_gpt":0.3741011480051643,"score_spread":0.24516706503730912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2306501823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89524984,0.0020297766,0.000055649747,0.00070018845,0.0022971372,0.001463953,0.002851156,0.0000039401248,0.09534834],"genre_scores_gemma":[0.97323406,0.004634699,0.0012691901,0.00107793,0.00023507138,0.00013345582,0.0031918155,0.00016921524,0.01605457],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99502295,0.00016266266,0.0019037669,0.0014879407,0.00014286874,0.0012798355],"domain_scores_gemma":[0.9961566,0.0002588546,0.0019721289,0.000766114,0.00015593838,0.0006903777],"candidate_categories":["metaepi_narrow","scholarly_communication","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0014131471,0.00086886156,0.0016072314,0.00042997775,0.0004321142,0.0011599554,0.0016473734,0.0006943396,0.0137442],"category_scores_gemma":[0.00045644224,0.0010563065,0.0005500786,0.00034612478,0.00020976155,0.0012441004,0.00040482805,0.00076894,0.0106201805],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007608178,0.0034996578,0.56561005,0.000522745,0.0010086526,0.000011509269,0.0033754273,0.0006539301,0.00007739427,0.0021878732,0.015768891,0.40652305],"study_design_scores_gemma":[0.005485008,0.00061143975,0.40993828,0.00094160484,0.0001138621,0.000002994898,0.00010549009,0.005532333,0.000656154,0.0027546037,0.57228804,0.0015702081],"about_ca_topic_score_codex":0.0035310625,"about_ca_topic_score_gemma":0.0012956552,"teacher_disagreement_score":0.55651915,"about_ca_system_score_codex":0.0009843493,"about_ca_system_score_gemma":0.000275304,"threshold_uncertainty_score":0.9998769},"labels":[],"label_agreement":null},{"id":"W2306625559","doi":"10.14288/1.0102579","title":"The impact of international trade agreements on health : patent system harmonization and medicines in Mexico","year":2012,"lang":"en","type":"article","venue":"cIRcle (University of British Columbia)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"International trade; Harmonization; Business; International economics; Economics","score_opus":0.04337602820954703,"score_gpt":0.24062634641321407,"score_spread":0.19725031820366704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2306625559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99501246,0.00093074853,0.000068322704,0.0013485168,0.00016471097,0.00012776378,0.0002962945,0.000004948101,0.0020462123],"genre_scores_gemma":[0.99826336,0.0015768547,0.000016133345,0.00008340385,0.00002386635,2.9775956e-7,0.000010012809,0.0000042608067,0.000021808959],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995058,0.00001542623,0.00019458348,0.00010937427,0.000027485721,0.0001472921],"domain_scores_gemma":[0.99957675,0.000030915202,0.00022068944,0.00007936876,0.00000813918,0.00008411503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036505863,0.000025014535,0.00018066312,0.000051364146,0.000067433655,0.00002176794,0.00012169668,0.0000301408,0.000024482682],"category_scores_gemma":[0.000015651662,0.000060409544,0.000049735525,0.00008181308,0.00006930125,0.00013693338,0.000035556735,0.000054190055,0.0000047617655],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017605409,0.00015202921,0.8885853,0.000053758187,0.00007834362,0.0000017392243,0.0005760954,0.000052755327,0.000005598081,0.0010373582,0.0026308906,0.10680852],"study_design_scores_gemma":[0.0006814056,0.000054203552,0.99476147,0.000053435215,0.0000018573987,0.000003945615,0.00032856636,0.0030827967,3.4466956e-7,0.00027258805,0.0007097746,0.00004958685],"about_ca_topic_score_codex":0.038815312,"about_ca_topic_score_gemma":0.008572454,"teacher_disagreement_score":0.10675894,"about_ca_system_score_codex":0.00018512589,"about_ca_system_score_gemma":0.00001701696,"threshold_uncertainty_score":0.9675853},"labels":[],"label_agreement":null},{"id":"W2308781355","doi":"10.1684/sss.2016.0102","title":"Le « spirituel », le biomédical et le politique","year":2016,"lang":"fr","type":"article","venue":"Sciences sociales et santé","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Humanities; Political science; Art","score_opus":0.14438223242937698,"score_gpt":0.3764713710166625,"score_spread":0.23208913858728553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2308781355","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.058192912,0.010414989,0.0022159023,0.51011866,0.00191922,0.00019086288,0.0011016974,0.000047802605,0.41579792],"genre_scores_gemma":[0.9708444,0.008705847,0.00079618004,0.014224736,0.00068334636,0.0000151380455,0.000006074553,0.000033450226,0.0046908436],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99712896,0.00020952553,0.0007775066,0.00077934895,0.00007995838,0.0010247027],"domain_scores_gemma":[0.99846786,0.00051601086,0.0003939076,0.00026974984,0.00003769053,0.00031476555],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003212403,0.00027235324,0.000565842,0.00026508715,0.00064440613,0.0003262468,0.000752152,0.000313357,0.0005809776],"category_scores_gemma":[0.00044782498,0.0002895164,0.0003135584,0.00044234635,0.004506275,0.0010335429,0.00028530898,0.0002591432,0.0012780303],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000055151954,0.00024642138,0.003050035,0.000025081086,0.000033829027,0.0000035359,0.00032080154,0.000008662143,0.00015799631,0.9798251,0.009129661,0.0071934075],"study_design_scores_gemma":[0.0007774519,0.00006133857,0.004643707,0.000049483115,0.0000039717947,0.0000072600465,0.0002154454,0.00025726043,0.00036081483,0.54521686,0.44803175,0.0003746726],"about_ca_topic_score_codex":0.007151708,"about_ca_topic_score_gemma":0.0016239886,"teacher_disagreement_score":0.9126515,"about_ca_system_score_codex":0.00027899176,"about_ca_system_score_gemma":0.003217218,"threshold_uncertainty_score":0.9999557},"labels":[],"label_agreement":null},{"id":"W2308882864","doi":"","title":"Towards an International Treaty on Antimicrobial Resistance","year":2016,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; York University","funders":"","keywords":"Treaty; Resistance (ecology); Antibiotic resistance; Political science; International trade; Law and economics; Business; Law; Economics; Microbiology; Biology; Antibiotics","score_opus":0.030230274506121337,"score_gpt":0.28244317801179725,"score_spread":0.25221290350567593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2308882864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7308653,0.00087835983,0.0064677293,0.048938524,0.0018834759,0.00015554746,0.00035409574,0.00006212942,0.21039481],"genre_scores_gemma":[0.98490286,0.0072552133,0.00008341645,0.0018266237,0.00085121725,0.0000031312507,0.000003909855,0.00002616066,0.005047481],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9979702,0.000018828106,0.00043087677,0.00029441263,0.000034660654,0.0012509812],"domain_scores_gemma":[0.99936867,0.00002506991,0.00023331972,0.00020864706,0.000025908294,0.00013838297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000994237,0.0001429544,0.00021988469,0.00018495639,0.00011436469,0.000087169494,0.00045989995,0.000074405114,0.00043299605],"category_scores_gemma":[0.0000711634,0.00011974084,0.00013359323,0.00006702014,0.000050345345,0.00042757904,0.000029384868,0.0005270472,0.0007257476],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012465168,0.00008908058,0.0022867017,0.0000012496762,0.000092433875,0.0000019983715,0.000031010397,0.0000039388187,0.0001532345,0.984437,0.0009581109,0.0118206255],"study_design_scores_gemma":[0.0015208842,0.00016755845,0.0026504179,0.000016185624,0.000004479752,0.000053207823,0.000014504241,0.000053983655,0.00038878064,0.7657333,0.22914305,0.00025362335],"about_ca_topic_score_codex":0.000024648547,"about_ca_topic_score_gemma":0.00021363048,"teacher_disagreement_score":0.25403753,"about_ca_system_score_codex":0.0011908265,"about_ca_system_score_gemma":0.00030018922,"threshold_uncertainty_score":0.9328259},"labels":[],"label_agreement":null},{"id":"W2309323648","doi":"","title":"Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.","year":2007,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Rosuvastatin; Medicine; Pravastatin; Atorvastatin; Dyslipidemia; Statin; Rosuvastatin Calcium; Cost effectiveness; Simvastatin; Willingness to pay; Pharmacology; Internal medicine; Cholesterol; Risk analysis (engineering)","score_opus":0.08803016733899666,"score_gpt":0.2806454956538217,"score_spread":0.19261532831482503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2309323648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97523785,0.0013496171,0.00092211424,0.00036402643,0.00012260828,0.0007750528,0.0015940885,0.000013363846,0.019621307],"genre_scores_gemma":[0.99849695,0.00020345647,0.00010510274,0.00081931707,0.000029512597,0.00020064377,0.000045906534,0.000017000573,0.000082081104],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99857223,0.00002664881,0.00053823437,0.000298899,0.000024726794,0.0005392712],"domain_scores_gemma":[0.99881,0.00023797876,0.00022787595,0.00021341308,0.000029300425,0.0004814258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014189852,0.00013396045,0.0005381141,0.0007674581,0.000065710134,0.000051127743,0.00014762723,0.000073933836,0.00010611719],"category_scores_gemma":[0.0001289893,0.00016076281,0.000107626525,0.0005621084,0.000093662595,0.00012483411,0.000036595877,0.00010748733,0.000011862956],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011657597,0.00010858263,0.7924339,0.00008919708,0.0017810552,0.000010168219,0.0006049171,0.0005563348,0.000010754637,0.07097379,0.00048549555,0.13282923],"study_design_scores_gemma":[0.00067178503,0.000013937928,0.9437257,0.0000015155455,0.000085006,9.2825525e-7,0.000017906586,0.0036494702,0.000084569474,0.0026958808,0.0488678,0.00018548747],"about_ca_topic_score_codex":0.044006396,"about_ca_topic_score_gemma":0.050865646,"teacher_disagreement_score":0.15129182,"about_ca_system_score_codex":0.00018822988,"about_ca_system_score_gemma":0.00003417604,"threshold_uncertainty_score":0.9664536},"labels":[],"label_agreement":null},{"id":"W2311899267","doi":"","title":"New drug approval times and safety warnings in the United States and Canada, 1992-2011.","year":2013,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto East General Hospital","funders":"","keywords":"Medicine; Drug approval; Drug; Pharmacology","score_opus":0.02232840750964075,"score_gpt":0.19828945190299652,"score_spread":0.17596104439335578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2311899267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95511746,0.0010579976,0.000013712079,0.032419357,0.000076057215,0.0004998749,0.000079504076,0.000009518412,0.010726541],"genre_scores_gemma":[0.9908983,0.0010486887,0.000045468132,0.0063623823,0.00007488601,0.00015461716,0.000025422902,0.000012239186,0.0013779799],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99913585,0.000016577203,0.00029182681,0.0002095264,0.000018150655,0.0003280727],"domain_scores_gemma":[0.9994721,0.00013369681,0.0000935064,0.00012220527,0.000005799896,0.00017272515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041644153,0.00010403234,0.00019051382,0.000107446955,0.00006111954,0.000108698456,0.00014244394,0.000033383472,0.00017798608],"category_scores_gemma":[0.00004113836,0.00009173266,0.000016999515,0.00007952125,0.00004481851,0.00013345227,0.000056545774,0.00014842727,0.000035556888],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056078294,0.00006739586,0.30818516,0.00008117421,0.00013162642,0.000006581523,0.005944875,0.00013044321,7.604692e-7,0.1438024,0.417897,0.12369653],"study_design_scores_gemma":[0.00045739062,0.000003285485,0.5105538,0.0000010587561,0.000002507899,0.000002880423,0.00009610044,0.0038918145,0.0000036205945,0.017454406,0.46739513,0.00013804605],"about_ca_topic_score_codex":0.8555452,"about_ca_topic_score_gemma":0.16081318,"teacher_disagreement_score":0.69473207,"about_ca_system_score_codex":0.00006253812,"about_ca_system_score_gemma":0.000027687696,"threshold_uncertainty_score":0.8544998},"labels":[],"label_agreement":null},{"id":"W2312616658","doi":"10.1177/171516350714000212","title":"What You Should Know about NAPRA's National Drug Schedules and Natural Health Products","year":2007,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Drug; Natural (archaeology); Medicine; Pharmacology; Geography","score_opus":0.06939565309677763,"score_gpt":0.3102690773532508,"score_spread":0.24087342425647318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2312616658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8474341,0.116111755,0.0001144355,0.014312861,0.014351713,0.00081655564,0.0018942164,0.000056974368,0.0049073743],"genre_scores_gemma":[0.9294136,0.044929884,0.000330882,0.022128886,0.0019290675,0.000008215941,0.000048051723,0.00006488047,0.0011465204],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963897,0.000055993503,0.0012123771,0.00066494884,0.00016937005,0.001507624],"domain_scores_gemma":[0.9958918,0.000118692435,0.0005970927,0.00021456204,0.00035564174,0.0028222245],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002853517,0.00042313655,0.00059743813,0.0007492884,0.0009995607,0.0007172396,0.0005754656,0.00006448927,0.00045345307],"category_scores_gemma":[0.00032164247,0.0005155396,0.0001325273,0.0005705666,0.0002670408,0.0012842665,0.000070387054,0.0010405021,0.00005568682],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050757686,0.00039248107,0.02912383,0.0017298259,0.001643699,0.016836919,0.008472174,0.001520451,0.00067748135,0.15470761,0.28562978,0.49875817],"study_design_scores_gemma":[0.0022387975,0.000028750323,0.0006058023,0.00005365525,0.00002349166,0.05628178,0.000035022087,0.0057635927,0.00073540246,0.0046699434,0.92849314,0.0010706105],"about_ca_topic_score_codex":0.019459633,"about_ca_topic_score_gemma":0.10098283,"teacher_disagreement_score":0.6428634,"about_ca_system_score_codex":0.0036891652,"about_ca_system_score_gemma":0.0030260864,"threshold_uncertainty_score":0.99972963},"labels":[],"label_agreement":null},{"id":"W2314281061","doi":"10.3821/1913-701x-143.5.226","title":"The Effect of US Pharmaceutical Drug Importation on the Canadian Pharmaceutical Supply","year":2010,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Drug; Business; Supply chain; Pharmaceutical industry; Distribution (mathematics); Brand names; Supply and demand; Medicine; Marketing; Pharmacology; Economics","score_opus":0.03291657335430672,"score_gpt":0.2767341657348822,"score_spread":0.24381759238057546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2314281061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96556,0.0012368775,0.0000055032897,0.006548711,0.006269221,0.0008253853,0.001785375,0.000021268183,0.01774766],"genre_scores_gemma":[0.9861825,0.0026184353,0.000019287092,0.009320367,0.0012480313,0.0000592063,0.000028376475,0.00008847428,0.00043531222],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956274,0.00024075918,0.0014216774,0.0005818893,0.00023932682,0.001888931],"domain_scores_gemma":[0.9935886,0.0010939465,0.0006027431,0.0005637223,0.00023217704,0.003918764],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0038751494,0.00056876714,0.0006583582,0.00051960826,0.0026950408,0.0005720408,0.0016526186,0.00015079285,0.0028766913],"category_scores_gemma":[0.00084843754,0.000452272,0.000383572,0.00065821066,0.0008324017,0.0003170312,0.00006114882,0.0026674576,0.00020748352],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015482868,0.00023740661,0.15922901,0.0005999459,0.002646186,0.017954558,0.002756919,0.0026067854,0.004803915,0.24170218,0.4114305,0.15448429],"study_design_scores_gemma":[0.0026454919,0.000098221564,0.00046042018,0.000013691748,0.00012234996,0.022584818,0.0000059068057,0.017952204,0.011700922,0.0019383342,0.9416467,0.000830969],"about_ca_topic_score_codex":0.29835042,"about_ca_topic_score_gemma":0.8494758,"teacher_disagreement_score":0.55112535,"about_ca_system_score_codex":0.0020614832,"about_ca_system_score_gemma":0.0029826113,"threshold_uncertainty_score":0.9997929},"labels":[],"label_agreement":null},{"id":"W2315382297","doi":"10.1177/1715163513494594","title":"Pace of growth in drug expenditures slows to lowest level in 16 years","year":2013,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pace; Medical prescription; Demographic economics; Prescription drug; Health care; Business; Economics; Public economics; Medicine; Economic growth; Geography; Pharmacology","score_opus":0.058945350216289744,"score_gpt":0.26234717651228245,"score_spread":0.2034018262959927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2315382297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879596,0.0009997954,0.000026398657,0.0008127493,0.0012401455,0.00042340174,0.00099673,0.0000063916996,0.0075347465],"genre_scores_gemma":[0.9916575,0.0019161173,0.00013355612,0.0053800843,0.00031256684,0.00003734248,0.000012161204,0.000049464,0.00050121965],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971999,0.000055573102,0.0011645062,0.00042980528,0.00008296239,0.0010672403],"domain_scores_gemma":[0.9975002,0.00009057277,0.00032486545,0.00021124707,0.000090958856,0.0017821523],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007141062,0.00029558985,0.00061663287,0.0012052229,0.00011411645,0.00014295333,0.0007396773,0.00006910851,0.0025396224],"category_scores_gemma":[0.00016187331,0.00038629436,0.00012852346,0.0005966459,0.000100095334,0.00047296632,0.000063743646,0.000616599,0.00017182836],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031649426,0.0006642105,0.32947502,0.00086820504,0.00052913965,0.031615794,0.015906744,0.012798719,0.0026853022,0.030287514,0.5021394,0.072713464],"study_design_scores_gemma":[0.02274461,0.00024939555,0.052729197,0.0003144766,0.00008837483,0.072084434,0.0002950748,0.021394284,0.013264721,0.043954592,0.7654768,0.007404038],"about_ca_topic_score_codex":0.39285427,"about_ca_topic_score_gemma":0.44693166,"teacher_disagreement_score":0.2767458,"about_ca_system_score_codex":0.0030010324,"about_ca_system_score_gemma":0.0009435897,"threshold_uncertainty_score":0.9998589},"labels":[],"label_agreement":null},{"id":"W2316837318","doi":"10.1097/00005650-200301000-00015","title":"Lowering Generic Drug Prices","year":2003,"lang":"en","type":"article","venue":"Medical Care","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre for Health Evaluation and Outcome Sciences; Providence Health Care","funders":"","keywords":"Formulary; Procurement; Generic drug; Drug prices; Business; Government (linguistics); Economics; Demographic economics; Agricultural economics; Monetary economics; Drug; Medicine; Marketing; Pharmacology","score_opus":0.04207700297570712,"score_gpt":0.27704116711700943,"score_spread":0.2349641641413023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2316837318","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47751665,0.016025985,0.0009616723,0.0027085135,0.0013823019,0.00013572734,0.00006337105,0.00006967951,0.50113606],"genre_scores_gemma":[0.9942097,0.00046184493,0.00021216122,0.004447134,0.00021382111,0.000014507246,0.000007422932,0.000019531664,0.00041385912],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.998991,0.0000083936475,0.00036154687,0.0002776095,0.000045854675,0.00031559216],"domain_scores_gemma":[0.9993362,0.00004095271,0.00008336174,0.00019720496,0.00001357492,0.0003287453],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00032845396,0.00011099842,0.00024620988,0.00007921098,0.0000711803,0.00003963658,0.0002266229,0.00008833235,0.0052540093],"category_scores_gemma":[0.00026005224,0.000121180616,0.00009432539,0.00013037852,0.000053447715,0.00007573091,0.000047282756,0.00019475346,0.0013714047],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009481229,0.00011729462,0.05789602,0.00019400715,0.00007887317,0.000055135417,0.0029654945,0.000055396842,0.000013063432,0.9045552,0.019619223,0.014440791],"study_design_scores_gemma":[0.0004092529,0.000013027631,0.0015229643,0.000007768899,0.0000027434332,0.0000063421585,0.00010402982,0.00042469904,0.00028153637,0.00874975,0.9882655,0.00021237743],"about_ca_topic_score_codex":0.00004894251,"about_ca_topic_score_gemma":0.000025730287,"teacher_disagreement_score":0.9686463,"about_ca_system_score_codex":0.0000853383,"about_ca_system_score_gemma":0.00004743535,"threshold_uncertainty_score":0.99940616},"labels":[],"label_agreement":null},{"id":"W2316918956","doi":"10.1016/j.cjca.2014.07.593","title":"A PHARMACODYNAMIC COMPARISON OF PERSONALIZED STRATEGY TO ANTIPLATLET THERAPY AGAINST TICAGRELOR IN ACHIEVING A THERAPEUTIC WINDOW","year":2014,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Ticagrelor; Prasugrel; Medicine; Clopidogrel; P2Y12; CYP2C19; Internal medicine; Conventional PCI; Percutaneous coronary intervention; Aspirin; Acute coronary syndrome; Pharmacodynamics; Cardiology; Myocardial infarction; Pharmacokinetics","score_opus":0.07940936019054527,"score_gpt":0.3170155043213086,"score_spread":0.2376061441307633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2316918956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9760032,0.0031491246,0.0027435855,0.0017002943,0.00043410462,0.00014482143,0.000078501755,0.0000024510368,0.015743913],"genre_scores_gemma":[0.99758047,0.00032166913,0.000062717205,0.0016851124,0.0003049262,0.0000028172876,0.000002881986,0.00001880908,0.000020586025],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984478,0.000094339244,0.00086212944,0.00017331084,0.00002281709,0.00039964082],"domain_scores_gemma":[0.9988961,0.00012272545,0.00037572504,0.00014484335,0.00004579174,0.00041479792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000897165,0.00014068856,0.00092788396,0.0006380082,0.00004206262,0.00002604075,0.00032673983,0.00010728214,0.000075581585],"category_scores_gemma":[0.000086988584,0.00015028084,0.00021063446,0.00018843728,0.000121340294,0.00008017307,0.000011071206,0.00031448793,0.000039021867],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038779728,0.000041697127,0.6908149,0.000049173716,0.0007845319,0.000038793547,0.0024233158,0.081254296,0.004417643,0.11501019,0.001980947,0.102796696],"study_design_scores_gemma":[0.006099584,0.001062561,0.20869309,0.0000629034,0.000030527193,0.000072263225,0.00024871383,0.019201614,0.0002825359,0.01017856,0.7534292,0.00063850434],"about_ca_topic_score_codex":0.0003870451,"about_ca_topic_score_gemma":0.00045567364,"teacher_disagreement_score":0.7514482,"about_ca_system_score_codex":0.00015008927,"about_ca_system_score_gemma":0.00021837489,"threshold_uncertainty_score":0.6128275},"labels":[],"label_agreement":null},{"id":"W2317727536","doi":"10.1016/j.jval.2014.08.404","title":"Assesing the Impact of Patent Loss on Overall Revenues and Stocks Price of Pharmaceutical Companies","year":2014,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Revenue; Total revenue; Business; Quarter (Canadian coin); Stock price; Stock (firearms); Agricultural economics; Commerce; Finance; Economics; Engineering","score_opus":0.2048130438536943,"score_gpt":0.3792123093480543,"score_spread":0.17439926549435997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2317727536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939631,0.0015818621,0.00009323097,0.001938517,0.00009201135,0.00019333904,0.00011220255,0.0000058568744,0.0020198564],"genre_scores_gemma":[0.99763,0.0015551677,0.000081386424,0.00065432244,0.00005507687,0.0000033735143,0.0000017329035,0.000010416023,0.000008526566],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9988449,0.00008666387,0.0006247261,0.00017288789,0.000025628326,0.00024517666],"domain_scores_gemma":[0.9990078,0.00034299697,0.00036092097,0.00017877817,0.00001134081,0.0000981343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001327657,0.000096467535,0.0004025583,0.00011402926,0.000040448358,0.000014153758,0.00012682617,0.00003995439,0.000028440316],"category_scores_gemma":[0.00011503014,0.00008091013,0.00007601821,0.000091261805,0.00009187094,0.000051028066,0.00004158809,0.00018067757,0.000008928402],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018944491,0.00045595563,0.29614702,0.00056586857,0.000094206225,8.6042724e-7,0.0020438826,0.04244609,0.000050350518,0.6515728,0.0008908175,0.005542689],"study_design_scores_gemma":[0.0017698825,0.0008026655,0.47992992,0.00021342818,0.000004996608,0.000006595465,0.00002181826,0.37796497,0.00013544579,0.12647489,0.0124172,0.00025818413],"about_ca_topic_score_codex":0.0034384488,"about_ca_topic_score_gemma":0.0000048257743,"teacher_disagreement_score":0.52509797,"about_ca_system_score_codex":0.00012191559,"about_ca_system_score_gemma":0.0000447731,"threshold_uncertainty_score":0.51979285},"labels":[],"label_agreement":null},{"id":"W2318896726","doi":"10.3821/1913-701x-144.5.205","title":"Tackling Drug Shortages Remains a Daunting Task but CPhA Reports Some Progress","year":2011,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Economic shortage; Task (project management); Drug; Political science; Environmental planning; Environmental science; Medicine; Economics; Pharmacology; Management; Philosophy","score_opus":0.06686427663010097,"score_gpt":0.2589190675039927,"score_spread":0.1920547908738917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2318896726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9695292,0.0080474205,0.00005664717,0.0003623445,0.0049883598,0.00049571187,0.0011629435,0.00006337862,0.01529397],"genre_scores_gemma":[0.98538953,0.0053545437,0.00044926236,0.005825899,0.0018742041,0.000036558624,0.00003351862,0.00012709598,0.0009093741],"study_design_codex":"case_report","study_design_gemma":"not_applicable","domain_scores_codex":[0.99516666,0.0000752966,0.0018553508,0.00086879835,0.00014094982,0.0018929291],"domain_scores_gemma":[0.9948912,0.00006852917,0.0010885425,0.00050555525,0.00021856546,0.0032275775],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017274811,0.00056904607,0.00082421326,0.0007766804,0.0010946633,0.00041684383,0.00089004164,0.000114341165,0.0020515563],"category_scores_gemma":[0.00023691914,0.00071100285,0.00033063974,0.0005253327,0.0003193291,0.0010863504,0.0001144784,0.0010632399,0.00009942438],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003367046,0.0006608254,0.2774492,0.0013446858,0.0027871048,0.423039,0.019030819,0.0013022734,0.0011375676,0.03856688,0.16734101,0.06700396],"study_design_scores_gemma":[0.003437518,0.000089835135,0.0008274391,0.00009367416,0.00023971444,0.41583106,0.00007541431,0.014816752,0.0047406713,0.020819787,0.5353817,0.0036464666],"about_ca_topic_score_codex":0.03708756,"about_ca_topic_score_gemma":0.039266575,"teacher_disagreement_score":0.36804065,"about_ca_system_score_codex":0.002313269,"about_ca_system_score_gemma":0.0017816409,"threshold_uncertainty_score":0.99953413},"labels":[],"label_agreement":null},{"id":"W2319489330","doi":"10.1177/171516350613900310","title":"Book Review: Two Views of the Pharmaceutical Industry","year":2006,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Pharmaceutical industry; Engineering ethics; Epistemology; Engineering; Philosophy; Medicine; Pharmacology","score_opus":0.065601345845865,"score_gpt":0.299229866300763,"score_spread":0.233628520454898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2319489330","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11974545,0.75700825,0.000109698,0.012886888,0.009360353,0.0018298579,0.005376995,0.00005340544,0.093629114],"genre_scores_gemma":[0.774807,0.08311921,0.000050086146,0.13549401,0.0016812381,0.000029197146,0.00002080792,0.00008560303,0.004712847],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996415,0.00012227561,0.001692365,0.0004688779,0.00014665957,0.0011547959],"domain_scores_gemma":[0.9969161,0.00008893719,0.0008551852,0.00045398067,0.00019358394,0.0014921976],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011221059,0.0004142829,0.0007832191,0.00028994476,0.0005784283,0.00011546787,0.0012333199,0.00012669871,0.008654646],"category_scores_gemma":[0.00016392107,0.00040944887,0.00041182933,0.00071692385,0.00036897755,0.00038232293,0.00010394114,0.0015771837,0.000093024544],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001918621,0.00006181678,0.0034036292,0.0004349931,0.0001263223,0.0013724797,0.00006972381,0.0005852154,0.00019133497,0.0037498027,0.9863668,0.003618685],"study_design_scores_gemma":[0.0013450924,0.000010228063,0.00006331471,0.000072290655,0.00007489813,0.031641454,6.7525565e-7,0.0020588362,0.0013399104,0.0010367732,0.9618856,0.00047095577],"about_ca_topic_score_codex":0.021912627,"about_ca_topic_score_gemma":0.016516745,"teacher_disagreement_score":0.67388904,"about_ca_system_score_codex":0.00181444,"about_ca_system_score_gemma":0.0017107829,"threshold_uncertainty_score":0.9998357},"labels":[],"label_agreement":null},{"id":"W2320624260","doi":"10.2174/1389557043403765","title":"Predicting Synthetic Accessibility: Application in Drug Discovery and Development","year":2004,"lang":"en","type":"review","venue":"Mini-Reviews in Medicinal Chemistry","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Drug discovery; Prioritization; Computer science; Process (computing); Retrosynthetic analysis; Synthetic data; Data science; Risk analysis (engineering); Artificial intelligence; Management science; Engineering; Bioinformatics; Medicine; Biology; Chemistry","score_opus":0.08561049642649078,"score_gpt":0.3521774650157009,"score_spread":0.26656696858921014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2320624260","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013516132,0.99273217,0.00005504853,0.000114660994,0.000118482836,0.000851209,0.00006495386,0.000012232936,0.004699612],"genre_scores_gemma":[0.0015558525,0.99695766,0.00022521713,0.00016194177,0.00020007108,0.0005689768,0.00008414573,0.000041948486,0.00020419886],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958282,0.000040854135,0.002665917,0.0009704039,0.000050375795,0.0004442109],"domain_scores_gemma":[0.9981762,0.00017416484,0.00097636814,0.0004969864,0.000005510272,0.00017075725],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023195131,0.00047885714,0.0025702084,0.00018994292,0.000046214835,0.00006488335,0.0005046326,0.0002965166,0.00009768522],"category_scores_gemma":[0.00036792865,0.00046875828,0.00016978808,0.00030877118,0.00012782485,0.00016468784,0.00019670717,0.0007975188,0.00012418356],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000040047144,0.00012444345,0.0019887234,0.05229574,0.000030524057,0.000009678288,0.00030482595,9.5233e-7,5.8526086e-7,0.00033237433,0.000050438128,0.9448577],"study_design_scores_gemma":[0.00034853775,0.0000039585348,0.00010219418,0.016245376,0.000034012537,0.000020717944,0.000021007312,0.00004195135,0.00000711532,0.00094628416,0.9817927,0.00043613912],"about_ca_topic_score_codex":0.000115230396,"about_ca_topic_score_gemma":0.00005203148,"teacher_disagreement_score":0.98174226,"about_ca_system_score_codex":0.0008801357,"about_ca_system_score_gemma":0.00026928494,"threshold_uncertainty_score":0.9997764},"labels":[],"label_agreement":null},{"id":"W2322087671","doi":"10.1177/1741134314545250","title":"Selection of the comparator product in the World Health Organisation Prequalification of Medicines Programme","year":2013,"lang":"en","type":"article","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Bioequivalence; Medicine; Product (mathematics); Innovator; Quality (philosophy); Pharmacology; Business","score_opus":0.14693579883615218,"score_gpt":0.33541004693518345,"score_spread":0.18847424809903127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2322087671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.64506334,0.02874327,0.006817991,0.3087183,0.007785512,0.002676696,0.000032572676,0.000010101957,0.00015219684],"genre_scores_gemma":[0.9821608,0.0043799323,0.00040718183,0.007612369,0.005160033,0.000069413305,0.0000065108607,0.000041920983,0.0001618052],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9958432,0.00028826686,0.0028391308,0.00021752562,0.0003606079,0.00045129526],"domain_scores_gemma":[0.9927701,0.00087246345,0.004918482,0.00048498737,0.0008007627,0.00015321582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00662223,0.00028979155,0.00100662,0.0004209845,0.00036263792,0.000057366167,0.0012817952,0.00006441866,0.00021940513],"category_scores_gemma":[0.0014108453,0.00012347208,0.0002503505,0.00190149,0.0004301162,0.00023738775,0.00005036067,0.0005384716,0.000004607135],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011627771,0.0017907766,0.13380389,0.0026945425,0.0020532983,0.0000057092307,0.029715544,0.015743747,0.028945906,0.012476919,0.693878,0.07772888],"study_design_scores_gemma":[0.010801719,0.0020188945,0.5178453,0.0014371948,0.00087878515,0.0029337008,0.008390268,0.03952822,0.0041046333,0.028452141,0.3826758,0.00093335763],"about_ca_topic_score_codex":0.00025962453,"about_ca_topic_score_gemma":0.00013767357,"teacher_disagreement_score":0.38404143,"about_ca_system_score_codex":0.00019202827,"about_ca_system_score_gemma":0.00044317503,"threshold_uncertainty_score":0.5035045},"labels":[],"label_agreement":null},{"id":"W2325832068","doi":"10.1016/j.jval.2012.03.110","title":"PHP34 Eliciting Preferences for Reimbursed Drugs Selection Criteria in Cote d'Ivoire","year":2012,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McMaster University; Programs for Assessment of Technology in Health Research Institute","funders":"","keywords":"Formulary; Listing (finance); Transparency (behavior); Health care; Medicine; Population; Actuarial science; Family medicine; Business; Environmental health; Computer science; Economics; Finance; Economic growth","score_opus":0.18082155817440582,"score_gpt":0.37261353063410063,"score_spread":0.19179197245969482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2325832068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98536265,0.002292738,0.00029598008,0.0034725028,0.0007446732,0.0005277815,0.00011678712,0.000026128546,0.007160767],"genre_scores_gemma":[0.9959072,0.0004995282,0.0010235622,0.0020528685,0.00034362776,0.000073744486,0.000013280019,0.000020475305,0.00006574896],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99822766,0.000051872372,0.00081162155,0.0002595144,0.000017893371,0.00063145364],"domain_scores_gemma":[0.999274,0.00017693492,0.00026950694,0.00011186101,0.000010570983,0.00015713455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019113388,0.00011955042,0.00036689354,0.00029237117,0.000078026205,0.000036724196,0.00011818043,0.00008911586,0.00009995634],"category_scores_gemma":[0.00015502203,0.00014967569,0.000054008127,0.00023628681,0.000021256608,0.00025016037,0.00002302687,0.00019106093,0.00007316879],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011725391,0.00046617413,0.4247071,0.0008184809,0.000029823022,3.5750753e-7,0.008324827,0.0033658913,0.00007176814,0.5361667,0.0026528502,0.023278745],"study_design_scores_gemma":[0.0038030907,0.00031407876,0.11530305,0.00027503917,0.000004409567,0.0000049845935,0.0004286136,0.38626605,0.00041085156,0.28418392,0.2081137,0.0008922116],"about_ca_topic_score_codex":0.004404387,"about_ca_topic_score_gemma":0.00008654718,"teacher_disagreement_score":0.38290018,"about_ca_system_score_codex":0.00038373854,"about_ca_system_score_gemma":0.00006846864,"threshold_uncertainty_score":0.6658145},"labels":[],"label_agreement":null},{"id":"W2327664688","doi":"10.1093/jlb/lsv060","title":"Orphan drug incentives in the pharmacogenomic context: policy responses in the USA and Canada","year":2016,"lang":"en","type":"article","venue":"Journal of Law and the Biosciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"","keywords":"Pharmacogenomics; Incentive; Context (archaeology); Orphan drug; Drug response; Medicine; Drug; Political science; Biology; Pharmacology; Economics; Bioinformatics","score_opus":0.04346633919352118,"score_gpt":0.2945346442872339,"score_spread":0.25106830509371275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2327664688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92576134,0.0023879062,0.0000018831882,0.067801066,0.00015019023,0.000083749685,0.00003720639,3.9218e-7,0.0037762688],"genre_scores_gemma":[0.9839552,0.003047619,0.0000035433975,0.012798149,0.00012508823,0.0000021951062,3.569696e-8,0.0000021149235,0.0000660559],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991208,0.00014061178,0.00040295906,0.00010579798,0.000046079687,0.00018375403],"domain_scores_gemma":[0.9987746,0.0008213537,0.00026402716,0.00008308757,0.000009707704,0.000047232996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031620336,0.00007453553,0.00019451285,0.00010412445,0.00014829413,0.00011612762,0.00047885976,0.000015451304,0.00001700116],"category_scores_gemma":[0.00013881728,0.000030011266,0.000036294015,0.00012424638,0.0006582391,0.00021189761,0.000041401687,0.00011437002,0.000002265442],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015387956,0.000028688075,0.055812497,0.0000037204993,0.000012501076,0.000008932054,0.0027012557,8.29149e-7,0.00011199332,0.9392659,0.00034388865,0.0015558903],"study_design_scores_gemma":[0.005551124,0.00011626157,0.23873608,0.000057740577,0.0000135871305,0.00020476434,0.0022857562,0.00018613826,0.0004435888,0.1785229,0.57359415,0.0002879236],"about_ca_topic_score_codex":0.17834833,"about_ca_topic_score_gemma":0.25033918,"teacher_disagreement_score":0.760743,"about_ca_system_score_codex":0.00005173188,"about_ca_system_score_gemma":0.00014719013,"threshold_uncertainty_score":0.8271231},"labels":[],"label_agreement":null},{"id":"W2327826446","doi":"10.1097/00126450-200307000-00013","title":"Consumers Devise Drug Cost-Cutting Measures","year":2003,"lang":"en","type":"article","venue":"The Health Care Manager","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Prescription drug; Pill; Per capita; Health care; Business; Prescription costs; Drug; Drug prices; Health care cost; Health insurance; Medicine; Environmental health; Actuarial science; Public economics; Pharmacology; Economic growth; Economics","score_opus":0.07284092232313097,"score_gpt":0.3160500224500772,"score_spread":0.24320910012694621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2327826446","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07989426,0.07727531,0.0014881302,0.068074234,0.0028083841,0.00221726,0.0003472011,0.0002128273,0.7676824],"genre_scores_gemma":[0.9673531,0.0012899346,0.00020458584,0.02996102,0.00008034512,0.000045621942,0.0000071641016,0.00003366545,0.001024554],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985016,0.00008038849,0.0005387127,0.00030871708,0.000032061267,0.00053854723],"domain_scores_gemma":[0.99898595,0.00012376577,0.00025680364,0.00040229168,0.000024298914,0.00020687636],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012520598,0.00015532301,0.00033669788,0.00011201263,0.00034672086,0.000081218655,0.00025886088,0.00004277294,0.00033222974],"category_scores_gemma":[0.0001464101,0.00014574605,0.000110993315,0.00016746542,0.0000874764,0.000083572835,0.00004953934,0.0002414073,0.0013628472],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011175836,0.000023994155,0.007170579,0.00012927297,0.00006588996,0.0000027815076,0.003133633,0.00008201435,5.292036e-7,0.9342087,0.033663955,0.02150746],"study_design_scores_gemma":[0.00035534194,0.000011419636,0.0009038339,0.00000940552,0.0000049363566,0.0000031051645,0.00068830216,0.00019943307,0.00002155212,0.008150549,0.9894728,0.00017932955],"about_ca_topic_score_codex":0.0006003088,"about_ca_topic_score_gemma":0.00010579658,"teacher_disagreement_score":0.9558088,"about_ca_system_score_codex":0.00025007376,"about_ca_system_score_gemma":0.00007286465,"threshold_uncertainty_score":0.9994147},"labels":[],"label_agreement":null},{"id":"W2327987781","doi":"10.1358/dot.2014.50.1.2118308","title":"A report from the 16th IGPA conference (December 9-11, 2013 -Brussels, Belgium)","year":2014,"lang":"en","type":"article","venue":"Drugs of today","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Alliance; Medicine; Negotiation; Member states; Economic growth; International trade; Political science; Business; Law","score_opus":0.042667258274655735,"score_gpt":0.26738202488049334,"score_spread":0.2247147666058376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2327987781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.69178915,0.0013265917,0.001135095,0.03353388,0.0012705021,0.00031480586,0.0006638777,0.000051093502,0.26991498],"genre_scores_gemma":[0.9937638,0.0003209885,0.00031764133,0.0030067163,0.00038524315,0.00001796096,0.00004561506,0.000025883817,0.0021161612],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983769,0.00002824924,0.00081064436,0.00041420365,0.000044163062,0.0003258338],"domain_scores_gemma":[0.99826807,0.00028789707,0.00053068966,0.0007280341,0.000043551223,0.00014174456],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00083405105,0.0001803581,0.00047522993,0.00006560413,0.00008830991,0.00007574691,0.00053258083,0.00010991014,0.0020339426],"category_scores_gemma":[0.00020013606,0.00016011426,0.00017301069,0.0001076208,0.00013451192,0.00015800798,0.00014810357,0.00017823525,0.0010583925],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002934696,0.00016408258,0.052651666,0.000026870906,0.00016479257,0.000005231296,0.0011917518,0.000103426944,0.00010253226,0.6882652,0.253209,0.004086115],"study_design_scores_gemma":[0.00046526073,0.0000151640015,0.014428478,0.0000135897135,0.000011879512,0.0000040171835,0.000029781211,0.004414522,0.00046227715,0.08874575,0.8911743,0.00023495493],"about_ca_topic_score_codex":0.0041257003,"about_ca_topic_score_gemma":0.00030527695,"teacher_disagreement_score":0.6379653,"about_ca_system_score_codex":0.000037129426,"about_ca_system_score_gemma":0.00003653784,"threshold_uncertainty_score":0.9997194},"labels":[],"label_agreement":null},{"id":"W2328948358","doi":"10.1177/1715163513482702","title":"Patient care and health compromised by drug shortages in Canada","year":2013,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Economic shortage; Drug; Health care; Medicine; Intensive care medicine; Medical emergency; Business; Political science; Pharmacology","score_opus":0.03543608171186143,"score_gpt":0.24453119183930333,"score_spread":0.2090951101274419,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2328948358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97506917,0.015052747,0.0000052822948,0.0016871258,0.0012977332,0.0005649572,0.0024566262,0.000008921402,0.0038574236],"genre_scores_gemma":[0.97392,0.009229288,0.000060301372,0.01634215,0.0001731081,0.000036413945,0.000052411968,0.000049128532,0.00013718354],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970027,0.000058262816,0.0011068729,0.00049027405,0.000089864625,0.0012520158],"domain_scores_gemma":[0.9962547,0.000054573753,0.00040301136,0.0002019913,0.000108905515,0.0029768297],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00032036725,0.00035566,0.0006268358,0.0003215013,0.0004621183,0.00023964237,0.00041093802,0.000040653602,0.00142995],"category_scores_gemma":[0.00003185516,0.000443581,0.000074820644,0.00030279675,0.00009349718,0.00036319136,0.000052564134,0.00064540067,0.00002523731],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000031703898,0.00006379498,0.114131525,0.0005086623,0.00022276251,0.005135993,0.004920168,0.0012047162,0.00009896317,0.00095788285,0.6636339,0.20908998],"study_design_scores_gemma":[0.0064694295,0.00013981882,0.0024951936,0.00006817912,0.000030178786,0.029392838,0.00038735793,0.026332371,0.00069682376,0.0015096669,0.929803,0.002675149],"about_ca_topic_score_codex":0.9930592,"about_ca_topic_score_gemma":0.9947984,"teacher_disagreement_score":0.26616913,"about_ca_system_score_codex":0.009782006,"about_ca_system_score_gemma":0.006061107,"threshold_uncertainty_score":0.9998016},"labels":[],"label_agreement":null},{"id":"W2329406519","doi":"","title":"Processus d’appels d’offres relatif à l’approvisionnement en médicaments au sein des centres hospitaliers du Québec","year":2016,"lang":"fr","type":"preprint","venue":"RePEc: Research Papers in Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Bidding; Interim; Business; Audit; Government (linguistics); Economic shortage; Political science; Welfare economics; Accounting; Marketing; Economics; Law","score_opus":0.05013385462371856,"score_gpt":0.32071749755239615,"score_spread":0.2705836429286776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2329406519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6688764,0.003931711,0.00006086453,0.02604065,0.0020947563,0.002205403,0.001627766,0.00007332818,0.29508913],"genre_scores_gemma":[0.9007327,0.071577035,0.0006982492,0.0007446665,0.0013952693,0.00062861847,0.00011183039,0.00027895902,0.023832656],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9899377,0.0004472385,0.0032345818,0.0028632933,0.00022414025,0.0032930367],"domain_scores_gemma":[0.9938319,0.0017030123,0.0012838698,0.0018251727,0.00017419214,0.0011818729],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.005123053,0.0011264984,0.001988531,0.0013472014,0.0008285257,0.000565112,0.002413912,0.0012655746,0.0023912974],"category_scores_gemma":[0.0020202866,0.0013066891,0.00073539885,0.00033608882,0.0024092395,0.00067164045,0.0028691383,0.0024794997,0.0013324257],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003747589,0.0013504009,0.42895064,0.0009945794,0.0010594173,0.00007347918,0.0056490563,0.004730198,0.000022582155,0.088088416,0.0020155734,0.4666909],"study_design_scores_gemma":[0.0034608128,0.00036827556,0.07201919,0.0009893609,0.000040190735,0.000018252738,0.0011465697,0.018912448,0.00013669542,0.060062587,0.84092605,0.001919541],"about_ca_topic_score_codex":0.014251888,"about_ca_topic_score_gemma":0.013317653,"teacher_disagreement_score":0.8389105,"about_ca_system_score_codex":0.013624425,"about_ca_system_score_gemma":0.0029620866,"threshold_uncertainty_score":0.99982184},"labels":[],"label_agreement":null},{"id":"W2330503964","doi":"10.1139/cjm-2013-0089","title":"Is the GAIN Act a turning point in new antibiotic discovery?","year":2013,"lang":"en","type":"article","venue":"Canadian Journal of Microbiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Canadian Institutes of Health Research","keywords":"Incentive; Antibiotics; Drug discovery; Legislation; Business; Turning point; Action (physics); Public economics; Biology; Economics; Political science; Bioinformatics; Law; Market economy; Microbiology","score_opus":0.035644665123110555,"score_gpt":0.24377122034081886,"score_spread":0.2081265552177083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2330503964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94700587,0.0040979073,0.00010761383,0.04171873,0.0011082469,0.00013735243,0.000095732816,0.0000015739915,0.0057269954],"genre_scores_gemma":[0.98779875,0.00015728574,0.0000837363,0.011042215,0.0003091035,4.0060308e-7,0.0000023461023,0.000011595991,0.000594581],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988625,0.000027459033,0.0005759481,0.00013418206,0.000004328591,0.0003955836],"domain_scores_gemma":[0.99915826,0.00007515493,0.0003070042,0.0001415481,0.00001774313,0.00030029175],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00042034846,0.000103499675,0.00031490688,0.00031591527,0.000053078165,0.000107747444,0.00035482654,0.00009273937,0.001392257],"category_scores_gemma":[0.00011707276,0.00008646383,0.0001260276,0.000118356766,0.000097808464,0.0002222726,0.000019903593,0.0003334783,0.00056077325],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026621927,0.00004984558,0.31655166,0.000028613234,0.0002970561,0.00006678845,0.004782527,0.00041541978,0.009431747,0.1013341,0.55933136,0.007684244],"study_design_scores_gemma":[0.0016149378,0.00017031499,0.057023115,0.00006472848,0.000011416413,0.00053271453,0.00023173077,0.0005700267,0.00139138,0.058424298,0.8795112,0.00045417098],"about_ca_topic_score_codex":0.018517796,"about_ca_topic_score_gemma":0.013590521,"teacher_disagreement_score":0.3201798,"about_ca_system_score_codex":0.00019671141,"about_ca_system_score_gemma":0.00048757024,"threshold_uncertainty_score":0.9995206},"labels":[],"label_agreement":null},{"id":"W2331265150","doi":"10.3821/1913-701x(2008)141[191:cipsea]2.0.co;2","title":"Canadian Internet pharmacies: Some ethical and economic issues","year":2008,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy; The Internet; Business; Internet privacy; Medicine; Family medicine; Computer science; World Wide Web","score_opus":0.07160511364793833,"score_gpt":0.2826959703774997,"score_spread":0.2110908567295614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2331265150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96054584,0.00912082,0.000030144289,0.0076902984,0.005172128,0.00044583358,0.003532512,0.000050367686,0.013412048],"genre_scores_gemma":[0.93539006,0.03242821,0.000108741144,0.028239327,0.0014297394,0.000019670482,0.00003732132,0.000095088966,0.0022518325],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959899,0.00008634802,0.0012668588,0.0007678695,0.00009654585,0.0017924727],"domain_scores_gemma":[0.9930563,0.00011408151,0.00039329228,0.0003172984,0.00011453177,0.006004474],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009905755,0.0005573871,0.00082925276,0.00096712244,0.0011389605,0.00036461977,0.00091685867,0.00024353793,0.004819027],"category_scores_gemma":[0.00016611292,0.00071543915,0.00021907203,0.00026709223,0.00049061567,0.00075368606,0.00009003689,0.0016878122,0.0005215403],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014889179,0.000075468815,0.03956025,0.00032969398,0.001063175,0.048973143,0.0061546047,0.0012275089,0.00016438258,0.068915404,0.8220094,0.01137811],"study_design_scores_gemma":[0.0017118729,0.00003594022,0.000101414895,0.000010396455,0.000033634453,0.18275478,0.0000069675134,0.012608336,0.0003183052,0.0037156998,0.7977249,0.0009777193],"about_ca_topic_score_codex":0.7754406,"about_ca_topic_score_gemma":0.72287244,"teacher_disagreement_score":0.13378164,"about_ca_system_score_codex":0.00633426,"about_ca_system_score_gemma":0.0046129785,"threshold_uncertainty_score":0.99952966},"labels":[],"label_agreement":null},{"id":"W2332270253","doi":"10.1177/171516350413700607","title":"BCE Emergis Acquires Pharmacy Management Systems","year":2004,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Pharmacy; Computer science; Business; Medicine; Family medicine","score_opus":0.06814307923856633,"score_gpt":0.272002194774843,"score_spread":0.20385911553627667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2332270253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80066884,0.02501048,0.001711328,0.0036949944,0.022586022,0.0018904423,0.0055293804,0.00018833771,0.13872018],"genre_scores_gemma":[0.967807,0.020782374,0.0002035423,0.007896414,0.00158141,0.000049322472,0.000036111553,0.00010930519,0.0015344996],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958397,0.000055708228,0.0014587702,0.00073293806,0.00015745974,0.0017554129],"domain_scores_gemma":[0.9954858,0.000046558296,0.0005883463,0.00042365975,0.00017064738,0.0032850313],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009056823,0.0005632258,0.0007238516,0.0008191374,0.0010108366,0.00056901213,0.001214539,0.00007807476,0.001982328],"category_scores_gemma":[0.00006285272,0.0007077969,0.00029145865,0.00071097113,0.00021372654,0.00072500925,0.00010612903,0.0007224044,0.00050127244],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004693203,0.0006589906,0.01003881,0.00214378,0.004491643,0.16812818,0.0043811076,0.11679948,0.00078565674,0.32356396,0.28712916,0.08140992],"study_design_scores_gemma":[0.005138102,0.00003149701,0.000042096177,0.000032200645,0.00009433986,0.09130922,0.00001637889,0.0063251364,0.00048220175,0.0055192765,0.8897708,0.0012387728],"about_ca_topic_score_codex":0.08205287,"about_ca_topic_score_gemma":0.024351548,"teacher_disagreement_score":0.6026416,"about_ca_system_score_codex":0.005121776,"about_ca_system_score_gemma":0.0013564401,"threshold_uncertainty_score":0.9995373},"labels":[],"label_agreement":null},{"id":"W2333326120","doi":"10.1097/fbp.0b013e328363d163","title":"Principles of assessment of abuse liability","year":2013,"lang":"en","type":"review","venue":"Behavioural Pharmacology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Bureau of Justice Statistics","keywords":"Abuse liability; Business; Liability; Jurisdiction; Substance abuse; Enforcement; Medicine; Risk analysis (engineering); Drug; Pharmacology; Political science; Law; Psychiatry; Accounting","score_opus":0.31778926003576896,"score_gpt":0.43888259735216006,"score_spread":0.1210933373163911,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2333326120","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0060634357,0.9774659,0.000016388789,0.000073438416,0.00120156,0.001266382,0.0016702866,0.000021620066,0.012220984],"genre_scores_gemma":[0.0030477108,0.9952256,0.0004869266,0.00010860091,0.00013677814,0.00024191894,0.000084011,0.00005365034,0.00061480334],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99627465,0.000104403734,0.002615971,0.0005380562,0.00003645956,0.00043048084],"domain_scores_gemma":[0.9967852,0.00022390459,0.0023085708,0.00043349335,0.000058025984,0.0001907894],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00068277,0.00040048026,0.0030815636,0.00037021597,0.000034903656,0.000014948947,0.0006860416,0.00039716405,0.0044724965],"category_scores_gemma":[0.000023567956,0.00040455515,0.00080606394,0.00019376786,0.00028007044,0.00012097058,0.00019927975,0.00053334306,0.0002381204],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003198552,0.004119838,0.026688559,0.048725653,0.002762249,0.000021732076,0.000341265,0.00005662683,0.000075888056,0.475574,0.009435666,0.43216655],"study_design_scores_gemma":[0.00040656075,0.000081114704,0.0007473525,0.0001978928,0.0003598881,0.0000058216233,0.000001952033,0.00019658201,0.000029978006,0.00040110212,0.9972242,0.00034754345],"about_ca_topic_score_codex":0.00022565121,"about_ca_topic_score_gemma":0.0000036254792,"teacher_disagreement_score":0.98778856,"about_ca_system_score_codex":0.00025583003,"about_ca_system_score_gemma":0.00018384737,"threshold_uncertainty_score":0.9998406},"labels":[],"label_agreement":null},{"id":"W2333798253","doi":"10.1097/00005650-200308000-00004","title":"Physician and Practice Characteristics Associated with the Early Utilization of New Prescription Drugs","year":2003,"lang":"en","type":"article","venue":"Medical Care","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":138,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"","keywords":"Medical prescription; Medicine; MEDLINE; Intensive care medicine; Family medicine; Pharmacology; Political science","score_opus":0.05608320431829633,"score_gpt":0.2916851483422187,"score_spread":0.23560194402392237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2333798253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9134624,0.0025055374,0.0013263113,0.007296339,0.00026136302,0.00027401585,0.00014202153,0.000023217415,0.07470879],"genre_scores_gemma":[0.9963192,0.00022745963,0.00003654749,0.0031479283,0.00007335278,0.000004232165,0.000018793544,0.000010886902,0.00016162195],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993908,0.000040135823,0.00023633621,0.00014397089,0.00005509739,0.00013369333],"domain_scores_gemma":[0.99933225,0.00015811945,0.00022887641,0.00011307161,0.000046730736,0.00012095704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003966077,0.0000745095,0.00018199916,0.000030734223,0.00005283702,0.000031887237,0.00008622909,0.00007616617,0.00011227185],"category_scores_gemma":[0.0010917418,0.000060965693,0.000026496575,0.00010856909,0.00008025958,0.00012222612,0.000017869177,0.00013867908,0.0000179404],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001731149,0.0002946475,0.055754308,0.0001442672,0.00032366844,0.0000074979043,0.03008496,0.000009843909,0.000029179933,0.8446804,0.008715418,0.05978269],"study_design_scores_gemma":[0.0023388104,0.00030502182,0.18614398,0.000085894244,0.00008317285,0.0000063342763,0.001992775,0.0018727038,0.00019370785,0.007889638,0.7986754,0.00041252343],"about_ca_topic_score_codex":0.00009212975,"about_ca_topic_score_gemma":0.00001660972,"teacher_disagreement_score":0.83679074,"about_ca_system_score_codex":0.000039116876,"about_ca_system_score_gemma":0.000055923578,"threshold_uncertainty_score":0.24861087},"labels":[],"label_agreement":null},{"id":"W2333810059","doi":"10.3324/haematol.2015.139931","title":"Securing reimbursement for patient centered haemophilia care: major collaborative efforts are needed","year":2016,"lang":"en","type":"editorial","venue":"Haematologica","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Hospital for Sick Children; Novo Nordisk; Bayer HealthCare; CSL Behring; Baxalta; Sick Kids Foundation; Biogen; Pfizer","keywords":"Reimbursement; Haemophilia; Business; Medicine; Cost–benefit analysis; Health care; Intensive care medicine; Medical emergency; Political science; Surgery","score_opus":0.031195118780093522,"score_gpt":0.2879831488459305,"score_spread":0.256788030065837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2333810059","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0077185635,0.011417653,0.00023700655,0.004522982,0.9154036,0.0036769316,0.035163164,0.00020164036,0.021658452],"genre_scores_gemma":[0.2019147,0.0066444976,0.0019458435,0.005137479,0.7729836,0.004610944,0.0034555749,0.0005944546,0.0027129212],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99624825,0.00003883249,0.0015070118,0.0011949715,0.00010193542,0.00090897904],"domain_scores_gemma":[0.99648446,0.00049631123,0.0017675107,0.0006866686,0.0002640413,0.00030099176],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003179964,0.00064845197,0.0018066354,0.00029498799,0.00028959417,0.00018322562,0.0005923602,0.0009941468,0.00041167627],"category_scores_gemma":[0.0007367318,0.0006028713,0.00045177084,0.00016090077,0.00013356049,0.00014615935,0.0003044214,0.00045147713,0.0005488395],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001980409,0.000093352086,0.00007999908,0.0004583482,0.0002447754,0.00003360523,0.0005598289,0.0000039408014,0.0000018272015,0.021690734,0.97617567,0.00045991063],"study_design_scores_gemma":[0.0018247608,0.0002752613,0.0000121695375,0.00021456646,0.000042353342,0.000003118481,0.00023108066,0.00003981481,0.00030131623,0.015855396,0.9804829,0.0007172651],"about_ca_topic_score_codex":0.000074039104,"about_ca_topic_score_gemma":0.00006478792,"teacher_disagreement_score":0.19419613,"about_ca_system_score_codex":0.0005994294,"about_ca_system_score_gemma":0.00013790661,"threshold_uncertainty_score":0.99964225},"labels":[],"label_agreement":null},{"id":"W2334865396","doi":"10.5539/ibr.v9n6p53","title":"A Quantitative Analysis of the Causes of Drug Shortages in Jordan: A Supply Chain Perspective","year":2016,"lang":"en","type":"article","venue":"International Business Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Economic shortage; Supply chain; Legislature; Business; Distribution (mathematics); Perspective (graphical); Drug; Marketing; Medicine; Pharmacology; Geography; Computer science","score_opus":0.1381664222172123,"score_gpt":0.4199900470063689,"score_spread":0.28182362478915657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2334865396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9677396,0.00037310197,0.00008925518,0.019049069,0.00013579972,0.00013364642,0.00079900224,0.000002186405,0.011678373],"genre_scores_gemma":[0.9986011,0.0004998207,0.000039658284,0.000068054374,0.00003054823,0.00002197289,0.0000034392629,0.00000771341,0.0007277419],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99895257,0.000052795716,0.00046495744,0.00023558708,0.0001072737,0.00018683786],"domain_scores_gemma":[0.99852556,0.00056129304,0.0001785513,0.00020523525,0.0004973491,0.0000319834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009927555,0.00006953574,0.00029572457,0.001280001,0.00002767333,0.000019834155,0.0005160237,0.000033453533,0.00072730694],"category_scores_gemma":[0.0011110764,0.000050219747,0.00012247305,0.0015423559,0.00030228405,0.00014925365,0.00017766134,0.00011469841,0.000032141583],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000079457015,0.00012651905,0.35695636,0.000009472991,0.0004366502,0.0000013190609,0.00088968425,0.0003800978,0.0005488537,0.6402451,0.00021647531,0.00011003378],"study_design_scores_gemma":[0.00044883756,0.0000148556155,0.9251877,0.000046263525,0.000010743477,3.6852182e-7,0.00036414925,0.003532799,0.0012414814,0.06685875,0.002204878,0.00008915922],"about_ca_topic_score_codex":0.0048570493,"about_ca_topic_score_gemma":0.0018138603,"teacher_disagreement_score":0.5733863,"about_ca_system_score_codex":0.00024300814,"about_ca_system_score_gemma":0.000071531664,"threshold_uncertainty_score":0.7963501},"labels":[],"label_agreement":null},{"id":"W2335916510","doi":"10.1097/tp.0000000000000782","title":"What Is the Future of Generics in Transplantation?","year":2015,"lang":"en","type":"review","venue":"Transplantation","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Generic drug; Innovator; Medicine; Drug; Bioequivalence; Scope (computer science); Substitution (logic); Risk analysis (engineering); Transplantation; Intensive care medicine; Business; Pharmacology; Computer science; Surgery","score_opus":0.11311823276975891,"score_gpt":0.3510769102565545,"score_spread":0.2379586774867956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2335916510","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000707955,0.9938669,0.00014744337,0.0006458906,0.0009116174,0.0004904804,0.0015941905,0.000009853112,0.0022628016],"genre_scores_gemma":[0.00009233464,0.99838626,0.00006770976,0.00057069975,0.00024268149,0.00006198567,0.00045986188,0.00003568896,0.000082748535],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99822354,0.00005051416,0.0011371142,0.00032384726,0.000043476804,0.0002214763],"domain_scores_gemma":[0.9990414,0.0000993334,0.0005107627,0.00025927348,0.000021069187,0.00006817189],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005913153,0.0002554343,0.0010581998,0.00027868993,0.000032679432,0.00006655341,0.00033819373,0.00026389986,0.00014713555],"category_scores_gemma":[0.0000019238294,0.0002187065,0.00028289005,0.00035643647,0.00005119358,0.00032147265,0.0000065944714,0.00029273215,0.0002284717],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050321054,0.00010545296,0.00010759786,0.023395134,0.00019347125,0.000018486695,0.0063169366,0.00006670638,1.7055187e-7,0.070651904,0.0013654246,0.8977284],"study_design_scores_gemma":[0.0004488952,0.000017671371,0.000045178334,0.00088003324,0.0001526239,0.000023549035,0.000048829563,0.00012856339,0.0000021603748,0.006398594,0.9916037,0.00025025103],"about_ca_topic_score_codex":0.000044505912,"about_ca_topic_score_gemma":0.00007188737,"teacher_disagreement_score":0.99023825,"about_ca_system_score_codex":0.00009113019,"about_ca_system_score_gemma":0.00009200268,"threshold_uncertainty_score":0.89185923},"labels":[],"label_agreement":null},{"id":"W2336377795","doi":"","title":"How cheap are Canada's drugs really?","year":2004,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Drug prices; Government (linguistics); Business; Economics; Schedule; Differential (mechanical device); Agricultural economics; Public economics; Engineering","score_opus":0.04372754451490109,"score_gpt":0.21087734989349172,"score_spread":0.16714980537859064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2336377795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3968303,0.0029690524,0.00020126076,0.21889037,0.0019587104,0.000970321,0.00093863055,0.000109178545,0.37713218],"genre_scores_gemma":[0.98892784,0.00015699645,0.000052184532,0.0071845395,0.00029894998,0.0002860175,0.000008900546,0.000023489256,0.0030610845],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99882895,0.0000042041047,0.0002914999,0.00031134038,0.000026712518,0.0005373128],"domain_scores_gemma":[0.9991996,0.000020096288,0.00019767547,0.0002632671,0.000013836971,0.00030551516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023809866,0.00013382379,0.00028597724,0.000116453324,0.00007115676,0.000121735735,0.00024254702,0.000066797365,0.000042873988],"category_scores_gemma":[0.00009057561,0.00016144772,0.00007464687,0.00016705591,0.00003573647,0.00014490902,0.00004973797,0.00014929204,0.000077099416],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024147515,0.00011363678,0.016371707,0.00005140122,0.00012851995,0.000021328487,0.00016801413,0.00020542998,0.0000015029176,0.92328674,0.026503261,0.033124324],"study_design_scores_gemma":[0.00071757147,0.0000034958366,0.14522837,0.0000020399111,0.0000031669215,0.0000026214375,0.00002771818,0.000042762946,0.00012891163,0.0446475,0.80894375,0.00025210835],"about_ca_topic_score_codex":0.09227935,"about_ca_topic_score_gemma":0.084727526,"teacher_disagreement_score":0.8786392,"about_ca_system_score_codex":0.00053087575,"about_ca_system_score_gemma":0.000077781726,"threshold_uncertainty_score":0.9319738},"labels":[],"label_agreement":null},{"id":"W2338102190","doi":"","title":"Congress, Illinois Think Canada Is Answer to Prescription Drug Woes","year":2003,"lang":"en","type":"article","venue":"Public interest law reporter","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Drug; Political science; Medicine; Pharmacology","score_opus":0.06726258631704106,"score_gpt":0.2623693629867958,"score_spread":0.19510677666975473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2338102190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.48955706,0.00047560586,0.000283868,0.050488558,0.005642589,0.0005646681,0.0005046458,0.00008197973,0.45240104],"genre_scores_gemma":[0.94298214,0.000028886212,0.00013759606,0.04812368,0.00015544372,0.00003822133,0.000021631868,0.000036838694,0.008475596],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977756,0.000024945411,0.0009818106,0.0005914794,0.00005170326,0.00057446235],"domain_scores_gemma":[0.9985438,0.000034321736,0.0003432783,0.00057220994,0.000089254994,0.00041712864],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005765387,0.00023367038,0.00040502322,0.00013165124,0.00013005927,0.0003339096,0.0003024828,0.000094067786,0.004224953],"category_scores_gemma":[0.00016787021,0.00025273912,0.00012552086,0.00015247367,0.00007020737,0.00042456566,0.000081322556,0.0002108791,0.00048659943],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000054874495,0.000044254262,0.007511051,0.000012482987,0.00006847694,0.00001735593,0.00019358454,0.000001974152,0.000009925876,0.7613505,0.23066778,0.00011711264],"study_design_scores_gemma":[0.00023191328,0.000015488322,0.0011158405,0.000007518062,0.000004908656,0.000025923744,0.000026100706,0.0001900067,0.0006494014,0.024747465,0.9726615,0.00032395666],"about_ca_topic_score_codex":0.12941223,"about_ca_topic_score_gemma":0.34522304,"teacher_disagreement_score":0.74199367,"about_ca_system_score_codex":0.000326546,"about_ca_system_score_gemma":0.00016376405,"threshold_uncertainty_score":0.9999925},"labels":[],"label_agreement":null},{"id":"W2339312117","doi":"10.1186/s40545-016-0064-8","title":"Upstream solutions for price-gouging on critical generic medicines","year":2016,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Policy and Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Divestment; Upstream (networking); Pharmacy; Drug prices; Business; Psychological intervention; Law and economics; Public relations; Economics; Medicine; Political science; Law; Public economics; Computer science; Finance; Telecommunications","score_opus":0.21312437811457274,"score_gpt":0.4391385945673652,"score_spread":0.22601421645279246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339312117","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004724775,0.00829129,0.0491721,0.8389114,0.0017998568,0.00038660463,0.00041393965,0.000034992197,0.09626501],"genre_scores_gemma":[0.95135146,0.0065387553,0.0027078066,0.03527623,0.0037285867,0.0000130936105,8.306163e-7,0.00003623654,0.0003470118],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99811643,0.00008632094,0.0008896877,0.00024466784,0.000068299545,0.0005945976],"domain_scores_gemma":[0.9919656,0.006712671,0.0004906896,0.0001473134,0.00013751232,0.00054622267],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.002556567,0.00018272093,0.00043764032,0.00036268742,0.00020786625,0.000073336596,0.00020975604,0.00010884515,0.00020448901],"category_scores_gemma":[0.015240057,0.00013884781,0.00017844042,0.00017807946,0.00025733703,0.00069420587,0.00006717234,0.00030009897,0.00010176987],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005023835,0.00024300202,0.000121299476,0.000044954748,0.00013496082,0.000010627835,0.000104510065,0.000010524925,0.0009085721,0.9760387,0.008471783,0.013408682],"study_design_scores_gemma":[0.0018479732,0.00035543236,0.00014137395,0.000045578123,0.0000710716,0.00033123093,0.000030789524,0.0006718119,0.00043075808,0.151989,0.84389,0.00019499261],"about_ca_topic_score_codex":0.000010281454,"about_ca_topic_score_gemma":4.4555864e-7,"teacher_disagreement_score":0.94662666,"about_ca_system_score_codex":0.00015560158,"about_ca_system_score_gemma":0.00011040004,"threshold_uncertainty_score":0.993055},"labels":[],"label_agreement":null},{"id":"W2339383866","doi":"10.1503/cmaj.109-5245","title":"US seeking more transparency from pharma","year":2016,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Transparency (behavior); Government (linguistics); Administration (probate law); Fiscal year; Business; Public administration; Medicine; Accounting; Computer science; Finance; Political science; Computer security; Law","score_opus":0.031265472286556795,"score_gpt":0.26117523024299577,"score_spread":0.22990975795643898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339383866","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5370474,0.0017469708,0.002589023,0.39291507,0.003797643,0.00013478559,0.0020291328,0.000040368275,0.059699632],"genre_scores_gemma":[0.95542014,0.00094539975,0.00006353542,0.040781885,0.002266746,0.0000042936044,0.0000068438735,0.000020193736,0.0004909522],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99845105,0.000029709587,0.00066570437,0.00020399845,0.00012425634,0.00052525115],"domain_scores_gemma":[0.9977879,0.00014997952,0.00029793035,0.00009969439,0.000050793144,0.0016137363],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010013783,0.00011356075,0.00027103766,0.00017691134,0.00016792268,0.000093216644,0.00030934703,0.00025505194,0.028460084],"category_scores_gemma":[0.00061073055,0.00010357988,0.00013385195,0.00010651784,0.000033847096,0.00022910492,0.000010947202,0.0004263349,0.0021782673],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001076955,0.000046010366,0.706281,0.0000050317153,0.00034281568,0.00017849317,0.00058290677,0.000004661041,0.00005729871,0.021774372,0.20559916,0.065117486],"study_design_scores_gemma":[0.0010592648,0.000009768097,0.044381086,0.000023887455,0.000006133025,0.000020120737,0.000015810057,0.0006356303,0.00001922328,0.013090212,0.9405573,0.00018153763],"about_ca_topic_score_codex":0.0036628263,"about_ca_topic_score_gemma":0.005448547,"teacher_disagreement_score":0.7349582,"about_ca_system_score_codex":0.001037564,"about_ca_system_score_gemma":0.000483778,"threshold_uncertainty_score":0.99859864},"labels":[],"label_agreement":null},{"id":"W2341632540","doi":"10.1177/0840470415588677","title":"Triage in times of drug shortage","year":2015,"lang":"en","type":"review","venue":"Healthcare Management Forum","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. John’s Health Sciences Centre; Newfoundland and Labrador Centre for Applied Health Research; Memorial University of Newfoundland","funders":"","keywords":"Economic shortage; Triage; Process (computing); Drug; Risk analysis (engineering); Business; Process management; Computer science; Medical emergency; Medicine; Pharmacology","score_opus":0.15777052451575213,"score_gpt":0.3883288184811249,"score_spread":0.23055829396537275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2341632540","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000024443036,0.860272,0.0000078381245,0.0016407213,0.0005036287,0.0012685655,0.000679241,0.000023276314,0.13560231],"genre_scores_gemma":[0.00031339037,0.9944933,0.00011602779,0.00081022485,0.00009218983,0.0001842641,0.00016483985,0.00007148277,0.0037542663],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964515,0.00006705169,0.002127496,0.0006299312,0.00005328632,0.00067070837],"domain_scores_gemma":[0.9981079,0.000060380768,0.00091884326,0.0006702011,0.000017734894,0.00022492047],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014520587,0.00039021115,0.0025875603,0.001001346,0.000036636204,0.000037278976,0.00058808556,0.00022297136,0.0005553599],"category_scores_gemma":[0.00002216592,0.0004333118,0.00045256078,0.00049923256,0.000048042904,0.000106431464,0.00034193153,0.00040401617,0.0008799223],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000005408164,0.00006440056,0.00014303315,0.015467925,0.00010251527,0.00001298772,0.00004989003,0.0000014837898,1.3660016e-10,0.54380906,0.0174285,0.42291483],"study_design_scores_gemma":[0.00040189034,0.000027427222,0.000009605077,0.0012761264,0.000038461054,0.0000012965957,0.000048431208,0.000066438,2.825951e-8,0.035356246,0.96243256,0.00034146846],"about_ca_topic_score_codex":0.00043961057,"about_ca_topic_score_gemma":0.0001696853,"teacher_disagreement_score":0.9450041,"about_ca_system_score_codex":0.00044531556,"about_ca_system_score_gemma":0.000084649466,"threshold_uncertainty_score":0.999898},"labels":[],"label_agreement":null},{"id":"W2341662826","doi":"10.1071/hc15093","title":"Guest Editorial: A drug by any other name... generic and brand-name drugs are clinically equivalent","year":2015,"lang":"en","type":"editorial","venue":"Journal of Primary Health Care","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Brand names; Drug; Medicine; Generic drug; MEDLINE; Family medicine; Pharmacology; Business; Advertising; Political science; Law","score_opus":0.03695820340460198,"score_gpt":0.3339786750175078,"score_spread":0.2970204716129058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2341662826","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006089215,0.12521249,0.000014514009,0.005810016,0.8592837,0.00032003273,0.0056935702,0.000020411895,0.0030363612],"genre_scores_gemma":[0.00034712887,0.038599744,0.00023050145,0.0069867955,0.95290494,0.000011900007,0.00019364464,0.00015110234,0.00057422975],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942678,0.00017037908,0.0036326114,0.0006945422,0.0003782733,0.0008563759],"domain_scores_gemma":[0.9911704,0.00064023427,0.005766661,0.0004957362,0.0006112965,0.0013156394],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004572871,0.0005648417,0.002668408,0.00037054985,0.00016654212,0.00023120473,0.0007937091,0.0009550329,0.00009985216],"category_scores_gemma":[0.00086201576,0.0005950659,0.00048963714,0.0001414068,0.00015532506,0.00034814005,0.00026155656,0.002385969,0.00013741759],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028966484,0.000115752824,0.00043076393,0.0008309564,0.0001653722,0.00000793083,0.0010232534,0.0000039443617,4.2909645e-7,0.00006185823,0.9959216,0.0011484725],"study_design_scores_gemma":[0.0031893393,0.00048578565,0.000044246084,0.00021559378,0.000044483095,0.0000070630867,0.0001292017,0.000010036701,5.939814e-7,0.0009000459,0.99443513,0.000538484],"about_ca_topic_score_codex":0.00036360242,"about_ca_topic_score_gemma":0.000025028135,"teacher_disagreement_score":0.09362128,"about_ca_system_score_codex":0.0024898946,"about_ca_system_score_gemma":0.002555937,"threshold_uncertainty_score":0.99991554},"labels":[],"label_agreement":null},{"id":"W2343104801","doi":"","title":"La relation entre le CMFC et l’industrie pharmaceutique et des soins de santé","year":2014,"lang":"fr","type":"article","venue":"Europe PMC (PubMed Central)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science; Humanities; Medicine; Philosophy","score_opus":0.06206803256118652,"score_gpt":0.29350222606836923,"score_spread":0.2314341935071827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343104801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5354295,0.010143749,0.0069990577,0.051098365,0.0021508012,0.0006883402,0.0007531624,0.0001396898,0.39259732],"genre_scores_gemma":[0.95256925,0.028570931,0.0006334835,0.008251228,0.00092705066,0.000044723656,0.000055126657,0.00013448448,0.008813699],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99561083,0.0007837989,0.0009529577,0.00073401537,0.000060464,0.0018579166],"domain_scores_gemma":[0.9977785,0.00044345227,0.00049257017,0.00037740075,0.0000481825,0.0008599415],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0033621779,0.00043434574,0.00056522776,0.00022226259,0.0002064441,0.00036499838,0.00047082803,0.00040610446,0.0009776518],"category_scores_gemma":[0.0010077853,0.0005902113,0.00023987143,0.00043043096,0.00034279472,0.00074887526,0.00019066532,0.0012660444,0.0010044439],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007636872,0.0005527172,0.09798458,0.00015279821,0.0002182745,0.000036788755,0.008874928,0.002311043,0.000096942174,0.7579384,0.025356798,0.106400356],"study_design_scores_gemma":[0.0016250738,0.00003762553,0.12936027,0.00006213195,0.000040419323,0.000035160803,0.00003830949,0.009903485,0.0008026567,0.016206708,0.841357,0.00053118495],"about_ca_topic_score_codex":0.0003073963,"about_ca_topic_score_gemma":0.00009767964,"teacher_disagreement_score":0.81600016,"about_ca_system_score_codex":0.00061198155,"about_ca_system_score_gemma":0.0004628285,"threshold_uncertainty_score":0.99993557},"labels":[],"label_agreement":null},{"id":"W2343292785","doi":"10.1016/j.jval.2015.03.587","title":"Evaluation Of A Pharmaceutical Risk-Sharing Agreement When Patients Are Screened For The Probability Of Success","year":2015,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of Alberta","funders":"","keywords":"Formulary; Subsidy; Stackelberg competition; Outcome (game theory); Listing (finance); Actuarial science; Business; Microeconomics; Welfare; Population; Distribution (mathematics); Prescription drug; Social Welfare; Economics; Medical prescription; Finance; Medicine; Pharmacology","score_opus":0.43066247223099796,"score_gpt":0.40867515345984246,"score_spread":0.021987318771155506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343292785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99105394,0.0023024722,0.00070294685,0.0024098938,0.0002793919,0.0017550187,0.000544834,0.0000049927776,0.00094651687],"genre_scores_gemma":[0.99877197,0.00022146343,0.0005339845,0.00029558814,0.000049795704,0.00010254131,0.000009094142,0.0000100021925,0.0000055788582],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9981582,0.00013055446,0.0010610265,0.00027285772,0.00011163552,0.00026570685],"domain_scores_gemma":[0.9982549,0.00022881826,0.00088128826,0.00029539812,0.00020493432,0.00013466158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011122038,0.0000945111,0.0003682272,0.00011239747,0.000046776284,0.000012523133,0.00026449462,0.000048305013,0.000055346813],"category_scores_gemma":[0.0011940909,0.000088018045,0.00008023619,0.0001308052,0.000060796392,0.00009412675,0.00007872462,0.00012250197,0.000008582749],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001408748,0.0004983183,0.9002341,0.00033538093,0.00006757259,2.3957641e-8,0.0010952201,0.03913493,6.232117e-7,0.046039067,0.00029445323,0.012159414],"study_design_scores_gemma":[0.0032606465,0.00015077142,0.117660224,0.000044005472,0.00002197676,7.4902005e-8,0.00004377362,0.6777192,0.000072519695,0.19786108,0.0030642801,0.00010148541],"about_ca_topic_score_codex":0.0052088103,"about_ca_topic_score_gemma":0.00013150627,"teacher_disagreement_score":0.7825739,"about_ca_system_score_codex":0.00046772588,"about_ca_system_score_gemma":0.00017985488,"threshold_uncertainty_score":0.7874198},"labels":[],"label_agreement":null},{"id":"W2343433672","doi":"10.1016/j.jval.2015.03.430","title":"Analysis of the Drug price reviews performed by the Canadian Patented Medicine Prices review Board (1998-2014)","year":2015,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Notice; Drug prices; Business; Database transaction; Descriptive statistics; Medicine; Economics; Monetary economics; Law","score_opus":0.1724730036183695,"score_gpt":0.34448059725966984,"score_spread":0.17200759364130033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343433672","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0713386,0.6579207,0.00001907898,0.24183261,0.0008590879,0.002163063,0.0003967701,0.000013663405,0.025456417],"genre_scores_gemma":[0.6281013,0.30678847,0.000060826216,0.06412792,0.00013474778,0.000084450534,0.000050447972,0.000025063737,0.00062675227],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976391,0.00018223087,0.0014278545,0.00027863416,0.000060548726,0.0004115868],"domain_scores_gemma":[0.9979937,0.00013465491,0.000902983,0.0005678841,0.00002904294,0.00037172917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0062609734,0.00014603401,0.00093236245,0.0002802318,0.00012510899,0.000015985774,0.00054882444,0.00004849097,0.00018449234],"category_scores_gemma":[0.0005351838,0.000092517104,0.00016695105,0.001282372,0.00011453045,0.000073852185,0.00005103584,0.0002725196,0.00014668558],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015534175,0.00011768011,0.21991898,0.0019820828,0.0004055639,7.594057e-7,0.004940164,0.001414331,9.4114876e-7,0.045257337,0.72157836,0.004368245],"study_design_scores_gemma":[0.00027263165,0.000027447233,0.01079282,0.00032977317,0.000051900213,7.204381e-7,0.000036306486,0.015015948,0.0000011096503,0.0011446899,0.97221434,0.00011232198],"about_ca_topic_score_codex":0.50457084,"about_ca_topic_score_gemma":0.09475469,"teacher_disagreement_score":0.5567627,"about_ca_system_score_codex":0.0006372948,"about_ca_system_score_gemma":0.0003676945,"threshold_uncertainty_score":0.92176366},"labels":[],"label_agreement":null},{"id":"W2343931953","doi":"10.7202/1035190ar","title":"Cooperation and Drug Policies in the Americas. Trends in the Twenty-First Century, Roberto Zepeda et Jonathan d. Rosen (dir.), 2015, Lanham, The Rowman and Littlefield Publishing Group, 249 p.","year":2015,"lang":"en","type":"article","venue":"Études internationales","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Publishing; Political science; Humanities; Art; Law","score_opus":0.0639309121217175,"score_gpt":0.31402827574382247,"score_spread":0.250097363622105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343931953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7675766,0.014258822,0.00003368092,0.18400872,0.00026683792,0.00022622473,0.00014593083,0.000013906339,0.033469312],"genre_scores_gemma":[0.9859791,0.0029546055,0.000029946923,0.010548668,0.00017270262,0.000040096784,0.000059256687,0.0000105107365,0.0002051187],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99907094,0.000076957345,0.00036745807,0.00022773717,0.00006830265,0.0001886],"domain_scores_gemma":[0.9992295,0.0003748795,0.00014139056,0.000183525,0.000022843158,0.000047863974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014751481,0.00012944637,0.00016929585,0.0002171606,0.00009078933,0.00083366234,0.00048420648,0.00004879846,0.00004209946],"category_scores_gemma":[0.00022331136,0.00008520021,0.000038748563,0.00019775797,0.00010761519,0.0006102206,0.00014056859,0.00028549315,0.000011290865],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012782525,0.000089006906,0.043070517,0.0000062135423,0.000024954203,0.0000022084048,0.010036793,0.00016596577,0.0000015939173,0.9231168,0.021162787,0.0023103857],"study_design_scores_gemma":[0.0006927016,0.000033711713,0.16142502,0.00001794085,0.000005160409,0.000020385627,0.0017703241,0.0058503733,0.0000032035296,0.013389825,0.8166048,0.00018657435],"about_ca_topic_score_codex":0.0076765,"about_ca_topic_score_gemma":0.024748154,"teacher_disagreement_score":0.909727,"about_ca_system_score_codex":0.00007227936,"about_ca_system_score_gemma":0.000014355767,"threshold_uncertainty_score":0.99893147},"labels":[],"label_agreement":null},{"id":"W2344145331","doi":"10.1016/j.jval.2015.03.1231","title":"The Disconnect Between Funding Decisions of Cancer Drugs And Companion Diagnostic Tests in Canada","year":2015,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Companion diagnostic; Diagnostic test; Medicine; Test (biology); Cancer; Cancer drugs; Family medicine; Intensive care medicine; Medical physics; Pediatrics; Internal medicine","score_opus":0.21203949751455525,"score_gpt":0.36278646560157163,"score_spread":0.15074696808701638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2344145331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98144704,0.009462362,0.000013110168,0.0077678235,0.0002709035,0.00018832646,0.00020876863,0.0000022579263,0.0006393898],"genre_scores_gemma":[0.995358,0.0040671234,0.000035293746,0.00044858534,0.00005635576,0.000014664389,0.000002896241,0.00000887002,0.000008209409],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99876183,0.00004563941,0.00067943556,0.0001737476,0.000026215286,0.00031310826],"domain_scores_gemma":[0.9970426,0.0023884734,0.00022012477,0.00013766873,0.000008282763,0.0002028331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011673906,0.00007661745,0.00032237556,0.00010858932,0.000055407054,0.000018661995,0.0001388825,0.000024709967,0.0000071513587],"category_scores_gemma":[0.00073457725,0.00007155967,0.000016892773,0.00019323526,0.00003549295,0.000057728616,0.000057134268,0.0001463127,0.0000048049756],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000003678949,0.000009767311,0.9542123,0.000017358754,0.0000051902935,5.172676e-7,0.00041640905,0.0038333428,9.182432e-8,0.036208868,0.000331898,0.004960581],"study_design_scores_gemma":[0.00076751754,0.00003174989,0.9092453,0.00012389426,0.0000014354978,4.9973113e-7,0.00025841448,0.02472021,0.0000045728543,0.048875205,0.015836004,0.00013518521],"about_ca_topic_score_codex":0.96438545,"about_ca_topic_score_gemma":0.8091171,"teacher_disagreement_score":0.15526837,"about_ca_system_score_codex":0.00093939446,"about_ca_system_score_gemma":0.00071502436,"threshold_uncertainty_score":0.29181185},"labels":[],"label_agreement":null},{"id":"W2345038106","doi":"10.1016/j.jval.2015.03.492","title":"Impact of Clinical and Health Economic Publications on Commercial success of Pharmaceutical products in the U.S","year":2015,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Medicine; Casual; Asthma; Confounding; Internal medicine; Geography","score_opus":0.5591690276145322,"score_gpt":0.5192826927033346,"score_spread":0.03988633491119764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345038106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94234467,0.0014125071,0.0000071257036,0.052059207,0.00032776676,0.00051611575,0.0002669988,0.000005421064,0.0030602063],"genre_scores_gemma":[0.9957394,0.0016446396,0.00010439631,0.0023180882,0.00014753922,0.000014712886,0.000010879231,0.000011529634,0.000008817556],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99721366,0.00023706736,0.0018522275,0.0003175087,0.000033901386,0.00034565025],"domain_scores_gemma":[0.9984335,0.00030613376,0.0006521987,0.00033390033,0.000020059591,0.0002542529],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0076124156,0.00011475069,0.0007021941,0.00031925368,0.000031077067,0.000020167885,0.00029524876,0.000068753005,0.000027319173],"category_scores_gemma":[0.00031858918,0.000103585524,0.00008319997,0.0002709951,0.00016629335,0.0001204732,0.000050448187,0.00035418506,0.000026544509],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006164313,0.0004261075,0.7222936,0.0000816795,0.00001390228,1.7158459e-7,0.00080235634,0.0016814733,8.564795e-8,0.26829585,0.0033323735,0.0030107151],"study_design_scores_gemma":[0.0020704984,0.0006025759,0.94518405,0.00003263288,0.0000013408123,0.0000031442678,0.000039620987,0.021739243,0.0000031552147,0.012952216,0.017249826,0.00012172108],"about_ca_topic_score_codex":0.018242722,"about_ca_topic_score_gemma":0.00027661625,"teacher_disagreement_score":0.25534365,"about_ca_system_score_codex":0.00026967976,"about_ca_system_score_gemma":0.0008330425,"threshold_uncertainty_score":0.9882949},"labels":[],"label_agreement":null},{"id":"W2346987006","doi":"","title":"Soundings: Geese of a different feather","year":2003,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Legislation; Revenue; Medicine; Business; Drug Company; Economic policy; Economics; Law; Political science; Finance","score_opus":0.06449739226768803,"score_gpt":0.2775112193344337,"score_spread":0.21301382706674565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2346987006","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4295,0.00033300405,0.00066109246,0.0003429936,0.00015931948,0.00006798951,0.000025298465,0.000012005909,0.56889826],"genre_scores_gemma":[0.9951523,0.00011849523,0.00021538543,0.0008944368,0.000027995171,0.0000066687867,0.0000010930299,0.0000125275155,0.003571107],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9992535,0.0000060411026,0.00036181914,0.00017151757,0.000010579896,0.000196524],"domain_scores_gemma":[0.99957144,0.000032725682,0.000121979014,0.00017956777,0.0000074192835,0.00008684593],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001948231,0.0000889919,0.00026150577,0.00009770338,0.000024785211,0.000019380916,0.0001064614,0.00004603154,0.0054174904],"category_scores_gemma":[0.000060095994,0.00008738463,0.00010172781,0.00006951275,0.00003816326,0.000060255028,0.00001968109,0.00006387845,0.00047771918],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000026991925,0.00007117545,0.024587467,0.0000072960015,0.000025150686,2.0065642e-7,0.00008538698,0.000002941328,0.000068662055,0.9740553,0.0009816419,0.000112074566],"study_design_scores_gemma":[0.00075867167,0.000050847182,0.0053340634,0.0000042526763,0.0000046040104,0.0000030157578,0.000035008667,0.0007029115,0.003206611,0.63776433,0.35188267,0.00025298801],"about_ca_topic_score_codex":0.00003321859,"about_ca_topic_score_gemma":0.0000053661256,"teacher_disagreement_score":0.56565225,"about_ca_system_score_codex":0.000037072794,"about_ca_system_score_gemma":0.000006721225,"threshold_uncertainty_score":0.9954917},"labels":[],"label_agreement":null},{"id":"W2348645494","doi":"","title":"Drug Expenditure and Drug Price Regulation in Canada","year":2009,"lang":"en","type":"article","venue":"Zhongguo yaofang","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Per capita; Drug; Drug prices; Drug pricing; Public economics; Economics; Business; Medicine; Pharmacology; Actuarial science; Environmental health","score_opus":0.01998588614738545,"score_gpt":0.23459213732313516,"score_spread":0.21460625117574972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2348645494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9386401,0.0021350775,0.000039440427,0.009197788,0.0002981397,0.00017239452,0.00008041187,0.00001824953,0.049418356],"genre_scores_gemma":[0.9954838,0.00019674489,0.00011927411,0.0032255747,0.00012872147,0.000005232213,0.000012001704,0.0000109653365,0.0008176732],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9989972,0.000010481355,0.00038341852,0.00029052445,0.000023468401,0.00029489808],"domain_scores_gemma":[0.9995111,0.00004789494,0.00013407411,0.00017447949,0.000006088489,0.00012636645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022815439,0.00012265917,0.0002511929,0.00012559725,0.000054910623,0.00004716642,0.0001289414,0.000037749123,0.00028399884],"category_scores_gemma":[0.000033917917,0.00014991903,0.000030857915,0.00012683538,0.00001568008,0.00020640114,0.000028246322,0.00015541268,0.000067065135],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006139919,0.00015433512,0.27272153,0.00007665847,0.000053537926,0.000049725135,0.003573596,0.0012361613,0.00023181601,0.5888855,0.11119682,0.021758888],"study_design_scores_gemma":[0.0009270796,0.00001271252,0.6502869,0.000029173225,0.0000036906117,0.000008277573,0.00017140724,0.008143834,0.00044775705,0.06696115,0.27246216,0.00054584665],"about_ca_topic_score_codex":0.28226373,"about_ca_topic_score_gemma":0.32321995,"teacher_disagreement_score":0.5219244,"about_ca_system_score_codex":0.00032749158,"about_ca_system_score_gemma":0.0000837621,"threshold_uncertainty_score":0.72251576},"labels":[],"label_agreement":null},{"id":"W2349864794","doi":"","title":"Summary and Analysis of the 2nd Quarter 2010 Results of the Global Top Ten Pharmaceutical Companies","year":2010,"lang":"en","type":"article","venue":"Chinese Journal of Pharmaceuticals","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chemistry; Quarter (Canadian coin); History","score_opus":0.03978681178303938,"score_gpt":0.3396183372690985,"score_spread":0.2998315254860591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2349864794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787855,0.001810786,0.000042647338,0.011350536,0.0015759228,0.00018150426,0.0012102425,0.0000048246084,0.0050380053],"genre_scores_gemma":[0.997624,0.00051558326,0.00014628566,0.0013604478,0.00025582954,0.0000016548487,0.0000020219193,0.000013122434,0.00008109273],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973271,0.00010341427,0.0018374597,0.0002590641,0.00013801044,0.00033496905],"domain_scores_gemma":[0.9972348,0.0005015818,0.0013256986,0.0004888639,0.00014973851,0.00029929992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018056342,0.0002514079,0.0010497597,0.00024265773,0.000107077845,0.000050442944,0.00089969655,0.00014591294,0.00027497328],"category_scores_gemma":[0.00077369297,0.00014743676,0.0007618337,0.0010154737,0.00067353394,0.00021165822,0.00029272054,0.0008253779,0.0000038676376],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000508533,0.00047470053,0.9422676,0.00009796158,0.0023932229,0.0000038605963,0.00049744087,0.00019405477,0.003992407,0.043183874,0.0049670893,0.0014192724],"study_design_scores_gemma":[0.004226381,0.00008454134,0.8598394,0.00004534164,0.0011958334,0.00007630466,0.000043003158,0.021265324,0.004113018,0.050119657,0.058614593,0.00037661058],"about_ca_topic_score_codex":0.000041171963,"about_ca_topic_score_gemma":0.00003981704,"teacher_disagreement_score":0.082428195,"about_ca_system_score_codex":0.000052068208,"about_ca_system_score_gemma":0.000077480436,"threshold_uncertainty_score":0.60122967},"labels":[],"label_agreement":null},{"id":"W2356090071","doi":"","title":"Evaluation and Analysis of The Component Ratio of The Drug Income in Outpatient","year":2012,"lang":"en","type":"article","venue":"Zhongguo yiyuan yongyao pingjia yu fenxi","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Beijing; Drug; Quarter (Canadian coin); Medicine; Outpatient clinic; Pharmacology; Internal medicine; Geography","score_opus":0.064307456535151,"score_gpt":0.29497056160434987,"score_spread":0.23066310506919885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2356090071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99207634,0.0015731684,0.000038488204,0.0010057663,0.0004574134,0.0004046313,0.00013864368,0.000004435077,0.004301133],"genre_scores_gemma":[0.99934894,0.00010461652,0.000039241342,0.00034571235,0.000044738335,0.00002223091,0.000006882904,0.000012249489,0.000075365366],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998424,0.00011591139,0.000864072,0.00021854819,0.00010493633,0.00027252737],"domain_scores_gemma":[0.99864954,0.00010701955,0.0006511932,0.00046160386,0.000053601998,0.000077046774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021412666,0.00013930284,0.00048316192,0.00032099854,0.00008236161,0.000022932454,0.00032375893,0.00006721708,0.00018653832],"category_scores_gemma":[0.00021032992,0.0001091028,0.00022564002,0.0007544286,0.00014632755,0.00016640838,0.0002119779,0.0001754789,0.000012407452],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007810044,0.00013527356,0.951349,0.000026856023,0.00024255073,2.3049239e-8,0.0020691757,0.0016410683,0.000083626524,0.04374595,0.00009043155,0.00060818356],"study_design_scores_gemma":[0.0005030318,0.0000105020035,0.93469316,0.000022013897,0.00016996342,3.6039975e-7,0.000060426966,0.058275167,0.00067597005,0.0033177647,0.002147289,0.00012434246],"about_ca_topic_score_codex":0.0005760505,"about_ca_topic_score_gemma":0.00020490786,"teacher_disagreement_score":0.0566341,"about_ca_system_score_codex":0.00017453171,"about_ca_system_score_gemma":0.000035828565,"threshold_uncertainty_score":0.44490832},"labels":[],"label_agreement":null},{"id":"W2356112331","doi":"10.1002/hec.3348","title":"Inducing optimal substitution between antibiotics under open access to the resource of antibiotic susceptibility","year":2016,"lang":"en","type":"article","venue":"Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Université Laval","funders":"Fonds de Recherche du Québec-Société et Culture","keywords":"Antibiotics; Subsidy; Resource (disambiguation); Quality (philosophy); Economics; Environmental economics; Business; Biology; Computer science; Microbiology","score_opus":0.2565137280104969,"score_gpt":0.4085173708935644,"score_spread":0.1520036428830675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2356112331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93626684,0.00024327505,0.004489868,0.052030917,0.0004072819,0.0009752455,0.0009586607,0.000024637557,0.004603292],"genre_scores_gemma":[0.9906405,0.0006062443,0.000529913,0.0077340193,0.00030360126,0.000002733063,0.000017686387,0.000037121492,0.00012816534],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99720854,0.000060459,0.0014086532,0.00066846964,0.000023654386,0.0006302399],"domain_scores_gemma":[0.9975625,0.00034727415,0.00081931404,0.0008621065,0.00003123424,0.00037752645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023658855,0.00022146042,0.0007672265,0.00021686697,0.0002505117,0.0003017538,0.0017161221,0.00013515656,0.00018608014],"category_scores_gemma":[0.00019665343,0.00018446872,0.00012148744,0.0002410146,0.00017207551,0.00073743117,0.0009693149,0.0001910535,0.00046226953],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011881236,0.0001962566,0.3691283,0.0001765816,0.00016365542,4.7661786e-7,0.00052204053,0.0058833566,0.000037784197,0.59267247,0.0069595887,0.024140684],"study_design_scores_gemma":[0.002309409,0.0003640174,0.47707266,0.00016543806,0.000020721902,0.00000456169,0.00011210231,0.002582866,0.0025733926,0.02777944,0.486086,0.000929378],"about_ca_topic_score_codex":0.000899343,"about_ca_topic_score_gemma":0.0003882424,"teacher_disagreement_score":0.564893,"about_ca_system_score_codex":0.0005919209,"about_ca_system_score_gemma":0.00027531743,"threshold_uncertainty_score":0.7522416},"labels":[],"label_agreement":null},{"id":"W2356701730","doi":"","title":"Investigation of Connotation and Way of Payment of Pharmaceutical Service Fee in Medical Institutions in China","year":2011,"lang":"en","type":"article","venue":"Zhongguo yaofang","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Payment; China; Fee-for-service; Service (business); Connotation; Medical prescription; Marketing; Medicine; Finance; Pharmacology; Health care; Economic growth; Economics; Law; Political science","score_opus":0.14742560366257068,"score_gpt":0.3188041699350903,"score_spread":0.17137856627251963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2356701730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98778695,0.00038297026,0.00009549923,0.00085879286,0.00008425568,0.00014849208,0.000075779855,0.0000037388083,0.010563533],"genre_scores_gemma":[0.9989724,0.00034405783,0.00028536917,0.00035305138,0.000014197988,0.000009900498,0.000009629548,0.000006534294,0.00000484111],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988176,0.000024290455,0.0008101474,0.00016592066,0.000038609916,0.00014343808],"domain_scores_gemma":[0.9994599,0.000058647955,0.00025509435,0.0001099312,0.000020327067,0.00009608099],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006139555,0.00008158475,0.00032603132,0.00029327936,0.000012076863,0.0000031931181,0.000121136036,0.00009238089,0.00028323816],"category_scores_gemma":[0.00012882821,0.00009435298,0.000033111475,0.0003095401,0.00016115705,0.00014565793,0.00005767025,0.0001344033,0.0000096999265],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047634527,0.00014718706,0.5010519,0.0002456191,0.000026033767,0.000002316701,0.0043999045,0.000051898238,0.00077955093,0.49150008,0.000017320594,0.0017305835],"study_design_scores_gemma":[0.0017439985,0.000056595014,0.9428494,0.00013827306,0.0000085904085,0.0000030056256,0.00010435178,0.014358772,0.011720301,0.028136652,0.0007177758,0.00016231678],"about_ca_topic_score_codex":0.0017652992,"about_ca_topic_score_gemma":0.00043552055,"teacher_disagreement_score":0.4633634,"about_ca_system_score_codex":0.0000387264,"about_ca_system_score_gemma":0.00005594756,"threshold_uncertainty_score":0.3847603},"labels":[],"label_agreement":null},{"id":"W2395091928","doi":"","title":"Promotion of drugs and devices at international conferences held in Canada.","year":2009,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Promotion (chess); Medicine; Business; Political science; Law","score_opus":0.05734305370875159,"score_gpt":0.23976745933885776,"score_spread":0.18242440563010617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2395091928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9393659,0.00034836069,0.0000030181097,0.007993813,0.00015112935,0.00013025552,0.00007298212,0.0000026068137,0.05193189],"genre_scores_gemma":[0.9987404,0.00020289482,0.000011087856,0.0007927164,0.000029697901,0.000030594387,0.000005596371,0.0000021126964,0.00018491696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994549,0.0000037901161,0.00026548575,0.00012437365,0.000014964477,0.00013647735],"domain_scores_gemma":[0.99974895,0.000019529098,0.00011719085,0.000049358576,0.0000075343632,0.000057469315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017021425,0.00004754413,0.00013865542,0.000079223435,0.000011845088,0.000014410964,0.00008918928,0.00002097317,0.00008226349],"category_scores_gemma":[0.000025985522,0.00005447399,0.000013253061,0.000045708555,0.000015505935,0.0000839679,0.000022348848,0.000040006445,0.0000041661137],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025534087,0.000062850784,0.72020775,0.000019845531,0.000026527483,0.0000013076124,0.00018711225,0.000023350289,0.0000039245083,0.18529968,0.00070801785,0.09343408],"study_design_scores_gemma":[0.00028260218,0.000004844371,0.95763534,0.000002517722,8.8022756e-7,7.325002e-7,0.000013812185,0.0011545442,0.00015342665,0.012123783,0.028556745,0.0000707688],"about_ca_topic_score_codex":0.110431194,"about_ca_topic_score_gemma":0.31018338,"teacher_disagreement_score":0.23742758,"about_ca_system_score_codex":0.0001759723,"about_ca_system_score_gemma":0.000038775746,"threshold_uncertainty_score":0.8954925},"labels":[],"label_agreement":null},{"id":"W2395780527","doi":"10.5539/gjhs.v9n1p163","title":"Requirements and Incentives for Implementation of Pharmaceutical Strategic Purchasing in Iranian Health System: A Qualitative Study","year":2016,"lang":"en","type":"article","venue":"Global Journal of Health Science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Snowball sampling; Purchasing; Incentive; Reimbursement; Business; Payment; Qualitative research; Marketing; Pharmaceutical industry; Profit margin; Service provider; Health care; Service (business); Economics; Medicine; Finance","score_opus":0.2514656708275062,"score_gpt":0.5104479060088445,"score_spread":0.2589822351813383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2395780527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913167,0.0011896244,0.0015069321,0.0048236703,0.00030997372,0.0005250337,0.0001844133,0.0000025138997,0.00014116729],"genre_scores_gemma":[0.9988156,0.0002806557,0.000561723,0.0002956653,0.000037246315,0.000004545347,2.4048867e-7,0.0000035317921,7.816884e-7],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9976814,0.00008141102,0.0015104335,0.00022576281,0.00008796062,0.0004130523],"domain_scores_gemma":[0.99820846,0.000058567388,0.0013373361,0.000076739394,0.000078795114,0.00024008045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0071839583,0.00008806017,0.00046079117,0.00023412725,0.00012706248,0.00003883918,0.00021770503,0.0000159943,0.000007753329],"category_scores_gemma":[0.00004053737,0.00007371492,0.000041303,0.00032005884,0.00020089681,0.00045332452,0.000046099012,0.000059483333,0.0000018256046],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035425104,0.0005819193,0.41033453,0.0006945191,0.00008212088,0.0000031037093,0.018349322,0.000013117587,0.0002006266,0.50805956,0.0000883279,0.061238635],"study_design_scores_gemma":[0.02983581,0.0077777784,0.63963294,0.001174987,0.000023107537,0.00013771906,0.18918344,0.0025119868,0.0002669166,0.12714526,0.001569049,0.0007410219],"about_ca_topic_score_codex":0.00036907525,"about_ca_topic_score_gemma":0.000063613596,"teacher_disagreement_score":0.38091427,"about_ca_system_score_codex":0.00090788706,"about_ca_system_score_gemma":0.00054351566,"threshold_uncertainty_score":0.3006007},"labels":[],"label_agreement":null},{"id":"W2395935292","doi":"10.1016/j.jval.2016.03.154","title":"A Comparison of Cardiovascular Drugs Approved by the Us Food and Drug Administration and Health Canada (1980-2014)","year":2016,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Food and drug administration; Drug; Medicine; Administration (probate law); Drug administration; Pharmacology; Business; Political science; Law","score_opus":0.07895263609743292,"score_gpt":0.3073892872669409,"score_spread":0.228436651169508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2395935292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9049203,0.03929053,0.00019235586,0.053980783,0.00018196467,0.00045449642,0.000509279,0.0000065987265,0.0004637231],"genre_scores_gemma":[0.9941582,0.0038316646,0.000056796605,0.0018608219,0.00003774193,0.000014086833,0.000005051039,0.00001123766,0.000024378181],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99859256,0.00007473399,0.000728443,0.00027796865,0.000037985596,0.00028830857],"domain_scores_gemma":[0.9991121,0.00012957731,0.00033231746,0.00023927253,0.0000086433965,0.00017803858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015228746,0.00010548569,0.00051599956,0.00005817421,0.000086240674,0.000019265284,0.00010398129,0.00003453236,0.000006317329],"category_scores_gemma":[0.00003244662,0.00008513397,0.00004403994,0.00007479154,0.00006678326,0.00006106346,0.00003469652,0.0001065764,0.0000024822946],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011065624,0.00039726647,0.28962237,0.0015730255,0.000542744,0.000001080877,0.007268574,0.0014617089,0.000010770378,0.51895356,0.09088399,0.089174256],"study_design_scores_gemma":[0.0027801085,0.0005149457,0.030188909,0.000116512776,0.0000094222,0.0000075672824,0.00031508258,0.020260092,0.0002472155,0.012494805,0.93264234,0.00042298282],"about_ca_topic_score_codex":0.5852434,"about_ca_topic_score_gemma":0.08086071,"teacher_disagreement_score":0.8417584,"about_ca_system_score_codex":0.00026099753,"about_ca_system_score_gemma":0.00041161315,"threshold_uncertainty_score":0.9359112},"labels":[],"label_agreement":null},{"id":"W2396616515","doi":"","title":"Combination Pharmacotherapy to Prevent Cardiovascular Disease: Present Status and Challenges","year":2013,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"","keywords":"Pill; Medicine; Tolerability; Polypill; Intensive care medicine; Combination therapy; Pharmacotherapy; Aspirin; Disease; Statin; Pharmacology; Internal medicine; Adverse effect","score_opus":0.0384150897321311,"score_gpt":0.2703013156562675,"score_spread":0.23188622592413644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2396616515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5152808,0.438633,0.001386078,0.039751884,0.00037672155,0.0007494084,0.000031948028,0.000031838503,0.0037583187],"genre_scores_gemma":[0.71013504,0.28864762,0.000020063631,0.00056599476,0.00022444152,0.00004197475,0.0000018848128,0.00002108213,0.00034191628],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99789894,0.000034115208,0.0003456364,0.00028429026,0.0000493524,0.0013876405],"domain_scores_gemma":[0.9992407,0.00002218582,0.000110325265,0.00019157592,0.00003012922,0.0004051052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097530935,0.00014287526,0.0002711278,0.00015987869,0.00010950576,0.00010884187,0.00016282743,0.000038405346,0.00019201628],"category_scores_gemma":[0.000023963388,0.0001539952,0.0001638588,0.00006974992,0.000024559973,0.0002697079,0.000044781867,0.0004704027,0.00030514254],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029354174,0.0002411704,0.0018068941,0.000029271909,0.0010770817,0.0000010522887,0.00030430677,0.00042640758,0.000023875029,0.84805584,0.00059621554,0.14740852],"study_design_scores_gemma":[0.0008810247,0.00012455603,0.007114731,0.0000061832884,0.00002162931,0.000012655141,0.000085012376,0.0017047357,0.000031276144,0.6059909,0.3837925,0.00023483766],"about_ca_topic_score_codex":0.00015065895,"about_ca_topic_score_gemma":0.000014750619,"teacher_disagreement_score":0.38319626,"about_ca_system_score_codex":0.00049594423,"about_ca_system_score_gemma":0.00015872571,"threshold_uncertainty_score":0.6279742},"labels":[],"label_agreement":null},{"id":"W2396658021","doi":"10.1097/mlr.0000000000000577","title":"The Impact of Price-cap Regulations on Exit by Generic Pharmaceutical Firms","year":2016,"lang":"en","type":"article","venue":"Medical Care","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre for Advancing Health Outcomes; Memorial University of Newfoundland; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Formulary; Competitor analysis; Business; Generic drug; Market share; Product (mathematics); Medical prescription; Poisson regression; Finance; Marketing; Medicine; Drug; Environmental health","score_opus":0.06535781078046521,"score_gpt":0.34338033349475494,"score_spread":0.27802252271428973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2396658021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.856836,0.009845036,0.0008291814,0.027901702,0.00077568804,0.00040978496,0.0015418377,0.000059873244,0.10180087],"genre_scores_gemma":[0.9961451,0.0021159607,0.0000151279055,0.00093057007,0.00023379308,0.00002190394,0.000013280097,0.000019864141,0.00050437025],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987302,0.000025233863,0.0005225722,0.0002645692,0.000082382234,0.00037506124],"domain_scores_gemma":[0.9987454,0.000361325,0.00015957224,0.00032089412,0.00003213571,0.00038069632],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00037324143,0.00013938684,0.00027450456,0.000096549236,0.00011747169,0.000024981347,0.00037815716,0.00013098105,0.003285844],"category_scores_gemma":[0.00043056198,0.00008230862,0.00022021533,0.00020005995,0.00022895998,0.00006158941,0.00007488395,0.00017139022,0.00053495937],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023856704,0.00042743416,0.0524096,0.00007419912,0.00043237858,0.000009392856,0.00082205806,0.00006709346,0.0006831205,0.30895215,0.48443532,0.15144868],"study_design_scores_gemma":[0.0019910522,0.00027474118,0.0291284,0.00003964527,0.00001080539,0.000005629413,0.000036915,0.004094811,0.00092302216,0.016303346,0.94682646,0.0003651727],"about_ca_topic_score_codex":0.0000692189,"about_ca_topic_score_gemma":0.000005409473,"teacher_disagreement_score":0.46239114,"about_ca_system_score_codex":0.00016170503,"about_ca_system_score_gemma":0.000064980355,"threshold_uncertainty_score":0.9976253},"labels":[],"label_agreement":null},{"id":"W2396728641","doi":"10.1213/ane.0000000000000798","title":"Survey of the National Drug Shortage Effect on Anesthesia and Patient Safety","year":2015,"lang":"en","type":"article","venue":"Anesthesia & Analgesia","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Windsor Regional Hospital","funders":"","keywords":"Medicine; Economic shortage; Confidence interval; Neostigmine; Family medicine; Anesthesia; Internal medicine","score_opus":0.05259130024727278,"score_gpt":0.27238286665967737,"score_spread":0.2197915664124046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2396728641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986267,0.0008100733,0.000004083995,0.005182081,0.000043997075,0.00025132837,0.00003907713,0.000015123097,0.007387292],"genre_scores_gemma":[0.9947469,0.00006338811,0.00001803033,0.004945814,0.000040188308,0.000012324065,0.000013292752,0.00002420004,0.00013582387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985896,0.00013782189,0.00057271606,0.00034562883,0.000097459204,0.0002568082],"domain_scores_gemma":[0.9989089,0.00025754047,0.00030963376,0.00027052,0.00006981063,0.00018363628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001508084,0.000200747,0.00044144693,0.00013074491,0.00009072441,0.00004303002,0.00028145965,0.00008541997,0.00005647568],"category_scores_gemma":[0.00017226663,0.00016816516,0.000115500814,0.0002602655,0.00013518502,0.00010290124,0.00003647764,0.0001642426,0.00013409407],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032506717,0.00021914304,0.7951743,0.00003998783,0.00011692448,0.000023979646,0.0007239345,0.00040105602,0.000010199996,0.18164502,0.018618265,0.0027020937],"study_design_scores_gemma":[0.0006516701,0.0002332121,0.9145285,0.00001696791,0.000009889665,0.000059019494,0.000012741715,0.0019436615,0.0002769597,0.005021911,0.07696674,0.00027876746],"about_ca_topic_score_codex":0.000606014,"about_ca_topic_score_gemma":0.000048886228,"teacher_disagreement_score":0.1766231,"about_ca_system_score_codex":0.00010046505,"about_ca_system_score_gemma":0.000058958532,"threshold_uncertainty_score":0.68575764},"labels":[],"label_agreement":null},{"id":"W2396932950","doi":"","title":"[Mechanism and implication of regulation of the pricing of essential medicines in the private pharmaceutical sector in Mali].","year":2010,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Restructuring; Private sector; Government (linguistics); Public sector; Context (archaeology); Pharmaceutical industry; Business; Distribution (mathematics); Public policy; Public economics; Economics; Finance; Economic growth; Medicine","score_opus":0.04394840788607885,"score_gpt":0.27383884559906213,"score_spread":0.2298904377129833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2396932950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955396,0.000085738466,0.000049154514,0.0023526116,0.00014546678,0.00043210492,0.000022012486,0.0000016094431,0.0013716788],"genre_scores_gemma":[0.99959934,0.00006969023,0.000035643232,0.00016483628,0.000049436367,0.00006817503,0.0000012964075,0.0000051401653,0.0000064450924],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99920523,0.000019987981,0.0004990328,0.00011814934,0.000026450292,0.00013113223],"domain_scores_gemma":[0.9994187,0.00009227088,0.00028237604,0.00017033606,0.000011599969,0.000024718394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095684495,0.000054568147,0.0001886372,0.0001187605,0.000012651481,0.0000055128266,0.0001698425,0.00005335714,0.000021211976],"category_scores_gemma":[0.00013182497,0.000041382325,0.000033385502,0.00019551083,0.00009563241,0.000061007,0.000045361845,0.00013476943,4.9503456e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003273625,0.000093609844,0.15663381,0.000101022706,0.000013836023,8.791904e-8,0.00064129947,0.000023085164,0.016346285,0.8215063,0.000018327175,0.004589608],"study_design_scores_gemma":[0.00050469785,0.0000049458395,0.90218216,0.0000051704073,0.0000047276226,0.0000013813874,0.00001191287,0.0026084366,0.025770377,0.068316676,0.0005467606,0.000042777],"about_ca_topic_score_codex":0.00010591974,"about_ca_topic_score_gemma":0.000049004557,"teacher_disagreement_score":0.7531896,"about_ca_system_score_codex":0.000013390081,"about_ca_system_score_gemma":0.0000074868194,"threshold_uncertainty_score":0.16875222},"labels":[],"label_agreement":null},{"id":"W2397649954","doi":"10.1016/j.jval.2016.03.655","title":"Evaluating The Cost Effectiveness of Personalised Medicine Co-Dependent Technologies: A Conceptual Framework","year":2016,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Test (biology); Point (geometry); Personalized medicine; Medicine; Health care; Marginal cost; Actuarial science; Computer science; Mathematics; Economics","score_opus":0.2810152615169229,"score_gpt":0.43742987770943853,"score_spread":0.15641461619251562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2397649954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9453673,0.008778394,0.004069115,0.03439109,0.00061657326,0.0015360644,0.000384722,0.00007426942,0.0047825123],"genre_scores_gemma":[0.9974511,0.0012651215,0.00020426823,0.0008728848,0.00007658975,0.00008158068,0.0000021502215,0.000016258069,0.000030026922],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9982142,0.00021770698,0.00080957275,0.00032718017,0.00005718339,0.0003741874],"domain_scores_gemma":[0.996354,0.0027555123,0.00045057957,0.00034642706,0.00002244029,0.00007108434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005475842,0.00013044114,0.000526452,0.00016934721,0.000077599274,0.000008190731,0.0003477092,0.00011777165,0.0002316301],"category_scores_gemma":[0.0018762415,0.00008712456,0.00006133369,0.00022264711,0.00044704293,0.000063974294,0.000058936334,0.0002497284,0.00008870772],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000115288945,0.00006410731,0.024610627,0.00017681578,0.000033151508,9.439024e-7,0.001379051,0.00066304696,0.00016126616,0.9640189,0.00015329446,0.008623527],"study_design_scores_gemma":[0.008340635,0.0019810954,0.029884009,0.002609921,0.0000115662915,0.000012294899,0.002049774,0.02540341,0.0013387037,0.89811975,0.029583974,0.00066487084],"about_ca_topic_score_codex":0.0014128188,"about_ca_topic_score_gemma":0.0000057239085,"teacher_disagreement_score":0.06589913,"about_ca_system_score_codex":0.00038782795,"about_ca_system_score_gemma":0.00011093999,"threshold_uncertainty_score":0.35528362},"labels":[],"label_agreement":null},{"id":"W2398268096","doi":"","title":"Pharmaceutical Pricing and Market Access Outlook Europe 2010-HealthNetwork Communications' fourth annual conference. 24-25 March 2010, London, UK.","year":2010,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Drug pricing; Market access; Business; Economics; Actuarial science; Geography; Economic growth; Health care","score_opus":0.12864864562859257,"score_gpt":0.3261058709861791,"score_spread":0.19745722535758653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2398268096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.42594087,0.011128804,0.0014717694,0.13753192,0.0116582895,0.005076035,0.0025129884,0.00035270842,0.40432662],"genre_scores_gemma":[0.97787106,0.0087990975,0.00078486244,0.005709607,0.00060376653,0.00055231835,0.000040927254,0.00006347925,0.0055748983],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973544,0.000083817475,0.0009240649,0.00060871866,0.00005730889,0.00097168965],"domain_scores_gemma":[0.9974517,0.00037417182,0.00037910606,0.0009710333,0.00010945101,0.0007145444],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001981534,0.00029291032,0.00056445383,0.00027906382,0.00030245347,0.00041817914,0.0012658552,0.00020310028,0.00106739],"category_scores_gemma":[0.00033474236,0.00033581784,0.00009071109,0.00032405427,0.00041222398,0.0005072918,0.00094046193,0.0011275087,0.00025219814],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025763526,0.000483276,0.3291666,0.00022786221,0.00029712007,0.000012775564,0.0005485931,0.000017404864,0.000013649966,0.24493322,0.2483353,0.17570658],"study_design_scores_gemma":[0.0009855477,0.000013764501,0.30405554,0.000006161015,0.000017517288,0.000017902488,0.00001105842,0.009297146,0.000016853755,0.008220258,0.6769642,0.00039406068],"about_ca_topic_score_codex":0.00024510516,"about_ca_topic_score_gemma":0.00018765463,"teacher_disagreement_score":0.5519302,"about_ca_system_score_codex":0.00008051891,"about_ca_system_score_gemma":0.000063815285,"threshold_uncertainty_score":0.9999094},"labels":[],"label_agreement":null},{"id":"W2398445710","doi":"","title":"We may lose dementia drugs that work.","year":2005,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alzheimer Society of Canada","funders":"","keywords":"Dementia; Work (physics); Psychology; Medicine; Engineering; Internal medicine; Disease","score_opus":0.08378079117423873,"score_gpt":0.2527808837611113,"score_spread":0.16900009258687257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2398445710","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3387014,0.012464026,0.00016369676,0.06480244,0.0011520772,0.0008399165,0.0002266312,0.0001372127,0.5815126],"genre_scores_gemma":[0.9869656,0.0009658326,0.00016979086,0.005307807,0.00046480354,0.00035695953,0.00000716018,0.000028521928,0.0057335114],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986271,0.000008881785,0.00041091253,0.00033906562,0.000023703858,0.0005903386],"domain_scores_gemma":[0.9992399,0.000039538427,0.0001696643,0.00028699258,0.0000062082354,0.0002576695],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00047177606,0.00014958323,0.00026913494,0.00015669677,0.00006726537,0.000110503956,0.00028171772,0.00008379864,0.001036529],"category_scores_gemma":[0.00002502538,0.0001778519,0.00013142702,0.00014913925,0.000047873364,0.0002599574,0.00009308792,0.00015338433,0.0031437704],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000341861,0.0002224495,0.08469373,0.000026890682,0.00028568602,0.000002079362,0.0005160198,0.00009780065,6.280562e-7,0.27633205,0.065570086,0.5722184],"study_design_scores_gemma":[0.00051134796,0.0000023832567,0.08556174,0.0000017084519,0.000008661497,7.3373633e-7,0.000008711144,0.00024333494,0.0001297695,0.012062558,0.90124285,0.00022619207],"about_ca_topic_score_codex":0.000018943707,"about_ca_topic_score_gemma":0.0000061271885,"teacher_disagreement_score":0.8356728,"about_ca_system_score_codex":0.00011927011,"about_ca_system_score_gemma":0.000007145088,"threshold_uncertainty_score":0.9998767},"labels":[],"label_agreement":null},{"id":"W2399061482","doi":"","title":"British Columbia poised to reduce drug coverage.","year":2002,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Government (linguistics); Medical prescription; Columbia university; Public administration; Political science; Prescription drug; Plan (archaeology); Medicine; History; Sociology; Media studies; Pharmacology","score_opus":0.05428801188230593,"score_gpt":0.22727636791817726,"score_spread":0.17298835603587134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2399061482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.67150205,0.0010934016,0.000038168302,0.006422548,0.00078651437,0.0007237138,0.00032904538,0.000074789015,0.31902978],"genre_scores_gemma":[0.9454905,0.0004267668,0.00005749493,0.009596112,0.00029842835,0.00062679476,0.0000058033493,0.00003167246,0.043466475],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99849635,0.000010317566,0.00046713694,0.00042049334,0.000024335135,0.00058135606],"domain_scores_gemma":[0.99912333,0.000037757567,0.0001162873,0.00027837054,0.000014345357,0.00042988028],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0003405067,0.000097489254,0.00030989762,0.000075955926,0.00008763807,0.0005416011,0.00028601039,0.000060969684,0.007524408],"category_scores_gemma":[0.00015296422,0.00019665054,0.00010983529,0.00022022115,0.000033428365,0.00018140326,0.000081197664,0.0001389206,0.0021622863],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000006448834,0.00015432003,0.018251555,0.00001574214,0.000051395447,0.000012912105,0.00014931157,0.000032699296,0.0000017683516,0.0052898903,0.82636344,0.14967051],"study_design_scores_gemma":[0.00062723574,0.00000630943,0.20731628,0.00000254484,0.0000030527394,0.000007981979,0.0000029510616,0.0004020855,0.000014945283,0.011765435,0.77957714,0.0002740385],"about_ca_topic_score_codex":0.0049374634,"about_ca_topic_score_gemma":0.0019230065,"teacher_disagreement_score":0.27556333,"about_ca_system_score_codex":0.00013671524,"about_ca_system_score_gemma":0.0000039953115,"threshold_uncertainty_score":0.99861467},"labels":[],"label_agreement":null},{"id":"W2399173259","doi":"10.1016/j.jval.2016.03.1274","title":"ANALYSIS OF TRENDS IN UTILIZATION AND COST OF INSULIN IN THE UNITED STATES AND CANADA","year":2016,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Insulin; Unit (ring theory); Quarter (Canadian coin); Business; Medicine; Agricultural economics; Agricultural science; Geography; Economics; Internal medicine; Environmental science","score_opus":0.1408378403607111,"score_gpt":0.3340619785729026,"score_spread":0.1932241382121915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2399173259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99460995,0.00093130756,0.000017706796,0.003793143,0.000016109674,0.00006813999,0.00033524618,6.2012344e-7,0.00022778101],"genre_scores_gemma":[0.99254555,0.006737819,0.0000100346415,0.00066808047,0.00000315539,0.0000030917872,0.000023084187,0.0000027746728,0.000006408122],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991825,0.000047688016,0.0005238169,0.0001117768,0.000013481943,0.000120717246],"domain_scores_gemma":[0.9995148,0.00018214004,0.00017640303,0.000085559324,0.0000056622553,0.000035407484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007351918,0.000044430344,0.00026311088,0.0008248901,0.000008599259,0.000003852199,0.000056096345,0.000023296941,0.000024506773],"category_scores_gemma":[0.00004439318,0.00003580138,0.000011749055,0.0008432206,0.00003359318,0.00003372882,0.000013394892,0.000044213055,1.5751674e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014747801,0.000037815505,0.9480302,0.000032038384,0.000018159382,3.9640435e-7,0.00089743757,0.0054800496,7.5059705e-7,0.0364017,0.0000596585,0.009027073],"study_design_scores_gemma":[0.00059945823,0.000025472824,0.8269954,0.000016889046,0.0000029576852,1.5797248e-7,0.000086878325,0.16223134,0.00000542698,0.0027736595,0.007213825,0.00004857844],"about_ca_topic_score_codex":0.8847222,"about_ca_topic_score_gemma":0.6468949,"teacher_disagreement_score":0.23782733,"about_ca_system_score_codex":0.00010788159,"about_ca_system_score_gemma":0.000051629188,"threshold_uncertainty_score":0.3595484},"labels":[],"label_agreement":null},{"id":"W2399640665","doi":"10.1016/j.jval.2016.03.754","title":"Prescription Factors Associated With A Do Not Substitute Prescription In Canada","year":2016,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"","keywords":"Medical prescription; Medicine; Specialty; Generic drug; Family medicine; Pharmacist; Brand names; Pharmacy; Drug; Pharmacology; Business; Advertising","score_opus":0.126930399827186,"score_gpt":0.2746551098800359,"score_spread":0.14772471005284987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2399640665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937989,0.00042426167,0.00008552869,0.0032528844,0.00038553518,0.00030613143,0.00035970085,0.000014068214,0.0013729769],"genre_scores_gemma":[0.99840516,0.00041771276,0.00002072842,0.0009594117,0.00003639945,0.000022035309,0.000011605152,0.000018070867,0.00010888222],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983859,0.000056281937,0.00070036907,0.0003371248,0.000040812098,0.00047950927],"domain_scores_gemma":[0.99922055,0.000118519885,0.00030147453,0.00018450052,0.000011534156,0.00016343559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006441749,0.00013593664,0.0003578155,0.00021960818,0.00004090143,0.000026118774,0.00014098306,0.00006371985,0.00009165845],"category_scores_gemma":[0.00016604306,0.000118529606,0.000028781693,0.00022031435,0.000026115804,0.00024157086,0.000022183103,0.0001554715,0.000026052243],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050220002,0.00008220084,0.918658,0.000043027034,0.000017843699,0.0000038325998,0.00039942458,0.0026431861,0.000026032945,0.07641173,0.00068596745,0.0009785384],"study_design_scores_gemma":[0.0018982595,0.00007777406,0.96542156,0.00022623334,0.0000014601065,6.7483796e-7,0.000034799235,0.008892456,0.000073316885,0.010269735,0.012801528,0.00030218053],"about_ca_topic_score_codex":0.8746451,"about_ca_topic_score_gemma":0.7282126,"teacher_disagreement_score":0.1464325,"about_ca_system_score_codex":0.0033880274,"about_ca_system_score_gemma":0.0005966977,"threshold_uncertainty_score":0.88595736},"labels":[],"label_agreement":null},{"id":"W2401695302","doi":"10.1016/j.jval.2016.03.1507","title":"Oncology Drugs Lag Between Europe and other Countries: Comparaison between EMA and others Agencies (FDA, Health Canada, TGA, and Swissmedic)","year":2016,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Food and drug administration; Drug approval; Agency (philosophy); Regulatory affairs; Drug; Regulatory agency; Family medicine; Internal medicine; Oncology; Pharmacology; Operations management; Political science","score_opus":0.1278358697310247,"score_gpt":0.3378959370583687,"score_spread":0.21006006732734397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2401695302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9072931,0.011553367,0.00008535012,0.07529918,0.00019745168,0.00041244703,0.0014461789,0.000019879999,0.0036930873],"genre_scores_gemma":[0.9743453,0.009495461,0.00013716123,0.015505901,0.00024453495,0.000009309288,0.0000050740464,0.000035778186,0.00022145802],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978254,0.00012507672,0.0009301963,0.00046589307,0.000044069668,0.0006094074],"domain_scores_gemma":[0.9981652,0.00065707875,0.00043594994,0.00018938366,0.000012897913,0.00053950096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017170793,0.00019642506,0.0008416882,0.00018485327,0.00015147141,0.000037063037,0.00013560936,0.00009568373,0.00006232489],"category_scores_gemma":[0.00007633914,0.00018364734,0.000020339792,0.00012682399,0.00024005614,0.00009629213,0.00007974638,0.00019002685,0.000029059012],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000185195,0.000019360945,0.90128213,0.00026792786,0.000054748794,0.0000024026924,0.00352891,0.000009274087,8.4114305e-7,0.06529049,0.007579519,0.021945864],"study_design_scores_gemma":[0.001119997,0.00020153017,0.17428993,0.00008574919,0.000002981962,0.0000033141198,0.0001305352,0.00038613257,0.0000027034557,0.0049390565,0.81863594,0.00020212166],"about_ca_topic_score_codex":0.5113867,"about_ca_topic_score_gemma":0.06270328,"teacher_disagreement_score":0.81105644,"about_ca_system_score_codex":0.0006479994,"about_ca_system_score_gemma":0.00078485266,"threshold_uncertainty_score":0.95439994},"labels":[],"label_agreement":null},{"id":"W2402029394","doi":"10.12927/hcpol.2016.24626","title":"Some Numbers behind Canada’s Decision to Adopt an Orphan Drug Policy: US Orphan Drug Approvals in Canada, 1997–2012","year":2016,"lang":"en","type":"article","venue":"Healthcare policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"Dalhousie University; Canada Research Chairs; Genome Canada","keywords":"Orphan drug; Medicine; Access to medicines; Drug; Drug approval; Family medicine; Pharmacology; Bioinformatics; Public health; Biology","score_opus":0.03465915678921029,"score_gpt":0.2997397643554006,"score_spread":0.26508060756619034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2402029394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79382354,0.0013091995,0.000020291542,0.19622356,0.0009844064,0.00069365225,0.0046386076,0.00003934973,0.0022673928],"genre_scores_gemma":[0.9367478,0.0008166904,0.00020763783,0.058497008,0.0020110072,0.000080789345,0.00004467638,0.00010860288,0.0014857966],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99512845,0.000108258064,0.0015999015,0.0010676377,0.00017615926,0.0019195939],"domain_scores_gemma":[0.9959862,0.00026438994,0.000461253,0.0009908533,0.00007097248,0.0022263261],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008577773,0.0005139029,0.0009977808,0.0009778384,0.00024370546,0.00009192261,0.0008939902,0.00016091135,0.00028967473],"category_scores_gemma":[0.00039597173,0.000521906,0.00012258197,0.00063414825,0.00006773203,0.00063402293,0.00024740488,0.00038679317,0.00036006668],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00028485275,0.00024940493,0.19677876,0.00024077248,0.000104877494,0.00008439992,0.0031112542,0.00026993637,0.00003599163,0.523371,0.19797519,0.07749359],"study_design_scores_gemma":[0.0018522502,0.00006373582,0.098635696,0.00011759314,0.0000051642537,0.000020962818,0.00015592946,0.00034310922,0.00020300719,0.041786134,0.85567653,0.00113987],"about_ca_topic_score_codex":0.9998031,"about_ca_topic_score_gemma":0.9998863,"teacher_disagreement_score":0.6577014,"about_ca_system_score_codex":0.009934399,"about_ca_system_score_gemma":0.0144292135,"threshold_uncertainty_score":0.99972326},"labels":[],"label_agreement":null},{"id":"W2402061885","doi":"10.1503/cmaj.109-5281","title":"Consensus mounts for national drug formulary","year":2016,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Formulary; Parliament; Multitude; Medicine; Public administration; Political science; Family medicine; Law; Politics","score_opus":0.0324228663964499,"score_gpt":0.27053441441059506,"score_spread":0.23811154801414516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2402061885","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15171261,0.0009269898,0.0016614377,0.7054037,0.004002477,0.0003983158,0.004348924,0.000035166217,0.13151036],"genre_scores_gemma":[0.92576987,0.00018871459,0.00029437963,0.064723484,0.002888721,0.000021343463,0.000010015769,0.000026783264,0.006076669],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99867135,0.000018534878,0.00057075784,0.00015423649,0.000131761,0.00045337237],"domain_scores_gemma":[0.9980252,0.00035525655,0.00029568598,0.000057108024,0.00018203504,0.0010847466],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.002309797,0.000087032,0.00020554385,0.00020586152,0.00019649285,0.00007008642,0.00020141651,0.00018930912,0.0073454515],"category_scores_gemma":[0.0024827041,0.000079402,0.00013214274,0.00007199997,0.00003068406,0.000114805036,0.000011107548,0.00022089109,0.0010944015],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007107424,0.000015446398,0.019288,0.000004303978,0.000094544455,0.000008976425,0.000048554753,0.0000012576688,0.0000049428104,0.1762563,0.79880905,0.005461501],"study_design_scores_gemma":[0.0011001263,0.000009972274,0.0038119738,0.000009495457,0.0000019764545,0.000033515687,0.0000068686227,0.00059455226,0.000012119341,0.09427955,0.9000202,0.000119647586],"about_ca_topic_score_codex":0.00022966022,"about_ca_topic_score_gemma":0.0040391604,"teacher_disagreement_score":0.77405727,"about_ca_system_score_codex":0.0015543806,"about_ca_system_score_gemma":0.0010288522,"threshold_uncertainty_score":0.9996834},"labels":[],"label_agreement":null},{"id":"W2402672329","doi":"","title":"Prescription drug prices in Canada.","year":2003,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Drug; Prescription drug; Business; Drug prices; Medicine; Pharmacology; Economics; Public economics","score_opus":0.04747730526664789,"score_gpt":0.2104754989316394,"score_spread":0.1629981936649915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2402672329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70452213,0.0015319064,0.000032411674,0.002345957,0.0007259326,0.00038660402,0.00006519909,0.000012305129,0.29037753],"genre_scores_gemma":[0.99690694,0.00015354718,0.00004284118,0.0016363182,0.000030584575,0.00029147192,0.0000022182862,0.000009610685,0.0009264789],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991014,0.0000075062326,0.00033068046,0.00019844808,0.000014069231,0.00034788912],"domain_scores_gemma":[0.9996268,0.000025031715,0.000095648225,0.00012945301,0.000004534652,0.000118516014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003781171,0.000073995856,0.00016805527,0.000095329844,0.0000231575,0.000030293586,0.000111262845,0.00002351522,0.00017356926],"category_scores_gemma":[0.000092413764,0.0000919168,0.00002660974,0.00012664404,0.000011211095,0.00013257327,0.000014498716,0.00009470083,0.000073993324],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007261749,0.000049504783,0.26637843,0.000019897328,0.000019677538,0.0000037880668,0.000096990756,0.00016602814,7.591595e-7,0.71392643,0.012912803,0.006418443],"study_design_scores_gemma":[0.00029647737,6.6300913e-7,0.41962087,7.3964554e-7,8.442612e-7,8.442587e-7,0.000013732775,0.00034416615,0.000072102106,0.023245996,0.5562778,0.00012571506],"about_ca_topic_score_codex":0.45385516,"about_ca_topic_score_gemma":0.68154657,"teacher_disagreement_score":0.69068044,"about_ca_system_score_codex":0.00048024947,"about_ca_system_score_gemma":0.00007623145,"threshold_uncertainty_score":0.5497817},"labels":[],"label_agreement":null},{"id":"W2403383281","doi":"10.1016/s0197-2510(11)70300-x","title":"10.1016/s0197-2510(11)70300-x","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Economic shortage; Philosophy; Linguistics; Government (linguistics)","score_opus":0.02642989772515737,"score_gpt":0.2121917994619067,"score_spread":0.18576190173674934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2403383281","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024583729,0.0002640531,0.0000020583268,0.0023574764,0.000006801171,0.00017319628,0.00023784915,0.00007614078,0.99442405],"genre_scores_gemma":[0.0015654707,0.000005489183,0.00010444099,0.00089857046,0.00029918042,0.000024015291,0.000018271263,0.000040269428,0.99704427],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99860656,0.000010609955,0.00050035917,0.00040041903,0.000023574556,0.00045846446],"domain_scores_gemma":[0.9991662,0.000048764097,0.00008631914,0.0003800258,0.000013023615,0.0003056822],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00029599626,0.00018231277,0.0003616861,0.00015615998,0.00008974338,0.000094106705,0.0003495778,0.000079764504,0.9976762],"category_scores_gemma":[0.0000439437,0.00022748462,0.00012828245,0.00020109503,0.000041507632,0.00015156543,0.000061348364,0.00013651283,0.9982884],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000617502,0.0001274876,0.000009093226,0.0000132189425,0.000053349893,0.000004893662,0.000036414243,0.00030673278,0.0000049331416,0.0021745078,0.75382406,0.24338356],"study_design_scores_gemma":[0.00037304114,0.00005676325,0.00008951595,0.0000044547887,0.0000045432857,0.0000047505073,3.139285e-7,0.0022496083,0.000024039773,0.0013267692,0.9955618,0.00030439923],"about_ca_topic_score_codex":0.00009390447,"about_ca_topic_score_gemma":6.7005993e-7,"teacher_disagreement_score":0.24307916,"about_ca_system_score_codex":0.000084651125,"about_ca_system_score_gemma":0.000016494856,"threshold_uncertainty_score":0.9276554},"labels":[],"label_agreement":null},{"id":"W2404563259","doi":"10.1016/j.jval.2016.03.1271","title":"A COMPARISON OF ANTI-TYPE 2 DIABETES MELLITUS DRUGS IN CANADA, UNITED STATES, AND UNITED KINGDOM BETWEEN 1958–2015","year":2016,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Regulatory agency; Type 2 Diabetes Mellitus; Food and drug administration; Drug; Pharmacology; Diabetes mellitus; Family medicine","score_opus":0.12513342820040843,"score_gpt":0.3400936963470292,"score_spread":0.21496026814662075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2404563259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896368,0.002934693,0.00000920689,0.0063867746,0.0001550447,0.00019138503,0.0005683405,0.0000072915127,0.00011049641],"genre_scores_gemma":[0.9959464,0.0029165968,0.000064373795,0.0009468769,0.000034557586,0.0000038864932,0.000059740127,0.000018381294,0.000009191511],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979845,0.0000847679,0.0011192838,0.00028156475,0.00003465701,0.00049520406],"domain_scores_gemma":[0.9986631,0.00048766652,0.00040348672,0.00020015988,0.000021988055,0.00022357011],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090779335,0.00013451035,0.00070691155,0.0006869209,0.000033148033,0.000013167221,0.0001621105,0.000064517146,0.00003592253],"category_scores_gemma":[0.00010146583,0.00013835162,0.000022546581,0.00068436307,0.000062760504,0.000076107615,0.000056423996,0.0001724423,0.00001347799],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009620717,0.000039120143,0.97734857,0.00011047304,0.000016347341,4.4042682e-7,0.00040839275,0.0014191299,0.0000029979012,0.018472498,0.0004661787,0.0017062457],"study_design_scores_gemma":[0.0021389434,0.00015727142,0.7419036,0.00024498088,0.0000040548866,2.6698143e-7,0.00011462723,0.08316202,0.00018352641,0.015057318,0.15663537,0.00039799706],"about_ca_topic_score_codex":0.9213691,"about_ca_topic_score_gemma":0.12336217,"teacher_disagreement_score":0.7980069,"about_ca_system_score_codex":0.0006610706,"about_ca_system_score_gemma":0.0003623282,"threshold_uncertainty_score":0.8926342},"labels":[],"label_agreement":null},{"id":"W2406062760","doi":"","title":"Why are drug prices lower in Canada?","year":2000,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Drug prices; Drug; Managed care; Intensive care medicine; Family medicine; Pharmacology; Health care; Public economics; Economic growth","score_opus":0.0354474246477301,"score_gpt":0.2065476486445004,"score_spread":0.1711002239967703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2406062760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7999357,0.0011884946,0.0000022356385,0.015348588,0.0003859595,0.00027632117,0.00015644298,0.000014194265,0.18269205],"genre_scores_gemma":[0.97948825,0.00035568172,0.000014362084,0.017492454,0.00011243819,0.0002389796,0.000003019691,0.000014809529,0.002280002],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99888,0.0000057494244,0.0003801925,0.00025720295,0.000018108583,0.00045872622],"domain_scores_gemma":[0.999509,0.000033011638,0.0001009343,0.00018134182,0.000004488813,0.00017125542],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022543698,0.00010191944,0.00024750625,0.00009070571,0.000029819359,0.000041265164,0.00020835327,0.000031555686,0.0020909284],"category_scores_gemma":[0.000025335532,0.00012326565,0.00004444039,0.00015444521,0.00001846506,0.00013965937,0.000021976957,0.00012718559,0.0002703423],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009502051,0.0002682833,0.49565488,0.000059489947,0.00009439321,0.000064569496,0.00025503867,0.0011023702,3.190591e-7,0.039068166,0.3426072,0.120730266],"study_design_scores_gemma":[0.00024260077,7.5219594e-7,0.32851014,0.0000013392981,7.784782e-7,6.5874025e-7,0.0000061276764,0.0003545573,0.000008515147,0.0037134334,0.66703343,0.00012766689],"about_ca_topic_score_codex":0.58772147,"about_ca_topic_score_gemma":0.7805579,"teacher_disagreement_score":0.32442623,"about_ca_system_score_codex":0.00042234195,"about_ca_system_score_gemma":0.000046575056,"threshold_uncertainty_score":0.9988213},"labels":[],"label_agreement":null},{"id":"W2406399824","doi":"10.1016/j.jval.2016.03.219","title":"Impact Of New Entrants To The Market For Multiple-Sclerosis Disease-Modifying Drugs In Canada","year":2016,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Fingolimod; Medical prescription; Glatiramer acetate; Medicine; Teriflunomide; Dimethyl fumarate; Multiple sclerosis; Pediatrics; Family medicine; Pharmacology; Psychiatry","score_opus":0.16186943729508668,"score_gpt":0.32432642627937486,"score_spread":0.16245698898428818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2406399824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791911,0.00089546473,0.00030221176,0.01702122,0.00023278782,0.0005652867,0.0015083879,0.0000032788057,0.00028020938],"genre_scores_gemma":[0.9974928,0.0008004311,0.00012999405,0.0013962378,0.000073013915,0.000031588355,0.0000018924071,0.000015070771,0.000059002352],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986134,0.00002732113,0.0006549083,0.00022984321,0.00002353561,0.0004509582],"domain_scores_gemma":[0.9988057,0.00044774465,0.00018072934,0.00022013496,0.00000669162,0.00033899504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007136752,0.00009801626,0.00030023506,0.0001328843,0.000032360604,0.000010487443,0.00021245769,0.000022857655,0.00016664363],"category_scores_gemma":[0.00026779372,0.00007598625,0.00008546648,0.00015828,0.000011402151,0.000061855404,0.000031064217,0.00006166755,0.000013301945],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028593218,0.00006268949,0.9470824,0.000113042544,0.000025771393,4.3271984e-7,0.0007560587,0.00888707,0.000009452486,0.006392425,0.014639628,0.021745076],"study_design_scores_gemma":[0.0017777495,0.00004935061,0.9374862,0.0001334846,0.0000011223218,1.5300226e-7,0.000020471914,0.041768778,0.000016562924,0.0048696767,0.013724291,0.00015217219],"about_ca_topic_score_codex":0.92357194,"about_ca_topic_score_gemma":0.35801715,"teacher_disagreement_score":0.5655548,"about_ca_system_score_codex":0.0012803967,"about_ca_system_score_gemma":0.0011746788,"threshold_uncertainty_score":0.6536974},"labels":[],"label_agreement":null},{"id":"W2407503563","doi":"","title":"Health Canada authorizes access to experimental HIV drugs, but only after a long struggle.","year":2006,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Human immunodeficiency virus (HIV); Business; Political science; Medicine; Virology","score_opus":0.04126160815445923,"score_gpt":0.2708850276264387,"score_spread":0.22962341947197945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2407503563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9410616,0.002808722,0.0000937701,0.026770411,0.0009251443,0.0008358495,0.0012408487,0.000043083135,0.026220558],"genre_scores_gemma":[0.98476696,0.00002584414,0.000059834358,0.011246357,0.0004465461,0.00081802846,0.000024318317,0.00003312159,0.0025789968],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99806714,0.000014588207,0.0006212338,0.00045286026,0.00004424902,0.00079991383],"domain_scores_gemma":[0.9990313,0.000030180796,0.00018192855,0.00026791342,0.000010987982,0.00047770867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027714163,0.00019302592,0.0004063902,0.00015405595,0.00010096828,0.00022205718,0.00036144737,0.000052660373,0.00029773518],"category_scores_gemma":[0.000019149085,0.00023681503,0.00007880257,0.00016913154,0.000028790679,0.00025085607,0.00016086013,0.00013237067,0.00013593613],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024662784,0.00051410584,0.36574665,0.00011724851,0.00015449946,0.000044215372,0.0005235339,0.00040755933,0.0000031038837,0.100704014,0.48274314,0.048795305],"study_design_scores_gemma":[0.0005489503,0.000012149908,0.6357423,0.000003791427,0.0000020812417,0.000003816321,0.000028759952,0.00018507209,0.00027073073,0.0017110014,0.36111793,0.00037341198],"about_ca_topic_score_codex":0.39416867,"about_ca_topic_score_gemma":0.22242053,"teacher_disagreement_score":0.26999566,"about_ca_system_score_codex":0.0008573354,"about_ca_system_score_gemma":0.00018852389,"threshold_uncertainty_score":0.96570367},"labels":[],"label_agreement":null},{"id":"W2409644905","doi":"","title":"XVI International AIDS Conference. New drug classes from Toronto. Plus some older ones.","year":2007,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Human immunodeficiency virus (HIV); Media studies; Library science; Medicine; Gerontology; Sociology; Family medicine; Pharmacology; Computer science","score_opus":0.07160809336894638,"score_gpt":0.273456847412095,"score_spread":0.20184875404314864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2409644905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5264533,0.0059272093,0.0026640887,0.009566388,0.006767442,0.00075627386,0.0007360397,0.00014642025,0.44698283],"genre_scores_gemma":[0.9845789,0.0007424597,0.00029572,0.0043769614,0.0017357831,0.00008052599,0.00005643913,0.00002820229,0.008104979],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.998344,0.000006793315,0.0006310902,0.0004234766,0.00004475788,0.0005498491],"domain_scores_gemma":[0.9989809,0.000105344094,0.00022607582,0.00026086497,0.000023974608,0.0004028577],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005186004,0.00017995028,0.0003537324,0.00011212877,0.00005397607,0.00017566454,0.0004564623,0.00010814488,0.0031848592],"category_scores_gemma":[0.00008694337,0.00021318693,0.00012974301,0.00006160433,0.000053695865,0.00061290205,0.00012173344,0.00016577427,0.0006567009],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008387856,0.00013555639,0.02585095,0.000009097407,0.0002815035,0.000007976206,0.00074025814,0.000020144376,0.000005711367,0.77793235,0.039342247,0.15559034],"study_design_scores_gemma":[0.0014436383,0.0000060761163,0.3253782,0.000003573587,0.000008298267,0.0000012358836,0.00006109227,0.00056342175,0.00020023176,0.07848682,0.5935141,0.00033332486],"about_ca_topic_score_codex":0.0053742277,"about_ca_topic_score_gemma":0.0011665598,"teacher_disagreement_score":0.69944555,"about_ca_system_score_codex":0.00051836483,"about_ca_system_score_gemma":0.000048148497,"threshold_uncertainty_score":0.9977264},"labels":[],"label_agreement":null},{"id":"W2409840291","doi":"","title":"Delivery past due: global precedent set under Canada's Access to Medicines Regime.","year":2008,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Parliament; Access to medicines; Developing country; Key (lock); Public health; Political science; Public administration; Business; International trade; Law and economics; Economics; Law; Economic growth; Medicine; Computer science; Computer security; Politics","score_opus":0.1105232199363151,"score_gpt":0.278808130186546,"score_spread":0.1682849102502309,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2409840291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8547985,0.0011275421,0.00018320997,0.05946578,0.0017168557,0.00080238975,0.0008249976,0.00005202975,0.0810287],"genre_scores_gemma":[0.9733602,0.00031045685,0.000020868012,0.024526618,0.0004622563,0.0003430356,0.000017682229,0.000018440753,0.00094044476],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9984238,0.000011321486,0.0004902824,0.00040933327,0.000052288146,0.00061294966],"domain_scores_gemma":[0.9989214,0.000046084966,0.0001527374,0.00030170617,0.000028952023,0.00054914644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023129208,0.00017598928,0.0003730793,0.000067160945,0.00012070103,0.00006916236,0.0004897236,0.0000703938,0.00019330582],"category_scores_gemma":[0.00007753785,0.0001986698,0.00006911286,0.0002743716,0.000055498265,0.000194863,0.00018186722,0.00010907981,0.00014586648],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006598443,0.0000742447,0.2125134,0.00003426118,0.00016169713,0.00004747923,0.00008463813,0.0008261955,3.639052e-7,0.018274002,0.7549992,0.012918487],"study_design_scores_gemma":[0.00037509558,0.0000068015506,0.59849906,0.0000023876134,0.000004703607,0.000024482837,0.0000087715025,0.0001368036,0.000014641545,0.0019736588,0.3987392,0.00021441159],"about_ca_topic_score_codex":0.12514465,"about_ca_topic_score_gemma":0.1204436,"teacher_disagreement_score":0.38598567,"about_ca_system_score_codex":0.00066554046,"about_ca_system_score_gemma":0.00009752182,"threshold_uncertainty_score":0.89560604},"labels":[],"label_agreement":null},{"id":"W2412189619","doi":"","title":"International pharmaceutical expenditure differentials: why?","year":2004,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Product (mathematics); Harm; Balance (ability); Business; Intellectual property; State (computer science); Prescription drug; Medical prescription; Public economics; Economics; Political science; Law; Medicine","score_opus":0.0967582142415576,"score_gpt":0.29470744710448005,"score_spread":0.19794923286292243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2412189619","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23166308,0.002925132,0.006848113,0.06313059,0.008728131,0.0012672392,0.00080431683,0.0002661564,0.68436724],"genre_scores_gemma":[0.99047637,0.00056061667,0.00012278826,0.0071669933,0.0007834454,0.00040982687,0.000023860357,0.000023604363,0.00043248382],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987421,0.0000069640037,0.00042968694,0.0003444349,0.00003339971,0.0004434072],"domain_scores_gemma":[0.99938893,0.00002440443,0.00012272061,0.00018839205,0.000011063534,0.0002644808],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002461695,0.00014329607,0.0002448198,0.0001529808,0.00005841695,0.00012260921,0.00036715975,0.0000911968,0.0012716659],"category_scores_gemma":[0.0000721982,0.00016330328,0.0001344547,0.00007449804,0.000061940926,0.00022877887,0.00010271982,0.00020257947,0.00085817184],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056254215,0.00037574646,0.0069204336,0.000017894938,0.00023973282,0.000014092838,0.00017314531,0.00014586274,0.000024355246,0.93750036,0.01368913,0.04084302],"study_design_scores_gemma":[0.001382012,0.000004739997,0.024879614,0.0000017081759,0.000005543612,0.0000063658927,0.0000060175985,0.00021539199,0.00054011797,0.08329389,0.8894374,0.00022720615],"about_ca_topic_score_codex":0.00004145513,"about_ca_topic_score_gemma":0.00000407137,"teacher_disagreement_score":0.8757483,"about_ca_system_score_codex":0.00018884172,"about_ca_system_score_gemma":0.000007705391,"threshold_uncertainty_score":0.9999198},"labels":[],"label_agreement":null},{"id":"W2413309707","doi":"","title":"Removing barriers? An overview of the Canadian Access to Medicines Regime.","year":2008,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Legislature; Access to medicines; Order (exchange); Business; Public health; Intersection (aeronautics); Human immunodeficiency virus (HIV); International trade; Developing country; Economic growth; Public administration; Political science; Medicine; Economics; Law; Engineering; Finance; Transport engineering; Virology","score_opus":0.24707737555519318,"score_gpt":0.3208551707366549,"score_spread":0.07377779518146174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2413309707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82995844,0.0030795445,0.000010339681,0.048706662,0.001119418,0.0009103671,0.0002282144,0.000022783812,0.11596421],"genre_scores_gemma":[0.977328,0.00040219206,0.000020829508,0.021558039,0.00018020053,0.00011800488,0.0000018815391,0.00001563729,0.00037521028],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989548,0.000015168286,0.0003801394,0.00023167433,0.000027703943,0.00039055402],"domain_scores_gemma":[0.9987218,0.000025879497,0.00014809324,0.00040629433,0.000021977708,0.00067600264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047475862,0.00009606584,0.0002640038,0.00013310881,0.00018818275,0.00004136149,0.0006230587,0.00006120696,0.0002241653],"category_scores_gemma":[0.0003578361,0.0000882122,0.000076964774,0.00030153684,0.000085158645,0.00022883405,0.00009210185,0.00010863014,0.000041270236],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026835276,0.00004812712,0.7015051,0.00009216137,0.00011290728,0.00001146728,0.0014494432,0.00021371523,0.0000033777712,0.20010206,0.06459757,0.031837195],"study_design_scores_gemma":[0.00016214524,0.0000050869025,0.6159011,0.0000046244218,0.000003183997,0.000005769268,0.0000063332354,0.00017200135,0.00006208517,0.0044610584,0.3791023,0.00011432472],"about_ca_topic_score_codex":0.046852607,"about_ca_topic_score_gemma":0.081615984,"teacher_disagreement_score":0.3145047,"about_ca_system_score_codex":0.0001722192,"about_ca_system_score_gemma":0.000087258144,"threshold_uncertainty_score":0.9594945},"labels":[],"label_agreement":null},{"id":"W2414866897","doi":"","title":"Cancer Care Ontario's New Drug Funding Program: controlled introduction of expensive anticancer drugs.","year":2002,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Cancer drugs; Family medicine; Advisory committee; Drug; Fiscal year; Cancer; Public administration; Finance; Pharmacology; Business; Internal medicine; Political science","score_opus":0.07186099767569792,"score_gpt":0.269627058369929,"score_spread":0.19776606069423108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2414866897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8424376,0.0241959,0.00004280582,0.019016586,0.0038399491,0.0039080484,0.0002283785,0.00012691312,0.1062038],"genre_scores_gemma":[0.9863892,0.0007436234,0.0001777826,0.00073981355,0.0011932936,0.0013698374,0.00001082126,0.000028520426,0.009347073],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983104,0.000013097847,0.00068146765,0.00042018644,0.000042190124,0.00053267844],"domain_scores_gemma":[0.9989809,0.00003188538,0.0004187341,0.00026454084,0.00005563775,0.00024831243],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023258304,0.0001824406,0.0006704182,0.00019036717,0.000070372764,0.00007002424,0.00019267228,0.00007333044,0.002713393],"category_scores_gemma":[0.00007537245,0.00020234885,0.00020055064,0.00017844101,0.000073360075,0.00020904347,0.00005130626,0.00018865652,0.0001087969],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048258284,0.00044117,0.059455924,0.00016003437,0.00071403704,0.000003707866,0.023131896,0.00043940364,0.000011331972,0.10584297,0.16169904,0.64761794],"study_design_scores_gemma":[0.0070248055,0.00003286749,0.031304054,0.000008825411,0.0000615665,0.0000017282798,0.00044108852,0.0011455058,0.00043496845,0.0049485583,0.95407045,0.0005256128],"about_ca_topic_score_codex":0.018454831,"about_ca_topic_score_gemma":0.0054438035,"teacher_disagreement_score":0.7923714,"about_ca_system_score_codex":0.00058149133,"about_ca_system_score_gemma":0.000033823573,"threshold_uncertainty_score":0.9981983},"labels":[],"label_agreement":null},{"id":"W2416250252","doi":"","title":"Blame Canada. New Hampshire will defy the FDA and buy drugs on the Net.","year":2003,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Blame; Drug approval; Business; Advertising; Political science; Internet privacy; Psychology; Medicine; Computer science; Drug; Pharmacology; Psychiatry","score_opus":0.04453381333965289,"score_gpt":0.20241723532458364,"score_spread":0.15788342198493074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2416250252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.48646444,0.003946939,0.000028165354,0.1324848,0.0010448076,0.0009684045,0.00016742939,0.00002653696,0.37486848],"genre_scores_gemma":[0.97068936,0.00042152128,0.0000079552765,0.024488466,0.00017785457,0.00014500525,0.0000016881573,0.000017846098,0.004050281],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99895257,0.000023556366,0.00029130484,0.00025622663,0.000028755141,0.00044758336],"domain_scores_gemma":[0.99908906,0.00023491973,0.0001213201,0.0003252887,0.000007043626,0.00022237192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005848413,0.00013761966,0.00019572747,0.000037923743,0.00017710892,0.00012320752,0.00025323327,0.000050762057,0.00023831823],"category_scores_gemma":[0.00023722458,0.00009824454,0.000051274506,0.00012022466,0.000072163464,0.00008098389,0.000039684943,0.0002136162,0.000053380467],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007979585,0.000013964035,0.0034348343,0.0000034659927,0.000047860336,0.0000010296969,0.00019043384,0.000039299757,1.7532454e-7,0.8908336,0.090795726,0.014631634],"study_design_scores_gemma":[0.0002738561,0.0000044777535,0.024052188,0.0000013495126,0.000004495551,0.0000024982733,0.000036303165,0.00021665756,0.000040806168,0.043386716,0.93183374,0.00014691181],"about_ca_topic_score_codex":0.042082418,"about_ca_topic_score_gemma":0.02532672,"teacher_disagreement_score":0.84744686,"about_ca_system_score_codex":0.00013531577,"about_ca_system_score_gemma":0.0000900925,"threshold_uncertainty_score":0.9924585},"labels":[],"label_agreement":null},{"id":"W2417865952","doi":"","title":"A comparison of United States and Canadian laws as they affect generic pharmaceutical market entry.","year":2000,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Affect (linguistics); Business; Public economics; Law and economics; Industrial organization; International trade; Economics; Sociology","score_opus":0.07446477824861633,"score_gpt":0.30066187766914365,"score_spread":0.22619709942052732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2417865952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8272231,0.0016143313,0.0000025747827,0.0023623253,0.0001066047,0.0003599764,0.00038307617,0.000017099293,0.1679309],"genre_scores_gemma":[0.99214345,0.0029446534,0.000026096803,0.003062819,0.00007175559,0.00013399529,0.000038278766,0.00002103259,0.0015579062],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986557,0.000032304994,0.0004561381,0.0002762143,0.000023236671,0.00055642764],"domain_scores_gemma":[0.99902487,0.00009893143,0.00010670607,0.00017568869,0.000011499704,0.00058233086],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00044420015,0.0001485187,0.000394754,0.00027944276,0.00007046631,0.0000608786,0.00017386327,0.00008447789,0.002737325],"category_scores_gemma":[0.000048350397,0.00016905533,0.00006583716,0.00019055608,0.00009152197,0.00008878726,0.000028471622,0.00015691406,0.00017040895],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040708802,0.000517896,0.50588036,0.00019545112,0.0005816677,0.000019865809,0.0017039892,0.00094019226,0.000008718145,0.09924965,0.052769434,0.33772573],"study_design_scores_gemma":[0.0007581131,0.000023664319,0.16708851,0.000002808205,0.000015050349,0.000005393823,0.000020448075,0.023363886,0.00012158317,0.006276599,0.8020861,0.00023782968],"about_ca_topic_score_codex":0.03384348,"about_ca_topic_score_gemma":0.0053287605,"teacher_disagreement_score":0.7493167,"about_ca_system_score_codex":0.000105571446,"about_ca_system_score_gemma":0.000025207099,"threshold_uncertainty_score":0.9981743},"labels":[],"label_agreement":null},{"id":"W2420469801","doi":"10.1161/circoutcomes.6.suppl_1.a153","title":"Abstract 153: Impact Of The Enhance Trial On The Use Of Ezetimibe In The Us And Canada","year":2013,"lang":"en","type":"article","venue":"Circulation Cardiovascular Quality and Outcomes","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences","funders":"","keywords":"Ezetimibe; Medicine; Medical prescription; Population; Clinical trial; Demography; Environmental health; Internal medicine; Statin; Pharmacology","score_opus":0.16331413585285623,"score_gpt":0.32360883537020124,"score_spread":0.160294699517345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2420469801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959302,0.00056785316,0.000020899819,0.002353139,0.00011060058,0.0004759009,0.00008963003,0.000001638505,0.00045016277],"genre_scores_gemma":[0.9985608,0.00014569398,0.0000047265808,0.0012276175,0.000029581992,0.00001670113,0.0000021530811,0.0000053777717,0.000007383385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989488,0.00012945934,0.00055220706,0.00016616793,0.000073234405,0.0001300901],"domain_scores_gemma":[0.9986326,0.0006089884,0.0002409766,0.00046234587,0.000021915246,0.000033182187],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012930145,0.0001019188,0.0004173411,0.000036842535,0.00007046115,0.000050757262,0.00014984675,0.00005234003,0.00004967986],"category_scores_gemma":[0.0003942608,0.00005817582,0.00040672426,0.00008916109,0.00009789894,0.000113901064,0.00003038046,0.00013330924,0.00000269575],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011451267,0.0000698736,0.9345292,0.00007008311,0.00084284955,4.2202214e-7,0.0006111294,0.011195275,0.000017871587,0.04944668,0.00043037155,0.0026717193],"study_design_scores_gemma":[0.001333687,0.000008839652,0.9931932,0.000005565417,0.000012566578,5.8386314e-7,0.00002319221,0.0005730427,0.000019497917,0.0027599616,0.0019925162,0.000077336714],"about_ca_topic_score_codex":0.3542158,"about_ca_topic_score_gemma":0.009755146,"teacher_disagreement_score":0.34446067,"about_ca_system_score_codex":0.00005827851,"about_ca_system_score_gemma":0.00004978475,"threshold_uncertainty_score":0.6500845},"labels":[],"label_agreement":null},{"id":"W2425036397","doi":"10.1093/ajhp/60.19.1943","title":"Use of a personal digital assistant in a pharmacy-directed warfarin dosing program","year":2003,"lang":"en","type":"article","venue":"American Journal of Health-System Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Pharmacy; Clinical pharmacy; Pharmacist; Medicine; Library science; Family medicine","score_opus":0.12163080215461872,"score_gpt":0.35693002085541636,"score_spread":0.23529921870079765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2425036397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98543257,0.0042534755,0.0004458544,0.005489539,0.00069627725,0.0005851397,0.00032699527,0.000056396286,0.0027137727],"genre_scores_gemma":[0.99668926,0.00066123036,0.0016042138,0.00084648764,0.00010331927,0.000017147044,0.000003838863,0.000046231307,0.000028266371],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958736,0.00021764454,0.0027892713,0.00032971785,0.00011086523,0.00067892304],"domain_scores_gemma":[0.9959361,0.00023225641,0.003087668,0.00018123933,0.00010795114,0.00045479438],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016922439,0.00027425657,0.0013947698,0.0006670352,0.00008812722,0.0001477802,0.00028192514,0.000026522663,0.0001042598],"category_scores_gemma":[0.00018455552,0.00029229547,0.00032710878,0.0007681177,0.00018965408,0.0007034581,0.000038147926,0.0004932848,0.00003101641],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013001837,0.0026409582,0.46494392,0.00092830637,0.0008303051,0.00017091048,0.0041583963,0.00030874307,0.0003898681,0.018326191,0.0026017404,0.5034005],"study_design_scores_gemma":[0.0073658554,0.00088896236,0.008325319,0.00046389794,0.000036372596,0.00070459495,0.0008397022,0.03353588,0.0004487348,0.00035967302,0.94625866,0.00077233755],"about_ca_topic_score_codex":0.0011697663,"about_ca_topic_score_gemma":0.000011611474,"teacher_disagreement_score":0.9436569,"about_ca_system_score_codex":0.0006700286,"about_ca_system_score_gemma":0.0004675875,"threshold_uncertainty_score":0.9999529},"labels":[],"label_agreement":null},{"id":"W2429636260","doi":"","title":"Legislative and regulatory modernization for therapeutic products.","year":2010,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Canada","funders":"","keywords":"Legislature; Modernization theory; Legislation; Business; Presentation (obstetrics); Work (physics); Action plan; Order (exchange); Health professionals; Action (physics); Consumer protection; Health care; Medicine; Political science; Engineering; Management; Finance; Economics; Commerce","score_opus":0.07737842813077492,"score_gpt":0.2514797362142745,"score_spread":0.17410130808349958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2429636260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83789134,0.002920226,0.005723162,0.026602948,0.002267706,0.003493692,0.0004115523,0.00012614724,0.120563224],"genre_scores_gemma":[0.99640393,0.00007516331,0.00030108768,0.0011260044,0.0002708742,0.0006064816,0.0000083031855,0.000019131545,0.0011890401],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99928546,0.0000034693353,0.00021604837,0.0002573369,0.000009378514,0.00022829551],"domain_scores_gemma":[0.99958557,0.000037824648,0.00010916792,0.00016296754,0.000022268614,0.00008220219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038426387,0.000079903126,0.00015259227,0.00007737832,0.00006459422,0.00005254916,0.00008120203,0.00006258234,0.000021458292],"category_scores_gemma":[0.00009964658,0.000090761736,0.000030898827,0.000059737347,0.00006368374,0.00016815256,0.000022009808,0.00009777758,0.00001899406],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017306753,0.000032572658,0.007036504,0.000023478104,0.000039146424,6.8700146e-8,0.00021226935,0.000010892164,0.00006833926,0.9328578,0.00078056374,0.058921028],"study_design_scores_gemma":[0.0006048803,0.000009846174,0.19426152,5.4618204e-7,0.000006902177,0.0000017724626,0.000003605321,0.0075444384,0.0006330399,0.2608167,0.5359085,0.00020825188],"about_ca_topic_score_codex":0.00001047824,"about_ca_topic_score_gemma":0.000008018575,"teacher_disagreement_score":0.6720411,"about_ca_system_score_codex":0.000019038267,"about_ca_system_score_gemma":0.000008624777,"threshold_uncertainty_score":0.3701156},"labels":[],"label_agreement":null},{"id":"W2430198404","doi":"","title":"Canada: Federal Court dismisses prohibition application for quetiapine tablets (SEROQUEL XR).","year":2013,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quetiapine; Quetiapine Fumarate; Federal court; Law; Medicine; Business; Political science; Psychiatry; Supreme court; Atypical antipsychotic; Schizophrenia (object-oriented programming); Antipsychotic","score_opus":0.03909270774846913,"score_gpt":0.22474106216165451,"score_spread":0.1856483544131854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2430198404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5033046,0.0034298033,0.036179923,0.2796552,0.00263175,0.021274054,0.0031650052,0.00032771524,0.15003198],"genre_scores_gemma":[0.98383343,0.00008558611,0.00015939555,0.005525417,0.00036544044,0.008406231,0.00009842138,0.000026853573,0.0014992236],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987599,0.000005273804,0.00043334995,0.00031634208,0.00002255704,0.0004625436],"domain_scores_gemma":[0.9993097,0.00004525404,0.0001998429,0.00019025571,0.000043248056,0.00021170144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022646275,0.00013106939,0.00024799345,0.00006267016,0.000118279066,0.00010848437,0.00015400759,0.00006523467,0.000119683944],"category_scores_gemma":[0.00007872389,0.00015279275,0.000059191538,0.00007953975,0.000026906479,0.00024659417,0.000029380199,0.00008090389,0.00011337503],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003666395,0.00018733669,0.012036487,0.00017102956,0.00011131428,5.9544e-7,0.00003996337,0.00014673559,0.000050625225,0.48996726,0.4294128,0.067839175],"study_design_scores_gemma":[0.00062516687,0.0000096991125,0.15135811,0.0000019724423,0.0000042359784,0.0000015462966,0.0000048999127,0.007542917,0.0003126932,0.059257448,0.78061616,0.0002651536],"about_ca_topic_score_codex":0.18753697,"about_ca_topic_score_gemma":0.039058935,"teacher_disagreement_score":0.48052886,"about_ca_system_score_codex":0.00028589898,"about_ca_system_score_gemma":0.000075658456,"threshold_uncertainty_score":0.97847575},"labels":[],"label_agreement":null},{"id":"W2432561189","doi":"","title":"Deals landscape: notable deals in the pharmaceutical industry in the first quarter of 2008.","year":2008,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Pharmaceutical industry; Business; Management; Economics; Medicine; Pharmacology; History","score_opus":0.1054695009722585,"score_gpt":0.2813184614801285,"score_spread":0.17584896050787002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2432561189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89627624,0.0015665982,0.000006521604,0.021183068,0.00015389985,0.00068664306,0.00009930438,0.000008017225,0.08001973],"genre_scores_gemma":[0.9883633,0.00048964546,0.000010204323,0.010321551,0.00015029327,0.00056065933,0.0000043794716,0.000011864299,0.00008808162],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983854,0.00005437996,0.00069908565,0.00024897177,0.00004915064,0.0005629582],"domain_scores_gemma":[0.99910986,0.0003162914,0.0001665133,0.00031720946,0.000009235123,0.000080864236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017494624,0.00013829494,0.0003482445,0.00019500303,0.00007508568,0.000039681287,0.0005704363,0.00023390818,0.00023994388],"category_scores_gemma":[0.00010853384,0.0001051751,0.00009236106,0.0004267223,0.000106539934,0.00014877935,0.00004456092,0.0007633242,0.000104641986],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005696062,0.0004712383,0.9050385,0.00004077781,0.000036808487,0.000029798462,0.0026847247,0.00020701365,6.8735216e-7,0.050803296,0.038106214,0.0025240183],"study_design_scores_gemma":[0.0010959166,0.000011878087,0.7644201,0.0000035028108,0.000004285463,0.0000239771,0.000115278635,0.000997017,0.000028667577,0.0046536415,0.22849026,0.0001555121],"about_ca_topic_score_codex":0.00027690548,"about_ca_topic_score_gemma":0.000157469,"teacher_disagreement_score":0.19038405,"about_ca_system_score_codex":0.000049039932,"about_ca_system_score_gemma":0.000019830115,"threshold_uncertainty_score":0.4288916},"labels":[],"label_agreement":null},{"id":"W24331064","doi":"","title":"Tifacogin (Chiron Corp/Pharmacia Corp).","year":2002,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Recombinant DNA; Tissue factor pathway inhibitor; Sepsis; Pharmacology; Medicine; Chemistry; Biochemistry; Gene; Internal medicine; Coagulation; Tissue factor","score_opus":0.14513373516470696,"score_gpt":0.24507400132998802,"score_spread":0.09994026616528107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W24331064","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2939807,0.0029538516,0.00016632154,0.0063344296,0.001583517,0.00079170795,0.00039645785,0.00015766286,0.69363534],"genre_scores_gemma":[0.9857513,0.00074233644,0.00007231782,0.005130835,0.00039412454,0.00042661183,0.000009175704,0.00003542292,0.0074378937],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99837554,0.0000129164655,0.00052713446,0.00040789953,0.00002660543,0.00064990926],"domain_scores_gemma":[0.99910164,0.000046789006,0.00021262637,0.0002965812,0.00001085241,0.00033154024],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00037098437,0.00018097593,0.00034179303,0.0001767727,0.00009192211,0.000098778415,0.00030525276,0.00007422279,0.0039622085],"category_scores_gemma":[0.000068597954,0.00022109631,0.0001363846,0.000175584,0.00007326905,0.00020385458,0.00007811338,0.00021396042,0.007146621],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050120903,0.0005104964,0.06387386,0.00005752258,0.00023259596,0.000028533092,0.00032315863,0.0001715968,0.000035853696,0.5258819,0.112687714,0.29614666],"study_design_scores_gemma":[0.0015054827,0.000010957423,0.04566056,0.0000014255361,0.00000926989,0.000010422216,0.0000032594955,0.011720684,0.0002935824,0.017119395,0.9232336,0.00043133512],"about_ca_topic_score_codex":0.00006123149,"about_ca_topic_score_gemma":0.0000064463834,"teacher_disagreement_score":0.8105459,"about_ca_system_score_codex":0.00012557615,"about_ca_system_score_gemma":0.0000032619478,"threshold_uncertainty_score":0.9969483},"labels":[],"label_agreement":null},{"id":"W2442133109","doi":"10.1071/hc15094","title":"The impact on health outcome measures of switching to generic medicines consequent to reference pricing: the case of olanzapine in New Zealand","year":2015,"lang":"en","type":"article","venue":"Journal of Primary Health Care","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Population and Public Health","funders":"University of Auckland","keywords":"Olanzapine; Medicine; Medical prescription; Subsidy; Actuarial science; Psychiatry; Business; Schizophrenia (object-oriented programming); Economics; Nursing","score_opus":0.2377371799552184,"score_gpt":0.4149426726992649,"score_spread":0.17720549274404648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2442133109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8398384,0.017603299,0.00021653701,0.1403885,0.000484858,0.00047912032,0.00010807996,0.000003274546,0.0008779566],"genre_scores_gemma":[0.97849333,0.0014545216,0.00028372282,0.019519735,0.00020642567,0.000002109432,0.0000015571437,0.000014010737,0.000024580926],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99759305,0.00010003728,0.0017393383,0.00014589741,0.0000825873,0.00033908128],"domain_scores_gemma":[0.9973545,0.00025391087,0.0013288776,0.0002742818,0.00012886197,0.00065957924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033159347,0.00014153848,0.0008185283,0.00031009872,0.00007679251,0.000020745356,0.0003190947,0.00003983018,0.0000068328154],"category_scores_gemma":[0.00044997758,0.00008466099,0.000105917294,0.00027687717,0.000027197446,0.00006141656,0.0000599574,0.0003471292,0.0000058429173],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004746733,0.00049879437,0.23585045,0.0012793395,0.0004420667,0.00024254895,0.07986772,0.03059493,0.00017150857,0.024552349,0.3599989,0.26175463],"study_design_scores_gemma":[0.013282175,0.016223077,0.41598776,0.0012259254,0.000043515476,0.001905059,0.007919071,0.001030854,0.00020020317,0.01713288,0.52399045,0.0010589879],"about_ca_topic_score_codex":0.011260626,"about_ca_topic_score_gemma":0.0018153521,"teacher_disagreement_score":0.26069564,"about_ca_system_score_codex":0.0011799394,"about_ca_system_score_gemma":0.0016430861,"threshold_uncertainty_score":0.9953235},"labels":[],"label_agreement":null},{"id":"W2443926831","doi":"10.1503/cmaj.160134","title":"The case for an essential medicines list for Canada","year":2016,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Ontario Drug Policy Research Network; Queen's University","funders":"McMaster University","keywords":"Essential medicines; MEDLINE; Developing country; Medicine; Computer science; World Wide Web; Data science; Economic growth; Political science; Public health; Nursing; Law","score_opus":0.026999029158899308,"score_gpt":0.27718927255860354,"score_spread":0.25019024339970425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2443926831","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.081932954,0.0008891132,0.0041587055,0.8968716,0.0070570987,0.0005113265,0.0030025712,0.000012766068,0.005563813],"genre_scores_gemma":[0.9495388,0.0003242343,0.00007577372,0.04175564,0.006872323,0.00005271989,0.000010877941,0.000027182952,0.0013424512],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987085,0.000022068678,0.00054527924,0.0001466914,0.000069275506,0.0005081713],"domain_scores_gemma":[0.9974386,0.00072917354,0.00029461842,0.0000970256,0.00014261671,0.0012979758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021426568,0.000084996005,0.00019089894,0.000063785184,0.000632144,0.0001169793,0.0002498555,0.00014097143,0.00073271256],"category_scores_gemma":[0.0029552127,0.000060081908,0.00008680246,0.00005161376,0.000041516185,0.00012004577,0.000007752938,0.00016337587,0.000017698205],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013920615,0.000009478963,0.0031704572,0.0000056396184,0.00010190292,0.00007676087,0.000054409706,0.0000011639956,0.0000021398755,0.08256,0.8764955,0.03750862],"study_design_scores_gemma":[0.00097299565,0.000035188612,0.00021772429,0.000006052405,0.0000063086627,0.00022141104,0.00006011241,0.001609185,0.000006552163,0.020189764,0.9765706,0.000104106715],"about_ca_topic_score_codex":0.2767626,"about_ca_topic_score_gemma":0.98236644,"teacher_disagreement_score":0.86760587,"about_ca_system_score_codex":0.0011572232,"about_ca_system_score_gemma":0.002166152,"threshold_uncertainty_score":0.80226886},"labels":[],"label_agreement":null},{"id":"W2460956080","doi":"10.12927/whp.2016.24670","title":"Negotiating Pharmaceutical Prices: A Change in Chinese Health Policy","year":2016,"lang":"en","type":"article","venue":"World health & population","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Negotiation; China; Pharmaceutical policy; Competition (biology); Drug prices; Business; Public economics; Health policy; Price policy; Economics; International economics; International trade; Health care; Economic growth; Political science; Law; Geography","score_opus":0.13519071952009268,"score_gpt":0.421726045225969,"score_spread":0.28653532570587636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2460956080","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.42455396,0.012422412,0.00163977,0.54636276,0.0018373788,0.0024511174,0.0005277926,0.00023748018,0.009967324],"genre_scores_gemma":[0.96745193,0.00153535,0.00036629132,0.029312534,0.00097616116,0.00007834994,0.000036014644,0.00003562184,0.00020771974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973802,0.000061342085,0.0012531981,0.00045136432,0.000044577017,0.00080931716],"domain_scores_gemma":[0.99858546,0.0001132608,0.0006336631,0.0002449982,0.000011653908,0.00041094134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011843989,0.00019905837,0.0005547729,0.00086681696,0.0001565018,0.00004571296,0.00016302097,0.00006072333,0.00021284632],"category_scores_gemma":[0.00014198894,0.00018259071,0.00007791893,0.0007844541,0.000027846721,0.00042925877,0.00006253046,0.00020694094,0.00031094978],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020979056,0.0000657673,0.5017223,0.00008709397,0.0000071443897,4.973828e-7,0.00063884206,0.00004763269,0.0000013822587,0.45069438,0.00041989103,0.04629409],"study_design_scores_gemma":[0.0013985065,0.00005480512,0.81068504,0.000091692724,7.457483e-7,0.0000019979007,0.0000064367687,0.015420018,5.7810695e-7,0.030665226,0.14140704,0.00026788897],"about_ca_topic_score_codex":0.025612064,"about_ca_topic_score_gemma":0.00464508,"teacher_disagreement_score":0.542898,"about_ca_system_score_codex":0.0016604824,"about_ca_system_score_gemma":0.00013470743,"threshold_uncertainty_score":0.98087645},"labels":[],"label_agreement":null},{"id":"W2462041422","doi":"10.1016/j.jval.2015.09.2521","title":"How Good Are Physicians And Chart Reviews At Capturing Health Resources And Drug Utilisation By Patients? Results Of The Pgrx-3 Prospective Real World Dataset Validation Study","year":2015,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Family medicine; Pharmacy; Depression (economics); Medical record; Alternative medicine; Informed consent; Internal medicine","score_opus":0.12260972437845959,"score_gpt":0.31762735581036905,"score_spread":0.19501763143190948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2462041422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97863674,0.0030893767,0.0000015666093,0.010942512,0.00013812757,0.0014048873,0.0054538096,0.0000064802607,0.00032648342],"genre_scores_gemma":[0.996485,0.0021985811,0.000022060744,0.0008159064,0.00005828819,0.000029618715,0.00023174605,0.00001255522,0.00014624855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983571,0.0002170886,0.0007636835,0.00038107892,0.000048127567,0.00023287986],"domain_scores_gemma":[0.99840194,0.00006962102,0.0011020561,0.00028075642,0.000017055827,0.00012858969],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021013513,0.0001249817,0.00046052292,0.00011280958,0.00012131896,0.00004861812,0.000113014125,0.000023999506,0.000001307509],"category_scores_gemma":[0.00015759394,0.00011572786,0.000023540239,0.00019803751,0.000054039858,0.00018743788,0.00010997279,0.00014419435,0.0000034221114],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007364624,0.00028822996,0.96194714,0.00019524586,0.000013450048,9.163707e-8,0.013977201,0.0000884374,5.1272843e-7,0.0019752143,0.019963507,0.0014773413],"study_design_scores_gemma":[0.0044227573,0.0003719135,0.74088144,0.00024613916,0.0000073377164,4.8196694e-7,0.0014364023,0.0027498235,0.00004022723,0.0033051232,0.24623442,0.00030392135],"about_ca_topic_score_codex":0.014431816,"about_ca_topic_score_gemma":0.0025464315,"teacher_disagreement_score":0.2262709,"about_ca_system_score_codex":0.00040723776,"about_ca_system_score_gemma":0.00003288972,"threshold_uncertainty_score":0.9921312},"labels":[],"label_agreement":null},{"id":"W2462357409","doi":"10.1213/ane.0000000000000823","title":"Drug Shortages in Perioperative Medicine","year":2015,"lang":"en","type":"letter","venue":"Anesthesia & Analgesia","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Economic shortage; Perioperative; Harm; Anesthesiology; Drug; Intensive care medicine; Pharmacology; Psychiatry; Surgery; Law; Government (linguistics)","score_opus":0.06384122520091927,"score_gpt":0.290348845079617,"score_spread":0.22650761987869772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2462357409","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008697336,0.007698566,0.0000066220227,0.914578,0.0001977822,0.00036166064,0.00005839206,0.000050890714,0.068350755],"genre_scores_gemma":[0.03060367,0.0016140096,0.00007081567,0.94882816,0.0039252276,0.00009404705,0.0003736461,0.00014757107,0.0143428305],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99691725,0.000081659884,0.0012324508,0.0009132688,0.000090374626,0.0007650134],"domain_scores_gemma":[0.9985104,0.00012435322,0.00045516517,0.0006493939,0.000055180863,0.00020549541],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.001005136,0.0005676063,0.0015216701,0.0007648718,0.00007527948,0.00010091067,0.00071775954,0.0006453045,0.0018736857],"category_scores_gemma":[0.00006380501,0.00059550576,0.00020570973,0.00038187593,0.00026850574,0.00021595156,0.00005343117,0.0016579381,0.0020221216],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010173823,0.000026724252,0.00491014,0.000054784534,0.00006347794,0.0010049135,0.00083252887,0.000012168584,5.5542836e-7,0.022054883,0.9708846,0.00014500534],"study_design_scores_gemma":[0.00057947636,0.000059435457,0.0022909108,0.00006114367,0.000019799985,0.000080325895,0.000052886488,0.0004973723,0.0000036801987,0.015125029,0.98056984,0.0006601121],"about_ca_topic_score_codex":0.0015699593,"about_ca_topic_score_gemma":0.00015030071,"teacher_disagreement_score":0.05400792,"about_ca_system_score_codex":0.00035279267,"about_ca_system_score_gemma":0.00011828232,"threshold_uncertainty_score":0.99964964},"labels":[],"label_agreement":null},{"id":"W2462866164","doi":"","title":"American Association of Pharmaceutical Scientists 2002 Annual Meeting and Exposition, Drug development in a global marketplace: challenges and opportunities. 10-14 November 2002, Toronto, Canada.","year":2003,"lang":"en","type":"other","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"","keywords":"Exposition (narrative); Association (psychology); Library science; Political science; Psychology; Computer science","score_opus":0.04180395314149797,"score_gpt":0.2504522796526228,"score_spread":0.2086483265111248,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2462866164","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0042307246,0.053710192,0.0000025230304,0.0021420075,0.00043647643,0.00054503867,0.0017040531,0.00001901425,0.93720996],"genre_scores_gemma":[0.062004685,0.086771645,0.0005079666,0.0036191302,0.00038749038,0.00084389246,0.000082007195,0.00031005515,0.8454731],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981536,0.00005854673,0.0006490701,0.00048183423,0.00008613493,0.0005707908],"domain_scores_gemma":[0.9987846,0.0000733809,0.00066882913,0.00013161598,0.000034825247,0.0003067288],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011821918,0.0002577947,0.0006285446,0.0001393024,0.000042180473,0.000042608594,0.00013015118,0.00013843656,0.0013913199],"category_scores_gemma":[0.00012465141,0.0003328352,0.00003136665,0.00008890902,0.000113565424,0.00011238075,0.000089889814,0.00012651362,0.000008047218],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000038656442,0.00013153676,0.006103456,0.0002554378,0.00026640476,0.000009065654,0.00027813355,0.0000014154814,9.577267e-8,0.009726148,0.8850347,0.09815499],"study_design_scores_gemma":[0.00074035465,0.0000040207137,0.03441531,0.000029666367,0.00001304269,0.0000034032507,0.00008930926,0.00004552434,0.0000034907905,0.000059532682,0.96425635,0.00034000087],"about_ca_topic_score_codex":0.044043202,"about_ca_topic_score_gemma":0.4619282,"teacher_disagreement_score":0.41788498,"about_ca_system_score_codex":0.00138198,"about_ca_system_score_gemma":0.00021059238,"threshold_uncertainty_score":0.9999124},"labels":[],"label_agreement":null},{"id":"W2463885522","doi":"10.1007/s10611-016-9627-5","title":"It came from the north: assessing the claim of Canada’s rising role as a global supplier of synthetic drugs","year":2016,"lang":"en","type":"article","venue":"Crime Law and Social Change","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Simon Fraser University; Université de Montréal; International Centre for Comparative Criminology","funders":"","keywords":"Scope (computer science); Production (economics); Exportation; Business; Quality (philosophy); Economics; International trade; Macroeconomics","score_opus":0.06373805513632705,"score_gpt":0.2928897934372456,"score_spread":0.22915173830091853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2463885522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91190284,0.001223518,0.000012719022,0.027644817,0.00020055939,0.00013218465,0.0014569837,0.0000047730587,0.05742158],"genre_scores_gemma":[0.99285585,0.00009583974,0.0000057264665,0.0066428403,0.0003270436,0.00000771924,0.000004353944,0.0000095696005,0.000051060942],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99923044,0.000025278065,0.00031170377,0.0001676536,0.00003580783,0.00022912577],"domain_scores_gemma":[0.9993736,0.00018920763,0.00021607333,0.000149086,0.000019721017,0.000052290543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020211919,0.00009973816,0.00027756827,0.00001054064,0.00023850227,0.000040193398,0.000197625,0.0000624551,0.00017436355],"category_scores_gemma":[0.000023983956,0.0000657951,0.00007361942,0.0000492315,0.0002434385,0.00009878823,0.00007944545,0.00007253576,0.000011381506],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019017707,0.000037038935,0.02318185,0.000022667735,0.00011087629,9.3807313e-7,0.009174229,2.73654e-7,0.000052606436,0.96052104,0.002452233,0.004427219],"study_design_scores_gemma":[0.0010569993,0.000037469545,0.13908319,0.000054000582,0.00007635598,0.000002169639,0.002274984,0.0001872821,0.00063288637,0.20595294,0.65019983,0.00044189973],"about_ca_topic_score_codex":0.3742612,"about_ca_topic_score_gemma":0.13063063,"teacher_disagreement_score":0.7545681,"about_ca_system_score_codex":0.00010188829,"about_ca_system_score_gemma":0.00009189055,"threshold_uncertainty_score":0.8852331},"labels":[],"label_agreement":null},{"id":"W2464934251","doi":"10.2147/dddt.s106802","title":"Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimod","year":2016,"lang":"en","type":"review","venue":"Drug Design Development and Therapy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"Novartis Pharma; World Health Organization","keywords":"Fingolimod; Medicine; Food and drug administration; Marketing authorization; Quality (philosophy); Authorization; Good manufacturing practice; Documentation; Agency (philosophy); Bioequivalence; Pharmacy; Risk analysis (engineering); Intensive care medicine; Business; Family medicine; Multiple sclerosis; Pharmacology; Marketing; Computer security; Bioinformatics; Computer science","score_opus":0.3702865754020696,"score_gpt":0.3829632242045164,"score_spread":0.012676648802446788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2464934251","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015903788,0.99287003,0.0021449884,0.0019598743,0.00031518284,0.0017064579,0.0003484529,0.000028580474,0.00046739355],"genre_scores_gemma":[0.0010067283,0.99482155,0.0018707552,0.0008305626,0.00027127087,0.00092153356,0.00005555608,0.0000698507,0.00015220011],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99714214,0.000063907806,0.0016208196,0.0007197261,0.000028070921,0.00042531724],"domain_scores_gemma":[0.9978202,0.0011371626,0.00052703236,0.00031602476,0.000025490928,0.00017409516],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018301223,0.00041035897,0.0016617851,0.00036848694,0.00014696608,0.000058315483,0.00032990653,0.00027036146,0.000042813655],"category_scores_gemma":[0.000096090786,0.00032948868,0.00027539628,0.00016301245,0.00009441703,0.000081211816,0.00003987102,0.00024743797,0.0001357071],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000566333,0.00009870876,0.0006021404,0.00025384792,0.00016229716,4.413407e-7,0.0001307051,2.1529955e-7,1.519295e-7,0.011157542,0.0018224937,0.98571485],"study_design_scores_gemma":[0.0018634418,0.000054513293,0.0006289183,0.00132724,0.000011941909,0.0000010994011,0.0000020854297,0.000017037823,0.000006002764,0.023349304,0.97228014,0.0004582599],"about_ca_topic_score_codex":0.000008353294,"about_ca_topic_score_gemma":0.000011907353,"teacher_disagreement_score":0.98525655,"about_ca_system_score_codex":0.00014444995,"about_ca_system_score_gemma":0.00022581172,"threshold_uncertainty_score":0.9999157},"labels":[],"label_agreement":null},{"id":"W2467894892","doi":"10.1017/s1092852900024706","title":"Generic Substitution for Psychotropic Drugs","year":2009,"lang":"en","type":"article","venue":"CNS Spectrums","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mental Health Research Canada","funders":"","keywords":"Bioequivalence; Drug; Generic drug; Medicine; Brand names; Food and drug administration; Pharmacology; Pharmacokinetics; Marketing; Business","score_opus":0.05915964262169584,"score_gpt":0.29233050901001884,"score_spread":0.233170866388323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2467894892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.67104,0.0039572758,0.026634915,0.028893342,0.0020764647,0.000801003,0.0003265089,0.00018447252,0.26608604],"genre_scores_gemma":[0.99126565,0.000397277,0.0008584886,0.006012709,0.00062289694,0.00002128168,0.000021786554,0.000014564698,0.00078534154],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989477,0.0000032696514,0.0003614802,0.0003195231,0.000013500657,0.000354555],"domain_scores_gemma":[0.99947953,0.000017295208,0.00012626348,0.00024777206,0.000009934197,0.00011920517],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014633794,0.00012609875,0.00024890515,0.00013329014,0.000102744416,0.00006703787,0.00019003905,0.000071939576,0.0003817396],"category_scores_gemma":[0.000022163127,0.0001504816,0.00014294431,0.00013819821,0.000035345503,0.00018983199,0.000009838353,0.00009038865,0.0009404617],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016874503,0.000054517317,0.0005244325,0.000005630222,0.000013742326,4.1223717e-7,0.00006377815,0.00004384916,0.00014198355,0.99177897,0.004340555,0.003015243],"study_design_scores_gemma":[0.0007269613,0.00009840019,0.008882003,0.000002764628,0.000004725166,0.0000026722385,0.000004071252,0.0042028795,0.00053384766,0.42363393,0.5616748,0.00023293197],"about_ca_topic_score_codex":0.00001320825,"about_ca_topic_score_gemma":0.0000027200063,"teacher_disagreement_score":0.56814504,"about_ca_system_score_codex":0.000116674186,"about_ca_system_score_gemma":0.00001520684,"threshold_uncertainty_score":0.9998374},"labels":[],"label_agreement":null},{"id":"W2471028722","doi":"","title":"Improving safety, quality and efficacy of medicines in the Americas.","year":2016,"lang":"en","type":"editorial","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Quality (philosophy); Business; Medicine; Traditional medicine; Physics","score_opus":0.06576026971609744,"score_gpt":0.32312730538353,"score_spread":0.2573670356674326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2471028722","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011062645,0.01309838,0.00012513257,0.014142762,0.8910881,0.0024917636,0.0042572645,0.000043724795,0.06369021],"genre_scores_gemma":[0.23617002,0.010019292,0.00003717434,0.002122548,0.75011283,0.0008264347,0.000092388065,0.000087704386,0.0005315838],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979536,0.00005598152,0.0011128711,0.00041186408,0.000062210915,0.00040350127],"domain_scores_gemma":[0.9970277,0.001649288,0.000812414,0.0003858551,0.000023723758,0.0001010369],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028187141,0.00020787554,0.00080396206,0.00021029086,0.000037116504,0.000039775063,0.00045860227,0.0002819435,0.000035936322],"category_scores_gemma":[0.002928778,0.00015085505,0.00011408303,0.00013823636,0.00021669541,0.00008531519,0.00012799237,0.00040556627,0.00002008848],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014419942,0.00012551429,0.0033120457,0.00030834586,0.0001126336,0.0000027240546,0.0003402741,7.2377543e-7,0.0000011040347,0.023350919,0.8211375,0.15116405],"study_design_scores_gemma":[0.001349871,0.000015628426,0.0738343,0.000013841334,0.00001679929,4.266184e-7,0.000010474098,0.00001543918,0.0000018672815,0.005996868,0.9185232,0.0002212847],"about_ca_topic_score_codex":0.0009043934,"about_ca_topic_score_gemma":0.000063786014,"teacher_disagreement_score":0.22510737,"about_ca_system_score_codex":0.00009978069,"about_ca_system_score_gemma":0.00003636016,"threshold_uncertainty_score":0.61516905},"labels":[],"label_agreement":null},{"id":"W2473960571","doi":"","title":"Pulse: Drug prices stable but total spending rises by 15%","year":2002,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Demographics; Population; Medicine; Drug prices; Price index; Agricultural economics; Index (typography); Demography; Economics; Demographic economics; Monetary economics; Environmental health","score_opus":0.02647678158875794,"score_gpt":0.2398846699334881,"score_spread":0.21340788834473015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2473960571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.54697084,0.009372015,0.00018514582,0.12180871,0.00336549,0.00020399812,0.001332402,0.000042959193,0.31671846],"genre_scores_gemma":[0.9705033,0.0019040221,0.00007218769,0.015528678,0.001765834,0.0000056106514,0.0000133838375,0.000028536451,0.010178448],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981995,0.00002991219,0.00069385633,0.00021775201,0.00015621685,0.00070271164],"domain_scores_gemma":[0.99758697,0.00012632454,0.00041095764,0.000098038225,0.0000429903,0.0017347209],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0013602568,0.00013518457,0.00031651734,0.00022895908,0.00033072292,0.00030772126,0.0002934167,0.0002193499,0.072681844],"category_scores_gemma":[0.0007805189,0.00015896886,0.00012055923,0.00017962244,0.000032524687,0.00035667408,0.00002322723,0.0007418372,0.0038404223],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000016660298,0.0000446568,0.05517947,0.0000066091743,0.000110920584,0.00004451824,0.00025201595,0.000011341311,0.0000037662217,0.009702823,0.92821336,0.006428843],"study_design_scores_gemma":[0.0005816346,0.000013291222,0.004366781,0.0000102805,0.000005786495,0.00006551128,0.00007397724,0.0051200325,0.000017962026,0.0025560232,0.98695666,0.0002320897],"about_ca_topic_score_codex":0.004193376,"about_ca_topic_score_gemma":0.0031089566,"teacher_disagreement_score":0.42353246,"about_ca_system_score_codex":0.0011921474,"about_ca_system_score_gemma":0.00015881898,"threshold_uncertainty_score":0.9969352},"labels":[],"label_agreement":null},{"id":"W2481684576","doi":"10.1111/ijpp.12288","title":"Emerging trends on drug use globally","year":2016,"lang":"en","type":"editorial","venue":"International Journal of Pharmacy Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Drug; Environmental health; Pharmacology","score_opus":0.05787431601986959,"score_gpt":0.4060232547565728,"score_spread":0.3481489387367032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2481684576","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000261527,0.0013503167,0.00019136189,0.035722554,0.8889674,0.000060256505,0.0022804316,0.000018031578,0.071148105],"genre_scores_gemma":[0.008139584,0.012124479,0.0004977208,0.007285264,0.96272796,0.000005709723,0.00006607375,0.0001029761,0.009050233],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968887,0.00009397867,0.0018077004,0.00041074312,0.00043461943,0.00036426345],"domain_scores_gemma":[0.9917371,0.0027542156,0.004089747,0.00025107563,0.0008643615,0.00030344448],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0021277957,0.00036073668,0.0006585285,0.0010076193,0.00006429277,0.0005845801,0.0016366146,0.00018932471,0.0021474801],"category_scores_gemma":[0.006195435,0.0003525144,0.00050102366,0.00013708773,0.00005960697,0.0023743003,0.00019669386,0.0014805084,0.001194934],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012035368,0.0002530622,0.000088251865,0.000009402327,0.0010789204,0.00020991263,0.00009544432,0.000047555597,0.000010148068,0.015613617,0.9708847,0.010505493],"study_design_scores_gemma":[0.0040867347,0.0000542265,0.000014996761,0.00009562684,0.00007650936,0.0000615315,0.0000075337302,0.0001741704,0.000056219043,0.0027740449,0.9922354,0.00036299438],"about_ca_topic_score_codex":0.00019714485,"about_ca_topic_score_gemma":0.0000051494676,"teacher_disagreement_score":0.07376055,"about_ca_system_score_codex":0.0008462317,"about_ca_system_score_gemma":0.00026524285,"threshold_uncertainty_score":0.9998927},"labels":[],"label_agreement":null},{"id":"W2482824289","doi":"10.1057/9780230244399_14","title":"The Partnership Prescription: Access to HIV/AIDS-related Medicines and Public—Private Partnerships","year":2009,"lang":"en","type":"book-chapter","venue":"Palgrave Macmillan UK eBooks","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University","funders":"","keywords":"Economic growth; General partnership; Public health; Civil society; Political science; Poverty; Population; Public–private partnership; Business; Politics; Public administration; Medicine; Environmental health; Economics; Finance","score_opus":0.11233988468592798,"score_gpt":0.2933265379832078,"score_spread":0.1809866532972798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2482824289","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006010007,0.0059582777,0.0000356188,0.011913746,0.00053667324,0.00089884107,0.00025682736,0.00010651535,0.9796925],"genre_scores_gemma":[0.95809853,0.0019593611,0.000059041187,0.00672494,0.00074094895,0.00007105388,0.0000707503,0.00012057271,0.032154784],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99651426,0.00003631849,0.0014159665,0.0010049572,0.00011156331,0.00091695506],"domain_scores_gemma":[0.99719846,0.00026285712,0.00070067047,0.00096068135,0.00007067242,0.00080665335],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001008794,0.00069930055,0.0010197146,0.0004577433,0.00041600005,0.00075646414,0.0010825035,0.0005080816,0.0006311719],"category_scores_gemma":[0.00019264451,0.000629385,0.00029774045,0.00006237739,0.00039876305,0.000008209401,0.0004372021,0.00068631116,0.0009951215],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004227762,8.827048e-7,0.0010384873,0.000033596414,0.00021311603,0.0000110399715,0.00017011711,0.0000015789176,0.000002278312,0.98481923,0.0019269785,0.011740393],"study_design_scores_gemma":[0.00042348524,0.00007181176,0.000478164,0.000046405396,0.00002924794,0.0000122883,0.000010275461,0.00010880182,0.0000084369385,0.61564106,0.38267922,0.00049078575],"about_ca_topic_score_codex":0.000016390622,"about_ca_topic_score_gemma":0.00010375197,"teacher_disagreement_score":0.95749754,"about_ca_system_score_codex":0.0001478733,"about_ca_system_score_gemma":0.00005689246,"threshold_uncertainty_score":0.99978274},"labels":[],"label_agreement":null},{"id":"W2483043008","doi":"","title":"Pénuries de médicaments : 10 ans de recul au Canada","year":2016,"lang":"fr","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science; Humanities; Economic shortage; Art; Philosophy","score_opus":0.03736077141760889,"score_gpt":0.2653573792023123,"score_spread":0.22799660778470338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2483043008","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1912768,0.007932707,0.0027354185,0.23659894,0.0026122208,0.00019937457,0.0021256602,0.00003288584,0.556486],"genre_scores_gemma":[0.7584781,0.006845635,0.0007230212,0.02394443,0.0008456847,0.000021406804,0.0000062546624,0.0000480907,0.20908739],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99770916,0.000034389614,0.0006601243,0.0004253066,0.000030237943,0.0011407933],"domain_scores_gemma":[0.9986563,0.00019010837,0.00021916804,0.00036394643,0.000022684533,0.0005478366],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0005683542,0.00023398755,0.00041117647,0.0001017212,0.00014238898,0.00007133798,0.000372506,0.00019839671,0.01980418],"category_scores_gemma":[0.00023671369,0.00024530647,0.00013133298,0.00012343147,0.00020616187,0.00023097041,0.00011301528,0.00015591695,0.0015409588],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003332255,0.000120283505,0.13973379,0.0000740634,0.00019945452,0.000020786769,0.00023022242,0.000021525842,0.000045560937,0.4618726,0.36386433,0.03378404],"study_design_scores_gemma":[0.0007333598,0.000042745156,0.017801818,0.000056983354,0.000013949179,0.000011419852,0.000023680455,0.0009992053,0.0006044821,0.02091871,0.95841265,0.00038099696],"about_ca_topic_score_codex":0.70007324,"about_ca_topic_score_gemma":0.6843218,"teacher_disagreement_score":0.5945483,"about_ca_system_score_codex":0.0029421286,"about_ca_system_score_gemma":0.0016631319,"threshold_uncertainty_score":0.99999994},"labels":[],"label_agreement":null},{"id":"W2492890185","doi":"10.1093/acprof:oso/9780195342109.003.00011","title":"Expanding Patent Rights in Pharmaceuticals","year":2008,"lang":"en","type":"book-chapter","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Law and economics; Economics","score_opus":0.21078797504574198,"score_gpt":0.31692684699665596,"score_spread":0.10613887195091398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2492890185","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00056388846,0.005524755,0.000037130023,0.00077766087,0.00056556665,0.00031899306,0.00025670297,0.000054315195,0.991901],"genre_scores_gemma":[0.12556374,0.023230735,0.0002462392,0.0057282406,0.00077725,0.000042914635,0.000082219056,0.00013556679,0.8441931],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974365,0.0000054017632,0.0012674716,0.00071099756,0.000037967886,0.00054161344],"domain_scores_gemma":[0.9988898,0.000082253515,0.00034697755,0.00037777633,0.000014620447,0.00028855345],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002971286,0.00042758713,0.00096829794,0.0006142979,0.00008588401,0.000054116234,0.00033528818,0.0004220563,0.012896302],"category_scores_gemma":[0.000013851568,0.00048273738,0.0003057166,0.000044767734,0.00011779155,0.00014130482,0.00013464644,0.00063286116,0.0097111035],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001446188,0.00003865668,0.00019281176,0.00002345239,0.00007146982,0.000055604814,0.000064813095,0.000012166717,0.0000016637946,0.98370373,0.014947308,0.000873853],"study_design_scores_gemma":[0.00060755847,0.000016817763,0.000044300163,0.00002976682,0.0000054864568,0.000011473971,4.7648336e-7,0.0004928928,0.000046085275,0.21822879,0.78001887,0.00049749727],"about_ca_topic_score_codex":0.00018234139,"about_ca_topic_score_gemma":0.000048893267,"teacher_disagreement_score":0.765475,"about_ca_system_score_codex":0.0003075192,"about_ca_system_score_gemma":0.000029839284,"threshold_uncertainty_score":0.9997624},"labels":[],"label_agreement":null},{"id":"W2493092156","doi":"10.5639/gabij.2016.0502.014","title":"Adjusted indirect comparisons between generics – bioequivalence and interchangeability","year":2016,"lang":"en","type":"article","venue":"Generics and Biosimilars Initiative Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Interchangeability; Bioequivalence; Medicine; Pharmacology; Computer science; Pharmacokinetics","score_opus":0.2569267108682741,"score_gpt":0.31465631857701165,"score_spread":0.05772960770873753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2493092156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8195518,0.010891667,0.023116875,0.13642408,0.0010600995,0.00035975498,0.0028842161,0.000057005618,0.005654467],"genre_scores_gemma":[0.953549,0.01665454,0.0020047468,0.027217153,0.00051371846,0.000008596402,0.0000062887684,0.000028880298,0.000017050785],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983223,0.00006773606,0.00071212923,0.00040869167,0.00004724344,0.0004418655],"domain_scores_gemma":[0.99869084,0.00021180371,0.0004685329,0.00017312834,0.00006756347,0.0003881319],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092031946,0.00023967441,0.00054158655,0.00025576475,0.00025963757,0.00014596005,0.0002173213,0.00014392239,0.00017949136],"category_scores_gemma":[0.00018530313,0.0001921394,0.0000989534,0.00019934136,0.00035672824,0.00028931166,0.00022266535,0.00028099716,0.000029050652],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054565236,0.000119402874,0.8289026,0.0000551865,0.0003496852,0.00001639149,0.00078787375,0.000002245309,0.0010090874,0.0020994674,0.13765924,0.02894426],"study_design_scores_gemma":[0.0025908845,0.00057506433,0.46298024,0.00010534228,0.00008443431,0.0001452027,0.00020913205,0.0012383888,0.0034277886,0.055438884,0.47204575,0.001158912],"about_ca_topic_score_codex":0.0000010670011,"about_ca_topic_score_gemma":0.00000870591,"teacher_disagreement_score":0.36592236,"about_ca_system_score_codex":0.00012337735,"about_ca_system_score_gemma":0.000039466147,"threshold_uncertainty_score":0.7835217},"labels":[],"label_agreement":null},{"id":"W2493427157","doi":"10.1136/ebm.14.3.81","title":"Review: brand-name drugs are not more effective than generic versions for treating cardiovascular disease","year":2009,"lang":"en","type":"letter","venue":"Evidence-Based Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Brand names; Disease; Medicine; Citation; Equivalence (formal languages); Computer science; Internal medicine; Advertising; World Wide Web; Linguistics; Business; Philosophy","score_opus":0.09080153094382207,"score_gpt":0.3133321435995569,"score_spread":0.22253061265573484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2493427157","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00034444706,0.3751501,0.00072595547,0.61976767,0.00067534373,0.0019453563,0.00090341765,0.00005827713,0.00042941744],"genre_scores_gemma":[0.0059862565,0.09182416,0.00014334213,0.89007354,0.009714615,0.00078176445,0.00067156175,0.000120363184,0.0006843756],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963325,0.00010483136,0.0012220999,0.0013215669,0.00018255216,0.00083643716],"domain_scores_gemma":[0.99551153,0.0016077255,0.0009351222,0.0013339368,0.0001294977,0.00048215967],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018216259,0.00071437267,0.002468539,0.0004781851,0.00024936546,0.000049335973,0.0006582233,0.00042456214,0.0003748328],"category_scores_gemma":[0.00268133,0.00068432995,0.001549513,0.00037715284,0.0002579017,0.00024315152,0.000063861466,0.0010917936,0.00025344905],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012805923,0.000037008238,0.00034388973,0.0045764823,0.00055018,0.000084113926,0.00007347977,0.00029787116,0.0000016737393,0.00012977097,0.9863248,0.007452682],"study_design_scores_gemma":[0.0021180564,0.00021689702,0.0010703006,0.013270647,0.0010162782,0.0000033148913,0.0000080939735,0.0032668128,0.000016354472,0.00083130214,0.9774457,0.0007362221],"about_ca_topic_score_codex":0.0003088161,"about_ca_topic_score_gemma":0.0000013160274,"teacher_disagreement_score":0.28332597,"about_ca_system_score_codex":0.0005949929,"about_ca_system_score_gemma":0.00017749146,"threshold_uncertainty_score":0.9995608},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"systematic_review","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"not_applicable","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"split"},{"id":"W2501073323","doi":"10.1057/9780230244399_13","title":"Patents, Policies and Pricing: Access to Medicines for Vulnerable Populations in a Global Economy*","year":2009,"lang":"en","type":"book-chapter","venue":"Palgrave Macmillan UK eBooks","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University","funders":"","keywords":"Business; Public economics; Premise; Essential medicines; Population; Economic growth; Health care; Development economics; Medicine; Economics; Environmental health","score_opus":0.12751267530729277,"score_gpt":0.33560621736212953,"score_spread":0.20809354205483677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2501073323","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00095663226,0.0019882296,0.00032345185,0.003754329,0.00032014673,0.0012792692,0.0019843425,0.00003892724,0.98935467],"genre_scores_gemma":[0.9859315,0.00025248865,0.00031388804,0.009769856,0.00043490622,0.0000991702,0.00011051876,0.00006216447,0.0030255197],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99766725,0.000008136458,0.0010337632,0.0007034814,0.000030395655,0.0005569805],"domain_scores_gemma":[0.99876934,0.0000792536,0.00039517076,0.00038247104,0.000040696435,0.00033306715],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036674217,0.00045395872,0.0009769662,0.0005252273,0.00014341554,0.00020022965,0.0003971006,0.00028907886,0.0001642786],"category_scores_gemma":[0.00007088173,0.00052648684,0.00017544019,0.00004277277,0.00006645452,0.000005209372,0.00018150595,0.00024121667,0.00007013367],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029528073,0.0000011390823,0.0049436036,0.00006150942,0.00005183405,0.000003066408,0.00011613908,0.000042434116,5.188002e-7,0.98714644,0.00049224286,0.0071115643],"study_design_scores_gemma":[0.00070889905,0.000085775755,0.0055475277,0.00007013008,0.000021113801,0.000006903888,0.0000051842608,0.000638206,0.000004158593,0.89686924,0.09552689,0.00051595364],"about_ca_topic_score_codex":0.000446838,"about_ca_topic_score_gemma":0.0007836098,"teacher_disagreement_score":0.98632914,"about_ca_system_score_codex":0.00028721185,"about_ca_system_score_gemma":0.000047419766,"threshold_uncertainty_score":0.99971867},"labels":[],"label_agreement":null},{"id":"W2501244108","doi":"10.4103/2468-5577.187082","title":"Seven alternative opportunities to overcome the \"Valley of Death\" for CNS drug candidates developed by academic researchers","year":2016,"lang":"en","type":"article","venue":"Asia Pacific Clinical and Translational Nervous System Diseases","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Drug; Medicine; Intensive care medicine; Pharmacology","score_opus":0.24415136270456247,"score_gpt":0.3825053458334726,"score_spread":0.13835398312891015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2501244108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79801553,0.0113183,0.004963861,0.11932255,0.00083111395,0.0026171594,0.045613877,0.00009217553,0.017225415],"genre_scores_gemma":[0.9964654,0.0011217347,0.00007310651,0.00038082286,0.0001793724,0.00011394506,0.00005939322,0.000020670182,0.0015855831],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981704,0.00008200938,0.0010225184,0.00037110594,0.0000704047,0.0002836113],"domain_scores_gemma":[0.99731976,0.0018623982,0.00023443547,0.0001728468,0.0000622207,0.00034836042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092728355,0.00015510958,0.00045009193,0.0000874857,0.00013627406,0.00003339924,0.00026442265,0.000081793245,0.00006191121],"category_scores_gemma":[0.00020639147,0.00010676015,0.0001849704,0.000065232634,0.00023479633,0.00013864019,0.000040102525,0.00010863847,0.000040798735],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006465001,0.00015247997,0.3400918,0.00023340117,0.00049583486,0.000002616834,0.00090484374,0.000027293363,0.000019421304,0.62475324,0.017407529,0.0152650485],"study_design_scores_gemma":[0.005059277,0.0002588164,0.28391737,0.0003759294,0.00012269267,0.000008890111,0.0013070928,0.0034787706,0.00010595377,0.16013835,0.54432,0.00090689334],"about_ca_topic_score_codex":0.00014012858,"about_ca_topic_score_gemma":0.000019540093,"teacher_disagreement_score":0.52691245,"about_ca_system_score_codex":0.000030525734,"about_ca_system_score_gemma":0.000108769644,"threshold_uncertainty_score":0.43535525},"labels":[],"label_agreement":null},{"id":"W2507917158","doi":"10.1186/s12967-016-0997-3","title":"Could patents interfere with the development of a cardiovascular polypill?","year":2016,"lang":"en","type":"article","venue":"Journal of Translational Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Population Health Research Institute; Institute of Population and Public Health; Hamilton Health Sciences; University of Ottawa","funders":"Canadian Institutes of Health Research; Government of Canada","keywords":"Polypill; Assertion; Medicine; Intellectual property; Pill; Alternative medicine; Brand names; Generic drug; Business; Drug; Family medicine; Pharmacology; Computer science; Political science; Marketing; Law","score_opus":0.0873083713006572,"score_gpt":0.2743798914096524,"score_spread":0.1870715201089952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2507917158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7342282,0.016249763,0.12289817,0.11478202,0.00066525297,0.00026027203,0.00009289621,0.00000656212,0.010816847],"genre_scores_gemma":[0.99842596,0.0002477128,0.0006740274,0.0003655728,0.00021201682,0.0000016013083,8.142716e-7,0.000008107142,0.00006419499],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990096,0.000011347444,0.0007067926,0.000080609556,0.000085918145,0.00010574469],"domain_scores_gemma":[0.9992712,0.00010741227,0.00036976373,0.00009962191,0.00007705716,0.000074919124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082060625,0.0000781365,0.00035743206,0.00012529384,0.00003279566,0.0000038177623,0.00017088061,0.00003119073,0.0003090817],"category_scores_gemma":[0.000032353717,0.00003683556,0.0001229181,0.00007749604,0.00010745455,0.00009559019,0.0000071076765,0.00009552527,0.000014099744],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027530852,0.0008143347,0.15227774,0.00043359588,0.018615529,0.00004947191,0.020028844,0.0025069606,0.003863352,0.29904565,0.0118908575,0.48772058],"study_design_scores_gemma":[0.008397834,0.0005214466,0.11570188,0.00048080386,0.0001590451,0.00008586961,0.00013210003,0.00026361455,0.0012422437,0.019087046,0.8536503,0.00027783948],"about_ca_topic_score_codex":0.0000064385204,"about_ca_topic_score_gemma":0.0000046317637,"teacher_disagreement_score":0.84175944,"about_ca_system_score_codex":0.000033654396,"about_ca_system_score_gemma":0.00005990586,"threshold_uncertainty_score":0.33842278},"labels":[],"label_agreement":null},{"id":"W2508484044","doi":"10.1177/0020731416662612","title":"The Trans Pacific Partnership Agreement and Pharmaceutical Regulation in Canada and Australia","year":2016,"lang":"en","type":"article","venue":"International Journal of Health Services","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University","funders":"","keywords":"Transparency (behavior); Formulary; General partnership; Pharmaceutical policy; Technical barriers to trade; Listing (finance); Intellectual property; Business; International trade; Access to medicines; Political science; Public administration; Public economics; Economics; Economic growth; Finance; Health policy; Law; Medicine; Trade barrier; Health care","score_opus":0.08727949480308496,"score_gpt":0.35360049134526406,"score_spread":0.2663209965421791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2508484044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91545445,0.0022013015,0.00006768263,0.08125216,0.0004975607,0.000068809626,0.00004245768,0.0000011113176,0.00041446407],"genre_scores_gemma":[0.99399596,0.004292268,0.000024110874,0.0015158278,0.0001037415,0.0000013925206,6.8990346e-7,0.000003487721,0.000062492254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99901897,0.00002583509,0.00065293617,0.00009206916,0.00005298022,0.00015720431],"domain_scores_gemma":[0.99932253,0.0001280133,0.00035720365,0.000043884265,0.00003290791,0.00011547536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007734582,0.000059608614,0.00014909214,0.00007444514,0.000042810876,0.000045712168,0.0001528685,0.000018165123,0.00008309023],"category_scores_gemma":[0.000008441517,0.00004131236,0.000020186095,0.000028632125,0.000030774852,0.00015953866,0.000018692297,0.000077656296,0.000004345514],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018788005,0.000046322806,0.8388441,0.00009625832,0.00014334307,0.000009492675,0.0010081555,0.000036754827,0.00005162672,0.1038098,0.00096356607,0.054802693],"study_design_scores_gemma":[0.0016000471,0.00004977289,0.703346,0.0001283863,0.0000029692599,0.000039622275,0.00024943086,0.0013395316,0.000063155436,0.024661489,0.26840806,0.000111551926],"about_ca_topic_score_codex":0.10782783,"about_ca_topic_score_gemma":0.30700928,"teacher_disagreement_score":0.2674445,"about_ca_system_score_codex":0.00030102127,"about_ca_system_score_gemma":0.0001128359,"threshold_uncertainty_score":0.89811325},"labels":[],"label_agreement":null},{"id":"W2508878195","doi":"10.4269/ajtmh.16-0099","title":"The Tropical Disease Priority Review Voucher: A Game-Changer for Tropical Disease Products","year":2016,"lang":"en","type":"review","venue":"American Journal of Tropical Medicine and Hygiene","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Institute of Mining, Metallurgy and Petroleum","funders":"","keywords":"Tropical disease; Voucher; Bedaquiline; Neglected tropical diseases; Product (mathematics); Medicine; Disease; Malaria; Business; Environmental health; Tuberculosis; Immunology; Pathology; Mycobacterium tuberculosis","score_opus":0.09606949253072214,"score_gpt":0.3663003961777781,"score_spread":0.27023090364705593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2508878195","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001202923,0.93241334,0.00056928373,0.064950146,0.00071248185,0.00086116395,0.00025179077,0.000011164041,0.000110355286],"genre_scores_gemma":[0.0005252692,0.9907096,0.00019001853,0.0041738157,0.003981569,0.000111777226,0.000008703192,0.00006477924,0.00023449323],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959356,0.00017604398,0.002426293,0.0006369624,0.00014482251,0.0006802406],"domain_scores_gemma":[0.99451494,0.0011125283,0.002146068,0.00063094863,0.00017521746,0.0014202659],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004977613,0.0005403235,0.0036389765,0.00023789771,0.00016547112,0.00006153522,0.00070826133,0.000101157435,0.0001276385],"category_scores_gemma":[0.0040557906,0.00030257652,0.0008722958,0.0003248067,0.0012176383,0.00013516107,0.00013817412,0.0006818374,0.00005144861],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026562795,0.00012697044,0.0006402326,0.007523911,0.00035508253,0.000036054047,0.000023439023,3.8255006e-8,5.7019445e-8,0.041355826,0.011934593,0.9377382],"study_design_scores_gemma":[0.0009070437,0.0007555569,0.0024956504,0.010093527,0.0007763412,0.000042044012,0.0000052174646,0.000011611479,4.0528228e-8,0.0057539535,0.9787941,0.0003649064],"about_ca_topic_score_codex":0.0000067593837,"about_ca_topic_score_gemma":0.0000014606145,"teacher_disagreement_score":0.9668595,"about_ca_system_score_codex":0.00020047583,"about_ca_system_score_gemma":0.0003804144,"threshold_uncertainty_score":0.99994266},"labels":[],"label_agreement":null},{"id":"W2513318489","doi":"10.1038/nbt.3664","title":"Which patent and where? Why international patent transparency by companies is needed for medicines","year":2016,"lang":"en","type":"article","venue":"Nature Biotechnology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Population and Public Health; University of Ottawa","funders":"Canadian Institutes of Health Research","keywords":"Business; Transparency (behavior); Patent law; International trade; Intellectual property; Political science; Law","score_opus":0.0531491252106876,"score_gpt":0.2750210722662557,"score_spread":0.22187194705556812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2513318489","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1888171,0.01477318,0.0059472984,0.7828965,0.0018201502,0.00044838976,0.0023195082,0.00014238035,0.0028354954],"genre_scores_gemma":[0.9826835,0.008413128,0.00033227625,0.008113649,0.00014035171,0.000038513233,0.000024559306,0.000019931842,0.00023412348],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988757,0.0000043483155,0.00039936285,0.00041828185,0.00002298896,0.00027934354],"domain_scores_gemma":[0.9994583,0.00006744349,0.00015648665,0.00019837533,0.000042157793,0.000077224606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001645316,0.00015842922,0.00032733663,0.00021243081,0.00005569033,0.00002361811,0.00030422877,0.0006710376,0.00036161396],"category_scores_gemma":[0.00009922089,0.00012762274,0.000061448925,0.00010544422,0.0001302527,0.00008882707,0.000056346213,0.00026095065,0.000054433123],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014403237,0.00015110281,0.01202811,0.000072350726,0.00030417243,0.0000012154267,0.00023172391,6.4001904e-7,0.006239054,0.7316471,0.22165981,0.027520737],"study_design_scores_gemma":[0.0015830019,0.00010603965,0.00070159254,0.000021080054,0.000008703317,0.000005680614,0.00003223613,0.00063197856,0.0065792985,0.055473574,0.9346395,0.00021732708],"about_ca_topic_score_codex":0.00006778319,"about_ca_topic_score_gemma":0.000090302834,"teacher_disagreement_score":0.7938664,"about_ca_system_score_codex":0.00006298069,"about_ca_system_score_gemma":0.000009654693,"threshold_uncertainty_score":0.5204304},"labels":[],"label_agreement":null},{"id":"W2516386876","doi":"","title":"South African Association of Pharmacists in Industry Report to the PSSA AGM","year":2016,"lang":"en","type":"article","venue":"South African Pharmaceutical Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Session (web analytics); Quarter (Canadian coin); Political science; General assembly; Public administration; Business; History; Law; Advertising; Archaeology","score_opus":0.07546944848336117,"score_gpt":0.32609067100979766,"score_spread":0.2506212225264365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2516386876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86659086,0.0006209782,0.0020114142,0.07592011,0.002149606,0.0007618487,0.001247164,0.00006095103,0.05063706],"genre_scores_gemma":[0.99404967,0.00010492939,0.00013224916,0.0035578348,0.0008437029,0.000028435516,0.000001922619,0.000043832486,0.0012374044],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99636894,0.0001447073,0.0017879567,0.00051703997,0.00019845221,0.0009828815],"domain_scores_gemma":[0.9971661,0.00031607912,0.0012027291,0.0003983453,0.00011085345,0.0008058836],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0037429912,0.00029726056,0.0006795116,0.0004978544,0.00015722647,0.000117296535,0.000743931,0.0002645623,0.0015748998],"category_scores_gemma":[0.0013106031,0.00022063639,0.00030339602,0.00074197917,0.00014379076,0.00024041823,0.00019802428,0.0013306809,0.0006948278],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092975335,0.0007383759,0.8970572,0.00006858566,0.0008449968,0.000471062,0.015594838,0.00051616854,0.0013896205,0.0303764,0.030758318,0.021254722],"study_design_scores_gemma":[0.008313337,0.00022085801,0.052030023,0.000116069765,0.00013084059,0.0005099112,0.0012358133,0.0014488824,0.0026046778,0.02700404,0.90497893,0.0014066],"about_ca_topic_score_codex":0.000010808158,"about_ca_topic_score_gemma":0.000004391441,"teacher_disagreement_score":0.8742206,"about_ca_system_score_codex":0.00075901864,"about_ca_system_score_gemma":0.00016455683,"threshold_uncertainty_score":0.9993378},"labels":[],"label_agreement":null},{"id":"W2519124869","doi":"10.1186/s12992-016-0190-8","title":"ReRouting biomedical innovation: observations from a mapping of the alternative research and development (R&amp;D) landscape","year":2016,"lang":"en","type":"article","venue":"Globalization and Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Engineers Without Borders Canada","funders":"World Health Organization; Open Society Foundations","keywords":"Redress; Health services research; Value (mathematics); Field (mathematics); Phase (matter); Health policy; Management science; Public relations; Computer science; Political science; Health care; Economics; Law","score_opus":0.4426786952154276,"score_gpt":0.4129090026843963,"score_spread":0.02976969253103129,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2519124869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92389697,0.0011063431,0.020073881,0.05151071,0.00023779977,0.00026558118,0.00030860453,0.000014671984,0.0025854104],"genre_scores_gemma":[0.99516165,0.0007150105,0.0015795308,0.0022974634,0.00008283613,0.0000069533867,0.00002481862,0.0000053041877,0.00012645948],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9991118,0.000023311892,0.0004877992,0.00017676907,0.000040392482,0.00015997417],"domain_scores_gemma":[0.9994798,0.00006152284,0.0002224248,0.0001026857,0.00006799189,0.000065610446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008757875,0.000051727806,0.00014125278,0.00013148312,0.00019863267,0.000025521662,0.00008375222,0.00003854275,0.000079055564],"category_scores_gemma":[0.00014265187,0.00003865622,0.000008188259,0.00041277675,0.000097745506,0.000070279384,0.0000952243,0.00005585013,0.000014203098],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000033972628,0.000026249629,0.32821,0.000022733006,0.00001654881,3.6142577e-8,0.0011767526,9.832006e-7,0.000020726844,0.66297185,0.0023624643,0.005188232],"study_design_scores_gemma":[0.00068027637,0.00001883558,0.49346069,0.00009382005,5.419185e-7,8.45611e-7,0.000108934444,0.00079450075,0.000025083813,0.08276856,0.42196107,0.00008684835],"about_ca_topic_score_codex":0.00032313782,"about_ca_topic_score_gemma":0.00007572593,"teacher_disagreement_score":0.5802033,"about_ca_system_score_codex":0.0000835523,"about_ca_system_score_gemma":0.0000989657,"threshold_uncertainty_score":0.1576355},"labels":[],"label_agreement":null},{"id":"W2520578273","doi":"10.1016/j.cjca.2016.08.010","title":"Drug Shortages: Patients and Health Care Providers Are All Drawing the Short Straw","year":2016,"lang":"en","type":"review","venue":"Canadian Journal of Cardiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; Workload; Economic shortage; Health care; Public health; Drug; Medical emergency; Intensive care medicine; Nursing; Psychiatry; Government (linguistics); Economic growth","score_opus":0.10218671265414604,"score_gpt":0.33189549667966345,"score_spread":0.22970878402551742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2520578273","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009218844,0.9893489,0.000030061625,0.0027268569,0.0011528376,0.0003736502,0.0011058777,0.0000026415714,0.0051670037],"genre_scores_gemma":[0.020780874,0.9762448,0.000008104802,0.0017935124,0.0010471563,0.000010819855,0.00002574705,0.000045796016,0.000043164797],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976766,0.000110195644,0.0012905356,0.00030766742,0.000024958408,0.0005900578],"domain_scores_gemma":[0.997789,0.0001189138,0.0009573278,0.00026738073,0.00006396825,0.0008034123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083361374,0.00029783978,0.0022060035,0.000429425,0.00016651112,0.00009928869,0.00050497474,0.00021973322,0.000025959498],"category_scores_gemma":[0.0000954449,0.00021786183,0.00057528587,0.00007653075,0.00020123369,0.000117795724,0.0000371682,0.00059093325,0.00003687062],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000034716268,0.0000022596482,0.0127022285,0.0019393851,0.0011898888,0.00004219027,0.00076175615,0.00001583742,2.160308e-9,0.006596735,0.08447518,0.89227104],"study_design_scores_gemma":[0.00015662292,0.00004694631,0.00063608115,0.0005981174,0.00006843656,0.000056882476,0.00007303036,6.3704954e-7,1.2062515e-8,0.0005102775,0.9976293,0.00022366068],"about_ca_topic_score_codex":0.0007115644,"about_ca_topic_score_gemma":0.002110942,"teacher_disagreement_score":0.9131541,"about_ca_system_score_codex":0.0007532261,"about_ca_system_score_gemma":0.0012985083,"threshold_uncertainty_score":0.88841474},"labels":[],"label_agreement":null},{"id":"W2521193918","doi":"10.11604/pamj.2016.25.18.10658","title":"An appeal for large scale production of antiretroviral drugs in Africa","year":2016,"lang":"en","type":"article","venue":"Pan African Medical Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"International Civil Aviation Organization","funders":"","keywords":"Medicine; Economic growth; Government (linguistics); Pandemic; Sustainability; Antiretroviral treatment; Politics; Millennium Development Goals; Scale (ratio); Development economics; Public health; Developing country; Distribution (mathematics); Human immunodeficiency virus (HIV); Scarcity; Antiretroviral therapy; Coronavirus disease 2019 (COVID-19); Economics; Political science; Disease; Immunology; Nursing; Viral load; Market economy","score_opus":0.03428552310859228,"score_gpt":0.28879873179133153,"score_spread":0.25451320868273924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2521193918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9705856,0.00046658856,0.0063783284,0.012262873,0.0009279932,0.0002495899,0.0002378411,0.00002003758,0.008871178],"genre_scores_gemma":[0.99784696,0.0003279651,0.0004824454,0.00032864232,0.0007867395,0.000013138837,0.0000025187153,0.000021128968,0.0001904681],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99813056,0.000043163283,0.0008919057,0.00029553144,0.00009258033,0.0005462843],"domain_scores_gemma":[0.99886197,0.00009559428,0.0003784046,0.00019235977,0.000037297934,0.0004343658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024789176,0.00012531635,0.00043308348,0.00030903777,0.000076141725,0.00002868506,0.00037013186,0.000116019815,0.0005501373],"category_scores_gemma":[0.000547795,0.00010216616,0.00014282898,0.00019238483,0.00012783508,0.00026254705,0.00003932848,0.0002460495,0.000061479586],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010156339,0.0034188172,0.39001533,0.00020548019,0.00023787003,0.000023412034,0.008862056,0.000011447786,0.0027581195,0.29382625,0.024349887,0.27527568],"study_design_scores_gemma":[0.015509142,0.0025232325,0.107601255,0.00040207588,0.00004673929,0.0001862942,0.0018894,0.015015167,0.002110971,0.3098137,0.543296,0.0016060611],"about_ca_topic_score_codex":0.000013843307,"about_ca_topic_score_gemma":0.000013189303,"teacher_disagreement_score":0.51894605,"about_ca_system_score_codex":0.00013647051,"about_ca_system_score_gemma":0.000103212435,"threshold_uncertainty_score":0.60236174},"labels":[],"label_agreement":null},{"id":"W2521668303","doi":"10.21518/1561-5936-2013-7-8-88-91","title":"Top list of pharmaceutical companies by production volume in the 1st quarter of 2013","year":2013,"lang":"en","type":"article","venue":"Remedium Journal about the Russian market of medicines and medical equipment","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Volume (thermodynamics); Production (economics); Business; Commerce; Agricultural economics; Economics; Geography; Physics; Archaeology","score_opus":0.024673093949437102,"score_gpt":0.27993897671834045,"score_spread":0.25526588276890333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2521668303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5227799,0.0195474,0.00021426438,0.44008198,0.0013764821,0.0006697807,0.00004305444,0.000005684061,0.01528144],"genre_scores_gemma":[0.97826856,0.018566407,0.000042654894,0.0023836005,0.0004912796,0.000015543188,0.0000030072647,0.000010148958,0.00021880145],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976523,0.0001264996,0.0014356793,0.0001924879,0.00026469838,0.00032832116],"domain_scores_gemma":[0.9985774,0.0002500324,0.0006289727,0.00022097879,0.00003954794,0.0002830285],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004132457,0.00016164096,0.0006142458,0.00014562135,0.00006951239,0.000024517109,0.00047236448,0.000102386635,0.0033639125],"category_scores_gemma":[0.00038028715,0.00009270566,0.00011374959,0.00017239091,0.00071442436,0.00012375745,0.00007574628,0.0005083448,0.000009675855],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047225566,0.0014941433,0.061152484,0.0011954745,0.00052046723,0.000015620677,0.007344063,0.000016767388,0.00076737953,0.048111714,0.8348471,0.044062532],"study_design_scores_gemma":[0.00675756,0.0011549735,0.14924917,0.0015187155,0.00015915756,0.00046436826,0.0038487127,0.028667158,0.00077878113,0.039692726,0.76707196,0.0006367394],"about_ca_topic_score_codex":0.00029137032,"about_ca_topic_score_gemma":0.000014408255,"teacher_disagreement_score":0.45548865,"about_ca_system_score_codex":0.000037017846,"about_ca_system_score_gemma":0.000064204614,"threshold_uncertainty_score":0.99754715},"labels":[],"label_agreement":null},{"id":"W2523601083","doi":"10.3851/imp3089","title":"Interchangeability between First-Line Generic Antiretroviral Products Prequalified by WHO using Adjusted Indirect Comparisons","year":2016,"lang":"en","type":"article","venue":"Antiviral Therapy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"Universiteit Utrecht; World Health Organization","keywords":"Interchangeability; Medicine; Statistics; Antiretroviral therapy; Human immunodeficiency virus (HIV); Mathematics; Computer science; Viral load; Virology","score_opus":0.2677889492011937,"score_gpt":0.3342942277627913,"score_spread":0.06650527856159755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2523601083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884913,0.0017772936,0.0023979142,0.003812721,0.0003485102,0.00042084558,0.0011170125,0.0000789543,0.0015554772],"genre_scores_gemma":[0.9961658,0.0018283908,0.00021816137,0.00070486974,0.0005017489,0.000017669418,0.000037587393,0.000053419782,0.00047233189],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99780124,0.00007605472,0.000787014,0.00069205737,0.00004509464,0.00059853087],"domain_scores_gemma":[0.9988207,0.00013737437,0.00039328422,0.0004906057,0.000030384512,0.00012765422],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006602314,0.00030821018,0.000796183,0.000188703,0.00015534411,0.00007641917,0.00039291574,0.00015862803,0.00019113584],"category_scores_gemma":[0.00008206438,0.00026580144,0.00016655208,0.00035019298,0.00019484473,0.0004051714,0.00010038437,0.00018476794,0.00028012792],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017704887,0.00032967806,0.93459916,0.000048640373,0.00029833414,0.0000019282386,0.00042388326,0.0000044426033,0.0069095613,0.0066070785,0.008456116,0.042144116],"study_design_scores_gemma":[0.007769396,0.0014311477,0.20768407,0.00014215485,0.000043489807,0.000004457404,0.000025348947,0.0048046466,0.12277824,0.0169394,0.6359271,0.0024505577],"about_ca_topic_score_codex":0.00033692576,"about_ca_topic_score_gemma":0.000018070217,"teacher_disagreement_score":0.7269151,"about_ca_system_score_codex":0.00016111511,"about_ca_system_score_gemma":0.000030115836,"threshold_uncertainty_score":0.99997944},"labels":[],"label_agreement":null},{"id":"W2523823607","doi":"10.1002/cpt.512","title":"Real World Data in Adaptive Biomedical Innovation: A Framework for Generating Evidence Fit for Decision‐Making","year":2016,"lang":"en","type":"article","venue":"Clinical Pharmacology & Therapeutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Real world evidence; Clinical decision making; Computer science; Data science; MEDLINE; Medical decision making; Management science; Medicine; Intensive care medicine; Engineering; Internal medicine; Political science; Medical emergency","score_opus":0.5963858748892129,"score_gpt":0.5456894304575541,"score_spread":0.05069644443165877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2523823607","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21848184,0.0016630952,0.7013025,0.068281464,0.0059928885,0.001879215,0.0020743154,0.000085489795,0.00023914366],"genre_scores_gemma":[0.7426407,0.003363071,0.15473346,0.095029965,0.0036979658,0.00030786006,0.000026639202,0.00007662917,0.00012374314],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99624044,0.00007845212,0.0020931666,0.0009289969,0.00004407083,0.0006148495],"domain_scores_gemma":[0.9815576,0.01688016,0.0007502485,0.00056998216,0.00010744978,0.00013454906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037987602,0.00023305377,0.00073789136,0.00037496712,0.00014055269,0.00004782637,0.0010030047,0.0002809942,0.0002701259],"category_scores_gemma":[0.001557288,0.00021070076,0.00015582975,0.00062251394,0.0004583805,0.00030415528,0.00033012938,0.00041763674,0.000091364185],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004469935,0.0013722901,0.07467407,0.00008434376,0.0012376404,0.000010371684,0.00026061852,0.00009023143,0.00067255367,0.466554,0.057423834,0.39315012],"study_design_scores_gemma":[0.0043063597,0.0006870984,0.0065490683,0.0003041464,0.00012871472,0.0000019716108,0.000016597736,0.17797771,0.00008208898,0.38111094,0.42817235,0.000662959],"about_ca_topic_score_codex":0.0000075195753,"about_ca_topic_score_gemma":0.00004073136,"teacher_disagreement_score":0.5465691,"about_ca_system_score_codex":0.00018170325,"about_ca_system_score_gemma":0.0001654041,"threshold_uncertainty_score":0.85921276},"labels":[],"label_agreement":null},{"id":"W2525448133","doi":"10.1177/1741134316669967","title":"A comparison of mechanisms for setting generic drug prices in Canada","year":2016,"lang":"en","type":"article","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University of Calgary","funders":"","keywords":"Reimbursement; Procurement; Benchmarking; Competition (biology); Business; Incentive; Discretion; Generic drug; Pharmacy; Public economics; Actuarial science; Drug; Industrial organization; Economics; Marketing; Microeconomics; Pharmacology; Medicine; Health care","score_opus":0.09433249734598782,"score_gpt":0.31471393864421765,"score_spread":0.22038144129822984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2525448133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5521918,0.055798937,0.2525699,0.118944496,0.018727435,0.0013519006,0.00027022042,0.000010823974,0.00013450076],"genre_scores_gemma":[0.97473174,0.007727169,0.0042153937,0.006336098,0.006577706,0.00006707605,0.0000057445586,0.0000990053,0.00024006268],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955886,0.00006743648,0.0030950771,0.00028339,0.00028429448,0.0006812273],"domain_scores_gemma":[0.9925028,0.002013001,0.0041667144,0.00039289062,0.00062582514,0.00029878426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040594838,0.00038446276,0.0015271676,0.00042542123,0.0003083825,0.000041097624,0.0012978312,0.00008647624,0.00017302482],"category_scores_gemma":[0.0016030741,0.0001871887,0.00033057158,0.0007610716,0.00019561675,0.00021291415,0.00008569393,0.0003436892,0.0000022320387],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003701697,0.00083779043,0.0748533,0.002388871,0.0038274915,0.000107647924,0.0077602924,0.046094723,0.052409686,0.017947227,0.6408601,0.14921117],"study_design_scores_gemma":[0.023769882,0.0015269135,0.04434815,0.00198629,0.0012178919,0.0023998546,0.006296022,0.09151376,0.0073132575,0.05874134,0.7590247,0.0018619784],"about_ca_topic_score_codex":0.00810625,"about_ca_topic_score_gemma":0.013210012,"teacher_disagreement_score":0.42253998,"about_ca_system_score_codex":0.00056618254,"about_ca_system_score_gemma":0.0011807905,"threshold_uncertainty_score":0.99849886},"labels":[],"label_agreement":null},{"id":"W2526266002","doi":"10.1080/01436597.2016.1233491","title":"PATH: pioneering innovation for global health at the public–private interface","year":2016,"lang":"en","type":"article","venue":"Third World Quarterly","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Balsillie School of International Affairs","funders":"GlaxoSmithKline; Bill and Melinda Gates Foundation","keywords":"Economic growth; Global health; Public health; Public relations; Multidisciplinary approach; Developing country; Business; Health care; Political science; Sociology; Economics; Medicine; Social science","score_opus":0.06120375483350839,"score_gpt":0.31810406611858594,"score_spread":0.25690031128507756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2526266002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49764132,0.0021818646,0.12063007,0.34657487,0.0027332993,0.0012130149,0.0015866784,0.00022148869,0.027217386],"genre_scores_gemma":[0.99135387,0.00005955603,0.0002668548,0.0052764304,0.00025148274,0.000066888955,0.000012664272,0.000021449692,0.002690824],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99840784,0.000016838763,0.0007371916,0.0003313108,0.000026098667,0.00048073084],"domain_scores_gemma":[0.99901634,0.00010777047,0.00037687345,0.00036013298,0.000032217642,0.00010668062],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00084390916,0.00015595138,0.00028780714,0.00013948497,0.00019922867,0.00010815483,0.0003049704,0.000043269712,0.00021884109],"category_scores_gemma":[0.00004967846,0.00011739645,0.00009283208,0.0003992075,0.000068596346,0.00027083143,0.00005189927,0.00008205919,0.0009262783],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025767065,0.00002529052,0.0017074373,0.000018601337,0.00003237938,1.4730188e-7,0.00015714813,0.0000020815762,0.00010788608,0.9471181,0.015314717,0.035490453],"study_design_scores_gemma":[0.00089507777,0.00016368208,0.002911793,0.00002302598,0.0000020992886,0.0000030062279,0.000014739852,0.00080365967,0.00011433613,0.22842929,0.7664162,0.00022309714],"about_ca_topic_score_codex":0.00003541469,"about_ca_topic_score_gemma":0.0002514896,"teacher_disagreement_score":0.7511015,"about_ca_system_score_codex":0.00055686425,"about_ca_system_score_gemma":0.00003601555,"threshold_uncertainty_score":0.99985164},"labels":[],"label_agreement":null},{"id":"W2527343785","doi":"10.1016/j.cjca.2016.07.438","title":"ADVERSE EVENTS FOLLOWING GENERIC ANTIHYPERTENSIVE DRUGS COMMERCIALIZATION IN QUÉBEC","year":2016,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Commercialization; Adverse effect; Drug; Brand names; Bioavailability; Pharmacology; Marketing; Business","score_opus":0.04502260531042499,"score_gpt":0.251639745957123,"score_spread":0.20661714064669803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2527343785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97036296,0.0015896715,0.0023727962,0.009487266,0.0018025227,0.00007905327,0.000076765005,0.0000026183939,0.014226336],"genre_scores_gemma":[0.99747515,0.00023134574,0.00003519512,0.0017720261,0.00039163107,0.000001445151,0.0000012975066,0.000012288882,0.000079643534],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990276,0.000036369976,0.0005208268,0.000119407494,0.000011820885,0.00028395565],"domain_scores_gemma":[0.9992884,0.00005730714,0.00022559451,0.00010698302,0.00003506158,0.00028665096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004018484,0.00008321064,0.00045216514,0.0004194403,0.00004256476,0.0000046387822,0.00017228846,0.00008723748,0.000059536025],"category_scores_gemma":[0.00019512833,0.00007655829,0.00019702553,0.000107319705,0.000048422346,0.0001415197,0.000010336758,0.00009453018,0.000113338414],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018049443,0.0000027361768,0.97112286,0.000004339843,0.00017242508,0.00009271977,0.00034448545,0.00090955204,0.00006812607,0.014796926,0.0072211134,0.0052466863],"study_design_scores_gemma":[0.0018219621,0.000060490962,0.19192891,0.000031291413,0.000016291042,0.000062479536,0.000059649556,0.000121300814,0.000025840845,0.011333759,0.79430664,0.00023139517],"about_ca_topic_score_codex":0.011785854,"about_ca_topic_score_gemma":0.012445141,"teacher_disagreement_score":0.78708553,"about_ca_system_score_codex":0.00042015043,"about_ca_system_score_gemma":0.0004524072,"threshold_uncertainty_score":0.9947947},"labels":[],"label_agreement":null},{"id":"W2527450042","doi":"10.51847/9kqlr7e4f6","title":"10.51847/9kQlR7E4f6","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Business; Drug; Environmental regulation; Public economics; Pharmacology; Economics; Medicine","score_opus":0.029545278218479097,"score_gpt":0.22240923156837925,"score_spread":0.19286395334990014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2527450042","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0030584466,0.00026908694,0.0000018504837,0.0021064419,0.000008462778,0.00012722243,0.0001677799,0.000060148177,0.9942006],"genre_scores_gemma":[0.0036762701,0.000006260079,0.00008577852,0.0015809574,0.00020324526,0.000017844264,0.000011907615,0.000027929465,0.99438983],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99895513,0.0000067818796,0.00037361676,0.00030268676,0.000016100614,0.0003456918],"domain_scores_gemma":[0.9993678,0.00003066766,0.000054932796,0.00029144957,0.000008626561,0.00024657138],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00021627938,0.00013119717,0.0002713909,0.00012025124,0.000064315594,0.000066927365,0.0002575313,0.0000665299,0.9950944],"category_scores_gemma":[0.000028683859,0.00016448401,0.000093807874,0.00015877945,0.0000285526,0.00011679236,0.00003920292,0.00009814782,0.99647003],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000074259835,0.0001154483,0.000010911036,0.000009617126,0.00006604904,0.0000038592607,0.000038936967,0.00030005333,0.000008894233,0.0050080908,0.13039313,0.86397076],"study_design_scores_gemma":[0.0002594415,0.00005037885,0.00014165923,0.000002576048,0.0000032152905,0.000002638625,1.4462132e-7,0.0018260935,0.000008809889,0.00072308816,0.99675876,0.00022320199],"about_ca_topic_score_codex":0.000045618224,"about_ca_topic_score_gemma":1.5559571e-7,"teacher_disagreement_score":0.8663656,"about_ca_system_score_codex":0.00006104668,"about_ca_system_score_gemma":0.000011231597,"threshold_uncertainty_score":0.6707463},"labels":[],"label_agreement":null},{"id":"W2528798488","doi":"","title":"Regulatory requirements for generic drugs (ANDS) in Canada","year":2015,"lang":"en","type":"article","venue":"Journal of Developing Drugs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science; Computational biology; Medicine; Pharmacology; Biology","score_opus":0.11564544587469897,"score_gpt":0.297484809420133,"score_spread":0.18183936354543404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2528798488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826642,0.0019211554,0.0008976522,0.0060876375,0.0018230582,0.00014210516,0.000040562547,0.000004061263,0.006419559],"genre_scores_gemma":[0.99266636,0.000202537,0.0033579082,0.0032762527,0.00029325284,0.000005452823,0.0000025685263,0.00002059643,0.00017508242],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.998433,0.000011853141,0.0010448829,0.00014910643,0.000058322265,0.00030284014],"domain_scores_gemma":[0.9988827,0.00005842161,0.00064681465,0.00012118024,0.000086135056,0.00020475776],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011233015,0.00011559217,0.00042084567,0.00023992846,0.00003310125,0.00003261251,0.00026639536,0.000046278044,0.000021852979],"category_scores_gemma":[0.00013646184,0.0001289965,0.00007734515,0.00016777424,0.000017030015,0.00022126213,0.000042563403,0.00013814546,0.000017059656],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060305605,0.00023458451,0.32111362,0.00039582554,0.00072871096,0.000069585076,0.009214926,0.0048434325,0.00007744214,0.39328623,0.23685507,0.032577515],"study_design_scores_gemma":[0.0051535713,0.000080623395,0.024281844,0.00010904072,0.00001204441,0.000024736244,0.00058143237,0.0044197394,0.00063836726,0.087865315,0.87622494,0.0006083743],"about_ca_topic_score_codex":0.032168154,"about_ca_topic_score_gemma":0.016880881,"teacher_disagreement_score":0.63936985,"about_ca_system_score_codex":0.0019113247,"about_ca_system_score_gemma":0.0018330805,"threshold_uncertainty_score":0.9742767},"labels":[],"label_agreement":null},{"id":"W2529647339","doi":"10.3138/9781442677609-007","title":"6. The Pharmaceutical Industry: Ending Canada's Compulsory Licensing Regime","year":2000,"lang":"en","type":"book-chapter","venue":"University of Toronto Press eBooks","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmaceutical industry; Business; Law and economics; Law; Political science; Economics; Medicine; Pharmacology","score_opus":0.0609606851332827,"score_gpt":0.24089337182394574,"score_spread":0.17993268669066304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2529647339","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008437201,0.006407398,0.000013955621,0.0003538892,0.00035685682,0.00020705108,0.0004591379,0.000022848695,0.9920945],"genre_scores_gemma":[0.023347344,0.0053892904,0.00008191479,0.0007339523,0.00036315172,3.5968677e-7,0.000021817394,0.000070928785,0.96999127],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99872965,0.000015198991,0.00041122836,0.00040080698,0.000061715626,0.0003814243],"domain_scores_gemma":[0.9986978,0.00014018311,0.0004586886,0.00042855792,0.000025457915,0.000249283],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019171616,0.00027625053,0.000542972,0.000028033026,0.00031940744,0.000045462908,0.0006249143,0.00042504902,0.0013008],"category_scores_gemma":[0.000007512067,0.0003398701,0.00018884821,0.0000014389736,0.00028895392,0.00007758294,0.00022040447,0.00067935284,0.000025694699],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000094347604,0.000008997565,0.000012856795,0.000030263473,0.0003076321,0.000026279407,0.00049905543,0.000026378717,0.0000011499623,0.9673969,0.01844784,0.01314828],"study_design_scores_gemma":[0.00041598413,0.00001574364,0.000042975036,0.00004724176,0.00004488653,0.0000034884758,0.000012281343,0.0006630924,0.000013532786,0.0060163843,0.9923849,0.0003395026],"about_ca_topic_score_codex":0.75636244,"about_ca_topic_score_gemma":0.4285784,"teacher_disagreement_score":0.97393703,"about_ca_system_score_codex":0.000823011,"about_ca_system_score_gemma":0.00020132739,"threshold_uncertainty_score":0.99990535},"labels":[],"label_agreement":null},{"id":"W2529976752","doi":"","title":"Le marketing pharmaceutique : les enjeux du développement et de la commercialisation des médicaments orphelins au Canada","year":2016,"lang":"fr","type":"article","venue":"Archipelago (Université du Québec à Montréal)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science; Humanities; Art","score_opus":0.027468840949278508,"score_gpt":0.2509334307204122,"score_spread":0.22346458977113368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2529976752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7936992,0.007611427,0.003426025,0.17751002,0.00046441276,0.000225108,0.0005530147,0.000032165888,0.016478637],"genre_scores_gemma":[0.9671127,0.026620056,0.00064171304,0.0045180637,0.0003263728,0.000011315662,0.000016933402,0.00005924952,0.00069359463],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99744713,0.0005333413,0.0006087264,0.0005154366,0.00007562792,0.0008197451],"domain_scores_gemma":[0.99723506,0.0014762734,0.00044660526,0.00030891,0.000059858296,0.00047329615],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018382911,0.0003441392,0.00048273036,0.00021494359,0.00079914695,0.00008162807,0.0005251564,0.0001813548,0.0016321263],"category_scores_gemma":[0.00042745416,0.00042237435,0.00019879504,0.00017947804,0.0005296635,0.00043882526,0.00037647353,0.00035182436,0.00013680101],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035690254,0.00043464015,0.3825655,0.00019246963,0.00055464345,0.00014661752,0.028717635,0.00044898098,0.0002213795,0.2726436,0.026187582,0.28753006],"study_design_scores_gemma":[0.002612607,0.00004244372,0.21656756,0.00017654785,0.000059230733,0.00004059386,0.0021557596,0.0032184413,0.00012379597,0.007260458,0.76717514,0.00056739675],"about_ca_topic_score_codex":0.98671347,"about_ca_topic_score_gemma":0.9887591,"teacher_disagreement_score":0.7409876,"about_ca_system_score_codex":0.005058679,"about_ca_system_score_gemma":0.0047242907,"threshold_uncertainty_score":0.9998228},"labels":[],"label_agreement":null},{"id":"W253643620","doi":"10.1093/oxfordhb/9780199742998.013.0015","title":"Empirical Evidence on the Value of Pharmaceuticals","year":2012,"lang":"en","type":"book-chapter","venue":"Oxford University Press eBooks","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"","keywords":"Health benefits; Public economics; Value (mathematics); Medical prescription; Cost–benefit analysis; Empirical evidence; Health economics; Economics; Business; Actuarial science; Medicine; Health care; Pharmacology; Economic growth; Political science; Traditional medicine","score_opus":0.27135607638238374,"score_gpt":0.31447842886326915,"score_spread":0.04312235248088542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W253643620","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00065714825,0.0014586844,0.00008386402,0.0009741215,0.0002492518,0.00035913286,0.00054657605,0.00002796901,0.99564326],"genre_scores_gemma":[0.0740647,0.0069259848,0.00008181128,0.0033663365,0.00037899608,0.000002640917,0.000009872703,0.00008093784,0.9150887],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99864596,0.00002928812,0.00047120513,0.0004155105,0.00006466286,0.00037337255],"domain_scores_gemma":[0.9980652,0.00053551793,0.0005215962,0.0006127255,0.000034870587,0.00023014036],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004898239,0.0003111013,0.0006043636,0.00017334029,0.00012591547,0.00002986903,0.00078722456,0.00032299777,0.00075214356],"category_scores_gemma":[0.00004949311,0.0003098822,0.00036802937,0.000012414901,0.00033205617,0.00010546237,0.00035371035,0.00062331755,0.000072452036],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008617952,0.000023784518,0.000081559534,0.00004943235,0.00016985978,0.0000047608287,0.00011195951,0.000008066684,0.0000041662724,0.99342287,0.004930026,0.0011073564],"study_design_scores_gemma":[0.0002571756,0.000049874667,0.000051758103,0.00009123287,0.00007204615,0.0000018958918,0.0000038798944,0.00027447386,0.00021479168,0.020920778,0.9777445,0.00031756336],"about_ca_topic_score_codex":0.000030098317,"about_ca_topic_score_gemma":0.0000011639636,"teacher_disagreement_score":0.9728145,"about_ca_system_score_codex":0.00020080202,"about_ca_system_score_gemma":0.000051290775,"threshold_uncertainty_score":0.9999353},"labels":[],"label_agreement":null},{"id":"W2547352560","doi":"10.4103/0253-7613.193309","title":"Assessment of knowledge and perceptions toward generic medicines among basic science undergraduate medical students at Aruba","year":2016,"lang":"en","type":"article","venue":"Indian Journal of Pharmacology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Respondent; Test (biology); Likert scale; Family medicine; Nationality; Medical education; Psychology; Perception; Health care; Medicine; Demography; Geography","score_opus":0.04689818290394433,"score_gpt":0.3807402770403581,"score_spread":0.3338420941364138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2547352560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832175,0.00082652626,0.00045876837,0.012319122,0.00124032,0.00009314795,0.000035802066,0.0000039678935,0.0018048824],"genre_scores_gemma":[0.99441993,0.0037577332,0.00013393047,0.001159027,0.00039187566,0.0000046069117,4.3419857e-7,0.000012087009,0.00012039716],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983718,0.000051932355,0.0008929569,0.00022656002,0.00012653891,0.00033020452],"domain_scores_gemma":[0.9984974,0.00018687751,0.00065307616,0.000091166905,0.00009536646,0.00047607906],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020436237,0.0001276612,0.00047976058,0.0005884029,0.000105870626,0.000021042582,0.00066931563,0.000082489176,0.0021979199],"category_scores_gemma":[0.00011924965,0.00010067988,0.00009628977,0.00022972662,0.00090606295,0.00025153116,0.00025276816,0.00021193323,0.00007340587],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004088885,0.0004330005,0.9562558,0.00007300667,0.00032847383,0.00010606577,0.0011980368,0.000016854263,0.014732924,0.010269187,0.009244226,0.007301561],"study_design_scores_gemma":[0.006581254,0.0006147999,0.95121783,0.000108766144,0.00009113601,0.00043413663,0.00007712967,0.0013766674,0.0023979328,0.008620475,0.028109359,0.0003705212],"about_ca_topic_score_codex":0.000007382775,"about_ca_topic_score_gemma":0.000009664581,"teacher_disagreement_score":0.018865133,"about_ca_system_score_codex":0.0003143545,"about_ca_system_score_gemma":0.00029976774,"threshold_uncertainty_score":0.9987142},"labels":[],"label_agreement":null},{"id":"W2547467223","doi":"10.1080/14737167.2017.1256775","title":"Outcome of the second Medicines Utilisation Research in Africa Group meeting to promote sustainable and appropriate medicine use in Africa","year":2016,"lang":"en","type":"article","venue":"Expert Review of Pharmacoeconomics & Outcomes Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Alternative medicine; Family medicine; Political science; Traditional medicine","score_opus":0.18886071628508216,"score_gpt":0.4957692279024389,"score_spread":0.3069085116173567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2547467223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77749807,0.09113318,0.00003547877,0.09609191,0.00056506996,0.0051236483,0.00019727931,0.000020632786,0.029334761],"genre_scores_gemma":[0.9455595,0.049198408,0.0002515556,0.0020893011,0.00015437641,0.00034138426,0.000002992107,0.00005847447,0.0023440095],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946971,0.0005318679,0.0025499344,0.00077716744,0.00022261987,0.0012213251],"domain_scores_gemma":[0.99630696,0.0019139979,0.00046904094,0.0007578948,0.00024599032,0.00030613018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01994463,0.0002879346,0.0014356675,0.0014760394,0.00012901872,0.00004819492,0.0010112954,0.00012591039,0.000782305],"category_scores_gemma":[0.0032277193,0.00019746106,0.00016205524,0.0012335368,0.000603173,0.0004969557,0.0008921743,0.0006464167,0.000055234417],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044523933,0.0008973868,0.67496234,0.015259508,0.00028695975,0.000031375253,0.014741795,0.000021703941,0.007976814,0.2216531,0.030573055,0.033150703],"study_design_scores_gemma":[0.003843206,0.00024404336,0.026673133,0.0041163876,0.000008874022,0.0000040139835,0.0007859083,0.00081406237,0.0011309474,0.028362295,0.9334997,0.00051742967],"about_ca_topic_score_codex":0.001622224,"about_ca_topic_score_gemma":0.0002666661,"teacher_disagreement_score":0.9029266,"about_ca_system_score_codex":0.0006704284,"about_ca_system_score_gemma":0.00010212906,"threshold_uncertainty_score":0.8565692},"labels":[],"label_agreement":null},{"id":"W2560037486","doi":"10.1503/cmaj.109-5363","title":"Brand-name drug costs expected to rise under CETA","year":2016,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Brand names; European union; Computer science; Business; Agricultural economics; International trade; Marketing; Economics","score_opus":0.021766611679500985,"score_gpt":0.2551134863785143,"score_spread":0.2333468746990133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560037486","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3389992,0.0008506251,0.0015172908,0.5952862,0.0025500187,0.0001996004,0.00055309996,0.000035324952,0.06000864],"genre_scores_gemma":[0.93748707,0.00039165217,0.000048621132,0.05744283,0.0015343892,0.000008202387,0.0000027545766,0.000024959187,0.0030595118],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99827254,0.000050286922,0.0006663162,0.00023160847,0.00013937548,0.0006398595],"domain_scores_gemma":[0.99650574,0.00018571591,0.00026468618,0.00013527652,0.00009142151,0.002817161],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0015112435,0.00012738838,0.00031016243,0.00031203747,0.000186686,0.0001348879,0.0003368899,0.00022016528,0.019176284],"category_scores_gemma":[0.0013698876,0.00011607976,0.0001252612,0.00018240274,0.000030280144,0.00019003614,0.000026820753,0.00039203468,0.006622982],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014513359,0.000043342017,0.07594154,0.0000031470563,0.00018616991,0.0000571751,0.00034797675,0.0000074969744,0.000013475707,0.07450385,0.81090486,0.03797644],"study_design_scores_gemma":[0.0011506992,0.00001545709,0.02430025,0.000024034396,0.000003973966,0.000028677003,0.000029246574,0.000100692974,0.000013828189,0.013254943,0.96086234,0.00021585381],"about_ca_topic_score_codex":0.0019695198,"about_ca_topic_score_gemma":0.011941778,"teacher_disagreement_score":0.59848785,"about_ca_system_score_codex":0.0024873293,"about_ca_system_score_gemma":0.0006086046,"threshold_uncertainty_score":0.99415046},"labels":[],"label_agreement":null},{"id":"W2561784549","doi":"","title":"Blame Canada (and the Rest of the World): The Twenty-Year War on Imported Prescription Drugs","year":2005,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Blame; Rest (music); Medical prescription; Political science; Medicine; Psychiatry; Nursing; Internal medicine","score_opus":0.021297038549947096,"score_gpt":0.23265071818830552,"score_spread":0.2113536796383584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2561784549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6955827,0.0006558409,0.0000058031833,0.08020532,0.0004340122,0.00041049827,0.00011819655,0.000010326368,0.22257732],"genre_scores_gemma":[0.9816761,0.00035830424,0.000013305186,0.010761311,0.00016972516,0.000013212307,0.0000016920577,0.000011135026,0.0069951955],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991047,0.000029139292,0.00044708914,0.00017963046,0.00003658732,0.00020286262],"domain_scores_gemma":[0.99913687,0.00016392539,0.00022361011,0.00040850337,0.000011799979,0.00005529559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055731053,0.000104192324,0.00019966326,0.000042942265,0.00014328945,0.000033048997,0.00033641528,0.00003065179,0.0004460963],"category_scores_gemma":[0.000056440516,0.00005572086,0.00008287658,0.00013961396,0.00018021822,0.00006406496,0.00009176514,0.00019599611,0.000050648738],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000069593865,0.000031002546,0.0072150305,0.0000074076793,0.0000613728,1.09676904e-7,0.00040780928,0.00032189034,0.000008254459,0.9463456,0.04442397,0.0011078999],"study_design_scores_gemma":[0.001385695,0.000012091552,0.042276464,0.000007754749,0.000012929105,0.000001067365,0.000091884984,0.011060801,0.00041286545,0.01624774,0.92834383,0.00014685359],"about_ca_topic_score_codex":0.15616867,"about_ca_topic_score_gemma":0.34086153,"teacher_disagreement_score":0.93009794,"about_ca_system_score_codex":0.00010005305,"about_ca_system_score_gemma":0.00005588217,"threshold_uncertainty_score":0.84945047},"labels":[],"label_agreement":null},{"id":"W2564973924","doi":"10.54648/bula2016013","title":"Parallel Trade in Pharmaceuticals: Re-Aligning National Patent Exhaustion and Life-Saving Drugs","year":2016,"lang":"en","type":"article","venue":"Business Law Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Context (archaeology); Intellectual property; Position (finance); Order (exchange); Law and economics; Economics; Access to medicines; International trade; Business; Public economics; Law; Political science; Finance","score_opus":0.19268689812017709,"score_gpt":0.33826957938159746,"score_spread":0.14558268126142038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564973924","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.032904185,0.6571911,0.0020472722,0.2242663,0.00100683,0.0019675172,0.0004311813,0.00015581174,0.08002979],"genre_scores_gemma":[0.7711477,0.2109172,0.00024193048,0.01738452,0.00015540537,0.00007414091,0.000009153358,0.000023577997,0.000046318888],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99842066,0.00003091695,0.00080686965,0.0003876277,0.000046057336,0.00030784844],"domain_scores_gemma":[0.9993046,0.00012712095,0.00023242993,0.00014414285,0.000030656287,0.00016104955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010737474,0.00017363693,0.0005104597,0.00009838863,0.000065080654,0.000047514488,0.00014301244,0.00007103855,0.00044292607],"category_scores_gemma":[0.00028178256,0.0001515378,0.000071119204,0.00024587507,0.000085798776,0.0003473416,0.000068415684,0.0001043194,0.00024917445],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017260598,0.00009434295,0.0026075165,0.0013879457,0.00003447848,0.000003799308,0.000045218057,0.000024966568,0.000044184264,0.9701272,0.0022966517,0.023316381],"study_design_scores_gemma":[0.0014266933,0.000008348482,0.012004558,0.0018874173,0.000018752207,0.0000067773994,0.0000027163098,0.0007604788,0.0000172727,0.028488614,0.9549621,0.00041632587],"about_ca_topic_score_codex":0.00009215636,"about_ca_topic_score_gemma":0.000011962556,"teacher_disagreement_score":0.9526654,"about_ca_system_score_codex":0.0001135655,"about_ca_system_score_gemma":0.00003475528,"threshold_uncertainty_score":0.6179532},"labels":[],"label_agreement":null},{"id":"W2565558088","doi":"10.1097/qad.0000000000001369","title":"To break patent or not to break patent","year":2016,"lang":"de","type":"article","venue":"AIDS","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"U.S. President’s Emergency Plan for AIDS Relief; Université de Montréal; Brown University; Global Fund to Fight AIDS, Tuberculosis and Malaria","keywords":"Intellectual property; Blueprint; TRIPS architecture; Right to health; Government (linguistics); Negotiation; Disappointment; TRIPS Agreement; Exclusive right; Human rights; Political science; Law; International trade; Economic growth; Business; Economics; Engineering","score_opus":0.15245929378222314,"score_gpt":0.30345704587026573,"score_spread":0.15099775208804259,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2565558088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88124317,0.0023350788,0.0030057412,0.08257455,0.0082803825,0.001534713,0.0069029117,0.00012482207,0.0139986565],"genre_scores_gemma":[0.944435,0.0020034306,0.00057193916,0.037250713,0.0015895631,0.000097691445,0.000016357315,0.00011169992,0.01392361],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996062,0.000039882947,0.0013911518,0.001145921,0.00007984597,0.001281225],"domain_scores_gemma":[0.997044,0.00024051844,0.00029628177,0.0009767452,0.00007127686,0.0013711762],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0007958696,0.0005107834,0.00097303436,0.0005394293,0.00016135313,0.00023084122,0.0007757772,0.00027127014,0.005852757],"category_scores_gemma":[0.00029827468,0.0004327607,0.00035821684,0.0004905522,0.000080704645,0.00024369406,0.0005694325,0.00022236907,0.07256402],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027280052,0.0013938578,0.049868133,0.00025561044,0.0015349445,0.00022507818,0.0025234625,0.00027378422,0.0014351568,0.2659541,0.21113737,0.4626705],"study_design_scores_gemma":[0.0018441741,0.00095404254,0.020426027,0.00011024044,0.000051107403,0.000012012995,0.000025493053,0.00031309642,0.0020693494,0.0033148744,0.9698661,0.0010134957],"about_ca_topic_score_codex":0.0006933457,"about_ca_topic_score_gemma":0.00006327416,"teacher_disagreement_score":0.75872874,"about_ca_system_score_codex":0.0005713746,"about_ca_system_score_gemma":0.00011342971,"threshold_uncertainty_score":0.9998124},"labels":[],"label_agreement":null},{"id":"W2574777418","doi":"","title":"Brand-name and Generic Drug Pricing in a Regulated Environment: Findings from Canadian Data","year":2012,"lang":"en","type":"preprint","venue":"RePEc: Research Papers in Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Product differentiation; Profitability index; Competition (biology); Generic drug; Context (archaeology); Business; Product (mathematics); Market share; Quality (philosophy); Marketing; Brand names; Advertising; Economics; Industrial organization; Microeconomics; Drug; Finance","score_opus":0.09039875302109344,"score_gpt":0.308945340895767,"score_spread":0.21854658787467351,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2574777418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9498265,0.0048882854,0.0000027689593,0.0020598557,0.000440716,0.0007887919,0.0031739809,0.000018635057,0.03880048],"genre_scores_gemma":[0.95737064,0.0397561,0.00044160913,0.00054296054,0.0003062071,0.00009083294,0.0007867143,0.0001091201,0.0005958053],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99512786,0.00011644913,0.001384193,0.0017740721,0.000059668255,0.0015377576],"domain_scores_gemma":[0.99666137,0.00036238437,0.00030800968,0.001871734,0.000011400134,0.00078508747],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0031405685,0.0004549418,0.0010720344,0.0013576418,0.00016183821,0.00029711716,0.0014725841,0.00059303787,0.0008089373],"category_scores_gemma":[0.0002416929,0.00062296906,0.0001024645,0.0001586607,0.00029861755,0.00037466508,0.0024870443,0.0019882123,0.0002063314],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022303108,0.00054617436,0.8164772,0.00046259223,0.0006975972,0.00012342913,0.0057889917,0.011892844,0.00009157057,0.015433404,0.0013340629,0.1469291],"study_design_scores_gemma":[0.003003277,0.000031915213,0.27132565,0.00027415575,0.000024210467,0.000012293416,0.00025049446,0.23010696,0.000053987416,0.040302802,0.45246467,0.0021495807],"about_ca_topic_score_codex":0.091611974,"about_ca_topic_score_gemma":0.053218264,"teacher_disagreement_score":0.5451516,"about_ca_system_score_codex":0.0023301532,"about_ca_system_score_gemma":0.00037342618,"threshold_uncertainty_score":0.99962217},"labels":[],"label_agreement":null},{"id":"W2577762934","doi":"10.1016/j.hcmf.2012.09.014","title":"Les ruptures d'approvisionnement en médicaments: Les stratégies canadiennes pour un problème mondial complexe","year":2012,"lang":"fr","type":"article","venue":"Healthcare Management Forum","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science; Humanities; Art","score_opus":0.06934214974738728,"score_gpt":0.310047422528066,"score_spread":0.24070527278067871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2577762934","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16077584,0.12683246,0.0032828725,0.60818607,0.008045995,0.0037904256,0.0040920353,0.00021036256,0.08478398],"genre_scores_gemma":[0.96995836,0.009690293,0.003622531,0.0075865905,0.0010030597,0.00021351781,0.00016774367,0.000100123136,0.007657776],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951895,0.00014857945,0.0014039605,0.00077554415,0.00012043991,0.0023619775],"domain_scores_gemma":[0.9978343,0.00011528334,0.0006108877,0.0006056618,0.000045990157,0.0007878618],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001082918,0.00057662214,0.00079114,0.0004963923,0.00073228864,0.00022501945,0.0006408115,0.0003404485,0.002537427],"category_scores_gemma":[0.000037322578,0.00072121335,0.00029934524,0.000286052,0.0002072051,0.00047939594,0.0005768885,0.00054739445,0.00063640904],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031564283,0.00043774908,0.051558487,0.0009562339,0.00036043362,0.000010002167,0.0009224544,0.00007579809,0.0000010922957,0.7705954,0.0183177,0.1567331],"study_design_scores_gemma":[0.0012276447,0.00018586939,0.05449643,0.00017229008,0.00006907652,0.000008944515,0.0041728723,0.0025309455,0.000017207365,0.03666637,0.89966756,0.00078479643],"about_ca_topic_score_codex":0.041026764,"about_ca_topic_score_gemma":0.009414198,"teacher_disagreement_score":0.88134986,"about_ca_system_score_codex":0.0011550481,"about_ca_system_score_gemma":0.000053220785,"threshold_uncertainty_score":0.9995239},"labels":[],"label_agreement":null},{"id":"W2582303529","doi":"10.1371/journal.pmed.1002191","title":"What Is the Purpose of the Orphan Drug Act?","year":2017,"lang":"en","type":"article","venue":"PLoS Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":102,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Canadian Institutes of Health Research","keywords":"Orphan drug; Drug; Medicine; Pharmacology; Bioinformatics; Biology","score_opus":0.09471316794752938,"score_gpt":0.3094459043501145,"score_spread":0.2147327364025851,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2582303529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.48189235,0.0063249934,0.000010921463,0.41274956,0.0026856123,0.00046436166,0.000081859864,0.00001397467,0.09577636],"genre_scores_gemma":[0.97898287,0.0036097867,0.0000069729417,0.013924163,0.0004887359,0.000012491078,0.0000012683163,0.000014917641,0.0029588062],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99912333,0.00001244504,0.00042075943,0.00019618576,0.00004058342,0.00020666941],"domain_scores_gemma":[0.9982422,0.00010242157,0.0005104904,0.0010394909,0.000022051683,0.00008337251],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005239948,0.00010967727,0.00032477372,0.000043618893,0.00028756974,0.000081400685,0.0009944852,0.000042467767,0.0012485859],"category_scores_gemma":[0.0002980271,0.000064173844,0.00009703098,0.000053207186,0.0004443094,0.00027001533,0.00019456776,0.00018271427,0.00028285183],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000079735386,0.0003939317,0.103974074,0.00022983427,0.00062884076,0.0000050886433,0.014467595,0.000007712083,0.00088960177,0.6413989,0.21187907,0.026045615],"study_design_scores_gemma":[0.0014124997,0.00004873912,0.03856111,0.00017497253,0.000047883623,0.0000035782443,0.00022105542,0.002342865,0.005147679,0.12614463,0.825675,0.00021999834],"about_ca_topic_score_codex":0.00020185036,"about_ca_topic_score_gemma":0.00003235832,"teacher_disagreement_score":0.61379594,"about_ca_system_score_codex":0.000028537514,"about_ca_system_score_gemma":0.000017187243,"threshold_uncertainty_score":0.9996644},"labels":[],"label_agreement":null},{"id":"W2582669396","doi":"10.1257/aer.p20171086","title":"Is American Health Care Uniquely Inefficient? Evidence from Prescription Drugs","year":2017,"lang":"en","type":"article","venue":"American Economic Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Common Fund; NIH Office of the Director; National Institute on Aging; National Science Foundation; National Institutes of Health; Pfizer","keywords":"Medical prescription; Quality (philosophy); Health care; Prescription drug; Drug; Medicine; Actuarial science; Business; Political science; Pharmacology; Law; Philosophy; Epistemology","score_opus":0.09844971992391113,"score_gpt":0.3812103827982905,"score_spread":0.2827606628743794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2582669396","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.35829943,0.45342514,0.00040118257,0.12814212,0.0016773811,0.0021233961,0.0029653334,0.00018237147,0.052783642],"genre_scores_gemma":[0.5996537,0.3604238,0.00069129653,0.038656734,0.00021739882,0.000083285355,0.000043278804,0.000052634015,0.00017786123],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969236,0.00007057002,0.0013469021,0.001006001,0.00003687547,0.0006160183],"domain_scores_gemma":[0.99452615,0.00011056047,0.0031003074,0.00182759,0.000029346318,0.0004060467],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00073147024,0.00035820404,0.0015631075,0.00012830396,0.0003966248,0.0002971396,0.0012344497,0.000039099894,0.0009518114],"category_scores_gemma":[0.00016447778,0.0004220547,0.00037223878,0.00008709324,0.000676893,0.00061506603,0.00027993813,0.0002688896,0.0053042592],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056617428,0.00010742889,0.093571424,0.0010463257,0.00033486748,0.000003348482,0.0031586504,0.000041624855,0.000007012092,0.027269468,0.1805669,0.69383633],"study_design_scores_gemma":[0.0003677654,0.00021422937,0.049321424,0.00089769077,0.000033097764,0.0000024930669,0.00018471724,0.001116993,0.00003260637,0.0017392525,0.94534373,0.0007459959],"about_ca_topic_score_codex":0.028022083,"about_ca_topic_score_gemma":0.0003547698,"teacher_disagreement_score":0.7647768,"about_ca_system_score_codex":0.0008280021,"about_ca_system_score_gemma":0.00018930368,"threshold_uncertainty_score":0.99996144},"labels":[],"label_agreement":null},{"id":"W2582749134","doi":"10.1007/s41669-017-0013-8","title":"Authors’ Reply to Holko: “Forecasting Pharmaceutical Prices for Economic Evaluations When There Is No Market: A Review”","year":2017,"lang":"en","type":"letter","venue":"PharmacoEconomics - Open","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics; University of Alberta","funders":"","keywords":"Economics; Financial economics; Econometrics","score_opus":0.2637735742554665,"score_gpt":0.4504590824979789,"score_spread":0.1866855082425124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2582749134","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014014487,0.007678807,0.00024617385,0.7512441,0.004983571,0.007687798,0.01687709,0.00008906204,0.21105324],"genre_scores_gemma":[0.00015457995,0.011419762,0.003919112,0.9297816,0.010145806,0.0033274437,0.0008378994,0.0004945185,0.039919272],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9913251,0.00013251527,0.0034639628,0.003030748,0.00009898108,0.0019487021],"domain_scores_gemma":[0.99233425,0.00083032803,0.0032825377,0.0024814147,0.00017893978,0.0008925604],"candidate_categories":["metaepi_narrow","scholarly_communication","open_science","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0057557034,0.0013530039,0.0030898578,0.0005963811,0.0009839743,0.0024970884,0.00638297,0.0007919878,0.03591286],"category_scores_gemma":[0.0006540652,0.0017029052,0.0011231482,0.00008537941,0.00020984227,0.0015733296,0.0020678814,0.00222808,0.01922839],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015476585,0.000070443144,0.00010556683,0.001308234,0.00091706065,0.000020441872,0.00018622915,0.00003853922,0.0000036917227,0.002026306,0.9912963,0.0038724472],"study_design_scores_gemma":[0.0022878007,0.00011180994,0.000019973984,0.00050445035,0.00035908702,0.00003181251,0.00000423991,0.036800876,0.00007249031,0.017555745,0.9402961,0.001955602],"about_ca_topic_score_codex":0.00084521656,"about_ca_topic_score_gemma":0.00002675344,"teacher_disagreement_score":0.17853749,"about_ca_system_score_codex":0.0015619231,"about_ca_system_score_gemma":0.0006866279,"threshold_uncertainty_score":0.9999221},"labels":[],"label_agreement":null},{"id":"W2586280892","doi":"10.18192/uojm.v7i1.1438","title":"Is Brand Name Best? Brand name versus generic pharmaceuticals in clinical practice","year":2017,"lang":"en","type":"article","venue":"University of Ottawa Journal of Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Ottawa","funders":"","keywords":"Brand names; Political science; Humanities; Medicine; Business; Advertising; Art","score_opus":0.17279746123905682,"score_gpt":0.39618807524055144,"score_spread":0.22339061400149463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586280892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7492132,0.01130455,0.000707753,0.09534263,0.002822976,0.00020633517,0.00009376132,0.000006451844,0.14030233],"genre_scores_gemma":[0.9784068,0.016974295,0.0011539866,0.002317429,0.0006179071,5.38553e-8,0.000001333952,0.0000139473605,0.00051424216],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982566,0.00006232212,0.0010965477,0.00022888437,0.00009274336,0.00026285625],"domain_scores_gemma":[0.9966493,0.0005343835,0.00200116,0.00034072928,0.00013455616,0.000339838],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027613975,0.00014376959,0.00085613097,0.00029151826,0.00014560191,0.000025414782,0.0007369414,0.00014578094,0.0016722447],"category_scores_gemma":[0.0017346188,0.00015712297,0.00021697256,0.0000811914,0.0006379426,0.000597987,0.000113274546,0.0005500346,0.00012794709],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009097285,0.0029957057,0.5765793,0.00037745645,0.0031904692,0.0018794693,0.007094809,0.00029914244,0.00018152411,0.12043285,0.15420985,0.123662174],"study_design_scores_gemma":[0.020565342,0.0006363525,0.028974097,0.00011101897,0.00014395882,0.00005373618,0.00035829478,0.0014018858,0.00003092751,0.0020296792,0.94549406,0.0002006724],"about_ca_topic_score_codex":0.00038747716,"about_ca_topic_score_gemma":0.00003009142,"teacher_disagreement_score":0.7912842,"about_ca_system_score_codex":0.000107831176,"about_ca_system_score_gemma":0.00009110297,"threshold_uncertainty_score":0.99924034},"labels":[],"label_agreement":null},{"id":"W2587542073","doi":"10.1093/ndt/gfw135.03","title":"MO031IS THE INCIDENCE OF RENAL REPLACEMENT THERAPY IN WESTERNIZED COUNTRIES DECLINING?","year":2016,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Renal replacement therapy; Incidence (geometry); Intensive care medicine; Internal medicine","score_opus":0.03616128925059323,"score_gpt":0.2869231237212905,"score_spread":0.2507618344706972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587542073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98904693,0.00038886533,0.003246606,0.0059408257,0.00009982356,0.00017183021,0.00012557613,0.000011240471,0.00096831034],"genre_scores_gemma":[0.98717123,0.00931859,0.000065110726,0.0032753153,0.000054563287,0.000047643985,0.000011179113,0.000008915675,0.000047474525],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99873674,0.00006156238,0.00071608915,0.00025275475,0.0000301496,0.00020267571],"domain_scores_gemma":[0.99897367,0.00043965093,0.00031850225,0.00021415317,0.000020942634,0.000033094442],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008499999,0.00010550065,0.00032933554,0.00018244972,0.000044742916,0.000013382824,0.00019894463,0.00009423667,0.0004788609],"category_scores_gemma":[0.00003395016,0.00007510523,0.000089292655,0.00014030027,0.00015684539,0.00015299063,0.000010012249,0.00007631158,0.00009440631],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026452586,0.0001405131,0.8964707,0.00003205136,0.00030587058,0.000006514645,0.004091835,0.00043613478,0.0044734706,0.08532647,0.00028898238,0.0057821483],"study_design_scores_gemma":[0.016828412,0.0006583709,0.8088983,0.00007346927,0.00010825724,0.000019203124,0.000051157276,0.003126387,0.0157085,0.07791205,0.07596404,0.0006518269],"about_ca_topic_score_codex":0.00023466634,"about_ca_topic_score_gemma":0.00042171846,"teacher_disagreement_score":0.087572426,"about_ca_system_score_codex":0.000042657746,"about_ca_system_score_gemma":0.0000244245,"threshold_uncertainty_score":0.5243191},"labels":[],"label_agreement":null},{"id":"W2588195939","doi":"10.1093/eurpub/ckw169.001","title":"Examining the unanticipated effects of public-private partnerships for preventing chronic disease","year":2016,"lang":"en","type":"article","venue":"European Journal of Public Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Public Health Agency of Canada; Impact; University of Waterloo","funders":"","keywords":"Disease; Medicine; Chronic disease; Intensive care medicine; Business; Internal medicine","score_opus":0.3635397401906284,"score_gpt":0.35317790156311907,"score_spread":0.010361838627509334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588195939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.788559,0.007501936,0.10838848,0.091396496,0.001189093,0.0006245434,0.000110405,0.000027184084,0.00220283],"genre_scores_gemma":[0.9966974,0.0009800822,0.0002801081,0.0012262021,0.0005943135,0.000004270091,0.0000022270528,0.000043300115,0.00017207576],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967431,0.00081812835,0.0014861003,0.00021573703,0.00005583559,0.0006810899],"domain_scores_gemma":[0.99633706,0.0006293042,0.0019495556,0.00030690365,0.00009072073,0.00068642985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01675799,0.00014756185,0.00046093302,0.00025566926,0.00015698842,0.00010429545,0.0005814133,0.000020835316,0.00007851546],"category_scores_gemma":[0.0027276564,0.000100044716,0.00020009681,0.00019907832,0.00011253106,0.00039102696,0.000102680606,0.00018606632,0.00005272604],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000425936,0.00045566246,0.06823482,0.0011883051,0.00053731486,0.000027780728,0.0011416632,0.000022898175,0.00034975976,0.5335256,0.00528742,0.38918617],"study_design_scores_gemma":[0.004400525,0.0009921462,0.17346399,0.0003930473,0.000022742684,0.000013455529,0.000045969915,0.0010622649,0.00012956216,0.006868005,0.81226546,0.00034284987],"about_ca_topic_score_codex":0.000003526121,"about_ca_topic_score_gemma":0.0000026029884,"teacher_disagreement_score":0.80697805,"about_ca_system_score_codex":0.00022249707,"about_ca_system_score_gemma":0.00044896608,"threshold_uncertainty_score":0.58080184},"labels":[],"label_agreement":null},{"id":"W2589088062","doi":"10.1016/j.healthpol.2017.02.002","title":"Payers’ experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia","year":2017,"lang":"en","type":"article","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":114,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"University of British Columbia; Commonwealth Fund","keywords":"Confidentiality; Negotiation; Business; Statutory law; Discounting; Public health; Revenue; Public economics; Actuarial science; Marketing; Economics; Law; Finance; Medicine; Political science; Nursing","score_opus":0.15116486108529856,"score_gpt":0.3988349864480218,"score_spread":0.24767012536272323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589088062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9808309,0.0046352404,0.00012036785,0.011392559,0.00018788734,0.0005054683,0.0008272925,0.000012134531,0.0014881191],"genre_scores_gemma":[0.9892712,0.007643214,0.000041992604,0.002771186,0.000110761735,0.000041853444,0.000019552686,0.000023340046,0.00007690498],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99762815,0.00016118505,0.00093031145,0.0004717345,0.00005730435,0.00075128785],"domain_scores_gemma":[0.99784654,0.00010338689,0.0009647908,0.00037476726,0.00004603317,0.00066450646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013047971,0.00020238495,0.0007580511,0.0003209878,0.00030213597,0.00027281215,0.00029366708,0.00005105874,0.000031141397],"category_scores_gemma":[0.00027757927,0.00020203344,0.000021655856,0.00027139793,0.0006328549,0.0004449873,0.0001333637,0.00025120535,0.000016971635],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009829481,0.00020103225,0.9212791,0.00068812893,0.000063966974,0.0000053786707,0.011470973,0.000015130972,8.7903675e-7,0.05690722,0.0011413571,0.008128583],"study_design_scores_gemma":[0.0014298594,0.00028355425,0.9211946,0.00003990058,0.0000016261625,0.000015326672,0.0008075176,0.0024974863,7.8112794e-7,0.000059296577,0.07341211,0.0002579466],"about_ca_topic_score_codex":0.105728,"about_ca_topic_score_gemma":0.0062295473,"teacher_disagreement_score":0.09949845,"about_ca_system_score_codex":0.00015676935,"about_ca_system_score_gemma":0.0006901307,"threshold_uncertainty_score":0.900227},"labels":[],"label_agreement":null},{"id":"W2589546335","doi":"10.1177/1715163517691254","title":"The misrepresentation of high drug costs","year":2017,"lang":"fr","type":"editorial","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Misrepresentation; Drug; Business; Pharmacology; Medicine; Political science; Law","score_opus":0.04023179273685439,"score_gpt":0.28747116861362493,"score_spread":0.24723937587677053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589546335","genre_codex":"editorial","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07763177,0.027333595,0.00005702713,0.0034942962,0.8476706,0.0010419057,0.026760573,0.000016864911,0.015993373],"genre_scores_gemma":[0.6499507,0.14842801,0.00005893021,0.0013353406,0.18416293,0.00004054139,0.00029410695,0.00018323834,0.01554624],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9934286,0.0002758522,0.002746344,0.0009633062,0.00034806188,0.002237851],"domain_scores_gemma":[0.989434,0.001405362,0.0038700784,0.0010754156,0.0010021228,0.0032130193],"candidate_categories":["metaepi_narrow","sts","scholarly_communication","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0028276867,0.00090327393,0.0015552671,0.00063133653,0.0038405235,0.0013949112,0.0034712935,0.00040657565,0.0019083358],"category_scores_gemma":[0.0023818067,0.0010436935,0.0006629476,0.00039172955,0.0013211623,0.00078091456,0.00021568929,0.002758261,0.00016721206],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00015537703,0.00005201389,0.00071101735,0.0003598184,0.0008450406,0.0056205723,0.00053880207,0.00079874054,0.000019817879,0.0037450832,0.9202404,0.06691332],"study_design_scores_gemma":[0.0026357544,0.00003707406,0.000032951797,0.00008444758,0.00021889273,0.018511966,0.000007968487,0.0033249978,0.000347013,0.0031403876,0.97061175,0.0010467739],"about_ca_topic_score_codex":0.35130706,"about_ca_topic_score_gemma":0.5192508,"teacher_disagreement_score":0.66350764,"about_ca_system_score_codex":0.010683085,"about_ca_system_score_gemma":0.010509662,"threshold_uncertainty_score":0.9996417},"labels":[],"label_agreement":null},{"id":"W2590702803","doi":"10.1200/jco.2013.31.31_suppl.192","title":"Managing chemotherapy drug shortages in Ontario.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Economic shortage; Chemotherapy; Drug; Intensive care medicine; Surgery; Pharmacology","score_opus":0.191689334561121,"score_gpt":0.43035365550137833,"score_spread":0.23866432094025733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590702803","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8669481,0.00046579842,0.000067712834,0.034798585,0.0012547225,0.00010454345,0.000002011168,0.0000037518448,0.096354745],"genre_scores_gemma":[0.98058885,0.0013947533,0.0011685138,0.014831438,0.00047692852,0.0000041968947,5.250364e-7,0.000014218116,0.0015205776],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99658483,0.000054141517,0.0028929396,0.00017687376,0.000026677675,0.0002645146],"domain_scores_gemma":[0.99755585,0.0005802579,0.001423437,0.00014056626,0.000054864133,0.00024502614],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0030017192,0.00010388753,0.0011400183,0.00020967853,0.000019564153,0.00003260422,0.00031537234,0.00017973267,0.003539822],"category_scores_gemma":[0.0003619749,0.000099708974,0.00028562348,0.000095053176,0.00008558298,0.00029268864,0.00004375821,0.0009431731,0.00054077624],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015435429,0.0007648441,0.85308695,0.000008333474,0.00017241285,0.000049278893,0.00046095488,0.000112567584,0.0000054013367,0.031510934,0.027767463,0.08590649],"study_design_scores_gemma":[0.0018629385,0.00027411175,0.43448883,0.000007822058,0.000004213582,0.000009904151,0.000025940892,0.0007310332,0.0000052025566,0.11242482,0.4500627,0.00010248632],"about_ca_topic_score_codex":0.008776841,"about_ca_topic_score_gemma":0.010467284,"teacher_disagreement_score":0.42229524,"about_ca_system_score_codex":0.00028068654,"about_ca_system_score_gemma":0.0003083064,"threshold_uncertainty_score":0.9978238},"labels":[],"label_agreement":null},{"id":"W2590797524","doi":"10.1080/13543776.2017.1296950","title":"Patent disclosure requirements for therapeutic antibody patents","year":2017,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Antibody; Pharmacology; Medicine; Immunology","score_opus":0.6197336892953145,"score_gpt":0.48238085560467564,"score_spread":0.13735283369063883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590797524","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000051169905,0.98292524,0.00058930635,0.0006519758,0.0072510946,0.0027831076,0.0020755837,0.00010030444,0.0036182478],"genre_scores_gemma":[0.00083029055,0.9915394,0.00005447129,0.0026717535,0.0011495723,0.0010927314,0.0013555785,0.00032210903,0.0009841014],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99441004,0.00013353545,0.0023056965,0.001689679,0.0001638075,0.0012972371],"domain_scores_gemma":[0.9951449,0.0001802049,0.0023257844,0.0018608046,0.000065744665,0.00042256434],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009184917,0.0012520087,0.0034055868,0.00055304385,0.0006277544,0.00044132688,0.0018363681,0.0007814199,0.00040062162],"category_scores_gemma":[0.0000575287,0.0011350765,0.0017445757,0.00016275383,0.00017011639,0.0003283029,0.00023831816,0.0006014791,0.0023635593],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000090607246,0.00066950574,0.00018393873,0.0015963544,0.0016298454,0.000004093841,0.00014737326,0.0000014809546,0.0000019003007,0.026272174,0.0017230725,0.9676797],"study_design_scores_gemma":[0.0017860071,0.000328142,0.00010965861,0.0023136893,0.000057207006,0.000006558915,0.0000072163743,0.00023863195,0.0000038103813,0.010600681,0.9832892,0.0012592106],"about_ca_topic_score_codex":0.000060597722,"about_ca_topic_score_gemma":0.0000011546329,"teacher_disagreement_score":0.98156613,"about_ca_system_score_codex":0.0005254365,"about_ca_system_score_gemma":0.00013296223,"threshold_uncertainty_score":0.9991099},"labels":[],"label_agreement":null},{"id":"W2593759362","doi":"10.3821/1913-701x-143.2.96","title":"The Sale of Non-Approved Marketed Health Products — A Regulatory Perspective","year":2010,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Perspective (graphical); Business; Marketing; Computer science","score_opus":0.0349640961202045,"score_gpt":0.2699871753106098,"score_spread":0.23502307919040527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593759362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95907325,0.0055068373,0.000052911077,0.0074224407,0.0076639885,0.0009228839,0.0031881705,0.000025965799,0.016143585],"genre_scores_gemma":[0.9895431,0.0042627393,0.00019145955,0.0038476395,0.0010049136,0.00001832325,0.000009939989,0.00005966328,0.0010622473],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971005,0.00006855971,0.0011106457,0.00048333782,0.00010112129,0.0011358568],"domain_scores_gemma":[0.9962642,0.00013225734,0.0008555461,0.0004765822,0.00042555123,0.0018458306],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019982313,0.0003160146,0.00056157995,0.0003472116,0.0010258065,0.00015428547,0.0009142606,0.0000738177,0.0004770527],"category_scores_gemma":[0.0005063221,0.0003238643,0.00018142154,0.0005610277,0.00043519298,0.00028487362,0.00005872523,0.0011025463,0.000031100783],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074920646,0.0004485744,0.010018833,0.001047384,0.0021666996,0.005505633,0.012171271,0.00085125293,0.014308639,0.12469387,0.702027,0.12601158],"study_design_scores_gemma":[0.0032784995,0.00010045337,0.00095435756,0.00001936494,0.000045207315,0.048263043,0.00006307837,0.015483071,0.0032180452,0.009097473,0.9183532,0.0011242051],"about_ca_topic_score_codex":0.05736312,"about_ca_topic_score_gemma":0.13556166,"teacher_disagreement_score":0.21632615,"about_ca_system_score_codex":0.0020036008,"about_ca_system_score_gemma":0.00468948,"threshold_uncertainty_score":0.9999213},"labels":[],"label_agreement":null},{"id":"W2594076047","doi":"10.1503/cmaj.161082","title":"Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada","year":2017,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Toronto; University of British Columbia","funders":"","keywords":"Essential medicines; Government (linguistics); Medical prescription; Essential drugs; Medicine; Public health; Generic drug; Business; Environmental health; Drug; Pharmacology; Population; Health services","score_opus":0.03224340550308577,"score_gpt":0.27353159747386263,"score_spread":0.24128819197077686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594076047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9478226,0.000076340046,0.00005465554,0.042057205,0.0010333929,0.00009219947,0.0003782277,0.0000031810873,0.008482233],"genre_scores_gemma":[0.99619627,0.00005860098,0.000046195826,0.003246417,0.0003789523,0.000001797407,0.000016008842,0.000011580042,0.000044163415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984541,0.00004937328,0.00071478105,0.00016046264,0.00016350274,0.000457762],"domain_scores_gemma":[0.9972308,0.00023420538,0.00080125383,0.00015726205,0.00013736881,0.0014390951],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001387357,0.00010139657,0.0004107628,0.00037915705,0.00022069355,0.00012396189,0.00052964565,0.00011659703,0.0007004107],"category_scores_gemma":[0.006742933,0.00012114336,0.000049612026,0.00014386585,0.000044558266,0.00035091475,0.000039785355,0.00040920704,0.000008525158],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001148164,0.000053708674,0.93920267,0.00006628552,0.0001388677,0.0002713728,0.0005782821,0.000083860665,0.00001614412,0.025451668,0.018718943,0.0154067455],"study_design_scores_gemma":[0.0062773596,0.00013004441,0.65890056,0.00045612757,0.00002981241,0.000072228395,0.0006934222,0.045839787,0.00024102043,0.0050242585,0.2815354,0.000800013],"about_ca_topic_score_codex":0.8218325,"about_ca_topic_score_gemma":0.98469865,"teacher_disagreement_score":0.2803021,"about_ca_system_score_codex":0.0018720005,"about_ca_system_score_gemma":0.00377081,"threshold_uncertainty_score":0.8072408},"labels":[],"label_agreement":null},{"id":"W2594128595","doi":"10.1038/543174a","title":"Show drugs work before selling them","year":2017,"lang":"en","type":"article","venue":"Nature","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Work (physics); Business; Chemistry; Engineering","score_opus":0.050694209092408765,"score_gpt":0.29551176398356355,"score_spread":0.24481755489115478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594128595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.517834,0.0020284425,0.00006589289,0.021063086,0.0017767526,0.00016445895,0.00019943704,0.00006064306,0.4568073],"genre_scores_gemma":[0.99045,0.00020705037,0.000404179,0.0048678517,0.0007261955,0.0000064490323,0.00000857779,0.0000258537,0.003303827],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99909693,0.0000036451881,0.00025552703,0.0003093401,0.00002145985,0.00031308705],"domain_scores_gemma":[0.9989863,0.000025017112,0.0002536192,0.000592845,0.00001590248,0.0001263365],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030867456,0.00013642374,0.0002621215,0.00005417699,0.00034255307,0.00027378454,0.0006186047,0.0007155097,0.0007453733],"category_scores_gemma":[0.00009715262,0.00014570933,0.00013232787,0.000052136656,0.00006429474,0.00023059081,0.00010912498,0.0013804914,0.0019610364],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020818778,0.000042837968,0.0722746,0.000020967018,0.00007054788,0.0000048600764,0.0005841045,0.000017862541,0.000004456087,0.8948724,0.020748878,0.011337662],"study_design_scores_gemma":[0.00041794084,0.000009654725,0.023667913,0.000014634718,0.000004826358,0.0000019670515,0.000011856243,0.0012420029,0.00012884851,0.19208595,0.78216535,0.00024905262],"about_ca_topic_score_codex":0.000020454947,"about_ca_topic_score_gemma":0.0000065331146,"teacher_disagreement_score":0.7614165,"about_ca_system_score_codex":0.00005535677,"about_ca_system_score_gemma":0.000012012299,"threshold_uncertainty_score":0.9988161},"labels":[],"label_agreement":null},{"id":"W2594847000","doi":"10.1208/s12248-017-0068-6","title":"Global Harmonization of Comparator Products for Bioequivalence Studies","year":2017,"lang":"en","type":"article","venue":"The AAPS Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"World Health Organization","keywords":"Comparator; Harmonization; Bioequivalence; Product (mathematics); Innovator; Risk analysis (engineering); Medicine; Business; Computer science; Pharmacology; Engineering; Mathematics; Intellectual property; Pharmacokinetics","score_opus":0.3103234213113339,"score_gpt":0.40726290997474685,"score_spread":0.09693948866341295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594847000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92546356,0.015102665,0.003584713,0.044951577,0.0025696005,0.0004355622,0.0004942425,0.0000124781045,0.0073855924],"genre_scores_gemma":[0.9966538,0.0017481965,0.00050102815,0.00047393108,0.00047333425,0.0000048684665,8.675152e-7,0.00000647594,0.00013747562],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99927396,0.000009237653,0.0004047376,0.000118637814,0.000018863342,0.00017457182],"domain_scores_gemma":[0.99877083,0.000036102774,0.0007402895,0.00029894937,0.000106820014,0.0000469829],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007566618,0.000075556076,0.0002504438,0.000030102903,0.0004681544,0.00012750522,0.0005036187,0.00002370645,0.000022900529],"category_scores_gemma":[0.0005073111,0.00005972605,0.00007397904,0.00004139476,0.00019047402,0.00021303704,0.00008026283,0.000071603696,0.00004311126],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015658129,0.00013466667,0.06876981,0.00014136685,0.00051842997,0.0000018641329,0.0008166256,0.00031093694,0.0003392457,0.84961534,0.07534819,0.003846918],"study_design_scores_gemma":[0.002392514,0.00022308952,0.078096196,0.000058937738,0.00006441571,0.000089237605,0.00015461155,0.0070131985,0.0037508323,0.7206692,0.18708323,0.0004045308],"about_ca_topic_score_codex":0.000009159858,"about_ca_topic_score_gemma":0.0000031458842,"teacher_disagreement_score":0.12894616,"about_ca_system_score_codex":0.000060849085,"about_ca_system_score_gemma":0.000030216997,"threshold_uncertainty_score":0.36007124},"labels":[],"label_agreement":null},{"id":"W2595954084","doi":"10.1056/jw200404060000002","title":"Restricting Access to Nebulizers: Creative and Successful Policy Experiment","year":2004,"lang":"en","type":"article","venue":"Journal watch","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Government (linguistics); Medicine; Public economics; Business; Finance; Economics; Economic growth; Health care","score_opus":0.08424132363743976,"score_gpt":0.3643301369220854,"score_spread":0.28008881328464563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595954084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8339242,0.00081077375,0.0009942785,0.13635473,0.0003054937,0.0001705668,0.000032077085,0.00001896347,0.027388923],"genre_scores_gemma":[0.98858726,0.0024452019,0.00086783135,0.006802465,0.00089590217,0.000012704351,0.0000011249552,0.000025533054,0.00036198745],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99869484,0.00001194156,0.0005736305,0.00027369038,0.00003504154,0.00041087306],"domain_scores_gemma":[0.9990436,0.000036540598,0.00025933707,0.00015131854,0.000031357096,0.00047783487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037601517,0.00015739936,0.0003295221,0.00028151652,0.00025670472,0.0005728021,0.00031941372,0.000068572925,0.00022269812],"category_scores_gemma":[0.00019584029,0.0001644939,0.00008387843,0.00030075203,0.000036658083,0.00056068896,0.00018086768,0.00028367224,0.00021221935],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004121802,0.00086410466,0.12063451,0.000096938944,0.0006406816,0.00019034512,0.022987742,0.0080825575,0.0011847841,0.7766361,0.04584822,0.022421785],"study_design_scores_gemma":[0.004260907,0.00041102173,0.031436995,0.00009585081,0.000017173807,0.00027006093,0.0006844095,0.00038479603,0.0063174446,0.4770671,0.47806722,0.000987014],"about_ca_topic_score_codex":0.001159538,"about_ca_topic_score_gemma":0.000017999648,"teacher_disagreement_score":0.432219,"about_ca_system_score_codex":0.00053541356,"about_ca_system_score_gemma":0.0000777556,"threshold_uncertainty_score":0.6707867},"labels":[],"label_agreement":null},{"id":"W2596575759","doi":"10.1287/msom.2017.0616","title":"Clinical Trials for New Drug Development: Optimal Investment and Application","year":2017,"lang":"en","type":"article","venue":"Manufacturing & Service Operations Management","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Interim; Clinical trial; Revenue; Interim analysis; Drug development; Investment (military); Value (mathematics); Computer science; Net present value; Actuarial science; Medicine; Test (biology); Operations management; Operations research; Drug; Business; Economics; Finance; Microeconomics; Mathematics; Production (economics); Pharmacology","score_opus":0.1940947930245319,"score_gpt":0.39059059635366644,"score_spread":0.19649580332913455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596575759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6981001,0.00084752345,0.1596443,0.062473174,0.0015078693,0.0061402414,0.00022610975,0.00015707781,0.07090359],"genre_scores_gemma":[0.8775868,0.00079798535,0.08913968,0.018946806,0.0008633756,0.00090441434,0.00016312489,0.000067279965,0.0115305735],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99814284,0.00002455302,0.001061006,0.0004986742,0.000026571619,0.00024636017],"domain_scores_gemma":[0.99878496,0.000074797295,0.00035679518,0.0005704997,0.000016718963,0.00019620675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023076236,0.00016960471,0.00042613034,0.00010873055,0.0006154268,0.0006138172,0.00041135735,0.000058007892,0.000077973564],"category_scores_gemma":[0.00006604728,0.00018721963,0.000088743465,0.000021513844,0.000030344598,0.0003215149,0.00029324862,0.00009359365,0.00031500013],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007700418,0.00028540764,0.0022008892,0.00035976403,0.00072534406,0.0000016032104,0.0011283167,0.007785516,0.000007603713,0.786971,0.010935967,0.1895216],"study_design_scores_gemma":[0.0018924273,0.000016659471,0.032558586,0.00001630518,0.000040781913,5.409299e-7,0.000051550403,0.031757493,0.0005292389,0.013291238,0.91951376,0.00033140887],"about_ca_topic_score_codex":0.00028796017,"about_ca_topic_score_gemma":0.00028158975,"teacher_disagreement_score":0.9085778,"about_ca_system_score_codex":0.00007480951,"about_ca_system_score_gemma":0.00002329436,"threshold_uncertainty_score":0.76345944},"labels":[],"label_agreement":null},{"id":"W2600754488","doi":"10.1093/schbul/sbx024.108","title":"SU112. The Dark Side of Haloperidol Decanoate Shortage in Canada","year":2017,"lang":"en","type":"article","venue":"Schizophrenia Bulletin","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean; Université Laval","funders":"","keywords":"Medicine; Economic shortage; Population; Pharmacy; Health care; Antipsychotic; Schizophrenia (object-oriented programming); Psychiatry; Family medicine; Environmental health; Political science; Government (linguistics)","score_opus":0.03332338507526344,"score_gpt":0.2442739957015216,"score_spread":0.21095061062625817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600754488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87850744,0.00080811227,0.0000071392733,0.019658325,0.0005746105,0.00020127551,0.0003425489,0.0000066983375,0.09989383],"genre_scores_gemma":[0.99727476,0.00024668328,0.00012849356,0.0016826929,0.00011709572,0.000021337622,0.000004987279,0.000022948963,0.00050101266],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985804,0.000019634917,0.00066967995,0.000314824,0.00003690396,0.00037856284],"domain_scores_gemma":[0.99851865,0.000090286296,0.00042922868,0.000828146,0.000016473095,0.00011724461],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005355458,0.00016243664,0.00041870534,0.000074566735,0.00020620335,0.00009730876,0.0009032401,0.00005488106,0.0010058333],"category_scores_gemma":[0.00024046439,0.00015216562,0.00008762872,0.000053045595,0.00013460658,0.00006200129,0.00019209388,0.0002602755,0.0003318074],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006587002,0.00016401004,0.38254356,0.00011935875,0.00022059334,0.000087481385,0.0004526348,0.0007415747,0.0002679884,0.5068967,0.09246258,0.01538484],"study_design_scores_gemma":[0.00166076,0.000023149149,0.25218987,0.000031247626,0.0000072381845,0.000005132544,0.000044587017,0.00085342576,0.001089029,0.018720351,0.72494537,0.00042985327],"about_ca_topic_score_codex":0.7749329,"about_ca_topic_score_gemma":0.76903456,"teacher_disagreement_score":0.63248277,"about_ca_system_score_codex":0.0001897703,"about_ca_system_score_gemma":0.00030310598,"threshold_uncertainty_score":0.9999074},"labels":[],"label_agreement":null},{"id":"W2600790561","doi":"10.1200/jco.2013.31.15_suppl.6614","title":"International comparison on the factors influencing reimbursement of expensive cancer drugs.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Medicine; Sunitinib; Erlotinib; Family medicine; Health care; Cancer; Internal medicine; Economic growth","score_opus":0.342264293485292,"score_gpt":0.4938104700091927,"score_spread":0.15154617652390068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600790561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9354493,0.00026384857,0.000024130706,0.024174795,0.0023388676,0.0001028425,0.000018603998,0.0000018467209,0.037625745],"genre_scores_gemma":[0.99215,0.0008044741,0.00012366309,0.0062839566,0.0005235848,0.00000543231,6.330645e-7,0.000007822974,0.00010039532],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99692917,0.00007094919,0.0026584638,0.00012711172,0.000058353828,0.0001559623],"domain_scores_gemma":[0.9947168,0.0016466246,0.0031866536,0.00013225847,0.00016914669,0.00014848492],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016104961,0.00009202024,0.00087084214,0.00011147529,0.000030611336,0.000020164507,0.00040320406,0.00013839715,0.002613118],"category_scores_gemma":[0.0012746938,0.000063998814,0.00032464552,0.0000532447,0.00013397208,0.0001373379,0.00006732163,0.00056407833,0.00013786244],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000369256,0.0013796437,0.71314263,0.000014636675,0.0012860101,0.0000053812423,0.0024904883,0.00089674536,0.00009890627,0.14491852,0.08293805,0.052459724],"study_design_scores_gemma":[0.0018955666,0.0012488989,0.35719672,0.00003757609,0.000026728023,0.0000020178259,0.00095027656,0.0022815985,0.00044251277,0.020194182,0.615563,0.00016095278],"about_ca_topic_score_codex":0.00032869558,"about_ca_topic_score_gemma":0.000011603814,"teacher_disagreement_score":0.5326249,"about_ca_system_score_codex":0.00017840076,"about_ca_system_score_gemma":0.00014155671,"threshold_uncertainty_score":0.99829865},"labels":[],"label_agreement":null},{"id":"W2604225864","doi":"10.1016/s2214-109x(17)30113-4","title":"Can a multistakeholder initiative improve transparency and accountability in the pharmaceutical sector? Evidence from the Medicines Transparency Alliance","year":2017,"lang":"en","type":"article","venue":"The Lancet Global Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Transparency (behavior); Accountability; Stakeholder; Alliance; Stakeholder engagement; Essential medicines; Public sector; Medicine; Business; Government (linguistics); Public health; Public relations; Political science; Nursing","score_opus":0.3617425865175071,"score_gpt":0.43384377090035775,"score_spread":0.07210118438285062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604225864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.570318,0.016750181,0.00018731532,0.40330583,0.000581963,0.0009609372,0.0042413045,0.000021873411,0.0036326111],"genre_scores_gemma":[0.9483734,0.011994952,0.000048526188,0.03884547,0.0006402307,0.00007288122,0.0000093481485,0.000009916138,0.0000052790233],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99790794,0.00018307073,0.00069320394,0.00050712685,0.00007942741,0.0006292493],"domain_scores_gemma":[0.9977857,0.0006558682,0.00040529942,0.0009804299,0.00002104076,0.0001516844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025004093,0.00022979845,0.0005923082,0.000011418388,0.0006284407,0.0002102769,0.0014254582,0.00007671262,0.00009640023],"category_scores_gemma":[0.00029094002,0.00013714666,0.00007687854,0.00011049879,0.00056784146,0.0002648092,0.000068742964,0.0005295583,0.00002641596],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044825047,0.00018766127,0.87046456,0.00017957244,0.00009911524,0.00000849138,0.022849405,0.00002550907,0.000007935571,0.07783662,0.005575703,0.02231718],"study_design_scores_gemma":[0.0013130107,0.00006307521,0.9210052,0.000099875106,0.000014489813,0.0000038432445,0.00034525542,0.0028466622,0.00000604378,0.061750505,0.012368126,0.0001839016],"about_ca_topic_score_codex":0.022022098,"about_ca_topic_score_gemma":0.022443749,"teacher_disagreement_score":0.37805542,"about_ca_system_score_codex":0.00024148337,"about_ca_system_score_gemma":0.00014180131,"threshold_uncertainty_score":0.9953941},"labels":[],"label_agreement":null},{"id":"W2605970134","doi":"","title":"MAKING DECISIONS UNDER UNCERTAINTY: THE VALUE OF ECONOMIC EVALUATIONS IN THE ASSESSMENT OF NON-DRUG HEALTH TECHNOLOGIES IN CANADA","year":2016,"lang":"en","type":"article","venue":"38th Annual North American Meeting of the Society for Medical Decision Making","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Value (mathematics); Risk analysis (engineering); Actuarial science; Computer science; Public economics; Economics; Medicine; Statistics; Mathematics","score_opus":0.04471865151052981,"score_gpt":0.38444427113596485,"score_spread":0.339725619625435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605970134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9602668,0.0005863973,0.008062013,0.029310713,0.00027262047,0.00062449585,0.00062673545,0.000006621122,0.00024357512],"genre_scores_gemma":[0.9936287,0.00051274203,0.0033025402,0.0024673978,0.000025719948,0.000042810174,0.0000021204537,0.000015155886,0.0000028379618],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99730796,0.000102887454,0.0015921384,0.00031892868,0.0002481126,0.0004299606],"domain_scores_gemma":[0.9920399,0.005853845,0.0014649737,0.0005366341,0.000055141423,0.000049471604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045795515,0.00016040236,0.00064630556,0.000110359164,0.00019442456,0.000015105943,0.0013047328,0.00005229753,0.000020044288],"category_scores_gemma":[0.0024068928,0.00008995424,0.00043237608,0.0005768077,0.000642048,0.00006763087,0.0003124646,0.00031132286,9.610471e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008646524,0.00018279724,0.4516152,0.00008747381,0.00021246796,6.811122e-7,0.0032756284,0.10639584,0.0000058765213,0.04730413,0.0064343447,0.3843991],"study_design_scores_gemma":[0.0019836866,0.00015712429,0.6535544,0.0013795412,0.00003389565,0.000004165151,0.017946072,0.24388297,0.000014440776,0.072593145,0.008048469,0.0004021309],"about_ca_topic_score_codex":0.08082453,"about_ca_topic_score_gemma":0.28793415,"teacher_disagreement_score":0.38399696,"about_ca_system_score_codex":0.00074888195,"about_ca_system_score_gemma":0.001967088,"threshold_uncertainty_score":0.92529637},"labels":[],"label_agreement":null},{"id":"W2606813978","doi":"10.9778/cmajo.20170001","title":"Publication of confirmatory studies required by Health Canada for drugs approved under a Notice of Compliance with conditions: a cohort study","year":2017,"lang":"en","type":"article","venue":"CMAJ Open","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"York University","funders":"","keywords":"Notice; Medicine; Confirmatory factor analysis; Health care; Web site; Family medicine; Business; Marketing; World Wide Web; Political science; Computer science; The Internet; Law","score_opus":0.22250544491531704,"score_gpt":0.405297029768289,"score_spread":0.18279158485297198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606813978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87247545,0.0034815958,0.0011371907,0.051121004,0.0007017052,0.012880471,0.010387093,0.000025901316,0.04778959],"genre_scores_gemma":[0.99676156,0.0000892093,0.00019798965,0.0021796306,0.0000173443,0.00018713748,0.000060456172,0.000015619942,0.00049102324],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99874985,0.00001830067,0.00069795974,0.00029949856,0.00003451133,0.00019990014],"domain_scores_gemma":[0.9976049,0.00011590879,0.0014133999,0.00059589284,0.0001742025,0.00009569239],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083036994,0.000113083835,0.000664815,0.000045535475,0.00025853893,0.00009815922,0.00065834203,0.000027048392,0.00003580457],"category_scores_gemma":[0.00017249114,0.00011895371,0.00003220963,0.000050273076,0.00017409284,0.0003435856,0.00015052411,0.000060002465,0.0000056937665],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003547837,0.0012050373,0.2977184,0.0009907089,0.0021533372,5.649577e-7,0.003569444,0.000096053096,0.000041606563,0.4633163,0.22973365,0.0008201249],"study_design_scores_gemma":[0.016834144,0.0012716639,0.6864707,0.00034756053,0.00013677216,0.0000032097819,0.009850223,0.006511072,0.00069452496,0.030955514,0.24560057,0.0013240629],"about_ca_topic_score_codex":0.28101084,"about_ca_topic_score_gemma":0.11046431,"teacher_disagreement_score":0.43236077,"about_ca_system_score_codex":0.00019357941,"about_ca_system_score_gemma":0.0003607375,"threshold_uncertainty_score":0.9057674},"labels":[],"label_agreement":null},{"id":"W2607317376","doi":"10.71781/25443","title":"De l'ADPIC à Cancún : l'accès aux médicaments comme enjeu de gouvernance internationale","year":2005,"lang":"fr","type":"dissertation","venue":"Open MIND","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science","score_opus":0.14270188726073582,"score_gpt":0.3798945332060354,"score_spread":0.23719264594529957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607317376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6575462,0.0053453282,0.00019307286,0.0067832917,0.0017429431,0.00063415046,0.002344691,0.0000030792455,0.3254072],"genre_scores_gemma":[0.74222654,0.008696213,0.008765715,0.0076045324,0.0012509448,0.0001988653,0.0011961923,0.00014853643,0.22991244],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99682486,0.000058376885,0.0012787036,0.00085724756,0.00006794894,0.0009128448],"domain_scores_gemma":[0.99767536,0.00018375488,0.0011667287,0.00048379207,0.00007280796,0.00041753068],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00095529546,0.00047114783,0.000888758,0.00025602087,0.00028283952,0.00087277184,0.0019011794,0.00050266733,0.024220739],"category_scores_gemma":[0.00022814145,0.00069689244,0.00026984594,0.00019177797,0.00011340372,0.0006021372,0.00035487043,0.0007373586,0.0063668303],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035958196,0.0015615463,0.23448549,0.00022909314,0.0013542655,0.00007009179,0.011545478,0.0021502746,0.00021031438,0.09201978,0.036751926,0.61926216],"study_design_scores_gemma":[0.0013786762,0.00005633877,0.050372228,0.00021683582,0.00005641603,0.000015502446,0.00021262263,0.02397598,0.0008382665,0.0051135514,0.9170341,0.00072948483],"about_ca_topic_score_codex":0.005057724,"about_ca_topic_score_gemma":0.0076537183,"teacher_disagreement_score":0.88028216,"about_ca_system_score_codex":0.002213212,"about_ca_system_score_gemma":0.00092154706,"threshold_uncertainty_score":0.9995482},"labels":[],"label_agreement":null},{"id":"W2607334866","doi":"10.1503/cmaj.1095168","title":"Canada wins legal battle to set patent rules","year":2017,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Battle; Computer science; Set (abstract data type); Data science; Operations research; World Wide Web; History; Engineering; Programming language; Ancient history","score_opus":0.05232028738140876,"score_gpt":0.2634194069348799,"score_spread":0.21109911955347116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607334866","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3184751,0.00021693934,0.000074139796,0.57547385,0.0053283963,0.00012029199,0.002064562,0.000008885345,0.098237865],"genre_scores_gemma":[0.91935915,0.000114990515,0.00004923308,0.07703882,0.00186142,0.0000048548773,0.0000102058475,0.000017152694,0.0015441844],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99856794,0.000018595309,0.000514102,0.00018019485,0.00014874298,0.0005704141],"domain_scores_gemma":[0.99673784,0.00006642025,0.00037077896,0.0002045027,0.00007223417,0.002548253],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0011584912,0.00010723857,0.0002677355,0.00012216478,0.0006587009,0.00046786296,0.00049012987,0.00022647598,0.006098476],"category_scores_gemma":[0.0023438626,0.00012390333,0.00008020064,0.000039241066,0.000024055009,0.0001996467,0.00004526679,0.0007037346,0.0012797273],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000002713895,0.000009176037,0.07213083,0.000002901103,0.00007885394,0.00016391152,0.00006444725,0.000015335703,4.1170395e-7,0.035535783,0.8879023,0.004093315],"study_design_scores_gemma":[0.0003381739,0.000011092733,0.08193813,0.000008301247,0.0000025343038,0.000034354463,0.000016288483,0.0005072543,0.0000031549423,0.0017239108,0.915269,0.00014778644],"about_ca_topic_score_codex":0.8520935,"about_ca_topic_score_gemma":0.97063154,"teacher_disagreement_score":0.6008841,"about_ca_system_score_codex":0.0021717597,"about_ca_system_score_gemma":0.0034074155,"threshold_uncertainty_score":0.9994979},"labels":[],"label_agreement":null},{"id":"W2607457584","doi":"10.1016/j.sapharm.2017.02.012","title":"Economic evaluation of pharmacy services","year":2017,"lang":"en","type":"article","venue":"Research in Social and Administrative Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Pharmacy; Business; Medicine; Nursing","score_opus":0.6413577111345987,"score_gpt":0.5809909106068237,"score_spread":0.06036680052777499,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607457584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8501964,0.0010100765,0.000001644127,0.007913312,0.0001444536,0.00033670352,0.00043701037,0.0000054867783,0.13995486],"genre_scores_gemma":[0.99849683,0.00083651347,0.00001879872,0.000120364624,0.0003750094,0.00006225413,0.000008679328,0.000010766594,0.00007078693],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9985046,0.00012726279,0.0005163043,0.00036843438,0.000094300594,0.00038910066],"domain_scores_gemma":[0.99914366,0.000090673806,0.00033423642,0.0001923696,0.00008561773,0.00015343864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003629545,0.00012668433,0.00033909062,0.00014652833,0.00052317267,0.0001990427,0.00043155265,0.000039519127,0.00064829376],"category_scores_gemma":[0.000065801105,0.00015085228,0.00007060253,0.00007538974,0.00047799438,0.000510478,0.00019356154,0.00027521345,0.00013565451],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020555775,0.0002500179,0.47036192,0.00020187059,0.000101819955,0.000006080497,0.0015302738,0.000008512373,0.00022803947,0.4881668,0.0004452025,0.038493875],"study_design_scores_gemma":[0.00947697,0.000092856164,0.20227835,0.000045374287,0.00002433053,0.000004053773,0.00054617896,0.04397863,0.0033438453,0.61414,0.1255496,0.0005198314],"about_ca_topic_score_codex":0.0022471973,"about_ca_topic_score_gemma":0.00034091366,"teacher_disagreement_score":0.2680836,"about_ca_system_score_codex":0.00022499602,"about_ca_system_score_gemma":0.00024189864,"threshold_uncertainty_score":0.70983624},"labels":[],"label_agreement":null},{"id":"W2607667747","doi":"","title":"Prohibiting Gray Market Prescription Drugs: The Ethical Dimensions","year":2017,"lang":"en","type":"article","venue":"Southern law journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Government (linguistics); Politics; China; Prescription drug; Gray (unit); Political science; Business; Law; Medicine","score_opus":0.0559869386348769,"score_gpt":0.29642626165330366,"score_spread":0.24043932301842674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607667747","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22945368,0.0011902133,0.00046925305,0.056514025,0.0018728583,0.00031325023,0.0004112541,0.000044854154,0.7097306],"genre_scores_gemma":[0.99200684,0.00012097784,0.00013453205,0.0057765013,0.0009032148,0.000007303402,0.0000013078637,0.000027562268,0.0010217471],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99879605,0.000053024578,0.0005204904,0.0002130848,0.00004589368,0.000371479],"domain_scores_gemma":[0.9986342,0.00007698211,0.0006115761,0.00045713445,0.00003410553,0.00018596805],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0020488612,0.00013541844,0.00023265238,0.00004264452,0.0023403238,0.00080173434,0.000572811,0.00015737872,0.0010831638],"category_scores_gemma":[0.0002613661,0.00010581584,0.00019284747,0.000024853382,0.0002714918,0.0002164216,0.00014480196,0.0011251536,0.00084367074],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043495347,0.000052668096,0.0069197747,0.000011289165,0.00010613219,0.000008517342,0.0020107145,0.000025018602,0.000050354647,0.9761416,0.01263062,0.0019998143],"study_design_scores_gemma":[0.00086985866,0.000031210406,0.003274647,0.00003897851,0.000017783786,0.000070087524,0.00047287607,0.0042053405,0.000047358437,0.4294887,0.561188,0.00029517754],"about_ca_topic_score_codex":0.00032944462,"about_ca_topic_score_gemma":0.00015751693,"teacher_disagreement_score":0.76255316,"about_ca_system_score_codex":0.00006237219,"about_ca_system_score_gemma":0.000020064414,"threshold_uncertainty_score":0.9999343},"labels":[],"label_agreement":null},{"id":"W2610291029","doi":"10.1016/j.socscimed.2017.05.012","title":"A method for understanding generic procurement of HIV medicines by developing countries with patent protection","year":2017,"lang":"en","type":"article","venue":"Social Science & Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"Canadian Institutes of Health Research","keywords":"Procurement; Business; Intellectual property; Developing country; Enforcement; Essential medicines; Relevance (law); International trade; Industrial organization; Marketing; Health care; Economics; Economic growth; Law; Political science","score_opus":0.29415058940251737,"score_gpt":0.38242238875379686,"score_spread":0.08827179935127949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2610291029","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.037076972,0.0006809809,0.8250119,0.12058137,0.00061308616,0.0013123102,0.00011188026,0.000028729906,0.01458276],"genre_scores_gemma":[0.9967646,0.00015682328,0.0012319796,0.001342631,0.00033433817,0.00008012738,0.0000034448776,0.000011231745,0.00007484908],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989351,0.000006220224,0.00037325878,0.00029285668,0.000091378075,0.00030117523],"domain_scores_gemma":[0.99909693,0.000029369097,0.000576412,0.00013467361,0.00007821937,0.00008441146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017865248,0.00010616295,0.00034382014,0.000122011945,0.00087293325,0.000061105406,0.0003153911,0.0000412983,0.000039197577],"category_scores_gemma":[0.00019431011,0.00008621917,0.000029937437,0.00015829847,0.0009271823,0.0002313279,0.000036473266,0.00006400378,0.0000024092687],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000100295474,0.000034794884,0.009921564,0.00019674869,0.000059483853,5.2182577e-7,0.0065675876,0.0000068253376,0.0017705923,0.97235435,0.004227549,0.0047596954],"study_design_scores_gemma":[0.009575422,0.0012483302,0.010164553,0.00054879446,0.00011577261,0.000009973828,0.0033758406,0.020330643,0.008354006,0.41316006,0.5319134,0.0012031874],"about_ca_topic_score_codex":0.00025250725,"about_ca_topic_score_gemma":0.000020537133,"teacher_disagreement_score":0.9596876,"about_ca_system_score_codex":0.0004024077,"about_ca_system_score_gemma":0.00012788104,"threshold_uncertainty_score":0.6713985},"labels":[],"label_agreement":null},{"id":"W2612689878","doi":"10.7202/1039145ar","title":"La croissance technologique et la privatisation passive des systèmes publics de santé : le cas du Québec","year":2017,"lang":"fr","type":"article","venue":"Revue Gouvernance","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"Canadian Medical Association","keywords":"Political science; Humanities; Philosophy","score_opus":0.03117651979444838,"score_gpt":0.28901183403802566,"score_spread":0.2578353142435773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612689878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7787564,0.023299236,0.008404549,0.1235161,0.0010745563,0.00042737494,0.00081091956,0.00010469524,0.06360622],"genre_scores_gemma":[0.95112294,0.038957413,0.0020234236,0.00085550256,0.0004638057,0.00012195629,0.0000057809034,0.00006195607,0.0063871946],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978788,0.00012819056,0.0007146078,0.0005996771,0.000033845896,0.00064490683],"domain_scores_gemma":[0.9969349,0.00040428818,0.0014988587,0.0009232714,0.000073231895,0.00016547347],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013200822,0.0003157606,0.00061414315,0.00012075816,0.000631816,0.00072445633,0.001035166,0.00058972824,0.000114010094],"category_scores_gemma":[0.0027831558,0.00044129443,0.0001990953,0.00012447801,0.0010989946,0.001123722,0.00034845734,0.00073111145,0.0002478825],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012136144,0.00013547062,0.30096933,0.00030295507,0.00007670704,0.000044966215,0.0010307787,0.00021238759,0.0000149967755,0.59314597,0.0072207316,0.096833594],"study_design_scores_gemma":[0.00050564564,0.000032509208,0.37072098,0.00031044873,0.000012961181,0.00009219262,0.000040887575,0.005767445,0.0002886595,0.05753214,0.5643104,0.00038574825],"about_ca_topic_score_codex":0.047729235,"about_ca_topic_score_gemma":0.03185885,"teacher_disagreement_score":0.5570896,"about_ca_system_score_codex":0.0015908197,"about_ca_system_score_gemma":0.00077503524,"threshold_uncertainty_score":0.9998039},"labels":[],"label_agreement":null},{"id":"W2614477129","doi":"10.1503/cmaj.170169","title":"The role and impact of cost-sharing mechanisms for prescription drug coverage","year":2017,"lang":"en","type":"letter","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Carleton University","funders":"","keywords":"Cost sharing; Medical prescription; Drug; Prescription drug; Medicine; Computer science; Pharmacology; Nursing","score_opus":0.02643571802987166,"score_gpt":0.27297820408646883,"score_spread":0.24654248605659718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2614477129","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0038953137,0.0026651628,0.00049537193,0.9730225,0.00251059,0.00057893683,0.0033509678,0.000007783831,0.0134733645],"genre_scores_gemma":[0.16253799,0.007750977,0.000110672154,0.8018179,0.016702812,0.00012893221,0.0002589102,0.00016259462,0.0105292015],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998426,0.000029049148,0.0006763885,0.0002111538,0.00011789895,0.00053951034],"domain_scores_gemma":[0.9976484,0.00027031917,0.001206267,0.00019098741,0.00011000528,0.0005740196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024424864,0.00015699651,0.00042310535,0.0001699389,0.0005609309,0.00047470562,0.000519515,0.0006498056,0.0005417054],"category_scores_gemma":[0.0013894578,0.00014164174,0.00027858233,0.00002934613,0.000048219543,0.0001578858,0.000036779664,0.0014836247,0.00004177146],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000054035017,0.000004046536,0.0043833666,0.000016032773,0.0002729759,0.000015128732,0.000070053495,0.0000037316559,5.2857933e-7,0.0077817296,0.98017323,0.0072737783],"study_design_scores_gemma":[0.00043632468,0.000022360162,0.0013906495,0.000024210194,0.0000133136755,0.000024703228,0.000005691829,0.0029161347,0.000001609006,0.11184216,0.88318676,0.0001360827],"about_ca_topic_score_codex":0.005483461,"about_ca_topic_score_gemma":0.00396852,"teacher_disagreement_score":0.17120461,"about_ca_system_score_codex":0.0012223237,"about_ca_system_score_gemma":0.00075560756,"threshold_uncertainty_score":0.8289389},"labels":[],"label_agreement":null},{"id":"W2614999677","doi":"","title":"Advance Market Commitment for Pneumococcal Vaccines: Putting Theory into practice/Engagement Prealable Relatif Au Marche Pour Les Vaccins Contre le Pneumocoque: Mettre la Theorie En pratique/Compromiso De Mercado Avanzado Para Vacunas Neumococicas: Poniendo En Practica la Teoria","year":2011,"lang":"fr","type":"article","venue":"Bulletin of the World Health Organization","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Incentive; Developing country; Vaccination; Sustainability; Business; Investment (military); Medicine; Marketing; Economic growth; Economics; Immunology; Political science","score_opus":0.03227675536921406,"score_gpt":0.3154956361983563,"score_spread":0.28321888082914226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2614999677","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008960245,0.0065193577,0.03048229,0.87443584,0.0017129257,0.008042856,0.00049737125,0.00021791077,0.06913119],"genre_scores_gemma":[0.75114757,0.015501723,0.15183292,0.016415505,0.0016708053,0.0009261412,0.00016043216,0.00082151906,0.061523356],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9913137,0.004616841,0.0020449646,0.0008786401,0.00011868818,0.0010271644],"domain_scores_gemma":[0.983867,0.011708543,0.0029121262,0.0008576738,0.00030657457,0.00034811624],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.013534507,0.00056997495,0.001025784,0.00027677897,0.0008970844,0.00018092342,0.0010301434,0.0003976686,0.0021146869],"category_scores_gemma":[0.009837799,0.00059459836,0.00024289536,0.0005849031,0.00018343708,0.00043032144,0.0006565794,0.001268319,0.00008270763],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006811767,0.0016042632,0.015356813,0.0013619398,0.00051826664,0.0000055434316,0.009214951,0.00034301914,0.00015623186,0.9134677,0.043781485,0.013508632],"study_design_scores_gemma":[0.0023217422,0.00020524631,0.027831977,0.0003504711,0.00018394797,0.000038673577,0.0013085747,0.0021459495,0.00077084755,0.0747817,0.88956755,0.00049331394],"about_ca_topic_score_codex":0.0029220474,"about_ca_topic_score_gemma":0.00043259808,"teacher_disagreement_score":0.85802037,"about_ca_system_score_codex":0.0018424623,"about_ca_system_score_gemma":0.0016451747,"threshold_uncertainty_score":0.99965054},"labels":[],"label_agreement":null},{"id":"W2615558757","doi":"10.1007/s40290-017-0191-9","title":"Myths and Realities About Why Prescription Drug Prices in the United States Are So High","year":2017,"lang":"en","type":"article","venue":"Pharmaceutical Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University; University of Toronto; University Health Network","funders":"","keywords":"Medical prescription; Drug; Medicine; Pharmacotherapy; Mythology; Drug prices; Environmental health; Political science; Family medicine; Traditional medicine; Pharmacology; Psychiatry; Public economics; Economics; History","score_opus":0.11022600024979189,"score_gpt":0.3562483066323625,"score_spread":0.2460223063825706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2615558757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7400207,0.0075216675,0.00016948195,0.23184708,0.00079260423,0.0005136729,0.0002285677,0.00004432607,0.018861908],"genre_scores_gemma":[0.95639664,0.0129571855,0.000041878964,0.02988726,0.0004382567,0.000044244465,0.000042598662,0.000020143103,0.00017181737],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984736,0.000046301284,0.00060500466,0.00037613715,0.000065281325,0.00043369769],"domain_scores_gemma":[0.9986402,0.0003201932,0.0003538154,0.00044542964,0.000028340743,0.0002120439],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013543292,0.00020650387,0.00044917193,0.00023444465,0.00038419786,0.00024642292,0.0005306696,0.00007152751,0.0003935994],"category_scores_gemma":[0.00045157812,0.00016065792,0.000041372707,0.000117157455,0.0007760411,0.00031011517,0.00012800905,0.00041967892,0.00007139183],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001832788,0.00021676783,0.05898045,0.000328688,0.00011334456,0.000037251673,0.007683188,0.000058368463,0.000037959184,0.88411283,0.0436376,0.004610263],"study_design_scores_gemma":[0.0020697427,0.0000482158,0.096060045,0.00008492452,0.000028533444,0.00000817533,0.00067287334,0.0154198455,0.000053153843,0.09118467,0.7941221,0.0002477514],"about_ca_topic_score_codex":0.004531271,"about_ca_topic_score_gemma":0.0001740647,"teacher_disagreement_score":0.79292816,"about_ca_system_score_codex":0.000055681452,"about_ca_system_score_gemma":0.000010325788,"threshold_uncertainty_score":0.68499565},"labels":[],"label_agreement":null},{"id":"W2615756116","doi":"10.3386/w23068","title":"Is American Health Care Uniquely Inefficient? Evidence from Prescription Drugs","year":2017,"lang":"en","type":"report","venue":"National Bureau of Economic Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Common Fund; NIH Office of the Director; National Institute on Aging; National Science Foundation; National Institutes of Health; Pfizer","keywords":"Medical prescription; Health care; Prescription drug; Business; Family medicine; Medicine; Nursing; Political science; Law","score_opus":0.5913179908200392,"score_gpt":0.5767842673581781,"score_spread":0.014533723461861103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2615756116","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01885272,0.039362606,0.000032677457,0.01786028,0.00219902,0.0015284603,0.011329989,0.00004728843,0.90878695],"genre_scores_gemma":[0.9458801,0.043085624,0.0003644495,0.00088550826,0.0016351483,0.00016456722,0.0012558434,0.00011783954,0.006610929],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954407,0.00013687303,0.0018783022,0.0013041581,0.0004493266,0.0007905994],"domain_scores_gemma":[0.99424344,0.00078055024,0.0024931738,0.0010907392,0.0010176823,0.0003743974],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.006023634,0.00038147668,0.0014087186,0.0012999353,0.00039457346,0.00032014181,0.0015620128,0.00036408313,0.0013298278],"category_scores_gemma":[0.0014796095,0.000481969,0.000427794,0.00015909692,0.00071266183,0.00045381254,0.00047597324,0.0011616366,0.0018598333],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00014465438,0.00015267094,0.00970441,0.00053557823,0.00051303295,0.0000021715723,0.0023376558,0.00030099862,0.0000114675795,0.184386,0.7904707,0.011440619],"study_design_scores_gemma":[0.00065832597,0.00028622663,0.0070217554,0.00043105034,0.0000134993015,0.0000032968526,0.00019062503,0.0023460903,0.00013833765,0.24614897,0.7420471,0.0007147374],"about_ca_topic_score_codex":0.07178463,"about_ca_topic_score_gemma":0.0006580919,"teacher_disagreement_score":0.92702734,"about_ca_system_score_codex":0.00640919,"about_ca_system_score_gemma":0.0060888766,"threshold_uncertainty_score":0.9997632},"labels":[],"label_agreement":null},{"id":"W2616641036","doi":"10.71781/26112","title":"Établissement d'un prototype de laboratoire et d'un pilote industriel d'amylose substitué pour la libération contrôlée de médicament à partir de comprimés matriciels","year":2005,"lang":"fr","type":"dissertation","venue":"Open MIND","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science; Chemistry","score_opus":0.06360537604681456,"score_gpt":0.34088684656576557,"score_spread":0.277281470518951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2616641036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9419958,0.0026441107,0.0012572374,0.013876412,0.00040917273,0.002841512,0.0015646174,0.000009077058,0.03540206],"genre_scores_gemma":[0.96568877,0.0033809731,0.01634403,0.0034444337,0.00056090375,0.0007555372,0.0010465183,0.00014497786,0.008633877],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958269,0.00031156992,0.0016438433,0.0009629243,0.00009843802,0.0011563469],"domain_scores_gemma":[0.9970975,0.0002933745,0.001290455,0.0005461826,0.00014306571,0.000629411],"candidate_categories":["metaepi_narrow","scholarly_communication","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0029013958,0.00064631994,0.0010648197,0.00033958757,0.00044970642,0.0016893336,0.0010611395,0.00095954747,0.007238582],"category_scores_gemma":[0.00030535526,0.0008676785,0.00021514384,0.00049735967,0.00015251974,0.0006603784,0.00022277235,0.0011460792,0.0016419098],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030477692,0.009445913,0.15354045,0.0006863876,0.0026374434,0.00036959312,0.039077424,0.010447781,0.009115738,0.21279553,0.011086705,0.5477493],"study_design_scores_gemma":[0.00521045,0.00032911758,0.048171118,0.0003571594,0.00027508047,0.000044840177,0.0007833291,0.033773765,0.05706782,0.0046781674,0.8477248,0.0015843771],"about_ca_topic_score_codex":0.0009407088,"about_ca_topic_score_gemma":0.00063464546,"teacher_disagreement_score":0.8366381,"about_ca_system_score_codex":0.0011168015,"about_ca_system_score_gemma":0.0018440617,"threshold_uncertainty_score":0.99937737},"labels":[],"label_agreement":null},{"id":"W2616945700","doi":"10.1503/cmaj.1095429","title":"Fair pricing or pricing for profit?","year":2017,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Profit (economics); sort; Drug pricing; Cash; Actuarial science; Medicine; Business; Computer science; Economics; Finance; Microeconomics; Information retrieval","score_opus":0.05832148119612866,"score_gpt":0.30569873728450303,"score_spread":0.24737725608837435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2616945700","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2903663,0.0008239052,0.0056129717,0.51617384,0.008083405,0.0009728107,0.00070707535,0.000054889333,0.1772048],"genre_scores_gemma":[0.9620525,0.00030010662,0.0005671097,0.030410446,0.003512891,0.000024001327,0.0000059159224,0.00003410285,0.003092911],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99851745,0.000014042206,0.00060753454,0.00019153034,0.00009088526,0.0005785708],"domain_scores_gemma":[0.997681,0.00014020178,0.0007267326,0.0001750502,0.000093933835,0.0011830357],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023480798,0.00010630269,0.00030502523,0.00017179332,0.00097314175,0.0004750417,0.0004943844,0.0002586434,0.00225798],"category_scores_gemma":[0.0048292554,0.00010678053,0.0001286786,0.000048939404,0.00003405944,0.0003043941,0.00002965237,0.00048678287,0.0003833088],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003728634,0.000025478483,0.4852817,0.000054043885,0.00034849302,0.00010010094,0.00065603753,0.000020786203,0.0000060843977,0.17173003,0.2912737,0.05046624],"study_design_scores_gemma":[0.0011099884,0.00003571116,0.045560878,0.000028378534,0.0000067810024,0.00003994848,0.00003972054,0.0048067137,0.000011016283,0.013286203,0.9348751,0.00019956873],"about_ca_topic_score_codex":0.0017077493,"about_ca_topic_score_gemma":0.010784854,"teacher_disagreement_score":0.67168623,"about_ca_system_score_codex":0.0009968455,"about_ca_system_score_gemma":0.0009086223,"threshold_uncertainty_score":0.99865407},"labels":[],"label_agreement":null},{"id":"W2620986503","doi":"","title":"Pharmaceutical M&A Activity: Effects on Prices, Innovation, and Competition","year":2017,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Upstream (networking); Downstream (manufacturing); Competition (biology); Pharmaceutical industry; Harm; Industrial organization; Business; Market concentration; Marketing; Politics; Product (mathematics); Distribution (mathematics); Market structure; Political science; Biotechnology; Engineering","score_opus":0.08957918890393224,"score_gpt":0.34046398662732147,"score_spread":0.25088479772338923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2620986503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7360349,0.00008761253,0.0009204833,0.014386243,0.0003574298,0.00017822535,0.000035102526,0.00003317689,0.24796678],"genre_scores_gemma":[0.9935071,0.0001718649,0.00016967436,0.0052974857,0.00021262637,0.000014570971,0.000003921249,0.000012968204,0.00060981396],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99925476,0.0000060909397,0.00023257069,0.00028524484,0.000017334905,0.00020402031],"domain_scores_gemma":[0.9992972,0.0000827593,0.00021262755,0.00029932178,0.00001613172,0.00009193068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003060288,0.00011302733,0.00022130823,0.00015017888,0.00029614216,0.00024286367,0.00016439475,0.00006747032,0.00029469572],"category_scores_gemma":[0.00015996375,0.00012459524,0.000029779443,0.00005671855,0.00008541687,0.00030308313,0.000087324406,0.00015809711,0.00062144897],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001960698,0.000049366376,0.006025028,0.0000295965,0.00002170196,0.000001477373,0.000015448664,9.0502346e-7,0.00018042707,0.98050255,0.00068024243,0.0124736335],"study_design_scores_gemma":[0.0020960227,0.00010718717,0.15249124,0.000022315826,0.000008078755,0.0000054489296,0.0000024723215,0.007289148,0.00961717,0.27640963,0.55151665,0.00043466222],"about_ca_topic_score_codex":0.0000404354,"about_ca_topic_score_gemma":0.000005000893,"teacher_disagreement_score":0.7040929,"about_ca_system_score_codex":0.000042978736,"about_ca_system_score_gemma":0.0000084446965,"threshold_uncertainty_score":0.7987676},"labels":[],"label_agreement":null},{"id":"W2621322531","doi":"10.17480/psk.2017.61.2.100","title":"The Review of Orphan or Anticancer Drugs Funding Programs from Foreign Countries' Experiences","year":2017,"lang":"en","type":"article","venue":"Yakhak Hoeji","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Orphan drug; Medicine; Pharmacology; Political science; Business; Bioinformatics; Biology","score_opus":0.11557511783315258,"score_gpt":0.3500591458298644,"score_spread":0.23448402799671184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621322531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.60279477,0.13356759,0.00023303425,0.017202277,0.002211971,0.0014631222,0.0006574631,0.0000751563,0.24179462],"genre_scores_gemma":[0.9270643,0.06930587,0.00015224142,0.0023440567,0.0003040541,0.00012760362,0.000011213776,0.0000210262,0.0006696263],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985444,0.000013240968,0.0006798638,0.00031918127,0.000050972263,0.00039237223],"domain_scores_gemma":[0.9982892,0.00013800916,0.00065365416,0.00075717893,0.00003791206,0.00012404234],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007941716,0.00015628542,0.00048164386,0.000033937013,0.0005303899,0.0002844005,0.00085530017,0.00006258193,0.0013328505],"category_scores_gemma":[0.00029977332,0.000116015515,0.00014117084,0.00006620819,0.00041412073,0.0002926916,0.00015859559,0.000116985524,0.00027964308],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016299958,0.00013846286,0.04314068,0.0011081966,0.0003096145,0.0000075818684,0.003758392,0.0000013057328,0.000010421305,0.875066,0.017747767,0.058548566],"study_design_scores_gemma":[0.00047538048,0.000065449145,0.0020110672,0.0005260573,0.000016354154,0.0000013723483,0.00045250164,0.0006637472,0.0003026515,0.022097105,0.97310954,0.00027877165],"about_ca_topic_score_codex":0.00064386614,"about_ca_topic_score_gemma":0.00006998449,"teacher_disagreement_score":0.9553618,"about_ca_system_score_codex":0.000059254693,"about_ca_system_score_gemma":0.000055489247,"threshold_uncertainty_score":0.9995801},"labels":[],"label_agreement":null},{"id":"W2624511976","doi":"10.1503/cmaj.161481","title":"Drivers of expenditure on primary care prescription drugs in 10 high-income countries with universal health coverage","year":2017,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"Commonwealth Fund","keywords":"Per capita; Medical prescription; Medicine; Health care; Per capita income; Environmental health; Demography; Economic growth; Economics; Population; Nursing","score_opus":0.010683231209502337,"score_gpt":0.23533816091115653,"score_spread":0.22465492970165418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624511976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89832795,0.00055104657,0.00004238351,0.055874575,0.0011510199,0.00021736095,0.0010012677,0.00000839601,0.042825993],"genre_scores_gemma":[0.9928153,0.00071252463,0.000026994572,0.0057659075,0.00033643434,0.0000019090533,0.000022715485,0.000011505174,0.00030668877],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988564,0.00003561432,0.00044371322,0.00016043163,0.00015392958,0.00034986265],"domain_scores_gemma":[0.99828005,0.000051941548,0.0007768581,0.00015443067,0.000064701526,0.0006720116],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007681986,0.000101548416,0.0003470642,0.0002566306,0.00030023785,0.00012184175,0.00031180904,0.00019476641,0.0015316856],"category_scores_gemma":[0.0001570228,0.000109138484,0.000056077748,0.000044676137,0.0000662486,0.00028948695,0.000018500277,0.0005168657,0.00010297418],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014641644,0.00006124482,0.84704554,0.00013710096,0.00019621395,0.000121716796,0.0045963735,0.00033701945,3.7275356e-7,0.097586334,0.042651046,0.0071206014],"study_design_scores_gemma":[0.0030557911,0.0001753339,0.5571583,0.00017124561,0.0000046342893,0.000008786661,0.00031956844,0.00022305184,0.0000041728763,0.0016568378,0.43700978,0.00021249102],"about_ca_topic_score_codex":0.009319956,"about_ca_topic_score_gemma":0.020837327,"teacher_disagreement_score":0.39435875,"about_ca_system_score_codex":0.0032703318,"about_ca_system_score_gemma":0.0013424606,"threshold_uncertainty_score":0.99938107},"labels":[],"label_agreement":null},{"id":"W2625162755","doi":"10.1503/cmaj.170440","title":"Drug prices: How do we get to a better place?","year":2017,"lang":"en","type":"letter","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"York University; University Health Network","funders":"","keywords":"Publicity; Drug prices; Medicine; Specialty; Drug; Drug approval; Advertising; Family medicine; Intensive care medicine; Pharmacology; Business; Economics; Marketing; Public economics","score_opus":0.02808735274091519,"score_gpt":0.25359936934868876,"score_spread":0.22551201660777356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2625162755","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00080440496,0.0014067491,0.000040230443,0.96557707,0.0036522977,0.00019755626,0.0013084109,0.000015087158,0.026998194],"genre_scores_gemma":[0.0011023869,0.0012922136,0.00013067262,0.9552216,0.028013745,0.00002446185,0.00005184593,0.00007739806,0.014085653],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968745,0.00007235274,0.0009055438,0.00052882597,0.00033799896,0.0012807483],"domain_scores_gemma":[0.9953754,0.00025267192,0.0013122548,0.0004348074,0.00013839414,0.0024864702],"candidate_categories":["metaepi_narrow","scholarly_communication","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0026059237,0.00036341973,0.0008739003,0.0007646895,0.0005252348,0.0015319332,0.001369656,0.0016344102,0.010132853],"category_scores_gemma":[0.002002024,0.00041473305,0.00036493785,0.00012716728,0.000055962206,0.00029536764,0.00008192032,0.0050297086,0.005625068],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000016445792,0.0000066772614,0.002240659,0.000023280536,0.00019878133,0.0005708317,0.00023568758,0.0000011959444,3.186195e-8,0.0007014631,0.9919836,0.0040361616],"study_design_scores_gemma":[0.0004982757,0.00001659442,0.00038307262,0.00009658383,0.00001598015,0.00009951066,0.0000136984145,0.00014276149,3.497447e-7,0.0069679646,0.9912713,0.0004938664],"about_ca_topic_score_codex":0.0018993746,"about_ca_topic_score_gemma":0.0064748633,"teacher_disagreement_score":0.024361448,"about_ca_system_score_codex":0.002796781,"about_ca_system_score_gemma":0.0016694801,"threshold_uncertainty_score":0.9998304},"labels":[],"label_agreement":null},{"id":"W2633062079","doi":"10.1503/cmaj.170372","title":"Importation of drugs into the United States from Canada","year":2017,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Lawson Health Research Institute","funders":"","keywords":"Economic shortage; Medical prescription; Medicine; Supply chain; Vulnerability (computing); Medical emergency; Business; Environmental health; Pharmacology; Computer science; Computer security; Marketing","score_opus":0.018799629971086952,"score_gpt":0.2529994476517882,"score_spread":0.23419981768070128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2633062079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.833863,0.00023787578,0.000022879769,0.15817986,0.00095114845,0.00004285747,0.00033796727,0.0000020254563,0.0063623525],"genre_scores_gemma":[0.9771849,0.00047331883,0.000020517997,0.02156552,0.0005837448,0.0000018111846,0.00004002783,0.0000078369385,0.00012233271],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99897957,0.000025033143,0.000536113,0.000096510674,0.000121939454,0.00024084229],"domain_scores_gemma":[0.9981465,0.00016069874,0.00081780984,0.00016479666,0.00009566656,0.00061455695],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011494089,0.00006701459,0.00018559878,0.00008936321,0.00047001202,0.0001458402,0.00045886953,0.00011391897,0.0022402469],"category_scores_gemma":[0.0013213863,0.00006173727,0.00005464408,0.000056921148,0.00004934589,0.00011167047,0.000018535478,0.0003884622,0.00005495585],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008375129,0.000019850037,0.5979124,0.0000070164665,0.0003667799,0.000037898855,0.0033556651,0.000112326365,0.0000016638234,0.036632337,0.34857947,0.012966247],"study_design_scores_gemma":[0.000391273,0.0000062214012,0.12488394,0.000008348923,0.0000053784033,0.0000018459103,0.00027212634,0.0044707907,0.0000124855405,0.02558505,0.8442717,0.00009082647],"about_ca_topic_score_codex":0.97888285,"about_ca_topic_score_gemma":0.9724671,"teacher_disagreement_score":0.49569225,"about_ca_system_score_codex":0.00080480264,"about_ca_system_score_gemma":0.0015089874,"threshold_uncertainty_score":0.9986718},"labels":[],"label_agreement":null},{"id":"W2649444365","doi":"","title":"The Delivery of Pharmaceutical Health Care in Nunavut, Canada: Language, Culture and Policy","year":2016,"lang":"en","type":"dissertation","venue":"TSpace","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Health care delivery; Health care; Political science; Medicine; Business; Economic growth; Economics","score_opus":0.02522676735923643,"score_gpt":0.3582756165664064,"score_spread":0.33304884920716993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2649444365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6216099,0.2033428,0.0000019919057,0.016173175,0.00090084784,0.0006023075,0.0012510265,0.000019174418,0.15609875],"genre_scores_gemma":[0.9546651,0.028008284,0.000022991935,0.0025116676,0.00032892718,0.000026477743,0.00013841865,0.000046739442,0.014251356],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987265,0.000024444189,0.00052782113,0.0002934894,0.000036648697,0.0003910845],"domain_scores_gemma":[0.99912906,0.00008770518,0.0003702374,0.00021708687,0.000028377292,0.0001675284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002130334,0.0001973318,0.00047556413,0.00013999068,0.000104019455,0.000029752686,0.00022536935,0.00014872302,0.000072170464],"category_scores_gemma":[0.000076779404,0.0001631114,0.000065655346,0.00013428324,0.000052383384,0.000039993032,0.0000381146,0.00030865992,0.00001797751],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007998948,0.00013849267,0.008630016,0.0023850682,0.00047715424,0.0000300956,0.094022535,0.000014470621,0.00018977541,0.67330426,0.06379825,0.15620999],"study_design_scores_gemma":[0.001395779,0.00006955626,0.011872383,0.00015776724,0.000011443379,0.0000035863807,0.008582671,0.00011990638,0.0005978072,0.0024252026,0.9742582,0.0005057072],"about_ca_topic_score_codex":0.34062222,"about_ca_topic_score_gemma":0.66668665,"teacher_disagreement_score":0.91045994,"about_ca_system_score_codex":0.0005605659,"about_ca_system_score_gemma":0.00091811066,"threshold_uncertainty_score":0.665149},"labels":[],"label_agreement":null},{"id":"W2660824563","doi":"10.1016/j.jval.2017.05.004","title":"Market Exclusivity Time for Top Selling Originator Drugs in Canada: A Cohort Study","year":2017,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University","funders":"","keywords":"Biosimilar; Competition (biology); Notice; Liberian dollar; Marketing authorization; Business; Generic drug; Product (mathematics); Market share; Authorization; Marketing; Pharmaceutical industry; Interquartile range; Medicine; Advertising; Drug; Finance; Pharmacology; Law","score_opus":0.06924952983056451,"score_gpt":0.32369687843816025,"score_spread":0.25444734860759577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2660824563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98465,0.00038827697,0.000022458684,0.0044511245,0.0005035425,0.0012600989,0.00026971294,0.000007900311,0.008446879],"genre_scores_gemma":[0.9979085,0.00029884995,0.00013468854,0.0010421845,0.000121059245,0.00009892482,0.0000038025569,0.000021916838,0.00037011108],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99816626,0.00004525269,0.0007868426,0.00043323997,0.000032712534,0.00053568603],"domain_scores_gemma":[0.9987023,0.00020239924,0.00042350276,0.0004719595,0.000012408825,0.0001874566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002968495,0.00013858845,0.00058817305,0.0001581582,0.00020430177,0.00007002351,0.000373154,0.000047532438,0.00016847179],"category_scores_gemma":[0.00020403869,0.00017617144,0.000047270598,0.000076739634,0.000022247894,0.00014549949,0.00007649591,0.00020044601,0.000050218303],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030797943,0.00012797344,0.9834059,0.000081565646,0.000018047029,0.0000031745863,0.00033886477,0.0007067447,1.2630196e-7,0.012759957,0.0018490573,0.00067778304],"study_design_scores_gemma":[0.0017201339,0.0000644327,0.68635035,0.00003544866,0.0000022222537,7.7344134e-7,0.00005479471,0.23359694,0.000003394631,0.012361918,0.0655194,0.00029018553],"about_ca_topic_score_codex":0.93922156,"about_ca_topic_score_gemma":0.50600415,"teacher_disagreement_score":0.43321744,"about_ca_system_score_codex":0.0018530834,"about_ca_system_score_gemma":0.0008721397,"threshold_uncertainty_score":0.71840626},"labels":[],"label_agreement":null},{"id":"W2700625500","doi":"10.1186/s12992-017-0262-4","title":"In which developing countries are patents on essential medicines being filed?","year":2017,"lang":"en","type":"article","venue":"Globalization and Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research","keywords":"Developing country; Index (typography); Medicine; Intellectual property; Essential medicines; Estate; Actuarial science; Public health; Business; Accounting; Economic growth; Finance; Economics; Political science; Law; Computer science","score_opus":0.08860450906852528,"score_gpt":0.3672285794589975,"score_spread":0.2786240703904722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2700625500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49324617,0.002080715,0.0032826194,0.43094146,0.0025785607,0.0006678203,0.00042094899,0.000057987603,0.06672371],"genre_scores_gemma":[0.96717113,0.00669582,0.00006449849,0.025822015,0.00014959941,0.0000053805657,0.000018629116,0.000007733617,0.00006517957],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9991614,0.000008745842,0.00037301594,0.00021605546,0.000022331098,0.00021840297],"domain_scores_gemma":[0.99937475,0.00001030499,0.0003476149,0.00014998359,0.000021792303,0.00009557832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038346858,0.00008539116,0.00025753546,0.00009484847,0.00031898328,0.00012822133,0.00011095667,0.000052092397,0.00011274979],"category_scores_gemma":[0.000083903105,0.00009636073,0.00001402857,0.000058549598,0.000034236473,0.00018196549,0.000043302334,0.000060386596,0.00007862075],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008324004,0.000014779849,0.27572852,0.00007139453,0.0000061627425,0.0000010489333,0.00027175926,0.000019633104,9.6036175e-8,0.7198501,0.0037292407,0.00029888435],"study_design_scores_gemma":[0.0010691432,0.000029884635,0.6690668,0.00013488738,0.0000013600059,0.0000018491182,0.000027823513,0.0044738217,0.000007694409,0.05124204,0.27376208,0.00018262837],"about_ca_topic_score_codex":0.0007119698,"about_ca_topic_score_gemma":0.00084604823,"teacher_disagreement_score":0.6686081,"about_ca_system_score_codex":0.00012907806,"about_ca_system_score_gemma":0.000052511707,"threshold_uncertainty_score":0.39294764},"labels":[],"label_agreement":null},{"id":"W2727801247","doi":"10.7196/samj.2017.v107i7.11356","title":"Inefficient procurement processes undermine access to medicines in the Western Cape Province of South Africa","year":2017,"lang":"en","type":"article","venue":"South African Medical Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Belgisch Ontwikkelingsagentschap; European Commission; University of the Western Cape; International Development Research Centre","keywords":"Call for bids; Medicine; Procurement; Essential medicines; Stock (firearms); Public health; Workload; Access to medicines; Public sector; Context (archaeology); Business; Marketing; Nursing","score_opus":0.10588044136775397,"score_gpt":0.335302430371814,"score_spread":0.22942198900406002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2727801247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.756186,0.0022184053,0.004440143,0.1849997,0.0011401519,0.0014765931,0.00023070295,0.000030688778,0.04927759],"genre_scores_gemma":[0.9938137,0.000081922175,0.00005393238,0.0053637256,0.0005351724,0.000032337946,0.0000013181757,0.000018932576,0.000098979355],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977233,0.000039919825,0.0010733621,0.00033785327,0.00028390187,0.0005416519],"domain_scores_gemma":[0.99784946,0.00011651771,0.0009481366,0.00046820065,0.00008802143,0.00052968477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002243372,0.00020244563,0.00054334407,0.00029679318,0.00027232085,0.00033435362,0.0022273227,0.00009690501,0.00023102577],"category_scores_gemma":[0.002939278,0.00014506745,0.000093892886,0.00025837167,0.0002963697,0.000222419,0.00030395924,0.0005475641,0.00006820799],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059784926,0.002019949,0.8132386,0.0011444205,0.00035090843,0.00050265784,0.12699345,0.0007418593,0.000022771726,0.012399968,0.029157521,0.012829996],"study_design_scores_gemma":[0.012554699,0.0019300327,0.37082732,0.0017380759,0.00016014175,0.00034845446,0.0102528315,0.00541321,0.00032200493,0.03157217,0.5624255,0.002455576],"about_ca_topic_score_codex":0.000031892683,"about_ca_topic_score_gemma":0.0001384038,"teacher_disagreement_score":0.533268,"about_ca_system_score_codex":0.000094054485,"about_ca_system_score_gemma":0.0005120895,"threshold_uncertainty_score":0.5915679},"labels":[],"label_agreement":null},{"id":"W2729536024","doi":"10.20959/wjpr20177-8722","title":"A REVIEW ON GENERIC DRUGS REGISTRATION PROCEDURE IN USA &amp; CANADA","year":2017,"lang":"en","type":"review","venue":"World Journal of Pharmaceutical Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacology; Medicine; Business","score_opus":0.5744497842545812,"score_gpt":0.5380934266051773,"score_spread":0.036356357649403814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2729536024","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000007980474,0.94169253,0.0000031229365,0.0058122184,0.0005671294,0.00077094696,0.00014724082,0.000002321235,0.05099648],"genre_scores_gemma":[0.0002036756,0.9897233,0.000041256582,0.0028679643,0.00085979764,0.000060905368,0.000015189116,0.00006353597,0.0061643687],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947318,0.0003745511,0.0029565978,0.00059100013,0.0003461885,0.0009998906],"domain_scores_gemma":[0.9955459,0.0008895861,0.0018915763,0.00070501876,0.00020476454,0.0007631589],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.008502247,0.00044344118,0.0028411888,0.0014319448,0.00020344557,0.0002126935,0.0016630233,0.00020173962,0.0020023433],"category_scores_gemma":[0.00238258,0.0004067588,0.00059656147,0.0009474718,0.0002151823,0.00021736982,0.00020446676,0.0040742727,0.0010678738],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006224975,0.00024795218,0.00006216052,0.03527224,0.00023200073,0.00015374152,0.000022021333,0.0000072942435,1.8864293e-7,0.02204195,0.3196342,0.62226397],"study_design_scores_gemma":[0.00042355456,0.00004323356,0.000010018111,0.022558011,0.00006251464,0.000063153566,0.0000012202822,0.00004432939,6.3336216e-7,0.0016918861,0.9747511,0.00035033133],"about_ca_topic_score_codex":0.007013755,"about_ca_topic_score_gemma":0.047918487,"teacher_disagreement_score":0.6551169,"about_ca_system_score_codex":0.0021031597,"about_ca_system_score_gemma":0.0034702902,"threshold_uncertainty_score":0.9998384},"labels":[],"label_agreement":null},{"id":"W2734611933","doi":"10.2139/ssrn.1329308","title":"Pharmaceutical Pricing and Reimbursement Policies in Canada","year":2007,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Business; Drug pricing; Actuarial science; Economics; Health care; Economic growth","score_opus":0.02875904113165939,"score_gpt":0.28240739020707656,"score_spread":0.25364834907541717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2734611933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9751858,0.0080144815,0.0010413284,0.005030693,0.0002490159,0.00009309969,0.000010747185,0.000005183942,0.0103696445],"genre_scores_gemma":[0.98981255,0.0072574485,0.000033506716,0.002519028,0.00019433918,0.0000014922164,9.697807e-7,0.000015299343,0.0001653353],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9970894,0.000010783633,0.0006030482,0.00019381323,0.00003590367,0.0020670844],"domain_scores_gemma":[0.9994921,0.00006109432,0.00015779593,0.00008793266,0.000010457603,0.00019060499],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023735785,0.00012477319,0.00024997606,0.00020778737,0.000089226094,0.00004071709,0.00015801091,0.00004089046,0.00006271556],"category_scores_gemma":[0.000045597393,0.00014101382,0.00004011364,0.00014503405,0.000032299635,0.00011878414,0.000045580575,0.0011143491,0.000019869854],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003305204,0.00003043419,0.18250915,0.00000698386,0.00006356554,0.0000100662355,0.000120650475,0.000050517174,0.00003291996,0.80443525,0.00015959394,0.012547827],"study_design_scores_gemma":[0.0030601309,0.00015286368,0.119452946,0.00002429719,0.000016447582,0.00049135345,0.0023374557,0.0037114515,0.00034738905,0.7234383,0.14622965,0.000737693],"about_ca_topic_score_codex":0.37203884,"about_ca_topic_score_gemma":0.8235317,"teacher_disagreement_score":0.45149282,"about_ca_system_score_codex":0.0036215223,"about_ca_system_score_gemma":0.0012642178,"threshold_uncertainty_score":0.94701546},"labels":[],"label_agreement":null},{"id":"W2735024050","doi":"10.1177/171516350413701002","title":"Drug Regulatory Bodies Dogged by Credibility Crisis","year":2004,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Credibility; Medicine; Political science; Law","score_opus":0.04321773927358489,"score_gpt":0.25552717853986784,"score_spread":0.21230943926628296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735024050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9657618,0.008451145,0.00016799822,0.00374858,0.004042797,0.00041131713,0.005013353,0.00005869384,0.01234431],"genre_scores_gemma":[0.977449,0.006316362,0.00015739062,0.014218799,0.0009342283,0.000019652265,0.00004619033,0.00008020353,0.00077815895],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996294,0.000063193715,0.0013079554,0.0007287321,0.00013019251,0.001475919],"domain_scores_gemma":[0.9954817,0.000065237626,0.00052715786,0.00045935326,0.00019090259,0.0032756315],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001257473,0.00048803998,0.00070201233,0.00046692122,0.0010240166,0.00036170956,0.0009385636,0.00010318245,0.0021495586],"category_scores_gemma":[0.00018239967,0.0006160732,0.00030137892,0.00036668376,0.00028846774,0.0006614609,0.0000735568,0.0009144938,0.00019694374],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015056858,0.00024524715,0.008474905,0.00033244837,0.00074631575,0.010537629,0.003736922,0.004556125,0.000775669,0.01456008,0.94732857,0.0085555],"study_design_scores_gemma":[0.005634453,0.00004878134,0.00017740793,0.000020738195,0.000094643314,0.057446476,0.0000361858,0.002131285,0.004894642,0.032912806,0.89462686,0.0019757368],"about_ca_topic_score_codex":0.08938795,"about_ca_topic_score_gemma":0.09596916,"teacher_disagreement_score":0.052701745,"about_ca_system_score_codex":0.0056910175,"about_ca_system_score_gemma":0.002104415,"threshold_uncertainty_score":0.9996291},"labels":[],"label_agreement":null},{"id":"W2736010367","doi":"10.1787/244264621247","title":"Pharmaceutical Pricing and Reimbursement Policies in Slovakia","year":2008,"lang":"en","type":"paratext","venue":"OECD health working papers","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Health Canada; Eötvös Loránd Tudományegyetem","keywords":"Reimbursement; Pharmaceutical policy; Incentive; Public economics; Payment; Limiting; Business; Quarter (Canadian coin); Scope (computer science); Competition (biology); Pharmaceutical industry; Economics; Health care; Health policy; Finance; Economic growth; Market economy","score_opus":0.11642908632103247,"score_gpt":0.35949354517050686,"score_spread":0.2430644588494744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2736010367","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009684385,0.067982614,0.000020471372,0.02008041,0.0032286928,0.0008802496,0.00024656366,0.00004694112,0.89782965],"genre_scores_gemma":[0.56378216,0.32890254,0.00049522665,0.062799975,0.0021844278,0.00015846723,0.00020803337,0.00025833232,0.04121081],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99617016,0.00006258656,0.0015407847,0.0009075686,0.00006448027,0.0012543981],"domain_scores_gemma":[0.99830234,0.0001569368,0.00069651066,0.00032513303,0.000007584475,0.00051151525],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0008344,0.00048788334,0.0013171894,0.0006660157,0.00029049173,0.00010704056,0.00030009038,0.0003809022,0.0021309133],"category_scores_gemma":[0.000029368906,0.0006050209,0.00015782347,0.00023628626,0.00018434899,0.000060693248,0.00019148189,0.0011720981,0.0039354004],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023521016,0.0005930565,0.03758734,0.0026690352,0.0005678614,0.000065763474,0.007421432,0.0010872467,0.00003192262,0.13913405,0.6706579,0.13994923],"study_design_scores_gemma":[0.00086935237,0.000056699195,0.002683497,0.0002317071,0.0000051213333,0.0000152083985,0.000038564234,0.00067416526,0.0000058673068,0.00036572645,0.994503,0.00055104983],"about_ca_topic_score_codex":0.0012104606,"about_ca_topic_score_gemma":0.00010942384,"teacher_disagreement_score":0.8566189,"about_ca_system_score_codex":0.0008886745,"about_ca_system_score_gemma":0.00023670438,"threshold_uncertainty_score":0.9996401},"labels":[],"label_agreement":null},{"id":"W2738563879","doi":"10.18579/jpcrkc/2017/16/2/116432","title":"Drug Master File Filing in US, Europe, Canada and Australia","year":2017,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Business; Medicine; Pharmacology","score_opus":0.38342138121012354,"score_gpt":0.4595554708074974,"score_spread":0.07613408959737389,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2738563879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9720147,0.0009005732,0.0000061593187,0.008649576,0.00044607912,0.00012428606,0.0003690767,0.0000019799252,0.017487569],"genre_scores_gemma":[0.99558276,0.00079366146,0.00012480802,0.00067240186,0.0003321079,0.0000030854737,0.0000020275927,0.000017578168,0.002471562],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981927,0.00007320738,0.0007761545,0.00022796726,0.00013202208,0.00059790775],"domain_scores_gemma":[0.9984183,0.0004037927,0.00030161176,0.00025626927,0.00010419433,0.00051588635],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0029253762,0.00011791755,0.00037835367,0.0002791326,0.00021128288,0.0002968523,0.00063801545,0.000057414567,0.00413013],"category_scores_gemma":[0.001447057,0.00011953786,0.000057980607,0.00012579712,0.00022579734,0.00036166067,0.00028139175,0.0012026263,0.00011739439],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044142574,0.00030649858,0.63997126,0.00022434026,0.00017246616,0.00093272864,0.00029134515,0.0001388452,0.00047085757,0.050308175,0.2993854,0.007356667],"study_design_scores_gemma":[0.0013304478,0.000046157882,0.16580585,0.00005680227,0.0000042621327,0.00003853381,0.000019213234,0.003926209,0.0005093318,0.0053885095,0.82268566,0.0001890387],"about_ca_topic_score_codex":0.07596918,"about_ca_topic_score_gemma":0.044124242,"teacher_disagreement_score":0.52330023,"about_ca_system_score_codex":0.00021118592,"about_ca_system_score_gemma":0.00022450674,"threshold_uncertainty_score":0.9967802},"labels":[],"label_agreement":null},{"id":"W2738734168","doi":"10.1056/nejmp1704489","title":"The Price of Crossing the Border for Medications","year":2017,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Competition (biology)","score_opus":0.08233974538477716,"score_gpt":0.37725898449067063,"score_spread":0.29491923910589346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2738734168","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12244616,0.01940771,0.014985762,0.78945214,0.0035840755,0.00035023448,0.000056621084,0.0000048734732,0.04971245],"genre_scores_gemma":[0.9924654,0.0018281715,0.00023917313,0.0014612684,0.0031384723,0.0000020432774,6.254524e-7,0.000008365852,0.000856485],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99913836,0.000009217861,0.00061815674,0.00006261736,0.000036432444,0.00013523603],"domain_scores_gemma":[0.9977757,0.0005768465,0.0011908594,0.00027807665,0.000073566975,0.00010500558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022005339,0.00005878695,0.00024724405,0.00004564544,0.00056293496,0.000075458214,0.0005304248,0.000028689687,0.00010282075],"category_scores_gemma":[0.0015457041,0.000031171327,0.0000719702,0.000030448655,0.000400269,0.00009470386,0.0000280863,0.00015696645,0.0000041371713],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003136351,0.000064169326,0.010961226,0.000044440003,0.00045212285,0.0000025797392,0.005769961,0.00007619418,0.00017947285,0.6313999,0.06583696,0.28489932],"study_design_scores_gemma":[0.0060089175,0.00009760852,0.009512496,0.000026255098,0.000020737967,0.00001932914,0.000043791144,0.00067542354,0.000039311228,0.06176081,0.92175865,0.000036667807],"about_ca_topic_score_codex":0.000100417994,"about_ca_topic_score_gemma":0.000023952873,"teacher_disagreement_score":0.87001926,"about_ca_system_score_codex":0.000018766526,"about_ca_system_score_gemma":0.00008922851,"threshold_uncertainty_score":0.43296978},"labels":[],"label_agreement":null},{"id":"W2743519407","doi":"10.1177/1715163517714201","title":"Drug costs in Canada","year":2017,"lang":"fr","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Business; Medicine; Pharmacology","score_opus":0.05891626071313478,"score_gpt":0.27431665280086104,"score_spread":0.21540039208772627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2743519407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85073924,0.034978263,0.000020764246,0.014612802,0.037852533,0.0006591136,0.011294717,0.000011201591,0.04983137],"genre_scores_gemma":[0.9211301,0.053415123,0.00005985903,0.013277187,0.0023531655,0.00001941036,0.000031754877,0.0001224636,0.009590931],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99382323,0.0001468561,0.0019547842,0.0009134553,0.00018943309,0.0029722669],"domain_scores_gemma":[0.9922786,0.000186546,0.0014581784,0.00090598024,0.00025299084,0.004917725],"candidate_categories":["metaepi_narrow","sts","scholarly_communication","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015236101,0.000751225,0.0012084577,0.0006382321,0.0022311942,0.0012315572,0.002650949,0.00015381027,0.0060348837],"category_scores_gemma":[0.00057850085,0.0011221232,0.00028728787,0.00037080544,0.0005157937,0.001294841,0.0002119149,0.0020534135,0.0001861209],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00011935897,0.00012213529,0.14838344,0.00054887345,0.00057502947,0.1530546,0.0010451556,0.0036405774,0.000024836903,0.007925382,0.43035322,0.2542074],"study_design_scores_gemma":[0.0034923514,0.000016778275,0.0015430013,0.00010260872,0.00006765617,0.08725601,0.00001642081,0.021997655,0.00019132668,0.0015152532,0.8822738,0.0015271502],"about_ca_topic_score_codex":0.9983862,"about_ca_topic_score_gemma":0.9998455,"teacher_disagreement_score":0.45192057,"about_ca_system_score_codex":0.043654185,"about_ca_system_score_gemma":0.028027913,"threshold_uncertainty_score":0.9998053},"labels":[],"label_agreement":null},{"id":"W2743792024","doi":"10.1177/1715163517711144","title":"Drug costs in Canada","year":2017,"lang":"fr","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Medicine; Pharmacology","score_opus":0.05891626071313478,"score_gpt":0.27431665280086104,"score_spread":0.21540039208772627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2743792024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85073924,0.034978263,0.000020764246,0.014612802,0.037852533,0.0006591136,0.011294717,0.000011201591,0.04983137],"genre_scores_gemma":[0.9211301,0.053415123,0.00005985903,0.013277187,0.0023531655,0.00001941036,0.000031754877,0.0001224636,0.009590931],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99382323,0.0001468561,0.0019547842,0.0009134553,0.00018943309,0.0029722669],"domain_scores_gemma":[0.9922786,0.000186546,0.0014581784,0.00090598024,0.00025299084,0.004917725],"candidate_categories":["metaepi_narrow","sts","scholarly_communication","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015236101,0.000751225,0.0012084577,0.0006382321,0.0022311942,0.0012315572,0.002650949,0.00015381027,0.0060348837],"category_scores_gemma":[0.00057850085,0.0011221232,0.00028728787,0.00037080544,0.0005157937,0.001294841,0.0002119149,0.0020534135,0.0001861209],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00011935897,0.00012213529,0.14838344,0.00054887345,0.00057502947,0.1530546,0.0010451556,0.0036405774,0.000024836903,0.007925382,0.43035322,0.2542074],"study_design_scores_gemma":[0.0034923514,0.000016778275,0.0015430013,0.00010260872,0.00006765617,0.08725601,0.00001642081,0.021997655,0.00019132668,0.0015152532,0.8822738,0.0015271502],"about_ca_topic_score_codex":0.9983862,"about_ca_topic_score_gemma":0.9998455,"teacher_disagreement_score":0.45192057,"about_ca_system_score_codex":0.043654185,"about_ca_system_score_gemma":0.028027913,"threshold_uncertainty_score":0.9998053},"labels":[],"label_agreement":null},{"id":"W2747517682","doi":"10.1186/s12992-017-0285-x","title":"Merger mania: mergers and acquisitions in the generic drug sector from 1995 to 2016","year":2017,"lang":"en","type":"article","venue":"Globalization and Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Carleton University","funders":"Canadian Institutes of Health Research; Bloomberg L.P.","keywords":"Mergers and acquisitions; Social policy; Quality of Life Research; Mania; Business; Public finance; Public health; Economics; Political science; Medicine; Finance; Psychiatry; Law; Market economy","score_opus":0.09444721960396195,"score_gpt":0.33800347680941223,"score_spread":0.24355625720545027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2747517682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73231804,0.009604324,0.0014583358,0.21585898,0.0008298118,0.00070654944,0.0015524487,0.000030706567,0.037640814],"genre_scores_gemma":[0.96441996,0.0054157665,0.00016502255,0.02965784,0.0001442577,0.000014397316,0.00003161109,0.000007756051,0.00014340934],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99925953,0.000018374532,0.00028729244,0.00022520397,0.000017089216,0.00019247942],"domain_scores_gemma":[0.99945366,0.000014891036,0.00015519363,0.0002266368,0.0000072992652,0.00014233212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003967093,0.00008023177,0.0001852589,0.00006626888,0.0003397553,0.00015501968,0.00014540867,0.000032921253,0.00020528314],"category_scores_gemma":[0.000022482962,0.00007472408,0.000021111415,0.00006517374,0.000035633166,0.00012371174,0.00005125153,0.00005225694,0.000100273326],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016296322,0.00007631042,0.14424574,0.00003954451,0.000030891526,0.0000016510861,0.002810334,0.00010820616,0.00000859704,0.6865497,0.16241734,0.0036953832],"study_design_scores_gemma":[0.00048339023,0.000018252478,0.59921134,0.000014292151,0.0000028002264,9.550215e-7,0.000082322316,0.0045384835,0.0000022349534,0.021194471,0.37430257,0.00014889294],"about_ca_topic_score_codex":0.0055321665,"about_ca_topic_score_gemma":0.0014055696,"teacher_disagreement_score":0.6653552,"about_ca_system_score_codex":0.00006368153,"about_ca_system_score_gemma":0.000024673507,"threshold_uncertainty_score":0.83630174},"labels":[],"label_agreement":null},{"id":"W2748295223","doi":"10.1371/journal.pone.0182742","title":"The cost of entry: An analysis of pharmaceutical registration fees in low-, middle-, and high-income countries","year":2017,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"University of British Columbia","keywords":"Gross domestic product; Business; Authorization; Population; Product (mathematics); Public economics; Medicine; Environmental health; Economics; Economic growth","score_opus":0.12290040756593322,"score_gpt":0.30926712340999885,"score_spread":0.1863667158440656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2748295223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943051,0.0005905958,0.00001913583,0.0019350186,0.00003592655,0.00015279563,0.00032678997,0.0000040322466,0.0026306303],"genre_scores_gemma":[0.9968771,0.0027781941,0.00006611615,0.00011588082,0.00004023443,0.000011303019,0.0000114758595,0.0000071977183,0.000092550996],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99904406,0.000016012578,0.0005416849,0.00018940184,0.00003827266,0.00017058394],"domain_scores_gemma":[0.99888426,0.00012746487,0.00047583797,0.0004017673,0.000031321502,0.00007933896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005633443,0.00008327863,0.0004461401,0.00015838955,0.00012131946,0.000095543,0.0002665027,0.000058945454,0.00008634749],"category_scores_gemma":[0.00017289631,0.00008161244,0.000049445604,0.000093422714,0.0002885082,0.00021341957,0.000058898102,0.00009606993,0.000010342263],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000104951876,0.00039119847,0.65196484,0.00014431133,0.00066909665,8.221041e-7,0.00016723113,0.00006313756,0.00013863573,0.346088,0.0000073351803,0.00026041907],"study_design_scores_gemma":[0.0011544294,0.00007573763,0.8702755,0.000087828885,0.00026909908,2.1580583e-7,0.000028330847,0.109729595,0.005738736,0.011382346,0.001058867,0.0001993054],"about_ca_topic_score_codex":0.000541806,"about_ca_topic_score_gemma":0.000588424,"teacher_disagreement_score":0.33470565,"about_ca_system_score_codex":0.000038736285,"about_ca_system_score_gemma":0.000016028305,"threshold_uncertainty_score":0.33280587},"labels":[],"label_agreement":null},{"id":"W2750285636","doi":"10.1503/cmaj.1095454","title":"Tackling Pharma corruption in Ukraine","year":2017,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Christian ministry; Guard (computer science); Language change; Procurement; Outsourcing; Business; Political science; Public administration; Medicine; Economic growth; Computer science; Law; Economics; Marketing","score_opus":0.04233519668014477,"score_gpt":0.3006444263596866,"score_spread":0.2583092296795418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2750285636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5967452,0.0009942228,0.00018806962,0.20336935,0.004207133,0.00015296484,0.00018457184,0.000015266374,0.19414325],"genre_scores_gemma":[0.97963685,0.00085662876,0.000041736403,0.017408885,0.0015418896,0.000003499846,0.0000041891294,0.000012418208,0.00049393275],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.998718,0.00002186298,0.00057236827,0.0001503803,0.00009022739,0.00044716644],"domain_scores_gemma":[0.9982861,0.000051234456,0.0004985771,0.00013599095,0.000046695197,0.0009813902],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0024904395,0.00008372307,0.00023626958,0.00024084246,0.000386554,0.00031130877,0.00038912724,0.0002265243,0.0061050556],"category_scores_gemma":[0.002129614,0.000102494356,0.000080548045,0.00005511633,0.00003113869,0.0003146766,0.000024478111,0.0007272926,0.0011802342],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009329411,0.000050824183,0.81888384,0.000008890815,0.00008350027,0.00024310587,0.00037088967,0.00004332597,0.000005159128,0.051568553,0.08254385,0.046188712],"study_design_scores_gemma":[0.0011183941,0.0000100774205,0.115518786,0.000017581116,0.0000020252473,0.000036824556,0.000018508556,0.008075826,0.0000036911713,0.007777158,0.8672737,0.00014746713],"about_ca_topic_score_codex":0.004822193,"about_ca_topic_score_gemma":0.0164034,"teacher_disagreement_score":0.78472984,"about_ca_system_score_codex":0.0010347138,"about_ca_system_score_gemma":0.0004016788,"threshold_uncertainty_score":0.9995975},"labels":[],"label_agreement":null},{"id":"W2751738273","doi":"10.2139/ssrn.3024095","title":"&lt;p&gt;&lt;b&gt;&lt;span&gt;Launch Price and Advertising as Strategic Substitutes: Evidence from Pharmaceutical Markets&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;","year":2017,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medical prescription; Power (physics); Business; Economics; Medicine; Pharmacology; Physics","score_opus":0.05740121175034991,"score_gpt":0.31022022908207775,"score_spread":0.25281901733172785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2751738273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8270198,0.11197092,0.002095569,0.00843068,0.002679861,0.0011399249,0.00052020035,0.00020259805,0.04594046],"genre_scores_gemma":[0.8533838,0.13826011,0.0004219893,0.0015912357,0.0026121924,0.00006987801,0.000051955845,0.00026864294,0.003340237],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.98583543,0.00037306407,0.0033459312,0.0026214619,0.0006143742,0.0072097583],"domain_scores_gemma":[0.9917799,0.0010303474,0.0027301859,0.0020808405,0.00034924323,0.002029436],"candidate_categories":["metaepi_narrow","sts","scholarly_communication","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.006804673,0.0017116653,0.0025072666,0.0009449241,0.002577452,0.0026814973,0.0033780301,0.0010263721,0.002629446],"category_scores_gemma":[0.0014772008,0.0019187727,0.0010102337,0.0006485522,0.0010128757,0.0034011106,0.00091494404,0.004599037,0.0019952958],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002503994,0.0011995034,0.014176306,0.00039003743,0.003670082,0.00039204035,0.0010217287,0.00068723364,0.035979904,0.90011585,0.007012212,0.03285108],"study_design_scores_gemma":[0.00963006,0.0010220924,0.026735978,0.00076962664,0.00070508587,0.0014382286,0.000121438025,0.04451053,0.0015617529,0.35490587,0.55424386,0.004355476],"about_ca_topic_score_codex":0.0002166846,"about_ca_topic_score_gemma":0.0017476081,"teacher_disagreement_score":0.5472317,"about_ca_system_score_codex":0.0034541504,"about_ca_system_score_gemma":0.0031370134,"threshold_uncertainty_score":0.999563},"labels":[],"label_agreement":null},{"id":"W2751849735","doi":"10.1016/s2468-2667(17)30141-x","title":"Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: an analysis of the PURE study data","year":2017,"lang":"en","type":"article","venue":"The Lancet Public Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":214,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hamilton Health Sciences; Université Laval; Simon Fraser University; Population Health Research Institute; McMaster University","funders":"Deanship of Scientific Research, King Saud University; Philippine Council for Health Research and Development; Canadian Institutes of Health Research; Servier; Uniwersytet Medyczny im. Piastów Slaskich we Wroclawiu; United Arab Emirates University; Universiti Kebangsaan Malaysia; Universiti Teknologi MARA; International Development Research Centre; Svenska Forskningsrådet Formas; Forskningsrådet för Arbetsliv och Socialvetenskap; Indian Council of Medical Research; North-West University; South Africa Netherlands research Programme on Alternatives in Development; Public Health Agency of Canada; AFA Försäkring; Sheikh Hamdan Bin Rashid Al Maktoum Award for Medical Sciences; Universidad de La Frontera; Ministerstwo Edukacji i Nauki; GlaxoSmithKline; Vetenskapsrådet; Heart and Stroke Foundation of Canada; Boehringer Ingelheim; Ministry of Higher Education, Malaysia; AstraZeneca Canada; AstraZeneca","keywords":"Developing country; Medicine; Environmental health; Business; Economics; Economic growth","score_opus":0.06005507458694665,"score_gpt":0.325043724570828,"score_spread":0.26498864998388133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2751849735","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9733336,0.0046344846,0.0000056710264,0.018300435,0.0001325871,0.0014364553,0.0019439483,0.000011390433,0.00020145545],"genre_scores_gemma":[0.99805164,0.0009502337,0.00000684112,0.0007852823,0.0001255644,0.000043742937,0.000008101997,0.000014480957,0.00001413388],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971846,0.00053239934,0.0010691698,0.0006452803,0.00010964074,0.00045893292],"domain_scores_gemma":[0.99420273,0.0013953643,0.0011206559,0.0030525248,0.00004302709,0.00018568628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014458709,0.00024216223,0.0017507313,0.0001616977,0.00044805673,0.00019841228,0.0014846097,0.000094141105,0.000031045867],"category_scores_gemma":[0.0015961203,0.00013753398,0.00007181195,0.00024802433,0.0010626091,0.0003572073,0.0006358422,0.00040584494,5.422724e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024714603,0.00019814204,0.98617214,0.0006672211,0.0015303105,3.5215422e-7,0.0009840464,0.00005001748,9.2840185e-7,0.009895218,0.0000073790948,0.0002471263],"study_design_scores_gemma":[0.00733894,0.0004386192,0.9745041,0.00006464826,0.0008719074,0.0000014140143,0.000060269977,0.014379408,0.0000061906426,0.0014837201,0.00071586954,0.00013488324],"about_ca_topic_score_codex":0.0045347465,"about_ca_topic_score_gemma":0.0034673207,"teacher_disagreement_score":0.024718046,"about_ca_system_score_codex":0.000016514037,"about_ca_system_score_gemma":0.00008083442,"threshold_uncertainty_score":0.68552107},"labels":[],"label_agreement":null},{"id":"W2752438457","doi":"10.1111/poms.12780","title":"Contracts to Promote Optimal Use of Optional Diagnostic Tests in Cancer Treatment","year":2017,"lang":"en","type":"article","venue":"Production and Operations Management","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Wilfrid Laurier University","funders":"Natural Sciences and Engineering Research Council of Canada; Hong Kong Polytechnic University; University of Hong Kong; Centers for Disease Control and Prevention; National Comprehensive Cancer Network","keywords":"Test (biology); Radiation oncologist; Health care; Moral hazard; Diagnostic test; Payment; Quality (philosophy); Medicine; Actuarial science; Adverse selection; Private information retrieval; Business; Incentive; Economics; Finance; Internal medicine; Computer science; Pediatrics; Microeconomics","score_opus":0.12128450182497498,"score_gpt":0.3441382699279324,"score_spread":0.22285376810295743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2752438457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9801963,0.00025845843,0.0002319311,0.01633071,0.00034814508,0.0007328932,0.00009335874,0.0000075246467,0.001800674],"genre_scores_gemma":[0.9927138,0.0021972244,0.002635407,0.0002881584,0.000093343595,0.00022834448,0.0000064753604,0.000006925282,0.0018303251],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99932575,0.000004807709,0.00027392857,0.00026044666,0.000015608015,0.00011944331],"domain_scores_gemma":[0.9996016,0.000012366499,0.000074006806,0.00023071913,0.00001976452,0.000061567844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001383595,0.00007792441,0.00015089166,0.00014469858,0.00015428728,0.00015072858,0.00006958397,0.000019247127,0.00009476806],"category_scores_gemma":[0.0001930489,0.000083759674,0.000021835038,0.000044064807,0.000035286725,0.00032500795,0.000051750423,0.00003218867,0.00004380848],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000077929006,0.0013795799,0.15105848,0.000089077985,0.00025703912,0.000007620467,0.0012044127,0.18339488,0.00022871407,0.5984022,0.0018799318,0.06202014],"study_design_scores_gemma":[0.0009327805,0.0001347418,0.7629989,0.00005501257,0.000021581249,0.000002091308,0.00002253973,0.016370485,0.00066109013,0.0012988398,0.21723172,0.00027026745],"about_ca_topic_score_codex":0.00063071196,"about_ca_topic_score_gemma":0.000605821,"teacher_disagreement_score":0.6119404,"about_ca_system_score_codex":0.00009605054,"about_ca_system_score_gemma":0.00000910198,"threshold_uncertainty_score":0.34156206},"labels":[],"label_agreement":null},{"id":"W2754568616","doi":"","title":"Pharmaceutical practices in France and in Quebec and exchange prospects","year":2002,"lang":"en","type":"article","venue":"Journal de Pharmacie Clinique","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science","score_opus":0.15613457282557777,"score_gpt":0.38498353689260834,"score_spread":0.22884896406703056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754568616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9528673,0.021566693,0.00006194329,0.015997222,0.00027425724,0.00025789766,0.000026626438,0.000014565558,0.008933448],"genre_scores_gemma":[0.9327594,0.058063645,0.0003435031,0.0077441926,0.00032343675,0.000025362113,5.065493e-7,0.000022702914,0.0007172549],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982519,0.00007679931,0.00080994325,0.0003469234,0.000031450923,0.00048296145],"domain_scores_gemma":[0.9987549,0.00024785387,0.0005266471,0.00009878615,0.000015241656,0.00035656712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016836595,0.00017538718,0.00041394983,0.00034387532,0.000070339665,0.00020406106,0.00016091796,0.000121338555,0.00078901544],"category_scores_gemma":[0.0003395689,0.00019978544,0.000055453842,0.00020600764,0.0001072601,0.0006941771,0.00007434879,0.0009970451,0.00007644026],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013499008,0.00067253434,0.94867957,0.0002456878,0.00006381261,0.0005067816,0.0026029304,0.000052280782,0.00047119727,0.011406914,0.0044735386,0.030689761],"study_design_scores_gemma":[0.0066912025,0.00010033971,0.12558417,0.00009144021,0.000016090664,0.00068795966,0.000049825496,0.11769915,0.000558771,0.0327039,0.7151197,0.00069744815],"about_ca_topic_score_codex":0.00034000032,"about_ca_topic_score_gemma":0.00029084497,"teacher_disagreement_score":0.8230954,"about_ca_system_score_codex":0.00015405452,"about_ca_system_score_gemma":0.000028104934,"threshold_uncertainty_score":0.8639165},"labels":[],"label_agreement":null},{"id":"W2755091626","doi":"10.55016/ojs/sppp.v2i1.42316","title":"Generic Drug Pricing and Procurement: A Policy for Alberta","year":2009,"lang":"en","type":"article","venue":"The School of Public Policy Publications","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Drug pricing; Procurement; Business; Drug; Actuarial science; Marketing; Pharmacology; Medicine","score_opus":0.08461818533324403,"score_gpt":0.31983079935070446,"score_spread":0.23521261401746044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2755091626","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05262781,0.001351002,0.0028960335,0.75766027,0.00008625916,0.001267565,0.00042487448,0.00008063884,0.18360554],"genre_scores_gemma":[0.97979563,0.00037250534,0.00075045315,0.0129331425,0.00076891045,0.00019372291,0.000033821627,0.000025731066,0.005126063],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982343,0.000027601516,0.00075898424,0.0003611361,0.00004337412,0.00057465804],"domain_scores_gemma":[0.9982098,0.00016255901,0.0004926032,0.0006360774,0.00011269729,0.00038628242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010345331,0.00018602707,0.00034732147,0.0008871541,0.00029055637,0.00027729842,0.0006711307,0.00007274329,0.00012929842],"category_scores_gemma":[0.0024479206,0.00017201324,0.00014068412,0.0011193468,0.00014203323,0.00057847076,0.00010021647,0.00016592973,0.00011018273],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000035453509,0.000088967856,0.0025310344,0.000015144007,0.000048271086,8.975144e-9,0.0002262645,0.000009155793,0.00005474878,0.9791538,0.015272442,0.0025966158],"study_design_scores_gemma":[0.0006606096,0.00004567481,0.05382581,0.000004894204,0.000011245201,0.0000049762257,0.000021683449,0.0021692547,0.00006412062,0.37378702,0.56917584,0.00022889515],"about_ca_topic_score_codex":0.0018674245,"about_ca_topic_score_gemma":0.0000804816,"teacher_disagreement_score":0.92716783,"about_ca_system_score_codex":0.00020488717,"about_ca_system_score_gemma":0.00045976057,"threshold_uncertainty_score":0.70144963},"labels":[],"label_agreement":null},{"id":"W2759020488","doi":"","title":"The role of the economic analysis in the decision making process at the Drug Quality and Therapeutics Committee of Ontario","year":2000,"lang":"en","type":"dissertation","venue":"TSpace (University of Toronto)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quality (philosophy); Drug; Process (computing); Medicine; Management science; Political science; Risk analysis (engineering); Pharmacology; Engineering; Computer science","score_opus":0.0325307249676474,"score_gpt":0.3070082247096982,"score_spread":0.27447749974205077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2759020488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9275469,0.004374535,0.000002552202,0.0008253935,0.00008321538,0.00024915452,0.00013617479,0.0000020804491,0.06677999],"genre_scores_gemma":[0.99573916,0.0020779567,0.00001645226,0.00009352132,0.000012650532,9.403935e-7,0.000015378675,0.000008923096,0.0020350046],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.9990195,0.000080073216,0.00042287982,0.00024246625,0.00006057398,0.00017448235],"domain_scores_gemma":[0.9979475,0.00041083142,0.0010153927,0.00057526864,0.000027364427,0.000023651566],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000926249,0.00015733924,0.0005238413,0.00006258375,0.0003054726,0.000027154223,0.0009572375,0.00012565563,0.0017330552],"category_scores_gemma":[0.00001166874,0.00011146157,0.00031434858,0.00010919695,0.00020676023,0.00012328287,0.00009501567,0.00023221891,0.0000058016635],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025853869,0.0002830951,0.39133018,0.0002425805,0.003275672,9.162119e-7,0.3971613,0.0040472616,0.00002572479,0.08423426,0.00043751352,0.1163761],"study_design_scores_gemma":[0.00036688717,0.00001832935,0.95514244,0.000029950068,0.00023816597,3.1944214e-7,0.016656758,0.0024289843,0.000026005428,0.008373006,0.016553301,0.00016585588],"about_ca_topic_score_codex":0.36763436,"about_ca_topic_score_gemma":0.93490404,"teacher_disagreement_score":0.5672697,"about_ca_system_score_codex":0.0006742742,"about_ca_system_score_gemma":0.0001576792,"threshold_uncertainty_score":0.9991795},"labels":[],"label_agreement":null},{"id":"W2762117546","doi":"10.1093/pch/pxy014","title":"What does mainstream media say about enzyme replacement therapies?","year":2018,"lang":"en","type":"article","venue":"Paediatrics & Child Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Mainstream; Medicine; Government (linguistics); Thematic analysis; Family medicine; Inclusion (mineral); Clinical trial; Health care; Psychology; Political science; Qualitative research; Pathology","score_opus":0.030421992523179786,"score_gpt":0.2905839722643495,"score_spread":0.2601619797411697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762117546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.33905667,0.17447524,0.0022787282,0.29672298,0.03180808,0.002905344,0.0027548308,0.00061892037,0.1493792],"genre_scores_gemma":[0.8378208,0.09820841,0.00074221636,0.056674264,0.005808489,0.00004710792,0.00009268423,0.00008356763,0.00052242016],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968345,0.00005367908,0.0012409979,0.0007807806,0.000084055,0.0010059709],"domain_scores_gemma":[0.9977281,0.00018505103,0.0007196214,0.0007020703,0.00005130496,0.0006138518],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0017806466,0.00032676978,0.0006737441,0.00040187562,0.0004582657,0.00028490374,0.00046334293,0.00017251183,0.0015893555],"category_scores_gemma":[0.00015747327,0.00030969872,0.0001977029,0.00042858967,0.00016096984,0.0004808792,0.00015169302,0.00041251178,0.0021995872],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016388435,0.0006250581,0.057627898,0.00022499572,0.00023968608,0.000004469433,0.013105303,0.000014441031,0.0000020847751,0.8066659,0.07915759,0.04216871],"study_design_scores_gemma":[0.0014097807,0.00024449392,0.016530493,0.000034175937,0.000008890212,0.0000053993595,0.00026759817,0.0007485101,0.000044756154,0.053107303,0.9270752,0.0005233988],"about_ca_topic_score_codex":0.0003002288,"about_ca_topic_score_gemma":0.0003552944,"teacher_disagreement_score":0.8479176,"about_ca_system_score_codex":0.00040275112,"about_ca_system_score_gemma":0.00014674882,"threshold_uncertainty_score":0.9999355},"labels":[],"label_agreement":null},{"id":"W2762459231","doi":"10.1080/13543776.2018.1388780","title":"Bill C-30: who wins and who loses in Canada’s pharmaceutical patent battles?","year":2017,"lang":"en","type":"editorial","venue":"Expert Opinion on Therapeutic Patents","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Business; Patent analysis; Patent troll; Patent law; Law; Political science; Computer science; Intellectual property","score_opus":0.14818294676430427,"score_gpt":0.340395631864411,"score_spread":0.19221268510010675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762459231","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0029532413,0.0511818,0.000027328722,0.008973849,0.91820467,0.0011719791,0.0044925166,0.00006134505,0.012933256],"genre_scores_gemma":[0.2103523,0.36314613,0.00003080716,0.016584542,0.40544635,0.00040165609,0.00081938243,0.0005129132,0.0027059314],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962104,0.000086010485,0.0012385906,0.0012533688,0.0002197559,0.000991851],"domain_scores_gemma":[0.9974678,0.00040028512,0.00072071876,0.00086819404,0.000054558677,0.0004884249],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00054935156,0.00073313003,0.0014452694,0.00035743456,0.0002475207,0.00027234983,0.0009233255,0.00088205305,0.00067152665],"category_scores_gemma":[0.00021061944,0.00069830916,0.0001906224,0.00008403948,0.00017652047,0.00021164463,0.00026044212,0.0015148621,0.00035966004],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002362267,0.00026977685,0.006360121,0.00009764858,0.00034396723,0.00002989989,0.00038900768,0.000022622351,0.000004368391,0.0037209417,0.96681917,0.021706257],"study_design_scores_gemma":[0.002473201,0.00011182373,0.0039258157,0.0002590413,0.0000052247497,0.0000016960946,0.000023778,0.0022276633,0.00003641045,0.0023628965,0.98769283,0.0008795951],"about_ca_topic_score_codex":0.35204232,"about_ca_topic_score_gemma":0.02710923,"teacher_disagreement_score":0.5127583,"about_ca_system_score_codex":0.0014072108,"about_ca_system_score_gemma":0.0008904919,"threshold_uncertainty_score":0.9995468},"labels":[],"label_agreement":null},{"id":"W2765265353","doi":"10.1177/1468018117734153","title":"The Trans Pacific Partnership Agreement, intellectual property and medicines: Differential outcomes for developed and developing countries","year":2017,"lang":"en","type":"article","venue":"Global Social Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Intellectual property; General partnership; Negotiation; Developing country; Legislature; Differential treatment; Political science; Criticism; Politics; Differential (mechanical device); Business; International trade; Law and economics; Economics; Economic growth; Law; Engineering","score_opus":0.12673319282987103,"score_gpt":0.35879654926922266,"score_spread":0.23206335643935164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765265353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5507858,0.0009607859,0.002832739,0.3770234,0.00081563985,0.0012465707,0.00110959,0.000057725945,0.06516781],"genre_scores_gemma":[0.993438,0.0019600748,0.000063470376,0.0028708864,0.0006874005,0.000049425507,0.0000075497446,0.000012971928,0.0009102379],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988282,0.000014016219,0.0004034558,0.0002761683,0.000031412084,0.00044678166],"domain_scores_gemma":[0.9994102,0.0000672345,0.00021933978,0.0001520903,0.000030492805,0.00012061965],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.00033204004,0.00018355051,0.00037190042,0.000037704893,0.0017335562,0.00047858997,0.0002808883,0.00010056916,0.000023369503],"category_scores_gemma":[0.00064307544,0.00012824789,0.000074752315,0.000046458023,0.00055871566,0.00014094965,0.000116267336,0.000080632664,0.00001985398],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000101912236,0.000020110496,0.029487994,0.00007317074,0.00022513898,4.2487596e-7,0.0031318872,8.6474415e-8,0.0000013253666,0.9177399,0.010283427,0.038934566],"study_design_scores_gemma":[0.0013170076,0.00003375405,0.21679902,0.000008411279,0.000016690217,0.0000019610368,0.0002186303,0.00017935793,0.000007879137,0.07003175,0.7111064,0.00027911257],"about_ca_topic_score_codex":0.0012056745,"about_ca_topic_score_gemma":0.00043580795,"teacher_disagreement_score":0.8477082,"about_ca_system_score_codex":0.00014884156,"about_ca_system_score_gemma":0.000118641336,"threshold_uncertainty_score":0.9995661},"labels":[],"label_agreement":null},{"id":"W2765388428","doi":"10.1016/j.jval.2017.08.2753","title":"Interrupted Time Series Analysis Evaluating The Impact of A Pro-Generic Policy on Drug Pricing and Utilization In Argentina","year":2017,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Unit price; Unit (ring theory); Interrupted time series; Interrupted Time Series Analysis; Generic drug; Panel data; Public economics; Economics; Drug; Business; Econometrics; Medicine; Macroeconomics; Statistics; Pharmacology; Mathematics","score_opus":0.25661781000631123,"score_gpt":0.4364669964465159,"score_spread":0.17984918644020464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765388428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99377114,0.0005470284,0.00002625108,0.0031684658,0.000037154598,0.00029060274,0.00005759984,0.0000049913933,0.0020967869],"genre_scores_gemma":[0.9988626,0.0006565518,0.000097205906,0.00022664007,0.000046962236,0.0000124508215,0.0000067756882,0.000010623539,0.000080192534],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99869615,0.00008251358,0.0006889386,0.00023958726,0.00002520956,0.00026762206],"domain_scores_gemma":[0.9988147,0.000082308776,0.00068594824,0.0003362841,0.000013348166,0.00006738498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019152606,0.000105925035,0.00041912595,0.00058913487,0.00013839312,0.000069277135,0.00019508826,0.000034978577,0.000042188214],"category_scores_gemma":[0.00047760544,0.00009255338,0.000090353446,0.00043029312,0.00006038283,0.00015175651,0.00007549736,0.00012977507,0.000013382577],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000111246554,0.00017557945,0.8564481,0.0001357178,0.00016720234,7.1480804e-7,0.004913103,0.07522281,0.000045470573,0.054045178,0.00005943036,0.008675455],"study_design_scores_gemma":[0.00030957785,0.00011935627,0.46811652,0.000034570643,0.0000037809386,5.5213906e-7,0.000020807956,0.5217729,0.000022804761,0.009442353,0.0000812567,0.00007551638],"about_ca_topic_score_codex":0.028919658,"about_ca_topic_score_gemma":0.00019135336,"teacher_disagreement_score":0.4465501,"about_ca_system_score_codex":0.00029517818,"about_ca_system_score_gemma":0.00014813096,"threshold_uncertainty_score":0.9775469},"labels":[],"label_agreement":null},{"id":"W2767071034","doi":"10.1684/pnv.2017.0679","title":"High rate of errors in pillbox filling by cognitively healthy elderly people","year":2017,"lang":"en","type":"article","venue":"Gériatrie et Psychologie Neuropsychiatrie du Viellissement","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psychology; Geriatric Depression Scale; Task (project management); Cognition; Stroop effect; Commit; Neuropsychology; Depressive symptoms; Psychiatry; Computer science","score_opus":0.05656790365275587,"score_gpt":0.3261221446164835,"score_spread":0.2695542409637276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767071034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93833196,0.0017336309,0.00055221416,0.046510298,0.0034972029,0.0007406176,0.0009561148,0.000054592914,0.007623344],"genre_scores_gemma":[0.97763926,0.013228294,0.00055332074,0.00791219,0.00032326707,0.00006403013,0.000057170073,0.00006995587,0.00015249678],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99618745,0.00013962976,0.0017497245,0.0010541627,0.00007999163,0.0007890502],"domain_scores_gemma":[0.9966934,0.00021926822,0.0016480392,0.0011017795,0.000063700856,0.00027384426],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020288792,0.00042851764,0.00096490234,0.00033330053,0.0003132598,0.00023028797,0.0013052761,0.00021316946,0.0004740406],"category_scores_gemma":[0.0003812291,0.0004992454,0.00026502906,0.000266539,0.00015405225,0.00040600504,0.00022986367,0.00056167337,0.0003334415],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027188247,0.0046236264,0.61420375,0.00038860666,0.0003594508,0.00005732607,0.0013902155,0.0011788156,0.0006558242,0.16400385,0.20077424,0.009645476],"study_design_scores_gemma":[0.015364574,0.002604184,0.5285166,0.00008891335,0.00006213645,0.000011030862,0.00015698442,0.0008072753,0.00080042897,0.08066154,0.3690339,0.001892419],"about_ca_topic_score_codex":0.0009734474,"about_ca_topic_score_gemma":0.00014622323,"teacher_disagreement_score":0.16825967,"about_ca_system_score_codex":0.00008142385,"about_ca_system_score_gemma":0.00007031974,"threshold_uncertainty_score":0.9997459},"labels":[],"label_agreement":null},{"id":"W2767845149","doi":"10.1161/circ.134.suppl_1.12799","title":"Abstract 12799: Hospitalizations and Emergency Consultations Following Generic Antihypertensive Drugs Commercialization in Quebec","year":2016,"lang":"en","type":"article","venue":"Circulation","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; Institut National de Santé Publique du Québec; Université Laval","funders":"","keywords":"Medicine; Commercialization; Emergency department; Family medicine; Medical emergency; Emergency medicine; Intensive care medicine; Nursing","score_opus":0.044759773805366436,"score_gpt":0.2789102906140184,"score_spread":0.23415051680865195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767845149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851377,0.0006671078,0.006355325,0.0025981236,0.00039845548,0.00020815704,0.00007348557,0.00003564287,0.0045260014],"genre_scores_gemma":[0.99890906,0.0004803397,0.00006392437,0.00032350892,0.00006474823,0.000019873383,0.00004653562,0.000017617142,0.00007441176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990206,0.000011478454,0.0005120866,0.0002582369,0.000021234368,0.00017641246],"domain_scores_gemma":[0.99953,0.00005369124,0.00018278873,0.00012944531,0.000035394216,0.000068649715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016270783,0.00010226556,0.00019650099,0.00022185003,0.0001028926,0.000038504488,0.000059790756,0.00007620907,0.00016192542],"category_scores_gemma":[0.0001302555,0.00010853117,0.00005757796,0.0002515902,0.000033091826,0.0004539466,0.000018577344,0.000040799812,0.00012725334],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000030099477,0.00004708795,0.80183524,0.000013910072,0.000029612727,0.0000011713456,0.0009702201,0.00030610798,0.0006890195,0.19078393,0.0005109494,0.0048097097],"study_design_scores_gemma":[0.00069696765,0.0000035718056,0.9683099,0.000017701313,0.000007102085,5.4604266e-7,0.00005715875,0.007296283,0.000027119257,0.018969176,0.004408572,0.00020591432],"about_ca_topic_score_codex":0.0019088885,"about_ca_topic_score_gemma":0.00065398513,"teacher_disagreement_score":0.17181475,"about_ca_system_score_codex":0.00012425007,"about_ca_system_score_gemma":0.000022152723,"threshold_uncertainty_score":0.44257724},"labels":[],"label_agreement":null},{"id":"W2768318977","doi":"10.1089/omi.2017.0141","title":"Genomic Medicine Without Borders: Which Strategies Should Developing Countries Employ to Invest in Precision Medicine? A New “Fast-Second Winner” Strategy","year":2017,"lang":"en","type":"article","venue":"OMICS A Journal of Integrative Biology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"National Heart, Lung, and Blood Institute; United Arab Emirates University","keywords":"Precision medicine; Genomic medicine; Personalized medicine; Computer science; Business; Biology; Computational biology; Genetics","score_opus":0.1397923509181222,"score_gpt":0.4010220524421782,"score_spread":0.261229701524056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768318977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89426273,0.004422024,0.010909193,0.05717103,0.0015979339,0.00042186608,0.00014969164,0.000011821398,0.03105368],"genre_scores_gemma":[0.9879552,0.0043610884,0.0017667083,0.004590739,0.00094242604,0.000008000406,0.000011336807,0.000038832426,0.00032563144],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9970868,0.00007149968,0.0018439476,0.000449437,0.000049604107,0.00049870874],"domain_scores_gemma":[0.99694824,0.00028198483,0.0017347358,0.0004051093,0.00028508733,0.00034484692],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016124191,0.00039532242,0.0014470113,0.00079572323,0.00019191581,0.00019096817,0.0010680339,0.00027728942,0.0005969829],"category_scores_gemma":[0.0013803092,0.00030182782,0.00010321124,0.0001877261,0.0004999905,0.00057734427,0.00016220327,0.00068756624,0.0000698677],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005230662,0.000043627508,0.078303374,0.00003469217,0.0002571712,0.0000139675185,0.0054756724,0.0001613758,0.002021307,0.9034828,0.0063901306,0.003292848],"study_design_scores_gemma":[0.0051445966,0.0023783862,0.084144205,0.0006105294,0.00003238618,0.00009821578,0.003097063,0.0010575426,0.0006730584,0.4724917,0.42943507,0.0008372336],"about_ca_topic_score_codex":0.0018517269,"about_ca_topic_score_gemma":0.008616509,"teacher_disagreement_score":0.43099105,"about_ca_system_score_codex":0.0004154925,"about_ca_system_score_gemma":0.0007878601,"threshold_uncertainty_score":0.9999434},"labels":[],"label_agreement":null},{"id":"W2769848324","doi":"10.2147/ceor.s144695","title":"Do reimbursement recommendation processes used by government drug plans in Canada adhere to good governance principles?","year":2017,"lang":"en","type":"article","venue":"ClinicoEconomics and Outcomes Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Fraser Institute; Institute of Health Services and Policy Research; Oakville-Trafalgar Memorial Hospital; Canadian Institute for Health Information","funders":"","keywords":"Accountability; Transparency (behavior); Health care; Corporate governance; Public administration; Reimbursement; Agency (philosophy); Government (linguistics); Political science; Public relations; Medicine; Business; Law; Sociology; Finance; Social science","score_opus":0.19176607204055293,"score_gpt":0.42345594978000467,"score_spread":0.23168987773945174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769848324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9315864,0.00038145212,0.000010361967,0.03173288,0.0005177902,0.00061499554,0.002621455,0.0000072345224,0.032527443],"genre_scores_gemma":[0.99126273,0.003256435,0.00008109831,0.0019719682,0.00009627382,0.00011823914,0.000025054884,0.000038337213,0.0031498661],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99711233,0.00003950118,0.001171717,0.00082677015,0.00009805325,0.0007516413],"domain_scores_gemma":[0.9976932,0.0005517956,0.0005521559,0.00075267284,0.000037287937,0.0004129353],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023883202,0.00024163621,0.000663621,0.000078997415,0.00038540224,0.0005314212,0.00086374726,0.0000898812,0.00050243695],"category_scores_gemma":[0.00083102984,0.0002762173,0.000065345615,0.00007865553,0.0000911047,0.00035122133,0.0006022791,0.00048617358,0.00020982923],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056157056,0.00010052836,0.95939255,0.00007020464,0.000052031817,0.0000031760496,0.00027720383,0.000058575686,0.0000019649642,0.02167354,0.009020811,0.009293276],"study_design_scores_gemma":[0.0017329967,0.00006754927,0.37355253,0.00003593405,0.00000299883,7.513724e-7,0.00030747996,0.0018446338,0.000100076555,0.0034863073,0.6184352,0.00043353174],"about_ca_topic_score_codex":0.2891398,"about_ca_topic_score_gemma":0.74102104,"teacher_disagreement_score":0.6094144,"about_ca_system_score_codex":0.0019083434,"about_ca_system_score_gemma":0.0005231879,"threshold_uncertainty_score":0.999969},"labels":[],"label_agreement":null},{"id":"W2770180185","doi":"10.1186/s13012-017-0671-z","title":"The impact of a physician detailing and sampling program for generic atorvastatin: an interrupted time series analysis","year":2017,"lang":"en","type":"article","venue":"Implementation Science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; University of Alberta; University of British Columbia","funders":"Institute of Health Services and Policy Research; National Institute of Diabetes and Digestive and Kidney Diseases; Canadian Institutes of Health Research; Michael Smith Health Research BC","keywords":"Atorvastatin; Medicine; Statin; Medical prescription; Family medicine; Internal medicine; Pharmacology","score_opus":0.20557690782907959,"score_gpt":0.5039357824066903,"score_spread":0.2983588745776108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770180185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99587667,0.00004485979,0.0028743593,0.0002622558,0.000041493964,0.00028623553,0.0002304763,0.000008508275,0.00037512142],"genre_scores_gemma":[0.9959807,0.000031777185,0.0038202533,0.00006317751,0.0000314448,0.000042469223,0.000012177805,0.000005283783,0.000012736977],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991434,0.000005838408,0.0003548153,0.00023283494,0.000026593572,0.000236501],"domain_scores_gemma":[0.9990296,0.000053392618,0.00050148094,0.00027213214,0.00006049914,0.00008293254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000911299,0.000071919865,0.00017847682,0.00013700228,0.00077485247,0.0005632257,0.00033860753,0.000011032363,0.000030814852],"category_scores_gemma":[0.00009245162,0.00006146622,0.000090793415,0.00021552744,0.00033079385,0.0007927418,0.00007331568,0.000026792897,0.0000043005502],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000100274454,0.000121515615,0.35815665,0.000024972944,0.00063698244,1.7637124e-7,0.0031267495,0.0011659047,0.009554066,0.07822146,0.000086353284,0.5488049],"study_design_scores_gemma":[0.0008338899,0.00042393757,0.69525796,0.0000032537237,0.00005583068,8.284799e-7,0.00052319304,0.27315706,0.0029798285,0.023307815,0.0031841008,0.00027231453],"about_ca_topic_score_codex":0.00032206744,"about_ca_topic_score_gemma":0.00012020302,"teacher_disagreement_score":0.54853255,"about_ca_system_score_codex":0.00005471145,"about_ca_system_score_gemma":0.000051543528,"threshold_uncertainty_score":0.5959617},"labels":[],"label_agreement":null},{"id":"W2770561817","doi":"10.21518/1561-5936-2017-10-62-65","title":"Financial results of pharmaceutical industry: I quarter of 2017","year":2017,"lang":"en","type":"article","venue":"Remedium Journal about the Russian market of medicines and medical equipment","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Business; Pharmaceutical industry; Finance; Medicine; Geography; Pharmacology","score_opus":0.05145097070951388,"score_gpt":0.3290579000827906,"score_spread":0.27760692937327675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770561817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39057368,0.015391342,0.00047782244,0.3494058,0.005011881,0.0006566244,0.00037902748,0.000012706776,0.23809111],"genre_scores_gemma":[0.98321897,0.013887441,0.000089136156,0.0014638545,0.0010286237,0.0000038910334,0.000002075243,0.000012061408,0.00029395663],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971886,0.000064945954,0.0018143351,0.00024120022,0.0002913447,0.0003995297],"domain_scores_gemma":[0.9968249,0.00026756967,0.0018302639,0.00047470143,0.00004789431,0.00055464974],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005482166,0.00019681985,0.00086636253,0.00015391462,0.00021775346,0.00003298229,0.00086375565,0.00030806847,0.0010422327],"category_scores_gemma":[0.0024531216,0.00013295707,0.00018733929,0.000064395346,0.001225332,0.00012960634,0.00023324898,0.0009203923,0.0000052083437],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052570263,0.0015805316,0.04962375,0.0016694021,0.0013128121,0.00022000525,0.0037004007,0.000009228088,0.00043481222,0.42878547,0.39117303,0.11623352],"study_design_scores_gemma":[0.019161358,0.0013199192,0.24237154,0.0025653376,0.00022765363,0.000453782,0.00031542007,0.006846222,0.0014663911,0.076956466,0.6476512,0.0006647306],"about_ca_topic_score_codex":0.00007304614,"about_ca_topic_score_gemma":0.000007938337,"teacher_disagreement_score":0.5926453,"about_ca_system_score_codex":0.000035262663,"about_ca_system_score_gemma":0.00022841839,"threshold_uncertainty_score":0.99987096},"labels":[],"label_agreement":null},{"id":"W2770849724","doi":"10.3389/fonc.2017.00273","title":"Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics","year":2017,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":286,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"","keywords":"Repurposing; Drug repositioning; Leverage (statistics); Clinical trial; Medicine; Cancer drugs; Drug development; Drug; Business; Approved drug; Alternative medicine; Government (linguistics); Pharmacology; Computer science; Engineering; Pathology","score_opus":0.10362814686053974,"score_gpt":0.3817537428207261,"score_spread":0.2781255959601864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770849724","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017192233,0.9782785,0.000039539143,0.0003293271,0.003157222,0.0008131068,0.00024470524,0.000017768056,0.0154005755],"genre_scores_gemma":[0.0008506463,0.994565,0.00080823415,0.0013896987,0.000552117,0.00030329864,0.000017502523,0.00009067983,0.0014228115],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99645793,0.00012084719,0.0015857542,0.0010115713,0.000037755464,0.00078614807],"domain_scores_gemma":[0.9975718,0.00020938259,0.0014857796,0.0005672807,0.000015377882,0.0001503263],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001438379,0.00053008826,0.003357133,0.00091624365,0.00017762274,0.00012408859,0.0006416778,0.0010339435,0.00012085543],"category_scores_gemma":[0.00015039255,0.00063809555,0.00030155657,0.00020309511,0.00034421112,0.00026746356,0.0003032978,0.001160379,0.000028127148],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029881498,0.00007009119,0.0010777945,0.0023518193,0.00011253576,0.000018271023,0.0017193576,0.0000036330703,2.1248586e-7,0.0064377887,0.001808082,0.9863705],"study_design_scores_gemma":[0.0009249436,0.000045622397,0.00015990176,0.0014481867,0.000049739247,0.000010271637,0.000073193034,0.0008311559,8.6138834e-7,0.015373728,0.9804485,0.00063390104],"about_ca_topic_score_codex":0.00029216707,"about_ca_topic_score_gemma":0.00027419557,"teacher_disagreement_score":0.9857366,"about_ca_system_score_codex":0.001860641,"about_ca_system_score_gemma":0.0006954378,"threshold_uncertainty_score":0.999607},"labels":[],"label_agreement":null},{"id":"W2772200885","doi":"","title":"The EpiPen Problem: Analyzing Unethical Drug Price Increases and the Need for Greater Government Regulation","year":2017,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Government (linguistics); Public economics; Drug; Economics; Pharmacology; Medicine","score_opus":0.047193452853052605,"score_gpt":0.28020897763526786,"score_spread":0.23301552478221527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2772200885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.42954454,0.0019276931,0.0045806,0.27125543,0.00040377676,0.0023370732,0.0002462775,0.000045693825,0.2896589],"genre_scores_gemma":[0.99342215,0.00044254112,0.00034951404,0.0015287127,0.00015098556,0.00008159365,0.0000022675397,0.000011700448,0.0040105386],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9991519,0.000019080824,0.00036252383,0.0002200511,0.000024927582,0.0002215533],"domain_scores_gemma":[0.9987628,0.0004426212,0.00031681894,0.0003914252,0.000014704388,0.00007164655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016279215,0.00009914436,0.00020983542,0.000015729698,0.00093224493,0.00054696813,0.00031677095,0.000047441543,0.00006641377],"category_scores_gemma":[0.00030817816,0.000060916333,0.00008439196,0.000020474516,0.00025132427,0.00017497742,0.00015851171,0.0001027728,0.000033532713],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012410153,0.000011426009,0.014730032,0.000010788249,0.000056891797,7.8388055e-8,0.00012509865,0.000013706842,0.0000031782818,0.9803676,0.0027387098,0.0018184059],"study_design_scores_gemma":[0.0031314292,0.000023562407,0.08030758,0.000009552557,0.000027336395,0.0000023643056,0.00005461648,0.06506559,0.00014099425,0.5324183,0.31857267,0.00024596477],"about_ca_topic_score_codex":0.0007148523,"about_ca_topic_score_gemma":0.00012497952,"teacher_disagreement_score":0.5638776,"about_ca_system_score_codex":0.000060404465,"about_ca_system_score_gemma":0.00000961807,"threshold_uncertainty_score":0.7170169},"labels":[],"label_agreement":null},{"id":"W2772655920","doi":"10.1111/epi.13974","title":"A longitudinal cohort study on the impact of the clobazam shortage on patients with epilepsy","year":2017,"lang":"en","type":"article","venue":"Epilepsia","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hotchkiss Brain Institute; University of Calgary","funders":"Canadian Institutes of Health Research; Cumming School of Medicine, University of Calgary; University of Calgary","keywords":"Clobazam; Epilepsy; Economic shortage; Medicine; Drug Resistant Epilepsy; Quality of life (healthcare); Family medicine; Cohort; Psychology; Psychiatry; Internal medicine; Nursing","score_opus":0.06361991238232872,"score_gpt":0.3136888269260263,"score_spread":0.25006891454369756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2772655920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93808466,0.0000126891555,0.0000042564257,0.00082610804,0.00025500782,0.0008695087,0.0003217144,0.000008594408,0.059617456],"genre_scores_gemma":[0.99918914,0.000012731618,0.000003385985,0.00041823921,0.000103500744,0.000050568106,0.0000037949,0.000026064738,0.00019258172],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987281,0.00003477296,0.00044715905,0.0003991894,0.000071500675,0.00031928075],"domain_scores_gemma":[0.9976151,0.00011472118,0.00061748264,0.0015258496,0.000030729178,0.00009610131],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005965694,0.0002199262,0.0004262837,0.000065836866,0.00044692768,0.00013553767,0.000911171,0.000057195957,0.0004538516],"category_scores_gemma":[0.00019427457,0.00012297207,0.0002357354,0.00007760598,0.00018909168,0.000116791365,0.00014429686,0.00030225463,0.00033138975],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010269679,0.0005554323,0.94925106,0.0000021172327,0.00020562063,0.0000010512551,0.000111325186,0.00008224419,3.754886e-7,0.047513854,0.0020498168,0.00012442542],"study_design_scores_gemma":[0.0008339885,0.0006589294,0.9943115,0.000014358659,0.000014895846,3.1646613e-7,0.000010544849,0.00029350977,0.000012835019,0.0026734942,0.0010112964,0.00016432026],"about_ca_topic_score_codex":0.0005230958,"about_ca_topic_score_gemma":0.000033684424,"teacher_disagreement_score":0.06110447,"about_ca_system_score_codex":0.00012815885,"about_ca_system_score_gemma":0.000029589224,"threshold_uncertainty_score":0.5014655},"labels":[],"label_agreement":null},{"id":"W2776969814","doi":"10.1503/cmaj.171070","title":"We need to mandate drug cost transparency on electronic medical records","year":2017,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"York University","funders":"","keywords":"Mandate; Transparency (behavior); Drug; Per capita; Medical prescription; Prescription drug; Medical record; Health care; Medicine; Business; Family medicine; Internet privacy; Computer science; Environmental health; Pharmacology; Computer security; Economic growth; Political science; Economics; Law; Internal medicine","score_opus":0.029832836080908177,"score_gpt":0.2845445318179955,"score_spread":0.2547116957370873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2776969814","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.094115384,0.00039234845,0.00024672475,0.79699767,0.0029265827,0.00022506306,0.00032907317,0.000019108578,0.10474803],"genre_scores_gemma":[0.92274016,0.0031515853,0.000022562157,0.06898491,0.0024460112,0.00001785182,0.000010003161,0.000031130665,0.002595766],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976236,0.00004710288,0.00079054467,0.0002908016,0.00028591327,0.0009619991],"domain_scores_gemma":[0.995459,0.0001152199,0.00045159284,0.00027569997,0.000059410795,0.0036390522],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0032627927,0.00016560103,0.00040660382,0.0002995237,0.00069136394,0.00037420506,0.00095453544,0.0003555449,0.018966883],"category_scores_gemma":[0.0026297998,0.00018422642,0.00015994787,0.00009490616,0.000046102177,0.00020186645,0.000029557563,0.0013852975,0.0037607143],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003866885,0.00008612364,0.065552555,0.000011396085,0.00023751239,0.00019555967,0.00060278084,0.000016554699,5.987067e-7,0.13570933,0.7065418,0.09100713],"study_design_scores_gemma":[0.001014221,0.000048496055,0.010895106,0.00004262977,0.0000052764613,0.00003120024,0.000025361614,0.001215738,0.000004624347,0.011979564,0.97451323,0.00022453793],"about_ca_topic_score_codex":0.0038286112,"about_ca_topic_score_gemma":0.058452684,"teacher_disagreement_score":0.8286248,"about_ca_system_score_codex":0.0016843121,"about_ca_system_score_gemma":0.0016107812,"threshold_uncertainty_score":0.997015},"labels":[],"label_agreement":null},{"id":"W2781278768","doi":"10.46827/ejefr.v0i0.223","title":"ETHICS AND SUSTAINABILITY: ELICITING MILLENNIAL PERSPECTIVES ON THE ETHICS WITHIN PHARMACEUTICALS","year":2017,"lang":"en","type":"article","venue":"European Journal of Economic and Financial Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Sustainability; Chemist; Pharmaceutical industry; Workforce; Business; Law; Political science; Medicine; Pharmacology","score_opus":0.3413175092739393,"score_gpt":0.4590533764949633,"score_spread":0.11773586722102403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2781278768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85980004,0.0030383049,0.00019811111,0.08685292,0.00044622738,0.00024882122,0.000059400758,0.000006176082,0.04934999],"genre_scores_gemma":[0.9899853,0.0071229762,0.000078696525,0.0015409484,0.0010427218,0.000002622437,2.9768384e-7,0.00003216884,0.00019430745],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99737006,0.00075086864,0.0009062354,0.0003964829,0.00008809113,0.00048824135],"domain_scores_gemma":[0.9960039,0.0023215148,0.0007117257,0.0004237925,0.00023624519,0.00030281008],"candidate_categories":["metaresearch","sts","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.032705445,0.00017976412,0.0004381595,0.00024810666,0.0020674078,0.00065273175,0.0007375272,0.0001275158,0.000103186096],"category_scores_gemma":[0.019162832,0.0001542812,0.0001244002,0.000044431683,0.0014143976,0.00030784754,0.00042919733,0.0040926435,0.000110951994],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021861662,0.000051429863,0.0022288994,0.000045722467,0.000048967613,0.000041329582,0.0136426315,0.00003779238,0.000011762087,0.97553176,0.0010836143,0.007057497],"study_design_scores_gemma":[0.003366561,0.0012236482,0.031724866,0.00018722957,0.000025495621,0.00011315973,0.00826548,0.0044779624,0.00018540732,0.3924197,0.5572666,0.0007438621],"about_ca_topic_score_codex":0.00007730856,"about_ca_topic_score_gemma":0.000016693075,"teacher_disagreement_score":0.583112,"about_ca_system_score_codex":0.00024811897,"about_ca_system_score_gemma":0.00041105636,"threshold_uncertainty_score":0.99923176},"labels":[],"label_agreement":null},{"id":"W2781608438","doi":"","title":"Does co-payment by consumers affect adherence to, and outcomes of, psychological treatment","year":2017,"lang":"en","type":"article","venue":"Epidemiology Open Access","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Copayment; Consumption (sociology); Public economics; Balance (ability); Payment; Economics; Affect (linguistics); Business; Actuarial science; Economic growth; Medicine; Health care; Finance; Psychology","score_opus":0.4093627957601251,"score_gpt":0.5485284429350138,"score_spread":0.13916564717488872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2781608438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9458997,0.0005373673,0.0001347824,0.018401604,0.0005569299,0.00073596707,0.00074631185,0.000010969738,0.03297635],"genre_scores_gemma":[0.99028367,0.0015287417,0.0004430261,0.006362344,0.000027962216,0.00013266664,0.000014496964,0.000011598824,0.0011954893],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99816453,0.0000852654,0.0007479493,0.00061601336,0.00001072803,0.00037550717],"domain_scores_gemma":[0.9976708,0.00071839895,0.0006922856,0.0006534899,0.000010040495,0.0002549388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013782349,0.00020063798,0.001146588,0.000070119124,0.0002265646,0.00020854255,0.0016313851,0.00013203252,0.00090628205],"category_scores_gemma":[0.0010545608,0.0001335059,0.00009732132,0.000027249838,0.00030132587,0.00042187492,0.00066044444,0.00010814632,0.00023588617],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000468174,0.00011219354,0.9348323,0.000006382496,0.00009819511,0.0000011091536,0.00003408444,0.0000018925593,0.000011303611,0.049188826,0.009471637,0.0061952616],"study_design_scores_gemma":[0.0011629561,0.00032413471,0.87751466,0.0000067344113,0.0000097592965,0.0000013659006,0.000005624615,0.00010404864,0.0002433557,0.036148883,0.08424584,0.0002326466],"about_ca_topic_score_codex":0.00309976,"about_ca_topic_score_gemma":0.00012129916,"teacher_disagreement_score":0.0747742,"about_ca_system_score_codex":0.00006146272,"about_ca_system_score_gemma":0.000011356372,"threshold_uncertainty_score":0.9923153},"labels":[],"label_agreement":null},{"id":"W2781939692","doi":"10.2139/ssrn.3095246","title":"Developing Novel Drugs","year":2017,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"","keywords":"Novelty; Drug; Drug development; Shock (circulatory); Business; Value (mathematics); Risk analysis (engineering); Economics; Microeconomics; Pharmacology; Medicine; Computer science; Psychology; Machine learning","score_opus":0.06670909538872312,"score_gpt":0.3087312871797478,"score_spread":0.2420221917910247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2781939692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5066772,0.009455847,0.1009973,0.08289049,0.0029860553,0.00031096648,0.00009455788,0.00007763421,0.29650995],"genre_scores_gemma":[0.98992777,0.0054727104,0.0004221698,0.0016124423,0.0005841177,0.0000035212659,0.0000014465721,0.000026470181,0.0019493558],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99751174,0.0000047770895,0.00044549518,0.000225263,0.000024756508,0.0017879925],"domain_scores_gemma":[0.99899447,0.00001952907,0.00051814684,0.0003293957,0.00002188674,0.00011657396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016863525,0.00013395732,0.00026472416,0.00011799383,0.0007146061,0.00034576986,0.0007105682,0.00007429341,0.000101550715],"category_scores_gemma":[0.0001294413,0.0001513546,0.00013625008,0.000034435936,0.00006539774,0.0004163818,0.00010587595,0.0010473587,0.0007434824],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00000775428,0.000018519555,0.003124045,0.0000024987683,0.00008255203,5.4698546e-7,0.0000620923,0.0000051240663,0.000013156326,0.991397,0.00013823656,0.005148436],"study_design_scores_gemma":[0.00077356136,0.000028253358,0.0027708379,0.0000060223183,0.0000039427578,0.000070671325,0.00006723411,0.00047107894,0.00004084692,0.8436976,0.15185346,0.00021650034],"about_ca_topic_score_codex":0.000115208655,"about_ca_topic_score_gemma":0.000117744086,"teacher_disagreement_score":0.48325056,"about_ca_system_score_codex":0.000944972,"about_ca_system_score_gemma":0.0006000295,"threshold_uncertainty_score":0.95562094},"labels":[],"label_agreement":null},{"id":"W2784138586","doi":"10.1161/circoutcomes.117.004425","title":"Elephant in the Room","year":2018,"lang":"en","type":"letter","venue":"Circulation Cardiovascular Quality and Outcomes","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Institute for Clinical Evaluative Sciences; Western University","funders":"","keywords":"Environmental science","score_opus":0.15397626202656695,"score_gpt":0.327548511722191,"score_spread":0.17357224969562407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2784138586","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.033799242,0.019498527,0.0017524138,0.9216353,0.0014152287,0.0010484607,0.0005758511,0.00006513978,0.020209812],"genre_scores_gemma":[0.21308877,0.0007433494,0.00004649203,0.7830657,0.0025528865,0.000064361375,0.0002063538,0.00004740332,0.00018469908],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99758184,0.00025225905,0.0010050216,0.0006363883,0.00011676918,0.00040770395],"domain_scores_gemma":[0.9984181,0.00029029927,0.00029600904,0.00091788085,0.000027163927,0.000050582254],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0035956712,0.00030015945,0.0011396005,0.0002438159,0.00013335345,0.00019599889,0.00037306285,0.0005453764,0.00012711206],"category_scores_gemma":[0.00022214615,0.00026885548,0.0010045627,0.00017990674,0.000115910334,0.00015311207,0.00006870051,0.00081110676,0.00037747878],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014775577,0.000110798435,0.34125742,0.00094058755,0.0044502094,0.00013732209,0.002552537,0.00035885442,7.9740516e-7,0.15770462,0.48743796,0.0050341147],"study_design_scores_gemma":[0.00042221945,0.000004717808,0.22878262,0.000008016436,0.000038946022,0.000008477813,0.000014088518,0.0002023075,4.185067e-7,0.03215279,0.7380616,0.00030375712],"about_ca_topic_score_codex":0.0004241675,"about_ca_topic_score_gemma":0.000017394526,"teacher_disagreement_score":0.25062367,"about_ca_system_score_codex":0.00010934994,"about_ca_system_score_gemma":0.000023662004,"threshold_uncertainty_score":0.99997634},"labels":[],"label_agreement":null},{"id":"W2784268328","doi":"10.1503/cmaj.109-5538","title":"Considering transparency and value for fairer drug prices","year":2018,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Transparency (behavior); Government (linguistics); Plan (archaeology); Point (geometry); Drug prices; Value (mathematics); Computer science; Business; Computer security; Public economics; Economics; Mathematics; Geography","score_opus":0.032346630505633966,"score_gpt":0.2659385589055039,"score_spread":0.23359192839986992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2784268328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5975518,0.003043677,0.0029805829,0.28535762,0.004076196,0.00043308322,0.0006844783,0.000037955513,0.10583459],"genre_scores_gemma":[0.9703701,0.0004007425,0.00053499744,0.026338382,0.0020152316,0.000007731723,0.0000030872764,0.000015303975,0.00031440565],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989413,0.000012822382,0.00045793795,0.00015574267,0.000056711462,0.0003755015],"domain_scores_gemma":[0.99857724,0.00013503528,0.00020393514,0.00005327579,0.000065666005,0.0009648531],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014078186,0.00007932597,0.00020668714,0.00014174866,0.00026803924,0.00012534273,0.00012832283,0.0001436235,0.0017213607],"category_scores_gemma":[0.0006643491,0.00009064655,0.00006441435,0.00006894406,0.000056947712,0.00014573931,0.000007865392,0.00025604878,0.00016617303],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014427445,0.000036728605,0.15185793,0.000041021085,0.00030496955,0.000023238143,0.0027256166,0.0000063729035,0.0000067712294,0.57004803,0.25254443,0.022390446],"study_design_scores_gemma":[0.0006258001,0.000024265015,0.00903976,0.000011640637,0.000005591022,0.000027594017,0.000049474005,0.0028531777,0.000012262879,0.035661843,0.9515569,0.00013165319],"about_ca_topic_score_codex":0.0010404729,"about_ca_topic_score_gemma":0.008006277,"teacher_disagreement_score":0.6990125,"about_ca_system_score_codex":0.00030924552,"about_ca_system_score_gemma":0.00036339526,"threshold_uncertainty_score":0.9991912},"labels":[],"label_agreement":null},{"id":"W2786242593","doi":"10.4000/lectures.24217","title":"Mathieu Noury, La nanosanté. La médecine à l’heure des nanotechnologies","year":2017,"lang":"fr","type":"article","venue":"Lectures","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Philosophy; Humanities","score_opus":0.052972131172721905,"score_gpt":0.31109076207612074,"score_spread":0.2581186309033988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2786242593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5094815,0.120822616,0.00201245,0.12166075,0.0042992663,0.0004430587,0.0011557854,0.00023983764,0.23988475],"genre_scores_gemma":[0.9583404,0.025408026,0.001384007,0.00211475,0.00057816657,0.000023644241,0.000008539753,0.00007388729,0.012068603],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99784386,0.0000543271,0.00061413005,0.00062820123,0.00004013215,0.0008193745],"domain_scores_gemma":[0.9977943,0.00031482027,0.0005826994,0.0011066891,0.00003155971,0.00016998115],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0006378884,0.00040415357,0.00070612394,0.00024236186,0.00084554375,0.0010162322,0.0012351321,0.00082596025,0.0009373308],"category_scores_gemma":[0.0011670176,0.00046599473,0.00029179623,0.0001086235,0.0015666748,0.00041525817,0.00048116755,0.00080975576,0.00096275],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000791682,0.00030777385,0.022527693,0.0003100842,0.00031410533,0.000111518624,0.0005410313,0.00037606343,0.00046137007,0.8158037,0.048419826,0.110747665],"study_design_scores_gemma":[0.0007681916,0.00007896027,0.030443793,0.00009044366,0.000025006677,0.00006579078,0.000017365675,0.00095866283,0.0025395935,0.27346274,0.6911088,0.00044063464],"about_ca_topic_score_codex":0.0005090656,"about_ca_topic_score_gemma":0.00016667072,"teacher_disagreement_score":0.642689,"about_ca_system_score_codex":0.00012722195,"about_ca_system_score_gemma":0.00006765675,"threshold_uncertainty_score":0.9999759},"labels":[],"label_agreement":null},{"id":"W2789814320","doi":"10.1161/circ.137.suppl_1.p146","title":"Abstract P146: Public Health Surveillance Reveals an Increase in Health Care Utilization for Generic versus Brand-name Warfarin Users","year":2018,"lang":"en","type":"article","venue":"Circulation","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; The Quebec Population Health Research Network; Institut National de Santé Publique du Québec; Université Laval","funders":"","keywords":"Medicine; Warfarin; Commercialization; Health care; Confidence interval; Public health; Emergency medicine; Environmental health; Family medicine; Internal medicine; Marketing; Nursing; Business","score_opus":0.24216637915183645,"score_gpt":0.37194903013301345,"score_spread":0.129782650981177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789814320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873229,0.0018504353,0.0039263605,0.003389683,0.0006260898,0.00070415833,0.0003809802,0.000050607374,0.0017487827],"genre_scores_gemma":[0.99634624,0.0003131648,0.00031659286,0.0020423206,0.00032851342,0.000036679714,0.0005769056,0.00003207374,0.0000075201337],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99816847,0.000052658925,0.0008250367,0.00045252874,0.00003183154,0.00046945192],"domain_scores_gemma":[0.9987846,0.00007102615,0.0005095351,0.0002988241,0.00006550813,0.00027047846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012725734,0.00014588928,0.00037184768,0.0002732222,0.00018553676,0.00009704573,0.00014992568,0.000096836244,0.00012593779],"category_scores_gemma":[0.0001958673,0.00019689917,0.00006869312,0.0002802395,0.00004732256,0.0004276298,0.000020427053,0.0000922608,0.00008313627],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034716158,0.00030282582,0.74635005,0.00060822093,0.000066146175,6.2248273e-7,0.004743908,0.00258992,0.00005143701,0.15797846,0.0014325657,0.08552867],"study_design_scores_gemma":[0.0022774455,0.00013443429,0.90899646,0.0000125689185,9.463197e-7,6.667409e-7,0.00008362576,0.037578464,0.0000053336403,0.0039168536,0.04672527,0.0002679187],"about_ca_topic_score_codex":0.0015264626,"about_ca_topic_score_gemma":0.0012307217,"teacher_disagreement_score":0.16264643,"about_ca_system_score_codex":0.00075494376,"about_ca_system_score_gemma":0.0001847888,"threshold_uncertainty_score":0.80293155},"labels":[],"label_agreement":null},{"id":"W2790556892","doi":"","title":"Défragmentation de discours de la chaîne d'approvisionnement en médicaments en vue d'une résilience collective aux pénuries de médicaments","year":2017,"lang":"fr","type":"article","venue":"Archipelago (University of Quebec in Montreal)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Humanities; Political science; Philosophy","score_opus":0.019912470153945715,"score_gpt":0.28296823473650945,"score_spread":0.26305576458256374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790556892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94144535,0.0007693322,0.004314367,0.02871482,0.00022979683,0.00042961008,0.00043156202,0.000012141433,0.023653008],"genre_scores_gemma":[0.97862196,0.0052983877,0.0031806177,0.00038945233,0.000081114,0.00000593987,0.000020227699,0.000023491828,0.012378784],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99792826,0.0002971496,0.00043355144,0.00052484544,0.000084369174,0.0007318074],"domain_scores_gemma":[0.998061,0.00043107502,0.0006832491,0.00048999814,0.000025716941,0.00030894033],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013356118,0.0002595428,0.0005566569,0.00035813576,0.000660601,0.00014790433,0.00095661666,0.0002640848,0.00025967896],"category_scores_gemma":[0.00021324542,0.00039979423,0.00019170374,0.0001572987,0.0010410295,0.0006559916,0.0004380336,0.00045604585,0.000056421108],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063011923,0.0018555695,0.3245899,0.0002769163,0.00050077605,0.00018781,0.19081749,0.004576878,0.00018906967,0.2291872,0.0030086045,0.24417965],"study_design_scores_gemma":[0.0030865492,0.00014800993,0.754228,0.00019881694,0.00006471849,0.000008158082,0.014698001,0.034762524,0.00009226323,0.18617658,0.0061562806,0.0003801128],"about_ca_topic_score_codex":0.5626992,"about_ca_topic_score_gemma":0.41659185,"teacher_disagreement_score":0.4296381,"about_ca_system_score_codex":0.0015349023,"about_ca_system_score_gemma":0.00054276094,"threshold_uncertainty_score":0.9998454},"labels":[],"label_agreement":null},{"id":"W2791189944","doi":"10.1002/ace.20259","title":"Learning in Global Collaborations for Impact and Innovation","year":2017,"lang":"en","type":"article","venue":"New Directions for Adult and Continuing Education","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Face (sociological concept); Adult Learning; Engineering ethics; Sociology; Knowledge management; Political science; Public relations; Adult education; Pedagogy; Engineering; Computer science; Social science","score_opus":0.03790203494020773,"score_gpt":0.3545179815282184,"score_spread":0.3166159465880107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791189944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98430246,0.00056821364,0.0018107519,0.0048784586,0.0005398173,0.00045080503,0.00013178654,0.000020428331,0.0072972844],"genre_scores_gemma":[0.996184,0.0002660855,0.0010267945,0.00019638751,0.00023845413,0.00013848105,0.00003880238,0.000008137405,0.0019028947],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99943763,0.0000034078716,0.00024474037,0.0001829525,0.000006677689,0.00012459992],"domain_scores_gemma":[0.9994881,0.000040550563,0.00021293433,0.00009421519,0.0001148188,0.000049360533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018381096,0.00007020937,0.00013554677,0.0001654748,0.00030162573,0.00026829133,0.00004741582,0.00005240652,0.000007685532],"category_scores_gemma":[0.00086536014,0.00008657984,0.000027766258,0.00014653485,0.000024915313,0.0003057537,0.000012023096,0.000049711434,0.0000022360828],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034779998,0.000055825876,0.20535412,0.00002344473,0.000018494422,1.3253405e-8,0.0006447759,0.00001906295,0.000052989144,0.39629737,0.0034475185,0.3940516],"study_design_scores_gemma":[0.0023225045,0.00016393885,0.52635854,0.00006958861,0.000020120553,0.000003490794,0.00058232516,0.014525562,0.000075185846,0.16969004,0.28584757,0.00034109573],"about_ca_topic_score_codex":0.0005296434,"about_ca_topic_score_gemma":0.0003904108,"teacher_disagreement_score":0.3937105,"about_ca_system_score_codex":0.00008551939,"about_ca_system_score_gemma":0.0000638067,"threshold_uncertainty_score":0.35306233},"labels":[],"label_agreement":null},{"id":"W2791408908","doi":"10.1136/bmj.k831","title":"Affordability and availability of off-patent drugs in the United States—the case for importing from abroad: observational study","year":2018,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences","keywords":"Orphan drug; Medical prescription; Medicine; Off-label use; Observational study; European union; Generic drug; Prescription drug; Package insert; Business; Drug; Family medicine; Pharmacology; International trade","score_opus":0.26441459102540815,"score_gpt":0.3858876853257406,"score_spread":0.12147309430033243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791408908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925587,0.000090332505,0.000035604815,0.0050745476,0.00009938363,0.0009734783,0.00066163926,0.000004840358,0.00050147745],"genre_scores_gemma":[0.9981227,0.000018206101,0.0001472539,0.0014133648,0.00013562423,0.00009705918,0.000038902275,0.000007288338,0.000019614052],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986321,0.0000548055,0.0008648212,0.00025243827,0.000021824839,0.00017403126],"domain_scores_gemma":[0.99855727,0.0006576275,0.00035366902,0.00034272054,0.000049254006,0.00003948163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033046952,0.00009067025,0.00022748337,0.000058064983,0.0001135408,0.000037859343,0.00017573831,0.00003615944,0.00013740422],"category_scores_gemma":[0.0004090374,0.00006833049,0.000053500607,0.0001646538,0.00015411699,0.00007621422,0.00007156036,0.00009577865,0.000011107747],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010796024,0.00038387062,0.97244537,0.000025040577,0.00005424861,0.0000028099403,0.008784305,0.000052576666,0.0000028517456,0.014217076,0.002211192,0.0017127102],"study_design_scores_gemma":[0.0014415055,0.00019486749,0.7941654,0.0000047376225,0.000014717858,0.00000588884,0.0031267104,0.089048706,0.000023192839,0.080180995,0.031618275,0.00017501046],"about_ca_topic_score_codex":0.0074277455,"about_ca_topic_score_gemma":0.0012704837,"teacher_disagreement_score":0.17827997,"about_ca_system_score_codex":0.00004738591,"about_ca_system_score_gemma":0.000023595194,"threshold_uncertainty_score":0.99918187},"labels":[],"label_agreement":null},{"id":"W2791772618","doi":"","title":"Price Discrimination in the United States: Why Are Pharmaceuticals Cheaper in Canada and Are Americans Seizing the Opportunities across the Border","year":2003,"lang":"en","type":"article","venue":"SMU Scholar (Southern Methodist University)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; International trade; Economics; Political science","score_opus":0.14179830239503377,"score_gpt":0.32120628993342765,"score_spread":0.17940798753839388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791772618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9764385,0.0007565366,0.0006940086,0.012930631,0.00010205702,0.00032890815,0.0007077934,0.000010011409,0.008031504],"genre_scores_gemma":[0.9838929,0.0015278071,0.00016757856,0.013855284,0.00002520881,0.000006226188,0.000019005902,0.000022695935,0.00048325333],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99823403,0.0006365067,0.0003271772,0.0003070238,0.00006191349,0.00043332658],"domain_scores_gemma":[0.99875593,0.00050473755,0.00028305769,0.00031505522,0.00003765534,0.00010356423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025780005,0.00018439892,0.00027794018,0.00018238861,0.000450263,0.00017580947,0.0004977583,0.000056941943,0.000104322964],"category_scores_gemma":[0.00035213048,0.00013557984,0.00005577436,0.0008087137,0.00022483175,0.00023657232,0.00008855084,0.0007222006,0.000010189383],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019382218,0.00032560225,0.6061109,0.00017585843,0.00025007667,0.00024138798,0.08888339,0.0036906837,0.00003422301,0.29031903,0.001293784,0.008481257],"study_design_scores_gemma":[0.00062487257,0.000007439629,0.028944641,0.000016161404,0.000016484102,0.0000043695973,0.1790364,0.0020516051,0.000011485095,0.0024385,0.7866111,0.00023694494],"about_ca_topic_score_codex":0.28589472,"about_ca_topic_score_gemma":0.34661114,"teacher_disagreement_score":0.7853173,"about_ca_system_score_codex":0.00041685737,"about_ca_system_score_gemma":0.00012446313,"threshold_uncertainty_score":0.71886057},"labels":[],"label_agreement":null},{"id":"W2792366488","doi":"10.9778/cmajo.20170132","title":"Catastrophic drug coverage: utilization insights from the Ontario Trillium Drug Program","year":2018,"lang":"en","type":"article","venue":"CMAJ Open","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Sunnybrook Hospital; University of Toronto; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre; St. Michael's Hospital","funders":"Ontario Ministry of Health and Long-Term Care; Institute for Clinical Evaluative Sciences","keywords":"Drug; Medicine; Government (linguistics); Population; Health care; Emergency medicine; Environmental health; Demography; Pharmacology; Economic growth","score_opus":0.09998687371225493,"score_gpt":0.3175620618307343,"score_spread":0.2175751881184794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792366488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8783467,0.00082838617,0.00019783768,0.004469586,0.0010294577,0.0012726141,0.0004095003,0.00004694862,0.11339896],"genre_scores_gemma":[0.9898994,0.00014257903,0.0002576037,0.0045438646,0.0006206486,0.000101788464,0.0001968104,0.00002906867,0.004208231],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99868596,0.00003019808,0.0005035901,0.00045452866,0.000029158082,0.00029655657],"domain_scores_gemma":[0.9989413,0.00007467583,0.0002526199,0.00055669324,0.00003590118,0.00013882459],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002865994,0.00017524284,0.00033317565,0.000055177847,0.0002958611,0.00056990975,0.00097381545,0.000062288775,0.0022343234],"category_scores_gemma":[0.000045236775,0.00015381238,0.00008286679,0.00017636461,0.00014070896,0.00044815495,0.0003966174,0.00022251245,0.0029683358],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003246671,0.0008254884,0.18771857,0.00002279075,0.000433334,0.000009507922,0.023079451,0.00008145987,0.000028196506,0.49584123,0.24918114,0.042454172],"study_design_scores_gemma":[0.0007682431,0.000037889382,0.05708583,0.000008641929,0.000009229114,7.0127436e-7,0.000027218615,0.00104397,0.00017563778,0.05124649,0.88938063,0.00021549768],"about_ca_topic_score_codex":0.14577919,"about_ca_topic_score_gemma":0.11734266,"teacher_disagreement_score":0.64019954,"about_ca_system_score_codex":0.00020980851,"about_ca_system_score_gemma":0.00010372685,"threshold_uncertainty_score":0.9986778},"labels":[],"label_agreement":null},{"id":"W2792379285","doi":"10.1177/0972063417747747","title":"Use of Generic Medicines","year":2018,"lang":"en","type":"article","venue":"Journal of Health Management","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Government (linguistics); Business; Quality (philosophy); Health care; Essential medicines; Access to medicines; Pharmaceutical policy; Argument (complex analysis); Health policy; Medicine; Economic growth; Public health; Nursing; Economics","score_opus":0.22408026156110017,"score_gpt":0.3633334338850559,"score_spread":0.13925317232395573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792379285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7593486,0.019576117,0.023330813,0.11784775,0.007112155,0.00082523125,0.00010785699,0.000025360949,0.071826145],"genre_scores_gemma":[0.97429144,0.005908797,0.0045613553,0.0142970085,0.0005272459,0.0000015160592,8.1552326e-7,0.000013724192,0.00039808327],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984881,0.000016289287,0.0011761318,0.0000934294,0.000034391247,0.00019163136],"domain_scores_gemma":[0.99850535,0.00002635652,0.0011616205,0.0001464536,0.00004441494,0.000115791685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010740416,0.000068356734,0.00038448378,0.00030135005,0.00004277584,0.000015873451,0.00016114429,0.000021373806,0.00027581587],"category_scores_gemma":[0.000031634456,0.00006536874,0.000083872445,0.00013673896,0.000059994418,0.00013822569,0.00004806637,0.00007548631,0.000079136975],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012268226,0.00040279713,0.023892479,0.00062954397,0.00055114605,0.000017127422,0.0008663806,0.000248024,0.000015294174,0.5424117,0.31050542,0.12033745],"study_design_scores_gemma":[0.00049256225,0.00033827973,0.024141189,0.00003824453,0.000007988013,0.000007873554,0.0000316705,0.0010211766,0.000026772192,0.013669751,0.960151,0.000073469055],"about_ca_topic_score_codex":0.000055113003,"about_ca_topic_score_gemma":0.0000041799335,"teacher_disagreement_score":0.6496456,"about_ca_system_score_codex":0.00008691079,"about_ca_system_score_gemma":0.000023879293,"threshold_uncertainty_score":0.30199903},"labels":[],"label_agreement":null},{"id":"W2792570196","doi":"10.3389/fphar.2018.00009","title":"The Turkish Medicines and Medical Devices Agency: Comparison of Its Registration Process with Australia, Canada, Saudi Arabia, and Singapore","year":2018,"lang":"en","type":"article","venue":"Frontiers in Pharmacology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Health Canada","keywords":"Agency (philosophy); Medicine; Certificate; Business; Computer science","score_opus":0.044637407938886334,"score_gpt":0.3365412927677193,"score_spread":0.291903884828833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792570196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812638,0.006541138,0.00010504854,0.008818455,0.0009919689,0.00020548329,0.000036609537,0.000005165782,0.002032287],"genre_scores_gemma":[0.99717027,0.0010157474,0.000098996024,0.0013552981,0.00020326686,0.00001540052,0.000004236903,0.000008234278,0.00012856055],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989179,0.000026365458,0.00050834735,0.00024619978,0.00004802625,0.00025316986],"domain_scores_gemma":[0.9993563,0.000083655774,0.00030650958,0.00007428482,0.000039279745,0.00013991262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046352478,0.000112324495,0.00035443326,0.00007873514,0.00010845275,0.000017526392,0.00017670992,0.00008991446,0.00010272166],"category_scores_gemma":[0.00007391165,0.00009473857,0.000011707374,0.00012628766,0.000530745,0.00008943785,0.000030075707,0.00019430168,0.0000014767918],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025867423,0.00008503738,0.85779583,0.00022154493,0.00018691264,0.000013506763,0.001727868,0.000025497382,0.000051752064,0.0056211324,0.12631184,0.007700374],"study_design_scores_gemma":[0.0056968266,0.00082452456,0.2663827,0.00013529243,0.00011973112,0.000057449546,0.0011230742,0.10882285,0.0045267027,0.0233334,0.58811206,0.0008654134],"about_ca_topic_score_codex":0.008849587,"about_ca_topic_score_gemma":0.100377664,"teacher_disagreement_score":0.59141314,"about_ca_system_score_codex":0.00005780494,"about_ca_system_score_gemma":0.00015698689,"threshold_uncertainty_score":0.9977506},"labels":[],"label_agreement":null},{"id":"W2793416798","doi":"10.1111/jwip.12091","title":"Broadening the conversation on the TRIPS agreement: Access to medicines includes addressing access to medical devices","year":2018,"lang":"en","type":"article","venue":"The Journal of World Intellectual Property","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Community Based Research; University of Ottawa","funders":"","keywords":"Intellectual property; TRIPS architecture; Access to medicines; TRIPS Agreement; Negotiation; Conversation; Business; General partnership; Developing country; International trade; Law and economics; Market access; Health care; Law; Economic growth; Political science; Economics; Finance; Sociology; Engineering","score_opus":0.2729941177595916,"score_gpt":0.38208092637995766,"score_spread":0.10908680862036607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793416798","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.31555054,0.00094506907,0.0018597522,0.6274651,0.0015474459,0.00079682015,0.000015418238,0.000016447837,0.051803373],"genre_scores_gemma":[0.8987155,0.00025074166,0.00001789174,0.09887966,0.0014830827,0.000008870135,5.4405405e-7,0.000018502395,0.0006251847],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99815756,0.00017090837,0.0009570728,0.00018683802,0.00019200053,0.0003356089],"domain_scores_gemma":[0.9971662,0.0015645304,0.0005145165,0.00031301775,0.00016302077,0.00027869086],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004107423,0.00018684397,0.00036864515,0.00033686453,0.0005261492,0.00044977537,0.0023562792,0.00004927754,0.0075789443],"category_scores_gemma":[0.004299352,0.00007470815,0.00009674604,0.00065770885,0.00028454512,0.00040224672,0.00056343444,0.00058248074,0.0006853043],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014298776,0.0001405067,0.0017978365,0.000033343444,0.0003954,0.0000041931157,0.026247859,0.0003508595,0.0001582129,0.0031273607,0.9330055,0.033309028],"study_design_scores_gemma":[0.00069114286,0.0005877476,0.0020107676,0.00039758976,0.0000493278,0.00004733023,0.0007339689,0.010744245,0.0043102265,0.003680585,0.97645086,0.0002962236],"about_ca_topic_score_codex":0.00019933365,"about_ca_topic_score_gemma":0.00048344006,"teacher_disagreement_score":0.583165,"about_ca_system_score_codex":0.00014282503,"about_ca_system_score_gemma":0.00011628157,"threshold_uncertainty_score":0.9933283},"labels":[],"label_agreement":null},{"id":"W2793482020","doi":"10.1017/s174413311700041x","title":"Expanding Canadian Medicare to include a national pharmaceutical benefit while controlling expenditures: possible lessons from Israel","year":2018,"lang":"en","type":"article","venue":"Health Economics Policy and Law","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Per capita; Distribution (mathematics); Business; Public economics; Constraint (computer-aided design); Health care; Economics; Economic growth; Medicine; Environmental health; Population","score_opus":0.121241974293171,"score_gpt":0.392363136024876,"score_spread":0.271121161731705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793482020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.41864794,0.0039783563,0.00032186878,0.27614897,0.0018064709,0.0011673559,0.014853996,0.00012092114,0.28295413],"genre_scores_gemma":[0.843951,0.0011077435,0.00038375286,0.15151224,0.002692211,0.000057419773,0.00010114457,0.00004635104,0.0001481703],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970785,0.000027031418,0.0010043145,0.00075383077,0.000041644245,0.0010947016],"domain_scores_gemma":[0.9971513,0.00023157286,0.00028505968,0.0002905641,0.00004325761,0.0019982497],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008782372,0.0003034053,0.0007018564,0.0005759226,0.0008548395,0.0002442371,0.00036882778,0.00021281905,0.0006896052],"category_scores_gemma":[0.00011623782,0.00038578475,0.00011061861,0.00014379936,0.00022998515,0.00030971208,0.0001560687,0.0003130727,0.00078521564],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004124111,0.00003041989,0.0010501842,0.000018693401,0.000071907765,0.0000010432497,0.0011793734,0.000054301545,0.000006891687,0.99321514,0.002896875,0.0014339448],"study_design_scores_gemma":[0.001371366,0.00009170461,0.0013463909,0.000031729356,0.00000533231,0.000007200338,0.00012316085,0.0068633514,0.00012962961,0.1681651,0.82143164,0.00043338476],"about_ca_topic_score_codex":0.2755784,"about_ca_topic_score_gemma":0.21743166,"teacher_disagreement_score":0.82505,"about_ca_system_score_codex":0.0012347501,"about_ca_system_score_gemma":0.00076176535,"threshold_uncertainty_score":0.9999928},"labels":[],"label_agreement":null},{"id":"W2793652288","doi":"10.1186/s40545-018-0132-3","title":"Pharmaceutical company spending on research and development and promotion in Canada, 2013-2016: a cohort analysis","year":2018,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Policy and Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University; University Health Network","funders":"Innovative Medicines Canada","keywords":"Promotion (chess); Context (archaeology); Marketing; Business; Pharmaceutical industry; Pharmacy; Advertising; Medicine; Family medicine; Political science","score_opus":0.2866072893969136,"score_gpt":0.46076754451485086,"score_spread":0.17416025511793726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793652288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94573975,0.0026946922,0.00015614429,0.034318086,0.0002175753,0.00027639943,0.00004555336,0.000005324805,0.016546482],"genre_scores_gemma":[0.9911141,0.0044409474,0.000660084,0.0031518643,0.00053457427,0.000004764254,0.0000015207619,0.000016436301,0.00007574408],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976052,0.00024228722,0.0010273837,0.0003756362,0.00016396308,0.00058552186],"domain_scores_gemma":[0.9969586,0.0017227527,0.00040232847,0.000111692556,0.00011391719,0.0006906864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052625425,0.00019697483,0.00059781526,0.0010492345,0.00022144927,0.0001543174,0.0001702803,0.000094104005,0.00021036206],"category_scores_gemma":[0.0012241097,0.00019754328,0.000043641932,0.00060911325,0.00034055815,0.00052399776,0.00014711506,0.0009346959,0.00004044935],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049025123,0.0018963289,0.5163125,0.00035613807,0.004175717,0.00037909744,0.003700642,0.00011924675,0.00058943033,0.4001236,0.007991631,0.059453182],"study_design_scores_gemma":[0.0028657124,0.0004353147,0.18231545,0.00006583527,0.00019032665,0.00038998423,0.00026420967,0.01405037,0.00087585516,0.007360653,0.79072315,0.00046312768],"about_ca_topic_score_codex":0.046787884,"about_ca_topic_score_gemma":0.016013708,"teacher_disagreement_score":0.78273153,"about_ca_system_score_codex":0.00064023555,"about_ca_system_score_gemma":0.00045988013,"threshold_uncertainty_score":0.9595596},"labels":[],"label_agreement":null},{"id":"W2794220948","doi":"10.20529/ijme.2018.022","title":"Combating corruption in the pharmaceutical arena","year":2018,"lang":"en","type":"article","venue":"Indian Journal of Medical Ethics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Sainte-Anne; Centre for Global Health Research; Carleton University; York University","funders":"","keywords":"Transparency (behavior); Incentive; Legislature; Sanctions; Language change; Intellectual property; Public relations; Business; Payment; Accountability; Health care; Pharmaceutical industry; Conflict of interest; Public economics; Accounting; Economics; Finance; Political science; Medicine; Law; Economic growth","score_opus":0.18990769590023285,"score_gpt":0.41661246137884844,"score_spread":0.2267047654786156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794220948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.59303737,0.0019253219,0.003551005,0.3756149,0.0028593638,0.00018057131,0.00003894438,0.000011686305,0.022780841],"genre_scores_gemma":[0.96634036,0.0010706132,0.00017522619,0.030970983,0.0014163405,0.0000015719355,0.0000011977228,0.000010859013,0.000012824503],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980787,0.00016432497,0.0010498456,0.00013421214,0.00026356295,0.00030932843],"domain_scores_gemma":[0.9978339,0.0011841796,0.0004572987,0.00014208161,0.000080215235,0.00030232876],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.013127489,0.00010256865,0.00030678837,0.00021861582,0.0001119569,0.00007935594,0.00075566396,0.0003872683,0.0012235715],"category_scores_gemma":[0.0050840853,0.00008254785,0.000114713825,0.00024504095,0.0004273341,0.00014559024,0.00005538661,0.0029226285,0.00029521168],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011262485,0.00043739405,0.02022171,0.00012553993,0.000104624654,0.00051397685,0.032683983,0.000022666216,0.000011539282,0.90942514,0.008091467,0.02824931],"study_design_scores_gemma":[0.00403978,0.00059031014,0.0075937207,0.0003920175,0.000019654339,0.0011626742,0.001333635,0.01566945,0.000115470946,0.20371033,0.7649326,0.0004403757],"about_ca_topic_score_codex":0.00004159685,"about_ca_topic_score_gemma":0.00007000547,"teacher_disagreement_score":0.7568411,"about_ca_system_score_codex":0.00007482155,"about_ca_system_score_gemma":0.00029668034,"threshold_uncertainty_score":0.99968946},"labels":[],"label_agreement":null},{"id":"W2795608932","doi":"","title":"The OECD publishes an interesting new report on competition in the pharmaceuticals sector","year":2014,"lang":"en","type":"article","venue":"e-Competitions Bulletin","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Competition (biology); Political science; Business; Economics; Accounting","score_opus":0.08292024654365691,"score_gpt":0.30912852209738084,"score_spread":0.22620827555372391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795608932","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15704247,0.00039544975,0.0013021021,0.1936445,0.0012901971,0.00061481516,0.00010649953,0.00012713142,0.6454768],"genre_scores_gemma":[0.9851695,0.00011341971,0.000381292,0.011682276,0.00094643707,0.00005840392,0.00006481066,0.000031448264,0.0015524317],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99812,0.00014471654,0.00079904223,0.00043656235,0.0000627871,0.000436894],"domain_scores_gemma":[0.9981396,0.0007730885,0.0002672245,0.00062123116,0.000023492777,0.0001753237],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.002370021,0.00019073933,0.00027152346,0.00016105309,0.00041153334,0.0005530463,0.0006333969,0.00007839494,0.0050534704],"category_scores_gemma":[0.0005754279,0.00015212611,0.00012071144,0.00016029901,0.00013875977,0.00013785144,0.000068007415,0.00049949833,0.004537716],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020021553,0.00015785951,0.0011769299,0.000007359895,0.000015013492,0.000008276137,0.0002441853,0.000101527694,0.000011357765,0.96063465,0.036460973,0.001161817],"study_design_scores_gemma":[0.00048867095,0.000070230846,0.0065765753,0.000018533094,0.000004269821,0.000040928713,0.00008793371,0.0017791857,0.000034502693,0.060222585,0.9304794,0.00019716099],"about_ca_topic_score_codex":0.0002295775,"about_ca_topic_score_gemma":0.00014790951,"teacher_disagreement_score":0.9004121,"about_ca_system_score_codex":0.00009274792,"about_ca_system_score_gemma":0.000029635583,"threshold_uncertainty_score":0.99623734},"labels":[],"label_agreement":null},{"id":"W2796682857","doi":"10.1161/circ.135.suppl_1.p251","title":"Abstract P251: Substitution to Generic Angiotensin II Receptor Blockers: Impact on Risk of Hospitalizations, Emergency Room Consultations and Mortality","year":2017,"lang":"en","type":"article","venue":"Circulation","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; The Quebec Population Health Research Network; Institut National de Santé Publique du Québec; Université Laval","funders":"","keywords":"Medicine; Candesartan; Losartan; Valsartan; Hazard ratio; Proportional hazards model; Internal medicine; Adverse effect; Emergency medicine; Angiotensin II; Confidence interval; Blood pressure","score_opus":0.06244090340085148,"score_gpt":0.3239219950167297,"score_spread":0.2614810916158782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2796682857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952208,0.00027215903,0.000866884,0.00076565915,0.00035536496,0.00026299062,0.0007281974,0.000015899795,0.0015120618],"genre_scores_gemma":[0.99905723,0.00037828085,0.00025667824,0.00007616929,0.00011153542,0.000010554163,0.00008049277,0.000013057699,0.000015989024],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99901825,0.000009985199,0.0005006709,0.0002805174,0.000030368401,0.00016020387],"domain_scores_gemma":[0.99880075,0.000021711909,0.0005932191,0.0003879298,0.00006834176,0.00012805116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029252833,0.00012443404,0.00023551361,0.0001553456,0.0004415588,0.000059444657,0.00011470077,0.00008433399,0.00025853896],"category_scores_gemma":[0.00039056494,0.00014251313,0.00010074375,0.00010474318,0.000044745357,0.00027113617,0.000034708217,0.00007350469,0.00010809524],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014030865,0.000095216696,0.9370455,0.000011141036,0.00010555564,2.2521526e-7,0.00029667444,0.006891501,0.00043979764,0.052975625,0.0010590695,0.0010656439],"study_design_scores_gemma":[0.0002902498,0.000028890829,0.9759057,0.000009110549,0.00001801927,3.1142454e-7,0.000005460464,0.011511962,0.00015427332,0.010192277,0.0017231818,0.00016054892],"about_ca_topic_score_codex":0.00083558855,"about_ca_topic_score_gemma":0.000033723918,"teacher_disagreement_score":0.042783346,"about_ca_system_score_codex":0.0001013735,"about_ca_system_score_gemma":0.000025261885,"threshold_uncertainty_score":0.58115166},"labels":[],"label_agreement":null},{"id":"W2796860482","doi":"10.5539/gjhs.v10n5p88","title":"Separating Prescription From Dispensation Medicines: Economic Effect Estimation in Japan","year":2018,"lang":"en","type":"article","venue":"Global Journal of Health Science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medical prescription; Medicine; Pharmacy; Separation (statistics); Variables; Regression analysis; Family medicine; Actuarial science; Business; Medical emergency; Statistics; Pharmacology; Mathematics","score_opus":0.04803466913417451,"score_gpt":0.37541665151012943,"score_spread":0.32738198237595495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2796860482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99051195,0.0005175224,0.0021882814,0.002446054,0.001351935,0.00013396036,0.00003416681,0.0000054669486,0.0028106805],"genre_scores_gemma":[0.99757385,0.00008946975,0.001027687,0.0010182628,0.00028092772,0.0000014887128,0.0000022401528,0.000003604093,0.0000024537076],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998289,0.000025135294,0.0010943406,0.00022603021,0.000059312595,0.00030620152],"domain_scores_gemma":[0.99863607,0.000042354448,0.0009768748,0.00012983748,0.00003646097,0.0001783882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031334388,0.000091787246,0.00035253557,0.0002082686,0.00014123968,0.000087765075,0.00030158777,0.00003709847,0.000086790875],"category_scores_gemma":[0.00019476278,0.00009148922,0.000045867113,0.00026909832,0.00021900218,0.00077831943,0.000036800564,0.00011644523,0.00020693353],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009950652,0.00005935584,0.89545596,0.000034632794,0.000016153044,0.0000016382794,0.00065168785,0.0028726032,0.00014465269,0.04967419,0.0015712511,0.04941835],"study_design_scores_gemma":[0.0010969898,0.00054373406,0.7401834,0.00009381018,0.0000033822564,0.00003179849,0.000043730157,0.20806491,0.0001524679,0.04801772,0.0016226214,0.00014545138],"about_ca_topic_score_codex":0.0010528676,"about_ca_topic_score_gemma":0.00014130308,"teacher_disagreement_score":0.2051923,"about_ca_system_score_codex":0.0010454389,"about_ca_system_score_gemma":0.0002636664,"threshold_uncertainty_score":0.37308222},"labels":[],"label_agreement":null},{"id":"W2797272908","doi":"10.1503/cmaj.180197","title":"New generic pricing scheme maintains high prices and risks of shortages","year":2018,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Toronto; University of British Columbia","funders":"","keywords":"Procurement; Economic shortage; Scheme (mathematics); Key (lock); Drug pricing; Computer science; Pharmacy; Business; Generic drug; Pharmaceutical Benefits Scheme; Finance; Risk analysis (engineering); Operations research; Actuarial science; Drug; Computer security; Medicine; Marketing; Pharmacology; Government (linguistics); Medical prescription; Family medicine; Engineering","score_opus":0.05394417246285982,"score_gpt":0.29600402285225097,"score_spread":0.24205985038939115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2797272908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9430972,0.0012390288,0.0015734782,0.03362736,0.0009633704,0.00008823122,0.00010367302,0.000009758107,0.019297952],"genre_scores_gemma":[0.9857727,0.0008506517,0.00157001,0.009397108,0.002108701,0.0000011132979,0.0000026819393,0.000013420597,0.00028358764],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988389,0.000016630267,0.00055047084,0.00014818754,0.000089160516,0.0003566711],"domain_scores_gemma":[0.9982152,0.0000698563,0.0003956351,0.00007467665,0.00007073678,0.0011738746],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011717159,0.000086120795,0.00026244216,0.0002256939,0.00014600168,0.00007763663,0.00017786826,0.00019482942,0.0043513826],"category_scores_gemma":[0.0006260616,0.000095634015,0.00005422231,0.00015928535,0.00005283361,0.00012996148,0.000024052368,0.0003409183,0.00014912795],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008135361,0.000026261529,0.6512805,0.000017776603,0.00030144094,0.00002630909,0.00069734216,0.0000064760266,0.00002467487,0.20507981,0.09988031,0.04265092],"study_design_scores_gemma":[0.0008325763,0.00008527399,0.21343,0.000023759352,0.000011528083,0.000044194014,0.000077914316,0.002510463,0.00006929146,0.023381742,0.7592958,0.00023746416],"about_ca_topic_score_codex":0.008541914,"about_ca_topic_score_gemma":0.008029341,"teacher_disagreement_score":0.6594155,"about_ca_system_score_codex":0.00039080228,"about_ca_system_score_gemma":0.0005856274,"threshold_uncertainty_score":0.9980603},"labels":[],"label_agreement":null},{"id":"W2799437595","doi":"10.1007/s40273-018-0664-z","title":"Highly Priced Gene Therapies: A Wake-Up Call for Early Price Regulation","year":2018,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"","keywords":"Health economics; Wake; Quality of Life Research; Public health; Health administration; Economics; Business; Actuarial science; Public economics; Medicine; Pathology; Engineering","score_opus":0.07024198141245815,"score_gpt":0.310089570329557,"score_spread":0.23984758891709884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799437595","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04688865,0.004234328,0.008048334,0.8541748,0.016853422,0.0051520765,0.014903255,0.00052562583,0.049219523],"genre_scores_gemma":[0.018235842,0.0021862742,0.0026755154,0.925758,0.027230741,0.0008156336,0.0016760622,0.00057909027,0.020842828],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99485654,0.000047795114,0.0020659596,0.0016025488,0.00005802479,0.0013691072],"domain_scores_gemma":[0.99639696,0.0004032834,0.0017874568,0.00096321496,0.00013853077,0.00031057608],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.001006927,0.0008850403,0.0015055961,0.00062647666,0.0003009478,0.0004604663,0.0012178886,0.001104673,0.001762763],"category_scores_gemma":[0.000074618016,0.0011400245,0.0007478942,0.00018111856,0.00021250639,0.00057906297,0.0001979389,0.0012428818,0.004280308],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012756127,0.000052120657,0.0001808614,0.00021826576,0.00070792285,0.0000047140916,0.0004661174,0.000035949368,0.00014403532,0.007616008,0.9898655,0.00058094604],"study_design_scores_gemma":[0.0024146908,0.00011649314,0.00017448979,0.000016343578,0.00008710131,0.000008973571,0.0000028740444,0.009794153,0.0010081095,0.029682362,0.9554048,0.0012895806],"about_ca_topic_score_codex":0.00016478638,"about_ca_topic_score_gemma":0.0000064254928,"teacher_disagreement_score":0.07158323,"about_ca_system_score_codex":0.0008781714,"about_ca_system_score_gemma":0.00016857994,"threshold_uncertainty_score":0.99914974},"labels":[],"label_agreement":null},{"id":"W2800515685","doi":"10.1016/j.yrtph.2018.05.002","title":"Canadian, European and United States new drug approval times now relatively similar","year":2018,"lang":"en","type":"article","venue":"Regulatory Toxicology and Pharmacology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Fraser Institute; Canadian Institute for Health Information","funders":"","keywords":"Food and drug administration; Medicine; Drug approval; Quartile; Drug; Environmental health; Internal medicine; Pharmacology; Confidence interval","score_opus":0.03401939678412594,"score_gpt":0.27452350339588766,"score_spread":0.24050410661176172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800515685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93494457,0.0023863094,0.000049074755,0.019135306,0.0008143684,0.0002550539,0.00018620957,0.000049933184,0.042179182],"genre_scores_gemma":[0.96619403,0.0011537486,0.00024011401,0.024814703,0.00065044756,0.000007807939,0.000037030186,0.000039507486,0.006862589],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99837923,0.00013187966,0.0004274794,0.00050048536,0.000014636777,0.00054628623],"domain_scores_gemma":[0.9988479,0.00014312795,0.00017551577,0.00014388515,0.000029872288,0.000659682],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00067282084,0.00022099353,0.00038825703,0.00042319382,0.00029626474,0.000035578647,0.00018399302,0.00017472506,0.002875081],"category_scores_gemma":[0.000026841533,0.00026009147,0.000044940687,0.0001736922,0.00060811295,0.00013971687,0.00011662794,0.00030614843,0.0006424306],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022885636,0.00013014513,0.029043272,0.00006216197,0.00060776103,0.00006441321,0.0028792743,0.00011890406,0.0010736167,0.4242275,0.5373795,0.0041845827],"study_design_scores_gemma":[0.0013289618,0.00015636743,0.024024822,0.000003331017,0.00003017255,0.000032824424,0.000026818077,0.006395887,0.00074841396,0.030952593,0.93597686,0.00032293124],"about_ca_topic_score_codex":0.0015276099,"about_ca_topic_score_gemma":0.0024186997,"teacher_disagreement_score":0.3985974,"about_ca_system_score_codex":0.000116549556,"about_ca_system_score_gemma":0.000115754614,"threshold_uncertainty_score":0.99998516},"labels":[],"label_agreement":null},{"id":"W2800955910","doi":"10.1136/bmj.k2133","title":"Trump promises to reduce drug prices but drops campaign promises","year":2018,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Data science; Computer science; Drug; Drug prices; World Wide Web; Medicine; Pharmacology; Economics; Public economics","score_opus":0.07459406788040011,"score_gpt":0.3305366650573484,"score_spread":0.2559425971769483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800955910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83279467,0.00035895174,0.00011409442,0.013561677,0.0007865755,0.000933452,0.0002082931,0.00008437738,0.15115792],"genre_scores_gemma":[0.98445076,0.00007841742,0.0017294314,0.0049935896,0.0019167454,0.00019484977,0.0000072882003,0.000046792877,0.006582104],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981181,0.000015697195,0.0007274641,0.00057307474,0.00003626188,0.0005294153],"domain_scores_gemma":[0.9987824,0.00006130835,0.00028849876,0.0004793558,0.000045467754,0.0003429526],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00063595286,0.00021749012,0.00042439316,0.00020972798,0.00016893678,0.00015390955,0.0004477977,0.00008396353,0.0013933213],"category_scores_gemma":[0.00027317932,0.00023880786,0.00011886877,0.00024525364,0.00012105399,0.0002444632,0.00014772946,0.00013403757,0.0070321783],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008240271,0.0007218691,0.024277668,0.00028365033,0.00034906098,0.000019761565,0.0070561613,0.00004762442,0.0014279473,0.41840684,0.53234076,0.014244604],"study_design_scores_gemma":[0.0010743315,0.000204816,0.012908299,0.000043954675,0.000011158573,0.00001211698,0.0001263683,0.0014590856,0.008967978,0.028346585,0.9461439,0.000701366],"about_ca_topic_score_codex":0.00030868757,"about_ca_topic_score_gemma":0.000054026797,"teacher_disagreement_score":0.41380316,"about_ca_system_score_codex":0.000109187626,"about_ca_system_score_gemma":0.00007158003,"threshold_uncertainty_score":0.9995195},"labels":[],"label_agreement":null},{"id":"W2801602939","doi":"10.1108/ijhg-12-2017-0062","title":"Policy to encourage the development of antimicrobials","year":2018,"lang":"en","type":"article","venue":"International Journal of Health Governance","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Incentive; Business; Intellectual property; Legislature; Antimicrobial stewardship; Public economics; Revenue; Procurement; Pharmaceutical industry; Economics; Antibiotic resistance; Political science; Marketing; Finance; Medicine; Market economy; Pharmacology","score_opus":0.07046330379538379,"score_gpt":0.3692006646353467,"score_spread":0.2987373608399629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801602939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.709481,0.0018604337,0.015601529,0.24824847,0.004425234,0.00027547684,0.0004128108,0.000008127923,0.01968692],"genre_scores_gemma":[0.98051643,0.00040233726,0.0032791288,0.014740458,0.0008856125,0.0000014431644,6.8911004e-7,0.0000096620715,0.00016423021],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99820536,0.000017950237,0.0013821152,0.00011083718,0.00008476507,0.00019897654],"domain_scores_gemma":[0.9978188,0.000058295038,0.0017066996,0.00012210438,0.00019110164,0.00010298982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013849708,0.000081447506,0.00029452133,0.00013892874,0.00007095865,0.000032435186,0.000714762,0.000026599262,0.00017410956],"category_scores_gemma":[0.0003049679,0.000069953356,0.00008665021,0.00013194243,0.00006392319,0.0001337445,0.00009086962,0.00011618951,0.00018568535],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031235733,0.00041728397,0.015156382,0.00006130533,0.00053950376,0.0000067165793,0.0106192455,0.00027715735,0.0011051064,0.7606173,0.081851296,0.1290363],"study_design_scores_gemma":[0.0006119475,0.00013472761,0.06153469,0.00010006409,0.0000013997825,0.000033730073,0.000030846037,0.000121166384,0.003782186,0.012830649,0.9206881,0.00013050686],"about_ca_topic_score_codex":0.00014861916,"about_ca_topic_score_gemma":0.000060782764,"teacher_disagreement_score":0.8388368,"about_ca_system_score_codex":0.00033336828,"about_ca_system_score_gemma":0.000414451,"threshold_uncertainty_score":0.28526148},"labels":[],"label_agreement":null},{"id":"W2801650451","doi":"10.1503/jpn.180051","title":"Drug coverage in Canada: gaps and opportunities","year":2018,"lang":"en","type":"editorial","venue":"Journal of Psychiatry and Neuroscience","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Public health; Health insurance; Political science; Economic growth; Public administration; Business; Medicine; Health care; Nursing; Economics; Law","score_opus":0.046545957747827646,"score_gpt":0.2725316829208049,"score_spread":0.22598572517297721,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801650451","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09413487,0.011505059,0.000012340837,0.0059356154,0.8847789,0.00007179322,0.00055360753,0.0000023202062,0.003005473],"genre_scores_gemma":[0.24370316,0.16123836,0.00016123112,0.011174801,0.5821227,0.00000432514,0.00000641034,0.00006915832,0.0015198534],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985152,0.000023725292,0.000831783,0.00028786884,0.000080254365,0.00026120292],"domain_scores_gemma":[0.9986126,0.00014592,0.00084170466,0.00012678283,0.000033938042,0.00023910073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007712506,0.00017265159,0.0005115985,0.00025584694,0.00008486517,0.00011589214,0.00031250285,0.00010665237,0.00003283977],"category_scores_gemma":[0.00020801509,0.00018058748,0.00005241952,0.00009032045,0.00016488883,0.00028328138,0.00008226398,0.0006128204,0.0000019169252],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031852338,0.000031497137,0.0064227455,0.000092859154,0.0000062836807,0.000026673291,0.00004974602,0.0000071426552,0.0000029435266,0.00789558,0.9852227,0.00020996192],"study_design_scores_gemma":[0.00044391846,0.000094058974,0.0025460022,0.00006817525,0.0000058610085,0.000028481321,0.000019678666,0.00017492057,0.0000028646311,0.0126983905,0.98372114,0.00019652517],"about_ca_topic_score_codex":0.03319693,"about_ca_topic_score_gemma":0.10895176,"teacher_disagreement_score":0.3026562,"about_ca_system_score_codex":0.00012480654,"about_ca_system_score_gemma":0.0016342378,"threshold_uncertainty_score":0.9732411},"labels":[],"label_agreement":null},{"id":"W2802367354","doi":"","title":"Usage des médicaments recommandés à la suite d'un premier infarctus aigu du myocarde au Québec chez les personnes âgées : effet de la défavorisation et du sexe","year":2016,"lang":"fr","type":"article","venue":"Corpus Université Laval (Université Laval)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Gynecology","score_opus":0.015857126735127486,"score_gpt":0.2166866123748827,"score_spread":0.20082948563975522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802367354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.896335,0.003969012,0.0008860195,0.027385455,0.0006775129,0.0003429797,0.0008227191,0.00011816578,0.06946315],"genre_scores_gemma":[0.92674506,0.045049816,0.00042356618,0.0008834331,0.00043161635,0.0000042957645,0.000040455485,0.00009811107,0.026323672],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967749,0.00062052265,0.0005367034,0.00090123917,0.00012312786,0.0010434955],"domain_scores_gemma":[0.99677,0.0013483793,0.0006200896,0.0005322887,0.00011091521,0.0006182966],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015814381,0.0006162107,0.00081870647,0.0006217789,0.001045467,0.00019771197,0.0009138832,0.00065838493,0.0009710108],"category_scores_gemma":[0.00024814976,0.00073237985,0.000529369,0.00044203573,0.0010140273,0.0011354962,0.00062547927,0.0005658724,0.0002530811],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042681603,0.00041005798,0.7471383,0.00017460897,0.0008202711,0.00019632778,0.060157493,0.00016952121,0.001808651,0.07618037,0.0041476884,0.1083699],"study_design_scores_gemma":[0.004353856,0.00024217984,0.27117473,0.00025467906,0.00030155253,0.00011325822,0.0020707985,0.0010394455,0.0026874929,0.0029130655,0.7138493,0.000999632],"about_ca_topic_score_codex":0.1504826,"about_ca_topic_score_gemma":0.03885609,"teacher_disagreement_score":0.70970166,"about_ca_system_score_codex":0.0052773794,"about_ca_system_score_gemma":0.0006770371,"threshold_uncertainty_score":0.99994224},"labels":[],"label_agreement":null},{"id":"W2803104889","doi":"10.29315/gm.v4i1.33","title":"Inovação Terapêutica, um Desafio de Farmacovigilância a Longo Prazo","year":2017,"lang":"pt","type":"article","venue":"Gazeta Médica","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovation Cluster (Canada)","funders":"","keywords":"Humanities; Philosophy; Medicine","score_opus":0.09756162896222598,"score_gpt":0.3397021914163031,"score_spread":0.2421405624540771,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803104889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49955192,0.0123207625,0.002791934,0.052360147,0.00569961,0.0014507961,0.003055512,0.0002042811,0.422565],"genre_scores_gemma":[0.9661893,0.0041789473,0.00055793824,0.011014952,0.001261111,0.000063288295,0.000032304844,0.00013724068,0.016564922],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953702,0.000064394204,0.0015095074,0.001197204,0.00009352213,0.0017651514],"domain_scores_gemma":[0.99515885,0.000117581636,0.0014157078,0.002184936,0.00006570768,0.0010572413],"candidate_categories":["metaepi_narrow","scholarly_communication","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0015501636,0.0006528391,0.0012066156,0.0004116921,0.001264689,0.0014002892,0.002218509,0.000578875,0.004075093],"category_scores_gemma":[0.0005975255,0.00084759993,0.0005765972,0.00016559711,0.0005936356,0.0007402674,0.00080767873,0.001066219,0.008605221],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042893496,0.0016590623,0.32249668,0.00069048733,0.0019005607,0.00029938258,0.0029234106,0.00011957287,0.00038453026,0.4452022,0.14169073,0.08220443],"study_design_scores_gemma":[0.0023347228,0.0001342281,0.09753133,0.0000731873,0.00010923137,0.00004077176,0.00003054823,0.022154301,0.00026657688,0.014676175,0.8615446,0.0011042913],"about_ca_topic_score_codex":0.0007393928,"about_ca_topic_score_gemma":0.0001404918,"teacher_disagreement_score":0.7198539,"about_ca_system_score_codex":0.0005082813,"about_ca_system_score_gemma":0.00036104975,"threshold_uncertainty_score":0.99963635},"labels":[],"label_agreement":null},{"id":"W2804241493","doi":"10.1136/bmj.k1039","title":"Healing an ailing pharmaceutical system: prescription for reform for United States and Canada","year":2018,"lang":"en","type":"review","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University","funders":"","keywords":"SAFER; Medical prescription; Business; Public administration; Law and economics; Political science; Medicine; Pharmacology; Computer security; Economics; Computer science","score_opus":0.21182328897110753,"score_gpt":0.40429781424051,"score_spread":0.19247452526940245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804241493","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016387599,0.98596925,0.0011211421,0.00055700954,0.0012679223,0.0027793276,0.006840975,0.000042979267,0.0012575098],"genre_scores_gemma":[0.00009688574,0.9939165,0.00091200933,0.00092348794,0.001563999,0.0006903159,0.0015559158,0.00009239727,0.0002484681],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99758506,0.000026701435,0.0012940202,0.0005708263,0.000024452796,0.00049893477],"domain_scores_gemma":[0.9985362,0.00019657161,0.00061121513,0.00029632912,0.000058431142,0.0003012091],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001207447,0.0003179927,0.0012707666,0.00024183409,0.0001935018,0.00012989517,0.00023940035,0.0002233824,0.000016929203],"category_scores_gemma":[0.000097520795,0.00032810593,0.00020089146,0.00009966789,0.00004747375,0.00013602295,0.00005698127,0.00017592887,0.000014561855],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022640532,0.00014147414,0.00004036562,0.16134602,0.0013195487,0.0000058792266,0.00024037903,0.00008239363,2.7689904e-7,0.47370583,0.07755667,0.28533477],"study_design_scores_gemma":[0.0004253937,0.00006515932,6.567212e-7,0.00084852864,0.0001250825,0.000012478426,0.000035583445,0.05534572,9.3341197e-7,0.00093299866,0.9418237,0.0003837625],"about_ca_topic_score_codex":0.10754357,"about_ca_topic_score_gemma":0.032507386,"teacher_disagreement_score":0.86426705,"about_ca_system_score_codex":0.001018985,"about_ca_system_score_gemma":0.00027360866,"threshold_uncertainty_score":0.9999171},"labels":[],"label_agreement":null},{"id":"W2804591124","doi":"10.1093/oso/9780190623784.003.0007","title":"The Demand for Pharmaceuticals in Major International Markets","year":2018,"lang":"en","type":"book","venue":"Oxford University Press eBooks","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Negotiation; China; Distribution (mathematics); Government (linguistics); Business; International market; Health care; Drug prices; Public economics; International trade; International economics; Economics; Economic growth; Political science","score_opus":0.05866647668375386,"score_gpt":0.27596711668569546,"score_spread":0.2173006400019416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804591124","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018296884,0.0004502045,0.00034544233,0.000547041,0.0009035964,0.0005934153,0.0013826044,0.000023352379,0.9955714],"genre_scores_gemma":[0.0009015611,0.0019434001,0.00013677488,0.0006055342,0.00046682285,0.0000099600775,0.000055291595,0.000040373587,0.9958403],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99864423,0.000021741776,0.00043538556,0.0004558356,0.000035258126,0.00040756608],"domain_scores_gemma":[0.99882877,0.00033422207,0.0003384062,0.0003131657,0.00004537505,0.00014008129],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00062759354,0.00023706794,0.0003897497,0.00020521352,0.00020196996,0.00011829335,0.0009013212,0.0002738821,0.00012919364],"category_scores_gemma":[0.00005114284,0.00026429284,0.0002276536,0.000013272887,0.00023342705,0.000096496755,0.00031528118,0.00032081318,0.000017059578],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000310865,0.000018595609,0.00005152059,0.00003925775,0.00020860901,0.0000066981806,0.0000564528,0.000002321919,5.307279e-7,0.8966429,0.1004,0.002262229],"study_design_scores_gemma":[0.0014533816,0.000021452011,0.00005128964,0.000024995887,0.000024951963,0.0000016760472,0.000005295853,0.0024625307,0.000017646704,0.037160575,0.95848954,0.000286661],"about_ca_topic_score_codex":0.000014068822,"about_ca_topic_score_gemma":0.000031627187,"teacher_disagreement_score":0.85948235,"about_ca_system_score_codex":0.00045402758,"about_ca_system_score_gemma":0.00008851829,"threshold_uncertainty_score":0.9999809},"labels":[],"label_agreement":null},{"id":"W2808961473","doi":"10.1016/j.jcjo.2018.04.017","title":"Randomized crossover trial comparing effectiveness and tolerability of generic and brand-name travoprost","year":2018,"lang":"en","type":"article","venue":"Canadian Journal of Ophthalmology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke","funders":"Department of Surgery; Centre Hospitalier Universitaire de Québec; Université de Sherbrooke","keywords":"Tolerability; Crossover study; Randomized controlled trial; Crossover; Travoprost; Medicine; Internal medicine; Alternative medicine; Computer science; Artificial intelligence; Surgery; Adverse effect; Placebo","score_opus":0.083037588767876,"score_gpt":0.31237278597445817,"score_spread":0.2293351972065822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808961473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858713,0.0021766063,0.000058009286,0.00017818253,0.00065112085,0.00023977768,0.00005113468,8.368279e-7,0.010773042],"genre_scores_gemma":[0.9995855,0.000028881275,0.00007710214,0.00006129156,0.00020416279,0.0000037323096,7.038634e-7,0.000010057741,0.000028582903],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9986971,0.000097659395,0.00077245117,0.0001748379,0.000013869813,0.00024410167],"domain_scores_gemma":[0.99871117,0.00028701322,0.0004593617,0.00011137446,0.00006359559,0.0003674835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015785747,0.000111815556,0.0010625374,0.00021772842,0.00008325931,0.000043389162,0.00012829015,0.00010325179,0.00046274773],"category_scores_gemma":[0.00036345373,0.000113889815,0.000117651194,0.000072150455,0.00086519116,0.000110998546,0.00002021755,0.00015194282,0.0000065640747],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38306904,0.00018835563,0.46766183,0.00033250745,0.0009621903,0.0005750945,0.002279071,0.000108656255,0.00015834768,0.14292027,0.00020155619,0.0015430782],"study_design_scores_gemma":[0.7118968,0.0012422694,0.1750592,0.000045283796,0.00006325202,0.009443438,0.000024681594,0.0021962828,0.00039763754,0.096927464,0.0022694345,0.00043426245],"about_ca_topic_score_codex":0.0024025065,"about_ca_topic_score_gemma":0.00008234067,"teacher_disagreement_score":0.32882777,"about_ca_system_score_codex":0.00006461292,"about_ca_system_score_gemma":0.00015078092,"threshold_uncertainty_score":0.5066763},"labels":[],"label_agreement":null},{"id":"W2809722184","doi":"10.1016/j.jval.2018.04.387","title":"Three-Part Pricing to Reward Pharmaceutical Innovation and Increase Access: Case of PCSK9 Inhibitors","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Business; Actuarial science; Accrual; Cash flow; Revenue; Public economics; Economics; Finance; Earnings","score_opus":0.185399073756288,"score_gpt":0.3928800009505027,"score_spread":0.20748092719421468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809722184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896321,0.0005795216,0.0005912225,0.0057110637,0.00038731107,0.00040147727,0.00010082981,0.000016878417,0.0025795905],"genre_scores_gemma":[0.9931201,0.00017014833,0.00075488235,0.0055338363,0.00037139573,0.000015364107,0.000003933012,0.000018871406,0.000011468589],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980835,0.000031589127,0.0011336072,0.00035736384,0.000025401461,0.0003685468],"domain_scores_gemma":[0.99908185,0.00011322328,0.00032012345,0.00020547064,0.00004307273,0.00023625793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00180991,0.00012559145,0.00038323004,0.0006218933,0.00008606642,0.00004442897,0.00013551363,0.00007172609,0.00010862752],"category_scores_gemma":[0.00034411345,0.00015108156,0.00002762527,0.0008375873,0.00009389874,0.00021414943,0.00014975722,0.00018062793,0.00007125829],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019539968,0.0002812316,0.19733053,0.00060504186,0.000043135977,0.00004350041,0.0019259168,0.0005110773,0.00008620967,0.76103127,0.0050335224,0.032913193],"study_design_scores_gemma":[0.005535748,0.0013694799,0.037531298,0.0006117854,0.000017605442,0.00036278617,0.00018497182,0.21579906,0.0038488132,0.25690734,0.47637928,0.0014518269],"about_ca_topic_score_codex":0.0111055905,"about_ca_topic_score_gemma":0.00027513405,"teacher_disagreement_score":0.50412387,"about_ca_system_score_codex":0.0001830514,"about_ca_system_score_gemma":0.00009464466,"threshold_uncertainty_score":0.9954795},"labels":[],"label_agreement":null},{"id":"W2809867426","doi":"10.1016/j.jval.2018.04.525","title":"The Cost of New Oral Anti-Diabetic Drugs in Canada and Internationally","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Canagliflozin; Sitagliptin; Metformin; Business; Market share; Public economics; International economics; Economics; Medicine; Diabetes mellitus; Type 2 diabetes; Health care; Finance; Economic growth; Endocrinology","score_opus":0.07862818365720377,"score_gpt":0.3103516778663703,"score_spread":0.23172349420916655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809867426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874701,0.0011919867,0.000013245906,0.008637389,0.00030803354,0.00013802538,0.000052852516,0.0000015866593,0.0021867908],"genre_scores_gemma":[0.9968506,0.0010945648,0.00006926178,0.0018358119,0.00005919183,0.0000029937346,0.000001376554,0.0000060331345,0.00008017451],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990966,0.000019173633,0.00051560765,0.00013261364,0.000018025883,0.00021803295],"domain_scores_gemma":[0.9995045,0.00012540314,0.00016320519,0.00010249802,0.000008342511,0.0000960557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006402378,0.00005377851,0.00019627142,0.00008606233,0.00003169728,0.000015077196,0.00013223087,0.000018756,0.000042388743],"category_scores_gemma":[0.000067953006,0.000053772907,0.000012813625,0.00011521022,0.00004873095,0.00004139989,0.0000360182,0.00009245816,0.000015077967],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014899689,0.000024674011,0.7030393,0.00004071735,0.0000113107635,5.434272e-7,0.00081290014,0.00062746234,0.000001122067,0.2801425,0.002375206,0.012909387],"study_design_scores_gemma":[0.0010665251,0.00006154318,0.7127048,0.000048542464,6.0989123e-7,0.000001362625,0.00007458362,0.091870196,0.000034709265,0.064727895,0.12926017,0.00014907912],"about_ca_topic_score_codex":0.9556698,"about_ca_topic_score_gemma":0.7797883,"teacher_disagreement_score":0.2154146,"about_ca_system_score_codex":0.0003818777,"about_ca_system_score_gemma":0.0006500172,"threshold_uncertainty_score":0.22422996},"labels":[],"label_agreement":null},{"id":"W2809869737","doi":"","title":"Navigating the Canadian drug establishment licensing system","year":2018,"lang":"en","type":"article","venue":"Journal of Developing Drugs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Computer science; Data science; Medicine; Pharmacology","score_opus":0.04110722154173923,"score_gpt":0.2897979904900463,"score_spread":0.24869076894830705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809869737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8795597,0.0014788182,0.00069998065,0.056878597,0.0038501343,0.00018327603,0.000030995438,0.000022095832,0.05729641],"genre_scores_gemma":[0.9923079,0.000055147724,0.0022256963,0.004240737,0.001086437,0.0000011397574,7.3613154e-7,0.000018456687,0.000063742016],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985425,0.000023419947,0.0008798143,0.00013885413,0.00004916061,0.00036625087],"domain_scores_gemma":[0.9986615,0.000086343476,0.0007179164,0.00016291419,0.00014738696,0.00022394228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017719815,0.000117544805,0.0003036475,0.00011988018,0.00045488536,0.0002692142,0.00037056618,0.00005343809,0.000048462345],"category_scores_gemma":[0.0001182103,0.0001009757,0.00010337126,0.00023322011,0.000088138586,0.00023965644,0.00005055051,0.0004473209,0.00027544587],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030418774,0.0000294963,0.019972611,0.00013442109,0.00038218126,0.00004042317,0.023364717,0.00012156559,0.000023395984,0.91159827,0.023420885,0.02088163],"study_design_scores_gemma":[0.00095576077,0.000055728553,0.008126363,0.00070272415,0.000023587469,0.0002512233,0.0020064623,0.0061736666,0.0010291308,0.014941422,0.965163,0.0005709675],"about_ca_topic_score_codex":0.0136751635,"about_ca_topic_score_gemma":0.00691512,"teacher_disagreement_score":0.94174206,"about_ca_system_score_codex":0.0009713081,"about_ca_system_score_gemma":0.00040315077,"threshold_uncertainty_score":0.99289286},"labels":[],"label_agreement":null},{"id":"W2809894823","doi":"10.1016/j.jval.2018.04.726","title":"Potential Impact of Changes to Basket of Comparator Countries from PMPRB7 to Pmprb12 has on Canadian Product List Prices","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Sample (material); Product (mathematics); Formulary; Comparator; Economics; Business; Database transaction; Agricultural economics; Actuarial science; Medicine; Computer science; Mathematics; Engineering","score_opus":0.1348878784726197,"score_gpt":0.34733144081204054,"score_spread":0.21244356233942083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809894823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97125894,0.00060564635,0.00003619139,0.022090867,0.00045912756,0.000500578,0.0036273005,0.0000073485726,0.0014139846],"genre_scores_gemma":[0.99404263,0.00013414264,0.00047665337,0.004841842,0.00042365328,0.000012997527,0.000016527118,0.000019132505,0.00003241539],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983874,0.000030557934,0.00069080124,0.00036942228,0.000039254894,0.00048255853],"domain_scores_gemma":[0.9987032,0.00006806029,0.00030692708,0.0003446832,0.000048598446,0.00052854087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068977143,0.00015069665,0.0005870333,0.00059438875,0.00008049932,0.000036122285,0.00025548186,0.00005321615,0.00047294406],"category_scores_gemma":[0.000112918926,0.00016594492,0.000065857326,0.00033160675,0.000087950204,0.00006342882,0.000041052503,0.000105950625,0.0003016149],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016884975,0.0010665711,0.52117,0.00090457447,0.00048892346,0.00001091664,0.025234846,0.031276096,0.00072257535,0.24518923,0.16696765,0.0052800993],"study_design_scores_gemma":[0.0012814328,0.0028058407,0.41521928,0.00023937577,0.000007360626,0.0000020514196,0.00007577945,0.011730911,0.003075072,0.0066982703,0.55820453,0.0006600847],"about_ca_topic_score_codex":0.7511462,"about_ca_topic_score_gemma":0.13189602,"teacher_disagreement_score":0.6192502,"about_ca_system_score_codex":0.00052838837,"about_ca_system_score_gemma":0.00052732375,"threshold_uncertainty_score":0.88394463},"labels":[],"label_agreement":null},{"id":"W2811394421","doi":"10.1016/j.jval.2018.04.1643","title":"The Cost of Drugs for Age-Related Macular Degeneration in Canada and Internationally","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Aflibercept; Macular degeneration; Ranibizumab; Reimbursement; Drug prices; Generic drug; Drug; Business; Medicine; International economics; Economics; Ophthalmology; Monetary economics; Pharmacology; Internal medicine; Economic growth; Bevacizumab; Health care","score_opus":0.06700896132124044,"score_gpt":0.3012974722135881,"score_spread":0.23428851089234765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2811394421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99037665,0.0011436578,0.00013157837,0.0062656663,0.00031304988,0.0003258492,0.00012316328,0.0000016291242,0.0013187323],"genre_scores_gemma":[0.99797064,0.0006587819,0.00014214838,0.0011030221,0.000040726412,0.000018921402,0.000008366997,0.0000058708333,0.000051513514],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9991838,0.000017210104,0.00051733514,0.00011658005,0.000013293411,0.00015181258],"domain_scores_gemma":[0.99957657,0.00012822042,0.00016447631,0.00007333484,0.00001294877,0.0000444776],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007508545,0.000043752763,0.00013914572,0.00007058795,0.000043528144,0.000012941753,0.00007930348,0.000021675985,0.000012383687],"category_scores_gemma":[0.000068812566,0.00004445074,0.000014343923,0.00007624232,0.000037339345,0.000033828273,0.000016156018,0.00005647818,0.000003253108],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028029614,0.000020709098,0.046297822,0.000049883587,0.000013139426,4.6675567e-7,0.00066728966,0.0033153058,0.0000094481,0.9421652,0.0007457696,0.0066869385],"study_design_scores_gemma":[0.0017446387,0.00009108162,0.06084327,0.000044846798,0.0000011578129,0.0000014269901,0.00006615606,0.65189713,0.00020685772,0.15959674,0.12533507,0.00017158478],"about_ca_topic_score_codex":0.765776,"about_ca_topic_score_gemma":0.7036595,"teacher_disagreement_score":0.78256845,"about_ca_system_score_codex":0.00039643215,"about_ca_system_score_gemma":0.00027110547,"threshold_uncertainty_score":0.30174798},"labels":[],"label_agreement":null},{"id":"W2821537775","doi":"10.22270/ijdra.v6i2.236","title":"Regulatory requirements for Drug master file in context to Canada and Australia","year":2018,"lang":"en","type":"article","venue":"International Journal of Drug Regulatory Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Health Canada","keywords":"Legislation; Context (archaeology); Terminology; Drug; Business; Quality (philosophy); Product (mathematics); Computer science; Political science; Pharmacology; Medicine; Law; Biology","score_opus":0.05655171049066777,"score_gpt":0.2988763481879289,"score_spread":0.24232463769726115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2821537775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99001896,0.00018445415,0.00004468629,0.0047029634,0.0019795727,0.00015498266,0.0007018607,0.0000033550418,0.002209183],"genre_scores_gemma":[0.994777,0.0000123362925,0.00035396148,0.001784901,0.0006641757,0.000008327753,0.000007914018,0.000017558788,0.0023738071],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985987,0.000013553864,0.00085173507,0.00021313017,0.00008981899,0.00023304374],"domain_scores_gemma":[0.99895483,0.00008471554,0.0004555639,0.00013404265,0.00015877694,0.00021208408],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00058375957,0.00013088294,0.0002934274,0.0003007966,0.000036446894,0.00006175239,0.00037520274,0.000041498806,0.0010628407],"category_scores_gemma":[0.00010871431,0.000148942,0.00008437106,0.000061819395,0.00007927412,0.00023150246,0.000074386284,0.00011609877,0.000037205937],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008616017,0.00022493472,0.1126641,0.000060875333,0.0007763158,0.000056536548,0.003913875,0.00028174446,0.00032697723,0.1393346,0.7337705,0.0077279443],"study_design_scores_gemma":[0.0036100869,0.00012828584,0.15818821,0.00018847246,0.000014648328,0.000048307655,0.0009091173,0.0008322592,0.0022841115,0.022516401,0.8107478,0.0005323257],"about_ca_topic_score_codex":0.011841508,"about_ca_topic_score_gemma":0.11450073,"teacher_disagreement_score":0.116818205,"about_ca_system_score_codex":0.000476729,"about_ca_system_score_gemma":0.00013622208,"threshold_uncertainty_score":0.99985033},"labels":[],"label_agreement":null},{"id":"W2870026317","doi":"10.4212/cjhp.v71i3.2581","title":"La valeur des études de stabilité des médicaments et de leur publication","year":2018,"lang":"fr","type":"editorial","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital","funders":"","keywords":"Philosophy; Political science","score_opus":0.05643973880521349,"score_gpt":0.3259648270227272,"score_spread":0.26952508821751375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2870026317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77489877,0.015130333,0.00023750002,0.024699548,0.15251257,0.0005413757,0.0033564016,0.000018099168,0.028605387],"genre_scores_gemma":[0.8631586,0.009427959,0.00076755014,0.0038445685,0.12056593,0.000025895808,0.00006493976,0.00016024201,0.0019843103],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996288,0.00040293738,0.0015152041,0.0004042617,0.00012747038,0.0012621129],"domain_scores_gemma":[0.994766,0.0008763472,0.0015956819,0.00043124805,0.00058221235,0.0017485401],"candidate_categories":["metaepi_narrow","scholarly_communication","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.006099337,0.0004701214,0.00075702305,0.00055004365,0.0006933445,0.0011540515,0.0017761381,0.0003783789,0.0018419008],"category_scores_gemma":[0.0035301286,0.00049071637,0.00049818703,0.00034049168,0.0018859571,0.001050108,0.00011059833,0.0019225945,0.00033518302],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00011745947,0.00034537577,0.103311494,0.00030209072,0.0010930231,0.00010304476,0.008291778,0.00021510749,0.000013737712,0.054166492,0.8228523,0.009188098],"study_design_scores_gemma":[0.0013568769,0.00033580503,0.0076674954,0.0001560534,0.0001374589,0.00008397412,0.00009464966,0.0003865744,0.000057382425,0.04808459,0.9411513,0.00048781122],"about_ca_topic_score_codex":0.04298433,"about_ca_topic_score_gemma":0.02757335,"teacher_disagreement_score":0.11829903,"about_ca_system_score_codex":0.0049463096,"about_ca_system_score_gemma":0.0075796535,"threshold_uncertainty_score":0.9998828},"labels":[],"label_agreement":null},{"id":"W2880424339","doi":"10.1002/hec.3796","title":"The effects of state‐level pharmacist regulations on generic substitution of prescription drugs","year":2018,"lang":"en","type":"article","venue":"Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute on Aging; U.S. Department of Health and Human Services; Agency for Healthcare Research and Quality; National Institutes of Health; National Heart, Lung, and Blood Institute; McGill University","keywords":"Generic drug; Medical prescription; Purchasing; Business; Prescription drug; Profit (economics); Pharmacist; Brand names; Pharmacy; Actuarial science; Difference in differences; Public economics; Substitution (logic); State (computer science); Work (physics); Law; Drug; Economics; Medicine; Pharmacology; Marketing; Microeconomics; Computer science; Econometrics; Political science","score_opus":0.11314325176040257,"score_gpt":0.33531745664970897,"score_spread":0.2221742048893064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2880424339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877897,0.0013267186,0.0005574408,0.0017229449,0.0017136645,0.0005068928,0.00047681545,0.000017694738,0.005888143],"genre_scores_gemma":[0.99249876,0.0052797967,0.00018332842,0.0014306486,0.00023163918,0.000028664934,0.000020278207,0.000022115079,0.00030475625],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982837,0.000032610318,0.0010545739,0.0002755189,0.000019462663,0.00033413182],"domain_scores_gemma":[0.9982999,0.00021216462,0.0009181888,0.00037958834,0.000048953258,0.00014121483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006880731,0.0001389437,0.00038281776,0.00015719568,0.0002460444,0.00003122315,0.00023047405,0.000057834855,0.00003316179],"category_scores_gemma":[0.00009467547,0.00014402998,0.00010755324,0.00012495776,0.0002702459,0.0001556104,0.000043169166,0.0001122577,0.00017260788],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021857183,0.0002250027,0.0038796277,0.0003911642,0.00012386638,1.5332087e-7,0.0013799114,0.00076097366,0.00018140637,0.9626568,0.005149138,0.025033388],"study_design_scores_gemma":[0.0038398216,0.0011200814,0.06288244,0.00009551237,0.00002080144,0.0000044090584,0.00004957375,0.09315697,0.016530914,0.13562965,0.6860023,0.00066749525],"about_ca_topic_score_codex":0.00023478732,"about_ca_topic_score_gemma":0.00006799743,"teacher_disagreement_score":0.82702714,"about_ca_system_score_codex":0.00025826637,"about_ca_system_score_gemma":0.00013124544,"threshold_uncertainty_score":0.58733726},"labels":[],"label_agreement":null},{"id":"W2883084383","doi":"10.1016/j.healthpol.2018.07.005","title":"An analysis of expenditures on primary care prescription drugs in the United States versus ten comparable countries","year":2018,"lang":"en","type":"article","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Commonwealth Fund","keywords":"Per capita; Medical prescription; Medicine; Primary care; Environmental health; Family medicine; Population; Nursing","score_opus":0.08342797164970099,"score_gpt":0.3844772828350063,"score_spread":0.3010493111853053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883084383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9747462,0.00082040444,0.0000220002,0.0075448817,0.00019088568,0.00028637514,0.0011268223,0.000019820543,0.015242606],"genre_scores_gemma":[0.97881216,0.0010173661,0.000034338264,0.019279214,0.0002707152,0.00002051126,0.00052974245,0.000012047229,0.000023887551],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99866,0.00008255463,0.0005868562,0.00024948255,0.00004454314,0.00037653826],"domain_scores_gemma":[0.9990019,0.0001410903,0.00031931253,0.00039449995,0.00002716456,0.000115994015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005537088,0.00012591617,0.0004478494,0.0011484047,0.0001434503,0.000052487056,0.0002971673,0.00006101978,0.00010602184],"category_scores_gemma":[0.000019755147,0.000115996445,0.00007682311,0.0005871142,0.00013846469,0.00012443074,0.00002336848,0.0001364807,0.00008218044],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073929015,0.0003590191,0.03921242,0.0002902156,0.00032989148,6.5850503e-7,0.06349739,0.007944724,0.0000021898143,0.87777835,0.008570053,0.0012758091],"study_design_scores_gemma":[0.002365712,0.0011033993,0.3405685,0.000031622552,0.000048440375,3.9530008e-7,0.0039838874,0.040970877,0.000048947615,0.0065007615,0.6040114,0.00036604053],"about_ca_topic_score_codex":0.037845466,"about_ca_topic_score_gemma":0.0016275181,"teacher_disagreement_score":0.8712776,"about_ca_system_score_codex":0.00041388802,"about_ca_system_score_gemma":0.00011172133,"threshold_uncertainty_score":0.9685616},"labels":[],"label_agreement":null},{"id":"W2883095823","doi":"","title":"Abstract 153: Impact Of The Enhance Trial On The Use Of Ezetimibe In The Us And Canada","year":2013,"lang":"en","type":"article","venue":"Circulation Cardiovascular Quality and Outcomes","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ezetimibe; Medical prescription; Medicine; Population; Clinical trial; Prescription drug; Family medicine; Demography; Environmental health; Internal medicine; Statin; Pharmacology","score_opus":0.16331413585285623,"score_gpt":0.32360883537020124,"score_spread":0.160294699517345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883095823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959302,0.00056785316,0.000020899819,0.002353139,0.00011060058,0.0004759009,0.00008963003,0.000001638505,0.00045016277],"genre_scores_gemma":[0.9985608,0.00014569398,0.0000047265808,0.0012276175,0.000029581992,0.00001670113,0.0000021530811,0.0000053777717,0.000007383385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989488,0.00012945934,0.00055220706,0.00016616793,0.000073234405,0.0001300901],"domain_scores_gemma":[0.9986326,0.0006089884,0.0002409766,0.00046234587,0.000021915246,0.000033182187],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012930145,0.0001019188,0.0004173411,0.000036842535,0.00007046115,0.000050757262,0.00014984675,0.00005234003,0.00004967986],"category_scores_gemma":[0.0003942608,0.00005817582,0.00040672426,0.00008916109,0.00009789894,0.000113901064,0.00003038046,0.00013330924,0.00000269575],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011451267,0.0000698736,0.9345292,0.00007008311,0.00084284955,4.2202214e-7,0.0006111294,0.011195275,0.000017871587,0.04944668,0.00043037155,0.0026717193],"study_design_scores_gemma":[0.001333687,0.000008839652,0.9931932,0.000005565417,0.000012566578,5.8386314e-7,0.00002319221,0.0005730427,0.000019497917,0.0027599616,0.0019925162,0.000077336714],"about_ca_topic_score_codex":0.3542158,"about_ca_topic_score_gemma":0.009755146,"teacher_disagreement_score":0.34446067,"about_ca_system_score_codex":0.00005827851,"about_ca_system_score_gemma":0.00004978475,"threshold_uncertainty_score":0.6500845},"labels":[],"label_agreement":null},{"id":"W2883423601","doi":"10.1128/jcm.01137-18","title":"A List To Cement the Rightful Place of Diagnostics in Health Care","year":2018,"lang":"en","type":"editorial","venue":"Journal of Clinical Microbiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Cement; MEDLINE; Medicine; Data science; Computer science; History; Political science; Archaeology; Law","score_opus":0.07406482268287204,"score_gpt":0.41702483786748434,"score_spread":0.3429600151846123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883423601","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.020406142,0.015141291,0.00007088714,0.016993014,0.9411674,0.000506201,0.003785289,0.0000042136708,0.0019255637],"genre_scores_gemma":[0.031929724,0.02881705,0.0010430929,0.010417725,0.9270623,0.000012747347,0.00013282134,0.00008553611,0.0004990145],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9936265,0.00024143815,0.0053091906,0.00036403013,0.00003113187,0.00042771368],"domain_scores_gemma":[0.9900886,0.00472447,0.0043174694,0.000380369,0.0002440184,0.00024506467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049891626,0.00024073214,0.0020963117,0.0003101982,0.000046782625,0.000025931786,0.0009504639,0.0007691549,0.00028131093],"category_scores_gemma":[0.006726209,0.00018925512,0.0005076622,0.00015323094,0.00028933948,0.000038023336,0.00023673518,0.0015809975,0.00017243104],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025225975,0.00017015426,0.000968542,0.000094526025,0.00013458557,0.000004056598,0.0003683103,0.000020325993,0.0000027643762,0.002207909,0.9953535,0.00042305703],"study_design_scores_gemma":[0.0013270234,0.0013929905,0.00021044641,0.00014252693,0.000014645525,0.000005094106,0.000033490338,0.0000069472017,0.000008117259,0.0015570831,0.99512744,0.0001742246],"about_ca_topic_score_codex":0.00022608908,"about_ca_topic_score_gemma":0.000399126,"teacher_disagreement_score":0.014105109,"about_ca_system_score_codex":0.00029776277,"about_ca_system_score_gemma":0.0007106317,"threshold_uncertainty_score":0.80523866},"labels":[],"label_agreement":null},{"id":"W2883710555","doi":"","title":"Prices, Competition and Regulation in Pharmaceuticals: A Cross-National Comparison","year":2000,"lang":"en","type":"article","venue":"Monographs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Competition (biology); Business; Industrial organization; Economics; Biology; Ecology","score_opus":0.08258621709521968,"score_gpt":0.35176539017023706,"score_spread":0.2691791730750174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883710555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91209584,0.002371692,0.00015410745,0.0011561177,0.000087207474,0.0001901827,0.0001419587,0.000034914614,0.08376795],"genre_scores_gemma":[0.9972828,0.0009230821,0.00035815238,0.0010924112,0.00006423521,0.000022997328,0.000042328607,0.000011375256,0.0002026363],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99892145,0.000012621396,0.0005279089,0.00028236918,0.000030500742,0.00022513936],"domain_scores_gemma":[0.9996293,0.00006167868,0.00010146956,0.000092445676,0.000014899456,0.00010016155],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00042782645,0.00010786135,0.00023263448,0.0002624254,0.000072318304,0.00010643611,0.000091615126,0.000076116856,0.0017891545],"category_scores_gemma":[0.000020383064,0.00013757407,0.00005405577,0.00025640012,0.000102304664,0.00026548584,0.000018647776,0.00014256567,0.0003500567],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000075086136,0.00023131057,0.46868348,0.000028437013,0.000030467148,9.951951e-7,0.00029124707,0.0010684945,0.000024615447,0.51369363,0.0010895791,0.014782671],"study_design_scores_gemma":[0.0012045614,0.00002496291,0.4125925,0.000009339225,0.0000026719017,0.0000030593628,0.000005382402,0.09006764,0.00007084882,0.10195512,0.39383638,0.0002275247],"about_ca_topic_score_codex":0.000058801288,"about_ca_topic_score_gemma":0.000017587257,"teacher_disagreement_score":0.41173849,"about_ca_system_score_codex":0.00004550113,"about_ca_system_score_gemma":0.000009855933,"threshold_uncertainty_score":0.99912333},"labels":[],"label_agreement":null},{"id":"W2883811532","doi":"10.1257/pol.20180489","title":"Preferred Pharmacy Networks and Drug Costs","year":2021,"lang":"en","type":"article","venue":"American Economic Journal Economic Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"","keywords":"Pharmacy; Business; Cost sharing; Subsidy; Medical prescription; Prescription drug; Health care; Medicare Part D; Drug; Marketing; Actuarial science; Family medicine; Medicine; Economics; Pharmacology; Nursing","score_opus":0.03243208827070266,"score_gpt":0.3073212594919792,"score_spread":0.27488917122127654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883811532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83192295,0.0061929715,0.00073668157,0.033013545,0.0023227155,0.00029262854,0.0006792039,0.000102560276,0.12473674],"genre_scores_gemma":[0.9667252,0.016732614,0.00029107343,0.011391125,0.0031158777,0.000022889148,0.000026201913,0.000113868606,0.0015811616],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960709,0.00009328964,0.0017426588,0.0009099455,0.000024439523,0.0011587645],"domain_scores_gemma":[0.9967852,0.00023099809,0.0013366925,0.0005735065,0.000026539277,0.001047032],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00091715023,0.0004984391,0.0012510767,0.00054568326,0.00035195192,0.00062029203,0.00056664576,0.000083338535,0.0017593646],"category_scores_gemma":[0.000105934385,0.00065255153,0.00038196458,0.0001623305,0.00051110785,0.0008259469,0.0003329075,0.0007262685,0.0022698718],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019817441,0.00022571991,0.08158827,0.00003131766,0.001403475,0.00010241709,0.0007467555,0.012323315,0.000050185667,0.70940924,0.06803238,0.12588874],"study_design_scores_gemma":[0.0036361564,0.00008592863,0.00939344,0.000024443465,0.000044076365,0.001460973,0.0002483974,0.045259066,0.00019781342,0.04900865,0.88923806,0.0014030046],"about_ca_topic_score_codex":0.0037613166,"about_ca_topic_score_gemma":0.000427376,"teacher_disagreement_score":0.8212057,"about_ca_system_score_codex":0.0023048955,"about_ca_system_score_gemma":0.0007493647,"threshold_uncertainty_score":0.9995926},"labels":[],"label_agreement":null},{"id":"W2883887224","doi":"10.1007/s40258-018-0406-6","title":"The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review","year":2018,"lang":"en","type":"review","venue":"Applied Health Economics and Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"EconLit; Drug prices; Expiration date; Generic drug; Drug pricing; Business; Drug; Health economics; Medicine; Actuarial science; Economics; MEDLINE; Public economics; Public health; Pharmacology; Political science; Law","score_opus":0.23120070494700198,"score_gpt":0.44387325458408705,"score_spread":0.21267254963708507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883887224","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000057763646,0.97585547,0.000003026497,0.011641676,0.00029915053,0.0051868604,0.0017310643,0.000026893611,0.005250084],"genre_scores_gemma":[0.000032974513,0.9797665,0.000047612426,0.018053135,0.0009156008,0.0007507704,0.00014856603,0.0001329087,0.00015195199],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99207914,0.0001447906,0.0053679734,0.0010247638,0.000044199776,0.0013391054],"domain_scores_gemma":[0.9903333,0.00052530144,0.006825819,0.0013303051,0.000042019965,0.0009432249],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0050727306,0.00087256194,0.0064706197,0.00067829114,0.00061049784,0.00020864456,0.00082242273,0.0003189587,0.000026936548],"category_scores_gemma":[0.00008842961,0.0006421265,0.0010030544,0.0005362546,0.0001966368,0.00009162794,0.00022915681,0.00080508145,0.00042189713],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000075676944,0.00006285479,0.0000012709552,0.46501085,0.00026153272,2.414582e-7,0.0003281266,0.0000017496021,2.868418e-10,0.46899748,0.018320495,0.047007833],"study_design_scores_gemma":[0.00032302306,0.00023783314,0.000009583316,0.103906795,0.00003507714,0.000018068336,0.000009423126,0.00007260879,1.1103324e-8,0.009585358,0.88535494,0.00044730006],"about_ca_topic_score_codex":0.0014619838,"about_ca_topic_score_gemma":0.00009370757,"teacher_disagreement_score":0.86703444,"about_ca_system_score_codex":0.0019911237,"about_ca_system_score_gemma":0.0025959262,"threshold_uncertainty_score":0.999603},"labels":[],"label_agreement":null},{"id":"W2883967689","doi":"10.1016/j.drudis.2018.07.006","title":"Patent term restoration for top-selling drugs in the United States","year":2018,"lang":"en","type":"article","venue":"Drug Discovery Today","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Laura and John Arnold Foundation","keywords":"Term (time); Competition (biology); Business; Patent law; Generic drug; Brand names; Drug approval; Intellectual property; Drug; Medicine; Marketing; Pharmacology; Law; Political science","score_opus":0.07311118270361142,"score_gpt":0.2924885767058551,"score_spread":0.21937739400224368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883967689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852966,0.00022344213,0.001647788,0.005989201,0.00046237418,0.00035046047,0.00032604914,0.0000150811065,0.005689001],"genre_scores_gemma":[0.9935679,0.0003507057,0.00007984928,0.004805092,0.0003805768,0.000061697705,0.00020055716,0.000017847828,0.00053576526],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99894625,0.000024565281,0.00044571699,0.00026713786,0.00002349009,0.00029281274],"domain_scores_gemma":[0.99936575,0.00015987051,0.00015864914,0.00025174842,0.000019629377,0.000044341698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077742874,0.00012086574,0.00019091622,0.00019417307,0.00012241132,0.00021530494,0.000258628,0.000046076693,0.000059942504],"category_scores_gemma":[0.000043572087,0.00010670919,0.000081286926,0.00022017804,0.00007157219,0.00035661864,0.000032227865,0.000107897016,0.00018187676],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021101878,0.00033416145,0.03697442,0.00008629853,0.00006830485,0.0000019136799,0.024588136,0.0025227393,0.00006337711,0.9071464,0.026776943,0.0012263093],"study_design_scores_gemma":[0.0016941949,0.000113574955,0.00843126,0.00003802818,0.00001190869,0.0000012971957,0.0013306992,0.07720463,0.0010928506,0.15570906,0.7538261,0.00054640026],"about_ca_topic_score_codex":0.00040381134,"about_ca_topic_score_gemma":0.00014571054,"teacher_disagreement_score":0.7514373,"about_ca_system_score_codex":0.0000858829,"about_ca_system_score_gemma":0.00001679328,"threshold_uncertainty_score":0.43514743},"labels":[],"label_agreement":null},{"id":"W2885482527","doi":"","title":"Abstract 22: Impact Of Drug Policy On Regional Trends In Ezetimibe Use","year":2014,"lang":"en","type":"article","venue":"Circulation Cardiovascular Quality and Outcomes","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ezetimibe; Formulary; Restrictiveness; Proxy (statistics); Medicine; Medical prescription; Demography; Population; Observational study; Treasury; Environmental health; Geography; Statistics; Family medicine; Mathematics; Pharmacology; Internal medicine","score_opus":0.148349463738525,"score_gpt":0.36434580763360935,"score_spread":0.21599634389508435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885482527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99042237,0.00054683577,0.0002517181,0.0012001236,0.000079787846,0.00009278085,0.00011821506,0.000016299127,0.0072718854],"genre_scores_gemma":[0.9986522,0.00017041762,0.000039783175,0.00092311506,0.00010516882,0.000005784251,0.000036362224,0.000016460723,0.00005070078],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998483,0.000083078376,0.00076597376,0.00035805395,0.00006985439,0.00024005317],"domain_scores_gemma":[0.9989017,0.00024821953,0.00024039355,0.0004630915,0.000022754206,0.00012382565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016706942,0.00017543408,0.00078845106,0.0005726216,0.00004964393,0.000053574353,0.00010910052,0.000104533756,0.000109261135],"category_scores_gemma":[0.00028907566,0.00018209871,0.0010190663,0.00025880686,0.00007679752,0.00023684693,0.000028296989,0.00014881,0.00003635512],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001443385,0.00006197994,0.7608472,0.00003087978,0.00038681875,5.0870716e-7,0.00018618377,0.012330203,0.0000049486166,0.2186585,0.00010352167,0.0073747984],"study_design_scores_gemma":[0.0010340104,0.000010702754,0.97515523,0.000008291422,0.000008811177,0.0000012819643,0.000006248737,0.001481865,0.000005648322,0.01586747,0.006217768,0.00020267392],"about_ca_topic_score_codex":0.004047383,"about_ca_topic_score_gemma":0.000021629292,"teacher_disagreement_score":0.21430802,"about_ca_system_score_codex":0.0001566512,"about_ca_system_score_gemma":0.000026692394,"threshold_uncertainty_score":0.742577},"labels":[],"label_agreement":null},{"id":"W2886822650","doi":"","title":"Stratégie biopharmaceutique québécoise poursuivre dans l'excellence en créant la richesse du Québec de demain / [ressource électronique] : [Gouvernement du Québec]","year":2009,"lang":"fr","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Excellence; Political science; Business; Humanities; Art","score_opus":0.016650226538618543,"score_gpt":0.2566329899479714,"score_spread":0.23998276340935287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886822650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.41176593,0.03665686,0.01494239,0.35178953,0.00092990516,0.0009915039,0.00057965535,0.00025305833,0.18209116],"genre_scores_gemma":[0.9237091,0.031367313,0.0011988751,0.01795947,0.0010644251,0.000073031755,0.000017157372,0.00011645872,0.024494177],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947037,0.00033570893,0.0016805289,0.0012602287,0.00010798745,0.0019118657],"domain_scores_gemma":[0.9966095,0.00076659664,0.00073502987,0.0007962198,0.00007684294,0.0010158159],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0024190275,0.0008685608,0.0011349471,0.0003477123,0.00047706356,0.00038247948,0.001249928,0.0006265535,0.0051618433],"category_scores_gemma":[0.0003417878,0.0010744513,0.00057699863,0.00039160016,0.00052277854,0.0005224195,0.0002488545,0.0011867177,0.0014464793],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043357743,0.0039416635,0.088574775,0.00038234843,0.0008542696,0.0003954374,0.012529708,0.004223863,0.0020189302,0.690433,0.1565982,0.03961419],"study_design_scores_gemma":[0.0017478892,0.00035355586,0.020196306,0.000089511435,0.00011988706,0.00013637789,0.0003551053,0.0521708,0.0032728168,0.009353876,0.9108879,0.0013159869],"about_ca_topic_score_codex":0.5152936,"about_ca_topic_score_gemma":0.31574634,"teacher_disagreement_score":0.7542897,"about_ca_system_score_codex":0.004638702,"about_ca_system_score_gemma":0.0035307873,"threshold_uncertainty_score":0.999331},"labels":[],"label_agreement":null},{"id":"W2887681591","doi":"10.3389/fphar.2018.00938","title":"Availability and Affordability of Drugs With a Conditional Approval by the European Medicines Agency; Comparison of Korea With Other Countries and the Implications","year":2018,"lang":"en","type":"article","venue":"Frontiers in Pharmacology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Agency (philosophy); Drug approval; Pharmacology; Medicine; Business; Traditional medicine; Drug","score_opus":0.022556895054590888,"score_gpt":0.2886370621784222,"score_spread":0.2660801671238313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887681591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96989137,0.002129556,0.0036052885,0.010102085,0.00015186769,0.00053364143,0.00052680174,0.000006318349,0.013053094],"genre_scores_gemma":[0.9978833,0.00017104113,0.0003740391,0.0014303016,0.00005963156,0.000033686712,0.000007098559,0.00000898048,0.000031897336],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99909776,0.000107319815,0.00041681773,0.00021188894,0.000022175996,0.00014404705],"domain_scores_gemma":[0.99926925,0.00019745032,0.00029729615,0.0001518766,0.000041991487,0.000042139676],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0010728099,0.00009632742,0.00036158136,0.00005336118,0.00008725253,0.000008546236,0.00016716581,0.000030096477,0.00009473913],"category_scores_gemma":[0.000021502952,0.00005822739,0.000020374342,0.000104299674,0.003856864,0.000056835157,0.000046315843,0.00012122985,0.0000020933626],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009831022,0.00019773812,0.88996524,0.00007883709,0.0002533871,1.3519347e-7,0.006006477,0.000017174825,0.00008039693,0.06586851,0.03496631,0.0015826735],"study_design_scores_gemma":[0.016837642,0.0008695698,0.44790587,0.000024113446,0.000229175,0.000020696238,0.001753531,0.014498939,0.0021433819,0.1732989,0.34187964,0.00053852546],"about_ca_topic_score_codex":0.000133457,"about_ca_topic_score_gemma":0.000036123787,"teacher_disagreement_score":0.44205937,"about_ca_system_score_codex":0.000024601788,"about_ca_system_score_gemma":0.000026499918,"threshold_uncertainty_score":0.99885404},"labels":[],"label_agreement":null},{"id":"W2887837505","doi":"","title":"Survol des décisions et des modifications législatives significatives en matières de brevets pharmaceutiques en 2017","year":2018,"lang":"fr","type":"article","venue":"Les Cahiers de propriété intellectuelle","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science; Humanities; Philosophy","score_opus":0.09597503590107938,"score_gpt":0.3566629990615595,"score_spread":0.26068796316048015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887837505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49615532,0.04558304,0.26754487,0.015964253,0.00095523195,0.001347883,0.0012278233,0.0002151653,0.17100643],"genre_scores_gemma":[0.8696709,0.051637694,0.034598283,0.0021936572,0.0006428457,0.00020022328,0.000038012087,0.0001429923,0.040875364],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99537575,0.0010053506,0.0012267965,0.00095129374,0.00008185255,0.0013589335],"domain_scores_gemma":[0.995565,0.002402496,0.000548621,0.0006724508,0.00025056142,0.00056087616],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.003195501,0.00060622016,0.00080860197,0.0005726192,0.0012075336,0.000411251,0.0010527398,0.00074700936,0.0033797498],"category_scores_gemma":[0.0030880603,0.0007380478,0.0003961702,0.000600589,0.0048414473,0.00071829034,0.00026443021,0.0013991856,0.0016726603],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038687864,0.0012943255,0.012738231,0.00067634525,0.0012333217,0.000018786097,0.23122936,0.00091668806,0.004659839,0.57783586,0.032473665,0.13653669],"study_design_scores_gemma":[0.0009592207,0.00038520712,0.0094027445,0.0002512475,0.00010773289,0.00007258071,0.0021426335,0.07179987,0.026703374,0.36962715,0.5173882,0.0011600185],"about_ca_topic_score_codex":0.00095529447,"about_ca_topic_score_gemma":0.00039596407,"teacher_disagreement_score":0.48491457,"about_ca_system_score_codex":0.0016183713,"about_ca_system_score_gemma":0.00036379142,"threshold_uncertainty_score":0.99950707},"labels":[],"label_agreement":null},{"id":"W2888116915","doi":"10.1161/circoutcomes.117.003891","title":"Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada","year":2017,"lang":"en","type":"article","venue":"Circulation Cardiovascular Quality and Outcomes","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université du Québec à Trois-Rivières; The Quebec Population Health Research Network","funders":"","keywords":"Angiotensin Receptor Blockers; Commercialization; Adverse effect; Receptor; Business; Pharmacology; Medicine; Internal medicine; Angiotensin-converting enzyme; Marketing","score_opus":0.10073162593953226,"score_gpt":0.31658607859373905,"score_spread":0.21585445265420677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888116915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970852,0.00035367408,0.00011444284,0.0015653347,0.00026670098,0.00019974427,0.00013024673,0.000002614249,0.00028202086],"genre_scores_gemma":[0.9995967,0.00006446843,0.000019997005,0.00024031494,0.000029631427,0.0000031564953,0.000010651244,0.00000862108,0.00002646675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989907,0.000058583337,0.0005529724,0.00019436266,0.00006961087,0.00013373044],"domain_scores_gemma":[0.9987735,0.00004383363,0.0004643795,0.000635561,0.00003356508,0.000049135524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006667187,0.000110713445,0.0005485373,0.00007146265,0.00016725872,0.0000077174245,0.00018419082,0.00007262574,0.000023195222],"category_scores_gemma":[0.00025810333,0.00009915349,0.00055270793,0.00007810944,0.000075009484,0.00011319594,0.000072905044,0.00007493118,0.0000017324097],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001050241,0.000028709637,0.98569375,0.000019977955,0.0003660022,1.2539968e-7,0.00010926803,0.0057717953,0.000010018088,0.0070052096,0.00006570066,0.0009189255],"study_design_scores_gemma":[0.0007636837,0.000005901708,0.994905,0.0000125260185,0.000019048995,1.8626467e-7,0.000007623275,0.0012232092,0.000036905625,0.0014729802,0.0014402389,0.00011268113],"about_ca_topic_score_codex":0.6770639,"about_ca_topic_score_gemma":0.30069163,"teacher_disagreement_score":0.37637225,"about_ca_system_score_codex":0.00023779501,"about_ca_system_score_gemma":0.00010442021,"threshold_uncertainty_score":0.7120689},"labels":[],"label_agreement":null},{"id":"W2888506300","doi":"10.1016/j.healthpol.2018.08.006","title":"Surviving niche busters: Main strategies employed by Canadian private insurers facing the arrival of high cost specialty drugs","year":2018,"lang":"en","type":"article","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Carleton University; Concordia University","funders":"Canadian Institutes of Health Research","keywords":"Specialty; Niche; Business; Niche market; Medicine; Family medicine; Marketing; Biology; Ecology","score_opus":0.05998470427813103,"score_gpt":0.3322116371568782,"score_spread":0.27222693287874716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888506300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8045943,0.00066586485,0.0004463394,0.14022659,0.0010999829,0.0010100038,0.0051330496,0.000051858533,0.046772014],"genre_scores_gemma":[0.97177684,0.000478817,0.00008675257,0.026360445,0.0009841177,0.000018473347,0.0000352828,0.00003971079,0.00021955764],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975601,0.00008527822,0.00093829853,0.0003707433,0.000048157508,0.0009974559],"domain_scores_gemma":[0.9982815,0.000120787925,0.00051717815,0.0004631281,0.000040251587,0.0005771977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013039093,0.00022036085,0.0005413088,0.00036334235,0.00039965485,0.00013372295,0.0004707528,0.00011752678,0.00033600783],"category_scores_gemma":[0.00019740283,0.00022103287,0.00009506211,0.00043059807,0.00035668662,0.00021488278,0.00008287948,0.000293695,0.00027595815],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032073665,0.00004812945,0.009927932,0.00012708617,0.00009340899,9.168614e-7,0.006625759,0.00008777762,0.000022443382,0.9333784,0.04568671,0.0039693345],"study_design_scores_gemma":[0.0010835994,0.00016234156,0.031448465,0.000042267373,0.0000051807283,0.000004337898,0.00062765024,0.0008930586,0.0001809138,0.05347145,0.91161174,0.00046900264],"about_ca_topic_score_codex":0.61357504,"about_ca_topic_score_gemma":0.19714049,"teacher_disagreement_score":0.87990695,"about_ca_system_score_codex":0.0007861468,"about_ca_system_score_gemma":0.0010739854,"threshold_uncertainty_score":0.90134585},"labels":[],"label_agreement":null},{"id":"W2888621937","doi":"10.1186/s12992-018-0402-5","title":"Transnational pharmacogovernance: emergent patterns in the jazz of pharmaceutical policy convergence","year":2018,"lang":"en","type":"article","venue":"Globalization and Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Brandon University; University of Toronto; York University","funders":"Canadian Institutes of Health Research; Canadian Patient Safety Institute","keywords":"Harmonization; Regulatory state; Globalization; Context (archaeology); Parallels; International trade; Corporate governance; Regulatory competition; Convergence (economics); European union; Economics; Political science; Business; Market economy; Economic growth; Finance; Biology","score_opus":0.10375770848868926,"score_gpt":0.3936725585011876,"score_spread":0.28991485001249834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888621937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5429155,0.0039534825,0.022972843,0.38916785,0.0014234787,0.0011794786,0.0025378559,0.000043488057,0.03580601],"genre_scores_gemma":[0.97458255,0.0031945645,0.000043220527,0.021950915,0.00016860916,0.00000850017,0.000020239651,0.0000059933313,0.00002540648],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989262,0.000031371277,0.0005575095,0.00019805392,0.000047027934,0.00023982699],"domain_scores_gemma":[0.9995481,0.000017008784,0.00020129936,0.0000997982,0.000027127544,0.00010666753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006481418,0.00008802636,0.00019592159,0.000104366,0.00007729623,0.000018094144,0.00015434493,0.000037150632,0.00073076226],"category_scores_gemma":[0.000019180668,0.00008535469,0.000037429763,0.00029910353,0.00009245823,0.0000933305,0.000020898244,0.00007772605,0.000023729635],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011294975,0.00006789863,0.08015957,0.000046412053,0.000008272564,1.9645641e-7,0.00061386236,0.000012730039,0.0000040349105,0.91620266,0.0018551811,0.0010178932],"study_design_scores_gemma":[0.0019245823,0.00012523735,0.4037665,0.000015452923,0.0000046165937,0.000008412333,0.00009793388,0.030083925,0.00012773063,0.04416597,0.5194458,0.00023385814],"about_ca_topic_score_codex":0.00047226695,"about_ca_topic_score_gemma":0.00013178909,"teacher_disagreement_score":0.8720367,"about_ca_system_score_codex":0.00008921965,"about_ca_system_score_gemma":0.00008673148,"threshold_uncertainty_score":0.80013347},"labels":[],"label_agreement":null},{"id":"W2889089805","doi":"10.1016/s2213-8587(18)30233-x","title":"Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study","year":2018,"lang":"en","type":"article","venue":"The Lancet Diabetes & Endocrinology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":200,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Simon Fraser University; Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec; Population Health Research Institute","funders":"Canadian Institutes of Health Research; Heart and Stroke Foundation of Canada","keywords":"Medicine; Metformin; Pharmacy; Environmental health; Audit; Diabetes mellitus; Glibenclamide; Epidemiology; Family medicine; Business; Internal medicine; Accounting; Endocrinology","score_opus":0.04565561249153537,"score_gpt":0.3240000573649068,"score_spread":0.2783444448733714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889089805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99071807,0.0011519036,0.000025905316,0.0049902173,0.0004864762,0.0013311798,0.0009994116,0.000054796645,0.00024203086],"genre_scores_gemma":[0.9972119,0.00032689958,0.00019453885,0.0012172756,0.000694541,0.00030022772,0.000007280625,0.000024616553,0.000022765322],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99645925,0.00015741316,0.0011310296,0.00080332457,0.00004257387,0.0014063969],"domain_scores_gemma":[0.99629647,0.002214541,0.0005322075,0.00069313205,0.00011701542,0.00014664374],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002958466,0.00034035605,0.001797273,0.00009165109,0.0002971315,0.000049265378,0.0004982794,0.00014201079,0.00012435307],"category_scores_gemma":[0.0015017182,0.0002586508,0.00011801735,0.00016430911,0.0025415656,0.00014512854,0.0004924671,0.00029312502,0.000026416199],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014511308,0.000136088,0.95304334,0.00029052002,0.00023477792,5.5338035e-7,0.00062094774,0.0000015139823,0.000037388574,0.045261696,0.00004418257,0.00018385271],"study_design_scores_gemma":[0.0026886642,0.0010052882,0.8742131,0.00002962061,0.000041381747,0.000001621042,0.00010442052,0.0009638983,0.00089167955,0.11846048,0.0013337869,0.00026608605],"about_ca_topic_score_codex":0.00010344302,"about_ca_topic_score_gemma":0.00015992922,"teacher_disagreement_score":0.078830294,"about_ca_system_score_codex":0.0000803325,"about_ca_system_score_gemma":0.00002262373,"threshold_uncertainty_score":0.9999866},"labels":[],"label_agreement":null},{"id":"W2889213083","doi":"10.1093/jlb/lsy019","title":"Addressing the needs of Canadians with rare diseases: an evaluation of orphan drug incentives","year":2018,"lang":"en","type":"article","venue":"Journal of Law and the Biosciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Saskatchewan","funders":"Government of Canada; Ontario Genomics; Ontario Genomics Institute; Genome Canada","keywords":"Orphan drug; Voucher; Incentive; Subsidy; Public economics; Business; Drug; Pharmaceutical industry; Order (exchange); Investment (military); Medicine; Actuarial science; Economics; Finance; Pharmacology; Political science; Accounting; Bioinformatics; Law; Market economy","score_opus":0.1253909957631091,"score_gpt":0.33721907695773534,"score_spread":0.21182808119462623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889213083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98702645,0.0019284202,0.00002411386,0.0022765326,0.00016023616,0.00007256792,0.000053187436,6.3821534e-7,0.0084578395],"genre_scores_gemma":[0.9991413,0.00014415628,0.000028213914,0.0005512517,0.000117817,7.250648e-7,2.3301881e-7,0.0000022719275,0.000014060771],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9994228,0.000053571643,0.00031344194,0.000055308767,0.00006189956,0.000092968825],"domain_scores_gemma":[0.99910337,0.00007413222,0.0005544428,0.00009015906,0.000106348525,0.000071541464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017750971,0.000047586076,0.00017770658,0.00008287751,0.00016191047,0.00005686187,0.00024915423,0.000012740935,0.000045774777],"category_scores_gemma":[0.000052251726,0.000024210263,0.000040316576,0.000145745,0.0013195343,0.0002810398,0.000019052031,0.00004700645,6.198694e-7],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018290988,0.00007739778,0.018670417,0.000017867837,0.000079065125,3.4356898e-7,0.012715463,0.000060167284,0.000079624675,0.96529925,0.00010740345,0.0027100898],"study_design_scores_gemma":[0.011880915,0.0019962757,0.13435423,0.00045690997,0.0005752602,0.00008611331,0.026466677,0.06560382,0.00618619,0.7023604,0.04928154,0.00075166626],"about_ca_topic_score_codex":0.0015971715,"about_ca_topic_score_gemma":0.0009374178,"teacher_disagreement_score":0.26293886,"about_ca_system_score_codex":0.000017687815,"about_ca_system_score_gemma":0.00010959653,"threshold_uncertainty_score":0.4861879},"labels":[],"label_agreement":null},{"id":"W2889860594","doi":"10.1177/1741134318799385","title":"Establishing healthy pharmaceutical regulations on statutory exclusivity: Lessons from the experience in the European Union, Canada, South Korea, Australia, and the United States","year":2018,"lang":"en","type":"article","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Statutory law; Legislation; European union; Business; International trade; Constructive; Law; Political science; Process (computing)","score_opus":0.1891385280060947,"score_gpt":0.35939947576919407,"score_spread":0.17026094776309936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889860594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6553069,0.006920203,0.0054075755,0.3267483,0.0048377826,0.0005054872,0.00014925573,0.0000056489184,0.000118880096],"genre_scores_gemma":[0.93424,0.0059508127,0.00007091401,0.04946756,0.010058288,0.0000217679,0.000019420706,0.0000456848,0.0001255883],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99618304,0.00096381735,0.0016076898,0.00028541722,0.00036301065,0.000597023],"domain_scores_gemma":[0.99277824,0.004310149,0.001623541,0.000581907,0.0004316181,0.0002745585],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.01032274,0.0003521798,0.0006854709,0.00022148142,0.0014458613,0.0002606239,0.0016823767,0.000063995896,0.00012470485],"category_scores_gemma":[0.0020361184,0.00013930789,0.00014848872,0.0011052841,0.001375929,0.00019453965,0.00013467361,0.0009796295,0.0000037396017],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037401067,0.00043828733,0.027777707,0.00021384287,0.0017978358,0.00020992008,0.13216339,0.035609774,0.00035571595,0.019071667,0.74960315,0.029018575],"study_design_scores_gemma":[0.0064703464,0.0003005992,0.12723677,0.00024714574,0.00031982298,0.000687076,0.011997288,0.02908934,0.000019183684,0.0070044347,0.8162357,0.00039228465],"about_ca_topic_score_codex":0.030518116,"about_ca_topic_score_gemma":0.01284225,"teacher_disagreement_score":0.2789331,"about_ca_system_score_codex":0.00021063401,"about_ca_system_score_gemma":0.00038885925,"threshold_uncertainty_score":0.99985415},"labels":[],"label_agreement":null},{"id":"W2890036184","doi":"","title":"A Comparative Study on Different Pharmaceutical Industries and Proposing a Model for the Context of Iran.","year":2018,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Context (archaeology); Pharmaceutical industry; Business; Order (exchange); Liberalization; Developing country; Marketing; Economic growth; Economics; Political science; Finance; Medicine; Geography; Law","score_opus":0.3461900757473962,"score_gpt":0.3612884879677138,"score_spread":0.015098412220317603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890036184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910081,0.00037417575,0.0010053014,0.0023408914,0.00015843823,0.0020870203,0.00021718591,0.000010500585,0.0027983896],"genre_scores_gemma":[0.99786305,0.00003296349,0.0000124206235,0.00097414287,0.00011712014,0.0008534814,0.000001137837,0.000010520755,0.00013517027],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9991137,0.000013634013,0.00036082507,0.00023060186,0.000021110909,0.00026014267],"domain_scores_gemma":[0.99935895,0.00022405223,0.00014548097,0.00014901922,0.000025956944,0.00009654271],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037527175,0.00011807459,0.000348845,0.00007031062,0.00012313516,0.00005024146,0.00014008075,0.000042493855,0.000010637515],"category_scores_gemma":[0.00007189499,0.000089802124,0.000047077545,0.00006579021,0.00025830843,0.0000619713,0.00005817379,0.00012432653,0.0000073005963],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023430847,0.0029111786,0.108310446,0.00010577848,0.0014772732,8.211788e-7,0.032832358,0.00017798216,0.00003828685,0.7150974,0.0059301807,0.13077517],"study_design_scores_gemma":[0.0082533145,0.0007481438,0.29440886,0.000013479952,0.00012922542,0.0000021951378,0.0025413656,0.6346128,0.0042110207,0.026980916,0.027470896,0.00062779617],"about_ca_topic_score_codex":0.000017519269,"about_ca_topic_score_gemma":0.000019478557,"teacher_disagreement_score":0.68811655,"about_ca_system_score_codex":0.000041149637,"about_ca_system_score_gemma":0.000008608194,"threshold_uncertainty_score":0.36620244},"labels":[],"label_agreement":null},{"id":"W2890118891","doi":"10.1200/jco.2017.35.15_suppl.6598","title":"Examining the relationship between cost of novel oncology drugs and their clinical benefit over time.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Clinical trial; Drug; Internal medicine; Oncology; Pharmacology","score_opus":0.5846933505889429,"score_gpt":0.5167507478294732,"score_spread":0.06794260275946973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890118891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95481664,0.00045830017,0.0002904517,0.014889672,0.0012979141,0.00015240502,0.00010949172,0.000003445911,0.027981708],"genre_scores_gemma":[0.9936724,0.000814049,0.0006665737,0.0026511538,0.0018867413,0.0000025608788,0.0000018049619,0.000018041732,0.00028668082],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947092,0.00017289704,0.004535975,0.00026949457,0.0000423179,0.00027012144],"domain_scores_gemma":[0.9729884,0.018875938,0.0072255023,0.0004633746,0.00010471822,0.0003420199],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.014368455,0.00015326492,0.0019658525,0.00011697517,0.00021535519,0.000052349435,0.0007718317,0.0006110217,0.00015766163],"category_scores_gemma":[0.012441451,0.00011226322,0.00045784633,0.000049535818,0.0009230126,0.0002706158,0.00029038856,0.0014000713,0.00006601993],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019794289,0.0003507152,0.88857275,0.000006739801,0.00023649,0.0000030690474,0.00015640672,0.000012098082,0.0000019102397,0.04314981,0.0013683013,0.06594374],"study_design_scores_gemma":[0.0035252543,0.0012100473,0.7863122,0.00001663973,0.000044087108,0.000012682202,0.00002861546,0.0009463282,0.0000022090749,0.025529925,0.18227121,0.00010075472],"about_ca_topic_score_codex":0.000047084715,"about_ca_topic_score_gemma":0.00002064095,"teacher_disagreement_score":0.18090291,"about_ca_system_score_codex":0.000092636365,"about_ca_system_score_gemma":0.00033262355,"threshold_uncertainty_score":0.99587715},"labels":[],"label_agreement":null},{"id":"W2890378724","doi":"10.2139/ssrn.3192558","title":"Assessing Canada's Drug Shortage Problem","year":2018,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Economic shortage; Drug; Political science; Medicine; Pharmacology; Government (linguistics); Philosophy","score_opus":0.027007804250252558,"score_gpt":0.2752467944481282,"score_spread":0.24823899019787565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890378724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7528678,0.006087763,0.004809865,0.01727447,0.0013952361,0.00021552137,0.00005172459,0.000045881763,0.21725169],"genre_scores_gemma":[0.9931301,0.0010679626,0.00014869266,0.0023515553,0.0010293406,0.000003392764,0.000003001338,0.000030103332,0.0022358384],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.997049,0.000017593748,0.0005561369,0.00025903503,0.000039903716,0.0020783308],"domain_scores_gemma":[0.999289,0.000028643823,0.00029310354,0.00017196087,0.00003858423,0.00017871414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016378926,0.00015251849,0.00027283115,0.00011789331,0.00030475733,0.0002294176,0.00034281443,0.000051483585,0.000328683],"category_scores_gemma":[0.000039964852,0.00016840652,0.00009010324,0.00014168509,0.00006332834,0.00037755017,0.000046705733,0.0011038803,0.00023912673],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008422892,0.00002950659,0.007834916,0.000004634735,0.000116060335,0.0000029845314,0.0000850821,0.000011150079,0.000018286824,0.98059946,0.0048651434,0.0064243684],"study_design_scores_gemma":[0.00042431772,0.00005514811,0.0014450916,0.0000075108746,0.0000076221754,0.00010876212,0.00022247357,0.0012291386,0.00007666824,0.6698769,0.326255,0.00029136767],"about_ca_topic_score_codex":0.05418181,"about_ca_topic_score_gemma":0.44835484,"teacher_disagreement_score":0.39417303,"about_ca_system_score_codex":0.0017594451,"about_ca_system_score_gemma":0.002518653,"threshold_uncertainty_score":0.9521165},"labels":[],"label_agreement":null},{"id":"W2890449704","doi":"10.1080/13571516.2011.584423","title":"Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century after the 1984 Waxman-Hatch Legislation","year":2011,"lang":"en","type":"article","venue":"International Journal of the Economics of Business","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Fell; Quarter (Canadian coin); Legislation; Medical prescription; Brand loyalty; Market share; Generic drug; Competition (biology); Index (typography); Price index; Economics; Business; Advertising; Marketing; Medicine; Drug; Microeconomics","score_opus":0.04733761495156,"score_gpt":0.26680568921646597,"score_spread":0.21946807426490597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890449704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98068655,0.0014638654,0.00015479591,0.011867807,0.0012415602,0.00015931667,0.000054586733,0.0000013416648,0.0043701725],"genre_scores_gemma":[0.9937262,0.0036493626,0.00006172311,0.0022555646,0.0002722326,0.0000070869282,0.000002052151,0.000010183089,0.000015587935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99868315,0.000053625652,0.00091966573,0.00013961423,0.00004597066,0.000157949],"domain_scores_gemma":[0.99886465,0.00013692891,0.00071478076,0.00016868657,0.00008006522,0.000034879984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010434304,0.00011613914,0.00025741904,0.0002138266,0.000031329637,0.00007935036,0.00070023746,0.000057582827,0.00015445185],"category_scores_gemma":[0.00005549002,0.000080036734,0.000104585066,0.00013028864,0.00012737382,0.00039616734,0.000105067214,0.0002468978,0.000012659404],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022659297,0.0013236789,0.6869956,0.00010598462,0.00057178055,0.0000344314,0.012209192,0.0066459943,0.00021245531,0.27817246,0.0011883337,0.010274116],"study_design_scores_gemma":[0.0021487137,0.000029624602,0.9052274,0.00007180622,0.000018448492,0.000114823626,0.00016669337,0.006976108,0.00014382544,0.057760365,0.027146844,0.00019534494],"about_ca_topic_score_codex":0.0001394542,"about_ca_topic_score_gemma":0.00008413916,"teacher_disagreement_score":0.22041209,"about_ca_system_score_codex":0.00010367567,"about_ca_system_score_gemma":0.0000393551,"threshold_uncertainty_score":0.32638034},"labels":[],"label_agreement":null},{"id":"W2893328979","doi":"10.1186/s13731-018-0092-5","title":"Emerging health technology firms’ strategies and their impact on economic and healthcare system actors: a qualitative study","year":2018,"lang":"en","type":"article","venue":"Journal of Innovation and Entrepreneurship","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Health care; Influencer marketing; Business; Thematic analysis; Public relations; Agency (philosophy); Health technology; Marketing; Qualitative research; Economics; Sociology; Economic growth; Political science","score_opus":0.10662757475939018,"score_gpt":0.39892363612155335,"score_spread":0.2922960613621632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893328979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98870754,0.0010480275,0.000081792154,0.009480288,0.0001960167,0.00014261571,0.000048764276,0.000012452981,0.00028248882],"genre_scores_gemma":[0.9989523,0.0002355618,0.000032001113,0.00058008096,0.00017722967,0.0000026670998,0.0000017634978,0.000011240275,0.0000071532886],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"qualitative","domain_scores_codex":[0.9985911,0.000060423354,0.00091713085,0.00021589531,0.000018542076,0.00019687372],"domain_scores_gemma":[0.99866796,0.00009213349,0.00094383094,0.00011339396,0.00007997309,0.00010271926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012760155,0.00015038715,0.00045667967,0.00070669904,0.00012429002,0.00014334563,0.00007901525,0.000061915176,0.00002012187],"category_scores_gemma":[0.000062279854,0.00012303135,0.000028518367,0.00024415707,0.000097824,0.00029540362,0.000035763198,0.00020785641,0.0000065514514],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024495219,0.00013392312,0.14082716,0.00012956641,0.0002541703,0.0000030146064,0.043851387,0.000022057997,0.00003867567,0.79834926,0.00040462855,0.015741214],"study_design_scores_gemma":[0.008025229,0.013524729,0.26220283,0.0005076647,0.000028427203,0.00042345765,0.43351752,0.0041956245,0.0004752751,0.2660254,0.00990402,0.0011698334],"about_ca_topic_score_codex":0.0001284484,"about_ca_topic_score_gemma":0.000029547882,"teacher_disagreement_score":0.53232384,"about_ca_system_score_codex":0.00015509098,"about_ca_system_score_gemma":0.00008753743,"threshold_uncertainty_score":0.5017073},"labels":[],"label_agreement":null},{"id":"W2893479309","doi":"10.1016/j.cjca.2018.07.151","title":"PUBLIC HEALTH SURVEILLANCE REVEALS AN INCREASE IN HEALTH CARE UTILIZATION FOR GENERIC VS. BRAND-NAME WARFARIN USERS","year":2018,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Cégep de Lévis","funders":"","keywords":"Medicine; Warfarin; Health care; Public health; Confidence interval; Reimbursement; Emergency medicine; Family medicine; Medical emergency; Pediatrics; Internal medicine; Nursing; Atrial fibrillation","score_opus":0.17958106890652795,"score_gpt":0.331143511998481,"score_spread":0.15156244309195308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893479309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89892006,0.021195576,0.016736029,0.048995912,0.0030560154,0.0008891234,0.0022356822,0.00001707739,0.007954528],"genre_scores_gemma":[0.9896677,0.00086141285,0.00032618886,0.008007988,0.0010317378,0.000007072357,0.000052905863,0.000024277388,0.000020719921],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978511,0.00017450756,0.0010237443,0.00025179086,0.000017883669,0.00068097276],"domain_scores_gemma":[0.99781173,0.00006111282,0.00063605834,0.00021902875,0.00014048838,0.0011315616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022824686,0.00013202279,0.00081816246,0.0006122551,0.00015313349,0.00005446993,0.00028825627,0.00011452889,0.00004664475],"category_scores_gemma":[0.0003454575,0.00015813111,0.00013466776,0.00021138266,0.00013410316,0.00019606439,0.000012067353,0.00017563159,0.00001787914],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015318648,0.000015180174,0.8397742,0.00018688123,0.00017151004,0.000013371057,0.0028583242,0.0018309384,0.0000034312027,0.08633867,0.033378877,0.03527546],"study_design_scores_gemma":[0.0011781694,0.0005897979,0.15953419,0.000011232987,0.0000015312294,0.000045228888,0.00008887075,0.0007596277,0.0000013180611,0.0046548867,0.83295316,0.0001820102],"about_ca_topic_score_codex":0.00867925,"about_ca_topic_score_gemma":0.031147378,"teacher_disagreement_score":0.79957426,"about_ca_system_score_codex":0.00090843317,"about_ca_system_score_gemma":0.0017715257,"threshold_uncertainty_score":0.99792206},"labels":[],"label_agreement":null},{"id":"W2894176568","doi":"10.1016/j.tips.2018.09.003","title":"Refining Early Antitumoral Drug Development","year":2018,"lang":"en","type":"review","venue":"Trends in Pharmacological Sciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"CRIS Cancer Foundation; Junta de Castilla y León","keywords":"Drug development; Drug; Failure rate; Medicine; Pharmacology; Intensive care medicine; Oncology; Internal medicine; Engineering; Reliability engineering","score_opus":0.3877860642907061,"score_gpt":0.44850539055289185,"score_spread":0.060719326262185735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894176568","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016792227,0.8906447,0.000002449138,0.0002001873,0.00096366636,0.00011755376,0.000078264515,0.000052859767,0.10626105],"genre_scores_gemma":[0.0024081415,0.9933873,0.00086786016,0.0006156448,0.0004239089,0.000112054055,0.00002073574,0.00002473859,0.0021396535],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996348,0.00008419155,0.001534644,0.0010744896,0.00007129294,0.00088735257],"domain_scores_gemma":[0.99874526,0.00018297776,0.00065264804,0.00016176939,0.000009979091,0.00024733332],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0022149363,0.00043927613,0.0016722671,0.00095354114,0.00027126304,0.00019996028,0.0012620027,0.00022061031,0.0043401388],"category_scores_gemma":[0.00005157223,0.00036709727,0.0003278573,0.001485534,0.00061182806,0.00024155444,0.00037511453,0.00056201563,0.0027061698],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000065961385,0.00021802461,0.00091299665,0.0003700995,0.00008900581,0.000032089596,0.00015594548,0.0000045065826,1.3794781e-7,0.02872795,0.007663996,0.96181864],"study_design_scores_gemma":[0.00023939501,0.000056167115,0.00031104314,0.00028042286,0.000025079851,0.000005347471,0.000001967586,0.00009733054,0.000001571072,0.0014665363,0.9969903,0.00052479666],"about_ca_topic_score_codex":0.00006961217,"about_ca_topic_score_gemma":0.000028438333,"teacher_disagreement_score":0.98932636,"about_ca_system_score_codex":0.00030830503,"about_ca_system_score_gemma":0.00012201295,"threshold_uncertainty_score":0.9998781},"labels":[],"label_agreement":null},{"id":"W2894335643","doi":"10.5539/gjhs.v10n10p152","title":"A Comparative Study on Medicine Pricing in Brazil, Russia, India, China and South Africa (BRICS)","year":2018,"lang":"en","type":"article","venue":"Global Journal of Health Science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Mental Health; Common Fund; Fogarty International Center; National Institutes of Health; National Research Foundation","keywords":"Transparency (behavior); China; Business; Emerging markets; Alliance; Population; Access to medicines; Control (management); Developing country; Economic growth; Economics; Medicine; Political science; Environmental health; Finance","score_opus":0.10372548278398984,"score_gpt":0.3984082257123087,"score_spread":0.29468274292831886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894335643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9754142,0.0011608214,0.00013195188,0.0032988198,0.00043676366,0.00019989809,0.000019141014,0.0000037302232,0.019334687],"genre_scores_gemma":[0.9979337,0.0000837073,0.00015352799,0.001654622,0.00016368857,0.0000010998752,1.0270603e-7,0.0000033237957,0.0000062486565],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981213,0.000029896319,0.0010134295,0.0002836877,0.00010525959,0.00044640593],"domain_scores_gemma":[0.9985695,0.000033556902,0.0008793857,0.00014075985,0.00004774258,0.0003290389],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033201189,0.000120555866,0.0005958595,0.0004275412,0.00022988085,0.00006208812,0.0003876725,0.00002691859,0.000032281896],"category_scores_gemma":[0.00012325177,0.00010509694,0.000028128577,0.00092877384,0.00053361105,0.00028096646,0.0000844163,0.00023119306,0.000044372715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011719216,0.00042359772,0.8966926,0.000021090698,0.000025974126,0.000014897238,0.027174382,0.000060403854,0.000008066777,0.07138867,0.0010691625,0.0030039935],"study_design_scores_gemma":[0.0012230669,0.0017047056,0.9796111,0.000055210305,0.0000020696775,0.000032339587,0.0009967729,0.0009259908,0.0000043199234,0.013767554,0.0015669215,0.000109959416],"about_ca_topic_score_codex":0.00019643114,"about_ca_topic_score_gemma":0.000019109137,"teacher_disagreement_score":0.08291852,"about_ca_system_score_codex":0.0003933265,"about_ca_system_score_gemma":0.00023751389,"threshold_uncertainty_score":0.42857286},"labels":[],"label_agreement":null},{"id":"W2894444481","doi":"10.9778/cmajo.20180049","title":"Canadian status of “drugs to avoid” in 2017: a descriptive analysis","year":2018,"lang":"en","type":"article","venue":"CMAJ Open","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"York University; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Agency for Healthcare Research and Quality; Government of Canada; Gordon and Betty Moore Foundation; National Health and Medical Research Council; St. Michael's Hospital Foundation; Medical Research Council; American Diabetes Association","keywords":"Formulary; Medicine; Listing (finance); Drug; Family medicine; Summary of Product Characteristics; Alternative medicine; Pharmacology; Business","score_opus":0.10058326846073487,"score_gpt":0.3342084100822495,"score_spread":0.23362514162151463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894444481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.591705,0.00019037715,0.00014606686,0.0019898436,0.00018191102,0.0003843491,0.0009111771,0.000004045773,0.40448722],"genre_scores_gemma":[0.9957248,0.00007328527,0.0005649512,0.0024523246,0.00005506418,0.000025459978,0.000013737249,0.000011673487,0.0010786857],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986437,0.000013569413,0.00051023124,0.00031472344,0.000014024138,0.00050375366],"domain_scores_gemma":[0.9989875,0.000024655139,0.00013980662,0.00032576307,0.000033405202,0.00048886024],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00051042176,0.00009949346,0.00045317344,0.0008057876,0.00005259213,0.000092610906,0.0005208347,0.0000588681,0.002019129],"category_scores_gemma":[0.000104738625,0.00012289833,0.00007930203,0.0008185334,0.000052061732,0.00019107203,0.00017478291,0.000086976404,0.0016117092],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010718013,0.00012414427,0.63442606,0.000019315092,0.0006441403,0.000006841928,0.015954284,0.00019345037,0.000040334264,0.32097837,0.023008928,0.0044969535],"study_design_scores_gemma":[0.00092236063,0.00012410597,0.25339675,0.0000151314425,0.000036332054,4.791366e-7,0.0004534068,0.0036415223,0.00036190115,0.024456833,0.716149,0.0004422167],"about_ca_topic_score_codex":0.7767871,"about_ca_topic_score_gemma":0.6745858,"teacher_disagreement_score":0.69314003,"about_ca_system_score_codex":0.00048893166,"about_ca_system_score_gemma":0.00018177587,"threshold_uncertainty_score":0.99916565},"labels":[],"label_agreement":null},{"id":"W2894720341","doi":"","title":"The Life Cycle of Pharmaceuticals: A Cross-National Perspective","year":2002,"lang":"en","type":"article","venue":"Monographs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Per capita; Consumption (sociology); Relative price; Investment (military); Economics; Price level; Pharmaceutical industry; Public economics; Agricultural economics; Point (geometry); Business; Monetary economics","score_opus":0.1116558898907889,"score_gpt":0.34786533591565555,"score_spread":0.23620944602486665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894720341","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3030028,0.035553113,0.00026394814,0.024604894,0.0007826992,0.00045344452,0.0008796348,0.00008293628,0.6343765],"genre_scores_gemma":[0.9954325,0.0019553993,0.000081058046,0.0018727622,0.00012260416,0.000026257725,0.0000017857365,0.000015540223,0.00049208873],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988815,0.000014993562,0.0005189358,0.00024517978,0.00004303788,0.00029634344],"domain_scores_gemma":[0.9991841,0.00017561686,0.0002092856,0.00019373097,0.00007870383,0.00015857187],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004800661,0.00011435711,0.00022177356,0.0001453494,0.00019210488,0.00009162783,0.00029732543,0.00006036809,0.000954154],"category_scores_gemma":[0.00025831186,0.000107364955,0.00020860402,0.0002797096,0.0002496756,0.00014501813,0.00005702449,0.00016378945,0.0005985299],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020389674,0.00013910275,0.01360593,0.000006796196,0.00015895609,4.696531e-7,0.00047541337,0.00020039344,0.000007713143,0.97497076,0.009507797,0.0009062576],"study_design_scores_gemma":[0.0010349124,0.000045869954,0.011225376,0.000003576578,0.000009848871,0.000002399681,0.000090639005,0.08132661,0.00015261992,0.42967921,0.4761599,0.00026903112],"about_ca_topic_score_codex":0.00005715534,"about_ca_topic_score_gemma":0.000004789647,"teacher_disagreement_score":0.6924297,"about_ca_system_score_codex":0.00007899259,"about_ca_system_score_gemma":0.000013618198,"threshold_uncertainty_score":0.9999591},"labels":[],"label_agreement":null},{"id":"W2897256035","doi":"10.33423/jabe.v20i6.369","title":"Do Focusing Events and Narratives Drive Pharma Rent-seeking: Evidence from Disease Outbreaks","year":2018,"lang":"en","type":"article","venue":"Journal of Applied Business and Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Outbreak; Narrative; Economic rent; Window of opportunity; Disease; Business; Economics; Medicine; Engineering; Market economy; Virology","score_opus":0.0624418156537383,"score_gpt":0.28767297370063105,"score_spread":0.22523115804689275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897256035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905195,0.0027226324,0.0009685499,0.002782957,0.0006350931,0.000128344,0.00010823844,0.000007312623,0.0021273785],"genre_scores_gemma":[0.98947036,0.0071556596,0.0011083917,0.00091237936,0.0012973314,0.000004311907,0.000003460826,0.000030156158,0.000017946397],"study_design_codex":"observational","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99835604,0.0000091722795,0.0009373181,0.0003865591,0.000025639658,0.0002852465],"domain_scores_gemma":[0.9982919,0.000101105914,0.0009801575,0.00019603553,0.000076629665,0.00035414935],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00048757863,0.0002331699,0.000603479,0.0002235093,0.00018617044,0.00023509977,0.00023067468,0.000086685344,0.00018408659],"category_scores_gemma":[0.00006169195,0.00024541776,0.00008464148,0.00010281014,0.00020674564,0.00068993605,0.00016078088,0.00019048191,0.00004658828],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061678467,0.00085366337,0.5784983,0.00046687413,0.0019628955,0.000050587314,0.02177296,0.0011370257,0.003724084,0.29993296,0.0035468559,0.08188592],"study_design_scores_gemma":[0.0046084905,0.00016175205,0.34776387,0.0003559093,0.00013397778,0.00004060688,0.0007881985,0.0094416,0.0005863551,0.5538959,0.08096615,0.0012572057],"about_ca_topic_score_codex":0.000046570283,"about_ca_topic_score_gemma":0.000010100144,"teacher_disagreement_score":0.25396293,"about_ca_system_score_codex":0.0000933788,"about_ca_system_score_gemma":0.000060047663,"threshold_uncertainty_score":0.9999998},"labels":[],"label_agreement":null},{"id":"W2897590646","doi":"10.1108/jes-01-2016-0002.html?utm_source=repec&utm_medium=feed&utm_campaign=repec","title":"The Search for New Drugs: A Theory of R&D in the Pharmaceutical Industry","year":2010,"lang":"en","type":"preprint","venue":"RePEc: Research Papers in Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Product (mathematics); Quality (philosophy); Externality; Microeconomics; Process (computing); Business; Industrial organization; Pharmaceutical industry; Brand names; Network effect; Unit price; Economics; Marketing; Biotechnology; Computer science; Mathematics","score_opus":0.1418124963604259,"score_gpt":0.4056171873832325,"score_spread":0.26380469102280657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897590646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74370354,0.0025360833,0.000037827478,0.020240586,0.0017020628,0.0037352676,0.0009849251,0.000025778303,0.22703393],"genre_scores_gemma":[0.9806873,0.014392207,0.00022908997,0.001215904,0.0008808818,0.0005591822,0.00003581652,0.0000983349,0.0019012571],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99542385,0.0003452191,0.0017459308,0.000995011,0.00011026835,0.0013797027],"domain_scores_gemma":[0.9929131,0.004831077,0.0004117543,0.001470005,0.0000692735,0.00030474245],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.015400159,0.00038144356,0.0008886563,0.00064283365,0.00025572022,0.00031522685,0.002640425,0.0012073395,0.00020882774],"category_scores_gemma":[0.0010995858,0.00032609497,0.0004121471,0.00026486948,0.00090001384,0.0001094231,0.0011088363,0.007359309,0.000038693448],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061923923,0.00041622567,0.0101514775,0.00029171037,0.00024033384,0.0000066673165,0.00378947,0.0025540213,0.000029717192,0.7435314,0.0010530661,0.23731664],"study_design_scores_gemma":[0.0024645228,0.00011873435,0.005625629,0.00011160365,0.000013716604,0.000007712134,0.0018028043,0.031968433,0.000384949,0.4432483,0.51354945,0.00070418505],"about_ca_topic_score_codex":0.000261172,"about_ca_topic_score_gemma":0.00027503667,"teacher_disagreement_score":0.51249635,"about_ca_system_score_codex":0.00051948725,"about_ca_system_score_gemma":0.0008817107,"threshold_uncertainty_score":0.9999191},"labels":[],"label_agreement":null},{"id":"W2898387476","doi":"10.1093/annonc/mdy297.007","title":"Magnitude of clinical benefit in trials supporting US Food and Drug Administration (FDA) accelerated approval (AA) and European Medicines Agency (EMA) conditional marketing authorisation (CMA) and subsequent trials supporting conversion to full approval","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical trial; Food and drug administration; Marketing authorization; Authorization; Family medicine; Internal medicine; Pharmacology; Bioinformatics","score_opus":0.4063064808284143,"score_gpt":0.4844896776090462,"score_spread":0.0781831967806319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898387476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98921734,0.00029235048,0.00011726061,0.005309225,0.00030247643,0.00059800857,0.00026419485,0.0000097518505,0.003889395],"genre_scores_gemma":[0.99691623,0.00064357097,0.0009343894,0.0009158743,0.00045023937,0.0000140112,0.00008095144,0.000017675406,0.00002704754],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99454516,0.0007529448,0.0037989612,0.000513277,0.00006332353,0.00032633328],"domain_scores_gemma":[0.99469846,0.0019274756,0.0028447784,0.00013125908,0.000169487,0.00022850848],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.033445496,0.00018009912,0.0014805872,0.00032149098,0.00008192144,0.000037023005,0.00011385397,0.00017174406,0.00023455925],"category_scores_gemma":[0.009414854,0.0001913689,0.00011999032,0.00015028006,0.00028257445,0.00019466801,0.00012307952,0.00018715649,0.0000066119055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010549448,0.0014791922,0.48549157,0.0013384549,0.000998762,0.000056158035,0.0069308495,0.000040511717,0.009836469,0.06504492,0.0064400355,0.41179362],"study_design_scores_gemma":[0.013223967,0.01002145,0.8987828,0.00019475726,0.00017553485,0.00006935987,0.0010012137,0.009883845,0.011945761,0.034091804,0.019719468,0.00089007843],"about_ca_topic_score_codex":0.0000693744,"about_ca_topic_score_gemma":0.00009244397,"teacher_disagreement_score":0.4132912,"about_ca_system_score_codex":0.000024806171,"about_ca_system_score_gemma":0.00011861162,"threshold_uncertainty_score":0.99892926},"labels":[],"label_agreement":null},{"id":"W2898425160","doi":"10.1016/j.gheart.2018.09.025","title":"MS06.5 Equivalence In Active Pharmaceutical Ingredient of Generic Antihypertensive Medicines Available In Three Nigerian States (EQUIMEDS): A Case For Further Surveillance","year":2018,"lang":"en","type":"article","venue":"Global Heart","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Medicine; Excellence; Heart disease; Health care; Medical emergency; Family medicine; Intensive care medicine; Cardiology; Economic growth","score_opus":0.08692875682813082,"score_gpt":0.33987196829942207,"score_spread":0.25294321147129123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898425160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887834,0.0015954241,0.00015741165,0.003165366,0.000549124,0.0005128093,0.0011046332,0.000014989054,0.0041168435],"genre_scores_gemma":[0.99618137,0.0003766883,0.00040178033,0.0027253414,0.00021444401,0.000041301548,0.000011361648,0.00001702907,0.000030703988],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981004,0.000027395861,0.0007406982,0.00047954268,0.000039417293,0.00061252614],"domain_scores_gemma":[0.9991912,0.00013365742,0.00017700458,0.0002427379,0.00008964,0.00016574711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065621175,0.00019236337,0.0006324765,0.00016166033,0.000045427325,0.000020051815,0.00017701571,0.000105324536,0.0005366847],"category_scores_gemma":[0.00015199113,0.00020820848,0.000085697975,0.00038471087,0.0002859018,0.00014990142,0.00009632662,0.00012218379,0.00031568168],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014273572,0.0006887253,0.95439225,0.00030532616,0.00015187259,0.00025364873,0.0015568578,0.0002258734,0.00055697554,0.01572118,0.019821517,0.004898396],"study_design_scores_gemma":[0.017024793,0.0021611308,0.22976974,0.00029868467,0.000038652503,0.0008978247,0.0010798859,0.28764674,0.0047551547,0.1104537,0.34357363,0.0023000774],"about_ca_topic_score_codex":0.0018295086,"about_ca_topic_score_gemma":0.0038758484,"teacher_disagreement_score":0.72462255,"about_ca_system_score_codex":0.00022795002,"about_ca_system_score_gemma":0.000068252455,"threshold_uncertainty_score":0.84904957},"labels":[],"label_agreement":null},{"id":"W2898784478","doi":"10.1016/j.yrtph.2018.10.019","title":"Comparison of numbers and timing of new medication regulatory approvals in Canada and New Zealand","year":2018,"lang":"en","type":"article","venue":"Regulatory Toxicology and Pharmacology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Fraser Institute; Canadian Institute for Health Information","funders":"","keywords":"Drug approval; Government (linguistics); Medicine; Orphan drug; Regulatory authority; Business; Pharmacology; Drug; Public administration; Political science","score_opus":0.0805506554114334,"score_gpt":0.3408345033275702,"score_spread":0.2602838479161368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898784478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99400544,0.0028313182,0.000018462815,0.0015744169,0.00035402956,0.00014979923,0.000021678918,0.0000042066113,0.0010406256],"genre_scores_gemma":[0.99800986,0.00040680644,0.0001740529,0.0009824344,0.00014019197,0.0000036194315,0.0000029830765,0.000009913105,0.00027013393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987762,0.00004036802,0.0006385177,0.00029044494,0.000021855201,0.00023261401],"domain_scores_gemma":[0.9991155,0.00014673902,0.00038435188,0.00010835403,0.000013716345,0.0002313122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003846834,0.0001213402,0.0005670339,0.00015683084,0.000039845865,0.0000037865489,0.00009565694,0.00015854293,0.00044399887],"category_scores_gemma":[0.000026521022,0.00014578504,0.000019683826,0.00008633302,0.0004030399,0.000072309114,0.00007210975,0.00014610647,0.0000023163805],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018379558,0.0000749763,0.91832864,0.00011662479,0.00014618674,0.0000018087916,0.0017492535,0.000032397347,0.0067916294,0.026101625,0.03655184,0.009921245],"study_design_scores_gemma":[0.0036717446,0.00027901048,0.8782102,0.000021542219,0.00005243901,0.000022844262,0.000113530106,0.0069124703,0.021770911,0.017822584,0.0707933,0.0003294173],"about_ca_topic_score_codex":0.09104295,"about_ca_topic_score_gemma":0.11369553,"teacher_disagreement_score":0.04011841,"about_ca_system_score_codex":0.00008892219,"about_ca_system_score_gemma":0.00037723428,"threshold_uncertainty_score":0.91500986},"labels":[],"label_agreement":null},{"id":"W2899402063","doi":"10.1159/000493119","title":"Prescription Drug Shortages: Impact on Neonatal Intensive Care","year":2018,"lang":"en","type":"article","venue":"Neonatology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Economic shortage; Medicine; Medical prescription; Interquartile range; Drug; Internal medicine; Pharmacology","score_opus":0.038681748679167786,"score_gpt":0.31206471261296853,"score_spread":0.27338296393380074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899402063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9411281,0.0019229929,0.00018722846,0.0025964926,0.0014241826,0.00020401791,0.00035910873,0.00005924304,0.052118685],"genre_scores_gemma":[0.99064845,0.00011344412,0.000053360367,0.008410837,0.00032774787,0.000017368102,0.00004420976,0.00002759213,0.00035698235],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.998622,0.000019751145,0.00040642216,0.00045372956,0.000020586398,0.00047753428],"domain_scores_gemma":[0.9991546,0.00006436981,0.0001577082,0.0003291158,0.00013532807,0.00015883996],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0001346393,0.00019566386,0.00039739267,0.00023254541,0.000114232345,0.00003706964,0.0002596697,0.00014661944,0.0016987837],"category_scores_gemma":[0.00012770439,0.00020258747,0.00016555228,0.000109674016,0.0002084095,0.00012886034,0.0000867603,0.00024762985,0.004463957],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045868717,0.000052134208,0.07698343,0.00004062673,0.00024692723,0.00004288213,0.011316766,0.00007216049,0.000038631573,0.82289237,0.06360412,0.024251254],"study_design_scores_gemma":[0.0014416912,0.000571875,0.028540436,0.000015697562,0.000014835862,0.00006596936,0.0011241541,0.004587635,0.0012184881,0.06026793,0.90152514,0.0006261614],"about_ca_topic_score_codex":0.00040565195,"about_ca_topic_score_gemma":0.00012568964,"teacher_disagreement_score":0.837921,"about_ca_system_score_codex":0.00017328787,"about_ca_system_score_gemma":0.00003104564,"threshold_uncertainty_score":0.9992138},"labels":[],"label_agreement":null},{"id":"W2899724228","doi":"10.11575/prism/32040","title":"Universal Prescription Drug Coverage: Rethinking Outpatient Pharmaceutical Provision in Alberta","year":2017,"lang":"en","type":"dissertation","venue":"Open MIND","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Drug; Business; Medicine; Pharmacology","score_opus":0.0871792487612392,"score_gpt":0.3523052466169871,"score_spread":0.26512599785574786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899724228","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45395547,0.00042945505,0.0000053148224,0.0009976701,0.0016607844,0.0010571986,0.00025980236,0.0000020663779,0.54163224],"genre_scores_gemma":[0.9116802,0.0007100302,0.00018296021,0.00023957004,0.00015432006,0.000043841042,0.001074985,0.00006414691,0.085849896],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99766636,0.00004319957,0.00090300373,0.00087831897,0.000057710153,0.00045140204],"domain_scores_gemma":[0.9982813,0.000085155014,0.0008541152,0.00055726914,0.00003284197,0.00018932232],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00080937473,0.00033978996,0.00071147486,0.00031352587,0.0002088937,0.00073652685,0.0011427493,0.00040335133,0.004344924],"category_scores_gemma":[0.00015968949,0.0004273846,0.00014997946,0.00008583373,0.00004550944,0.0008197955,0.00020156345,0.00084997213,0.0023949593],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043243817,0.0027011891,0.03071154,0.0009000805,0.0007285952,0.00019840535,0.06948236,0.00064242905,0.00029680878,0.15223351,0.020988435,0.7167923],"study_design_scores_gemma":[0.00233362,0.00006803834,0.0037995642,0.00027509572,0.000035903933,0.0000020037069,0.00015193282,0.006098978,0.00090581924,0.014559042,0.9709501,0.0008198869],"about_ca_topic_score_codex":0.00513491,"about_ca_topic_score_gemma":0.008034057,"teacher_disagreement_score":0.94996166,"about_ca_system_score_codex":0.00042023815,"about_ca_system_score_gemma":0.00016999102,"threshold_uncertainty_score":0.9998178},"labels":[],"label_agreement":null},{"id":"W2899812694","doi":"10.11575/sppp.v11i0.53048","title":"Making Sure Orphan Drugs Don’t Get Left Behind","year":2018,"lang":"en","type":"article","venue":"RePEc: Research Papers in Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Orphan drug; Incentive; Business; Yardstick; Government (linguistics); Competitor analysis; Reimbursement; Pharmaceutical industry; Profit (economics); Public economics; Industrial organization; Actuarial science; Economics; Marketing; Health care; Medicine; Microeconomics; Economic growth","score_opus":0.08603383365744059,"score_gpt":0.36544796682228614,"score_spread":0.27941413316484554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899812694","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45600763,0.0003218671,0.000010049344,0.0019186229,0.0006129995,0.00036030728,0.00018736516,0.000044603854,0.5405366],"genre_scores_gemma":[0.99005955,0.0025391087,0.00038794725,0.0016386553,0.00096863636,0.00003800213,0.00001998628,0.000090664864,0.0042574354],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99635184,0.00008193107,0.0011019917,0.0010146769,0.00006731522,0.0013822224],"domain_scores_gemma":[0.99813044,0.00031629897,0.0002734611,0.00087286806,0.00006732959,0.0003396094],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.002862121,0.0003091993,0.0006549091,0.0007863805,0.0003417048,0.00026729502,0.00084936933,0.00029635138,0.0029976717],"category_scores_gemma":[0.00032384004,0.00039203683,0.00019815254,0.00014873194,0.00060147746,0.00038458215,0.0004223473,0.00081750355,0.0012669298],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005892243,0.0009954943,0.3540375,0.00026686926,0.0005810043,0.00007737169,0.010298446,0.00084999047,0.0003403978,0.29902944,0.0063660764,0.32656822],"study_design_scores_gemma":[0.0013653947,0.00018690391,0.012922187,0.00004725006,0.0000040194145,0.00001888364,0.00032633526,0.015861059,0.0003254677,0.034572594,0.9336542,0.0007157416],"about_ca_topic_score_codex":0.0001542352,"about_ca_topic_score_gemma":0.00070084335,"teacher_disagreement_score":0.9272881,"about_ca_system_score_codex":0.00078930584,"about_ca_system_score_gemma":0.00015257274,"threshold_uncertainty_score":0.99985313},"labels":[],"label_agreement":null},{"id":"W2899914486","doi":"10.1136/heartasia-2018-011034","title":"Single-use medical devices: economic issues","year":2018,"lang":"en","type":"article","venue":"Heart Asia","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Institute of Health Economics","funders":"","keywords":"Medicine; Intensive care medicine","score_opus":0.10668737320955592,"score_gpt":0.3349997483859336,"score_spread":0.2283123751763777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899914486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7366251,0.0018259126,0.0001964606,0.041379754,0.0022486462,0.00029561855,0.00022830992,0.00018849435,0.2170117],"genre_scores_gemma":[0.98478866,0.00016044913,0.0007042939,0.010846622,0.0017369533,0.000011567133,0.000011546281,0.0000400618,0.0016998409],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984572,0.000016904749,0.00060597766,0.0004340825,0.00003255813,0.00045331017],"domain_scores_gemma":[0.99904996,0.00007763341,0.00012363806,0.00037282842,0.00001762195,0.00035833532],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00046904114,0.00016930263,0.00040195233,0.00014758446,0.000119072196,0.00016854506,0.00027635798,0.00017102806,0.0105144465],"category_scores_gemma":[0.00013896273,0.00019992009,0.0001234633,0.00008241531,0.00020410246,0.00035732522,0.00010539894,0.00017036973,0.026782228],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004227605,0.00021012592,0.10714259,0.00003080276,0.00011391254,0.000009306419,0.00041156565,0.0000046574964,0.0000752951,0.6718687,0.21694067,0.0031501183],"study_design_scores_gemma":[0.00033753092,0.00008311727,0.010270006,0.000010961087,0.000003042449,0.000018061612,0.000010076688,0.003457969,0.00040641864,0.010758206,0.97439927,0.0002453436],"about_ca_topic_score_codex":0.00042122803,"about_ca_topic_score_gemma":0.0002923474,"teacher_disagreement_score":0.75745857,"about_ca_system_score_codex":0.00013193152,"about_ca_system_score_gemma":0.000053324176,"threshold_uncertainty_score":0.99039006},"labels":[],"label_agreement":null},{"id":"W2900339493","doi":"","title":"Data That Heals: A Three Horizon Analysis","year":2018,"lang":"en","type":"other","venue":"OCAD University Open Research Repository (OCAD University)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario College of Art and Design","funders":"","keywords":"Business; Futures studies; Big data; Marketing; Emerging markets; Health care; Emerging technologies; Position (finance); Product (mathematics); Industrial organization; Economics; Finance; Economic growth; Computer science","score_opus":0.33377910629579666,"score_gpt":0.36793778656367104,"score_spread":0.034158680267874386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900339493","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00071922695,0.0005507463,0.0007365589,0.0007317236,0.0004299742,0.0008424446,0.0032145854,0.0001179845,0.99265677],"genre_scores_gemma":[0.0058261575,0.0019392439,0.00044108776,0.00008188434,0.0004501641,6.1721136e-7,0.00039921873,0.00019772026,0.9906639],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960547,0.00033094452,0.00038163707,0.0019760183,0.0002192853,0.0010373855],"domain_scores_gemma":[0.99532014,0.00014980091,0.00063980825,0.0030470807,0.00012674886,0.00071642315],"candidate_categories":["metaepi_narrow","open_science","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016902447,0.0004630609,0.0012423652,0.0035289133,0.0009419692,0.000513783,0.007458956,0.0007449925,0.0004118923],"category_scores_gemma":[0.00005618371,0.00064169464,0.00036737704,0.0025196841,0.0009110511,0.0009697327,0.003593904,0.00095177745,0.0025280416],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013281802,0.0001256852,0.0049484055,0.00004338207,0.0018649827,0.0002464635,0.000036164372,0.0000034260888,0.0000022618187,0.7574554,0.23494858,0.00019242919],"study_design_scores_gemma":[0.00106661,0.00016760355,0.0009263413,0.000060472936,0.00029316996,0.0000043863324,0.00017048902,0.0014414631,0.0000070247306,0.00066367426,0.9945192,0.0006795863],"about_ca_topic_score_codex":0.019738337,"about_ca_topic_score_gemma":0.010861359,"teacher_disagreement_score":0.7595706,"about_ca_system_score_codex":0.0011181382,"about_ca_system_score_gemma":0.00046474478,"threshold_uncertainty_score":0.99960345},"labels":[],"label_agreement":null},{"id":"W2901198550","doi":"10.1007/s40256-018-0309-9","title":"Trends in Hospital Visits for Generic and Brand-Name Warfarin Users in Québec, Canada: A Population-Based Time Series Analysis","year":2018,"lang":"en","type":"article","venue":"American Journal of Cardiovascular Drugs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; The Quebec Population Health Research Network; Université du Québec à Trois-Rivières; Université Laval; Institut National de Santé Publique du Québec","funders":"Fonds de Recherche du Québec - Santé; Abbott Vascular; Institut National de Santé Publique du Québec","keywords":"Medicine; Warfarin; Population; Pharmacotherapy; Brand names; Series (stratigraphy); Advertising; Internal medicine; Atrial fibrillation; Business; Environmental health","score_opus":0.010188573071487614,"score_gpt":0.226260074158103,"score_spread":0.21607150108661538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901198550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99283236,0.0031273228,0.0006746109,0.0027687673,0.000109722074,0.000084923755,0.0000868754,0.000003514309,0.00031187324],"genre_scores_gemma":[0.99852115,0.00020024095,0.0005695286,0.0004884534,0.00014489908,0.000006847262,0.000010847886,0.000019828774,0.000038203176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99862576,0.00004163837,0.0007275429,0.00025290193,0.000066469045,0.00028572144],"domain_scores_gemma":[0.99911386,0.000069696485,0.0004023438,0.0002136105,0.00005158185,0.00014892966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072676723,0.00015350216,0.0010618143,0.0008711441,0.000045466517,0.000041846593,0.00016654296,0.000036237285,0.000059684473],"category_scores_gemma":[0.000059146194,0.00017096609,0.0006027531,0.0008794681,0.00009496031,0.0001796684,0.00002210361,0.00012147205,0.0000032376372],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038089,0.0001633316,0.78553766,0.000032308064,0.008044674,0.00003659111,0.0015376352,0.056319848,0.0000039395,0.0009020212,0.001109826,0.1459313],"study_design_scores_gemma":[0.0033117593,0.0005171231,0.8253762,0.000019745492,0.00049832166,0.000013214608,0.00017374998,0.034025587,0.00003476087,0.00045701227,0.13493869,0.00063380884],"about_ca_topic_score_codex":0.42501554,"about_ca_topic_score_gemma":0.1643688,"teacher_disagreement_score":0.26064673,"about_ca_system_score_codex":0.0004222453,"about_ca_system_score_gemma":0.00020025161,"threshold_uncertainty_score":0.8508793},"labels":[],"label_agreement":null},{"id":"W2902080463","doi":"10.12688/wellcomeopenres.14947.1","title":"Ideation and implementation of an open science drug discovery business model – M4K Pharma","year":2018,"lang":"en","type":"preprint","venue":"Wellcome Open Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalton Pharma Services (Canada); Structural Genomics Consortium; University of Toronto","funders":"Structural Genomics Consortium; Brain Tumour Charity; Ontario Institute for Cancer Research; Wellcome Trust; Wellcome","keywords":"Intellectual property; Business; Venture capital; Ideation; Government (linguistics); Business model; Investment (military); Key (lock); Foundation (evidence); Asset (computer security); Finance; Industrial organization; Marketing; Computer science; Political science; Computer security","score_opus":0.32673138679746005,"score_gpt":0.4993886351626393,"score_spread":0.17265724836517926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902080463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9296496,0.00035191755,0.00046252762,0.0028079401,0.00031660523,0.0024788703,0.0014636752,0.000008642675,0.06246021],"genre_scores_gemma":[0.99525917,0.0011246114,0.001483937,0.00025076995,0.00015343055,0.00021808225,0.00015510143,0.000042192813,0.0013127273],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99700695,0.000087588975,0.0009074161,0.0012317008,0.00016318497,0.00060318527],"domain_scores_gemma":[0.997842,0.00008536222,0.00047853636,0.0009600719,0.00035864091,0.00027537002],"candidate_categories":["metaepi_narrow","scholarly_communication","open_science"],"consensus_categories":[],"category_scores_codex":[0.009592861,0.00021906508,0.00062302605,0.0007821635,0.0004157982,0.0035125387,0.0052625267,0.00011197608,0.0005536629],"category_scores_gemma":[0.00012532542,0.00025205864,0.00003969331,0.00064703455,0.00074089156,0.0029072901,0.014110923,0.00050426397,0.00012034438],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047591495,0.00089188875,0.026688365,0.0009855657,0.00019687998,0.000005033235,0.0032703688,0.0050428207,0.0020001756,0.92892075,0.009771495,0.021750724],"study_design_scores_gemma":[0.0023696509,0.00015750158,0.042154867,0.00012526168,0.000014245006,0.00000264222,0.00026193808,0.26676455,0.006674099,0.6706124,0.01007728,0.00078556145],"about_ca_topic_score_codex":0.013924659,"about_ca_topic_score_gemma":0.0003907691,"teacher_disagreement_score":0.26172173,"about_ca_system_score_codex":0.00032612222,"about_ca_system_score_gemma":0.0008756312,"threshold_uncertainty_score":0.99999315},"labels":[],"label_agreement":null},{"id":"W2902306742","doi":"10.1128/jcm.01637-18","title":"Industry Perspectives on the WHO Essential Diagnostics List","year":2018,"lang":"en","type":"letter","venue":"Journal of Clinical Microbiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Outbreak; Communicable disease; Healthcare system; Medicine; Low and middle income countries; Global health; Intensive care medicine; Health care; Environmental health; Business; Developing country; Public health; Economic growth; Virology; Pathology","score_opus":0.13043208718089475,"score_gpt":0.383639576013895,"score_spread":0.25320748883300026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902306742","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.051589012,0.0025515892,0.00003207246,0.9269445,0.005977315,0.00016341583,0.0008689438,0.0000072705875,0.011865858],"genre_scores_gemma":[0.023573766,0.006702965,0.00007107776,0.9224463,0.045208838,0.0000036375814,0.000025128742,0.00006243136,0.0019058608],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958151,0.00027089924,0.0029433647,0.00046431256,0.000023892004,0.00048244037],"domain_scores_gemma":[0.9918263,0.0040090573,0.0033781948,0.00047739138,0.00017142388,0.00013763385],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.002591633,0.0003251317,0.0016299529,0.00024300719,0.00010594316,0.00009853656,0.0011020357,0.0037232128,0.0030866324],"category_scores_gemma":[0.004393476,0.00024339774,0.00095295924,0.00010586614,0.0009795252,0.000065711916,0.00018000246,0.011444649,0.0010817408],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059784325,0.00012083388,0.0012035207,0.000012182269,0.00041992622,0.000055385586,0.00009107329,0.000001415494,0.0000042601764,0.012162058,0.9857618,0.00010771645],"study_design_scores_gemma":[0.0006007907,0.00053952,0.00032779097,0.000060747065,0.000045162367,0.00010183786,0.000029029328,0.000015405058,0.000020234149,0.011517976,0.9864745,0.0002669849],"about_ca_topic_score_codex":0.000011915028,"about_ca_topic_score_gemma":0.0000027004014,"teacher_disagreement_score":0.03923152,"about_ca_system_score_codex":0.0001048457,"about_ca_system_score_gemma":0.00016602986,"threshold_uncertainty_score":0.999696},"labels":[],"label_agreement":null},{"id":"W2902663565","doi":"10.1257/aer.20140202","title":"Identifying Industry Margins with Price Constraints: Structural Estimation on Pharmaceuticals","year":2018,"lang":"en","type":"article","venue":"American Economic Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Center for Interuniversity Research and Analysis on Organizations","funders":"Agence Nationale de la Recherche","keywords":"Counterfactual thinking; Economics; Consumption (sociology); Estimation; Relative price; Price setting; Reference price; Microeconomics; Structural estimation; Limit price; Pharmaceutical industry; Mid price; Econometrics; Price level; Monetary economics","score_opus":0.082991323703105,"score_gpt":0.3758207466615359,"score_spread":0.29282942295843095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902663565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.48278672,0.018195584,0.0032278635,0.023436656,0.0016522921,0.002458989,0.00093641895,0.0002761014,0.46702936],"genre_scores_gemma":[0.9607313,0.00997914,0.0017032025,0.02681354,0.0004077396,0.000063589396,0.000025572279,0.000057741676,0.0002181617],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977307,0.00004199095,0.00097571,0.0006696978,0.00003363031,0.00054828584],"domain_scores_gemma":[0.9981821,0.0001103593,0.00085681595,0.00050935976,0.000025508289,0.00031586533],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00059688033,0.00032038506,0.00090206217,0.00016928557,0.00014941194,0.00011652554,0.0003950143,0.00008519064,0.005189942],"category_scores_gemma":[0.00008531286,0.00032342898,0.00014313078,0.00023033944,0.0009786449,0.00034789188,0.000072276984,0.0004591323,0.006515566],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013507635,0.00012868867,0.018683009,0.0009946218,0.00070461194,0.000015520798,0.0003108221,0.0003186415,0.000016266851,0.6467051,0.02115559,0.31083208],"study_design_scores_gemma":[0.0026471557,0.0009801553,0.028211307,0.0017729548,0.0001623082,0.00019946399,0.00010481912,0.03448881,0.0003965801,0.021141917,0.9074466,0.0024478808],"about_ca_topic_score_codex":0.000094242074,"about_ca_topic_score_gemma":0.000010149252,"teacher_disagreement_score":0.8862911,"about_ca_system_score_codex":0.00037547792,"about_ca_system_score_gemma":0.000084392894,"threshold_uncertainty_score":0.9999218},"labels":[],"label_agreement":null},{"id":"W2903790720","doi":"10.5703/1288284316836","title":"The Pharmaceutical Industry: A Pharmacy Student's Guide","year":2018,"lang":"en","type":"article","venue":"Purdue Journal of Service-Learning and International Engagement","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Nuclear Safety Commission","keywords":"Internship; Pharmacy; Graduation (instrument); Medical education; Pharmaceutical industry; Work (physics); Pharmacy practice; Management; Medicine; Psychology; Engineering; Pharmacology; Family medicine","score_opus":0.09629959071635974,"score_gpt":0.39024732780850807,"score_spread":0.29394773709214833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903790720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.72928715,0.0038175064,0.0005688293,0.11629934,0.004240513,0.00022868092,0.000031831027,0.000031264026,0.14549492],"genre_scores_gemma":[0.9852193,0.0034451669,0.00025749317,0.0069618886,0.0017780453,0.0000058911596,0.0000021387398,0.00001949711,0.0023106053],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986118,0.000063440995,0.00080849795,0.00017255131,0.000091979666,0.0002517043],"domain_scores_gemma":[0.9987674,0.00017554364,0.0005661306,0.00008555521,0.00021253509,0.00019286452],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022581604,0.00013018935,0.00021513022,0.00015411206,0.00033889824,0.00027467348,0.00046866614,0.000056011544,0.0009533189],"category_scores_gemma":[0.00023319815,0.000110238565,0.00008559302,0.000116984666,0.00008564012,0.00026194582,0.00022441425,0.0010036401,0.0001956839],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00091444905,0.0009580372,0.31322283,0.0001033868,0.0041055805,0.00005915828,0.0079303635,0.0011667841,0.00089638494,0.46814582,0.05799299,0.1445042],"study_design_scores_gemma":[0.0012264476,0.00010123967,0.005647187,0.000021711086,0.000018420986,0.00003743313,0.00039757055,0.012262399,0.000112465,0.0027661931,0.97728616,0.00012275093],"about_ca_topic_score_codex":0.000037935715,"about_ca_topic_score_gemma":0.000007036945,"teacher_disagreement_score":0.91929317,"about_ca_system_score_codex":0.00012330804,"about_ca_system_score_gemma":0.000039130442,"threshold_uncertainty_score":0.99995995},"labels":[],"label_agreement":null},{"id":"W2905138060","doi":"10.1177/1741134318810061","title":"Tough medicine: Ensuring access to affordable drugs requires fixing trade agreements starting with NAFTA","year":2018,"lang":"en","type":"article","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Intellectual property; International trade; General partnership; Negotiation; Market access; Business; Biosimilar; International trade law; Modernization theory; Subsidy; Balance (ability); International economics; Economics; Law; Economic growth; Political science; Finance; Medicine; Market economy","score_opus":0.14072967902078418,"score_gpt":0.3383205404430396,"score_spread":0.19759086142225543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905138060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.59248334,0.024109982,0.07785508,0.28221202,0.019865053,0.0014598061,0.00006419749,0.00004098593,0.0019095531],"genre_scores_gemma":[0.88645184,0.006996338,0.002593382,0.054850865,0.047980778,0.00006733138,0.000009515828,0.00020631966,0.00084364624],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953629,0.000096810625,0.0026415696,0.00045111144,0.00046509306,0.0009825425],"domain_scores_gemma":[0.9940626,0.0009113817,0.0030254128,0.0006622545,0.0007106044,0.00062776904],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0054971245,0.0005447911,0.0013885574,0.0006272137,0.0011231869,0.00023207415,0.0020983808,0.000114223105,0.00062498334],"category_scores_gemma":[0.0017419743,0.0002769775,0.00025614505,0.0015497043,0.0006193139,0.0006119239,0.0002039202,0.0006115202,0.000017194698],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037178542,0.0003393234,0.013794894,0.00081743597,0.00347896,0.0001704655,0.021002784,0.014556698,0.008537538,0.00164416,0.8699169,0.062022947],"study_design_scores_gemma":[0.009973076,0.003085464,0.017416408,0.0018807633,0.00094930234,0.0027396171,0.003874057,0.013056616,0.0015743783,0.009541259,0.9347428,0.0011662468],"about_ca_topic_score_codex":0.00013564993,"about_ca_topic_score_gemma":0.000049144295,"teacher_disagreement_score":0.2939685,"about_ca_system_score_codex":0.00027444315,"about_ca_system_score_gemma":0.00027559354,"threshold_uncertainty_score":0.99996823},"labels":[],"label_agreement":null},{"id":"W2906206060","doi":"10.3968/10512","title":"Legal and Economic Analysis of Medicine Purchased Oversea","year":2018,"lang":"en","type":"article","venue":"Canadian social science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Principle of legality; Intellectual property; Counterfeit; Business; Purchasing; Balance (ability); Law and economics; Law; Medicine; Marketing; Economics; Political science","score_opus":0.046352609813666824,"score_gpt":0.3064504852286596,"score_spread":0.26009787541499274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906206060","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4266711,0.00008969077,0.000048403595,0.003461195,0.00029003434,0.000061297986,0.0003982596,0.0000055622804,0.5689745],"genre_scores_gemma":[0.9972265,0.000021558364,0.000024868094,0.0023242703,0.00026574978,0.0000016783929,0.000003370245,0.000004469706,0.00012755903],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990698,0.000004682024,0.000284111,0.00028187977,0.00002204446,0.00033748028],"domain_scores_gemma":[0.999293,0.000019558232,0.00013275034,0.00012570371,0.000026152142,0.0004027952],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006265576,0.00007119701,0.00029691713,0.0008191979,0.00025351482,0.0000417573,0.00025269383,0.000044632827,0.0012793982],"category_scores_gemma":[0.00006972684,0.00008460437,0.000052580748,0.00079230464,0.0021551943,0.00019083048,0.00003148403,0.000052979794,0.000085993604],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000024881576,0.0000027489602,0.034286488,0.0000018320978,0.000057695488,6.105178e-7,0.00045787438,0.0000010125868,0.00008074881,0.96290886,0.0009493466,0.001250292],"study_design_scores_gemma":[0.00077647687,0.00010997408,0.20715158,0.000004141641,0.00010038136,0.0000014782704,0.0003154776,0.01843909,0.00027897867,0.019957421,0.75244904,0.0004159683],"about_ca_topic_score_codex":0.12651879,"about_ca_topic_score_gemma":0.061672475,"teacher_disagreement_score":0.94295144,"about_ca_system_score_codex":0.00036043345,"about_ca_system_score_gemma":0.00021707959,"threshold_uncertainty_score":0.99963355},"labels":[],"label_agreement":null},{"id":"W2906254779","doi":"10.1016/j.jval.2018.09.1178","title":"PHP284 - TIME TO HTA DECISION FOR INTERNATIONALISED MEDICINES IN AUSTRALIA, CANADA AND EUROPE","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cohort; Internal medicine","score_opus":0.12341032519558928,"score_gpt":0.3578184141197676,"score_spread":0.23440808892417833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906254779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98305357,0.0002836148,0.00010175187,0.013951234,0.00048362804,0.00033790228,0.00019118158,0.0000044673275,0.0015926831],"genre_scores_gemma":[0.98475885,0.00016834914,0.00093894574,0.012537378,0.0002981135,0.000015217173,0.000012282298,0.000016546725,0.0012542958],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989448,0.000013393171,0.00054206373,0.00023530141,0.000020712932,0.0002436845],"domain_scores_gemma":[0.99943215,0.00017662595,0.00010018584,0.000104900864,0.000023834687,0.00016227804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072623184,0.000074173615,0.00023406203,0.00020169279,0.000027144495,0.000017479751,0.00012267295,0.000028049206,0.00034506398],"category_scores_gemma":[0.00035489185,0.000084924315,0.000011727488,0.00019881487,0.000023150349,0.000051738105,0.00003576249,0.00006456844,0.00020819962],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00086135743,0.00035560888,0.23360798,0.00049228687,0.00007158102,0.000018850444,0.004172495,0.0065714484,0.00008540707,0.29274577,0.4296485,0.03136872],"study_design_scores_gemma":[0.0012229496,0.00021618638,0.04742431,0.00008978538,6.8499276e-7,0.0000024490064,0.0000070682145,0.056648873,0.000019977448,0.032886226,0.86130023,0.0001812826],"about_ca_topic_score_codex":0.57995844,"about_ca_topic_score_gemma":0.2048522,"teacher_disagreement_score":0.4316517,"about_ca_system_score_codex":0.00025896408,"about_ca_system_score_gemma":0.0001463267,"threshold_uncertainty_score":0.80965716},"labels":[],"label_agreement":null},{"id":"W2907166494","doi":"10.1016/j.mayocp.2018.07.027","title":"Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials","year":2019,"lang":"en","type":"article","venue":"Mayo Clinic Proceedings","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; CRIS Cancer Foundation","keywords":"Medicine; Food and drug administration; Drug; Postmarketing surveillance; Pharmacology; Randomized controlled trial; Drug approval; Intensive care medicine; Clinical trial; Safety profile; Adverse effect; Internal medicine","score_opus":0.0380535121699198,"score_gpt":0.3018423973481216,"score_spread":0.2637888851782018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907166494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9508562,0.0033860428,0.000041932843,0.0080860965,0.00015189957,0.0025890365,0.00033316005,0.000027211106,0.03452839],"genre_scores_gemma":[0.9958242,0.0018806054,0.000100236284,0.00045420957,0.000083828934,0.00011924436,0.000025861982,0.000025385061,0.0014864327],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99633473,0.000111738416,0.0027918986,0.00045847645,0.00004914353,0.00025399344],"domain_scores_gemma":[0.99385047,0.0034846752,0.0023113098,0.0001624299,0.00006756444,0.00012357334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015551274,0.0002253953,0.0026607674,0.000136429,0.00012835347,0.00014196374,0.00020829235,0.00015889357,0.00015861905],"category_scores_gemma":[0.0030973474,0.00017374963,0.00033724948,0.00011343702,0.00023510706,0.00020174045,0.00007316658,0.00027202783,0.000058514765],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13166115,0.0006420149,0.20939499,0.0010095614,0.008022179,2.0507866e-7,0.010199021,0.000010742167,0.0011677549,0.6025802,0.024263376,0.01104885],"study_design_scores_gemma":[0.7225114,0.0006925349,0.010566488,0.00021332807,0.001397069,0.000009899609,0.0011146788,0.053687423,0.0009980683,0.14638723,0.06080665,0.0016151943],"about_ca_topic_score_codex":0.000055970755,"about_ca_topic_score_gemma":0.0000014666012,"teacher_disagreement_score":0.5908503,"about_ca_system_score_codex":0.000027210584,"about_ca_system_score_gemma":0.00003787181,"threshold_uncertainty_score":0.7085305},"labels":[],"label_agreement":null},{"id":"W2907169668","doi":"10.22215/etd/2009-08900","title":"The review of Bill C-91 : pharmaceutical policy development under a majority Liberal government","year":2009,"lang":"en","type":"dissertation","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Health Canada; Industry Canada; Australian Government; Queen's University; McGill University","keywords":"Political science; Government (linguistics); Public administration; Humanities; Philosophy; Linguistics","score_opus":0.05492035577011735,"score_gpt":0.3368289630221087,"score_spread":0.28190860725199135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907169668","genre_codex":"other","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0058125635,0.14014284,0.000070488866,0.031263646,0.0013322715,0.0013538791,0.00032195714,0.000059455084,0.8196429],"genre_scores_gemma":[0.116428524,0.67338324,0.0012005579,0.07084045,0.0013814637,0.00030806387,0.00060194114,0.0002087353,0.13564703],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970728,0.000029895076,0.0017270225,0.000495574,0.00012693941,0.0005477744],"domain_scores_gemma":[0.9983256,0.00012868333,0.00079588394,0.00045584122,0.00005156041,0.00024246154],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009644265,0.0003826703,0.0008785759,0.00010514139,0.00017138069,0.00007416187,0.0005814573,0.00023037514,0.00089323],"category_scores_gemma":[0.00014498051,0.00028749992,0.00034499067,0.00025741063,0.000058677088,0.00009005675,0.00007310426,0.00046554202,0.0005105326],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015885242,0.00037834034,0.0001622764,0.003497941,0.00050557696,0.0000021251763,0.00019536832,0.0000058527817,0.000014206245,0.8524121,0.052109893,0.09055743],"study_design_scores_gemma":[0.0005258539,0.000042213418,0.0030516097,0.0007041952,0.00003346659,0.000002188871,0.000027089109,0.00016381989,0.00067864853,0.051155932,0.94313115,0.00048381297],"about_ca_topic_score_codex":0.00022292783,"about_ca_topic_score_gemma":0.00018433426,"teacher_disagreement_score":0.89102125,"about_ca_system_score_codex":0.00065158855,"about_ca_system_score_gemma":0.00033554368,"threshold_uncertainty_score":0.99995774},"labels":[],"label_agreement":null},{"id":"W2907596760","doi":"10.1017/s0266462318001745","title":"OP172 Do Expedited Regulatory Pathways Affect Time To Health Technology Assessment Decision?","year":2018,"lang":"en","type":"article","venue":"International Journal of Technology Assessment in Health Care","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Health technology; Drug approval; Regulatory science; Regulatory authority; Pharmacology; Political science; Health care; Public administration; Drug","score_opus":0.03681897121431954,"score_gpt":0.40337846501788205,"score_spread":0.3665594938035625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907596760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7009833,0.006547195,0.007150279,0.27254325,0.005139572,0.0010119645,0.0005058669,0.0001651972,0.0059533757],"genre_scores_gemma":[0.97545433,0.00054876093,0.017130079,0.006259209,0.00048755633,0.00003483044,0.000015477517,0.000035522655,0.000034215052],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99659985,0.000052288065,0.0021228504,0.00047062148,0.00017899221,0.00057538296],"domain_scores_gemma":[0.9971696,0.00012354179,0.0015915154,0.000436044,0.00040266573,0.00027662521],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001744789,0.00024123985,0.0008319063,0.0037056548,0.00014413343,0.00007260722,0.0012683157,0.00030751454,0.0007469315],"category_scores_gemma":[0.00023762754,0.00026909666,0.00014948267,0.0007135338,0.00016890485,0.00021773548,0.0003690892,0.0008854111,0.00030305696],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019601396,0.00066153996,0.08843511,0.00008864289,0.00036083988,0.00010219643,0.000901798,0.0003450513,0.00014200188,0.68901294,0.031403158,0.18835072],"study_design_scores_gemma":[0.005884446,0.005148387,0.08160969,0.0010255093,0.000009343996,0.0004236155,0.0031033047,0.0025657313,0.00039629417,0.16188434,0.7370015,0.000947847],"about_ca_topic_score_codex":0.00004082969,"about_ca_topic_score_gemma":0.000033653483,"teacher_disagreement_score":0.70559835,"about_ca_system_score_codex":0.0032208797,"about_ca_system_score_gemma":0.00087628706,"threshold_uncertainty_score":0.9999761},"labels":[],"label_agreement":null},{"id":"W2907669356","doi":"10.1161/circ.135.suppl_1.p250","title":"Abstract P250: Emergency Room Consultations and Hospitalizations Following Generic Clopidogrel Commercialization in Quebec, Canada","year":2017,"lang":"en","type":"article","venue":"Circulation","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; The Quebec Population Health Research Network; Institut National de Santé Publique du Québec; Université Laval","funders":"","keywords":"Clopidogrel; Medicine; Commercialization; Adverse effect; Emergency medicine; Internal medicine; Aspirin; Marketing; Business","score_opus":0.051762168949510086,"score_gpt":0.289765514441781,"score_spread":0.23800334549227092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907669356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836305,0.0007018053,0.0014696658,0.0028433301,0.0007965106,0.00020300534,0.000082093306,0.000013317821,0.010259798],"genre_scores_gemma":[0.999137,0.00021059385,0.000046737736,0.00029277758,0.000082532686,0.000018598801,0.00010117923,0.00001532165,0.00009528949],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990723,0.000007638852,0.00048625554,0.00023300882,0.000025048104,0.00017572228],"domain_scores_gemma":[0.99931455,0.000023672257,0.0003217172,0.00023708251,0.000023637524,0.00007935052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014761907,0.00010064807,0.00018743733,0.00011084831,0.00036843665,0.00013233155,0.00012491718,0.000066426874,0.00014005916],"category_scores_gemma":[0.00020719656,0.000140675,0.0000417283,0.0000962525,0.000019458475,0.00045004915,0.000030026786,0.00006968886,0.000021835489],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000012148117,0.00002126526,0.9087343,0.000011829485,0.000018655619,0.0000014037277,0.00022559229,0.0016894544,0.000019976917,0.087280594,0.0008095487,0.0011861577],"study_design_scores_gemma":[0.00034979515,0.0000013034887,0.960714,0.0000075723797,0.0000050402637,2.2127452e-7,0.000021927151,0.019723026,0.00000437512,0.010512925,0.0084950775,0.00016473654],"about_ca_topic_score_codex":0.5742254,"about_ca_topic_score_gemma":0.7738628,"teacher_disagreement_score":0.19963735,"about_ca_system_score_codex":0.0002040464,"about_ca_system_score_gemma":0.00008698567,"threshold_uncertainty_score":0.57365596},"labels":[],"label_agreement":null},{"id":"W2907795332","doi":"10.3390/pharmacy7010006","title":"Evaluation of Prescription Adaptation Following Changes to A Provincial Drug Insurance Formulary","year":2019,"lang":"en","type":"article","venue":"Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Formulary; Prescription drug; Medical prescription; Adaptation (eye); Drug; Business; Actuarial science; Medicine; Pharmacology; Psychology","score_opus":0.12990815543427484,"score_gpt":0.3426043152502544,"score_spread":0.21269615981597959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907795332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98219514,0.00094168144,0.00028542153,0.0015171284,0.0008415657,0.0008784097,0.00013865976,0.000021983735,0.013180027],"genre_scores_gemma":[0.9980797,0.00006907164,0.00019193336,0.0012018764,0.00016724167,0.00009050822,0.00001734069,0.000018862698,0.00016344093],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9989998,0.000033602555,0.00039060964,0.00026998634,0.000095237236,0.00021078948],"domain_scores_gemma":[0.9994281,0.000027473563,0.00021727657,0.00016785298,0.00007199268,0.000087335335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015848931,0.00010883272,0.00024458364,0.00020039156,0.000037160386,0.000028677001,0.00015352818,0.000024419003,0.00030445002],"category_scores_gemma":[0.00010664382,0.00013541093,0.00009474436,0.00016632797,0.0000082666,0.0003724401,0.00004647799,0.00008233912,0.00052344013],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007788926,0.0010358838,0.3229089,0.0006875283,0.00091260154,0.0000032095409,0.021930885,0.02936064,0.042507593,0.136671,0.008681882,0.43452096],"study_design_scores_gemma":[0.0070180455,0.00012641288,0.042059887,0.000069699076,0.000103196864,0.0000017394387,0.000118018965,0.7059289,0.017844498,0.036695503,0.18929301,0.0007410671],"about_ca_topic_score_codex":0.000530105,"about_ca_topic_score_gemma":0.00010514373,"teacher_disagreement_score":0.67656827,"about_ca_system_score_codex":0.00015645455,"about_ca_system_score_gemma":0.000058320744,"threshold_uncertainty_score":0.67279387},"labels":[],"label_agreement":null},{"id":"W2907797723","doi":"10.1002/soej.12325","title":"The Effects of Competition on Prescription Payments in Retail Pharmacy Markets","year":2019,"lang":"en","type":"article","venue":"Southern Economic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy; Ceteris paribus; Competition (biology); Market power; Payment; Business; Medical prescription; Market concentration; Quarter (Canadian coin); Percentile; Marketing; Economics; Industrial organization; Market structure; Microeconomics; Finance; Medicine; Pharmacology; Monopoly; Family medicine; Statistics","score_opus":0.02485515604065731,"score_gpt":0.25655106368478237,"score_spread":0.23169590764412507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907797723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97217065,0.00087106123,0.000014264736,0.0011132221,0.0019495407,0.0002705386,0.00008005933,0.000006916251,0.023523722],"genre_scores_gemma":[0.9967762,0.0011849111,0.000011052775,0.0005633038,0.00019710867,0.000008975784,0.0000033997806,0.000024894698,0.0012301247],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99857455,0.000054738848,0.0007970648,0.00022306648,0.000025137393,0.00032542695],"domain_scores_gemma":[0.9988881,0.00019575647,0.00057965994,0.00022911494,0.0000098389755,0.00009757029],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000981575,0.00014282702,0.00032280828,0.00017150876,0.00008848297,0.000096398195,0.00030865145,0.000052828447,0.0011116851],"category_scores_gemma":[0.00004953262,0.0001316312,0.0001548111,0.000042931544,0.000050599836,0.0001800016,0.000042107033,0.00034254877,0.0036377965],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011654375,0.000433376,0.7125813,0.00021165631,0.00048876763,0.000013665778,0.0022878775,0.0013999408,0.0009059814,0.2532779,0.0035439264,0.023690205],"study_design_scores_gemma":[0.020220416,0.000661332,0.13987242,0.0004069812,0.000038749964,0.0000872532,0.00069842103,0.04867646,0.0024027247,0.26491588,0.52069527,0.0013240795],"about_ca_topic_score_codex":0.000050296567,"about_ca_topic_score_gemma":0.000021392492,"teacher_disagreement_score":0.57270885,"about_ca_system_score_codex":0.00030463503,"about_ca_system_score_gemma":0.000037289945,"threshold_uncertainty_score":0.99980146},"labels":[],"label_agreement":null},{"id":"W2907973703","doi":"10.18433/jpps30215","title":"A Survey of the Regulatory Requirements for the Acceptance of Foreign Comparator Products by Participating Regulators and Organizations of the International Generic Drug Regulators Programme","year":2019,"lang":"en","type":"article","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Health Canada","funders":"","keywords":"Bioequivalence; European union; Product (mathematics); Jurisdiction; Business; Medicine; Public economics; International trade; Pharmacology; Political science; Economics; Law","score_opus":0.16345039461533242,"score_gpt":0.3704488296778767,"score_spread":0.20699843506254426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907973703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911091,0.0029988831,0.000062534564,0.0038885514,0.0009222753,0.0005759382,0.00016881303,0.0000029227797,0.00027102517],"genre_scores_gemma":[0.9988545,0.00026723428,0.00019561833,0.000498202,0.00009267255,0.000010760032,0.0000011079978,0.000013118385,0.00006678159],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978232,0.00009963429,0.0012894613,0.00024532207,0.00023485311,0.0003075511],"domain_scores_gemma":[0.997075,0.00041947834,0.0017702826,0.00024540932,0.00037462637,0.000115166724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035160987,0.00014658217,0.00040891883,0.000085523614,0.0001879647,0.000052927073,0.0012169284,0.000029288167,0.00015183019],"category_scores_gemma":[0.0007005758,0.00008774637,0.00014525428,0.00089646346,0.0008316278,0.00033170488,0.00023480957,0.00018855881,0.0000014250583],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010696113,0.00023846359,0.95293385,0.000112390735,0.0002321098,6.637095e-8,0.00047199996,0.001062044,0.015318687,0.022236643,0.004389668,0.0028971084],"study_design_scores_gemma":[0.004357212,0.00016473008,0.3831256,0.00013380611,0.00020342125,0.000016826518,0.0003423428,0.15028608,0.37075603,0.0046866434,0.08549332,0.0004339748],"about_ca_topic_score_codex":0.00007560927,"about_ca_topic_score_gemma":0.000008912252,"teacher_disagreement_score":0.56980824,"about_ca_system_score_codex":0.000069130234,"about_ca_system_score_gemma":0.00022270174,"threshold_uncertainty_score":0.35781932},"labels":[],"label_agreement":null},{"id":"W2909254160","doi":"10.1016/j.pharma.2018.11.007","title":"Drug shortages in Canada: Data for 2016–2017 and perspectives on the problem","year":2019,"lang":"en","type":"article","venue":"Annales Pharmaceutiques Françaises","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"Teva Pharmaceutical Industries; Mylan; Pfizer","keywords":"Economic shortage; Context (archaeology); Medicine; Business; Drug; Pharmacology; Geography; Government (linguistics)","score_opus":0.1433892823090276,"score_gpt":0.32761893555663707,"score_spread":0.18422965324760948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2909254160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9074661,0.026344292,0.000014773458,0.025717389,0.00023852714,0.00121943,0.0021405555,0.000029090232,0.036829833],"genre_scores_gemma":[0.9843599,0.00968631,0.00010429153,0.0049668807,0.00012635958,0.000073751275,0.00003965245,0.000029794406,0.0006130435],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984681,0.000027432698,0.00044168025,0.00061624404,0.000036625846,0.00040994358],"domain_scores_gemma":[0.9986936,0.0004403602,0.00017192416,0.0005496632,0.000025248424,0.00011921097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007226066,0.00021500049,0.00037973095,0.00011917147,0.00012147609,0.000082510756,0.0006552651,0.0000438783,0.00030438945],"category_scores_gemma":[0.000055439854,0.00018806515,0.000054486478,0.00009439085,0.000099302706,0.00032459,0.00018099234,0.00025803965,0.00010435674],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026308303,0.00023616305,0.407468,0.00027620883,0.00028634546,0.000009612139,0.004021751,0.0001728277,0.000065292734,0.38436642,0.19775103,0.0050832685],"study_design_scores_gemma":[0.00085928536,0.000039184102,0.016347025,0.00004647443,0.000010257177,0.0000030802025,0.00082635914,0.010232461,0.00037906482,0.0066448343,0.96419454,0.0004174586],"about_ca_topic_score_codex":0.11836504,"about_ca_topic_score_gemma":0.17209539,"teacher_disagreement_score":0.7664435,"about_ca_system_score_codex":0.000102715465,"about_ca_system_score_gemma":0.00022257579,"threshold_uncertainty_score":0.8875058},"labels":[],"label_agreement":null},{"id":"W2910979606","doi":"10.1111/hiv.12701","title":"De‐simplifying single‐tablet antiretroviral treatments: uptake, risks and cost savings","year":2019,"lang":"en","type":"article","venue":"HIV Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Hip and Knee Clinic; University of Calgary","funders":"","keywords":"Medicine; Abacavir; Lamivudine; Viral load; Incentive; Human immunodeficiency virus (HIV); Antiretroviral therapy; Generic drug; Family medicine; Drug; Pharmacology; Virology","score_opus":0.12773601658021735,"score_gpt":0.31837524491124336,"score_spread":0.190639228331026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910979606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8384747,0.002592059,0.00030201176,0.0033811869,0.00038279901,0.0002899352,0.0001301704,0.00003978549,0.15440735],"genre_scores_gemma":[0.9896843,0.0008231587,0.00019216657,0.0057413233,0.00029622205,0.000012382878,0.00003049802,0.000030514806,0.003189446],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99868083,0.0000099973595,0.00047916998,0.00037118825,0.000027429352,0.00043141027],"domain_scores_gemma":[0.9992273,0.00008367849,0.0001983203,0.0002504567,0.000011814072,0.0002284699],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0004029924,0.00018081395,0.0004898297,0.00017131139,0.00007321559,0.000049333903,0.00013804116,0.00009099418,0.0017302899],"category_scores_gemma":[0.00010130173,0.00018159578,0.000051059364,0.00012735171,0.0001047649,0.00017502172,0.000058728885,0.00016883448,0.0008484057],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008492913,0.00018719574,0.7900899,0.00013058746,0.00020523739,0.000018717137,0.0011095144,0.0000344012,0.0016961951,0.1551532,0.019716205,0.031573925],"study_design_scores_gemma":[0.0057458584,0.00059453445,0.11887317,0.00009895465,0.000049215487,0.00003963403,0.0001456067,0.0087429825,0.00014889047,0.014314232,0.850757,0.0004898893],"about_ca_topic_score_codex":0.00040909887,"about_ca_topic_score_gemma":0.0000037662003,"teacher_disagreement_score":0.8310408,"about_ca_system_score_codex":0.00017328096,"about_ca_system_score_gemma":0.000014992656,"threshold_uncertainty_score":0.99992955},"labels":[],"label_agreement":null},{"id":"W2911140943","doi":"10.4155/ppa-2018-0024","title":"Discussions on the New Molecular Formula and New Molecular Entity Definitions of Pharmaceutical Innovation","year":2018,"lang":"en","type":"article","venue":"Pharmaceutical Patent Analyst","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services","funders":"","keywords":"MEDLINE; Medicine; Library science; Computer science; Political science","score_opus":0.27535559192031356,"score_gpt":0.35251569796290894,"score_spread":0.07716010604259538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911140943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7989794,0.0020850971,0.041897245,0.08300163,0.0007009267,0.0010266638,0.00044177048,0.00010556726,0.071761705],"genre_scores_gemma":[0.9896103,0.000640491,0.00037418888,0.0088803135,0.00023982183,0.000015315774,0.00003466005,0.00003444378,0.00017044984],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99777466,0.00006209431,0.0009970035,0.0005235644,0.000114451745,0.0005282304],"domain_scores_gemma":[0.99854964,0.000162837,0.00029170644,0.00041168137,0.00008302351,0.0005011325],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00064532354,0.00028733065,0.00047359554,0.0003902283,0.00021039165,0.00010349621,0.0003593334,0.00012314453,0.002122444],"category_scores_gemma":[0.0003375623,0.00023539287,0.00022482658,0.0009297541,0.00036948008,0.00018342167,0.00020186299,0.00043568472,0.0005894832],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000069164154,0.0001772069,0.0015428313,0.00002058369,0.00022566506,0.0000046879827,0.00009304212,0.000036625755,0.0073486343,0.98411506,0.00394977,0.0024167344],"study_design_scores_gemma":[0.003399339,0.00028190826,0.0023961049,0.000067300134,0.00034332802,0.000013641356,0.00005308085,0.050480448,0.094889194,0.6603082,0.1868683,0.0008992137],"about_ca_topic_score_codex":0.0001319652,"about_ca_topic_score_gemma":0.000009394551,"teacher_disagreement_score":0.3238069,"about_ca_system_score_codex":0.00008063318,"about_ca_system_score_gemma":0.00006945327,"threshold_uncertainty_score":0.9987897},"labels":[],"label_agreement":null},{"id":"W2912496264","doi":"10.1177/0272989x18818165","title":"Prescriber Variation in Relation to Prescribing Trends within the Preferred Drugs Initiative in Ireland (2012–2015): An Interrupted Time-Series Study Using Latent Curve Models","year":2019,"lang":"en","type":"article","venue":"Medical Decision Making","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Queen's University; Queen's University Belfast","keywords":"Medicine; Interrupted Time Series Analysis; Pharmacy; Pharmacoepidemiology; Drug class; Population; Medical prescription; Drug; Pharmaceutical Benefits Scheme; Emergency medicine; Family medicine; Pharmacology; Environmental health","score_opus":0.1263360287822225,"score_gpt":0.35236520173614216,"score_spread":0.22602917295391967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912496264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871124,0.00011465606,0.007160763,0.0006932584,0.00047067858,0.0006312406,0.000029244513,0.00002210817,0.0037656617],"genre_scores_gemma":[0.9981194,0.000011143202,0.00090350513,0.00069709076,0.00007469922,0.0000355851,0.000010256682,0.000029360464,0.00011892587],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9975662,0.0001786183,0.0011996126,0.00055495097,0.00017210175,0.0003284841],"domain_scores_gemma":[0.9988048,0.00032687833,0.00031699514,0.0003699168,0.000032006195,0.00014939599],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029490208,0.00019530513,0.00046199272,0.00062917644,0.00007404307,0.00013815242,0.00037350148,0.00017502141,0.0008349871],"category_scores_gemma":[0.000492747,0.0001720731,0.000057265417,0.0005502476,0.000030672283,0.0011065409,0.00024631387,0.0004675427,0.0001767253],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027235108,0.0021061937,0.3122873,0.000049853108,0.00023459017,0.000047744685,0.1447694,0.41189057,0.00011747114,0.06993416,0.0007098068,0.05512938],"study_design_scores_gemma":[0.0013203896,0.00015061199,0.14798062,0.00016169247,0.000006169598,0.0000023412163,0.00024511217,0.81635845,0.0000022879508,0.033337172,0.00021963002,0.0002155064],"about_ca_topic_score_codex":0.00029226622,"about_ca_topic_score_gemma":0.00042308253,"teacher_disagreement_score":0.40446788,"about_ca_system_score_codex":0.00030033218,"about_ca_system_score_gemma":0.000048892045,"threshold_uncertainty_score":0.91425234},"labels":[],"label_agreement":null},{"id":"W2912844763","doi":"10.1080/13651501.2018.1508724","title":"Switching medication products during the treatment of psychiatric illness","year":2019,"lang":"en","type":"review","venue":"International Journal of Psychiatry in Clinical Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Ottawa Mental Health Centre; Pfizer (Canada); Dalhousie University; University of Ottawa","funders":"Pfizer","keywords":"Tolerability; Medicine; Psychiatry; Drug class; Mood; Generic drug; Drug; Pharmacology; Adverse effect","score_opus":0.1746879947255537,"score_gpt":0.4861467449533723,"score_spread":0.31145875022781855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912844763","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011094868,0.96244305,0.00004279926,0.014045642,0.018140003,0.00041168314,0.000083224964,0.0000039376246,0.0037201776],"genre_scores_gemma":[0.0014293127,0.99225867,0.0013655263,0.00052096345,0.0042850184,0.00001145311,0.0000076106553,0.000035986035,0.00008543589],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939106,0.00023486196,0.005103872,0.0003785124,0.0001690455,0.00020311918],"domain_scores_gemma":[0.98877215,0.0019939167,0.008469945,0.00044035158,0.00022621485,0.000097389275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029894875,0.00026769348,0.0016582694,0.00057060027,0.000040961564,0.0000712638,0.0011520854,0.0002777721,0.00012171085],"category_scores_gemma":[0.0021264262,0.00019950801,0.00089053425,0.00030136507,0.00006257021,0.00042571436,0.000061607214,0.00094959757,0.00019907746],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048846466,0.0067320555,0.0072219903,0.0036687518,0.004605816,0.000030451945,0.00042906962,0.000069707414,1.4995312e-7,0.076395184,0.0016575096,0.89870083],"study_design_scores_gemma":[0.0011548199,0.00022459701,0.00065238564,0.00086420076,0.0003340099,0.00015423956,0.00003715879,0.00004776685,1.7704387e-7,0.0044642272,0.9918657,0.00020072567],"about_ca_topic_score_codex":0.00004302436,"about_ca_topic_score_gemma":0.000010121538,"teacher_disagreement_score":0.9902082,"about_ca_system_score_codex":0.00035747283,"about_ca_system_score_gemma":0.000611301,"threshold_uncertainty_score":0.8135701},"labels":[],"label_agreement":null},{"id":"W2913167212","doi":"10.1177/2325958218822304","title":"Desimplification of Single Tablet Antiretroviral (ART) Regimens—A Practical Cost-Savings Strategy?","year":2019,"lang":"en","type":"article","venue":"Journal of the International Association of Providers of AIDS Care (JIAPAC)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Hip and Knee Clinic; University of Calgary","funders":"","keywords":"Antiretroviral therapy; Control (management); Human immunodeficiency virus (HIV); Quality (philosophy); Operations management; Cost control; Medicine; Actuarial science; Business; Economics; Family medicine; Viral load","score_opus":0.040890408243349254,"score_gpt":0.29038804655517686,"score_spread":0.2494976383118276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913167212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96944904,0.00026922955,0.0003511699,0.009858741,0.0012486014,0.00033044754,0.00033711997,0.000004976878,0.018150646],"genre_scores_gemma":[0.99729216,0.000072871655,0.0009911332,0.00035231258,0.00012478183,0.0000018768714,0.000009785267,0.0000147814435,0.0011403087],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980655,0.000046890935,0.0013433314,0.00014938177,0.0002333839,0.00016153046],"domain_scores_gemma":[0.9937664,0.00031856922,0.004941319,0.00018905624,0.00072760944,0.000057027133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010923762,0.00011572554,0.0004722572,0.0002546542,0.000027336831,0.000049602462,0.0004645277,0.00012495145,0.00019771107],"category_scores_gemma":[0.0013673919,0.0001093514,0.00034392506,0.00016320367,0.000057042853,0.0006250669,0.00007437663,0.0002458385,0.000025632478],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006783069,0.00092129945,0.6686464,0.0003554468,0.0017493208,0.0000019246088,0.0021731039,0.0038814356,0.05181022,0.22267625,0.043805532,0.0033007395],"study_design_scores_gemma":[0.017781386,0.0069292774,0.19449195,0.0010511976,0.00063163403,0.000091781694,0.006220462,0.011203858,0.3004321,0.11889199,0.34051123,0.0017631282],"about_ca_topic_score_codex":0.00006735993,"about_ca_topic_score_gemma":0.0000073555443,"teacher_disagreement_score":0.47415447,"about_ca_system_score_codex":0.0007194437,"about_ca_system_score_gemma":0.00019471062,"threshold_uncertainty_score":0.44592208},"labels":[],"label_agreement":null},{"id":"W2914255516","doi":"10.5539/gjhs.v11n3p23","title":"An Exploratory Study Into the Use and Pricing of Schedule Zero Medicines Post Exemption From the Single Exit Price Policy in South Africa","year":2019,"lang":"en","type":"article","venue":"Global Journal of Health Science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medical prescription; Schedule; Legislation; Medicine; Business; Economics; Pharmacology","score_opus":0.10820288710548952,"score_gpt":0.34478945341974465,"score_spread":0.23658656631425512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914255516","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920663,0.002400954,0.00014898497,0.004668042,0.0002524411,0.00024073859,0.000027568181,0.0000025926536,0.00019236002],"genre_scores_gemma":[0.9972331,0.00026115467,0.00026616963,0.0021414212,0.000090763766,0.0000012634184,3.0604807e-7,0.000004272845,0.0000015429885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99846244,0.00006176888,0.00085965666,0.00021455463,0.00010758132,0.00029397718],"domain_scores_gemma":[0.99847573,0.0001098798,0.0008987912,0.00025961464,0.000088784705,0.00016719676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032638907,0.00009366209,0.00033071495,0.00025096326,0.00016237877,0.00011741893,0.0005584173,0.000026303578,0.000014763484],"category_scores_gemma":[0.0003130237,0.00006266972,0.00003299811,0.0008965609,0.0002556515,0.00080614415,0.00010664797,0.0001769727,0.000010003191],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007302735,0.0003294043,0.95186895,0.00002180058,0.000017081411,0.0000015140945,0.030727629,0.0005727349,0.00034696056,0.011542222,0.00008913097,0.004409544],"study_design_scores_gemma":[0.0010665896,0.00083131954,0.97576183,0.00007096505,0.0000048572115,0.000009458874,0.007148978,0.0020987666,0.000024846426,0.010750604,0.0021072414,0.00012456639],"about_ca_topic_score_codex":0.001224291,"about_ca_topic_score_gemma":0.00011104552,"teacher_disagreement_score":0.023892857,"about_ca_system_score_codex":0.0002480988,"about_ca_system_score_gemma":0.00033552237,"threshold_uncertainty_score":0.25555968},"labels":[],"label_agreement":null},{"id":"W2915100501","doi":"10.4212/cjhp.v66i1.1211","title":"Drug Shortages in Health Care Institutions: Perspectives in Early 2013","year":2013,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Economic shortage; Drug; Health care; Business; Medicine; Family medicine; Political science; Pharmacology; Government (linguistics)","score_opus":0.052564066889183345,"score_gpt":0.30751464066545764,"score_spread":0.2549505737762743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915100501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90498525,0.025965782,0.0000028848572,0.061406083,0.0005214851,0.0002902657,0.00006593745,0.0000027672015,0.006759551],"genre_scores_gemma":[0.9964843,0.0014278755,0.000040903113,0.0017375043,0.00018575318,0.000011894975,0.0000014803211,0.000014181222,0.000096154916],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998605,0.000034857872,0.00075280026,0.0001499822,0.00002763114,0.0004297026],"domain_scores_gemma":[0.99901164,0.000035285357,0.0003097866,0.00013659238,0.00005794189,0.00044872926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005058837,0.00012607794,0.00031632493,0.00053149654,0.00013644707,0.00015708627,0.0004230919,0.000026340344,0.00043022525],"category_scores_gemma":[0.00005793657,0.000117890064,0.0001028753,0.00024512637,0.00015248539,0.00059886876,0.000019210955,0.0005009459,0.00025959619],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018923269,0.00015778228,0.59533626,0.00005361711,0.00010994247,0.00007722556,0.07338365,0.0015766725,0.000002303121,0.28731364,0.038850684,0.0031193113],"study_design_scores_gemma":[0.0037848619,0.00028801884,0.52281827,0.00013711925,0.000008820829,0.000030306097,0.009819997,0.0010426773,0.00003388939,0.04105401,0.42021027,0.00077179936],"about_ca_topic_score_codex":0.29462576,"about_ca_topic_score_gemma":0.11134529,"teacher_disagreement_score":0.38135958,"about_ca_system_score_codex":0.0008726844,"about_ca_system_score_gemma":0.0007834973,"threshold_uncertainty_score":0.90487033},"labels":[],"label_agreement":null},{"id":"W2915394608","doi":"10.21518/1561-5936-2016-6-54-58","title":"Pharmaceutical industry in quarter I 2016","year":2016,"lang":"en","type":"article","venue":"Remedium Journal about the Russian market of medicines and medical equipment","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Pharmaceutical industry; Business; Commerce; History; Medicine; Pharmacology; Archaeology","score_opus":0.033051913347888075,"score_gpt":0.30152530976617875,"score_spread":0.26847339641829066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915394608","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.160429,0.01634528,0.0008486285,0.7490944,0.0024194582,0.0003883651,0.00004837087,0.000018166664,0.0704083],"genre_scores_gemma":[0.96004736,0.028089313,0.00004508318,0.009735266,0.001215466,0.00001212416,6.284344e-7,0.000019911877,0.0008348457],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997487,0.0000929645,0.0013498048,0.00027724114,0.00022853797,0.00056447065],"domain_scores_gemma":[0.99808335,0.00042721682,0.00039623762,0.00021594895,0.000016578297,0.0008606549],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0045705987,0.00020751379,0.0005964179,0.00022728031,0.000084445404,0.00002675358,0.0004467229,0.00038756678,0.0065181977],"category_scores_gemma":[0.00061765185,0.0001094683,0.00011948868,0.00014660797,0.00054913707,0.0001372182,0.00013527281,0.00115699,0.00004742843],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012085611,0.00091837195,0.09483796,0.00040669215,0.000617196,0.00038527307,0.0017116659,0.0000018958281,0.0003970504,0.2850577,0.24705786,0.36739978],"study_design_scores_gemma":[0.008889148,0.00028825706,0.09045011,0.0017182792,0.000039757742,0.00051409175,0.00020787561,0.0014715714,0.00011116582,0.058424078,0.83744454,0.00044114498],"about_ca_topic_score_codex":0.00002140024,"about_ca_topic_score_gemma":0.000006942085,"teacher_disagreement_score":0.79961836,"about_ca_system_score_codex":0.00011231282,"about_ca_system_score_gemma":0.00016353572,"threshold_uncertainty_score":0.99438995},"labels":[],"label_agreement":null},{"id":"W2915570611","doi":"10.4212/cjhp.v72i1.2863","title":"Drug Shortages in Canada and Selected European Countries: A Cross-Sectional, Institution-Level Comparison","year":2019,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Cross-sectional study; Economic shortage; Cross country; Institution; Political science; Medicine; Demographic economics; Economics; Law","score_opus":0.04561149111757885,"score_gpt":0.2789338870765939,"score_spread":0.23332239595901505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915570611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987739,0.0018541357,0.000005254713,0.0027103184,0.0011723366,0.00014022825,0.0002768122,0.0000023392674,0.006099547],"genre_scores_gemma":[0.9980286,0.00018564909,0.000013555912,0.0014296566,0.00016345918,0.000001201269,0.0000041334097,0.000015929982,0.00015782709],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99870545,0.000030104433,0.0007348204,0.00015563103,0.000044722023,0.00032927323],"domain_scores_gemma":[0.9990057,0.00006748833,0.00035154505,0.000114296636,0.00008535435,0.00037562518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006740066,0.00012831138,0.00028797847,0.00019317273,0.00015911051,0.00020132483,0.00034839314,0.000018154316,0.00049337815],"category_scores_gemma":[0.000064538326,0.00012292077,0.00004801618,0.00018205334,0.000115056966,0.0003025115,0.000022977534,0.0004158487,0.000107588414],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012902603,0.000010302333,0.9892685,0.000009821167,0.00004545541,0.000022930726,0.00039268748,0.00076627947,0.000001563758,0.0064908233,0.0028806592,0.00009808496],"study_design_scores_gemma":[0.00092250336,0.000027490922,0.8622164,0.000010933162,0.0000040101377,0.000022937184,0.000040886105,0.0012153283,0.000025529698,0.0007802649,0.13456081,0.00017287949],"about_ca_topic_score_codex":0.9136528,"about_ca_topic_score_gemma":0.9678958,"teacher_disagreement_score":0.13168015,"about_ca_system_score_codex":0.00088640215,"about_ca_system_score_gemma":0.002156032,"threshold_uncertainty_score":0.5402145},"labels":[],"label_agreement":null},{"id":"W2915644223","doi":"10.4212/cjhp.v67i5.1394","title":"Drug Shortages in Health Care Institutions: Perspectives in Early 2014","year":2014,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Economic shortage; Drug; Health care; Medicine; Family medicine; Business; Nursing; Political science; Pharmacology; Government (linguistics)","score_opus":0.04621862564451133,"score_gpt":0.3106650756337845,"score_spread":0.26444644998927314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915644223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92997426,0.018765705,0.000015932026,0.037112504,0.0007066655,0.00018546375,0.00007704938,0.0000033028718,0.013159115],"genre_scores_gemma":[0.9969315,0.00083501026,0.000040135114,0.001851791,0.00026540883,0.0000042725105,0.000001549983,0.000014088278,0.000056224468],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99864465,0.000053125263,0.00071936613,0.00015673533,0.00002814061,0.00039799005],"domain_scores_gemma":[0.9990344,0.00005039138,0.00032507867,0.00014696302,0.000040442286,0.0004027178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010184912,0.0001224184,0.0003346241,0.0005199572,0.0001439386,0.00010641661,0.0004220417,0.000025782372,0.0001319352],"category_scores_gemma":[0.00010866004,0.00011714796,0.00010565576,0.00019828213,0.0001495587,0.00033167968,0.00001758747,0.00048553428,0.00010887803],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024063713,0.00008408916,0.41485086,0.000037277194,0.00005477367,0.00003534544,0.035829652,0.0014238048,9.819717e-7,0.5346373,0.010735206,0.002286672],"study_design_scores_gemma":[0.003354474,0.00028957575,0.23507701,0.00010307234,0.000008238579,0.000020888947,0.00319895,0.0010622672,0.000031923348,0.03176432,0.7245255,0.0005637451],"about_ca_topic_score_codex":0.07722576,"about_ca_topic_score_gemma":0.08944868,"teacher_disagreement_score":0.7137903,"about_ca_system_score_codex":0.00076292735,"about_ca_system_score_gemma":0.0006774504,"threshold_uncertainty_score":0.9289191},"labels":[],"label_agreement":null},{"id":"W2916169982","doi":"10.4212/cjhp.v72i1.2860","title":"Drug Shortages: More than Just Background Noise","year":2019,"lang":"en","type":"editorial","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Nova Scotia Health Authority; Dalhousie University","funders":"","keywords":"Economic shortage; Drug; Medicine; Pharmacology","score_opus":0.04607434770409242,"score_gpt":0.3041020493665591,"score_spread":0.2580277016624667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916169982","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.034726433,0.0126503855,0.000006244213,0.016225472,0.91366976,0.00045832235,0.0036282537,0.0000115465855,0.01862358],"genre_scores_gemma":[0.35093358,0.0025214104,0.000025275765,0.0020286322,0.6384237,0.000010248974,0.00011424227,0.00018392841,0.005758976],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968966,0.000046822242,0.0015400157,0.00044087478,0.00016015643,0.0009155199],"domain_scores_gemma":[0.99589914,0.000398312,0.0016339215,0.00060948095,0.00024690293,0.0012122318],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0014913654,0.0005303627,0.0011415776,0.0005847266,0.00033681537,0.0006498572,0.002101238,0.00030515433,0.0015334003],"category_scores_gemma":[0.00034408286,0.00048493946,0.0007087057,0.00023396726,0.0003331339,0.0005485154,0.00009094116,0.0024966658,0.001672043],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002694714,0.00003639766,0.0014527367,0.00006430928,0.00038072834,0.00008238112,0.000909956,0.000077154116,4.891115e-7,0.0031255696,0.9936683,0.0001749959],"study_design_scores_gemma":[0.0011751988,0.00009559696,0.00026293437,0.00006730208,0.00010221528,0.000011373862,0.0001306249,0.0001817654,0.0000100785655,0.0030976846,0.9942624,0.0006028455],"about_ca_topic_score_codex":0.029614093,"about_ca_topic_score_gemma":0.011251407,"teacher_disagreement_score":0.31620714,"about_ca_system_score_codex":0.0010852321,"about_ca_system_score_gemma":0.0026955642,"threshold_uncertainty_score":0.9998046},"labels":[],"label_agreement":null},{"id":"W2916282897","doi":"10.3138/cpp.2018-021","title":"Can Competition and Patent Policies Avert the Antibiotic Crisis?","year":2019,"lang":"en","type":"article","venue":"Canadian Public Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Subsidy; Business; Competition (biology); Competitor analysis; Incentive; Public economics; Antibiotics; Economics; Industrial organization; Economic policy; Market economy; Marketing","score_opus":0.05972796083446977,"score_gpt":0.24416927528542517,"score_spread":0.1844413144509554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916282897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5438049,0.0006768071,0.000006652393,0.3387812,0.00034734554,0.00028974624,0.00089659914,0.000027163882,0.11516958],"genre_scores_gemma":[0.95238155,0.00036606437,0.000008575947,0.046012897,0.0002925978,0.000006029743,0.000027265109,0.000023536813,0.0008815045],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99865335,0.000018474426,0.0003261135,0.00029665596,0.000023239738,0.00068214035],"domain_scores_gemma":[0.998775,0.000034352834,0.00011339549,0.0003769753,0.00002280576,0.0006774425],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029322298,0.00015667711,0.00026357945,0.00058163295,0.00021219811,0.00030934342,0.00030688138,0.00009240335,0.0004920804],"category_scores_gemma":[0.00007879273,0.00015148768,0.000073413496,0.00031900636,0.00011369076,0.00017427455,0.000062406056,0.00017670389,0.00087728666],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[8.5903827e-7,0.00000794607,0.022426046,0.000011897959,0.000027149585,8.934119e-7,0.00022781637,0.000004181992,0.000004535001,0.969269,0.00736579,0.0006539288],"study_design_scores_gemma":[0.0004648341,0.000033542325,0.07422382,0.0000063993816,0.000004197487,0.000021341795,0.00014146762,0.002032669,0.000019008334,0.053557295,0.8691616,0.00033382696],"about_ca_topic_score_codex":0.3523448,"about_ca_topic_score_gemma":0.08714251,"teacher_disagreement_score":0.91571164,"about_ca_system_score_codex":0.00044905118,"about_ca_system_score_gemma":0.00048592963,"threshold_uncertainty_score":0.99990064},"labels":[],"label_agreement":null},{"id":"W2917947737","doi":"","title":"Access Delayed, Access Denied Waiting for New Medicines in Canada 2011 Report","year":2011,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Internet privacy; Business; Computer security; Computer science","score_opus":0.22677063767406186,"score_gpt":0.34039137682998305,"score_spread":0.11362073915592119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2917947737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.69849974,0.00077654346,0.0039061008,0.0069161966,0.0015376079,0.0006947184,0.00016138957,0.00004107904,0.28746662],"genre_scores_gemma":[0.99170786,0.00014557716,0.0005454273,0.005862919,0.00027798215,0.00004475224,0.000020384121,0.000028648892,0.0013664247],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99812526,0.0000049134887,0.0009774698,0.0004110278,0.000023380479,0.0004579646],"domain_scores_gemma":[0.99898815,0.00009332998,0.00035050805,0.00027914633,0.000025316594,0.0002635739],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00042113068,0.00016156668,0.00042536116,0.000184191,0.000051730614,0.000067830006,0.00061636046,0.00006581264,0.0034270613],"category_scores_gemma":[0.00013657335,0.00017535304,0.00006971684,0.00012769339,0.000021245414,0.00048534566,0.00015184011,0.00012222123,0.000062117746],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008491474,0.000048945505,0.77043366,0.000046005156,0.000091808906,0.00006902106,0.00021156525,0.000055361186,0.0000027386595,0.12913013,0.0964589,0.003366941],"study_design_scores_gemma":[0.004984535,0.00008490879,0.3198836,0.000036619243,0.000036464116,0.000104474064,0.0001840122,0.048877385,0.0018551104,0.29862058,0.3237425,0.0015897966],"about_ca_topic_score_codex":0.9604627,"about_ca_topic_score_gemma":0.91046584,"teacher_disagreement_score":0.45055005,"about_ca_system_score_codex":0.00024630863,"about_ca_system_score_gemma":0.0005691456,"threshold_uncertainty_score":0.99748397},"labels":[],"label_agreement":null},{"id":"W2920524859","doi":"10.1007/bf03405283","title":"A Global Call to Action for Science-based Drug Policy","year":2010,"lang":"en","type":"article","venue":"Canadian Journal of Public Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Canadian Public Health Association","funders":"","keywords":"Call to action; Action (physics); Drug; Computer science; Business; Medicine; Pharmacology; Advertising; Physics","score_opus":0.14827468074706104,"score_gpt":0.37566054054880954,"score_spread":0.2273858598017485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920524859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5687793,0.00020450247,0.0077122403,0.40953696,0.002797517,0.0003439746,0.0009778517,0.0000085175,0.009639129],"genre_scores_gemma":[0.96864384,0.000010856022,0.0018021052,0.028553683,0.0008665696,0.0000055085043,0.0000027203018,0.000011215977,0.00010347896],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982523,0.000012490675,0.0006410431,0.00018973005,0.000035993242,0.0008684699],"domain_scores_gemma":[0.99489665,0.0000383166,0.00038755144,0.00018272865,0.00016843426,0.0043263263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003723873,0.0000948987,0.00029042168,0.0011437332,0.0002972638,0.00027279122,0.00047415655,0.000052501255,0.00015196124],"category_scores_gemma":[0.0015131715,0.000109175526,0.00010831983,0.00075349596,0.00014365686,0.0003291202,0.000010514236,0.00021193064,0.00005759785],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007070394,0.000033835186,0.029987346,0.000027613758,0.000016715567,0.0000019081501,0.00043299017,0.0000869871,0.000011800168,0.8905052,0.040028,0.038860567],"study_design_scores_gemma":[0.00050059677,0.00009773729,0.024811883,0.0000045042048,8.807268e-7,0.000017901215,0.000032998774,0.001178166,0.000009660387,0.015632542,0.9575932,0.00011995665],"about_ca_topic_score_codex":0.03706992,"about_ca_topic_score_gemma":0.14560139,"teacher_disagreement_score":0.91756517,"about_ca_system_score_codex":0.0018723523,"about_ca_system_score_gemma":0.018803574,"threshold_uncertainty_score":0.9867589},"labels":[],"label_agreement":null},{"id":"W2921045172","doi":"","title":"Comité régional sur les services pharmaceutiques de Montréal : règlement concernant la composition, la durée du mandat, les modalités d'élection et de nomination [ressource électronique]","year":2008,"lang":"fr","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nomination; Political science","score_opus":0.04320070539307163,"score_gpt":0.2958104670835288,"score_spread":0.2526097616904572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921045172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89548594,0.01565363,0.01543583,0.042645857,0.00036386258,0.00042642772,0.0008684673,0.00011924969,0.029000731],"genre_scores_gemma":[0.9188044,0.07279561,0.0012078884,0.0040337658,0.00046433965,0.00007767244,0.00017236503,0.000064934524,0.002379034],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99714303,0.0004574596,0.00097130495,0.0005821,0.00008063067,0.0007654474],"domain_scores_gemma":[0.9983156,0.0005029956,0.0005333549,0.00022694323,0.0001186124,0.00030253903],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016930471,0.00041667483,0.00056717824,0.00024292331,0.00058346876,0.00019455927,0.00033332172,0.00040990982,0.0011777134],"category_scores_gemma":[0.000032015756,0.0005324785,0.00026673145,0.00015730578,0.00030525983,0.00056739413,0.00015191842,0.0006395043,0.00008586598],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044666216,0.001446512,0.18272147,0.00046967386,0.0006212813,0.000073685485,0.006463221,0.010091911,0.001146419,0.7691833,0.015926972,0.011408902],"study_design_scores_gemma":[0.0023393189,0.000111705216,0.07475307,0.00009658023,0.00005979259,0.00041297026,0.00012359278,0.21624571,0.004242885,0.008965348,0.69202256,0.00062644033],"about_ca_topic_score_codex":0.026397109,"about_ca_topic_score_gemma":0.002509792,"teacher_disagreement_score":0.76021796,"about_ca_system_score_codex":0.0012454139,"about_ca_system_score_gemma":0.0002198263,"threshold_uncertainty_score":0.99973536},"labels":[],"label_agreement":null},{"id":"W2921733062","doi":"10.1503/cmaj.181041","title":"The impact of pharmaceutical rebates on patients’ drug expenditures","year":2019,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Institute of Health Economics; University of Calgary","funders":"","keywords":"Drug; Business; Private insurance; Pharmaceutical industry; Drug industry; Key (lock); Public economics; Health insurance; Pharmacology; Medicine; Computer science; Economics; Health care; Economic growth; Biotechnology; Computer security","score_opus":0.018282389163884492,"score_gpt":0.2842291619788378,"score_spread":0.2659467728149533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921733062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9262137,0.00048144307,0.0000023157916,0.019393437,0.0013733301,0.00013277667,0.00021107281,0.000005522119,0.052186422],"genre_scores_gemma":[0.9927874,0.00045725456,0.000004193932,0.005705362,0.0005082881,0.0000025305976,0.000006364199,0.000013132564,0.0005154591],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99857205,0.000052489686,0.00062046736,0.00013971132,0.00015228908,0.00046298347],"domain_scores_gemma":[0.99809617,0.00037340514,0.00040440055,0.00012295473,0.00007057806,0.00093251787],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0015870953,0.00010764144,0.00025769052,0.0001464305,0.00017527869,0.0001012792,0.0003409784,0.00015379164,0.0080007175],"category_scores_gemma":[0.00074861024,0.000083011015,0.00022535313,0.00008295047,0.00004029867,0.000099808225,0.000018098657,0.00068316114,0.0015405185],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026621938,0.000068584624,0.6218233,0.000004018931,0.00022361976,0.0000049514388,0.00017851124,0.00006417665,0.0000013615819,0.040333156,0.3315545,0.005717196],"study_design_scores_gemma":[0.0014535137,0.00010265602,0.16921937,0.000016305612,0.000004236095,0.0000069733605,0.000043416534,0.0023705056,0.000027583472,0.010465124,0.81611013,0.00018017316],"about_ca_topic_score_codex":0.0016099729,"about_ca_topic_score_gemma":0.0006775292,"teacher_disagreement_score":0.48455563,"about_ca_system_score_codex":0.00093999115,"about_ca_system_score_gemma":0.00044156416,"threshold_uncertainty_score":0.9992369},"labels":[],"label_agreement":null},{"id":"W2925101360","doi":"","title":"Pharmaceutical Prices in the United States, Canada, and Europe : Why Differences Exist and Economic Consequences","year":2019,"lang":"en","type":"dissertation","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Economics; International economics; Political science; International trade; Development economics","score_opus":0.06616721102229767,"score_gpt":0.30039701230579324,"score_spread":0.23422980128349558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2925101360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93135023,0.0035214243,0.0000023757557,0.0041088355,0.00052839617,0.00035598013,0.0006061872,0.0000109378225,0.05951561],"genre_scores_gemma":[0.9695863,0.018312635,0.000022994165,0.009266586,0.00008015569,0.00003308555,0.00054614415,0.00003295803,0.0021191232],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982927,0.000037495127,0.000703124,0.00055485894,0.000035049787,0.00037677435],"domain_scores_gemma":[0.9989439,0.00037137466,0.0003203373,0.00020439902,0.000017239518,0.00014275385],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004344418,0.0003138199,0.0005779166,0.00027627707,0.000097478434,0.00028782888,0.00036288763,0.00014359555,0.00046569743],"category_scores_gemma":[0.00004145287,0.0002675887,0.000035906236,0.000145999,0.00016378234,0.00012961419,0.000045596196,0.00042140798,0.000078772326],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013016119,0.00007745089,0.10219742,0.00050018413,0.00021296354,0.000026630423,0.0021990621,0.00006957198,0.0000065398353,0.87908185,0.0143228695,0.0011753115],"study_design_scores_gemma":[0.001244444,0.00009772928,0.12642555,0.00006663044,0.000045989742,0.000020979154,0.0018703537,0.016902942,0.000038266935,0.028496196,0.8236447,0.0011462077],"about_ca_topic_score_codex":0.638372,"about_ca_topic_score_gemma":0.6848267,"teacher_disagreement_score":0.85058564,"about_ca_system_score_codex":0.00011304816,"about_ca_system_score_gemma":0.0002361809,"threshold_uncertainty_score":0.99997765},"labels":[],"label_agreement":null},{"id":"W2925824047","doi":"","title":"FDA Issues Warning to CanaRx","year":2019,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science; Computer security","score_opus":0.05577438013880978,"score_gpt":0.29738087720839285,"score_spread":0.24160649706958306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2925824047","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.44832194,0.00036493098,0.00019232191,0.01172879,0.00046712212,0.00015482293,0.00003898439,0.000041036066,0.53869003],"genre_scores_gemma":[0.9451955,0.00007133653,0.00061951816,0.012148836,0.00015278725,0.000008277037,0.0000037750583,0.000018561976,0.04178142],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99910873,0.0000035817263,0.00030343095,0.00027925352,0.000011609777,0.0002933851],"domain_scores_gemma":[0.9994902,0.00002425646,0.00006002652,0.00023689965,0.000008728063,0.0001799064],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00021910128,0.00009533326,0.00024476694,0.00019194314,0.000033883847,0.00005810846,0.00018877568,0.0000454479,0.009243815],"category_scores_gemma":[0.000032587945,0.000109265915,0.00006141402,0.000121911864,0.00000912201,0.00011297887,0.00007187301,0.000089970286,0.038487785],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000068457302,0.000020998854,0.06192795,0.000011416692,0.000026699176,8.755945e-7,0.00036060918,0.00030841294,0.000079787394,0.9057324,0.03029435,0.0012296443],"study_design_scores_gemma":[0.00019815874,0.00003274315,0.0046494105,0.000002854995,8.200441e-7,8.754638e-7,0.000022821547,0.0035004076,0.0002650981,0.014146497,0.9769872,0.00019312074],"about_ca_topic_score_codex":0.0013937247,"about_ca_topic_score_gemma":0.00008811518,"teacher_disagreement_score":0.9466928,"about_ca_system_score_codex":0.000068887166,"about_ca_system_score_gemma":0.0000112392945,"threshold_uncertainty_score":0.99166185},"labels":[],"label_agreement":null},{"id":"W2935300031","doi":"10.1001/jama.2019.2280","title":"Canada’s Amendment to Patented Drug Price Regulation","year":2019,"lang":"en","type":"article","venue":"JAMA","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Impact","funders":"","keywords":"Medicine; Amendment; Drug; Drug prices; Pharmacology; Law; Public economics","score_opus":0.028950503740531524,"score_gpt":0.2393885861356744,"score_spread":0.2104380823951429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2935300031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.807454,0.00011172149,0.00008381516,0.030379092,0.00065594126,0.00029747648,0.00021446681,0.000018880826,0.16078463],"genre_scores_gemma":[0.97521156,0.000020191568,0.00011640973,0.016560555,0.0001315956,0.000011609163,0.00001734578,0.000014228246,0.007916493],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99913955,0.000006007484,0.00032808149,0.00025249284,0.000025069254,0.0002488256],"domain_scores_gemma":[0.99945086,0.000025945326,0.00011567061,0.0002306288,0.000016847887,0.000160061],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00020360392,0.00008944342,0.00018937174,0.00008247977,0.00003330078,0.00005632734,0.0001477783,0.00003456653,0.0017544471],"category_scores_gemma":[0.000030983567,0.00010736188,0.00003885573,0.00010712712,0.000005557869,0.00011412089,0.000054199678,0.00008472065,0.0026799042],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006660176,0.000084190775,0.039563414,0.000048735325,0.000075772405,0.000003000451,0.0004419425,0.0016863517,0.00046424332,0.5688286,0.38255063,0.0061865607],"study_design_scores_gemma":[0.00047725666,0.0000140479315,0.051951263,0.0000052953483,0.0000012033523,6.4546555e-7,0.000012435295,0.0040742545,0.00049431686,0.004292686,0.9385149,0.00016171082],"about_ca_topic_score_codex":0.17102207,"about_ca_topic_score_gemma":0.033753067,"teacher_disagreement_score":0.56453586,"about_ca_system_score_codex":0.00036302654,"about_ca_system_score_gemma":0.000089350855,"threshold_uncertainty_score":0.9991581},"labels":[],"label_agreement":null},{"id":"W2943349812","doi":"10.1377/hlthaff.2018.05207","title":"Using External Reference Pricing In Medicare Part D To Reduce Drug Price Differentials With Other Countries","year":2019,"lang":"en","type":"article","venue":"Health Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reference price; Drug prices; Drug pricing; Medicare Part D; Economics; List price; Differential (mechanical device); Brand names; Business; Actuarial science; Monetary economics; Prescription drug; Finance; Microeconomics; Medicine; Advertising; Medical prescription; Pharmacology","score_opus":0.08785879272333032,"score_gpt":0.33781160926171766,"score_spread":0.24995281653838736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943349812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96632653,0.0014442186,0.00091329485,0.0075376565,0.0004826186,0.00069008244,0.00016548173,0.000033372744,0.022406768],"genre_scores_gemma":[0.9927084,0.00030226458,0.0010594772,0.0052510197,0.00015341637,0.00002420791,0.0000043386754,0.000035118053,0.00046177857],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99809283,0.00003385674,0.0007167973,0.000473052,0.000058376,0.0006250641],"domain_scores_gemma":[0.9989053,0.00007350101,0.00034659042,0.00031046686,0.000021086793,0.00034304737],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007343328,0.00018046191,0.0005387391,0.00024274261,0.00007317166,0.000066073204,0.00023285078,0.000063687425,0.0009989329],"category_scores_gemma":[0.000033906806,0.00018279806,0.00003578425,0.00022414955,0.000038296457,0.00016382131,0.000068345864,0.00023537326,0.00064826384],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006219387,0.00037399968,0.5073852,0.0015482053,0.000115494964,0.000012649865,0.012516557,0.002838469,0.00017661687,0.46524015,0.0066052736,0.0025654794],"study_design_scores_gemma":[0.004811898,0.00045380837,0.073301,0.0016995401,0.000011790646,0.000028127411,0.0019447197,0.0104284175,0.000545062,0.009498197,0.89559865,0.0016787996],"about_ca_topic_score_codex":0.0015069252,"about_ca_topic_score_gemma":0.00030208094,"teacher_disagreement_score":0.8889934,"about_ca_system_score_codex":0.0003875863,"about_ca_system_score_gemma":0.0001824335,"threshold_uncertainty_score":0.9999143},"labels":[],"label_agreement":null},{"id":"W2944534256","doi":"10.1007/s40266-019-00679-4","title":"Did Generic Clopidogrel Commercialization Affect Trends of ER Consultations and Hospitalizations in the Population Treated with Clopidogrel?","year":2019,"lang":"en","type":"article","venue":"Drugs & Aging","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Trois-Rivières; The Quebec Population Health Research Network; Institut universitaire de cardiologie et de pneumologie de Québec; Université Laval; Institut National de Santé Publique du Québec","funders":"","keywords":"Clopidogrel; Medicine; Population; Confidence interval; Internal medicine; Emergency medicine; Aspirin; Environmental health","score_opus":0.024673320030101645,"score_gpt":0.2744015478837693,"score_spread":0.24972822785366766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944534256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876654,0.00038508364,0.00032597242,0.0014022113,0.00006945378,0.00021356792,0.00008182982,0.000015233548,0.009841231],"genre_scores_gemma":[0.9987259,0.00017312197,0.00011512015,0.00062625366,0.000033818476,0.000021040281,0.0001793572,0.00001640712,0.00010900385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999188,0.000033820517,0.00037641,0.00021092425,0.000027523873,0.00016333895],"domain_scores_gemma":[0.9994508,0.00009873915,0.00022513619,0.00017091677,0.000020112917,0.00003429919],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025976048,0.00011069015,0.00024337042,0.0003109134,0.00007254847,0.000052584568,0.000099015095,0.00004598062,0.00006672549],"category_scores_gemma":[0.000019441542,0.0000987155,0.000037253874,0.0006171717,0.000046255613,0.00018320378,0.00001992751,0.00007916549,0.000019145695],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000071041686,0.00004417406,0.86347735,0.00002142515,0.000021224638,2.6046595e-7,0.002371349,0.001024699,0.000006428889,0.13081564,0.000113027425,0.0020973114],"study_design_scores_gemma":[0.001099908,0.000051207557,0.9644326,0.000026673391,0.000018099934,0.0000020582265,0.00013630498,0.026336692,0.000020832636,0.0023718118,0.005303608,0.00020017955],"about_ca_topic_score_codex":0.0010243342,"about_ca_topic_score_gemma":0.00012748956,"teacher_disagreement_score":0.12844382,"about_ca_system_score_codex":0.00004356308,"about_ca_system_score_gemma":0.000008626171,"threshold_uncertainty_score":0.40255013},"labels":[],"label_agreement":null},{"id":"W2944574521","doi":"10.1001/jamanetworkopen.2019.3392","title":"Pharmaceutical Industry–Initiated Postapproval Studies—Not Requested by the US FDA, Little Value, and Many Questions","year":2019,"lang":"en","type":"letter","venue":"JAMA Network Open","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University; University of Toronto","funders":"National Health and Medical Research Council; Canadian Institutes of Health Research; Government of Canada; American Diabetes Association; Medical Research Council; Gordon and Betty Moore Foundation","keywords":"Postmarketing surveillance; Pharmaceutical industry; Clinical trial; Medicine; Value (mathematics); Drug industry; Drug approval; Business; Pharmacology; Adverse effect; Engineering; Drug; Computer science; Engineering ethics","score_opus":0.1707176296327443,"score_gpt":0.3700630340247693,"score_spread":0.199345404392025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944574521","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007656403,0.015710128,0.000022624552,0.91144,0.0020699897,0.0019846924,0.002642487,0.00006876007,0.05840488],"genre_scores_gemma":[0.011034392,0.006508574,0.00015303468,0.96026814,0.006300356,0.00023108165,0.00062001764,0.00016514622,0.014719246],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959755,0.00032129194,0.0013209664,0.0011408132,0.000090481655,0.0011509414],"domain_scores_gemma":[0.99699736,0.0009846822,0.00078583864,0.00092841446,0.000086025706,0.00021765588],"candidate_categories":["metaepi_narrow","scholarly_communication","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.002294675,0.0006268435,0.0013597584,0.00013239925,0.00041930494,0.0011649531,0.001614363,0.0017731573,0.0007183744],"category_scores_gemma":[0.00030264963,0.000582204,0.00020025983,0.0003795186,0.00038343758,0.00062877726,0.0013881645,0.005488906,0.0011424517],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006668726,0.000039467795,0.0014257606,0.00007957441,0.0006831396,0.000033790137,0.00007557377,0.00011237818,7.8097963e-7,0.040672217,0.9561526,0.00065800926],"study_design_scores_gemma":[0.0013917042,0.00008044199,0.0012922385,0.00014396982,0.00010580898,0.000042716583,0.000013408628,0.00575698,0.0000053851813,0.013227352,0.97719663,0.0007433465],"about_ca_topic_score_codex":0.00063025043,"about_ca_topic_score_gemma":0.0000090161,"teacher_disagreement_score":0.048828118,"about_ca_system_score_codex":0.00030903102,"about_ca_system_score_gemma":0.00012840347,"threshold_uncertainty_score":0.9998719},"labels":[],"label_agreement":null},{"id":"W2945189225","doi":"10.4324/9780429439186-8","title":"Regional trade agreements, TRIPS-plus provisions and the African access to medicines conundrum","year":2019,"lang":"en","type":"book-chapter","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"TRIPS architecture; Access to medicines; International trade; Regional trade; TRIPS Agreement; Business; Political science; Intellectual property; Free trade; Law; Computer science","score_opus":0.12219970398366592,"score_gpt":0.3098346432104223,"score_spread":0.1876349392267564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945189225","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007354763,0.0022879336,0.00013051089,0.13369414,0.0004899936,0.0011727585,0.00043659905,0.000024918341,0.86168957],"genre_scores_gemma":[0.03910644,0.0073036905,0.00011930824,0.11039379,0.001070262,0.00009331087,0.00010027643,0.00013899607,0.8416739],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99802434,0.000009271101,0.0008861393,0.00065254193,0.000060450333,0.0003672421],"domain_scores_gemma":[0.99843675,0.0002839324,0.00043495605,0.0005262119,0.000018599048,0.00029954413],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00052283367,0.0003718627,0.0009901328,0.0003094809,0.00013163555,0.000207611,0.00068441516,0.00022421962,0.0027384392],"category_scores_gemma":[0.000057130164,0.00028778758,0.00021865605,0.000053611566,0.0003082273,0.0001498539,0.00033695006,0.00038879522,0.0010233191],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008624811,0.000009236368,0.00004952738,0.000030642997,0.00013747606,0.000001307895,0.0001508111,0.000006274344,2.0654157e-7,0.8651448,0.13280962,0.0015738562],"study_design_scores_gemma":[0.0018556968,0.000048586156,0.00022130975,0.000033305256,0.000030573272,0.000006469352,0.000016684866,0.00079063704,0.0000010443354,0.13003603,0.8666115,0.0003482057],"about_ca_topic_score_codex":0.00014921169,"about_ca_topic_score_gemma":0.000096100965,"teacher_disagreement_score":0.73510873,"about_ca_system_score_codex":0.00013507924,"about_ca_system_score_gemma":0.00010773435,"threshold_uncertainty_score":0.99995744},"labels":[],"label_agreement":null},{"id":"W2946348981","doi":"10.1016/s2214-109x(19)30039-7","title":"The AEIOU of essential diagnostics: align, expand, implement, oversee, and update","year":2019,"lang":"en","type":"article","venue":"The Lancet Global Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Montreal Children's Hospital","funders":"","keywords":"Medical diagnosis; Scopus; Medicine; Diagnostic test; Health care; Family medicine; MEDLINE; Alternative medicine; Medical emergency; Political science; Pediatrics; Pathology","score_opus":0.039620463568611444,"score_gpt":0.35076239487999494,"score_spread":0.3111419313113835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946348981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84729373,0.015615996,0.00017519183,0.09067638,0.0013398028,0.0008404824,0.003403121,0.000033065462,0.040622197],"genre_scores_gemma":[0.9605606,0.027512662,0.000048101796,0.01148561,0.00029549663,0.000008836679,0.000012176904,0.000008491319,0.00006800129],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987621,0.000033305467,0.000501377,0.00021060949,0.00003027271,0.0004623561],"domain_scores_gemma":[0.99896574,0.00015786121,0.00035132095,0.00040057563,0.000012520719,0.00011200651],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094155286,0.00010882472,0.00039961448,0.000017337941,0.00015416191,0.00005637145,0.00032254733,0.0000347609,0.00015594873],"category_scores_gemma":[0.000042429394,0.00007881561,0.00005936453,0.000097238684,0.00009002221,0.0000635824,0.00014977512,0.0001057316,0.00032166546],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045374825,0.000019292767,0.042185113,0.000032483153,0.0000447219,2.1068787e-7,0.000080207414,0.000008158791,0.0000011985302,0.93018174,0.0248139,0.0025876043],"study_design_scores_gemma":[0.0013054736,0.000092887036,0.07175477,0.0000125972965,0.0000058099436,0.000004189143,0.00006724101,0.00094181154,0.00001858767,0.15351912,0.77213347,0.00014404279],"about_ca_topic_score_codex":0.00076433195,"about_ca_topic_score_gemma":0.0002069986,"teacher_disagreement_score":0.7766626,"about_ca_system_score_codex":0.000093954084,"about_ca_system_score_gemma":0.00005560831,"threshold_uncertainty_score":0.4134466},"labels":[],"label_agreement":null},{"id":"W2951842580","doi":"10.1093/ajhp/zxz109","title":"National trends in prescription drug expenditures and projections for 2019","year":2019,"lang":"en","type":"article","venue":"American Journal of Health-System Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Drug Policy Research Network; Women's College Hospital","funders":"Eisai","keywords":"Medical prescription; Prescription drug; Specialty; Medicine; Drug; Business; Family medicine; Pharmacology","score_opus":0.05982580759082185,"score_gpt":0.3604819375848714,"score_spread":0.30065612999404956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951842580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93476355,0.007558731,0.0009185704,0.04389052,0.0025837948,0.0008763682,0.000648748,0.000028528255,0.0087312],"genre_scores_gemma":[0.9973189,0.00039604207,0.00037988898,0.0013559599,0.00021882493,0.000022816996,0.000008327295,0.000018796722,0.00028040426],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99828947,0.00006224925,0.0011152059,0.0002062034,0.000049914677,0.00027693767],"domain_scores_gemma":[0.9984066,0.000102648715,0.0012149591,0.000081856306,0.00004760096,0.00014632862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014949921,0.00012035134,0.00056812,0.0007258305,0.000069968904,0.000046116336,0.0001419691,0.00001678879,0.00008366187],"category_scores_gemma":[0.00001880069,0.00012804296,0.00011883509,0.00018347772,0.000045083976,0.00032983962,0.00002007107,0.00019142588,0.00003535565],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013688888,0.00082329364,0.26260853,0.001003012,0.0005573016,0.0000068907193,0.005946828,0.0024027023,0.00031484535,0.2772617,0.13367864,0.31402737],"study_design_scores_gemma":[0.0069678165,0.000626348,0.040735103,0.00013814148,0.000013192408,0.00020710652,0.0010076764,0.028388096,0.00008275641,0.0029258963,0.9184384,0.00046948457],"about_ca_topic_score_codex":0.00090735,"about_ca_topic_score_gemma":0.000020194871,"teacher_disagreement_score":0.78475976,"about_ca_system_score_codex":0.00036870793,"about_ca_system_score_gemma":0.00012734953,"threshold_uncertainty_score":0.522144},"labels":[],"label_agreement":null},{"id":"W2952092910","doi":"","title":"Brevet Pharmaceutique: le critère de l’utilité canadien – fluctuations et divergences","year":2019,"lang":"fr","type":"article","venue":"Les Cahiers de propriété intellectuelle","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Humanities; Philosophy","score_opus":0.032137349166446116,"score_gpt":0.28494104439376855,"score_spread":0.25280369522732243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952092910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70437855,0.042646114,0.008100787,0.04791415,0.0035274362,0.0011360012,0.0011721643,0.000104825674,0.19101995],"genre_scores_gemma":[0.86082107,0.01445666,0.0017890466,0.01086493,0.00030897962,0.00007745046,0.0000513608,0.000100661986,0.11152984],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963983,0.00025853302,0.0009800364,0.0008632491,0.00007642118,0.0014234451],"domain_scores_gemma":[0.9978616,0.0005180358,0.0003628345,0.00055658567,0.000098342556,0.00060256344],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0018526431,0.00047119107,0.0007394493,0.00038977744,0.0004631715,0.00023505141,0.0008009692,0.00068285264,0.012810957],"category_scores_gemma":[0.0006317632,0.00063463434,0.000398209,0.0005346221,0.0006311393,0.00043214837,0.00021397302,0.0015349538,0.0028177076],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020028139,0.0005137644,0.03265601,0.00067509385,0.00072258955,0.000037274905,0.021877851,0.0035874748,0.0006472605,0.8361816,0.059775643,0.043125186],"study_design_scores_gemma":[0.0009778959,0.00015972948,0.001482739,0.00007263149,0.000049949445,0.00006842805,0.00085164007,0.08511427,0.0026798965,0.064876504,0.84290004,0.0007662855],"about_ca_topic_score_codex":0.01318685,"about_ca_topic_score_gemma":0.0020861458,"teacher_disagreement_score":0.7831244,"about_ca_system_score_codex":0.0017717442,"about_ca_system_score_gemma":0.00086062116,"threshold_uncertainty_score":0.9996105},"labels":[],"label_agreement":null},{"id":"W2952840127","doi":"10.1093/ndt/gfz103.sp677","title":"SP677IMPLEMENTING A PATIENT-REPORTED OUTCOME MEASURE FOR HEMODIALYSIS PATIENTS IN ROUTINE CLINICAL CARE: PERSPECTIVES OF PATIENTS AND CLINICIANS","year":2019,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; London Health Sciences Centre; Ontario Stroke Network","funders":"","keywords":"Medicine; Hemodialysis; Intensive care medicine; Patient-reported outcome; MEDLINE; Measure (data warehouse); Quality of life (healthcare); Surgery; Nursing","score_opus":0.0530823228496729,"score_gpt":0.32524749755570087,"score_spread":0.27216517470602797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952840127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969707,0.00016168592,0.0003432107,0.00021558329,0.00022958247,0.0007415534,0.00070696586,0.000012378618,0.0006183176],"genre_scores_gemma":[0.9981228,0.00032836167,0.00032148,0.0006636003,0.000044000975,0.000045161618,0.00044828237,0.000020986781,0.000005304024],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970686,0.00008341129,0.0019458673,0.00055045297,0.000047288435,0.0003043888],"domain_scores_gemma":[0.9984199,0.00031929804,0.0008652998,0.00019478913,0.00012721676,0.000073519506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076052366,0.00017576524,0.00083117594,0.00035907087,0.000049120667,0.000017019327,0.000111653884,0.0001960518,0.00007191347],"category_scores_gemma":[0.00017896734,0.00020414765,0.00027785441,0.00020385583,0.00007331198,0.0001700939,0.000020784248,0.00015411501,0.000016815527],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000392179,0.00028669738,0.9896885,0.00007805616,0.00020976969,3.521011e-7,0.004008135,0.00006632225,0.000008590451,0.00168268,0.000012859013,0.0035658586],"study_design_scores_gemma":[0.007972559,0.00032140486,0.98811376,0.000006686978,0.00017969216,1.7826764e-7,0.00031661693,0.0010452231,0.000034129618,0.0009338836,0.0008612256,0.00021461297],"about_ca_topic_score_codex":0.00020340795,"about_ca_topic_score_gemma":0.0003652732,"teacher_disagreement_score":0.00758038,"about_ca_system_score_codex":0.00006774204,"about_ca_system_score_gemma":0.000020871676,"threshold_uncertainty_score":0.83248997},"labels":[],"label_agreement":null},{"id":"W2952893943","doi":"10.4324/9781315677972-9","title":"The Price of Exclusivity","year":2017,"lang":"en","type":"book-chapter","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Economics; Business","score_opus":0.09984760495861708,"score_gpt":0.29264391056409844,"score_spread":0.19279630560548136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952893943","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000027360973,0.0029556507,0.00007273227,0.002199211,0.0005054326,0.00015657143,0.00031953395,0.000012197892,0.9937513],"genre_scores_gemma":[0.016426843,0.0060247607,0.000047343783,0.0006644266,0.00028504062,0.000004955616,0.0000066252255,0.000040950687,0.9764991],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988349,0.0000021127435,0.00063245464,0.00028546882,0.000021075057,0.00022397697],"domain_scores_gemma":[0.99792176,0.0001352023,0.00096674036,0.0008549088,0.000027227225,0.00009418401],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00051309686,0.00019133113,0.0005092951,0.00007508375,0.00022536183,0.000085348554,0.000679457,0.00021110968,0.002061391],"category_scores_gemma":[0.00008202603,0.0001657585,0.0002570834,0.000004850791,0.00024097206,0.000073056515,0.00023692149,0.00026927312,0.0019786656],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00000565835,0.000006140285,0.00004035421,0.00001753915,0.0000781916,6.562812e-7,0.000013897402,7.6193425e-7,4.6198045e-7,0.985405,0.011731755,0.0026995416],"study_design_scores_gemma":[0.000083637664,0.000009512235,0.00009282539,0.000006505417,0.0000036922677,7.3965094e-7,2.9541798e-7,0.00010420686,0.000007235267,0.40136698,0.59820366,0.00012069106],"about_ca_topic_score_codex":0.00007399306,"about_ca_topic_score_gemma":0.000045540335,"teacher_disagreement_score":0.5864719,"about_ca_system_score_codex":0.000063305626,"about_ca_system_score_gemma":0.000039903243,"threshold_uncertainty_score":0.9988509},"labels":[],"label_agreement":null},{"id":"W2953069276","doi":"10.1016/j.jhealeco.2019.102228","title":"Medical innovation, education, and labor market outcomes of cancer patients","year":2019,"lang":"en","type":"article","venue":"Journal of Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Statistics Canada","funders":"W.E. Upjohn Institute for Employment Research","keywords":"Medicine; Cancer; Prostate cancer; Breast cancer; Educational attainment; Cancer registry; Economics; Internal medicine; Economic growth","score_opus":0.033604685302864666,"score_gpt":0.34833318741701724,"score_spread":0.3147285021141526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953069276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9752882,0.0032935427,0.00000816984,0.016507132,0.0015122348,0.00014175953,0.00014625191,0.0000021992455,0.0031004716],"genre_scores_gemma":[0.9775376,0.007369951,0.00028336217,0.014275358,0.00014315218,0.0000038103765,0.0000048621387,0.000018239054,0.00036369776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976091,0.000019283634,0.0020018152,0.00014686625,0.00003001776,0.00019291062],"domain_scores_gemma":[0.997265,0.000078478166,0.0021956032,0.00013442241,0.00015949251,0.00016701558],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013603915,0.000106129395,0.00067432673,0.00037499174,0.000034697125,0.0000225834,0.00019894577,0.000085104766,0.0015637843],"category_scores_gemma":[0.00021227257,0.00011086106,0.000065900094,0.00013714987,0.000042012478,0.00024800748,0.000043833632,0.00018491849,0.00003126357],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001597422,0.00016447436,0.8994383,0.00008084272,0.00006678037,4.1060073e-8,0.000117323776,0.000011905687,1.7166305e-7,0.08548923,0.0048245373,0.009790405],"study_design_scores_gemma":[0.0011026992,0.00011029644,0.8160677,0.000032334458,0.0000035956537,0.0000028521988,0.00003019517,0.0004258318,0.000006667495,0.020657698,0.16144677,0.000113360446],"about_ca_topic_score_codex":0.00020390772,"about_ca_topic_score_gemma":0.000024090947,"teacher_disagreement_score":0.15662223,"about_ca_system_score_codex":0.00018864677,"about_ca_system_score_gemma":0.0007997608,"threshold_uncertainty_score":0.99934894},"labels":[],"label_agreement":null},{"id":"W2953974800","doi":"10.1016/j.jval.2019.04.739","title":"PDG60 DID CITIZEN PETITIONS PROLONG THE NUMBER OF APPROVAL DAYS OF GENERIC DRUGS?","year":2019,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Medicine; Value (mathematics); Food and drug administration; Pharmacology; Geography; Statistics; Mathematics","score_opus":0.07224846029655808,"score_gpt":0.3052642194823649,"score_spread":0.2330157591858068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953974800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9473473,0.00082040887,0.00004411976,0.0041111847,0.0002885191,0.00041046634,0.00023272447,0.000007612322,0.046737682],"genre_scores_gemma":[0.99752074,0.00070400134,0.00039052122,0.0010234992,0.000075176984,0.000021607,0.000008584399,0.000015991023,0.00023989227],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99860895,0.000046687608,0.00081602146,0.00021888755,0.000028995324,0.00028046107],"domain_scores_gemma":[0.9990147,0.00013744067,0.00043769236,0.0003232725,0.00001505978,0.00007184434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010017466,0.000091185146,0.00039774834,0.000109266184,0.00003640859,0.000010265231,0.00023587882,0.00005293931,0.0004605272],"category_scores_gemma":[0.00004161422,0.00008720073,0.000095262345,0.00023897097,0.000073333016,0.00006522207,0.000060879607,0.00016716144,0.00029983508],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018832852,0.00013333035,0.12472758,0.00032598904,0.000026731914,2.410613e-7,0.0012580055,0.0049613803,0.000016406217,0.8673815,0.00047010908,0.0006799123],"study_design_scores_gemma":[0.004184293,0.0003677929,0.18904105,0.0002550985,0.000014369772,0.000022449876,0.00053375115,0.22100623,0.00045938478,0.40162235,0.18163122,0.0008619969],"about_ca_topic_score_codex":0.002450069,"about_ca_topic_score_gemma":0.000009105116,"teacher_disagreement_score":0.46575913,"about_ca_system_score_codex":0.00009007742,"about_ca_system_score_gemma":0.00009840478,"threshold_uncertainty_score":0.504245},"labels":[],"label_agreement":null},{"id":"W2956015350","doi":"10.1016/j.jval.2019.04.766","title":"PDG87 DRUG UTILIZATION IN PERSISTENT NAMD PATIENTS TREATED WITH LICENSED ANTI-VEGFS IN CANADA: A REAL WORLD STUDY USING THE ONTARIO PUBLIC CLAIMS DATABASE","year":2019,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Aflibercept; Ranibizumab; Medicine; Cohort; Macular degeneration; Retrospective cohort study; Dosing; Cohort study; Medical prescription; Bevacizumab; Pediatrics; Internal medicine; Pro re nata; Ophthalmology; Pharmacology; Chemotherapy","score_opus":0.20157718155231333,"score_gpt":0.2979772143020565,"score_spread":0.09640003274974315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956015350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961997,0.00013616575,0.0000012110831,0.0009932915,0.0001734999,0.0012121224,0.00013093198,0.0000059794056,0.0011470972],"genre_scores_gemma":[0.9986816,0.0001175031,0.000025837657,0.0009461793,0.00001734122,0.000019453448,0.000059835496,0.000022270573,0.00010997549],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979243,0.00013208979,0.00089348404,0.00045123868,0.00006287692,0.0005359817],"domain_scores_gemma":[0.9990577,0.000083804494,0.00033348138,0.00036121285,0.000020282465,0.00014349792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009553723,0.00017064196,0.00047586288,0.0004902526,0.000069745,0.000051448762,0.00021874678,0.00002975403,0.00010825193],"category_scores_gemma":[0.000018588917,0.00015906028,0.00003402515,0.000756219,0.000020597454,0.00021279759,0.000062905536,0.0003457126,0.000015525331],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000052424064,0.0003577633,0.9869727,0.000029748247,0.000015056969,0.0000036654276,0.002560149,0.008321365,1.5389936e-7,0.001537138,0.000037250033,0.00011262037],"study_design_scores_gemma":[0.002833626,0.00010985748,0.8752036,0.00006399257,0.0000026544676,5.5813626e-7,0.0005451761,0.11867503,8.114887e-7,0.000055922028,0.002312829,0.00019592939],"about_ca_topic_score_codex":0.9971488,"about_ca_topic_score_gemma":0.99795306,"teacher_disagreement_score":0.11176906,"about_ca_system_score_codex":0.0057225754,"about_ca_system_score_gemma":0.0014552698,"threshold_uncertainty_score":0.99809426},"labels":[],"label_agreement":null},{"id":"W2959633209","doi":"10.1016/s1470-2045(19)30459-0","title":"Improving affordability of new Essential Cancer Medicines","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Public Health Ontario","funders":"","keywords":"Essential medicines; Business; Access to medicines; Investment (military); Workforce; Quality (philosophy); Low and middle income countries; Supply chain; Cancer drugs; Medicine; Health care; Cancer; Economic growth; Developing country; Marketing; Nursing; Public health; Political science; Economics","score_opus":0.08620239956862087,"score_gpt":0.3603103379768915,"score_spread":0.27410793840827063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2959633209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.906022,0.0014620711,0.0002242099,0.031075407,0.0014052602,0.00023945868,0.00008818429,0.000018510686,0.05946488],"genre_scores_gemma":[0.9929344,0.00048561188,0.00018249913,0.004374633,0.0011341488,0.000011049198,0.000002758122,0.000010805203,0.0008641076],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990865,0.000021870412,0.00040897037,0.00019842837,0.000015939255,0.00026830204],"domain_scores_gemma":[0.9991373,0.0001366479,0.00031323393,0.00033268894,0.000014181116,0.00006595186],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007376635,0.00008516996,0.0005552163,0.000044451255,0.000027933449,0.0000084953635,0.00033620044,0.00008076758,0.0024153974],"category_scores_gemma":[0.00007263185,0.00006842923,0.00007523077,0.00008805793,0.00010286015,0.000060029048,0.00009396695,0.0001690304,0.00031693594],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004268916,0.00017436969,0.2302528,0.00027798535,0.00022631178,0.0000016498941,0.0019924399,0.00042460105,0.0030034839,0.6823355,0.03972759,0.041156366],"study_design_scores_gemma":[0.002928004,0.00020671549,0.031844888,0.000011062979,0.000021855565,0.000004595723,0.00006571269,0.0070486255,0.0013143008,0.099344335,0.85698617,0.00022371892],"about_ca_topic_score_codex":0.0019928506,"about_ca_topic_score_gemma":0.0002257174,"teacher_disagreement_score":0.8172586,"about_ca_system_score_codex":0.00009538725,"about_ca_system_score_gemma":0.00010754612,"threshold_uncertainty_score":0.99849653},"labels":[],"label_agreement":null},{"id":"W2959919038","doi":"","title":"Drug Product Registration in US, EUROPE, JAPAN and CANADA for New Drug and Generics","year":2014,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Product (mathematics); Business; Drug approval; Approved drug; Marketing; Drug development; Medicine; Pharmacology","score_opus":0.03460662745522742,"score_gpt":0.23820609364860984,"score_spread":0.20359946619338243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2959919038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9552278,0.0007725159,0.00032532474,0.016518777,0.0002045902,0.00025759448,0.000055860615,0.0000100821035,0.026627436],"genre_scores_gemma":[0.98678416,0.00052157737,0.0008974329,0.0046818145,0.00023278943,0.0000042793336,0.000012585288,0.000016023689,0.006849336],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991885,0.0000069946777,0.00031563608,0.0002940517,0.000010634749,0.00018421766],"domain_scores_gemma":[0.99957603,0.000047900372,0.00009949911,0.0001348009,0.000011362786,0.00013037857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034590645,0.00009204733,0.00019313282,0.000058706497,0.000043217828,0.00006460729,0.000065811626,0.000018172192,0.000027358572],"category_scores_gemma":[0.00009691698,0.00010416602,0.000012865604,0.00006434318,0.000023023245,0.00010690212,0.00002901119,0.00006031109,0.0000055978417],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023176644,0.000029552897,0.1517823,0.000085780746,0.000019680387,4.6316885e-7,0.00031176704,0.00013068362,0.000032403652,0.6165861,0.22218905,0.008809049],"study_design_scores_gemma":[0.00061744574,0.000014078266,0.046680912,0.000003140524,0.0000026035943,0.0000020698712,0.000011524542,0.017762767,0.00015499412,0.0131837595,0.92135537,0.0002113574],"about_ca_topic_score_codex":0.3400138,"about_ca_topic_score_gemma":0.6011639,"teacher_disagreement_score":0.6991663,"about_ca_system_score_codex":0.00004180394,"about_ca_system_score_gemma":0.00007937083,"threshold_uncertainty_score":0.6643811},"labels":[],"label_agreement":null},{"id":"W2965709677","doi":"10.1016/j.gheart.2019.07.008","title":"Access to Essential Medicines for Circulatory Diseases: A Call to Action","year":2019,"lang":"en","type":"letter","venue":"Global Heart","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"World Heart Federation; Sanofi","keywords":"Medicine; Checklist; Observational study; Global health; Call to action; Strengthening the reporting of observational studies in epidemiology; Alternative medicine; Download; Family medicine; Systematic review; Medical education; Public health; MEDLINE; Pathology; Political science; Business; Psychology; Computer science; World Wide Web","score_opus":0.08889832200331568,"score_gpt":0.3729764602790041,"score_spread":0.2840781382756884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965709677","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0068915603,0.00056155754,0.00139997,0.9648399,0.006392122,0.0018999848,0.01056595,0.00007425876,0.007374739],"genre_scores_gemma":[0.015343658,0.00003515493,0.00010336316,0.97435373,0.008559182,0.00021475468,0.00032913405,0.00005414647,0.0010068994],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978142,0.000013768237,0.00062637345,0.0008186248,0.000058397593,0.000668662],"domain_scores_gemma":[0.9988626,0.00008022548,0.00017358895,0.000515052,0.00004886039,0.00031967473],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001788471,0.00031896762,0.00080159184,0.00021875375,0.00008006831,0.00021313714,0.000527562,0.0004326135,0.0003576034],"category_scores_gemma":[0.00012996087,0.00038502534,0.00032683165,0.00021947287,0.000031458756,0.0001862583,0.00019023556,0.0003322691,0.004083771],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000038314123,0.00002347113,0.003566713,0.00021876929,0.000065665234,0.000003428847,0.00001306496,0.00006474411,0.000002269312,0.0014362965,0.99428856,0.00027870302],"study_design_scores_gemma":[0.00042853304,0.00007145593,0.006377408,0.000035558074,0.000030259396,0.0000054053016,0.0000014594365,0.00031661105,0.000004639598,0.005205677,0.98708695,0.00043604992],"about_ca_topic_score_codex":0.0003815082,"about_ca_topic_score_gemma":0.000038148344,"teacher_disagreement_score":0.010236816,"about_ca_system_score_codex":0.0005402101,"about_ca_system_score_gemma":0.000112870795,"threshold_uncertainty_score":0.99986017},"labels":[],"label_agreement":null},{"id":"W2967833784","doi":"10.1371/journal.pone.0220781","title":"Selection of WHO-recommended essential medicines for non-communicable diseases on National Essential Medicines Lists","year":2019,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"Essential medicines; Medicine; Selection (genetic algorithm); MEDLINE; Traditional medicine; Biology; Public health; Computer science","score_opus":0.06477105250715584,"score_gpt":0.30091967244005324,"score_spread":0.2361486199328974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967833784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9548466,0.0003220508,0.00016376535,0.0107291965,0.00050338375,0.00083138567,0.00082585594,0.00004009583,0.031737667],"genre_scores_gemma":[0.99575204,0.0003571024,0.0003175889,0.0018615985,0.0006768639,0.00006379865,0.000120372424,0.000028430592,0.00082221505],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9987894,0.00001413281,0.000580938,0.0002846783,0.000083028484,0.00024778408],"domain_scores_gemma":[0.9989441,0.00029184588,0.00032596337,0.00021689406,0.00010999112,0.0001111804],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031415655,0.00014888424,0.00061446417,0.00024234307,0.000076874916,0.000026206995,0.00024944585,0.0000867043,0.001295011],"category_scores_gemma":[0.00022591319,0.00016369588,0.0001233039,0.00014920729,0.000056346482,0.00015377221,0.0000566409,0.00013372197,0.00018479374],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024733793,0.014387889,0.24332577,0.0038336108,0.0046964884,0.0000015708877,0.001067725,0.00065119955,0.030114459,0.5952383,0.10302533,0.0011842465],"study_design_scores_gemma":[0.024416253,0.0028879538,0.07355588,0.001208958,0.00065939844,0.0000050220883,0.00012670069,0.49339938,0.13184997,0.19969016,0.069853686,0.0023466311],"about_ca_topic_score_codex":0.00006268891,"about_ca_topic_score_gemma":0.000019634674,"teacher_disagreement_score":0.49274817,"about_ca_system_score_codex":0.00008204784,"about_ca_system_score_gemma":0.000050645747,"threshold_uncertainty_score":0.99961793},"labels":[],"label_agreement":null},{"id":"W2969793212","doi":"10.1016/s2468-2667(19)30165-3","title":"Essential medicines and essential diagnostics: a package deal","year":2019,"lang":"en","type":"letter","venue":"The Lancet Public Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Essential medicines; Medicine; Family medicine; Public health; Nursing","score_opus":0.10184946357700442,"score_gpt":0.3273830573798961,"score_spread":0.22553359380289167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969793212","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018914061,0.006728283,0.00033497452,0.97418565,0.0017896233,0.0005645215,0.0015281024,0.00006792795,0.012909499],"genre_scores_gemma":[0.0124863535,0.016741551,0.00007336702,0.94592583,0.023016097,0.000052502113,0.00044366668,0.000088313616,0.001172346],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996674,0.00014436294,0.0010177847,0.00071171054,0.00008841256,0.0013637057],"domain_scores_gemma":[0.997324,0.0006935862,0.0008149292,0.000880231,0.000033885917,0.00025339593],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002169084,0.00039719313,0.0015009015,0.00026840766,0.00023465561,0.00036188654,0.0008236233,0.00046879213,0.0007110054],"category_scores_gemma":[0.0003380335,0.00033786203,0.00015447389,0.00018740346,0.00028781345,0.00018019462,0.00028261018,0.001926302,0.0011084375],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000053903436,0.000021026868,0.0011777601,0.0003527514,0.00011036475,0.000012315828,0.00032050663,5.2090974e-7,2.1480605e-7,0.035808682,0.96102554,0.0011649568],"study_design_scores_gemma":[0.00084629224,0.00005733406,0.0010111793,0.000034497578,0.000011108527,0.000022817403,0.000012006829,0.00041381537,8.0046505e-7,0.0116013065,0.98564017,0.0003487036],"about_ca_topic_score_codex":0.0007300853,"about_ca_topic_score_gemma":0.000057242625,"teacher_disagreement_score":0.02825986,"about_ca_system_score_codex":0.00018191997,"about_ca_system_score_gemma":0.0003648089,"threshold_uncertainty_score":0.9999073},"labels":[],"label_agreement":null},{"id":"W2970343731","doi":"10.1200/jco.2007.25.18_suppl.6612","title":"The utilization of new oncology drugs: A global perspective","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Vintage; Cancer; Cancer drugs; Drug; Demography; Environmental health; Internal medicine; Pharmacology; Geography","score_opus":0.3505697983439747,"score_gpt":0.5386506553253644,"score_spread":0.18808085698138965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970343731","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3065338,0.009470615,0.008585136,0.062360674,0.007055943,0.0002652997,0.000047491303,0.000010871763,0.60567015],"genre_scores_gemma":[0.9885485,0.003849465,0.0013317389,0.0042842277,0.0016462844,5.543704e-7,4.859049e-7,0.000009600898,0.00032912826],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958754,0.00009993268,0.0035207474,0.00016693491,0.000048704962,0.00028828395],"domain_scores_gemma":[0.99314636,0.0023717505,0.0037271185,0.00016442873,0.0002305096,0.00035983126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0088026,0.000100018035,0.0010632302,0.000089607376,0.000059717797,0.00001425818,0.000402858,0.00034250502,0.00015650257],"category_scores_gemma":[0.0042246617,0.000078992314,0.00046858925,0.00020165074,0.00029726556,0.00012327074,0.00007141875,0.00053632545,0.00008424875],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010986257,0.00048000875,0.014870202,0.0000034527695,0.0002567594,0.000015809694,0.0004025397,0.000028846871,0.0000017941629,0.7701917,0.01193628,0.20071395],"study_design_scores_gemma":[0.00216357,0.001699768,0.036826853,0.0000044431536,0.000023912007,0.000028254899,0.0004653458,0.00024686023,0.0000134080665,0.23269199,0.7257651,0.000070507755],"about_ca_topic_score_codex":0.00017885369,"about_ca_topic_score_gemma":0.00021074727,"teacher_disagreement_score":0.7138288,"about_ca_system_score_codex":0.00068931095,"about_ca_system_score_gemma":0.0010495546,"threshold_uncertainty_score":0.50576204},"labels":[],"label_agreement":null},{"id":"W2971990713","doi":"10.1186/s40545-019-0187-9","title":"Assessing national governance of medicine promotion: an exploratory study in Ghana to trial a structured set of indicators","year":2019,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Policy and Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Global Health Research; Public Health Ontario; University of Toronto","funders":"","keywords":"Transparency (behavior); Accountability; Corporate governance; Promotion (chess); Business; Good governance; Essential medicines; Medical prescription; Medicine; Desk; Public relations; Public health; Nursing; Political science; Finance","score_opus":0.21834318702432393,"score_gpt":0.4694165047824969,"score_spread":0.251073317758173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971990713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97853154,0.00049388275,0.000051174757,0.013891424,0.0004047599,0.00045895015,0.00006647193,0.0000027067251,0.006099106],"genre_scores_gemma":[0.9966072,0.00017503247,0.00037058987,0.0020615833,0.0007514694,0.0000041261733,0.0000012273026,0.000014080567,0.00001468565],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976592,0.00026234225,0.0014618783,0.00022112606,0.00017931544,0.00021614354],"domain_scores_gemma":[0.99705595,0.0008116948,0.0015628726,0.00013701594,0.00014202224,0.00029043312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004522089,0.00014599181,0.0006672985,0.0006332534,0.000029447705,0.000036990878,0.00025254334,0.000086132684,0.00025422245],"category_scores_gemma":[0.0035470473,0.00014103336,0.00006649139,0.00060091546,0.00011682748,0.001402191,0.00006993444,0.0004420802,0.00000889936],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05460266,0.0070666336,0.04033011,0.0006914495,0.0012917988,0.00008570282,0.034040835,0.0009764303,0.0054092114,0.82652444,0.0014398469,0.027540883],"study_design_scores_gemma":[0.34748152,0.031133305,0.14539644,0.0008367656,0.0006626983,0.0008153414,0.022817846,0.00989688,0.006818785,0.14692728,0.28452423,0.0026889117],"about_ca_topic_score_codex":0.00007011076,"about_ca_topic_score_gemma":0.00000913383,"teacher_disagreement_score":0.67959714,"about_ca_system_score_codex":0.00015481733,"about_ca_system_score_gemma":0.00025942468,"threshold_uncertainty_score":0.57511735},"labels":[],"label_agreement":null},{"id":"W2972150441","doi":"10.1080/21556660.2019.1658313","title":"Understanding purchasing patterns and product access of newly launched specialty generics","year":2019,"lang":"en","type":"article","venue":"Journal of Drug Assessment","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Product (mathematics); Purchasing; Pharmacy; Launched; Specialty; Marketing; Business; Medicine; Advertising; Family medicine; Engineering","score_opus":0.16158098750113523,"score_gpt":0.3508699535733115,"score_spread":0.1892889660721763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972150441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97610503,0.0005194651,0.007898462,0.0042520724,0.0008879787,0.00014983221,0.000050000854,0.000003418903,0.010133765],"genre_scores_gemma":[0.9972143,0.00094990944,0.0009836487,0.0004213209,0.0003406517,7.449289e-7,0.0000014552356,0.000015867925,0.00007209337],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987156,0.000020388323,0.00083214464,0.0001753398,0.00005902024,0.00019754747],"domain_scores_gemma":[0.9985746,0.00006480782,0.0010400565,0.00015737549,0.000040538784,0.00012257847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009508028,0.000114421775,0.00048207174,0.00023798416,0.00003765443,0.00011943975,0.00023735146,0.000033628014,0.00023994996],"category_scores_gemma":[0.000026949641,0.000116315474,0.00010880247,0.000111359135,0.00003091296,0.00040595693,0.00010612999,0.0002235721,0.000007220786],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004178894,0.00018397995,0.897267,0.00019958905,0.00021988261,0.000006698383,0.0005985216,0.0010683874,0.00047862402,0.09713116,0.001486285,0.0013180786],"study_design_scores_gemma":[0.008357989,0.0005683503,0.69243294,0.00036319558,0.00012369467,0.00012380762,0.0016263698,0.029734973,0.0039267507,0.19246788,0.06899367,0.0012804006],"about_ca_topic_score_codex":0.000036380854,"about_ca_topic_score_gemma":0.000012848564,"teacher_disagreement_score":0.20483409,"about_ca_system_score_codex":0.0003125482,"about_ca_system_score_gemma":0.0000847001,"threshold_uncertainty_score":0.47432074},"labels":[],"label_agreement":null},{"id":"W2973094055","doi":"10.1503/cmaj.190289","title":"Do practice guidelines cause drug shortages? The historical example of β-blockers","year":2019,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Economic shortage; Authorization; Drug; Medicine; Intensive care medicine; Pharmacology; Computer science; Computer security","score_opus":0.06497287707141305,"score_gpt":0.30936009485317956,"score_spread":0.2443872177817665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2973094055","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1874119,0.005641728,0.00010110711,0.74744344,0.0052525736,0.00029612836,0.00017936126,0.000016313235,0.053657457],"genre_scores_gemma":[0.81905156,0.0043863393,0.0007723805,0.16511543,0.0038003013,0.000012274297,0.000011042959,0.000058021797,0.0067926445],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99811643,0.00006711615,0.0010277702,0.00018677268,0.00020205311,0.0003998826],"domain_scores_gemma":[0.99749005,0.00044755885,0.0007151542,0.00019752618,0.00032915676,0.00082054926],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.004491917,0.000106030864,0.00032346012,0.00016656125,0.00013566812,0.0000917024,0.00040277943,0.00019239087,0.0060292734],"category_scores_gemma":[0.0043216916,0.00009532684,0.00014544757,0.00019045296,0.000026121184,0.00020619183,0.00002739476,0.00071758806,0.0008198562],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000006119965,0.000026656942,0.06742816,0.000005655927,0.00017269554,0.000019020787,0.00034552213,0.000026458709,0.0000010993193,0.040299013,0.8888804,0.0027892229],"study_design_scores_gemma":[0.00038032216,0.000016167442,0.0026221597,0.000009059604,0.0000120423365,0.000047225985,0.0001244123,0.0008775916,0.0000020595735,0.00215286,0.99364096,0.00011514351],"about_ca_topic_score_codex":0.018907238,"about_ca_topic_score_gemma":0.0046524056,"teacher_disagreement_score":0.63163966,"about_ca_system_score_codex":0.0018308248,"about_ca_system_score_gemma":0.00080555334,"threshold_uncertainty_score":0.9999581},"labels":[],"label_agreement":null},{"id":"W2973726810","doi":"10.1016/j.healthpol.2019.09.005","title":"How will recent trade agreements that extend market protections for brand-name prescription pharmaceuticals impact expenditures and generic access in Canada?","year":2019,"lang":"en","type":"article","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Context (archaeology); Multinational corporation; Medical prescription; Competition (biology); Business; European union; Market access; International trade; Public economics; Economics; International economics; Finance; Medicine","score_opus":0.1440734088236462,"score_gpt":0.3934999045225454,"score_spread":0.24942649569889921,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2973726810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7156226,0.012726297,0.0007290662,0.25143766,0.0014956372,0.006761087,0.0041538635,0.000054350992,0.0070194234],"genre_scores_gemma":[0.97650284,0.0087132035,0.00008078484,0.013594445,0.0003116908,0.0002788333,0.0000320541,0.000037154787,0.0004489737],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99808383,0.000057113146,0.000537149,0.00047426953,0.00004733866,0.0008002818],"domain_scores_gemma":[0.99887687,0.00008122014,0.0003349819,0.0002453799,0.000009078227,0.00045247015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048692516,0.00022803732,0.00051597663,0.00034138298,0.00012462478,0.00017708479,0.00022104784,0.00008169608,0.00048483122],"category_scores_gemma":[0.000067039655,0.0002433636,0.00007853536,0.000171767,0.000030135214,0.0005231096,0.00007050055,0.00022088175,0.000009202224],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013831876,0.0008863622,0.45375752,0.0035180943,0.00062958285,0.000008320792,0.0026116648,0.001157343,0.00026732226,0.08241764,0.22084668,0.23251627],"study_design_scores_gemma":[0.0025418384,0.00010674731,0.21466185,0.000031215255,0.0000046679343,0.000009480158,0.000048147194,0.013102231,0.00011264163,0.0076376973,0.7613812,0.00036225514],"about_ca_topic_score_codex":0.3994872,"about_ca_topic_score_gemma":0.11227982,"teacher_disagreement_score":0.54053456,"about_ca_system_score_codex":0.001675211,"about_ca_system_score_gemma":0.0007497229,"threshold_uncertainty_score":0.9924079},"labels":[],"label_agreement":null},{"id":"W2973742237","doi":"10.1016/s2352-4642(19)30294-9","title":"NCDs and the WHO Essential Medicines Lists: children need universal health coverage too","year":2019,"lang":"en","type":"review","venue":"The Lancet Child & Adolescent Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; McMaster University Medical Centre; BC Children's Hospital","funders":"World Diabetes Foundation; World Heart Federation; American Academy of Pediatrics","keywords":"Equity (law); Medicine; MEDLINE; Alternative medicine; Family medicine; Medical education; Business; Political science; Pathology","score_opus":0.06956492419658926,"score_gpt":0.3398701215782803,"score_spread":0.270305197381691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2973742237","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002853735,0.8882578,0.00007319342,0.10125061,0.0010599637,0.0022358708,0.0014490054,0.000048850867,0.005596176],"genre_scores_gemma":[0.0007651988,0.93331355,0.000008118871,0.06063709,0.0047169817,0.000019154812,0.00021710739,0.000081054925,0.00024177051],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961568,0.0003841478,0.0015810443,0.000763402,0.00008988193,0.0010246977],"domain_scores_gemma":[0.996485,0.00023203903,0.0018053001,0.001098154,0.000016672493,0.00036285925],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0028642658,0.0005971526,0.0042962153,0.00020615537,0.0005477317,0.00018498713,0.0010849012,0.00019902561,0.00009033204],"category_scores_gemma":[0.000065817454,0.00039037073,0.00049052597,0.00030861347,0.00039406779,0.00011408152,0.00036019058,0.0019597095,0.00029594466],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017142447,0.00016935181,0.00084798376,0.013795368,0.0006621343,0.00000143253,0.001125076,0.000014540188,1.4966764e-9,0.49637228,0.22232148,0.26451892],"study_design_scores_gemma":[0.0027322576,0.000058287707,0.00113387,0.0028527726,0.00007872544,0.000046380046,0.000014649595,0.0001547113,9.95279e-9,0.001443645,0.991108,0.00037667944],"about_ca_topic_score_codex":0.0013374287,"about_ca_topic_score_gemma":0.00007262424,"teacher_disagreement_score":0.76878655,"about_ca_system_score_codex":0.0005057268,"about_ca_system_score_gemma":0.00046829262,"threshold_uncertainty_score":0.9998548},"labels":[],"label_agreement":null},{"id":"W2974366251","doi":"10.1016/j.jcjd.2019.07.092","title":"83 - Patient and Family Physician Perspectives on Facilitated Relay to Enhance Use of Statins","year":2019,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Alberta Bible College","funders":"","keywords":"Medicine; Psychological intervention; Guideline; Intervention (counseling); Family medicine; Statin; Relay; Intensive care medicine; Nursing; Internal medicine","score_opus":0.030379899083035566,"score_gpt":0.24572857772167644,"score_spread":0.21534867863864088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2974366251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940236,0.0013356605,0.000006103316,0.000871066,0.0001887459,0.0001075667,0.00064040115,0.0000015386805,0.002825289],"genre_scores_gemma":[0.9967251,0.00005240958,0.00018131502,0.002911748,0.000031338233,0.000001299421,0.0000013988272,0.000011997613,0.00008342614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991168,0.000014081829,0.0004370639,0.0001572908,0.000020926143,0.00025387766],"domain_scores_gemma":[0.9990025,0.00010516087,0.00027796047,0.00013111447,0.00006381947,0.00041943006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001534227,0.00009981222,0.00033601807,0.0003313101,0.000033316202,0.000048951413,0.000107782434,0.00003699637,0.00007354203],"category_scores_gemma":[0.00014029158,0.00010889053,0.0000728319,0.00011809663,0.00005300699,0.00019010654,0.000010263134,0.0001389757,0.000103854385],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000094153154,0.00038858212,0.6624772,0.00023979502,0.001116271,0.000014821565,0.054255642,0.00943525,0.0075204335,0.18494844,0.02375407,0.05575534],"study_design_scores_gemma":[0.001657164,0.0043521114,0.4837814,0.0003959342,0.00003526842,0.0000012065752,0.0053919344,0.0028034865,0.0076214923,0.0136813335,0.47901857,0.0012601083],"about_ca_topic_score_codex":0.00055137,"about_ca_topic_score_gemma":0.00024293995,"teacher_disagreement_score":0.4552645,"about_ca_system_score_codex":0.00012721216,"about_ca_system_score_gemma":0.00009735451,"threshold_uncertainty_score":0.44404265},"labels":[],"label_agreement":null},{"id":"W2974532578","doi":"10.1093/acrefore/9780190625979.013.77","title":"The Effect of Government Policy on Pharmaceutical Drug Innovation","year":2019,"lang":"en","type":"reference-entry","venue":"Oxford Research Encyclopedia of Economics and Finance","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Underinsured; Business; Public economics; Revenue; Intellectual property; Drug; Public policy; Government (linguistics); Tax revenue; Drug development; Finance; Economics; Pharmacology; Economic growth; Medicine; Health insurance; Political science; Health care; Law","score_opus":0.06208273139301879,"score_gpt":0.3482250298800441,"score_spread":0.2861422984870253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2974532578","genre_codex":"other","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15840685,0.010545421,0.000004216166,0.0031234282,0.0011325359,0.0010319473,0.0030752197,0.0000062416925,0.82267416],"genre_scores_gemma":[0.07492729,0.885298,0.000031170235,0.00019228629,0.00068116764,0.00011533154,0.00005961479,0.00007004777,0.038625084],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99635243,0.00011699549,0.0017290828,0.00080408866,0.00013165727,0.0008657574],"domain_scores_gemma":[0.99595326,0.0018344758,0.0011820693,0.0008285097,0.000084938256,0.000116768766],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0033954515,0.00044064602,0.0012862788,0.0005430097,0.0002355693,0.00010199232,0.0008664422,0.00038203903,0.00005147406],"category_scores_gemma":[0.00077645906,0.00038479554,0.00023544997,0.0005212224,0.00059746846,0.00015563674,0.00049946626,0.0012793108,0.00010030087],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037337522,0.000077041965,0.002400486,0.00052354496,0.00015447431,9.909527e-7,0.000059896727,0.00010653185,3.079573e-7,0.7890734,0.03445264,0.17277731],"study_design_scores_gemma":[0.0010766671,0.0005671995,0.0005556556,0.00014616571,0.00000952296,0.0000014519959,0.000010490118,0.0019385386,0.00013659942,0.026715621,0.9685099,0.00033219246],"about_ca_topic_score_codex":0.00020506966,"about_ca_topic_score_gemma":0.000027796628,"teacher_disagreement_score":0.93405724,"about_ca_system_score_codex":0.0004983025,"about_ca_system_score_gemma":0.00036450155,"threshold_uncertainty_score":0.9998604},"labels":[],"label_agreement":null},{"id":"W2974685686","doi":"10.1186/s12992-019-0497-3","title":"A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications","year":2019,"lang":"en","type":"review","venue":"Globalization and Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Calgary","funders":"","keywords":"Intellectual property; Essential medicines; Formulary; Negotiation; Medicine; Treaty; Health policy; Public economics; Health care; Business; Economic growth; Political science; Economics; Family medicine; Law","score_opus":0.1973249682521508,"score_gpt":0.45781894500895015,"score_spread":0.26049397675679936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2974685686","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000004741512,0.9694657,0.0007692305,0.02500551,0.0001638485,0.0018874616,0.0015320105,0.0000049092737,0.001166606],"genre_scores_gemma":[0.00010086065,0.9969436,0.00009644442,0.0022426704,0.00009371003,0.00013775151,0.00006676328,0.0000143613825,0.00030385383],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998836,0.000030254889,0.00064796297,0.00032178152,0.000025787707,0.00013820904],"domain_scores_gemma":[0.9992055,0.000044443117,0.00043742187,0.00016909896,0.0000062814897,0.00013724217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037863667,0.00014032813,0.0006754996,0.00009480822,0.00009549221,0.000029700741,0.00018846254,0.000070259346,0.00016816067],"category_scores_gemma":[0.000063146836,0.00009410198,0.00007892383,0.00012071969,0.00008786288,0.00005426289,0.00021420374,0.00006742259,0.000004466606],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011626346,0.00015911418,0.0007291347,0.08808837,0.00024012174,3.3719566e-8,0.00054992543,0.000005712854,2.9637324e-8,0.20039888,0.025977213,0.68383986],"study_design_scores_gemma":[0.0001577041,0.000020140342,0.0003725608,0.0031798314,0.000037959617,0.000002360538,0.0000017634096,0.0003601586,6.968528e-8,0.0016408926,0.9941226,0.00010395875],"about_ca_topic_score_codex":0.00048315848,"about_ca_topic_score_gemma":0.00007987525,"teacher_disagreement_score":0.9681454,"about_ca_system_score_codex":0.000188356,"about_ca_system_score_gemma":0.00018839349,"threshold_uncertainty_score":0.38373676},"labels":[],"label_agreement":null},{"id":"W2978302277","doi":"10.22270/ijdra.v7i3.327","title":"Intellectual Property Right in India- A Review","year":2019,"lang":"en","type":"review","venue":"International Journal of Drug Regulatory Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Prevention of Organ Failure","funders":"","keywords":"Business; Intellectual property; Order (exchange); Quality (philosophy); Process (computing); Risk analysis (engineering); Marketing; Computer science; Law; Finance; Political science","score_opus":0.07087529224784708,"score_gpt":0.3310711663333638,"score_spread":0.2601958740855167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978302277","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002063362,0.9647783,0.000007711682,0.00075886096,0.0026145973,0.00043261825,0.00016514139,0.000007384144,0.03121474],"genre_scores_gemma":[0.0005654407,0.995933,0.00005454195,0.00075549504,0.0006969799,0.00001675011,0.000024683166,0.00006128333,0.0018918518],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960882,0.000095767566,0.002969302,0.00039329063,0.00014447849,0.0003089319],"domain_scores_gemma":[0.9964962,0.00028268268,0.0025724513,0.0003419216,0.00013206889,0.00017469942],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.001676112,0.00039489142,0.0024653033,0.0011878364,0.000020846932,0.00008734457,0.0015239549,0.00021954051,0.0019425252],"category_scores_gemma":[0.00043657245,0.00030502898,0.0011097033,0.00027301683,0.00008819386,0.00036873476,0.00019749458,0.00094928907,0.0015765305],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007489903,0.0006376797,0.00015773776,0.027172979,0.0033454048,0.0003877089,0.00065893395,0.000025880652,2.0841323e-7,0.07365856,0.15656507,0.73731494],"study_design_scores_gemma":[0.00043220943,0.000026637665,0.000017666945,0.020250492,0.00009859025,0.00024769353,0.00001137778,0.00002774976,6.993301e-7,0.0015807855,0.97695094,0.00035513],"about_ca_topic_score_codex":0.000008400555,"about_ca_topic_score_gemma":0.000002484939,"teacher_disagreement_score":0.8203859,"about_ca_system_score_codex":0.0008791619,"about_ca_system_score_gemma":0.00045690197,"threshold_uncertainty_score":0.99994016},"labels":[],"label_agreement":null},{"id":"W2979994774","doi":"10.1109/icesi.2019.8863026","title":"Comprehensive Literature Review about Drug Shortages in the Canadian Hospital's Pharmacy Supply Chain","year":2019,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"École de Technologie Supérieure","funders":"","keywords":"Supply chain; Pharmacy; Economic shortage; Compromise; Hospital pharmacy; Business; Health care; Drug; Medicine; Medical emergency; Operations management; Marketing; Family medicine; Pharmacology; Engineering; Economics; Government (linguistics)","score_opus":0.029414643803349506,"score_gpt":0.2862807713794999,"score_spread":0.2568661275761504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979994774","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23175107,0.25946078,0.0000017334534,0.15234874,0.0010309919,0.0019742239,0.0008306516,0.000034320557,0.3525675],"genre_scores_gemma":[0.8379178,0.07560218,0.000030893167,0.08421769,0.00012732022,0.000048857382,0.000071514296,0.000020708512,0.0019630394],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985003,0.000035438257,0.00054982357,0.00038826076,0.000030796047,0.0004953863],"domain_scores_gemma":[0.9991376,0.000085889405,0.0001245944,0.0004208159,0.000029396904,0.00020173032],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0005439585,0.00020706866,0.0004551291,0.00022729339,0.00008242884,0.00020123557,0.0005434107,0.00005913656,0.0026912934],"category_scores_gemma":[0.000023012683,0.00017788904,0.00014883657,0.00037039016,0.000041419797,0.00024048719,0.000043497712,0.00042389284,0.0025585757],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000075556904,0.000112034846,0.1656716,0.00086465635,0.00007813515,0.000049908547,0.002378857,0.000027436132,0.0000037428126,0.6212176,0.20671403,0.0028744333],"study_design_scores_gemma":[0.00043339125,0.00001384807,0.024538873,0.0002214461,0.0000039961465,0.000005921004,0.00003683458,0.00079156476,0.00000733635,0.003813073,0.96985,0.0002837062],"about_ca_topic_score_codex":0.03696441,"about_ca_topic_score_gemma":0.029474037,"teacher_disagreement_score":0.76313597,"about_ca_system_score_codex":0.00014769325,"about_ca_system_score_gemma":0.00006977227,"threshold_uncertainty_score":0.9982204},"labels":[],"label_agreement":null},{"id":"W2981787459","doi":"10.4212/cjhp.v72i5.2935","title":"Should Medical Devices Be Regulated as Rigorously as Drugs?","year":2019,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Computer science; Medicine; Data science","score_opus":0.04366684319506033,"score_gpt":0.301962483706302,"score_spread":0.2582956405112417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981787459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8211175,0.0028889477,0.0000023299108,0.09198106,0.001972221,0.00018686458,0.000065972825,0.000008556568,0.08177655],"genre_scores_gemma":[0.9740673,0.00031784468,0.000015358974,0.02367718,0.0005587664,0.000002375287,0.0000044278886,0.000037266986,0.001319532],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981568,0.0000363525,0.0008901419,0.00022719533,0.00012211081,0.00056742993],"domain_scores_gemma":[0.997616,0.00012751808,0.000572354,0.00028288417,0.000088327244,0.0013128945],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0013023304,0.0002090825,0.00046771037,0.0002813687,0.00020366446,0.00022336422,0.0010598613,0.00010705119,0.013551559],"category_scores_gemma":[0.0002455799,0.00018040076,0.00025953224,0.0002192491,0.00019145604,0.00043443762,0.00005002427,0.0007487289,0.003242369],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021627067,0.00026420355,0.107086055,0.00008962556,0.001491369,0.0006673847,0.0077901217,0.00040647396,0.000031629184,0.72355616,0.14701752,0.01138321],"study_design_scores_gemma":[0.0017943541,0.00024323506,0.0026073952,0.000033792014,0.000028983524,0.00016968808,0.00012867538,0.0013620561,0.00020306646,0.044601534,0.9484613,0.00036589897],"about_ca_topic_score_codex":0.026936207,"about_ca_topic_score_gemma":0.0045544417,"teacher_disagreement_score":0.8014438,"about_ca_system_score_codex":0.0003192352,"about_ca_system_score_gemma":0.0011955977,"threshold_uncertainty_score":0.99753374},"labels":[],"label_agreement":null},{"id":"W2981884241","doi":"10.3233/jrs-195007","title":"Affordability versus innovation: Is compulsory licensing the solution?","year":2019,"lang":"en","type":"review","venue":"International Journal of Risk & Safety in Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Premise; Access to medicines; Intellectual property; Business; Investment (military); Life expectancy; Health technology; Public economics; Developing country; Politics; Health care; Economic growth; Economics; Political science; Medicine; Law; Environmental health","score_opus":0.19841033989054546,"score_gpt":0.4201610780763578,"score_spread":0.2217507381858123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981884241","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013275867,0.9719785,0.0007125966,0.01127902,0.008302993,0.00024869767,0.00030856667,0.000005024911,0.0070318417],"genre_scores_gemma":[0.0019161401,0.99399596,0.00015466202,0.0014657279,0.00232869,0.0000026699995,0.000040855004,0.000025415064,0.00006986972],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99619645,0.00009759813,0.0030535916,0.0002689219,0.0001543911,0.00022904051],"domain_scores_gemma":[0.99465895,0.001256373,0.0034156458,0.00031446398,0.0002860113,0.000068529516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003408684,0.00026531427,0.0015948792,0.0008527314,0.000062533894,0.00004111557,0.0010108433,0.00018383631,0.00083907763],"category_scores_gemma":[0.0011809833,0.0001953677,0.00038246,0.0005060186,0.00019782658,0.00017719141,0.00013959306,0.0012132667,0.00025374035],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027655286,0.00011426739,0.0006761627,0.00048813564,0.0010038763,0.000017068483,0.00082012464,0.000113021575,6.3049605e-8,0.05442258,0.010733383,0.9313348],"study_design_scores_gemma":[0.0016282911,0.000066941764,0.0003979734,0.0015889053,0.000110868925,0.0000567967,0.000041103536,0.00042322997,1.0537393e-7,0.008201336,0.987311,0.00017346021],"about_ca_topic_score_codex":0.00014762477,"about_ca_topic_score_gemma":0.000015617252,"teacher_disagreement_score":0.9765776,"about_ca_system_score_codex":0.0008152784,"about_ca_system_score_gemma":0.0002095034,"threshold_uncertainty_score":0.9187312},"labels":[],"label_agreement":null},{"id":"W2982160900","doi":"10.1007/s40264-019-00871-w","title":"Healthcare Database Networks for Drug Regulatory Policies: International Workshop on the Canadian, US and Spanish Experience and Future Steps for Italy","year":2019,"lang":"en","type":"article","venue":"Drug Safety","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Health care; Drug; Database; Pharmacology; Economic growth","score_opus":0.03774148058192039,"score_gpt":0.28706842246698766,"score_spread":0.24932694188506727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982160900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79658777,0.0041994015,0.00028552575,0.17573541,0.0034462106,0.0019853623,0.006479105,0.000029316929,0.011251907],"genre_scores_gemma":[0.9784066,0.0015429191,0.00012313177,0.017715888,0.0009872972,0.00009212062,0.00012168147,0.000026082269,0.0009842848],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99891466,0.0000108865415,0.00032957338,0.0003708097,0.00002354233,0.00035052368],"domain_scores_gemma":[0.9990421,0.00026957016,0.00013986102,0.00029050728,0.000030230405,0.0002277443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050125166,0.00014360719,0.00022389044,0.000089783935,0.00027124688,0.00012527568,0.00023353787,0.00007594768,0.00008815668],"category_scores_gemma":[0.00004050743,0.00013690283,0.00006209378,0.00006118683,0.00007617288,0.0001642097,0.00006551536,0.0001620189,0.000014878114],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012519333,0.000017836104,0.014254141,0.000046329907,0.000051946332,3.710356e-7,0.002443247,0.00015259336,0.0000011145607,0.963056,0.015551701,0.0042994735],"study_design_scores_gemma":[0.0006288397,0.000013527496,0.016616082,0.000020037232,0.0000032671662,0.0000018620796,0.00069544476,0.024225092,0.0000059383647,0.003929334,0.9536504,0.00021018316],"about_ca_topic_score_codex":0.007255445,"about_ca_topic_score_gemma":0.019842763,"teacher_disagreement_score":0.9591267,"about_ca_system_score_codex":0.00018100033,"about_ca_system_score_gemma":0.000057946792,"threshold_uncertainty_score":0.9993553},"labels":[],"label_agreement":null},{"id":"W2983518626","doi":"10.1503/cmaj.191447","title":"Co-pay cards in Canada: Improving choice or institutionalizing bribes?","year":2019,"lang":"en","type":"letter","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Carleton University","funders":"Health Canada","keywords":"Key (lock); Competition (biology); Computer science; Business; Operations research; Advertising; Computer security; Engineering","score_opus":0.03412926311961462,"score_gpt":0.2606043335636188,"score_spread":0.22647507044400417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983518626","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0028329464,0.00065447914,0.000022246672,0.9598393,0.00521623,0.00021574428,0.0014643087,0.0000082054585,0.029746572],"genre_scores_gemma":[0.01274934,0.00040322432,0.000017160633,0.9719841,0.011587906,0.000011523387,0.00015285426,0.000050007184,0.0030439221],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99662757,0.00008226529,0.0013782149,0.0004121348,0.00036308597,0.0011367039],"domain_scores_gemma":[0.997368,0.0004912279,0.000921785,0.00019264886,0.000104938605,0.0009214383],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.001843988,0.00028646158,0.0008174667,0.00057478854,0.00019776379,0.00022913147,0.00063508673,0.001210395,0.010655127],"category_scores_gemma":[0.002814775,0.0002870378,0.00017144984,0.000247775,0.000034933546,0.00023037074,0.000025949957,0.0044598794,0.0010528031],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0000018859249,0.0000040432406,0.059233844,0.000037739108,0.00009681179,0.00066956197,0.000026481666,0.000022347576,6.8193174e-8,0.0004560632,0.9374974,0.0019537779],"study_design_scores_gemma":[0.0007393076,0.000010183345,0.008354016,0.00006641997,0.000007954445,0.00011508453,0.000012805395,0.0010938155,4.8790633e-7,0.00033692902,0.9888691,0.00039393848],"about_ca_topic_score_codex":0.9600662,"about_ca_topic_score_gemma":0.99024695,"teacher_disagreement_score":0.051371682,"about_ca_system_score_codex":0.021906601,"about_ca_system_score_gemma":0.03822682,"threshold_uncertainty_score":0.99995816},"labels":[],"label_agreement":null},{"id":"W2984254829","doi":"","title":"Comparaison des processus de mise sur le marché des médicaments et autres produits de santé entre le Canada et l'Europe sur l'année 2017-2018","year":2019,"lang":"fr","type":"article","venue":"HAL (Le Centre pour la Communication Scientifique Directe)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science; Humanities; European union; Art; Business","score_opus":0.04205244839686926,"score_gpt":0.26595383028397146,"score_spread":0.2239013818871022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2984254829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82882166,0.013784472,0.002272932,0.057319902,0.00043604293,0.0005577997,0.0008677221,0.00006732268,0.095872134],"genre_scores_gemma":[0.9291674,0.0073803663,0.0040049236,0.0017128736,0.000044812565,0.00003743006,0.00015999062,0.00007875637,0.057413433],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99554956,0.0017371341,0.00080936356,0.00079464156,0.000118239885,0.0009910319],"domain_scores_gemma":[0.9961665,0.0010766068,0.000613677,0.0010441507,0.0006235106,0.0004755069],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004665489,0.0003758682,0.0005821372,0.00017993989,0.00043656482,0.00051938335,0.0011023685,0.00017356504,0.0005761726],"category_scores_gemma":[0.0014244993,0.00046893844,0.00015925267,0.00046108387,0.00042333102,0.0005864819,0.00046904254,0.00050132186,0.00023733012],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013038503,0.003856996,0.45546845,0.0018833976,0.000469343,0.000035225297,0.02132002,0.0015742909,0.001483305,0.37354535,0.07851778,0.061715446],"study_design_scores_gemma":[0.0020946858,0.000003651555,0.11000599,0.0010817356,0.000031043553,0.000028224085,0.00021053874,0.05160995,0.010312794,0.0061873444,0.8176616,0.0007724822],"about_ca_topic_score_codex":0.30928555,"about_ca_topic_score_gemma":0.47316962,"teacher_disagreement_score":0.7391438,"about_ca_system_score_codex":0.00073384185,"about_ca_system_score_gemma":0.0027072756,"threshold_uncertainty_score":0.99977624},"labels":[],"label_agreement":null},{"id":"W2988982017","doi":"10.1177/0020731419886526","title":"Does an Orphan Drug Policy Make a Difference in Access? A Comparison of Canada and Australia","year":2019,"lang":"en","type":"article","venue":"International Journal of Health Services","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; York University","funders":"","keywords":"Orphan drug; Government (linguistics); Food and drug administration; Drug; Business; Medicine; Political science; Environmental health; Pharmacology","score_opus":0.06257735410674499,"score_gpt":0.3923231565615992,"score_spread":0.32974580245485424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988982017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900095,0.00040938528,0.0000048113047,0.0084287515,0.0006848644,0.00006852649,0.00012651518,0.0000012805914,0.0002663576],"genre_scores_gemma":[0.9967619,0.00026893493,0.000063026346,0.0026591853,0.00013944901,8.963357e-7,0.000003888069,0.000005901989,0.000096802796],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99858767,0.000023109034,0.0010186479,0.00012547156,0.00006751133,0.00017759118],"domain_scores_gemma":[0.9985855,0.00005147055,0.0010763124,0.0000831989,0.000065459986,0.0001380453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004332324,0.00008272262,0.0004031419,0.00030841053,0.000017560764,0.000064883105,0.0005073149,0.000027334192,0.00014350098],"category_scores_gemma":[0.000010014737,0.00006796143,0.000031439886,0.00007928571,0.000016676588,0.00026274516,0.00007014718,0.00014284784,0.0000036937072],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004981835,0.000085730906,0.981425,0.00013379854,0.000036775287,0.0000019858508,0.0011738015,0.00018908897,0.000015338455,0.015420106,0.0000430741,0.0014254877],"study_design_scores_gemma":[0.0008364973,0.00006893374,0.97068995,0.00013243716,0.0000012736159,0.0000072236653,0.00027846504,0.0037064885,0.000087581335,0.016977368,0.0071101016,0.00010366282],"about_ca_topic_score_codex":0.5740269,"about_ca_topic_score_gemma":0.5637322,"teacher_disagreement_score":0.0107350275,"about_ca_system_score_codex":0.00021867987,"about_ca_system_score_gemma":0.0002864828,"threshold_uncertainty_score":0.44422853},"labels":[],"label_agreement":null},{"id":"W2993505955","doi":"10.1371/journal.pone.0225429","title":"Withdrawn medicines included in the essential medicines lists of 136 countries","year":2019,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"NIHR School for Primary Care Research; Canadian Institutes of Health Research; National Institute for Health and Care Research; Wellcome Trust","keywords":"Traditional medicine; Medicine; Pharmacology","score_opus":0.05401948122909569,"score_gpt":0.2696207607289425,"score_spread":0.21560127949984678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993505955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9521823,0.0014542271,0.000006650357,0.0132941855,0.00014996735,0.00029824028,0.00006987179,0.000010667581,0.03253388],"genre_scores_gemma":[0.99418896,0.00081144203,0.000054486954,0.004354146,0.00026947993,0.000017047443,0.000011844793,0.000013993623,0.00027858242],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988633,0.000018139524,0.00060947175,0.00021356685,0.00006993609,0.00022562232],"domain_scores_gemma":[0.9991694,0.00019175268,0.00025411762,0.00030197785,0.00003136569,0.000051366384],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00067255175,0.00011785073,0.00052392646,0.0001739146,0.000032844655,0.000025128218,0.00034310855,0.00007079763,0.0009634775],"category_scores_gemma":[0.00014633397,0.000097746866,0.00004920845,0.00018913714,0.00014912269,0.00012107006,0.00006148278,0.00015988201,0.00040812689],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018812987,0.0016777638,0.5866677,0.0010736815,0.00042355162,0.000007957133,0.0064020483,0.000028873283,0.0017722538,0.39790818,0.0037391314,0.00011072183],"study_design_scores_gemma":[0.019456755,0.0015843916,0.4515598,0.0020834676,0.00039308652,0.000022024415,0.0017552284,0.030143745,0.03365295,0.30355668,0.15329246,0.0024993934],"about_ca_topic_score_codex":0.00025316517,"about_ca_topic_score_gemma":0.00009090147,"teacher_disagreement_score":0.14955333,"about_ca_system_score_codex":0.000032103126,"about_ca_system_score_gemma":0.000030002095,"threshold_uncertainty_score":0.99994975},"labels":[],"label_agreement":null},{"id":"W2995633581","doi":"","title":"Pharmacy Associations Offer Perspective on Canada Drug Import Proposal","year":2019,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy; Perspective (graphical); Drug; Business; Medicine; Pharmacology; Family medicine; Computer science","score_opus":0.03333513892710892,"score_gpt":0.2903337143017926,"score_spread":0.2569985753746837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995633581","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34864762,0.00009648485,0.0000052105875,0.020731002,0.0006782,0.0002592272,0.0004450668,0.000026826714,0.62911034],"genre_scores_gemma":[0.9697528,0.000039403498,0.000049158698,0.010508556,0.00016280518,0.000012497196,0.000018906525,0.00002161369,0.019434288],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989128,0.000009282691,0.0003758762,0.00034460594,0.000034656765,0.00032275403],"domain_scores_gemma":[0.99937344,0.00006668533,0.00016839117,0.00021038324,0.000032752374,0.0001483672],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00023614602,0.00013682355,0.00028367658,0.0000925886,0.00007151461,0.00004923634,0.00018454994,0.000030536103,0.0060219034],"category_scores_gemma":[0.000045170724,0.0001496868,0.000088724046,0.00011260949,0.00001679217,0.00013513773,0.00004206182,0.0002002855,0.0027062634],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009081549,0.000060139206,0.06805432,0.0000035279415,0.00006917392,0.0000013612973,0.0001234385,0.000053566473,0.000010602522,0.8592249,0.07234064,0.000049252718],"study_design_scores_gemma":[0.0015896518,0.000045135013,0.037570383,0.0000043820805,0.000009990019,0.000002235503,0.00022836761,0.010274128,0.0009547425,0.07782795,0.87083155,0.00066145964],"about_ca_topic_score_codex":0.45552677,"about_ca_topic_score_gemma":0.12522642,"teacher_disagreement_score":0.79849094,"about_ca_system_score_codex":0.0010727122,"about_ca_system_score_gemma":0.00038239465,"threshold_uncertainty_score":0.99807024},"labels":[],"label_agreement":null},{"id":"W2995889671","doi":"10.1016/j.jval.2019.09.2661","title":"PSY33 HTA REVIEW OF DECISIONS FOR PRODUCTS INDICATED IN THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND LUPUS NEPHRITIS (N) IN UK, GERMANY, FRANCE, ITALY, SPAIN, CANADA AND TURKEY","year":2019,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Belimumab; Medicine; Lupus nephritis; Rituximab; Systemic lupus erythematosus; European union; Reimbursement; Disease; Dermatology; Immunology; Internal medicine; Lymphoma","score_opus":0.04953274642682193,"score_gpt":0.28781476204506123,"score_spread":0.2382820156182393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995889671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.847621,0.14710161,0.0000020909565,0.0030035763,0.0002909983,0.0015154178,0.00030744384,0.0000017041189,0.00015611867],"genre_scores_gemma":[0.8395835,0.15926296,0.00007962718,0.0009105912,0.00001911897,0.00007306507,0.000011253754,0.000011213295,0.000048649134],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99812067,0.00006723023,0.0011670867,0.00031618285,0.0000362766,0.00029255034],"domain_scores_gemma":[0.9987228,0.00043837994,0.00045043824,0.00029551005,0.000015616135,0.00007725488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011620469,0.00013521111,0.00078719016,0.00023339574,0.000022849212,0.000010859098,0.00014354651,0.00005611233,0.000010494817],"category_scores_gemma":[0.00014822645,0.000119983204,0.000037261798,0.00034187266,0.000038506885,0.000050892588,0.000022135378,0.00009706758,0.0000024937224],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009129811,0.00043827636,0.9343131,0.014208797,0.00005214273,0.000009157137,0.0037375467,0.00048186193,0.000011475546,0.037404984,0.0019924094,0.007258915],"study_design_scores_gemma":[0.031983122,0.003394465,0.3503357,0.041370746,0.00006452581,0.001144342,0.0012513732,0.053416062,0.000114132046,0.041717913,0.47298682,0.0022208046],"about_ca_topic_score_codex":0.26635176,"about_ca_topic_score_gemma":0.026780333,"teacher_disagreement_score":0.58397746,"about_ca_system_score_codex":0.00025349436,"about_ca_system_score_gemma":0.00027502966,"threshold_uncertainty_score":0.99097836},"labels":[],"label_agreement":null},{"id":"W2996570620","doi":"10.1016/j.jval.2019.09.2408","title":"PRO78 THE CURRENT AND FUTURE COSTS OF ORPHAN DRUGS IN CANADA - A PUBLIC PAYER BUDGET IMPACT ANALYSIS","year":2019,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Orphan drug; Medicine; Drug; Population; Public health; Environmental health; Pharmacology; Bioinformatics","score_opus":0.04297398827064129,"score_gpt":0.306910077215501,"score_spread":0.2639360889448597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996570620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97895706,0.007471821,0.000002965047,0.01189754,0.00025314203,0.00035292236,0.0002933721,0.000002405194,0.0007687762],"genre_scores_gemma":[0.9959207,0.003099923,0.00000999488,0.00086288684,0.00006447737,0.000011962687,0.0000116648525,0.000008971095,0.000009428875],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99857163,0.00006501506,0.00070039195,0.0002554453,0.000033203876,0.00037432014],"domain_scores_gemma":[0.9991409,0.00011183393,0.00031666452,0.00026115897,0.000011614054,0.00015783796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010583402,0.0001114541,0.00049706333,0.00035595338,0.00002659657,0.000027269367,0.0001767735,0.00003229493,0.00015683747],"category_scores_gemma":[0.000025971603,0.000093178605,0.00007190515,0.0007315917,0.000020797062,0.00009108981,0.000046023477,0.00025512898,0.000014510063],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011150375,0.00004552156,0.9426829,0.00007772796,0.000058351015,2.6056236e-7,0.0005394686,0.0014648823,2.2610544e-7,0.043566454,0.00031218954,0.011240819],"study_design_scores_gemma":[0.00087758905,0.00005608239,0.82183105,0.000024129258,0.0000068217614,8.8582357e-7,0.0001698131,0.10483691,0.000002192542,0.0045848354,0.0673947,0.00021497953],"about_ca_topic_score_codex":0.8667844,"about_ca_topic_score_gemma":0.4326932,"teacher_disagreement_score":0.4340912,"about_ca_system_score_codex":0.0010951498,"about_ca_system_score_gemma":0.0008302782,"threshold_uncertainty_score":0.57765865},"labels":[],"label_agreement":null},{"id":"W2996599204","doi":"10.1093/heapol/czz084","title":"How does performance-based financing affect the availability of essential medicines in Cameroon? A qualitative study","year":2019,"lang":"en","type":"article","venue":"Health Policy and Planning","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Canadian Institutes of Health Research; Alliance for Health Policy and Systems Research","keywords":"Nonprobability sampling; Accountability; Essential medicines; Business; Qualitative research; Autonomy; Health care; Thematic analysis; Pharmacy; Health facility; Psychological intervention; Payment; Nursing; Medicine; Environmental health; Public health; Finance; Economic growth; Population; Health services","score_opus":0.08255505547302189,"score_gpt":0.3981021488320766,"score_spread":0.31554709335905473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996599204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844881,0.00086138566,0.000035113313,0.012919699,0.00017978478,0.00056132925,0.00007863703,0.000008239745,0.00086766394],"genre_scores_gemma":[0.9967751,0.00010757547,0.00002646002,0.0028209167,0.0001629807,0.000023169556,0.000004520074,0.000009924638,0.000069364665],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99864584,0.00013902847,0.0005547961,0.00027438955,0.00003436732,0.00035154892],"domain_scores_gemma":[0.99869317,0.00061946386,0.00037602521,0.00020968408,0.000014720795,0.00008693452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023760297,0.00013329869,0.0005073147,0.00024805608,0.000105836305,0.00003187301,0.00012422894,0.00004865403,0.000027510325],"category_scores_gemma":[0.00022784172,0.00009801946,0.000042318836,0.00023853048,0.00009061423,0.00012441221,0.000039381204,0.00022799977,0.000010997143],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001399223,0.00016467975,0.87977856,0.00087445497,0.00003665846,0.0000011501293,0.10211164,0.0005009229,0.000010191365,0.014648461,0.00022426712,0.0015090781],"study_design_scores_gemma":[0.005857759,0.0015358013,0.8916674,0.00045137623,0.0000122927895,0.0000033052238,0.04049098,0.03943326,0.00017718131,0.008117067,0.01162564,0.00062793156],"about_ca_topic_score_codex":0.0037658531,"about_ca_topic_score_gemma":0.00020562834,"teacher_disagreement_score":0.061620656,"about_ca_system_score_codex":0.00008331943,"about_ca_system_score_gemma":0.00013945995,"threshold_uncertainty_score":0.5692868},"labels":[],"label_agreement":null},{"id":"W2997149761","doi":"10.1016/j.healthpol.2019.12.010","title":"Variation in the prescription drugs covered by health systems across high-income countries: A review of and recommendations for the academic literature","year":2019,"lang":"en","type":"review","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; York University; University of British Columbia","funders":"","keywords":"Formulary; Medicine; Concordance; Family medicine; Variety (cybernetics); Transparency (behavior); Medical prescription; Variation (astronomy); Alternative medicine; MEDLINE; Specialty; Inclusion (mineral); Actuarial science; Business; Psychology; Political science; Computer science; Nursing","score_opus":0.13748444372214425,"score_gpt":0.46242274539414563,"score_spread":0.3249383016720014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2997149761","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000015256485,0.8740758,0.00011791814,0.101276,0.0004720999,0.004518466,0.019443564,0.000008533934,0.00008613795],"genre_scores_gemma":[0.00006433085,0.9647252,0.000022189855,0.03301468,0.00049690955,0.00076788967,0.0006578558,0.000039409417,0.0002115351],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961156,0.00033678106,0.0024803688,0.00043841155,0.00005405161,0.0005747482],"domain_scores_gemma":[0.99534553,0.0010855447,0.002858062,0.0005422163,0.000043469496,0.00012518842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0056067654,0.00030726707,0.0020321805,0.0002211698,0.00024582326,0.00012862626,0.0004959627,0.0002981296,0.000012690555],"category_scores_gemma":[0.000297764,0.00022368708,0.00021149966,0.00057545403,0.000055760986,0.00018911877,0.00007098952,0.0007251991,0.00003703244],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008714936,0.000027405733,0.0000067609008,0.35652113,0.00009222691,3.4628002e-8,0.0036070028,0.0000032086548,3.1370577e-9,0.46491367,0.08655432,0.08826554],"study_design_scores_gemma":[0.00035674177,0.00006267191,0.00003380134,0.030541025,0.00002338987,0.0000058337146,0.00002371091,0.00023106487,2.1204467e-9,0.0017050602,0.9668538,0.00016290057],"about_ca_topic_score_codex":0.0046707676,"about_ca_topic_score_gemma":0.00002267484,"teacher_disagreement_score":0.88029945,"about_ca_system_score_codex":0.00076557515,"about_ca_system_score_gemma":0.0007198183,"threshold_uncertainty_score":0.91216946},"labels":[],"label_agreement":null},{"id":"W2998196003","doi":"","title":"Les ruptures de médicaments : comparaison transversale entre la France, la Belgique, l'Espagne, la Suisse et le Canada","year":2018,"lang":"fr","type":"article","venue":"ORBi (University of Liège)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Humanities; Political science; Art","score_opus":0.022543386939042596,"score_gpt":0.24743892405230075,"score_spread":0.22489553711325816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998196003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6092227,0.0058837016,0.001240106,0.031020308,0.00047880434,0.00018459854,0.0014655676,0.000026944106,0.35047728],"genre_scores_gemma":[0.9668185,0.0023910853,0.00088992744,0.00110626,0.00009664661,4.2318146e-7,0.000017272863,0.000026050788,0.028653806],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986498,0.00015765197,0.00028642543,0.00037958415,0.00005554218,0.0004709995],"domain_scores_gemma":[0.9988252,0.00030296226,0.00029022858,0.00025943536,0.000044708137,0.00027744862],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005001019,0.00022464513,0.0005206617,0.0001603427,0.00024587032,0.000055997418,0.0004887858,0.0003143444,0.0023831103],"category_scores_gemma":[0.000010613206,0.00036484923,0.00017462179,0.0002088216,0.0006784794,0.00027555524,0.000107506195,0.00040757153,0.00009906441],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014152778,0.0005737064,0.13618684,0.00023535655,0.00038133137,0.000119876626,0.0030878165,0.00018147215,0.00007648784,0.7696209,0.08248897,0.006905733],"study_design_scores_gemma":[0.0015731181,0.00006383029,0.09371997,0.00006832234,0.000037846454,0.0000129291475,0.0003937805,0.0024494876,0.00008848173,0.0013254371,0.89994824,0.00031854972],"about_ca_topic_score_codex":0.77045923,"about_ca_topic_score_gemma":0.41968352,"teacher_disagreement_score":0.8174593,"about_ca_system_score_codex":0.0002013479,"about_ca_system_score_gemma":0.0005705676,"threshold_uncertainty_score":0.9998804},"labels":[],"label_agreement":null},{"id":"W2998221831","doi":"10.1016/j.sapharm.2019.12.015","title":"Did citizen petitions prolong the number of approval days of generic drugs?","year":2019,"lang":"en","type":"article","venue":"Research in Social and Administrative Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Medicine; Value (mathematics); Statistics; Geography; Mathematics","score_opus":0.3508905521151091,"score_gpt":0.48007574395070096,"score_spread":0.12918519183559185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998221831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84808826,0.0003137944,0.0000056541644,0.0042194454,0.000055539742,0.00033631883,0.00041815278,0.0000033841425,0.14655946],"genre_scores_gemma":[0.9987987,0.0004944274,0.000042352276,0.00013489743,0.00014704184,0.000048222242,0.000007953467,0.00000851668,0.0003178807],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9988522,0.00009951143,0.00044357468,0.00023225386,0.00006642902,0.00030601866],"domain_scores_gemma":[0.99937403,0.00022156045,0.00016175359,0.00010716024,0.00005639609,0.000079072895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011202326,0.000090659785,0.000301241,0.00007631432,0.00011930708,0.00003071478,0.00022203749,0.00003816682,0.00064475473],"category_scores_gemma":[0.000043353517,0.00008274613,0.00008050607,0.0003803199,0.0004724253,0.00011267446,0.00011824996,0.00029878254,0.0000881024],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010246298,0.00021428091,0.15725438,0.00014720058,0.00006350416,0.0000018311335,0.0021252737,0.000002563428,0.0003250047,0.83720833,0.0004105317,0.0021446135],"study_design_scores_gemma":[0.006004087,0.00028395405,0.13840248,0.000074457144,0.000018500941,0.000013343681,0.0035167895,0.0049512614,0.0054619755,0.7086199,0.13197619,0.0006770802],"about_ca_topic_score_codex":0.00023454007,"about_ca_topic_score_gemma":0.0000084420135,"teacher_disagreement_score":0.15071046,"about_ca_system_score_codex":0.000051481973,"about_ca_system_score_gemma":0.00012434943,"threshold_uncertainty_score":0.7059612},"labels":[],"label_agreement":null},{"id":"W2999258267","doi":"10.1136/bmj.l4627","title":"Pricing of pharmaceuticals is becoming a major challenge for health systems","year":2020,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":141,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"World Health Organization","keywords":"Drug pricing; Business; Market power; Healthcare system; Industrial organization; Risk analysis (engineering); Economics; Computer science; Health care; Marketing; Microeconomics; Actuarial science; Economic growth","score_opus":0.26048616987151846,"score_gpt":0.4106091592542288,"score_spread":0.15012298938271035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999258267","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06521276,0.033503544,0.031390578,0.7690756,0.0021179197,0.0057256916,0.0036777335,0.00018804657,0.089108184],"genre_scores_gemma":[0.97214544,0.0010361035,0.0009796517,0.02487091,0.0007022742,0.00009699707,0.00000764354,0.000037126567,0.00012385153],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982854,0.000014219398,0.0009992325,0.0003198642,0.000023527624,0.00035775328],"domain_scores_gemma":[0.99888855,0.00014463994,0.0005041148,0.00017263598,0.000016302894,0.00027373797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073087786,0.00012902556,0.0005909082,0.0000817279,0.00006565295,0.000032625467,0.00019912019,0.000063242696,0.00018496778],"category_scores_gemma":[0.00015457628,0.00015430617,0.00015565722,0.000109310895,0.000028729984,0.00009067673,0.000059220103,0.00011126494,0.00018392305],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031367817,0.00030801492,0.0027660779,0.0036669231,0.00051829655,0.000002931006,0.0076262536,0.00034880982,0.00017812544,0.8333114,0.13942619,0.01153331],"study_design_scores_gemma":[0.001438447,0.00015973886,0.00014520429,0.00003206117,0.0000090285985,0.0000018333112,0.00008720397,0.12124231,0.00032197303,0.0050170817,0.8713037,0.00024146409],"about_ca_topic_score_codex":0.00008405182,"about_ca_topic_score_gemma":0.000001622794,"teacher_disagreement_score":0.9069327,"about_ca_system_score_codex":0.0000736425,"about_ca_system_score_gemma":0.000050444633,"threshold_uncertainty_score":0.6292423},"labels":[],"label_agreement":null},{"id":"W2999388575","doi":"10.15171/ijhpm.2020.03","title":"It’s Time to Finally Kill the Zombies Comment on \"Universal Pharmacare in Canada\"","year":2020,"lang":"en","type":"letter","venue":"International Journal of Health Policy and Management","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University; University of Toronto; University Health Network","funders":"","keywords":"Underinsured; Multinational corporation; Cover (algebra); Plan (archaeology); Political science; Public administration; Law; History; Engineering; Health insurance; Health care","score_opus":0.06739283782282568,"score_gpt":0.3337474092298733,"score_spread":0.2663545714070476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999388575","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009552347,0.00034810466,0.000029086432,0.98311096,0.00071811775,0.00025823727,0.0004095774,0.0000025962465,0.015027771],"genre_scores_gemma":[0.0067898664,0.0032299946,0.000040444156,0.98732746,0.0016632889,0.000007989597,0.000020489473,0.000018743589,0.000901735],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99827725,0.00005638657,0.0009869506,0.00021329122,0.00014143564,0.0003246969],"domain_scores_gemma":[0.9988516,0.0001286462,0.000714019,0.00011800352,0.00003953066,0.00014821175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043492636,0.00018587736,0.00045552963,0.0005380482,0.00006474777,0.00007836192,0.0007121753,0.000048570364,0.00026050038],"category_scores_gemma":[0.000043457432,0.00017260057,0.000092076465,0.000102924445,0.000025793039,0.00006904354,0.00021178891,0.00072128314,0.00015416264],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042502874,0.000018660792,0.000034225777,0.00006401189,0.00022011947,0.00025639808,0.0002889367,0.00020728017,2.9867756e-8,0.015259478,0.97983533,0.003773017],"study_design_scores_gemma":[0.0006592032,0.000088810484,0.00037410136,0.00011258937,0.000006007772,0.000014931943,0.000042950745,0.0002966581,4.76228e-7,0.0029994731,0.99526286,0.00014195184],"about_ca_topic_score_codex":0.15919645,"about_ca_topic_score_gemma":0.010764009,"teacher_disagreement_score":0.14843243,"about_ca_system_score_codex":0.0021500438,"about_ca_system_score_gemma":0.00048582588,"threshold_uncertainty_score":0.8464025},"labels":[],"label_agreement":null},{"id":"W2999591574","doi":"10.1136/bmj.l4408","title":"New business models for research and development with affordability requirements are needed to achieve fair pricing of medicines","year":2020,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Pooling; Business; Business model; Marketing; Risk analysis (engineering); Finance; Process management; Computer science","score_opus":0.4007367688829906,"score_gpt":0.40736535361088905,"score_spread":0.006628584727898457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999591574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70393133,0.00037601774,0.11522062,0.1696965,0.00014391844,0.0023483634,0.00013440245,0.000029877257,0.008118994],"genre_scores_gemma":[0.9744423,0.000034490367,0.020624803,0.0044402913,0.00021456958,0.00007451333,0.000007576154,0.000022227003,0.0001391958],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99884653,0.000007639176,0.0005079175,0.0003201877,0.000046237823,0.00027146083],"domain_scores_gemma":[0.99923486,0.000076083816,0.00016312805,0.00015317103,0.00010575714,0.00026699112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077593967,0.000102073165,0.00034738416,0.00011745164,0.0000729901,0.000027855198,0.00016194966,0.000042538082,0.000028286315],"category_scores_gemma":[0.0002134905,0.00009761098,0.000018113109,0.00028409288,0.00004505842,0.00013231083,0.0001217044,0.00007719792,0.000015346623],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0121806925,0.00096404116,0.10724558,0.0060297004,0.0011311446,0.000012527493,0.044945367,0.018561253,0.0011618213,0.49187005,0.25723904,0.058658767],"study_design_scores_gemma":[0.015678814,0.0035451916,0.0611027,0.00069813355,0.00003885671,0.000008532874,0.0044942982,0.10249308,0.009742386,0.21745418,0.582574,0.002169842],"about_ca_topic_score_codex":0.0002273733,"about_ca_topic_score_gemma":0.000067720495,"teacher_disagreement_score":0.32533494,"about_ca_system_score_codex":0.00006446561,"about_ca_system_score_gemma":0.00011206543,"threshold_uncertainty_score":0.39804602},"labels":[],"label_agreement":null},{"id":"W3000339863","doi":"10.1136/bmjinnov-2019-000370","title":"Switching among branded and generic medication products during ongoing treatment of psychiatric illness","year":2020,"lang":"en","type":"article","venue":"BMJ Innovations","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; McGill University; Pfizer (Canada); University of Toronto; Dalhousie University; Thornhill Medical (Canada)","funders":"Pfizer Canada; Pfizer","keywords":"Tolerability; Pharmacy; Medicine; Generic drug; Drug; Product (mathematics); Intensive care medicine; Psychiatry; Pharmacology; Adverse effect; Family medicine","score_opus":0.07910411897296551,"score_gpt":0.3016740841160494,"score_spread":0.2225699651430839,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000339863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837749,0.00046776724,0.0006802433,0.011890902,0.00013154796,0.0003350622,0.000041703683,0.000026851461,0.0026510337],"genre_scores_gemma":[0.9979318,0.00034919407,0.00083998585,0.0004730293,0.0002944637,0.000048583694,0.000018003422,0.000014667934,0.000030303945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99896157,0.0000069466173,0.00060727034,0.00026074177,0.000021570431,0.00014189846],"domain_scores_gemma":[0.9993712,0.00002183311,0.00034800588,0.00015402348,0.000035064942,0.0000698836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012334183,0.0000988207,0.00024757718,0.00019938343,0.00012258791,0.00002803988,0.00007738998,0.000043930788,0.000050944527],"category_scores_gemma":[0.000118874676,0.00011091987,0.00003092736,0.00065390574,0.000033309407,0.00016066323,0.000026636377,0.000058883063,0.000022605933],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006960215,0.0005128963,0.53006524,0.0005498632,0.000359247,0.0000028966233,0.007852884,0.0004493996,0.01033976,0.4319077,0.0007467574,0.017143779],"study_design_scores_gemma":[0.004333651,0.00022821233,0.8958211,0.000032677897,0.000056379988,0.000010851903,0.00022231622,0.04304484,0.010909656,0.012340379,0.032163464,0.0008364766],"about_ca_topic_score_codex":0.000051851643,"about_ca_topic_score_gemma":0.0000051065904,"teacher_disagreement_score":0.41956732,"about_ca_system_score_codex":0.000047564303,"about_ca_system_score_gemma":0.000033090506,"threshold_uncertainty_score":0.4523181},"labels":[],"label_agreement":null},{"id":"W3000585251","doi":"10.1200/jgo.19.00300","title":"Access to WHO Essential Medicines for Childhood Cancer Care in Trinidad and Tobago: A Health System Analysis of Barriers and Enablers","year":2020,"lang":"en","type":"article","venue":"JCO Global Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Public Health Ontario; University of Toronto; University of British Columbia","funders":"Hospital for Sick Children","keywords":"Essential medicines; Access to medicines; Procurement; Business; Incentive; Context (archaeology); Childhood cancer; Qualitative research; Health care; Medicine; Family medicine; Cancer; Nursing; Public economics; Economic growth; Marketing; Economics; Geography; Sociology","score_opus":0.04562358146426952,"score_gpt":0.3757707441144798,"score_spread":0.33014716265021027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000585251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9370661,0.0067518977,0.0002582602,0.048381418,0.00029043917,0.0007307425,0.0028449115,0.000014465639,0.0036617778],"genre_scores_gemma":[0.98417085,0.00087726285,0.00008448643,0.014661053,0.000118723205,0.00006422879,0.000013668663,0.000007162464,0.000002565691],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986938,0.000023071387,0.00060571916,0.00037740674,0.000018337016,0.0002816553],"domain_scores_gemma":[0.99905443,0.000059085993,0.00026321725,0.00009104454,0.000025451687,0.0005067581],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023328394,0.000118125194,0.0009790265,0.00019788522,0.000044233606,0.000027760047,0.00016103919,0.00009659112,0.00003774836],"category_scores_gemma":[0.00014224362,0.00013067525,0.000080525126,0.0005848101,0.000056797657,0.00008021941,0.00010700897,0.00006732448,0.0000015492288],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008017414,0.000086721906,0.82084846,0.0011403469,0.0016127579,0.000008280157,0.010584122,0.0038269972,0.000008106933,0.121001765,0.008691151,0.031389568],"study_design_scores_gemma":[0.0107647255,0.0022154148,0.53754896,0.000112448164,0.0005468621,0.0000061675732,0.005848166,0.04463984,0.000049752693,0.0015087444,0.39595616,0.00080277777],"about_ca_topic_score_codex":0.0027444444,"about_ca_topic_score_gemma":0.0037897266,"teacher_disagreement_score":0.387265,"about_ca_system_score_codex":0.00042385465,"about_ca_system_score_gemma":0.00023172193,"threshold_uncertainty_score":0.5328782},"labels":[],"label_agreement":null},{"id":"W3001328276","doi":"10.1007/s43441-020-00114-6","title":"Complex Generic Products: Insight of Current Regulatory Frameworks in US, EU and Canada and the Need of Harmonisation","year":2020,"lang":"en","type":"review","venue":"Therapeutic Innovation & Regulatory Science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Authorization; Competitor analysis; Business; Competition (biology); Product (mathematics); Harmonization; Law and economics; Medicine; Marketing; Computer science; Economics; Computer security; Biology","score_opus":0.14794574260159118,"score_gpt":0.3219237387184541,"score_spread":0.1739779961168629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3001328276","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.026913643,0.97035354,0.00007040529,0.0011030985,0.00037032692,0.0007533444,0.0000913679,0.0000070538763,0.0003371946],"genre_scores_gemma":[0.31119177,0.687323,0.000096615055,0.0012252182,0.000084092164,0.000026129603,0.000020045201,0.000022671959,0.000010446162],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975488,0.00006445123,0.0015351226,0.00050059013,0.00011533236,0.00023571416],"domain_scores_gemma":[0.9978111,0.00011603827,0.0014696787,0.00041532912,0.00013331891,0.000054561482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017419757,0.00024035964,0.0011730896,0.0005442875,0.00010157209,0.000047806618,0.00041489184,0.0001375009,0.000018388462],"category_scores_gemma":[0.00013888867,0.0002052238,0.00004812144,0.0021374694,0.0013276417,0.00018853109,0.0001346294,0.0004382793,0.0000015451865],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015738135,0.000023579378,0.0005096919,0.0015364995,0.000043268374,1.936825e-7,0.000348621,0.0000130660155,0.000030384494,0.6705621,0.00007425739,0.32684258],"study_design_scores_gemma":[0.00057128986,0.000021429974,0.012538209,0.00042875833,0.000037547565,0.000004259825,0.000014588089,0.0023751603,0.000038733906,0.009699547,0.97395897,0.00031151477],"about_ca_topic_score_codex":0.0049307756,"about_ca_topic_score_gemma":0.0007498706,"teacher_disagreement_score":0.9738847,"about_ca_system_score_codex":0.00025700612,"about_ca_system_score_gemma":0.0010619672,"threshold_uncertainty_score":0.83687836},"labels":[],"label_agreement":null},{"id":"W3001960456","doi":"10.26633/rpsp.2020.5","title":"A comparison of national essential medicines lists in the Americas","year":2020,"lang":"en","type":"article","venue":"Revista Panamericana de Salud Pública","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Essential medicines; Geography; Latin Americans; Public health; Business; Political science; Medicine; Library science; Computer science","score_opus":0.1179361448584686,"score_gpt":0.38490938613814274,"score_spread":0.26697324127967414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3001960456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6077956,0.011046798,0.004972098,0.2605741,0.00023796855,0.001061273,0.00089930557,0.00009342046,0.11331945],"genre_scores_gemma":[0.98354477,0.0002962571,0.0002504867,0.015575897,0.00026497385,0.000019659507,0.000020279735,0.000016096763,0.000011577403],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99847656,0.000060657916,0.00080990867,0.00028913454,0.000078680445,0.00028504277],"domain_scores_gemma":[0.9989507,0.0002112112,0.00045925062,0.00019452067,0.000032210934,0.00015211372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051810953,0.00013878862,0.0006116075,0.00014168887,0.00004316689,0.000049778042,0.00046988722,0.00004518928,0.00038997436],"category_scores_gemma":[0.00048995204,0.00012977562,0.00012879424,0.00077055127,0.00021103719,0.00006788978,0.000052998934,0.00023429647,0.000121693665],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009162741,0.00039698704,0.3051161,0.0002257,0.0001525848,0.000010728934,0.0069094975,0.0004497869,0.00033488413,0.6087868,0.07249593,0.005029335],"study_design_scores_gemma":[0.00067973055,0.00017694494,0.05461166,0.000021255906,0.000016805137,0.0000060476414,0.00052117294,0.043238938,0.00004878697,0.003663211,0.89667964,0.00033577697],"about_ca_topic_score_codex":0.0005566317,"about_ca_topic_score_gemma":0.000016411845,"teacher_disagreement_score":0.82418376,"about_ca_system_score_codex":0.00008561903,"about_ca_system_score_gemma":0.00008986311,"threshold_uncertainty_score":0.5292096},"labels":[],"label_agreement":null},{"id":"W3004553411","doi":"10.1177/0020731420902600","title":"A Critical Discourse Analysis of Intellectual Property Rights Within NAFTA 1.0: Implications for NAFTA 2.0 and for Democratic (Health) Governance in Canada","year":2020,"lang":"en","type":"article","venue":"International Journal of Health Services","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University","funders":"","keywords":"Intellectual property; Ratification; Government (linguistics); Competition (biology); International trade; Democracy; Business; Economics; Political science; Law; Politics","score_opus":0.07331061639543,"score_gpt":0.37268528562620973,"score_spread":0.2993746692307797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004553411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5414871,0.0061558834,0.008661071,0.4381732,0.0006723087,0.0006598877,0.0039930944,0.000004821609,0.00019265003],"genre_scores_gemma":[0.9859688,0.0004524979,0.0014829201,0.011926797,0.000115049836,0.000017063021,0.000020708623,0.000008899428,0.0000072381913],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9980162,0.00002283414,0.0015061845,0.00019333982,0.000054533775,0.0002069306],"domain_scores_gemma":[0.9979696,0.00045690997,0.0011077549,0.00007632218,0.0001759453,0.00021341776],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057842274,0.00009927962,0.00060506305,0.00017443433,0.00006447787,0.00003589842,0.0003571977,0.000028018972,0.000035580393],"category_scores_gemma":[0.00020746511,0.00008531958,0.000106297404,0.0001993003,0.00003642691,0.00021185695,0.000037398408,0.00011488385,7.164579e-7],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001374233,0.0006475351,0.15187034,0.00263163,0.0034268838,0.000005314331,0.018427491,0.006973662,0.00003662612,0.78901076,0.00875053,0.016844997],"study_design_scores_gemma":[0.0042511867,0.0009898532,0.1461454,0.00045722895,0.00015665934,0.00002683319,0.0013584127,0.6595191,0.00006928391,0.12547782,0.06099628,0.0005519503],"about_ca_topic_score_codex":0.17317797,"about_ca_topic_score_gemma":0.32488957,"teacher_disagreement_score":0.6635329,"about_ca_system_score_codex":0.00040346794,"about_ca_system_score_gemma":0.0007629048,"threshold_uncertainty_score":0.8323279},"labels":[],"label_agreement":null},{"id":"W3006990860","doi":"10.3917/vaca.089.0132","title":"Le Conseil constitutionnel contre la transparence du prix des médicaments","year":2020,"lang":"fr","type":"article","venue":"Vacarme","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Intégré de Santé et de Services Sociaux des Laurentides","funders":"","keywords":"Political science; Philosophy","score_opus":0.07406654749651886,"score_gpt":0.2618192328633744,"score_spread":0.18775268536685552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006990860","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24070737,0.04304602,0.0136221,0.29283625,0.002518791,0.00077290426,0.0048016426,0.00015520585,0.4015397],"genre_scores_gemma":[0.9721742,0.008872172,0.00049166166,0.015427678,0.00049036724,0.000025050214,0.000025787844,0.000036563397,0.0024565137],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978479,0.00007297755,0.00080697326,0.0006044145,0.00003740582,0.00063028565],"domain_scores_gemma":[0.9986813,0.00021033073,0.00027871228,0.00022793296,0.00004116062,0.00056054926],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00035411585,0.0002957213,0.0006487969,0.00008576759,0.00028471107,0.00019066027,0.00041100688,0.00026626533,0.0014771177],"category_scores_gemma":[0.0002461422,0.00042494707,0.0002547108,0.00025773264,0.0011947479,0.00038186408,0.00009613829,0.00040378192,0.002547046],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059251226,0.0002533853,0.02575324,0.00022039341,0.00022461977,0.00004924819,0.0013503814,0.00044002655,0.000056038814,0.9450593,0.020622255,0.005911889],"study_design_scores_gemma":[0.0025520392,0.00008817882,0.0045955535,0.00007282552,0.000040040868,0.00002912245,0.00011142743,0.0136000905,0.00016944976,0.016015993,0.9622383,0.00048698988],"about_ca_topic_score_codex":0.0006458578,"about_ca_topic_score_gemma":0.00002645428,"teacher_disagreement_score":0.94161606,"about_ca_system_score_codex":0.00012251193,"about_ca_system_score_gemma":0.00048228164,"threshold_uncertainty_score":0.99982023},"labels":[],"label_agreement":null},{"id":"W3010104093","doi":"10.1161/circ.141.suppl_1.p373","title":"Abstract P373: Are Generic Drugs Used in Cardiology as Effective and Safe as Their Brand-name Counterparts? A Systematic Review and Meta-analysis","year":2020,"lang":"en","type":"review","venue":"Circulation","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Institut National de Santé Publique du Québec; Université du Québec à Trois-Rivières","funders":"","keywords":"Medicine; Meta-analysis; Confidence interval; MEDLINE; Systematic review; Publication bias; Subgroup analysis; Relative risk; Generic drug; Internal medicine; Brand names; Intensive care medicine; Drug; Pharmacology","score_opus":0.12818646474173778,"score_gpt":0.34098992793424626,"score_spread":0.21280346319250848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010104093","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030501903,0.99486053,0.000046012807,0.0003472288,0.000049143917,0.0026007635,0.0005139647,0.000014463052,0.001262892],"genre_scores_gemma":[0.08800665,0.9100923,0.0000036082565,0.0011226899,0.000048533628,0.00055852387,0.00011616433,0.00003688088,0.000014627388],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9971445,0.00022758797,0.0015749303,0.0007701508,0.000034139626,0.0002486526],"domain_scores_gemma":[0.9975171,0.000478692,0.0014306665,0.0003964648,0.000023847333,0.0001532462],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011236677,0.0004552123,0.008799676,0.0004301862,0.00005621377,0.0001070846,0.00017074424,0.00027243394,0.00019783105],"category_scores_gemma":[0.00024028611,0.0004004994,0.0013553674,0.00049700524,0.000057232035,0.00014505285,0.000067241905,0.0003123735,0.00031681187],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000074033055,0.000042964177,0.00084587454,0.8618117,0.12152812,0.000030128274,0.0005032939,0.00018065042,1.1026897e-7,0.008728418,0.00006806141,0.0062532844],"study_design_scores_gemma":[0.0010322708,0.000057712747,0.0047007003,0.01467158,0.6011328,0.00015991804,0.00004801383,0.0028111339,1.907725e-7,0.009430688,0.36359292,0.0023620287],"about_ca_topic_score_codex":0.00009736453,"about_ca_topic_score_gemma":0.000012400785,"teacher_disagreement_score":0.84714013,"about_ca_system_score_codex":0.00022117217,"about_ca_system_score_gemma":0.000041380626,"threshold_uncertainty_score":0.9998447},"labels":[],"label_agreement":null},{"id":"W3011217342","doi":"10.20529/ijme.2020.027","title":"On being heckled at a National Health Technology Conference: Patient participation and democratic discourse","year":2020,"lang":"en","type":"article","venue":"Indian Journal of Medical Ethics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"","keywords":"Democracy; Political science; Sociology; Politics; Law","score_opus":0.1471069526644052,"score_gpt":0.4049433546229817,"score_spread":0.2578364019585765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011217342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.527819,0.00047213255,0.00080140674,0.46938464,0.0001922958,0.00007436084,0.000033705226,0.0000067266365,0.0012157365],"genre_scores_gemma":[0.9679324,0.00091813534,0.00015334773,0.030810256,0.00016171514,0.0000030023812,0.0000028747463,0.000009460828,0.0000087987355],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9984592,0.000059706497,0.00086905307,0.00015871756,0.00022986064,0.00022345452],"domain_scores_gemma":[0.99824655,0.0003828535,0.0006103118,0.00005796154,0.00007942824,0.0006228971],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017009444,0.000096960015,0.0003547429,0.00018662085,0.00014965543,0.000035059613,0.00018773819,0.0002863796,0.0003927491],"category_scores_gemma":[0.004856197,0.00009451914,0.000056998517,0.00013988881,0.00021953198,0.00008794558,0.00006882028,0.0012994169,0.00006205815],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007453805,0.0001263395,0.00381082,0.00011162968,0.00008753553,0.00006920611,0.012210748,0.00013342062,0.000004056906,0.9690471,0.0028903764,0.011434227],"study_design_scores_gemma":[0.0044211126,0.0026487703,0.0021889594,0.0005347579,0.000016329312,0.00021594985,0.0009652285,0.037286572,0.00019143894,0.9042018,0.046794582,0.0005345105],"about_ca_topic_score_codex":0.0000077363475,"about_ca_topic_score_gemma":0.000027985727,"teacher_disagreement_score":0.4401134,"about_ca_system_score_codex":0.00013914079,"about_ca_system_score_gemma":0.0005646127,"threshold_uncertainty_score":0.58136725},"labels":[],"label_agreement":null},{"id":"W3011937804","doi":"10.1080/16549716.2019.1694745","title":"The risk of corruption in public pharmaceutical procurement: how anti-corruption, transparency and accountability measures may reduce this risk","year":2020,"lang":"en","type":"review","venue":"Global Health Action","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":121,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"World Health Organization","keywords":"Transparency (behavior); Procurement; Accountability; Language change; Business; Corporate governance; Accounting; Public relations; Public economics; Economics; Finance; Marketing; Political science; Law","score_opus":0.27567535385746905,"score_gpt":0.4388084882619515,"score_spread":0.16313313440448246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011937804","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009088553,0.98777485,0.0003339367,0.004209856,0.0011055393,0.0016027828,0.003149098,0.000038582322,0.00087650475],"genre_scores_gemma":[0.08858112,0.91071606,0.00003489309,0.0001886523,0.00025615902,0.00011587548,0.00007349251,0.000024205683,0.000009528301],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963136,0.000428148,0.0017380699,0.0007912528,0.000108333224,0.00062059885],"domain_scores_gemma":[0.9969479,0.00017460808,0.0020575605,0.00037424205,0.00006714602,0.0003785476],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0031291815,0.00040303188,0.0016052838,0.00016350388,0.0003450326,0.0001722807,0.0003449193,0.00034477725,0.00005632916],"category_scores_gemma":[0.0004966857,0.00036181783,0.00032477718,0.0006709471,0.00017704867,0.00035822138,0.000062975414,0.0009825575,0.000070981456],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041462026,0.000117957316,0.007771612,0.0037608328,0.000109380235,2.837672e-7,0.00007057192,0.0000028907061,5.472276e-8,0.008195653,0.00060544634,0.97932386],"study_design_scores_gemma":[0.00048558574,0.00008015087,0.004623059,0.0003056418,0.000104219274,0.000009703622,0.00002139582,0.0008246398,4.4929502e-7,0.0041061174,0.98916537,0.00027364254],"about_ca_topic_score_codex":0.0012079118,"about_ca_topic_score_gemma":0.00038487397,"teacher_disagreement_score":0.98855996,"about_ca_system_score_codex":0.0015532052,"about_ca_system_score_gemma":0.0005283423,"threshold_uncertainty_score":0.99988335},"labels":[],"label_agreement":null},{"id":"W3012043672","doi":"10.1016/s0735-1097(20)31820-9","title":"DUAL ANTIPLATELET VS. DUAL PATHWAY STRATEGIES: AN IN VITRO MECHANISTIC STUDY","year":2020,"lang":"en","type":"article","venue":"Journal of the American College of Cardiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Dual (grammatical number); In vitro; Pharmacology; Biochemistry","score_opus":0.048542225950742875,"score_gpt":0.2847921519922366,"score_spread":0.23624992604149375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012043672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99353826,0.00013718763,0.00023451418,0.003149575,0.00038437604,0.00018269925,0.0005271721,0.000004254642,0.0018419353],"genre_scores_gemma":[0.99789494,0.00009470647,0.00015583518,0.0013704363,0.00045497005,0.0000027837204,9.374104e-7,0.000017861372,0.0000075141184],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99823445,0.0001799204,0.0010548836,0.00021355081,0.0000492301,0.0002679888],"domain_scores_gemma":[0.9982649,0.00013080939,0.0011687326,0.00022973075,0.000047871872,0.00015793537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079020957,0.0001503799,0.0012837503,0.00017521669,0.0000428786,0.000017543427,0.0004240163,0.000048300884,0.000024037054],"category_scores_gemma":[0.00018040679,0.00013011167,0.00026037343,0.00037427762,0.00019822322,0.00015318173,0.00011845442,0.00036593823,0.00001263191],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024237122,0.0029415877,0.28429565,0.00027932515,0.0067236773,0.006839376,0.008140116,0.07051931,0.08506297,0.4912154,0.014826814,0.0049186535],"study_design_scores_gemma":[0.03711687,0.045387827,0.35091117,0.000098808814,0.0005837647,0.0048513315,0.046716217,0.0421519,0.015009416,0.23085535,0.22216126,0.0041561006],"about_ca_topic_score_codex":0.000040292096,"about_ca_topic_score_gemma":0.000008127142,"teacher_disagreement_score":0.26036006,"about_ca_system_score_codex":0.00007352608,"about_ca_system_score_gemma":0.00016070981,"threshold_uncertainty_score":0.53058},"labels":[],"label_agreement":null},{"id":"W3012663038","doi":"10.15586/jptcp.v27i1.658","title":"Alignment of health technology assessments and price negotiations for new drugs for rare disorders in Canada: Does it lead to improved patient access?","year":2020,"lang":"en","type":"article","venue":"Journal of Population Therapeutics and Clinical Pharmacology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Fraser Institute; Canadian Institute for Health Information","funders":"","keywords":"Negotiation; Lead (geology); Business; Public economics; Medicine; Risk analysis (engineering); Economics; Political science; Biology","score_opus":0.13099916809363715,"score_gpt":0.4388243945956525,"score_spread":0.3078252265020153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012663038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73553455,0.00095609046,0.010033145,0.25147912,0.00086725084,0.0009005199,0.00020035545,0.0000029518087,0.000026005331],"genre_scores_gemma":[0.97381,0.0017777914,0.0012039044,0.02304698,0.00012546139,0.0000132204,0.0000056453864,0.000010758067,0.0000062124545],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99808025,0.000030890256,0.0014969837,0.00018204447,0.000023935829,0.00018590252],"domain_scores_gemma":[0.9983977,0.00028109868,0.0010543121,0.00004722564,0.00004359612,0.0001760557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004479939,0.00009260193,0.00051438634,0.00012714366,0.000045122182,0.000015918251,0.0001324124,0.000069581954,0.000020402103],"category_scores_gemma":[0.000073809824,0.00008672999,0.00007074534,0.0001134504,0.000024307685,0.000093592476,0.00005090228,0.00014121493,1.8870955e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014283073,0.00063648407,0.6270769,0.0002926669,0.0009703288,5.118112e-7,0.0014780528,0.0018238819,0.00027833227,0.019962138,0.0068917167,0.33916065],"study_design_scores_gemma":[0.017106805,0.0050817067,0.18914136,0.000048395726,0.00018215839,0.0000024765375,0.0011779449,0.13714999,0.00028452423,0.10730789,0.54188,0.0006367288],"about_ca_topic_score_codex":0.008925912,"about_ca_topic_score_gemma":0.017765138,"teacher_disagreement_score":0.5349883,"about_ca_system_score_codex":0.00015714415,"about_ca_system_score_gemma":0.00026802204,"threshold_uncertainty_score":0.99767375},"labels":[],"label_agreement":null},{"id":"W3013750113","doi":"10.1007/s10728-020-00394-x","title":"When are Pharmaceuticals Priced Fairly? An Alternative Risk-Sharing Model for Pharmaceutical Pricing","year":2020,"lang":"en","type":"article","venue":"Health Care Analysis","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"","keywords":"Philosophy of medicine; Business; Health informatics; Actuarial science; Drug pricing; Public health; Medicine; Alternative medicine","score_opus":0.198469277717815,"score_gpt":0.4060448817579801,"score_spread":0.2075756040401651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013750113","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15970401,0.012342914,0.75892395,0.053096943,0.000448006,0.002477777,0.007085036,0.0004015474,0.0055198167],"genre_scores_gemma":[0.95419407,0.0012006281,0.005164384,0.038509656,0.00049930153,0.00012011493,0.00016707808,0.000068238565,0.00007654569],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99637884,0.00005201244,0.0013456013,0.0012131267,0.00008563942,0.0009248069],"domain_scores_gemma":[0.99701524,0.00015050713,0.0009692287,0.00045232294,0.00012472182,0.001287995],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00084297784,0.00035589313,0.0012740564,0.0004451956,0.00039484593,0.00017670347,0.0006022095,0.00013273419,0.0003328618],"category_scores_gemma":[0.00020259914,0.0004240516,0.0006250392,0.0007235423,0.00006349035,0.00040457444,0.00016901294,0.0004917587,0.00015715715],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011164115,0.00083171314,0.1950551,0.0021877503,0.010536444,0.000019436136,0.08142594,0.4129471,0.00006975349,0.25771,0.009106056,0.028994285],"study_design_scores_gemma":[0.0012359457,0.000099225,0.0006168213,0.00000791316,0.00037775884,4.1838607e-7,0.00038167057,0.9627212,0.00008441286,0.009312945,0.024718734,0.00044293187],"about_ca_topic_score_codex":0.00038918704,"about_ca_topic_score_gemma":0.00011537883,"teacher_disagreement_score":0.79449004,"about_ca_system_score_codex":0.00047338114,"about_ca_system_score_gemma":0.000089483,"threshold_uncertainty_score":0.9998211},"labels":[],"label_agreement":null},{"id":"W3015964222","doi":"","title":"Quelle transparence pour une utilisation sécuritaire des médicaments en dehors de l’étiquette?","year":2020,"lang":"fr","type":"article","venue":"Lex Electronica","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Philosophy; Political science","score_opus":0.06450244904673559,"score_gpt":0.2986999481819888,"score_spread":0.23419749913525323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3015964222","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34461188,0.07700773,0.016024655,0.47391543,0.0010239851,0.00074355735,0.0006277783,0.000159458,0.085885555],"genre_scores_gemma":[0.9613809,0.021008752,0.0010075244,0.013348903,0.0009500232,0.00003968531,0.000034790122,0.000068789865,0.002160639],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99707454,0.000108717635,0.0008255763,0.00069289724,0.00004936494,0.001248905],"domain_scores_gemma":[0.99876076,0.00014757577,0.00028592988,0.00028572173,0.000027372458,0.00049263326],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00048172742,0.0003418301,0.0005604031,0.00009866209,0.0002286661,0.00013281975,0.00055084174,0.00033902004,0.0018930394],"category_scores_gemma":[0.00016629529,0.00049561734,0.00026176922,0.00044755486,0.0002710483,0.00038851873,0.0000691769,0.0007719641,0.0013375017],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001226924,0.00035976482,0.021673376,0.00032431367,0.00033033505,0.0000146594475,0.0031733105,0.0014417998,0.0007855559,0.89508,0.032302555,0.044391684],"study_design_scores_gemma":[0.0011341769,0.00032514412,0.0054707625,0.000056141762,0.000057536552,0.000011769572,0.00007200072,0.06616249,0.0017115361,0.14309211,0.7812981,0.0006082143],"about_ca_topic_score_codex":0.00085708895,"about_ca_topic_score_gemma":0.00023349098,"teacher_disagreement_score":0.7519878,"about_ca_system_score_codex":0.0006210496,"about_ca_system_score_gemma":0.00037151296,"threshold_uncertainty_score":0.99974954},"labels":[],"label_agreement":null},{"id":"W3016167110","doi":"10.1007/s40265-020-01296-x","title":"Are Generic Drugs Used in Cardiology as Effective and Safe as their Brand-name Counterparts? A Systematic Review and Meta-analysis","year":2020,"lang":"en","type":"review","venue":"Drugs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Trois-Rivières; McGill University; Université Laval; Institut National de Santé Publique du Québec","funders":"Université du Québec à Trois-Rivières","keywords":"Medicine; Meta-analysis; Confidence interval; MEDLINE; Brand names; Subgroup analysis; Systematic review; Internal medicine; Relative risk; Randomized controlled trial; Emergency medicine","score_opus":0.10560598533298951,"score_gpt":0.34000375411428563,"score_spread":0.23439776878129612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016167110","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000064906664,0.9911708,0.000011180361,0.0009864268,0.00006792884,0.0029894044,0.001445179,0.000019697596,0.0032444664],"genre_scores_gemma":[0.0025558514,0.9901236,0.0000070654837,0.0056672194,0.000064803535,0.0012269861,0.00006904329,0.00006429983,0.0002211139],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959981,0.0004725143,0.001955001,0.001099568,0.000043026517,0.00043182608],"domain_scores_gemma":[0.99643004,0.0008139717,0.0018297276,0.00062061264,0.000025066562,0.00028060362],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0015839282,0.0007209779,0.016060315,0.0005578126,0.000068789486,0.00013679368,0.00038395036,0.0003155195,0.0002907402],"category_scores_gemma":[0.00030854772,0.0005900285,0.002228522,0.00073442364,0.00011994317,0.00012056155,0.00022546419,0.0005075572,0.00069605384],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010397309,0.00004771667,0.00007450912,0.8054777,0.17788291,0.000059484988,0.0010324375,0.000008629595,1.1899969e-8,0.010735439,0.0005183217,0.0041524745],"study_design_scores_gemma":[0.0003617984,0.0000375788,0.000012647351,0.0043909247,0.2264098,0.00005628815,0.000045638597,0.00016454817,7.8580904e-8,0.0018372054,0.76585245,0.0008310813],"about_ca_topic_score_codex":0.00015758029,"about_ca_topic_score_gemma":0.000017207363,"teacher_disagreement_score":0.8010867,"about_ca_system_score_codex":0.00021185224,"about_ca_system_score_gemma":0.000057258265,"threshold_uncertainty_score":0.9996551},"labels":[],"label_agreement":null},{"id":"W3016416029","doi":"10.1177/1741134320918339","title":"A Novel Development and Portfolio Management Strategy for Generic Small Molecule Drug Products: Watergile ANDA","year":2020,"lang":"en","type":"article","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Apotex (Canada)","funders":"","keywords":"Portfolio; Business; New product development; Commercialization; Project portfolio management; Drug development; Product (mathematics); Process (computing); Risk analysis (engineering); Process management; Marketing; Industrial organization; Drug; Economics; Computer science; Finance; Project management; Pharmacology; Medicine; Management","score_opus":0.13791547266274154,"score_gpt":0.2835873039882082,"score_spread":0.14567183132546666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016416029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47554958,0.08765281,0.2508801,0.17230561,0.010286518,0.0026482448,0.00017067383,0.00003899533,0.0004674671],"genre_scores_gemma":[0.747736,0.062176485,0.0439779,0.09300935,0.048248284,0.0005254058,0.00010647749,0.0005635583,0.0036565904],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965749,0.00003815326,0.002109312,0.00042125906,0.00020506144,0.00065133715],"domain_scores_gemma":[0.9964364,0.000264217,0.0019239888,0.00032009796,0.00055914244,0.0004961251],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024345322,0.00046343642,0.0010706611,0.00028794093,0.0005619035,0.00015435719,0.0009711745,0.00008589366,0.000099306904],"category_scores_gemma":[0.00044807722,0.00026281006,0.00023561885,0.00072633824,0.00021882818,0.00018341656,0.00014318692,0.00037574116,0.0000058352493],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047196047,0.0010909648,0.0022387581,0.005850605,0.009093847,0.0003291955,0.015503438,0.042103123,0.024853056,0.009491338,0.7566099,0.12811616],"study_design_scores_gemma":[0.007119031,0.0005554957,0.002295981,0.00018538214,0.00059938425,0.0017126234,0.0012197148,0.018843919,0.0016073176,0.001920499,0.9632936,0.0006470202],"about_ca_topic_score_codex":0.000017450471,"about_ca_topic_score_gemma":0.0000068715976,"teacher_disagreement_score":0.27218637,"about_ca_system_score_codex":0.00012959239,"about_ca_system_score_gemma":0.0002711009,"threshold_uncertainty_score":0.9999824},"labels":[],"label_agreement":null},{"id":"W3016738206","doi":"10.1097/02024458-200912000-00056","title":"The importance of knowledge brokering and the role of knowledge brokers in the formulation of Swiss Drug Policy","year":2009,"lang":"en","type":"article","venue":"The Canadian Journal of Addiction","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Drug; Business; Knowledge management; Computer science; Pharmacology; Medicine","score_opus":0.01975994752557149,"score_gpt":0.2569806246863683,"score_spread":0.2372206771607968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016738206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9364986,0.02352567,0.000018919698,0.009543513,0.00018550313,0.00022611019,0.00006220657,0.0000013248564,0.029938195],"genre_scores_gemma":[0.9986116,0.00097265036,0.00000803267,0.00019921045,0.00015724587,0.0000016216075,7.761576e-7,0.0000058161777,0.00004299074],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9989326,0.000057665988,0.00074269046,0.000065790824,0.000027419324,0.00017385768],"domain_scores_gemma":[0.9987081,0.0002397809,0.00072979863,0.00017984807,0.00006374926,0.00007868217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001910499,0.000077405464,0.00024518915,0.00022397947,0.00016749214,0.000029486748,0.00032486222,0.000040626524,0.000010347001],"category_scores_gemma":[0.0001668905,0.000045459732,0.00010840734,0.00027310775,0.00019925645,0.00012893137,0.000011167901,0.0002116487,0.0000018857444],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000114874376,0.000030690648,0.023606122,0.000014984728,0.000078721,3.733866e-7,0.011089826,0.00047225464,0.000060841103,0.94504833,0.00084696506,0.018636007],"study_design_scores_gemma":[0.0027895237,0.00020324656,0.41120842,0.00012377111,0.000061469065,0.000048349088,0.0014378277,0.020490397,0.001148759,0.45808864,0.10418819,0.0002114186],"about_ca_topic_score_codex":0.005485308,"about_ca_topic_score_gemma":0.03644269,"teacher_disagreement_score":0.4869597,"about_ca_system_score_codex":0.0001339026,"about_ca_system_score_gemma":0.0002390961,"threshold_uncertainty_score":0.9811397},"labels":[],"label_agreement":null},{"id":"W3016847231","doi":"10.1097/02024458-200912000-00084","title":"Decade Lecture #6: Trends in Prescription Drug Misuse: Strategies for Addressing a Growing Global Public Health Problem","year":2009,"lang":"en","type":"article","venue":"The Canadian Journal of Addiction","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Public health; Medical prescription; Drug misuse; Drug; Prescription drug; Medicine; Political science; Environmental health; Psychiatry; Pharmacology; Nursing","score_opus":0.09851279950154208,"score_gpt":0.3189647399884825,"score_spread":0.22045194048694045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016847231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5179419,0.025330616,0.009684252,0.41478422,0.0021800876,0.00078306644,0.00091671397,0.00003912112,0.028340004],"genre_scores_gemma":[0.99575835,0.000092592825,0.00031036965,0.0035609568,0.00022059407,0.0000034384263,0.000011860219,0.000007988604,0.000033841105],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9988311,0.000032987933,0.0005921819,0.0001233226,0.00002558909,0.00039483828],"domain_scores_gemma":[0.9990807,0.000017935012,0.00043755668,0.00009017518,0.000037585716,0.00033601618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001065909,0.00009990704,0.00023822443,0.00041396104,0.0002520789,0.00031821092,0.00019264281,0.00006639515,0.00006965713],"category_scores_gemma":[0.00003918011,0.00009482944,0.00010869862,0.0003117156,0.000034979017,0.0006979166,0.0000035663265,0.00024966258,0.000003724696],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009487063,0.00007616375,0.0045970473,0.000036452082,0.00013235507,0.000008408179,0.0050154277,0.009725552,0.000028779014,0.6720773,0.046112478,0.26209518],"study_design_scores_gemma":[0.0022935676,0.00038481937,0.07764429,0.0001401318,0.000019382118,0.00012667498,0.00040230004,0.011185485,0.000020161422,0.49265164,0.4147621,0.00036941908],"about_ca_topic_score_codex":0.0068265027,"about_ca_topic_score_gemma":0.06918644,"teacher_disagreement_score":0.47781643,"about_ca_system_score_codex":0.0010273666,"about_ca_system_score_gemma":0.00065344706,"threshold_uncertainty_score":0.99978715},"labels":[],"label_agreement":null},{"id":"W3017378975","doi":"","title":"Le respect des Bonnes pratiques dans le secteur pharmaceutique français","year":2020,"lang":"fr","type":"article","venue":"Lex Electronica","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Political science","score_opus":0.04526026856775616,"score_gpt":0.2816317558050605,"score_spread":0.23637148723730433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3017378975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.31613734,0.14326158,0.005291898,0.24157336,0.0015580293,0.0008910759,0.0007460685,0.00031205954,0.29022858],"genre_scores_gemma":[0.9515559,0.022337321,0.00078452576,0.015874352,0.0023778472,0.00006360992,0.000037915102,0.00014368356,0.006824838],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99615383,0.00017651086,0.0011155127,0.0010202997,0.00005427896,0.0014795774],"domain_scores_gemma":[0.9983415,0.00016698932,0.00041059667,0.00045072965,0.00005248552,0.0005776878],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0006303112,0.0004931971,0.0008871017,0.000150425,0.000487889,0.00030233437,0.0007635892,0.00038097415,0.0013521515],"category_scores_gemma":[0.00023025421,0.00071459607,0.0004198209,0.000559607,0.000532379,0.0007085199,0.00021910643,0.0011884621,0.0015644807],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001546985,0.00035096926,0.0033349374,0.00023987384,0.00036571064,0.000020209396,0.004872554,0.00032053964,0.00304745,0.9504814,0.029066639,0.0077450005],"study_design_scores_gemma":[0.0014840445,0.00040155885,0.0017016855,0.000030430725,0.00003351662,0.000021821272,0.00010341747,0.014013712,0.018853962,0.072970904,0.88962054,0.0007644071],"about_ca_topic_score_codex":0.0034343232,"about_ca_topic_score_gemma":0.0021573817,"teacher_disagreement_score":0.8775105,"about_ca_system_score_codex":0.00035983065,"about_ca_system_score_gemma":0.00095242116,"threshold_uncertainty_score":0.9995608},"labels":[],"label_agreement":null},{"id":"W3020645024","doi":"10.1007/s40268-020-00307-2","title":"Public Health Outcomes May Differ After Switching from Brand-Name to Generic Angiotensin II Receptor Blockers","year":2020,"lang":"en","type":"article","venue":"Drugs in R&D","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institut Universitaire de Cardiologie et de Pneumologie de Québec; Université Laval; Institut National de Santé Publique du Québec","funders":"Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval; Institut National de Santé Publique du Québec","keywords":"Angiotensin Receptor Blockers; Pharmacology; Brand names; Business; Chemistry; Medicine; Internal medicine; Renin–angiotensin system; Advertising","score_opus":0.10373590454889006,"score_gpt":0.28739270910938797,"score_spread":0.1836568045604979,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3020645024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75284266,0.000817324,0.00026135036,0.24408124,0.00042691297,0.00021483559,0.00048058378,0.000041756262,0.0008333191],"genre_scores_gemma":[0.90756863,0.00018611182,0.0020114582,0.089675136,0.0002993435,0.000033784443,0.000035849418,0.000044189717,0.00014550271],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979302,0.00003062299,0.0007789919,0.0005995353,0.000040484494,0.0006201536],"domain_scores_gemma":[0.9988492,0.00007031884,0.00018135979,0.00029462046,0.000009403755,0.00059510383],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00035541708,0.00023826907,0.00067782943,0.00022333398,0.000095507654,0.00011578094,0.00031505286,0.00010233007,0.0010147132],"category_scores_gemma":[0.00011451491,0.0002671138,0.00017091612,0.00031768516,0.000025958787,0.00017388513,0.00024002079,0.00027835296,0.0013177588],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017781448,0.00041001107,0.84484595,0.000057831272,0.00030379352,0.000011378842,0.035881594,0.00020831278,0.00015726984,0.023571331,0.0714888,0.022885917],"study_design_scores_gemma":[0.001504822,0.00007905866,0.14030385,0.000015880818,0.0000038498797,4.6223903e-7,0.00010398717,0.0055378242,0.00006832211,0.003867316,0.84790003,0.0006145685],"about_ca_topic_score_codex":0.00068431644,"about_ca_topic_score_gemma":0.00007909807,"teacher_disagreement_score":0.77641124,"about_ca_system_score_codex":0.00024059789,"about_ca_system_score_gemma":0.00004593614,"threshold_uncertainty_score":0.9999781},"labels":[],"label_agreement":null},{"id":"W3022487952","doi":"10.1016/j.cjca.2020.04.033","title":"Corporate Lobbyists: Open Season on Academic Health Science?","year":2020,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Université du Québec à Trois-Rivières; Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"Abbott Vascular; Servier; Sanofi; Roche; Pfizer","keywords":"Face (sociological concept); Medicine; Institution; Work (physics); Public relations; Academic institution; Affect (linguistics); Health care; Engineering ethics; Medical education; Management; Political science; Social science; Sociology","score_opus":0.2514492318961906,"score_gpt":0.3437562517202675,"score_spread":0.09230701982407691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3022487952","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30966327,0.0066093416,0.0018250748,0.31334275,0.0042603766,0.0006416704,0.0009659117,0.000014902327,0.3626767],"genre_scores_gemma":[0.9701467,0.00033567598,0.00007136229,0.028410912,0.0009761928,0.0000014320896,0.0000023891384,0.0000129755335,0.00004236127],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.998591,0.000024609657,0.00064065534,0.00023894403,0.000023528513,0.00048126225],"domain_scores_gemma":[0.99727833,0.000024435984,0.0007307772,0.00014166364,0.00005379869,0.0017709694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001341202,0.00010592141,0.00062738784,0.00029913924,0.00015980456,0.00009788038,0.0010255441,0.000085070504,0.00010885013],"category_scores_gemma":[0.00024288292,0.00011659615,0.00010974883,0.00029489535,0.00028080237,0.00023092602,0.000052372132,0.00051096163,0.0003704174],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008920283,0.0000024405438,0.091769144,0.00001762085,0.00011099282,0.00006572147,0.00042871755,0.0042185206,0.000020065798,0.7315351,0.1668926,0.004849881],"study_design_scores_gemma":[0.0006291097,0.00039761982,0.018581599,0.000011245871,0.0000033881045,0.00006351558,0.00002990404,0.00042301512,0.000021424914,0.029986188,0.9496999,0.0001530826],"about_ca_topic_score_codex":0.00057333475,"about_ca_topic_score_gemma":0.00011329139,"teacher_disagreement_score":0.7828073,"about_ca_system_score_codex":0.0004596691,"about_ca_system_score_gemma":0.0021892742,"threshold_uncertainty_score":0.476109},"labels":[],"label_agreement":null},{"id":"W3022749090","doi":"10.1016/s0140-6736(20)30160-4","title":"Unfortunate distinction or corporate protectionism by design?","year":2020,"lang":"en","type":"letter","venue":"The Lancet","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Scopus; Intellectual property; Protectionism; Government (linguistics); Democracy; Medical prescription; Political science; Prescription drug; Corporate governance; Medicine; Business; Law; MEDLINE; International trade; Economics; Politics; Nursing; Management","score_opus":0.245760973841721,"score_gpt":0.2897544372364884,"score_spread":0.043993463394767424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3022749090","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000057420613,0.00046625434,0.0074334918,0.9747184,0.0009554865,0.0006935239,0.001977562,0.00012519056,0.0135726575],"genre_scores_gemma":[0.003073672,0.00091609394,0.00021271662,0.97553754,0.009903331,0.00020309887,0.00032507576,0.000087588276,0.009740864],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99838305,0.000056141642,0.0005764379,0.00046918503,0.000036390695,0.00047881567],"domain_scores_gemma":[0.9984327,0.00011047921,0.0008397075,0.00052391214,0.0000151083705,0.00007809072],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00038171536,0.00029131604,0.0008098695,0.00006403419,0.00023705096,0.0002433234,0.0006414468,0.00030538018,0.0009342577],"category_scores_gemma":[0.000101211146,0.000230692,0.0001256059,0.00017846684,0.00011689183,0.000101929785,0.000092116,0.0015245371,0.0028368237],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008055699,0.000008147315,0.000026220974,0.00006913723,0.0000899188,0.000021091902,0.00004644108,0.000020868965,0.0000049189994,0.0031089925,0.99605274,0.00047099215],"study_design_scores_gemma":[0.0004701236,0.00006096697,0.000017257385,0.000009834844,0.00001536367,0.000010300679,0.000001605611,0.0041195946,0.000048171278,0.0742364,0.9206755,0.00033486547],"about_ca_topic_score_codex":0.000108377215,"about_ca_topic_score_gemma":0.000003355956,"teacher_disagreement_score":0.075377196,"about_ca_system_score_codex":0.00013507906,"about_ca_system_score_gemma":0.000045430126,"threshold_uncertainty_score":0.999979},"labels":[],"label_agreement":null},{"id":"W3023863232","doi":"10.1017/dem.2018.11","title":"THE IMPACT OF NEW DRUG LAUNCHES ON LIFE-YEARS LOST IN 2015 FROM 19 TYPES OF CANCER IN 36 COUNTRIES","year":2018,"lang":"en","type":"article","venue":"Journal of Demographic Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute on Aging; Incyte","keywords":"Cancer drugs; Medicine; Demography; Drug; Cancer; Population; Cancer incidence; Incidence (geometry); Environmental health; Mathematics; Pharmacology; Internal medicine","score_opus":0.03581662994321924,"score_gpt":0.31419359977584327,"score_spread":0.27837696983262405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3023863232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863166,0.009261164,0.0000038766725,0.0022575322,0.00045665356,0.000093353614,0.00037307353,0.0000015213794,0.0012362222],"genre_scores_gemma":[0.978324,0.020804677,0.00005827521,0.00037654163,0.00036938733,0.0000012184363,0.0000012973551,0.000019120162,0.000045465167],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99802285,0.000025098861,0.0014797639,0.0001763753,0.000026508416,0.00026939582],"domain_scores_gemma":[0.99774474,0.000348897,0.0014272317,0.00024092225,0.000049260572,0.00018892044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009879236,0.00015682049,0.0007068331,0.0006171152,0.000028541444,0.000044308214,0.00043761087,0.00010641289,0.00030953612],"category_scores_gemma":[0.00014915068,0.0001395486,0.00029978904,0.00025287032,0.0002469888,0.00021122229,0.000045823836,0.00028990093,0.000034824418],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066117576,0.00011203439,0.9685476,0.000011305831,0.00037306902,0.0000017790896,0.00091720617,0.0044952873,0.0000091081065,0.017662954,0.005725651,0.0014828644],"study_design_scores_gemma":[0.0022175491,0.00029694478,0.8706502,0.000085721345,0.000019126062,0.0000021184267,0.00010687811,0.0033629283,0.00016726337,0.10100894,0.021843137,0.00023922064],"about_ca_topic_score_codex":0.0058327923,"about_ca_topic_score_gemma":0.005128876,"teacher_disagreement_score":0.09789739,"about_ca_system_score_codex":0.00019689953,"about_ca_system_score_gemma":0.00037003634,"threshold_uncertainty_score":0.8817476},"labels":[],"label_agreement":null},{"id":"W3025432734","doi":"10.1093/ajhp/zxaa116","title":"National trends in prescription drug expenditures and projections for 2020","year":2020,"lang":"en","type":"article","venue":"American Journal of Health-System Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Drug Policy Research Network; St. Michael's Hospital","funders":"","keywords":"Biosimilar; Medical prescription; Specialty; Prescription drug; Drug; Business; Medicine; Legislation; Family medicine; Pharmacology; Political science","score_opus":0.09670610145906848,"score_gpt":0.3671401722862621,"score_spread":0.2704340708271936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3025432734","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4229917,0.014233953,0.0047281664,0.5451912,0.0020561866,0.0011353473,0.001289723,0.00006762589,0.008306067],"genre_scores_gemma":[0.9931416,0.0005212237,0.0005782392,0.0051594116,0.00051749044,0.000026898218,0.0000068201216,0.000018219129,0.000030079998],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982623,0.000065228276,0.0011627062,0.00021223986,0.000047853784,0.00024969724],"domain_scores_gemma":[0.99844295,0.0000824692,0.0011215532,0.000050423383,0.00004279424,0.0002598238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009466396,0.00011964909,0.0005567342,0.00033056107,0.00009184239,0.000048043457,0.00014494422,0.000014365109,0.000054295913],"category_scores_gemma":[0.000048251142,0.00013030301,0.00011725034,0.00024342033,0.000056370533,0.0002771143,0.000022455435,0.00020758972,0.0000118351645],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021240548,0.0007056588,0.085134216,0.0013887357,0.0006788161,0.000026832264,0.017185707,0.0026892885,0.00029707892,0.1688635,0.33222058,0.38868552],"study_design_scores_gemma":[0.0042217458,0.0005041163,0.008475951,0.000056928737,0.000012101861,0.000117732,0.0010751849,0.03972216,0.00006256988,0.0014712635,0.9439685,0.00031175232],"about_ca_topic_score_codex":0.00040165082,"about_ca_topic_score_gemma":0.000017633001,"teacher_disagreement_score":0.6117479,"about_ca_system_score_codex":0.0002446676,"about_ca_system_score_gemma":0.00012235618,"threshold_uncertainty_score":0.53136027},"labels":[],"label_agreement":null},{"id":"W3026036024","doi":"10.1016/j.jval.2020.04.1082","title":"PNS79 MONOPSONY BUYER: A CRITIQUE OF THE NATIONAL PHARMACEUTICAL PROGRAM PROPOSED FOR CANADA","year":2020,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Monopsony; Government (linguistics); Agency (philosophy); Prescription drug; Medical prescription; Investment (military); Business; Public economics; Political science; Public administration; Economic growth; Economics; Politics; Medicine; Law; Labour economics; Sociology","score_opus":0.1793486899776441,"score_gpt":0.37779381546604734,"score_spread":0.19844512548840323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3026036024","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30195674,0.0030369672,0.0004966047,0.6775442,0.0010420308,0.004931735,0.0024506627,0.00006089601,0.008480149],"genre_scores_gemma":[0.970869,0.00015273876,0.00093842746,0.027719384,0.00017453008,0.0000870526,0.0000055506584,0.000017474915,0.00003580783],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99854517,0.000038609727,0.0007729395,0.00025900902,0.000047494024,0.00033679407],"domain_scores_gemma":[0.99929154,0.0001395497,0.00023519555,0.000090990696,0.000037007834,0.00020573233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062129996,0.000101331105,0.0003243444,0.00004814359,0.00006137453,0.0000170224,0.0002528426,0.00004900213,0.000045035827],"category_scores_gemma":[0.00036833395,0.00009969303,0.00008523675,0.00021967757,0.000033482822,0.000052266692,0.000045521017,0.00020188015,0.0000061334954],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001513879,0.00044516218,0.02477724,0.0014560684,0.00006700765,0.0000011447105,0.0007415559,0.007906521,0.00004446936,0.91822946,0.039977822,0.0062021594],"study_design_scores_gemma":[0.0011443781,0.00012827493,0.0033925157,0.000026335756,0.0000019484796,0.000001407816,0.00001584671,0.33932513,0.00036091765,0.024521448,0.63091886,0.00016297725],"about_ca_topic_score_codex":0.14228459,"about_ca_topic_score_gemma":0.008158775,"teacher_disagreement_score":0.893708,"about_ca_system_score_codex":0.0005776845,"about_ca_system_score_gemma":0.00096088497,"threshold_uncertainty_score":0.863427},"labels":[],"label_agreement":null},{"id":"W3026957398","doi":"10.1016/j.healthpol.2020.05.001","title":"What happens to drug use and expenditure when cost sharing is completely removed? Evidence from a Canadian provincial public drug plan","year":2020,"lang":"en","type":"article","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; Centre for Advancing Health Outcomes; University of British Columbia","funders":"National Health and Medical Research Council; Canada Research Chairs; Michael Smith Health Research BC","keywords":"Cost sharing; Medical prescription; Business; Public economics; Drug; Actuarial science; Demographic economics; Medicine; Economics; Pharmacology; Nursing","score_opus":0.2820006895554179,"score_gpt":0.3537951674710592,"score_spread":0.07179447791564131,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3026957398","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32913563,0.0023163834,0.000045375782,0.662501,0.00038276636,0.00090252695,0.0034820612,0.00005263859,0.0011816395],"genre_scores_gemma":[0.6616097,0.0017625558,0.00035117686,0.3345701,0.0012452987,0.00004182301,0.00006595331,0.000048872065,0.0003044674],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99711835,0.000041352796,0.00082132674,0.00087867735,0.000054083903,0.0010862325],"domain_scores_gemma":[0.99594086,0.00016676782,0.000302839,0.00043040715,0.000029239824,0.0031298853],"candidate_categories":["metaepi_narrow","scholarly_communication","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00046353604,0.00028768764,0.00063973945,0.0004077572,0.00037220478,0.0011932114,0.00054363994,0.000107908454,0.00056331436],"category_scores_gemma":[0.00051107834,0.0003606221,0.00008357334,0.0002533648,0.000062121755,0.0014348077,0.0002879828,0.0004229541,0.0010139424],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012999521,0.00006760074,0.1468532,0.00033667148,0.00012577281,0.000029976336,0.101569526,0.000033959757,0.000018800773,0.21787995,0.5206445,0.012310055],"study_design_scores_gemma":[0.0005106473,0.00003899927,0.023353368,0.00010564281,0.0000031064528,0.000004051066,0.00028714197,0.0053314,0.000012579439,0.006871422,0.96304476,0.0004369058],"about_ca_topic_score_codex":0.77441293,"about_ca_topic_score_gemma":0.38553134,"teacher_disagreement_score":0.44240025,"about_ca_system_score_codex":0.0007853673,"about_ca_system_score_gemma":0.0008151219,"threshold_uncertainty_score":0.99988455},"labels":[],"label_agreement":null},{"id":"W3027314007","doi":"10.1016/j.jval.2020.04.1073","title":"PNS70 US “IMPORT-FROM-CANADA” DRUG LEGISLATION: WILL IT LOWER DRUG COSTS FOR AMERICAN CONSUMERS?","year":2020,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Legislation; European union; Business; Medical prescription; CINAHL; MEDLINE; Public economics; Medicine; International trade; Economics; Political science; Pharmacology; Law","score_opus":0.07922509688112722,"score_gpt":0.30170426512868065,"score_spread":0.22247916824755343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3027314007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6645003,0.003149574,0.00038354585,0.31733617,0.0013568095,0.0010326632,0.002950267,0.000046369078,0.009244292],"genre_scores_gemma":[0.9407404,0.0010149784,0.0005297238,0.057057384,0.0003355743,0.000039411152,0.00006905735,0.00003882555,0.0001746675],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99770945,0.000044635406,0.0010865151,0.00054684473,0.000045516023,0.00056701305],"domain_scores_gemma":[0.9982973,0.0003278322,0.00058242865,0.00026975118,0.00002056185,0.00050214457],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00057243323,0.00019926365,0.0006457387,0.00009874583,0.000104829414,0.000053003747,0.0002799382,0.00004033982,0.0003076032],"category_scores_gemma":[0.00018249112,0.0002576392,0.00010379511,0.00027924363,0.00008194788,0.00019373084,0.000055893503,0.00024759897,0.00011850094],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003878179,0.00031580462,0.39686823,0.00037428635,0.0002255296,0.000027406866,0.004123639,0.009822451,0.00000719016,0.18547267,0.38752306,0.014851921],"study_design_scores_gemma":[0.0010076405,0.00006250575,0.008233032,0.000022862956,0.0000033830884,7.791585e-7,0.00008370085,0.05825362,0.000014431474,0.0058177076,0.9261768,0.00032357598],"about_ca_topic_score_codex":0.67718726,"about_ca_topic_score_gemma":0.09455421,"teacher_disagreement_score":0.5826331,"about_ca_system_score_codex":0.00068639644,"about_ca_system_score_gemma":0.0005819069,"threshold_uncertainty_score":0.9999876},"labels":[],"label_agreement":null},{"id":"W3028345760","doi":"10.1016/j.jval.2020.04.136","title":"PCV31 COST-EFFECTIVENESS OF EVOLOCUMAB FOR THE TREATMENT OF PATIENTS WITH HYPERCHOLESTEROLEMIA IN THE KINGDOM OF SAUDI ARABIA","year":2020,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada)","funders":"","keywords":"Evolocumab; Medicine; Familial hypercholesterolemia; Ezetimibe; PCSK9; Statin; Internal medicine; Population; Atherosclerotic cardiovascular disease; Cohort; Observational study; Gastroenterology; Cholesterol; Lipoprotein; Disease; LDL receptor","score_opus":0.17483326838493118,"score_gpt":0.3406081854431775,"score_spread":0.16577491705824632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028345760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994803,0.0009790284,0.0001708335,0.0019108545,0.000055741682,0.0015127873,0.00043658094,0.0000017496931,0.00012941919],"genre_scores_gemma":[0.9986746,0.0005785618,0.00008159477,0.00051612494,0.000020741616,0.0001080716,0.0000090020785,0.000010492736,8.2107914e-7],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988842,0.00009238488,0.00063248014,0.00017576394,0.000029456476,0.00018573852],"domain_scores_gemma":[0.9985466,0.00080610043,0.00037593744,0.00020863434,0.000020172647,0.000042578118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008410685,0.00009292513,0.00046287818,0.000063376756,0.000023106817,0.0000052996,0.00018888815,0.000036970854,0.000006340121],"category_scores_gemma":[0.00007154437,0.00006235105,0.00006905515,0.00019672212,0.000067043424,0.000039808114,0.000012788486,0.00007307724,0.0000018629181],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010766082,0.0009760172,0.9064401,0.0009378599,0.000071211856,2.687281e-7,0.0047606924,0.024416517,0.0000072745534,0.054723594,0.00003254562,0.006557343],"study_design_scores_gemma":[0.0064029177,0.0024549626,0.9486011,0.00011596761,0.0000100792395,2.2664224e-7,0.00008753053,0.023145754,0.00021679638,0.0051012454,0.013736885,0.00012650546],"about_ca_topic_score_codex":0.0026099086,"about_ca_topic_score_gemma":0.00004970836,"teacher_disagreement_score":0.049622346,"about_ca_system_score_codex":0.00015227613,"about_ca_system_score_gemma":0.00006295376,"threshold_uncertainty_score":0.39454186},"labels":[],"label_agreement":null},{"id":"W3032207135","doi":"10.1177/1715163520929387","title":"Role of Canadian pharmacists in managing drug shortage concerns amid the COVID-19 pandemic","year":2020,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Pandemic; Coronavirus disease 2019 (COVID-19); Economic shortage; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Drug; Virology; Business; Medicine; Pharmacology; Infectious disease (medical specialty); Outbreak; Government (linguistics); Internal medicine","score_opus":0.1395501260332121,"score_gpt":0.3000084131879554,"score_spread":0.1604582871547433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032207135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93597835,0.011745668,0.000069374815,0.010693987,0.002205838,0.0011361411,0.0076122857,0.000053137628,0.030505206],"genre_scores_gemma":[0.93557274,0.015957758,0.000030226802,0.047278043,0.00082352717,0.000026441021,0.00004009115,0.000078291305,0.00019289002],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958261,0.00014672143,0.0015630587,0.0006792808,0.00014551876,0.0016392723],"domain_scores_gemma":[0.9923797,0.00019823818,0.0006257695,0.0003400891,0.00011900777,0.006337175],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014378525,0.0004940221,0.0008183356,0.0012709853,0.0007070762,0.00023897244,0.0015950744,0.00009666507,0.0029957863],"category_scores_gemma":[0.00038229502,0.00055329123,0.00026843132,0.0016277612,0.00035839202,0.0004446682,0.00009314539,0.0012813038,0.00008297594],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067421625,0.00020238927,0.42930853,0.001529523,0.0017578019,0.057703514,0.050575476,0.054208282,0.0030826388,0.03578623,0.30362457,0.061546825],"study_design_scores_gemma":[0.0031902813,0.000028420971,0.0001561763,0.000012051246,0.00006751376,0.031128738,0.00009781214,0.042610336,0.00039508665,0.0037301758,0.9174896,0.0010938215],"about_ca_topic_score_codex":0.5760144,"about_ca_topic_score_gemma":0.812776,"teacher_disagreement_score":0.613865,"about_ca_system_score_codex":0.004684122,"about_ca_system_score_gemma":0.005070411,"threshold_uncertainty_score":0.99969184},"labels":[],"label_agreement":null},{"id":"W3032641233","doi":"10.1377/hlthaff.2019.00673","title":"Estimating The Cost Of Delayed Generic Drug Entry To Medicaid","year":2020,"lang":"en","type":"article","venue":"Health Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicaid; Quarter (Canadian coin); Generic drug; Brand names; Market share; Business; Medicine; Actuarial science; Advertising; Marketing; Economics; Health care; Drug; Pharmacology","score_opus":0.08222174286204792,"score_gpt":0.3187130681155804,"score_spread":0.2364913252535325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032641233","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14944024,0.0068287607,0.025133684,0.7482871,0.0017281013,0.0017663741,0.0009909739,0.00012409635,0.06570071],"genre_scores_gemma":[0.9551749,0.00021779977,0.0027276697,0.041426573,0.0003447845,0.00003173417,0.000009326811,0.000019757052,0.000047437406],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985848,0.000017442055,0.000730307,0.000262933,0.0000325759,0.0003719277],"domain_scores_gemma":[0.9988326,0.00008975587,0.00032921345,0.00021232647,0.00001285637,0.0005232915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056994107,0.000109134526,0.00036030984,0.00005739953,0.00010329471,0.000019650553,0.00030299154,0.000034280267,0.00035278202],"category_scores_gemma":[0.0001912263,0.00010295555,0.00007545524,0.0002592619,0.000048390295,0.000051658935,0.00009548146,0.00017323815,0.00062379194],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016532987,0.00019005567,0.0076005226,0.00064711244,0.00018084688,0.0000055401842,0.018913679,0.020057704,0.00003462124,0.34490544,0.5649481,0.042351056],"study_design_scores_gemma":[0.0010223177,0.00020272621,0.0015040049,0.000030892297,0.0000069436055,0.0000042090737,0.000566122,0.33019334,0.00011104872,0.00730527,0.65869963,0.0003534879],"about_ca_topic_score_codex":0.00028641176,"about_ca_topic_score_gemma":0.000026204325,"teacher_disagreement_score":0.8057347,"about_ca_system_score_codex":0.00008324062,"about_ca_system_score_gemma":0.00009929156,"threshold_uncertainty_score":0.8017792},"labels":[],"label_agreement":null},{"id":"W3032689621","doi":"10.1542/28.12.15","title":"Manufacturing issue leads to shortage of PedvaxHIB vaccine","year":2007,"lang":"en","type":"article","venue":"AAP News","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Economic shortage; Quarter (Canadian coin); Conjugate vaccine; Business; Virology; Medicine; Immunization; Immunology; Antigen; Geography","score_opus":0.04836549465739591,"score_gpt":0.3077629444850202,"score_spread":0.25939744982762425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032689621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.850664,0.00041973928,0.0011329218,0.0034101147,0.00043122555,0.00018018538,0.00006798361,0.000025584337,0.1436682],"genre_scores_gemma":[0.991221,0.00013465404,0.0006457874,0.004568039,0.00036613594,0.000004268597,0.0000057802317,0.000025087644,0.003029234],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986414,0.000003759959,0.00067871186,0.00028369436,0.000020197262,0.0003722607],"domain_scores_gemma":[0.999243,0.00005740538,0.00016200801,0.00031410897,0.000009999419,0.00021347872],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00046473107,0.0001326844,0.0003771158,0.00023996148,0.000036788304,0.00002266299,0.00024048302,0.00007526957,0.0016044133],"category_scores_gemma":[0.000043983237,0.00015674895,0.00010348391,0.00011506394,0.000013733363,0.000107091444,0.00008348102,0.00014126931,0.002673082],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035531438,0.00055586844,0.23849651,0.000284629,0.0003072876,0.000047653946,0.0030611742,0.0009841311,0.005361471,0.53798217,0.13174471,0.0808191],"study_design_scores_gemma":[0.00039503447,0.00006401203,0.030788321,0.000006495931,0.000005794321,0.0000024113463,0.000027777109,0.00009325201,0.027086273,0.005479689,0.93581223,0.00023872104],"about_ca_topic_score_codex":0.0003593131,"about_ca_topic_score_gemma":0.00024400711,"teacher_disagreement_score":0.8040675,"about_ca_system_score_codex":0.00005065135,"about_ca_system_score_gemma":0.000009144858,"threshold_uncertainty_score":0.9993082},"labels":[],"label_agreement":null},{"id":"W3033230077","doi":"10.1177/0972266120929146","title":"Pharmaceutical Market and Drug Price Policy in India","year":2020,"lang":"en","type":"article","venue":"Review of Development and Change","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute on Governance","funders":"","keywords":"Drug prices; Business; Pharmaceutical industry; Drug pricing; Health care; Price policy; Public economics; Drug; Economics; Industrial organization; Economic growth; Actuarial science; Pharmacology; Medicine","score_opus":0.10543514359858008,"score_gpt":0.31927073114878085,"score_spread":0.21383558755020077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033230077","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15429123,0.699228,0.00001670912,0.06488385,0.000113085654,0.0010828172,0.000115018076,0.000025646788,0.08024366],"genre_scores_gemma":[0.40355816,0.5571844,0.00054017425,0.038369246,0.00016511205,0.000057563044,0.000008910745,0.000016195738,0.000100236706],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99904114,0.000014220835,0.00050406216,0.0002227298,0.000020372847,0.00019748883],"domain_scores_gemma":[0.9995798,0.000033041222,0.00013732188,0.000059599355,0.000006348162,0.0001838911],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004342724,0.000113930626,0.00041955826,0.00010649841,0.000021985867,0.000012746607,0.000091763206,0.000033270753,0.00031094856],"category_scores_gemma":[0.00007038608,0.000121660465,0.0000294669,0.00021875289,0.000036909816,0.000101355035,0.00011179508,0.00010192063,0.000044794557],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008571636,0.00027048035,0.2320966,0.046933834,0.00021305263,0.000022713511,0.016365975,5.8341683e-8,0.000020700087,0.3114495,0.019654771,0.37288663],"study_design_scores_gemma":[0.00047098575,0.000011253657,0.07977128,0.0005482649,0.0000043623027,0.000002269839,0.000013236684,0.00015174766,0.000064781016,0.0006714362,0.91809756,0.00019284453],"about_ca_topic_score_codex":0.000015468902,"about_ca_topic_score_gemma":0.0000014392642,"teacher_disagreement_score":0.89844275,"about_ca_system_score_codex":0.000031720527,"about_ca_system_score_gemma":0.000030981308,"threshold_uncertainty_score":0.49611697},"labels":[],"label_agreement":null},{"id":"W3034059041","doi":"10.1186/s12992-020-00579-y","title":"Revisiting the public health implications of the United States–Mexico– Canada agreement","year":2020,"lang":"en","type":"letter","venue":"Globalization and Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Public health; Agreement; Social policy; Biosimilar; Political science; Free trade agreement; Health services research; Medicine; Law; International trade; Business; Health care; Free trade","score_opus":0.13236834519523386,"score_gpt":0.3292878207365232,"score_spread":0.19691947554128933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034059041","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000747011,0.00248508,0.0010464109,0.9907182,0.00028538005,0.0004722801,0.0026636096,0.000011679103,0.002242655],"genre_scores_gemma":[0.010788571,0.007105876,0.00002359231,0.980262,0.00052009826,0.000015195974,0.0011537742,0.000018289858,0.00011262486],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99812716,0.000101230165,0.0009818292,0.00031150022,0.000058297424,0.00041999188],"domain_scores_gemma":[0.9980702,0.000049764276,0.0012601196,0.00038208498,0.00005202418,0.00018582138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005814177,0.00016754675,0.00043799105,0.00007812998,0.0004417642,0.00008670354,0.0003621737,0.000082874074,0.00010554789],"category_scores_gemma":[0.000059392725,0.00013530099,0.00006634149,0.00052547146,0.00007114664,0.00003812076,0.0001202746,0.00043473142,0.000011563411],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[4.0759878e-7,0.000003875761,0.0035307684,0.000195515,0.00002749521,1.732066e-7,0.0001421982,0.00003832805,6.529501e-9,0.14781086,0.8473326,0.00091777096],"study_design_scores_gemma":[0.00014074988,0.000012043423,0.0061797895,0.000029310015,0.000002841199,0.0000024894798,0.000031969543,0.0026835399,9.3548124e-8,0.00571681,0.98508805,0.0001122879],"about_ca_topic_score_codex":0.24739344,"about_ca_topic_score_gemma":0.032455076,"teacher_disagreement_score":0.21493836,"about_ca_system_score_codex":0.0007145117,"about_ca_system_score_gemma":0.0011573604,"threshold_uncertainty_score":0.9852001},"labels":[],"label_agreement":null},{"id":"W3034406571","doi":"10.7189/jogh.10.010314","title":"Collective pharmaceutical procurement in China may have unintended consequences in supply and pricing","year":2020,"lang":"en","type":"review","venue":"Journal of Global Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Procurement; Business; Unintended consequences; China; Drug prices; Drug industry; Industrial organization; Commerce; Monetary economics; Economics; Marketing","score_opus":0.13724960773687855,"score_gpt":0.43478856578825276,"score_spread":0.2975389580513742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034406571","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001650806,0.9836823,0.000028659091,0.010880503,0.00031409136,0.0006961025,0.00034284272,0.000004122478,0.0038863285],"genre_scores_gemma":[0.015538175,0.98265624,0.00025319995,0.0013382174,0.00015947771,0.0000117814725,0.0000037114598,0.000018673287,0.000020506204],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963933,0.00015211555,0.0024970754,0.00037494296,0.00006235142,0.0005201754],"domain_scores_gemma":[0.9975963,0.00008486254,0.0017246521,0.00009637694,0.000027863378,0.00046992846],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015305325,0.00032135934,0.0026818146,0.0003527926,0.00004950919,0.0000718584,0.00029870286,0.00017414808,0.00005140122],"category_scores_gemma":[0.00018688709,0.00030891242,0.00023977495,0.000543742,0.00019437708,0.00014246962,0.00009415017,0.0009959813,0.00001962343],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021590549,0.0004357101,0.013807862,0.009244773,0.00036723344,0.0003523382,0.001130202,0.000021744576,6.079244e-8,0.15865894,0.002301734,0.8134635],"study_design_scores_gemma":[0.0012348876,0.00033810423,0.0013391847,0.0031177418,0.000030056088,0.0003376505,0.00004494853,0.00031194702,2.2622702e-7,0.021915339,0.97104394,0.00028596364],"about_ca_topic_score_codex":0.00045957995,"about_ca_topic_score_gemma":0.00025945486,"teacher_disagreement_score":0.9687422,"about_ca_system_score_codex":0.0065052733,"about_ca_system_score_gemma":0.003512614,"threshold_uncertainty_score":0.9999363},"labels":[],"label_agreement":null},{"id":"W3034653469","doi":"10.1016/j.sapharm.2020.06.007","title":"Drug price transparency initiative: The need for a broader view","year":2020,"lang":"en","type":"letter","venue":"Research in Social and Administrative Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences","funders":"","keywords":"Transparency (behavior); Drug; Business; Accounting; Computer science; Medicine; Pharmacology; Computer security","score_opus":0.5817841710345911,"score_gpt":0.5001402218073251,"score_spread":0.08164394922726603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034653469","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000505633,0.004274625,0.00006381256,0.95089793,0.00018767627,0.0015079094,0.0039300458,0.000020033187,0.03861231],"genre_scores_gemma":[0.24601524,0.0063695293,0.00006816958,0.73708224,0.0077368007,0.0012829946,0.00027638036,0.00008862618,0.0010800457],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99699295,0.00031090408,0.00086420745,0.0007690549,0.00011961962,0.000943264],"domain_scores_gemma":[0.9981862,0.0010912151,0.0002838119,0.00015468987,0.00008915531,0.00019496275],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0012783029,0.00035646989,0.00079465023,0.00017206246,0.0006164482,0.00028072987,0.00063092425,0.00019517736,0.00039012468],"category_scores_gemma":[0.00016656087,0.00033262649,0.0002444304,0.0006192865,0.00067505037,0.00021073483,0.00013012304,0.0027709764,0.00013381218],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001266705,0.00009440912,0.0005830664,0.00072717224,0.00018871161,0.00007160841,0.0037921474,1.9455743e-7,0.00000369347,0.0699716,0.921835,0.002605699],"study_design_scores_gemma":[0.0011501629,0.000057075984,0.00015808878,0.00003171184,0.000010656702,0.0000021618575,0.00019208528,0.00029440367,0.000021233278,0.15156706,0.8461963,0.00031905583],"about_ca_topic_score_codex":0.00016795032,"about_ca_topic_score_gemma":0.000025692965,"teacher_disagreement_score":0.24550961,"about_ca_system_score_codex":0.00022176994,"about_ca_system_score_gemma":0.00041995835,"threshold_uncertainty_score":0.99991256},"labels":[],"label_agreement":null},{"id":"W3035438457","doi":"10.15586/jptcp.v27i2.673","title":"Regulatory approval and public drug plan listing of new drugs for rare disorders in Canada and New Zealand","year":2020,"lang":"en","type":"article","venue":"Journal of Population Therapeutics and Clinical Pharmacology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Fraser Institute; Canadian Institute for Health Information","funders":"","keywords":"Formulary; Orphan drug; Listing (finance); Negotiation; Business; Reimbursement; Public health; Population; Pharmaceutical industry; Medicine; Family medicine; Health care; Finance; Environmental health; Political science; Economic growth; Pharmacology; Economics","score_opus":0.13788971459259763,"score_gpt":0.35350292540534456,"score_spread":0.21561321081274692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035438457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9689051,0.0019031104,0.0000950956,0.028502015,0.00037029033,0.00013923435,0.000036290017,0.0000018801126,0.00004696631],"genre_scores_gemma":[0.99191886,0.0023909132,0.00028030062,0.0049356394,0.0004233757,7.185544e-7,0.000004200506,0.000011588412,0.0000343974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99849755,0.00003483586,0.00110689,0.0001692529,0.000027006075,0.0001644594],"domain_scores_gemma":[0.9985577,0.00033605346,0.00071774493,0.00003960762,0.000020788637,0.00032813058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049520965,0.0000977485,0.00047755384,0.000078847865,0.000032228807,0.000021983478,0.00008921525,0.0000693922,0.00003094985],"category_scores_gemma":[0.00007473935,0.00010112424,0.00006069054,0.00006624134,0.00004990733,0.00011032382,0.000036275134,0.00023099703,1.9710112e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032736507,0.000048833692,0.946172,0.000051080635,0.00018106114,8.499899e-7,0.0005946733,0.00010322275,0.000023674711,0.00492013,0.0034428544,0.044134248],"study_design_scores_gemma":[0.011229928,0.00042114078,0.6633187,0.000020344918,0.000118709024,0.00001029239,0.00030415374,0.04729881,0.00002368071,0.06303427,0.2138522,0.00036779],"about_ca_topic_score_codex":0.043584365,"about_ca_topic_score_gemma":0.04162596,"teacher_disagreement_score":0.28285334,"about_ca_system_score_codex":0.000045967696,"about_ca_system_score_gemma":0.00021168335,"threshold_uncertainty_score":0.97586185},"labels":[],"label_agreement":null},{"id":"W3036463221","doi":"10.71781/4599","title":"L’impact du type d’assurance médicaments (privée/publique) sur le coût des médicaments et les dépenses des Québécois","year":2019,"lang":"fr","type":"dissertation","venue":"Open MIND","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Université de Montréal","keywords":"Political science; Medicine","score_opus":0.11288569780830918,"score_gpt":0.3546237424207439,"score_spread":0.24173804461243473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036463221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9008971,0.0092600165,0.00006340366,0.0016833771,0.0014020954,0.0011358408,0.0019627213,0.000006304559,0.083589144],"genre_scores_gemma":[0.94912493,0.017934414,0.0021196222,0.00096838747,0.00017678582,0.00006492261,0.0011788121,0.00016776724,0.02826436],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955849,0.00016052354,0.0017271853,0.0013195855,0.00011066666,0.0010971609],"domain_scores_gemma":[0.9964986,0.00042877422,0.0015428996,0.0007709995,0.0002673632,0.00049135165],"candidate_categories":["metaepi_narrow","scholarly_communication","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0014084142,0.00082429824,0.0015874646,0.00043997326,0.0005572762,0.001439212,0.0016956648,0.0007415064,0.009167123],"category_scores_gemma":[0.0007840969,0.0010065074,0.00046692308,0.0005057956,0.0004423598,0.0016408844,0.00040961715,0.00077919563,0.006080982],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009959472,0.002437843,0.7728266,0.0006131061,0.0020985475,0.00003281405,0.008582933,0.0010175903,0.0003274146,0.01636016,0.0077992417,0.18690778],"study_design_scores_gemma":[0.0031478668,0.00048934016,0.3811647,0.00064521196,0.00011211813,0.000020728086,0.0006186885,0.0029807198,0.0007925981,0.0025111444,0.6059687,0.0015481765],"about_ca_topic_score_codex":0.0870146,"about_ca_topic_score_gemma":0.023413623,"teacher_disagreement_score":0.59816945,"about_ca_system_score_codex":0.0007294089,"about_ca_system_score_gemma":0.001821958,"threshold_uncertainty_score":0.9995974},"labels":[],"label_agreement":null},{"id":"W3036756415","doi":"10.1177/0840470420932185","title":"Gross profits of Canadian pharmacies: A changing policy regime","year":2020,"lang":"en","type":"article","venue":"Healthcare Management Forum","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; University of Alberta","funders":"Association des pharmaciens du Canada","keywords":"Gross profit; Pharmacy; Business; Profit (economics); Finance; Government (linguistics); Agricultural economics; Economics; Public economics","score_opus":0.10983196799634733,"score_gpt":0.3117122706118717,"score_spread":0.20188030261552437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036756415","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018081196,0.0023438847,0.00051261386,0.7109817,0.00051047263,0.0012964486,0.0010756259,0.00010304202,0.26509497],"genre_scores_gemma":[0.9385307,0.0015693866,0.00026337538,0.058510467,0.00025113573,0.000049750335,0.000026665257,0.00003514996,0.00076336367],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980663,0.000013186658,0.00060754956,0.00039311888,0.000036880327,0.00088296906],"domain_scores_gemma":[0.99884355,0.000011788735,0.00024166788,0.00024536793,0.00002234911,0.0006352766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002785539,0.00016929668,0.00037377002,0.0013170436,0.00015302493,0.000041907922,0.0003347275,0.00006638776,0.00023973343],"category_scores_gemma":[0.000029150035,0.00021739647,0.000117611526,0.0013339294,0.00004435432,0.00014229007,0.00016522009,0.00015365909,0.0005604405],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015812291,0.00001608318,0.0042893887,0.00047158994,0.0000666848,0.000009899993,0.0010565433,0.000028061053,0.0000023324185,0.9785117,0.011491796,0.0040401192],"study_design_scores_gemma":[0.00067158643,0.00007743736,0.00094546477,0.000026490537,0.0000062699223,0.0000018299944,0.00054357655,0.0040082433,0.000110081266,0.014661861,0.97866815,0.00027902966],"about_ca_topic_score_codex":0.033841547,"about_ca_topic_score_gemma":0.0027427783,"teacher_disagreement_score":0.9671763,"about_ca_system_score_codex":0.0002109967,"about_ca_system_score_gemma":0.00007721991,"threshold_uncertainty_score":0.9725922},"labels":[],"label_agreement":null},{"id":"W3038035002","doi":"10.1186/s12916-020-01661-3","title":"Why the COVID-19 pandemic should be a call for action to advance equitable access to medicines","year":2020,"lang":"en","type":"article","venue":"BMC Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto","funders":"","keywords":"Medicine; Coronavirus disease 2019 (COVID-19); Pandemic; 2019-20 coronavirus outbreak; Call to action; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Virology; Action (physics); Coronavirus Infections; Betacoronavirus; Infectious disease (medical specialty); Outbreak; Disease; Internal medicine; Marketing","score_opus":0.5341244586341032,"score_gpt":0.46794289125974886,"score_spread":0.06618156737435432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3038035002","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008231569,0.0012857943,0.19103171,0.79260945,0.0008086322,0.0012380836,0.00023670135,0.00007837424,0.0044796728],"genre_scores_gemma":[0.14901617,0.0003949581,0.0005144693,0.84734654,0.0019488521,0.00029874715,0.000025259438,0.00003566803,0.0004193456],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998273,0.000018648409,0.00064267847,0.00052363065,0.000058311325,0.00048372566],"domain_scores_gemma":[0.9979122,0.0006051738,0.00018579923,0.00033376276,0.000036437305,0.00092660345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010613888,0.0001946949,0.0005259455,0.00014202064,0.00016918103,0.000046834844,0.0006433258,0.000078986675,0.0007061335],"category_scores_gemma":[0.0038681808,0.00015255164,0.00007931715,0.00041504408,0.00007724924,0.00018598852,0.0001904108,0.00017469341,0.00014025603],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027823632,0.000020531756,0.013687704,0.00020268242,0.000032982207,0.0000010216496,0.0013524628,0.0017561478,0.00025068483,0.017755385,0.9635675,0.001094687],"study_design_scores_gemma":[0.0013253023,0.0002641748,0.00062098505,0.000015356169,0.000018623694,0.0000043575606,0.00011552564,0.0052965055,0.000042874497,0.006052968,0.9860525,0.00019082565],"about_ca_topic_score_codex":0.0005000352,"about_ca_topic_score_gemma":0.00077593344,"teacher_disagreement_score":0.19051725,"about_ca_system_score_codex":0.00018493771,"about_ca_system_score_gemma":0.000076970406,"threshold_uncertainty_score":0.77316666},"labels":[],"label_agreement":null},{"id":"W3038651714","doi":"10.1002/cpt.1981","title":"Comparing Onset of Biosimilar Versus Generic Competition in the United States","year":2020,"lang":"en","type":"article","venue":"Clinical Pharmacology & Therapeutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Novo Nordisk Fonden","keywords":"Biosimilar; Statutory law; Competition (biology); Medicine; Generic drug; Business; Pharmacology; Drug; Internal medicine; Law; Political science","score_opus":0.40271137957245057,"score_gpt":0.4240386167015656,"score_spread":0.02132723712911505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3038651714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94120705,0.0007787431,0.00022539425,0.055346504,0.000867384,0.00022571834,0.00013414495,0.000022222626,0.0011928537],"genre_scores_gemma":[0.8154889,0.003560462,0.00008202631,0.18055524,0.00023064714,0.000009769814,0.000055628385,0.000014770822,0.0000026057385],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99815834,0.00018612287,0.0010509667,0.0002917514,0.000027748887,0.00028508174],"domain_scores_gemma":[0.9984891,0.00086347613,0.00034409433,0.00016458811,0.000025392257,0.00011337913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077820395,0.00014727173,0.00050741434,0.0001112062,0.00005409466,0.000019415613,0.0004888057,0.00012670158,0.00027934264],"category_scores_gemma":[0.000028137676,0.00014074187,0.00015262883,0.00041181047,0.00032045043,0.00005343423,0.000083248764,0.00049992424,0.00017966254],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007798483,0.005549202,0.7319812,0.0003534078,0.0041902564,0.000099116645,0.010524081,0.030823823,0.0011817612,0.09944703,0.1056435,0.0024080907],"study_design_scores_gemma":[0.0075814305,0.0007077862,0.031169273,0.0000069022653,0.00015971906,0.0000023846646,0.00022854091,0.2889323,0.00048611267,0.0051106396,0.6652296,0.00038530416],"about_ca_topic_score_codex":0.000030653737,"about_ca_topic_score_gemma":0.0000072255843,"teacher_disagreement_score":0.700812,"about_ca_system_score_codex":0.00003546677,"about_ca_system_score_gemma":0.000025656249,"threshold_uncertainty_score":0.5739287},"labels":[],"label_agreement":null},{"id":"W3039703740","doi":"10.34172/ijhpm.2020.100","title":"Development Time and Patent Extension for Prescription Drugs in Canada: A Cohort Study","year":2020,"lang":"en","type":"article","venue":"International Journal of Health Policy and Management","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University; University of Toronto; University Health Network","funders":"","keywords":"Medical prescription; Medicine; Cohort; Demography; Pharmacology; Internal medicine","score_opus":0.10679156050896219,"score_gpt":0.33212547263110587,"score_spread":0.22533391212214368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3039703740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92749363,0.0008356838,0.00041966248,0.069534294,0.00027507136,0.00069639506,0.000046182024,0.0000029272235,0.00069615175],"genre_scores_gemma":[0.9842659,0.0013997769,0.00052750617,0.013604279,0.0001315636,0.00001511257,0.000003615816,0.0000063721664,0.000045866855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99892604,0.000014034479,0.00072560203,0.00014124632,0.000053071617,0.00013999674],"domain_scores_gemma":[0.9994428,0.000022046299,0.0003435326,0.000034368495,0.00002957264,0.00012768031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006809993,0.00006870995,0.00023498865,0.00017738076,0.000035351874,0.000029387482,0.00010262399,0.000011384343,0.000012508675],"category_scores_gemma":[0.000033579534,0.00007268151,0.000019354353,0.00004085649,0.0000076598335,0.00008506818,0.00007546726,0.000060453094,0.0000035610542],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012362333,0.0011197145,0.35554972,0.000764624,0.0021559526,0.00010897572,0.018191354,0.0015184308,0.000018477702,0.29068762,0.027123654,0.30152524],"study_design_scores_gemma":[0.002998662,0.00018245645,0.6304522,0.000048847625,0.0000073973247,0.0000090907615,0.00037376786,0.008709465,0.000004240685,0.003305221,0.35375288,0.00015577135],"about_ca_topic_score_codex":0.076255366,"about_ca_topic_score_gemma":0.013386173,"teacher_disagreement_score":0.32662922,"about_ca_system_score_codex":0.00054649956,"about_ca_system_score_gemma":0.0001887433,"threshold_uncertainty_score":0.92989594},"labels":[],"label_agreement":null},{"id":"W3041069404","doi":"10.1136/bmj.m2797","title":"US purchases world stocks of remdesivir: why the rest of the world should be glad to be at the back of the queue","year":2020,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Rest (music); Queue; Coronavirus disease 2019 (COVID-19); Economics; History; Computer science; Medicine; Internal medicine","score_opus":0.20237255918506483,"score_gpt":0.3375962559495461,"score_spread":0.1352236967644813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3041069404","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3691216,0.0008657166,0.000019987876,0.54396224,0.00045559253,0.0011711314,0.0010705332,0.000008418285,0.08332479],"genre_scores_gemma":[0.93502,0.00008087004,0.000035691213,0.056599222,0.00024700616,0.000037292717,0.0000027334277,0.000027831076,0.007949317],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983721,0.00008134315,0.00090844795,0.00028092225,0.00008049359,0.00027674023],"domain_scores_gemma":[0.9977751,0.00045848594,0.00066278945,0.00096711545,0.000037673435,0.000098855955],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007396468,0.00017138432,0.00043612963,0.00007389331,0.00014427213,0.000031325657,0.0011922824,0.000055530618,0.0010273429],"category_scores_gemma":[0.00040810945,0.00009514351,0.0003362577,0.0007110094,0.00036491058,0.00006238304,0.0006431667,0.00028597066,0.00007230819],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024422893,0.00012771836,0.047655325,0.000106646854,0.00022320442,5.993315e-7,0.0018922525,0.0028700228,0.00075518014,0.26866755,0.67673135,0.0007259507],"study_design_scores_gemma":[0.0003518159,0.000039530878,0.026741691,0.000029649542,0.000023249095,0.0000010332593,0.000064097556,0.0010735935,0.0063046915,0.002308739,0.96291316,0.00014874678],"about_ca_topic_score_codex":0.0018508509,"about_ca_topic_score_gemma":0.015686098,"teacher_disagreement_score":0.5658984,"about_ca_system_score_codex":0.0000721993,"about_ca_system_score_gemma":0.0000646812,"threshold_uncertainty_score":0.99988586},"labels":[],"label_agreement":null},{"id":"W3041984362","doi":"10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a4764","title":"Attitudes and Behaviours of Physicians Towards Use of Industry-Provided Inhaled Medication Samples","year":2020,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"","keywords":"Environmental health; Medicine","score_opus":0.18539430333581702,"score_gpt":0.32094811586713934,"score_spread":0.13555381253132232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3041984362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99031985,0.00030272282,0.0006565876,0.0060394155,0.00004069855,0.00012671357,0.0004083898,0.0000135743,0.002092049],"genre_scores_gemma":[0.9963585,0.00032038894,0.00092524115,0.0022837908,0.000046888315,0.000004451507,0.000013912942,0.000009862318,0.000036968275],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9992018,0.00000759305,0.0004642342,0.00019013598,0.000020078898,0.00011615718],"domain_scores_gemma":[0.9994406,0.00005007853,0.00027891315,0.0001246221,0.000020461746,0.000085293956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011476662,0.00008187408,0.00032253796,0.00006501845,0.000017137792,0.000017638427,0.000112681075,0.00010597758,0.00026329732],"category_scores_gemma":[0.00014679834,0.00009239988,0.00005386284,0.00010247742,0.0000946282,0.00017435777,0.000064347965,0.00012720919,0.000009846191],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004295755,0.0002190362,0.4496778,0.00021014441,0.00013765329,0.0000015405835,0.0011272541,0.000054850552,0.00093125284,0.5292217,0.003696214,0.01467959],"study_design_scores_gemma":[0.0016946943,0.00026045134,0.9272507,0.00004338806,0.00004758834,0.0000031568302,0.00010094603,0.014440075,0.01831052,0.0074428166,0.029906508,0.00049917895],"about_ca_topic_score_codex":0.0009439827,"about_ca_topic_score_gemma":0.00003776933,"teacher_disagreement_score":0.5217789,"about_ca_system_score_codex":0.000014260116,"about_ca_system_score_gemma":0.00002177442,"threshold_uncertainty_score":0.3767958},"labels":[],"label_agreement":null},{"id":"W3043637706","doi":"","title":"School of Pharmacy Intellectual Property Report FY20, Fourth Quarter Report","year":2020,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Pharmacy; Property (philosophy); Pharmacy school; Multistate Pharmacy Jurisprudence Examination; Medicine; Pharmacy practice; Pharmaconomist; Family medicine; History","score_opus":0.12491231922106276,"score_gpt":0.30972583799707804,"score_spread":0.18481351877601526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3043637706","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14772281,0.00043813983,0.008177986,0.033667326,0.0006112931,0.0005563073,0.00011427484,0.00013500813,0.8085768],"genre_scores_gemma":[0.9826822,0.00015211191,0.00090819556,0.00798607,0.0004216773,0.000018960442,0.000024194876,0.000034415,0.007772172],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99764615,0.000012362155,0.0014327989,0.00054485496,0.00003833508,0.00032550865],"domain_scores_gemma":[0.9986015,0.00005662958,0.00049363426,0.0003788612,0.00005020366,0.00041920212],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00047255264,0.00018822515,0.0005407471,0.000112165544,0.00004640746,0.000051355022,0.00028149222,0.00006301874,0.015516998],"category_scores_gemma":[0.00093829754,0.00016269548,0.00021046607,0.00022437767,0.0000757991,0.00024429584,0.00011674355,0.00025258734,0.0041062767],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000368288,0.00047941017,0.16619717,0.00026512492,0.0005495471,0.00088390434,0.001921863,0.00017596524,0.0011176716,0.039963223,0.7857097,0.0023681736],"study_design_scores_gemma":[0.0008413746,0.000083933715,0.000624796,0.0000042365004,0.000010674784,0.000199933,0.00004177034,0.019388035,0.0021987674,0.0025335567,0.9737596,0.00031335125],"about_ca_topic_score_codex":0.0003451175,"about_ca_topic_score_gemma":0.0000064175515,"teacher_disagreement_score":0.8349594,"about_ca_system_score_codex":0.00005264559,"about_ca_system_score_gemma":0.000098750614,"threshold_uncertainty_score":0.9966691},"labels":[],"label_agreement":null},{"id":"W3043725192","doi":"10.1038/s41416-020-0990-8","title":"Increasing operational and scientific efficiency in clinical trials","year":2020,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Clinical trial; Drug development; Key (lock); Medicine; MEDLINE; Intensive care medicine; Medical physics; Computer science; Drug; Pathology; Pharmacology; Political science","score_opus":0.23072288466261529,"score_gpt":0.42167349427240414,"score_spread":0.19095060960978885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3043725192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96020955,0.03201961,0.00019284856,0.0057476326,0.0005911426,0.000072891824,0.00010855746,0.000002194436,0.0010555773],"genre_scores_gemma":[0.9918173,0.0045792027,0.00025858838,0.0026532072,0.0006524223,0.0000017443846,0.0000010000279,0.000007227792,0.000029341049],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99800766,0.00010618692,0.0015451106,0.00017208097,0.000031924086,0.00013701638],"domain_scores_gemma":[0.9989715,0.00022711515,0.00052464183,0.00003610314,0.00004187019,0.00019873037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006476092,0.000054744683,0.00050369557,0.00008844203,0.00006199133,0.0002879545,0.00013009417,0.00004998397,0.00047488508],"category_scores_gemma":[0.002348506,0.000068398294,0.00011806719,0.0001398903,0.000102219456,0.00023338896,0.000033547436,0.00026000713,0.000017067227],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041628422,0.00031346316,0.6444348,0.00007544739,0.00018174523,0.00016010458,0.0007293669,0.001216445,0.00030157284,0.054655828,0.012344518,0.2851704],"study_design_scores_gemma":[0.0062251673,0.00017573684,0.34221354,0.0002062639,0.000025611529,0.00035648362,0.000048140428,0.024872366,0.000076947465,0.013722329,0.6116691,0.00040827674],"about_ca_topic_score_codex":0.00018863821,"about_ca_topic_score_gemma":0.000073168136,"teacher_disagreement_score":0.59932464,"about_ca_system_score_codex":0.000041085386,"about_ca_system_score_gemma":0.00011599856,"threshold_uncertainty_score":0.5199659},"labels":[],"label_agreement":null},{"id":"W3047321073","doi":"10.1377/hlthaff.2019.01554","title":"Compared With Other Countries, Women In The US Are More Likely Than Men To Forgo Medicines Because Of Cost","year":2020,"lang":"en","type":"article","venue":"Health Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Business; Family medicine; Environmental health","score_opus":0.07361314984354529,"score_gpt":0.3114713086377136,"score_spread":0.23785815879416833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047321073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6091657,0.0016355423,0.00019949439,0.36490467,0.00013643302,0.0017713862,0.0015702121,0.000040135004,0.020576404],"genre_scores_gemma":[0.9517532,0.00022670017,0.00006677375,0.04765451,0.00012251985,0.00010013581,0.000009839695,0.000023982424,0.000042365704],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985051,0.000027041622,0.0006080451,0.0002797867,0.00005089945,0.000529085],"domain_scores_gemma":[0.9988869,0.00008898263,0.00034510056,0.0002450702,0.00002030299,0.00041364421],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066225935,0.00014888353,0.0005876266,0.00011538438,0.00005808372,0.000026253272,0.0003177341,0.000045256173,0.00018451051],"category_scores_gemma":[0.000060379443,0.000120601275,0.000034780875,0.0003292448,0.00008063948,0.00007588275,0.000040442836,0.00016059272,0.0001147325],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012039911,0.0003361385,0.6963359,0.0009948921,0.00016608216,0.000015671872,0.10218363,0.0016397953,0.0000035128087,0.07605206,0.12045699,0.00061131275],"study_design_scores_gemma":[0.0022181917,0.00046408726,0.096029855,0.0000699362,0.000004048034,0.000003209162,0.007481538,0.0030562293,0.0000137554725,0.0010343834,0.88934714,0.00027762674],"about_ca_topic_score_codex":0.001121326,"about_ca_topic_score_gemma":0.0009066722,"teacher_disagreement_score":0.76889014,"about_ca_system_score_codex":0.00019977572,"about_ca_system_score_gemma":0.00011699907,"threshold_uncertainty_score":0.49179772},"labels":[],"label_agreement":null},{"id":"W3047360337","doi":"10.5639/gabij.2020.0901.005","title":"It is time to change US trade policy to foster access to medicines","year":2020,"lang":"en","type":"article","venue":"Generics and Biosimilars Initiative Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Negotiation; Biosimilar; Balance (ability); Business; Access to medicines; Sustainability; International trade; International economics; Economics; Economic growth; Political science; Medicine; Developing country; Law","score_opus":0.24197099643837727,"score_gpt":0.3549841684586827,"score_spread":0.11301317202030542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047360337","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033036915,0.0004938664,0.0007714231,0.9836418,0.0002366159,0.00034943834,0.0008442479,0.0000132134755,0.010345684],"genre_scores_gemma":[0.013691104,0.0010393392,0.00065875443,0.9823121,0.0022217925,0.000026351689,0.000004581224,0.000034704797,0.000011304944],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983526,0.00002250931,0.00063287595,0.00042195187,0.000065289896,0.00050478097],"domain_scores_gemma":[0.9982475,0.00004151148,0.00020439952,0.00013845194,0.00004537789,0.0013227405],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00032650525,0.0002530052,0.00050938345,0.00042924535,0.00018051277,0.00034064028,0.00043882686,0.00009326837,0.0011357549],"category_scores_gemma":[0.00019916578,0.00025134414,0.00011107652,0.000672654,0.000035989127,0.00031169917,0.00033676458,0.00024386492,0.00074828387],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000442651,0.00002432208,0.0017192968,0.000011777191,0.000058325084,0.000010710915,0.0038075869,0.000019090798,0.00016242448,0.000017114713,0.991272,0.002853089],"study_design_scores_gemma":[0.0004523714,0.00040331922,0.00601594,0.00002329949,0.0000112958205,0.000017901295,0.00004803901,0.00092870585,0.00058913295,0.0011917218,0.9899622,0.00035602495],"about_ca_topic_score_codex":4.2711486e-7,"about_ca_topic_score_gemma":0.000005164245,"teacher_disagreement_score":0.010387412,"about_ca_system_score_codex":0.00010641686,"about_ca_system_score_gemma":0.000053359563,"threshold_uncertainty_score":0.99999386},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"},{"model":"gpt","categories":[],"domain":null,"study_design":"not_applicable","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W3047994869","doi":"10.2139/ssrn.3667006","title":"Pharmaceutical Policies from 1978 Alma Ata to 2018 Ebola: A Critical Interpretive Synthesis","year":2020,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University","funders":"","keywords":"Ebola virus; Political science; Engineering ethics; Medicine; Virology; Engineering","score_opus":0.04981366501919154,"score_gpt":0.319813220938039,"score_spread":0.26999955591884744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047994869","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28889683,0.021056358,0.05576922,0.55948806,0.0021110696,0.00072983117,0.0029580747,0.00023498679,0.06875554],"genre_scores_gemma":[0.97207236,0.0029340456,0.00025524342,0.023114176,0.0014388544,0.000020761374,0.000002524068,0.00004605333,0.00011596137],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9959998,0.000060886407,0.0008311031,0.00055152545,0.00006899787,0.0024876683],"domain_scores_gemma":[0.9980744,0.00064593635,0.0001704345,0.00023333554,0.000039270697,0.0008366367],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00088975753,0.00029721102,0.00062227476,0.00018449331,0.00019938793,0.00020696376,0.0007254574,0.00013891734,0.0016364751],"category_scores_gemma":[0.002693294,0.0003309093,0.00028536597,0.00024375811,0.0001394041,0.000307782,0.00023334344,0.0018475665,0.003395213],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025984718,0.000110127825,0.0016013726,0.000010662502,0.00041061657,0.000008938143,0.0011732143,0.000023401388,0.000374274,0.98629254,0.0058264197,0.0039085825],"study_design_scores_gemma":[0.0007432111,0.0006244178,0.00088022987,0.00008244657,0.00011150205,0.00011662328,0.0010690553,0.007651378,0.0013730994,0.5096685,0.47658885,0.0010906558],"about_ca_topic_score_codex":0.00030621738,"about_ca_topic_score_gemma":0.00008517989,"teacher_disagreement_score":0.68317556,"about_ca_system_score_codex":0.00095844927,"about_ca_system_score_gemma":0.0004360408,"threshold_uncertainty_score":0.9999143},"labels":[],"label_agreement":null},{"id":"W3049236550","doi":"10.3389/fsoc.2020.00058","title":"Access to Medicines, Access to Markets","year":2020,"lang":"en","type":"review","venue":"Frontiers in Sociology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Access to medicines; Context (archaeology); Market access; Business; Public relations; Universal design; Pharmaceutical industry; Marketing; Economic growth; Developing country; Political science; Economics; Medicine; Engineering","score_opus":0.16917839079106953,"score_gpt":0.4108678165250835,"score_spread":0.24168942573401395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3049236550","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000014999216,0.9595366,0.0017938041,0.014637842,0.0049292203,0.0012401242,0.00064404256,0.000037152222,0.017166175],"genre_scores_gemma":[0.00003117838,0.9627634,0.0007598076,0.03467411,0.00095875247,0.00040453364,0.000091902715,0.000088262,0.00022802291],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965103,0.00011430968,0.0015091278,0.001075143,0.000028505743,0.00076257513],"domain_scores_gemma":[0.99827754,0.0001856304,0.0004878499,0.00048337647,0.000016405522,0.00054921996],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007326382,0.0004978376,0.0037222311,0.00089778326,0.000062014464,0.00011167456,0.002278749,0.00067846285,0.00062928407],"category_scores_gemma":[0.00050765433,0.0005470689,0.00039983055,0.00061119493,0.00019384,0.00019973016,0.0009626771,0.0007900757,0.0015795904],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001870542,0.000025407922,0.0015144597,0.0011940052,0.00017688681,0.00002015966,0.0003301853,0.000003979836,4.942731e-9,0.004162264,0.64896464,0.34358928],"study_design_scores_gemma":[0.0002493752,0.000038866074,0.00030697588,0.0003377748,0.000040922194,0.0000036013698,0.000013753014,0.000052764353,5.268333e-8,0.015536301,0.98288167,0.00053797395],"about_ca_topic_score_codex":0.000042040014,"about_ca_topic_score_gemma":0.000010531255,"teacher_disagreement_score":0.3430513,"about_ca_system_score_codex":0.00068603415,"about_ca_system_score_gemma":0.0001780311,"threshold_uncertainty_score":0.9996981},"labels":[],"label_agreement":null},{"id":"W3056551509","doi":"10.3389/fmed.2020.00457","title":"The World Health Organization Global Benchmarking Tool an Instrument to Strengthen Medical Products Regulation and Promote Universal Health Coverage","year":2020,"lang":"en","type":"article","venue":"Frontiers in Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences","funders":"World Health Organization","keywords":"Benchmarking; Business; Process management; Knowledge management; Engineering management; Computer science; Engineering; Marketing","score_opus":0.03681927475095572,"score_gpt":0.2817846207367667,"score_spread":0.24496534598581096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3056551509","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18774799,0.0022858935,0.017756972,0.78826594,0.0014193398,0.0009500063,0.00008223501,0.000044675995,0.0014469173],"genre_scores_gemma":[0.96097386,0.0019853262,0.003162483,0.032895073,0.00079533836,0.000005878532,0.00009319084,0.000020180489,0.00006866425],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998619,0.000059980433,0.0005815984,0.00036822385,0.0000761378,0.0002950414],"domain_scores_gemma":[0.9991706,0.000024821902,0.00022084103,0.00015987743,0.000019192285,0.00040463658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012788953,0.000117170406,0.0003757243,0.00009649138,0.00016055543,0.000035828638,0.00018600769,0.000041022613,0.00008787553],"category_scores_gemma":[0.00048349297,0.00010743825,0.000010685728,0.0006398018,0.00008051089,0.00014159892,0.00007205701,0.00016216749,0.000006363206],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014456663,0.00009209788,0.16975465,0.00015802431,0.0000682257,0.0000045734173,0.0064874743,0.00047411842,0.0000020974353,0.21823955,0.13122979,0.47334483],"study_design_scores_gemma":[0.0029692524,0.0009026607,0.11011149,0.00015860975,0.000006366157,0.000005424567,0.00044304217,0.13849767,0.0000079906795,0.01609553,0.7304204,0.0003815779],"about_ca_topic_score_codex":0.00024750602,"about_ca_topic_score_gemma":0.00022552433,"teacher_disagreement_score":0.7732259,"about_ca_system_score_codex":0.0004587548,"about_ca_system_score_gemma":0.00016199991,"threshold_uncertainty_score":0.43812048},"labels":[],"label_agreement":null},{"id":"W3080884038","doi":"10.1111/jphs.12379","title":"Why healthcare market needs government intervention to improve access to essential medicines and healthcare efficiency: a scoping review from pharmaceutical price regulation perspective","year":2020,"lang":"en","type":"review","venue":"Journal of Pharmaceutical Health Services Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Essential medicines; Government (linguistics); Health care; Access to medicines; Economic interventionism; Quality (philosophy); Intervention (counseling); Medicine; Business; Market access; Public economics; Marketing; Public health; Economic growth; Nursing; Economics","score_opus":0.19242216909559795,"score_gpt":0.5392150905523204,"score_spread":0.34679292145672247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3080884038","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000033302833,0.83607095,0.00059240026,0.15628998,0.0009804735,0.004755691,0.00090825686,0.00002106017,0.00034785492],"genre_scores_gemma":[0.0008328853,0.938207,0.00023560876,0.0584841,0.0018842368,0.00019540511,0.000027586884,0.000106247186,0.000026947073],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99048144,0.001380402,0.0045532864,0.0012246536,0.0008627468,0.0014974899],"domain_scores_gemma":[0.991649,0.0012090912,0.0020783083,0.00050349097,0.0006710773,0.0038890506],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008154483,0.00068663084,0.0040660272,0.0011212393,0.00038698406,0.00044246615,0.0016128274,0.0003480856,0.0009384276],"category_scores_gemma":[0.0005077302,0.00065769785,0.00063696393,0.0023217232,0.00014720077,0.00059365435,0.0013638785,0.0028501183,0.00015589042],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007773489,0.0004546906,0.000058329275,0.37678763,0.0004929131,0.00004296863,0.0020238017,0.0000037641303,0.000002749136,0.003507642,0.010617368,0.6052308],"study_design_scores_gemma":[0.0010714455,0.00086186564,0.000035709192,0.16268781,0.00015132435,0.000045660374,0.00033026157,0.001341438,0.0000066627535,0.00086998986,0.83212644,0.00047138752],"about_ca_topic_score_codex":0.0015533834,"about_ca_topic_score_gemma":0.00022915757,"teacher_disagreement_score":0.82150906,"about_ca_system_score_codex":0.0034637456,"about_ca_system_score_gemma":0.0011409048,"threshold_uncertainty_score":0.99997485},"labels":[],"label_agreement":null},{"id":"W3081616766","doi":"10.3138/cpp.2020-107","title":"COVID-19’s Limited Impact on Drug Shortages in Canada","year":2020,"lang":"en","type":"article","venue":"Canadian Public Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Economic shortage; Coronavirus disease 2019 (COVID-19); Pandemic; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Medicine; Drug; Business; Demography; Environmental health; Disease; Virology; Infectious disease (medical specialty); Internal medicine; Pharmacology; Outbreak; Sociology","score_opus":0.08655622030873825,"score_gpt":0.2946264292240056,"score_spread":0.20807020891526737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081616766","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.40883273,0.00043116155,0.0000048562247,0.49572286,0.00019206086,0.0002644706,0.004025951,0.00003228378,0.090493634],"genre_scores_gemma":[0.7685772,0.00009487817,0.000004984067,0.23074102,0.00032502724,0.000016707492,0.000055082553,0.0000292416,0.00015585993],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978413,0.000026680293,0.0005567011,0.00047541925,0.000036443096,0.0010634835],"domain_scores_gemma":[0.9934491,0.000097330994,0.00013302123,0.00032144476,0.000013848948,0.005985266],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002504437,0.00024590816,0.00044941143,0.00089827715,0.00011666019,0.00014491938,0.00054169423,0.00008324688,0.0026828868],"category_scores_gemma":[0.001365925,0.00029183106,0.000112049376,0.00092206633,0.00004927423,0.00019212344,0.00004335145,0.0003466871,0.0005193602],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000014820553,0.000020143145,0.15447381,0.000027393844,0.00006379022,0.00008356226,0.0004312238,0.00070226094,0.0000010241117,0.5283948,0.31383517,0.0019519926],"study_design_scores_gemma":[0.0005752071,0.000025371348,0.042931568,0.0000024582996,0.0000013899026,0.000003671161,0.000043779382,0.006845991,0.0000042654297,0.005487075,0.9436873,0.00039188744],"about_ca_topic_score_codex":0.99901384,"about_ca_topic_score_gemma":0.9987541,"teacher_disagreement_score":0.6298522,"about_ca_system_score_codex":0.009469049,"about_ca_system_score_gemma":0.03027544,"threshold_uncertainty_score":0.9999534},"labels":[],"label_agreement":null},{"id":"W3082494315","doi":"10.9778/cmajo.20200036","title":"Factors associated with drug shortages in Canada: a retrospective cohort study","year":2020,"lang":"en","type":"article","venue":"CMAJ Open","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Centre for Advancing Health Outcomes; Ontario Drug Policy Research Network; University of Calgary; University of British Columbia","funders":"Canadian Institutes of Health Research; Teva Pharmaceutical Industries","keywords":"Economic shortage; Medical prescription; Retrospective cohort study; Medicine; Logistic regression; Odds ratio; Business; Workload; Generic drug; Drug; Emergency medicine; Internal medicine; Pharmacology; Economics","score_opus":0.10502986373352755,"score_gpt":0.29231469785483166,"score_spread":0.18728483412130412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3082494315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96604085,0.00005675306,0.0000028390195,0.0018655942,0.00008249767,0.00093555986,0.00034602633,0.000011205469,0.030658696],"genre_scores_gemma":[0.99761987,0.000011308895,0.0000036630515,0.0020188598,0.000029515884,0.000054390377,0.000022567958,0.000024086332,0.00021571913],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99876887,0.000023051425,0.00042109244,0.000457938,0.00003638648,0.0002926379],"domain_scores_gemma":[0.99936235,0.000054545493,0.00018845063,0.00018449864,0.000016927506,0.00019322641],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003389567,0.00016006712,0.00062782643,0.00005180055,0.000059238628,0.000118860335,0.0005067812,0.000029782275,0.00057354535],"category_scores_gemma":[0.0001401502,0.00015851077,0.000030421543,0.0002886019,0.000021761036,0.00021100848,0.00019880554,0.00022805817,0.00003951365],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001244901,0.00007055911,0.99325347,0.0000018995139,0.00012130914,0.000008721097,0.0009410169,0.000055060944,2.815043e-7,0.0029034344,0.0026130285,0.000018752928],"study_design_scores_gemma":[0.0007994176,0.000058761605,0.9942476,0.0000045264615,0.000007292541,5.647989e-8,0.0004681812,0.0008378473,0.000012535985,0.0005489633,0.0027833695,0.00023144636],"about_ca_topic_score_codex":0.8407966,"about_ca_topic_score_gemma":0.9357014,"teacher_disagreement_score":0.09490479,"about_ca_system_score_codex":0.0010118952,"about_ca_system_score_gemma":0.00027738,"threshold_uncertainty_score":0.6463882},"labels":[],"label_agreement":null},{"id":"W3083281660","doi":"10.34172/ijhpm.2020.166","title":"Public Risk-Taking and Rewards During the COVID-19 Pandemic - A Case Study of Remdesivir in the Context of Global Health Equity","year":2020,"lang":"en","type":"article","venue":"International Journal of Health Policy and Management","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Montreal Children's Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Gilead Sciences","keywords":"Equity (law); Pandemic; Public health; Business; Context (archaeology); Transparency (behavior); Economics; Public economics; Public relations; Coronavirus disease 2019 (COVID-19); Political science; Medicine; Disease; Infectious disease (medical specialty)","score_opus":0.3335500280267978,"score_gpt":0.47862457763086746,"score_spread":0.14507454960406968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083281660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8359656,0.0020632104,0.00023791548,0.16061613,0.00009543739,0.0003357598,0.0001274822,0.000002382161,0.0005561232],"genre_scores_gemma":[0.96401644,0.00647244,0.000024370143,0.029350352,0.00012439866,0.0000048092625,4.6982154e-7,0.0000040273176,0.0000027116396],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982443,0.00017571426,0.0011601531,0.00013884067,0.000091199414,0.00018978192],"domain_scores_gemma":[0.9971404,0.00013973337,0.0024199046,0.000099152945,0.00003303952,0.00016774055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032768715,0.00008456962,0.00033906216,0.00016608922,0.00011507352,0.00005042731,0.00033964717,0.000020002428,0.000007943975],"category_scores_gemma":[0.0004589522,0.000064482134,0.000052342806,0.00016798817,0.00006883115,0.000113011236,0.00018721932,0.00018171596,5.4395565e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024873123,0.0005194438,0.4713421,0.0006021964,0.00057055405,0.00018368321,0.026330434,0.00030657012,7.2754926e-7,0.45170465,0.001157459,0.047033455],"study_design_scores_gemma":[0.01595582,0.0023251988,0.72698253,0.00014651602,0.00004523958,0.0034298676,0.03708272,0.0030247038,0.0000010699704,0.07059189,0.14001651,0.0003979061],"about_ca_topic_score_codex":0.014874139,"about_ca_topic_score_gemma":0.0019260659,"teacher_disagreement_score":0.38111275,"about_ca_system_score_codex":0.0004504092,"about_ca_system_score_gemma":0.00017572215,"threshold_uncertainty_score":0.9916859},"labels":[],"label_agreement":null},{"id":"W3084095311","doi":"10.1186/s12992-020-00610-2","title":"Disease burden metrics and the innovations of leading pharmaceutical companies: a global and regional comparative study","year":2020,"lang":"en","type":"article","venue":"Globalization and Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Research Foundation of Korea; Ministry of Science and ICT, South Korea; Korea Institute of Science and Technology Information; Korea Institute of Science and Technology; National Research Foundation","keywords":"Business; Population; Global health; Public health; Economic growth; Geography; Economics; Environmental health; Health care; Medicine","score_opus":0.28110521488243534,"score_gpt":0.42250992008401955,"score_spread":0.1414047052015842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3084095311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7589262,0.023633933,0.010096671,0.19814393,0.00015838275,0.001774566,0.0010696747,0.000052593787,0.006144048],"genre_scores_gemma":[0.98816746,0.0019022344,0.000079787016,0.009760622,0.000058354322,0.000007287379,0.00001518946,0.0000038357985,0.0000052200685],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9990614,0.000044652803,0.00048122482,0.00023338209,0.000035361296,0.00014395131],"domain_scores_gemma":[0.9993437,0.000058799644,0.00022232346,0.000071176975,0.000036337748,0.00026764986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042980167,0.00009615624,0.00038165055,0.000054058637,0.00016584364,0.00006182474,0.000070652146,0.00002212027,0.000021126998],"category_scores_gemma":[0.000072416726,0.00008826101,0.000021473781,0.00046602765,0.00021432276,0.00009045843,0.00007862729,0.00007428028,0.0000057810767],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008494867,0.000047789694,0.09621571,0.00006269944,0.00004278703,2.2665462e-7,0.0024031023,0.00007783498,1.3247636e-7,0.89929867,0.0013301424,0.00043593897],"study_design_scores_gemma":[0.011184861,0.00028697762,0.3129691,0.000033281976,0.00006523742,0.000007699178,0.0034729477,0.48750645,9.022286e-7,0.07096353,0.113074824,0.0004342059],"about_ca_topic_score_codex":0.00020621142,"about_ca_topic_score_gemma":0.00002002827,"teacher_disagreement_score":0.82833517,"about_ca_system_score_codex":0.000047208647,"about_ca_system_score_gemma":0.000049125963,"threshold_uncertainty_score":0.35991797},"labels":[],"label_agreement":null},{"id":"W3085196972","doi":"10.1016/s0140-6736(20)31876-6","title":"An activist history of drug shortages and its silos","year":2020,"lang":"en","type":"article","venue":"The Lancet","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Economic shortage; Drug; Information silo; Medicine; Business; Medical emergency; Silo; Pharmacology; History; Archaeology","score_opus":0.1384564861851789,"score_gpt":0.29575425988813586,"score_spread":0.15729777370295697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3085196972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91174567,0.006113706,0.00002546214,0.022955442,0.00016339745,0.000109425804,0.00024630193,0.000025915158,0.058614682],"genre_scores_gemma":[0.99116445,0.0006489253,0.000028806617,0.0074407626,0.000423709,0.000003913235,0.0000029190132,0.0000101213855,0.00027641802],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99949604,0.000011702705,0.0001939525,0.00015357556,0.0000104075225,0.00013430261],"domain_scores_gemma":[0.9995824,0.00003595951,0.000111159825,0.00017869374,0.0000055530018,0.00008620901],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020093347,0.000066832195,0.00030456073,0.00002076298,0.000020950614,0.000013534426,0.00023839658,0.00002183404,0.00024849433],"category_scores_gemma":[0.000034418983,0.000060954735,0.000030807063,0.000033226428,0.000053535212,0.00010326598,0.000038509126,0.00010780974,0.00009155667],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016618961,0.000098639284,0.028885603,0.00019485525,0.00011866526,0.0000025740949,0.008245034,0.000102504215,0.0024909044,0.8355826,0.12184644,0.0022659837],"study_design_scores_gemma":[0.00075257727,0.000066689856,0.018077575,0.0000052229852,0.000009702399,0.0000012109554,0.000048001995,0.027207779,0.00093935564,0.013306059,0.9393618,0.00022398599],"about_ca_topic_score_codex":0.000036512007,"about_ca_topic_score_gemma":0.0000050100593,"teacher_disagreement_score":0.82227653,"about_ca_system_score_codex":0.00003565666,"about_ca_system_score_gemma":0.000013401796,"threshold_uncertainty_score":0.27208385},"labels":[],"label_agreement":null},{"id":"W3085644262","doi":"10.1002/hec.4160","title":"Patient income and health innovation","year":2020,"lang":"en","type":"article","venue":"Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Canadian Institutes of Health Research; Seventh Framework Programme","keywords":"Harm; Clinical trial; Investment (military); Disease; Medicine; Business; Actuarial science; Psychology; Pathology; Political science","score_opus":0.17481105262612476,"score_gpt":0.3397922161482721,"score_spread":0.16498116352214734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3085644262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.668828,0.005177996,0.0007738355,0.31372645,0.00056654244,0.0006939481,0.0005834243,0.000097735916,0.009552083],"genre_scores_gemma":[0.847749,0.0036343613,0.0007910663,0.14751354,0.0002065687,0.0000179053,0.000036176938,0.00003170644,0.000019687344],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978115,0.000015050283,0.0012776367,0.0004508584,0.000010307755,0.00043464606],"domain_scores_gemma":[0.99860287,0.000024959172,0.0007224901,0.00018370208,0.00001359667,0.00045240717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005439334,0.00016132457,0.000542576,0.00017153002,0.00015955459,0.00007313487,0.00011279916,0.00006467364,0.0001517029],"category_scores_gemma":[0.000040233714,0.00021613369,0.00004405927,0.00021234044,0.000044791075,0.00020889472,0.00010147529,0.00020125096,0.00046326968],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016434902,0.000034016426,0.021457057,0.00016349461,0.000024921761,3.4885963e-7,0.0014453854,0.0001198942,4.5740254e-7,0.9368058,0.0052835867,0.034648612],"study_design_scores_gemma":[0.0010350432,0.00047940915,0.02565534,0.000014864763,0.0000010465889,0.000006381681,0.00007914849,0.028548654,0.000011899158,0.051089935,0.8926677,0.0004105549],"about_ca_topic_score_codex":0.0002778788,"about_ca_topic_score_gemma":0.000031426745,"teacher_disagreement_score":0.8873841,"about_ca_system_score_codex":0.00029439275,"about_ca_system_score_gemma":0.00017019142,"threshold_uncertainty_score":0.8813676},"labels":[],"label_agreement":null},{"id":"W3086015271","doi":"10.33974/ijrpst.v1i4.196","title":"An overview on comparative study of registration requirements for generics in US, Canada and Europe","year":2020,"lang":"en","type":"article","venue":"International Journal of Research in Pharmaceutical Sciences and Technology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"U.S. Food and Drug Administration; World Health Organization","keywords":"Product (mathematics); Agency (philosophy); Business; Authorization; Marketing authorization; Process (computing); European market; Regulatory agency; New product development; Marketing; Industrial organization; International trade; Computer science; Computer security; Political science; Public administration","score_opus":0.5678317604296913,"score_gpt":0.539922613965676,"score_spread":0.027909146464015322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3086015271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9784715,0.0010298955,0.000022021497,0.019742502,0.0000906651,0.00016096105,0.000025158692,0.0000013071591,0.00045595033],"genre_scores_gemma":[0.9973597,0.0018169669,0.00013338868,0.0006387968,0.00004248437,0.0000044096255,4.4984066e-7,0.0000022917793,0.0000015416402],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99900746,0.000042303145,0.00048944907,0.0001806706,0.00011967887,0.00016046445],"domain_scores_gemma":[0.9994376,0.00014179698,0.00016784626,0.000039794348,0.00011374413,0.00009922095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013221817,0.0000516613,0.00020181204,0.00040189963,0.00003310958,0.00003678407,0.00036199304,0.000029866385,0.000013358152],"category_scores_gemma":[0.00020653216,0.000048588023,0.000009807131,0.00046383587,0.00023903053,0.00014521011,0.00007366283,0.00024544512,5.0241175e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044323286,0.00082352926,0.5607187,0.000051162006,0.00007301652,0.00007009498,0.0005602273,0.000855606,0.00075580145,0.42348617,0.0005152601,0.011647156],"study_design_scores_gemma":[0.015658956,0.015197302,0.12944394,0.00027205565,0.000015674243,0.00007817103,0.0037601988,0.39691147,0.0048661428,0.19691086,0.23620199,0.0006832536],"about_ca_topic_score_codex":0.003838927,"about_ca_topic_score_gemma":0.009122383,"teacher_disagreement_score":0.4312748,"about_ca_system_score_codex":0.000075539305,"about_ca_system_score_gemma":0.00011031684,"threshold_uncertainty_score":0.58033353},"labels":[],"label_agreement":null},{"id":"W3087510675","doi":"10.1212/wnl.94.15_supplement.2804","title":"A comparative analysis of licensing and reimbursement of anti-epileptic drugs in Canada and Australia (2804)","year":2020,"lang":"en","type":"article","venue":"Neurology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Medicine; Political science; Law; Health care","score_opus":0.08843257227484601,"score_gpt":0.298854448855535,"score_spread":0.210421876580689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087510675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997013,0.00017611735,0.000005000168,0.0020850718,0.000037339007,0.000060804294,0.00009981466,0.0000012493834,0.00052165875],"genre_scores_gemma":[0.9978334,0.00013101625,0.000022712053,0.001994201,0.000009534168,0.0000011029123,0.000002969488,0.0000028651389,0.0000022023019],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99920785,0.000018999202,0.00042114293,0.00020646965,0.000011369232,0.00013414808],"domain_scores_gemma":[0.99956554,0.00008039174,0.00019340088,0.00007460803,0.000008234116,0.00007783557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008273511,0.0000688629,0.00057680433,0.00014771074,0.000009508039,0.0000040650552,0.000054928634,0.000031602463,0.000086395194],"category_scores_gemma":[0.000017008348,0.0000840839,0.000028853416,0.00023307042,0.0000684547,0.000028159158,0.00004454683,0.0000999282,0.000001843808],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058761245,0.000019426661,0.98391366,0.000028827968,0.00021614133,0.0000033451515,0.0010692683,0.0012615656,0.00024630735,0.012986912,0.000104167775,0.000091642316],"study_design_scores_gemma":[0.0004111317,0.00012469129,0.94866955,0.00000133276,0.00004857899,7.3030736e-7,0.00002728029,0.048706487,0.00017630578,0.00037698058,0.0013756466,0.00008127561],"about_ca_topic_score_codex":0.44528112,"about_ca_topic_score_gemma":0.2976003,"teacher_disagreement_score":0.14768082,"about_ca_system_score_codex":0.000017342909,"about_ca_system_score_gemma":0.000030447358,"threshold_uncertainty_score":0.7152167},"labels":[],"label_agreement":null},{"id":"W3089069670","doi":"10.1136/bmjgh-2020-002906","title":"Health system determinants of access to essential medicines for children with cancer in Ghana","year":2020,"lang":"en","type":"article","venue":"BMJ Global Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Institute for Clinical Evaluative Sciences; SickKids Foundation; Hospital for Sick Children","funders":"Hospital for Sick Children","keywords":"Access to medicines; Essential medicines; Medicine; Environmental health; Public health; Cancer; Family medicine; Political science; Economic growth; Nursing; Internal medicine; Economics","score_opus":0.09233797436299467,"score_gpt":0.4295418200016156,"score_spread":0.33720384563862094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089069670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83521104,0.003618509,0.003205434,0.14413387,0.0006162917,0.004061763,0.0079894345,0.00004809964,0.0011155627],"genre_scores_gemma":[0.9790657,0.0001790327,0.00034250395,0.019947771,0.00032627943,0.00010646029,0.000012489203,0.000015879003,0.000003856644],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981148,0.000019425734,0.00096605223,0.0003831831,0.000036802565,0.0004796961],"domain_scores_gemma":[0.99876124,0.000020584444,0.0005465621,0.00015876126,0.000022665723,0.0004902174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044734802,0.00014390568,0.00082277565,0.00008110477,0.000056357847,0.00002588392,0.00030898687,0.000045038545,0.000022773751],"category_scores_gemma":[0.00003584358,0.00014522792,0.00005583941,0.0003603786,0.00002957711,0.0001044924,0.00007189319,0.00006742747,0.000018289285],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049463124,0.00010589982,0.8991296,0.0017447523,0.000072104805,0.0000020596217,0.0007015252,0.00081874756,3.0615675e-7,0.045503926,0.01791867,0.03350772],"study_design_scores_gemma":[0.0057983347,0.0015340836,0.9494436,0.00070611876,0.000012262164,0.000021106673,0.0002021093,0.032363784,0.000054602024,0.001143231,0.008080404,0.000640366],"about_ca_topic_score_codex":0.011372561,"about_ca_topic_score_gemma":0.0059380103,"teacher_disagreement_score":0.1438547,"about_ca_system_score_codex":0.0004783942,"about_ca_system_score_gemma":0.00046678033,"threshold_uncertainty_score":0.99521077},"labels":[],"label_agreement":null},{"id":"W3090451134","doi":"10.1177/1715163520958023","title":"How do community pharmacies in Ontario manage drug shortage problems? Results of an exploratory qualitative study","year":2020,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"Ontario College of Pharmacists","keywords":"Economic shortage; Pharmacy; Government (linguistics); Exploratory research; Qualitative research; Business; Medicine; Nursing; Sociology","score_opus":0.17353538607677,"score_gpt":0.3090060159147469,"score_spread":0.13547062983797692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3090451134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98996836,0.00067974103,0.000016853108,0.0008075352,0.0007311691,0.00073169067,0.002535018,0.000020456808,0.0045091473],"genre_scores_gemma":[0.9950985,0.000768613,0.00007120979,0.0033175924,0.00026952068,0.000037613478,0.00006158548,0.000071351504,0.00030403913],"study_design_codex":"qualitative","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957715,0.0006814515,0.0016983781,0.00062282325,0.00016233294,0.0010635064],"domain_scores_gemma":[0.99566644,0.00019012048,0.000879561,0.0004402956,0.00020677861,0.0026168271],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003208806,0.00050742936,0.0010085683,0.0006704585,0.00057856063,0.00041460388,0.0013603801,0.00007057463,0.0004708253],"category_scores_gemma":[0.00027628266,0.0006334512,0.00019047121,0.00076938845,0.00026293183,0.0013501918,0.00013967279,0.00205756,0.000017777487],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087102543,0.0010799951,0.018311923,0.0005971587,0.00087292446,0.016886424,0.9364108,0.0043519926,0.00041975285,0.0013675396,0.011097775,0.0077326857],"study_design_scores_gemma":[0.07868311,0.0026055572,0.0025705812,0.00024127142,0.00070128305,0.031108608,0.07353357,0.042633735,0.006488463,0.01666761,0.7332296,0.011536613],"about_ca_topic_score_codex":0.44888884,"about_ca_topic_score_gemma":0.93650395,"teacher_disagreement_score":0.86287725,"about_ca_system_score_codex":0.002946726,"about_ca_system_score_gemma":0.0016888411,"threshold_uncertainty_score":0.9996117},"labels":[],"label_agreement":null},{"id":"W3092276302","doi":"10.1200/jco.2020.38.29_suppl.60","title":"Better treatment at what cost? A study of myeloma spending.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; Juravinski Cancer Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Multiple myeloma; Cancer drugs; Lenalidomide; Cancer; Pharmacy; Bortezomib; Government (linguistics); Family medicine; Internal medicine","score_opus":0.43226107861873403,"score_gpt":0.4829282545247874,"score_spread":0.05066717590605335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092276302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96938217,0.00089473656,0.000027490107,0.021053819,0.0012544658,0.00022652485,0.000020642365,0.0000035905152,0.007136551],"genre_scores_gemma":[0.9873249,0.002534185,0.00023544222,0.008682243,0.0011134074,0.0000039136803,9.3923813e-7,0.00001522941,0.000089722154],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.996001,0.000109997614,0.0033931134,0.00023582173,0.000042126478,0.00021792411],"domain_scores_gemma":[0.99563366,0.0009193252,0.0027901297,0.00015893644,0.000045472276,0.00045247813],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014220458,0.00013384319,0.0017484531,0.00010530338,0.00003259942,0.000027637874,0.00029318038,0.00018313024,0.001033459],"category_scores_gemma":[0.0006585592,0.0001168982,0.0004818651,0.00009974476,0.00009115511,0.00026826584,0.000110850866,0.0003561889,0.0003635708],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002986818,0.0068536173,0.6100637,0.00002559092,0.0017039587,0.00031882292,0.0032351778,0.00015233988,0.000033960663,0.0074103917,0.005867923,0.36134776],"study_design_scores_gemma":[0.011665231,0.02077284,0.11488063,0.000011787651,0.000102045466,0.000027705406,0.000414783,0.001000534,0.0000616651,0.002805881,0.84806186,0.00019505474],"about_ca_topic_score_codex":0.000018254965,"about_ca_topic_score_gemma":0.000029656574,"teacher_disagreement_score":0.8421939,"about_ca_system_score_codex":0.00024103258,"about_ca_system_score_gemma":0.000110028326,"threshold_uncertainty_score":0.9998797},"labels":[],"label_agreement":null},{"id":"W3092486526","doi":"10.1093/eurpub/ckaa165.1054","title":"Measures to manage, reduce and prevent medicines shortages in European countries in 2020","year":2020,"lang":"en","type":"article","venue":"European Journal of Public Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Economic shortage; Business; Reimbursement; Public health; Quarter (Canadian coin); Sanctions; Medicine; Environmental health; Economic growth; Health care; Political science; Government (linguistics); Economics; Geography; Nursing","score_opus":0.16824046598448542,"score_gpt":0.3316727112019646,"score_spread":0.1634322452174792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092486526","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4741743,0.008535578,0.00172805,0.48016202,0.000340725,0.00027885684,0.00005095663,0.00001512731,0.0347144],"genre_scores_gemma":[0.96745324,0.004855065,0.00024633814,0.026891686,0.00047273288,6.963523e-7,0.0000014279193,0.000031413892,0.000047376026],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971718,0.00067538774,0.0014360452,0.00026021572,0.000059248665,0.00039730937],"domain_scores_gemma":[0.9985602,0.000053410273,0.0004675865,0.000118057025,0.0000312076,0.00076955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01091284,0.00013680656,0.00049874355,0.00036137574,0.00003966563,0.00010721269,0.00034098158,0.0000142322215,0.000087742155],"category_scores_gemma":[0.0005791561,0.0001400425,0.000050040257,0.0003302581,0.00004079815,0.00024318064,0.000109044144,0.00034890897,0.0001226573],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019681244,0.0007872671,0.34338436,0.0009258451,0.00029031085,0.0018818892,0.072020784,0.00094638375,0.000073765346,0.06883458,0.14019749,0.37046054],"study_design_scores_gemma":[0.0009060758,0.00033539464,0.24390726,0.00006947013,0.0000015898079,0.00002520251,0.0002528017,0.00024083999,0.000003159174,0.0003337918,0.7537658,0.00015857787],"about_ca_topic_score_codex":0.000034696717,"about_ca_topic_score_gemma":0.00004060532,"teacher_disagreement_score":0.61356837,"about_ca_system_score_codex":0.00011423568,"about_ca_system_score_gemma":0.00007872124,"threshold_uncertainty_score":0.57107675},"labels":[],"label_agreement":null},{"id":"W3095012872","doi":"10.1371/journal.pone.0240966","title":"How long do new medicines take to reach Canadian patients after companies file a submission: A cohort study","year":2020,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University; University of Toronto; University Health Network","funders":"","keywords":"Notice; Marketing authorization; Medicine; Authorization; Product (mathematics); Family medicine; Business; Marketing; Computer science; Political science; Bioinformatics","score_opus":0.10152309232902855,"score_gpt":0.24574030204348993,"score_spread":0.1442172097144614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095012872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95157903,0.00034132905,0.000010250257,0.03806143,0.000093284034,0.0009370854,0.0013130221,0.000032435608,0.0076321154],"genre_scores_gemma":[0.98664474,0.000037475656,0.00013857317,0.011267682,0.00043430435,0.00009969116,0.0000760839,0.000031865304,0.0012695584],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867976,0.000012650901,0.00038730973,0.00045958962,0.0000668298,0.00039386458],"domain_scores_gemma":[0.99827105,0.000036718913,0.000106038206,0.0002675897,0.000041903542,0.001276717],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00013188468,0.00018018203,0.0005546654,0.00016849558,0.00007476959,0.00016164247,0.0002595567,0.00006305326,0.0050435457],"category_scores_gemma":[0.0003207184,0.00019932388,0.000056144036,0.00023987365,0.00002220755,0.00014105739,0.00008360538,0.00017049411,0.0009851801],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039469865,0.00053714245,0.94068974,0.000029491533,0.00020334111,0.00001069028,0.0014421042,0.0000023721846,0.0000017917891,0.00026366263,0.056472916,0.00030725193],"study_design_scores_gemma":[0.0009060418,0.00038981502,0.89168155,0.00003970726,0.000044557946,2.0149882e-7,0.00009139612,0.000640021,0.000022701823,0.0003710577,0.10546133,0.00035163682],"about_ca_topic_score_codex":0.011550809,"about_ca_topic_score_gemma":0.011573361,"teacher_disagreement_score":0.04900823,"about_ca_system_score_codex":0.00013698597,"about_ca_system_score_gemma":0.00007068661,"threshold_uncertainty_score":0.9997927},"labels":[],"label_agreement":null},{"id":"W3095341396","doi":"","title":"Liste canadienne des médicaments essentiels: Potentiel et incertitudes.","year":2017,"lang":"fr","type":"article","venue":"Europe PMC (PubMed Central)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Library science; Computer science; Data science","score_opus":0.06941845999817141,"score_gpt":0.27293754980809143,"score_spread":0.20351908980992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095341396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73987997,0.023223594,0.0001752663,0.0372186,0.01445197,0.0006824753,0.001616058,0.00005793202,0.18269414],"genre_scores_gemma":[0.9017389,0.03529,0.00032777383,0.004400216,0.0010512356,0.000054793883,0.00003668664,0.0001255247,0.05697488],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947313,0.00009924438,0.0011195336,0.0009989684,0.00007129659,0.0029796606],"domain_scores_gemma":[0.99595165,0.00008009323,0.0010085946,0.0013838427,0.0000778858,0.0014979102],"candidate_categories":["metaepi_narrow","scholarly_communication","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0013476498,0.0005104998,0.00077421375,0.00021330659,0.00088134623,0.0014129187,0.0015693404,0.00024245982,0.002244741],"category_scores_gemma":[0.0011583228,0.0006802524,0.00031049593,0.00018745127,0.0009088305,0.0012243893,0.0006560391,0.00066705164,0.0016537319],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001275766,0.0010552866,0.46272168,0.0005020356,0.0010198269,0.00039941762,0.006493438,0.00018172832,0.000038657927,0.33480373,0.057055064,0.13560157],"study_design_scores_gemma":[0.0009745871,0.000032258515,0.34802726,0.00008382926,0.00004343515,0.000015812282,0.000018575902,0.0005369931,0.00009986106,0.005895026,0.64377403,0.0004983057],"about_ca_topic_score_codex":0.011180222,"about_ca_topic_score_gemma":0.0032675848,"teacher_disagreement_score":0.586719,"about_ca_system_score_codex":0.00091952493,"about_ca_system_score_gemma":0.0001748354,"threshold_uncertainty_score":0.9996237},"labels":[],"label_agreement":null},{"id":"W3095577850","doi":"10.1101/2020.10.27.20220871","title":"Estimating the Financial Impact of Gene Therapy*","year":2020,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Quest University Canada","funders":"","keywords":"Proxy (statistics); Payment; Actuarial science; Medicine; Demography; Finance; Economics; Statistics","score_opus":0.1243739019988602,"score_gpt":0.33659603873633887,"score_spread":0.21222213673747867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095577850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9797315,0.0036986128,0.00306065,0.0030642734,0.0010252922,0.0003699936,0.00068502006,0.000030601434,0.008334082],"genre_scores_gemma":[0.9962753,0.00040892998,0.0012530744,0.0010964783,0.0008372345,0.00003721511,0.000024104937,0.000039002698,0.000028632629],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99838036,0.0000255778,0.0008273178,0.00044392305,0.000029383662,0.00029342604],"domain_scores_gemma":[0.9984885,0.00008679741,0.0007214403,0.0005552301,0.000024739269,0.00012328822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056523335,0.00025867647,0.00068603194,0.000095838805,0.000069992624,0.000068273876,0.00074640947,0.00018902971,0.0005201681],"category_scores_gemma":[0.00029862812,0.0002133037,0.0005548717,0.00013056974,0.00010036602,0.00004471428,0.0003127678,0.0006074169,0.00024880137],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038334704,0.00066470174,0.59968936,0.000711734,0.002369069,0.000034219935,0.008349798,0.12439054,0.001816279,0.21252361,0.013064519,0.036002815],"study_design_scores_gemma":[0.00092701125,0.00016231829,0.26477814,0.000038438495,0.000022398855,0.0000045941197,0.000004354118,0.36686814,0.0009034809,0.35028607,0.015242671,0.00076237944],"about_ca_topic_score_codex":0.00034219923,"about_ca_topic_score_gemma":0.000004201403,"teacher_disagreement_score":0.33491123,"about_ca_system_score_codex":0.00008679308,"about_ca_system_score_gemma":0.00012899704,"threshold_uncertainty_score":0.8698273},"labels":[],"label_agreement":null},{"id":"W3095635585","doi":"10.1136/bmjgh-2020-002640","title":"Availability and affordability of medicines and cardiovascular outcomes in 21 high-income, middle-income and low-income countries","year":2020,"lang":"en","type":"article","venue":"BMJ Global Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":128,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; McMaster University; Population Health Research Institute; Simon Fraser University","funders":"Faculty of Medicine and Health, University of Sydney; McMaster University; Hamilton Health Sciences","keywords":"Low and middle income countries; Income distribution; High income countries; Comprehensive income; Economics; Adjusted gross income; Business; Public economics; Gross income; Economic growth; Developing country; Inequality","score_opus":0.043750542612328275,"score_gpt":0.3226200611086289,"score_spread":0.2788695184963006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095635585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97035193,0.012675479,0.00004295726,0.014456615,0.00018063295,0.00067970593,0.0010563249,0.000023188504,0.0005331851],"genre_scores_gemma":[0.9937916,0.0032700228,0.00028264162,0.0025332419,0.000081858576,0.00001751545,0.0000050623253,0.000012376402,0.000005701036],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99752665,0.00007488335,0.0012629766,0.00063011784,0.00007305898,0.00043233437],"domain_scores_gemma":[0.9986031,0.0001780124,0.00030802275,0.0003855402,0.000031353546,0.00049396086],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018545296,0.0002448028,0.0014979464,0.00008164759,0.00008305166,0.000039246523,0.0001538959,0.000120504366,0.000046689205],"category_scores_gemma":[0.00037274364,0.0002489374,0.00011378322,0.00022745594,0.00039017716,0.00017773874,0.00021667217,0.0001695281,0.000015176428],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007009244,0.00003334272,0.9616125,0.0014420218,0.000083248175,0.0000029012629,0.0002235157,0.000015242598,1.2542736e-7,0.035480533,0.000027243315,0.0010092368],"study_design_scores_gemma":[0.001720244,0.00017333812,0.9729158,0.00008195497,0.000011619594,0.0000097408665,0.00005278405,0.0015536735,0.0000034920258,0.020900056,0.002349566,0.0002277284],"about_ca_topic_score_codex":0.0033477051,"about_ca_topic_score_gemma":0.00047676126,"teacher_disagreement_score":0.02343967,"about_ca_system_score_codex":0.0002031419,"about_ca_system_score_gemma":0.000118511154,"threshold_uncertainty_score":0.9999963},"labels":[],"label_agreement":null},{"id":"W3097249531","doi":"","title":"Reputation and Authority: The FDA and the Fight over U.S. Prescription Drug Importation","year":2020,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Rulemaking; Notice; Medical prescription; Legislation; Business; Generic drug; Statutory law; Prescription drug; Public economics; Law and economics; Drug; Political science; Law; Pharmacology; Medicine; Economics","score_opus":0.021611360939218508,"score_gpt":0.24769835720536648,"score_spread":0.22608699626614798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097249531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7923784,0.025368523,0.0033738245,0.17423266,0.00032467963,0.00048351972,0.00003723981,0.000024052059,0.003777062],"genre_scores_gemma":[0.9804402,0.0138631975,0.000013470238,0.005165419,0.00026553837,0.000010065033,0.0000038787794,0.000010603727,0.00022760943],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9989446,0.00004019446,0.0003444188,0.00016673956,0.000026291134,0.0004777487],"domain_scores_gemma":[0.9995151,0.00006793002,0.0002573577,0.00007467034,0.000012999155,0.000071918555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016084897,0.00008629019,0.00015356259,0.0000344398,0.00025533684,0.00017905094,0.00010851895,0.000036132013,0.000039975952],"category_scores_gemma":[0.00010953253,0.00006012166,0.00005449138,0.00007744275,0.00007700247,0.00025570704,0.000030696057,0.0007244055,0.000019282214],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006879117,0.0000060394323,0.0032412547,0.000005178497,0.0000641737,2.6044304e-7,0.0011595773,0.000024405696,0.00000899441,0.9891688,0.0011371247,0.0051153856],"study_design_scores_gemma":[0.0013101199,0.00004507698,0.00751767,0.0000024464998,0.000020506328,0.00003708622,0.00030393607,0.02489505,0.0000095144205,0.9028853,0.06286655,0.00010671528],"about_ca_topic_score_codex":0.00012915237,"about_ca_topic_score_gemma":0.0001409221,"teacher_disagreement_score":0.18806177,"about_ca_system_score_codex":0.000107539476,"about_ca_system_score_gemma":0.0000896143,"threshold_uncertainty_score":0.31472218},"labels":[],"label_agreement":null},{"id":"W3097362378","doi":"","title":"La production, le contrôle, l'assurance qualité et la distribution des produits pharmaceutiques au Canada","year":2017,"lang":"fr","type":"article","venue":"Publications Pimido","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science","score_opus":0.08039366196907588,"score_gpt":0.354669537821509,"score_spread":0.2742758758524331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097362378","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18181296,0.0116890995,0.0020821574,0.5481818,0.0034446418,0.00095399725,0.0078119026,0.00011914412,0.24390432],"genre_scores_gemma":[0.973452,0.0070981877,0.00027726995,0.0013600125,0.0007405496,0.0002824966,0.00036253722,0.000049855153,0.01637709],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973342,0.00023533017,0.0008871077,0.00076785544,0.000068080415,0.00070746173],"domain_scores_gemma":[0.9969007,0.00031904323,0.00096703664,0.0011861043,0.0002818767,0.00034526642],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0025050144,0.00030630585,0.0004714237,0.000118780205,0.001393291,0.0009957299,0.00086142647,0.0002208409,0.00019474383],"category_scores_gemma":[0.0035244548,0.00042171235,0.00013442073,0.00024118205,0.0008371442,0.0017586651,0.00019287546,0.0005188367,0.00013884282],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013571589,0.0003411236,0.055536423,0.00018405472,0.00013808925,0.0000014569481,0.00036846526,0.0001259056,0.000012371564,0.8292768,0.079438835,0.034562882],"study_design_scores_gemma":[0.0004911013,0.000008696885,0.23565438,0.000049507486,0.000020092628,0.000022414926,0.00003986017,0.00089599565,0.00032143405,0.013654356,0.74848795,0.0003541954],"about_ca_topic_score_codex":0.3216721,"about_ca_topic_score_gemma":0.43376985,"teacher_disagreement_score":0.81562245,"about_ca_system_score_codex":0.000933303,"about_ca_system_score_gemma":0.0028174575,"threshold_uncertainty_score":0.9999068},"labels":[],"label_agreement":null},{"id":"W3099001503","doi":"10.1136/bmjgh-2020-003282","title":"Shortages and price variability of essential cytotoxic medicines for treating children with cancers","year":2020,"lang":"en","type":"article","venue":"BMJ Global Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster Children's Hospital","funders":"Fogarty International Center; World Health Organization","keywords":"Medicine; Purchasing power parity; Essential medicines; Access to medicines; Gross national income; Economic shortage; Developing country; Environmental health; Business; Finance; Public health; Economic growth; Economics","score_opus":0.04170877436286529,"score_gpt":0.3616002697051675,"score_spread":0.3198914953423022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3099001503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9683798,0.0009928909,0.0056143356,0.017475791,0.00009356891,0.0011822166,0.0019521688,0.000025994788,0.004283229],"genre_scores_gemma":[0.99405587,0.0002515508,0.0011500159,0.0042379415,0.00024263708,0.000029915618,0.00001881469,0.000009140366,0.0000041411035],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988579,0.000015130182,0.0005248604,0.00031683253,0.000022506214,0.00026278457],"domain_scores_gemma":[0.9992145,0.00005791855,0.00033343,0.00011800584,0.00001804548,0.00025812048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046239427,0.00011192764,0.00044500656,0.00002151362,0.00006724432,0.000014586285,0.00009894041,0.00004198376,0.000034330937],"category_scores_gemma":[0.0001187827,0.00010968454,0.00004343089,0.0001354299,0.00008083877,0.000065783766,0.000031620315,0.000058192476,0.0000028514314],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025614174,0.00006244372,0.82366896,0.00047047087,0.00015946207,4.4719323e-7,0.0004886577,0.0002957504,0.00000844524,0.16671999,0.002503248,0.00536598],"study_design_scores_gemma":[0.0059797303,0.0019856186,0.89642066,0.00010528383,0.00005310281,0.000026562973,0.00013090258,0.054015033,0.00017993811,0.028678577,0.011666373,0.0007582099],"about_ca_topic_score_codex":0.001232016,"about_ca_topic_score_gemma":0.000116477415,"teacher_disagreement_score":0.13804142,"about_ca_system_score_codex":0.00017483214,"about_ca_system_score_gemma":0.00020720821,"threshold_uncertainty_score":0.44728056},"labels":[],"label_agreement":null},{"id":"W3103659536","doi":"10.34172/ijhpm.2020.215","title":"The Impact of Tiered-Pricing Framework on Generic Entry in Canada","year":2020,"lang":"en","type":"article","venue":"International Journal of Health Policy and Management","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University of Calgary; Centre for Advancing Health Outcomes; University of British Columbia","funders":"Canadian Institutes of Health Research; Michael Smith Health Research BC","keywords":"Listing (finance); Generic drug; Medical prescription; Business; Market share; Market size; Actuarial science; Finance; Medicine; Drug; Pharmacology; Commerce","score_opus":0.07440123481709053,"score_gpt":0.37071387874853184,"score_spread":0.2963126439314413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3103659536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6255858,0.0061300965,0.0014600579,0.34643263,0.0010953498,0.00029202877,0.00016495305,0.0000035361031,0.018835567],"genre_scores_gemma":[0.9739751,0.010133512,0.00009903575,0.015514613,0.0002542072,0.0000012486637,5.19053e-7,0.000004973937,0.000016751821],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989971,0.000018415632,0.0006942662,0.00007846302,0.00005055843,0.00016117473],"domain_scores_gemma":[0.9991692,0.00011218485,0.00054887537,0.00005501132,0.000018757592,0.00009600948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036289508,0.00006345136,0.00020232602,0.00014684413,0.000032839533,0.000023676745,0.00023833799,0.00001452318,0.000023913586],"category_scores_gemma":[0.00011545867,0.000051635525,0.00005841061,0.000095657306,0.000015877531,0.000046030178,0.000058359754,0.0001403644,0.000003719585],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016477547,0.000057820656,0.015029615,0.00005798115,0.00037385715,0.000024021487,0.0006330249,0.009567625,0.0000010039928,0.91181505,0.013488224,0.048787013],"study_design_scores_gemma":[0.0026421947,0.0007020736,0.33211288,0.00033284037,0.000008011765,0.000029709388,0.0004659133,0.022888841,0.000022826356,0.18484399,0.45560244,0.00034828455],"about_ca_topic_score_codex":0.21875395,"about_ca_topic_score_gemma":0.0064225127,"teacher_disagreement_score":0.72697103,"about_ca_system_score_codex":0.00070472836,"about_ca_system_score_gemma":0.0002815562,"threshold_uncertainty_score":0.7864484},"labels":[],"label_agreement":null},{"id":"W3106342198","doi":"10.1016/j.arcmed.2020.10.021","title":"Drug Repurposing: Considerations to Surpass While Re-directing Old Compounds for New Treatments","year":2020,"lang":"en","type":"review","venue":"Archives of Medical Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Repurposing; Drug repositioning; Pharmaceutical industry; Drug; Revenue; Business; Government (linguistics); Risk analysis (engineering); Pharmacology; Medicine; Engineering; Finance","score_opus":0.43808934115265624,"score_gpt":0.48985832056164524,"score_spread":0.051768979408989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3106342198","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000013575866,0.9364291,0.00038681022,0.017338984,0.00035751166,0.0017628223,0.000888501,0.000031963587,0.042790752],"genre_scores_gemma":[0.00024110063,0.99289435,0.0020090598,0.0007203184,0.00077907107,0.00027632125,0.000118320546,0.0000819301,0.0028795283],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962387,0.00021962723,0.0016322407,0.00087588426,0.00025286953,0.00078067096],"domain_scores_gemma":[0.988785,0.008852182,0.00037886522,0.0005428701,0.000040157924,0.0014008846],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024976893,0.00031684234,0.0021172904,0.00074675906,0.00026409357,0.00015376325,0.0008984155,0.00022654905,0.00087212614],"category_scores_gemma":[0.007177624,0.0003224012,0.0006236732,0.00043550582,0.0002618061,0.00007106189,0.000571365,0.0010072204,0.00042212545],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002634856,0.00015142212,0.000024006376,0.0026188276,0.00043446457,0.000014939357,0.00086089934,0.0000015023189,4.05944e-7,0.1399532,0.08697842,0.76893556],"study_design_scores_gemma":[0.0005449129,0.00012620674,0.000003492893,0.0018782485,0.000040307303,0.0000070979395,0.000021589558,0.00076647237,0.000005745395,0.04041625,0.95594,0.00024967277],"about_ca_topic_score_codex":0.00092899764,"about_ca_topic_score_gemma":0.00013196014,"teacher_disagreement_score":0.8689616,"about_ca_system_score_codex":0.00016509753,"about_ca_system_score_gemma":0.0011546697,"threshold_uncertainty_score":0.9999228},"labels":[],"label_agreement":null},{"id":"W3108815630","doi":"10.3389/fphar.2020.594549","title":"Companies’ Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study","year":2020,"lang":"en","type":"article","venue":"Frontiers in Pharmacology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Health technology; Business; Medicine; Product (mathematics); Accounting; Health care; Economic growth","score_opus":0.09243305490311675,"score_gpt":0.38178799816593745,"score_spread":0.2893549432628207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3108815630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9788452,0.0032261366,0.00010589975,0.01590674,0.0007248639,0.0005462456,0.00012149781,0.000019153887,0.0005042678],"genre_scores_gemma":[0.9934501,0.0008165147,0.0007234952,0.0047713467,0.00013018903,0.000050722505,0.00000794591,0.000017753531,0.000031943655],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980271,0.00012038468,0.0007265966,0.0005876394,0.00003741422,0.00050085207],"domain_scores_gemma":[0.9989506,0.00007968713,0.0005329232,0.00012712722,0.000014982881,0.00029470518],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007382816,0.00021295875,0.00072813645,0.00057219854,0.00007383546,0.00008470177,0.0002717357,0.00022280718,0.00008419132],"category_scores_gemma":[0.000043122152,0.00026750253,0.000016243714,0.00063014525,0.00013865468,0.0004625217,0.00013509828,0.0011004852,0.0000026818718],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005220359,0.00029037526,0.986916,0.00006568199,0.000120866935,0.000069881215,0.0012684215,0.00040269608,0.00000888197,0.005376387,0.003017597,0.0024109797],"study_design_scores_gemma":[0.009217974,0.0012064623,0.7122605,0.000009813132,0.000038419937,0.000019030545,0.015197174,0.068088725,0.000016273532,0.008163723,0.18494308,0.0008388283],"about_ca_topic_score_codex":0.071228914,"about_ca_topic_score_gemma":0.05621642,"teacher_disagreement_score":0.27465552,"about_ca_system_score_codex":0.00027213412,"about_ca_system_score_gemma":0.0003370131,"threshold_uncertainty_score":0.9999777},"labels":[],"label_agreement":null},{"id":"W3111185175","doi":"10.1016/j.jval.2020.08.743","title":"PDG60 The IMPACT of International Reference Pricing (IRP) in France, Italy, Spain, United Kingdom, and Canada to New and Existing Marketed Medications","year":2020,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Negotiation; Publication; International economics; Developing country; Confidentiality; Price index; Business; Economics; International trade; Public economics; Political science; Economic growth; Advertising; Macroeconomics; Law","score_opus":0.17518797701970895,"score_gpt":0.3549262249663573,"score_spread":0.17973824794664833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111185175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96491975,0.0005601074,0.00015675263,0.031826183,0.00006301432,0.00018581687,0.00012861346,0.0000040452946,0.0021557382],"genre_scores_gemma":[0.9951839,0.00042416118,0.00027967137,0.004022249,0.000052179235,0.0000041946896,0.000008315422,0.00000667689,0.000018688117],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990691,0.000030465793,0.0005126117,0.0001840856,0.000024874915,0.00017889474],"domain_scores_gemma":[0.999248,0.00025126737,0.00019471427,0.00008730025,0.00001210049,0.00020657359],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005671754,0.00007111887,0.00021131172,0.00017170484,0.00003550602,0.000018689305,0.0001410386,0.000026263173,0.000040967367],"category_scores_gemma":[0.0004858391,0.00006827604,0.000013205418,0.0003268252,0.000024178955,0.000048862297,0.00006082442,0.00016535417,0.0000018171708],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003399743,0.00002849468,0.8939643,0.000117178475,0.000042060758,0.0000022403149,0.002580193,0.013920728,0.0000135160635,0.08343278,0.0021658966,0.0036986151],"study_design_scores_gemma":[0.0007396188,0.000068542155,0.68140715,0.00010793706,0.000001316185,0.0000023417736,0.00008391508,0.27114615,0.0000031242844,0.0034445543,0.042847637,0.00014774478],"about_ca_topic_score_codex":0.88715345,"about_ca_topic_score_gemma":0.047393024,"teacher_disagreement_score":0.8397604,"about_ca_system_score_codex":0.00019746595,"about_ca_system_score_gemma":0.00031796072,"threshold_uncertainty_score":0.9699896},"labels":[],"label_agreement":null},{"id":"W3111651503","doi":"10.1016/j.jval.2020.08.567","title":"PCV76 NEWLY Introduced Drugs for Second-LINE Treatment of Stable Angina: Approvals and Reimbursement Decisions in the UK, Canada, Australia and Scotland","year":2020,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ranolazine; Reimbursement; Trimetazidine; Ivabradine; Medicine; Nicorandil; Angina; Formulary; Health care; Intensive care medicine; Pharmacology; Internal medicine; Political science","score_opus":0.18607472664411934,"score_gpt":0.33849278440518543,"score_spread":0.1524180577610661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111651503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9679545,0.0022938875,0.00006529624,0.027742274,0.0000964573,0.00076323596,0.0008992713,0.0000021095111,0.00018297472],"genre_scores_gemma":[0.9957536,0.0012499612,0.00052461284,0.002212905,0.000094639814,0.000044948683,0.000018215007,0.000009307998,0.00009179429],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99868333,0.000033073575,0.00065623666,0.00029939556,0.00002490152,0.00030307085],"domain_scores_gemma":[0.99923813,0.00026466747,0.00018457144,0.00015088212,0.000009052168,0.00015272245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066981895,0.00011558402,0.00042967626,0.00009400976,0.000050309303,0.000024873292,0.000096089316,0.00003732152,0.000042830805],"category_scores_gemma":[0.0000797181,0.00010291009,0.00002973526,0.00014785971,0.000029191675,0.000042824613,0.000022728182,0.00007732068,0.0000020688392],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087616296,0.0010290544,0.32768044,0.0014865434,0.00027444857,0.00001639897,0.0284466,0.017899822,0.0001481459,0.55716324,0.042491294,0.022487862],"study_design_scores_gemma":[0.01720941,0.003412782,0.12006545,0.00016429447,0.00003112104,0.000011514943,0.0017617649,0.12876005,0.00087670225,0.051690884,0.6750262,0.0009898607],"about_ca_topic_score_codex":0.33143672,"about_ca_topic_score_gemma":0.092168726,"teacher_disagreement_score":0.63253486,"about_ca_system_score_codex":0.0002067646,"about_ca_system_score_gemma":0.00015686202,"threshold_uncertainty_score":0.9243968},"labels":[],"label_agreement":null},{"id":"W3118556611","doi":"10.1186/s40545-020-00282-8","title":"Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997","year":2021,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Policy and Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Canadian Institutes of Health Research; Arnold Ventures","keywords":"Medicine; Repurposing; Status quo; Drug repositioning; Drug; Pharmacy; Cohort; Generic drug; Pharmacology; Actuarial science; Business; Family medicine; Economics; Internal medicine","score_opus":0.15032365945261286,"score_gpt":0.412750019562576,"score_spread":0.2624263601099631,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3118556611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9204186,0.013229641,0.0037971288,0.044474315,0.00091768993,0.0010780974,0.00024916115,0.000012949154,0.015822425],"genre_scores_gemma":[0.9914622,0.0019858505,0.0021946228,0.0032839298,0.00077293976,0.000003885717,0.0000020115647,0.00002242962,0.00027214608],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977321,0.00018547544,0.0014695383,0.00023501874,0.000110878755,0.00026696638],"domain_scores_gemma":[0.9948933,0.0022568172,0.0021313701,0.00024280847,0.00020537696,0.0002702978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002039673,0.00016145578,0.0006000258,0.00020942651,0.00014455503,0.0000762781,0.00028225782,0.000090382106,0.000052428884],"category_scores_gemma":[0.007567739,0.0001490886,0.0001894115,0.00043592913,0.00012391488,0.00062112766,0.00012480296,0.00042315296,0.00000234564],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016981169,0.002810049,0.057816993,0.00069753616,0.0023941398,0.000026564667,0.021219034,0.00030886824,0.006715052,0.86964816,0.004604027,0.03206148],"study_design_scores_gemma":[0.015185879,0.0011054178,0.025136478,0.00047558665,0.0015411371,0.00093459536,0.0049406635,0.005078915,0.017462356,0.2245218,0.7026312,0.0009859737],"about_ca_topic_score_codex":0.0007679492,"about_ca_topic_score_gemma":0.000022530876,"teacher_disagreement_score":0.6980272,"about_ca_system_score_codex":0.000113556394,"about_ca_system_score_gemma":0.0005933323,"threshold_uncertainty_score":0.90598375},"labels":[],"label_agreement":null},{"id":"W3119641211","doi":"10.1287/mnsc.2020.3857","title":"Alleviating Drug Shortages: The Role of Mandated Reporting Induced Operational Transparency","year":2021,"lang":"en","type":"article","venue":"Management Science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Transparency (behavior); Mandate; Economic shortage; Leverage (statistics); Public economics; Economics; Government (linguistics); Political science","score_opus":0.07525656714082045,"score_gpt":0.3060672752210256,"score_spread":0.23081070808020515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119641211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75090235,0.0004592934,0.00051669293,0.002923926,0.00021884356,0.00017573393,0.000023055867,0.000016622083,0.24476351],"genre_scores_gemma":[0.9977959,0.000115134164,0.00065080356,0.0008833875,0.000033724402,0.000014284438,0.000006066035,0.0000058425885,0.0004948975],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9983969,0.00000967375,0.00092221814,0.0003603526,0.000068508576,0.00024234934],"domain_scores_gemma":[0.9990586,0.000026274243,0.00051483285,0.00030788616,0.00003655977,0.000055824494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017872865,0.00007892577,0.0001762291,0.00010604728,0.0002498067,0.00012577111,0.0004010025,0.00001574474,0.000387777],"category_scores_gemma":[0.00016087948,0.00007442832,0.00005936744,0.00051832217,0.00010849918,0.00024471091,0.00015342869,0.00008885507,0.000050906314],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000024535468,0.0000665188,0.051301826,0.000028675233,0.000042118038,0.000007138314,0.00092299544,0.0006454637,0.00209445,0.93844014,0.00016635751,0.0062818574],"study_design_scores_gemma":[0.0012966588,0.000051556337,0.34563848,0.000104462575,0.00005029681,0.000017183756,0.0031562252,0.18763804,0.05910247,0.20948118,0.19239847,0.0010649589],"about_ca_topic_score_codex":0.000067147965,"about_ca_topic_score_gemma":0.000016091115,"teacher_disagreement_score":0.72895896,"about_ca_system_score_codex":0.000045244124,"about_ca_system_score_gemma":0.000036103884,"threshold_uncertainty_score":0.42458862},"labels":[],"label_agreement":null},{"id":"W3120260298","doi":"10.1177/1073110520979391","title":"Generic Competition for Drugs Treating Rare Diseases","year":2020,"lang":"en","type":"article","venue":"The Journal of Law Medicine & Ethics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"","keywords":"Competition (biology); Internet privacy; Business; Content (measure theory); Computer science; Medicine; Biology","score_opus":0.23318470178039563,"score_gpt":0.37127673689967505,"score_spread":0.13809203511927942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120260298","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10976196,0.018984096,0.020424927,0.80174494,0.0014026564,0.00048369783,0.00043907567,0.000036056048,0.046722617],"genre_scores_gemma":[0.94669586,0.0015346191,0.00023704763,0.049512397,0.0019483424,0.0000022765407,0.000007659994,0.000018204302,0.000043580654],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989384,0.000049426333,0.0007035479,0.00009235745,0.000052930736,0.00016332611],"domain_scores_gemma":[0.99803734,0.000948254,0.00061888114,0.00010689835,0.00008727072,0.000201384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011451861,0.00010161465,0.0003978352,0.00004346568,0.00016736223,0.000018639364,0.00026696202,0.00006860667,0.00019394363],"category_scores_gemma":[0.000739831,0.00007377878,0.0001171393,0.000089111774,0.00019395209,0.000114199654,0.000029861316,0.0005059908,0.000024629842],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015656333,0.000031116662,0.00032847948,0.00012571088,0.00008811449,0.0000025059674,0.009062247,0.00044036537,0.00010044813,0.9844147,0.004343164,0.0009066073],"study_design_scores_gemma":[0.0027910043,0.0007444367,0.00025028715,0.000120067496,0.00015428431,0.000028860586,0.0011595646,0.010363831,0.00015232086,0.20703144,0.77698785,0.00021607964],"about_ca_topic_score_codex":0.00007642897,"about_ca_topic_score_gemma":0.0000065263125,"teacher_disagreement_score":0.8369339,"about_ca_system_score_codex":0.00004436878,"about_ca_system_score_gemma":0.000047336984,"threshold_uncertainty_score":0.30086112},"labels":[],"label_agreement":null},{"id":"W3120931056","doi":"10.1111/dom.14316","title":"Essential diabetes medicines and health outcomes in 127 countries","year":2021,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Queen's University; St. Michael's Hospital","funders":"St. Michael's Hospital Foundation; Canadian Institutes of Health Research; Ontario SPOR SUPPORT Unit","keywords":"Medicine; Diabetes mellitus; Per capita; Population; Interquartile range; Gross domestic product; Confidence interval; Environmental health; Internal medicine; Demography; Endocrinology","score_opus":0.026657386207932794,"score_gpt":0.2758455092691804,"score_spread":0.2491881230612476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120931056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93761075,0.044703193,0.000007794626,0.015974171,0.00042806,0.000116237934,0.00020556846,0.000018836316,0.00093538966],"genre_scores_gemma":[0.9759914,0.010193529,0.00013020223,0.013295509,0.0001609463,0.0000146600005,0.000022409735,0.000015515758,0.0001758226],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985624,0.00003044889,0.00051282113,0.0003976686,0.000030585525,0.00046606926],"domain_scores_gemma":[0.9993331,0.00010158888,0.00015215247,0.00017723849,0.000021132988,0.00021481214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000686597,0.00018140674,0.0008338776,0.00017597186,0.000120163066,0.00010831741,0.00009332459,0.00008829806,0.00014658533],"category_scores_gemma":[0.00010980504,0.00019475973,0.000063920656,0.00013931545,0.00014906743,0.00022855392,0.00012222919,0.00016547639,0.000037387756],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000011310408,0.00007220057,0.8831957,0.000096563555,0.000051583673,0.0000015541885,0.00027278822,0.0000013211273,0.000023591625,0.11516418,0.00036193858,0.0007574635],"study_design_scores_gemma":[0.00093093555,0.000012121723,0.87510276,0.000019750789,0.0000121086705,5.780046e-7,0.000027935615,0.00054119894,0.000549837,0.03509187,0.08748537,0.00022554398],"about_ca_topic_score_codex":0.00015807031,"about_ca_topic_score_gemma":0.00013990054,"teacher_disagreement_score":0.08712343,"about_ca_system_score_codex":0.000023476969,"about_ca_system_score_gemma":0.000041554384,"threshold_uncertainty_score":0.79420716},"labels":[],"label_agreement":null},{"id":"W3121136854","doi":"10.1111/j.1467-9701.2005.00668.x","title":"AIDS Policy and Pharmaceutical Patents: Brazil's Strategy to Safeguard Public Health","year":2005,"lang":"en","type":"article","venue":"World Economy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Negotiation; Context (archaeology); Developing country; Balance (ability); International trade; Pharmaceutical industry; Business; Access to medicines; Safeguard; Public health; Economics; International economics; Economic growth; Political science; Law; Medicine","score_opus":0.111899194250039,"score_gpt":0.3541797735718175,"score_spread":0.24228057932177852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3121136854","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.099766634,0.0037150944,0.0009944695,0.2818548,0.00039688736,0.0009336992,0.00047269478,0.00018288913,0.61168283],"genre_scores_gemma":[0.91993374,0.000518702,0.00096681295,0.07297205,0.0011599059,0.000066682536,0.000022243396,0.00005560112,0.0043042805],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969587,0.000032801003,0.0010980308,0.0007609361,0.000026086367,0.0011234432],"domain_scores_gemma":[0.9978731,0.00008183188,0.0002595057,0.00041423974,0.00002352392,0.0013477937],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0009214685,0.0003255333,0.000693013,0.00094314275,0.00021238043,0.00036459081,0.00038092808,0.000082509076,0.0025328123],"category_scores_gemma":[0.000067834044,0.00041104542,0.00014066881,0.00049379386,0.000116801275,0.00066975475,0.00021477594,0.00032316902,0.0042757783],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015249148,0.00014956332,0.0076148496,0.000032949854,0.00007975274,0.0000012434328,0.00020996016,0.00011670506,0.0000030012004,0.8417428,0.011728924,0.13830496],"study_design_scores_gemma":[0.0009776342,0.00011135037,0.0037188726,0.000006998218,0.0000029164314,0.000008969653,0.000020639067,0.0023608976,0.000033568507,0.0205641,0.9717635,0.00043057898],"about_ca_topic_score_codex":0.00026389817,"about_ca_topic_score_gemma":0.00026803906,"teacher_disagreement_score":0.96003455,"about_ca_system_score_codex":0.00064394955,"about_ca_system_score_gemma":0.00018412528,"threshold_uncertainty_score":0.9998341},"labels":[],"label_agreement":null},{"id":"W3121226665","doi":"10.1057/jgm.2010.14","title":"Ever-Greening: A Status Check in Selected Countries","year":2010,"lang":"en","type":"article","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Mylan","keywords":"Business; Greening; Product (mathematics); Index (typography); Developing country; Duration (music); Generic drug; International trade; Development economics; International economics; Economics; Economic growth; Medicine; Political science","score_opus":0.06957175371250879,"score_gpt":0.29925292180352275,"score_spread":0.22968116809101397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3121226665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85543925,0.033885725,0.011117498,0.07646413,0.021858202,0.00072419096,0.0000889045,0.000020466143,0.00040166016],"genre_scores_gemma":[0.9394869,0.02361667,0.0014170589,0.014579663,0.019957652,0.00004889825,0.000013839798,0.00014035818,0.0007389594],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959655,0.00007821047,0.0024757038,0.00029805198,0.00028756796,0.00089499925],"domain_scores_gemma":[0.9945201,0.0010293832,0.0025538395,0.00048302585,0.0009520929,0.00046154903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044632116,0.00043790694,0.0012387367,0.0006304607,0.00047704653,0.00014712414,0.0012865367,0.00018998362,0.0007076688],"category_scores_gemma":[0.002943882,0.0002436109,0.0003000222,0.0015076932,0.00046513867,0.00032229454,0.000089001325,0.0013347361,0.000021927028],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047856555,0.001005124,0.20362222,0.0010759005,0.00375163,0.00044434817,0.014006245,0.015627274,0.029302709,0.013826132,0.67871124,0.03384151],"study_design_scores_gemma":[0.005969588,0.00041449687,0.074026905,0.00016559682,0.0002619729,0.0032164557,0.0005522882,0.013595161,0.00026064028,0.0072638066,0.89375836,0.0005147265],"about_ca_topic_score_codex":0.00013329116,"about_ca_topic_score_gemma":0.00015747844,"teacher_disagreement_score":0.2150471,"about_ca_system_score_codex":0.0001931127,"about_ca_system_score_gemma":0.0006327936,"threshold_uncertainty_score":0.9934164},"labels":[],"label_agreement":null},{"id":"W3121236048","doi":"","title":"Monitoring and Forecasting Currency Crises","year":2005,"lang":"en","type":"preprint","venue":"RePEc: Research Papers in Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Voting; Currency; Logit; Medical prescription; Economics; Business; Actuarial science; Public economics; Monetary economics; Political science; Econometrics; Law; Politics","score_opus":0.2116574126150867,"score_gpt":0.3907073941798291,"score_spread":0.1790499815647424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3121236048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7073514,0.0061229365,0.000005256142,0.0011235485,0.0011559415,0.0005852648,0.0003367372,0.000049243958,0.28326967],"genre_scores_gemma":[0.9286716,0.06749993,0.0009813044,0.00014154131,0.0013979418,0.00019684584,0.000020567497,0.00010193614,0.0009883532],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957497,0.00006949845,0.0015655259,0.0013680201,0.000058455327,0.0011888153],"domain_scores_gemma":[0.9977357,0.0004997453,0.00050027494,0.0008066699,0.000051260187,0.00040634142],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023694925,0.00044158904,0.0010348187,0.00096799893,0.0002219076,0.00038452834,0.0007282537,0.00052269426,0.00021136315],"category_scores_gemma":[0.0006718178,0.0005975194,0.00022282341,0.00013324707,0.00029102332,0.00024716285,0.0015897682,0.0022104548,0.00008803633],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000072713454,0.00026102827,0.20756418,0.00052445516,0.00020473276,0.000023891762,0.00084371166,0.0049024075,0.000022409537,0.024757199,0.00014189101,0.7606814],"study_design_scores_gemma":[0.0038172053,0.0002264186,0.10943857,0.0011173205,0.000026713662,0.000052018237,0.00062687095,0.15971951,0.00044791022,0.21545371,0.50502664,0.004047097],"about_ca_topic_score_codex":0.00019529695,"about_ca_topic_score_gemma":0.00006026392,"teacher_disagreement_score":0.7566343,"about_ca_system_score_codex":0.00090411736,"about_ca_system_score_gemma":0.00017539547,"threshold_uncertainty_score":0.9996476},"labels":[],"label_agreement":null},{"id":"W3121390674","doi":"10.1111/joie.12026","title":"Innovation Incentives under Transferable Fast‐Track Regulatory Review","year":2013,"lang":"en","type":"article","venue":"Journal of Industrial Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Voucher; Track (disk drive); Incentive; Competition (biology); Fast track; Empirical evidence; Public economics; Business; Computer science; Economics; Industrial organization; Microeconomics; Accounting","score_opus":0.1277136331172883,"score_gpt":0.28954549005368146,"score_spread":0.16183185693639315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3121390674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9452147,0.0073805354,0.0004620921,0.020109298,0.0021096575,0.00055088854,0.000097338394,0.000016207661,0.024059316],"genre_scores_gemma":[0.95875,0.024450572,0.00040552518,0.0136935655,0.0019147471,0.000017057278,0.000015432555,0.000058994443,0.0006940765],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970377,0.000032192504,0.0023328722,0.00023620414,0.000029970906,0.00033106413],"domain_scores_gemma":[0.997887,0.00008568833,0.0014518376,0.0002487755,0.0001455263,0.00018113153],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014037628,0.000205686,0.0008112628,0.00040683316,0.00007517924,0.00013727468,0.00037880774,0.00022704437,0.0024523553],"category_scores_gemma":[0.00017638247,0.00022594034,0.00024911814,0.0002998559,0.0000850867,0.0011214917,0.000037339374,0.00057712535,0.0005593145],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011285176,0.00035392848,0.007458117,0.00017978474,0.0006143039,0.0000033152687,0.00018220369,0.0016912009,0.00017611166,0.8158662,0.122720316,0.05064167],"study_design_scores_gemma":[0.0059777377,0.0004080781,0.005665488,0.00068772584,0.00008039012,0.00008970631,0.0001527455,0.0019348135,0.0013122903,0.29536492,0.6872524,0.0010737072],"about_ca_topic_score_codex":0.00004367797,"about_ca_topic_score_gemma":0.0000025599438,"teacher_disagreement_score":0.5645321,"about_ca_system_score_codex":0.0003378251,"about_ca_system_score_gemma":0.00018078144,"threshold_uncertainty_score":0.9984595},"labels":[],"label_agreement":null},{"id":"W3121470554","doi":"","title":"High Drug Prices, Big R&D Spenders and “Free Riders”: Canada in the Topsy Turvy World of Pharmaceuticals","year":2019,"lang":"en","type":"article","venue":"C.D. Howe Institute Commentary","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Subsidy; Government (linguistics); Negotiation; Purchasing; Pharmaceutical industry; Public economics; Incentive; Finance; Economics; Marketing; Market economy; Law; Political science; Biotechnology","score_opus":0.049627100195706694,"score_gpt":0.2595724084930369,"score_spread":0.2099453082973302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3121470554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8950829,0.0024671517,0.0000143516245,0.07507586,0.0017736289,0.0005087158,0.00047622624,0.000010193688,0.024590984],"genre_scores_gemma":[0.9513687,0.0007381613,0.00016121347,0.047307946,0.00015765776,0.000014220077,0.000037653263,0.000015009928,0.00019947195],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99855715,0.00002761871,0.0006367063,0.0003383677,0.00005733444,0.00038283798],"domain_scores_gemma":[0.9989519,0.00019040084,0.00021749937,0.0004987748,0.000010065392,0.00013132673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005743313,0.00019600782,0.0004404545,0.00020555276,0.00007341663,0.000051423784,0.0006436929,0.000039868504,0.00036482318],"category_scores_gemma":[0.000028926977,0.00018845382,0.00006344489,0.0002759942,0.00015043984,0.00024781117,0.00021910625,0.00033479292,0.00003397703],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014066033,0.00038248237,0.21897748,0.00029692493,0.00030075703,0.00006545412,0.0013518521,0.0004936096,0.00007280837,0.444586,0.32652596,0.006806032],"study_design_scores_gemma":[0.002320144,0.000023516435,0.020361185,0.000030619416,0.000015250257,0.000008760504,0.0002170585,0.0006033217,0.00036795446,0.016339606,0.95936745,0.00034513118],"about_ca_topic_score_codex":0.23273781,"about_ca_topic_score_gemma":0.28190875,"teacher_disagreement_score":0.6328415,"about_ca_system_score_codex":0.00024633258,"about_ca_system_score_gemma":0.000094027426,"threshold_uncertainty_score":0.7723715},"labels":[],"label_agreement":null},{"id":"W3121502174","doi":"","title":"Cross-National Evidence on Generic Pharmaceuticals: Pharmacy vs. Physician-Driven Markets","year":2011,"lang":"en","type":"preprint","venue":"RePEc: Research Papers in Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Incentive; Competition (biology); Pharmacy; Business; Public economics; Industrial organization; Monetary economics; Economics; Microeconomics; Political science","score_opus":0.27095662518883845,"score_gpt":0.4402510333360323,"score_spread":0.16929440814719388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3121502174","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25980926,0.0028557563,0.000020050184,0.0035123066,0.0027288862,0.001815325,0.0019985237,0.00013010617,0.72712976],"genre_scores_gemma":[0.9226408,0.064259514,0.0004796702,0.006508087,0.0019158116,0.00071397657,0.00013526685,0.00022815213,0.0031187031],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99317527,0.0002718812,0.0020992015,0.002436749,0.00021959332,0.0017973048],"domain_scores_gemma":[0.9958813,0.0010278566,0.00081992475,0.0013675776,0.0002054588,0.0006978649],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0044829277,0.00078586466,0.0014228099,0.001377247,0.00030448777,0.00052748824,0.0022319504,0.0005654143,0.0022797375],"category_scores_gemma":[0.0010680525,0.0010182074,0.0006215532,0.0003275046,0.0006389774,0.00050288084,0.0018855757,0.0034065794,0.0021459681],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055848598,0.005469134,0.14631,0.0023403883,0.0027603111,0.0002702204,0.0018103549,0.10429034,0.00030537834,0.27609327,0.015479712,0.43928602],"study_design_scores_gemma":[0.0028230366,0.00016892077,0.025674233,0.00044912836,0.000022584401,0.000011181543,0.000021317952,0.20403054,0.0007951773,0.056808427,0.70710415,0.0020913058],"about_ca_topic_score_codex":0.00015840452,"about_ca_topic_score_gemma":0.00004119741,"teacher_disagreement_score":0.72401106,"about_ca_system_score_codex":0.0025688715,"about_ca_system_score_gemma":0.0007345815,"threshold_uncertainty_score":0.9992268},"labels":[],"label_agreement":null},{"id":"W3121538607","doi":"10.17848/wp19-306","title":"Medical Innovation, Education, and Labor Market Outcomes for Cancer Patients","year":2019,"lang":"en","type":"report","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Statistics Canada","funders":"Syddansk Universitet; Institut für Arbeitsmarkt- und Berufsforschung; W.E. Upjohn Institute for Employment Research","keywords":"Cancer; Educational attainment; Medicine; Prostate cancer; Breast cancer; Cancer treatment; Cancer registry; Work (physics); Economics; Internal medicine; Economic growth","score_opus":0.06855752737312243,"score_gpt":0.3701336889775521,"score_spread":0.3015761616044297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3121538607","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01036584,0.0025428964,0.000052750063,0.008499166,0.004416776,0.0008799118,0.0027341552,0.000033670578,0.97047484],"genre_scores_gemma":[0.044819895,0.012434984,0.0004699018,0.024370309,0.001289445,0.00064632535,0.00057628436,0.00022255906,0.9151703],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99821526,0.00000521087,0.0009795799,0.0004731479,0.00006946889,0.00025733004],"domain_scores_gemma":[0.9985653,0.000110093126,0.0006083767,0.00024392612,0.0003331551,0.00013915527],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000705306,0.00022860654,0.00066187547,0.00042329787,0.000045253022,0.00006366747,0.00020475576,0.00036037332,0.019118069],"category_scores_gemma":[0.0012021889,0.00023407635,0.0000818556,0.00018334987,0.00004402471,0.00008653751,0.00008485365,0.00017361212,0.0002452025],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000002507016,0.00008543267,0.41951132,0.00013906584,0.00008327808,2.6323278e-8,0.00000942577,6.471856e-8,1.0444195e-8,0.10391861,0.47105685,0.005193409],"study_design_scores_gemma":[0.00043576295,0.000014449829,0.15383513,0.000026201702,0.00000980915,5.089586e-7,0.0000023790758,0.000117672185,6.7220986e-7,0.010037185,0.8352658,0.0002544242],"about_ca_topic_score_codex":0.0006784336,"about_ca_topic_score_gemma":0.000109606975,"teacher_disagreement_score":0.36420897,"about_ca_system_score_codex":0.00022187323,"about_ca_system_score_gemma":0.0011994271,"threshold_uncertainty_score":0.98177856},"labels":[],"label_agreement":null},{"id":"W3121702970","doi":"10.24926/15529541.3494","title":"Structure-Function Analysis of Global Pharmaceutical Linkage Regulations","year":2011,"lang":"en","type":"article","venue":"Minnesota journal of law, science & technology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Incentive; Linkage (software); Tying; Business; Intellectual property; Generic drug; Public economics; Function (biology); International trade; Industrial organization; Law and economics; Economics; Law; Drug; Political science; Medicine; Pharmacology","score_opus":0.06382007411605199,"score_gpt":0.3134450849888588,"score_spread":0.2496250108728068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3121702970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9726134,0.0009513836,0.0070677535,0.0015856801,0.000575442,0.00007795013,0.00015526982,0.000019372774,0.016953783],"genre_scores_gemma":[0.9969229,0.00007883942,0.0025417993,0.0003844222,0.0000510059,0.0000010875167,0.0000010946032,0.0000060286748,0.000012827452],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.998241,0.000011291399,0.0010381227,0.00027917244,0.00007565888,0.00035473512],"domain_scores_gemma":[0.9984365,0.000027035645,0.0008574053,0.00032913013,0.00018819101,0.00016175045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084284856,0.00012743178,0.0005666066,0.001489189,0.00013549122,0.000029292132,0.00078455324,0.0001615183,0.00066976604],"category_scores_gemma":[0.00016130452,0.00012931661,0.00021158218,0.0037449822,0.0014385756,0.00047020058,0.00012391254,0.00024506627,0.000019741268],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028558887,0.000087288725,0.057042647,0.0000042965676,0.00023528839,0.0000037676873,0.00009634613,0.00013711228,0.0016142352,0.9394336,0.000033779997,0.0012831189],"study_design_scores_gemma":[0.0014148805,0.0005984708,0.13754927,0.000020017007,0.00079417205,0.00016707437,0.00012748405,0.016784819,0.019106608,0.77357733,0.049339846,0.0005200249],"about_ca_topic_score_codex":0.000043651104,"about_ca_topic_score_gemma":0.000035070043,"teacher_disagreement_score":0.16585621,"about_ca_system_score_codex":0.00018657897,"about_ca_system_score_gemma":0.000089978814,"threshold_uncertainty_score":0.7333469},"labels":[],"label_agreement":null},{"id":"W3121980999","doi":"10.2139/ssrn.3353887","title":"Medical Innovation, Education, and Labor Market Outcomes of Cancer Patients","year":2019,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Statistics Canada","funders":"","keywords":"Labour economics; Business; Cancer; Economics; Medicine; Internal medicine","score_opus":0.011114487463749656,"score_gpt":0.2873216248207831,"score_spread":0.27620713735703345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3121980999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981139,0.0038162514,0.00003105989,0.00575489,0.0005057091,0.0000925227,0.000043626347,0.0000041559565,0.0086127985],"genre_scores_gemma":[0.98753196,0.0069275354,0.00001753522,0.0027066702,0.00010263384,0.000005483303,0.000004314159,0.00001302556,0.0026908577],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986189,0.0000131672,0.00057954807,0.00014705754,0.000044764667,0.00059655897],"domain_scores_gemma":[0.9993253,0.00004096791,0.00036338824,0.000096486874,0.00009962228,0.000074271906],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012226525,0.00008862669,0.00025636915,0.00021489675,0.000040675626,0.000022535316,0.00016900833,0.00007018994,0.0017839428],"category_scores_gemma":[0.00020234958,0.00008838435,0.00004025353,0.00020690316,0.00003279603,0.0001495157,0.000033966422,0.0004937805,0.000059268164],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000055104747,0.00006417566,0.56343436,0.0000057555994,0.000060169972,1.3527636e-8,0.00002568399,4.9305675e-7,7.1895766e-7,0.43113586,0.00061489455,0.004652374],"study_design_scores_gemma":[0.00088157126,0.000064149404,0.50251055,0.000010452971,0.0000058116,0.0000046975956,0.000053361193,0.00018451455,0.000009132957,0.45401245,0.04213109,0.00013223922],"about_ca_topic_score_codex":0.00013160068,"about_ca_topic_score_gemma":0.000107532105,"teacher_disagreement_score":0.060923792,"about_ca_system_score_codex":0.0002557976,"about_ca_system_score_gemma":0.0011036606,"threshold_uncertainty_score":0.9991286},"labels":[],"label_agreement":null},{"id":"W3122208036","doi":"10.3386/w20469","title":"Poor Quality Drugs and Global Trade: A Pilot Study","year":2014,"lang":"en","type":"preprint","venue":"National Bureau of Economic Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Population and Public Health; University of Ottawa","funders":"Social Sciences and Humanities Research Council of Canada","keywords":"Business; Quality (philosophy); Intermediary; Consumption (sociology); Distribution (mathematics); Pharmaceutical industry; Commerce; International trade; Marketing; Medicine; Pharmacology","score_opus":0.5521944559050764,"score_gpt":0.5542266859490793,"score_spread":0.0020322300440028807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3122208036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6299293,0.0015039779,0.000035399014,0.013171093,0.0007443692,0.0015647307,0.0023211923,0.00003534422,0.35069457],"genre_scores_gemma":[0.99792033,0.00033435575,0.00012487883,0.00046385327,0.00059944525,0.00014677082,0.00010564534,0.000035077785,0.00026966498],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.996145,0.00023797112,0.0017226781,0.001132071,0.00018949975,0.00057276385],"domain_scores_gemma":[0.99760276,0.0007328446,0.00068414636,0.0005395387,0.00013266098,0.00030803695],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.008835933,0.00032429752,0.0011046727,0.0005584461,0.00015130307,0.00022699345,0.00085600984,0.0002506688,0.00039592135],"category_scores_gemma":[0.0005814573,0.0004073047,0.00017468413,0.00014110419,0.0003845211,0.00015135838,0.001030575,0.00097100367,0.0004601588],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015196059,0.0005845734,0.016566379,0.00015446838,0.00027935219,6.153e-7,0.00017826808,0.00056541193,0.0000039603215,0.9752487,0.0057418174,0.0005244891],"study_design_scores_gemma":[0.00148401,0.00045407258,0.024067272,0.000019120956,0.00000805227,0.0000019816173,0.00007072991,0.007074727,0.000009747204,0.95966774,0.0067603257,0.00038220233],"about_ca_topic_score_codex":0.003960476,"about_ca_topic_score_gemma":0.00023882271,"teacher_disagreement_score":0.367991,"about_ca_system_score_codex":0.0012153569,"about_ca_system_score_gemma":0.00042816333,"threshold_uncertainty_score":0.9998379},"labels":[],"label_agreement":null},{"id":"W3122229012","doi":"","title":"Foreign Free Riders and the High Price of U.S. Medicines","year":2005,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Argument (complex analysis); Order (exchange); Government (linguistics); Pharmaceutical industry; Business; Economics; Public economics; International economics; Monetary economics; Finance","score_opus":0.015440610335339758,"score_gpt":0.23762914882340563,"score_spread":0.22218853848806588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3122229012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6450912,0.080732025,0.00873345,0.15032588,0.0004633694,0.0004607543,0.0000747338,0.000028434584,0.114090204],"genre_scores_gemma":[0.97371775,0.023070429,0.00012998695,0.0022704466,0.00045940105,0.0000035562255,7.88645e-7,0.000013448627,0.000334184],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9984357,0.000017522812,0.0005106408,0.00013688883,0.000029470813,0.00086981157],"domain_scores_gemma":[0.9992677,0.00011240803,0.00034016627,0.00018436105,0.000019991494,0.000075375945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022336037,0.00010220633,0.00030956045,0.000108482614,0.00010555023,0.00002868945,0.00032698706,0.000048738322,0.00012776894],"category_scores_gemma":[0.00016284073,0.00007787522,0.00009341266,0.000089738496,0.00018959775,0.00015110732,0.000054753546,0.0006705343,0.000034100936],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050373892,0.000016224261,0.0012389098,0.0000041849275,0.00010748131,1.5322897e-7,0.00011623092,0.000037663478,0.000003644993,0.99333423,0.0008190826,0.0042718127],"study_design_scores_gemma":[0.002683052,0.000062311075,0.00069964794,0.0000042540073,0.000013630887,0.00007450258,0.00015840969,0.0011045273,0.000032305437,0.9523005,0.042772777,0.00009409169],"about_ca_topic_score_codex":0.00013404808,"about_ca_topic_score_gemma":0.00017242736,"teacher_disagreement_score":0.3286266,"about_ca_system_score_codex":0.00019549782,"about_ca_system_score_gemma":0.0001615853,"threshold_uncertainty_score":0.31756595},"labels":[],"label_agreement":null},{"id":"W3122706492","doi":"10.2139/ssrn.1139226","title":"Liberalization and Protection: Antidumping Duties in the Indian Pharmaceutical Industry","year":2007,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Carleton University; University of British Columbia","funders":"","keywords":"Pharmaceutical industry; International trade; Business; Liberalization; International economics; Economics; Law; Political science; Medicine","score_opus":0.051178187883626124,"score_gpt":0.3022812672424783,"score_spread":0.2511030793588522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3122706492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9735466,0.0039979084,0.0032129926,0.011732775,0.00022760761,0.0002252291,0.000005318879,0.000013781318,0.0070377896],"genre_scores_gemma":[0.9939112,0.0032121504,0.000019031319,0.0023208049,0.0003814553,0.0000048198194,0.0000011631354,0.000012985631,0.00013636248],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9981084,0.000031052154,0.0004535602,0.00016906163,0.000032483833,0.0012054517],"domain_scores_gemma":[0.9996175,0.00004091041,0.00015961971,0.000088274115,0.00001308908,0.00008058835],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004099851,0.000108278524,0.00016184147,0.00024676166,0.00018221722,0.00012261685,0.00017563015,0.00015801929,0.00006049867],"category_scores_gemma":[0.00006800574,0.00010012251,0.000041308434,0.00027749018,0.000063691194,0.0002545156,0.000026542957,0.0024826792,0.00003110612],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033734475,0.000051642284,0.029006466,0.0000097228785,0.000041891908,0.0000065469553,0.0009896961,0.00002427734,0.000021780614,0.96075493,0.000050786508,0.009008544],"study_design_scores_gemma":[0.0013375926,0.00013437218,0.026544694,0.000018112096,0.000008495079,0.0008984261,0.0018607444,0.0009909293,0.00011955529,0.90430826,0.06346984,0.0003089885],"about_ca_topic_score_codex":0.00007169648,"about_ca_topic_score_gemma":0.0002767062,"teacher_disagreement_score":0.06341905,"about_ca_system_score_codex":0.00035089193,"about_ca_system_score_gemma":0.00015932023,"threshold_uncertainty_score":0.9998186},"labels":[],"label_agreement":null},{"id":"W3123073191","doi":"","title":"Monopoly Pricing of an Antibiotic Subject to Bacterial Resistance","year":2009,"lang":"en","type":"preprint","venue":"RePEc: Research Papers in Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Monopoly; Externality; Economics; Antibiotics; Antibiotic resistance; Microeconomics; Population; Quality (philosophy); Industrial organization; Biology; Microbiology","score_opus":0.06558288736456924,"score_gpt":0.34728194405641616,"score_spread":0.2816990566918469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123073191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8235995,0.00039121817,0.00001166826,0.00094442035,0.0007311111,0.0009346131,0.00067774276,0.000035559642,0.17267416],"genre_scores_gemma":[0.9905512,0.00458315,0.0025213324,0.0005051847,0.0006040003,0.000049257742,0.000089386354,0.000111539186,0.0009850026],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948843,0.00016120129,0.0020226014,0.0016015213,0.00008411287,0.0012462649],"domain_scores_gemma":[0.99676085,0.0002782916,0.0006818538,0.0016446045,0.00008218445,0.00055224134],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0034478933,0.00048278665,0.0015267447,0.001474965,0.00013040943,0.0002551185,0.0014326047,0.0005960005,0.00021062802],"category_scores_gemma":[0.0005625655,0.00065519824,0.00030215844,0.00031605567,0.00023692547,0.00024041327,0.00086404686,0.0014445931,0.000098307224],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005429093,0.0051913518,0.041991062,0.0038430623,0.0014313775,0.0002463967,0.0074561,0.06501975,0.0062005217,0.35616854,0.0021399062,0.5048829],"study_design_scores_gemma":[0.008139709,0.0021327345,0.1566424,0.0020583584,0.00006098576,0.000026449481,0.0006337874,0.05794967,0.015141297,0.34442183,0.40545627,0.0073364857],"about_ca_topic_score_codex":0.00034303695,"about_ca_topic_score_gemma":0.00073583773,"teacher_disagreement_score":0.49754637,"about_ca_system_score_codex":0.0011977009,"about_ca_system_score_gemma":0.00038813194,"threshold_uncertainty_score":0.9995899},"labels":[],"label_agreement":null},{"id":"W3123155668","doi":"","title":"Clinical Trials for New Drug Development: Optimal Investment and Application","year":2016,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Interim; Clinical trial; Revenue; Interim analysis; Drug development; Investment (military); Net present value; Value (mathematics); Actuarial science; Medicine; Test (biology); Computer science; Drug; Operations management; Business; Economics; Finance; Microeconomics; Pharmacology; Production (economics)","score_opus":0.13029262257687854,"score_gpt":0.37911165261758556,"score_spread":0.24881903004070702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123155668","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.29002997,0.015586402,0.6557369,0.033182196,0.0007414232,0.0010927086,0.000075525575,0.000044272692,0.0035105816],"genre_scores_gemma":[0.95415485,0.025775034,0.0058639166,0.004649063,0.0022685926,0.00008385095,0.000008966688,0.00006021588,0.007135495],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9973416,0.000047473826,0.0012674378,0.0002911528,0.000020944017,0.0010314111],"domain_scores_gemma":[0.9986611,0.00034944955,0.000594434,0.00012286055,0.000019174127,0.00025298155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01048909,0.00012791913,0.0004647717,0.00010787899,0.0001302866,0.000057140773,0.0001842518,0.00008013461,0.00004773217],"category_scores_gemma":[0.00046123055,0.00010292084,0.00016029713,0.000045596058,0.000044971035,0.00016971197,0.000037135036,0.00035041996,0.00015725732],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060546303,0.00003359647,0.002696887,0.0000031787831,0.00015285429,6.395778e-8,0.00005279702,0.0000022772954,0.000017464366,0.8087157,0.0017174038,0.18654723],"study_design_scores_gemma":[0.0019001842,0.00006373919,0.00078758167,0.0000050628646,0.000009755867,0.000012721459,0.000016776308,0.00026401668,0.00006418754,0.5670322,0.42970878,0.00013499927],"about_ca_topic_score_codex":0.000012792606,"about_ca_topic_score_gemma":0.000050973267,"teacher_disagreement_score":0.6641249,"about_ca_system_score_codex":0.00045874613,"about_ca_system_score_gemma":0.0008182725,"threshold_uncertainty_score":0.419699},"labels":[],"label_agreement":null},{"id":"W3123210912","doi":"10.2139/ssrn.3262241","title":"Innovation and Antibiotic Use Within Antibiotic Classes: Market Incentives and Economic Instruments","year":2013,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Treasury Board of Canada Secretariat; Université Laval","funders":"","keywords":"Exploit; Incentive; Subsidy; Antibiotics; Industrial organization; Business; Public economics; Economics; Microeconomics; Market economy; Computer science; Computer security","score_opus":0.03355401645458533,"score_gpt":0.2715443589131024,"score_spread":0.23799034245851708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123210912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904047,0.0036505228,0.0002090073,0.0013697774,0.0009549063,0.00040265324,0.00016518333,0.000024008106,0.0028192329],"genre_scores_gemma":[0.9588621,0.039002385,0.00024205341,0.0006209671,0.0003002254,0.000003578346,0.000028906108,0.0000623282,0.0008774485],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9962738,0.000059004044,0.0013156221,0.00073530775,0.000039263683,0.0015769986],"domain_scores_gemma":[0.99802655,0.00006612548,0.0013714253,0.00031585887,0.000045026823,0.00017502048],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0019958417,0.0004364713,0.00077807705,0.00073221966,0.00021111764,0.00093398156,0.0003409377,0.00037697476,0.00010688111],"category_scores_gemma":[0.0001238795,0.00050131464,0.00010478491,0.00012999539,0.00019910098,0.0008070054,0.0005119783,0.00277172,0.000117280026],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045249977,0.00006946625,0.15766808,0.00011097521,0.00061091,0.0000014248137,0.00016762021,0.000050299754,0.000022550661,0.83572525,0.00047379333,0.005054382],"study_design_scores_gemma":[0.0014912912,0.0001749913,0.06512383,0.00014004028,0.0000540279,0.0001777255,0.00019641158,0.01688942,0.0000562774,0.9105595,0.004283003,0.0008535144],"about_ca_topic_score_codex":0.00050107035,"about_ca_topic_score_gemma":0.00020513097,"teacher_disagreement_score":0.09254425,"about_ca_system_score_codex":0.0013644586,"about_ca_system_score_gemma":0.00079373695,"threshold_uncertainty_score":0.9997438},"labels":[],"label_agreement":null},{"id":"W3123337039","doi":"","title":"A Dynamic Oligopoly Structural Model for the Prescription Drug Market After Patent Expiration","year":2004,"lang":"en","type":"preprint","venue":"RePEc: Research Papers in Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Stylized fact; Oligopoly; Economics; Microeconomics; Expiration date; Nested logit; Dynamic pricing; Discrete choice; Econometrics; Cournot competition","score_opus":0.08745713741393496,"score_gpt":0.33445026735143374,"score_spread":0.24699312993749878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123337039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89381975,0.0061603426,0.0028448522,0.010414305,0.0038373559,0.007973569,0.0062935455,0.000120676945,0.068535626],"genre_scores_gemma":[0.9811767,0.010420501,0.0009367777,0.00077389117,0.00023445104,0.0020180466,0.0001297253,0.0001077021,0.004202241],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99614686,0.00006957326,0.0014044498,0.0012412409,0.00007428826,0.0010635953],"domain_scores_gemma":[0.9977518,0.00032340945,0.00047884698,0.0011413386,0.000076349555,0.00022827541],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021734913,0.00046025845,0.00074297877,0.0005546951,0.0002732427,0.00044438953,0.0009524969,0.0004549027,0.00031397704],"category_scores_gemma":[0.00022225981,0.00047529212,0.0004477265,0.00009889751,0.00029737857,0.00026786508,0.0007929662,0.0014232162,0.00004450509],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001332275,0.00024802805,0.005139387,0.00093244517,0.0006012062,0.0000103254315,0.0036545435,0.8615401,0.000025873192,0.057127234,0.00096438086,0.06842425],"study_design_scores_gemma":[0.0008626184,0.000027210548,0.0049814642,0.000055645763,0.000010478859,0.0000022866195,0.00006324204,0.8194586,0.000009814082,0.16566487,0.008422553,0.00044121605],"about_ca_topic_score_codex":0.00034833103,"about_ca_topic_score_gemma":0.0011670246,"teacher_disagreement_score":0.10853764,"about_ca_system_score_codex":0.0024311906,"about_ca_system_score_gemma":0.00039649504,"threshold_uncertainty_score":0.99976987},"labels":[],"label_agreement":null},{"id":"W3123463615","doi":"10.1257/pandp.20211104","title":"Private and Social Returns to R&amp;D: Drug Development and Demographics","year":2021,"lang":"en","type":"article","venue":"AEA Papers and Proceedings","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"","keywords":"Productivity; Demographics; Life expectancy; Investment (military); Welfare; Demographic economics; Business; Capital (architecture); Economics; Monetary economics; Labour economics; Public economics; Economic growth; Market economy; Demography; Geography; Environmental health; Medicine; Political science","score_opus":0.043646406593664006,"score_gpt":0.25682264080211864,"score_spread":0.21317623420845463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123463615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9727174,0.0014196262,0.000003782271,0.008584161,0.00006028621,0.00008826504,0.000026091582,0.000016737002,0.017083658],"genre_scores_gemma":[0.99045444,0.0014420071,0.0018354742,0.0054681734,0.00009215956,0.000013050988,0.000006035674,0.000017476368,0.0006711998],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99906665,0.0000019489107,0.00027900992,0.00037629713,0.000020331367,0.00025575113],"domain_scores_gemma":[0.9996522,0.00002112603,0.00007827639,0.00004032407,0.000022394077,0.00018565729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025528015,0.00013564296,0.00025323223,0.000091701564,0.00022745793,0.00018471065,0.000057370675,0.00007397841,0.00005145081],"category_scores_gemma":[0.000033210163,0.00015596171,0.000028398506,0.00013319592,0.000064435204,0.000112653695,0.00013998506,0.00012569361,0.00001843548],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033703775,0.000042681542,0.283084,0.00023586242,0.00012334039,0.000003340497,0.013318062,1.6579567e-7,0.001078757,0.6840501,0.0036931543,0.014336834],"study_design_scores_gemma":[0.00040474674,0.000013002118,0.07880749,0.000012249064,0.000007631931,0.00001572294,0.0002455746,0.000034940447,0.0002866273,0.009127104,0.9107499,0.00029502157],"about_ca_topic_score_codex":0.000008915728,"about_ca_topic_score_gemma":0.000032692868,"teacher_disagreement_score":0.90705675,"about_ca_system_score_codex":0.000019948868,"about_ca_system_score_gemma":0.000014723884,"threshold_uncertainty_score":0.6359934},"labels":[],"label_agreement":null},{"id":"W3123480629","doi":"10.2139/ssrn.3262741","title":"Open Access to the Resource of Antibiotic Treatment Efficacy Subject to Bacterial Resistance","year":2013,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Antibiotics; Context (archaeology); Antibiotic resistance; Quality (philosophy); Resource (disambiguation); Intensive care medicine; Economics; Business; Medicine; Computer science; Biology; Microbiology","score_opus":0.062272553518112374,"score_gpt":0.3292029225876436,"score_spread":0.2669303690695312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123480629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92944705,0.0012080823,0.00045275682,0.043834705,0.00033099944,0.0011113815,0.00007251852,0.000010624867,0.02353186],"genre_scores_gemma":[0.993055,0.0010543264,0.0000759159,0.0022009325,0.000409799,0.000020371697,0.0000034369136,0.000028927527,0.0031512892],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976139,0.000042835465,0.0006209204,0.00031155936,0.000035070934,0.0013757045],"domain_scores_gemma":[0.9989396,0.000107856395,0.00030677186,0.00039499786,0.000032528038,0.00021829088],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012269665,0.00017094033,0.00041902388,0.00018026671,0.00018258012,0.00070515584,0.001838018,0.00005116873,0.00042900443],"category_scores_gemma":[0.00015232945,0.0001374113,0.00013274087,0.00030132377,0.000030579482,0.00041071782,0.0003643818,0.0003860548,0.00089657545],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008969798,0.00065024133,0.008488954,0.000020190504,0.000820679,0.0000025077632,0.0013114921,0.00092631986,0.0007887828,0.9071975,0.03661046,0.042285945],"study_design_scores_gemma":[0.0020575114,0.0007070002,0.02051755,0.000029121415,0.000021794689,0.000018935947,0.00014232502,0.000097289805,0.0011213183,0.11044323,0.8644407,0.00040323447],"about_ca_topic_score_codex":0.0007859789,"about_ca_topic_score_gemma":0.0017583309,"teacher_disagreement_score":0.82783026,"about_ca_system_score_codex":0.0008958312,"about_ca_system_score_gemma":0.00040843332,"threshold_uncertainty_score":0.9998813},"labels":[],"label_agreement":null},{"id":"W3123587989","doi":"10.1787/346071162287","title":"Pharmaceutical Pricing and Reimbursement Policies in Canada","year":2006,"lang":"en","type":"report","venue":"OECD health working papers","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Health Canada","keywords":"Reimbursement; Business; Economics; Health care; Economic growth","score_opus":0.1197748693753356,"score_gpt":0.3462153728127145,"score_spread":0.22644050343737887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123587989","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022799797,0.04422901,0.000006866657,0.020219138,0.0030853308,0.00082665344,0.00038079591,0.00004519301,0.9084072],"genre_scores_gemma":[0.9417261,0.038844723,0.00010542634,0.015775656,0.0009404831,0.000057634606,0.00009593802,0.00010682495,0.0023471972],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.996318,0.000037134196,0.0016547263,0.00073674956,0.00012884388,0.0011245528],"domain_scores_gemma":[0.99835336,0.00014280091,0.0007997506,0.00027209616,0.000014321779,0.0004176712],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014182151,0.00039774584,0.0011789756,0.00037943877,0.00017522494,0.00008035899,0.0002200894,0.0002033505,0.00028667974],"category_scores_gemma":[0.0000524274,0.0004949437,0.00009998605,0.00016703026,0.00006823567,0.000034675875,0.00013644893,0.0009159911,0.000039119295],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042073898,0.00014536867,0.6644081,0.0020498878,0.00025377164,0.000080972815,0.0005020961,0.00065333047,0.0000037268217,0.036038313,0.14376882,0.15205356],"study_design_scores_gemma":[0.00043079225,0.000018278595,0.04045527,0.00020068018,0.000007418463,0.000012148283,0.00003413989,0.0005877148,0.0000019602944,0.00044275838,0.9573667,0.00044213145],"about_ca_topic_score_codex":0.94267356,"about_ca_topic_score_gemma":0.84420174,"teacher_disagreement_score":0.9189263,"about_ca_system_score_codex":0.0070084706,"about_ca_system_score_gemma":0.0040642563,"threshold_uncertainty_score":0.9997502},"labels":[],"label_agreement":null},{"id":"W3123636550","doi":"","title":"Consumer Out-of-Pocket Spending for Pharmaceuticals in Kazakhstan: Implications for Sectoral Reform","year":2007,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Revenue; Restructuring; Government revenue; Business; Rural area; Government (linguistics); Payment; Health care; Psychological intervention; Informal sector; Public economics; Development economics; Economic growth; Economics; Finance","score_opus":0.112846958860362,"score_gpt":0.3836861376218571,"score_spread":0.2708391787614951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123636550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6125766,0.025483985,0.3057251,0.018764542,0.0026577555,0.0028677925,0.001618549,0.00006422315,0.030241465],"genre_scores_gemma":[0.99542713,0.002439317,0.00076594,0.00067574275,0.00035484842,0.00003421626,0.000015798549,0.000038318674,0.00024868207],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99662894,0.000008609801,0.0010466991,0.00026597417,0.00002194901,0.0020278052],"domain_scores_gemma":[0.99896955,0.00022067502,0.00043913492,0.00016616876,0.000047171936,0.00015731055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042175413,0.00016070323,0.0004324843,0.00035537966,0.00012672888,0.00003883625,0.00029654754,0.00011141771,0.00007972824],"category_scores_gemma":[0.0001322378,0.00017982915,0.0002416012,0.00015464403,0.000059776037,0.00019568714,0.000028572747,0.00064709084,0.000027553004],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015826698,0.00008944407,0.015300941,0.000023406183,0.00012041626,1.8276091e-7,0.00008034402,0.000009026274,0.00033946388,0.9757056,0.00017480018,0.007998111],"study_design_scores_gemma":[0.00258112,0.00017261608,0.0037476858,0.000010310483,0.000020156112,0.00002388904,0.0001460302,0.0007165842,0.0007952569,0.8829426,0.10857017,0.00027355383],"about_ca_topic_score_codex":0.000036491554,"about_ca_topic_score_gemma":0.0006181662,"teacher_disagreement_score":0.38285056,"about_ca_system_score_codex":0.0017117402,"about_ca_system_score_gemma":0.00029716585,"threshold_uncertainty_score":0.73332196},"labels":[],"label_agreement":null},{"id":"W3123696229","doi":"","title":"Healthcare's Grand Challenge: Stimulating Basic Science on Diseases that Primarily Afflict the Poor","year":2016,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"TRIPS architecture; Intellectual property; TRIPS Agreement; Health care; Political science; Grand Challenges; Public economics; Economics; Business; Economic growth; Law; Engineering","score_opus":0.05374224915885468,"score_gpt":0.30054913214872053,"score_spread":0.24680688298986586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123696229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6470928,0.025754513,0.0026893034,0.28886485,0.001611651,0.0006633334,0.00022878483,0.000091214715,0.033003528],"genre_scores_gemma":[0.9844748,0.011252163,0.000010063746,0.0031625165,0.0005034053,0.000009572846,8.053879e-7,0.000024356692,0.0005623357],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99678236,0.000035298865,0.00045066327,0.00039905545,0.00009479605,0.0022378166],"domain_scores_gemma":[0.99883956,0.0002085894,0.00034940836,0.00030759705,0.000036448288,0.00025839775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024987834,0.00019194698,0.0002952668,0.00022838397,0.00069683534,0.00017079347,0.00066196785,0.000054855886,0.00012279791],"category_scores_gemma":[0.00020653923,0.00012462342,0.00016372505,0.00020733447,0.00026482603,0.00039727596,0.00008657398,0.0008296821,0.00041168486],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006121895,0.000063521555,0.007909299,0.0000053115987,0.000051564402,0.0000010761842,0.00008209933,0.000029796556,0.000029436336,0.9576429,0.00019969704,0.03392407],"study_design_scores_gemma":[0.0017226299,0.0005317741,0.012062329,0.00003795226,0.000013726852,0.000057219535,0.00007950415,0.00086050486,0.000083834486,0.92300045,0.06118282,0.00036722096],"about_ca_topic_score_codex":0.000044955814,"about_ca_topic_score_gemma":0.00005812912,"teacher_disagreement_score":0.33738196,"about_ca_system_score_codex":0.0013604282,"about_ca_system_score_gemma":0.0009547851,"threshold_uncertainty_score":0.53595644},"labels":[],"label_agreement":null},{"id":"W3124106193","doi":"10.3386/w21239","title":"The Impact of Pharmaceutical Innovation on Premature Cancer Mortality in Canada, 2000-2011","year":2015,"lang":"en","type":"preprint","venue":"National Bureau of Economic Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Demography; Sociology","score_opus":0.5239881777160328,"score_gpt":0.5570451334642875,"score_spread":0.033056955748254735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124106193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87140393,0.0025165088,0.0000010247265,0.0028938383,0.0006223246,0.00074380136,0.0033620482,0.0000044289454,0.118452094],"genre_scores_gemma":[0.9977095,0.0012440962,0.000009958084,0.0001032682,0.00031138532,0.00013568443,0.00015346453,0.000028422337,0.00030418238],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9969004,0.000114003655,0.0016600748,0.0005538334,0.0002365342,0.00053515047],"domain_scores_gemma":[0.9973385,0.0006818086,0.0008125367,0.00044386953,0.0005698364,0.00015346862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005579947,0.00024674198,0.0007300668,0.0007839434,0.00007054474,0.00005813251,0.0008606183,0.00029483976,0.000835128],"category_scores_gemma":[0.00059134664,0.00022878381,0.00017410806,0.00029135254,0.00023599899,0.00010711386,0.00038115543,0.0014725847,0.00008612589],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00024617082,0.00013493992,0.08698045,0.00010971046,0.00039548843,0.0000013170385,0.00008657392,0.076771505,0.000014593834,0.79727715,0.03748056,0.0005015506],"study_design_scores_gemma":[0.00079970213,0.000059066133,0.068968825,0.000058248097,0.0000046722766,8.559074e-7,0.000014439767,0.06617295,0.000247281,0.8597903,0.0036168343,0.00026681877],"about_ca_topic_score_codex":0.76375145,"about_ca_topic_score_gemma":0.2649692,"teacher_disagreement_score":0.49878225,"about_ca_system_score_codex":0.010215015,"about_ca_system_score_gemma":0.01184116,"threshold_uncertainty_score":0.99376076},"labels":[],"label_agreement":null},{"id":"W3124219969","doi":"","title":"Intellectual Property Protection And Drug Plan Coverage: Evidence From Ontario","year":2015,"lang":"en","type":"preprint","venue":"RePEc: Research Papers in Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Formulary; Revenue; Business; Intellectual property; Plan (archaeology); Generic drug; Drug; Finance; Pharmacology; Medicine; Political science; Law; Geography","score_opus":0.18944166173265897,"score_gpt":0.3360256779149801,"score_spread":0.14658401618232114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124219969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9045498,0.0016672461,0.000023116083,0.0019438589,0.0008980284,0.0015613263,0.00053779356,0.00004808932,0.088770784],"genre_scores_gemma":[0.9724108,0.017997587,0.0002494691,0.00036690844,0.00051355234,0.00043357248,0.00009222414,0.000097002405,0.007838901],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959187,0.00016813018,0.001289549,0.001649864,0.000084602674,0.0008891581],"domain_scores_gemma":[0.9973907,0.0006365587,0.00042326123,0.0009774719,0.00008668814,0.0004853374],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0032789125,0.0004706642,0.0010493625,0.0006712152,0.00017567912,0.0005099349,0.00080658536,0.0005560062,0.0007811424],"category_scores_gemma":[0.0015402506,0.0004935202,0.00016888502,0.00012419905,0.00035048262,0.0003586335,0.0017026128,0.003114134,0.0002729235],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041361786,0.0017511704,0.26060244,0.001536174,0.0019267547,0.0001836894,0.06910943,0.028067514,0.0001999364,0.008830858,0.016110988,0.60754484],"study_design_scores_gemma":[0.0024047699,0.00031775484,0.01500686,0.0007692689,0.000022471944,0.00002250112,0.00038914997,0.089469604,0.00018823301,0.14467037,0.7446053,0.0021336856],"about_ca_topic_score_codex":0.06299331,"about_ca_topic_score_gemma":0.04550191,"teacher_disagreement_score":0.72849435,"about_ca_system_score_codex":0.003605789,"about_ca_system_score_gemma":0.0010222723,"threshold_uncertainty_score":0.9997516},"labels":[],"label_agreement":null},{"id":"W3124418915","doi":"10.1177/009885880603200206","title":"Oy Canada! Trade's Non-Solution to “<i>the</i> Problem” of U.S. Drug Prices","year":2006,"lang":"en","type":"article","venue":"American Journal of Law & Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"SAFER; Law; Political science; Law and economics; Sociology; Computer security","score_opus":0.01601723944256,"score_gpt":0.2502375098141847,"score_spread":0.23422027037162468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124418915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6240167,0.0041240263,0.0019762304,0.26541653,0.0009157677,0.00036645005,0.0001465428,0.000008888282,0.10302887],"genre_scores_gemma":[0.98976636,0.00016313427,0.00068197836,0.008527463,0.0007417571,0.0000027421236,0.0000022276797,0.000014345426,0.00010001805],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984109,0.000016451044,0.0010913349,0.00013813633,0.00008029218,0.00026292246],"domain_scores_gemma":[0.99833083,0.00010638201,0.001173351,0.00015780694,0.00004410069,0.00018755413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007224038,0.00012468397,0.00062275375,0.000106214655,0.000061162194,0.000010375702,0.0003378142,0.000017414804,0.000089570254],"category_scores_gemma":[0.00002169481,0.00009714035,0.00008315688,0.0002789753,0.00028050455,0.00009328771,0.000019093868,0.00019369625,0.00000863376],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002899485,0.00033335888,0.018298142,0.00012133469,0.0003683488,0.000039027447,0.0033694566,0.003060073,0.0011878718,0.55361336,0.39311212,0.026206937],"study_design_scores_gemma":[0.0007151082,0.0003628029,0.0092117535,0.00005890855,0.000026425985,0.00003352014,0.00013912587,0.00024663872,0.0002891983,0.0041347314,0.98463225,0.00014951582],"about_ca_topic_score_codex":0.38611895,"about_ca_topic_score_gemma":0.07581714,"teacher_disagreement_score":0.59152013,"about_ca_system_score_codex":0.00016087347,"about_ca_system_score_gemma":0.00012243254,"threshold_uncertainty_score":0.9410468},"labels":[],"label_agreement":null},{"id":"W3124476680","doi":"10.1093/rfs/hhab024","title":"Missing Novelty in Drug Development","year":2021,"lang":"en","type":"article","venue":"Review of Financial Studies","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"","keywords":"Novelty; Shock (circulatory); Drug; Business; Drug development; Value (mathematics); Economics; Microeconomics; Pharmacology; Computer science; Medicine; Psychology; Machine learning","score_opus":0.13248601471570198,"score_gpt":0.35391681117802987,"score_spread":0.22143079646232788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124476680","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.041949272,0.9309681,0.00004007345,0.0052708657,0.00030548315,0.0001434813,0.000033563778,0.0000071101967,0.02128202],"genre_scores_gemma":[0.13395855,0.8515546,0.0028826217,0.010876741,0.00014793235,0.00004146712,0.0000092057635,0.000017982451,0.00051092426],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986597,0.000013347964,0.0008779869,0.00022609213,0.00002095973,0.00020194612],"domain_scores_gemma":[0.9994743,0.000058825655,0.00023731416,0.00013852323,0.000050532693,0.000040526502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063275726,0.00010899708,0.00073314056,0.000059371567,0.000050626884,0.0000071337995,0.00010155458,0.000026891648,0.000109228524],"category_scores_gemma":[0.00081380154,0.000121117206,0.000100536934,0.00025473017,0.00004408945,0.00006151604,0.00010812379,0.00009297014,0.00012345839],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001354603,0.00048230388,0.03260315,0.025105702,0.00020482302,0.000049758557,0.0026340554,0.000007444664,0.00004567975,0.64542395,0.03450277,0.25892684],"study_design_scores_gemma":[0.00024760328,0.000004588561,0.022182127,0.0026831888,0.000005049361,0.0000019182173,0.000013771504,0.000009031501,0.0005992288,0.010293279,0.96377844,0.0001817721],"about_ca_topic_score_codex":0.00002573618,"about_ca_topic_score_gemma":0.000077525045,"teacher_disagreement_score":0.9292757,"about_ca_system_score_codex":0.00011997683,"about_ca_system_score_gemma":0.000115720984,"threshold_uncertainty_score":0.49390164},"labels":[],"label_agreement":null},{"id":"W3124578120","doi":"","title":"Funding Antibiotic Innovation with Vouchers: Recommendations on How to Strengthen a Flawed Incentive Policy","year":2016,"lang":"en","type":"article","venue":"eYLS (Yale Law School)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Voucher; Liberian dollar; Notice; Public economics; Incentive; Business; Antibiotics; Value (mathematics); Economics; Finance; Accounting; Political science; Market economy; Law","score_opus":0.07285952110814095,"score_gpt":0.2981186263086669,"score_spread":0.22525910520052597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124578120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80281407,0.00007058917,0.0026877439,0.110684626,0.00048417423,0.00062605395,0.0008311966,0.00012513087,0.08167642],"genre_scores_gemma":[0.9863369,0.00007709337,0.00093616487,0.008894744,0.00044952094,0.00002477852,0.000026034677,0.000041490362,0.00321327],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.998512,0.000020770045,0.00044673184,0.0004974564,0.00003598953,0.0004870487],"domain_scores_gemma":[0.9988847,0.00012914091,0.0002798534,0.00038875372,0.000059337246,0.0002582355],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00038004803,0.00021485882,0.00032227836,0.0005103557,0.00018374517,0.00019283143,0.00026994155,0.00009463092,0.0005481725],"category_scores_gemma":[0.00034624583,0.00018725595,0.000060286,0.0007894141,0.000072949384,0.0004964838,0.000079411904,0.00018271002,0.0021799565],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005365128,0.000078363904,0.0046245344,0.000007779558,0.00007060638,0.0000010365748,0.0001243105,0.00002058266,0.00026507958,0.98354775,0.0037870214,0.0074192975],"study_design_scores_gemma":[0.003345622,0.00054566126,0.0078671165,0.00026617543,0.000015757834,0.000003883905,0.00013104866,0.00041748892,0.004290817,0.07333643,0.9087427,0.0010372513],"about_ca_topic_score_codex":0.0003610589,"about_ca_topic_score_gemma":0.0002046433,"teacher_disagreement_score":0.9102113,"about_ca_system_score_codex":0.0005012204,"about_ca_system_score_gemma":0.00006312611,"threshold_uncertainty_score":0.99859697},"labels":[],"label_agreement":null},{"id":"W3124610394","doi":"","title":"Orphan Drug Incentives in the Pharmacogenomic Context: Policy Responses in the US and Canada","year":2015,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Saskatchewan; University of Toronto","funders":"","keywords":"Incentive; Pharmacogenomics; Context (archaeology); Orphan drug; Drug; Business; Public economics; Economics; Pharmacology; Medicine; Geography; Bioinformatics; Biology; Market economy","score_opus":0.03254740105091719,"score_gpt":0.2816638010917783,"score_spread":0.2491164000408611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124610394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95415246,0.011690765,0.00000985805,0.030842962,0.00013279176,0.00016645541,0.000046750174,0.000002196554,0.0029557282],"genre_scores_gemma":[0.9834208,0.00637867,0.0000023389605,0.009677874,0.0002807087,0.000010591204,0.0000019681731,0.0000126077875,0.00021446813],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99783766,0.00019194503,0.00048006565,0.00018939128,0.00005029938,0.0012506089],"domain_scores_gemma":[0.9993525,0.00019255867,0.00019360444,0.00014973585,0.000013874149,0.000097723016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049107363,0.00014128818,0.00023741745,0.00023041839,0.000115597155,0.0001226922,0.0005427333,0.000034314784,0.000014296433],"category_scores_gemma":[0.00017544265,0.00010603866,0.00004696661,0.0002201676,0.00007532002,0.00017255524,0.000044006403,0.0011777423,0.000020284697],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026715227,0.0001156598,0.16844451,0.000005969209,0.00008749772,0.00002973916,0.0049375235,0.00006821258,0.000014190306,0.8176911,0.0033548502,0.0049836156],"study_design_scores_gemma":[0.004140539,0.0001289651,0.040178508,0.000011628198,0.000011867552,0.0005711367,0.010964703,0.00087962154,0.000027917642,0.6190267,0.3236377,0.0004206967],"about_ca_topic_score_codex":0.3938634,"about_ca_topic_score_gemma":0.76454705,"teacher_disagreement_score":0.37068364,"about_ca_system_score_codex":0.0015178369,"about_ca_system_score_gemma":0.0028584837,"threshold_uncertainty_score":0.61017287},"labels":[],"label_agreement":null},{"id":"W3124722174","doi":"10.2139/ssrn.2858703","title":"The Trans Pacific Partnership Agreement and Pharmaceutical Regulation in Canada and Australia","year":2016,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University","funders":"","keywords":"Download; General partnership; Agreement; Political science; World Wide Web; Computer science; Business; Internet privacy; Law","score_opus":0.055435387865612744,"score_gpt":0.28667293687004936,"score_spread":0.2312375490044366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124722174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.966245,0.0037673607,0.00042861595,0.027500138,0.00015567472,0.00012475876,0.000017996173,0.0000032700707,0.0017571984],"genre_scores_gemma":[0.9812673,0.017459868,0.0000040345517,0.00020068293,0.00008679461,0.000004238337,4.293649e-7,0.0000075969933,0.0009690535],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9983075,0.000027180326,0.00037880856,0.00016919909,0.000028723056,0.0010885566],"domain_scores_gemma":[0.999575,0.00009596569,0.000106499094,0.00008153773,0.000007709546,0.0001332403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012979314,0.00009718298,0.00014939283,0.000053897038,0.00012330656,0.000053414842,0.00010101562,0.000034433528,0.0000780503],"category_scores_gemma":[0.000027180373,0.00006938366,0.000027596912,0.000055493212,0.0000671238,0.00011779453,0.000015154267,0.00042584937,0.000012974462],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047004938,0.00001191849,0.13645695,0.0000046126515,0.000059201546,0.0000011972293,0.00007368358,0.000004765109,0.00005720698,0.8395853,0.00035643982,0.023341713],"study_design_scores_gemma":[0.0021517174,0.00008302395,0.10887051,0.000016421018,0.0000112997295,0.00010743136,0.0002892876,0.00090422126,0.00010341791,0.7314067,0.1557654,0.00029056735],"about_ca_topic_score_codex":0.038848374,"about_ca_topic_score_gemma":0.6551957,"teacher_disagreement_score":0.6163474,"about_ca_system_score_codex":0.0011489661,"about_ca_system_score_gemma":0.00046318202,"threshold_uncertainty_score":0.967552},"labels":[],"label_agreement":null},{"id":"W3125080756","doi":"","title":"Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century after the 1984 Waxman-Hatch Legislation","year":2010,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Brand loyalty; Legislation; Competition (biology); Business; Loyalty; Marketing; Advertising; Law; Political science; Biology; Geography","score_opus":0.017079788326487426,"score_gpt":0.26399444263107846,"score_spread":0.24691465430459103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125080756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9683688,0.008157781,0.00028951137,0.017239029,0.00035191997,0.00024790328,0.000014057556,0.0000055110377,0.0053254366],"genre_scores_gemma":[0.9792094,0.017106596,0.0000127948615,0.00318142,0.0003898935,0.00002286473,0.0000037158024,0.000013806364,0.00005946762],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99805903,0.000076179895,0.0005150965,0.00022182518,0.00004550723,0.0010823429],"domain_scores_gemma":[0.9994581,0.00011830732,0.00017686708,0.00016833386,0.000011842868,0.00006654552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027504717,0.00014217077,0.00020615858,0.00016072184,0.0001163271,0.00016727143,0.0002665832,0.00009103213,0.00017478787],"category_scores_gemma":[0.000031633655,0.00010657954,0.000070355905,0.00018964554,0.00008271311,0.00026210287,0.000034227753,0.002085416,0.00007135208],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022696191,0.00026427538,0.11656833,0.000017927729,0.000074558455,0.0000079885085,0.0021089094,0.00007337067,0.0002724079,0.86793154,0.00032492948,0.012128826],"study_design_scores_gemma":[0.0032400761,0.00012176878,0.16845623,0.000016421009,0.000020058693,0.0003968701,0.00055869087,0.008977621,0.000029122362,0.6064291,0.21131325,0.00044080135],"about_ca_topic_score_codex":0.000086266984,"about_ca_topic_score_gemma":0.0013555476,"teacher_disagreement_score":0.26150241,"about_ca_system_score_codex":0.0001848824,"about_ca_system_score_gemma":0.00012444334,"threshold_uncertainty_score":0.9060212},"labels":[],"label_agreement":null},{"id":"W3125183276","doi":"","title":"Externalities and Benefit Design in Health Insurance","year":2015,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"","keywords":"Externality; Prescription drug; Download; Subsidy; Incentive; Business; Public economics; Prescription costs; Medical prescription; Consumption (sociology); Actuarial science; Medicare Part D; Economics; Microeconomics; Pharmacology; Medicine","score_opus":0.08196332851849211,"score_gpt":0.29564165059986897,"score_spread":0.21367832208137685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125183276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8877551,0.078867495,0.014504686,0.012676742,0.00039724205,0.00021405399,0.00003814803,0.000021346414,0.005525185],"genre_scores_gemma":[0.97417414,0.022959376,0.0002460748,0.0015934701,0.00015399765,0.000004636843,7.4073466e-7,0.000016386039,0.0008511885],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99789643,0.000023290768,0.00054332666,0.00018174647,0.000024210638,0.0013310164],"domain_scores_gemma":[0.9994079,0.00003573717,0.00024371695,0.00009496641,0.000013698459,0.00020400615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033192972,0.000109709385,0.00029052893,0.0001830857,0.00006277143,0.00007424957,0.00016075821,0.00004553449,0.000018885721],"category_scores_gemma":[0.00005316201,0.00012389137,0.000039776172,0.00009755184,0.00003664343,0.00023843301,0.00002929556,0.00074130355,0.00006869137],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003411349,0.000027935135,0.04624228,0.0000062502318,0.000023971215,0.0000012112305,0.00039076345,0.00033113387,8.551175e-7,0.94693667,0.000101459176,0.0059033805],"study_design_scores_gemma":[0.0009768207,0.00016588959,0.0072898488,0.000011228299,5.152015e-7,0.00011491241,0.0002034066,0.0013660376,0.0000036394674,0.97875565,0.01097535,0.00013671731],"about_ca_topic_score_codex":0.0004918089,"about_ca_topic_score_gemma":0.00038681232,"teacher_disagreement_score":0.08641902,"about_ca_system_score_codex":0.0009023959,"about_ca_system_score_gemma":0.00043748485,"threshold_uncertainty_score":0.50521433},"labels":[],"label_agreement":null},{"id":"W3125347212","doi":"","title":"The Impact of Pharmaceutical Innovation on Premature Cancer Mortality in Canada, 2000-2011","year":2015,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Mortality rate; Developing country; Download; Access to medicines; Cancer; Pharmaceutical industry; Developed country; Demography; Economics; Demographic economics; Medicine; Economic growth; Population; Sociology","score_opus":0.07341799769722925,"score_gpt":0.34664858433126133,"score_spread":0.2732305866340321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125347212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98665,0.005771343,0.000027329397,0.0023070483,0.0003036863,0.00011594485,0.000084611514,0.0000029894986,0.0047370517],"genre_scores_gemma":[0.9953804,0.0038526077,0.0000021058897,0.0003661473,0.0001735145,0.000007119174,0.0000027786004,0.0000136350745,0.00020169221],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9979052,0.000031719588,0.00067096547,0.00015539637,0.000060693907,0.001176039],"domain_scores_gemma":[0.99924433,0.000049862298,0.00037796664,0.00014799941,0.000062844425,0.00011698402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021978174,0.00012780621,0.0002689126,0.00013790288,0.000063052365,0.000030359139,0.00027330776,0.00005855588,0.00010533662],"category_scores_gemma":[0.00010362656,0.00010054283,0.000078887395,0.00026304173,0.000037254376,0.00011607439,0.000024371973,0.0013067531,0.000026028945],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00018677187,0.0000807242,0.32302475,0.00000509256,0.00027869042,0.0000020251227,0.00009741436,0.0033903716,0.000014609628,0.665984,0.0029762622,0.003959292],"study_design_scores_gemma":[0.002248018,0.0002744119,0.18562149,0.00001732605,0.0000136863555,0.00004388553,0.00016323575,0.014516617,0.00018336662,0.78058386,0.015981082,0.0003530566],"about_ca_topic_score_codex":0.4137091,"about_ca_topic_score_gemma":0.5510575,"teacher_disagreement_score":0.13740328,"about_ca_system_score_codex":0.0072259437,"about_ca_system_score_gemma":0.009258819,"threshold_uncertainty_score":0.99658513},"labels":[],"label_agreement":null},{"id":"W3125490444","doi":"","title":"Assessing Canada’s Drug Shortage Problem","year":2018,"lang":"en","type":"article","venue":"C.D. Howe Institute Commentary","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Economic shortage; Innovator; Medical prescription; Harm; Business; Medicine; Health care; Enforcement; Economic growth; Nursing; Economics; Political science; Finance; Government (linguistics); Law","score_opus":0.07127745277737396,"score_gpt":0.2994371149421321,"score_spread":0.22815966216475814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125490444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5570589,0.0011569811,0.0008438688,0.09873478,0.004716307,0.00046031794,0.0005197942,0.000101076,0.33640802],"genre_scores_gemma":[0.93347377,0.00011123341,0.0012156473,0.06370383,0.00092389947,0.000018260866,0.00008446406,0.000028888633,0.00043998906],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99845374,0.000012922411,0.00058891246,0.0004078926,0.000037786027,0.0004987781],"domain_scores_gemma":[0.99911684,0.000032094667,0.0001962824,0.0003827512,0.0000244353,0.0002475947],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035092104,0.0002082072,0.00034269414,0.000117979,0.00036411808,0.00020132076,0.00042278657,0.00005460289,0.0007296165],"category_scores_gemma":[0.000019567591,0.0002509656,0.00007709869,0.00014325354,0.00020514196,0.0008287943,0.00018045677,0.0002366723,0.00031067134],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015937607,0.00013748299,0.032386538,0.00004440336,0.00014535639,0.000035678517,0.0003645284,0.000036111996,0.000040198523,0.16059606,0.79982966,0.0063680494],"study_design_scores_gemma":[0.00043088218,0.00001824426,0.003083667,0.00001814596,0.0000070158985,0.000005926619,0.00005538873,0.0011530397,0.00031956987,0.008222825,0.9863576,0.0003276928],"about_ca_topic_score_codex":0.22492051,"about_ca_topic_score_gemma":0.30631557,"teacher_disagreement_score":0.37641492,"about_ca_system_score_codex":0.00051352644,"about_ca_system_score_gemma":0.00020165942,"threshold_uncertainty_score":0.9999943},"labels":[],"label_agreement":null},{"id":"W3125788429","doi":"","title":"Tough Choices: The Private Sale of Drugs in Public Hospitals","year":2014,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Business; Public economics; Law and economics; Economics","score_opus":0.022420106456979685,"score_gpt":0.25268388802295294,"score_spread":0.23026378156597327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125788429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94312245,0.0044050063,0.0008220021,0.011740747,0.00028330326,0.00014622264,0.000014432406,0.000010557382,0.03945527],"genre_scores_gemma":[0.9928639,0.0054650586,0.000028285362,0.00093757984,0.00025490194,0.0000066195635,0.0000016424639,0.000019489584,0.00042250648],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9976374,0.00003996392,0.0006861122,0.00018930672,0.00003466943,0.0014125351],"domain_scores_gemma":[0.9991142,0.00010158443,0.00044079428,0.00024164609,0.000019497546,0.00008223486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033928666,0.00012370227,0.00032384155,0.00018758838,0.00008903059,0.00007695408,0.0005457801,0.00006851371,0.0001401011],"category_scores_gemma":[0.00016892969,0.0001070056,0.00013868466,0.0002252617,0.00007535076,0.00025735085,0.000060774906,0.0009952668,0.00015340459],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007042654,0.000038919778,0.024708401,0.000004973512,0.000050369024,8.310592e-8,0.00014691384,0.000027301643,0.000008242451,0.9707004,0.00008589744,0.00422149],"study_design_scores_gemma":[0.0007198062,0.00009747119,0.00805874,0.0000062640543,0.0000035226162,0.000012338047,0.000091847,0.0011564381,0.00004189953,0.86735225,0.12231532,0.00014412683],"about_ca_topic_score_codex":0.00010113392,"about_ca_topic_score_gemma":0.00019231363,"teacher_disagreement_score":0.12222942,"about_ca_system_score_codex":0.00038397656,"about_ca_system_score_gemma":0.00021361867,"threshold_uncertainty_score":0.4363562},"labels":[],"label_agreement":null},{"id":"W312868857","doi":"10.1177/009885880603200204","title":"How Parallel Trade Affects Drug Policies and Prices in Canada and the United States","year":2006,"lang":"en","type":"article","venue":"American Journal of Law & Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"The King's University; Institute of Health Economics; University of Calgary","funders":"","keywords":"Scrutiny; Drug prices; Economics; International trade; Pharmaceutical industry; International economics; Commercial policy; Business; Public economics; Political science; Law; Biotechnology","score_opus":0.01748899685676759,"score_gpt":0.24304247799975154,"score_spread":0.22555348114298396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W312868857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87909216,0.0044682575,0.00002928745,0.11466005,0.000071718925,0.000061315426,0.000015609598,0.0000015859258,0.0016000462],"genre_scores_gemma":[0.98771477,0.0032546695,0.0000621895,0.008758278,0.00017142395,0.0000015127691,0.0000024199499,0.0000084342255,0.00002629396],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992341,0.000027688086,0.00040143315,0.00009813055,0.00003650753,0.00020217191],"domain_scores_gemma":[0.99888635,0.00038851696,0.00052316254,0.00007497325,0.000009770226,0.0001172268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048643578,0.00010589979,0.0005256726,0.00013704246,0.00004557293,0.00003462625,0.000120643424,0.000010735989,0.000008572465],"category_scores_gemma":[0.000042486503,0.00007216785,0.000024794326,0.00018343754,0.0007206646,0.000093211274,0.000015605729,0.00018121391,2.1636274e-7],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024008175,0.00004196036,0.099449344,0.000042807267,0.00013608055,0.000044383803,0.004094529,0.00075433333,0.00001358614,0.88493574,0.0071894433,0.003057722],"study_design_scores_gemma":[0.01137918,0.00049076864,0.24529067,0.00013991604,0.000066735345,0.00025791037,0.005462509,0.0075878664,0.00003846087,0.07634755,0.6524225,0.00051592116],"about_ca_topic_score_codex":0.89113235,"about_ca_topic_score_gemma":0.46800122,"teacher_disagreement_score":0.8085882,"about_ca_system_score_codex":0.00008927425,"about_ca_system_score_gemma":0.000049625756,"threshold_uncertainty_score":0.5417064},"labels":[],"label_agreement":null},{"id":"W3133577532","doi":"10.3917/ems.bent.2019.01.0360","title":"Supply Chain Management de la santé","year":2019,"lang":"fr","type":"book-chapter","venue":"EMS Editions eBooks","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Intégré de Santé et Services Sociaux de Chaudière-Appalache; Musée de la Civilisation; Ministère de l’Emploi et de la Solidarité Sociale (Québec); Université du Québec à Montréal","funders":"","keywords":"Business","score_opus":0.03140389886087217,"score_gpt":0.28206560490196236,"score_spread":0.25066170604109017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133577532","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001014579,0.0015621107,0.0009951551,0.0014641094,0.004168515,0.00067355804,0.0047600437,0.000060227678,0.9853017],"genre_scores_gemma":[0.104868546,0.00536143,0.0018375674,0.0059951283,0.0046155313,0.00014175207,0.00034689248,0.00022647141,0.8766067],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972602,0.00004555181,0.0010526333,0.0007967815,0.000057582576,0.00078722415],"domain_scores_gemma":[0.997975,0.00039146078,0.0005219575,0.0007641727,0.000029012605,0.0003183911],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00091414235,0.0005505632,0.0008114751,0.00062397606,0.00028466087,0.00023448694,0.0005342901,0.00070089375,0.010834956],"category_scores_gemma":[0.000028409262,0.00080401934,0.0005367428,0.000031552157,0.00059047696,0.00010657734,0.00026795195,0.0009140902,0.011131717],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001145911,0.00006157681,0.00022326484,0.00017066914,0.0003939057,0.00004451309,0.00020901984,0.00006020125,0.0000033648298,0.95256823,0.032770578,0.013483243],"study_design_scores_gemma":[0.00061090325,0.000047066995,0.0010267845,0.00014616236,0.00006507791,0.000026961588,0.000019272176,0.00079429214,0.000013691226,0.28668794,0.70996016,0.0006016524],"about_ca_topic_score_codex":0.00007289257,"about_ca_topic_score_gemma":0.000020294645,"teacher_disagreement_score":0.6771896,"about_ca_system_score_codex":0.00059455726,"about_ca_system_score_gemma":0.00010051231,"threshold_uncertainty_score":0.9994411},"labels":[],"label_agreement":null},{"id":"W3133774058","doi":"10.1001/jamanetworkopen.2021.1143","title":"Time to Marketing of Generic Drugs After Patent Expiration in Canada","year":2021,"lang":"en","type":"article","venue":"JAMA Network Open","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University","funders":"","keywords":"Expiration; Expiration date; Business; Marketing; Medicine; Advertising; Internal medicine; Chemistry; Food science","score_opus":0.051733867047955406,"score_gpt":0.24136504879544468,"score_spread":0.18963118174748927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133774058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9391096,0.0008412859,0.00002069806,0.004654549,0.00018999394,0.0002126858,0.00008952946,0.0000024713593,0.054879144],"genre_scores_gemma":[0.9895699,0.00012302342,0.0005327798,0.008268483,0.00018621178,0.000050459956,0.000018018094,0.000014935932,0.0012361964],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988622,0.00004610987,0.0005461529,0.00025627267,0.000020255751,0.00026900033],"domain_scores_gemma":[0.9994467,0.0000732857,0.00014832415,0.00020724462,0.000020359554,0.000104116385],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00081455056,0.00008539994,0.00030597678,0.000040934672,0.00002388135,0.00008237087,0.00024024799,0.000039289753,0.0034437974],"category_scores_gemma":[0.000064162145,0.000108598055,0.000035089735,0.0002718936,0.000007570654,0.0001401385,0.00029679033,0.00008830908,0.00028947412],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008058719,0.00019788426,0.6383185,0.00013136685,0.00019943899,0.00010767373,0.001489466,0.09428209,0.00008625664,0.011578774,0.18003033,0.07277237],"study_design_scores_gemma":[0.0009359893,0.00001813149,0.42277572,0.000088538116,0.0000042769116,0.0000019553322,0.000051813135,0.04937828,0.00013665213,0.0022141943,0.5240136,0.00038088448],"about_ca_topic_score_codex":0.16159488,"about_ca_topic_score_gemma":0.13184667,"teacher_disagreement_score":0.34398323,"about_ca_system_score_codex":0.0003090247,"about_ca_system_score_gemma":0.00023831485,"threshold_uncertainty_score":0.9974672},"labels":[],"label_agreement":null},{"id":"W3135068797","doi":"10.1007/s40273-021-01007-8","title":"The Continued Need for Transparent Evidence on the Cost Effectiveness of Drugs for Rare Diseases","year":2021,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Quality of Life Research; Health economics; Health administration; Public health; Pharmacoeconomics; Medicine; Intensive care medicine; Nursing","score_opus":0.16470911239705432,"score_gpt":0.3657572656773199,"score_spread":0.2010481532802656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135068797","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0098531395,0.020099068,0.0027390402,0.9080444,0.0064672083,0.010254539,0.039989274,0.000066689885,0.0024866336],"genre_scores_gemma":[0.22462004,0.01356928,0.000094823066,0.7420322,0.006893497,0.0092712045,0.0016142578,0.000420503,0.0014841864],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99683625,0.00015956322,0.0013394741,0.0008477237,0.00004548066,0.0007715396],"domain_scores_gemma":[0.98317647,0.014715461,0.0010735414,0.00077411695,0.00012397909,0.0001364178],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017973104,0.0005356057,0.0012844125,0.0001350044,0.00041320518,0.00028865546,0.001231831,0.00031485068,0.00017197529],"category_scores_gemma":[0.00053448544,0.00044671635,0.0010871025,0.00010176615,0.00026858872,0.00016893054,0.000094494724,0.0007677406,0.000066996545],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011518406,0.000111022295,0.00026598736,0.0016039275,0.0011272378,0.0000028170057,0.00015857191,0.000501186,0.00005799548,0.06546263,0.92696804,0.0025887713],"study_design_scores_gemma":[0.0020139797,0.00008858404,0.00010310802,0.00020378122,0.00017780958,0.0000011697018,0.000027586695,0.006248415,0.0024761274,0.01695476,0.9711578,0.00054691476],"about_ca_topic_score_codex":0.000039247065,"about_ca_topic_score_gemma":0.0000053718177,"teacher_disagreement_score":0.2147669,"about_ca_system_score_codex":0.0003866493,"about_ca_system_score_gemma":0.0001894502,"threshold_uncertainty_score":0.9997985},"labels":[],"label_agreement":null},{"id":"W3135225309","doi":"10.1038/s41429-021-00414-5","title":"Market concentration of new antibiotic sales","year":2021,"lang":"en","type":"article","venue":"The Journal of Antibiotics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Canadian Institutes of Health Research","keywords":"Antibiotics; Revenue; Business; Incentive; Value (mathematics); Economics; Microeconomics; Finance; Chemistry; Mathematics","score_opus":0.05698176783501902,"score_gpt":0.28348680470215804,"score_spread":0.22650503686713902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135225309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9575641,0.0065084174,0.002074648,0.008413613,0.0009334726,0.00007227239,0.00006955209,0.000004833666,0.024359073],"genre_scores_gemma":[0.9924752,0.005197403,0.0007477262,0.00067934894,0.00026552312,6.8609973e-10,0.0000017559308,0.0000107656515,0.00062227313],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989363,0.000031160944,0.00076726655,0.000073288254,0.000035252702,0.00015675659],"domain_scores_gemma":[0.9987804,0.00012244511,0.000741635,0.00018102792,0.000077784214,0.00009670263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006951332,0.00008237826,0.0003378186,0.000053231317,0.000037751404,0.00003064258,0.00021927524,0.000055140335,0.0003123209],"category_scores_gemma":[0.00018334742,0.000070634414,0.00013018015,0.00015062922,0.00008003543,0.000118435324,0.000039374292,0.00016580388,0.000052411593],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040201977,0.000746078,0.14176916,0.00031028214,0.0010629422,0.00006762201,0.0026481615,0.0017515646,0.026152644,0.6754028,0.14470442,0.0049822624],"study_design_scores_gemma":[0.005117564,0.00068682875,0.15095668,0.00035542474,0.0003173759,0.0007563974,0.00075680634,0.015844634,0.44542223,0.18991789,0.18900661,0.0008615644],"about_ca_topic_score_codex":0.000015165093,"about_ca_topic_score_gemma":0.0000038888243,"teacher_disagreement_score":0.48548496,"about_ca_system_score_codex":0.00003223753,"about_ca_system_score_gemma":0.00012782593,"threshold_uncertainty_score":0.3419695},"labels":[],"label_agreement":null},{"id":"W3139400359","doi":"10.1007/s10389-021-01485-2","title":"The challenges of drug shortages in the Canadian hospital pharmacy supply chain — a systematic literature review","year":2021,"lang":"en","type":"article","venue":"Journal of Public Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"École de Technologie Supérieure","funders":"","keywords":"Pharmacy; Economic shortage; Medicine; Hospital pharmacy; Supply chain; MEDLINE; Business; Systematic review; Environmental health; Family medicine; Medical emergency; Political science; Marketing","score_opus":0.09439757050382781,"score_gpt":0.34034468046644306,"score_spread":0.24594710996261526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3139400359","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0056348117,0.5569127,0.0000023382108,0.43471128,0.00029539113,0.00024212361,0.000064842105,0.0000011492049,0.0021353723],"genre_scores_gemma":[0.5624546,0.4273286,0.000018409186,0.009993238,0.00014342507,0.000009886152,0.0000021628473,0.000007754708,0.00004197617],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974229,0.00036597252,0.0015666554,0.00013492764,0.00007585168,0.00043370735],"domain_scores_gemma":[0.997855,0.00031068557,0.0010617175,0.00028494018,0.00013834823,0.00034928956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010856332,0.00011628927,0.00070560334,0.00022808516,0.00013967056,0.00018595968,0.000537204,0.000036754733,0.000048678376],"category_scores_gemma":[0.0007912655,0.00007664256,0.00019784996,0.00040145914,0.000043090906,0.0002302929,0.000026589874,0.00051519804,0.000011196528],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000035393211,0.0002591443,0.0056526144,0.031501092,0.00021818135,0.000106674655,0.01294902,0.0000037474895,3.4570118e-7,0.91083664,0.031844366,0.0066246116],"study_design_scores_gemma":[0.0012688392,0.00017177725,0.015416884,0.017518587,0.000024796633,0.0004503787,0.0025361325,0.0005115738,0.0000039937686,0.01567187,0.94606507,0.00036012765],"about_ca_topic_score_codex":0.002100318,"about_ca_topic_score_gemma":0.027277764,"teacher_disagreement_score":0.9142207,"about_ca_system_score_codex":0.00030357455,"about_ca_system_score_gemma":0.0011525643,"threshold_uncertainty_score":0.9904719},"labels":[],"label_agreement":null},{"id":"W3139447851","doi":"10.1186/s12872-021-01955-1","title":"Associations between essential medicines and health outcomes for cardiovascular disease","year":2021,"lang":"en","type":"article","venue":"BMC Cardiovascular Disorders","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Athabasca University; St. Michael's Hospital","funders":"Canadian Institutes of Health Research; Canada Research Chairs; St. Michael's Hospital Foundation","keywords":"Medicine; Reimbursement; Disease; Health care; Angiology; Heart disease; Public health; Family medicine; Emergency medicine; Internal medicine; Nursing","score_opus":0.07080388545600512,"score_gpt":0.3076432253559906,"score_spread":0.23683933989998546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3139447851","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0825381,0.5615351,0.29807803,0.037649512,0.0024674719,0.0029980035,0.008896907,0.00026247313,0.005574377],"genre_scores_gemma":[0.9829127,0.01116186,0.001810116,0.0021819943,0.00076662644,0.00017981826,0.0006823068,0.00009448622,0.00021007337],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980497,0.000063040214,0.00063969364,0.00068129983,0.000097105454,0.00046917278],"domain_scores_gemma":[0.9985969,0.0001323957,0.00014837571,0.0007111357,0.0000457943,0.0003653824],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015270129,0.00022765122,0.0012649184,0.00013016287,0.00025899938,0.0000919948,0.00015248095,0.00008867552,0.000036283058],"category_scores_gemma":[0.00038209502,0.00027144575,0.0027896408,0.00018951448,0.00008120134,0.0001406501,0.00009766589,0.00012034571,0.00003658775],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009854313,0.00012163434,0.8779677,0.00032849255,0.016429305,0.000003451872,0.0002523374,0.0033261327,2.598789e-7,0.08316337,0.003197529,0.01519991],"study_design_scores_gemma":[0.002866291,0.000018467956,0.54255295,0.000012455326,0.00063957454,0.000001469205,0.000057854835,0.00096174737,0.0000032989135,0.047126103,0.4052735,0.0004863095],"about_ca_topic_score_codex":0.0004896811,"about_ca_topic_score_gemma":0.00012176193,"teacher_disagreement_score":0.90037465,"about_ca_system_score_codex":0.0001137294,"about_ca_system_score_gemma":0.00015846724,"threshold_uncertainty_score":0.9999738},"labels":[],"label_agreement":null},{"id":"W313968408","doi":"","title":"Patents for second medical indications and their potential impact on pharmacare in Canada.","year":2001,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"","keywords":"Formulary; Medicine; Appeal; Notice; Law; Political science; Family medicine","score_opus":0.054384051330907554,"score_gpt":0.2660631059125948,"score_spread":0.21167905458168723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W313968408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872355,0.00047849157,0.000078061166,0.004951784,0.00026574975,0.0004937039,0.0011458977,0.000007578252,0.005343262],"genre_scores_gemma":[0.99558103,0.0002504,0.0000034075106,0.0033700236,0.00012768974,0.0004789548,0.000033221073,0.000014549479,0.00014069374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998976,0.0000085700685,0.00034616332,0.00024201407,0.000022949169,0.00040428725],"domain_scores_gemma":[0.9993742,0.00007355821,0.00010191485,0.000111286194,0.000008133976,0.0003309047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031069032,0.00011533687,0.00023489216,0.00014485119,0.00004979551,0.00003059435,0.00015941291,0.000060011484,0.0006085533],"category_scores_gemma":[0.00006486578,0.0001096774,0.0000561082,0.00010050197,0.000021059379,0.00007932422,0.00003350173,0.00014489368,0.000013441046],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033900965,0.0003681283,0.7044321,0.00007144833,0.00034954236,0.000033467102,0.00036832906,0.00032195696,0.0000040720465,0.031172188,0.023938557,0.23860124],"study_design_scores_gemma":[0.001874994,0.000012872739,0.8863241,0.0000032197818,0.0000030494925,0.000011594711,0.000021997039,0.011701933,0.000052103172,0.009199833,0.090566084,0.00022821646],"about_ca_topic_score_codex":0.060491547,"about_ca_topic_score_gemma":0.11282007,"teacher_disagreement_score":0.23837303,"about_ca_system_score_codex":0.00034929914,"about_ca_system_score_gemma":0.00013294711,"threshold_uncertainty_score":0.9457647},"labels":[],"label_agreement":null},{"id":"W3143498503","doi":"10.1136/bmjgh-2021-005518","title":"Overriding drug and medical technology patents for pandemic recovery: a legitimate move for high-income countries, too","year":2021,"lang":"en","type":"article","venue":"BMJ Global Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Unitaid","keywords":"Intellectual property; TRIPS architecture; Business; TRIPS Agreement; Essential medicines; Market access; Public health; Pandemic; International trade; Monopolistic competition; Access to medicines; Global health; Economic growth; Public economics; Law and economics; Health care; Coronavirus disease 2019 (COVID-19); Economics; Political science; Monopoly; Medicine; Law; Market economy; Infectious disease (medical specialty)","score_opus":0.048613461184934495,"score_gpt":0.37063407129528136,"score_spread":0.3220206101103469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3143498503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7280611,0.023930373,0.017185668,0.1929783,0.0041633653,0.003859407,0.024857119,0.00027858015,0.0046861023],"genre_scores_gemma":[0.9631089,0.0078057493,0.00300652,0.024719216,0.00045306113,0.0003406245,0.00015731805,0.000040275296,0.000368355],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9978858,0.000016042997,0.0008408424,0.00053151796,0.00004466805,0.0006810897],"domain_scores_gemma":[0.99884105,0.00016906818,0.00035743878,0.00024085314,0.000054638334,0.00033694503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010804129,0.00018145135,0.0006681797,0.000091158305,0.00020239931,0.00007637209,0.0001909111,0.00020791213,0.00008286226],"category_scores_gemma":[0.00038228938,0.00021761571,0.0000972586,0.00018410193,0.00008145263,0.00013732542,0.00013981412,0.00013846064,0.000046624456],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011529345,0.000046614197,0.03515483,0.00032723704,0.000075233744,0.0000054176335,0.000025284191,0.00001203175,4.4476047e-7,0.9389421,0.015306172,0.009989353],"study_design_scores_gemma":[0.0035593042,0.00017252489,0.0072047384,0.000115983166,0.000010336969,0.000083506515,0.00003216969,0.010681095,0.000026493124,0.5888482,0.38887277,0.0003929438],"about_ca_topic_score_codex":0.00042886788,"about_ca_topic_score_gemma":0.0002286847,"teacher_disagreement_score":0.3735666,"about_ca_system_score_codex":0.0006529609,"about_ca_system_score_gemma":0.00054192235,"threshold_uncertainty_score":0.8874112},"labels":[],"label_agreement":null},{"id":"W3146414094","doi":"10.1371/journal.pone.0248567","title":"Examining therapeutic equivalence between branded and generic warfarin in Brazil: The WARFA crossover randomized controlled trial","year":2021,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Impact; McMaster University; Population Health Research Institute","funders":"Fundação de Amparo à Pesquisa do Estado de São Paulo","keywords":"Warfarin; Medicine; Confidence interval; Randomized controlled trial; Randomization; Crossover study; Atrial fibrillation; Internal medicine; Placebo","score_opus":0.20442747505756972,"score_gpt":0.3054063070032948,"score_spread":0.10097883194572507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3146414094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9789053,0.0065603866,0.00013047036,0.0034412616,0.00013958367,0.0015112845,0.000045277364,0.000023427134,0.0092429705],"genre_scores_gemma":[0.9927702,0.0029223715,0.00014191607,0.0026428238,0.00032390963,0.00028116314,0.000008490129,0.000029589362,0.0008795453],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977548,0.00018264214,0.0011155304,0.00046598472,0.00006243288,0.00041856835],"domain_scores_gemma":[0.99758637,0.0015741896,0.0003527959,0.00034663378,0.000029048326,0.00011093487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002035307,0.00021318476,0.0018589123,0.00012552695,0.00012322147,0.00020661493,0.00024022128,0.00012501536,0.00047139733],"category_scores_gemma":[0.00073435664,0.00017903226,0.00019275052,0.00021898242,0.00019730798,0.00016060735,0.00013978493,0.00031283108,0.00009765359],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7338373,0.0028281964,0.076082185,0.00026992607,0.005940495,0.000032696134,0.0033524537,0.00008568538,0.002423249,0.17127387,0.00015983781,0.003714115],"study_design_scores_gemma":[0.9487794,0.000064206215,0.004985733,0.000034975532,0.00015971065,0.0000013214731,0.000022159815,0.0073848395,0.00073645136,0.036962666,0.0005428938,0.0003256314],"about_ca_topic_score_codex":0.000056958896,"about_ca_topic_score_gemma":0.000014590261,"teacher_disagreement_score":0.21494213,"about_ca_system_score_codex":0.000062521685,"about_ca_system_score_gemma":0.000055771663,"threshold_uncertainty_score":0.7300724},"labels":[],"label_agreement":null},{"id":"W3148820128","doi":"10.1053/j.seminoncol.2021.03.001","title":"Can locally developed me-too drugs aid price negotiation? An example of cancer therapies from China","year":2021,"lang":"en","type":"article","venue":"Seminars in Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Natural Science Foundation of China","keywords":"Medicine; Gefitinib; Erlotinib; Reimbursement; Public economics; Cancer; Economic growth; Epidermal growth factor receptor; Economics; Health care; Internal medicine","score_opus":0.054499248969912276,"score_gpt":0.3286563674087065,"score_spread":0.27415711843879426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3148820128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96575373,0.00602802,0.00014241299,0.00573608,0.0005822354,0.00013994273,0.00032774,0.000015805826,0.02127403],"genre_scores_gemma":[0.9870002,0.0060898853,0.0028012875,0.0030905704,0.00017745889,0.000049380138,0.00008217266,0.000029470595,0.00067956466],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983766,0.00005370763,0.0007351664,0.000465889,0.00002725901,0.00034138002],"domain_scores_gemma":[0.9989397,0.00022955795,0.00034959114,0.00031925752,0.00004505958,0.00011683316],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00042746926,0.00015758195,0.000584742,0.00015220974,0.00005122051,0.000023829767,0.00028758304,0.00019249973,0.0015358073],"category_scores_gemma":[0.00007941341,0.00019410405,0.00006634231,0.0002904719,0.000101413134,0.00012999726,0.000108759916,0.00022398331,0.00004298198],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026486182,0.0012525663,0.4699381,0.000082130005,0.00046864903,0.000056290093,0.056819804,0.0014685713,0.0018877317,0.34217787,0.004031567,0.12155186],"study_design_scores_gemma":[0.002730136,0.00022653166,0.22827345,0.00004782165,0.00001957655,0.000005830975,0.001203572,0.0057272594,0.0038766607,0.19512974,0.5621379,0.00062151946],"about_ca_topic_score_codex":0.014788714,"about_ca_topic_score_gemma":0.007387414,"teacher_disagreement_score":0.5581063,"about_ca_system_score_codex":0.00045675103,"about_ca_system_score_gemma":0.00037031705,"threshold_uncertainty_score":0.99937695},"labels":[],"label_agreement":null},{"id":"W3149592704","doi":"","title":"The determinants of pricing in pharmaceuticals : are U.S. prices really higher than those of Canada?","year":2007,"lang":"en","type":"article","venue":"RePEc: Research Papers in Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nationality; Market power; Economics; Monetary economics; Product (mathematics); Quality (philosophy); Power (physics); Phenomenon; International economics; Business; Market economy","score_opus":0.08286905979129951,"score_gpt":0.3714895997745227,"score_spread":0.28862053998322323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3149592704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86269397,0.001119204,0.0000010880597,0.0007533222,0.00026323888,0.0003449108,0.000082710976,0.000004997501,0.13473655],"genre_scores_gemma":[0.99054223,0.0083305845,0.00008362341,0.0002077679,0.00007748865,0.000020884467,0.0000015903498,0.000031516676,0.00070433976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967543,0.000056879395,0.0016392716,0.0004484339,0.000081566795,0.0010195308],"domain_scores_gemma":[0.99730605,0.0012880021,0.0006164786,0.0005127865,0.000056522636,0.0002201786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053464305,0.00018357422,0.0006438952,0.00042996742,0.000116565214,0.000035506127,0.00068069494,0.00013724192,0.00007302464],"category_scores_gemma":[0.00050043873,0.00018177608,0.00010152719,0.00033261755,0.00030676075,0.00013507572,0.00022399318,0.0005154371,0.000004911552],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033849382,0.00026156276,0.85905474,0.00018265173,0.00007814506,0.000037099144,0.00041443043,0.00057663466,0.00017786867,0.04083956,0.0001382653,0.097900525],"study_design_scores_gemma":[0.0017115293,0.00010410888,0.79105514,0.00015325997,0.0000045040397,0.0000052416713,0.000559461,0.009043718,0.0041531827,0.010156581,0.18256232,0.000490946],"about_ca_topic_score_codex":0.017431732,"about_ca_topic_score_gemma":0.22419104,"teacher_disagreement_score":0.2067593,"about_ca_system_score_codex":0.0006620623,"about_ca_system_score_gemma":0.00037043198,"threshold_uncertainty_score":0.9891113},"labels":[],"label_agreement":null},{"id":"W3150852188","doi":"","title":"INFRINGING ON INVESTMENT: HOW ONE COMPANY IS USING INVESTMENT PROTECTIONS OF NAFTA TO SAVE ITS INTELLECTUAL PROPERTY","year":2015,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Tariff; International trade; Intellectual property; Investment (military); Order (exchange); Business; Free trade agreement; Clothing; Prescription drug; Medical prescription; Free trade; International economics; Economics; Finance; Political science; Law","score_opus":0.34872923892520585,"score_gpt":0.3147525149365832,"score_spread":0.03397672398862267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3150852188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7657564,0.00030846035,0.002531743,0.011675589,0.00038899563,0.0014082184,0.0001784706,0.00006979692,0.21768229],"genre_scores_gemma":[0.9785198,0.00003060147,0.0023667072,0.01628173,0.000119968994,0.00005439262,0.0000036104068,0.00003240195,0.0025907997],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986828,0.000018979546,0.0005152391,0.00037994198,0.00004911226,0.0003539449],"domain_scores_gemma":[0.9990003,0.000043157303,0.00019208627,0.00030088093,0.00006140286,0.00040216066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003939639,0.00019016213,0.0004265695,0.00042451016,0.00008429399,0.00008604581,0.0002156054,0.00007723854,0.00035038227],"category_scores_gemma":[0.00033478573,0.00017735334,0.0000881788,0.00034568267,0.00005474385,0.00018542721,0.00016600979,0.00018215938,0.0006751866],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018102677,0.0010463638,0.0018815731,0.00015511233,0.000450132,0.000002194138,0.010950433,0.005060515,0.002167661,0.9476666,0.028918061,0.0015203416],"study_design_scores_gemma":[0.0020432617,0.000934794,0.0004162142,0.00012890795,0.000026471038,0.00001079888,0.0003845187,0.19743706,0.045166075,0.03136106,0.7211042,0.0009866406],"about_ca_topic_score_codex":0.00044440638,"about_ca_topic_score_gemma":0.000024474519,"teacher_disagreement_score":0.91630554,"about_ca_system_score_codex":0.00039992688,"about_ca_system_score_gemma":0.00008227951,"threshold_uncertainty_score":0.8678382},"labels":[],"label_agreement":null},{"id":"W3151177152","doi":"","title":"Rebuttal: Does family medicine have a professional obligation to play a leading role in pharmaceutical industry?sponsored drug research?: YES.","year":2011,"lang":"en","type":"article","venue":"Canadian Family Physician","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Rebuttal; Obligation; Drug industry; Medicine; Alternative medicine; Family medicine; Management; Medical education; Library science; Political science; Law; Engineering ethics; Engineering; Computer science","score_opus":0.18021284942450377,"score_gpt":0.36716376808869194,"score_spread":0.18695091866418817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3151177152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.67957634,0.0005634037,0.0000071004456,0.005978264,0.0006322473,0.00060457655,0.0003875808,0.00002927768,0.3122212],"genre_scores_gemma":[0.93410534,0.00005173856,0.00008747569,0.06358348,0.00051718816,0.00012740857,0.00003714707,0.000058405694,0.0014318348],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99707353,0.0001108822,0.00076773507,0.00071983086,0.00010681654,0.0012212176],"domain_scores_gemma":[0.99794185,0.00013692178,0.00014079009,0.00040757842,0.00007577006,0.0012971136],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015488252,0.00028139868,0.00055882474,0.0014961282,0.00024704225,0.000062790394,0.00056942506,0.00028191655,0.00011997212],"category_scores_gemma":[0.0001382503,0.0002902473,0.00008784146,0.0008363509,0.00027568662,0.00033194426,0.00010349078,0.0012847584,0.001115074],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043449533,0.0005866825,0.036840994,0.00012093509,0.00023664256,0.00018251054,0.025537329,0.0001238135,0.008267894,0.68767214,0.20446527,0.035531264],"study_design_scores_gemma":[0.0019779224,0.00012920727,0.12013473,0.00026587077,0.000014136394,0.0000011078033,0.007448997,0.004024755,0.001308764,0.114145696,0.7495923,0.0009564885],"about_ca_topic_score_codex":0.0475041,"about_ca_topic_score_gemma":0.01758464,"teacher_disagreement_score":0.5735265,"about_ca_system_score_codex":0.0009984295,"about_ca_system_score_gemma":0.00039526907,"threshold_uncertainty_score":0.99995494},"labels":[],"label_agreement":null},{"id":"W3151383188","doi":"","title":"Pharmaceutical Patent Policy in Developing Countries: Learning from the Canadian Experience","year":2011,"lang":"en","type":"article","venue":"Chapters","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Intellectual property; Harmonization; Globalization; Context (archaeology); International trade; Access to medicines; Politics; Developing country; Business; Production (economics); Political science; Economic growth; Economics; Law; Geography","score_opus":0.25889257821766615,"score_gpt":0.30954313838660646,"score_spread":0.05065056016894032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3151383188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8857912,0.0011537375,0.00030021791,0.021327058,0.0005732963,0.0002599687,0.00009759978,0.000036773108,0.09046014],"genre_scores_gemma":[0.97911555,0.0010483195,0.00011338103,0.01947834,0.0001399176,0.00002587482,0.0000060002426,0.000017350849,0.000055254553],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987837,0.00001535913,0.0003897225,0.0002954043,0.00002255422,0.0004932446],"domain_scores_gemma":[0.9994303,0.000061537205,0.00009290008,0.00017072163,0.000009935498,0.00023462437],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00028570867,0.00013376269,0.0002016475,0.00018187611,0.0001931126,0.00007309283,0.0003393865,0.00007613236,0.00089288375],"category_scores_gemma":[0.00008415546,0.0001319514,0.000052332,0.00016447243,0.00014599798,0.00014478709,0.00006279368,0.00025400796,0.00081458635],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001489908,0.000010520094,0.24574263,0.0000042687243,0.000023194458,0.00001167772,0.017898524,0.00002953806,0.0000026410971,0.73512435,0.00012624756,0.0010115374],"study_design_scores_gemma":[0.0005359052,0.00001381108,0.10706463,0.00001914599,0.0000024421129,0.0000025662034,0.00043739614,0.0045560994,0.00017778573,0.01771132,0.86913085,0.00034808205],"about_ca_topic_score_codex":0.3352334,"about_ca_topic_score_gemma":0.060178943,"teacher_disagreement_score":0.86900455,"about_ca_system_score_codex":0.00049047766,"about_ca_system_score_gemma":0.000132986,"threshold_uncertainty_score":0.9999634},"labels":[],"label_agreement":null},{"id":"W3154522180","doi":"10.1002/cncr.33568","title":"Forecasting essential childhood cancer drug need: An innovative model‐based approach","year":2021,"lang":"en","type":"article","venue":"Cancer","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children","funders":"","keywords":"Medicine; Health care; Procurement; Environmental health; Economic growth; Business; Marketing; Economics","score_opus":0.09705375534285139,"score_gpt":0.31242406542869056,"score_spread":0.21537031008583918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3154522180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9014601,0.005649323,0.012281609,0.0043622204,0.0010593294,0.00032922815,0.0019173577,0.000079567166,0.07286124],"genre_scores_gemma":[0.9893758,0.00028832426,0.0017566839,0.0068375254,0.0006987848,0.00017674151,0.00008981227,0.00005241508,0.00072390225],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99842805,0.00001518404,0.00050030346,0.0005771806,0.000033272587,0.00044602648],"domain_scores_gemma":[0.9991399,0.000023755125,0.00024889072,0.00030316165,0.000106526895,0.0001777749],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002137737,0.000205875,0.00040523897,0.00013779588,0.00014104547,0.000115586925,0.00022830523,0.00009318388,0.0011273521],"category_scores_gemma":[0.00003914843,0.00025215096,0.000101189886,0.0005122105,0.00006620684,0.00030775153,0.000078383346,0.00027931985,0.00003627969],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000107693835,0.0012542245,0.03758672,0.0002884631,0.0006026251,0.000018746809,0.007360244,0.5473455,0.0005503846,0.36049202,0.014686628,0.029706728],"study_design_scores_gemma":[0.0010502127,0.000009600652,0.0009348333,0.000019708621,0.0000128088595,0.0000018897703,0.00007268035,0.96203804,0.00246874,0.009041629,0.023911778,0.00043805543],"about_ca_topic_score_codex":0.00044304898,"about_ca_topic_score_gemma":0.00011430489,"teacher_disagreement_score":0.41469255,"about_ca_system_score_codex":0.00023298108,"about_ca_system_score_gemma":0.00036343213,"threshold_uncertainty_score":0.9999931},"labels":[],"label_agreement":null},{"id":"W3154938279","doi":"10.1093/ajhp/zxab160","title":"National trends in prescription drug expenditures and projections for 2021","year":2021,"lang":"en","type":"article","venue":"American Journal of Health-System Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Drug Policy Research Network; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Biosimilar; Medical prescription; Specialty; Prescription drug; Medicine; Drug; Legislation; Business; Pharmacy; Family medicine; Pharmacology; Political science","score_opus":0.08007821918919704,"score_gpt":0.37293936534222777,"score_spread":0.2928611461530307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3154938279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6965542,0.039338943,0.0048107677,0.23047304,0.0049662995,0.0009463569,0.0015699975,0.000041971452,0.021298463],"genre_scores_gemma":[0.9959008,0.0010486145,0.000841309,0.0015586447,0.00039791514,0.000029268638,0.000012281626,0.000016981372,0.0001941942],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998221,0.00009099662,0.0011524468,0.00021843413,0.000049251994,0.00026790213],"domain_scores_gemma":[0.99855465,0.00010845366,0.0010056698,0.00007892858,0.000085594314,0.00016672384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012718635,0.000114173665,0.0005501183,0.0005179315,0.00010819721,0.000060858652,0.00010489824,0.000016071928,0.0001211063],"category_scores_gemma":[0.00005076987,0.0001289117,0.00013038021,0.00026344656,0.000054206183,0.0002663386,0.000024034838,0.00019372173,0.00000936564],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067008485,0.001053055,0.065501384,0.0007644566,0.0006240141,0.000049405287,0.0061721634,0.0013319447,0.0003454555,0.25599775,0.10590224,0.56158805],"study_design_scores_gemma":[0.003959887,0.00020414335,0.0116604725,0.00010304457,0.000013332461,0.00037684885,0.001476512,0.010953103,0.0002159845,0.003506642,0.967219,0.00031105417],"about_ca_topic_score_codex":0.0004701083,"about_ca_topic_score_gemma":0.00006946629,"teacher_disagreement_score":0.86131674,"about_ca_system_score_codex":0.0003670859,"about_ca_system_score_gemma":0.00024135325,"threshold_uncertainty_score":0.5256867},"labels":[],"label_agreement":null},{"id":"W3155589128","doi":"10.1182/blood.v130.suppl_1.3403.3403","title":"Incremental Financial and Health-Related Burden of Novel Drugs Used in the Treatment of Relapsed and/or Refractory Multiple Myeloma (RRMM): A Meta-Analysis of Phase III Randomized Controlled Trials (RCTs)","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Pomalidomide; Medicine; Randomized controlled trial; Internal medicine; Meta-analysis; Refractory (planetary science); Oncology; Multiple myeloma; Lenalidomide","score_opus":0.1858870700279212,"score_gpt":0.37302470508607205,"score_spread":0.18713763505815084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3155589128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869835,0.008303694,0.00002118794,0.0012146496,0.000050824972,0.0019286138,0.0010847445,0.0000034914203,0.0004093329],"genre_scores_gemma":[0.9965993,0.0028484464,0.00015204333,0.00010895039,0.00003054392,0.00017221888,0.000020294061,0.000011384503,0.00005681057],"study_design_codex":"meta_analysis","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959098,0.00027764842,0.0032241591,0.0003176402,0.00005850541,0.00021224041],"domain_scores_gemma":[0.99304736,0.0023104667,0.004051011,0.00047776234,0.000029608274,0.00008378884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0077899364,0.00022635954,0.008067688,0.0004599971,0.00010149904,0.000035808465,0.00023099167,0.00011772641,0.00014944153],"category_scores_gemma":[0.0016548027,0.00014413233,0.0015468335,0.00015379307,0.00022554706,0.000105163446,0.00004115804,0.00008880488,8.659787e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32795477,0.02857186,0.007666612,0.00034563505,0.5086902,0.000017866947,0.045790914,0.00024227425,0.004808488,0.070337154,0.00009767726,0.005476538],"study_design_scores_gemma":[0.9469375,0.0007259589,0.0016606648,0.000010761037,0.034985915,0.0000013533648,0.00015064859,0.013266088,0.00090927916,0.0008060961,0.0003417311,0.00020400246],"about_ca_topic_score_codex":0.0053997063,"about_ca_topic_score_gemma":0.0003645577,"teacher_disagreement_score":0.61898273,"about_ca_system_score_codex":0.00003562632,"about_ca_system_score_gemma":0.00007913743,"threshold_uncertainty_score":0.8162777},"labels":[],"label_agreement":null},{"id":"W3158347929","doi":"10.1016/j.ptdy.2021.04.012","title":"Cash-based pharmacies deliver transparency, savings","year":2021,"lang":"en","type":"article","venue":"Pharmacy Today","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy; Cash; Pharmacist; Business; Medical prescription; Transparency (behavior); Quarter (Canadian coin); Finance; Family medicine; Medicine; Nursing; Law; Political science","score_opus":0.11352079610011583,"score_gpt":0.3209135052362714,"score_spread":0.20739270913615554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158347929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6810266,0.019006575,0.004356192,0.033521265,0.0031148037,0.0005285224,0.0021814588,0.00036315198,0.25590146],"genre_scores_gemma":[0.97976476,0.0014162617,0.000507477,0.016401198,0.00031949687,0.000039494742,0.00005958686,0.000050201597,0.0014414935],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980055,0.00003388701,0.00072914717,0.000595443,0.000048604288,0.0005874326],"domain_scores_gemma":[0.9989838,0.00010807995,0.0001883939,0.00033670745,0.000058705464,0.00032432252],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00036653457,0.00026796636,0.00046461556,0.0001611426,0.0001648477,0.00012863429,0.00034335718,0.000056625813,0.013696945],"category_scores_gemma":[0.00006120524,0.00033730938,0.00027852965,0.0003084533,0.00009359645,0.0003285337,0.00006454532,0.00030916167,0.0027245376],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005050918,0.0027835465,0.25023332,0.00086307875,0.0013569078,0.00091817713,0.0042238375,0.0057034297,0.027698984,0.4766065,0.17715392,0.051953238],"study_design_scores_gemma":[0.0024939163,0.000012878025,0.0015447888,0.000012053701,0.00002875236,0.000018284449,0.0000109038265,0.026476298,0.03507687,0.00699835,0.9268094,0.0005175053],"about_ca_topic_score_codex":0.00020548255,"about_ca_topic_score_gemma":0.0000193058,"teacher_disagreement_score":0.7496555,"about_ca_system_score_codex":0.0001282145,"about_ca_system_score_gemma":0.00010026758,"threshold_uncertainty_score":0.9999079},"labels":[],"label_agreement":null},{"id":"W3158871097","doi":"10.1503/cmaj.210531","title":"Managing drug shortages during a pandemic: tocilizumab and COVID-19","year":2021,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Hamilton Regional Laboratory Medicine Program; Health Sciences Centre; McMaster University; Women's College Hospital; Trillium Health Centre; Hamilton Health Sciences; University of Toronto; University Health Network; Sinai Health System; Sunnybrook Health Science Centre; St. Michael's Hospital","funders":"","keywords":"Pandemic; Economic shortage; Coronavirus disease 2019 (COVID-19); Tocilizumab; Supply chain; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Drug; Key (lock); Distribution (mathematics); Computer science; Business; Medicine; Virology; Pharmacology; Computer security; Pathology; Marketing; Infectious disease (medical specialty); Disease","score_opus":0.032834146659226134,"score_gpt":0.27987997617109117,"score_spread":0.24704582951186504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158871097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.60075396,0.006812451,0.0003473636,0.34086713,0.0011231642,0.00011592338,0.00027470317,0.000038175447,0.04966713],"genre_scores_gemma":[0.9224722,0.005459374,0.00007015883,0.068758644,0.0010508414,0.000005677974,0.000008113419,0.000020009826,0.0021550036],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986551,0.000045121553,0.0005196319,0.00022579217,0.00009832358,0.00045605845],"domain_scores_gemma":[0.99712944,0.00013129174,0.0002045454,0.000088829125,0.000047289286,0.0023986038],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013876875,0.000100123565,0.00026528141,0.00018035702,0.0003453515,0.00021166979,0.00014640692,0.00017327018,0.006211603],"category_scores_gemma":[0.0018570333,0.00012425984,0.00008384712,0.00013947488,0.000033327033,0.00015253408,0.00003769071,0.0006146883,0.00018092514],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010382516,0.00003502719,0.79025286,0.00007237263,0.00032857468,0.0012272998,0.0016104305,0.00007567971,0.0000075393777,0.057523202,0.13173063,0.017125973],"study_design_scores_gemma":[0.0011504086,0.000005211901,0.030046742,0.000014438003,0.0000075795774,0.0005723546,0.00027993158,0.0017241556,0.000006976035,0.032706216,0.93325907,0.00022688977],"about_ca_topic_score_codex":0.0020498466,"about_ca_topic_score_gemma":0.023441577,"teacher_disagreement_score":0.80152845,"about_ca_system_score_codex":0.0014643276,"about_ca_system_score_gemma":0.001166024,"threshold_uncertainty_score":0.99469686},"labels":[],"label_agreement":null},{"id":"W3158905218","doi":"10.1016/j.rcsop.2021.100020","title":"A systematic review of pharmaceutical price mark-up practice and its implementation","year":2021,"lang":"en","type":"review","venue":"Exploratory Research in Clinical and Social Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Margin (machine learning); Control (management); Value (mathematics); Pharmaceutical industry; Systematic review; Business; Economics; MEDLINE; Medicine; Political science; Management; Computer science","score_opus":0.6866369439326083,"score_gpt":0.6337531141768776,"score_spread":0.052883829755730694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158905218","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003670593,0.99253225,0.000002180338,0.00281407,0.00038212765,0.002289291,0.00044212566,0.000012065405,0.0014891918],"genre_scores_gemma":[0.00015743979,0.99609447,0.000020243986,0.00252836,0.0004481137,0.0005414646,0.00006451289,0.000054968248,0.00009040326],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99110544,0.0027905053,0.0043660095,0.0008852659,0.00019717582,0.0006555927],"domain_scores_gemma":[0.99346036,0.0043566977,0.0012639347,0.00026990616,0.00026239434,0.0003867344],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.020386219,0.0003685346,0.0041277045,0.00039408932,0.0001779498,0.00012118995,0.00042798585,0.0002596476,0.00039101794],"category_scores_gemma":[0.0030797943,0.0003756406,0.0005098028,0.0007800373,0.00036528526,0.0004932827,0.00059899385,0.0019346222,0.00019257607],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024078034,0.00027070483,0.000025983214,0.8913261,0.00051603577,0.000035542915,0.0003112869,6.3661596e-9,9.006048e-8,0.052073527,0.0030871308,0.052329473],"study_design_scores_gemma":[0.0010206255,0.000041179657,0.0000016194167,0.07819508,0.00030807848,0.000011893964,0.00020296458,0.00004082234,6.6722714e-7,0.0011801581,0.9186524,0.00034451086],"about_ca_topic_score_codex":0.00002091006,"about_ca_topic_score_gemma":0.0000023525201,"teacher_disagreement_score":0.91556525,"about_ca_system_score_codex":0.00015357671,"about_ca_system_score_gemma":0.0005605623,"threshold_uncertainty_score":0.9998695},"labels":[],"label_agreement":null},{"id":"W3160997078","doi":"10.5334/gh.927","title":"Health System Capacity and Access Barriers to Diagnosis and Treatment of CVD and Diabetes in Nepal","year":2021,"lang":"en","type":"review","venue":"Global Heart","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Pharmacy; Descriptive statistics; Health facility; Essential medicines; Private sector; Public health; Environmental health; Public sector; Family medicine; Economic growth; Population; Health services; Nursing","score_opus":0.14902970365781118,"score_gpt":0.3843194712923159,"score_spread":0.23528976763450474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3160997078","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05841329,0.93671775,4.750118e-7,0.00068560836,0.00014846706,0.00057312596,0.0029211696,0.000006915836,0.0005332169],"genre_scores_gemma":[0.014389175,0.98486626,0.000067330846,0.00046368837,0.000056906374,0.00012177333,0.000015229265,0.000013371067,0.000006267738],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983463,0.000053138916,0.00074450346,0.00049664744,0.000017449656,0.0003419249],"domain_scores_gemma":[0.99893916,0.00009534265,0.00021067366,0.00018723648,0.000008240717,0.00055932335],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026540912,0.00025494487,0.0021955308,0.00013715806,0.000056074106,0.00009850446,0.00008513399,0.00014091913,0.000024422987],"category_scores_gemma":[0.000050408944,0.00026492827,0.000118235206,0.00022032227,0.00006674675,0.00008093218,0.00012424949,0.00007598833,0.000012571734],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000055407513,0.00009661431,0.3651541,0.013468369,0.00022291462,0.000004756317,0.00013357855,0.0000017092691,8.17752e-9,0.036090273,0.0013969592,0.58342516],"study_design_scores_gemma":[0.0002973398,0.0001285277,0.005865125,0.0015696704,0.000029125253,0.000011329524,0.000012767716,0.00007018188,3.1741592e-7,0.00023647473,0.9915471,0.0002320056],"about_ca_topic_score_codex":0.002243651,"about_ca_topic_score_gemma":0.0003815928,"teacher_disagreement_score":0.99015015,"about_ca_system_score_codex":0.00051570626,"about_ca_system_score_gemma":0.000114540366,"threshold_uncertainty_score":0.9999803},"labels":[],"label_agreement":null},{"id":"W3162560322","doi":"10.1111/cts.13046","title":"The timing of 30‐month stay expirations and generic entry: A cohort study of first generics, 2013–2020","year":2021,"lang":"en","type":"article","venue":"Clinical and Translational Science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Novo Nordisk Fonden","keywords":"Generic drug; Paragraph; Medicine; Certification; Brand names; Food and drug administration; Advertising; Business; Drug; Medical emergency; Pharmacology; Law; Political science","score_opus":0.15052911303879832,"score_gpt":0.3585425818910221,"score_spread":0.2080134688522238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3162560322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99174947,0.0020694202,0.00030788442,0.0030432148,0.00014862604,0.00014308683,0.000073231844,0.0000027486149,0.0024623196],"genre_scores_gemma":[0.99666923,0.002693009,0.0003517867,0.0001770863,0.000054146618,0.0000069730036,0.0000024512126,0.0000031179245,0.000042209278],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988694,0.000017115315,0.000648218,0.00028616627,0.00005215555,0.00012695027],"domain_scores_gemma":[0.9992129,0.00032387298,0.00016624182,0.00013763767,0.000056713125,0.000102607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009522002,0.00006023899,0.00021887438,0.000030157233,0.00024449173,0.000042782158,0.0001295005,0.000029454832,0.00008633171],"category_scores_gemma":[0.0001408277,0.0000520007,0.000041398005,0.00023079602,0.00060273684,0.00011311076,0.00005257125,0.0000757993,0.0000037559691],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007794948,0.00019727788,0.9637941,0.000007455619,0.00003190583,6.0978437e-7,0.00025975532,0.00014392263,0.000018242017,0.03312405,0.00012715775,0.0022876954],"study_design_scores_gemma":[0.0005510354,0.00007502875,0.94373614,0.0000035260498,0.000012138293,0.0000013700151,0.00007073845,0.03051868,0.000030305617,0.011064136,0.013853118,0.00008376213],"about_ca_topic_score_codex":0.0000588062,"about_ca_topic_score_gemma":0.00017220704,"teacher_disagreement_score":0.030374758,"about_ca_system_score_codex":0.0000044411886,"about_ca_system_score_gemma":0.000060638613,"threshold_uncertainty_score":0.2220809},"labels":[],"label_agreement":null},{"id":"W3164318960","doi":"10.3233/jrs-210013","title":"Companies’ statements about drugs withdrawn from the Canadian market: A descriptive analysis","year":2021,"lang":"en","type":"article","venue":"International Journal of Risk & Safety in Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University","funders":"","keywords":"Government (linguistics); Business; Drug Company; Descriptive statistics; Drug; Position (finance); Brand names; Product (mathematics); Drug withdrawal; Medicine; Marketing; Finance; Psychiatry; Management; Economics","score_opus":0.037290061303913415,"score_gpt":0.3274937796348996,"score_spread":0.2902037183309862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164318960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7642863,0.015233995,0.004871295,0.1258561,0.0051047173,0.00021498145,0.0045674453,0.000008645042,0.07985654],"genre_scores_gemma":[0.9887097,0.0055777947,0.00028462018,0.0046250145,0.0005821424,0.000001539076,0.000054330794,0.000009810479,0.00015506172],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99822,0.00007678251,0.001176697,0.00018236504,0.00013287136,0.00021125923],"domain_scores_gemma":[0.9982216,0.00037785768,0.00077408494,0.00016659281,0.00025199054,0.00020792117],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014732138,0.000121040706,0.0005020443,0.00047376804,0.0000871354,0.00007290283,0.0005412613,0.000051545965,0.0043180343],"category_scores_gemma":[0.0005526461,0.00009935586,0.00017154912,0.0003891264,0.0001247524,0.00019900185,0.000052081312,0.00043306276,0.000048098194],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004965743,0.00017576579,0.8832575,0.000004463821,0.007586649,0.00040149144,0.020003185,0.0044876025,0.0000072418056,0.05057853,0.022512386,0.010488575],"study_design_scores_gemma":[0.0024617638,0.000029242756,0.641774,0.00007890007,0.0001578805,0.000016812579,0.0016285343,0.008693669,0.00000827207,0.03745613,0.30754483,0.0001499561],"about_ca_topic_score_codex":0.15641755,"about_ca_topic_score_gemma":0.21651559,"teacher_disagreement_score":0.28503245,"about_ca_system_score_codex":0.00076906825,"about_ca_system_score_gemma":0.00022490518,"threshold_uncertainty_score":0.99659216},"labels":[],"label_agreement":null},{"id":"W3164448554","doi":"10.1002/prp2.794","title":"Exploring the Food and Drug Administration’s review and approval of Entresto (sacubitril/valsartan)","year":2021,"lang":"en","type":"review","venue":"Pharmacology Research & Perspectives","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital; Dalhousie University","funders":"Canadian Institutes of Health Research","keywords":"Food and drug administration; Regulatory science; Sacubitril, Valsartan; Valsartan; Agency (philosophy); Medicine; Drug development; Business; Strengths and weaknesses; Pharmacology; Sacubitril; Drug; Psychology","score_opus":0.4617126359250331,"score_gpt":0.4775476366956166,"score_spread":0.01583500077058353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164448554","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005079068,0.98864174,0.000002045123,0.0059716096,0.00020057884,0.0012982772,0.000392305,0.000012499227,0.002973045],"genre_scores_gemma":[0.0024915412,0.9956887,0.000031189233,0.0002705331,0.00035146723,0.0007025367,0.00001589849,0.00004413116,0.00040405223],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970224,0.00054839184,0.00094234606,0.0008527405,0.000075182164,0.0005589585],"domain_scores_gemma":[0.99758244,0.0012791657,0.0004080177,0.00034738792,0.00014476787,0.00023821736],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0028658297,0.00033097915,0.0023749445,0.00037949797,0.00026901544,0.000094693954,0.00045839674,0.000104753475,0.0005065912],"category_scores_gemma":[0.0004626137,0.0002867689,0.00028701036,0.0005269504,0.0008322285,0.00024583424,0.00046508506,0.0011722351,0.000052216146],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005531552,0.00085456204,0.00008158404,0.06911215,0.004108433,0.00004992698,0.0060676895,6.441555e-7,0.0000070031406,0.6078665,0.039510995,0.27228516],"study_design_scores_gemma":[0.00025173623,0.00010564565,0.000012417182,0.0011526404,0.0003377633,0.000048271155,0.00040084563,0.000009622301,0.000018308381,0.0015838776,0.9958119,0.00026701836],"about_ca_topic_score_codex":0.000030988664,"about_ca_topic_score_gemma":0.000012085507,"teacher_disagreement_score":0.95630085,"about_ca_system_score_codex":0.00018654426,"about_ca_system_score_gemma":0.00033626298,"threshold_uncertainty_score":0.99995846},"labels":[],"label_agreement":null},{"id":"W3171961774","doi":"10.3386/w28866","title":"Common Agent or Double Agent? Pharmacy Benefit Managers in the Prescription Drug Market","year":2021,"lang":"en","type":"preprint","venue":"National Bureau of Economic Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Quest University Canada","funders":"","keywords":"Pharmacy; Medical prescription; Business; Drug; Prescription drug; Pharmacology; Medicine; Family medicine","score_opus":0.46272300715943177,"score_gpt":0.5027236993859804,"score_spread":0.04000069222654862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171961774","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30465868,0.003125644,0.0000130071885,0.0146410875,0.0013746883,0.0017411247,0.0007727774,0.000019068852,0.6736539],"genre_scores_gemma":[0.98564535,0.005218225,0.00013440251,0.00095054373,0.0004493258,0.0004154092,0.00049394346,0.0000478148,0.006645008],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9963381,0.00019173697,0.0016121243,0.00095326325,0.0002320646,0.00067269127],"domain_scores_gemma":[0.99765664,0.00072343263,0.0005816621,0.00071580627,0.00016036176,0.00016211485],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.007125543,0.00032687074,0.0008110874,0.0011099582,0.00016089212,0.00046558602,0.0015903179,0.00023903795,0.005603252],"category_scores_gemma":[0.00015343458,0.00033079702,0.0003516472,0.00030445692,0.0002216196,0.00034342235,0.00095373497,0.0015276063,0.0005024828],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006776582,0.00046502738,0.0075860815,0.000497623,0.0004036773,0.000028183327,0.0014836908,0.014376144,0.000013291006,0.87171596,0.1013084,0.0014442451],"study_design_scores_gemma":[0.0029894628,0.000040116982,0.006341554,0.00012555951,0.00001730357,0.000010219904,0.00040420282,0.045626756,0.0001706889,0.8114387,0.13223852,0.0005969501],"about_ca_topic_score_codex":0.0076099555,"about_ca_topic_score_gemma":0.0018043091,"teacher_disagreement_score":0.68098664,"about_ca_system_score_codex":0.0015921671,"about_ca_system_score_gemma":0.0004529201,"threshold_uncertainty_score":0.9999144},"labels":[],"label_agreement":null},{"id":"W3173458844","doi":"","title":"CANADIAN PHARMACEUTICAL INDUSTRY IN GLOBAL VALUE CHAINS: THE INFLUENCE OF DOMINANT TRADING PARTNER","year":2019,"lang":"en","type":"article","venue":"World Economy and International Relations","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Value (mathematics); Industrial organization; Commerce; International trade; Mathematics; Statistics","score_opus":0.040918460155378894,"score_gpt":0.31083228159211557,"score_spread":0.2699138214367367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173458844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.67673486,0.00023707736,0.000014771548,0.014238369,0.00019494107,0.00014914747,0.00013136283,0.000003253044,0.30829623],"genre_scores_gemma":[0.9929947,0.00005619085,0.000035782086,0.0027642213,0.000058540187,0.000018930474,0.000008850466,0.0000061455607,0.004056616],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990296,0.000012415199,0.0005093899,0.00021810054,0.00001552622,0.00021499756],"domain_scores_gemma":[0.9994748,0.00010189255,0.00014361863,0.0001284738,0.000016173937,0.00013499701],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036282762,0.00009574849,0.00018589289,0.00023892468,0.000060179405,0.000047672176,0.00021923022,0.00011769761,0.0018413175],"category_scores_gemma":[0.000049199294,0.000097926284,0.000055353332,0.0001855142,0.00007369741,0.00031519632,0.00004310172,0.00041591973,0.00033926126],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000004303107,0.000012551111,0.36114094,0.0000026473829,0.000024644198,3.539691e-7,0.00006467769,0.00281719,0.0000014381794,0.63547224,0.00029596782,0.00016301796],"study_design_scores_gemma":[0.00071784476,0.000010930296,0.36339927,0.000026271267,0.000005331259,0.000006374946,0.000038116854,0.09826731,0.000013450764,0.12407912,0.4132549,0.00018108462],"about_ca_topic_score_codex":0.006764151,"about_ca_topic_score_gemma":0.008870091,"teacher_disagreement_score":0.51139313,"about_ca_system_score_codex":0.00035414295,"about_ca_system_score_gemma":0.00008304214,"threshold_uncertainty_score":0.9998499},"labels":[],"label_agreement":null},{"id":"W3177665412","doi":"10.1038/s41408-021-00522-3","title":"Drug importation: limitations of current proposals and opportunities for improvement","year":2021,"lang":"en","type":"editorial","venue":"Blood Cancer Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Panacea (medicine); Business; Drug prices; Authorization; Drug; International trade; Law; Public economics; Economic policy; Medicine; Economics; Pharmacology; Political science; Computer security; Alternative medicine","score_opus":0.18921442342185205,"score_gpt":0.34818537186670157,"score_spread":0.15897094844484952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3177665412","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0040859776,0.14466165,0.00030769117,0.0054711215,0.8318887,0.0006296435,0.011242264,0.000013188717,0.0016998092],"genre_scores_gemma":[0.0035056786,0.34860322,0.00045477637,0.00044766083,0.6449021,0.00031181777,0.0003294555,0.00008126015,0.0013640301],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99819005,0.000014436208,0.0011561937,0.0002953573,0.000070188,0.0002737751],"domain_scores_gemma":[0.99776405,0.00030736285,0.0012859826,0.00015064291,0.00029339385,0.0001985489],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065389933,0.00021276184,0.00063715427,0.00020417469,0.00013974519,0.00017991061,0.00018679924,0.00015612894,0.00014183378],"category_scores_gemma":[0.00027871254,0.00024202191,0.0002195378,0.000051664574,0.000068519534,0.00016649779,0.000053099426,0.00048268042,0.0000017091613],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019340796,0.00013130136,0.000087178996,0.00040871478,0.00043245932,0.0000030094832,0.00028170773,0.00000841103,0.000010552569,0.013667286,0.9621394,0.02281063],"study_design_scores_gemma":[0.0012778768,0.00009589959,0.0000132171745,0.00013242546,0.00014698638,0.0000028813527,0.00009073844,0.00008821197,0.00016024188,0.014405115,0.9833281,0.00025829792],"about_ca_topic_score_codex":0.00003341833,"about_ca_topic_score_gemma":0.00006219655,"teacher_disagreement_score":0.20394155,"about_ca_system_score_codex":0.00009892012,"about_ca_system_score_gemma":0.00091737614,"threshold_uncertainty_score":0.9869367},"labels":[],"label_agreement":null},{"id":"W3178430533","doi":"10.4212/cjhp.v74i3.3155","title":"Pénuries de médicaments en établissement de santé : une étude qualitative à partir de cas réels pris en charge par les pharmaciens hospitaliers","year":2021,"lang":"fr","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Political science; Humanities; Art","score_opus":0.0450229921323941,"score_gpt":0.34931794896148616,"score_spread":0.3042949568290921,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3178430533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84399116,0.037452362,0.00026674772,0.111680835,0.0022835277,0.0003021985,0.0015140211,0.000008604473,0.0025005317],"genre_scores_gemma":[0.975686,0.015123821,0.0004955625,0.006144983,0.0014576043,0.00002452082,0.000015814005,0.00008485058,0.0009668188],"study_design_codex":"qualitative","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953991,0.0006529356,0.0015142176,0.00043596292,0.00013825524,0.0018594953],"domain_scores_gemma":[0.99579686,0.0005098825,0.0010727271,0.00034238328,0.00022753474,0.0020505886],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0041741733,0.00048791696,0.00085120375,0.0003488629,0.0008676211,0.0006658176,0.0010288561,0.00018349124,0.0027285924],"category_scores_gemma":[0.0007681226,0.0005406795,0.0005593794,0.00053818844,0.0009220022,0.000709761,0.00011700913,0.0013121413,0.0002012016],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022029121,0.001242833,0.2934874,0.00042860713,0.0052906377,0.003595177,0.4610402,0.0017954356,0.0010951621,0.0843316,0.12334491,0.024127752],"study_design_scores_gemma":[0.005690495,0.00064304646,0.048091326,0.00029803382,0.0007502789,0.0007583633,0.009822784,0.004977522,0.03237713,0.03198415,0.86287445,0.00173239],"about_ca_topic_score_codex":0.028451113,"about_ca_topic_score_gemma":0.0066253757,"teacher_disagreement_score":0.73952955,"about_ca_system_score_codex":0.0028088598,"about_ca_system_score_gemma":0.0033792937,"threshold_uncertainty_score":0.9997045},"labels":[],"label_agreement":null},{"id":"W3178864507","doi":"10.33731/22021.236692","title":"Pharmaceutical nationalism as an instrument to ensure the access to medicines","year":2021,"lang":"en","type":"article","venue":"Theory and Practice of Intellectual Property","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Access to medicines; Nationalism; Medicine; Business; Traditional medicine; Political science; Law; Nursing; Politics; Public health","score_opus":0.14831300892680452,"score_gpt":0.38966866282480667,"score_spread":0.24135565389800215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3178864507","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3147807,0.00227692,0.0030089472,0.26342493,0.00067874405,0.0007334882,0.0001248378,0.0000335412,0.41493785],"genre_scores_gemma":[0.9093315,0.0007098641,0.00037915216,0.08828431,0.00019614192,0.000026263986,0.000006263221,0.000016717917,0.0010497839],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986823,0.0002871496,0.00043503358,0.00033164362,0.00005431371,0.00020952057],"domain_scores_gemma":[0.99665684,0.0025824145,0.000112138805,0.00025444178,0.00013453017,0.00025962925],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002895447,0.0001340367,0.0002615129,0.0000965539,0.000140078,0.00013426514,0.0003294185,0.00005853858,0.003633333],"category_scores_gemma":[0.013478673,0.00008698,0.00004461996,0.00025995998,0.00012092933,0.00045103577,0.00026131267,0.00023379573,0.0004294692],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019449276,0.00030428934,0.000070114045,0.000041119907,0.00019225318,0.000008365754,0.010176469,0.00005871585,0.001046118,0.93177855,0.013082343,0.041296713],"study_design_scores_gemma":[0.00033577517,0.00023642239,0.00008710397,0.000017989787,0.000025842513,0.000120469966,0.0008560004,0.00047136567,0.0063787163,0.08908144,0.9022025,0.00018642255],"about_ca_topic_score_codex":0.00006328086,"about_ca_topic_score_gemma":0.000009257456,"teacher_disagreement_score":0.8891201,"about_ca_system_score_codex":0.00003352241,"about_ca_system_score_gemma":0.00007412145,"threshold_uncertainty_score":0.9972775},"labels":[],"label_agreement":null},{"id":"W3181614690","doi":"10.1093/cid/ciab612","title":"Patient Access in 14 High-Income Countries to New Antibacterials Approved by the US Food and Drug Administration, European Medicines Agency, Japanese Pharmaceuticals and Medical Devices Agency, or Health Canada, 2010–2020","year":2021,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Norwegian Institute of Public Health; Basilea Pharmaceutica; Shionogi; Norges Forskningsråd; Novo Holdings; Roivant Sciences; Meiji Seika Pharma; Bill and Melinda Gates Foundation; European Commission; Wellcome Trust","keywords":"Medicine; Food and drug administration; Agency (philosophy); Drug; Administration (probate law); Antibiotics; Family medicine; Environmental health; Pharmacology; Law","score_opus":0.0570680239702596,"score_gpt":0.36910930934883496,"score_spread":0.31204128537857534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3181614690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93245775,0.006794697,0.000016618747,0.057628766,0.0012063524,0.0004544257,0.001056935,0.000028859811,0.00035558463],"genre_scores_gemma":[0.94248515,0.008559477,0.000006584979,0.048231374,0.0004807683,0.00002427405,0.00005673381,0.00002735269,0.00012829168],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99682987,0.00034593773,0.0016274172,0.0006624309,0.00010717605,0.0004271878],"domain_scores_gemma":[0.9968314,0.0010905294,0.0004203618,0.00029907815,0.000056589055,0.0013020382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011330226,0.00025796914,0.0008033588,0.00006274949,0.00019565225,0.0002822539,0.00028196673,0.00008214827,0.00075911224],"category_scores_gemma":[0.0023420951,0.00020997589,0.00007213879,0.00024892937,0.00024039202,0.00020657158,0.0003206526,0.00027050235,0.000024027477],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020232108,0.0005069269,0.8563714,0.0003271252,0.00022900198,0.00010694228,0.0005610382,0.000008852251,0.0000021506987,0.0015309908,0.1256113,0.014541963],"study_design_scores_gemma":[0.0019978117,0.0004041015,0.8369821,0.00010041624,0.000041426472,0.000023818166,0.000040512223,0.00014451229,0.000024893554,0.0016768472,0.15816355,0.0004000224],"about_ca_topic_score_codex":0.038442492,"about_ca_topic_score_gemma":0.25040284,"teacher_disagreement_score":0.21196035,"about_ca_system_score_codex":0.00009172881,"about_ca_system_score_gemma":0.001190936,"threshold_uncertainty_score":0.9679606},"labels":[],"label_agreement":null},{"id":"W3182324768","doi":"10.1136/bmjopen-2020-047557","title":"Time to market for drugs approved in Canada between 2014 and 2018: an observational study","year":2021,"lang":"en","type":"article","venue":"BMJ Open","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University","funders":"","keywords":"Medicine; Observational study; Trademark; Psychological intervention; Family medicine; Internal medicine; Law; Psychiatry","score_opus":0.3012718976363224,"score_gpt":0.40056220960087513,"score_spread":0.09929031196455274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3182324768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94038254,0.0000512845,0.00003972502,0.01528158,0.00013424565,0.0050038737,0.0016878528,0.0000047808335,0.03741413],"genre_scores_gemma":[0.96577305,0.000011759102,0.0020074234,0.015853502,0.00034728347,0.001602154,0.00021872719,0.000047606878,0.014138513],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989437,0.00002467043,0.00044981734,0.0003510425,0.00002068365,0.00021009723],"domain_scores_gemma":[0.99933475,0.00013014911,0.000099373014,0.00025020985,0.000020194291,0.00016533927],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009747567,0.000091204594,0.00035166406,0.000050459752,0.0000484993,0.00012573258,0.0002879613,0.000028408702,0.0012228725],"category_scores_gemma":[0.00010918385,0.00011565373,0.00001967921,0.00009201916,0.000008554068,0.0002082529,0.00026763047,0.00005695799,0.00013027198],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014193701,0.0001880957,0.72941816,0.00003963361,0.00010061403,0.0000054645243,0.00056268193,0.00009162112,0.0000072106627,0.00688256,0.25901806,0.0035439718],"study_design_scores_gemma":[0.001546988,0.00006697819,0.62960225,0.000007190229,0.000004815799,6.3968776e-7,0.00016789953,0.008946147,0.000011084362,0.005414916,0.3539484,0.00028265978],"about_ca_topic_score_codex":0.24154349,"about_ca_topic_score_gemma":0.35659042,"teacher_disagreement_score":0.11504694,"about_ca_system_score_codex":0.00018800372,"about_ca_system_score_gemma":0.00044466788,"threshold_uncertainty_score":0.9996901},"labels":[],"label_agreement":null},{"id":"W3182527377","doi":"10.24926/iip.v12i3.3939","title":"Comparison of Drug Withdrawal Processes in the U.S. and Other Nations","year":2021,"lang":"en","type":"review","venue":"INNOVATIONS in pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Agency (philosophy); Drug withdrawal; Business; Medicine; Pharmacology; Process (computing); Variety (cybernetics); Political science; Computer science; Sociology","score_opus":0.2164653586927439,"score_gpt":0.45154307371031543,"score_spread":0.23507771501757155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3182527377","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00062557595,0.98026925,0.000015725205,0.00070891296,0.00013676564,0.00045174686,0.00043010112,0.000006200722,0.01735571],"genre_scores_gemma":[0.019889917,0.9788196,0.00010437854,0.0007241683,0.00008658136,0.00020421726,0.00006869233,0.000026543774,0.000075907716],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99797726,0.000047621153,0.0014673353,0.0002919885,0.000029927098,0.00018584248],"domain_scores_gemma":[0.99869585,0.00041834454,0.0005944795,0.00021990314,0.00004908097,0.000022359216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006799375,0.00019019005,0.001033712,0.0009874902,0.0000576535,0.00006710903,0.00034549733,0.00006506002,0.00016111664],"category_scores_gemma":[0.000272123,0.00017826064,0.00007283731,0.0027841637,0.00009334898,0.00013226067,0.000070437054,0.00045930542,0.00002913073],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000002609705,0.0006627626,0.024099227,0.0071658115,0.00012207124,0.0000031902462,0.0029300782,0.000029976893,1.1695322e-7,0.82108045,0.0030498959,0.14085379],"study_design_scores_gemma":[0.00029334988,0.0000031010259,0.000049281658,0.0006812221,0.000018652043,0.0000047774447,0.000057270245,0.00018274227,0.0000017837706,0.0026657293,0.9958661,0.00017595876],"about_ca_topic_score_codex":0.00017631387,"about_ca_topic_score_gemma":0.00022304093,"teacher_disagreement_score":0.9928162,"about_ca_system_score_codex":0.00007613538,"about_ca_system_score_gemma":0.00022575217,"threshold_uncertainty_score":0.7269258},"labels":[],"label_agreement":null},{"id":"W3183715790","doi":"10.1177/17411343211035168","title":"Brand drug companies impeding generic drug company access to product samples: Estimated prevalence and impact on drug costs","year":2021,"lang":"en","type":"article","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"Association canadienne du médicament générique","keywords":"Generic drug; Drug; Business; Market share; Brand names; Product (mathematics); Drug development; Marketing; Competition (biology); Order (exchange); Medicine; Pharmacology; Finance","score_opus":0.13494569130732337,"score_gpt":0.3561349865959504,"score_spread":0.22118929528862702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3183715790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8658375,0.06614396,0.0041012913,0.05489251,0.007998499,0.0007411134,0.00017578676,0.000021049946,0.00008828648],"genre_scores_gemma":[0.9435695,0.03267647,0.0005935409,0.012975441,0.009510084,0.000038751616,0.00001694142,0.00011488196,0.00050439866],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9955907,0.00019634094,0.0023555967,0.00058297924,0.0003976308,0.0008767765],"domain_scores_gemma":[0.9933135,0.0018430027,0.0023195248,0.00067942427,0.0010678717,0.00077670097],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004033514,0.00067751884,0.0017459961,0.0005911926,0.00088806066,0.0005064062,0.0016168685,0.00007582792,0.00036595116],"category_scores_gemma":[0.0023905437,0.00037700558,0.00041400953,0.0015378051,0.00039064963,0.0005075355,0.00029232146,0.0007699854,0.000014763645],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026980427,0.0005641332,0.062131178,0.0017911212,0.0031490338,0.00028079387,0.011478774,0.08605342,0.006551709,0.0009221086,0.7964705,0.027909147],"study_design_scores_gemma":[0.022521898,0.0015655326,0.46174943,0.0049752416,0.0032404868,0.025914557,0.004521591,0.090187296,0.005142019,0.012930476,0.36321765,0.0040338123],"about_ca_topic_score_codex":0.00013208989,"about_ca_topic_score_gemma":0.000037309026,"teacher_disagreement_score":0.43325287,"about_ca_system_score_codex":0.0004032318,"about_ca_system_score_gemma":0.00047682732,"threshold_uncertainty_score":0.9998682},"labels":[],"label_agreement":null},{"id":"W3184416667","doi":"10.2139/ssrn.3240967","title":"Preferred Pharmacy Networks and Drug Costs","year":2018,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"","keywords":"Pharmacy; Drug; Business; Medicine; Pharmacology; Family medicine","score_opus":0.031757733459773424,"score_gpt":0.2865006707293634,"score_spread":0.25474293726958996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3184416667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8625071,0.034006666,0.0130672855,0.011566968,0.0015777956,0.00030401172,0.00004062955,0.00006790424,0.076861665],"genre_scores_gemma":[0.97661155,0.018651038,0.000025470195,0.0020442489,0.0012919684,0.0000041174408,0.0000025682612,0.00002769172,0.0013413475],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9975278,0.000021558766,0.0004491648,0.00026200686,0.000021771642,0.0017177027],"domain_scores_gemma":[0.9993642,0.000036123718,0.00023210015,0.00013999005,0.000028010969,0.00019960763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014784578,0.00015207613,0.0002586544,0.00013485666,0.00023327544,0.00012548895,0.00023871339,0.0000477124,0.00026659438],"category_scores_gemma":[0.000036885594,0.00016721948,0.000082232145,0.00011717004,0.0001126454,0.00026057113,0.00006587906,0.0010489719,0.00034642546],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007257987,0.000051611794,0.014835499,0.0000032362452,0.00019057229,0.0000012817262,0.00012628628,0.000023068713,0.000012879156,0.9518365,0.0037430457,0.029103419],"study_design_scores_gemma":[0.0018505526,0.00013810795,0.0014384799,0.000008151263,0.000015495967,0.00020711748,0.0000613166,0.013769348,0.000051578136,0.67432916,0.3077715,0.0003592246],"about_ca_topic_score_codex":0.00012749083,"about_ca_topic_score_gemma":0.0003208182,"teacher_disagreement_score":0.30402845,"about_ca_system_score_codex":0.00055947434,"about_ca_system_score_gemma":0.00020208851,"threshold_uncertainty_score":0.6819012},"labels":[],"label_agreement":null},{"id":"W3187423611","doi":"10.1136/bmjopen-2020-045262","title":"Assessing variation among the national essential medicines lists of 21 high-income countries: a cross-sectional study","year":2021,"lang":"en","type":"article","venue":"BMJ Open","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; North York General Hospital; University of Toronto","funders":"Canadian Institutes of Health Research; Department of Family and Community Medicine, University of Toronto; University of Toronto","keywords":"Medicine; High income countries; Essential medicines; Developing country; Gross national income; Developed country; Cross-sectional study; Traditional medicine; Environmental health; Family medicine; Public health; Population; Economic growth; Pathology","score_opus":0.13136520759752374,"score_gpt":0.44430424446326117,"score_spread":0.31293903686573743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3187423611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9752311,0.00005313265,0.00040068763,0.0025109902,0.00087273284,0.0012738352,0.00020350478,0.0000088338475,0.01944519],"genre_scores_gemma":[0.9976298,0.000011366936,0.00013627675,0.00096558756,0.00057171733,0.00016434642,0.000027829088,0.000012904049,0.00048017415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985412,0.00005223132,0.00084234995,0.00030275935,0.000103850274,0.00015763294],"domain_scores_gemma":[0.99877536,0.00024333295,0.0005223709,0.00021150507,0.00019347937,0.000053971962],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002424934,0.000101776866,0.0003133702,0.00008362311,0.00020325015,0.0007373718,0.00040761405,0.00006545156,0.0015036153],"category_scores_gemma":[0.00050112384,0.00009586186,0.0000662447,0.00020826943,0.00010382577,0.00068333454,0.00030504772,0.00012469204,0.00009619119],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033660643,0.00013471981,0.87570274,0.000029719084,0.00012838509,0.000003114661,0.00035298598,0.00042847238,0.000013827959,0.12276831,0.00038583513,0.000018236393],"study_design_scores_gemma":[0.0010855624,0.000022620176,0.97399616,0.000014933171,0.0000074299037,0.0000053687204,0.000051709256,0.002934456,0.00005267504,0.018526299,0.0031810158,0.00012179499],"about_ca_topic_score_codex":0.00091827015,"about_ca_topic_score_gemma":0.0001738197,"teacher_disagreement_score":0.10424201,"about_ca_system_score_codex":0.00011358224,"about_ca_system_score_gemma":0.00022830168,"threshold_uncertainty_score":0.99940914},"labels":[],"label_agreement":null},{"id":"W3189159100","doi":"10.1016/s0140-6736(21)01378-7","title":"What are the obligations of pharmaceutical companies in a global health emergency?","year":2021,"lang":"en","type":"review","venue":"The Lancet","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; University of Toronto","funders":"Colton Foundation","keywords":"Pandemic; Coronavirus disease 2019 (COVID-19); Business; Global health; Medical emergency; 2019-20 coronavirus outbreak; Public relations; Medicine; Political science; Infectious disease (medical specialty); Disease; Public health; Virology; Nursing; Outbreak","score_opus":0.3107279181499173,"score_gpt":0.4581563595230358,"score_spread":0.1474284413731185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3189159100","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007677708,0.97504723,0.000012416133,0.018822853,0.001123797,0.0004308039,0.0015305766,0.000011255965,0.0029442841],"genre_scores_gemma":[0.0007463315,0.9960486,0.000020185935,0.002338399,0.0006189867,0.0000664481,0.000054194516,0.0000197826,0.00008703893],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977599,0.00015928777,0.0012906278,0.00031842617,0.000035774727,0.0004360148],"domain_scores_gemma":[0.99815255,0.00017035095,0.0008801029,0.0006931212,0.00001799133,0.00008585115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011394905,0.0002396704,0.0024056819,0.000070910675,0.00010011193,0.000103831146,0.0008919742,0.00010865865,0.00039159544],"category_scores_gemma":[0.00009100386,0.00016682895,0.0004016197,0.0005913708,0.00013329399,0.00011520313,0.00020669683,0.0005000794,0.00021690244],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000064780697,0.00012903022,0.0012591222,0.0041988026,0.0003420855,0.0000025011773,0.0003532181,0.00004494892,5.5506244e-9,0.76845425,0.0366525,0.18855706],"study_design_scores_gemma":[0.00021081963,0.000007255425,0.00029194073,0.0012192705,0.000032635504,0.0000075970484,0.00008969392,0.00026593264,5.090439e-8,0.017327916,0.98038965,0.00015725907],"about_ca_topic_score_codex":0.00013024485,"about_ca_topic_score_gemma":0.00018841025,"teacher_disagreement_score":0.94373715,"about_ca_system_score_codex":0.00022631236,"about_ca_system_score_gemma":0.00016249866,"threshold_uncertainty_score":0.6803087},"labels":[],"label_agreement":null},{"id":"W3190464317","doi":"10.1016/j.jval.2021.04.1277","title":"Reimagining Pharmaceutical Market Exclusivities: Should the Duration of Guaranteed Monopoly Periods Be Value Based?","year":2021,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Novo Nordisk Fonden","keywords":"Tying; Monopoly; Duration (music); Product (mathematics); Competition (biology); Business; Value (mathematics); New product development; Prescription drug; Generic drug; Pharmaceutical industry; Industrial organization; Medical prescription; Marketing; Economics; Drug; Microeconomics; Computer science; Medicine; Pharmacology","score_opus":0.1694680259873237,"score_gpt":0.36037445588318173,"score_spread":0.19090642989585804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3190464317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49811402,0.02359201,0.004317141,0.3737872,0.00324666,0.0014659368,0.0015564141,0.00011523362,0.093805395],"genre_scores_gemma":[0.97181976,0.0015110199,0.0010664373,0.025017345,0.00019903913,0.000030425223,0.000016554077,0.000034619825,0.00030479653],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99742806,0.00022013979,0.001350093,0.00042311748,0.00006730523,0.0005112783],"domain_scores_gemma":[0.9984832,0.0005031699,0.0004065318,0.00041629613,0.000031275416,0.00015953174],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00249702,0.0001840586,0.00053920696,0.00019671877,0.00015730187,0.00007019272,0.00027129045,0.00009641161,0.0009784785],"category_scores_gemma":[0.00036318682,0.00017352555,0.0001526302,0.0003909377,0.00014779018,0.00014798343,0.000094533425,0.0004924743,0.000030730396],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018763603,0.00045636197,0.03275722,0.0008123747,0.000096961565,0.000023673643,0.0038530764,0.019022476,0.00015888401,0.9303454,0.008597454,0.0036884446],"study_design_scores_gemma":[0.0010862839,0.00005870262,0.0044006533,0.00007732601,0.0000060181496,0.000012511088,0.00025705565,0.7410864,0.0005376616,0.015414347,0.23682922,0.00023377925],"about_ca_topic_score_codex":0.0026098336,"about_ca_topic_score_gemma":0.00003552586,"teacher_disagreement_score":0.9149311,"about_ca_system_score_codex":0.00027829612,"about_ca_system_score_gemma":0.0004591329,"threshold_uncertainty_score":0.99993473},"labels":[],"label_agreement":null},{"id":"W3190681024","doi":"10.21203/rs.3.rs-725738/v1","title":"An International Comparative Analysis Highlighting that Canada is Not Keeping Pace With Patient Access to Drugs for Rare Diseases","year":2021,"lang":"en","type":"preprint","venue":"Research Square","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Novartis (Canada); University of Ottawa","funders":"University of Ottawa","keywords":"Pace; Business; Medicine; Regional science; Political science; International trade; Geography","score_opus":0.19871769268058312,"score_gpt":0.43448957018199674,"score_spread":0.23577187750141362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3190681024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95659,0.00070244604,0.0016606186,0.01676298,0.0004273228,0.0014883969,0.01831113,0.000029197849,0.0040279026],"genre_scores_gemma":[0.99443924,0.00024256774,0.00040287554,0.0027501953,0.00025884924,0.0005311562,0.0012508443,0.00003462207,0.00008965893],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997192,0.000089072804,0.00058885064,0.0011793113,0.0002544356,0.0006963333],"domain_scores_gemma":[0.9974514,0.00041570055,0.00034352374,0.00070370623,0.00048106504,0.00060459983],"candidate_categories":["metaepi_narrow","scholarly_communication"],"consensus_categories":[],"category_scores_codex":[0.00050400826,0.00029750512,0.0008720894,0.0008355598,0.0003027344,0.0013343126,0.0010952903,0.00012286105,0.0005963203],"category_scores_gemma":[0.00013719336,0.00032474694,0.00026640942,0.0006318093,0.00006009046,0.0003977827,0.0010212603,0.00056519575,0.000014227443],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015118113,0.0011599694,0.73422563,0.0020523749,0.011896289,0.000114783026,0.026242675,0.14438322,0.000022816705,0.036992997,0.035013035,0.0063844025],"study_design_scores_gemma":[0.002140785,0.00045645,0.34711456,0.00081752555,0.00031213835,0.0000020201248,0.006643159,0.29206866,0.0046276934,0.0033817308,0.3395851,0.0028501844],"about_ca_topic_score_codex":0.16785172,"about_ca_topic_score_gemma":0.09493521,"teacher_disagreement_score":0.38711107,"about_ca_system_score_codex":0.0012317959,"about_ca_system_score_gemma":0.0007553762,"threshold_uncertainty_score":0.9999205},"labels":[],"label_agreement":null},{"id":"W3191283888","doi":"10.1016/j.chest.2021.08.007","title":"Changes in Purchases for Intensive Care Medicines During the COVID-19 Pandemic","year":2021,"lang":"en","type":"article","venue":"CHEST Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"Agency for Healthcare Research and Quality; National Institutes of Health; Canadian Institutes of Health Research; Soochow University; Health Services Research and Development","keywords":"Coronavirus disease 2019 (COVID-19); Pandemic; 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Business; Medicine; Virology; Infectious disease (medical specialty); Outbreak; Internal medicine","score_opus":0.18119868262674801,"score_gpt":0.358086953817939,"score_spread":0.17688827119119097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3191283888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88471854,0.017166877,0.00039041342,0.09481987,0.00092248875,0.0002112598,0.00022790105,0.000015798503,0.0015268378],"genre_scores_gemma":[0.96482724,0.005141956,0.000060368497,0.028796162,0.0009056071,0.000029028884,0.000009708877,0.000017801956,0.0002121079],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991242,0.000015736954,0.00036663804,0.00018773883,0.00001925052,0.00028639537],"domain_scores_gemma":[0.9991979,0.00016897569,0.00019195191,0.00013586116,0.0001097881,0.00019553794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042931348,0.00010358366,0.00028158407,0.00013077435,0.00018767265,0.00007798077,0.00018555285,0.0000620181,0.00031076776],"category_scores_gemma":[0.0015676144,0.00008889891,0.00009670346,0.00011746966,0.000071882205,0.0000713093,0.000055925233,0.000283359,0.000023724562],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010709915,0.000053048832,0.95437187,0.000597158,0.00015414334,0.00014950651,0.015175665,0.0003552907,0.00060902577,0.015286673,0.010082065,0.003058427],"study_design_scores_gemma":[0.002494163,0.000049571107,0.04335029,0.00003545814,0.000012955284,0.00071279344,0.0057106586,0.00040920277,0.0005151575,0.027437424,0.9190135,0.00025882066],"about_ca_topic_score_codex":0.000023168108,"about_ca_topic_score_gemma":0.0005312835,"teacher_disagreement_score":0.9110216,"about_ca_system_score_codex":0.0003233991,"about_ca_system_score_gemma":0.000108380955,"threshold_uncertainty_score":0.3625192},"labels":[],"label_agreement":null},{"id":"W3193584288","doi":"","title":"Regulating Medicines in a Globalized World With Increased Recognition and Reliance Among Regulators: A National Academies Report","year":2020,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Agency (philosophy); Jurisdiction; Government (linguistics); Product (mathematics); Pharmaceutical industry; Harm; Public health; Medicine; Political science; Pharmacology; Law","score_opus":0.045676362677783994,"score_gpt":0.273355394810436,"score_spread":0.22767903213265203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3193584288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9755278,0.0028805435,0.00036958267,0.014885838,0.000062714564,0.00016570711,0.000024623758,0.000024715975,0.006058435],"genre_scores_gemma":[0.9950297,0.001729275,0.00021935639,0.0024254837,0.00040505867,0.000011012357,0.000014187149,0.000021317115,0.00014464777],"study_design_codex":"observational","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9980037,0.000027938228,0.0007302117,0.00032587897,0.00006859771,0.0008436809],"domain_scores_gemma":[0.9991039,0.000061471386,0.0005419363,0.00007143269,0.000047301583,0.00017395626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018958448,0.00015057751,0.0003526473,0.00022483365,0.00009338891,0.000059826485,0.00012433673,0.00007819606,0.00005036015],"category_scores_gemma":[0.000473036,0.00015133155,0.00005053828,0.0004346104,0.00009534635,0.0003616298,0.00003089686,0.0010415447,0.000024552508],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065081654,0.000078103614,0.6689748,0.00006714199,0.0003400254,0.00005360224,0.0007347341,0.00022505416,0.00010566016,0.32235783,0.0017337024,0.0046785343],"study_design_scores_gemma":[0.0033121852,0.00016434993,0.057043873,0.0001260681,0.00001745427,0.0006304224,0.00022867837,0.0066559114,0.000054174117,0.9205383,0.010827477,0.00040108358],"about_ca_topic_score_codex":0.00016077161,"about_ca_topic_score_gemma":0.00068283785,"teacher_disagreement_score":0.6119309,"about_ca_system_score_codex":0.00052944844,"about_ca_system_score_gemma":0.00037998878,"threshold_uncertainty_score":0.61711216},"labels":[],"label_agreement":null},{"id":"W3194340912","doi":"10.1016/s2214-109x(21)00287-4","title":"Determinants of access to childhood cancer medicines: a comparative, mixed-methods analysis of four Caribbean countries","year":2021,"lang":"en","type":"article","venue":"The Lancet Global Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of British Columbia; Institute for Clinical Evaluative Sciences; SickKids Foundation; Hospital for Sick Children","funders":"Hospital for Sick Children","keywords":"Caribbean region; Environmental health; Medicine; Geography; Demography; Political science; Latin Americans; Sociology","score_opus":0.16894696253683233,"score_gpt":0.48251927669594086,"score_spread":0.3135723141591085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194340912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9559044,0.0087155225,0.0012675391,0.02223216,0.00054381666,0.00029025145,0.0060300594,0.000013875385,0.005002336],"genre_scores_gemma":[0.9797721,0.0035581128,0.00095381495,0.015494333,0.00016518887,0.000018211123,0.000014928158,0.0000069703615,0.000016337171],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982605,0.00011041143,0.00089257327,0.0002919389,0.000048610054,0.0003959675],"domain_scores_gemma":[0.99848765,0.00017130579,0.0006212098,0.0004615366,0.00008284024,0.00017547871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001129734,0.0001414579,0.0015491474,0.00012066959,0.00008045559,0.000031577663,0.000513946,0.000047539233,0.00019258265],"category_scores_gemma":[0.00009660556,0.00012266976,0.00015960664,0.0011996226,0.000104052866,0.000081128215,0.00017302301,0.00010371651,0.00001362204],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010399467,0.00016162515,0.87941873,0.00024614108,0.0012672909,0.0000022697338,0.0025923362,0.0021789395,0.00000407977,0.08373977,0.017348025,0.012936801],"study_design_scores_gemma":[0.00060649164,0.00006390402,0.9463153,0.00005062864,0.00011339702,0.0000026709452,0.00015553356,0.00491221,0.00028048738,0.008386635,0.038956434,0.00015632095],"about_ca_topic_score_codex":0.0043259053,"about_ca_topic_score_gemma":0.0073137684,"teacher_disagreement_score":0.07535314,"about_ca_system_score_codex":0.00019534164,"about_ca_system_score_gemma":0.00028265777,"threshold_uncertainty_score":0.6539504},"labels":[],"label_agreement":null},{"id":"W3195112423","doi":"10.1016/j.jaad.2021.06.242","title":"25200 Public versus private drug insurance and psoriasis degree of severity in patients with prescribed biologics in Canada: A retrospective cohort study","year":2021,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Psoriasis; Retrospective cohort study; Drug; Cohort; Private insurance; Public health insurance; Health insurance; Family medicine; Cohort study; Internal medicine; Dermatology; Pharmacology; Health care","score_opus":0.03783819804355346,"score_gpt":0.2634106845124622,"score_spread":0.22557248646890873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195112423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99556154,0.00037957318,0.0000017791028,0.0034903768,0.00013052819,0.00017518652,0.00009839527,8.863115e-7,0.00016174087],"genre_scores_gemma":[0.9990398,0.00041472074,0.00009952171,0.0004212446,0.0000123161635,0.0000029912728,5.107242e-7,0.000007177204,0.0000016703368],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984879,0.00013371448,0.0009176195,0.00018092639,0.00005914768,0.00022068412],"domain_scores_gemma":[0.9980035,0.00014367663,0.0016121314,0.00011982858,0.00005212633,0.00006874828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029978759,0.00011263148,0.0009530624,0.00017349373,0.000021211401,0.0000061010496,0.00031561594,0.000040499548,0.000007935889],"category_scores_gemma":[0.0003065087,0.000093392475,0.0000526945,0.00046751517,0.0002265812,0.000121929384,0.0001285855,0.00043429414,2.7030947e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031393857,0.00018004705,0.9977378,0.000010304166,0.00014742496,0.0000048542224,0.00013605179,0.00002422398,0.0000027905223,0.0011105131,0.00007996311,0.00025206982],"study_design_scores_gemma":[0.0025422892,0.00008260398,0.99557656,0.000010978556,0.000010631466,0.00001704507,0.000104512575,0.000078383644,0.00008358352,0.0010444584,0.00035607113,0.00009288746],"about_ca_topic_score_codex":0.03240976,"about_ca_topic_score_gemma":0.039048344,"teacher_disagreement_score":0.006638583,"about_ca_system_score_codex":0.00032648566,"about_ca_system_score_gemma":0.00022149434,"threshold_uncertainty_score":0.97848654},"labels":[],"label_agreement":null},{"id":"W3195451158","doi":"10.1080/00207543.2021.1950937","title":"Data analytics in pharmaceutical supply chains: state of the art, opportunities, and challenges","year":2021,"lang":"en","type":"article","venue":"International Journal of Production Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":129,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Polytechnique Montréal","funders":"","keywords":"Supply chain; Analytics; Scopus; Data science; Computer science; Supply chain management; Economic shortage; Big data; Data analysis; Knowledge management; Business; Data mining; MEDLINE; Marketing; Government (linguistics)","score_opus":0.6582236673124685,"score_gpt":0.46822801534568353,"score_spread":0.18999565196678497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195451158","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.471471,0.030452853,0.00008976555,0.48541507,0.0025642514,0.00019144155,0.00071355223,0.000003777759,0.009098293],"genre_scores_gemma":[0.8829544,0.1148845,0.00014137903,0.00030683505,0.000446374,0.0000015430468,0.000009385399,0.000009048657,0.0012464891],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987546,0.00009463966,0.00063523324,0.0001988329,0.00015908782,0.00015755929],"domain_scores_gemma":[0.9988896,0.00011137446,0.00024651742,0.0002619673,0.00041218253,0.00007833661],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032302581,0.000056004163,0.00018519127,0.00036575322,0.000029766552,0.00005183585,0.0005797479,0.00002777743,0.00016727466],"category_scores_gemma":[0.0010123505,0.000051530285,0.000041942214,0.0001565017,0.00017618452,0.00029090742,0.00038215105,0.00040872087,0.000009597315],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005841157,0.001792656,0.04726668,0.00034988878,0.0013438623,0.00033873273,0.0024484722,0.0020272636,0.0018651773,0.6545435,0.04003689,0.24740273],"study_design_scores_gemma":[0.0007344346,0.000039257207,0.016357977,0.00007734008,0.000005321038,0.00019495639,0.0003034919,0.0061976667,0.0022466704,0.0343827,0.9393642,0.00009600012],"about_ca_topic_score_codex":0.000014337239,"about_ca_topic_score_gemma":0.00005696702,"teacher_disagreement_score":0.8993273,"about_ca_system_score_codex":0.000098693716,"about_ca_system_score_gemma":0.0001849324,"threshold_uncertainty_score":0.2101344},"labels":[],"label_agreement":null},{"id":"W3196294283","doi":"10.1177/17411343211029995","title":"Comparison of generic drug registration strategies between health Canada and Gulf Cooperation Council","year":2021,"lang":"en","type":"article","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Innovator; Product (mathematics); Health care; Business; Quality (philosophy); Political science; Finance; Law","score_opus":0.19154054837280224,"score_gpt":0.33928873365898493,"score_spread":0.1477481852861827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3196294283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6310532,0.16168089,0.068339355,0.12825081,0.009641175,0.0005604431,0.00019526575,0.000009698089,0.00026916465],"genre_scores_gemma":[0.9637112,0.021185245,0.0007514063,0.0066659907,0.0072363345,0.000010859991,0.000030773845,0.0000494354,0.00035873044],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961643,0.0001333088,0.0026432502,0.0002486485,0.0003905032,0.00041997497],"domain_scores_gemma":[0.99364674,0.0006880631,0.0034898918,0.00035076597,0.0015045553,0.00032000043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038093447,0.00031085225,0.0013433719,0.00014331871,0.0005223746,0.00012849299,0.000546496,0.000079903635,0.0001096045],"category_scores_gemma":[0.0010830129,0.00018902172,0.00016229613,0.00068514666,0.00026592333,0.00025649616,0.000056915662,0.0004501941,0.0000010054047],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052327546,0.00029821697,0.035530984,0.0013738938,0.0020673063,0.00006222464,0.0074175396,0.054452352,0.0052198856,0.0057804123,0.85894954,0.028324395],"study_design_scores_gemma":[0.0065480857,0.00096315995,0.04781315,0.00054742815,0.00072983187,0.002584291,0.0067811604,0.031444807,0.0010619262,0.00810357,0.8925868,0.0008357655],"about_ca_topic_score_codex":0.009870277,"about_ca_topic_score_gemma":0.021747636,"teacher_disagreement_score":0.33265802,"about_ca_system_score_codex":0.00049610354,"about_ca_system_score_gemma":0.0044023236,"threshold_uncertainty_score":0.99672306},"labels":[],"label_agreement":null},{"id":"W3197163053","doi":"","title":"Big pharma official to Congress: Force countries to pay more for drugs in new trade deals","year":2019,"lang":"en","type":"article","venue":"FOXBusiness","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug industry; Business; International trade; Political science; Law; Engineering","score_opus":0.05179029078199631,"score_gpt":0.30919942569684133,"score_spread":0.257409134914845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197163053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9472635,0.00034620726,0.002493877,0.039913565,0.0030474898,0.0017165855,0.0010103573,0.00004880328,0.004159633],"genre_scores_gemma":[0.9745547,0.000051735737,0.0003893807,0.021266222,0.0008150474,0.000081867875,0.00002893974,0.0000591403,0.0027529355],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99824435,0.000006715185,0.0006567311,0.00049250445,0.000036199486,0.00056352],"domain_scores_gemma":[0.99916226,0.000104693376,0.00015359573,0.00028093057,0.000029786845,0.00026873252],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00034404753,0.00022530343,0.00058946724,0.00035965542,0.00005205755,0.00012236806,0.00036687168,0.00011408692,0.00035455698],"category_scores_gemma":[0.000097908276,0.00023783288,0.00010720475,0.0004119213,0.000026149073,0.00018626153,0.00008448254,0.00011793295,0.0011371188],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025372454,0.0004806504,0.13673434,0.0008168978,0.000263018,0.000010192274,0.0101731345,0.011121828,0.0010361342,0.6500574,0.15037368,0.03639547],"study_design_scores_gemma":[0.0022293143,0.00006673225,0.017562134,0.00003727754,0.0000068951945,0.000001521346,0.000052027397,0.004230155,0.0010230278,0.006843646,0.9674463,0.0005009391],"about_ca_topic_score_codex":0.00041404163,"about_ca_topic_score_gemma":0.00011055523,"teacher_disagreement_score":0.81707263,"about_ca_system_score_codex":0.00015260633,"about_ca_system_score_gemma":0.00014144338,"threshold_uncertainty_score":0.9996406},"labels":[],"label_agreement":null},{"id":"W3197805492","doi":"10.1186/s12992-021-00744-x","title":"The Health Impact Fund: making the case for engagement with pharmaceutical laboratories in Brazil, Russia, India, and China","year":2021,"lang":"en","type":"article","venue":"Globalization and Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"McGill University","keywords":"BRIC; Business; Essential medicines; General partnership; Economic growth; Global health; Poverty; Pharmaceutical industry; Developing country; Health economics; Health policy; Health care; Economics; Finance; Emerging markets; Medicine","score_opus":0.10041900311789678,"score_gpt":0.421353670059538,"score_spread":0.3209346669416412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197805492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.50260293,0.10075407,0.011837108,0.37031743,0.0008528765,0.0030405961,0.0024952826,0.000077951925,0.008021764],"genre_scores_gemma":[0.97243285,0.009535171,0.00020693017,0.017664513,0.000074451185,0.000028230683,0.000022634284,0.000011887143,0.000023313569],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988832,0.0000750731,0.0004162947,0.00024271429,0.000020970392,0.00036174388],"domain_scores_gemma":[0.9993936,0.0000832837,0.00020482238,0.00013590929,0.000020236854,0.00016213726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014360724,0.00011228288,0.00024005375,0.000044706623,0.0006825147,0.0002360322,0.00006128654,0.000034103294,0.000035751316],"category_scores_gemma":[0.000044721193,0.00007950126,0.000024002009,0.00026064826,0.00007723674,0.00010048336,0.00004994419,0.00013936004,0.0000031064712],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046365774,0.000042047304,0.050105616,0.000116774834,0.000035278244,0.000009392091,0.0013924948,0.000047932626,8.298267e-8,0.9327056,0.0037967733,0.011701638],"study_design_scores_gemma":[0.0025087472,0.00028933768,0.19382674,0.00004838989,0.000007631154,0.00023181157,0.00092143996,0.020127533,0.0000033329986,0.028661752,0.75309086,0.00028242674],"about_ca_topic_score_codex":0.00057478435,"about_ca_topic_score_gemma":0.0014429559,"teacher_disagreement_score":0.90404385,"about_ca_system_score_codex":0.00019926621,"about_ca_system_score_gemma":0.0002655557,"threshold_uncertainty_score":0.524942},"labels":[],"label_agreement":null},{"id":"W3198450170","doi":"10.18192/uojm.v11is1.5927","title":"A Time for Change: The Argument for National Pharmacare","year":2021,"lang":"en","type":"article","venue":"University of Ottawa Journal of Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Milestone; Argument (complex analysis); Plan (archaeology); Health care; Public relations; Medicine; Political science; Medical education; History; Law","score_opus":0.09424989256261795,"score_gpt":0.30427287540805137,"score_spread":0.21002298284543341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198450170","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13357708,0.027226016,0.019735329,0.7359205,0.0029230549,0.0015153642,0.003089821,0.000016488339,0.07599634],"genre_scores_gemma":[0.97349554,0.0019339727,0.0030549674,0.0130683845,0.0024520217,0.000001699794,0.00004194947,0.000021951973,0.0059294906],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994952,0.000008611627,0.00028080316,0.00007699195,0.000037908336,0.00010046968],"domain_scores_gemma":[0.9990144,0.00019103562,0.0004205642,0.000055920544,0.0002479033,0.00007020206],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00073477393,0.00005237853,0.0002551262,0.00010152548,0.000069668284,0.0000036718104,0.00018122898,0.000029384912,0.0012031802],"category_scores_gemma":[0.00016656175,0.000047924852,0.0001386241,0.000066876986,0.00010119161,0.000086001804,0.000021551936,0.00007351726,0.000009827732],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023298408,0.00020905302,0.0015594917,0.00018789835,0.00067027024,0.0000145434915,0.0028334518,0.00009319954,0.0005261435,0.38994265,0.59791154,0.005818761],"study_design_scores_gemma":[0.0032385208,0.00012851511,0.0006039617,0.000025463853,0.00003245066,0.000016714883,0.00019864165,0.0024633238,0.00020278186,0.011719151,0.98131865,0.00005184686],"about_ca_topic_score_codex":0.000007785416,"about_ca_topic_score_gemma":0.0000055745318,"teacher_disagreement_score":0.8399185,"about_ca_system_score_codex":0.00007472188,"about_ca_system_score_gemma":0.000058070767,"threshold_uncertainty_score":0.99970984},"labels":[],"label_agreement":null},{"id":"W3200608261","doi":"10.1016/s1470-2045(21)00463-0","title":"Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":171,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Queen's University; World Health Organization","keywords":"Medicine; Snowball sampling; Essential medicines; Access to medicines; Cross-sectional study; Family medicine; Developing country; Descriptive statistics; Public health; Alternative medicine; Global health; Cancer; Environmental health; Nursing; Economic growth; Pathology","score_opus":0.23093750127483378,"score_gpt":0.4812587039765077,"score_spread":0.2503212027016739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200608261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95457447,0.00055089424,0.0001476658,0.026889702,0.0028767665,0.00017112188,0.0018973252,0.000020435718,0.012871644],"genre_scores_gemma":[0.96115494,0.002720609,0.00004782794,0.03393634,0.0013841426,0.00010694603,0.00015099123,0.000016187552,0.00048200943],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99846995,0.0001157134,0.0005776199,0.0004174659,0.000041415777,0.000377862],"domain_scores_gemma":[0.9989272,0.00036824823,0.00021041956,0.0002821682,0.00009297308,0.00011903418],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001665211,0.00012509049,0.00048908475,0.000101376194,0.00008520898,0.00017186214,0.00080623734,0.00014760358,0.003280643],"category_scores_gemma":[0.0003741306,0.00011897841,0.000043359698,0.00022788285,0.00016115859,0.0002671804,0.00022279371,0.00025661144,0.00019862193],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022327536,0.00012656284,0.96727604,0.0000076045153,0.0000648899,0.00001070202,0.00015891709,0.0005552324,0.000046874473,0.014603609,0.01655523,0.0003710804],"study_design_scores_gemma":[0.0009216608,0.000035765264,0.61910063,0.0000019763079,0.0000015185635,0.0000051995544,0.0000063193597,0.00067470147,0.0000746928,0.0034764213,0.37560058,0.00010052198],"about_ca_topic_score_codex":0.0018904585,"about_ca_topic_score_gemma":0.011558396,"teacher_disagreement_score":0.35904536,"about_ca_system_score_codex":0.00052846107,"about_ca_system_score_gemma":0.00021945311,"threshold_uncertainty_score":0.9976305},"labels":[],"label_agreement":null},{"id":"W3203471344","doi":"10.2139/ssrn.3926761","title":"Procurement Institutions and Essential Drug Supply in Low and Middle-Income Countries","year":2021,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Procurement; Pooling; Business; Instrumental variable; Developing country; Estimation; Identification (biology); Biopharmaceutical; Industrial organization; Public economics; Economics; Economic growth; Marketing; Biotechnology","score_opus":0.022270858696866028,"score_gpt":0.2632794089533283,"score_spread":0.24100855025646228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203471344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9578143,0.028538331,0.00031717404,0.0106886,0.00021594722,0.00010517275,0.00004627334,0.000007926689,0.0022663188],"genre_scores_gemma":[0.9627403,0.036045954,0.000048796854,0.00059802795,0.00014692284,0.0000066021153,0.0000038104326,0.000010602005,0.00039896538],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9983373,0.00001613841,0.00043277495,0.0002310336,0.00002610506,0.0009566337],"domain_scores_gemma":[0.9996225,0.000025293888,0.0001294261,0.000089673726,0.00002382502,0.00010926309],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082243764,0.00011512771,0.00024217823,0.00015375199,0.00015668973,0.00015103498,0.00009099344,0.000050191473,0.00009000131],"category_scores_gemma":[0.00004657763,0.0001334355,0.00005381855,0.00011584682,0.00008709476,0.00025421756,0.00006194342,0.00070034544,0.00003473936],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001548568,0.000044823388,0.045016956,0.000044336655,0.000069352274,0.0000074975933,0.00020371641,0.000027317663,0.0000051389907,0.9543207,0.000023195704,0.0002214278],"study_design_scores_gemma":[0.002896307,0.00007779368,0.020895999,0.00015744382,0.000022298022,0.0005976049,0.00043268604,0.0013021526,0.00020647472,0.92704934,0.045901604,0.00046032047],"about_ca_topic_score_codex":0.00007986543,"about_ca_topic_score_gemma":0.0021053148,"teacher_disagreement_score":0.045878407,"about_ca_system_score_codex":0.00044280195,"about_ca_system_score_gemma":0.00077154033,"threshold_uncertainty_score":0.5441342},"labels":[],"label_agreement":null},{"id":"W3206808995","doi":"10.1016/j.lanepe.2021.100219","title":"Impact of the European Union on access to medicines in low- and middle-income countries: A scoping review","year":2021,"lang":"en","type":"review","venue":"The Lancet Regional Health - Europe","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"European union; Authorization; Political science; Accession; Welfare economics; Humanities; Member states; Business; Geography; International trade; Economics","score_opus":0.3258325079105963,"score_gpt":0.46635105421863565,"score_spread":0.14051854630803934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206808995","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010278569,0.95774615,0.0000030436004,0.035743583,0.00022829876,0.0013989537,0.000273319,0.000009193065,0.0044946866],"genre_scores_gemma":[0.00011493271,0.96991795,0.000005762213,0.02925606,0.00053533213,0.00003232319,0.000023212784,0.000052675296,0.00006171889],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966386,0.00088445947,0.0014875497,0.00046701025,0.00006857177,0.0004538225],"domain_scores_gemma":[0.997408,0.0004487724,0.0011515695,0.0007629004,0.000041283325,0.00018753033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004244176,0.00032404557,0.0025394938,0.00017882002,0.000110582056,0.00006262343,0.0010000339,0.00005569841,0.000061210005],"category_scores_gemma":[0.00031834238,0.00019593594,0.00028150508,0.0007620432,0.00012397682,0.00007295184,0.00040515445,0.0005314271,0.00012062768],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051307212,0.0002090671,0.0036615694,0.6924611,0.00038837004,0.000033013046,0.0005191554,0.00009150536,9.502141e-9,0.057538074,0.059640378,0.18540648],"study_design_scores_gemma":[0.0001859516,0.000052822692,0.0030948913,0.3717428,0.000014884466,0.000017869785,4.986039e-7,0.000005871748,7.660289e-9,0.00012701993,0.62460697,0.0001504199],"about_ca_topic_score_codex":0.0002208766,"about_ca_topic_score_gemma":0.00007203897,"teacher_disagreement_score":0.56496656,"about_ca_system_score_codex":0.0002368157,"about_ca_system_score_gemma":0.0004990564,"threshold_uncertainty_score":0.79900354},"labels":[],"label_agreement":null},{"id":"W3211053119","doi":"10.2139/ssrn.3940088","title":"Competitive Bidding in Drug Procurement: Evidence from China","year":2021,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"","keywords":"Bidding; Procurement; Business; China; Drug; Industrial organization; Marketing; Pharmacology; Medicine; Political science; Law","score_opus":0.03818976762224978,"score_gpt":0.2786745380140626,"score_spread":0.24048477039181282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211053119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90382695,0.045110937,0.0013869936,0.011740457,0.00052557676,0.0001448667,0.00006480424,0.00002004098,0.037179388],"genre_scores_gemma":[0.97564566,0.022626601,0.00011992959,0.00057170325,0.0003183996,0.0000061142396,0.0000064074,0.0000201445,0.0006850593],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9976154,0.00004000257,0.00057348894,0.00033031852,0.000037428577,0.001403367],"domain_scores_gemma":[0.99938315,0.00008136284,0.00024581177,0.00015912586,0.000025608539,0.00010491931],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014110585,0.00014215248,0.00032637094,0.00015689086,0.000103897735,0.000118671276,0.0002650547,0.000053751366,0.0005558781],"category_scores_gemma":[0.00019130151,0.00016957999,0.000119350996,0.00023518929,0.00003005625,0.00036794346,0.000073505646,0.0013997334,0.00033095674],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020153011,0.00007223687,0.027316032,0.0000057339885,0.00008849444,0.000012468384,0.000487452,0.00008772788,0.000105162864,0.96971494,0.000120802884,0.0019688157],"study_design_scores_gemma":[0.0009793959,0.00004274904,0.025083426,0.00010415104,0.000008944185,0.00006179931,0.00048886955,0.0014846596,0.0005272831,0.9402984,0.030596433,0.00032388826],"about_ca_topic_score_codex":0.000557721,"about_ca_topic_score_gemma":0.0034359633,"teacher_disagreement_score":0.07181871,"about_ca_system_score_codex":0.0012255191,"about_ca_system_score_gemma":0.0006725997,"threshold_uncertainty_score":0.6915271},"labels":[],"label_agreement":null},{"id":"W3216045111","doi":"10.1016/j.therap.2022.05.001","title":"Public perceptions of the association between drug effectiveness and drug novelty in France during the COVID-19 pandemic","year":2022,"lang":"en","type":"article","venue":"Therapies","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pandemic; Health literacy; Novelty; Quarter (Canadian coin); Public health; Pharmaceutical industry; Drug; Health care; Medicine; Population; Drug development; Coronavirus disease 2019 (COVID-19); Psychology; Family medicine; Public relations; Business; Disease; Environmental health; Pharmacology; Political science; Nursing; Geography; Social psychology","score_opus":0.06547488920242431,"score_gpt":0.2930643236378194,"score_spread":0.22758943443539512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216045111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883162,0.0013559203,0.000018747856,0.009042112,0.00011756646,0.00022256076,0.00034218002,0.000012498571,0.0005722314],"genre_scores_gemma":[0.99818695,0.00035918644,0.0000031657478,0.00103594,0.00004989484,0.000071228875,0.0000027193869,0.000010162133,0.0002807828],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99918973,0.00015705882,0.0002776911,0.00016636333,0.000034029646,0.0001751257],"domain_scores_gemma":[0.9990628,0.00048355106,0.00023005789,0.0001753149,0.000008279647,0.00004003418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016967378,0.00007874065,0.00021576967,0.0000887593,0.0003616868,0.000034521327,0.00026363996,0.000025732455,0.00020481218],"category_scores_gemma":[0.00011199229,0.000065296954,0.000067241795,0.00022872098,0.000079350255,0.000095549156,0.0001529058,0.00025930014,0.000007721249],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000050384947,0.000021007803,0.98354423,0.000022691609,0.00004620437,4.478e-8,0.003582971,0.00018135412,0.00008140455,0.012278569,0.000049258255,0.00018723441],"study_design_scores_gemma":[0.0005916896,0.000004757714,0.951024,0.0000019949102,0.0000034500479,8.9848487e-7,0.00026587033,0.000106246735,0.000014786367,0.019717975,0.028186096,0.00008226065],"about_ca_topic_score_codex":0.0005327159,"about_ca_topic_score_gemma":0.000121944584,"teacher_disagreement_score":0.032520246,"about_ca_system_score_codex":0.0003890386,"about_ca_system_score_gemma":0.00003075223,"threshold_uncertainty_score":0.2781839},"labels":[],"label_agreement":null},{"id":"W3216742648","doi":"10.5639/gabij.2021.1003.016","title":"A critical review of substitution policy for biosimilars in Canada","year":2021,"lang":"en","type":"review","venue":"Generics and Biosimilars Initiative Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Competition (biology); Business; Market competition; Public economics; Marketing; Medicine; Economics; Market economy","score_opus":0.21793994318783752,"score_gpt":0.38310764969058575,"score_spread":0.16516770650274823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216742648","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000022755382,0.980559,0.0002693212,0.013752228,0.000577302,0.00040457683,0.0035455602,0.000002424411,0.00088733796],"genre_scores_gemma":[0.000015646325,0.9408448,0.0005960849,0.058003925,0.0003712407,0.00004911429,0.000079329715,0.000037490543,0.0000023756452],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967796,0.00010138561,0.0021057383,0.00043675076,0.00006635862,0.00051012996],"domain_scores_gemma":[0.9978085,0.00040155032,0.0011234649,0.00021414655,0.00017654117,0.00027576942],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010295104,0.0003920257,0.0026000151,0.0004893036,0.00011433661,0.000073108116,0.00029578383,0.00021295663,0.00013250425],"category_scores_gemma":[0.0014114714,0.0003906618,0.000507506,0.0006122927,0.00013086866,0.0001420823,0.00011339146,0.00055547676,0.0000024991025],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021404101,0.00031427306,0.00033927354,0.15958695,0.0010075764,0.00016684711,0.00008663859,0.000008048853,8.681021e-7,0.06856056,0.49760902,0.27229854],"study_design_scores_gemma":[0.00027212023,0.000044248347,0.000015406793,0.019636437,0.00012363885,0.00012724464,0.000009671651,0.00008699213,0.0000031364257,0.0037358631,0.9755476,0.00039763324],"about_ca_topic_score_codex":0.0005993452,"about_ca_topic_score_gemma":0.0058799423,"teacher_disagreement_score":0.4779386,"about_ca_system_score_codex":0.001058837,"about_ca_system_score_gemma":0.004143869,"threshold_uncertainty_score":0.9998545},"labels":[],"label_agreement":null},{"id":"W3216749353","doi":"10.51731/cjht.2021.209","title":"Canadian Trends and Projections in Prescription Drug Purchases: 2001–2023","year":2021,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; Women's College Hospital; Nova Scotia Health Authority; University of Calgary; Institute for Clinical Evaluative Sciences; Université Laval; Queen Elizabeth II Health Sciences Centre; University of British Columbia; Public Health Ontario; University of Toronto","funders":"","keywords":"Medical prescription; Pace; Audit; Prescription drug; Specialty; Business; Annual growth %; Medicine; Family medicine; Agricultural economics; Accounting; Pharmacology; Economics; Geography","score_opus":0.0745478460040486,"score_gpt":0.30158214108106585,"score_spread":0.22703429507701725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216749353","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32538083,0.16633885,0.00007140917,0.4863225,0.0014836664,0.00025205972,0.00091315387,0.000048492584,0.019189019],"genre_scores_gemma":[0.99445605,0.0032452622,0.0001963549,0.0014797283,0.000015397456,0.0000069269036,0.00000579617,0.000010738533,0.0005837561],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99860233,0.000020701455,0.00066227093,0.00017251639,0.000014470228,0.0005277359],"domain_scores_gemma":[0.99928844,0.00002153416,0.00025730033,0.00015244407,0.00003836457,0.00024193953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006605949,0.00009451645,0.0003350518,0.0019236229,0.00017043031,0.00007987911,0.00017259597,0.000107780645,0.00016997449],"category_scores_gemma":[0.0003122745,0.000113985065,0.0000492223,0.0005771194,0.000087373664,0.00018530243,0.000016252281,0.0003869259,0.000018390103],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010124929,0.000070003785,0.2078938,0.00016515332,0.00010590904,0.0004113226,0.0018550133,0.0001851958,0.000009135655,0.22763342,0.103151225,0.45850968],"study_design_scores_gemma":[0.00037406577,0.0000513169,0.034744218,0.000049809725,0.0000023422585,0.00014871608,0.001078306,0.00033889478,0.000023273144,0.039848052,0.923182,0.00015897429],"about_ca_topic_score_codex":0.52341783,"about_ca_topic_score_gemma":0.904001,"teacher_disagreement_score":0.8200308,"about_ca_system_score_codex":0.0010502454,"about_ca_system_score_gemma":0.002161203,"threshold_uncertainty_score":0.4797558},"labels":[],"label_agreement":null},{"id":"W3217537576","doi":"10.1186/s40545-021-00381-0","title":"Pharmacists’ perceptions and attitudes toward drug importation into the State of Florida","year":2021,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Policy and Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy; Action plan; Pharmacist; Medicine; Family medicine; Descriptive statistics; Management","score_opus":0.09571015455046528,"score_gpt":0.40938947577119245,"score_spread":0.31367932122072717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217537576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8806184,0.01819057,0.0007050538,0.089869395,0.00053834304,0.00015080378,0.00011294195,0.000008645168,0.009805842],"genre_scores_gemma":[0.9582415,0.03245318,0.0009391535,0.007654068,0.0005091465,0.0000025452953,0.0000020227662,0.000014427438,0.00018395735],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984515,0.00014736525,0.0009172664,0.00018415012,0.00007169024,0.00022802857],"domain_scores_gemma":[0.997444,0.0012911604,0.0006884726,0.00012331232,0.00017223867,0.00028084655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001875503,0.000139939,0.00036910834,0.00016492097,0.00013110667,0.00011666313,0.00015067015,0.000043037286,0.00020199356],"category_scores_gemma":[0.0017612836,0.00012215237,0.00011829075,0.00023952831,0.00023990376,0.0007143302,0.00009696908,0.00049299933,0.000021232518],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028011822,0.0017124751,0.029366273,0.0013412125,0.0030806644,0.0003136132,0.061506115,0.00079945644,0.02145168,0.67878795,0.01324771,0.18559165],"study_design_scores_gemma":[0.004316386,0.00018979216,0.021922233,0.000056336317,0.00036006665,0.0020364407,0.001124579,0.005080737,0.0065374793,0.1667508,0.7910483,0.0005768756],"about_ca_topic_score_codex":0.00009696089,"about_ca_topic_score_gemma":0.000005298127,"teacher_disagreement_score":0.77780056,"about_ca_system_score_codex":0.00006192222,"about_ca_system_score_gemma":0.00014553919,"threshold_uncertainty_score":0.4981229},"labels":[],"label_agreement":null},{"id":"W376535567","doi":"10.1155/2015/789369","title":"Antimicrobial Shortages: Another Hurdle for Clinicians","year":2015,"lang":"en","type":"article","venue":"Canadian Journal of Infectious Diseases and Medical Microbiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Inland Hospital; University of Calgary; Université de Sherbrooke","funders":"","keywords":"Antimicrobial stewardship; Business; Economic shortage; Discontinuation; Intensive care medicine; Quality (philosophy); Risk analysis (engineering); Medicine; Antibiotic resistance; Antibiotics; Surgery","score_opus":0.042768933100784924,"score_gpt":0.28639386744789086,"score_spread":0.24362493434710594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W376535567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95279914,0.015491567,0.0030267006,0.015768208,0.004417917,0.00034462407,0.002298887,0.000016960126,0.0058360063],"genre_scores_gemma":[0.9849906,0.0004308549,0.000055420627,0.013725057,0.0006753748,0.000003633557,0.000015252792,0.000018518753,0.00008528439],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988625,0.000021708605,0.00059190026,0.0001666038,0.0000100087145,0.00034729953],"domain_scores_gemma":[0.99826044,0.000094929834,0.00024923298,0.000086045526,0.000071204886,0.0012381708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048882695,0.00011418317,0.00042845856,0.0002265988,0.00007623866,0.000038793878,0.00016260959,0.00017773695,0.00038899516],"category_scores_gemma":[0.00072743057,0.00011322138,0.0001578654,0.00006116102,0.0002589553,0.000070730646,0.000016041118,0.0001729832,0.000040345447],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018505304,0.00032619893,0.46591172,0.00012399803,0.00065397937,0.00018391678,0.0008628218,0.00006514965,0.00018702055,0.09463558,0.41731992,0.01954462],"study_design_scores_gemma":[0.0023795934,0.00035191842,0.0018198901,0.000027137941,0.000032811142,0.0004462217,0.00004108618,0.00014054097,0.000019274104,0.014715703,0.979809,0.00021683091],"about_ca_topic_score_codex":0.0012969166,"about_ca_topic_score_gemma":0.0032501356,"teacher_disagreement_score":0.5624891,"about_ca_system_score_codex":0.00011497998,"about_ca_system_score_gemma":0.00077879586,"threshold_uncertainty_score":0.4617034},"labels":[],"label_agreement":null},{"id":"W3859919","doi":"","title":"The economics of prescription drug prices, government intervention, and the importation of drugs from Canada.","year":2006,"lang":"en","type":"article","venue":"Bulletin of the American Physical Society","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Prescription drug; Incentive; Government (linguistics); Business; Intervention (counseling); Public economics; Drug prices; Economic interventionism; Health care; Drug; Prescription costs; Health economics; Finance; Economics; Economic growth; Medicine; Pharmacology; Political science; Nursing; Market economy","score_opus":0.004944201188767932,"score_gpt":0.19609721507417444,"score_spread":0.1911530138854065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3859919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98715067,0.0004062832,0.00002719688,0.010177704,0.00008574123,0.0001611102,0.00040216022,0.000002079114,0.0015870305],"genre_scores_gemma":[0.9988047,0.00038003392,0.000078980556,0.00048081146,0.000075138836,0.000011472509,0.00000451414,0.0000083545,0.00015601053],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9991216,0.000031127107,0.000533718,0.00014533587,0.0000491077,0.0001190811],"domain_scores_gemma":[0.9980755,0.00032439988,0.0013161424,0.00024032302,0.000019756038,0.000023904066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003532908,0.00008726357,0.0003229353,0.000003476216,0.00008555737,0.000015579122,0.0002790935,0.000013270379,0.000013651823],"category_scores_gemma":[0.000032755477,0.00005721283,0.0002723559,0.000059459242,0.0006522905,0.000017665641,0.00011037717,0.00009023427,0.0000012263098],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043709725,0.00060423027,0.03741089,0.00012290345,0.00084033684,5.0360086e-8,0.0030265294,0.0016092189,0.00045487346,0.82564616,0.11943149,0.010416189],"study_design_scores_gemma":[0.003610712,0.00008457227,0.41063705,0.00004525217,0.00013549441,3.8471535e-7,0.002578773,0.024392422,0.006469317,0.19937259,0.3522404,0.00043301552],"about_ca_topic_score_codex":0.47780228,"about_ca_topic_score_gemma":0.007384499,"teacher_disagreement_score":0.62627363,"about_ca_system_score_codex":0.00010506883,"about_ca_system_score_gemma":0.000027207818,"threshold_uncertainty_score":0.52567506},"labels":[],"label_agreement":null},{"id":"W40167909","doi":"","title":"World Trade Organization: Canada First Notice to Manufacture Generic Drug for Export : Introductory Note","year":2007,"lang":"en","type":"article","venue":"International Legal Materials","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Notice; International trade; Business; Drug; World trade; Political science; Law; Medicine; Pharmacology","score_opus":0.020532945780819403,"score_gpt":0.2544194955989843,"score_spread":0.2338865498181649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W40167909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86977875,0.000106709085,0.0042165797,0.08867717,0.017361717,0.0005041378,0.0034630809,0.000060793776,0.01583105],"genre_scores_gemma":[0.97980285,0.000011607471,0.0009732425,0.012755571,0.0028779502,0.000019380685,0.00017688645,0.00003916961,0.0033433302],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99858624,0.0000048912657,0.00069555547,0.0003566361,0.00005335778,0.00030331014],"domain_scores_gemma":[0.9993014,0.00008390653,0.00022086594,0.00018016946,0.00005000262,0.0001636673],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004395,0.00016105516,0.0002791352,0.00019671964,0.00009049338,0.00016064462,0.00037230295,0.00004770028,0.0025640135],"category_scores_gemma":[0.00017188831,0.00019208096,0.0000424179,0.00013677299,0.000017513048,0.00018854324,0.00006710299,0.00007047067,0.00017134068],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002866679,0.00015690015,0.005321808,0.0001051935,0.000253512,0.00003434735,0.00061944645,0.001387598,0.007962088,0.52955997,0.4535151,0.0007973602],"study_design_scores_gemma":[0.00031515656,0.00000850767,0.016257983,0.0000052300725,0.000004550002,0.0000056387944,0.0000069982225,0.000045000044,0.044431735,0.00090304925,0.93778664,0.00022953961],"about_ca_topic_score_codex":0.029594157,"about_ca_topic_score_gemma":0.10754241,"teacher_disagreement_score":0.5286569,"about_ca_system_score_codex":0.00054069405,"about_ca_system_score_gemma":0.00009821738,"threshold_uncertainty_score":0.99834776},"labels":[],"label_agreement":null},{"id":"W414373","doi":"","title":"Drugs Via Canada: The Side Effects Could Hurt","year":2004,"lang":"en","type":"article","venue":"Business week","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business","score_opus":0.02681023007619758,"score_gpt":0.22902740675137204,"score_spread":0.20221717667517447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W414373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.711613,0.0052400357,0.0049055754,0.116456956,0.0045777974,0.00091612875,0.00033306485,0.000119501565,0.15583795],"genre_scores_gemma":[0.98661965,0.00015530232,0.00006635902,0.012375271,0.00031725844,0.000030992793,0.0000091095,0.000028963492,0.00039708643],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99891496,0.000007757981,0.0003766143,0.0002817153,0.00003418756,0.00038477016],"domain_scores_gemma":[0.99925363,0.0001012107,0.00015947016,0.0003296899,0.000034079218,0.000121892386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021723122,0.00016645073,0.0003033133,0.00006375067,0.00016234913,0.000069825575,0.00032815727,0.00006644836,0.000095401716],"category_scores_gemma":[0.000089599685,0.00015178246,0.00006292517,0.00028307107,0.00007431891,0.000121226694,0.00007369051,0.00017296472,0.0006010606],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000650582,0.00041134367,0.0048670946,0.00029319408,0.00026731097,0.000078832825,0.0007014695,0.009592836,0.00017149822,0.9385982,0.028976338,0.015976818],"study_design_scores_gemma":[0.0015595746,0.000024255793,0.13114256,0.000022554475,0.000015831012,0.00001542952,0.000019322435,0.0013116247,0.00045710703,0.09383105,0.7710912,0.00050947256],"about_ca_topic_score_codex":0.3664217,"about_ca_topic_score_gemma":0.089087546,"teacher_disagreement_score":0.84476715,"about_ca_system_score_codex":0.0003017767,"about_ca_system_score_gemma":0.00025553835,"threshold_uncertainty_score":0.9275342},"labels":[],"label_agreement":null},{"id":"W4200104033","doi":"10.9778/cmajo.20200232","title":"Extent of a valsartan drug shortage and its effect on antihypertensive drug use in the Canadian population: a national cross-sectional study","year":2021,"lang":"en","type":"article","venue":"CMAJ Open","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Alberta Health; Women's College Hospital; University of Toronto; Alberta Health Services","funders":"","keywords":"Valsartan; Medicine; Medical prescription; Drug; Antihypertensive drug; Economic shortage; Population; Pharmacology; Internal medicine; Blood pressure; Environmental health","score_opus":0.1207520102464535,"score_gpt":0.3587804840500626,"score_spread":0.2380284738036091,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200104033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98946404,0.00019557544,2.0325606e-7,0.000940334,0.0001626758,0.0005902969,0.00035764524,0.0000021216513,0.008287092],"genre_scores_gemma":[0.99720603,0.000017537483,0.000008453498,0.0021907114,0.00005926611,0.00004738111,0.000043946293,0.000009876285,0.00041681947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989726,0.00006976715,0.00041586833,0.0003180708,0.00005226932,0.00017144062],"domain_scores_gemma":[0.99933326,0.00023064,0.0001122475,0.00016212308,0.00006789108,0.000093817354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011766987,0.00010167839,0.00028921265,0.0001486752,0.0001591556,0.00038284573,0.000235214,0.000040096416,0.00020251075],"category_scores_gemma":[0.0002756945,0.00009559707,0.000049332953,0.00017303777,0.000025071251,0.00026596576,0.00008924621,0.00015560538,0.000049524733],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002065218,0.00010375237,0.9356669,0.000007764892,0.000034112494,0.000015415479,0.00046661292,0.00015138717,0.0000029173473,0.06316302,0.00032028073,0.000047171805],"study_design_scores_gemma":[0.0007695097,0.00003926726,0.9919512,0.0000068164322,0.000003282851,0.00000699292,0.00004663304,0.0012292014,0.000029595925,0.003145485,0.002661242,0.000110767396],"about_ca_topic_score_codex":0.1586755,"about_ca_topic_score_gemma":0.3163207,"teacher_disagreement_score":0.15764518,"about_ca_system_score_codex":0.00015168589,"about_ca_system_score_gemma":0.000097659584,"threshold_uncertainty_score":0.8469269},"labels":[],"label_agreement":null},{"id":"W4200138363","doi":"10.54194/yqyb2454","title":"Rogue Regulator: PMPRB’s false narrative is driving dangerous drug price controls","year":2021,"lang":"en","type":"article","venue":"Canadian Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Regulator; Narrative; Computer security; Drug; Criminology; Law and economics; Forensic engineering; Psychology; Computer science; Economics; Medicine; Pharmacology; Engineering; Biology; Literature; Art","score_opus":0.0505062294203681,"score_gpt":0.322771688282505,"score_spread":0.27226545886213693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200138363","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19479391,0.018181423,0.00015150024,0.65537775,0.0015325532,0.0010686252,0.0050943727,0.00011982733,0.12368004],"genre_scores_gemma":[0.81317246,0.0010142463,0.00024025407,0.17904904,0.0011404512,0.00004535154,0.00006991159,0.00006654173,0.0052017528],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968986,0.000070399576,0.0009476101,0.0006592915,0.00004015222,0.0013839547],"domain_scores_gemma":[0.99657625,0.000109253604,0.00039050766,0.0006179069,0.000072812945,0.0022332433],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0006186026,0.00027820966,0.0007508395,0.00056403206,0.0004858595,0.00017112025,0.00032826542,0.00015178256,0.0012083984],"category_scores_gemma":[0.00037482477,0.0003790656,0.00017927193,0.0005745,0.000089973495,0.00022953605,0.000064903455,0.00037722217,0.0011877776],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000006127508,0.00004796974,0.006278594,0.00008547852,0.00011810137,0.000034241955,0.011429747,0.000041327225,0.000009435898,0.75806206,0.21927397,0.0046129604],"study_design_scores_gemma":[0.00070547196,0.000026409483,0.0064576226,0.000026635591,0.0000029283817,0.000022696862,0.00026049925,0.00065773,0.000052197618,0.02075206,0.97064894,0.0003868018],"about_ca_topic_score_codex":0.3214623,"about_ca_topic_score_gemma":0.21745378,"teacher_disagreement_score":0.75137496,"about_ca_system_score_codex":0.0023105145,"about_ca_system_score_gemma":0.0036060724,"threshold_uncertainty_score":0.9998661},"labels":[],"label_agreement":null},{"id":"W4200344687","doi":"10.21203/rs.3.rs-1173063/v1","title":"Access to and Barriers to Access for Essential Medicines in Nephrology and Related Non-Communicable Diseases: A Scoping Review Protocol","year":2021,"lang":"en","type":"review","venue":"Research Square","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of British Columbia","funders":"","keywords":"Protocol (science); Medicine; Business; Alternative medicine","score_opus":0.21578064015120194,"score_gpt":0.5493818243270466,"score_spread":0.3336011841758447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200344687","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000019576199,0.86959493,0.000019083556,0.0043429905,0.00007013936,0.12462812,0.0004236578,0.000011277824,0.0008902501],"genre_scores_gemma":[0.0000185526,0.83013576,0.000040696796,0.0017820863,0.000114534174,0.16772477,0.00006882432,0.00005786314,0.000056917343],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964481,0.00026890024,0.0014121404,0.0009595248,0.00007565394,0.0008356526],"domain_scores_gemma":[0.9970121,0.00090027443,0.0002679636,0.0006667886,0.000111370624,0.0010415505],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026037905,0.00034488254,0.0028200748,0.0010404368,0.0002336401,0.00048797834,0.0010963446,0.0002711982,0.0006664261],"category_scores_gemma":[0.0028969406,0.00034808944,0.00021139001,0.0012886947,0.00015215995,0.00034406222,0.0020048944,0.0006810552,0.00004585368],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011907219,0.00016240469,0.0013989398,0.75394696,0.00032511176,0.000053959768,0.00030203743,0.000011947441,2.5178696e-7,0.0074145845,0.027250724,0.209014],"study_design_scores_gemma":[0.0006750458,0.000121320525,0.000078886645,0.11629037,0.000038913404,0.000007717766,0.000010854506,0.00012710926,3.2341788e-7,0.0011547157,0.88113946,0.00035528638],"about_ca_topic_score_codex":0.00019839662,"about_ca_topic_score_gemma":0.00016862093,"teacher_disagreement_score":0.85388875,"about_ca_system_score_codex":0.00021156545,"about_ca_system_score_gemma":0.0007320242,"threshold_uncertainty_score":0.9998971},"labels":[],"label_agreement":null},{"id":"W4200451039","doi":"10.3138/9781487529055-fm","title":"Frontmatter","year":2021,"lang":"en","type":"book-chapter","venue":"University of Toronto Press eBooks","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"ECW Press (Canada); Dalhousie University","funders":"","keywords":"Computer science","score_opus":0.05705843300925302,"score_gpt":0.22454872195676284,"score_spread":0.16749028894750984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200451039","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000016679476,0.007997769,0.00011466482,0.000091586844,0.0002594404,0.00012331929,0.000773195,0.000020895743,0.99060243],"genre_scores_gemma":[0.00035094348,0.000873996,0.0002837039,0.00034005713,0.000115960895,1.7064957e-7,0.000029884774,0.000032386943,0.9979729],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.999076,0.0000050171775,0.0003084425,0.00038813672,0.000027502692,0.00019487839],"domain_scores_gemma":[0.9989866,0.000025314135,0.00039286798,0.00043026032,0.000035564553,0.00012939401],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008641653,0.00020822698,0.0006047252,0.000027922075,0.000057245215,0.000021633421,0.00037465442,0.00028334855,0.02115694],"category_scores_gemma":[0.0000039743168,0.00031916227,0.00030675853,4.2276946e-7,0.00012191502,0.00009136599,0.0002494892,0.00017774256,0.0004821047],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019601106,0.000011580206,0.000008834913,0.000058080852,0.00022898226,0.00001703062,0.00045191208,0.0000022845084,0.0000032431278,0.9299425,0.06782041,0.0014355532],"study_design_scores_gemma":[0.0003830696,0.000019825622,0.000023818176,0.000039265935,0.000032665263,0.0000015123053,0.000005320307,0.00008424269,0.000021208578,0.008875218,0.9902127,0.00030119446],"about_ca_topic_score_codex":0.021124098,"about_ca_topic_score_gemma":0.0029081143,"teacher_disagreement_score":0.92239225,"about_ca_system_score_codex":0.00024260781,"about_ca_system_score_gemma":0.000033167416,"threshold_uncertainty_score":0.99992603},"labels":[],"label_agreement":null},{"id":"W4200559252","doi":"10.1007/s40278-021-04835-4","title":"Health Canada seizes unauthorised injectable drugs, medical devices","year":2021,"lang":"en","type":"article","venue":"Reactions Weekly","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Medicine","score_opus":0.038911877414166234,"score_gpt":0.2953924568948479,"score_spread":0.25648057948068165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200559252","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12396206,0.012099188,0.00092062604,0.4405572,0.0038959372,0.00032307426,0.0012016081,0.00016838504,0.4168719],"genre_scores_gemma":[0.97787577,0.0013939203,0.00025619927,0.014019264,0.00034958564,0.0000182857,0.00007023413,0.000027679953,0.0059890696],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985002,0.000030279773,0.000640035,0.00035701966,0.0000619755,0.00041044084],"domain_scores_gemma":[0.998874,0.00013371462,0.0002225778,0.0002960004,0.000034264987,0.00043943312],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00044088784,0.0001308489,0.00039174603,0.00009785487,0.00023312826,0.00006996747,0.00018037611,0.000090963724,0.0024385122],"category_scores_gemma":[0.00021613031,0.00016349625,0.00008384188,0.00032915562,0.00003634498,0.00015075332,0.00006469859,0.0002959871,0.00038842816],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014523283,0.000429567,0.010911708,0.00022397413,0.0002728061,0.000048883336,0.00046296587,0.00017241211,0.000017835191,0.582274,0.38959813,0.015573165],"study_design_scores_gemma":[0.00032257786,0.000011960375,0.0034713564,0.000014369462,0.000003418871,0.000026966956,0.0001712624,0.0022900652,0.00007307837,0.004444281,0.98898846,0.00018217729],"about_ca_topic_score_codex":0.48709312,"about_ca_topic_score_gemma":0.37273133,"teacher_disagreement_score":0.8539137,"about_ca_system_score_codex":0.0004947501,"about_ca_system_score_gemma":0.0017535924,"threshold_uncertainty_score":0.9984734},"labels":[],"label_agreement":null},{"id":"W4205538827","doi":"10.21065/19257430.168.1","title":"REVIEW OF THE BASIC COMPONENTS OF CLINICAL PHARMACEUTICAL CARE IN PAKISTAN","year":2011,"lang":"en","type":"article","venue":"Canadian Journal of Applied Sciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Health care; Pharmaceutical care; Developing country; Quality (philosophy); Medicine; Business; Nursing; Economic growth; Economics","score_opus":0.2463575681449729,"score_gpt":0.3929560541419099,"score_spread":0.14659848599693703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205538827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7993352,0.031382173,0.0000054214947,0.00093930477,0.00076681323,0.00020363899,0.00011512723,9.297387e-7,0.16725142],"genre_scores_gemma":[0.99467283,0.00281299,0.00017102197,0.002290465,0.000043385906,9.88424e-7,3.2186082e-7,0.0000041398584,0.0000038698713],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99818915,0.000025574062,0.0013901292,0.00013443304,0.000040556042,0.00022015297],"domain_scores_gemma":[0.99867815,0.00006451278,0.0007802345,0.0001372657,0.000044025648,0.0002958022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021111772,0.00007308422,0.00048373087,0.00018933276,0.000052059215,0.0000097508255,0.0006925537,0.000046146542,0.0004133246],"category_scores_gemma":[0.000080276106,0.00005882037,0.00016659642,0.00033625733,0.0006475957,0.00007056737,0.000026077314,0.00023077831,0.000011940388],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007434013,0.00012922888,0.3996337,0.0012263907,0.00007588241,0.000010044332,0.0028811838,0.000036071313,0.00005489202,0.5790375,0.0023612077,0.01447956],"study_design_scores_gemma":[0.0029851766,0.00041630576,0.45378205,0.0028552732,0.000066702916,0.000029446333,0.0011351435,0.00055218156,0.0017379278,0.06528729,0.4705455,0.00060698617],"about_ca_topic_score_codex":0.0011729816,"about_ca_topic_score_gemma":0.0015980538,"teacher_disagreement_score":0.5137502,"about_ca_system_score_codex":0.000058002744,"about_ca_system_score_gemma":0.000515879,"threshold_uncertainty_score":0.45256147},"labels":[],"label_agreement":null},{"id":"W4205704930","doi":"10.1038/s41574-021-00621-y","title":"Global accessibility of therapeutics for diabetes mellitus","year":2022,"lang":"en","type":"review","venue":"Nature Reviews Endocrinology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":118,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; University of Toronto","funders":"NIHR Leicester Biomedical Research Centre; Madras Diabetes Research Foundation; Universidade Federal do Rio Grande do Sul; University of Toronto; National Institute for Health and Care Research","keywords":"Medicine; Diabetes mellitus; Intensive care medicine; Type 2 Diabetes Mellitus; Health care; Endocrinology; Economic growth","score_opus":0.19314444386505936,"score_gpt":0.4247148174847424,"score_spread":0.23157037361968302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205704930","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000033474037,0.9838693,0.00003910061,0.00025698938,0.001523209,0.0020144535,0.004018993,0.000027315977,0.00824729],"genre_scores_gemma":[0.000022228855,0.99606335,0.00037656302,0.0020217972,0.0002903186,0.0008275675,0.0002624704,0.00005469552,0.00008099146],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955632,0.00018028419,0.0025076556,0.00094331655,0.00003348367,0.00077202177],"domain_scores_gemma":[0.9961916,0.0005324594,0.0021684065,0.0009687941,0.000026568534,0.00011216503],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009198596,0.0005599316,0.0050889608,0.00024181098,0.000095005606,0.000029513421,0.001266037,0.0006970988,0.0008643844],"category_scores_gemma":[0.00039810722,0.00052604836,0.0018338322,0.00049384043,0.00014755652,0.000079812824,0.0003514806,0.0010594673,0.00012535481],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000038579738,0.00008062153,0.00008303723,0.011781701,0.00028798246,7.08472e-7,0.000004893233,1.739049e-7,1.1360218e-8,0.15698974,0.0013637141,0.8294036],"study_design_scores_gemma":[0.00025219776,0.00007172577,0.000010037314,0.0002824324,0.0003127705,0.000009038249,6.499362e-7,0.000013310555,5.136354e-7,0.024229638,0.9744047,0.0004130215],"about_ca_topic_score_codex":0.000007843634,"about_ca_topic_score_gemma":0.0000047606964,"teacher_disagreement_score":0.97304094,"about_ca_system_score_codex":0.00045248386,"about_ca_system_score_gemma":0.00013420948,"threshold_uncertainty_score":0.9997191},"labels":[],"label_agreement":null},{"id":"W4206302808","doi":"10.1177/171516350714000307","title":"Canadian Internet Pharmacy Sales to US Cut in Half in 2006","year":2007,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy; Business; The Internet; Medicine; Advertising; Family medicine; World Wide Web; Computer science","score_opus":0.05936089931618948,"score_gpt":0.2892019651350632,"score_spread":0.2298410658188737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206302808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9699802,0.001880689,0.00007966146,0.0020739522,0.003602613,0.0005158165,0.0015081968,0.000018296874,0.02034059],"genre_scores_gemma":[0.9769598,0.0020356413,0.00011048609,0.01901931,0.0008103952,0.000020921178,0.000043180302,0.000095947085,0.0009042945],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99471676,0.00007054493,0.0017459425,0.000735026,0.000112758724,0.0026189769],"domain_scores_gemma":[0.993161,0.00014434196,0.00031921407,0.00030435986,0.00012548806,0.005945557],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023991822,0.0005171468,0.00075672334,0.003178085,0.00028172397,0.00030295356,0.0011394968,0.00011461068,0.002320189],"category_scores_gemma":[0.00029360736,0.0007068816,0.00017459359,0.0014309239,0.00011396697,0.0005420995,0.000072517876,0.0012177442,0.0004662625],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039630357,0.000225826,0.66233915,0.00024040627,0.00030725193,0.1335775,0.00514361,0.007847682,0.0003674869,0.009909578,0.12967263,0.049972575],"study_design_scores_gemma":[0.0034423496,0.00003311304,0.0028851593,0.000037780224,0.00001707681,0.03393187,0.000014819248,0.0081380755,0.0007420009,0.0010666216,0.9483938,0.0012973283],"about_ca_topic_score_codex":0.9344933,"about_ca_topic_score_gemma":0.9967243,"teacher_disagreement_score":0.8187212,"about_ca_system_score_codex":0.0134141985,"about_ca_system_score_gemma":0.0035599147,"threshold_uncertainty_score":0.99953824},"labels":[],"label_agreement":null},{"id":"W4206578020","doi":"10.7895/ijadr.347","title":"Correlates and comparisons of use of a variety of drugs and associated harms in various high and middle-income countries","year":2021,"lang":"en","type":"article","venue":"The International Journal of Alcohol and Drug Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Variety (cybernetics); Econometrics; Low and middle income countries; Computer science; Economics; Developing country; Artificial intelligence; Economic growth","score_opus":0.126214143375046,"score_gpt":0.35714120791997694,"score_spread":0.23092706454493095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206578020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908696,0.0038164237,0.000017781202,0.0046712845,0.00008320919,0.00005424657,0.00020797872,6.803379e-7,0.00027880596],"genre_scores_gemma":[0.99037486,0.009293494,0.00010622925,0.0001019178,0.000023639206,8.5239844e-7,0.0000021871565,0.0000053242547,0.00009152165],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989438,0.00006168247,0.0006473876,0.000109380584,0.000111559275,0.00012621352],"domain_scores_gemma":[0.9980633,0.0010902957,0.00039818432,0.00007001743,0.00030942424,0.000068765105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017814346,0.000065699285,0.00036877417,0.00024731006,0.000038635506,0.000075954216,0.00015426309,0.000046352965,0.000036792157],"category_scores_gemma":[0.00038477263,0.00005578849,0.000037080266,0.00011487273,0.0003723915,0.00017101866,0.0002157725,0.0002856148,5.717168e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053455215,0.0002588931,0.80669165,0.00014170192,0.00067073054,0.000021474123,0.005730257,0.00013359521,0.00028239615,0.18454625,0.00045721157,0.00053127727],"study_design_scores_gemma":[0.005324509,0.0002441076,0.83003783,0.00061226415,0.000039518207,0.00012918202,0.0010544972,0.017502442,0.002513755,0.13831976,0.0040044566,0.00021770259],"about_ca_topic_score_codex":0.0010497447,"about_ca_topic_score_gemma":0.00009083313,"teacher_disagreement_score":0.04622648,"about_ca_system_score_codex":0.000036371457,"about_ca_system_score_gemma":0.00006748403,"threshold_uncertainty_score":0.22749884},"labels":[],"label_agreement":null},{"id":"W4210321301","doi":"","title":"Classifying antibiotics in the WHO Essential Medicines List for optimal use-be AWaRe","year":2018,"lang":"en","type":"article","venue":"Archive ouverte UNIGE (University of Geneva)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":216,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Essential medicines; Economic shortage; Scopus; Antibiotic resistance; Business; Medicine; Antibiotics; Political science; Health care; MEDLINE; Biology; Law","score_opus":0.07596587356098482,"score_gpt":0.27042834704100666,"score_spread":0.19446247348002182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210321301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91634744,0.0001084893,0.059645865,0.0072556967,0.00038386259,0.00043351186,0.0011115534,0.000019060208,0.014694498],"genre_scores_gemma":[0.9947363,0.00047805108,0.002453581,0.0017150022,0.00018449772,1.562093e-7,0.000042349435,0.000014757432,0.00037527268],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99913514,0.000030308036,0.00022356682,0.00028396084,0.000034609544,0.00029244792],"domain_scores_gemma":[0.99923295,0.00018960905,0.0001884254,0.0002703315,0.000038031663,0.00008065869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031928436,0.00012094834,0.00031352474,0.00023314892,0.0002457831,0.000031103616,0.00051933073,0.000068113775,0.00014657155],"category_scores_gemma":[0.000052467425,0.00013761946,0.00013819647,0.00016993836,0.00042498438,0.0002167006,0.00013253957,0.00013065379,0.00002761102],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006582495,0.00044728437,0.08562774,0.00024138707,0.00041290512,0.000039127222,0.028882273,0.00043886827,0.0011248649,0.7616755,0.116775885,0.0036759593],"study_design_scores_gemma":[0.0036155104,0.0004651979,0.054844968,0.00007179053,0.00006597081,0.0000065599656,0.004812431,0.41162267,0.00041689674,0.019654086,0.5038033,0.0006205917],"about_ca_topic_score_codex":0.0007523512,"about_ca_topic_score_gemma":0.0018086022,"teacher_disagreement_score":0.7420214,"about_ca_system_score_codex":0.00004438431,"about_ca_system_score_gemma":0.000041679286,"threshold_uncertainty_score":0.56119585},"labels":[],"label_agreement":null},{"id":"W4210330881","doi":"10.1016/j.ssaho.2022.100255","title":"“Health for all” and the challenges for pharmaceutical policies: A critical interpretive synthesis over 40 years","year":2022,"lang":"en","type":"article","venue":"Social Sciences & Humanities Open","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal","funders":"","keywords":"Mainstream; Politics; Declaration; Globe; Pharmaceutical policy; Value (mathematics); Political science; Health care; Public relations; Inclusion (mineral); Health policy; Sociology; Medicine; Social science; Law; Computer science","score_opus":0.26003601200546744,"score_gpt":0.44046451460758534,"score_spread":0.1804285026021179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210330881","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.044298902,0.022417132,0.0005510036,0.5653487,0.0025406748,0.0071220845,0.0108592585,0.00009547494,0.34676677],"genre_scores_gemma":[0.9727524,0.0006270199,0.00013729499,0.024568837,0.00031377742,0.0013631036,0.0000020402565,0.000017871473,0.00021767066],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986363,0.00008400074,0.00037109392,0.0003690203,0.000050367602,0.0004892008],"domain_scores_gemma":[0.99755883,0.0021119388,0.00015587082,0.000088854955,0.000015957667,0.00006851888],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0028090233,0.00011674405,0.0004191089,0.000087738736,0.00179964,0.0004461086,0.0008617818,0.000031671483,0.0005867676],"category_scores_gemma":[0.000578804,0.00011316265,0.00013501743,0.00007543952,0.0013939838,0.00025453625,0.0006306278,0.00014182078,0.000007690042],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013485293,0.00003741741,0.000022474595,0.000026197706,0.000039054667,1.0489366e-7,0.015706908,0.0000018913564,3.037675e-7,0.97694486,0.005053789,0.0020321563],"study_design_scores_gemma":[0.0006204326,0.00017054721,0.00042834188,0.000009061833,0.000014442099,0.0000015493902,0.007703039,0.0025666053,0.0000016610979,0.36763975,0.6206471,0.00019748264],"about_ca_topic_score_codex":0.00084778055,"about_ca_topic_score_gemma":0.00016210736,"teacher_disagreement_score":0.9284535,"about_ca_system_score_codex":0.00019401277,"about_ca_system_score_gemma":0.00009680663,"threshold_uncertainty_score":0.99949986},"labels":[],"label_agreement":null},{"id":"W4210434457","doi":"10.1007/bf03275923","title":"US seniors retaliate against GSK over reduced drug supplies in Canada","year":2003,"lang":"en","type":"article","venue":"PharmacoEconomics & Outcomes News","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quality of Life Research; Public health; Drug; Environmental health; Business; Medicine; Pharmacology; Nursing","score_opus":0.02673352025819704,"score_gpt":0.2930338517553045,"score_spread":0.26630033149710747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210434457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92963636,0.00086950517,0.000005705007,0.007646137,0.0024069755,0.0004645359,0.0006183226,0.000042522675,0.058309942],"genre_scores_gemma":[0.94695705,0.0016516844,0.0001812377,0.049380213,0.00013386339,0.000068833,0.00004381783,0.00010205076,0.0014812521],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.995935,0.00006641295,0.001895711,0.0009310234,0.0000495393,0.0011222953],"domain_scores_gemma":[0.9980068,0.00021396716,0.00063822506,0.00061981706,0.000017523209,0.0005036183],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0006916742,0.00056180655,0.0012780749,0.00039722858,0.00013020022,0.00015297436,0.0006086795,0.0001096285,0.0022989884],"category_scores_gemma":[0.00009880281,0.0006943548,0.00031967415,0.00023541121,0.00006372432,0.00048941694,0.00012910947,0.00055232784,0.00085673155],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047084242,0.00012462595,0.8811791,0.000048890197,0.00028553786,0.000032836182,0.00040325703,0.003104948,0.00015183788,0.064981766,0.04885511,0.00078500685],"study_design_scores_gemma":[0.0041710166,0.000010815378,0.05769782,0.000009997631,0.000027568363,0.0000072706393,0.00015251168,0.006414312,0.0017607202,0.011200801,0.9171717,0.0013754481],"about_ca_topic_score_codex":0.5327762,"about_ca_topic_score_gemma":0.5608751,"teacher_disagreement_score":0.8683166,"about_ca_system_score_codex":0.0019679146,"about_ca_system_score_gemma":0.0006815873,"threshold_uncertainty_score":0.9999212},"labels":[],"label_agreement":null},{"id":"W4210693913","doi":"10.3821/1913-701x-143.2.73.a","title":"NAPRA Directive on Sale of NHPs in Pharmacies","year":2010,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Directive; Pharmacy; Business; Medicine; Family medicine; Computer science","score_opus":0.05010579447535842,"score_gpt":0.2678952313800483,"score_spread":0.21778943690468985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210693913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9578794,0.00075895095,0.000014327818,0.0004425781,0.0038827253,0.0002900148,0.0017105665,0.00001547948,0.035005935],"genre_scores_gemma":[0.99167114,0.0030307544,0.00010389666,0.0039426666,0.0007322759,0.000019567877,0.000014708693,0.00006294342,0.00042203715],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970498,0.00005880963,0.0011879719,0.0005078362,0.00010637597,0.0010892039],"domain_scores_gemma":[0.9971286,0.0001783969,0.0005482147,0.00031092623,0.00016067589,0.001673184],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010799121,0.00038469583,0.0006969019,0.0009879533,0.00032698744,0.00012859145,0.00080083794,0.000108699416,0.0028012295],"category_scores_gemma":[0.00032707606,0.00047436196,0.00021378467,0.0006767081,0.00028313592,0.00040927547,0.000050381543,0.0014159642,0.00010231875],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019330546,0.0020675359,0.22644585,0.0015356711,0.0024765301,0.07214761,0.016703723,0.013858505,0.048035465,0.20384647,0.17035206,0.24059753],"study_design_scores_gemma":[0.01023389,0.00019832434,0.001780989,0.00005779147,0.00008810478,0.08477008,0.000031086573,0.02189171,0.031246444,0.014585698,0.83233595,0.002779939],"about_ca_topic_score_codex":0.030350924,"about_ca_topic_score_gemma":0.12100093,"teacher_disagreement_score":0.6619839,"about_ca_system_score_codex":0.0013824755,"about_ca_system_score_gemma":0.0013604625,"threshold_uncertainty_score":0.9997708},"labels":[],"label_agreement":null},{"id":"W4210700769","doi":"10.1037/e533742006-001","title":"Technical Report for the Price and Purity of Illicit Drugs: 1981 Through the Second Quarter of 2003","year":2004,"lang":"en","type":"dataset","venue":"PsycEXTRA Dataset","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Economics; Business; History; Archaeology","score_opus":0.05099725095179771,"score_gpt":0.3263705390992224,"score_spread":0.27537328814742473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210700769","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004931763,0.0033821168,0.000377616,0.0028192056,0.00042812567,0.0009816407,0.99121237,0.0000062106787,0.00074341934],"genre_scores_gemma":[0.0004871225,0.0025751372,0.00033648507,0.0023997056,0.00024838213,0.00014888778,0.9937185,0.000025470868,0.000060306837],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972923,0.000024414654,0.001581332,0.00063459895,0.00006680889,0.0004005929],"domain_scores_gemma":[0.9961163,0.00048290216,0.0014233644,0.0018249798,0.000058347134,0.00009413452],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00131925,0.0003367301,0.00085777894,0.000100203695,0.00013964353,0.00006857637,0.0010916148,0.00031880112,0.0010554527],"category_scores_gemma":[0.00031226306,0.00024986838,0.00018124229,0.00025232995,0.0005044532,0.00018115889,0.00023457182,0.00052253326,0.00006779459],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041692263,0.0001414031,0.000014341057,0.00037637036,0.00015434648,0.0000028290885,0.0000494562,0.000003935625,0.0000026700939,0.014754742,0.984407,0.0000512116],"study_design_scores_gemma":[0.0006140039,0.00007476476,0.00011175456,0.000027216523,0.00008260099,0.00005582405,0.000026579208,0.000042430416,0.000025946636,0.017852139,0.9808028,0.00028393755],"about_ca_topic_score_codex":0.0013198837,"about_ca_topic_score_gemma":0.0003719147,"teacher_disagreement_score":0.003604199,"about_ca_system_score_codex":0.000059245613,"about_ca_system_score_gemma":0.00011857877,"threshold_uncertainty_score":0.99999535},"labels":[],"label_agreement":null},{"id":"W4210745007","doi":"10.1136/bmj.o316","title":"Can medical product development be better aligned with global needs?","year":2022,"lang":"en","type":"editorial","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact","funders":"World Health Organization","keywords":"Computer science; Data science; Product (mathematics); New product development; World Wide Web; Business; Marketing; Mathematics","score_opus":0.03674261430554597,"score_gpt":0.30001883262093315,"score_spread":0.26327621831538717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210745007","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016904211,0.0011620732,0.000043928678,0.080954045,0.8281929,0.0009824327,0.0046910592,0.00010925944,0.082173906],"genre_scores_gemma":[0.0032785693,0.00032930798,0.0011152026,0.012924148,0.974517,0.0005940459,0.0018696571,0.00014555706,0.0052265036],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970738,0.00003377859,0.0011388274,0.00080258865,0.00028009646,0.00067085784],"domain_scores_gemma":[0.9982237,0.00013297048,0.00059037213,0.00059125625,0.000045280427,0.00041638492],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013354983,0.0004264263,0.0008786509,0.00021752287,0.00019238587,0.00013063409,0.00084595423,0.00043506408,0.0056274026],"category_scores_gemma":[0.00053985056,0.00045722042,0.00014055111,0.00032885783,0.000107520005,0.00007936667,0.00041469518,0.000640797,0.00043456245],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005143995,0.00007791811,0.0014778245,0.00006431009,0.00026521218,0.000037275953,0.00015899909,0.000007081134,4.5156096e-8,0.0049757515,0.9909711,0.0019130559],"study_design_scores_gemma":[0.00086665223,0.00006052265,0.00027027164,0.000021657024,0.000016772963,0.000009823818,0.000014117102,0.00006881298,0.0000044125986,0.0016053059,0.99639857,0.0006630625],"about_ca_topic_score_codex":0.00051916006,"about_ca_topic_score_gemma":0.00038961114,"teacher_disagreement_score":0.14632413,"about_ca_system_score_codex":0.00094306574,"about_ca_system_score_gemma":0.0014168643,"threshold_uncertainty_score":0.9997879},"labels":[],"label_agreement":null},{"id":"W4210845468","doi":"10.1177/171516350714000209","title":"Move by US Congress Raises Risk to Canada's Drug Supply, Say Pharmacy Groups","year":2007,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy; Medicine; Drug; Family medicine; Political science; Pharmacology","score_opus":0.027318698234613158,"score_gpt":0.2602021589784698,"score_spread":0.23288346074385666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210845468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94885916,0.0053681866,0.00025558993,0.0022968526,0.009261476,0.0007659738,0.018025117,0.00004635324,0.015121279],"genre_scores_gemma":[0.9521436,0.007851519,0.00011571015,0.035652805,0.0016567667,0.000025479172,0.00010040146,0.00014620727,0.002307491],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940213,0.00010806356,0.0018976908,0.0009668166,0.00025319282,0.0027529541],"domain_scores_gemma":[0.9904477,0.0003242666,0.00086479366,0.00047784336,0.0003164376,0.0075689303],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002134617,0.00077053154,0.0009936948,0.0007731903,0.0013184556,0.00047448097,0.0015439839,0.00009362068,0.0029749365],"category_scores_gemma":[0.0003957623,0.0009788794,0.0002829171,0.000919181,0.00021442802,0.00047797576,0.0001297892,0.0013928867,0.00015240439],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026676312,0.00010550186,0.062468134,0.00012634112,0.0006190168,0.017683113,0.000887106,0.0017202419,0.00038070467,0.0014706688,0.8701312,0.0441412],"study_design_scores_gemma":[0.0028743711,0.000023020348,0.00044032955,0.000013862179,0.000072132745,0.022160899,0.000015983884,0.0027290017,0.0040120985,0.0005554338,0.9657393,0.0013635407],"about_ca_topic_score_codex":0.94867945,"about_ca_topic_score_gemma":0.9840507,"teacher_disagreement_score":0.095608115,"about_ca_system_score_codex":0.007786551,"about_ca_system_score_gemma":0.0046442626,"threshold_uncertainty_score":0.9999817},"labels":[],"label_agreement":null},{"id":"W4210984771","doi":"10.1136/bmjopen-2021-053349","title":"Global status of essential medicine selection: a systematic comparison of national essential medicine lists with recommendations by WHO","year":2022,"lang":"en","type":"article","venue":"BMJ Open","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Hamilton Regional Laboratory Medicine Program; McMaster University; Impact","funders":"Foreign, Commonwealth and Development Office; Irish Aid; European Commission; National Institute for Health and Care Research; Ministère de l'Europe et des Affaires Étrangères; World Health Organization","keywords":"Medicine; Alternative medicine; Selection (genetic algorithm); Family medicine; MEDLINE; Traditional medicine; Pathology","score_opus":0.12780785009405132,"score_gpt":0.44134294264697743,"score_spread":0.3135350925529261,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210984771","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.206702,0.0059655327,0.014356904,0.09325773,0.004116437,0.023256516,0.015534124,0.000106206375,0.63670456],"genre_scores_gemma":[0.99784124,0.00004339304,0.00019356435,0.0006046905,0.00014918865,0.0003947214,0.0002362072,0.000013866156,0.0005231413],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99795985,0.00008581451,0.0013148016,0.0002707372,0.00013760665,0.00023118999],"domain_scores_gemma":[0.99824584,0.0001297852,0.0012064198,0.0001948141,0.00010173201,0.00012142427],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012268712,0.00013045632,0.00090398535,0.00015079736,0.00015638558,0.000024796353,0.00043895398,0.000035390003,0.0045131375],"category_scores_gemma":[0.00019553666,0.00012806532,0.000048582686,0.0005169723,0.00014314959,0.00016142598,0.00025378444,0.00011955282,0.000013291445],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005614314,0.0006639761,0.069512,0.0027598187,0.00068041135,0.0000012548693,0.0022065428,0.0021708698,0.00007875173,0.58589864,0.33532232,0.00014401546],"study_design_scores_gemma":[0.04332084,0.0076868697,0.037566073,0.0057629165,0.00070376205,0.0002560999,0.008317323,0.26819348,0.001000085,0.11341707,0.5106026,0.0031728696],"about_ca_topic_score_codex":0.002673087,"about_ca_topic_score_gemma":0.00025507098,"teacher_disagreement_score":0.79113925,"about_ca_system_score_codex":0.00028245244,"about_ca_system_score_gemma":0.00017090265,"threshold_uncertainty_score":0.9963969},"labels":[],"label_agreement":null},{"id":"W4212892338","doi":"10.3390/curroncol29020100","title":"Treatment Access, Health Economics, and the Wave of a Magic Wand","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; McGill University; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Drug prices; Medicine; Magic bullet; Inflation (cosmology); Economic shortage; Health economics; Government (linguistics); Public economics; Actuarial science; Economics; Public health; Bioinformatics","score_opus":0.31686726860562864,"score_gpt":0.42542248772631214,"score_spread":0.1085552191206835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212892338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7301638,0.084715955,0.00012095633,0.11118839,0.00436553,0.0015892835,0.0021356775,0.000031040392,0.06568935],"genre_scores_gemma":[0.96683526,0.030959833,0.00003040509,0.001714359,0.00013900624,0.000111806134,0.000026310163,0.000013909881,0.00016910695],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987969,0.00007427849,0.00059363164,0.00027394327,0.0000104611345,0.00025082575],"domain_scores_gemma":[0.99905235,0.00015322055,0.00047889305,0.00020948041,0.0000073524366,0.000098699245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005766589,0.00011455289,0.0005714584,0.00011583557,0.00016770835,0.00002591193,0.00020958793,0.000025990736,0.0006115879],"category_scores_gemma":[0.00002025544,0.0001014414,0.000108223074,0.00007383779,0.00022614998,0.00006516161,0.00028840132,0.00015785605,0.000023792583],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018629576,0.00038200067,0.0066644694,0.0000299628,0.000092473056,9.657572e-7,0.0012488057,0.00012987455,2.637916e-7,0.9079307,0.0038386444,0.079495594],"study_design_scores_gemma":[0.0033178832,0.0002951616,0.001316562,9.610471e-7,0.0000073151978,0.000015710504,0.0000570868,0.008743283,0.0000037857596,0.07070962,0.915439,0.000093611285],"about_ca_topic_score_codex":0.00029703623,"about_ca_topic_score_gemma":0.00004731165,"teacher_disagreement_score":0.91160035,"about_ca_system_score_codex":0.00051452516,"about_ca_system_score_gemma":0.0001503452,"threshold_uncertainty_score":0.66964585},"labels":[],"label_agreement":null},{"id":"W4214578304","doi":"10.1002/9780470041000.cedt101","title":"Pharmaceutical Pricing and Reimbursement in Canada","year":2006,"lang":"en","type":"other","venue":"Wiley Handbook of Current and Emerging Drug Therapies","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Currency; Business; European market; Market size; International trade; Health care; Economics; Commerce; Economic growth; Monetary economics","score_opus":0.0360708801900133,"score_gpt":0.28192519576755565,"score_spread":0.24585431557754234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214578304","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0200698,0.9080986,0.000091799884,0.0008807326,0.0011374956,0.00043613635,0.0003822175,0.00003353639,0.068869725],"genre_scores_gemma":[0.30103737,0.6668591,0.00040016355,0.0010555894,0.001203559,0.000098956596,0.00011478335,0.0006315765,0.028598923],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99863714,0.000017836925,0.00058870664,0.00037435812,0.0000443631,0.00033761398],"domain_scores_gemma":[0.99936736,0.000043346896,0.00032521447,0.00015250136,0.000006618932,0.000104954226],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021974716,0.0002735552,0.00064430136,0.00033050447,0.00003685288,0.000026804415,0.00012943006,0.000063406005,0.00033044085],"category_scores_gemma":[0.0000073706924,0.00030186467,0.000051829516,0.00007752734,0.00010275654,0.00004542194,0.000079313904,0.00023848018,0.000006048049],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000666195,0.00020344905,0.1464983,0.0016924168,0.00045804915,0.000008898909,0.0017532256,0.00004459264,0.000039861596,0.038086027,0.67476183,0.13638674],"study_design_scores_gemma":[0.0008491765,0.000008403907,0.0005321782,0.0010428383,0.000015053001,9.033297e-7,0.000034539204,0.00092457037,0.000052077427,0.0026673009,0.99350643,0.00036654205],"about_ca_topic_score_codex":0.28749654,"about_ca_topic_score_gemma":0.27324483,"teacher_disagreement_score":0.31874457,"about_ca_system_score_codex":0.000118900665,"about_ca_system_score_gemma":0.00009727895,"threshold_uncertainty_score":0.9999434},"labels":[],"label_agreement":null},{"id":"W4214855737","doi":"10.1017/9781108975759.005","title":"The Harrington Discovery Institute and Alzheimer’s Disease Drug Development","year":2022,"lang":"en","type":"book-chapter","venue":"Cambridge University Press eBooks","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Portfolio; Disease; Drug discovery; Medicine; Drug development; Action (physics); Engineering ethics; Political science; Drug; Business; Engineering; Pharmacology; Bioinformatics; Pathology; Finance","score_opus":0.05975326701860171,"score_gpt":0.22219423513874004,"score_spread":0.16244096812013833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214855737","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010459236,0.0045825946,0.00003613538,0.00034782113,0.00061291986,0.00035462374,0.0011219465,0.00004024519,0.99185777],"genre_scores_gemma":[0.0066172904,0.0026928321,0.000022134775,0.00044285026,0.00011953172,0.0000047008925,0.00007323141,0.000046307163,0.9899811],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987261,0.000011012003,0.00035110646,0.0005520724,0.00004781038,0.00031186533],"domain_scores_gemma":[0.99887013,0.00006310041,0.00032665837,0.0004336789,0.000015664808,0.00029078685],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021982468,0.00030232593,0.00036583468,0.00013962593,0.0007564648,0.00018488316,0.00051855826,0.000085523796,0.000020554577],"category_scores_gemma":[0.000009926557,0.00034896674,0.00015641458,0.0000072961648,0.00030955905,0.00026236573,0.0008729725,0.00043881094,0.000041933457],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006569866,0.0000071881395,0.000034745844,0.00002424631,0.00022719002,0.000042707445,0.000047781192,0.000007465177,1.587671e-7,0.9842112,0.014161571,0.0011700417],"study_design_scores_gemma":[0.00035928164,0.0000069753896,0.00019494927,0.000018169869,0.00006733739,0.0000020227592,0.0000069324124,0.0001207771,0.000008927921,0.0005877456,0.99819463,0.00043222614],"about_ca_topic_score_codex":0.0001282689,"about_ca_topic_score_gemma":0.00000771962,"teacher_disagreement_score":0.9840331,"about_ca_system_score_codex":0.00027582317,"about_ca_system_score_gemma":0.00013778132,"threshold_uncertainty_score":0.9998962},"labels":[],"label_agreement":null},{"id":"W4220701728","doi":"10.1016/j.vhri.2022.01.006","title":"Prevalence and Factors Associated With Out-of-Pocket Pharmaceutical Expenditure Among Primary Healthcare Patients: Evidence From the Prover Project","year":2022,"lang":"en","type":"article","venue":"Value in Health Regional Issues","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Fundação Oswaldo Cruz; Fundação de Amparo à Pesquisa do Estado de Minas Gerais","keywords":"Medicine; Confidence interval; Odds ratio; Logistic regression; Descriptive statistics; Family medicine; Health care; Environmental health; Population; Internal medicine","score_opus":0.2302382974945727,"score_gpt":0.37134424277588074,"score_spread":0.14110594528130804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220701728","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95815605,0.026446115,0.000003840716,0.012912702,0.00028108712,0.0010498746,0.001060084,0.000019663528,0.00007056743],"genre_scores_gemma":[0.990189,0.003960274,0.000051342755,0.005374684,0.00009022963,0.0001389386,0.00009491431,0.000026318894,0.000074288124],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99784654,0.00029975068,0.0007831722,0.00051200436,0.00014379667,0.00041474777],"domain_scores_gemma":[0.99808174,0.0008768342,0.00061782816,0.00024893132,0.000032381053,0.0001422573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001009004,0.00019773845,0.00048461504,0.00012032846,0.00023962083,0.000034110053,0.0003511461,0.00006821175,0.00011836604],"category_scores_gemma":[0.00022329143,0.00016694111,0.0000619448,0.00021184533,0.00021223475,0.0002570481,0.00018937059,0.00053755956,0.0000033209599],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009381009,0.00018337973,0.9860842,0.00022634295,0.00004188745,0.0000012630755,0.0065134712,0.00013987008,6.4132115e-7,0.004131576,0.002399144,0.00018438387],"study_design_scores_gemma":[0.0009136972,0.00038159036,0.95980096,0.0003595264,0.000008019211,4.7258968e-7,0.00034297945,0.0023665123,0.00000871276,0.0032439576,0.03229962,0.00027393253],"about_ca_topic_score_codex":0.0063531483,"about_ca_topic_score_gemma":0.00013716951,"teacher_disagreement_score":0.032032944,"about_ca_system_score_codex":0.00048318206,"about_ca_system_score_gemma":0.00020387635,"threshold_uncertainty_score":0.9604102},"labels":[],"label_agreement":null},{"id":"W4220736806","doi":"10.1136/bmj.o693","title":"High US drug prices have global implications","year":2022,"lang":"en","type":"editorial","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Drug; Drug prices; Business; Economics; Medicine; Monetary economics; Pharmacology","score_opus":0.04113243283835117,"score_gpt":0.33308069017508357,"score_spread":0.2919482573367324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220736806","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006705254,0.0019004033,0.000042473886,0.0112309735,0.7889268,0.0005522125,0.026762713,0.000080368714,0.16983356],"genre_scores_gemma":[0.0035768237,0.0015796348,0.000447902,0.0021746135,0.9820724,0.00057048217,0.0019381355,0.00008959882,0.0075504025],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976125,0.000020605941,0.0010515124,0.00075690786,0.00006877615,0.00048972166],"domain_scores_gemma":[0.9978494,0.0002606809,0.00087793433,0.00076110364,0.00004218533,0.00020871079],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000698582,0.0003139679,0.0007145448,0.00015032299,0.00023361015,0.00018941156,0.0008751338,0.00035237355,0.003988002],"category_scores_gemma":[0.00039088336,0.0004143178,0.00028091352,0.00019380225,0.00006596987,0.00013606674,0.00041421084,0.0006775862,0.0018505369],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010154652,0.000053845968,0.0010011557,0.000027964785,0.00009385595,0.0000021394144,0.000026083444,0.000053436823,7.5959505e-8,0.14847752,0.85001594,0.00023781965],"study_design_scores_gemma":[0.0003940321,0.000019650974,0.0014391431,0.0000046489217,0.000018243009,0.0000016044601,0.000006474258,0.00009901709,7.2515536e-7,0.068388924,0.9291874,0.00044014637],"about_ca_topic_score_codex":0.0022235126,"about_ca_topic_score_gemma":0.0001787852,"teacher_disagreement_score":0.19314563,"about_ca_system_score_codex":0.000781512,"about_ca_system_score_gemma":0.00023527138,"threshold_uncertainty_score":0.99983084},"labels":[],"label_agreement":null},{"id":"W4220994714","doi":"10.4212/cjhp.v75i1.3090","title":"Gestion des approvisionnements en médicaments pendant la pandémie de COVID-19 : expérience québécoise en établissement de santé","year":2022,"lang":"fr","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Centre intégré de santé et de services sociaux de la Montérégie-Centre; Centre Intégré de Santé et Services Sociaux de Chaudière-Appalache; Université de Montréal; Santé Montérégie; Montreal Heart Institute; Centre hospitalier universitaire de Québec; Centre Intégré de Santé et de Services Sociaux du Bas-Saint-Laurent","funders":"","keywords":"Coronavirus disease 2019 (COVID-19); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Medicine; Political science; Virology; Infectious disease (medical specialty)","score_opus":0.04156462629408934,"score_gpt":0.3117706846471695,"score_spread":0.27020605835308015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220994714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87591696,0.020699834,0.00072671054,0.094012715,0.0026393135,0.00045344504,0.0010831492,0.000008690488,0.0044591622],"genre_scores_gemma":[0.9845705,0.004373431,0.0002680448,0.009111702,0.0005824968,0.00003678546,0.00000810778,0.000043979802,0.0010049739],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970597,0.0005268947,0.0009933438,0.00030481903,0.00012961571,0.0009856],"domain_scores_gemma":[0.99658746,0.00043864758,0.00078366144,0.0002530602,0.000053431926,0.0018837315],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00492049,0.00027542782,0.00041931783,0.00040564316,0.0012195848,0.00034035518,0.001213857,0.00007396762,0.0050997776],"category_scores_gemma":[0.0007729102,0.0003046849,0.00027004344,0.00031059855,0.00041377777,0.00048546435,0.00019645272,0.0011417189,0.00006631945],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005107697,0.0018005144,0.41898373,0.00044177024,0.0017195793,0.003008766,0.13231008,0.044512115,0.00020778434,0.12245206,0.15972286,0.11432998],"study_design_scores_gemma":[0.0023582268,0.00043484467,0.02062459,0.000053163858,0.00010665211,0.00051227654,0.0014731016,0.008174622,0.00008905116,0.027914122,0.93782485,0.00043453038],"about_ca_topic_score_codex":0.14733341,"about_ca_topic_score_gemma":0.013157542,"teacher_disagreement_score":0.778102,"about_ca_system_score_codex":0.0071682655,"about_ca_system_score_gemma":0.004071671,"threshold_uncertainty_score":0.9999405},"labels":[],"label_agreement":null},{"id":"W4221078239","doi":"10.3390/diabetology3010014","title":"Availability and Affordability of Medicines for Diabetes and Cardiovascular Disease across Countries: Information Learned from the Prospective Urban Rural Epidemiological Study","year":2022,"lang":"en","type":"article","venue":"Diabetology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"","keywords":"Epidemiology; Environmental health; Medicine; Disease; Diabetes mellitus; Developing country; Prospective cohort study; Incidence (geometry); Cohort; Economic growth; Geography; Socioeconomics; Economics; Internal medicine","score_opus":0.05058501668805227,"score_gpt":0.29279513372318944,"score_spread":0.24221011703513717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221078239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98905003,0.0039782105,0.000052349755,0.003329888,0.00016318397,0.0009758941,0.0023654243,0.000012279331,0.0000727504],"genre_scores_gemma":[0.9977986,0.00015467504,0.000018915449,0.0015125244,0.00005512636,0.0004000211,0.000051418796,0.00000554475,0.0000031448062],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987167,0.00013623101,0.0005667599,0.0002874288,0.000029410092,0.00026343163],"domain_scores_gemma":[0.9982046,0.001137837,0.00020522666,0.00032988703,0.00003332431,0.000089135756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002593358,0.00012350593,0.0006844202,0.000028729468,0.00026530144,0.000021392223,0.00016148764,0.000045209945,0.0000967163],"category_scores_gemma":[0.0013911003,0.00009999768,0.00012411196,0.000069130125,0.00045677507,0.00014356378,0.0002425607,0.00015347672,0.0000034760178],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000985782,0.00007170809,0.9886914,0.000030037747,0.00024584826,1.08083626e-7,0.002275491,0.00006375314,4.7484838e-7,0.007429532,0.00024426414,0.0008488317],"study_design_scores_gemma":[0.0012445527,0.00024646663,0.89772946,0.0000013440335,0.000047105637,2.0786727e-7,0.0013905261,0.0034915213,0.0000051104485,0.07154216,0.02418198,0.00011956277],"about_ca_topic_score_codex":0.00021344256,"about_ca_topic_score_gemma":0.000011023508,"teacher_disagreement_score":0.0909619,"about_ca_system_score_codex":0.000050091978,"about_ca_system_score_gemma":0.000018455396,"threshold_uncertainty_score":0.4077787},"labels":[],"label_agreement":null},{"id":"W4223889261","doi":"10.1016/j.ijindorg.2022.102841","title":"R&amp;D competition and the direction of innovation","year":2022,"lang":"en","type":"article","venue":"International Journal of Industrial Organization","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Toronto","funders":"Social Sciences and Humanities Research Council of Canada","keywords":"Social planner; Competition (biology); Subsidy; Context (archaeology); Distortion (music); Economics; Industrial organization; Ex-ante; Value (mathematics); Planner; Value creation; Coronavirus disease 2019 (COVID-19); Microeconomics; Business; Market economy","score_opus":0.07693062535061311,"score_gpt":0.28164557783853095,"score_spread":0.20471495248791782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223889261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97071046,0.0002177145,0.005246647,0.018058546,0.0032891182,0.00013462531,0.0001230773,0.0000065702397,0.002213227],"genre_scores_gemma":[0.9986698,0.00013033455,0.00006256388,0.00055126904,0.00048551022,0.0000014020737,0.000032551736,0.000007695491,0.000058876754],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99900424,0.000041086456,0.0007720464,0.000063523534,0.00007211468,0.00004697568],"domain_scores_gemma":[0.9983943,0.00007680754,0.0011464306,0.000047077287,0.00031884943,0.00001654477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010489259,0.000045630455,0.00015406881,0.00031392707,0.00007542983,0.000037245718,0.00017732661,0.000031372776,0.0006608929],"category_scores_gemma":[0.00076577923,0.000043269963,0.000028650127,0.00045403457,0.000052022315,0.00016683417,0.000069164555,0.00018617473,0.0000057618213],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021025327,0.00007223623,0.026801223,0.0000016754652,0.0001255617,6.292711e-7,0.00042479383,0.0011621861,0.0004475732,0.9661969,0.0023775978,0.0021793977],"study_design_scores_gemma":[0.022991266,0.00035161374,0.01743096,0.000048425612,0.0000700514,0.00042629152,0.00048485884,0.0027782132,0.005670419,0.2159965,0.7333011,0.00045028978],"about_ca_topic_score_codex":0.000037679827,"about_ca_topic_score_gemma":0.000001257658,"teacher_disagreement_score":0.75020033,"about_ca_system_score_codex":0.0001298021,"about_ca_system_score_gemma":0.000043762626,"threshold_uncertainty_score":0.7236314},"labels":[],"label_agreement":null},{"id":"W4223997537","doi":"10.54194/gcap7754","title":"Access to new medicines in Canada 2016-2021 Federal-provincial public drug programs and private sector drug plans","year":2022,"lang":"en","type":"article","venue":"Canadian Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Private sector; Public administration; Drug; Public sector; Public health; Business; Political science; Medicine; Pharmacology; Law; Nursing","score_opus":0.07772323839453224,"score_gpt":0.31431870365319126,"score_spread":0.23659546525865902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223997537","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4339014,0.0014101953,0.0000051526754,0.5553276,0.0008208222,0.0009921122,0.002345799,0.00001567222,0.005181243],"genre_scores_gemma":[0.82137287,0.0002859036,0.000039559873,0.17596737,0.00097305066,0.00012888914,0.00010185844,0.00004441861,0.0010860824],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99732983,0.000054534103,0.0007485986,0.0005170775,0.00005791012,0.0012920753],"domain_scores_gemma":[0.99643797,0.000050305967,0.00021222043,0.00028761072,0.000012889946,0.0029990198],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00055154413,0.00021631568,0.0005221963,0.0008727773,0.0004297353,0.00019653361,0.00055794616,0.000035397145,0.0008788955],"category_scores_gemma":[0.000102750484,0.00028085933,0.00003915021,0.00076164416,0.000032653625,0.00020529835,0.00020961142,0.0003807908,0.00004449484],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000019544857,0.000031080624,0.2888554,0.00008735822,0.000032463166,0.000031766795,0.0024474906,0.00011548807,2.9219302e-7,0.0775696,0.5918213,0.03898818],"study_design_scores_gemma":[0.0006119616,0.000035917576,0.041606877,0.000011786089,9.4571095e-7,0.0000073387837,0.00011586929,0.00038312702,7.818112e-7,0.004737849,0.9521936,0.00029393643],"about_ca_topic_score_codex":0.99972063,"about_ca_topic_score_gemma":0.9998738,"teacher_disagreement_score":0.38747147,"about_ca_system_score_codex":0.0066238274,"about_ca_system_score_gemma":0.021749016,"threshold_uncertainty_score":0.99996436},"labels":[],"label_agreement":null},{"id":"W4224019748","doi":"10.3390/curroncol29040204","title":"Access Denied? The Unintended Consequences of Pending Drug Pricing Rules","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Toronto; St. Michael's Hospital; Essar Steel Algoma (Canada); University of Ottawa; Jewish General Hospital; Ottawa Hospital","funders":"Seagen; Pfizer; AstraZeneca; Eli Lilly and Company; Amgen","keywords":"Government (linguistics); Cornerstone; Medicine; Unintended consequences; Drug pricing; Clinical trial; Health care; Duty; Business; Medical emergency; Actuarial science; Law; Political science","score_opus":0.2949148983371442,"score_gpt":0.4304033890130218,"score_spread":0.1354884906758776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224019748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8899228,0.009138896,0.00020388866,0.017682364,0.004106201,0.00039091147,0.00047061642,0.00003345562,0.07805089],"genre_scores_gemma":[0.9982856,0.00062610663,0.000036045,0.0007502556,0.00011788279,0.00006485492,0.000014667448,0.000010906107,0.00009367767],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987961,0.00008090028,0.0005657975,0.0002510052,0.000028285227,0.00027790194],"domain_scores_gemma":[0.9990002,0.00022843613,0.00048825413,0.00020078449,0.000019081675,0.000063257925],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008849897,0.00010393143,0.0003601383,0.00017458694,0.00025985437,0.00003492298,0.0007291352,0.000026579779,0.001961676],"category_scores_gemma":[0.000101386024,0.00009875351,0.00010749686,0.00017907152,0.00041638038,0.00010963812,0.00050123566,0.00035703124,0.00007336699],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000312748,0.00016443983,0.03439264,0.00003461163,0.000054845197,0.0000028704856,0.0011608619,0.00028673984,0.00005460742,0.9491991,0.0068826657,0.0077353376],"study_design_scores_gemma":[0.00062906696,0.00007243646,0.0042719254,0.0000062604663,0.0000142630715,0.000021465356,0.00049045833,0.0033763784,0.00035231232,0.17856875,0.8120022,0.00019451621],"about_ca_topic_score_codex":0.00015464639,"about_ca_topic_score_gemma":0.000015248675,"teacher_disagreement_score":0.8051195,"about_ca_system_score_codex":0.00027399306,"about_ca_system_score_gemma":0.00009708388,"threshold_uncertainty_score":0.99895066},"labels":[],"label_agreement":null},{"id":"W4224020286","doi":"10.17749/2070-4909/farmakoekonomika.2022.107","title":"The real practice of clinical and economic research of drugs included in the Federal Program of High-Cost Nosologies","year":2022,"lang":"en","type":"article","venue":"FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Clinical Practice; Quarter (Canadian coin); Economic evaluation; Russian federation; Quality (philosophy); Actuarial science; Accounting; Family medicine; Business; Pathology","score_opus":0.277111289096794,"score_gpt":0.5229341812689959,"score_spread":0.24582289217220193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224020286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9700104,0.0054145823,0.000033083346,0.013744744,0.0009090284,0.0014422277,0.0008750807,0.00001715241,0.007553715],"genre_scores_gemma":[0.9584345,0.03816263,0.00037813213,0.0022501512,0.00022657448,0.0004512225,0.000029071676,0.00004046092,0.000027261269],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99204063,0.002084409,0.0040837624,0.00086804974,0.00007343885,0.00084969995],"domain_scores_gemma":[0.9863851,0.010559646,0.0022227557,0.0005638233,0.00007703079,0.00019161914],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.02510515,0.00034011088,0.0016840175,0.0003891564,0.000516923,0.00005149416,0.0012290501,0.00017878404,0.00010605783],"category_scores_gemma":[0.000623177,0.0003031047,0.0002766875,0.00019113216,0.001785861,0.0003018205,0.0012240149,0.0014942294,0.000008994094],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035535814,0.0012112489,0.19585024,0.00021602235,0.0008774117,0.000007315074,0.0037418625,0.014156525,0.0001594075,0.701409,0.0073195207,0.071497895],"study_design_scores_gemma":[0.0096856225,0.0011478502,0.03247094,0.000014542855,0.00010912907,0.00004946529,0.0021399176,0.29514152,0.00045945036,0.16998038,0.4880007,0.00080047536],"about_ca_topic_score_codex":0.0043454957,"about_ca_topic_score_gemma":0.00010265648,"teacher_disagreement_score":0.5314286,"about_ca_system_score_codex":0.00015437715,"about_ca_system_score_gemma":0.00022086511,"threshold_uncertainty_score":0.9999421},"labels":[],"label_agreement":null},{"id":"W4224222628","doi":"10.1016/j.lanepe.2022.100375","title":"European governments should align medicines pricing practices with global transparency norms and legal principles","year":2022,"lang":"en","type":"article","venue":"The Lancet Regional Health - Europe","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Vlaamse Interuniversitaire Raad","keywords":"Transparency (behavior); Business; Accounting; Law and economics; Political science; Economics; Law","score_opus":0.2568805748780021,"score_gpt":0.36279313596244495,"score_spread":0.10591256108444286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224222628","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34740084,0.009976988,0.00040786667,0.4059884,0.00054872845,0.0007806524,0.0009657434,0.00011163611,0.23381917],"genre_scores_gemma":[0.9309839,0.0046550413,0.00032878353,0.062401623,0.00073208753,0.000027595817,0.000033232835,0.00004166595,0.00079609494],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99833024,0.000162016,0.0005282558,0.00040441175,0.000118919765,0.00045615743],"domain_scores_gemma":[0.9985364,0.00009958638,0.0008499003,0.00031392122,0.0000150933665,0.00018509134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017089929,0.00017601087,0.00041167557,0.000037433936,0.00052935886,0.00007055501,0.0004577321,0.0000151518425,0.00010843569],"category_scores_gemma":[0.00005648032,0.00013352996,0.000036708414,0.00024376245,0.00012932884,0.00018289997,0.00017879411,0.000352521,0.000056426612],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004976155,0.00019382768,0.10159346,0.00019424142,0.00014610763,0.000059303275,0.00089536567,0.00080553506,0.000004080832,0.8652887,0.026565501,0.0037562842],"study_design_scores_gemma":[0.00087666867,0.00025692873,0.09055299,0.000018745279,0.000008158016,0.00013864845,0.00007075395,0.0014796964,6.1647637e-7,0.0013442901,0.9050825,0.00016999873],"about_ca_topic_score_codex":0.0006049455,"about_ca_topic_score_gemma":0.00010472507,"teacher_disagreement_score":0.878517,"about_ca_system_score_codex":0.00019690939,"about_ca_system_score_gemma":0.00009579003,"threshold_uncertainty_score":0.54451936},"labels":[],"label_agreement":null},{"id":"W4225016550","doi":"10.51731/cjht.2022.321","title":"Harmonization of Public Coverage Policies for Biologic Drugs in the Treatment of Rheumatoid Arthritis","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"U.S. Department of Veterans Affairs","keywords":"Veterans Affairs; Medicine; Public administration; Political science; Internal medicine","score_opus":0.09433791284355138,"score_gpt":0.2939799318032812,"score_spread":0.19964201895972983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225016550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8351662,0.110024385,0.00024803757,0.052758954,0.0002293225,0.0003580949,0.00092141767,0.000008183963,0.00028541102],"genre_scores_gemma":[0.97084373,0.02851571,0.00007883727,0.0005096886,0.0000049141872,0.000029427609,0.0000072335615,0.0000059746376,0.000004456616],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99873316,0.0000370173,0.0008514883,0.00008631067,0.000019207497,0.0002728002],"domain_scores_gemma":[0.9988456,0.000109383735,0.000838792,0.00014277581,0.00003090553,0.000032582582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009839056,0.000072353636,0.0004069933,0.00072452566,0.00014963873,0.000017488488,0.00033594403,0.000045540546,0.00003673693],"category_scores_gemma":[0.0001873999,0.00006422936,0.00009366394,0.00031551445,0.0001238722,0.00006494191,0.000012876316,0.00011268936,8.550645e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020038322,0.00021540785,0.0726715,0.000058057143,0.00007146811,0.0000036461922,0.004979141,0.00047886203,0.000009054757,0.5966421,0.0018987289,0.322952],"study_design_scores_gemma":[0.0012865671,0.001549647,0.009713904,0.000019914438,0.0000012578791,0.000030498337,0.004890561,0.00026177667,0.00019130137,0.1375092,0.84442174,0.00012363815],"about_ca_topic_score_codex":0.0046534254,"about_ca_topic_score_gemma":0.0012136772,"teacher_disagreement_score":0.84252304,"about_ca_system_score_codex":0.00043146012,"about_ca_system_score_gemma":0.0004504627,"threshold_uncertainty_score":0.7034618},"labels":[],"label_agreement":null},{"id":"W4225408416","doi":"10.1002/14651858.cd011703.pub2","title":"Pharmaceutical policies: effects of regulating drug insurance schemes","year":2022,"lang":"en","type":"review","venue":"Cochrane Database of Systematic Reviews","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Medicine; MEDLINE; Payment; Citation; Actuarial science; Alternative medicine; Systematic review; Family medicine; Drug; Health care; Business; Pharmacology; Political science; Computer science; World Wide Web; Pathology","score_opus":0.20117095391088036,"score_gpt":0.4072512196268243,"score_spread":0.20608026571594396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225408416","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000019756215,0.98794854,0.00008785038,0.000025677044,0.00069089304,0.005573214,0.0029546928,0.000022854558,0.0026765338],"genre_scores_gemma":[0.00005262569,0.99722826,0.00041810932,0.00015750917,0.00016891272,0.0013284371,0.00035165605,0.00010067361,0.00019379906],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99022174,0.00072507525,0.007579085,0.0007874603,0.00015765084,0.00052901276],"domain_scores_gemma":[0.98751444,0.0028963722,0.007301798,0.0020025508,0.000042576576,0.00024227568],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005286302,0.00075291714,0.011658703,0.00058636616,0.00010395273,0.000041730185,0.0014036862,0.00016093564,0.0009509202],"category_scores_gemma":[0.004473827,0.00067092234,0.0017484698,0.00080959173,0.00018985238,0.00022894183,0.0005282888,0.0006110549,0.00047531913],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000002925475,0.00012431815,0.0000062828612,0.95628077,0.00029744403,0.000004012367,0.00012327607,5.0442117e-7,0.0000016247793,0.028522858,0.0013326409,0.013303316],"study_design_scores_gemma":[0.0002962526,0.000018988712,3.7331574e-7,0.3284736,0.00044965214,0.00002354501,0.000008302669,0.000082210805,0.000012519733,0.00015011597,0.6700772,0.00040723066],"about_ca_topic_score_codex":0.00005892129,"about_ca_topic_score_gemma":0.0000011996946,"teacher_disagreement_score":0.66874456,"about_ca_system_score_codex":0.0002091261,"about_ca_system_score_gemma":0.00011950273,"threshold_uncertainty_score":0.99996233},"labels":[],"label_agreement":null},{"id":"W4225654180","doi":"10.2139/ssrn.4086763","title":"Rethinking Business Model for Drug Discovery, Post-COVID","year":2022,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Telus (Canada)","funders":"","keywords":"Coronavirus disease 2019 (COVID-19); Business model; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Business; 2019-20 coronavirus outbreak; Virology; Medicine; Outbreak; Internal medicine; Infectious disease (medical specialty); Marketing","score_opus":0.040726789223837295,"score_gpt":0.27152109873617064,"score_spread":0.23079430951233335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225654180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.62280977,0.015053181,0.27164274,0.076644346,0.0021926947,0.0008710381,0.0014947249,0.00009683287,0.00919466],"genre_scores_gemma":[0.98580194,0.0019702027,0.00019851972,0.006110714,0.00036540214,0.000055438886,0.00003239362,0.000052204174,0.005413194],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9971675,0.00002296686,0.0005854278,0.0003350018,0.00004843075,0.0018406737],"domain_scores_gemma":[0.99917865,0.00006650197,0.00039225185,0.0002027948,0.00004409584,0.000115697156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029380624,0.00016754627,0.0003267546,0.00023904175,0.0007593902,0.00017101933,0.0005459273,0.00004235002,0.00012879456],"category_scores_gemma":[0.00011970735,0.00020086124,0.00023042894,0.00019727107,0.00003368501,0.00044754316,0.00016002175,0.0014443392,0.000035383673],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000103540966,0.00006973857,0.00042780055,0.000011199309,0.000101506084,8.957121e-7,0.00065796403,0.017785443,0.000025871574,0.97891057,0.0010242906,0.00088119396],"study_design_scores_gemma":[0.00086706306,0.00006617861,0.0000547582,0.0000018304297,0.0000102840595,0.00008621677,0.0001814307,0.102052934,0.0000054322572,0.85768247,0.038749993,0.00024141865],"about_ca_topic_score_codex":0.00012308925,"about_ca_topic_score_gemma":0.00024809834,"teacher_disagreement_score":0.36299214,"about_ca_system_score_codex":0.0019004134,"about_ca_system_score_gemma":0.0013790258,"threshold_uncertainty_score":0.81908834},"labels":[],"label_agreement":null},{"id":"W4225984271","doi":"10.2139/ssrn.4037548","title":"Equilibrium Effects of Pharmaceutical Bundling: Evidence from India","year":2022,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"","keywords":"Business; Economics","score_opus":0.04066466494971812,"score_gpt":0.29435463163979986,"score_spread":0.25368996669008176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225984271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.947188,0.044863585,0.0015234232,0.0027288578,0.0011177224,0.00019939756,0.00009357702,0.000023217863,0.002262224],"genre_scores_gemma":[0.9917573,0.0063602314,0.000060507376,0.0011121441,0.00037396984,0.000018535704,0.000005614782,0.00003300267,0.0002787417],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9971008,0.000080917576,0.00074114,0.0003296004,0.00007996974,0.0016675945],"domain_scores_gemma":[0.99871755,0.00036865525,0.00047981463,0.00023351319,0.000019664365,0.00018077996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019809708,0.00017106757,0.0004407871,0.00022982246,0.00016072964,0.000047944235,0.00064229465,0.000058537255,0.0008484966],"category_scores_gemma":[0.00023045987,0.00020854258,0.00023698957,0.00024543353,0.00006984609,0.00026174934,0.0002597711,0.002177677,0.00014036309],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003238167,0.0004627573,0.04656676,0.000064208994,0.00081256987,0.000020687978,0.0007360125,0.0007067768,0.0040265797,0.9376301,0.0010651745,0.00758455],"study_design_scores_gemma":[0.0019708637,0.0006108685,0.0033716925,0.000026477248,0.00005470595,0.000120115976,0.0001605162,0.0050968644,0.0025120755,0.94372076,0.041892454,0.00046258376],"about_ca_topic_score_codex":0.00015273604,"about_ca_topic_score_gemma":0.000011015716,"teacher_disagreement_score":0.044569258,"about_ca_system_score_codex":0.0010637793,"about_ca_system_score_gemma":0.00063047203,"threshold_uncertainty_score":0.94610435},"labels":[],"label_agreement":null},{"id":"W4226081173","doi":"10.1093/ajhp/zxac102","title":"National trends in prescription drug expenditures and projections for 2022","year":2022,"lang":"en","type":"article","venue":"American Journal of Health-System Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Drug Policy Research Network; St. Michael's Hospital","funders":"","keywords":"Medical prescription; Biosimilar; Prescription drug; Specialty; Business; Legislation; Drug; Medicine; Family medicine; Pharmacology; Political science","score_opus":0.0760131426806438,"score_gpt":0.3648791130348588,"score_spread":0.288865970354215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226081173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8030615,0.021154648,0.0016403199,0.15437397,0.005027459,0.0013739369,0.002900388,0.000058879436,0.010408913],"genre_scores_gemma":[0.99690825,0.00030352979,0.00025408773,0.0019916017,0.00023601398,0.00011647512,0.000012634805,0.000018957871,0.0001584797],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981961,0.00012738617,0.0011282824,0.00020427376,0.000071070914,0.000272839],"domain_scores_gemma":[0.99837685,0.000096712305,0.0012838977,0.000070942566,0.000032469794,0.00013912436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002240848,0.000109108856,0.00048949494,0.0008749103,0.0002675036,0.00003607839,0.00017505694,0.000008198412,0.00018850369],"category_scores_gemma":[0.000022177333,0.00012841825,0.00012048928,0.00028783607,0.000050268518,0.00021786928,0.000049406408,0.00029213887,0.0000036621766],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016884314,0.0013277614,0.06879269,0.00054665364,0.0005478564,0.000022166509,0.010490847,0.007529322,0.00017240371,0.2930247,0.24786842,0.36798877],"study_design_scores_gemma":[0.0028225335,0.0003859778,0.0052829855,0.000016095746,0.000007084187,0.00022847268,0.0016614371,0.015418271,0.000016433269,0.0024745848,0.9714745,0.00021158361],"about_ca_topic_score_codex":0.0008894904,"about_ca_topic_score_gemma":0.000028492263,"teacher_disagreement_score":0.7236061,"about_ca_system_score_codex":0.00071779446,"about_ca_system_score_gemma":0.0001610242,"threshold_uncertainty_score":0.5236744},"labels":[],"label_agreement":null},{"id":"W4226174514","doi":"10.2139/ssrn.4076263","title":"Does Entry Remedy Collusion? Evidence from the Generic Prescription Drug Cartel","year":2022,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"","keywords":"Cartel; Collusion; Business; Medical prescription; Drug; Pharmacology; Industrial organization; Medicine","score_opus":0.03313510832817863,"score_gpt":0.2545927019690797,"score_spread":0.22145759364090106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226174514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93435436,0.03166679,0.0007936771,0.028779693,0.0023292366,0.00027310144,0.00020748394,0.00002826291,0.0015673712],"genre_scores_gemma":[0.96964127,0.023183566,0.000027740287,0.0031641815,0.00076280447,0.000035528457,0.0000092488735,0.000025362398,0.0031502915],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9976347,0.00011001072,0.0005570541,0.00032523333,0.000078356476,0.0012946485],"domain_scores_gemma":[0.99903226,0.00014967828,0.0003879766,0.00030871836,0.000017601831,0.0001037752],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0025066242,0.00014903098,0.0002446577,0.00008825749,0.00083820283,0.00013248097,0.0007109126,0.000035981,0.001190723],"category_scores_gemma":[0.00010556517,0.00010863633,0.00017270785,0.00020215492,0.0000474342,0.00027046917,0.00024176057,0.0017221086,0.00016709931],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041736508,0.00039493004,0.17340605,0.000014275596,0.00086412474,0.000014772017,0.005113435,0.0035560024,0.0010798835,0.7390193,0.060037874,0.016082048],"study_design_scores_gemma":[0.00068864034,0.00010636154,0.007954301,0.000009448414,0.000027347318,0.000058793674,0.0011136596,0.0042887977,0.00006208401,0.6609214,0.32446635,0.00030281272],"about_ca_topic_score_codex":0.0012821293,"about_ca_topic_score_gemma":0.0011410455,"teacher_disagreement_score":0.26442847,"about_ca_system_score_codex":0.0015871682,"about_ca_system_score_gemma":0.00046730213,"threshold_uncertainty_score":0.9997223},"labels":[],"label_agreement":null},{"id":"W4226227114","doi":"10.1201/9781003063858-2","title":"Canadian Public Policies and Practices Related to Drug Prices, Utilization and Expenditures","year":2022,"lang":"en","type":"book-chapter","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Drug; Public economics; Economics; Medicine; Pharmacology","score_opus":0.11506167346968993,"score_gpt":0.3141541879059953,"score_spread":0.19909251443630538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226227114","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021380156,0.009182787,0.0000024741316,0.035991807,0.00028110668,0.0003502892,0.0007169755,0.000034536355,0.951302],"genre_scores_gemma":[0.19294424,0.034548264,0.00024104599,0.021678893,0.00029771216,0.00007312517,0.0004499523,0.00018771499,0.7495791],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99855226,0.0000071351287,0.0005280153,0.0005393191,0.00002976355,0.0003434803],"domain_scores_gemma":[0.9985117,0.00008449861,0.0005702493,0.0002450204,0.000015697102,0.0005728586],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036417236,0.00025732283,0.00041563064,0.0008507339,0.0002730709,0.00031210555,0.0001993165,0.0001832667,0.009103142],"category_scores_gemma":[0.000092758244,0.00031429896,0.000050714483,0.000048162783,0.00005511797,0.00035777592,0.00020136866,0.00033826515,0.00024812107],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000030846477,0.000005188645,0.0006929691,0.00002006547,0.00006849684,0.0000028719344,0.00030817447,0.0000015310412,1.8326668e-7,0.9819471,0.015346254,0.0016040632],"study_design_scores_gemma":[0.00013964609,0.000021237563,0.00053171255,0.0000052293417,0.00000957373,0.000011881382,0.00003802822,0.0001907707,9.2865866e-7,0.09613163,0.9025831,0.00033624694],"about_ca_topic_score_codex":0.053238954,"about_ca_topic_score_gemma":0.07830231,"teacher_disagreement_score":0.88723683,"about_ca_system_score_codex":0.00029491406,"about_ca_system_score_gemma":0.00012674634,"threshold_uncertainty_score":0.9999309},"labels":[],"label_agreement":null},{"id":"W4229027994","doi":"10.5539/gjhs.v14n5p1","title":"Drug Shortages and Its Effects on Service Delivery among Key Informants (KIs) in Fiji","year":2022,"lang":"en","type":"article","venue":"Global Journal of Health Science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Economic shortage; Pharmacy; Workload; Family medicine; Emergency medicine; Environmental health; Medical emergency","score_opus":0.036927977399999944,"score_gpt":0.31321879633767535,"score_spread":0.27629081893767543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229027994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904321,0.002373166,0.0000027681365,0.004056559,0.0005752232,0.00013120822,0.000059321228,0.000003855864,0.0023658331],"genre_scores_gemma":[0.99019873,0.00077260815,0.00004080006,0.00892464,0.000045691755,0.0000031199866,5.1881665e-7,0.0000037041941,0.000010195352],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99848247,0.000023280725,0.0007593334,0.00019711899,0.00011014276,0.00042767104],"domain_scores_gemma":[0.99895054,0.000046793317,0.0005765503,0.000102992,0.00003807749,0.0002850398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002603901,0.000098245764,0.00033102062,0.00030253653,0.00029304685,0.00006995912,0.00048477846,0.000018749384,0.000041025083],"category_scores_gemma":[0.000058877387,0.000106549174,0.000039226677,0.00066983374,0.000059079626,0.0005869271,0.00021132336,0.00029769447,0.000029303355],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011742307,0.0001733983,0.9027124,0.00020483285,0.00001933869,0.000046193374,0.0009423399,0.0052285083,0.00001587838,0.07301308,0.00193787,0.015588738],"study_design_scores_gemma":[0.0010935559,0.00031928968,0.9633999,0.00006207386,0.000002030139,0.000102400794,0.00013693536,0.013999395,0.000053977656,0.0060955244,0.01452188,0.00021305986],"about_ca_topic_score_codex":0.00028150642,"about_ca_topic_score_gemma":0.00006138886,"teacher_disagreement_score":0.06691755,"about_ca_system_score_codex":0.0005455631,"about_ca_system_score_gemma":0.00026887833,"threshold_uncertainty_score":0.4344949},"labels":[],"label_agreement":null},{"id":"W4229374356","doi":"10.1016/j.jsxm.2022.03.427","title":"156 Direct-To-Consumer vs. Traditional Prescriptions of PDE5 Inhibitors: A Contemporary Cost-Analysis","year":2022,"lang":"en","type":"article","venue":"The Journal of Sexual Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Pharmacy; Reimbursement; Family medicine; Medicine; Business; Telehealth; Health care; Telemedicine; Nursing; Political science","score_opus":0.1618433259708692,"score_gpt":0.3099797790188621,"score_spread":0.1481364530479929,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229374356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87953717,0.012161765,0.00089091447,0.064689204,0.0020485152,0.00058221456,0.0017710542,0.000015533702,0.038303625],"genre_scores_gemma":[0.99469984,0.0001562317,0.00004105561,0.003987056,0.0005293708,0.000013391718,0.000014493183,0.0000136780445,0.00054489775],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981945,0.000090983194,0.0012714594,0.00013932858,0.00012302726,0.00018068917],"domain_scores_gemma":[0.99821836,0.0003663114,0.00090730534,0.00023279266,0.00006730039,0.00020795374],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002318532,0.00012265344,0.00072273664,0.0006841465,0.00014869888,0.000009437961,0.0004142327,0.000029821611,0.00278487],"category_scores_gemma":[0.00022355255,0.00009828693,0.00008666781,0.0006688418,0.00017211273,0.00012714033,0.00008578738,0.0003884196,0.00002645531],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002190123,0.0015234266,0.027451394,0.00011782275,0.008841212,0.00004267461,0.01683004,0.016413122,0.006222477,0.07526508,0.84237313,0.002729499],"study_design_scores_gemma":[0.004261523,0.0049068723,0.027926201,0.000043054362,0.0012751317,0.00014316197,0.002234008,0.0038504535,0.0002717449,0.018886747,0.9357212,0.00047987798],"about_ca_topic_score_codex":0.0002941147,"about_ca_topic_score_gemma":0.000010366892,"teacher_disagreement_score":0.115162656,"about_ca_system_score_codex":0.00012286403,"about_ca_system_score_gemma":0.000075466975,"threshold_uncertainty_score":0.99812675},"labels":[],"label_agreement":null},{"id":"W4229757230","doi":"10.1037/e306002005-001","title":"Rx Depot Agrees to Stop Importing Unapproved Drugs from Canada","year":2004,"lang":"en","type":"dataset","venue":"PsycEXTRA Dataset","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Depot; Business; Political science; Law","score_opus":0.04287161131428772,"score_gpt":0.28501746107081166,"score_spread":0.24214584975652395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229757230","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012386361,0.001115954,0.000027406879,0.0026396168,0.0016413365,0.00048745106,0.99234885,0.00002615443,0.00047458592],"genre_scores_gemma":[0.0009505558,0.00050123467,0.00029701443,0.01796489,0.000898655,0.0000750604,0.97921234,0.00006505549,0.000035193687],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956339,0.000024947665,0.0017940133,0.0014290083,0.00011359247,0.0010045146],"domain_scores_gemma":[0.99613935,0.00015924934,0.0010079357,0.0018625793,0.000022071808,0.0008088157],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00049226684,0.0006832106,0.0011990025,0.0003051886,0.00018782166,0.00027557134,0.0016524621,0.00036882586,0.0032474834],"category_scores_gemma":[0.00024322026,0.0008449593,0.0001668627,0.0002873941,0.00006639225,0.00021902299,0.00048886094,0.0008109061,0.003338963],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000299259,0.000091994065,0.0000937969,0.00007734711,0.00018748887,0.00004524023,0.0000276334,0.00006951233,0.0000024930243,0.0005073425,0.9985127,0.00035453326],"study_design_scores_gemma":[0.0007072548,0.0000314843,0.00027720377,0.000047818456,0.000046053392,0.0000052409305,0.000020666073,0.000056838246,0.000023416545,0.003617072,0.99415505,0.0010119271],"about_ca_topic_score_codex":0.8925975,"about_ca_topic_score_gemma":0.6352048,"teacher_disagreement_score":0.2573927,"about_ca_system_score_codex":0.00080231787,"about_ca_system_score_gemma":0.00066542765,"threshold_uncertainty_score":0.99940014},"labels":[],"label_agreement":null},{"id":"W4230018298","doi":"10.1111/j.1538-7836.2007.02673.x","title":"TALKING ABOUT…","year":2007,"lang":"en","type":"article","venue":"Journal of Thrombosis and Haemostasis","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"World Federation of Science Journalists","funders":"","keywords":"Medicine","score_opus":0.11837957648128075,"score_gpt":0.3458084260836932,"score_spread":0.22742884960241247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230018298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95445937,0.005883574,0.0021520273,0.0045673335,0.0006472125,0.00006486728,0.000048411275,0.000007885032,0.03216935],"genre_scores_gemma":[0.9920368,0.004017517,0.0014516655,0.0021224655,0.00031145805,3.6064765e-7,6.528877e-7,0.000015183831,0.00004384997],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99874055,0.0000059642684,0.00083609816,0.00013039602,0.00003173351,0.00025524493],"domain_scores_gemma":[0.998973,0.00008104157,0.00059330085,0.00010903558,0.000039415012,0.0002042083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013360386,0.00010688684,0.00042705366,0.00024178173,0.000089516034,0.00008214902,0.0001513922,0.000072185074,0.0003879041],"category_scores_gemma":[0.000067965506,0.000107344385,0.00015769154,0.00012138949,0.00006458205,0.00024903833,0.000047452475,0.00018978624,0.00005493178],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019046551,0.00044328734,0.22608581,0.00012426016,0.0010549461,0.000039227132,0.0023516498,0.00003987013,0.0006390463,0.6163284,0.033419196,0.119283795],"study_design_scores_gemma":[0.0018229749,0.00020531677,0.28147998,0.00005860953,0.0000502578,0.000085725645,0.00020357888,0.00026135924,0.0017088578,0.05760071,0.65612483,0.00039778053],"about_ca_topic_score_codex":0.00003157278,"about_ca_topic_score_gemma":0.0000071825593,"teacher_disagreement_score":0.62270564,"about_ca_system_score_codex":0.000061848354,"about_ca_system_score_gemma":0.000013173021,"threshold_uncertainty_score":0.4377377},"labels":[],"label_agreement":null},{"id":"W4230131359","doi":"10.3821/1913-701x-143.5.209","title":"BC Deal Lowers Generic Drug Prices and Increases Reimbursement to Pharmacy","year":2010,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Reimbursement; Pharmacy; Drug; Drug prices; Medicine; Business; Generic drug; Family medicine; Pharmacology; Monetary economics; Economics; Health care","score_opus":0.04552413883228632,"score_gpt":0.26972190635796794,"score_spread":0.22419776752568163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230131359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848782,0.0015593295,0.000058737933,0.0015356275,0.0029578991,0.00041434038,0.0011959828,0.00002971673,0.0073701795],"genre_scores_gemma":[0.97609675,0.0056585474,0.0007066115,0.015199535,0.00157152,0.000034781224,0.00002233941,0.00008054504,0.0006293897],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99671113,0.000042944514,0.0010343774,0.0006992038,0.00011985799,0.0013924988],"domain_scores_gemma":[0.9940292,0.00010560462,0.00041036215,0.00031034555,0.00016331916,0.004981132],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010274082,0.00047864695,0.00060030643,0.00073458196,0.0008479387,0.00048586767,0.000827437,0.00006210299,0.0030832712],"category_scores_gemma":[0.00016519449,0.00058645353,0.00016181929,0.0005440802,0.00020984416,0.0005330803,0.00012341712,0.00097352086,0.00016651774],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006027749,0.0005795523,0.15524131,0.0007525653,0.001820555,0.036855854,0.005932731,0.0028576467,0.011757617,0.030070484,0.49251625,0.26101264],"study_design_scores_gemma":[0.0021055152,0.00002992014,0.00031868645,0.0000090741205,0.00006175601,0.041823186,0.000009863634,0.005347126,0.0015150609,0.0011697257,0.94659114,0.0010189299],"about_ca_topic_score_codex":0.12733616,"about_ca_topic_score_gemma":0.16736315,"teacher_disagreement_score":0.45407492,"about_ca_system_score_codex":0.0012520305,"about_ca_system_score_gemma":0.0015111177,"threshold_uncertainty_score":0.9996587},"labels":[],"label_agreement":null},{"id":"W4232172019","doi":"10.1002/div.5471","title":"Abbott Laboratories","year":2007,"lang":"en","type":"article","venue":"Mergent s Dividend Achievers","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Joint venture; Product line; Business; Commerce; Manufacturing engineering; Engineering","score_opus":0.049215644571057454,"score_gpt":0.28248594109782005,"score_spread":0.2332702965267626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232172019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8199184,0.0036050023,0.0034447452,0.005623796,0.0035137753,0.00025205428,0.00037730494,0.00014076669,0.16312416],"genre_scores_gemma":[0.9943347,0.0003990131,0.00036698245,0.0031408793,0.00037227361,0.000006389079,0.000015975884,0.000029322891,0.0013344928],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99849904,0.000008115415,0.0005879933,0.00035033206,0.00003818359,0.00051632605],"domain_scores_gemma":[0.99918264,0.000055518667,0.00018622068,0.00028445202,0.000019761712,0.00027140617],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0009331305,0.00017221938,0.00029120964,0.00018264506,0.00013604863,0.000063449996,0.0002848731,0.000091669266,0.0019501016],"category_scores_gemma":[0.000107316126,0.00020479968,0.00013025828,0.0002918579,0.00007319325,0.00026710515,0.00008697385,0.00018372803,0.0029181135],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003685065,0.00010815492,0.16563077,0.000021625166,0.00012307763,0.00001249743,0.00035928542,0.00003986746,0.00021696147,0.8075473,0.024361152,0.0015424698],"study_design_scores_gemma":[0.00043495683,0.00002776315,0.040047638,0.000004126193,0.00000712416,0.0000015144267,0.000056282424,0.00011141971,0.0013052279,0.02431906,0.9333634,0.00032149372],"about_ca_topic_score_codex":0.00013851057,"about_ca_topic_score_gemma":0.000052807467,"teacher_disagreement_score":0.90900224,"about_ca_system_score_codex":0.000106421234,"about_ca_system_score_gemma":0.000017569197,"threshold_uncertainty_score":0.9989622},"labels":[],"label_agreement":null},{"id":"W4232524019","doi":"10.2165/00128415-201213950-00011","title":"Apotex Inc. is recalling one lot of ramipril [Apo-Ramipril] 5mg capsules from retail outlets across Canada,","year":2012,"lang":"en","type":"article","venue":"Reactions Weekly","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ramipril; Business; Medicine; Internal medicine","score_opus":0.10349865834339776,"score_gpt":0.2879434823452813,"score_spread":0.1844448240018835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232524019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9600247,0.002700473,0.0006218306,0.0061752633,0.0012606004,0.00021022743,0.0038722937,0.000045136105,0.025089443],"genre_scores_gemma":[0.99362534,0.0009861084,0.00071342883,0.0015802984,0.0005978931,0.00001616567,0.00009651636,0.00004841502,0.0023358266],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99781495,0.000022959195,0.0010131822,0.0003990757,0.00006779583,0.00068201235],"domain_scores_gemma":[0.99829286,0.00018533964,0.00054286467,0.0005679331,0.000056367506,0.00035462316],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0005223424,0.00023457929,0.0006052768,0.0000947985,0.00020210448,0.000064606946,0.00031631833,0.00020254536,0.0018039229],"category_scores_gemma":[0.00015789337,0.00029949404,0.00015041197,0.00021572184,0.00010514961,0.00038603978,0.00011556449,0.0003858037,0.00092022197],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046895357,0.0047544334,0.3044417,0.0007569551,0.0045764516,0.000021932909,0.014385065,0.0017550322,0.016119774,0.38778442,0.16244179,0.102493495],"study_design_scores_gemma":[0.0006115867,0.00002267159,0.03911731,0.000027837032,0.000027029437,0.0000039410243,0.00020967177,0.0027954,0.0027524512,0.0037056191,0.95027417,0.00045230307],"about_ca_topic_score_codex":0.509839,"about_ca_topic_score_gemma":0.04654761,"teacher_disagreement_score":0.7878324,"about_ca_system_score_codex":0.0004924064,"about_ca_system_score_gemma":0.00012124002,"threshold_uncertainty_score":0.9999457},"labels":[],"label_agreement":null},{"id":"W4233594955","doi":"10.1201/9780429155826","title":"Economic Evaluation of Cancer Drugs","year":2019,"lang":"en","type":"book","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; Cancer drugs; Medicine; Internal medicine","score_opus":0.10319243788967612,"score_gpt":0.3505644891733145,"score_spread":0.24737205128363837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233594955","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002050778,0.0073115746,0.000009039732,0.00053879217,0.0014637881,0.0005045542,0.0017145261,0.000016818114,0.9863901],"genre_scores_gemma":[0.027938105,0.002826123,0.00003850198,0.0012345441,0.00066916493,0.00006623866,0.00014575035,0.000089226,0.9669923],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981308,0.000012302815,0.0010346668,0.0005103331,0.000048471695,0.00026344333],"domain_scores_gemma":[0.99834245,0.00006682081,0.00093452627,0.0005050576,0.00005550007,0.00009566145],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0011260434,0.00026143782,0.00086058077,0.00031519044,0.000022662525,0.000032522992,0.00034842963,0.000333515,0.03153043],"category_scores_gemma":[0.000017780283,0.0003220636,0.00030133416,0.000027436152,0.000065434564,0.00011943757,0.00009330195,0.00023376307,0.009518479],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008627293,0.000018795243,0.00057566754,0.00010027465,0.00027746052,6.450019e-8,0.00008711638,0.0009922201,9.683813e-7,0.83199346,0.16053759,0.0054077734],"study_design_scores_gemma":[0.0006990422,0.000017180862,0.0001789691,0.000029434927,0.000064626365,2.2373847e-7,0.0000028587156,0.018204033,0.000035702556,0.20056191,0.77985555,0.00035046524],"about_ca_topic_score_codex":0.00047025207,"about_ca_topic_score_gemma":0.00011720786,"teacher_disagreement_score":0.6314315,"about_ca_system_score_codex":0.0013544153,"about_ca_system_score_gemma":0.00074819574,"threshold_uncertainty_score":0.99992317},"labels":[],"label_agreement":null},{"id":"W4234163504","doi":"10.1007/bf03267040","title":"Canada's health system restricts drug access","year":2000,"lang":"en","type":"article","venue":"PharmacoEconomics & Outcomes News","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quality of Life Research; Public health; Drug; Health economics; Business; Environmental health; Medicine; Pharmacology; Nursing","score_opus":0.05204346335349221,"score_gpt":0.34481938233646964,"score_spread":0.29277591898297745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234163504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4669187,0.005010622,0.000075225274,0.22799346,0.0045784097,0.0015540117,0.00409961,0.00038532796,0.28938463],"genre_scores_gemma":[0.84214646,0.0025850064,0.00015440218,0.14820977,0.000527664,0.00008519354,0.00006616832,0.0001122645,0.0061130947],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958774,0.000057521323,0.001960968,0.000918762,0.00005492444,0.001130411],"domain_scores_gemma":[0.99750656,0.00017730081,0.0007220483,0.0007108476,0.000020124351,0.0008631233],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00066582696,0.0005016398,0.0013350942,0.00026414395,0.00031675037,0.00035020793,0.0012520537,0.00008824339,0.0043838294],"category_scores_gemma":[0.000025469832,0.00060388027,0.0003054431,0.0002364215,0.000051944076,0.0006392839,0.00017309966,0.00043717874,0.0027237812],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008212475,0.00015879015,0.06761753,0.00020510363,0.00045215592,0.000024853365,0.00024748305,0.0027196493,0.0000023402147,0.12089738,0.7862963,0.021296259],"study_design_scores_gemma":[0.0016828082,0.000013613574,0.009542703,0.0000120099585,0.000014989807,0.000012306358,0.00003428415,0.006622483,0.000043736512,0.0018434504,0.9795212,0.00065639475],"about_ca_topic_score_codex":0.7155321,"about_ca_topic_score_gemma":0.22920483,"teacher_disagreement_score":0.4863273,"about_ca_system_score_codex":0.0017849773,"about_ca_system_score_gemma":0.0008503885,"threshold_uncertainty_score":0.99964124},"labels":[],"label_agreement":null},{"id":"W4234596508","doi":"10.2165/00151234-200504830-00043","title":"Trastuzumab to be provided free in British Columbia","year":2005,"lang":"en","type":"article","venue":"PharmacoEconomics & Outcomes News","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quality of Life Research; Public health; Medicine","score_opus":0.04803241967852492,"score_gpt":0.3218295073160283,"score_spread":0.2737970876375034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234596508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8955699,0.00063333276,0.00010655839,0.07243314,0.00096509774,0.0010581549,0.0013544101,0.000119271346,0.027760139],"genre_scores_gemma":[0.8397127,0.0004543648,0.0015917799,0.15306328,0.0004950543,0.0002276368,0.00003175647,0.00011216015,0.004311257],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99597645,0.000030053303,0.0018276768,0.0009996908,0.000041056763,0.0011250693],"domain_scores_gemma":[0.998058,0.00015095896,0.0003827513,0.0007096353,0.000021313565,0.0006773129],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00074510346,0.00032781268,0.0011420328,0.00032094854,0.0001383813,0.000773762,0.0011099117,0.00015972326,0.004778081],"category_scores_gemma":[0.00018523357,0.0006319182,0.00034334304,0.00025437598,0.000039866063,0.00073225657,0.00035840785,0.0004515028,0.0027490174],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000648445,0.00086426723,0.5451635,0.0000662215,0.00033906425,0.000031398693,0.0013432606,0.0030901646,0.000091553884,0.01824784,0.3912028,0.039495032],"study_design_scores_gemma":[0.0039913524,0.00004618854,0.042504977,0.000008603437,0.000015531445,0.000013726304,0.00006512801,0.005641128,0.000054987773,0.009622189,0.9371986,0.0008376246],"about_ca_topic_score_codex":0.03459939,"about_ca_topic_score_gemma":0.2510622,"teacher_disagreement_score":0.5459958,"about_ca_system_score_codex":0.0009177133,"about_ca_system_score_gemma":0.00010720617,"threshold_uncertainty_score":0.9996132},"labels":[],"label_agreement":null},{"id":"W4235067815","doi":"10.1002/div.6224","title":"Abbott Laboratories","year":2007,"lang":"en","type":"article","venue":"Mergent s Dividend Achievers","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Joint venture; Medical prescription; Business; Commerce; Pharmacology","score_opus":0.049215644571057454,"score_gpt":0.28248594109782005,"score_spread":0.2332702965267626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235067815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8199184,0.0036050023,0.0034447452,0.005623796,0.0035137753,0.00025205428,0.00037730494,0.00014076669,0.16312416],"genre_scores_gemma":[0.9943347,0.0003990131,0.00036698245,0.0031408793,0.00037227361,0.000006389079,0.000015975884,0.000029322891,0.0013344928],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99849904,0.000008115415,0.0005879933,0.00035033206,0.00003818359,0.00051632605],"domain_scores_gemma":[0.99918264,0.000055518667,0.00018622068,0.00028445202,0.000019761712,0.00027140617],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0009331305,0.00017221938,0.00029120964,0.00018264506,0.00013604863,0.000063449996,0.0002848731,0.000091669266,0.0019501016],"category_scores_gemma":[0.000107316126,0.00020479968,0.00013025828,0.0002918579,0.00007319325,0.00026710515,0.00008697385,0.00018372803,0.0029181135],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003685065,0.00010815492,0.16563077,0.000021625166,0.00012307763,0.00001249743,0.00035928542,0.00003986746,0.00021696147,0.8075473,0.024361152,0.0015424698],"study_design_scores_gemma":[0.00043495683,0.00002776315,0.040047638,0.000004126193,0.00000712416,0.0000015144267,0.000056282424,0.00011141971,0.0013052279,0.02431906,0.9333634,0.00032149372],"about_ca_topic_score_codex":0.00013851057,"about_ca_topic_score_gemma":0.000052807467,"teacher_disagreement_score":0.90900224,"about_ca_system_score_codex":0.000106421234,"about_ca_system_score_gemma":0.000017569197,"threshold_uncertainty_score":0.9989622},"labels":[],"label_agreement":null},{"id":"W4235233362","doi":"10.1111/j.1538-7836.2007.02416.x","title":"TALKING ABOUT…","year":2007,"lang":"en","type":"article","venue":"Journal of Thrombosis and Haemostasis","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"World Federation of Science Journalists","funders":"","keywords":"Chagas disease; Food and drug administration; Medicine; Test (biology); Disease; Virology; Environmental health; Biology; Pathology","score_opus":0.11837957648128075,"score_gpt":0.3458084260836932,"score_spread":0.22742884960241247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235233362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95445937,0.005883574,0.0021520273,0.0045673335,0.0006472125,0.00006486728,0.000048411275,0.000007885032,0.03216935],"genre_scores_gemma":[0.9920368,0.004017517,0.0014516655,0.0021224655,0.00031145805,3.6064765e-7,6.528877e-7,0.000015183831,0.00004384997],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99874055,0.0000059642684,0.00083609816,0.00013039602,0.00003173351,0.00025524493],"domain_scores_gemma":[0.998973,0.00008104157,0.00059330085,0.00010903558,0.000039415012,0.0002042083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013360386,0.00010688684,0.00042705366,0.00024178173,0.000089516034,0.00008214902,0.0001513922,0.000072185074,0.0003879041],"category_scores_gemma":[0.000067965506,0.000107344385,0.00015769154,0.00012138949,0.00006458205,0.00024903833,0.000047452475,0.00018978624,0.00005493178],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019046551,0.00044328734,0.22608581,0.00012426016,0.0010549461,0.000039227132,0.0023516498,0.00003987013,0.0006390463,0.6163284,0.033419196,0.119283795],"study_design_scores_gemma":[0.0018229749,0.00020531677,0.28147998,0.00005860953,0.0000502578,0.000085725645,0.00020357888,0.00026135924,0.0017088578,0.05760071,0.65612483,0.00039778053],"about_ca_topic_score_codex":0.00003157278,"about_ca_topic_score_gemma":0.0000071825593,"teacher_disagreement_score":0.62270564,"about_ca_system_score_codex":0.000061848354,"about_ca_system_score_gemma":0.000013173021,"threshold_uncertainty_score":0.4377377},"labels":[],"label_agreement":null},{"id":"W4235376273","doi":"10.21518/1561-5936-2014-1-2-93-98","title":"Steps to success: changes in the ranking of pharmaceutical producers in the III quarter of 2013","year":2014,"lang":"en","type":"article","venue":"Remedium Journal about the Russian market of medicines and medical equipment","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Ranking (information retrieval); Business; Marketing; Operations management; Computer science; Economics; Information retrieval; Geography","score_opus":0.03101080426950721,"score_gpt":0.3016633879560541,"score_spread":0.2706525836865469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235376273","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.43145624,0.006305229,0.00031983215,0.5440701,0.0008219159,0.00074399123,0.000015611984,0.000003120487,0.016263923],"genre_scores_gemma":[0.98050225,0.009286528,0.000035061137,0.0095259175,0.0005950935,0.000020940219,0.0000010295221,0.000009652745,0.000023528919],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974673,0.00028399963,0.0012896762,0.00021294125,0.0003467439,0.00039937097],"domain_scores_gemma":[0.9981665,0.0007942877,0.00050545606,0.0002797497,0.000022466029,0.0002315654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014420548,0.00016913653,0.0006525012,0.00026280587,0.00006543844,0.000022984606,0.0008303053,0.00009301969,0.00058467133],"category_scores_gemma":[0.00060705777,0.000084687555,0.000094985546,0.0003037847,0.0003954144,0.00006000922,0.0000949051,0.00058588514,0.0000024957835],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003685636,0.0028558867,0.12582946,0.003216621,0.000901242,0.00012010545,0.09460427,0.00015394948,0.0006039479,0.39076832,0.10814513,0.26911545],"study_design_scores_gemma":[0.016793787,0.002143057,0.25246066,0.003704149,0.00020331475,0.0004311691,0.008326627,0.02318191,0.0005288185,0.040961467,0.6504457,0.0008193117],"about_ca_topic_score_codex":0.0001645587,"about_ca_topic_score_gemma":0.00014902384,"teacher_disagreement_score":0.54904604,"about_ca_system_score_codex":0.000036929996,"about_ca_system_score_gemma":0.00006602814,"threshold_uncertainty_score":0.6401741},"labels":[],"label_agreement":null},{"id":"W4235698704","doi":"10.3821/1913-701x-144.6.254","title":"BC Government Re-Opens Talks on Generic Drug Pricing Because Promised Savings Fall Short","year":2011,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Drug pricing; Government (linguistics); Drug; Business; Law and economics; Operations research; Economics; Engineering; Actuarial science; Medicine; Philosophy; Pharmacology","score_opus":0.10920721802770139,"score_gpt":0.2542881119863801,"score_spread":0.14508089395867874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235698704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9264481,0.00076417305,0.00006585494,0.00042117556,0.0027366881,0.00060215214,0.0015762135,0.000036749858,0.067348905],"genre_scores_gemma":[0.982341,0.0031878625,0.00024791207,0.011037614,0.00087755505,0.000041028085,0.000020181777,0.00012054937,0.002126321],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960209,0.00007080579,0.0013292452,0.000787687,0.00019706947,0.0015942643],"domain_scores_gemma":[0.9956524,0.000078134515,0.0005315739,0.00046121285,0.000120997334,0.0031557085],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010697079,0.0005739417,0.00073566724,0.00040176793,0.0008038373,0.0002943819,0.0010962606,0.00009976067,0.0030490367],"category_scores_gemma":[0.00015179464,0.0006920547,0.00028441622,0.0004649031,0.00017243318,0.0005163417,0.000104415514,0.0009737619,0.00023261095],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017504375,0.0017286701,0.14508565,0.0013212959,0.004385549,0.12305191,0.0316554,0.0059541725,0.004065541,0.035366006,0.4711691,0.17446625],"study_design_scores_gemma":[0.005595153,0.00023325384,0.0009793652,0.00007887342,0.00022913754,0.047456656,0.00006674156,0.018710075,0.011497621,0.0031366234,0.90838706,0.0036294458],"about_ca_topic_score_codex":0.050831538,"about_ca_topic_score_gemma":0.088255,"teacher_disagreement_score":0.43721795,"about_ca_system_score_codex":0.005868123,"about_ca_system_score_gemma":0.0011617284,"threshold_uncertainty_score":0.9995531},"labels":[],"label_agreement":null},{"id":"W4236816095","doi":"10.1002/div.5059","title":"Abbott Laboratories","year":2006,"lang":"en","type":"article","venue":"Mergent s Dividend Achievers","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Joint venture; Business; Commerce","score_opus":0.0318628504712109,"score_gpt":0.24495603045411096,"score_spread":0.21309317998290006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236816095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78003985,0.004765696,0.0007912082,0.009056991,0.0025563047,0.00024854054,0.0007480322,0.00015633258,0.20163703],"genre_scores_gemma":[0.9946649,0.00026381528,0.00024339884,0.001632584,0.00046469725,0.000017628443,0.000036875048,0.000029181903,0.0026468893],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986858,0.000011495927,0.0005207013,0.00034914332,0.000033673747,0.0003992108],"domain_scores_gemma":[0.9993798,0.00002894419,0.00017688757,0.0002673352,0.00001662058,0.00013040296],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00029405789,0.00017216902,0.0002920001,0.00013462115,0.00013431034,0.000088449786,0.00025449725,0.000078035824,0.002024371],"category_scores_gemma":[0.000040831925,0.00020457456,0.00013168887,0.00023759635,0.00006848927,0.000267495,0.000074237876,0.00014199503,0.002999903],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010262237,0.00008931605,0.1221276,0.0000141825385,0.00004849329,0.0000042674314,0.00005529378,0.00019062457,0.00012703887,0.8130136,0.064115375,0.00020390916],"study_design_scores_gemma":[0.0004085727,0.000017794138,0.03409641,0.0000033653298,0.000007059978,9.992194e-7,0.000013809973,0.00033194266,0.00063250144,0.07435118,0.8898377,0.00029866234],"about_ca_topic_score_codex":0.00060921744,"about_ca_topic_score_gemma":0.000061583596,"teacher_disagreement_score":0.82572234,"about_ca_system_score_codex":0.00008664277,"about_ca_system_score_gemma":0.000017916293,"threshold_uncertainty_score":0.9988879},"labels":[],"label_agreement":null},{"id":"W4236823326","doi":"10.3821/1913-701x(2007)140[354:baapsi]2.0.co;2","title":"BC and Alberta pharmacists seek input into joint buying strategy","year":2007,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Joint (building); Marketing; Business; Advertising; Engineering","score_opus":0.06874095744618008,"score_gpt":0.2767010859288065,"score_spread":0.2079601284826264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236823326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9440075,0.00530682,0.00070202997,0.00083198707,0.0037307986,0.0005344228,0.00069963036,0.000042713567,0.04414409],"genre_scores_gemma":[0.98044616,0.008113114,0.00021831352,0.00842731,0.0013805883,0.000011666747,0.000031034986,0.00010665983,0.0012651739],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954462,0.00006121962,0.0016677238,0.00079609564,0.00013574692,0.0018929944],"domain_scores_gemma":[0.9941659,0.00019319092,0.00064862514,0.00033194956,0.00019723982,0.0044630766],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019582056,0.0006034196,0.00081646926,0.0009101112,0.0011017064,0.00052457023,0.00071074866,0.00014437884,0.0023256275],"category_scores_gemma":[0.00024003933,0.00075997354,0.00022876062,0.0006160847,0.00032864246,0.00076576864,0.00011500923,0.0011458603,0.00017960789],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008198188,0.00053611974,0.046582054,0.002029813,0.0029525238,0.118718915,0.015127983,0.0058465907,0.008131347,0.062302835,0.13439567,0.60255635],"study_design_scores_gemma":[0.0069554583,0.00013044338,0.00043640388,0.000043579465,0.00015205485,0.26566246,0.00004215533,0.03593034,0.0040474604,0.016437056,0.6671504,0.0030122157],"about_ca_topic_score_codex":0.10187044,"about_ca_topic_score_gemma":0.14546987,"teacher_disagreement_score":0.5995441,"about_ca_system_score_codex":0.0029584717,"about_ca_system_score_gemma":0.0014112411,"threshold_uncertainty_score":0.99948514},"labels":[],"label_agreement":null},{"id":"W4237064351","doi":"10.3821/1913-701x-144.4.156a","title":"Saskatchewan Pharmacists Adjust to New Generic Price Regime with Aid of Additional Compensation","year":2011,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Compensation (psychology); Business; Computer science; Psychology","score_opus":0.09231855320419673,"score_gpt":0.24615709552159404,"score_spread":0.1538385423173973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237064351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8843988,0.0022646072,0.004747006,0.0010043989,0.004577441,0.0016204246,0.026397206,0.00009334111,0.074896745],"genre_scores_gemma":[0.98481154,0.0008983122,0.0034918345,0.0076673036,0.0010275441,0.000028433336,0.00015287225,0.00009186531,0.0018303032],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99690986,0.000055061337,0.0011783501,0.0005892846,0.00015665515,0.001110804],"domain_scores_gemma":[0.99487424,0.00008274151,0.0007571246,0.00033635777,0.00029740934,0.0036521426],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00052289886,0.00045012543,0.0006859445,0.0007396845,0.0003983219,0.00011485868,0.00085312425,0.0000822832,0.021998484],"category_scores_gemma":[0.00009723616,0.00052914483,0.00018320238,0.0008587867,0.00018190434,0.0005331869,0.00006055475,0.00055972586,0.0002025915],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013190393,0.0004285392,0.009200942,0.00050736463,0.0016298139,0.01618667,0.014476499,0.0042031347,0.0015916728,0.01017554,0.8706342,0.069646604],"study_design_scores_gemma":[0.006728389,0.00030171915,0.00058934774,0.00006405863,0.00017103292,0.11939725,0.00004857536,0.0044368193,0.006434565,0.0042375443,0.8553471,0.0022435812],"about_ca_topic_score_codex":0.037898153,"about_ca_topic_score_gemma":0.04452976,"teacher_disagreement_score":0.10321058,"about_ca_system_score_codex":0.0019267472,"about_ca_system_score_gemma":0.004172692,"threshold_uncertainty_score":0.999716},"labels":[],"label_agreement":null},{"id":"W4238184128","doi":"10.3821/1913-701x-144.3.109b","title":"30 Years of Growth in Canadian Pharmaceutical Sales Projected to End in 2011","year":2011,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Marketing","score_opus":0.09849729603284312,"score_gpt":0.2809651125494973,"score_spread":0.18246781651665417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238184128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979274,0.0011060396,0.000010617787,0.00034644047,0.0012962049,0.0005384166,0.001748778,0.000010954759,0.0156686],"genre_scores_gemma":[0.99219865,0.0026841303,0.00020844117,0.0044456692,0.0002435035,0.000030557396,0.000019328223,0.00006747034,0.000102239195],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99599755,0.00008937392,0.0014144024,0.0005654374,0.000099312754,0.0018339466],"domain_scores_gemma":[0.99518925,0.00007830572,0.000297991,0.00024368726,0.0001471765,0.004043609],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012831911,0.00036284688,0.0007231031,0.0023584894,0.00015288124,0.00007624643,0.0009173106,0.00012553856,0.0054535205],"category_scores_gemma":[0.00028265768,0.00050775835,0.00014321072,0.0009790843,0.00018632847,0.00036379925,0.00005981702,0.0008464383,0.00027752406],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061942247,0.00067575846,0.73938483,0.0007689703,0.00067029666,0.09502417,0.02167833,0.0011822499,0.0011670272,0.044563893,0.037456445,0.056808613],"study_design_scores_gemma":[0.021993943,0.00049395167,0.09296223,0.00025905587,0.00020145025,0.100815356,0.00013675823,0.029665986,0.011221286,0.018511184,0.7159515,0.007787307],"about_ca_topic_score_codex":0.89618903,"about_ca_topic_score_gemma":0.9502581,"teacher_disagreement_score":0.67849505,"about_ca_system_score_codex":0.004346263,"about_ca_system_score_gemma":0.004108348,"threshold_uncertainty_score":0.9997374},"labels":[],"label_agreement":null},{"id":"W4238428746","doi":"10.3821/1913-701x-143.6.264","title":"New Momentum for a Pan-Canadian Purchasing Alliance for Prescription Drugs","year":2010,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Alliance; Medical prescription; Purchasing; Momentum (technical analysis); Business; Medicine; Marketing; Pharmacology; History; Finance; Archaeology","score_opus":0.059600275183962804,"score_gpt":0.27952967275080925,"score_spread":0.21992939756684646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238428746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84454805,0.008689895,0.016718965,0.0151087865,0.04686399,0.0071204104,0.030926742,0.00014265026,0.0298805],"genre_scores_gemma":[0.98039573,0.0019439821,0.0025933932,0.008667123,0.0033584565,0.00012344032,0.000096581454,0.00011908394,0.002702185],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99650025,0.000020631234,0.0010014207,0.00062719785,0.00007491191,0.0017755771],"domain_scores_gemma":[0.99422234,0.00012355782,0.00045341463,0.00031317113,0.00024259729,0.0046448996],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010200815,0.0004168099,0.00055384485,0.00055376114,0.0011138382,0.0005416202,0.00086152,0.00014733023,0.0012418235],"category_scores_gemma":[0.00030847738,0.00055376085,0.0003161611,0.0003293636,0.000111576366,0.00062197424,0.000027768594,0.00073697604,0.000059392427],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032606974,0.00009011797,0.0024862378,0.0005520481,0.00074184727,0.0014687624,0.0027546838,0.00095217174,0.004063918,0.08102986,0.622629,0.2829053],"study_design_scores_gemma":[0.0025243578,0.000038816837,0.00003115543,0.000009066266,0.00004512254,0.008125598,0.0000055215933,0.019494731,0.000787446,0.012389279,0.95584255,0.00070637645],"about_ca_topic_score_codex":0.3017039,"about_ca_topic_score_gemma":0.7134702,"teacher_disagreement_score":0.41176632,"about_ca_system_score_codex":0.002703376,"about_ca_system_score_gemma":0.0047600046,"threshold_uncertainty_score":0.99969137},"labels":[],"label_agreement":null},{"id":"W4238438364","doi":"10.1007/bf03276740","title":"Pharmaceutical sales rise by 14% in Canada, China","year":2003,"lang":"en","type":"article","venue":"PharmacoEconomics & Outcomes News","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quality of Life Research; China; Business; Public health; Political science; Medicine; Law","score_opus":0.03730183461446839,"score_gpt":0.3188371479028117,"score_spread":0.2815353132883433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238438364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8608174,0.007772555,0.00016764435,0.02766632,0.0032087325,0.0008420942,0.0018596028,0.000084274274,0.09758142],"genre_scores_gemma":[0.9583903,0.002766737,0.00023670682,0.03700163,0.00011496951,0.00008526203,0.00004766042,0.00010552465,0.0012512299],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958569,0.000085653126,0.0018253728,0.00094977283,0.000055250857,0.0012270568],"domain_scores_gemma":[0.9980443,0.00023574007,0.00047552842,0.00051851996,0.000015483225,0.0007104045],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00078478415,0.00056553504,0.0012398898,0.00030565835,0.00012786334,0.00013166547,0.0006798221,0.00013772667,0.0038542615],"category_scores_gemma":[0.00014162775,0.00069746183,0.0002842976,0.00022870411,0.00008395893,0.00045768084,0.000119549026,0.00070813147,0.0017507551],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006577478,0.00035036184,0.6543245,0.000057183745,0.00031005434,0.000030055307,0.00022283725,0.0008641853,0.00013325897,0.12721859,0.21410184,0.002321389],"study_design_scores_gemma":[0.0037289283,0.000015711184,0.013736768,0.000005166952,0.000023956098,0.000011250544,0.000050406197,0.00618301,0.000808617,0.011091871,0.96340334,0.00094095315],"about_ca_topic_score_codex":0.3888573,"about_ca_topic_score_gemma":0.28669405,"teacher_disagreement_score":0.7493015,"about_ca_system_score_codex":0.0016942587,"about_ca_system_score_gemma":0.00055792084,"threshold_uncertainty_score":0.99954766},"labels":[],"label_agreement":null},{"id":"W4238611738","doi":"10.1007/bf03269365","title":"Formulary listing times drop in 4 Canadian provinces","year":2001,"lang":"en","type":"article","venue":"PharmacoEconomics & Outcomes News","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Formulary; Listing (finance); Quality of Life Research; Business; Medicine; Public health; Finance; Family medicine","score_opus":0.048418104041826705,"score_gpt":0.3334772051408186,"score_spread":0.28505910109899185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238611738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6274456,0.0018124037,0.000057052854,0.032978214,0.00135107,0.00069500477,0.0003952786,0.000098890996,0.3351665],"genre_scores_gemma":[0.95956486,0.0014016095,0.000310566,0.03575219,0.00032121007,0.00006941111,0.00004231597,0.000077395795,0.0024604131],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965508,0.000024767365,0.0013924391,0.0007186265,0.000026756343,0.0012866282],"domain_scores_gemma":[0.99826306,0.00014848185,0.00039591698,0.00041407955,0.000016743194,0.0007617216],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0007947841,0.00039654813,0.00087521353,0.0008002485,0.00017455188,0.00022129895,0.00066288235,0.00015487758,0.0029624612],"category_scores_gemma":[0.00011003173,0.0004871629,0.00026556107,0.00024526007,0.000064468695,0.00075183436,0.0001307171,0.00042579637,0.0032315797],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029391505,0.00009329272,0.87650156,0.000025583166,0.000115957,0.0000452182,0.00033350836,0.0004763192,0.000019908322,0.10826182,0.008570551,0.0055268714],"study_design_scores_gemma":[0.0016686091,0.000023959796,0.029763492,0.000008820469,0.000013575535,0.000018145907,0.00005258756,0.036024947,0.000052167823,0.026858203,0.90477973,0.0007357635],"about_ca_topic_score_codex":0.32025513,"about_ca_topic_score_gemma":0.27377757,"teacher_disagreement_score":0.8962092,"about_ca_system_score_codex":0.001045867,"about_ca_system_score_gemma":0.00028392853,"threshold_uncertainty_score":0.999758},"labels":[],"label_agreement":null},{"id":"W4238683263","doi":"10.4324/9781315614601-23","title":"Price Competition in the Chinese Pharmaceutical Market","year":2016,"lang":"en","type":"book-chapter","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Competition (biology); Business; Chinese market; Industrial organization; China; Geography; Biology","score_opus":0.05401953543150875,"score_gpt":0.29674821737440127,"score_spread":0.24272868194289252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238683263","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011932481,0.00120828,0.00018554405,0.010409953,0.00040127686,0.00035761204,0.0004922288,0.000028871213,0.9867969],"genre_scores_gemma":[0.123363145,0.00596105,0.00008727707,0.023539098,0.0013199614,0.000053042368,0.000045400902,0.000111512236,0.84551954],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982628,0.000015878326,0.0008083195,0.0004891462,0.000042418167,0.00038141222],"domain_scores_gemma":[0.9988571,0.00029597548,0.00027121886,0.00043584284,0.00001462385,0.00012527985],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0008881997,0.00033811067,0.0005612796,0.0002734998,0.000059246286,0.00008325539,0.00053375936,0.00027930416,0.034116153],"category_scores_gemma":[0.000043633303,0.0002423216,0.00023139862,0.00005216944,0.00012584304,0.00013045646,0.00010719265,0.0005212655,0.0066524805],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021631246,0.000031125182,0.00035975713,0.000026554697,0.000036996655,0.0000089084115,0.000037658687,5.0085157e-7,7.410141e-7,0.98680437,0.011632705,0.0010390406],"study_design_scores_gemma":[0.00040718267,0.000012595197,0.0007033047,0.000018700912,0.0000039976458,0.00000834951,0.0000010635652,0.0003720767,5.384112e-7,0.36365822,0.6345682,0.00024577003],"about_ca_topic_score_codex":0.0000122568335,"about_ca_topic_score_gemma":0.000020352709,"teacher_disagreement_score":0.6231462,"about_ca_system_score_codex":0.00016493363,"about_ca_system_score_gemma":0.000025296962,"threshold_uncertainty_score":0.99412096},"labels":[],"label_agreement":null},{"id":"W4239993890","doi":"10.4135/9781483349985.n88","title":"Canada: Variation in Prescription Drug Benefits byProvince/Territory","year":2016,"lang":"en","type":"reference-entry","venue":"The SAGE Encyclopedia of Pharmacology and Society","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Variation (astronomy); Medical prescription; Drug; Prescription drug; Geography; Medicine; Pharmacology","score_opus":0.01899929944331407,"score_gpt":0.2471093315104131,"score_spread":0.228110032067099,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239993890","genre_codex":"other","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1606828,0.15242185,0.00013391962,0.022149796,0.018232828,0.002161007,0.013571671,0.00005925734,0.63058686],"genre_scores_gemma":[0.13091075,0.8357635,0.00004045393,0.00467453,0.0017257473,0.0001047754,0.00007240855,0.000043635482,0.026664164],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982869,0.00007627441,0.0007665171,0.00042863537,0.000047466903,0.00039420737],"domain_scores_gemma":[0.99887025,0.00026693137,0.00056926254,0.00018166426,0.000020521293,0.00009134748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006779742,0.00026260395,0.00061131135,0.000071706105,0.00012292246,0.00001454353,0.0003609341,0.00033036154,0.00058964145],"category_scores_gemma":[0.000025402038,0.00022630353,0.00015196599,0.00008093593,0.00017218434,0.00014201053,0.00016076163,0.0006270179,0.000018513652],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044040044,0.00011210806,0.0019308539,0.00039890606,0.00034567917,0.000002990976,0.0027623018,0.000029187238,0.000010651416,0.011776183,0.96570545,0.016881635],"study_design_scores_gemma":[0.0011194042,0.00001952574,0.022457233,0.00007706338,0.00006549444,0.0000015550767,0.000038166607,0.000585723,0.000016922506,0.006472535,0.9688061,0.00034026356],"about_ca_topic_score_codex":0.14958015,"about_ca_topic_score_gemma":0.039548144,"teacher_disagreement_score":0.6833417,"about_ca_system_score_codex":0.000404643,"about_ca_system_score_gemma":0.0005657213,"threshold_uncertainty_score":0.9779776},"labels":[],"label_agreement":null},{"id":"W4240245679","doi":"10.2139/ssrn.946400","title":"Informational Spillovers and Strategic Launch Delay of Pharmaceutical Drugs","year":2006,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"International Health Economics Association","funders":"","keywords":"Business; Industrial organization; Marketing","score_opus":0.024375922371507697,"score_gpt":0.2646331026692938,"score_spread":0.2402571802977861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240245679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8878691,0.0055934926,0.0006422099,0.0018908336,0.00017468269,0.000093858886,0.00007822947,0.0000120986015,0.10364549],"genre_scores_gemma":[0.9949916,0.0038185287,0.00006790662,0.00047124617,0.00020912758,0.0000019227969,0.000007949221,0.000012582926,0.0004191646],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9981036,0.0000110606925,0.0006543164,0.0001432223,0.000042721033,0.001045052],"domain_scores_gemma":[0.9994415,0.00004020062,0.00030416402,0.000084226915,0.00002827828,0.000101620164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001119472,0.00012555876,0.00025404693,0.00017600706,0.000088906,0.0000570592,0.00015515878,0.00007307555,0.00022723639],"category_scores_gemma":[0.00001374783,0.00013593111,0.00009970089,0.00011134177,0.000091451504,0.00027117695,0.0000329087,0.0007426897,0.00009498219],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025362442,0.000039725892,0.0035653543,0.0000103362045,0.00006296293,4.8158614e-7,0.00004098191,0.00012354263,0.00002458561,0.9951748,0.00014226437,0.00078959845],"study_design_scores_gemma":[0.0011862068,0.00007956775,0.0007562876,0.0000038483813,0.0000094609995,0.00012486897,0.00014140757,0.0056657493,0.00006560117,0.9612975,0.03049828,0.00017123837],"about_ca_topic_score_codex":0.00010824836,"about_ca_topic_score_gemma":0.000043184962,"teacher_disagreement_score":0.107122466,"about_ca_system_score_codex":0.00031680395,"about_ca_system_score_gemma":0.0003270726,"threshold_uncertainty_score":0.554311},"labels":[],"label_agreement":null},{"id":"W4240252137","doi":"10.3821/1913-701x-142.6.271.a","title":"BC Government Invests in New UBC Facility to Support Education of More Pharmacists","year":2009,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Government (linguistics); Medicine; Business; Medical education; Family medicine","score_opus":0.061703458918506524,"score_gpt":0.2953443771967481,"score_spread":0.23364091827824157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240252137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97254866,0.0010203299,0.00010829641,0.002007796,0.0023246934,0.00063291634,0.0027122719,0.000016548396,0.018628472],"genre_scores_gemma":[0.9766863,0.0019557117,0.00022179769,0.018970465,0.0005393964,0.000011548292,0.000038172304,0.0000303734,0.0015462544],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965347,0.000051990064,0.001526178,0.0005900719,0.00018244702,0.0011146085],"domain_scores_gemma":[0.9953059,0.00004801523,0.00052515627,0.0003494821,0.00012968702,0.003641778],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008748826,0.0004142646,0.0007150466,0.00057141494,0.00021146247,0.0001449453,0.0008453449,0.000089335816,0.0022202095],"category_scores_gemma":[0.00022866363,0.0005429089,0.00019904053,0.0007686747,0.000097011965,0.00049190444,0.000050517814,0.00062111276,0.00012101532],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048609078,0.000719678,0.076654315,0.00038729762,0.0003183402,0.0069367513,0.006624758,0.0047996524,0.002885186,0.011011454,0.38182583,0.5073506],"study_design_scores_gemma":[0.006504315,0.0003027375,0.0043619275,0.00005695507,0.000083845654,0.039590962,0.000036570193,0.0037906072,0.00923815,0.009241198,0.9244701,0.0023225904],"about_ca_topic_score_codex":0.028360032,"about_ca_topic_score_gemma":0.031492244,"teacher_disagreement_score":0.5426443,"about_ca_system_score_codex":0.0049799914,"about_ca_system_score_gemma":0.0053002005,"threshold_uncertainty_score":0.9997022},"labels":[],"label_agreement":null},{"id":"W4240390045","doi":"10.3821/1913-701x-142.3.117.a","title":"Retail Prescription Volume up 7.1% in 2008: Generic Prescriptions Now Account for Majority","year":2009,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medical prescription; Business; Volume (thermodynamics); Medicine; Pharmacology; Physics","score_opus":0.08390761934245095,"score_gpt":0.2736221673259697,"score_spread":0.18971454798351878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240390045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9458562,0.01037529,0.0019482704,0.0053171883,0.011708202,0.0018798028,0.007814659,0.000074046824,0.015026342],"genre_scores_gemma":[0.97910595,0.006864221,0.00032764758,0.008700715,0.0013157404,0.0000546926,0.00007586272,0.000054078264,0.0035010949],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996615,0.000053177773,0.00123319,0.00060800876,0.00009148076,0.0013991514],"domain_scores_gemma":[0.9972141,0.000044755852,0.00044735937,0.00031748784,0.00021138025,0.0017649318],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00100741,0.00039762468,0.0006120807,0.00075870054,0.00062808144,0.00037503405,0.00075025175,0.00012911602,0.0016107782],"category_scores_gemma":[0.0001897192,0.0005265672,0.00025139324,0.0005917582,0.00010720433,0.0008308117,0.000030332012,0.00071706565,0.00010224614],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056543254,0.00045474482,0.029895637,0.0004625023,0.00048263045,0.0066356612,0.0023901057,0.013006219,0.0025596851,0.019731173,0.8215841,0.102232106],"study_design_scores_gemma":[0.00317311,0.000075213684,0.0012339717,0.000014309185,0.000047645783,0.01606025,0.00000575384,0.07913779,0.00023390623,0.00782136,0.8912708,0.0009259017],"about_ca_topic_score_codex":0.01953976,"about_ca_topic_score_gemma":0.09810875,"teacher_disagreement_score":0.1013062,"about_ca_system_score_codex":0.004093929,"about_ca_system_score_gemma":0.0014175196,"threshold_uncertainty_score":0.99972916},"labels":[],"label_agreement":null},{"id":"W4240991983","doi":"10.3109/9781420073553-13","title":"A Primer of Drug/Device Law","year":2008,"lang":"es","type":"book-chapter","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Primer (cosmetics); Law; Drug; Medicine; Political science; Pharmacology; Physics; Thermodynamics","score_opus":0.08261269360930884,"score_gpt":0.2820376533771653,"score_spread":0.19942495976785646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240991983","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033935993,0.0080855405,0.000028715987,0.001602815,0.00069853466,0.00040010962,0.0012207505,0.00003334404,0.9845366],"genre_scores_gemma":[0.59717834,0.062384456,0.0007561692,0.011437574,0.0008667275,0.000020179592,0.00009048132,0.00024522468,0.32702082],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965487,0.000009990117,0.0019828642,0.0008476554,0.000057069086,0.0005537086],"domain_scores_gemma":[0.9973284,0.0001850742,0.0012222958,0.0008452619,0.00008284015,0.0003361453],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00034597254,0.0006075944,0.0016783145,0.00039229874,0.00013632499,0.000058856644,0.0006251769,0.0004977663,0.011339451],"category_scores_gemma":[0.00002386916,0.0007520025,0.0007248777,0.00006741397,0.0005450397,0.0002026934,0.00028628853,0.0005670911,0.0078388695],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028849196,0.00008503581,0.0006110161,0.0001710813,0.0003865337,0.0000067827627,0.0001472311,0.000012044913,0.000005183512,0.99025875,0.007325856,0.00096164213],"study_design_scores_gemma":[0.00066615135,0.0000561552,0.00026159553,0.00007383203,0.00004510366,0.000011945353,0.0000048481306,0.00049675023,0.00031506518,0.033451308,0.9638243,0.0007929733],"about_ca_topic_score_codex":0.0015840549,"about_ca_topic_score_gemma":0.00008749575,"teacher_disagreement_score":0.95680743,"about_ca_system_score_codex":0.00013109247,"about_ca_system_score_gemma":0.00008339628,"threshold_uncertainty_score":0.9994931},"labels":[],"label_agreement":null},{"id":"W4240996743","doi":"10.1002/div.6574","title":"Abbott Laboratories","year":2008,"lang":"en","type":"article","venue":"Mergent s Dividend Achievers","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Joint venture; Medical prescription; Business; Commerce; Pharmacology","score_opus":0.08134316636998808,"score_gpt":0.2612341988136709,"score_spread":0.17989103244368282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240996743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91556823,0.003148095,0.00037224623,0.0052903285,0.0018986452,0.00017286846,0.00039707747,0.00010740637,0.073045105],"genre_scores_gemma":[0.9926317,0.0017965595,0.0002464446,0.0028025685,0.00028316933,0.000017337808,0.000017817216,0.000028858587,0.002175579],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99871737,0.000012649545,0.00048216665,0.00035545594,0.000037087477,0.00039524553],"domain_scores_gemma":[0.9992642,0.000031453088,0.00016309637,0.00029731126,0.00001859782,0.00022533716],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000244544,0.00017346839,0.00032208927,0.0001363336,0.00022880756,0.000034637673,0.00028470927,0.00007849441,0.0023883714],"category_scores_gemma":[0.000087185625,0.00020523142,0.00013992572,0.00024862672,0.00011440702,0.00029966474,0.000087721826,0.00017021288,0.0041196127],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030257754,0.00017206643,0.3479397,0.000025303847,0.00018451853,0.000029920913,0.0008303233,0.00014162807,0.00013931711,0.5426235,0.10752351,0.000359933],"study_design_scores_gemma":[0.0004975138,0.00003008118,0.038608328,0.0000034382163,0.0000058837436,0.0000067359365,0.000023798786,0.00027873748,0.00053795235,0.013186138,0.9464771,0.00034426528],"about_ca_topic_score_codex":0.00014939478,"about_ca_topic_score_gemma":0.000011521872,"teacher_disagreement_score":0.8389536,"about_ca_system_score_codex":0.00007918714,"about_ca_system_score_gemma":0.000029960838,"threshold_uncertainty_score":0.9985236},"labels":[],"label_agreement":null},{"id":"W4241240264","doi":"10.3821/1913-701x-142.4.172","title":"Economic Woes Lead More Employers to Implement or Consider Drug Benefit Changes","year":2009,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Lead (geology); Drug; Business; Risk analysis (engineering); Medicine; Pharmacology","score_opus":0.08331422154918329,"score_gpt":0.31656979228697857,"score_spread":0.2332555707377953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241240264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9556653,0.0024186473,0.00011582705,0.02009856,0.004719368,0.0009573316,0.0066121262,0.00006778767,0.009345049],"genre_scores_gemma":[0.93907505,0.004728582,0.00030188073,0.052144974,0.0014793961,0.000028994406,0.000033862645,0.00007704244,0.002130189],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961862,0.000035109264,0.0011718257,0.0007391986,0.000096869146,0.0017707797],"domain_scores_gemma":[0.99526405,0.00009918454,0.00045181264,0.000393128,0.0001248921,0.003666942],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00076119474,0.0005541095,0.0008074175,0.0008351858,0.00076433446,0.0004472988,0.000927384,0.000081108294,0.005362214],"category_scores_gemma":[0.00010274266,0.00063325185,0.00021527786,0.00038133826,0.000108549,0.0004126298,0.000054644715,0.0005949433,0.00036412827],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005708759,0.00015831078,0.008151472,0.00022066082,0.0010923829,0.02518785,0.0064202035,0.0132123055,0.0011166532,0.025829274,0.7686454,0.14939463],"study_design_scores_gemma":[0.0028215847,0.00013777762,0.0001906192,0.000022366941,0.00007202799,0.037163425,0.00004150991,0.0050739027,0.0021831426,0.0050981008,0.9455634,0.0016321836],"about_ca_topic_score_codex":0.02980882,"about_ca_topic_score_gemma":0.28426194,"teacher_disagreement_score":0.25445312,"about_ca_system_score_codex":0.0050168713,"about_ca_system_score_gemma":0.0018047199,"threshold_uncertainty_score":0.99961185},"labels":[],"label_agreement":null},{"id":"W4241437092","doi":"10.1177/171516350714000601","title":"BC and Alberta Pharmacists Seek Input into Joint Buying Strategy","year":2007,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Joint (building); Business; Marketing; Advertising; Medicine; Family medicine; Engineering","score_opus":0.06874095744618008,"score_gpt":0.2767010859288065,"score_spread":0.2079601284826264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241437092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9440075,0.00530682,0.00070202997,0.00083198707,0.0037307986,0.0005344228,0.00069963036,0.000042713567,0.04414409],"genre_scores_gemma":[0.98044616,0.008113114,0.00021831352,0.00842731,0.0013805883,0.000011666747,0.000031034986,0.00010665983,0.0012651739],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954462,0.00006121962,0.0016677238,0.00079609564,0.00013574692,0.0018929944],"domain_scores_gemma":[0.9941659,0.00019319092,0.00064862514,0.00033194956,0.00019723982,0.0044630766],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019582056,0.0006034196,0.00081646926,0.0009101112,0.0011017064,0.00052457023,0.00071074866,0.00014437884,0.0023256275],"category_scores_gemma":[0.00024003933,0.00075997354,0.00022876062,0.0006160847,0.00032864246,0.00076576864,0.00011500923,0.0011458603,0.00017960789],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008198188,0.00053611974,0.046582054,0.002029813,0.0029525238,0.118718915,0.015127983,0.0058465907,0.008131347,0.062302835,0.13439567,0.60255635],"study_design_scores_gemma":[0.0069554583,0.00013044338,0.00043640388,0.000043579465,0.00015205485,0.26566246,0.00004215533,0.03593034,0.0040474604,0.016437056,0.6671504,0.0030122157],"about_ca_topic_score_codex":0.10187044,"about_ca_topic_score_gemma":0.14546987,"teacher_disagreement_score":0.5995441,"about_ca_system_score_codex":0.0029584717,"about_ca_system_score_gemma":0.0014112411,"threshold_uncertainty_score":0.99948514},"labels":[],"label_agreement":null},{"id":"W4241638634","doi":"10.1002/div.7606","title":"Abbott Laboratories","year":2008,"lang":"en","type":"article","venue":"Mergent s Dividend Achievers","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Joint venture; Medical prescription; Business; Commerce; Pharmacology","score_opus":0.08134316636998808,"score_gpt":0.2612341988136709,"score_spread":0.17989103244368282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241638634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91556823,0.003148095,0.00037224623,0.0052903285,0.0018986452,0.00017286846,0.00039707747,0.00010740637,0.073045105],"genre_scores_gemma":[0.9926317,0.0017965595,0.0002464446,0.0028025685,0.00028316933,0.000017337808,0.000017817216,0.000028858587,0.002175579],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99871737,0.000012649545,0.00048216665,0.00035545594,0.000037087477,0.00039524553],"domain_scores_gemma":[0.9992642,0.000031453088,0.00016309637,0.00029731126,0.00001859782,0.00022533716],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000244544,0.00017346839,0.00032208927,0.0001363336,0.00022880756,0.000034637673,0.00028470927,0.00007849441,0.0023883714],"category_scores_gemma":[0.000087185625,0.00020523142,0.00013992572,0.00024862672,0.00011440702,0.00029966474,0.000087721826,0.00017021288,0.0041196127],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030257754,0.00017206643,0.3479397,0.000025303847,0.00018451853,0.000029920913,0.0008303233,0.00014162807,0.00013931711,0.5426235,0.10752351,0.000359933],"study_design_scores_gemma":[0.0004975138,0.00003008118,0.038608328,0.0000034382163,0.0000058837436,0.0000067359365,0.000023798786,0.00027873748,0.00053795235,0.013186138,0.9464771,0.00034426528],"about_ca_topic_score_codex":0.00014939478,"about_ca_topic_score_gemma":0.000011521872,"teacher_disagreement_score":0.8389536,"about_ca_system_score_codex":0.00007918714,"about_ca_system_score_gemma":0.000029960838,"threshold_uncertainty_score":0.9985236},"labels":[],"label_agreement":null},{"id":"W4241790324","doi":"10.3821/1913-701x-143.4.164","title":"Pharmacists in Canada Challenged to Deal with Drug Shortages","year":2010,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Economic shortage; Drug; Business; Medicine; Pharmacology; Philosophy; Government (linguistics)","score_opus":0.038957714271485,"score_gpt":0.248686951541044,"score_spread":0.209729237269559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241790324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981653,0.00072947016,0.000025509877,0.0016107506,0.0024048795,0.0005084812,0.0017709105,0.000020197693,0.011276853],"genre_scores_gemma":[0.98356515,0.0019597332,0.0003597622,0.012402606,0.0009781712,0.000051816514,0.000026315874,0.00011078645,0.0005456802],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956985,0.000060970404,0.0012781786,0.0008102896,0.0001878873,0.001964139],"domain_scores_gemma":[0.99423057,0.00012804872,0.00039706976,0.00038866376,0.00019288248,0.004662744],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009780003,0.00059360574,0.00083288347,0.0008143953,0.00055700075,0.00027243886,0.0012229537,0.000078555466,0.0026925209],"category_scores_gemma":[0.000077531724,0.0006946046,0.00012929415,0.0008301559,0.00014408652,0.00047869794,0.00008007897,0.0017884076,0.00009075799],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0010515157,0.00043250594,0.26804018,0.00075879635,0.0014250756,0.20989242,0.008335352,0.016793564,0.0028978784,0.014190447,0.30795154,0.16823071],"study_design_scores_gemma":[0.005373271,0.000056927758,0.0015250606,0.000029255398,0.000057847166,0.1179997,0.00003867666,0.008708163,0.0020550073,0.0010587057,0.8606024,0.0024949894],"about_ca_topic_score_codex":0.9260782,"about_ca_topic_score_gemma":0.99833894,"teacher_disagreement_score":0.55265087,"about_ca_system_score_codex":0.0056947675,"about_ca_system_score_gemma":0.009878004,"threshold_uncertainty_score":0.9995505},"labels":[],"label_agreement":null},{"id":"W4242395580","doi":"10.3821/145.5.cpj380","title":"Canada falls short on safeguarding its drug supply","year":2012,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Safeguarding; Drug; Business; Computer security; Criminology; Medicine; Psychology; Psychiatry; Computer science; Nursing","score_opus":0.06841401077393293,"score_gpt":0.2652409268873919,"score_spread":0.19682691611345898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242395580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9214836,0.006203463,0.000028252045,0.0017317444,0.010069645,0.0005095342,0.0063018487,0.00003357035,0.053638373],"genre_scores_gemma":[0.9696087,0.004033756,0.000044212124,0.02188871,0.0025966312,0.000020869524,0.000044542016,0.00010254217,0.0016599828],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956786,0.00007825748,0.00120597,0.00053778064,0.00018095119,0.0023184104],"domain_scores_gemma":[0.9939174,0.00015757214,0.0003594496,0.00035113064,0.00015667532,0.0050577708],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011944098,0.00055126724,0.0007307175,0.0005344695,0.0009554254,0.00027068082,0.0009416694,0.00008623152,0.0033986],"category_scores_gemma":[0.00020969698,0.0006848568,0.00023303692,0.00050648977,0.00009978141,0.000721046,0.000069940645,0.001058363,0.00022540521],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015806517,0.00019617798,0.050691377,0.00030961374,0.00095479557,0.01536012,0.0018169195,0.0034953337,0.00041630672,0.028258674,0.85996145,0.038381174],"study_design_scores_gemma":[0.0010893388,0.000018424967,0.00031006552,0.000017451852,0.000046219455,0.038208153,0.000010943077,0.0037539902,0.0017605778,0.00026328204,0.95340496,0.0011165661],"about_ca_topic_score_codex":0.71821094,"about_ca_topic_score_gemma":0.8847168,"teacher_disagreement_score":0.16650587,"about_ca_system_score_codex":0.008054723,"about_ca_system_score_gemma":0.004596712,"threshold_uncertainty_score":0.99956024},"labels":[],"label_agreement":null},{"id":"W4242669538","doi":"10.1177/171516351114400401","title":"Alberta Also Moving into Pharmacy Technician Regulation","year":2011,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy technician; Pharmacy; Technician; Business; Medicine; Medical education; Family medicine; Engineering; Electrical engineering","score_opus":0.08393959551566883,"score_gpt":0.2667134031083221,"score_spread":0.18277380759265327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242669538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7312583,0.005690322,0.0014365617,0.0018117024,0.009408608,0.0012264882,0.0013692406,0.00014012484,0.24765867],"genre_scores_gemma":[0.9853912,0.0035847116,0.0006005443,0.0077019725,0.0010840847,0.000026119866,0.00003088619,0.00010817192,0.0014723224],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964015,0.000068381596,0.0013664631,0.0006651197,0.00010841938,0.0013901261],"domain_scores_gemma":[0.99590695,0.000082738035,0.0006681929,0.00041047006,0.0001920886,0.0027395783],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00093475723,0.00049369247,0.00063071545,0.00081770367,0.0009862619,0.00024994917,0.0010549767,0.00010132967,0.0082181785],"category_scores_gemma":[0.00021938118,0.000632911,0.00026569117,0.0006698231,0.00022918207,0.00090037147,0.000093384435,0.0008260358,0.00037963095],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088927126,0.0007960205,0.084239885,0.0011916403,0.0029406154,0.04316013,0.029109547,0.003139305,0.0069944826,0.14207697,0.3231925,0.36226964],"study_design_scores_gemma":[0.0030641535,0.000050859075,0.00026399718,0.000025809233,0.00009875881,0.07088079,0.0000142176,0.026368782,0.004478279,0.022854593,0.8701921,0.0017076206],"about_ca_topic_score_codex":0.29634634,"about_ca_topic_score_gemma":0.22399114,"teacher_disagreement_score":0.54699963,"about_ca_system_score_codex":0.0031226105,"about_ca_system_score_gemma":0.0014828044,"threshold_uncertainty_score":0.9996122},"labels":[],"label_agreement":null},{"id":"W4243601053","doi":"10.13162/hro-ors.v4i2.2681","title":"Reforming the Regulation of Therapeutic Products in Canada: The Protecting of Canadians from Unsafe Drugs Act (Vanessa’s Law)","year":2016,"lang":"fr","type":"article","venue":"Health Reform Observer - Observatoire des Réformes de Santé","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"","keywords":"Law; Business; Political science","score_opus":0.0651486595134997,"score_gpt":0.2744713208779029,"score_spread":0.2093226613644032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243601053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.904102,0.026431108,0.00003715841,0.0646828,0.00080147834,0.0011812202,0.0010915109,0.000012240393,0.0016604604],"genre_scores_gemma":[0.9870097,0.0062921233,0.00023696474,0.005483981,0.0002567877,0.000076443495,0.000023228065,0.00006850323,0.00055227394],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9954366,0.00025380138,0.002252069,0.0005464353,0.00015005204,0.0013610459],"domain_scores_gemma":[0.9963027,0.0005433783,0.0017909842,0.0009830935,0.00013277761,0.00024703876],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002891111,0.00040385846,0.0010103014,0.0001135573,0.00052729534,0.0000382846,0.00086214504,0.0002166702,0.00013050769],"category_scores_gemma":[0.00021164276,0.0002638172,0.00018585009,0.0006743414,0.0005415338,0.0007315628,0.00014953938,0.0005832362,0.000010467743],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034547294,0.00016482278,0.40423486,0.0024378505,0.00038332545,0.000005257445,0.015894497,0.0003889637,0.00017612324,0.1119835,0.0003353341,0.46365002],"study_design_scores_gemma":[0.0012132522,0.00012797888,0.87436014,0.001190264,0.000028681048,0.000012021893,0.0026424353,0.0050844196,0.0015641765,0.024548044,0.08874824,0.00048034286],"about_ca_topic_score_codex":0.98749757,"about_ca_topic_score_gemma":0.98668075,"teacher_disagreement_score":0.4701253,"about_ca_system_score_codex":0.011426298,"about_ca_system_score_gemma":0.004779274,"threshold_uncertainty_score":0.9999814},"labels":[],"label_agreement":null},{"id":"W4243725364","doi":"10.3821/1913-701x-142.4.165","title":"Drug Purchasing Scheme Triggers Hefty Fines and Criminal Charges for Pharmacies, Wholesalers and Generic Drug Companies","year":2009,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Purchasing; Pharmacy; Business; Drug; Medicine; Pharmacology; Marketing; Family medicine","score_opus":0.07312520284831585,"score_gpt":0.2730096610454079,"score_spread":0.19988445819709205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243725364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9749937,0.016951928,0.00013634813,0.002884374,0.0014541551,0.0005046491,0.0019261191,0.000033356107,0.0011153545],"genre_scores_gemma":[0.96747833,0.02026408,0.00070168293,0.009867084,0.0010191771,0.000020730457,0.00003930876,0.000061056264,0.0005485248],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969061,0.00005149297,0.000983794,0.00067113544,0.00009118813,0.0012963149],"domain_scores_gemma":[0.9966796,0.00013952721,0.00046928498,0.00019819313,0.0001618409,0.0023515574],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009166712,0.000514798,0.00077383145,0.00060934725,0.0011897706,0.00059113046,0.0004877215,0.000065820364,0.00026186957],"category_scores_gemma":[0.00013082189,0.00062489155,0.00017902296,0.00033611918,0.00033341834,0.0007006782,0.000047792015,0.00056382274,0.000009161263],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016588445,0.0005834164,0.024884263,0.0034462078,0.0024140843,0.01218793,0.025406376,0.003480796,0.01102436,0.051444422,0.39885548,0.46461383],"study_design_scores_gemma":[0.009116118,0.000115327195,0.00043214273,0.000059332826,0.00026293364,0.07906911,0.00012190641,0.09264001,0.0030747212,0.007186893,0.8052784,0.0026430755],"about_ca_topic_score_codex":0.006059407,"about_ca_topic_score_gemma":0.007834242,"teacher_disagreement_score":0.46197075,"about_ca_system_score_codex":0.0011299005,"about_ca_system_score_gemma":0.00077118893,"threshold_uncertainty_score":0.99962026},"labels":[],"label_agreement":null},{"id":"W4243737142","doi":"10.1038/s41571-018-0120-1","title":"Addendum: Low-value approvals and high prices might incentivize ineffective drug development","year":2018,"lang":"en","type":"review","venue":"Nature Reviews Clinical Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"","keywords":"Revenue; Hindsight bias; Profit (economics); Actuarial science; Finance; Economics; Business; Microeconomics","score_opus":0.18648345030762592,"score_gpt":0.46972368995637276,"score_spread":0.28324023964874684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243737142","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000059192287,0.9801551,0.00003904147,0.0005837398,0.0037157186,0.0028130685,0.00023167538,0.000043152864,0.012359327],"genre_scores_gemma":[0.000023796469,0.98736024,0.0037532959,0.004286945,0.0030307893,0.0005087626,0.00015651391,0.00010043604,0.00077924354],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9904404,0.00089445664,0.0058834017,0.0019171571,0.00006654724,0.00079800707],"domain_scores_gemma":[0.99085534,0.0030588345,0.0046426947,0.0007988199,0.00007484609,0.0005694432],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.009595575,0.000933531,0.009418636,0.00039166494,0.00017517296,0.00009795895,0.0010200599,0.0030322727,0.00045448446],"category_scores_gemma":[0.002824406,0.00077013846,0.0013352312,0.0005095702,0.00049870356,0.00018765172,0.0007297791,0.0037421887,0.004435952],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001702269,0.0003586101,0.00005806608,0.008337315,0.0005108477,0.000010266283,0.000045952977,2.4445804e-8,6.500835e-9,0.037982505,0.03258297,0.9200964],"study_design_scores_gemma":[0.0007468043,0.00017633129,0.00010010836,0.0033969039,0.00031762663,0.00001648375,0.0000011144489,0.000012802863,3.5648833e-7,0.0036708848,0.9907381,0.00082246953],"about_ca_topic_score_codex":0.000019885174,"about_ca_topic_score_gemma":0.00003581387,"teacher_disagreement_score":0.95815516,"about_ca_system_score_codex":0.00069071376,"about_ca_system_score_gemma":0.00065649947,"threshold_uncertainty_score":0.99947494},"labels":[],"label_agreement":null},{"id":"W4243838391","doi":"10.1345/aph.1l590a","title":"Comment: The Impact of Methodological Approach on Cost Findings in Comparison of Epoetin Alfa with Darbepoetin Alfa","year":2010,"lang":"en","type":"letter","venue":"Annals of Pharmacotherapy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Darbepoetin alfa; Epoetin alfa; Medicine; Medical physics; Intensive care medicine; Internal medicine; Erythropoietin","score_opus":0.4256081945036461,"score_gpt":0.47627577323056536,"score_spread":0.05066757872691924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243838391","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25580785,0.00503856,0.0005162074,0.6982455,0.00043552002,0.0025798758,0.004497034,0.00002886031,0.032850597],"genre_scores_gemma":[0.55386776,0.004251079,0.0010309373,0.4395943,0.00065774185,0.00012405239,0.00021673764,0.00013816524,0.0001192461],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996681,0.00028419538,0.0017500155,0.0005590765,0.00011528969,0.00061046844],"domain_scores_gemma":[0.99620926,0.0011392685,0.001871985,0.00059920206,0.00007773273,0.0001025271],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002526547,0.0004958649,0.002010705,0.0005259508,0.00004957751,0.000031252323,0.0010186465,0.0007442837,0.00093002897],"category_scores_gemma":[0.00008595037,0.00036172208,0.00059916644,0.0003597738,0.00047632697,0.00008164845,0.000069967486,0.002927088,0.000021599528],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010898629,0.0013204389,0.014125982,0.00026847294,0.0011116394,0.0000050911685,0.001117213,0.0011554369,0.0022700226,0.006331895,0.96764106,0.0035629098],"study_design_scores_gemma":[0.0028772491,0.0010441835,0.0025438052,0.0001026529,0.000034732144,0.0000050118415,0.000028917264,0.00441329,0.041405145,0.005682647,0.9411824,0.00067998114],"about_ca_topic_score_codex":0.0008795859,"about_ca_topic_score_gemma":0.0000060327784,"teacher_disagreement_score":0.2980599,"about_ca_system_score_codex":0.00005081465,"about_ca_system_score_gemma":0.00006321722,"threshold_uncertainty_score":0.99998325},"labels":[],"label_agreement":null},{"id":"W4243894068","doi":"10.3821/1913-701x-143.2.63","title":"Alberta Compromises on Generic Drug Pricing to Soften Impact of Cost-Reduction Measures on Pharmacies","year":2010,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy; Drug pricing; Reduction (mathematics); Drug; Business; Generic drug; Medicine; Actuarial science; Pharmacology; Family medicine; Mathematics","score_opus":0.07341108497266996,"score_gpt":0.29706570197717314,"score_spread":0.22365461700450318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243894068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837547,0.00028802504,0.00003649555,0.0006706552,0.003853703,0.00059334014,0.0014996628,0.000018925266,0.009284477],"genre_scores_gemma":[0.9925184,0.0011573603,0.000106847336,0.004075481,0.0012935608,0.000035170073,0.000023719887,0.000087625616,0.0007018363],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968578,0.00006488746,0.0011206878,0.00060800253,0.0001571376,0.0011914652],"domain_scores_gemma":[0.99570847,0.00016914605,0.0006034425,0.0003975178,0.00025472426,0.002866733],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008534304,0.00051479676,0.0007528985,0.0010471204,0.00061787496,0.00023347056,0.00086531567,0.00008441121,0.0017579617],"category_scores_gemma":[0.0003349725,0.0005628806,0.00037841094,0.000677581,0.00018375106,0.00034735058,0.000050601935,0.0010784331,0.00016296122],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002307772,0.0011169494,0.024746073,0.0005634815,0.0031601307,0.005891279,0.009694695,0.15232475,0.08739403,0.014945595,0.435292,0.26256323],"study_design_scores_gemma":[0.008979956,0.0005917168,0.0012345433,0.00008943917,0.00023006945,0.08010791,0.00002709247,0.030298034,0.061057817,0.0024469632,0.8111268,0.0038096113],"about_ca_topic_score_codex":0.09092759,"about_ca_topic_score_gemma":0.05488123,"teacher_disagreement_score":0.37583485,"about_ca_system_score_codex":0.0023733128,"about_ca_system_score_gemma":0.0015819735,"threshold_uncertainty_score":0.99968225},"labels":[],"label_agreement":null},{"id":"W4244057138","doi":"10.1503/cmaj.170248","title":"Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada","year":2017,"lang":"en","type":"erratum","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science; Public health; Medicine; Essential drugs; Data science; Environmental health; Nursing; Health services","score_opus":0.029587557810663533,"score_gpt":0.27049652574935146,"score_spread":0.24090896793868793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244057138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38006192,0.0036878756,0.00019439828,0.23648924,0.0926719,0.0012621273,0.014179837,0.000039504135,0.2714132],"genre_scores_gemma":[0.98287517,0.00085947465,0.000053745563,0.008098621,0.004098885,0.000008136783,0.00048676442,0.00006904221,0.003450173],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971336,0.00010443396,0.0013375345,0.00031749962,0.00032673168,0.0007801629],"domain_scores_gemma":[0.99495375,0.00035090145,0.0018674223,0.00024466732,0.00027581706,0.0023074246],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019721894,0.00024452823,0.0010275246,0.0009770759,0.00021550532,0.00017063813,0.00092346565,0.0005117998,0.0012610428],"category_scores_gemma":[0.009711889,0.0002995758,0.000118258475,0.00027914136,0.000063857835,0.00032458862,0.00006481358,0.0016288803,0.000014562919],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0000083643445,0.000045105473,0.05456087,0.00020133152,0.00025077627,0.00043052033,0.0003529631,0.000029662726,0.0000010964633,0.0049636536,0.93192434,0.007231313],"study_design_scores_gemma":[0.0013652582,0.0000446169,0.015177338,0.00051873026,0.000022573946,0.000030066092,0.00012701993,0.0067292107,0.0000059113113,0.00080817787,0.9747696,0.00040153],"about_ca_topic_score_codex":0.86701846,"about_ca_topic_score_gemma":0.9921846,"teacher_disagreement_score":0.60281324,"about_ca_system_score_codex":0.0048756376,"about_ca_system_score_gemma":0.016364764,"threshold_uncertainty_score":0.99994564},"labels":[],"label_agreement":null},{"id":"W4244145168","doi":"10.1016/j.kint.2016.09.025","title":"The Authors Reply","year":2016,"lang":"en","type":"letter","venue":"Kidney International","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto; University Health Network","funders":"","keywords":"Disease; Kidney disease; Medicine; Scopus; Heredity; Counterfeit; Traditional medicine; Family medicine; MEDLINE; Pathology; Genetics; Internal medicine; Political science; Biology","score_opus":0.05207962826794838,"score_gpt":0.28826474626607634,"score_spread":0.23618511799812797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244145168","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000005233486,0.00018967994,0.00010779537,0.70304346,0.0064754845,0.00008308386,0.0022592663,0.00002821998,0.28780776],"genre_scores_gemma":[0.00019918739,0.0006096491,0.00006016185,0.8670997,0.01397967,0.000045760808,0.00022497933,0.00004701494,0.11773385],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99829507,0.000016793192,0.00071967725,0.000470331,0.0000626163,0.0004355281],"domain_scores_gemma":[0.9986322,0.00020627328,0.0004839221,0.0004726544,0.000044352433,0.00016058293],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0005180394,0.00022064037,0.0002765997,0.00017104675,0.00015525916,0.00027508594,0.0011097128,0.00032174936,0.004128129],"category_scores_gemma":[0.00062256696,0.00017291273,0.0002585647,0.000047930585,0.00013161864,0.00012632184,0.00016328701,0.00087328884,0.009267279],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000038728126,0.000003672607,0.00014238407,0.0000049637483,0.00016438267,0.00000970163,0.000013544513,1.5773193e-7,6.4687964e-7,0.14403513,0.85484755,0.0007740134],"study_design_scores_gemma":[0.0002221095,0.0000067909464,0.000041859763,0.000016443444,0.000003936139,0.0000077188415,5.751132e-7,0.00021282898,0.0000072136395,0.12329991,0.8759609,0.000219699],"about_ca_topic_score_codex":0.000048794926,"about_ca_topic_score_gemma":0.0000012693561,"teacher_disagreement_score":0.17007393,"about_ca_system_score_codex":0.000270128,"about_ca_system_score_gemma":0.00008652037,"threshold_uncertainty_score":0.99678224},"labels":[],"label_agreement":null},{"id":"W4244575943","doi":"10.1038/ki.2010.121","title":"The Authors Reply:","year":2010,"lang":"en","type":"article","venue":"Kidney International","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Scopus; Rosuvastatin; Medicine; Statin; Atorvastatin; Randomized controlled trial; Medical prescription; MEDLINE; Hemodialysis; Family medicine; Internal medicine; Pharmacology; Political science; Law","score_opus":0.03509962690311793,"score_gpt":0.2935718319874536,"score_spread":0.2584722050843357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244575943","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.033690855,0.000069382986,0.00023075208,0.23146984,0.010418094,0.00009016081,0.00038098317,0.00004490608,0.72360504],"genre_scores_gemma":[0.9564793,0.00012475277,0.0005767629,0.025083289,0.0013058025,0.000025487061,0.00003172889,0.000018972623,0.016353896],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993053,0.000003532554,0.00031386927,0.00018189603,0.000023588389,0.00017179742],"domain_scores_gemma":[0.9993868,0.00005996037,0.00012459011,0.00022002604,0.000022270695,0.00018638858],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0004604344,0.00006841386,0.00008470791,0.000060821123,0.00013063554,0.00015193805,0.00044191512,0.00004598268,0.0025652573],"category_scores_gemma":[0.00071843126,0.000061838866,0.00007758105,0.000045745797,0.0000753073,0.00010911529,0.00006961927,0.00026280014,0.0024385336],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000004162345,0.000013759125,0.0048446734,6.029867e-7,0.00003195271,4.9223354e-7,0.00003350332,0.0000011747549,0.00007834973,0.8365368,0.15754935,0.0009051677],"study_design_scores_gemma":[0.000163556,0.0000037139307,0.0029884612,7.855514e-7,8.146768e-7,0.000004155383,0.00000271074,0.0037531096,0.00012373038,0.13350995,0.85937697,0.00007205278],"about_ca_topic_score_codex":0.00005647021,"about_ca_topic_score_gemma":0.000013993377,"teacher_disagreement_score":0.92278844,"about_ca_system_score_codex":0.000031090178,"about_ca_system_score_gemma":0.000029748768,"threshold_uncertainty_score":0.9983465},"labels":[],"label_agreement":null},{"id":"W4244895795","doi":"10.1377/forefront.20130528.031611","title":"Strengthen Medicare: End Drug Company Price Setting","year":2013,"lang":"en","type":"dataset","venue":"Forefront Group","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Drug; Operations management; Actuarial science; Economics; Medicine; Pharmacology","score_opus":0.035019468074938824,"score_gpt":0.2571944976735281,"score_spread":0.22217502959858926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244895795","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006712215,0.0030873758,0.00004032734,0.0017522607,0.0018851757,0.00051214953,0.9796127,0.00005937607,0.012379398],"genre_scores_gemma":[0.0024022488,0.00179095,0.0003882603,0.004108402,0.0017687941,0.00016554026,0.98815846,0.000083361025,0.0011339932],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99670476,0.000036979938,0.0013535506,0.00090607855,0.00008686727,0.000911755],"domain_scores_gemma":[0.99733555,0.00019936547,0.0009857978,0.0009804969,0.000026613518,0.0004721966],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000791667,0.0005640337,0.0011227796,0.0003484184,0.00018247894,0.00021914279,0.0011792975,0.0004347311,0.01171226],"category_scores_gemma":[0.00014522012,0.0006259015,0.00032157367,0.00014048106,0.00016616678,0.00028358086,0.00044471378,0.00094881497,0.011518434],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000006516735,0.000103189115,0.00009832405,0.0001429511,0.00015081782,0.000006061207,0.00008671479,0.0000048144634,3.511377e-7,0.012513824,0.98590624,0.0009802118],"study_design_scores_gemma":[0.00062586454,0.00003929314,0.00032362904,0.000043211392,0.00002992243,0.0000052092787,0.000022097602,0.0011771263,0.0000017758631,0.010871875,0.9861583,0.00070170086],"about_ca_topic_score_codex":0.0025829386,"about_ca_topic_score_gemma":0.00033046099,"teacher_disagreement_score":0.011245404,"about_ca_system_score_codex":0.00036572316,"about_ca_system_score_gemma":0.00005444115,"threshold_uncertainty_score":0.99961925},"labels":[],"label_agreement":null},{"id":"W4245736962","doi":"10.4102/hsag.v21i0.991","title":"Maximum potential cost-savings attributable to generic substitution of antipsychotics 2008 to 2013","year":2016,"lang":"en","type":"article","venue":"Health SA Gesondheid","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences North","funders":"","keywords":"Antipsychotic; Defined daily dose; Medicine; Pharmacoepidemiology; Population; Psychiatry; Schizophrenia (object-oriented programming); Medical prescription; Environmental health; Drug; Pharmacology","score_opus":0.08670254261078536,"score_gpt":0.3180471346277256,"score_spread":0.23134459201694024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245736962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8077034,0.0038374367,0.06937337,0.10940591,0.0027052914,0.0016895568,0.0030189415,0.00009062537,0.0021754976],"genre_scores_gemma":[0.9782067,0.003177051,0.0025607944,0.014796771,0.00035679014,0.000052416664,0.000019816642,0.000042418716,0.0007872657],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975939,0.000021490741,0.0009897044,0.00051381084,0.000053542964,0.00082756736],"domain_scores_gemma":[0.9983633,0.000041697196,0.0003642662,0.00044555482,0.00007098699,0.00071417005],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007077684,0.00020429573,0.00061584014,0.00033548992,0.000134871,0.00003803768,0.00031583797,0.00011234421,0.0005991373],"category_scores_gemma":[0.00008546725,0.00020294213,0.00011761296,0.00039753324,0.00005363991,0.00018696231,0.00010456344,0.00011305606,0.0037821736],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00086832326,0.00086292194,0.03891895,0.0004877828,0.00018489237,0.000013507802,0.0009595779,0.002731436,0.005795559,0.21207587,0.6475764,0.08952478],"study_design_scores_gemma":[0.0010207815,0.00024109047,0.028337339,0.000052834774,0.000004577395,0.000009463569,0.0000067062806,0.0005824926,0.0011429628,0.0062678014,0.96197325,0.00036070327],"about_ca_topic_score_codex":0.00052228564,"about_ca_topic_score_gemma":0.0000614015,"teacher_disagreement_score":0.31439686,"about_ca_system_score_codex":0.00032344993,"about_ca_system_score_gemma":0.0001163117,"threshold_uncertainty_score":0.9969935},"labels":[],"label_agreement":null},{"id":"W4245833257","doi":"10.1377/forefront.20200925.874730","title":"Administration Finalizes Drug Importation Plans, But Legal And Practical Questions Remain","year":2020,"lang":"en","type":"dataset","venue":"Forefront Group","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Yesterday; Administration (probate law); Element (criminal law); Business; Drug administration; Prescription drug; Medical prescription; Public administration; Food and drug administration; Law and economics; Political science; Law; Pharmacology; Economics; Risk analysis (engineering); Medicine","score_opus":0.047043340236014045,"score_gpt":0.31083553922784696,"score_spread":0.2637921989918329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245833257","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009023005,0.0005857277,0.0002919638,0.0064066146,0.0005493089,0.0003250472,0.98971725,0.000033929802,0.0011878506],"genre_scores_gemma":[0.006491468,0.0021435828,0.00081155944,0.002574278,0.00078285806,0.00008507419,0.9867396,0.000033611213,0.00033801427],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981159,0.00003212468,0.0008753627,0.0006078445,0.000046948328,0.00032182297],"domain_scores_gemma":[0.9987058,0.00010752611,0.0005825473,0.00030750592,0.00001562109,0.00028099798],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00038627777,0.0003037287,0.0005551773,0.00015811645,0.00013926999,0.0002399023,0.0001531868,0.00027608685,0.0003383576],"category_scores_gemma":[0.00024486397,0.00036335335,0.0001192247,0.00007716707,0.00009659047,0.0003800817,0.00008272722,0.0005370558,0.000991591],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059841288,0.00007514362,0.00012234015,0.00009857792,0.00005267095,0.000038657927,0.000030876705,0.0000011851356,0.0000010177905,0.102217615,0.89723045,0.00007164052],"study_design_scores_gemma":[0.0003989895,0.00015563697,0.000743817,0.000020714388,0.000044887463,0.00004056969,0.00001587002,0.000647599,0.000003917934,0.013950808,0.98358864,0.00038856143],"about_ca_topic_score_codex":0.000893325,"about_ca_topic_score_gemma":0.001807687,"teacher_disagreement_score":0.088266805,"about_ca_system_score_codex":0.00012445102,"about_ca_system_score_gemma":0.000106115294,"threshold_uncertainty_score":0.99988186},"labels":[],"label_agreement":null},{"id":"W4245860914","doi":"10.32388/0zwgt7","title":"Canada DrugBank","year":2020,"lang":"en","type":"reference-entry","venue":"Definitions","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"DrugBank; Medicine; Pharmacology","score_opus":0.1670936865811174,"score_gpt":0.27161503631682643,"score_spread":0.10452134973570903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245860914","genre_codex":"other","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000040138326,0.0068329033,0.000056389257,0.015515765,0.0017107138,0.00013806499,0.037252642,0.00004099248,0.93841237],"genre_scores_gemma":[0.1162295,0.5041308,0.0011972652,0.18901277,0.009493067,0.00057512755,0.020218024,0.0005634021,0.1585801],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99832577,0.000011417623,0.0007081929,0.0004978289,0.000037103604,0.0004197135],"domain_scores_gemma":[0.99886894,0.00011125841,0.0003256462,0.0003429253,0.00002138987,0.00032985857],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00007317245,0.00028204598,0.00066697306,0.00014480132,0.00014723152,0.0000937738,0.00036311196,0.00023592732,0.004216802],"category_scores_gemma":[0.00011698531,0.00037033783,0.00019485464,0.00018976752,0.000048322712,0.00006367001,0.000109489054,0.00067150005,0.004631669],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000011588312,0.000014648612,0.0000419634,0.00004548726,0.000056308563,0.000007792399,0.000013182769,0.000001967537,7.861583e-9,0.37701285,0.62240946,0.0003951624],"study_design_scores_gemma":[0.00019389029,0.000009968628,0.00012097513,0.000028283563,0.000017020166,0.000004084936,0.0000058386004,0.00013964674,0.0000011093454,0.09541873,0.90368587,0.00037459732],"about_ca_topic_score_codex":0.2527433,"about_ca_topic_score_gemma":0.1605183,"teacher_disagreement_score":0.7798323,"about_ca_system_score_codex":0.00038595422,"about_ca_system_score_gemma":0.0010278284,"threshold_uncertainty_score":0.99987483},"labels":[],"label_agreement":null},{"id":"W4246684384","doi":"10.1503/cmaj.050460","title":"Prescription drug expenditures rising -- too fast?","year":2005,"lang":"en","type":"letter","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Drug; Computer science; Prescription drug; Data science; Medicine; World Wide Web; Pharmacology","score_opus":0.023715853902406086,"score_gpt":0.24948181486364404,"score_spread":0.22576596096123797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246684384","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006787906,0.0021505496,0.00006349349,0.9329252,0.0044575785,0.00012955861,0.00064059073,0.000023439343,0.0589308],"genre_scores_gemma":[0.003185049,0.001173507,0.00007418687,0.9498853,0.035295065,0.000011104037,0.0001390423,0.00006515292,0.010171568],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968754,0.00009817528,0.0012624635,0.0004070867,0.00031034942,0.0010465187],"domain_scores_gemma":[0.99719846,0.00014950373,0.0010295133,0.00021157651,0.000083855906,0.0013270681],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0019317312,0.0003066376,0.0006520106,0.00063253025,0.00035382912,0.00056031806,0.000635386,0.0016779016,0.019582182],"category_scores_gemma":[0.0006638222,0.00036840807,0.00034306067,0.00010380753,0.000047356123,0.00033684465,0.000036513044,0.005328623,0.0038391661],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000012904087,0.000008752499,0.001288169,0.000011683778,0.00013503215,0.00020760506,0.00014805609,0.000007595569,9.869364e-8,0.0010594827,0.99232525,0.004806983],"study_design_scores_gemma":[0.0004419963,0.000009165128,0.0006175118,0.00003750874,0.000014418424,0.0001121414,0.000020108564,0.0005853281,0.0000012983629,0.004891923,0.9928775,0.00039111116],"about_ca_topic_score_codex":0.004408412,"about_ca_topic_score_gemma":0.0072233127,"teacher_disagreement_score":0.04875923,"about_ca_system_score_codex":0.0033941227,"about_ca_system_score_gemma":0.0010846354,"threshold_uncertainty_score":0.9998768},"labels":[],"label_agreement":null},{"id":"W4246933292","doi":"10.2139/ssrn.2261740","title":"Pharmaceutical Followers","year":2013,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Business","score_opus":0.03190136203016355,"score_gpt":0.279585688794307,"score_spread":0.24768432676414345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246933292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.65067863,0.02157642,0.0123102665,0.04843499,0.002187427,0.0006254156,0.00004102137,0.00013364208,0.26401216],"genre_scores_gemma":[0.98606616,0.006280866,0.000094907315,0.0041369516,0.00047215124,0.00001606248,0.0000022380884,0.00003352139,0.002897133],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99662155,0.000017502563,0.0005649288,0.00025798462,0.00003397566,0.0025040328],"domain_scores_gemma":[0.99929094,0.00003790406,0.00019551617,0.0001721745,0.000026469692,0.0002769716],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0011830138,0.0001663979,0.00029470248,0.00017440628,0.00015904693,0.00015570753,0.00036657316,0.000090050955,0.0024288339],"category_scores_gemma":[0.00006536218,0.00017848812,0.00021468129,0.00013999964,0.00006162177,0.00040853897,0.000050245962,0.0015367293,0.007937783],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008852442,0.00005766692,0.004270326,0.0000028679042,0.00014994833,0.0000011617134,0.00004264462,0.000012454648,0.000048835813,0.9817529,0.0037154972,0.009936878],"study_design_scores_gemma":[0.00078100176,0.000070922055,0.0006516967,0.0000021793167,0.000006917745,0.0001109528,0.00009540325,0.0017045584,0.0000350846,0.81492615,0.18138959,0.00022553571],"about_ca_topic_score_codex":0.00009840939,"about_ca_topic_score_gemma":0.00002477401,"teacher_disagreement_score":0.3353875,"about_ca_system_score_codex":0.00072509184,"about_ca_system_score_gemma":0.0002792155,"threshold_uncertainty_score":0.99848306},"labels":[],"label_agreement":null},{"id":"W4247614496","doi":"10.2174/1874120701004010025","title":"Achieving a Dream: Meeting Policy Goals Related to Improving Drug Access","year":2010,"lang":"en","type":"article","venue":"The Open AIDS Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; Canadian Society for International Health; University of Toronto; Health Canada","funders":"","keywords":"Human immunodeficiency virus (HIV); Medicine; Face (sociological concept); Access to medicines; Public relations; Economic growth; Developing country; Development economics; Internet privacy; Political science; Social science; Sociology; Family medicine; Economics; Computer science","score_opus":0.05368159080485699,"score_gpt":0.35792932113244624,"score_spread":0.3042477303275892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247614496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78412926,0.00019911192,0.00011454239,0.031189192,0.0008998537,0.0003593584,0.00003890388,0.00002062238,0.18304914],"genre_scores_gemma":[0.98687905,0.00013408174,0.0011900516,0.008319925,0.00084282324,0.00001692828,0.0000015427303,0.00005142228,0.002564198],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979584,0.000057400845,0.0009821213,0.00033587642,0.000046115238,0.0006200489],"domain_scores_gemma":[0.9982484,0.00016707834,0.0006260592,0.00047833033,0.000043619788,0.00043648764],"candidate_categories":["scholarly_communication","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.004477764,0.0002074546,0.00045310194,0.00036032478,0.00074957724,0.002456236,0.002816333,0.000089797366,0.0012516481],"category_scores_gemma":[0.00086937024,0.00017711127,0.00016632197,0.00048696017,0.00006902679,0.001082757,0.0013023064,0.0012114558,0.0008842102],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013283234,0.00018768369,0.050931875,0.000029073883,0.00035223152,0.000020917973,0.0044972156,0.0007662574,0.009522923,0.8393119,0.016173417,0.07807368],"study_design_scores_gemma":[0.0032728673,0.0001865141,0.031031705,0.00011280384,0.000052854182,0.00057478296,0.00031447114,0.005052267,0.0025713716,0.38724306,0.56811744,0.0014698878],"about_ca_topic_score_codex":0.0012715727,"about_ca_topic_score_gemma":0.000097438526,"teacher_disagreement_score":0.551944,"about_ca_system_score_codex":0.00014267248,"about_ca_system_score_gemma":0.00013741328,"threshold_uncertainty_score":0.9998937},"labels":[],"label_agreement":null},{"id":"W4248447100","doi":"10.3821/1913-701x-144.4.161","title":"Alberta also moving into pharmacy technician regulation","year":2011,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy technician; Pharmacy; Technician; Medical education; Medicine; Nursing; Engineering; Electrical engineering","score_opus":0.08393959551566883,"score_gpt":0.2667134031083221,"score_spread":0.18277380759265327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248447100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7312583,0.005690322,0.0014365617,0.0018117024,0.009408608,0.0012264882,0.0013692406,0.00014012484,0.24765867],"genre_scores_gemma":[0.9853912,0.0035847116,0.0006005443,0.0077019725,0.0010840847,0.000026119866,0.00003088619,0.00010817192,0.0014723224],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964015,0.000068381596,0.0013664631,0.0006651197,0.00010841938,0.0013901261],"domain_scores_gemma":[0.99590695,0.000082738035,0.0006681929,0.00041047006,0.0001920886,0.0027395783],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00093475723,0.00049369247,0.00063071545,0.00081770367,0.0009862619,0.00024994917,0.0010549767,0.00010132967,0.0082181785],"category_scores_gemma":[0.00021938118,0.000632911,0.00026569117,0.0006698231,0.00022918207,0.00090037147,0.000093384435,0.0008260358,0.00037963095],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088927126,0.0007960205,0.084239885,0.0011916403,0.0029406154,0.04316013,0.029109547,0.003139305,0.0069944826,0.14207697,0.3231925,0.36226964],"study_design_scores_gemma":[0.0030641535,0.000050859075,0.00026399718,0.000025809233,0.00009875881,0.07088079,0.0000142176,0.026368782,0.004478279,0.022854593,0.8701921,0.0017076206],"about_ca_topic_score_codex":0.29634634,"about_ca_topic_score_gemma":0.22399114,"teacher_disagreement_score":0.54699963,"about_ca_system_score_codex":0.0031226105,"about_ca_system_score_gemma":0.0014828044,"threshold_uncertainty_score":0.9996122},"labels":[],"label_agreement":null},{"id":"W4248681043","doi":"10.3821/1913-701x-144.1.12b","title":"Quebec Government Reveals Details of Plan to Match Ontario Generic Drug Pricing","year":2011,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug pricing; Plan (archaeology); Government (linguistics); Business; Computer science; Geography; Actuarial science; Archaeology","score_opus":0.08995293817803823,"score_gpt":0.23718299521928152,"score_spread":0.14723005704124328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248681043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97786087,0.00068242085,0.00016685808,0.00019102891,0.0018076467,0.0003669195,0.0012507319,0.000011998081,0.017661538],"genre_scores_gemma":[0.9893014,0.0007976666,0.0006691788,0.0051601753,0.00035449612,0.000018661874,0.00000903178,0.000061239196,0.0036281405],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99680424,0.00005100884,0.0013599542,0.00049610593,0.00014123207,0.0011474531],"domain_scores_gemma":[0.9961455,0.00005353241,0.00065169076,0.00034322095,0.000123394,0.0026826565],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009676227,0.00038237264,0.00071494683,0.00036103293,0.00036125522,0.00012403393,0.0008821716,0.00006473017,0.004367287],"category_scores_gemma":[0.000083798324,0.00047235284,0.00020931994,0.00042427087,0.00010090324,0.00035476798,0.0000882114,0.00054147514,0.00011402093],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010197489,0.0007610816,0.39710063,0.0015988727,0.0030321444,0.038171,0.084440134,0.005527322,0.0064066397,0.04125835,0.3452185,0.075465545],"study_design_scores_gemma":[0.0066947285,0.00023893247,0.012193207,0.00014387119,0.00031810146,0.08634802,0.00012575366,0.0044839596,0.021260902,0.0070892135,0.8565804,0.0045229318],"about_ca_topic_score_codex":0.8126481,"about_ca_topic_score_gemma":0.93836206,"teacher_disagreement_score":0.51136184,"about_ca_system_score_codex":0.0075593754,"about_ca_system_score_gemma":0.0020684083,"threshold_uncertainty_score":0.9997728},"labels":[],"label_agreement":null},{"id":"W4249018754","doi":"10.21518/1561-5936-2014-4-48-53","title":"Steps to Success: changes in the ranking of pharmaceutical producers in the iv quarter of 2013","year":2014,"lang":"en","type":"article","venue":"Remedium Journal about the Russian market of medicines and medical equipment","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Ranking (information retrieval); Business; Computer science; Information retrieval; Geography","score_opus":0.032355899338920684,"score_gpt":0.30273915032552595,"score_spread":0.27038325098660526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249018754","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.41478628,0.0061503374,0.00027075398,0.5624794,0.00079341687,0.000704405,0.000017018052,0.0000030113918,0.014795375],"genre_scores_gemma":[0.9803875,0.009272264,0.00003922507,0.009645732,0.0006024551,0.000020525446,0.0000010234256,0.000009937003,0.000021341184],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99748397,0.00030031434,0.0012577301,0.00021284338,0.0003463081,0.0003988609],"domain_scores_gemma":[0.99815786,0.0008163199,0.00049291283,0.00027898976,0.000022426919,0.00023150395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014406873,0.00016862123,0.0006353182,0.00026205732,0.000063005515,0.000023543324,0.00083084265,0.00009272229,0.0005673771],"category_scores_gemma":[0.0007140455,0.000084402374,0.00009460679,0.00030301436,0.000391407,0.00006007461,0.000092342125,0.00058525195,0.0000029437613],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031763015,0.0028081671,0.16578741,0.0035069294,0.00085684157,0.00012027219,0.08190405,0.00015017687,0.0006013498,0.36629176,0.10609709,0.26869965],"study_design_scores_gemma":[0.012371794,0.001930391,0.27911708,0.0032758336,0.00017484426,0.00038082845,0.006453229,0.022400575,0.00040606956,0.039486803,0.63328236,0.00072018465],"about_ca_topic_score_codex":0.00013256751,"about_ca_topic_score_gemma":0.00013477454,"teacher_disagreement_score":0.5656012,"about_ca_system_score_codex":0.000036954163,"about_ca_system_score_gemma":0.00006563736,"threshold_uncertainty_score":0.6212381},"labels":[],"label_agreement":null},{"id":"W4249522221","doi":"10.1111/j.1538-7836.2006.01863.x","title":"Talking about…","year":2006,"lang":"en","type":"article","venue":"Journal of Thrombosis and Haemostasis","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"World Federation of Science Journalists","funders":"","keywords":"Certification; Audit; Business; German; Management; Accounting; Economics","score_opus":0.08685233289832375,"score_gpt":0.3135475061597368,"score_spread":0.22669517326141306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249522221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94445646,0.0076310392,0.0005496795,0.007123022,0.00048139892,0.00006408432,0.00009154467,0.000008696281,0.039594058],"genre_scores_gemma":[0.9946184,0.0027449958,0.0009948562,0.0011577251,0.00038356634,9.266905e-7,0.0000014217537,0.000015149204,0.00008297189],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99888504,0.000008245491,0.00074744475,0.00012999534,0.00002825205,0.00020103174],"domain_scores_gemma":[0.99914944,0.000044275163,0.0005663934,0.00010293286,0.0000335871,0.00010339085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045732205,0.000106899,0.00042852113,0.00018221434,0.00008853749,0.000112017406,0.00013635813,0.00006218188,0.0004013209],"category_scores_gemma":[0.000027680024,0.000107262524,0.00015948263,0.00010025877,0.00006072907,0.00024949946,0.00004096103,0.00014948669,0.000056254765],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054694352,0.00034973814,0.16088113,0.00007910167,0.00041852833,0.0000136220915,0.00038932476,0.00016070162,0.00036645384,0.74090683,0.079033904,0.017345946],"study_design_scores_gemma":[0.0016073706,0.00012696831,0.22762506,0.0000453856,0.000046601555,0.00005459548,0.000051550964,0.0006737659,0.0008144315,0.15257291,0.6160344,0.00034699228],"about_ca_topic_score_codex":0.0001251036,"about_ca_topic_score_gemma":0.000008291872,"teacher_disagreement_score":0.58833396,"about_ca_system_score_codex":0.000051124967,"about_ca_system_score_gemma":0.000013417777,"threshold_uncertainty_score":0.43941823},"labels":[],"label_agreement":null},{"id":"W4249635125","doi":"10.1177/171516350714000111","title":"Threat to Canadian Drug Supply Increases","year":2007,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Business; Medicine; Pharmacology","score_opus":0.04631851956006836,"score_gpt":0.26696087519509504,"score_spread":0.22064235563502668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249635125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93304557,0.0028516958,0.00014535502,0.0029444708,0.0039428957,0.0005835445,0.0049000676,0.000040357467,0.05154606],"genre_scores_gemma":[0.95605135,0.0021789393,0.00022840763,0.038160253,0.0016614262,0.000014257451,0.0000487925,0.00009863926,0.001557946],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99541545,0.000044867335,0.0012660993,0.0006677536,0.000121355915,0.002484447],"domain_scores_gemma":[0.98794013,0.00014066431,0.000315162,0.00039409508,0.00025755062,0.010952406],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018898787,0.0005082012,0.0006652721,0.0012657418,0.0011301719,0.0004086405,0.0011207344,0.00010432088,0.0049162256],"category_scores_gemma":[0.0003327692,0.0006561277,0.00024000417,0.00091672316,0.0001551838,0.00049510703,0.00006639905,0.0008069019,0.0006699255],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002501078,0.00015965957,0.086062334,0.00020604451,0.0007264054,0.08097147,0.0037567043,0.0019554484,0.000299542,0.032989997,0.72482514,0.06779714],"study_design_scores_gemma":[0.0014724549,0.000032103846,0.0008211304,0.00001580081,0.00003986015,0.07340157,0.000017981529,0.0011065721,0.00074546016,0.002785479,0.9183817,0.0011798858],"about_ca_topic_score_codex":0.8949006,"about_ca_topic_score_gemma":0.982509,"teacher_disagreement_score":0.19355656,"about_ca_system_score_codex":0.008423531,"about_ca_system_score_gemma":0.004391825,"threshold_uncertainty_score":0.999589},"labels":[],"label_agreement":null},{"id":"W4249687475","doi":"10.1089/blr.2007.9911","title":"PTO Agrees to Review Patents on Anti-HIV Drug; Canadian Decision May or May Not Have Profound Implications; PTO Strives to Get a Handle on <i>Markush</i> Claim; CAFC Agrees Patent Law Preempts D.C. Price-Control Measure","year":2007,"lang":"en","type":"article","venue":"Biotechnology Law Report","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Human immunodeficiency virus (HIV); Patent law; Law; Control (management); Political science; Law and economics; Business; Economics; Medicine; Virology; Intellectual property; Management","score_opus":0.084812807088495,"score_gpt":0.31325044976366906,"score_spread":0.22843764267517405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249687475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6139976,0.004373537,0.0020615407,0.26833802,0.0017759962,0.009937884,0.0034944084,0.00050901604,0.09551201],"genre_scores_gemma":[0.96280706,0.0014171433,0.0008680296,0.03283168,0.00014991176,0.00027254404,0.00007191224,0.000075957476,0.001505767],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953243,0.00003233877,0.0018271258,0.0014471178,0.00014328015,0.0012258425],"domain_scores_gemma":[0.996487,0.00016369969,0.0006983765,0.0016170348,0.00014481625,0.00088904396],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001966374,0.0005426423,0.0011266862,0.0007055955,0.00043280076,0.00012281701,0.0008403908,0.00064974366,0.00017514313],"category_scores_gemma":[0.00049417635,0.00051410124,0.00024720017,0.0005612403,0.00020400871,0.00015851174,0.00018433656,0.00056526135,0.0013786486],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010228266,0.0010136438,0.06788173,0.0003588017,0.0006352305,0.00088523683,0.000199068,0.00019601104,0.0008390351,0.83984286,0.06077554,0.026350005],"study_design_scores_gemma":[0.0010182727,0.00032420523,0.028694618,0.0004630279,0.000041794392,0.00016123439,0.000013629006,0.000026063983,0.004718727,0.0028266958,0.96092975,0.00078195217],"about_ca_topic_score_codex":0.017565848,"about_ca_topic_score_gemma":0.09828815,"teacher_disagreement_score":0.90015423,"about_ca_system_score_codex":0.00079956936,"about_ca_system_score_gemma":0.00020653993,"threshold_uncertainty_score":0.99973106},"labels":[],"label_agreement":null},{"id":"W4249714071","doi":"10.1177/171516350714000313","title":"BC Program — Extra Compensation for Deciding Not to Fill a Prescription","year":2007,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medical prescription; Compensation (psychology); Medicine; Business; Psychology; Pharmacology; Social psychology","score_opus":0.11667514674457966,"score_gpt":0.3281795375108488,"score_spread":0.21150439076626912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249714071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.967713,0.00074593007,0.010276338,0.0012658396,0.00566163,0.0020371089,0.0025483004,0.00007276183,0.009679084],"genre_scores_gemma":[0.9851466,0.0006672936,0.0024261603,0.009561102,0.0014659874,0.000059474976,0.00005131872,0.00007044766,0.00055163616],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968525,0.000026847722,0.0011349004,0.0005144529,0.00009140752,0.0013798638],"domain_scores_gemma":[0.99619466,0.00014735352,0.00040472773,0.00022182138,0.00025090462,0.0027805585],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017681386,0.00033106084,0.00046632247,0.00070218864,0.0007439683,0.0003627781,0.00055933377,0.00008979197,0.00071035314],"category_scores_gemma":[0.00031286868,0.00043306567,0.00021090149,0.00047568764,0.000077166216,0.00045173368,0.000037290476,0.000427509,0.00008851005],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010854934,0.0003599026,0.008961448,0.00062178704,0.0007494026,0.006984225,0.0047424906,0.0064217653,0.0050017703,0.043309774,0.16257763,0.7591843],"study_design_scores_gemma":[0.0024121434,0.00011610596,0.00040227608,0.000017269555,0.000046683897,0.018708855,0.000011556644,0.025922196,0.0034025619,0.0021681907,0.94588584,0.00090630597],"about_ca_topic_score_codex":0.017159488,"about_ca_topic_score_gemma":0.07144033,"teacher_disagreement_score":0.7833082,"about_ca_system_score_codex":0.0032527614,"about_ca_system_score_gemma":0.00076811726,"threshold_uncertainty_score":0.9998121},"labels":[],"label_agreement":null},{"id":"W4249848371","doi":"10.1142/s0219030315000816","title":"INSIDE INDUSTRY","year":2015,"lang":"en","type":"article","venue":"Asia-Pacific Biotech News","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Daratumumab; Health care; Disease control; Business; Quarter (Canadian coin); Engineering; Medicine; Management; Medical education; Political science; Environmental health; Internal medicine; Geography; Economics","score_opus":0.12173767522859101,"score_gpt":0.29511956228963204,"score_spread":0.17338188706104102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249848371","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10628293,0.0018928876,0.00047562484,0.027390674,0.0013691871,0.00029351676,0.0002954759,0.0001793442,0.86182034],"genre_scores_gemma":[0.9919474,0.00021747989,0.0008202304,0.0028873319,0.00046817612,0.000018674482,0.000022421767,0.000042826814,0.0035754344],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99833876,0.000017403469,0.00064333115,0.00048206537,0.000036370922,0.00048205457],"domain_scores_gemma":[0.9986733,0.000028902161,0.0002344715,0.0005440649,0.000024199684,0.0004950505],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00050619134,0.00021622019,0.0004246162,0.000256909,0.00006946256,0.00012262171,0.00035393322,0.00060896727,0.000498187],"category_scores_gemma":[0.00015064456,0.0002512711,0.0001221263,0.00034224882,0.00010229545,0.0002501145,0.00011806296,0.0007571904,0.005353836],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055805034,0.00026196614,0.027984135,0.000025311872,0.00014679362,0.000027999306,0.00084777165,0.00007504041,0.00021108706,0.49715948,0.45582443,0.01738018],"study_design_scores_gemma":[0.0006249955,0.000053547472,0.00073728885,0.000005321408,0.000004670477,0.000015227261,0.000386982,0.0006220452,0.0010667868,0.0764322,0.91971487,0.00033608658],"about_ca_topic_score_codex":0.00039382972,"about_ca_topic_score_gemma":0.000024844987,"teacher_disagreement_score":0.8856645,"about_ca_system_score_codex":0.00015987297,"about_ca_system_score_gemma":0.00008262023,"threshold_uncertainty_score":0.999994},"labels":[],"label_agreement":null},{"id":"W4250067304","doi":"10.1177/1715163517706056","title":"The cost of drugs","year":2017,"lang":"fr","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Business; Computer science","score_opus":0.07378903314630209,"score_gpt":0.2963373003694376,"score_spread":0.22254826722313553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250067304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49503675,0.15595457,0.00027091402,0.04286982,0.09400846,0.0020323389,0.024909267,0.000029443934,0.18488845],"genre_scores_gemma":[0.85581464,0.12455816,0.00006282722,0.003970863,0.002359227,0.000016317039,0.000011850601,0.00008035136,0.013125757],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99556273,0.000114382725,0.0016864851,0.0005331896,0.00014416024,0.001959042],"domain_scores_gemma":[0.9933176,0.00030525806,0.0020598215,0.0009597514,0.00039719205,0.0029603883],"candidate_categories":["metaepi_narrow","sts","scholarly_communication","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022365924,0.00050106324,0.00082953495,0.0003114886,0.0048285704,0.0013700126,0.0028436063,0.00016252966,0.0022989472],"category_scores_gemma":[0.0007539624,0.0005789551,0.00044130554,0.00023539123,0.0016208416,0.00084571476,0.00019591353,0.0012824041,0.00016587926],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016735391,0.00011737555,0.009062826,0.000522271,0.0012129417,0.012251189,0.002006759,0.0014050795,0.00006478995,0.053963132,0.2928394,0.6263869],"study_design_scores_gemma":[0.0018269807,0.000029264173,0.00014835883,0.000041110554,0.000094314426,0.04258807,0.000012087675,0.01335511,0.00043459953,0.0033957274,0.9374231,0.00065127993],"about_ca_topic_score_codex":0.1322876,"about_ca_topic_score_gemma":0.22383825,"teacher_disagreement_score":0.6445837,"about_ca_system_score_codex":0.0037771715,"about_ca_system_score_gemma":0.004014226,"threshold_uncertainty_score":0.99966663},"labels":[],"label_agreement":null},{"id":"W4250075058","doi":"10.1002/div.6918","title":"Abbott Laboratories","year":2008,"lang":"en","type":"article","venue":"Mergent s Dividend Achievers","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Joint venture; Medical prescription; Business; Commerce; Pharmacology","score_opus":0.08134316636998808,"score_gpt":0.2612341988136709,"score_spread":0.17989103244368282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250075058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91556823,0.003148095,0.00037224623,0.0052903285,0.0018986452,0.00017286846,0.00039707747,0.00010740637,0.073045105],"genre_scores_gemma":[0.9926317,0.0017965595,0.0002464446,0.0028025685,0.00028316933,0.000017337808,0.000017817216,0.000028858587,0.002175579],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99871737,0.000012649545,0.00048216665,0.00035545594,0.000037087477,0.00039524553],"domain_scores_gemma":[0.9992642,0.000031453088,0.00016309637,0.00029731126,0.00001859782,0.00022533716],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000244544,0.00017346839,0.00032208927,0.0001363336,0.00022880756,0.000034637673,0.00028470927,0.00007849441,0.0023883714],"category_scores_gemma":[0.000087185625,0.00020523142,0.00013992572,0.00024862672,0.00011440702,0.00029966474,0.000087721826,0.00017021288,0.0041196127],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030257754,0.00017206643,0.3479397,0.000025303847,0.00018451853,0.000029920913,0.0008303233,0.00014162807,0.00013931711,0.5426235,0.10752351,0.000359933],"study_design_scores_gemma":[0.0004975138,0.00003008118,0.038608328,0.0000034382163,0.0000058837436,0.0000067359365,0.000023798786,0.00027873748,0.00053795235,0.013186138,0.9464771,0.00034426528],"about_ca_topic_score_codex":0.00014939478,"about_ca_topic_score_gemma":0.000011521872,"teacher_disagreement_score":0.8389536,"about_ca_system_score_codex":0.00007918714,"about_ca_system_score_gemma":0.000029960838,"threshold_uncertainty_score":0.9985236},"labels":[],"label_agreement":null},{"id":"W4250378947","doi":"10.1016/s2213-8587(17)30115-8","title":"Insulin affordability","year":2017,"lang":"en","type":"letter","venue":"The Lancet Diabetes & Endocrinology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Hippocratic Oath; Dilemma; Biography; Oath; Classics; Law; Philosophy; Political science; Psychiatry; History; Epistemology","score_opus":0.10115656115893289,"score_gpt":0.30389343822611214,"score_spread":0.20273687706717924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250378947","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017472174,0.005672391,0.0000056927297,0.880151,0.0020502335,0.00035357295,0.0014921632,0.000105573265,0.092697226],"genre_scores_gemma":[0.061029546,0.0021955324,0.00007332156,0.9192728,0.014096678,0.00018448746,0.00020676824,0.000096426586,0.002844472],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958325,0.00008781541,0.0007963124,0.00080533564,0.00003694337,0.0024410938],"domain_scores_gemma":[0.99624115,0.00041856046,0.00082811323,0.0024045014,0.000026424956,0.000081264334],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00083303236,0.00045414272,0.0016416038,0.00016682467,0.00033395793,0.00020263038,0.0024526084,0.00058116036,0.001119106],"category_scores_gemma":[0.00036960898,0.00040315615,0.0003481358,0.00006377393,0.00067191746,0.00012517079,0.0005353486,0.002749635,0.005043751],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007446292,0.000021441117,0.0084433565,0.00009532728,0.00023299964,0.00003347878,0.000038973314,0.000002430614,0.0000021939536,0.038443968,0.9505958,0.0020826044],"study_design_scores_gemma":[0.0004991651,0.000034531433,0.0027867744,0.000009404788,0.00002124117,0.0000075184885,9.875943e-7,0.00014577457,0.000040744755,0.17715162,0.81892276,0.00037950044],"about_ca_topic_score_codex":0.00015245803,"about_ca_topic_score_gemma":0.000016346963,"teacher_disagreement_score":0.13870765,"about_ca_system_score_codex":0.00015030893,"about_ca_system_score_gemma":0.000045248744,"threshold_uncertainty_score":0.99984205},"labels":[],"label_agreement":null},{"id":"W4250458882","doi":"10.1503/cmaj.1041127","title":"Correction","year":2004,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Computer science; Information retrieval; World Wide Web; Data science","score_opus":0.021946549106719865,"score_gpt":0.24808749571057748,"score_spread":0.2261409466038576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250458882","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11403049,0.0010883948,0.0021271366,0.3345272,0.0172449,0.00014547669,0.00013132697,0.00004951629,0.53065556],"genre_scores_gemma":[0.93328506,0.00038215742,0.00008268603,0.06245868,0.0023667046,0.0000033616827,0.000004729158,0.000015958469,0.0014006479],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99899936,0.0000118808075,0.00042933223,0.00011659377,0.00008249199,0.00036032984],"domain_scores_gemma":[0.9984537,0.00003842669,0.00020527904,0.000060081627,0.000048941387,0.0011935727],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0011278526,0.000067732195,0.00016159512,0.00018657527,0.00018242172,0.00010595838,0.0001573885,0.00022107415,0.0070181894],"category_scores_gemma":[0.0009955338,0.0000812183,0.00008652943,0.0001341529,0.000017296474,0.00014535485,0.000007920618,0.0006011159,0.004007333],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000043815076,0.000054746473,0.057910353,0.000003628415,0.0001334353,0.00011062854,0.0003862575,0.00025499726,0.0000018438685,0.24261728,0.6818791,0.016643373],"study_design_scores_gemma":[0.0005951765,0.000015552265,0.00999044,0.000008080893,0.0000017711739,0.000111590016,0.000022216198,0.00059019227,0.000007181016,0.039594315,0.94895524,0.00010822658],"about_ca_topic_score_codex":0.003496618,"about_ca_topic_score_gemma":0.010481504,"teacher_disagreement_score":0.8192546,"about_ca_system_score_codex":0.0017320086,"about_ca_system_score_gemma":0.0007501247,"threshold_uncertainty_score":0.9967682},"labels":[],"label_agreement":null},{"id":"W4250541937","doi":"10.3917/dec.orang.2014.01.0440","title":"Histoire secrète du patronat de 1945 à nos jours","year":2014,"lang":"fr","type":"book-chapter","venue":"Cahiers libres","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ministry of Labour, Employment and Social Solidarity","funders":"","keywords":"Political science; Art","score_opus":0.025476628047227726,"score_gpt":0.22187255731990527,"score_spread":0.19639592927267754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250541937","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012256715,0.020048177,0.0025791246,0.021338584,0.0061207297,0.00047817884,0.0020401957,0.00010786466,0.9350304],"genre_scores_gemma":[0.5049487,0.018749503,0.0010711214,0.023887048,0.005346395,0.00005587442,0.00022807317,0.0004950628,0.44521824],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99618083,0.000048138358,0.0014281715,0.0010676044,0.00006758932,0.001207641],"domain_scores_gemma":[0.9968508,0.00037104165,0.0010795537,0.0008235565,0.00005213104,0.0008229233],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0007565566,0.0008257337,0.0014854645,0.0005423579,0.0006296707,0.00026472413,0.00092367013,0.0013887761,0.0052614673],"category_scores_gemma":[0.00020703037,0.0011419153,0.0008821145,0.00007387211,0.0016847099,0.00027274262,0.00021127684,0.0015261915,0.0047200164],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045608478,0.00003711834,0.0025664067,0.00018002417,0.00031330547,0.000037826627,0.00041304715,0.0001962634,0.000007605929,0.9463242,0.02720469,0.0226739],"study_design_scores_gemma":[0.00080791855,0.000116925316,0.0012587062,0.000117912474,0.000085281565,0.000042420445,0.0000164962,0.003970816,0.000022395765,0.13403144,0.858457,0.0010726799],"about_ca_topic_score_codex":0.00031624877,"about_ca_topic_score_gemma":0.00006602694,"teacher_disagreement_score":0.83125234,"about_ca_system_score_codex":0.0013762468,"about_ca_system_score_gemma":0.00021870945,"threshold_uncertainty_score":0.9999076},"labels":[],"label_agreement":null},{"id":"W4250745188","doi":"10.1007/bf03266922","title":"Generics deal for pharmaceutical industry in Quebec?","year":2000,"lang":"en","type":"article","venue":"PharmacoEconomics & Outcomes News","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quality of Life Research; Business; Pharmaceutical industry; Public health; Medicine; Pharmacology","score_opus":0.08134391400180845,"score_gpt":0.3750161646133117,"score_spread":0.29367225061150326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250745188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.885884,0.001571468,0.00028636807,0.051483005,0.0013618028,0.0013280886,0.0011706031,0.00014308885,0.0567716],"genre_scores_gemma":[0.7654191,0.0032231084,0.0027616813,0.21118554,0.0013044055,0.00059163786,0.00013917632,0.00025357492,0.015121771],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960387,0.000036177564,0.0017904076,0.000944923,0.00003502876,0.0011547722],"domain_scores_gemma":[0.99836135,0.00028801538,0.00032473486,0.00045262885,0.000019286645,0.000553966],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00072949997,0.0005052983,0.0011413135,0.0003950515,0.00013628256,0.00021529118,0.0007209897,0.00058130926,0.008758296],"category_scores_gemma":[0.000044694887,0.00063087215,0.00046147255,0.00022485387,0.000106790816,0.0006261113,0.000100752804,0.0011590227,0.0026333288],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00081064407,0.001350383,0.41175357,0.00021178779,0.00084962137,0.000033813398,0.0012177094,0.009199678,0.00018825514,0.22710688,0.16120851,0.18606915],"study_design_scores_gemma":[0.004604417,0.00003017869,0.007058868,0.000005461523,0.000028956885,0.000005775483,0.000031261676,0.026096413,0.0002350475,0.013623022,0.9475074,0.00077323895],"about_ca_topic_score_codex":0.004456807,"about_ca_topic_score_gemma":0.0022605474,"teacher_disagreement_score":0.7862989,"about_ca_system_score_codex":0.0005640064,"about_ca_system_score_gemma":0.00012439216,"threshold_uncertainty_score":0.99961424},"labels":[],"label_agreement":null},{"id":"W4250881677","doi":"10.2165/00151234-200604990-00023","title":"Canadian generic market grows, but new drug access lags","year":2006,"lang":"en","type":"article","venue":"PharmacoEconomics & Outcomes News","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quality of Life Research; Drug; Business; Economics; Public health; Medicine; Pharmacology","score_opus":0.04633601836258157,"score_gpt":0.31835120293496816,"score_spread":0.2720151845723866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250881677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4629406,0.003997582,0.0002920209,0.1071378,0.004923614,0.00105416,0.00240604,0.00025255614,0.4169956],"genre_scores_gemma":[0.81657803,0.002000114,0.0008967309,0.117828265,0.002422054,0.00009768167,0.00019114104,0.00024502733,0.05974094],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99583143,0.000036444355,0.0016723061,0.0010378539,0.000042749016,0.0013792433],"domain_scores_gemma":[0.9972529,0.00015402399,0.00062337896,0.0007104153,0.000027127899,0.0012321944],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00058314664,0.00061326456,0.0011325856,0.0007650822,0.00027546065,0.0006746858,0.0014484195,0.00018147031,0.0101796435],"category_scores_gemma":[0.000039288407,0.00076692965,0.0005069676,0.0002737073,0.000070380425,0.0010654583,0.00028224709,0.0004527771,0.0044510053],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002490325,0.000072241615,0.17572305,0.000023161081,0.00017995159,0.0000143819725,0.00006253165,0.00055579835,0.000019581394,0.061773386,0.7592892,0.002261795],"study_design_scores_gemma":[0.001837082,0.0000092681485,0.032578133,0.000003571653,0.000037453025,0.000010684317,0.000014210701,0.005413193,0.0002319699,0.04948328,0.9094504,0.0009307201],"about_ca_topic_score_codex":0.57540125,"about_ca_topic_score_gemma":0.17827682,"teacher_disagreement_score":0.39712444,"about_ca_system_score_codex":0.0011258756,"about_ca_system_score_gemma":0.00047176747,"threshold_uncertainty_score":0.99947816},"labels":[],"label_agreement":null},{"id":"W4251029145","doi":"10.1108/ijhcqa.2012.06225daa.003","title":"Canada - Canadian government increases options for natural health products","year":2012,"lang":"en","type":"article","venue":"International Journal of Health Care Quality Assurance","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Government (linguistics); Natural (archaeology); Geography","score_opus":0.07275373504630955,"score_gpt":0.37011618051676287,"score_spread":0.2973624454704533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251029145","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23303206,0.12972037,0.0010984802,0.59762776,0.01829172,0.0009421295,0.01696526,0.000015834308,0.0023063652],"genre_scores_gemma":[0.9685944,0.00069637294,0.0011414138,0.028409647,0.0010239576,0.000009904656,0.000043941058,0.000013186937,0.00006721517],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99783266,0.00007285109,0.0013147149,0.00015004494,0.00015030515,0.00047944274],"domain_scores_gemma":[0.9976285,0.00017295941,0.0013018035,0.00012934943,0.00026647755,0.00050090393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001997085,0.00011710983,0.00042762203,0.00009991115,0.00014940211,0.000046158988,0.0003501126,0.00002651659,0.00004435923],"category_scores_gemma":[0.0006537446,0.00013184699,0.00010695984,0.0000704457,0.000024392648,0.00031097146,0.000021204689,0.00020004663,0.000009239782],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002048435,0.00033030316,0.17280799,0.0005675785,0.0005796868,0.0000051676748,0.002373792,0.0004493726,0.0000054230413,0.50222397,0.29723525,0.02321664],"study_design_scores_gemma":[0.0005985831,0.0000411828,0.11098117,0.000039883264,0.0000016164654,0.000023461585,0.0002246576,0.000043304386,0.000018947028,0.00072001613,0.88715756,0.00014960775],"about_ca_topic_score_codex":0.90543365,"about_ca_topic_score_gemma":0.8785243,"teacher_disagreement_score":0.7355623,"about_ca_system_score_codex":0.00497109,"about_ca_system_score_gemma":0.0038278175,"threshold_uncertainty_score":0.9988487},"labels":[],"label_agreement":null},{"id":"W4251307755","doi":"10.1177/171516350714000208","title":"BC Study Itemizing Costs of Pharmacy Services is Potential Template for other Jurisdictions","year":2007,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Pharmacy; Business; Medicine; Family medicine","score_opus":0.062380855740922884,"score_gpt":0.30885133944865395,"score_spread":0.24647048370773106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251307755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97933793,0.0018264444,0.0015269654,0.00039177033,0.0036431968,0.0010156804,0.005266912,0.000028322816,0.0069627794],"genre_scores_gemma":[0.99144024,0.0011663793,0.00023244982,0.0054331473,0.0011827591,0.00002485766,0.000021979964,0.00009146837,0.0004067242],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99642533,0.00004211044,0.0016061331,0.00054437196,0.000118991906,0.0012630483],"domain_scores_gemma":[0.99655604,0.00013118229,0.00081864325,0.00029112678,0.00030942578,0.0018935511],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017629431,0.00040551645,0.00067105814,0.00081702037,0.00081832265,0.00020152327,0.0007848661,0.00007330525,0.0016294381],"category_scores_gemma":[0.000046104404,0.00050936604,0.00030542404,0.00053657044,0.00012915811,0.00050145324,0.00005649856,0.0005261131,0.000045258923],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046028458,0.0038558338,0.46067807,0.004107367,0.0114632705,0.0363603,0.049593896,0.014336526,0.013864186,0.022365699,0.1589992,0.2197728],"study_design_scores_gemma":[0.0133451205,0.0001945233,0.00035425051,0.000042207506,0.00035744446,0.032456517,0.00014598118,0.036723603,0.006332189,0.0019074556,0.90636635,0.001774385],"about_ca_topic_score_codex":0.09674563,"about_ca_topic_score_gemma":0.09196264,"teacher_disagreement_score":0.74736714,"about_ca_system_score_codex":0.0019011453,"about_ca_system_score_gemma":0.0008841429,"threshold_uncertainty_score":0.9997358},"labels":[],"label_agreement":null},{"id":"W4251325721","doi":"10.18433/j37g80","title":"Similarities and Differences of International Practices and Procedures for the Regulation for Active Substance Master Files/Drug Master Files of Human Use: Moving Toward Regulatory Convergence","year":2016,"lang":"en","type":"article","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"Ministry of Food and Drug Safety; American Sleep Medicine Foundation","keywords":"Agency (philosophy); European union; Certification; Good manufacturing practice; Christian ministry; Business; Food and drug administration; Medicine; Environmental health; Marketing; Management; Political science; Supply chain","score_opus":0.23924886246479937,"score_gpt":0.38687395133013114,"score_spread":0.14762508886533177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251325721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840933,0.0040211226,0.0012131084,0.009296146,0.0004288254,0.00035143684,0.00042094526,0.000004037173,0.00017107335],"genre_scores_gemma":[0.9937007,0.0048387824,0.0007286938,0.00036636402,0.0002128488,0.00001831824,8.532273e-7,0.000009338987,0.00012410176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984696,0.0000358984,0.00086593337,0.0002628746,0.00012269261,0.00024302426],"domain_scores_gemma":[0.99620646,0.0017701101,0.0016410588,0.00007542285,0.00018617969,0.00012078819],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001288288,0.00014991676,0.000369355,0.00017021169,0.00016958152,0.000106567095,0.00039936727,0.000036267054,0.00030973332],"category_scores_gemma":[0.00054377783,0.000098109704,0.00011867401,0.00009598938,0.0009022791,0.0013635918,0.00007432969,0.00011347027,5.228413e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002526227,0.00037669129,0.67598176,0.0012161382,0.00079757837,0.0000016349494,0.004850189,0.00008387868,0.103501305,0.1653724,0.003258442,0.04203378],"study_design_scores_gemma":[0.011967808,0.0008204553,0.4327737,0.00092550804,0.00043527846,0.000073698575,0.0022652112,0.079959,0.23453137,0.10615688,0.12895119,0.0011398738],"about_ca_topic_score_codex":0.000021079,"about_ca_topic_score_gemma":0.000011807153,"teacher_disagreement_score":0.24320802,"about_ca_system_score_codex":0.000037803064,"about_ca_system_score_gemma":0.00006594122,"threshold_uncertainty_score":0.40007976},"labels":[],"label_agreement":null},{"id":"W4251475153","doi":"10.21518/1561-5936-2014-11-78-83","title":"Steps to Success: changes in the ranking of pharmaceutical producers in quarter II 2014","year":2014,"lang":"en","type":"article","venue":"Remedium Journal about the Russian market of medicines and medical equipment","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Ranking (information retrieval); Business; Advertising; Agricultural economics; Geography; Computer science; Economics; Information retrieval; Archaeology","score_opus":0.027464634708670492,"score_gpt":0.2984104831746834,"score_spread":0.2709458484660129,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251475153","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.43558827,0.0061794226,0.00039016106,0.5368733,0.0011697985,0.0006349605,0.00001455008,0.000005641887,0.019143922],"genre_scores_gemma":[0.9795299,0.008328256,0.00005676805,0.011226992,0.0007720852,0.000020832429,0.0000011490168,0.000012870796,0.000051112194],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975423,0.00020327355,0.0012201406,0.000265369,0.00029240493,0.00047650372],"domain_scores_gemma":[0.9984815,0.0004802627,0.00039505534,0.00024572606,0.000018344874,0.00037907396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011895325,0.00018579859,0.00066695624,0.00033418756,0.00009487636,0.000025356638,0.00063327036,0.000107135216,0.00086149335],"category_scores_gemma":[0.0007579793,0.000108805456,0.00008411771,0.00025918105,0.000303501,0.000069158144,0.00014578098,0.0006244301,0.0000058054115],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002976869,0.0024449974,0.19950064,0.0023930292,0.0006753082,0.00015897606,0.04407097,0.00012816222,0.00062018563,0.2921301,0.12816268,0.3267381],"study_design_scores_gemma":[0.010505678,0.0015525176,0.1825868,0.0023756437,0.0000865252,0.0002805614,0.0016948977,0.017741885,0.00032456339,0.027687764,0.75450265,0.00066050136],"about_ca_topic_score_codex":0.00008142669,"about_ca_topic_score_gemma":0.0001252295,"teacher_disagreement_score":0.62634,"about_ca_system_score_codex":0.000062178566,"about_ca_system_score_gemma":0.00007114665,"threshold_uncertainty_score":0.9432748},"labels":[],"label_agreement":null},{"id":"W4251576488","doi":"10.1377/forefront.20190731.727552","title":"Trump Administration, In Shift, Announces Plan To Permit Drug Importation","year":2019,"lang":"en","type":"dataset","venue":"Forefront Group","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Administration (probate law); Plan (archaeology); Drug administration; Business; Drug; Food and drug administration; Pharmacology; Political science; Medicine; Geography; Risk analysis (engineering); Law","score_opus":0.05084466596624171,"score_gpt":0.29111825311813105,"score_spread":0.24027358715188935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251576488","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014078776,0.00053686433,0.000021530592,0.0014720655,0.0013007179,0.00060809834,0.97881544,0.000015637817,0.0031508578],"genre_scores_gemma":[0.030610077,0.0003571398,0.00008006211,0.0026716252,0.00045638788,0.0001331592,0.9650255,0.000034093548,0.000631973],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99758077,0.000017573966,0.0011297904,0.00072345324,0.000053079963,0.0004953191],"domain_scores_gemma":[0.9986618,0.000057280544,0.0005004973,0.0005531159,0.000012051109,0.00021523176],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00053650956,0.00035252696,0.00074780185,0.0004941882,0.000061080966,0.00015790018,0.0004588391,0.00027793206,0.000950075],"category_scores_gemma":[0.0000581157,0.0004206635,0.00014991604,0.00018104879,0.00003566086,0.00027036908,0.00009030762,0.0003937944,0.0045370753],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005488502,0.00010196761,0.0023523932,0.00010750271,0.000030509664,0.000007777126,0.00016826541,0.000033338336,3.224834e-7,0.008443307,0.98862815,0.00007158715],"study_design_scores_gemma":[0.00047867835,0.00014329907,0.008190813,0.00003304188,0.000009106274,0.0000026301127,0.000022357663,0.00017318783,0.0000022626066,0.008121507,0.98231685,0.0005062631],"about_ca_topic_score_codex":0.0010821115,"about_ca_topic_score_gemma":0.006377703,"teacher_disagreement_score":0.0165313,"about_ca_system_score_codex":0.0002890088,"about_ca_system_score_gemma":0.000081700746,"threshold_uncertainty_score":0.99996316},"labels":[],"label_agreement":null},{"id":"W4251772664","doi":"10.1002/div.7263","title":"Abbott Laboratories","year":2008,"lang":"en","type":"article","venue":"Mergent s Dividend Achievers","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Joint venture; Medical prescription; Business; Commerce; Pharmacology","score_opus":0.08134316636998808,"score_gpt":0.2612341988136709,"score_spread":0.17989103244368282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251772664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91556823,0.003148095,0.00037224623,0.0052903285,0.0018986452,0.00017286846,0.00039707747,0.00010740637,0.073045105],"genre_scores_gemma":[0.9926317,0.0017965595,0.0002464446,0.0028025685,0.00028316933,0.000017337808,0.000017817216,0.000028858587,0.002175579],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99871737,0.000012649545,0.00048216665,0.00035545594,0.000037087477,0.00039524553],"domain_scores_gemma":[0.9992642,0.000031453088,0.00016309637,0.00029731126,0.00001859782,0.00022533716],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000244544,0.00017346839,0.00032208927,0.0001363336,0.00022880756,0.000034637673,0.00028470927,0.00007849441,0.0023883714],"category_scores_gemma":[0.000087185625,0.00020523142,0.00013992572,0.00024862672,0.00011440702,0.00029966474,0.000087721826,0.00017021288,0.0041196127],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030257754,0.00017206643,0.3479397,0.000025303847,0.00018451853,0.000029920913,0.0008303233,0.00014162807,0.00013931711,0.5426235,0.10752351,0.000359933],"study_design_scores_gemma":[0.0004975138,0.00003008118,0.038608328,0.0000034382163,0.0000058837436,0.0000067359365,0.000023798786,0.00027873748,0.00053795235,0.013186138,0.9464771,0.00034426528],"about_ca_topic_score_codex":0.00014939478,"about_ca_topic_score_gemma":0.000011521872,"teacher_disagreement_score":0.8389536,"about_ca_system_score_codex":0.00007918714,"about_ca_system_score_gemma":0.000029960838,"threshold_uncertainty_score":0.9985236},"labels":[],"label_agreement":null},{"id":"W4251774901","doi":"10.3821/1913-701x-143.6.263","title":"Steps Being Taken to Ease Drug Shortages","year":2010,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Economic shortage; Drug; Medicine; Computer science; Pharmacology; Philosophy","score_opus":0.03860060843814241,"score_gpt":0.26016843006468676,"score_spread":0.22156782162654434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251774901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9583007,0.00054759457,0.00009021879,0.0019331274,0.0063307015,0.0004080857,0.0019266001,0.00003719786,0.030425766],"genre_scores_gemma":[0.97612,0.0011508608,0.00037432875,0.018284535,0.002050931,0.000026148222,0.000024375282,0.0000939112,0.001874894],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99656373,0.000042056025,0.0011029545,0.0006472839,0.00011033747,0.0015336066],"domain_scores_gemma":[0.99360645,0.00010250179,0.00034332418,0.00042204972,0.0001840267,0.005341673],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011443773,0.00044991652,0.0006102783,0.0007634768,0.00088692555,0.0005138666,0.0011414272,0.000092333576,0.0048740357],"category_scores_gemma":[0.000339722,0.00057253224,0.00023350018,0.0005860938,0.00015211875,0.0005366567,0.00009208805,0.0013300977,0.00043942474],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027484534,0.00031675788,0.06434417,0.00047407733,0.0012084575,0.062258944,0.008023393,0.003993953,0.008053002,0.07898957,0.62961483,0.14244798],"study_design_scores_gemma":[0.0013538374,0.000022855238,0.00018372246,0.000009537568,0.00004196381,0.045400124,0.000008347002,0.004700714,0.0016473823,0.00405496,0.941473,0.0011035275],"about_ca_topic_score_codex":0.040249478,"about_ca_topic_score_gemma":0.21656135,"teacher_disagreement_score":0.31185818,"about_ca_system_score_codex":0.0014638993,"about_ca_system_score_gemma":0.0015744689,"threshold_uncertainty_score":0.9996726},"labels":[],"label_agreement":null},{"id":"W4252192041","doi":"10.4414/cvm.2005.01108","title":"Directives 2005 concernant les contrôles de patients porteurs de stimulateurs cardiaques","year":2005,"lang":"fr","type":"article","venue":"Kardiovask Med","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ministère de l’Emploi et de la Solidarité Sociale (Québec)","funders":"","keywords":"Philosophy; Political science","score_opus":0.036004933760991883,"score_gpt":0.2773360917101871,"score_spread":0.24133115794919519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252192041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73729974,0.18765394,0.00096964795,0.014455098,0.0027070043,0.0006250372,0.0023822456,0.00011252303,0.05379478],"genre_scores_gemma":[0.9413717,0.044494882,0.00096415816,0.0028777285,0.0018675855,0.000051261843,0.00004951804,0.000107229454,0.00821596],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963971,0.00017144499,0.0010740412,0.0007441227,0.00008409443,0.0015292066],"domain_scores_gemma":[0.9979787,0.00029634306,0.00048165213,0.00051652227,0.00008182737,0.000644978],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0013639678,0.00047346286,0.0012115753,0.00024333727,0.0002358805,0.00014080798,0.00045369213,0.0004154281,0.0009732665],"category_scores_gemma":[0.0004291804,0.00061967893,0.0007558132,0.00016333025,0.00039837207,0.00045826446,0.00013464052,0.00051318115,0.0008324978],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019812699,0.0008049758,0.3873703,0.00015850695,0.0026976387,0.00005074231,0.002747507,0.016922578,0.000032454096,0.04065277,0.07446938,0.47389504],"study_design_scores_gemma":[0.002448549,0.000065490414,0.12888302,0.00007277456,0.00014249289,0.000015832926,0.000065899585,0.014138143,0.0005309592,0.0035371315,0.84942126,0.0006784343],"about_ca_topic_score_codex":0.0019258537,"about_ca_topic_score_gemma":0.00032390858,"teacher_disagreement_score":0.7749519,"about_ca_system_score_codex":0.0012603449,"about_ca_system_score_gemma":0.0002141251,"threshold_uncertainty_score":0.99994546},"labels":[],"label_agreement":null},{"id":"W4252445278","doi":"10.1057/9781137453648_8","title":"A multi-agent simulation of the pharmaceutical supply chain","year":2014,"lang":"en","type":"book-chapter","venue":"Palgrave Macmillan UK eBooks","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Profitability index; Supply chain; Business; Industrial organization; Tracing; Pharmaceutical industry; Quarter (Canadian coin); Product (mathematics); Work (physics); Computer science; Marketing; Engineering; Finance; Mathematics","score_opus":0.07615983211597162,"score_gpt":0.2923086054928009,"score_spread":0.2161487733768293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252445278","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008123517,0.0019014756,0.0018830018,0.00046231554,0.0010490665,0.0009556291,0.0014441132,0.000045356534,0.9914467],"genre_scores_gemma":[0.98742765,0.00021299675,0.00015172023,0.0017795615,0.00039837422,0.000021479518,0.00003026883,0.000110462046,0.009867488],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99753356,0.000026884,0.0012574985,0.00062948174,0.00008320382,0.00046939438],"domain_scores_gemma":[0.99782354,0.00018671718,0.0008855102,0.00081070355,0.00005322669,0.00024028728],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00053358596,0.00048955495,0.00092541066,0.00025618626,0.00011567479,0.00004600015,0.0006304135,0.00040997507,0.0013931678],"category_scores_gemma":[0.00007430097,0.00046284165,0.00062922406,0.000025369953,0.00029055882,9.375173e-7,0.00029865035,0.0005148885,0.00078246],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026488156,0.0000015462059,0.0006134917,0.00009259764,0.00017078537,0.0000019991935,0.00015702918,0.0005188124,0.000036750353,0.9950382,0.000039556508,0.0033027614],"study_design_scores_gemma":[0.0011914629,0.000046568806,0.0008341632,0.00008237277,0.000064240674,0.0000047537665,0.0000027123426,0.0694154,0.00021123885,0.78403664,0.14345615,0.0006542822],"about_ca_topic_score_codex":0.00004418124,"about_ca_topic_score_gemma":0.000028783661,"teacher_disagreement_score":0.9866153,"about_ca_system_score_codex":0.00015889278,"about_ca_system_score_gemma":0.00004676069,"threshold_uncertainty_score":0.9999955},"labels":[],"label_agreement":null},{"id":"W4252658922","doi":"10.1201/b14674-36","title":"Canadian Health Products and Food Branch (HPFB) and Therapeutic Products Directorate (TPD)","year":2012,"lang":"en","type":"book-chapter","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Food products; Business; Environmental health; Environmental science; Food science; Medicine; Chemistry","score_opus":0.09076159160031785,"score_gpt":0.2600745730170859,"score_spread":0.16931298141676807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252658922","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027359517,0.20450729,0.000005680426,0.043549195,0.0009932396,0.0012808945,0.0017848903,0.000072855364,0.74507],"genre_scores_gemma":[0.59584945,0.03625139,0.0002026932,0.018039849,0.0016149015,0.000034082277,0.00013882451,0.00025645664,0.34761238],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99765444,0.000011093781,0.0006998506,0.00085292646,0.000028741255,0.0007529643],"domain_scores_gemma":[0.9982737,0.00003319407,0.00039108846,0.0004747939,0.000044340264,0.00078291347],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00059634633,0.00045532675,0.0008760963,0.00043204223,0.0001888574,0.00014955444,0.00017374668,0.0002687276,0.00086894544],"category_scores_gemma":[0.000028449726,0.00050713914,0.000057128116,0.00006238425,0.00013132,0.00015537089,0.00008297061,0.000412531,0.00064067537],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000060551247,0.000016963199,0.0007629005,0.0002593173,0.00019411511,6.7849396e-7,0.00024172464,3.4727515e-7,0.0000022716965,0.9668744,0.0077066114,0.023934597],"study_design_scores_gemma":[0.00028383915,0.000097975426,0.0012715169,0.00002515741,0.000014450123,0.000014768279,0.0000012725083,0.000038278642,0.000015022814,0.068803765,0.9288609,0.00057304144],"about_ca_topic_score_codex":0.013916135,"about_ca_topic_score_gemma":0.017402088,"teacher_disagreement_score":0.9211543,"about_ca_system_score_codex":0.00031841858,"about_ca_system_score_gemma":0.00034492812,"threshold_uncertainty_score":0.99973804},"labels":[],"label_agreement":null},{"id":"W4253296631","doi":"10.1353/crv.2013.0007","title":"The Maple Peril: From Presidential Policy to Pharmaceutical Importation, 1992-Present","year":2013,"lang":"en","type":"article","venue":"Canadian Review of American Studies","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Philosophy","score_opus":0.06144120684799439,"score_gpt":0.35823525986087323,"score_spread":0.29679405301287887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253296631","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.066499494,0.5069,0.000031456304,0.39038914,0.000682281,0.0019390546,0.0015601156,0.000032147887,0.031966295],"genre_scores_gemma":[0.5917647,0.3359484,0.00034179725,0.07015467,0.0008408065,0.0003912505,0.000022757617,0.000043568012,0.0004920636],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982792,0.000034945708,0.0008293505,0.0003137901,0.00004477236,0.00049795676],"domain_scores_gemma":[0.99840635,0.00019310015,0.00033257212,0.00038816847,0.00009397395,0.00058580533],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030011358,0.00017688693,0.0006698148,0.00016118167,0.00019757409,0.000059845188,0.0004048701,0.000021349933,0.0007585475],"category_scores_gemma":[0.00062068197,0.00015452683,0.00016260422,0.0003960179,0.00038443686,0.000097751385,0.00010181303,0.00011667264,0.001006463],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010148998,0.00003163885,0.0091523025,0.0006181519,0.00085669383,0.0000052656865,0.0008964856,0.000013566407,0.000015960779,0.08236475,0.8237966,0.08223846],"study_design_scores_gemma":[0.00010982929,0.000032043576,0.01488318,0.00013253577,0.00002027487,0.0000010196687,0.00026240663,0.00008452384,0.000021755619,0.0063647153,0.9778949,0.00019282618],"about_ca_topic_score_codex":0.2968825,"about_ca_topic_score_gemma":0.024280906,"teacher_disagreement_score":0.52526516,"about_ca_system_score_codex":0.0002645781,"about_ca_system_score_gemma":0.00019326464,"threshold_uncertainty_score":0.99977136},"labels":[],"label_agreement":null},{"id":"W4253716176","doi":"10.1037/e533732006-001","title":"The Price and Purity of Illicit Drugs: 1981 Through the Second Quarter of 2003","year":2004,"lang":"en","type":"dataset","venue":"PsycEXTRA Dataset","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Illicit drug; Pharmacology; Medicine; Geography; Drug","score_opus":0.03715002072952046,"score_gpt":0.29703845382078464,"score_spread":0.2598884330912642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253716176","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025717614,0.006514387,0.000012315734,0.0019591653,0.0004960331,0.00045570012,0.98851955,0.000004554308,0.0017811228],"genre_scores_gemma":[0.00081883755,0.0090085175,0.000059074104,0.0025188965,0.00020459092,0.000042383843,0.98724335,0.000023820152,0.000080547296],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99755543,0.000048153895,0.0013255104,0.00054377905,0.00006943301,0.0004576744],"domain_scores_gemma":[0.99674135,0.00032596462,0.0011828392,0.0015922594,0.000043733584,0.00011382081],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00093358575,0.0003533574,0.00076809875,0.00009690387,0.00019476563,0.000111708854,0.0012280804,0.00025709308,0.0015035368],"category_scores_gemma":[0.0001382413,0.00026354525,0.00012817651,0.0002849278,0.00058035617,0.00022086338,0.00026046616,0.0005796371,0.00031372986],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030638224,0.00010396479,0.000018266503,0.00026710826,0.00018108892,0.0000010215481,0.00011889454,0.0000025483162,8.1300107e-7,0.02479788,0.97439605,0.000081729544],"study_design_scores_gemma":[0.000557925,0.00005840987,0.00011181321,0.000026923586,0.000038556245,0.0000076552815,0.00004987495,0.000025156996,0.000023808745,0.023882324,0.974929,0.00028858607],"about_ca_topic_score_codex":0.0019291919,"about_ca_topic_score_gemma":0.00056634727,"teacher_disagreement_score":0.0024941305,"about_ca_system_score_codex":0.000056523077,"about_ca_system_score_gemma":0.00009932299,"threshold_uncertainty_score":0.9999817},"labels":[],"label_agreement":null},{"id":"W4255275834","doi":"10.1021/cen-09433-notw11","title":"Piramal to acquire API maker Ash Stevens","year":2016,"lang":"en","type":"article","venue":"C&EN Global Enterprise","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmaceutical industry; Business; Medicine; Pharmacology","score_opus":0.029874759922232607,"score_gpt":0.28390996173172334,"score_spread":0.25403520180949074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255275834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7392324,0.0008326707,0.0102972565,0.025948538,0.0020666874,0.00052031525,0.002966053,0.00015593854,0.21798012],"genre_scores_gemma":[0.98671323,0.00013655117,0.00045016094,0.009668958,0.00037298424,0.00002916526,0.0000052016335,0.000027188295,0.0025965783],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99828035,0.000018055383,0.0005553465,0.000526536,0.000035462064,0.00058425416],"domain_scores_gemma":[0.99889815,0.000048606766,0.00013516976,0.00045107314,0.000021453996,0.00044552304],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002789615,0.00022143006,0.00037998467,0.00008850075,0.00006260386,0.000088024266,0.0004475424,0.00012584486,0.001767567],"category_scores_gemma":[0.00013326286,0.00020383646,0.0001879687,0.00016911882,0.000059325117,0.00021377121,0.00027933452,0.00007848392,0.015133121],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002597911,0.00036299892,0.14694433,0.000039437804,0.00022564316,0.00004101688,0.00042416115,0.000046521818,0.00028469853,0.6522358,0.12134134,0.07779426],"study_design_scores_gemma":[0.0010512758,0.00008647651,0.022719385,0.00003021824,0.0000069262614,0.000010929793,0.00001119781,0.00013646197,0.000096140735,0.032153305,0.9433068,0.00039088694],"about_ca_topic_score_codex":0.000067069406,"about_ca_topic_score_gemma":0.000022883387,"teacher_disagreement_score":0.82196546,"about_ca_system_score_codex":0.00041531425,"about_ca_system_score_gemma":0.000028934332,"threshold_uncertainty_score":0.999145},"labels":[],"label_agreement":null},{"id":"W4255714731","doi":"10.1179/175380609790795707","title":"Drug pricing and reimbursement in Europe: Strategy and tactics","year":2009,"lang":"en","type":"article","venue":"Journal of Communications In Healthcare","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Business; Product (mathematics); Pricing strategies; Marketing; Investment (military); Control (management); New product development; Return on investment; Health care; Industrial organization; Economics; Production (economics); Microeconomics; Economic growth","score_opus":0.14868549785318158,"score_gpt":0.39255738209891966,"score_spread":0.24387188424573808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255714731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82364506,0.03561989,0.00002328357,0.13172816,0.00006873301,0.00014321863,0.000015230702,0.000003221288,0.008753236],"genre_scores_gemma":[0.95650584,0.040489495,0.0010857921,0.0018658864,0.000024082457,0.0000011666352,0.0000010528851,0.0000048991706,0.000021798282],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99893737,0.00005458499,0.0007763975,0.00008111457,0.000016350828,0.00013417607],"domain_scores_gemma":[0.9991343,0.00010697728,0.0003462043,0.0002751375,0.000046589557,0.000090803595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008871847,0.00006123629,0.00023970912,0.0002808772,0.00005237815,0.000039718798,0.00023478424,0.00003509796,0.000004304975],"category_scores_gemma":[0.0001033455,0.00006991263,0.00001625607,0.00021564748,0.000038301867,0.00017458902,0.000059969225,0.00042568482,0.0000022059505],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022693592,0.00015563723,0.1891925,0.000041240473,0.000010250123,0.0000056656636,0.001353912,0.00014776712,0.00001072419,0.77882516,0.00020341217,0.030031027],"study_design_scores_gemma":[0.0016169838,0.00031563189,0.6968175,0.00018500985,0.000005725551,0.00006949021,0.0004573285,0.00960567,0.000013656736,0.18894781,0.1017079,0.0002572655],"about_ca_topic_score_codex":0.00022994562,"about_ca_topic_score_gemma":0.00023098223,"teacher_disagreement_score":0.58987737,"about_ca_system_score_codex":0.0001015608,"about_ca_system_score_gemma":0.000050122406,"threshold_uncertainty_score":0.28509545},"labels":[],"label_agreement":null},{"id":"W4255896083","doi":"10.1037/e407442005-001","title":"The Price and Purity of Illicit Drugs: 1981 Through the Second Quarter of 2003","year":2004,"lang":"en","type":"dataset","venue":"PsycEXTRA Dataset","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Illicit drug; Business; Economics; Medicine; Pharmacology; Drug; Geography","score_opus":0.03715002072952046,"score_gpt":0.29703845382078464,"score_spread":0.2598884330912642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255896083","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025717614,0.006514387,0.000012315734,0.0019591653,0.0004960331,0.00045570012,0.98851955,0.000004554308,0.0017811228],"genre_scores_gemma":[0.00081883755,0.0090085175,0.000059074104,0.0025188965,0.00020459092,0.000042383843,0.98724335,0.000023820152,0.000080547296],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99755543,0.000048153895,0.0013255104,0.00054377905,0.00006943301,0.0004576744],"domain_scores_gemma":[0.99674135,0.00032596462,0.0011828392,0.0015922594,0.000043733584,0.00011382081],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00093358575,0.0003533574,0.00076809875,0.00009690387,0.00019476563,0.000111708854,0.0012280804,0.00025709308,0.0015035368],"category_scores_gemma":[0.0001382413,0.00026354525,0.00012817651,0.0002849278,0.00058035617,0.00022086338,0.00026046616,0.0005796371,0.00031372986],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030638224,0.00010396479,0.000018266503,0.00026710826,0.00018108892,0.0000010215481,0.00011889454,0.0000025483162,8.1300107e-7,0.02479788,0.97439605,0.000081729544],"study_design_scores_gemma":[0.000557925,0.00005840987,0.00011181321,0.000026923586,0.000038556245,0.0000076552815,0.00004987495,0.000025156996,0.000023808745,0.023882324,0.974929,0.00028858607],"about_ca_topic_score_codex":0.0019291919,"about_ca_topic_score_gemma":0.00056634727,"teacher_disagreement_score":0.0024941305,"about_ca_system_score_codex":0.000056523077,"about_ca_system_score_gemma":0.00009932299,"threshold_uncertainty_score":0.9999817},"labels":[],"label_agreement":null},{"id":"W4256019501","doi":"10.1177/171516350714000210","title":"Manitoba Drug Plan Brings in New Option for Patients Facing High Drug Costs","year":2007,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Plan (archaeology); Medicine; Business; Intensive care medicine; Risk analysis (engineering); Pharmacology; History","score_opus":0.04475039639649905,"score_gpt":0.2526263616058926,"score_spread":0.20787596520939353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4256019501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990124,0.0007111477,0.0005160254,0.00040888716,0.0034526156,0.0006052774,0.0016131197,0.000018708632,0.0025502357],"genre_scores_gemma":[0.9912523,0.0015393753,0.00029069735,0.0048027555,0.0012212858,0.000011544458,0.00009574152,0.00007494968,0.0007113559],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99654555,0.000029831253,0.0012894439,0.00054213137,0.000096609576,0.0014964492],"domain_scores_gemma":[0.9964572,0.00016464316,0.0005194713,0.00020407118,0.00014447709,0.002510121],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013243944,0.00038553242,0.00055595033,0.0008763217,0.00048820119,0.0002702356,0.00063017354,0.00007813485,0.00036311132],"category_scores_gemma":[0.00018049499,0.00051757554,0.00017592941,0.00044125013,0.00007545502,0.00058199477,0.00004676359,0.00063719455,0.00006232587],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010890372,0.0004912237,0.30558467,0.00073059974,0.0006963938,0.012571876,0.0065468317,0.005078646,0.0004112514,0.04056059,0.26354215,0.36269674],"study_design_scores_gemma":[0.018866755,0.000107522785,0.0056188847,0.00009926311,0.00009700244,0.018198038,0.00005658254,0.013177921,0.0027976604,0.015914172,0.92191815,0.0031480552],"about_ca_topic_score_codex":0.22151394,"about_ca_topic_score_gemma":0.56840205,"teacher_disagreement_score":0.658376,"about_ca_system_score_codex":0.006805376,"about_ca_system_score_gemma":0.0012524114,"threshold_uncertainty_score":0.9997276},"labels":[],"label_agreement":null},{"id":"W4256036976","doi":"10.3821/1913-701x(2008)141[135:cbspfa]2.0.co;2","title":"Competition Bureau shouldn't point finger at pharmacies","year":2008,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Competition (biology); Pharmacy; Point (geometry); Business; Advertising; Marketing; Medicine; Family medicine; Mathematics; Biology","score_opus":0.10679685866139066,"score_gpt":0.27391626499236205,"score_spread":0.1671194063309714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4256036976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9197619,0.0058903163,0.00028275672,0.0020745217,0.0060291085,0.0005598266,0.003371935,0.00008916294,0.06194049],"genre_scores_gemma":[0.9645347,0.016623357,0.00015706621,0.014331387,0.0015815323,0.000025978623,0.0000959757,0.000100617974,0.0025493612],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99619496,0.0000771993,0.0013025857,0.00067779643,0.00015328651,0.001594159],"domain_scores_gemma":[0.9956468,0.00010956323,0.00056915276,0.0003640003,0.0002198492,0.0030906668],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007542408,0.0005438336,0.0007589915,0.00067839416,0.0018452494,0.0002015625,0.0008396407,0.000119673874,0.009701867],"category_scores_gemma":[0.00015061277,0.00068003277,0.00034698538,0.00055123295,0.00041353307,0.0006935726,0.00011522028,0.0008899358,0.00063702645],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005144531,0.00042371397,0.03275706,0.0005553734,0.0015270195,0.1096209,0.0068784733,0.0056248135,0.004129466,0.042124387,0.7782507,0.01759366],"study_design_scores_gemma":[0.0025259645,0.000038655147,0.000107079846,0.000011504686,0.000046046338,0.2775429,0.000005040926,0.007680313,0.0018155767,0.0030348233,0.7061156,0.0010764962],"about_ca_topic_score_codex":0.02303206,"about_ca_topic_score_gemma":0.029742498,"teacher_disagreement_score":0.167922,"about_ca_system_score_codex":0.005143895,"about_ca_system_score_gemma":0.0012353724,"threshold_uncertainty_score":0.99956506},"labels":[],"label_agreement":null},{"id":"W4256136035","doi":"10.1212/01.wnl.0000313154.55518.25","title":"Clinical consequences of generic substitution of lamotrigine for patients with epilepsy","year":2008,"lang":"en","type":"article","venue":"Neurology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":117,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Lamotrigine; Medicine; Epilepsy; Gabapentin; Carbamazepine; Pharmacy; Psychiatry; Family medicine; Alternative medicine","score_opus":0.10281787248921477,"score_gpt":0.3094421319751415,"score_spread":0.20662425948592672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4256136035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99705523,0.00016927076,0.0004581686,0.00044783656,0.00026357567,0.00016997184,0.00017459062,0.0000057707193,0.0012555803],"genre_scores_gemma":[0.99810326,0.00034296603,0.00042564017,0.0010303542,0.000055940458,0.000009915082,0.000012218239,0.000007640443,0.000012058769],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990317,0.000015597834,0.0005945288,0.0001989426,0.000012164,0.000147062],"domain_scores_gemma":[0.99923915,0.00014892656,0.00037928642,0.00013745723,0.000045951227,0.000049248338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016370477,0.0000693101,0.00037210528,0.0000873626,0.000027108534,0.0000014980187,0.000115713294,0.000081227525,0.000053229338],"category_scores_gemma":[0.000093762406,0.00006842098,0.00007872653,0.00007714502,0.00046208044,0.0000494982,0.000016327438,0.000077082965,0.000017144925],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032993354,0.00016040527,0.9100612,0.000017947026,0.000026609863,9.09829e-7,0.000014872959,0.00009060667,0.000016558906,0.08892668,0.00016385021,0.00019044876],"study_design_scores_gemma":[0.0030812763,0.0026558174,0.912859,0.0000025515697,0.00001192637,0.000007929801,2.6720247e-7,0.0014889935,0.00033210407,0.011349037,0.06805988,0.0001512132],"about_ca_topic_score_codex":0.00004897161,"about_ca_topic_score_gemma":0.00000538022,"teacher_disagreement_score":0.07757764,"about_ca_system_score_codex":0.000005165253,"about_ca_system_score_gemma":0.0000332888,"threshold_uncertainty_score":0.27901268},"labels":[],"label_agreement":null},{"id":"W4256674571","doi":"10.1517/eotp.13.7.979.22985","title":"Epilepsy drug review: patent activity from 1999 to 2002","year":2003,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Patents","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Drug; Epilepsy; Pharmacology; Drug development; Medicine; Business; Psychiatry","score_opus":0.17062245208788937,"score_gpt":0.33226603316605974,"score_spread":0.16164358107817037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4256674571","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13445053,0.62454265,0.004326316,0.06019541,0.019984692,0.0045797336,0.002359498,0.00044747005,0.1491137],"genre_scores_gemma":[0.78931385,0.12211672,0.00025765243,0.08655911,0.0003685197,0.00023626452,0.000042301926,0.00008661969,0.0010189633],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99797744,0.00009431571,0.00063037744,0.00069777697,0.00007326147,0.00052685867],"domain_scores_gemma":[0.9986452,0.00008638442,0.00025295714,0.00063305127,0.000022554255,0.0003598856],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00046476396,0.00031960555,0.0006048853,0.00015004275,0.00012547753,0.000058195255,0.00035416946,0.00009876434,0.0037607115],"category_scores_gemma":[0.00006983469,0.000332518,0.00022008373,0.00020683337,0.000034059107,0.00014839001,0.000053196556,0.00023101109,0.008814076],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060512003,0.004090342,0.029112028,0.00021650529,0.0012287801,0.000016868913,0.003172449,0.00018148206,0.0020071846,0.21418634,0.50546366,0.23971921],"study_design_scores_gemma":[0.00081860286,0.00008121943,0.0056225862,0.00013692743,0.0000022496624,0.0000011515227,0.0000102990725,0.0003391176,0.001496792,0.0065655983,0.9844742,0.0004512521],"about_ca_topic_score_codex":0.0003936263,"about_ca_topic_score_gemma":0.0000032660405,"teacher_disagreement_score":0.6548633,"about_ca_system_score_codex":0.00019598169,"about_ca_system_score_gemma":0.00002275695,"threshold_uncertainty_score":0.9999127},"labels":[],"label_agreement":null},{"id":"W4280498760","doi":"10.1016/j.healthpol.2022.05.003","title":"The effect of patented drug price on the share of new medicines across OECD countries","year":2022,"lang":"en","type":"article","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute on Governance; University of Toronto","funders":"Innovative Medicines Canada","keywords":"Drug prices; Government (linguistics); Extant taxon; Drug; Public economics; Economics; Estimation; Business; Actuarial science; Medicine; Pharmacology; Biology","score_opus":0.06423632173922453,"score_gpt":0.37588932529915237,"score_spread":0.31165300355992787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280498760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6866248,0.0061146733,0.000006308609,0.29445794,0.0005741814,0.0008831659,0.0024497902,0.000024112684,0.008865012],"genre_scores_gemma":[0.9766009,0.0016000316,0.0000023405262,0.02046939,0.0003052591,0.000060994553,0.000012961486,0.00002121743,0.0009268897],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983987,0.00010787906,0.00076695037,0.00019518999,0.000065254004,0.00046600285],"domain_scores_gemma":[0.9978256,0.0009064433,0.00070798927,0.0003962358,0.000015109889,0.00014862101],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021441276,0.00013412081,0.00044732037,0.00009807935,0.00055192295,0.000021573513,0.0004713083,0.00002666942,0.0004902281],"category_scores_gemma":[0.0002953753,0.00009073162,0.00011478382,0.00024403165,0.00014363961,0.000037595284,0.00017857454,0.000263866,0.00010369315],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030339436,0.00005412044,0.013682803,0.00034257653,0.00010118939,6.4660674e-7,0.007067595,0.00021209428,0.0000031337709,0.79420346,0.17928675,0.0047422256],"study_design_scores_gemma":[0.000967823,0.0005174377,0.008033363,0.000018750214,0.000002979388,0.0000025424195,0.00021290933,0.0007585308,0.00023576916,0.008377887,0.9807607,0.00011129558],"about_ca_topic_score_codex":0.0061144764,"about_ca_topic_score_gemma":0.00007887397,"teacher_disagreement_score":0.801474,"about_ca_system_score_codex":0.00020133438,"about_ca_system_score_gemma":0.00021946132,"threshold_uncertainty_score":0.92433006},"labels":[],"label_agreement":null},{"id":"W4280526549","doi":"10.3386/w30053","title":"Bargaining and International Reference Pricing in the Pharmaceutical Industry","year":2022,"lang":"en","type":"report","venue":"National Bureau of Economic Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Agence Nationale de la Recherche; National Institute for Health Care Management Foundation","keywords":"Pharmaceutical industry; Industrial organization; Business; Microeconomics; Economics; Commerce; Biotechnology","score_opus":0.7229083225269128,"score_gpt":0.5841179119715677,"score_spread":0.13879041055534513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280526549","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009974998,0.0023613991,0.0000019487206,0.004924355,0.00056325964,0.00038568556,0.00062391063,0.0000073716624,0.98115706],"genre_scores_gemma":[0.98926955,0.006154948,0.000053506505,0.0006589798,0.0007940392,0.00016693516,0.0002795915,0.00003928497,0.0025831426],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971025,0.00014637332,0.0012576337,0.000664031,0.0003435355,0.00048593528],"domain_scores_gemma":[0.9976915,0.0012529355,0.00046517022,0.00027801617,0.00019624009,0.00011615222],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.012923012,0.00020992577,0.0005455391,0.0012718209,0.00016698192,0.00014591473,0.0010692064,0.00044711438,0.004543989],"category_scores_gemma":[0.0013136549,0.00022450747,0.00010716981,0.00025381354,0.0002727106,0.0002112667,0.0005580403,0.0033794907,0.00013229452],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035578665,0.00009290667,0.012527284,0.000047815454,0.00012100515,0.0000057366483,0.00026833732,0.0004239268,0.0000039011124,0.96450984,0.020414865,0.0015487992],"study_design_scores_gemma":[0.000621173,0.00004763064,0.003287017,0.000034860437,0.000004703076,0.00004122238,0.0001934441,0.0044868654,0.0000061969176,0.49454117,0.496479,0.00025672503],"about_ca_topic_score_codex":0.001245925,"about_ca_topic_score_gemma":0.00006578178,"teacher_disagreement_score":0.9792946,"about_ca_system_score_codex":0.0019640394,"about_ca_system_score_gemma":0.0010721472,"threshold_uncertainty_score":0.9989197},"labels":[],"label_agreement":null},{"id":"W4281556573","doi":"10.3389/fddsv.2022.898654","title":"Overcoming Market Failures in Pandemic Drug Discovery Through Open Science: A Canadian Solution","year":2022,"lang":"en","type":"article","venue":"Frontiers in Drug Discovery","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Structural Genomics Consortium; University of Toronto; McGill University","funders":"","keywords":"Pandemic; Business; Private sector; Incentive; Variety (cybernetics); Investment (military); Drug development; Market failure; Coronavirus disease 2019 (COVID-19); Public relations; Public economics; Industrial organization; Economics; Economic growth; Drug; Political science; Market economy; Pharmacology; Infectious disease (medical specialty); Medicine","score_opus":0.031947902120840796,"score_gpt":0.27624080807343865,"score_spread":0.24429290595259784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281556573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8485042,0.0036078289,0.00062767084,0.006587354,0.00424293,0.0009822652,0.0016449124,0.000024397848,0.13377845],"genre_scores_gemma":[0.9903434,0.0005340468,0.0006048325,0.0031269891,0.0001010111,0.00017585506,0.000042215706,0.00003719937,0.0050344416],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970957,0.0000804162,0.0008143024,0.0008893111,0.00009681923,0.0010234381],"domain_scores_gemma":[0.9989642,0.000063068364,0.0002606849,0.0005084928,0.000008731577,0.00019482322],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026381013,0.00025078497,0.00059860724,0.0010624717,0.0005081976,0.00079877424,0.0019437515,0.000059915743,0.00036501468],"category_scores_gemma":[0.00013498134,0.0003268537,0.00012138726,0.001069454,0.00028420176,0.00430248,0.0012408582,0.00062471296,0.000026270303],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001517926,0.00017863128,0.6962614,0.000031856744,0.000040302068,0.000030564388,0.003129507,0.0031144454,0.000018010589,0.10236834,0.19397831,0.00069682905],"study_design_scores_gemma":[0.0030154593,0.000033232358,0.07490181,0.00005648072,0.0000101819705,0.000011405095,0.0037689835,0.030814148,0.000059362337,0.23512453,0.6509868,0.0012176012],"about_ca_topic_score_codex":0.29398006,"about_ca_topic_score_gemma":0.10873166,"teacher_disagreement_score":0.6213596,"about_ca_system_score_codex":0.003775787,"about_ca_system_score_gemma":0.000855632,"threshold_uncertainty_score":0.99991834},"labels":[],"label_agreement":null},{"id":"W4281745128","doi":"10.2337/db22-680-p","title":"680-P: Effect of the FreeStyle Libre System on Diabetes Treatment for People with T2D: Results from a Retrospective Cohort Study Using Canadian Private Payer Claims Database","year":2022,"lang":"en","type":"article","venue":"Diabetes","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Concomitant; Diabetes mellitus; Type 2 diabetes; Cohort; Glycemic; Reimbursement; Retrospective cohort study; Internal medicine; Insulin; Endocrinology; Health care","score_opus":0.026113028722674476,"score_gpt":0.24502088775554412,"score_spread":0.21890785903286963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281745128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9731691,0.00013215048,0.0000015866505,0.0003168671,0.00031317634,0.0020957082,0.023043312,0.000021534674,0.00090659334],"genre_scores_gemma":[0.99876654,0.000004082337,0.00003408373,0.0001863689,0.000098739074,0.0006007493,0.0002184324,0.000047433885,0.00004356881],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998304,0.00008879901,0.0004960677,0.0005812407,0.00006049376,0.00046938757],"domain_scores_gemma":[0.9983669,0.00037648375,0.0003864147,0.0006929844,0.000017347693,0.0001599029],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064150896,0.00024836374,0.0007409112,0.00015954806,0.00040422272,0.00006140088,0.00034868432,0.000042072083,0.000046587425],"category_scores_gemma":[0.00007306609,0.00019449828,0.00014880447,0.00031583878,0.00004372698,0.000097603435,0.00011659449,0.00015683551,0.000012488],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009818274,0.00011686211,0.99597716,0.000026888734,0.00040925114,9.80205e-7,0.00045163266,0.0008320472,0.00005253787,0.0017606075,0.00020678624,0.00006706566],"study_design_scores_gemma":[0.0058106217,0.0030206197,0.9467224,0.000059411832,0.00019574269,2.8113973e-7,0.0002107942,0.033911306,0.0046583894,0.00060416973,0.0043192296,0.00048701934],"about_ca_topic_score_codex":0.052484617,"about_ca_topic_score_gemma":0.009440913,"teacher_disagreement_score":0.04925474,"about_ca_system_score_codex":0.0011181509,"about_ca_system_score_gemma":0.00006878396,"threshold_uncertainty_score":0.953825},"labels":[],"label_agreement":null},{"id":"W4281978943","doi":"10.1056/nejmp2200601","title":"Perverse Incentives — HIV Prevention and the 340B Drug Pricing Program","year":2022,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Human immunodeficiency virus (HIV); Incentive; Drug pricing; Quarter (Canadian coin); Drug; Business; Medicine; Actuarial science; Economics; Family medicine; Pharmacology; Microeconomics","score_opus":0.03581128909195185,"score_gpt":0.292668399218413,"score_spread":0.2568571101264611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281978943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86811095,0.015422357,0.0004989026,0.09654725,0.0011343875,0.00041494347,0.000017455692,0.000013939635,0.017839832],"genre_scores_gemma":[0.99447685,0.0015115299,0.00017369485,0.0012741773,0.0012537426,0.0000059015324,0.0000025682077,0.0000092739265,0.0012922678],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990522,0.00007568715,0.0005679508,0.00010738417,0.00005364311,0.00014313293],"domain_scores_gemma":[0.9990942,0.00015199208,0.0005226722,0.00008886496,0.000018519071,0.00012378418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024514573,0.00008138573,0.00034221675,0.0001398917,0.00015078679,0.000022539607,0.0001713383,0.000013890848,0.0006445148],"category_scores_gemma":[0.00015681772,0.000057376084,0.00007404944,0.00011564187,0.00012749426,0.00011157114,0.00007672634,0.00034068958,0.000006016315],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020763634,0.00039828732,0.037955362,0.0000816773,0.0005130915,0.0000524281,0.023055945,0.0007503165,0.000040174124,0.41283464,0.06967008,0.45257163],"study_design_scores_gemma":[0.03930626,0.00038713112,0.003564776,0.000029158173,0.000040755844,0.00018147606,0.00062655786,0.0037842097,0.0000066221705,0.07329102,0.8786804,0.000101600504],"about_ca_topic_score_codex":0.00008427166,"about_ca_topic_score_gemma":0.0000075466464,"teacher_disagreement_score":0.8090103,"about_ca_system_score_codex":0.00005779704,"about_ca_system_score_gemma":0.000036140333,"threshold_uncertainty_score":0.7056985},"labels":[],"label_agreement":null},{"id":"W4281988284","doi":"10.12927/hcpol.2022.26829","title":"Commentary: University Technology Transfer Has Made a Significant Contribution to Fighting COVID-19 while Ensuring Global Access","year":2022,"lang":"en","type":"letter","venue":"Healthcare policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Coronavirus disease 2019 (COVID-19); Technology transfer; Pandemic; Bench to bedside; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Personal protective equipment; Health care; Business; Public health; Public sector; Public relations; Political science; Engineering ethics; Medicine; Virology; Engineering; Law; International trade; Nursing","score_opus":0.13231464744672883,"score_gpt":0.3447495712387703,"score_spread":0.21243492379204149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281988284","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004397514,0.00057113246,0.0008172844,0.96536213,0.0005658957,0.0010505315,0.0251874,0.0002058338,0.0018422513],"genre_scores_gemma":[0.15066934,0.00044731933,0.00004696454,0.8456205,0.0018787549,0.000065769855,0.0010181543,0.000058555575,0.00019465384],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99630845,0.00015958151,0.0009467168,0.0011080429,0.00008799964,0.001389193],"domain_scores_gemma":[0.9980508,0.00016401488,0.00034433408,0.00067511504,0.000054257594,0.0007114874],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005555773,0.000481465,0.0010618845,0.0012869217,0.0009134632,0.00019904997,0.0012785405,0.0008203534,0.001245992],"category_scores_gemma":[0.00022812694,0.00068732403,0.00028025446,0.0013844351,0.00016597747,0.00019026629,0.0006081289,0.0019706113,0.00026946177],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000991686,0.000053837513,0.005814793,0.00039819223,0.0001362758,0.00019969381,0.00024954785,0.000103608916,0.0000019251017,0.17134656,0.82107013,0.00052628014],"study_design_scores_gemma":[0.0009044392,0.00013129253,0.00030924327,0.000023690518,0.000017187705,0.000025492283,0.000039446346,0.00013390755,0.000011855982,0.01697625,0.9808094,0.00061779167],"about_ca_topic_score_codex":0.0406046,"about_ca_topic_score_gemma":0.00072379975,"teacher_disagreement_score":0.15973929,"about_ca_system_score_codex":0.007845436,"about_ca_system_score_gemma":0.0008870821,"threshold_uncertainty_score":0.999667},"labels":[],"label_agreement":null},{"id":"W4282553966","doi":"10.1503/cmaj.212070","title":"COVID-19 and the prevalence of drug shortages in Canada: a cross-sectional time-series analysis from April 2017 to April 2022","year":2022,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Women's College Hospital; University of Calgary","funders":"","keywords":"Economic shortage; Pandemic; Medicine; Medical prescription; Coronavirus disease 2019 (COVID-19); Demography; Government (linguistics); Environmental health; Internal medicine; Infectious disease (medical specialty); Pharmacology","score_opus":0.02103351348107317,"score_gpt":0.2660224292272247,"score_spread":0.2449889157461515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282553966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91552114,0.001736041,0.000031520678,0.0754913,0.00053796393,0.00014402266,0.0045253406,0.0000030486808,0.002009612],"genre_scores_gemma":[0.9706749,0.00051549386,0.0000192733,0.027269106,0.00023285074,0.00002336493,0.000019775665,0.0000075801013,0.0012376778],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983633,0.00012720251,0.00074700924,0.00022116725,0.00023211121,0.00030921132],"domain_scores_gemma":[0.99784076,0.00039066805,0.0004001132,0.00012087109,0.000041990632,0.00120559],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003411993,0.000089318,0.00036135415,0.00033914414,0.0003789636,0.00008035114,0.00039281318,0.00006195131,0.022698771],"category_scores_gemma":[0.0019572163,0.000092713606,0.00010584777,0.00043452263,0.00007054894,0.00009930179,0.000082030674,0.0005796795,0.000020740868],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027692678,0.00000773089,0.96712714,0.0000072958533,0.00020877614,0.000019130717,0.00042970217,0.0013064168,2.3838253e-7,0.0029474949,0.027806085,0.00011231772],"study_design_scores_gemma":[0.00076599966,0.000007989519,0.7657152,0.0000015439625,0.000021784825,0.000010744579,0.00011385994,0.004403805,4.990079e-7,0.0038939402,0.22495028,0.000114350245],"about_ca_topic_score_codex":0.8718379,"about_ca_topic_score_gemma":0.95551765,"teacher_disagreement_score":0.20141192,"about_ca_system_score_codex":0.0040201647,"about_ca_system_score_gemma":0.005355282,"threshold_uncertainty_score":0.99980325},"labels":[],"label_agreement":null},{"id":"W4282828457","doi":"10.1097/01.hjh.0000838088.86579.f9","title":"THE CHRONIC KIDNEY DISEASE IN AFRICA (CKD-AFRICA) COLLABORATION: A NEW PAN-AFRICAN NETWORK","year":2022,"lang":"en","type":"article","venue":"Journal of Hypertension","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Kidney disease; Disease; Internal medicine","score_opus":0.06498537054336183,"score_gpt":0.2553227033943191,"score_spread":0.19033733285095727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282828457","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.31018037,0.21313381,0.00050520664,0.42534152,0.011008445,0.0013219976,0.0005602969,0.0000623877,0.037885975],"genre_scores_gemma":[0.99373883,0.0019868363,0.00010816585,0.0021681269,0.0009621665,0.000010499296,0.000003802971,0.0000226195,0.0009989516],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998377,0.000066275505,0.0008772141,0.0001907943,0.00008431573,0.00040438081],"domain_scores_gemma":[0.998498,0.00015100105,0.0006366586,0.00024505233,0.00005145366,0.00041783665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010862388,0.00012962492,0.00038578347,0.0001721647,0.00037000893,0.00010593442,0.0003862929,0.000034411503,0.00033009722],"category_scores_gemma":[0.0002829344,0.00011271147,0.00016254328,0.00062174635,0.000041401523,0.0001809355,0.00015203038,0.00042556316,0.000055052657],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069921685,0.00028142263,0.0053382437,0.000015182166,0.000118587835,0.00020038211,0.000644446,0.022585656,0.00010224355,0.06556379,0.9004194,0.0040314174],"study_design_scores_gemma":[0.0011156471,0.00017969051,0.0031706805,0.000011983949,0.000014353054,0.000026996318,0.00007573896,0.015198191,0.0000022701709,0.03325877,0.9468006,0.00014508147],"about_ca_topic_score_codex":0.000036138914,"about_ca_topic_score_gemma":0.000017252709,"teacher_disagreement_score":0.68355846,"about_ca_system_score_codex":0.0004897099,"about_ca_system_score_gemma":0.00054886506,"threshold_uncertainty_score":0.45962402},"labels":[],"label_agreement":null},{"id":"W4283695065","doi":"10.1007/s13311-022-01259-y","title":"Quantifying Patient Investment in Novel Neurological Drug Development","year":2022,"lang":"en","type":"article","venue":"Neurotherapeutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Drug; Drug development; Clinical trial; Neurology; Drug trial; Neurosurgery; Intensive care medicine; Emergency medicine; Internal medicine; Pharmacology; Psychiatry","score_opus":0.1701863428192845,"score_gpt":0.2955142501117551,"score_spread":0.1253279072924706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283695065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848316,0.00060824456,0.00013239204,0.0034342995,0.0006761622,0.00035892206,0.000074491785,0.000043630094,0.00984028],"genre_scores_gemma":[0.9455669,0.000043310767,0.0006587786,0.05339094,0.000043475477,0.0001336526,0.00000707112,0.000034459485,0.00012143954],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99841315,0.00003857912,0.000673129,0.0004276094,0.00005240197,0.00039515877],"domain_scores_gemma":[0.9994192,0.00006384614,0.0001813813,0.0002299869,0.000005771579,0.000099806035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034464552,0.00016429454,0.0002743056,0.00022189453,0.00017901436,0.000041881907,0.00028589903,0.000033877273,0.00045319513],"category_scores_gemma":[0.000014994636,0.00020331216,0.0000690201,0.00023544584,0.00003563935,0.00005986682,0.00017882141,0.0004171118,0.00013364873],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022477555,0.0030961037,0.22643495,0.000053228832,0.0001161956,0.00007904207,0.011034789,0.016620575,0.0011180392,0.7218569,0.0013292285,0.018036172],"study_design_scores_gemma":[0.0007750656,0.00010898037,0.015233625,0.000001417651,0.0000017151643,0.0000086206055,0.00003896183,0.015872015,0.00019184858,0.0037674739,0.96372783,0.00027243263],"about_ca_topic_score_codex":0.00002983945,"about_ca_topic_score_gemma":0.000020078089,"teacher_disagreement_score":0.9623986,"about_ca_system_score_codex":0.00019743382,"about_ca_system_score_gemma":0.00006109165,"threshold_uncertainty_score":0.8290829},"labels":[],"label_agreement":null},{"id":"W4284664108","doi":"10.4212/cjhp.3257","title":"Drug Optimization, Sustainability, and Evaluation (DOSE) Project in Alberta Health Services","year":2022,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Alberta Health; University of Alberta; Alberta Health Services","funders":"","keywords":"Sustainability; Drug; Business; Medicine; Pharmacology","score_opus":0.0350320599945246,"score_gpt":0.3195058206936279,"score_spread":0.2844737606991033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4284664108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8752256,0.006119873,0.000010414565,0.11453374,0.00068096153,0.00075850176,0.00011298728,0.0000025407585,0.0025553727],"genre_scores_gemma":[0.99642336,0.00019967665,0.000034211145,0.0031150081,0.000096169264,0.00002036402,0.000007990384,0.000014013306,0.0000891784],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9987785,0.00011019771,0.0006103956,0.00014971985,0.000051993648,0.00029915696],"domain_scores_gemma":[0.9990297,0.000058644066,0.0004607212,0.00012186887,0.000082848324,0.00024621072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025680764,0.000096604395,0.00023344951,0.00035533626,0.00036886657,0.00011357963,0.00033490142,0.000011363291,0.000465606],"category_scores_gemma":[0.00006408651,0.000097282624,0.0000571999,0.00027640912,0.000064569445,0.00029068746,0.000055762044,0.00031364878,0.000004286408],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001408954,0.00034701018,0.39282522,0.00027616014,0.00023838013,0.00003892629,0.06368812,0.41470733,4.6121176e-7,0.10052486,0.01639432,0.010818331],"study_design_scores_gemma":[0.0056326496,0.00044910065,0.027135639,0.000029803547,0.000035068362,0.00008913008,0.0037391933,0.4480865,0.0000052892765,0.14607881,0.36812672,0.0005921074],"about_ca_topic_score_codex":0.22670522,"about_ca_topic_score_gemma":0.07018996,"teacher_disagreement_score":0.36568958,"about_ca_system_score_codex":0.0011591074,"about_ca_system_score_gemma":0.0016322668,"threshold_uncertainty_score":0.9467766},"labels":[],"label_agreement":null},{"id":"W4285085793","doi":"10.54194/zjih9721","title":"Effect of amended Patented Medicine Regulations on industry decisions to launch new drugs in Canada","year":2022,"lang":"en","type":"article","venue":"Canadian Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Market access; Business; Access to medicines; Political science; Law; Intellectual property; Geography","score_opus":0.08258027770115917,"score_gpt":0.3543446535820593,"score_spread":0.27176437588090013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285085793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76712877,0.00028417748,0.000002426652,0.21497032,0.0004190118,0.0005725529,0.0024196096,0.0000070422043,0.01419608],"genre_scores_gemma":[0.94901276,0.00003652245,0.000011274065,0.05006724,0.00018497117,0.00004334738,0.00004854082,0.000021137066,0.0005741851],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981598,0.00008262778,0.00076383096,0.0002930507,0.000054916585,0.00064577366],"domain_scores_gemma":[0.9974995,0.00027986048,0.00020741472,0.00033114068,0.000010408337,0.0016716518],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00075515336,0.00014036738,0.0005033946,0.0012873681,0.00018512073,0.0000067996307,0.00028396185,0.000060641607,0.0012909123],"category_scores_gemma":[0.00048634078,0.00017020326,0.000040377512,0.0010748669,0.000021963286,0.000029492689,0.000050649145,0.00047875565,0.00004141981],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00009992743,0.00003757211,0.04853721,0.00005925081,0.00004519867,0.000011983691,0.0029011513,0.009071041,0.000003551025,0.41507682,0.4889599,0.035196394],"study_design_scores_gemma":[0.002180757,0.00075895834,0.10813332,0.000060856943,0.0000029063965,0.00000460754,0.00022338366,0.0016249977,0.00001914697,0.0105031105,0.876152,0.0003359529],"about_ca_topic_score_codex":0.9993028,"about_ca_topic_score_gemma":0.99388933,"teacher_disagreement_score":0.4045737,"about_ca_system_score_codex":0.0072792755,"about_ca_system_score_gemma":0.008390086,"threshold_uncertainty_score":0.99962205},"labels":[],"label_agreement":null},{"id":"W4285530742","doi":"10.2139/ssrn.3841485","title":"Reconsidering Repositioning Incentives: An Empirical Legal Analysis of Market Protection for New Therapeutic Indications","year":2021,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"","keywords":"Incentive; Business; Law and economics; Economics; Public economics; Actuarial science; Microeconomics","score_opus":0.10132708045213218,"score_gpt":0.3286953274778326,"score_spread":0.2273682470257004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285530742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5057334,0.006221407,0.4720306,0.009355836,0.00030741442,0.0003571745,0.00009527126,0.000031109877,0.005867788],"genre_scores_gemma":[0.9963062,0.0013687263,0.0007625572,0.00050558016,0.00018691673,0.000015416459,0.000019993053,0.000017600678,0.0008170488],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9982602,0.00004540066,0.00066591485,0.00026959242,0.00002774323,0.00073112384],"domain_scores_gemma":[0.9990908,0.00006120074,0.00048572823,0.00018534577,0.00006306629,0.00011386237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001275218,0.00010229008,0.00034970065,0.00040564375,0.00019769445,0.00010547934,0.00013152268,0.000077100005,0.00030102575],"category_scores_gemma":[0.00012410189,0.00012394547,0.0002800248,0.0005462198,0.000029284178,0.0003359443,0.000020611153,0.00055745384,0.000006048316],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001658681,0.00037053225,0.03330199,0.000024262916,0.005698646,0.000002160211,0.0010088821,0.0011873682,0.00077811966,0.9267111,0.00030051763,0.030450558],"study_design_scores_gemma":[0.0011243395,0.00027834094,0.015060449,0.000014765158,0.0004349201,0.0001591085,0.00087115343,0.050831128,0.00089808204,0.91134924,0.018639302,0.00033919502],"about_ca_topic_score_codex":0.000058556045,"about_ca_topic_score_gemma":0.000571338,"teacher_disagreement_score":0.49057278,"about_ca_system_score_codex":0.0004392072,"about_ca_system_score_gemma":0.00097147556,"threshold_uncertainty_score":0.50543493},"labels":[],"label_agreement":null},{"id":"W4286255302","doi":"10.1200/go.22.00060","title":"Cancer Medicines: What Is Essential and Affordable in India?","year":2022,"lang":"en","type":"article","venue":"JCO Global Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Medical Research Council; Pfizer; Servier; European Society for Medical Oncology; World Health Organization; Genentech; AstraZeneca","keywords":"Medicine; Family medicine; Essential medicines; Cohort; Snowball sampling; Public health; Population; Environmental health; Internal medicine; Nursing; Pathology","score_opus":0.033042006242484594,"score_gpt":0.3401625093126421,"score_spread":0.3071205030701575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286255302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83809143,0.02080998,0.000018538181,0.040781632,0.0028569873,0.00031675998,0.0007162454,0.000022866703,0.09638557],"genre_scores_gemma":[0.9611041,0.006359134,0.000046254827,0.03189312,0.00020911598,0.000115273375,0.0000113959995,0.000010226819,0.00025136958],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.998847,0.000025318555,0.00042709307,0.00032959442,0.000023831068,0.00034712887],"domain_scores_gemma":[0.9995299,0.00004338173,0.00017146836,0.00012784699,0.00000689658,0.00012052422],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00038163352,0.000108905115,0.0004000487,0.00011520322,0.00009653169,0.000040148854,0.00018689771,0.00008509218,0.003708774],"category_scores_gemma":[0.000016288828,0.0001337513,0.000047486083,0.00025580815,0.00008443876,0.00020605561,0.00024480646,0.00021145455,0.00009568894],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023390772,0.0005186536,0.2932602,0.000054991062,0.00015131108,0.00010098548,0.0019715219,0.00037164835,0.000020739597,0.59288704,0.061868805,0.04856021],"study_design_scores_gemma":[0.0014888521,0.00015472676,0.021714674,0.000004160014,0.0000063664506,0.000022814453,0.00035416748,0.0020306446,0.000009377931,0.052011758,0.92202735,0.00017508735],"about_ca_topic_score_codex":0.0012755913,"about_ca_topic_score_gemma":0.00025219982,"teacher_disagreement_score":0.86015856,"about_ca_system_score_codex":0.00076408824,"about_ca_system_score_gemma":0.00010832068,"threshold_uncertainty_score":0.997202},"labels":[],"label_agreement":null},{"id":"W4286293804","doi":"10.1200/jco.2022.40.16_suppl.6598","title":"National trends in post-launch cancer prescription drug prices and the impact of generic entry, 2014-2020.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"American Cancer Society","keywords":"Medicine; Cancer drugs; Medical prescription; Drug prices; Cancer; Observational study; Competition (biology); Drug; Cohort; Ordinary least squares; Internal medicine; Oncology; Pharmacology; Public economics; Econometrics","score_opus":0.15504623829462838,"score_gpt":0.46430494089556673,"score_spread":0.30925870260093835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286293804","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96678716,0.0050136815,0.000006468868,0.017236168,0.0008925273,0.00007220765,0.00018118994,0.000001348316,0.009809229],"genre_scores_gemma":[0.991918,0.0052120574,0.00007496393,0.0020537137,0.00042945083,0.000010520519,0.0000031546606,0.0000070270603,0.00029109739],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975149,0.00018648729,0.0019441557,0.00014262802,0.000058801383,0.00015301706],"domain_scores_gemma":[0.9968342,0.0007992642,0.0021086757,0.00007582056,0.00007612075,0.000105927094],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004945603,0.00008011545,0.000803073,0.00022266121,0.000048181744,0.000013723281,0.0002470675,0.00007446424,0.002148838],"category_scores_gemma":[0.0004898211,0.00005991082,0.00036507507,0.0001719544,0.00015665052,0.00013196823,0.00011921242,0.0005855017,0.000005947995],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008407999,0.0030029502,0.52595264,0.00003183959,0.0014787205,0.000031735548,0.0019326435,0.03165951,0.000060850478,0.09058986,0.20968111,0.12717013],"study_design_scores_gemma":[0.007299778,0.0010998538,0.79305136,0.00000328512,0.00002328036,0.000038413236,0.000051597835,0.017706107,0.0000019529427,0.025449056,0.15516523,0.00011007316],"about_ca_topic_score_codex":0.00096871535,"about_ca_topic_score_gemma":0.0001410921,"teacher_disagreement_score":0.26709872,"about_ca_system_score_codex":0.00029509902,"about_ca_system_score_gemma":0.00043660827,"threshold_uncertainty_score":0.9987633},"labels":[],"label_agreement":null},{"id":"W4286793490","doi":"","title":"Canadian Medication Cost Savings Associated with Combinatorial Pharmacogenomic Guidance for Psychiatric Medications","year":2019,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacogenomics; Psychiatry; Medicine; Pharmacology","score_opus":0.19512289948268033,"score_gpt":0.5016387625671583,"score_spread":0.306515863084478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286793490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9210698,0.015838282,0.00071708596,0.0069687464,0.0047946963,0.0029256928,0.0025403923,0.00004791972,0.04509737],"genre_scores_gemma":[0.99255276,0.0041926824,0.00012216813,0.0021060635,0.00032484072,0.00017022724,0.00011713487,0.00006273664,0.0003513729],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99762183,0.000049657257,0.0011681196,0.00050767855,0.00011155176,0.0005411805],"domain_scores_gemma":[0.9969384,0.00033455985,0.0015382603,0.00040731617,0.00016255624,0.0006189012],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019421298,0.00025394346,0.00075675006,0.0009993989,0.0002718169,0.00051495485,0.002059262,0.00015148858,0.0086632315],"category_scores_gemma":[0.00030027144,0.000279995,0.00016057579,0.00075780466,0.00009017438,0.00108596,0.00015756648,0.00032599625,0.00017186887],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014437476,0.00028516576,0.8499708,0.00007390063,0.0006318774,0.0000018027002,0.00014826121,0.00016142402,0.0010107062,0.040751014,0.10474986,0.0020708013],"study_design_scores_gemma":[0.004963467,0.000037764803,0.47739974,0.00016168832,0.00014447566,0.000005150856,0.000022740996,0.0039583268,0.0008322458,0.09795309,0.4135962,0.00092509185],"about_ca_topic_score_codex":0.016835293,"about_ca_topic_score_gemma":0.0027771948,"teacher_disagreement_score":0.37257108,"about_ca_system_score_codex":0.0007328968,"about_ca_system_score_gemma":0.0005631398,"threshold_uncertainty_score":0.99996525},"labels":[],"label_agreement":null},{"id":"W4288006027","doi":"","title":"North American cost analysis of brand name versus generic drugs for the treatment of glaucoma","year":2019,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Brand names; Glaucoma; Optometry; Advertising; Medicine; Business; Ophthalmology","score_opus":0.3032576435521129,"score_gpt":0.5168849147495224,"score_spread":0.21362727119740949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4288006027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98279154,0.011584918,0.00018532609,0.00023541824,0.00043027545,0.00069127226,0.0012335035,0.0000049450236,0.002842801],"genre_scores_gemma":[0.96579504,0.033556636,0.00007900107,0.00022226365,0.00008161913,0.000056499983,0.000030127187,0.000029115567,0.00014969303],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99802125,0.000037778063,0.0011868393,0.0003588699,0.0000785264,0.00031672936],"domain_scores_gemma":[0.99649495,0.0008007445,0.0018773379,0.0005660395,0.000100658726,0.00016027795],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005463239,0.00023065186,0.001476968,0.00084336044,0.00009098652,0.0002063401,0.0013665403,0.000044326443,0.0033424657],"category_scores_gemma":[0.000061120394,0.00019612299,0.00063549186,0.0013767848,0.00018034587,0.0004268958,0.00016199808,0.000095737196,0.00002317676],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063959445,0.00035941787,0.9690961,0.000034527948,0.0035725469,4.9372557e-7,0.00030987526,0.0012525372,0.00019668342,0.0012052068,0.0010304803,0.022302521],"study_design_scores_gemma":[0.0018462758,0.0000853793,0.9045054,0.000009715325,0.00049177284,2.8858713e-7,0.00004736407,0.009374113,0.0012716072,0.00067815627,0.08143365,0.0002563298],"about_ca_topic_score_codex":0.003022621,"about_ca_topic_score_gemma":0.00041879882,"teacher_disagreement_score":0.080403164,"about_ca_system_score_codex":0.00016036698,"about_ca_system_score_gemma":0.000057039768,"threshold_uncertainty_score":0.9975686},"labels":[],"label_agreement":null},{"id":"W4289261040","doi":"10.1093/ajhp/zxac210","title":"US drug shortages compared to the World Health Organization’s Model List of Essential Medicines for Children: A cross-sectional study","year":2022,"lang":"en","type":"article","venue":"American Journal of Health-System Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Western University","funders":"","keywords":"Economic shortage; Interquartile range; Medicine; Formulary; Family medicine; Surgery; Government (linguistics)","score_opus":0.05493826230208361,"score_gpt":0.3763516243403229,"score_spread":0.3214133620382393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289261040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.932306,0.0014744176,0.0032587666,0.05900204,0.0013109775,0.0011012245,0.0013979666,0.000019694573,0.00012893794],"genre_scores_gemma":[0.99056524,0.00008180233,0.00028090383,0.008267601,0.00056694157,0.000057605303,0.000023462915,0.000043415548,0.00011305491],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963087,0.00021276073,0.002600666,0.00030577354,0.00016298048,0.00040910745],"domain_scores_gemma":[0.99595714,0.00019575564,0.0030806756,0.00024336921,0.0001872586,0.00033579665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003827149,0.0001873844,0.0010447283,0.00050048606,0.0007150067,0.00007053528,0.00066050474,0.0000071794775,0.00018493822],"category_scores_gemma":[0.00006559515,0.00017542373,0.00018406044,0.0008325064,0.00010064354,0.00013255463,0.00013536011,0.0003344358,0.0000070217893],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003123169,0.0005619153,0.8977603,0.00010922656,0.0003379857,0.0000013002596,0.0030701233,0.0694062,0.0000058721707,0.0042278725,0.02279921,0.0014077184],"study_design_scores_gemma":[0.015451248,0.0031188254,0.65444607,0.00010613599,0.00010737592,0.00044152816,0.00577246,0.12231428,0.000086963126,0.00058467477,0.19643621,0.0011342206],"about_ca_topic_score_codex":0.0027444062,"about_ca_topic_score_gemma":0.00019310629,"teacher_disagreement_score":0.24331418,"about_ca_system_score_codex":0.00065581145,"about_ca_system_score_gemma":0.00057321746,"threshold_uncertainty_score":0.7153572},"labels":[],"label_agreement":null},{"id":"W4290465140","doi":"10.5281/zenodo.1079864","title":"Generic Drug In Global Market And Regulatory Environment","year":2017,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Drug; Pharmacology; Medicine","score_opus":0.05578305027386,"score_gpt":0.2503811975851249,"score_spread":0.1945981473112649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4290465140","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.36018002,0.0006507632,0.00023716943,0.0036891035,0.0001177153,0.00024513766,0.0005552008,0.00008292691,0.634242],"genre_scores_gemma":[0.9974781,0.0007297675,0.000100063284,0.00033496876,0.00008059485,4.083396e-8,0.000054661497,0.00023912678,0.0009826525],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991146,0.000036330708,0.00024432022,0.00032593904,0.000030827832,0.000248013],"domain_scores_gemma":[0.99925166,0.000006168936,0.0001458837,0.00044131107,0.000013603311,0.00014139233],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0006381593,0.000087883855,0.00014821168,0.000084666026,0.00096145144,0.00057166297,0.0005811468,0.000038768343,0.008206918],"category_scores_gemma":[0.00013998324,0.000112976406,0.000029026032,0.00004992936,0.00016628555,0.00021987491,0.0008557965,0.00011256089,0.0038885165],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013858982,0.0003572481,0.008344624,0.0001234111,0.00010721521,0.0000323985,0.0009258758,0.00016333447,0.00019222457,0.42122748,0.36957976,0.19880782],"study_design_scores_gemma":[0.00045078003,0.000020335796,0.07796283,0.000004625887,0.0000015676596,0.000012558329,0.00001970859,0.0017935381,0.000014025472,0.007063448,0.91252977,0.00012681505],"about_ca_topic_score_codex":0.00006522119,"about_ca_topic_score_gemma":9.794763e-7,"teacher_disagreement_score":0.6372981,"about_ca_system_score_codex":0.00018764606,"about_ca_system_score_gemma":0.0000011357035,"threshold_uncertainty_score":0.9968871},"labels":[],"label_agreement":null},{"id":"W4291312838","doi":"10.1016/j.jhealeco.2022.102671","title":"Global drug diffusion and innovation with the medicines patent pool","year":2022,"lang":"en","type":"article","venue":"Journal of Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Institute for Humane Studies, George Mason University; Cornell University","keywords":"License; Business; Drug; Procurement; Industrial organization; Clinical trial; Drug approval; Product (mathematics); International trade; Pharmacology; Public economics; Marketing; Medicine; Economics; Computer science","score_opus":0.07989695667515356,"score_gpt":0.30393930599111557,"score_spread":0.224042349315962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4291312838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89193666,0.003286478,0.000281293,0.10263794,0.000520765,0.00015448534,0.00010570978,0.000004194076,0.0010724562],"genre_scores_gemma":[0.97726804,0.0019098838,0.000113006,0.020407379,0.00020645447,0.0000074155078,0.00000485944,0.000012378458,0.000070560825],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984922,0.00003969284,0.0010645363,0.00015047869,0.000027940025,0.00022514816],"domain_scores_gemma":[0.9981005,0.000059659793,0.0015724401,0.00013380175,0.00003330133,0.00010029153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020659345,0.00010691816,0.00040329577,0.00022420388,0.00033308068,0.000046160567,0.00021334829,0.000020089976,0.0001313658],"category_scores_gemma":[0.000024773659,0.00008493093,0.000048153044,0.0002624525,0.00006093984,0.0001539898,0.00010444757,0.0002469729,0.000006220677],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035944046,0.00025245806,0.15541252,0.00009280355,0.00016669226,0.0000073520187,0.0018452524,0.006839704,0.000002743142,0.7585047,0.045545273,0.030971086],"study_design_scores_gemma":[0.0023319502,0.00057348574,0.05433874,0.000012726701,0.000011353304,0.00028866273,0.0008099526,0.007311942,0.0000032036362,0.05159766,0.88249636,0.00022396921],"about_ca_topic_score_codex":0.00011437797,"about_ca_topic_score_gemma":0.000038260572,"teacher_disagreement_score":0.8369511,"about_ca_system_score_codex":0.00044454928,"about_ca_system_score_gemma":0.00017335084,"threshold_uncertainty_score":0.34633827},"labels":[],"label_agreement":null},{"id":"W4292367025","doi":"10.1001/jamahealthforum.2022.2685","title":"Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021","year":2022,"lang":"en","type":"article","venue":"JAMA Health Forum","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Arnold Ventures; Swiss Cancer Research Foundation; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Kaiser Permanente; National Science Foundation","keywords":"Marketing authorization; Medicine; Authorization; European union; Agency (philosophy); Value (mathematics); Cohort; Drug; Family medicine; Business; Pharmacology; Internal medicine; Bioinformatics","score_opus":0.05984786430854934,"score_gpt":0.3167756284411808,"score_spread":0.25692776413263146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292367025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90603167,0.0019196348,0.0010779874,0.07933831,0.00058141653,0.00095018395,0.0030427037,0.000015978223,0.007042099],"genre_scores_gemma":[0.97102064,0.00030477706,0.0001596795,0.028015705,0.00010208028,0.000059488393,0.0001994061,0.000017629802,0.00012060754],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985093,0.00020003135,0.0006385908,0.00028238352,0.000048997346,0.0003207114],"domain_scores_gemma":[0.99916714,0.000288588,0.00028494507,0.00014751943,0.000019543828,0.00009227493],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020350874,0.00010180925,0.0002778328,0.00017807054,0.00023081082,0.00005511193,0.0002046623,0.000038112154,0.001242721],"category_scores_gemma":[0.00012273817,0.000096339034,0.000033687178,0.000479004,0.00002939451,0.000101495214,0.00010850584,0.00026531154,0.000035448582],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016046176,0.0005386429,0.08294333,0.00016041142,0.00012255245,0.000009202466,0.0054738573,0.0034141354,0.000080913735,0.8405127,0.028813383,0.036326267],"study_design_scores_gemma":[0.00243345,0.0003117616,0.28491202,0.000023667333,0.0000059154163,0.000008199396,0.00095008104,0.09609385,0.00002074543,0.02916866,0.5857642,0.00030743325],"about_ca_topic_score_codex":0.0009090654,"about_ca_topic_score_gemma":0.00004373578,"teacher_disagreement_score":0.811344,"about_ca_system_score_codex":0.00010570721,"about_ca_system_score_gemma":0.000104761144,"threshold_uncertainty_score":0.99967027},"labels":[],"label_agreement":null},{"id":"W4292493763","doi":"10.1186/s40545-022-00442-y","title":"State capture through indemnification demands? Effects on equity in the global distribution of COVID-19 vaccines","year":2022,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Policy and Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Connaught Fund","keywords":"Coronavirus disease 2019 (COVID-19); 2019-20 coronavirus outbreak; Equity (law); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Pandemic; Pharmacy; Business; Medicine; Virology; Computer science; Infectious disease (medical specialty); Political science; Family medicine; Outbreak; Internal medicine","score_opus":0.141513377471131,"score_gpt":0.4567318546955813,"score_spread":0.3152184772244503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292493763","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4608202,0.012119745,0.0058604195,0.4760365,0.0010407029,0.0009618797,0.0019425674,0.000018879395,0.041199125],"genre_scores_gemma":[0.9635567,0.001960022,0.00005886943,0.0341196,0.00026547656,0.00001054762,0.000009199222,0.0000070616557,0.000012490532],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980852,0.00048325988,0.0008444356,0.00018560584,0.00012268357,0.00027881633],"domain_scores_gemma":[0.9962695,0.0023755222,0.0009567268,0.00015043496,0.000042391435,0.0002053849],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004179131,0.00013874435,0.00035576808,0.00011653735,0.00018169606,0.00005974527,0.00034762104,0.00005920929,0.000069628666],"category_scores_gemma":[0.0046738912,0.00012045283,0.00010932682,0.00049803243,0.00007485001,0.00045308983,0.00014264132,0.0007144544,0.000008421058],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00215105,0.00071086077,0.004637325,0.0002092555,0.00014482324,0.000052290332,0.0021790697,0.0023211113,0.000051112125,0.9775819,0.0051035853,0.0048575853],"study_design_scores_gemma":[0.0024648139,0.00035138862,0.007154942,0.000009216237,0.000056098936,0.00041145014,0.0002862781,0.0011111009,0.00010339718,0.2608104,0.7270752,0.00016568544],"about_ca_topic_score_codex":0.00039098313,"about_ca_topic_score_gemma":0.0000069908547,"teacher_disagreement_score":0.72197163,"about_ca_system_score_codex":0.0005481859,"about_ca_system_score_gemma":0.00020085592,"threshold_uncertainty_score":0.55954224},"labels":[],"label_agreement":null},{"id":"W4292507975","doi":"10.1016/j.healthpol.2022.08.006","title":"Reforms to the patented medicine prices review board and the introduction of new drugs in Canada: An observational study","year":2022,"lang":"en","type":"article","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Observational study; Drug approval; Drug prices; Food and drug administration; Alternative medicine; Family medicine; Drug; Environmental health; Pharmacology; Public economics; Internal medicine","score_opus":0.22429368624676035,"score_gpt":0.3960988533050458,"score_spread":0.17180516705828544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292507975","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24487087,0.0075382385,0.0000030554418,0.74595237,0.00018089691,0.00089584786,0.000081632876,0.000003437959,0.00047367284],"genre_scores_gemma":[0.8500211,0.008855019,0.000020153953,0.1398872,0.0008187478,0.00013823438,0.00002492583,0.000012058588,0.00022254758],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986643,0.000085789456,0.0007752738,0.00020188275,0.00005654838,0.00021621076],"domain_scores_gemma":[0.99917156,0.000060309776,0.00035325857,0.00025965774,0.000014268365,0.00014096571],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002227833,0.000079353806,0.00038757137,0.00011960237,0.00016314485,0.000006230279,0.00023121391,0.000008044209,0.00018362084],"category_scores_gemma":[0.00018225773,0.000052652395,0.000019027118,0.0005082776,0.000034549004,0.00006135109,0.0001089666,0.00017633937,0.000003914964],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001864078,0.00016119258,0.049506165,0.0003885142,0.000059430877,4.259669e-7,0.019796684,0.00065165706,3.9841214e-7,0.72430813,0.18250376,0.022437224],"study_design_scores_gemma":[0.0013560128,0.00020198782,0.22735044,0.000019422716,0.0000040098357,0.0000022055387,0.0012265049,0.0008921368,2.0698484e-7,0.0077585923,0.76110363,0.00008483658],"about_ca_topic_score_codex":0.962594,"about_ca_topic_score_gemma":0.5353475,"teacher_disagreement_score":0.7165496,"about_ca_system_score_codex":0.00076006656,"about_ca_system_score_gemma":0.0008907031,"threshold_uncertainty_score":0.4731312},"labels":[],"label_agreement":null},{"id":"W4292940661","doi":"10.1016/j.ijpharm.2022.122119","title":"Dosage unit uniformity and dissolution testing of extended-release pharmaceutical products marketed in the U.S.","year":2022,"lang":"en","type":"article","venue":"International Journal of Pharmaceutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Oak Ridge Institute for Science and Education; U.S. Food and Drug Administration; U.S. Department of Energy","keywords":"Innovator; Dosage form; Dissolution testing; Immediate release; Dissolution; Bioequivalence; Product (mathematics); Pharmaceutical manufacturing; Unit (ring theory); Six Sigma; Medical prescription; Generic drug; Business; Drug; Mathematics; Toxicology; Operations management; Pharmacology; Chemistry; Medicine; Marketing; Engineering; Bioavailability","score_opus":0.10813284835462067,"score_gpt":0.3489740002751549,"score_spread":0.24084115192053424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292940661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833802,0.002412208,0.00015083794,0.008639635,0.0009942007,0.00019244975,0.00030695923,0.0000062951444,0.0039172005],"genre_scores_gemma":[0.99694693,0.0007077787,0.00036248012,0.0016862338,0.00023581427,0.000006604459,0.000007262945,0.0000134619395,0.00003342911],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983198,0.00012364791,0.0009915206,0.00017091964,0.00016838753,0.0002257066],"domain_scores_gemma":[0.9985463,0.00031954751,0.000761476,0.000120016906,0.0001533536,0.000099316356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024904995,0.00012716414,0.00027135233,0.00038334777,0.00009035722,0.00004846666,0.00066876423,0.000032007603,0.00026642025],"category_scores_gemma":[0.00048678383,0.00012311738,0.00008355824,0.0003600897,0.000117644,0.00025104248,0.00021994599,0.0006724097,0.000005355864],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027398323,0.0044113314,0.5412708,0.00031003472,0.0012894976,0.0006416488,0.004938615,0.0106566865,0.014084766,0.31452227,0.002544863,0.10258967],"study_design_scores_gemma":[0.009894164,0.0004850618,0.19722718,0.00008412294,0.00014507395,0.0018240775,0.0010298592,0.18524793,0.0073937504,0.06014776,0.5357309,0.00079014763],"about_ca_topic_score_codex":0.000032557033,"about_ca_topic_score_gemma":0.0000022378545,"teacher_disagreement_score":0.533186,"about_ca_system_score_codex":0.00016302023,"about_ca_system_score_gemma":0.00008509671,"threshold_uncertainty_score":0.5020581},"labels":[],"label_agreement":null},{"id":"W4293382228","doi":"10.1016/j.kint.2022.07.029","title":"Barriers to accessing essential medicines for kidney disease in low- and lower middle–income countries|","year":2022,"lang":"en","type":"article","venue":"Kidney International","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster Children's Hospital; University of British Columbia","funders":"","keywords":"Essential medicines; Medicine; Context (archaeology); Public health; Population; Developing country; Health care; Environmental health; Family medicine; Business; Economic growth; Nursing","score_opus":0.02513666136522155,"score_gpt":0.2971133236447651,"score_spread":0.2719766622795436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293382228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70808756,0.00040049836,0.001329686,0.25684053,0.0077940156,0.00078199245,0.013628201,0.00004505773,0.0110924365],"genre_scores_gemma":[0.95173925,0.000047244524,0.00018593486,0.046678122,0.0004366706,0.00016974493,0.000120386976,0.00002114476,0.00060148153],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988874,0.000010060056,0.00044904134,0.00034498997,0.000056348694,0.0002521479],"domain_scores_gemma":[0.998687,0.000059815295,0.0001274034,0.00012184749,0.000025301086,0.0009786116],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00038316555,0.00011916424,0.00020799664,0.00033909403,0.0001569625,0.00011168412,0.0003204231,0.000027080278,0.005397581],"category_scores_gemma":[0.0009862996,0.00015033539,0.00006760929,0.00010904764,0.000052174822,0.00020291339,0.00021294219,0.00012455528,0.000037294358],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012223326,0.00018299618,0.46449167,0.00030058625,0.00025037854,0.00003628891,0.0013849129,0.0015059079,0.000053214884,0.43767536,0.09269637,0.0002000072],"study_design_scores_gemma":[0.0020778805,0.000040935673,0.011070469,0.0000647741,0.00000832445,0.0000026191922,0.000030466272,0.037597395,0.00002644038,0.020625263,0.9281715,0.00028393968],"about_ca_topic_score_codex":0.00008821798,"about_ca_topic_score_gemma":0.0000070048254,"teacher_disagreement_score":0.83547515,"about_ca_system_score_codex":0.00023743566,"about_ca_system_score_gemma":0.00019156217,"threshold_uncertainty_score":0.9955116},"labels":[],"label_agreement":null},{"id":"W4293826008","doi":"10.1111/1756-2171.12422","title":"Does consumer demand pull scientifically novel drug innovation?","year":2022,"lang":"en","type":"article","venue":"The RAND Journal of Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"","keywords":"Novelty; Consumer demand; On demand; Economics; Drug; Industrial organization; Microeconomics; Computer science; Commerce; Pharmacology; Medicine; Psychology","score_opus":0.05755306486378076,"score_gpt":0.266729548639784,"score_spread":0.20917648377600323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293826008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9754851,0.000944981,0.00069920113,0.012486591,0.0029345527,0.00017416057,0.00041167307,0.000006883953,0.0068568587],"genre_scores_gemma":[0.99361795,0.0005205608,0.00024077404,0.0038446176,0.00036537705,0.000009063822,0.000005808051,0.000024374945,0.0013714487],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980127,0.00003179387,0.0014238418,0.00021547974,0.000029344927,0.00028682352],"domain_scores_gemma":[0.998075,0.00018940073,0.0012815777,0.00028646833,0.00006702577,0.000100519086],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0036601382,0.00014324413,0.00045969765,0.0003827899,0.00045693174,0.0001625491,0.0006821797,0.000033137258,0.0013477722],"category_scores_gemma":[0.00010532846,0.000102380174,0.00019217607,0.0002873758,0.00016561044,0.00027642652,0.00018114047,0.0004529008,0.00008848283],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003145379,0.00029307033,0.009532788,0.00001735655,0.00030121775,0.0000038909043,0.0008744269,0.012378871,0.00020562457,0.9611203,0.013732195,0.0012257186],"study_design_scores_gemma":[0.002834195,0.00005670094,0.0011847323,0.000004531614,0.000027019722,0.000087576555,0.00020894031,0.006760693,0.00028621085,0.18662392,0.8016413,0.00028422728],"about_ca_topic_score_codex":0.00002443069,"about_ca_topic_score_gemma":0.00001278198,"teacher_disagreement_score":0.7879091,"about_ca_system_score_codex":0.00017346791,"about_ca_system_score_gemma":0.000107612104,"threshold_uncertainty_score":0.9995651},"labels":[],"label_agreement":null},{"id":"W4294114282","doi":"","title":"Industrial manufacture of pharmaceutical tablets: 1° part: origins to 1945.","year":2016,"lang":"en","type":"preprint","venue":"HAL (Le Centre pour la Communication Scientifique Directe)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Society for the History of Medicine","funders":"","keywords":"Business; Process engineering; Manufacturing engineering; Engineering","score_opus":0.06806925802266213,"score_gpt":0.28445571005485976,"score_spread":0.21638645203219764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294114282","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.29841667,0.0032181244,0.0676705,0.14013645,0.003638679,0.0020670702,0.008419081,0.00029673963,0.47613668],"genre_scores_gemma":[0.9855773,0.0014307201,0.0036174087,0.0015179402,0.0003055661,0.000107251755,0.00025528332,0.00008776195,0.0071007763],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965875,0.0006499191,0.0011937469,0.00091574935,0.00010029407,0.00055279717],"domain_scores_gemma":[0.99597955,0.00075988966,0.00081262906,0.0015990298,0.0003688343,0.0004800747],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004057115,0.0003819319,0.00080644904,0.0003502693,0.00014233144,0.00020889618,0.0013228016,0.00050215784,0.0018727458],"category_scores_gemma":[0.0011321999,0.00041276772,0.0003152267,0.00024067123,0.00020794634,0.00012746008,0.0012860739,0.00081763376,0.0006392099],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046679368,0.0004737444,0.004055993,0.000147788,0.00022906804,0.0000030631672,0.0015718635,0.00007016057,0.00036843726,0.95243055,0.020225165,0.020377465],"study_design_scores_gemma":[0.0010103835,7.171395e-7,0.00045798373,0.0005497447,0.000026434673,0.0000025286176,0.000008578187,0.0016619678,0.026696354,0.05682543,0.9122288,0.0005310732],"about_ca_topic_score_codex":0.00059397693,"about_ca_topic_score_gemma":0.00013982301,"teacher_disagreement_score":0.89560515,"about_ca_system_score_codex":0.00030721794,"about_ca_system_score_gemma":0.00020994314,"threshold_uncertainty_score":0.9998324},"labels":[],"label_agreement":null},{"id":"W4295242180","doi":"10.1016/j.ijindorg.2022.102878","title":"Collusion in the US generic drug industry","year":2022,"lang":"en","type":"article","venue":"International Journal of Industrial Organization","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Center for Interuniversity Research and Analysis on Organizations; Queen's University","funders":"","keywords":"Collusion; Damages; Medicaid; Drug prices; Biosimilar; Control (management); Business; Economics; Competition (biology); Industrial organization; Public economics; Medicine; Health care; Law; Political science; Economic growth","score_opus":0.06563573854717865,"score_gpt":0.2768993012980632,"score_spread":0.2112635627508846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295242180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97688377,0.0001400687,0.000110092114,0.018067695,0.0027932832,0.00009571332,0.00008195594,0.000004023537,0.0018233984],"genre_scores_gemma":[0.99481606,0.00006198334,0.000026454261,0.0038550654,0.0011086441,0.000002677966,0.000018996143,0.000012862776,0.00009722785],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988712,0.00006903104,0.00072670094,0.000103019236,0.0001203406,0.00010967502],"domain_scores_gemma":[0.9990525,0.000062694446,0.00066220405,0.00008183934,0.00009900832,0.000041735693],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011260572,0.00007204317,0.00016043935,0.0003557657,0.000095692165,0.00008872813,0.00069388264,0.00007822458,0.0019040325],"category_scores_gemma":[0.00034543715,0.00007008153,0.000052773783,0.00055266597,0.0000194128,0.00020533844,0.00013015786,0.00073715753,0.00003155923],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016507528,0.0006257271,0.7733231,0.00000227585,0.00017595258,0.000121537174,0.0027958814,0.031818382,0.00023541949,0.10935018,0.078198664,0.0031877737],"study_design_scores_gemma":[0.007587208,0.00024405688,0.055450957,0.000026291573,0.000023147717,0.0006237616,0.0011059192,0.0027315882,0.00095952133,0.022276929,0.90847224,0.0004983817],"about_ca_topic_score_codex":0.00008493126,"about_ca_topic_score_gemma":0.0000048613456,"teacher_disagreement_score":0.83027357,"about_ca_system_score_codex":0.0004146311,"about_ca_system_score_gemma":0.00011464808,"threshold_uncertainty_score":0.99900836},"labels":[],"label_agreement":null},{"id":"W4296654187","doi":"10.23880/pdraj-16000105","title":"Generic Drugs: The Landscape is Evolving So are the Mentalities?","year":2018,"lang":"en","type":"article","venue":"Pharmaceutical Drug Regulatory Affairs Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Geography","score_opus":0.05306494190187391,"score_gpt":0.2984594521955941,"score_spread":0.2453945102937202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296654187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.58443487,0.03506219,0.00039031994,0.18665332,0.0065050516,0.0008683195,0.00042270712,0.00016613338,0.18549713],"genre_scores_gemma":[0.9702228,0.0010959936,0.0000617254,0.02375884,0.0034894424,0.000021754131,0.0000025000588,0.000060739163,0.001286238],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972204,0.00015626974,0.0010345266,0.00048139214,0.00016993466,0.00093750295],"domain_scores_gemma":[0.9978886,0.00026511194,0.0006128308,0.00060838467,0.000101539845,0.00052351644],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0025443358,0.00035886772,0.00046485855,0.0001700978,0.0017135799,0.0007689059,0.0011496554,0.00011043788,0.0072661606],"category_scores_gemma":[0.00010441221,0.0002493072,0.000416783,0.00033496352,0.001122045,0.00045946977,0.00031049852,0.0010369522,0.0018758995],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018360512,0.0003108198,0.01957155,0.00007397502,0.00093604124,0.00002646105,0.012182309,0.00012023141,0.00014014728,0.15752958,0.80024916,0.008676143],"study_design_scores_gemma":[0.0013539079,0.000045512574,0.0044834763,0.000033289394,0.0000702189,0.00019699302,0.0037717668,0.03680066,0.0012861731,0.045751583,0.9056585,0.00054793234],"about_ca_topic_score_codex":0.000010609234,"about_ca_topic_score_gemma":0.00000488211,"teacher_disagreement_score":0.38578793,"about_ca_system_score_codex":0.00024906083,"about_ca_system_score_gemma":0.000096151285,"threshold_uncertainty_score":0.99999595},"labels":[],"label_agreement":null},{"id":"W4297903762","doi":"","title":"Les dessous d’une vente en ligne de médicaments enfin encadrée","year":2014,"lang":"fr","type":"preprint","venue":"HAL (Le Centre pour la Communication Scientifique Directe)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Humanities; Political science; Philosophy","score_opus":0.03127907694969249,"score_gpt":0.26669068541863733,"score_spread":0.23541160846894485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297903762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4284123,0.010493721,0.11657736,0.101368785,0.0013214422,0.00084698084,0.0009558879,0.00019595778,0.3398276],"genre_scores_gemma":[0.9416723,0.008425938,0.017771637,0.0012552297,0.00017021918,0.00011993154,0.00036270265,0.000117699434,0.030104317],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9934292,0.002731706,0.0014785636,0.0012670498,0.00012289082,0.00097060465],"domain_scores_gemma":[0.9936996,0.001882527,0.0013460026,0.0020962348,0.0004417529,0.00053387287],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0093658855,0.00058425765,0.0009946849,0.00034931581,0.00052117335,0.0006214029,0.002000355,0.00075220125,0.0013950522],"category_scores_gemma":[0.0017810692,0.0008244061,0.00053445896,0.00036514926,0.00047101043,0.00019206203,0.001456513,0.0012856745,0.0012391008],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022867966,0.00091655087,0.018967634,0.00028793278,0.0002964399,0.000007654068,0.00714655,0.00048071463,0.00031050786,0.89023846,0.0037475557,0.07757716],"study_design_scores_gemma":[0.0012493104,0.00000165035,0.020952689,0.0012060769,0.00007562011,0.000022925635,0.00005961591,0.0857303,0.005968752,0.064704426,0.8190023,0.0010263694],"about_ca_topic_score_codex":0.010711341,"about_ca_topic_score_gemma":0.0013575506,"teacher_disagreement_score":0.825534,"about_ca_system_score_codex":0.0007936947,"about_ca_system_score_gemma":0.00022032403,"threshold_uncertainty_score":0.99953854},"labels":[],"label_agreement":null},{"id":"W4298088755","doi":"10.1001/jamanetworkopen.2022.31475","title":"Evaluation of Medicare Coverage and Estimated Out-of-Pocket Costs for Generic Abiraterone Products","year":2022,"lang":"en","type":"article","venue":"JAMA Network Open","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Leukemia and Lymphoma Society; Arnold Ventures; Commonwealth Fund; Robert Wood Johnson Foundation","keywords":"Abiraterone; Medicare Part D; Actuarial science; Medicine; Computer science; Business; Pharmacology; Internal medicine; Prescription drug; Prostate cancer; Cancer; Medical prescription","score_opus":0.1913653680839787,"score_gpt":0.35833672226122176,"score_spread":0.16697135417724307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298088755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96576136,0.010562934,0.00040569884,0.005000595,0.0011432277,0.0023357875,0.0013340473,0.000012177212,0.0134441815],"genre_scores_gemma":[0.9972937,0.00031990712,0.0006726684,0.0010355959,0.00017968267,0.00026492705,0.0001131009,0.000020650321,0.000099744095],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9987875,0.00008608859,0.0005561868,0.00029644018,0.00006442664,0.00020935807],"domain_scores_gemma":[0.9990389,0.00007937963,0.0004779604,0.00023371649,0.000104535284,0.00006553852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046219467,0.000097332646,0.00038936487,0.00006133642,0.00011319622,0.000053500793,0.0003344906,0.000044468976,0.00054512837],"category_scores_gemma":[0.00026252505,0.00011701102,0.000036148653,0.00018008814,0.00004324162,0.00017352671,0.00037901793,0.000097946715,0.000007573842],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014305252,0.00083687814,0.075691484,0.0005926309,0.0013635154,0.0000034295483,0.0031672507,0.13539629,0.00056027184,0.22033602,0.23100393,0.3296178],"study_design_scores_gemma":[0.008239356,0.0005708269,0.047463845,0.00007295929,0.00015582542,0.0000044946164,0.000079305864,0.62255937,0.0005709797,0.09828641,0.22142412,0.0005725404],"about_ca_topic_score_codex":0.000103449776,"about_ca_topic_score_gemma":0.000012485345,"teacher_disagreement_score":0.48716304,"about_ca_system_score_codex":0.00014234788,"about_ca_system_score_gemma":0.000095390096,"threshold_uncertainty_score":0.59687734},"labels":[],"label_agreement":null},{"id":"W4298147309","doi":"10.1200/jco.2022.40.28_suppl.013","title":"Medicare coverage and cost-sharing for abiraterone following generic entry.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Conquer Cancer Foundation","keywords":"Medicine; Beneficiary; Formulary; Medicare Part D; Cost sharing; Prescription drug; Market share; Generic drug; Product (mathematics); Competition (biology); Medical prescription; Marketing; Business; Family medicine; Drug; Finance; Pharmacology; Mathematics","score_opus":0.2614241358421591,"score_gpt":0.450878591896307,"score_spread":0.1894544560541479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298147309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96067363,0.004020707,0.0021070044,0.014758396,0.005863854,0.00029845137,0.00015756777,0.000007904019,0.012112502],"genre_scores_gemma":[0.98560154,0.0013927154,0.0007938787,0.010858305,0.00091899093,0.000024598901,0.0000047593203,0.000018876517,0.00038630728],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997275,0.000062298815,0.0021392251,0.00022967003,0.000041308722,0.00025250536],"domain_scores_gemma":[0.9970869,0.00092703634,0.0015454938,0.00011900693,0.000028512075,0.0002930841],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004710939,0.00009525941,0.0010293192,0.00012363089,0.00013482485,0.000027155205,0.00029985484,0.00012156094,0.00054438773],"category_scores_gemma":[0.0010752389,0.00010038925,0.0004055952,0.000072400224,0.000055810742,0.0001274653,0.0002141775,0.0005837338,0.000015240237],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002607255,0.0022148974,0.31788117,0.00011728865,0.0022058792,0.0004247524,0.0009967941,0.0021646095,0.00010404939,0.17254971,0.073334225,0.4253994],"study_design_scores_gemma":[0.004826217,0.0014938457,0.008800233,0.0000040085765,0.000035377732,0.00004502813,0.000042323853,0.004144947,0.000003986584,0.031985644,0.948493,0.00012535603],"about_ca_topic_score_codex":0.000014324165,"about_ca_topic_score_gemma":0.0000048788247,"teacher_disagreement_score":0.8751588,"about_ca_system_score_codex":0.00018264668,"about_ca_system_score_gemma":0.00017609948,"threshold_uncertainty_score":0.5960664},"labels":[],"label_agreement":null},{"id":"W4299985524","doi":"","title":"Un partenariat émergent avec les patients permet de transformer un nouveau système relationnel dans le système de santé","year":2014,"lang":"fr","type":"preprint","venue":"HAL (Le Centre pour la Communication Scientifique Directe)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal","funders":"","keywords":"General partnership; Healthcare system; Computer science; Health care; Knowledge management; Process management; Business; Political science","score_opus":0.018095537401854933,"score_gpt":0.22644043438479772,"score_spread":0.20834489698294278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4299985524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4929244,0.0028598418,0.39734915,0.030183077,0.00089155126,0.0008865521,0.0012346528,0.00013272197,0.07353806],"genre_scores_gemma":[0.9743739,0.0055015115,0.01287848,0.00054703257,0.00014046654,0.00017127978,0.0008566306,0.00013239181,0.005398309],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9923727,0.003189887,0.001888158,0.0012663035,0.00015045764,0.0011325171],"domain_scores_gemma":[0.9944602,0.0010814448,0.0013592775,0.0018080473,0.00067097653,0.00062004087],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008495196,0.00066512125,0.0010550028,0.00034867672,0.0009832473,0.0004736299,0.0015489246,0.0007925531,0.0010422206],"category_scores_gemma":[0.0012851158,0.0008812959,0.0006731532,0.000384342,0.0004209325,0.00028520857,0.0004826054,0.001049709,0.00047108816],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003366062,0.0015170613,0.07581232,0.0004252761,0.00047261626,0.0000035355642,0.024406493,0.002980404,0.00017597848,0.8677045,0.0008076487,0.025660496],"study_design_scores_gemma":[0.0033702273,0.0000045632055,0.2801674,0.0013982209,0.00023925758,0.000024737301,0.00025472548,0.42901015,0.00559975,0.12269466,0.15534182,0.0018944787],"about_ca_topic_score_codex":0.0070557585,"about_ca_topic_score_gemma":0.0011006477,"teacher_disagreement_score":0.74500984,"about_ca_system_score_codex":0.0021034623,"about_ca_system_score_gemma":0.0005206623,"threshold_uncertainty_score":0.99987096},"labels":[],"label_agreement":null},{"id":"W4300556305","doi":"","title":"Disease Management Partnerships: Creating Health Solutions. Proceedings from a special symposium of the 4th annual Canadian Therapeutics Congress, May 27, 2007, Halifax, Nova Scotia, Canada.","year":2008,"lang":"en","type":"other","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nova scotia; Viewpoints; Medicine; Government (linguistics); Disease; Gerontology; Family medicine; Geography; Pathology; Archaeology","score_opus":0.07511817081654039,"score_gpt":0.24957106893856876,"score_spread":0.17445289812202835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4300556305","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004838457,0.005981543,0.0000037284879,0.023880392,0.0046090297,0.0020661475,0.025135994,0.00003613369,0.9378032],"genre_scores_gemma":[0.23113555,0.00956851,0.0001744929,0.03300164,0.010110445,0.00063408376,0.0006398349,0.0009254697,0.71380997],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99737906,0.000023860683,0.00081465545,0.0005945001,0.000100317025,0.0010876055],"domain_scores_gemma":[0.9978999,0.00003215675,0.00092232256,0.00042034293,0.000027523882,0.0006977356],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029766647,0.0003759964,0.0006877259,0.00031023714,0.00018693345,0.00007742747,0.00066121493,0.00017531135,0.0010741242],"category_scores_gemma":[0.00002877602,0.0003901013,0.00016928255,0.00024982606,0.00021060242,0.00007434024,0.00013522808,0.0003262104,0.00006671318],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015984746,0.000051910163,0.018860897,0.00012537914,0.00035943193,0.0000058884298,0.00011770444,0.00000917554,1.0310995e-8,0.050392114,0.92908114,0.0009803737],"study_design_scores_gemma":[0.00046255783,0.0000040824625,0.036277458,0.00006419247,0.000045626784,0.0000011205697,0.00004960561,0.000094016876,9.1644335e-7,0.00069595163,0.9619202,0.0003842763],"about_ca_topic_score_codex":0.8914536,"about_ca_topic_score_gemma":0.9531097,"teacher_disagreement_score":0.23065169,"about_ca_system_score_codex":0.00093443616,"about_ca_system_score_gemma":0.00088265195,"threshold_uncertainty_score":0.9998551},"labels":[],"label_agreement":null},{"id":"W4301228716","doi":"","title":"Pharmaceuticals Ampoules, Industrial Pharmaceutical Production","year":2018,"lang":"fr","type":"preprint","venue":"HAL (Le Centre pour la Communication Scientifique Directe)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Society for the History of Medicine","funders":"","keywords":"Ampoule; Production (economics); Business; Process engineering; Waste management; Engineering; Chemistry; Organic chemistry; Economics","score_opus":0.09219639712258808,"score_gpt":0.302752053586162,"score_spread":0.21055565646357388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4301228716","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.31100568,0.014536798,0.041541647,0.31281433,0.011614152,0.002766989,0.0023779564,0.0005030455,0.3028394],"genre_scores_gemma":[0.8744488,0.020113377,0.022598628,0.0037420765,0.0027089685,0.00033909484,0.0011585692,0.00034099453,0.07454954],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9901089,0.0037531157,0.0022791321,0.002296667,0.00022645664,0.0013356934],"domain_scores_gemma":[0.992289,0.0015408683,0.0015226068,0.0024725879,0.0012760967,0.000898835],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.014394512,0.0008615723,0.0012950774,0.00048048588,0.00070152397,0.0008421789,0.0019628832,0.0011716823,0.005297658],"category_scores_gemma":[0.0045280373,0.0011837359,0.0006685276,0.00070826727,0.0014621863,0.00045572082,0.0019516138,0.0024334341,0.0035519078],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012071182,0.00216075,0.011645017,0.00033065706,0.00064415165,0.000010180032,0.0032822622,0.00011877413,0.00053425704,0.8258716,0.043860476,0.1114212],"study_design_scores_gemma":[0.0018452691,0.0000014802068,0.0013062777,0.0009703154,0.00014323581,0.000041724845,0.000034157856,0.039221678,0.034573168,0.032428317,0.8882357,0.0011987073],"about_ca_topic_score_codex":0.0008056029,"about_ca_topic_score_gemma":0.00025745723,"teacher_disagreement_score":0.8443752,"about_ca_system_score_codex":0.00073580805,"about_ca_system_score_gemma":0.0004288487,"threshold_uncertainty_score":0.999868},"labels":[],"label_agreement":null},{"id":"W4302345706","doi":"","title":"Editorial: Guidelines for choosing drugs in chronic heart failure ||FREE PAPER||","year":2005,"lang":"en","type":"editorial","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Heart failure; Medicine; Intensive care medicine; Internal medicine","score_opus":0.2743391260302212,"score_gpt":0.5508293905336885,"score_spread":0.2764902645034673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4302345706","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009260095,0.06494065,0.00006439303,0.0043409416,0.92162436,0.0012399852,0.0037892591,0.000044456738,0.0030299744],"genre_scores_gemma":[0.0010486793,0.047277447,0.0007119698,0.0010883205,0.94861954,0.00023565134,0.00022070204,0.00024656908,0.0005510959],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99317884,0.0000965252,0.003969431,0.0012836071,0.00035333037,0.0011182545],"domain_scores_gemma":[0.9933764,0.0014114266,0.0028200138,0.001197795,0.00069936755,0.00049503404],"candidate_categories":["metaepi_narrow","scholarly_communication","open_science","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0047462108,0.0008544953,0.00294267,0.0018705277,0.0002720684,0.0024367156,0.0057368125,0.0013019145,0.00547026],"category_scores_gemma":[0.005034399,0.0009961191,0.00079293223,0.00076558423,0.00015610464,0.003005421,0.0015458821,0.0018521367,0.00013129717],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014577682,0.00012559566,0.0015284398,0.0002809218,0.00022394506,0.0000012857637,0.000053310894,0.0003921865,0.00031499515,0.000597665,0.994646,0.0016898741],"study_design_scores_gemma":[0.0022978259,0.00001888394,0.00071227044,0.0005347398,0.00004979377,9.142786e-7,0.00001016149,0.0003780311,0.00019340256,0.033155385,0.9616131,0.001035452],"about_ca_topic_score_codex":0.0027896008,"about_ca_topic_score_gemma":0.00070014154,"teacher_disagreement_score":0.033032864,"about_ca_system_score_codex":0.0016339481,"about_ca_system_score_gemma":0.0010449316,"threshold_uncertainty_score":0.9999946},"labels":[],"label_agreement":null},{"id":"W4306317550","doi":"","title":"Research Ethics and Commercial Drug Development: When Integrity Threatens Profitability","year":2016,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Profitability index; Business; Drug development; Drug; Engineering ethics; Pharmacology; Medicine; Engineering; Finance","score_opus":0.7272862728730055,"score_gpt":0.6255946185515461,"score_spread":0.10169165432145943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306317550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95666647,0.008719929,0.0002545244,0.010552111,0.00044282703,0.0005516331,0.00026728862,0.000022900153,0.022522295],"genre_scores_gemma":[0.985618,0.012118119,0.0003987062,0.0009862337,0.00018779132,0.00005093328,0.0000048170505,0.000040980176,0.00059439923],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968067,0.00037758442,0.0013376245,0.0006624234,0.00017437863,0.00064132776],"domain_scores_gemma":[0.99650335,0.001629685,0.0005971454,0.00051252707,0.0003092169,0.00044805463],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.012863227,0.000267176,0.00087446475,0.0007843531,0.00059946417,0.000929918,0.002055303,0.00023721012,0.007912188],"category_scores_gemma":[0.0017424814,0.00022679401,0.0001238178,0.00043013255,0.00054124504,0.0017514077,0.0016990013,0.0016434934,0.00020572373],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014813613,0.00022173669,0.92184114,0.000108750544,0.00014334157,0.000004272169,0.0014441618,9.351315e-7,0.0005353356,0.031236868,0.021045286,0.023270007],"study_design_scores_gemma":[0.0005723237,0.000005615795,0.61839354,0.0001270921,0.0000065763597,0.0000028627294,0.00004370507,0.000027852235,0.0028318856,0.2654108,0.112255864,0.0003219069],"about_ca_topic_score_codex":0.001803102,"about_ca_topic_score_gemma":0.00038317536,"teacher_disagreement_score":0.30344766,"about_ca_system_score_codex":0.00031906035,"about_ca_system_score_gemma":0.00029333477,"threshold_uncertainty_score":0.9929947},"labels":[],"label_agreement":null},{"id":"W4306710478","doi":"10.5281/zenodo.7217469","title":"Towards a national PID strategy for Canada - Vers une stratégie nationale sur les PID pour le Canada","year":2022,"lang":"fr","type":"report","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"PID controller; Humanities; Political science; Art; Engineering; Control engineering","score_opus":0.14737988622984852,"score_gpt":0.27991805761930993,"score_spread":0.13253817138946142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306710478","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0065476196,0.0036385027,0.001208507,0.02825949,0.0022491722,0.0015238478,0.09157803,0.00015841206,0.8648364],"genre_scores_gemma":[0.84327394,0.004581345,0.00029786685,0.0033718096,0.0024205202,0.0000039827037,0.05191574,0.0041346033,0.0900002],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964295,0.00015056161,0.0011600471,0.0009552655,0.0004628651,0.0008417393],"domain_scores_gemma":[0.9968673,0.00017419826,0.0007963824,0.00040301334,0.0013395263,0.00041960753],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015541471,0.0004045923,0.0006191549,0.00036772375,0.003165212,0.00072453776,0.001452066,0.0001862087,0.03918251],"category_scores_gemma":[0.0017743588,0.0006037153,0.00019264637,0.00059269037,0.0001641394,0.00027787738,0.00075504143,0.00077756046,0.00035439496],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000057479527,0.00017452626,0.000017563643,0.00033341986,0.00035347408,0.000022532004,0.00009320414,0.008703976,0.000020647203,0.16361202,0.79823047,0.028380698],"study_design_scores_gemma":[0.0010426501,0.000121807454,0.0009123194,0.000025499938,0.000023631048,0.00008340172,0.00029954675,0.007567689,0.00002670985,0.0025373427,0.9867691,0.0005902983],"about_ca_topic_score_codex":0.9492082,"about_ca_topic_score_gemma":0.69276935,"teacher_disagreement_score":0.8367263,"about_ca_system_score_codex":0.008021198,"about_ca_system_score_gemma":0.0043488215,"threshold_uncertainty_score":0.9996414},"labels":[],"label_agreement":null},{"id":"W4307134787","doi":"10.1186/s40545-022-00464-6","title":"Competitive tenders on analogue hospital pharmaceuticals in Denmark 2017–2020","year":2022,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Policy and Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"","keywords":"Call for bids; Pharmacy; Business; Medicine; Medical emergency; Pharmacology; Computer science; Family medicine; Marketing; Procurement","score_opus":0.09498626884349634,"score_gpt":0.38939722757637607,"score_spread":0.2944109587328797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307134787","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07473998,0.011067705,0.00021604518,0.41647968,0.0028896735,0.0008005085,0.0008548649,0.00003022398,0.49292132],"genre_scores_gemma":[0.947564,0.0048183524,0.0002842468,0.046318438,0.00082986633,0.000015756605,0.0000042144256,0.000031942775,0.00013319364],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99715227,0.00041651298,0.0012686466,0.00038927584,0.00016099557,0.00061232963],"domain_scores_gemma":[0.9958454,0.002445804,0.0008832817,0.00018206034,0.00006808301,0.0005754146],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0035792415,0.000268562,0.0006666873,0.0006604507,0.00023894937,0.00011304407,0.0004389499,0.00009062045,0.00122059],"category_scores_gemma":[0.002764017,0.00029842285,0.00021345678,0.00059822167,0.00022166266,0.0007225255,0.00025972252,0.0017881646,0.00023209876],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020086945,0.0016808185,0.0016404726,0.000049085906,0.00038215643,0.00077322766,0.0010752521,0.00074590294,0.00013962814,0.97015506,0.017467398,0.003882299],"study_design_scores_gemma":[0.0032312016,0.0006326008,0.0018217382,0.0000146922985,0.000053358446,0.0008288486,0.00058692385,0.0019816041,0.00007795756,0.02284396,0.96755624,0.0003708719],"about_ca_topic_score_codex":0.00006688865,"about_ca_topic_score_gemma":0.0000026910643,"teacher_disagreement_score":0.95008886,"about_ca_system_score_codex":0.0004770631,"about_ca_system_score_gemma":0.00017246894,"threshold_uncertainty_score":0.9999468},"labels":[],"label_agreement":null},{"id":"W4307741138","doi":"10.22541/au.166723062.20984842/v1","title":"Is Thailand's hepatitis C treatment program at risk from its plans to join an Asia-Pacific trade pact?","year":2022,"lang":"en","type":"preprint","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Intellectual property; Business; International trade; Trade agreement; General partnership; Market share; International economics; Economics; Political science; Finance; Law; Free trade","score_opus":0.09986663059078404,"score_gpt":0.3180389169392703,"score_spread":0.21817228634848623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307741138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77333397,0.001486621,0.00006596362,0.009724024,0.0014689257,0.0022126923,0.08955878,0.00027699154,0.12187204],"genre_scores_gemma":[0.9688229,0.013326491,0.0015165436,0.00281974,0.0007452954,0.0015709472,0.0031316134,0.0001637341,0.0079027545],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99635047,0.000070459355,0.0011247902,0.0016348158,0.00006840288,0.00075104437],"domain_scores_gemma":[0.9973795,0.00010198335,0.0005852011,0.0011738624,0.000010478043,0.0007490077],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00032299478,0.00065737026,0.0012131615,0.0003652215,0.00029095437,0.0003654894,0.00068193435,0.00038257934,0.023962656],"category_scores_gemma":[0.00002870332,0.0007231884,0.0005311241,0.00015847098,0.000040237763,0.00014665656,0.0006932783,0.0006488475,0.0022964552],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004247941,0.0037637095,0.79301876,0.0001295618,0.0026834107,0.00008785449,0.010836067,0.0023784584,0.000020974167,0.030389538,0.090806566,0.065460294],"study_design_scores_gemma":[0.0009138743,0.0005998418,0.06060092,0.000010860067,0.00006125076,0.0000028175236,0.000079203695,0.012793782,0.00027167198,0.011347732,0.91233885,0.0009791881],"about_ca_topic_score_codex":0.012227152,"about_ca_topic_score_gemma":0.0029444937,"teacher_disagreement_score":0.8215323,"about_ca_system_score_codex":0.001411207,"about_ca_system_score_gemma":0.00008642411,"threshold_uncertainty_score":0.9995219},"labels":[],"label_agreement":null},{"id":"W4308797786","doi":"10.1136/bmjgh-2022-010057","title":"A global social contract to ensure access to essential medicines and health technologies","year":2022,"lang":"en","type":"article","venue":"BMJ Global Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto","funders":"Center for Substance Abuse Prevention; UCB; United States Pharmacopeia; Unitaid; Leslie Dan Faculty of Pharmacy, University of Toronto; Gilead Sciences; University of Toronto; World Health Organization","keywords":"Social contract; Business; Global health; Public health; Public relations; Public administration; Medicine; Political science; Nursing; Politics; Law","score_opus":0.10424392277804646,"score_gpt":0.4529918066405506,"score_spread":0.34874788386250416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308797786","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16085662,0.006074207,0.0010779094,0.80881476,0.0014926201,0.002096317,0.0070754807,0.00025416934,0.012257944],"genre_scores_gemma":[0.91583335,0.0002431148,0.00020321982,0.08328449,0.0002375694,0.00013977627,0.00002220225,0.00001240683,0.000023842356],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976815,0.000045078203,0.00083484605,0.0005749531,0.00007897675,0.000784645],"domain_scores_gemma":[0.99897575,0.000018780302,0.00036401616,0.00023508898,0.000020803474,0.0003855647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012287357,0.00020308726,0.0007080295,0.00013041373,0.0006025181,0.000117606214,0.0005108277,0.00006994215,0.00017077719],"category_scores_gemma":[0.000089755704,0.00024492206,0.00007825024,0.00070330035,0.00006243923,0.00011451637,0.000716876,0.00018667825,0.00007794969],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001612047,0.0001666779,0.041902937,0.000107311454,0.00005913944,0.000009361016,0.0004120291,0.00017234225,3.9268454e-7,0.5393664,0.29166284,0.12597938],"study_design_scores_gemma":[0.001264138,0.00057315774,0.29899138,0.000016858956,0.000004114095,0.000059404592,0.00034065664,0.00067209365,0.0000011162839,0.058788534,0.6388692,0.00041931684],"about_ca_topic_score_codex":0.0061467066,"about_ca_topic_score_gemma":0.0011484459,"teacher_disagreement_score":0.75497675,"about_ca_system_score_codex":0.0014676399,"about_ca_system_score_gemma":0.000410811,"threshold_uncertainty_score":0.9987632},"labels":[],"label_agreement":null},{"id":"W4308949677","doi":"10.1016/j.jval.2022.11.003","title":"Modeling Tiered Pricing Frameworks: A Simulation Approach","year":2022,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Centre for Advancing Health Outcomes; University of British Columbia; St. Paul's Hospital; University of Toronto","funders":"Institute of Population and Public Health; Canadian Institutes of Health Research","keywords":"Computer science","score_opus":0.1747292760358831,"score_gpt":0.3388581767082557,"score_spread":0.1641289006723726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308949677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7753909,0.0072619235,0.18343398,0.007945858,0.001090701,0.0011130412,0.00023639946,0.000111723464,0.023415472],"genre_scores_gemma":[0.99322534,0.00014311027,0.002290708,0.004097485,0.00010638536,0.000048436064,0.000016838292,0.000023164519,0.00004854123],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99847573,0.00006140035,0.0007340861,0.0003282183,0.0000317337,0.00036882347],"domain_scores_gemma":[0.99942285,0.00007926113,0.00018162106,0.0002046839,0.0000055298965,0.00010603972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014310379,0.00009492031,0.00029904812,0.00028626694,0.00020199835,0.000030709252,0.00017245827,0.00006815624,0.00015536723],"category_scores_gemma":[0.00007342726,0.00013247131,0.000058658305,0.0003255388,0.000010157888,0.00009731097,0.00010129003,0.00062964926,0.000041970492],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009484019,0.00006597398,0.0016105548,0.000037017617,0.000004803999,3.335327e-7,0.0008269672,0.86393744,1.8650105e-7,0.13287716,0.00003990175,0.0005901695],"study_design_scores_gemma":[0.0003110283,0.000032043725,0.00012783411,0.000006380666,4.7572792e-7,0.0000011343959,0.00009836932,0.9210173,1.6900049e-7,0.0688457,0.0094397655,0.00011983274],"about_ca_topic_score_codex":0.002506144,"about_ca_topic_score_gemma":0.0000022018633,"teacher_disagreement_score":0.21783443,"about_ca_system_score_codex":0.0005882072,"about_ca_system_score_gemma":0.00006949568,"threshold_uncertainty_score":0.5402023},"labels":[],"label_agreement":null},{"id":"W4309048291","doi":"10.9778/cmajo.20220063","title":"Time to potential for listing of new drugs on public and private formularies in Canada: a cross-sectional study","year":2022,"lang":"en","type":"article","venue":"CMAJ Open","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Toronto; York University","funders":"","keywords":"Formulary; Notice; Agency (philosophy); Listing (finance); Medicine; Marketing; Business; Public relations; Family medicine; Political science; Finance; Law","score_opus":0.09382472957189025,"score_gpt":0.32130927710620466,"score_spread":0.2274845475343144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309048291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935882,0.000035485347,0.000030735937,0.0014594737,0.00012935442,0.0007997936,0.00050868804,0.0000026106827,0.0034456784],"genre_scores_gemma":[0.99742913,0.0000014356447,0.00011218906,0.0010392357,0.000047512498,0.00010009298,0.000014723625,0.000011750099,0.0012439307],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99909246,0.000009086748,0.0004221959,0.0002498853,0.000027004258,0.00019938238],"domain_scores_gemma":[0.99957263,0.000053844575,0.00013734984,0.00012055691,0.000010607874,0.00010500702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005735694,0.00007251561,0.00024173535,0.00012043773,0.00015104852,0.00014671656,0.00031995017,0.0000147794635,0.000782403],"category_scores_gemma":[0.00009411118,0.000092593946,0.000026431817,0.00011978013,0.000013369033,0.00013928353,0.0004947979,0.00009174559,0.000017749997],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003930785,0.00025782234,0.88250124,0.000024892715,0.000096692835,0.0000035621788,0.0013285779,0.0054349056,0.000015389996,0.102122426,0.004408229,0.0034131808],"study_design_scores_gemma":[0.0032978286,0.00036260005,0.78050685,0.000003167431,0.0000033749116,0.000002536867,0.00018378705,0.015517065,0.000027641041,0.017927054,0.18186869,0.00029939096],"about_ca_topic_score_codex":0.45729795,"about_ca_topic_score_gemma":0.10011533,"teacher_disagreement_score":0.35718262,"about_ca_system_score_codex":0.00033524388,"about_ca_system_score_gemma":0.00029950266,"threshold_uncertainty_score":0.91630524},"labels":[],"label_agreement":null},{"id":"W4309361791","doi":"10.1503/cmaj.220324-f","title":"Sécurité d’approvisionnement pharmaceutique au Canada","year":2022,"lang":"fr","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"York University; University of Toronto; University of Alberta; Mount Sinai Hospital","funders":"","keywords":"Population; Political science; Humanities; Medicine; Art; Environmental health","score_opus":0.020493225284868775,"score_gpt":0.2529000913621309,"score_spread":0.2324068660772621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309361791","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04548907,0.016257988,0.000053559463,0.8243492,0.029819107,0.0002752652,0.004032861,0.000010905197,0.07971199],"genre_scores_gemma":[0.62170243,0.0048465654,0.00007339562,0.33170527,0.011489514,0.00006133447,0.00008207505,0.00008556806,0.029953832],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99602085,0.000269193,0.0013415173,0.00037946866,0.00052741874,0.00146157],"domain_scores_gemma":[0.995213,0.0002560498,0.00082128576,0.000180087,0.000114816314,0.0034147764],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004772776,0.0002438696,0.0005104075,0.00031692526,0.0015103836,0.0001749261,0.00074532884,0.0003086596,0.13901316],"category_scores_gemma":[0.0008678635,0.00036187939,0.00022519479,0.00038859394,0.000058885096,0.00019177077,0.00015453715,0.0030723708,0.0004370118],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0000071360687,0.000086832784,0.03203216,0.000022141996,0.00027678174,0.00047784828,0.00032245708,0.00047298238,2.8350783e-7,0.063471965,0.86770374,0.035125673],"study_design_scores_gemma":[0.0012095755,0.000050794395,0.002299713,0.000019545174,0.000019390009,0.00033656476,0.000330134,0.008225267,0.0000029774926,0.0018982792,0.9852222,0.00038551778],"about_ca_topic_score_codex":0.89181775,"about_ca_topic_score_gemma":0.97569185,"teacher_disagreement_score":0.57621336,"about_ca_system_score_codex":0.023083707,"about_ca_system_score_gemma":0.026759256,"threshold_uncertainty_score":0.9998833},"labels":[],"label_agreement":null},{"id":"W4310688617","doi":"10.12927/hcpol.2022.26973","title":"Patent “Evergreening” of Medicine–Device Combination Products: A Global Perspective","year":2022,"lang":"en","type":"article","venue":"Healthcare policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Bruyère; University of Calgary","funders":"","keywords":"Perspective (graphical); Business; Intellectual property; Computer science; Political science; Artificial intelligence; Law","score_opus":0.1749606082079628,"score_gpt":0.3748205591258012,"score_spread":0.1998599509178384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310688617","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13262333,0.009611994,0.00008940745,0.75555646,0.0011433273,0.0009045373,0.0024135942,0.00009297249,0.097564355],"genre_scores_gemma":[0.98643774,0.00023558045,0.00007276636,0.012522587,0.00040438626,0.00006672761,0.000032406228,0.000019008827,0.00020879821],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99832255,0.0000724082,0.0007214832,0.00041852242,0.00007222201,0.00039280954],"domain_scores_gemma":[0.9988355,0.0000369005,0.0004945462,0.00032692548,0.00012920071,0.00017693886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006544669,0.00015049936,0.00043891268,0.00029356268,0.0002093807,0.000010840157,0.00029450716,0.000049013805,0.00037173156],"category_scores_gemma":[0.0003321981,0.000183621,0.00007934309,0.00087657827,0.00012145442,0.00009905009,0.00018222253,0.00024398151,0.000073098105],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004164698,0.000111098634,0.009581193,0.000090908965,0.000027813281,0.0000016051032,0.0015753364,0.00004349212,0.0000052561268,0.98385817,0.003519781,0.0011437141],"study_design_scores_gemma":[0.0023497634,0.00075455406,0.034568343,0.00001818809,0.0000100000725,0.00003438219,0.0014632985,0.0019006664,0.00003561209,0.6849265,0.27355975,0.0003789163],"about_ca_topic_score_codex":0.039850496,"about_ca_topic_score_gemma":0.00013928337,"teacher_disagreement_score":0.8538144,"about_ca_system_score_codex":0.0017993372,"about_ca_system_score_gemma":0.0002608299,"threshold_uncertainty_score":0.9665432},"labels":[],"label_agreement":null},{"id":"W4311150483","doi":"10.51731/cjht.2022.512","title":"Canadian Trends in Estimated Pharmaceutical Drug Purchases and Projections: 2023","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Audit; Annual growth %; Specialty; Private sector; Agricultural economics; Medicine; Accounting; Economics; Economic growth; Family medicine","score_opus":0.11798662010314265,"score_gpt":0.34642342254702213,"score_spread":0.22843680244387948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311150483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.44272834,0.1872669,0.000022645634,0.35969174,0.0013327686,0.00039547423,0.0016227202,0.00007511541,0.0068642832],"genre_scores_gemma":[0.9965386,0.0010750428,0.00011364261,0.0020554469,0.000010793107,0.00002211211,0.0000069396438,0.0000140825105,0.00016334136],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983707,0.000034792512,0.0007609639,0.00019164322,0.000024880414,0.00061701384],"domain_scores_gemma":[0.99923795,0.00003882256,0.0003001662,0.00013517114,0.0000184231,0.0002694753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011312452,0.00011590397,0.00038763965,0.003238026,0.00042144093,0.000056343182,0.00032025058,0.00006143071,0.00052258465],"category_scores_gemma":[0.00018132341,0.00014114103,0.00005293797,0.00077443465,0.00013483754,0.00013375311,0.00004327577,0.0007083123,0.000013340008],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032176653,0.00009071203,0.16217197,0.00008933747,0.000106894826,0.00038554255,0.0015211597,0.0010939859,0.0000029380187,0.17013194,0.060363054,0.6040103],"study_design_scores_gemma":[0.00061382685,0.00012650389,0.012449106,0.0000191378,0.0000030943409,0.00024618147,0.0011862727,0.0022879888,0.000008763598,0.02901044,0.9538424,0.00020626542],"about_ca_topic_score_codex":0.42060557,"about_ca_topic_score_gemma":0.38922948,"teacher_disagreement_score":0.89347935,"about_ca_system_score_codex":0.0016941138,"about_ca_system_score_gemma":0.001364097,"threshold_uncertainty_score":0.6219155},"labels":[],"label_agreement":null},{"id":"W4312203309","doi":"10.1177/17411343221146094","title":"Abbreviated new drug submission approval process: An overview","year":2022,"lang":"en","type":"article","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Bioequivalence; Innovator; Generic drug; Brand names; Product (mathematics); Drug; Business; Medical prescription; Prescription drug; Pharmacology; Marketing; Medicine; Mathematics; Finance; Pharmacokinetics","score_opus":0.17414686862717058,"score_gpt":0.34405085586261713,"score_spread":0.16990398723544656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312203309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.43038937,0.34198883,0.017077947,0.17853835,0.02984197,0.0015774562,0.00016988779,0.000049633218,0.00036656647],"genre_scores_gemma":[0.7745844,0.09138581,0.0015470249,0.070419215,0.056826048,0.00019157807,0.000090619986,0.00043028756,0.0045249844],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958334,0.00019947009,0.002469788,0.00037145108,0.00044509885,0.0006807671],"domain_scores_gemma":[0.99436694,0.0004974894,0.0033600167,0.0005749215,0.00053130405,0.0006693529],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0061074723,0.0004674189,0.0012908849,0.0004675744,0.0012790619,0.0001343131,0.0020794661,0.00008120799,0.0018829111],"category_scores_gemma":[0.00093202165,0.00026162926,0.00045939462,0.0014515575,0.0002116552,0.00039284042,0.00017124107,0.0010186434,0.000012336726],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022000943,0.00080453994,0.0042235563,0.00083850144,0.0018158661,0.00015801223,0.009134772,0.05967806,0.002179674,0.004141168,0.8562401,0.058585685],"study_design_scores_gemma":[0.0050082356,0.00074867636,0.0042161928,0.00016450307,0.00045770596,0.0051922495,0.0017758193,0.021133844,0.00008954635,0.021941671,0.93872905,0.00054253545],"about_ca_topic_score_codex":0.00010593529,"about_ca_topic_score_gemma":0.000009652794,"teacher_disagreement_score":0.34419507,"about_ca_system_score_codex":0.0002877186,"about_ca_system_score_gemma":0.0007382371,"threshold_uncertainty_score":0.9999836},"labels":[],"label_agreement":null},{"id":"W4312325246","doi":"10.56530/spectroscopy.mf9790d5","title":"Quo Vadis Analytical Procedure Development and Validation?","year":2022,"lang":"en","type":"article","venue":"Spectroscopy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Quest University Canada","funders":"","keywords":"Status quo; Pharmacopoeia; Computer science; Political science; Medicine; Law; Alternative medicine","score_opus":0.045783568263870485,"score_gpt":0.29474839649282036,"score_spread":0.24896482822894989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312325246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9212941,0.00094230723,0.0004240747,0.0052069253,0.00024819365,0.00020188546,0.00012602634,0.00004592882,0.071510546],"genre_scores_gemma":[0.9950498,0.000054861877,0.0014759592,0.0019438431,0.00009819486,0.000061059545,0.00002456948,0.00001925308,0.0012725124],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990194,0.000008794244,0.00034390952,0.0003251258,0.00002896824,0.00027383844],"domain_scores_gemma":[0.99960864,0.000019653786,0.000100275465,0.00014082638,0.0000053478666,0.00012527866],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029900987,0.000106529755,0.00021317787,0.0001374143,0.00025805592,0.000062889936,0.00014382419,0.000026603864,0.002652786],"category_scores_gemma":[0.000023614599,0.00013447854,0.00003934627,0.00015838293,0.000035985657,0.00008064839,0.00013614411,0.00018626981,0.00028855403],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002860224,0.00012851512,0.057969913,0.000024267458,0.00006935675,0.0000041716394,0.00067916774,0.00008112424,0.00013194651,0.93056524,0.010011857,0.00030585914],"study_design_scores_gemma":[0.00074171537,0.00010612005,0.015686188,0.0000023436044,0.000008498134,0.000017540706,0.000101954436,0.0069361464,0.0044209957,0.080385685,0.89116436,0.0004284572],"about_ca_topic_score_codex":0.00001823607,"about_ca_topic_score_gemma":0.0000032051366,"teacher_disagreement_score":0.8811525,"about_ca_system_score_codex":0.00019722579,"about_ca_system_score_gemma":0.00005380145,"threshold_uncertainty_score":0.99825895},"labels":[],"label_agreement":null},{"id":"W4312491467","doi":"10.52937/hira.22.2.2.e8","title":"A Review of Foreign Pharmaceutical Pricing Structure: Focusing on a Drug Price Formula Based on Ex-factory Prices","year":2022,"lang":"en","type":"review","venue":"Health Insurance Review & Assessment Service Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Factory (object-oriented programming); Drug prices; Business; Economics; Computer science; Monetary economics","score_opus":0.36709803707687516,"score_gpt":0.5246153618002687,"score_spread":0.15751732472339353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312491467","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000058339824,0.9646717,0.00005446661,0.007199862,0.00037539707,0.008263425,0.0021668277,0.00005446122,0.01720805],"genre_scores_gemma":[0.00008280975,0.94431776,0.00054680614,0.053011283,0.00028171338,0.0011054429,0.00041431308,0.0002122959,0.000027571912],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9881224,0.001894681,0.0051365346,0.00191518,0.00083047384,0.002100744],"domain_scores_gemma":[0.9899446,0.0030171792,0.0038693415,0.002022482,0.00027350854,0.00087289436],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.016765878,0.0010836395,0.006786223,0.0012995119,0.00065855496,0.00011524049,0.0020436652,0.00026739627,0.003161241],"category_scores_gemma":[0.000635037,0.0010272684,0.0011378304,0.003748034,0.0001220763,0.00031613337,0.0005602092,0.004482329,0.00031016377],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016260577,0.0003458476,0.000038383903,0.6603052,0.0001228597,0.0000058234327,0.000020094543,0.000013956532,5.0213337e-8,0.013029994,0.0029112906,0.32319024],"study_design_scores_gemma":[0.00042455946,0.00022634823,0.000027501415,0.254217,0.00005969723,0.000009170265,0.0000062215254,0.00071324606,4.106882e-7,0.0005164369,0.74322057,0.000578821],"about_ca_topic_score_codex":0.00024122534,"about_ca_topic_score_gemma":0.000011224297,"teacher_disagreement_score":0.7403093,"about_ca_system_score_codex":0.004160291,"about_ca_system_score_gemma":0.003587891,"threshold_uncertainty_score":0.9996626},"labels":[],"label_agreement":null},{"id":"W4312694691","doi":"10.30699/mmlj17.5.2.38","title":"Advanced therapeutic medicinal products (ATMPs) in Ischemic Stroke; novel therapeutic modalities from financial perspective","year":2022,"lang":"en","type":"article","venue":"Modern Medical Laboratory Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Therapeutic modalities; Modalities; Perspective (graphical); Ischemic stroke; Medicine; Stroke (engine); Treatment modality; Therapeutic effect; Business; Cardiology; Internal medicine; Computer science; Ischemia; Engineering; Artificial intelligence","score_opus":0.03666390862104501,"score_gpt":0.27802823023353423,"score_spread":0.24136432161248922,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312694691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87783206,0.05383942,0.0054575903,0.046303954,0.002961759,0.0005037518,0.0025125388,0.00007506233,0.010513843],"genre_scores_gemma":[0.98291636,0.0005869221,0.00020066029,0.015050337,0.0009508341,0.000069701084,0.00001632095,0.000054733104,0.00015411412],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99715275,0.00012670418,0.0010568406,0.00063327095,0.00032668925,0.00070377096],"domain_scores_gemma":[0.9985069,0.00016201902,0.0004532759,0.00033250594,0.00010711025,0.0004381776],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018282706,0.0003104253,0.000697605,0.0003431985,0.0003817487,0.00008687279,0.00077372475,0.00016666377,0.003579255],"category_scores_gemma":[0.00041447816,0.00033808226,0.0001403442,0.00042017925,0.00022409306,0.0003492589,0.00019143657,0.0021527717,0.00006569743],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033198788,0.0060456824,0.045988016,0.00016462764,0.0017123553,0.0009109611,0.037023917,0.007972992,0.017853277,0.78555965,0.020531174,0.072917484],"study_design_scores_gemma":[0.011249958,0.00051463314,0.013092496,0.00007369443,0.000055662786,0.00016622664,0.0026653423,0.0563154,0.00069847447,0.31676108,0.5969688,0.0014382103],"about_ca_topic_score_codex":0.00015515367,"about_ca_topic_score_gemma":0.000039798593,"teacher_disagreement_score":0.57643765,"about_ca_system_score_codex":0.0009927946,"about_ca_system_score_gemma":0.0010666876,"threshold_uncertainty_score":0.99990714},"labels":[],"label_agreement":null},{"id":"W4313246318","doi":"10.30968/rbfhss.2022.134.0897","title":"Pharmaceutical Pricing and Reimbursement Policies: lessons learnt and perspectives for Brazil","year":2022,"lang":"en","type":"article","venue":"Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Benchmarking; Sustainability; Business; Pharmaceutical policy; Pharmacy; Health policy; Health care; Public economics; Marketing; Economics; Medicine; Economic growth; Nursing","score_opus":0.06186880260856023,"score_gpt":0.3327012919209148,"score_spread":0.2708324893123546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313246318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96968865,0.01372027,0.00090970437,0.010833949,0.000117092364,0.00083728146,0.0006706545,0.000072592265,0.0031497783],"genre_scores_gemma":[0.98954785,0.002006251,0.0008608303,0.0067756325,0.00021750774,0.00023780091,0.00002460819,0.000077803124,0.0002517267],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99771166,0.000073012474,0.00060983247,0.0007343854,0.00006332248,0.00080777996],"domain_scores_gemma":[0.9987725,0.00019460186,0.00026532318,0.00032884613,0.000049562103,0.00038913725],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012587571,0.00030937628,0.00059024803,0.00024475704,0.00059641694,0.00028787166,0.0003465849,0.000098115845,0.0003214086],"category_scores_gemma":[0.0002352181,0.0004002302,0.00017905497,0.00024653762,0.00014511056,0.00018801258,0.00044199312,0.00048959535,0.000018880537],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000079058205,0.000325634,0.1857574,0.0003683433,0.00025031748,0.000011108356,0.0059529985,0.00019719847,0.00041152892,0.800836,0.0022606368,0.0035497767],"study_design_scores_gemma":[0.0035494743,0.00067409547,0.48996416,0.00005948612,0.00014314288,0.00015327198,0.004690714,0.034378506,0.00019789081,0.017771393,0.44694972,0.0014681241],"about_ca_topic_score_codex":0.00016742042,"about_ca_topic_score_gemma":0.000005676499,"teacher_disagreement_score":0.7830646,"about_ca_system_score_codex":0.00061777065,"about_ca_system_score_gemma":0.000096798096,"threshold_uncertainty_score":0.99984497},"labels":[],"label_agreement":null},{"id":"W4313464329","doi":"10.22270/ijdra.v10i2.514","title":"A Comparison of the Drug Approval Process in the United States and Canada","year":2022,"lang":"en","type":"article","venue":"International Journal of Drug Regulatory Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Drug approval; Approved drug; Food and drug administration; Population; Clinical trial; Drug; Business; Family medicine; Pharmacology; Environmental health","score_opus":0.02606590921075354,"score_gpt":0.28600587898892915,"score_spread":0.25993996977817563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313464329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869058,0.0005059629,0.000002961731,0.010725391,0.00055751204,0.00006958131,0.00011307217,0.0000010492687,0.0011186793],"genre_scores_gemma":[0.99899095,0.00003875457,0.00000856899,0.00083016965,0.00006803332,0.0000041462918,0.0000043255077,0.000006391646,0.000048635928],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990008,0.00005305839,0.0006226918,0.0000878982,0.00013485026,0.000100687794],"domain_scores_gemma":[0.99902105,0.00011537087,0.0006729389,0.000096812735,0.000057177782,0.00003661947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078438903,0.00006883163,0.00019182601,0.00017370911,0.000067358575,0.000027608776,0.0006978095,0.0000111018635,0.000070914786],"category_scores_gemma":[0.00004355947,0.000053481945,0.00006237274,0.00013262451,0.00007311102,0.00008319885,0.00009987955,0.0002918939,4.252769e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020248003,0.0004177161,0.72167724,0.00004349351,0.00035307146,0.000019657595,0.02084548,0.105933115,0.000018156012,0.12776357,0.02227779,0.00044821014],"study_design_scores_gemma":[0.0050826683,0.00012398082,0.33256072,0.00009531807,0.0000478434,0.00029903432,0.07935655,0.092815794,0.0013210578,0.103226915,0.38441893,0.0006511804],"about_ca_topic_score_codex":0.021917077,"about_ca_topic_score_gemma":0.014929733,"teacher_disagreement_score":0.38911653,"about_ca_system_score_codex":0.00019849735,"about_ca_system_score_gemma":0.00016072481,"threshold_uncertainty_score":0.9845961},"labels":[],"label_agreement":null},{"id":"W4313885874","doi":"10.4212/cjhp.3422","title":"Correction apportée à l’article « Pénuries de médicaments au Canada au cours des 24 derniers mois : la situation ne fait que qu’empirer »","year":2023,"lang":"fr","type":"erratum","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Gynecology; Humanities; Philosophy; Political science; Medicine","score_opus":0.03698480578361835,"score_gpt":0.27588317375853,"score_spread":0.23889836797491165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313885874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8452022,0.005473901,0.00012044345,0.054134052,0.073457465,0.0004525346,0.0012507797,0.000017245455,0.019891376],"genre_scores_gemma":[0.9722597,0.0023780006,0.000029223198,0.0026935588,0.0034577823,0.000018012146,0.000059064692,0.00012657318,0.018978102],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963578,0.00016656306,0.0014821897,0.0003928442,0.00016089904,0.0014397025],"domain_scores_gemma":[0.99613804,0.0002877947,0.001267077,0.00030887255,0.00021345323,0.0017847846],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001922035,0.0004987365,0.0008083572,0.00050782727,0.0010852726,0.00047912102,0.00088320766,0.00026684714,0.00068683206],"category_scores_gemma":[0.0006872688,0.0005521038,0.0003878016,0.0004681961,0.0007768411,0.0006099468,0.000065040695,0.0018340731,0.0001851601],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00004895204,0.00007644955,0.13030694,0.00010480811,0.00083784043,0.00027447648,0.006018227,0.0035681007,0.000004715616,0.0024482831,0.8479665,0.008344696],"study_design_scores_gemma":[0.0013031006,0.00019322366,0.07810459,0.0002731714,0.00028012047,0.0001495098,0.0011761871,0.011031763,0.00018045351,0.0052754297,0.9012497,0.00078273995],"about_ca_topic_score_codex":0.9648955,"about_ca_topic_score_gemma":0.98646474,"teacher_disagreement_score":0.1270575,"about_ca_system_score_codex":0.010750544,"about_ca_system_score_gemma":0.02461203,"threshold_uncertainty_score":0.99969304},"labels":[],"label_agreement":null},{"id":"W4316661889","doi":"10.30953/bhty.v6.264","title":"Three Reasons Why Blockchain Adoption in Healthcare is a Success in Africa and LATAM","year":2023,"lang":"en","type":"article","venue":"Blockchain in Healthcare Today","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact","funders":"","keywords":"Blockchain; Session (web analytics); Business; Developing country; Health care; Healthcare system; Economics; Economic growth; Computer science; Computer security; Advertising","score_opus":0.08549450850414887,"score_gpt":0.3140297600175179,"score_spread":0.22853525151336906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4316661889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8077621,0.0057503735,0.000013662433,0.18365054,0.00036536087,0.0008615405,0.0005806193,0.00008723214,0.0009286182],"genre_scores_gemma":[0.99051917,0.0021591228,0.00012187123,0.0065796217,0.00015267429,0.00025864277,0.000030751668,0.000060538023,0.000117586715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961429,0.00011339825,0.0014308138,0.0009727234,0.00007997927,0.0012601349],"domain_scores_gemma":[0.99845994,0.00031241885,0.00028942036,0.0005157472,0.000034021257,0.00038843928],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00238559,0.00034011863,0.0008472039,0.0015550238,0.000115910574,0.00006610459,0.0003501871,0.0004024058,0.00008301151],"category_scores_gemma":[0.00021202133,0.00043746896,0.00009288292,0.0018576819,0.000088539695,0.00008428095,0.00021275737,0.0008124541,0.00020018236],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000077327684,0.00012472985,0.8533492,0.00039351737,0.00001166377,0.00006514853,0.0022879425,0.00048074746,0.0000027262397,0.13650942,0.002300412,0.0043971543],"study_design_scores_gemma":[0.00309402,0.00020592891,0.59339535,0.00037222417,0.0000035175315,0.000015595797,0.00029353087,0.11093877,0.000013515146,0.25411043,0.03656281,0.0009942878],"about_ca_topic_score_codex":0.04315171,"about_ca_topic_score_gemma":0.051900133,"teacher_disagreement_score":0.25995383,"about_ca_system_score_codex":0.0005656341,"about_ca_system_score_gemma":0.00012136057,"threshold_uncertainty_score":0.9998077},"labels":[],"label_agreement":null},{"id":"W4316814831","doi":"10.54194/hkbh7107","title":"Canada falls behind in new drug submissions compared with the United States and Europe","year":2023,"lang":"en","type":"article","venue":"Canadian Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ceiling (cloud); Government (linguistics); Political science; Public administration; Economic history; History; Engineering","score_opus":0.07689724101818252,"score_gpt":0.31065178410661276,"score_spread":0.23375454308843024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4316814831","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.44610652,0.00059724465,0.000001953687,0.5448882,0.00008148602,0.0003019683,0.0016219019,0.000018627745,0.0063821115],"genre_scores_gemma":[0.83481085,0.0022087384,0.000014057055,0.15673427,0.00022723388,0.000011433063,0.00021878464,0.00004243555,0.0057321684],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99856454,0.000033427546,0.000359951,0.00024630505,0.000023876813,0.0007718724],"domain_scores_gemma":[0.99809164,0.00011975184,0.00011512376,0.00022071025,0.000014517574,0.0014382855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034787823,0.00013367817,0.00027241276,0.0006804306,0.00023713704,0.00006572492,0.00021788981,0.000029898189,0.000095303796],"category_scores_gemma":[0.00007562265,0.0001227633,0.000014768076,0.0009975666,0.00005924933,0.00005262196,0.000033801956,0.000225101,0.0001238752],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000067632595,0.0000053618783,0.018537067,0.000028158593,0.00001821152,0.000018147264,0.0024931438,0.0012851256,1.083465e-7,0.11379061,0.86304,0.00077735493],"study_design_scores_gemma":[0.00036137918,0.0000118417665,0.08662653,0.000010942152,7.760266e-7,0.0000026679138,0.00012839655,0.004831856,4.980221e-7,0.0015588114,0.9063312,0.00013513978],"about_ca_topic_score_codex":0.99962276,"about_ca_topic_score_gemma":0.9995611,"teacher_disagreement_score":0.38870436,"about_ca_system_score_codex":0.0007030838,"about_ca_system_score_gemma":0.0074079433,"threshold_uncertainty_score":0.99821913},"labels":[],"label_agreement":null},{"id":"W4317207459","doi":"10.1136/bmjgh-2022-010615","title":"Pandemic preparedness and response: beyond the Access to COVID-19 Tools Accelerator","year":2023,"lang":"en","type":"review","venue":"BMJ Global Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Göteborgs Universitet; Binghamton University; University of Oxford; Bowling Green State University","keywords":"Business; Intellectual property; Transparency (behavior); Essential medicines; Preparedness; Health care; Economic growth; Economics; Political science; Law","score_opus":0.5196650525038878,"score_gpt":0.5622340756270625,"score_spread":0.042569023123174676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317207459","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002443109,0.9665626,0.0000783322,0.013916369,0.0010950654,0.0038477238,0.011459947,0.00013874668,0.0026568773],"genre_scores_gemma":[0.000058301386,0.9566088,0.000038830996,0.04166936,0.00048626275,0.0006683932,0.00009802671,0.00006550306,0.00030653825],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99581957,0.00028125057,0.001915718,0.001025676,0.000065525215,0.0008922386],"domain_scores_gemma":[0.995895,0.00090334145,0.0010313519,0.00085556105,0.00002229763,0.0012923998],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004179975,0.0004978462,0.0022506474,0.00023577793,0.0004002029,0.0006918135,0.00129636,0.0003291861,0.00014780363],"category_scores_gemma":[0.0013046236,0.00043226863,0.00031978538,0.0009679339,0.00010775664,0.00023547893,0.00084648054,0.00041602904,0.0015083363],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001613926,0.000045444565,0.00026727587,0.008416749,0.00021726814,0.000013331864,0.00044142257,0.000011316934,3.3504512e-9,0.07432549,0.24450342,0.6715969],"study_design_scores_gemma":[0.0002663842,0.000065898115,0.00021610214,0.0004272191,0.000027157637,0.000055666576,0.000023734243,0.00003327103,4.49774e-9,0.013562725,0.9848846,0.00043722874],"about_ca_topic_score_codex":0.0008952331,"about_ca_topic_score_gemma":0.00042768463,"teacher_disagreement_score":0.7403812,"about_ca_system_score_codex":0.0032998144,"about_ca_system_score_gemma":0.0036104633,"threshold_uncertainty_score":0.9998129},"labels":[],"label_agreement":null},{"id":"W4317209651","doi":"10.1007/s40258-022-00787-0","title":"The Impact of Suboxone’s Market Exclusivity on Cost of Opioid Use Disorder Treatment","year":2023,"lang":"en","type":"article","venue":"Applied Health Economics and Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Work & Health; Humber River Regional Hospital; University of Toronto; Lunenfeld-Tanenbaum Research Institute","funders":"Health Canada","keywords":"Buprenorphine; (+)-Naloxone; Medicine; Methadone; Opioid use disorder; Formulary; Public health; Listing (finance); Opioid; Emergency medicine; Anesthesia; Business; Family medicine; Finance; Internal medicine; Nursing","score_opus":0.14296312611907702,"score_gpt":0.40779766061785044,"score_spread":0.2648345344987734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317209651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8870287,0.0024994833,0.000043140903,0.086307585,0.00036083034,0.00294268,0.0050822427,0.00006500404,0.015670314],"genre_scores_gemma":[0.86485106,0.1303375,0.0000458338,0.004062138,0.00020310917,0.00012356126,0.000052171516,0.000048998336,0.00027562334],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99699473,0.000036574555,0.0015472748,0.00046837112,0.000024601999,0.00092841685],"domain_scores_gemma":[0.9971753,0.00046162782,0.0012429783,0.0005675775,0.000018269615,0.00053429377],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015467787,0.00029561538,0.0010612487,0.00044741682,0.00044191198,0.000059966835,0.00023144967,0.00011073888,0.000050349354],"category_scores_gemma":[0.00004262987,0.00026014648,0.00021670327,0.000318024,0.00019195498,0.00008966056,0.00011760794,0.00017416614,0.000096194206],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001860243,0.00022058765,0.013019582,0.00018663322,0.00014216053,1.5290688e-7,0.00113611,0.0012260422,7.521887e-7,0.9233572,0.011785137,0.04873964],"study_design_scores_gemma":[0.0028577335,0.0011808816,0.36568564,0.000028091112,0.000004367958,0.0000023006035,0.00011300726,0.016720416,0.000013194227,0.06993325,0.5430492,0.00041188058],"about_ca_topic_score_codex":0.037921794,"about_ca_topic_score_gemma":0.0015344558,"teacher_disagreement_score":0.85342395,"about_ca_system_score_codex":0.000986133,"about_ca_system_score_gemma":0.001011756,"threshold_uncertainty_score":0.9999851},"labels":[],"label_agreement":null},{"id":"W4317757184","doi":"10.12927/hcpap.2023.27000","title":"Expensive Drugs for Rare Diseases in Canada: What Value and At What Cost?","year":2023,"lang":"en","type":"review","venue":"A Nudge Too Far? A Nudge at All? On Paying People to Be Healthy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Ministry of Health; Canadian Centre for Applied Research in Cancer Control; Provincial Health Services Authority; Centre for Advancing Health Outcomes; Fraser Health; University of British Columbia","funders":"","keywords":"Value (mathematics); Medicine; Statistics; Mathematics","score_opus":0.17968401712704157,"score_gpt":0.369998009857088,"score_spread":0.1903139927300464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317757184","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0051607285,0.82145005,0.0000050887415,0.16285296,0.0019273364,0.0040767714,0.0042830007,0.00006914985,0.00017489913],"genre_scores_gemma":[0.00003803406,0.57902205,0.000022277927,0.41813704,0.00006020796,0.0015878201,0.0005172722,0.00017718338,0.00043815243],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99377733,0.00014163257,0.0023385873,0.0018728286,0.00013207138,0.0017375327],"domain_scores_gemma":[0.99423945,0.0023598848,0.0010488197,0.00090369215,0.000058053167,0.0013901241],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000797202,0.001014056,0.003867927,0.0007239045,0.000417343,0.000533553,0.00067447015,0.0004208034,0.00017533297],"category_scores_gemma":[0.00041691805,0.0011169577,0.0005949678,0.00067733706,0.000051655414,0.00067290553,0.00069919415,0.0005725096,0.00079353445],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037933458,0.00016383905,0.00025894554,0.009049001,0.0003864109,0.000063030966,0.0031186799,0.000030413374,7.1325005e-8,0.01269478,0.6513749,0.3224806],"study_design_scores_gemma":[0.0012961334,0.00017695104,0.00015235772,0.00011151046,0.000101869664,0.000016475446,0.00052874704,0.0005975143,4.4071123e-7,0.0006167799,0.99525076,0.0011504425],"about_ca_topic_score_codex":0.11081679,"about_ca_topic_score_gemma":0.33403888,"teacher_disagreement_score":0.34387589,"about_ca_system_score_codex":0.008168105,"about_ca_system_score_gemma":0.0017065702,"threshold_uncertainty_score":0.99998444},"labels":[],"label_agreement":null},{"id":"W4317757296","doi":"10.12927/hcpap.2023.26996","title":"Expensive Drug Prices for Rare Cancers: Are Patients Truly Benefitting?","year":2023,"lang":"en","type":"letter","venue":"A Nudge Too Far? A Nudge at All? On Paying People to Be Healthy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Queen's University; University of British Columbia","funders":"","keywords":"Notice; Cancer drugs; Orphan drug; Medicine; Incentive; Cancer; Drug prices; Drug; Business; Pharmacology; Public economics; Bioinformatics; Internal medicine; Political science; Law; Economics","score_opus":0.11183386456248043,"score_gpt":0.32111253317854244,"score_spread":0.209278668616062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317757296","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10204935,0.0007821709,0.00004782758,0.8773387,0.0033899785,0.0027576878,0.011673664,0.0002747602,0.0016858279],"genre_scores_gemma":[0.0012511535,0.0010795111,0.00033309672,0.98597294,0.0009895479,0.0020111636,0.0021302646,0.000507261,0.005725083],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99258095,0.00008780996,0.0023051,0.0023801257,0.00021410178,0.0024319317],"domain_scores_gemma":[0.99404967,0.001546793,0.0021474417,0.0012250972,0.00023065945,0.0008003444],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009117099,0.0011666729,0.0023632685,0.000953428,0.00072618504,0.00042244792,0.0011857406,0.00100156,0.0003366973],"category_scores_gemma":[0.0007203905,0.0013752435,0.00080103485,0.0006654199,0.00006177507,0.0003810915,0.00051809836,0.0016118106,0.0029630086],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034228223,0.000115081166,0.0023567588,0.00055480085,0.00025032446,0.000027231432,0.0031254292,0.000045984896,6.2979984e-7,0.0017692096,0.99056315,0.0008491293],"study_design_scores_gemma":[0.0024288788,0.00054037746,0.00234819,0.0000066239913,0.000049070946,0.00000350045,0.00013700781,0.0007703138,0.000012354582,0.001431377,0.9907727,0.0014996005],"about_ca_topic_score_codex":0.0025031245,"about_ca_topic_score_gemma":0.001728546,"teacher_disagreement_score":0.10863418,"about_ca_system_score_codex":0.0034048085,"about_ca_system_score_gemma":0.00033779346,"threshold_uncertainty_score":0.9988697},"labels":[],"label_agreement":null},{"id":"W4317801938","doi":"10.12927/hcpap.2023.26994","title":"Can Managed Access Agreements Mitigate Evidentiary, Economic and Ethical Issues with Access to Expensive Drugs for Rare Diseases in the Canadian Context?","year":2023,"lang":"en","type":"letter","venue":"A Nudge Too Far? A Nudge at All? On Paying People to Be Healthy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Simon Fraser University","funders":"","keywords":"Reimbursement; Context (archaeology); Business; Ethical issues; Political science; Engineering ethics; Law; Engineering; Health care","score_opus":0.13700332465864373,"score_gpt":0.3796049516641499,"score_spread":0.2426016270055062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317801938","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12852265,0.00054215256,0.0000067383103,0.8595879,0.000715477,0.0035440112,0.0065421187,0.00005969847,0.00047927874],"genre_scores_gemma":[0.06263202,0.0009239618,0.000028690498,0.93192005,0.0003367,0.0022184812,0.0009178157,0.00021615191,0.0008061517],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99461794,0.0002062227,0.0013802449,0.0017870427,0.0001576641,0.0018508865],"domain_scores_gemma":[0.9959853,0.0012582213,0.00058629876,0.00097431964,0.00007424623,0.0011215652],"candidate_categories":["metaepi_narrow","scholarly_communication"],"consensus_categories":[],"category_scores_codex":[0.0010957263,0.00082868815,0.0015903828,0.0012107284,0.00074470317,0.0015496596,0.0018641086,0.00078383705,0.00020359254],"category_scores_gemma":[0.00028373091,0.00080300245,0.00026545863,0.00046801296,0.00010805484,0.0003360992,0.0006009974,0.0017022545,0.0005563579],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000329752,0.00003011111,0.0061476696,0.00031061546,0.00019683194,0.00011675429,0.0061357743,0.000039835108,1.3694708e-7,0.002723729,0.98338556,0.000583233],"study_design_scores_gemma":[0.0017766636,0.0003914419,0.01836591,0.000011568049,0.000062744366,0.00001021394,0.0003102832,0.0004926747,0.0000034342959,0.0022453633,0.9752456,0.001084092],"about_ca_topic_score_codex":0.2810497,"about_ca_topic_score_gemma":0.70887977,"teacher_disagreement_score":0.42783007,"about_ca_system_score_codex":0.0023489057,"about_ca_system_score_gemma":0.0006324762,"threshold_uncertainty_score":0.9994868},"labels":[],"label_agreement":null},{"id":"W4317936571","doi":"10.1016/j.jval.2023.01.008","title":"Generic Price Regulation and Drug Expenditures: Evidence From Canada","year":2023,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"University of Nottingham Ningbo China","keywords":"Copayment; Per capita; Incentive; Public economics; Government (linguistics); Prescription drug; Medical prescription; Cost sharing; Price elasticity of demand; Economics; Business; Health care; Health insurance; Economic growth; Microeconomics; Environmental health","score_opus":0.1379334060196279,"score_gpt":0.31495871854030644,"score_spread":0.17702531252067855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317936571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9744055,0.007908102,0.00004650523,0.015894733,0.0005167926,0.00018408356,0.0001732079,0.000026118485,0.00084495486],"genre_scores_gemma":[0.9915165,0.005221063,0.00018848633,0.0026755813,0.00016834661,0.0000151399645,0.00002060445,0.000013707274,0.00018057636],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988246,0.000036429283,0.0004968867,0.00031069672,0.000027141357,0.00030427004],"domain_scores_gemma":[0.9991887,0.00028503023,0.00018197662,0.0001819913,0.000004080512,0.00015820355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066546694,0.000087743305,0.00023728788,0.00014197575,0.00007251214,0.000031323267,0.00011859043,0.00003486196,0.00011245387],"category_scores_gemma":[0.00010409716,0.00010866996,0.000019086623,0.00020432647,0.000017749051,0.00012713771,0.00005091884,0.000113875096,0.00010583933],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000073019575,0.000088752335,0.50035137,0.00063096447,0.000072813265,0.000032173546,0.007745332,0.083551094,0.0000967781,0.2175911,0.17886715,0.010899447],"study_design_scores_gemma":[0.00047323594,0.000021659387,0.5241464,0.000112829424,0.0000012348764,0.0000016308297,0.00009875835,0.22461131,0.000060804992,0.07000513,0.18015562,0.00031137787],"about_ca_topic_score_codex":0.8753782,"about_ca_topic_score_gemma":0.118845254,"teacher_disagreement_score":0.7565329,"about_ca_system_score_codex":0.000379215,"about_ca_system_score_gemma":0.00022593739,"threshold_uncertainty_score":0.89723355},"labels":[],"label_agreement":null},{"id":"W4318263088","doi":"10.1071/ah22280","title":"Potential therapeutic value of new drugs approved in Australia: a retrospective cohort study","year":2023,"lang":"en","type":"article","venue":"Australian Health Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University; University of Toronto","funders":"","keywords":"Medicine; Food and drug administration; Pharmacology; Family medicine","score_opus":0.15016167952997864,"score_gpt":0.4036443178556346,"score_spread":0.253482638325656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318263088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8484404,0.050423205,0.00006469149,0.08317453,0.0016815701,0.0111415,0.0006266012,0.00019809809,0.0042493897],"genre_scores_gemma":[0.9472062,0.045217037,0.0000586366,0.0035369915,0.00012371608,0.00010608509,0.000029300301,0.000034898185,0.0036871114],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99694973,0.000096570286,0.0016590237,0.0005771736,0.000073161034,0.00064434117],"domain_scores_gemma":[0.9985194,0.00003454883,0.0006422492,0.00048040078,0.000022628865,0.00030075663],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002514222,0.00023368197,0.0013479494,0.00027808102,0.00005187777,0.0000247975,0.00033873072,0.000087626526,0.00070199376],"category_scores_gemma":[0.000069310976,0.00026195956,0.00020559305,0.0010232985,0.000048708265,0.0001293514,0.000064835855,0.00035518757,0.0011794458],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002936272,0.0005247824,0.85236186,0.0032644405,0.0002705831,0.000014014561,0.0013390735,0.00008351401,0.0000038964417,0.07561959,0.060226057,0.006262826],"study_design_scores_gemma":[0.0010044322,0.00023634938,0.9192237,0.0004039939,0.000028158298,0.0000027909741,0.000064890635,0.0002096115,0.0000038001442,0.017172715,0.061350133,0.0002994252],"about_ca_topic_score_codex":0.007036381,"about_ca_topic_score_gemma":0.000093588955,"teacher_disagreement_score":0.098765805,"about_ca_system_score_codex":0.00032534008,"about_ca_system_score_gemma":0.00012953243,"threshold_uncertainty_score":0.99998325},"labels":[],"label_agreement":null},{"id":"W4318392168","doi":"10.1136/bmjopen-2022-068233","title":"Effects of the July 2018 worldwide valsartan recall and shortage on global trends in antihypertensive medication use: a time-series analysis in 83 countries","year":2023,"lang":"en","type":"article","venue":"BMJ Open","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"National Heart, Lung, and Blood Institute","keywords":"Valsartan; Medicine; Economic shortage; Developing country; Angiotensin Receptor Blockers; Internal medicine; Economic growth; Blood pressure; Renin–angiotensin system; Economics","score_opus":0.07420581863229862,"score_gpt":0.36336065262001416,"score_spread":0.2891548339877155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318392168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98164946,0.00014938206,0.0000042902884,0.008099334,0.00014498457,0.0010555716,0.00044962962,0.000009969311,0.008437366],"genre_scores_gemma":[0.99627334,0.00035255027,0.000033221775,0.0017499542,0.000027321545,0.00012104729,0.00003346709,0.000010055347,0.0013990705],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989329,0.00004711301,0.0005110239,0.0002752328,0.00003593696,0.00019780763],"domain_scores_gemma":[0.999254,0.00018567202,0.00022358508,0.00027257754,0.000012201867,0.000051968684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076286873,0.00010663406,0.0005318416,0.00037011417,0.000038655744,0.000091090675,0.00029996337,0.000067221634,0.00010205576],"category_scores_gemma":[0.00023556242,0.000095725394,0.00006982755,0.0012810586,0.000089819674,0.00024526837,0.00020720741,0.00008482342,0.00014302826],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055717817,0.0002295358,0.88979197,0.00012592498,0.0005224971,0.000029466162,0.00095224305,0.00061861123,0.000040245126,0.07910902,0.024245987,0.0037773238],"study_design_scores_gemma":[0.0010583985,0.00005087777,0.96375054,0.000049980245,0.00003528625,8.487602e-7,0.0000139792855,0.0071863625,0.00010431106,0.004701438,0.022894993,0.00015297375],"about_ca_topic_score_codex":0.0009994706,"about_ca_topic_score_gemma":0.0014214402,"teacher_disagreement_score":0.074407585,"about_ca_system_score_codex":0.00008151124,"about_ca_system_score_gemma":0.000027256528,"threshold_uncertainty_score":0.3903568},"labels":[],"label_agreement":null},{"id":"W4318481751","doi":"10.2139/ssrn.4300678","title":"Valuing Pharmaceutical Drug Innovations","year":2023,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Drug; Business; Medicine; Pharmacology","score_opus":0.05936415886304829,"score_gpt":0.32074639959600765,"score_spread":0.26138224073295935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318481751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8222588,0.0070930906,0.0074324533,0.06770516,0.0022990997,0.00035266575,0.000119702265,0.0003604843,0.09237859],"genre_scores_gemma":[0.984029,0.008282129,0.000047882015,0.0022691726,0.00065667846,0.000010359867,0.000012104434,0.000038647955,0.0046540275],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9967707,0.00002056724,0.00063028774,0.00025685082,0.00004168919,0.0022799426],"domain_scores_gemma":[0.99938065,0.000070283466,0.00020111093,0.00016306875,0.000033081342,0.00015183222],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0030911344,0.0001455344,0.00025854318,0.0004726635,0.0002778774,0.000112663576,0.00033247552,0.00006260324,0.00032917788],"category_scores_gemma":[0.00013129802,0.00016934457,0.0001464932,0.00076261745,0.00005156698,0.0002668416,0.000075362164,0.0015904594,0.0041521876],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008205972,0.000029128052,0.0033497019,0.0000041468593,0.00010373171,0.000002400817,0.00010810781,0.00010150937,0.000047512214,0.9873398,0.0047001173,0.004205644],"study_design_scores_gemma":[0.0005592899,0.000022502356,0.0007968102,0.0000035045555,0.000006340121,0.00005996177,0.00014286394,0.005747781,0.00004194237,0.7499588,0.24247187,0.00018831987],"about_ca_topic_score_codex":0.00002499227,"about_ca_topic_score_gemma":0.000033649907,"teacher_disagreement_score":0.23777175,"about_ca_system_score_codex":0.00064114225,"about_ca_system_score_gemma":0.00038635082,"threshold_uncertainty_score":0.9966232},"labels":[],"label_agreement":null},{"id":"W4318482378","doi":"10.1007/s40278-023-32266-x","title":"Health Canada removes seven unauthorised health products from sale","year":2023,"lang":"en","type":"article","venue":"Reactions Weekly","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Environmental health; Medicine","score_opus":0.0803977831446766,"score_gpt":0.3074767637964718,"score_spread":0.22707898065179521,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318482378","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21300913,0.0041616014,0.00020980655,0.7307801,0.0044131353,0.00085893646,0.006092087,0.00043798427,0.040037192],"genre_scores_gemma":[0.97180206,0.0031692204,0.00052006193,0.010605687,0.0008423984,0.000032418764,0.00050002534,0.00006800821,0.012460135],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99820775,0.000031198855,0.0007121394,0.0004736954,0.000039290484,0.0005359425],"domain_scores_gemma":[0.9987323,0.000101448946,0.00038255283,0.000433795,0.000019827683,0.0003300702],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00052121555,0.00015066126,0.00044924184,0.00020610778,0.00026776743,0.000054835356,0.00018931659,0.00005370171,0.00019892787],"category_scores_gemma":[0.00013624247,0.00019151052,0.00006493587,0.0006026825,0.000027467335,0.00014340146,0.00005109604,0.0002391212,0.0014812236],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012374503,0.000084856736,0.0030077908,0.00008254042,0.00010932606,0.000004604415,0.0005038174,0.00026993454,0.000035764886,0.06405311,0.9223036,0.009532259],"study_design_scores_gemma":[0.00025765385,0.000025971349,0.036630362,0.000013633224,0.0000016024219,0.0000025938762,0.00010527883,0.0019968464,0.00002833352,0.010368025,0.9503834,0.00018626843],"about_ca_topic_score_codex":0.7754866,"about_ca_topic_score_gemma":0.22954845,"teacher_disagreement_score":0.75879294,"about_ca_system_score_codex":0.0008230754,"about_ca_system_score_gemma":0.00097502576,"threshold_uncertainty_score":0.99929625},"labels":[],"label_agreement":null},{"id":"W4318586248","doi":"10.1186/s40545-022-00497-x","title":"Bridging the gap? Local production of medicines on the national essential medicine lists of Kenya, Tanzania and Uganda","year":2023,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Policy and Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Population and Public Health","funders":"","keywords":"Tanzania; Essential medicines; Pharmacy; Business; Population; Medicine; Health care; Environmental health; Socioeconomics; Economic growth; Family medicine; Economics","score_opus":0.1414093113311773,"score_gpt":0.4141109217024941,"score_spread":0.2727016103713168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318586248","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24341202,0.0031673212,0.000294587,0.7301705,0.00091335684,0.00025045525,0.00005940932,0.000009472255,0.021722892],"genre_scores_gemma":[0.9831925,0.006376043,0.00002415958,0.008328393,0.0019474858,0.0000019500358,9.979586e-7,0.0000111132595,0.00011734049],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984957,0.00014529644,0.00085961545,0.00015333848,0.00015396898,0.0001920705],"domain_scores_gemma":[0.99587077,0.0028221256,0.0008940171,0.00009944067,0.0001804871,0.00013315812],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005116099,0.00011902319,0.0003549307,0.00028178692,0.00012496424,0.000023200702,0.00017486821,0.00005754578,0.00009124162],"category_scores_gemma":[0.008934378,0.000075381,0.000067510264,0.0004180161,0.00069240737,0.00026812995,0.00006620967,0.00043481818,0.000010688907],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014524255,0.00022276497,0.0007282035,0.00024230544,0.00049452344,0.000011961164,0.0024093897,0.0004861147,0.0046541234,0.91606146,0.057841137,0.015395564],"study_design_scores_gemma":[0.00344816,0.0007131224,0.009610926,0.00027044863,0.00028865994,0.001005416,0.0007845784,0.027766312,0.006498028,0.12616953,0.82310504,0.00033975058],"about_ca_topic_score_codex":0.00008625121,"about_ca_topic_score_gemma":0.0000020764999,"teacher_disagreement_score":0.78989196,"about_ca_system_score_codex":0.000041461226,"about_ca_system_score_gemma":0.00007866165,"threshold_uncertainty_score":0.9994138},"labels":[],"label_agreement":null},{"id":"W4319304079","doi":"10.1021/cen-10105-buscon12","title":"Seqens opens a new research center","year":2023,"lang":"en","type":"article","venue":"C&EN Global Enterprise","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Center (category theory); Research center; Quarter (Canadian coin); Business; Technology transfer; Coronavirus disease 2019 (COVID-19); Chemistry; Political science; Medicine","score_opus":0.181746638650275,"score_gpt":0.40693887645403737,"score_spread":0.22519223780376238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319304079","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.41601104,0.0008455757,0.00035283185,0.020666912,0.0017536725,0.0005328272,0.0017402511,0.00026148802,0.5578354],"genre_scores_gemma":[0.9861928,0.0008877466,0.00013895803,0.0030804488,0.0005884123,0.000024848658,0.000056472294,0.000035312507,0.008994971],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99802285,0.000040496983,0.00051308895,0.00052762666,0.00006039649,0.000835545],"domain_scores_gemma":[0.99887985,0.00008294837,0.00008700321,0.0004582365,0.000028537163,0.0004634418],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00091831473,0.00016923025,0.00033862103,0.00023172279,0.00012876344,0.000188395,0.00060000457,0.00012384569,0.0014684618],"category_scores_gemma":[0.00020835124,0.00020038095,0.00017053308,0.00073189,0.000081668906,0.00019792799,0.00050361373,0.00028727498,0.030269561],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006565933,0.00012989054,0.07636672,0.000024795612,0.00009075751,0.000048762184,0.00054671423,0.000059148257,0.0000117213685,0.32141176,0.59582317,0.0054209097],"study_design_scores_gemma":[0.00091766735,0.000043602835,0.018452924,0.00001658971,0.0000024581095,0.000008731853,0.000041411877,0.002410291,0.000014169593,0.09364658,0.8842211,0.00022451553],"about_ca_topic_score_codex":0.0006067095,"about_ca_topic_score_gemma":0.000055160785,"teacher_disagreement_score":0.5701818,"about_ca_system_score_codex":0.0003759252,"about_ca_system_score_gemma":0.00007314197,"threshold_uncertainty_score":0.9994443},"labels":[],"label_agreement":null},{"id":"W4319655654","doi":"10.1371/journal.pone.0281076","title":"Identifying drugs with the greatest increases and decreases in spending per beneficiary using Medicare Part D: A cross-sectional study","year":2023,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Sinai Health System","funders":"","keywords":"Cross-sectional study; Beneficiary; Medicine; Medicare Part D; Environmental health; Demography; Pharmacology; Business; Medical prescription; Finance; Prescription drug","score_opus":0.21101877892498927,"score_gpt":0.32973123845466196,"score_spread":0.11871245952967269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319655654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979623,0.000494683,0.000003062487,0.00026125845,0.000038983064,0.00027922934,0.00011219156,0.00003584665,0.0008124659],"genre_scores_gemma":[0.9991373,0.00023957035,0.000054568853,0.00022290138,0.00018076299,0.000041972464,0.000018767332,0.000025007692,0.00007918428],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99887663,0.000023866156,0.00038758002,0.00035085544,0.00006915379,0.00029191],"domain_scores_gemma":[0.9993248,0.00024322094,0.00013525858,0.0001684423,0.000017110304,0.00011115684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073608354,0.00013133592,0.00029633535,0.00026021403,0.00023185185,0.0002139972,0.00014874373,0.000045419554,0.00028482435],"category_scores_gemma":[0.00011751488,0.00011854,0.000033778942,0.00028841296,0.000088813664,0.00022319479,0.0001358813,0.0001747032,0.00011951458],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002563559,0.00045257484,0.99680907,0.000029151006,0.00013228685,0.00001056733,0.0005517594,0.00006602566,0.000024325544,0.0018498662,0.000011418891,0.00003735221],"study_design_scores_gemma":[0.0007971088,0.000059943617,0.9880476,0.00005764598,0.000028637913,0.000005289509,0.00063640776,0.007951927,0.0000502596,0.0020519684,0.00011820355,0.00019503661],"about_ca_topic_score_codex":0.0019316263,"about_ca_topic_score_gemma":0.00042278095,"teacher_disagreement_score":0.008761466,"about_ca_system_score_codex":0.00008755656,"about_ca_system_score_gemma":0.000022685825,"threshold_uncertainty_score":0.4833921},"labels":[],"label_agreement":null},{"id":"W4319741390","doi":"10.21203/rs.3.rs-2205634/v1","title":"Compliance of Public Health Facilities with Essential Medicines and Health Supplies Redistribution Guidelines in Mbale District, Eastern Uganda: A mixed-methods study","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Erasmus+; Trent University; Nottingham Trent University","keywords":"Redistribution (election); Compliance (psychology); Business; Public health; Environmental health; Medicine; Nursing; Political science; Psychology","score_opus":0.4832757902443569,"score_gpt":0.5372476069966008,"score_spread":0.053971816752243884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319741390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7867066,0.031607714,0.020406809,0.13145006,0.0010934141,0.005383807,0.022183815,0.00014865203,0.0010190954],"genre_scores_gemma":[0.99119574,0.0063798856,0.0007808653,0.00013818422,0.00025119772,0.00029637295,0.0005012173,0.000046954647,0.00040959066],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99534106,0.00055941707,0.001863663,0.00097976,0.00022420145,0.0010319095],"domain_scores_gemma":[0.9974639,0.00039881418,0.00069326046,0.000598596,0.00033701418,0.0005084491],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.013207324,0.00032239783,0.0014103727,0.0009515308,0.00022253211,0.00019516423,0.00050055626,0.00016563313,0.000072595896],"category_scores_gemma":[0.0010696877,0.00032445937,0.000097032076,0.0007009419,0.00047643227,0.00013351305,0.0010455721,0.0009974916,0.000023988732],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019636282,0.0012184213,0.8526953,0.014241198,0.00044808412,0.000022042255,0.010281213,0.00037823332,0.000004048074,0.04019052,0.019535966,0.060788613],"study_design_scores_gemma":[0.00490591,0.0025058414,0.8142635,0.0020817707,0.000010022137,0.00001138383,0.020837512,0.029403854,0.000032785563,0.054986984,0.06981244,0.0011479654],"about_ca_topic_score_codex":0.016169153,"about_ca_topic_score_gemma":0.00442578,"teacher_disagreement_score":0.2044891,"about_ca_system_score_codex":0.00061371643,"about_ca_system_score_gemma":0.0009169804,"threshold_uncertainty_score":0.9999207},"labels":[],"label_agreement":null},{"id":"W4320015086","doi":"10.2139/ssrn.4322653","title":"‘A Most Equitable Drug’: How the Clinical Studies of Convalescent Plasma as a Treatment for SARS-CoV-2 Might Usefully Inform Post-Pandemic Public Sector Approaches to Drug Development","year":2023,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; University of Toronto","funders":"","keywords":"Pandemic; Convalescent plasma; Drug; Drug development; Coronavirus disease 2019 (COVID-19); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Medicine; 2019-20 coronavirus outbreak; Virology; Intensive care medicine; Pharmacology; Infectious disease (medical specialty); Disease; Internal medicine","score_opus":0.4085873330674294,"score_gpt":0.3713114373033053,"score_spread":0.0372758957641241,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320015086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96202195,0.003379939,0.00017401054,0.032182835,0.0005256199,0.00084924523,0.0001355849,0.000038656617,0.00069215917],"genre_scores_gemma":[0.9848876,0.009468154,0.0001470149,0.0018537885,0.00036238102,0.00017479007,0.00002837679,0.000049978735,0.0030279348],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958371,0.000047060217,0.0012441211,0.00040876088,0.00008228613,0.0023806496],"domain_scores_gemma":[0.99834377,0.0004346296,0.0006288737,0.00028695818,0.00012999728,0.00017577858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050306083,0.00030925617,0.0007802333,0.00036083808,0.00040750467,0.0001700307,0.00056885224,0.00009649174,0.000011046412],"category_scores_gemma":[0.000479371,0.00024130836,0.00031506753,0.0004175753,0.00012347056,0.00026377488,0.00019797355,0.0006540783,0.000253743],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006600294,0.0006337458,0.024412045,0.00013630705,0.005059181,0.0000032080388,0.007359094,0.00013643416,0.00016505396,0.8991411,0.014987091,0.04730674],"study_design_scores_gemma":[0.006607845,0.0014112812,0.0018057862,0.00005530867,0.00010781203,0.0001066875,0.0075591127,0.002818923,0.003646831,0.13222724,0.8426994,0.00095375243],"about_ca_topic_score_codex":0.000059072623,"about_ca_topic_score_gemma":0.0020036993,"teacher_disagreement_score":0.8277123,"about_ca_system_score_codex":0.001892493,"about_ca_system_score_gemma":0.0026006438,"threshold_uncertainty_score":0.9840269},"labels":[],"label_agreement":null},{"id":"W4320489785","doi":"10.1186/s12913-023-09095-2","title":"Launch sequencing of pharmaceuticals with multiple therapeutic indications: evidence from seven countries","year":2023,"lang":"en","type":"article","venue":"BMC Health Services Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"London School of Economics and Political Science; Novartis","keywords":"Medicine; Reimbursement; Orphan drug; Authorization; Marketing authorization; Clinical trial; Food and drug administration; Drug approval; Family medicine; Medical emergency; Drug; Pharmacology; Internal medicine; Health care","score_opus":0.3014443096088063,"score_gpt":0.46646999681391416,"score_spread":0.16502568720510785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320489785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9732227,0.016964689,0.0006463605,0.005602007,0.00013825049,0.0010588343,0.0010677188,0.00010605284,0.0011934377],"genre_scores_gemma":[0.9875164,0.008565504,0.00057472277,0.0027930078,0.00015635899,0.00013849235,0.000050450748,0.000037184604,0.00016784755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973579,0.00019105391,0.00086906913,0.0005409476,0.0001872569,0.00085379457],"domain_scores_gemma":[0.9964911,0.0021325073,0.0003420352,0.00053747994,0.000146568,0.00035034266],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003853247,0.00015920954,0.0004956728,0.00056638214,0.0003169309,0.00010344978,0.0006664427,0.00010305351,0.00052937045],"category_scores_gemma":[0.00009602484,0.00015878442,0.00006143001,0.0011703534,0.00020441579,0.0003585023,0.00019859013,0.000411679,0.0018868995],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034023402,0.00012580193,0.9435474,0.003267733,0.00018744517,0.0000047016174,0.01801697,0.0008984691,0.00031757838,0.030688006,0.0004397762,0.0021658435],"study_design_scores_gemma":[0.0031983375,0.0005546142,0.4489852,0.0014894472,0.00001720417,0.00000451587,0.0061081643,0.28188083,0.0028504066,0.065872595,0.18815844,0.00088027335],"about_ca_topic_score_codex":0.005222885,"about_ca_topic_score_gemma":0.00081475417,"teacher_disagreement_score":0.49456227,"about_ca_system_score_codex":0.0003940525,"about_ca_system_score_gemma":0.000707002,"threshold_uncertainty_score":0.9988902},"labels":[],"label_agreement":null},{"id":"W4321366269","doi":"10.1111/caje.12647","title":"Pharmaceutical regulation under market integration through parallel trade","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Economics/Revue canadienne d économique","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Reimbursement; Business; Limit (mathematics); Authorization; International economics; International trade; Economics; Economic growth; Computer science","score_opus":0.30446322202520276,"score_gpt":0.2592729801322343,"score_spread":0.04519024189296844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321366269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9454485,0.0005842972,0.0011424008,0.02603365,0.0026635546,0.00033468028,0.00063693954,0.00003051352,0.023125434],"genre_scores_gemma":[0.9917649,0.0008860866,0.0006105892,0.004369362,0.0009973992,0.000021344966,0.00006100505,0.0000856671,0.0012036723],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9967195,0.000050976603,0.00168609,0.0004999567,0.0000025413035,0.0010409836],"domain_scores_gemma":[0.996896,0.00019112971,0.0008818051,0.000408813,0.000055813212,0.0015664387],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013275682,0.00034911453,0.00083874253,0.0010210646,0.00022167685,0.00022656699,0.0006052647,0.00029862177,0.0022534807],"category_scores_gemma":[0.00021045002,0.00046225535,0.00038850936,0.00035230038,0.00020729899,0.0009240528,0.00002987633,0.0005331447,0.00050546543],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006208709,0.000014163659,0.0018407295,0.000023806962,0.00015667797,0.000034409386,0.00075064204,0.008886235,0.0000123697755,0.96944153,0.01721883,0.0015585131],"study_design_scores_gemma":[0.0009871146,0.000112219685,0.005541327,0.00003392822,0.000022736418,0.00014419222,0.00018954433,0.036157865,0.00007593027,0.723675,0.23259208,0.00046807245],"about_ca_topic_score_codex":0.017265674,"about_ca_topic_score_gemma":0.39409608,"teacher_disagreement_score":0.3768304,"about_ca_system_score_codex":0.0018495902,"about_ca_system_score_gemma":0.0007094657,"threshold_uncertainty_score":0.9997829},"labels":[],"label_agreement":null},{"id":"W4322579181","doi":"10.1016/b978-0-12-821047-5.00016-6","title":"Overview of Drug Development","year":2023,"lang":"en","type":"book-chapter","venue":"Elsevier eBooks","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Drug; Drug development; Medicine; Pharmacology","score_opus":0.11950277853261856,"score_gpt":0.29495843378124637,"score_spread":0.1754556552486278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322579181","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001020104,0.0062288744,0.0000016302381,0.00017658394,0.0005928136,0.0002822978,0.00035418963,0.00004726929,0.9922143],"genre_scores_gemma":[0.00056611834,0.0020028623,0.0001970536,0.00095509307,0.00020043286,0.000026319896,0.000036086658,0.00012406745,0.995892],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978745,0.0000048437414,0.0012815363,0.0004750751,0.000045014287,0.0003190062],"domain_scores_gemma":[0.9985723,0.00006435165,0.00071103516,0.000466519,0.000028638411,0.00015714929],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0005295784,0.00033906,0.0009803056,0.0003239261,0.000056606354,0.000028949244,0.00039001094,0.00022083156,0.0012978332],"category_scores_gemma":[0.000016898208,0.00041139644,0.00032096924,0.000020006259,0.000093480856,0.00003439055,0.00022804078,0.00032653043,0.008879069],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000041521726,0.000007507567,0.000024652345,0.00026802532,0.00018345722,0.000004259662,0.0002033533,8.470009e-7,5.5941933e-7,0.6153079,0.0015161774,0.3824791],"study_design_scores_gemma":[0.00018530844,0.000007683042,0.00005936829,0.00015328842,0.000012786966,0.0000010928255,0.0000011216399,0.00001513074,0.000030498684,0.19141088,0.8077799,0.00034292202],"about_ca_topic_score_codex":0.0000016019416,"about_ca_topic_score_gemma":0.000022675356,"teacher_disagreement_score":0.80626374,"about_ca_system_score_codex":0.00013314701,"about_ca_system_score_gemma":0.000100638594,"threshold_uncertainty_score":0.99983376},"labels":[],"label_agreement":null},{"id":"W4322705791","doi":"10.2139/ssrn.4368340","title":"Strategic Tier Design in Health Insurance: The Case of Medicare Part D","year":2023,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Formulary; Cost sharing; Actuarial science; Business; Tier 2 network; Medicare Part D; Population; Medicine; Operations management; Finance; Economics; Environmental health; Family medicine; Prescription drug; Engineering; Medical prescription; Nursing","score_opus":0.09244601672265143,"score_gpt":0.3205471601852412,"score_spread":0.22810114346258978,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322705791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95346755,0.016336298,0.0011036692,0.0225985,0.00063179975,0.00036108325,0.00012450195,0.00002895951,0.0053476496],"genre_scores_gemma":[0.9739287,0.024884582,0.000014409525,0.0007234338,0.00016711587,0.000008885998,0.0000027103483,0.000016502125,0.0002536781],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9975607,0.00008274274,0.00075807754,0.0001677285,0.000025720965,0.0014050354],"domain_scores_gemma":[0.99922705,0.000117751784,0.00037332225,0.00016540982,0.0000151021795,0.00010136413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0056645568,0.00010495507,0.0003050982,0.00022117056,0.00012764188,0.000029989173,0.0002534915,0.000058640464,0.00010712276],"category_scores_gemma":[0.00006606549,0.00009053403,0.00009100595,0.00043315324,0.00006468194,0.00009171426,0.000029246916,0.0010885567,0.00014421859],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002428372,0.00004075482,0.004452251,0.000021389133,0.00007883557,0.000043472246,0.0004323849,0.0013808713,0.0000019110264,0.985754,0.0010474988,0.0067223418],"study_design_scores_gemma":[0.0007473813,0.0001634166,0.00092164107,0.000017104518,0.0000017693867,0.00059062795,0.0012541895,0.007435256,0.0000055517216,0.9802303,0.00850491,0.00012790412],"about_ca_topic_score_codex":0.0003998542,"about_ca_topic_score_gemma":0.0008097681,"teacher_disagreement_score":0.021875065,"about_ca_system_score_codex":0.00044778708,"about_ca_system_score_gemma":0.0009158772,"threshold_uncertainty_score":0.47292975},"labels":[],"label_agreement":null},{"id":"W4323066860","doi":"10.1136/bmj.p524","title":"Canada’s promise to reform drug prices left in doubt as regulator is hit by wave of resignations","year":2023,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Regulator; Drug; Drug prices; Computer science; Medicine; Political science; Business; Data science; Law and economics; Economics; Public economics; Pharmacology; Chemistry","score_opus":0.05341636750969777,"score_gpt":0.2984884466091468,"score_spread":0.24507207909944903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323066860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6791403,0.00026262327,0.0000072191815,0.11967665,0.0002948451,0.0007091163,0.0014721499,0.000028604461,0.19840848],"genre_scores_gemma":[0.97662675,0.00010975218,0.000112137845,0.0042965407,0.00008520003,0.00004493146,0.000028611701,0.000021887608,0.01867421],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987942,0.0000062997974,0.00062170904,0.0002596761,0.000037645103,0.00028046884],"domain_scores_gemma":[0.99933594,0.000043075834,0.00019484235,0.00025848212,0.000020055137,0.00014761183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004969611,0.000098989425,0.00027238828,0.00024582236,0.00004273254,0.00002352363,0.0001894284,0.00005093024,0.00051109394],"category_scores_gemma":[0.00009714588,0.00011571492,0.00004685317,0.00029474,0.000020160422,0.0000970145,0.000074429605,0.00008747033,0.00036717908],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028750525,0.000041147414,0.0027350949,0.00004846875,0.000035117468,0.000004754971,0.0010126706,0.0000795174,0.00010480538,0.1196152,0.8757973,0.0004972318],"study_design_scores_gemma":[0.00047701655,0.000020403842,0.01718887,0.000016293903,0.0000024784838,0.000001238554,0.00008351583,0.0028826792,0.0019631037,0.0169053,0.9602266,0.00023249611],"about_ca_topic_score_codex":0.32709098,"about_ca_topic_score_gemma":0.1552231,"teacher_disagreement_score":0.29748642,"about_ca_system_score_codex":0.00041299878,"about_ca_system_score_gemma":0.00029470614,"threshold_uncertainty_score":0.8601919},"labels":[],"label_agreement":null},{"id":"W4323321720","doi":"10.1377/hlthaff.2022.00873","title":"Patent Challenges And Litigation On Inhalers For Asthma And COPD","year":2023,"lang":"en","type":"article","venue":"Health Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Generic drug; Certification; Formulary; Paragraph; Brand names; Medicine; Food and drug administration; Business; Competition (biology); Tying; Asthma; Marketing; Drug; Pharmacology; Law","score_opus":0.2140562939056647,"score_gpt":0.3259402132449904,"score_spread":0.1118839193393257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323321720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6194355,0.03458003,0.00012344476,0.29870132,0.0010656974,0.0016388253,0.0009254065,0.00022151493,0.043308254],"genre_scores_gemma":[0.96641415,0.030661855,0.00010015981,0.0024545302,0.00010932508,0.00006783506,0.000024145927,0.000017813776,0.00015017914],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.999116,0.000009232221,0.0002908163,0.0002769946,0.000012638734,0.00029429697],"domain_scores_gemma":[0.99946165,0.00010227291,0.000118929915,0.00009839729,0.0000072848075,0.00021147913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051814463,0.000088366316,0.0002220602,0.00015034451,0.00009488749,0.000025352534,0.00003958298,0.000052818097,0.000016266042],"category_scores_gemma":[0.000049416667,0.00010376764,0.000029194753,0.000057841415,0.00003770668,0.00006419911,0.00002566922,0.00006914652,0.00014076126],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003181637,0.00002663233,0.00054153195,0.0003535517,0.000016811191,6.3943605e-7,0.0014378272,0.000023327095,0.0000014339741,0.93579996,0.00748978,0.05427671],"study_design_scores_gemma":[0.0019815627,0.00061079743,0.05466646,0.00005796208,0.0000020560249,0.0000042881547,0.0009989354,0.02097139,0.0000231204,0.1569973,0.76333296,0.00035315435],"about_ca_topic_score_codex":0.000030422489,"about_ca_topic_score_gemma":0.00002781628,"teacher_disagreement_score":0.77880263,"about_ca_system_score_codex":0.000055309712,"about_ca_system_score_gemma":0.000019187502,"threshold_uncertainty_score":0.42315215},"labels":[],"label_agreement":null},{"id":"W4323566916","doi":"10.3389/fpubh.2023.1103555","title":"Characteristics, risk management and GMP standards of pharmaceutical companies in China","year":2023,"lang":"en","type":"article","venue":"Frontiers in Public Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Business; Good manufacturing practice; Quality (philosophy); China; Production (economics); Product (mathematics); Risk analysis (engineering); Industrial organization; Marketing; Accounting; Finance; Economics","score_opus":0.062028872479209275,"score_gpt":0.32777889908420454,"score_spread":0.26575002660499525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323566916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93875563,0.0042452,0.0050812988,0.020443413,0.002190945,0.00083320256,0.003764329,0.00008484427,0.024601141],"genre_scores_gemma":[0.96813774,0.029626306,0.0011393463,0.00087111996,0.000047495927,0.0000215526,0.000034575452,0.000019323814,0.00010254407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980443,0.00006451042,0.00090673676,0.00034024887,0.000052028416,0.00059218943],"domain_scores_gemma":[0.99923414,0.00003338148,0.00027917948,0.00019326144,0.000012028445,0.00024802846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003131088,0.00013355854,0.0006094944,0.00090695254,0.00005577088,0.000048453818,0.00019178473,0.0000648193,0.00007402959],"category_scores_gemma":[0.00012477403,0.0001642148,0.000045234763,0.00057249435,0.00012233887,0.00015378972,0.00012831615,0.0002826021,0.000022297938],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026113292,0.00010777781,0.83144814,0.0002653564,0.000048384703,0.0000053713648,0.0009780298,0.000025001973,5.503287e-8,0.112559386,0.015742831,0.038793568],"study_design_scores_gemma":[0.0009411031,0.000031982465,0.59222907,0.000017421702,0.000001398681,5.556276e-7,0.00011863575,0.03274266,6.085848e-7,0.022961095,0.35082567,0.00012981921],"about_ca_topic_score_codex":0.00026688667,"about_ca_topic_score_gemma":0.000022231605,"teacher_disagreement_score":0.33508283,"about_ca_system_score_codex":0.00037306457,"about_ca_system_score_gemma":0.00008659783,"threshold_uncertainty_score":0.6696485},"labels":[],"label_agreement":null},{"id":"W4323657124","doi":"10.12927/hcpol.2023.27038","title":"Multinational Pharmaceutical Companies Shortchange Canada in Research and Development Investments: Is It Time to Pursue Other Options?","year":2023,"lang":"en","type":"article","venue":"Healthcare policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"York University; Mount Sinai Hospital","funders":"","keywords":"Multinational corporation; Business; Legislation; Competition (biology); Pharmaceutical industry; Government (linguistics); Finance; Marketing; Industrial organization; Commerce; Biotechnology; Law","score_opus":0.4702360390005788,"score_gpt":0.47700875196003295,"score_spread":0.006772712959454141,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323657124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5066336,0.00096775015,0.000004347283,0.47788072,0.00015771798,0.00081183895,0.0012591236,0.00004481312,0.012240108],"genre_scores_gemma":[0.85331374,0.0008058387,0.0007443517,0.13557312,0.000559952,0.00042178668,0.00011063806,0.00007321157,0.008397374],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981182,0.00004536994,0.0005711891,0.0004244467,0.00009334934,0.0007474085],"domain_scores_gemma":[0.99906063,0.00013670653,0.000058142083,0.00017240478,0.000059973423,0.00051215076],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00089274766,0.00014516513,0.00028893215,0.00089856336,0.0001934351,0.000063445965,0.00019914085,0.000079880134,0.000830473],"category_scores_gemma":[0.00013892399,0.00018169294,0.000018762072,0.00081571337,0.0000700012,0.00009220435,0.00021699452,0.0002768811,0.0031851137],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000076937176,0.00025120136,0.05287275,0.00033221208,0.00009636446,0.000022168684,0.009053292,0.00013396534,0.00001527795,0.6190868,0.30184984,0.016209217],"study_design_scores_gemma":[0.0004306429,0.000027114662,0.044629183,0.000025295309,4.0535767e-7,0.000002399752,0.00010555119,0.0039373618,0.000041881074,0.0062233205,0.9443793,0.00019751368],"about_ca_topic_score_codex":0.26330522,"about_ca_topic_score_gemma":0.13351917,"teacher_disagreement_score":0.6425295,"about_ca_system_score_codex":0.0010895769,"about_ca_system_score_gemma":0.00071774697,"threshold_uncertainty_score":0.997591},"labels":[],"label_agreement":null},{"id":"W4323657395","doi":"10.12927/hcpol.2023.27037","title":"Commentary: Reconsidering Pharmaceutical Research and Development Investments","year":2023,"lang":"en","type":"letter","venue":"Healthcare policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Carleton University","funders":"","keywords":"Investment (military); Narrative; Pharmaceutical industry; Economics; Narrative review; Accounting; Public economics; Political science; Business; Psychology; Law; Medicine; Philosophy; Politics","score_opus":0.561412250067235,"score_gpt":0.4614487213034497,"score_spread":0.09996352876378534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323657395","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024134598,0.002792048,0.000004242971,0.9875138,0.00078122236,0.0006611157,0.0007915302,0.00013589578,0.0049066944],"genre_scores_gemma":[0.0023529818,0.0034568005,0.00039759424,0.9848518,0.0061775884,0.00023778254,0.00039581402,0.00019723551,0.0019324176],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99556196,0.00014779673,0.0013120912,0.0010777102,0.00012866635,0.0017717914],"domain_scores_gemma":[0.99796593,0.0004843836,0.00029996276,0.0005687659,0.00007040869,0.00061055814],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016436042,0.0004561864,0.00090758177,0.0016324274,0.00051157514,0.00022826984,0.00047317648,0.0007999026,0.00020449398],"category_scores_gemma":[0.00021223587,0.0005819573,0.00009117259,0.0005211671,0.00033990157,0.00013999677,0.0006469033,0.0034972928,0.00400385],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008720939,0.000029156014,0.001843781,0.00066855724,0.00012316462,0.00008069586,0.00062826124,3.3738525e-7,3.758373e-7,0.022383664,0.97059155,0.0036417209],"study_design_scores_gemma":[0.00046024597,0.000052001298,0.00047681143,0.00009016399,0.0000028108095,0.000021002505,0.000024088862,0.00009890792,0.000025463407,0.06374381,0.9345366,0.0004681428],"about_ca_topic_score_codex":0.0040658196,"about_ca_topic_score_gemma":0.00016570637,"teacher_disagreement_score":0.04136014,"about_ca_system_score_codex":0.0013228011,"about_ca_system_score_gemma":0.0004662506,"threshold_uncertainty_score":0.9996632},"labels":[],"label_agreement":null},{"id":"W4324020367","doi":"10.1007/s10729-022-09627-y","title":"Predicting drug shortages using pharmacy data and machine learning","year":2023,"lang":"en","type":"article","venue":"Health Care Management Science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"National Research Council Canada","funders":"","keywords":"Economic shortage; Pharmacy; Health informatics; Medicine; Drug; Business; Public health; Family medicine; Pharmacology; Nursing","score_opus":0.1761174851863908,"score_gpt":0.3976542399635269,"score_spread":0.22153675477713608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324020367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92455906,0.012558895,0.0012593175,0.014477372,0.001651141,0.0010487796,0.00079474685,0.00043792312,0.043212797],"genre_scores_gemma":[0.99142295,0.0048095346,0.0008033138,0.0024982137,0.000096047195,0.00000741846,0.000053145868,0.000018027667,0.0002913664],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9981659,0.00001696905,0.0004363274,0.00071730925,0.000069504444,0.00059399876],"domain_scores_gemma":[0.99908954,0.000045300596,0.00020020187,0.00041216784,0.000012424627,0.00024038783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002292125,0.00011993062,0.00021657124,0.0004585845,0.00072598865,0.0001920909,0.00064995216,0.0000117972695,0.00004835664],"category_scores_gemma":[0.00008085339,0.00014424336,0.000020688583,0.00079783064,0.00015798757,0.0005199581,0.0012270497,0.00017182823,0.00012618839],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016960386,0.000043858447,0.7919962,0.0011561869,0.000067054134,0.00002719088,0.0061641796,0.0039139153,0.000021832799,0.10166536,0.00525037,0.08967689],"study_design_scores_gemma":[0.0003582947,0.000012758435,0.010647988,0.000024426963,0.0000050491526,0.00000217556,0.000730815,0.6957733,0.000009473418,0.0007787334,0.29146242,0.00019455462],"about_ca_topic_score_codex":0.00078271836,"about_ca_topic_score_gemma":0.00004959796,"teacher_disagreement_score":0.7813482,"about_ca_system_score_codex":0.00016683088,"about_ca_system_score_gemma":0.000045914272,"threshold_uncertainty_score":0.58820736},"labels":[],"label_agreement":null},{"id":"W4327861569","doi":"10.46542/pe.2023.231.165179","title":"Towards a national pharmaceutical strategy in Lebanon: Ensuring access to quality and safe medications for all","year":2023,"lang":"en","type":"article","venue":"Pharmacy Education","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Business; Quality (philosophy); Accountability; Situation analysis; Pharmaceutical policy; Strategic planning; Population; Situational ethics; Pharmaceutical industry; Health care; Public relations; Health policy; Marketing; Medicine; Economic growth; Political science; Environmental health; Economics","score_opus":0.4150611379884795,"score_gpt":0.5223179111113145,"score_spread":0.10725677312283505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327861569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8137927,0.0010363507,0.0009299466,0.1278209,0.0012598675,0.0014401199,0.0007406211,0.00010379989,0.052875705],"genre_scores_gemma":[0.9870116,0.00074334914,0.0002509288,0.010545633,0.0004297724,0.0005773314,0.00014025012,0.000021708549,0.00027941825],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99854493,0.000025823503,0.00063539925,0.0004064086,0.000051017247,0.00033642058],"domain_scores_gemma":[0.9992178,0.00019186542,0.00013491833,0.000117743424,0.00006379501,0.00027387787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013068283,0.00012964339,0.00023165763,0.00048188458,0.00008320448,0.00013263646,0.0002466846,0.00004124789,0.0003353013],"category_scores_gemma":[0.0002383178,0.00016848765,0.000053059357,0.00042997536,0.000036152083,0.00038807848,0.00008985927,0.00014052559,0.0002968757],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016147156,0.0007182762,0.06765351,0.00035045794,0.00019116391,7.5374476e-7,0.0016547649,0.001170122,0.00087331526,0.7793503,0.06234017,0.08553572],"study_design_scores_gemma":[0.0016274493,0.000018466204,0.19231097,0.000017098608,0.000016168506,0.000003042998,0.000066777815,0.032218985,0.000923086,0.15351078,0.6188707,0.00041647413],"about_ca_topic_score_codex":0.00034802957,"about_ca_topic_score_gemma":0.00004136139,"teacher_disagreement_score":0.6258395,"about_ca_system_score_codex":0.00021664766,"about_ca_system_score_gemma":0.00029268983,"threshold_uncertainty_score":0.6870727},"labels":[],"label_agreement":null},{"id":"W4328055071","doi":"10.1136/bmjebm-2022-112005","title":"US Food and Drug Administration regulatory reviewer disagreements and postmarket safety actions among new therapeutics","year":2023,"lang":"en","type":"article","venue":"BMJ evidence-based medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Food and drug administration; Drug; Pharmacology; Patient safety; Health care","score_opus":0.18732288818352935,"score_gpt":0.37053351688652847,"score_spread":0.18321062870299912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4328055071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8485906,0.024121726,0.00047450932,0.12014555,0.0010704914,0.0012633255,0.00015090278,0.000105817664,0.0040770946],"genre_scores_gemma":[0.9686149,0.021708995,0.000120822355,0.0074289744,0.00063491607,0.000038257556,0.00003851426,0.000026173215,0.0013884492],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99842966,0.000048186743,0.00075354485,0.00041342914,0.0000695785,0.00028560907],"domain_scores_gemma":[0.9985431,0.00043509208,0.00032039738,0.00034501374,0.000040475596,0.00031591882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016810895,0.00019274598,0.00043335874,0.00021947871,0.00014831254,0.000045724955,0.00012639133,0.00008246075,0.00038132234],"category_scores_gemma":[0.0006690101,0.00018725758,0.000057484882,0.0003061307,0.00022858707,0.0003301934,0.000050775907,0.00016930506,0.00007946143],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007603352,0.00016268932,0.6631355,0.0011288218,0.00051755784,0.000022745913,0.0012568497,0.000078303514,0.00019253927,0.08983959,0.16411734,0.078787684],"study_design_scores_gemma":[0.0021503882,0.000454872,0.6230991,0.00094010896,0.00010096082,0.0000073656456,0.00008674299,0.0050995057,0.00012607718,0.012969443,0.35452014,0.00044529908],"about_ca_topic_score_codex":0.00014172471,"about_ca_topic_score_gemma":0.000120115365,"teacher_disagreement_score":0.1904028,"about_ca_system_score_codex":0.00008133269,"about_ca_system_score_gemma":0.000105547,"threshold_uncertainty_score":0.76361424},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W4361017494","doi":"10.1371/journal.pone.0281665","title":"Health professionals’ perceptions on local production and bioequivalence study of generic medicines: A cross-sectional survey of physicians and pharmacy professionals in Addis Ababa, Ethiopia","year":2023,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Addis Ababa University","keywords":"Cross-sectional study; Medicine; Pharmacy; Family medicine; Descriptive statistics; Logistic regression; Public health; Multinomial logistic regression; Environmental health; Nursing","score_opus":0.2699100975351207,"score_gpt":0.4109659955495149,"score_spread":0.14105589801439422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361017494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99595267,0.00031864658,0.000006530058,0.0024344458,0.00014132551,0.0006464159,0.00042016612,0.00001617959,0.000063606894],"genre_scores_gemma":[0.99809355,0.00087009295,0.00002570651,0.00062401296,0.000085317304,0.000084319276,0.000041396477,0.000016513948,0.00015912345],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99840045,0.00010265213,0.0007668792,0.00041745097,0.0000902455,0.0002223479],"domain_scores_gemma":[0.9991244,0.0001907159,0.00037022223,0.0001605547,0.00007932621,0.000074791766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011064517,0.00012578383,0.00049931393,0.0003738065,0.00010667514,0.000010965924,0.000099824014,0.00005102992,0.00006981359],"category_scores_gemma":[0.0002708768,0.00013184032,0.000025958052,0.0005213488,0.00017695363,0.00013967867,0.0000864547,0.00022974791,0.000020316304],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009319615,0.0034561425,0.9921347,0.0003024929,0.000081981496,5.729983e-7,0.0022246048,0.0001011481,0.0002591046,0.0005691566,0.0003038855,0.0004729998],"study_design_scores_gemma":[0.0008287943,0.00025468098,0.99286216,0.00017646208,0.0000052166756,7.415497e-7,0.00034724988,0.0049002813,0.0001425519,0.00035405788,0.000012254986,0.000115538816],"about_ca_topic_score_codex":0.0011208749,"about_ca_topic_score_gemma":0.00041747635,"teacher_disagreement_score":0.004799133,"about_ca_system_score_codex":0.000067128385,"about_ca_system_score_gemma":0.00007092787,"threshold_uncertainty_score":0.53762925},"labels":[],"label_agreement":null},{"id":"W4362576010","doi":"10.1016/s1470-2045(23)00072-4","title":"Access to essential cancer medicines for children: a comparative mixed-methods analysis of availability, price, and health-system determinants in east Africa","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Western University; Institute for Clinical Evaluative Sciences; SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Tanzania; Medicine; Essential medicines; Referral; Health care; Family medicine; Public health; Environmental health; Socioeconomics; Economic growth; Nursing","score_opus":0.2611706477913128,"score_gpt":0.49857130540933786,"score_spread":0.23740065761802503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362576010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9667097,0.0010690516,0.0010889723,0.026802035,0.00044995555,0.0008697284,0.0010292602,0.000024767658,0.0019565583],"genre_scores_gemma":[0.9971028,0.0004186861,0.000491306,0.0014596696,0.00021727088,0.0002562363,0.000009941882,0.000009182659,0.00003493407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984349,0.00012529606,0.0007072694,0.00032561726,0.000019162315,0.0003877755],"domain_scores_gemma":[0.99879825,0.00043165256,0.0004003023,0.00024283912,0.000026089481,0.000100864665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029033227,0.000114342176,0.0013259128,0.0004650994,0.00006929223,0.000022197362,0.0003711214,0.00006875772,0.000044686094],"category_scores_gemma":[0.00007829098,0.00009777691,0.0000844358,0.0010613599,0.00011212371,0.000058453676,0.00019943426,0.000106083986,0.000015709213],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004908595,0.00020920175,0.8878933,0.00045770864,0.0012477174,0.0000019712897,0.013009879,0.0032420685,0.000047469857,0.036415104,0.028210154,0.028774565],"study_design_scores_gemma":[0.001370498,0.00017173479,0.904808,0.00002174637,0.00007337718,0.0000016636408,0.0002439128,0.05801369,0.00006276865,0.0024879968,0.03258751,0.00015714156],"about_ca_topic_score_codex":0.00088460656,"about_ca_topic_score_gemma":0.0032854355,"teacher_disagreement_score":0.05477162,"about_ca_system_score_codex":0.00017970252,"about_ca_system_score_gemma":0.00006718162,"threshold_uncertainty_score":0.39872265},"labels":[],"label_agreement":null},{"id":"W4364378002","doi":"10.51731/cjht.2023.616","title":"Belimumab (Benlysta)","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Belimumab; Reimbursement; Vial; Lupus nephritis; Medicine; Family medicine; Drug; Pharmacology; Internal medicine; Political science; Chemistry; Immunology","score_opus":0.11443310875397324,"score_gpt":0.3097521052128289,"score_spread":0.1953189964588557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4364378002","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3322343,0.16190349,0.0005756452,0.47773436,0.0034006895,0.0004164156,0.000652696,0.0004963466,0.02258607],"genre_scores_gemma":[0.9958449,0.0021348984,0.00012060327,0.0017086485,0.000022481976,0.0000029702687,0.0000025298486,0.000015466278,0.00014749984],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984864,0.000009794315,0.00080864236,0.00013149648,0.000018475894,0.0005452129],"domain_scores_gemma":[0.9990952,0.000040826122,0.0005007112,0.00020240314,0.000031463223,0.00012941315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010565044,0.00009323055,0.00039552106,0.0012115239,0.00018464892,0.000050986207,0.00043168955,0.000110147565,0.00010974892],"category_scores_gemma":[0.00039377538,0.0001028444,0.0000960376,0.0005181478,0.000118913485,0.00012834238,0.000026960786,0.00031396034,0.0006434631],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000059621134,0.000014245081,0.014736054,0.00009130451,0.000082226135,0.000094673014,0.0005039897,0.000157589,0.0000046548384,0.6485941,0.10224702,0.23346817],"study_design_scores_gemma":[0.0002283288,0.00007244617,0.0049543763,0.00001858953,0.0000010095467,0.000026543548,0.00030643784,0.00018324888,0.000025576723,0.19058649,0.8034953,0.00010163591],"about_ca_topic_score_codex":0.0021085169,"about_ca_topic_score_gemma":0.00086869835,"teacher_disagreement_score":0.7012483,"about_ca_system_score_codex":0.000314862,"about_ca_system_score_gemma":0.0005877073,"threshold_uncertainty_score":0.8270631},"labels":[],"label_agreement":null},{"id":"W4365799752","doi":"10.1093/jlb/lsad008","title":"Lessons from Canada’s notice of compliance with conditions policy for the life-cycle regulation of drugs","year":2023,"lang":"en","type":"article","venue":"Journal of Law and the Biosciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Simon Fraser University","funders":"Health Canada; Simon Fraser University; Genome British Columbia; Public Health Agency; Public Health Agency of Canada; Genome Canada","keywords":"Notice; Compliance (psychology); Medicine; Business; Political science; Psychology; Law; Social psychology","score_opus":0.08908924928794298,"score_gpt":0.32358909040785355,"score_spread":0.23449984111991057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365799752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83948255,0.0016203102,0.00037046874,0.14538658,0.00051325286,0.00023665147,0.0014177411,0.0000035761655,0.010968881],"genre_scores_gemma":[0.9982693,0.00028855228,0.000066020635,0.0012200127,0.000104847895,0.0000016193444,0.0000010656122,0.000002578307,0.00004599347],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99944544,0.000010607,0.0003427239,0.00006575863,0.00003913486,0.0000963564],"domain_scores_gemma":[0.9986992,0.000585811,0.00053708465,0.000083596045,0.00004586194,0.000048473517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005780781,0.00004348832,0.00019797424,0.00005230449,0.00016383317,0.00002588171,0.0002169931,0.000015301028,0.000013209665],"category_scores_gemma":[0.000100262,0.000024729818,0.000047277394,0.00015922349,0.0004867886,0.00010017848,0.000020644044,0.000047629837,8.2013173e-7],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047147023,0.000010006629,0.0004569303,0.000010390134,0.0000443718,7.483646e-8,0.00036679118,0.0007931143,0.000057071178,0.9977482,0.00034257182,0.00012336281],"study_design_scores_gemma":[0.0033787508,0.00018794971,0.18124,0.00010948235,0.00008814275,0.000007268202,0.0011711927,0.061010882,0.0012760157,0.682759,0.068560936,0.0002104052],"about_ca_topic_score_codex":0.087893955,"about_ca_topic_score_gemma":0.016031539,"teacher_disagreement_score":0.3149892,"about_ca_system_score_codex":0.000015617052,"about_ca_system_score_gemma":0.00020202596,"threshold_uncertainty_score":0.9181798},"labels":[],"label_agreement":null},{"id":"W4366003793","doi":"10.54194/ubaw5789","title":"Economic cost of cardiomyopathy in Canada 2018 to 2021: opportunity for cost avoidance through pharmaceutical innovation.","year":2023,"lang":"en","type":"article","venue":"Canadian Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"Bristol-Myers Squibb","keywords":"Cardiomyopathy; Productivity; Economic cost; Indirect costs; Business; Pharmaceutical industry; Medicine; Economics; Economic growth; Pharmacology; Heart failure; Accounting; Cardiology; Microeconomics","score_opus":0.1912754188480488,"score_gpt":0.39449892813338494,"score_spread":0.20322350928533614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366003793","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.36755514,0.0015810193,0.000632838,0.47616678,0.0044296985,0.0072762896,0.082069665,0.000063978514,0.06022459],"genre_scores_gemma":[0.92108166,0.0010156309,0.00012662486,0.07607545,0.0006802409,0.00034893144,0.00025928562,0.000056187855,0.00035600585],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968932,0.000035594418,0.0013158844,0.00046288563,0.000032634696,0.0012597687],"domain_scores_gemma":[0.9977761,0.00016752523,0.000310712,0.00038922767,0.00004704235,0.0013093882],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010958471,0.00020915034,0.0007113509,0.001190376,0.00015311058,0.000028792852,0.0003659302,0.000090720714,0.00033027248],"category_scores_gemma":[0.00045935583,0.00030074842,0.00007609908,0.001360264,0.00005859915,0.0001502193,0.00005665436,0.0002294313,0.00041833927],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000029560402,0.000016053196,0.017577983,0.0001754529,0.000042607815,0.0000075789653,0.00052569725,0.0033425987,0.00000290951,0.57829666,0.38646945,0.013513422],"study_design_scores_gemma":[0.00075970835,0.000034911096,0.01480775,0.000020422665,0.0000014294609,0.0000020775221,0.000078666795,0.0044607557,0.000034467874,0.009219142,0.9702969,0.00028373662],"about_ca_topic_score_codex":0.9960128,"about_ca_topic_score_gemma":0.993706,"teacher_disagreement_score":0.5838275,"about_ca_system_score_codex":0.008119206,"about_ca_system_score_gemma":0.019540993,"threshold_uncertainty_score":0.99994445},"labels":[],"label_agreement":null},{"id":"W4366241520","doi":"10.1001/jama.2023.4034","title":"Added Therapeutic Benefit of Top-Selling Brand-name Drugs in Medicare","year":2023,"lang":"en","type":"article","venue":"JAMA","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Medicare Part D; Medical prescription; Prescription drug; Medicare Advantage; Food and drug administration; Drug; Drug prices; Pharmacology; Public economics; Health care","score_opus":0.05251317172981099,"score_gpt":0.29046966829078247,"score_spread":0.23795649656097148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366241520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95299673,0.0018116815,0.00004482071,0.008194228,0.0003408315,0.00015241669,0.00020436704,0.000046611465,0.036208298],"genre_scores_gemma":[0.99603415,0.0013517569,0.000037055983,0.0017878003,0.00015542509,0.000015456126,0.000021077576,0.000021357971,0.0005759263],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.998882,0.000009123747,0.00051456643,0.0002520664,0.000029300996,0.0003129723],"domain_scores_gemma":[0.99936223,0.0001476761,0.00016309222,0.0002212322,0.000015096054,0.00009069298],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00058378966,0.00010774884,0.0003609673,0.00030951705,0.000029721437,0.00003191439,0.00024037997,0.00011828712,0.0007054039],"category_scores_gemma":[0.00006408881,0.00012511393,0.000105874984,0.00038645233,0.000043909888,0.0001200118,0.00005555004,0.000181301,0.00088630524],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000089752495,0.00013056866,0.11686187,0.00016959803,0.00015638031,0.000008677107,0.005286701,0.0010961439,0.00012416985,0.7753164,0.0033543315,0.09740538],"study_design_scores_gemma":[0.0051186355,0.000080669604,0.1299416,0.00009326975,0.0000146334305,0.000002613741,0.00045666535,0.07433689,0.0013494813,0.33089098,0.4570174,0.0006971842],"about_ca_topic_score_codex":0.00017762306,"about_ca_topic_score_gemma":0.000033151337,"teacher_disagreement_score":0.45366305,"about_ca_system_score_codex":0.000052032065,"about_ca_system_score_gemma":0.000017926108,"threshold_uncertainty_score":0.99989164},"labels":[],"label_agreement":null},{"id":"W4366449959","doi":"10.54194/iyua1228","title":"New cancer drugs in Canada 2012 to 2021: an economic analysis of cost, benefit, availability, and public insurance coverage.","year":2023,"lang":"en","type":"article","venue":"Canadian Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer drugs; Business; Actuarial science; Public economics; Public health insurance; Health insurance; Economics; Economic growth; Medicine; Pharmacology; Health care; Drug","score_opus":0.06901277142227487,"score_gpt":0.33992617383932594,"score_spread":0.2709134024170511,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366449959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9134919,0.0014246673,0.0000043940763,0.06907027,0.00029800556,0.00042756685,0.012513666,0.000009499859,0.0027600338],"genre_scores_gemma":[0.97785974,0.0032309275,0.000019180541,0.018071698,0.00023133348,0.000046648984,0.00010357285,0.000028220715,0.00040867616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973378,0.000030851374,0.00095842086,0.00054703804,0.00003239877,0.0010934694],"domain_scores_gemma":[0.9963957,0.00009258227,0.00025884382,0.00045653188,0.00002123223,0.0027750814],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00058084127,0.00019497552,0.0008206652,0.0025438585,0.00010257166,0.000059768212,0.0003299743,0.0000801454,0.0013944441],"category_scores_gemma":[0.00007845195,0.0002736096,0.000072821655,0.0020168233,0.000034505934,0.00028470455,0.0000633645,0.00017177284,0.00016212265],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0000095212645,0.0000104742985,0.8316198,0.000048213613,0.00015001668,0.000001833023,0.0008065322,0.007920886,4.0765406e-7,0.08753758,0.028624022,0.043270722],"study_design_scores_gemma":[0.0003624847,0.000021990665,0.7568631,0.000007866075,0.0000060739812,3.5096727e-7,0.000043634267,0.007285505,0.0000013186256,0.0030311032,0.23212455,0.000252038],"about_ca_topic_score_codex":0.99984384,"about_ca_topic_score_gemma":0.9999169,"teacher_disagreement_score":0.20350052,"about_ca_system_score_codex":0.006306879,"about_ca_system_score_gemma":0.012119863,"threshold_uncertainty_score":0.9999716},"labels":[],"label_agreement":null},{"id":"W4366815796","doi":"10.1093/ajhp/zxad086","title":"National trends in prescription drug expenditures and projections for 2023","year":2023,"lang":"en","type":"article","venue":"American Journal of Health-System Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Prescription drug; Medical prescription; Medicine; Business; Drug; Biosimilar; Pharmacy; Environmental health; Family medicine; Pharmacology","score_opus":0.10673272107599613,"score_gpt":0.38887506839737795,"score_spread":0.2821423473213818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366815796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8310236,0.0069053033,0.001107519,0.14483283,0.003791195,0.0010219641,0.0014997972,0.00010668004,0.00971114],"genre_scores_gemma":[0.997428,0.00080058636,0.00021818846,0.000873413,0.00034973654,0.000052758107,0.000014387589,0.000020154017,0.00024278123],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982279,0.00006545788,0.001133727,0.00019972002,0.00005309305,0.00032010188],"domain_scores_gemma":[0.9985879,0.00013408576,0.001001575,0.00006910581,0.000044568118,0.00016277679],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019955449,0.000115512725,0.0005102108,0.0011498568,0.00012282538,0.000048457507,0.00013804522,0.000015949121,0.000042396994],"category_scores_gemma":[0.000042525004,0.00012588076,0.00011722607,0.000459279,0.00006046161,0.00026247135,0.00002492731,0.00017925796,0.000036717345],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008268656,0.000499847,0.06642868,0.0008923692,0.0005170595,0.000023506616,0.006584777,0.0030986154,0.0001824991,0.1808292,0.37065405,0.36946252],"study_design_scores_gemma":[0.0041791843,0.0002839081,0.033946,0.000101648446,0.000011161882,0.0001364655,0.0015050984,0.040267237,0.00004573268,0.0053765983,0.91378367,0.00036331997],"about_ca_topic_score_codex":0.0008474942,"about_ca_topic_score_gemma":0.00005194659,"teacher_disagreement_score":0.54312956,"about_ca_system_score_codex":0.0003218983,"about_ca_system_score_gemma":0.00011727616,"threshold_uncertainty_score":0.5133269},"labels":[],"label_agreement":null},{"id":"W4367017517","doi":"10.1021/cen-09930-buscon10","title":"Canadian chemistry CROs to merge","year":2021,"lang":"en","type":"article","venue":"C&EN Global Enterprise","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Merge (version control); Management; Engineering; Library science; Chemistry; Business; Political science; Computer science; Economics; Information retrieval","score_opus":0.01829397506086774,"score_gpt":0.2677132402367854,"score_spread":0.24941926517591764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367017517","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45665017,0.0015057118,0.00038178582,0.01464403,0.0009041444,0.00013795774,0.0026128527,0.000043427703,0.5231199],"genre_scores_gemma":[0.98387134,0.00013566847,0.0002543998,0.012300751,0.00022609324,0.000015681373,0.000038492108,0.000017309067,0.0031402786],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986919,0.000007593974,0.00037403728,0.0004133762,0.000019927671,0.00049313443],"domain_scores_gemma":[0.99875206,0.000013111417,0.00006043549,0.00035396224,0.000026493675,0.0007939147],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00013817303,0.00014855312,0.00027096938,0.0000400941,0.000074207404,0.00011623822,0.00029073356,0.00010615752,0.0041296934],"category_scores_gemma":[0.00013981712,0.00020319289,0.00013110662,0.00022944783,0.000019715031,0.000084763575,0.00012824922,0.00011573345,0.0046242955],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008446912,0.00042935918,0.32979318,0.00016169141,0.0004454611,0.00048980117,0.0009831177,0.00067664124,0.00080315024,0.35091776,0.3049703,0.010245078],"study_design_scores_gemma":[0.00034611253,0.000008348858,0.00790568,0.000010009068,0.000004721087,0.000018770257,0.000022575447,0.00069117686,0.0006057838,0.010636646,0.97946095,0.00028919958],"about_ca_topic_score_codex":0.01705922,"about_ca_topic_score_gemma":0.008611538,"teacher_disagreement_score":0.6744907,"about_ca_system_score_codex":0.0008233817,"about_ca_system_score_gemma":0.00018608752,"threshold_uncertainty_score":0.9967807},"labels":[],"label_agreement":null},{"id":"W4367181317","doi":"10.1007/s10961-023-10007-z","title":"Role of global public sector research in discovering new drugs and vaccines","year":2023,"lang":"en","type":"article","venue":"The Journal of Technology Transfer","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Intellectual property; Context (archaeology); Monetization; Product (mathematics); Biosimilar; Business; Medicine; Public relations; Political science; Law; Economics; Geography","score_opus":0.0910314511083042,"score_gpt":0.3314782690551307,"score_spread":0.24044681794682654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367181317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9613852,0.0033010289,0.000058171387,0.033618454,0.000068043104,0.00006192644,0.000025894642,0.000009834753,0.001471446],"genre_scores_gemma":[0.9966248,0.0031772282,0.000025511074,0.000082473154,0.000052523897,0.0000011945682,2.0529616e-7,0.000007503812,0.000028523214],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99912083,0.000018676084,0.0004812651,0.00008974047,0.000029704514,0.00025980675],"domain_scores_gemma":[0.9996362,0.00008299326,0.00006259675,0.0001352443,0.000023970193,0.00005901066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013106805,0.00006589521,0.00027200644,0.000543968,0.000038054684,0.0000170428,0.00036835784,0.00009889024,0.000045862755],"category_scores_gemma":[0.000056965233,0.000054225053,0.00004973024,0.0009221843,0.00011535057,0.00013481878,0.000066879875,0.00035527066,0.000025236448],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014114771,0.000079038844,0.17623085,0.000041643987,0.00013554144,0.0000057779853,0.0011376436,0.0001221261,0.002648169,0.7982501,0.00066105265,0.020546911],"study_design_scores_gemma":[0.0015533781,0.00019003314,0.08813619,0.00003854752,0.000008961896,0.000052545536,0.0008887483,0.0009749811,0.001784638,0.88090575,0.025328238,0.0001380036],"about_ca_topic_score_codex":0.00013534329,"about_ca_topic_score_gemma":0.00009403342,"teacher_disagreement_score":0.08809466,"about_ca_system_score_codex":0.00005619371,"about_ca_system_score_gemma":0.00004794696,"threshold_uncertainty_score":0.22112335},"labels":[],"label_agreement":null},{"id":"W4375948981","doi":"10.54194/llaj7141","title":"Evaluation of the PMPRB regulatory performance on price review for new patented drugs in Canada, 2008-2021","year":2023,"lang":"en","type":"article","venue":"Canadian Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Medicine","score_opus":0.14617859514532203,"score_gpt":0.3523666923102085,"score_spread":0.20618809716488648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4375948981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5904646,0.019068802,0.0000010200205,0.36512664,0.001081559,0.0031696085,0.0025031052,0.000012701386,0.018571954],"genre_scores_gemma":[0.94169474,0.009294469,0.0000069144216,0.047927573,0.0002576859,0.00008861285,0.00004212307,0.00002540933,0.0006625032],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983251,0.00005624562,0.00069636793,0.00024008461,0.000077137694,0.0006050496],"domain_scores_gemma":[0.9986853,0.0000592506,0.0003162889,0.00037173793,0.000058486643,0.00050892803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002255246,0.00011416477,0.00035078646,0.00038972608,0.000107445434,0.0000076019824,0.0002535444,0.000045393972,0.00019952698],"category_scores_gemma":[0.00045399598,0.00012068708,0.00006731318,0.00085802615,0.000024339664,0.00005351092,0.000020122909,0.0001370996,0.00009990798],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000011828732,0.000020766101,0.014627908,0.0014654608,0.000049817467,4.1406017e-7,0.00068255496,0.0024676246,0.0000012078452,0.107157476,0.76208687,0.11142808],"study_design_scores_gemma":[0.00091500796,0.000038917504,0.39158925,0.0004966713,0.000007934885,7.0410454e-7,0.000022995542,0.020795114,0.000016473145,0.005527933,0.5803678,0.00022118058],"about_ca_topic_score_codex":0.99081796,"about_ca_topic_score_gemma":0.9848231,"teacher_disagreement_score":0.37696135,"about_ca_system_score_codex":0.005164763,"about_ca_system_score_gemma":0.021720503,"threshold_uncertainty_score":0.99865425},"labels":[],"label_agreement":null},{"id":"W4376113782","doi":"10.1177/00222429231177627","title":"Scientific Evidence Production and Specialty Drug Diffusion","year":2023,"lang":"en","type":"article","venue":"Journal of Marketing","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Tech University; McGill University","funders":"","keywords":"Specialty; Scientific evidence; Incentive; Novelty; Production (economics); Medical prescription; Business; Medicine; Marketing; Psychology; Family medicine; Pharmacology; Economics; Social psychology","score_opus":0.08508632673609888,"score_gpt":0.30096317634000214,"score_spread":0.21587684960390324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376113782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98663515,0.0016576075,0.000014524385,0.007303815,0.0016975489,0.000052952793,0.0000049960418,0.0000099391145,0.0026234826],"genre_scores_gemma":[0.9951353,0.0022845333,0.00017052819,0.0001220921,0.00079826906,7.462164e-7,3.9881604e-7,0.000009207698,0.0014788895],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999022,0.000048698552,0.00054480706,0.00017156378,0.00003886521,0.00017405563],"domain_scores_gemma":[0.99896806,0.00029962862,0.0004885245,0.00009913476,0.000048617152,0.000096002885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0090962695,0.000063919644,0.00019621376,0.00032721824,0.00016307917,0.00016630048,0.00012125381,0.000025528258,0.0001316644],"category_scores_gemma":[0.0040632137,0.00006609922,0.00006547536,0.00028402833,0.00006125077,0.00038798945,0.00007823428,0.00016001664,0.00011385582],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087261695,0.00018847013,0.66464967,0.00055975013,0.00013826705,0.000053938187,0.0032941906,0.00042570598,0.0069562276,0.01679205,0.24673872,0.059330374],"study_design_scores_gemma":[0.0005606788,0.000050114857,0.651634,0.0005551683,0.000016838938,0.000091194765,0.00023643918,0.009949659,0.0006832327,0.023505561,0.31235734,0.00035978504],"about_ca_topic_score_codex":0.0000053395734,"about_ca_topic_score_gemma":0.000006590389,"teacher_disagreement_score":0.065618604,"about_ca_system_score_codex":0.000056482175,"about_ca_system_score_gemma":0.000022231998,"threshold_uncertainty_score":0.48643395},"labels":[],"label_agreement":null},{"id":"W4376871824","doi":"10.1002/jia2.26097","title":"Antibodies for HIV prevention: the path forward","year":2023,"lang":"en","type":"article","venue":"Journal of the International AIDS Society","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"World Health Organization","keywords":"Medicine; Commercialization; Licensure; Developing country; Human immunodeficiency virus (HIV); Public relations; Marketing; Economic growth; Business; Political science; Immunology; Economics","score_opus":0.070296958503392,"score_gpt":0.32802633374838935,"score_spread":0.25772937524499734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376871824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.61496586,0.0013365505,0.009065187,0.3436373,0.008662,0.0005086274,0.00090603466,0.000035069694,0.020883389],"genre_scores_gemma":[0.9770108,0.0012336245,0.00140554,0.0058266553,0.0017582214,0.000013600185,0.000006801172,0.000019768604,0.012725016],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99924046,0.000007955852,0.00047898578,0.000084900166,0.000055684774,0.0001320089],"domain_scores_gemma":[0.9991295,0.00015339264,0.0004965895,0.000111190726,0.0000759656,0.00003339263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001106528,0.00006696425,0.00015708931,0.000037885482,0.00013937592,0.000081322796,0.0006331872,0.000037844613,0.00011746928],"category_scores_gemma":[0.00016074287,0.000043365384,0.00073078915,0.00010883251,0.00005395748,0.00015040924,0.000119246244,0.00015639495,0.00007973259],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026694777,0.000055242763,0.017908702,0.000016447122,0.00062590674,4.4975e-7,0.0007424977,0.00073748187,0.000080378435,0.28368708,0.69497275,0.0011463905],"study_design_scores_gemma":[0.0005635753,0.000035362587,0.006870957,0.000016008418,0.000013411385,0.000010289488,0.00015148363,0.013928442,0.0001422631,0.25436157,0.7238381,0.000068554975],"about_ca_topic_score_codex":0.000003087321,"about_ca_topic_score_gemma":9.232799e-7,"teacher_disagreement_score":0.36204493,"about_ca_system_score_codex":0.00009825455,"about_ca_system_score_gemma":0.000034565284,"threshold_uncertainty_score":0.1768389},"labels":[],"label_agreement":null},{"id":"W4378877688","doi":"10.1211/pj.2023.1.187380","title":"United States, Japan and Australia added to UK fast-track medicines approvals list","year":2023,"lang":"en","type":"article","venue":"Pharmaceutical journal/˜The œpharmaceutical journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Track (disk drive); Fast track; Business; Medicine; Engineering; Surgery; Mechanical engineering","score_opus":0.15077431501147326,"score_gpt":0.3890188955159428,"score_spread":0.23824458050446956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378877688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74280035,0.0056873504,0.0028173053,0.23563589,0.0059640664,0.0014868691,0.00066490966,0.0003543006,0.0045889383],"genre_scores_gemma":[0.9056548,0.019719174,0.0005632561,0.06709418,0.00438768,0.000055403078,0.000056058736,0.00020792677,0.0022615623],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99279356,0.00041799078,0.0028361226,0.0009331728,0.00047269958,0.0025464352],"domain_scores_gemma":[0.99278635,0.0010407534,0.0007917522,0.00053216255,0.00030678473,0.00454219],"candidate_categories":["metaepi_narrow","sts","scholarly_communication","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.006926387,0.00085866917,0.0013118514,0.0015286205,0.0013737937,0.0014555131,0.0016165519,0.0003339765,0.0058429483],"category_scores_gemma":[0.00080657646,0.00070555805,0.0005662433,0.0021745523,0.0008046584,0.00056812004,0.0006071606,0.004347316,0.0038431087],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017884402,0.0009679626,0.03470865,0.00037028498,0.0028271226,0.0013922467,0.0053807986,0.005512433,0.003334155,0.054332186,0.8429627,0.04642306],"study_design_scores_gemma":[0.004009612,0.00024089479,0.003127368,0.0000994808,0.0002420014,0.0031161592,0.000532407,0.050654206,0.0006007772,0.026228748,0.9101515,0.0009968774],"about_ca_topic_score_codex":0.000049520277,"about_ca_topic_score_gemma":0.000012520957,"teacher_disagreement_score":0.16854171,"about_ca_system_score_codex":0.00039930642,"about_ca_system_score_gemma":0.00012748927,"threshold_uncertainty_score":0.99992627},"labels":[],"label_agreement":null},{"id":"W4378953889","doi":"10.1161/atvbaha.123.319633","title":"Academic-Industry Partnerships: Transparency, Potential Conflict of Interest, and Communicating State-of-the-Art Technologies","year":2023,"lang":"en","type":"letter","venue":"Arteriosclerosis Thrombosis and Vascular Biology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Grossman; Transparency (behavior); Library science; Medicine; Management; Political science; Law; Computer science","score_opus":0.33023247671162037,"score_gpt":0.34352235789877433,"score_spread":0.013289881187153962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378953889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73645365,0.0021676065,0.000068908805,0.25855958,0.0004828477,0.00045885885,0.0014354911,0.00008248164,0.0002905952],"genre_scores_gemma":[0.93311125,0.042623773,0.00007978277,0.023848278,0.000121734534,0.00005002504,0.00007805401,0.000056906007,0.000030168354],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99780864,0.00010416528,0.0011075954,0.0005262916,0.000026416008,0.00042688282],"domain_scores_gemma":[0.99827063,0.00017052157,0.0007792981,0.0007026492,0.000026867367,0.000050048126],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00056297967,0.000317015,0.0011047765,0.00017668342,0.000114539085,0.00003182811,0.0007126687,0.0013478212,0.00003359254],"category_scores_gemma":[0.00008069273,0.0002901362,0.00029234172,0.00016805559,0.001019621,0.0000736087,0.00051279616,0.0019084384,0.00001863089],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019977808,0.0003151795,0.5666359,0.0035103713,0.006703414,9.5195554e-7,0.0035035803,0.000021815511,0.025106363,0.0596828,0.32719466,0.0073049944],"study_design_scores_gemma":[0.0011727777,0.000270337,0.26301995,0.0005739339,0.00019581223,0.000001597548,0.0001452159,0.0006953307,0.00070430443,0.020156477,0.7121465,0.0009177255],"about_ca_topic_score_codex":0.00009478776,"about_ca_topic_score_gemma":0.000030452553,"teacher_disagreement_score":0.3849519,"about_ca_system_score_codex":0.000024604355,"about_ca_system_score_gemma":0.000020164889,"threshold_uncertainty_score":0.99995506},"labels":[],"label_agreement":null},{"id":"W4379209049","doi":"10.1007/s10620-023-07958-6","title":"Major Shifts in Acid Suppression Drug Utilization After the 2019 Ranitidine Recalls in Canada and United States","year":2023,"lang":"en","type":"article","venue":"Digestive Diseases and Sciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Waterloo; Women's College Hospital; University of Toronto","funders":"Agency for Healthcare Research and Quality; U.S. Department of Veterans Affairs","keywords":"Ranitidine; Economic shortage; Purchasing; Medicine; Business; Internal medicine; Marketing","score_opus":0.04252442719544593,"score_gpt":0.27674267282974574,"score_spread":0.23421824563429983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379209049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924926,0.0026198532,0.0000016279363,0.0036798932,0.00009043964,0.00012219138,0.0006994168,0.0000053720796,0.00028859277],"genre_scores_gemma":[0.99558663,0.0032823528,0.0000027475749,0.0010040636,0.000013760916,0.000017898683,0.000045213903,0.0000040367895,0.000043284264],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99927527,0.00002374035,0.00021280062,0.0002398957,0.000028994455,0.00021927897],"domain_scores_gemma":[0.99961513,0.000173723,0.000055341723,0.00005904105,0.000008198046,0.000088553374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026189038,0.000080074926,0.00013748024,0.00019919768,0.000098382676,0.00008391708,0.00010082205,0.000014643607,0.00004562196],"category_scores_gemma":[0.000083507766,0.00006260557,0.000013423548,0.00050848065,0.00015536974,0.0001739209,0.000067112785,0.000056139113,0.000007657307],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029981555,0.000011955715,0.9931368,0.000008473857,0.0000026003906,0.0000053588574,0.00038034975,0.0003138697,0.0000023783793,0.0052989773,0.00042380285,0.00038543402],"study_design_scores_gemma":[0.00024217897,0.000009582903,0.95842767,0.00001960279,0.000001662367,2.1428752e-7,0.00031202933,0.027571296,0.000011902823,0.010597496,0.0027132134,0.000093163326],"about_ca_topic_score_codex":0.27867174,"about_ca_topic_score_gemma":0.12965387,"teacher_disagreement_score":0.14901789,"about_ca_system_score_codex":0.000048071604,"about_ca_system_score_gemma":0.000079523285,"threshold_uncertainty_score":0.88622767},"labels":[],"label_agreement":null},{"id":"W4379780978","doi":"10.2139/ssrn.4458169","title":"Legislating Bureaucratic Autonomy as a Potential Blame Avoidance Strategy in Westminster Polities: A Comparative Study of the Adoption of Oncology Drugs into the Provincial Formularies of Alberta and Ontario","year":2023,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University","funders":"","keywords":"Blame; Formulary; Bureaucracy; Autonomy; Public administration; Political science; Pharmacology; Medicine; Law; Psychiatry","score_opus":0.03028208467888856,"score_gpt":0.29312128129419246,"score_spread":0.2628391966153039,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379780978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939356,0.00032704955,0.000031437135,0.0008073167,0.00007801996,0.0003719159,0.0000059939257,0.0000020677126,0.004440604],"genre_scores_gemma":[0.99912274,0.00015224551,0.0000070263504,0.00006255262,0.00005288748,0.000013747996,0.0000014011971,0.000008155319,0.0005792243],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99829924,0.00007818676,0.0008362908,0.00015436925,0.000045869172,0.00058606867],"domain_scores_gemma":[0.9989075,0.00013933751,0.00074555696,0.00014086968,0.00003479405,0.000031915006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012423729,0.00011870005,0.00044052803,0.00016067526,0.00011784179,0.000027328739,0.000253701,0.00006345017,0.000015225738],"category_scores_gemma":[0.000044810477,0.00009116827,0.00008645889,0.00019376395,0.00017006778,0.00018506275,0.00009556389,0.00076637475,0.000004295233],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021147933,0.0003373918,0.047453847,0.000037345595,0.00032390174,7.64766e-7,0.14913562,0.0030163052,0.00010387523,0.79732084,0.000009255471,0.002049397],"study_design_scores_gemma":[0.0039062211,0.00278604,0.06845221,0.00005248812,0.00006249357,0.000041378302,0.06732898,0.014965764,0.00011599659,0.8405272,0.0014841993,0.0002770641],"about_ca_topic_score_codex":0.07829271,"about_ca_topic_score_gemma":0.39347145,"teacher_disagreement_score":0.31517875,"about_ca_system_score_codex":0.00076389173,"about_ca_system_score_gemma":0.0020438537,"threshold_uncertainty_score":0.927845},"labels":[],"label_agreement":null},{"id":"W4380047185","doi":"10.36646/mjlr.56.2.inequitable","title":"Inequitable by Design: The Patent Culture, Law, and Politics Behind COVID-19 Vaccine Global Access","year":2023,"lang":"en","type":"article","venue":"University of Michigan Journal of Law Reform","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of British Columbia; Yale University; GAVI Alliance","keywords":"Intellectual property; Equity (law); Scholarship; Context (archaeology); Politics; Global health; Health equity; Health care; Economics; Political science; Economic growth; Development economics; Law","score_opus":0.11493325089429801,"score_gpt":0.29714423648135635,"score_spread":0.18221098558705834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380047185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86027884,0.0031086623,0.002517774,0.023889523,0.0004871557,0.00033116748,0.0017773168,0.00003411939,0.107575424],"genre_scores_gemma":[0.9931113,0.0020577516,0.00018335514,0.0040565417,0.00008136961,7.297057e-8,0.0000099141835,0.000008190875,0.00049152033],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991953,0.000018744722,0.00036788222,0.00012625339,0.000040702485,0.00025112132],"domain_scores_gemma":[0.99903077,0.00004419761,0.00045744088,0.00013407647,0.000046673216,0.000286854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061660976,0.00010543658,0.00032150184,0.00006928476,0.0002481244,0.000053354495,0.0004998521,0.00007234287,0.000082773135],"category_scores_gemma":[0.000025923297,0.00009014268,0.00010493745,0.00012211247,0.00013957461,0.00035296084,0.00019533887,0.00016476387,0.000021521626],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012930724,0.00007073674,0.0022801466,0.00005574615,0.00021854919,0.000029095523,0.0022695544,0.00034893875,0.000042777086,0.9854675,0.009014174,0.000073474206],"study_design_scores_gemma":[0.0022770974,0.00022051239,0.00090245606,0.000017532087,0.00004679182,0.000065056694,0.00069147424,0.0007648013,0.00024356662,0.10640761,0.8881612,0.00020189193],"about_ca_topic_score_codex":0.0020550026,"about_ca_topic_score_gemma":0.0004938461,"teacher_disagreement_score":0.87914705,"about_ca_system_score_codex":0.00022510331,"about_ca_system_score_gemma":0.000058919508,"threshold_uncertainty_score":0.3675912},"labels":[],"label_agreement":null},{"id":"W4380149549","doi":"10.1016/j.jval.2023.03.1267","title":"HPR120 The Pan-Canadian Tiered Pricing Framework and Chinese National Volume-Based Procurement: A Comparative Study Using Donabedian's Structure-Process-Outcome Framework","year":2023,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Procurement; Pooling; Purchasing; Business; Process (computing); Outcome (game theory); Purchasing power; Process management; Economics; Marketing; Computer science; Microeconomics","score_opus":0.18835347595039248,"score_gpt":0.4017387286497625,"score_spread":0.21338525269937003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380149549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868492,0.0007509884,0.0004420055,0.00961785,0.00041936213,0.0011286888,0.0003875639,0.000033864802,0.0003704871],"genre_scores_gemma":[0.9936073,0.000044614524,0.0008622646,0.005134159,0.00024723983,0.000045482164,0.000016129015,0.000028422415,0.000014385601],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9978285,0.000091679736,0.0008936978,0.0004765415,0.00009462711,0.0006149866],"domain_scores_gemma":[0.9986034,0.00047651882,0.0003602404,0.00023358336,0.00004220669,0.0002840485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014969939,0.00022714197,0.0005356077,0.0005715255,0.0003969347,0.00013892692,0.00028122554,0.0001324745,0.0000928658],"category_scores_gemma":[0.00057768414,0.00021020646,0.0000538509,0.0011698978,0.000078937665,0.00013327021,0.000049604478,0.0006391474,0.000067480585],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002058863,0.00007857942,0.8723401,0.00014119524,0.00004606435,0.0000029581765,0.008647112,0.061501015,2.9658366e-7,0.056915935,0.00015940674,0.00014677772],"study_design_scores_gemma":[0.00058658066,0.000079603305,0.26873192,0.00006354592,0.0000036503486,0.0000013995435,0.00044032873,0.4744651,7.140767e-7,0.25327256,0.002088696,0.00026589097],"about_ca_topic_score_codex":0.028898802,"about_ca_topic_score_gemma":0.0048773373,"teacher_disagreement_score":0.60360813,"about_ca_system_score_codex":0.0006260327,"about_ca_system_score_gemma":0.00049678714,"threshold_uncertainty_score":0.97756785},"labels":[],"label_agreement":null},{"id":"W4380149737","doi":"10.1016/j.jval.2023.03.951","title":"EPH69 Economic Impact of Clozapine Treatment Persistence: A Canadian Perspective","year":2023,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Douglas Mental Health University Institute","funders":"","keywords":"Clozapine; Persistence (discontinuity); Schizophrenia (object-oriented programming); Perspective (graphical); Psychiatry; Medicine; Psychology; Computer science; Engineering; Artificial intelligence","score_opus":0.18758604027506046,"score_gpt":0.3728724681580302,"score_spread":0.18528642788296976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380149737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96971023,0.0021047841,0.0000021921574,0.007856493,0.0003069676,0.0003708661,0.001491449,0.00002543556,0.018131569],"genre_scores_gemma":[0.9944977,0.004719379,0.000044526976,0.0003543334,0.00010592394,0.000021736001,0.000020230838,0.00002160315,0.0002145334],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99838215,0.000029609353,0.00065147365,0.00034461453,0.000013499545,0.0005786374],"domain_scores_gemma":[0.99903524,0.000074100004,0.00022340858,0.00025145974,0.000011138258,0.00040466187],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005961249,0.00014820846,0.00050869177,0.00078377465,0.0000682758,0.00001938788,0.00016026084,0.000070451744,0.0004772283],"category_scores_gemma":[0.00004580109,0.00016526008,0.00021945768,0.0003121368,0.000051599727,0.00008306663,0.000021141195,0.00010422536,0.0010934918],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000645291,0.00012191741,0.17617755,0.000074268166,0.00023145977,0.000014133411,0.00852519,0.12229903,0.0000047577096,0.68692744,0.0037736092,0.0017861429],"study_design_scores_gemma":[0.0038162612,0.0016273812,0.3226631,0.00007437376,0.000008035825,0.0000150862625,0.0010956011,0.4566111,0.00002623921,0.14987591,0.06342999,0.0007569322],"about_ca_topic_score_codex":0.8965977,"about_ca_topic_score_gemma":0.06597067,"teacher_disagreement_score":0.830627,"about_ca_system_score_codex":0.0084588425,"about_ca_system_score_gemma":0.0013037116,"threshold_uncertainty_score":0.9996843},"labels":[],"label_agreement":null},{"id":"W4380319178","doi":"10.1211/pj.2023.1.174004","title":"World-renowned transparency expert appointed to lead pharmacy journal","year":2023,"lang":"en","type":"article","venue":"Pharmaceutical journal/˜The œpharmaceutical journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy; Transparency (behavior); Lead (geology); Business; Accounting; Medicine; Family medicine; Political science; Law; Biology","score_opus":0.19157781068085414,"score_gpt":0.39733003742291373,"score_spread":0.2057522267420596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380319178","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09604298,0.03648307,0.042592738,0.7341667,0.034527972,0.0030147915,0.0006710401,0.0011465872,0.05135414],"genre_scores_gemma":[0.81178707,0.049865704,0.0020364465,0.11298992,0.017442241,0.00012273542,0.000024732186,0.00059050205,0.005140625],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9881681,0.00080364954,0.0049207234,0.0011719514,0.0008364069,0.004099141],"domain_scores_gemma":[0.9900849,0.0011240089,0.001360623,0.0007653651,0.000514124,0.0061510117],"candidate_categories":["metaepi_narrow","sts","scholarly_communication","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.009949422,0.0012820142,0.0018693369,0.0026351549,0.0029876481,0.0027847725,0.003750765,0.0002878912,0.011799443],"category_scores_gemma":[0.0008440781,0.0010690227,0.0017874965,0.00349837,0.0006870142,0.0015422435,0.0005982451,0.008750255,0.014563993],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002834539,0.0016809192,0.0045821965,0.00015102104,0.0031039652,0.0033901238,0.0051496727,0.0025046535,0.0099833775,0.025330748,0.80049634,0.14079246],"study_design_scores_gemma":[0.0069917655,0.00019559274,0.00049088226,0.0001363503,0.00021552845,0.007697767,0.00029584396,0.027227655,0.0023183979,0.029966056,0.9230869,0.0013772995],"about_ca_topic_score_codex":0.000014776019,"about_ca_topic_score_gemma":0.000012239448,"teacher_disagreement_score":0.71574414,"about_ca_system_score_codex":0.0011210953,"about_ca_system_score_gemma":0.00050271396,"threshold_uncertainty_score":0.99999315},"labels":[],"label_agreement":null},{"id":"W4380761282","doi":"10.2139/ssrn.4472407","title":"Linking Medication Errors to Supply Chain Disruptions: Evidence from Heparin Shortages Caused by Hurricane Maria","year":2023,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Quest University Canada","funders":"","keywords":"Economic shortage; Heparin; Supply chain; Business; Medicine; Actuarial science; Medical emergency; Internal medicine; Marketing","score_opus":0.044692274174022745,"score_gpt":0.3121411252201872,"score_spread":0.26744885104616445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380761282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9361391,0.009053376,0.009887646,0.042570826,0.00076819834,0.00032281678,0.0003231979,0.00011034268,0.0008245052],"genre_scores_gemma":[0.9712087,0.025556143,0.000082080456,0.0014915797,0.0005162593,0.00003941818,0.00009341066,0.000041058163,0.00097133906],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9969138,0.000044704968,0.000760014,0.0004387113,0.00007844466,0.001764331],"domain_scores_gemma":[0.9988762,0.00020021701,0.00031940482,0.00028357626,0.000025390878,0.00029519343],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0026316259,0.00019626296,0.0003782713,0.00036779774,0.0002486974,0.00014307364,0.00052478537,0.00011910007,0.0003542804],"category_scores_gemma":[0.00032262458,0.00022595662,0.00013258905,0.00049786887,0.000045538167,0.00032557067,0.00010368492,0.001126898,0.0014891684],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013612241,0.00023873767,0.28427804,0.000035510868,0.00090948516,0.000023287732,0.0028117083,0.0010978326,0.0025107192,0.609943,0.03532107,0.06269453],"study_design_scores_gemma":[0.000992593,0.0002718701,0.053533502,0.000121248544,0.00004677754,0.000034224144,0.0006005253,0.016689554,0.00019114587,0.8243875,0.1023034,0.0008276554],"about_ca_topic_score_codex":0.00085887796,"about_ca_topic_score_gemma":0.0012498928,"teacher_disagreement_score":0.23074454,"about_ca_system_score_codex":0.0010503223,"about_ca_system_score_gemma":0.00036519693,"threshold_uncertainty_score":0.99928826},"labels":[],"label_agreement":null},{"id":"W4380794665","doi":"10.1161/circ.146.suppl_1.11314","title":"Abstract 11314: Essential and Evidence-Based Cardiovascular Disease Medicine Availability in Low-Cost Generic Drug Plans","year":2022,"lang":"en","type":"article","venue":"Circulation","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Formulary; Guideline; Canadian Cardiovascular Society; Pharmacy; Disease; Angina; Intensive care medicine; Family medicine; Internal medicine; Myocardial infarction","score_opus":0.07950785660559355,"score_gpt":0.2762262089856539,"score_spread":0.19671835238006036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380794665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98707515,0.008216326,0.00041959732,0.0027234275,0.0003220594,0.00036572208,0.00017168143,0.000019372575,0.0006866924],"genre_scores_gemma":[0.9985877,0.0002508349,0.000009815697,0.00081287604,0.00016237464,0.00008184995,0.00006806663,0.000014652062,0.000011796977],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987661,0.00003940717,0.0004892242,0.0004389159,0.000060696264,0.00020564852],"domain_scores_gemma":[0.99926263,0.00009731966,0.000139512,0.00034172944,0.000011903728,0.00014688188],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001145258,0.00011571157,0.00029509515,0.00019790139,0.00013489464,0.000030890908,0.00012432018,0.000029031773,0.0011946054],"category_scores_gemma":[0.00013679659,0.00014651424,0.000117772724,0.00020524581,0.00007578154,0.00020348546,0.000052793624,0.00016903545,0.00006676948],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010037663,0.00013898901,0.79514366,0.00023788313,0.000077411205,0.000017812745,0.0004840164,0.19250964,0.00007296789,0.0069957953,0.0003514358,0.003870032],"study_design_scores_gemma":[0.0008453952,0.000005026186,0.85150343,0.000024555251,0.000017239641,9.73788e-7,0.00001312014,0.1285376,0.000010232998,0.0037149203,0.015138909,0.00018858332],"about_ca_topic_score_codex":0.0006915589,"about_ca_topic_score_gemma":0.000014748925,"teacher_disagreement_score":0.06397204,"about_ca_system_score_codex":0.0002608664,"about_ca_system_score_gemma":0.000050194118,"threshold_uncertainty_score":0.9997184},"labels":[],"label_agreement":null},{"id":"W4380854239","doi":"10.1371/journal.pone.0286802","title":"New drug submissions in Canada and a comparison with the Food and Drug Administration and the European Medicines Agency: Cross-sectional analysis","year":2023,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University; University of Toronto; University Health Network","funders":"","keywords":"Food and drug administration; Medicine; Agency (philosophy); Interquartile range; Environmental health; Family medicine; Surgery","score_opus":0.09656901190583728,"score_gpt":0.27768889680693015,"score_spread":0.18111988490109288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380854239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98058736,0.00089884835,0.000013063463,0.015788391,0.000016783235,0.00013120506,0.00006991514,0.000007363015,0.0024870606],"genre_scores_gemma":[0.9983572,0.0005453518,0.000025639407,0.0005132041,0.00007013498,0.000007980556,0.000012743728,0.000007688616,0.00046005673],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993224,0.00003710128,0.0002736921,0.00019712394,0.00003647642,0.00013320966],"domain_scores_gemma":[0.99946576,0.00019634496,0.00011160611,0.00011130407,0.000009692608,0.00010531015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062351563,0.00007840137,0.00023833354,0.00009730656,0.00014284515,0.00009211338,0.000080374964,0.000012233868,0.000041649895],"category_scores_gemma":[0.000048313996,0.000053169802,0.000017633301,0.00030742062,0.00009619608,0.000056236076,0.000046753332,0.00012366769,0.0000046828522],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035668116,0.000024662711,0.99158674,0.000015292519,0.00028105587,0.0000014730985,0.0009343101,0.000058457954,0.000003029346,0.005815597,0.00096358405,0.00028012233],"study_design_scores_gemma":[0.0007822587,0.000016064025,0.97903067,0.000006354881,0.00005603022,9.3715215e-7,0.000092022616,0.016605902,0.000018538598,0.002399619,0.00090998336,0.00008163442],"about_ca_topic_score_codex":0.12834248,"about_ca_topic_score_gemma":0.66698956,"teacher_disagreement_score":0.5386471,"about_ca_system_score_codex":0.00003365247,"about_ca_system_score_gemma":0.000086831365,"threshold_uncertainty_score":0.87746197},"labels":[],"label_agreement":null},{"id":"W4382048761","doi":"10.21203/rs.3.rs-3000650/v1","title":"Strengthening Access to Cancer Medicines for Children in East Africa: Policy Options to Enhance Medicine Procurement, Forecasting, and Regulations","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Hospital for Sick Children","keywords":"Procurement; Access to medicines; Business; Economic growth; Economics; Developing country; Marketing","score_opus":0.3873772056037338,"score_gpt":0.5009164817878442,"score_spread":0.11353927618411042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382048761","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46776995,0.007968478,0.0047048647,0.48580012,0.00096916454,0.013704001,0.010191224,0.00019484952,0.008697353],"genre_scores_gemma":[0.98749834,0.0022774152,0.0007383502,0.0007356678,0.0021614684,0.0047770552,0.00019744546,0.00010292989,0.0015113306],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99702483,0.00004709661,0.0009106924,0.0009884911,0.00013167724,0.00089722115],"domain_scores_gemma":[0.99822855,0.0003714072,0.0002222273,0.00045058187,0.00021295866,0.00051425654],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002278141,0.00027371082,0.00065933587,0.002507179,0.00025718196,0.00020829093,0.00069218356,0.00018781632,0.00014101602],"category_scores_gemma":[0.002971739,0.0002969505,0.00007908207,0.0012777997,0.0001258035,0.00014428313,0.0013088649,0.0006515119,0.000051829866],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043190512,0.0004993362,0.32906976,0.0041556605,0.0007592477,0.000008510054,0.031106794,0.047585946,0.00019182153,0.3044773,0.23719834,0.044515386],"study_design_scores_gemma":[0.0022936699,0.00067278097,0.44638845,0.005242775,0.0000401166,0.0000036119457,0.00065369543,0.04511995,0.00018822259,0.3754024,0.12233543,0.0016589183],"about_ca_topic_score_codex":0.005598854,"about_ca_topic_score_gemma":0.0031147152,"teacher_disagreement_score":0.51972836,"about_ca_system_score_codex":0.0005721677,"about_ca_system_score_gemma":0.00024902544,"threshold_uncertainty_score":0.99994826},"labels":[],"label_agreement":null},{"id":"W4383620169","doi":"10.29259/jep.v21i1.20779","title":"Concentration and Competition in the Pharmaceutical Sector in an Era of Challenges","year":2023,"lang":"en","type":"article","venue":"Jurnal Ekonomi Pembangunan","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Al-Azhar University","keywords":"Competition (biology); Market share; Market concentration; Oligopoly; Pharmaceutical industry; Quarter (Canadian coin); Business; Index (typography); Herfindahl index; Industrial organization; Competitor analysis; Economics; Market structure; Marketing; Market economy","score_opus":0.12280218860041645,"score_gpt":0.33154994657540104,"score_spread":0.2087477579749846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383620169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869615,0.0014602366,0.000004527266,0.005468673,0.00013498352,0.00017572446,0.000059004327,0.000012070455,0.0057233176],"genre_scores_gemma":[0.9950223,0.004045313,0.000009824531,0.00073902874,0.00013310806,0.000020374868,0.000015629452,0.000010821237,0.0000035777127],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99894655,0.00005147387,0.00049936416,0.00022941087,0.000024515559,0.00024867294],"domain_scores_gemma":[0.9995353,0.000116369854,0.00013024203,0.0001384017,0.000009172472,0.000070511975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074850343,0.00010134424,0.00025945227,0.00012271332,0.00003295398,0.00004178999,0.00016298666,0.0000684959,0.00004138269],"category_scores_gemma":[0.00002865177,0.000100230376,0.000042760174,0.00020115175,0.000076162425,0.00022570456,0.000029617178,0.00026733408,0.00003939652],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008089229,0.00018589184,0.18748334,0.00006895046,0.00001494697,0.000011834643,0.004151848,0.00025452612,0.0003257883,0.79725283,0.00006176663,0.010107394],"study_design_scores_gemma":[0.0014851753,0.000098160956,0.9415171,0.000028419889,0.0000034038787,0.0000073662936,0.0005120958,0.028559921,0.00014414804,0.016474145,0.010986416,0.00018364073],"about_ca_topic_score_codex":0.00008754328,"about_ca_topic_score_gemma":0.00020334909,"teacher_disagreement_score":0.7807787,"about_ca_system_score_codex":0.000054513268,"about_ca_system_score_gemma":0.00001975915,"threshold_uncertainty_score":0.40872762},"labels":[],"label_agreement":null},{"id":"W4384469248","doi":"10.54097/hbem.v15i.9223","title":"Assessing the Financial Stability &amp; Investment Potential of Pfizer Inc.","year":2023,"lang":"en","type":"article","venue":"Highlights in Business Economics and Management","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Restructuring; Competitor analysis; Business; Capitalization; Accounting; Market capitalization; Finance; Stock market; Marketing","score_opus":0.07114409728497086,"score_gpt":0.28418836389609525,"score_spread":0.2130442666111244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384469248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9387745,0.00054537447,0.0004533399,0.025060453,0.0011981139,0.00065277494,0.0001038115,0.00004097334,0.033170648],"genre_scores_gemma":[0.9595799,0.03752839,0.00050479104,0.0017460268,0.00015814036,0.000097260454,0.000052839277,0.0000313523,0.0003013441],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99824274,0.000021563801,0.00086626783,0.00047216626,0.00002555529,0.00037169157],"domain_scores_gemma":[0.9991109,0.00005323802,0.00031382733,0.00042159896,0.000024424093,0.000076050135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009306122,0.00019656726,0.00043510384,0.0003618209,0.00014608167,0.00016543826,0.00029240033,0.0000849917,0.00011132381],"category_scores_gemma":[0.00002704853,0.00018296625,0.00006829577,0.00038170654,0.00018273546,0.0003247081,0.0003803184,0.00008637239,0.00015211622],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012863863,0.00007769979,0.0007034944,0.00012217741,0.00004049871,0.000003008963,0.00014702023,0.0018014337,0.000010935645,0.9954228,0.0008683021,0.0007897601],"study_design_scores_gemma":[0.0008092096,0.000008541997,0.22299226,0.000016065764,0.000012924015,0.0000014018489,0.000048877857,0.010624541,0.000031457832,0.069943056,0.69524574,0.00026594714],"about_ca_topic_score_codex":0.00022476961,"about_ca_topic_score_gemma":0.00016813519,"teacher_disagreement_score":0.92547977,"about_ca_system_score_codex":0.00011718748,"about_ca_system_score_gemma":0.000025205749,"threshold_uncertainty_score":0.7461147},"labels":[],"label_agreement":null},{"id":"W4384655740","doi":"10.1136/bmjgh-2022-011535","title":"Improving access to medicines and beyond: the national volume-based procurement policy in China","year":2023,"lang":"en","type":"review","venue":"BMJ Global Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University; University of Toronto","funders":"National Natural Science Foundation of China","keywords":"China; Procurement; Business; Health policy; Public administration; Public health; Medicine; Political science; Nursing; Marketing","score_opus":0.1955670357689519,"score_gpt":0.4918127980902169,"score_spread":0.296245762321265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384655740","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000015053586,0.9064538,0.00009539478,0.0809664,0.0004613407,0.0029408631,0.0021494867,0.00003988076,0.0068777665],"genre_scores_gemma":[0.00022734392,0.95912635,0.00008415205,0.0388336,0.0009933047,0.00051603076,0.00007724481,0.000041680785,0.00010028579],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972455,0.000060611455,0.0014341808,0.00057815836,0.00008514974,0.0005963834],"domain_scores_gemma":[0.99857867,0.00009222537,0.00074357225,0.00023310112,0.0000219987,0.00033041203],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021986524,0.00031487885,0.0013067254,0.00045111286,0.00014239078,0.00016471691,0.0005775272,0.00014361434,0.00003329734],"category_scores_gemma":[0.00047019884,0.00026657037,0.00015349648,0.0010293807,0.000055121134,0.000100922734,0.00027927,0.0002952672,0.00028928416],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011262979,0.000073330106,0.00072412926,0.010718489,0.00006377202,0.000002442748,0.000081668855,0.0000695434,1.5134604e-9,0.11885575,0.060922153,0.80847746],"study_design_scores_gemma":[0.0002912076,0.000054241074,0.002251526,0.00076150807,0.000008901887,0.0000061403225,0.000003136866,0.0021428938,6.2621632e-9,0.012675726,0.98155004,0.0002546487],"about_ca_topic_score_codex":0.003847538,"about_ca_topic_score_gemma":0.00094116613,"teacher_disagreement_score":0.9206279,"about_ca_system_score_codex":0.0019389008,"about_ca_system_score_gemma":0.0017929036,"threshold_uncertainty_score":0.99997866},"labels":[],"label_agreement":null},{"id":"W4385330768","doi":"10.1001/jama.2023.13872","title":"Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists","year":2023,"lang":"en","type":"article","venue":"JAMA","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Arnold Ventures; West Virginia University; National Heart, Lung, and Blood Institute; Gilead Sciences","keywords":"Medicine; Food and drug administration; Drug approval; Pharmacology; Drug","score_opus":0.07064725726388224,"score_gpt":0.2768829414632664,"score_spread":0.20623568419938418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385330768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9325112,0.0003944896,0.000008595264,0.008226136,0.0006433814,0.00010920562,0.00033869012,0.00008966676,0.057678655],"genre_scores_gemma":[0.98953754,0.00078696944,0.00003771335,0.0048983875,0.00034197848,0.00001879756,0.000027130647,0.000026070364,0.0043254206],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991232,0.000009211627,0.0002827991,0.0002855472,0.000021331438,0.00027789184],"domain_scores_gemma":[0.9994887,0.00006356633,0.00010081579,0.00020863544,0.000008759617,0.00012949565],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003207119,0.0001129514,0.00022430526,0.00017792394,0.00010388197,0.00010598714,0.000121594814,0.000092362345,0.00040783314],"category_scores_gemma":[0.000079862024,0.00013165406,0.00005763041,0.00013123872,0.000053151747,0.00013800255,0.000095044394,0.00012619412,0.0045567127],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000067305846,0.000070618975,0.0140469875,0.00007349891,0.00008152562,0.000009656759,0.0007499418,0.0000827451,0.00012259575,0.78852344,0.16053964,0.03563207],"study_design_scores_gemma":[0.00092407735,0.00006187172,0.08685292,0.000016817057,0.0000023645553,0.0000018042514,0.000032841872,0.0029985304,0.00043494438,0.06806717,0.8403183,0.00028832175],"about_ca_topic_score_codex":0.00004539441,"about_ca_topic_score_gemma":0.0000024456976,"teacher_disagreement_score":0.72045624,"about_ca_system_score_codex":0.000060945014,"about_ca_system_score_gemma":0.000009621129,"threshold_uncertainty_score":0.9962184},"labels":[],"label_agreement":null},{"id":"W4385600166","doi":"10.59962/9780774829212","title":"When Good Drugs Go Bad","year":2015,"lang":"en","type":"book","venue":"University of British Columbia Press eBooks","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.0369789116063117,"score_gpt":0.20661030923766546,"score_spread":0.16963139763135376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385600166","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006197474,0.0018840096,0.000029157332,0.000053547767,0.0003717733,0.0003715204,0.0077885464,0.00006095034,0.98882073],"genre_scores_gemma":[0.0017120211,0.00057284185,0.0002432997,0.00029092826,0.00019208482,0.0000010497328,0.0001158066,0.000059903236,0.99681205],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99832475,0.000021815593,0.00052496593,0.0006461865,0.00007414798,0.00040816158],"domain_scores_gemma":[0.9983066,0.00005224132,0.0006789173,0.00050546334,0.000112832415,0.00034394424],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035729716,0.00019093057,0.0009485945,0.00010207999,0.000113564834,0.000207973,0.00084423844,0.00050309586,0.0013463064],"category_scores_gemma":[0.000018574463,0.00055044657,0.0003415772,0.000013369456,0.00034811595,0.00013978165,0.00045524107,0.0004616918,0.00034985883],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014319442,0.000044470577,0.000084565516,0.00012363789,0.000232313,0.000051023442,0.00043809743,0.000002847542,1.9559424e-7,0.030659072,0.9608657,0.0074837687],"study_design_scores_gemma":[0.0011157519,0.000048502432,0.00010105532,0.000115818606,0.000050478393,0.000011322861,0.000017973436,0.00014050282,4.6980486e-7,0.090153165,0.9077573,0.00048766396],"about_ca_topic_score_codex":0.098611385,"about_ca_topic_score_gemma":0.029504497,"teacher_disagreement_score":0.06910689,"about_ca_system_score_codex":0.00041870674,"about_ca_system_score_gemma":0.0002790383,"threshold_uncertainty_score":0.9996947},"labels":[],"label_agreement":null},{"id":"W4385712134","doi":"10.2139/ssrn.4524999","title":"Revisiting Canada’s Access to Medicines Regime in Response to COVID-19: A Review of the Legislation and its Underlying Objectives","year":2023,"lang":"en","type":"review","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Legislation; Coronavirus disease 2019 (COVID-19); 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Political science; Business; Medicine; Law and economics; Virology; Law; Economics; Outbreak; Infectious disease (medical specialty)","score_opus":0.17228192262712638,"score_gpt":0.4173108091332957,"score_spread":0.24502888650616933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385712134","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014493914,0.96189165,0.000071088456,0.036239497,0.00020211039,0.0009006188,0.00007767163,0.0000063678544,0.0004660763],"genre_scores_gemma":[0.0008567709,0.9903677,0.000003994931,0.0081933895,0.00018621921,0.000039117524,0.000003231701,0.00004266741,0.00030690653],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996771,0.00025429376,0.0014414217,0.00038579083,0.00007461906,0.0010729161],"domain_scores_gemma":[0.99777514,0.000603052,0.0010505653,0.00024813623,0.000039950024,0.00028315242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00755988,0.00025954793,0.0014424762,0.0005367326,0.00014475123,0.000063749285,0.0006621183,0.00009891399,0.000024922996],"category_scores_gemma":[0.0054258527,0.00021973283,0.000196165,0.00094476173,0.00002035249,0.00014489226,0.00021646397,0.0012522073,0.000015622016],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0002580807,0.00005173263,0.0008152733,0.10424673,0.001285926,0.00003109939,0.00094682537,0.00022825763,0.0000018144714,0.2919747,0.010893476,0.5892661],"study_design_scores_gemma":[0.00019685339,0.000038461905,0.00018825581,0.023666529,0.000063585045,0.00010150994,0.00005205035,0.00002576115,7.807096e-8,0.014459494,0.9609471,0.0002603385],"about_ca_topic_score_codex":0.010333082,"about_ca_topic_score_gemma":0.10201831,"teacher_disagreement_score":0.95005363,"about_ca_system_score_codex":0.0038651188,"about_ca_system_score_gemma":0.010738131,"threshold_uncertainty_score":0.9999589},"labels":[],"label_agreement":null},{"id":"W4385799063","doi":"10.1177/27551938231195434","title":"Canada and the pharmaceutical industry in the time of COVID-19","year":2023,"lang":"en","type":"article","venue":"International Journal of Social Determinants of Health and Health Services","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University; University of Toronto","funders":"","keywords":"Government (linguistics); Intellectual property; Coronavirus disease 2019 (COVID-19); Waiver; Business; Pandemic; Pharmaceutical industry; 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Economic growth; International trade; Political science; Medicine; Economics; Virology; Law","score_opus":0.09653762858303372,"score_gpt":0.42031398331893055,"score_spread":0.32377635473589683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385799063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82801366,0.002868094,0.0000013809446,0.1683795,0.00024423256,0.00013056045,0.00020856367,0.0000013836044,0.00015260058],"genre_scores_gemma":[0.9466233,0.003929432,0.0000079655965,0.04927746,0.0001394907,0.0000023065807,0.0000028051702,0.000004552635,0.000012667887],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99838173,0.00008817192,0.0011430623,0.000088853485,0.00009768146,0.00020046945],"domain_scores_gemma":[0.9982627,0.0002791118,0.0011891504,0.000047702328,0.000044322376,0.00017701452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003162739,0.000070666625,0.0004391974,0.00015571824,0.000111506124,0.000022045635,0.0003468242,0.00007279335,0.000029073815],"category_scores_gemma":[0.00005356672,0.000051694926,0.000045182358,0.0001231173,0.00012665543,0.000089141824,0.00006118822,0.00034525795,0.000001690248],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014529065,0.00028932386,0.72473407,0.004108682,0.00028746953,0.000062813415,0.06540819,0.00007040001,0.0000030716915,0.13412471,0.016096922,0.05336144],"study_design_scores_gemma":[0.008849917,0.00030272643,0.7037357,0.00028016974,0.000011954583,0.00014647022,0.007009511,0.009911034,0.000009548357,0.04566958,0.22382925,0.00024410778],"about_ca_topic_score_codex":0.18016256,"about_ca_topic_score_gemma":0.03942969,"teacher_disagreement_score":0.20773233,"about_ca_system_score_codex":0.00011629259,"about_ca_system_score_gemma":0.0010367557,"threshold_uncertainty_score":0.9780982},"labels":[],"label_agreement":null},{"id":"W4385811185","doi":"10.1021/cen-10126-buscon3","title":"Sygnature acquires NuChem","year":2023,"lang":"en","type":"article","venue":"C&EN Global Enterprise","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Management; Marketing; Economics","score_opus":0.030960350725625047,"score_gpt":0.2937015129826314,"score_spread":0.2627411622570064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385811185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.63603216,0.0029412226,0.00033175896,0.010541594,0.002361514,0.00030225416,0.0019139808,0.00047800684,0.34509748],"genre_scores_gemma":[0.99317235,0.0006972515,0.00009604662,0.0040647755,0.00033160215,0.000019414178,0.000045947287,0.000022951222,0.001549678],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986665,0.000011552023,0.0004150733,0.00040154267,0.000028913797,0.00047642106],"domain_scores_gemma":[0.9992769,0.000041509287,0.000120281475,0.00033276,0.0000123494,0.00021624642],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026466578,0.00017605921,0.000311847,0.0001063022,0.000073476025,0.00009349054,0.00041166207,0.0001522611,0.0007412637],"category_scores_gemma":[0.00010862673,0.00020554259,0.0001793373,0.0004029078,0.000054892273,0.00016845268,0.00021365011,0.0001540201,0.012834112],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005938049,0.00012052427,0.06338542,0.000058485522,0.00015053191,0.00005184004,0.000386061,0.00017967935,0.000041700616,0.66393965,0.26551548,0.0061112666],"study_design_scores_gemma":[0.0006983359,0.000031096995,0.031129587,0.000017274102,0.000007278298,0.000009039911,0.000039926854,0.007088697,0.00007556958,0.11749352,0.84303695,0.00037273337],"about_ca_topic_score_codex":0.00006741595,"about_ca_topic_score_gemma":0.000008544511,"teacher_disagreement_score":0.57752144,"about_ca_system_score_codex":0.00020097713,"about_ca_system_score_gemma":0.000020251198,"threshold_uncertainty_score":0.9879345},"labels":[],"label_agreement":null},{"id":"W4386014965","doi":"10.5267/j.ijdns.2023.7.016","title":"Balancing quality, cost, and uncertainty in pharmaceutical supply chain: A robust possibilistic flexible programming approach","year":2023,"lang":"en","type":"article","venue":"International Journal of Data and Network Science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Supply chain; Robustness (evolution); Computer science; Risk analysis (engineering); Quality (philosophy); Compromise; Operations research; Supply chain management; Key (lock); Supply chain risk management; Management science; Service management; Engineering; Business","score_opus":0.20755897052586952,"score_gpt":0.40705098369067055,"score_spread":0.19949201316480103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386014965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9729165,0.0031734495,0.008817419,0.008393001,0.0017198462,0.0003735557,0.00055760046,0.000032502478,0.004016155],"genre_scores_gemma":[0.994711,0.00170139,0.0023935772,0.00070434366,0.00042308125,0.0000031889515,0.00002670184,0.0000068237555,0.000029938288],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99850017,0.000020866024,0.00066440296,0.0003454404,0.00011588247,0.00035324745],"domain_scores_gemma":[0.99909925,0.00018336737,0.0002881829,0.00016405898,0.00006307565,0.0002020603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004726547,0.000093489165,0.0002584082,0.00033869836,0.00009334359,0.00030243906,0.0008885817,0.000034986406,0.00002014806],"category_scores_gemma":[0.0003217561,0.00009275809,0.000026966196,0.0005011381,0.00030612113,0.0008016626,0.0005866975,0.00023515082,0.0000081533435],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003083421,0.00027957634,0.49917507,0.00008898717,0.00015308562,0.000083650826,0.0012211642,0.047225535,0.00011329428,0.28819755,0.0036647941,0.15948896],"study_design_scores_gemma":[0.0012937641,0.000044089807,0.060400493,0.00007164047,0.000006457676,0.00011907499,0.00014920085,0.88146913,0.000007904181,0.01743557,0.038782686,0.00021995898],"about_ca_topic_score_codex":0.00006935372,"about_ca_topic_score_gemma":0.000017933333,"teacher_disagreement_score":0.8342436,"about_ca_system_score_codex":0.00009586782,"about_ca_system_score_gemma":0.00008998515,"threshold_uncertainty_score":0.37825653},"labels":[],"label_agreement":null},{"id":"W4386020454","doi":"10.11575/sppp.v15i1.74116","title":"Innovation in the United States Health-Care System’s Organization and Delivery","year":2022,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Health care delivery; Business; Delivery system; Health care; Medicine; Economic growth; Economics","score_opus":0.2832983419416387,"score_gpt":0.4974444714562654,"score_spread":0.2141461295146267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386020454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9801912,0.014682913,0.00013159576,0.0019493913,0.0002883917,0.00040135192,0.00035650877,0.000013531747,0.001985161],"genre_scores_gemma":[0.98608917,0.00856225,0.000024527335,0.0050051943,0.000059069567,0.000032163203,0.00018288354,0.000024859839,0.000019880721],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982389,0.00014784173,0.0010638791,0.00025510753,0.0000742037,0.00022007442],"domain_scores_gemma":[0.9985072,0.00014970811,0.0009584311,0.00021239108,0.000107126354,0.00006513984],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018944421,0.00013173796,0.0004107732,0.0013654666,0.00036661347,0.0005978591,0.0010078342,0.000035354762,0.0017969301],"category_scores_gemma":[0.00012285759,0.00013503297,0.000031886884,0.0025791386,0.000040438972,0.00069370505,0.00050964777,0.00030761756,0.000010335274],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009182392,0.00020507237,0.8266804,0.00031780126,0.00011172265,0.00001115091,0.0056276177,0.0051241056,0.00021195658,0.12269334,0.03462182,0.0043031564],"study_design_scores_gemma":[0.00153574,0.000037921298,0.6696405,0.000098502205,0.000017134846,0.000033041983,0.0044101747,0.0063086804,0.0002615302,0.024950262,0.29209405,0.0006124431],"about_ca_topic_score_codex":0.0024164594,"about_ca_topic_score_gemma":0.000029145967,"teacher_disagreement_score":0.25747225,"about_ca_system_score_codex":0.0003331421,"about_ca_system_score_gemma":0.00007710057,"threshold_uncertainty_score":0.9991156},"labels":[],"label_agreement":null},{"id":"W4386158489","doi":"10.1016/j.healthpol.2023.104901","title":"Therapeutic value of new medicines not submitted to Health Canada 2014-2021: Cross-sectional study","year":2023,"lang":"en","type":"article","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University; University of Toronto","funders":"","keywords":"Medicine; Alternative medicine; Food and drug administration; Value (mathematics); Family medicine; Environmental health","score_opus":0.1520727065641252,"score_gpt":0.43020886283504717,"score_spread":0.278136156270922,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386158489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.69678193,0.0010928909,0.00009219711,0.29572368,0.0015692626,0.0012057518,0.0011463601,0.00006818029,0.0023197571],"genre_scores_gemma":[0.90259,0.0006090226,0.00003609682,0.094047345,0.001152035,0.00003195677,0.000031085474,0.00003947812,0.0014630137],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997055,0.00006072582,0.0014500477,0.0004783461,0.00010327997,0.0008526177],"domain_scores_gemma":[0.99798876,0.00015454117,0.0005066449,0.00041331226,0.000037521782,0.00089920626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001481089,0.00020396877,0.0007136628,0.0006130427,0.00022176513,0.00003802181,0.0003286239,0.00006368741,0.00037893618],"category_scores_gemma":[0.00018144806,0.00023199804,0.000085978885,0.0009341753,0.00004264882,0.00007232089,0.00009881731,0.00021806239,0.0006477458],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007555145,0.00016758534,0.5592216,0.00018651703,0.00013137769,0.0000026171197,0.0026185035,0.0010996987,0.000004811315,0.15346448,0.2780773,0.0049499143],"study_design_scores_gemma":[0.00081893965,0.00025775936,0.74086624,0.0000075826747,0.0000011599357,0.0000019340387,0.00005920508,0.0007454683,0.000006308217,0.004487695,0.25259453,0.00015317803],"about_ca_topic_score_codex":0.91830605,"about_ca_topic_score_gemma":0.29603535,"teacher_disagreement_score":0.62227064,"about_ca_system_score_codex":0.00090525247,"about_ca_system_score_gemma":0.0038980613,"threshold_uncertainty_score":0.9460606},"labels":[],"label_agreement":null},{"id":"W4386444416","doi":"10.1136/bmj-2023-076783","title":"Essential medicines lists are for high income countries too","year":2023,"lang":"en","type":"editorial","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Business; Traditional medicine; Medicine","score_opus":0.037359651623008465,"score_gpt":0.3385627885716187,"score_spread":0.30120313694861023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386444416","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000385189,0.0010247988,0.00010113862,0.016973494,0.9633271,0.0006590078,0.014277072,0.000115951574,0.0031362553],"genre_scores_gemma":[0.002078985,0.0018939705,0.000094870986,0.0011103514,0.98395216,0.0003637014,0.0009471774,0.00015054352,0.009408208],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974366,0.0000126147615,0.0012235015,0.00066570647,0.00008731592,0.0005742969],"domain_scores_gemma":[0.99676526,0.0014231048,0.0010150934,0.00048699675,0.0001229235,0.00018662946],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010761614,0.00036668478,0.0011454427,0.0003294733,0.00014256297,0.00019004178,0.0005548391,0.00079990196,0.00035182573],"category_scores_gemma":[0.0027451909,0.00042477655,0.00025806064,0.00015327569,0.00013168354,0.00013246977,0.00017594156,0.00044237214,0.0021213605],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006180114,0.00001688105,0.0002377711,0.00043613295,0.00015218517,0.0000079119945,0.000038400834,0.000008933368,1.6017907e-7,0.039086934,0.9599108,0.00004207144],"study_design_scores_gemma":[0.0010671393,0.00005044078,0.00034211105,0.00009383415,0.000032984368,4.8292395e-7,0.000005733287,0.0002349785,0.000007228479,0.033851933,0.96382314,0.000489985],"about_ca_topic_score_codex":0.0004130177,"about_ca_topic_score_gemma":0.00016097806,"teacher_disagreement_score":0.020625098,"about_ca_system_score_codex":0.00020655406,"about_ca_system_score_gemma":0.00017531365,"threshold_uncertainty_score":0.9998204},"labels":[],"label_agreement":null},{"id":"W4386459882","doi":"10.1503/cmaj.230339-f","title":"Le Canada manque-t-il le bateau? Un inventaire des médicaments approuvés à l’international entre 2016 et 2020 qui n’ont pas été soumis à Santé Canada","year":2023,"lang":"fr","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"BP (Canada); University of Toronto","funders":"","keywords":"Humanities; Political science; Art","score_opus":0.016681296520231374,"score_gpt":0.2409230604027202,"score_spread":0.22424176388248884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386459882","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11438755,0.0043157525,0.000073039984,0.8172358,0.011637581,0.00023405533,0.006179151,0.000022810902,0.045914218],"genre_scores_gemma":[0.84762686,0.014111797,0.00007128405,0.11921347,0.0039329748,0.000025176994,0.00035719684,0.00008747917,0.014573735],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959489,0.00019528587,0.0013805318,0.00047537003,0.000542777,0.0014571163],"domain_scores_gemma":[0.9953711,0.00026741112,0.0008035566,0.00018889064,0.00019746061,0.0031716018],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021441446,0.00032701762,0.0005855074,0.00027367342,0.00073950295,0.00033747728,0.0007944222,0.00047201873,0.009700279],"category_scores_gemma":[0.0012839508,0.00044073412,0.00020746546,0.0004473895,0.00013248592,0.00036659391,0.00011321652,0.0013693998,0.00040921534],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0000072065027,0.000055611046,0.067835964,0.00002626069,0.000579628,0.0006970972,0.0002635162,0.000215236,5.889605e-7,0.021682225,0.88505876,0.023577929],"study_design_scores_gemma":[0.0015378356,0.000018012612,0.029805103,0.00009847188,0.00001901587,0.00009303716,0.0011227542,0.007482628,0.00000852236,0.0056863525,0.9536915,0.00043680266],"about_ca_topic_score_codex":0.99541295,"about_ca_topic_score_gemma":0.99958545,"teacher_disagreement_score":0.73323935,"about_ca_system_score_codex":0.010143849,"about_ca_system_score_gemma":0.045024168,"threshold_uncertainty_score":0.99980444},"labels":[],"label_agreement":null},{"id":"W4386802621","doi":"10.1080/17441692.2023.2256822","title":"Can we move beyond vaccine apartheid? Examining the determinants of the COVID-19 vaccine gap","year":2023,"lang":"en","type":"article","venue":"Global Public Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto","funders":"","keywords":"Waiver; Global health; Health equity; Intellectual property; Political science; Right to health; Treaty; Public health; Economic growth; Social determinants of health; International Health Regulations; Pandemic; Business; Development economics; Coronavirus disease 2019 (COVID-19); Economics; Health care; Medicine; Infectious disease (medical specialty); Law","score_opus":0.17815326601026643,"score_gpt":0.36392277040081156,"score_spread":0.18576950439054513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386802621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.54262483,0.0016396388,0.000048511916,0.43954042,0.0010573439,0.00060603954,0.002945911,0.000087705484,0.011449579],"genre_scores_gemma":[0.94805896,0.0013838498,0.000016534535,0.049982276,0.00019631286,0.00002819043,0.000019339139,0.00002010944,0.00029442564],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99748176,0.00010189651,0.0010427741,0.00042476246,0.000066839246,0.00088197173],"domain_scores_gemma":[0.9977753,0.00020035109,0.0006756578,0.00070204906,0.000029608316,0.0006170257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002593432,0.00020508352,0.00056359987,0.00012878234,0.00036692419,0.00009278842,0.00081821403,0.00009685584,0.00028246202],"category_scores_gemma":[0.0007316492,0.00015364634,0.00013658221,0.0011196962,0.000061088715,0.0001313609,0.00034432748,0.00022695978,0.0002160987],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021037513,0.00009729079,0.50673485,0.00018937376,0.00008408315,0.0000034249372,0.0013087575,0.00019855455,0.0000012078939,0.3617055,0.10574087,0.023915019],"study_design_scores_gemma":[0.0011807174,0.00008529658,0.17623611,0.000011162567,0.00000470822,0.00002085379,0.00022276299,0.006601832,0.000004745028,0.10001791,0.715374,0.00023994099],"about_ca_topic_score_codex":0.002465865,"about_ca_topic_score_gemma":0.0018170566,"teacher_disagreement_score":0.6096331,"about_ca_system_score_codex":0.00050176255,"about_ca_system_score_gemma":0.00063531596,"threshold_uncertainty_score":0.6265516},"labels":[],"label_agreement":null},{"id":"W4386810205","doi":"10.1007/s40278-023-46020-2","title":"Unauthorised health products seized in Canada pose health risks","year":2023,"lang":"en","type":"article","venue":"Reactions Weekly","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Health risk; Environmental health; Business; Risk analysis (engineering); Medicine","score_opus":0.17403334397051054,"score_gpt":0.35339055990986845,"score_spread":0.1793572159393579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386810205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5910648,0.002321317,0.00007228886,0.37193155,0.003427334,0.0011232406,0.0015103136,0.00022442071,0.028324721],"genre_scores_gemma":[0.99063176,0.0025272847,0.00012256848,0.004520156,0.00021736299,0.00003523296,0.00008544376,0.000033551813,0.00182667],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980062,0.00004148605,0.000862283,0.00042741944,0.000034478187,0.00062810344],"domain_scores_gemma":[0.9988996,0.0000813575,0.000357999,0.00035250545,0.000016392854,0.00029217784],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00093417894,0.00014406804,0.0004714487,0.00041563896,0.00015882807,0.00003673215,0.00016490599,0.000044758963,0.00015877104],"category_scores_gemma":[0.00014635889,0.00018532739,0.000055320725,0.0010105344,0.000020237363,0.00013164678,0.000043856686,0.00030989948,0.0010497764],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000081177604,0.00042372136,0.078292385,0.0005004558,0.00018191655,0.000032001462,0.0014239333,0.0037935197,0.00005468975,0.24109592,0.6377796,0.036340687],"study_design_scores_gemma":[0.0007342442,0.000039049173,0.14471722,0.00001896941,0.0000011346315,0.00000534848,0.00016466892,0.0068347,0.000017474225,0.0068202666,0.84041053,0.00023639062],"about_ca_topic_score_codex":0.951681,"about_ca_topic_score_gemma":0.648147,"teacher_disagreement_score":0.39956692,"about_ca_system_score_codex":0.002043878,"about_ca_system_score_gemma":0.0020368684,"threshold_uncertainty_score":0.999728},"labels":[],"label_agreement":null},{"id":"W4386915635","doi":"10.2139/ssrn.4565049","title":"Repositioning Generic Drugs: Empirical Findings and Policy Implications","year":2023,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"","keywords":"Business","score_opus":0.05022915073974444,"score_gpt":0.32727096795832034,"score_spread":0.2770418172185759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386915635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9154674,0.0027317484,0.0016430909,0.06358281,0.00016364205,0.00011354607,0.000047236546,0.0000862308,0.0161643],"genre_scores_gemma":[0.9838128,0.011715038,0.000061819046,0.0025969425,0.0005008386,0.00001330589,0.000009652841,0.000027508211,0.001262095],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9977144,0.000014850783,0.00047277735,0.00026892495,0.000023210481,0.001505826],"domain_scores_gemma":[0.99943924,0.000054733056,0.00016313232,0.00015734251,0.000018213344,0.000167314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012038494,0.00012137201,0.0002205821,0.00046005537,0.00039075292,0.00014447766,0.00018777208,0.00007520484,0.00003764175],"category_scores_gemma":[0.000104363724,0.00014070769,0.00010124727,0.0005458001,0.00005324836,0.00019453747,0.0000741229,0.0007528696,0.00047758903],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000005354675,0.000017234173,0.013858576,0.0000036278734,0.00007303831,8.5575977e-7,0.00027930638,0.00003854802,0.00006323756,0.9804338,0.0015512346,0.0036751672],"study_design_scores_gemma":[0.0003884943,0.000055404966,0.022513429,0.0000037851182,0.000006750724,0.00023970914,0.00015857138,0.0015274192,0.000015284517,0.9280829,0.046819385,0.00018889984],"about_ca_topic_score_codex":0.00006240814,"about_ca_topic_score_gemma":0.00002088032,"teacher_disagreement_score":0.068345405,"about_ca_system_score_codex":0.00068783126,"about_ca_system_score_gemma":0.00042256934,"threshold_uncertainty_score":0.61386},"labels":[],"label_agreement":null},{"id":"W4386997187","doi":"10.22270/ijdra.v11i3.613","title":"Similarities and differences in filing for Drug Master File in US, Canada and Europe","year":2023,"lang":"en","type":"article","venue":"International Journal of Drug Regulatory Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"American Sleep Medicine Foundation","keywords":"Discretion; Confidentiality; Business; Database; Computer science; Law; Computer security; Political science","score_opus":0.037005608732142564,"score_gpt":0.24562269380943796,"score_spread":0.2086170850772954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386997187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937678,0.00058170414,0.000003327911,0.003355079,0.00046937642,0.00005407107,0.00056205055,0.0000028160434,0.0012037902],"genre_scores_gemma":[0.99841875,0.00044568354,0.000068373476,0.00033841046,0.00012774424,0.0000040292703,0.000009593903,0.000009572444,0.00057785516],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99916667,0.000011753857,0.0005100534,0.00012714189,0.000042696178,0.00014165753],"domain_scores_gemma":[0.99941516,0.00023023157,0.00021217893,0.000044874392,0.0000311661,0.000066394394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040431094,0.00007927762,0.00021956266,0.00032474424,0.000020193564,0.0000586335,0.00016223456,0.000023618551,0.00013873972],"category_scores_gemma":[0.000107745174,0.00008601268,0.000032184704,0.00007279343,0.00004390207,0.00018839163,0.0000596487,0.00011906209,0.000002583817],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001448938,0.000059392616,0.91550523,0.00009657236,0.00016616227,0.00009632777,0.0018148748,0.0009165059,0.000024113882,0.038547415,0.0405977,0.0020308336],"study_design_scores_gemma":[0.0017880624,0.000022974908,0.8819018,0.00015157452,0.000004416349,0.000025479812,0.0009568599,0.017708741,0.00008387994,0.02455716,0.07253766,0.0002614078],"about_ca_topic_score_codex":0.0060708686,"about_ca_topic_score_gemma":0.047576208,"teacher_disagreement_score":0.04150534,"about_ca_system_score_codex":0.00009326134,"about_ca_system_score_gemma":0.00006926527,"threshold_uncertainty_score":0.96980304},"labels":[],"label_agreement":null},{"id":"W4387122640","doi":"10.18357/anthropologica65120232605","title":"In Shortage: Understanding Global Antibiotic Supply Chains Through Pharmaceutical Trade Fairs","year":2023,"lang":"en","type":"article","venue":"Anthropologica","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"The Scarborough Hospital; University of Toronto","funders":"Norges Forskningsråd; Universitetet i Oslo","keywords":"Supply chain; Business; Economic shortage; Government (linguistics); China; Pharmaceutical industry; Industrial organization; Marketing; Medicine; Political science; Law","score_opus":0.2098393832347273,"score_gpt":0.3869765093128333,"score_spread":0.17713712607810597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387122640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49278212,0.0033504686,0.003427137,0.18014315,0.0037455854,0.0009625072,0.0013811133,0.00061869883,0.31358925],"genre_scores_gemma":[0.9886372,0.005733628,0.000116125266,0.005107883,0.00018865902,0.000008974585,0.000026127382,0.000024121015,0.00015729934],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99772716,0.000033982782,0.00067806896,0.00062225224,0.000040978433,0.0008975359],"domain_scores_gemma":[0.99932104,0.00010885576,0.00013021089,0.00026633576,0.0000027690583,0.00017077473],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00037164422,0.00025120616,0.000540835,0.00017160634,0.00031170278,0.000079841,0.00034955176,0.0002114521,0.002057779],"category_scores_gemma":[0.000064537766,0.00027368194,0.0001657814,0.0008831332,0.00055451796,0.0003144644,0.00014368069,0.00031524705,0.0014623406],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022145829,0.00012234197,0.062295172,0.000022760842,0.000038739814,0.000103053295,0.0003173382,0.00007123003,0.000029080298,0.92647743,0.010307092,0.0001935847],"study_design_scores_gemma":[0.0028087888,0.00028833572,0.06625779,0.000037148857,0.000023184803,0.000050333798,0.004035804,0.028164627,0.00064736494,0.7374474,0.15895739,0.0012818761],"about_ca_topic_score_codex":0.00024245211,"about_ca_topic_score_gemma":0.000065167194,"teacher_disagreement_score":0.4958551,"about_ca_system_score_codex":0.00035069883,"about_ca_system_score_gemma":0.000025606718,"threshold_uncertainty_score":0.9999715},"labels":[],"label_agreement":null},{"id":"W4387259703","doi":"10.32983/2222-4459-2023-8-23-29","title":"The USA in the Global Pharmaceutical Market: The Current State and Development Prospects","year":2023,"lang":"en","type":"article","venue":"Business Inform","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Kementerian Pendidikan Nasional","keywords":"Pharmaceutical industry; Business; Pharmaceutical manufacturing; China; Capitalization; International trade; Political science; Biotechnology; Medicine; Law","score_opus":0.0943428840544055,"score_gpt":0.33530939012227207,"score_spread":0.24096650606786657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387259703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81241316,0.0049178433,0.00012882047,0.037254877,0.0018912392,0.0014605639,0.00021698185,0.000056656132,0.14165986],"genre_scores_gemma":[0.9913502,0.005330389,0.000018475499,0.0025927462,0.00013192593,0.00014656388,0.000007512329,0.000011242501,0.00041096704],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99882,0.000011472222,0.000499876,0.00018003598,0.000052149084,0.00043643778],"domain_scores_gemma":[0.99939793,0.00016788456,0.000122711,0.00022533677,0.00002381603,0.000062343235],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013723996,0.00013914848,0.00015899734,0.000055970657,0.00032601165,0.00028848066,0.0004371031,0.000026042195,0.00006914399],"category_scores_gemma":[0.00011821147,0.00007949464,0.000030369369,0.00060003536,0.00015961214,0.00015197993,0.0002073744,0.00021436754,0.0009090218],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007030827,0.000057852754,0.1499968,0.000079143676,0.000044849716,0.0000055617734,0.0012092144,0.00010516006,1.5973735e-7,0.24898662,0.009661929,0.5897824],"study_design_scores_gemma":[0.00022760904,0.0000023137086,0.425962,0.0000043214227,0.0000010631832,0.0000029185771,0.000014523149,0.002648746,0.0000016295008,0.011004586,0.5600503,0.00007996017],"about_ca_topic_score_codex":0.00004844178,"about_ca_topic_score_gemma":0.0003297438,"teacher_disagreement_score":0.5897024,"about_ca_system_score_codex":0.00011871498,"about_ca_system_score_gemma":0.000086121414,"threshold_uncertainty_score":0.99986887},"labels":[],"label_agreement":null},{"id":"W4387300633","doi":"10.4212/cjhp.3400","title":"Development of a Provincial Hospital Drug Formulary from 12 Former Regional Health Authority Formularies: Methods of Alignment","year":2023,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Saskatchewan Health; Saskatchewan Health Authority","funders":"","keywords":"Formulary; Drug; Medicine; Business; Family medicine; Pharmacology","score_opus":0.08855982958662595,"score_gpt":0.3439521878237842,"score_spread":0.2553923582371582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387300633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9723033,0.0028172792,0.0010506695,0.019712174,0.0015706116,0.0005002158,0.0007830698,0.000009659138,0.0012530356],"genre_scores_gemma":[0.99133515,0.00028148346,0.007001097,0.00090539723,0.0003248435,0.000010869461,0.00002749528,0.00003129538,0.00008239214],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974209,0.00005183773,0.001657651,0.00020623773,0.000105154955,0.0005582091],"domain_scores_gemma":[0.9974557,0.0001318599,0.0014545443,0.00022424402,0.00009760441,0.0006360243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024874816,0.00020596702,0.0006722871,0.0003749325,0.00028348275,0.00005101358,0.0006463885,0.000053240987,0.00020080812],"category_scores_gemma":[0.00012354192,0.00018710615,0.00030951423,0.00025657774,0.00018393,0.00036437335,0.00008053116,0.00034872626,0.000037323684],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063010695,0.0012927111,0.10179034,0.00075743475,0.0049213422,0.00011283679,0.19204238,0.00058201764,0.00051200413,0.36846447,0.16953665,0.1593577],"study_design_scores_gemma":[0.0034100702,0.00047274638,0.029439015,0.0001183161,0.00006087734,0.000010340376,0.0011478727,0.002783072,0.0049913675,0.12899709,0.8278832,0.0006860611],"about_ca_topic_score_codex":0.017519265,"about_ca_topic_score_gemma":0.0073359464,"teacher_disagreement_score":0.65834653,"about_ca_system_score_codex":0.0005234204,"about_ca_system_score_gemma":0.0020730833,"threshold_uncertainty_score":0.98902315},"labels":[],"label_agreement":null},{"id":"W4387489899","doi":"10.61093/hem.2023.3-05","title":"A global analysis of trade policies in antimicrobial medicines","year":2023,"lang":"en","type":"article","venue":"Health Economics and Management Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Protectionism; International trade; Tariff; Revenue; China; Business; Commercial policy; International economics; Trade barrier; Access to medicines; Economics; Developing country; Economic growth; Political science; Finance","score_opus":0.08565237065164412,"score_gpt":0.36695176725364137,"score_spread":0.28129939660199726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387489899","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2866714,0.32601255,0.00012922753,0.32726806,0.00084881764,0.0031121713,0.002234387,0.000117632575,0.05360577],"genre_scores_gemma":[0.11175773,0.86442006,0.000074646276,0.023575637,0.000026665182,0.000030780346,0.00005936721,0.0000094448305,0.000045653815],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980478,0.000018041512,0.0012049128,0.00035135628,0.000012875421,0.0003649751],"domain_scores_gemma":[0.9991527,0.000027101087,0.0004299906,0.00025257518,0.000003529308,0.00013405891],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010669731,0.00014584731,0.0010802676,0.000493315,0.000040978055,0.000020142954,0.00016976464,0.000037108883,0.000059754784],"category_scores_gemma":[0.000011207765,0.0001673393,0.00016381836,0.0012058049,0.000055878652,0.000079293015,0.00011340183,0.000050146155,0.000044476015],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000068343643,0.00008338846,0.043314125,0.005627235,0.0007047705,0.0000025823604,0.00012512818,0.00048228304,7.29842e-8,0.8994335,0.026945231,0.02327487],"study_design_scores_gemma":[0.0005293942,0.000030168008,0.28759453,0.00033918547,0.00013671612,0.0000012586416,0.000020880274,0.0073034586,2.2746667e-7,0.005987168,0.6978441,0.00021292479],"about_ca_topic_score_codex":0.0005390015,"about_ca_topic_score_gemma":0.0006163708,"teacher_disagreement_score":0.8934463,"about_ca_system_score_codex":0.00010479973,"about_ca_system_score_gemma":0.000024403042,"threshold_uncertainty_score":0.68238986},"labels":[],"label_agreement":null},{"id":"W4387603337","doi":"10.3389/fphar.2023.1153680","title":"Reimbursement decision-making system in Poland systematically compared to other countries","year":2023,"lang":"en","type":"review","venue":"Frontiers in Pharmacology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Agency (philosophy); Business; Specialty; Product (mathematics); Developed country; Grey literature; MEDLINE; Medicine; Actuarial science; Accounting; Health care; Family medicine; Economic growth; Environmental health; Political science; Economics","score_opus":0.08999092595789074,"score_gpt":0.384195768818402,"score_spread":0.2942048428605113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387603337","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009266666,0.9799532,0.0024454654,0.00018586121,0.008263111,0.0024901114,0.00093666563,0.000078277866,0.0055546407],"genre_scores_gemma":[0.0011030618,0.99396104,0.0015957305,0.0015236018,0.0004860997,0.0009445884,0.000022496513,0.00016104497,0.00020232036],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.995071,0.00016927006,0.0029249312,0.0008930536,0.00006347885,0.00087828387],"domain_scores_gemma":[0.9980048,0.00059063954,0.00076205947,0.00039672863,0.000021710397,0.0002240685],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019526522,0.0005216201,0.004009395,0.0021356845,0.00006423617,0.00009670203,0.0008517741,0.00042492955,0.0002779856],"category_scores_gemma":[0.00011986051,0.00056800386,0.0003161391,0.00084019173,0.000075240176,0.000090999514,0.00027204677,0.0005771032,0.0025726147],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004922951,0.0006115121,0.0075372057,0.14583567,0.0033280293,0.0008498476,0.0016948531,0.002374058,2.3407229e-7,0.14828943,0.52459127,0.16439562],"study_design_scores_gemma":[0.00074671075,0.000024497569,0.000025048623,0.008920227,0.00009836727,0.0000113929555,0.00007107833,0.004469799,8.804931e-8,0.0021468718,0.98293954,0.0005463523],"about_ca_topic_score_codex":0.00008012119,"about_ca_topic_score_gemma":0.00006037396,"teacher_disagreement_score":0.4583483,"about_ca_system_score_codex":0.0020469218,"about_ca_system_score_gemma":0.00015579081,"threshold_uncertainty_score":0.9996771},"labels":[],"label_agreement":null},{"id":"W4387709855","doi":"10.1161/circoutcomes.123.010329","title":"Complex Picture of Prescription Drug Discount Programs and Out-of-Pocket Costs in Cardiovascular Disease","year":2023,"lang":"en","type":"letter","venue":"Circulation Cardiovascular Quality and Outcomes","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Work & Health; Western University","funders":"","keywords":"Drug; Disease; Medical prescription; Prescription drug; Medicine; Intensive care medicine; Risk analysis (engineering); Business; Pharmacology; Internal medicine","score_opus":0.1554042076780597,"score_gpt":0.3223366822801893,"score_spread":0.1669324746021296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387709855","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6542189,0.15605795,0.0042018606,0.16468906,0.0044624847,0.0068123783,0.0068745585,0.00027930006,0.0024035058],"genre_scores_gemma":[0.9730226,0.0029091334,0.000081346334,0.021926811,0.00052632357,0.000113424794,0.0012130318,0.0001008767,0.0001064871],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99674803,0.0002752612,0.0015010361,0.000852678,0.00023196268,0.00039104588],"domain_scores_gemma":[0.9980702,0.00017429795,0.00051393115,0.0010307285,0.00006825259,0.00014261203],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024451863,0.0004066344,0.0023429112,0.00040979745,0.00007152849,0.000086977634,0.00022221553,0.0004118318,0.000019954457],"category_scores_gemma":[0.00022831526,0.00044763065,0.001739373,0.00022432867,0.00026335736,0.00021153493,0.00015064357,0.0005708943,0.000014562251],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000062676365,0.00017392464,0.9250332,0.00664997,0.014114101,0.0000721771,0.002083319,0.004152185,0.000005005767,0.021209069,0.010212765,0.016231598],"study_design_scores_gemma":[0.0012475501,0.0000093787,0.7189918,0.00011061787,0.00038427007,0.0000016713847,0.00005556658,0.0013129882,0.0000018230439,0.010212046,0.26710907,0.00056320126],"about_ca_topic_score_codex":0.0012698672,"about_ca_topic_score_gemma":0.000044574124,"teacher_disagreement_score":0.31880367,"about_ca_system_score_codex":0.00015973956,"about_ca_system_score_gemma":0.00004045902,"threshold_uncertainty_score":0.9997975},"labels":[],"label_agreement":null},{"id":"W4388140755","doi":"10.53738/revmed.2023.19.848.2031","title":"Sommes-nous prêts à trouver le médicament qui guérit ?","year":2023,"lang":"fr","type":"editorial","venue":"Revue Médicale Suisse","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut Universitaire de Gériatrie de Montréal","funders":"","keywords":"Physics","score_opus":0.04046216915727042,"score_gpt":0.28321336022061216,"score_spread":0.24275119106334175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388140755","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0034261523,0.04365276,0.00030429565,0.035797834,0.86233383,0.0014080084,0.0076748473,0.00037189064,0.045030385],"genre_scores_gemma":[0.003598012,0.038785715,0.00060194667,0.0028248818,0.6304311,0.00045600405,0.0013092146,0.00074946333,0.32124364],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9917832,0.00015076852,0.0031390658,0.0022725686,0.0002269627,0.002427412],"domain_scores_gemma":[0.9934124,0.0019147972,0.0014989441,0.0016652934,0.00013981323,0.0013687849],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0020770775,0.0011814095,0.0028444114,0.00077503844,0.00054570584,0.00054137164,0.0018033211,0.002355904,0.003727459],"category_scores_gemma":[0.00284624,0.0016758332,0.0013737947,0.0008286759,0.0006651068,0.00038409117,0.0008480534,0.002713818,0.025175486],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009511897,0.000890352,0.0008414329,0.0009626772,0.0005553315,0.00020140345,0.00041571836,0.00017585616,0.0000071697964,0.06127669,0.9258129,0.008765367],"study_design_scores_gemma":[0.0026984264,0.00026840298,0.0003144649,0.0004942147,0.0001207267,0.000015431515,0.00011879873,0.00461598,0.000023415858,0.012847594,0.9767838,0.0016987175],"about_ca_topic_score_codex":0.0017262237,"about_ca_topic_score_gemma":0.000273356,"teacher_disagreement_score":0.27621326,"about_ca_system_score_codex":0.0016460686,"about_ca_system_score_gemma":0.0008925503,"threshold_uncertainty_score":0.99958694},"labels":[],"label_agreement":null},{"id":"W4388204217","doi":"10.1200/op.2023.19.11_suppl.149","title":"Who goes first? Patterns of cancer drug approvals across four major regulatory authorities: EMA, FDA, Health Canada, and PMDA.","year":2023,"lang":"en","type":"article","venue":"JCO Oncology Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"National Institutes of Health","keywords":"Medicine; Drug approval; Marketing authorization; Authorization; Drug; Regulatory agency; Cancer drugs; Regulatory science; Orphan drug; Pharmacology; Agency (philosophy); Food and drug administration; Public administration; Political science; Bioinformatics","score_opus":0.07314741834660451,"score_gpt":0.37649837883215,"score_spread":0.30335096048554544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388204217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87729627,0.0033388608,0.000026801948,0.10894201,0.001316366,0.00039101983,0.0023737464,0.00004589222,0.0062690657],"genre_scores_gemma":[0.9640457,0.010361407,0.0002873073,0.017718662,0.00045491333,0.00013337591,0.000026183505,0.000057739893,0.0069146845],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977806,0.00009560921,0.0009174782,0.0005002409,0.00005551908,0.0006505189],"domain_scores_gemma":[0.9971658,0.0011125628,0.0010367092,0.00034602874,0.00005811353,0.000280763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020406402,0.00020136657,0.0007856809,0.00013327187,0.00027895338,0.000051186933,0.00027183836,0.00015993687,0.00020566116],"category_scores_gemma":[0.0004837279,0.0002412437,0.00007659194,0.00022304045,0.00012228999,0.00037406923,0.00021625271,0.0003788384,0.000067174224],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037426062,0.00041458162,0.34371737,0.0015892934,0.0011117787,0.00011744426,0.014889762,0.00053082104,0.000014266013,0.17953844,0.4293551,0.028346881],"study_design_scores_gemma":[0.00089849357,0.00008179828,0.10451234,0.000029352865,0.0000180693,0.000015405607,0.0012898922,0.0014102467,0.000027485203,0.002372476,0.8890904,0.00025400118],"about_ca_topic_score_codex":0.6240506,"about_ca_topic_score_gemma":0.6727708,"teacher_disagreement_score":0.45973533,"about_ca_system_score_codex":0.00070327224,"about_ca_system_score_gemma":0.00070149737,"threshold_uncertainty_score":0.9837633},"labels":[],"label_agreement":null},{"id":"W4388364365","doi":"10.1093/oso/9780195300956.003.0009","title":"Pricing Pharmaceuticals in a World Environment","year":2006,"lang":"en","type":"book-chapter","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Government (linguistics); Drug prices; Medical prescription; Pharmaceutical industry; Business; Political science; Public administration; Economics; Public economics; Medicine","score_opus":0.08465381535890906,"score_gpt":0.2776025955278644,"score_spread":0.19294878016895536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388364365","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006219055,0.0033658827,0.00024438,0.0014004046,0.0002215485,0.00034608963,0.00018906564,0.00003678471,0.99413365],"genre_scores_gemma":[0.013272137,0.003804884,0.00033784407,0.004924726,0.00040642428,0.000028140652,0.00005351919,0.00012096765,0.9770514],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99752295,0.000004592012,0.0012398128,0.0006931859,0.00003669367,0.0005027939],"domain_scores_gemma":[0.9989624,0.00010973427,0.00035839647,0.0003840768,0.000003146376,0.0001822394],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00041303603,0.0004017209,0.0008276911,0.0007485304,0.000039638548,0.00006271012,0.00028646176,0.0002493248,0.021126043],"category_scores_gemma":[0.000009967,0.00049848645,0.00024437121,0.0000443915,0.000093172006,0.00009603628,0.00015113408,0.00060317153,0.010165305],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007950863,0.000046709196,0.00045259317,0.000030754498,0.00004653303,0.000016014745,0.000013673636,0.00016297479,0.0000017698295,0.9822169,0.014746684,0.0022574218],"study_design_scores_gemma":[0.0004231025,0.000009740136,0.00012935752,0.000020300085,0.000007777949,0.0000015604992,3.6630226e-7,0.0017974552,0.000017040056,0.21490125,0.78224355,0.0004484882],"about_ca_topic_score_codex":0.00012710331,"about_ca_topic_score_gemma":0.00007377357,"teacher_disagreement_score":0.7674969,"about_ca_system_score_codex":0.0005033798,"about_ca_system_score_gemma":0.000020670852,"threshold_uncertainty_score":0.9997467},"labels":[],"label_agreement":null},{"id":"W4388573101","doi":"10.7189/jogh.13.04137","title":"The pan-Canadian Tiered Pricing Framework and Chinese National Volume-Based Procurement: A comparative study using Donabedian’s structure-process-outcome framework","year":2023,"lang":"en","type":"article","venue":"Journal of Global Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Public Health Ontario; University of Toronto","funders":"University of Toronto; National Natural Science Foundation of China","keywords":"Outcome (game theory); Procurement; Process (computing); Business; Process management; Medicine; Computer science; Economics; Marketing","score_opus":0.10447860885336144,"score_gpt":0.42757986079761007,"score_spread":0.32310125194424866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388573101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829464,0.0016520465,0.0009190774,0.012424761,0.00080484257,0.0004407052,0.00044603873,0.000012154586,0.0003539566],"genre_scores_gemma":[0.9946884,0.00008637617,0.00089051,0.003880976,0.00042692386,0.0000038558132,0.0000029552486,0.000013131165,0.000006877614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979371,0.00005428321,0.0011332281,0.00022872964,0.00013507895,0.00051161624],"domain_scores_gemma":[0.9980499,0.00023819675,0.0009649315,0.000134414,0.00014167455,0.0004708818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014520211,0.00018680205,0.0005614358,0.00021239746,0.0005468165,0.00019765741,0.00030004815,0.000102293365,0.00003783302],"category_scores_gemma":[0.0005222299,0.00015447362,0.00009264264,0.0007771555,0.00007318152,0.00017385365,0.00003568568,0.0005343531,0.000027494432],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008053314,0.000084890446,0.9415094,0.00005570709,0.00014160997,0.000006898281,0.001696541,0.0034914145,1.7893532e-7,0.051232856,0.00092848396,0.00077147805],"study_design_scores_gemma":[0.00093200454,0.0002953651,0.54415786,0.00006631046,0.000010849376,0.000018263177,0.0005291693,0.041173518,3.6679805e-7,0.40746164,0.0051223263,0.00023232527],"about_ca_topic_score_codex":0.0023466488,"about_ca_topic_score_gemma":0.0054698726,"teacher_disagreement_score":0.39735153,"about_ca_system_score_codex":0.0015442655,"about_ca_system_score_gemma":0.0011170995,"threshold_uncertainty_score":0.62992513},"labels":[],"label_agreement":null},{"id":"W4388595568","doi":"10.1093/eurheartj/ehad655.2879","title":"Sex differences in incidence of self-reported adverse drug reactions after percutaneous coronary intervention","year":2023,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Regina","funders":"","keywords":"Medicine; Percutaneous coronary intervention; Incidence (geometry); Conventional PCI; Odds ratio; Internal medicine; Acute coronary syndrome; Medical record; Cohort; Logistic regression; Pediatrics; Myocardial infarction","score_opus":0.0773156912344031,"score_gpt":0.30421478546780123,"score_spread":0.22689909423339813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388595568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99048203,0.00025780356,0.00001891787,0.00092788774,0.0004151127,0.000078424004,0.00003478336,0.000035989575,0.0077490564],"genre_scores_gemma":[0.9976483,0.0008416324,0.0001246009,0.00028377367,0.00014090387,0.0000024064818,0.0000036889712,0.000021510728,0.00093319913],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853647,0.000105024075,0.0008741061,0.00020122166,0.000037495316,0.0002457063],"domain_scores_gemma":[0.99928397,0.000076254895,0.00033098058,0.00015836192,0.000020584295,0.0001298603],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013419818,0.00010694032,0.00027296733,0.00037870707,0.000069445225,0.00003883049,0.0001555674,0.000026902275,0.00075260253],"category_scores_gemma":[0.000096965494,0.00011956787,0.00016248725,0.0002327243,0.00004401421,0.00021922668,0.00008574252,0.00034178692,0.0010199136],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005797822,0.00019393544,0.99131125,0.0000443451,0.00010033865,0.000849626,0.0016697645,0.00014483841,0.00017200498,0.0011099253,0.0035358067,0.0008101903],"study_design_scores_gemma":[0.00039948834,0.00006083779,0.9687166,0.000077055236,0.000008145544,0.0010322641,0.00015324571,0.0032303797,0.000019251183,0.0023858666,0.023750631,0.00016618725],"about_ca_topic_score_codex":0.000049318514,"about_ca_topic_score_gemma":0.00001833339,"teacher_disagreement_score":0.022594599,"about_ca_system_score_codex":0.00008618387,"about_ca_system_score_gemma":0.000019170975,"threshold_uncertainty_score":0.9997579},"labels":[],"label_agreement":null},{"id":"W4388682094","doi":"10.1177/10245294231210975","title":"Sick with “shareholder value”: US pharma’s financialized business model during the pandemic","year":2023,"lang":"en","type":"article","venue":"Competition & Change","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute for New Economic Thinking; Canadian Institute for Advanced Research","keywords":"Shareholder value; Shareholder; Business; Context (archaeology); Remuneration; Leverage (statistics); Argument (complex analysis); Economics; Finance; Corporate governance","score_opus":0.17579415078561544,"score_gpt":0.29735847495960993,"score_spread":0.12156432417399449,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388682094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791558,0.00056372077,0.00059377734,0.0060870824,0.0004835268,0.0004888147,0.00085867307,0.00023837625,0.011530275],"genre_scores_gemma":[0.99201053,0.0018471773,0.000047454007,0.0038647756,0.00063215353,0.00024828472,0.00010980744,0.000046386274,0.0011934194],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9988167,0.000015674499,0.00035071623,0.0003565816,0.00004237552,0.0004179273],"domain_scores_gemma":[0.9993298,0.00004431134,0.00018433214,0.00030312518,0.00003946583,0.00009895153],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00028715446,0.00018601789,0.00030208478,0.00019074275,0.00025852336,0.00008541198,0.00028021864,0.00007026146,0.0006466989],"category_scores_gemma":[0.000020636282,0.00016597683,0.00008357682,0.00052698626,0.00008179625,0.00026721906,0.000088271176,0.00018841043,0.0016662658],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040738643,0.00035448966,0.061230518,0.0006086544,0.0002672459,0.00005028618,0.00534556,0.020070296,0.00074789696,0.8965251,0.012219586,0.0021729826],"study_design_scores_gemma":[0.0052681193,0.000047762343,0.38423595,0.00012449543,0.000033436478,0.000032286807,0.00006084578,0.23523007,0.00017438833,0.041711435,0.33201423,0.0010669664],"about_ca_topic_score_codex":0.0001374732,"about_ca_topic_score_gemma":0.00006334302,"teacher_disagreement_score":0.85481364,"about_ca_system_score_codex":0.00010972833,"about_ca_system_score_gemma":0.000024860143,"threshold_uncertainty_score":0.99911106},"labels":[],"label_agreement":null},{"id":"W4388723593","doi":"10.5731/pdajpst.2023.012850","title":"Worldwide Regulatory Reliance: Launching a Pilot on a Chemistry, Manufacturing, and Control Post Approval Change for a Vaccine","year":2023,"lang":"en","type":"article","venue":"PDA Journal of Pharmaceutical Science and Technology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sanofi (Canada)","funders":"","keywords":"Timeline; Marketing authorization; Business; Authorization; Process (computing); Control (management); Process management; Medicine; Risk analysis (engineering); Computer science; Computer security","score_opus":0.06622890492828186,"score_gpt":0.31985040457497715,"score_spread":0.2536214996466953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388723593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94818705,0.0018061051,0.00018092414,0.048528492,0.00027297894,0.00030899915,0.00006818374,0.000047172165,0.0006000943],"genre_scores_gemma":[0.99529076,0.0011125486,0.00022263256,0.003054675,0.00022840008,0.000026491183,6.9016227e-7,0.000014285427,0.00004951994],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998541,0.0000064277565,0.00050923025,0.00035420503,0.00007339814,0.0005157702],"domain_scores_gemma":[0.99903774,0.00013885784,0.00029931118,0.00014613681,0.00009365747,0.00028426846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017969516,0.00015136681,0.0003971349,0.0006172481,0.00021386577,0.000077005156,0.00035524918,0.00008874457,0.000046881938],"category_scores_gemma":[0.0005173122,0.00014155914,0.00005226177,0.00050520577,0.00041113954,0.00024946316,0.00012548982,0.00038891876,0.000022790451],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020992337,0.00069884263,0.014841151,0.0007260259,0.000379645,0.00013395137,0.00053729943,0.00003262812,0.1449453,0.36582002,0.0044580842,0.46532783],"study_design_scores_gemma":[0.012629447,0.001857521,0.016683677,0.00016527831,0.00008653975,0.00048149854,0.00015181491,0.023563331,0.10190934,0.15024066,0.6913154,0.0009154668],"about_ca_topic_score_codex":0.0000063363022,"about_ca_topic_score_gemma":0.0000013402034,"teacher_disagreement_score":0.68685734,"about_ca_system_score_codex":0.00008898263,"about_ca_system_score_gemma":0.000053909425,"threshold_uncertainty_score":0.5772614},"labels":[],"label_agreement":null},{"id":"W4388729178","doi":"10.1371/journal.pmed.1004309","title":"Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986–2019","year":2023,"lang":"en","type":"article","venue":"PLoS Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Heart, Lung, and Blood Institute; West Virginia University; Arnold Ventures; Commonwealth Fund","keywords":"Medicine; Food and drug administration; Approved drug; Pharmacology; Business; Drug","score_opus":0.16312666031079368,"score_gpt":0.30623227175366174,"score_spread":0.14310561144286807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388729178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820471,0.001421421,0.0000065763984,0.010518939,0.0005163301,0.00060510123,0.00032550286,0.0001010352,0.00445804],"genre_scores_gemma":[0.99483097,0.0010559307,0.000023468616,0.0016917279,0.0006545871,0.000058727688,0.000099518176,0.000040098494,0.0015449636],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99823105,0.000026781066,0.0006214303,0.00064928015,0.000078357276,0.0003931104],"domain_scores_gemma":[0.9988848,0.00012935617,0.00021290685,0.00053998915,0.000030876363,0.00020208064],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008780216,0.00022659384,0.0005665539,0.00042045707,0.00012712188,0.000030550636,0.00021875926,0.00005855887,0.00022392262],"category_scores_gemma":[0.0005481076,0.00021590106,0.0000329572,0.00037971343,0.00014899058,0.00016773223,0.00020721975,0.00023961629,0.0008146505],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011514209,0.005129045,0.43286622,0.0016977581,0.0020307659,0.0003902933,0.016215598,0.0001463672,0.0019741354,0.22594589,0.29938796,0.013064539],"study_design_scores_gemma":[0.015790682,0.002810388,0.72302336,0.00048664652,0.000193548,0.000022272816,0.0015827094,0.025670461,0.0010862311,0.02727371,0.20027092,0.0017890501],"about_ca_topic_score_codex":0.0002363004,"about_ca_topic_score_gemma":0.000013433368,"teacher_disagreement_score":0.29015714,"about_ca_system_score_codex":0.00006985668,"about_ca_system_score_gemma":0.000023714432,"threshold_uncertainty_score":0.99996334},"labels":[],"label_agreement":null},{"id":"W4388835034","doi":"10.1001/jamainternmed.2023.6256","title":"Therapeutic Benefit From New Drugs From Pharmaceutical Companies","year":2023,"lang":"en","type":"letter","venue":"JAMA Internal Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; York University","funders":"","keywords":"Medicine; Otorhinolaryngology; Family medicine; Neurology; Psychiatry","score_opus":0.10819153057653096,"score_gpt":0.3272168631452734,"score_spread":0.2190253325687424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388835034","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005890537,0.011426326,0.00047418883,0.93308866,0.008246977,0.0003137005,0.0037481466,0.00020688627,0.036604606],"genre_scores_gemma":[0.0138985105,0.0030530875,0.000100925725,0.91217345,0.04976421,0.000030989213,0.0013482621,0.0002287947,0.01940176],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99601954,0.000040314295,0.0017189255,0.0011742124,0.0001718604,0.0008751369],"domain_scores_gemma":[0.9965382,0.0014385987,0.0007618089,0.0007598574,0.00004364556,0.00045786635],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0003837755,0.00071526354,0.0018085414,0.0005033796,0.00007957629,0.00022171672,0.0014287296,0.00095298036,0.017232455],"category_scores_gemma":[0.00022050586,0.00070776936,0.00039801607,0.00022599689,0.00029273995,0.00020643981,0.00032719228,0.0035298578,0.013487364],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000086048945,0.00002490277,0.0010216874,0.000038613787,0.0010006492,0.00015987248,0.00090033346,0.000006456957,0.000009860484,0.005261873,0.98359555,0.00789414],"study_design_scores_gemma":[0.0020697329,0.00008130367,0.0014668499,0.00028079448,0.000109266184,0.0000046920095,0.000031336833,0.0029754955,0.000032543972,0.20843288,0.7839656,0.0005494818],"about_ca_topic_score_codex":0.036120504,"about_ca_topic_score_gemma":0.00011966929,"teacher_disagreement_score":0.20317101,"about_ca_system_score_codex":0.0003461508,"about_ca_system_score_gemma":0.000054998625,"threshold_uncertainty_score":0.99953735},"labels":[],"label_agreement":null},{"id":"W4388917607","doi":"10.5334/aogh.4151","title":"Improving Middle-Income Countries Access to Vaccines. A Blueprint to Overcome Current Challenges","year":2023,"lang":"en","type":"article","venue":"Annals of Global Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Universitat Autònoma de Barcelona; University of Toronto; University of Washington; Florida International University","keywords":"Blueprint; Government (linguistics); Incentive; Business; Population; Economic growth; Public relations; Political science; Economics; Medicine; Environmental health; Engineering","score_opus":0.24258314271861117,"score_gpt":0.4428879483532788,"score_spread":0.20030480563466765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388917607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7444309,0.013740883,0.00018028583,0.23375154,0.0012793111,0.00075704727,0.0019814775,0.00012200534,0.0037565494],"genre_scores_gemma":[0.9667216,0.016715372,0.00008508234,0.016126458,0.00024725797,0.000044624816,0.0000074653985,0.000021512853,0.000030626463],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9977775,0.000019726487,0.0008468843,0.00051090686,0.000059779555,0.0007851999],"domain_scores_gemma":[0.998447,0.0000593995,0.00034477696,0.0004148136,0.000074346426,0.0006596587],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010897431,0.0002021944,0.0006526385,0.00025094234,0.00009820634,0.00008926974,0.0005821536,0.00006170278,0.0000807919],"category_scores_gemma":[0.00015463459,0.00023856269,0.00013483538,0.00061311154,0.00002141563,0.0002307202,0.000493326,0.000118522046,0.0017448827],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017076636,0.00017711574,0.053630084,0.0017717609,0.00009035133,0.000003902705,0.0008942849,0.0006159556,0.0000011216028,0.83290714,0.02650553,0.08323198],"study_design_scores_gemma":[0.0004483652,0.00029501662,0.50350505,0.00020852433,0.0000023638604,0.0000018970076,0.00003654617,0.0010224675,0.000045554243,0.047381412,0.44664362,0.00040915434],"about_ca_topic_score_codex":0.0014018496,"about_ca_topic_score_gemma":0.00043039944,"teacher_disagreement_score":0.78552574,"about_ca_system_score_codex":0.00023197934,"about_ca_system_score_gemma":0.00015276505,"threshold_uncertainty_score":0.9990324},"labels":[],"label_agreement":null},{"id":"W4389000566","doi":"10.1007/s40278-023-49354-x","title":"Sabril (vigabatrin) 500mg tablets containing trace amounts of tiapride released on Canadian market","year":2023,"lang":"en","type":"article","venue":"Reactions Weekly","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Vigabatrin; Tiapride; TRACE (psycholinguistics); Chemistry; Pharmacology; Chromatography; Medicine; Psychiatry; Epilepsy; Anticonvulsant; Philosophy","score_opus":0.058716800843080334,"score_gpt":0.2784391706306147,"score_spread":0.21972236978753434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389000566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6086324,0.00020399627,0.000025575631,0.0062965364,0.00063386484,0.00023318791,0.0010182005,0.000086590764,0.38286963],"genre_scores_gemma":[0.98983824,0.00046051343,0.000034723147,0.0008450012,0.00015816202,0.00002379164,0.00003952517,0.00003714938,0.008562896],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984817,0.000018828327,0.0006184073,0.00034805943,0.00003508908,0.0004979036],"domain_scores_gemma":[0.9987854,0.00022137002,0.0002575375,0.00036790656,0.000026485712,0.0003413323],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0005127328,0.0001643029,0.00038222581,0.00069508445,0.00016689727,0.000052392053,0.0002041036,0.00012493423,0.0011933857],"category_scores_gemma":[0.00023716489,0.00020867927,0.00014978764,0.00049633137,0.00005255563,0.00017993199,0.000026057094,0.00026034724,0.0023758227],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028512086,0.00034749662,0.050140947,0.00018967586,0.0005262239,0.00007499826,0.00053306937,0.0022306729,0.0012429114,0.6284576,0.30619124,0.009780058],"study_design_scores_gemma":[0.0006289469,0.00008130232,0.06872459,0.00002844217,0.000010308231,0.0000069169296,0.00008472912,0.008395404,0.00033570934,0.0051644524,0.91625774,0.00028146117],"about_ca_topic_score_codex":0.064781934,"about_ca_topic_score_gemma":0.009632168,"teacher_disagreement_score":0.62329316,"about_ca_system_score_codex":0.00035230318,"about_ca_system_score_gemma":0.0001243542,"threshold_uncertainty_score":0.9997197},"labels":[],"label_agreement":null},{"id":"W4389222395","doi":"10.1182/blood-2023-179050","title":"The GLAMM1 Study - Global Access to Myeloma Medications: Potential Barriers to Chimeric Antigen Receptors (CART) and T-Cell-Engaging Bispecific Antibodies (TCE) Globally","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Chimeric antigen receptor; Multiple myeloma; Health care; Expanded access; Family medicine; Internal medicine; Cancer; Immunotherapy; Economic growth","score_opus":0.035043998705333854,"score_gpt":0.3037439020210804,"score_spread":0.26869990331574656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389222395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791915,0.0012061537,0.000081890925,0.008353445,0.0009888493,0.0007423989,0.00027070715,0.00010618415,0.009058875],"genre_scores_gemma":[0.99604404,0.001933404,0.00010877276,0.001354049,0.0002818271,0.00006806263,0.000012946704,0.000027374674,0.00016951449],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980602,0.000047522804,0.0006143949,0.00060730235,0.000081316866,0.00058921194],"domain_scores_gemma":[0.99868417,0.00008130631,0.00016178483,0.0004371007,0.00003243293,0.0006032161],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009438868,0.00022518063,0.00035551644,0.00020988638,0.000778707,0.0006130131,0.0008060849,0.00006405986,0.00012613673],"category_scores_gemma":[0.0002607269,0.00022220988,0.00008613658,0.0010111488,0.00007974155,0.00021178249,0.00055222533,0.00014980114,0.0008741529],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000074815645,0.00047191832,0.9182345,0.000037793958,0.0007521887,0.000030465884,0.0027725238,0.00039716723,0.00021177743,0.026477473,0.03828267,0.012256669],"study_design_scores_gemma":[0.0022182863,0.00024469668,0.737602,0.000018800927,0.00007411894,0.0000101775595,0.0026506046,0.00092011184,0.00024149084,0.006813723,0.24848127,0.0007247218],"about_ca_topic_score_codex":0.00019522692,"about_ca_topic_score_gemma":0.000112524736,"teacher_disagreement_score":0.21019861,"about_ca_system_score_codex":0.00006944746,"about_ca_system_score_gemma":0.00007000951,"threshold_uncertainty_score":0.9999038},"labels":[],"label_agreement":null},{"id":"W4389279230","doi":"10.33140/tapi.06.01.14","title":"The Successful Launch and Diffusion of New Therapies","year":2023,"lang":"en","type":"article","venue":"Toxicology and Applied Pharmacology Insights","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Karachi; University of Calgary","keywords":"Promotion (chess); Risk analysis (engineering); Pharmaceutical industry; Business; Value (mathematics); Field (mathematics); Marketing; Management science; Process management; Computer science; Engineering; Biotechnology","score_opus":0.04498046211781146,"score_gpt":0.2958214113893288,"score_spread":0.25084094927151734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389279230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97543436,0.0036399732,0.00001587799,0.0062261247,0.00044812978,0.00022492952,0.000018863042,0.000038856768,0.013952902],"genre_scores_gemma":[0.98787546,0.008634045,0.000024003908,0.00233445,0.00016886985,0.00003653651,0.000004383108,0.000012940963,0.00090929464],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990014,0.000022689686,0.00038254654,0.00028280963,0.000014970692,0.00029561017],"domain_scores_gemma":[0.99920607,0.00036816456,0.00017704131,0.0001118117,0.000008147068,0.00012876342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027244078,0.00013708854,0.0003345707,0.00013709528,0.00029100222,0.00002231873,0.00017270898,0.00015986798,0.0002590877],"category_scores_gemma":[0.000011105944,0.00011241257,0.0000345666,0.00017373389,0.00042374615,0.000051461713,0.00015846327,0.0001975386,0.00013289254],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017155205,0.00007894507,0.005222467,0.000030428057,0.00018502094,0.000003505633,0.0022141617,0.000017310598,0.016904062,0.9492821,0.017151441,0.008739013],"study_design_scores_gemma":[0.0023139243,0.00013648829,0.031435035,0.0000026329712,0.000024940784,0.0000068584764,0.00015437712,0.0016646534,0.007817856,0.35129747,0.6048858,0.00025994424],"about_ca_topic_score_codex":0.000016402888,"about_ca_topic_score_gemma":0.000017195292,"teacher_disagreement_score":0.5979846,"about_ca_system_score_codex":0.000012758602,"about_ca_system_score_gemma":0.000020624382,"threshold_uncertainty_score":0.45840517},"labels":[],"label_agreement":null},{"id":"W4389568577","doi":"10.59890/ijaeam.v1i4.913","title":"International Trade in Pharmaceutical Products","year":2023,"lang":"en","type":"article","venue":"International Journal of Applied Economics Accounting and Management (IJAEAM)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Karachi; University of Calgary","keywords":"Business; Intellectual property; Context (archaeology); Supply chain; Pharmaceutical industry; Globalization; Equity (law); Public economics; Industrial organization; International trade; Economics; Marketing; Biotechnology; Political science","score_opus":0.04632787595956736,"score_gpt":0.29711067106174577,"score_spread":0.2507827951021784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389568577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6883198,0.00028681807,0.0001458638,0.041103303,0.0046891207,0.00036350483,0.000114509065,0.000055210963,0.26492187],"genre_scores_gemma":[0.98692137,0.008970425,0.0007035445,0.0023842202,0.0008373353,0.0000150079,0.000021077958,0.00002953228,0.000117515025],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99819666,0.0000052745813,0.0010825258,0.0003459605,0.00006428229,0.0003052898],"domain_scores_gemma":[0.9991136,0.000055767454,0.0005820407,0.00013260733,0.000021459598,0.000094532996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012120261,0.00017057135,0.0003403335,0.0009842601,0.0000421005,0.00025181583,0.0006741397,0.00006875008,0.00011235631],"category_scores_gemma":[0.000034044486,0.00020726411,0.00009285252,0.0001803861,0.000059523463,0.0003824154,0.000270954,0.00025255306,0.00017496136],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022297175,0.00017912853,0.007057853,0.00005854262,0.0006569744,0.000044577693,0.0004113573,0.0037597874,0.00009489229,0.94479185,0.0071162623,0.03560582],"study_design_scores_gemma":[0.0026061411,0.000018005983,0.02015857,0.00003140971,0.000015628828,0.000027280239,0.00018176634,0.013898298,0.00019919407,0.069619775,0.89291793,0.000325976],"about_ca_topic_score_codex":0.00000953711,"about_ca_topic_score_gemma":0.0000031231343,"teacher_disagreement_score":0.8858017,"about_ca_system_score_codex":0.00020188933,"about_ca_system_score_gemma":0.000016628093,"threshold_uncertainty_score":0.8451985},"labels":[],"label_agreement":null},{"id":"W4389783746","doi":"10.19181/population.2023.26.4.15","title":"Economic affordability of medicines and its impact on households in Russia","year":2023,"lang":"en","type":"article","venue":"POPULATION","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Poverty; Population; Business; Consumption (sociology); Payment; Government (linguistics); Quarter (Canadian coin); Receipt; Health care; Economic growth; Economics; Environmental health; Medicine; Finance; Geography","score_opus":0.07679951011362599,"score_gpt":0.3512057057307321,"score_spread":0.2744061956171061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389783746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99589413,0.00014311956,0.0000022279735,0.0009891514,0.00014471903,0.00012336177,0.00014453658,0.000020601252,0.0025381611],"genre_scores_gemma":[0.99952614,0.00021146041,0.0000070403207,0.00011614884,0.00006357873,0.0000068744366,0.000031140702,0.000010876376,0.000026733343],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99921805,0.000009052739,0.0004249624,0.00018580545,0.00001136302,0.00015077273],"domain_scores_gemma":[0.9996186,0.00006134532,0.00014459502,0.000116293726,0.0000028755849,0.000056327033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004439506,0.00008134194,0.000255817,0.0002236316,0.000021905751,0.000010325578,0.000057287398,0.00005633936,0.00011475344],"category_scores_gemma":[0.000054984008,0.00008292071,0.000046894453,0.00012417992,0.000017214059,0.00011834453,0.000023061619,0.00006106406,0.0001612059],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027789092,0.000020581027,0.89326346,0.000026859845,0.000009522589,3.2323965e-7,0.000129859,0.0034526708,0.000017204682,0.10186678,0.00018024608,0.001004674],"study_design_scores_gemma":[0.00032536924,0.000037875863,0.8986656,0.0000073180763,0.0000013005651,3.5191943e-7,0.000004563416,0.054591477,0.000047326037,0.045904912,0.00033860793,0.00007528695],"about_ca_topic_score_codex":0.0006963246,"about_ca_topic_score_gemma":0.00010067338,"teacher_disagreement_score":0.055961873,"about_ca_system_score_codex":0.00011358462,"about_ca_system_score_gemma":0.000007286435,"threshold_uncertainty_score":0.33814085},"labels":[],"label_agreement":null},{"id":"W4390047045","doi":"10.1371/journal.pone.0293497","title":"Early observations of Tier-3 drug shortages on purchasing trends across Canada: A cross-sectional analysis of 3 case-example drugs","year":2023,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; Women's College Hospital; University of Toronto","funders":"","keywords":"Purchasing; Economic shortage; Medicine; Business; Tier 1 network; Environmental health; Demography; Computer science; Marketing","score_opus":0.22252209926742111,"score_gpt":0.32329267258706695,"score_spread":0.10077057331964584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390047045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909411,0.00007752449,0.000006842163,0.00048359297,0.000082355815,0.000068071495,0.006560532,0.000021453972,0.0017585303],"genre_scores_gemma":[0.9978395,0.00005392323,0.00009064637,0.00019001163,0.00008256405,0.000018614799,0.00017915072,0.000019068213,0.0015265369],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985041,0.0000118560865,0.0007772953,0.0003136075,0.00007915017,0.0003139767],"domain_scores_gemma":[0.998961,0.00021623999,0.000343877,0.00030239508,0.0000664445,0.00011005988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045613543,0.00012206865,0.0005534046,0.00040434866,0.0001403217,0.000046230063,0.00017727545,0.000061537765,0.00028662098],"category_scores_gemma":[0.00008353055,0.00015439789,0.00018186835,0.0014924865,0.000082465405,0.00011462688,0.00006458777,0.00013556141,0.000023669927],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021980239,0.0003378706,0.9820567,0.000048952672,0.0022324673,0.000011973856,0.0010471875,0.002657059,0.00014791409,0.010938119,0.00031215692,0.00018761528],"study_design_scores_gemma":[0.00029030617,0.000027015547,0.9766055,0.000008245665,0.0000993286,6.883522e-7,0.00005354098,0.020156888,0.0008512769,0.0006565352,0.0010846439,0.0001660508],"about_ca_topic_score_codex":0.26519907,"about_ca_topic_score_gemma":0.119345784,"teacher_disagreement_score":0.14585328,"about_ca_system_score_codex":0.0001612739,"about_ca_system_score_gemma":0.000055797682,"threshold_uncertainty_score":0.89672387},"labels":[],"label_agreement":null},{"id":"W4390054136","doi":"10.57220/jatpb.v2i3.171","title":"Les métiers de l’industrie pharmaceutique et chaines de valeurs - Communication Introductive","year":2023,"lang":"fr","type":"article","venue":"Journal Africain de Technologie Pharmaceutique et Biopharmacie (JATPB)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science; Humanities; Art","score_opus":0.17023462981949525,"score_gpt":0.4080190340451326,"score_spread":0.23778440422563737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390054136","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32595164,0.0613173,0.0073931506,0.5887131,0.0034205008,0.0014937599,0.0020406109,0.0016222934,0.008047604],"genre_scores_gemma":[0.6260218,0.34882736,0.0044546057,0.01504963,0.0010915233,0.0002654647,0.000080297395,0.00026754473,0.00394178],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9905158,0.0018005102,0.0024553018,0.0013837246,0.00026230174,0.0035823544],"domain_scores_gemma":[0.9935645,0.0014826744,0.0020798407,0.0011798759,0.00031085225,0.0013822803],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.017154085,0.0012381222,0.0015270859,0.0024805425,0.0011357665,0.0008696467,0.0033572004,0.0016767966,0.0015011978],"category_scores_gemma":[0.0028556078,0.0015675245,0.0008787235,0.0033709446,0.0013889325,0.0015602977,0.0013613516,0.009301105,0.0008341483],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010424262,0.0025119733,0.035921182,0.0009397204,0.00338627,0.0017148987,0.009737175,0.030160103,0.03284744,0.21947603,0.46235177,0.19991101],"study_design_scores_gemma":[0.00392468,0.00019034147,0.0012418837,0.00024022286,0.0002571187,0.001569483,0.0011329743,0.071493514,0.034462694,0.065644965,0.8182322,0.0016099628],"about_ca_topic_score_codex":0.00036307014,"about_ca_topic_score_gemma":0.00002148406,"teacher_disagreement_score":0.57366353,"about_ca_system_score_codex":0.0048442082,"about_ca_system_score_gemma":0.0012949442,"threshold_uncertainty_score":0.9999438},"labels":[],"label_agreement":null},{"id":"W4390104714","doi":"10.1007/s40258-023-00860-2","title":"An Optional Delinked Reward System: Making Pharmaceutical Innovation Work for Everyone","year":2023,"lang":"en","type":"article","venue":"Applied Health Economics and Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Reimbursement; Negotiation; Payment; Reward system; Pharmaceutical industry; Business; Work (physics); Marketing; Health economics; Health care; Economics; Finance; Medicine; Pharmacology; Economic growth","score_opus":0.2573959301387196,"score_gpt":0.4467395295543763,"score_spread":0.1893435994156567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390104714","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.43129745,0.009088484,0.023782814,0.48369244,0.0042385194,0.011975452,0.007355249,0.0018013471,0.026768252],"genre_scores_gemma":[0.92014855,0.0062843454,0.0029074452,0.067469984,0.0019963838,0.00048043433,0.0004897805,0.00011049023,0.000112574366],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99563754,0.000028724824,0.0021156797,0.0008625699,0.00003369009,0.0013217885],"domain_scores_gemma":[0.99780566,0.00013434929,0.0009668409,0.00040842552,0.000045276593,0.00063947856],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0033558586,0.00032630347,0.00095282844,0.0011090174,0.0007054345,0.00016296364,0.00028677093,0.00020950292,0.00003240933],"category_scores_gemma":[0.0000349993,0.00043177963,0.00009438145,0.00086265954,0.00009276257,0.00017791282,0.000103377475,0.00031090566,0.00039477614],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008918817,0.00004384699,0.00095444755,0.0005645341,0.000040018786,1.9614623e-7,0.0004281426,0.0008873915,0.0000016424264,0.97783923,0.008642385,0.010508969],"study_design_scores_gemma":[0.0033506574,0.00027054196,0.019810341,0.00007117638,0.0000069674415,0.000010153249,0.00022427097,0.0693704,0.0000056591657,0.1157307,0.79036856,0.0007805573],"about_ca_topic_score_codex":0.0005079435,"about_ca_topic_score_gemma":0.0000505848,"teacher_disagreement_score":0.8621085,"about_ca_system_score_codex":0.0011554119,"about_ca_system_score_gemma":0.0008026383,"threshold_uncertainty_score":0.9998134},"labels":[],"label_agreement":null},{"id":"W4390399552","doi":"10.1016/j.ijcard.2023.131498","title":"Budget impact analysis of empagliflozin in the treatment of heart failure with reduced ejection fraction (BIAEMHeart)","year":2023,"lang":"en","type":"article","venue":"International Journal of Cardiology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"","keywords":"Medicine; Empagliflozin; Ejection fraction; Heart failure; Cardiology; Internal medicine; Diabetes mellitus; Type 2 diabetes; Endocrinology","score_opus":0.0469847117435571,"score_gpt":0.3486967612350542,"score_spread":0.3017120494914971,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390399552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956183,0.000125294,0.00025315836,0.0026154558,0.0002633753,0.000055040055,0.00012728076,0.0000021625387,0.00093997637],"genre_scores_gemma":[0.99900633,0.0005642384,0.000067103756,0.00009038725,0.00023573001,0.0000035542912,0.000017944038,0.000004968724,0.000009747807],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991048,0.000052218857,0.0005923735,0.00009592509,0.00005097353,0.000103682585],"domain_scores_gemma":[0.9991152,0.00016832832,0.00048432327,0.000103360166,0.00009951463,0.000029224286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053641264,0.00007157291,0.0005283658,0.0010047744,0.000011617436,0.000012068764,0.00015274005,0.000055056273,0.00006296617],"category_scores_gemma":[0.00004945225,0.000051986666,0.0003778378,0.0004508331,0.000044391767,0.00009682677,0.000007921688,0.00009135657,0.000013148635],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004821095,0.0001451404,0.8931993,0.0000043128707,0.0061739725,0.00002307252,0.00059259735,0.09087025,0.0011186446,0.0038267814,0.0027373945,0.0008263993],"study_design_scores_gemma":[0.0013034486,0.0008141524,0.9438475,0.000008768397,0.00017210553,0.00008444568,0.00022002167,0.0048077377,0.0005622823,0.0030291823,0.04505851,0.00009189347],"about_ca_topic_score_codex":0.00015699402,"about_ca_topic_score_gemma":0.00003329523,"teacher_disagreement_score":0.086062506,"about_ca_system_score_codex":0.00017154204,"about_ca_system_score_gemma":0.00003578715,"threshold_uncertainty_score":0.21199547},"labels":[],"label_agreement":null},{"id":"W4390572338","doi":"10.22270/ijdra.v11i4.631","title":"A Review on Approval and Registration Process of Medical Devices in Canada and India","year":2023,"lang":"en","type":"review","venue":"International Journal of Drug Regulatory Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Public Health Agency of Canada; Canadian Institutes of Health Research","funders":"","keywords":"Business; Health technology; Population; Medicine; Health care; Order (exchange); Marketing; Medical emergency; Finance; Environmental health; Economic growth","score_opus":0.05931262392609347,"score_gpt":0.34678687639898353,"score_spread":0.28747425247289005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390572338","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027563393,0.9943492,9.361109e-7,0.0012649695,0.00045785177,0.00017120394,0.00013108189,0.0000021680778,0.00086624495],"genre_scores_gemma":[0.016601259,0.9827795,0.000008909643,0.00036149498,0.000185549,0.000007687225,0.000010172245,0.000020293162,0.000025111432],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977086,0.00003952834,0.001712509,0.00021439594,0.00019832671,0.0001266379],"domain_scores_gemma":[0.9975163,0.00020829354,0.0019569106,0.00010396011,0.00006335963,0.0001512094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014510524,0.0001793119,0.0011468404,0.0004086367,0.000012547646,0.00002931265,0.0004787018,0.000109478104,0.000049571845],"category_scores_gemma":[0.00030377248,0.0001688237,0.00013368097,0.00013677336,0.00006772591,0.00013265834,0.000066649634,0.00040365855,0.0000046379687],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007505041,0.00021815028,0.0046341857,0.092164725,0.0021451474,0.0003465085,0.00050931127,0.000038212966,5.110343e-8,0.11916475,0.01120317,0.76950073],"study_design_scores_gemma":[0.0007515826,0.00004091403,0.0012124776,0.0658865,0.00010514327,0.0002881244,0.00012369534,0.00020289485,8.782562e-7,0.0046267095,0.92638063,0.00038047743],"about_ca_topic_score_codex":0.011328008,"about_ca_topic_score_gemma":0.0406322,"teacher_disagreement_score":0.91517746,"about_ca_system_score_codex":0.0003434882,"about_ca_system_score_gemma":0.0012483608,"threshold_uncertainty_score":0.99525565},"labels":[],"label_agreement":null},{"id":"W4390589706","doi":"10.5206/uwomj.v91i1.15684","title":"Primer on the Economics of Antimicrobial Resistance","year":2024,"lang":"en","type":"article","venue":"University of Western Ontario Medical Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Antibiotic resistance; Antimicrobial; Antibiotics; Incentive; Resistance (ecology); Drug resistance; Biotechnology; Biology; Intensive care medicine; Medicine; Microbiology; Economics; Ecology; Market economy","score_opus":0.03831665147591422,"score_gpt":0.23049730581301903,"score_spread":0.1921806543371048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390589706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94314784,0.00033277555,0.0006305932,0.019147228,0.00058816554,0.00006422872,0.0000763683,0.000007771736,0.036005024],"genre_scores_gemma":[0.99371386,0.0008586547,0.00013480829,0.0014315614,0.00014444612,4.553413e-8,0.000001997862,0.000009951139,0.0037046827],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992343,0.000017408354,0.00037647894,0.00015856764,0.000044493358,0.00016876204],"domain_scores_gemma":[0.99933016,0.00013166021,0.00021221871,0.00014922168,0.000018679655,0.00015803124],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00064399745,0.0000875739,0.00027742988,0.00013333745,0.00008050331,0.0000341796,0.00045044036,0.00009399122,0.0027250594],"category_scores_gemma":[0.000036104055,0.00008273286,0.00018116765,0.000058518723,0.00020787575,0.00012140908,0.00007177677,0.00048183958,0.00016256783],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005478597,0.00044271373,0.07619531,0.00022074112,0.0010684569,0.00023850761,0.008377847,0.00015600922,0.00008637384,0.8301907,0.077722065,0.004753419],"study_design_scores_gemma":[0.00068081135,0.000073762225,0.01091267,0.00024708032,0.000023527651,0.000043761425,0.00006819263,0.00037418772,0.00015538809,0.010457824,0.9767909,0.0001718847],"about_ca_topic_score_codex":0.0017559973,"about_ca_topic_score_gemma":0.010246974,"teacher_disagreement_score":0.89906883,"about_ca_system_score_codex":0.00021564716,"about_ca_system_score_gemma":0.00029413326,"threshold_uncertainty_score":0.9981866},"labels":[],"label_agreement":null},{"id":"W4390690958","doi":"10.1136/bmj.q61","title":"US states want to buy cheap drugs from Canada—and the FDA says yes after three year delay","year":2024,"lang":"en","type":"editorial","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Internet privacy; Medicine; Law; Advertising; Psychology; Political science; Computer science","score_opus":0.015749725202793937,"score_gpt":0.2616464993760273,"score_spread":0.24589677417323336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390690958","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02066261,0.017575456,0.00001949521,0.036823463,0.8754488,0.0008711178,0.024351379,0.00004215823,0.024205478],"genre_scores_gemma":[0.035322078,0.006069855,0.00016983949,0.0065044495,0.9466707,0.00042094683,0.0003531639,0.00018541346,0.004303522],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980139,0.000020232814,0.00077737396,0.00065131264,0.00008862149,0.0004485655],"domain_scores_gemma":[0.99832034,0.000678353,0.00021029668,0.0005113597,0.00003225685,0.00024738495],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007055921,0.00033274098,0.0007419539,0.00011518391,0.000069304515,0.00027724614,0.00042622173,0.00031512624,0.00053778366],"category_scores_gemma":[0.00026577478,0.00028355813,0.00015532342,0.00008912468,0.0000993736,0.000059428345,0.0003187629,0.0006381791,0.0012976299],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012797539,0.000007342796,0.00021963421,0.000049675415,0.00020169043,0.000013898223,0.0004113696,0.000014312907,6.4429784e-8,0.007663072,0.99086374,0.00042723655],"study_design_scores_gemma":[0.00060171937,0.000014749945,0.00054740027,0.0000423064,0.000037458543,5.0978514e-7,0.000020017187,0.00045827538,0.0000021988926,0.050973874,0.9469151,0.00038637046],"about_ca_topic_score_codex":0.6276735,"about_ca_topic_score_gemma":0.4367767,"teacher_disagreement_score":0.19089678,"about_ca_system_score_codex":0.0003219794,"about_ca_system_score_gemma":0.00039954067,"threshold_uncertainty_score":0.9999617},"labels":[],"label_agreement":null},{"id":"W4390706712","doi":"10.1136/bmj.p2983","title":"US states want to buy cheap drugs from Canada—and the FDA says yes after three year delay","year":2024,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Sign (mathematics); Business; Advertising; Drug approval; Control (management); Drug; Political science; Law; Medicine; Economics; Pharmacology; Management","score_opus":0.022759852932865986,"score_gpt":0.25905948532396683,"score_spread":0.23629963239110086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390706712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88846827,0.009940875,0.000095132804,0.07360242,0.0011796628,0.00034001342,0.0016027485,0.000027060527,0.024743795],"genre_scores_gemma":[0.9897935,0.0007409412,0.00013265466,0.008048306,0.0005772585,0.00006966335,0.00000956248,0.000024368766,0.0006037433],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990494,0.000009779393,0.00036105668,0.0002968337,0.000026471705,0.0002564386],"domain_scores_gemma":[0.99938357,0.00017886082,0.000045932295,0.00023851306,0.000007965826,0.00014515291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003755966,0.00012203598,0.000247749,0.00005666613,0.000046933234,0.00015266894,0.00015965848,0.000043505817,0.00061757234],"category_scores_gemma":[0.000039336246,0.000100096775,0.000062825566,0.00007438589,0.000055834902,0.000068257075,0.00010557436,0.00013356598,0.0007587822],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038688362,0.00004032275,0.035946585,0.000113613896,0.0005960608,0.00007437804,0.00531373,0.0002952611,0.0000075518265,0.63022166,0.31109393,0.01591001],"study_design_scores_gemma":[0.00040862025,0.000010671975,0.027418066,0.000017110799,0.000011309757,0.000002090267,0.000042858705,0.0065293307,0.00002775893,0.09520809,0.87011313,0.0002109507],"about_ca_topic_score_codex":0.39725444,"about_ca_topic_score_gemma":0.21935569,"teacher_disagreement_score":0.5590192,"about_ca_system_score_codex":0.000104934865,"about_ca_system_score_gemma":0.000084142834,"threshold_uncertainty_score":0.9752863},"labels":[],"label_agreement":null},{"id":"W4390718475","doi":"10.1136/bmj.q6","title":"“Safer supply” alternatives to toxic unregulated drug markets","year":2024,"lang":"en","type":"editorial","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Medical Research Council","keywords":"SAFER; Drug; Risk analysis (engineering); Computer science; Business; Pharmacology; Medicine; Data science; Computer security","score_opus":0.03137083908377133,"score_gpt":0.32380174966286995,"score_spread":0.29243091057909865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390718475","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015630276,0.003132198,0.000022788796,0.015325722,0.8497113,0.0006802255,0.006436389,0.00011582848,0.12301253],"genre_scores_gemma":[0.008117128,0.0012928467,0.00019933941,0.0018250509,0.89361924,0.00019748863,0.00046939816,0.00021291396,0.09406657],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970065,0.0000333657,0.001201691,0.0010213751,0.00009369141,0.0006433826],"domain_scores_gemma":[0.9981788,0.00039122225,0.00034669784,0.0006505542,0.0000531107,0.00037963915],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0011045502,0.000478187,0.00093488797,0.0006070603,0.00007258852,0.00037932396,0.00074774044,0.0005320042,0.0029110273],"category_scores_gemma":[0.0006116797,0.000559717,0.00033970148,0.00029037346,0.00006163576,0.0001572912,0.000392466,0.0008502051,0.019202854],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053743126,0.000038554637,0.00003517387,0.000117292446,0.00023913273,0.000023464314,0.00020509881,0.000021514395,0.0000029713974,0.016784744,0.98180985,0.0006684571],"study_design_scores_gemma":[0.000388243,0.000027998527,0.00018333507,0.00011038972,0.000021258604,0.0000015819988,0.000005593606,0.00079305685,0.000041076164,0.026677601,0.9710645,0.0006853716],"about_ca_topic_score_codex":0.0002657612,"about_ca_topic_score_gemma":0.000052694973,"teacher_disagreement_score":0.043907974,"about_ca_system_score_codex":0.00038970992,"about_ca_system_score_gemma":0.00015269386,"threshold_uncertainty_score":0.9996854},"labels":[],"label_agreement":null},{"id":"W4391174480","doi":"10.1001/jama.2023.27966","title":"FDA Approves First State Program to Import Rx Drugs From Canada","year":2024,"lang":"en","type":"article","venue":"JAMA","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; State (computer science); Family medicine; Pharmacology","score_opus":0.026196290745270495,"score_gpt":0.2634359670214808,"score_spread":0.23723967627621032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391174480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84857774,0.0035791679,0.00012844951,0.054956947,0.0022445158,0.0006421073,0.0039505963,0.00019656772,0.08572392],"genre_scores_gemma":[0.9884622,0.00025686907,0.0003545952,0.0078061316,0.00050112524,0.00010589654,0.000059954233,0.00004220571,0.0024109916],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986456,0.0000043191067,0.00047065484,0.00045539622,0.000030331401,0.00039370605],"domain_scores_gemma":[0.99927765,0.00008277172,0.00006813877,0.00026672985,0.00001154202,0.0002931841],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019786364,0.00015915542,0.00028092408,0.00010473729,0.000064052045,0.0003509044,0.0002489779,0.00006013633,0.0006224962],"category_scores_gemma":[0.000047637484,0.00017992029,0.00008447426,0.00019749645,0.000022857968,0.00017305689,0.00009776081,0.00019729936,0.001085676],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053787724,0.00015807818,0.012070874,0.0001802182,0.0003807768,0.00008410882,0.0021363287,0.00031465833,0.000017791888,0.08469791,0.51215136,0.3877541],"study_design_scores_gemma":[0.00020932592,0.000027240974,0.0049081123,0.000017619419,0.0000039413862,9.567614e-7,0.000019381201,0.011244544,0.00011174027,0.016302321,0.9669094,0.0002453937],"about_ca_topic_score_codex":0.45279205,"about_ca_topic_score_gemma":0.13898152,"teacher_disagreement_score":0.45475805,"about_ca_system_score_codex":0.00028297622,"about_ca_system_score_gemma":0.00016908831,"threshold_uncertainty_score":0.9996921},"labels":[],"label_agreement":null},{"id":"W4391331128","doi":"10.61096/ijamscr.v11.iss4.2023.405-412","title":"Planning and execution of dossier compilation of countries Germany, Canada and Australia","year":2023,"lang":"en","type":"article","venue":"International Journal of Allied Medical Sciences and Clinical Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science; Library science; Computer science","score_opus":0.4447478001565659,"score_gpt":0.5472880720657594,"score_spread":0.10254027190919346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391331128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890824,0.0005442509,0.000047437254,0.009416113,0.0002590326,0.000029615845,0.00004042045,8.33222e-7,0.00057992234],"genre_scores_gemma":[0.99536693,0.004205933,0.000057183577,0.00017596422,0.0001430491,3.4712897e-7,0.000001173259,0.000001657115,0.000047733767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986295,0.00003353276,0.00076683756,0.00011994988,0.00031096695,0.00013918425],"domain_scores_gemma":[0.9982814,0.0010701641,0.00029122303,0.00003189216,0.000116733805,0.00020853862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005413765,0.000039083086,0.00021236448,0.00020895907,0.000049603423,0.000038053135,0.00022101884,0.000058187998,0.00019038048],"category_scores_gemma":[0.0011246356,0.000032926087,0.000028140419,0.00014903749,0.00090295635,0.000108530454,0.000114908755,0.00023364347,0.0000025378213],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012604911,0.00005427223,0.817425,0.000036444115,0.00011421789,0.000025625315,0.00020846676,0.000055068336,0.00002289306,0.17120035,0.0028922432,0.007839352],"study_design_scores_gemma":[0.0008686625,0.0002818701,0.92525214,0.00011226442,0.0000042750335,0.000019974119,0.000116278636,0.011450518,0.0000451284,0.037197866,0.024582596,0.000068398374],"about_ca_topic_score_codex":0.010847442,"about_ca_topic_score_gemma":0.00296025,"teacher_disagreement_score":0.13400248,"about_ca_system_score_codex":0.000029416618,"about_ca_system_score_gemma":0.00028047353,"threshold_uncertainty_score":0.9957394},"labels":[],"label_agreement":null},{"id":"W4391339917","doi":"10.1200/jco.23.02259","title":"Progression-Free Survival Gain: A Reliable Primary End Point for Drug Registration That Can Accelerate Patient Access to Urgently Needed Therapies","year":2024,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Ottawa Hospital; University of Toronto; University of Calgary; University of Ottawa","funders":"","keywords":"Medicine; Clinical endpoint; Expanded access; Drug; Progression-free survival; Oncology; End point; Surrogate endpoint; Intensive care medicine; Medical physics; Internal medicine; Overall survival; Clinical trial; Pharmacology","score_opus":0.2902808959613531,"score_gpt":0.4476403663145367,"score_spread":0.1573594703531836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391339917","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007521292,0.0021972007,0.00031028336,0.9630408,0.011114844,0.0009386962,0.0007339258,0.000021374064,0.014121584],"genre_scores_gemma":[0.010883231,0.0030406662,0.0033398964,0.9692978,0.011580416,0.00013164384,0.000113230824,0.00012752564,0.001485553],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9934818,0.00018325297,0.0048320824,0.00066446717,0.00019121917,0.0006471626],"domain_scores_gemma":[0.9910074,0.0025512408,0.005190568,0.0005610071,0.00023829695,0.00045152762],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.005885046,0.00041804538,0.00274521,0.00049094675,0.000104081184,0.0004036455,0.0012939079,0.0011168587,0.0004126026],"category_scores_gemma":[0.0018071784,0.00036537088,0.0011411449,0.0001873963,0.00015270636,0.0003729267,0.00040437718,0.0028214678,0.00008282844],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007022697,0.00026690142,0.00060034654,0.00020147415,0.00056076556,0.00015849395,0.00023311765,0.00003495783,0.0000013666545,0.0040856567,0.978364,0.014790656],"study_design_scores_gemma":[0.0017209814,0.0015941549,0.0004505709,0.00012580505,0.00008817374,0.000022749868,0.00004570133,0.0001561988,0.000027055572,0.08920828,0.9061883,0.00037202524],"about_ca_topic_score_codex":0.00014740504,"about_ca_topic_score_gemma":0.000101661964,"teacher_disagreement_score":0.08512263,"about_ca_system_score_codex":0.00062702835,"about_ca_system_score_gemma":0.0013156045,"threshold_uncertainty_score":0.99987984},"labels":[],"label_agreement":null},{"id":"W4391391486","doi":"10.1177/17151635241228274","title":"Navigating rare disease medications: A pharmacist’s primer","year":2024,"lang":"fr","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Pharmacist; Primer (cosmetics); Disease; Family medicine; Pharmacy; Internal medicine; Chemistry","score_opus":0.06664439356504911,"score_gpt":0.3193632350511423,"score_spread":0.25271884148609314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391391486","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17647707,0.67235386,0.00097051554,0.03717993,0.067351654,0.0014662497,0.032197714,0.0001851295,0.011817869],"genre_scores_gemma":[0.8021866,0.16604888,0.00029823123,0.016626975,0.0067211716,0.00007446955,0.000219639,0.00023673032,0.0075872834],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99344355,0.00021003876,0.0022196078,0.0012792,0.00026079634,0.002586825],"domain_scores_gemma":[0.9902776,0.00035588432,0.0006200462,0.0005617322,0.0003313507,0.00785338],"candidate_categories":["metaepi_narrow","sts","scholarly_communication","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0018436356,0.0008944294,0.0009571453,0.0005927035,0.0015064967,0.0015752148,0.0014247649,0.00021318205,0.017047644],"category_scores_gemma":[0.00039559422,0.0012286311,0.000652686,0.0012810826,0.00072528014,0.0015473498,0.00014805367,0.003275044,0.0017858257],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000104704566,0.00017296887,0.0038414274,0.00263861,0.0019123947,0.12331208,0.0030319567,0.002282398,0.00007479354,0.015312223,0.5002444,0.3470721],"study_design_scores_gemma":[0.0011962808,0.00002146633,0.000019134455,0.00029802148,0.00035373587,0.107009195,0.0000093170065,0.105999574,0.00011883506,0.0030455603,0.78076786,0.0011610113],"about_ca_topic_score_codex":0.03564143,"about_ca_topic_score_gemma":0.020888075,"teacher_disagreement_score":0.62570953,"about_ca_system_score_codex":0.008418778,"about_ca_system_score_gemma":0.009130169,"threshold_uncertainty_score":0.9997934},"labels":[],"label_agreement":null},{"id":"W4391925966","doi":"10.1186/s12962-024-00521-8","title":"Out-of-pocket pharmaceutical expenditure and its determinants among Iranian households with elderly members: a double-hurdle model","year":2024,"lang":"en","type":"article","venue":"Cost Effectiveness and Resource Allocation","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Regina","funders":"Iran University of Medical Sciences","keywords":"Socioeconomic status; Medicine; Residence; Household income; Environmental health; Population; Socioeconomics; Demographic economics; Economics; Geography","score_opus":0.07406317561500915,"score_gpt":0.3215947664437094,"score_spread":0.24753159082870024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391925966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880493,0.006964221,0.0020888036,0.00030084324,0.00012331914,0.0006237078,0.0000822955,0.000046259556,0.0017212514],"genre_scores_gemma":[0.9988446,0.00062358537,0.00003632399,0.00016667109,0.00008457721,0.000111222624,0.000011366835,0.000042625692,0.00007900963],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99882543,0.000035732042,0.00033150872,0.00049913605,0.000040756593,0.00026744677],"domain_scores_gemma":[0.99938107,0.0001429818,0.00010910046,0.00016066332,0.00002222876,0.00018396215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005204463,0.00021181068,0.00038386523,0.00015059285,0.00010823752,0.00013999695,0.00011233095,0.0001494968,0.000027982434],"category_scores_gemma":[0.000012615595,0.00019660078,0.000057140838,0.00012477725,0.00013205479,0.00030325173,0.000057243295,0.00021331232,0.0000143848065],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069283857,0.0016065288,0.16102281,0.016218748,0.0025452394,0.0001966936,0.027820174,0.038618147,0.012537536,0.4309167,0.0013633468,0.3002257],"study_design_scores_gemma":[0.0042319275,0.0003665675,0.02108949,0.0006207837,0.00012085729,0.000031550382,0.00013152449,0.9220597,0.009681467,0.002932783,0.03793913,0.00079418614],"about_ca_topic_score_codex":0.000046729667,"about_ca_topic_score_gemma":0.000024532705,"teacher_disagreement_score":0.88344157,"about_ca_system_score_codex":0.00006196442,"about_ca_system_score_gemma":0.000026611335,"threshold_uncertainty_score":0.8017147},"labels":[],"label_agreement":null},{"id":"W4391943901","doi":"10.1186/s12992-024-01019-x","title":"Pull me – push you? The disparate financing mechanisms of drug research in global health","year":2024,"lang":"en","type":"article","venue":"Globalization and Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Canadian Institutes of Health Research","keywords":"Incentive; Economics; Health services research; Public economics; Business; Poverty; Pharmaceutical industry; Health care; Medicine; Economic growth; Market economy; Pharmacology","score_opus":0.14091040608390143,"score_gpt":0.4275877422889962,"score_spread":0.2866773362050948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391943901","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12294668,0.1637418,0.054811317,0.5784699,0.003509461,0.0030075717,0.0040054405,0.00019259776,0.069315284],"genre_scores_gemma":[0.98457664,0.009396199,0.00012110657,0.005639539,0.00006572841,0.0000134669945,0.000026125606,0.0000103336515,0.00015085102],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9984109,0.000080628095,0.0006906017,0.00032473158,0.00005078344,0.00044239368],"domain_scores_gemma":[0.9994601,0.000037672693,0.00015017037,0.00017763302,0.00001950308,0.00015490587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003389242,0.00009824484,0.0003194763,0.00015298417,0.00016695049,0.00010604951,0.00015362982,0.00004702777,0.00004715558],"category_scores_gemma":[0.000022410431,0.000091496535,0.000041098992,0.000747025,0.000067245805,0.00011946608,0.000076847005,0.0001683162,0.00006062482],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000004578407,0.00002474391,0.0038808964,0.00019899615,0.0000067940064,5.256877e-7,0.0004573999,0.00015038085,3.913978e-7,0.9840857,0.007536409,0.0036532201],"study_design_scores_gemma":[0.000420866,0.000072966446,0.027227093,0.00015191332,0.0000013013731,0.0000061590845,0.00022471558,0.048736792,0.000007250606,0.7878523,0.13515373,0.00014494763],"about_ca_topic_score_codex":0.005830992,"about_ca_topic_score_gemma":0.0011788381,"teacher_disagreement_score":0.86162996,"about_ca_system_score_codex":0.0004938364,"about_ca_system_score_gemma":0.00029398233,"threshold_uncertainty_score":0.88147545},"labels":[],"label_agreement":null},{"id":"W4392012970","doi":"10.46747/cfp.700285","title":"How to navigate drug shortages with patients in primary care","year":2024,"lang":"en","type":"article","venue":"Canadian Family Physician","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"South Health Campus; Alberta Health Services","funders":"","keywords":"Economic shortage; Primary care; Drug; Primary (astronomy); Medicine; Business; Intensive care medicine; Pharmacology; Family medicine; Philosophy; Government (linguistics)","score_opus":0.019744556382947236,"score_gpt":0.22161957527016152,"score_spread":0.2018750188872143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392012970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.71592367,0.0026825413,0.000008817028,0.0030405181,0.00042713623,0.00033559708,0.001589825,0.000030525505,0.27596137],"genre_scores_gemma":[0.93897706,0.000055976547,0.000048252536,0.060084812,0.00016414544,0.0000379914,0.00013351649,0.000046797264,0.00045141616],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99880236,0.0000063974353,0.00021891035,0.00044056325,0.000024884901,0.00050685334],"domain_scores_gemma":[0.99923575,0.000015924761,0.00003358595,0.00022973567,0.000019040463,0.00046596018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006698465,0.00017765301,0.00028350877,0.0004070517,0.000057705634,0.00027430174,0.00022015725,0.000048864134,0.0000037635602],"category_scores_gemma":[0.0000029964876,0.00020291258,0.00006306614,0.00039610598,0.00003478571,0.00025648205,0.000026237401,0.00019959292,0.0005043383],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000079244426,0.00021896306,0.15444139,0.0012801307,0.00042454014,0.0003993512,0.008438679,0.0010094661,0.00012719889,0.3683915,0.1517985,0.31339103],"study_design_scores_gemma":[0.00029839532,0.00004678363,0.11338478,0.00011196252,0.0000050913795,1.0568567e-7,0.00024181149,0.00025879318,0.00003217303,0.0023477157,0.8828284,0.000443948],"about_ca_topic_score_codex":0.012487174,"about_ca_topic_score_gemma":0.024337554,"teacher_disagreement_score":0.7310299,"about_ca_system_score_codex":0.00090054167,"about_ca_system_score_gemma":0.00018599672,"threshold_uncertainty_score":0.99408877},"labels":[],"label_agreement":null},{"id":"W4392140350","doi":"","title":"Prescription and Non-Prescription Drug Classification Systems Across Countries: Lessons Learned for Thailand","year":2020,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Drug; Prescription drug; Medicine; Pharmacology","score_opus":0.499759900350272,"score_gpt":0.5469659205551132,"score_spread":0.04720602020484116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392140350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9481929,0.0243199,0.0074424436,0.009085945,0.0013195887,0.0016159107,0.0022788558,0.000049892682,0.0056945905],"genre_scores_gemma":[0.97445595,0.023361383,0.000063555664,0.0012201066,0.00033064687,0.0001252303,0.00004709736,0.000047669517,0.00034834826],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977603,0.000052670457,0.0011236086,0.00058364164,0.00008366886,0.0003961369],"domain_scores_gemma":[0.9979075,0.00018133128,0.0011525056,0.00029556002,0.00012672339,0.00033635108],"candidate_categories":["metaepi_narrow","scholarly_communication"],"consensus_categories":[],"category_scores_codex":[0.0014250422,0.0002491679,0.0007854318,0.00024575758,0.00031659822,0.0022040857,0.001036585,0.0001346064,0.00061416905],"category_scores_gemma":[0.0002754429,0.00027777077,0.00014318565,0.00028984572,0.00011685182,0.0021920477,0.0003454227,0.00026693923,0.000057277684],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012989742,0.00032556138,0.69972056,0.001495206,0.00062656566,0.0000048078236,0.0040844134,0.0015327181,0.02601328,0.06089099,0.19658385,0.007423088],"study_design_scores_gemma":[0.002475757,0.000031366682,0.39222896,0.00018419123,0.00006202932,0.000004366554,0.000413593,0.07577522,0.0018482625,0.02975692,0.49642387,0.0007954527],"about_ca_topic_score_codex":0.0007752135,"about_ca_topic_score_gemma":0.00003218743,"teacher_disagreement_score":0.30749157,"about_ca_system_score_codex":0.0001196624,"about_ca_system_score_gemma":0.00004952736,"threshold_uncertainty_score":0.99996746},"labels":[],"label_agreement":null},{"id":"W4392580932","doi":"10.1007/s43441-024-00624-7","title":"Industry Perceptions and Experiences with the Access Consortium New Active Substance Work-Sharing Initiative (NASWSI): Survey Results and Recommendations","year":2024,"lang":"en","type":"article","venue":"Therapeutic Innovation & Regulatory Science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Innovative Medicines Canada","funders":"Association of the British Pharmaceutical Industry; State Key Laboratory of Synthetical Automation for Process Industries; Innovative Medicines Canada","keywords":"Harmonization; Business; Market access; Work (physics); Transparency (behavior); Flexibility (engineering); Pharmacy; Public relations; Marketing; Medicine; Political science; Family medicine; Management; Engineering","score_opus":0.1849746633734487,"score_gpt":0.3627485352672676,"score_spread":0.17777387189381888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392580932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820434,0.0005567209,0.0010160876,0.012885876,0.00024897244,0.00022241661,0.000103265076,0.00004009723,0.0028832033],"genre_scores_gemma":[0.99677414,0.00008560465,0.00007774564,0.0025702806,0.00006755598,0.000034690584,0.00001347451,0.00001248932,0.00036401674],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99862754,0.000028280394,0.00043756192,0.0005654234,0.000064966036,0.00027623324],"domain_scores_gemma":[0.99910676,0.00021878173,0.00022103975,0.00026147775,0.00010326873,0.00008869156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017063302,0.00014812169,0.00017306869,0.00037747715,0.0005275941,0.00070147024,0.00036301796,0.00010449993,0.00014573944],"category_scores_gemma":[0.00006875587,0.00012218981,0.000014017991,0.0025045136,0.001092835,0.0014252,0.0000942462,0.0004717341,0.000016017131],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021322974,0.000053841213,0.05733602,0.000024105191,0.00013878323,0.0000016544573,0.070271716,0.00007236706,0.00023619388,0.82076824,0.0023151806,0.048568685],"study_design_scores_gemma":[0.0006103982,0.000072545285,0.9507757,0.00007049919,0.0000112826265,0.000012412456,0.006435027,0.004132026,0.0005786809,0.024305455,0.012517761,0.0004782276],"about_ca_topic_score_codex":0.00006887686,"about_ca_topic_score_gemma":0.00005580958,"teacher_disagreement_score":0.89343965,"about_ca_system_score_codex":0.00011294875,"about_ca_system_score_gemma":0.00020197112,"threshold_uncertainty_score":0.6764294},"labels":[],"label_agreement":null},{"id":"W4392598004","doi":"10.18192/aporia.v16i1.7104","title":"Plaidoyer pour une « anti-préparation » consciente à la maternité","year":2024,"lang":"fr","type":"article","venue":"Aporia","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Humanities; Philosophy","score_opus":0.05900861195264472,"score_gpt":0.31842066510261413,"score_spread":0.2594120531499694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392598004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4784789,0.047969613,0.0018899484,0.10163894,0.028283965,0.0004004482,0.0023267022,0.00016059243,0.3388509],"genre_scores_gemma":[0.91844034,0.005847779,0.0002896475,0.0022207862,0.0014411199,0.00001784871,0.00006395397,0.000060046073,0.07161846],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981335,0.00003465644,0.00069919735,0.0005767038,0.00003421421,0.00052172976],"domain_scores_gemma":[0.9991616,0.0001928401,0.00015068536,0.00028723356,0.000021818998,0.00018583912],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00069732836,0.00024269817,0.0004074184,0.00026226256,0.00010274259,0.0006148814,0.00023526492,0.00025833113,0.0036436333],"category_scores_gemma":[0.00004684485,0.00031617694,0.00019259591,0.00037796242,0.00018564568,0.00047019115,0.000091991904,0.00035962576,0.021569692],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008404113,0.00007513714,0.0033196032,0.0001628597,0.00012524854,0.000049400092,0.00034364755,0.00009526449,0.00012994146,0.88361967,0.1071777,0.0048931534],"study_design_scores_gemma":[0.00037352394,0.00002466959,0.0031073245,0.00008804121,0.000028533794,0.00004045452,0.000020220421,0.03953248,0.000331731,0.08007348,0.8760499,0.00032966956],"about_ca_topic_score_codex":0.00041688402,"about_ca_topic_score_gemma":0.000031164655,"teacher_disagreement_score":0.8035462,"about_ca_system_score_codex":0.00015502448,"about_ca_system_score_gemma":0.00010369664,"threshold_uncertainty_score":0.999929},"labels":[],"label_agreement":null},{"id":"W4392739550","doi":"10.1007/s40273-024-01369-9","title":"Reply to Comment on “A Framework for Fair Pricing of Medicines”","year":2024,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Quality of Life Research; Health economics; Health administration; Public health; Business; Actuarial science; Economics; Medicine; Nursing","score_opus":0.08685281343077769,"score_gpt":0.36353599715388063,"score_spread":0.27668318372310297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392739550","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002356549,0.0012262606,0.003935648,0.9676817,0.0054554595,0.0013910014,0.004678685,0.00008536698,0.015310205],"genre_scores_gemma":[0.0016268154,0.0005044477,0.0034438511,0.98512614,0.0074531804,0.00033930255,0.00022882706,0.0002471453,0.0010302695],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959355,0.00002075817,0.00198441,0.001191889,0.000048959144,0.00081848167],"domain_scores_gemma":[0.99704367,0.00094163214,0.00088081346,0.00081420207,0.00004607522,0.00027359146],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00091832946,0.00061905844,0.0015584382,0.00082881976,0.00008545317,0.00012555037,0.0008963132,0.0005407555,0.00093017734],"category_scores_gemma":[0.00020150347,0.0007417631,0.00060906826,0.00015478149,0.000085049694,0.00010663896,0.0002318502,0.001700598,0.0024753017],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006531991,0.000045863704,0.000023561533,0.0006185335,0.000407268,0.0000087354,0.0002953188,0.0001961975,0.000004087111,0.13133317,0.8662455,0.00075646443],"study_design_scores_gemma":[0.0005164495,0.00016466068,0.0000024534838,0.00015813629,0.00008379154,0.000002796269,0.000007990874,0.0028010819,0.00045208607,0.19281185,0.8024205,0.00057817507],"about_ca_topic_score_codex":0.00013254482,"about_ca_topic_score_gemma":0.0000011919493,"teacher_disagreement_score":0.06382495,"about_ca_system_score_codex":0.00055629096,"about_ca_system_score_gemma":0.00008968459,"threshold_uncertainty_score":0.99998313},"labels":[],"label_agreement":null},{"id":"W4392763898","doi":"10.54194/ryjn9568","title":"Patented Medicines Expenditure in Canada 1990–2022 8TH Edition","year":2024,"lang":"en","type":"article","venue":"Canadian Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Attribution; Access to medicines; Operations research; Computer science; Library science; Medicine; Engineering; Psychology; Nursing; Public health; Social psychology","score_opus":0.05509737628602205,"score_gpt":0.31531164264622763,"score_spread":0.26021426636020556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392763898","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08484011,0.034305062,0.0000380297,0.80077404,0.008600371,0.0009556061,0.0112284925,0.00009538927,0.05916292],"genre_scores_gemma":[0.9155347,0.0016972456,0.000009231608,0.08041396,0.0017571624,0.000037401263,0.00019304057,0.000034108016,0.00032316978],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99802846,0.000022720107,0.0006605782,0.00037744516,0.000033432836,0.00087734405],"domain_scores_gemma":[0.9984743,0.000055451346,0.00009265959,0.00021673807,0.0000089049,0.0011519243],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003600085,0.00016673564,0.00037014045,0.0010087875,0.000104470484,0.000052276962,0.00019685178,0.000082316335,0.0011424193],"category_scores_gemma":[0.00008433217,0.00020141805,0.000051591134,0.00055884046,0.00003121899,0.00013426074,0.000019109491,0.00035683293,0.00035409787],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000003409853,0.000008841905,0.0062628873,0.0001822453,0.000024780373,0.00008648948,0.0005824554,0.000057360514,0.0000010803243,0.35153067,0.6337143,0.007545454],"study_design_scores_gemma":[0.00023753589,0.000020967189,0.014456222,0.00005433703,0.0000010529285,0.000011534376,0.00007229211,0.003575219,0.0000034069105,0.012792416,0.96857285,0.00020217434],"about_ca_topic_score_codex":0.99965435,"about_ca_topic_score_gemma":0.9995365,"teacher_disagreement_score":0.83069456,"about_ca_system_score_codex":0.0069174394,"about_ca_system_score_gemma":0.009983166,"threshold_uncertainty_score":0.9997707},"labels":[],"label_agreement":null},{"id":"W4392778751","doi":"10.1017/jme.2024.20","title":"Aducanumab, Accelerated Approvals &amp; the Agency: Why the FDA Needs Structural Reform","year":2023,"lang":"en","type":"article","venue":"The Journal of Law Medicine & Ethics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Canadian Institutes of Health Research","keywords":"Agency (philosophy); Food and drug administration; Hard core; Drug approval; Public administration; Political science; Business; Drug; Medicine; Pharmacology; Sociology; Risk analysis (engineering)","score_opus":0.3608648809949944,"score_gpt":0.4087868544371139,"score_spread":0.04792197344211946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392778751","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3376101,0.004029643,0.00012902275,0.5869254,0.0025756424,0.00029980598,0.000052707786,0.000031804255,0.068345904],"genre_scores_gemma":[0.9443243,0.004624176,0.000020824209,0.04771532,0.0018185602,0.000004430052,0.0000071980553,0.00003391647,0.0014512439],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979121,0.00018964567,0.0011849322,0.00012666467,0.00016307247,0.00042360026],"domain_scores_gemma":[0.9969035,0.0012710764,0.0009534783,0.00055312226,0.00016555689,0.0001532788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010002775,0.00020440204,0.00050039106,0.00016566554,0.00065898057,0.000078499295,0.0012828944,0.00016630116,0.0004616684],"category_scores_gemma":[0.0007954405,0.00009259426,0.0001662771,0.0006832688,0.0007890163,0.00019617725,0.00014884729,0.0023010417,0.00023302814],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010024677,0.000014035333,0.00012912505,0.000038710154,0.00024712915,0.000004225426,0.03311123,0.00043442732,0.0001243896,0.9270605,0.03750348,0.0012325227],"study_design_scores_gemma":[0.00068839104,0.00011145423,0.0010199004,0.000042379124,0.000059426136,0.00010824743,0.0011566515,0.0013229668,0.00005298857,0.23218922,0.76310533,0.00014306125],"about_ca_topic_score_codex":0.0018613361,"about_ca_topic_score_gemma":0.00031960628,"teacher_disagreement_score":0.72560185,"about_ca_system_score_codex":0.00015327153,"about_ca_system_score_gemma":0.00013242323,"threshold_uncertainty_score":0.9997009},"labels":[],"label_agreement":null},{"id":"W4392824428","doi":"10.2196/54250","title":"Development of a Consolidated Health Facility Masterlist Using Data From Polio Electronic Surveillance in the World Health Organization African Region","year":2024,"lang":"en","type":"article","venue":"JMIR Public Health and Surveillance","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"World Health Organization","keywords":"Preprint; Poliomyelitis; Public health surveillance; Environmental health; Public health; Medicine; Virology; Computer science; World Wide Web","score_opus":0.17143091647165362,"score_gpt":0.35544023634374566,"score_spread":0.18400931987209204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392824428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.754204,0.036379647,0.0068425206,0.19268055,0.00057381723,0.0020026588,0.005642466,0.00015629927,0.0015180905],"genre_scores_gemma":[0.98983145,0.0019114686,0.0002787799,0.0065190936,0.000078577774,0.000016397331,0.0013056853,0.00002204737,0.000036506142],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965026,0.00031352317,0.0014649696,0.00073048926,0.000073940515,0.00091448],"domain_scores_gemma":[0.99814266,0.00024008677,0.0005535388,0.00064218946,0.000035840698,0.00038568545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043495595,0.00021419182,0.00072982477,0.00037598202,0.00022906497,0.00021640497,0.000494872,0.00006129337,0.000052376454],"category_scores_gemma":[0.00015483343,0.00020751118,0.000030617484,0.0014231491,0.000094823394,0.00027583356,0.00015342371,0.0003550195,0.00002408573],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000099798126,0.0005218453,0.768649,0.0019611025,0.00017999037,0.00000564249,0.021783208,0.000023184926,0.000006611191,0.10889976,0.019427434,0.07844247],"study_design_scores_gemma":[0.00059671036,0.00006802108,0.14729396,0.000042614796,2.1713156e-7,0.000011059678,0.00045025852,0.015141041,4.9883437e-7,0.0011291848,0.83495116,0.0003152785],"about_ca_topic_score_codex":0.0030001167,"about_ca_topic_score_gemma":0.014894909,"teacher_disagreement_score":0.81552374,"about_ca_system_score_codex":0.00072581973,"about_ca_system_score_gemma":0.0027346031,"threshold_uncertainty_score":0.846206},"labels":[],"label_agreement":null},{"id":"W4392850706","doi":"10.38124/ijisrt/ijisrt24mar495","title":"Review on “Regulatory Approval Process of INDA, NDA and Anda in India and Foreign Countries (Us, Europe, China, Australia, Canada)”","year":2024,"lang":"en","type":"article","venue":"International Journal of Innovative Science and Research Technology (IJISRT)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"China; Business; International trade; Political science; Law","score_opus":0.06179209962641355,"score_gpt":0.3987023435406956,"score_spread":0.33691024391428204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392850706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787969,0.010184302,0.000007050121,0.0074273683,0.0001365099,0.00013356899,0.00008858951,0.0000039219767,0.0032218199],"genre_scores_gemma":[0.9915773,0.007783524,0.000053264193,0.0005001532,0.000039933246,0.000004827246,9.1865246e-7,0.0000054551956,0.000034626428],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99869525,0.000016955837,0.00057689036,0.000250059,0.00022596,0.00023489071],"domain_scores_gemma":[0.9986736,0.00007697085,0.00022685193,0.000080626916,0.0008733134,0.00006860546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036367928,0.000090747206,0.00027487657,0.0018370918,0.00007860995,0.00009008781,0.00044255258,0.00006355717,0.00001996572],"category_scores_gemma":[0.0008378057,0.00007769316,0.000011608653,0.0017634059,0.0016824872,0.0003519684,0.00016780206,0.00062304706,0.0000019383713],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041948286,0.00003126931,0.06418154,0.00033007647,0.00006022929,0.000070393995,0.00018855844,0.000002617048,0.0002017646,0.9264696,0.001212423,0.0072095394],"study_design_scores_gemma":[0.0017268223,0.0009766974,0.6264311,0.004309787,0.000008332435,0.0006990704,0.0008972782,0.0014963774,0.010643153,0.21871737,0.13356271,0.0005312603],"about_ca_topic_score_codex":0.0017164359,"about_ca_topic_score_gemma":0.00028296842,"teacher_disagreement_score":0.7077523,"about_ca_system_score_codex":0.00021789184,"about_ca_system_score_gemma":0.0007952683,"threshold_uncertainty_score":0.6199194},"labels":[],"label_agreement":null},{"id":"W4392969076","doi":"","title":"Rational Drug Use Evaluation Based on World Health Organization Core Drug Use Indicators in Ethiopia: A Systematic Review","year":2021,"lang":"en","type":"review","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Core (optical fiber); Medicine; Pharmacology; Computer science","score_opus":0.5424333075270054,"score_gpt":0.5827205667513982,"score_spread":0.0402872592243928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392969076","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00026385149,0.99240094,0.00005719735,0.00078758266,0.0006676453,0.004459046,0.00077823637,0.000019389994,0.00056610414],"genre_scores_gemma":[0.0008450094,0.9910745,0.00009033683,0.0059838137,0.00013712647,0.00038057598,0.0009171617,0.00013839852,0.00043306683],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99179703,0.0013050688,0.0050581605,0.0009665694,0.00037464206,0.00049852836],"domain_scores_gemma":[0.9891055,0.0020400058,0.007134349,0.0009627011,0.00032281218,0.00043458544],"candidate_categories":["metaepi_narrow","scholarly_communication","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.010028835,0.00067838345,0.005727247,0.004634105,0.00022485548,0.0019230061,0.0020090116,0.00023269346,0.009068806],"category_scores_gemma":[0.0058251224,0.0006894474,0.00060701626,0.005380057,0.00007075457,0.0020139166,0.00044501983,0.0012589045,0.00015630608],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030773404,0.0013086454,0.041011307,0.7553742,0.0012271188,0.000033486038,0.0003135257,0.00087967236,5.564273e-7,0.030051947,0.14187573,0.027893072],"study_design_scores_gemma":[0.00092263205,0.000007870528,0.004739793,0.5224612,0.00084937917,0.000011156468,0.000008445047,0.0017481244,0.000003229642,0.0023713915,0.46548006,0.0013967399],"about_ca_topic_score_codex":0.00061128923,"about_ca_topic_score_gemma":0.00021692493,"teacher_disagreement_score":0.32360432,"about_ca_system_score_codex":0.0016843844,"about_ca_system_score_gemma":0.0016468152,"threshold_uncertainty_score":0.99955565},"labels":[],"label_agreement":null},{"id":"W4393192621","doi":"10.1186/s12910-024-01038-8","title":"Understanding drug exceptional access programs (DEAPs) in Canada, and their associated social and political issues","year":2024,"lang":"en","type":"letter","venue":"BMC Medical Ethics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Centre Intégré de Santé et de Services Sociaux des Laurentides; Simon Fraser University; Cegep Edouard Montpetit; Université de Montréal","funders":"","keywords":"Philosophy of medicine; Politics; Raising (metalworking); Context (archaeology); Political science; Political philosophy; Sociology; Public relations; Engineering ethics; Medicine; Law; Alternative medicine","score_opus":0.37904468244966255,"score_gpt":0.38707258716987186,"score_spread":0.008027904720209311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393192621","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006831354,0.0017780426,0.00023260144,0.9840042,0.0008657603,0.00024401044,0.0009202724,0.0000371105,0.0050866613],"genre_scores_gemma":[0.3521401,0.0020798491,0.000022395765,0.6412912,0.0032106922,0.000043656873,0.0003461365,0.00008475426,0.00078121346],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99721456,0.00016723409,0.00087166956,0.00068317197,0.00022036782,0.00084297505],"domain_scores_gemma":[0.9961476,0.0031230887,0.00019735386,0.00013391527,0.000025822223,0.00037223814],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0021058475,0.00035303214,0.00082772213,0.00023135476,0.00015340466,0.00033994304,0.00038953783,0.0016673735,0.00045362065],"category_scores_gemma":[0.002179104,0.00036035315,0.00010535106,0.00018173842,0.00052281213,0.000115035786,0.00036830362,0.005815024,0.000027069062],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000075368093,0.000031907857,0.014597441,0.0013437987,0.00012401192,0.000088666835,0.0007910562,5.786892e-7,2.773767e-8,0.570274,0.41259703,0.00014394592],"study_design_scores_gemma":[0.00061846414,0.000015347887,0.002593799,0.00042747473,0.00001844527,0.000014590129,0.00023187812,0.004218877,3.7984157e-7,0.6173907,0.3738515,0.00061854866],"about_ca_topic_score_codex":0.52508146,"about_ca_topic_score_gemma":0.92126167,"teacher_disagreement_score":0.39618024,"about_ca_system_score_codex":0.0016814979,"about_ca_system_score_gemma":0.0046331584,"threshold_uncertainty_score":0.99988484},"labels":[],"label_agreement":null},{"id":"W4393227939","doi":"10.1186/s12961-024-01131-9","title":"Choosing and accessing COVID-19 treatment options: a qualitative study with patients, caregivers, and health care providers in Lebanon","year":2024,"lang":"en","type":"article","venue":"Health Research Policy and Systems","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Saskatchewan","funders":"","keywords":"Thematic analysis; Pandemic; Qualitative research; Medicine; Health care; Pharmacy; Health administration; Health services research; Public health; Public relations; Nursing; Family medicine; Coronavirus disease 2019 (COVID-19); Economic growth; Political science; Disease; Sociology; Infectious disease (medical specialty)","score_opus":0.5203466824144755,"score_gpt":0.5666672211335124,"score_spread":0.04632053871903696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393227939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82044405,0.13004693,0.000052791107,0.043474663,0.00011973605,0.0038694378,0.00065019325,0.000041992367,0.0013002075],"genre_scores_gemma":[0.98929125,0.009347839,0.0000270678,0.0008390102,0.00011645046,0.00022627483,0.00001990142,0.000022890865,0.00010930487],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.99748343,0.00054058747,0.0006229345,0.00059886946,0.00008288308,0.00067126926],"domain_scores_gemma":[0.99849546,0.00044128468,0.0001397111,0.00015990807,0.00004067487,0.00072297524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032393418,0.00017106505,0.00051140046,0.00096709,0.00055229245,0.00054161524,0.00007085251,0.000056336678,0.0000031591746],"category_scores_gemma":[0.00017712651,0.00015452343,0.000020177753,0.0004597737,0.00017660332,0.000331866,0.00007163858,0.00027268857,0.0000051642664],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013976438,0.00025544304,0.059890132,0.005215054,0.00012006648,0.000016981809,0.7587371,0.00006118212,1.540755e-7,0.15816246,0.0014168984,0.0159848],"study_design_scores_gemma":[0.009707542,0.008694576,0.02937373,0.001231861,0.000010208055,0.000035130408,0.5983928,0.0099064,6.7207856e-7,0.005449875,0.33635345,0.0008437693],"about_ca_topic_score_codex":0.12709548,"about_ca_topic_score_gemma":0.0052443,"teacher_disagreement_score":0.33493656,"about_ca_system_score_codex":0.002585192,"about_ca_system_score_gemma":0.00133006,"threshold_uncertainty_score":0.87871724},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"qualitative","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"qualitative","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W4393243232","doi":"","title":"Encouraging the Development of New Antibiotics: Are Financial Incentives the Right Way Forward? A Systematic Review and Case Study","year":2021,"lang":"en","type":"review","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Incentive; Business; Finance; Economics; Microeconomics","score_opus":0.3983765309248992,"score_gpt":0.5533024237406292,"score_spread":0.15492589281573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393243232","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017452734,0.9934155,0.000067114,0.00017116283,0.0003782873,0.0032946847,0.00019039038,0.00000633824,0.0007312961],"genre_scores_gemma":[0.006760928,0.9923341,0.000059896352,0.0004297219,0.00013202251,0.000054312,0.0000073803167,0.0000556794,0.0001659153],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99454296,0.0004205546,0.0038838806,0.00061447144,0.000138078,0.00040006693],"domain_scores_gemma":[0.99251825,0.0007848321,0.005496173,0.0008399677,0.00013170639,0.00022907577],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004840818,0.00056467636,0.0055095507,0.0004943849,0.00045231628,0.0009866552,0.0026934536,0.00013958322,0.0012543495],"category_scores_gemma":[0.00091279135,0.00035928158,0.00060552877,0.0008853521,0.00013837303,0.0005950757,0.0015517502,0.0006899498,0.00002234282],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015251965,0.0010088575,0.009060236,0.82064706,0.0062417584,0.00055352144,0.003950342,0.000006704461,8.401649e-7,0.0038956834,0.019192185,0.13542756],"study_design_scores_gemma":[0.00062989636,0.000014872759,0.0019208789,0.295123,0.0044037024,0.0005793729,0.00067756156,0.000031305528,0.000014868474,0.002826133,0.6924323,0.0013460906],"about_ca_topic_score_codex":0.00029783213,"about_ca_topic_score_gemma":0.00014290726,"teacher_disagreement_score":0.6732401,"about_ca_system_score_codex":0.00018357158,"about_ca_system_score_gemma":0.00052088714,"threshold_uncertainty_score":0.9998859},"labels":[],"label_agreement":null},{"id":"W4393246464","doi":"10.1097/01.cot.0001011416.51657.a8","title":"New Emphasis on Strategies to Increase Diversity in Clinical Trials","year":2024,"lang":"en","type":"article","venue":"Oncology Times","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Emphasis (telecommunications); Diversity (politics); Psychology; Political science; Computer science; Telecommunications; Law","score_opus":0.2980308675641286,"score_gpt":0.46849855631652465,"score_spread":0.17046768875239604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393246464","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.29300687,0.0015795984,0.0004501198,0.02443968,0.0019208143,0.00037354094,0.00024624725,0.000082552244,0.6779006],"genre_scores_gemma":[0.9832242,0.0006543243,0.0006931334,0.0072470433,0.0006852071,0.000013670655,0.0000066089938,0.000017492343,0.007458296],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982187,0.0001473677,0.0009331472,0.00041953573,0.00001654104,0.00026468872],"domain_scores_gemma":[0.99799985,0.0014241629,0.000116956195,0.00017781643,0.0000058805604,0.00027535568],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.003757862,0.00012621556,0.00073676056,0.00033455342,0.00005607165,0.000091749185,0.00023603954,0.00020278065,0.0033215627],"category_scores_gemma":[0.00078414637,0.00013359192,0.00021148894,0.00019557329,0.000043771714,0.00014978921,0.00021249441,0.00028236798,0.0067180474],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002090779,0.00016248494,0.008302009,0.00001318736,0.00012537751,0.00006646301,0.0004520175,0.00012361314,0.0000027265967,0.6608539,0.25295722,0.076731905],"study_design_scores_gemma":[0.00090100453,0.00031304703,0.009080463,0.000012452231,0.000012889248,0.0000023705716,0.000038962535,0.0012010189,0.0000091940465,0.13074373,0.85751504,0.00016983827],"about_ca_topic_score_codex":0.0011495841,"about_ca_topic_score_gemma":0.0001922725,"teacher_disagreement_score":0.6902174,"about_ca_system_score_codex":0.00028024978,"about_ca_system_score_gemma":0.00026786682,"threshold_uncertainty_score":0.9975895},"labels":[],"label_agreement":null},{"id":"W4393436566","doi":"10.1177/27551938241242602","title":"Cambodia's Imminent Graduation from Least Developed Country Status: What Will be the Impact of the TRIPS Agreement on Access to HIV and Hepatitis C Medicines in Cambodia?","year":2024,"lang":"en","type":"article","venue":"International Journal of Social Determinants of Health and Health Services","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"La Trobe University","keywords":"Graduation (instrument); TRIPS architecture; Intellectual property; Medicine; Developing country; Accession; Economic growth; Environmental health; Business; International trade; Political science; Economics; Law; Engineering","score_opus":0.07557188960058904,"score_gpt":0.4129608070347674,"score_spread":0.33738891743417837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393436566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9242306,0.008579681,0.0000075209928,0.06544725,0.00080952945,0.00023514444,0.00064360024,0.0000014248532,0.000045299796],"genre_scores_gemma":[0.9622075,0.027906302,0.000018176004,0.009593309,0.00024297892,0.0000050763383,0.000012883563,0.0000079985975,0.000005799299],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99822426,0.000051609422,0.0012299612,0.00014851057,0.0001279941,0.00021765218],"domain_scores_gemma":[0.998548,0.00013136819,0.0010042449,0.00006545736,0.000090462745,0.00016050017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009885943,0.00011435133,0.00045249166,0.00024353852,0.00009873804,0.00013401113,0.00030526027,0.00004295038,0.000026635425],"category_scores_gemma":[0.000025912186,0.00007793534,0.00007220827,0.00013105592,0.000056453424,0.00048418727,0.000082381266,0.00016792954,0.0000014162684],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029089526,0.00013668984,0.8963699,0.00061498757,0.00015943559,0.000005014951,0.020231592,0.00005055547,0.0000033833262,0.003266326,0.0016415387,0.0772297],"study_design_scores_gemma":[0.0007244178,0.00024030745,0.9846318,0.00091785425,0.000004671496,0.000005417036,0.0010224732,0.0018456479,0.000008761821,0.0036411278,0.006880473,0.000077083416],"about_ca_topic_score_codex":0.019005097,"about_ca_topic_score_gemma":0.004967182,"teacher_disagreement_score":0.08826189,"about_ca_system_score_codex":0.00033360455,"about_ca_system_score_gemma":0.00046709974,"threshold_uncertainty_score":0.98752743},"labels":[],"label_agreement":null},{"id":"W4393995435","doi":"10.1001/jamanetworkopen.2024.4246","title":"Drug Shortages Prior to and During the COVID-19 Pandemic","year":2024,"lang":"en","type":"article","venue":"JAMA Network Open","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"Health Canada; Centers for Disease Control and Prevention; Agency for Healthcare Research and Quality; National Institutes of Health; Pfizer; Soochow University; Bristol-Myers Squibb; U.S. Department of Veterans Affairs","keywords":"Supply chain; Pandemic; Medicine; Economic shortage; Pharmacy; Drug; Business; Influenza pandemic; Odds; Logistic regression; Coronavirus disease 2019 (COVID-19); Environmental health; Family medicine; Marketing; Pharmacology; Disease","score_opus":0.08931792177657857,"score_gpt":0.34445319094747623,"score_spread":0.2551352691708977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393995435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8476905,0.012582231,0.00020677852,0.09364108,0.00077274506,0.000934071,0.00020268038,0.00009106893,0.04387883],"genre_scores_gemma":[0.9654324,0.0021253412,0.00014269495,0.024942534,0.0008951684,0.00009324758,0.0000050088343,0.000030659012,0.006332944],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99878025,0.000028115292,0.00038440962,0.00042730477,0.00001764723,0.00036224962],"domain_scores_gemma":[0.9990643,0.00027653607,0.0000626412,0.0002800012,0.000004925774,0.00031156623],"candidate_categories":["scholarly_communication"],"consensus_categories":[],"category_scores_codex":[0.0015564446,0.00013449174,0.00026644304,0.00006879041,0.00026263532,0.001129641,0.00057682546,0.00006218444,0.00064706756],"category_scores_gemma":[0.00010653671,0.000117039446,0.00005786349,0.00023238937,0.0000488385,0.0002803628,0.00061721745,0.00025200783,0.00066326925],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010794153,0.000022447579,0.29380682,0.00014961617,0.0002049446,0.000026853939,0.0024333964,0.0033656745,0.0000086611935,0.44922873,0.24019098,0.010453907],"study_design_scores_gemma":[0.00026840076,0.000009730706,0.03304416,0.000020403793,0.0000057914444,0.000017950542,0.000024815434,0.004027363,0.0000024181893,0.030574411,0.9318165,0.0001880388],"about_ca_topic_score_codex":0.00039032887,"about_ca_topic_score_gemma":0.00026069523,"teacher_disagreement_score":0.69162554,"about_ca_system_score_codex":0.0001372765,"about_ca_system_score_gemma":0.00004419482,"threshold_uncertainty_score":0.99990726},"labels":[],"label_agreement":null},{"id":"W4394013687","doi":"10.1016/j.clcc.2024.04.001","title":"Appropriate Relevancy and Reliability of Real-World Data for the Utilization of Regulatory Submission","year":2024,"lang":"en","type":"article","venue":"Clinical Colorectal Cancer","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Canada; Eisai; Chugai Pharmaceutical; Ministry of Health, Labour and Welfare","keywords":"Reliability (semiconductor); Medicine","score_opus":0.2529162556889884,"score_gpt":0.44079737142532893,"score_spread":0.18788111573634053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394013687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97792107,0.01034183,0.0006760594,0.0035537917,0.0013922913,0.00064410485,0.0020630716,0.000028064367,0.0033796995],"genre_scores_gemma":[0.9873625,0.011757615,0.0002142553,0.00015623994,0.00023500624,0.000033291013,0.00002319373,0.000017739349,0.00020017453],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.998408,0.000027224834,0.0009642079,0.0004342881,0.000025503628,0.00014076523],"domain_scores_gemma":[0.9979222,0.0012162498,0.00030474414,0.0004418928,0.000042854328,0.00007206464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020587668,0.00008968511,0.00039902303,0.00006107527,0.000042265958,0.000020357202,0.0002796586,0.00007837952,0.000091964714],"category_scores_gemma":[0.000729209,0.000071764465,0.00010962968,0.00019994492,0.000352284,0.00012697706,0.00017550334,0.00015809738,0.0000051703882],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015082251,0.0003199683,0.2745666,0.0017621706,0.0003242945,7.017873e-7,0.00025987424,0.00022892412,0.00015307918,0.5146347,0.019885149,0.1863563],"study_design_scores_gemma":[0.0006963357,0.00024870035,0.38104925,0.000103395454,0.00007490963,3.669198e-7,0.000012870811,0.2282109,0.0005869968,0.09380127,0.29499438,0.00022062213],"about_ca_topic_score_codex":0.0003018165,"about_ca_topic_score_gemma":0.00014743913,"teacher_disagreement_score":0.42083347,"about_ca_system_score_codex":0.000044355642,"about_ca_system_score_gemma":0.000086658656,"threshold_uncertainty_score":0.292647},"labels":[],"label_agreement":null},{"id":"W4394063741","doi":"10.1016/j.healthpol.2024.105064","title":"The impact of changing the reference countries on the list prices for patented medicines in Canada: A policy analysis","year":2024,"lang":"en","type":"article","venue":"Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; University of British Columbia; University of Toronto; Providence Health Care","funders":"Canadian Institutes of Health Research; Michael Smith Health Research BC","keywords":"Product (mathematics); Reference price; Access to medicines; Economics; Drug prices; Business; Agricultural economics; Public economics; International economics; Developing country; Economic growth","score_opus":0.11381578181981207,"score_gpt":0.4023067996559829,"score_spread":0.28849101783617087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394063741","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.27490667,0.008329091,0.0000630732,0.7068831,0.00023588841,0.00089952635,0.002384116,0.000019983805,0.0062786043],"genre_scores_gemma":[0.9812026,0.004369506,0.00000263501,0.013740903,0.0004063114,0.00009120026,0.000012386287,0.000015336473,0.00015914127],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983644,0.000041461844,0.00070400815,0.00022111452,0.00004565457,0.000623396],"domain_scores_gemma":[0.99795175,0.0012567571,0.00030911533,0.00034018888,0.000028338367,0.0001138726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015344283,0.00014862405,0.00040810488,0.0006170599,0.00032068862,0.000087407694,0.00037783512,0.000036004985,0.000046551628],"category_scores_gemma":[0.00041765076,0.000076967306,0.00016238952,0.0016879747,0.0001092884,0.000051142368,0.000050123675,0.00020542351,0.000012626006],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030185922,0.000012551528,0.004999617,0.0000922875,0.000284595,4.317106e-7,0.001754034,0.0005086863,4.4858993e-7,0.9828871,0.0075749657,0.001855087],"study_design_scores_gemma":[0.0007023742,0.00030238568,0.11492948,0.00016576906,0.000052765157,0.0000038560743,0.0013177064,0.17016514,0.000025298432,0.070601985,0.6413246,0.00040867977],"about_ca_topic_score_codex":0.94573426,"about_ca_topic_score_gemma":0.6926863,"teacher_disagreement_score":0.91228515,"about_ca_system_score_codex":0.0013630454,"about_ca_system_score_gemma":0.0027055873,"threshold_uncertainty_score":0.47995958},"labels":[],"label_agreement":null},{"id":"W4394074624","doi":"10.6084/m9.figshare.14282639","title":"Access to medication in universal health systems – perspectives and challenges","year":2021,"lang":"en","type":"dataset","venue":"Figshare","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Healthcare system; Computer science; Medicine; Health care; Political science","score_opus":0.24263575858736344,"score_gpt":0.3623568729058299,"score_spread":0.11972111431846647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394074624","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000005276709,0.07537751,1.666234e-7,0.007870937,0.0001485907,0.00028244415,0.91529113,0.000009203717,0.0010147226],"genre_scores_gemma":[0.00021440581,0.027608978,0.000003021163,0.0011688651,0.00025326235,0.00011529575,0.9705896,0.000015492713,0.000031101703],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99872833,0.0000283429,0.0004017944,0.0005469362,0.000026172827,0.00026844503],"domain_scores_gemma":[0.9990546,0.000079899764,0.00028995422,0.00032124238,0.000023130964,0.00023113332],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00016173367,0.00017474667,0.0005210306,0.00037889366,0.00004344492,0.00017097703,0.00037895053,0.00018366949,0.018830433],"category_scores_gemma":[0.00039247036,0.0002271878,0.00004247809,0.00014043543,0.0000074482987,0.00016594061,0.00029736286,0.00027229066,0.0012915843],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000024315482,0.00003128312,0.0000050940384,0.00075828773,0.000021129374,0.00000593884,0.00019322857,0.000013590452,4.971641e-9,0.0011973997,0.9974863,0.0002852989],"study_design_scores_gemma":[0.00018498763,0.000022847182,0.0009809268,0.0006638073,0.0000013793093,0.0000031151826,0.00020773572,0.00013662702,1.05345386e-7,0.000105686355,0.99747485,0.00021792791],"about_ca_topic_score_codex":0.0006095308,"about_ca_topic_score_gemma":0.0005009912,"teacher_disagreement_score":0.05529843,"about_ca_system_score_codex":0.00032733748,"about_ca_system_score_gemma":0.00013039935,"threshold_uncertainty_score":0.999486},"labels":[],"label_agreement":null},{"id":"W4394078214","doi":"10.6084/m9.figshare.5976178","title":"Additional file 3: of Pharmaceutical company spending on research and development and promotion in Canada, 2013-2016: a cohort analysis","year":2018,"lang":"en","type":"dataset","venue":"Figshare","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Promotion (chess); Business; Cohort; Marketing; Medicine; Political science; Internal medicine","score_opus":0.22865380175844738,"score_gpt":0.3596082705807672,"score_spread":0.13095446882231984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394078214","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012799741,0.00012860172,1.8041398e-8,0.00006457512,0.00002449134,0.00024304014,0.9985925,0.000002509623,0.00081627537],"genre_scores_gemma":[0.00030395127,0.00007034012,0.000039821225,0.00011724972,0.00010237102,0.0003741587,0.9988569,0.000011980951,0.00012321872],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984048,0.000029757724,0.0005969738,0.00051237707,0.00009060624,0.00036547365],"domain_scores_gemma":[0.9983779,0.00091250514,0.0002771888,0.00018402595,0.000043282234,0.00020505453],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00021947407,0.00018834807,0.00056512415,0.000757741,0.00008606459,0.000051797433,0.00021647639,0.00014696359,0.96907806],"category_scores_gemma":[0.00061159284,0.00022368466,0.000039415776,0.00031100103,0.000040463532,0.000066598994,0.00022062215,0.00044541858,0.0015324834],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010534888,0.00005866666,0.0001991011,0.00017753859,0.00018248653,0.0000065380036,0.0000061659443,0.000002422835,1.2491495e-8,0.00001766509,0.99921936,0.000119515455],"study_design_scores_gemma":[0.00015879617,0.000030196017,0.025147205,0.00050511555,0.000007892274,0.0000017426223,0.0000030983465,0.00090258394,0.0000028748711,0.00007397982,0.97295374,0.00021278857],"about_ca_topic_score_codex":0.04686927,"about_ca_topic_score_gemma":0.2518824,"teacher_disagreement_score":0.96754557,"about_ca_system_score_codex":0.00052842224,"about_ca_system_score_gemma":0.00045077957,"threshold_uncertainty_score":0.9992449},"labels":[],"label_agreement":null},{"id":"W4394134852","doi":"10.6084/m9.figshare.16836902","title":"Comparison of the registration process of the medicines control authority of Zimbabwe with Australia, Canada, Singapore, and Switzerland: benchmarking best practices","year":2021,"lang":"en","type":"dataset","venue":"Figshare","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Benchmarking; Control (management); Process (computing); Business; Best practice; Operations management; Political science; Management; Marketing; Computer science; Engineering; Law; Economics","score_opus":0.16097664669030567,"score_gpt":0.3714897834477506,"score_spread":0.2105131367574449,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394134852","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004066497,0.0011625446,1.8915706e-7,0.0007834309,0.00014126526,0.0002919017,0.9931195,0.0000010814447,0.0004335952],"genre_scores_gemma":[0.32063353,0.000044081524,0.0000057059397,0.00020272764,0.000136072,0.000025762844,0.6788729,0.000009578831,0.00006966399],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986778,0.00003500466,0.0007789227,0.00025924563,0.000093614086,0.00015542495],"domain_scores_gemma":[0.9951673,0.00023874315,0.003988434,0.00042023876,0.00012868404,0.000056562832],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018514373,0.00017498259,0.00067040976,0.000047400103,0.00007410092,0.0000288359,0.00041655826,0.00015376284,0.0032158513],"category_scores_gemma":[0.0011676161,0.00012283387,0.00006865514,0.00017705481,0.000062851985,0.00008076422,0.00007805412,0.0003616199,0.0000020340055],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021027598,0.000065295055,0.00830445,0.0017141601,0.00008798042,8.9045324e-7,0.00006118637,0.0000952482,0.000001745773,0.000075244665,0.989529,0.00004375881],"study_design_scores_gemma":[0.00053445646,0.000079707665,0.013759622,0.001986461,0.0001024144,0.0000063211696,0.00008989946,0.0005684885,0.00024605694,0.0001478084,0.9822721,0.00020667765],"about_ca_topic_score_codex":0.10262669,"about_ca_topic_score_gemma":0.31023166,"teacher_disagreement_score":0.31656703,"about_ca_system_score_codex":0.00004832903,"about_ca_system_score_gemma":0.00049196626,"threshold_uncertainty_score":0.9976953},"labels":[],"label_agreement":null},{"id":"W4394294089","doi":"10.6084/m9.figshare.5976139","title":"Additional file 1: of Pharmaceutical company spending on research and development and promotion in Canada, 2013-2016: a cohort analysis","year":2018,"lang":"en","type":"dataset","venue":"Figshare","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Promotion (chess); Cohort; Business; Medicine; Political science; Internal medicine","score_opus":0.22976055365128062,"score_gpt":0.3583567912286175,"score_spread":0.1285962375773369,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394294089","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012802902,0.00012859867,1.802756e-8,0.00006509918,0.000024492576,0.00024299351,0.9985951,0.0000025105332,0.0008131211],"genre_scores_gemma":[0.00030088416,0.00007038004,0.000039824103,0.00011727227,0.000102469814,0.00037411702,0.99885994,0.000011980839,0.00012311671],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99840486,0.000029757255,0.00059694547,0.00051235233,0.000090605274,0.0003654711],"domain_scores_gemma":[0.99837804,0.00091252814,0.00027717286,0.000183954,0.00004327965,0.00020505262],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00021951334,0.00018834374,0.0005650783,0.0007577698,0.00008605268,0.00005179948,0.00021639842,0.00014696395,0.9690912],"category_scores_gemma":[0.00061139255,0.00022368209,0.000039415416,0.0003110737,0.00004046012,0.000066598564,0.00022054763,0.00044541416,0.0015319333],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010566411,0.000058662026,0.00019571683,0.00017725845,0.00018247415,0.000006565825,0.0000061653654,0.0000024226567,1.2536253e-8,0.000017305345,0.99922216,0.0001206986],"study_design_scores_gemma":[0.0001589107,0.00003015762,0.025317585,0.00050294166,0.000007889694,0.000001725353,0.0000030952804,0.0009084167,0.0000028519564,0.00007444917,0.9727792,0.00021275511],"about_ca_topic_score_codex":0.047029536,"about_ca_topic_score_gemma":0.24995282,"teacher_disagreement_score":0.9675592,"about_ca_system_score_codex":0.0005312665,"about_ca_system_score_gemma":0.0004508052,"threshold_uncertainty_score":0.99924546},"labels":[],"label_agreement":null},{"id":"W4394294954","doi":"10.6084/m9.figshare.5976196","title":"Additional file 4: of Pharmaceutical company spending on research and development and promotion in Canada, 2013-2016: a cohort analysis","year":2018,"lang":"en","type":"dataset","venue":"Figshare","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Promotion (chess); Business; Cohort; Marketing; Medicine; Political science; Internal medicine","score_opus":0.22707546494107814,"score_gpt":0.35919722462146814,"score_spread":0.13212175968039,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394294954","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012707671,0.00012835566,1.803531e-8,0.00006540522,0.00002449258,0.0002429992,0.9985954,0.0000025096344,0.0008137558],"genre_scores_gemma":[0.0002990809,0.00007038177,0.000039819526,0.00011809858,0.00010234234,0.00037410684,0.99886036,0.000011980283,0.00012384553],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984048,0.00002978933,0.000596934,0.00051236944,0.00009060604,0.00036547938],"domain_scores_gemma":[0.9983777,0.0009128403,0.00027717577,0.00018395351,0.000043283002,0.00020505743],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002196495,0.00018834416,0.0005651099,0.00075796735,0.000086069915,0.000051797924,0.00021633472,0.00014696275,0.96936816],"category_scores_gemma":[0.00060751237,0.00022368312,0.000039416776,0.00030871123,0.00004046462,0.000066587214,0.00022053964,0.00044543904,0.0015516769],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000105346535,0.00005864052,0.00019516001,0.00017753,0.0001824783,0.0000065661143,0.000006177007,0.0000024232193,1.2512372e-8,0.00001737637,0.99922276,0.00012037037],"study_design_scores_gemma":[0.00015874804,0.000030194662,0.024914384,0.0005026753,0.0000078937655,0.000001742257,0.0000031020663,0.0009086679,0.000002874824,0.000074655414,0.9731822,0.00021283665],"about_ca_topic_score_codex":0.04658569,"about_ca_topic_score_gemma":0.24885799,"teacher_disagreement_score":0.9678165,"about_ca_system_score_codex":0.00052846276,"about_ca_system_score_gemma":0.00045072442,"threshold_uncertainty_score":0.99922574},"labels":[],"label_agreement":null},{"id":"W4394513493","doi":"10.6084/m9.figshare.5976160","title":"Additional file 2: of Pharmaceutical company spending on research and development and promotion in Canada, 2013-2016: a cohort analysis","year":2018,"lang":"en","type":"dataset","venue":"Figshare","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Promotion (chess); Cohort; Business; Medicine; Political science; Internal medicine","score_opus":0.2240532599363119,"score_gpt":0.35846030474405927,"score_spread":0.13440704480774737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394513493","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001292412,0.00012826646,1.7853312e-8,0.00006504072,0.000024479796,0.00024282586,0.9986036,0.000002509434,0.00080402574],"genre_scores_gemma":[0.00031549763,0.000070341215,0.000039511422,0.000117130774,0.00010187627,0.00037050457,0.9988508,0.000011979841,0.00012233041],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99840546,0.000029753324,0.00059670187,0.0005121827,0.00009055484,0.00036536204],"domain_scores_gemma":[0.99834925,0.0009415968,0.00027699958,0.00018387788,0.000043258104,0.00020499429],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00021946616,0.00018831163,0.0005648726,0.000757789,0.00008605155,0.00005178936,0.00021634046,0.0001469199,0.96981114],"category_scores_gemma":[0.0006382795,0.00022364754,0.000039403447,0.00031102847,0.000040457537,0.00006659552,0.00022048084,0.00044536448,0.0015263767],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010542865,0.000058339614,0.0001942509,0.00017394128,0.00018242105,0.0000065682934,0.0000061623887,0.0000023923424,1.2503829e-8,0.000017135853,0.99922323,0.00012500046],"study_design_scores_gemma":[0.00015861071,0.000029966748,0.025575323,0.0005210424,0.000007884268,0.0000017568017,0.0000030777915,0.0008994188,0.000002935563,0.00007430946,0.97251296,0.00021268667],"about_ca_topic_score_codex":0.045785125,"about_ca_topic_score_gemma":0.24876726,"teacher_disagreement_score":0.9682848,"about_ca_system_score_codex":0.00052798877,"about_ca_system_score_gemma":0.00045062933,"threshold_uncertainty_score":0.99925107},"labels":[],"label_agreement":null},{"id":"W4394726519","doi":"10.54194/qqvc3893","title":"Waiting for new medicines in Canada, Europe, and the United States","year":2024,"lang":"en","type":"article","venue":"Canadian Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Canadian Institute for Health Information","funders":"","keywords":"Political science; Business","score_opus":0.08095497517038194,"score_gpt":0.3309384742608487,"score_spread":0.24998349909046677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394726519","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04528932,0.015493473,0.000039352155,0.929202,0.000475034,0.0005531855,0.0015261796,0.000015270178,0.0074061723],"genre_scores_gemma":[0.747487,0.005563421,0.000031485288,0.24483354,0.00096730335,0.000029942055,0.00009098653,0.00004002881,0.0009562493],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987471,0.000018768014,0.000452715,0.00020747946,0.000012094029,0.0005618241],"domain_scores_gemma":[0.9987916,0.0002916601,0.00006409506,0.000114964765,0.000011155916,0.000726537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005572617,0.00010004757,0.000265715,0.0005417146,0.00011028001,0.00006630139,0.00012852188,0.000026928928,0.000050976054],"category_scores_gemma":[0.00027845494,0.000091548776,0.00002283816,0.00052944064,0.000053910986,0.000046729823,0.000015300473,0.00015236402,0.00002253705],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000051849793,7.670119e-7,0.0009507799,0.000085760505,0.000012298392,0.0000032375021,0.0007781951,0.00011849429,1.9807482e-8,0.85185593,0.14112455,0.0050647724],"study_design_scores_gemma":[0.00051934505,0.000009530213,0.0018974792,0.000028228658,0.0000012024476,0.0000037449597,0.000056963476,0.08166375,2.4549882e-7,0.030207163,0.88552445,0.00008790106],"about_ca_topic_score_codex":0.99980503,"about_ca_topic_score_gemma":0.9989921,"teacher_disagreement_score":0.8216488,"about_ca_system_score_codex":0.00087902695,"about_ca_system_score_gemma":0.00700957,"threshold_uncertainty_score":0.99861974},"labels":[],"label_agreement":null},{"id":"W4394743629","doi":"10.2139/ssrn.4789836","title":"Examining the Zero-Markup Drug Policy in China: A Structural Approach","year":2024,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bank of Canada; Government of Canada","funders":"","keywords":"Markup language; China; Drug; Zero (linguistics); Zero tolerance; Business; Political science; Computer science; Pharmacology; Medicine; XML; Linguistics; World Wide Web; Philosophy; Law","score_opus":0.028550087602585445,"score_gpt":0.2716049803296615,"score_spread":0.24305489272707606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394743629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87285256,0.041714896,0.002661567,0.014999667,0.0008092199,0.00026177874,0.000047574642,0.000057979618,0.06659475],"genre_scores_gemma":[0.99120444,0.0053468524,0.00004812539,0.00074242684,0.0008393945,0.000011417848,0.0000041218486,0.000038983457,0.001764227],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99707043,0.00004172388,0.0005984478,0.00033234555,0.00003877811,0.0019182821],"domain_scores_gemma":[0.99948084,0.0000705022,0.00013879106,0.00020262491,0.000006404419,0.00010081143],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0025837538,0.00019378024,0.00030054018,0.00044483744,0.00018244983,0.00031859352,0.00047966748,0.00007230912,0.00007703435],"category_scores_gemma":[0.0000790333,0.00015875456,0.00014784974,0.00048089493,0.00007105046,0.00031385518,0.00008099016,0.0024133932,0.00016766746],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011304463,0.000013967974,0.0037352939,0.000012874425,0.00009923673,0.0000029497241,0.00084318535,0.00031229208,0.0000050200333,0.9860014,0.0004061144,0.008556364],"study_design_scores_gemma":[0.00041087216,0.00004022715,0.00618145,0.000012601459,0.0000065426316,0.00029432628,0.00028741136,0.025356522,0.000003853051,0.9424315,0.024745401,0.0002292913],"about_ca_topic_score_codex":0.00053568673,"about_ca_topic_score_gemma":0.00017504542,"teacher_disagreement_score":0.118351884,"about_ca_system_score_codex":0.0013183744,"about_ca_system_score_gemma":0.00067287066,"threshold_uncertainty_score":0.99988806},"labels":[],"label_agreement":null},{"id":"W4394931179","doi":"10.3389/fphar.2024.1376009","title":"Generic orphan drug substitution: a critical analysis of global practices and Saudi Arabia’s perspective","year":2024,"lang":"en","type":"article","venue":"Frontiers in Pharmacology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Janssen Pharmaceuticals","keywords":"Bioequivalence; Biosimilar; Medicine; Orphan drug; Risk analysis (engineering); Generic drug; Drug; Pharmacology; Intensive care medicine; Bioavailability; Bioinformatics","score_opus":0.04399446159296608,"score_gpt":0.3600853454760251,"score_spread":0.31609088388305906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394931179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84953415,0.09701196,0.0066690873,0.018478522,0.0058294632,0.0002944994,0.0009158201,0.000057395086,0.02120909],"genre_scores_gemma":[0.99411416,0.003156798,0.001294611,0.0011235647,0.00018828748,0.000027132202,0.0000075278285,0.000009967178,0.00007793894],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99857247,0.000054179665,0.0005147615,0.00051271205,0.000025210937,0.00032069365],"domain_scores_gemma":[0.99938464,0.00014706783,0.00019130336,0.000113896655,0.0000314415,0.00013163633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049504486,0.00014723316,0.0005822164,0.0005305188,0.00004397026,0.000052604868,0.00017147798,0.00009688364,0.0004623583],"category_scores_gemma":[0.00016116575,0.00017595162,0.00014387172,0.0011401637,0.00035277748,0.00028363772,0.000072376846,0.0002205681,0.000034827674],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011560821,0.00018990441,0.14687732,0.00010464082,0.0021373916,0.000064080006,0.00069564604,0.00048933015,0.00010112038,0.82038534,0.028076997,0.00076264417],"study_design_scores_gemma":[0.0015942365,0.00011772879,0.061679095,0.00002130861,0.001681377,0.000033781977,0.00064468663,0.45916173,0.0003707728,0.22778527,0.24613996,0.0007700409],"about_ca_topic_score_codex":0.00035960157,"about_ca_topic_score_gemma":0.000053560318,"teacher_disagreement_score":0.59260005,"about_ca_system_score_codex":0.00044924172,"about_ca_system_score_gemma":0.000078499615,"threshold_uncertainty_score":0.71750987},"labels":[],"label_agreement":null},{"id":"W4394999067","doi":"10.1136/bmj.q887","title":"When will Canada have national pharmacare?","year":2024,"lang":"en","type":"editorial","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia Hospital","funders":"","keywords":"Data science; Computer science; World Wide Web; Political science","score_opus":0.04842766164545893,"score_gpt":0.32485254233805333,"score_spread":0.2764248806925944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394999067","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000018450608,0.0031534738,0.000008741054,0.012383415,0.7394701,0.00023350163,0.01503447,0.000034149827,0.22966368],"genre_scores_gemma":[0.0015981446,0.00059322634,0.00006833864,0.003800787,0.96040785,0.00010341024,0.00085354113,0.00010457359,0.032470122],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99777836,0.000013034127,0.00095039053,0.0006573195,0.00015621033,0.00044468982],"domain_scores_gemma":[0.9987248,0.00030666284,0.00036902793,0.00026898106,0.00010114701,0.00022934531],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0006671119,0.00032714373,0.0006042444,0.0002203544,0.000071364135,0.0001930163,0.00050130096,0.0004368511,0.0024853298],"category_scores_gemma":[0.0005840252,0.0004060257,0.00020048583,0.000076979675,0.00004390309,0.00014508967,0.0001744239,0.00093184377,0.001912791],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008751089,0.000013198927,0.000033006785,0.000100146186,0.00018726755,0.000018854977,0.00004103749,0.000022937651,1.9154369e-7,0.0254458,0.9739881,0.0001406894],"study_design_scores_gemma":[0.0003213082,0.000008360799,0.000006764888,0.000027312408,0.000015782052,0.0000019319418,0.0000033836925,0.001596464,0.0000038467288,0.05465121,0.9428999,0.00046375353],"about_ca_topic_score_codex":0.18185359,"about_ca_topic_score_gemma":0.10304275,"teacher_disagreement_score":0.22093774,"about_ca_system_score_codex":0.0013059783,"about_ca_system_score_gemma":0.0019258228,"threshold_uncertainty_score":0.9998392},"labels":[],"label_agreement":null},{"id":"W4395004529","doi":"10.1136/bmjgh-2024-015122","title":"Quality and safety for substances of human origins: scientific evidence and the new EU regulations","year":2024,"lang":"en","type":"article","venue":"BMJ Global Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Quality (philosophy); Scientific evidence; Human health; Public health; Business; Environmental health; Political science; Risk analysis (engineering); Engineering ethics; Medicine; Engineering; Nursing; Epistemology; Philosophy","score_opus":0.24835577733704775,"score_gpt":0.4884743484454923,"score_spread":0.24011857110844456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395004529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5244029,0.22357742,0.0065298444,0.22547963,0.0019236056,0.0029184977,0.0033648806,0.00007809012,0.011725113],"genre_scores_gemma":[0.9958522,0.0020597097,0.00038839888,0.0012667171,0.00013821958,0.000015607018,0.0000075707644,0.000005173172,0.00026640974],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9988026,0.000028480088,0.0006513359,0.00029408315,0.000024600438,0.00019890054],"domain_scores_gemma":[0.9992042,0.00026348684,0.00019604628,0.00018582595,0.000017650515,0.00013277165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002550846,0.000076363875,0.00029688,0.000044797333,0.0002575049,0.00014860292,0.00010790729,0.00003201529,0.000022737968],"category_scores_gemma":[0.00013008535,0.000065666245,0.00005946811,0.00020055346,0.00029168875,0.00016830144,0.000037573274,0.000053382802,0.0000093582075],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040020215,0.0000074831805,0.0021060135,0.0001909899,0.000014350595,5.4131515e-8,0.00023431481,0.00000774191,9.670032e-7,0.98588926,0.0052664783,0.006242353],"study_design_scores_gemma":[0.0006949118,0.000042416963,0.03870825,0.000098596145,0.0000049229334,0.0000027055953,0.00003181538,0.0060344255,0.000003780411,0.69711244,0.25716236,0.00010335602],"about_ca_topic_score_codex":0.0015003416,"about_ca_topic_score_gemma":0.000690095,"teacher_disagreement_score":0.4714493,"about_ca_system_score_codex":0.00016926561,"about_ca_system_score_gemma":0.00020359477,"threshold_uncertainty_score":0.26777917},"labels":[],"label_agreement":null},{"id":"W4395064528","doi":"10.1093/ajhp/zxae105","title":"National trends in prescription drug expenditures and projections for 2024","year":2024,"lang":"en","type":"article","venue":"American Journal of Health-System Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Drug Policy Research Network; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medical prescription; Prescription drug; Drug; Business; Medicine; Pharmacology","score_opus":0.08118293247098035,"score_gpt":0.38488180118219284,"score_spread":0.3036988687112125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395064528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46604702,0.13314003,0.008758972,0.32958162,0.017293671,0.002043169,0.0030763869,0.00019312708,0.039865993],"genre_scores_gemma":[0.9967963,0.00089490094,0.00037428536,0.0009572025,0.0005093781,0.000041903888,0.000006125973,0.000022288852,0.0003975903],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983103,0.000055108976,0.0011043854,0.00022140512,0.00004779033,0.00026096753],"domain_scores_gemma":[0.9990959,0.00012684109,0.00053308194,0.00005933683,0.000033824846,0.0001510111],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016082993,0.00012132888,0.0004650396,0.0009914243,0.00008431687,0.00010632174,0.000115479495,0.000015832731,0.00008465235],"category_scores_gemma":[0.000022537213,0.0001249154,0.0001340189,0.00028469288,0.00006031462,0.00034168083,0.000018078323,0.00023853479,0.000018562976],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003632364,0.0002850816,0.0098118335,0.0012355824,0.0004469418,0.000021508049,0.004752136,0.00066952314,0.000073584095,0.30451483,0.21949309,0.45833266],"study_design_scores_gemma":[0.0011145854,0.00017505177,0.0020138132,0.0001329442,0.000009896306,0.00018146452,0.00044130112,0.031033402,0.000022895294,0.0036550758,0.96104,0.00017955866],"about_ca_topic_score_codex":0.00064274104,"about_ca_topic_score_gemma":0.000035828452,"teacher_disagreement_score":0.7415469,"about_ca_system_score_codex":0.00044181963,"about_ca_system_score_gemma":0.00016887212,"threshold_uncertainty_score":0.5093902},"labels":[],"label_agreement":null},{"id":"W4395097595","doi":"10.2139/ssrn.4756803","title":"Implementation of Pharmaceutical Alternatives to a Toxic Drug Supply in British Columbia: A Mixed Methods Study","year":2024,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Centre for Disease Control; Providence Health Care; Simon Fraser University; University of Victoria","funders":"","keywords":"Drug; Business; Pharmaceutical sciences; Medicine; Pharmacology","score_opus":0.04697056385672035,"score_gpt":0.41170571349269874,"score_spread":0.3647351496359784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395097595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98264855,0.010830487,0.0010334983,0.0021294989,0.0012932976,0.000999364,0.00051766145,0.00002047905,0.00052719115],"genre_scores_gemma":[0.99129283,0.0067272135,0.0005782671,0.0003643699,0.00033914077,0.00013364722,0.000014474373,0.0000684584,0.0004816184],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.995371,0.00023971358,0.0017430029,0.00073205814,0.000080590224,0.0018336448],"domain_scores_gemma":[0.9987796,0.0001145272,0.00056103535,0.0002673762,0.000049694343,0.00022779561],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0069039995,0.00025597052,0.0009705171,0.0005365049,0.00007370087,0.0005665594,0.0006743338,0.00013676721,0.00053347764],"category_scores_gemma":[0.000089005734,0.00044249996,0.0003257277,0.0003358667,0.000050853785,0.00011322331,0.00083569286,0.0038824175,0.00007527603],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015082797,0.0024648723,0.3859472,0.0005574343,0.0049229627,0.00011522184,0.009483809,0.0008488676,0.00016258773,0.14358331,0.005909143,0.44585377],"study_design_scores_gemma":[0.0021413034,0.00037181232,0.03284999,0.00010888918,0.00009379787,0.00009698366,0.0063452013,0.0014733621,0.0001230074,0.9505853,0.0051892973,0.00062103185],"about_ca_topic_score_codex":0.03252202,"about_ca_topic_score_gemma":0.315541,"teacher_disagreement_score":0.807002,"about_ca_system_score_codex":0.002064655,"about_ca_system_score_gemma":0.001238997,"threshold_uncertainty_score":0.99980265},"labels":[],"label_agreement":null},{"id":"W4396529856","doi":"10.1211/pj.2024.1.310914","title":"Medicines shortages affect almost a quarter of patients, patient group report shows","year":2024,"lang":"en","type":"article","venue":"Pharmaceutical journal/˜The œpharmaceutical journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Economic shortage; Affect (linguistics); Quarter (Canadian coin); Group (periodic table); Medicine; Psychology; Geography; Chemistry; Communication; Archaeology","score_opus":0.05550231240624844,"score_gpt":0.3435196739663424,"score_spread":0.288017361560094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396529856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45277148,0.1879696,0.029884163,0.16632,0.04946234,0.0048495685,0.0020898741,0.00074830174,0.10590466],"genre_scores_gemma":[0.9776934,0.00757254,0.0003461304,0.011124011,0.0028696186,0.000034881865,0.000023221888,0.00015245868,0.00018377198],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99250734,0.0004151888,0.003972672,0.0008692338,0.00058303145,0.0016525191],"domain_scores_gemma":[0.99501014,0.0011080435,0.0010687532,0.00057674304,0.00030368366,0.0019326475],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0051514306,0.00078644895,0.0013652192,0.0007826937,0.00066884345,0.00093883625,0.0012723505,0.0003175336,0.0051981737],"category_scores_gemma":[0.000566762,0.00058874546,0.0012420018,0.0007875512,0.00078091834,0.0009597972,0.0003437504,0.0042455434,0.0006436345],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020873838,0.0046365983,0.06917723,0.0014799503,0.0070027485,0.006907891,0.0048117116,0.00044064483,0.0027588808,0.12161388,0.5959485,0.18313453],"study_design_scores_gemma":[0.0025163451,0.0005087171,0.0021810806,0.00024763588,0.00042307135,0.0069768634,0.00018839783,0.018115051,0.000854592,0.022931838,0.9441905,0.0008658945],"about_ca_topic_score_codex":0.000008282827,"about_ca_topic_score_gemma":0.0000034112743,"teacher_disagreement_score":0.5249219,"about_ca_system_score_codex":0.00048733575,"about_ca_system_score_gemma":0.00020505674,"threshold_uncertainty_score":0.9996564},"labels":[],"label_agreement":null},{"id":"W4396691844","doi":"10.1002/puh2.172","title":"A new era for African health systems: Market shaping and the African Continental Free Trade Area (AfCFTA)","year":2024,"lang":"en","type":"article","venue":"Public Health Challenges","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child, Adolescent and Family Mental Health","funders":"School of Oriental and African Studies, University of London","keywords":"Free trade; International trade; Business; Geography","score_opus":0.21764034752515427,"score_gpt":0.32911683666548014,"score_spread":0.11147648914032587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396691844","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00036712064,0.23759288,0.0016026765,0.7295711,0.00084137096,0.0010647759,0.00082152535,0.00011197405,0.028026575],"genre_scores_gemma":[0.92422974,0.06292025,0.00037158234,0.010505903,0.0010447373,0.0003303993,0.000022111202,0.00007181053,0.0005034586],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971488,0.00011159429,0.0010346378,0.00066084036,0.00005589595,0.0009882468],"domain_scores_gemma":[0.997657,0.0007294414,0.00035389248,0.00042199728,0.00001348983,0.0008241493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004399975,0.0002637043,0.0008764367,0.00030956653,0.00029866095,0.00047012191,0.0004308107,0.00009761963,0.00013220955],"category_scores_gemma":[0.00025696214,0.00023304216,0.00016927741,0.00020322955,0.0001299448,0.00026568281,0.00012263366,0.00035490564,0.000024111796],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003537501,0.000035447236,0.00003004482,0.00089760683,0.00011906296,7.2060107e-7,0.0053933193,0.0000016202702,6.867786e-8,0.85873383,0.084499426,0.050253447],"study_design_scores_gemma":[0.0016924575,0.00012549882,0.001007649,0.000074782154,0.000004078759,0.00001715549,0.0014386035,0.029496573,1.1532766e-7,0.02555595,0.94035745,0.00022971751],"about_ca_topic_score_codex":0.0014450555,"about_ca_topic_score_gemma":0.00034013033,"teacher_disagreement_score":0.92386264,"about_ca_system_score_codex":0.0003807059,"about_ca_system_score_gemma":0.0005146653,"threshold_uncertainty_score":0.95031834},"labels":[],"label_agreement":null},{"id":"W4396771372","doi":"10.1002/puh2.185","title":"COVAX and COVID‐19 Vaccine Inequity: A case study of G‐20 and African Union","year":2024,"lang":"en","type":"article","venue":"Public Health Challenges","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Alberta; Centre for Global Health Research","funders":"","keywords":"Coronavirus disease 2019 (COVID-19); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Virology; Political science; Medicine; Infectious disease (medical specialty); Internal medicine; Outbreak","score_opus":0.3107931576374252,"score_gpt":0.39251075421302517,"score_spread":0.08171759657559996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396771372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6809945,0.09192111,0.00012758255,0.22085781,0.00020826331,0.00049542607,0.0002282228,0.00006861927,0.0050984346],"genre_scores_gemma":[0.97025347,0.027702088,0.000029333924,0.0017935525,0.00011118651,0.00003386841,0.000004589693,0.000020815773,0.000051113973],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984261,0.00007464503,0.0006348953,0.00046424178,0.000027182286,0.00037297246],"domain_scores_gemma":[0.9986823,0.00021551899,0.00016814897,0.00022379195,0.000017384506,0.00069285627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024010553,0.00014674442,0.0004941638,0.0004204063,0.00011795682,0.00009685653,0.0000960994,0.000067551824,0.00007450846],"category_scores_gemma":[0.0001513007,0.00015723739,0.000028993598,0.00020509055,0.00004595069,0.00020376443,0.00015096352,0.00019204261,0.000011997452],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021565036,0.00077462074,0.00876954,0.0027607733,0.00027590574,0.00024086612,0.047962233,0.000009283679,8.6268517e-7,0.73406917,0.002422942,0.20269226],"study_design_scores_gemma":[0.0016195386,0.00088993006,0.003941007,0.000020132511,0.0000089823925,0.00053632306,0.010617831,0.007942163,3.8208012e-7,0.017310677,0.956812,0.0003010278],"about_ca_topic_score_codex":0.0023278948,"about_ca_topic_score_gemma":0.0019589672,"teacher_disagreement_score":0.95438904,"about_ca_system_score_codex":0.00013833826,"about_ca_system_score_gemma":0.0001620963,"threshold_uncertainty_score":0.6411955},"labels":[],"label_agreement":null},{"id":"W4396904214","doi":"10.3389/fmed.2024.1379966","title":"Exploring regulatory flexibility to create novel incentives to optimize drug discovery","year":2024,"lang":"en","type":"article","venue":"Frontiers in Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Western University","funders":"Genome British Columbia; Genome Canada","keywords":"Incentive; Flexibility (engineering); Business; Drug development; Set (abstract data type); Drug discovery; Drug; Face (sociological concept); Industrial organization; Public relations; Public economics; Knowledge management; Political science; Economics; Pharmacology; Medicine; Computer science; Market economy; Management","score_opus":0.14934270902731375,"score_gpt":0.31616412274447814,"score_spread":0.16682141371716439,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396904214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81475586,0.008333099,0.11213446,0.03544729,0.009577845,0.0007085242,0.0002654122,0.00011807686,0.01865947],"genre_scores_gemma":[0.9794834,0.0010525135,0.009801975,0.0051537533,0.0008737799,0.00014295187,0.000014081316,0.000053487638,0.0034240286],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99813205,0.000013695052,0.00069577614,0.00067778106,0.000047938374,0.00043277163],"domain_scores_gemma":[0.9991731,0.00005875823,0.00005721264,0.0003911684,0.00001143951,0.00030832563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011484195,0.00020242052,0.0006379341,0.0006996339,0.000047743164,0.00007581746,0.00030417935,0.00004741477,0.00013817706],"category_scores_gemma":[0.00023608837,0.00020956378,0.000083610816,0.00055115216,0.00010608726,0.0005686013,0.00014349005,0.00024724417,0.00020027104],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063166826,0.00037950854,0.05660462,0.00063111103,0.00045981625,0.00006421382,0.029864438,0.0122072855,0.00055750925,0.38104105,0.49392053,0.023638243],"study_design_scores_gemma":[0.0017520153,0.00015653402,0.0415389,0.0006491081,0.000027190488,0.0000033120998,0.0014446276,0.029474273,0.0005896749,0.048754804,0.87471575,0.0008938336],"about_ca_topic_score_codex":0.00037830122,"about_ca_topic_score_gemma":0.000015566618,"teacher_disagreement_score":0.38079518,"about_ca_system_score_codex":0.00045029796,"about_ca_system_score_gemma":0.00003040018,"threshold_uncertainty_score":0.8545763},"labels":[],"label_agreement":null},{"id":"W4399024288","doi":"10.1093/oso/9780197512883.002.0005","title":"Preface","year":2021,"lang":"en","type":"book-chapter","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.10397851534805674,"score_gpt":0.27247607361984594,"score_spread":0.1684975582717892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399024288","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000015339383,0.006415646,0.0001425799,0.0019879804,0.00052517815,0.00011483756,0.0004160588,0.000045968834,0.9903364],"genre_scores_gemma":[0.0010777626,0.0028165926,0.00026247714,0.0050433045,0.00039545502,0.0000055399596,0.00006669497,0.00007325289,0.99025893],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99859893,0.000001542756,0.00061276945,0.0005161824,0.000016652235,0.00025389233],"domain_scores_gemma":[0.9990736,0.00003273343,0.00025723036,0.00045196517,0.00001893615,0.00016553616],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00014620184,0.0002563309,0.0006037225,0.00013660968,0.00004298742,0.000083627965,0.00023354508,0.0003207973,0.053434074],"category_scores_gemma":[0.000018519717,0.00032349007,0.00027929049,0.00001651919,0.000050469145,0.00006850251,0.00014106074,0.00033839265,0.01730268],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000015996276,0.00000819251,0.000018313141,0.000019858071,0.00008618008,0.0000065552954,0.000010717282,0.0000028794743,6.153406e-7,0.96321875,0.035863157,0.0007631745],"study_design_scores_gemma":[0.000112870206,0.000008021004,0.000010432022,0.000010357158,0.000004934394,0.0000033804251,5.9176983e-7,0.00011705624,0.000010924852,0.30973226,0.68971705,0.0002720956],"about_ca_topic_score_codex":0.000021029846,"about_ca_topic_score_gemma":0.000012938662,"teacher_disagreement_score":0.6538539,"about_ca_system_score_codex":0.00011236507,"about_ca_system_score_gemma":0.000039629267,"threshold_uncertainty_score":0.99992174},"labels":[],"label_agreement":null},{"id":"W4399051980","doi":"10.1503/cmaj.231485","title":"The impact of proposed price regulations on new patented medicine launches in Canada: a retrospective cohort study","year":2024,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Centre for Advancing Health Outcomes; Ontario Drug Policy Research Network; University of Calgary; University of British Columbia; Providence Health Care","funders":"Canadian Institutes of Health Research; Michael Smith Health Research BC","keywords":"Retrospective cohort study; Cohort; Medicine; Business; Emergency medicine; Family medicine; Internal medicine","score_opus":0.026588856464486228,"score_gpt":0.2784963872388695,"score_spread":0.25190753077438327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399051980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92034584,0.00078594364,0.000012995506,0.06333844,0.0009437459,0.0003833093,0.00014596868,0.000006758818,0.014037021],"genre_scores_gemma":[0.9978723,0.00023006808,0.0000022509353,0.0009821415,0.0005044331,0.0000046032806,0.000004085299,0.000011485689,0.00038863314],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844867,0.000060132694,0.0007605822,0.00017421557,0.00020471691,0.00035166173],"domain_scores_gemma":[0.998513,0.00029099907,0.00026384206,0.00011060279,0.00007984718,0.0007417418],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002473219,0.00010244669,0.00033017865,0.0002524773,0.00013163881,0.000063185355,0.0002085551,0.000090586705,0.0017790115],"category_scores_gemma":[0.0019010521,0.0000766306,0.00007864944,0.00043958926,0.000030472063,0.000074575044,0.000010426923,0.00066713226,0.000040028826],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0000069293924,0.00002154726,0.9022846,0.0000019976314,0.0002451008,0.00003841052,0.00036627668,0.00007528748,4.0601424e-7,0.008968522,0.086742654,0.0012482281],"study_design_scores_gemma":[0.00053104456,0.00010219839,0.96316993,0.000035472014,0.000006626792,0.000008422019,0.00015472632,0.0055969283,5.492875e-7,0.0064142942,0.023898903,0.0000809176],"about_ca_topic_score_codex":0.93113834,"about_ca_topic_score_gemma":0.96817064,"teacher_disagreement_score":0.07752649,"about_ca_system_score_codex":0.009653381,"about_ca_system_score_gemma":0.007693536,"threshold_uncertainty_score":0.9991335},"labels":[],"label_agreement":null},{"id":"W4399130092","doi":"10.31579/2578-8949/155","title":"The Role and Impact of Generics in Pharmaceutical Markets","year":2024,"lang":"en","type":"article","venue":"Dermatology and Dermatitis","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Karachi; University of Calgary","keywords":"Business; Economics","score_opus":0.0237849108650893,"score_gpt":0.3010564534153847,"score_spread":0.27727154255029535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399130092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8918473,0.08189022,0.00013086201,0.0065072794,0.00019358953,0.000113871174,0.00012926596,0.000018849156,0.019168735],"genre_scores_gemma":[0.98589474,0.0131441215,0.000046253124,0.00084654434,0.000021461527,0.000010989833,0.0000033283943,0.000009079393,0.000023454695],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991647,0.000027226506,0.000400327,0.00016949305,0.000011226481,0.00022700237],"domain_scores_gemma":[0.9995027,0.00025904487,0.00005254553,0.000096125514,0.000005839048,0.000083730774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020028611,0.00009772584,0.0002462489,0.00013036164,0.00006419056,0.000067328845,0.000079682526,0.0000865484,0.00007721189],"category_scores_gemma":[0.000033782067,0.000082919185,0.000056456654,0.00011084489,0.00020179278,0.00012715314,0.00006304477,0.00016058878,0.00004633397],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023212131,0.000037750793,0.42037588,0.0001704428,0.00016921564,0.000078484416,0.00071007415,0.000011174531,0.00003506813,0.5336445,0.0066373264,0.03810688],"study_design_scores_gemma":[0.000588366,0.000019945837,0.24478942,0.000023647353,0.000011204413,0.0008563147,0.00004031553,0.19164759,0.0002729876,0.19449769,0.36701596,0.0002365486],"about_ca_topic_score_codex":0.000056698354,"about_ca_topic_score_gemma":0.00001723074,"teacher_disagreement_score":0.36037865,"about_ca_system_score_codex":0.00002233662,"about_ca_system_score_gemma":0.000020827767,"threshold_uncertainty_score":0.33813462},"labels":[],"label_agreement":null},{"id":"W4399287699","doi":"10.7202/1105315ar","title":"L’IMPACT DU PARTAGE DES COÛTSSUR LA CONSOMMATIONDE MÉDICAMENTS","year":2000,"lang":"fr","type":"article","venue":"Assurances :","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Political science","score_opus":0.042976560350666194,"score_gpt":0.3052173484943256,"score_spread":0.26224078814365936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399287699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5828068,0.021404427,0.000088134555,0.0073668347,0.000822255,0.00019007965,0.0011948533,0.00003626385,0.3860903],"genre_scores_gemma":[0.9495656,0.0297628,0.00019843252,0.0016808528,0.00051187526,0.000028746603,0.00003372486,0.000043934255,0.018174054],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99776655,0.00010248861,0.00086187205,0.00048192823,0.00004852714,0.0007386008],"domain_scores_gemma":[0.9986774,0.00032161086,0.00029284065,0.0003570283,0.000030474352,0.00032065672],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000750311,0.00032037887,0.0006292338,0.00012819078,0.00025506734,0.00031978017,0.00036664284,0.00023938001,0.035721883],"category_scores_gemma":[0.00009695697,0.00039907894,0.00031511497,0.0002781083,0.0006263368,0.0007373872,0.000035107074,0.00031337354,0.010720315],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012505252,0.0008644187,0.40747544,0.00021453004,0.0007928164,0.00004868844,0.0015729227,0.0078113256,0.000009151268,0.108906016,0.07055006,0.4016296],"study_design_scores_gemma":[0.0011131113,0.000078539895,0.12469508,0.00006245366,0.000024588733,0.000028727653,0.000016228389,0.0095782615,0.000022775215,0.020347953,0.8436241,0.0004081532],"about_ca_topic_score_codex":0.0010924146,"about_ca_topic_score_gemma":0.0001000777,"teacher_disagreement_score":0.7730741,"about_ca_system_score_codex":0.00022142117,"about_ca_system_score_gemma":0.00006321488,"threshold_uncertainty_score":0.9998461},"labels":[],"label_agreement":null},{"id":"W4399615943","doi":"10.1016/j.phacli.2024.04.193","title":"Émergence de pharmacies de spécialités en Amérique du Nord : état des lieux, opportunités et enjeux","year":2024,"lang":"fr","type":"article","venue":"Le Pharmacien Clinicien","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Political science","score_opus":0.2783287277807524,"score_gpt":0.43998976770509557,"score_spread":0.16166103992434316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399615943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.59247684,0.14308207,0.012280702,0.13402103,0.013104774,0.0009054043,0.0036903014,0.0004360943,0.1000028],"genre_scores_gemma":[0.75313276,0.19774295,0.001893748,0.023308583,0.002709734,0.00011300132,0.00005910715,0.0001775464,0.020862572],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942023,0.00042234155,0.0019575765,0.0013079282,0.00011478175,0.0019950287],"domain_scores_gemma":[0.99635565,0.0014530217,0.00042145583,0.00056758773,0.000106930485,0.0010953535],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.007165169,0.000673498,0.0009742052,0.00052524375,0.00044893654,0.00080446195,0.0013286866,0.00044617764,0.0044379653],"category_scores_gemma":[0.0008996892,0.0008990736,0.0007652954,0.0011726463,0.00089823455,0.001247661,0.00056094554,0.0015743545,0.0028641932],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020556014,0.001401716,0.026470443,0.0019806293,0.0009436527,0.00080112077,0.026804026,0.0042751664,0.0016690756,0.53270584,0.06767047,0.33507228],"study_design_scores_gemma":[0.0009835385,0.000102929596,0.0007162618,0.00016412795,0.00009606921,0.00022633128,0.00023270262,0.1548874,0.0021535433,0.045103088,0.79449034,0.00084367226],"about_ca_topic_score_codex":0.001263714,"about_ca_topic_score_gemma":0.0001240631,"teacher_disagreement_score":0.7268199,"about_ca_system_score_codex":0.0008137043,"about_ca_system_score_gemma":0.0015331991,"threshold_uncertainty_score":0.999346},"labels":[],"label_agreement":null},{"id":"W4399700239","doi":"10.1016/j.jval.2024.03.575","title":"EE276 Understanding Trends in Launch Prices across Canada, EU4, UK and the US for High-Revenue Drugs","year":2024,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Revenue; Business; Economics; Finance","score_opus":0.1167373823229765,"score_gpt":0.33843671197016073,"score_spread":0.22169932964718425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399700239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9112405,0.017394742,0.00023430042,0.06444228,0.0012566044,0.0004736922,0.0022636962,0.00001510178,0.0026790807],"genre_scores_gemma":[0.9955267,0.0013034774,0.00006436507,0.0025954056,0.000115622606,0.000040298175,0.000010629651,0.000017989487,0.00032553382],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99863434,0.000028332492,0.0005671684,0.0003014156,0.000022737784,0.00044602386],"domain_scores_gemma":[0.999243,0.0004091395,0.00011510223,0.00013315008,0.0000032679716,0.00009630298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017673465,0.00010916896,0.0003450906,0.00013516824,0.0001119258,0.000107547276,0.00013428947,0.000052697556,0.000037264603],"category_scores_gemma":[0.000043984128,0.0001027862,0.000041576925,0.00031124608,0.00006438411,0.00007407739,0.00004229532,0.00020594081,0.0000060270963],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032940945,0.000011604348,0.0047270944,0.00021719343,0.000017552367,0.0000023542984,0.0025601597,0.0013336499,1.3453e-7,0.9848344,0.0031319861,0.00313097],"study_design_scores_gemma":[0.0031753061,0.000062045794,0.017274242,0.00014920798,0.000003592257,0.000004821818,0.00043585536,0.1692797,0.000004472961,0.5055474,0.30371374,0.0003496112],"about_ca_topic_score_codex":0.69774544,"about_ca_topic_score_gemma":0.40056145,"teacher_disagreement_score":0.47928697,"about_ca_system_score_codex":0.0009908266,"about_ca_system_score_gemma":0.00017184991,"threshold_uncertainty_score":0.6103768},"labels":[],"label_agreement":null},{"id":"W4399701066","doi":"10.1016/j.jval.2024.03.052","title":"P26 Analyzing Drug Shortages and Pricing: Lessons from Canada","year":2024,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Economic shortage; Drug pricing; Business; Drug; Actuarial science; Medicine; Pharmacology","score_opus":0.09840679164151186,"score_gpt":0.32820577453091004,"score_spread":0.22979898288939818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399701066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8988318,0.046068862,0.00011488501,0.049234416,0.000772877,0.00015374426,0.00059614494,0.000031093234,0.004196216],"genre_scores_gemma":[0.9932118,0.0038447168,0.00017079379,0.002447861,0.00015557389,0.000006214181,0.000012215901,0.000018602344,0.00013218763],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987361,0.000022611343,0.00053399743,0.00036538922,0.000015996726,0.00032590594],"domain_scores_gemma":[0.9993737,0.00021364751,0.000079112106,0.00014670509,0.0000033030549,0.0001835488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056899106,0.000106475825,0.00031146593,0.00017697948,0.00006406534,0.00008822783,0.00010459487,0.000035080397,0.00009799891],"category_scores_gemma":[0.00004083317,0.00012615682,0.000031830365,0.00019326655,0.000021493275,0.000092780545,0.000044041684,0.00022867211,0.00003305702],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000067092233,0.000036332138,0.15289794,0.00036149423,0.00007956654,0.000032956268,0.0018699573,0.0036147148,0.000006361792,0.81619835,0.01073899,0.014156613],"study_design_scores_gemma":[0.0003512455,0.000022329765,0.06026569,0.00018324825,0.0000053607523,0.0000037345537,0.00011747653,0.31027272,0.000037116948,0.12971945,0.4985916,0.0004300427],"about_ca_topic_score_codex":0.91504616,"about_ca_topic_score_gemma":0.28404453,"teacher_disagreement_score":0.6864789,"about_ca_system_score_codex":0.00041088345,"about_ca_system_score_gemma":0.00028876006,"threshold_uncertainty_score":0.7290198},"labels":[],"label_agreement":null},{"id":"W4399707392","doi":"10.1016/j.jval.2024.03.1416","title":"HTA65 How Does Conditional Regulatory Approval Affect the Reimbursement of Drugs in Canada?","year":2024,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Affect (linguistics); Business; Actuarial science; Medicine; Public economics; Economics; Political science; Psychology; Law; Health care","score_opus":0.05515011141921904,"score_gpt":0.284748897095249,"score_spread":0.22959878567602993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399707392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94869596,0.004281339,0.000030970794,0.042865872,0.0008475677,0.00039609833,0.0004524815,0.000008014923,0.0024216722],"genre_scores_gemma":[0.9977182,0.0004978822,0.000038394184,0.0014304005,0.00011468625,0.00003189863,0.000013276254,0.000013354531,0.00014190514],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9987928,0.000046691566,0.0005541242,0.00025816396,0.00004252309,0.00030565987],"domain_scores_gemma":[0.999363,0.0002141514,0.00014107344,0.00019296358,0.000005417102,0.000083377934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013671723,0.00009798183,0.00029733384,0.00018601322,0.00003353454,0.000026920148,0.00016483509,0.00003616905,0.000099362755],"category_scores_gemma":[0.000032016054,0.00008100053,0.00005583105,0.00020891393,0.000050307157,0.000071069175,0.000035611458,0.00023221376,0.000016595506],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012188091,0.000046062854,0.02871211,0.0005438391,0.00003420707,0.000004926031,0.0007973018,0.0052521722,0.000005424066,0.9549425,0.00795802,0.0016912167],"study_design_scores_gemma":[0.0011379009,0.0000962393,0.26273084,0.0003226405,0.000004519666,0.0000057496427,0.0005673977,0.3152925,0.00023194875,0.21015702,0.20900165,0.00045159433],"about_ca_topic_score_codex":0.5720229,"about_ca_topic_score_gemma":0.13960208,"teacher_disagreement_score":0.7447855,"about_ca_system_score_codex":0.0010847509,"about_ca_system_score_gemma":0.0009531361,"threshold_uncertainty_score":0.8760979},"labels":[],"label_agreement":null},{"id":"W4399814181","doi":"10.1007/s40278-024-60672-3","title":"Temporary importation of US-authorised carbamazepine in Canada","year":2024,"lang":"en","type":"article","venue":"Reactions Weekly","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Carbamazepine; Business; Neuroscience; Biology; Epilepsy","score_opus":0.04380543677391887,"score_gpt":0.27350236457286003,"score_spread":0.22969692779894116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399814181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.931788,0.0022183862,0.0001019747,0.0034856063,0.000871464,0.00013491965,0.00047890193,0.000025175485,0.060895532],"genre_scores_gemma":[0.9985698,0.0003393084,0.000046294892,0.00018690334,0.000081406586,0.000014852407,0.000032735286,0.000015308497,0.0007134025],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990143,0.000006918686,0.00060016324,0.00020346776,0.000019347042,0.00015578521],"domain_scores_gemma":[0.99959093,0.00006430148,0.0001151141,0.00015019832,0.000009461765,0.000069983806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020187983,0.00008066281,0.00021517143,0.00026313562,0.000020754203,0.00002174484,0.00007930307,0.000043508764,0.0003487193],"category_scores_gemma":[0.00003471713,0.000100178906,0.00005847383,0.00032722083,0.000015445165,0.00016392233,0.000013243696,0.00015412421,0.00008726268],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027854783,0.00014850417,0.4145688,0.00038626837,0.00019168464,0.000053537162,0.00029895152,0.0015603416,0.0010081016,0.54280967,0.031923857,0.0070223827],"study_design_scores_gemma":[0.00030784673,0.000023340996,0.14541616,0.000043949214,0.000007334588,0.0000068490576,0.00007381199,0.035412885,0.00045782028,0.016352393,0.8016565,0.00024111583],"about_ca_topic_score_codex":0.86114854,"about_ca_topic_score_gemma":0.4217575,"teacher_disagreement_score":0.76973265,"about_ca_system_score_codex":0.00044205962,"about_ca_system_score_gemma":0.0004062923,"threshold_uncertainty_score":0.58879393},"labels":[],"label_agreement":null},{"id":"W4399920437","doi":"10.9734/bpi/prrat/v3/807","title":"Generic Drugs: The Evolving Landscape and the Mentalities","year":2024,"lang":"en","type":"book-chapter","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Geography; Environmental ethics; Philosophy","score_opus":0.045822250736645545,"score_gpt":0.24446887345810717,"score_spread":0.1986466227214616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399920437","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008483877,0.05936779,0.000008729344,0.0125573585,0.00054384716,0.00022684249,0.0002704186,0.000031790874,0.9269084],"genre_scores_gemma":[0.040271983,0.014464346,0.000019524923,0.008140542,0.000692546,0.000030155028,0.000016915988,0.000066750494,0.93629724],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99887544,0.000005247002,0.00052107323,0.00035144782,0.00002540223,0.00022136778],"domain_scores_gemma":[0.999196,0.00020789399,0.00017867127,0.0003426642,0.000008787364,0.000065967164],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00059564866,0.0002504842,0.00043946138,0.000105848776,0.00015807299,0.00035489193,0.00029998648,0.00013255927,0.004625224],"category_scores_gemma":[0.000012404238,0.00015158579,0.00021263168,0.000023410066,0.00031392058,0.00006887966,0.00026596242,0.0003610627,0.0020488398],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000058605474,0.0000016882778,0.0000145121085,0.000029307104,0.00017062508,8.195984e-7,0.0004446268,0.0000020392479,5.013515e-8,0.9668638,0.032045033,0.0004216104],"study_design_scores_gemma":[0.00019360436,0.000004282473,0.0000058860833,0.000010104764,0.00002153936,0.0000041052613,0.000050711526,0.003118994,5.46756e-7,0.44923228,0.5472227,0.00013527487],"about_ca_topic_score_codex":0.00009366703,"about_ca_topic_score_gemma":0.00001774165,"teacher_disagreement_score":0.51763153,"about_ca_system_score_codex":0.000054266657,"about_ca_system_score_gemma":0.000015923695,"threshold_uncertainty_score":0.99872816},"labels":[],"label_agreement":null},{"id":"W4400142158","doi":"10.1016/j.drugpo.2024.104500","title":"Structuring adaptations: Resilience, restrictive deterrence, and the Cunningham precursor control papers","year":2024,"lang":"en","type":"article","venue":"International Journal of Drug Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of the Fraser Valley; Simon Fraser University","funders":"Social Sciences and Humanities Research Council of Canada","keywords":"Structuring; Scholarship; Deterrence theory; Resilience (materials science); Control (management); Psychological resilience; Work (physics); Psychological intervention; Deterrence (psychology); Sociology; Law and economics; Public relations; Business; Political science; Psychology; Social psychology; Economics; Law; Engineering; Management","score_opus":0.01986170707947487,"score_gpt":0.2962057741875001,"score_spread":0.2763440671080252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400142158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7299141,0.024234103,0.0023471972,0.10606527,0.0053004916,0.00047025198,0.00063059916,0.000049915503,0.13098806],"genre_scores_gemma":[0.9945497,0.0021222774,0.00015274432,0.0017082179,0.0010546835,0.0000063548464,0.0000012108466,0.000011665108,0.00039313594],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99895674,0.000029506342,0.0006294355,0.00015334885,0.00007144034,0.00015950884],"domain_scores_gemma":[0.99901843,0.00040752583,0.00032768003,0.00008262138,0.00006864425,0.0000950943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005786761,0.00010436797,0.00022483403,0.00051772106,0.00006325263,0.00028389646,0.00040008378,0.000033937242,0.00007491104],"category_scores_gemma":[0.0004322208,0.00008198765,0.00014221751,0.00015324594,0.00018607751,0.00035315534,0.000051090177,0.00027041993,0.000039454426],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016044152,0.00001664747,0.0028544618,0.000007175221,0.00036711872,0.000017713128,0.0027753785,0.0010203737,0.00002819982,0.9754739,0.0014833459,0.015795242],"study_design_scores_gemma":[0.004180496,0.000063709136,0.020599045,0.00014350691,0.00004166816,0.00028787603,0.00036753563,0.030112159,0.0001060784,0.6687205,0.2750913,0.00028618198],"about_ca_topic_score_codex":0.0001754707,"about_ca_topic_score_gemma":0.000013056754,"teacher_disagreement_score":0.30675343,"about_ca_system_score_codex":0.00014129648,"about_ca_system_score_gemma":0.000118374584,"threshold_uncertainty_score":0.33433592},"labels":[],"label_agreement":null},{"id":"W4400264482","doi":"10.1186/s41256-024-00365-y","title":"Strengthening access to cancer medicines for children in East Africa: policy options to enhance medicine procurement, forecasting, and regulations","year":2024,"lang":"en","type":"article","venue":"Global Health Research and Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; SickKids Foundation; Hospital for Sick Children","funders":"Canadian Institutes of Health Research; Hospital for Sick Children","keywords":"Procurement; Harmonization; Essential medicines; Medicine; Business; Health care; Public health; Economic growth; Environmental health; Marketing; Nursing; Economics","score_opus":0.3348119429142283,"score_gpt":0.5405538434238999,"score_spread":0.20574190050967162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400264482","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16038497,0.025528997,0.0010602215,0.79561013,0.0002266563,0.0028345324,0.003618733,0.000056999506,0.010678761],"genre_scores_gemma":[0.9845056,0.0048162844,0.00041959475,0.007070093,0.002010385,0.0005823004,0.000029852075,0.000023763856,0.0005421608],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977743,0.00003299441,0.0006161784,0.00054559245,0.00007682298,0.000954131],"domain_scores_gemma":[0.99864143,0.00016206922,0.00007149439,0.0001725746,0.00006997497,0.0008824462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015098434,0.0001590682,0.0003665109,0.001127749,0.00029402037,0.00018206736,0.00023863025,0.000063259475,0.000042661013],"category_scores_gemma":[0.00088487356,0.00015800858,0.000027097834,0.0018443058,0.00013596915,0.00020087579,0.00021481051,0.00021168187,0.00002067829],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007731012,0.0000520205,0.010896674,0.0003755532,0.000044686712,8.029521e-7,0.002895418,0.00010930356,0.0000056419353,0.79557604,0.0724507,0.11751583],"study_design_scores_gemma":[0.0010621547,0.00102438,0.101428024,0.0008881778,0.0000056323784,0.00001613644,0.00016307653,0.008246229,0.000012383359,0.36516985,0.52158254,0.00040144392],"about_ca_topic_score_codex":0.019088015,"about_ca_topic_score_gemma":0.004087633,"teacher_disagreement_score":0.8241206,"about_ca_system_score_codex":0.0007233921,"about_ca_system_score_gemma":0.0005683097,"threshold_uncertainty_score":0.987444},"labels":[],"label_agreement":null},{"id":"W4400453556","doi":"10.1136/bmjebm-2024-sdc.111","title":"112 Dual use of prescription insurance: drivers and challenges","year":2024,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dual (grammatical number); Medical prescription; Business; Actuarial science; Computer science; Internet privacy; Medicine; Pharmacology","score_opus":0.17338242162222942,"score_gpt":0.28193197541469667,"score_spread":0.10854955379246725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400453556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90901667,0.0329162,0.00016516008,0.0051798243,0.0006291762,0.00013946116,0.00034992292,0.00006248917,0.0515411],"genre_scores_gemma":[0.96377677,0.03500993,0.00017491102,0.00025956967,0.00006790656,0.00000432823,0.0000028071718,0.000010438391,0.00069336116],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99938715,0.000004721241,0.0002614044,0.0002116927,0.000010455616,0.00012457612],"domain_scores_gemma":[0.9997317,0.000052770753,0.00004317527,0.00010351952,0.0000070663154,0.000061755854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001417089,0.00007293269,0.00017138656,0.00013174229,0.00001844122,0.000062160405,0.000041477033,0.000054090855,0.00020147303],"category_scores_gemma":[0.000023142386,0.00007895453,0.0000468837,0.000055458495,0.000056023255,0.0003541875,0.000037704845,0.00007146782,0.00012099487],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000059765575,0.000020413117,0.006630062,0.00014296356,0.000046628007,0.000001687407,0.00035413203,0.0000188647,0.000056592435,0.9822156,0.0014498554,0.009057269],"study_design_scores_gemma":[0.00026848796,0.00005092631,0.064492844,0.000024320794,0.0000053193826,0.0000054204997,0.00003524856,0.014449687,0.00022655215,0.04183566,0.87841564,0.0001899057],"about_ca_topic_score_codex":0.00009258668,"about_ca_topic_score_gemma":0.000013266845,"teacher_disagreement_score":0.9403799,"about_ca_system_score_codex":0.00002089902,"about_ca_system_score_gemma":0.000007237321,"threshold_uncertainty_score":0.32196724},"labels":[],"label_agreement":null},{"id":"W4400482662","doi":"10.55016/ojs/cpai.v3i2.71473","title":"International Day of Action (IDoA) Against Contract Cheating 2020—Update from the chair of the IDoA planning committee","year":2020,"lang":"en","type":"article","venue":"Canadian Perspectives on Academic Integrity","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Humber Polytechnic","funders":"","keywords":"Action (physics); Cheating; Business; Psychology; Social psychology","score_opus":0.0925396043227488,"score_gpt":0.31554512319227357,"score_spread":0.22300551886952477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400482662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8267232,0.0011870032,0.00008787858,0.12606403,0.0007561042,0.00026455245,0.002829508,0.000014424642,0.04207327],"genre_scores_gemma":[0.9863638,0.0005816506,0.00002773905,0.012371352,0.00058754405,0.000006622208,0.000020449454,0.000015664926,0.000025120498],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988073,0.000056795303,0.0005239175,0.0003167785,0.000050732782,0.00024448917],"domain_scores_gemma":[0.9988082,0.00028128098,0.00044162557,0.00022089532,0.00005030465,0.00019771355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005016663,0.00014772848,0.00031298038,0.000075167765,0.00012786359,0.000025964415,0.0007501377,0.00019807318,0.00039221236],"category_scores_gemma":[0.0010039918,0.00012395385,0.00015957672,0.00017278794,0.00019199759,0.00014026205,0.000067569534,0.00173402,0.00005030685],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001731359,0.00007618303,0.2179819,0.000031768133,0.0006558027,0.0000043808154,0.04276678,0.0013371543,0.0023174658,0.6974043,0.03135584,0.005895272],"study_design_scores_gemma":[0.0022270454,0.00011092065,0.41550174,0.00028809404,0.00004585362,0.0000039968922,0.017448511,0.104991645,0.0050166068,0.03282727,0.42066085,0.00087746466],"about_ca_topic_score_codex":0.018700685,"about_ca_topic_score_gemma":0.0017916287,"teacher_disagreement_score":0.66457707,"about_ca_system_score_codex":0.0004590797,"about_ca_system_score_gemma":0.00014808163,"threshold_uncertainty_score":0.98783386},"labels":[],"label_agreement":null},{"id":"W4400560618","doi":"10.34172/ijhpm.2024.8471","title":"Profits First, Health Second: The Pharmaceutical Industry and the Global South Comment on \"More Pain, More Gain! The Delivery of COVID-19 Vaccines and the Pharmaceutical Industry’s Role in Widening the Access Gap\"","year":2024,"lang":"en","type":"article","venue":"International Journal of Health Policy and Management","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University; University of Toronto","funders":"","keywords":"Pharmaceutical industry; Pandemic; Revenue; Equity (law); Global health; Negotiation; Coronavirus disease 2019 (COVID-19); Business; Economic growth; Health care; Economics; Medicine; Political science; Infectious disease (medical specialty); Finance; Law; Pharmacology","score_opus":0.1220237708135889,"score_gpt":0.43751940417401086,"score_spread":0.31549563336042197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400560618","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.062788896,0.016150419,0.00019915146,0.91850567,0.0003676574,0.000826851,0.00015996616,0.00000650025,0.0009948711],"genre_scores_gemma":[0.7251363,0.010706745,0.000008524884,0.26368695,0.0003805808,0.000036150414,0.0000016682279,0.000009496448,0.0000336099],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977123,0.0003879116,0.0011207699,0.0002408267,0.00016818896,0.0003700163],"domain_scores_gemma":[0.9976148,0.0013210118,0.0006166863,0.00018264615,0.000040947234,0.00022389772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007638636,0.00019710805,0.00040574098,0.00019609672,0.00039373184,0.00035105261,0.0007858279,0.00009468102,0.000059614013],"category_scores_gemma":[0.000251494,0.00009573662,0.000108684326,0.00021370013,0.00054950005,0.00016546046,0.00051116827,0.001200589,0.0000022380723],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080889615,0.0000847781,0.0073703662,0.00036067038,0.00064575125,0.000015696722,0.008128726,0.0011320277,5.3245675e-8,0.9384735,0.018359372,0.024620125],"study_design_scores_gemma":[0.0072594774,0.00010965323,0.013043249,0.00028299162,0.000054708187,0.00016877135,0.004467838,0.048159156,0.0000028783688,0.0700885,0.8561672,0.00019555505],"about_ca_topic_score_codex":0.0015532917,"about_ca_topic_score_gemma":0.00011778402,"teacher_disagreement_score":0.868385,"about_ca_system_score_codex":0.000396764,"about_ca_system_score_gemma":0.00024223722,"threshold_uncertainty_score":0.52160287},"labels":[],"label_agreement":null},{"id":"W4400575844","doi":"10.1016/j.drugalcdep.2023.109995","title":"ACCESS TO NO-COST PHARMACEUTICAL ALTERNATIVES TO ILLICIT DRUGS DURING INTERSECTING COVID-19 AND OVERDOSE HEALTH EMERGENCIES IN BRITISH COLUMBIA, CANADA: A QUALITATIVE STUDY","year":2024,"lang":"en","type":"article","venue":"Drug and Alcohol Dependence","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"British Columbia Centre on Substance Use; University of British Columbia","funders":"","keywords":"Coronavirus disease 2019 (COVID-19); 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Illicit drug; Medicine; Drug overdose; Medical emergency; Poison control; Virology; Drug; Pharmacology; Infectious disease (medical specialty)","score_opus":0.10169088519342474,"score_gpt":0.4116953125910158,"score_spread":0.3100044273975911,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400575844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98999524,0.0018437407,0.00008112241,0.005449619,0.0004623251,0.00085178466,0.000764684,0.00003171744,0.0005197944],"genre_scores_gemma":[0.9904665,0.0007454678,0.000035037498,0.008031667,0.00009827498,0.00012170235,0.0000045533643,0.000024673172,0.00047217356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978391,0.000090484726,0.0006710318,0.00080332643,0.00007652267,0.0005195195],"domain_scores_gemma":[0.99869514,0.00026996774,0.000096490636,0.00013667157,0.000023393954,0.0007783595],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012391069,0.00016822729,0.00044898014,0.00020652205,0.00023364792,0.00087028375,0.0002841261,0.00003156926,0.00019669424],"category_scores_gemma":[0.0003270116,0.00027181336,0.00003744806,0.0003769443,0.000053475447,0.00041377687,0.00040621104,0.00030942025,0.00003170656],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014634346,0.00045054805,0.5787371,0.0014760105,0.00040966665,0.0005329082,0.38316694,0.0005699218,0.00007297722,0.00441332,0.013238205,0.016786061],"study_design_scores_gemma":[0.008207456,0.0005868021,0.55290276,0.001182071,0.000051874144,0.00020699175,0.20454249,0.026503205,0.00021553047,0.010100196,0.19128214,0.004218464],"about_ca_topic_score_codex":0.8894735,"about_ca_topic_score_gemma":0.93678147,"teacher_disagreement_score":0.17862445,"about_ca_system_score_codex":0.0006037181,"about_ca_system_score_gemma":0.00025022312,"threshold_uncertainty_score":0.9999734},"labels":[],"label_agreement":null},{"id":"W4400607151","doi":"10.51731/cjht.2024.929","title":"Trends in Public Drug Plan Expenditures for Patients With Crohn Disease and Ulcerative Colitis Initiating Targeted Immune Modulator Therapy","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ulcerative colitis; Medicine; Drug; Disease; Immune system; Crohn's disease; Pharmacotherapy; Immunology; Internal medicine; Pharmacology","score_opus":0.05527035259973597,"score_gpt":0.2868505913691179,"score_spread":0.2315802387693819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400607151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90152013,0.06935947,0.00006398311,0.026966449,0.00030839856,0.00030073512,0.0012517938,0.000035977453,0.00019309437],"genre_scores_gemma":[0.99822956,0.000969745,0.00014579848,0.00055017025,0.0000192948,0.000027728644,0.000024912675,0.0000187413,0.000014042864],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99877685,0.00001630052,0.00060318905,0.00018188529,0.000019241561,0.0004025319],"domain_scores_gemma":[0.99936444,0.0000711366,0.00027357804,0.00010375631,0.000028042417,0.00015905616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039508432,0.00012431247,0.00035650266,0.0012363724,0.00015108654,0.0001697805,0.00017110766,0.00006200281,0.000039379556],"category_scores_gemma":[0.000116923606,0.00011416279,0.00005359289,0.0001979384,0.00011337976,0.00029479238,0.000012402983,0.00025720836,0.0000015481801],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025714526,0.00009380499,0.14844663,0.000239162,0.0002648471,0.00011175805,0.0026671991,0.00006748493,5.3720254e-7,0.27211425,0.0049207956,0.5708164],"study_design_scores_gemma":[0.0016155285,0.00028011546,0.8053315,0.00013907212,0.000003318063,0.000006093835,0.0005375301,0.0013224997,0.000011851782,0.061759252,0.12871839,0.00027483524],"about_ca_topic_score_codex":0.0012572934,"about_ca_topic_score_gemma":0.0021391516,"teacher_disagreement_score":0.65688485,"about_ca_system_score_codex":0.00030430435,"about_ca_system_score_gemma":0.0004389021,"threshold_uncertainty_score":0.46554235},"labels":[],"label_agreement":null},{"id":"W4400761056","doi":"10.3390/jcm13144160","title":"The Hurdle of Access to Emerging Therapies and Potential Solutions in the Management of Dyslipidemias","year":2024,"lang":"en","type":"review","venue":"Journal of Clinical Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Reimbursement; Medicine; Psychological intervention; Health care; Payment; Telemedicine; Public relations; Business; Nursing; Economic growth; Finance","score_opus":0.4487408114422912,"score_gpt":0.5329116212130095,"score_spread":0.08417080977071828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400761056","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002038277,0.97231746,0.000098749595,0.020727275,0.0014380866,0.00027881667,0.000031669475,0.0000011217237,0.004902973],"genre_scores_gemma":[0.005796451,0.99261236,0.00006993539,0.0005689706,0.00085545157,0.000007698261,9.053369e-7,0.000014415086,0.00007383815],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99533224,0.000118910466,0.0041096397,0.00017043525,0.00007570899,0.00019304262],"domain_scores_gemma":[0.996538,0.0011515521,0.0019204329,0.00025167217,0.00003674804,0.00010161571],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008497895,0.00015842533,0.0019459527,0.0002871241,0.000044917306,0.000031493386,0.00078143616,0.000117019285,0.000058134596],"category_scores_gemma":[0.00044389255,0.000080622645,0.00046738476,0.00032550373,0.0002392095,0.000067875204,0.00020850806,0.0007079277,0.000009920035],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034729397,0.000091706854,0.000097653356,0.0040093986,0.0011334794,0.000021573553,0.00025445074,0.00001278662,3.1521918e-8,0.101510294,0.011435113,0.8813988],"study_design_scores_gemma":[0.00039045748,0.00016978028,0.0005199555,0.0042440137,0.00043144793,0.000023019553,0.00010685222,0.00008168637,2.5973582e-8,0.018450052,0.9755058,0.00007685754],"about_ca_topic_score_codex":0.000015658916,"about_ca_topic_score_gemma":0.0000039971987,"teacher_disagreement_score":0.96407074,"about_ca_system_score_codex":0.000027068525,"about_ca_system_score_gemma":0.000049104565,"threshold_uncertainty_score":0.3287696},"labels":[],"label_agreement":null},{"id":"W4400777797","doi":"10.31579/2690-8808/195","title":"Innovation and Marketing in the Pharmaceutical Industry","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Case Reports and Studies","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Karachi; University of Calgary","keywords":"Business; Pharmaceutical industry; Marketing; Industrial organization; Biotechnology","score_opus":0.3565552915519358,"score_gpt":0.49582272537934163,"score_spread":0.1392674338274058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400777797","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95038605,0.035351597,0.000012286388,0.01058847,0.0006748274,0.000056125424,0.0000048190414,0.0000029305145,0.0029228984],"genre_scores_gemma":[0.9882146,0.009454914,0.00006164602,0.001693243,0.0005222458,0.0000017577897,1.5648509e-7,0.000005457962,0.00004599131],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976624,0.00006190088,0.0019636087,0.00016205161,0.00002995283,0.00012005084],"domain_scores_gemma":[0.9981117,0.0012457824,0.00047334327,0.00006539279,0.0000458703,0.000057857425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011403912,0.0000798333,0.00043439996,0.00016568629,0.000058444395,0.000098119766,0.000028164768,0.000104615945,0.000021151152],"category_scores_gemma":[0.0025824215,0.000054036813,0.00007195031,0.0001897589,0.00014130068,0.00015473456,0.0000513516,0.0008082605,0.0000012681761],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017211346,0.00023988429,0.4799799,0.0005211515,0.00086060533,0.08480781,0.002627107,0.000012740738,0.000003522445,0.2731766,0.014143408,0.14345516],"study_design_scores_gemma":[0.00095677195,0.00023046581,0.10360291,0.00026543788,0.00009236089,0.08390702,0.0019128709,0.003315652,0.0000039394713,0.123356745,0.6820527,0.000303183],"about_ca_topic_score_codex":0.0000060347397,"about_ca_topic_score_gemma":0.000003269306,"teacher_disagreement_score":0.66790926,"about_ca_system_score_codex":0.000016370836,"about_ca_system_score_gemma":0.000028213253,"threshold_uncertainty_score":0.39523908},"labels":[],"label_agreement":null},{"id":"W4400850656","doi":"10.1057/s41599-024-03452-0","title":"Novel insights from financial analysis of the failure to commercialise plazomicin: Implications for the antibiotic investment ecosystem","year":2024,"lang":"en","type":"article","venue":"Humanities and Social Sciences Communications","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Finance; Demise; Bankruptcy; Financial services","score_opus":0.24234068727900754,"score_gpt":0.3431836947426274,"score_spread":0.10084300746361985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400850656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.60160637,0.015972642,0.0050641233,0.3175617,0.0010649216,0.002202439,0.018399142,0.00007579103,0.03805288],"genre_scores_gemma":[0.9937232,0.00026591655,0.0002577984,0.005532497,0.00008506806,0.000049393537,0.000024750876,0.0000052730384,0.000056091056],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993124,0.000020679627,0.00034592598,0.00017232823,0.000022173543,0.00012649894],"domain_scores_gemma":[0.9989478,0.00050035794,0.0001210327,0.0003836014,0.000026124635,0.000021068327],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0002674863,0.0000763137,0.00021906203,0.00014958375,0.0016134976,0.0002392029,0.0008713676,0.000040163857,0.000016418648],"category_scores_gemma":[0.00003699632,0.000056499353,0.00015599362,0.00053945015,0.00045456982,0.000100383666,0.00026623104,0.000086627784,0.000005301372],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[7.867957e-7,0.000021873828,0.0006133421,0.000007126314,0.00011266668,3.1338767e-9,0.004661809,0.000055903733,0.00003243071,0.9926724,0.0016520973,0.00016958662],"study_design_scores_gemma":[0.00014325742,0.00002543373,0.09359873,0.000020802163,0.00025787024,2.0327519e-7,0.0015634515,0.028241048,0.000015237921,0.09268953,0.78326374,0.00018070114],"about_ca_topic_score_codex":0.0011590329,"about_ca_topic_score_gemma":0.012789937,"teacher_disagreement_score":0.89998287,"about_ca_system_score_codex":0.00005749302,"about_ca_system_score_gemma":0.000055934892,"threshold_uncertainty_score":0.99968624},"labels":[],"label_agreement":null},{"id":"W4400882126","doi":"10.54194/gvuq2702","title":"Effects of the COVID-19 pandemic on the number and characteristics of public drug program beneficiaries in Ontario, Canada","year":2024,"lang":"en","type":"article","venue":"Canadian Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pandemic; Coronavirus disease 2019 (COVID-19); 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Public health; Virology; Medicine; Political science; Geography; Nursing; Outbreak; Infectious disease (medical specialty)","score_opus":0.0803262306349016,"score_gpt":0.3250904177784581,"score_spread":0.2447641871435565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400882126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8815512,0.00087097945,6.4589204e-7,0.11368542,0.000301449,0.0005288182,0.00078117405,0.0000074798986,0.00227281],"genre_scores_gemma":[0.9677041,0.00034479183,0.0000035887554,0.031639777,0.00007250666,0.000040507228,0.0000078270705,0.000014378131,0.00017247877],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99873966,0.000049282542,0.00052193494,0.00019761102,0.000028314516,0.00046317952],"domain_scores_gemma":[0.99864626,0.0004051712,0.00017046287,0.0002118286,0.000010733923,0.00055552495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058725866,0.00011671739,0.00032007907,0.00020862598,0.000116096395,0.000049395665,0.00022279388,0.000056920217,0.00011524549],"category_scores_gemma":[0.00047605683,0.000095136784,0.000046137207,0.000317184,0.00009264161,0.000040698385,0.000035004196,0.00031658728,0.0000079640995],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000025397048,0.000015946072,0.24847071,0.00034464008,0.000022521797,0.0000023835403,0.0012357665,0.0000062720414,2.3868427e-7,0.7393512,0.006331821,0.0042159236],"study_design_scores_gemma":[0.00015115843,0.000017358558,0.29824007,0.000040576462,0.0000022548581,0.0000044227972,0.000019688776,0.00034131785,0.0000027700758,0.011208436,0.6898707,0.000101223566],"about_ca_topic_score_codex":0.9995188,"about_ca_topic_score_gemma":0.9998484,"teacher_disagreement_score":0.7281428,"about_ca_system_score_codex":0.0027643447,"about_ca_system_score_gemma":0.011672951,"threshold_uncertainty_score":0.9939299},"labels":[],"label_agreement":null},{"id":"W4400885269","doi":"10.4324/9781003449331","title":"Economics of the Pharmaceutical and Medical Device Industry","year":2024,"lang":"en","type":"book","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"George Brown College","funders":"","keywords":"Pharmaceutical industry; Economics; Neoclassical economics; Medicine; Pharmacology","score_opus":0.08600410024668714,"score_gpt":0.3204982374258354,"score_spread":0.23449413717914824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400885269","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002865982,0.008105443,0.000009941491,0.012395189,0.0012583376,0.00024356833,0.00070296065,0.000029300763,0.97438926],"genre_scores_gemma":[0.042827446,0.009421582,0.00006517885,0.022331944,0.0013719848,0.00002402977,0.000026166308,0.00016177581,0.9237699],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99795806,0.000013158925,0.0010912743,0.0005607671,0.00004492592,0.0003317894],"domain_scores_gemma":[0.9986941,0.00017806454,0.00032930612,0.00043236755,0.000016398768,0.00034975423],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00067693566,0.00031632624,0.000761615,0.00017577867,0.000052345167,0.000074916614,0.00062636373,0.0012776391,0.0048381137],"category_scores_gemma":[0.00010659166,0.0002759765,0.00027685903,0.00007729378,0.00042629708,0.00007551785,0.0006503181,0.0019328546,0.00090586185],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000050655462,0.000021126745,0.00038394978,0.00021349725,0.00018959198,0.000002549769,0.000040543455,0.0000028543836,1.916983e-7,0.9230074,0.07359085,0.0025423637],"study_design_scores_gemma":[0.00023714328,0.000010646782,0.00006308238,0.00007741804,0.00003563133,0.000020330792,0.0000030291333,0.004050431,0.00001814208,0.20573997,0.7894917,0.00025244983],"about_ca_topic_score_codex":0.000032058826,"about_ca_topic_score_gemma":0.000029857309,"teacher_disagreement_score":0.71726745,"about_ca_system_score_codex":0.00019941657,"about_ca_system_score_gemma":0.00044757206,"threshold_uncertainty_score":0.99996924},"labels":[],"label_agreement":null},{"id":"W4401022200","doi":"10.1001/jama.2024.13386","title":"FDA Greenlights Second Alzheimer Drug, Donanemab","year":2024,"lang":"en","type":"article","venue":"JAMA","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Art history; Humanities; Art; Philosophy","score_opus":0.056795041827866495,"score_gpt":0.2863818921707187,"score_spread":0.2295868503428522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401022200","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19251837,0.03981001,0.00012621198,0.025363635,0.0027606438,0.00027114354,0.0008905528,0.00022288896,0.7380366],"genre_scores_gemma":[0.98201203,0.0003734721,0.00016379132,0.0065348865,0.0010313202,0.000024422303,0.00002345662,0.00004646579,0.009790147],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986572,0.000009089199,0.0004855133,0.0004547076,0.000022689348,0.00037078065],"domain_scores_gemma":[0.9993568,0.000087602486,0.00007451482,0.00029185542,0.000012579084,0.00017661335],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0003413338,0.00017183574,0.00029756172,0.00021766197,0.00007127972,0.00031941105,0.00025434582,0.00011142791,0.008667943],"category_scores_gemma":[0.000021661896,0.00018472348,0.00017520341,0.00019265086,0.000053266227,0.00038746206,0.00007893221,0.00027420884,0.015485488],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009585136,0.000036823665,0.00047109698,0.00005464075,0.00021028674,0.000030055251,0.0004202781,0.0000065206427,0.000024053337,0.7924947,0.18634929,0.019892666],"study_design_scores_gemma":[0.0003098855,0.000012576947,0.0011942582,0.000012682339,0.0000111629415,0.0000115924495,0.0000074588374,0.0042809853,0.00043248356,0.09692621,0.89655817,0.00024255879],"about_ca_topic_score_codex":0.000111623514,"about_ca_topic_score_gemma":0.00005309426,"teacher_disagreement_score":0.7894937,"about_ca_system_score_codex":0.00006208205,"about_ca_system_score_gemma":0.000029868059,"threshold_uncertainty_score":0.9922383},"labels":[],"label_agreement":null},{"id":"W4401177491","doi":"10.1257/pol.20220505","title":"Competitive Bidding in Drug Procurement: Evidence from China","year":2024,"lang":"en","type":"article","venue":"American Economic Journal Economic Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"","keywords":"Bidding; China; Procurement; Business; Drug; Industrial organization; Public economics; Economics; Marketing; Pharmacology; Medicine; Political science","score_opus":0.03789529403700796,"score_gpt":0.3186712153463611,"score_spread":0.28077592130935314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401177491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8570125,0.007223563,0.00022101439,0.024040692,0.0024648495,0.00038814815,0.0011464467,0.00012528902,0.10737751],"genre_scores_gemma":[0.98540974,0.008548994,0.00038851146,0.0017595679,0.003133743,0.000043449487,0.000016334618,0.000114100374,0.0005855914],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99573666,0.00007782508,0.0020164226,0.0010453842,0.00003453558,0.0010891592],"domain_scores_gemma":[0.9976883,0.00042342857,0.00084615004,0.0004809328,0.0000093976205,0.00055180286],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0014246765,0.0005092676,0.0011835083,0.0015211628,0.0001737291,0.0008509009,0.00090830686,0.000096011194,0.0025644565],"category_scores_gemma":[0.0001305981,0.00062256615,0.0004338155,0.00027950073,0.00039373548,0.0016074833,0.00022426432,0.0009419166,0.009299133],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000097023585,0.00008331724,0.025363205,0.000046452296,0.0005291533,0.00007233542,0.0035938448,0.0052782525,0.000054793825,0.9279868,0.0103452895,0.026549539],"study_design_scores_gemma":[0.0017264093,0.0002049657,0.0604566,0.00057488354,0.000042711108,0.00023990594,0.00068394514,0.078207776,0.00026345538,0.2070005,0.64859706,0.0020017694],"about_ca_topic_score_codex":0.030004421,"about_ca_topic_score_gemma":0.0020589493,"teacher_disagreement_score":0.7209863,"about_ca_system_score_codex":0.004926356,"about_ca_system_score_gemma":0.0008267404,"threshold_uncertainty_score":0.9996226},"labels":[],"label_agreement":null},{"id":"W4401210807","doi":"10.1371/journal.pone.0308118","title":"Canadian status of “not acceptable” drugs as evaluated by Prescrire: A cohort study","year":2024,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University; University of Toronto","funders":"Health Canada","keywords":"Medicine; Interquartile range; Drug; Family medicine; Alternative medicine; Pharmacology; Internal medicine; Pathology","score_opus":0.088827961021543,"score_gpt":0.29628785591597306,"score_spread":0.20745989489443006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401210807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89698,0.0029913222,0.0000031112654,0.0014211797,0.0001547278,0.00077536603,0.0017806648,0.00004680381,0.09584685],"genre_scores_gemma":[0.99230117,0.0009549481,0.00003270291,0.00092476455,0.00007749262,0.000097264594,0.000053782478,0.000043342574,0.0055145114],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981672,0.000024915493,0.0006798905,0.00045940862,0.000072381605,0.0005962075],"domain_scores_gemma":[0.9989552,0.00007132188,0.000111872316,0.00034562606,0.000038554615,0.00047743035],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00068736164,0.00016493438,0.0005255377,0.00030800828,0.000063662985,0.0001324884,0.0002502786,0.0000838081,0.004528363],"category_scores_gemma":[0.00016555439,0.00020071097,0.000077169425,0.00030020502,0.000039795195,0.00019531218,0.000061703824,0.00022565732,0.0018978388],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013086553,0.006659482,0.80646276,0.00055859337,0.0066455603,0.000030135714,0.005039978,0.00006745662,0.001046087,0.11515843,0.053503875,0.0046967533],"study_design_scores_gemma":[0.0047826646,0.0017302248,0.1529317,0.00027015418,0.0009946515,0.0000033847548,0.0006166643,0.118010044,0.011067053,0.03774041,0.66928923,0.0025637876],"about_ca_topic_score_codex":0.19990322,"about_ca_topic_score_gemma":0.0067819566,"teacher_disagreement_score":0.6535311,"about_ca_system_score_codex":0.0004920033,"about_ca_system_score_gemma":0.00028219455,"threshold_uncertainty_score":0.9988793},"labels":[],"label_agreement":null},{"id":"W4401220050","doi":"10.51731/cjht.2024.945","title":"Drug Shortages: A Scoring System to Evaluate and Prioritize the Clinical Importance of Drugs in Canada","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Tolerability; Health care; Economic shortage; Psychological intervention; Population; Risk analysis (engineering); Intensive care medicine; Actuarial science; Business; Adverse effect; Environmental health; Nursing; Pharmacology","score_opus":0.0839966089288163,"score_gpt":0.3449682227445677,"score_spread":0.2609716138157514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401220050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8445538,0.1081234,0.000016038266,0.045670927,0.00077567424,0.00020250962,0.00010364442,0.000013068421,0.0005408967],"genre_scores_gemma":[0.99734896,0.001667515,0.000106493666,0.00082748575,0.000021705264,0.00000555613,2.4896306e-7,0.000010810587,0.00001122172],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99796665,0.000029594468,0.0014327727,0.00017948869,0.000031997206,0.0003594832],"domain_scores_gemma":[0.99910694,0.00018225166,0.00034950583,0.00019506982,0.000027539074,0.00013870174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00293746,0.000095347954,0.0005093366,0.00042046426,0.00006802605,0.00004715458,0.00034774435,0.00005249554,0.000009568528],"category_scores_gemma":[0.00033395493,0.00008264357,0.00006816836,0.0003068736,0.000097975804,0.00008133321,0.000034791352,0.00044558177,0.0000042739357],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014211873,0.000008641906,0.590525,0.00082099583,0.00012941223,0.0001392113,0.0014575756,0.00018508598,8.5079796e-7,0.20675367,0.009846508,0.19011883],"study_design_scores_gemma":[0.0013630249,0.00036386188,0.31757256,0.0029334691,0.000034536337,0.0003397451,0.02576148,0.010788884,0.000053446347,0.05489549,0.58504134,0.0008521685],"about_ca_topic_score_codex":0.6570575,"about_ca_topic_score_gemma":0.86363685,"teacher_disagreement_score":0.57519484,"about_ca_system_score_codex":0.001177436,"about_ca_system_score_gemma":0.0042411974,"threshold_uncertainty_score":0.7523702},"labels":[],"label_agreement":null},{"id":"W4401515421","doi":"10.1177/08404704241271237","title":"Do high drug prices fund pharmaceutical innovation?","year":2024,"lang":"en","type":"article","venue":"Healthcare Management Forum","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Institute for New Economic Thinking; Canadian Institute for Advanced Research","keywords":"Business; Stock (firearms); Dividend; Shareholder; Corporation; Cash; Monetary economics; Finance; Drug prices; Economics; Corporate governance","score_opus":0.10299272116347642,"score_gpt":0.36692248912746706,"score_spread":0.26392976796399065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401515421","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.081980325,0.030522963,0.0041436106,0.45768914,0.0073708673,0.0018455687,0.0008995533,0.0007547592,0.41479322],"genre_scores_gemma":[0.97447866,0.0024789716,0.00057163637,0.017787993,0.00033719811,0.00010272015,0.00005983982,0.000050200557,0.004132751],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99774945,0.000015040285,0.0008496835,0.000643524,0.000058415015,0.00068388507],"domain_scores_gemma":[0.9992726,0.000054336677,0.0001264587,0.00034668524,0.000026548296,0.00017341012],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000732029,0.00021683605,0.00031461727,0.0007034364,0.00016812432,0.00034460943,0.00030666214,0.000078070196,0.0013593155],"category_scores_gemma":[0.000011520303,0.0002485073,0.000098825054,0.0009224479,0.00005450363,0.00031306234,0.0002274792,0.0003178345,0.003576778],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011028712,0.00004249002,0.0021917897,0.00055050716,0.00011023428,0.00001964827,0.00009974101,0.000012400885,7.154124e-7,0.92292905,0.04913961,0.024892787],"study_design_scores_gemma":[0.00027529776,0.000020760857,0.0012571041,0.000036369085,0.000008569827,0.0000024388833,0.0000805124,0.002877647,0.000016219466,0.2147364,0.7804609,0.00022777218],"about_ca_topic_score_codex":0.00017268924,"about_ca_topic_score_gemma":0.000021452131,"teacher_disagreement_score":0.8924984,"about_ca_system_score_codex":0.00023738363,"about_ca_system_score_gemma":0.000025286006,"threshold_uncertainty_score":0.9999967},"labels":[],"label_agreement":null},{"id":"W4401600345","doi":"10.1016/j.atherosclerosis.2024.118210","title":"Validation of site-less strategies and long-distance drone-based delivery and collection system to promote access to innovative treatments for patients with rare or severe dyslipidemias","year":2024,"lang":"en","type":"article","venue":"Atherosclerosis","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Innovaderm (Canada); Université du Québec à Chicoutimi","funders":"","keywords":"Drone; Delivery system; Computer science; Medicine; Operations management; Engineering; Biomedical engineering; Biology","score_opus":0.0673597188745463,"score_gpt":0.2918716164650965,"score_spread":0.22451189759055024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401600345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923217,0.00009342634,0.0046328525,0.00028977002,0.00010716002,0.0011096103,0.0012807625,0.000030357884,0.00013432885],"genre_scores_gemma":[0.9986749,0.000030409254,0.00067761424,0.00021664368,0.00002532525,0.00022071927,0.000046963614,0.000029447869,0.00007794988],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99902165,0.000011095181,0.00036467522,0.00039311618,0.000029207833,0.00018025209],"domain_scores_gemma":[0.9994648,0.00008863106,0.0001415708,0.00012295869,0.00008891477,0.000093133836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014763573,0.00016052062,0.00031649295,0.0001900909,0.00009245766,0.00030075086,0.000082526545,0.000064364365,0.000011418658],"category_scores_gemma":[0.000024673478,0.0001450597,0.000027148433,0.0004967993,0.000030945506,0.0004760156,0.00004007676,0.000046329358,0.00000722985],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022177303,0.00046326435,0.94102424,0.002526198,0.0007391009,0.0000013671207,0.004228591,0.0022197817,0.0006732171,0.03531382,0.0012599357,0.009332771],"study_design_scores_gemma":[0.0067787254,0.0031130079,0.9496086,0.0015859897,0.00015519852,0.0000017393421,0.00060311187,0.025600147,0.007523523,0.0011607589,0.0026660326,0.001203114],"about_ca_topic_score_codex":0.00016021795,"about_ca_topic_score_gemma":0.00009537692,"teacher_disagreement_score":0.03415306,"about_ca_system_score_codex":0.00020326635,"about_ca_system_score_gemma":0.000053468368,"threshold_uncertainty_score":0.5915363},"labels":[],"label_agreement":null},{"id":"W4401667000","doi":"10.31579/2693-4779/204","title":"Phase IV Drug Development:Post-Marketing Studies","year":2024,"lang":"en","type":"article","venue":"Clinical Research and Clinical Trials","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Karachi; University of Calgary","keywords":"Drug development; Drug; Business; Marketing; Pharmacology; Medicine","score_opus":0.8494036240734456,"score_gpt":0.6818881618903232,"score_spread":0.1675154621831224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401667000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89508605,0.056104034,0.00007526234,0.023754932,0.003723224,0.0009873336,0.00031577103,0.00014133494,0.019812051],"genre_scores_gemma":[0.92001706,0.064665146,0.0007391528,0.0034911542,0.004530021,0.00010686433,0.000026016092,0.000072370865,0.006352198],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9885328,0.002459359,0.006577334,0.001350277,0.00014037862,0.0009398895],"domain_scores_gemma":[0.89154875,0.10585765,0.00051705167,0.00056880695,0.00027691247,0.0012308407],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.19820248,0.0002589967,0.0020816794,0.00035448527,0.00033864137,0.00047878557,0.00048029225,0.00033640786,0.0008686474],"category_scores_gemma":[0.17249846,0.00022491468,0.00066537905,0.0004304135,0.0011451477,0.00019489342,0.0005687742,0.001838421,0.00361383],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016313386,0.0020061051,0.009429168,0.0003896244,0.0020062844,0.0000821701,0.0003078362,3.8528125e-7,0.000006516416,0.16917804,0.094670646,0.7202919],"study_design_scores_gemma":[0.004315454,0.00069662265,0.0017401768,0.00019879531,0.00002685919,0.0000023072023,0.00017182849,0.0016549046,0.00002341006,0.1345777,0.8562425,0.00034943805],"about_ca_topic_score_codex":0.000016029779,"about_ca_topic_score_gemma":0.00001834489,"teacher_disagreement_score":0.7615718,"about_ca_system_score_codex":0.00009235246,"about_ca_system_score_gemma":0.0003465526,"threshold_uncertainty_score":0.997162},"labels":[],"label_agreement":null},{"id":"W4401705679","doi":"10.2139/ssrn.4894485","title":"When Haste Makes Waste: Fair And Equitable Treatment Violations in Canada's Feed-in Tariff Program Implementation and Lessons for Vietnam","year":2024,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Tariff; Business; Natural resource economics; Waste management; Economic growth; Economics; International trade; Engineering","score_opus":0.037571521202226274,"score_gpt":0.3213171437703761,"score_spread":0.28374562256814984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401705679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9287875,0.036624115,0.0015239951,0.030176027,0.00027889403,0.0009727563,0.00036396814,0.000018579938,0.001254152],"genre_scores_gemma":[0.9926382,0.006655332,0.00015424244,0.00012291134,0.00008866672,0.00010212983,0.000017275415,0.000017447213,0.00020381575],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99823153,0.000010704972,0.00041626726,0.00023087155,0.000017343009,0.0010932708],"domain_scores_gemma":[0.9997208,0.000050378112,0.000082086335,0.000058653164,0.000007711741,0.00008038244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006115397,0.00011964045,0.00022390657,0.00020625298,0.000101079975,0.00015736034,0.000061709536,0.000036690384,0.000028402681],"category_scores_gemma":[0.000008246499,0.00012588265,0.00004020796,0.00009641553,0.000015202661,0.00019836583,0.000021189624,0.00030723933,0.000002592714],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000264413,0.000058208432,0.028062234,0.000032948326,0.00012713412,0.0000027345739,0.00046378636,0.00013501164,0.000017711009,0.7105967,0.00022694826,0.26025015],"study_design_scores_gemma":[0.0029758636,0.0005639292,0.009309485,0.00004109277,0.00003245766,0.00007621514,0.003007727,0.06128741,0.000035540714,0.8383274,0.08396049,0.0003823728],"about_ca_topic_score_codex":0.1052754,"about_ca_topic_score_gemma":0.90633214,"teacher_disagreement_score":0.80105674,"about_ca_system_score_codex":0.0025865487,"about_ca_system_score_gemma":0.0013917538,"threshold_uncertainty_score":0.9006826},"labels":[],"label_agreement":null},{"id":"W4401707212","doi":"10.34172/ijhpm.8578","title":"Political Prioritization of Access to Medicines and Right to Health: Need for an Effective Global Health Governance Through Global Health Diplomacy Comment on \"More Pain, More Gain! The Delivery of COVID-19 Vaccines and the Pharmaceutical Industry’s Role in Widening the Access Gap\"","year":2024,"lang":"en","type":"article","venue":"International Journal of Health Policy and Management","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Global Health Research; University of Toronto","funders":"","keywords":"Global health; Diplomacy; Essential medicines; Business; Corporate governance; Equity (law); Global governance; Intellectual property; Right to health; Politics; Health policy; Public relations; Economic growth; Political science; Health care; Economics; Law; Finance","score_opus":0.09869667137899918,"score_gpt":0.49157980994348005,"score_spread":0.39288313856448087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401707212","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023214579,0.009324802,0.007320742,0.957388,0.00031304563,0.0016650201,0.0005203176,0.0000060739267,0.00024741143],"genre_scores_gemma":[0.6584141,0.006187405,0.00010330407,0.33496165,0.00027832828,0.00004111804,0.0000047052094,0.000007389253,0.000001978219],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9977194,0.00026006962,0.001206132,0.00026073577,0.00015779513,0.00039587254],"domain_scores_gemma":[0.99803096,0.0006906991,0.00066979,0.00013123991,0.00007344628,0.00040388256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003903822,0.000165584,0.0005345557,0.00014728334,0.00019200066,0.0001609957,0.0005029678,0.000043230248,0.0000046486775],"category_scores_gemma":[0.0003500921,0.00010875602,0.000064281594,0.00030361782,0.0001517321,0.00027436268,0.00028625835,0.0002354617,2.6586372e-7],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005747921,0.000099285004,0.0036828835,0.00060074596,0.00017020266,0.0000021487422,0.0021679306,0.0006956665,7.7589625e-8,0.9369997,0.01222385,0.042782754],"study_design_scores_gemma":[0.0086391475,0.0020122973,0.14295493,0.0015992222,0.000037296166,0.000101549405,0.0027517786,0.024751147,0.000008235274,0.46784946,0.34896317,0.0003317522],"about_ca_topic_score_codex":0.009124489,"about_ca_topic_score_gemma":0.00046472982,"teacher_disagreement_score":0.63519955,"about_ca_system_score_codex":0.0012612396,"about_ca_system_score_gemma":0.00041990392,"threshold_uncertainty_score":0.99747384},"labels":[],"label_agreement":null},{"id":"W4401809601","doi":"10.55016/ojs/sppp.v16i1.75913","title":"Canadian Competitiveness in the Health Life Sciences","year":2023,"lang":"en","type":"article","venue":"The School of Public Policy Publications","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Regional science; Political science; Geography","score_opus":0.183320896328144,"score_gpt":0.3692191266091547,"score_spread":0.18589823028101068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401809601","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.036694482,0.0005447484,0.000043379197,0.7902993,0.00009308898,0.0003172472,0.00055461924,0.00003774614,0.1714154],"genre_scores_gemma":[0.9704312,0.00051941595,0.000025374751,0.027914567,0.00021258887,0.00011623605,0.000037777092,0.0000111141935,0.00073174783],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982889,0.00012419204,0.00061440683,0.00024496624,0.000057948262,0.00066954124],"domain_scores_gemma":[0.99843615,0.00028169865,0.00027177893,0.00052843126,0.000043870907,0.0004380744],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005127717,0.00010334709,0.0002381247,0.0015430008,0.00048769562,0.00021809878,0.0014597949,0.000047079102,0.00057082315],"category_scores_gemma":[0.0019076638,0.00008037326,0.00008183948,0.0040775137,0.00031719336,0.00036962877,0.00009180211,0.00023210452,0.0014309214],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[3.7218058e-7,0.00002346043,0.040025596,0.0000051932384,0.000010953959,4.998008e-8,0.00028234097,0.00004341917,4.1556845e-7,0.9355936,0.02372884,0.00028574097],"study_design_scores_gemma":[0.00015021185,0.000016664695,0.39500314,0.0000031896702,7.678568e-7,0.0000016343243,0.00028665023,0.0011296958,6.0438026e-7,0.09158416,0.5117382,0.00008513624],"about_ca_topic_score_codex":0.18969612,"about_ca_topic_score_gemma":0.049413785,"teacher_disagreement_score":0.9337367,"about_ca_system_score_codex":0.00031837335,"about_ca_system_score_gemma":0.002809444,"threshold_uncertainty_score":0.99934655},"labels":[],"label_agreement":null},{"id":"W4401947764","doi":"10.1101/2024.08.26.24312600","title":"An evaluation of the adequacy of Indian national and state Essential Medicines Lists (EMLs) for palliative care medical needs - a comparative analysis","year":2024,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Palliative care; Medicine; State (computer science); Traditional medicine; Family medicine; Business; Nursing; Computer science","score_opus":0.1354627508960776,"score_gpt":0.41681064245982663,"score_spread":0.28134789156374906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401947764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98780626,0.0032527472,0.00015160577,0.002084492,0.00048341637,0.00061943766,0.0028993716,0.0000071543195,0.0026955295],"genre_scores_gemma":[0.9989709,0.00022734972,0.0000485641,0.00017320453,0.00023012047,0.000106755506,0.00020609223,0.000013142207,0.000023848166],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99825156,0.00007105083,0.0009071622,0.00038812973,0.00022267185,0.0001594266],"domain_scores_gemma":[0.9982946,0.00021821776,0.00071974617,0.00026137684,0.0003765153,0.00012954371],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018982741,0.00018946471,0.0007638437,0.00062498654,0.000048817117,0.000038409242,0.00037209265,0.00018478122,0.00032348727],"category_scores_gemma":[0.00038824248,0.00016363071,0.00027719812,0.00046144423,0.00025213519,0.00004871145,0.00021420245,0.00032679518,0.00000607044],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030814938,0.00064818846,0.5007944,0.005153162,0.013944154,0.0000025556044,0.17159015,0.041218054,0.00012012736,0.2578974,0.0021131025,0.0062105814],"study_design_scores_gemma":[0.0015667545,0.00009909132,0.2329812,0.00021410063,0.0011280004,5.003577e-7,0.0008600795,0.5043181,0.001446086,0.25540596,0.001549611,0.0004304677],"about_ca_topic_score_codex":0.00033806145,"about_ca_topic_score_gemma":0.00043327015,"teacher_disagreement_score":0.46310008,"about_ca_system_score_codex":0.00013169755,"about_ca_system_score_gemma":0.0004394709,"threshold_uncertainty_score":0.66726667},"labels":[],"label_agreement":null},{"id":"W4401982116","doi":"10.54194/kjry1417","title":"Benefit of expedited regulatory approval for oncology drugs eliminated by slow reimbursement reviews and price negotiations","year":2024,"lang":"en","type":"article","venue":"Canadian Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Reimbursement; Negotiation; Drug approval; Business; Pharmacology; Medicine; Political science; Law; Drug","score_opus":0.07052812717698538,"score_gpt":0.36358557158349397,"score_spread":0.2930574444065086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401982116","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09353334,0.25447887,0.0010154877,0.54407835,0.0033178017,0.0068873046,0.02267745,0.00015593758,0.073855475],"genre_scores_gemma":[0.86415726,0.034840304,0.00147513,0.0881545,0.0022952645,0.0007542271,0.00076126005,0.00015815906,0.007403904],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980978,0.000022734092,0.00090931694,0.0003700872,0.000017438062,0.0005826643],"domain_scores_gemma":[0.99854356,0.00011962415,0.00026762552,0.00023868395,0.000026793188,0.00080373854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000864717,0.00015071969,0.0005185693,0.0006340503,0.0001354558,0.00003765463,0.000143763,0.00013221728,0.00011408137],"category_scores_gemma":[0.00015387815,0.00018508533,0.00009342456,0.00033338624,0.00007393825,0.00010185161,0.000022143591,0.00014813493,0.0000576516],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000005419767,0.000021635366,0.00008190442,0.00048194602,0.000037016223,4.117376e-7,0.0014206481,0.0000070040323,0.000006767636,0.6447219,0.31745976,0.035755523],"study_design_scores_gemma":[0.0003111642,0.000111921785,0.00061424763,0.000040731073,0.0000057162524,0.000002423041,0.0000331741,0.003427197,0.000013565639,0.011698095,0.9835874,0.00015436149],"about_ca_topic_score_codex":0.09354807,"about_ca_topic_score_gemma":0.008173726,"teacher_disagreement_score":0.7706239,"about_ca_system_score_codex":0.0013216443,"about_ca_system_score_gemma":0.0011122649,"threshold_uncertainty_score":0.9124881},"labels":[],"label_agreement":null},{"id":"W4402002883","doi":"10.14740/jem997","title":"Trends in Teprotumumab Insurance Authorization and Socioeconomic Determinants of Teprotumumab Access","year":2024,"lang":"en","type":"article","venue":"Journal of Endocrinology and Metabolism","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Socioeconomic status; Authorization; Environmental health; Computer security; Population","score_opus":0.053306856012336985,"score_gpt":0.3432354785950316,"score_spread":0.28992862258269464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402002883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9672657,0.029066741,0.000083877276,0.0010627824,0.0007487778,0.00007649455,0.00008134141,0.000005688028,0.0016085609],"genre_scores_gemma":[0.99211466,0.0072886096,0.000125326,0.00016215752,0.0001708093,0.000006992647,0.0000012135405,0.000013605554,0.00011659643],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99856,0.00002710442,0.00092656584,0.0002277718,0.000016914204,0.0002416148],"domain_scores_gemma":[0.99932545,0.00007383567,0.00040279102,0.00009597753,0.000020907228,0.00008105503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041478386,0.0001294401,0.0006257487,0.00088328496,0.000034024888,0.000058329988,0.00017081598,0.000094861774,0.00013333942],"category_scores_gemma":[0.000051999836,0.00012976282,0.00009270037,0.0001436692,0.0001403501,0.00053924235,0.000079190206,0.0002970013,0.0000090067215],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012679504,0.00011263798,0.3719435,0.00019193588,0.00017628245,0.000064566484,0.00089171826,0.000037864007,0.0002801451,0.4152758,0.00034024336,0.21055849],"study_design_scores_gemma":[0.0019206749,0.00009031073,0.8399537,0.00005364475,0.0000311959,0.00030930506,0.000029095856,0.0021508152,0.001070756,0.090247035,0.06391051,0.0002329265],"about_ca_topic_score_codex":0.000054307257,"about_ca_topic_score_gemma":0.000018396733,"teacher_disagreement_score":0.46801025,"about_ca_system_score_codex":0.000029788793,"about_ca_system_score_gemma":0.00003340287,"threshold_uncertainty_score":0.52915746},"labels":[],"label_agreement":null},{"id":"W4402079230","doi":"10.1101/2024.08.28.24312695","title":"Trends of use of drugs with suggested shortages and their alternatives across 52 real world data sources and 18 countries in Europe and North America","year":2024,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Economic shortage; Real world data; Real world evidence; Development economics; Geography; Business; Natural resource economics; Economics; Data science; Computer science; Medicine","score_opus":0.11314689983133565,"score_gpt":0.32855807219478633,"score_spread":0.2154111723634507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402079230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98437876,0.005139631,0.0000067474675,0.00055328535,0.00006972188,0.00011807698,0.008665312,0.00001255295,0.001055905],"genre_scores_gemma":[0.9696264,0.029705105,0.00009305829,0.000104818275,0.000045540994,0.000008067654,0.00011371389,0.000034632776,0.00026860906],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983511,0.000030037476,0.00065474474,0.000696083,0.000029287672,0.00023873812],"domain_scores_gemma":[0.9986076,0.00025352775,0.0004984721,0.0005117689,0.000029656287,0.000098987606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037453778,0.00027002214,0.0008611119,0.00036690984,0.000031455376,0.00017473535,0.00032116196,0.00005547692,0.000021674594],"category_scores_gemma":[0.000051093408,0.00023687349,0.000028575021,0.00033425982,0.0008004069,0.00015510338,0.0014709292,0.00034917146,0.000001730298],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007870877,0.00003520635,0.9875218,0.00034153287,0.00019629032,0.0000053900167,0.0045540305,0.00008574115,0.0000037051796,0.0021228606,0.000072083705,0.0049826],"study_design_scores_gemma":[0.00045695738,0.000082232065,0.9438243,0.00017127677,0.000029212897,0.000002467556,0.00020179136,0.0078057316,0.00007550008,0.0012314505,0.045718323,0.00040077334],"about_ca_topic_score_codex":0.0023951237,"about_ca_topic_score_gemma":0.0042078984,"teacher_disagreement_score":0.04564624,"about_ca_system_score_codex":0.000015248177,"about_ca_system_score_gemma":0.00003047214,"threshold_uncertainty_score":0.965942},"labels":[],"label_agreement":null},{"id":"W4402151108","doi":"10.53879/id.61.07.p0005","title":"GLAD TIDINGS FOR INDIAN PHARMACEUTICAL INDUSTRY","year":2024,"lang":"en","type":"article","venue":"INDIAN DRUGS","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Clinical trial; Government (linguistics); Waiver; Medicine; Procurement; European union; Approved drug; Business; Political science; Pharmacology; Drug; Law; International trade","score_opus":0.0641451679386877,"score_gpt":0.33054280192797586,"score_spread":0.2663976339892882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402151108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8409994,0.005938091,0.0003680185,0.033063274,0.003827337,0.00096649845,0.0027670304,0.0003672413,0.11170311],"genre_scores_gemma":[0.9897532,0.00018967502,0.00022874479,0.006176106,0.0010831656,0.00010158169,0.00003897364,0.0000707381,0.002357841],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981666,0.000009387849,0.000581993,0.0005600635,0.000031499494,0.00065044936],"domain_scores_gemma":[0.99907184,0.00017405064,0.00009058564,0.00024336673,0.00001428161,0.00040589878],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0006111447,0.00022477946,0.0003524926,0.00041440982,0.00012684603,0.00032297536,0.0003370128,0.0003953765,0.0014739342],"category_scores_gemma":[0.000078307305,0.00027019644,0.00023306011,0.00030608315,0.00010222095,0.00031232805,0.00007551023,0.0007148534,0.003800993],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004596712,0.0001310771,0.0050157667,0.0005102059,0.00033487758,0.00007985188,0.006439944,0.000018798653,0.00007173469,0.8487202,0.07505581,0.063575774],"study_design_scores_gemma":[0.00051447086,0.000032553686,0.0003054485,0.00003489066,0.000010835688,0.00001805011,0.00008847555,0.002447567,0.0009686662,0.066649236,0.9285629,0.0003669278],"about_ca_topic_score_codex":0.000059070535,"about_ca_topic_score_gemma":0.000004582046,"teacher_disagreement_score":0.85350704,"about_ca_system_score_codex":0.00020454763,"about_ca_system_score_gemma":0.00009169981,"threshold_uncertainty_score":0.999975},"labels":[],"label_agreement":null},{"id":"W4402240112","doi":"10.12927/hcpol.2024.27334","title":"Federal Funding for Expensive Drugs for Rare Diseases: How Do We Pick and Choose?","year":2024,"lang":"en","type":"article","venue":"Healthcare policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of British Columbia; York University","funders":"","keywords":"Business","score_opus":0.1032238011079362,"score_gpt":0.3693521126074052,"score_spread":0.266128311499469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402240112","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.081429385,0.11916116,0.0020326471,0.7758614,0.0022509862,0.003016596,0.012962602,0.00026765288,0.0030175783],"genre_scores_gemma":[0.97986794,0.005692211,0.0003661989,0.009868894,0.0024560797,0.00047239006,0.00008029301,0.00008259693,0.0011134251],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981614,0.000014137869,0.0004477949,0.0006203856,0.000023991355,0.0007323416],"domain_scores_gemma":[0.99876755,0.00032537332,0.00012980308,0.00023309483,0.000042912056,0.00050124177],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023334098,0.00023944526,0.00048402717,0.00039389773,0.00029985694,0.0005337932,0.0001561772,0.00013945746,0.000033835655],"category_scores_gemma":[0.00020611369,0.00027456332,0.00022929104,0.00017845575,0.000061845865,0.00028047222,0.0000755493,0.00016252919,0.000064833],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005254025,0.000020236708,0.0009317002,0.0013952064,0.00006751207,0.0000017295961,0.0016824068,0.000002523414,0.0000036907006,0.9218905,0.024468545,0.04948338],"study_design_scores_gemma":[0.000705502,0.00009035861,0.00081919576,0.000084452106,0.000008130048,0.0000058585315,0.00034414223,0.0054206387,0.00001603305,0.2759055,0.7163013,0.0002988424],"about_ca_topic_score_codex":0.0005933175,"about_ca_topic_score_gemma":0.00004262157,"teacher_disagreement_score":0.8984385,"about_ca_system_score_codex":0.0003496885,"about_ca_system_score_gemma":0.00019842217,"threshold_uncertainty_score":0.9999707},"labels":[],"label_agreement":null},{"id":"W4402297416","doi":"10.55016/ojs/jah.v2023y2023.77200","title":"Responding to Unexpected Urine Drug Test Results: A Phenomenological Approach","year":2023,"lang":"en","type":"article","venue":"Journal of Applied Hermeneutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Test (biology); Urine; Drug; Psychology; Medicine; Internal medicine; Psychiatry; Geology","score_opus":0.06779407493633377,"score_gpt":0.28959157288263754,"score_spread":0.22179749794630377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402297416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5890225,0.00004989349,0.00004632485,0.005410496,0.0003718262,0.00026272942,0.00032703427,0.000074210184,0.40443495],"genre_scores_gemma":[0.9931798,0.0003259624,0.0023329337,0.0020699392,0.0005870681,0.000014414146,0.000015166434,0.000041981064,0.0014327448],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976101,0.000012668949,0.0014370272,0.00033597287,0.0000731983,0.00053102913],"domain_scores_gemma":[0.998371,0.00024588546,0.00067635404,0.00029704985,0.000049939787,0.00035977826],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013391951,0.00020790209,0.0006216158,0.0012466762,0.00011351613,0.000098363795,0.00049682905,0.000117272895,0.000082630584],"category_scores_gemma":[0.00027529182,0.00021141721,0.00014575779,0.0015341245,0.000059661368,0.000095523304,0.00018452013,0.00044657628,0.00087713357],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014039085,0.0009804844,0.0013436734,0.00009704533,0.00037278238,0.00010842277,0.019795991,0.013789633,0.0041085747,0.90193117,0.0536702,0.0023981195],"study_design_scores_gemma":[0.004421617,0.00039263122,0.004519319,0.000026405309,0.00003985574,0.00005406973,0.0020494785,0.009766363,0.0011118527,0.3343925,0.6423889,0.00083701545],"about_ca_topic_score_codex":0.0000013140804,"about_ca_topic_score_gemma":7.235793e-7,"teacher_disagreement_score":0.5887187,"about_ca_system_score_codex":0.00023529399,"about_ca_system_score_gemma":0.00004930085,"threshold_uncertainty_score":0.9999008},"labels":[],"label_agreement":null},{"id":"W4402394418","doi":"10.1108/jfc-05-2024-0150","title":"Valeant pharmaceuticals fraud","year":2024,"lang":"en","type":"article","venue":"Journal of Financial Crime","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal","funders":"","keywords":"Business; Criminology; Law and economics; Economics; Psychology","score_opus":0.08431013818497925,"score_gpt":0.3395549638580178,"score_spread":0.2552448256730386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402394418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.54836464,0.12608695,0.011268979,0.02405078,0.017456116,0.0004147597,0.0005704862,0.00013937766,0.27164793],"genre_scores_gemma":[0.9914325,0.0017585009,0.00047714618,0.0035417546,0.0020518177,0.0000021653027,0.0000011064989,0.00003059667,0.00070445205],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99834216,0.000014655542,0.001056365,0.00020322255,0.000048036403,0.00033553856],"domain_scores_gemma":[0.99920094,0.00010761854,0.00026833854,0.00013577064,0.000046718014,0.00024058599],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010016542,0.00015195536,0.0004765293,0.0003595124,0.000057155365,0.0001478356,0.00029490254,0.000110519686,0.0013559258],"category_scores_gemma":[0.0002682444,0.00015269617,0.00036397885,0.00022876266,0.000067135996,0.00036774104,0.000047940794,0.00051584153,0.0017170955],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005943164,0.00011534162,0.00093631557,0.000095881674,0.000091416645,0.00025608405,0.0002957295,0.000039720962,0.00041332317,0.9063104,0.07836292,0.013023448],"study_design_scores_gemma":[0.00037896936,0.00010648138,0.00404569,0.000044283413,0.000022616721,0.00012931623,0.0000040285395,0.0015817751,0.0008883136,0.1295065,0.8630962,0.0001958689],"about_ca_topic_score_codex":0.0000104683295,"about_ca_topic_score_gemma":6.211612e-7,"teacher_disagreement_score":0.78473324,"about_ca_system_score_codex":0.00012725007,"about_ca_system_score_gemma":0.00014663396,"threshold_uncertainty_score":0.99955696},"labels":[],"label_agreement":null},{"id":"W4402413658","doi":"10.51731/cjht.2024.970","title":"Drug Shortages and Patient Harms","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Economic shortage; Medicine; Intensive care medicine; Business; Pharmacology; Government (linguistics)","score_opus":0.05190415301851258,"score_gpt":0.2854990001977715,"score_spread":0.23359484717925894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402413658","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22198825,0.6111461,0.00011664971,0.16235949,0.0011306145,0.00012278091,0.00019260707,0.000071420814,0.0028721022],"genre_scores_gemma":[0.993201,0.004897763,0.00015474779,0.001669707,0.000014182055,0.0000024033948,6.196973e-7,0.000011598118,0.000047987258],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99893594,0.000006891517,0.0005970598,0.00013694185,0.000012861902,0.0003103061],"domain_scores_gemma":[0.9995478,0.000036357433,0.00017775362,0.000107835294,0.00001457558,0.00011571339],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043347047,0.000085917556,0.0002819603,0.0006366892,0.00010213222,0.00012395524,0.0001713684,0.0000634122,0.00007116549],"category_scores_gemma":[0.00011035286,0.00008461013,0.000055780085,0.00014747759,0.00012748322,0.00015289435,0.000020174222,0.0003119702,0.000048648315],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000001950151,0.0000069406556,0.005028225,0.00012099062,0.0000569264,0.00007778012,0.0009990684,0.000012951375,0.0000018189758,0.34735465,0.039361537,0.60697716],"study_design_scores_gemma":[0.00006169984,0.00005984894,0.0010658822,0.000053984804,0.0000015971264,0.000060878447,0.0004100454,0.00020803037,0.00004233465,0.1008058,0.8971401,0.00008983179],"about_ca_topic_score_codex":0.0019581344,"about_ca_topic_score_gemma":0.0007351631,"teacher_disagreement_score":0.85777855,"about_ca_system_score_codex":0.00020144379,"about_ca_system_score_gemma":0.0003570776,"threshold_uncertainty_score":0.34503013},"labels":[],"label_agreement":null},{"id":"W4402602162","doi":"10.1007/s10018-024-00411-6","title":"Bioprospecting, drug choices and conservation of biological diversity under free trade","year":2024,"lang":"en","type":"article","venue":"Environmental Economics and Policy Studies","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; MacEwan University","funders":"","keywords":"Bioprospecting; Diversity (politics); Social policy; Economics; Biology; Ecology; Political science; Market economy","score_opus":0.08351119623504226,"score_gpt":0.28663156292944125,"score_spread":0.20312036669439898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402602162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95868546,0.023414504,0.000005160769,0.014640889,0.00016517482,0.000115535,0.00070581975,0.000017856084,0.0022496097],"genre_scores_gemma":[0.9328655,0.06510202,0.0000664472,0.0015614585,0.0001549057,0.000006324834,0.000007229531,0.000012147221,0.00022395776],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9990285,0.0000070745114,0.0003902033,0.00036452405,0.000010715539,0.00019899003],"domain_scores_gemma":[0.9995171,0.00013023506,0.00013027195,0.0001351217,0.0000010269149,0.00008624684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023373707,0.00016380593,0.00037379065,0.00014519478,0.0001899317,0.000049226528,0.00011531865,0.000063342544,0.000044412587],"category_scores_gemma":[0.00002196606,0.00017062185,0.0000713259,0.000046562134,0.00046976557,0.00017609568,0.00055301207,0.00009892845,0.000025195464],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013461528,0.000044824625,0.10495773,0.00006877102,0.00033476768,9.4908006e-7,0.0018855992,0.000024114384,0.00006341638,0.89051425,0.0007942937,0.0012978015],"study_design_scores_gemma":[0.0009067624,0.00010463374,0.24177383,0.000024643188,0.0000306222,0.000014109769,0.0009838288,0.0032811896,0.0004256253,0.6157173,0.13623592,0.0005015686],"about_ca_topic_score_codex":0.00040883003,"about_ca_topic_score_gemma":0.00005335268,"teacher_disagreement_score":0.27479702,"about_ca_system_score_codex":0.0001221084,"about_ca_system_score_gemma":0.0000064935616,"threshold_uncertainty_score":0.6957757},"labels":[],"label_agreement":null},{"id":"W4402657255","doi":"10.1515/9782760650541-010","title":"Chapitre 9 Stayin’ Alive. L’importation de médicaments destinés au marché canadien comme stratégie de diminution des coûts aux États-Unis ?","year":2024,"lang":"fr","type":"book-chapter","venue":"Les Presses de l'Université de Montréal eBooks","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science","score_opus":0.06120549390267122,"score_gpt":0.24737485392561856,"score_spread":0.18616936002294734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402657255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.56650555,0.014878129,0.0019326995,0.0032767,0.00040453978,0.0007441245,0.005395581,0.00014042361,0.40672225],"genre_scores_gemma":[0.9464639,0.009710422,0.0013933281,0.0015873951,0.00033113692,0.00003692316,0.0003374505,0.00019659952,0.039942883],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964652,0.00007935322,0.0008844983,0.00089172344,0.000107338434,0.0015718753],"domain_scores_gemma":[0.9973642,0.00030913472,0.0006804397,0.0005225984,0.00009419783,0.0010294006],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00052013376,0.0007371529,0.00086217065,0.0005221087,0.001266385,0.00026200214,0.00076208345,0.0007384646,0.001508294],"category_scores_gemma":[0.00007314423,0.0010656969,0.00043895884,0.00006392298,0.0009266862,0.00023015172,0.0005060286,0.00096414454,0.00031332942],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004828015,0.0001403502,0.052488085,0.001285304,0.0015104181,0.0025972524,0.009765231,0.0030589858,0.00028224898,0.85144687,0.0043772757,0.07256516],"study_design_scores_gemma":[0.0020147755,0.0004427862,0.048433784,0.0008731758,0.00087175844,0.00045182093,0.00074608467,0.04466411,0.00055442296,0.39168903,0.5074073,0.0018509113],"about_ca_topic_score_codex":0.23242168,"about_ca_topic_score_gemma":0.17234236,"teacher_disagreement_score":0.50303006,"about_ca_system_score_codex":0.009069446,"about_ca_system_score_gemma":0.0007547475,"threshold_uncertainty_score":0.9994045},"labels":[],"label_agreement":null},{"id":"W4402740932","doi":"10.62848/bjpain.v2i2.7711","title":"Estimation of Annual Need, Production and Per Capita Consumptions of Oral Morphine in Bangladesh","year":2022,"lang":"en","type":"article","venue":"Bangladesh Journal of Pain.","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario","funders":"","keywords":"Per capita; Estimation; Morphine; Production (economics); Agricultural economics; Economics; Econometrics; Medicine; Anesthesia; Environmental health; Macroeconomics","score_opus":0.037667646529220465,"score_gpt":0.2737302867947965,"score_spread":0.23606264026557602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402740932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99312437,0.0021319017,0.00041980293,0.0033397297,0.00026959257,0.00013472639,0.00029837558,0.0000033590084,0.00027813695],"genre_scores_gemma":[0.998501,0.00025456215,0.0009051216,0.00018870429,0.00006192084,0.000006183614,0.000008087234,0.000012483831,0.00006191521],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986238,0.00007247403,0.0009587633,0.00013850743,0.00005370895,0.00015278264],"domain_scores_gemma":[0.99887085,0.00008299951,0.0007973704,0.00011760724,0.000058005935,0.00007313831],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002069311,0.00009469813,0.00040770977,0.0005266413,0.000052974032,0.000011556533,0.00014501606,0.00004149956,0.00068408385],"category_scores_gemma":[0.00025707154,0.00011091112,0.000092342125,0.00016902953,0.0000958863,0.0002606104,0.00006128261,0.00025573498,0.0000068255426],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009900057,0.0026570894,0.5405377,0.0007748786,0.0006463597,0.000051318653,0.015053968,0.11257314,0.0044969935,0.25554344,0.029183595,0.037491515],"study_design_scores_gemma":[0.014693111,0.0036753614,0.47866517,0.00032758928,0.0002440234,0.0011951221,0.007906912,0.20845778,0.0038247877,0.16964266,0.10939065,0.0019768223],"about_ca_topic_score_codex":0.000106677406,"about_ca_topic_score_gemma":0.000018578263,"teacher_disagreement_score":0.09588464,"about_ca_system_score_codex":0.00010610019,"about_ca_system_score_gemma":0.000048619866,"threshold_uncertainty_score":0.74902385},"labels":[],"label_agreement":null},{"id":"W4402850765","doi":"10.7324/japs.2024.204337","title":"A deep dive into the development of complex generics: A comprehensive review","year":2024,"lang":"en","type":"review","venue":"Journal of Applied Pharmaceutical Science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Development (topology); Computer science; Artificial intelligence; History; Mathematics","score_opus":0.26800963047942034,"score_gpt":0.43417693833985627,"score_spread":0.16616730786043593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402850765","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000012477382,0.98832697,0.00047195604,0.00078054075,0.00063032005,0.00065831287,0.00003315332,0.000008810282,0.009077436],"genre_scores_gemma":[0.0002084055,0.9920221,0.0042234473,0.0031682374,0.00028553294,0.00003766744,0.0000041291587,0.000037212336,0.000013242669],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951764,0.000038433303,0.00342641,0.00053520146,0.00025380048,0.00056975096],"domain_scores_gemma":[0.9964669,0.00030570175,0.0021791144,0.00039067946,0.00017035542,0.00048725403],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003146279,0.0004557463,0.002629161,0.0005033814,0.0002371954,0.00013959616,0.0021463416,0.00013007139,0.00038426457],"category_scores_gemma":[0.00010854852,0.00030100395,0.0007144983,0.0015480138,0.0010245567,0.0001460637,0.0007189109,0.0011169373,0.0006513253],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014326524,0.000108200824,6.5216926e-7,0.024450669,0.000434062,0.000008339852,0.000886594,0.000011884306,0.000014103149,0.05963875,0.002686612,0.9117458],"study_design_scores_gemma":[0.0001764825,0.00002452129,0.0000022800343,0.0032326574,0.0004677812,0.00004465815,0.000024438204,0.0006636458,0.000015649706,0.0061580827,0.9888595,0.00033033625],"about_ca_topic_score_codex":0.0000020071368,"about_ca_topic_score_gemma":8.81648e-7,"teacher_disagreement_score":0.98617285,"about_ca_system_score_codex":0.00053223193,"about_ca_system_score_gemma":0.0008933994,"threshold_uncertainty_score":0.9999442},"labels":[],"label_agreement":null},{"id":"W4402854708","doi":"10.2471/blt.24.292359","title":"WHO Model list of essential medicines: visions for the future","year":2024,"lang":"en","type":"article","venue":"Bulletin of the World Health Organization","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"World Health Organization","keywords":"Vision; Medicine; Data science; Computer science; Sociology","score_opus":0.024842999854390504,"score_gpt":0.3049278993978199,"score_spread":0.2800848995434294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402854708","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033452483,0.0132685555,0.022915455,0.95161426,0.0026264195,0.0009981018,0.0006248296,0.00004185487,0.004565278],"genre_scores_gemma":[0.9769271,0.0027702632,0.00060881296,0.013155163,0.0009771036,0.000014019628,0.00002506767,0.00005077927,0.0054716873],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990974,0.000011218927,0.00055935123,0.0001578304,0.000028512079,0.00014570642],"domain_scores_gemma":[0.99922794,0.00016954412,0.00026916136,0.00023494041,0.000051706564,0.000046704645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051265163,0.00007812088,0.00022927909,0.000094751544,0.00015879609,0.00002210085,0.00026309484,0.00003833473,0.00076191046],"category_scores_gemma":[0.000118176125,0.000055669203,0.000077753626,0.00039581404,0.000064019645,0.000018216662,0.00006667086,0.00011045635,0.0000342989],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007785003,0.000026270127,0.00047482795,0.0003284696,0.000029526991,2.2545914e-8,0.00040940222,0.0018405996,0.000012216205,0.6693435,0.3269528,0.0005746179],"study_design_scores_gemma":[0.00023969736,0.000018504135,0.00083470915,0.00009662654,0.000014754849,6.8783356e-7,0.000035036363,0.07817147,0.00021249152,0.015219393,0.9050827,0.0000739387],"about_ca_topic_score_codex":0.000104091094,"about_ca_topic_score_gemma":0.000075345044,"teacher_disagreement_score":0.97358185,"about_ca_system_score_codex":0.000060481147,"about_ca_system_score_gemma":0.00009470018,"threshold_uncertainty_score":0.8342385},"labels":[],"label_agreement":null},{"id":"W4402931038","doi":"10.58502/dtt.23.0033","title":"Organoid Global Regulatory Policy: A Cross-Sectional Study","year":2024,"lang":"en","type":"article","venue":"Drug Targets and Therapeutics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Ministry of Science and ICT, South Korea; National Research Foundation of Korea; Ministry of Education; National Research Foundation","keywords":"Organoid; Cross-sectional study; Environmental health; Medicine; Psychology; Neuroscience; Pathology","score_opus":0.043906901384400246,"score_gpt":0.32589823303287774,"score_spread":0.2819913316484775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402931038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9608336,0.015425286,0.00014749577,0.002472423,0.0010853098,0.0002542605,0.000568294,0.00012433145,0.019089004],"genre_scores_gemma":[0.99507326,0.00057358603,0.00005595836,0.0025840378,0.0006068881,0.000013545843,0.000010758188,0.000031128082,0.0010508529],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9986375,0.000016223434,0.0004951254,0.00046988518,0.000040786836,0.00034046758],"domain_scores_gemma":[0.9994924,0.0000412999,0.00007388062,0.00022690502,0.000019984856,0.00014552061],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004861009,0.00019345085,0.00026250974,0.00014343497,0.0001649801,0.0004046033,0.00017004153,0.000087631146,0.00029331728],"category_scores_gemma":[0.000011288826,0.00020223914,0.00010068099,0.00024903804,0.000115826784,0.00018895525,0.00009349161,0.00018837299,0.0004497029],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015926684,0.00013183035,0.45558992,0.000025829884,0.0002278368,0.000006967217,0.00056341133,0.000018856803,0.000012315727,0.54151875,0.00036557546,0.0015227831],"study_design_scores_gemma":[0.0005036055,0.000052259667,0.43486005,0.000003601197,0.000011320202,0.000014159826,0.000032525564,0.0042047915,0.00003175495,0.18179779,0.37819353,0.00029461735],"about_ca_topic_score_codex":0.00021209278,"about_ca_topic_score_gemma":0.000027101265,"teacher_disagreement_score":0.37782794,"about_ca_system_score_codex":0.00017979844,"about_ca_system_score_gemma":0.00007114361,"threshold_uncertainty_score":0.82470727},"labels":[],"label_agreement":null},{"id":"W4403087705","doi":"10.1016/s0140-6736(24)01549-6","title":"WHO shapes priorities for medicines? An analysis of the applicants and decision makers within the historical evolution of the WHO Model Lists of Essential Medicines","year":2024,"lang":"en","type":"review","venue":"The Lancet","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; National Science Foundation","keywords":"Medicine; Management science; Business; Economics","score_opus":0.10596408588449997,"score_gpt":0.3644612869135918,"score_spread":0.25849720102909185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403087705","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0061612152,0.98635924,0.000880412,0.002994867,0.00050686824,0.0010308892,0.0015943578,0.0000073326023,0.00046481102],"genre_scores_gemma":[0.059475966,0.93892616,0.0000808146,0.00041118826,0.0007476097,0.00009738537,0.00000914433,0.00003685599,0.00021485498],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99819434,0.000056827528,0.001154659,0.00030899723,0.000095344294,0.00018985501],"domain_scores_gemma":[0.9975654,0.00045986212,0.0011461297,0.00073906936,0.00004593001,0.00004364229],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014939902,0.0002277884,0.0021769388,0.00018303996,0.00010303843,0.000023064082,0.0010118553,0.00014852018,0.000010322427],"category_scores_gemma":[0.00021614422,0.000100630234,0.00055837876,0.0005929307,0.00041267165,0.000046798363,0.00022603247,0.0002856058,8.7735407e-7],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028603975,0.00011839065,0.0023651165,0.018051378,0.0047995183,3.7998456e-7,0.003406181,0.0033299709,0.0000070615815,0.85373414,0.026800314,0.08710151],"study_design_scores_gemma":[0.0008446723,0.00008119687,0.0023180235,0.0033345437,0.007265661,0.000005435482,0.0000986615,0.4088929,0.000003932288,0.13062973,0.44614518,0.00038005866],"about_ca_topic_score_codex":0.0003284432,"about_ca_topic_score_gemma":0.00022553209,"teacher_disagreement_score":0.7231044,"about_ca_system_score_codex":0.00019457757,"about_ca_system_score_gemma":0.00012948416,"threshold_uncertainty_score":0.4103582},"labels":[],"label_agreement":null},{"id":"W4403238055","doi":"10.3389/jpps.2024.13694","title":"Expanding the eligibility criteria for drugs in Canada’s time-limited health technology assessment and temporary drug access processes will further accelerate access to new medicines","year":2024,"lang":"en","type":"editorial","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Business; Medicine; Pharmacology","score_opus":0.12993870346823802,"score_gpt":0.48394426767465515,"score_spread":0.35400556420641716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403238055","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09538089,0.048434626,0.00024326758,0.54395556,0.30637413,0.0027596955,0.0015750334,0.00006507455,0.0012117289],"genre_scores_gemma":[0.6925402,0.033800118,0.000673738,0.029672379,0.24252068,0.00018958101,0.00004226578,0.00019417834,0.00036685812],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99521613,0.00011721252,0.0023605425,0.0009429856,0.00037821571,0.0009848888],"domain_scores_gemma":[0.99574006,0.001642141,0.001296528,0.00024102055,0.00023493936,0.00084528566],"candidate_categories":["metaepi_narrow","scholarly_communication"],"consensus_categories":[],"category_scores_codex":[0.005222407,0.0005289202,0.0014396425,0.0010473835,0.0003242496,0.0012312715,0.0026834859,0.00015232092,0.00043076527],"category_scores_gemma":[0.0008728692,0.00039917903,0.00015735696,0.0015904678,0.00037539922,0.0015079522,0.00077330327,0.0015304671,0.000010382586],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018516165,0.000087546556,0.0070807873,0.00070327095,0.00013207828,0.000012215335,0.00050066045,0.000070780494,0.000030655603,0.00020730635,0.98090476,0.010084781],"study_design_scores_gemma":[0.0016502934,0.00011267834,0.00019057444,0.00033320882,0.000061745086,0.000012721249,0.00019672707,0.0034042757,0.00032615266,0.01072861,0.982509,0.00047400498],"about_ca_topic_score_codex":0.06265996,"about_ca_topic_score_gemma":0.02253516,"teacher_disagreement_score":0.5971593,"about_ca_system_score_codex":0.0014283103,"about_ca_system_score_gemma":0.011225222,"threshold_uncertainty_score":0.999846},"labels":[],"label_agreement":null},{"id":"W4403315467","doi":"10.1038/s43856-024-00594-9","title":"Antimicrobial drug pricing","year":2024,"lang":"en","type":"article","venue":"Communications Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Pfizer","keywords":"Antimicrobial drug; Antimicrobial; Drug pricing; Drug; Medicine; Business; Pharmacology; Microbiology; Biology","score_opus":0.11445133773982903,"score_gpt":0.34767839557450547,"score_spread":0.23322705783467645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403315467","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014206484,0.07021723,0.0028946295,0.266351,0.0014691731,0.00027082695,0.00011597543,0.00027155408,0.6442031],"genre_scores_gemma":[0.9861336,0.006204699,0.0008458558,0.0042456277,0.00030586708,0.000015717056,0.000043690812,0.000022746293,0.0021821933],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991405,0.000015132843,0.00045747013,0.00019807807,0.000013237779,0.00017556554],"domain_scores_gemma":[0.99874204,0.00017989134,0.000066216824,0.0009112175,0.000013570386,0.000087077475],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005481118,0.00009290155,0.00022466354,0.00023958026,0.00012805346,0.00004785841,0.0006265586,0.000036043777,0.00066631485],"category_scores_gemma":[0.00009104207,0.00009573202,0.00005584517,0.00029758978,0.00022155025,0.00012980386,0.00019165855,0.0002520899,0.0019657058],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000013375196,0.000028541197,0.0005450099,0.000037844387,0.00003544259,0.0000013633995,0.00094106095,0.000005308002,0.00012854683,0.9019678,0.09196203,0.0043456876],"study_design_scores_gemma":[0.00018589594,0.000007901488,0.0003662712,0.000076697674,0.000008302868,0.000008074636,0.000027803797,0.015949355,0.000039592993,0.037611533,0.94560456,0.00011400098],"about_ca_topic_score_codex":0.00017599596,"about_ca_topic_score_gemma":0.000016654716,"teacher_disagreement_score":0.9719271,"about_ca_system_score_codex":0.00007910676,"about_ca_system_score_gemma":0.000021527158,"threshold_uncertainty_score":0.99881136},"labels":[],"label_agreement":null},{"id":"W4403333758","doi":"10.1001/jamahealthforum.2024.3391","title":"Competition in International Generic Drug Markets","year":2024,"lang":"en","type":"article","venue":"JAMA Health Forum","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Government of Canada; Women's College Hospital; Public Health Ontario; University of Toronto","funders":"","keywords":"Competition (biology); Drug; Business; International market; Generic drug; Industrial organization; Drug prices; International trade; International economics; Public economics; Economics; Pharmacology; Medicine; Biology","score_opus":0.04426216404522113,"score_gpt":0.3156063757311991,"score_spread":0.27134421168597794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403333758","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14557153,0.016606323,0.0011705535,0.575025,0.006378552,0.00042383902,0.000929906,0.00013866571,0.25375563],"genre_scores_gemma":[0.9752546,0.0026244298,0.00023151957,0.020412756,0.00033372795,0.000026235683,0.00006060531,0.000019740324,0.0010363727],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99882996,0.0000143221605,0.0005237492,0.00027205143,0.000020522744,0.00033938885],"domain_scores_gemma":[0.99962384,0.000050138886,0.00008524977,0.00011547009,0.000006279779,0.000119040604],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000643463,0.00008764354,0.00019708938,0.00031577505,0.00004285313,0.00013199706,0.00015682142,0.000049433558,0.0010047372],"category_scores_gemma":[0.000026417287,0.00010698348,0.0000653975,0.00017051125,0.000020173022,0.00025402007,0.000056136018,0.00021378385,0.0013712315],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013712568,0.000041917796,0.0073379953,0.000080459664,0.000015608815,0.0000058589994,0.00023406078,0.000038129285,0.0000015038056,0.9139174,0.056337938,0.021975407],"study_design_scores_gemma":[0.00029749935,0.000011136491,0.013609053,0.000033896904,3.507707e-7,0.0000046777327,0.000027210192,0.053653847,0.000005060101,0.073123515,0.85912895,0.000104792896],"about_ca_topic_score_codex":0.00042659385,"about_ca_topic_score_gemma":0.00015995762,"teacher_disagreement_score":0.8407939,"about_ca_system_score_codex":0.00036879283,"about_ca_system_score_gemma":0.000059487895,"threshold_uncertainty_score":0.9999085},"labels":[],"label_agreement":null},{"id":"W4403503072","doi":"10.1002/pds.70035","title":"Keep Your Guard Up: The Potential Impact of Drug Shortages on Pharmacoepidemiological Studies","year":2024,"lang":"en","type":"article","venue":"Pharmacoepidemiology and Drug Safety","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Pharmacoepidemiology; Drug; Economic shortage; Guard (computer science); Pharmacology; Medical prescription","score_opus":0.13480210616756663,"score_gpt":0.42431282890752264,"score_spread":0.28951072273995604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403503072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7695207,0.14800443,0.0013419052,0.064320564,0.004789639,0.00074912334,0.0016219195,0.00020761898,0.009444067],"genre_scores_gemma":[0.9439197,0.04724474,0.000070286784,0.007203119,0.00076993,0.000044303186,0.00002742749,0.000033180102,0.00068728655],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9961587,0.00062907336,0.0016313262,0.0008243433,0.000040544808,0.0007160062],"domain_scores_gemma":[0.99444056,0.004554857,0.00038867965,0.00032654486,0.000038328817,0.00025105645],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0071587707,0.00043877657,0.0013393088,0.00023358231,0.00027843012,0.000031350308,0.00044301266,0.0001490929,0.00087809004],"category_scores_gemma":[0.0010692172,0.0002975833,0.0006746895,0.0002284119,0.0007058076,0.00021004437,0.00024618855,0.0009144969,0.00034204873],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013921077,0.00025053576,0.05918541,0.00042932868,0.0050294846,0.000074539734,0.0027322168,0.015456482,0.00048219005,0.539138,0.35082608,0.025003599],"study_design_scores_gemma":[0.0031890583,0.00034422372,0.05647843,0.00015182504,0.00043206947,0.00013944715,0.0004830207,0.17073204,0.00065409136,0.407788,0.35805422,0.0015535905],"about_ca_topic_score_codex":0.00023570425,"about_ca_topic_score_gemma":0.0000049031087,"teacher_disagreement_score":0.174399,"about_ca_system_score_codex":0.00014053621,"about_ca_system_score_gemma":0.000047296617,"threshold_uncertainty_score":0.9999476},"labels":[],"label_agreement":null},{"id":"W4403536808","doi":"10.1177/20499361241281136","title":"Prescribing equity: physicians as advocates for access to essential medicines. A call to action from medical graduates","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Infectious Disease","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"McGill University","keywords":"Call to action; Equity (law); Action (physics); Access to medicines; Business; Family medicine; Medicine; Medical education; Public relations; Nursing; Political science; Marketing; Law","score_opus":0.07538764527644878,"score_gpt":0.40894845515167544,"score_spread":0.3335608098752266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403536808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6682178,0.045110837,0.2042533,0.058211822,0.008471306,0.003386686,0.001436372,0.00062769576,0.010284201],"genre_scores_gemma":[0.9791461,0.002329221,0.000056989255,0.016807836,0.0009981031,0.0004956576,0.000043109227,0.000054402994,0.000068570705],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9981747,0.000022732296,0.00055891305,0.0006671119,0.000087639455,0.00048888416],"domain_scores_gemma":[0.9987969,0.00035315857,0.00008906332,0.00026174416,0.00002679102,0.00047236742],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035106702,0.0002413967,0.00041829783,0.00035209153,0.0000970266,0.00024163787,0.00040481423,0.00007929868,0.00036594408],"category_scores_gemma":[0.00030517933,0.0002636259,0.00014704574,0.00042504148,0.000072745584,0.0006470846,0.00018998454,0.00020547373,0.00038738694],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092995504,0.0007862397,0.016569033,0.00068482204,0.00042895114,0.000053674365,0.0021437511,0.007901632,0.00032269116,0.16716258,0.003540294,0.7994764],"study_design_scores_gemma":[0.0010106226,0.00016405665,0.0022103926,0.00028056916,0.000064872365,0.0000019892134,0.000035627352,0.035300676,0.0005138597,0.6853519,0.27450153,0.00056389626],"about_ca_topic_score_codex":0.0005054335,"about_ca_topic_score_gemma":0.0005101654,"teacher_disagreement_score":0.79891247,"about_ca_system_score_codex":0.0002574388,"about_ca_system_score_gemma":0.00011388267,"threshold_uncertainty_score":0.9999816},"labels":[],"label_agreement":null},{"id":"W4403652681","doi":"10.1017/cts.2024.635","title":"93 Investigating the minimal requirements for startup procurement by healthcare institutions in Ontario, Canada – CORRIGENDUM","year":2024,"lang":"en","type":"erratum","venue":"Journal of Clinical and Translational Science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Procurement; Business; Health care; Engineering management; Operations management; Engineering; Economic growth; Marketing; Economics","score_opus":0.35582486771904426,"score_gpt":0.4187223117681354,"score_spread":0.06289744404909114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403652681","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15003535,0.05660959,0.0013410915,0.54051894,0.16142981,0.003523763,0.0091743255,0.000022196878,0.077344924],"genre_scores_gemma":[0.97430086,0.001409634,0.0011119016,0.010573798,0.0020866126,0.00003624415,0.00009723175,0.000028238115,0.010355459],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971149,0.000019504367,0.0020513223,0.000334883,0.00017762922,0.0003017928],"domain_scores_gemma":[0.9985451,0.00018812597,0.00076796644,0.000095468764,0.00011260903,0.00029070358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032027354,0.00014841612,0.0005095605,0.0001338689,0.00023162371,0.00012399115,0.00039603675,0.00013006758,0.000063409665],"category_scores_gemma":[0.00034313617,0.00011758504,0.00014584324,0.00021123854,0.0004968801,0.00025301095,0.00003689635,0.0011521248,0.0000025940506],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006699668,0.00014232058,0.086713105,0.00021732783,0.00012902131,0.00000716148,0.00053111505,0.00010659849,0.000002807554,0.18589857,0.7237003,0.0024846697],"study_design_scores_gemma":[0.00047711312,0.00010111232,0.030560335,0.00013634279,0.00001585621,0.0000047733524,0.000015451173,0.0022586726,0.0000010930721,0.047887612,0.9184016,0.00014002026],"about_ca_topic_score_codex":0.20692067,"about_ca_topic_score_gemma":0.8003783,"teacher_disagreement_score":0.82426554,"about_ca_system_score_codex":0.00024243782,"about_ca_system_score_gemma":0.009232901,"threshold_uncertainty_score":0.99638385},"labels":[],"label_agreement":null},{"id":"W4403835855","doi":"10.54194/pggo7479","title":"State importation programs are unrealistic: diverting prescription drugs to American consumers would rapidly deplete the Canadian drug supply","year":2024,"lang":"en","type":"article","venue":"Canadian Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"U.S. Food and Drug Administration; Innovative Medicines Canada; U.S. Department of Health and Human Services","keywords":"Business; Prescription drug; Medical prescription; Drug; State (computer science); Pharmacology; Medicine; Computer science","score_opus":0.05622939593768062,"score_gpt":0.32703699240706535,"score_spread":0.27080759646938474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403835855","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24190167,0.0048607923,0.0000750725,0.721571,0.0017152275,0.0025857259,0.01232429,0.00018692811,0.014779286],"genre_scores_gemma":[0.9107224,0.00046016602,0.000070331596,0.08732137,0.00036453718,0.00012580362,0.00019678124,0.000063712956,0.0006748972],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969666,0.00006273337,0.00083066407,0.0005656532,0.000055348733,0.0015189772],"domain_scores_gemma":[0.9962369,0.000077578494,0.00028422478,0.00037760733,0.00004593524,0.0029777554],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009498706,0.00026126672,0.0004182621,0.001177422,0.0007148364,0.0005557825,0.00036667893,0.00009454785,0.000106055864],"category_scores_gemma":[0.00019877721,0.00027873568,0.00011730241,0.0010090705,0.00017662156,0.00018945536,0.000030707193,0.0005719897,0.0007780267],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022090477,0.000024463652,0.09500807,0.00034248587,0.0002108437,0.000046252266,0.021865208,0.00035925838,0.0000016459477,0.421542,0.19156697,0.26901072],"study_design_scores_gemma":[0.00015308984,0.000047507838,0.054160293,0.00005481811,0.0000065560903,0.000004991673,0.00033906623,0.0035438673,0.000002218682,0.006340588,0.93500453,0.00034248814],"about_ca_topic_score_codex":0.9972234,"about_ca_topic_score_gemma":0.99587345,"teacher_disagreement_score":0.7434375,"about_ca_system_score_codex":0.004048895,"about_ca_system_score_gemma":0.003991805,"threshold_uncertainty_score":1},"labels":[],"label_agreement":null},{"id":"W4403835971","doi":"10.54194/kjid4264","title":"Les programmes d’importation des États-Unis sont irréalistes : détourner les médicaments d’ordonnance vers les consommateurs américains épuiserait rapidement l’approvisionnement en médicaments au Canada","year":2024,"lang":"fr","type":"article","venue":"Canadian Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Canadian Institute for Health Information","funders":"","keywords":"Humanities; Political science; Forestry; Art; Geography","score_opus":0.07533527885452804,"score_gpt":0.3474552270517634,"score_spread":0.2721199481972354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403835971","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2905933,0.12480797,0.00024095837,0.53689796,0.0048693814,0.002811758,0.013873303,0.00014356642,0.025761789],"genre_scores_gemma":[0.9390116,0.03075617,0.0006954807,0.021467522,0.0015018436,0.0002906068,0.00042707284,0.00017334858,0.0056763715],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9932315,0.00025669244,0.002125694,0.0011525045,0.00019330392,0.0030403475],"domain_scores_gemma":[0.9951995,0.00034876232,0.00070688047,0.00056245,0.000091425725,0.003090955],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016132504,0.0007209552,0.0010242363,0.0010929649,0.0018229001,0.0004985281,0.0006537795,0.000370217,0.0011435542],"category_scores_gemma":[0.00043107086,0.0009167594,0.00029660016,0.00081378216,0.00074180186,0.00037673902,0.000115708724,0.00076333346,0.00018446677],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000018456205,0.00016471455,0.03994607,0.0017298814,0.00047481645,0.00007963149,0.0048317425,0.00045093716,0.000001094388,0.37091732,0.13000289,0.45138246],"study_design_scores_gemma":[0.000859429,0.00021155116,0.0375305,0.0006861572,0.00004265426,0.000014093779,0.0013551987,0.0036634603,0.00000902814,0.0040402478,0.9508152,0.0007724964],"about_ca_topic_score_codex":0.9987731,"about_ca_topic_score_gemma":0.99515146,"teacher_disagreement_score":0.8208123,"about_ca_system_score_codex":0.023757054,"about_ca_system_score_gemma":0.01896813,"threshold_uncertainty_score":0.9997695},"labels":[],"label_agreement":null},{"id":"W4403940449","doi":"10.1001/jama.2024.17688","title":"Differences in Drug Shortages in the US and Canada","year":2024,"lang":"en","type":"article","venue":"JAMA","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"Agency for Healthcare Research and Quality","keywords":"Medicine; Economic shortage; Pandemic; Drug; Coronavirus disease 2019 (COVID-19); Public health; Environmental health; Pharmacology; Nursing; Disease; Internal medicine","score_opus":0.03758942869400588,"score_gpt":0.2566276584935385,"score_spread":0.21903822979953264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403940449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9503368,0.0036407735,0.0000010563338,0.014266592,0.00018780243,0.000059294245,0.00007719838,0.000004081597,0.031426378],"genre_scores_gemma":[0.9953127,0.00071742176,0.000004712705,0.0036225487,0.0000804623,0.000011597193,0.0000018331427,0.000004698373,0.00024401143],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994643,0.000009706521,0.00020955464,0.00015703183,0.000011553889,0.00014787632],"domain_scores_gemma":[0.99974656,0.00012307453,0.000018598523,0.000079881494,0.000001427046,0.000030443767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029317863,0.000059038488,0.00013191791,0.000085066684,0.000017179318,0.00013504036,0.00012372735,0.00002589504,0.000092488015],"category_scores_gemma":[0.000024559846,0.000049255115,0.00001539554,0.00009344611,0.000022030172,0.00008581264,0.000024145455,0.00016134628,0.000023259838],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000004002914,0.000018587587,0.5926345,0.00004238782,0.000012338821,0.00004638954,0.001133952,0.000008386669,0.0000013482869,0.38628054,0.012799887,0.007017673],"study_design_scores_gemma":[0.00017229428,0.000005099552,0.5966166,0.000014574986,0.0000010046265,0.0000029330845,0.000093686045,0.006876958,0.0000071838153,0.022140278,0.37395906,0.000110307396],"about_ca_topic_score_codex":0.5397732,"about_ca_topic_score_gemma":0.7477154,"teacher_disagreement_score":0.36414024,"about_ca_system_score_codex":0.000058380756,"about_ca_system_score_gemma":0.00003804321,"threshold_uncertainty_score":0.46329147},"labels":[],"label_agreement":null},{"id":"W4403976976","doi":"10.1371/journal.pone.0313298","title":"Impact of supply chain disruptions and drug shortages on drug utilization: A scoping review protocol","year":2024,"lang":"en","type":"review","venue":"PLoS ONE","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; St. Francis Xavier University; University of Toronto","funders":"","keywords":"Drug; Economic shortage; Protocol (science); Medicine; Pharmacology; Risk analysis (engineering); Intensive care medicine; Business; Alternative medicine; Pathology","score_opus":0.2755033707614196,"score_gpt":0.43813831595506075,"score_spread":0.16263494519364113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403976976","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000019848287,0.9372313,0.0000022411634,0.00033586792,0.00003879354,0.057282776,0.0015857741,0.000033670833,0.0034697105],"genre_scores_gemma":[0.00002341969,0.9541446,0.000053421903,0.0001878924,0.000178042,0.044681266,0.00010544407,0.00007679671,0.00054912566],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9974838,0.000052634983,0.0015050309,0.0005976506,0.00005090288,0.00030999043],"domain_scores_gemma":[0.9985027,0.00014757394,0.00066900183,0.0004711593,0.000027021597,0.00018257645],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00061044935,0.00041884094,0.0026518172,0.00039653655,0.000061430685,0.00009448454,0.00026470542,0.00012284846,0.0008423762],"category_scores_gemma":[0.00014347737,0.0003785845,0.0005697521,0.00038518046,0.0000763578,0.000114243616,0.0001381129,0.00040336477,0.0005012169],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008318399,0.0012115253,0.00022752516,0.88175505,0.0016695305,0.00000849823,0.00011348403,9.676793e-7,1.2534086e-7,0.035228524,0.0048722606,0.07490421],"study_design_scores_gemma":[0.0003246235,0.00013207672,0.000022820022,0.65297014,0.001098238,0.000007611046,0.0000016600286,0.00027626113,0.000002761985,0.0026216242,0.3416907,0.00085146225],"about_ca_topic_score_codex":0.000036277906,"about_ca_topic_score_gemma":0.000011277439,"teacher_disagreement_score":0.33681843,"about_ca_system_score_codex":0.00017510209,"about_ca_system_score_gemma":0.00017929795,"threshold_uncertainty_score":0.9998666},"labels":[],"label_agreement":null},{"id":"W4404329146","doi":"10.1111/caje.12744","title":"The design of external reference pricing schemes and the choice of reference countries and pricing rules","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Economics/Revue canadienne d économique","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Reference price; Economics; Computer science; Econometrics; Business; Microeconomics","score_opus":0.22697849723629257,"score_gpt":0.2409314679348503,"score_spread":0.01395297069855772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404329146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97158647,0.022430351,0.0005897253,0.0030866945,0.00046342038,0.00024152514,0.00029462585,0.0000033453302,0.0013038486],"genre_scores_gemma":[0.98976046,0.009017902,0.00042680505,0.00042787357,0.000194537,0.000009452092,0.0000016175275,0.000029437788,0.00013192555],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9978283,0.00005428347,0.0013460267,0.00029539253,0.0000029031185,0.00047310884],"domain_scores_gemma":[0.9968253,0.0013739747,0.0008992319,0.00028757553,0.000094206676,0.0005197043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00213149,0.0002219165,0.000746674,0.00040658482,0.0002238816,0.00028187694,0.0005143506,0.00012480703,0.000058136688],"category_scores_gemma":[0.0004063192,0.00018683796,0.00010849785,0.00009294551,0.00081623724,0.0003856123,0.000051208124,0.000406711,0.0000072139883],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000069649584,0.0000026034434,0.003726901,0.00011819556,0.00013650795,0.000005833981,0.0008571818,0.0006039245,0.000015450812,0.99218017,0.00009415863,0.002189437],"study_design_scores_gemma":[0.0014926665,0.00026950685,0.0035927123,0.0005192105,0.00008765018,0.0002716573,0.0003763224,0.037174683,0.0003948044,0.81075585,0.14454764,0.0005173242],"about_ca_topic_score_codex":0.046619754,"about_ca_topic_score_gemma":0.20692928,"teacher_disagreement_score":0.18142433,"about_ca_system_score_codex":0.00039261873,"about_ca_system_score_gemma":0.00077643624,"threshold_uncertainty_score":0.9597289},"labels":[],"label_agreement":null},{"id":"W4404538988","doi":"10.1016/j.jcjd.2024.09.074","title":"Health-care Practitioners’ Intersectional Biases Towards T2D and Indigenous Populations","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Kelowna General Hospital","funders":"","keywords":"Medicine; Indigenous; Ecology","score_opus":0.08332580543600103,"score_gpt":0.31111351683627786,"score_spread":0.22778771140027682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404538988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92254865,0.052630965,0.000055627504,0.018015675,0.0017059948,0.000083999555,0.0008803174,0.000009167554,0.004069605],"genre_scores_gemma":[0.99704814,0.00013964446,0.00019247824,0.0021902306,0.00033643385,0.0000023212222,0.000016245353,0.0000135296905,0.000060987688],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99921143,0.000010697533,0.00041125473,0.00011434217,0.000015852229,0.00023643182],"domain_scores_gemma":[0.99924386,0.000046366753,0.00015403873,0.000057066685,0.000033428696,0.00046524874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022815935,0.000077823606,0.0002099378,0.000558713,0.000140721,0.0002029668,0.00008032684,0.000044015193,0.0003719932],"category_scores_gemma":[0.00011488031,0.00008819134,0.00008453525,0.00012858414,0.00005384846,0.0002959346,0.000007498473,0.00018837907,0.000051309602],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000005676279,0.000056727633,0.40315884,0.0004685718,0.0007066324,0.000044790497,0.028302891,0.000532791,0.0000121818475,0.40138838,0.08136278,0.08395975],"study_design_scores_gemma":[0.00042267801,0.0003108787,0.18023604,0.00024250516,0.000024848705,0.000052512623,0.00083171733,0.001214059,0.000029815626,0.047588456,0.76867074,0.0003757789],"about_ca_topic_score_codex":0.0020037878,"about_ca_topic_score_gemma":0.005564107,"teacher_disagreement_score":0.68730795,"about_ca_system_score_codex":0.00032513123,"about_ca_system_score_gemma":0.0006073129,"threshold_uncertainty_score":0.40730646},"labels":[],"label_agreement":null},{"id":"W4404734405","doi":"10.1016/j.ejor.2024.11.031","title":"Optimal co-development contracts for companion diagnostics","year":2024,"lang":"en","type":"article","venue":"European Journal of Operational Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Computer science; Business; Process management; Operations research; Mathematics","score_opus":0.2772292910362888,"score_gpt":0.4276035565451992,"score_spread":0.15037426550891042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404734405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6023257,0.02707568,0.06726126,0.039465882,0.0025807542,0.0011674298,0.0006514106,0.000049102044,0.25942284],"genre_scores_gemma":[0.99190426,0.0008220013,0.0041125803,0.00051697553,0.0011538643,0.000005824658,0.000025149378,0.000034768957,0.0014245945],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985879,0.000090318055,0.0007751411,0.00016905121,0.00010227853,0.00027530157],"domain_scores_gemma":[0.9986934,0.00070604234,0.00009466711,0.00007972561,0.00023310899,0.00019305763],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0061736167,0.0000847169,0.00020052042,0.00035099016,0.00018427761,0.00042718032,0.00027076135,0.000021699936,0.0005323067],"category_scores_gemma":[0.0007362943,0.00008351142,0.00009489176,0.00011301551,0.00007134631,0.00025757423,0.000045017812,0.00039603078,0.0012619809],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013627791,0.00024027108,0.0008701208,0.00008929535,0.00026989888,0.00018094463,0.0011094657,0.004112391,0.0003611123,0.6000675,0.38154754,0.011015159],"study_design_scores_gemma":[0.0005190613,0.00016607251,0.0031809853,0.000045762157,0.0000021165301,0.00003239152,0.000021240843,0.009198409,0.00041982287,0.0016614787,0.98465025,0.0001024049],"about_ca_topic_score_codex":0.0000013745496,"about_ca_topic_score_gemma":3.572241e-7,"teacher_disagreement_score":0.6031027,"about_ca_system_score_codex":0.00015666921,"about_ca_system_score_gemma":0.00023514035,"threshold_uncertainty_score":0.99951565},"labels":[],"label_agreement":null},{"id":"W4404850065","doi":"10.18553/jmcp.2024.30.12.1349","title":"Fear of missing out: Drug availability in the United States vs Canada","year":2024,"lang":"en","type":"article","venue":"Journal of Managed Care & Specialty Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"Agency for Healthcare Research and Quality","keywords":"Drug; MEDLINE; Medicine; Environmental health; Pharmacology; Political science; Law","score_opus":0.04763722699797736,"score_gpt":0.3059557295201401,"score_spread":0.25831850252216276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404850065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93992513,0.009182723,0.00007924083,0.02636973,0.0019995617,0.0002471783,0.00038850057,0.000009029517,0.021798894],"genre_scores_gemma":[0.99411887,0.0018081304,0.00006637029,0.0031711655,0.0006802252,0.0000017418761,0.000011345544,0.00002128317,0.0001208692],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981169,0.00010102346,0.0011851512,0.00020445563,0.000101626814,0.0002908088],"domain_scores_gemma":[0.9988173,0.00032013224,0.00044459567,0.0002100494,0.00007668552,0.00013118923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016483084,0.0001618282,0.000482357,0.00041631464,0.000070539005,0.00014529297,0.00054048497,0.000027331522,0.0005553173],"category_scores_gemma":[0.00012350263,0.000142315,0.00019884047,0.00044167668,0.00007017101,0.00019587687,0.00005670438,0.00064013136,0.000031184794],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011564111,0.0007197602,0.088631764,0.0039370516,0.0013076378,0.0020606106,0.06899616,0.012014345,0.000104935694,0.09697787,0.6625788,0.061514623],"study_design_scores_gemma":[0.00079841196,0.000023604834,0.005194257,0.00006887669,0.00003134948,0.000016338943,0.0011582471,0.0048528393,0.00019091756,0.008154355,0.97933185,0.00017897574],"about_ca_topic_score_codex":0.07210945,"about_ca_topic_score_gemma":0.06288425,"teacher_disagreement_score":0.316753,"about_ca_system_score_codex":0.00061029114,"about_ca_system_score_gemma":0.00031021526,"threshold_uncertainty_score":0.95421565},"labels":[],"label_agreement":null},{"id":"W4404863334","doi":"10.1017/s0266462324004768","title":"The intersection of prescription drugs and medical devices: the evaluation and funding challenges of two categories of emerging health technologies","year":2024,"lang":"en","type":"article","venue":"International Journal of Technology Assessment in Health Care","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Public Health Ontario; University of Toronto","funders":"","keywords":"Medical prescription; Health technology; Intersection (aeronautics); Emerging technologies; Business; Medicine; Political science; Pharmacology; Health care; Computer science; Engineering; Transport engineering","score_opus":0.07380527049704576,"score_gpt":0.4383761041072198,"score_spread":0.364570833610174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404863334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6074404,0.20792438,0.00066893076,0.18217482,0.0011406995,0.00023757137,0.000032780943,0.000015463653,0.0003649616],"genre_scores_gemma":[0.96635854,0.033338297,0.00018036636,0.000080122954,0.000027082533,0.000008408381,0.0000015085977,0.0000047791086,8.889713e-7],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9986261,0.000045206092,0.0009914659,0.00011215662,0.00011518211,0.00010984982],"domain_scores_gemma":[0.99867076,0.000192712,0.0008852296,0.00008383509,0.00014817984,0.000019270097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002690357,0.00006380071,0.00025102665,0.0005034838,0.000050319806,0.000018826551,0.0002667324,0.00007530817,0.0000057750863],"category_scores_gemma":[0.00021375867,0.00004778903,0.000038838978,0.00013567193,0.00021454053,0.00013278716,0.00010796691,0.00034301396,1.1979658e-7],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015628011,0.000018841554,0.009209185,0.00025926088,0.00009507393,5.421039e-7,0.002220189,0.00004938885,0.000009034551,0.6885187,0.000022162278,0.299582],"study_design_scores_gemma":[0.002446303,0.0011954706,0.046812832,0.003060502,0.0000350557,0.00018488114,0.1264189,0.059930924,0.00066117075,0.7326286,0.026372097,0.00025330624],"about_ca_topic_score_codex":0.00020855259,"about_ca_topic_score_gemma":0.00022068893,"teacher_disagreement_score":0.35891813,"about_ca_system_score_codex":0.00034224108,"about_ca_system_score_gemma":0.0002506331,"threshold_uncertainty_score":0.19487801},"labels":[],"label_agreement":null},{"id":"W4404947648","doi":"10.1377/hlthaff.2023.01244","title":"US Trends In Anticancer Medicine Pricing And The Impact Of Competition, 2014–20","year":2024,"lang":"en","type":"article","venue":"Health Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Biosimilar; Competition (biology); Drug prices; Inflation (cosmology); Medicine; Business; Public economics; Economics","score_opus":0.047256224064171945,"score_gpt":0.3620782030402909,"score_spread":0.31482197897611897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404947648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4086211,0.11730292,0.0005237236,0.23390993,0.0012295457,0.0006763701,0.0006609154,0.00007806804,0.23699743],"genre_scores_gemma":[0.9929418,0.005861259,0.000024719151,0.0008903582,0.00013831444,0.000008946884,0.0000098416995,0.0000120256345,0.00011276027],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99891305,0.000024396408,0.000585323,0.00020612092,0.000018213237,0.00025291846],"domain_scores_gemma":[0.99945426,0.00014808148,0.00013718658,0.00013953926,0.000007214131,0.000113720795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010015974,0.000095573865,0.00043061818,0.00033826425,0.00003936268,0.000020259426,0.00008312526,0.00003552628,0.00075057254],"category_scores_gemma":[0.000029231667,0.000069677444,0.00007225407,0.00030166618,0.00020254662,0.000076416305,0.000026491174,0.00016191984,0.000045756922],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060016748,0.00003071645,0.021502778,0.0001867288,0.000051217077,0.0000018810886,0.0018613907,0.0002764305,0.000003374326,0.95140934,0.019248476,0.00536766],"study_design_scores_gemma":[0.0077766622,0.00064580387,0.34887746,0.0005223966,0.000018300327,0.000036507165,0.0004592807,0.24683735,0.000011018427,0.1795101,0.21474749,0.0005576474],"about_ca_topic_score_codex":0.0042912527,"about_ca_topic_score_gemma":0.00021125886,"teacher_disagreement_score":0.7718992,"about_ca_system_score_codex":0.00015522016,"about_ca_system_score_gemma":0.000057201018,"threshold_uncertainty_score":0.82182425},"labels":[],"label_agreement":null},{"id":"W4404971548","doi":"10.1080/20523211.2024.2430441","title":"A pharmaceutical policy accident: collision of shareholder capitalism and Chinese state capitalism driving the shortage of an essential antibiotic","year":2024,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Policy and Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Global Health Research","funders":"Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; National Science Foundation","keywords":"Piperacillin/tazobactam; Economic shortage; Business; Capitalism; State (computer science); Piperacillin; Medicine; Computer science; Political science; Law; Government (linguistics); Politics","score_opus":0.04635057395091741,"score_gpt":0.3942808531185116,"score_spread":0.34793027916759417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404971548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9509353,0.016101485,0.00024787028,0.027668858,0.00057791633,0.0003058963,0.00033340673,0.000016902546,0.003812356],"genre_scores_gemma":[0.9811503,0.014529307,0.00026328512,0.0026715545,0.0012462263,0.0000022859797,0.0000045049023,0.000048848287,0.000083672596],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969332,0.00027021265,0.0016819399,0.00040034953,0.00018964309,0.000524623],"domain_scores_gemma":[0.9959617,0.0021313822,0.0008497944,0.00027286983,0.00014964004,0.00063461176],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0031186787,0.0003325501,0.00081159896,0.00075033127,0.00015062456,0.00032612222,0.00043499836,0.00016194432,0.00015734872],"category_scores_gemma":[0.0024735832,0.0002690448,0.00025611394,0.0006410259,0.00055003783,0.0017974047,0.00026762858,0.000920007,0.000016553273],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002411368,0.0020581777,0.0077261417,0.0020499772,0.0030893178,0.0005738451,0.018041762,0.00079434586,0.020880433,0.8975092,0.002338981,0.042526424],"study_design_scores_gemma":[0.0126859695,0.0022796525,0.050923146,0.001079559,0.001976083,0.009231527,0.0018281142,0.15260604,0.029383637,0.24051154,0.49464032,0.0028544138],"about_ca_topic_score_codex":0.0005124409,"about_ca_topic_score_gemma":0.000013503244,"teacher_disagreement_score":0.6569977,"about_ca_system_score_codex":0.000108644665,"about_ca_system_score_gemma":0.0002762057,"threshold_uncertainty_score":0.99997616},"labels":[],"label_agreement":null},{"id":"W4405034894","doi":"10.1016/j.pharma.2024.12.001","title":"Drug shortages in Canada, 2019–2023: A descriptive study","year":2024,"lang":"en","type":"article","venue":"Annales Pharmaceutiques Françaises","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Economic shortage; Drug; Descriptive research; Business; Medicine; Pharmacology; Sociology; Social science","score_opus":0.07047308805051646,"score_gpt":0.3192722898304774,"score_spread":0.24879920177996095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405034894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8996646,0.06047689,0.000022965378,0.0036882588,0.0012168338,0.00063243415,0.0008348907,0.000112087844,0.033351045],"genre_scores_gemma":[0.9913079,0.0040475815,0.00003113826,0.0025685623,0.00024905943,0.0001099958,0.000021180986,0.000057995232,0.0016065425],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976126,0.000055359214,0.0008896997,0.00072750804,0.00006862924,0.00064619025],"domain_scores_gemma":[0.999141,0.0001757257,0.00010631469,0.00028473954,0.000026829352,0.00026541887],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00065146794,0.00034096415,0.00057914184,0.0004577806,0.000103565806,0.00018826367,0.00043081935,0.000058805483,0.0014308412],"category_scores_gemma":[0.000036220466,0.00038684584,0.00014492623,0.00047526538,0.0000838308,0.0005095482,0.00012509068,0.0005350405,0.0008142896],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014843632,0.00080046296,0.6076768,0.00030209226,0.000730048,0.0009353755,0.013181564,0.00041662683,0.000100518184,0.046534374,0.31460443,0.014569297],"study_design_scores_gemma":[0.00076541794,0.000060131195,0.04375677,0.000069866735,0.000028046781,0.000010674636,0.0011107831,0.009234842,0.0007209707,0.004607166,0.93888235,0.000752992],"about_ca_topic_score_codex":0.75201774,"about_ca_topic_score_gemma":0.7901821,"teacher_disagreement_score":0.6242779,"about_ca_system_score_codex":0.00060410745,"about_ca_system_score_gemma":0.00051800854,"threshold_uncertainty_score":0.9999637},"labels":[],"label_agreement":null},{"id":"W4405397181","doi":"10.1177/00469580241307446","title":"Competition Among Pharmacies as a Determinant of Drug Expenditures","year":2024,"lang":"en","type":"article","venue":"INQUIRY The Journal of Health Care Organization Provision and Financing","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Southeast University","keywords":"Pharmacy; Competition (biology); Drug prices; Drug; Market share; Business; Medicine; Public economics; Marketing; Economics; Pharmacology; Family medicine","score_opus":0.032050853813311644,"score_gpt":0.31792147072619686,"score_spread":0.28587061691288523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405397181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.961039,0.028413655,0.004728392,0.0040422943,0.0013232512,0.0001814222,0.000028250228,0.000015256557,0.00022847178],"genre_scores_gemma":[0.9931625,0.005347366,0.00008077209,0.001164289,0.00018403686,8.021116e-7,0.0000051005914,0.000019816565,0.00003529336],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99869925,0.000052258805,0.00093195925,0.00012044151,0.000048557817,0.000147528],"domain_scores_gemma":[0.9989867,0.000102835016,0.0006488299,0.00009587433,0.00009084955,0.00007487062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010119403,0.00009978077,0.00031833025,0.00023153807,0.0001705305,0.00007011771,0.00013777961,0.0000546906,0.00010877832],"category_scores_gemma":[0.00011111456,0.000078850055,0.00005152769,0.00019004384,0.00009527871,0.0003167788,0.000053285432,0.0002543832,0.000017441544],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002481081,0.00028749363,0.05834588,0.0053703785,0.00028067242,0.000065468055,0.33171222,0.0013034701,0.0026750648,0.4035613,0.03578688,0.16036306],"study_design_scores_gemma":[0.0063775843,0.0025050028,0.1400488,0.004995345,0.00022011272,0.0017053676,0.04872117,0.016104799,0.04258969,0.050860938,0.6838274,0.0020437576],"about_ca_topic_score_codex":0.0000771311,"about_ca_topic_score_gemma":0.0000069798434,"teacher_disagreement_score":0.64804053,"about_ca_system_score_codex":0.00010269604,"about_ca_system_score_gemma":0.00014166613,"threshold_uncertainty_score":0.3215412},"labels":[],"label_agreement":null},{"id":"W4405483415","doi":"10.12927/hcq.2024.27492","title":"The Siren Call for Business Model Innovation in Healthcare","year":2024,"lang":"en","type":"article","venue":"Healthcare Quarterly","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Institute of Health Services and Policy Research","funders":"","keywords":"Siren (mythology); Health care; Business; Business model; Best practice; Health administration; Marketing; Management; Operations management; Public relations; Engineering; Political science; Economics; History","score_opus":0.09833059128394396,"score_gpt":0.35286216298461065,"score_spread":0.2545315717006667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405483415","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12495245,0.021253696,0.015195831,0.82776594,0.003173588,0.0019910715,0.001777393,0.00022095189,0.0036690761],"genre_scores_gemma":[0.99211603,0.0004483187,0.00025286,0.0059792805,0.0003233525,0.00025637585,0.00006551975,0.00004166787,0.0005165695],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99796927,0.0000192081,0.0010351101,0.0004222097,0.000028459355,0.00052574696],"domain_scores_gemma":[0.99921525,0.00016715325,0.00014404526,0.00027625577,0.00009749256,0.00009982684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009601514,0.00015584288,0.00028908768,0.00031435845,0.000180276,0.00019985311,0.00021193945,0.00013990181,0.000006678687],"category_scores_gemma":[0.000054184988,0.00014999122,0.000069541165,0.00071438163,0.00004121678,0.00020857743,0.000012784381,0.00027256444,0.00014503316],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026442942,0.00001648371,0.0006374357,0.00032902852,0.000010760429,0.0000014472643,0.0008088769,0.00008334121,0.000003259046,0.94594735,0.0035746556,0.048560895],"study_design_scores_gemma":[0.00036741758,0.000139145,0.0026640522,0.000053084197,0.0000017673788,0.0000031277323,0.00005893897,0.24638943,0.0000033417402,0.5341561,0.21592939,0.00023422284],"about_ca_topic_score_codex":0.0017426613,"about_ca_topic_score_gemma":0.0020584858,"teacher_disagreement_score":0.8671636,"about_ca_system_score_codex":0.00030942785,"about_ca_system_score_gemma":0.0002745886,"threshold_uncertainty_score":0.6116465},"labels":[],"label_agreement":null},{"id":"W4405494467","doi":"10.1016/j.amjms.2024.12.009","title":"Medical care and prescription medication affordability by age group in the US, 2019 to 2023","year":2024,"lang":"en","type":"letter","venue":"The American Journal of the Medical Sciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Key Research and Development Program of China","keywords":"Medicine; Medical prescription; Family medicine; Gerontology; Pharmacology","score_opus":0.03870002137705613,"score_gpt":0.31212884796082435,"score_spread":0.2734288265837682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405494467","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12583226,0.005026676,0.000047558697,0.8659225,0.0012013495,0.00020315468,0.00009312939,0.000004055334,0.0016693033],"genre_scores_gemma":[0.27474722,0.0035352206,0.000045842007,0.7189414,0.0025304367,0.00001785529,0.000008308064,0.000016353555,0.00015733863],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974035,0.00033381535,0.00092363876,0.00033727798,0.0006065239,0.00039521398],"domain_scores_gemma":[0.99804413,0.0006786111,0.00069962617,0.00032938473,0.000013960569,0.00023426737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007859353,0.00018443837,0.0005417846,0.00016855134,0.00018858112,0.00018584439,0.0028482794,0.0001691065,0.00031395303],"category_scores_gemma":[0.0010344958,0.00008741033,0.0001854983,0.0006570185,0.0024382686,0.00010536274,0.0003180583,0.002131351,0.00006055595],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011748488,0.000026407197,0.0013655786,0.00003638247,0.000035231755,0.000032885404,0.0012170759,0.00000530412,0.0000012474734,0.0018935741,0.9795251,0.01584946],"study_design_scores_gemma":[0.00013933485,0.00028063366,0.0035509754,0.00013494033,0.000021682647,0.000114117785,0.00026366205,0.00046522744,9.2113277e-7,0.017846616,0.9770396,0.00014234168],"about_ca_topic_score_codex":0.0015284108,"about_ca_topic_score_gemma":0.00020982187,"teacher_disagreement_score":0.14891498,"about_ca_system_score_codex":0.00014913452,"about_ca_system_score_gemma":0.00019459492,"threshold_uncertainty_score":0.9259778},"labels":[],"label_agreement":null},{"id":"W4405573853","doi":"10.51731/cjht.2024.1049","title":"Canadian Trends in Estimated Drug Purchases and Projections: 2024 and 2025","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Audit; Business; Biosimilar; Specialty; Agricultural economics; Medicine; Accounting; Economics; Family medicine","score_opus":0.08836610602824099,"score_gpt":0.3365487014798369,"score_spread":0.2481825954515959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405573853","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24024144,0.5153702,0.000021368058,0.23760319,0.000966269,0.00017493777,0.0004965801,0.000057165453,0.005068874],"genre_scores_gemma":[0.99268705,0.00610257,0.00013984756,0.0006535093,0.000013259779,0.000005941311,0.0000023267319,0.000011567318,0.00038393188],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988487,0.000009930732,0.00054780504,0.00017672186,0.00001105582,0.00040581502],"domain_scores_gemma":[0.99954253,0.000038787715,0.000112201626,0.00009193166,0.0000134245065,0.00020109938],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060670543,0.0001020942,0.0003052599,0.0031915142,0.0001399332,0.00015271688,0.00012922025,0.000094205396,0.000099577606],"category_scores_gemma":[0.00014505094,0.000109046116,0.000031433417,0.00053272414,0.00013211757,0.0001803229,0.000015002077,0.00039662726,0.000013858499],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000041009407,0.000009830757,0.049273312,0.00019092744,0.000061870094,0.00019194781,0.0009193146,0.00003596236,9.2174236e-7,0.1777246,0.03996275,0.7316245],"study_design_scores_gemma":[0.00026485106,0.000091914306,0.01857855,0.00021698904,0.000004575162,0.00021791502,0.0006475872,0.0033274044,0.000007631679,0.09704435,0.87938774,0.00021047157],"about_ca_topic_score_codex":0.4111923,"about_ca_topic_score_gemma":0.5399578,"teacher_disagreement_score":0.839425,"about_ca_system_score_codex":0.0006318073,"about_ca_system_score_gemma":0.0010455014,"threshold_uncertainty_score":0.5927286},"labels":[],"label_agreement":null},{"id":"W4405748357","doi":"10.1016/j.jval.2024.10.472","title":"EE188 Cost-Effectiveness of Rivaroxaban and Acetylsalicylic Acid Combination Therapy in Stable Cardiovascular Disease: A Global Perspective","year":2024,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health","funders":"","keywords":"Rivaroxaban; Perspective (graphical); Medicine; Disease; Intensive care medicine; Internal medicine; Computer science; Artificial intelligence","score_opus":0.10481337094114629,"score_gpt":0.351128353095938,"score_spread":0.2463149821547917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405748357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88408875,0.10981446,0.0003016771,0.0019401511,0.00027666625,0.0010124217,0.00048802322,0.000023581697,0.0020542643],"genre_scores_gemma":[0.98851186,0.011126631,0.0000351993,0.00017964165,0.000033269767,0.00008059835,0.000009432001,0.000016199105,0.0000071939744],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9985932,0.00016816378,0.00046609266,0.00043076187,0.00003852242,0.00030324457],"domain_scores_gemma":[0.9994106,0.00012640216,0.00007930625,0.0002229311,0.000017948996,0.00014276142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002116492,0.00013000706,0.00049908826,0.0002515509,0.000031843618,0.00004484093,0.00010483895,0.00005919514,0.000017673903],"category_scores_gemma":[0.0000847739,0.00015300399,0.00012048083,0.00049369293,0.00006114986,0.00017819129,0.00003971343,0.00016037967,0.00001630887],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008576077,0.00015519746,0.04451819,0.000517879,0.00011506505,0.0000060289685,0.00059386657,0.0055904756,0.000006845392,0.9447042,0.000019364006,0.0036871526],"study_design_scores_gemma":[0.0032444869,0.00023903378,0.43518156,0.0003869807,0.000008403741,0.0000051806874,0.0001237941,0.12304667,0.000088444984,0.41723725,0.020066213,0.00037198537],"about_ca_topic_score_codex":0.015589716,"about_ca_topic_score_gemma":0.00003790331,"teacher_disagreement_score":0.52746695,"about_ca_system_score_codex":0.0011714462,"about_ca_system_score_gemma":0.00017750617,"threshold_uncertainty_score":0.99096555},"labels":[],"label_agreement":null},{"id":"W4405748418","doi":"10.1016/j.jval.2024.10.812","title":"EE532 Budget Impact Analyses of Hemoglobin a1C and Lipid Panel Point-of-Care Testing With Afinion™ 2 in Italy and Canada","year":2024,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Abbott (Canada); EVERSANA (Canada)","funders":"","keywords":"Point of care; Hemoglobin; Point-of-care testing; Point (geometry); Medicine; Internal medicine; Mathematics; Nursing; Immunology","score_opus":0.13227492991107148,"score_gpt":0.3457175300520665,"score_spread":0.21344260014099503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405748418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832846,0.013565688,0.000012477907,0.0012867722,0.000083483836,0.00015383594,0.00042851595,0.0000057338375,0.0011788853],"genre_scores_gemma":[0.99830335,0.0009781794,0.00038621106,0.00026294027,0.00003384388,0.000004160133,0.000009704851,0.000014635371,0.000006999094],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987392,0.000026063663,0.00067653117,0.0002692615,0.000024331972,0.00026460527],"domain_scores_gemma":[0.9992379,0.0003082492,0.0001820647,0.00012385265,0.000014154868,0.00013380116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004805334,0.00011925357,0.00048105777,0.00030450497,0.000021977263,0.000025483956,0.00007115135,0.00004143068,0.000015851014],"category_scores_gemma":[0.00010461668,0.0001163281,0.00002731015,0.0003448271,0.000050574214,0.00010015286,0.000037857168,0.0001561616,0.0000011891309],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000062657666,0.00005752698,0.95700735,0.0026734355,0.000072596355,0.00001737319,0.001934832,0.01059792,0.000052527335,0.020629596,0.00025695542,0.0066372263],"study_design_scores_gemma":[0.0024621855,0.0011344864,0.7020805,0.0015623444,0.000018344494,0.000060183127,0.001020499,0.26766625,0.00032000808,0.01613945,0.006746981,0.00078876223],"about_ca_topic_score_codex":0.80315095,"about_ca_topic_score_gemma":0.10424437,"teacher_disagreement_score":0.6989066,"about_ca_system_score_codex":0.00028035164,"about_ca_system_score_gemma":0.0005137291,"threshold_uncertainty_score":0.91210085},"labels":[],"label_agreement":null},{"id":"W4405751655","doi":"10.1016/j.jval.2024.10.1963","title":"HTA138 NICE vs SMC: Reimbursement Differences for Non-Oncology Orphan Drugs","year":2024,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Nice; Reimbursement; Orphan drug; Medicine; Internal medicine; Family medicine; Oncology; Bioinformatics; Economics; Biology; Computer science; Economic growth; Health care","score_opus":0.13097741370356253,"score_gpt":0.3695815115593293,"score_spread":0.23860409785576675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405751655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75943446,0.023084743,0.0027349337,0.15145656,0.008274988,0.002649683,0.0013445608,0.00018069836,0.05083938],"genre_scores_gemma":[0.9868478,0.0035837204,0.0007928259,0.007311967,0.00049066835,0.00017130049,0.000019034695,0.000034573484,0.0007481041],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.997899,0.0000331119,0.00094733125,0.00051010837,0.000024991952,0.00058548164],"domain_scores_gemma":[0.9989772,0.00039518398,0.00018371038,0.00022086148,0.00001053008,0.00021254444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015527174,0.00016270077,0.0005458219,0.00032371876,0.00008664016,0.00007848917,0.0002460212,0.00011473349,0.00023233132],"category_scores_gemma":[0.000060835693,0.00018010385,0.00012261455,0.00022747756,0.000048778646,0.00011473368,0.000058536567,0.00024567163,0.00049071957],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007628791,0.00022164756,0.007181615,0.0009900565,0.00007003841,0.0000057217694,0.0043621273,0.00070320076,0.0000072718058,0.95451784,0.0134307835,0.018433385],"study_design_scores_gemma":[0.0006813078,0.00037998334,0.0024186627,0.00009045413,0.000003513439,0.0000025336055,0.00006194211,0.17187162,0.00002198199,0.09186725,0.73237234,0.00022842566],"about_ca_topic_score_codex":0.0028784524,"about_ca_topic_score_gemma":0.00005484799,"teacher_disagreement_score":0.86265063,"about_ca_system_score_codex":0.00063078967,"about_ca_system_score_gemma":0.00026069288,"threshold_uncertainty_score":0.7344422},"labels":[],"label_agreement":null},{"id":"W4405751835","doi":"10.1016/j.jval.2024.10.1000","title":"EE720 Cost-Effectiveness of Faricimab in Canada for the Treatment of Patients With Macular Edema Secondary to Retinal Vein Occlusion","year":2024,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Roche (Canada)","funders":"","keywords":"Macular edema; Medicine; Retinal Vein; Ophthalmology; Occlusion; Central retinal vein occlusion; Retinal; Edema; Surgery","score_opus":0.05709161194486376,"score_gpt":0.30844445534623777,"score_spread":0.251352843401374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405751835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905245,0.0041843713,0.00032278974,0.0018291555,0.0002358584,0.0015192524,0.0011506275,0.0000027915169,0.00023071094],"genre_scores_gemma":[0.99907994,0.0003694625,0.00007868956,0.00035652053,0.000014821068,0.00005495691,0.000021635235,0.0000147353,0.000009256297],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989565,0.000045006476,0.00049770257,0.00023143656,0.000028569484,0.00024077675],"domain_scores_gemma":[0.99919325,0.0004599077,0.000123211,0.00014935572,0.000016046833,0.000058199872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062453124,0.00010073455,0.00038478183,0.00016384474,0.000028893543,0.0000087237,0.00010218651,0.000028007456,0.00002713089],"category_scores_gemma":[0.000022131051,0.00008176357,0.000045841087,0.00023792467,0.000018024179,0.000035892674,0.000019692383,0.000070660935,0.0000029481912],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002872262,0.0017748459,0.5778193,0.0064698663,0.00033664797,0.000022286127,0.0077927927,0.17247812,0.000020523243,0.13157865,0.0010226629,0.09781203],"study_design_scores_gemma":[0.0050547756,0.002308336,0.63774455,0.0004901578,0.000012483304,0.0000013062661,0.0001769214,0.14136113,0.0003888713,0.0049776183,0.20712386,0.00035998956],"about_ca_topic_score_codex":0.66041064,"about_ca_topic_score_gemma":0.11775257,"teacher_disagreement_score":0.54265803,"about_ca_system_score_codex":0.0014888663,"about_ca_system_score_gemma":0.000662666,"threshold_uncertainty_score":0.8983461},"labels":[],"label_agreement":null},{"id":"W4405814046","doi":"10.1136/bmjopen-2024-087190","title":"Systematic review of the impact of the National Medication Price Negotiated Policy on the accessibility of drugs in China, 2016–2024","year":2024,"lang":"en","type":"review","venue":"BMJ Open","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; China; Systematic review; Data extraction; Negotiation; Quality (philosophy); Government (linguistics); Drug prices; Scale (ratio); MEDLINE; Family medicine; Environmental health; Public economics; Political science; Geography","score_opus":0.19814285347898564,"score_gpt":0.49554012272792175,"score_spread":0.2973972692489361,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405814046","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006882226,0.9319133,5.2336634e-7,0.0032351664,0.00023692413,0.011643507,0.0013538864,0.0000025455665,0.051545307],"genre_scores_gemma":[0.0059737023,0.9917306,0.0000025015331,0.0006283117,0.00007984166,0.00083509384,0.00001601543,0.000026430063,0.00070751057],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.996226,0.0003841799,0.0027683713,0.00032489718,0.00012331581,0.00017320339],"domain_scores_gemma":[0.9949262,0.0004908515,0.0034600096,0.001021001,0.00005819052,0.000043719236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0065514008,0.0002522425,0.0021814026,0.00020951036,0.000039202983,0.00005200624,0.0026048382,0.00013669084,0.00038362594],"category_scores_gemma":[0.0032240467,0.000113897186,0.00092850666,0.0012058192,0.00012575081,0.00010444856,0.00079882686,0.00040894985,0.00011134007],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000069368602,0.0001438681,0.00008613887,0.86214674,0.00057820335,6.278547e-8,0.00021252752,0.000008506947,7.691705e-8,0.124144085,0.011465658,0.0012071884],"study_design_scores_gemma":[0.00031186565,0.0000417572,0.003624614,0.91358525,0.00043207657,0.000006659875,0.000010918046,0.00080075447,0.0000023047958,0.035424147,0.04537536,0.0003842717],"about_ca_topic_score_codex":0.0014006803,"about_ca_topic_score_gemma":0.000010951755,"teacher_disagreement_score":0.088719934,"about_ca_system_score_codex":0.000527003,"about_ca_system_score_gemma":0.0016876385,"threshold_uncertainty_score":0.4840481},"labels":[],"label_agreement":null},{"id":"W4405883997","doi":"10.1007/s11245-024-10147-3","title":"There’s a Pill for That: Bad Pharmaceutical Scaffolding and Psychiatrization","year":2024,"lang":"en","type":"article","venue":"Topoi","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Pill; Traditional medicine; Business; Medicine; Pharmacology","score_opus":0.09126687245089607,"score_gpt":0.3329104018149814,"score_spread":0.2416435293640853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405883997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6165582,0.06851313,0.042921267,0.050044574,0.005528568,0.0015563973,0.0013779879,0.00049501273,0.21300489],"genre_scores_gemma":[0.9949069,0.001206163,0.00059732323,0.0019524492,0.00045062916,0.000059165446,0.000011313859,0.000031272124,0.0007847802],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99914837,0.0000055027963,0.00026077984,0.0003218133,0.00001362258,0.00024993144],"domain_scores_gemma":[0.9996334,0.00009114998,0.000044357384,0.00011023327,0.000006577809,0.00011430273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033009826,0.00011233709,0.00018896224,0.00013100912,0.00007833519,0.00016944452,0.00009341713,0.000069917085,0.00064691494],"category_scores_gemma":[0.000023714789,0.00012259404,0.000085599604,0.00009686654,0.000038879574,0.00017884905,0.00003537799,0.000090780464,0.0002862725],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015937,0.000022171227,0.0026750518,0.000098078744,0.00004364035,0.00000103346,0.0001555444,0.000012013959,0.000049143986,0.9821047,0.005377344,0.009445343],"study_design_scores_gemma":[0.0004547642,0.000032159165,0.0008168176,0.000014673792,0.000014505962,0.0000054207344,0.000010585021,0.07137623,0.00028039856,0.18206729,0.74473023,0.0001969483],"about_ca_topic_score_codex":0.000013508839,"about_ca_topic_score_gemma":0.000003185211,"teacher_disagreement_score":0.8000374,"about_ca_system_score_codex":0.000041792453,"about_ca_system_score_gemma":0.000014948189,"threshold_uncertainty_score":0.7083265},"labels":[],"label_agreement":null},{"id":"W4406147092","doi":"10.1017/s0266462324001399","title":"OD01 Delays In Funded Access To Medicines: A Global Perspective","year":2024,"lang":"en","type":"article","venue":"International Journal of Technology Assessment in Health Care","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Perspective (graphical); Access to medicines; Medicine; Family medicine; Business; Political science; Computer science; Nursing; Public health","score_opus":0.06452434491338832,"score_gpt":0.47013865551383216,"score_spread":0.40561431060044384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406147092","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25767356,0.021621266,0.0031862312,0.6952192,0.0047043273,0.0004013975,0.00033190244,0.000049595772,0.016812505],"genre_scores_gemma":[0.99093956,0.0010484246,0.0008744938,0.0069185677,0.00018332854,0.000014891927,0.0000037755851,0.000009880566,0.0000070547107],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9983894,0.000016260414,0.0010356766,0.00024111208,0.00007010029,0.00024743407],"domain_scores_gemma":[0.9993114,0.00005633749,0.00028353522,0.000103446786,0.00014232117,0.000103000144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005746137,0.000108220665,0.00036059105,0.0016164551,0.000019509524,0.00008639281,0.00071992463,0.00011792485,0.00014025891],"category_scores_gemma":[0.00014886963,0.00011720474,0.00007912309,0.00057539233,0.000040981322,0.00027356573,0.00015768738,0.0005526751,0.000033282853],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000048401067,0.00009142359,0.14014158,0.000055714343,0.0001016654,0.0002137432,0.0008296555,0.00063710357,0.0000017131011,0.8450826,0.002435838,0.010360586],"study_design_scores_gemma":[0.0025839754,0.00065570784,0.10726128,0.0009989396,0.000007124933,0.0003571731,0.00885274,0.005117929,0.000023614062,0.6531017,0.22062811,0.00041172735],"about_ca_topic_score_codex":0.00050697505,"about_ca_topic_score_gemma":0.0006832749,"teacher_disagreement_score":0.733266,"about_ca_system_score_codex":0.0048146304,"about_ca_system_score_gemma":0.00038575134,"threshold_uncertainty_score":0.99900573},"labels":[],"label_agreement":null},{"id":"W4406147582","doi":"10.1017/s0266462324001053","title":"OP43 Incorporating Mathematical Modeling To Improve Accuracy Of Budget Impact Analysis: Using Screening For Hepatitis C As An Example","year":2024,"lang":"en","type":"article","venue":"International Journal of Technology Assessment in Health Care","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science; Operations research; Management science; Econometrics; Medicine; Mathematics; Engineering","score_opus":0.1044055751217923,"score_gpt":0.4564719522510591,"score_spread":0.3520663771292668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406147582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7272482,0.0010170272,0.26681843,0.0038854338,0.00033865118,0.00023750254,0.00030521437,0.000016524693,0.0001330126],"genre_scores_gemma":[0.93943185,0.000088003115,0.059972312,0.00032983118,0.00012281531,0.000013463489,0.000020985219,0.000018115437,0.0000026351665],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9978821,0.000018519324,0.0015512952,0.00024602836,0.00007555783,0.00022649865],"domain_scores_gemma":[0.9985742,0.00015374634,0.00076964515,0.00015542898,0.0002282877,0.000118666314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011144453,0.00012323043,0.00055494125,0.0021162964,0.000043865297,0.00008784433,0.00044305337,0.00011316807,0.00010596],"category_scores_gemma":[0.00023402994,0.00013147357,0.00022812939,0.000453529,0.000025816495,0.00036626775,0.00010104985,0.00034700846,0.00000454255],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014827169,0.00022020303,0.04316099,0.00040138577,0.0018417593,0.00003636177,0.0017195314,0.2563324,0.00023513276,0.6551872,0.000042764437,0.04067402],"study_design_scores_gemma":[0.00041231335,0.00047037454,0.00045432916,0.00021987174,0.00002936374,0.000029834866,0.00070908,0.89059854,0.0000858743,0.106412746,0.00044532248,0.00013236531],"about_ca_topic_score_codex":0.0012863136,"about_ca_topic_score_gemma":0.00007630669,"teacher_disagreement_score":0.63426614,"about_ca_system_score_codex":0.0007802853,"about_ca_system_score_gemma":0.00033887482,"threshold_uncertainty_score":0.53613365},"labels":[],"label_agreement":null},{"id":"W4406218141","doi":"10.1002/alz.091118","title":"Potential Eligibility for Disease Modifying Therapies Among Individuals Referred to A Tertiary Care Memory Clinic in Calgary, Alberta, Canada: Implications for AD Biomarker Testing","year":2024,"lang":"en","type":"article","venue":"Alzheimer s & Dementia","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hotchkiss Brain Institute; University of Calgary","funders":"","keywords":"Tertiary care; Biomarker; Gerontology; Disease; Medicine; Memory clinic; Family medicine; Psychiatry; Internal medicine; Cognitive impairment; Biology","score_opus":0.10142102305452218,"score_gpt":0.3454987637283511,"score_spread":0.24407774067382892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406218141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7287276,0.23357688,0.0047038207,0.01685857,0.0018897572,0.0052234083,0.0064613475,0.000116580304,0.0024420787],"genre_scores_gemma":[0.99506897,0.000067782006,0.0014603481,0.0019079236,0.00009993429,0.0010912147,0.00022362106,0.000053800468,0.000026413767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99779886,0.000020250038,0.0008893122,0.0007343315,0.000029910452,0.0005273593],"domain_scores_gemma":[0.99875283,0.00039547583,0.00014293625,0.00038112677,0.000048429152,0.00027920248],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004694823,0.00022986393,0.00033889388,0.00022476591,0.00017664694,0.000154783,0.00030060761,0.00008173372,0.00009553002],"category_scores_gemma":[0.00015684738,0.00027009178,0.0001818287,0.00021336973,0.000044360677,0.00021286994,0.00011599119,0.00011519306,0.000030977502],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013971566,0.00024488027,0.78784287,0.00034224064,0.00908077,0.000006115829,0.0020476237,0.00038029323,0.00016328838,0.009853374,0.023089692,0.16680911],"study_design_scores_gemma":[0.0008276597,0.000028943023,0.9037038,0.0000459543,0.0011019345,7.2537534e-7,0.00007529705,0.023204958,0.00008471121,0.017078273,0.053275336,0.0005724062],"about_ca_topic_score_codex":0.08826956,"about_ca_topic_score_gemma":0.1026271,"teacher_disagreement_score":0.2663414,"about_ca_system_score_codex":0.00008929566,"about_ca_system_score_gemma":0.00030283234,"threshold_uncertainty_score":0.99997514},"labels":[],"label_agreement":null},{"id":"W4406274851","doi":"10.1007/s40273-024-01465-w","title":"Projections of Public Spending on Pharmaceuticals: A Review of Methods","year":2025,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Institut National d'assurance Maladie-Invalidité; Uppsala Universitet; Universidad Carlos III de Madrid","keywords":"Quality of Life Research; Health economics; Public health; Health administration; Public finance; Business; Medicine; Public economics; Economics; Nursing","score_opus":0.4462416303200376,"score_gpt":0.5513911100974495,"score_spread":0.10514947977741185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406274851","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000014781275,0.89392984,0.00059329043,0.00044896113,0.0011525794,0.0015126844,0.0021108403,0.000039429953,0.1002109],"genre_scores_gemma":[0.000011720791,0.99495214,0.0017568233,0.0020052795,0.00025303403,0.00028873913,0.00010464446,0.00009677021,0.000530854],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9936994,0.0003304511,0.0043178094,0.0009515957,0.00003782879,0.0006629583],"domain_scores_gemma":[0.9942344,0.0014705305,0.0031927023,0.0007252365,0.000060831142,0.00031633084],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003994062,0.0007121903,0.0052604694,0.0014802159,0.00008476899,0.000049348175,0.0011702375,0.0003263252,0.0029940058],"category_scores_gemma":[0.0007761569,0.0008001796,0.0018665667,0.0008251894,0.00020287365,0.0002344193,0.00035190914,0.00088708196,0.00062473473],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000072066746,0.00027800127,0.0000138046125,0.18278424,0.0009660872,7.889914e-7,0.000012252918,0.0000027971257,9.1487146e-7,0.19274357,0.0063245413,0.61686575],"study_design_scores_gemma":[0.0004307724,0.000039789757,6.5867033e-7,0.022059659,0.00058867206,0.000006716486,0.0000025710958,0.0003368305,0.00006152588,0.0023444197,0.973558,0.00057039526],"about_ca_topic_score_codex":0.000023615998,"about_ca_topic_score_gemma":8.4465256e-7,"teacher_disagreement_score":0.9672334,"about_ca_system_score_codex":0.00051360164,"about_ca_system_score_gemma":0.00044422643,"threshold_uncertainty_score":0.9994449},"labels":[],"label_agreement":null},{"id":"W4406412918","doi":"10.1016/s1541-9800(06)70999-1","title":"10.1016/s1541-9800(06)70999-1","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Pill; Type 2 diabetes; Medicine; Pharmacology; Intensive care medicine; Diabetes mellitus; Endocrinology","score_opus":0.02599463254762982,"score_gpt":0.211687255459111,"score_spread":0.18569262291148117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406412918","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016236235,0.00033734358,0.000002196818,0.002093804,0.0000049719606,0.00017273657,0.0002358065,0.00007512602,0.9954544],"genre_scores_gemma":[0.0017060436,0.000007399556,0.00008848172,0.0010126173,0.00029181593,0.0000252956,0.00002515992,0.00004039942,0.9968028],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986101,0.000010422516,0.0004943618,0.00039987144,0.000023735372,0.0004615522],"domain_scores_gemma":[0.9991593,0.00004362218,0.00008121397,0.00037942064,0.000013078255,0.00032340843],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00028139487,0.00018406965,0.0003647997,0.0001627235,0.00008838598,0.00009507715,0.0003456168,0.00009687602,0.99773824],"category_scores_gemma":[0.00004066906,0.00022945573,0.00013174902,0.00020213253,0.00004143844,0.0001604438,0.000059604434,0.00015767443,0.99902296],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053757172,0.00010968009,0.0000067693477,0.000010563578,0.000056006567,0.0000034910288,0.000035335408,0.00024141539,0.000004590933,0.0016371463,0.8294518,0.16838942],"study_design_scores_gemma":[0.00036816765,0.000059166996,0.00012048519,0.000004311474,0.000004660204,0.0000039111333,2.602566e-7,0.002261803,0.000022181364,0.0015327127,0.9953148,0.0003075699],"about_ca_topic_score_codex":0.000055466826,"about_ca_topic_score_gemma":2.7368364e-7,"teacher_disagreement_score":0.16808186,"about_ca_system_score_codex":0.00008878943,"about_ca_system_score_gemma":0.000017777482,"threshold_uncertainty_score":0.9356933},"labels":[],"label_agreement":null},{"id":"W4406424652","doi":"10.1016/s0029-7437(07)70719-x","title":"10.1016/s0029-7437(07)70719-x","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Vital signs; Antibiotics; Business; Environmental science; Economics; Medicine; Anesthesia; Microbiology; Biology","score_opus":0.028707871958831753,"score_gpt":0.220413195142507,"score_spread":0.19170532318367525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406424652","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013193672,0.00031474954,0.0000028912038,0.0018909657,0.0000015525201,0.00017249228,0.0002501995,0.000087075685,0.9959607],"genre_scores_gemma":[0.0011531246,0.000007051289,0.00010774866,0.0009087436,0.00029929576,0.000025254614,0.0000179797,0.000040222534,0.9974406],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986152,0.000010159431,0.0004938608,0.00039993695,0.000023453966,0.00045741323],"domain_scores_gemma":[0.99916357,0.000043653992,0.00008268804,0.0003801522,0.00001297083,0.00031698993],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00027787298,0.00018385577,0.00036425758,0.0001530123,0.00008861344,0.000095224954,0.00034589152,0.00009634451,0.9987303],"category_scores_gemma":[0.000039569975,0.00022923603,0.00013183948,0.00018090768,0.000041192947,0.00016070677,0.00005944891,0.000157088,0.99929893],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004382685,0.00007315338,0.0000023837194,0.000006922081,0.000037388465,0.0000019648887,0.000022136384,0.00014297572,0.00000269855,0.0011267597,0.92945105,0.06908871],"study_design_scores_gemma":[0.00035837886,0.0000676025,0.00008414508,0.0000043594773,0.0000046664945,0.000004154935,2.8183604e-7,0.00219752,0.000021653133,0.0016669629,0.99528295,0.0003072996],"about_ca_topic_score_codex":0.0000614134,"about_ca_topic_score_gemma":2.8361595e-7,"teacher_disagreement_score":0.06878141,"about_ca_system_score_codex":0.00008784841,"about_ca_system_score_gemma":0.000016742291,"threshold_uncertainty_score":0.9347974},"labels":[],"label_agreement":null},{"id":"W4406430700","doi":"10.1016/s0029-7437(05)71082-x","title":"10.1016/s0029-7437(05)71082-x","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Drug; Business; Medicine; Pharmacology","score_opus":0.028634951249743162,"score_gpt":0.22028570712836135,"score_spread":0.19165075587861818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406430700","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013826499,0.00028317212,0.0000029589694,0.0022097123,0.0000018050309,0.00017272503,0.00025662387,0.00008688419,0.99560344],"genre_scores_gemma":[0.0010993816,0.00000683948,0.000110394656,0.0010862667,0.00029733576,0.000024869909,0.000018802373,0.000040215175,0.9973159],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99860674,0.000010449164,0.0004974582,0.0004000651,0.00002327454,0.00046202104],"domain_scores_gemma":[0.99915785,0.000044985387,0.0000835789,0.00038026358,0.000012856436,0.00032047328],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00028449393,0.0001843342,0.0003681996,0.00016181829,0.000087728025,0.000093366034,0.00034510044,0.00009616285,0.9981275],"category_scores_gemma":[0.000041194497,0.00022919949,0.0001326531,0.00020123579,0.000041255575,0.00016040297,0.00005937647,0.00015617836,0.998722],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039900326,0.0000679053,0.000001904856,0.0000064146475,0.00003402451,0.0000020890698,0.000020762953,0.00013378676,0.000002845901,0.0011115228,0.92700255,0.07157629],"study_design_scores_gemma":[0.00036517406,0.000074579686,0.00007763421,0.0000044340854,0.0000046539462,0.0000050566014,2.898436e-7,0.0023285944,0.000023683591,0.001623118,0.9951868,0.00030600154],"about_ca_topic_score_codex":0.00006483052,"about_ca_topic_score_gemma":3.3789368e-7,"teacher_disagreement_score":0.07127029,"about_ca_system_score_codex":0.00008905854,"about_ca_system_score_gemma":0.000016654023,"threshold_uncertainty_score":0.93464833},"labels":[],"label_agreement":null},{"id":"W4406441492","doi":"10.1016/s0029-7437(07)70349-x","title":"10.1016/s0029-7437(07)70349-x","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Drugs of abuse; Psychology; Internet privacy; Business; Psychiatry; Computer science; Drug","score_opus":0.02859036513994322,"score_gpt":0.22036912489471336,"score_spread":0.19177875975477013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406441492","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012728166,0.00032518044,0.0000029313915,0.0018793312,0.0000015382295,0.00017296273,0.00025227154,0.00008702858,0.99600595],"genre_scores_gemma":[0.0011613749,0.000007423742,0.00010499781,0.00089055055,0.00029934716,0.00002536926,0.000018174505,0.000040242652,0.9974525],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986168,0.0000102458225,0.0004920105,0.00040041594,0.000023579893,0.0004569055],"domain_scores_gemma":[0.99916166,0.000043986507,0.000081910264,0.00038303915,0.000012955487,0.0003164755],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002804732,0.00018374129,0.00036629778,0.00015281395,0.000088494126,0.000094928735,0.00034572906,0.0000962237,0.99874836],"category_scores_gemma":[0.000039870953,0.00022914146,0.00013446016,0.00018119233,0.00004059819,0.00015970768,0.000059507598,0.0001569466,0.9993108],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043796023,0.000074155556,0.0000023224095,0.0000070386836,0.000039283124,0.0000019443362,0.000022363967,0.0001474789,0.0000027862704,0.0010978619,0.9235245,0.07503649],"study_design_scores_gemma":[0.00035670365,0.00006700551,0.00008378922,0.000004380058,0.0000047720036,0.000004130028,2.7754416e-7,0.0021885443,0.00002217388,0.0016274997,0.99533355,0.00030717303],"about_ca_topic_score_codex":0.00006457012,"about_ca_topic_score_gemma":2.938324e-7,"teacher_disagreement_score":0.074729316,"about_ca_system_score_codex":0.000087634384,"about_ca_system_score_gemma":0.000016867496,"threshold_uncertainty_score":0.9344117},"labels":[],"label_agreement":null},{"id":"W4406456288","doi":"10.1016/s0029-7437(05)70293-7","title":"10.1016/s0029-7437(05)70293-7","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Drug; Internet privacy; Medicine; Computer science; Pharmacology","score_opus":0.028228682005537003,"score_gpt":0.22016898416012312,"score_spread":0.19194030215458613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406456288","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013221764,0.00027877942,0.000002896766,0.002169253,0.0000017867667,0.00017394687,0.00025745016,0.00008779398,0.9957059],"genre_scores_gemma":[0.0010099516,0.0000062623144,0.00011118537,0.0010521839,0.00029501328,0.000025532983,0.00001881058,0.000040529736,0.9974405],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99860096,0.000008066351,0.00050115876,0.0004018074,0.000023293738,0.00046472545],"domain_scores_gemma":[0.99915284,0.000044571352,0.000084329935,0.00038221304,0.000013485108,0.00032254145],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002739896,0.00018570636,0.00036987456,0.00016254195,0.000089170826,0.00009369561,0.00034774304,0.00009651566,0.99813044],"category_scores_gemma":[0.000036988095,0.00023087287,0.00013348507,0.00020308427,0.000041545853,0.00015883698,0.00005944068,0.00015523794,0.9986621],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004347965,0.000072179406,0.0000018187216,0.0000066782336,0.00003604531,0.0000022238871,0.000021829488,0.00014212045,0.000002949966,0.0015833621,0.9187603,0.07932704],"study_design_scores_gemma":[0.00036481026,0.00007442121,0.000079037956,0.000004399893,0.000004636449,0.0000051149846,2.9708374e-7,0.0024035615,0.00002350687,0.0025021338,0.99423015,0.00030791687],"about_ca_topic_score_codex":0.000063517065,"about_ca_topic_score_gemma":3.2739496e-7,"teacher_disagreement_score":0.07901912,"about_ca_system_score_codex":0.00008989575,"about_ca_system_score_gemma":0.000014165189,"threshold_uncertainty_score":0.9414723},"labels":[],"label_agreement":null},{"id":"W4406457157","doi":"10.1016/s1544-8800(08)70406-8","title":"10.1016/s1544-8800(08)70406-8","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Business; Medicine","score_opus":0.025871300324584498,"score_gpt":0.2114233789467951,"score_spread":0.18555207862221063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406457157","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017485764,0.000310424,0.0000026479079,0.002062395,0.000006984943,0.00017425332,0.0002501667,0.000075087424,0.9953695],"genre_scores_gemma":[0.0016219737,0.0000069428115,0.00009598875,0.00087119546,0.00029595476,0.000025135801,0.00001862087,0.000040431463,0.99702376],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99859416,0.000010407351,0.00051270385,0.00040006303,0.000023621526,0.00045905198],"domain_scores_gemma":[0.99915904,0.000043688833,0.000086346285,0.00037975385,0.000013008789,0.0003181376],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002790097,0.00018421009,0.0003652564,0.00016138771,0.00008873634,0.0000950564,0.00034550365,0.00009683801,0.99799824],"category_scores_gemma":[0.00003915617,0.00022956055,0.00013662675,0.00020224426,0.000041889623,0.0001605038,0.000059339996,0.00015743311,0.99896485],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000079900135,0.00012451925,0.000004041378,0.000012121688,0.000063709005,0.00000420167,0.00003960939,0.00027541755,0.0000059850336,0.0019427027,0.6326513,0.3647965],"study_design_scores_gemma":[0.0003728173,0.00006705061,0.00013339666,0.000004367621,0.000004700089,0.0000039828296,2.8863013e-7,0.0021430461,0.00002569794,0.0015201025,0.99541694,0.00030762822],"about_ca_topic_score_codex":0.000082390216,"about_ca_topic_score_gemma":4.0949743e-7,"teacher_disagreement_score":0.36448884,"about_ca_system_score_codex":0.00008866617,"about_ca_system_score_gemma":0.000018012397,"threshold_uncertainty_score":0.93612075},"labels":[],"label_agreement":null},{"id":"W4406478161","doi":"10.1016/s0029-7437(08)70385-9","title":"10.1016/s0029-7437(08)70385-9","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Drug; Medicine; Pharmacology","score_opus":0.02776337876948659,"score_gpt":0.21923287689649548,"score_spread":0.1914694981270089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406478161","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013468565,0.00032029557,0.0000028510815,0.0019799564,0.0000015487406,0.00017240341,0.0002444251,0.0000870138,0.99584466],"genre_scores_gemma":[0.0012415955,0.0000070674632,0.00010439318,0.00091683416,0.00029814505,0.00002517295,0.000017896053,0.000040191902,0.9973487],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986137,0.000010103074,0.0004967309,0.00039946294,0.000023376791,0.00045658287],"domain_scores_gemma":[0.99916375,0.000043832108,0.00008306322,0.00037975374,0.000012964545,0.00031661568],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00027679626,0.00018375965,0.00036413132,0.00016145613,0.00008883293,0.00009526241,0.0003478808,0.000095940144,0.9984928],"category_scores_gemma":[0.000040024814,0.00022897759,0.00013143504,0.00020211635,0.000041592724,0.00016104507,0.000059796577,0.00015698346,0.9990656],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000429342,0.00007184285,0.00000237027,0.000006877854,0.000036769343,0.0000018420766,0.00002283984,0.00014426751,0.0000032418955,0.0010697911,0.93179274,0.0668045],"study_design_scores_gemma":[0.0003700148,0.000066896646,0.000084862295,0.0000044153417,0.000004654518,0.0000039457927,2.8963336e-7,0.002275099,0.000025132822,0.0015575888,0.9953002,0.0003069078],"about_ca_topic_score_codex":0.00006129252,"about_ca_topic_score_gemma":3.369479e-7,"teacher_disagreement_score":0.06649759,"about_ca_system_score_codex":0.000089292924,"about_ca_system_score_gemma":0.000017445225,"threshold_uncertainty_score":0.9337435},"labels":[],"label_agreement":null},{"id":"W4406486819","doi":"10.1016/s0029-7437(07)70150-7","title":"10.1016/s0029-7437(07)70150-7","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Business; Drug; Pharmacology; Medicine","score_opus":0.029123797176607,"score_gpt":0.22112468531389062,"score_spread":0.1920008881372836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406486819","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001373806,0.00031753807,0.0000026498,0.0019147155,0.0000015297788,0.00017179135,0.00025421387,0.00008679549,0.99587697],"genre_scores_gemma":[0.001175228,0.00000675916,0.00010524416,0.00089872006,0.00029641442,0.00002508686,0.00001844892,0.00004008007,0.997434],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986214,0.000010196336,0.00049193803,0.00039807463,0.000023594617,0.00045477692],"domain_scores_gemma":[0.99916416,0.000042926404,0.00008243643,0.00037797014,0.000013242198,0.0003192471],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00028090697,0.00018319413,0.00036338007,0.00015260492,0.000086966604,0.000093783754,0.00034360023,0.00009624768,0.99868745],"category_scores_gemma":[0.000039675502,0.00022840682,0.00012898019,0.00018245168,0.000040610706,0.00015726172,0.000059288286,0.00015716266,0.9993042],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004391324,0.0000728852,0.0000023014607,0.000006824562,0.000037068905,0.0000019172928,0.00002204246,0.00014500541,0.000002677423,0.0011173538,0.92887014,0.06967786],"study_design_scores_gemma":[0.00036009366,0.00006766548,0.00008497198,0.0000042743372,0.000004649637,0.000004099696,2.932241e-7,0.0021441353,0.000021272766,0.0016521452,0.9953502,0.00030622794],"about_ca_topic_score_codex":0.000061333056,"about_ca_topic_score_gemma":2.8691795e-7,"teacher_disagreement_score":0.06937163,"about_ca_system_score_codex":0.00008879319,"about_ca_system_score_gemma":0.000016973821,"threshold_uncertainty_score":0.931416},"labels":[],"label_agreement":null},{"id":"W4406519309","doi":"10.1016/s0029-7437(08)70399-9","title":"10.1016/s0029-7437(08)70399-9","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medical prescription; Drug; Distribution (mathematics); Vital signs; Medicine; Pharmacology; Anesthesia; Mathematics","score_opus":0.027765111778826547,"score_gpt":0.21923854629980688,"score_spread":0.19147343452098034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406519309","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012772882,0.0003220465,0.0000028417217,0.0019024096,0.0000015873123,0.00017350096,0.00023509005,0.0000873971,0.99599785],"genre_scores_gemma":[0.0011405598,0.0000071321488,0.000112309535,0.0009026244,0.00030264098,0.000025383402,0.000017805081,0.000040207284,0.99745136],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986101,0.000009957932,0.0004927157,0.0004009607,0.000023437675,0.00046281973],"domain_scores_gemma":[0.9991667,0.000042931086,0.00008245821,0.00038115584,0.000012998281,0.0003137419],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00027833242,0.00018385194,0.0003658449,0.00015929356,0.00008942496,0.00009687746,0.00034600068,0.00009639176,0.99848014],"category_scores_gemma":[0.000038900387,0.00022930054,0.00013132904,0.0002044288,0.000040992178,0.0001655518,0.00005942202,0.00015705737,0.99909294],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043130658,0.00007220381,0.000002324053,0.0000069569446,0.000036952297,0.0000018376459,0.00002248908,0.00015463012,0.000003166002,0.0011255257,0.9335135,0.06501725],"study_design_scores_gemma":[0.0003708422,0.00006709039,0.00007770727,0.000004427399,0.000004653256,0.0000039407123,2.854581e-7,0.002278621,0.000026872425,0.0016663426,0.99519193,0.00030730842],"about_ca_topic_score_codex":0.000059630253,"about_ca_topic_score_gemma":3.0297747e-7,"teacher_disagreement_score":0.06470995,"about_ca_system_score_codex":0.0000884972,"about_ca_system_score_gemma":0.00001714134,"threshold_uncertainty_score":0.93506044},"labels":[],"label_agreement":null},{"id":"W4406521958","doi":"10.1016/s0029-7437(07)70666-3","title":"10.1016/s0029-7437(07)70666-3","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Traditional medicine","score_opus":0.028705292440169877,"score_gpt":0.220386226494674,"score_spread":0.19168093405450412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406521958","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001439818,0.00029665386,0.0000027918356,0.0018995819,0.0000015523682,0.00017259501,0.00025043593,0.00008700636,0.99584955],"genre_scores_gemma":[0.0012667424,0.0000067076826,0.00010355213,0.0009093294,0.00029895283,0.000025278168,0.000017939428,0.00004021262,0.99733126],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986169,0.000010155363,0.0004926693,0.00039981806,0.000023441025,0.00045705985],"domain_scores_gemma":[0.9991644,0.000043498916,0.000082551436,0.00037967012,0.000012960822,0.00031689415],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00027715374,0.00018379424,0.00036407716,0.00015487817,0.0000884445,0.00009512245,0.0003455055,0.000096282914,0.9987346],"category_scores_gemma":[0.000039416638,0.00022916558,0.00013147482,0.00018364155,0.000041149076,0.00016060066,0.000059349386,0.00015697039,0.9993052],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004535912,0.00007568315,0.0000024029462,0.0000071580807,0.000038631697,0.0000020327561,0.000023241448,0.00014475327,0.0000035733012,0.0012091392,0.9241205,0.07432752],"study_design_scores_gemma":[0.0003586891,0.00006773209,0.00008105376,0.000004359247,0.000004614418,0.0000041547387,2.902789e-7,0.0021439316,0.000027586599,0.0016431056,0.9953573,0.0003072255],"about_ca_topic_score_codex":0.000063150655,"about_ca_topic_score_gemma":2.6189886e-7,"teacher_disagreement_score":0.0740203,"about_ca_system_score_codex":0.00008911101,"about_ca_system_score_gemma":0.000017121449,"threshold_uncertainty_score":0.9345101},"labels":[],"label_agreement":null},{"id":"W4406544985","doi":"10.1016/s1544-8800(11)70366-9","title":"10.1016/s1544-8800(11)70366-9","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Rivaroxaban; Medicine; Stroke (engine); Cardiology; Internal medicine; Atrial fibrillation; Warfarin; Engineering","score_opus":0.025935663386603074,"score_gpt":0.21137618844623124,"score_spread":0.18544052505962816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406544985","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0026187166,0.00026656175,0.000002610977,0.0019480741,0.000007291438,0.00017256557,0.0002377829,0.00007467871,0.9946717],"genre_scores_gemma":[0.0016507626,0.000005791202,0.000087028915,0.00085047784,0.00029848036,0.000025301179,0.000017980516,0.0000403483,0.9970238],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986196,0.000010449688,0.00049144856,0.00039899052,0.00002356745,0.00045594748],"domain_scores_gemma":[0.99916357,0.000046902805,0.00008229944,0.0003821832,0.000012853155,0.0003122019],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002744217,0.00018307954,0.0003624012,0.0001577652,0.000088330584,0.00009436262,0.00035031576,0.00009657063,0.9977244],"category_scores_gemma":[0.00003883653,0.00022834569,0.00013053663,0.00019696094,0.000042493917,0.00015603582,0.000060134145,0.00013526462,0.99839956],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000066645254,0.00013403039,0.000008919482,0.000013210281,0.000055359596,0.000004446143,0.000044147444,0.00025173512,0.0000043760015,0.0033621574,0.7444918,0.25156316],"study_design_scores_gemma":[0.00035700257,0.000055612123,0.000158533,0.000004326288,0.0000046137034,0.0000039122206,2.8609065e-7,0.002588525,0.00002351124,0.001348997,0.9951489,0.00030580853],"about_ca_topic_score_codex":0.00012276122,"about_ca_topic_score_gemma":8.514108e-7,"teacher_disagreement_score":0.25125733,"about_ca_system_score_codex":0.00008725273,"about_ca_system_score_gemma":0.000017131042,"threshold_uncertainty_score":0.93116665},"labels":[],"label_agreement":null},{"id":"W4406547413","doi":"10.1016/s1541-9800(05)70502-0","title":"10.1016/s1541-9800(05)70502-0","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Purchasing; Business; Economics; Marketing","score_opus":0.026391010340227453,"score_gpt":0.21255329252011973,"score_spread":0.18616228217989228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406547413","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013693752,0.0002926481,0.0000022408476,0.002317703,0.000008099416,0.00017168872,0.00026081136,0.00007474035,0.9955027],"genre_scores_gemma":[0.0014697808,0.0000064740298,0.00009541397,0.0011369738,0.00030701444,0.00002432457,0.000020336482,0.000040004983,0.99689966],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99861586,0.000010314243,0.00049095845,0.00039875146,0.000023560277,0.00046053124],"domain_scores_gemma":[0.9991652,0.00004155421,0.00008229845,0.0003790229,0.000012980329,0.00031894524],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002756734,0.00018395203,0.0003643,0.00016241215,0.00008786342,0.000094216826,0.00034423705,0.000095986914,0.9979628],"category_scores_gemma":[0.000039387236,0.00022878824,0.00013151238,0.00019803102,0.000041606636,0.00015581919,0.000058621063,0.00015559986,0.99866277],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000064570224,0.00010498012,0.0000027739463,0.000009901968,0.000052828556,0.0000044691055,0.000034225926,0.00019863558,0.0000045517545,0.0016357685,0.71744376,0.2804435],"study_design_scores_gemma":[0.0003762461,0.000072789335,0.00008193979,0.000004384864,0.000004653028,0.0000053433464,2.9404836e-7,0.00213104,0.00002407082,0.0017672007,0.99522597,0.00030607783],"about_ca_topic_score_codex":0.000068211986,"about_ca_topic_score_gemma":3.5192352e-7,"teacher_disagreement_score":0.28013742,"about_ca_system_score_codex":0.00008708734,"about_ca_system_score_gemma":0.000017207047,"threshold_uncertainty_score":0.93297136},"labels":[],"label_agreement":null},{"id":"W4406550215","doi":"10.1016/s1541-9800(05)70294-5","title":"10.1016/s1541-9800(05)70294-5","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Valdecoxib; Medicine; Chemistry","score_opus":0.02619341044334982,"score_gpt":0.21251417814070803,"score_spread":0.1863207676973582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406550215","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00160632,0.0002757211,0.0000023799385,0.0022467254,0.0000081081225,0.0001726859,0.00025848963,0.00007409393,0.9953555],"genre_scores_gemma":[0.0014562989,0.0000062766244,0.000094933,0.0011400378,0.00030258117,0.000025358459,0.000020143627,0.00004032674,0.996914],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99861413,0.000010497884,0.00049285573,0.00039817858,0.000023454784,0.000460856],"domain_scores_gemma":[0.9991616,0.000043443222,0.00008273485,0.00038060162,0.000012753556,0.00031887981],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002803537,0.00018397064,0.00036493226,0.00016264137,0.000090392554,0.0001006586,0.00034584518,0.00009639242,0.9979463],"category_scores_gemma":[0.000038911126,0.0002289265,0.00013166519,0.00020033747,0.0000423099,0.00016503806,0.000058753725,0.00015675453,0.9986198],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006270273,0.0001058416,0.0000027823714,0.000009582901,0.000052622345,0.0000041379344,0.000034620232,0.00017787794,0.0000052104556,0.0016370466,0.74092793,0.25697967],"study_design_scores_gemma":[0.000374909,0.000074263386,0.00008119908,0.0000042439424,0.0000046729865,0.0000051308207,3.0585926e-7,0.0018739748,0.000024797013,0.0018048991,0.9954454,0.00030622925],"about_ca_topic_score_codex":0.00006849325,"about_ca_topic_score_gemma":3.7914734e-7,"teacher_disagreement_score":0.25667343,"about_ca_system_score_codex":0.00009209238,"about_ca_system_score_gemma":0.00001773958,"threshold_uncertainty_score":0.9335351},"labels":[],"label_agreement":null},{"id":"W4406550742","doi":"10.1016/s1541-9800(10)70047-8","title":"10.1016/s1541-9800(10)70047-8","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Business; Internet privacy; Drug; Advertising; Web site; Computer security; The Internet; Medicine; World Wide Web; Pharmacology; Computer science","score_opus":0.027240964507213774,"score_gpt":0.21232299963668608,"score_spread":0.1850820351294723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406550742","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012383624,0.00032578048,0.000001892033,0.0019575502,0.000006552968,0.00017295552,0.00028230756,0.00007719044,0.9959374],"genre_scores_gemma":[0.0011049858,0.0000062475174,0.00008651883,0.00083701214,0.00030615175,0.000026516756,0.000024474177,0.00004231106,0.9975658],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99855864,0.000010971183,0.00051343325,0.00041704162,0.000025016592,0.0004749222],"domain_scores_gemma":[0.9991239,0.00004682289,0.00008857328,0.00039859168,0.0000152130615,0.0003269527],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00028753927,0.00019409,0.00038183865,0.00016853631,0.00009246,0.00010097844,0.00036175727,0.00010268381,0.9990015],"category_scores_gemma":[0.000046286572,0.00024162729,0.00014058716,0.00020797939,0.000044017896,0.0001662163,0.000063767344,0.00014976085,0.9991204],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008055974,0.00010582904,0.0000019784309,0.000010242896,0.000054646676,0.0000033821061,0.000029351713,0.00020911769,0.000004212423,0.0011838322,0.79805195,0.20026492],"study_design_scores_gemma":[0.00040196796,0.000077684235,0.00006924783,0.0000045425354,0.000005190283,0.0000036222307,2.8568593e-7,0.0022878204,0.000026259238,0.0014326785,0.9953687,0.00032199567],"about_ca_topic_score_codex":0.000059555015,"about_ca_topic_score_gemma":3.469082e-7,"teacher_disagreement_score":0.19994292,"about_ca_system_score_codex":0.00009679055,"about_ca_system_score_gemma":0.000019808702,"threshold_uncertainty_score":0.9853275},"labels":[],"label_agreement":null},{"id":"W4406551952","doi":"10.1016/s1544-8800(12)70391-3","title":"10.1016/s1544-8800(12)70391-3","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Drug; Medicine; Pharmacology","score_opus":0.027931763668062326,"score_gpt":0.20970490931573402,"score_spread":0.1817731456476717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406551952","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015805932,0.00026118953,0.00000266802,0.0019071774,0.00000705916,0.00017377755,0.00022992626,0.00007444188,0.9957632],"genre_scores_gemma":[0.0015846216,0.0000068367863,0.00009327659,0.00090509414,0.0002935995,0.000024434168,0.000017647557,0.00003994828,0.99703455],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986212,0.000010253387,0.00049089896,0.00039728492,0.000023472072,0.00045689227],"domain_scores_gemma":[0.9991694,0.000043499378,0.00008222042,0.00037759315,0.000011161587,0.00031611495],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00026529495,0.00018356988,0.00036436084,0.0001587529,0.00008752072,0.00009251606,0.00034240593,0.00009529955,0.99770164],"category_scores_gemma":[0.000036667763,0.00022867536,0.00013031636,0.00016026583,0.000040911687,0.00015938086,0.000058425037,0.0001549115,0.99856967],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000825269,0.000118078344,0.0000050245153,0.0000110814635,0.00005998484,0.0000040976215,0.00004413486,0.00024409025,0.0000054506163,0.001420674,0.6221676,0.37583727],"study_design_scores_gemma":[0.0003663336,0.0000718778,0.00015778196,0.0000042935976,0.000004671111,0.00000408409,3.1218752e-7,0.0021778764,0.000022640974,0.001449364,0.99543446,0.00030630906],"about_ca_topic_score_codex":0.00009066346,"about_ca_topic_score_gemma":6.472502e-7,"teacher_disagreement_score":0.37553096,"about_ca_system_score_codex":0.00008808739,"about_ca_system_score_gemma":0.000017356137,"threshold_uncertainty_score":0.93251103},"labels":[],"label_agreement":null},{"id":"W4406552316","doi":"10.1016/s1553-3212(08)70162-6","title":"10.1016/s1553-3212(08)70162-6","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Drug pricing; Drug; Business; Medicine; Actuarial science; Psychiatry","score_opus":0.025938670110545424,"score_gpt":0.21121112305851594,"score_spread":0.1852724529479705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406552316","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014439616,0.00032128367,0.0000039156816,0.002064279,0.0000070764586,0.0001744972,0.00024880146,0.00007638546,0.9956598],"genre_scores_gemma":[0.0015360244,0.0000071944205,0.00009413318,0.0010107482,0.00030409757,0.00002554661,0.000018434172,0.000040787272,0.996963],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99860144,0.000010417164,0.0004974846,0.00040342426,0.000023877908,0.0004633843],"domain_scores_gemma":[0.99915445,0.000044282704,0.00008554719,0.00038254765,0.000013005684,0.00032015925],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00027991727,0.00018561442,0.00036818627,0.00016376041,0.00008912819,0.00009472894,0.00034858612,0.00009701239,0.99816585],"category_scores_gemma":[0.00004000156,0.00022967368,0.00013277294,0.00020127844,0.00004228061,0.00016229454,0.00005995325,0.00015657337,0.9990936],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000079927144,0.00012599258,0.0000035133437,0.0000120007435,0.000064877866,0.000004297704,0.00004345494,0.00025247663,0.00000624436,0.002577042,0.72733045,0.26949975],"study_design_scores_gemma":[0.00037851807,0.000067284585,0.00009220277,0.0000044190074,0.0000045837064,0.000003936402,3.007455e-7,0.0025667783,0.000026304102,0.0015596994,0.9949862,0.0003097691],"about_ca_topic_score_codex":0.000060094477,"about_ca_topic_score_gemma":2.5509817e-7,"teacher_disagreement_score":0.26918998,"about_ca_system_score_codex":0.000092049544,"about_ca_system_score_gemma":0.00001839694,"threshold_uncertainty_score":0.9365821},"labels":[],"label_agreement":null},{"id":"W4406552542","doi":"10.1016/s1558-0164(07)70380-2","title":"10.1016/s1558-0164(07)70380-2","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Drug; User fee; Internet privacy; Pharmacology; Law; Political science; Computer science","score_opus":0.026647612257589846,"score_gpt":0.21276397070661227,"score_spread":0.1861163584490224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406552542","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014545625,0.00032143688,0.0000028606103,0.0020123594,0.000006608757,0.00017101946,0.00023442532,0.000075499716,0.9957212],"genre_scores_gemma":[0.001435003,0.0000070294927,0.000091713795,0.00097594655,0.00029426545,0.000025018104,0.000017972314,0.000040549003,0.9971125],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986181,0.000010311932,0.00049243466,0.00039980782,0.000023595932,0.00045574264],"domain_scores_gemma":[0.9991664,0.000043956774,0.00008381783,0.00037812558,0.000012898961,0.00031480033],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00027555838,0.00018387033,0.00036456628,0.00015403822,0.00008793347,0.000094757204,0.0003453688,0.000094696676,0.9984711],"category_scores_gemma":[0.00003996417,0.00022808723,0.00013220425,0.0001793776,0.00004164061,0.0001587561,0.000059169575,0.0001560088,0.99971396],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007517793,0.00011335253,0.0000010532525,0.000011054688,0.00005989429,0.000004184665,0.000036913323,0.0002311306,0.0000052304463,0.001773988,0.9245398,0.0731482],"study_design_scores_gemma":[0.00035857016,0.00006748758,0.00008462492,0.000004332433,0.0000046175714,0.000004224102,2.8061658e-7,0.0020156316,0.000024647414,0.0016037237,0.99552405,0.00030783043],"about_ca_topic_score_codex":0.00006962261,"about_ca_topic_score_gemma":3.0848057e-7,"teacher_disagreement_score":0.07284037,"about_ca_system_score_codex":0.00009064256,"about_ca_system_score_gemma":0.000018212973,"threshold_uncertainty_score":0.9301127},"labels":[],"label_agreement":null},{"id":"W4406553560","doi":"10.1016/s1558-0164(09)70352-9","title":"10.1016/s1558-0164(09)70352-9","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Darbepoetin alfa; Medicine; Internal medicine; Cardiology; Kidney disease","score_opus":0.026148924671377267,"score_gpt":0.21188890949036543,"score_spread":0.18573998481898815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406553560","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014194152,0.00031269854,0.0000035143073,0.0019646497,0.0000069164794,0.0001735364,0.0002495793,0.00007575647,0.99579394],"genre_scores_gemma":[0.0011335778,0.000007089506,0.000085218046,0.00077177887,0.00029407002,0.000025266663,0.000018383083,0.00004077669,0.99762386],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986118,0.000010354548,0.00049430015,0.00040157413,0.000023801946,0.00045816007],"domain_scores_gemma":[0.9991619,0.000043618624,0.0000842676,0.0003797226,0.000012972894,0.00031753074],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00027776975,0.00018468704,0.00036601152,0.00016333969,0.00008817,0.0000945979,0.00034735646,0.000095426905,0.99786586],"category_scores_gemma":[0.000039552207,0.00022917864,0.0001326046,0.00020148585,0.00004142043,0.0001594034,0.000059360784,0.0001577266,0.9995677],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007901237,0.00012385617,0.0000013333103,0.000011797188,0.00006371142,0.000004274149,0.000039751696,0.0002957898,0.00000598007,0.001932559,0.901119,0.09632293],"study_design_scores_gemma":[0.00036100313,0.00006873596,0.000085547385,0.000004383707,0.0000046272703,0.0000034005059,2.9311934e-7,0.0022623474,0.000025242818,0.001560653,0.99531454,0.00030922453],"about_ca_topic_score_codex":0.00006572103,"about_ca_topic_score_gemma":3.2691275e-7,"teacher_disagreement_score":0.0960137,"about_ca_system_score_codex":0.00008945476,"about_ca_system_score_gemma":0.00001778424,"threshold_uncertainty_score":0.93456334},"labels":[],"label_agreement":null},{"id":"W4406554175","doi":"10.1016/s1558-0164(11)70462-x","title":"10.1016/s1558-0164(11)70462-x","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Toll; Medicine; Economic shortage; Drug; Intensive care medicine; Death toll; Medical emergency; Pharmacology; Environmental health; Immunology","score_opus":0.02578226111751708,"score_gpt":0.21112772458101117,"score_spread":0.1853454634634941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406554175","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022647022,0.000256902,0.0000027901206,0.0021200185,0.0000072569865,0.00017168948,0.0002438275,0.00007533583,0.9948575],"genre_scores_gemma":[0.001566844,0.00000587181,0.000103421735,0.0009267492,0.00029856956,0.00002525018,0.000018441631,0.00004066076,0.99701416],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99861705,0.000010479975,0.00049251574,0.0004008174,0.000023770684,0.00045535018],"domain_scores_gemma":[0.9991616,0.000046926885,0.00008389652,0.00038259884,0.000012680007,0.00031228003],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00028341243,0.00018361813,0.0003634837,0.00016108103,0.00008860487,0.00009434142,0.0003520058,0.000096104646,0.9978965],"category_scores_gemma":[0.00004051045,0.0002280562,0.00013112412,0.0001944757,0.000042580155,0.00015560017,0.000060515005,0.00013557097,0.99941355],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055587865,0.00011771538,0.0000021598312,0.0000114262575,0.000049176582,0.0000040084287,0.000037072183,0.0002581225,0.0000045983315,0.0023159601,0.9452688,0.051875368],"study_design_scores_gemma":[0.00035311864,0.00005589713,0.00011216461,0.0000043625537,0.0000045781762,0.000003943959,2.9793475e-7,0.00201974,0.0000250434,0.0014491933,0.995664,0.00030763922],"about_ca_topic_score_codex":0.0000879802,"about_ca_topic_score_gemma":6.504095e-7,"teacher_disagreement_score":0.05156773,"about_ca_system_score_codex":0.00008935261,"about_ca_system_score_gemma":0.000017470771,"threshold_uncertainty_score":0.92998624},"labels":[],"label_agreement":null},{"id":"W4406576689","doi":"10.1016/s1553-3212(05)71129-8","title":"10.1016/s1553-3212(05)71129-8","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Business; Risk analysis (engineering); Medical emergency","score_opus":0.026922904835989067,"score_gpt":0.21353737456050176,"score_spread":0.18661446972451268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406576689","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015618168,0.00030104333,0.0000027293434,0.0022743777,0.00000799015,0.00017231204,0.00024006513,0.0000756532,0.995364],"genre_scores_gemma":[0.001470191,0.0000071387826,0.00009336039,0.001138971,0.00030226025,0.000025330814,0.000019105788,0.00004041046,0.99690324],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986131,0.000010599076,0.00049137004,0.00039974906,0.000023614559,0.00046153102],"domain_scores_gemma":[0.99915904,0.00004434922,0.000083285995,0.0003805815,0.000012859573,0.00031985945],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002835055,0.00018409976,0.0003644615,0.00016020959,0.000087895605,0.00009536714,0.00034597065,0.00009652555,0.9976138],"category_scores_gemma":[0.00003985348,0.00022907271,0.00013143316,0.00019648462,0.000041323874,0.00016348183,0.00005954009,0.00015604644,0.99859077],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007316077,0.00011194573,0.0000027195636,0.000010397682,0.0000564761,0.0000046154973,0.00003854335,0.00024244297,0.0000046749137,0.0017409968,0.72266185,0.27505216],"study_design_scores_gemma":[0.00040783448,0.00007394116,0.000084214524,0.0000042166466,0.000004517176,0.0000049642313,3.3236972e-7,0.0020603803,0.000024121215,0.0016146082,0.9954145,0.00030639282],"about_ca_topic_score_codex":0.00006778184,"about_ca_topic_score_gemma":3.8360935e-7,"teacher_disagreement_score":0.27474576,"about_ca_system_score_codex":0.0000896132,"about_ca_system_score_gemma":0.000017485467,"threshold_uncertainty_score":0.9341314},"labels":[],"label_agreement":null},{"id":"W4406577037","doi":"10.1016/s1544-8800(11)70320-7","title":"10.1016/s1544-8800(11)70320-7","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Cloud computing; Computer science","score_opus":0.025632120920001538,"score_gpt":0.21127035574530703,"score_spread":0.1856382348253055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406577037","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0026859853,0.0002764051,0.0000025868537,0.0022860968,0.000007338639,0.00017246188,0.00023979928,0.00007463207,0.9942547],"genre_scores_gemma":[0.0015826292,0.000005590097,0.0001066757,0.0008248361,0.00029857346,0.000024844476,0.000017548284,0.000040315193,0.997099],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986177,0.000010434437,0.00049378007,0.00039925193,0.000023571607,0.0004552505],"domain_scores_gemma":[0.99916375,0.00004640778,0.000082658065,0.00038272797,0.0000128780675,0.00031157662],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00027533856,0.00018293709,0.00036336225,0.0001579677,0.000088662615,0.00009377604,0.00035017252,0.00009665961,0.99770266],"category_scores_gemma":[0.000038996994,0.00022813106,0.00013041678,0.00019788093,0.00004257731,0.00015319319,0.00006010727,0.00013532751,0.9983381],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000063825224,0.00012919607,0.000008362712,0.000012726159,0.00005331529,0.000004276016,0.000044358214,0.0003142978,0.000004920144,0.0023359125,0.7082235,0.2888053],"study_design_scores_gemma":[0.0003552059,0.00005555617,0.00015317372,0.0000043332116,0.000004617746,0.0000038833314,2.991741e-7,0.0022526907,0.000024039662,0.001345948,0.9954946,0.0003056405],"about_ca_topic_score_codex":0.000117977266,"about_ca_topic_score_gemma":8.453549e-7,"teacher_disagreement_score":0.28849968,"about_ca_system_score_codex":0.000087023385,"about_ca_system_score_gemma":0.000017020593,"threshold_uncertainty_score":0.9302915},"labels":[],"label_agreement":null},{"id":"W4406577073","doi":"10.1016/s1544-8800(12)70062-3","title":"10.1016/s1544-8800(12)70062-3","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"TOPS; Medicine; Internal medicine; Cardiology; Mathematics; Geometry","score_opus":0.027668782084862974,"score_gpt":0.20923693613771624,"score_spread":0.18156815405285326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406577073","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013806112,0.00025547875,0.0000026104985,0.0022006806,0.000006992756,0.00017416096,0.00023799941,0.000074367505,0.9956671],"genre_scores_gemma":[0.0013735305,0.000006586155,0.000094721414,0.0008842363,0.00030872846,0.000024911333,0.000018603576,0.000040266466,0.9972484],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99862146,0.000010232947,0.0004916205,0.00039668314,0.0000234764,0.00045654672],"domain_scores_gemma":[0.9991742,0.000043162763,0.00008229474,0.00037645767,0.000010854713,0.0003130541],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00026488226,0.00018343933,0.0003632965,0.00015861192,0.00008844186,0.00009400168,0.00034099256,0.00009521004,0.9977523],"category_scores_gemma":[0.00003476235,0.00022855592,0.00013023721,0.00015623326,0.000041090985,0.00015892573,0.000058669626,0.00015421298,0.9986025],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000079246005,0.00011419712,0.0000046958844,0.000010906886,0.000058010246,0.000003760683,0.000037160626,0.00024654926,0.0000053115527,0.0015120425,0.6584756,0.33945256],"study_design_scores_gemma":[0.00036668146,0.000070221686,0.00015985698,0.0000041516623,0.000004664282,0.0000038849876,2.779629e-7,0.0020307603,0.000023260936,0.0014283769,0.9956017,0.00030617148],"about_ca_topic_score_codex":0.00010301969,"about_ca_topic_score_gemma":7.0837297e-7,"teacher_disagreement_score":0.33914638,"about_ca_system_score_codex":0.000089518944,"about_ca_system_score_gemma":0.000017832965,"threshold_uncertainty_score":0.932024},"labels":[],"label_agreement":null},{"id":"W4406577317","doi":"10.1016/s1544-8800(10)70057-9","title":"10.1016/s1544-8800(10)70057-9","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Cardiology; Psychiatry","score_opus":0.027131316626220314,"score_gpt":0.21248002331367394,"score_spread":0.18534870668745362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406577317","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015581964,0.00032206927,0.000002053929,0.0019638357,0.000006452944,0.00017188018,0.00022894175,0.00007557898,0.995671],"genre_scores_gemma":[0.0011533955,0.000006699361,0.000088456254,0.00076327054,0.00030826783,0.000026143867,0.000022503858,0.000042204007,0.99758905],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985616,0.000011035388,0.00051201653,0.00041447088,0.00002480728,0.00047606454],"domain_scores_gemma":[0.9991254,0.000047540158,0.00008872992,0.00039567074,0.000014995238,0.00032764729],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00028072463,0.00019350054,0.00038033974,0.0001670521,0.00009181395,0.00010025492,0.00035950186,0.00010240147,0.9988799],"category_scores_gemma":[0.000043961027,0.00024100937,0.00013874038,0.00020226132,0.000043734944,0.00015856832,0.00006359455,0.00014925619,0.99912345],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008262514,0.0001029176,0.0000019377594,0.000009689274,0.000052558924,0.0000032077528,0.0000313995,0.00021315199,0.000004091814,0.0009703279,0.7726735,0.22585464],"study_design_scores_gemma":[0.00038652323,0.00007645962,0.00010487854,0.0000043814957,0.000005134201,0.0000035870733,3.2625837e-7,0.0024311822,0.000024144458,0.0012173963,0.99542505,0.00032096804],"about_ca_topic_score_codex":0.00007642107,"about_ca_topic_score_gemma":3.594698e-7,"teacher_disagreement_score":0.22553366,"about_ca_system_score_codex":0.000095316325,"about_ca_system_score_gemma":0.000019781972,"threshold_uncertainty_score":0.9828077},"labels":[],"label_agreement":null},{"id":"W4406577396","doi":"10.1016/s1544-8800(10)70220-7","title":"10.1016/s1544-8800(10)70220-7","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Business; Advertising; Marketing","score_opus":0.02722052396972117,"score_gpt":0.2122894372475023,"score_spread":0.18506891327778113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406577396","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015270318,0.0003100904,0.0000018615044,0.0019022777,0.000006576239,0.00017253631,0.00028269435,0.000075249925,0.9957217],"genre_scores_gemma":[0.0011407153,0.000005961234,0.000085157866,0.0007321134,0.00029864933,0.000026365347,0.000023966879,0.00004210093,0.99764496],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99856555,0.000011187025,0.0005115207,0.00041479638,0.000025039633,0.000471884],"domain_scores_gemma":[0.99912834,0.000047757545,0.00008912719,0.00039604574,0.0000150787655,0.00032362866],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00028140753,0.00019268949,0.00037985598,0.000167254,0.00009360542,0.000099019555,0.00036123284,0.00010067879,0.9989383],"category_scores_gemma":[0.00004429825,0.0002403803,0.00013863746,0.00020705954,0.000043505457,0.00016181581,0.000063609004,0.00015070217,0.9990755],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000863058,0.00010671993,0.000002050903,0.000010061726,0.000053696782,0.0000033513725,0.000028236009,0.000224269,0.000004130721,0.001185995,0.7450154,0.2532798],"study_design_scores_gemma":[0.00038833448,0.000078615376,0.00010400659,0.0000042503784,0.0000051219768,0.0000036246945,2.9262432e-7,0.0024501418,0.000024073885,0.0011923095,0.995429,0.0003202596],"about_ca_topic_score_codex":0.00008052542,"about_ca_topic_score_gemma":4.187943e-7,"teacher_disagreement_score":0.25295955,"about_ca_system_score_codex":0.00009585386,"about_ca_system_score_gemma":0.000019552763,"threshold_uncertainty_score":0.98024243},"labels":[],"label_agreement":null},{"id":"W4406578574","doi":"10.1016/s1541-9800(11)70561-0","title":"10.1016/s1541-9800(11)70561-0","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Economic shortage; Drug; Business; Medicine; Pharmacology","score_opus":0.025921668061136226,"score_gpt":0.21129178116410732,"score_spread":0.1853701131029711,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406578574","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002354891,0.00027866696,0.0000023937798,0.0022525778,0.0000069790995,0.00017279478,0.00024741597,0.000074635645,0.99460965],"genre_scores_gemma":[0.0017240572,0.0000059734757,0.000102341466,0.000963065,0.00029870146,0.000025017922,0.000019525043,0.00004006848,0.9968212],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99861664,0.000010506505,0.0004925145,0.00040003806,0.000023661067,0.00045666005],"domain_scores_gemma":[0.99916166,0.00004658056,0.000082416605,0.0003839286,0.0000127790645,0.00031264778],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00028271668,0.0001833363,0.0003624173,0.00015974419,0.00008843977,0.000094245246,0.00035136886,0.00009663173,0.99802476],"category_scores_gemma":[0.000039962008,0.00022864563,0.00013051841,0.00019732623,0.000042509168,0.00015622121,0.00005920991,0.00013541828,0.99848294],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059831833,0.00012519961,0.000008347862,0.000012391474,0.000052569667,0.0000041613257,0.000039136172,0.0002938919,0.000006438063,0.0021930304,0.78752196,0.20968308],"study_design_scores_gemma":[0.00036200113,0.000055971825,0.000094456416,0.0000043454156,0.00000462326,0.0000038997396,2.9356545e-7,0.002198947,0.000033656925,0.0015051481,0.99543023,0.00030641147],"about_ca_topic_score_codex":0.000090603186,"about_ca_topic_score_gemma":6.995661e-7,"teacher_disagreement_score":0.20937666,"about_ca_system_score_codex":0.00008578157,"about_ca_system_score_gemma":0.000016585705,"threshold_uncertainty_score":0.9323898},"labels":[],"label_agreement":null},{"id":"W4406578755","doi":"10.1016/s1544-8800(05)70501-7","title":"10.1016/s1544-8800(05)70501-7","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Restructuring; Drug; Business; Medicine; Pharmacology; Finance","score_opus":0.02627010568766792,"score_gpt":0.2124217790510539,"score_spread":0.18615167336338598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406578755","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016536642,0.0002832756,0.0000024259878,0.0023218335,0.000007966135,0.00017240236,0.0002526411,0.00007468145,0.9952311],"genre_scores_gemma":[0.0014721223,0.000006531122,0.00010090823,0.0010385166,0.00029620834,0.000024269215,0.00001963252,0.00003997596,0.9970018],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986191,0.000010270371,0.0004902778,0.00039731403,0.000023460192,0.00045958944],"domain_scores_gemma":[0.9991667,0.000042918222,0.000082308616,0.00037685048,0.000012827043,0.0003183972],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00026363158,0.00018361317,0.00036298882,0.0001606623,0.000088650435,0.000093946226,0.0003427868,0.00009600798,0.99754125],"category_scores_gemma":[0.000037092123,0.00022843118,0.0001306343,0.00019878997,0.000040837782,0.00015715125,0.000058301193,0.00015562249,0.9985774],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006342687,0.00009996063,0.0000025309864,0.0000093520985,0.000050127517,0.0000041019784,0.000030819774,0.00021423775,0.0000046552373,0.0015437494,0.6691347,0.32884237],"study_design_scores_gemma":[0.00036638704,0.00007433486,0.00012261725,0.000004287044,0.0000046493346,0.000004856564,2.9658702e-7,0.002141137,0.000024180665,0.0015073282,0.9954444,0.0003055167],"about_ca_topic_score_codex":0.00009734075,"about_ca_topic_score_gemma":4.3661282e-7,"teacher_disagreement_score":0.32853687,"about_ca_system_score_codex":0.000087331,"about_ca_system_score_gemma":0.000017039241,"threshold_uncertainty_score":0.9315153},"labels":[],"label_agreement":null},{"id":"W4406578958","doi":"10.1016/s1544-8800(06)70590-5","title":"10.1016/s1544-8800(06)70590-5","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Business; Internal medicine","score_opus":0.026186897944017806,"score_gpt":0.21198253377700163,"score_spread":0.18579563583298384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406578958","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019321216,0.00030836565,0.0000025128702,0.0021561454,0.0000049452456,0.00017266738,0.00025359393,0.00007479937,0.99509484],"genre_scores_gemma":[0.0016738407,0.000007068909,0.00009280204,0.0008851297,0.00029109552,0.00002440727,0.000023843319,0.000039984698,0.99696183],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99861777,0.000010224397,0.00049108354,0.00039783516,0.000023591123,0.0004595249],"domain_scores_gemma":[0.99916476,0.000043346114,0.000081120634,0.00037879133,0.000012911183,0.00031905397],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00026904515,0.00018360095,0.00036420068,0.00015909219,0.00008820033,0.00009422016,0.00034352497,0.00009669773,0.9974351],"category_scores_gemma":[0.000038671285,0.00022894793,0.0001317184,0.00019890878,0.000041897656,0.00016149251,0.000058729343,0.00015698209,0.9990313],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058265334,0.000112124326,0.0000052434907,0.000011039399,0.00005713626,0.000003533228,0.000034971486,0.00025545782,0.000005349589,0.0017038552,0.7692535,0.22849955],"study_design_scores_gemma":[0.00035590483,0.00005883332,0.00015459594,0.0000043047908,0.00000465566,0.000003882008,2.8373398e-7,0.0022061146,0.000022170532,0.00148147,0.99540114,0.00030664372],"about_ca_topic_score_codex":0.00007754184,"about_ca_topic_score_gemma":3.677277e-7,"teacher_disagreement_score":0.22819291,"about_ca_system_score_codex":0.000088686385,"about_ca_system_score_gemma":0.000017837945,"threshold_uncertainty_score":0.9336226},"labels":[],"label_agreement":null},{"id":"W4406579626","doi":"10.1016/s1541-9800(07)70169-2","title":"10.1016/s1541-9800(07)70169-2","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Spiral (railway); Computer science; Risk analysis (engineering); Medicine; Engineering; Mechanical engineering","score_opus":0.02666217223257894,"score_gpt":0.2128706147667031,"score_spread":0.18620844253412416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406579626","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014421721,0.0003275313,0.0000025391992,0.0021105686,0.0000068080667,0.00017352782,0.00025433511,0.00007562135,0.9956069],"genre_scores_gemma":[0.0014317962,0.0000073271904,0.00009387748,0.0010052674,0.00029884733,0.000025103463,0.000018523477,0.00004060688,0.99707866],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986039,0.000010516704,0.00049677124,0.00040299847,0.000023826815,0.0004619958],"domain_scores_gemma":[0.99916,0.000044162953,0.00008317458,0.00038203405,0.000013126057,0.0003175266],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00028094184,0.00018531411,0.00036713268,0.00015467037,0.00008895844,0.00009466428,0.00034769962,0.00009686994,0.99863976],"category_scores_gemma":[0.000039680363,0.00022929293,0.00013272864,0.00018217327,0.000042138727,0.00016233118,0.000059829767,0.00015606206,0.9993304],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007562265,0.00012150804,0.0000034631034,0.0000115206585,0.00006239084,0.0000042620472,0.000038690236,0.00021847713,0.0000054529933,0.0018118942,0.7267006,0.27094615],"study_design_scores_gemma":[0.00037288404,0.0000673764,0.00008651088,0.00000448734,0.000004673767,0.0000040979207,2.8972408e-7,0.001921081,0.000025454086,0.0017477109,0.99545604,0.00030941344],"about_ca_topic_score_codex":0.00006482191,"about_ca_topic_score_gemma":2.8997985e-7,"teacher_disagreement_score":0.27063674,"about_ca_system_score_codex":0.00008949588,"about_ca_system_score_gemma":0.000017839564,"threshold_uncertainty_score":0.9350294},"labels":[],"label_agreement":null},{"id":"W4406579791","doi":"10.1016/s1541-9800(07)70660-9","title":"10.1016/s1541-9800(07)70660-9","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Class (philosophy); Drug; Drug class; Over-the-counter; Computer science; Artificial intelligence; Medicine; Pharmacology; Medical prescription","score_opus":0.026666071456422687,"score_gpt":0.21279161187513104,"score_spread":0.18612554041870835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406579791","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015437618,0.00031511972,0.0000023681694,0.0020927575,0.0000069199646,0.00017301906,0.00025195788,0.00007514896,0.99553895],"genre_scores_gemma":[0.0015417968,0.000007157923,0.0000944085,0.0010093913,0.00029758114,0.000025371073,0.000018899214,0.00004045184,0.99696493],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986104,0.000010406811,0.00049464,0.0004011528,0.000023708717,0.0004597363],"domain_scores_gemma":[0.99916154,0.00004342177,0.000082598606,0.00038136038,0.000013040581,0.00031804584],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002797503,0.00018436625,0.00036618303,0.00015571163,0.00008867493,0.00009523089,0.00034683652,0.0000965883,0.9985544],"category_scores_gemma":[0.000039515027,0.00022968202,0.00013192689,0.00018438934,0.000041662155,0.000161245,0.000059666127,0.00015718555,0.9992536],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007633728,0.0001241236,0.0000040037253,0.000011817772,0.000063263265,0.0000043992845,0.000040013732,0.00024370305,0.000005247727,0.0018407701,0.7202833,0.277303],"study_design_scores_gemma":[0.00036882548,0.00006723913,0.000092970644,0.000004358851,0.0000046764485,0.000004178454,2.9015825e-7,0.0020173278,0.000024249803,0.0017383643,0.9953696,0.00030793162],"about_ca_topic_score_codex":0.00006687289,"about_ca_topic_score_gemma":3.0965566e-7,"teacher_disagreement_score":0.2769951,"about_ca_system_score_codex":0.00008892011,"about_ca_system_score_gemma":0.000017653072,"threshold_uncertainty_score":0.93661606},"labels":[],"label_agreement":null},{"id":"W4406579854","doi":"10.1016/s1541-9800(05)70839-5","title":"10.1016/s1541-9800(05)70839-5","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Drug; Medical prescription; Prescription drug; Medicine; Family medicine; Internet privacy; Business; Pharmacology; Computer science","score_opus":0.026363787988863224,"score_gpt":0.21255457446099763,"score_spread":0.1861907864721344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406579854","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013882769,0.00029120073,0.0000023980529,0.002337353,0.000008077327,0.0001723102,0.00032102285,0.00007508275,0.9954043],"genre_scores_gemma":[0.0014318542,0.0000067371902,0.00009359658,0.0011564337,0.00030232812,0.000025169034,0.000022698408,0.000040374813,0.9969208],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99861497,0.000010353751,0.0004923759,0.00039780722,0.000023635852,0.00046086335],"domain_scores_gemma":[0.9991619,0.000043000382,0.00008258264,0.00038045648,0.000012867724,0.00031921713],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002768942,0.00018412883,0.0003650634,0.00016234117,0.00008838932,0.0000941296,0.0003454805,0.00009626124,0.9978205],"category_scores_gemma":[0.00003891183,0.00022888403,0.00013174552,0.0002004623,0.00004157321,0.00015978857,0.00005895842,0.00015594826,0.99862593],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058552665,0.00009524842,0.000002281592,0.000009011115,0.000048198668,0.000003890481,0.000031868145,0.0001857739,0.0000046535883,0.0015180712,0.75230753,0.24573493],"study_design_scores_gemma":[0.0003748585,0.00007470172,0.00007405431,0.000004334348,0.000004666231,0.0000050511558,3.0275362e-7,0.0020681391,0.000026977856,0.0017137413,0.9953471,0.00030607544],"about_ca_topic_score_codex":0.00008123075,"about_ca_topic_score_gemma":4.226232e-7,"teacher_disagreement_score":0.24542885,"about_ca_system_score_codex":0.000090607246,"about_ca_system_score_gemma":0.000017448583,"threshold_uncertainty_score":0.933362},"labels":[],"label_agreement":null},{"id":"W4406580593","doi":"10.1016/s1541-9800(06)71251-0","title":"10.1016/s1541-9800(06)71251-0","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Pharmacology","score_opus":0.026268584284418826,"score_gpt":0.2119329118657042,"score_spread":0.18566432758128537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406580593","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017604771,0.00032307935,0.0000025347879,0.0020582534,0.0000047510475,0.00017356605,0.00025969985,0.00007520253,0.99534243],"genre_scores_gemma":[0.0016794581,0.000007284179,0.00008777919,0.0010140042,0.00029086764,0.000025306672,0.000025162746,0.00004044758,0.9968297],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986057,0.0000104338915,0.0004942467,0.00040065456,0.000023729854,0.0004652052],"domain_scores_gemma":[0.9991585,0.000043601067,0.000081182334,0.00038081064,0.000013031612,0.00032286],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00028291045,0.00018431211,0.00036576367,0.0001627227,0.00008973177,0.00009636179,0.00034569108,0.000096934025,0.99774563],"category_scores_gemma":[0.000040228577,0.00022961311,0.00013193,0.00020115962,0.000042128126,0.00016023438,0.000059672722,0.00015862349,0.99903184],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054936187,0.00011222292,0.0000047423227,0.000010874476,0.000057557256,0.0000035138992,0.00003684414,0.00025612922,0.0000051610027,0.0018284785,0.8170457,0.18058386],"study_design_scores_gemma":[0.00036829637,0.000059074253,0.00009627254,0.000004356703,0.000004672187,0.000003904899,2.9428156e-7,0.0022629814,0.000023180768,0.0017201859,0.995149,0.0003077914],"about_ca_topic_score_codex":0.000056918823,"about_ca_topic_score_gemma":2.915317e-7,"teacher_disagreement_score":0.18027608,"about_ca_system_score_codex":0.000089277615,"about_ca_system_score_gemma":0.000018055269,"threshold_uncertainty_score":0.9363351},"labels":[],"label_agreement":null},{"id":"W4406653031","doi":"10.1016/b978-0-7020-7005-1.00056-3","title":"10.1016/b978-0-7020-7005-1.00056-3","year":2000,"lang":"en","type":"book-chapter","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Pharmaceutics; Medicine; Pharmacology","score_opus":0.0326948860166008,"score_gpt":0.20874598089232527,"score_spread":0.17605109487572446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406653031","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000001893286,0.0016011056,0.0000014563336,0.0011665513,0.000020648979,0.00040479106,0.0019652932,0.00011314469,0.9947251],"genre_scores_gemma":[0.000007086896,0.000028074313,0.000053529817,0.0010627237,0.0008899499,0.000028484457,0.0001660838,0.00019516588,0.9975689],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99735266,0.000006765838,0.001069295,0.0008820522,0.00005174346,0.00063750433],"domain_scores_gemma":[0.9981955,0.00007575551,0.0003771212,0.00078627083,0.000029460793,0.00053588033],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00030355147,0.00058337406,0.0010865922,0.00052729435,0.00010959561,0.00015074998,0.0006773835,0.0005195126,0.9983819],"category_scores_gemma":[0.000032183212,0.0007665077,0.00042341877,0.00006491156,0.00009868157,0.00014020849,0.0001885607,0.0005710194,0.99906766],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010072633,0.000055345256,1.12053144e-7,0.000039479924,0.00027321884,0.00001689165,0.00001903716,0.00006793667,6.3100936e-7,0.06190477,0.60258687,0.33493498],"study_design_scores_gemma":[0.00034864727,0.00009983677,0.0000017395523,0.000036106874,0.000026905118,0.00000837375,7.458957e-8,0.00029454895,0.000003156881,0.024805082,0.97349745,0.0008780809],"about_ca_topic_score_codex":0.000034734938,"about_ca_topic_score_gemma":5.7502035e-7,"teacher_disagreement_score":0.37091058,"about_ca_system_score_codex":0.00025817665,"about_ca_system_score_gemma":0.00005830024,"threshold_uncertainty_score":0.9994786},"labels":[],"label_agreement":null},{"id":"W4406660250","doi":"10.1525/gp.2025.127997","title":"The Inequitable Access to Vaccines and Medicines in Africa: A Critical Review of the African Pharmaceutical Technology Foundation (APTF)","year":2025,"lang":"en","type":"review","venue":"Global Perspectives","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Foundation (evidence); Access to medicines; Medicine; Political science; Engineering ethics; Engineering; Law; Intellectual property","score_opus":0.12031864409570749,"score_gpt":0.42761216014910686,"score_spread":0.3072935160533994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406660250","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000076231295,0.93227154,0.000026087673,0.039859246,0.000432237,0.000957329,0.00024274566,0.000016349406,0.026186861],"genre_scores_gemma":[0.0011454597,0.9975663,0.00003397161,0.0008287339,0.00011791764,0.00020908257,0.0000026310265,0.000013318289,0.00008261828],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.997724,0.00008927835,0.0010869751,0.0005771799,0.00005260427,0.00046998472],"domain_scores_gemma":[0.9982977,0.0006983887,0.00032542806,0.0004758582,0.000090327376,0.000112324546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008586715,0.00031129873,0.001545547,0.0002744638,0.00014786489,0.00010295728,0.0010244694,0.00017921659,0.00009206389],"category_scores_gemma":[0.0048079942,0.00020928301,0.00023908642,0.001928399,0.00037116348,0.00013905823,0.00080708426,0.00038729524,0.000031736996],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001172994,0.00008187533,0.00026556183,0.017692922,0.00012018187,0.0000013833901,0.000092588656,4.0709855e-7,3.9874564e-8,0.78867435,0.0052899616,0.18776903],"study_design_scores_gemma":[0.00015781622,0.000025006473,0.00014576461,0.01039735,0.00012513658,0.0000096833965,0.00012342705,0.000020249612,2.3545468e-7,0.036795788,0.9519999,0.00019966348],"about_ca_topic_score_codex":0.00006485412,"about_ca_topic_score_gemma":0.000054096825,"teacher_disagreement_score":0.94670993,"about_ca_system_score_codex":0.0004302091,"about_ca_system_score_gemma":0.00021058651,"threshold_uncertainty_score":0.85343134},"labels":[],"label_agreement":null},{"id":"W4406731639","doi":"10.1101/2025.01.21.25320791","title":"Modelling the impact of changes to prescription medicine cost-sharing schemes among middle aged and older adults","year":2025,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medical prescription; Gerontology; Medicine; Nursing","score_opus":0.1245899008535493,"score_gpt":0.3228488154196551,"score_spread":0.19825891456610578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406731639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863893,0.004367199,0.0021471847,0.0018166334,0.00039215657,0.00085429644,0.00036107216,0.000022788956,0.0036494127],"genre_scores_gemma":[0.9962145,0.0023612238,0.00011944775,0.00039081118,0.00024326112,0.00012973858,0.000025942165,0.000022362832,0.0004926769],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99843985,0.00001928412,0.0006273346,0.0005756005,0.000033338525,0.00030458998],"domain_scores_gemma":[0.99877626,0.000091565,0.00040172777,0.0005367874,0.000037550948,0.00015610624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007896313,0.00026399552,0.0006565936,0.00034172682,0.00007949569,0.000058160134,0.00045941243,0.00018618924,0.00015934448],"category_scores_gemma":[0.000119649,0.00021989841,0.00014023895,0.00014541566,0.00011151729,0.00006809405,0.00059901335,0.00043949432,0.000011088931],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037473987,0.0002666489,0.7010848,0.0027322632,0.0013463742,0.000004720117,0.023849454,0.21935882,0.0001450049,0.04083208,0.003629021,0.0063760784],"study_design_scores_gemma":[0.0010782271,0.00008174508,0.08569907,0.0012968263,0.000047821744,9.556353e-7,0.00010744989,0.88981307,0.00026477146,0.017190842,0.0039253514,0.0004938645],"about_ca_topic_score_codex":0.0052896584,"about_ca_topic_score_gemma":0.00012362619,"teacher_disagreement_score":0.67045426,"about_ca_system_score_codex":0.00009990496,"about_ca_system_score_gemma":0.000023556628,"threshold_uncertainty_score":0.89671975},"labels":[],"label_agreement":null},{"id":"W4406774139","doi":"10.1007/978-981-99-4566-5_4","title":"Application of Technology in Sub-Saharan Africa: The Rwandan Healthcare System Experience","year":2024,"lang":"en","type":"book-chapter","venue":"Translational systems sciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Collège Boréal","funders":"","keywords":"Healthcare system; Health care; Geography; Computer science; Economic growth; Economics","score_opus":0.08452655635681565,"score_gpt":0.2960653719225102,"score_spread":0.21153881556569454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406774139","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002300992,0.18314523,0.0010256188,0.014367147,0.0013211548,0.0016687097,0.0017924109,0.00010172033,0.794277],"genre_scores_gemma":[0.99527824,0.00070629147,0.000024565537,0.000035672365,0.00013204532,0.00012471591,0.000012295393,0.000019416062,0.0036667786],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99807566,0.000008547596,0.0010560813,0.0005186908,0.00009854515,0.00024247501],"domain_scores_gemma":[0.99915606,0.00009290368,0.0004220084,0.00024220695,0.000033974167,0.00005287212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008622207,0.00019075787,0.0004918968,0.00058677804,0.00013371273,0.0000655426,0.0005433763,0.0002392692,0.000021141741],"category_scores_gemma":[0.0000063705215,0.00016500009,0.000113589376,0.00029911104,0.00052259344,0.00010517917,0.000030166913,0.00026921043,0.0002899705],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000031366815,0.000005177001,0.00045140652,0.00023333692,0.000014760102,7.6201036e-7,0.00030123183,0.00036853104,0.000012453011,0.9981834,0.000073909185,0.00035184462],"study_design_scores_gemma":[0.00018999989,0.00005077413,0.00029301044,0.00043709285,0.000010191485,0.000018137802,0.00014351057,0.034420215,0.000022676555,0.415667,0.5483925,0.0003549154],"about_ca_topic_score_codex":0.00033465467,"about_ca_topic_score_gemma":0.00007994933,"teacher_disagreement_score":0.9929772,"about_ca_system_score_codex":0.00012451892,"about_ca_system_score_gemma":0.000088777895,"threshold_uncertainty_score":0.67285085},"labels":[],"label_agreement":null},{"id":"W4406811012","doi":"","title":"Methods for the comparative evaluation of pharmaceuticals","year":2005,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.797716233771923,"score_gpt":0.710190704503193,"score_spread":0.08752552926873003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406811012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47137475,0.33345693,0.05708381,0.009473226,0.0024649322,0.0053361272,0.0012738215,0.00004235516,0.119494066],"genre_scores_gemma":[0.98346967,0.010327661,0.003970279,0.001559306,0.00032789377,0.0001651611,0.000007787943,0.00003060782,0.00014160876],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975276,0.00022929952,0.0014432274,0.0003506161,0.000115365634,0.00033387422],"domain_scores_gemma":[0.9962438,0.001514254,0.0013578179,0.00039243058,0.00031009203,0.0001816098],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009380652,0.00021448144,0.0009160207,0.00043928338,0.00018601053,0.000401396,0.0018240487,0.00008434197,0.0136965625],"category_scores_gemma":[0.00060898595,0.00018916378,0.00029624533,0.00045363294,0.00017921785,0.0011521055,0.0003598105,0.00026137242,0.00005428853],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008054889,0.0013348537,0.07219423,0.00022237083,0.0027333957,5.698588e-7,0.0019464499,0.019367449,0.024622515,0.15826559,0.11889731,0.5996098],"study_design_scores_gemma":[0.0019159877,0.000013218944,0.059886828,0.00004620596,0.00022081951,0.0000025169963,0.000050789262,0.17155899,0.047615033,0.17652906,0.5417472,0.00041334447],"about_ca_topic_score_codex":0.00014957532,"about_ca_topic_score_gemma":0.000013593922,"teacher_disagreement_score":0.59919643,"about_ca_system_score_codex":0.0001733766,"about_ca_system_score_gemma":0.000108034954,"threshold_uncertainty_score":0.987205},"labels":[],"label_agreement":null},{"id":"W4406829526","doi":"10.1186/s12872-024-04411-y","title":"Cardiovascular disease essential medicines listing by countries: changes over time and association with health outcomes","year":2025,"lang":"en","type":"article","venue":"BMC Cardiovascular Disorders","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Disease; Angiology; Heart disease; Essential medicines; Mortality rate; Intensive care medicine; Environmental health; Emergency medicine; Internal medicine; Public health; Pathology","score_opus":0.012704913442558106,"score_gpt":0.2463618022628229,"score_spread":0.23365688882026478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406829526","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.33874992,0.58130366,0.024297204,0.034595154,0.0016222267,0.0028289482,0.0024259123,0.00036223824,0.01381477],"genre_scores_gemma":[0.9630536,0.025434019,0.00023184004,0.00823119,0.0003651311,0.00020219732,0.0002353163,0.000110823275,0.0021359099],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982491,0.0000731052,0.00042581945,0.00062738144,0.00014841584,0.00047617735],"domain_scores_gemma":[0.99886954,0.00013477112,0.00019515403,0.00055487646,0.00003268061,0.00021295508],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015255092,0.00027030395,0.0010517809,0.00019873462,0.0002265587,0.00012561768,0.00016314842,0.00010179815,0.00006859149],"category_scores_gemma":[0.00022950133,0.0002782647,0.00065795437,0.00023856707,0.00009967107,0.00014885094,0.00008450716,0.0001534711,0.00004703923],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000100891186,0.0001329447,0.935529,0.0007997123,0.01701741,0.0000038368476,0.00043789766,0.0034556333,0.000001176176,0.012354931,0.022634882,0.0075317197],"study_design_scores_gemma":[0.003674266,0.000038780472,0.09876914,0.00006761241,0.00056997023,0.0000011091072,0.00006220661,0.0052686445,0.0000053468298,0.0018805474,0.8890748,0.00058757304],"about_ca_topic_score_codex":0.0014182298,"about_ca_topic_score_gemma":0.00019313434,"teacher_disagreement_score":0.86643994,"about_ca_system_score_codex":0.00026429357,"about_ca_system_score_gemma":0.000105626474,"threshold_uncertainty_score":0.999967},"labels":[],"label_agreement":null},{"id":"W4406843692","doi":"10.1016/j.ekir.2024.11.1225","title":"WCN25-19 THE IMPACT OF PUBLIC-PRIVATE PARTNERSHIP (PPP) IN NEPHROLOGY OF LOW-INCOME COUNTRIES (LIC), CASE OF RWANDA","year":2025,"lang":"en","type":"article","venue":"Kidney International Reports","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Inland Hospital","funders":"","keywords":"Medicine; General partnership; Public–private partnership; Nephrology; Internal medicine; Family medicine; Economic growth; Finance; Economics","score_opus":0.042343939961860866,"score_gpt":0.3448422649274905,"score_spread":0.3024983249656296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406843692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9515995,0.00029769205,0.000107856926,0.0075448817,0.00040064374,0.00016036043,0.00041091154,0.000005778199,0.039472394],"genre_scores_gemma":[0.9982523,0.0001705477,0.000032729607,0.0011471129,0.000045925026,0.00001475918,0.000021981143,0.000008314293,0.00030637745],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99811655,0.000027831038,0.0013727482,0.00023254569,0.00004205053,0.00020828896],"domain_scores_gemma":[0.99819124,0.00022218129,0.0010109086,0.0003490658,0.00010966002,0.00011695309],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001221754,0.000121061144,0.00044001747,0.0004491415,0.000026755522,0.000025245386,0.00026679004,0.00009454549,0.00074426923],"category_scores_gemma":[0.0016471932,0.0001080884,0.00020599384,0.00023447219,0.0002256103,0.00014702909,0.000129014,0.00014394241,0.000007763867],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000546731,0.00010648807,0.57208765,0.00006680802,0.00028936783,0.000122577,0.00019823833,0.00035688357,0.000053107713,0.42284998,0.003686634,0.00012755682],"study_design_scores_gemma":[0.002484012,0.00017224925,0.3774439,0.00017996816,0.000031226802,0.00079190714,0.00007636036,0.014971213,0.00292668,0.35236382,0.24811243,0.00044622796],"about_ca_topic_score_codex":0.0019522876,"about_ca_topic_score_gemma":0.00011943224,"teacher_disagreement_score":0.24442579,"about_ca_system_score_codex":0.00018085589,"about_ca_system_score_gemma":0.00032847334,"threshold_uncertainty_score":0.81492263},"labels":[],"label_agreement":null},{"id":"W4406955750","doi":"10.1093/ofid/ofae631.153","title":"501. Impact of Implementation of World Health Organization (WHO) National Action Plans (NAP) on Antibiotic Rates: A Time Series Analysis of 38 Countries","year":2025,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Nap; Action (physics); Series (stratigraphy); Gerontology","score_opus":0.030685544137812968,"score_gpt":0.3797908788430524,"score_spread":0.3491053347052394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406955750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.973321,0.00019209328,0.00017967721,0.0014642905,0.00012376651,0.00058080023,0.009743776,0.000019461893,0.014375109],"genre_scores_gemma":[0.9985695,0.0002787462,0.000009948426,0.00044345693,0.000011130592,0.0000062602708,0.0004559312,0.0000108754575,0.0002141476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988569,0.000027973414,0.0007080494,0.00020300582,0.00004277652,0.0001612903],"domain_scores_gemma":[0.9987841,0.00010151789,0.0007686245,0.00014980984,0.00013808248,0.000057817928],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022271139,0.00011960075,0.00057535217,0.00094798306,0.00010146985,0.000064197404,0.000150109,0.000033566368,0.0013425354],"category_scores_gemma":[0.00008866224,0.0001318434,0.00016276611,0.0013517197,0.00006318261,0.0003735778,0.000065037566,0.000042594973,0.00002082003],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000073152914,0.00020404131,0.86792696,0.00007918257,0.0012228049,5.2829225e-8,0.000084251034,0.0034713394,0.000022928112,0.12379783,0.0028318828,0.00028558285],"study_design_scores_gemma":[0.00090352644,0.00030930928,0.9848061,0.000041023435,0.00016119811,2.7818206e-7,0.00008102345,0.0017807453,0.0019911833,0.008935847,0.00084378495,0.00014598764],"about_ca_topic_score_codex":0.002260063,"about_ca_topic_score_gemma":0.0012913576,"teacher_disagreement_score":0.116879135,"about_ca_system_score_codex":0.00032449426,"about_ca_system_score_gemma":0.00031556553,"threshold_uncertainty_score":0.99957037},"labels":[],"label_agreement":null},{"id":"W4407022977","doi":"10.1080/19460171.2025.2457529","title":"A critique of the moral economy of pharmaceutical development","year":2025,"lang":"en","type":"article","venue":"Critical Policy Studies","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research","keywords":"Moral economy; Economics; Economic system; Neoclassical economics; Political science; Positive economics; Sociology; Law; Politics","score_opus":0.1546600620893087,"score_gpt":0.42580587153243804,"score_spread":0.2711458094431294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407022977","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11433529,0.020720428,0.000818224,0.20873177,0.0012438472,0.0006384635,0.00034608823,0.00005028009,0.65311563],"genre_scores_gemma":[0.98856413,0.00024208328,0.00033590582,0.010326524,0.00010639733,0.0000383106,6.6491106e-7,0.000010774587,0.00037518417],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99833506,0.000029360845,0.000976487,0.00026748408,0.000024518939,0.0003671076],"domain_scores_gemma":[0.9989592,0.0004422677,0.000118954384,0.0002866898,0.00010383399,0.000089063455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003947421,0.00016332458,0.00062226126,0.00022629055,0.00012143093,0.000015742919,0.00035753672,0.000077353594,0.00005679759],"category_scores_gemma":[0.0017513013,0.00014649484,0.00018944696,0.0003178631,0.00094974693,0.00008752113,0.00035512782,0.00018806575,0.00003529591],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013523403,0.00010924733,0.0051076254,0.00036730518,0.00018423189,3.4424446e-7,0.000324542,0.000004405571,0.000031872645,0.989927,0.0032828916,0.00064704346],"study_design_scores_gemma":[0.00051530683,0.00002061592,0.006794619,0.00008182774,0.000023891302,0.0000012718151,0.0001362238,0.00027835133,0.010864166,0.8185988,0.16250466,0.0001802762],"about_ca_topic_score_codex":0.000046632864,"about_ca_topic_score_gemma":0.000007193089,"teacher_disagreement_score":0.8742289,"about_ca_system_score_codex":0.00014244174,"about_ca_system_score_gemma":0.00016901382,"threshold_uncertainty_score":0.5973886},"labels":[],"label_agreement":null},{"id":"W4407039729","doi":"10.1177/02698811241301219","title":"Challenges for switching central nervous system and psychiatric medication products: A review of the literature","year":2025,"lang":"en","type":"review","venue":"Journal of Psychopharmacology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre for Addiction and Mental Health; McGill University; Lakehead University; Royal Ottawa Mental Health Centre; Adler; University of Ottawa; BC Mental Health & Substance Use Services; START Clinic; University of Toronto; NOSM University; University of British Columbia","funders":"Otsuka Pharmaceutical Development and Commercialization; Otsuka Pharmaceutical","keywords":"Central nervous system; Psychiatry; Medicine; Neuroscience; Psychology","score_opus":0.06234756944655868,"score_gpt":0.3709337971838254,"score_spread":0.30858622773726674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407039729","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000009661053,0.9834977,0.000044891294,0.008164614,0.0057410877,0.0010689016,0.0002067658,0.000004731197,0.0012616714],"genre_scores_gemma":[0.00011756832,0.9968652,0.0001999957,0.0013365047,0.0013390889,0.00005733077,0.0000053836934,0.000024715351,0.000054174056],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970229,0.00013578779,0.002198638,0.00032862092,0.000040934632,0.00027311873],"domain_scores_gemma":[0.99538237,0.00027821213,0.003813405,0.00027976092,0.00012823395,0.0001179908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015779097,0.00027075302,0.002116509,0.00043515945,0.00006585482,0.000022265558,0.000616773,0.00025900404,0.000019073106],"category_scores_gemma":[0.0002776275,0.00019727659,0.0006751555,0.0003971497,0.0000425939,0.00009363139,0.00006412878,0.0006485271,0.0000031579082],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003748899,0.000099286575,0.0000068569802,0.5022716,0.00061758846,0.000002031992,0.00013644794,7.0621587e-7,5.5292475e-7,0.018530022,0.022844292,0.45545313],"study_design_scores_gemma":[0.0006525487,0.00006599127,0.000036039895,0.046664834,0.0006829424,0.00016915717,0.000006395009,0.000013501154,3.577436e-7,0.0013263259,0.950234,0.00014790715],"about_ca_topic_score_codex":0.0000013737614,"about_ca_topic_score_gemma":4.7453327e-7,"teacher_disagreement_score":0.9273897,"about_ca_system_score_codex":0.00015075602,"about_ca_system_score_gemma":0.0002897288,"threshold_uncertainty_score":0.8044706},"labels":[],"label_agreement":null},{"id":"W4407052318","doi":"10.1186/s12992-024-01092-2","title":"States, global power and access to medicines: a comparative case study of China, India and the United States, 2000–2019","year":2025,"lang":"en","type":"article","venue":"Globalization and Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"Norwegian Institute of Public Health; Norges Forskningsråd","keywords":"Social policy; China; Health services research; Public health; Power (physics); Political science; Quality of Life Research; Economic growth; Health policy; Development economics; Socioeconomics; Medicine; Environmental health; Economics; Law; Nursing","score_opus":0.0695027404215106,"score_gpt":0.40318520942417524,"score_spread":0.33368246900266463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407052318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9761311,0.0040858006,0.0010815223,0.014663501,0.00012182905,0.0008877365,0.0005917116,0.00001140243,0.0024254196],"genre_scores_gemma":[0.9770788,0.0032243107,0.00001964224,0.01958006,0.000009986034,0.0000105899735,0.00004454127,0.000003446795,0.000028621373],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99900556,0.000054324282,0.00050656736,0.00023639116,0.000023367476,0.00017376615],"domain_scores_gemma":[0.9994273,0.000043654196,0.00020662877,0.00012501626,0.000034789584,0.00016257721],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056184724,0.00011260997,0.0004207676,0.00014622333,0.00015846574,0.000094216804,0.00008626798,0.000032995937,0.000024645968],"category_scores_gemma":[0.000021423099,0.000094594565,0.000012458893,0.0005261373,0.000105965024,0.00008906274,0.0001147756,0.0000621121,0.0000022365552],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000276369,0.00041899405,0.39399612,0.00019016214,0.00020338902,0.000009605501,0.03327693,0.0009836167,2.8713654e-8,0.5215201,0.04752032,0.0016044031],"study_design_scores_gemma":[0.013466236,0.000860846,0.7407823,0.000085688014,0.00004315334,0.00008467567,0.014167734,0.045041,5.96656e-7,0.049781553,0.13528565,0.0004005782],"about_ca_topic_score_codex":0.025023965,"about_ca_topic_score_gemma":0.0022188106,"teacher_disagreement_score":0.47173852,"about_ca_system_score_codex":0.00009138112,"about_ca_system_score_gemma":0.000065326276,"threshold_uncertainty_score":0.9814685},"labels":[],"label_agreement":null},{"id":"W4407153016","doi":"10.1080/14479338.2024.2446894","title":"Rethinking medical innovation: organizing R&amp;D, responding to crisis, delivering health services","year":2025,"lang":"en","type":"article","venue":"Innovation","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Business; Health services; Knowledge management; Medicine; Environmental health; Computer science","score_opus":0.08358214901746831,"score_gpt":0.35736626304380625,"score_spread":0.27378411402633795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407153016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8715044,0.00051685836,0.035142604,0.07382403,0.0010708197,0.0002718339,0.00003916015,0.0001286802,0.017501611],"genre_scores_gemma":[0.9112144,0.000075356016,0.002733164,0.08523375,0.00022952634,0.000015293648,0.00006235792,0.000020621175,0.00041552781],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979865,0.000017813669,0.0012284279,0.00038358368,0.000063100466,0.0003205895],"domain_scores_gemma":[0.9990919,0.00005862667,0.00036115563,0.00026106197,0.00016162366,0.00006563216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021895075,0.00013586192,0.00029946995,0.0027994642,0.00023549046,0.00015103372,0.00030215277,0.00013370742,0.00033849652],"category_scores_gemma":[0.00034878298,0.00017832078,0.000024763258,0.0075427503,0.000015455593,0.0002944989,0.00017434653,0.00028068948,0.00033952616],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015264342,0.000020092006,0.0044885143,0.00009848185,0.000027382004,6.326302e-7,0.0013134923,0.000044289147,0.00022724405,0.9842464,0.0044739074,0.0050443104],"study_design_scores_gemma":[0.00062251044,0.00003338556,0.0056460234,0.00028395225,0.0000027983738,0.0000036479598,0.00013356903,0.0026758343,0.0007385992,0.34224978,0.64726496,0.00034494433],"about_ca_topic_score_codex":0.0003206971,"about_ca_topic_score_gemma":0.000066351044,"teacher_disagreement_score":0.64279103,"about_ca_system_score_codex":0.00035203545,"about_ca_system_score_gemma":0.0001392283,"threshold_uncertainty_score":0.727171},"labels":[],"label_agreement":null},{"id":"W4407302242","doi":"10.1016/j.pmedr.2025.103004","title":"Sociodemographic variation in experiences with medication shortages among US adults","year":2025,"lang":"en","type":"article","venue":"Preventive Medicine Reports","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"York University; New York University","keywords":"Medicine; Ethnic group; Medical prescription; Educational attainment; Marital status; Cross-sectional study; Demography; Anxiety; Household income; Socioeconomic status; Environmental health; Psychiatry; Population; Geography; Nursing","score_opus":0.01767686836340181,"score_gpt":0.28409588356086996,"score_spread":0.26641901519746813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407302242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9698206,0.0025903482,0.0023607449,0.0019829192,0.00044768857,0.00036176803,0.0000034592697,0.000024973242,0.022407498],"genre_scores_gemma":[0.9984197,0.0004712287,0.000052373205,0.00042497466,0.00008731065,0.00020328783,0.000016171241,0.000008820096,0.0003161589],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99843633,0.000026114789,0.00082562864,0.00044545467,0.000048530666,0.00021792449],"domain_scores_gemma":[0.9990987,0.00006680153,0.00048603624,0.000240107,0.000031304808,0.00007704346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096691854,0.00013513179,0.00037548097,0.00042689362,0.000059727307,0.000015617787,0.00010503881,0.00007759677,0.00030433742],"category_scores_gemma":[0.00022165221,0.000123254,0.000049280712,0.00042080085,0.00022330924,0.00019437895,0.000032192416,0.00015728518,0.000005724397],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021668538,0.000081065846,0.9797514,0.0000472247,0.00006648182,0.000026550382,0.0066711768,0.000017687378,0.0000055893697,0.011464618,0.0004058349,0.0014406778],"study_design_scores_gemma":[0.0006245344,0.00006156117,0.9672934,0.00023163404,0.000016521335,0.000006930671,0.00097152503,0.0019180116,0.000047917038,0.025181785,0.0034876238,0.00015855407],"about_ca_topic_score_codex":0.0009075557,"about_ca_topic_score_gemma":0.0002338093,"teacher_disagreement_score":0.028599074,"about_ca_system_score_codex":0.000086356944,"about_ca_system_score_gemma":0.000042566207,"threshold_uncertainty_score":0.5026152},"labels":[],"label_agreement":null},{"id":"W4407394598","doi":"10.1371/journal.pmed.1004540","title":"Predicting patent challenges for small-molecule drugs: A cross-sectional study","year":2025,"lang":"en","type":"article","venue":"PLoS Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Calgary","funders":"Canada Research Chairs; Arnold Ventures; Commonwealth Fund","keywords":"Scrutiny; Incentive; Business; Prescription drug; Competitor analysis; Biopharmaceutical; Competition (biology); Marketing; Medicine; Medical prescription; Public economics; Actuarial science; Economics; Pharmacology","score_opus":0.22884645656263,"score_gpt":0.3485031722485653,"score_spread":0.1196567156859353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407394598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92564505,0.0043699015,0.000275408,0.0063262214,0.0008402902,0.0010618528,0.00010512264,0.00006886449,0.061307278],"genre_scores_gemma":[0.9958088,0.00043600626,0.000043300428,0.0017571835,0.0005608377,0.00036419087,0.000015430107,0.000020618138,0.0009936547],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984507,0.000012857081,0.0007385011,0.00045550332,0.000033171145,0.00030924476],"domain_scores_gemma":[0.9991921,0.00021408305,0.00018518628,0.0002466671,0.000051793704,0.00011017989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074757676,0.00015509185,0.00040590402,0.0002461952,0.00014187556,0.00003609158,0.00022783369,0.00007846502,0.00020195507],"category_scores_gemma":[0.0003494494,0.00015832394,0.000084723935,0.00012469824,0.000077837154,0.00006182813,0.00007673207,0.0001626828,0.00006822934],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000132469,0.0009051798,0.85029536,0.00028357984,0.0005394257,0.0000026202279,0.0021767516,0.000031048992,0.00005325333,0.14361306,0.0007613657,0.001205891],"study_design_scores_gemma":[0.013648012,0.0013765894,0.8106478,0.00017562794,0.00009671266,0.00000327669,0.001254703,0.03437351,0.00034924765,0.078462385,0.058921028,0.0006911232],"about_ca_topic_score_codex":0.00009349173,"about_ca_topic_score_gemma":0.000024439367,"teacher_disagreement_score":0.07016372,"about_ca_system_score_codex":0.00010732053,"about_ca_system_score_gemma":0.00002574884,"threshold_uncertainty_score":0.64562625},"labels":[],"label_agreement":null},{"id":"W4407406073","doi":"10.1080/23995270.2025.2466383","title":"Letter in reply: orphan drugs approved in Canada: availability and additional therapeutic value","year":2025,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Wilfrid Laurier University; Arthur B. McDonald-Canadian Astroparticle Physics Research Institute; Fraser Institute","funders":"","keywords":"Orphan drug; Value (mathematics); Medicine; Mathematics; Biology; Bioinformatics; Statistics","score_opus":0.013255557436094852,"score_gpt":0.22773559034760632,"score_spread":0.21448003291151146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407406073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8287176,0.02443658,0.000037526577,0.09103368,0.0018001238,0.0009991503,0.023751732,0.0000515418,0.029172055],"genre_scores_gemma":[0.95387137,0.00019977205,0.00002653052,0.0451395,0.00026276792,0.00008373153,0.00021466652,0.000010955645,0.00019073495],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988711,0.000028031454,0.00042003894,0.00039722383,0.000023268372,0.00026034666],"domain_scores_gemma":[0.999431,0.0001523036,0.000080369486,0.00022486398,0.00000983732,0.00010159642],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012119683,0.00013948986,0.00030481914,0.00016162424,0.000042420965,0.00003676166,0.00013917651,0.000049365226,0.0017345761],"category_scores_gemma":[0.00006915155,0.00015737925,0.000053361397,0.0002068753,0.00004557552,0.000115087154,0.000053687974,0.00016254337,0.000022985028],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012914273,0.00022129346,0.59320796,0.00017524419,0.00007103615,0.000019323146,0.00018780063,0.00006070543,0.0000023672492,0.14933422,0.2503234,0.006267482],"study_design_scores_gemma":[0.00052334525,0.000004174756,0.4583047,0.000016486996,0.000003920496,3.642345e-7,0.000055867873,0.0011772014,0.000004578924,0.022907123,0.5168571,0.00014517843],"about_ca_topic_score_codex":0.1097101,"about_ca_topic_score_gemma":0.15603107,"teacher_disagreement_score":0.26653367,"about_ca_system_score_codex":0.00051283085,"about_ca_system_score_gemma":0.00041399826,"threshold_uncertainty_score":0.999178},"labels":[],"label_agreement":null},{"id":"W4407406145","doi":"10.1164/rccm.202406-1267rl","title":"Association between Industry Payments and Prescription of Inhaled Medications","year":2025,"lang":"en","type":"letter","venue":"American Journal of Respiratory and Critical Care Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health Research Institute; University of British Columbia; Vancouver Coastal Health","funders":"U.S. Department of Veterans Affairs","keywords":"Medicine; Medical prescription; Payment; Association (psychology); Intensive care medicine; Environmental health; Pharmacology; Finance; Business","score_opus":0.04825964764613834,"score_gpt":0.33299041891708964,"score_spread":0.2847307712709513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407406145","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1201362,0.01833399,0.00026671294,0.85365427,0.00075859786,0.00019455934,0.0007057324,0.000009288653,0.005940662],"genre_scores_gemma":[0.6775735,0.0008956766,0.000077391735,0.31799734,0.003240473,0.000006823512,0.000026747512,0.000020772552,0.00016130014],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981357,0.00010919724,0.0011843285,0.0002284244,0.00011433823,0.00022803401],"domain_scores_gemma":[0.9975884,0.00075185444,0.0010915681,0.00015372786,0.00022167839,0.00019275286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008253489,0.00017672179,0.0010201645,0.00043627483,0.000060345606,0.000020317495,0.00017420722,0.0004440049,0.00012479363],"category_scores_gemma":[0.0013105967,0.0001704344,0.00008684436,0.00018690394,0.00063560647,0.00011496307,0.000053097523,0.0017611309,0.0000021079925],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000061189865,0.0000627789,0.27874246,0.0017086813,0.0013315907,0.00011377206,0.0015349641,6.792816e-7,0.0000251388,0.009367649,0.6688059,0.03824521],"study_design_scores_gemma":[0.00089852326,0.001101094,0.01636664,0.00040336282,0.00045368832,0.00001511686,0.0004418002,0.0000058238193,0.000022315751,0.00544833,0.9746306,0.00021273023],"about_ca_topic_score_codex":0.000058630518,"about_ca_topic_score_gemma":0.0000010324791,"teacher_disagreement_score":0.5574373,"about_ca_system_score_codex":0.00015287992,"about_ca_system_score_gemma":0.000099268924,"threshold_uncertainty_score":0.7651335},"labels":[],"label_agreement":null},{"id":"W4407694825","doi":"10.1136/bmjgh-2024-017788","title":"Public patient forwarding to private pharmacies: an analysis of data linking patients, facilities and pharmacies in the state of Odisha, India","year":2025,"lang":"en","type":"article","venue":"BMJ Global Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of British Columbia","funders":"Tata Trusts; Bill and Melinda Gates Foundation","keywords":"Pharmacy; Private sector; Business; Medicine; Family medicine; Public health; Hospital pharmacy; Finance; Environmental health; Economic growth; Nursing; Economics","score_opus":0.16418873677861898,"score_gpt":0.41380805231089623,"score_spread":0.24961931553227726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407694825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98265696,0.0010894741,0.00047062212,0.001668139,0.0001269201,0.00060451444,0.011798228,0.0000083463365,0.0015767759],"genre_scores_gemma":[0.9947163,0.00084826985,0.00023531029,0.0039348025,0.000012390558,0.000020233763,0.00022050142,0.0000046602463,0.0000075492317],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979146,0.00008101186,0.0011670849,0.000390853,0.00006228068,0.00038416003],"domain_scores_gemma":[0.9987623,0.00009707389,0.00046294977,0.00049525104,0.0000405426,0.00014185626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014559223,0.00014053732,0.00061790657,0.0004995781,0.00008500035,0.00007333878,0.00058335374,0.000031388034,0.000023335628],"category_scores_gemma":[0.00011031404,0.00013637,0.00007096688,0.0011964904,0.000077630626,0.00040741838,0.00036459442,0.000109060966,0.0000033539302],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007934947,0.0003047895,0.80424035,0.00035479228,0.00041559016,6.06864e-7,0.0044849734,0.00081473356,0.000001193417,0.09690231,0.0005745303,0.09182681],"study_design_scores_gemma":[0.0025813677,0.0004197675,0.7022297,0.00011448639,0.0001238331,0.0000010630356,0.0013957247,0.098529875,0.00004605542,0.035270937,0.15868588,0.0006013294],"about_ca_topic_score_codex":0.001231886,"about_ca_topic_score_gemma":0.00032626302,"teacher_disagreement_score":0.15811135,"about_ca_system_score_codex":0.000198097,"about_ca_system_score_gemma":0.00011845128,"threshold_uncertainty_score":0.5561007},"labels":[],"label_agreement":null},{"id":"W4407710006","doi":"10.1080/23995270.2025.2466380","title":"Orphan drugs approved in Canada: availability and additional therapeutic value","year":2025,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University; University of Toronto","funders":"","keywords":"Orphan drug; Value (mathematics); Medicine; Business; Pharmacology; Mathematics; Statistics; Biology; Bioinformatics","score_opus":0.01286622521603255,"score_gpt":0.2277308317862886,"score_spread":0.21486460657025605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407710006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7413703,0.059730016,0.00012745682,0.043750517,0.003050843,0.0012703332,0.06779404,0.00010393106,0.08280256],"genre_scores_gemma":[0.9904802,0.00030107208,0.000032044296,0.008343544,0.00022447771,0.00006452736,0.00027058966,0.000010201113,0.00027333223],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99903023,0.000019902005,0.0003437374,0.0003458195,0.000022276932,0.00023804461],"domain_scores_gemma":[0.9994305,0.00014535694,0.00007824044,0.000198994,0.000013317929,0.00013361336],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000083773375,0.00013578967,0.00028132214,0.000108294815,0.00006743259,0.000039859446,0.00014289346,0.000050658433,0.0027831087],"category_scores_gemma":[0.000060804156,0.00015155782,0.00005908792,0.00016768917,0.000048339025,0.00010136311,0.000052911957,0.00012364767,0.00003443984],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009897644,0.00019893819,0.288751,0.00018158616,0.00012280536,0.000008272271,0.00013444136,0.00004087598,0.0000022095692,0.57574356,0.122128904,0.012588441],"study_design_scores_gemma":[0.0005204068,0.0000060307943,0.43725887,0.000013773377,0.0000083743225,5.1105644e-7,0.000121294805,0.001753134,0.000005073103,0.061959937,0.49817306,0.00017954333],"about_ca_topic_score_codex":0.082264505,"about_ca_topic_score_gemma":0.1004792,"teacher_disagreement_score":0.5137836,"about_ca_system_score_codex":0.00041029422,"about_ca_system_score_gemma":0.0005483784,"threshold_uncertainty_score":0.9981285},"labels":[],"label_agreement":null},{"id":"W4407729573","doi":"10.1111/1758-5899.13485","title":"Protecting Access to Medicines After Cambodia Graduates From Least Developed Country Status: A Policy Analysis","year":2025,"lang":"en","type":"article","venue":"Global Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"University of Melbourne","keywords":"Graduation (instrument); Developing country; Business; Economic growth; Data collection; Public relations; Medical education; Political science; Medicine; Economics; Sociology; Engineering","score_opus":0.04403181996748217,"score_gpt":0.353463855924092,"score_spread":0.30943203595660984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407729573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6748509,0.002237801,0.0030369784,0.10725546,0.0006338868,0.001094376,0.00998506,0.00019667452,0.20070887],"genre_scores_gemma":[0.949227,0.00024275466,0.00037242303,0.04859763,0.0008792866,0.00015435122,0.000079029276,0.000020806283,0.0004267611],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99731195,0.000037725385,0.000922241,0.0007236926,0.00005937911,0.0009450321],"domain_scores_gemma":[0.9986107,0.00008679332,0.0002558032,0.00050774566,0.00006698255,0.0004719823],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033969304,0.00034445722,0.00082413695,0.001209486,0.00018569395,0.0004067251,0.0006285238,0.00015720117,0.0002815174],"category_scores_gemma":[0.0010720539,0.00038337312,0.00021825678,0.0045830747,0.00009831719,0.0003229194,0.0004517342,0.00023849348,0.00067071227],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022299169,0.00015002859,0.72549504,0.00008243908,0.0020182598,0.000010905806,0.00080724695,0.0005679281,0.000012798819,0.23679599,0.02413003,0.009706321],"study_design_scores_gemma":[0.00084698555,0.000025375382,0.5704631,0.00004088505,0.00012459287,0.0000011318597,0.00006755121,0.0015769292,0.000052801348,0.12116968,0.305096,0.0005349508],"about_ca_topic_score_codex":0.09045414,"about_ca_topic_score_gemma":0.005158669,"teacher_disagreement_score":0.28096595,"about_ca_system_score_codex":0.0010217378,"about_ca_system_score_gemma":0.00050428946,"threshold_uncertainty_score":0.99986184},"labels":[],"label_agreement":null},{"id":"W4407875256","doi":"10.1080/20523211.2025.2465801","title":"Monitoring the impact of regulatory measures on medicine pricing in Thailand: an observation over a 16-year span","year":2025,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Policy and Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Health Systems Research Institute","keywords":"Span (engineering); Pharmacy; Medicine; Computer science; Family medicine; Engineering","score_opus":0.17182518522057164,"score_gpt":0.44777266721469966,"score_spread":0.275947481994128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407875256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9406654,0.0034692,0.00017914406,0.02302364,0.00034064378,0.00016289449,0.000016346643,0.000005390946,0.032137293],"genre_scores_gemma":[0.9933037,0.0031538752,0.00008220941,0.002681179,0.00070552796,0.0000017389084,3.9666148e-7,0.000010789649,0.00006057887],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99845487,0.00017896644,0.0008896487,0.00015767706,0.00007850126,0.00024035716],"domain_scores_gemma":[0.9973669,0.0015411113,0.0006748749,0.00017620699,0.00007742029,0.00016347448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003494575,0.00014381182,0.00042603436,0.00047620464,0.00007195395,0.00004438119,0.00021487309,0.000087607616,0.000058032747],"category_scores_gemma":[0.003262836,0.00010486509,0.00010908187,0.00039579655,0.00012994073,0.0006103849,0.000041226194,0.0005818159,0.0000036386882],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005306803,0.0010087239,0.28270832,0.00018234934,0.000950637,0.000019940904,0.003493179,0.0037248086,0.0036210958,0.6554326,0.0031853002,0.04036627],"study_design_scores_gemma":[0.0070558665,0.001073246,0.7542208,0.0004619327,0.00016603588,0.000087214954,0.000598735,0.008158047,0.001993199,0.10822596,0.11755762,0.00040133565],"about_ca_topic_score_codex":0.00099016,"about_ca_topic_score_gemma":0.0000050064314,"teacher_disagreement_score":0.54720664,"about_ca_system_score_codex":0.00029186677,"about_ca_system_score_gemma":0.0001295532,"threshold_uncertainty_score":0.4276274},"labels":[],"label_agreement":null},{"id":"W4408045715","doi":"10.1016/b978-0-443-23848-2.00001-2","title":"The modern-day drug discovery","year":2025,"lang":"en","type":"book-chapter","venue":"Elsevier eBooks","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Metropolitan University","funders":"","keywords":"Drug; Medicine; Pharmacology","score_opus":0.029514141111000442,"score_gpt":0.25209926167335367,"score_spread":0.22258512056235322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408045715","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000013679864,0.012634217,0.000031146654,0.0022258474,0.0014006837,0.0004089555,0.0007309311,0.00004072813,0.9825138],"genre_scores_gemma":[0.001498223,0.0033090606,0.00002609739,0.003679139,0.0005684863,0.000048869402,0.000024118333,0.00007986948,0.9907661],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99783105,0.000012905232,0.0009886165,0.00064386596,0.000043524367,0.00048003197],"domain_scores_gemma":[0.9981689,0.0002701893,0.0004943657,0.00089692057,0.000024812647,0.00014482284],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007211346,0.00043946746,0.00074653834,0.00018243621,0.00030539525,0.000372748,0.0007593328,0.00026169102,0.00022949789],"category_scores_gemma":[0.000046882786,0.00040349818,0.000508022,0.000014926276,0.00021877624,0.00010571566,0.00032906595,0.0006852403,0.0014436733],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000059855784,0.000003773628,0.000005829021,0.000025147494,0.00012836706,0.0000022898241,0.00006733252,0.0000018236453,2.1254547e-7,0.6075226,0.006219578,0.38601708],"study_design_scores_gemma":[0.00012202426,0.0000046186456,0.000005074599,0.000039335748,0.00001537537,7.651774e-7,7.189512e-7,0.00024781653,0.0000032766904,0.4427165,0.55659044,0.00025403273],"about_ca_topic_score_codex":0.0000033501876,"about_ca_topic_score_gemma":0.000042931802,"teacher_disagreement_score":0.5503709,"about_ca_system_score_codex":0.0002125243,"about_ca_system_score_gemma":0.00011345931,"threshold_uncertainty_score":0.9998417},"labels":[],"label_agreement":null},{"id":"W4408070139","doi":"10.1111/1468-0009.70001","title":"The Political Economy of the World Health Organization Model Lists of Essential Medicines","year":2025,"lang":"en","type":"article","venue":"Milbank Quarterly","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Politics; Population health; Health policy; Business; Political science; Economic growth; Health care; Economics","score_opus":0.019511533130018296,"score_gpt":0.2904597148692898,"score_spread":0.2709481817392715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408070139","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19000013,0.0038165671,0.011974549,0.47878116,0.002169647,0.0010487089,0.000493513,0.000052245043,0.31166348],"genre_scores_gemma":[0.9920365,0.000025018613,0.000057488764,0.006998595,0.00008385011,0.0000061126348,0.0000046686628,0.000010959549,0.0007767624],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9987041,0.000024515026,0.0007929324,0.00017964393,0.000021025477,0.00027779344],"domain_scores_gemma":[0.99906516,0.00013854812,0.00031963328,0.00035559543,0.00005081426,0.00007027385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031795754,0.00010054235,0.00032074345,0.00012481707,0.00013146824,0.000028816032,0.00036167953,0.000043588505,0.000051555184],"category_scores_gemma":[0.000053038795,0.00007706489,0.000096072676,0.00033783648,0.00020482147,0.0000678543,0.000037318205,0.00011506051,0.00001537978],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000066095754,0.000034539582,0.0037202253,0.000049023405,0.000034858745,3.429622e-8,0.00021633017,0.000039241928,0.00002021023,0.98928493,0.005966289,0.0006277129],"study_design_scores_gemma":[0.0007796541,0.00007581396,0.008873598,0.000046062076,0.00001579408,9.074998e-7,0.00014765178,0.039121687,0.00122391,0.9114518,0.03810922,0.00015386283],"about_ca_topic_score_codex":0.00017565113,"about_ca_topic_score_gemma":0.00022639462,"teacher_disagreement_score":0.8020364,"about_ca_system_score_codex":0.000083362334,"about_ca_system_score_gemma":0.00014771115,"threshold_uncertainty_score":0.3142615},"labels":[],"label_agreement":null},{"id":"W4408323895","doi":"10.1371/journal.pone.0319674","title":"Comparison of generic drug prices in Korea and eight high-income countries across four therapeutic classes","year":2025,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Ministry of Health and Welfare","keywords":"Purchasing power parity; Index (typography); Currency; Price index; Drug prices; Purchasing power; Drug; Generic drug; Economics; Medicine; Pharmacology; Exchange rate; Public economics; Monetary economics; Macroeconomics","score_opus":0.10472904124764496,"score_gpt":0.32065322119760464,"score_spread":0.2159241799499597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408323895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9839419,0.008858389,0.000048445225,0.0027757853,0.00008688616,0.00018209395,0.00019918062,0.000014555894,0.0038927454],"genre_scores_gemma":[0.9957481,0.002662343,0.00039657878,0.0008045459,0.00004379604,0.000024222687,0.0000056405556,0.000012795177,0.0003019739],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987679,0.000011185071,0.000639282,0.0002709679,0.000029745552,0.00028091946],"domain_scores_gemma":[0.9992998,0.00017369328,0.00024331023,0.00020442228,0.00002419288,0.000054549677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024401264,0.00013492501,0.00065606245,0.00018846839,0.00006467875,0.000068990215,0.00019991977,0.00007616054,0.00008548949],"category_scores_gemma":[0.0000340682,0.00015123506,0.00004068094,0.00023665879,0.00012506449,0.00014432472,0.00010081102,0.00014831524,0.000046762256],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003707535,0.00044405213,0.80957603,0.00034537062,0.00021544889,7.120251e-7,0.0005342827,0.000028361772,0.00017801467,0.18823102,0.000092489856,0.0003171493],"study_design_scores_gemma":[0.0018859857,0.00008348258,0.87502855,0.0001915257,0.000054989483,4.4910666e-7,0.00011516331,0.017262429,0.012513585,0.07574425,0.016658673,0.00046093395],"about_ca_topic_score_codex":0.0002610467,"about_ca_topic_score_gemma":0.00020091202,"teacher_disagreement_score":0.11248678,"about_ca_system_score_codex":0.000073601645,"about_ca_system_score_gemma":0.000025597861,"threshold_uncertainty_score":0.61671865},"labels":[],"label_agreement":null},{"id":"W4408331463","doi":"10.2139/ssrn.5173506","title":"From Patents To Regulatory Exclusivities In Drug Development: A Comparative Transaction Cost Analysis","year":2025,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Toronto","funders":"","keywords":"Transaction cost; Drug development; Business; Drug; Pharmacology; Medicine; Finance","score_opus":0.03822719959103591,"score_gpt":0.29305337889533845,"score_spread":0.2548261793043025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408331463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97304595,0.0021680787,0.017033573,0.001712064,0.00023259119,0.00016702434,0.000047363366,0.000011470269,0.0055818683],"genre_scores_gemma":[0.99666315,0.00074341614,0.00009605251,0.0009061312,0.00006701764,0.000020353076,0.000013663918,0.000008539483,0.0014816503],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99797726,0.00003284431,0.00065670366,0.00027907238,0.000031298143,0.0010228248],"domain_scores_gemma":[0.999535,0.000046746434,0.00016995464,0.00013204908,0.000019837584,0.000096374424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010467755,0.00014461663,0.00046328845,0.0008962944,0.00013557092,0.000076586286,0.00023065253,0.000057855326,0.00014399705],"category_scores_gemma":[0.0000121369985,0.00017238368,0.00013974152,0.0006619133,0.000023934428,0.00018653095,0.0000269938,0.0007185132,0.00013866175],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042606387,0.00048060098,0.10559097,0.000018965611,0.0063117575,0.0000049718083,0.014753427,0.010882909,0.0000931916,0.8335717,0.001260963,0.026604507],"study_design_scores_gemma":[0.0027332483,0.000050489773,0.14737777,0.000045455516,0.00014286909,0.0000045988872,0.0032710596,0.008600177,0.00081432174,0.73979884,0.09644586,0.00071528147],"about_ca_topic_score_codex":0.0008275468,"about_ca_topic_score_gemma":0.009473918,"teacher_disagreement_score":0.0951849,"about_ca_system_score_codex":0.0019238177,"about_ca_system_score_gemma":0.00048070055,"threshold_uncertainty_score":0.70296025},"labels":[],"label_agreement":null},{"id":"W4408415758","doi":"10.1007/978-3-031-75570-5_11","title":"Legalization as an Alternative to Drug Prohibition","year":2025,"lang":"en","type":"book-chapter","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Tech University","funders":"","keywords":"Legalization; Drug; Business; Law and economics; Political science; Internet privacy; Law; Computer security; Medicine; Pharmacology; Computer science; Economics","score_opus":0.058841173331446374,"score_gpt":0.30395242437583975,"score_spread":0.24511125104439338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408415758","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008515787,0.00020453996,0.0018493478,0.0063807345,0.0005586358,0.00050953164,0.000996978,0.0000614191,0.98935366],"genre_scores_gemma":[0.0038729494,0.0004413716,0.00032392392,0.01598497,0.00047225913,0.000029542443,0.00036612913,0.000054270164,0.9784546],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985016,0.0000049672517,0.0006274379,0.00061716966,0.000023160355,0.00022567628],"domain_scores_gemma":[0.9991109,0.000019605182,0.00026140828,0.00034849843,0.00004911728,0.0002104893],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00022314896,0.00026982007,0.0004632143,0.00048652288,0.0000711051,0.00013602959,0.00026142393,0.00018077277,0.0061273365],"category_scores_gemma":[0.00003376477,0.00034008088,0.00013226127,0.000044950215,0.000030113526,0.00024210074,0.00010256887,0.00021532862,0.006285182],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013254751,0.000019681205,0.0000071497802,0.00001837621,0.00004857479,0.000001321636,0.00010524024,0.00003821759,7.7965603e-7,0.9485454,0.04923599,0.0019660254],"study_design_scores_gemma":[0.0001241624,0.000028226603,0.0000064735705,0.00002268387,0.0000052448995,6.169382e-7,0.000001487256,0.0010443764,0.000045835728,0.44603324,0.55246055,0.00022712242],"about_ca_topic_score_codex":0.00026697657,"about_ca_topic_score_gemma":0.00011063838,"teacher_disagreement_score":0.50322455,"about_ca_system_score_codex":0.00023966767,"about_ca_system_score_gemma":0.00005504501,"threshold_uncertainty_score":0.9999051},"labels":[],"label_agreement":null},{"id":"W4408415837","doi":"10.1007/978-3-031-75570-5_6","title":"International Drug Law","year":2025,"lang":"en","type":"book-chapter","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Tech University","funders":"","keywords":"Drug; Law; Political science; Medicine; Pharmacology","score_opus":0.053721091987186956,"score_gpt":0.2766218533856966,"score_spread":0.22290076139850967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408415837","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000015206323,0.0007761831,0.00009736297,0.007203273,0.0016291955,0.0001078545,0.0008701229,0.000045995588,0.9892685],"genre_scores_gemma":[0.0015330139,0.0014849029,0.00021577891,0.01401454,0.00047319467,0.0000063336397,0.00008775689,0.000030917156,0.98215353],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988045,0.0000011315192,0.0005901144,0.00040586398,0.000018234172,0.0001801579],"domain_scores_gemma":[0.9993308,0.00004376441,0.00021686885,0.0002951459,0.00002014149,0.0000932392],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00015599385,0.0002151968,0.00041491265,0.00022003119,0.000046239787,0.00009175004,0.00041663705,0.0001868606,0.02766506],"category_scores_gemma":[0.000011000182,0.00026823007,0.0002350154,0.000012177685,0.000070670576,0.00008937622,0.00017833407,0.0002930673,0.008074606],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000003192638,0.0000074171794,0.000010622609,0.000010590429,0.00011251092,0.0000016906347,0.000009244567,0.000001483763,9.04609e-8,0.8507084,0.1481589,0.00097586337],"study_design_scores_gemma":[0.000118359814,0.0000021368285,0.0000018619311,0.000009567529,0.0000035296807,5.8908284e-7,3.2471667e-7,0.00024812747,0.000003345554,0.4148434,0.5846083,0.00016041503],"about_ca_topic_score_codex":0.00013716033,"about_ca_topic_score_gemma":0.00004515858,"teacher_disagreement_score":0.43644944,"about_ca_system_score_codex":0.00014853125,"about_ca_system_score_gemma":0.000022505657,"threshold_uncertainty_score":0.999977},"labels":[],"label_agreement":null},{"id":"W4408729540","doi":"10.1093/oxfordhb/9780197766859.013.0029","title":"Pharmacare and Access to Medicines","year":2025,"lang":"en","type":"book-chapter","venue":"Oxford University Press eBooks","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Carleton University","funders":"","keywords":"Traditional medicine; Business; Medicine","score_opus":0.079158638753823,"score_gpt":0.27754526452566664,"score_spread":0.19838662577184363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408729540","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000099938894,0.00062339497,0.0001382099,0.0012420797,0.00033208213,0.0003633625,0.0011487458,0.000046747824,0.9960054],"genre_scores_gemma":[0.0012436843,0.0027114893,0.00007070871,0.0051434697,0.00017436128,0.0000017216964,0.000024429903,0.00003102899,0.9905991],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99889684,0.0000047618355,0.0002909142,0.0005258326,0.000026808168,0.000254869],"domain_scores_gemma":[0.9991421,0.000054798194,0.0001947949,0.00030060517,0.0000336445,0.00027404798],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010135697,0.0002763865,0.0005437051,0.00039613337,0.00011902245,0.00009247806,0.0005686239,0.00023050324,0.00021940327],"category_scores_gemma":[0.000012328196,0.00036909245,0.00012183341,0.000012392422,0.00009986772,0.00012060442,0.0007158993,0.00030722062,0.000009402026],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004485066,0.000004374612,0.000065546585,0.000098923316,0.00013468936,0.00001775628,0.00007604496,0.0000032597359,6.714353e-7,0.94532955,0.048384994,0.005839329],"study_design_scores_gemma":[0.0005162083,0.000022615624,0.00003235646,0.000070163114,0.000050865634,0.0000017415651,0.000004460866,0.00015567044,0.000018175202,0.011724404,0.9870523,0.0003510435],"about_ca_topic_score_codex":0.000069185546,"about_ca_topic_score_gemma":0.000018521085,"teacher_disagreement_score":0.9386673,"about_ca_system_score_codex":0.00012958275,"about_ca_system_score_gemma":0.000038862705,"threshold_uncertainty_score":0.9998761},"labels":[],"label_agreement":null},{"id":"W4408735635","doi":"10.63485/y5pjr-xme81","title":"Bioline budget in jeopardy","year":2008,"lang":"en","type":"preprint","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Double jeopardy; Business; Political science; Law","score_opus":0.10441882242277167,"score_gpt":0.308214273088274,"score_spread":0.2037954506655023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408735635","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25152308,0.0042205635,0.00052877754,0.006866355,0.0016679852,0.000494372,0.0010263362,0.00009958737,0.73357296],"genre_scores_gemma":[0.9776563,0.012592737,0.00095445034,0.0052986853,0.00050844013,0.000069979345,0.00012320516,0.000054780372,0.0027414416],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99774575,0.000012053078,0.0010733829,0.0006996403,0.000017277021,0.000451907],"domain_scores_gemma":[0.99891025,0.00004342855,0.0003087123,0.0005557873,0.000013278365,0.00016857145],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00036913803,0.00029298305,0.0008129252,0.000492168,0.00003256109,0.00006316343,0.0004818926,0.00037901354,0.0013312061],"category_scores_gemma":[0.000067530746,0.00035886833,0.00022421006,0.00013532204,0.00007114225,0.0000697122,0.0005978715,0.00072839024,0.003144944],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044369714,0.00053234346,0.07918802,0.00020265247,0.0001715721,0.000054016615,0.000520623,0.0045707696,0.0000076349315,0.85692036,0.0555561,0.00223153],"study_design_scores_gemma":[0.00091615686,0.000023318207,0.013327759,0.000027070942,0.0000035742114,0.000008243833,0.0000061273777,0.034329716,0.0000800885,0.28785527,0.6625648,0.0008578708],"about_ca_topic_score_codex":0.001150879,"about_ca_topic_score_gemma":0.00011285719,"teacher_disagreement_score":0.7308315,"about_ca_system_score_codex":0.00020590436,"about_ca_system_score_gemma":0.00006732101,"threshold_uncertainty_score":0.99988633},"labels":[],"label_agreement":null},{"id":"W4409003440","doi":"10.53469/jssh.2025.7(03).08","title":"Regulatory in the Pharmaceutical Industry","year":2025,"lang":"en","type":"article","venue":"Journal of Social Science and Humanities","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Pharmaceutical industry; Medicine; Pharmacology","score_opus":0.1147506876549185,"score_gpt":0.3505887686937873,"score_spread":0.2358380810388688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409003440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70345056,0.00095354253,0.000003897685,0.007151195,0.00031213005,0.000038225015,0.000004712307,0.0000016563791,0.28808406],"genre_scores_gemma":[0.991401,0.00013018622,0.0000061270616,0.007965105,0.00021181937,0.0000011151077,4.6300958e-8,0.0000016593572,0.00028294427],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993568,0.000011886928,0.00034086648,0.00007691147,0.000051129406,0.00016239431],"domain_scores_gemma":[0.999697,0.000046800964,0.00014074576,0.000042356634,0.0000440182,0.000029076562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020761774,0.000047992762,0.00015362108,0.00027239037,0.0002734814,0.00017091389,0.00030182293,0.000054372915,0.00008142323],"category_scores_gemma":[0.00008040773,0.000039927334,0.00003767779,0.00023155367,0.0006886649,0.000318331,0.000042005275,0.0003699008,0.0000049455352],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000052099135,0.000022719754,0.0037164139,0.000006497268,0.0000055681007,0.0000017107374,0.0026066469,4.849664e-7,0.000017723887,0.9900266,0.0026150423,0.00097539125],"study_design_scores_gemma":[0.00053555536,0.00003336455,0.14968905,0.000015320287,0.0000075185853,0.000008282769,0.0038025905,0.00010980487,0.00007286409,0.2575578,0.5880623,0.0001055629],"about_ca_topic_score_codex":0.000011720337,"about_ca_topic_score_gemma":0.0000044746303,"teacher_disagreement_score":0.7324688,"about_ca_system_score_codex":0.00009573009,"about_ca_system_score_gemma":0.00010430019,"threshold_uncertainty_score":0.25374144},"labels":[],"label_agreement":null},{"id":"W4409004611","doi":"10.1001/jama.2025.4583","title":"Trade Tariffs on Canadian Pharmaceuticals—Implications for US Drug Supply and Costs","year":2025,"lang":"en","type":"article","venue":"JAMA","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"National Heart, Lung, and Blood Institute","keywords":"Medicine; Food and drug administration; Drug; Drug administration; International trade; Environmental health; Pharmacology; Business","score_opus":0.05027744393695012,"score_gpt":0.3193100062258937,"score_spread":0.2690325622889436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409004611","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18666753,0.0024252688,0.00035360776,0.5039095,0.0007301288,0.0010525547,0.0053904946,0.00005355232,0.29941735],"genre_scores_gemma":[0.9448619,0.000413417,0.00019706745,0.053291656,0.00013609193,0.00011477714,0.000043605167,0.000015943004,0.0009255308],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989649,0.000007881128,0.00032654696,0.0003266608,0.000008072532,0.00036591408],"domain_scores_gemma":[0.99920666,0.00019377041,0.00006161634,0.00021277029,0.000011787169,0.00031338923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025196778,0.00012289717,0.00023140958,0.00025258661,0.00017728067,0.00013019395,0.00017727619,0.000092690716,0.00013096603],"category_scores_gemma":[0.00011596576,0.00015120214,0.000072497314,0.0001389841,0.000057228517,0.00009605645,0.000023578012,0.00016726353,0.000113459995],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017803555,0.000035988225,0.021799106,0.000016450613,0.000040409686,3.307689e-7,0.000050403327,0.000009083337,0.000016772032,0.8731753,0.06796145,0.03687691],"study_design_scores_gemma":[0.0009395315,0.000013848146,0.099988475,0.000008636541,0.000008598966,9.89503e-7,0.0000057979437,0.0020559106,0.0001599623,0.044427156,0.85224634,0.00014474652],"about_ca_topic_score_codex":0.0068538985,"about_ca_topic_score_gemma":0.00638415,"teacher_disagreement_score":0.82874817,"about_ca_system_score_codex":0.00026080324,"about_ca_system_score_gemma":0.00008327838,"threshold_uncertainty_score":0.99975955},"labels":[],"label_agreement":null},{"id":"W4409027491","doi":"10.1093/jphsr/rmaf003","title":"Trust, transparency, and accountability in health and pharmaceutical systems","year":2024,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Health Services Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Transparency (behavior); Accountability; Law","score_opus":0.21673898432230537,"score_gpt":0.49982114948346024,"score_spread":0.28308216516115486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409027491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49461576,0.4542856,0.00026353617,0.045799203,0.0012515886,0.001001832,0.00028750548,0.000036587433,0.0024583978],"genre_scores_gemma":[0.9240352,0.07159026,0.00010693316,0.0037439943,0.00041349113,0.000015815527,0.0000034121497,0.000034462944,0.00005642226],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953179,0.00042149457,0.0023166845,0.00057250645,0.00023102069,0.0011403981],"domain_scores_gemma":[0.9969578,0.000754957,0.00027237047,0.0001951743,0.00009675459,0.0017229728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01253774,0.00023695375,0.00095044693,0.0009886115,0.00019745539,0.00040705779,0.00038921132,0.00015148646,0.0002156835],"category_scores_gemma":[0.00004517036,0.0002298621,0.000103493796,0.0007294863,0.00029987085,0.0006135299,0.00014925894,0.0020083664,0.000065399385],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029164753,0.0020089436,0.1380751,0.08603052,0.00064451416,0.00033952785,0.033421554,0.00034841071,0.00016103189,0.5529131,0.003727209,0.17941362],"study_design_scores_gemma":[0.002616,0.0007576388,0.005580071,0.0013964787,0.00000891856,0.00031011057,0.0017334289,0.2725179,0.000030234374,0.019904226,0.69477504,0.00036995727],"about_ca_topic_score_codex":0.0012266847,"about_ca_topic_score_gemma":0.00006151325,"teacher_disagreement_score":0.69104785,"about_ca_system_score_codex":0.00064058014,"about_ca_system_score_gemma":0.00052507094,"threshold_uncertainty_score":0.93735045},"labels":[],"label_agreement":null},{"id":"W4409111735","doi":"10.1093/eurheartj/ehaf134","title":"Critical medications in cardiology: strategic policy of the European Medicines Agency","year":2025,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"National Institutes of Health; Deutsche Forschungsgemeinschaft; European Commission","keywords":"Medicine; Agency (philosophy); Cardiology; Internal medicine","score_opus":0.11174514372226377,"score_gpt":0.3648778749610622,"score_spread":0.2531327312387984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409111735","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.096610904,0.0020118402,0.00023871973,0.063880615,0.000895253,0.00008945611,0.00004082786,0.000011045878,0.83622134],"genre_scores_gemma":[0.993057,0.00054715853,0.00007556901,0.0052168905,0.00077054056,9.744564e-7,0.0000010024112,0.000016526797,0.0003143259],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9983282,0.00040689687,0.00077185093,0.00018136224,0.000031015068,0.00028067981],"domain_scores_gemma":[0.99926126,0.00013600868,0.00015937729,0.00028261743,0.000033965713,0.00012676472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024867966,0.00010623954,0.00031115505,0.0003510983,0.00014257497,0.00004261657,0.00045182556,0.000029786637,0.00015536939],"category_scores_gemma":[0.00066668866,0.00008973364,0.00016283272,0.00038868026,0.00025388357,0.00008262252,0.00012892376,0.00048776224,0.00020858338],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009228334,0.000097649856,0.1502132,0.00004409014,0.00009118465,0.00003858945,0.0004524736,0.00018209417,0.00024238872,0.8220906,0.025010377,0.00152807],"study_design_scores_gemma":[0.0005421882,0.000027872808,0.7582952,0.00007347776,0.000010946095,0.000086884545,0.00005462126,0.00024212027,0.000015041413,0.108364545,0.13217135,0.000115802686],"about_ca_topic_score_codex":0.000023115414,"about_ca_topic_score_gemma":0.0000048511374,"teacher_disagreement_score":0.8964461,"about_ca_system_score_codex":0.00006777853,"about_ca_system_score_gemma":0.000121039506,"threshold_uncertainty_score":0.36592317},"labels":[],"label_agreement":null},{"id":"W4409323342","doi":"10.1016/j.jhealeco.2025.102996","title":"Procurement institutions and essential drug supply in low and middle-income countries","year":2025,"lang":"en","type":"article","venue":"Journal of Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Procurement; Low and middle income countries; Business; Developing country; Economics; Economic growth; Marketing","score_opus":0.04875792013136287,"score_gpt":0.32286762259252866,"score_spread":0.2741097024611658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409323342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9459495,0.015099618,0.00015985282,0.035984073,0.0007195657,0.00022755763,0.00009511562,0.0000043955665,0.0017603192],"genre_scores_gemma":[0.9733176,0.021975886,0.00039298876,0.004109745,0.000101222395,0.000005962862,0.0000017828742,0.000008904883,0.000085859574],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99801713,0.000020154754,0.0014702564,0.00019597197,0.000012878414,0.00028363467],"domain_scores_gemma":[0.99892884,0.000074883355,0.0007035848,0.00011089226,0.00002577821,0.0001559876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013062593,0.00012772491,0.00058011635,0.00049979903,0.00012572277,0.00010835366,0.0001358242,0.000060521903,0.00003559684],"category_scores_gemma":[0.000051581348,0.00014878335,0.00006978798,0.00008884894,0.0001173073,0.0003438964,0.0000697969,0.00024713576,0.000011672268],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000083196945,0.00011578326,0.19449681,0.00087802333,0.00010639879,0.00000349753,0.0007157579,0.0005539053,4.380165e-7,0.8014404,0.00059609674,0.0010097023],"study_design_scores_gemma":[0.00785065,0.00026134125,0.2538631,0.0014225486,0.000030789237,0.00010356636,0.0003489815,0.009849938,0.00008379414,0.21125045,0.5142316,0.00070319365],"about_ca_topic_score_codex":0.00016390676,"about_ca_topic_score_gemma":0.00031614603,"teacher_disagreement_score":0.59018993,"about_ca_system_score_codex":0.00036784026,"about_ca_system_score_gemma":0.0004480751,"threshold_uncertainty_score":0.6067209},"labels":[],"label_agreement":null},{"id":"W4409665036","doi":"10.1093/ajhp/zxaf092","title":"National trends in prescription drug expenditures and projections for 2025","year":2025,"lang":"en","type":"article","venue":"American Journal of Health-System Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Drug Policy Research Network; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Disclaimer; Medical prescription; Prescription drug; Biosimilar; Drug; Medicine; Legislation; Business; Family medicine; Pharmacology; Political science; Law","score_opus":0.07321165051098799,"score_gpt":0.3892106735295695,"score_spread":0.3159990230185815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409665036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.54110575,0.037162308,0.012279166,0.3395154,0.007280517,0.00202992,0.0013859026,0.000091857924,0.05914918],"genre_scores_gemma":[0.9959091,0.000601938,0.000487858,0.0023880142,0.0001826935,0.000044309938,0.0000054824372,0.000011001414,0.0003696245],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99825704,0.00006722095,0.0011903924,0.00019478193,0.000037346505,0.0002532338],"domain_scores_gemma":[0.9987222,0.00012539267,0.00091497175,0.00007200594,0.00005427829,0.000111132525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014697955,0.00011494353,0.00053815154,0.0010557835,0.00011925489,0.000050686947,0.00014357669,0.000016738479,0.000032840144],"category_scores_gemma":[0.0000407631,0.0001252563,0.00011477601,0.00030428485,0.000065216875,0.00023276215,0.000023395087,0.00019043824,0.0000053493013],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070236804,0.0004990053,0.062384363,0.00071283814,0.00042499838,0.0000046170067,0.0022213515,0.0008049711,0.0000643358,0.4364004,0.16054013,0.3352406],"study_design_scores_gemma":[0.0038134537,0.00018274505,0.017600799,0.00014427195,0.000014020946,0.000045845958,0.0007051454,0.014247365,0.00006275018,0.0069152443,0.9560401,0.00022825188],"about_ca_topic_score_codex":0.0008622853,"about_ca_topic_score_gemma":0.000051434385,"teacher_disagreement_score":0.7955,"about_ca_system_score_codex":0.00044444206,"about_ca_system_score_gemma":0.00020322092,"threshold_uncertainty_score":0.51078033},"labels":[],"label_agreement":null},{"id":"W4409920326","doi":"10.1007/978-3-031-76774-6_7","title":"World Health Organization (WHO)","year":2025,"lang":"en","type":"book-chapter","venue":"AAPS advances in the pharmaceutical sciences series","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Business","score_opus":0.07528081969239535,"score_gpt":0.35499471303970803,"score_spread":0.27971389334731267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409920326","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000023330385,0.04744779,0.00020403847,0.040787604,0.0010139872,0.0004708583,0.0003051637,0.00004857085,0.90969867],"genre_scores_gemma":[0.042672593,0.35306174,0.0016663785,0.10152837,0.0015673896,0.00010217866,0.00014794072,0.00015417839,0.49909922],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973884,0.000040118524,0.0010396,0.0007639415,0.000114723494,0.00065322296],"domain_scores_gemma":[0.9986258,0.0003522591,0.00047024348,0.0003635112,0.00003132074,0.00015684572],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015017065,0.00038146012,0.00073219143,0.00048122535,0.00040864781,0.00023309507,0.0012319428,0.00012577946,0.0016948017],"category_scores_gemma":[0.00015776465,0.00033464612,0.00012805307,0.0006468625,0.0010051345,0.000771878,0.00024902448,0.00068276614,0.0004329026],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010679968,0.00002616866,0.00046701485,0.000093130955,0.000015579335,0.0000031106886,0.0002883129,0.00011079387,2.45493e-7,0.98698825,0.0046582446,0.0073384694],"study_design_scores_gemma":[0.00014441191,0.000036649733,0.000030564566,0.00006610946,0.000005271573,0.0000049593973,0.000024505141,0.0002792351,0.0000107089445,0.37275472,0.62640816,0.00023471849],"about_ca_topic_score_codex":0.000028958002,"about_ca_topic_score_gemma":0.00025804777,"teacher_disagreement_score":0.6217499,"about_ca_system_score_codex":0.00025794996,"about_ca_system_score_gemma":0.0001620242,"threshold_uncertainty_score":0.99991053},"labels":[],"label_agreement":null},{"id":"W4409963014","doi":"10.1257/aer.20220276","title":"Does Entry Remedy Collusion? Evidence from the Generic Prescription Drug Cartel","year":2025,"lang":"en","type":"article","venue":"American Economic Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"","keywords":"Cartel; Collusion; Medical prescription; Drug; Business; Pharmacology; Medicine; Industrial organization","score_opus":0.04669584478231093,"score_gpt":0.3102293564347684,"score_spread":0.2635335116524575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409963014","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26816007,0.5214682,0.0005336129,0.14868097,0.0050860974,0.002410078,0.00096889416,0.00014910351,0.05254298],"genre_scores_gemma":[0.37942946,0.56681633,0.0002493166,0.049937032,0.00037697196,0.00020156273,0.000028610377,0.000031130712,0.0029296225],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99758315,0.00010097656,0.0011811448,0.00071356894,0.000024865654,0.0003962696],"domain_scores_gemma":[0.997698,0.0004522632,0.00073044456,0.00096655823,0.000018433098,0.00013431096],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000906037,0.00026906288,0.00091182225,0.00008467726,0.00018476683,0.00012279314,0.00082154194,0.000041898566,0.0012070156],"category_scores_gemma":[0.00023649704,0.00019241699,0.00029523048,0.00026215403,0.0002848159,0.00029968153,0.0002465695,0.00023396513,0.0021732587],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005319794,0.00011482084,0.13209552,0.0006218581,0.00053882477,0.0000035057853,0.00048960804,0.00014226415,0.000058075253,0.06076954,0.6610544,0.1440584],"study_design_scores_gemma":[0.00021899867,0.00001624337,0.024322983,0.00071458175,0.00006257523,0.0000010269154,0.000042993135,0.0015615254,0.000044287364,0.008053342,0.9646427,0.0003187285],"about_ca_topic_score_codex":0.005840868,"about_ca_topic_score_gemma":0.00063224696,"teacher_disagreement_score":0.30358833,"about_ca_system_score_codex":0.0004179645,"about_ca_system_score_gemma":0.00012286364,"threshold_uncertainty_score":0.99970603},"labels":[],"label_agreement":null},{"id":"W4409974707","doi":"10.2196/preprints.76730","title":"Medico-economic Evaluation of a Telehealth Platform for Elective Outpatient Surgeries: A Randomized Controlled Trial (Preprint)","year":2025,"lang":"en","type":"preprint","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Preprint; Randomized controlled trial; Telehealth; Medicine; Telemedicine; Effi; Physical therapy; Computer science; Surgery; World Wide Web; Health care; Economics; Database; Economic growth","score_opus":0.10149156870091623,"score_gpt":0.3680540091472616,"score_spread":0.26656244044634536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409974707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5052314,0.005956301,0.021268206,0.004190958,0.015824273,0.098493166,0.0057233158,0.00017066732,0.3431417],"genre_scores_gemma":[0.9738248,0.0019943912,0.00076119514,0.0009083553,0.0006356985,0.020390697,0.00027464353,0.000052732634,0.0011575079],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9932361,0.00022617201,0.0047533265,0.0011058132,0.000111748406,0.00056680903],"domain_scores_gemma":[0.991888,0.0031946402,0.0036111968,0.0007755479,0.00032247126,0.0002081545],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.01799099,0.0005384749,0.0060307505,0.00085024134,0.000099245895,0.00009262187,0.0005281124,0.0006301517,0.0017370182],"category_scores_gemma":[0.0042515374,0.0005379485,0.0021547007,0.00009604989,0.00019626014,0.00012797855,0.0003703841,0.0005482218,0.00006363563],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6650739,0.00029576712,0.00004904695,0.00030203743,0.0019352364,6.698705e-8,0.00072075025,0.0037661565,2.958741e-7,0.32387993,0.0015395341,0.0024372968],"study_design_scores_gemma":[0.5524119,0.00012038854,0.000007059815,0.000047921945,0.00023776955,1.7183831e-7,0.00003150022,0.21039636,0.000041139538,0.23321804,0.0031925705,0.0002951311],"about_ca_topic_score_codex":0.0013485065,"about_ca_topic_score_gemma":0.00014784401,"teacher_disagreement_score":0.4685934,"about_ca_system_score_codex":0.0014067987,"about_ca_system_score_gemma":0.0020414458,"threshold_uncertainty_score":0.9997072},"labels":[],"label_agreement":null},{"id":"W4410006109","doi":"10.53555/sfs.v10i3.3564","title":"Next-Generation Medicines for Neurological and Neurodegenerative Disorders: From Discovery to Commercialization","year":2023,"lang":"en","type":"article","venue":"Journal of Survey in Fisheries Sciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Commercialization; Drug discovery; Neuroscience; Medicine; Business; Psychology; Bioinformatics; Biology; Marketing","score_opus":0.4626763968984163,"score_gpt":0.3418901994057735,"score_spread":0.1207861974926428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410006109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773072,0.0002586012,0.0013832998,0.019873016,0.00076576375,0.00010506915,0.0001648958,0.000003894724,0.00013827225],"genre_scores_gemma":[0.99628264,0.0009463515,0.00026338632,0.0022156874,0.0002462386,0.0000061106907,0.000013404041,0.000005159862,0.000021000307],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991003,0.000058908827,0.00047951358,0.00017907252,0.00003424418,0.00014794424],"domain_scores_gemma":[0.9992228,0.00042776545,0.00021231182,0.00004715995,0.000026878344,0.000063056454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016776493,0.00007193818,0.00024824985,0.00021433669,0.00011196255,0.00021747057,0.00016341622,0.000035851823,0.000021056763],"category_scores_gemma":[0.001194431,0.00006364773,0.0000327783,0.00040171092,0.00013659621,0.0006984279,0.000042153864,0.00006698017,0.0000037253026],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005104752,0.000024826239,0.9838173,0.0000035946828,0.0000067047304,7.2310314e-7,0.00059584447,0.0014004221,0.00016456872,0.0045739263,0.007805993,0.0015550569],"study_design_scores_gemma":[0.00035905384,0.00047201262,0.93915,0.000007602496,0.000002445256,0.0000010058181,0.00009587902,0.022205058,0.000049978054,0.024273818,0.013252843,0.00013032737],"about_ca_topic_score_codex":0.00028196097,"about_ca_topic_score_gemma":0.0016904094,"teacher_disagreement_score":0.044667315,"about_ca_system_score_codex":0.000013398775,"about_ca_system_score_gemma":0.000023584664,"threshold_uncertainty_score":0.2595479},"labels":[],"label_agreement":null},{"id":"W4410208254","doi":"10.22214/ijraset.2025.70266","title":"A Review: Regulatory Affairs in Pharmaceutical Industry","year":2025,"lang":"en","type":"article","venue":"International Journal for Research in Applied Science and Engineering Technology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Regulatory affairs; Business; Pharmaceutical industry; Pharmacology; Political science; Medicine; Public administration","score_opus":0.11577416562913742,"score_gpt":0.43786508556008047,"score_spread":0.3220909199309431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410208254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.50942504,0.06285977,0.0037848519,0.32175454,0.0045693866,0.002284698,0.00008430962,0.00015828274,0.09507911],"genre_scores_gemma":[0.99239886,0.005979467,0.0005751075,0.00086249685,0.00005462237,0.00008356059,4.5641062e-7,0.0000059269805,0.000039506853],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988325,0.0000038094934,0.0003998332,0.0002556435,0.000081258804,0.00042691772],"domain_scores_gemma":[0.9995885,0.000085323656,0.000042604865,0.000110112356,0.000087306034,0.00008618644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043260204,0.00006905229,0.0001785053,0.0028412763,0.00006886766,0.000080721475,0.0007069482,0.00013468956,0.000016401918],"category_scores_gemma":[0.0006567244,0.00007863907,0.000021506308,0.0011630652,0.00030988757,0.00011533262,0.00022401726,0.0010891911,0.00000984149],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001778025,0.00003665285,0.001743749,0.00006720188,0.00001190685,0.000007285787,0.000016794625,0.0001762882,0.0010530718,0.98218614,0.0018562821,0.01282687],"study_design_scores_gemma":[0.0013653532,0.000029380684,0.0017489666,0.00059851597,0.0000013938052,0.000047236907,0.00009543081,0.046088286,0.0011816315,0.36140853,0.5872404,0.00019487122],"about_ca_topic_score_codex":0.0000057521156,"about_ca_topic_score_gemma":0.0000023170064,"teacher_disagreement_score":0.6207776,"about_ca_system_score_codex":0.0005021556,"about_ca_system_score_gemma":0.00014042202,"threshold_uncertainty_score":0.47320536},"labels":[],"label_agreement":null},{"id":"W4410345262","doi":"10.1080/14636778.2025.2500756","title":"Capitalizing a cure: how finance controls the price and value of medicines","year":2025,"lang":"en","type":"article","venue":"New Genetics and Society","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Value (mathematics); Economics; Finance; Financial economics; Business; Mathematics; Statistics","score_opus":0.02679235073809223,"score_gpt":0.269839559880074,"score_spread":0.2430472091419818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410345262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8123364,0.1031363,0.004071383,0.06620009,0.00040080212,0.00038898483,0.00010575976,0.000013323235,0.013346991],"genre_scores_gemma":[0.9568349,0.036004253,0.0009191991,0.005449432,0.00011199062,0.0000060696984,0.0000012755519,0.000007650891,0.000665198],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99936026,0.0000072125895,0.00024812482,0.0001991615,0.00001748846,0.00016774757],"domain_scores_gemma":[0.99952626,0.000108825916,0.00013495027,0.00015811689,0.000016647267,0.000055199296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028073453,0.00009815472,0.0002663788,0.000022268201,0.00009943449,0.000053658016,0.00011875964,0.000075853735,0.000009013314],"category_scores_gemma":[0.000035107783,0.000084889776,0.000078763645,0.0000990944,0.0001576842,0.00003451224,0.00007956997,0.00010414072,0.0000013913104],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000005422346,0.000019731264,0.012220519,0.00007622826,0.00012344836,1.752191e-7,0.0019467833,0.000051592986,0.00022214072,0.95726144,0.02349405,0.004578438],"study_design_scores_gemma":[0.001724965,0.00006223262,0.048270423,0.000034781842,0.000038291088,0.0000021877531,0.00033543978,0.048587922,0.00035741169,0.18040317,0.71996135,0.00022181626],"about_ca_topic_score_codex":0.00007150924,"about_ca_topic_score_gemma":0.0000050265758,"teacher_disagreement_score":0.77685827,"about_ca_system_score_codex":0.000014843067,"about_ca_system_score_gemma":0.00003885905,"threshold_uncertainty_score":0.34617046},"labels":[],"label_agreement":null},{"id":"W4410490267","doi":"10.1073/pnas.2424665122","title":"Framework to identify innovative sources of value creation from platform technologies","year":2025,"lang":"en","type":"review","venue":"Proceedings of the National Academy of Sciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bridgepoint Active Healthcare","funders":"Pfizer","keywords":"Valuation (finance); Value capture; Portfolio; Competitive advantage; Knowledge management; Transformative learning; Emerging technologies; Process management; Business value; Computer science; Business; Risk analysis (engineering); Data science; Value creation; Marketing; Economics","score_opus":0.17395507902883053,"score_gpt":0.42278791214257494,"score_spread":0.2488328331137444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410490267","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005437496,0.96112067,0.000018941726,0.0027607705,0.00010074497,0.00068522524,0.0011611349,0.000024416997,0.028690578],"genre_scores_gemma":[0.045621842,0.9504275,0.0032791174,0.00038246065,0.000095234245,0.000055991317,0.0000017025804,0.000010065041,0.0001261131],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9981252,0.0000027072367,0.00117991,0.0003726971,0.00015988147,0.0001596103],"domain_scores_gemma":[0.99729687,0.0005116288,0.0019887378,0.000020612519,0.00015958643,0.0000225773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012234101,0.00017288394,0.0009486001,0.00087812665,0.000099473866,0.000042327585,0.0015489601,0.00034162877,0.000024616678],"category_scores_gemma":[0.00273088,0.00013601714,0.00021189055,0.0023469867,0.0005862879,0.00028791436,0.00042380605,0.00035423832,0.000010103925],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000028291327,0.00002449559,0.00043310787,0.0015858297,0.00008145433,1.2360797e-9,0.00010563709,0.000010897886,0.000017303955,0.9649245,0.0003587683,0.032455172],"study_design_scores_gemma":[0.000055156157,0.00002098676,0.0008806622,0.0040018214,0.000032168693,4.84157e-7,0.000060734368,0.000084317006,0.0017944187,0.8495331,0.14337501,0.00016114641],"about_ca_topic_score_codex":0.000027701884,"about_ca_topic_score_gemma":4.0358024e-8,"teacher_disagreement_score":0.14301623,"about_ca_system_score_codex":0.00009431562,"about_ca_system_score_gemma":0.00007291063,"threshold_uncertainty_score":0.5546618},"labels":[],"label_agreement":null},{"id":"W4410741822","doi":"10.1080/14787210.2025.2511958","title":"Surge of branded generics and antimicrobial resistance: analyzing the antibiotic market dynamics in Pakistan through the WHO essential medicines and AWaRe lens","year":2025,"lang":"en","type":"article","venue":"Expert Review of Anti-infective Therapy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Antibiotic resistance; Antibiotics; Antimicrobial; Resistance (ecology); Business; Traditional medicine; Medicine; Microbiology; Biology; Ecology","score_opus":0.022668821646140185,"score_gpt":0.3385934287291436,"score_spread":0.3159246070830034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410741822","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45492715,0.5095397,0.0013260717,0.02180272,0.0004051849,0.0010426787,0.00022500691,0.0000128544025,0.0107186455],"genre_scores_gemma":[0.5109882,0.4857355,0.000026326396,0.0031712425,0.00003706979,0.000004193994,0.000004417273,0.000009606087,0.000023427812],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984839,0.00012542552,0.0008225284,0.00031444675,0.000032334377,0.00022135022],"domain_scores_gemma":[0.9988232,0.00034332482,0.00042572065,0.0003253452,0.00005712578,0.000025251815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010736084,0.00020172802,0.0009048128,0.00011660455,0.00011573975,0.00003108329,0.00021160743,0.00007040705,0.000053064086],"category_scores_gemma":[0.00007516805,0.00013904172,0.00014463787,0.00045904086,0.00047689097,0.00013494867,0.00007640299,0.00016769505,5.7815214e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006329398,0.0008003286,0.48056993,0.010787794,0.0018465783,0.0000108074255,0.0061403415,0.00001869298,0.0024717883,0.41512108,0.054752953,0.026846752],"study_design_scores_gemma":[0.012536322,0.00039523255,0.45490757,0.017334823,0.00024586634,0.000030738003,0.001243886,0.010448421,0.014471921,0.039982937,0.44613576,0.0022665458],"about_ca_topic_score_codex":0.00030507732,"about_ca_topic_score_gemma":0.00019332486,"teacher_disagreement_score":0.39138278,"about_ca_system_score_codex":0.00006489139,"about_ca_system_score_gemma":0.00004481744,"threshold_uncertainty_score":0.5669957},"labels":[],"label_agreement":null},{"id":"W4410771339","doi":"10.1371/journal.pone.0304930","title":"Key stakeholders’ views on the causes of medicine stock-outs in Mauritania: A qualitative study","year":2025,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"European Commission","keywords":"Procurement; Business; Essential medicines; Purchasing; Qualitative research; Pharmacy; Sustainability; Corporate governance; Accountability; Thematic analysis; Focus group; Health care; Marketing; Public relations; Medicine; Nursing; Finance; Economic growth; Economics","score_opus":0.49511013128402875,"score_gpt":0.384788650125002,"score_spread":0.11032148115902674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410771339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92051303,0.00088667485,0.000014622277,0.016172923,0.000063660205,0.00072388584,0.0001345873,0.000010684207,0.061479907],"genre_scores_gemma":[0.99552435,0.0001878637,0.000031837884,0.003015716,0.000042029253,0.00008961978,0.0000028826614,0.000012307586,0.0010933863],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.998569,0.00009961919,0.0007814262,0.00028427245,0.000048815822,0.00021682543],"domain_scores_gemma":[0.99877834,0.0005576764,0.00023335963,0.00035294067,0.000028766217,0.00004891602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001350249,0.00014020111,0.0006561725,0.0003009814,0.000047993028,0.000014682453,0.00026812212,0.00005017599,0.00059960736],"category_scores_gemma":[0.0004885497,0.00011742675,0.000050070903,0.00035997722,0.00012969511,0.00006086967,0.00006214813,0.00023750654,0.0001503758],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013581934,0.0070680464,0.018100532,0.00016125977,0.0007901318,0.000004416097,0.09085723,0.0000144753885,0.00019792911,0.8779017,0.0045200186,0.00024845236],"study_design_scores_gemma":[0.017402884,0.0045484286,0.10080865,0.0017546561,0.0003555917,6.52059e-7,0.09684464,0.0051207836,0.0043474883,0.7427736,0.024474427,0.0015681908],"about_ca_topic_score_codex":0.00047480664,"about_ca_topic_score_gemma":0.00041035705,"teacher_disagreement_score":0.13512808,"about_ca_system_score_codex":0.000102121485,"about_ca_system_score_gemma":0.000024218552,"threshold_uncertainty_score":0.656528},"labels":[],"label_agreement":null},{"id":"W4410785113","doi":"10.1093/9780199289011.003.0077","title":"Other Data Exclusivity Periods for Pharmaceuticals","year":2011,"lang":"en","type":"book-chapter","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business","score_opus":0.4203723916308167,"score_gpt":0.3738697711365231,"score_spread":0.0465026204942936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410785113","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00000844913,0.0034083968,0.0053973105,0.0015093331,0.00080545834,0.000684588,0.012652371,0.0000765929,0.9754575],"genre_scores_gemma":[0.0026089386,0.0022994555,0.0017448021,0.015054935,0.0014285658,0.00005264127,0.00043376887,0.00027250408,0.9761044],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99730605,0.000004706125,0.0010091027,0.0011180233,0.000028750614,0.0005333601],"domain_scores_gemma":[0.9974824,0.00013117502,0.0004841672,0.0015461101,0.000034181347,0.00032197605],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00082458917,0.00047103767,0.0009873033,0.00022471364,0.00011988837,0.00010373902,0.0012776186,0.00047794852,0.039008263],"category_scores_gemma":[0.000067759516,0.0005390362,0.00031727558,0.000021113505,0.0001793448,0.00024278322,0.0006769471,0.0003903686,0.006529912],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030666728,0.00003685353,0.000037955033,0.00006800817,0.00022663528,0.0000012002355,0.000032122833,3.930522e-7,0.0000013735803,0.93628585,0.058814704,0.0044642263],"study_design_scores_gemma":[0.0003825816,0.000022928498,0.0000062641857,0.000009260421,0.000029797146,0.0000021176618,4.768295e-7,0.0012827412,0.000010183335,0.38073972,0.6170786,0.0004353027],"about_ca_topic_score_codex":0.00007928312,"about_ca_topic_score_gemma":0.000033843196,"teacher_disagreement_score":0.5582639,"about_ca_system_score_codex":0.0001092914,"about_ca_system_score_gemma":0.000063365194,"threshold_uncertainty_score":0.9997061},"labels":[],"label_agreement":null},{"id":"W4410785146","doi":"10.1093/9780199289011.003.0067","title":"The Pharmaceutical Regulatory Approval Process","year":2011,"lang":"en","type":"book-chapter","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Process (computing); Business; Computer science","score_opus":0.11884694240391803,"score_gpt":0.2976088339147337,"score_spread":0.17876189151081567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410785146","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009055632,0.005515441,0.000075016476,0.0015904593,0.0008331095,0.00035952506,0.00016734638,0.00008191919,0.99128664],"genre_scores_gemma":[0.03525887,0.0044872877,0.000053909767,0.004162605,0.00094860554,0.00004765262,0.000022446839,0.0001672822,0.9548513],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99776065,0.000005397054,0.0009868403,0.000656797,0.000046996844,0.00054331805],"domain_scores_gemma":[0.9984372,0.00009681994,0.00046033208,0.0006608647,0.000040142026,0.00030462342],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0006463644,0.0004193587,0.00060796505,0.00013950237,0.00025143469,0.0001238775,0.00073736423,0.00042255336,0.0072986344],"category_scores_gemma":[0.00003223197,0.0003652503,0.0003428287,0.000027989396,0.0003980131,0.00011597395,0.0001604898,0.00074439944,0.008886023],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026050355,0.000017532751,0.000036054913,0.00003520073,0.00015230116,0.0000029878536,0.000053981134,0.0000010294152,2.8014657e-7,0.9826792,0.012139425,0.0048559965],"study_design_scores_gemma":[0.00016463028,0.000013203061,0.000025566564,0.0000067032406,0.000012076605,0.0000054242378,0.0000016822693,0.00023293024,0.000018909152,0.44378182,0.5554453,0.0002917522],"about_ca_topic_score_codex":0.000015769492,"about_ca_topic_score_gemma":0.000008186992,"teacher_disagreement_score":0.5433059,"about_ca_system_score_codex":0.00012430227,"about_ca_system_score_gemma":0.00007638129,"threshold_uncertainty_score":0.99987996},"labels":[],"label_agreement":null},{"id":"W4410785208","doi":"10.1093/9780199289011.003.0010","title":"Drafting Pharmaceutical Patents","year":2011,"lang":"en","type":"book-chapter","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business","score_opus":0.20637588000820187,"score_gpt":0.2992198143972779,"score_spread":0.09284393438907604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410785208","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000041716994,0.0021738214,0.00024020977,0.00062694424,0.00081887416,0.00022588206,0.0003746071,0.0000986781,0.99539924],"genre_scores_gemma":[0.027857827,0.003168218,0.00028274814,0.0070754522,0.0007104343,0.000014589443,0.00005670841,0.0001780008,0.96065605],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976817,0.0000036872786,0.0010537638,0.00070374494,0.00003146228,0.00052568206],"domain_scores_gemma":[0.99868727,0.000045273347,0.00042466528,0.00044418089,0.000024738905,0.000373879],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00033739145,0.0004349028,0.00078698085,0.00028048642,0.00008720832,0.000074556716,0.0004320288,0.00046178722,0.051707417],"category_scores_gemma":[0.000022358918,0.00051581336,0.00037771006,0.000022914619,0.00012529464,0.00013222359,0.00022700851,0.0006444255,0.03644593],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011254923,0.000024462332,0.00018409168,0.00003165583,0.00015249594,0.000010737993,0.00005585949,6.022399e-7,0.0000010763339,0.9882512,0.006991245,0.00428529],"study_design_scores_gemma":[0.00027052616,0.000017308475,0.000026477383,0.00001483287,0.00001499001,0.00000498111,4.7481885e-7,0.00023344357,0.00001915883,0.34782583,0.65115094,0.00042104637],"about_ca_topic_score_codex":0.00004969671,"about_ca_topic_score_gemma":0.000004636185,"teacher_disagreement_score":0.6441597,"about_ca_system_score_codex":0.00014181457,"about_ca_system_score_gemma":0.000029075367,"threshold_uncertainty_score":0.99972934},"labels":[],"label_agreement":null},{"id":"W4410785284","doi":"10.1093/9780199289011.003.0078","title":"Certified (Listed) Patents and Approval of Generic Drugs","year":2011,"lang":"en","type":"book-chapter","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Certification; Business; Accounting; Law; Political science","score_opus":0.17339035689725518,"score_gpt":0.24916240777988546,"score_spread":0.07577205088263028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410785284","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001802755,0.0026450336,0.000075156895,0.00015983036,0.00030989797,0.0001927414,0.0004191213,0.000021617412,0.99437386],"genre_scores_gemma":[0.22396529,0.007160841,0.0004354836,0.0017922118,0.00028538398,0.000015248107,0.00007543475,0.00013939019,0.7661307],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984106,0.0000028251332,0.0008488799,0.00047266434,0.000021664475,0.00024337621],"domain_scores_gemma":[0.9988979,0.000025165042,0.0005321287,0.00035205565,0.000023525648,0.00016922415],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00019094929,0.00028120037,0.0007387557,0.00024468996,0.000034076536,0.000026962463,0.0002235429,0.00031093444,0.004001721],"category_scores_gemma":[0.000009067898,0.0003146819,0.00018372192,0.000020999332,0.00014552678,0.00007296181,0.00015931191,0.00021370097,0.00083668507],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017273145,0.00002108451,0.00015732985,0.000079584854,0.00012982197,0.0000012270942,0.00011578303,8.775985e-7,0.00000423329,0.99038106,0.001981668,0.0071100537],"study_design_scores_gemma":[0.0004394288,0.00004638889,0.00028269688,0.000017972834,0.000024373318,0.0000033459842,0.0000024531803,0.00047895144,0.00006879978,0.37032416,0.6278603,0.0004510881],"about_ca_topic_score_codex":0.00021789611,"about_ca_topic_score_gemma":0.0000074355316,"teacher_disagreement_score":0.6258787,"about_ca_system_score_codex":0.00004350409,"about_ca_system_score_gemma":0.00002080109,"threshold_uncertainty_score":0.9999413},"labels":[],"label_agreement":null},{"id":"W4411002193","doi":"10.1093/ajhp/zxaf147","title":"Recent and anticipated novel drug approvals (2Q 2025 through 1Q 2026)","year":2025,"lang":"en","type":"article","venue":"American Journal of Health-System Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Formulary; Pipeline (software); Drug; Medicine; Food and drug administration; Quarter (Canadian coin); Drug approval; Family medicine; Medical emergency; Pharmacology; Engineering","score_opus":0.09972721393004036,"score_gpt":0.37745700625177975,"score_spread":0.2777297923217394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411002193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.50549376,0.07977358,0.0129304305,0.33627737,0.005840409,0.0013678132,0.00066325587,0.00011397861,0.05753943],"genre_scores_gemma":[0.9629381,0.022535687,0.0013294438,0.012631601,0.0002596704,0.000013010201,0.000004125165,0.000033387238,0.00025498957],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964649,0.00013136501,0.0023446595,0.0003889845,0.000067041925,0.00060301204],"domain_scores_gemma":[0.99672204,0.00020678941,0.002352738,0.00026352418,0.0001246414,0.00033026753],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002282153,0.00026681,0.0013815595,0.00041330172,0.00021132245,0.00010350985,0.00039544687,0.000032390326,0.00015946763],"category_scores_gemma":[0.00010107914,0.00027852296,0.00018374663,0.000672639,0.00019688012,0.00033151908,0.0001030593,0.000460756,0.00007339904],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008735632,0.0011510389,0.047580484,0.0017224466,0.0019080128,0.000044148277,0.004282134,0.00042199512,0.0003677733,0.2887488,0.08018289,0.5727167],"study_design_scores_gemma":[0.0028391317,0.00013985747,0.0016168611,0.00017871252,0.00003390497,0.000079133795,0.0005616956,0.0035710703,0.00019839677,0.0013810343,0.9891148,0.00028536172],"about_ca_topic_score_codex":0.001238636,"about_ca_topic_score_gemma":0.0000072505018,"teacher_disagreement_score":0.908932,"about_ca_system_score_codex":0.0004309357,"about_ca_system_score_gemma":0.00039204495,"threshold_uncertainty_score":0.9999667},"labels":[],"label_agreement":null},{"id":"W4411094243","doi":"10.1038/s41571-025-01031-z","title":"Surrogate end points in oncology: aligning drug development incentives and patient needs","year":2025,"lang":"en","type":"review","venue":"Nature Reviews Clinical Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Surrogate endpoint; Drug development; Incentive; Oncology; Drug; Internal medicine; Intensive care medicine; Medical physics; Pharmacology","score_opus":0.1841165872883653,"score_gpt":0.47868406450756495,"score_spread":0.2945674772191996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411094243","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006754356,0.96260065,0.000005028256,0.0020377846,0.0023465976,0.0017981913,0.00013149052,0.000022385306,0.030990304],"genre_scores_gemma":[0.000051245406,0.98829144,0.001724522,0.008706672,0.00027433774,0.00033011902,0.0000948128,0.000045840196,0.00048101548],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99030447,0.0011194152,0.0065978006,0.0011984984,0.000046072306,0.0007337361],"domain_scores_gemma":[0.99188834,0.0041133445,0.0030585579,0.0005099093,0.000038906895,0.0003909402],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0071969978,0.000701266,0.00846018,0.0009329194,0.00010044161,0.00004934788,0.0006578033,0.0025927227,0.00023762869],"category_scores_gemma":[0.0030275716,0.0006418506,0.0009385559,0.0007788568,0.00029665543,0.00012772241,0.0007374032,0.0039716535,0.0007082347],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014989864,0.000351096,0.00030160957,0.0044131936,0.0001791259,0.000024548159,0.00019421057,7.948804e-8,3.5278795e-9,0.016063655,0.005791952,0.97266555],"study_design_scores_gemma":[0.00080837164,0.00013872962,0.00008327067,0.004859928,0.000128959,0.000011647262,0.000012661575,0.000006713018,1.2254833e-7,0.0020867938,0.9913021,0.00056071463],"about_ca_topic_score_codex":0.000018300745,"about_ca_topic_score_gemma":0.00011498427,"teacher_disagreement_score":0.9855101,"about_ca_system_score_codex":0.0012150885,"about_ca_system_score_gemma":0.0012064698,"threshold_uncertainty_score":0.9996033},"labels":[],"label_agreement":null},{"id":"W4411170659","doi":"10.17161/gjcpp.v9i2.20712","title":"Access to Indigenous and allopathic medicines: A systematic review of barriers and facilitators","year":2018,"lang":"en","type":"review","venue":"Global Journal of Community Psychology Practice","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal","funders":"","keywords":"Indigenous; Traditional medicine; Medicine; Biology; Ecology","score_opus":0.15300739185184553,"score_gpt":0.4731624022940539,"score_spread":0.32015501044220834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411170659","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003320501,0.99181974,0.000098039185,0.0026314845,0.00046734407,0.0008240839,0.0003518276,0.0000046840473,0.0034707342],"genre_scores_gemma":[0.00026042422,0.97973883,0.00017170525,0.019714558,0.000071386916,0.000015969896,0.000004433099,0.00001799133,0.0000046695886],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99504614,0.0015030091,0.0028965075,0.00019708998,0.00006984626,0.00028742978],"domain_scores_gemma":[0.9925644,0.0013004534,0.0046669757,0.00070316973,0.00026223145,0.00050281413],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00896916,0.00033948806,0.00389911,0.0003497049,0.00015078411,0.0000721872,0.00128582,0.00030395368,0.000054493146],"category_scores_gemma":[0.010705635,0.00030377932,0.00029096977,0.00044068866,0.00031542667,0.0004599265,0.00036563652,0.001224146,0.00005160559],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007249122,0.0001677796,0.00017610239,0.96566623,0.001840668,0.00002700043,0.0014397239,1.2697167e-7,1.8326965e-8,0.001979073,0.007256098,0.0213747],"study_design_scores_gemma":[0.00033623024,0.00044825903,0.000046235436,0.13945566,0.0012689828,0.002639325,0.00013813787,3.2993395e-7,1.1419661e-8,0.0024681927,0.85295767,0.00024098138],"about_ca_topic_score_codex":0.000080486214,"about_ca_topic_score_gemma":0.00000658698,"teacher_disagreement_score":0.8457016,"about_ca_system_score_codex":0.00015739337,"about_ca_system_score_gemma":0.00020234555,"threshold_uncertainty_score":0.9999414},"labels":[],"label_agreement":null},{"id":"W4411254450","doi":"10.1101/2025.06.11.25329435","title":"Social and private value created through commercialization of Gilead Sciences’ innovative medicines for Hepatitis C and HIV: a cross-sectional analysis","year":2025,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Quest University Canada","funders":"Bentley University","keywords":"Commercialization; Cross-sectional study; Value (mathematics); Human immunodeficiency virus (HIV); Medicine; Political science; Psychology; Sociology; Virology; Computer science","score_opus":0.1420615727454391,"score_gpt":0.40017154643666814,"score_spread":0.258109973691229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411254450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9752406,0.0006669268,0.014066385,0.0020562457,0.0002927343,0.0004137916,0.002760832,0.00001742615,0.0044850507],"genre_scores_gemma":[0.99613774,0.0010639079,0.0010044224,0.0011414818,0.00018223278,0.00007187714,0.00023589176,0.000011643328,0.00015080038],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982772,0.000028853146,0.0008806576,0.00056438294,0.000041658415,0.00020724375],"domain_scores_gemma":[0.9988139,0.00018919988,0.0006670653,0.00014045415,0.00014587019,0.00004349337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086029846,0.00019816497,0.0007769076,0.0005221486,0.0002475697,0.00010832322,0.00020545702,0.00023238761,0.00005684598],"category_scores_gemma":[0.00027811364,0.00022386665,0.00013044708,0.000842933,0.00057370594,0.00011534954,0.00028346595,0.00018552839,0.0000015677632],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017698185,0.000022951905,0.69774175,0.00014763934,0.00035649745,1.1456208e-7,0.00039235162,0.0002610302,0.0000048699203,0.30086237,0.00013695033,0.000055764136],"study_design_scores_gemma":[0.0005801663,0.000033187294,0.8252569,0.000023014341,0.000088065775,3.4747774e-7,0.000007915542,0.033844706,0.00009243131,0.1343591,0.005504405,0.00020976292],"about_ca_topic_score_codex":0.0006417235,"about_ca_topic_score_gemma":0.00005746571,"teacher_disagreement_score":0.16650325,"about_ca_system_score_codex":0.00006595028,"about_ca_system_score_gemma":0.00007494087,"threshold_uncertainty_score":0.9129017},"labels":[],"label_agreement":null},{"id":"W4411460274","doi":"10.35629/4494-100227652769","title":"Pharmaceutical regulatory agencies and organization around the world scope and challenges in drug development","year":2025,"lang":"en","type":"article","venue":"International Journal of Pharmaceutical Research and Applications","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Transparency (behavior); Harmonization; Scope (computer science); Agency (philosophy); Drug development; Regulatory science; Globalization; Public relations; Medicine; Political science; Pharmacology; Drug","score_opus":0.23045994455796437,"score_gpt":0.4367126384633554,"score_spread":0.20625269390539103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411460274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6713467,0.1300375,0.0015136227,0.16456804,0.0004048974,0.00089869485,0.00005279689,0.000019795214,0.031157918],"genre_scores_gemma":[0.9511437,0.047037166,0.00023201374,0.0009471317,0.00019645879,0.00003217737,0.0000022621014,0.000009015238,0.0004000961],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988087,0.000050210198,0.0005677238,0.00022760149,0.00011501516,0.00023079077],"domain_scores_gemma":[0.9988404,0.00055407383,0.000110026296,0.000094027586,0.0002162527,0.00018522805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018848116,0.00009630486,0.0001856583,0.00055117765,0.00016911983,0.00017892904,0.00032435654,0.000039705086,0.000072339986],"category_scores_gemma":[0.00019511546,0.00008515095,0.00002093745,0.0003369381,0.00040356722,0.00019038536,0.00025463366,0.00047421188,0.000015919735],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005727699,0.0001448057,0.01302228,0.00005865214,0.00012308557,0.000004729289,0.00033218527,0.000008669507,0.00023321,0.9270249,0.00087089796,0.058119297],"study_design_scores_gemma":[0.0009644268,0.000013850246,0.026943289,0.000057601643,0.0000075557105,0.000027124996,0.0002896603,0.0011929655,0.0018133357,0.070996456,0.8975794,0.00011436631],"about_ca_topic_score_codex":0.000009496495,"about_ca_topic_score_gemma":0.000035151683,"teacher_disagreement_score":0.8967085,"about_ca_system_score_codex":0.00016900052,"about_ca_system_score_gemma":0.0001181704,"threshold_uncertainty_score":0.34723547},"labels":[],"label_agreement":null},{"id":"W4411660605","doi":"10.51847/g68bgxyh0y","title":"10.51847/g68BGxyH0y","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Rivaroxaban; Drug; Medicine; Pharmacology; Internal medicine","score_opus":0.029545278218479097,"score_gpt":0.22240923156837925,"score_spread":0.19286395334990014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411660605","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0031077757,0.00024161683,0.000001889052,0.0026390126,0.000008491402,0.00012795633,0.00016598433,0.000060090966,0.99364716],"genre_scores_gemma":[0.0028289487,0.0000068332242,0.00008890322,0.0015670256,0.00020645602,0.000017548717,0.0000120178065,0.000028065386,0.9952442],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989394,0.000006670199,0.00038677192,0.0003033309,0.000016077152,0.00034777785],"domain_scores_gemma":[0.99936706,0.00002944152,0.00005667293,0.00029207306,0.000008649851,0.00024612993],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00022065068,0.00013174072,0.0002826629,0.00012016518,0.00006330854,0.0000670607,0.0002582011,0.0000666646,0.99515885],"category_scores_gemma":[0.000028290706,0.00016521341,0.000093965595,0.00015853191,0.000023140577,0.0001180925,0.000039959905,0.00009844041,0.9964907],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000063579726,0.000103025144,0.000008736164,0.000008607644,0.000050996216,0.000003531584,0.000034338726,0.00026022425,0.0000078930425,0.0035666474,0.13668363,0.85920876],"study_design_scores_gemma":[0.0002667276,0.000050415634,0.00011519819,0.000002676014,0.0000027449955,0.0000027137764,1.4770724e-7,0.0018279066,0.000009455716,0.000712514,0.99678594,0.00022354646],"about_ca_topic_score_codex":0.000056840832,"about_ca_topic_score_gemma":1.9885647e-7,"teacher_disagreement_score":0.8601023,"about_ca_system_score_codex":0.000082500876,"about_ca_system_score_gemma":0.000011702045,"threshold_uncertainty_score":0.6737208},"labels":[],"label_agreement":null},{"id":"W4411730067","doi":"10.25040/ntsh2025.01.22","title":"DIRECTIONS FOR IMPROVING PATIENTS’ ACCESS TO TREATMENT IN UKRAINE: CHALLENGES AND NEW OPPORTUNITIES FOR PHARMACEUTICAL PROVISION IN WARTIME","year":2025,"lang":"en","type":"article","venue":"Proceedings of the Shevchenko Scientific Society Medical Sciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Business; Process management; Medicine; Engineering management; Engineering","score_opus":0.26532890988373137,"score_gpt":0.37884841326584384,"score_spread":0.11351950338211247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411730067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90279233,0.002842877,0.00010125654,0.087904066,0.00092560396,0.0017303777,0.00007381754,0.000019034795,0.0036106154],"genre_scores_gemma":[0.9940636,0.0014969934,0.0013381126,0.001580132,0.000095847034,0.00037282574,0.0000023856378,0.000010350671,0.0010397636],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984317,0.0000043176865,0.000522193,0.0005477809,0.00009795336,0.00039608372],"domain_scores_gemma":[0.99928963,0.0002371659,0.0001455873,0.00007152339,0.000052148316,0.00020393745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023647575,0.00012537606,0.00029438842,0.00020842854,0.00027189747,0.00021621918,0.0005936095,0.00009108691,0.00001846934],"category_scores_gemma":[0.0010276333,0.000098162294,0.00014038594,0.00056855596,0.00052004063,0.0003617686,0.0002671808,0.00009186766,7.93285e-7],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011060503,0.0011253231,0.07820893,0.0009923442,0.00007805151,1.072763e-7,0.011691401,0.000028229726,0.0004602012,0.33409804,0.01684127,0.5563655],"study_design_scores_gemma":[0.008175268,0.00071999116,0.06404295,0.00052868744,0.00006245683,0.0000012675947,0.0046437187,0.1479796,0.0070444234,0.22570568,0.5402127,0.00088324986],"about_ca_topic_score_codex":0.00012839913,"about_ca_topic_score_gemma":0.00008107091,"teacher_disagreement_score":0.55548227,"about_ca_system_score_codex":0.00016190922,"about_ca_system_score_gemma":0.0002243443,"threshold_uncertainty_score":0.4002942},"labels":[],"label_agreement":null},{"id":"W4411873872","doi":"10.2196/65978","title":"Financial Feasibility of Developing Sustained-Release Incrementally Modified Drugs in Thailand’s Pharmaceutical Industry: Mixed Methods Study","year":2025,"lang":"en","type":"article","venue":"JMIRx Med","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Timeline; Activity-based costing; Investment (military); Clinical trial; Business; Pharmaceutical industry; Payback period; Process (computing); Operations management; Finance; Risk analysis (engineering); Actuarial science; Operations research; Computer science; Medicine; Marketing; Economics; Engineering; Pharmacology; Production (economics); Geography","score_opus":0.10734961138691243,"score_gpt":0.419332029649971,"score_spread":0.3119824182630586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411873872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97812724,0.00028347078,0.0013892202,0.0044591855,0.00049606746,0.0011122961,0.00008689787,0.000031244326,0.014014376],"genre_scores_gemma":[0.99640447,0.000042853328,0.0012287447,0.0014366024,0.000058765967,0.000118624506,0.000011471345,0.000018695124,0.0006797972],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972813,0.00021114675,0.0013417484,0.00059126195,0.000053782223,0.00052076665],"domain_scores_gemma":[0.9988322,0.00028332067,0.00029086624,0.00039922053,0.000056486107,0.00013786892],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0030674175,0.00025474542,0.0008188312,0.0005230568,0.00007806628,0.000044725595,0.0004350971,0.0002850617,0.00017345625],"category_scores_gemma":[0.00092479395,0.00029745715,0.00013414814,0.0007417622,0.00010997527,0.00015794457,0.00030777848,0.00068028306,0.000023388944],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083077257,0.002190757,0.5015486,0.0003075372,0.00023353148,0.000013403294,0.0021377571,0.0001725116,0.00026357386,0.47439557,0.003939508,0.013966483],"study_design_scores_gemma":[0.022025056,0.0003180853,0.6990586,0.0001317552,0.000092098504,0.0000021236772,0.0031443038,0.02774955,0.006906774,0.18592042,0.053075474,0.001575757],"about_ca_topic_score_codex":0.00040416062,"about_ca_topic_score_gemma":0.00011893816,"teacher_disagreement_score":0.28847516,"about_ca_system_score_codex":0.0005319916,"about_ca_system_score_gemma":0.00031818872,"threshold_uncertainty_score":0.9999477},"labels":[],"label_agreement":null},{"id":"W4411924841","doi":"10.1002/pds.70178","title":"Impact of Supply Chain Disruptions and Drug Shortages on Drug Utilization: A Scoping Review","year":2025,"lang":"en","type":"review","venue":"Pharmacoepidemiology and Drug Safety","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; St. Francis Xavier University; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Grey literature; Medicine; Observational study; Economic shortage; Drug; Medical prescription; Population; MEDLINE; Environmental health; Pharmacology; Pathology","score_opus":0.15614154994512472,"score_gpt":0.4606250153813216,"score_spread":0.30448346543619687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411924841","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000045193465,0.98717165,0.00011261773,0.0029504565,0.00038190623,0.0015902806,0.0027045158,0.00003489487,0.005008501],"genre_scores_gemma":[0.0005069918,0.99517125,0.00006803427,0.0029447947,0.00019714239,0.0001826379,0.0003541424,0.000041265168,0.0005337494],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951087,0.0007136387,0.0026227282,0.0009654532,0.000028811954,0.0005606232],"domain_scores_gemma":[0.9936898,0.0042214813,0.001289569,0.00045417523,0.0000338535,0.00031117152],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00432454,0.0006458543,0.0045012324,0.00047341353,0.00022563498,0.000022321492,0.00035422493,0.00022461775,0.0007077741],"category_scores_gemma":[0.0010762201,0.00059124787,0.0008118291,0.0003781176,0.00030233595,0.00015471134,0.00026196815,0.00072364905,0.000065602966],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007525838,0.0002797743,0.0054976996,0.19707602,0.001352401,0.000011792856,0.00021244283,0.00003994909,6.829136e-8,0.12785164,0.05118572,0.6164172],"study_design_scores_gemma":[0.0007575335,0.000039312887,0.00049518835,0.10191551,0.00070552854,0.000033748252,0.000005351282,0.000494751,5.4591743e-7,0.0048564514,0.8897792,0.0009168822],"about_ca_topic_score_codex":0.00017111242,"about_ca_topic_score_gemma":0.000026030708,"teacher_disagreement_score":0.8385935,"about_ca_system_score_codex":0.00014142845,"about_ca_system_score_gemma":0.00024021463,"threshold_uncertainty_score":0.9996539},"labels":[],"label_agreement":null},{"id":"W4412136694","doi":"10.17480/psk.2025.69.3.233","title":"Comparison of the Collection Status of Unused Medicines Domestically and Internationally and Derivation of Policy Implications","year":2025,"lang":"en","type":"article","venue":"Yakhak Hoeji","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business","score_opus":0.05404561871012296,"score_gpt":0.3692358187901013,"score_spread":0.31519020007997833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412136694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97140026,0.0007714542,0.0015541229,0.009614353,0.00009706826,0.00017570975,0.00014133306,0.0000043900227,0.016241278],"genre_scores_gemma":[0.9987939,0.0005003374,0.00023744741,0.00034063935,0.00001776327,0.000006792866,0.0000045036336,0.0000037420787,0.00009487996],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99926746,0.000009457485,0.0005059984,0.0001097287,0.000017341588,0.00008998954],"domain_scores_gemma":[0.99930316,0.00017672892,0.0003033841,0.00012222289,0.000059000435,0.000035473717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013185458,0.00005454247,0.00024010071,0.0002197764,0.000036706027,0.00000729986,0.00008617674,0.00004104044,0.000015478468],"category_scores_gemma":[0.00045559756,0.00005087191,0.000030319052,0.00029925632,0.00016681815,0.00004374543,0.000059432557,0.00005203144,5.666661e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000134172915,0.00004757353,0.3878702,0.00005383194,0.000035921606,4.940255e-9,0.00025299538,0.000027234915,0.001198206,0.6087208,0.0003753864,0.0014044676],"study_design_scores_gemma":[0.0005293429,0.000037640642,0.8992336,0.000025405969,0.000012102569,4.3724305e-7,0.000038155762,0.0039919224,0.0021707441,0.08796837,0.005946256,0.00004601486],"about_ca_topic_score_codex":0.00044510182,"about_ca_topic_score_gemma":0.00006517591,"teacher_disagreement_score":0.5207524,"about_ca_system_score_codex":0.000042705055,"about_ca_system_score_gemma":0.00007791809,"threshold_uncertainty_score":0.20744962},"labels":[],"label_agreement":null},{"id":"W4412264885","doi":"","title":"Ethicists’ commentary on appropriate use of pharmaceuticals","year":2022,"lang":"en","type":"article","venue":"Research at the University of Copenhagen (University of Copenhagen)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Computer science","score_opus":0.23526841565592915,"score_gpt":0.3347452267743214,"score_spread":0.09947681111839224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412264885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77101445,0.003677724,0.0005681784,0.016330827,0.00018935915,0.0012791174,0.0027830284,0.000028286375,0.20412906],"genre_scores_gemma":[0.89816296,0.0006897361,0.00020996369,0.00083763845,0.000017937908,3.3842463e-7,0.00004992526,0.000019630977,0.10001184],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99785703,0.00056017895,0.00036108276,0.00044709985,0.0002804458,0.00049414026],"domain_scores_gemma":[0.9977509,0.0007857306,0.00040598266,0.0006810937,0.00014128798,0.00023500953],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0027848391,0.00016640274,0.00059584016,0.00035041937,0.0011526179,0.000018970897,0.0015043146,0.000092974835,0.3814939],"category_scores_gemma":[0.00008935835,0.00021650514,0.00029702764,0.00068484823,0.0009501437,0.0003100873,0.0018282912,0.0007517099,0.01643512],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013697145,0.00039753428,0.00004450534,0.00009364787,0.00030279218,0.000040590807,0.002477637,0.0016476524,0.0010612436,0.012187517,0.97941715,0.0009599979],"study_design_scores_gemma":[0.0016113172,0.00035128067,0.0014700114,0.000016387752,0.00003292057,0.0000025009115,0.0018382607,0.0036236243,0.0015017852,0.00028562036,0.98906416,0.00020214933],"about_ca_topic_score_codex":0.0024561484,"about_ca_topic_score_gemma":0.00012979154,"teacher_disagreement_score":0.36505878,"about_ca_system_score_codex":0.0005163202,"about_ca_system_score_gemma":0.00013111003,"threshold_uncertainty_score":0.9843307},"labels":[],"label_agreement":null},{"id":"W4412442816","doi":"10.1016/j.jval.2025.04.398","title":"EE106 Pressures Behind the Rising Costs in Canadian Private Drug Plans: 2018-2023","year":2025,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Government of Canada","funders":"","keywords":"Business; Drug; Natural resource economics; Economics; Pharmacology; Medicine","score_opus":0.06595050093101903,"score_gpt":0.3183061291014316,"score_spread":0.25235562817041257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412442816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84819394,0.017450655,0.000025717662,0.07034803,0.0014970271,0.0009510188,0.00086666626,0.000022618646,0.06064432],"genre_scores_gemma":[0.98809546,0.002024798,0.000043243646,0.009156379,0.000085137166,0.000026404163,0.000010346457,0.000014185772,0.0005440698],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981485,0.00007648238,0.0007600732,0.0003176639,0.00002029285,0.0006769711],"domain_scores_gemma":[0.9990987,0.0002216192,0.00016106619,0.00030425529,0.000005406655,0.00020891787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019246637,0.00012592379,0.00033144467,0.0005332626,0.00013915279,0.00007859457,0.00034717596,0.00007708671,0.00007414432],"category_scores_gemma":[0.00014970049,0.0001311114,0.000045161407,0.0003020814,0.000047955487,0.000100979196,0.000057180623,0.00037471933,0.00016277225],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019429137,0.00006072171,0.34461164,0.00014487951,0.000028787943,0.000006896751,0.0016733928,0.011122774,8.874886e-7,0.6216325,0.018390294,0.00230775],"study_design_scores_gemma":[0.00065519335,0.000014852546,0.18787163,0.00014696139,0.0000016783725,0.0000010987709,0.000056062345,0.05955341,0.000011085491,0.06462779,0.6868588,0.00020145622],"about_ca_topic_score_codex":0.8734664,"about_ca_topic_score_gemma":0.546375,"teacher_disagreement_score":0.6684685,"about_ca_system_score_codex":0.00096451456,"about_ca_system_score_gemma":0.00041511818,"threshold_uncertainty_score":0.53465676},"labels":[],"label_agreement":null},{"id":"W4412443590","doi":"10.1016/j.jval.2025.04.877","title":"HPR153 The Reimbursement Status of Ustekinumab Across HTAs: A Global Perspective","year":2025,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Ustekinumab; Reimbursement; Perspective (graphical); Medicine; Data science; Computer science; Internal medicine; Economics; Economic growth; Artificial intelligence; Disease","score_opus":0.10754833739723527,"score_gpt":0.40213819708472887,"score_spread":0.2945898596874936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412443590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7699216,0.032663707,0.00064883905,0.0616656,0.001538023,0.0012372688,0.0022839156,0.000036872483,0.1300042],"genre_scores_gemma":[0.99262714,0.0025387492,0.00014218596,0.004452697,0.000050890652,0.000023850302,0.0000032829764,0.000007392197,0.00015380359],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9981796,0.000054234177,0.0008102962,0.0003089951,0.000027224893,0.0006196634],"domain_scores_gemma":[0.9991212,0.00011170117,0.00029717415,0.0003319046,0.000026713647,0.00011131784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001049541,0.00011527597,0.00038594494,0.00008654187,0.00009988426,0.00003255985,0.00025386416,0.00005785169,0.00006635565],"category_scores_gemma":[0.00017499128,0.00011184591,0.000093752846,0.0004448911,0.00010276392,0.00006103795,0.00010950112,0.00018963916,0.000058985697],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030002453,0.00009757842,0.034994826,0.000069773574,0.000036800087,5.6274945e-7,0.0013961282,0.001825631,4.2172329e-7,0.9588049,0.0012051864,0.0015381793],"study_design_scores_gemma":[0.0019821494,0.00015460096,0.109710865,0.00010606229,0.000004382416,0.0000018657659,0.002599956,0.023938853,0.0000235123,0.53383833,0.32739732,0.00024211],"about_ca_topic_score_codex":0.033286877,"about_ca_topic_score_gemma":0.00048710458,"teacher_disagreement_score":0.4249666,"about_ca_system_score_codex":0.0017535466,"about_ca_system_score_gemma":0.0002864002,"threshold_uncertainty_score":0.97315055},"labels":[],"label_agreement":null},{"id":"W4412752731","doi":"10.31579/2835-7957/036","title":"The Determinants of Study Productivity in Ethical Drug Discovery","year":2023,"lang":"en","type":"article","venue":"Clinical Reviews and Case Reports","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Calgary","keywords":"Drug discovery; Productivity; Drug; Business; Medicine; Pharmacology; Economics; Biology; Bioinformatics; Economic growth","score_opus":0.2354669300811779,"score_gpt":0.4596220946425224,"score_spread":0.22415516456134452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412752731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99016476,0.006657823,0.0000016700532,0.0013302899,0.00050520967,0.0006485198,0.0000107691085,0.000007995059,0.0006729785],"genre_scores_gemma":[0.9755032,0.023653602,0.000006196025,0.00027151575,0.00011270708,0.00005762561,9.020345e-7,0.000009964389,0.0003842991],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966621,0.0001590597,0.0024432908,0.0004750838,0.000026820737,0.00023365577],"domain_scores_gemma":[0.9979141,0.00069073756,0.00075813534,0.00051463407,0.000013001208,0.00010939978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013697147,0.00011540668,0.00080690073,0.000060613747,0.00009187236,0.000052865344,0.0000715115,0.00009307599,0.000010076913],"category_scores_gemma":[0.0037824202,0.0000842158,0.00017624274,0.0002459755,0.00017834599,0.00010143611,0.00016701053,0.00043259448,0.000040575564],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016689719,0.00027254602,0.9314633,0.00009177922,0.000019024255,0.0030995058,0.00017437016,0.0000012692225,3.5947798e-7,0.0037075153,0.0015974975,0.05955615],"study_design_scores_gemma":[0.000611705,0.0001892407,0.35362932,0.00009163171,0.000026252115,0.0013436743,0.0001284043,0.0009933345,0.000007945465,0.041966297,0.6006643,0.000347896],"about_ca_topic_score_codex":0.00016958527,"about_ca_topic_score_gemma":0.00052040105,"teacher_disagreement_score":0.5990668,"about_ca_system_score_codex":0.000015479136,"about_ca_system_score_gemma":0.00002941769,"threshold_uncertainty_score":0.4747185},"labels":[],"label_agreement":null},{"id":"W4412840461","doi":"10.1186/s12913-025-13211-9","title":"Decolonizing global health: Africa’s pursuit of pharmaceutical sovereignty","year":2025,"lang":"en","type":"review","venue":"BMC Health Services Research","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario","funders":"","keywords":"Medicine; Health informatics; Nursing research; Public health; Health administration; Sovereignty; Healthcare policy; Health policy; International health; Nursing; Political science; Law; Politics","score_opus":0.3543299700210595,"score_gpt":0.5415522939152496,"score_spread":0.18722232389419013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412840461","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000041195203,0.93909913,0.00007007584,0.0008429977,0.00061095797,0.0021566052,0.0039547137,0.000047164616,0.053214256],"genre_scores_gemma":[0.00020891706,0.9956673,0.00051325257,0.0022358184,0.00037808158,0.00026544658,0.00016885184,0.00006519926,0.00049716834],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99164605,0.0007849898,0.0035873693,0.0013198382,0.00029042538,0.0023713552],"domain_scores_gemma":[0.9947405,0.0013745301,0.0014686689,0.0010696106,0.00015023029,0.0011964875],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.009007473,0.00057545135,0.0042265733,0.0010568199,0.00046233129,0.00023202335,0.0023881875,0.0005546672,0.00113578],"category_scores_gemma":[0.00015175542,0.0006345184,0.00075927196,0.002253311,0.00021333626,0.00018525489,0.0012553913,0.0015051722,0.0013334156],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031650492,0.00028964924,0.00026800248,0.22296076,0.00018408323,0.0000026619819,0.0002191818,0.000005002246,3.5524839e-9,0.31793323,0.0026798146,0.45542595],"study_design_scores_gemma":[0.00047743655,0.0001413384,0.000063571366,0.007421682,0.000018786082,0.0000056885574,0.000052094034,0.0006363583,1.1053282e-7,0.02357942,0.96725136,0.00035215242],"about_ca_topic_score_codex":0.0012101439,"about_ca_topic_score_gemma":0.00028438153,"teacher_disagreement_score":0.96457154,"about_ca_system_score_codex":0.0029539985,"about_ca_system_score_gemma":0.0061918604,"threshold_uncertainty_score":0.9997773},"labels":[],"label_agreement":null},{"id":"W4412910932","doi":"10.3389/fpubh.2025.1588227","title":"Lessons learned from redesigning public health medicines supply chain model in Uttar Pradesh, India","year":2025,"lang":"en","type":"review","venue":"Frontiers in Public Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Manitoba Health","funders":"University of Manitoba; Bill and Melinda Gates Foundation","keywords":"Procurement; Business; Essential medicines; Supply chain; Vendor; Health facility; Operations management; Call for bids; Public health; Medicine; Marketing; Environmental health; Engineering","score_opus":0.3267707216040615,"score_gpt":0.40658743431958383,"score_spread":0.07981671271552232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412910932","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000006227471,0.8451221,0.008057662,0.13605873,0.0017549983,0.0015760851,0.0027365207,0.00007550459,0.004612184],"genre_scores_gemma":[0.00034589428,0.9763464,0.005370475,0.0149550345,0.00036999813,0.00043353127,0.0014282331,0.0001292438,0.00062124594],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99057335,0.00069147086,0.0043070815,0.0018124913,0.00012783743,0.0024877784],"domain_scores_gemma":[0.99504554,0.00040889377,0.0022089183,0.0010471786,0.00003273445,0.001256737],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.008821378,0.00083983014,0.0058218357,0.0046227737,0.00024210461,0.00032210056,0.0014528657,0.00082198065,0.00014069748],"category_scores_gemma":[0.0011965455,0.0009782241,0.00046724835,0.002260213,0.00017723725,0.0005397782,0.00032462247,0.0022578018,0.00007678418],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000004168164,0.0002265029,0.0016494965,0.0054575983,0.00015559232,0.000005810356,0.0012807215,0.00003068954,1.727463e-9,0.062472507,0.08117862,0.8475383],"study_design_scores_gemma":[0.0009193488,0.000052181585,0.00016560117,0.0026451596,0.000009307464,0.000001961987,0.00014092939,0.012980133,6.4724905e-9,0.028706742,0.9537376,0.00064098625],"about_ca_topic_score_codex":0.0028286264,"about_ca_topic_score_gemma":0.00038926682,"teacher_disagreement_score":0.872559,"about_ca_system_score_codex":0.004729705,"about_ca_system_score_gemma":0.009619693,"threshold_uncertainty_score":0.9992668},"labels":[],"label_agreement":null},{"id":"W4413092746","doi":"10.2139/ssrn.5354318","title":"Lagged-Price Reimbursement Contracts: The Impact of Medicare Part B on Pharmaceutical Price Growth","year":2025,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"","keywords":"Reimbursement; Economics; Business; Monetary economics; Actuarial science; Health care; Economic growth","score_opus":0.042356727904565065,"score_gpt":0.3385289669320769,"score_spread":0.29617223902751183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413092746","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32316306,0.12527244,0.0074082254,0.09109404,0.008662521,0.0039033105,0.004862777,0.00018987033,0.43544376],"genre_scores_gemma":[0.9226727,0.07255831,0.000021084881,0.0024725553,0.0011321381,0.000045736033,0.000032791544,0.00004556562,0.0010191051],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99472827,0.00014650954,0.0016670403,0.00064178585,0.00014618275,0.0026702376],"domain_scores_gemma":[0.9969773,0.00042495938,0.0014736829,0.0006475794,0.0001501437,0.00032630854],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0052589295,0.0005228892,0.0010751173,0.0003948873,0.00023157249,0.00014459748,0.0014375076,0.0003992272,0.0006375859],"category_scores_gemma":[0.000587081,0.00042029927,0.00094636134,0.00026056386,0.0001793112,0.00011304973,0.00043293415,0.007318887,0.00014036255],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029280226,0.00048416018,0.00246767,0.00010005531,0.0030698562,0.0000056552403,0.000275552,0.0013997955,0.000008047962,0.97777,0.010577454,0.0035489812],"study_design_scores_gemma":[0.0023784551,0.00055383705,0.0017826319,0.0002392192,0.00016463989,0.000069551505,0.00017560754,0.0045350306,0.00012104469,0.8898207,0.09942522,0.0007340367],"about_ca_topic_score_codex":0.0004111202,"about_ca_topic_score_gemma":0.00004201765,"teacher_disagreement_score":0.59950966,"about_ca_system_score_codex":0.003348567,"about_ca_system_score_gemma":0.003320435,"threshold_uncertainty_score":0.9998249},"labels":[],"label_agreement":null},{"id":"W4413228424","doi":"10.22541/au.175489038.81543204/v1","title":"Maximizing Medicine Access through Trade Credit Optimization in Subsidized Fixed-Price Markets","year":2025,"lang":"en","type":"preprint","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Subsidy; Business; Economics; Monetary economics; Market economy","score_opus":0.13751882401341683,"score_gpt":0.35093172933214944,"score_spread":0.2134129053187326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413228424","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004055496,0.0065800096,0.054454044,0.043831926,0.0037603632,0.0011807423,0.000751881,0.000166872,0.8852187],"genre_scores_gemma":[0.83192647,0.07221701,0.03218053,0.048419558,0.003260619,0.00075725367,0.0013649663,0.00026800463,0.009605568],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99647856,0.000054389002,0.0017535004,0.0010723879,0.00005144462,0.00058969646],"domain_scores_gemma":[0.99811274,0.0002957689,0.0006945309,0.000717741,0.000024980824,0.00015426068],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010181353,0.0004746927,0.0013301943,0.00069655676,0.0000807142,0.00020855687,0.0011571785,0.0005716363,0.005265346],"category_scores_gemma":[0.00036506704,0.0005494694,0.00021538098,0.00048515762,0.00010653051,0.0004347744,0.0009884748,0.0009235338,0.00007108763],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041361433,0.0005412966,0.017750064,0.0018389488,0.0006232737,0.000036610603,0.0023808738,0.2662515,0.0000058787127,0.61378926,0.09422448,0.002144184],"study_design_scores_gemma":[0.0043466683,0.000033757147,0.0097514875,0.00047843487,0.00005141365,0.0000037252635,0.000055050314,0.5472535,0.00011749196,0.22968908,0.20680937,0.0014100448],"about_ca_topic_score_codex":0.0014158454,"about_ca_topic_score_gemma":0.000083595995,"teacher_disagreement_score":0.8756131,"about_ca_system_score_codex":0.00045136863,"about_ca_system_score_gemma":0.00012720887,"threshold_uncertainty_score":0.99969566},"labels":[],"label_agreement":null},{"id":"W4413418246","doi":"10.1001/jamahealthforum.2025.2631","title":"Estimating Costs of Market Exclusivity Extensions For 4 Top-Selling Prescription Drugs in the US","year":2025,"lang":"en","type":"article","venue":"JAMA Health Forum","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicare Part D; Competition (biology); Prescription drug; Generic drug; Biosimilar; Market share; Managed care; Business; Drug prices; Actuarial science; Medical prescription; Orphan drug; Marketing; Health care; Medicine; Economics; Public economics; Drug; Pharmacology","score_opus":0.046400109252674154,"score_gpt":0.3416201360266369,"score_spread":0.29522002677396275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413418246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70830965,0.005542183,0.04258825,0.1758258,0.0023031617,0.0028024658,0.0009636374,0.000045020523,0.06161983],"genre_scores_gemma":[0.97936124,0.0003032912,0.0026814141,0.017300949,0.000086214706,0.00008291153,0.000013479239,0.000010245464,0.00016027351],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99854785,0.000040451443,0.0007558329,0.00023707534,0.000021056403,0.00039776147],"domain_scores_gemma":[0.9989585,0.00038662695,0.00032022907,0.0002493136,0.000024729492,0.000060597045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021045895,0.00009654874,0.00033267168,0.00019059161,0.00017778446,0.000045791163,0.00021020496,0.000078277866,0.000032882577],"category_scores_gemma":[0.00032076496,0.00009624753,0.000092963164,0.00021082142,0.000032972242,0.00014115502,0.00005802465,0.00018770243,0.000009599471],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010777985,0.00018704218,0.032040797,0.00048537625,0.000024074227,2.9563117e-7,0.0010039654,0.0014088626,0.000007126042,0.8877806,0.044557463,0.03239664],"study_design_scores_gemma":[0.0014834235,0.000074485906,0.037615232,0.00019019045,0.0000049017335,0.0000012609065,0.000263353,0.65991765,0.000029714287,0.16251603,0.1377305,0.00017327134],"about_ca_topic_score_codex":0.0010848859,"about_ca_topic_score_gemma":0.00024163754,"teacher_disagreement_score":0.72526455,"about_ca_system_score_codex":0.00019294408,"about_ca_system_score_gemma":0.00008046086,"threshold_uncertainty_score":0.39248604},"labels":[],"label_agreement":null},{"id":"W4413524744","doi":"10.64628/aam.pdkrm3vgr","title":"With a pharmacare bill on the horizon, Big Pharma’s attack on single-payer drug coverage for Canadians needs a fact check","year":2023,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University; University of Toronto","funders":"","keywords":"Business; Drug; Advertising; Marketing; Internet privacy; Public relations; Computer science; Medicine; Political science; Pharmacology","score_opus":0.1597124393687321,"score_gpt":0.3040678482647292,"score_spread":0.1443554088959971,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413524744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74104834,0.000121612655,0.00016553776,0.06498244,0.0009851992,0.0012675248,0.0031317633,0.00018384853,0.18811376],"genre_scores_gemma":[0.9636853,0.00022671222,0.000015488451,0.023425132,0.00048329134,0.00018203632,0.00006248636,0.00008560709,0.011833959],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982036,0.000018492567,0.00047860647,0.00049111055,0.000050292307,0.0007579307],"domain_scores_gemma":[0.99866444,0.00038228356,0.00018908479,0.00040933114,0.00003394668,0.00032089633],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0004394973,0.00032391152,0.00041985096,0.00047397052,0.00025546827,0.00018322417,0.00041263812,0.00007888536,0.0009375212],"category_scores_gemma":[0.000066399756,0.00022363327,0.0002487127,0.0006188048,0.00006898251,0.000117434654,0.00004819304,0.00029154378,0.0021378724],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005731267,0.00042853548,0.0037717298,0.00010320188,0.0007611804,0.000025032214,0.0023333859,0.0037607357,0.00017073302,0.29447326,0.6756059,0.017993221],"study_design_scores_gemma":[0.0018927986,0.0003739395,0.00040792327,0.000017393977,0.00001974414,0.000002553989,0.00021739081,0.00934877,0.0015159237,0.0041974564,0.9814854,0.00052070105],"about_ca_topic_score_codex":0.002271617,"about_ca_topic_score_gemma":0.0010174367,"teacher_disagreement_score":0.30587953,"about_ca_system_score_codex":0.00029447395,"about_ca_system_score_gemma":0.000088751214,"threshold_uncertainty_score":0.99997574},"labels":[],"label_agreement":null},{"id":"W4413553793","doi":"10.64628/aam.5u6t5dmv6","title":"How coronavirus is contributing to drug shortages in Canada","year":2020,"lang":"en","type":"preprint","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Coronavirus disease 2019 (COVID-19); Economic shortage; Coronavirus; Pandemic; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Drug; Business; Virology; Medicine; Pharmacology; Outbreak; Infectious disease (medical specialty); Government (linguistics)","score_opus":0.11115672424989165,"score_gpt":0.29711354379569005,"score_spread":0.1859568195457984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413553793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6361811,0.0035090747,0.0008868208,0.27042457,0.002491269,0.0012630734,0.009345746,0.00007099921,0.07582735],"genre_scores_gemma":[0.96056163,0.00037650496,0.00021279855,0.037338503,0.0002475497,0.000056393077,0.00005706477,0.00004148102,0.001108043],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99745375,0.0000138731575,0.0008318454,0.00087985577,0.000038794424,0.0007818995],"domain_scores_gemma":[0.99870557,0.00009304976,0.00029810358,0.00042809016,0.00002222332,0.0004529654],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003709884,0.00034162734,0.0009793488,0.00016760544,0.00005450441,0.000259219,0.0006196614,0.00014236315,0.00084148056],"category_scores_gemma":[0.0001370157,0.0004391658,0.00014253083,0.00015364765,0.000018005163,0.000077422184,0.0010971706,0.0007437556,0.00029870836],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007762426,0.000094762414,0.53118366,0.00043559735,0.00041888718,0.00013470337,0.0015531698,0.001919898,0.000023173532,0.2762747,0.17591706,0.011966757],"study_design_scores_gemma":[0.0007926413,0.000016617028,0.03749893,0.00006153103,0.0000115342655,0.0000015381258,0.0002202402,0.022167979,0.0006687665,0.06995646,0.8671979,0.0014058753],"about_ca_topic_score_codex":0.9035511,"about_ca_topic_score_gemma":0.8782161,"teacher_disagreement_score":0.69128084,"about_ca_system_score_codex":0.0014613013,"about_ca_system_score_gemma":0.0006444117,"threshold_uncertainty_score":0.999806},"labels":[],"label_agreement":null},{"id":"W4413604366","doi":"10.64628/aam.aekeksfp3","title":"High drug prices in Canada are just one side of a bad equation","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"York University; University of Toronto; University of British Columbia","funders":"","keywords":"Drug; Drug prices; Economics; Econometrics; Medicine; Monetary economics; Pharmacology","score_opus":0.16855811577615437,"score_gpt":0.2889533723425736,"score_spread":0.12039525656641925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413604366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95304966,0.00092128164,0.00045719676,0.012419658,0.0017649484,0.00054654997,0.0022484383,0.000040734016,0.028551532],"genre_scores_gemma":[0.9961619,0.0010691403,0.00053574983,0.00096711924,0.00014761677,0.00005293442,0.00009849786,0.000036572605,0.0009305123],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99791247,0.000010677561,0.0011973636,0.000512582,0.000040965617,0.00032595373],"domain_scores_gemma":[0.99840176,0.00016598702,0.0008836246,0.00040804248,0.000027978946,0.00011259638],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00048784737,0.00020883825,0.0008124377,0.0003654858,0.000022711016,0.000041928128,0.00039706487,0.00013877175,0.0005464551],"category_scores_gemma":[0.0001307612,0.00027206878,0.00010164932,0.00019203332,0.000025668833,0.000074744414,0.00041024302,0.00040945454,0.0002335456],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040268616,0.00021392413,0.13474633,0.0011709189,0.00032451356,0.000015571866,0.00057765027,0.051761083,0.000009158854,0.79595083,0.013843339,0.0013463893],"study_design_scores_gemma":[0.0013701019,0.000018774594,0.4431009,0.00029633788,0.000030759566,5.149567e-7,0.00032880518,0.0938396,0.0006712383,0.4423149,0.016738512,0.0012895515],"about_ca_topic_score_codex":0.9742001,"about_ca_topic_score_gemma":0.96111387,"teacher_disagreement_score":0.35363597,"about_ca_system_score_codex":0.00092410843,"about_ca_system_score_gemma":0.0005453019,"threshold_uncertainty_score":0.9999732},"labels":[],"label_agreement":null},{"id":"W4413610783","doi":"10.64628/aam.r77cf6mka","title":"NAFTA negotiations may threaten pharmacare","year":2018,"lang":"en","type":"preprint","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Negotiation; International trade; Political science; Business; Law and economics; Economics; Law","score_opus":0.1456492107694341,"score_gpt":0.34386428390033874,"score_spread":0.19821507313090464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413610783","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04621222,0.0027078772,0.0013172433,0.0132877,0.003623329,0.0006208618,0.003210869,0.00022016131,0.92879975],"genre_scores_gemma":[0.97482413,0.0019632843,0.0012937919,0.008339249,0.0019773943,0.0001214967,0.00033515054,0.00009817129,0.011047342],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976636,0.000015574135,0.0009256182,0.00085257454,0.00002899242,0.0005136267],"domain_scores_gemma":[0.99839413,0.00004825511,0.0004523429,0.0007689816,0.000056567256,0.00027969308],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00037296815,0.00037085617,0.0006831373,0.00031153846,0.00013401578,0.00024780666,0.00072957674,0.00038877627,0.015161149],"category_scores_gemma":[0.000056026875,0.0004377779,0.0003524965,0.00012431509,0.00011983142,0.00014221518,0.00087875745,0.00061455264,0.011967624],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021958758,0.00017125558,0.021786124,0.00016559429,0.0005224845,0.0000053838958,0.00042263727,0.00045923132,0.000005023842,0.74340594,0.2316818,0.0013525641],"study_design_scores_gemma":[0.0005691805,0.000023558925,0.002581304,0.000021899363,0.000027916492,0.0000034181605,0.000012533591,0.01829747,0.0001777956,0.3123702,0.6651692,0.0007455556],"about_ca_topic_score_codex":0.000487071,"about_ca_topic_score_gemma":0.00003235891,"teacher_disagreement_score":0.9286119,"about_ca_system_score_codex":0.0002205223,"about_ca_system_score_gemma":0.000081583814,"threshold_uncertainty_score":0.9998074},"labels":[],"label_agreement":null},{"id":"W4413632792","doi":"10.64628/aam.hajum63tw","title":"How the pharmaceutical industry uses disinformation to undermine drug price reform","year":2023,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Disinformation; Pharmaceutical industry; Drug; Business; Law and economics; Economics; Political science; Pharmacology; Medicine; Law; Social media","score_opus":0.1344081908847762,"score_gpt":0.3305701986658463,"score_spread":0.1961620077810701,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413632792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3954414,0.00013652255,0.0006953338,0.2890101,0.0007833436,0.0005128136,0.00019890569,0.00024701096,0.31297454],"genre_scores_gemma":[0.96668524,0.00019678258,0.000070204114,0.016137814,0.00029624562,0.00004223001,0.000021219086,0.000022044964,0.016528241],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988233,0.000009183095,0.00042355535,0.0002435792,0.000039672024,0.00046071893],"domain_scores_gemma":[0.99920493,0.00009216485,0.00011592516,0.00031553768,0.000019106728,0.00025230373],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00063650316,0.00015022054,0.000220553,0.00022269863,0.00017056151,0.00029787124,0.0003672161,0.00011665671,0.0005009773],"category_scores_gemma":[0.000113678114,0.00011950703,0.00008731721,0.0006442858,0.000055179356,0.00048668403,0.00019850259,0.00037216712,0.0045465794],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001756885,0.00003755638,0.001902018,0.00002872243,0.000051287825,0.000001944473,0.0007125447,0.00016984376,0.000027338703,0.9136912,0.07972554,0.0036344116],"study_design_scores_gemma":[0.00035357723,0.000015522468,0.005592321,0.0000044932776,0.0000044315316,0.0000041664007,0.00045277676,0.018119173,0.00052537705,0.01623163,0.95845306,0.00024345596],"about_ca_topic_score_codex":0.00010146863,"about_ca_topic_score_gemma":0.000023277664,"teacher_disagreement_score":0.89745957,"about_ca_system_score_codex":0.00021121868,"about_ca_system_score_gemma":0.00002291976,"threshold_uncertainty_score":0.9962285},"labels":[],"label_agreement":null},{"id":"W4413654452","doi":"10.64628/aam.frre7j36d","title":"How Big Pharma deceives you about drug safety","year":2018,"lang":"en","type":"preprint","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Drug; Business; Pharmacology; Medicine","score_opus":0.07817871533396767,"score_gpt":0.2955563714328716,"score_spread":0.21737765609890394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413654452","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07632422,0.010457298,0.0062290365,0.062250175,0.012412037,0.0012506059,0.0055443593,0.00040656046,0.8251257],"genre_scores_gemma":[0.895563,0.01422831,0.0021398745,0.011718321,0.0059536668,0.00013142546,0.00031128302,0.00020638386,0.06974773],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968464,0.000030303632,0.0010864707,0.0012291463,0.000043765383,0.00076391076],"domain_scores_gemma":[0.9976662,0.00009204015,0.00074377167,0.0010047093,0.00006161134,0.00043171228],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0008000437,0.00056838297,0.0011009166,0.00041890406,0.00017540168,0.00068097527,0.0010578787,0.00040984023,0.0031858918],"category_scores_gemma":[0.00012573821,0.0005716534,0.00053133216,0.00014486708,0.0002443568,0.00020031372,0.0011028221,0.00081952894,0.003403717],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019718085,0.00050483627,0.014462097,0.00068242196,0.0014193822,0.000017972663,0.0015354904,0.00026001758,0.00002073323,0.66802794,0.2548215,0.058050413],"study_design_scores_gemma":[0.00067779823,0.00001686525,0.0018697837,0.000029602794,0.00001925194,0.000002855441,0.0000210096,0.005359961,0.0004383507,0.11741557,0.87334484,0.00080409733],"about_ca_topic_score_codex":0.0003602771,"about_ca_topic_score_gemma":0.000052330688,"teacher_disagreement_score":0.8192388,"about_ca_system_score_codex":0.00027858064,"about_ca_system_score_gemma":0.00010960535,"threshold_uncertainty_score":0.9996735},"labels":[],"label_agreement":null},{"id":"W4413723315","doi":"10.1080/19397038.2025.2547595","title":"Enhancing sustainability of medical devices procurement in Low- and Middle-Income Countries","year":2025,"lang":"en","type":"article","venue":"International Journal of Sustainable Engineering","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Heart Institute","funders":"","keywords":"Sustainability; Low and middle income countries; Procurement; Business; Middle income; Low income; Natural resource economics; Developing country; Economic growth; Economics; Socioeconomics; Marketing; Demographic economics","score_opus":0.011374227882080068,"score_gpt":0.2766659095221207,"score_spread":0.26529168164004063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413723315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981112,0.0032907447,0.00707919,0.0073067984,0.00041439012,0.00012373774,0.0000069736325,0.0000052888827,0.0006608827],"genre_scores_gemma":[0.9990538,0.00043931714,0.00015906809,0.00016944412,0.00007824801,0.000003782691,3.9135088e-7,0.0000060482585,0.00008993201],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99870074,0.0000064165006,0.00088791165,0.000108883774,0.00009578398,0.00020025492],"domain_scores_gemma":[0.999192,0.00012383927,0.0002662559,0.00006197207,0.00028487365,0.00007107644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014191847,0.00008601048,0.0002884099,0.0006279092,0.000015424052,0.000056938054,0.00032020986,0.00006581866,0.00006131921],"category_scores_gemma":[0.0009116652,0.00009595507,0.00005581973,0.00014227304,0.000036207384,0.00028965343,0.00012777287,0.00019967525,8.613214e-7],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000660122,0.00007983914,0.074534506,0.0018136598,0.00017394329,0.00011028036,0.0006609433,0.00737197,0.00000688261,0.9150394,0.000014596787,0.00012794662],"study_design_scores_gemma":[0.012870341,0.00040061143,0.30900234,0.009758743,0.000064650354,0.00019581031,0.011038036,0.17281127,0.009560098,0.31037632,0.16243228,0.001489479],"about_ca_topic_score_codex":0.00013495785,"about_ca_topic_score_gemma":0.000014883807,"teacher_disagreement_score":0.6046631,"about_ca_system_score_codex":0.00053860346,"about_ca_system_score_gemma":0.00021502814,"threshold_uncertainty_score":0.3912934},"labels":[],"label_agreement":null},{"id":"W4413817962","doi":"10.1093/ajhp/zxaf237","title":"Recent and anticipated novel drug approvals (3Q 2025 through 2Q 2026)","year":2025,"lang":"en","type":"article","venue":"American Journal of Health-System Pharmacy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Formulary; Medicine; Drug; Pipeline (software); Food and drug administration; Drug approval; Quarter (Canadian coin); Approved drug; Family medicine; Medical emergency; Pharmacology","score_opus":0.0997740453492516,"score_gpt":0.37765968062551564,"score_spread":0.27788563527626403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413817962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5149167,0.07660307,0.011859791,0.33171865,0.0056565544,0.0013342194,0.000616238,0.000110983565,0.057183787],"genre_scores_gemma":[0.9631896,0.022385813,0.0012825727,0.012575745,0.00025932104,0.000012958805,0.0000040186233,0.000033281325,0.00025669564],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99646324,0.00013159358,0.0023484158,0.00038847857,0.000067156354,0.00060109334],"domain_scores_gemma":[0.9968039,0.00020436727,0.002275791,0.0002629228,0.0001237062,0.00032934113],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002272239,0.00026717133,0.0013835897,0.00041365455,0.00021169569,0.000102660415,0.00039605718,0.00003242305,0.00015943359],"category_scores_gemma":[0.000096265125,0.00027885346,0.00018507043,0.0006737079,0.00019729818,0.00033239299,0.00010455946,0.0004616778,0.00007354423],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088459335,0.0011656642,0.047279343,0.0017465443,0.0019311946,0.000045440673,0.0043484713,0.0004274189,0.00038330097,0.28143093,0.08033482,0.5800223],"study_design_scores_gemma":[0.002879407,0.00014160346,0.0016390153,0.00018133354,0.000034289184,0.00008059374,0.0005630855,0.003681561,0.0002074559,0.0013806438,0.9889224,0.0002885997],"about_ca_topic_score_codex":0.0011508263,"about_ca_topic_score_gemma":0.000007166336,"teacher_disagreement_score":0.9085876,"about_ca_system_score_codex":0.00043003488,"about_ca_system_score_gemma":0.00037363183,"threshold_uncertainty_score":0.9999664},"labels":[],"label_agreement":null},{"id":"W4413989514","doi":"10.4103/equest.equest_16_23","title":"The generic dilemma","year":2023,"lang":"en","type":"article","venue":"EyeQuest","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dilemma; Computer science; Epistemology; Philosophy","score_opus":0.10457971171092077,"score_gpt":0.29915470496726093,"score_spread":0.19457499325634015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413989514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5092434,0.002867264,0.00013213836,0.036419354,0.0029420112,0.0002743103,0.0002748237,0.00036937467,0.4474773],"genre_scores_gemma":[0.9892306,0.0017093166,0.000035517798,0.0022864877,0.0005284603,0.000037118734,0.000016124837,0.00002535718,0.0061310553],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991736,0.000007779888,0.00028978768,0.00018799643,0.000013639256,0.00032719912],"domain_scores_gemma":[0.9994631,0.000089031215,0.00008343082,0.00026479142,0.000008483048,0.00009119496],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00047098336,0.00008036415,0.00013310871,0.00007177878,0.00020172494,0.000117085336,0.00025899944,0.000040002666,0.00022857815],"category_scores_gemma":[0.00008886337,0.0000715881,0.00006892275,0.00025667142,0.000061033672,0.0000813084,0.000081859915,0.0001003635,0.018098058],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000028191241,0.000008508756,0.0045134444,0.0000034132424,0.000018471292,0.0000035710962,0.000053432734,0.00005711496,0.000015263884,0.9202694,0.07220098,0.0028535407],"study_design_scores_gemma":[0.000112364716,0.000009722942,0.010170741,9.6133e-7,8.678174e-7,0.0000011831762,0.0000051640004,0.0048293727,0.000035639267,0.08484176,0.8998931,0.00009913059],"about_ca_topic_score_codex":0.00007598737,"about_ca_topic_score_gemma":0.000018445335,"teacher_disagreement_score":0.8354277,"about_ca_system_score_codex":0.000043437984,"about_ca_system_score_gemma":0.000011965698,"threshold_uncertainty_score":0.9826665},"labels":[],"label_agreement":null},{"id":"W4414030360","doi":"10.20944/preprints202506.2476.v2","title":"Reforming Drug Pricing: Institutional Lessons from Most Favored Nation (MFN) and Value‐Based Care (VBC) Across Three Health Systems","year":2025,"lang":"en","type":"preprint","venue":"Preprints.org","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Value (mathematics); Drug; Drug pricing; Health care; Business; Economics; Economic growth; Medicine; Pharmacology; Actuarial science; Statistics; Mathematics","score_opus":0.24988319166014705,"score_gpt":0.4013813811024603,"score_spread":0.15149818944231325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414030360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9529906,0.008046532,0.002197122,0.007260615,0.0026402925,0.0013421555,0.008496428,0.00015837017,0.016867897],"genre_scores_gemma":[0.99554986,0.0010030936,0.00025151303,0.0014423548,0.00038798843,0.00019832986,0.0008309871,0.000039251998,0.0002966099],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962912,0.00006656097,0.0014342513,0.001488211,0.00009746059,0.0006222829],"domain_scores_gemma":[0.9973835,0.00014603711,0.0010455676,0.0010135017,0.00010941683,0.00030200763],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012711324,0.00047094258,0.0010839836,0.00032230697,0.0005312584,0.00017106978,0.0006881712,0.00040443474,0.0000785008],"category_scores_gemma":[0.00024769563,0.0005867012,0.00022603177,0.00021140206,0.00016435765,0.00022284126,0.0015253368,0.0010122692,0.00027995353],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009418887,0.00020841157,0.6368426,0.002184703,0.0004964746,0.0000063102234,0.007106467,0.042715967,0.000039775663,0.30638582,0.00014204117,0.0037772073],"study_design_scores_gemma":[0.00448652,0.000042373802,0.51154524,0.00201715,0.00009442403,0.000006763042,0.0012288542,0.23969679,0.0014220139,0.07549948,0.1613617,0.002598708],"about_ca_topic_score_codex":0.025936246,"about_ca_topic_score_gemma":0.001045044,"teacher_disagreement_score":0.23088634,"about_ca_system_score_codex":0.0016188743,"about_ca_system_score_gemma":0.0007438071,"threshold_uncertainty_score":0.99965847},"labels":[],"label_agreement":null},{"id":"W4414085393","doi":"10.1111/dewb.70004","title":"Making Advanced Therapies Affordable and Accessible: Two Strategic Approaches","year":2025,"lang":"en","type":"article","venue":"Developing World Bioethics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Stem Cell Network; Government of Canada","keywords":"Intellectual property; Reimbursement; Market access; Transformative learning; Access to medicines; Expanded access","score_opus":0.4161552245505158,"score_gpt":0.4065649724819838,"score_spread":0.00959025206853198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414085393","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20915695,0.023771096,0.011150301,0.09483345,0.0018548754,0.000752834,0.00013819229,0.0002853703,0.6580569],"genre_scores_gemma":[0.9775005,0.0013654683,0.012363799,0.0068354122,0.00007322037,0.0000301528,0.000009726223,0.000021458332,0.0018002777],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99864006,0.000019231524,0.0005088168,0.00043130893,0.000023871908,0.00037670112],"domain_scores_gemma":[0.999351,0.00015504524,0.00019065391,0.00022522322,0.000023633122,0.00005444401],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006783637,0.0001994663,0.0003594139,0.00041604685,0.0002572217,0.00029318218,0.0002751951,0.00010039738,0.00006197443],"category_scores_gemma":[0.000047869973,0.00022047805,0.00005270275,0.0006182348,0.00024172876,0.00022456006,0.00017237087,0.00037962385,0.00004476623],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001224368,0.000013366328,0.01013916,0.00010244394,0.000060074566,7.887691e-7,0.00019096486,0.000056423618,0.0000066767516,0.98470294,0.00011433605,0.004600564],"study_design_scores_gemma":[0.0007444476,0.000010478976,0.004434022,0.00013474573,0.0000077313925,0.0000016022193,0.00025930168,0.0059846365,0.00038222776,0.8493235,0.13827091,0.00044637782],"about_ca_topic_score_codex":0.00006585921,"about_ca_topic_score_gemma":0.00036226682,"teacher_disagreement_score":0.76834357,"about_ca_system_score_codex":0.00010192322,"about_ca_system_score_gemma":0.00012423767,"threshold_uncertainty_score":0.89908344},"labels":[],"label_agreement":null},{"id":"W4414300864","doi":"10.12927/hcpol.2025.27665","title":"Access, Value, and Reform: An Analysis of Canada’s Pharmaceutical Policy Framework","year":2025,"lang":"en","type":"article","venue":"Healthcare policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Canadian Arthritis Patient Alliance","funders":"","keywords":"Legitimacy; Argument (complex analysis); Intellectual property; Pharmaceutical industry; Pharmaceutical policy; Focus (optics)","score_opus":0.07612181545382497,"score_gpt":0.4148379755231695,"score_spread":0.3387161600693445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414300864","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3982699,0.0069854837,0.0010065781,0.4577282,0.00060175406,0.00063262373,0.0032356374,0.00009172582,0.1314481],"genre_scores_gemma":[0.9492098,0.0020048372,0.00022533842,0.047879383,0.00031672211,0.00001820506,0.00003071568,0.00002113486,0.00029382875],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9976775,0.000053983273,0.0009821166,0.0005236561,0.000054728833,0.00070803915],"domain_scores_gemma":[0.99838644,0.00010119423,0.00029734903,0.00056301226,0.000058871447,0.00059310655],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00049515645,0.00022861148,0.00084738195,0.0016632813,0.0001861342,0.00008587161,0.0004761552,0.00020212366,0.00012759185],"category_scores_gemma":[0.0003768789,0.00026464794,0.00014257737,0.0021555144,0.00013648148,0.00023513571,0.0002270702,0.0003670965,0.0000068885047],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030070032,0.00005064267,0.033619378,0.00013866709,0.00034977714,0.0000016555538,0.00016540162,0.000104977655,0.0000022259462,0.9618694,0.00040062005,0.003267189],"study_design_scores_gemma":[0.0006952282,0.00006930747,0.39253083,0.00004767094,0.00014801709,0.0000037828163,0.000094320974,0.03663635,0.00017454936,0.43348044,0.13558763,0.000531886],"about_ca_topic_score_codex":0.90843064,"about_ca_topic_score_gemma":0.24682659,"teacher_disagreement_score":0.66160405,"about_ca_system_score_codex":0.0012520603,"about_ca_system_score_gemma":0.0021384663,"threshold_uncertainty_score":0.99998057},"labels":[],"label_agreement":null},{"id":"W4414316021","doi":"10.20944/preprints202506.2476.v3","title":"Balancing Innovation, Access, and Equity in Drug Pricing: Comparative Institutional Lessons for Advancing Universal Health Coverage","year":2025,"lang":"en","type":"preprint","venue":"Preprints.org","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Equity (law); Incentive; Reimbursement; Health care; Prescription drug; Universal design; Drug prices; Drug pricing","score_opus":0.37451414521758114,"score_gpt":0.47499740253716755,"score_spread":0.1004832573195864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414316021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88543606,0.00087378285,0.011618076,0.013531709,0.0010870981,0.0017248347,0.0019615183,0.00007140903,0.08369551],"genre_scores_gemma":[0.99514514,0.001139754,0.00039879078,0.0024369913,0.00012049092,0.00011944232,0.00019023554,0.0000150896,0.00043408724],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9972356,0.000041422853,0.0011984145,0.0009865953,0.00004241859,0.0004955744],"domain_scores_gemma":[0.99833965,0.00019823239,0.00081772986,0.00042162513,0.000093589726,0.00012919256],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001842215,0.00030161228,0.00090117817,0.00070867315,0.00022945867,0.00008937267,0.00055572885,0.00017620357,0.00010231915],"category_scores_gemma":[0.00033335527,0.00041568835,0.00009683637,0.00040278488,0.0001100295,0.00038244348,0.0024181278,0.00074527296,0.000042365293],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000048313286,0.000098027966,0.2700323,0.00052737136,0.00007852311,0.0000010076502,0.0011455595,0.011189661,0.00001362938,0.7161088,0.00030813008,0.0004486961],"study_design_scores_gemma":[0.0023905355,0.00001820932,0.42063823,0.00052614306,0.000015334908,0.0000022712666,0.000091460366,0.03141013,0.00061817304,0.45259273,0.0908559,0.00084088434],"about_ca_topic_score_codex":0.0019358675,"about_ca_topic_score_gemma":0.000525949,"teacher_disagreement_score":0.26351607,"about_ca_system_score_codex":0.00135667,"about_ca_system_score_gemma":0.0008776729,"threshold_uncertainty_score":0.9998295},"labels":[],"label_agreement":null},{"id":"W4414372245","doi":"10.52609/jmlph.v5i4.225","title":"Pharmaceutical Access and the Human Right to Science","year":2025,"lang":"en","type":"article","venue":"The Journal of Medicine Law & Public Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Human rights; Right to health; Access to medicines; Right to development; Foundation (evidence); Sociology of scientific knowledge","score_opus":0.16149570208009176,"score_gpt":0.4463558219406761,"score_spread":0.28486011986058435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414372245","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05267106,0.0038319426,0.0009856866,0.8505177,0.0006718292,0.00026015757,0.0000072798293,0.0000067159945,0.09104767],"genre_scores_gemma":[0.8346368,0.001483044,0.000023241953,0.1633109,0.00038540608,0.0000026338678,2.429592e-7,0.0000058817923,0.0001518156],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99813485,0.00012182133,0.0010300032,0.00015722687,0.00009526618,0.0004608124],"domain_scores_gemma":[0.99823105,0.00039805422,0.00046838532,0.00028056186,0.00009656919,0.0005253755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017178029,0.00011221817,0.0005228206,0.00031482027,0.0006558738,0.00015160668,0.0012150452,0.000029234327,0.0002443986],"category_scores_gemma":[0.0005266458,0.00006051683,0.000049700393,0.0006623353,0.0018613529,0.0003427046,0.00025364375,0.0004751969,0.000014434817],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030243194,0.000025993391,0.00041826649,0.00002032022,0.00003077393,6.123713e-7,0.000642065,0.0000044206317,0.00000946212,0.98324376,0.012875497,0.0026985991],"study_design_scores_gemma":[0.0026727254,0.00010671108,0.0026680853,0.00004126032,0.00001162398,0.000037277656,0.00007473784,0.0006119888,0.00002775431,0.17167884,0.8220009,0.000068045694],"about_ca_topic_score_codex":0.00064427435,"about_ca_topic_score_gemma":0.00005330607,"teacher_disagreement_score":0.8115649,"about_ca_system_score_codex":0.00018923935,"about_ca_system_score_gemma":0.00032174832,"threshold_uncertainty_score":0.68582326},"labels":[],"label_agreement":null},{"id":"W4414417581","doi":"10.1016/s2468-2667(25)00194-x","title":"Changes in use and utilisation patterns of drugs with reported shortages between 2010 and 2024 in Europe and North America: a network cohort study","year":2025,"lang":"en","type":"article","venue":"The Lancet Public Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Efficacy and Mechanism Evaluation Programme; Health Canada; Sanofi Genzyme; Horizon 2020 Framework Programme; Innovative Medicines Initiative; Teva Pharmaceutical Industries; National Institute for Health and Care Research; Regeneron Pharmaceuticals; Gilead Sciences; European Federation of Pharmaceutical Industries and Associations; European Commission; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline","keywords":"Economic shortage; Cohort study; Cohort; MEDLINE; Cross-sectional study; Health services research","score_opus":0.15431116463588618,"score_gpt":0.328001423853658,"score_spread":0.17369025921777181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414417581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97801715,0.0006056709,0.000035234563,0.020242838,0.000049569288,0.0005205449,0.00012009981,0.000007666579,0.00040124063],"genre_scores_gemma":[0.9914129,0.0059922403,0.000029559005,0.0023532733,0.0000704515,0.000030158672,0.00001875763,0.00000851378,0.00008418411],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998835,0.00008313214,0.0004707189,0.00028710725,0.0000222431,0.00030176705],"domain_scores_gemma":[0.9992557,0.00015858766,0.00025311735,0.00023064064,0.00001788847,0.0000840438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016319031,0.000100990386,0.00055385235,0.00015972428,0.0000489414,0.0000787347,0.000088176064,0.00002812088,0.000008881745],"category_scores_gemma":[0.00009172766,0.00008454534,0.0000065828985,0.00046020732,0.00007366854,0.00013348997,0.00009126325,0.00020377745,5.7567144e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012476191,0.000035051075,0.99083394,0.00004561439,0.000042148404,9.749074e-7,0.0013320684,0.000009807806,3.9684874e-8,0.0018211168,0.00028196344,0.0055847955],"study_design_scores_gemma":[0.0005805352,0.00007967906,0.98313695,0.000019916193,0.000004665503,6.339126e-7,0.00017421352,0.00066300645,9.968637e-8,0.00029002226,0.01497564,0.000074608215],"about_ca_topic_score_codex":0.005216944,"about_ca_topic_score_gemma":0.0119268885,"teacher_disagreement_score":0.017889565,"about_ca_system_score_codex":0.000036808866,"about_ca_system_score_gemma":0.00005652891,"threshold_uncertainty_score":0.7886493},"labels":[],"label_agreement":null},{"id":"W4414783537","doi":"10.1136/bmj.r2086","title":"No supply, no survival: why patients must be involved in global trade decisions","year":2025,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Diabetes Canada","funders":"","keywords":"Global health; MEDLINE; Globalization; Trade barrier","score_opus":0.08241594915191612,"score_gpt":0.3325882499405844,"score_spread":0.25017230078866826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414783537","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.37859893,0.00047341635,0.00016108356,0.028061891,0.0037104657,0.00075625605,0.0020743606,0.000053135947,0.5861105],"genre_scores_gemma":[0.9785531,0.00042602976,0.00036068528,0.019011984,0.00023186795,0.00006088163,0.000093096314,0.00002056234,0.0012417791],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982972,0.000024444256,0.0008404399,0.0004007471,0.00003224455,0.0004049151],"domain_scores_gemma":[0.999156,0.00015811497,0.00015505223,0.00036055924,0.00002575749,0.00014453859],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00045770418,0.00017057754,0.00042058728,0.00018693654,0.00006422601,0.000076310534,0.00035534214,0.0001426355,0.0005336554],"category_scores_gemma":[0.0006410133,0.00020688861,0.0001388015,0.00037674565,0.000051553954,0.00015452178,0.00014659791,0.00017398868,0.0013443262],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005919561,0.00030340522,0.5262046,0.00001791093,0.000044324766,0.0000028110671,0.000039250357,0.000045735662,0.0000017825241,0.19934383,0.27248466,0.0014525101],"study_design_scores_gemma":[0.001370064,0.000026276193,0.23875345,0.00002097303,0.000003538623,1.3048925e-7,0.000007906035,0.002789862,0.0000053324384,0.021526203,0.73529243,0.00020383023],"about_ca_topic_score_codex":0.00070703315,"about_ca_topic_score_gemma":0.0006580929,"teacher_disagreement_score":0.5999542,"about_ca_system_score_codex":0.0002693061,"about_ca_system_score_gemma":0.000058569407,"threshold_uncertainty_score":0.9994332},"labels":[],"label_agreement":null},{"id":"W4414810172","doi":"10.1177/17151635251365666","title":"Empowering pharmacists in Canada’s drug shortage response","year":2025,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Women's College Hospital; Southlake Regional Health Center; University of Toronto","funders":"","keywords":"Economic shortage; Drug; MEDLINE; Pharmacy; Action (physics)","score_opus":0.03707103138297102,"score_gpt":0.28469199977417464,"score_spread":0.24762096839120362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414810172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9648131,0.004039493,0.00006061001,0.0017548726,0.005555779,0.00044636906,0.0019283564,0.000024842086,0.021376567],"genre_scores_gemma":[0.9776465,0.0042663454,0.000069126145,0.01508846,0.000316764,0.000031940886,0.000022060762,0.00007121019,0.0024875356],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953365,0.00015970375,0.0017414499,0.0007711633,0.0001403508,0.0018508808],"domain_scores_gemma":[0.9964242,0.00026993267,0.00043705263,0.00042905574,0.00015116385,0.002288595],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018560019,0.0005618574,0.0008770686,0.0012587665,0.00065371505,0.0003020773,0.0012487014,0.00008161981,0.0022507778],"category_scores_gemma":[0.0003590457,0.00075501116,0.00020853845,0.0011011871,0.00014554238,0.00051067886,0.000118045085,0.0012681048,0.000057258665],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0022793326,0.00028149938,0.16224675,0.00092794263,0.0013567443,0.17049378,0.004520307,0.020530103,0.0017882505,0.011750381,0.57362884,0.05019609],"study_design_scores_gemma":[0.0058275396,0.000020878751,0.0014635032,0.00006577876,0.00006332567,0.04151685,0.000045045243,0.03160179,0.0019853855,0.0027016401,0.9128036,0.0019046662],"about_ca_topic_score_codex":0.9156759,"about_ca_topic_score_gemma":0.9885799,"teacher_disagreement_score":0.33917478,"about_ca_system_score_codex":0.01732645,"about_ca_system_score_gemma":0.018649228,"threshold_uncertainty_score":0.9994901},"labels":[],"label_agreement":null},{"id":"W4414870087","doi":"10.1377/hlthaff.2024.01476","title":"Impact Of Risk Evaluation And Mitigation Strategies On Generic Approvals Of US Pharmaceutical Products","year":2025,"lang":"en","type":"article","venue":"Health Affairs","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Orphan drug; Drug approval; Risk assessment; Generic drug; Drug; MEDLINE","score_opus":0.08643639301125396,"score_gpt":0.39813488528357427,"score_spread":0.3116984922723203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414870087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97945756,0.0041249,0.0001819395,0.0018231173,0.00018946038,0.0005264308,0.00027742036,0.000010981635,0.013408195],"genre_scores_gemma":[0.9974743,0.0019262396,0.00027035837,0.0002194114,0.00004817274,0.000021116983,0.000019151465,0.000008721136,0.000012510009],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99871284,0.000066432585,0.00067447615,0.00028199516,0.000038298876,0.00022596342],"domain_scores_gemma":[0.9990483,0.00009717758,0.00049124693,0.00019564824,0.00006550847,0.000102096834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012709867,0.000112967944,0.00038509475,0.00026047052,0.00005140423,0.000020065381,0.00007963755,0.000059158712,0.00006877361],"category_scores_gemma":[0.0002467542,0.00011892296,0.000073339754,0.00027436722,0.00009160501,0.00011397736,0.000024205405,0.00012895776,0.000012586742],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003821954,0.0006989684,0.13024087,0.0015010457,0.00035723267,3.230008e-7,0.0015223528,0.009572188,0.00044065653,0.76803046,0.004434808,0.08281886],"study_design_scores_gemma":[0.0037293162,0.0007708532,0.71048766,0.00011990842,0.00005911681,0.0000022327795,0.00037004842,0.14406635,0.0025181088,0.12940408,0.008072397,0.0003999396],"about_ca_topic_score_codex":0.00042995374,"about_ca_topic_score_gemma":0.000013808687,"teacher_disagreement_score":0.6386264,"about_ca_system_score_codex":0.00017136404,"about_ca_system_score_gemma":0.00036412786,"threshold_uncertainty_score":0.48495376},"labels":[],"label_agreement":null},{"id":"W4415240387","doi":"10.12927/hcpap.2025.27699","title":"Of Big and Small Swings: Toward a Hybrid View of Healthcare Systems Governance","year":2025,"lang":"en","type":"article","venue":"A Nudge Too Far? A Nudge at All? On Paying People to Be Healthy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Decentralization; Corporate governance; Politics; Healthcare system; Multi-level governance; Health care","score_opus":0.10186257084592829,"score_gpt":0.31345880171901924,"score_spread":0.21159623087309096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415240387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5230857,0.011161113,0.00030058363,0.4583112,0.0009044878,0.0008713819,0.0011554265,0.000047249945,0.004162866],"genre_scores_gemma":[0.55965346,0.0043479046,0.00014535217,0.43532607,0.000020882128,0.00010046345,0.000016643135,0.000037883365,0.00035136018],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964559,0.00007765922,0.0017716999,0.0008386872,0.00008109301,0.0007749736],"domain_scores_gemma":[0.9975541,0.0003723287,0.00087223336,0.0006514438,0.00009158434,0.00045829342],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010676389,0.00037776158,0.0014356188,0.000333436,0.00015261234,0.000059858092,0.0004827905,0.00016444446,0.000043798045],"category_scores_gemma":[0.00025723185,0.00043016218,0.00021737444,0.00054650154,0.000067836154,0.000101284386,0.00034537882,0.00031556806,0.00008827025],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009469524,0.0005126512,0.02370252,0.0045242067,0.00032569608,0.000010284941,0.0041060806,0.00009896426,0.0001288321,0.77494127,0.17228867,0.01841385],"study_design_scores_gemma":[0.001956279,0.0007194885,0.012163888,0.000015768253,0.000027445149,0.000014498141,0.0001294579,0.003394674,0.00025746346,0.0023028788,0.97846746,0.00055067276],"about_ca_topic_score_codex":0.006108455,"about_ca_topic_score_gemma":0.00066273054,"teacher_disagreement_score":0.8061788,"about_ca_system_score_codex":0.0005718989,"about_ca_system_score_gemma":0.00023962115,"threshold_uncertainty_score":0.99981505},"labels":[],"label_agreement":null},{"id":"W4415262181","doi":"10.1161/hyp.82.suppl_1.th144","title":"Abstract TH144: Single-Pill vs Multi-Pill Antihypertensive Therapy: A Systematic Review of Adherence and Outcomes","year":2025,"lang":"en","type":"article","venue":"Hypertension","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Blood pressure; Pill; Randomized controlled trial; Antihypertensive drug; Medication adherence; Clinical trial; Meta-analysis","score_opus":0.11327410363315352,"score_gpt":0.3026027819117154,"score_spread":0.1893286782785619,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415262181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5573563,0.4111261,0.00008560877,0.008885075,0.0009188222,0.002469051,0.00022517156,0.00009537171,0.018838516],"genre_scores_gemma":[0.92139024,0.05903346,0.00019517171,0.019057607,0.000015792239,0.000029538205,0.000007134127,0.000020921192,0.00025015904],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99824893,0.000025908728,0.0010360299,0.00039579973,0.00003573788,0.0002576064],"domain_scores_gemma":[0.99867153,0.00022141809,0.00045590647,0.00044482845,0.00011560571,0.00009069466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044288745,0.00023096432,0.0014143477,0.00019032841,0.00006324363,0.000032392272,0.00020014487,0.000110249675,0.00006182364],"category_scores_gemma":[0.0005716589,0.00019536378,0.00018124572,0.00018698309,0.00008763283,0.000112473266,0.000082700135,0.00014499447,0.00007785629],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035612774,0.003687428,0.09244991,0.74188596,0.0028643683,0.00010255958,0.00092860725,0.000014952798,0.01703533,0.11753972,0.016447358,0.00668766],"study_design_scores_gemma":[0.026070803,0.0017858765,0.381731,0.4293526,0.0014578211,0.00028767512,0.00063262915,0.044320103,0.013408029,0.041593462,0.05306157,0.0062984177],"about_ca_topic_score_codex":0.00019110953,"about_ca_topic_score_gemma":0.000007136907,"teacher_disagreement_score":0.36403394,"about_ca_system_score_codex":0.000038220645,"about_ca_system_score_gemma":0.000024508538,"threshold_uncertainty_score":0.79667044},"labels":[],"label_agreement":null},{"id":"W4415341523","doi":"10.51594/imsrj.v5i8.2073","title":"Pharmaceutical market analytics for therapeutic equity: Data-Driven models for expanding access to essential medicines","year":2025,"lang":"","type":"article","venue":"International Medical Science Research Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child, Adolescent and Family Mental Health","funders":"","keywords":"Analytics; Transparency (behavior); Essential medicines; Predictive analytics; Equity (law); Big data; Corporate governance; Pharmaceutical industry; Personalized medicine","score_opus":0.509892727248921,"score_gpt":0.6056956383928648,"score_spread":0.09580291114394379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415341523","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022444488,0.0019671184,0.5722066,0.3826283,0.010127819,0.0016611461,0.0015564015,0.000016719488,0.027591432],"genre_scores_gemma":[0.95377433,0.013213927,0.002579544,0.021978864,0.0064763087,0.00022176368,0.00005023006,0.000052437088,0.0016526042],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9925164,0.00013467057,0.00206016,0.001462767,0.0015980945,0.0022278975],"domain_scores_gemma":[0.9914545,0.0033940668,0.0004156757,0.00069860026,0.0015309158,0.0025062754],"candidate_categories":["metaresearch","metaepi_narrow","sts","scholarly_communication","open_science","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.034364678,0.00034081252,0.00079395605,0.002964518,0.0015918151,0.0035951007,0.011923766,0.0002842731,0.0033331185],"category_scores_gemma":[0.015280987,0.0003377021,0.00030141394,0.0018856612,0.002126983,0.002554635,0.0056102215,0.0016132669,0.00004727276],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00166061,0.00092236366,0.0016715873,0.000314021,0.0011820093,0.000035683584,0.00031073185,0.0029574942,0.00023852408,0.48213837,0.27379864,0.23476996],"study_design_scores_gemma":[0.001700812,0.00012225007,0.00014002826,0.00025468724,0.000033056633,0.000024270194,0.000072080875,0.60241234,0.00011376174,0.17114055,0.2237784,0.00020776001],"about_ca_topic_score_codex":0.000034066983,"about_ca_topic_score_gemma":0.000035371057,"teacher_disagreement_score":0.95152986,"about_ca_system_score_codex":0.0017540345,"about_ca_system_score_gemma":0.0043910434,"threshold_uncertainty_score":0.9999075},"labels":[],"label_agreement":null},{"id":"W4415364752","doi":"10.3389/jpps.2025.14721","title":"A survey of regulatory recommendations for waivers of in vivo bioequivalence studies of generic products for certain dosage forms by participating regulators and organisations of the International Pharmaceutical Regulators Programme. Part 2","year":2025,"lang":"en","type":"review","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"World Health Organization","keywords":"Bioequivalence; Dosage form; Biopharmaceutics; Pharmaceutical industry; Pharmaceutical technology; Biopharmaceutics Classification System","score_opus":0.3901406023800169,"score_gpt":0.46923390284230093,"score_spread":0.07909330046228402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415364752","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05321651,0.93489456,0.00011663326,0.0037297911,0.0015694083,0.002268588,0.0040659304,0.0000069135494,0.00013167236],"genre_scores_gemma":[0.15908448,0.839229,0.0011848087,0.00015806849,0.000115253824,0.00012797443,0.000015080414,0.000028521894,0.000056793608],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99510795,0.00020309127,0.0035230897,0.00046993332,0.00021506802,0.00048085002],"domain_scores_gemma":[0.9933092,0.0021372891,0.0036626577,0.00022473882,0.00049387437,0.0001722544],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0060940827,0.00033482024,0.0019019054,0.0005952732,0.00013755314,0.000032138785,0.0010417956,0.00011079434,0.000075572156],"category_scores_gemma":[0.0027149662,0.00026045568,0.00050050166,0.0013133022,0.0013282273,0.00035180734,0.00028322544,0.00031827076,2.2285288e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007049033,0.002707303,0.0431239,0.051938895,0.0042822766,0.0000014644833,0.0021724412,0.00030823253,0.0026982496,0.056077026,0.019268494,0.8167168],"study_design_scores_gemma":[0.0029337802,0.00028029468,0.0002762135,0.0033708205,0.0009699987,0.00000875884,0.00025742134,0.0066823983,0.022916717,0.0026124404,0.95919424,0.00049694104],"about_ca_topic_score_codex":0.000057060723,"about_ca_topic_score_gemma":0.0000126463265,"teacher_disagreement_score":0.93992573,"about_ca_system_score_codex":0.00022889982,"about_ca_system_score_gemma":0.0007573269,"threshold_uncertainty_score":0.99998474},"labels":[],"label_agreement":null},{"id":"W4416118304","doi":"10.1136/bmj-2023-074982","title":"Pharmaceutical governance system for costly drugs through human rights due diligence","year":2025,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto","funders":"","keywords":"Due diligence; Human rights; Corporate governance; Access to medicines; Drug industry; Pharmaceutical industry","score_opus":0.07714213236827773,"score_gpt":0.37202548228979476,"score_spread":0.29488334992151705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416118304","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10671661,0.0035635,0.007911123,0.01656269,0.0034616524,0.0020310674,0.0013190066,0.00021213766,0.8582222],"genre_scores_gemma":[0.99176615,0.000059893755,0.00056121766,0.0029419523,0.0004542053,0.00023541161,0.000016349462,0.000022402986,0.003942441],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980426,0.000017377755,0.0008830367,0.0005326126,0.00003279331,0.0004916196],"domain_scores_gemma":[0.9989873,0.00015809353,0.00028627997,0.00041335187,0.000035236833,0.000119696764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058000826,0.00021030095,0.00051347376,0.00006687469,0.0003385864,0.00009759364,0.0004355459,0.00013172669,0.00014546617],"category_scores_gemma":[0.000054194606,0.00023869508,0.0002158023,0.00019200749,0.00010008573,0.00021865456,0.00010344807,0.00018347996,0.0005993362],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034397795,0.00005870676,0.0005815414,0.00016575094,0.000075779346,0.0000028643224,0.00008611457,0.000027956534,0.000030498108,0.95267385,0.045909103,0.00035345397],"study_design_scores_gemma":[0.0011738767,0.000025430934,0.0012770478,0.000056735844,0.00001994392,0.0000037413165,0.000015514914,0.005052699,0.002075652,0.14197378,0.84801733,0.00030823934],"about_ca_topic_score_codex":0.00027409056,"about_ca_topic_score_gemma":0.000026462278,"teacher_disagreement_score":0.8850495,"about_ca_system_score_codex":0.00031593745,"about_ca_system_score_gemma":0.000035644363,"threshold_uncertainty_score":0.97337025},"labels":[],"label_agreement":null},{"id":"W4416118360","doi":"10.1136/bmj-2025-084839","title":"Collective international action to increase access to costly drugs: pooled procurement and equity based tiered pricing","year":2025,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Engineering Link (Canada)","funders":"Helse- og Omsorgsdepartementet","keywords":"Equity (law); Reimbursement; Procurement; Collective action; Drug pricing; Cost sharing; Action (physics); Drug industry","score_opus":0.12570153501976172,"score_gpt":0.41489632833850487,"score_spread":0.28919479331874315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416118360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5506311,0.00011151996,0.011658638,0.08326832,0.0012641359,0.0022018636,0.00035176842,0.000056889243,0.35045573],"genre_scores_gemma":[0.9765616,0.000012339812,0.0005499643,0.020744871,0.00013376586,0.0001889605,0.000009592853,0.000009326337,0.0017895688],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99908096,0.000013366248,0.00037079692,0.00031361205,0.00003015105,0.00019113526],"domain_scores_gemma":[0.9994809,0.00006212848,0.000114978306,0.0001393614,0.000046536432,0.00015612105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054280914,0.00010188561,0.00020403764,0.00036837536,0.00008871582,0.0002100875,0.00022531344,0.000045240427,0.00017431912],"category_scores_gemma":[0.00034230057,0.00012527677,0.000038876784,0.00028265873,0.000012995713,0.0001676323,0.0002843209,0.000083733714,0.00010096535],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036846725,0.0011622475,0.13506293,0.0004482551,0.0012740989,0.000009851717,0.0037972783,0.0067908433,0.0018646977,0.25544566,0.46561787,0.1248416],"study_design_scores_gemma":[0.004199223,0.00017083631,0.16355994,0.00013908188,0.000040365594,0.0000015533622,0.00011896151,0.072226524,0.0053066644,0.044307776,0.7091848,0.0007442635],"about_ca_topic_score_codex":0.0003343925,"about_ca_topic_score_gemma":0.00007647421,"teacher_disagreement_score":0.42593047,"about_ca_system_score_codex":0.0007363884,"about_ca_system_score_gemma":0.00016143979,"threshold_uncertainty_score":0.51086384},"labels":[],"label_agreement":null},{"id":"W4416121160","doi":"10.1208/s12248-025-01159-x","title":"Regulatory Divergence in Narrow Therapeutic Index Drugs: A Comparative Review of the US, EU, Japan, Canada, and South Korea","year":2025,"lang":"en","type":"article","venue":"The AAPS Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Ministry of Science and ICT, South Korea; Ministry of Food and Drug Safety; Chung-Ang University","keywords":"Harmonization; Regulatory science; Interchangeability; Bioequivalence; European union; Guideline; Index (typography); Divergence (linguistics)","score_opus":0.04029268370459185,"score_gpt":0.27603438765258287,"score_spread":0.23574170394799102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416121160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.880836,0.09096114,0.000013612363,0.015914598,0.00044639813,0.00024278337,0.00007920479,0.0000025545069,0.011503703],"genre_scores_gemma":[0.97957444,0.0066509186,0.0000042871575,0.01339207,0.000040410046,0.00000437322,3.9279095e-7,0.0000050528442,0.0003280303],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99898267,0.00007164907,0.00057439436,0.00013233366,0.00004082119,0.0001981331],"domain_scores_gemma":[0.9992085,0.000075476884,0.0003829752,0.0002453958,0.000028914877,0.00005875077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008721966,0.0001075689,0.00035676156,0.000070980954,0.00014702138,0.000027459726,0.00042078842,0.000032442676,0.00013151666],"category_scores_gemma":[0.000041768384,0.00007313435,0.00007877388,0.0002371929,0.00015219438,0.000063166066,0.000104323866,0.00036436992,0.0000053542544],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006529896,0.00008679649,0.7792368,0.0006818475,0.0003498959,0.0000021164133,0.005517996,0.00055388664,0.000027325323,0.17895551,0.03144132,0.0030812297],"study_design_scores_gemma":[0.0008010567,0.000019448,0.8343407,0.0009068654,0.000033832956,0.000018985176,0.00027780462,0.0026146134,0.00008775304,0.043740574,0.11693282,0.00022558887],"about_ca_topic_score_codex":0.014287065,"about_ca_topic_score_gemma":0.013098806,"teacher_disagreement_score":0.13521494,"about_ca_system_score_codex":0.00014056277,"about_ca_system_score_gemma":0.00023892621,"threshold_uncertainty_score":0.9922769},"labels":[],"label_agreement":null},{"id":"W4416291706","doi":"10.1136/bmj-2025-086516","title":"Policies to promote affordability and access across the life cycle of costly new drugs","year":2025,"lang":"en","type":"article","venue":"BMJ","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Engineering Link (Canada)","funders":"Helse- og Omsorgsdepartementet","keywords":"Equity (law); Health insurance; Access to medicines; MEDLINE; Health policy","score_opus":0.06965475877918414,"score_gpt":0.3892486314678055,"score_spread":0.3195938726886213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416291706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89508224,0.0005388658,0.00015808412,0.07014278,0.0001969029,0.0004456267,0.00019450288,0.00001292548,0.033228047],"genre_scores_gemma":[0.98880225,0.000105130515,0.00011591341,0.009759826,0.00012225645,0.000022632168,0.0000013173076,0.000007759217,0.0010629114],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990361,0.000010054762,0.00047834826,0.00021747853,0.000015977754,0.00024209442],"domain_scores_gemma":[0.9992859,0.000087707995,0.0001402439,0.00032661663,0.000016696922,0.000142861],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065737066,0.00009367415,0.00027623432,0.00006214209,0.0000931579,0.00011962946,0.00035287673,0.00004978261,0.00008133544],"category_scores_gemma":[0.00031602997,0.0000841555,0.00006514543,0.0002207471,0.000091819784,0.00011894671,0.00032661518,0.00009001977,0.00005888798],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017029404,0.00017942542,0.12595962,0.00022402988,0.00025038046,4.385051e-7,0.009088308,0.00061757455,0.0000625852,0.7227685,0.093554884,0.047123954],"study_design_scores_gemma":[0.0007471017,0.00003962949,0.27872494,0.000022105964,0.000009747812,7.4533193e-7,0.0001827094,0.0027270375,0.0007670946,0.15132883,0.5652191,0.00023092059],"about_ca_topic_score_codex":0.0016826938,"about_ca_topic_score_gemma":0.00011035147,"teacher_disagreement_score":0.5714397,"about_ca_system_score_codex":0.000033137225,"about_ca_system_score_gemma":0.000064116466,"threshold_uncertainty_score":0.34317616},"labels":[],"label_agreement":null},{"id":"W4416432011","doi":"10.2139/ssrn.5748329","title":"Pharmaceutical Governance System for Costly Drugs Through Human Rights Due Diligence","year":2025,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Due diligence; Human rights; Corporate governance; Legislation; Pharmaceutical industry","score_opus":0.04790202717491207,"score_gpt":0.3326700863694269,"score_spread":0.28476805919451487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416432011","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20486152,0.16470233,0.13401279,0.025694892,0.023731831,0.0070387716,0.011221899,0.0007154922,0.42802048],"genre_scores_gemma":[0.9839593,0.0080509735,0.00028960023,0.0010568358,0.0017376741,0.00016707309,0.000060554856,0.000069372625,0.004608572],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.993607,0.000063314656,0.0017539267,0.0010430551,0.00009852279,0.0034341905],"domain_scores_gemma":[0.997504,0.00017277696,0.0013177602,0.0006379444,0.00011269677,0.00025485127],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0026888365,0.00061491755,0.0013090742,0.00018865985,0.000760413,0.0003135333,0.0014888501,0.0005358343,0.0000856223],"category_scores_gemma":[0.000062209176,0.0006958933,0.0008234165,0.00017702997,0.00013777723,0.00028148197,0.0004680485,0.004857868,0.00020652906],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000077059565,0.000105549116,0.00015921368,0.00032367877,0.0006205702,0.0000037807242,0.00015571153,0.00026931433,0.000005317665,0.99547285,0.0019819543,0.0008249873],"study_design_scores_gemma":[0.0012968208,0.000084722036,0.00005290295,0.00016527058,0.000093630806,0.000063591484,0.00005712487,0.0029081139,0.0002008679,0.7889122,0.20553313,0.0006316729],"about_ca_topic_score_codex":0.00054069905,"about_ca_topic_score_gemma":0.00032455442,"teacher_disagreement_score":0.77909786,"about_ca_system_score_codex":0.0053807735,"about_ca_system_score_gemma":0.0013366329,"threshold_uncertainty_score":0.9995492},"labels":[],"label_agreement":null},{"id":"W4416564553","doi":"10.1136/bmjgh-2025-018960","title":"The association between drug shortages and prices across 74 countries: uncovering global access inequities","year":2025,"lang":"en","type":"article","venue":"BMJ Global Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"","keywords":"Economic shortage; Per capita; Global health; Association (psychology); Health policy; Inequality; Global South","score_opus":0.050820532014487795,"score_gpt":0.4272680012587912,"score_spread":0.37644746924430345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416564553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8696256,0.013380071,0.00043853998,0.052064147,0.0013825101,0.00073729904,0.0052551795,0.00008140764,0.057035223],"genre_scores_gemma":[0.98599064,0.0056436984,0.00003482698,0.007547938,0.00027964718,0.000029913432,0.000016994782,0.0000066936677,0.00044962356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981499,0.000028968272,0.00080256833,0.00032632725,0.00005259583,0.0006396885],"domain_scores_gemma":[0.9988413,0.0002463649,0.00051547406,0.00021397478,0.000032935262,0.00014996294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018492909,0.00016048968,0.00044496421,0.00002603262,0.0006053524,0.00068964966,0.00038524598,0.0000912261,0.000011472178],"category_scores_gemma":[0.00017569147,0.0001570752,0.00006574435,0.0002646994,0.000082725586,0.00034205886,0.00032032913,0.0001306324,0.000047676687],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013671576,0.000008298213,0.6737485,0.000079674865,0.00007838474,2.5741474e-7,0.000095649884,0.00003133935,6.9096657e-9,0.3106564,0.010652237,0.0046355957],"study_design_scores_gemma":[0.00035569942,0.000016135304,0.4950155,0.000027123884,0.000005576383,5.9628087e-7,0.00010937644,0.00031146276,0.0000016022013,0.09419557,0.4098222,0.00013915803],"about_ca_topic_score_codex":0.0035605351,"about_ca_topic_score_gemma":0.002464236,"teacher_disagreement_score":0.39916995,"about_ca_system_score_codex":0.0018257062,"about_ca_system_score_gemma":0.00025497033,"threshold_uncertainty_score":0.6650308},"labels":[],"label_agreement":null},{"id":"W4416716456","doi":"10.1001/jamahealthforum.2025.4078","title":"Adherence, Switches, and Drug Spending After Angiotensin Receptor Blocker Recalls and Shortages","year":2025,"lang":"en","type":"article","venue":"JAMA Health Forum","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"Health Canada; Agency for Healthcare Research and Quality; National Institutes of Health; U.S. Department of Veterans Affairs; Arnold Ventures; University of Southern California; Soochow University","keywords":"Drug; Economic shortage; Angiotensin Receptor Blockers; Health care; Beta blocker; Cohort; Drug approval","score_opus":0.03200195601084249,"score_gpt":0.30027097698535626,"score_spread":0.26826902097451377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416716456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80874664,0.024869751,0.00011910716,0.1510459,0.00081700576,0.0004966797,0.0003597225,0.000049189766,0.013495998],"genre_scores_gemma":[0.96739703,0.0059090774,0.0010860574,0.022758316,0.00013019348,0.000029808118,0.000011759074,0.000020865444,0.0026569036],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983718,0.000017180058,0.00060553424,0.00045192122,0.00001912861,0.0005344707],"domain_scores_gemma":[0.99925524,0.000088216424,0.00017444293,0.00020941689,0.000012472006,0.00026018659],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064363616,0.00017108572,0.0004500519,0.00023833416,0.00015525182,0.00015259946,0.00010317755,0.000117914526,0.00027794746],"category_scores_gemma":[0.00006649223,0.00019326196,0.00005866048,0.00016190144,0.00007758716,0.00020159456,0.00014388766,0.0002560775,0.00014417554],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010131594,0.000059772872,0.5808258,0.00020409437,0.00007748129,0.0000027251476,0.0004694796,0.0000010387669,0.000014997311,0.22536376,0.1448371,0.048042398],"study_design_scores_gemma":[0.00075542065,0.000053702028,0.11059813,0.00009065229,0.000004869403,0.0000035405596,0.000085832806,0.00090148003,0.000072007584,0.032953642,0.8542197,0.00026101866],"about_ca_topic_score_codex":0.00047806118,"about_ca_topic_score_gemma":0.00020489059,"teacher_disagreement_score":0.7093826,"about_ca_system_score_codex":0.000105834035,"about_ca_system_score_gemma":0.000049115115,"threshold_uncertainty_score":0.7880994},"labels":[],"label_agreement":null},{"id":"W4416784074","doi":"10.1017/s026646232510322x","title":"A method to identify prescription drug targets for health technology reassessment","year":2025,"lang":"en","type":"article","venue":"International Journal of Technology Assessment in Health Care","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CARE Canada; University of British Columbia; University of Alberta; University of Calgary","funders":"Health Canada","keywords":"Medical prescription; Specialty; Health technology; Perspective (graphical); Prescription drug; Drug; Focus (optics)","score_opus":0.04389190415973355,"score_gpt":0.48394699974316047,"score_spread":0.4400550955834269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416784074","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019401152,0.009196645,0.220464,0.7448931,0.0031409233,0.001062769,0.00035392994,0.00006418315,0.0014233327],"genre_scores_gemma":[0.86966574,0.001007856,0.11551454,0.013410406,0.00010726633,0.00014273505,0.000021970056,0.000020353753,0.000109114],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972858,0.000045391665,0.0018412599,0.0003482851,0.00007532778,0.00040392438],"domain_scores_gemma":[0.9980943,0.00008710211,0.0011715133,0.000217867,0.00031296167,0.00011624052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00187607,0.00015886035,0.00064619066,0.0036182862,0.00009436054,0.00005534676,0.0008570428,0.00017173938,0.000037593687],"category_scores_gemma":[0.00016172863,0.00018773999,0.0001411226,0.00054240966,0.000041578754,0.00017120247,0.00020076035,0.0005793461,0.000009652628],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000918144,0.00021860146,0.027183408,0.00017395601,0.00020015775,0.0000073073334,0.00030049932,0.00045975493,0.000044934153,0.87509835,0.01205601,0.084165186],"study_design_scores_gemma":[0.0022186958,0.00041999103,0.020596575,0.0003740261,0.000005992389,0.000031883323,0.0016152906,0.0010793209,0.0002700126,0.25821844,0.71495616,0.00021360567],"about_ca_topic_score_codex":0.00015366208,"about_ca_topic_score_gemma":0.00010238237,"teacher_disagreement_score":0.8502646,"about_ca_system_score_codex":0.0026405721,"about_ca_system_score_gemma":0.00066451373,"threshold_uncertainty_score":0.7655815},"labels":[],"label_agreement":null},{"id":"W4417300028","doi":"10.1002/hec.70073","title":"Physician Agency and the Zero‐Markup Drug Policy in China: Evidence From a Structural Model","year":2025,"lang":"en","type":"article","venue":"Health Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bank of Canada","funders":"National Natural Science Foundation of China","keywords":"Agency (philosophy); Government (linguistics); Profit margin; Medical prescription; Margin (machine learning); Drug; Prescription drug; Profit (economics); Public policy","score_opus":0.052911106474017984,"score_gpt":0.33294176342045273,"score_spread":0.28003065694643475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417300028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89749485,0.012280901,0.0004433623,0.07619191,0.0004215967,0.0005931787,0.00041286618,0.00002640209,0.012134928],"genre_scores_gemma":[0.95498216,0.01541845,0.0003697233,0.028561141,0.00018385769,0.000053503136,0.00001178727,0.000023873677,0.00039551585],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9977208,0.00005287209,0.0010797748,0.00057800673,0.000013054464,0.0005555352],"domain_scores_gemma":[0.9986575,0.00026797483,0.00041614124,0.00047922254,0.000007665869,0.00017144856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009057899,0.0002416602,0.0007550874,0.0003062356,0.0002266775,0.00013837522,0.0004208812,0.00008574691,0.000031758285],"category_scores_gemma":[0.00012622814,0.00024249255,0.00012450479,0.0002197216,0.00020631934,0.00036146052,0.00021239564,0.00036173465,0.00007142816],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012565113,0.000023461567,0.011700753,0.00007497251,0.00004629857,3.3724916e-7,0.0029311518,0.0047159893,7.5170715e-7,0.966868,0.0014709622,0.012041689],"study_design_scores_gemma":[0.0012664945,0.000007202095,0.03611746,0.000037350706,0.0000029878106,4.1415282e-7,0.000020161135,0.4040963,0.000003478879,0.553918,0.0043619536,0.00016818853],"about_ca_topic_score_codex":0.013843846,"about_ca_topic_score_gemma":0.0012758572,"teacher_disagreement_score":0.41294998,"about_ca_system_score_codex":0.00052371935,"about_ca_system_score_gemma":0.0003503189,"threshold_uncertainty_score":0.99272305},"labels":[],"label_agreement":null},{"id":"W4417474620","doi":"10.63209/2025.1611","title":"Le médicament est une technologie de plus en plus coûteuse : sommes-nous prêts à la financer et l’encadrer adéquatement?","year":2025,"lang":"","type":"article","venue":"Pharmactuel","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Government (linguistics); Context (archaeology); China; Investment (military)","score_opus":0.044820504759147006,"score_gpt":0.3444996867297355,"score_spread":0.2996791819705885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417474620","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19483902,0.04631891,0.0273615,0.23814473,0.0053354725,0.0044451575,0.003470406,0.00072709186,0.47935772],"genre_scores_gemma":[0.92685086,0.04331723,0.00072298484,0.024545155,0.00020796356,0.000404339,0.00004585325,0.00011703874,0.0037885706],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9943753,0.00018238949,0.002040338,0.0014839824,0.00011547101,0.0018025038],"domain_scores_gemma":[0.9968719,0.0006329112,0.0008541124,0.0010608553,0.000073622236,0.00050660566],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.002313263,0.00088249176,0.0014939199,0.0008744975,0.00047683538,0.00050484104,0.0016683287,0.0008523756,0.0009826529],"category_scores_gemma":[0.00039845513,0.0011508852,0.00053074444,0.0010204499,0.000555283,0.0006465097,0.0010957975,0.0022630496,0.0014662908],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059902994,0.0014892189,0.0025996454,0.0005911613,0.0012080519,0.000107683656,0.0018274239,0.0085297935,0.00029272618,0.90584147,0.05109823,0.025815595],"study_design_scores_gemma":[0.009690897,0.000113499176,0.0026275238,0.00017302913,0.00016687157,0.000019731799,0.00025424245,0.079350494,0.0027623514,0.05738839,0.84625304,0.001199934],"about_ca_topic_score_codex":0.0018819476,"about_ca_topic_score_gemma":0.00010524246,"teacher_disagreement_score":0.84845304,"about_ca_system_score_codex":0.002243822,"about_ca_system_score_gemma":0.0027138414,"threshold_uncertainty_score":0.99993056},"labels":[],"label_agreement":null},{"id":"W45620804","doi":"10.1533/9781908818089.17","title":"Background: drug approval, drug patenting, pharmaceutical linkage, and public health policy * *This chapter is based upon material in: M. Sawicka and R.A. Bouchard, ‘Empirical Analysis of Canadian Drug Approval Data 2001–2008: Are Canadian Pharmaceutical Players “Doing More With Less?”’ McGill Journal of Law &amp; Health 3: 87–151 (2009); R.A. Bouchard, J. Sawani, C. McLelland, M. Sawicka, and R. Hawkins, ‘The Pas de Deux of Pharmaceutical Regulation and Innovation: Who’s Leading Whom?’ Berkeley Technology Law Journal 24(3): 1461–522 (2009); R.A. Bouchard, R.W. Hawkins, R. Clark, R. Hagtvedt, and J. Sawani, ‘Empirical Analysis of Drug Approval-Patenting Linkage for High Value Pharmaceuticals,’ Northwestern Journal of Technology &amp; Intellectual Property 8(2): 1–86 (2010).","year":2012,"lang":"en","type":"book-chapter","venue":"Elsevier eBooks","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Linkage (software); Record linkage; Public health; Drug; Political science; Public economics; Medicine; Economics; Pharmacology; Environmental health; Chemistry; Population","score_opus":0.15380247312126555,"score_gpt":0.33563357590399856,"score_spread":0.181831102782733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W45620804","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86291975,0.03762529,0.0015218506,0.07394196,0.0010205498,0.0042879777,0.015841471,0.00007553953,0.0027655908],"genre_scores_gemma":[0.9629989,0.0173023,0.0071116444,0.009484211,0.00066241866,0.000042023818,0.0005939529,0.000310647,0.0014938593],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98968285,0.0004345267,0.0054611024,0.0015596413,0.0006037344,0.0022581585],"domain_scores_gemma":[0.98997617,0.0006538872,0.005237948,0.0009786447,0.0010283124,0.002125051],"candidate_categories":["metaepi_narrow","bibliometrics","sts","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0092010405,0.0012791916,0.0046474794,0.011581412,0.0010810664,0.00048682693,0.001177689,0.0008913909,0.00016746456],"category_scores_gemma":[0.00036901142,0.0011225706,0.00048234133,0.0018874366,0.003005548,0.00071643235,0.0006575509,0.0032461055,0.0000020044777],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058923536,0.002140228,0.30931836,0.011280856,0.04452576,0.00024605723,0.025449075,0.00082562084,0.0010574397,0.1467807,0.011704876,0.44077867],"study_design_scores_gemma":[0.0075203,0.00034905053,0.0017433874,0.0010936606,0.0043150294,0.0009204628,0.0008375153,0.021714512,0.00043892712,0.0011301747,0.95830506,0.0016319295],"about_ca_topic_score_codex":0.027859464,"about_ca_topic_score_gemma":0.17966466,"teacher_disagreement_score":0.9466002,"about_ca_system_score_codex":0.0009968448,"about_ca_system_score_gemma":0.0022444776,"threshold_uncertainty_score":0.999996},"labels":[],"label_agreement":null},{"id":"W48989372","doi":"10.1007/bf03256677","title":"Drug Approval Times and User Fees","year":2008,"lang":"en","type":"article","venue":"Pharmaceutical Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University; University of Toronto; University Health Network","funders":"","keywords":"Government (linguistics); Business; Agency (philosophy); Approved drug; Drug; Payment; User fee; Finance; Drug approval; Resource (disambiguation); Orphan drug; Public economics; Medicine; Pharmacology; Economics","score_opus":0.10931244738849398,"score_gpt":0.3302034876115756,"score_spread":0.2208910402230816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W48989372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.57438964,0.025729215,0.00095937,0.09242645,0.0014855998,0.0006404282,0.0001234595,0.0002278579,0.304018],"genre_scores_gemma":[0.97813016,0.0044898666,0.00038130485,0.012859771,0.0007901703,0.000022164912,0.000009113189,0.000034147008,0.0032832911],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.998402,0.000021766033,0.0006011615,0.0004589773,0.000051426403,0.0004646947],"domain_scores_gemma":[0.99893665,0.00019100888,0.000116085954,0.00021885618,0.000020395146,0.0005169784],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0005009905,0.00022033745,0.00053516554,0.00017206985,0.00016157042,0.000016319518,0.00020855656,0.0000723441,0.0033496036],"category_scores_gemma":[0.0001933353,0.00020901828,0.000066661254,0.00017073343,0.0006289909,0.0001722554,0.00011109378,0.00033690786,0.0009487564],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011850854,0.00022475401,0.056953076,0.000118704906,0.0001785476,0.00006462248,0.0012854412,0.000009132183,0.0003069952,0.80616987,0.12963592,0.004934454],"study_design_scores_gemma":[0.0023305384,0.000059042886,0.0076095406,0.000016490028,0.000021880767,0.00010746801,0.000030596337,0.006931934,0.0004498573,0.023824219,0.9582787,0.0003397306],"about_ca_topic_score_codex":0.00008801797,"about_ca_topic_score_gemma":0.0000018645197,"teacher_disagreement_score":0.8286428,"about_ca_system_score_codex":0.000045823967,"about_ca_system_score_gemma":0.000016730008,"threshold_uncertainty_score":0.9998291},"labels":[],"label_agreement":null},{"id":"W51974226","doi":"10.25071/1929-8404.34702","title":"Trade Agreements and Pharmaceutical Patent Protection: Implications for the Governance over Pharmaceutical Products in Canada","year":2012,"lang":"en","type":"article","venue":"Healthy Dialogue","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"York University","funders":"","keywords":"Business; Intellectual property; Pharmaceutical industry; Government (linguistics); Revenue; Corporate governance; Legislation; International trade; Profit (economics); Commerce; Industrial organization; Economics; Finance; Law; Biotechnology","score_opus":0.21825874156395117,"score_gpt":0.3369003616118901,"score_spread":0.1186416200479389,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W51974226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.50571465,0.036870647,0.0014782326,0.43816873,0.0044251313,0.006643021,0.003810409,0.000055443612,0.002833712],"genre_scores_gemma":[0.9829386,0.0027571018,0.00008377714,0.013020551,0.00056248443,0.0005760305,0.000016537493,0.000022525046,0.000022383549],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982762,0.000029444263,0.00058993435,0.00034819677,0.00003455058,0.00072168757],"domain_scores_gemma":[0.99906796,0.00018841556,0.00017308476,0.00023261122,0.0000119147835,0.0003260346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062953756,0.00016394767,0.00028280038,0.000042393258,0.00018945792,0.000036529258,0.00017089708,0.000060576003,0.00007791627],"category_scores_gemma":[0.00012313225,0.00015503235,0.00004465177,0.00018390878,0.00006699083,0.00017796623,0.000055478326,0.00028997049,0.000023449344],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032151496,0.0005483954,0.37912455,0.0004497857,0.000121783225,0.0000011361307,0.0005448351,0.00008097469,0.0000925068,0.5562977,0.017751826,0.04466493],"study_design_scores_gemma":[0.0012255551,0.000027582617,0.4172937,0.0000056868844,0.000009588199,0.000007030557,0.000011985787,0.0042724977,0.00006801934,0.0020755474,0.5748131,0.00018971054],"about_ca_topic_score_codex":0.119454,"about_ca_topic_score_gemma":0.051968195,"teacher_disagreement_score":0.55706125,"about_ca_system_score_codex":0.00071432197,"about_ca_system_score_gemma":0.00026457856,"threshold_uncertainty_score":0.9653309},"labels":[],"label_agreement":null},{"id":"W53958636","doi":"","title":"Generic drug pricing in Canada: components of the value-chain","year":2010,"lang":"en","type":"preprint","venue":"RePEc: Research Papers in Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Incentive; Business; Production (economics); Quality (philosophy); Set (abstract data type); Value (mathematics); Pharmacy; Predictability; Generic drug; Industrial organization; Actuarial science; Economics; Microeconomics; Computer science","score_opus":0.07276100822290306,"score_gpt":0.306301668767136,"score_spread":0.23354066054423295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W53958636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9318342,0.00049198937,0.0000011778956,0.0019368684,0.0014399311,0.00075527135,0.00045794479,0.00000726669,0.06307535],"genre_scores_gemma":[0.99415356,0.0042185797,0.00016088436,0.00060365023,0.0001811715,0.00010503059,0.000028119945,0.00007260645,0.00047641862],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99590015,0.0001581105,0.0018320257,0.0009787543,0.000099503995,0.0010314545],"domain_scores_gemma":[0.9971603,0.0004564952,0.0007537467,0.0013549965,0.000041345927,0.00023311233],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0027477404,0.00036584123,0.0011094308,0.0006654093,0.000112434696,0.000073059935,0.0017002417,0.00035922,0.00014672564],"category_scores_gemma":[0.00039985028,0.00040014138,0.00024968904,0.00027591767,0.00028231117,0.00007983777,0.0019028647,0.0031806796,0.000016500022],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015560466,0.00063254935,0.69209695,0.00092661905,0.0003534839,0.000041748695,0.0017098928,0.18074782,0.00050459814,0.08190504,0.00070599106,0.040219694],"study_design_scores_gemma":[0.002366975,0.00003096406,0.4395985,0.0003991064,0.000010925243,0.000010048582,0.0003354124,0.38342977,0.00078362663,0.06117914,0.110294424,0.0015611209],"about_ca_topic_score_codex":0.6055997,"about_ca_topic_score_gemma":0.69797814,"teacher_disagreement_score":0.25249845,"about_ca_system_score_codex":0.0036796043,"about_ca_system_score_gemma":0.0018661539,"threshold_uncertainty_score":0.999845},"labels":[],"label_agreement":null},{"id":"W603589202","doi":"10.5040/9798400658679","title":"Government Relations in the Health Care Industry","year":2003,"lang":"en","type":"book","venue":"Praeger eBooks","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Government (linguistics); Health care; Business; Political science; Public relations; Public administration; Law; Philosophy; Linguistics","score_opus":0.06575916763636572,"score_gpt":0.29240046226551675,"score_spread":0.22664129462915103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W603589202","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001723079,0.0045720916,0.000014278944,0.003833954,0.00034732107,0.0005241474,0.0008324071,0.000014000205,0.98968947],"genre_scores_gemma":[0.018857956,0.00017643814,0.00009919773,0.032757457,0.00041014454,0.00014454193,0.000072749484,0.00008542803,0.9473961],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99824625,0.00004210831,0.00082734,0.0004244299,0.00006112315,0.00039875568],"domain_scores_gemma":[0.99875885,0.00009806466,0.0005111961,0.0005035763,0.000009191823,0.0001190934],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00064693065,0.00025685102,0.0004912408,0.00011425885,0.00012160478,0.00008395737,0.00038009245,0.0005055153,0.000471919],"category_scores_gemma":[0.00003350716,0.0002617691,0.00015752921,0.000037154612,0.00006929395,0.000044260272,0.00006502842,0.0015144357,0.0009763112],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000004444291,0.000022158203,0.00063704565,0.000048974325,0.000037266323,0.0000037121226,0.0018801827,0.000008535165,3.0829085e-8,0.7943155,0.20152025,0.0015218938],"study_design_scores_gemma":[0.00028530622,0.00003337301,0.00027650275,0.000027684258,0.000005416053,0.000003553157,0.00007677375,0.000019041425,7.784845e-7,0.08090228,0.9181231,0.00024616474],"about_ca_topic_score_codex":0.000051118725,"about_ca_topic_score_gemma":0.000086059415,"teacher_disagreement_score":0.71660286,"about_ca_system_score_codex":0.0014125068,"about_ca_system_score_gemma":0.0003983386,"threshold_uncertainty_score":0.99998343},"labels":[],"label_agreement":null},{"id":"W617391686","doi":"","title":"PATENT EXPIRATION AND COMPETITION: A DYNAMIC LIMIT PRICE MODEL","year":2014,"lang":"en","type":"preprint","venue":"RePEc: Research Papers in Economics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Limit price; Economics; Monopoly; Microeconomics; Expiration date; Price elasticity of demand; Competition (biology); Limit (mathematics); Price discrimination; Product (mathematics); Industrial organization; Price level; Monetary economics","score_opus":0.1283713316083809,"score_gpt":0.3382978775211224,"score_spread":0.20992654591274149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W617391686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.68392074,0.001349877,0.000717309,0.0044911266,0.00071142294,0.001324423,0.0007351314,0.00007979898,0.3066702],"genre_scores_gemma":[0.9716457,0.024434693,0.0009253182,0.0009918024,0.00021803341,0.00029051313,0.00014499838,0.00008872488,0.0012602195],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99633795,0.00009102851,0.0013092342,0.001327828,0.00006190174,0.00087206723],"domain_scores_gemma":[0.99793416,0.00025922226,0.00046987124,0.00091786217,0.00006055808,0.0003583448],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021622044,0.00040491408,0.0009272924,0.0007673624,0.00018555192,0.00034062864,0.0005927103,0.00055869255,0.000171806],"category_scores_gemma":[0.00022193689,0.00053785805,0.00019598754,0.00010271175,0.00029499663,0.00018345077,0.001086764,0.0015582829,0.00013160998],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023254393,0.0006588353,0.009080226,0.0011278435,0.0003521739,0.00002060927,0.0013721506,0.25180352,0.00007685461,0.64104384,0.00027624256,0.09395513],"study_design_scores_gemma":[0.00074726116,0.000059136135,0.0021379164,0.00007819641,0.000004619356,0.00000543229,0.00003695641,0.81507766,0.0000104327655,0.14795016,0.03335746,0.0005347795],"about_ca_topic_score_codex":0.00006702608,"about_ca_topic_score_gemma":0.00014492599,"teacher_disagreement_score":0.56327415,"about_ca_system_score_codex":0.0010873727,"about_ca_system_score_gemma":0.00019779876,"threshold_uncertainty_score":0.9997073},"labels":[],"label_agreement":null},{"id":"W62752865","doi":"","title":"Pulse : Drug price index sees first increase in 5 years","year":2000,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Index (typography); Price index; Medicine; Population; Mandate; Consumer price index (South Africa); Agricultural economics; Business; Economics; Monetary economics; Environmental health; Econometrics; Law","score_opus":0.011922423602531165,"score_gpt":0.2281588042150788,"score_spread":0.21623638061254763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W62752865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83075047,0.0006269823,0.0000066522143,0.05805522,0.0004411317,0.00008905503,0.00013418963,0.000010615452,0.10988569],"genre_scores_gemma":[0.97179896,0.0010048503,0.000018389102,0.024822325,0.00075915625,0.0000053406748,0.0000056627478,0.000015334965,0.0015700103],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985134,0.000037576363,0.0006345292,0.00017586628,0.000109931185,0.0005287256],"domain_scores_gemma":[0.99819064,0.00010429269,0.00017833825,0.00009298356,0.00002572054,0.0014080066],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0018097957,0.000097692784,0.00025585713,0.000310966,0.00011896287,0.00012478737,0.00027577055,0.00022232528,0.051471066],"category_scores_gemma":[0.0006100383,0.00012406049,0.00010494276,0.0002567149,0.000026112042,0.00020144791,0.000012234673,0.0007667108,0.0029469563],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018235192,0.00009713035,0.7398184,0.000009761019,0.000108839624,0.0003724864,0.0009966358,0.00021017078,1.3337458e-7,0.009667787,0.20656766,0.042132795],"study_design_scores_gemma":[0.0006728985,0.0000057087464,0.21713966,0.0000119225315,0.000001570462,0.000028720597,0.000019981217,0.0024083678,1.952722e-7,0.004278566,0.7753036,0.00012879526],"about_ca_topic_score_codex":0.019207565,"about_ca_topic_score_gemma":0.07303278,"teacher_disagreement_score":0.56873596,"about_ca_system_score_codex":0.0012837754,"about_ca_system_score_gemma":0.0005540461,"threshold_uncertainty_score":0.9978294},"labels":[],"label_agreement":null},{"id":"W64546397","doi":"10.1007/978-94-007-6205-3_9","title":"Beyond Benefit Sharing: Steps Towards Realizing the Human Right to Health","year":2013,"lang":"en","type":"book-chapter","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Right to health; Computer science; Business; Internet privacy; Political science; Human rights; Law","score_opus":0.11236233673714394,"score_gpt":0.31545841366198446,"score_spread":0.20309607692484052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W64546397","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025293688,0.0018196937,0.00008218748,0.021498723,0.00045751056,0.00076353265,0.00063360005,0.00007155341,0.97442025],"genre_scores_gemma":[0.010120478,0.0012007991,0.0002706985,0.038823314,0.0009712428,0.00006210307,0.00010908343,0.00016116367,0.9482811],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969387,0.0000032802,0.0013829574,0.0009246431,0.00005443306,0.0006959602],"domain_scores_gemma":[0.99769074,0.000041537685,0.00064764306,0.0010449594,0.000038739927,0.0005363817],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00069588795,0.0004992186,0.0010191979,0.00035986296,0.00039157132,0.0003433348,0.0010338457,0.00030931027,0.021275532],"category_scores_gemma":[0.000011797189,0.000444934,0.00034182076,0.000053035845,0.00008234137,0.00014828413,0.000513069,0.0006025216,0.011191599],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000020017262,0.00001226619,0.00003352061,0.000033094886,0.000099998084,0.0000011324305,0.00013061929,0.000012613556,5.4301216e-7,0.93670446,0.060050193,0.0029195324],"study_design_scores_gemma":[0.00012303576,0.0000398752,0.00011425858,0.000020168387,0.0000049331957,0.0000020973227,0.000003675805,0.00013015492,0.000004127488,0.45543242,0.5438081,0.00031712922],"about_ca_topic_score_codex":0.0026176872,"about_ca_topic_score_gemma":0.00048154156,"teacher_disagreement_score":0.48375794,"about_ca_system_score_codex":0.00046770842,"about_ca_system_score_gemma":0.000048495007,"threshold_uncertainty_score":0.99980026},"labels":[],"label_agreement":null},{"id":"W6885838126","doi":"10.1371/journal.pone.0238618.s002","title":"Total pharmacies in British Columbia by regional Health Authority, 2018.","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Regional hospital; Public health; Pharmacy; MEDLINE","score_opus":0.15783933262593325,"score_gpt":0.30685439525341834,"score_spread":0.1490150626274851,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6885838126","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.026321888,0.009835993,0.0000035224084,0.028184442,0.00020754826,0.00048219567,0.91869193,0.00011067088,0.016161824],"genre_scores_gemma":[0.8959847,0.00055126456,0.00008011881,0.05601443,0.0006968559,0.00017541045,0.044257816,0.00006949614,0.0021699204],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986948,0.000014287633,0.0004913087,0.00038727937,0.000027691933,0.0003846705],"domain_scores_gemma":[0.99932706,0.0000379666,0.00018114803,0.00010589713,0.000010300556,0.0003376017],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000092234564,0.000094690186,0.0003389516,0.00003150115,0.00008716299,0.00030869903,0.00023316806,0.00007612671,0.14831404],"category_scores_gemma":[0.000177889,0.0001978292,0.00009155151,0.00018533184,0.000012126975,0.00020938215,0.00011916566,0.0002593045,0.004425207],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000002439736,0.000037743033,0.0029551436,0.00007120239,0.000009680008,0.000005609108,0.00010018166,0.000008203453,0.000001698322,0.00018312536,0.9951562,0.0014687633],"study_design_scores_gemma":[0.0005906067,0.000039430284,0.009270421,0.00007007783,5.247548e-7,0.000009370923,0.000012206813,0.003420526,0.000004079659,0.0010592939,0.98528826,0.00023518997],"about_ca_topic_score_codex":0.0041820845,"about_ca_topic_score_gemma":0.0017604473,"teacher_disagreement_score":0.8744341,"about_ca_system_score_codex":0.00011581515,"about_ca_system_score_gemma":0.0000599607,"threshold_uncertainty_score":0.99635},"labels":[],"label_agreement":null},{"id":"W6886001749","doi":"10.14288/1.0048260","title":"Toward a national pharmaceuticals strategy : a summary of the 2006 health policy conference of the UBC Centre for Health Services and Policy Research","year":2014,"lang":"en","type":"article","venue":"cIRcle (University of British Columbia)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Formulary; Pharmaceutical policy; Health policy; Health care; Activity-based costing; Medical prescription; Health economics; Healthcare policy; Health services","score_opus":0.10230072085461027,"score_gpt":0.32295164033279244,"score_spread":0.22065091947818216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6886001749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9075284,0.0012603255,0.000111577145,0.07160728,0.00011066709,0.0009841536,0.0075720153,0.000011818793,0.010813766],"genre_scores_gemma":[0.99666643,0.0009472452,0.00006488186,0.0018064913,0.00007556756,9.658401e-7,0.000008254649,0.000009129529,0.00042101264],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988076,0.0001168077,0.0003492747,0.00027341474,0.00009491283,0.00035800322],"domain_scores_gemma":[0.9988193,0.00014762497,0.00044695186,0.00021149515,0.00021005348,0.00016457221],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012385712,0.0000477906,0.00038490738,0.00011410784,0.00027037587,0.0000552749,0.000528274,0.00006773885,0.000037299895],"category_scores_gemma":[0.00009721573,0.000100560734,0.0001286294,0.00040521883,0.00048438282,0.00013777241,0.00025783954,0.00016457785,0.0000029374944],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015703864,0.0010933345,0.08260123,0.0068520433,0.00040392752,0.0000011933117,0.006256128,0.00020909429,0.00014083642,0.38526705,0.043245807,0.47377232],"study_design_scores_gemma":[0.0017272774,0.00011853594,0.869919,0.00023832475,0.0000054718575,0.0000067826654,0.0006325993,0.0061119464,0.000005687897,0.09049972,0.030593593,0.00014106685],"about_ca_topic_score_codex":0.19479686,"about_ca_topic_score_gemma":0.07140995,"teacher_disagreement_score":0.78731775,"about_ca_system_score_codex":0.00017331897,"about_ca_system_score_gemma":0.00076140696,"threshold_uncertainty_score":0.9455344},"labels":[],"label_agreement":null},{"id":"W6887928990","doi":"10.17632/msfp8h2nb8.1","title":"Data File 1.15 with descriptives","year":2024,"lang":"en","type":"dataset","venue":"Data Archiving and Networked Services (DANS)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Data collection; Multinational corporation; Investment (military); Pharmaceutical industry","score_opus":0.08292197931516887,"score_gpt":0.2867628703411219,"score_spread":0.20384089102595304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6887928990","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00033940442,0.006899337,0.00006827421,0.00034614943,0.00059401704,0.00023849453,0.98831856,0.00006981514,0.0031259535],"genre_scores_gemma":[0.00031598032,0.008643392,0.0005207049,0.0014928348,0.0011776938,0.000026485095,0.9874786,0.000080002785,0.000264311],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99649495,0.00004891669,0.0007715829,0.0019142722,0.00006367182,0.00070659944],"domain_scores_gemma":[0.9949109,0.00031200735,0.00041470182,0.0040248204,0.000009922104,0.00032768206],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0007569453,0.0005712932,0.000875363,0.0002730484,0.0002396338,0.0006863214,0.004632044,0.00020584335,0.0012736666],"category_scores_gemma":[0.000025165833,0.0005362279,0.00005554922,0.00026199955,0.00020437986,0.0007199909,0.004962726,0.0008826233,0.0027020315],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004186348,0.000051715935,0.00021466542,0.0007714672,0.0003526196,0.000032388794,0.00015752554,0.00004191336,2.7789903e-7,0.00029895484,0.997241,0.0007955979],"study_design_scores_gemma":[0.00023259642,0.00004701409,0.00045033023,0.00045062313,0.00011478894,0.000027313077,0.000067771725,0.083447985,1.4130164e-7,0.0022003842,0.9123283,0.00063275883],"about_ca_topic_score_codex":0.0020402246,"about_ca_topic_score_gemma":0.0064670527,"teacher_disagreement_score":0.08491272,"about_ca_system_score_codex":0.00003938962,"about_ca_system_score_gemma":0.00006360339,"threshold_uncertainty_score":0.99970895},"labels":[],"label_agreement":null},{"id":"W6888493640","doi":"10.20381/ruor-28250","title":"Neglecting the Essentials: Addressing Barriers to Accessing Off-Patent Essential Medicines for Neglected Diseases in Canada","year":2022,"lang":"en","type":"article","venue":"uO Research (University of Ottawa)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Essential medicines; Access to medicines; Context (archaeology); Essential drugs; Developing country; Government (linguistics); Health care; Malaria; Global health","score_opus":0.15089084588209475,"score_gpt":0.3357436257738092,"score_spread":0.18485277989171442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6888493640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97064227,0.0005878985,0.0004612016,0.021437835,0.00040889732,0.0006784721,0.00073004974,0.000013441889,0.0050399248],"genre_scores_gemma":[0.9988931,0.00007872052,0.00008757477,0.0005519531,0.00008640823,0.000008856221,0.000021026986,0.000015817262,0.0002565481],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985235,0.00013138965,0.0002983901,0.00035115532,0.00014407485,0.0005515375],"domain_scores_gemma":[0.99873763,0.00046027693,0.00017125784,0.00023206245,0.000075923,0.00032287004],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007777489,0.00009851926,0.00030955064,0.0005140512,0.0011717863,0.000055572593,0.0007544335,0.000026759973,0.0015768372],"category_scores_gemma":[0.00064526865,0.00011916127,0.00008521549,0.0008503059,0.00012952814,0.00017223028,0.0004740125,0.00034158785,0.0000051824713],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044331644,0.00043464295,0.6340006,0.00060615,0.0005654061,0.00019479233,0.009533912,0.030723521,0.003205223,0.11261538,0.17042482,0.037252225],"study_design_scores_gemma":[0.0038519318,0.0002569902,0.15660022,0.000092017246,0.000040932504,0.0000067556384,0.023010502,0.14561011,0.00050266564,0.009837883,0.65947515,0.0007148444],"about_ca_topic_score_codex":0.27592495,"about_ca_topic_score_gemma":0.40191585,"teacher_disagreement_score":0.48905033,"about_ca_system_score_codex":0.00090385135,"about_ca_system_score_gemma":0.0010120341,"threshold_uncertainty_score":0.9993359},"labels":[],"label_agreement":null},{"id":"W6892867441","doi":"10.5281/zenodo.12808805","title":"Conscience May 2024 Policy Brief - European Parliament Proposes Reforms to Legislation Around Pharmaceutical Data Exclusivity","year":2024,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Parliament; Legislation; Economic shortage; Pharmaceutical industry; European commission; Legislature; European union","score_opus":0.15732390372923538,"score_gpt":0.34985003780658586,"score_spread":0.19252613407735047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6892867441","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011817916,0.0012540863,0.013217957,0.03781755,0.0008915615,0.001053,0.004458712,0.00090542453,0.9285838],"genre_scores_gemma":[0.9896234,0.0006567677,0.00030716974,0.0032456731,0.0009139098,1.7428599e-7,0.00096661586,0.0008043064,0.003481964],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99762875,0.00013207461,0.0005685012,0.0009559411,0.00012501444,0.0005897123],"domain_scores_gemma":[0.99846417,0.00003786653,0.00010693927,0.00084977207,0.000093188755,0.00044807466],"candidate_categories":["scholarly_communication","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0023084478,0.00020135024,0.00023667829,0.00051321165,0.0010643844,0.0022261264,0.001695394,0.000053497293,0.006816935],"category_scores_gemma":[0.00066387584,0.0002154376,0.00006375035,0.0009036887,0.00024644673,0.0008705948,0.0027242508,0.00037210714,0.033124264],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005799209,0.00021120823,0.000037788242,0.00016578798,0.00010587137,0.000037042635,0.0011616137,0.00020347592,0.0008346071,0.47963092,0.28908265,0.22847107],"study_design_scores_gemma":[0.00027163397,0.00010063496,0.00032912177,0.000033396762,0.00000782301,0.000058424077,0.00005050183,0.014516726,0.000109259585,0.0036798206,0.9805704,0.00027229384],"about_ca_topic_score_codex":0.00013724041,"about_ca_topic_score_gemma":0.0000016448887,"teacher_disagreement_score":0.9778055,"about_ca_system_score_codex":0.00046317716,"about_ca_system_score_gemma":0.000019230427,"threshold_uncertainty_score":0.99880964},"labels":[],"label_agreement":null},{"id":"W6902442863","doi":"10.6084/m9.figshare.7305146.v1","title":"Additional file 1: of Prescription drug coverage in Canada: a review of the economic, policy and political considerations for universal pharmacare","year":2018,"lang":"en","type":"article","venue":"Figshare","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Politics; Medical prescription; Prescription drug; Government (linguistics); Access to medicines; Drug industry; Drug","score_opus":0.06281212473487068,"score_gpt":0.2760136842271803,"score_spread":0.21320155949230962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902442863","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016799684,0.000377929,1.4853897e-7,0.0015388259,0.000033576274,0.0002530387,0.9811206,0.0000020479622,0.016505832],"genre_scores_gemma":[0.5083582,0.00039650843,0.00020439846,0.02043592,0.0007111833,0.0008263094,0.46825904,0.000043430286,0.00076500874],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992855,0.000012500969,0.00037206436,0.00014542413,0.000015690866,0.0001687936],"domain_scores_gemma":[0.99875426,0.00079564255,0.00021544383,0.00011769065,0.000046328678,0.000070620335],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00003676413,0.00007288198,0.00022095836,0.000061762024,0.00004261361,0.000008535234,0.000097543154,0.000026359263,0.85795206],"category_scores_gemma":[0.0019091205,0.00007740181,0.00006146363,0.00005582325,0.000031108786,0.00009183694,0.00006291692,0.00006237123,0.000070752154],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000029848331,0.000006053834,0.00002952164,0.00037829837,0.000010625379,1.3307252e-7,0.0000143176485,0.0000029913135,3.1068737e-7,0.04035555,0.95913595,0.00006326199],"study_design_scores_gemma":[0.00026021464,0.000009797716,0.0023761156,0.0013045864,0.0000026149535,0.0000023396965,0.000008415862,0.0018018687,0.000058559697,0.0076139085,0.98647475,0.00008679891],"about_ca_topic_score_codex":0.046888467,"about_ca_topic_score_gemma":0.08630026,"teacher_disagreement_score":0.8578813,"about_ca_system_score_codex":0.00046530654,"about_ca_system_score_gemma":0.0012353433,"threshold_uncertainty_score":0.9594584},"labels":[],"label_agreement":null},{"id":"W6904840632","doi":"10.1371/journal.pone.0318509.s003","title":"Proportion of generic drugs by quarter (%).","year":2025,"lang":"en","type":"article","venue":"Figshare","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Drug industry; Payment; Procurement","score_opus":0.05071055892004477,"score_gpt":0.2780006825665216,"score_spread":0.22729012364647683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6904840632","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.027946271,0.0059788213,0.00006310693,0.0035177614,0.0003414368,0.00050777406,0.4960215,0.00007492934,0.4655484],"genre_scores_gemma":[0.98338616,0.00003476228,0.00004157007,0.0022904729,0.000057839436,0.00008739147,0.01207842,0.000011897544,0.0020114896],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992836,0.0000040548443,0.00036950174,0.00018089045,0.000012374064,0.00014954504],"domain_scores_gemma":[0.9995735,0.000020602794,0.000173269,0.00016822194,0.000020989593,0.000043363052],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000056402856,0.000076016324,0.00019221714,0.00009918425,0.000027500799,0.000022102826,0.00014498681,0.00006334885,0.064104766],"category_scores_gemma":[0.00008857895,0.00008985197,0.00007604578,0.00014652379,0.000006708759,0.000083210834,0.000042067677,0.00006955847,0.0024410586],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000003852446,0.00004009387,0.00044750667,0.000103175305,0.000023530183,1.5280412e-7,0.000046887362,0.0000080389555,0.000042274984,0.014876095,0.9830285,0.0013799416],"study_design_scores_gemma":[0.00024117094,0.000014704192,0.0012327962,0.0000603436,0.0000019482488,2.071126e-7,0.000006441386,0.0020216883,0.0018592178,0.006880022,0.9875697,0.0001117824],"about_ca_topic_score_codex":0.000013783704,"about_ca_topic_score_gemma":7.6678316e-7,"teacher_disagreement_score":0.95543987,"about_ca_system_score_codex":0.000039338098,"about_ca_system_score_gemma":0.000021997717,"threshold_uncertainty_score":0.99833566},"labels":[],"label_agreement":null},{"id":"W6911824122","doi":"10.5281/zenodo.12808014","title":"Conscience June 2024 Policy Brief - FTC Challenges Improper Patent Listings","year":2024,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Commission; Enforcement; Food and drug administration; Pharmaceutical industry; Government (linguistics); Administration (probate law); Drug industry; Statement (logic)","score_opus":0.15457951881237803,"score_gpt":0.288046317309842,"score_spread":0.13346679849746396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6911824122","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010721898,0.007504091,0.0010410282,0.03611689,0.0010071631,0.0004601868,0.0012755718,0.00089609413,0.9409771],"genre_scores_gemma":[0.9796608,0.005047682,0.00008748897,0.0015630891,0.00072412106,1.745644e-7,0.0001940307,0.0010167462,0.011705859],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99835855,0.000047112833,0.00041602633,0.0006229935,0.00006759862,0.0004877427],"domain_scores_gemma":[0.9991628,0.000028603514,0.00009021676,0.00035709052,0.0000990848,0.00026220558],"candidate_categories":["scholarly_communication","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0009667615,0.00015606685,0.00021985573,0.00044478907,0.00081590173,0.0012670859,0.00075925246,0.000071372146,0.013778079],"category_scores_gemma":[0.0005130425,0.00017305538,0.00008718775,0.0005471157,0.00022818458,0.00035387036,0.0007635779,0.00031190974,0.030502835],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001411555,0.000077445795,0.0000036753156,0.00015036351,0.0000528466,0.000015348538,0.0015254505,0.000027701588,0.0003995389,0.7565492,0.15044838,0.09073595],"study_design_scores_gemma":[0.00020999476,0.00007580296,0.0001709886,0.000026628875,0.0000042149654,0.00005644428,0.000067107125,0.005059826,0.00007972006,0.009749039,0.9842889,0.00021133664],"about_ca_topic_score_codex":0.00010523685,"about_ca_topic_score_gemma":7.2332875e-7,"teacher_disagreement_score":0.9689389,"about_ca_system_score_codex":0.00023639838,"about_ca_system_score_gemma":0.000009860478,"threshold_uncertainty_score":0.9997697},"labels":[],"label_agreement":null},{"id":"W6911910953","doi":"10.5281/zenodo.12808015","title":"Conscience June 2024 Policy Brief - FTC Challenges Improper Patent Listings","year":2024,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Commission; Enforcement; Food and drug administration; Pharmaceutical industry; Government (linguistics); Administration (probate law); Drug industry; Statement (logic)","score_opus":0.15457951881237803,"score_gpt":0.288046317309842,"score_spread":0.13346679849746396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6911910953","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010721898,0.007504091,0.0010410282,0.03611689,0.0010071631,0.0004601868,0.0012755718,0.00089609413,0.9409771],"genre_scores_gemma":[0.9796608,0.005047682,0.00008748897,0.0015630891,0.00072412106,1.745644e-7,0.0001940307,0.0010167462,0.011705859],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99835855,0.000047112833,0.00041602633,0.0006229935,0.00006759862,0.0004877427],"domain_scores_gemma":[0.9991628,0.000028603514,0.00009021676,0.00035709052,0.0000990848,0.00026220558],"candidate_categories":["scholarly_communication","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0009667615,0.00015606685,0.00021985573,0.00044478907,0.00081590173,0.0012670859,0.00075925246,0.000071372146,0.013778079],"category_scores_gemma":[0.0005130425,0.00017305538,0.00008718775,0.0005471157,0.00022818458,0.00035387036,0.0007635779,0.00031190974,0.030502835],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001411555,0.000077445795,0.0000036753156,0.00015036351,0.0000528466,0.000015348538,0.0015254505,0.000027701588,0.0003995389,0.7565492,0.15044838,0.09073595],"study_design_scores_gemma":[0.00020999476,0.00007580296,0.0001709886,0.000026628875,0.0000042149654,0.00005644428,0.000067107125,0.005059826,0.00007972006,0.009749039,0.9842889,0.00021133664],"about_ca_topic_score_codex":0.00010523685,"about_ca_topic_score_gemma":7.2332875e-7,"teacher_disagreement_score":0.9689389,"about_ca_system_score_codex":0.00023639838,"about_ca_system_score_gemma":0.000009860478,"threshold_uncertainty_score":0.9997697},"labels":[],"label_agreement":null},{"id":"W6911923086","doi":"10.5281/zenodo.14373074","title":"Conscience Issue Tracker - December 2024","year":2024,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"","keywords":"Conscience; Intellectual property; Diversity (politics); Property (philosophy); Ethical issues","score_opus":0.07832215433419211,"score_gpt":0.2921950974026684,"score_spread":0.21387294306847632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6911923086","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0110749025,0.0016850991,0.0021650654,0.0067684795,0.00075164903,0.0002449142,0.0008283559,0.0005217157,0.97595984],"genre_scores_gemma":[0.9785226,0.0007112499,0.00020736441,0.001977835,0.00053625903,9.376862e-8,0.00029466357,0.0010639349,0.016686022],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99876076,0.000034468016,0.0003296295,0.00047043271,0.00004848529,0.0003562255],"domain_scores_gemma":[0.9993772,0.000027607522,0.000054437794,0.00028548666,0.00005998762,0.00019531084],"candidate_categories":["scholarly_communication","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00073211297,0.000113433176,0.00015847593,0.0002712134,0.00070848694,0.0013016843,0.0006069222,0.000057844853,0.090469815],"category_scores_gemma":[0.000230923,0.00013220093,0.000065808796,0.00048155346,0.00017045814,0.000350028,0.00040463285,0.00025405013,0.13735445],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008122285,0.000045895573,0.000006147954,0.000052505737,0.00003500163,0.000011680969,0.0005347615,0.000035382487,0.0002037537,0.30047938,0.6677484,0.030838972],"study_design_scores_gemma":[0.00014703746,0.000042604497,0.00010377171,0.000013050512,0.0000038385183,0.000052575288,0.00003341537,0.005408956,0.00010989301,0.0094149215,0.9845064,0.00016348211],"about_ca_topic_score_codex":0.000018422028,"about_ca_topic_score_gemma":3.0947695e-7,"teacher_disagreement_score":0.9674477,"about_ca_system_score_codex":0.00013115257,"about_ca_system_score_gemma":0.000003653294,"threshold_uncertainty_score":0.99973506},"labels":[],"label_agreement":null},{"id":"W6920139598","doi":"10.60692/0n3wp-c2q08","title":"A Survey of the Criteria Used for the Selection of Alternative Comparator Products by Participating Regulators and Organizations of the International Pharmaceutical Regulators Programme","year":2022,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Innovator; Product (mathematics); Comparator; Bioequivalence; Selection (genetic algorithm); Interchangeability","score_opus":0.12779784346627945,"score_gpt":0.29902041718757816,"score_spread":0.1712225737212987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920139598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99510336,0.000018124958,0.00084151566,0.00066775834,0.0005622973,0.0007240199,0.001992214,0.000008572494,0.00008213904],"genre_scores_gemma":[0.9996476,4.1162377e-7,0.000029855784,0.00011666316,0.000026316826,0.00012873365,0.000016043388,0.00000805921,0.000026318514],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99879086,0.00007354438,0.00081642024,0.00011044124,0.00007831799,0.00013042161],"domain_scores_gemma":[0.9985597,0.00005607547,0.00094588916,0.00019341845,0.0002157866,0.000029116307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010482015,0.000085314496,0.00021236387,0.000072106675,0.00020296001,0.000042959087,0.00030641328,0.000026048,0.00003945891],"category_scores_gemma":[0.00020316182,0.000058407164,0.000050808663,0.0004328985,0.00009415946,0.00015756126,0.00015835994,0.0000809082,0.0000015847277],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005281646,0.000017708817,0.9664694,0.00017492266,0.00018281807,5.8448264e-9,0.017774059,0.0013612866,0.00006107067,0.013042506,0.000787134,0.00007627219],"study_design_scores_gemma":[0.0019030146,0.000065467284,0.5209403,0.00003812788,0.000056001994,0.00000660422,0.0023436246,0.4402015,0.027882071,0.00007621089,0.006278921,0.00020817283],"about_ca_topic_score_codex":0.000096793534,"about_ca_topic_score_gemma":0.00000215992,"teacher_disagreement_score":0.4455291,"about_ca_system_score_codex":0.00009244453,"about_ca_system_score_gemma":0.0000465206,"threshold_uncertainty_score":0.2381775},"labels":[],"label_agreement":null},{"id":"W6920327271","doi":"10.60692/0zr1n-0ew62","title":"A Survey of the Criteria Used for the Selection of Alternative Comparator Products by Participating Regulators and Organizations of the International Pharmaceutical Regulators Programme","year":2022,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Innovator; Product (mathematics); Comparator; Bioequivalence; Selection (genetic algorithm); Interchangeability","score_opus":0.12779784346627945,"score_gpt":0.29902041718757816,"score_spread":0.1712225737212987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920327271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99510336,0.000018124958,0.00084151566,0.00066775834,0.0005622973,0.0007240199,0.001992214,0.000008572494,0.00008213904],"genre_scores_gemma":[0.9996476,4.1162377e-7,0.000029855784,0.00011666316,0.000026316826,0.00012873365,0.000016043388,0.00000805921,0.000026318514],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99879086,0.00007354438,0.00081642024,0.00011044124,0.00007831799,0.00013042161],"domain_scores_gemma":[0.9985597,0.00005607547,0.00094588916,0.00019341845,0.0002157866,0.000029116307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010482015,0.000085314496,0.00021236387,0.000072106675,0.00020296001,0.000042959087,0.00030641328,0.000026048,0.00003945891],"category_scores_gemma":[0.00020316182,0.000058407164,0.000050808663,0.0004328985,0.00009415946,0.00015756126,0.00015835994,0.0000809082,0.0000015847277],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005281646,0.000017708817,0.9664694,0.00017492266,0.00018281807,5.8448264e-9,0.017774059,0.0013612866,0.00006107067,0.013042506,0.000787134,0.00007627219],"study_design_scores_gemma":[0.0019030146,0.000065467284,0.5209403,0.00003812788,0.000056001994,0.00000660422,0.0023436246,0.4402015,0.027882071,0.00007621089,0.006278921,0.00020817283],"about_ca_topic_score_codex":0.000096793534,"about_ca_topic_score_gemma":0.00000215992,"teacher_disagreement_score":0.4455291,"about_ca_system_score_codex":0.00009244453,"about_ca_system_score_gemma":0.0000465206,"threshold_uncertainty_score":0.2381775},"labels":[],"label_agreement":null},{"id":"W6920726385","doi":"10.6084/m9.figshare.13520769","title":"Additional file 2 of Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Repurposing; Cohort study; Cohort; Research design; Drug repositioning","score_opus":0.10711145725889681,"score_gpt":0.29908811177450473,"score_spread":0.19197665451560791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920726385","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0061625694,0.00027951808,0.0000057814605,0.00011451355,0.000041601175,0.00040738302,0.9881496,0.0000074052527,0.0048316643],"genre_scores_gemma":[0.35558212,0.000018413355,0.0017861087,0.00054689706,0.00039050245,0.000576048,0.6384517,0.0000531217,0.0025950966],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99889076,0.000016328622,0.0006699433,0.00023642786,0.000045187873,0.0001413312],"domain_scores_gemma":[0.9977862,0.00087016146,0.0009055746,0.00028614327,0.000093548966,0.00005835608],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000069210626,0.00009897136,0.00033691092,0.000080838196,0.000069662165,0.000020077587,0.0002303107,0.0000592618,0.6178611],"category_scores_gemma":[0.0032710757,0.00010700945,0.00013743287,0.00024463946,0.000016636392,0.00012042411,0.00011043006,0.00008701444,0.000047753187],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000065907657,0.00012785546,0.00087420945,0.00015311943,0.0000822654,3.0419585e-7,0.00075905566,0.000026206371,0.000013506184,0.0025207496,0.99465245,0.0007836615],"study_design_scores_gemma":[0.0011921574,0.00011414065,0.044518612,0.0019002213,0.000029956303,0.000004078607,0.00047576777,0.0021565899,0.0013511857,0.015410541,0.9325088,0.0003379031],"about_ca_topic_score_codex":0.00018382,"about_ca_topic_score_gemma":0.00008940879,"teacher_disagreement_score":0.61781335,"about_ca_system_score_codex":0.000053058855,"about_ca_system_score_gemma":0.00029554308,"threshold_uncertainty_score":0.43637186},"labels":[],"label_agreement":null},{"id":"W6923187526","doi":"10.1371/journal.pgph.0003173.s002","title":"Disclosure Package from Global Affairs Canada.","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Product (mathematics); Underpinning; Good manufacturing practice; Technology transfer; Control (management); Global health; Biopharmaceutical; Incentive","score_opus":0.05622127931285924,"score_gpt":0.26242137251785114,"score_spread":0.20620009320499189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6923187526","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0020210478,0.0067385873,0.0000027834255,0.0028703697,0.00045986133,0.000084542255,0.84384716,0.00006768539,0.14390796],"genre_scores_gemma":[0.9612617,0.000026335874,0.000019181382,0.0015333345,0.00051056524,0.00003997248,0.03593853,0.000024766046,0.00064564275],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990022,0.0000051322604,0.00029761466,0.00037071895,0.000025405412,0.00029889052],"domain_scores_gemma":[0.99944603,0.00006947681,0.000056209043,0.0002354446,0.000008771545,0.00018404309],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000034791094,0.00014446661,0.00021788897,0.000032484542,0.00004778863,0.00019102368,0.00025278074,0.00008055788,0.2538497],"category_scores_gemma":[0.00014725658,0.0001634641,0.000096871685,0.00016522537,0.0000055475107,0.00014989813,0.00009430175,0.000152971,0.015622569],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000017903561,0.00000782317,0.00047855722,0.000046305304,0.000051286563,0.000035812693,0.000026409365,0.000009440485,0.0000010805444,0.022894846,0.97569585,0.0007508203],"study_design_scores_gemma":[0.00010073773,0.000005415283,0.005546635,0.000115842326,0.00000289793,0.000002034505,0.000012380261,0.0025027024,0.000028727323,0.013686328,0.9777738,0.0002225388],"about_ca_topic_score_codex":0.058274444,"about_ca_topic_score_gemma":0.097670294,"teacher_disagreement_score":0.9592406,"about_ca_system_score_codex":0.0003247924,"about_ca_system_score_gemma":0.00019047406,"threshold_uncertainty_score":0.9851439},"labels":[],"label_agreement":null},{"id":"W6928842172","doi":"10.3897/jhr.61.13466.figures12-17","title":"Figures 12-17 from: Zhang YM, Gates MW, Shorthouse JD (2017) Revision of Canadian Eurytomidae (Hymenoptera, Chalcidoidea) associated with galls induced by cynipid wasps of the genus Diplolepis Geoffroy (Hymenoptera, Cynipidae) and description of a new species. Journal of Hymenoptera Research 61: 1-29. https://doi.org/10.3897/jhr.61.13466","year":2018,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nucleofection; Gestational period; TSG101; Dysgeusia; Liquation; Hyporeflexia; Fusible alloy; Triacetin; Diafiltration","score_opus":0.1097413014785781,"score_gpt":0.2647673897106358,"score_spread":0.1550260882320577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6928842172","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3221127,0.0028380395,0.000053377637,0.0008624253,0.0002541856,0.0010458253,0.0021926998,0.00006344284,0.6705773],"genre_scores_gemma":[0.8136168,0.0042470214,0.00021441742,0.00022324576,0.0008387798,3.4927314e-7,0.0008866874,0.002220733,0.17775194],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99644506,0.00040016204,0.0013838077,0.0006642233,0.0003703352,0.0007364393],"domain_scores_gemma":[0.9959698,0.0001040589,0.0018822671,0.00083372986,0.0006793204,0.0005308762],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0021565005,0.0004116305,0.001037799,0.0017426795,0.0006546631,0.00048375176,0.0015411859,0.0003683612,0.042817056],"category_scores_gemma":[0.0010018981,0.00038682445,0.0001660213,0.00091565977,0.00069478404,0.00029735814,0.0007490582,0.00084228587,0.001222558],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002859596,0.0002734718,0.00079375907,0.00026148473,0.00076327706,0.000009073615,0.0023935349,0.000010099165,0.004241965,0.0020440966,0.9817261,0.0071971477],"study_design_scores_gemma":[0.0012882914,0.00073468866,0.0035627582,0.0006944948,0.00006383682,0.0000053632834,0.00012558927,0.00010658292,0.0019954743,0.0002704443,0.99078864,0.0003638108],"about_ca_topic_score_codex":0.010549427,"about_ca_topic_score_gemma":0.00041948902,"teacher_disagreement_score":0.49282533,"about_ca_system_score_codex":0.0004487575,"about_ca_system_score_gemma":0.000108942964,"threshold_uncertainty_score":0.9998584},"labels":[],"label_agreement":null},{"id":"W6930118434","doi":"10.5281/zenodo.12738404","title":"Fostering Second Language Acquisition of Canadian Primary School Children: A Critical Evaluation of Vygotsky's Learning Theory in the French Immersion Programme","year":2024,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Learning theory; Curriculum; Second language; Language acquisition; Second-language acquisition; Activity theory; Social learning theory; Perspective (graphical); Comprehension approach","score_opus":0.07939214198086982,"score_gpt":0.29950015817948505,"score_spread":0.22010801619861525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930118434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.61857074,0.0026477638,0.0003857092,0.0013612758,0.000111076246,0.0006251707,0.0005248268,0.00007222159,0.37570125],"genre_scores_gemma":[0.99903846,0.000080423466,0.00003683687,0.00017602675,0.000062625986,1.6344363e-7,0.00038766905,0.00015850262,0.000059301416],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988763,0.00022897689,0.0003378234,0.00023061113,0.00008053321,0.00024580755],"domain_scores_gemma":[0.9994944,0.00005749968,0.00007280971,0.00017888015,0.000093961724,0.000102488535],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0033441666,0.00007609871,0.00013688179,0.00067082053,0.000250425,0.00023714468,0.00035331913,0.000052353233,0.010736392],"category_scores_gemma":[0.000523472,0.00007909277,0.000051997962,0.000548843,0.00008877147,0.00020600342,0.000248587,0.00025855983,0.0008181818],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007841124,0.00031340367,0.00064252864,0.0008601772,0.00019255647,0.000015931877,0.017538436,0.0005256162,0.003146915,0.29883826,0.014826454,0.6630213],"study_design_scores_gemma":[0.0027958846,0.0009360347,0.11689527,0.00054934394,0.00011773395,0.00020924778,0.0045393407,0.045524072,0.001333277,0.05695329,0.769184,0.00096253],"about_ca_topic_score_codex":0.0011773431,"about_ca_topic_score_gemma":0.000039142033,"teacher_disagreement_score":0.7543575,"about_ca_system_score_codex":0.00021716904,"about_ca_system_score_gemma":0.000014985318,"threshold_uncertainty_score":0.99995977},"labels":[],"label_agreement":null},{"id":"W6939251345","doi":"10.6084/m9.figshare.15982357.v1","title":"Additional file 1 of Intellectual property and access to medicines: mapping public attitudes toward pharmaceuticals during the United States-Mexico-Canada Agreement (USMCA) negotiation process","year":2021,"lang":"en","type":"article","venue":"Open MIND","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Intellectual property; Process (computing); Negotiation; Property (philosophy); Public access","score_opus":0.17733928516874625,"score_gpt":0.34571894096086764,"score_spread":0.16837965579212139,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939251345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5262634,0.00042077308,0.00024952914,0.06318897,0.00032929008,0.0018292073,0.36122477,0.0000064646465,0.04648757],"genre_scores_gemma":[0.96677214,0.00031671824,0.0007477011,0.011948228,0.00021009914,0.000457554,0.017021393,0.000034406465,0.0024917857],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987656,0.000028311284,0.00052514725,0.0003520248,0.000063701176,0.00026525737],"domain_scores_gemma":[0.99876463,0.0005668419,0.0002022172,0.00016805391,0.000112001864,0.00018623247],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023547636,0.00013246744,0.00028552354,0.00013265389,0.00014046684,0.00030220105,0.00046737844,0.00003620139,0.5844436],"category_scores_gemma":[0.0011033933,0.00010464342,0.0000301085,0.0004832069,0.00006863373,0.00031717776,0.00040908728,0.00014053877,0.0001510554],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000062055355,0.00017179728,0.0026626636,0.00015377323,0.0002506786,0.000009084812,0.0021774042,0.00044805993,0.000028533184,0.00018138206,0.98274875,0.0111058],"study_design_scores_gemma":[0.00035085922,0.000022035218,0.005772687,0.00007625068,0.0000051586653,0.000007027344,0.0004598425,0.0061982563,0.0005493393,0.00019459212,0.9861957,0.00016827478],"about_ca_topic_score_codex":0.0025514078,"about_ca_topic_score_gemma":0.007228776,"teacher_disagreement_score":0.58429253,"about_ca_system_score_codex":0.0001420255,"about_ca_system_score_gemma":0.00035048684,"threshold_uncertainty_score":0.42672348},"labels":[],"label_agreement":null},{"id":"W6939270230","doi":"10.60692/7cydj-hev51","title":"The availability of essential medicines for cardiovascular diseases at healthcare facilities in low- and middle-income countries: The case of Bangladesh","year":2022,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Poisson regression; Health care; Public health; Disease; Quality (philosophy); Essential medicines; Thiazide","score_opus":0.043504558252278794,"score_gpt":0.23853931963378847,"score_spread":0.19503476138150966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939270230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98961854,0.0011251521,0.0001372421,0.0006051877,0.00026953078,0.000620375,0.0074385116,0.000008692502,0.00017677118],"genre_scores_gemma":[0.99960065,0.000013303151,0.000003738228,0.00011849378,0.000031334097,0.00018262786,0.000013134352,0.000004472235,0.000032269243],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.9986986,0.000050475413,0.0009337178,0.00011127056,0.000044556415,0.00016136542],"domain_scores_gemma":[0.99910325,0.00009247582,0.0003871948,0.00031701458,0.00005341418,0.000046628567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011889149,0.00008912921,0.00036139876,0.000104866216,0.00028300902,0.000032802483,0.00014091705,0.000030011553,0.000028020535],"category_scores_gemma":[0.000054946788,0.0000653062,0.0001640522,0.000097182914,0.00013979897,0.00014387461,0.00011590283,0.000059826383,0.0000075009616],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005834906,0.0000103064285,0.7531719,0.015518963,0.000561793,0.000007730695,0.13802716,0.0022208984,5.0995986e-8,0.089558356,0.0001319786,0.00020733138],"study_design_scores_gemma":[0.022585643,0.0009549244,0.25530946,0.001186741,0.00045331562,0.0010039612,0.36483088,0.1813056,0.0003277737,0.0045387335,0.16537009,0.0021328984],"about_ca_topic_score_codex":0.00034912847,"about_ca_topic_score_gemma":0.000014895433,"teacher_disagreement_score":0.4978625,"about_ca_system_score_codex":0.00015707959,"about_ca_system_score_gemma":0.000028937744,"threshold_uncertainty_score":0.26631096},"labels":[],"label_agreement":null},{"id":"W6939811928","doi":"10.6084/m9.figshare.15982357","title":"Additional file 1 of Intellectual property and access to medicines: mapping public attitudes toward pharmaceuticals during the United States-Mexico-Canada Agreement (USMCA) negotiation process","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Intellectual property; Process (computing); Negotiation; Property (philosophy); Public access","score_opus":0.1685218022715173,"score_gpt":0.3158965118918517,"score_spread":0.1473747096203344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939811928","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0040736482,0.00020036308,0.0000059035683,0.0077905594,0.00004418837,0.00027957634,0.9844538,0.0000136110175,0.003138358],"genre_scores_gemma":[0.29648572,0.00010500563,0.0000579904,0.01738068,0.00024130348,0.0009801516,0.6841137,0.000033125663,0.000602362],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988427,0.000022101156,0.00046425333,0.00031318874,0.00007282644,0.00028490296],"domain_scores_gemma":[0.9984948,0.00079037953,0.00019916355,0.00015835137,0.00016525657,0.00019202572],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00007173167,0.00014293208,0.00025193024,0.00014876893,0.0001294563,0.00014780776,0.00029969498,0.00004357562,0.93539035],"category_scores_gemma":[0.004106513,0.00011523156,0.00004158476,0.00052165997,0.000020416845,0.00021962449,0.00024989794,0.00016422298,0.00033543457],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008674136,0.000035399113,0.00021422874,0.00030232692,0.00006458534,0.0000033085716,0.0003220597,0.00016407695,0.0000021305525,0.000038418566,0.99838424,0.00046056593],"study_design_scores_gemma":[0.00021817909,0.000015699778,0.008058735,0.00036695664,0.0000025452318,0.0000064014603,0.00015657944,0.0073202667,0.00018854714,0.00013626869,0.98335946,0.00017033944],"about_ca_topic_score_codex":0.0006868379,"about_ca_topic_score_gemma":0.0023390625,"teacher_disagreement_score":0.9350549,"about_ca_system_score_codex":0.00014946618,"about_ca_system_score_gemma":0.00028682718,"threshold_uncertainty_score":0.49161765},"labels":[],"label_agreement":null},{"id":"W6958049139","doi":"10.6084/m9.figshare.13520769.v1","title":"Additional file 2 of Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Repurposing; Cohort study; Cohort; Research design; Drug repositioning","score_opus":0.10711145725889681,"score_gpt":0.29908811177450473,"score_spread":0.19197665451560791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958049139","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0061625694,0.00027951808,0.0000057814605,0.00011451355,0.000041601175,0.00040738302,0.9881496,0.0000074052527,0.0048316643],"genre_scores_gemma":[0.35558212,0.000018413355,0.0017861087,0.00054689706,0.00039050245,0.000576048,0.6384517,0.0000531217,0.0025950966],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99889076,0.000016328622,0.0006699433,0.00023642786,0.000045187873,0.0001413312],"domain_scores_gemma":[0.9977862,0.00087016146,0.0009055746,0.00028614327,0.000093548966,0.00005835608],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000069210626,0.00009897136,0.00033691092,0.000080838196,0.000069662165,0.000020077587,0.0002303107,0.0000592618,0.6178611],"category_scores_gemma":[0.0032710757,0.00010700945,0.00013743287,0.00024463946,0.000016636392,0.00012042411,0.00011043006,0.00008701444,0.000047753187],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000065907657,0.00012785546,0.00087420945,0.00015311943,0.0000822654,3.0419585e-7,0.00075905566,0.000026206371,0.000013506184,0.0025207496,0.99465245,0.0007836615],"study_design_scores_gemma":[0.0011921574,0.00011414065,0.044518612,0.0019002213,0.000029956303,0.000004078607,0.00047576777,0.0021565899,0.0013511857,0.015410541,0.9325088,0.0003379031],"about_ca_topic_score_codex":0.00018382,"about_ca_topic_score_gemma":0.00008940879,"teacher_disagreement_score":0.61781335,"about_ca_system_score_codex":0.000053058855,"about_ca_system_score_gemma":0.00029554308,"threshold_uncertainty_score":0.43637186},"labels":[],"label_agreement":null},{"id":"W6958214953","doi":"10.6084/m9.figshare.19382403","title":"Additional file 1 of Trends in Canadian prescription drug purchasing: 2001–2020","year":2022,"lang":"en","type":"article","venue":"Open MIND","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Women's College Hospital; Queen Elizabeth II Health Sciences Centre; Université Laval; University of British Columbia; University of Toronto; Institute for Clinical Evaluative Sciences; University of Calgary","funders":"","keywords":"Medical prescription; Prescription drug; Drug; MEDLINE","score_opus":0.07907137573426799,"score_gpt":0.2933697309112414,"score_spread":0.21429835517697343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958214953","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008241803,0.000032502918,2.080123e-7,0.0014152302,0.00008552597,0.00008384792,0.6504478,4.2960914e-7,0.33969265],"genre_scores_gemma":[0.74308264,0.000019213026,0.0024163073,0.0021150298,0.0002020054,0.0006924462,0.1695992,0.000048483602,0.08182468],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.999111,0.000015595897,0.00034885525,0.00023402239,0.000018897756,0.0002716309],"domain_scores_gemma":[0.9994786,0.00006799457,0.00014838848,0.00013734851,0.0000061351548,0.00016155884],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002527162,0.00006918718,0.00019137657,0.00032821015,0.000087888126,0.000048765854,0.00034543278,0.000025281164,0.98723894],"category_scores_gemma":[0.000060079976,0.000099778714,0.000049635506,0.0002799386,0.000026312895,0.0001604201,0.00014890323,0.00014523762,0.00094878854],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008466366,0.00004678934,0.00032010654,8.460831e-7,0.000008617094,0.0000036888766,0.00017777416,0.00012810992,0.0000010606365,0.0012002302,0.98797786,0.010126451],"study_design_scores_gemma":[0.00021431982,0.000018092944,0.0045677735,0.0000033105791,9.043196e-7,0.000003103782,0.0000440682,0.004783302,0.0000054056536,0.0015768711,0.98867315,0.00010971662],"about_ca_topic_score_codex":0.07210751,"about_ca_topic_score_gemma":0.11101787,"teacher_disagreement_score":0.98629016,"about_ca_system_score_codex":0.00029846994,"about_ca_system_score_gemma":0.00014789212,"threshold_uncertainty_score":0.9998291},"labels":[],"label_agreement":null},{"id":"W6958653981","doi":"10.6084/m9.figshare.19382403.v1","title":"Additional file 1 of Trends in Canadian prescription drug purchasing: 2001–2020","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Women's College Hospital; Queen Elizabeth II Health Sciences Centre; Université Laval; University of British Columbia; University of Toronto; Institute for Clinical Evaluative Sciences; University of Calgary","funders":"","keywords":"Medical prescription; Prescription drug; Drug; MEDLINE","score_opus":0.07381285126224263,"score_gpt":0.25989332782598645,"score_spread":0.18608047656374382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958653981","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000973466,0.00008211395,1.2240102e-8,0.00062373007,0.000044091095,0.000052436146,0.89122087,0.0000072743724,0.107872106],"genre_scores_gemma":[0.043704513,0.0000014279133,0.00003127755,0.001023907,0.00007275483,0.0005918659,0.9501459,0.0000146326665,0.0044136965],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.999152,0.000011814619,0.00030507645,0.00020437663,0.000023048158,0.00030368307],"domain_scores_gemma":[0.99943894,0.0001054029,0.00014845142,0.00012827928,0.000010085942,0.0001688453],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000059520815,0.00007720382,0.0001663482,0.00039602508,0.0000806094,0.000019602983,0.0002009874,0.00003174829,0.9993648],"category_scores_gemma":[0.0003157848,0.00011437536,0.00007543275,0.0003200371,0.000005854017,0.000102980746,0.000081636914,0.0001797114,0.0025736683],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000027678022,0.000024974328,0.000051984338,0.0000073918036,0.00000593192,0.000003979384,0.000057808593,0.00013879986,1.582458e-7,0.0006648947,0.9983428,0.0006984737],"study_design_scores_gemma":[0.0001245161,0.000012505904,0.0070756306,0.000024833433,3.884402e-7,0.0000029413984,0.000011470594,0.0060927295,0.000001489106,0.001078748,0.98545784,0.000116887684],"about_ca_topic_score_codex":0.014032081,"about_ca_topic_score_gemma":0.027285716,"teacher_disagreement_score":0.9967911,"about_ca_system_score_codex":0.00032518248,"about_ca_system_score_gemma":0.000116382675,"threshold_uncertainty_score":0.9982029},"labels":[],"label_agreement":null},{"id":"W6966599021","doi":"10.48448/7m2p-c507","title":"Economic analysis of the sustainability ofnational pharmacare in Canada","year":2022,"lang":"en","type":"other","venue":"Underline Science Inc.","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Economic analysis; Sustainability; Government (linguistics); Production (economics)","score_opus":0.027269151129613155,"score_gpt":0.29310477551452846,"score_spread":0.2658356243849153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6966599021","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06248258,0.0015448229,0.000036061672,0.0071844566,0.0020835765,0.0008550839,0.010370113,0.00002727363,0.915416],"genre_scores_gemma":[0.9842814,0.00011029255,0.00003994223,0.0012836052,0.00007883955,0.000026269036,0.00006967504,0.000060041082,0.014049914],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99834514,0.000022756682,0.00066418486,0.0005284861,0.000089723435,0.00034973802],"domain_scores_gemma":[0.99871725,0.00006939744,0.00058728014,0.0005047911,0.00002635672,0.000094926254],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007827432,0.0001600748,0.00053079263,0.0011698003,0.00009607281,0.000027585429,0.0011333725,0.000050816758,0.020950355],"category_scores_gemma":[0.000113839444,0.00016294164,0.00013967387,0.0014590084,0.00034284784,0.000076338394,0.00037386458,0.0002751688,0.000016202268],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000006749911,0.00008940667,0.54297143,0.00006129391,0.00042644885,0.0000023619452,0.00012755576,0.045784265,0.0000017347793,0.35886782,0.050418872,0.001242081],"study_design_scores_gemma":[0.00041093735,0.000008751735,0.055264246,0.000004732624,0.00007262177,6.24518e-7,0.00019738755,0.16629957,0.000010778461,0.010993014,0.76634616,0.0003911656],"about_ca_topic_score_codex":0.8311716,"about_ca_topic_score_gemma":0.921677,"teacher_disagreement_score":0.9217988,"about_ca_system_score_codex":0.0057923705,"about_ca_system_score_gemma":0.004496914,"threshold_uncertainty_score":0.9980242},"labels":[],"label_agreement":null},{"id":"W6968165057","doi":"10.5281/zenodo.12808804","title":"Conscience May 2024 Policy Brief - European Parliament Proposes Reforms to Legislation Around Pharmaceutical Data Exclusivity","year":2024,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Parliament; Legislation; Economic shortage; Pharmaceutical industry; European commission; Legislature; European union","score_opus":0.15732390372923538,"score_gpt":0.34985003780658586,"score_spread":0.19252613407735047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6968165057","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011817916,0.0012540863,0.013217957,0.03781755,0.0008915615,0.001053,0.004458712,0.00090542453,0.9285838],"genre_scores_gemma":[0.9896234,0.0006567677,0.00030716974,0.0032456731,0.0009139098,1.7428599e-7,0.00096661586,0.0008043064,0.003481964],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99762875,0.00013207461,0.0005685012,0.0009559411,0.00012501444,0.0005897123],"domain_scores_gemma":[0.99846417,0.00003786653,0.00010693927,0.00084977207,0.000093188755,0.00044807466],"candidate_categories":["scholarly_communication","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0023084478,0.00020135024,0.00023667829,0.00051321165,0.0010643844,0.0022261264,0.001695394,0.000053497293,0.006816935],"category_scores_gemma":[0.00066387584,0.0002154376,0.00006375035,0.0009036887,0.00024644673,0.0008705948,0.0027242508,0.00037210714,0.033124264],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005799209,0.00021120823,0.000037788242,0.00016578798,0.00010587137,0.000037042635,0.0011616137,0.00020347592,0.0008346071,0.47963092,0.28908265,0.22847107],"study_design_scores_gemma":[0.00027163397,0.00010063496,0.00032912177,0.000033396762,0.00000782301,0.000058424077,0.00005050183,0.014516726,0.000109259585,0.0036798206,0.9805704,0.00027229384],"about_ca_topic_score_codex":0.00013724041,"about_ca_topic_score_gemma":0.0000016448887,"teacher_disagreement_score":0.9778055,"about_ca_system_score_codex":0.00046317716,"about_ca_system_score_gemma":0.000019230427,"threshold_uncertainty_score":0.99880964},"labels":[],"label_agreement":null},{"id":"W6968605403","doi":"10.5281/zenodo.14373075","title":"Conscience Issue Tracker - December 2024","year":2024,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"","keywords":"Conscience; Intellectual property; Diversity (politics); Property (philosophy); Ethical issues","score_opus":0.07832215433419211,"score_gpt":0.2921950974026684,"score_spread":0.21387294306847632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6968605403","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0110749025,0.0016850991,0.0021650654,0.0067684795,0.00075164903,0.0002449142,0.0008283559,0.0005217157,0.97595984],"genre_scores_gemma":[0.9785226,0.0007112499,0.00020736441,0.001977835,0.00053625903,9.376862e-8,0.00029466357,0.0010639349,0.016686022],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99876076,0.000034468016,0.0003296295,0.00047043271,0.00004848529,0.0003562255],"domain_scores_gemma":[0.9993772,0.000027607522,0.000054437794,0.00028548666,0.00005998762,0.00019531084],"candidate_categories":["scholarly_communication","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00073211297,0.000113433176,0.00015847593,0.0002712134,0.00070848694,0.0013016843,0.0006069222,0.000057844853,0.090469815],"category_scores_gemma":[0.000230923,0.00013220093,0.000065808796,0.00048155346,0.00017045814,0.000350028,0.00040463285,0.00025405013,0.13735445],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008122285,0.000045895573,0.000006147954,0.000052505737,0.00003500163,0.000011680969,0.0005347615,0.000035382487,0.0002037537,0.30047938,0.6677484,0.030838972],"study_design_scores_gemma":[0.00014703746,0.000042604497,0.00010377171,0.000013050512,0.0000038385183,0.000052575288,0.00003341537,0.005408956,0.00010989301,0.0094149215,0.9845064,0.00016348211],"about_ca_topic_score_codex":0.000018422028,"about_ca_topic_score_gemma":3.0947695e-7,"teacher_disagreement_score":0.9674477,"about_ca_system_score_codex":0.00013115257,"about_ca_system_score_gemma":0.000003653294,"threshold_uncertainty_score":0.99973506},"labels":[],"label_agreement":null},{"id":"W6979717166","doi":"","title":"Access to Medicines and Pharmaceutical Policy in New Zealand: Comparing the issues with United Kingdom, Australia and Canada","year":2012,"lang":"en","type":"dissertation","venue":"ResearchSpace (University of Auckland)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Government (linguistics); Legislation; Public policy; Access to medicines; MEDLINE","score_opus":0.16589470376204832,"score_gpt":0.3852437831592027,"score_spread":0.2193490793971544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6979717166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95077085,0.0004198125,0.0000029636235,0.04551462,0.00008798856,0.00027414845,0.00008236295,0.0000060332154,0.0028412438],"genre_scores_gemma":[0.98919016,0.0014024348,0.00003732723,0.00031159975,0.00014787374,6.3667136e-7,0.00007570147,0.000016940636,0.008817317],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990118,0.000030285895,0.0001720582,0.00028486925,0.00008201812,0.00041893037],"domain_scores_gemma":[0.9990953,0.00010920626,0.00014158576,0.00017728322,0.000030205856,0.0004463828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036356624,0.00016599246,0.00045353864,0.00064735627,0.0001099165,0.00007148197,0.0004390449,0.00010738822,0.00019304072],"category_scores_gemma":[0.00006687531,0.00016052375,0.000024469924,0.00039300724,0.00011215327,0.00016915108,0.00016604716,0.00041195157,0.000009099638],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009970603,0.000050582945,0.87484014,0.00033760932,0.00025493858,0.000032583248,0.0044396245,0.00006332647,0.000024325931,0.027732924,0.090533845,0.0006930193],"study_design_scores_gemma":[0.0011662662,0.000040699637,0.46612522,0.00009844825,0.0000194557,0.000003549339,0.00067025487,0.0004972268,0.000016612057,0.00038806838,0.53076,0.00021418887],"about_ca_topic_score_codex":0.9480881,"about_ca_topic_score_gemma":0.93723655,"teacher_disagreement_score":0.44022617,"about_ca_system_score_codex":0.00016600727,"about_ca_system_score_gemma":0.0002920015,"threshold_uncertainty_score":0.65459687},"labels":[],"label_agreement":null},{"id":"W6980405817","doi":"","title":"Canadaâs Patented Medicines (Notice of Compliance) Regulations: Removing Inefficiencies to Encourage Generic Competition","year":2011,"lang":"en","type":"dissertation","venue":"Library and Archives Canada (Government of Canada)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Intellectual property; Monopoly; Incentive; Competition (biology); Key (lock); Competition law; Action (physics); Property (philosophy)","score_opus":0.02593581445305174,"score_gpt":0.19429556188577377,"score_spread":0.16835974743272203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6980405817","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.398502,0.0023266312,0.00016902012,0.002681471,0.0011853589,0.00046597325,0.0021774832,0.000012734164,0.59247935],"genre_scores_gemma":[0.9887361,0.00053821877,0.00055933185,0.0017992888,0.0000807761,0.000010687161,0.00013210635,0.000031252057,0.008112232],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9983416,0.000019146899,0.0007850334,0.00032037508,0.00025323455,0.00028056538],"domain_scores_gemma":[0.9987373,0.00012756331,0.0006414379,0.00022686717,0.0000024552437,0.00026438426],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000028565213,0.00022756562,0.0005567606,0.00010521933,0.00012382415,0.000015412712,0.00028532153,0.000054925364,0.00015753563],"category_scores_gemma":[0.000015992022,0.00026329813,0.000045139506,0.0001474047,0.00005666609,0.00017130167,0.00005961953,0.00014633004,3.048831e-8],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047063772,0.000078081976,0.0117808785,0.001651804,0.00021772222,0.000023828206,0.0008295061,0.0005567098,0.0049449587,0.9736826,0.0019637877,0.0037995225],"study_design_scores_gemma":[0.0020041594,0.00043072508,0.6573942,0.0029855075,0.00017600725,0.000015640342,0.011026367,0.04111778,0.07362298,0.03971386,0.16885515,0.002657686],"about_ca_topic_score_codex":0.034329787,"about_ca_topic_score_gemma":0.16108193,"teacher_disagreement_score":0.9339687,"about_ca_system_score_codex":0.00002145718,"about_ca_system_score_gemma":0.0008505533,"threshold_uncertainty_score":0.99998194},"labels":[],"label_agreement":null},{"id":"W6986330833","doi":"","title":"Pattern Development Secures Power Purchase Agreement For 147 MW Wind Project In Quebec | Press Releases News | Print Financial &amp;amp; Investing Articles","year":2015,"lang":"en","type":"other","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Power (physics); Investment (military); Framework agreement; Wind power; Agreement","score_opus":0.15204177243044553,"score_gpt":0.322231385339997,"score_spread":0.17018961290955148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6986330833","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11318843,0.0071045007,0.005121721,0.0018537316,0.0016021021,0.0061095706,0.0032154438,0.0002765803,0.8615279],"genre_scores_gemma":[0.0191121,0.00068226445,0.011792687,0.0056980746,0.0014162167,0.0009036943,0.00073095754,0.0007902967,0.9588737],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997322,0.000025112184,0.001223122,0.00068386213,0.00006120827,0.00068465626],"domain_scores_gemma":[0.99860287,0.00005647781,0.0006306868,0.00043788002,0.000033141318,0.00023895869],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005465999,0.00045099054,0.0007700349,0.0005078627,0.000056051926,0.00016219668,0.0003674544,0.00030869732,0.0014661262],"category_scores_gemma":[0.00027507872,0.00048295117,0.00012510088,0.00014474479,0.00007423895,0.00011063535,0.00023361234,0.00025834763,0.0007458083],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059462258,0.00039329982,0.0043850015,0.00030496073,0.0001291322,0.000003875944,0.002416203,0.000060852344,0.0000035609978,0.00832926,0.9676668,0.016247598],"study_design_scores_gemma":[0.0012059638,0.000028094124,0.00033480691,0.00010654499,0.000007911471,0.0000015052481,0.000041411502,0.00017294251,0.000033175314,0.0018081203,0.9956044,0.00065515336],"about_ca_topic_score_codex":0.0611892,"about_ca_topic_score_gemma":0.24291736,"teacher_disagreement_score":0.18172815,"about_ca_system_score_codex":0.00041033135,"about_ca_system_score_gemma":0.00046082286,"threshold_uncertainty_score":0.99976224},"labels":[],"label_agreement":null},{"id":"W6986792601","doi":"","title":"Regulating Prescription Drug Costs","year":2020,"lang":"en","type":"article","venue":"eYLS (Yale Law School)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Legislation; Prescription drug; Drug prices; Drug; Government (linguistics); Pharmaceutical industry; Pharmacy; Negotiation","score_opus":0.04680653514389867,"score_gpt":0.2647484021467481,"score_spread":0.21794186700284945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6986792601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.50047517,0.0027025866,0.0011137113,0.028184956,0.0010003946,0.0005234416,0.0003647145,0.0002719786,0.46536306],"genre_scores_gemma":[0.9783709,0.00009879826,0.00045497567,0.019555971,0.0005909716,0.00001946373,0.00002182658,0.0000358527,0.0008512417],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985468,0.00002005558,0.0005816503,0.0004509866,0.00003163186,0.00036890237],"domain_scores_gemma":[0.9990182,0.00003975013,0.00021602695,0.00026540214,0.000018348195,0.00044225855],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00029348192,0.00016760315,0.00033519993,0.000048400496,0.00014331001,0.00017170004,0.00028046736,0.000082889164,0.0016923957],"category_scores_gemma":[0.00015324503,0.00021181063,0.00013009757,0.00015540606,0.000058459504,0.00041150584,0.00011120033,0.00028645122,0.00572206],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002842106,0.00003351834,0.008742484,0.000030222862,0.000038027563,0.0000027790452,0.00023955245,0.00014403732,0.00029017878,0.9644755,0.024819573,0.0011556651],"study_design_scores_gemma":[0.0010901763,0.000045218298,0.003981391,0.00001901322,0.000008498847,0.0000027817157,0.000035687233,0.014946533,0.0018099936,0.05274857,0.92482466,0.00048748028],"about_ca_topic_score_codex":0.00077320065,"about_ca_topic_score_gemma":0.00009271799,"teacher_disagreement_score":0.91172695,"about_ca_system_score_codex":0.00013731953,"about_ca_system_score_gemma":0.00001760307,"threshold_uncertainty_score":0.9992202},"labels":[],"label_agreement":null},{"id":"W6988033236","doi":"","title":"What happens to drug use and expenditure when cost sharing is completely removed? Evidence from a Canadian provincial public drug plan","year":2020,"lang":"en","type":"article","venue":"UTS ePRESS (University of Technology Sydney)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cost sharing; Medical prescription; Prescription drug; Drug; Public health; Public expenditure; Interrupted time series","score_opus":0.11421004361224801,"score_gpt":0.24098269376778977,"score_spread":0.12677265015554176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6988033236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8358109,0.00086008303,0.00020341431,0.16036409,0.00016854475,0.00037282403,0.0013754058,0.00007201431,0.0007727249],"genre_scores_gemma":[0.992286,0.00054975017,0.0012306537,0.0055199102,0.000053205353,0.0000018385176,0.000027261018,0.000018888946,0.00031249464],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985594,0.000011492184,0.00025434315,0.00070658955,0.000035103963,0.0004330568],"domain_scores_gemma":[0.99865973,0.000069319234,0.00020540196,0.0004254652,0.000037959,0.00060213084],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013377049,0.0001875942,0.0004874333,0.0005606598,0.00022821006,0.00019766089,0.000974306,0.00022494009,0.0006527572],"category_scores_gemma":[0.00018229561,0.00026902452,0.0000772175,0.00022688865,0.00022145433,0.0013110781,0.0006794298,0.00037026443,0.00023458186],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019867612,0.000085866624,0.7262045,0.00011516179,0.00041261717,0.00017249033,0.03064231,0.000033919237,0.00048666145,0.1394967,0.09364283,0.008508249],"study_design_scores_gemma":[0.0013161271,0.00006228031,0.034466904,0.00018707392,0.000041636842,0.0000082829665,0.003881025,0.013119781,0.0005547866,0.020302843,0.92519706,0.0008621784],"about_ca_topic_score_codex":0.15592349,"about_ca_topic_score_gemma":0.1173654,"teacher_disagreement_score":0.83155423,"about_ca_system_score_codex":0.00016365263,"about_ca_system_score_gemma":0.000074594536,"threshold_uncertainty_score":0.9999762},"labels":[],"label_agreement":null},{"id":"W6990104931","doi":"","title":"Cost-Control Mechanisms in Canadian Private Drug Plans","year":2013,"lang":"en","type":"article","venue":"PubMed Central","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Prescription drug; Medical prescription; Private sector; MEDLINE","score_opus":0.03216132063005531,"score_gpt":0.22208007700175467,"score_spread":0.18991875637169936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6990104931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9011469,0.00042073496,0.0008753619,0.023348577,0.0021755,0.0022739691,0.0013428923,0.00005902125,0.06835704],"genre_scores_gemma":[0.9920173,0.00008342642,0.00010935961,0.0067361994,0.00018921167,0.00042142803,0.000020565074,0.000024070183,0.0003983876],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9969493,0.000013711297,0.00046465133,0.000314169,0.000019113366,0.0022390105],"domain_scores_gemma":[0.99837077,0.000029823559,0.00009870657,0.0002077839,0.0000061259398,0.0012868029],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000509377,0.00015290071,0.000301854,0.0002689667,0.00005512345,0.00012495561,0.00028782125,0.00008613685,0.0013569081],"category_scores_gemma":[0.000074650656,0.0001851407,0.00007861367,0.0001324294,0.00003021035,0.00026588983,0.00002326195,0.00021272642,0.0016716203],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008696769,0.0000501955,0.30797562,0.000010199254,0.000039476297,0.0000081392545,0.0003039644,0.00028721616,0.0000059939666,0.6830106,0.0046399795,0.0036599594],"study_design_scores_gemma":[0.001291419,0.0000058423525,0.65753293,0.0000028850977,0.000002915436,0.0000024746612,0.000013904318,0.011716384,0.000076843615,0.10975568,0.219282,0.0003167063],"about_ca_topic_score_codex":0.19018307,"about_ca_topic_score_gemma":0.14774516,"teacher_disagreement_score":0.5732549,"about_ca_system_score_codex":0.0007985791,"about_ca_system_score_gemma":0.00008766795,"threshold_uncertainty_score":0.999556},"labels":[],"label_agreement":null},{"id":"W6990586902","doi":"","title":"Drug importation programs","year":2019,"lang":"en","type":"article","venue":"State Elections Enforcement Commission (State of Connecticut)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Legislation; Agency (philosophy); State (computer science); Work (physics); Federal law; Public health; Prescription drug","score_opus":0.028965842298806894,"score_gpt":0.27425889389174574,"score_spread":0.24529305159293885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6990586902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.72135484,0.0003584777,0.0027290937,0.0010029887,0.00097358855,0.0010435346,0.00012008424,0.00012259035,0.2722948],"genre_scores_gemma":[0.98184174,0.00026000146,0.00028049675,0.00026684222,0.000032459473,0.000047252222,0.00006218143,0.00003584528,0.017173184],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99803746,0.000026684074,0.0010444664,0.00038409894,0.00006885843,0.00043845538],"domain_scores_gemma":[0.9986281,0.000087987435,0.0006063467,0.00038670297,0.00009254828,0.00019833767],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0005316549,0.00021813257,0.00043404312,0.00034795413,0.00014483802,0.00007862477,0.00022322407,0.000043817166,0.002488395],"category_scores_gemma":[0.000050269966,0.00024166743,0.00016636438,0.00041593052,0.000055958055,0.00031265005,0.000049744733,0.000221463,0.0008164364],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005697253,0.0013722688,0.08696926,0.0005073225,0.0008782678,0.00000707823,0.005851068,0.012879446,0.0032676924,0.8032539,0.022880321,0.061563674],"study_design_scores_gemma":[0.0025800127,0.0005803488,0.0034502556,0.000063094456,0.000022916396,0.000009591199,0.0002541992,0.028354125,0.0102626765,0.12644233,0.8272376,0.0007428433],"about_ca_topic_score_codex":0.00056327623,"about_ca_topic_score_gemma":0.000086548614,"teacher_disagreement_score":0.8043573,"about_ca_system_score_codex":0.0001594092,"about_ca_system_score_gemma":0.00006734428,"threshold_uncertainty_score":0.99996156},"labels":[],"label_agreement":null},{"id":"W6995590984","doi":"","title":"Pharmacy Choice - Pharmaceutical News - Enanta Pharmaceuticals Posts 3rd Quarter Financial Results [Manufacturing Close - Up]","year":2014,"lang":"en","type":"other","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Pharmacy; Community pharmacy; Pharmaceutical industry; Financial Audit","score_opus":0.07110142399607393,"score_gpt":0.34022185369366537,"score_spread":0.2691204296975914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6995590984","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010499099,0.0039683944,0.00055480085,0.008924055,0.005801625,0.0013257693,0.0039483756,0.0006859137,0.9737412],"genre_scores_gemma":[0.052038386,0.01129588,0.0006684373,0.0519746,0.013287588,0.00023171758,0.0007220627,0.0019887572,0.86779255],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9926526,0.00013664854,0.0026427894,0.0023379698,0.00017239817,0.0020576073],"domain_scores_gemma":[0.99549353,0.0004398726,0.0012918689,0.0013722535,0.00003465117,0.0013678132],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0011128852,0.0013884903,0.0022009956,0.0010795344,0.00021785549,0.00037948223,0.0014419137,0.00087871676,0.025719449],"category_scores_gemma":[0.00041353283,0.0015155296,0.0007955346,0.00028437967,0.00032752624,0.0003349941,0.00047177877,0.0017382959,0.027017104],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026053458,0.000266038,0.0003913882,0.00023651608,0.00033400417,0.000023906045,0.00008152703,0.0000049429095,0.00003323487,0.028413106,0.9589986,0.0109561775],"study_design_scores_gemma":[0.0073344004,0.00007519441,0.00014996999,0.00009906337,0.00011327863,0.000022504179,0.0000054617185,0.0021825945,0.0015739057,0.0032718012,0.9832939,0.0018779078],"about_ca_topic_score_codex":0.0020211933,"about_ca_topic_score_gemma":0.0003361901,"teacher_disagreement_score":0.10594858,"about_ca_system_score_codex":0.00031502772,"about_ca_system_score_gemma":0.00016110776,"threshold_uncertainty_score":0.9998866},"labels":[],"label_agreement":null},{"id":"W6998544407","doi":"","title":"An Analysis of Trends of Generic Drugs and Biologic Prices in the U.S.","year":2023,"lang":"en","type":"article","venue":"Chapman University Digital Commons (Chapman University)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Generic drug; Medicaid; Drug prices; Quarter (Canadian coin); Prescription drug; Medical prescription; Health care; Competition (biology)","score_opus":0.05731280158880058,"score_gpt":0.23954448636631454,"score_spread":0.18223168477751395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6998544407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92875546,0.00005651487,0.000049353843,0.0003254186,0.000022999631,0.00006613141,0.0008587667,0.00002779065,0.06983758],"genre_scores_gemma":[0.9989847,0.00024778154,0.00001706014,0.00005205922,0.000008320474,3.687951e-8,0.00012813092,0.000006443382,0.00055547757],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9991267,0.00002806538,0.00024350586,0.00032397866,0.000034433117,0.000243348],"domain_scores_gemma":[0.99915135,0.00011391804,0.00025909522,0.00035192235,0.000022783075,0.00010095588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020514605,0.0001395795,0.00046333147,0.0030967223,0.00010396639,0.000032320953,0.0006775334,0.000087943255,0.000056921523],"category_scores_gemma":[0.000009427272,0.00015615487,0.00019680319,0.0037776243,0.00031519926,0.0004809777,0.00021901361,0.00012092109,0.000015225572],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008080251,0.00026142452,0.18644686,0.00002698894,0.00044263108,0.00003977183,0.0032829961,0.0011072127,0.000029453902,0.80594456,0.00015464604,0.0021826508],"study_design_scores_gemma":[0.0020608306,0.00046196772,0.81326026,0.00001478669,0.00033422504,0.0000026838259,0.016768094,0.039961442,0.000039753475,0.00649181,0.11982678,0.0007773984],"about_ca_topic_score_codex":0.00035134895,"about_ca_topic_score_gemma":0.00029345,"teacher_disagreement_score":0.7994527,"about_ca_system_score_codex":0.0000778996,"about_ca_system_score_gemma":0.000014321143,"threshold_uncertainty_score":0.63678104},"labels":[],"label_agreement":null},{"id":"W6998936394","doi":"","title":"$1.43 Billion in Sales Expected for Olin Co. (NYSE:OLN) This Quarter","year":2021,"lang":"en","type":"other","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Payment; Economic forecasting","score_opus":0.08764716818813396,"score_gpt":0.3213196038342383,"score_spread":0.23367243564610435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6998936394","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00041171565,0.0076500876,0.0005094429,0.0018597485,0.00075217,0.0005836015,0.0011755185,0.00008561449,0.9869721],"genre_scores_gemma":[0.009773767,0.004872731,0.0018411224,0.0049905377,0.0013651678,0.00031647255,0.0010704666,0.0006456849,0.97512406],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99802434,0.000016861915,0.000777585,0.0006855171,0.00002103951,0.00047464724],"domain_scores_gemma":[0.9989782,0.000100629775,0.00034481747,0.00042541168,0.000013428472,0.00013753826],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002474232,0.00033027862,0.00087897823,0.0007073316,0.000030873794,0.00008857817,0.00027288796,0.00048231665,0.04277217],"category_scores_gemma":[0.000057292757,0.00037224,0.0002668058,0.00019988856,0.000051283474,0.00005257739,0.000047037967,0.00023253828,0.0022284247],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014406679,0.00011499018,0.0012889612,0.00012998463,0.000088626635,0.0000039932147,0.00011257743,0.0000024828696,0.000008891379,0.12133276,0.87653387,0.0003684473],"study_design_scores_gemma":[0.0010428707,0.000033451943,0.00022906953,0.00005751453,0.000005392298,0.0000015823111,0.00002591399,0.0010418288,0.000046742818,0.0064899325,0.990526,0.0004997022],"about_ca_topic_score_codex":0.00074851734,"about_ca_topic_score_gemma":0.00088481756,"teacher_disagreement_score":0.114842825,"about_ca_system_score_codex":0.00014403419,"about_ca_system_score_gemma":0.00005170895,"threshold_uncertainty_score":0.999873},"labels":[],"label_agreement":null},{"id":"W7000498065","doi":"","title":"Financieringssystemen van ziekenhuisgeneesmiddelen : een beschrijvende studie van een aantal Europese landen en Canada","year":2004,"lang":"nl","type":"article","venue":"KCE repository (Belgian Health Care Knowledge Centre)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Work (physics); Action (physics); Higher education; Government (linguistics)","score_opus":0.0195610633908832,"score_gpt":0.2641517286258521,"score_spread":0.24459066523496892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7000498065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3988096,0.22956857,0.00015457784,0.009142397,0.016217142,0.0038140612,0.0049957787,0.0003075568,0.3369903],"genre_scores_gemma":[0.9769232,0.004475266,0.00010101859,0.0019398201,0.0027933125,0.00005153782,0.00018608557,0.0002433003,0.013286427],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9918557,0.0003648414,0.0030061167,0.0019455049,0.00022654477,0.0026013257],"domain_scores_gemma":[0.9946978,0.0002202868,0.0013922759,0.0013623993,0.00030608472,0.0020211271],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00091731665,0.0011265991,0.002136009,0.0004195691,0.0012383885,0.0002825639,0.0012589388,0.00047702255,0.00035054528],"category_scores_gemma":[0.00014060033,0.0013905527,0.00052365445,0.00062260544,0.00016872385,0.00034674528,0.0006804783,0.0011948334,0.0027566813],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00091168424,0.004889039,0.35511923,0.027470285,0.0062054875,0.002984523,0.17151998,0.007871534,0.00014067904,0.068129085,0.30593848,0.04881998],"study_design_scores_gemma":[0.004253727,0.00038626613,0.022548359,0.0007955674,0.0000938068,0.00010284654,0.003110091,0.0004915932,0.00037118793,0.00025466928,0.96569526,0.001896597],"about_ca_topic_score_codex":0.16553734,"about_ca_topic_score_gemma":0.2625902,"teacher_disagreement_score":0.65975684,"about_ca_system_score_codex":0.0107649425,"about_ca_system_score_gemma":0.007079804,"threshold_uncertainty_score":0.9988544},"labels":[],"label_agreement":null},{"id":"W7000827123","doi":"","title":"Glossary of landscape terminology = A tájmeghatározások szószedete (részlet)","year":2010,"lang":"hu","type":"article","venue":"Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Québec Science (Canada)","funders":"","keywords":"Glossary; Terminology; Subject (documents); Medical terminology","score_opus":0.032958275106286,"score_gpt":0.2568176636346533,"score_spread":0.2238593885283673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7000827123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8774934,0.0071515213,0.0000019428956,0.052666895,0.0022724546,0.0008388512,0.0008730644,0.000047456728,0.058654405],"genre_scores_gemma":[0.98653406,0.0016742605,0.0009549878,0.0037295762,0.00077488006,0.000011632976,0.000003390024,0.000089419824,0.006227796],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99350655,0.00036923125,0.0036516606,0.0011244256,0.000369984,0.000978135],"domain_scores_gemma":[0.99248433,0.00070204446,0.0055038393,0.0009265805,0.000017029037,0.00036616507],"candidate_categories":["metaepi_narrow","sts","open_science","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0012911047,0.00064421946,0.0018790745,0.0007139873,0.0005902785,0.00011846421,0.008606573,0.0013473917,0.0007250843],"category_scores_gemma":[0.00017270836,0.0005105612,0.001342948,0.0016025,0.006868716,0.0035149404,0.0032838425,0.0025751416,0.000031164695],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004420529,0.0006521374,0.4250346,0.0012266263,0.00070151757,0.0000020142002,0.0011018004,0.00040925053,0.05492804,0.4816522,0.03217047,0.001679278],"study_design_scores_gemma":[0.0017541349,0.0002890333,0.3122545,0.00060831703,0.00022118437,0.00011458662,0.000115803916,0.0066931667,0.45779717,0.10035764,0.11885823,0.00093623926],"about_ca_topic_score_codex":0.000034726017,"about_ca_topic_score_gemma":3.3936146e-7,"teacher_disagreement_score":0.40286914,"about_ca_system_score_codex":0.000020696743,"about_ca_system_score_gemma":0.0004913242,"threshold_uncertainty_score":0.9999491},"labels":[],"label_agreement":null},{"id":"W7001760524","doi":"","title":"Le marché pharmaceutique canadien, cas des antiasthmatiques","year":2005,"lang":"fr","type":"other","venue":"OpenGrey (Institut de l'Information Scientifique et Technique)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Context (archaeology); Line (geometry); Identification (biology)","score_opus":0.04510073411197137,"score_gpt":0.30839487814859584,"score_spread":0.2632941440366245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7001760524","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012448506,0.0013414373,0.12004339,0.012421888,0.0015301874,0.0065220976,0.002259008,0.0002903636,0.85434675],"genre_scores_gemma":[0.115365535,0.03539137,0.124063425,0.039042313,0.0016821708,0.0054657804,0.0018435527,0.00084304746,0.6763028],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949318,0.00022014299,0.0022568116,0.00090254395,0.0001643831,0.0015242752],"domain_scores_gemma":[0.9961995,0.00012835124,0.0015536651,0.0010173711,0.0002841458,0.00081697555],"candidate_categories":["metaepi_narrow","scholarly_communication","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.005170657,0.00085089525,0.0011550862,0.0018057436,0.00074813055,0.0015380249,0.0015303501,0.0009972375,0.01526388],"category_scores_gemma":[0.00056639675,0.0010356045,0.0004433283,0.0008758615,0.001036985,0.004518257,0.000496742,0.0013753496,0.004779608],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032284242,0.00018475986,0.0008755028,0.001275754,0.0001622069,0.000028353814,0.0033994378,0.00075957837,0.00013201518,0.73554593,0.08580345,0.1718007],"study_design_scores_gemma":[0.0008347948,0.00004154291,0.0010251455,0.00085445173,0.000027168158,0.00013202478,0.00007090986,0.008523602,0.006771682,0.0066187414,0.9738355,0.0012644305],"about_ca_topic_score_codex":0.011064213,"about_ca_topic_score_gemma":0.023814937,"teacher_disagreement_score":0.8880321,"about_ca_system_score_codex":0.002146883,"about_ca_system_score_gemma":0.0018741064,"threshold_uncertainty_score":0.9994985},"labels":[],"label_agreement":null},{"id":"W7001773500","doi":"","title":"L’antiextractivisme comme engagement transnational ancré en ville : parcours de vie et d’engagement de personnes migrantes","year":2023,"lang":"fr","type":"dissertation","venue":"EspaceINRS Institutional Digital Repository (Institut National de la Recherche Scientifique)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Politics; Identity (music); Ethnic group; Face (sociological concept)","score_opus":0.19920147407238492,"score_gpt":0.37586445733250157,"score_spread":0.17666298326011665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7001773500","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.31130758,0.0034185492,0.036875922,0.027055053,0.006799608,0.002012036,0.0054781903,0.00038761582,0.60666543],"genre_scores_gemma":[0.9545449,0.0017262944,0.010409207,0.0016781851,0.0008185399,0.0005230561,0.0022380413,0.000131867,0.027929937],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9932873,0.0018293103,0.001536021,0.0014562404,0.0006685897,0.001222489],"domain_scores_gemma":[0.9919717,0.005683767,0.00082395365,0.0003860378,0.0005316952,0.0006028466],"candidate_categories":["metaepi_narrow","sts","scholarly_communication","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.016305055,0.0008278107,0.00083114684,0.0011930275,0.0014998834,0.0018688418,0.0010134885,0.0014124195,0.0002076769],"category_scores_gemma":[0.007004188,0.0010913394,0.00084486447,0.0009938354,0.0010621595,0.0018170861,0.00017722097,0.003044891,0.00035341803],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00018291695,0.0010809293,0.005485963,0.0005650125,0.0006898753,0.000115091876,0.00827112,0.03874865,0.002635257,0.9356493,0.005065666,0.0015102214],"study_design_scores_gemma":[0.0020337321,0.00010132974,0.044666998,0.0008315296,0.0001572883,0.00027992902,0.0017515486,0.091881655,0.003200808,0.23173927,0.6215199,0.0018359798],"about_ca_topic_score_codex":0.0003242272,"about_ca_topic_score_gemma":0.00037164008,"teacher_disagreement_score":0.70391005,"about_ca_system_score_codex":0.008168804,"about_ca_system_score_gemma":0.007699613,"threshold_uncertainty_score":0.99988395},"labels":[],"label_agreement":null},{"id":"W7001874183","doi":"","title":"Les Aspects financiers de la formation et du perfectionnement des maîtres au Québec : rapport préliminaire /","year":2015,"lang":"fr","type":"other","venue":"Bibliothèque et Archives nationales du Québec (Québec government)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Context (archaeology); Perspective (graphical); Class (philosophy); Government (linguistics)","score_opus":0.02916627549098894,"score_gpt":0.2553178151566228,"score_spread":0.22615153966563384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7001874183","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18601988,0.015246115,0.002462088,0.023292312,0.00033931778,0.0006247678,0.00095407764,0.000104236016,0.7709572],"genre_scores_gemma":[0.76527876,0.006697247,0.0008316967,0.0030811108,0.00077174057,0.00030184747,0.00009642659,0.0002831894,0.22265796],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963531,0.00035867345,0.0012995368,0.0008776194,0.00028785708,0.0008232054],"domain_scores_gemma":[0.99397045,0.0036672053,0.0013262553,0.00047331525,0.00007162383,0.0004911204],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0017185728,0.00078277674,0.00087422045,0.0014580546,0.000589621,0.0005624718,0.0007940027,0.00032675063,0.0119492505],"category_scores_gemma":[0.003084544,0.0009434952,0.00049913605,0.00058875297,0.00096164725,0.00095103733,0.00042706484,0.00072297914,0.0011666752],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00024009861,0.0012043592,0.23475823,0.0007902473,0.000724942,0.00003535026,0.025601499,0.0017516405,0.000044489796,0.24354148,0.48319837,0.008109288],"study_design_scores_gemma":[0.0015325155,0.00019169458,0.17828022,0.00022604773,0.00008296596,0.000094007315,0.00034445588,0.0050745816,0.000064789616,0.003509208,0.8097862,0.00081332243],"about_ca_topic_score_codex":0.64217436,"about_ca_topic_score_gemma":0.9833503,"teacher_disagreement_score":0.5792589,"about_ca_system_score_codex":0.027816985,"about_ca_system_score_gemma":0.058035098,"threshold_uncertainty_score":0.999611},"labels":[],"label_agreement":null},{"id":"W7002144078","doi":"","title":"Mitattavasti, tavoitteellisesti ja toteutettavuus huomioiden : vanhuspalvelusuunnitelmien toimenpiteet tarkastelussa","year":2022,"lang":"fi","type":"dissertation","venue":"Jyväskylä University Digital Archive (University of Jyväskylä)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Set (abstract data type); Quarter (Canadian coin); Order (exchange)","score_opus":0.022988034281606666,"score_gpt":0.21205952639748826,"score_spread":0.1890714921158816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7002144078","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46077397,0.00215896,0.0049765403,0.0021285035,0.002758432,0.0023001248,0.057617083,0.0002911085,0.46699527],"genre_scores_gemma":[0.66863775,0.008092971,0.0036491812,0.0009892831,0.0005819201,0.0000030435342,0.017945375,0.0004646268,0.29963583],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.993622,0.00024802878,0.0013854521,0.0025429574,0.00044048252,0.001761049],"domain_scores_gemma":[0.99306744,0.0011177904,0.0028122826,0.0014719005,0.00027350095,0.0012570897],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0005687968,0.0014121209,0.0027989286,0.0026395593,0.0017164112,0.00033957767,0.0036507985,0.00075464457,0.0095922565],"category_scores_gemma":[0.00025578163,0.002403885,0.0021697206,0.0015824313,0.0012074157,0.002551003,0.0021208937,0.0021038542,0.002523564],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024817154,0.012156618,0.06287586,0.006607863,0.019604724,0.0058133844,0.10146746,0.015192105,0.0013346042,0.4504845,0.17372808,0.12591763],"study_design_scores_gemma":[0.0058827903,0.0008896647,0.018775163,0.00026961113,0.00057149713,0.0000396747,0.026659885,0.00532836,0.000025970976,0.0121540595,0.9264841,0.0029192232],"about_ca_topic_score_codex":0.003206474,"about_ca_topic_score_gemma":0.0010272785,"teacher_disagreement_score":0.752756,"about_ca_system_score_codex":0.0014566767,"about_ca_system_score_gemma":0.00075332285,"threshold_uncertainty_score":0.9998629},"labels":[],"label_agreement":null},{"id":"W7002173420","doi":"","title":"The Minnesota Daily, December 1, 2008","year":2008,"lang":"en","type":"other","venue":"University of Minnesota Digital Conservancy (University of Minnesota)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Microform; Postal service; Quarter (Canadian coin)","score_opus":0.030013827553690847,"score_gpt":0.20100284433330529,"score_spread":0.17098901677961445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7002173420","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017961575,0.009450731,0.00031155758,0.0044694305,0.00065178593,0.0006526691,0.008175662,0.00014362056,0.958183],"genre_scores_gemma":[0.02720467,0.050390266,0.0010377044,0.00025447257,0.00022118211,3.9743924e-7,0.00041855895,0.0004023498,0.9200704],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974167,0.000051185234,0.0006223956,0.00095928117,0.00016800193,0.00078243256],"domain_scores_gemma":[0.99623567,0.00033861678,0.0016659184,0.0012111291,0.00015376497,0.00039491817],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002669052,0.000622619,0.0014518942,0.00068395596,0.000514747,0.00005509795,0.0018523127,0.00065029255,0.003639898],"category_scores_gemma":[0.000101224694,0.0008290762,0.00081220263,0.00056757126,0.0019146175,0.0007337388,0.00072669936,0.00045734624,0.0020559684],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021803878,0.0002620891,0.006119403,0.00017585383,0.0005691334,0.00014472593,0.0006828435,0.0000056386675,0.000006699729,0.017873498,0.9724868,0.0014552956],"study_design_scores_gemma":[0.0019960888,0.00010142389,0.0011821673,0.00013926905,0.00008532377,0.0000341681,0.0009141105,0.0002671397,0.0000059139197,0.0008261383,0.99365395,0.00079429115],"about_ca_topic_score_codex":0.0033073924,"about_ca_topic_score_gemma":0.0041180826,"teacher_disagreement_score":0.040939536,"about_ca_system_score_codex":0.00017678841,"about_ca_system_score_gemma":0.0002434763,"threshold_uncertainty_score":0.999416},"labels":[],"label_agreement":null},{"id":"W7002227520","doi":"","title":"Monilajisen empatian ilmaisuja alakoulussa","year":2024,"lang":"fi","type":"other","venue":"Lauda (University of Lapland)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Life style; Civil servants; Quarter (Canadian coin)","score_opus":0.034725154147827154,"score_gpt":0.23499068947438337,"score_spread":0.20026553532655622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7002227520","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009128596,0.0078207,0.00021154445,0.004102481,0.0015492587,0.00036625357,0.005323881,0.00007864487,0.9714186],"genre_scores_gemma":[0.10935145,0.0073074545,0.00047018012,0.000650528,0.0005029383,7.4117423e-7,0.00018472906,0.0002566275,0.88127536],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997868,0.0000318523,0.00052972184,0.00089383085,0.00006663174,0.0006099472],"domain_scores_gemma":[0.9982057,0.000061323844,0.0006745818,0.0006478503,0.000028818245,0.00038171312],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00032317187,0.00046777906,0.0012381958,0.00073693716,0.00012665876,0.00008528212,0.00082515634,0.0006872392,0.039620865],"category_scores_gemma":[0.000019386767,0.0006746794,0.00055815873,0.00033674244,0.00030166734,0.00018284672,0.00038523847,0.000624185,0.030632883],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001960759,0.0004117478,0.011302367,0.0018196298,0.002245363,0.00033506955,0.0047559254,0.000058640104,0.000014278787,0.253641,0.7185955,0.0066243885],"study_design_scores_gemma":[0.0010139097,0.00009713702,0.0014723554,0.0002361245,0.00014803918,0.000008874011,0.0003090627,0.002090615,0.000006640574,0.011031327,0.98288625,0.0006996728],"about_ca_topic_score_codex":0.002634409,"about_ca_topic_score_gemma":0.0016559865,"teacher_disagreement_score":0.26429075,"about_ca_system_score_codex":0.00019289764,"about_ca_system_score_gemma":0.00009346688,"threshold_uncertainty_score":0.9995704},"labels":[],"label_agreement":null},{"id":"W7002252651","doi":"","title":"$183.30 Million in Sales Expected for Ameresco, Inc. (AMRC) This Quarter","year":2017,"lang":"en","type":"other","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Payment; Revenue; Work (physics)","score_opus":0.07510458233060528,"score_gpt":0.311888415331472,"score_spread":0.2367838330008667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7002252651","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021039364,0.0044805314,0.0003474874,0.0014059927,0.00080914085,0.00065604504,0.0016039285,0.000089455425,0.99039704],"genre_scores_gemma":[0.012877954,0.0057196496,0.0013242734,0.0029770306,0.0014308682,0.00030734233,0.00044356164,0.00063240965,0.9742869],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982068,0.00001169136,0.00060936227,0.00064992585,0.000020962292,0.0005012687],"domain_scores_gemma":[0.9983857,0.00006784235,0.0006024155,0.000786943,0.000012484784,0.00014458633],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00025379748,0.00035218807,0.00087730953,0.00072197936,0.00006693801,0.00012788463,0.000670253,0.00048600067,0.018471384],"category_scores_gemma":[0.00010541458,0.00039599987,0.0002010495,0.00006097616,0.00009777183,0.000097989985,0.00012236023,0.00024539037,0.0058694906],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015756275,0.000063492276,0.00078311906,0.00007748073,0.0000756756,0.0000019672614,0.0000638734,6.253282e-7,0.000002233679,0.04587523,0.9515391,0.001501477],"study_design_scores_gemma":[0.0010880843,0.00004106891,0.0003131009,0.000059630784,0.0000067743167,7.519369e-7,0.000009335241,0.0011658615,0.000010921799,0.010438723,0.98634446,0.0005212623],"about_ca_topic_score_codex":0.0030488041,"about_ca_topic_score_gemma":0.001819349,"teacher_disagreement_score":0.035436507,"about_ca_system_score_codex":0.00012578702,"about_ca_system_score_gemma":0.00003560583,"threshold_uncertainty_score":0.9998492},"labels":[],"label_agreement":null},{"id":"W7002630461","doi":"","title":"Neki aspekti demografske prošlosti župe Nova Gradiška prema matičnoj knjizi krštenih župe Nova Gradiška 1878.-1890. = Some aspects of the demographic past of the parish of Nova Gradiška = according to the parish registers of baptisms from 1878-1890","year":2017,"lang":"sh","type":"other","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nova (rocket); Nova scotia; Metis","score_opus":0.07524214947052232,"score_gpt":0.28349770185384304,"score_spread":0.20825555238332072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7002630461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.59829634,0.018328851,0.00039434782,0.02175423,0.013408442,0.011129993,0.015949905,0.00016536885,0.3205725],"genre_scores_gemma":[0.98205405,0.005248426,0.0007159012,0.0023056827,0.0013218467,0.000104633305,0.00009802323,0.0006644303,0.0074870293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9879534,0.00043602905,0.0060801934,0.0026014168,0.00071890256,0.0022100168],"domain_scores_gemma":[0.9790555,0.0011593575,0.01159543,0.0070462455,0.0004275114,0.00071595924],"candidate_categories":["metaepi_narrow","sts","open_science","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.002879777,0.0021749893,0.0057184086,0.0016347839,0.0006626179,0.00046634523,0.008779294,0.0016534788,0.002552717],"category_scores_gemma":[0.0010476894,0.0016357267,0.0032966447,0.0025140047,0.0032016297,0.00068203907,0.0023190985,0.0022793694,0.0002608596],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077070296,0.0027510137,0.55103534,0.0042188778,0.011169949,0.000021031086,0.0024974004,0.00085155806,0.0007976349,0.28009564,0.12773922,0.018051634],"study_design_scores_gemma":[0.011049909,0.001413277,0.516866,0.008219666,0.003630869,0.00011087586,0.0011187459,0.0047549093,0.004724344,0.069258004,0.37234548,0.0065079024],"about_ca_topic_score_codex":0.018400159,"about_ca_topic_score_gemma":0.01178122,"teacher_disagreement_score":0.38375768,"about_ca_system_score_codex":0.0003829142,"about_ca_system_score_gemma":0.00067320466,"threshold_uncertainty_score":0.9996426},"labels":[],"label_agreement":null},{"id":"W7014270823","doi":"","title":"Pharmaceutical Exhaustion","year":2019,"lang":"en","type":"article","venue":"Scholarly Commons (University of the Pacific)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Intellectual property; Statute; Drug prices; Pharmaceutical industry; Position (finance); Order (exchange); Patent law; Patent infringement","score_opus":0.05096727005572499,"score_gpt":0.23701106875059164,"score_spread":0.18604379869486665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7014270823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7134071,0.00025609232,0.0002920761,0.008244923,0.000532606,0.0002067731,0.00019286177,0.00002652108,0.27684107],"genre_scores_gemma":[0.9947793,0.000074308206,0.00017202928,0.00026533523,0.000026576186,1.8095709e-7,0.0000039215147,0.000010063354,0.004668285],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992881,0.000033330944,0.00018672843,0.00023303331,0.00003720675,0.00022163657],"domain_scores_gemma":[0.9991456,0.000046918365,0.00018338078,0.00048386335,0.000029517854,0.00011070584],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00042549905,0.00009751706,0.00024411337,0.00012903102,0.00017855575,0.00006721974,0.00065130217,0.000095494725,0.00189086],"category_scores_gemma":[0.00003088938,0.0001120075,0.0002023444,0.00025147462,0.00012772529,0.00066428777,0.00025195777,0.00039952516,0.0028099543],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008069823,0.00016500072,0.29921806,0.000041692845,0.00012242702,0.0000018844711,0.0007732938,0.000109938,0.0010870058,0.6902413,0.006893532,0.0012651751],"study_design_scores_gemma":[0.0015464689,0.00005045707,0.117808454,0.000023536224,0.000027576494,0.000006218222,0.00067770056,0.0061485367,0.00031624534,0.035768393,0.8372787,0.00034771627],"about_ca_topic_score_codex":0.00013575768,"about_ca_topic_score_gemma":0.000019190706,"teacher_disagreement_score":0.83038515,"about_ca_system_score_codex":0.00009100368,"about_ca_system_score_gemma":0.000021103064,"threshold_uncertainty_score":0.99902153},"labels":[],"label_agreement":null},{"id":"W7017607181","doi":"","title":"Breaking the Vial: Leveraging North American Regulatory Models and Market Practices to Reform Insulin Pricing in the United States","year":2025,"lang":"en","type":"article","venue":"Digital USD (University of San Diego)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Expediting; Restructuring; Enforcement; Legislature; Government (linguistics); Limiting; Constraint (computer-aided design); Evasion (ethics); Vetting","score_opus":0.04583983515196348,"score_gpt":0.25258009365123973,"score_spread":0.20674025849927624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7017607181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94648,0.00012749353,0.00058045186,0.003911997,0.000027265532,0.00015007087,0.00010487027,0.000010894256,0.048606962],"genre_scores_gemma":[0.99769855,0.00024149394,0.0000638579,0.0018037028,0.000011066388,5.2519624e-7,0.000018434135,0.0000061791784,0.00015619636],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993464,0.00001758614,0.00019599544,0.00021756397,0.000028362634,0.00019411994],"domain_scores_gemma":[0.9992235,0.00018252479,0.00031562048,0.00020896124,0.000020259386,0.0000491556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003337697,0.000096317206,0.00021451889,0.00032336332,0.0001513639,0.00011200407,0.0003398969,0.00002193993,0.0000144634505],"category_scores_gemma":[0.00005101945,0.00009100018,0.000045600475,0.00065204134,0.00015892363,0.0005870461,0.0002014162,0.00014734254,0.000006376571],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00086549495,0.00050930324,0.4171827,0.00033176495,0.0005922596,0.000041725336,0.057751592,0.014252541,0.000009139325,0.38522348,0.007882722,0.11535728],"study_design_scores_gemma":[0.0007592401,0.000072083996,0.7263587,0.000052619638,0.000022646069,0.0000034179018,0.017685974,0.120068766,0.0000035199448,0.022192178,0.11244824,0.00033263292],"about_ca_topic_score_codex":0.005582537,"about_ca_topic_score_gemma":0.0019040172,"teacher_disagreement_score":0.3630313,"about_ca_system_score_codex":0.0001337546,"about_ca_system_score_gemma":0.000020176774,"threshold_uncertainty_score":0.84391636},"labels":[],"label_agreement":null},{"id":"W7019278859","doi":"","title":"Forward Pharma Reports Fourth Quarter and Year End 2016 Financial and Operational Results","year":2017,"lang":"en","type":"other","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Financial Audit; Work (physics); Revenue; Payment","score_opus":0.039128289001113654,"score_gpt":0.28421300199751903,"score_spread":0.24508471299640538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7019278859","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003109143,0.0022082394,0.00012922814,0.0024914744,0.000705376,0.0002482897,0.0015680321,0.00003474085,0.9923037],"genre_scores_gemma":[0.025648376,0.0077038878,0.0010912154,0.0026108704,0.0018929155,0.000031748055,0.00014364767,0.00020282445,0.9606745],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99861723,0.0000068974337,0.0004921112,0.00059428514,0.000024645984,0.00026483485],"domain_scores_gemma":[0.9989062,0.000027333992,0.00049589196,0.00037277522,0.000010478503,0.00018734632],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035443803,0.00023732653,0.00048694856,0.00020293123,0.00010507224,0.00019277162,0.00012077766,0.00025730388,0.0030089582],"category_scores_gemma":[0.00010767886,0.00024928214,0.00007100997,0.000018848934,0.00012396814,0.00013464621,0.00010191769,0.00017768577,0.00037884415],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018110908,0.00001732895,0.00081214367,0.00002586618,0.00004992665,0.000013364585,0.00003283025,2.4739e-7,7.9516974e-7,0.04272098,0.9548257,0.0014827288],"study_design_scores_gemma":[0.0008798456,0.000029820225,0.0010963063,0.000030127987,0.000009035513,0.000022129889,0.000001594108,0.00025468628,0.000005307577,0.0073738936,0.98996615,0.0003310833],"about_ca_topic_score_codex":0.0005625189,"about_ca_topic_score_gemma":0.00017458548,"teacher_disagreement_score":0.03534709,"about_ca_system_score_codex":0.000026809348,"about_ca_system_score_gemma":0.000062086554,"threshold_uncertainty_score":0.99999595},"labels":[],"label_agreement":null},{"id":"W7023538373","doi":"","title":"Pharmacy Choice - Pharmaceutical News - Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2014","year":2014,"lang":"en","type":"other","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Pharmacy; Fiscal year; Community pharmacy; Revenue","score_opus":0.08429951513084548,"score_gpt":0.3551227256445844,"score_spread":0.2708232105137389,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7023538373","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024759697,0.00478095,0.0014946634,0.01080026,0.0050471923,0.00309396,0.009784722,0.00044006144,0.9643106],"genre_scores_gemma":[0.009922201,0.003846587,0.0013054812,0.029931983,0.0115457345,0.00093231694,0.0012613231,0.0012587076,0.93999565],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9913587,0.000113155504,0.0034625425,0.0027228228,0.00016738492,0.0021753858],"domain_scores_gemma":[0.99463236,0.000807987,0.0018052381,0.0013366598,0.00007638627,0.0013413549],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0019545625,0.0013353869,0.0024753653,0.0009944638,0.00023580404,0.00033711424,0.0010645145,0.0010211958,0.02347955],"category_scores_gemma":[0.0008461213,0.0014704558,0.0010247715,0.00030378124,0.0002789747,0.00030792577,0.0003684749,0.0013513636,0.008093048],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037330555,0.00029420113,0.0003726751,0.0005156188,0.0003676855,0.000035111098,0.00003438917,0.0000037580148,0.00011012423,0.020622661,0.9761255,0.0011450134],"study_design_scores_gemma":[0.007206214,0.00012784869,0.00010010951,0.0000699026,0.00013552014,0.000061499195,0.00000308416,0.006226929,0.00095781946,0.0039838254,0.9793113,0.0018159328],"about_ca_topic_score_codex":0.00023729265,"about_ca_topic_score_gemma":0.00033559624,"teacher_disagreement_score":0.024314929,"about_ca_system_score_codex":0.00030622573,"about_ca_system_score_gemma":0.00027031315,"threshold_uncertainty_score":0.99993974},"labels":[],"label_agreement":null},{"id":"W7037115462","doi":"","title":"Concerning Expanding the Canadian Prescription Drug Importation Program to Include Prescription Drug Suppliers from Nations Other Than Canada upon the Enactment of Legislation by the United States Congress Authorizing Such Practice.","year":2021,"lang":"en","type":"article","venue":"eYLS (Yale Law School)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Legislation; Medical prescription; Prescription drug; Drug; Drug industry","score_opus":0.03282459435015501,"score_gpt":0.28928899233461713,"score_spread":0.25646439798446213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7037115462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90396535,0.0014817633,0.00040040977,0.07845432,0.0016458839,0.0018634084,0.0025985227,0.00005023181,0.009540105],"genre_scores_gemma":[0.9924234,0.0001297513,0.0001535518,0.005196819,0.00012745096,0.00022881586,0.00081858994,0.00003161738,0.00088997005],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99826217,0.00018737023,0.00066502165,0.00035862136,0.00013170995,0.00039509655],"domain_scores_gemma":[0.9982019,0.0004842002,0.0005400325,0.00039313425,0.00015175846,0.00022896152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001021922,0.00018871274,0.00022704779,0.00011295115,0.0009750933,0.00049532246,0.00034657994,0.00006936906,0.00022926916],"category_scores_gemma":[0.0003785031,0.00013971791,0.00006936057,0.00042982367,0.00008261147,0.0004795836,0.000057443904,0.0003735145,0.00002157488],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023046149,0.00036317421,0.06456735,0.00007481813,0.0013058436,0.000012859102,0.04187315,0.03724188,0.0019539304,0.6772468,0.17020456,0.0049251504],"study_design_scores_gemma":[0.00044414462,0.000019158786,0.003370104,0.000033674525,0.00004333262,0.0000016240982,0.0040397667,0.016160531,0.0029080187,0.0030775652,0.96966577,0.00023630177],"about_ca_topic_score_codex":0.981536,"about_ca_topic_score_gemma":0.98939204,"teacher_disagreement_score":0.7994612,"about_ca_system_score_codex":0.00094046246,"about_ca_system_score_gemma":0.00044579065,"threshold_uncertainty_score":0.74997276},"labels":[],"label_agreement":null},{"id":"W7042713180","doi":"","title":"Preliminary discussion of Canadian drug purchasing programs","year":2003,"lang":"en","type":"book","venue":"State Library's electronic repository (State Library of Massachusetts)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Purchasing; Government (linguistics); Drug industry; Drug Company","score_opus":0.016581637183766887,"score_gpt":0.21422839305242344,"score_spread":0.19764675586865654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7042713180","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008024757,0.014687055,0.000023222428,0.0057196156,0.00097278133,0.0016033819,0.0026841538,0.0002280488,0.966057],"genre_scores_gemma":[0.025646616,0.009187369,0.0006421668,0.0010380012,0.00032922922,0.00007912891,0.0017033143,0.00060779264,0.9607664],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99301547,0.00018590655,0.0032838932,0.0014200131,0.00017881747,0.0019159131],"domain_scores_gemma":[0.9948673,0.00013937528,0.0026988916,0.0013505577,0.000028725295,0.0009151313],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044299578,0.0010273455,0.0020483003,0.0023936173,0.0002460898,0.00032486347,0.001490724,0.0005302282,0.0008987244],"category_scores_gemma":[0.000017285318,0.0010291041,0.0008059876,0.0007617969,0.00050338946,0.0027639437,0.0003563427,0.0015358886,0.00012486365],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00091330986,0.0006242616,0.011781615,0.0025428971,0.0018735311,0.00026275325,0.0022358901,0.00034941587,0.0000854446,0.20862871,0.76252705,0.008175127],"study_design_scores_gemma":[0.0007147727,0.0004551574,0.00025501236,0.00029891793,0.00005304994,0.00003235227,0.000015197262,0.0002885031,0.0023184298,0.21488099,0.7797151,0.0009725033],"about_ca_topic_score_codex":0.0013231036,"about_ca_topic_score_gemma":0.00012871581,"teacher_disagreement_score":0.01762186,"about_ca_system_score_codex":0.00038550864,"about_ca_system_score_gemma":0.003541854,"threshold_uncertainty_score":0.9992159},"labels":[],"label_agreement":null},{"id":"W7042902537","doi":"","title":"Research Output of the Canadian Pharmaceutical Industry: Where Has All the R&amp;D Gone?","year":2006,"lang":"en","type":"article","venue":"PubMed Central","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Mandate; Accountability; Productivity; Pharmaceutical industry; Data collection; Relation (database)","score_opus":0.22960896577037648,"score_gpt":0.33509372884882765,"score_spread":0.10548476307845117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7042902537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.69421715,0.0029014652,0.000011799878,0.1301125,0.0016861898,0.00091344747,0.0007466434,0.000021661146,0.16938913],"genre_scores_gemma":[0.9932138,0.00011805142,0.000016898668,0.0024926323,0.00079003116,0.000070420545,0.0000104750225,0.00002540255,0.0032623208],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99690944,0.00008664622,0.00053870096,0.00031632796,0.00008984924,0.0020590308],"domain_scores_gemma":[0.9985999,0.000121173485,0.00013827662,0.00048220693,0.00003561027,0.0006228563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020672998,0.00015112817,0.00025333994,0.00015993377,0.00039929687,0.00022049992,0.0008116393,0.0002652483,0.000573332],"category_scores_gemma":[0.00016515734,0.00011711904,0.00015838919,0.00039319077,0.0005711015,0.00010151738,0.00013985008,0.0012586829,0.00026510487],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002180279,0.00012204686,0.25549397,0.000024714993,0.000097889795,0.0000025779475,0.00033690766,0.0005322453,0.0000075787434,0.5605765,0.18078661,0.0019971633],"study_design_scores_gemma":[0.00028366398,0.0000032256692,0.2632912,0.000002942907,0.000006165392,0.0000030049298,0.000013671633,0.00043884123,0.00008442727,0.014116324,0.7216488,0.00010772331],"about_ca_topic_score_codex":0.14437197,"about_ca_topic_score_gemma":0.22518621,"teacher_disagreement_score":0.54646015,"about_ca_system_score_codex":0.00078154524,"about_ca_system_score_gemma":0.00037572286,"threshold_uncertainty_score":0.86132574},"labels":[],"label_agreement":null},{"id":"W7070996707","doi":"","title":"THE ROLE OF COMMUNITY RADIO IN POLITICAL PARTICIPATION IN THAILAND A CASE STUDY:THE 3 SOUTHERN BORDER PROVINCES OF THAILAND(YALA- PATTANI- NARATHIWAT)","year":2025,"lang":"en","type":"other","venue":"Andalas University eThesis (Andalas University)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Constitution; Community radio; Legislation; State (computer science); Government (linguistics); Politics; Subject (documents); Control (management)","score_opus":0.029102923079181168,"score_gpt":0.26799353621721644,"score_spread":0.23889061313803528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7070996707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5960515,0.0006601785,0.000025805595,0.00077162846,0.000104578234,0.00078405056,0.0010551955,0.00002783162,0.40051922],"genre_scores_gemma":[0.9500972,0.00061670237,0.00000982531,0.00004571646,0.000026592315,0.0000010671181,0.000010194713,0.000041446983,0.049151275],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982289,0.00048797842,0.00046388793,0.00031090403,0.00006916756,0.00043913216],"domain_scores_gemma":[0.99803686,0.00072941714,0.000511685,0.00056536804,0.00004993343,0.00010676246],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008804493,0.00027376457,0.0007207219,0.0009648423,0.00027818655,0.000031356467,0.000746832,0.0003028882,0.00021083606],"category_scores_gemma":[0.00010263315,0.00025765708,0.00018600962,0.00072366465,0.00046197834,0.000114012415,0.0002990854,0.0006512362,0.00001638505],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009376859,0.0024560213,0.71947104,0.00027963656,0.0011544293,0.000565411,0.024747705,0.00013867737,0.0000058412065,0.2430085,0.0031042977,0.004130753],"study_design_scores_gemma":[0.00429894,0.00029308753,0.009712963,0.00015109367,0.00020062705,0.000009870535,0.07940348,0.00074240426,0.000052301817,0.0031725832,0.9013776,0.00058502227],"about_ca_topic_score_codex":0.045338888,"about_ca_topic_score_gemma":0.06684067,"teacher_disagreement_score":0.89827335,"about_ca_system_score_codex":0.0003074094,"about_ca_system_score_gemma":0.00024150732,"threshold_uncertainty_score":0.99998754},"labels":[],"label_agreement":null},{"id":"W7072191129","doi":"","title":"United Therapeutics Corporation Reports 2017 Fourth Quarter And Annual Financial Results","year":2018,"lang":"en","type":"other","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Corporation; Quarter (Canadian coin); Annual report; Financial Audit","score_opus":0.06956009106558061,"score_gpt":0.289212810338711,"score_spread":0.21965271927313038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7072191129","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004894325,0.0006605766,0.0005725295,0.0015666148,0.0012459875,0.00031181454,0.0017834719,0.00010388359,0.9932657],"genre_scores_gemma":[0.0113273775,0.0023055545,0.0011736068,0.006746448,0.0024110961,0.000023939852,0.00067446876,0.0003381321,0.97499937],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99822944,0.000015235141,0.0008039483,0.00061183725,0.000028263334,0.00031128776],"domain_scores_gemma":[0.99830943,0.0000297259,0.0009858782,0.0004994625,0.000033052584,0.00014246946],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0004133478,0.00029445396,0.0005035182,0.0005298395,0.00007071285,0.00010904395,0.0001390755,0.000464284,0.0013879583],"category_scores_gemma":[0.00006030498,0.00032069374,0.00008371809,0.00014702854,0.00015001668,0.000109371955,0.0000632042,0.00018354194,0.0012915223],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002760229,0.000034621495,0.00043322644,0.00001755908,0.00006109246,0.0000113782235,0.00009852371,7.661147e-7,4.288247e-7,0.054027937,0.94496495,0.00032194157],"study_design_scores_gemma":[0.0005466131,0.00009191453,0.0005146062,0.000018781733,0.000014415067,0.000018455761,0.000007719707,0.0009031927,0.000003770747,0.017319463,0.98015535,0.00040572835],"about_ca_topic_score_codex":0.0005505676,"about_ca_topic_score_gemma":0.00032155935,"teacher_disagreement_score":0.036708474,"about_ca_system_score_codex":0.000043892487,"about_ca_system_score_gemma":0.000049637714,"threshold_uncertainty_score":0.99992454},"labels":[],"label_agreement":null},{"id":"W7094423423","doi":"","title":"Rebuttal: Are drugs too expensive in Canada?","year":2006,"lang":"en","type":"article","venue":"PubMed Central","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"","score_opus":0.027320650565238868,"score_gpt":0.20900810707096062,"score_spread":0.18168745650572177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7094423423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93066466,0.00091282924,0.000012406444,0.005072439,0.00095064595,0.00022986373,0.00028558882,0.000016031789,0.061855547],"genre_scores_gemma":[0.99509215,0.00008879361,0.000029446726,0.0036589769,0.00038349297,0.00005887314,0.00002034755,0.000019582734,0.00064836],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99782145,0.000009278629,0.00050742977,0.00031070146,0.000027078928,0.0013240499],"domain_scores_gemma":[0.9993097,0.000034892048,0.0001803506,0.00018460298,0.000007695125,0.000282763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021366854,0.00013713582,0.00031248125,0.000101376434,0.000036110585,0.000045852026,0.0001868387,0.000052861767,0.00020400494],"category_scores_gemma":[0.000049445283,0.00017436028,0.00006499382,0.00013459743,0.000027701697,0.00013362922,0.000041698186,0.00016299955,0.00009396414],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019629939,0.00006689855,0.7856185,0.000014864481,0.000019386714,0.000033620378,0.0001503751,0.0006544329,0.0000018132142,0.16422728,0.047232747,0.0019605046],"study_design_scores_gemma":[0.0005362481,0.0000020960706,0.7280568,0.0000025248978,0.0000013758278,0.0000019091992,0.00006444423,0.0009037464,0.000107325286,0.011199594,0.25891247,0.00021148547],"about_ca_topic_score_codex":0.74381596,"about_ca_topic_score_gemma":0.7038444,"teacher_disagreement_score":0.21167971,"about_ca_system_score_codex":0.0017389092,"about_ca_system_score_gemma":0.00020496358,"threshold_uncertainty_score":0.7110206},"labels":[],"label_agreement":null},{"id":"W7095689335","doi":"","title":"Based Pricing, and Drug R&amp;amp;D: A Critique of the National Forum on Health’s Recommendations for","year":2016,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmaceutical policy; Drug pricing; Pharmaceutical industry; Drug industry; Health policy","score_opus":0.14177728946198262,"score_gpt":0.3759072137089961,"score_spread":0.23412992424701348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7095689335","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016908383,0.00015082459,0.019446269,0.9312892,0.00030678016,0.00057321694,0.0020562978,0.000019129136,0.02924993],"genre_scores_gemma":[0.92527795,0.00021388264,0.0039149057,0.06630754,0.00008163538,0.00008010124,0.000013568027,0.00001767764,0.0040927245],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992462,0.0000125514825,0.00038068814,0.0001737807,0.000015893578,0.00017088937],"domain_scores_gemma":[0.99922293,0.0003711053,0.00018762893,0.00011998659,0.000032373744,0.00006598261],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004917149,0.000071044095,0.00016378613,0.00009691239,0.000102250335,0.0000163299,0.00010753091,0.000030029738,0.00040479007],"category_scores_gemma":[0.00024827514,0.000050633367,0.000075129945,0.000058276437,0.00004348685,0.000072340335,0.000027794478,0.000044768196,0.000057129877],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010398232,0.000047625475,0.0016576542,0.000017034037,0.0000103007005,1.7952845e-9,0.000042460837,0.000005041851,0.000018552397,0.8123724,0.1835729,0.002245638],"study_design_scores_gemma":[0.0006023898,0.000016808248,0.0008921757,0.000018301116,8.3677895e-7,2.561283e-7,0.0000046957884,0.0005519937,0.00021037733,0.1498443,0.8477842,0.00007360845],"about_ca_topic_score_codex":0.0001139035,"about_ca_topic_score_gemma":0.0002809882,"teacher_disagreement_score":0.9083696,"about_ca_system_score_codex":0.00008980371,"about_ca_system_score_gemma":0.000054869914,"threshold_uncertainty_score":0.44321674},"labels":[],"label_agreement":null},{"id":"W7095857588","doi":"","title":"Stand-specific litter moisture content calibrations for the Canadian Fine Fuel Moisture Code","year":2016,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Litter; Water content; Moisture; Hydrology (agriculture); Growing season; Summer season","score_opus":0.13995058770106816,"score_gpt":0.27580489241558204,"score_spread":0.13585430471451387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7095857588","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010457682,0.012762814,0.045111597,0.7068755,0.0022217731,0.0020720775,0.016672445,0.00011329683,0.20371279],"genre_scores_gemma":[0.9669377,0.0008000491,0.00029502634,0.0121500725,0.0004887757,0.00012852666,0.000024261417,0.00003245472,0.019143095],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99878347,0.000007164521,0.0004429021,0.000321048,0.000019994859,0.00042543246],"domain_scores_gemma":[0.9989807,0.00021345877,0.00011075588,0.000376019,0.000044295197,0.00027476862],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002853906,0.0001577552,0.0002466204,0.000098873,0.00027796096,0.00016451675,0.0003078966,0.0001233497,0.0026524821],"category_scores_gemma":[0.000062337785,0.00010007902,0.00015051762,0.00007842807,0.00009764646,0.00015745567,0.000031923322,0.00011806725,0.0008239783],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014763833,0.000017927236,0.0053985547,0.000007722197,0.00005820071,6.774012e-7,0.000093876355,0.000010350466,0.00002386774,0.8274833,0.165808,0.0010827518],"study_design_scores_gemma":[0.0007268465,0.000022433369,0.01623447,0.000004678438,0.0000051056304,0.0000016981502,0.00001587715,0.00053219247,0.00005892843,0.038284738,0.9439239,0.00018912982],"about_ca_topic_score_codex":0.015591027,"about_ca_topic_score_gemma":0.2381072,"teacher_disagreement_score":0.95648,"about_ca_system_score_codex":0.0002721923,"about_ca_system_score_gemma":0.00009282867,"threshold_uncertainty_score":0.999954},"labels":[],"label_agreement":null},{"id":"W7095922627","doi":"","title":"All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association. CMAJ Commentary © 2009 Canadian Medical Association or its licensors Online-1","year":2015,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Health care; Action (physics); Prescription drug; Modalities; Public health; Quality (philosophy); Health policy","score_opus":0.06897379749991155,"score_gpt":0.3233310078082529,"score_spread":0.25435721030834135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7095922627","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14331242,0.0001714183,6.782943e-7,0.80359817,0.01663477,0.000559684,0.0033273154,0.0000071176914,0.032388423],"genre_scores_gemma":[0.864683,0.00033904833,0.000017776161,0.124228425,0.0061750035,0.000023511637,0.000021882965,0.000029367447,0.0044820076],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978139,0.00018449304,0.00089137297,0.0002519787,0.0003804558,0.0004778186],"domain_scores_gemma":[0.9977244,0.0004951549,0.0004710853,0.00033996574,0.00012427312,0.0008450819],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0036122077,0.00014438204,0.00036275032,0.0001488615,0.0001572472,0.000059073365,0.00076592166,0.00062319444,0.0075017726],"category_scores_gemma":[0.0040311185,0.00009332612,0.000103650724,0.0002986927,0.00009498219,0.00012609533,0.00018384037,0.0008358913,0.00017630389],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009659733,0.000037170812,0.24442472,0.0000052825044,0.000070170434,6.9751144e-7,0.0004618779,0.00001872122,1.6079069e-7,0.0025913364,0.75232476,0.000055425528],"study_design_scores_gemma":[0.0008809548,0.000012059692,0.23093912,0.000022429867,0.000012316996,0.0000015385892,0.00011763667,0.0027962301,0.0000105160125,0.00028400173,0.7648023,0.00012089373],"about_ca_topic_score_codex":0.82975787,"about_ca_topic_score_gemma":0.9610393,"teacher_disagreement_score":0.7213706,"about_ca_system_score_codex":0.0011390878,"about_ca_system_score_gemma":0.0018468096,"threshold_uncertainty_score":0.9934055},"labels":[],"label_agreement":null},{"id":"W7096147182","doi":"","title":"Editorials Shortages of medicines: a complex global challenge","year":2011,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Economic shortage; Listing (finance); Medical prescription; Pharmacy; Developed country","score_opus":0.22820267274929762,"score_gpt":0.3320988859884149,"score_spread":0.1038962132391173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7096147182","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.026537564,0.0008802264,0.000589764,0.002001211,0.0032981928,0.0001646144,0.0003619566,0.000040981762,0.9661255],"genre_scores_gemma":[0.99614847,0.00046665678,0.0006522837,0.0010083563,0.0015493288,0.000008276473,0.000006200676,0.000010025669,0.00015040855],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988725,0.0000070779465,0.0006450973,0.00022636044,0.000021106829,0.00022783403],"domain_scores_gemma":[0.9993678,0.000033398792,0.00020660256,0.00023686685,0.000023082313,0.00013225888],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00033900273,0.000114372444,0.0004338689,0.00006543024,0.000024458435,0.000007863314,0.00024494657,0.00008294525,0.00643187],"category_scores_gemma":[0.00006523939,0.00011675078,0.00010021218,0.000097777236,0.00009411711,0.000095088326,0.000059605776,0.000057209614,0.0004835543],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017081862,0.0001258973,0.0127732,0.00002450646,0.000061824096,0.0000012343743,0.0002669682,6.588945e-7,0.000012552057,0.9535748,0.032617316,0.00052400737],"study_design_scores_gemma":[0.0010548967,0.0001718066,0.032773644,0.000010330964,0.000014313813,0.0000027016777,0.00011199715,0.00073108095,0.00026294094,0.39650166,0.5680062,0.00035842892],"about_ca_topic_score_codex":0.0004319834,"about_ca_topic_score_gemma":0.000055473323,"teacher_disagreement_score":0.96961087,"about_ca_system_score_codex":0.00004010797,"about_ca_system_score_gemma":0.0000152752,"threshold_uncertainty_score":0.9944764},"labels":[],"label_agreement":null},{"id":"W7096393613","doi":"","title":"Chapter 7. Follow-Up of Drugs After Market Entry","year":2015,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Confusion; Order (exchange); European union; Point (geometry); Relevant market; Pace; European market; Recall","score_opus":0.056829135645747764,"score_gpt":0.26390494302479994,"score_spread":0.20707580737905218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7096393613","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21795282,0.0006951864,0.00014015472,0.001500077,0.0005240083,0.00008167263,0.00011226357,0.000016423372,0.7789774],"genre_scores_gemma":[0.9798022,0.00015168877,0.0002554056,0.0025311504,0.00010468346,0.000011096358,0.0000025658694,0.000016104997,0.017125096],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990881,0.000004979506,0.0004494068,0.00021448526,0.000019760057,0.00022325003],"domain_scores_gemma":[0.99937946,0.000024545036,0.00012908452,0.00024017841,0.000021713655,0.00020504993],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00037750514,0.00010664095,0.00028339121,0.00011763398,0.000012391891,0.000022914739,0.00015271854,0.00006463274,0.00797118],"category_scores_gemma":[0.000036926496,0.00011523044,0.000117512725,0.000060197515,0.000048725535,0.00014072895,0.00007975071,0.00007441647,0.0015112701],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020333372,0.00007963541,0.03905641,0.00002390855,0.000082126266,0.0000023139594,0.00078187557,0.000004634551,0.0000071344894,0.9153706,0.04209125,0.002296797],"study_design_scores_gemma":[0.0019495354,0.00005160971,0.004919499,0.000006077379,0.000006409376,0.0000020200675,0.00006494642,0.0023625349,0.00039645567,0.103465565,0.88648236,0.00029298713],"about_ca_topic_score_codex":0.000111062975,"about_ca_topic_score_gemma":0.000008859646,"teacher_disagreement_score":0.8443911,"about_ca_system_score_codex":0.000038440903,"about_ca_system_score_gemma":0.000014168396,"threshold_uncertainty_score":0.99926615},"labels":[],"label_agreement":null},{"id":"W7096731832","doi":"","title":"1 Prescription Drug Importation, Investment and Employment in Michigan","year":2004,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Prescription drug; Authorization; Investment (military); Drug prices; Profit (economics); Developed country; Legislation","score_opus":0.04145971896364928,"score_gpt":0.2684537624425883,"score_spread":0.226994043478939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7096731832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9637809,0.00063271314,0.00013184974,0.0047814855,0.000120132834,0.00017130496,0.000022299158,0.000018021328,0.03034129],"genre_scores_gemma":[0.99199086,0.00032312755,0.00056631834,0.00653129,0.000028559165,0.000023728306,0.000009434716,0.000009796932,0.00051689125],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9992027,0.000003752735,0.00039348193,0.00022141192,0.000010686891,0.0001679398],"domain_scores_gemma":[0.99970704,0.000008022397,0.000080378304,0.00010485215,0.000004452931,0.00009525117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002020439,0.00008214605,0.00014995079,0.00013648854,0.000028341967,0.00004156271,0.000058235608,0.00003092731,0.00013346272],"category_scores_gemma":[0.000012601864,0.00009496374,0.000025373327,0.00007147121,0.000027340064,0.00016231858,0.000026634292,0.000066027795,0.00016613684],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000047927806,0.00007240999,0.047480527,0.000007487718,0.000010011865,0.000001094013,0.0008725583,0.00020544158,0.00004390247,0.9507913,0.000355714,0.00015476022],"study_design_scores_gemma":[0.0017303766,0.000034772303,0.20954514,0.000009075191,0.0000024547437,0.0000025109225,0.000084475614,0.0010100462,0.00073947397,0.7234933,0.063095145,0.00025327917],"about_ca_topic_score_codex":0.0014585211,"about_ca_topic_score_gemma":0.0015957219,"teacher_disagreement_score":0.22729805,"about_ca_system_score_codex":0.000077806166,"about_ca_system_score_gemma":0.0000140057755,"threshold_uncertainty_score":0.3872509},"labels":[],"label_agreement":null},{"id":"W7096934275","doi":"","title":"Pharmaceuticals:Therapeutic Interchange and Pricing Policies","year":2003,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Public policy; Government (linguistics); Policy analysis; Control (management); Negotiation","score_opus":0.14755683101077438,"score_gpt":0.3356307257229736,"score_spread":0.1880738947121992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7096934275","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.27844208,0.009225608,0.0042038173,0.006813508,0.0004860138,0.00029916485,0.000049482715,0.00010298685,0.70037735],"genre_scores_gemma":[0.98512167,0.0010829302,0.0003847963,0.012005806,0.000066239125,0.000013131496,0.0000010905086,0.000022324917,0.0013020369],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989326,0.000017979226,0.00037589902,0.0002870328,0.000014098982,0.0003724068],"domain_scores_gemma":[0.99947965,0.00007655595,0.00008089591,0.00016404218,0.000009384946,0.00018948472],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00042807753,0.00014344456,0.00027180216,0.00016726869,0.000081749255,0.000085592124,0.00010906317,0.0000641618,0.0016153875],"category_scores_gemma":[0.00006342772,0.000154165,0.000059682945,0.00012824366,0.00009181081,0.00014843582,0.000047640842,0.0001455963,0.0006364271],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000037011557,0.000032185584,0.010204107,0.000016909953,0.000026599848,7.0312063e-7,0.00027448556,0.0000019113513,0.00012821594,0.987005,0.00046056125,0.0018456513],"study_design_scores_gemma":[0.0007448437,0.000043494805,0.0023371829,0.000005286216,0.000009161278,0.000021923308,0.00008507252,0.0020466512,0.0023803299,0.19842085,0.79353654,0.0003686438],"about_ca_topic_score_codex":0.0000666504,"about_ca_topic_score_gemma":0.0000075694115,"teacher_disagreement_score":0.793076,"about_ca_system_score_codex":0.00005235248,"about_ca_system_score_gemma":0.000009365649,"threshold_uncertainty_score":0.99929726},"labels":[],"label_agreement":null},{"id":"W7100260058","doi":"","title":"The structural dynamics of the pharmaceutical industry.” The Industrial Geographer 1(2","year":2004,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prima facie; Monopoly; Pharmaceutical industry; Profitability index; Marginal cost; Drug prices; Production (economics); Function (biology)","score_opus":0.07547870745844683,"score_gpt":0.30357298793757814,"score_spread":0.22809428047913133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7100260058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85528904,0.0006850785,0.00008734082,0.07730449,0.0019437304,0.00052955915,0.00025268874,0.000026841453,0.06388125],"genre_scores_gemma":[0.9958426,0.0001289832,0.00002138113,0.0030286997,0.00030980157,0.000013955619,0.000002683888,0.00001791307,0.0006339779],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9986042,0.00003155314,0.0006550644,0.00023389084,0.00005298772,0.00042234897],"domain_scores_gemma":[0.99889904,0.00016698483,0.00028275646,0.000518991,0.000023556378,0.000108663204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006242061,0.00016742584,0.00023744279,0.000043982447,0.00043612032,0.000119883145,0.0009406083,0.0002490287,0.00056269957],"category_scores_gemma":[0.00013710633,0.00008734079,0.00024677737,0.0003559916,0.00059695885,0.000100042285,0.0002378211,0.0009883849,0.00008096634],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002033993,0.000019297158,0.028150653,0.000002406073,0.00007876963,2.2431371e-7,0.000075603,0.0003599993,0.0000025874556,0.96706957,0.00093027495,0.003290251],"study_design_scores_gemma":[0.0032606064,0.000059603277,0.050137132,0.000013347164,0.00004319974,0.000018534894,0.0002803998,0.014241139,0.00063542865,0.5815284,0.3493131,0.0004691118],"about_ca_topic_score_codex":0.0004758299,"about_ca_topic_score_gemma":0.00022182033,"teacher_disagreement_score":0.3855412,"about_ca_system_score_codex":0.0001281745,"about_ca_system_score_gemma":0.00007244852,"threshold_uncertainty_score":0.6161165},"labels":[],"label_agreement":null},{"id":"W7100451192","doi":"","title":"that full credit, including © notice, is given to the source. Poor Quality Drugs and Global Trade: A Pilot Study","year":2014,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Subject (documents); Quality (philosophy); Developing country; Cover (algebra); Data collection; Developed country","score_opus":0.14914574327520916,"score_gpt":0.3432836778518924,"score_spread":0.19413793457668324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7100451192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.882283,0.00019044717,0.0022196637,0.06132327,0.00039156465,0.0005472067,0.00024674606,0.00005086412,0.05274728],"genre_scores_gemma":[0.97642785,0.000035693738,0.0001434155,0.022520505,0.00037807302,0.000026939679,0.0000021184464,0.0000187133,0.00044671696],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99838,0.00006043229,0.00057095825,0.0005222646,0.00004954013,0.0004168106],"domain_scores_gemma":[0.9989179,0.0002012132,0.00019169637,0.0003975268,0.0000104452665,0.00028121148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016725803,0.00020959141,0.00045223406,0.000077241486,0.00025159048,0.00022918858,0.0004068558,0.000049372153,0.00034053528],"category_scores_gemma":[0.00013010358,0.00018237354,0.00007552901,0.00018739764,0.000063052896,0.00015661861,0.00032470457,0.0001698743,0.00062362885],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004751365,0.0015592262,0.33640668,0.000085910244,0.00048509263,0.0000016303973,0.011092242,0.0001657312,0.0000279181,0.5397876,0.08919169,0.020721134],"study_design_scores_gemma":[0.002088294,0.0010232556,0.18622275,0.000006338395,0.000027670867,0.000004190518,0.0010498167,0.011883988,0.00003307417,0.026727414,0.7703173,0.0006159031],"about_ca_topic_score_codex":0.0016569842,"about_ca_topic_score_gemma":0.0003866429,"teacher_disagreement_score":0.68112564,"about_ca_system_score_codex":0.00010770279,"about_ca_system_score_gemma":0.0000129075825,"threshold_uncertainty_score":0.8015695},"labels":[],"label_agreement":null},{"id":"W7103226220","doi":"","title":"Product Listing Agreements (PLAs): A New Tool for Reaching Quebec's Pharmaceutical Policy Objectives?","year":2013,"lang":"en","type":"article","venue":"PubMed Central","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Listing (finance); Product (mathematics); Confidentiality; Biopharmaceutical; Control (management); Pharmaceutical industry; Set (abstract data type)","score_opus":0.06969561617402108,"score_gpt":0.2964608127857783,"score_spread":0.2267651966117572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7103226220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91222644,0.001339314,0.0062119854,0.028784396,0.0028892932,0.0046408656,0.00048790674,0.0002206538,0.04319916],"genre_scores_gemma":[0.9835726,0.00013142452,0.0016225913,0.0044584046,0.0043178177,0.00054963387,0.000042460913,0.00006389235,0.0052411733],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962183,0.00002412626,0.00078368775,0.00067677326,0.000046909387,0.002250154],"domain_scores_gemma":[0.9983586,0.0001239958,0.000283771,0.0003168348,0.00002713632,0.00088964123],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00068508985,0.00028780705,0.000458224,0.00024309572,0.00018530803,0.00035566918,0.00037032604,0.00009614959,0.00046772294],"category_scores_gemma":[0.0010832236,0.00033369646,0.00022426655,0.00022147477,0.00006972347,0.00068184704,0.00011964651,0.0003093795,0.00047380256],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001547599,0.00044143194,0.12631068,0.00019591542,0.00046691872,0.000003276073,0.0022286102,0.00023233984,0.0002349741,0.53918535,0.04824744,0.28229827],"study_design_scores_gemma":[0.0034263432,0.000044132426,0.33483508,0.000018490698,0.000031766827,0.000008900381,0.000039797083,0.012815481,0.0010074334,0.06301496,0.5838206,0.00093701796],"about_ca_topic_score_codex":0.008440446,"about_ca_topic_score_gemma":0.0001775248,"teacher_disagreement_score":0.5355732,"about_ca_system_score_codex":0.00095872115,"about_ca_system_score_gemma":0.0002276121,"threshold_uncertainty_score":0.9999115},"labels":[],"label_agreement":null},{"id":"W7110897213","doi":"10.5281/zenodo.17860521","title":"Conscience December 2025 Policy Brief - GENEROUS Model Impacts on Prescription Drug Prices for Medicaid","year":2025,"lang":"","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicaid; Prescription drug; Medical prescription; Drug prices; Medicare Part D; Government (linguistics)","score_opus":0.07184608447955902,"score_gpt":0.3091163548979934,"score_spread":0.23727027041843435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7110897213","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05499163,0.0027129583,0.05411787,0.03811301,0.0013921204,0.0031907738,0.0076593775,0.000545673,0.8372766],"genre_scores_gemma":[0.9695227,0.005277924,0.0006466641,0.009677605,0.00053053093,9.868587e-7,0.00084296765,0.0011813632,0.0123192165],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99635273,0.00012484992,0.0010728502,0.0011970089,0.00015473075,0.0010978371],"domain_scores_gemma":[0.99754024,0.00012865379,0.00050577265,0.00084019406,0.0003970238,0.0005881178],"candidate_categories":["metaepi_narrow","sts","scholarly_communication","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0019693023,0.00038202706,0.0005509794,0.0011645379,0.0029230572,0.0019033547,0.001828975,0.00020919519,0.0036627762],"category_scores_gemma":[0.0025007778,0.0004819827,0.0002196958,0.0011691452,0.00051539845,0.00063295587,0.0012908615,0.00050304027,0.004050724],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024789615,0.00041534184,0.000013804103,0.00028427874,0.00015969352,0.0000018501438,0.0010419016,0.0049819658,0.00036759416,0.4901916,0.46766743,0.034626637],"study_design_scores_gemma":[0.0014806018,0.00019599895,0.00021081607,0.000080359314,0.000028225475,0.000008148734,0.00006044968,0.16057481,0.0003393697,0.023433326,0.81320727,0.00038060284],"about_ca_topic_score_codex":0.00016835699,"about_ca_topic_score_gemma":0.000004358065,"teacher_disagreement_score":0.9145311,"about_ca_system_score_codex":0.00092315243,"about_ca_system_score_gemma":0.000085934924,"threshold_uncertainty_score":0.9997632},"labels":[],"label_agreement":null},{"id":"W7110939033","doi":"10.5281/zenodo.17860520","title":"Conscience December 2025 Policy Brief - GENEROUS Model Impacts on Prescription Drug Prices for Medicaid","year":2025,"lang":"","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicaid; Prescription drug; Medical prescription; Drug prices; Medicare Part D; Government (linguistics)","score_opus":0.07184608447955902,"score_gpt":0.3091163548979934,"score_spread":0.23727027041843435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7110939033","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05499163,0.0027129583,0.05411787,0.03811301,0.0013921204,0.0031907738,0.0076593775,0.000545673,0.8372766],"genre_scores_gemma":[0.9695227,0.005277924,0.0006466641,0.009677605,0.00053053093,9.868587e-7,0.00084296765,0.0011813632,0.0123192165],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99635273,0.00012484992,0.0010728502,0.0011970089,0.00015473075,0.0010978371],"domain_scores_gemma":[0.99754024,0.00012865379,0.00050577265,0.00084019406,0.0003970238,0.0005881178],"candidate_categories":["metaepi_narrow","sts","scholarly_communication","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0019693023,0.00038202706,0.0005509794,0.0011645379,0.0029230572,0.0019033547,0.001828975,0.00020919519,0.0036627762],"category_scores_gemma":[0.0025007778,0.0004819827,0.0002196958,0.0011691452,0.00051539845,0.00063295587,0.0012908615,0.00050304027,0.004050724],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024789615,0.00041534184,0.000013804103,0.00028427874,0.00015969352,0.0000018501438,0.0010419016,0.0049819658,0.00036759416,0.4901916,0.46766743,0.034626637],"study_design_scores_gemma":[0.0014806018,0.00019599895,0.00021081607,0.000080359314,0.000028225475,0.000008148734,0.00006044968,0.16057481,0.0003393697,0.023433326,0.81320727,0.00038060284],"about_ca_topic_score_codex":0.00016835699,"about_ca_topic_score_gemma":0.000004358065,"teacher_disagreement_score":0.9145311,"about_ca_system_score_codex":0.00092315243,"about_ca_system_score_gemma":0.000085934924,"threshold_uncertainty_score":0.9997632},"labels":[],"label_agreement":null},{"id":"W7112968676","doi":"","title":"The Supply and Demand of Ozempic in America: An Economic Analysis","year":2025,"lang":"","type":"article","venue":"Hollins Digital Commons (Hollins University)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Supply and demand; Market rate; Demand management; Market demand schedule; Negotiation; Pace; Price mechanism; Government (linguistics); Economic shortage; Demand shock","score_opus":0.023722796400801657,"score_gpt":0.24570150802754773,"score_spread":0.22197871162674607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7112968676","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88516885,0.002958576,0.0009298527,0.0023726828,0.0002988724,0.00038873483,0.0032988766,0.000020491047,0.10456306],"genre_scores_gemma":[0.98355997,0.012984643,0.00005083286,0.00021256058,0.00003802172,0.0000020567682,0.00007596231,0.000024311927,0.0030516188],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969919,0.00009454533,0.0012798592,0.0008908619,0.0000427126,0.00070017],"domain_scores_gemma":[0.99735594,0.000642261,0.00064121437,0.0009716482,0.000047392015,0.00034152842],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047052372,0.0004333518,0.0013087175,0.002957427,0.0004538634,0.00055766414,0.0010899523,0.00027048966,0.0000887774],"category_scores_gemma":[0.00006815178,0.00052098057,0.0005163004,0.0028664593,0.0009827154,0.0011124912,0.00056584325,0.0005111294,0.000065319],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033675248,0.0005904383,0.57103497,0.000057920504,0.0018917752,0.000024506624,0.00046783968,0.00880136,0.0000026901666,0.40658057,0.00021905237,0.0099921115],"study_design_scores_gemma":[0.003862121,0.00038777856,0.14805755,0.00006235093,0.0007013086,0.0000027237024,0.0013742631,0.11372757,0.00005223864,0.015152983,0.7155424,0.0010767321],"about_ca_topic_score_codex":0.0009221727,"about_ca_topic_score_gemma":0.004098301,"teacher_disagreement_score":0.7153233,"about_ca_system_score_codex":0.00047485286,"about_ca_system_score_gemma":0.00024153176,"threshold_uncertainty_score":0.99972415},"labels":[],"label_agreement":null},{"id":"W7113389128","doi":"","title":"The Problem With Consumer Affordability of Prescription Medications in the United States","year":2025,"lang":"","type":"article","venue":"ScholarWorks (Walden University)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prescription drug; Medical prescription; Sample (material); Test (biology); Categorical variable; Perception; Perspective (graphical); Politics; Independence (probability theory)","score_opus":0.02377217500834838,"score_gpt":0.24721514213832327,"score_spread":0.22344296712997488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7113389128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8473685,0.0056213764,0.0028774599,0.051674236,0.00046702407,0.0021162606,0.00053637015,0.000031659463,0.089307144],"genre_scores_gemma":[0.9826162,0.012495096,0.00018271655,0.0010478153,0.000026762922,0.0000095743335,0.00005713063,0.000013779006,0.003550946],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99802446,0.00027323695,0.0007112797,0.00045757083,0.000069750706,0.00046371188],"domain_scores_gemma":[0.9977426,0.00077103823,0.00048520527,0.0007540893,0.00014017477,0.00010692688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019539723,0.00022634742,0.00038871507,0.0008148336,0.0006468181,0.0002334472,0.0012178692,0.0002120585,0.000094385054],"category_scores_gemma":[0.00011302229,0.00018536791,0.00013189079,0.0028019096,0.0008643997,0.00047637985,0.00020899644,0.0009796168,0.000026113375],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035733203,0.00041376162,0.123104,0.00012872875,0.0004547263,0.0000055254086,0.001991774,0.0023576545,0.0000034380437,0.8665515,0.0022009243,0.002430596],"study_design_scores_gemma":[0.0018027219,0.00009108336,0.044659905,0.00015889734,0.00013709904,0.0000015096499,0.0034339852,0.008748229,0.000021459842,0.034005135,0.9066603,0.00027965254],"about_ca_topic_score_codex":0.0011401211,"about_ca_topic_score_gemma":0.0014342591,"teacher_disagreement_score":0.9044594,"about_ca_system_score_codex":0.0003203899,"about_ca_system_score_gemma":0.00025600527,"threshold_uncertainty_score":0.7559084},"labels":[],"label_agreement":null},{"id":"W7117187611","doi":"","title":"Consequences of Canada&amp;rsquo;s Drug Agency Reimbursement Recommendations for New Medicines and Pan-Canadian Pharmaceutical Alliance Price Negotiations on Patient Access","year":2025,"lang":"en","type":"article","venue":"Dove Medical Press (Taylor and Francis Group)","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Government (linguistics); Negotiation; Alliance; Medical prescription; Legislation; Agency (philosophy); Pharmaceutical industry","score_opus":0.08296075741659138,"score_gpt":0.34195497486780824,"score_spread":0.25899421745121687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117187611","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.051994294,0.053108517,0.17695071,0.5976126,0.00968568,0.004875597,0.0066175153,0.000095434356,0.09905965],"genre_scores_gemma":[0.9783622,0.00046051107,0.00025534155,0.020488326,0.00018160667,0.000103844744,0.000059323396,0.000013546311,0.00007530676],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982017,0.00003003189,0.00079656416,0.00045143065,0.000089491994,0.00043077755],"domain_scores_gemma":[0.9983464,0.00053437776,0.00021042464,0.00021698324,0.00004746151,0.0006443597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047041694,0.00019700847,0.0004528733,0.000139942,0.00020930327,0.00006402944,0.00031187298,0.00010837559,0.0006402767],"category_scores_gemma":[0.00070205575,0.00019790014,0.00006254174,0.0001670865,0.00023457877,0.00014446817,0.0000880767,0.0002451965,0.0000037386178],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014175694,0.00023802088,0.009848884,0.0003958451,0.0003247724,0.000005490963,0.0010367928,0.0000413098,0.000034835066,0.51576144,0.06338314,0.4087877],"study_design_scores_gemma":[0.002088796,0.000085522486,0.004325522,0.000030954114,0.000058715093,0.0000027571652,0.000059382473,0.03923219,0.0003159436,0.05502323,0.8983836,0.00039338917],"about_ca_topic_score_codex":0.26604012,"about_ca_topic_score_gemma":0.23660585,"teacher_disagreement_score":0.9263679,"about_ca_system_score_codex":0.00012558077,"about_ca_system_score_gemma":0.00007043446,"threshold_uncertainty_score":0.8070134},"labels":[],"label_agreement":null},{"id":"W7118160689","doi":"10.65393/qcpr1945","title":"PATENT LINKAGE: NEXUS BETWEEN INNOVATION, ACCESS, AND REGULATORY AUTHORITY","year":2025,"lang":"","type":"article","venue":"Indian Journal of Legal Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Intellectual property; Discretion; Patent infringement; Linkage (software); Incentive; Generic drug; Biosimilar; Premise; Pharmaceutical industry","score_opus":0.12608247779494702,"score_gpt":0.3632457093283946,"score_spread":0.2371632315334476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7118160689","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0939615,0.8112371,0.0005546017,0.07293612,0.00274201,0.00071226346,0.0003735007,0.000009303007,0.017473623],"genre_scores_gemma":[0.6502569,0.3369635,0.00009879763,0.011343837,0.0007510286,0.0000047632493,0.0000065871736,0.000023885596,0.0005507433],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99461097,0.00012400052,0.004251786,0.00042504715,0.00008581468,0.0005023989],"domain_scores_gemma":[0.99554026,0.00019271701,0.0030895614,0.00043382708,0.0003557877,0.00038783337],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0044850465,0.00036777917,0.0018543967,0.001047269,0.00021424194,0.0005468798,0.0008631281,0.00027002217,0.00046695422],"category_scores_gemma":[0.0010665961,0.00040826757,0.0003735151,0.001542306,0.00021780777,0.0012659795,0.0002878566,0.0013183887,0.00008061532],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043125227,0.0001954863,0.110935755,0.011886808,0.0011288153,0.00014320534,0.00021947632,0.000012839952,0.0000022260917,0.5540546,0.04104926,0.28032836],"study_design_scores_gemma":[0.00092020934,0.00011603718,0.06360267,0.0057311095,0.0002129464,0.000065224085,0.000006601574,0.00004817532,0.000021164547,0.05810414,0.87080115,0.0003705893],"about_ca_topic_score_codex":0.000029430514,"about_ca_topic_score_gemma":0.0000032284538,"teacher_disagreement_score":0.82975185,"about_ca_system_score_codex":0.0003231372,"about_ca_system_score_gemma":0.0007584207,"threshold_uncertainty_score":0.9998369},"labels":[],"label_agreement":null},{"id":"W7123667155","doi":"10.18609/cgti.2020.195","title":"Under construction: roadmaps for HTA, pricing and reimbursement of cell and gene therapies","year":2020,"lang":"en","type":"article","venue":"Cell and Gene Therapy Insights","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Health care; Health economics; Strategic planning; Primary care; Pricing strategies","score_opus":0.06493991700503458,"score_gpt":0.24846393984950116,"score_spread":0.18352402284446656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7123667155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95175433,0.042655624,0.0010219592,0.001570148,0.00011188344,0.00026698067,0.000059437392,0.000010387948,0.0025492301],"genre_scores_gemma":[0.9653489,0.030398177,0.001511155,0.002456818,0.00015367582,0.00001246198,0.0000071566387,0.000017298971,0.00009436073],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999159,0.000010302157,0.00034608928,0.00031066744,0.000015891786,0.00015807377],"domain_scores_gemma":[0.9995237,0.000047594447,0.00017343827,0.00010455289,0.000017570128,0.00013313872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000098307035,0.000145405,0.00032346827,0.000062471794,0.00010931914,0.00004522887,0.00006267518,0.000067369256,0.00005206297],"category_scores_gemma":[0.0000023529842,0.00014003253,0.00004602721,0.000056121207,0.00012024237,0.000079789796,0.000033607033,0.00006670634,0.0000040527048],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013550313,0.00062667514,0.02032582,0.0010382384,0.0010301138,0.0000064568794,0.03793266,0.00040676072,0.48225185,0.37718773,0.0019213937,0.07591725],"study_design_scores_gemma":[0.008118531,0.0011147286,0.005338894,0.000015681975,0.000039009734,0.000010683782,0.0006952303,0.006898325,0.5539309,0.15207192,0.270887,0.0008791423],"about_ca_topic_score_codex":0.000020671861,"about_ca_topic_score_gemma":0.000002069516,"teacher_disagreement_score":0.26896557,"about_ca_system_score_codex":0.000010374581,"about_ca_system_score_gemma":0.0000122272195,"threshold_uncertainty_score":0.5710361},"labels":[],"label_agreement":null},{"id":"W7125587383","doi":"10.1109/iciip68302.2025.11346187","title":"Predicting Drug Shortages for Healthcare Supply Chain Optimization Using Machine Learning","year":2025,"lang":"","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Supply chain; Economic shortage; Discontinuation; Reimbursement; Random forest; Health care; Predictive analytics; Support vector machine","score_opus":0.05552146520820622,"score_gpt":0.3229401431799093,"score_spread":0.2674186779717031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7125587383","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21548021,0.067975014,0.5582938,0.086252615,0.008894084,0.0061221267,0.0055896775,0.0004175124,0.050974924],"genre_scores_gemma":[0.96704704,0.007672252,0.012218954,0.00457349,0.0005292502,0.0000770892,0.00022013455,0.00009326508,0.0075685303],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9961581,0.00006913577,0.0017997721,0.0009719839,0.000036178284,0.0009648316],"domain_scores_gemma":[0.9981121,0.00048453498,0.0006547142,0.0003594911,0.00010155815,0.000287598],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015461821,0.00044090964,0.00093486067,0.000716937,0.0010226629,0.00037864788,0.00037704906,0.00029050824,0.0008533018],"category_scores_gemma":[0.00050367194,0.0005987876,0.00035712917,0.00052753574,0.000092506685,0.0004082876,0.00023492132,0.0005995232,0.000026838934],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010732463,0.00012970337,0.35758176,0.0007297145,0.00028384788,9.772317e-7,0.0005638708,0.422077,0.0000073803717,0.21453643,0.00040589646,0.00357608],"study_design_scores_gemma":[0.0013082508,0.00006835569,0.00046806358,0.00012063018,0.000050760118,0.000001561807,0.00019286612,0.93714297,0.00014525412,0.0040728413,0.05595031,0.00047811447],"about_ca_topic_score_codex":0.0026125459,"about_ca_topic_score_gemma":0.00048106277,"teacher_disagreement_score":0.7515668,"about_ca_system_score_codex":0.0005274671,"about_ca_system_score_gemma":0.00017649229,"threshold_uncertainty_score":0.99964637},"labels":[],"label_agreement":null},{"id":"W7127003672","doi":"","title":"The determinants of pricing in pharmaceuticals: are U.S. prices really higher than those of Canada?","year":2007,"lang":"en","type":"article","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nationality; Quality (philosophy); Product (mathematics); Power (physics); Market power; Phenomenon","score_opus":0.07821765299775091,"score_gpt":0.330124632635825,"score_spread":0.25190697963807407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7127003672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88789606,0.002691205,0.000041125808,0.0012702226,0.00034018158,0.00019004551,0.00006186543,0.000007073134,0.10750222],"genre_scores_gemma":[0.99760365,0.0009090389,0.00012820648,0.00065986527,0.00005037614,0.000003935548,5.7097543e-7,0.000013916799,0.0006304278],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998225,0.000010934304,0.0010650272,0.00021130801,0.000041934272,0.0004458298],"domain_scores_gemma":[0.9986773,0.00036756974,0.0005576681,0.0002447265,0.000029424573,0.00012329282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014688453,0.00012204991,0.0004058988,0.00012745247,0.00005574616,0.000015571424,0.000334882,0.00006343534,0.00013826146],"category_scores_gemma":[0.00011103131,0.00010317175,0.00006637039,0.00023041127,0.00008766898,0.00008744751,0.00008012601,0.00014127024,0.000008196549],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011075644,0.00013603579,0.7727186,0.000118678145,0.00005402099,0.000011270951,0.00021932468,0.000050914732,0.0001240247,0.21624896,0.0010941485,0.0091132885],"study_design_scores_gemma":[0.0009523443,0.000042634918,0.82188296,0.00005756044,0.000007760359,0.0000022666477,0.00015719546,0.004010741,0.011567266,0.01308424,0.14791305,0.00032199407],"about_ca_topic_score_codex":0.063566566,"about_ca_topic_score_gemma":0.2956232,"teacher_disagreement_score":0.23205665,"about_ca_system_score_codex":0.00011756532,"about_ca_system_score_gemma":0.000102538375,"threshold_uncertainty_score":0.9426692},"labels":[],"label_agreement":null},{"id":"W7132882939","doi":"","title":"Are brand-name and generic warfarin interchangeable?: a pharmacological and behavioural investigation","year":2003,"lang":"","type":"dissertation","venue":"TSpace","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bibliographical Society of Canada","funders":"Canadian Institutes of Health Research","keywords":"Warfarin; Anticoagulant; Clinical trial; Significant difference; Major bleeding","score_opus":0.1835528815152761,"score_gpt":0.3598957590367011,"score_spread":0.17634287752142502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7132882939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9720767,0.017892523,0.00004790304,0.0033312982,0.0012587786,0.0007411725,0.00022725943,0.000036132726,0.004388194],"genre_scores_gemma":[0.9603479,0.02310244,0.00031486835,0.004639632,0.0002486174,0.00014774098,0.00023162627,0.00010595041,0.010861214],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966668,0.000108017746,0.0011039269,0.0012718003,0.00006010714,0.00078935584],"domain_scores_gemma":[0.9973602,0.00012923259,0.0014419485,0.0002771747,0.00006507561,0.0007263388],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006506991,0.0007220043,0.0012693801,0.0004658625,0.0003442389,0.0003906585,0.0002624099,0.00074631185,0.001641773],"category_scores_gemma":[0.00016630441,0.00089579925,0.00018153156,0.000282375,0.00033791995,0.0003125843,0.00015661615,0.0009388138,0.0002004888],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015953301,0.0013039884,0.8188709,0.0034622871,0.002353536,0.00020336025,0.05092254,0.00017145196,0.0044998177,0.068879746,0.018977847,0.028759168],"study_design_scores_gemma":[0.017015615,0.0014035467,0.6746612,0.00080387504,0.0017442725,0.00031433455,0.011338232,0.07764289,0.006749631,0.036584508,0.1627927,0.008949176],"about_ca_topic_score_codex":0.00059357873,"about_ca_topic_score_gemma":0.00019534523,"teacher_disagreement_score":0.1442097,"about_ca_system_score_codex":0.00024747592,"about_ca_system_score_gemma":0.000068136025,"threshold_uncertainty_score":0.9993493},"labels":[],"label_agreement":null},{"id":"W7132927048","doi":"","title":"From inventors to predators: Have brand firms crossed the line by marketing authorized generics","year":2007,"lang":"","type":"dissertation","venue":"TSpace","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Heritage; Library and Archives Canada","funders":"University of Toronto","keywords":"Incentive; Innovator; Intersection (aeronautics); Product (mathematics); Product line; Brand names; Generic drug","score_opus":0.060187578765359,"score_gpt":0.37574419182412033,"score_spread":0.3155566130587613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7132927048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93719506,0.010264793,0.0030562647,0.011824428,0.0055885925,0.0019087944,0.0037464728,0.00008044998,0.026335144],"genre_scores_gemma":[0.8285644,0.011530972,0.0027071543,0.020154005,0.00821374,0.00041067926,0.0069413185,0.0008140438,0.12066371],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99397117,0.0001660018,0.0024544252,0.0017511331,0.00016747876,0.0014897728],"domain_scores_gemma":[0.9946674,0.001142613,0.0018425994,0.0012305465,0.00013654551,0.0009802575],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0035367073,0.0010528726,0.0016500541,0.0004913667,0.00074209564,0.0009983436,0.0014020782,0.0010810277,0.0037685016],"category_scores_gemma":[0.0013300157,0.0011314453,0.0006310561,0.00071874174,0.00018599966,0.00024566747,0.00028620622,0.0013639112,0.0013320601],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013529118,0.0023792088,0.028437529,0.0016619695,0.0056509813,0.00006855031,0.17598286,0.0042692665,0.007956101,0.0097863525,0.6843142,0.06596386],"study_design_scores_gemma":[0.0024727418,0.0001500283,0.0027950082,0.00017593408,0.00014843153,0.0000013238289,0.0032737856,0.030020623,0.0027411175,0.002338243,0.9541536,0.0017291489],"about_ca_topic_score_codex":0.004351426,"about_ca_topic_score_gemma":0.00056649855,"teacher_disagreement_score":0.2698394,"about_ca_system_score_codex":0.0005701038,"about_ca_system_score_gemma":0.00020506789,"threshold_uncertainty_score":0.9994455},"labels":[],"label_agreement":null},{"id":"W7162564964","doi":"10.1071/hp070408","title":"'Linkage' pharmaceutical evergreening in Canada and Australia","year":2007,"lang":"en","type":"article","venue":"Australia and New Zealand Health Policy","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Monopoly; Competitor analysis; Pharmaceutical industry; Product (mathematics); Intellectual property; Quality (philosophy); Patent infringement; Drug prices; Generic drug; Monopolistic competition","score_opus":0.17966585111918265,"score_gpt":0.40400948994738667,"score_spread":0.22434363882820402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7162564964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9643788,0.00052494154,0.00002478026,0.033779975,0.00022455164,0.00021131836,0.00012008157,0.000013411073,0.00072214165],"genre_scores_gemma":[0.983412,0.0010305454,0.00017971394,0.010658549,0.0004793613,0.0000032246655,0.000009880035,0.00001904682,0.004207632],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99765944,0.000018770172,0.0008583143,0.00041678222,0.000040180832,0.001006486],"domain_scores_gemma":[0.99842304,0.00009644559,0.00019657514,0.00015226989,0.000007428956,0.0011242308],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007227148,0.00022020236,0.0005017015,0.000304717,0.00009790255,0.000048790236,0.00012322242,0.000108848966,0.00025546184],"category_scores_gemma":[0.00004140761,0.00025336305,0.000035993584,0.00024547998,0.0000623626,0.00013761512,0.00006031554,0.0003945884,0.000057954967],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005191831,0.000024883986,0.8728833,0.00009114635,0.000026851634,0.000022230619,0.00047244912,0.000010311285,0.000010379043,0.09466309,0.027488988,0.0042544543],"study_design_scores_gemma":[0.0014413013,0.000051215033,0.6776663,0.00002298351,0.0000030029526,0.000028448381,0.00002124534,0.00014803585,0.000031209725,0.00853369,0.3117849,0.00026766158],"about_ca_topic_score_codex":0.9857707,"about_ca_topic_score_gemma":0.8987026,"teacher_disagreement_score":0.28429592,"about_ca_system_score_codex":0.0005179975,"about_ca_system_score_gemma":0.00052850356,"threshold_uncertainty_score":0.99999183},"labels":[],"label_agreement":null},{"id":"W73329298","doi":"10.1007/978-0-387-44961-6_15","title":"The Application of PK/PD Modeling and Simulations During Lead Optimization","year":2007,"lang":"en","type":"book-chapter","venue":"","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Pharmaceutical industry; Drug development; Lead (geology); Food and drug administration; Business; Risk analysis (engineering); Operations research; Engineering; Medicine; Drug; Pharmacology","score_opus":0.09603546112784378,"score_gpt":0.29652023711340475,"score_spread":0.20048477598556097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W73329298","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00078024896,0.0024376588,0.21766509,0.00044831185,0.00009821322,0.0003307797,0.00017530198,0.000024548934,0.7780399],"genre_scores_gemma":[0.8598905,0.008571743,0.005347046,0.0005298159,0.00043226726,0.000015826357,0.00011889561,0.00012477752,0.12496909],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99890226,0.0000015894042,0.0006752864,0.00025270873,0.000019432297,0.00014869725],"domain_scores_gemma":[0.9992404,0.00008231806,0.00034077824,0.00024559582,0.000036212223,0.000054695283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022434998,0.0001419521,0.00026397733,0.00016433961,0.00015000574,0.000041212264,0.00011920675,0.00017298343,0.0001298426],"category_scores_gemma":[0.00001929013,0.00014429473,0.00007284968,0.00002615816,0.00006341138,0.000081488644,0.000058784673,0.0001536725,0.00005298405],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000071984273,0.0000041106528,0.000051392562,0.000019644598,0.000030350215,5.255321e-8,0.000019876228,0.19030254,0.0000017722383,0.80818343,0.000013018298,0.0013666223],"study_design_scores_gemma":[0.00015621378,0.000005494426,0.000010865967,0.000006994821,0.000007913704,6.6596425e-7,0.0000024099054,0.86709726,0.0000093854205,0.09655899,0.03600019,0.00014363081],"about_ca_topic_score_codex":0.00004015591,"about_ca_topic_score_gemma":0.000040964238,"teacher_disagreement_score":0.8591103,"about_ca_system_score_codex":0.000059202874,"about_ca_system_score_gemma":0.000010813602,"threshold_uncertainty_score":0.5884168},"labels":[],"label_agreement":null},{"id":"W75642366","doi":"10.1007/978-90-481-9051-5_16","title":"Medical Market Failures and Their Remedy","year":2010,"lang":"en","type":"book-chapter","venue":"Boston studies in the philosophy of science","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Market failure; Intellectual property; Medical research; Stimulus (psychology); Business; Government (linguistics); Public economics; Government regulation; Law and economics; Public relations; Political science; Economics; Medicine; Law; Psychology; Microeconomics; Pathology; Psychotherapist","score_opus":0.1378611544377615,"score_gpt":0.330159618704188,"score_spread":0.19229846426642647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W75642366","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016346959,0.013927303,0.0000043274395,0.026305329,0.00066914305,0.00024924916,0.00018200488,0.00000941914,0.95701855],"genre_scores_gemma":[0.963653,0.022035277,0.00018563746,0.0053225895,0.0006836163,0.000024990615,0.0000022405695,0.00003860575,0.008054008],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.998261,0.00000977215,0.00073492725,0.00055185886,0.00013001342,0.0003124706],"domain_scores_gemma":[0.9984897,0.00038193146,0.00044637214,0.0005072437,0.00005385181,0.000120945064],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.003188996,0.00027111985,0.00071888487,0.00040213243,0.00023151076,0.00003419917,0.0011996379,0.00020029386,0.0002739413],"category_scores_gemma":[0.0005577399,0.00020272758,0.0001131612,0.00011496019,0.008063461,0.00013491415,0.00055881176,0.00068229396,0.00004444226],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009854873,0.000017887554,0.00006565677,0.00005667478,0.000038234703,0.0000037360787,0.0012279528,1.8290262e-7,0.000008098091,0.99681664,0.00087373034,0.0008813605],"study_design_scores_gemma":[0.0001710287,0.00003916021,0.00014358261,0.00008449081,0.00000433077,0.0000139279155,0.00006795511,0.00007061894,0.000023684135,0.7588539,0.2403351,0.00019222114],"about_ca_topic_score_codex":0.000032478045,"about_ca_topic_score_gemma":0.000040640243,"teacher_disagreement_score":0.9620183,"about_ca_system_score_codex":0.000058326958,"about_ca_system_score_gemma":0.00007376231,"threshold_uncertainty_score":0.994636},"labels":[],"label_agreement":null},{"id":"W848354343","doi":"","title":"America's New War on Drugs: Should the United States Legalize Prescription Drug Reimportation;Note","year":2005,"lang":"en","type":"article","venue":"Journal of legislation","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medical prescription; Prescription drug; Drug; Political science; Law; Law and economics; Medicine; Economics; Pharmacology","score_opus":0.06479299018952714,"score_gpt":0.314348602120677,"score_spread":0.24955561193114986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W848354343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6167497,0.0037998727,0.023499968,0.28383055,0.002323158,0.00060596917,0.00014581154,0.00006524078,0.068979725],"genre_scores_gemma":[0.9845248,0.0019704653,0.001053582,0.009629613,0.0011979456,0.0000025826873,0.000036422072,0.000024351277,0.0015602651],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99864525,0.0000355599,0.0009172198,0.00014031254,0.00007396767,0.00018768676],"domain_scores_gemma":[0.9984038,0.00013027817,0.001098191,0.00017629664,0.00006602013,0.00012539908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006693382,0.00012588245,0.00024737522,0.00033435883,0.00010277501,0.0000971963,0.00020778729,0.000056913388,0.0002615633],"category_scores_gemma":[0.00012388587,0.00010610168,0.00014374491,0.00025340702,0.000039644026,0.00061269,0.0000144085925,0.00034352794,0.00021885608],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004259982,0.00030852287,0.0041414546,0.000019110075,0.00026835842,0.0000050030703,0.015965907,0.26524273,0.00014074471,0.22256377,0.42988697,0.061031442],"study_design_scores_gemma":[0.000645873,0.00006668381,0.0026965865,0.0000137091365,0.000014170224,0.000004612059,0.00008952123,0.057887822,0.00012730791,0.023153203,0.9151779,0.00012260473],"about_ca_topic_score_codex":0.00055788626,"about_ca_topic_score_gemma":0.00003416674,"teacher_disagreement_score":0.48529094,"about_ca_system_score_codex":0.0001817556,"about_ca_system_score_gemma":0.00006320564,"threshold_uncertainty_score":0.4326701},"labels":[],"label_agreement":null},{"id":"W866392653","doi":"10.1503/cmaj.150395","title":"Generic drugs in Canada: an examination of tiered pricing","year":2015,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Reimbursement; Drug pricing; Scheme (mathematics); Computer science; Operations research; Medicine; Business; Actuarial science; Political science; Law; Engineering; Mathematics; Health care","score_opus":0.04195725427389521,"score_gpt":0.2453930281293674,"score_spread":0.20343577385547218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W866392653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97180724,0.00031724837,0.000037490423,0.007895358,0.000669896,0.000051162973,0.000062625484,0.0000023290177,0.019156648],"genre_scores_gemma":[0.9944249,0.00007653237,0.00005586411,0.005008971,0.00034101028,0.0000018768062,0.000006842537,0.000008629909,0.00007541126],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987323,0.000057225054,0.0006417308,0.000113305825,0.00014282741,0.0003125934],"domain_scores_gemma":[0.99820846,0.00004837177,0.00035338593,0.00006930007,0.000091635135,0.0012288345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024910371,0.00006645569,0.00023776361,0.00025810668,0.000038971477,0.000028986291,0.00018604267,0.00012248875,0.00070002157],"category_scores_gemma":[0.00077181513,0.00008136504,0.000029299053,0.00021252024,0.000011798155,0.00016998171,0.0000098248765,0.00033645798,0.000040010444],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000011090242,0.000090115595,0.81142867,0.000019310057,0.00011124057,0.00008900445,0.004505438,0.00078261836,0.000004273297,0.032333344,0.05673026,0.09389462],"study_design_scores_gemma":[0.0022522104,0.00006026091,0.6362312,0.000025082043,0.000005692199,0.000038317266,0.0014194051,0.050630912,0.000023912306,0.0069398647,0.30202103,0.00035210184],"about_ca_topic_score_codex":0.81523687,"about_ca_topic_score_gemma":0.9641107,"teacher_disagreement_score":0.24529077,"about_ca_system_score_codex":0.0056375028,"about_ca_system_score_gemma":0.0056757038,"threshold_uncertainty_score":0.9999612},"labels":[],"label_agreement":null},{"id":"W86747047","doi":"","title":"Human resources for the approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States.","year":2002,"lang":"en","type":"article","venue":"PubMed","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Medicine; Agency (philosophy); Food and drug administration; Kingdom; Family medicine; Environmental health","score_opus":0.16624883208139715,"score_gpt":0.2785195936212857,"score_spread":0.11227076153988855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W86747047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97019523,0.00058089284,0.000012307214,0.026598435,0.00012362553,0.0008765128,0.0001566587,0.000004933597,0.0014514056],"genre_scores_gemma":[0.99428725,0.00024158874,0.000005293996,0.0029085383,0.00010903494,0.00027283322,0.000009400054,0.000013598574,0.002152448],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99887115,0.000032077718,0.00049899204,0.00018535713,0.000031738677,0.00038069507],"domain_scores_gemma":[0.99886787,0.00049823703,0.0002521829,0.00026891928,0.000015680524,0.00009712607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009175951,0.000119789394,0.00025865348,0.0001433023,0.0001593462,0.000077481374,0.00041245486,0.000040627412,0.000088531364],"category_scores_gemma":[0.000111201414,0.000074282216,0.00006148988,0.00036003705,0.00020972877,0.00004379498,0.00006717665,0.00019414905,0.000004283589],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002557708,0.000116523515,0.048103143,0.000105606356,0.0005387919,0.0000017223871,0.01143524,0.007537318,9.785828e-7,0.7679558,0.14818314,0.015765965],"study_design_scores_gemma":[0.0026419803,0.000008644318,0.16234602,0.000003554025,0.000021469927,0.0000012856995,0.00036302183,0.038133014,0.000011746366,0.01585736,0.78044105,0.00017083713],"about_ca_topic_score_codex":0.84441483,"about_ca_topic_score_gemma":0.22719039,"teacher_disagreement_score":0.75209844,"about_ca_system_score_codex":0.0001204921,"about_ca_system_score_gemma":0.000016329428,"threshold_uncertainty_score":0.78691137},"labels":[],"label_agreement":null},{"id":"W883499483","doi":"10.1007/s00228-015-1889-9","title":"Influence of point estimates and study power of bioequivalence studies on establishing bioequivalence between generics by adjusted indirect comparisons","year":2015,"lang":"en","type":"article","venue":"European Journal of Clinical Pharmacology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Interchangeability; Bioequivalence; Equivalence (formal languages); Point estimation; Sample size determination; Statistics; Econometrics; Medicine; Statistical power; Sample (material); Mathematics; Computer science; Pharmacology; Pharmacokinetics; Chromatography","score_opus":0.3642071753732102,"score_gpt":0.45116830184339196,"score_spread":0.08696112647018178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W883499483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931662,0.0034192952,0.00010447494,0.0010965075,0.0008918209,0.00017760853,0.0001504155,0.000009223614,0.0009844498],"genre_scores_gemma":[0.99664164,0.0012361136,0.0007468973,0.0010899993,0.00024483548,0.0000010906973,0.0000012718161,0.00002676856,0.000011376897],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99517035,0.00057242054,0.0035288043,0.00034035443,0.00009591971,0.0002921308],"domain_scores_gemma":[0.9939953,0.0018574498,0.0032642898,0.00020338655,0.00027345374,0.0004060842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008415866,0.00022152833,0.0015484745,0.0002915657,0.00004639495,0.000024403867,0.00063116313,0.0000614737,0.00002580352],"category_scores_gemma":[0.0031360448,0.00020934813,0.00016609096,0.00025190786,0.0006256157,0.00029921616,0.0003113297,0.0006233934,0.000026191134],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008017011,0.0019183474,0.9431192,0.00012766187,0.001713386,0.00010615315,0.0038297696,0.007077661,0.00078567123,0.00065606873,0.037545845,0.0023185315],"study_design_scores_gemma":[0.023760373,0.02546935,0.8856111,0.00036917554,0.001071417,0.000066614506,0.0033184255,0.0032154096,0.0147396065,0.0041381842,0.036693815,0.0015464979],"about_ca_topic_score_codex":0.000010222588,"about_ca_topic_score_gemma":6.909377e-7,"teacher_disagreement_score":0.05750807,"about_ca_system_score_codex":0.000042809243,"about_ca_system_score_gemma":0.00008005933,"threshold_uncertainty_score":0.8536969},"labels":[],"label_agreement":null},{"id":"W911318732","doi":"10.1177/009885880803400404","title":"Right Idea, Wrong Result—Canada's Access to Medicines Regime","year":2008,"lang":"en","type":"article","venue":"American Journal of Law & Medicine","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; CITES; Developing country; Population; Essential medicines; Developed country; Health care; Environmental health; Economic growth; Economics","score_opus":0.06179088103315592,"score_gpt":0.321001022982301,"score_spread":0.25921014194914505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W911318732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5118355,0.0035635584,0.0007687366,0.2877315,0.0021683483,0.0002401582,0.00008430767,0.000020938196,0.19358698],"genre_scores_gemma":[0.93496925,0.00087781297,0.00023536372,0.061961014,0.001571962,0.000002934577,0.0000029864061,0.00002773099,0.00035093378],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977305,0.00003076238,0.0014225093,0.00026410064,0.00013205281,0.00042009138],"domain_scores_gemma":[0.99744004,0.00023445582,0.0011719541,0.00031536297,0.0001227789,0.0007154178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076755695,0.00021029444,0.0010880386,0.00027050707,0.00013450105,0.00001981345,0.0007214757,0.00003518434,0.00074521103],"category_scores_gemma":[0.00035938123,0.00017771224,0.00010249089,0.00041911256,0.0006177342,0.0002506461,0.000059643462,0.0003414249,0.000052810672],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050545746,0.00014810478,0.033940423,0.000038445574,0.000492742,0.0008999005,0.001867568,0.0002779433,0.0001482383,0.16456312,0.7888692,0.008248861],"study_design_scores_gemma":[0.0012890036,0.00060015055,0.01434199,0.00008828003,0.000023566867,0.00039320352,0.00008750319,0.000082497696,0.00010738858,0.0034072842,0.9793282,0.0002509258],"about_ca_topic_score_codex":0.08742478,"about_ca_topic_score_gemma":0.013595,"teacher_disagreement_score":0.42313376,"about_ca_system_score_codex":0.00023810715,"about_ca_system_score_gemma":0.00021122607,"threshold_uncertainty_score":0.9186521},"labels":[],"label_agreement":null},{"id":"W935276731","doi":"10.1080/12507970.2004.11516814","title":"Réapprovisionnement des unités de soins : Portrait de six hôpitaux québécois et français","year":2004,"lang":"fr","type":"article","venue":"Logistique & Management","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"HEC Montréal","funders":"","keywords":"Humanities; Political science; Art","score_opus":0.06065155444455676,"score_gpt":0.30938147143113737,"score_spread":0.2487299169865806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W935276731","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18790707,0.029821023,0.1833747,0.12517421,0.0019314884,0.0016653734,0.0010057205,0.0002174563,0.46890298],"genre_scores_gemma":[0.93093944,0.020938938,0.02033613,0.01944127,0.0003040157,0.00015306544,0.000053681844,0.000082956365,0.007750485],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.996619,0.00007551769,0.0010886642,0.0008077867,0.00006949714,0.0013395513],"domain_scores_gemma":[0.9983589,0.00008577448,0.00038437737,0.0006560335,0.000038692455,0.0004761894],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0016724516,0.0004746874,0.00061044074,0.0003615106,0.00028611845,0.00026420967,0.0006443309,0.00030024676,0.0013817425],"category_scores_gemma":[0.00010402838,0.00064359227,0.0003319599,0.00033915276,0.00043009236,0.00030263886,0.00040770535,0.000541843,0.0011420703],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029954057,0.0007446939,0.005323523,0.000499738,0.00033398074,0.00017268097,0.002830962,0.019346187,0.0000045972506,0.93148416,0.0034290329,0.03580049],"study_design_scores_gemma":[0.0014197949,0.00014169462,0.047528867,0.00014236102,0.00007744569,0.000017455324,0.00040815628,0.0023436688,0.00005808177,0.33412892,0.61315,0.0005835631],"about_ca_topic_score_codex":0.05401022,"about_ca_topic_score_gemma":0.018961348,"teacher_disagreement_score":0.7430324,"about_ca_system_score_codex":0.001837111,"about_ca_system_score_gemma":0.00032655118,"threshold_uncertainty_score":0.99963564},"labels":[],"label_agreement":null},{"id":"W935542713","doi":"","title":"Confusion and Contradiction: Untangling Drug Importation and Counterfeit Drugs","year":2005,"lang":"en","type":"article","venue":"California Western international law journal","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Counterfeit; Confusion; Contradiction; Drug; Counterfeit Drugs; Business; Pharmacology; Medicine; Law; Psychology; Political science; Philosophy; Epistemology; Psychoanalysis","score_opus":0.020017478445066964,"score_gpt":0.26013142341088263,"score_spread":0.24011394496581567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W935542713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9496468,0.0018656339,0.0009425703,0.01738758,0.000866193,0.000102884114,0.00048475238,0.000023928342,0.028679674],"genre_scores_gemma":[0.99209934,0.0011510829,0.00016355429,0.00532196,0.00093928445,0.0000042380248,0.000022199865,0.00001709094,0.00028126195],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989302,0.000011363825,0.0006066707,0.00021560822,0.00005141349,0.00018472815],"domain_scores_gemma":[0.99930865,0.00005349025,0.00032116487,0.00006846951,0.000048997863,0.00019921041],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046911402,0.000129372,0.00020829207,0.00011998912,0.00022154473,0.00034462122,0.00012641428,0.00005721341,0.00039734112],"category_scores_gemma":[0.000020187326,0.00014129019,0.000054735567,0.000027621216,0.000094183684,0.00044350603,0.00004547813,0.0002400459,0.00019211457],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001351828,0.00009902621,0.119755656,0.00002346794,0.0002324803,0.000017289049,0.0016925376,0.00025977494,0.000103980215,0.866576,0.001671564,0.009433013],"study_design_scores_gemma":[0.0018861782,0.00002868765,0.004369661,0.000037758706,0.000014123072,0.0004251999,0.000110962625,0.037504133,0.00012738114,0.024731806,0.9304939,0.00027022458],"about_ca_topic_score_codex":0.00006797599,"about_ca_topic_score_gemma":0.00014605056,"teacher_disagreement_score":0.92882234,"about_ca_system_score_codex":0.00013399957,"about_ca_system_score_gemma":0.000011773604,"threshold_uncertainty_score":0.57616466},"labels":[],"label_agreement":null},{"id":"W93927275","doi":"10.1017/s0012217300003978","title":"Accès aux médicaments : quelle responsabilité pour les compagnies pharmaceutiques?","year":2004,"lang":"fr","type":"article","venue":"Dialogue","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Political science; Philosophy; Humanities","score_opus":0.11500926255038771,"score_gpt":0.34708948757365726,"score_spread":0.23208022502326955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W93927275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.66004384,0.07636527,0.0011241552,0.15864235,0.0061756647,0.0009203061,0.004276152,0.00016638145,0.0922859],"genre_scores_gemma":[0.9596239,0.016186766,0.0013291133,0.010306007,0.0014848595,0.00007536444,0.00013410718,0.000108452645,0.010751438],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965774,0.00012226411,0.0012815972,0.00086132356,0.00006415414,0.001093306],"domain_scores_gemma":[0.9980611,0.00031577237,0.0004697866,0.00059577165,0.00006470794,0.0004928259],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010367171,0.00049197575,0.00090474915,0.00034783292,0.0003622001,0.00022432441,0.0007138032,0.00044275422,0.0035411469],"category_scores_gemma":[0.00038988222,0.0006765729,0.0004299223,0.00033050362,0.0005978041,0.0004898257,0.00031235587,0.0007310746,0.005716206],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023605379,0.0015238974,0.03957699,0.00027325083,0.0004431744,0.00005417024,0.001771137,0.0016090082,0.00016922141,0.8773586,0.039531842,0.037452668],"study_design_scores_gemma":[0.0028801002,0.000117131545,0.007875508,0.00009110858,0.000041163723,0.000016944481,0.000105876,0.0017556486,0.0013748123,0.1111111,0.87390906,0.0007215241],"about_ca_topic_score_codex":0.0036071686,"about_ca_topic_score_gemma":0.00039881887,"teacher_disagreement_score":0.8343772,"about_ca_system_score_codex":0.00079802715,"about_ca_system_score_gemma":0.00033185896,"threshold_uncertainty_score":0.9995685},"labels":[],"label_agreement":null},{"id":"W94138530","doi":"10.1177/070674371205700405","title":"A Population-Based Study of the Use of Selective Serotonin Reuptake Inhibitors before and after Introduction of Generic Equivalents","year":2012,"lang":"en","type":"article","venue":"The Canadian Journal of Psychiatry","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Manitoba Health; University of Manitoba","funders":"Canadian Institutes of Health Research","keywords":"Paroxetine; Sertraline; Escitalopram; Citalopram; Medical prescription; Fluoxetine; Fluvoxamine; Venlafaxine; Medicine; Population; Pharmacoepidemiology; Psychiatry; Reuptake inhibitor; Antidepressant; Pharmacology; Serotonin; Internal medicine; Environmental health","score_opus":0.04942814246395809,"score_gpt":0.260365855879023,"score_spread":0.2109377134150649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W94138530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950727,0.00055013906,0.0000051878046,0.0030836845,0.0009844045,0.00018841727,0.00008292359,5.4852296e-7,0.000031996253],"genre_scores_gemma":[0.9991218,0.0000062087174,0.00020297195,0.00022753302,0.00041199508,0.0000027228027,7.607482e-7,0.000010386801,0.000015617788],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990466,0.000043672284,0.00064316526,0.00007429596,0.000033926503,0.00015830109],"domain_scores_gemma":[0.99877274,0.000019208159,0.000827215,0.00018549747,0.000056181474,0.00013913767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004572684,0.00007771934,0.00025014486,0.00020650282,0.00006662059,0.000013208526,0.00014276904,0.00004483048,0.000050716397],"category_scores_gemma":[0.00005886662,0.0000586511,0.00009106953,0.00020398413,0.00006279592,0.0001446301,0.000012989856,0.00015796651,8.9381876e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035218036,0.00007092376,0.9934384,0.00001937748,0.00007523342,5.954424e-8,0.0008701624,0.00063762197,0.0000037826446,0.004295201,0.0004223991,0.00013158534],"study_design_scores_gemma":[0.0004325351,0.00015142006,0.99404466,0.000015328078,0.00003574047,0.000004255927,0.00009674122,0.00020585106,0.000052980864,0.0037760956,0.001127546,0.000056862857],"about_ca_topic_score_codex":0.00923437,"about_ca_topic_score_gemma":0.070436485,"teacher_disagreement_score":0.06120212,"about_ca_system_score_codex":0.00009500133,"about_ca_system_score_gemma":0.00019671781,"threshold_uncertainty_score":0.9973632},"labels":[],"label_agreement":null},{"id":"W9436761","doi":"10.3833/pdr.v2011i9.1531","title":"Sanofi’s Aventis Pharma Subsidiary to Acquire Nutraceuticals Business of India’s Universal Medicare","year":2011,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Nutraceutical; Portfolio; Quarter (Canadian coin); Marketing; Finance; Medicine","score_opus":0.1334269315679914,"score_gpt":0.33087790487588586,"score_spread":0.19745097330789446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W9436761","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06785249,0.6190192,0.0013026427,0.02153996,0.0024899025,0.0036544816,0.0030361894,0.00023067788,0.28087443],"genre_scores_gemma":[0.71366584,0.2646221,0.0005725984,0.020419786,0.00024788934,0.0000907452,0.000047531692,0.000069864305,0.00026361804],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973291,0.000068887675,0.0013900574,0.00054884265,0.00007806792,0.0005850063],"domain_scores_gemma":[0.9981944,0.00008175366,0.0005428947,0.00048056262,0.00010259908,0.0005978125],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010835252,0.0003144762,0.0011577088,0.00028253847,0.00006586849,0.000018828265,0.00072085066,0.000112795446,0.012603162],"category_scores_gemma":[0.00020078536,0.00035042228,0.00029291172,0.000762057,0.00013657362,0.00033391351,0.00020959924,0.00022713827,0.0025417975],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000408995,0.0025100834,0.06552561,0.0288814,0.0018528017,0.00027334245,0.004251315,0.000012941757,0.001111723,0.56074935,0.21529813,0.11912429],"study_design_scores_gemma":[0.0012575816,0.00006690047,0.019218506,0.001318685,0.00016304938,0.00002809988,0.00002797008,0.000087608976,0.0029426499,0.005657011,0.96846384,0.0007681038],"about_ca_topic_score_codex":0.000120105935,"about_ca_topic_score_gemma":0.0000025422114,"teacher_disagreement_score":0.7531657,"about_ca_system_score_codex":0.00010258176,"about_ca_system_score_gemma":0.00008258168,"threshold_uncertainty_score":0.9998948},"labels":[],"label_agreement":null}]}